[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "DUX4, a homeobox-containing gene present in a tandem array, is implicated in facioscapulohumeral muscular dystrophy (FSHD), a dominant autosomal disease. New findings about DUX4 have raised as many fundamental questions about the molecular pathology of this unique disease as they have answered. This review discusses recent studies addressing the question of whether there is extensive FSHD-related transcription dysregulation in adult-derived myoblasts and myotubes, the precursors for muscle repair. Two models for the role of DUX4 in FSHD are presented. One involves transient pathogenic expression of DUX4 in many cells in the muscle lineage before the myoblast stage resulting in a persistent, disease-related transcription profile ('Majority Rules'), which might be enhanced by subsequent oscillatory expression of DUX4. The other model emphasizes the toxic effects of inappropriate expression of DUX4 in only an extremely small percentage of FSHD myoblasts or myotube nuclei ('Minority Rules'). The currently favored Minority Rules model is not supported by recent studies of transcription dysregulation in FSHD myoblasts and myotubes. It also presents other difficulties, for example, explaining the expression of full-length DUX4 transcripts in FSHD fibroblasts. The Majority Rules model is the simpler explanation of findings about FSHD-associated gene expression and the DUX4-encoded homeodomain-type protein.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "6a92b3312fe9468e9d709a8e59c9fadc", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[64, 64], [160, 160], [91, 91], [188, 188], [20, 20], [212, 212], [226, 226]], "char_spans": [[387, 390], [950, 953], [538, 541], [1115, 1118], [117, 120], [1255, 1258], [1343, 1346]]}]}], "context_tokens": [["DUX4", 0], [",", 4], ["a", 6], ["homeobox", 8], ["-", 16], ["containing", 17], ["gene", 28], ["present", 33], ["in", 41], ["a", 44], ["tandem", 46], ["array", 53], [",", 58], ["is", 60], ["implicated", 63], ["in", 74], ["facioscapulohumeral", 77], ["muscular", 97], ["dystrophy", 106], ["(", 116], ["FSHD", 117], [")", 121], [",", 122], ["a", 124], ["dominant", 126], ["autosomal", 135], ["disease", 145], [".", 152], ["New", 154], ["findings", 158], ["about", 167], ["DUX4", 173], ["have", 178], ["raised", 183], ["as", 190], ["many", 193], ["fundamental", 198], ["questions", 210], ["about", 220], ["the", 226], ["molecular", 230], ["pathology", 240], ["of", 250], ["this", 253], ["unique", 258], ["disease", 265], ["as", 273], ["they", 276], ["have", 281], ["answered", 286], [".", 294], ["This", 296], ["review", 301], ["discusses", 308], ["recent", 318], ["studies", 325], ["addressing", 333], ["the", 344], ["question", 348], ["of", 357], ["whether", 360], ["there", 368], ["is", 374], ["extensive", 377], ["FSHD", 387], ["-", 391], ["related", 392], ["transcription", 400], ["dysregulation", 414], ["in", 428], ["adult", 431], ["-", 436], ["derived", 437], ["myoblasts", 445], ["and", 455], ["myotubes", 459], [",", 467], ["the", 469], ["precursors", 473], ["for", 484], ["muscle", 488], ["repair", 495], [".", 501], ["Two", 503], ["models", 507], ["for", 514], ["the", 518], ["role", 522], ["of", 527], ["DUX4", 530], ["in", 535], ["FSHD", 538], ["are", 543], ["presented", 547], [".", 556], ["One", 558], ["involves", 562], ["transient", 571], ["pathogenic", 581], ["expression", 592], ["of", 603], ["DUX4", 606], ["in", 611], ["many", 614], ["cells", 619], ["in", 625], ["the", 628], ["muscle", 632], ["lineage", 639], ["before", 647], ["the", 654], ["myoblast", 658], ["stage", 667], ["resulting", 673], ["in", 683], ["a", 686], ["persistent", 688], [",", 698], ["disease", 700], ["-", 707], ["related", 708], ["transcription", 716], ["profile", 730], ["(", 738], ["'", 739], ["Majority", 740], ["Rules", 749], ["'", 754], [")", 755], [",", 756], ["which", 758], ["might", 764], ["be", 770], ["enhanced", 773], ["by", 782], ["subsequent", 785], ["oscillatory", 796], ["expression", 808], ["of", 819], ["DUX4", 822], [".", 826], ["The", 828], ["other", 832], ["model", 838], ["emphasizes", 844], ["the", 855], ["toxic", 859], ["effects", 865], ["of", 873], ["inappropriate", 876], ["expression", 890], ["of", 901], ["DUX4", 904], ["in", 909], ["only", 912], ["an", 917], ["extremely", 920], ["small", 930], ["percentage", 936], ["of", 947], ["FSHD", 950], ["myoblasts", 955], ["or", 965], ["myotube", 968], ["nuclei", 976], ["(", 983], ["'", 984], ["Minority", 985], ["Rules", 994], ["'", 999], [")", 1000], [".", 1001], ["The", 1003], ["currently", 1007], ["favored", 1017], ["Minority", 1025], ["Rules", 1034], ["model", 1040], ["is", 1046], ["not", 1049], ["supported", 1053], ["by", 1063], ["recent", 1066], ["studies", 1073], ["of", 1081], ["transcription", 1084], ["dysregulation", 1098], ["in", 1112], ["FSHD", 1115], ["myoblasts", 1120], ["and", 1130], ["myotubes", 1134], [".", 1142], ["It", 1144], ["also", 1147], ["presents", 1152], ["other", 1161], ["difficulties", 1167], [",", 1179], ["for", 1181], ["example", 1185], [",", 1192], ["explaining", 1194], ["the", 1205], ["expression", 1209], ["of", 1220], ["full", 1223], ["-", 1227], ["length", 1228], ["DUX4", 1235], ["transcripts", 1240], ["in", 1252], ["FSHD", 1255], ["fibroblasts", 1260], [".", 1271], ["The", 1273], ["Majority", 1277], ["Rules", 1286], ["model", 1292], ["is", 1298], ["the", 1301], ["simpler", 1305], ["explanation", 1313], ["of", 1325], ["findings", 1328], ["about", 1337], ["FSHD", 1343], ["-", 1347], ["associated", 1348], ["gene", 1359], ["expression", 1364], ["and", 1375], ["the", 1379], ["DUX4-encoded", 1383], ["homeodomain", 1396], ["-", 1407], ["type", 1408], ["protein", 1413], [".", 1420]]}
{"context": "Iron deficiency anemia is common in people with chronic kidney disease (CKD) and its importance in supporting erythropoiesis is unquestioned especially in those patients treated with erythropoietin. Clinical symptomatology such as fatigability, cold intolerance, failure to concentrate and poor effort intolerance is often attributed to anemia or uremia. That iron deficiency, per se, can cause these symptoms is poorly recognized. Clinical and animal studies that support the benefits of iron supplementation, independent of increasing hemoglobin, such as those on immune function, physical performance, thermoregulation, cognition, and restless leg syndrome and aluminum absorption is the subject of this narrative review.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "9a096b481413444ea01bcdaa55383924", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [55, 55], [78, 78]], "char_spans": [[0, 3], [360, 363], [489, 492]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["anemia", 16], ["is", 23], ["common", 26], ["in", 33], ["people", 36], ["with", 43], ["chronic", 48], ["kidney", 56], ["disease", 63], ["(", 71], ["CKD", 72], [")", 75], ["and", 77], ["its", 81], ["importance", 85], ["in", 96], ["supporting", 99], ["erythropoiesis", 110], ["is", 125], ["unquestioned", 128], ["especially", 141], ["in", 152], ["those", 155], ["patients", 161], ["treated", 170], ["with", 178], ["erythropoietin", 183], [".", 197], ["Clinical", 199], ["symptomatology", 208], ["such", 223], ["as", 228], ["fatigability", 231], [",", 243], ["cold", 245], ["intolerance", 250], [",", 261], ["failure", 263], ["to", 271], ["concentrate", 274], ["and", 286], ["poor", 290], ["effort", 295], ["intolerance", 302], ["is", 314], ["often", 317], ["attributed", 323], ["to", 334], ["anemia", 337], ["or", 344], ["uremia", 347], [".", 353], ["That", 355], ["iron", 360], ["deficiency", 365], [",", 375], ["per", 377], ["se", 381], [",", 383], ["can", 385], ["cause", 389], ["these", 395], ["symptoms", 401], ["is", 410], ["poorly", 413], ["recognized", 420], [".", 430], ["Clinical", 432], ["and", 441], ["animal", 445], ["studies", 452], ["that", 460], ["support", 465], ["the", 473], ["benefits", 477], ["of", 486], ["iron", 489], ["supplementation", 494], [",", 509], ["independent", 511], ["of", 523], ["increasing", 526], ["hemoglobin", 537], [",", 547], ["such", 549], ["as", 554], ["those", 557], ["on", 563], ["immune", 566], ["function", 573], [",", 581], ["physical", 583], ["performance", 592], [",", 603], ["thermoregulation", 605], [",", 621], ["cognition", 623], [",", 632], ["and", 634], ["restless", 638], ["leg", 647], ["syndrome", 651], ["and", 660], ["aluminum", 664], ["absorption", 673], ["is", 684], ["the", 687], ["subject", 691], ["of", 699], ["this", 702], ["narrative", 707], ["review", 717], [".", 723]]}
{"context": "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission. Both drugs had a favorable therapeutic index. A 24-h treatment with 1,000 nM UC-781 or 100 nM TMC120-R147681 prevented cell-free HIV infection, whereas 10-fold-higher concentrations blocked cell-associated HIV.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c3236d984bae4fe9a702753a63371250", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[74, 74], [17, 17], [62, 62]], "char_spans": [[479, 481], [142, 144], [402, 404]]}]}], "context_tokens": [["The", 0], ["nonnucleoside", 4], ["reverse", 18], ["transcriptase", 26], ["inhibitors", 40], ["UC-781", 51], ["and", 58], ["TMC120-R147681", 62], ["(", 77], ["Dapivirine", 78], [")", 88], ["effectively", 90], ["prevented", 102], ["human", 112], ["immunodeficiency", 118], ["virus", 135], ["(", 141], ["HIV", 142], [")", 145], ["infection", 147], ["in", 157], ["cocultures", 160], ["of", 171], ["monocyte", 174], ["-", 182], ["derived", 183], ["dendritic", 191], ["cells", 201], ["and", 207], ["T", 211], ["cells", 213], [",", 218], ["representing", 220], ["primary", 233], ["targets", 241], ["in", 249], ["sexual", 252], ["transmission", 259], [".", 271], ["Both", 273], ["drugs", 278], ["had", 284], ["a", 288], ["favorable", 290], ["therapeutic", 300], ["index", 312], [".", 317], ["A", 319], ["24-h", 321], ["treatment", 326], ["with", 336], ["1,000", 341], ["nM", 347], ["UC-781", 350], ["or", 357], ["100", 360], ["nM", 364], ["TMC120-R147681", 367], ["prevented", 382], ["cell", 392], ["-", 396], ["free", 397], ["HIV", 402], ["infection", 406], [",", 415], ["whereas", 417], ["10-fold", 425], ["-", 432], ["higher", 433], ["concentrations", 440], ["blocked", 455], ["cell", 463], ["-", 467], ["associated", 468], ["HIV", 479], [".", 482]]}
{"context": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates. Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design. Population estimates and correlations were obtained for PTSD, generalized anxiety and depression. The reliability, factor structure, and convergent validity of the DTS-S were assessed. Cross-validation was employed to confirm the results of the factor analyses. Using the cut-offs adopted by the scale's author, 136 (13.4 percent) of the inmates are likely to have current PTSD and 117 (11.6 percent) reach the cut-off for sub-threshold PTSD. Confirmatory factor analysis generated two factors explaining 53 percent of the variance. High reliabilities were obtained for the total scale (\u03b1=0.95) and for the frequency and severity scales (\u03b1=0.90 and 0.91). Significantly higher DTS-S scores were found for females (t=2.26, p<0.025), for inmates diagnosed with depression or anxiety (t=2.02, p<0.05), and those reporting suicide attempts (t=4.47, p<0.0001). Findings support that the DTS-S is a reliable and valid measure to assess PTSD symptoms in Latino inmate populations and to identify individuals at risk for the disorder that require confirmatory diagnosis and clinical interventions.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b6a2b5c8312645a99ca848d823503319", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[34, 38]], "char_spans": [[178, 207]]}, {"text": "PTSD", "token_spans": [[160, 160], [144, 144], [40, 40], [254, 254], [81, 81]], "char_spans": [[844, 847], [780, 783], [210, 213], [1337, 1340], [463, 466]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["paper", 20], ["is", 26], ["to", 29], ["assess", 32], ["the", 39], ["reliability", 43], ["and", 55], ["validity", 59], ["of", 68], ["the", 71], ["Spanish", 75], ["version", 83], ["of", 91], ["the", 94], ["Davidson", 98], ["trauma", 107], ["scale", 114], ["(", 120], ["DTS", 121], ["-", 124], ["S", 125], [")", 126], ["and", 128], ["to", 132], ["determine", 135], ["the", 145], ["prevalence", 149], ["and", 160], ["correlates", 164], ["of", 175], ["post", 178], ["-", 182], ["traumatic", 183], ["stress", 193], ["disorder", 200], ["(", 209], ["PTSD", 210], [")", 214], ["symptoms", 216], ["in", 225], ["a", 228], ["non", 230], ["-", 233], ["clinical", 234], ["random", 243], ["sample", 250], ["of", 257], ["prison", 260], ["inmates", 267], [".", 274], ["Probabilistic", 276], ["samples", 290], ["of", 298], ["1,179", 301], ["inmates", 307], ["from", 315], ["26", 320], ["penal", 323], ["institutions", 329], ["in", 342], ["Puerto", 345], ["Rico", 352], ["were", 357], ["selected", 362], ["using", 371], ["a", 377], ["multistage", 379], ["sampling", 390], ["design", 399], [".", 405], ["Population", 407], ["estimates", 418], ["and", 428], ["correlations", 432], ["were", 445], ["obtained", 450], ["for", 459], ["PTSD", 463], [",", 467], ["generalized", 469], ["anxiety", 481], ["and", 489], ["depression", 493], [".", 503], ["The", 505], ["reliability", 509], [",", 520], ["factor", 522], ["structure", 529], [",", 538], ["and", 540], ["convergent", 544], ["validity", 555], ["of", 564], ["the", 567], ["DTS", 571], ["-", 574], ["S", 575], ["were", 577], ["assessed", 582], [".", 590], ["Cross", 592], ["-", 597], ["validation", 598], ["was", 609], ["employed", 613], ["to", 622], ["confirm", 625], ["the", 633], ["results", 637], ["of", 645], ["the", 648], ["factor", 652], ["analyses", 659], [".", 667], ["Using", 669], ["the", 675], ["cut", 679], ["-", 682], ["offs", 683], ["adopted", 688], ["by", 696], ["the", 699], ["scale", 703], ["'s", 708], ["author", 711], [",", 717], ["136", 719], ["(", 723], ["13.4", 724], ["percent", 729], [")", 736], ["of", 738], ["the", 741], ["inmates", 745], ["are", 753], ["likely", 757], ["to", 764], ["have", 767], ["current", 772], ["PTSD", 780], ["and", 785], ["117", 789], ["(", 793], ["11.6", 794], ["percent", 799], [")", 806], ["reach", 808], ["the", 814], ["cut", 818], ["-", 821], ["off", 822], ["for", 826], ["sub", 830], ["-", 833], ["threshold", 834], ["PTSD", 844], [".", 848], ["Confirmatory", 850], ["factor", 863], ["analysis", 870], ["generated", 879], ["two", 889], ["factors", 893], ["explaining", 901], ["53", 912], ["percent", 915], ["of", 923], ["the", 926], ["variance", 930], [".", 938], ["High", 940], ["reliabilities", 945], ["were", 959], ["obtained", 964], ["for", 973], ["the", 977], ["total", 981], ["scale", 987], ["(", 993], ["\u03b1=0.95", 994], [")", 1000], ["and", 1002], ["for", 1006], ["the", 1010], ["frequency", 1014], ["and", 1024], ["severity", 1028], ["scales", 1037], ["(", 1044], ["\u03b1=0.90", 1045], ["and", 1052], ["0.91", 1056], [")", 1060], [".", 1061], ["Significantly", 1063], ["higher", 1077], ["DTS", 1084], ["-", 1087], ["S", 1088], ["scores", 1090], ["were", 1097], ["found", 1102], ["for", 1108], ["females", 1112], ["(", 1120], ["t=2.26", 1121], [",", 1127], ["p<0.025", 1129], [")", 1136], [",", 1137], ["for", 1139], ["inmates", 1143], ["diagnosed", 1151], ["with", 1161], ["depression", 1166], ["or", 1177], ["anxiety", 1180], ["(", 1188], ["t=2.02", 1189], [",", 1195], ["p<0.05", 1197], [")", 1203], [",", 1204], ["and", 1206], ["those", 1210], ["reporting", 1216], ["suicide", 1226], ["attempts", 1234], ["(", 1243], ["t=4.47", 1244], [",", 1250], ["p<0.0001", 1252], [")", 1260], [".", 1261], ["Findings", 1263], ["support", 1272], ["that", 1280], ["the", 1285], ["DTS", 1289], ["-", 1292], ["S", 1293], ["is", 1295], ["a", 1298], ["reliable", 1300], ["and", 1309], ["valid", 1313], ["measure", 1319], ["to", 1327], ["assess", 1330], ["PTSD", 1337], ["symptoms", 1342], ["in", 1351], ["Latino", 1354], ["inmate", 1361], ["populations", 1368], ["and", 1380], ["to", 1384], ["identify", 1387], ["individuals", 1396], ["at", 1408], ["risk", 1411], ["for", 1416], ["the", 1420], ["disorder", 1424], ["that", 1433], ["require", 1438], ["confirmatory", 1446], ["diagnosis", 1459], ["and", 1469], ["clinical", 1473], ["interventions", 1482], [".", 1495]]}
{"context": "To assess the potential of polymeric nanoparticles (NPs) to affect the genital distribution and local and systemic pharmacokinetics (PK) of the anti-HIV microbicide drug candidate dapivirine after vaginal delivery. Dapivirine-loaded, poly(ethylene oxide)-coated poly(epsilon-caprolactone) (PEO-PCL) NPs were prepared by a nanoprecipitation method. Genital distribution of NPs and their ability to modify the PK of dapivirine up to 24 h was assessed after vaginal instillation in a female mouse model. Also, the safety of NPs upon daily administration for 14 days was assessed by histological analysis and chemokine/cytokine content in vaginal lavages. PEO-PCL NPs (180-200 nm) were rapidly eliminated after administration but able to distribute throughout the vagina and lower uterus, and capable of tackling mucus and penetrate the epithelial lining. Nanocarriers modified the PK of dapivirine, with higher drug levels being recovered from vaginal lavages and vaginal/lower uterine tissues as compared to a drug suspension. Systemic drug exposure was reduced when NPs were used. Also, NPs were shown safe upon administration for 14 days. Dapivirine-loaded PEO-PCL NPs were able to provide likely favorable genital drug levels, thus attesting the potential value of using this vaginal drug delivery nanosystem in the context of HIV prophylaxis.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "1e55c4f1758248f58dd8977c35ab8ead", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[27, 27], [234, 234]], "char_spans": [[149, 151], [1328, 1330]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["potential", 14], ["of", 24], ["polymeric", 27], ["nanoparticles", 37], ["(", 51], ["NPs", 52], [")", 55], ["to", 57], ["affect", 60], ["the", 67], ["genital", 71], ["distribution", 79], ["and", 92], ["local", 96], ["and", 102], ["systemic", 106], ["pharmacokinetics", 115], ["(", 132], ["PK", 133], [")", 135], ["of", 137], ["the", 140], ["anti", 144], ["-", 148], ["HIV", 149], ["microbicide", 153], ["drug", 165], ["candidate", 170], ["dapivirine", 180], ["after", 191], ["vaginal", 197], ["delivery", 205], [".", 213], ["Dapivirine", 215], ["-", 225], ["loaded", 226], [",", 232], ["poly(ethylene", 234], ["oxide)-coated", 248], ["poly(epsilon", 262], ["-", 274], ["caprolactone", 275], [")", 287], ["(", 289], ["PEO", 290], ["-", 293], ["PCL", 294], [")", 297], ["NPs", 299], ["were", 303], ["prepared", 308], ["by", 317], ["a", 320], ["nanoprecipitation", 322], ["method", 340], [".", 346], ["Genital", 348], ["distribution", 356], ["of", 369], ["NPs", 372], ["and", 376], ["their", 380], ["ability", 386], ["to", 394], ["modify", 397], ["the", 404], ["PK", 408], ["of", 411], ["dapivirine", 414], ["up", 425], ["to", 428], ["24", 431], ["h", 434], ["was", 436], ["assessed", 440], ["after", 449], ["vaginal", 455], ["instillation", 463], ["in", 476], ["a", 479], ["female", 481], ["mouse", 488], ["model", 494], [".", 499], ["Also", 501], [",", 505], ["the", 507], ["safety", 511], ["of", 518], ["NPs", 521], ["upon", 525], ["daily", 530], ["administration", 536], ["for", 551], ["14", 555], ["days", 558], ["was", 563], ["assessed", 567], ["by", 576], ["histological", 579], ["analysis", 592], ["and", 601], ["chemokine", 605], ["/", 614], ["cytokine", 615], ["content", 624], ["in", 632], ["vaginal", 635], ["lavages", 643], [".", 650], ["PEO", 652], ["-", 655], ["PCL", 656], ["NPs", 660], ["(", 664], ["180", 665], ["-", 668], ["200", 669], ["nm", 673], [")", 675], ["were", 677], ["rapidly", 682], ["eliminated", 690], ["after", 701], ["administration", 707], ["but", 722], ["able", 726], ["to", 731], ["distribute", 734], ["throughout", 745], ["the", 756], ["vagina", 760], ["and", 767], ["lower", 771], ["uterus", 777], [",", 783], ["and", 785], ["capable", 789], ["of", 797], ["tackling", 800], ["mucus", 809], ["and", 815], ["penetrate", 819], ["the", 829], ["epithelial", 833], ["lining", 844], [".", 850], ["Nanocarriers", 852], ["modified", 865], ["the", 874], ["PK", 878], ["of", 881], ["dapivirine", 884], [",", 894], ["with", 896], ["higher", 901], ["drug", 908], ["levels", 913], ["being", 920], ["recovered", 926], ["from", 936], ["vaginal", 941], ["lavages", 949], ["and", 957], ["vaginal", 961], ["/", 968], ["lower", 969], ["uterine", 975], ["tissues", 983], ["as", 991], ["compared", 994], ["to", 1003], ["a", 1006], ["drug", 1008], ["suspension", 1013], [".", 1023], ["Systemic", 1025], ["drug", 1034], ["exposure", 1039], ["was", 1048], ["reduced", 1052], ["when", 1060], ["NPs", 1065], ["were", 1069], ["used", 1074], [".", 1078], ["Also", 1080], [",", 1084], ["NPs", 1086], ["were", 1090], ["shown", 1095], ["safe", 1101], ["upon", 1106], ["administration", 1111], ["for", 1126], ["14", 1130], ["days", 1133], [".", 1137], ["Dapivirine", 1139], ["-", 1149], ["loaded", 1150], ["PEO", 1157], ["-", 1160], ["PCL", 1161], ["NPs", 1165], ["were", 1169], ["able", 1174], ["to", 1179], ["provide", 1182], ["likely", 1190], ["favorable", 1197], ["genital", 1207], ["drug", 1215], ["levels", 1220], [",", 1226], ["thus", 1228], ["attesting", 1233], ["the", 1243], ["potential", 1247], ["value", 1257], ["of", 1263], ["using", 1266], ["this", 1272], ["vaginal", 1277], ["drug", 1285], ["delivery", 1290], ["nanosystem", 1299], ["in", 1310], ["the", 1313], ["context", 1317], ["of", 1325], ["HIV", 1328], ["prophylaxis", 1332], [".", 1343]]}
{"context": "By using monoclonal antibodies raised against isolated clam centrosomes, we have identified a novel 135-kD centrosomal protein (Cep135), present in a wide range of organisms. Cep135 is located at the centrosome throughout the cell cycle, and localization is independent of the microtubule network. It distributes throughout the centrosomal area in association with the electron-dense material surrounding centrioles. Sequence analysis of cDNA isolated from CHO cells predicted a protein of 1,145-amino acid residues with extensive alpha-helical domains. Expression of a series of deletion constructs revealed the presence of three independent centrosome-targeting domains. Overexpression of Cep135 resulted in the accumulation of unique whorl-like particles in both the centrosome and the cytoplasm. Although their size, shape, and number varied according to the level of protein expression, these whorls were composed of parallel dense lines arranged in a 6-nm space. Altered levels of Cep135 by protein overexpression and/or suppression of endogenous Cep135 by RNA interference caused disorganization of interphase and mitotic spindle microtubules. Thus, Cep135 may play an important role in the centrosomal function of organizing microtubules in mammalian cells.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "531659cef16e4f2d9ad354129f13c0c8", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[123, 123], [35, 35], [102, 102]], "char_spans": [[770, 779], [200, 209], [643, 652]]}]}], "context_tokens": [["By", 0], ["using", 3], ["monoclonal", 9], ["antibodies", 20], ["raised", 31], ["against", 38], ["isolated", 46], ["clam", 55], ["centrosomes", 60], [",", 71], ["we", 73], ["have", 76], ["identified", 81], ["a", 92], ["novel", 94], ["135-kD", 100], ["centrosomal", 107], ["protein", 119], ["(", 127], ["Cep135", 128], [")", 134], [",", 135], ["present", 137], ["in", 145], ["a", 148], ["wide", 150], ["range", 155], ["of", 161], ["organisms", 164], [".", 173], ["Cep135", 175], ["is", 182], ["located", 185], ["at", 193], ["the", 196], ["centrosome", 200], ["throughout", 211], ["the", 222], ["cell", 226], ["cycle", 231], [",", 236], ["and", 238], ["localization", 242], ["is", 255], ["independent", 258], ["of", 270], ["the", 273], ["microtubule", 277], ["network", 289], [".", 296], ["It", 298], ["distributes", 301], ["throughout", 313], ["the", 324], ["centrosomal", 328], ["area", 340], ["in", 345], ["association", 348], ["with", 360], ["the", 365], ["electron", 369], ["-", 377], ["dense", 378], ["material", 384], ["surrounding", 393], ["centrioles", 405], [".", 415], ["Sequence", 417], ["analysis", 426], ["of", 435], ["cDNA", 438], ["isolated", 443], ["from", 452], ["CHO", 457], ["cells", 461], ["predicted", 467], ["a", 477], ["protein", 479], ["of", 487], ["1,145-amino", 490], ["acid", 502], ["residues", 507], ["with", 516], ["extensive", 521], ["alpha", 531], ["-", 536], ["helical", 537], ["domains", 545], [".", 552], ["Expression", 554], ["of", 565], ["a", 568], ["series", 570], ["of", 577], ["deletion", 580], ["constructs", 589], ["revealed", 600], ["the", 609], ["presence", 613], ["of", 622], ["three", 625], ["independent", 631], ["centrosome", 643], ["-", 653], ["targeting", 654], ["domains", 664], [".", 671], ["Overexpression", 673], ["of", 688], ["Cep135", 691], ["resulted", 698], ["in", 707], ["the", 710], ["accumulation", 714], ["of", 727], ["unique", 730], ["whorl", 737], ["-", 742], ["like", 743], ["particles", 748], ["in", 758], ["both", 761], ["the", 766], ["centrosome", 770], ["and", 781], ["the", 785], ["cytoplasm", 789], [".", 798], ["Although", 800], ["their", 809], ["size", 815], [",", 819], ["shape", 821], [",", 826], ["and", 828], ["number", 832], ["varied", 839], ["according", 846], ["to", 856], ["the", 859], ["level", 863], ["of", 869], ["protein", 872], ["expression", 880], [",", 890], ["these", 892], ["whorls", 898], ["were", 905], ["composed", 910], ["of", 919], ["parallel", 922], ["dense", 931], ["lines", 937], ["arranged", 943], ["in", 952], ["a", 955], ["6-nm", 957], ["space", 962], [".", 967], ["Altered", 969], ["levels", 977], ["of", 984], ["Cep135", 987], ["by", 994], ["protein", 997], ["overexpression", 1005], ["and/or", 1020], ["suppression", 1027], ["of", 1039], ["endogenous", 1042], ["Cep135", 1053], ["by", 1060], ["RNA", 1063], ["interference", 1067], ["caused", 1080], ["disorganization", 1087], ["of", 1103], ["interphase", 1106], ["and", 1117], ["mitotic", 1121], ["spindle", 1129], ["microtubules", 1137], [".", 1149], ["Thus", 1151], [",", 1155], ["Cep135", 1157], ["may", 1164], ["play", 1168], ["an", 1173], ["important", 1176], ["role", 1186], ["in", 1191], ["the", 1194], ["centrosomal", 1198], ["function", 1210], ["of", 1219], ["organizing", 1222], ["microtubules", 1233], ["in", 1246], ["mammalian", 1249], ["cells", 1259], [".", 1264]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by hypoproliferative anemia, associated physical malformations and a predisposition to cancer. DBA has been associated with mutations and deletions in the large and small ribosomal protein genes, and genetic aberrations have been detected in \u223c50-60% of patients. In this study, nine Korean DBA patients were screened for mutations in eight known DBA genes (RPS19, RPS24, RPS17, RPS10, RPS26, RPL35A, RPL5 and RPL11) using the direct sequencing method. Mutations in RPS19, RPS26 and RPS17 were detected in four, two and one patient, respectively. Among the mutations detected in RPS19, two mutations were novel (c.26T>A, c.357-2A>G). For the mutation-negative cases, array-CGH analysis was performed to identify copy-number variations, and no deletions involving the known DBA gene regions were identified. The relative mRNA expression of RPS19 estimated using real-time quantitative PCR analysis revealed two- to fourfold reductions in RPS19 mRNA expression in three patients with RPS19 mutations, and p53 protein expression analysis by immunohistochemistry showed variable but significant nuclear staining in the DBA patients. In conclusion, heterozygous mutations in the known DBA genes RPS19, RPS26 and RPS17 were detected in seven out of nine Korean DBA patients. Among these patients, RPS19 was the most frequently mutated gene. In addition, decreased RPS19 mRNA expression and p53 overexpression were observed in the Korean DBA patients, which supports the hypothesis that haploinsufficiency and p53 hyperactivation represent a central pathway underlying the pathogenesis of DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "7b98e597897f4b24bd7030143bae73d8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [229, 229], [74, 74], [218, 218], [294, 294], [28, 28], [244, 244], [167, 167], [274, 274], [65, 65]], "char_spans": [[25, 27], [1268, 1270], [435, 437], [1203, 1205], [1670, 1672], [184, 186], [1343, 1345], [861, 863], [1519, 1521], [379, 381]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["hypoproliferative", 92], ["anemia", 110], [",", 116], ["associated", 118], ["physical", 129], ["malformations", 138], ["and", 152], ["a", 156], ["predisposition", 158], ["to", 173], ["cancer", 176], [".", 182], ["DBA", 184], ["has", 188], ["been", 192], ["associated", 197], ["with", 208], ["mutations", 213], ["and", 223], ["deletions", 227], ["in", 237], ["the", 240], ["large", 244], ["and", 250], ["small", 254], ["ribosomal", 260], ["protein", 270], ["genes", 278], [",", 283], ["and", 285], ["genetic", 289], ["aberrations", 297], ["have", 309], ["been", 314], ["detected", 319], ["in", 328], ["\u223c50", 331], ["-", 334], ["60", 335], ["%", 337], ["of", 339], ["patients", 342], [".", 350], ["In", 352], ["this", 355], ["study", 360], [",", 365], ["nine", 367], ["Korean", 372], ["DBA", 379], ["patients", 383], ["were", 392], ["screened", 397], ["for", 406], ["mutations", 410], ["in", 420], ["eight", 423], ["known", 429], ["DBA", 435], ["genes", 439], ["(", 445], ["RPS19", 446], [",", 451], ["RPS24", 453], [",", 458], ["RPS17", 460], [",", 465], ["RPS10", 467], [",", 472], ["RPS26", 474], [",", 479], ["RPL35A", 481], [",", 487], ["RPL5", 489], ["and", 494], ["RPL11", 498], [")", 503], ["using", 505], ["the", 511], ["direct", 515], ["sequencing", 522], ["method", 533], [".", 539], ["Mutations", 541], ["in", 551], ["RPS19", 554], [",", 559], ["RPS26", 561], ["and", 567], ["RPS17", 571], ["were", 577], ["detected", 582], ["in", 591], ["four", 594], [",", 598], ["two", 600], ["and", 604], ["one", 608], ["patient", 612], [",", 619], ["respectively", 621], [".", 633], ["Among", 635], ["the", 641], ["mutations", 645], ["detected", 655], ["in", 664], ["RPS19", 667], [",", 672], ["two", 674], ["mutations", 678], ["were", 688], ["novel", 693], ["(", 699], ["c.26T", 700], [">", 705], ["A", 706], [",", 707], ["c.357", 709], ["-", 714], ["2A", 715], [">", 717], ["G", 718], [")", 719], [".", 720], ["For", 722], ["the", 726], ["mutation", 730], ["-", 738], ["negative", 739], ["cases", 748], [",", 753], ["array", 755], ["-", 760], ["CGH", 761], ["analysis", 765], ["was", 774], ["performed", 778], ["to", 788], ["identify", 791], ["copy", 800], ["-", 804], ["number", 805], ["variations", 812], [",", 822], ["and", 824], ["no", 828], ["deletions", 831], ["involving", 841], ["the", 851], ["known", 855], ["DBA", 861], ["gene", 865], ["regions", 870], ["were", 878], ["identified", 883], [".", 893], ["The", 895], ["relative", 899], ["mRNA", 908], ["expression", 913], ["of", 924], ["RPS19", 927], ["estimated", 933], ["using", 943], ["real", 949], ["-", 953], ["time", 954], ["quantitative", 959], ["PCR", 972], ["analysis", 976], ["revealed", 985], ["two-", 994], ["to", 999], ["fourfold", 1002], ["reductions", 1011], ["in", 1022], ["RPS19", 1025], ["mRNA", 1031], ["expression", 1036], ["in", 1047], ["three", 1050], ["patients", 1056], ["with", 1065], ["RPS19", 1070], ["mutations", 1076], [",", 1085], ["and", 1087], ["p53", 1091], ["protein", 1095], ["expression", 1103], ["analysis", 1114], ["by", 1123], ["immunohistochemistry", 1126], ["showed", 1147], ["variable", 1154], ["but", 1163], ["significant", 1167], ["nuclear", 1179], ["staining", 1187], ["in", 1196], ["the", 1199], ["DBA", 1203], ["patients", 1207], [".", 1215], ["In", 1217], ["conclusion", 1220], [",", 1230], ["heterozygous", 1232], ["mutations", 1245], ["in", 1255], ["the", 1258], ["known", 1262], ["DBA", 1268], ["genes", 1272], ["RPS19", 1278], [",", 1283], ["RPS26", 1285], ["and", 1291], ["RPS17", 1295], ["were", 1301], ["detected", 1306], ["in", 1315], ["seven", 1318], ["out", 1324], ["of", 1328], ["nine", 1331], ["Korean", 1336], ["DBA", 1343], ["patients", 1347], [".", 1355], ["Among", 1357], ["these", 1363], ["patients", 1369], [",", 1377], ["RPS19", 1379], ["was", 1385], ["the", 1389], ["most", 1393], ["frequently", 1398], ["mutated", 1409], ["gene", 1417], [".", 1421], ["In", 1423], ["addition", 1426], [",", 1434], ["decreased", 1436], ["RPS19", 1446], ["mRNA", 1452], ["expression", 1457], ["and", 1468], ["p53", 1472], ["overexpression", 1476], ["were", 1491], ["observed", 1496], ["in", 1505], ["the", 1508], ["Korean", 1512], ["DBA", 1519], ["patients", 1523], [",", 1531], ["which", 1533], ["supports", 1539], ["the", 1548], ["hypothesis", 1552], ["that", 1563], ["haploinsufficiency", 1568], ["and", 1587], ["p53", 1591], ["hyperactivation", 1595], ["represent", 1611], ["a", 1621], ["central", 1623], ["pathway", 1631], ["underlying", 1639], ["the", 1650], ["pathogenesis", 1654], ["of", 1667], ["DBA", 1670], [".", 1673]]}
{"context": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome. Men, however, are more likely than women to die from extra-articular complications of rheumatoid disease. This chapter discusses the outcome and mortality studies that substantiate these conclusions and then examines the possible mechanisms that may account for them, including the HLA system, seropositivity, compliance, response to therapy and pain threshold. In particular, sex and sex hormones emerge as independent risk factors in rheumatoid disease. The epidemiological evidence points towards a peak age of onset of RA at the time of the menopause in women and towards later in life in men. Premenopausal women may fare better than postmenopausal women with RA. The possible protective effects of the oral contraceptive pill and the dramatic amelioration with pregnancy are well documented. In vivo and in vitro studies have demonstrated that sex hormones interfere with a number of the putative processes involved in the pathogenesis of RA, including immunoregulation, interaction with inflammatory mediators and the cytokine system, and direct effects on cartilage itself. All these observations point towards the importance of gonadal hormones. However, trials on the potential therapeutic use of sex hormones in RA are limited and, as yet, disappointing. Further work is necessary to determine whether the roles of sex hormones are as central protagonists or just supporting cast in the complex arena of rheumatoid disease.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "dd55ff8b09a7433aa467295dae5b0c62", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[16, 16], [127, 127], [137, 137], [40, 40], [143, 143]], "char_spans": [[86, 90], [721, 725], [775, 779], [198, 202], [817, 821]]}]}], "context_tokens": [["Disease", 0], ["patterns", 8], ["in", 17], ["RA", 20], ["vary", 23], ["between", 28], ["the", 36], ["sexes", 40], [";", 45], ["the", 47], ["condition", 51], ["is", 61], ["more", 64], ["commonly", 69], ["seen", 78], ["in", 83], ["women", 86], [",", 91], ["who", 93], ["exhibit", 97], ["a", 105], ["more", 107], ["aggressive", 112], ["disease", 123], ["and", 131], ["a", 135], ["poorer", 137], ["long", 144], ["-", 148], ["term", 149], ["outcome", 154], [".", 161], ["Men", 163], [",", 166], ["however", 168], [",", 175], ["are", 177], ["more", 181], ["likely", 186], ["than", 193], ["women", 198], ["to", 204], ["die", 207], ["from", 211], ["extra", 216], ["-", 221], ["articular", 222], ["complications", 232], ["of", 246], ["rheumatoid", 249], ["disease", 260], [".", 267], ["This", 269], ["chapter", 274], ["discusses", 282], ["the", 292], ["outcome", 296], ["and", 304], ["mortality", 308], ["studies", 318], ["that", 326], ["substantiate", 331], ["these", 344], ["conclusions", 350], ["and", 362], ["then", 366], ["examines", 371], ["the", 380], ["possible", 384], ["mechanisms", 393], ["that", 404], ["may", 409], ["account", 413], ["for", 421], ["them", 425], [",", 429], ["including", 431], ["the", 441], ["HLA", 445], ["system", 449], [",", 455], ["seropositivity", 457], [",", 471], ["compliance", 473], [",", 483], ["response", 485], ["to", 494], ["therapy", 497], ["and", 505], ["pain", 509], ["threshold", 514], [".", 523], ["In", 525], ["particular", 528], [",", 538], ["sex", 540], ["and", 544], ["sex", 548], ["hormones", 552], ["emerge", 561], ["as", 568], ["independent", 571], ["risk", 583], ["factors", 588], ["in", 596], ["rheumatoid", 599], ["disease", 610], [".", 617], ["The", 619], ["epidemiological", 623], ["evidence", 639], ["points", 648], ["towards", 655], ["a", 663], ["peak", 665], ["age", 670], ["of", 674], ["onset", 677], ["of", 683], ["RA", 686], ["at", 689], ["the", 692], ["time", 696], ["of", 701], ["the", 704], ["menopause", 708], ["in", 718], ["women", 721], ["and", 727], ["towards", 731], ["later", 739], ["in", 745], ["life", 748], ["in", 753], ["men", 756], [".", 759], ["Premenopausal", 761], ["women", 775], ["may", 781], ["fare", 785], ["better", 790], ["than", 797], ["postmenopausal", 802], ["women", 817], ["with", 823], ["RA", 828], [".", 830], ["The", 832], ["possible", 836], ["protective", 845], ["effects", 856], ["of", 864], ["the", 867], ["oral", 871], ["contraceptive", 876], ["pill", 890], ["and", 895], ["the", 899], ["dramatic", 903], ["amelioration", 912], ["with", 925], ["pregnancy", 930], ["are", 940], ["well", 944], ["documented", 949], [".", 959], ["In", 961], ["vivo", 964], ["and", 969], ["in", 973], ["vitro", 976], ["studies", 982], ["have", 990], ["demonstrated", 995], ["that", 1008], ["sex", 1013], ["hormones", 1017], ["interfere", 1026], ["with", 1036], ["a", 1041], ["number", 1043], ["of", 1050], ["the", 1053], ["putative", 1057], ["processes", 1066], ["involved", 1076], ["in", 1085], ["the", 1088], ["pathogenesis", 1092], ["of", 1105], ["RA", 1108], [",", 1110], ["including", 1112], ["immunoregulation", 1122], [",", 1138], ["interaction", 1140], ["with", 1152], ["inflammatory", 1157], ["mediators", 1170], ["and", 1180], ["the", 1184], ["cytokine", 1188], ["system", 1197], [",", 1203], ["and", 1205], ["direct", 1209], ["effects", 1216], ["on", 1224], ["cartilage", 1227], ["itself", 1237], [".", 1243], ["All", 1245], ["these", 1249], ["observations", 1255], ["point", 1268], ["towards", 1274], ["the", 1282], ["importance", 1286], ["of", 1297], ["gonadal", 1300], ["hormones", 1308], [".", 1316], ["However", 1318], [",", 1325], ["trials", 1327], ["on", 1334], ["the", 1337], ["potential", 1341], ["therapeutic", 1351], ["use", 1363], ["of", 1367], ["sex", 1370], ["hormones", 1374], ["in", 1383], ["RA", 1386], ["are", 1389], ["limited", 1393], ["and", 1401], [",", 1404], ["as", 1406], ["yet", 1409], [",", 1412], ["disappointing", 1414], [".", 1427], ["Further", 1429], ["work", 1437], ["is", 1442], ["necessary", 1445], ["to", 1455], ["determine", 1458], ["whether", 1468], ["the", 1476], ["roles", 1480], ["of", 1486], ["sex", 1489], ["hormones", 1493], ["are", 1502], ["as", 1506], ["central", 1509], ["protagonists", 1517], ["or", 1530], ["just", 1533], ["supporting", 1538], ["cast", 1549], ["in", 1554], ["the", 1557], ["complex", 1561], ["arena", 1569], ["of", 1575], ["rheumatoid", 1578], ["disease", 1589], [".", 1596]]}
{"context": "There has been much debate about the appropriate statistical methodology for the evaluation of malaria field studies and the challenges in interpreting data arising from these trials. The present paper describes, for a pivotal phase III efficacy of the RTS, S/AS01 malaria vaccine, the methods of the statistical analysis and the rationale for their selection. The methods used to estimate efficacy of the primary course of vaccination, and of a booster dose, in preventing clinical episodes of uncomplicated and severe malaria, and to determine the duration of protection, are described. The interpretation of various measures of efficacy in terms of the potential public health impact of the vaccine is discussed. The methodology selected to analyse the clinical trial must be scientifically sound, acceptable to regulatory authorities and meaningful to those responsible for malaria control and public health policy.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "565e79886a2d468ab49544a0c8e4d2c9", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[146, 146], [89, 89], [46, 46], [14, 14]], "char_spans": [[878, 884], [520, 526], [265, 271], [95, 101]]}]}], "context_tokens": [["There", 0], ["has", 6], ["been", 10], ["much", 15], ["debate", 20], ["about", 27], ["the", 33], ["appropriate", 37], ["statistical", 49], ["methodology", 61], ["for", 73], ["the", 77], ["evaluation", 81], ["of", 92], ["malaria", 95], ["field", 103], ["studies", 109], ["and", 117], ["the", 121], ["challenges", 125], ["in", 136], ["interpreting", 139], ["data", 152], ["arising", 157], ["from", 165], ["these", 170], ["trials", 176], [".", 182], ["The", 184], ["present", 188], ["paper", 196], ["describes", 202], [",", 211], ["for", 213], ["a", 217], ["pivotal", 219], ["phase", 227], ["III", 233], ["efficacy", 237], ["of", 246], ["the", 249], ["RTS", 253], [",", 256], ["S", 258], ["/", 259], ["AS01", 260], ["malaria", 265], ["vaccine", 273], [",", 280], ["the", 282], ["methods", 286], ["of", 294], ["the", 297], ["statistical", 301], ["analysis", 313], ["and", 322], ["the", 326], ["rationale", 330], ["for", 340], ["their", 344], ["selection", 350], [".", 359], ["The", 361], ["methods", 365], ["used", 373], ["to", 378], ["estimate", 381], ["efficacy", 390], ["of", 399], ["the", 402], ["primary", 406], ["course", 414], ["of", 421], ["vaccination", 424], [",", 435], ["and", 437], ["of", 441], ["a", 444], ["booster", 446], ["dose", 454], [",", 458], ["in", 460], ["preventing", 463], ["clinical", 474], ["episodes", 483], ["of", 492], ["uncomplicated", 495], ["and", 509], ["severe", 513], ["malaria", 520], [",", 527], ["and", 529], ["to", 533], ["determine", 536], ["the", 546], ["duration", 550], ["of", 559], ["protection", 562], [",", 572], ["are", 574], ["described", 578], [".", 587], ["The", 589], ["interpretation", 593], ["of", 608], ["various", 611], ["measures", 619], ["of", 628], ["efficacy", 631], ["in", 640], ["terms", 643], ["of", 649], ["the", 652], ["potential", 656], ["public", 666], ["health", 673], ["impact", 680], ["of", 687], ["the", 690], ["vaccine", 694], ["is", 702], ["discussed", 705], [".", 714], ["The", 716], ["methodology", 720], ["selected", 732], ["to", 741], ["analyse", 744], ["the", 752], ["clinical", 756], ["trial", 765], ["must", 771], ["be", 776], ["scientifically", 779], ["sound", 794], [",", 799], ["acceptable", 801], ["to", 812], ["regulatory", 815], ["authorities", 826], ["and", 838], ["meaningful", 842], ["to", 853], ["those", 856], ["responsible", 862], ["for", 874], ["malaria", 878], ["control", 886], ["and", 894], ["public", 898], ["health", 905], ["policy", 912], [".", 918]]}
{"context": "Stroke recognition tools have been shown to improve diagnostic accuracy in adults. Development of a similar tool in children is needed to reduce lag time to diagnosis. A critical first step is to determine whether adult stoke scales can be applied in childhood stroke.Our objective was to assess the applicability of adult stroke scales in childhood arterial ischemic stroke (AIS) METHODS: Children aged 1 month to < 18 years with radiologically confirmed acute AIS who presented to a tertiary emergency department (ED) (2003 to 2008) were identified retrospectively. Signs, symptoms, risk factors and initial management were extracted. Two adult stroke recognition tools; ROSIER (Recognition of Stroke in the Emergency Room) and FAST (Face Arm Speech Test) scales were applied retrospectively to all patients to determine test sensitivity. 47 children with AIS were identified. 34 had anterior, 12 had posterior and 1 child had anterior and posterior circulation infarcts. Median age was 9 years and 51% were male. Median time from symptom onset to ED presentation was 21 hours but one third of children presented within 6 hours. The most common presenting stroke symptoms were arm (63%), face (62%), leg weakness (57%), speech disturbance (46%) and headache (46%). The most common signs were arm (61%), face (70%) or leg weakness (57%) and dysarthria (34%). 36 (78%) of children had at least one positive variable on FAST and 38 (81%) had a positive score of \u22651 on the ROSIER scale. Positive scores were less likely in children with posterior circulation stroke. The presenting features of pediatric stroke appear similar to adult strokes. Two adult stroke recognition tools have fair to good sensitivity in radiologically confirmed childhood AIS but require further development and modification. Specificity of the tools also needs to be determined in a prospective cohort of children with stroke and non-stroke brain attacks.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "1c541feb2e3d42fa943dbf7eb67303a8", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[0, 0], [208, 208], [45, 45], [315, 315], [122, 122], [331, 331], [371, 371], [62, 62], [56, 56], [322, 322], [114, 114], [367, 367]], "char_spans": [[0, 5], [1158, 1163], [261, 266], [1557, 1562], [696, 701], [1652, 1657], [1908, 1913], [368, 373], [323, 328], [1602, 1607], [647, 652], [1893, 1898]]}]}], "context_tokens": [["Stroke", 0], ["recognition", 7], ["tools", 19], ["have", 25], ["been", 30], ["shown", 35], ["to", 41], ["improve", 44], ["diagnostic", 52], ["accuracy", 63], ["in", 72], ["adults", 75], [".", 81], ["Development", 83], ["of", 95], ["a", 98], ["similar", 100], ["tool", 108], ["in", 113], ["children", 116], ["is", 125], ["needed", 128], ["to", 135], ["reduce", 138], ["lag", 145], ["time", 149], ["to", 154], ["diagnosis", 157], [".", 166], ["A", 168], ["critical", 170], ["first", 179], ["step", 185], ["is", 190], ["to", 193], ["determine", 196], ["whether", 206], ["adult", 214], ["stoke", 220], ["scales", 226], ["can", 233], ["be", 237], ["applied", 240], ["in", 248], ["childhood", 251], ["stroke", 261], [".", 267], ["Our", 268], ["objective", 272], ["was", 282], ["to", 286], ["assess", 289], ["the", 296], ["applicability", 300], ["of", 314], ["adult", 317], ["stroke", 323], ["scales", 330], ["in", 337], ["childhood", 340], ["arterial", 350], ["ischemic", 359], ["stroke", 368], ["(", 375], ["AIS", 376], [")", 379], ["METHODS", 381], [":", 388], ["Children", 390], ["aged", 399], ["1", 404], ["month", 406], ["to", 412], ["<", 415], ["18", 417], ["years", 420], ["with", 426], ["radiologically", 431], ["confirmed", 446], ["acute", 456], ["AIS", 462], ["who", 466], ["presented", 470], ["to", 480], ["a", 483], ["tertiary", 485], ["emergency", 494], ["department", 504], ["(", 515], ["ED", 516], [")", 518], ["(", 520], ["2003", 521], ["to", 526], ["2008", 529], [")", 533], ["were", 535], ["identified", 540], ["retrospectively", 551], [".", 566], ["Signs", 568], [",", 573], ["symptoms", 575], [",", 583], ["risk", 585], ["factors", 590], ["and", 598], ["initial", 602], ["management", 610], ["were", 621], ["extracted", 626], [".", 635], ["Two", 637], ["adult", 641], ["stroke", 647], ["recognition", 654], ["tools", 666], [";", 671], ["ROSIER", 673], ["(", 680], ["Recognition", 681], ["of", 693], ["Stroke", 696], ["in", 703], ["the", 706], ["Emergency", 710], ["Room", 720], [")", 724], ["and", 726], ["FAST", 730], ["(", 735], ["Face", 736], ["Arm", 741], ["Speech", 745], ["Test", 752], [")", 756], ["scales", 758], ["were", 765], ["applied", 770], ["retrospectively", 778], ["to", 794], ["all", 797], ["patients", 801], ["to", 810], ["determine", 813], ["test", 823], ["sensitivity", 828], [".", 839], ["47", 841], ["children", 844], ["with", 853], ["AIS", 858], ["were", 862], ["identified", 867], [".", 877], ["34", 879], ["had", 882], ["anterior", 886], [",", 894], ["12", 896], ["had", 899], ["posterior", 903], ["and", 913], ["1", 917], ["child", 919], ["had", 925], ["anterior", 929], ["and", 938], ["posterior", 942], ["circulation", 952], ["infarcts", 964], [".", 972], ["Median", 974], ["age", 981], ["was", 985], ["9", 989], ["years", 991], ["and", 997], ["51", 1001], ["%", 1003], ["were", 1005], ["male", 1010], [".", 1014], ["Median", 1016], ["time", 1023], ["from", 1028], ["symptom", 1033], ["onset", 1041], ["to", 1047], ["ED", 1050], ["presentation", 1053], ["was", 1066], ["21", 1070], ["hours", 1073], ["but", 1079], ["one", 1083], ["third", 1087], ["of", 1093], ["children", 1096], ["presented", 1105], ["within", 1115], ["6", 1122], ["hours", 1124], [".", 1129], ["The", 1131], ["most", 1135], ["common", 1140], ["presenting", 1147], ["stroke", 1158], ["symptoms", 1165], ["were", 1174], ["arm", 1179], ["(", 1183], ["63", 1184], ["%", 1186], [")", 1187], [",", 1188], ["face", 1190], ["(", 1195], ["62", 1196], ["%", 1198], [")", 1199], [",", 1200], ["leg", 1202], ["weakness", 1206], ["(", 1215], ["57", 1216], ["%", 1218], [")", 1219], [",", 1220], ["speech", 1222], ["disturbance", 1229], ["(", 1241], ["46", 1242], ["%", 1244], [")", 1245], ["and", 1247], ["headache", 1251], ["(", 1260], ["46", 1261], ["%", 1263], [")", 1264], [".", 1265], ["The", 1267], ["most", 1271], ["common", 1276], ["signs", 1283], ["were", 1289], ["arm", 1294], ["(", 1298], ["61", 1299], ["%", 1301], [")", 1302], [",", 1303], ["face", 1305], ["(", 1310], ["70", 1311], ["%", 1313], [")", 1314], ["or", 1316], ["leg", 1319], ["weakness", 1323], ["(", 1332], ["57", 1333], ["%", 1335], [")", 1336], ["and", 1338], ["dysarthria", 1342], ["(", 1353], ["34", 1354], ["%", 1356], [")", 1357], [".", 1358], ["36", 1360], ["(", 1363], ["78", 1364], ["%", 1366], [")", 1367], ["of", 1369], ["children", 1372], ["had", 1381], ["at", 1385], ["least", 1388], ["one", 1394], ["positive", 1398], ["variable", 1407], ["on", 1416], ["FAST", 1419], ["and", 1424], ["38", 1428], ["(", 1431], ["81", 1432], ["%", 1434], [")", 1435], ["had", 1437], ["a", 1441], ["positive", 1443], ["score", 1452], ["of", 1458], ["\u22651", 1461], ["on", 1464], ["the", 1467], ["ROSIER", 1471], ["scale", 1478], [".", 1483], ["Positive", 1485], ["scores", 1494], ["were", 1501], ["less", 1506], ["likely", 1511], ["in", 1518], ["children", 1521], ["with", 1530], ["posterior", 1535], ["circulation", 1545], ["stroke", 1557], [".", 1563], ["The", 1565], ["presenting", 1569], ["features", 1580], ["of", 1589], ["pediatric", 1592], ["stroke", 1602], ["appear", 1609], ["similar", 1616], ["to", 1624], ["adult", 1627], ["strokes", 1633], [".", 1640], ["Two", 1642], ["adult", 1646], ["stroke", 1652], ["recognition", 1659], ["tools", 1671], ["have", 1677], ["fair", 1682], ["to", 1687], ["good", 1690], ["sensitivity", 1695], ["in", 1707], ["radiologically", 1710], ["confirmed", 1725], ["childhood", 1735], ["AIS", 1745], ["but", 1749], ["require", 1753], ["further", 1761], ["development", 1769], ["and", 1781], ["modification", 1785], [".", 1797], ["Specificity", 1799], ["of", 1811], ["the", 1814], ["tools", 1818], ["also", 1824], ["needs", 1829], ["to", 1835], ["be", 1838], ["determined", 1841], ["in", 1852], ["a", 1855], ["prospective", 1857], ["cohort", 1869], ["of", 1876], ["children", 1879], ["with", 1888], ["stroke", 1893], ["and", 1900], ["non", 1904], ["-", 1907], ["stroke", 1908], ["brain", 1915], ["attacks", 1921], [".", 1928]]}
{"context": "The major protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein, but other proteins, in particular the microtubule-associated protein tau, have been implicated in the pathogenesis of LBs. Tau is the major structural component of neurofibrillary tangles (NFTs). Both direct immunochemical studies of partially purified LBs and indirect immunohistochemical studies have suggested that LBs may contain tau, but most of these studies were based upon a single tau antibody, and immunologic cross-reactivity was not completely excluded. To gain insight into the relation between tau and alpha-synuclein in LBs, double immunostaining was performed in Lewy body cases with a rabbit polyclonal antibody to alpha-synuclein and a panel of monoclonal antibodies to phospho- and nonphospho-tau epitopes (Alz50, CP9, CP13, PG5, TG3, PHFI) that spanned the length of the tau molecule. Tau-immunoreactive LBs were present in the medulla in 80% of the cases, irrespective of Braak stage. All tau antibodies recognized at least some LBs, arguing against nonspecific antibody cross-reactivity. In most lesions the tau immunostaining was present at the periphery of the LB. The phospho-tau antibody, TG3, detected more LBs than any of the other tau antibodies. The proportion of LBs with tau immunoreactivity was greatest in neurons vulnerable to NETs, such as those in the locus ceruleus and basal nucleus of Meynert, and least in neurons resistant to NFTs, such as the dorsal motor nucleus of the vagus in the medulla. The present results suggest that tau may coaggregate with alpha-synuclein in LBs, especially in neuronal populations vulnerable to both NFTs and LBs.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "dd51992abbdc4acdbe0da902d5a6786a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[306, 308], [138, 140], [118, 120], [27, 29]], "char_spans": [[1661, 1675], [799, 813], [683, 697], [150, 164]]}]}], "context_tokens": [["The", 0], ["major", 4], ["protein", 10], ["constituent", 18], ["of", 30], ["Lewy", 33], ["bodies", 38], ["(", 45], ["LBs", 46], [")", 49], [",", 50], ["the", 52], ["pathological", 56], ["hallmark", 69], ["of", 78], ["Parkinson", 81], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [",", 128], ["is", 130], ["considered", 133], ["to", 144], ["be", 147], ["alpha", 150], ["-", 155], ["synuclein", 156], [",", 165], ["but", 167], ["other", 171], ["proteins", 177], [",", 185], ["in", 187], ["particular", 190], ["the", 201], ["microtubule", 205], ["-", 216], ["associated", 217], ["protein", 228], ["tau", 236], [",", 239], ["have", 241], ["been", 246], ["implicated", 251], ["in", 262], ["the", 265], ["pathogenesis", 269], ["of", 282], ["LBs", 285], [".", 288], ["Tau", 290], ["is", 294], ["the", 297], ["major", 301], ["structural", 307], ["component", 318], ["of", 328], ["neurofibrillary", 331], ["tangles", 347], ["(", 355], ["NFTs", 356], [")", 360], [".", 361], ["Both", 363], ["direct", 368], ["immunochemical", 375], ["studies", 390], ["of", 398], ["partially", 401], ["purified", 411], ["LBs", 420], ["and", 424], ["indirect", 428], ["immunohistochemical", 437], ["studies", 457], ["have", 465], ["suggested", 470], ["that", 480], ["LBs", 485], ["may", 489], ["contain", 493], ["tau", 501], [",", 504], ["but", 506], ["most", 510], ["of", 515], ["these", 518], ["studies", 524], ["were", 532], ["based", 537], ["upon", 543], ["a", 548], ["single", 550], ["tau", 557], ["antibody", 561], [",", 569], ["and", 571], ["immunologic", 575], ["cross", 587], ["-", 592], ["reactivity", 593], ["was", 604], ["not", 608], ["completely", 612], ["excluded", 623], [".", 631], ["To", 633], ["gain", 636], ["insight", 641], ["into", 649], ["the", 654], ["relation", 658], ["between", 667], ["tau", 675], ["and", 679], ["alpha", 683], ["-", 688], ["synuclein", 689], ["in", 699], ["LBs", 702], [",", 705], ["double", 707], ["immunostaining", 714], ["was", 729], ["performed", 733], ["in", 743], ["Lewy", 746], ["body", 751], ["cases", 756], ["with", 762], ["a", 767], ["rabbit", 769], ["polyclonal", 776], ["antibody", 787], ["to", 796], ["alpha", 799], ["-", 804], ["synuclein", 805], ["and", 815], ["a", 819], ["panel", 821], ["of", 827], ["monoclonal", 830], ["antibodies", 841], ["to", 852], ["phospho-", 855], ["and", 864], ["nonphospho", 868], ["-", 878], ["tau", 879], ["epitopes", 883], ["(", 892], ["Alz50", 893], [",", 898], ["CP9", 900], [",", 903], ["CP13", 905], [",", 909], ["PG5", 911], [",", 914], ["TG3", 916], [",", 919], ["PHFI", 921], [")", 925], ["that", 927], ["spanned", 932], ["the", 940], ["length", 944], ["of", 951], ["the", 954], ["tau", 958], ["molecule", 962], [".", 970], ["Tau", 972], ["-", 975], ["immunoreactive", 976], ["LBs", 991], ["were", 995], ["present", 1000], ["in", 1008], ["the", 1011], ["medulla", 1015], ["in", 1023], ["80", 1026], ["%", 1028], ["of", 1030], ["the", 1033], ["cases", 1037], [",", 1042], ["irrespective", 1044], ["of", 1057], ["Braak", 1060], ["stage", 1066], [".", 1071], ["All", 1073], ["tau", 1077], ["antibodies", 1081], ["recognized", 1092], ["at", 1103], ["least", 1106], ["some", 1112], ["LBs", 1117], [",", 1120], ["arguing", 1122], ["against", 1130], ["nonspecific", 1138], ["antibody", 1150], ["cross", 1159], ["-", 1164], ["reactivity", 1165], [".", 1175], ["In", 1177], ["most", 1180], ["lesions", 1185], ["the", 1193], ["tau", 1197], ["immunostaining", 1201], ["was", 1216], ["present", 1220], ["at", 1228], ["the", 1231], ["periphery", 1235], ["of", 1245], ["the", 1248], ["LB", 1252], [".", 1254], ["The", 1256], ["phospho", 1260], ["-", 1267], ["tau", 1268], ["antibody", 1272], [",", 1280], ["TG3", 1282], [",", 1285], ["detected", 1287], ["more", 1296], ["LBs", 1301], ["than", 1305], ["any", 1310], ["of", 1314], ["the", 1317], ["other", 1321], ["tau", 1327], ["antibodies", 1331], [".", 1341], ["The", 1343], ["proportion", 1347], ["of", 1358], ["LBs", 1361], ["with", 1365], ["tau", 1370], ["immunoreactivity", 1374], ["was", 1391], ["greatest", 1395], ["in", 1404], ["neurons", 1407], ["vulnerable", 1415], ["to", 1426], ["NETs", 1429], [",", 1433], ["such", 1435], ["as", 1440], ["those", 1443], ["in", 1449], ["the", 1452], ["locus", 1456], ["ceruleus", 1462], ["and", 1471], ["basal", 1475], ["nucleus", 1481], ["of", 1489], ["Meynert", 1492], [",", 1499], ["and", 1501], ["least", 1505], ["in", 1511], ["neurons", 1514], ["resistant", 1522], ["to", 1532], ["NFTs", 1535], [",", 1539], ["such", 1541], ["as", 1546], ["the", 1549], ["dorsal", 1553], ["motor", 1560], ["nucleus", 1566], ["of", 1574], ["the", 1577], ["vagus", 1581], ["in", 1587], ["the", 1590], ["medulla", 1594], [".", 1601], ["The", 1603], ["present", 1607], ["results", 1615], ["suggest", 1623], ["that", 1631], ["tau", 1636], ["may", 1640], ["coaggregate", 1644], ["with", 1656], ["alpha", 1661], ["-", 1666], ["synuclein", 1667], ["in", 1677], ["LBs", 1680], [",", 1683], ["especially", 1685], ["in", 1696], ["neuronal", 1699], ["populations", 1708], ["vulnerable", 1720], ["to", 1731], ["both", 1734], ["NFTs", 1739], ["and", 1744], ["LBs", 1748], [".", 1751]]}
{"context": "We review the current evidence for medical and surgical treatments of spontaneous intracerebral hemorrhage (ICH). Therapy with hemostatic agents (e.g. factor VIIa and tranexamic acid) if started early after bleeding onset may reduce hematoma expansion, but their clinical effectiveness has not been shown. Rapid anticoagulation reversal with prothrombin concentrates (PCC) plus vitamin K is the first choice in vitamin K antagonist-related ICH. In ICH related to dabigatran, anticoagulation can be rapidly reversed with idarucizumab. PCC are recommended for ICH related to FXa inhibitors, whereas specific reversal agents are not yet approved. While awaiting ongoing trials studying minimally invasive approaches or hemicraniectomy, the role of surgery in ICH remains to be defined. Therapies targeting downstream molecular cascades in order to prevent secondary neuronal damage are promising, but the complexity and multi-phased nature of ICH pathophysiology is challenging. Finally, in addition to blood pressure control, antithrombotic prevention after ICH has to consider the risk of recurrent bleeding as well as the risk of ischemic events. Treatment of acute ICH remains challenging, and many promising interventions for acute ICH await further evidence from trials.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d40ca4a4e2a1425fbe7308353258a879", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[78, 78]], "char_spans": [[463, 472]]}]}], "context_tokens": [["We", 0], ["review", 3], ["the", 10], ["current", 14], ["evidence", 22], ["for", 31], ["medical", 35], ["and", 43], ["surgical", 47], ["treatments", 56], ["of", 67], ["spontaneous", 70], ["intracerebral", 82], ["hemorrhage", 96], ["(", 107], ["ICH", 108], [")", 111], [".", 112], ["Therapy", 114], ["with", 122], ["hemostatic", 127], ["agents", 138], ["(", 145], ["e.g.", 146], ["factor", 151], ["VIIa", 158], ["and", 163], ["tranexamic", 167], ["acid", 178], [")", 182], ["if", 184], ["started", 187], ["early", 195], ["after", 201], ["bleeding", 207], ["onset", 216], ["may", 222], ["reduce", 226], ["hematoma", 233], ["expansion", 242], [",", 251], ["but", 253], ["their", 257], ["clinical", 263], ["effectiveness", 272], ["has", 286], ["not", 290], ["been", 294], ["shown", 299], [".", 304], ["Rapid", 306], ["anticoagulation", 312], ["reversal", 328], ["with", 337], ["prothrombin", 342], ["concentrates", 354], ["(", 367], ["PCC", 368], [")", 371], ["plus", 373], ["vitamin", 378], ["K", 386], ["is", 388], ["the", 391], ["first", 395], ["choice", 401], ["in", 408], ["vitamin", 411], ["K", 419], ["antagonist", 421], ["-", 431], ["related", 432], ["ICH", 440], [".", 443], ["In", 445], ["ICH", 448], ["related", 452], ["to", 460], ["dabigatran", 463], [",", 473], ["anticoagulation", 475], ["can", 491], ["be", 495], ["rapidly", 498], ["reversed", 506], ["with", 515], ["idarucizumab", 520], [".", 532], ["PCC", 534], ["are", 538], ["recommended", 542], ["for", 554], ["ICH", 558], ["related", 562], ["to", 570], ["FXa", 573], ["inhibitors", 577], [",", 587], ["whereas", 589], ["specific", 597], ["reversal", 606], ["agents", 615], ["are", 622], ["not", 626], ["yet", 630], ["approved", 634], [".", 642], ["While", 644], ["awaiting", 650], ["ongoing", 659], ["trials", 667], ["studying", 674], ["minimally", 683], ["invasive", 693], ["approaches", 702], ["or", 713], ["hemicraniectomy", 716], [",", 731], ["the", 733], ["role", 737], ["of", 742], ["surgery", 745], ["in", 753], ["ICH", 756], ["remains", 760], ["to", 768], ["be", 771], ["defined", 774], [".", 781], ["Therapies", 783], ["targeting", 793], ["downstream", 803], ["molecular", 814], ["cascades", 824], ["in", 833], ["order", 836], ["to", 842], ["prevent", 845], ["secondary", 853], ["neuronal", 863], ["damage", 872], ["are", 879], ["promising", 883], [",", 892], ["but", 894], ["the", 898], ["complexity", 902], ["and", 913], ["multi", 917], ["-", 922], ["phased", 923], ["nature", 930], ["of", 937], ["ICH", 940], ["pathophysiology", 944], ["is", 960], ["challenging", 963], [".", 974], ["Finally", 976], [",", 983], ["in", 985], ["addition", 988], ["to", 997], ["blood", 1000], ["pressure", 1006], ["control", 1015], [",", 1022], ["antithrombotic", 1024], ["prevention", 1039], ["after", 1050], ["ICH", 1056], ["has", 1060], ["to", 1064], ["consider", 1067], ["the", 1076], ["risk", 1080], ["of", 1085], ["recurrent", 1088], ["bleeding", 1098], ["as", 1107], ["well", 1110], ["as", 1115], ["the", 1118], ["risk", 1122], ["of", 1127], ["ischemic", 1130], ["events", 1139], [".", 1145], ["Treatment", 1147], ["of", 1157], ["acute", 1160], ["ICH", 1166], ["remains", 1170], ["challenging", 1178], [",", 1189], ["and", 1191], ["many", 1195], ["promising", 1200], ["interventions", 1210], ["for", 1224], ["acute", 1228], ["ICH", 1234], ["await", 1238], ["further", 1244], ["evidence", 1252], ["from", 1261], ["trials", 1266], [".", 1272]]}
{"context": "H2A.Z is a highly conserved variant of histone H2A with well-characterized roles in transcriptional regulation. We previously reported that H2A.Z and Mcd1, a subunit of the cohesin complex, regulate the establishment of transcriptional silencing at telomeres in Saccharomyces cerevisiae and that H2A.Z broadly dissociated from chromatin during the anaphase-to-telophase transition, coincident with the dissociation of Mcd1 from chromosomes and dissolution of cohesion. In this study, we show that depletion of H2A.Z causes precocious loss of sister chromatid cohesion in yeast without loss of Mcd1 from chromosomes. H2A.Z is deposited into chromatin by the SWR1 complex and is subject to acetylation of its four N-terminal tail lysine residues by the NuA4 and SAGA histone acetyltransferase complexes. We found that cells compromised for function of the SWR1 complex were defective in cohesion, as were cells expressing a form of H2A.Z not subject to acetylation. Finally, inactivation of H2A.Z in metaphase-blocked cells led immediately to cohesion defects, suggesting a direct role for H2A.Z in the maintenance of sister chromatid cohesion.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "4ef05543761e4948b74e9fa078a5e4bc", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[140, 140], [106, 106]], "char_spans": [[854, 857], [657, 660]]}]}], "context_tokens": [["H2A.Z", 0], ["is", 6], ["a", 9], ["highly", 11], ["conserved", 18], ["variant", 28], ["of", 36], ["histone", 39], ["H2A", 47], ["with", 51], ["well", 56], ["-", 60], ["characterized", 61], ["roles", 75], ["in", 81], ["transcriptional", 84], ["regulation", 100], [".", 110], ["We", 112], ["previously", 115], ["reported", 126], ["that", 135], ["H2A.Z", 140], ["and", 146], ["Mcd1", 150], [",", 154], ["a", 156], ["subunit", 158], ["of", 166], ["the", 169], ["cohesin", 173], ["complex", 181], [",", 188], ["regulate", 190], ["the", 199], ["establishment", 203], ["of", 217], ["transcriptional", 220], ["silencing", 236], ["at", 246], ["telomeres", 249], ["in", 259], ["Saccharomyces", 262], ["cerevisiae", 276], ["and", 287], ["that", 291], ["H2A.Z", 296], ["broadly", 302], ["dissociated", 310], ["from", 322], ["chromatin", 327], ["during", 337], ["the", 344], ["anaphase", 348], ["-", 356], ["to", 357], ["-", 359], ["telophase", 360], ["transition", 370], [",", 380], ["coincident", 382], ["with", 393], ["the", 398], ["dissociation", 402], ["of", 415], ["Mcd1", 418], ["from", 423], ["chromosomes", 428], ["and", 440], ["dissolution", 444], ["of", 456], ["cohesion", 459], [".", 467], ["In", 469], ["this", 472], ["study", 477], [",", 482], ["we", 484], ["show", 487], ["that", 492], ["depletion", 497], ["of", 507], ["H2A.Z", 510], ["causes", 516], ["precocious", 523], ["loss", 534], ["of", 539], ["sister", 542], ["chromatid", 549], ["cohesion", 559], ["in", 568], ["yeast", 571], ["without", 577], ["loss", 585], ["of", 590], ["Mcd1", 593], ["from", 598], ["chromosomes", 603], [".", 614], ["H2A.Z", 616], ["is", 622], ["deposited", 625], ["into", 635], ["chromatin", 640], ["by", 650], ["the", 653], ["SWR1", 657], ["complex", 662], ["and", 670], ["is", 674], ["subject", 677], ["to", 685], ["acetylation", 688], ["of", 700], ["its", 703], ["four", 707], ["N", 712], ["-", 713], ["terminal", 714], ["tail", 723], ["lysine", 728], ["residues", 735], ["by", 744], ["the", 747], ["NuA4", 751], ["and", 756], ["SAGA", 760], ["histone", 765], ["acetyltransferase", 773], ["complexes", 791], [".", 800], ["We", 802], ["found", 805], ["that", 811], ["cells", 816], ["compromised", 822], ["for", 834], ["function", 838], ["of", 847], ["the", 850], ["SWR1", 854], ["complex", 859], ["were", 867], ["defective", 872], ["in", 882], ["cohesion", 885], [",", 893], ["as", 895], ["were", 898], ["cells", 903], ["expressing", 909], ["a", 920], ["form", 922], ["of", 927], ["H2A.Z", 930], ["not", 936], ["subject", 940], ["to", 948], ["acetylation", 951], [".", 962], ["Finally", 964], [",", 971], ["inactivation", 973], ["of", 986], ["H2A.Z", 989], ["in", 995], ["metaphase", 998], ["-", 1007], ["blocked", 1008], ["cells", 1016], ["led", 1022], ["immediately", 1026], ["to", 1038], ["cohesion", 1041], ["defects", 1050], [",", 1057], ["suggesting", 1059], ["a", 1070], ["direct", 1072], ["role", 1079], ["for", 1084], ["H2A.Z", 1088], ["in", 1094], ["the", 1097], ["maintenance", 1101], ["of", 1113], ["sister", 1116], ["chromatid", 1123], ["cohesion", 1133], [".", 1141]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "2c9a3ae9437648e1834a87d46d29cd29", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "Mammalian selenium-containing proteins identified thus far contain selenium in the form of a selenocysteine residue encoded by UGA. These proteins lack common amino acid sequence motifs, but 3'-untranslated regions of selenoprotein genes contain a common stem-loop structure, selenocysteine insertion sequence (SECIS) element, that is necessary for decoding UGA as selenocysteine rather than a stop signal. We describe here a computer program, SECISearch, that identifies mammalian selenoprotein genes by recognizing SECIS elements on the basis of their primary and secondary structures and free energy requirements. When SECISearch was applied to search human dbEST, two new mammalian selenoproteins, designated SelT and SelR, were identified. We determined their cDNA sequences and expressed them in a monkey cell line as fusion proteins with a green fluorescent protein. Incorporation of selenium into new proteins was confirmed by metabolic labeling with (75)Se, and expression of SelT was additionally documented in immunoblot assays. SelT and SelR did not have homology to previously characterized proteins, but their putative homologs were detected in various organisms. SelR homologs were present in every organism characterized by complete genome sequencing. The data suggest applicability of SECISearch for identification of new selenoprotein genes in nucleotide data bases.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d1597667c614526ba0ceede9a3ecc54", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[48, 48], [82, 82]], "char_spans": [[311, 315], [517, 521]]}]}], "context_tokens": [["Mammalian", 0], ["selenium", 10], ["-", 18], ["containing", 19], ["proteins", 30], ["identified", 39], ["thus", 50], ["far", 55], ["contain", 59], ["selenium", 67], ["in", 76], ["the", 79], ["form", 83], ["of", 88], ["a", 91], ["selenocysteine", 93], ["residue", 108], ["encoded", 116], ["by", 124], ["UGA", 127], [".", 130], ["These", 132], ["proteins", 138], ["lack", 147], ["common", 152], ["amino", 159], ["acid", 165], ["sequence", 170], ["motifs", 179], [",", 185], ["but", 187], ["3'-untranslated", 191], ["regions", 207], ["of", 215], ["selenoprotein", 218], ["genes", 232], ["contain", 238], ["a", 246], ["common", 248], ["stem", 255], ["-", 259], ["loop", 260], ["structure", 265], [",", 274], ["selenocysteine", 276], ["insertion", 291], ["sequence", 301], ["(", 310], ["SECIS", 311], [")", 316], ["element", 318], [",", 325], ["that", 327], ["is", 332], ["necessary", 335], ["for", 345], ["decoding", 349], ["UGA", 358], ["as", 362], ["selenocysteine", 365], ["rather", 380], ["than", 387], ["a", 392], ["stop", 394], ["signal", 399], [".", 405], ["We", 407], ["describe", 410], ["here", 419], ["a", 424], ["computer", 426], ["program", 435], [",", 442], ["SECISearch", 444], [",", 454], ["that", 456], ["identifies", 461], ["mammalian", 472], ["selenoprotein", 482], ["genes", 496], ["by", 502], ["recognizing", 505], ["SECIS", 517], ["elements", 523], ["on", 532], ["the", 535], ["basis", 539], ["of", 545], ["their", 548], ["primary", 554], ["and", 562], ["secondary", 566], ["structures", 576], ["and", 587], ["free", 591], ["energy", 596], ["requirements", 603], [".", 615], ["When", 617], ["SECISearch", 622], ["was", 633], ["applied", 637], ["to", 645], ["search", 648], ["human", 655], ["dbEST", 661], [",", 666], ["two", 668], ["new", 672], ["mammalian", 676], ["selenoproteins", 686], [",", 700], ["designated", 702], ["SelT", 713], ["and", 718], ["SelR", 722], [",", 726], ["were", 728], ["identified", 733], [".", 743], ["We", 745], ["determined", 748], ["their", 759], ["cDNA", 765], ["sequences", 770], ["and", 780], ["expressed", 784], ["them", 794], ["in", 799], ["a", 802], ["monkey", 804], ["cell", 811], ["line", 816], ["as", 821], ["fusion", 824], ["proteins", 831], ["with", 840], ["a", 845], ["green", 847], ["fluorescent", 853], ["protein", 865], [".", 872], ["Incorporation", 874], ["of", 888], ["selenium", 891], ["into", 900], ["new", 905], ["proteins", 909], ["was", 918], ["confirmed", 922], ["by", 932], ["metabolic", 935], ["labeling", 945], ["with", 954], ["(", 959], ["75)Se", 960], [",", 965], ["and", 967], ["expression", 971], ["of", 982], ["SelT", 985], ["was", 990], ["additionally", 994], ["documented", 1007], ["in", 1018], ["immunoblot", 1021], ["assays", 1032], [".", 1038], ["SelT", 1040], ["and", 1045], ["SelR", 1049], ["did", 1054], ["not", 1058], ["have", 1062], ["homology", 1067], ["to", 1076], ["previously", 1079], ["characterized", 1090], ["proteins", 1104], [",", 1112], ["but", 1114], ["their", 1118], ["putative", 1124], ["homologs", 1133], ["were", 1142], ["detected", 1147], ["in", 1156], ["various", 1159], ["organisms", 1167], [".", 1176], ["SelR", 1178], ["homologs", 1183], ["were", 1192], ["present", 1197], ["in", 1205], ["every", 1208], ["organism", 1214], ["characterized", 1223], ["by", 1237], ["complete", 1240], ["genome", 1249], ["sequencing", 1256], [".", 1266], ["The", 1268], ["data", 1272], ["suggest", 1277], ["applicability", 1285], ["of", 1299], ["SECISearch", 1302], ["for", 1313], ["identification", 1317], ["of", 1332], ["new", 1335], ["selenoprotein", 1339], ["genes", 1353], ["in", 1359], ["nucleotide", 1362], ["data", 1373], ["bases", 1378], [".", 1383]]}
{"context": "Chronic inflammation contributes to a wide variety of human disorders. In the stomach, longstanding gastritis often results in structural alterations in the gastric mucosa, including metaplastic changes and gastric cancers. Therefore, it is important to elucidate factors that are involved in gastric inflammation. Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins. Here, we have demonstrated that Nrdc crucially regulates gastric inflammation caused by Helicobacter felis infection or forced expression of prostaglandin E", "qas": [{"question": "Which is the enzymatic activity of nardilysin?", "answers": ["Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins."], "qid": "133771e8d5b9448681074f5d120771a8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["nardilysin", 35], ["?", 45]], "detected_answers": [{"text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.", "token_spans": [[49, 93]], "char_spans": [[315, 595]]}]}], "context_tokens": [["Chronic", 0], ["inflammation", 8], ["contributes", 21], ["to", 33], ["a", 36], ["wide", 38], ["variety", 43], ["of", 51], ["human", 54], ["disorders", 60], [".", 69], ["In", 71], ["the", 74], ["stomach", 78], [",", 85], ["longstanding", 87], ["gastritis", 100], ["often", 110], ["results", 116], ["in", 124], ["structural", 127], ["alterations", 138], ["in", 150], ["the", 153], ["gastric", 157], ["mucosa", 165], [",", 171], ["including", 173], ["metaplastic", 183], ["changes", 195], ["and", 203], ["gastric", 207], ["cancers", 215], [".", 222], ["Therefore", 224], [",", 233], ["it", 235], ["is", 238], ["important", 241], ["to", 251], ["elucidate", 254], ["factors", 264], ["that", 272], ["are", 277], ["involved", 281], ["in", 290], ["gastric", 293], ["inflammation", 301], [".", 313], ["Nardilysin", 315], ["(", 326], ["N", 327], ["-", 328], ["arginine", 329], ["dibasic", 338], ["convertase", 346], [";", 356], ["Nrdc", 358], [")", 362], ["is", 364], ["a", 367], ["metalloendopeptidase", 369], ["of", 390], ["the", 393], ["M16", 397], ["family", 401], ["that", 408], ["promotes", 413], ["ectodomain", 422], ["shedding", 433], ["of", 442], ["the", 445], ["precursor", 449], ["forms", 459], ["of", 465], ["various", 468], ["growth", 476], ["factors", 483], ["and", 491], ["cytokines", 495], ["by", 505], ["enhancing", 508], ["the", 518], ["protease", 522], ["activities", 531], ["of", 542], ["a", 545], ["disintegrin", 547], ["and", 559], ["metalloproteinase", 563], ["(", 581], ["ADAM", 582], [")", 586], ["proteins", 588], [".", 596], ["Here", 598], [",", 602], ["we", 604], ["have", 607], ["demonstrated", 612], ["that", 625], ["Nrdc", 630], ["crucially", 635], ["regulates", 645], ["gastric", 655], ["inflammation", 663], ["caused", 676], ["by", 683], ["Helicobacter", 686], ["felis", 699], ["infection", 705], ["or", 715], ["forced", 718], ["expression", 725], ["of", 736], ["prostaglandin", 739], ["E", 753]]}
{"context": "The Romano-Ward long-QT Syndrome (LQTS) is an autosomal dominant inherited trait characterized by prolonged QT interval on ECG, life-threatening arrhythmias, syncope, and sudden death in affected individuals. A gene responsible for this disorder has been shown to be linked to the Harvey ras-1 locus (H-ras-1) DNA marker on the short arm of chromosome 11 (11p) in 7 families. The purpose of this study was to determine, by analyzing 23 families with LQTS for linkage to chromosome 11p, whether evidence exists for more than one gene causing LQTS (ie, locus heterogeneity). Twenty-three families (262 family members) were clinically evaluated using medical histories, ECGs, and Holter recordings. Each corrected QT interval (QTc) were determined using Bazett's formula. Blood for DNA extraction and cell line immortalization was obtained after informed consent. Southern blotting and polymerase chain reaction were performed, and linkage analysis carried out using the LINKAGE computer program (v 5.03). Genetic heterogeneity was determined using the HOMOG 2 (v 2.51) computer program. Twenty-three families were studied for evidence of linkage to chromosome 11p using the H-ras-1 locus probe pTBB-2 and multiple flanking markers, including tyrosine hydroxylase (TH). Two-point linkage analysis using pTBB-2 and TH markers was consistent with linkage in 15 of 23 families, with the maximum single-family LOD score of +3.038 occurring at theta = 0. However, 8 of 23 families had negative LOD scores, with the values in 4 families being less than -2 at theta = 0, consistent with exclusion of linkage. Analysis with the HOMOG program was consistent with genetic heterogeneity (P < .0001). Multipoint linkage data using pTBB-2 and TH were also examined for evidence of heterogeneity. HOMOG analysis of multipoint LOD scores from 100 cM surrounding the H-ras-1 locus also supported heterogeneity (P < .001). In the 23 families with LQTS analyzed for linkage to the H-ras-1 locus on chromosome 11p15.5, 15 of 23 families had LOD scores consistent with linkage. The remaining 8 of 23 families had negative LOD scores, 4 of which were definitively excluded from linkage. Thus, genetic heterogeneity is definitively (P < .001) demonstrated for this disorder.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "16cda57d6f444810a77096b293729095", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[13, 14]], "char_spans": [[46, 63]]}]}], "context_tokens": [["The", 0], ["Romano", 4], ["-", 10], ["Ward", 11], ["long", 16], ["-", 20], ["QT", 21], ["Syndrome", 24], ["(", 33], ["LQTS", 34], [")", 38], ["is", 40], ["an", 43], ["autosomal", 46], ["dominant", 56], ["inherited", 65], ["trait", 75], ["characterized", 81], ["by", 95], ["prolonged", 98], ["QT", 108], ["interval", 111], ["on", 120], ["ECG", 123], [",", 126], ["life", 128], ["-", 132], ["threatening", 133], ["arrhythmias", 145], [",", 156], ["syncope", 158], [",", 165], ["and", 167], ["sudden", 171], ["death", 178], ["in", 184], ["affected", 187], ["individuals", 196], [".", 207], ["A", 209], ["gene", 211], ["responsible", 216], ["for", 228], ["this", 232], ["disorder", 237], ["has", 246], ["been", 250], ["shown", 255], ["to", 261], ["be", 264], ["linked", 267], ["to", 274], ["the", 277], ["Harvey", 281], ["ras-1", 288], ["locus", 294], ["(", 300], ["H", 301], ["-", 302], ["ras-1", 303], [")", 308], ["DNA", 310], ["marker", 314], ["on", 321], ["the", 324], ["short", 328], ["arm", 334], ["of", 338], ["chromosome", 341], ["11", 352], ["(", 355], ["11p", 356], [")", 359], ["in", 361], ["7", 364], ["families", 366], [".", 374], ["The", 376], ["purpose", 380], ["of", 388], ["this", 391], ["study", 396], ["was", 402], ["to", 406], ["determine", 409], [",", 418], ["by", 420], ["analyzing", 423], ["23", 433], ["families", 436], ["with", 445], ["LQTS", 450], ["for", 455], ["linkage", 459], ["to", 467], ["chromosome", 470], ["11p", 481], [",", 484], ["whether", 486], ["evidence", 494], ["exists", 503], ["for", 510], ["more", 514], ["than", 519], ["one", 524], ["gene", 528], ["causing", 533], ["LQTS", 541], ["(", 546], ["ie", 547], [",", 549], ["locus", 551], ["heterogeneity", 557], [")", 570], [".", 571], ["Twenty", 573], ["-", 579], ["three", 580], ["families", 586], ["(", 595], ["262", 596], ["family", 600], ["members", 607], [")", 614], ["were", 616], ["clinically", 621], ["evaluated", 632], ["using", 642], ["medical", 648], ["histories", 656], [",", 665], ["ECGs", 667], [",", 671], ["and", 673], ["Holter", 677], ["recordings", 684], [".", 694], ["Each", 696], ["corrected", 701], ["QT", 711], ["interval", 714], ["(", 723], ["QTc", 724], [")", 727], ["were", 729], ["determined", 734], ["using", 745], ["Bazett", 751], ["'s", 757], ["formula", 760], [".", 767], ["Blood", 769], ["for", 775], ["DNA", 779], ["extraction", 783], ["and", 794], ["cell", 798], ["line", 803], ["immortalization", 808], ["was", 824], ["obtained", 828], ["after", 837], ["informed", 843], ["consent", 852], [".", 859], ["Southern", 861], ["blotting", 870], ["and", 879], ["polymerase", 883], ["chain", 894], ["reaction", 900], ["were", 909], ["performed", 914], [",", 923], ["and", 925], ["linkage", 929], ["analysis", 937], ["carried", 946], ["out", 954], ["using", 958], ["the", 964], ["LINKAGE", 968], ["computer", 976], ["program", 985], ["(", 993], ["v", 994], ["5.03", 996], [")", 1000], [".", 1001], ["Genetic", 1003], ["heterogeneity", 1011], ["was", 1025], ["determined", 1029], ["using", 1040], ["the", 1046], ["HOMOG", 1050], ["2", 1056], ["(", 1058], ["v", 1059], ["2.51", 1061], [")", 1065], ["computer", 1067], ["program", 1076], [".", 1083], ["Twenty", 1085], ["-", 1091], ["three", 1092], ["families", 1098], ["were", 1107], ["studied", 1112], ["for", 1120], ["evidence", 1124], ["of", 1133], ["linkage", 1136], ["to", 1144], ["chromosome", 1147], ["11p", 1158], ["using", 1162], ["the", 1168], ["H", 1172], ["-", 1173], ["ras-1", 1174], ["locus", 1180], ["probe", 1186], ["pTBB-2", 1192], ["and", 1199], ["multiple", 1203], ["flanking", 1212], ["markers", 1221], [",", 1228], ["including", 1230], ["tyrosine", 1240], ["hydroxylase", 1249], ["(", 1261], ["TH", 1262], [")", 1264], [".", 1265], ["Two", 1267], ["-", 1270], ["point", 1271], ["linkage", 1277], ["analysis", 1285], ["using", 1294], ["pTBB-2", 1300], ["and", 1307], ["TH", 1311], ["markers", 1314], ["was", 1322], ["consistent", 1326], ["with", 1337], ["linkage", 1342], ["in", 1350], ["15", 1353], ["of", 1356], ["23", 1359], ["families", 1362], [",", 1370], ["with", 1372], ["the", 1377], ["maximum", 1381], ["single", 1389], ["-", 1395], ["family", 1396], ["LOD", 1403], ["score", 1407], ["of", 1413], ["+3.038", 1416], ["occurring", 1423], ["at", 1433], ["theta", 1436], ["=", 1442], ["0", 1444], [".", 1445], ["However", 1447], [",", 1454], ["8", 1456], ["of", 1458], ["23", 1461], ["families", 1464], ["had", 1473], ["negative", 1477], ["LOD", 1486], ["scores", 1490], [",", 1496], ["with", 1498], ["the", 1503], ["values", 1507], ["in", 1514], ["4", 1517], ["families", 1519], ["being", 1528], ["less", 1534], ["than", 1539], ["-2", 1544], ["at", 1547], ["theta", 1550], ["=", 1556], ["0", 1558], [",", 1559], ["consistent", 1561], ["with", 1572], ["exclusion", 1577], ["of", 1587], ["linkage", 1590], [".", 1597], ["Analysis", 1599], ["with", 1608], ["the", 1613], ["HOMOG", 1617], ["program", 1623], ["was", 1631], ["consistent", 1635], ["with", 1646], ["genetic", 1651], ["heterogeneity", 1659], ["(", 1673], ["P", 1674], ["<", 1676], [".0001", 1678], [")", 1683], [".", 1684], ["Multipoint", 1686], ["linkage", 1697], ["data", 1705], ["using", 1710], ["pTBB-2", 1716], ["and", 1723], ["TH", 1727], ["were", 1730], ["also", 1735], ["examined", 1740], ["for", 1749], ["evidence", 1753], ["of", 1762], ["heterogeneity", 1765], [".", 1778], ["HOMOG", 1780], ["analysis", 1786], ["of", 1795], ["multipoint", 1798], ["LOD", 1809], ["scores", 1813], ["from", 1820], ["100", 1825], ["cM", 1829], ["surrounding", 1832], ["the", 1844], ["H", 1848], ["-", 1849], ["ras-1", 1850], ["locus", 1856], ["also", 1862], ["supported", 1867], ["heterogeneity", 1877], ["(", 1891], ["P", 1892], ["<", 1894], [".001", 1896], [")", 1900], [".", 1901], ["In", 1903], ["the", 1906], ["23", 1910], ["families", 1913], ["with", 1922], ["LQTS", 1927], ["analyzed", 1932], ["for", 1941], ["linkage", 1945], ["to", 1953], ["the", 1956], ["H", 1960], ["-", 1961], ["ras-1", 1962], ["locus", 1968], ["on", 1974], ["chromosome", 1977], ["11p15.5", 1988], [",", 1995], ["15", 1997], ["of", 2000], ["23", 2003], ["families", 2006], ["had", 2015], ["LOD", 2019], ["scores", 2023], ["consistent", 2030], ["with", 2041], ["linkage", 2046], [".", 2053], ["The", 2055], ["remaining", 2059], ["8", 2069], ["of", 2071], ["23", 2074], ["families", 2077], ["had", 2086], ["negative", 2090], ["LOD", 2099], ["scores", 2103], [",", 2109], ["4", 2111], ["of", 2113], ["which", 2116], ["were", 2122], ["definitively", 2127], ["excluded", 2140], ["from", 2149], ["linkage", 2154], [".", 2161], ["Thus", 2163], [",", 2167], ["genetic", 2169], ["heterogeneity", 2177], ["is", 2191], ["definitively", 2194], ["(", 2207], ["P", 2208], ["<", 2210], [".001", 2212], [")", 2216], ["demonstrated", 2218], ["for", 2231], ["this", 2235], ["disorder", 2240], [".", 2248]]}
{"context": "X monosomic mice (39,XO) have a remarkably mild phenotype when compared to women with Turner syndrome (45,XO). The generally accepted hypothesis to explain this discrepancy is that the number of genes on the mouse X chromosome which escape X inactivation, and thus are expressed at higher levels in females, is very small. However this hypothesis has never been tested and only a small number of genes have been assayed for their X-inactivation status in the mouse. We performed a global expression analysis in four somatic tissues (brain, liver, kidney and muscle) of adult 40,XX and 39,XO mice using the Illumina Mouse WG-6 v1_1 Expression BeadChip and an extensive validation by quantitative real time PCR, in order to identify which genes are expressed from both X chromosomes. We identified several genes on the X chromosome which are overexpressed in XX females, including those previously reported as escaping X inactivation, as well as new candidates. However, the results obtained by microarray and qPCR were not fully concordant, illustrating the difficulty in ascertaining modest fold changes, such as those expected for genes escaping X inactivation. Remarkably, considerable variation was observed between tissues, suggesting that inactivation patterns may be tissue-dependent. Our analysis also exposed several autosomal genes involved in mitochondrial metabolism and in protein translation which are differentially expressed between XX and XO mice, revealing secondary transcriptional changes to the alteration in X chromosome dosage. Our results support the prediction that the mouse inactive X chromosome is largely silent, while providing a list of the genes potentially escaping X inactivation in rodents. Although the lower expression of X-linked genes in XO mice may not be relevant in the particular tissues/systems which are affected in human X chromosome monosomy, genes deregulated in XO mice are good candidates for further study in an involvement in Turner Syndrome phenotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "f60eb4dfa5774b8c8a56567d0989deff", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[0, 0], [43, 43], [149, 149], [203, 203], [286, 286], [140, 140], [164, 164], [39, 39], [296, 296], [318, 318], [258, 258], [79, 79], [271, 271]], "char_spans": [[0, 0], [240, 240], [817, 817], [1147, 1147], [1698, 1698], [767, 767], [917, 917], [214, 214], [1758, 1758], [1866, 1866], [1529, 1529], [430, 430], [1609, 1609]]}]}], "context_tokens": [["X", 0], ["monosomic", 2], ["mice", 12], ["(", 17], ["39,XO", 18], [")", 23], ["have", 25], ["a", 30], ["remarkably", 32], ["mild", 43], ["phenotype", 48], ["when", 58], ["compared", 63], ["to", 72], ["women", 75], ["with", 81], ["Turner", 86], ["syndrome", 93], ["(", 102], ["45,XO", 103], [")", 108], [".", 109], ["The", 111], ["generally", 115], ["accepted", 125], ["hypothesis", 134], ["to", 145], ["explain", 148], ["this", 156], ["discrepancy", 161], ["is", 173], ["that", 176], ["the", 181], ["number", 185], ["of", 192], ["genes", 195], ["on", 201], ["the", 204], ["mouse", 208], ["X", 214], ["chromosome", 216], ["which", 227], ["escape", 233], ["X", 240], ["inactivation", 242], [",", 254], ["and", 256], ["thus", 260], ["are", 265], ["expressed", 269], ["at", 279], ["higher", 282], ["levels", 289], ["in", 296], ["females", 299], [",", 306], ["is", 308], ["very", 311], ["small", 316], [".", 321], ["However", 323], ["this", 331], ["hypothesis", 336], ["has", 347], ["never", 351], ["been", 357], ["tested", 362], ["and", 369], ["only", 373], ["a", 378], ["small", 380], ["number", 386], ["of", 393], ["genes", 396], ["have", 402], ["been", 407], ["assayed", 412], ["for", 420], ["their", 424], ["X", 430], ["-", 431], ["inactivation", 432], ["status", 445], ["in", 452], ["the", 455], ["mouse", 459], [".", 464], ["We", 466], ["performed", 469], ["a", 479], ["global", 481], ["expression", 488], ["analysis", 499], ["in", 508], ["four", 511], ["somatic", 516], ["tissues", 524], ["(", 532], ["brain", 533], [",", 538], ["liver", 540], [",", 545], ["kidney", 547], ["and", 554], ["muscle", 558], [")", 564], ["of", 566], ["adult", 569], ["40,XX", 575], ["and", 581], ["39,XO", 585], ["mice", 591], ["using", 596], ["the", 602], ["Illumina", 606], ["Mouse", 615], ["WG-6", 621], ["v1_1", 626], ["Expression", 631], ["BeadChip", 642], ["and", 651], ["an", 655], ["extensive", 658], ["validation", 668], ["by", 679], ["quantitative", 682], ["real", 695], ["time", 700], ["PCR", 705], [",", 708], ["in", 710], ["order", 713], ["to", 719], ["identify", 722], ["which", 731], ["genes", 737], ["are", 743], ["expressed", 747], ["from", 757], ["both", 762], ["X", 767], ["chromosomes", 769], [".", 780], ["We", 782], ["identified", 785], ["several", 796], ["genes", 804], ["on", 810], ["the", 813], ["X", 817], ["chromosome", 819], ["which", 830], ["are", 836], ["overexpressed", 840], ["in", 854], ["XX", 857], ["females", 860], [",", 867], ["including", 869], ["those", 879], ["previously", 885], ["reported", 896], ["as", 905], ["escaping", 908], ["X", 917], ["inactivation", 919], [",", 931], ["as", 933], ["well", 936], ["as", 941], ["new", 944], ["candidates", 948], [".", 958], ["However", 960], [",", 967], ["the", 969], ["results", 973], ["obtained", 981], ["by", 990], ["microarray", 993], ["and", 1004], ["qPCR", 1008], ["were", 1013], ["not", 1018], ["fully", 1022], ["concordant", 1028], [",", 1038], ["illustrating", 1040], ["the", 1053], ["difficulty", 1057], ["in", 1068], ["ascertaining", 1071], ["modest", 1084], ["fold", 1091], ["changes", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["those", 1113], ["expected", 1119], ["for", 1128], ["genes", 1132], ["escaping", 1138], ["X", 1147], ["inactivation", 1149], [".", 1161], ["Remarkably", 1163], [",", 1173], ["considerable", 1175], ["variation", 1188], ["was", 1198], ["observed", 1202], ["between", 1211], ["tissues", 1219], [",", 1226], ["suggesting", 1228], ["that", 1239], ["inactivation", 1244], ["patterns", 1257], ["may", 1266], ["be", 1270], ["tissue", 1273], ["-", 1279], ["dependent", 1280], [".", 1289], ["Our", 1291], ["analysis", 1295], ["also", 1304], ["exposed", 1309], ["several", 1317], ["autosomal", 1325], ["genes", 1335], ["involved", 1341], ["in", 1350], ["mitochondrial", 1353], ["metabolism", 1367], ["and", 1378], ["in", 1382], ["protein", 1385], ["translation", 1393], ["which", 1405], ["are", 1411], ["differentially", 1415], ["expressed", 1430], ["between", 1440], ["XX", 1448], ["and", 1451], ["XO", 1455], ["mice", 1458], [",", 1462], ["revealing", 1464], ["secondary", 1474], ["transcriptional", 1484], ["changes", 1500], ["to", 1508], ["the", 1511], ["alteration", 1515], ["in", 1526], ["X", 1529], ["chromosome", 1531], ["dosage", 1542], [".", 1548], ["Our", 1550], ["results", 1554], ["support", 1562], ["the", 1570], ["prediction", 1574], ["that", 1585], ["the", 1590], ["mouse", 1594], ["inactive", 1600], ["X", 1609], ["chromosome", 1611], ["is", 1622], ["largely", 1625], ["silent", 1633], [",", 1639], ["while", 1641], ["providing", 1647], ["a", 1657], ["list", 1659], ["of", 1664], ["the", 1667], ["genes", 1671], ["potentially", 1677], ["escaping", 1689], ["X", 1698], ["inactivation", 1700], ["in", 1713], ["rodents", 1716], [".", 1723], ["Although", 1725], ["the", 1734], ["lower", 1738], ["expression", 1744], ["of", 1755], ["X", 1758], ["-", 1759], ["linked", 1760], ["genes", 1767], ["in", 1773], ["XO", 1776], ["mice", 1779], ["may", 1784], ["not", 1788], ["be", 1792], ["relevant", 1795], ["in", 1804], ["the", 1807], ["particular", 1811], ["tissues", 1822], ["/", 1829], ["systems", 1830], ["which", 1838], ["are", 1844], ["affected", 1848], ["in", 1857], ["human", 1860], ["X", 1866], ["chromosome", 1868], ["monosomy", 1879], [",", 1887], ["genes", 1889], ["deregulated", 1895], ["in", 1907], ["XO", 1910], ["mice", 1913], ["are", 1918], ["good", 1922], ["candidates", 1927], ["for", 1938], ["further", 1942], ["study", 1950], ["in", 1956], ["an", 1959], ["involvement", 1962], ["in", 1974], ["Turner", 1977], ["Syndrome", 1984], ["phenotype", 1993], [".", 2002]]}
{"context": "We report a novel mutation in the XK gene (XK) in a Japanese patient with McLeod syndrome. A 50-year-old man showed progressive muscular atrophy, choreic movement, elevated level of serum creatinine kinase, and acanthocytosis. The expression level of all the Kell antigens in erythrocyte was decreased and molecular analysis revealed a single-base (T) deletion at the nucleotide position 1095 in XK. This deletion caused a frameshift in translation, leading to a premature stop codon at the amino acid position 408. We conclude this single-base deletion causes defective Kx protein, which is responsible for the McLeod phenotype in this patient.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "682f059c5e1247ec92d678ce3cc5a4cc", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[7, 7], [73, 73], [10, 10]], "char_spans": [[34, 35], [396, 397], [43, 44]]}]}], "context_tokens": [["We", 0], ["report", 3], ["a", 10], ["novel", 12], ["mutation", 18], ["in", 27], ["the", 30], ["XK", 34], ["gene", 37], ["(", 42], ["XK", 43], [")", 45], ["in", 47], ["a", 50], ["Japanese", 52], ["patient", 61], ["with", 69], ["McLeod", 74], ["syndrome", 81], [".", 89], ["A", 91], ["50-year", 93], ["-", 100], ["old", 101], ["man", 105], ["showed", 109], ["progressive", 116], ["muscular", 128], ["atrophy", 137], [",", 144], ["choreic", 146], ["movement", 154], [",", 162], ["elevated", 164], ["level", 173], ["of", 179], ["serum", 182], ["creatinine", 188], ["kinase", 199], [",", 205], ["and", 207], ["acanthocytosis", 211], [".", 225], ["The", 227], ["expression", 231], ["level", 242], ["of", 248], ["all", 251], ["the", 255], ["Kell", 259], ["antigens", 264], ["in", 273], ["erythrocyte", 276], ["was", 288], ["decreased", 292], ["and", 302], ["molecular", 306], ["analysis", 316], ["revealed", 325], ["a", 334], ["single", 336], ["-", 342], ["base", 343], ["(", 348], ["T", 349], [")", 350], ["deletion", 352], ["at", 361], ["the", 364], ["nucleotide", 368], ["position", 379], ["1095", 388], ["in", 393], ["XK", 396], [".", 398], ["This", 400], ["deletion", 405], ["caused", 414], ["a", 421], ["frameshift", 423], ["in", 434], ["translation", 437], [",", 448], ["leading", 450], ["to", 458], ["a", 461], ["premature", 463], ["stop", 473], ["codon", 478], ["at", 484], ["the", 487], ["amino", 491], ["acid", 497], ["position", 502], ["408", 511], [".", 514], ["We", 516], ["conclude", 519], ["this", 528], ["single", 533], ["-", 539], ["base", 540], ["deletion", 545], ["causes", 554], ["defective", 561], ["Kx", 571], ["protein", 574], [",", 581], ["which", 583], ["is", 589], ["responsible", 592], ["for", 604], ["the", 608], ["McLeod", 612], ["phenotype", 619], ["in", 629], ["this", 632], ["patient", 637], [".", 644]]}
{"context": "Insulin is the cornerstone of type 1 diabetes mellitus (T1DM) therapy. However, it cannot achieve a delay in the onset or evolution of this condition, while cardiovascular morbidity remains an unquestionable threat. In this review, the authors discuss gevokizumab (XOMA 052), a recombinant monoclonal antibody that can neutralize human IL-1\u03b2 by binding to it. This is relevant, because this IL has been associated with \u03b2-cell toxicity in both diabetes types. Moreover, gevokizumab presents two major advantages: it spares IL-1\u03b1 and it exhibits favorable pharmacokinetic properties. Gevokizumab has already proven its safety and efficacy in improving glycemic control, \u03b2 cell function and inflammation markers in clinical trials in diabetic patients. Despite the very promising characteristics of gevokizumab, important questions remain to be answered. One important question is what to expect from a combination of this agent with insulin and if there is a subset of patients that might respond more favorably to treatment. We also need to know at what stage in the natural history of T1DM could gevokizumab be most efficacious, as well as its potential effects on cardiovascular outcomes.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "c44c66126f324ce3acbc22cbc8a73352", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[60, 60]], "char_spans": [[336, 340]]}]}], "context_tokens": [["Insulin", 0], ["is", 8], ["the", 11], ["cornerstone", 15], ["of", 27], ["type", 30], ["1", 35], ["diabetes", 37], ["mellitus", 46], ["(", 55], ["T1DM", 56], [")", 60], ["therapy", 62], [".", 69], ["However", 71], [",", 78], ["it", 80], ["can", 83], ["not", 86], ["achieve", 90], ["a", 98], ["delay", 100], ["in", 106], ["the", 109], ["onset", 113], ["or", 119], ["evolution", 122], ["of", 132], ["this", 135], ["condition", 140], [",", 149], ["while", 151], ["cardiovascular", 157], ["morbidity", 172], ["remains", 182], ["an", 190], ["unquestionable", 193], ["threat", 208], [".", 214], ["In", 216], ["this", 219], ["review", 224], [",", 230], ["the", 232], ["authors", 236], ["discuss", 244], ["gevokizumab", 252], ["(", 264], ["XOMA", 265], ["052", 270], [")", 273], [",", 274], ["a", 276], ["recombinant", 278], ["monoclonal", 290], ["antibody", 301], ["that", 310], ["can", 315], ["neutralize", 319], ["human", 330], ["IL-1\u03b2", 336], ["by", 342], ["binding", 345], ["to", 353], ["it", 356], [".", 358], ["This", 360], ["is", 365], ["relevant", 368], [",", 376], ["because", 378], ["this", 386], ["IL", 391], ["has", 394], ["been", 398], ["associated", 403], ["with", 414], ["\u03b2", 419], ["-", 420], ["cell", 421], ["toxicity", 426], ["in", 435], ["both", 438], ["diabetes", 443], ["types", 452], [".", 457], ["Moreover", 459], [",", 467], ["gevokizumab", 469], ["presents", 481], ["two", 490], ["major", 494], ["advantages", 500], [":", 510], ["it", 512], ["spares", 515], ["IL-1\u03b1", 522], ["and", 528], ["it", 532], ["exhibits", 535], ["favorable", 544], ["pharmacokinetic", 554], ["properties", 570], [".", 580], ["Gevokizumab", 582], ["has", 594], ["already", 598], ["proven", 606], ["its", 613], ["safety", 617], ["and", 624], ["efficacy", 628], ["in", 637], ["improving", 640], ["glycemic", 650], ["control", 659], [",", 666], ["\u03b2", 668], ["cell", 670], ["function", 675], ["and", 684], ["inflammation", 688], ["markers", 701], ["in", 709], ["clinical", 712], ["trials", 721], ["in", 728], ["diabetic", 731], ["patients", 740], [".", 748], ["Despite", 750], ["the", 758], ["very", 762], ["promising", 767], ["characteristics", 777], ["of", 793], ["gevokizumab", 796], [",", 807], ["important", 809], ["questions", 819], ["remain", 829], ["to", 836], ["be", 839], ["answered", 842], [".", 850], ["One", 852], ["important", 856], ["question", 866], ["is", 875], ["what", 878], ["to", 883], ["expect", 886], ["from", 893], ["a", 898], ["combination", 900], ["of", 912], ["this", 915], ["agent", 920], ["with", 926], ["insulin", 931], ["and", 939], ["if", 943], ["there", 946], ["is", 952], ["a", 955], ["subset", 957], ["of", 964], ["patients", 967], ["that", 976], ["might", 981], ["respond", 987], ["more", 995], ["favorably", 1000], ["to", 1010], ["treatment", 1013], [".", 1022], ["We", 1024], ["also", 1027], ["need", 1032], ["to", 1037], ["know", 1040], ["at", 1045], ["what", 1048], ["stage", 1053], ["in", 1059], ["the", 1062], ["natural", 1066], ["history", 1074], ["of", 1082], ["T1DM", 1085], ["could", 1090], ["gevokizumab", 1096], ["be", 1108], ["most", 1111], ["efficacious", 1116], [",", 1127], ["as", 1129], ["well", 1132], ["as", 1137], ["its", 1140], ["potential", 1144], ["effects", 1154], ["on", 1162], ["cardiovascular", 1165], ["outcomes", 1180], [".", 1188]]}
{"context": "Mutations and deletions of the NSD1 gene, located on chromosome 5q35, are responsible for over 90% of cases of Sotos syndrome. Fluorescent in situ hybridization analysis (FISH), MLPA or multiplex quantitative PCR allow detection of total/partial NSD1 deletions and direct sequencing allows detection of NSD1 mutations. We describe two boys with Sotos syndrome in whom PCR amplification and direct sequencing of the NSD1 gene identified two novel mutations not previously described: c.4736dupG in exon 12 and c.3938_3939insT in exon 7. In addition to the cardinal and major features of the syndrome (abnormal facial appearance, overgrowth, cardiac anomalies, renal anomalies, hypotonia, neonatal jaundice, seizures and brain MRI abnormalities) in both patients, one boy also had cryptorchidism and vertebral anomalies, features considered not common. Despite the wide range of possible combinations of phenotypic features, molecular analysis can correctly identify Sotos syndrome.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "da2112b55fe74ffe80afbc48f42143f7", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[5, 6], [72, 73]], "char_spans": [[31, 39], [415, 423]]}]}], "context_tokens": [["Mutations", 0], ["and", 10], ["deletions", 14], ["of", 24], ["the", 27], ["NSD1", 31], ["gene", 36], [",", 40], ["located", 42], ["on", 50], ["chromosome", 53], ["5q35", 64], [",", 68], ["are", 70], ["responsible", 74], ["for", 86], ["over", 90], ["90", 95], ["%", 97], ["of", 99], ["cases", 102], ["of", 108], ["Sotos", 111], ["syndrome", 117], [".", 125], ["Fluorescent", 127], ["in", 139], ["situ", 142], ["hybridization", 147], ["analysis", 161], ["(", 170], ["FISH", 171], [")", 175], [",", 176], ["MLPA", 178], ["or", 183], ["multiplex", 186], ["quantitative", 196], ["PCR", 209], ["allow", 213], ["detection", 219], ["of", 229], ["total", 232], ["/", 237], ["partial", 238], ["NSD1", 246], ["deletions", 251], ["and", 261], ["direct", 265], ["sequencing", 272], ["allows", 283], ["detection", 290], ["of", 300], ["NSD1", 303], ["mutations", 308], [".", 317], ["We", 319], ["describe", 322], ["two", 331], ["boys", 335], ["with", 340], ["Sotos", 345], ["syndrome", 351], ["in", 360], ["whom", 363], ["PCR", 368], ["amplification", 372], ["and", 386], ["direct", 390], ["sequencing", 397], ["of", 408], ["the", 411], ["NSD1", 415], ["gene", 420], ["identified", 425], ["two", 436], ["novel", 440], ["mutations", 446], ["not", 456], ["previously", 460], ["described", 471], [":", 480], ["c.4736dupG", 482], ["in", 493], ["exon", 496], ["12", 501], ["and", 504], ["c.3938_3939insT", 508], ["in", 524], ["exon", 527], ["7", 532], [".", 533], ["In", 535], ["addition", 538], ["to", 547], ["the", 550], ["cardinal", 554], ["and", 563], ["major", 567], ["features", 573], ["of", 582], ["the", 585], ["syndrome", 589], ["(", 598], ["abnormal", 599], ["facial", 608], ["appearance", 615], [",", 625], ["overgrowth", 627], [",", 637], ["cardiac", 639], ["anomalies", 647], [",", 656], ["renal", 658], ["anomalies", 664], [",", 673], ["hypotonia", 675], [",", 684], ["neonatal", 686], ["jaundice", 695], [",", 703], ["seizures", 705], ["and", 714], ["brain", 718], ["MRI", 724], ["abnormalities", 728], [")", 741], ["in", 743], ["both", 746], ["patients", 751], [",", 759], ["one", 761], ["boy", 765], ["also", 769], ["had", 774], ["cryptorchidism", 778], ["and", 793], ["vertebral", 797], ["anomalies", 807], [",", 816], ["features", 818], ["considered", 827], ["not", 838], ["common", 842], [".", 848], ["Despite", 850], ["the", 858], ["wide", 862], ["range", 867], ["of", 873], ["possible", 876], ["combinations", 885], ["of", 898], ["phenotypic", 901], ["features", 912], [",", 920], ["molecular", 922], ["analysis", 932], ["can", 941], ["correctly", 945], ["identify", 955], ["Sotos", 964], ["syndrome", 970], [".", 978]]}
{"context": "The expression of selenoproteins requires the translational recoding of the UGA stop codon to selenocysteine. In eukaryotes, this requires an RNA stem loop structure in the 3'-untranslated region, termed a selenocysteine insertion sequence (SECIS), and SECIS-binding protein 2 (SBP2). This study implicates SBP2 in dictating the hierarchy of selenoprotein expression, because it is the first to show that SBP2 distinguishes between SECIS elements in vitro. Using RNA electrophoretic mobility shift assays, we demonstrate that a naturally occurring mutation in SBP2, which correlates with abnormal thyroid hormone function in humans, lies within a novel, bipartite RNA-binding domain. This mutation alters the RNA binding affinity of SBP2 such that it no longer stably interacts with a subset of SECIS elements. Assays performed under competitive conditions to mimic intracellular conditions suggest that the differential affinity of SBP2 for various SECIS elements will determine the expression pattern of the selenoproteome. We hypothesize that the selective loss of a subset of selenoproteins, including some involved in thyroid hormone homeostasis, is responsible for the abnormal thyroid hormone metabolism previously observed in the affected individuals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "4a2ea59ce04b469fb5deddf4edb5b587", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[157, 157], [37, 37], [41, 41], [73, 73], [136, 136]], "char_spans": [[950, 954], [241, 245], [253, 257], [432, 436], [795, 799]]}]}], "context_tokens": [["The", 0], ["expression", 4], ["of", 15], ["selenoproteins", 18], ["requires", 33], ["the", 42], ["translational", 46], ["recoding", 60], ["of", 69], ["the", 72], ["UGA", 76], ["stop", 80], ["codon", 85], ["to", 91], ["selenocysteine", 94], [".", 108], ["In", 110], ["eukaryotes", 113], [",", 123], ["this", 125], ["requires", 130], ["an", 139], ["RNA", 142], ["stem", 146], ["loop", 151], ["structure", 156], ["in", 166], ["the", 169], ["3'-untranslated", 173], ["region", 189], [",", 195], ["termed", 197], ["a", 204], ["selenocysteine", 206], ["insertion", 221], ["sequence", 231], ["(", 240], ["SECIS", 241], [")", 246], [",", 247], ["and", 249], ["SECIS", 253], ["-", 258], ["binding", 259], ["protein", 267], ["2", 275], ["(", 277], ["SBP2", 278], [")", 282], [".", 283], ["This", 285], ["study", 290], ["implicates", 296], ["SBP2", 307], ["in", 312], ["dictating", 315], ["the", 325], ["hierarchy", 329], ["of", 339], ["selenoprotein", 342], ["expression", 356], [",", 366], ["because", 368], ["it", 376], ["is", 379], ["the", 382], ["first", 386], ["to", 392], ["show", 395], ["that", 400], ["SBP2", 405], ["distinguishes", 410], ["between", 424], ["SECIS", 432], ["elements", 438], ["in", 447], ["vitro", 450], [".", 455], ["Using", 457], ["RNA", 463], ["electrophoretic", 467], ["mobility", 483], ["shift", 492], ["assays", 498], [",", 504], ["we", 506], ["demonstrate", 509], ["that", 521], ["a", 526], ["naturally", 528], ["occurring", 538], ["mutation", 548], ["in", 557], ["SBP2", 560], [",", 564], ["which", 566], ["correlates", 572], ["with", 583], ["abnormal", 588], ["thyroid", 597], ["hormone", 605], ["function", 613], ["in", 622], ["humans", 625], [",", 631], ["lies", 633], ["within", 638], ["a", 645], ["novel", 647], [",", 652], ["bipartite", 654], ["RNA", 664], ["-", 667], ["binding", 668], ["domain", 676], [".", 682], ["This", 684], ["mutation", 689], ["alters", 698], ["the", 705], ["RNA", 709], ["binding", 713], ["affinity", 721], ["of", 730], ["SBP2", 733], ["such", 738], ["that", 743], ["it", 748], ["no", 751], ["longer", 754], ["stably", 761], ["interacts", 768], ["with", 778], ["a", 783], ["subset", 785], ["of", 792], ["SECIS", 795], ["elements", 801], [".", 809], ["Assays", 811], ["performed", 818], ["under", 828], ["competitive", 834], ["conditions", 846], ["to", 857], ["mimic", 860], ["intracellular", 866], ["conditions", 880], ["suggest", 891], ["that", 899], ["the", 904], ["differential", 908], ["affinity", 921], ["of", 930], ["SBP2", 933], ["for", 938], ["various", 942], ["SECIS", 950], ["elements", 956], ["will", 965], ["determine", 970], ["the", 980], ["expression", 984], ["pattern", 995], ["of", 1003], ["the", 1006], ["selenoproteome", 1010], [".", 1024], ["We", 1026], ["hypothesize", 1029], ["that", 1041], ["the", 1046], ["selective", 1050], ["loss", 1060], ["of", 1065], ["a", 1068], ["subset", 1070], ["of", 1077], ["selenoproteins", 1080], [",", 1094], ["including", 1096], ["some", 1106], ["involved", 1111], ["in", 1120], ["thyroid", 1123], ["hormone", 1131], ["homeostasis", 1139], [",", 1150], ["is", 1152], ["responsible", 1155], ["for", 1167], ["the", 1171], ["abnormal", 1175], ["thyroid", 1184], ["hormone", 1192], ["metabolism", 1200], ["previously", 1211], ["observed", 1222], ["in", 1231], ["the", 1234], ["affected", 1238], ["individuals", 1247], [".", 1258]]}
{"context": "Centrosomes are composed of a centriole pair surrounded by an intricate proteinaceous matrix referred to as pericentriolar material. Although the mechanisms underpinning the control of centriole duplication are now well understood, we know relatively little about the control of centrosome size and shape. Here we used interaction proteomics to identify the E3 ligase HERC2 and the neuralized homologue NEURL4 as novel interaction partners of the centrosomal protein CP110. Using high resolution imaging, we find that HERC2 and NEURL4 localize to the centrosome and that interfering with their function alters centrosome morphology through the appearance of aberrant filamentous structures that stain for a subset of pericentriolar material proteins including pericentrin and CEP135. Using an RNA interference-resistant transgene approach in combination with structure-function analyses, we show that the association between CP110 and HERC2 depends on nonoverlapping regions of NEURL4. Whereas CP110 binding to NEURL4 is dispensable for the regulation of pericentriolar material architecture, its association with HERC2 is required to maintain normal centrosome integrity. NEURL4 is a substrate of HERC2, and together these results indicate that the NEURL4-HERC2 complex participates in the ubiquitin-dependent regulation of centrosome architecture.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "edb15e5cd3594668933fa0a9f6c83206", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[173, 173], [86, 86], [41, 41], [200, 200], [94, 94]], "char_spans": [[1151, 1160], [551, 560], [279, 288], [1325, 1334], [610, 619]]}]}], "context_tokens": [["Centrosomes", 0], ["are", 12], ["composed", 16], ["of", 25], ["a", 28], ["centriole", 30], ["pair", 40], ["surrounded", 45], ["by", 56], ["an", 59], ["intricate", 62], ["proteinaceous", 72], ["matrix", 86], ["referred", 93], ["to", 102], ["as", 105], ["pericentriolar", 108], ["material", 123], [".", 131], ["Although", 133], ["the", 142], ["mechanisms", 146], ["underpinning", 157], ["the", 170], ["control", 174], ["of", 182], ["centriole", 185], ["duplication", 195], ["are", 207], ["now", 211], ["well", 215], ["understood", 220], [",", 230], ["we", 232], ["know", 235], ["relatively", 240], ["little", 251], ["about", 258], ["the", 264], ["control", 268], ["of", 276], ["centrosome", 279], ["size", 290], ["and", 295], ["shape", 299], [".", 304], ["Here", 306], ["we", 311], ["used", 314], ["interaction", 319], ["proteomics", 331], ["to", 342], ["identify", 345], ["the", 354], ["E3", 358], ["ligase", 361], ["HERC2", 368], ["and", 374], ["the", 378], ["neuralized", 382], ["homologue", 393], ["NEURL4", 403], ["as", 410], ["novel", 413], ["interaction", 419], ["partners", 431], ["of", 440], ["the", 443], ["centrosomal", 447], ["protein", 459], ["CP110", 467], [".", 472], ["Using", 474], ["high", 480], ["resolution", 485], ["imaging", 496], [",", 503], ["we", 505], ["find", 508], ["that", 513], ["HERC2", 518], ["and", 524], ["NEURL4", 528], ["localize", 535], ["to", 544], ["the", 547], ["centrosome", 551], ["and", 562], ["that", 566], ["interfering", 571], ["with", 583], ["their", 588], ["function", 594], ["alters", 603], ["centrosome", 610], ["morphology", 621], ["through", 632], ["the", 640], ["appearance", 644], ["of", 655], ["aberrant", 658], ["filamentous", 667], ["structures", 679], ["that", 690], ["stain", 695], ["for", 701], ["a", 705], ["subset", 707], ["of", 714], ["pericentriolar", 717], ["material", 732], ["proteins", 741], ["including", 750], ["pericentrin", 760], ["and", 772], ["CEP135", 776], [".", 782], ["Using", 784], ["an", 790], ["RNA", 793], ["interference", 797], ["-", 809], ["resistant", 810], ["transgene", 820], ["approach", 830], ["in", 839], ["combination", 842], ["with", 854], ["structure", 859], ["-", 868], ["function", 869], ["analyses", 878], [",", 886], ["we", 888], ["show", 891], ["that", 896], ["the", 901], ["association", 905], ["between", 917], ["CP110", 925], ["and", 931], ["HERC2", 935], ["depends", 941], ["on", 949], ["nonoverlapping", 952], ["regions", 967], ["of", 975], ["NEURL4", 978], [".", 984], ["Whereas", 986], ["CP110", 994], ["binding", 1000], ["to", 1008], ["NEURL4", 1011], ["is", 1018], ["dispensable", 1021], ["for", 1033], ["the", 1037], ["regulation", 1041], ["of", 1052], ["pericentriolar", 1055], ["material", 1070], ["architecture", 1079], [",", 1091], ["its", 1093], ["association", 1097], ["with", 1109], ["HERC2", 1114], ["is", 1120], ["required", 1123], ["to", 1132], ["maintain", 1135], ["normal", 1144], ["centrosome", 1151], ["integrity", 1162], [".", 1171], ["NEURL4", 1173], ["is", 1180], ["a", 1183], ["substrate", 1185], ["of", 1195], ["HERC2", 1198], [",", 1203], ["and", 1205], ["together", 1209], ["these", 1218], ["results", 1224], ["indicate", 1232], ["that", 1241], ["the", 1246], ["NEURL4-HERC2", 1250], ["complex", 1263], ["participates", 1271], ["in", 1284], ["the", 1287], ["ubiquitin", 1291], ["-", 1300], ["dependent", 1301], ["regulation", 1311], ["of", 1322], ["centrosome", 1325], ["architecture", 1336], [".", 1348]]}
{"context": "The BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22. The majority of CML patients have a breakpoint in the major BCR region of the BCR gene giving rise to e13a2 or e14a2 BCR-ABL transcripts. Occasionally, other BCR breakpoints occur. The current report describes two e6a2 CML patients with imatinib treatment failure and unusual disease progression. One patient was Philadelphia chromosome positive and one was Philadelphia chromosome negative with an atypical BCR-ABL rearrangement, ins (22;9).", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "da064d93bc6d4d6fa5b680d9a08d7890", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[95, 97], [1, 3], [51, 53]], "char_spans": [[559, 565], [4, 10], [268, 274]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["-", 7], ["ABL", 8], ["fusion", 12], ["gene", 19], ["represents", 24], ["the", 35], ["hallmark", 39], ["of", 48], ["chronic", 51], ["myelogenous", 59], ["leukemia", 71], ["(", 80], ["CML", 81], [")", 84], ["and", 86], ["is", 90], ["derived", 93], ["from", 101], ["a", 106], ["translocation", 108], ["between", 122], ["chromosome", 130], ["9", 141], ["and", 143], ["22", 147], [".", 149], ["The", 151], ["majority", 155], ["of", 164], ["CML", 167], ["patients", 171], ["have", 180], ["a", 185], ["breakpoint", 187], ["in", 198], ["the", 201], ["major", 205], ["BCR", 211], ["region", 215], ["of", 222], ["the", 225], ["BCR", 229], ["gene", 233], ["giving", 238], ["rise", 245], ["to", 250], ["e13a2", 253], ["or", 259], ["e14a2", 262], ["BCR", 268], ["-", 271], ["ABL", 272], ["transcripts", 276], [".", 287], ["Occasionally", 289], [",", 301], ["other", 303], ["BCR", 309], ["breakpoints", 313], ["occur", 325], [".", 330], ["The", 332], ["current", 336], ["report", 344], ["describes", 351], ["two", 361], ["e6a2", 365], ["CML", 370], ["patients", 374], ["with", 383], ["imatinib", 388], ["treatment", 397], ["failure", 407], ["and", 415], ["unusual", 419], ["disease", 427], ["progression", 435], [".", 446], ["One", 448], ["patient", 452], ["was", 460], ["Philadelphia", 464], ["chromosome", 477], ["positive", 488], ["and", 497], ["one", 501], ["was", 505], ["Philadelphia", 509], ["chromosome", 522], ["negative", 533], ["with", 542], ["an", 547], ["atypical", 550], ["BCR", 559], ["-", 562], ["ABL", 563], ["rearrangement", 567], [",", 580], ["ins", 582], ["(", 586], ["22;9", 587], [")", 591], [".", 592]]}
{"context": "Parkinson's disease (PD) is a neurodegnerative disorder that is pathologically characterized by the presence of Lewy bodies in the brain. We show that Lewy bodies in PD are strongly immunoreactive for torsinA, the protein product of the DYT1 gene, which is associated with primary generalized dystonia. In the substantia nigra, torsinA immunoreactivity is localized to the periphery of Lewy bodies, whereas, in cortical Lewy bodies it is uniformly distributed. The significance of this finding is unknown, but may implicate torsinA in neuronal dysfunction that occurs in PD as well as in primary dystonia.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "630e6932bb704bc7a85107087e4dd2ea", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegnerative", 30], ["disorder", 47], ["that", 56], ["is", 61], ["pathologically", 64], ["characterized", 79], ["by", 93], ["the", 96], ["presence", 100], ["of", 109], ["Lewy", 112], ["bodies", 117], ["in", 124], ["the", 127], ["brain", 131], [".", 136], ["We", 138], ["show", 141], ["that", 146], ["Lewy", 151], ["bodies", 156], ["in", 163], ["PD", 166], ["are", 169], ["strongly", 173], ["immunoreactive", 182], ["for", 197], ["torsinA", 201], [",", 208], ["the", 210], ["protein", 214], ["product", 222], ["of", 230], ["the", 233], ["DYT1", 237], ["gene", 242], [",", 246], ["which", 248], ["is", 254], ["associated", 257], ["with", 268], ["primary", 273], ["generalized", 281], ["dystonia", 293], [".", 301], ["In", 303], ["the", 306], ["substantia", 310], ["nigra", 321], [",", 326], ["torsinA", 328], ["immunoreactivity", 336], ["is", 353], ["localized", 356], ["to", 366], ["the", 369], ["periphery", 373], ["of", 383], ["Lewy", 386], ["bodies", 391], [",", 397], ["whereas", 399], [",", 406], ["in", 408], ["cortical", 411], ["Lewy", 420], ["bodies", 425], ["it", 432], ["is", 435], ["uniformly", 438], ["distributed", 448], [".", 459], ["The", 461], ["significance", 465], ["of", 478], ["this", 481], ["finding", 486], ["is", 494], ["unknown", 497], [",", 504], ["but", 506], ["may", 510], ["implicate", 514], ["torsinA", 524], ["in", 532], ["neuronal", 535], ["dysfunction", 544], ["that", 556], ["occurs", 561], ["in", 568], ["PD", 571], ["as", 574], ["well", 577], ["as", 582], ["in", 585], ["primary", 588], ["dystonia", 596], [".", 604]]}
{"context": "To study the clinical and molecular characteristics of methicillin-resistant Staphylococcus aureus (MRSA) infection in children. A total of 37 MRSA strains were isolated from hospitalized patients in Children's Hospital of Fudan University from March 2009 to November 2011. The clinical characteristics were investigated by a cohort study. Furthermore, the mecA, Panton-Valentine leucocidin (PVL) genes were detected by polymerase chain reaction (PCR), and the genotypes of SCCmec were determined by multiplex PCR. (1) Among the 37 MRSA isolates, infections with 21 were acquired from hospital (HA-MRSA), and 16 isolates were acquired from community (CA-MRSA). (2) In the study, MRSA frequently caused respiratory tract infection, and most of the strains were isolated from intensive care unit (ICU). (3) CA-MRSA was most frequently associated with skin and soft tissue infections (SSTI), suppurative tonsillitis, even pneumonia and septicemia. HA-MRSA infection was more aggressive, most frequently associated with pneumonia, septicemia, and central nervous system (CNS) infections, such as meningitis. In children with fever caused by HA-MRSA or CA-MRSA infection, HA-MRSA showed a longer duration of fever, for 10.5 days. C-reactive protein (CRP) level caused by HA-MRSA (63.00 mg/L) was higher than CA-MRSA (9.50 mg/L) , and there were statistically significant differences between the groups (t = 2.5670, P < 0.05). However, there were no statistically significant differences between the groups in white blood cell count (WBC) or procalcitonin (PCT) level. (4) Among 37 MRSA isolates, the whole isolates were mecA gene positive (100%). SCCmec genotyping results showed that the most frequent SCCmec types were type III, 17 isolates, the others including type IV 8 isolates, type II1 isolates, nontypable 11 isolates, type I and type V were not found in this group. Therein, among 21 HA-MRSA isolates, SCCmec III was the most common, 15 isolates, type IV 1 isolates, nontypable 5 isolates; among 16 CA-MRSA isolates, SCCmec type IV was the most common, 7 isolates, type III 2 isolates, type II 1 isolate, nontypable 6 isolates. (5) Among the 37 MRSA isolates, 28 were PVL gene positive; and among 21 HA-MRSA isolates, 17 were PVL gene positive; Among 16 CA-MRSA isolates, 11 were PVL gene positive; There were no statistically significant differences between the groups (\u03c7(2) = 0.735, P > 0.05) . Compared with CA-MRSA, HA-MRSA infection was more aggressive, and induced higher C reactive protein; the dominant epidemic strains of CA-MRSA was SCCmec type IV, and HA-MRSA was SCCmec type III; the positive rate of PVL gene was high.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b4d2ae32fe78473ead5fbb79a9000745", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[461, 461], [531, 531], [108, 108], [121, 121], [263, 263], [131, 131], [251, 251], [387, 387], [507, 507], [222, 222], [14, 14], [447, 447], [321, 321], [511, 511], [218, 218], [474, 474], [24, 24], [227, 227], [413, 413], [540, 540], [183, 183], [158, 158], [95, 95]], "char_spans": [[2208, 2211], [2539, 2542], [598, 601], [654, 657], [1306, 1309], [679, 682], [1269, 1272], [1892, 1895], [2419, 2422], [1151, 1154], [100, 103], [2150, 2153], [1576, 1579], [2428, 2431], [1140, 1143], [2262, 2265], [143, 146], [1170, 1173], [2007, 2010], [2571, 2574], [948, 951], [808, 811], [532, 535]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["clinical", 13], ["and", 22], ["molecular", 26], ["characteristics", 36], ["of", 52], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["infection", 106], ["in", 116], ["children", 119], [".", 127], ["A", 129], ["total", 131], ["of", 137], ["37", 140], ["MRSA", 143], ["strains", 148], ["were", 156], ["isolated", 161], ["from", 170], ["hospitalized", 175], ["patients", 188], ["in", 197], ["Children", 200], ["'s", 208], ["Hospital", 211], ["of", 220], ["Fudan", 223], ["University", 229], ["from", 240], ["March", 245], ["2009", 251], ["to", 256], ["November", 259], ["2011", 268], [".", 272], ["The", 274], ["clinical", 278], ["characteristics", 287], ["were", 303], ["investigated", 308], ["by", 321], ["a", 324], ["cohort", 326], ["study", 333], [".", 338], ["Furthermore", 340], [",", 351], ["the", 353], ["mecA", 357], [",", 361], ["Panton", 363], ["-", 369], ["Valentine", 370], ["leucocidin", 380], ["(", 391], ["PVL", 392], [")", 395], ["genes", 397], ["were", 403], ["detected", 408], ["by", 417], ["polymerase", 420], ["chain", 431], ["reaction", 437], ["(", 446], ["PCR", 447], [")", 450], [",", 451], ["and", 453], ["the", 457], ["genotypes", 461], ["of", 471], ["SCCmec", 474], ["were", 481], ["determined", 486], ["by", 497], ["multiplex", 500], ["PCR", 510], [".", 513], ["(", 515], ["1", 516], [")", 517], ["Among", 519], ["the", 525], ["37", 529], ["MRSA", 532], ["isolates", 537], [",", 545], ["infections", 547], ["with", 558], ["21", 563], ["were", 566], ["acquired", 571], ["from", 580], ["hospital", 585], ["(", 594], ["HA", 595], ["-", 597], ["MRSA", 598], [")", 602], [",", 603], ["and", 605], ["16", 609], ["isolates", 612], ["were", 621], ["acquired", 626], ["from", 635], ["community", 640], ["(", 650], ["CA", 651], ["-", 653], ["MRSA", 654], [")", 658], [".", 659], ["(", 661], ["2", 662], [")", 663], ["In", 665], ["the", 668], ["study", 672], [",", 677], ["MRSA", 679], ["frequently", 684], ["caused", 695], ["respiratory", 702], ["tract", 714], ["infection", 720], [",", 729], ["and", 731], ["most", 735], ["of", 740], ["the", 743], ["strains", 747], ["were", 755], ["isolated", 760], ["from", 769], ["intensive", 774], ["care", 784], ["unit", 789], ["(", 794], ["ICU", 795], [")", 798], [".", 799], ["(", 801], ["3", 802], [")", 803], ["CA", 805], ["-", 807], ["MRSA", 808], ["was", 813], ["most", 817], ["frequently", 822], ["associated", 833], ["with", 844], ["skin", 849], ["and", 854], ["soft", 858], ["tissue", 863], ["infections", 870], ["(", 881], ["SSTI", 882], [")", 886], [",", 887], ["suppurative", 889], ["tonsillitis", 901], [",", 912], ["even", 914], ["pneumonia", 919], ["and", 929], ["septicemia", 933], [".", 943], ["HA", 945], ["-", 947], ["MRSA", 948], ["infection", 953], ["was", 963], ["more", 967], ["aggressive", 972], [",", 982], ["most", 984], ["frequently", 989], ["associated", 1000], ["with", 1011], ["pneumonia", 1016], [",", 1025], ["septicemia", 1027], [",", 1037], ["and", 1039], ["central", 1043], ["nervous", 1051], ["system", 1059], ["(", 1066], ["CNS", 1067], [")", 1070], ["infections", 1072], [",", 1082], ["such", 1084], ["as", 1089], ["meningitis", 1092], [".", 1102], ["In", 1104], ["children", 1107], ["with", 1116], ["fever", 1121], ["caused", 1127], ["by", 1134], ["HA", 1137], ["-", 1139], ["MRSA", 1140], ["or", 1145], ["CA", 1148], ["-", 1150], ["MRSA", 1151], ["infection", 1156], [",", 1165], ["HA", 1167], ["-", 1169], ["MRSA", 1170], ["showed", 1175], ["a", 1182], ["longer", 1184], ["duration", 1191], ["of", 1200], ["fever", 1203], [",", 1208], ["for", 1210], ["10.5", 1214], ["days", 1219], [".", 1223], ["C", 1225], ["-", 1226], ["reactive", 1227], ["protein", 1236], ["(", 1244], ["CRP", 1245], [")", 1248], ["level", 1250], ["caused", 1256], ["by", 1263], ["HA", 1266], ["-", 1268], ["MRSA", 1269], ["(", 1274], ["63.00", 1275], ["mg", 1281], ["/", 1283], ["L", 1284], [")", 1285], ["was", 1287], ["higher", 1291], ["than", 1298], ["CA", 1303], ["-", 1305], ["MRSA", 1306], ["(", 1311], ["9.50", 1312], ["mg", 1317], ["/", 1319], ["L", 1320], [")", 1321], [",", 1323], ["and", 1325], ["there", 1329], ["were", 1335], ["statistically", 1340], ["significant", 1354], ["differences", 1366], ["between", 1378], ["the", 1386], ["groups", 1390], ["(", 1397], ["t", 1398], ["=", 1400], ["2.5670", 1402], [",", 1408], ["P", 1410], ["<", 1412], ["0.05", 1414], [")", 1418], [".", 1419], ["However", 1421], [",", 1428], ["there", 1430], ["were", 1436], ["no", 1441], ["statistically", 1444], ["significant", 1458], ["differences", 1470], ["between", 1482], ["the", 1490], ["groups", 1494], ["in", 1501], ["white", 1504], ["blood", 1510], ["cell", 1516], ["count", 1521], ["(", 1527], ["WBC", 1528], [")", 1531], ["or", 1533], ["procalcitonin", 1536], ["(", 1550], ["PCT", 1551], [")", 1554], ["level", 1556], [".", 1561], ["(", 1563], ["4", 1564], [")", 1565], ["Among", 1567], ["37", 1573], ["MRSA", 1576], ["isolates", 1581], [",", 1589], ["the", 1591], ["whole", 1595], ["isolates", 1601], ["were", 1610], ["mecA", 1615], ["gene", 1620], ["positive", 1625], ["(", 1634], ["100", 1635], ["%", 1638], [")", 1639], [".", 1640], ["SCCmec", 1642], ["genotyping", 1649], ["results", 1660], ["showed", 1668], ["that", 1675], ["the", 1680], ["most", 1684], ["frequent", 1689], ["SCCmec", 1698], ["types", 1705], ["were", 1711], ["type", 1716], ["III", 1721], [",", 1724], ["17", 1726], ["isolates", 1729], [",", 1737], ["the", 1739], ["others", 1743], ["including", 1750], ["type", 1760], ["IV", 1765], ["8", 1768], ["isolates", 1770], [",", 1778], ["type", 1780], ["II1", 1785], ["isolates", 1789], [",", 1797], ["nontypable", 1799], ["11", 1810], ["isolates", 1813], [",", 1821], ["type", 1823], ["I", 1828], ["and", 1830], ["type", 1834], ["V", 1839], ["were", 1841], ["not", 1846], ["found", 1850], ["in", 1856], ["this", 1859], ["group", 1864], [".", 1869], ["Therein", 1871], [",", 1878], ["among", 1880], ["21", 1886], ["HA", 1889], ["-", 1891], ["MRSA", 1892], ["isolates", 1897], [",", 1905], ["SCCmec", 1907], ["III", 1914], ["was", 1918], ["the", 1922], ["most", 1926], ["common", 1931], [",", 1937], ["15", 1939], ["isolates", 1942], [",", 1950], ["type", 1952], ["IV", 1957], ["1", 1960], ["isolates", 1962], [",", 1970], ["nontypable", 1972], ["5", 1983], ["isolates", 1985], [";", 1993], ["among", 1995], ["16", 2001], ["CA", 2004], ["-", 2006], ["MRSA", 2007], ["isolates", 2012], [",", 2020], ["SCCmec", 2022], ["type", 2029], ["IV", 2034], ["was", 2037], ["the", 2041], ["most", 2045], ["common", 2050], [",", 2056], ["7", 2058], ["isolates", 2060], [",", 2068], ["type", 2070], ["III", 2075], ["2", 2079], ["isolates", 2081], [",", 2089], ["type", 2091], ["II", 2096], ["1", 2099], ["isolate", 2101], [",", 2108], ["nontypable", 2110], ["6", 2121], ["isolates", 2123], [".", 2131], ["(", 2133], ["5", 2134], [")", 2135], ["Among", 2137], ["the", 2143], ["37", 2147], ["MRSA", 2150], ["isolates", 2155], [",", 2163], ["28", 2165], ["were", 2168], ["PVL", 2173], ["gene", 2177], ["positive", 2182], [";", 2190], ["and", 2192], ["among", 2196], ["21", 2202], ["HA", 2205], ["-", 2207], ["MRSA", 2208], ["isolates", 2213], [",", 2221], ["17", 2223], ["were", 2226], ["PVL", 2231], ["gene", 2235], ["positive", 2240], [";", 2248], ["Among", 2250], ["16", 2256], ["CA", 2259], ["-", 2261], ["MRSA", 2262], ["isolates", 2267], [",", 2275], ["11", 2277], ["were", 2280], ["PVL", 2285], ["gene", 2289], ["positive", 2294], [";", 2302], ["There", 2304], ["were", 2310], ["no", 2315], ["statistically", 2318], ["significant", 2332], ["differences", 2344], ["between", 2356], ["the", 2364], ["groups", 2368], ["(", 2375], ["\u03c7(2", 2376], [")", 2379], ["=", 2381], ["0.735", 2383], [",", 2388], ["P", 2390], [">", 2392], ["0.05", 2394], [")", 2398], [".", 2400], ["Compared", 2402], ["with", 2411], ["CA", 2416], ["-", 2418], ["MRSA", 2419], [",", 2423], ["HA", 2425], ["-", 2427], ["MRSA", 2428], ["infection", 2433], ["was", 2443], ["more", 2447], ["aggressive", 2452], [",", 2462], ["and", 2464], ["induced", 2468], ["higher", 2476], ["C", 2483], ["reactive", 2485], ["protein", 2494], [";", 2501], ["the", 2503], ["dominant", 2507], ["epidemic", 2516], ["strains", 2525], ["of", 2533], ["CA", 2536], ["-", 2538], ["MRSA", 2539], ["was", 2544], ["SCCmec", 2548], ["type", 2555], ["IV", 2560], [",", 2562], ["and", 2564], ["HA", 2568], ["-", 2570], ["MRSA", 2571], ["was", 2576], ["SCCmec", 2580], ["type", 2587], ["III", 2592], [";", 2595], ["the", 2597], ["positive", 2601], ["rate", 2610], ["of", 2615], ["PVL", 2618], ["gene", 2622], ["was", 2627], ["high", 2631], [".", 2635]]}
{"context": "Infectious mononucleosis is a common, usually self-limited disease. However, infectious mononucleosis may present with severe manifestations. Complications may also occur. Consequently, diagnostic and treatment issues regarding infectious mononucleosis are of major importance. In this review, we focus on the evaluation of articles providing diagnosis and treatment data for infectious mononucleosis, published during the past 2 years. Twelve studies, deriving from extended search in PubMed, were included. Nine studies provided diagnosis data. The evaluated diagnostic methods were real-time PCR (RT-PCR), IgM/IgG antibodies measured with different assays [measurement of Epstein-Barr virus viral load (EBV-VL) in peripheral blood, neutrophil/lymphocyte/monocyte counts, C-reactive protein values, and monospot test]. The sensitivities reported for RT-PCR were high. The available treatment data were scarce (three studies). Two of them suggested that antivirals (mainly acyclovir and valacyclovir) may have a role in the treatment of infectious mononucleosis with complications, whereas the remaining study presented novel potential therapeutic patents including 5-substituted uracyle, azacytosine derivatives, and peptides inhibiting EBV-mediated membrane fusion. RT-PCR and measurement of EBV-VL may provide useful tools for the early diagnosis of infectious mononucleosis in cases with inconclusive serological results. Antiviral agents may provide a useful treatment option in patients with severe infectious mononucleosis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "fba1c150697a4864bbf8aedacd2d8a94", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[113, 116]], "char_spans": [[675, 692]]}]}], "context_tokens": [["Infectious", 0], ["mononucleosis", 11], ["is", 25], ["a", 28], ["common", 30], [",", 36], ["usually", 38], ["self", 46], ["-", 50], ["limited", 51], ["disease", 59], [".", 66], ["However", 68], [",", 75], ["infectious", 77], ["mononucleosis", 88], ["may", 102], ["present", 106], ["with", 114], ["severe", 119], ["manifestations", 126], [".", 140], ["Complications", 142], ["may", 156], ["also", 160], ["occur", 165], [".", 170], ["Consequently", 172], [",", 184], ["diagnostic", 186], ["and", 197], ["treatment", 201], ["issues", 211], ["regarding", 218], ["infectious", 228], ["mononucleosis", 239], ["are", 253], ["of", 257], ["major", 260], ["importance", 266], [".", 276], ["In", 278], ["this", 281], ["review", 286], [",", 292], ["we", 294], ["focus", 297], ["on", 303], ["the", 306], ["evaluation", 310], ["of", 321], ["articles", 324], ["providing", 333], ["diagnosis", 343], ["and", 353], ["treatment", 357], ["data", 367], ["for", 372], ["infectious", 376], ["mononucleosis", 387], [",", 400], ["published", 402], ["during", 412], ["the", 419], ["past", 423], ["2", 428], ["years", 430], [".", 435], ["Twelve", 437], ["studies", 444], [",", 451], ["deriving", 453], ["from", 462], ["extended", 467], ["search", 476], ["in", 483], ["PubMed", 486], [",", 492], ["were", 494], ["included", 499], [".", 507], ["Nine", 509], ["studies", 514], ["provided", 522], ["diagnosis", 531], ["data", 541], [".", 545], ["The", 547], ["evaluated", 551], ["diagnostic", 561], ["methods", 572], ["were", 580], ["real", 585], ["-", 589], ["time", 590], ["PCR", 595], ["(", 599], ["RT", 600], ["-", 602], ["PCR", 603], [")", 606], [",", 607], ["IgM", 609], ["/", 612], ["IgG", 613], ["antibodies", 617], ["measured", 628], ["with", 637], ["different", 642], ["assays", 652], ["[", 659], ["measurement", 660], ["of", 672], ["Epstein", 675], ["-", 682], ["Barr", 683], ["virus", 688], ["viral", 694], ["load", 700], ["(", 705], ["EBV", 706], ["-", 709], ["VL", 710], [")", 712], ["in", 714], ["peripheral", 717], ["blood", 728], [",", 733], ["neutrophil", 735], ["/", 745], ["lymphocyte", 746], ["/", 756], ["monocyte", 757], ["counts", 766], [",", 772], ["C", 774], ["-", 775], ["reactive", 776], ["protein", 785], ["values", 793], [",", 799], ["and", 801], ["monospot", 805], ["test].", 814], ["The", 821], ["sensitivities", 825], ["reported", 839], ["for", 848], ["RT", 852], ["-", 854], ["PCR", 855], ["were", 859], ["high", 864], [".", 868], ["The", 870], ["available", 874], ["treatment", 884], ["data", 894], ["were", 899], ["scarce", 904], ["(", 911], ["three", 912], ["studies", 918], [")", 925], [".", 926], ["Two", 928], ["of", 932], ["them", 935], ["suggested", 940], ["that", 950], ["antivirals", 955], ["(", 966], ["mainly", 967], ["acyclovir", 974], ["and", 984], ["valacyclovir", 988], [")", 1000], ["may", 1002], ["have", 1006], ["a", 1011], ["role", 1013], ["in", 1018], ["the", 1021], ["treatment", 1025], ["of", 1035], ["infectious", 1038], ["mononucleosis", 1049], ["with", 1063], ["complications", 1068], [",", 1081], ["whereas", 1083], ["the", 1091], ["remaining", 1095], ["study", 1105], ["presented", 1111], ["novel", 1121], ["potential", 1127], ["therapeutic", 1137], ["patents", 1149], ["including", 1157], ["5-substituted", 1167], ["uracyle", 1181], [",", 1188], ["azacytosine", 1190], ["derivatives", 1202], [",", 1213], ["and", 1215], ["peptides", 1219], ["inhibiting", 1228], ["EBV", 1239], ["-", 1242], ["mediated", 1243], ["membrane", 1252], ["fusion", 1261], [".", 1267], ["RT", 1269], ["-", 1271], ["PCR", 1272], ["and", 1276], ["measurement", 1280], ["of", 1292], ["EBV", 1295], ["-", 1298], ["VL", 1299], ["may", 1302], ["provide", 1306], ["useful", 1314], ["tools", 1321], ["for", 1327], ["the", 1331], ["early", 1335], ["diagnosis", 1341], ["of", 1351], ["infectious", 1354], ["mononucleosis", 1365], ["in", 1379], ["cases", 1382], ["with", 1388], ["inconclusive", 1393], ["serological", 1406], ["results", 1418], [".", 1425], ["Antiviral", 1427], ["agents", 1437], ["may", 1444], ["provide", 1448], ["a", 1456], ["useful", 1458], ["treatment", 1465], ["option", 1475], ["in", 1482], ["patients", 1485], ["with", 1494], ["severe", 1499], ["infectious", 1506], ["mononucleosis", 1517], [".", 1530]]}
{"context": "Deubiquitinating enzymes (DUbs) play important roles in many ubiquitin-dependent pathways, yet how DUbs themselves are regulated is not well understood. Here, we provide insight into the mechanism by which ubiquitination directly enhances the activity of ataxin-3, a DUb implicated in protein quality control and the disease protein in the polyglutamine neurodegenerative disorder, Spinocerebellar Ataxia Type 3. We identify Lys-117, which resides near the catalytic triad, as the primary site of ubiquitination in wild type and pathogenic ataxin-3. Further studies indicate that ubiquitin-dependent activation of ataxin-3 at Lys-117 is important for its ability to reduce high molecular weight ubiquitinated species in cells. Ubiquitination at Lys-117 also facilitates the ability of ataxin-3 to induce aggresome formation in cells. Finally, structure-function studies support a model of activation whereby ubiquitination at Lys-117 enhances ataxin-3 activity independent of the known ubiquitin-binding sites in ataxin-3, most likely through a direct conformational change in or near the catalytic domain.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "76df6ea078eb43ef838474f8a30b5d15", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[160, 160], [149, 149], [99, 99], [125, 125], [42, 42], [88, 88]], "char_spans": [[1013, 1020], [943, 950], [614, 621], [785, 792], [255, 262], [540, 547]]}]}], "context_tokens": [["Deubiquitinating", 0], ["enzymes", 17], ["(", 25], ["DUbs", 26], [")", 30], ["play", 32], ["important", 37], ["roles", 47], ["in", 53], ["many", 56], ["ubiquitin", 61], ["-", 70], ["dependent", 71], ["pathways", 81], [",", 89], ["yet", 91], ["how", 95], ["DUbs", 99], ["themselves", 104], ["are", 115], ["regulated", 119], ["is", 129], ["not", 132], ["well", 136], ["understood", 141], [".", 151], ["Here", 153], [",", 157], ["we", 159], ["provide", 162], ["insight", 170], ["into", 178], ["the", 183], ["mechanism", 187], ["by", 197], ["which", 200], ["ubiquitination", 206], ["directly", 221], ["enhances", 230], ["the", 239], ["activity", 243], ["of", 252], ["ataxin-3", 255], [",", 263], ["a", 265], ["DUb", 267], ["implicated", 271], ["in", 282], ["protein", 285], ["quality", 293], ["control", 301], ["and", 309], ["the", 313], ["disease", 317], ["protein", 325], ["in", 333], ["the", 336], ["polyglutamine", 340], ["neurodegenerative", 354], ["disorder", 372], [",", 380], ["Spinocerebellar", 382], ["Ataxia", 398], ["Type", 405], ["3", 410], [".", 411], ["We", 413], ["identify", 416], ["Lys-117", 425], [",", 432], ["which", 434], ["resides", 440], ["near", 448], ["the", 453], ["catalytic", 457], ["triad", 467], [",", 472], ["as", 474], ["the", 477], ["primary", 481], ["site", 489], ["of", 494], ["ubiquitination", 497], ["in", 512], ["wild", 515], ["type", 520], ["and", 525], ["pathogenic", 529], ["ataxin-3", 540], [".", 548], ["Further", 550], ["studies", 558], ["indicate", 566], ["that", 575], ["ubiquitin", 580], ["-", 589], ["dependent", 590], ["activation", 600], ["of", 611], ["ataxin-3", 614], ["at", 623], ["Lys-117", 626], ["is", 634], ["important", 637], ["for", 647], ["its", 651], ["ability", 655], ["to", 663], ["reduce", 666], ["high", 673], ["molecular", 678], ["weight", 688], ["ubiquitinated", 695], ["species", 709], ["in", 717], ["cells", 720], [".", 725], ["Ubiquitination", 727], ["at", 742], ["Lys-117", 745], ["also", 753], ["facilitates", 758], ["the", 770], ["ability", 774], ["of", 782], ["ataxin-3", 785], ["to", 794], ["induce", 797], ["aggresome", 804], ["formation", 814], ["in", 824], ["cells", 827], [".", 832], ["Finally", 834], [",", 841], ["structure", 843], ["-", 852], ["function", 853], ["studies", 862], ["support", 870], ["a", 878], ["model", 880], ["of", 886], ["activation", 889], ["whereby", 900], ["ubiquitination", 908], ["at", 923], ["Lys-117", 926], ["enhances", 934], ["ataxin-3", 943], ["activity", 952], ["independent", 961], ["of", 973], ["the", 976], ["known", 980], ["ubiquitin", 986], ["-", 995], ["binding", 996], ["sites", 1004], ["in", 1010], ["ataxin-3", 1013], [",", 1021], ["most", 1023], ["likely", 1028], ["through", 1035], ["a", 1043], ["direct", 1045], ["conformational", 1052], ["change", 1067], ["in", 1074], ["or", 1077], ["near", 1080], ["the", 1085], ["catalytic", 1089], ["domain", 1099], [".", 1105]]}
{"context": "Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE \u03b52, ApoE \u03b53 and ApoE \u03b54 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE \u03b54 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the \u03b54 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n=68) of heterozygous \u03b53\u03b54 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n=669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2594b3b5c34d4b7f830baf5eb3094b4c", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[286, 287]], "char_spans": [[1598, 1610]]}]}], "context_tokens": [["Allelic", 0], ["polymorphism", 8], ["of", 21], ["the", 24], ["apolipoprotein", 28], ["E", 43], ["(", 45], ["ApoE", 46], [")", 50], ["gene", 52], ["(", 57], ["ApoE", 58], ["\u03b52", 63], [",", 65], ["ApoE", 67], ["\u03b53", 72], ["and", 75], ["ApoE", 79], ["\u03b54", 84], ["alleles", 87], [")", 94], ["gives", 96], ["rise", 102], ["to", 107], ["three", 110], ["protein", 116], ["isoforms", 124], ["(", 133], ["ApoE2", 134], [",", 139], ["ApoE3", 141], ["and", 147], ["ApoE4", 151], [")", 156], ["that", 158], ["differ", 163], ["by", 170], ["1", 173], ["or", 175], ["2", 178], ["amino", 180], ["acids", 186], [".", 191], ["Inheritance", 193], ["of", 205], ["the", 208], ["ApoE", 212], ["\u03b54", 217], ["allele", 220], ["is", 227], ["a", 230], ["risk", 232], ["factor", 237], ["for", 244], ["developing", 248], ["Alzheimer", 259], ["'s", 268], ["disease", 271], ["(", 279], ["AD", 280], [")", 282], [".", 283], ["The", 285], ["potential", 289], ["diagnostic", 299], ["value", 310], ["of", 316], ["ApoE", 319], ["protein", 324], ["levels", 332], ["in", 339], ["biological", 342], ["fluids", 353], ["(", 360], ["i.e.", 361], ["cerebrospinal", 366], ["fluid", 380], [",", 385], ["plasma", 387], ["and", 394], ["serum", 398], [")", 403], ["for", 405], ["distinguishing", 409], ["between", 424], ["AD", 432], ["patients", 435], ["and", 444], ["healthy", 448], ["elderly", 456], ["subjects", 464], ["is", 473], ["subject", 476], ["to", 484], ["great", 487], ["controversy", 493], [".", 504], ["Although", 506], ["a", 515], ["recent", 517], ["study", 524], ["reported", 530], ["subnormal", 539], ["total", 549], ["ApoE", 555], ["and", 560], ["ApoE4", 564], ["levels", 570], ["in", 577], ["the", 580], ["plasma", 584], ["of", 591], ["AD", 594], ["patients", 597], [",", 605], ["other", 607], ["studies", 613], ["have", 621], ["found", 626], ["normal", 632], ["or", 639], ["even", 642], ["elevated", 647], ["protein", 656], ["levels", 664], ["(", 671], ["versus", 672], ["controls", 679], [")", 687], [".", 688], ["Because", 690], ["all", 698], ["previously", 702], ["reported", 713], ["assays", 722], ["were", 729], ["based", 734], ["on", 740], ["immunoenzymatic", 743], ["techniques", 759], [",", 769], ["we", 771], ["decided", 774], ["to", 782], ["develop", 785], ["an", 793], ["orthogonal", 796], ["assay", 807], ["based", 813], ["on", 819], ["targeted", 822], ["mass", 831], ["spectrometry", 836], ["by", 849], ["tracking", 852], ["(", 861], ["i", 862], [")", 863], ["a", 865], ["proteotypic", 867], ["peptide", 879], ["common", 887], ["to", 894], ["all", 897], ["ApoE", 901], ["isoforms", 906], ["and", 915], ["(", 919], ["ii", 920], [")", 922], ["a", 924], ["peptide", 926], ["that", 934], ["is", 939], ["specific", 942], ["for", 951], ["the", 955], ["\u03b54", 959], ["allele", 962], [".", 968], ["After", 970], ["trypsin", 976], ["digestion", 984], [",", 993], ["the", 995], ["ApoE4-specific", 999], ["peptide", 1014], ["contains", 1022], ["an", 1031], ["oxidation", 1034], ["-", 1043], ["prone", 1044], ["methionine", 1050], ["residue", 1061], [".", 1068], ["The", 1070], ["endogenous", 1074], ["methionine", 1085], ["oxidation", 1096], ["level", 1106], ["was", 1112], ["evaluated", 1116], ["in", 1126], ["a", 1129], ["small", 1131], ["cohort", 1137], ["(", 1144], ["n=68", 1145], [")", 1149], ["of", 1151], ["heterozygous", 1154], ["\u03b53\u03b54", 1167], ["carriers", 1172], ["containing", 1181], ["both", 1192], ["healthy", 1197], ["controls", 1205], ["and", 1214], ["AD", 1218], ["patients", 1221], [".", 1229], ["As", 1231], ["expected", 1234], [",", 1242], ["the", 1244], ["proportion", 1248], ["of", 1259], ["oxidized", 1262], ["residues", 1271], ["varied", 1280], ["from", 1287], ["0", 1292], ["to", 1294], ["10", 1297], ["%", 1299], [",", 1300], ["with", 1302], ["an", 1307], ["average", 1310], ["of", 1318], ["5", 1321], ["%", 1322], [".", 1323], ["We", 1325], ["therefore", 1328], ["developed", 1338], ["a", 1348], ["standardized", 1350], ["strategy", 1363], ["for", 1372], ["the", 1376], ["unbiased", 1380], [",", 1388], ["absolute", 1390], ["quantification", 1399], ["of", 1414], ["ApoE4", 1417], [",", 1422], ["based", 1424], ["on", 1430], ["performic", 1433], ["acid", 1443], ["oxidization", 1448], ["of", 1460], ["methionine", 1463], [".", 1473], ["Once", 1475], ["the", 1480], ["sample", 1484], ["workflow", 1491], ["had", 1500], ["been", 1504], ["thoroughly", 1509], ["validated", 1520], [",", 1529], ["it", 1531], ["was", 1534], ["applied", 1538], ["to", 1546], ["the", 1549], ["concomitant", 1553], ["quantification", 1565], ["of", 1580], ["total", 1583], ["ApoE", 1589], ["and", 1594], ["ApoE4", 1598], ["isoform", 1604], ["in", 1612], ["a", 1615], ["large", 1617], ["case", 1623], ["-", 1627], ["control", 1628], ["study", 1636], ["(", 1642], ["n=669", 1643], [")", 1648], [".", 1649], ["The", 1651], ["final", 1655], ["measurements", 1661], ["were", 1674], ["consistent", 1679], ["with", 1690], ["most", 1695], ["previously", 1700], ["reported", 1711], ["ApoE", 1720], ["concentration", 1725], ["values", 1739], ["and", 1746], ["confirm", 1750], ["the", 1758], ["influence", 1762], ["of", 1772], ["the", 1775], ["different", 1779], ["alleles", 1789], ["on", 1797], ["the", 1800], ["protein", 1804], ["expression", 1812], ["level", 1823], [".", 1828], ["Our", 1830], ["results", 1834], ["illustrate", 1842], ["(", 1853], ["i", 1854], [")", 1855], ["the", 1857], ["reliability", 1861], ["of", 1873], ["selected", 1876], ["reaction", 1885], ["monitoring", 1894], ["-", 1904], ["based", 1905], ["assays", 1911], ["and", 1918], ["(", 1922], ["ii", 1923], [")", 1925], ["the", 1927], ["value", 1931], ["of", 1937], ["the", 1940], ["oxidization", 1944], ["step", 1956], ["for", 1961], ["unbiased", 1965], ["monitoring", 1974], ["of", 1985], ["methionine", 1988], ["-", 1998], ["containing", 1999], ["proteotypic", 2010], ["peptides", 2022], [".", 2030], ["Furthermore", 2032], [",", 2043], ["a", 2045], ["statistical", 2047], ["analysis", 2059], ["indicated", 2068], ["that", 2078], ["neither", 2083], ["total", 2091], ["ApoE", 2097], ["and", 2102], ["ApoE4", 2106], ["levels", 2112], ["nor", 2119], ["the", 2123], ["ApoE", 2127], ["/", 2131], ["ApoE4", 2132], ["ratio", 2138], ["correlated", 2144], ["with", 2155], ["the", 2160], ["diagnosis", 2164], ["of", 2174], ["AD", 2177], [".", 2179], ["These", 2181], ["findings", 2187], ["reinforce", 2196], ["the", 2206], ["conclusions", 2210], ["of", 2222], ["previous", 2225], ["studies", 2234], ["in", 2242], ["which", 2245], ["plasma", 2251], ["ApoE", 2258], ["levels", 2263], ["had", 2270], ["no", 2274], ["obvious", 2277], ["clinical", 2285], ["significance", 2294], [".", 2306]]}
{"context": "A 75-year-old woman presented with altered mental status, septic picture, and influenza-like symptoms. Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result. Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection. Herein, we report the first case of a heterophile-positive mononucleosis syndrome caused by acute CMV infection in an elderly immunocompetent woman. This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "0460fc84d839453e88d73ec2691da940", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[54, 57], [43, 46]], "char_spans": [[324, 341], [271, 288]]}]}], "context_tokens": [["A", 0], ["75-year", 2], ["-", 9], ["old", 10], ["woman", 14], ["presented", 20], ["with", 30], ["altered", 35], ["mental", 43], ["status", 50], [",", 56], ["septic", 58], ["picture", 65], [",", 72], ["and", 74], ["influenza", 78], ["-", 87], ["like", 88], ["symptoms", 93], [".", 101], ["Initial", 103], ["investigations", 111], ["revealed", 126], ["atypical", 135], ["lymphocytosis", 144], [",", 157], ["thrombocytopenia", 159], [",", 175], ["elevated", 177], ["liver", 186], ["enzymes", 192], [",", 199], ["and", 201], ["a", 205], ["positive", 207], ["monospot", 216], ["test", 225], ["result", 230], [".", 236], ["Further", 238], ["investigation", 246], ["showed", 260], ["the", 267], ["Epstein", 271], ["-", 278], ["Barr", 279], ["virus", 284], ["viral", 290], ["capsid", 296], ["antibody", 303], ["IgM", 312], ["/", 315], ["IgG", 316], ["and", 320], ["Epstein", 324], ["-", 331], ["Barr", 332], ["virus", 337], ["DNA", 343], ["by", 347], ["polymerase", 350], ["chain", 361], ["reaction", 367], ["to", 376], ["be", 379], ["negative", 382], [";", 390], ["however", 392], [",", 399], ["interestingly", 401], ["her", 415], ["cytomegalovirus", 419], ["(", 435], ["CMV", 436], [")", 439], ["IgM", 441], ["and", 445], ["IgG", 449], ["were", 453], ["positive", 458], [",", 466], ["suggesting", 468], ["that", 479], ["her", 484], ["mononucleosis", 488], ["-", 501], ["like", 502], ["syndrome", 507], ["was", 516], ["due", 520], ["to", 524], ["acute", 527], ["CMV", 533], ["infection", 537], [".", 546], ["Herein", 548], [",", 554], ["we", 556], ["report", 559], ["the", 566], ["first", 570], ["case", 576], ["of", 581], ["a", 584], ["heterophile", 586], ["-", 597], ["positive", 598], ["mononucleosis", 607], ["syndrome", 621], ["caused", 630], ["by", 637], ["acute", 640], ["CMV", 646], ["infection", 650], ["in", 660], ["an", 663], ["elderly", 666], ["immunocompetent", 674], ["woman", 690], [".", 695], ["This", 697], ["case", 702], ["conveys", 707], ["that", 715], ["monospot", 720], ["test", 729], ["can", 734], ["yield", 738], ["false", 744], ["-", 749], ["positive", 750], ["result", 759], ["in", 766], ["the", 769], ["setting", 773], ["of", 781], ["acute", 784], ["CMV", 790], ["infection", 794], [".", 803]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate (STI571; formerly CGP57148B), successfully suppressed proliferation/survival of the BCR-ABL positive clones. In clinical studies, hematologic and cytogenetic remissions have been achieved in most patients with chronic phase CML; in accelerated and blastic phases of CML, STI571 appeared less effective. In the current study, the authors tested combinations of STI571 and cytarabine and homoharringtonine (HHT), drugs with documented activity in CML. The single agents and their combinations were studied for in vitro effect on proliferation of BCR-ABL positive cell lines KBM5 and KBM7 by 3(4,5-dimethylthiazol-2yl)-2,5 diphenyl-tetrazolium bromide assay and on primary patient-derived BCR-ABL cells by clonogenic assays. The in vitro additive, synergistic, or antagonistic effects of cytarabine and HHT with STI571 were then investigated by computer-assisted analysis using the CalcuSyn software. STI571 consistently suppressed BCR-ABL positive cell proliferation with a dose-effect correlation. In the model system used, STI571/cytarabine and STI571/HHT combinations were more effective in inhibiting KBM5 and KBM7 cell growth than each drug as single agent. These results were also verified in primary CML-derived clonogenic cells in semisolid cultures. In this experimental system, our studies documented additive or synergistic effects with STI571 plus cytarabine or HHT, supporting the future use of STI571 combinations in clinical trials in patients with Philadelphia chromosome-positive leukemias.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee0fc9bc759e4496ab701a203ebb0a81", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[148, 150], [69, 71], [170, 172], [40, 42], [210, 212], [15, 17]], "char_spans": [[853, 859], [393, 399], [995, 1001], [218, 224], [1238, 1244], [88, 94]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["a", 55], ["molecular", 57], ["aberration", 67], [",", 77], ["a", 79], ["fusion", 81], ["BCR", 88], ["-", 91], ["ABL", 92], ["gene", 96], ["encoding", 101], ["for", 110], ["aberrant", 114], ["tyrosine", 123], ["kinase", 132], ["activity", 139], [",", 147], ["which", 149], ["is", 155], ["crucial", 158], ["in", 166], ["the", 169], ["pathogenesis", 173], ["of", 186], ["CML", 189], [".", 192], ["In", 194], ["vitro", 197], [",", 202], ["inhibition", 204], ["of", 215], ["BCR", 218], ["-", 221], ["ABL", 222], ["protein", 226], ["tyrosine", 234], ["kinase", 243], ["activity", 250], ["by", 259], ["a", 262], ["tyrosine", 264], ["kinase", 273], ["inhibitor", 280], [",", 289], ["Imatinib", 291], ["mesylate", 300], ["(", 309], ["STI571", 310], [";", 316], ["formerly", 318], ["CGP57148B", 327], [")", 336], [",", 337], ["successfully", 339], ["suppressed", 352], ["proliferation", 363], ["/", 376], ["survival", 377], ["of", 386], ["the", 389], ["BCR", 393], ["-", 396], ["ABL", 397], ["positive", 401], ["clones", 410], [".", 416], ["In", 418], ["clinical", 421], ["studies", 430], [",", 437], ["hematologic", 439], ["and", 451], ["cytogenetic", 455], ["remissions", 467], ["have", 478], ["been", 483], ["achieved", 488], ["in", 497], ["most", 500], ["patients", 505], ["with", 514], ["chronic", 519], ["phase", 527], ["CML", 533], [";", 536], ["in", 538], ["accelerated", 541], ["and", 553], ["blastic", 557], ["phases", 565], ["of", 572], ["CML", 575], [",", 578], ["STI571", 580], ["appeared", 587], ["less", 596], ["effective", 601], [".", 610], ["In", 612], ["the", 615], ["current", 619], ["study", 627], [",", 632], ["the", 634], ["authors", 638], ["tested", 646], ["combinations", 653], ["of", 666], ["STI571", 669], ["and", 676], ["cytarabine", 680], ["and", 691], ["homoharringtonine", 695], ["(", 713], ["HHT", 714], [")", 717], [",", 718], ["drugs", 720], ["with", 726], ["documented", 731], ["activity", 742], ["in", 751], ["CML", 754], [".", 757], ["The", 759], ["single", 763], ["agents", 770], ["and", 777], ["their", 781], ["combinations", 787], ["were", 800], ["studied", 805], ["for", 813], ["in", 817], ["vitro", 820], ["effect", 826], ["on", 833], ["proliferation", 836], ["of", 850], ["BCR", 853], ["-", 856], ["ABL", 857], ["positive", 861], ["cell", 870], ["lines", 875], ["KBM5", 881], ["and", 886], ["KBM7", 890], ["by", 895], ["3(4,5-dimethylthiazol-2yl)-2,5", 898], ["diphenyl", 929], ["-", 937], ["tetrazolium", 938], ["bromide", 950], ["assay", 958], ["and", 964], ["on", 968], ["primary", 971], ["patient", 979], ["-", 986], ["derived", 987], ["BCR", 995], ["-", 998], ["ABL", 999], ["cells", 1003], ["by", 1009], ["clonogenic", 1012], ["assays", 1023], [".", 1029], ["The", 1031], ["in", 1035], ["vitro", 1038], ["additive", 1044], [",", 1052], ["synergistic", 1054], [",", 1065], ["or", 1067], ["antagonistic", 1070], ["effects", 1083], ["of", 1091], ["cytarabine", 1094], ["and", 1105], ["HHT", 1109], ["with", 1113], ["STI571", 1118], ["were", 1125], ["then", 1130], ["investigated", 1135], ["by", 1148], ["computer", 1151], ["-", 1159], ["assisted", 1160], ["analysis", 1169], ["using", 1178], ["the", 1184], ["CalcuSyn", 1188], ["software", 1197], [".", 1205], ["STI571", 1207], ["consistently", 1214], ["suppressed", 1227], ["BCR", 1238], ["-", 1241], ["ABL", 1242], ["positive", 1246], ["cell", 1255], ["proliferation", 1260], ["with", 1274], ["a", 1279], ["dose", 1281], ["-", 1285], ["effect", 1286], ["correlation", 1293], [".", 1304], ["In", 1306], ["the", 1309], ["model", 1313], ["system", 1319], ["used", 1326], [",", 1330], ["STI571/cytarabine", 1332], ["and", 1350], ["STI571/HHT", 1354], ["combinations", 1365], ["were", 1378], ["more", 1383], ["effective", 1388], ["in", 1398], ["inhibiting", 1401], ["KBM5", 1412], ["and", 1417], ["KBM7", 1421], ["cell", 1426], ["growth", 1431], ["than", 1438], ["each", 1443], ["drug", 1448], ["as", 1453], ["single", 1456], ["agent", 1463], [".", 1468], ["These", 1470], ["results", 1476], ["were", 1484], ["also", 1489], ["verified", 1494], ["in", 1503], ["primary", 1506], ["CML", 1514], ["-", 1517], ["derived", 1518], ["clonogenic", 1526], ["cells", 1537], ["in", 1543], ["semisolid", 1546], ["cultures", 1556], [".", 1564], ["In", 1566], ["this", 1569], ["experimental", 1574], ["system", 1587], [",", 1593], ["our", 1595], ["studies", 1599], ["documented", 1607], ["additive", 1618], ["or", 1627], ["synergistic", 1630], ["effects", 1642], ["with", 1650], ["STI571", 1655], ["plus", 1662], ["cytarabine", 1667], ["or", 1678], ["HHT", 1681], [",", 1684], ["supporting", 1686], ["the", 1697], ["future", 1701], ["use", 1708], ["of", 1712], ["STI571", 1715], ["combinations", 1722], ["in", 1735], ["clinical", 1738], ["trials", 1747], ["in", 1754], ["patients", 1757], ["with", 1766], ["Philadelphia", 1771], ["chromosome", 1784], ["-", 1794], ["positive", 1795], ["leukemias", 1804], [".", 1813]]}
{"context": "Chronic myeloid leukaemia (CML) is characterized cytogenetically by a t(9;22)(q34;ql1) reciprocal translocation which gives origin to a hybrid BCR-ABL gene, encoding a p2lO(BCR-ABL) fusion protein with elevated tyrosine kinase activity and transforming abilities. The t(9;22) was suggested to be associated with genomic imprinting of centromeric regions of chromosomes 9 and 22, but the genes directly affected by the translocation, ABL and BCR, were shown not to be imprinted. For most diagnostic and research purposes the BCR-ABL gene can be efficiently identified by reverse-transcription and polymerase chain reaction (RT/PCR) amplification of its fusion transcripts, which can be quantified by competitive PCR and similar assays for assessment of residual disease in the follow-up of therapy. In the great majority of CML patients the BCR-ABL transcripts exhibit a b2a2 and/or a b3a2 junction; in rare cases, the only detectable BCR-ABL transcripts have unusual junctions, such as b2a3, b3a3, e1a2 or e6a2. There is a recent suggestion that the BCR-ABL gene may not be always 'functional', since extremely low levels of BCR-ABL transcripts can be found in leucocytes from normal individuals and, conversely, it appears that no BCR-ABL transcription can be detected in a proportion of Ph-positive haematopoietic progenitors from some CML patients. The role, if any, of the reciprocal ABL-BCR hybrid gene in CML is unknown. Although its mRNA message is in frame, no ABL-BCR fusion protein has yet been identified in CML patients. The blast crisis of CML has been variably associated with abnormalities of proto-oncogenes, such as RAS and MYC, or of tumour suppressor genes, in particular RB, p53 and p16, or with the generation of chimeric transcription factors, as in the AML1-EVI1 gene fusion. It is likely, therefore, that multiple and alternative molecular defects, as opposed to a single universal mechanism, underlie the acute transformation of the disease.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "bab3517808284dd78fb78dee6116e087", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[278, 281]], "char_spans": [[1469, 1482]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["characterized", 35], ["cytogenetically", 49], ["by", 65], ["a", 68], ["t(9;22)(q34;ql1", 70], [")", 85], ["reciprocal", 87], ["translocation", 98], ["which", 112], ["gives", 118], ["origin", 124], ["to", 131], ["a", 134], ["hybrid", 136], ["BCR", 143], ["-", 146], ["ABL", 147], ["gene", 151], [",", 155], ["encoding", 157], ["a", 166], ["p2lO(BCR", 168], ["-", 176], ["ABL", 177], [")", 180], ["fusion", 182], ["protein", 189], ["with", 197], ["elevated", 202], ["tyrosine", 211], ["kinase", 220], ["activity", 227], ["and", 236], ["transforming", 240], ["abilities", 253], [".", 262], ["The", 264], ["t(9;22", 268], [")", 274], ["was", 276], ["suggested", 280], ["to", 290], ["be", 293], ["associated", 296], ["with", 307], ["genomic", 312], ["imprinting", 320], ["of", 331], ["centromeric", 334], ["regions", 346], ["of", 354], ["chromosomes", 357], ["9", 369], ["and", 371], ["22", 375], [",", 377], ["but", 379], ["the", 383], ["genes", 387], ["directly", 393], ["affected", 402], ["by", 411], ["the", 414], ["translocation", 418], [",", 431], ["ABL", 433], ["and", 437], ["BCR", 441], [",", 444], ["were", 446], ["shown", 451], ["not", 457], ["to", 461], ["be", 464], ["imprinted", 467], [".", 476], ["For", 478], ["most", 482], ["diagnostic", 487], ["and", 498], ["research", 502], ["purposes", 511], ["the", 520], ["BCR", 524], ["-", 527], ["ABL", 528], ["gene", 532], ["can", 537], ["be", 541], ["efficiently", 544], ["identified", 556], ["by", 567], ["reverse", 570], ["-", 577], ["transcription", 578], ["and", 592], ["polymerase", 596], ["chain", 607], ["reaction", 613], ["(", 622], ["RT", 623], ["/", 625], ["PCR", 626], [")", 629], ["amplification", 631], ["of", 645], ["its", 648], ["fusion", 652], ["transcripts", 659], [",", 670], ["which", 672], ["can", 678], ["be", 682], ["quantified", 685], ["by", 696], ["competitive", 699], ["PCR", 711], ["and", 715], ["similar", 719], ["assays", 727], ["for", 734], ["assessment", 738], ["of", 749], ["residual", 752], ["disease", 761], ["in", 769], ["the", 772], ["follow", 776], ["-", 782], ["up", 783], ["of", 786], ["therapy", 789], [".", 796], ["In", 798], ["the", 801], ["great", 805], ["majority", 811], ["of", 820], ["CML", 823], ["patients", 827], ["the", 836], ["BCR", 840], ["-", 843], ["ABL", 844], ["transcripts", 848], ["exhibit", 860], ["a", 868], ["b2a2", 870], ["and/or", 875], ["a", 882], ["b3a2", 884], ["junction", 889], [";", 897], ["in", 899], ["rare", 902], ["cases", 907], [",", 912], ["the", 914], ["only", 918], ["detectable", 923], ["BCR", 934], ["-", 937], ["ABL", 938], ["transcripts", 942], ["have", 954], ["unusual", 959], ["junctions", 967], [",", 976], ["such", 978], ["as", 983], ["b2a3", 986], [",", 990], ["b3a3", 992], [",", 996], ["e1a2", 998], ["or", 1003], ["e6a2", 1006], [".", 1010], ["There", 1012], ["is", 1018], ["a", 1021], ["recent", 1023], ["suggestion", 1030], ["that", 1041], ["the", 1046], ["BCR", 1050], ["-", 1053], ["ABL", 1054], ["gene", 1058], ["may", 1063], ["not", 1067], ["be", 1071], ["always", 1074], ["'", 1081], ["functional", 1082], ["'", 1092], [",", 1093], ["since", 1095], ["extremely", 1101], ["low", 1111], ["levels", 1115], ["of", 1122], ["BCR", 1125], ["-", 1128], ["ABL", 1129], ["transcripts", 1133], ["can", 1145], ["be", 1149], ["found", 1152], ["in", 1158], ["leucocytes", 1161], ["from", 1172], ["normal", 1177], ["individuals", 1184], ["and", 1196], [",", 1199], ["conversely", 1201], [",", 1211], ["it", 1213], ["appears", 1216], ["that", 1224], ["no", 1229], ["BCR", 1232], ["-", 1235], ["ABL", 1236], ["transcription", 1240], ["can", 1254], ["be", 1258], ["detected", 1261], ["in", 1270], ["a", 1273], ["proportion", 1275], ["of", 1286], ["Ph", 1289], ["-", 1291], ["positive", 1292], ["haematopoietic", 1301], ["progenitors", 1316], ["from", 1328], ["some", 1333], ["CML", 1338], ["patients", 1342], [".", 1350], ["The", 1352], ["role", 1356], [",", 1360], ["if", 1362], ["any", 1365], [",", 1368], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["hybrid", 1396], ["gene", 1403], ["in", 1408], ["CML", 1411], ["is", 1415], ["unknown", 1418], [".", 1425], ["Although", 1427], ["its", 1436], ["mRNA", 1440], ["message", 1445], ["is", 1453], ["in", 1456], ["frame", 1459], [",", 1464], ["no", 1466], ["ABL", 1469], ["-", 1472], ["BCR", 1473], ["fusion", 1477], ["protein", 1484], ["has", 1492], ["yet", 1496], ["been", 1500], ["identified", 1505], ["in", 1516], ["CML", 1519], ["patients", 1523], [".", 1531], ["The", 1533], ["blast", 1537], ["crisis", 1543], ["of", 1550], ["CML", 1553], ["has", 1557], ["been", 1561], ["variably", 1566], ["associated", 1575], ["with", 1586], ["abnormalities", 1591], ["of", 1605], ["proto", 1608], ["-", 1613], ["oncogenes", 1614], [",", 1623], ["such", 1625], ["as", 1630], ["RAS", 1633], ["and", 1637], ["MYC", 1641], [",", 1644], ["or", 1646], ["of", 1649], ["tumour", 1652], ["suppressor", 1659], ["genes", 1670], [",", 1675], ["in", 1677], ["particular", 1680], ["RB", 1691], [",", 1693], ["p53", 1695], ["and", 1699], ["p16", 1703], [",", 1706], ["or", 1708], ["with", 1711], ["the", 1716], ["generation", 1720], ["of", 1731], ["chimeric", 1734], ["transcription", 1743], ["factors", 1757], [",", 1764], ["as", 1766], ["in", 1769], ["the", 1772], ["AML1-EVI1", 1776], ["gene", 1786], ["fusion", 1791], [".", 1797], ["It", 1799], ["is", 1802], ["likely", 1805], [",", 1811], ["therefore", 1813], [",", 1822], ["that", 1824], ["multiple", 1829], ["and", 1838], ["alternative", 1842], ["molecular", 1854], ["defects", 1864], [",", 1871], ["as", 1873], ["opposed", 1876], ["to", 1884], ["a", 1887], ["single", 1889], ["universal", 1896], ["mechanism", 1906], [",", 1915], ["underlie", 1917], ["the", 1926], ["acute", 1930], ["transformation", 1936], ["of", 1951], ["the", 1954], ["disease", 1958], [".", 1965]]}
{"context": "A mutation in the alpha-synuclein gene has recently been linked to some cases of familial Parkinson's disease (PD). We characterized the expression of this presynaptic protein in the midbrain, striatum, and temporal cortex of control, PD, and dementia with Lewy bodies (DLB) brain. Control brain showed punctate pericellular immunostaining. PD brain demonstrated alpha-synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites. Rare neuronal soma in PD brain were immunoreactive for alpha-synuclein. DLB cases demonstrated these findings as well as alpha-synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites. These results suggest that, even in sporadic cases, there is an early and direct role for alpha-synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "65a878a609f441afbfab92ba3203df80", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[134, 136], [102, 104], [4, 6], [90, 92], [66, 68]], "char_spans": [[742, 756], [575, 589], [18, 32], [509, 523], [363, 377]]}]}], "context_tokens": [["A", 0], ["mutation", 2], ["in", 11], ["the", 14], ["alpha", 18], ["-", 23], ["synuclein", 24], ["gene", 34], ["has", 39], ["recently", 43], ["been", 52], ["linked", 57], ["to", 64], ["some", 67], ["cases", 72], ["of", 78], ["familial", 81], ["Parkinson", 90], ["'s", 99], ["disease", 102], ["(", 110], ["PD", 111], [")", 113], [".", 114], ["We", 116], ["characterized", 119], ["the", 133], ["expression", 137], ["of", 148], ["this", 151], ["presynaptic", 156], ["protein", 168], ["in", 176], ["the", 179], ["midbrain", 183], [",", 191], ["striatum", 193], [",", 201], ["and", 203], ["temporal", 207], ["cortex", 216], ["of", 223], ["control", 226], [",", 233], ["PD", 235], [",", 237], ["and", 239], ["dementia", 243], ["with", 252], ["Lewy", 257], ["bodies", 262], ["(", 269], ["DLB", 270], [")", 273], ["brain", 275], [".", 280], ["Control", 282], ["brain", 290], ["showed", 296], ["punctate", 303], ["pericellular", 312], ["immunostaining", 325], [".", 339], ["PD", 341], ["brain", 344], ["demonstrated", 350], ["alpha", 363], ["-", 368], ["synuclein", 369], ["immunoreactivity", 379], ["in", 396], ["nigral", 399], ["Lewy", 406], ["bodies", 411], [",", 417], ["pale", 419], ["bodies", 424], ["and", 431], ["abnormal", 435], ["neurites", 444], [".", 452], ["Rare", 454], ["neuronal", 459], ["soma", 468], ["in", 473], ["PD", 476], ["brain", 479], ["were", 485], ["immunoreactive", 490], ["for", 505], ["alpha", 509], ["-", 514], ["synuclein", 515], [".", 524], ["DLB", 526], ["cases", 530], ["demonstrated", 536], ["these", 549], ["findings", 555], ["as", 564], ["well", 567], ["as", 572], ["alpha", 575], ["-", 580], ["synuclein", 581], ["immunoreactivity", 591], ["in", 608], ["cortical", 611], ["Lewy", 620], ["bodies", 625], ["and", 632], ["CA2", 636], ["-", 639], ["3", 640], ["neurites", 642], [".", 650], ["These", 652], ["results", 658], ["suggest", 666], ["that", 674], [",", 678], ["even", 680], ["in", 685], ["sporadic", 688], ["cases", 697], [",", 702], ["there", 704], ["is", 710], ["an", 713], ["early", 716], ["and", 722], ["direct", 726], ["role", 733], ["for", 738], ["alpha", 742], ["-", 747], ["synuclein", 748], ["in", 758], ["the", 761], ["pathogenesis", 765], ["of", 778], ["PD", 781], ["and", 784], ["the", 788], ["neuropathologically", 792], ["related", 812], ["disorder", 820], ["DLB", 829], [".", 832]]}
{"context": "The subventricular zone (SVZ) is an embryonic remnant that persists and remains mitotically active throughout adulthood. The rodent SVZ harbors neuronal precursors, principally in its anterior part, and generates neuroblasts that migrate tangentially into the olfactory bulb, thus forming the so-called rostral migratory stream. This study aimed at characterizing the SVZ in the human brain. Antibodies raised against the widely used SVZ molecular markers nestin, glial fibrillary acidic protein, beta-tubulin-III and polysialylated neural cell adhesion molecule, have allowed us to characterize in detail a zone similar to the rodent SVZ in humans. Virtually all portions of the lateral ventricle, as well as the ventral (hypothalamic) sector of the third ventricle, displayed immunoreactivity for most of the molecular markers. The midline region of the septum (septal recess) and the ventral portion of the SVZ displayed a particularly intense immunostaining for all SVZ markers. These two regions may represent zones of adult neurogenesis that are unique to primates. Furthermore, the anti-apoptotic protein Bcl-2 was found to be actively synthesized and co-expressed with all the other markers throughout the entire SVZ. This study reveals that a well-developed SVZ exists in the adult human brain and suggests that Bcl-2 might play an important role in the functional organization of such a system.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2c9f3d096d9b474e81e534d2b2027f2b", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[74, 74]], "char_spans": [[456, 461]]}]}], "context_tokens": [["The", 0], ["subventricular", 4], ["zone", 19], ["(", 24], ["SVZ", 25], [")", 28], ["is", 30], ["an", 33], ["embryonic", 36], ["remnant", 46], ["that", 54], ["persists", 59], ["and", 68], ["remains", 72], ["mitotically", 80], ["active", 92], ["throughout", 99], ["adulthood", 110], [".", 119], ["The", 121], ["rodent", 125], ["SVZ", 132], ["harbors", 136], ["neuronal", 144], ["precursors", 153], [",", 163], ["principally", 165], ["in", 177], ["its", 180], ["anterior", 184], ["part", 193], [",", 197], ["and", 199], ["generates", 203], ["neuroblasts", 213], ["that", 225], ["migrate", 230], ["tangentially", 238], ["into", 251], ["the", 256], ["olfactory", 260], ["bulb", 270], [",", 274], ["thus", 276], ["forming", 281], ["the", 289], ["so", 293], ["-", 295], ["called", 296], ["rostral", 303], ["migratory", 311], ["stream", 321], [".", 327], ["This", 329], ["study", 334], ["aimed", 340], ["at", 346], ["characterizing", 349], ["the", 364], ["SVZ", 368], ["in", 372], ["the", 375], ["human", 379], ["brain", 385], [".", 390], ["Antibodies", 392], ["raised", 403], ["against", 410], ["the", 418], ["widely", 422], ["used", 429], ["SVZ", 434], ["molecular", 438], ["markers", 448], ["nestin", 456], [",", 462], ["glial", 464], ["fibrillary", 470], ["acidic", 481], ["protein", 488], [",", 495], ["beta", 497], ["-", 501], ["tubulin", 502], ["-", 509], ["III", 510], ["and", 514], ["polysialylated", 518], ["neural", 533], ["cell", 540], ["adhesion", 545], ["molecule", 554], [",", 562], ["have", 564], ["allowed", 569], ["us", 577], ["to", 580], ["characterize", 583], ["in", 596], ["detail", 599], ["a", 606], ["zone", 608], ["similar", 613], ["to", 621], ["the", 624], ["rodent", 628], ["SVZ", 635], ["in", 639], ["humans", 642], [".", 648], ["Virtually", 650], ["all", 660], ["portions", 664], ["of", 673], ["the", 676], ["lateral", 680], ["ventricle", 688], [",", 697], ["as", 699], ["well", 702], ["as", 707], ["the", 710], ["ventral", 714], ["(", 722], ["hypothalamic", 723], [")", 735], ["sector", 737], ["of", 744], ["the", 747], ["third", 751], ["ventricle", 757], [",", 766], ["displayed", 768], ["immunoreactivity", 778], ["for", 795], ["most", 799], ["of", 804], ["the", 807], ["molecular", 811], ["markers", 821], [".", 828], ["The", 830], ["midline", 834], ["region", 842], ["of", 849], ["the", 852], ["septum", 856], ["(", 863], ["septal", 864], ["recess", 871], [")", 877], ["and", 879], ["the", 883], ["ventral", 887], ["portion", 895], ["of", 903], ["the", 906], ["SVZ", 910], ["displayed", 914], ["a", 924], ["particularly", 926], ["intense", 939], ["immunostaining", 947], ["for", 962], ["all", 966], ["SVZ", 970], ["markers", 974], [".", 981], ["These", 983], ["two", 989], ["regions", 993], ["may", 1001], ["represent", 1005], ["zones", 1015], ["of", 1021], ["adult", 1024], ["neurogenesis", 1030], ["that", 1043], ["are", 1048], ["unique", 1052], ["to", 1059], ["primates", 1062], [".", 1070], ["Furthermore", 1072], [",", 1083], ["the", 1085], ["anti", 1089], ["-", 1093], ["apoptotic", 1094], ["protein", 1104], ["Bcl-2", 1112], ["was", 1118], ["found", 1122], ["to", 1128], ["be", 1131], ["actively", 1134], ["synthesized", 1143], ["and", 1155], ["co", 1159], ["-", 1161], ["expressed", 1162], ["with", 1172], ["all", 1177], ["the", 1181], ["other", 1185], ["markers", 1191], ["throughout", 1199], ["the", 1210], ["entire", 1214], ["SVZ", 1221], [".", 1224], ["This", 1226], ["study", 1231], ["reveals", 1237], ["that", 1245], ["a", 1250], ["well", 1252], ["-", 1256], ["developed", 1257], ["SVZ", 1267], ["exists", 1271], ["in", 1278], ["the", 1281], ["adult", 1285], ["human", 1291], ["brain", 1297], ["and", 1303], ["suggests", 1307], ["that", 1316], ["Bcl-2", 1321], ["might", 1327], ["play", 1333], ["an", 1338], ["important", 1341], ["role", 1351], ["in", 1356], ["the", 1359], ["functional", 1363], ["organization", 1374], ["of", 1387], ["such", 1390], ["a", 1395], ["system", 1397], [".", 1403]]}
{"context": "RNA editing usually affects only a fraction of expressed transcripts and there is a vast amount of variation in editing levels of ADAR (adenosine deaminase, RNA-specific) targets. Here we explore natural genetic variation affecting editing levels of particular sites in 81 natural strains of Drosophila melanogaster. The analysis of associations between editing levels and single-nucleotide polymorphisms allows us to map putative cis-regulatory regions affecting editing of 16 A-to-I editing sites (cis-RNA editing quantitative trait loci or cis-edQTLs, P\u00a0<\u00a010(-8)). The observed changes in editing levels are validated by independent molecular technique. All identified regulatory variants are located in close proximity of modulated editing sites. Moreover, colocalized editing sites are often regulated by same loci. Similar to expression and splicing QTL studies, the characterization of edQTLs will greatly expand our understanding of cis-regulatory evolution of gene expression.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "d56d38b84b684192b16ecad81b0152c7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[22, 22]], "char_spans": [[130, 133]]}, {"text": "adenosine deaminase, RNA-specific", "token_spans": [[24, 29]], "char_spans": [[136, 168]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["usually", 12], ["affects", 20], ["only", 28], ["a", 33], ["fraction", 35], ["of", 44], ["expressed", 47], ["transcripts", 57], ["and", 69], ["there", 73], ["is", 79], ["a", 82], ["vast", 84], ["amount", 89], ["of", 96], ["variation", 99], ["in", 109], ["editing", 112], ["levels", 120], ["of", 127], ["ADAR", 130], ["(", 135], ["adenosine", 136], ["deaminase", 146], [",", 155], ["RNA", 157], ["-", 160], ["specific", 161], [")", 169], ["targets", 171], [".", 178], ["Here", 180], ["we", 185], ["explore", 188], ["natural", 196], ["genetic", 204], ["variation", 212], ["affecting", 222], ["editing", 232], ["levels", 240], ["of", 247], ["particular", 250], ["sites", 261], ["in", 267], ["81", 270], ["natural", 273], ["strains", 281], ["of", 289], ["Drosophila", 292], ["melanogaster", 303], [".", 315], ["The", 317], ["analysis", 321], ["of", 330], ["associations", 333], ["between", 346], ["editing", 354], ["levels", 362], ["and", 369], ["single", 373], ["-", 379], ["nucleotide", 380], ["polymorphisms", 391], ["allows", 405], ["us", 412], ["to", 415], ["map", 418], ["putative", 422], ["cis", 431], ["-", 434], ["regulatory", 435], ["regions", 446], ["affecting", 454], ["editing", 464], ["of", 472], ["16", 475], ["A", 478], ["-", 479], ["to", 480], ["-", 482], ["I", 483], ["editing", 485], ["sites", 493], ["(", 499], ["cis", 500], ["-", 503], ["RNA", 504], ["editing", 508], ["quantitative", 516], ["trait", 529], ["loci", 535], ["or", 540], ["cis", 543], ["-", 546], ["edQTLs", 547], [",", 553], ["P", 555], ["<", 557], ["10(-8", 559], [")", 564], [")", 565], [".", 566], ["The", 568], ["observed", 572], ["changes", 581], ["in", 589], ["editing", 592], ["levels", 600], ["are", 607], ["validated", 611], ["by", 621], ["independent", 624], ["molecular", 636], ["technique", 646], [".", 655], ["All", 657], ["identified", 661], ["regulatory", 672], ["variants", 683], ["are", 692], ["located", 696], ["in", 704], ["close", 707], ["proximity", 713], ["of", 723], ["modulated", 726], ["editing", 736], ["sites", 744], [".", 749], ["Moreover", 751], [",", 759], ["colocalized", 761], ["editing", 773], ["sites", 781], ["are", 787], ["often", 791], ["regulated", 797], ["by", 807], ["same", 810], ["loci", 815], [".", 819], ["Similar", 821], ["to", 829], ["expression", 832], ["and", 843], ["splicing", 847], ["QTL", 856], ["studies", 860], [",", 867], ["the", 869], ["characterization", 873], ["of", 890], ["edQTLs", 893], ["will", 900], ["greatly", 905], ["expand", 913], ["our", 920], ["understanding", 924], ["of", 938], ["cis", 941], ["-", 944], ["regulatory", 945], ["evolution", 956], ["of", 966], ["gene", 969], ["expression", 974], [".", 984]]}
{"context": "Prader-Willi syndrome (PWS) results from a deletion of the paternal genes in the region of chromosome 15q11-q13. PWS develops hyperphagia, which when left unmanaged, leads to an excessive ingestion of food. To date there is inadequate pharmacological treatment or supplementation for modification of the PWS hyperphagia and/or the associated behaviors. Therefore, the best practice is familial supervision and restriction of diet and environment. We aimed to determine if the natural supplement of Caralluma fimbriata extract (CFE) could attenuate hyperphagia or the associated appetite behaviors in children and adolescents with PWS over the 4-week pilot trial period. We conducted a placebo-controlled, double-blind, randomized crossover trial over a 10-week period to investigate the effects of CFE on hunger control, in a cohort of children and adolescents with confirmed PWS (n =15, mean age 9.27 \u00b1 3.16 years, body weight 43.98 \u00b1 23.99 kg). Participants from Australia and New Zealand ingested CFE or a placebo of maltodextrin/cabbage leaf over a 4-week period, with a 2-week washout before the crossover to the other treatment. Weekly comparisons in appetite behavior, severity, and drive were recorded by parents, as scaled time-point measures on a hyperphagia questionnaire validated for PWS. CFE administration was found to induce a significant accumulative easing of hyperphagia (P = 0.05), with decreases evident in one-third of the participants. Furthermore due to CFE supplementation, a significant decrease (P \u2264 0.05) was recorded in the category of behavior and a decrease in hyperphagia (n = 8, P = 0.009) was observed at the highest dose 1,000 mg/day (recommended adult dose). There were no reported adverse effects at any dose. We demonstrate that an extract of the Indian cactus succulent Caralluma fimbriata eases hyperphagic appetite behavior within a cohort of children and adolescents (n = 15) with PWS without notable adverse effects. The outcomes of this study will have a potential positive impact on PWS management.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "8b979d0ca3aa47dbbd35ea426dc78be3", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 20]]}]}], "context_tokens": [["Prader", 0], ["-", 6], ["Willi", 7], ["syndrome", 13], ["(", 22], ["PWS", 23], [")", 26], ["results", 28], ["from", 36], ["a", 41], ["deletion", 43], ["of", 52], ["the", 55], ["paternal", 59], ["genes", 68], ["in", 74], ["the", 77], ["region", 81], ["of", 88], ["chromosome", 91], ["15q11-q13", 102], [".", 111], ["PWS", 113], ["develops", 117], ["hyperphagia", 126], [",", 137], ["which", 139], ["when", 145], ["left", 150], ["unmanaged", 155], [",", 164], ["leads", 166], ["to", 172], ["an", 175], ["excessive", 178], ["ingestion", 188], ["of", 198], ["food", 201], [".", 205], ["To", 207], ["date", 210], ["there", 215], ["is", 221], ["inadequate", 224], ["pharmacological", 235], ["treatment", 251], ["or", 261], ["supplementation", 264], ["for", 280], ["modification", 284], ["of", 297], ["the", 300], ["PWS", 304], ["hyperphagia", 308], ["and/or", 320], ["the", 327], ["associated", 331], ["behaviors", 342], [".", 351], ["Therefore", 353], [",", 362], ["the", 364], ["best", 368], ["practice", 373], ["is", 382], ["familial", 385], ["supervision", 394], ["and", 406], ["restriction", 410], ["of", 422], ["diet", 425], ["and", 430], ["environment", 434], [".", 445], ["We", 447], ["aimed", 450], ["to", 456], ["determine", 459], ["if", 469], ["the", 472], ["natural", 476], ["supplement", 484], ["of", 495], ["Caralluma", 498], ["fimbriata", 508], ["extract", 518], ["(", 526], ["CFE", 527], [")", 530], ["could", 532], ["attenuate", 538], ["hyperphagia", 548], ["or", 560], ["the", 563], ["associated", 567], ["appetite", 578], ["behaviors", 587], ["in", 597], ["children", 600], ["and", 609], ["adolescents", 613], ["with", 625], ["PWS", 630], ["over", 634], ["the", 639], ["4-week", 643], ["pilot", 650], ["trial", 656], ["period", 662], [".", 668], ["We", 670], ["conducted", 673], ["a", 683], ["placebo", 685], ["-", 692], ["controlled", 693], [",", 703], ["double", 705], ["-", 711], ["blind", 712], [",", 717], ["randomized", 719], ["crossover", 730], ["trial", 740], ["over", 746], ["a", 751], ["10-week", 753], ["period", 761], ["to", 768], ["investigate", 771], ["the", 783], ["effects", 787], ["of", 795], ["CFE", 798], ["on", 802], ["hunger", 805], ["control", 812], [",", 819], ["in", 821], ["a", 824], ["cohort", 826], ["of", 833], ["children", 836], ["and", 845], ["adolescents", 849], ["with", 861], ["confirmed", 866], ["PWS", 876], ["(", 880], ["n", 881], ["=", 883], ["15", 884], [",", 886], ["mean", 888], ["age", 893], ["9.27", 897], ["\u00b1", 902], ["3.16", 904], ["years", 909], [",", 914], ["body", 916], ["weight", 921], ["43.98", 928], ["\u00b1", 934], ["23.99", 936], ["kg", 942], [")", 944], [".", 945], ["Participants", 947], ["from", 960], ["Australia", 965], ["and", 975], ["New", 979], ["Zealand", 983], ["ingested", 991], ["CFE", 1000], ["or", 1004], ["a", 1007], ["placebo", 1009], ["of", 1017], ["maltodextrin", 1020], ["/", 1032], ["cabbage", 1033], ["leaf", 1041], ["over", 1046], ["a", 1051], ["4-week", 1053], ["period", 1060], [",", 1066], ["with", 1068], ["a", 1073], ["2-week", 1075], ["washout", 1082], ["before", 1090], ["the", 1097], ["crossover", 1101], ["to", 1111], ["the", 1114], ["other", 1118], ["treatment", 1124], [".", 1133], ["Weekly", 1135], ["comparisons", 1142], ["in", 1154], ["appetite", 1157], ["behavior", 1166], [",", 1174], ["severity", 1176], [",", 1184], ["and", 1186], ["drive", 1190], ["were", 1196], ["recorded", 1201], ["by", 1210], ["parents", 1213], [",", 1220], ["as", 1222], ["scaled", 1225], ["time", 1232], ["-", 1236], ["point", 1237], ["measures", 1243], ["on", 1252], ["a", 1255], ["hyperphagia", 1257], ["questionnaire", 1269], ["validated", 1283], ["for", 1293], ["PWS", 1297], [".", 1300], ["CFE", 1302], ["administration", 1306], ["was", 1321], ["found", 1325], ["to", 1331], ["induce", 1334], ["a", 1341], ["significant", 1343], ["accumulative", 1355], ["easing", 1368], ["of", 1375], ["hyperphagia", 1378], ["(", 1390], ["P", 1391], ["=", 1393], ["0.05", 1395], [")", 1399], [",", 1400], ["with", 1402], ["decreases", 1407], ["evident", 1417], ["in", 1425], ["one", 1428], ["-", 1431], ["third", 1432], ["of", 1438], ["the", 1441], ["participants", 1445], [".", 1457], ["Furthermore", 1459], ["due", 1471], ["to", 1475], ["CFE", 1478], ["supplementation", 1482], [",", 1497], ["a", 1499], ["significant", 1501], ["decrease", 1513], ["(", 1522], ["P", 1523], ["\u2264", 1525], ["0.05", 1527], [")", 1531], ["was", 1533], ["recorded", 1537], ["in", 1546], ["the", 1549], ["category", 1553], ["of", 1562], ["behavior", 1565], ["and", 1574], ["a", 1578], ["decrease", 1580], ["in", 1589], ["hyperphagia", 1592], ["(", 1604], ["n", 1605], ["=", 1607], ["8", 1609], [",", 1610], ["P", 1612], ["=", 1614], ["0.009", 1616], [")", 1621], ["was", 1623], ["observed", 1627], ["at", 1636], ["the", 1639], ["highest", 1643], ["dose", 1651], ["1,000", 1656], ["mg", 1662], ["/", 1664], ["day", 1665], ["(", 1669], ["recommended", 1670], ["adult", 1682], ["dose", 1688], [")", 1692], [".", 1693], ["There", 1695], ["were", 1701], ["no", 1706], ["reported", 1709], ["adverse", 1718], ["effects", 1726], ["at", 1734], ["any", 1737], ["dose", 1741], [".", 1745], ["We", 1747], ["demonstrate", 1750], ["that", 1762], ["an", 1767], ["extract", 1770], ["of", 1778], ["the", 1781], ["Indian", 1785], ["cactus", 1792], ["succulent", 1799], ["Caralluma", 1809], ["fimbriata", 1819], ["eases", 1829], ["hyperphagic", 1835], ["appetite", 1847], ["behavior", 1856], ["within", 1865], ["a", 1872], ["cohort", 1874], ["of", 1881], ["children", 1884], ["and", 1893], ["adolescents", 1897], ["(", 1909], ["n", 1910], ["=", 1912], ["15", 1914], [")", 1916], ["with", 1918], ["PWS", 1923], ["without", 1927], ["notable", 1935], ["adverse", 1943], ["effects", 1951], [".", 1958], ["The", 1960], ["outcomes", 1964], ["of", 1973], ["this", 1976], ["study", 1981], ["will", 1987], ["have", 1992], ["a", 1997], ["potential", 1999], ["positive", 2009], ["impact", 2018], ["on", 2025], ["PWS", 2028], ["management", 2032], [".", 2042]]}
{"context": "The translocation (9;22) gives rise to the p190(Bcr-Abl) and p210(Bcr-Abl) tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph(+)) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph(+) acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29% of ALL patients (CHR, 19%; marrow-CR, 10%), which were sustained for at least 4 weeks in 6% of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38%) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9% of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54% and 27% of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph(+) acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "51a1889816af46d0bc6c17f5001e75f4", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[65, 67]], "char_spans": [[374, 380]]}]}], "context_tokens": [["The", 0], ["translocation", 4], ["(", 18], ["9;22", 19], [")", 23], ["gives", 25], ["rise", 31], ["to", 36], ["the", 39], ["p190(Bcr", 43], ["-", 51], ["Abl", 52], [")", 55], ["and", 57], ["p210(Bcr", 61], ["-", 69], ["Abl", 70], [")", 73], ["tyrosine", 75], ["kinase", 84], ["proteins", 91], [",", 99], ["considered", 101], ["sufficient", 112], ["for", 123], ["leukemic", 127], ["transformation", 136], [".", 150], ["Philadelphia", 152], ["-", 164], ["positive", 165], ["(", 174], ["Ph(+", 175], [")", 179], [")", 180], ["acute", 182], ["leukemia", 188], ["patients", 197], ["failing", 206], ["to", 214], ["respond", 217], ["to", 225], ["initial", 228], ["induction", 236], ["therapy", 246], ["have", 254], ["a", 259], ["poor", 261], ["prognosis", 266], ["with", 276], ["few", 281], ["effective", 285], ["treatment", 295], ["options", 305], [".", 312], ["Imatinib", 314], ["is", 323], ["an", 326], ["orally", 329], ["administered", 336], [",", 348], ["potent", 350], ["inhibitor", 357], ["of", 367], ["the", 370], ["Bcr", 374], ["-", 377], ["Abl", 378], ["tyrosine", 382], ["kinase", 391], [".", 397], ["We", 399], ["conducted", 402], ["a", 412], ["clinical", 414], ["trial", 423], ["in", 429], ["56", 432], ["patients", 435], ["with", 444], ["relapsed", 449], ["or", 458], ["refractory", 461], ["Ph(+", 472], [")", 476], ["acute", 478], ["lymphoblastic", 484], ["leukemia", 498], ["(", 507], ["ALL", 508], [";", 511], ["48", 513], ["patients", 516], [")", 524], ["or", 526], ["chronic", 529], ["myelogenous", 537], ["leukemia", 549], ["in", 558], ["lymphoid", 561], ["blast", 570], ["crisis", 576], ["(", 583], ["LyBC", 584], [";", 588], ["8", 590], ["patients", 592], [")", 600], [".", 601], ["Imatinib", 603], ["was", 612], ["given", 616], ["once", 622], ["daily", 627], ["at", 633], ["400", 636], ["mg", 640], ["or", 643], ["600", 646], ["mg", 650], [".", 652], ["Imatinib", 654], ["induced", 663], ["complete", 671], ["hematologic", 680], ["responses", 692], ["(", 702], ["CHRs", 703], [")", 707], ["and", 709], ["complete", 713], ["marrow", 722], ["responses", 729], ["(", 739], ["marrow", 740], ["-", 746], ["CRs", 747], [")", 750], ["in", 752], ["29", 755], ["%", 757], ["of", 759], ["ALL", 762], ["patients", 766], ["(", 775], ["CHR", 776], [",", 779], ["19", 781], ["%", 783], [";", 784], ["marrow", 786], ["-", 792], ["CR", 793], [",", 795], ["10", 797], ["%", 799], [")", 800], [",", 801], ["which", 803], ["were", 809], ["sustained", 814], ["for", 824], ["at", 828], ["least", 831], ["4", 837], ["weeks", 839], ["in", 845], ["6", 848], ["%", 849], ["of", 851], ["patients", 854], [".", 862], ["Median", 864], ["estimated", 871], ["time", 881], ["to", 886], ["progression", 889], ["and", 901], ["overall", 905], ["survival", 913], ["for", 922], ["ALL", 926], ["patients", 930], ["were", 939], ["2.2", 944], ["and", 948], ["4.9", 952], ["months", 956], [",", 962], ["respectively", 964], [".", 976], ["CHRs", 978], ["were", 983], ["reported", 988], ["for", 997], ["3", 1001], ["(", 1003], ["38", 1004], ["%", 1006], [")", 1007], ["of", 1009], ["the", 1012], ["patients", 1016], ["with", 1025], ["LyBC", 1030], ["(", 1035], ["one", 1036], ["sustained", 1040], ["CHR", 1050], [")", 1053], [".", 1054], ["Grade", 1056], ["3", 1062], ["or", 1064], ["4", 1067], ["treatment", 1069], ["-", 1078], ["related", 1079], ["nonhematologic", 1087], ["toxicity", 1102], ["was", 1111], ["reported", 1115], ["for", 1124], ["9", 1128], ["%", 1129], ["of", 1131], ["patients", 1134], [";", 1142], ["none", 1144], ["of", 1149], ["the", 1152], ["patients", 1156], ["discontinued", 1165], ["therapy", 1178], ["because", 1186], ["of", 1194], ["nonhematologic", 1197], ["adverse", 1212], ["reactions", 1220], [".", 1229], ["Grade", 1231], ["4", 1237], ["neutropenia", 1239], ["and", 1251], ["thrombocytopenia", 1255], ["occurred", 1272], ["in", 1281], ["54", 1284], ["%", 1286], ["and", 1288], ["27", 1292], ["%", 1294], ["of", 1296], ["patients", 1299], [",", 1307], ["respectively", 1309], [".", 1321], ["Imatinib", 1323], ["therapy", 1332], ["resulted", 1340], ["in", 1349], ["a", 1352], ["clinically", 1354], ["relevant", 1365], ["hematologic", 1374], ["response", 1386], ["rate", 1395], ["in", 1400], ["relapsed", 1403], ["or", 1412], ["refractory", 1415], ["Ph(+", 1426], [")", 1430], ["acute", 1432], ["lymphoid", 1438], ["leukemia", 1447], ["patients", 1456], [",", 1464], ["but", 1466], ["development", 1470], ["of", 1482], ["resistance", 1485], ["and", 1496], ["subsequent", 1500], ["disease", 1511], ["progression", 1519], ["were", 1531], ["rapid", 1536], [".", 1541], ["Further", 1543], ["studies", 1551], ["are", 1559], ["warranted", 1563], ["to", 1573], ["test", 1576], ["the", 1581], ["effects", 1585], ["of", 1593], ["imatinib", 1596], ["in", 1605], ["combination", 1608], ["with", 1620], ["other", 1625], ["agents", 1631], ["and", 1638], ["to", 1642], ["define", 1645], ["the", 1652], ["mechanisms", 1656], ["of", 1667], ["resistance", 1670], ["to", 1681], ["imatinib", 1684], [".", 1692]]}
{"context": "AtxA, a unique regulatory protein of unknown molecular function, positively controls expression of the major virulence genes of Bacillus anthracis. The 475 amino acid sequence of AtxA reveals DNA binding motifs and regions similar to proteins associated with the phosphoenolpyruvate: carbohydrate phosphotransferase system (PTS). We used strains producing native and functional epitope-tagged AtxA proteins to examine protein-protein interactions in cell lysates and in solutions of purified protein. Co-affinity purification, non-denaturing polyacrylamide gel electrophoresis and bis(maleimido)hexane (BMH) cross-linking experiments revealed AtxA homo-multimers. Dimers were the most abundant species. BMH cross-links available cysteines within 13 \u00c5. To localize interaction sites, six AtxA mutants containing distinct Cys\u2192Ser substitutions were tested for multimerization and cross-linking. All mutants multimerized, but one mutation, C402S, prevented cross-linking. Thus, BMH uses C402 to make the inter-molecular bond between AtxA proteins, but C402 is not required for protein-protein interaction. C402 is in a region bearing amino acid similarity to Enzyme IIB proteins of the PTS. The AtxA EIIB motif may function in protein oligomerization. Finally, cultures grown with elevated CO(2) /bicarbonate exhibited increased AtxA dimer/monomer ratios and increased AtxA activity, relative to cultures grown without added CO(2) /bicarbonate, suggesting that this host-associated signal enhances AtxA function by shifting the dimer/monomer equilibrium towards the dimeric state.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "47491f59f6b14de09b72e1a703284430", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "bicarbonate", "token_spans": [[240, 240], [219, 219]], "char_spans": [[1428, 1439], [1293, 1304]]}]}], "context_tokens": [["AtxA", 0], [",", 4], ["a", 6], ["unique", 8], ["regulatory", 15], ["protein", 26], ["of", 34], ["unknown", 37], ["molecular", 45], ["function", 55], [",", 63], ["positively", 65], ["controls", 76], ["expression", 85], ["of", 96], ["the", 99], ["major", 103], ["virulence", 109], ["genes", 119], ["of", 125], ["Bacillus", 128], ["anthracis", 137], [".", 146], ["The", 148], ["475", 152], ["amino", 156], ["acid", 162], ["sequence", 167], ["of", 176], ["AtxA", 179], ["reveals", 184], ["DNA", 192], ["binding", 196], ["motifs", 204], ["and", 211], ["regions", 215], ["similar", 223], ["to", 231], ["proteins", 234], ["associated", 243], ["with", 254], ["the", 259], ["phosphoenolpyruvate", 263], [":", 282], ["carbohydrate", 284], ["phosphotransferase", 297], ["system", 316], ["(", 323], ["PTS", 324], [")", 327], [".", 328], ["We", 330], ["used", 333], ["strains", 338], ["producing", 346], ["native", 356], ["and", 363], ["functional", 367], ["epitope", 378], ["-", 385], ["tagged", 386], ["AtxA", 393], ["proteins", 398], ["to", 407], ["examine", 410], ["protein", 418], ["-", 425], ["protein", 426], ["interactions", 434], ["in", 447], ["cell", 450], ["lysates", 455], ["and", 463], ["in", 467], ["solutions", 470], ["of", 480], ["purified", 483], ["protein", 492], [".", 499], ["Co", 501], ["-", 503], ["affinity", 504], ["purification", 513], [",", 525], ["non", 527], ["-", 530], ["denaturing", 531], ["polyacrylamide", 542], ["gel", 557], ["electrophoresis", 561], ["and", 577], ["bis(maleimido)hexane", 581], ["(", 602], ["BMH", 603], [")", 606], ["cross", 608], ["-", 613], ["linking", 614], ["experiments", 622], ["revealed", 634], ["AtxA", 643], ["homo", 648], ["-", 652], ["multimers", 653], [".", 662], ["Dimers", 664], ["were", 671], ["the", 676], ["most", 680], ["abundant", 685], ["species", 694], [".", 701], ["BMH", 703], ["cross", 707], ["-", 712], ["links", 713], ["available", 719], ["cysteines", 729], ["within", 739], ["13", 746], ["\u00c5.", 749], ["To", 752], ["localize", 755], ["interaction", 764], ["sites", 776], [",", 781], ["six", 783], ["AtxA", 787], ["mutants", 792], ["containing", 800], ["distinct", 811], ["Cys\u2192Ser", 820], ["substitutions", 828], ["were", 842], ["tested", 847], ["for", 854], ["multimerization", 858], ["and", 874], ["cross", 878], ["-", 883], ["linking", 884], [".", 891], ["All", 893], ["mutants", 897], ["multimerized", 905], [",", 917], ["but", 919], ["one", 923], ["mutation", 927], [",", 935], ["C402S", 937], [",", 942], ["prevented", 944], ["cross", 954], ["-", 959], ["linking", 960], [".", 967], ["Thus", 969], [",", 973], ["BMH", 975], ["uses", 979], ["C402", 984], ["to", 989], ["make", 992], ["the", 997], ["inter", 1001], ["-", 1006], ["molecular", 1007], ["bond", 1017], ["between", 1022], ["AtxA", 1030], ["proteins", 1035], [",", 1043], ["but", 1045], ["C402", 1049], ["is", 1054], ["not", 1057], ["required", 1061], ["for", 1070], ["protein", 1074], ["-", 1081], ["protein", 1082], ["interaction", 1090], [".", 1101], ["C402", 1103], ["is", 1108], ["in", 1111], ["a", 1114], ["region", 1116], ["bearing", 1123], ["amino", 1131], ["acid", 1137], ["similarity", 1142], ["to", 1153], ["Enzyme", 1156], ["IIB", 1163], ["proteins", 1167], ["of", 1176], ["the", 1179], ["PTS", 1183], [".", 1186], ["The", 1188], ["AtxA", 1192], ["EIIB", 1197], ["motif", 1202], ["may", 1208], ["function", 1212], ["in", 1221], ["protein", 1224], ["oligomerization", 1232], [".", 1247], ["Finally", 1249], [",", 1256], ["cultures", 1258], ["grown", 1267], ["with", 1273], ["elevated", 1278], ["CO(2", 1287], [")", 1291], ["/bicarbonate", 1293], ["exhibited", 1306], ["increased", 1316], ["AtxA", 1326], ["dimer", 1331], ["/", 1336], ["monomer", 1337], ["ratios", 1345], ["and", 1352], ["increased", 1356], ["AtxA", 1366], ["activity", 1371], [",", 1379], ["relative", 1381], ["to", 1390], ["cultures", 1393], ["grown", 1402], ["without", 1408], ["added", 1416], ["CO(2", 1422], [")", 1426], ["/bicarbonate", 1428], [",", 1440], ["suggesting", 1442], ["that", 1453], ["this", 1458], ["host", 1463], ["-", 1467], ["associated", 1468], ["signal", 1479], ["enhances", 1486], ["AtxA", 1495], ["function", 1500], ["by", 1509], ["shifting", 1512], ["the", 1521], ["dimer", 1525], ["/", 1530], ["monomer", 1531], ["equilibrium", 1539], ["towards", 1551], ["the", 1559], ["dimeric", 1563], ["state", 1571], [".", 1576]]}
{"context": "An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis. Idarucizumab is an antibody fragment that binds dabigatran with high affinity. It reverses the anticoagulant effect of dabigatran within minutes and is approved for the reversal of dabigatran during emergency situations. We describe the use of idarucizumab in the management of a 68-year-old woman who was taking dabigatran 150\u2009mg twice daily and ingested 125 capsules. Despite gastric lavage and administration of activated charcoal within two hours of drug intake, the activated partial thromboplastin time (aPTT) and prothrombin time (PT) remained prolonged. The administration of 5\u2009g of intravenous idarucizumab promptly and completely reversed the anticoagulant activity of dabigatran as assessed by routine and specific coagulation assays (aPTT from to 75 to 26\u2009s, PT from 26 to 11\u2009s and diluted thrombin time from 92 to 27\u2009s). The initially planned emergency hemodialysis was canceled. This case highlights the potential use of idarucizumab for the management of massive dabigatran overdoses.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2b3f550f6fc74ff89e6391af6883b958", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[13, 13], [61, 61], [42, 42], [163, 163], [219, 219], [105, 105], [72, 72], [82, 82]], "char_spans": [[95, 104], [368, 377], [250, 259], [999, 1008], [1298, 1307], [633, 642], [439, 448], [501, 510]]}]}], "context_tokens": [["An", 0], ["overdose", 3], ["of", 12], ["oral", 15], ["anticoagulants", 20], ["represents", 35], ["a", 46], ["challenging", 48], ["scenario", 60], ["for", 69], ["emergency", 73], ["physicians", 83], [".", 93], ["Dabigatran", 95], [",", 105], ["an", 107], ["oral", 110], ["direct", 115], ["thrombin", 122], ["inhibitor", 131], [",", 140], ["is", 142], ["increasingly", 145], ["used", 158], ["in", 163], ["place", 166], ["of", 172], ["warfarin", 175], [".", 183], ["The", 185], ["lack", 189], ["of", 194], ["an", 197], ["antidote", 200], ["is", 209], ["a", 212], ["concern", 214], ["in", 222], ["patients", 225], ["who", 234], ["overdose", 238], ["on", 247], ["dabigatran", 250], [",", 260], ["even", 262], ["though", 267], ["the", 274], ["drug", 278], ["can", 283], ["be", 287], ["eliminated", 290], ["with", 301], ["hemodialysis", 306], [".", 318], ["Idarucizumab", 320], ["is", 333], ["an", 336], ["antibody", 339], ["fragment", 348], ["that", 357], ["binds", 362], ["dabigatran", 368], ["with", 379], ["high", 384], ["affinity", 389], [".", 397], ["It", 399], ["reverses", 402], ["the", 411], ["anticoagulant", 415], ["effect", 429], ["of", 436], ["dabigatran", 439], ["within", 450], ["minutes", 457], ["and", 465], ["is", 469], ["approved", 472], ["for", 481], ["the", 485], ["reversal", 489], ["of", 498], ["dabigatran", 501], ["during", 512], ["emergency", 519], ["situations", 529], [".", 539], ["We", 541], ["describe", 544], ["the", 553], ["use", 557], ["of", 561], ["idarucizumab", 564], ["in", 577], ["the", 580], ["management", 584], ["of", 595], ["a", 598], ["68-year", 600], ["-", 607], ["old", 608], ["woman", 612], ["who", 618], ["was", 622], ["taking", 626], ["dabigatran", 633], ["150", 644], ["mg", 648], ["twice", 651], ["daily", 657], ["and", 663], ["ingested", 667], ["125", 676], ["capsules", 680], [".", 688], ["Despite", 690], ["gastric", 698], ["lavage", 706], ["and", 713], ["administration", 717], ["of", 732], ["activated", 735], ["charcoal", 745], ["within", 754], ["two", 761], ["hours", 765], ["of", 771], ["drug", 774], ["intake", 779], [",", 785], ["the", 787], ["activated", 791], ["partial", 801], ["thromboplastin", 809], ["time", 824], ["(", 829], ["aPTT", 830], [")", 834], ["and", 836], ["prothrombin", 840], ["time", 852], ["(", 857], ["PT", 858], [")", 860], ["remained", 862], ["prolonged", 871], [".", 880], ["The", 882], ["administration", 886], ["of", 901], ["5", 904], ["g", 906], ["of", 908], ["intravenous", 911], ["idarucizumab", 923], ["promptly", 936], ["and", 945], ["completely", 949], ["reversed", 960], ["the", 969], ["anticoagulant", 973], ["activity", 987], ["of", 996], ["dabigatran", 999], ["as", 1010], ["assessed", 1013], ["by", 1022], ["routine", 1025], ["and", 1033], ["specific", 1037], ["coagulation", 1046], ["assays", 1058], ["(", 1065], ["aPTT", 1066], ["from", 1071], ["to", 1076], ["75", 1079], ["to", 1082], ["26", 1085], ["s", 1088], [",", 1089], ["PT", 1091], ["from", 1094], ["26", 1099], ["to", 1102], ["11", 1105], ["s", 1108], ["and", 1110], ["diluted", 1114], ["thrombin", 1122], ["time", 1131], ["from", 1136], ["92", 1141], ["to", 1144], ["27", 1147], ["s", 1150], [")", 1151], [".", 1152], ["The", 1154], ["initially", 1158], ["planned", 1168], ["emergency", 1176], ["hemodialysis", 1186], ["was", 1199], ["canceled", 1203], [".", 1211], ["This", 1213], ["case", 1218], ["highlights", 1223], ["the", 1234], ["potential", 1238], ["use", 1248], ["of", 1252], ["idarucizumab", 1255], ["for", 1268], ["the", 1272], ["management", 1276], ["of", 1287], ["massive", 1290], ["dabigatran", 1298], ["overdoses", 1309], [".", 1318]]}
{"context": "The apolipoprotein E (ApoE) \u03b54 allele is the strongest risk factor of sporadic Alzheimer's disease (AD), however, the fluid concentrations of ApoE and its different isoforms (ApoE2, ApoE3 and ApoE4) in AD patients and among APOE genotypes (APOE \u03b52, \u03b53, \u03b54) remain controversial. Using a novel mass spectrometry-based method, we quantified total ApoE and specific ApoE isoform concentrations and potential associations with age, cognitive status, cholesterol levels and established AD biomarkers in cerebrospinal fluid (CSF) from AD patients versus non-AD individuals with different APOE genotypes. We also investigated plasma total ApoE and ApoE isoform composition in a subset of these individuals. In total n = 43 AD and n = 43 non-AD subjects were included. We found that CSF and plasma total ApoE levels did not correlate with age or cognitive status and did not differ between AD and non-AD subjects deeming ApoE as an unfit diagnostic marker for AD. Also, whereas CSF ApoE levels did not vary between APOE genotypes APOE \u03b54 carriers exhibited significantly decreased plasma ApoE levels attributed to a specific decrease in the ApoE4 isoform concentrations. CSF total ApoE concentrations were positively associated with CSF, total tau, tau phosphorylated at Thr181 and A\u03b21-42 of which the latter association was weaker and only present in APOE \u03b54 carriers indicating a differential involvement of ApoE in tau versus A\u03b2-linked neuropathological processes. Future studies need to elucidate whether the observed plasma ApoE4 deficiency is a life-long condition in APOE \u025b4 carriers and whether this decrease in plasma ApoE predisposes APOE \u025b4 carriers to AD.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "19f812e350824082b6b21522a0ba9fa9", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[210, 211]], "char_spans": [[1133, 1145]]}]}], "context_tokens": [["The", 0], ["apolipoprotein", 4], ["E", 19], ["(", 21], ["ApoE", 22], [")", 26], ["\u03b54", 28], ["allele", 31], ["is", 38], ["the", 41], ["strongest", 45], ["risk", 55], ["factor", 60], ["of", 67], ["sporadic", 70], ["Alzheimer", 79], ["'s", 88], ["disease", 91], ["(", 99], ["AD", 100], [")", 102], [",", 103], ["however", 105], [",", 112], ["the", 114], ["fluid", 118], ["concentrations", 124], ["of", 139], ["ApoE", 142], ["and", 147], ["its", 151], ["different", 155], ["isoforms", 165], ["(", 174], ["ApoE2", 175], [",", 180], ["ApoE3", 182], ["and", 188], ["ApoE4", 192], [")", 197], ["in", 199], ["AD", 202], ["patients", 205], ["and", 214], ["among", 218], ["APOE", 224], ["genotypes", 229], ["(", 239], ["APOE", 240], ["\u03b52", 245], [",", 247], ["\u03b53", 249], [",", 251], ["\u03b54", 253], [")", 255], ["remain", 257], ["controversial", 264], [".", 277], ["Using", 279], ["a", 285], ["novel", 287], ["mass", 293], ["spectrometry", 298], ["-", 310], ["based", 311], ["method", 317], [",", 323], ["we", 325], ["quantified", 328], ["total", 339], ["ApoE", 345], ["and", 350], ["specific", 354], ["ApoE", 363], ["isoform", 368], ["concentrations", 376], ["and", 391], ["potential", 395], ["associations", 405], ["with", 418], ["age", 423], [",", 426], ["cognitive", 428], ["status", 438], [",", 444], ["cholesterol", 446], ["levels", 458], ["and", 465], ["established", 469], ["AD", 481], ["biomarkers", 484], ["in", 495], ["cerebrospinal", 498], ["fluid", 512], ["(", 518], ["CSF", 519], [")", 522], ["from", 524], ["AD", 529], ["patients", 532], ["versus", 541], ["non", 548], ["-", 551], ["AD", 552], ["individuals", 555], ["with", 567], ["different", 572], ["APOE", 582], ["genotypes", 587], [".", 596], ["We", 598], ["also", 601], ["investigated", 606], ["plasma", 619], ["total", 626], ["ApoE", 632], ["and", 637], ["ApoE", 641], ["isoform", 646], ["composition", 654], ["in", 666], ["a", 669], ["subset", 671], ["of", 678], ["these", 681], ["individuals", 687], [".", 698], ["In", 700], ["total", 703], ["n", 709], ["=", 711], ["43", 713], ["AD", 716], ["and", 719], ["n", 723], ["=", 725], ["43", 727], ["non", 730], ["-", 733], ["AD", 734], ["subjects", 737], ["were", 746], ["included", 751], [".", 759], ["We", 761], ["found", 764], ["that", 770], ["CSF", 775], ["and", 779], ["plasma", 783], ["total", 790], ["ApoE", 796], ["levels", 801], ["did", 808], ["not", 812], ["correlate", 816], ["with", 826], ["age", 831], ["or", 835], ["cognitive", 838], ["status", 848], ["and", 855], ["did", 859], ["not", 863], ["differ", 867], ["between", 874], ["AD", 882], ["and", 885], ["non", 889], ["-", 892], ["AD", 893], ["subjects", 896], ["deeming", 905], ["ApoE", 913], ["as", 918], ["an", 921], ["unfit", 924], ["diagnostic", 930], ["marker", 941], ["for", 948], ["AD", 952], [".", 954], ["Also", 956], [",", 960], ["whereas", 962], ["CSF", 970], ["ApoE", 974], ["levels", 979], ["did", 986], ["not", 990], ["vary", 994], ["between", 999], ["APOE", 1007], ["genotypes", 1012], ["APOE", 1022], ["\u03b54", 1027], ["carriers", 1030], ["exhibited", 1039], ["significantly", 1049], ["decreased", 1063], ["plasma", 1073], ["ApoE", 1080], ["levels", 1085], ["attributed", 1092], ["to", 1103], ["a", 1106], ["specific", 1108], ["decrease", 1117], ["in", 1126], ["the", 1129], ["ApoE4", 1133], ["isoform", 1139], ["concentrations", 1147], [".", 1161], ["CSF", 1163], ["total", 1167], ["ApoE", 1173], ["concentrations", 1178], ["were", 1193], ["positively", 1198], ["associated", 1209], ["with", 1220], ["CSF", 1225], [",", 1228], ["total", 1230], ["tau", 1236], [",", 1239], ["tau", 1241], ["phosphorylated", 1245], ["at", 1260], ["Thr181", 1263], ["and", 1270], ["A\u03b21", 1274], ["-", 1277], ["42", 1278], ["of", 1281], ["which", 1284], ["the", 1290], ["latter", 1294], ["association", 1301], ["was", 1313], ["weaker", 1317], ["and", 1324], ["only", 1328], ["present", 1333], ["in", 1341], ["APOE", 1344], ["\u03b54", 1349], ["carriers", 1352], ["indicating", 1361], ["a", 1372], ["differential", 1374], ["involvement", 1387], ["of", 1399], ["ApoE", 1402], ["in", 1407], ["tau", 1410], ["versus", 1414], ["A\u03b2", 1421], ["-", 1423], ["linked", 1424], ["neuropathological", 1431], ["processes", 1449], [".", 1458], ["Future", 1460], ["studies", 1467], ["need", 1475], ["to", 1480], ["elucidate", 1483], ["whether", 1493], ["the", 1501], ["observed", 1505], ["plasma", 1514], ["ApoE4", 1521], ["deficiency", 1527], ["is", 1538], ["a", 1541], ["life", 1543], ["-", 1547], ["long", 1548], ["condition", 1553], ["in", 1563], ["APOE", 1566], ["\u025b4", 1571], ["carriers", 1574], ["and", 1583], ["whether", 1587], ["this", 1595], ["decrease", 1600], ["in", 1609], ["plasma", 1612], ["ApoE", 1619], ["predisposes", 1624], ["APOE", 1636], ["\u025b4", 1641], ["carriers", 1644], ["to", 1653], ["AD", 1656], [".", 1658]]}
{"context": "Siltuximab, a chimeric monoclonal antibody with high affinity and specificity for interleukin-6, has been shown to enhance anti-multiple myeloma activity of bortezomib and corticosteroid in vitro. We evaluated the safety, pharmacokinetics, immunogenicity, and antitumor effect of siltuximab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. This open-label, phase 1, dose-escalating study used two doses of siltuximab: 5.5 and 11.0 mg/kg (administered on day 1 of each 21-day cycle). In total, nine patients were treated. The most common grade 3/4 adverse events, lymphopenia (89 %) and thrombocytopenia (44 %), occurred in patients receiving both doses of siltuximab; however, no dose-limiting toxicities (DLTs) were observed. Following intravenous administration of siltuximab at 5.5 and 11.0 mg/kg, the maximum serum concentration and the area under the curve from 0 to 21 days and from 0 to infinity increased in an approximately dose-proportional manner. Mean half-life, total systemic clearance, and volume of distribution were similar at doses of 5.5 and 11.0 mg/kg. Across both doses, six of the nine patients had complete or partial response (22 and 44 %, respectively). In conclusion, as no DLT was observed, the recommended dose for this combination is 11.0 mg/kg once every 3 weeks. The study is registered at http://www.clinicaltrials.gov as NCT01309412.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "5cd7ff3ebd7f4aeea91e08b630ebba14", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[12, 12]], "char_spans": [[82, 94]]}]}], "context_tokens": [["Siltuximab", 0], [",", 10], ["a", 12], ["chimeric", 14], ["monoclonal", 23], ["antibody", 34], ["with", 43], ["high", 48], ["affinity", 53], ["and", 62], ["specificity", 66], ["for", 78], ["interleukin-6", 82], [",", 95], ["has", 97], ["been", 101], ["shown", 106], ["to", 112], ["enhance", 115], ["anti", 123], ["-", 127], ["multiple", 128], ["myeloma", 137], ["activity", 145], ["of", 154], ["bortezomib", 157], ["and", 168], ["corticosteroid", 172], ["in", 187], ["vitro", 190], [".", 195], ["We", 197], ["evaluated", 200], ["the", 210], ["safety", 214], [",", 220], ["pharmacokinetics", 222], [",", 238], ["immunogenicity", 240], [",", 254], ["and", 256], ["antitumor", 260], ["effect", 270], ["of", 277], ["siltuximab", 280], ["in", 291], ["combination", 294], ["with", 306], ["bortezomib", 311], ["and", 322], ["dexamethasone", 326], ["in", 340], ["Japanese", 343], ["patients", 352], ["with", 361], ["relapsed", 366], ["or", 375], ["refractory", 378], ["multiple", 389], ["myeloma", 398], [".", 405], ["This", 407], ["open", 412], ["-", 416], ["label", 417], [",", 422], ["phase", 424], ["1", 430], [",", 431], ["dose", 433], ["-", 437], ["escalating", 438], ["study", 449], ["used", 455], ["two", 460], ["doses", 464], ["of", 470], ["siltuximab", 473], [":", 483], ["5.5", 485], ["and", 489], ["11.0", 493], ["mg", 498], ["/", 500], ["kg", 501], ["(", 504], ["administered", 505], ["on", 518], ["day", 521], ["1", 525], ["of", 527], ["each", 530], ["21-day", 535], ["cycle", 542], [")", 547], [".", 548], ["In", 550], ["total", 553], [",", 558], ["nine", 560], ["patients", 565], ["were", 574], ["treated", 579], [".", 586], ["The", 588], ["most", 592], ["common", 597], ["grade", 604], ["3/4", 610], ["adverse", 614], ["events", 622], [",", 628], ["lymphopenia", 630], ["(", 642], ["89", 643], ["%", 646], [")", 647], ["and", 649], ["thrombocytopenia", 653], ["(", 670], ["44", 671], ["%", 674], [")", 675], [",", 676], ["occurred", 678], ["in", 687], ["patients", 690], ["receiving", 699], ["both", 709], ["doses", 714], ["of", 720], ["siltuximab", 723], [";", 733], ["however", 735], [",", 742], ["no", 744], ["dose", 747], ["-", 751], ["limiting", 752], ["toxicities", 761], ["(", 772], ["DLTs", 773], [")", 777], ["were", 779], ["observed", 784], [".", 792], ["Following", 794], ["intravenous", 804], ["administration", 816], ["of", 831], ["siltuximab", 834], ["at", 845], ["5.5", 848], ["and", 852], ["11.0", 856], ["mg", 861], ["/", 863], ["kg", 864], [",", 866], ["the", 868], ["maximum", 872], ["serum", 880], ["concentration", 886], ["and", 900], ["the", 904], ["area", 908], ["under", 913], ["the", 919], ["curve", 923], ["from", 929], ["0", 934], ["to", 936], ["21", 939], ["days", 942], ["and", 947], ["from", 951], ["0", 956], ["to", 958], ["infinity", 961], ["increased", 970], ["in", 980], ["an", 983], ["approximately", 986], ["dose", 1000], ["-", 1004], ["proportional", 1005], ["manner", 1018], [".", 1024], ["Mean", 1026], ["half", 1031], ["-", 1035], ["life", 1036], [",", 1040], ["total", 1042], ["systemic", 1048], ["clearance", 1057], [",", 1066], ["and", 1068], ["volume", 1072], ["of", 1079], ["distribution", 1082], ["were", 1095], ["similar", 1100], ["at", 1108], ["doses", 1111], ["of", 1117], ["5.5", 1120], ["and", 1124], ["11.0", 1128], ["mg", 1133], ["/", 1135], ["kg", 1136], [".", 1138], ["Across", 1140], ["both", 1147], ["doses", 1152], [",", 1157], ["six", 1159], ["of", 1163], ["the", 1166], ["nine", 1170], ["patients", 1175], ["had", 1184], ["complete", 1188], ["or", 1197], ["partial", 1200], ["response", 1208], ["(", 1217], ["22", 1218], ["and", 1221], ["44", 1225], ["%", 1228], [",", 1229], ["respectively", 1231], [")", 1243], [".", 1244], ["In", 1246], ["conclusion", 1249], [",", 1259], ["as", 1261], ["no", 1264], ["DLT", 1267], ["was", 1271], ["observed", 1275], [",", 1283], ["the", 1285], ["recommended", 1289], ["dose", 1301], ["for", 1306], ["this", 1310], ["combination", 1315], ["is", 1327], ["11.0", 1330], ["mg", 1335], ["/", 1337], ["kg", 1338], ["once", 1341], ["every", 1346], ["3", 1352], ["weeks", 1354], [".", 1359], ["The", 1361], ["study", 1365], ["is", 1371], ["registered", 1374], ["at", 1385], ["http://www.clinicaltrials.gov", 1388], ["as", 1418], ["NCT01309412", 1421], [".", 1432]]}
{"context": "In mammals, most of the selenium contained in the body is present as an unusual amino acid, selenocysteine (Sec), whose codon is UGA. Because the UGA codon is typically recognized as a translation stop signal, it is intriguing how a cell recognizes and distinguishes a UGA Sec codon from a UGA stop codon. For eukaryotic selenoprotein mRNAs, it has been proposed that a conserved stem-loop structure designated the Sec insertion sequence (SECIS) in the 3'-untranslated (3'-UTR) region is required for recognition of UGA as a Sec codon. Some proteins which bind to SECIS (SBP) have been reported. However, it is not clear how the SECIS element in the 3'-UTR can mediate Sec insertion far at the in-frame UGA Sec codons. The idea that there must be a signal near the UGA Sec codon is still considered. Therefore, we searched for a protein which binds to an RNA sequence surrounding the UGA Sec codon on human glutathione peroxidase (GPx) mRNA. We found a protein which strongly bound to the RNA fragment upstream of the UGA Sec codon. However, this protein did not bind to the RNA sequence downstream of the UGA codon. This protein also bound to the SECIS sequence in the 3'-UTR of human GPx, and this binding to SECIS was competed with the RNA fragment upstream of the UGA Sec codon. Comparison of the RNA fragment with the SECIS fragment identified the conserved regions, which appeared in the region upstream of the in-frame UGA Sec codon of Se-protein mRNAs. Thus, this study proposes a novel model to understand the mechanisms of Sec incorporation at the UGA Sec codon, especially the regions upstream of the UGA codon of mRNAs of mammalian selenoproteins. This model explains that the stem-loop structure covering the UGA codon is recognized by SBP and how the UGA Sec codon escapes from attack by eRF of the peptide releasing factor.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0d37ab3d489b4d7da2bc133cfa75a2d3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[83, 83], [262, 262], [124, 124], [108, 108], [228, 228], [241, 241]], "char_spans": [[439, 443], [1323, 1327], [629, 633], [564, 568], [1148, 1152], [1211, 1215]]}]}], "context_tokens": [["In", 0], ["mammals", 3], [",", 10], ["most", 12], ["of", 17], ["the", 20], ["selenium", 24], ["contained", 33], ["in", 43], ["the", 46], ["body", 50], ["is", 55], ["present", 58], ["as", 66], ["an", 69], ["unusual", 72], ["amino", 80], ["acid", 86], [",", 90], ["selenocysteine", 92], ["(", 107], ["Sec", 108], [")", 111], [",", 112], ["whose", 114], ["codon", 120], ["is", 126], ["UGA", 129], [".", 132], ["Because", 134], ["the", 142], ["UGA", 146], ["codon", 150], ["is", 156], ["typically", 159], ["recognized", 169], ["as", 180], ["a", 183], ["translation", 185], ["stop", 197], ["signal", 202], [",", 208], ["it", 210], ["is", 213], ["intriguing", 216], ["how", 227], ["a", 231], ["cell", 233], ["recognizes", 238], ["and", 249], ["distinguishes", 253], ["a", 267], ["UGA", 269], ["Sec", 273], ["codon", 277], ["from", 283], ["a", 288], ["UGA", 290], ["stop", 294], ["codon", 299], [".", 304], ["For", 306], ["eukaryotic", 310], ["selenoprotein", 321], ["mRNAs", 335], [",", 340], ["it", 342], ["has", 345], ["been", 349], ["proposed", 354], ["that", 363], ["a", 368], ["conserved", 370], ["stem", 380], ["-", 384], ["loop", 385], ["structure", 390], ["designated", 400], ["the", 411], ["Sec", 415], ["insertion", 419], ["sequence", 429], ["(", 438], ["SECIS", 439], [")", 444], ["in", 446], ["the", 449], ["3'-untranslated", 453], ["(", 469], ["3'-UTR", 470], [")", 476], ["region", 478], ["is", 485], ["required", 488], ["for", 497], ["recognition", 501], ["of", 513], ["UGA", 516], ["as", 520], ["a", 523], ["Sec", 525], ["codon", 529], [".", 534], ["Some", 536], ["proteins", 541], ["which", 550], ["bind", 556], ["to", 561], ["SECIS", 564], ["(", 570], ["SBP", 571], [")", 574], ["have", 576], ["been", 581], ["reported", 586], [".", 594], ["However", 596], [",", 603], ["it", 605], ["is", 608], ["not", 611], ["clear", 615], ["how", 621], ["the", 625], ["SECIS", 629], ["element", 635], ["in", 643], ["the", 646], ["3'-UTR", 650], ["can", 657], ["mediate", 661], ["Sec", 669], ["insertion", 673], ["far", 683], ["at", 687], ["the", 690], ["in", 694], ["-", 696], ["frame", 697], ["UGA", 703], ["Sec", 707], ["codons", 711], [".", 717], ["The", 719], ["idea", 723], ["that", 728], ["there", 733], ["must", 739], ["be", 744], ["a", 747], ["signal", 749], ["near", 756], ["the", 761], ["UGA", 765], ["Sec", 769], ["codon", 773], ["is", 779], ["still", 782], ["considered", 788], [".", 798], ["Therefore", 800], [",", 809], ["we", 811], ["searched", 814], ["for", 823], ["a", 827], ["protein", 829], ["which", 837], ["binds", 843], ["to", 849], ["an", 852], ["RNA", 855], ["sequence", 859], ["surrounding", 868], ["the", 880], ["UGA", 884], ["Sec", 888], ["codon", 892], ["on", 898], ["human", 901], ["glutathione", 907], ["peroxidase", 919], ["(", 930], ["GPx", 931], [")", 934], ["mRNA", 936], [".", 940], ["We", 942], ["found", 945], ["a", 951], ["protein", 953], ["which", 961], ["strongly", 967], ["bound", 976], ["to", 982], ["the", 985], ["RNA", 989], ["fragment", 993], ["upstream", 1002], ["of", 1011], ["the", 1014], ["UGA", 1018], ["Sec", 1022], ["codon", 1026], [".", 1031], ["However", 1033], [",", 1040], ["this", 1042], ["protein", 1047], ["did", 1055], ["not", 1059], ["bind", 1063], ["to", 1068], ["the", 1071], ["RNA", 1075], ["sequence", 1079], ["downstream", 1088], ["of", 1099], ["the", 1102], ["UGA", 1106], ["codon", 1110], [".", 1115], ["This", 1117], ["protein", 1122], ["also", 1130], ["bound", 1135], ["to", 1141], ["the", 1144], ["SECIS", 1148], ["sequence", 1154], ["in", 1163], ["the", 1166], ["3'-UTR", 1170], ["of", 1177], ["human", 1180], ["GPx", 1186], [",", 1189], ["and", 1191], ["this", 1195], ["binding", 1200], ["to", 1208], ["SECIS", 1211], ["was", 1217], ["competed", 1221], ["with", 1230], ["the", 1235], ["RNA", 1239], ["fragment", 1243], ["upstream", 1252], ["of", 1261], ["the", 1264], ["UGA", 1268], ["Sec", 1272], ["codon", 1276], [".", 1281], ["Comparison", 1283], ["of", 1294], ["the", 1297], ["RNA", 1301], ["fragment", 1305], ["with", 1314], ["the", 1319], ["SECIS", 1323], ["fragment", 1329], ["identified", 1338], ["the", 1349], ["conserved", 1353], ["regions", 1363], [",", 1370], ["which", 1372], ["appeared", 1378], ["in", 1387], ["the", 1390], ["region", 1394], ["upstream", 1401], ["of", 1410], ["the", 1413], ["in", 1417], ["-", 1419], ["frame", 1420], ["UGA", 1426], ["Sec", 1430], ["codon", 1434], ["of", 1440], ["Se", 1443], ["-", 1445], ["protein", 1446], ["mRNAs", 1454], [".", 1459], ["Thus", 1461], [",", 1465], ["this", 1467], ["study", 1472], ["proposes", 1478], ["a", 1487], ["novel", 1489], ["model", 1495], ["to", 1501], ["understand", 1504], ["the", 1515], ["mechanisms", 1519], ["of", 1530], ["Sec", 1533], ["incorporation", 1537], ["at", 1551], ["the", 1554], ["UGA", 1558], ["Sec", 1562], ["codon", 1566], [",", 1571], ["especially", 1573], ["the", 1584], ["regions", 1588], ["upstream", 1596], ["of", 1605], ["the", 1608], ["UGA", 1612], ["codon", 1616], ["of", 1622], ["mRNAs", 1625], ["of", 1631], ["mammalian", 1634], ["selenoproteins", 1644], [".", 1658], ["This", 1660], ["model", 1665], ["explains", 1671], ["that", 1680], ["the", 1685], ["stem", 1689], ["-", 1693], ["loop", 1694], ["structure", 1699], ["covering", 1709], ["the", 1718], ["UGA", 1722], ["codon", 1726], ["is", 1732], ["recognized", 1735], ["by", 1746], ["SBP", 1749], ["and", 1753], ["how", 1757], ["the", 1761], ["UGA", 1765], ["Sec", 1769], ["codon", 1773], ["escapes", 1779], ["from", 1787], ["attack", 1792], ["by", 1799], ["eRF", 1802], ["of", 1806], ["the", 1809], ["peptide", 1813], ["releasing", 1821], ["factor", 1831], [".", 1837]]}
{"context": "Growth differentiation factor 15 (GDF15), a distant member of the transforming growth factor (TGF)-\u03b2 family, is a secreted protein that circulates as a 25-kDa dimer. In humans, elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown. Here we show that recombinant GDF15 induces weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity. Furthermore, we find that GDF15 binds with high affinity to GDNF family receptor \u03b1-like (GFRAL), a distant relative of receptors for a distinct class of the TGF-\u03b2 superfamily ligands. Gfral is expressed in neurons of the area postrema and nucleus of the solitary tract in mice and humans, and genetic deletion of the receptor abrogates the ability of GDF15 to decrease food intake and body weight in mice. In addition, diet-induced obesity and insulin resistance are exacerbated in GFRAL-deficient mice, suggesting a homeostatic role for this receptor in metabolism. Finally, we demonstrate that GDF15-induced cell signaling requires the interaction of GFRAL with the coreceptor RET. Our data identify GFRAL as a new regulator of body weight and as the bona fide receptor mediating the metabolic effects of GDF15, enabling a more comprehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.", "qas": [{"question": "How does increased GDF15 affect body weight?", "answers": ["Reduces body weight"], "qid": "de1a17e690e849e3a857822511b54678", "question_tokens": [["How", 0], ["does", 4], ["increased", 9], ["GDF15", 19], ["affect", 25], ["body", 32], ["weight", 37], ["?", 43]], "detected_answers": [{"text": "Reduces body weight", "token_spans": [[69, 71], [50, 52]], "char_spans": [[375, 393], [274, 292]]}]}], "context_tokens": [["Growth", 0], ["differentiation", 7], ["factor", 23], ["15", 30], ["(", 33], ["GDF15", 34], [")", 39], [",", 40], ["a", 42], ["distant", 44], ["member", 52], ["of", 59], ["the", 62], ["transforming", 66], ["growth", 79], ["factor", 86], ["(", 93], ["TGF)-\u03b2", 94], ["family", 101], [",", 107], ["is", 109], ["a", 112], ["secreted", 114], ["protein", 123], ["that", 131], ["circulates", 136], ["as", 147], ["a", 150], ["25-kDa", 152], ["dimer", 159], [".", 164], ["In", 166], ["humans", 169], [",", 175], ["elevated", 177], ["GDF15", 186], ["correlates", 192], ["with", 203], ["weight", 208], ["loss", 215], [",", 219], ["and", 221], ["the", 225], ["administration", 229], ["of", 244], ["GDF15", 247], ["to", 253], ["mice", 256], ["with", 261], ["obesity", 266], ["reduces", 274], ["body", 282], ["weight", 287], [",", 293], ["at", 295], ["least", 298], ["in", 304], ["part", 307], [",", 311], ["by", 313], ["decreasing", 316], ["food", 327], ["intake", 332], [".", 338], ["The", 340], ["mechanisms", 344], ["through", 355], ["which", 363], ["GDF15", 369], ["reduces", 375], ["body", 383], ["weight", 388], ["remain", 395], ["poorly", 402], ["understood", 409], [",", 419], ["because", 421], ["the", 429], ["cognate", 433], ["receptor", 441], ["for", 450], ["GDF15", 454], ["is", 460], ["unknown", 463], [".", 470], ["Here", 472], ["we", 477], ["show", 480], ["that", 485], ["recombinant", 490], ["GDF15", 502], ["induces", 508], ["weight", 516], ["loss", 523], ["in", 528], ["mice", 531], ["fed", 536], ["a", 540], ["high", 542], ["-", 546], ["fat", 547], ["diet", 551], ["and", 556], ["in", 560], ["nonhuman", 563], ["primates", 572], ["with", 581], ["spontaneous", 586], ["obesity", 598], [".", 605], ["Furthermore", 607], [",", 618], ["we", 620], ["find", 623], ["that", 628], ["GDF15", 633], ["binds", 639], ["with", 645], ["high", 650], ["affinity", 655], ["to", 664], ["GDNF", 667], ["family", 672], ["receptor", 679], ["\u03b1", 688], ["-", 689], ["like", 690], ["(", 695], ["GFRAL", 696], [")", 701], [",", 702], ["a", 704], ["distant", 706], ["relative", 714], ["of", 723], ["receptors", 726], ["for", 736], ["a", 740], ["distinct", 742], ["class", 751], ["of", 757], ["the", 760], ["TGF", 764], ["-", 767], ["\u03b2", 768], ["superfamily", 770], ["ligands", 782], [".", 789], ["Gfral", 791], ["is", 797], ["expressed", 800], ["in", 810], ["neurons", 813], ["of", 821], ["the", 824], ["area", 828], ["postrema", 833], ["and", 842], ["nucleus", 846], ["of", 854], ["the", 857], ["solitary", 861], ["tract", 870], ["in", 876], ["mice", 879], ["and", 884], ["humans", 888], [",", 894], ["and", 896], ["genetic", 900], ["deletion", 908], ["of", 917], ["the", 920], ["receptor", 924], ["abrogates", 933], ["the", 943], ["ability", 947], ["of", 955], ["GDF15", 958], ["to", 964], ["decrease", 967], ["food", 976], ["intake", 981], ["and", 988], ["body", 992], ["weight", 997], ["in", 1004], ["mice", 1007], [".", 1011], ["In", 1013], ["addition", 1016], [",", 1024], ["diet", 1026], ["-", 1030], ["induced", 1031], ["obesity", 1039], ["and", 1047], ["insulin", 1051], ["resistance", 1059], ["are", 1070], ["exacerbated", 1074], ["in", 1086], ["GFRAL", 1089], ["-", 1094], ["deficient", 1095], ["mice", 1105], [",", 1109], ["suggesting", 1111], ["a", 1122], ["homeostatic", 1124], ["role", 1136], ["for", 1141], ["this", 1145], ["receptor", 1150], ["in", 1159], ["metabolism", 1162], [".", 1172], ["Finally", 1174], [",", 1181], ["we", 1183], ["demonstrate", 1186], ["that", 1198], ["GDF15-induced", 1203], ["cell", 1217], ["signaling", 1222], ["requires", 1232], ["the", 1241], ["interaction", 1245], ["of", 1257], ["GFRAL", 1260], ["with", 1266], ["the", 1271], ["coreceptor", 1275], ["RET", 1286], [".", 1289], ["Our", 1291], ["data", 1295], ["identify", 1300], ["GFRAL", 1309], ["as", 1315], ["a", 1318], ["new", 1320], ["regulator", 1324], ["of", 1334], ["body", 1337], ["weight", 1342], ["and", 1349], ["as", 1353], ["the", 1356], ["bona", 1360], ["fide", 1365], ["receptor", 1370], ["mediating", 1379], ["the", 1389], ["metabolic", 1393], ["effects", 1403], ["of", 1411], ["GDF15", 1414], [",", 1419], ["enabling", 1421], ["a", 1430], ["more", 1432], ["comprehensive", 1437], ["assessment", 1451], ["of", 1462], ["GDF15", 1465], ["as", 1471], ["a", 1474], ["potential", 1476], ["pharmacotherapy", 1486], ["for", 1502], ["the", 1506], ["treatment", 1510], ["of", 1520], ["obesity", 1523], [".", 1530]]}
{"context": "The discovery of the Hippo pathway can be traced back to two areas of research. Genetic screens in fruit flies led to the identification of the Hippo pathway kinases and scaffolding proteins that function together to suppress cell proliferation and tumor growth. Independent research, often in the context of muscle biology, described Tead (TEA domain) transcription factors, which bind CATTCC DNA motifs to regulate gene expression. These two research areas were joined by the finding that the Hippo pathway regulates the activity of Tead transcription factors mainly through phosphorylation of the transcriptional coactivators Yap and Taz, which bind to and activate Teads. Additionally, many other signal transduction proteins crosstalk to members of the Hippo pathway forming a Hippo signal transduction network. We discuss evidence that the Hippo signal transduction network plays important roles in myogenesis, regeneration, muscular dystrophy, and rhabdomyosarcoma in skeletal muscle, as well as in myogenesis, organ size control, and regeneration of the heart. Understanding the role of Hippo kinases in skeletal and heart muscle physiology could have important implications for translational research.", "qas": [{"question": "Which are the coactivators of the Yes-associated protein (yap)?", "answers": ["Tead (TEA domain) transcription factors."], "qid": "42652e9339554e27af6c273cfd698386", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["coactivators", 14], ["of", 27], ["the", 30], ["Yes", 34], ["-", 37], ["associated", 38], ["protein", 49], ["(", 57], ["yap", 58], [")", 61], ["?", 62]], "detected_answers": [{"text": "Tead (TEA domain) transcription factors.", "token_spans": [[56, 62]], "char_spans": [[335, 373]]}]}], "context_tokens": [["The", 0], ["discovery", 4], ["of", 14], ["the", 17], ["Hippo", 21], ["pathway", 27], ["can", 35], ["be", 39], ["traced", 42], ["back", 49], ["to", 54], ["two", 57], ["areas", 61], ["of", 67], ["research", 70], [".", 78], ["Genetic", 80], ["screens", 88], ["in", 96], ["fruit", 99], ["flies", 105], ["led", 111], ["to", 115], ["the", 118], ["identification", 122], ["of", 137], ["the", 140], ["Hippo", 144], ["pathway", 150], ["kinases", 158], ["and", 166], ["scaffolding", 170], ["proteins", 182], ["that", 191], ["function", 196], ["together", 205], ["to", 214], ["suppress", 217], ["cell", 226], ["proliferation", 231], ["and", 245], ["tumor", 249], ["growth", 255], [".", 261], ["Independent", 263], ["research", 275], [",", 283], ["often", 285], ["in", 291], ["the", 294], ["context", 298], ["of", 306], ["muscle", 309], ["biology", 316], [",", 323], ["described", 325], ["Tead", 335], ["(", 340], ["TEA", 341], ["domain", 345], [")", 351], ["transcription", 353], ["factors", 367], [",", 374], ["which", 376], ["bind", 382], ["CATTCC", 387], ["DNA", 394], ["motifs", 398], ["to", 405], ["regulate", 408], ["gene", 417], ["expression", 422], [".", 432], ["These", 434], ["two", 440], ["research", 444], ["areas", 453], ["were", 459], ["joined", 464], ["by", 471], ["the", 474], ["finding", 478], ["that", 486], ["the", 491], ["Hippo", 495], ["pathway", 501], ["regulates", 509], ["the", 519], ["activity", 523], ["of", 532], ["Tead", 535], ["transcription", 540], ["factors", 554], ["mainly", 562], ["through", 569], ["phosphorylation", 577], ["of", 593], ["the", 596], ["transcriptional", 600], ["coactivators", 616], ["Yap", 629], ["and", 633], ["Taz", 637], [",", 640], ["which", 642], ["bind", 648], ["to", 653], ["and", 656], ["activate", 660], ["Teads", 669], [".", 674], ["Additionally", 676], [",", 688], ["many", 690], ["other", 695], ["signal", 701], ["transduction", 708], ["proteins", 721], ["crosstalk", 730], ["to", 740], ["members", 743], ["of", 751], ["the", 754], ["Hippo", 758], ["pathway", 764], ["forming", 772], ["a", 780], ["Hippo", 782], ["signal", 788], ["transduction", 795], ["network", 808], [".", 815], ["We", 817], ["discuss", 820], ["evidence", 828], ["that", 837], ["the", 842], ["Hippo", 846], ["signal", 852], ["transduction", 859], ["network", 872], ["plays", 880], ["important", 886], ["roles", 896], ["in", 902], ["myogenesis", 905], [",", 915], ["regeneration", 917], [",", 929], ["muscular", 931], ["dystrophy", 940], [",", 949], ["and", 951], ["rhabdomyosarcoma", 955], ["in", 972], ["skeletal", 975], ["muscle", 984], [",", 990], ["as", 992], ["well", 995], ["as", 1000], ["in", 1003], ["myogenesis", 1006], [",", 1016], ["organ", 1018], ["size", 1024], ["control", 1029], [",", 1036], ["and", 1038], ["regeneration", 1042], ["of", 1055], ["the", 1058], ["heart", 1062], [".", 1067], ["Understanding", 1069], ["the", 1083], ["role", 1087], ["of", 1092], ["Hippo", 1095], ["kinases", 1101], ["in", 1109], ["skeletal", 1112], ["and", 1121], ["heart", 1125], ["muscle", 1131], ["physiology", 1138], ["could", 1149], ["have", 1155], ["important", 1160], ["implications", 1170], ["for", 1183], ["translational", 1187], ["research", 1201], [".", 1209]]}
{"context": "The organic cation transporter 3 (OCT3) is a widely expressed transporter for endogenous and exogenous organic cations. Of particular interest is OCT3 expression and function in the brain, where it plays a role in serotonin clearance and influences mood and behavior. Protein kinase signaling mediates rapid modulation of cerebral processes, but little is known about acute regulation of OCT3 by protein kinases. Therefore, we cloned mouse OCT3 (mOCT3) and generated a human embryonic kidney cell line stably expressing the transporter to study transport characteristics, acute regulation by protein kinases, and interaction with psychotropic drugs. Uptake measurement was performed using the fluorescent cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP(+), 1\u00a0\u03bcM) as a substrate. The translational value of these findings was determined by comparing results obtained with cloned mouse and human OCT3. mOCT3-mediated transport is membrane potential dependent and pH independent. ASP(+) uptake by mOCT3 and human OCT3 (hOCT3) was efficiently inhibited by 1-methyl-4-phenylpyridinium, tetrapentylammonium (TPA(+)), corticosterone, serotonin, and histamine and by the drugs ketamine, fluoxetine, and diazepam. The half maximal inhibitory concentrations of mOCT3 and hOCT3 for TPA(+), serotonin, diazepam, and ketamine are significantly different. Diazepam is a non-transported inhibitor. Furthermore, the activities of mOCT3 and hOCT3 are acutely regulated by the p56 (lck) tyrosine kinase by decreasing their V max. Studies with freshly isolated renal proximal tubules from mOCT1/2(-/-) mice, in which mOCT3 is the only OCT present, confirmed this regulation pathway. Only the activity of hOCT3 is regulated by calmodulin. These findings suggest that even though many transport properties of mOCT3 and hOCT3 are similar, there are also species-specific aspects of OCT3 function.", "qas": [{"question": "How is OCT3 associated with serotonin?", "answers": ["serotonin clearance"], "qid": "bf90e54a60234266b05dd70fed882e86", "question_tokens": [["How", 0], ["is", 4], ["OCT3", 7], ["associated", 12], ["with", 23], ["serotonin", 28], ["?", 37]], "detected_answers": [{"text": "serotonin clearance", "token_spans": [[38, 39]], "char_spans": [[214, 232]]}]}], "context_tokens": [["The", 0], ["organic", 4], ["cation", 12], ["transporter", 19], ["3", 31], ["(", 33], ["OCT3", 34], [")", 38], ["is", 40], ["a", 43], ["widely", 45], ["expressed", 52], ["transporter", 62], ["for", 74], ["endogenous", 78], ["and", 89], ["exogenous", 93], ["organic", 103], ["cations", 111], [".", 118], ["Of", 120], ["particular", 123], ["interest", 134], ["is", 143], ["OCT3", 146], ["expression", 151], ["and", 162], ["function", 166], ["in", 175], ["the", 178], ["brain", 182], [",", 187], ["where", 189], ["it", 195], ["plays", 198], ["a", 204], ["role", 206], ["in", 211], ["serotonin", 214], ["clearance", 224], ["and", 234], ["influences", 238], ["mood", 249], ["and", 254], ["behavior", 258], [".", 266], ["Protein", 268], ["kinase", 276], ["signaling", 283], ["mediates", 293], ["rapid", 302], ["modulation", 308], ["of", 319], ["cerebral", 322], ["processes", 331], [",", 340], ["but", 342], ["little", 346], ["is", 353], ["known", 356], ["about", 362], ["acute", 368], ["regulation", 374], ["of", 385], ["OCT3", 388], ["by", 393], ["protein", 396], ["kinases", 404], [".", 411], ["Therefore", 413], [",", 422], ["we", 424], ["cloned", 427], ["mouse", 434], ["OCT3", 440], ["(", 445], ["mOCT3", 446], [")", 451], ["and", 453], ["generated", 457], ["a", 467], ["human", 469], ["embryonic", 475], ["kidney", 485], ["cell", 492], ["line", 497], ["stably", 502], ["expressing", 509], ["the", 520], ["transporter", 524], ["to", 536], ["study", 539], ["transport", 545], ["characteristics", 555], [",", 570], ["acute", 572], ["regulation", 578], ["by", 589], ["protein", 592], ["kinases", 600], [",", 607], ["and", 609], ["interaction", 613], ["with", 625], ["psychotropic", 630], ["drugs", 643], [".", 648], ["Uptake", 650], ["measurement", 657], ["was", 669], ["performed", 673], ["using", 683], ["the", 689], ["fluorescent", 693], ["cation", 705], ["4-(4-(dimethylamino)styryl)-N", 712], ["-", 741], ["methylpyridinium", 742], ["iodide", 759], ["(", 766], ["ASP(+", 767], [")", 772], [",", 773], ["1", 775], ["\u03bcM", 777], [")", 779], ["as", 781], ["a", 784], ["substrate", 786], [".", 795], ["The", 797], ["translational", 801], ["value", 815], ["of", 821], ["these", 824], ["findings", 830], ["was", 839], ["determined", 843], ["by", 854], ["comparing", 857], ["results", 867], ["obtained", 875], ["with", 884], ["cloned", 889], ["mouse", 896], ["and", 902], ["human", 906], ["OCT3", 912], [".", 916], ["mOCT3-mediated", 918], ["transport", 933], ["is", 943], ["membrane", 946], ["potential", 955], ["dependent", 965], ["and", 975], ["pH", 979], ["independent", 982], [".", 993], ["ASP(+", 995], [")", 1000], ["uptake", 1002], ["by", 1009], ["mOCT3", 1012], ["and", 1018], ["human", 1022], ["OCT3", 1028], ["(", 1033], ["hOCT3", 1034], [")", 1039], ["was", 1041], ["efficiently", 1045], ["inhibited", 1057], ["by", 1067], ["1-methyl-4-phenylpyridinium", 1070], [",", 1097], ["tetrapentylammonium", 1099], ["(", 1119], ["TPA(+", 1120], [")", 1125], [")", 1126], [",", 1127], ["corticosterone", 1129], [",", 1143], ["serotonin", 1145], [",", 1154], ["and", 1156], ["histamine", 1160], ["and", 1170], ["by", 1174], ["the", 1177], ["drugs", 1181], ["ketamine", 1187], [",", 1195], ["fluoxetine", 1197], [",", 1207], ["and", 1209], ["diazepam", 1213], [".", 1221], ["The", 1223], ["half", 1227], ["maximal", 1232], ["inhibitory", 1240], ["concentrations", 1251], ["of", 1266], ["mOCT3", 1269], ["and", 1275], ["hOCT3", 1279], ["for", 1285], ["TPA(+", 1289], [")", 1294], [",", 1295], ["serotonin", 1297], [",", 1306], ["diazepam", 1308], [",", 1316], ["and", 1318], ["ketamine", 1322], ["are", 1331], ["significantly", 1335], ["different", 1349], [".", 1358], ["Diazepam", 1360], ["is", 1369], ["a", 1372], ["non", 1374], ["-", 1377], ["transported", 1378], ["inhibitor", 1390], [".", 1399], ["Furthermore", 1401], [",", 1412], ["the", 1414], ["activities", 1418], ["of", 1429], ["mOCT3", 1432], ["and", 1438], ["hOCT3", 1442], ["are", 1448], ["acutely", 1452], ["regulated", 1460], ["by", 1470], ["the", 1473], ["p56", 1477], ["(", 1481], ["lck", 1482], [")", 1485], ["tyrosine", 1487], ["kinase", 1496], ["by", 1503], ["decreasing", 1506], ["their", 1517], ["V", 1523], ["max", 1525], [".", 1528], ["Studies", 1530], ["with", 1538], ["freshly", 1543], ["isolated", 1551], ["renal", 1560], ["proximal", 1566], ["tubules", 1575], ["from", 1583], ["mOCT1/2(-/-", 1588], [")", 1599], ["mice", 1601], [",", 1605], ["in", 1607], ["which", 1610], ["mOCT3", 1616], ["is", 1622], ["the", 1625], ["only", 1629], ["OCT", 1634], ["present", 1638], [",", 1645], ["confirmed", 1647], ["this", 1657], ["regulation", 1662], ["pathway", 1673], [".", 1680], ["Only", 1682], ["the", 1687], ["activity", 1691], ["of", 1700], ["hOCT3", 1703], ["is", 1709], ["regulated", 1712], ["by", 1722], ["calmodulin", 1725], [".", 1735], ["These", 1737], ["findings", 1743], ["suggest", 1752], ["that", 1760], ["even", 1765], ["though", 1770], ["many", 1777], ["transport", 1782], ["properties", 1792], ["of", 1803], ["mOCT3", 1806], ["and", 1812], ["hOCT3", 1816], ["are", 1822], ["similar", 1826], [",", 1833], ["there", 1835], ["are", 1841], ["also", 1845], ["species", 1850], ["-", 1857], ["specific", 1858], ["aspects", 1867], ["of", 1875], ["OCT3", 1878], ["function", 1883], [".", 1891]]}
{"context": "Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation). Here we present the results of the proof-of-concept part of the study. In this randomised, placebo-controlled, double-blind, proof-of-concept phase 1 study, we enrolled healthy volunteers (aged 18-45 years) with a body-mass index of 18\u00b75-29\u00b79 kg/m(2) into one of four dose groups at SGS Life Sciences Clinical Research Services, Belgium. Participants were randomly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number generator and a supplied seed number. Participants and care providers were masked to treatment assignment. All participants received oral dabigatran etexilate 220 mg twice daily for 3 days and a final dose on day 4. Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g plus 2\u00b75 g in two 5-min infusions given 1 h apart) was administered about 2 h after the final dabigatran etexilate dose. The primary endpoint was incidence of drug-related adverse events, analysed in all randomly assigned participants who received at least one dose of dabigatran etexilate. Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4. This trial is registered with ClinicalTrials.gov, number NCT01688830. Between Feb 23, and Nov 29, 2013, 47 men completed this part of the study. 12 were enrolled into each of the 1 g, 2 g, or 5 g plus 2\u00b75 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to placebo). Drug-related adverse events were all of mild intensity and reported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flushes), one in the 5 g plus 2\u00b75 g idarucizumab group (epistaxis); one receiving placebo (infusion site haematoma), and four during dabigatran etexilate pretreatment (three haematuria and one epistaxis). Idarucizumab immediately and completely reversed dabigatran-induced anticoagulation in a dose-dependent manner; the mean ratio of day 4 AUEC2-12 to day 3 AUEC2-12 for dTT was 1\u00b701 with placebo, 0\u00b726 with 1 g idarucizumab (74% reduction), 0\u00b706 with 2 g idarucizumab (94% reduction), 0\u00b702 with 4 g idarucizumab (98% reduction), and 0\u00b701 with 5 g plus 2\u00b75 g idarucizumab (99% reduction). No serious or severe adverse events were reported, no adverse event led to discontinuation of treatment, and no clinically relevant difference in incidence of adverse events was noted between treatment groups. These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. Further clinical studies are in progress. Boehringer Ingelheim Pharma GmbH & Co KG.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2997ce0116fe4da1afc9fa4cdf7e48d6", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[267, 267], [474, 474], [490, 490], [324, 324], [39, 39], [184, 184], [8, 8], [238, 238], [623, 623]], "char_spans": [[1357, 1366], [2353, 2362], [2474, 2483], [1630, 1639], [246, 255], [956, 965], [58, 67], [1182, 1191], [3132, 3141]]}]}], "context_tokens": [["Idarucizumab", 0], ["is", 13], ["a", 16], ["monoclonal", 18], ["antibody", 29], ["fragment", 38], ["that", 47], ["binds", 52], ["dabigatran", 58], ["with", 69], ["high", 74], ["affinity", 79], ["in", 88], ["a", 91], ["1:1", 93], ["molar", 97], ["ratio", 103], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["safety", 130], [",", 136], ["tolerability", 138], [",", 150], ["and", 152], ["efficacy", 156], ["of", 165], ["increasing", 168], ["doses", 179], ["of", 185], ["idarucizumab", 188], ["for", 201], ["the", 205], ["reversal", 209], ["of", 218], ["anticoagulant", 221], ["effects", 235], ["of", 243], ["dabigatran", 246], ["in", 257], ["a", 260], ["two", 262], ["-", 265], ["part", 266], ["phase", 271], ["1", 277], ["study", 279], ["(", 285], ["rising", 286], ["-", 292], ["dose", 293], ["assessment", 298], ["and", 309], ["dose", 313], ["-", 317], ["finding", 318], [",", 325], ["proof", 327], ["-", 332], ["of", 333], ["-", 335], ["concept", 336], ["investigation", 344], [")", 357], [".", 358], ["Here", 360], ["we", 365], ["present", 368], ["the", 376], ["results", 380], ["of", 388], ["the", 391], ["proof", 395], ["-", 400], ["of", 401], ["-", 403], ["concept", 404], ["part", 412], ["of", 417], ["the", 420], ["study", 424], [".", 429], ["In", 431], ["this", 434], ["randomised", 439], [",", 449], ["placebo", 451], ["-", 458], ["controlled", 459], [",", 469], ["double", 471], ["-", 477], ["blind", 478], [",", 483], ["proof", 485], ["-", 490], ["of", 491], ["-", 493], ["concept", 494], ["phase", 502], ["1", 508], ["study", 510], [",", 515], ["we", 517], ["enrolled", 520], ["healthy", 529], ["volunteers", 537], ["(", 548], ["aged", 549], ["18", 554], ["-", 556], ["45", 557], ["years", 560], [")", 565], ["with", 567], ["a", 572], ["body", 574], ["-", 578], ["mass", 579], ["index", 584], ["of", 590], ["18\u00b75", 593], ["-", 597], ["29\u00b79", 598], ["kg", 603], ["/", 605], ["m(2", 606], [")", 609], ["into", 611], ["one", 616], ["of", 620], ["four", 623], ["dose", 628], ["groups", 633], ["at", 640], ["SGS", 643], ["Life", 647], ["Sciences", 652], ["Clinical", 661], ["Research", 670], ["Services", 679], [",", 687], ["Belgium", 689], [".", 696], ["Participants", 698], ["were", 711], ["randomly", 716], ["assigned", 725], ["within", 734], ["groups", 741], ["in", 748], ["a", 751], ["3:1", 753], ["ratio", 757], ["to", 763], ["idarucizumab", 766], ["or", 779], ["placebo", 782], ["using", 790], ["a", 796], ["pseudorandom", 798], ["number", 811], ["generator", 818], ["and", 828], ["a", 832], ["supplied", 834], ["seed", 843], ["number", 848], [".", 854], ["Participants", 856], ["and", 869], ["care", 873], ["providers", 878], ["were", 888], ["masked", 893], ["to", 900], ["treatment", 903], ["assignment", 913], [".", 923], ["All", 925], ["participants", 929], ["received", 942], ["oral", 951], ["dabigatran", 956], ["etexilate", 967], ["220", 977], ["mg", 981], ["twice", 984], ["daily", 990], ["for", 996], ["3", 1000], ["days", 1002], ["and", 1007], ["a", 1011], ["final", 1013], ["dose", 1019], ["on", 1024], ["day", 1027], ["4", 1031], [".", 1032], ["Idarucizumab", 1034], ["(", 1047], ["1", 1048], ["g", 1050], [",", 1051], ["2", 1053], ["g", 1055], [",", 1056], ["or", 1058], ["4", 1061], ["g", 1063], ["5-min", 1065], ["infusion", 1071], [",", 1079], ["or", 1081], ["5", 1084], ["g", 1086], ["plus", 1088], ["2\u00b75", 1093], ["g", 1097], ["in", 1099], ["two", 1102], ["5-min", 1106], ["infusions", 1112], ["given", 1122], ["1", 1128], ["h", 1130], ["apart", 1132], [")", 1137], ["was", 1139], ["administered", 1143], ["about", 1156], ["2", 1162], ["h", 1164], ["after", 1166], ["the", 1172], ["final", 1176], ["dabigatran", 1182], ["etexilate", 1193], ["dose", 1203], [".", 1207], ["The", 1209], ["primary", 1213], ["endpoint", 1221], ["was", 1230], ["incidence", 1234], ["of", 1244], ["drug", 1247], ["-", 1251], ["related", 1252], ["adverse", 1260], ["events", 1268], [",", 1274], ["analysed", 1276], ["in", 1285], ["all", 1288], ["randomly", 1292], ["assigned", 1301], ["participants", 1310], ["who", 1323], ["received", 1327], ["at", 1336], ["least", 1339], ["one", 1345], ["dose", 1349], ["of", 1354], ["dabigatran", 1357], ["etexilate", 1368], [".", 1377], ["Reversal", 1379], ["of", 1388], ["diluted", 1391], ["thrombin", 1399], ["time", 1408], ["(", 1413], ["dTT", 1414], [")", 1417], [",", 1418], ["ecarin", 1420], ["clotting", 1427], ["time", 1436], ["(", 1441], ["ECT", 1442], [")", 1445], [",", 1446], ["activated", 1448], ["partial", 1458], ["thromboplastin", 1466], ["time", 1481], ["(", 1486], ["aPTT", 1487], [")", 1491], [",", 1492], ["and", 1494], ["thrombin", 1498], ["time", 1507], ["(", 1512], ["TT", 1513], [")", 1515], ["were", 1517], ["secondary", 1522], ["endpoints", 1532], ["assessed", 1542], ["by", 1551], ["measuring", 1554], ["the", 1564], ["area", 1568], ["under", 1573], ["the", 1579], ["effect", 1583], ["curve", 1590], ["from", 1596], ["2", 1601], ["h", 1603], ["to", 1605], ["12", 1608], ["h", 1611], ["(", 1613], ["AUEC2", 1614], ["-", 1619], ["12", 1620], [")", 1622], ["after", 1624], ["dabigatran", 1630], ["etexilate", 1641], ["ingestion", 1651], ["on", 1661], ["days", 1664], ["3", 1669], ["and", 1671], ["4", 1675], [".", 1676], ["This", 1678], ["trial", 1683], ["is", 1689], ["registered", 1692], ["with", 1703], ["ClinicalTrials.gov", 1708], [",", 1726], ["number", 1728], ["NCT01688830", 1735], [".", 1746], ["Between", 1748], ["Feb", 1756], ["23", 1760], [",", 1762], ["and", 1764], ["Nov", 1768], ["29", 1772], [",", 1774], ["2013", 1776], [",", 1780], ["47", 1782], ["men", 1785], ["completed", 1789], ["this", 1799], ["part", 1804], ["of", 1809], ["the", 1812], ["study", 1816], [".", 1821], ["12", 1823], ["were", 1826], ["enrolled", 1831], ["into", 1840], ["each", 1845], ["of", 1850], ["the", 1853], ["1", 1857], ["g", 1859], [",", 1860], ["2", 1862], ["g", 1864], [",", 1865], ["or", 1867], ["5", 1870], ["g", 1872], ["plus", 1874], ["2\u00b75", 1879], ["g", 1883], ["idarucizumab", 1885], ["groups", 1898], ["(", 1905], ["nine", 1906], ["to", 1911], ["idarucizumab", 1914], ["and", 1927], ["three", 1931], ["to", 1937], ["placebo", 1940], ["in", 1948], ["each", 1951], ["group", 1956], [")", 1961], [",", 1962], ["and", 1964], ["11", 1968], ["were", 1971], ["enrolled", 1976], ["into", 1985], ["the", 1990], ["4", 1994], ["g", 1996], ["idarucizumab", 1998], ["group", 2011], ["(", 2017], ["eight", 2018], ["to", 2024], ["idarucizumab", 2027], ["and", 2040], ["three", 2044], ["to", 2050], ["placebo", 2053], [")", 2060], [".", 2061], ["Drug", 2063], ["-", 2067], ["related", 2068], ["adverse", 2076], ["events", 2084], ["were", 2091], ["all", 2096], ["of", 2100], ["mild", 2103], ["intensity", 2108], ["and", 2118], ["reported", 2122], ["in", 2131], ["seven", 2134], ["participants", 2140], [":", 2152], ["one", 2154], ["in", 2158], ["the", 2161], ["1", 2165], ["g", 2167], ["idarucizumab", 2169], ["group", 2182], ["(", 2188], ["infusion", 2189], ["site", 2198], ["erythema", 2203], ["and", 2212], ["hot", 2216], ["flushes", 2220], [")", 2227], [",", 2228], ["one", 2230], ["in", 2234], ["the", 2237], ["5", 2241], ["g", 2243], ["plus", 2245], ["2\u00b75", 2250], ["g", 2254], ["idarucizumab", 2256], ["group", 2269], ["(", 2275], ["epistaxis", 2276], [")", 2285], [";", 2286], ["one", 2288], ["receiving", 2292], ["placebo", 2302], ["(", 2310], ["infusion", 2311], ["site", 2320], ["haematoma", 2325], [")", 2334], [",", 2335], ["and", 2337], ["four", 2341], ["during", 2346], ["dabigatran", 2353], ["etexilate", 2364], ["pretreatment", 2374], ["(", 2387], ["three", 2388], ["haematuria", 2394], ["and", 2405], ["one", 2409], ["epistaxis", 2413], [")", 2422], [".", 2423], ["Idarucizumab", 2425], ["immediately", 2438], ["and", 2450], ["completely", 2454], ["reversed", 2465], ["dabigatran", 2474], ["-", 2484], ["induced", 2485], ["anticoagulation", 2493], ["in", 2509], ["a", 2512], ["dose", 2514], ["-", 2518], ["dependent", 2519], ["manner", 2529], [";", 2535], ["the", 2537], ["mean", 2541], ["ratio", 2546], ["of", 2552], ["day", 2555], ["4", 2559], ["AUEC2", 2561], ["-", 2566], ["12", 2567], ["to", 2570], ["day", 2573], ["3", 2577], ["AUEC2", 2579], ["-", 2584], ["12", 2585], ["for", 2588], ["dTT", 2592], ["was", 2596], ["1\u00b701", 2600], ["with", 2605], ["placebo", 2610], [",", 2617], ["0\u00b726", 2619], ["with", 2624], ["1", 2629], ["g", 2631], ["idarucizumab", 2633], ["(", 2646], ["74", 2647], ["%", 2649], ["reduction", 2651], [")", 2660], [",", 2661], ["0\u00b706", 2663], ["with", 2668], ["2", 2673], ["g", 2675], ["idarucizumab", 2677], ["(", 2690], ["94", 2691], ["%", 2693], ["reduction", 2695], [")", 2704], [",", 2705], ["0\u00b702", 2707], ["with", 2712], ["4", 2717], ["g", 2719], ["idarucizumab", 2721], ["(", 2734], ["98", 2735], ["%", 2737], ["reduction", 2739], [")", 2748], [",", 2749], ["and", 2751], ["0\u00b701", 2755], ["with", 2760], ["5", 2765], ["g", 2767], ["plus", 2769], ["2\u00b75", 2774], ["g", 2778], ["idarucizumab", 2780], ["(", 2793], ["99", 2794], ["%", 2796], ["reduction", 2798], [")", 2807], [".", 2808], ["No", 2810], ["serious", 2813], ["or", 2821], ["severe", 2824], ["adverse", 2831], ["events", 2839], ["were", 2846], ["reported", 2851], [",", 2859], ["no", 2861], ["adverse", 2864], ["event", 2872], ["led", 2878], ["to", 2882], ["discontinuation", 2885], ["of", 2901], ["treatment", 2904], [",", 2913], ["and", 2915], ["no", 2919], ["clinically", 2922], ["relevant", 2933], ["difference", 2942], ["in", 2953], ["incidence", 2956], ["of", 2966], ["adverse", 2969], ["events", 2977], ["was", 2984], ["noted", 2988], ["between", 2994], ["treatment", 3002], ["groups", 3012], [".", 3018], ["These", 3020], ["phase", 3026], ["1", 3032], ["results", 3034], ["show", 3042], ["that", 3047], ["idarucizumab", 3052], ["was", 3065], ["associated", 3069], ["with", 3080], ["immediate", 3085], [",", 3094], ["complete", 3096], [",", 3104], ["and", 3106], ["sustained", 3110], ["reversal", 3120], ["of", 3129], ["dabigatran", 3132], ["-", 3142], ["induced", 3143], ["anticoagulation", 3151], ["in", 3167], ["healthy", 3170], ["men", 3178], [",", 3181], ["and", 3183], ["was", 3187], ["well", 3191], ["tolerated", 3196], ["with", 3206], ["no", 3211], ["unexpected", 3214], ["or", 3225], ["clinically", 3228], ["relevant", 3239], ["safety", 3248], ["concerns", 3255], [",", 3263], ["supporting", 3265], ["further", 3276], ["testing", 3284], [".", 3291], ["Further", 3293], ["clinical", 3301], ["studies", 3310], ["are", 3318], ["in", 3322], ["progress", 3325], [".", 3333], ["Boehringer", 3335], ["Ingelheim", 3346], ["Pharma", 3356], ["GmbH", 3363], ["&", 3368], ["Co", 3370], ["KG", 3373], [".", 3375]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene. CADASIL progresses, in some cases, to subcortical dementia with a particular cognitive impairment. Different diseases in the dementia spectrum share a central cholinergic and sensorimotor plasticity alteration. We aimed to study different intracortical circuits and sensorimotor plasticity in CADASIL patients using transcranial magnetic stimulation protocols, and to determine whether these characteristics correlated with the results of clinical neuropsychological evaluation. Ten CADASIL patients and 10 healthy subjects were included in the study. All subjects underwent a transcranial magnetic stimulation study examining different intracortical circuits. Sensorimotor plasticity was also assessed using a paired associative stimulation and extensive neuropsychological tests. CADASIL patients showed a lack of intracortical facilitation, short latency afferent inhibition and sensorimotor plasticity when compared with control subjects. CADASIL patients also showed an altered neuropsychological profile. Correlation between sensorimotor plasticity and neuropsychological alterations was observed in CADASIL patients. These results suggest that acetylcholine and glutamate could be involved in the dementia process in CADASIL and that abnormal sensorimotor plasticity correlates with the neuropsychological profile in CADASIL patients.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "27c99f3d44a94401b785406bd2f20967", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[25, 26]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["small", 106], ["vessel", 112], ["disease", 119], ["of", 127], ["the", 130], ["brain", 134], ["caused", 140], ["by", 147], ["mutations", 150], ["in", 160], ["the", 163], ["NOTCH3", 167], ["gene", 174], [".", 178], ["CADASIL", 180], ["progresses", 188], [",", 198], ["in", 200], ["some", 203], ["cases", 208], [",", 213], ["to", 215], ["subcortical", 218], ["dementia", 230], ["with", 239], ["a", 244], ["particular", 246], ["cognitive", 257], ["impairment", 267], [".", 277], ["Different", 279], ["diseases", 289], ["in", 298], ["the", 301], ["dementia", 305], ["spectrum", 314], ["share", 323], ["a", 329], ["central", 331], ["cholinergic", 339], ["and", 351], ["sensorimotor", 355], ["plasticity", 368], ["alteration", 379], [".", 389], ["We", 391], ["aimed", 394], ["to", 400], ["study", 403], ["different", 409], ["intracortical", 419], ["circuits", 433], ["and", 442], ["sensorimotor", 446], ["plasticity", 459], ["in", 470], ["CADASIL", 473], ["patients", 481], ["using", 490], ["transcranial", 496], ["magnetic", 509], ["stimulation", 518], ["protocols", 530], [",", 539], ["and", 541], ["to", 545], ["determine", 548], ["whether", 558], ["these", 566], ["characteristics", 572], ["correlated", 588], ["with", 599], ["the", 604], ["results", 608], ["of", 616], ["clinical", 619], ["neuropsychological", 628], ["evaluation", 647], [".", 657], ["Ten", 659], ["CADASIL", 663], ["patients", 671], ["and", 680], ["10", 684], ["healthy", 687], ["subjects", 695], ["were", 704], ["included", 709], ["in", 718], ["the", 721], ["study", 725], [".", 730], ["All", 732], ["subjects", 736], ["underwent", 745], ["a", 755], ["transcranial", 757], ["magnetic", 770], ["stimulation", 779], ["study", 791], ["examining", 797], ["different", 807], ["intracortical", 817], ["circuits", 831], [".", 839], ["Sensorimotor", 841], ["plasticity", 854], ["was", 865], ["also", 869], ["assessed", 874], ["using", 883], ["a", 889], ["paired", 891], ["associative", 898], ["stimulation", 910], ["and", 922], ["extensive", 926], ["neuropsychological", 936], ["tests", 955], [".", 960], ["CADASIL", 962], ["patients", 970], ["showed", 979], ["a", 986], ["lack", 988], ["of", 993], ["intracortical", 996], ["facilitation", 1010], [",", 1022], ["short", 1024], ["latency", 1030], ["afferent", 1038], ["inhibition", 1047], ["and", 1058], ["sensorimotor", 1062], ["plasticity", 1075], ["when", 1086], ["compared", 1091], ["with", 1100], ["control", 1105], ["subjects", 1113], [".", 1121], ["CADASIL", 1123], ["patients", 1131], ["also", 1140], ["showed", 1145], ["an", 1152], ["altered", 1155], ["neuropsychological", 1163], ["profile", 1182], [".", 1189], ["Correlation", 1191], ["between", 1203], ["sensorimotor", 1211], ["plasticity", 1224], ["and", 1235], ["neuropsychological", 1239], ["alterations", 1258], ["was", 1270], ["observed", 1274], ["in", 1283], ["CADASIL", 1286], ["patients", 1294], [".", 1302], ["These", 1304], ["results", 1310], ["suggest", 1318], ["that", 1326], ["acetylcholine", 1331], ["and", 1345], ["glutamate", 1349], ["could", 1359], ["be", 1365], ["involved", 1368], ["in", 1377], ["the", 1380], ["dementia", 1384], ["process", 1393], ["in", 1401], ["CADASIL", 1404], ["and", 1412], ["that", 1416], ["abnormal", 1421], ["sensorimotor", 1430], ["plasticity", 1443], ["correlates", 1454], ["with", 1465], ["the", 1470], ["neuropsychological", 1474], ["profile", 1493], ["in", 1501], ["CADASIL", 1504], ["patients", 1512], [".", 1520]]}
{"context": "Given the potential clinical benefit of inhibiting Na+/Ca2+ exchanger (NCX) activity during myocardial ischemia reperfusion (I/R), pharmacological approaches have been pursued to both inhibit and clarify the importance of this exchanger. SEA0400 was reported to have a potent NCX selectivity. Thus, we examined the effect of SEA0400 on NCX currents and I/R induced intracellular Ca2+ overload in mouse ventricular myocytes using patch clamp techniques and fluorescence measurements. Ischemia significantly inhibited inward and outward NCX current (from -0.04+/-0.01 nA to 0 nA at -100 mV; from 0.23+/-0.08 nA to 0.11+/-0.03 nA at +50 mV, n=7), Subsequent reperfusion not only restored the current rapidly but enhanced the current amplitude obviously, especially the outward currents (from 0.23+/-0.08 nA to 0.49+/-0.12 nA at +50 mV, n=7). [Ca2+]i, expressed as the ratio of Fura-2 fluorescence intensity, increased to 138+/-7% (P<0.01) during ischemia and to 210+/-11% (P<0.01) after reperfusion. The change of NCX current and the increase of [Ca2+]i during I/R can be blocked by SEA0400 in a dose-dependent manner with an EC50 value of 31 nM and 28 nM for the inward and outward NCX current, respectively. The results suggested that SEA0400 is a potent NCX inhibitor, which can protect mouse cardiac myocytes from Ca2+ overload during I/R injuries.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "adf00e4aac1141ad956eda51c049bd02", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[59, 59], [11, 11], [181, 181], [219, 219], [88, 88], [232, 232], [47, 47]], "char_spans": [[336, 338], [71, 73], [1011, 1013], [1180, 1182], [535, 537], [1254, 1256], [276, 278]]}]}], "context_tokens": [["Given", 0], ["the", 6], ["potential", 10], ["clinical", 20], ["benefit", 29], ["of", 37], ["inhibiting", 40], ["Na+/Ca2", 51], ["+", 58], ["exchanger", 60], ["(", 70], ["NCX", 71], [")", 74], ["activity", 76], ["during", 85], ["myocardial", 92], ["ischemia", 103], ["reperfusion", 112], ["(", 124], ["I", 125], ["/", 126], ["R", 127], [")", 128], [",", 129], ["pharmacological", 131], ["approaches", 147], ["have", 158], ["been", 163], ["pursued", 168], ["to", 176], ["both", 179], ["inhibit", 184], ["and", 192], ["clarify", 196], ["the", 204], ["importance", 208], ["of", 219], ["this", 222], ["exchanger", 227], [".", 236], ["SEA0400", 238], ["was", 246], ["reported", 250], ["to", 259], ["have", 262], ["a", 267], ["potent", 269], ["NCX", 276], ["selectivity", 280], [".", 291], ["Thus", 293], [",", 297], ["we", 299], ["examined", 302], ["the", 311], ["effect", 315], ["of", 322], ["SEA0400", 325], ["on", 333], ["NCX", 336], ["currents", 340], ["and", 349], ["I", 353], ["/", 354], ["R", 355], ["induced", 357], ["intracellular", 365], ["Ca2", 379], ["+", 382], ["overload", 384], ["in", 393], ["mouse", 396], ["ventricular", 402], ["myocytes", 414], ["using", 423], ["patch", 429], ["clamp", 435], ["techniques", 441], ["and", 452], ["fluorescence", 456], ["measurements", 469], [".", 481], ["Ischemia", 483], ["significantly", 492], ["inhibited", 506], ["inward", 516], ["and", 523], ["outward", 527], ["NCX", 535], ["current", 539], ["(", 547], ["from", 548], ["-0.04+/-0.01", 553], ["nA", 566], ["to", 569], ["0", 572], ["nA", 574], ["at", 577], ["-100", 580], ["mV", 585], [";", 587], ["from", 589], ["0.23+/-0.08", 594], ["nA", 606], ["to", 609], ["0.11+/-0.03", 612], ["nA", 624], ["at", 627], ["+50", 630], ["mV", 634], [",", 636], ["n=7", 638], [")", 641], [",", 642], ["Subsequent", 644], ["reperfusion", 655], ["not", 667], ["only", 671], ["restored", 676], ["the", 685], ["current", 689], ["rapidly", 697], ["but", 705], ["enhanced", 709], ["the", 718], ["current", 722], ["amplitude", 730], ["obviously", 740], [",", 749], ["especially", 751], ["the", 762], ["outward", 766], ["currents", 774], ["(", 783], ["from", 784], ["0.23+/-0.08", 789], ["nA", 801], ["to", 804], ["0.49+/-0.12", 807], ["nA", 819], ["at", 822], ["+50", 825], ["mV", 829], [",", 831], ["n=7", 833], [")", 836], [".", 837], ["[", 839], ["Ca2+]i", 840], [",", 846], ["expressed", 848], ["as", 858], ["the", 861], ["ratio", 865], ["of", 871], ["Fura-2", 874], ["fluorescence", 881], ["intensity", 894], [",", 903], ["increased", 905], ["to", 915], ["138+/-7", 918], ["%", 925], ["(", 927], ["P<0.01", 928], [")", 934], ["during", 936], ["ischemia", 943], ["and", 952], ["to", 956], ["210+/-11", 959], ["%", 967], ["(", 969], ["P<0.01", 970], [")", 976], ["after", 978], ["reperfusion", 984], [".", 995], ["The", 997], ["change", 1001], ["of", 1008], ["NCX", 1011], ["current", 1015], ["and", 1023], ["the", 1027], ["increase", 1031], ["of", 1040], ["[", 1043], ["Ca2+]i", 1044], ["during", 1051], ["I", 1058], ["/", 1059], ["R", 1060], ["can", 1062], ["be", 1066], ["blocked", 1069], ["by", 1077], ["SEA0400", 1080], ["in", 1088], ["a", 1091], ["dose", 1093], ["-", 1097], ["dependent", 1098], ["manner", 1108], ["with", 1115], ["an", 1120], ["EC50", 1123], ["value", 1128], ["of", 1134], ["31", 1137], ["nM", 1140], ["and", 1143], ["28", 1147], ["nM", 1150], ["for", 1153], ["the", 1157], ["inward", 1161], ["and", 1168], ["outward", 1172], ["NCX", 1180], ["current", 1184], [",", 1191], ["respectively", 1193], [".", 1205], ["The", 1207], ["results", 1211], ["suggested", 1219], ["that", 1229], ["SEA0400", 1234], ["is", 1242], ["a", 1245], ["potent", 1247], ["NCX", 1254], ["inhibitor", 1258], [",", 1267], ["which", 1269], ["can", 1275], ["protect", 1279], ["mouse", 1287], ["cardiac", 1293], ["myocytes", 1301], ["from", 1310], ["Ca2", 1315], ["+", 1318], ["overload", 1320], ["during", 1329], ["I", 1336], ["/", 1337], ["R", 1338], ["injuries", 1340], [".", 1348]]}
{"context": "Recombinant tissue plasminogen activator (rT-PA) is an effective treatment for acute ischaemic stroke when given within 3h of symptom onset but can be delayed as patients wait for a diagnosis. The ROSIER assessment tool (Fig. 1) has been found to be effective in diagnosing stroke but to date has only been tested when used by doctors. To compare registered nurses' ability to diagnose stroke using the ROSIER assessment tool with doctors' ability to diagnose stroke using traditional neurological assessment. A prospective audit of all suspected stroke patients (n=106) admitted to the stroke unit of a district general hospital over an eight month period, assessed by registered nurses trained to use the ROSIER assessment tool to identify stroke. Time from admission to the stroke unit until initial assessment by doctors and registered nurses. Comparison of initial diagnosis by doctors and registered nurses with final diagnosis by a consultant for stroke. Of 106 suspected stroke patients, 78 (73.5%) had a final diagnosis of stroke or transient ischaemic attack (TIA) and 28 (26.4%) had an alternative diagnosis. Six patients with TIA were subsequently excluded as they were asymptomatic at the time of assessment, leaving 100 participants in the validation phase of the study. Using the ROSIER tool registered nurses achieved a diagnostic sensitivity for stroke of 98% (95% confidence interval 88-99), positive predictive value (PPV) 83% (95% confidence interval 73-90). Doctors using standard neurological assessment had a similar diagnostic sensitivity of 94% (95% confidence interval 86-98), PPV 80% (95% confidence interval 70-88). The mean time from initial assessment by registered nurses using the ROSIER tool, until assessment by doctor on the stroke unit was 75 min (SD=65.8 min). Registered nurses working on a stroke unit using the ROSIER assessment tool are able to diagnose stroke with a degree of accuracy comparable to doctors using clinical neurological assessment. Prompt assessment of suspected stroke patients by registered nurses using the ROSIER tool could reduce delays in eligible stroke patients being assessed for rT-PA treatment.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "6f0bc4db6f3244efa75413fbbed77285", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[16, 16], [85, 85], [131, 131], [138, 138], [165, 165], [170, 170], [355, 355], [52, 52], [373, 373], [73, 73], [105, 105], [183, 183], [329, 329], [387, 387], [344, 344], [97, 97], [241, 241]], "char_spans": [[95, 100], [460, 465], [742, 747], [777, 782], [954, 959], [979, 984], [1895, 1900], [274, 279], [2021, 2026], [386, 391], [587, 592], [1032, 1037], [1760, 1765], [2112, 2117], [1829, 1834], [547, 552], [1363, 1368]]}]}], "context_tokens": [["Recombinant", 0], ["tissue", 12], ["plasminogen", 19], ["activator", 31], ["(", 41], ["rT", 42], ["-", 44], ["PA", 45], [")", 47], ["is", 49], ["an", 52], ["effective", 55], ["treatment", 65], ["for", 75], ["acute", 79], ["ischaemic", 85], ["stroke", 95], ["when", 102], ["given", 107], ["within", 113], ["3h", 120], ["of", 123], ["symptom", 126], ["onset", 134], ["but", 140], ["can", 144], ["be", 148], ["delayed", 151], ["as", 159], ["patients", 162], ["wait", 171], ["for", 176], ["a", 180], ["diagnosis", 182], [".", 191], ["The", 193], ["ROSIER", 197], ["assessment", 204], ["tool", 215], ["(", 220], ["Fig", 221], [".", 224], ["1", 226], [")", 227], ["has", 229], ["been", 233], ["found", 238], ["to", 244], ["be", 247], ["effective", 250], ["in", 260], ["diagnosing", 263], ["stroke", 274], ["but", 281], ["to", 285], ["date", 288], ["has", 293], ["only", 297], ["been", 302], ["tested", 307], ["when", 314], ["used", 319], ["by", 324], ["doctors", 327], [".", 334], ["To", 336], ["compare", 339], ["registered", 347], ["nurses", 358], ["'", 364], ["ability", 366], ["to", 374], ["diagnose", 377], ["stroke", 386], ["using", 393], ["the", 399], ["ROSIER", 403], ["assessment", 410], ["tool", 421], ["with", 426], ["doctors", 431], ["'", 438], ["ability", 440], ["to", 448], ["diagnose", 451], ["stroke", 460], ["using", 467], ["traditional", 473], ["neurological", 485], ["assessment", 498], [".", 508], ["A", 510], ["prospective", 512], ["audit", 524], ["of", 530], ["all", 533], ["suspected", 537], ["stroke", 547], ["patients", 554], ["(", 563], ["n=106", 564], [")", 569], ["admitted", 571], ["to", 580], ["the", 583], ["stroke", 587], ["unit", 594], ["of", 599], ["a", 602], ["district", 604], ["general", 613], ["hospital", 621], ["over", 630], ["an", 635], ["eight", 638], ["month", 644], ["period", 650], [",", 656], ["assessed", 658], ["by", 667], ["registered", 670], ["nurses", 681], ["trained", 688], ["to", 696], ["use", 699], ["the", 703], ["ROSIER", 707], ["assessment", 714], ["tool", 725], ["to", 730], ["identify", 733], ["stroke", 742], [".", 748], ["Time", 750], ["from", 755], ["admission", 760], ["to", 770], ["the", 773], ["stroke", 777], ["unit", 784], ["until", 789], ["initial", 795], ["assessment", 803], ["by", 814], ["doctors", 817], ["and", 825], ["registered", 829], ["nurses", 840], [".", 846], ["Comparison", 848], ["of", 859], ["initial", 862], ["diagnosis", 870], ["by", 880], ["doctors", 883], ["and", 891], ["registered", 895], ["nurses", 906], ["with", 913], ["final", 918], ["diagnosis", 924], ["by", 934], ["a", 937], ["consultant", 939], ["for", 950], ["stroke", 954], [".", 960], ["Of", 962], ["106", 965], ["suspected", 969], ["stroke", 979], ["patients", 986], [",", 994], ["78", 996], ["(", 999], ["73.5", 1000], ["%", 1004], [")", 1005], ["had", 1007], ["a", 1011], ["final", 1013], ["diagnosis", 1019], ["of", 1029], ["stroke", 1032], ["or", 1039], ["transient", 1042], ["ischaemic", 1052], ["attack", 1062], ["(", 1069], ["TIA", 1070], [")", 1073], ["and", 1075], ["28", 1079], ["(", 1082], ["26.4", 1083], ["%", 1087], [")", 1088], ["had", 1090], ["an", 1094], ["alternative", 1097], ["diagnosis", 1109], [".", 1118], ["Six", 1120], ["patients", 1124], ["with", 1133], ["TIA", 1138], ["were", 1142], ["subsequently", 1147], ["excluded", 1160], ["as", 1169], ["they", 1172], ["were", 1177], ["asymptomatic", 1182], ["at", 1195], ["the", 1198], ["time", 1202], ["of", 1207], ["assessment", 1210], [",", 1220], ["leaving", 1222], ["100", 1230], ["participants", 1234], ["in", 1247], ["the", 1250], ["validation", 1254], ["phase", 1265], ["of", 1271], ["the", 1274], ["study", 1278], [".", 1283], ["Using", 1285], ["the", 1291], ["ROSIER", 1295], ["tool", 1302], ["registered", 1307], ["nurses", 1318], ["achieved", 1325], ["a", 1334], ["diagnostic", 1336], ["sensitivity", 1347], ["for", 1359], ["stroke", 1363], ["of", 1370], ["98", 1373], ["%", 1375], ["(", 1377], ["95", 1378], ["%", 1380], ["confidence", 1382], ["interval", 1393], ["88", 1402], ["-", 1404], ["99", 1405], [")", 1407], [",", 1408], ["positive", 1410], ["predictive", 1419], ["value", 1430], ["(", 1436], ["PPV", 1437], [")", 1440], ["83", 1442], ["%", 1444], ["(", 1446], ["95", 1447], ["%", 1449], ["confidence", 1451], ["interval", 1462], ["73", 1471], ["-", 1473], ["90", 1474], [")", 1476], [".", 1477], ["Doctors", 1479], ["using", 1487], ["standard", 1493], ["neurological", 1502], ["assessment", 1515], ["had", 1526], ["a", 1530], ["similar", 1532], ["diagnostic", 1540], ["sensitivity", 1551], ["of", 1563], ["94", 1566], ["%", 1568], ["(", 1570], ["95", 1571], ["%", 1573], ["confidence", 1575], ["interval", 1586], ["86", 1595], ["-", 1597], ["98", 1598], [")", 1600], [",", 1601], ["PPV", 1603], ["80", 1607], ["%", 1609], ["(", 1611], ["95", 1612], ["%", 1614], ["confidence", 1616], ["interval", 1627], ["70", 1636], ["-", 1638], ["88", 1639], [")", 1641], [".", 1642], ["The", 1644], ["mean", 1648], ["time", 1653], ["from", 1658], ["initial", 1663], ["assessment", 1671], ["by", 1682], ["registered", 1685], ["nurses", 1696], ["using", 1703], ["the", 1709], ["ROSIER", 1713], ["tool", 1720], [",", 1724], ["until", 1726], ["assessment", 1732], ["by", 1743], ["doctor", 1746], ["on", 1753], ["the", 1756], ["stroke", 1760], ["unit", 1767], ["was", 1772], ["75", 1776], ["min", 1779], ["(", 1783], ["SD=65.8", 1784], ["min", 1792], [")", 1795], [".", 1796], ["Registered", 1798], ["nurses", 1809], ["working", 1816], ["on", 1824], ["a", 1827], ["stroke", 1829], ["unit", 1836], ["using", 1841], ["the", 1847], ["ROSIER", 1851], ["assessment", 1858], ["tool", 1869], ["are", 1874], ["able", 1878], ["to", 1883], ["diagnose", 1886], ["stroke", 1895], ["with", 1902], ["a", 1907], ["degree", 1909], ["of", 1916], ["accuracy", 1919], ["comparable", 1928], ["to", 1939], ["doctors", 1942], ["using", 1950], ["clinical", 1956], ["neurological", 1965], ["assessment", 1978], [".", 1988], ["Prompt", 1990], ["assessment", 1997], ["of", 2008], ["suspected", 2011], ["stroke", 2021], ["patients", 2028], ["by", 2037], ["registered", 2040], ["nurses", 2051], ["using", 2058], ["the", 2064], ["ROSIER", 2068], ["tool", 2075], ["could", 2080], ["reduce", 2086], ["delays", 2093], ["in", 2100], ["eligible", 2103], ["stroke", 2112], ["patients", 2119], ["being", 2128], ["assessed", 2134], ["for", 2143], ["rT", 2147], ["-", 2149], ["PA", 2150], ["treatment", 2153], [".", 2162]]}
{"context": "Recently, the sex determining region Y ( Sry) and the cerebellar degeneration-related protein 1 ( CDR1as) RNA transcripts have been described to function as a new class of post-transcriptional regulatory RNAs that behave as circular endogenous RNA sponges for the micro RNAs (miRNAs) miR-138 and miR-7, respectively. A special feature of the Sry gene is its ability to generate linear and circular transcripts, both transcribed in the sense orientation. Here we remark that both sense (e.g. Sry RNA) and antisense (e.g. CDR1as) transcripts could circularize and behave as miRNAs sponges, and importantly, that also protein-coding segments of mRNAs could also assume this role. Thus, it is reasonable to think that the linear Sry sense transcript could additionally act as a miRNA sponge, or as an endogenous competing RNA for miR-138.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "71b0e329f10047c39ece3b5149f7ae9c", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[52, 52], [153, 153]], "char_spans": [[284, 290], [826, 832]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["the", 10], ["sex", 14], ["determining", 18], ["region", 30], ["Y", 37], ["(", 39], ["Sry", 41], [")", 44], ["and", 46], ["the", 50], ["cerebellar", 54], ["degeneration", 65], ["-", 77], ["related", 78], ["protein", 86], ["1", 94], ["(", 96], ["CDR1as", 98], [")", 104], ["RNA", 106], ["transcripts", 110], ["have", 122], ["been", 127], ["described", 132], ["to", 142], ["function", 145], ["as", 154], ["a", 157], ["new", 159], ["class", 163], ["of", 169], ["post", 172], ["-", 176], ["transcriptional", 177], ["regulatory", 193], ["RNAs", 204], ["that", 209], ["behave", 214], ["as", 221], ["circular", 224], ["endogenous", 233], ["RNA", 244], ["sponges", 248], ["for", 256], ["the", 260], ["micro", 264], ["RNAs", 270], ["(", 275], ["miRNAs", 276], [")", 282], ["miR-138", 284], ["and", 292], ["miR-7", 296], [",", 301], ["respectively", 303], [".", 315], ["A", 317], ["special", 319], ["feature", 327], ["of", 335], ["the", 338], ["Sry", 342], ["gene", 346], ["is", 351], ["its", 354], ["ability", 358], ["to", 366], ["generate", 369], ["linear", 378], ["and", 385], ["circular", 389], ["transcripts", 398], [",", 409], ["both", 411], ["transcribed", 416], ["in", 428], ["the", 431], ["sense", 435], ["orientation", 441], [".", 452], ["Here", 454], ["we", 459], ["remark", 462], ["that", 469], ["both", 474], ["sense", 479], ["(", 485], ["e.g.", 486], ["Sry", 491], ["RNA", 495], [")", 498], ["and", 500], ["antisense", 504], ["(", 514], ["e.g.", 515], ["CDR1as", 520], [")", 526], ["transcripts", 528], ["could", 540], ["circularize", 546], ["and", 558], ["behave", 562], ["as", 569], ["miRNAs", 572], ["sponges", 579], [",", 586], ["and", 588], ["importantly", 592], [",", 603], ["that", 605], ["also", 610], ["protein", 615], ["-", 622], ["coding", 623], ["segments", 630], ["of", 639], ["mRNAs", 642], ["could", 648], ["also", 654], ["assume", 659], ["this", 666], ["role", 671], [".", 675], ["Thus", 677], [",", 681], ["it", 683], ["is", 686], ["reasonable", 689], ["to", 700], ["think", 703], ["that", 709], ["the", 714], ["linear", 718], ["Sry", 725], ["sense", 729], ["transcript", 735], ["could", 746], ["additionally", 752], ["act", 765], ["as", 769], ["a", 772], ["miRNA", 774], ["sponge", 780], [",", 786], ["or", 788], ["as", 791], ["an", 794], ["endogenous", 797], ["competing", 808], ["RNA", 818], ["for", 822], ["miR-138", 826], [".", 833]]}
{"context": "This article explains what methicillin-resistant Staphylococcus aureus (MRSA) is, how it is spread and what the real challenges are in healthcare settings in the UK. It explores the different strains of MRSA and points out the main ways to control their spread. It is intended to be a reference source for all nurses.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "2227001cc02f46f4b3d6c776d15071cd", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[37, 37], [10, 10]], "char_spans": [[203, 206], [72, 75]]}]}], "context_tokens": [["This", 0], ["article", 5], ["explains", 13], ["what", 22], ["methicillin", 27], ["-", 38], ["resistant", 39], ["Staphylococcus", 49], ["aureus", 64], ["(", 71], ["MRSA", 72], [")", 76], ["is", 78], [",", 80], ["how", 82], ["it", 86], ["is", 89], ["spread", 92], ["and", 99], ["what", 103], ["the", 108], ["real", 112], ["challenges", 117], ["are", 128], ["in", 132], ["healthcare", 135], ["settings", 146], ["in", 155], ["the", 158], ["UK", 162], [".", 164], ["It", 166], ["explores", 169], ["the", 178], ["different", 182], ["strains", 192], ["of", 200], ["MRSA", 203], ["and", 208], ["points", 212], ["out", 219], ["the", 223], ["main", 227], ["ways", 232], ["to", 237], ["control", 240], ["their", 248], ["spread", 254], [".", 260], ["It", 262], ["is", 265], ["intended", 268], ["to", 277], ["be", 280], ["a", 283], ["reference", 285], ["source", 295], ["for", 302], ["all", 306], ["nurses", 310], [".", 316]]}
{"context": "Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML). Because of the excellent hematologic and cytogenetic responses, imatinib has moved toward first-line treatment for newly diagnosed CML. However, the emergence of resistance to imatinib remains a major problem in the treatment of Ph-positive leukemia. Several mechanisms of imatinib resistance have been identified, including BCR-ABL gene amplification that leads to overexpression of the BCR-ABL protein, point mutations in the BCR-ABL kinase domain that interfere with imatinib binding, and point mutations outside of the kinase domain that allosterically inhibit imatinib binding to BCR-ABL. The need for alternative or additional treatment for imatinib-resistant BCR-ABL-positive leukemia has guided the way to the design of a second generation of targeted therapies, which has resulted mainly in the development of novel small-molecule inhibitors such as AMN107, dasatinib, NS-187, and ON012380. The major goal of these efforts is to create new compounds that are more potent than imatinib and/or more effective against imatinib-resistant BCR-ABL clones. In this review, we discuss the next generation of BCR-ABL kinase inhibitors for overcoming imatinib resistance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "f60b00cd2c9944dc95889093639a4381", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[102, 104], [142, 144], [211, 213], [93, 95], [13, 15], [226, 228], [82, 84], [127, 129]], "char_spans": [[609, 615], [847, 853], [1224, 1230], [569, 575], [93, 99], [1290, 1296], [506, 512], [766, 772]]}]}], "context_tokens": [["Imatinib", 0], ["was", 9], ["developed", 13], ["as", 23], ["the", 26], ["first", 30], ["molecularly", 36], ["targeted", 48], ["therapy", 57], ["to", 65], ["specifically", 68], ["inhibit", 81], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["kinase", 101], ["in", 108], ["Philadelphia", 111], ["chromosome", 124], ["(", 135], ["Ph)-positive", 136], ["chronic", 149], ["myeloid", 157], ["leukemia", 165], ["(", 174], ["CML", 175], [")", 178], [".", 179], ["Because", 181], ["of", 189], ["the", 192], ["excellent", 196], ["hematologic", 206], ["and", 218], ["cytogenetic", 222], ["responses", 234], [",", 243], ["imatinib", 245], ["has", 254], ["moved", 258], ["toward", 264], ["first", 271], ["-", 276], ["line", 277], ["treatment", 282], ["for", 292], ["newly", 296], ["diagnosed", 302], ["CML", 312], [".", 315], ["However", 317], [",", 324], ["the", 326], ["emergence", 330], ["of", 340], ["resistance", 343], ["to", 354], ["imatinib", 357], ["remains", 366], ["a", 374], ["major", 376], ["problem", 382], ["in", 390], ["the", 393], ["treatment", 397], ["of", 407], ["Ph", 410], ["-", 412], ["positive", 413], ["leukemia", 422], [".", 430], ["Several", 432], ["mechanisms", 440], ["of", 451], ["imatinib", 454], ["resistance", 463], ["have", 474], ["been", 479], ["identified", 484], [",", 494], ["including", 496], ["BCR", 506], ["-", 509], ["ABL", 510], ["gene", 514], ["amplification", 519], ["that", 533], ["leads", 538], ["to", 544], ["overexpression", 547], ["of", 562], ["the", 565], ["BCR", 569], ["-", 572], ["ABL", 573], ["protein", 577], [",", 584], ["point", 586], ["mutations", 592], ["in", 602], ["the", 605], ["BCR", 609], ["-", 612], ["ABL", 613], ["kinase", 617], ["domain", 624], ["that", 631], ["interfere", 636], ["with", 646], ["imatinib", 651], ["binding", 660], [",", 667], ["and", 669], ["point", 673], ["mutations", 679], ["outside", 689], ["of", 697], ["the", 700], ["kinase", 704], ["domain", 711], ["that", 718], ["allosterically", 723], ["inhibit", 738], ["imatinib", 746], ["binding", 755], ["to", 763], ["BCR", 766], ["-", 769], ["ABL", 770], [".", 773], ["The", 775], ["need", 779], ["for", 784], ["alternative", 788], ["or", 800], ["additional", 803], ["treatment", 814], ["for", 824], ["imatinib", 828], ["-", 836], ["resistant", 837], ["BCR", 847], ["-", 850], ["ABL", 851], ["-", 854], ["positive", 855], ["leukemia", 864], ["has", 873], ["guided", 877], ["the", 884], ["way", 888], ["to", 892], ["the", 895], ["design", 899], ["of", 906], ["a", 909], ["second", 911], ["generation", 918], ["of", 929], ["targeted", 932], ["therapies", 941], [",", 950], ["which", 952], ["has", 958], ["resulted", 962], ["mainly", 971], ["in", 978], ["the", 981], ["development", 985], ["of", 997], ["novel", 1000], ["small", 1006], ["-", 1011], ["molecule", 1012], ["inhibitors", 1021], ["such", 1032], ["as", 1037], ["AMN107", 1040], [",", 1046], ["dasatinib", 1048], [",", 1057], ["NS-187", 1059], [",", 1065], ["and", 1067], ["ON012380", 1071], [".", 1079], ["The", 1081], ["major", 1085], ["goal", 1091], ["of", 1096], ["these", 1099], ["efforts", 1105], ["is", 1113], ["to", 1116], ["create", 1119], ["new", 1126], ["compounds", 1130], ["that", 1140], ["are", 1145], ["more", 1149], ["potent", 1154], ["than", 1161], ["imatinib", 1166], ["and/or", 1175], ["more", 1182], ["effective", 1187], ["against", 1197], ["imatinib", 1205], ["-", 1213], ["resistant", 1214], ["BCR", 1224], ["-", 1227], ["ABL", 1228], ["clones", 1232], [".", 1238], ["In", 1240], ["this", 1243], ["review", 1248], [",", 1254], ["we", 1256], ["discuss", 1259], ["the", 1267], ["next", 1271], ["generation", 1276], ["of", 1287], ["BCR", 1290], ["-", 1293], ["ABL", 1294], ["kinase", 1298], ["inhibitors", 1305], ["for", 1316], ["overcoming", 1320], ["imatinib", 1331], ["resistance", 1340], [".", 1350]]}
{"context": "Since the discovery of non-coding, small, highly structured, satellite RNAs (satRNAs) and viroids as subviral pathogens of plants , have been of great interest to molecular biologists as possible living fossils of pre-cellular evolution in an RNA world. Despite extensive studies performed in the last four decades, there is still mystery surrounding the origin and evolutionary relationship between these subviral pathogens. Recent technical advances revealed some commonly shared replication features between these two subviral pathogens. In this review, we discuss our current perception of replication and evolutionary origin of these petite RNA pathogens.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "0133a9c3b1f74db79d96f61d59105870", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[19, 19]], "char_spans": [[90, 96]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["discovery", 10], ["of", 20], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["small", 35], [",", 40], ["highly", 42], ["structured", 49], [",", 59], ["satellite", 61], ["RNAs", 71], ["(", 76], ["satRNAs", 77], [")", 84], ["and", 86], ["viroids", 90], ["as", 98], ["subviral", 101], ["pathogens", 110], ["of", 120], ["plants", 123], [",", 130], ["have", 132], ["been", 137], ["of", 142], ["great", 145], ["interest", 151], ["to", 160], ["molecular", 163], ["biologists", 173], ["as", 184], ["possible", 187], ["living", 196], ["fossils", 203], ["of", 211], ["pre", 214], ["-", 217], ["cellular", 218], ["evolution", 227], ["in", 237], ["an", 240], ["RNA", 243], ["world", 247], [".", 252], ["Despite", 254], ["extensive", 262], ["studies", 272], ["performed", 280], ["in", 290], ["the", 293], ["last", 297], ["four", 302], ["decades", 307], [",", 314], ["there", 316], ["is", 322], ["still", 325], ["mystery", 331], ["surrounding", 339], ["the", 351], ["origin", 355], ["and", 362], ["evolutionary", 366], ["relationship", 379], ["between", 392], ["these", 400], ["subviral", 406], ["pathogens", 415], [".", 424], ["Recent", 426], ["technical", 433], ["advances", 443], ["revealed", 452], ["some", 461], ["commonly", 466], ["shared", 475], ["replication", 482], ["features", 494], ["between", 503], ["these", 511], ["two", 517], ["subviral", 521], ["pathogens", 530], [".", 539], ["In", 541], ["this", 544], ["review", 549], [",", 555], ["we", 557], ["discuss", 560], ["our", 568], ["current", 572], ["perception", 580], ["of", 591], ["replication", 594], ["and", 606], ["evolutionary", 610], ["origin", 623], ["of", 630], ["these", 633], ["petite", 639], ["RNA", 646], ["pathogens", 650], [".", 659]]}
{"context": "Transcription-coupled repair (TCR) is the major pathway involved in the removal of UV-induced photolesions from the transcribed strand of active genes. Two Cockayne syndrome (CS) complementation group proteins, CSA and CSB, are important for TCR repair. The molecular mechanisms by which CS proteins regulate TCR remain elusive. Here, we report the characterization of KIAA1530, an evolutionarily conserved protein that participates in this pathway through its interaction with CSA and the TFIIH complex. We found that UV irradiation led to the recruitment of KIAA1530 onto chromatin in a CSA-dependent manner. Cells lacking KIAA1530 were highly sensitive to UV irradiation and displayed deficiency in TCR. In addition, KIAA1530 depletion abrogated stability of the CSB protein following UV irradiation. More excitingly, we found that a unique CSA mutant (W361C), which was previously identified in a patient with UV(s)S syndrome, showed defective KIAA1530 binding and resulted in a failure of recruiting KIAA1530 and stabilizing CSB after UV treatment. Together, our data not only reveal that KIAA1530 is an important player in TCR but also lead to a better understanding of the molecular mechanism underlying UV(s)S syndrome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "0ee48960a85e4cb08d71437204c23131", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[22, 23]], "char_spans": [[116, 133]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["the", 38], ["major", 42], ["pathway", 48], ["involved", 56], ["in", 65], ["the", 68], ["removal", 72], ["of", 80], ["UV", 83], ["-", 85], ["induced", 86], ["photolesions", 94], ["from", 107], ["the", 112], ["transcribed", 116], ["strand", 128], ["of", 135], ["active", 138], ["genes", 145], [".", 150], ["Two", 152], ["Cockayne", 156], ["syndrome", 165], ["(", 174], ["CS", 175], [")", 177], ["complementation", 179], ["group", 195], ["proteins", 201], [",", 209], ["CSA", 211], ["and", 215], ["CSB", 219], [",", 222], ["are", 224], ["important", 228], ["for", 238], ["TCR", 242], ["repair", 246], [".", 252], ["The", 254], ["molecular", 258], ["mechanisms", 268], ["by", 279], ["which", 282], ["CS", 288], ["proteins", 291], ["regulate", 300], ["TCR", 309], ["remain", 313], ["elusive", 320], [".", 327], ["Here", 329], [",", 333], ["we", 335], ["report", 338], ["the", 345], ["characterization", 349], ["of", 366], ["KIAA1530", 369], [",", 377], ["an", 379], ["evolutionarily", 382], ["conserved", 397], ["protein", 407], ["that", 415], ["participates", 420], ["in", 433], ["this", 436], ["pathway", 441], ["through", 449], ["its", 457], ["interaction", 461], ["with", 473], ["CSA", 478], ["and", 482], ["the", 486], ["TFIIH", 490], ["complex", 496], [".", 503], ["We", 505], ["found", 508], ["that", 514], ["UV", 519], ["irradiation", 522], ["led", 534], ["to", 538], ["the", 541], ["recruitment", 545], ["of", 557], ["KIAA1530", 560], ["onto", 569], ["chromatin", 574], ["in", 584], ["a", 587], ["CSA", 589], ["-", 592], ["dependent", 593], ["manner", 603], [".", 609], ["Cells", 611], ["lacking", 617], ["KIAA1530", 625], ["were", 634], ["highly", 639], ["sensitive", 646], ["to", 656], ["UV", 659], ["irradiation", 662], ["and", 674], ["displayed", 678], ["deficiency", 688], ["in", 699], ["TCR", 702], [".", 705], ["In", 707], ["addition", 710], [",", 718], ["KIAA1530", 720], ["depletion", 729], ["abrogated", 739], ["stability", 749], ["of", 759], ["the", 762], ["CSB", 766], ["protein", 770], ["following", 778], ["UV", 788], ["irradiation", 791], [".", 802], ["More", 804], ["excitingly", 809], [",", 819], ["we", 821], ["found", 824], ["that", 830], ["a", 835], ["unique", 837], ["CSA", 844], ["mutant", 848], ["(", 855], ["W361C", 856], [")", 861], [",", 862], ["which", 864], ["was", 870], ["previously", 874], ["identified", 885], ["in", 896], ["a", 899], ["patient", 901], ["with", 909], ["UV(s)S", 914], ["syndrome", 921], [",", 929], ["showed", 931], ["defective", 938], ["KIAA1530", 948], ["binding", 957], ["and", 965], ["resulted", 969], ["in", 978], ["a", 981], ["failure", 983], ["of", 991], ["recruiting", 994], ["KIAA1530", 1005], ["and", 1014], ["stabilizing", 1018], ["CSB", 1030], ["after", 1034], ["UV", 1040], ["treatment", 1043], [".", 1052], ["Together", 1054], [",", 1062], ["our", 1064], ["data", 1068], ["not", 1073], ["only", 1077], ["reveal", 1082], ["that", 1089], ["KIAA1530", 1094], ["is", 1103], ["an", 1106], ["important", 1109], ["player", 1119], ["in", 1126], ["TCR", 1129], ["but", 1133], ["also", 1137], ["lead", 1142], ["to", 1147], ["a", 1150], ["better", 1152], ["understanding", 1159], ["of", 1173], ["the", 1176], ["molecular", 1180], ["mechanism", 1190], ["underlying", 1200], ["UV(s)S", 1211], ["syndrome", 1218], [".", 1226]]}
{"context": "We have used a non-replicating recombinant adenovirus, Ad5MCMVlacZ, which expresses the beta-galactosidase reporter gene, to examine both constitutive and inducible repair of UV-damaged DNA in repair proficient CHO-AA8 Chinese hamster ovary cells and in mutant CHO-UV61 cells which are deficient in the transcription-coupled repair (TCR) pathway of nucleotide excision repair. Host cell reactivation (HCR) of beta-galactosidase activity for UV-irradiated Ad5MCMVlacZ was significantly reduced in non-irradiated CHO-UV61 cells compared to that in non-irradiated CHO-AA8 cells suggesting that repair in the transcribed strand of the UV-damaged reporter gene in untreated cells utilizes TCR. Prior UV-irradiation of cells with low UV fluences resulted in a transient enhancement of HCR for expression of the UV-damaged reporter gene in CHO-AA8 cells but not in TCR deficient CHO-UV61 cells. These results suggest the presence of an inducible DNA pathway in CHO cells that results from an enhancement of TCR or a mechanism that involves the TCR pathway.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "eda2a1c711434788b5b1baf539f5db9a", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[111, 112]], "char_spans": [[605, 622]]}]}], "context_tokens": [["We", 0], ["have", 3], ["used", 8], ["a", 13], ["non", 15], ["-", 18], ["replicating", 19], ["recombinant", 31], ["adenovirus", 43], [",", 53], ["Ad5MCMVlacZ", 55], [",", 66], ["which", 68], ["expresses", 74], ["the", 84], ["beta", 88], ["-", 92], ["galactosidase", 93], ["reporter", 107], ["gene", 116], [",", 120], ["to", 122], ["examine", 125], ["both", 133], ["constitutive", 138], ["and", 151], ["inducible", 155], ["repair", 165], ["of", 172], ["UV", 175], ["-", 177], ["damaged", 178], ["DNA", 186], ["in", 190], ["repair", 193], ["proficient", 200], ["CHO", 211], ["-", 214], ["AA8", 215], ["Chinese", 219], ["hamster", 227], ["ovary", 235], ["cells", 241], ["and", 247], ["in", 251], ["mutant", 254], ["CHO", 261], ["-", 264], ["UV61", 265], ["cells", 270], ["which", 276], ["are", 282], ["deficient", 286], ["in", 296], ["the", 299], ["transcription", 303], ["-", 316], ["coupled", 317], ["repair", 325], ["(", 332], ["TCR", 333], [")", 336], ["pathway", 338], ["of", 346], ["nucleotide", 349], ["excision", 360], ["repair", 369], [".", 375], ["Host", 377], ["cell", 382], ["reactivation", 387], ["(", 400], ["HCR", 401], [")", 404], ["of", 406], ["beta", 409], ["-", 413], ["galactosidase", 414], ["activity", 428], ["for", 437], ["UV", 441], ["-", 443], ["irradiated", 444], ["Ad5MCMVlacZ", 455], ["was", 467], ["significantly", 471], ["reduced", 485], ["in", 493], ["non", 496], ["-", 499], ["irradiated", 500], ["CHO", 511], ["-", 514], ["UV61", 515], ["cells", 520], ["compared", 526], ["to", 535], ["that", 538], ["in", 543], ["non", 546], ["-", 549], ["irradiated", 550], ["CHO", 561], ["-", 564], ["AA8", 565], ["cells", 569], ["suggesting", 575], ["that", 586], ["repair", 591], ["in", 598], ["the", 601], ["transcribed", 605], ["strand", 617], ["of", 624], ["the", 627], ["UV", 631], ["-", 633], ["damaged", 634], ["reporter", 642], ["gene", 651], ["in", 656], ["untreated", 659], ["cells", 669], ["utilizes", 675], ["TCR", 684], [".", 687], ["Prior", 689], ["UV", 695], ["-", 697], ["irradiation", 698], ["of", 710], ["cells", 713], ["with", 719], ["low", 724], ["UV", 728], ["fluences", 731], ["resulted", 740], ["in", 749], ["a", 752], ["transient", 754], ["enhancement", 764], ["of", 776], ["HCR", 779], ["for", 783], ["expression", 787], ["of", 798], ["the", 801], ["UV", 805], ["-", 807], ["damaged", 808], ["reporter", 816], ["gene", 825], ["in", 830], ["CHO", 833], ["-", 836], ["AA8", 837], ["cells", 841], ["but", 847], ["not", 851], ["in", 855], ["TCR", 858], ["deficient", 862], ["CHO", 872], ["-", 875], ["UV61", 876], ["cells", 881], [".", 886], ["These", 888], ["results", 894], ["suggest", 902], ["the", 910], ["presence", 914], ["of", 923], ["an", 926], ["inducible", 929], ["DNA", 939], ["pathway", 943], ["in", 951], ["CHO", 954], ["cells", 958], ["that", 964], ["results", 969], ["from", 977], ["an", 982], ["enhancement", 985], ["of", 997], ["TCR", 1000], ["or", 1004], ["a", 1007], ["mechanism", 1009], ["that", 1019], ["involves", 1024], ["the", 1033], ["TCR", 1037], ["pathway", 1041], [".", 1048]]}
{"context": "Previous X-ray crystal structures have shown that linkers of five amino acid residues connecting pairs of chicken brain alpha-spectrin and human erythroid beta-spectrin repeats can undergo bending without losing their alpha-helical structure. To test whether bending at one linker can influence bending at an adjacent linker, the structures of two and three repeat fragments of chicken brain alpha-spectrin have been determined by X-ray crystallography. The structure of the three-repeat fragment clearly shows that bending at one linker can occur independently of bending at an adjacent linker. This observation increases the possible trajectories of modeled chains of spectrin repeats. Furthermore, the three-repeat molecule crystallized as an antiparallel dimer with a significantly smaller buried interfacial area than that of alpha-actinin, a spectrin-related molecule, but large enough and of a type indicating biological specificity. Comparison of the structures of the spectrin and alpha-actinin dimers supports weak association of the former, which could not be detected by analytical ultracentrifugation, versus strong association of the latter, which has been observed by others. To correlate features of the structure with solution properties and to test a previous model of stable spectrin and dystrophin repeats, the number of inter-helical interactions in each repeat of several spectrin structures were counted and compared to their thermal stabilities. Inter-helical interactions, but not all interactions, increased in parallel with measured thermal stabilities of each repeat and in agreement with the thermal stabilities of two and three repeats and also partial repeats of spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "159e2ef1d3ca4a3b889fd3fd5ef2acb9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[127, 127]], "char_spans": [[746, 757]]}]}], "context_tokens": [["Previous", 0], ["X", 9], ["-", 10], ["ray", 11], ["crystal", 15], ["structures", 23], ["have", 34], ["shown", 39], ["that", 45], ["linkers", 50], ["of", 58], ["five", 61], ["amino", 66], ["acid", 72], ["residues", 77], ["connecting", 86], ["pairs", 97], ["of", 103], ["chicken", 106], ["brain", 114], ["alpha", 120], ["-", 125], ["spectrin", 126], ["and", 135], ["human", 139], ["erythroid", 145], ["beta", 155], ["-", 159], ["spectrin", 160], ["repeats", 169], ["can", 177], ["undergo", 181], ["bending", 189], ["without", 197], ["losing", 205], ["their", 212], ["alpha", 218], ["-", 223], ["helical", 224], ["structure", 232], [".", 241], ["To", 243], ["test", 246], ["whether", 251], ["bending", 259], ["at", 267], ["one", 270], ["linker", 274], ["can", 281], ["influence", 285], ["bending", 295], ["at", 303], ["an", 306], ["adjacent", 309], ["linker", 318], [",", 324], ["the", 326], ["structures", 330], ["of", 341], ["two", 344], ["and", 348], ["three", 352], ["repeat", 358], ["fragments", 365], ["of", 375], ["chicken", 378], ["brain", 386], ["alpha", 392], ["-", 397], ["spectrin", 398], ["have", 407], ["been", 412], ["determined", 417], ["by", 428], ["X", 431], ["-", 432], ["ray", 433], ["crystallography", 437], [".", 452], ["The", 454], ["structure", 458], ["of", 468], ["the", 471], ["three", 475], ["-", 480], ["repeat", 481], ["fragment", 488], ["clearly", 497], ["shows", 505], ["that", 511], ["bending", 516], ["at", 524], ["one", 527], ["linker", 531], ["can", 538], ["occur", 542], ["independently", 548], ["of", 562], ["bending", 565], ["at", 573], ["an", 576], ["adjacent", 579], ["linker", 588], [".", 594], ["This", 596], ["observation", 601], ["increases", 613], ["the", 623], ["possible", 627], ["trajectories", 636], ["of", 649], ["modeled", 652], ["chains", 660], ["of", 667], ["spectrin", 670], ["repeats", 679], [".", 686], ["Furthermore", 688], [",", 699], ["the", 701], ["three", 705], ["-", 710], ["repeat", 711], ["molecule", 718], ["crystallized", 727], ["as", 740], ["an", 743], ["antiparallel", 746], ["dimer", 759], ["with", 765], ["a", 770], ["significantly", 772], ["smaller", 786], ["buried", 794], ["interfacial", 801], ["area", 813], ["than", 818], ["that", 823], ["of", 828], ["alpha", 831], ["-", 836], ["actinin", 837], [",", 844], ["a", 846], ["spectrin", 848], ["-", 856], ["related", 857], ["molecule", 865], [",", 873], ["but", 875], ["large", 879], ["enough", 885], ["and", 892], ["of", 896], ["a", 899], ["type", 901], ["indicating", 906], ["biological", 917], ["specificity", 928], [".", 939], ["Comparison", 941], ["of", 952], ["the", 955], ["structures", 959], ["of", 970], ["the", 973], ["spectrin", 977], ["and", 986], ["alpha", 990], ["-", 995], ["actinin", 996], ["dimers", 1004], ["supports", 1011], ["weak", 1020], ["association", 1025], ["of", 1037], ["the", 1040], ["former", 1044], [",", 1050], ["which", 1052], ["could", 1058], ["not", 1064], ["be", 1068], ["detected", 1071], ["by", 1080], ["analytical", 1083], ["ultracentrifugation", 1094], [",", 1113], ["versus", 1115], ["strong", 1122], ["association", 1129], ["of", 1141], ["the", 1144], ["latter", 1148], [",", 1154], ["which", 1156], ["has", 1162], ["been", 1166], ["observed", 1171], ["by", 1180], ["others", 1183], [".", 1189], ["To", 1191], ["correlate", 1194], ["features", 1204], ["of", 1213], ["the", 1216], ["structure", 1220], ["with", 1230], ["solution", 1235], ["properties", 1244], ["and", 1255], ["to", 1259], ["test", 1262], ["a", 1267], ["previous", 1269], ["model", 1278], ["of", 1284], ["stable", 1287], ["spectrin", 1294], ["and", 1303], ["dystrophin", 1307], ["repeats", 1318], [",", 1325], ["the", 1327], ["number", 1331], ["of", 1338], ["inter", 1341], ["-", 1346], ["helical", 1347], ["interactions", 1355], ["in", 1368], ["each", 1371], ["repeat", 1376], ["of", 1383], ["several", 1386], ["spectrin", 1394], ["structures", 1403], ["were", 1414], ["counted", 1419], ["and", 1427], ["compared", 1431], ["to", 1440], ["their", 1443], ["thermal", 1449], ["stabilities", 1457], [".", 1468], ["Inter", 1470], ["-", 1475], ["helical", 1476], ["interactions", 1484], [",", 1496], ["but", 1498], ["not", 1502], ["all", 1506], ["interactions", 1510], [",", 1522], ["increased", 1524], ["in", 1534], ["parallel", 1537], ["with", 1546], ["measured", 1551], ["thermal", 1560], ["stabilities", 1568], ["of", 1580], ["each", 1583], ["repeat", 1588], ["and", 1595], ["in", 1599], ["agreement", 1602], ["with", 1612], ["the", 1617], ["thermal", 1621], ["stabilities", 1629], ["of", 1641], ["two", 1644], ["and", 1648], ["three", 1652], ["repeats", 1658], ["and", 1666], ["also", 1670], ["partial", 1675], ["repeats", 1683], ["of", 1691], ["spectrin", 1694], [".", 1702]]}
{"context": "Christianson syndrome is an X-linked mental retardation syndrome characterized by microcephaly, impaired ocular movement, severe global developmental delay, hypotonia which progresses to spasticity, and early onset seizures of variable types. Gilfillan et al.2008] reported mutations in SLC9A6, the gene encoding the sodium/hydrogen exchanger NHE6, in the family first reported and in three others. They also noted the clinical similarities to Angelman syndrome and found cerebellar atrophy on MRI and elevated glutamate/glutamine in the basal ganglia on MRS. Here we report on nonsense mutations in two additional families. The natural history is detailed in childhood and adult life, the similarities to Angelman syndrome confirmed, and the MRI/MRS findings documented in three affected boys.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "75877e12360244ecaad667bb28813b4c", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[44, 44]], "char_spans": [[287, 292]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["is", 22], ["an", 25], ["X", 28], ["-", 29], ["linked", 30], ["mental", 37], ["retardation", 44], ["syndrome", 56], ["characterized", 65], ["by", 79], ["microcephaly", 82], [",", 94], ["impaired", 96], ["ocular", 105], ["movement", 112], [",", 120], ["severe", 122], ["global", 129], ["developmental", 136], ["delay", 150], [",", 155], ["hypotonia", 157], ["which", 167], ["progresses", 173], ["to", 184], ["spasticity", 187], [",", 197], ["and", 199], ["early", 203], ["onset", 209], ["seizures", 215], ["of", 224], ["variable", 227], ["types", 236], [".", 241], ["Gilfillan", 243], ["et", 253], ["al.2008", 256], ["]", 263], ["reported", 265], ["mutations", 274], ["in", 284], ["SLC9A6", 287], [",", 293], ["the", 295], ["gene", 299], ["encoding", 304], ["the", 313], ["sodium", 317], ["/", 323], ["hydrogen", 324], ["exchanger", 333], ["NHE6", 343], [",", 347], ["in", 349], ["the", 352], ["family", 356], ["first", 363], ["reported", 369], ["and", 378], ["in", 382], ["three", 385], ["others", 391], [".", 397], ["They", 399], ["also", 404], ["noted", 409], ["the", 415], ["clinical", 419], ["similarities", 428], ["to", 441], ["Angelman", 444], ["syndrome", 453], ["and", 462], ["found", 466], ["cerebellar", 472], ["atrophy", 483], ["on", 491], ["MRI", 494], ["and", 498], ["elevated", 502], ["glutamate", 511], ["/", 520], ["glutamine", 521], ["in", 531], ["the", 534], ["basal", 538], ["ganglia", 544], ["on", 552], ["MRS", 555], [".", 558], ["Here", 560], ["we", 565], ["report", 568], ["on", 575], ["nonsense", 578], ["mutations", 587], ["in", 597], ["two", 600], ["additional", 604], ["families", 615], [".", 623], ["The", 625], ["natural", 629], ["history", 637], ["is", 645], ["detailed", 648], ["in", 657], ["childhood", 660], ["and", 670], ["adult", 674], ["life", 680], [",", 684], ["the", 686], ["similarities", 690], ["to", 703], ["Angelman", 706], ["syndrome", 715], ["confirmed", 724], [",", 733], ["and", 735], ["the", 739], ["MRI", 743], ["/", 746], ["MRS", 747], ["findings", 751], ["documented", 760], ["in", 771], ["three", 774], ["affected", 780], ["boys", 789], [".", 793]]}
{"context": "Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "daeaeaba2d634317b4b23a5d6051f0e1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[37, 39], [71, 73]], "char_spans": [[238, 244], [418, 424]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["progressive", 40], ["and", 52], ["often", 56], ["fatal", 62], ["hematopoietic", 68], ["neoplasm", 82], ["characterized", 91], ["by", 105], ["the", 108], ["presence", 112], ["of", 121], ["the", 124], ["Philadelphia", 128], ["chromosome", 141], [".", 151], ["This", 153], ["arises", 158], ["from", 165], ["a", 170], ["balanced", 172], ["translocation", 181], ["between", 195], ["chromosomes", 203], ["9", 215], ["and", 217], ["22", 221], [",", 223], ["creating", 225], ["the", 234], ["bcr", 238], ["-", 241], ["abl", 242], ["fusion", 246], ["gene", 253], [".", 257], ["It", 259], ["is", 262], ["often", 265], ["stated", 271], ["that", 278], ["the", 283], ["only", 287], ["proven", 292], ["curative", 299], ["option", 308], ["is", 315], ["allogeneic", 318], ["stem", 329], ["cell", 334], ["transplantation", 339], [",", 354], ["which", 356], ["is", 362], ["indicated", 365], ["for", 375], ["only", 379], ["a", 384], ["limited", 386], ["subset", 394], ["of", 401], ["patients", 404], [".", 412], ["The", 414], ["Bcr", 418], ["-", 421], ["Abl", 422], ["tyrosine", 426], ["kinase", 435], ["inhibitor", 442], ["imatinib", 452], ["represented", 461], ["a", 473], ["major", 475], ["advance", 481], ["over", 489], ["conventional", 494], ["CML", 507], ["therapy", 511], [".", 518], ["After", 520], ["imatinib", 526], ["treatment", 535], [",", 544], [">", 546], ["90", 548], ["%", 550], ["of", 552], ["patients", 555], ["had", 564], ["a", 568], ["complete", 570], ["hematologic", 579], ["response", 591], [",", 599], ["and", 601], ["70%-80", 605], ["%", 611], ["had", 613], ["a", 617], ["complete", 619], ["cytogenetic", 628], ["response", 640], [".", 648], ["With", 650], ["5", 655], ["years", 657], ["of", 663], ["follow", 666], ["-", 672], ["up", 673], [",", 675], ["the", 677], ["data", 681], ["are", 686], ["very", 690], ["encouraging", 695], ["and", 707], ["exhibit", 711], ["a", 719], ["major", 721], ["change", 727], ["in", 734], ["the", 737], ["natural", 741], ["history", 749], ["of", 757], ["the", 760], ["disease", 764], [".", 771], ["The", 773], ["understanding", 777], ["of", 791], ["some", 794], ["of", 799], ["the", 802], ["mechanisms", 806], ["of", 817], ["resistance", 820], ["to", 831], ["imatinib", 834], ["has", 843], ["led", 847], ["to", 851], ["a", 854], ["rapid", 856], ["development", 862], ["of", 874], ["new", 877], ["agents", 881], ["that", 888], ["might", 893], ["overcome", 899], ["this", 908], ["resistance", 913], [".", 923], ["The", 925], ["outlook", 929], ["today", 937], ["for", 943], ["patients", 947], ["with", 956], ["CML", 961], ["is", 965], ["much", 968], ["brighter", 973], ["than", 982], ["that", 987], ["of", 992], ["a", 995], ["few", 997], ["years", 1001], ["ago", 1007], [".", 1010]]}
{"context": "Atg8-family proteins are the best-studied proteins of the core autophagic machinery. They are essential for the elongation and closure of the phagophore into a proper autophagosome. Moreover, Atg8-family proteins are associated with the phagophore from the initiation of the autophagic process to, or just prior to, the fusion between autophagosomes with lysosomes. In addition to their implication in autophagosome biogenesis, they are crucial for selective autophagy through their ability to interact with selective autophagy receptor proteins necessary for the specific targeting of substrates for autophagic degradation. In the past few years it has been revealed that Atg8-interacting proteins include not only receptors but also components of the core autophagic machinery, proteins associated with vesicles and their transport, and specific proteins that are selectively degraded by autophagy. Atg8-interacting proteins contain a short linear LC3-interacting region/LC3 recognition sequence/Atg8-interacting motif (LIR/LRS/AIM) motif which is responsible for their interaction with Atg8-family proteins. These proteins are referred to as LIR-containing proteins (LIRCPs). So far, many experimental efforts have been carried out to identify new LIRCPs, leading to the characterization of some of them in the past 10\u00a0years. Given the need for the identification of LIRCPs in various organisms, we developed the iLIR database ( https://ilir.warwick.ac.uk ) as a freely available web resource, listing all the putative canonical LIRCPs identified in silico in the proteomes of 8 model organisms using the iLIR server, combined with a Gene Ontology (GO) term analysis. Additionally, a curated text-mining analysis of the literature permitted us to identify novel putative LICRPs in mammals that have not previously been associated with autophagy.", "qas": [{"question": "Which web resource for LIR motif-containing proteins in eukaryotes has been developed?", "answers": ["The iLIR database"], "qid": "16c89e69edec4f89b7e12d57432d4b48", "question_tokens": [["Which", 0], ["web", 6], ["resource", 10], ["for", 19], ["LIR", 23], ["motif", 27], ["-", 32], ["containing", 33], ["proteins", 44], ["in", 53], ["eukaryotes", 56], ["has", 67], ["been", 71], ["developed", 76], ["?", 85]], "detected_answers": [{"text": "The iLIR database", "token_spans": [[230, 231]], "char_spans": [[1416, 1428]]}]}], "context_tokens": [["Atg8-family", 0], ["proteins", 12], ["are", 21], ["the", 25], ["best", 29], ["-", 33], ["studied", 34], ["proteins", 42], ["of", 51], ["the", 54], ["core", 58], ["autophagic", 63], ["machinery", 74], [".", 83], ["They", 85], ["are", 90], ["essential", 94], ["for", 104], ["the", 108], ["elongation", 112], ["and", 123], ["closure", 127], ["of", 135], ["the", 138], ["phagophore", 142], ["into", 153], ["a", 158], ["proper", 160], ["autophagosome", 167], [".", 180], ["Moreover", 182], [",", 190], ["Atg8-family", 192], ["proteins", 204], ["are", 213], ["associated", 217], ["with", 228], ["the", 233], ["phagophore", 237], ["from", 248], ["the", 253], ["initiation", 257], ["of", 268], ["the", 271], ["autophagic", 275], ["process", 286], ["to", 294], [",", 296], ["or", 298], ["just", 301], ["prior", 306], ["to", 312], [",", 314], ["the", 316], ["fusion", 320], ["between", 327], ["autophagosomes", 335], ["with", 350], ["lysosomes", 355], [".", 364], ["In", 366], ["addition", 369], ["to", 378], ["their", 381], ["implication", 387], ["in", 399], ["autophagosome", 402], ["biogenesis", 416], [",", 426], ["they", 428], ["are", 433], ["crucial", 437], ["for", 445], ["selective", 449], ["autophagy", 459], ["through", 469], ["their", 477], ["ability", 483], ["to", 491], ["interact", 494], ["with", 503], ["selective", 508], ["autophagy", 518], ["receptor", 528], ["proteins", 537], ["necessary", 546], ["for", 556], ["the", 560], ["specific", 564], ["targeting", 573], ["of", 583], ["substrates", 586], ["for", 597], ["autophagic", 601], ["degradation", 612], [".", 623], ["In", 625], ["the", 628], ["past", 632], ["few", 637], ["years", 641], ["it", 647], ["has", 650], ["been", 654], ["revealed", 659], ["that", 668], ["Atg8-interacting", 673], ["proteins", 690], ["include", 699], ["not", 707], ["only", 711], ["receptors", 716], ["but", 726], ["also", 730], ["components", 735], ["of", 746], ["the", 749], ["core", 753], ["autophagic", 758], ["machinery", 769], [",", 778], ["proteins", 780], ["associated", 789], ["with", 800], ["vesicles", 805], ["and", 814], ["their", 818], ["transport", 824], [",", 833], ["and", 835], ["specific", 839], ["proteins", 848], ["that", 857], ["are", 862], ["selectively", 866], ["degraded", 878], ["by", 887], ["autophagy", 890], [".", 899], ["Atg8-interacting", 901], ["proteins", 918], ["contain", 927], ["a", 935], ["short", 937], ["linear", 943], ["LC3-interacting", 950], ["region", 966], ["/", 972], ["LC3", 973], ["recognition", 977], ["sequence", 989], ["/", 997], ["Atg8-interacting", 998], ["motif", 1015], ["(", 1021], ["LIR", 1022], ["/", 1025], ["LRS", 1026], ["/", 1029], ["AIM", 1030], [")", 1033], ["motif", 1035], ["which", 1041], ["is", 1047], ["responsible", 1050], ["for", 1062], ["their", 1066], ["interaction", 1072], ["with", 1084], ["Atg8-family", 1089], ["proteins", 1101], [".", 1109], ["These", 1111], ["proteins", 1117], ["are", 1126], ["referred", 1130], ["to", 1139], ["as", 1142], ["LIR", 1145], ["-", 1148], ["containing", 1149], ["proteins", 1160], ["(", 1169], ["LIRCPs", 1170], [")", 1176], [".", 1177], ["So", 1179], ["far", 1182], [",", 1185], ["many", 1187], ["experimental", 1192], ["efforts", 1205], ["have", 1213], ["been", 1218], ["carried", 1223], ["out", 1231], ["to", 1235], ["identify", 1238], ["new", 1247], ["LIRCPs", 1251], [",", 1257], ["leading", 1259], ["to", 1267], ["the", 1270], ["characterization", 1274], ["of", 1291], ["some", 1294], ["of", 1299], ["them", 1302], ["in", 1307], ["the", 1310], ["past", 1314], ["10", 1319], ["years", 1322], [".", 1327], ["Given", 1329], ["the", 1335], ["need", 1339], ["for", 1344], ["the", 1348], ["identification", 1352], ["of", 1367], ["LIRCPs", 1370], ["in", 1377], ["various", 1380], ["organisms", 1388], [",", 1397], ["we", 1399], ["developed", 1402], ["the", 1412], ["iLIR", 1416], ["database", 1421], ["(", 1430], ["https://ilir.warwick.ac.uk", 1432], [")", 1459], ["as", 1461], ["a", 1464], ["freely", 1466], ["available", 1473], ["web", 1483], ["resource", 1487], [",", 1495], ["listing", 1497], ["all", 1505], ["the", 1509], ["putative", 1513], ["canonical", 1522], ["LIRCPs", 1532], ["identified", 1539], ["in", 1550], ["silico", 1553], ["in", 1560], ["the", 1563], ["proteomes", 1567], ["of", 1577], ["8", 1580], ["model", 1582], ["organisms", 1588], ["using", 1598], ["the", 1604], ["iLIR", 1608], ["server", 1613], [",", 1619], ["combined", 1621], ["with", 1630], ["a", 1635], ["Gene", 1637], ["Ontology", 1642], ["(", 1651], ["GO", 1652], [")", 1654], ["term", 1656], ["analysis", 1661], [".", 1669], ["Additionally", 1671], [",", 1683], ["a", 1685], ["curated", 1687], ["text", 1695], ["-", 1699], ["mining", 1700], ["analysis", 1707], ["of", 1716], ["the", 1719], ["literature", 1723], ["permitted", 1734], ["us", 1744], ["to", 1747], ["identify", 1750], ["novel", 1759], ["putative", 1765], ["LICRPs", 1774], ["in", 1781], ["mammals", 1784], ["that", 1792], ["have", 1797], ["not", 1802], ["previously", 1806], ["been", 1817], ["associated", 1822], ["with", 1833], ["autophagy", 1838], [".", 1847]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "76dece4105a44e9e9041be62fc48fbed", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[31, 31]], "char_spans": [[193, 196]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "The proliferation and migration of vascular smooth muscle cells (VSMCs) in the intima of an artery, known as intimal hyperplasia, is an important component of cardiovascular diseases. This is seen most clearly in the case of in-stent restenosis, where drug eluting stents are used to deliver agents that prevent VSMC proliferation and migration. One class of agents that are highly effective in the prevention of in-stent restenosis is the mammalian Target of Rapamycin (mTOR) inhibitors. Inhibition of mTOR blocks protein synthesis, cell cycle progression, and cell migration. Key to the effects on cell cycle progression and cell migration is the inhibition of mTOR-mediated degradation of p27Kip1 protein. p27Kip1 is a cyclin dependent kinase inhibitor that is elevated in quiescent VSMCs and inhibits the G1 to S phase transition and cell migration. Under normal conditions, vascular injury promotes degradation of p27Kip1 protein in an mTOR dependent manner. Recent reports from our lab suggest that in the presence of diabetes mellitus, elevation of extracellular signal response kinase activity may promote decreased p27Kip1 mRNA and produce a relative resistance to mTOR inhibition. Here we review these findings and their relevance to designing treatments for cardiovascular disease in the presence of diabetes mellitus.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "4512014da03b487ba5925f69cc357394", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[80, 83]], "char_spans": [[440, 468]]}]}], "context_tokens": [["The", 0], ["proliferation", 4], ["and", 18], ["migration", 22], ["of", 32], ["vascular", 35], ["smooth", 44], ["muscle", 51], ["cells", 58], ["(", 64], ["VSMCs", 65], [")", 70], ["in", 72], ["the", 75], ["intima", 79], ["of", 86], ["an", 89], ["artery", 92], [",", 98], ["known", 100], ["as", 106], ["intimal", 109], ["hyperplasia", 117], [",", 128], ["is", 130], ["an", 133], ["important", 136], ["component", 146], ["of", 156], ["cardiovascular", 159], ["diseases", 174], [".", 182], ["This", 184], ["is", 189], ["seen", 192], ["most", 197], ["clearly", 202], ["in", 210], ["the", 213], ["case", 217], ["of", 222], ["in", 225], ["-", 227], ["stent", 228], ["restenosis", 234], [",", 244], ["where", 246], ["drug", 252], ["eluting", 257], ["stents", 265], ["are", 272], ["used", 276], ["to", 281], ["deliver", 284], ["agents", 292], ["that", 299], ["prevent", 304], ["VSMC", 312], ["proliferation", 317], ["and", 331], ["migration", 335], [".", 344], ["One", 346], ["class", 350], ["of", 356], ["agents", 359], ["that", 366], ["are", 371], ["highly", 375], ["effective", 382], ["in", 392], ["the", 395], ["prevention", 399], ["of", 410], ["in", 413], ["-", 415], ["stent", 416], ["restenosis", 422], ["is", 433], ["the", 436], ["mammalian", 440], ["Target", 450], ["of", 457], ["Rapamycin", 460], ["(", 470], ["mTOR", 471], [")", 475], ["inhibitors", 477], [".", 487], ["Inhibition", 489], ["of", 500], ["mTOR", 503], ["blocks", 508], ["protein", 515], ["synthesis", 523], [",", 532], ["cell", 534], ["cycle", 539], ["progression", 545], [",", 556], ["and", 558], ["cell", 562], ["migration", 567], [".", 576], ["Key", 578], ["to", 582], ["the", 585], ["effects", 589], ["on", 597], ["cell", 600], ["cycle", 605], ["progression", 611], ["and", 623], ["cell", 627], ["migration", 632], ["is", 642], ["the", 645], ["inhibition", 649], ["of", 660], ["mTOR", 663], ["-", 667], ["mediated", 668], ["degradation", 677], ["of", 689], ["p27Kip1", 692], ["protein", 700], [".", 707], ["p27Kip1", 709], ["is", 717], ["a", 720], ["cyclin", 722], ["dependent", 729], ["kinase", 739], ["inhibitor", 746], ["that", 756], ["is", 761], ["elevated", 764], ["in", 773], ["quiescent", 776], ["VSMCs", 786], ["and", 792], ["inhibits", 796], ["the", 805], ["G1", 809], ["to", 812], ["S", 815], ["phase", 817], ["transition", 823], ["and", 834], ["cell", 838], ["migration", 843], [".", 852], ["Under", 854], ["normal", 860], ["conditions", 867], [",", 877], ["vascular", 879], ["injury", 888], ["promotes", 895], ["degradation", 904], ["of", 916], ["p27Kip1", 919], ["protein", 927], ["in", 935], ["an", 938], ["mTOR", 941], ["dependent", 946], ["manner", 956], [".", 962], ["Recent", 964], ["reports", 971], ["from", 979], ["our", 984], ["lab", 988], ["suggest", 992], ["that", 1000], ["in", 1005], ["the", 1008], ["presence", 1012], ["of", 1021], ["diabetes", 1024], ["mellitus", 1033], [",", 1041], ["elevation", 1043], ["of", 1053], ["extracellular", 1056], ["signal", 1070], ["response", 1077], ["kinase", 1086], ["activity", 1093], ["may", 1102], ["promote", 1106], ["decreased", 1114], ["p27Kip1", 1124], ["mRNA", 1132], ["and", 1137], ["produce", 1141], ["a", 1149], ["relative", 1151], ["resistance", 1160], ["to", 1171], ["mTOR", 1174], ["inhibition", 1179], [".", 1189], ["Here", 1191], ["we", 1196], ["review", 1199], ["these", 1206], ["findings", 1212], ["and", 1221], ["their", 1225], ["relevance", 1231], ["to", 1241], ["designing", 1244], ["treatments", 1254], ["for", 1265], ["cardiovascular", 1269], ["disease", 1284], ["in", 1292], ["the", 1295], ["presence", 1299], ["of", 1308], ["diabetes", 1311], ["mellitus", 1320], [".", 1328]]}
{"context": "The manifestation of Lewy bodies (LB) in the brain is a hallmark of Parkinson's disease. Here, we present a comprehensive analysis of protein elements in Lewy bodies by comparative mass spectrometry. Cortical LB inclusions were enriched by sucrose gradient centrifugation from postmortem brains, and a negative control sample was prepared from specimen without LB pathology. Whereas approximately 550 proteins were identified in the LB-enriched sample by mass spectrometry, quantitative comparison with the control sample revealed that approximately 40 proteins were co-enriched with alpha-synuclein, the major component in Lewy bodies. As expected, the list of proteins included previously reported constituents, such as those involved in protein folding, membrane trafficking and oxidative stress. More interestingly, we discovered in the LB-enriched sample several kinases (MAPKK1/MEK1, protein kinase C, and doublecortin-like kinase), a novel deubiquitinating enzyme (otubain 1), and numerous ubiquitin ligases (KPC and SCF). The proteomic studies provide enzyme candidates to investigate the regulation of alpha-synuclein and/or other LB proteins, which may contribute to the formation of Lewy bodies and the toxicity of alpha-synuclein in the related neurodegenerative disorders.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "c30df28116514592a00694925f3d7a42", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[189, 191], [210, 212], [95, 97]], "char_spans": [[1111, 1125], [1226, 1240], [584, 598]]}]}], "context_tokens": [["The", 0], ["manifestation", 4], ["of", 18], ["Lewy", 21], ["bodies", 26], ["(", 33], ["LB", 34], [")", 36], ["in", 38], ["the", 41], ["brain", 45], ["is", 51], ["a", 54], ["hallmark", 56], ["of", 65], ["Parkinson", 68], ["'s", 77], ["disease", 80], [".", 87], ["Here", 89], [",", 93], ["we", 95], ["present", 98], ["a", 106], ["comprehensive", 108], ["analysis", 122], ["of", 131], ["protein", 134], ["elements", 142], ["in", 151], ["Lewy", 154], ["bodies", 159], ["by", 166], ["comparative", 169], ["mass", 181], ["spectrometry", 186], [".", 198], ["Cortical", 200], ["LB", 209], ["inclusions", 212], ["were", 223], ["enriched", 228], ["by", 237], ["sucrose", 240], ["gradient", 248], ["centrifugation", 257], ["from", 272], ["postmortem", 277], ["brains", 288], [",", 294], ["and", 296], ["a", 300], ["negative", 302], ["control", 311], ["sample", 319], ["was", 326], ["prepared", 330], ["from", 339], ["specimen", 344], ["without", 353], ["LB", 361], ["pathology", 364], [".", 373], ["Whereas", 375], ["approximately", 383], ["550", 397], ["proteins", 401], ["were", 410], ["identified", 415], ["in", 426], ["the", 429], ["LB", 433], ["-", 435], ["enriched", 436], ["sample", 445], ["by", 452], ["mass", 455], ["spectrometry", 460], [",", 472], ["quantitative", 474], ["comparison", 487], ["with", 498], ["the", 503], ["control", 507], ["sample", 515], ["revealed", 522], ["that", 531], ["approximately", 536], ["40", 550], ["proteins", 553], ["were", 562], ["co", 567], ["-", 569], ["enriched", 570], ["with", 579], ["alpha", 584], ["-", 589], ["synuclein", 590], [",", 599], ["the", 601], ["major", 605], ["component", 611], ["in", 621], ["Lewy", 624], ["bodies", 629], [".", 635], ["As", 637], ["expected", 640], [",", 648], ["the", 650], ["list", 654], ["of", 659], ["proteins", 662], ["included", 671], ["previously", 680], ["reported", 691], ["constituents", 700], [",", 712], ["such", 714], ["as", 719], ["those", 722], ["involved", 728], ["in", 737], ["protein", 740], ["folding", 748], [",", 755], ["membrane", 757], ["trafficking", 766], ["and", 778], ["oxidative", 782], ["stress", 792], [".", 798], ["More", 800], ["interestingly", 805], [",", 818], ["we", 820], ["discovered", 823], ["in", 834], ["the", 837], ["LB", 841], ["-", 843], ["enriched", 844], ["sample", 853], ["several", 860], ["kinases", 868], ["(", 876], ["MAPKK1/MEK1", 877], [",", 888], ["protein", 890], ["kinase", 898], ["C", 905], [",", 906], ["and", 908], ["doublecortin", 912], ["-", 924], ["like", 925], ["kinase", 930], [")", 936], [",", 937], ["a", 939], ["novel", 941], ["deubiquitinating", 947], ["enzyme", 964], ["(", 971], ["otubain", 972], ["1", 980], [")", 981], [",", 982], ["and", 984], ["numerous", 988], ["ubiquitin", 997], ["ligases", 1007], ["(", 1015], ["KPC", 1016], ["and", 1020], ["SCF", 1024], [")", 1027], [".", 1028], ["The", 1030], ["proteomic", 1034], ["studies", 1044], ["provide", 1052], ["enzyme", 1060], ["candidates", 1067], ["to", 1078], ["investigate", 1081], ["the", 1093], ["regulation", 1097], ["of", 1108], ["alpha", 1111], ["-", 1116], ["synuclein", 1117], ["and/or", 1127], ["other", 1134], ["LB", 1140], ["proteins", 1143], [",", 1151], ["which", 1153], ["may", 1159], ["contribute", 1163], ["to", 1174], ["the", 1177], ["formation", 1181], ["of", 1191], ["Lewy", 1194], ["bodies", 1199], ["and", 1206], ["the", 1210], ["toxicity", 1214], ["of", 1223], ["alpha", 1226], ["-", 1231], ["synuclein", 1232], ["in", 1242], ["the", 1245], ["related", 1249], ["neurodegenerative", 1257], ["disorders", 1275], [".", 1284]]}
{"context": "To determine long-term efficacy and safety of epilepsy surgery in children and adolescents with malformations of cortical development (MCD) and to identify differences in seizure outcome of the various MCD subgroups. Special focus was set on the newly introduced International League Against Epilepsy (ILAE) classification of focal cortical dysplasia (FCD). This is a single center retrospective cross-sectional analysis of prospectively collected data. age at surgery <18 years, pre-surgical evaluation and epilepsy surgery performed at the Vienna pediatric epilepsy center, histologically proven MCD, complete follow-up data for at least 12 months. Clinical variables evaluated: type and localization of MCD, type of surgery and a variety of clinical characteristics reported to be associated with (un-)favorable outcomes. MCD were classified following the existing classification schemes (Barkovich et al., 2012. Brain. 135, 1348-1369; Palmini et al., 2004. Neurology. 62, S2-S8) and the ILAE classification for FCD recently proposed by Bl\u00fcmcke in 2011. Seizure outcome was classified using the ILAE classification proposed by Wieser in 2001. 60 Patients (51.7% male) were included. Follow up was up to 14 (mean 4.4 \u00b1 3.2) years. Mean age at surgery was 8.0 \u00b1 6.0 (median 6.0) years; mean age at epilepsy onset was 2.9 \u00b1 3.2 (median 2.0) years; duration of epilepsy before surgery was 4.8 \u00b1 4.4 (median 3.0) years. 80% of the patients were seizure free at last follow-up. AEDs were successfully withdrawn in 56.7% of all patients. Extended surgery, lesion localization in the temporal lobes and absence of inter-ictal spikes in postsurgical EEG recordings were predictive of favorable seizure outcomes after surgery. However, no association was found between outcome and MCD sub-types. Epilepsy surgery is highly effective in carefully selected drug-resistant children with MCD. Surrogate markers for complete resection of the epileptogenic zone remain the only significant predictors for seizure freedom after surgery.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "1ca976e520c446edbad5c210775e0dc5", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[53, 55]], "char_spans": [[326, 349]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["long", 13], ["-", 17], ["term", 18], ["efficacy", 23], ["and", 32], ["safety", 36], ["of", 43], ["epilepsy", 46], ["surgery", 55], ["in", 63], ["children", 66], ["and", 75], ["adolescents", 79], ["with", 91], ["malformations", 96], ["of", 110], ["cortical", 113], ["development", 122], ["(", 134], ["MCD", 135], [")", 138], ["and", 140], ["to", 144], ["identify", 147], ["differences", 156], ["in", 168], ["seizure", 171], ["outcome", 179], ["of", 187], ["the", 190], ["various", 194], ["MCD", 202], ["subgroups", 206], [".", 215], ["Special", 217], ["focus", 225], ["was", 231], ["set", 235], ["on", 239], ["the", 242], ["newly", 246], ["introduced", 252], ["International", 263], ["League", 277], ["Against", 284], ["Epilepsy", 292], ["(", 301], ["ILAE", 302], [")", 306], ["classification", 308], ["of", 323], ["focal", 326], ["cortical", 332], ["dysplasia", 341], ["(", 351], ["FCD", 352], [")", 355], [".", 356], ["This", 358], ["is", 363], ["a", 366], ["single", 368], ["center", 375], ["retrospective", 382], ["cross", 396], ["-", 401], ["sectional", 402], ["analysis", 412], ["of", 421], ["prospectively", 424], ["collected", 438], ["data", 448], [".", 452], ["age", 454], ["at", 458], ["surgery", 461], ["<", 469], ["18", 470], ["years", 473], [",", 478], ["pre", 480], ["-", 483], ["surgical", 484], ["evaluation", 493], ["and", 504], ["epilepsy", 508], ["surgery", 517], ["performed", 525], ["at", 535], ["the", 538], ["Vienna", 542], ["pediatric", 549], ["epilepsy", 559], ["center", 568], [",", 574], ["histologically", 576], ["proven", 591], ["MCD", 598], [",", 601], ["complete", 603], ["follow", 612], ["-", 618], ["up", 619], ["data", 622], ["for", 627], ["at", 631], ["least", 634], ["12", 640], ["months", 643], [".", 649], ["Clinical", 651], ["variables", 660], ["evaluated", 670], [":", 679], ["type", 681], ["and", 686], ["localization", 690], ["of", 703], ["MCD", 706], [",", 709], ["type", 711], ["of", 716], ["surgery", 719], ["and", 727], ["a", 731], ["variety", 733], ["of", 741], ["clinical", 744], ["characteristics", 753], ["reported", 769], ["to", 778], ["be", 781], ["associated", 784], ["with", 795], ["(", 800], ["un-)favorable", 801], ["outcomes", 815], [".", 823], ["MCD", 825], ["were", 829], ["classified", 834], ["following", 845], ["the", 855], ["existing", 859], ["classification", 868], ["schemes", 883], ["(", 891], ["Barkovich", 892], ["et", 902], ["al", 905], [".", 907], [",", 908], ["2012", 910], [".", 914], ["Brain", 916], [".", 921], ["135", 923], [",", 926], ["1348", 928], ["-", 932], ["1369", 933], [";", 937], ["Palmini", 939], ["et", 947], ["al", 950], [".", 952], [",", 953], ["2004", 955], [".", 959], ["Neurology", 961], [".", 970], ["62", 972], [",", 974], ["S2-S8", 976], [")", 981], ["and", 983], ["the", 987], ["ILAE", 991], ["classification", 996], ["for", 1011], ["FCD", 1015], ["recently", 1019], ["proposed", 1028], ["by", 1037], ["Bl\u00fcmcke", 1040], ["in", 1048], ["2011", 1051], [".", 1055], ["Seizure", 1057], ["outcome", 1065], ["was", 1073], ["classified", 1077], ["using", 1088], ["the", 1094], ["ILAE", 1098], ["classification", 1103], ["proposed", 1118], ["by", 1127], ["Wieser", 1130], ["in", 1137], ["2001", 1140], [".", 1144], ["60", 1146], ["Patients", 1149], ["(", 1158], ["51.7", 1159], ["%", 1163], ["male", 1165], [")", 1169], ["were", 1171], ["included", 1176], [".", 1184], ["Follow", 1186], ["up", 1193], ["was", 1196], ["up", 1200], ["to", 1203], ["14", 1206], ["(", 1209], ["mean", 1210], ["4.4", 1215], ["\u00b1", 1219], ["3.2", 1221], [")", 1224], ["years", 1226], [".", 1231], ["Mean", 1233], ["age", 1238], ["at", 1242], ["surgery", 1245], ["was", 1253], ["8.0", 1257], ["\u00b1", 1261], ["6.0", 1263], ["(", 1267], ["median", 1268], ["6.0", 1275], [")", 1278], ["years", 1280], [";", 1285], ["mean", 1287], ["age", 1292], ["at", 1296], ["epilepsy", 1299], ["onset", 1308], ["was", 1314], ["2.9", 1318], ["\u00b1", 1322], ["3.2", 1324], ["(", 1328], ["median", 1329], ["2.0", 1336], [")", 1339], ["years", 1341], [";", 1346], ["duration", 1348], ["of", 1357], ["epilepsy", 1360], ["before", 1369], ["surgery", 1376], ["was", 1384], ["4.8", 1388], ["\u00b1", 1392], ["4.4", 1394], ["(", 1398], ["median", 1399], ["3.0", 1406], [")", 1409], ["years", 1411], [".", 1416], ["80", 1418], ["%", 1420], ["of", 1422], ["the", 1425], ["patients", 1429], ["were", 1438], ["seizure", 1443], ["free", 1451], ["at", 1456], ["last", 1459], ["follow", 1464], ["-", 1470], ["up", 1471], [".", 1473], ["AEDs", 1475], ["were", 1480], ["successfully", 1485], ["withdrawn", 1498], ["in", 1508], ["56.7", 1511], ["%", 1515], ["of", 1517], ["all", 1520], ["patients", 1524], [".", 1532], ["Extended", 1534], ["surgery", 1543], [",", 1550], ["lesion", 1552], ["localization", 1559], ["in", 1572], ["the", 1575], ["temporal", 1579], ["lobes", 1588], ["and", 1594], ["absence", 1598], ["of", 1606], ["inter", 1609], ["-", 1614], ["ictal", 1615], ["spikes", 1621], ["in", 1628], ["postsurgical", 1631], ["EEG", 1644], ["recordings", 1648], ["were", 1659], ["predictive", 1664], ["of", 1675], ["favorable", 1678], ["seizure", 1688], ["outcomes", 1696], ["after", 1705], ["surgery", 1711], [".", 1718], ["However", 1720], [",", 1727], ["no", 1729], ["association", 1732], ["was", 1744], ["found", 1748], ["between", 1754], ["outcome", 1762], ["and", 1770], ["MCD", 1774], ["sub", 1778], ["-", 1781], ["types", 1782], [".", 1787], ["Epilepsy", 1789], ["surgery", 1798], ["is", 1806], ["highly", 1809], ["effective", 1816], ["in", 1826], ["carefully", 1829], ["selected", 1839], ["drug", 1848], ["-", 1852], ["resistant", 1853], ["children", 1863], ["with", 1872], ["MCD", 1877], [".", 1880], ["Surrogate", 1882], ["markers", 1892], ["for", 1900], ["complete", 1904], ["resection", 1913], ["of", 1923], ["the", 1926], ["epileptogenic", 1930], ["zone", 1944], ["remain", 1949], ["the", 1956], ["only", 1960], ["significant", 1965], ["predictors", 1977], ["for", 1988], ["seizure", 1992], ["freedom", 2000], ["after", 2008], ["surgery", 2014], [".", 2021]]}
{"context": "Lysosomal storage diseases arise from a genetic loss-of-function defect in enzymes mediating key catabolic steps resulting in accumulation of substrate within the lysosome. Treatment of several of these disorders has been achieved by enzyme replacement therapy (ERT), in which a recombinant version of the defective enzyme is expressed in vitro and administered by infusion. However, in many cases the biodistribution of the administered protein does not match that of the accumulated substrate due to the glycosylation-mediated clearance of the enzymes from circulation, resulting in poor or absent substrate clearance from some tissues. To overcome this limitation, we have evaluated several peptide-based targeting motifs to redirect recombinant human alpha-galactosidase (rhalphaGal) to specific receptors. A reversible thiol-based PEGylation chemistry was developed to achieve multivalent peptide display with lysosomal release. In vitro, cell uptake was peptide dependent and independent of the normal mannose-6-phosphate receptor mediated pathway. Surprisingly, despite increased plasma half-life and decreased liver uptake, none of the peptide conjugates showed significantly altered biodistribution in alphaGal-knockout mice. This suggests that these peptide-based targeting motifs are unlikely to provide substantial therapeutic benefit likely due to the complexity of factors affecting PK and biodistribution.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "17805ad0408c48df91cdeb947ccf3371", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[124, 126]], "char_spans": [[755, 773]]}]}], "context_tokens": [["Lysosomal", 0], ["storage", 10], ["diseases", 18], ["arise", 27], ["from", 33], ["a", 38], ["genetic", 40], ["loss", 48], ["-", 52], ["of", 53], ["-", 55], ["function", 56], ["defect", 65], ["in", 72], ["enzymes", 75], ["mediating", 83], ["key", 93], ["catabolic", 97], ["steps", 107], ["resulting", 113], ["in", 123], ["accumulation", 126], ["of", 139], ["substrate", 142], ["within", 152], ["the", 159], ["lysosome", 163], [".", 171], ["Treatment", 173], ["of", 183], ["several", 186], ["of", 194], ["these", 197], ["disorders", 203], ["has", 213], ["been", 217], ["achieved", 222], ["by", 231], ["enzyme", 234], ["replacement", 241], ["therapy", 253], ["(", 261], ["ERT", 262], [")", 265], [",", 266], ["in", 268], ["which", 271], ["a", 277], ["recombinant", 279], ["version", 291], ["of", 299], ["the", 302], ["defective", 306], ["enzyme", 316], ["is", 323], ["expressed", 326], ["in", 336], ["vitro", 339], ["and", 345], ["administered", 349], ["by", 362], ["infusion", 365], [".", 373], ["However", 375], [",", 382], ["in", 384], ["many", 387], ["cases", 392], ["the", 398], ["biodistribution", 402], ["of", 418], ["the", 421], ["administered", 425], ["protein", 438], ["does", 446], ["not", 451], ["match", 455], ["that", 461], ["of", 466], ["the", 469], ["accumulated", 473], ["substrate", 485], ["due", 495], ["to", 499], ["the", 502], ["glycosylation", 506], ["-", 519], ["mediated", 520], ["clearance", 529], ["of", 539], ["the", 542], ["enzymes", 546], ["from", 554], ["circulation", 559], [",", 570], ["resulting", 572], ["in", 582], ["poor", 585], ["or", 590], ["absent", 593], ["substrate", 600], ["clearance", 610], ["from", 620], ["some", 625], ["tissues", 630], [".", 637], ["To", 639], ["overcome", 642], ["this", 651], ["limitation", 656], [",", 666], ["we", 668], ["have", 671], ["evaluated", 676], ["several", 686], ["peptide", 694], ["-", 701], ["based", 702], ["targeting", 708], ["motifs", 718], ["to", 725], ["redirect", 728], ["recombinant", 737], ["human", 749], ["alpha", 755], ["-", 760], ["galactosidase", 761], ["(", 775], ["rhalphaGal", 776], [")", 786], ["to", 788], ["specific", 791], ["receptors", 800], [".", 809], ["A", 811], ["reversible", 813], ["thiol", 824], ["-", 829], ["based", 830], ["PEGylation", 836], ["chemistry", 847], ["was", 857], ["developed", 861], ["to", 871], ["achieve", 874], ["multivalent", 882], ["peptide", 894], ["display", 902], ["with", 910], ["lysosomal", 915], ["release", 925], [".", 932], ["In", 934], ["vitro", 937], [",", 942], ["cell", 944], ["uptake", 949], ["was", 956], ["peptide", 960], ["dependent", 968], ["and", 978], ["independent", 982], ["of", 994], ["the", 997], ["normal", 1001], ["mannose-6-phosphate", 1008], ["receptor", 1028], ["mediated", 1037], ["pathway", 1046], [".", 1053], ["Surprisingly", 1055], [",", 1067], ["despite", 1069], ["increased", 1077], ["plasma", 1087], ["half", 1094], ["-", 1098], ["life", 1099], ["and", 1104], ["decreased", 1108], ["liver", 1118], ["uptake", 1124], [",", 1130], ["none", 1132], ["of", 1137], ["the", 1140], ["peptide", 1144], ["conjugates", 1152], ["showed", 1163], ["significantly", 1170], ["altered", 1184], ["biodistribution", 1192], ["in", 1208], ["alphaGal", 1211], ["-", 1219], ["knockout", 1220], ["mice", 1229], [".", 1233], ["This", 1235], ["suggests", 1240], ["that", 1249], ["these", 1254], ["peptide", 1260], ["-", 1267], ["based", 1268], ["targeting", 1274], ["motifs", 1284], ["are", 1291], ["unlikely", 1295], ["to", 1304], ["provide", 1307], ["substantial", 1315], ["therapeutic", 1327], ["benefit", 1339], ["likely", 1347], ["due", 1354], ["to", 1358], ["the", 1361], ["complexity", 1365], ["of", 1376], ["factors", 1379], ["affecting", 1387], ["PK", 1397], ["and", 1400], ["biodistribution", 1404], [".", 1419]]}
{"context": "The relevance of the Simpson grading system as a predictor of meningioma progression or recurrence in modern neurosurgical practice has recently been called into question. The aim of our study was to compare the risk of progression/recurrence of tumours that had been treated with different Simpson grade resections in a contemporary population of benign (WHO grade I) meningioma patients. One hundred eighty-three patients with histologically confirmed WHO grade I meningioma were retrospectively analysed. All patients underwent first-time craniotomy as their initial therapy between 2004 and 2012. Univariate analysis was performed using log-rank testing and Kaplan-Meier analysis for progression/recurrence-free survival. Multivariate analysis was performed using Cox proportional hazards regression modelling. The three-year progression/recurrence-free survival rates for patients receiving Simpson grade 1, 2 or 4 resections were 95 %, 87 % and 67 %, respectively. Simpson grade 4 resections progressed/recurred at a significantly greater rate than Simpson grade 1 resections (hazard ratio [HR]\u2009=\u20093.26, P\u2009=\u20090.04), whereas Simpson grade 2 resections did not progress/recur at a significantly greater rate than Simpson grade 1 resections (HR\u2009=\u20091.78, P\u2009=\u20090.29). Subtotal resections progressed/recurred at a significantly greater rate than gross-total resections (HR\u2009=\u20092.47, P\u2009=\u20090.03). Tumours that undergo subtotal resection are at a significantly greater risk of progression/recurrence than tumours that undergo gross-total resection. Gross-total resection should therefore be the aim of surgery. However, given modern access to follow-up imaging and stereotactic radiosurgery, these results should not be used to justify overly 'heroic' tumour resection.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "44e178e35d844cdd95994960d939d4dd", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[11, 11], [77, 77], [62, 62]], "char_spans": [[62, 71], [466, 475], [369, 378]]}]}], "context_tokens": [["The", 0], ["relevance", 4], ["of", 14], ["the", 17], ["Simpson", 21], ["grading", 29], ["system", 37], ["as", 44], ["a", 47], ["predictor", 49], ["of", 59], ["meningioma", 62], ["progression", 73], ["or", 85], ["recurrence", 88], ["in", 99], ["modern", 102], ["neurosurgical", 109], ["practice", 123], ["has", 132], ["recently", 136], ["been", 145], ["called", 150], ["into", 157], ["question", 162], [".", 170], ["The", 172], ["aim", 176], ["of", 180], ["our", 183], ["study", 187], ["was", 193], ["to", 197], ["compare", 200], ["the", 208], ["risk", 212], ["of", 217], ["progression", 220], ["/", 231], ["recurrence", 232], ["of", 243], ["tumours", 246], ["that", 254], ["had", 259], ["been", 263], ["treated", 268], ["with", 276], ["different", 281], ["Simpson", 291], ["grade", 299], ["resections", 305], ["in", 316], ["a", 319], ["contemporary", 321], ["population", 334], ["of", 345], ["benign", 348], ["(", 355], ["WHO", 356], ["grade", 360], ["I", 366], [")", 367], ["meningioma", 369], ["patients", 380], [".", 388], ["One", 390], ["hundred", 394], ["eighty", 402], ["-", 408], ["three", 409], ["patients", 415], ["with", 424], ["histologically", 429], ["confirmed", 444], ["WHO", 454], ["grade", 458], ["I", 464], ["meningioma", 466], ["were", 477], ["retrospectively", 482], ["analysed", 498], [".", 506], ["All", 508], ["patients", 512], ["underwent", 521], ["first", 531], ["-", 536], ["time", 537], ["craniotomy", 542], ["as", 553], ["their", 556], ["initial", 562], ["therapy", 570], ["between", 578], ["2004", 586], ["and", 591], ["2012", 595], [".", 599], ["Univariate", 601], ["analysis", 612], ["was", 621], ["performed", 625], ["using", 635], ["log", 641], ["-", 644], ["rank", 645], ["testing", 650], ["and", 658], ["Kaplan", 662], ["-", 668], ["Meier", 669], ["analysis", 675], ["for", 684], ["progression", 688], ["/", 699], ["recurrence", 700], ["-", 710], ["free", 711], ["survival", 716], [".", 724], ["Multivariate", 726], ["analysis", 739], ["was", 748], ["performed", 752], ["using", 762], ["Cox", 768], ["proportional", 772], ["hazards", 785], ["regression", 793], ["modelling", 804], [".", 813], ["The", 815], ["three", 819], ["-", 824], ["year", 825], ["progression", 830], ["/", 841], ["recurrence", 842], ["-", 852], ["free", 853], ["survival", 858], ["rates", 867], ["for", 873], ["patients", 877], ["receiving", 886], ["Simpson", 896], ["grade", 904], ["1", 910], [",", 911], ["2", 913], ["or", 915], ["4", 918], ["resections", 920], ["were", 931], ["95", 936], ["%", 939], [",", 940], ["87", 942], ["%", 945], ["and", 947], ["67", 951], ["%", 954], [",", 955], ["respectively", 957], [".", 969], ["Simpson", 971], ["grade", 979], ["4", 985], ["resections", 987], ["progressed", 998], ["/", 1008], ["recurred", 1009], ["at", 1018], ["a", 1021], ["significantly", 1023], ["greater", 1037], ["rate", 1045], ["than", 1050], ["Simpson", 1055], ["grade", 1063], ["1", 1069], ["resections", 1071], ["(", 1082], ["hazard", 1083], ["ratio", 1090], ["[", 1096], ["HR", 1097], ["]", 1099], ["=", 1101], ["3.26", 1103], [",", 1107], ["P", 1109], ["=", 1111], ["0.04", 1113], [")", 1117], [",", 1118], ["whereas", 1120], ["Simpson", 1128], ["grade", 1136], ["2", 1142], ["resections", 1144], ["did", 1155], ["not", 1159], ["progress", 1163], ["/", 1171], ["recur", 1172], ["at", 1178], ["a", 1181], ["significantly", 1183], ["greater", 1197], ["rate", 1205], ["than", 1210], ["Simpson", 1215], ["grade", 1223], ["1", 1229], ["resections", 1231], ["(", 1242], ["HR", 1243], ["=", 1246], ["1.78", 1248], [",", 1252], ["P", 1254], ["=", 1256], ["0.29", 1258], [")", 1262], [".", 1263], ["Subtotal", 1265], ["resections", 1274], ["progressed", 1285], ["/", 1295], ["recurred", 1296], ["at", 1305], ["a", 1308], ["significantly", 1310], ["greater", 1324], ["rate", 1332], ["than", 1337], ["gross", 1342], ["-", 1347], ["total", 1348], ["resections", 1354], ["(", 1365], ["HR", 1366], ["=", 1369], ["2.47", 1371], [",", 1375], ["P", 1377], ["=", 1379], ["0.03", 1381], [")", 1385], [".", 1386], ["Tumours", 1388], ["that", 1396], ["undergo", 1401], ["subtotal", 1409], ["resection", 1418], ["are", 1428], ["at", 1432], ["a", 1435], ["significantly", 1437], ["greater", 1451], ["risk", 1459], ["of", 1464], ["progression", 1467], ["/", 1478], ["recurrence", 1479], ["than", 1490], ["tumours", 1495], ["that", 1503], ["undergo", 1508], ["gross", 1516], ["-", 1521], ["total", 1522], ["resection", 1528], [".", 1537], ["Gross", 1539], ["-", 1544], ["total", 1545], ["resection", 1551], ["should", 1561], ["therefore", 1568], ["be", 1578], ["the", 1581], ["aim", 1585], ["of", 1589], ["surgery", 1592], [".", 1599], ["However", 1601], [",", 1608], ["given", 1610], ["modern", 1616], ["access", 1623], ["to", 1630], ["follow", 1633], ["-", 1639], ["up", 1640], ["imaging", 1643], ["and", 1651], ["stereotactic", 1655], ["radiosurgery", 1668], [",", 1680], ["these", 1682], ["results", 1688], ["should", 1696], ["not", 1703], ["be", 1707], ["used", 1710], ["to", 1715], ["justify", 1718], ["overly", 1726], ["'", 1733], ["heroic", 1734], ["'", 1740], ["tumour", 1742], ["resection", 1749], [".", 1758]]}
{"context": "TGF-\u03b21 regulates bone metabolism and mediates bone turnover during postmenopause. Sclerostin negatively regulates Wnt signaling pathway and also has an important role in postmenopausal bone loss. Little is known about the relationship between serum TGF-\u03b21 and sclerostin during menopause. We compared serum levels of TGF-\u03b21 and sclerostin in pre- and postmenopausal women and assessed the potential correlations of these levels with each other and with serum levels of bone turnover markers and bone mineral density. A total of 176 women (58 premenopausal, 62 early postmenopausal, and 56 late postmenopausal) were included in this study. Serum TGF-\u03b21 level was significantly higher in early postmenopausal women compared with premenopausal (32.0\u00b17.19 vs. 26.55\u00b16.67 ng/ml, p=0.01) and late postmenopausal (32.0\u00b17.19 vs. 28.65\u00b17.70 pg/ml, p=0.031) women, and no significant differences in serum sclerostin levels were observed among the 3 groups. There was a significant negative correlation between TGF-\u03b21 and sclerostin in early postmenopausal women, but not in other groups of women. Based on multiple regression analysis, only TGF-\u03b21 (\u03b2=-0.362; p=0.007) was an independent predictor of sclerostin during early postmenopause. Our findings suggest that serum TGF-\u03b21 level increases during postmenopause and declines in old age. Sclerostin production is inhibited by TGF-\u03b21 during early postmenopause.", "qas": [{"question": "Sclerostin regulates what process?", "answers": ["bone metabolism"], "qid": "ba738d6a94a647e9b9d8ac77b74a34a3", "question_tokens": [["Sclerostin", 0], ["regulates", 11], ["what", 21], ["process", 26], ["?", 33]], "detected_answers": [{"text": "bone metabolism", "token_spans": [[4, 5]], "char_spans": [[17, 31]]}]}], "context_tokens": [["TGF", 0], ["-", 3], ["\u03b21", 4], ["regulates", 7], ["bone", 17], ["metabolism", 22], ["and", 33], ["mediates", 37], ["bone", 46], ["turnover", 51], ["during", 60], ["postmenopause", 67], [".", 80], ["Sclerostin", 82], ["negatively", 93], ["regulates", 104], ["Wnt", 114], ["signaling", 118], ["pathway", 128], ["and", 136], ["also", 140], ["has", 145], ["an", 149], ["important", 152], ["role", 162], ["in", 167], ["postmenopausal", 170], ["bone", 185], ["loss", 190], [".", 194], ["Little", 196], ["is", 203], ["known", 206], ["about", 212], ["the", 218], ["relationship", 222], ["between", 235], ["serum", 243], ["TGF", 249], ["-", 252], ["\u03b21", 253], ["and", 256], ["sclerostin", 260], ["during", 271], ["menopause", 278], [".", 287], ["We", 289], ["compared", 292], ["serum", 301], ["levels", 307], ["of", 314], ["TGF", 317], ["-", 320], ["\u03b21", 321], ["and", 324], ["sclerostin", 328], ["in", 339], ["pre-", 342], ["and", 347], ["postmenopausal", 351], ["women", 366], ["and", 372], ["assessed", 376], ["the", 385], ["potential", 389], ["correlations", 399], ["of", 412], ["these", 415], ["levels", 421], ["with", 428], ["each", 433], ["other", 438], ["and", 444], ["with", 448], ["serum", 453], ["levels", 459], ["of", 466], ["bone", 469], ["turnover", 474], ["markers", 483], ["and", 491], ["bone", 495], ["mineral", 500], ["density", 508], [".", 515], ["A", 517], ["total", 519], ["of", 525], ["176", 528], ["women", 532], ["(", 538], ["58", 539], ["premenopausal", 542], [",", 555], ["62", 557], ["early", 560], ["postmenopausal", 566], [",", 580], ["and", 582], ["56", 586], ["late", 589], ["postmenopausal", 594], [")", 608], ["were", 610], ["included", 615], ["in", 624], ["this", 627], ["study", 632], [".", 637], ["Serum", 639], ["TGF", 645], ["-", 648], ["\u03b21", 649], ["level", 652], ["was", 658], ["significantly", 662], ["higher", 676], ["in", 683], ["early", 686], ["postmenopausal", 692], ["women", 707], ["compared", 713], ["with", 722], ["premenopausal", 727], ["(", 741], ["32.0\u00b17.19", 742], ["vs.", 752], ["26.55\u00b16.67", 756], ["ng", 767], ["/", 769], ["ml", 770], [",", 772], ["p=0.01", 774], [")", 780], ["and", 782], ["late", 786], ["postmenopausal", 791], ["(", 806], ["32.0\u00b17.19", 807], ["vs.", 817], ["28.65\u00b17.70", 821], ["pg", 832], ["/", 834], ["ml", 835], [",", 837], ["p=0.031", 839], [")", 846], ["women", 848], [",", 853], ["and", 855], ["no", 859], ["significant", 862], ["differences", 874], ["in", 886], ["serum", 889], ["sclerostin", 895], ["levels", 906], ["were", 913], ["observed", 918], ["among", 927], ["the", 933], ["3", 937], ["groups", 939], [".", 945], ["There", 947], ["was", 953], ["a", 957], ["significant", 959], ["negative", 971], ["correlation", 980], ["between", 992], ["TGF", 1000], ["-", 1003], ["\u03b21", 1004], ["and", 1007], ["sclerostin", 1011], ["in", 1022], ["early", 1025], ["postmenopausal", 1031], ["women", 1046], [",", 1051], ["but", 1053], ["not", 1057], ["in", 1061], ["other", 1064], ["groups", 1070], ["of", 1077], ["women", 1080], [".", 1085], ["Based", 1087], ["on", 1093], ["multiple", 1096], ["regression", 1105], ["analysis", 1116], [",", 1124], ["only", 1126], ["TGF", 1131], ["-", 1134], ["\u03b21", 1135], ["(", 1138], ["\u03b2=-0.362", 1139], [";", 1147], ["p=0.007", 1149], [")", 1156], ["was", 1158], ["an", 1162], ["independent", 1165], ["predictor", 1177], ["of", 1187], ["sclerostin", 1190], ["during", 1201], ["early", 1208], ["postmenopause", 1214], [".", 1227], ["Our", 1229], ["findings", 1233], ["suggest", 1242], ["that", 1250], ["serum", 1255], ["TGF", 1261], ["-", 1264], ["\u03b21", 1265], ["level", 1268], ["increases", 1274], ["during", 1284], ["postmenopause", 1291], ["and", 1305], ["declines", 1309], ["in", 1318], ["old", 1321], ["age", 1325], [".", 1328], ["Sclerostin", 1330], ["production", 1341], ["is", 1352], ["inhibited", 1355], ["by", 1365], ["TGF", 1368], ["-", 1371], ["\u03b21", 1372], ["during", 1375], ["early", 1382], ["postmenopause", 1388], [".", 1401]]}
{"context": "More than 500 unrelated patients with neurofibromatosis type 1 (NF1) were screened for mutations in the NF1 gene. For each patient, the whole coding sequence and all splice sites were studied for aberrations, either by the protein truncation test (PTT), temperature-gradient gel electrophoresis (TGGE) of genomic PCR products, or, most often, by direct genomic sequencing (DGS) of all individual exons. A total of 301 sequence variants, including 278 bona fide pathogenic mutations, were identified. As many as 216 or 183 of the genuine mutations, comprising 179 or 161 different ones, can be considered novel when compared to the recent findings of Upadhyaya and Cooper, or to the NNFF mutation database. Mutation-detection efficiencies of the various screening methods were similar: 47.1% for PTT, 53.7% for TGGE, and 54.9% for DGS. Some 224 mutations (80.2%) yielded directly or indirectly premature termination codons. These mutations showed even distribution over the whole gene from exon 1 to exon 47. Of all sequence variants determined in our study, <20% represent C-->T or G-->A transitions within a CpG dinucleotide, and only six different mutations also occur in NF1 pseudogenes, with five being typical C-->T transitions in a CpG. Thus, neither frequent deamination of 5-methylcytosines nor interchromosomal gene conversion may account for the high mutation rate of the NF1 gene. As opposed to the truncating mutations, the 28 (10.1%) missense or single-amino-acid-deletion mutations identified clustered in two distinct regions, the GAP-related domain (GRD) and an upstream gene segment comprising exons 11-17. The latter forms a so-called cysteine/serine-rich domain with three cysteine pairs suggestive of ATP binding, as well as three potential cAMP-dependent protein kinase (PKA) recognition sites obviously phosphorylated by PKA. Coincidence of mutated amino acids and those conserved between human and Drosophila strongly suggest significant functional relevance of this region, with major roles played by exons 12a and 15 and part of exon 16.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "beeb58f583fa4c9192e2fdb72f727d1a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[224, 224], [18, 18], [256, 256], [10, 10]], "char_spans": [[1174, 1176], [104, 106], [1382, 1384], [64, 66]]}]}], "context_tokens": [["More", 0], ["than", 5], ["500", 10], ["unrelated", 14], ["patients", 24], ["with", 33], ["neurofibromatosis", 38], ["type", 56], ["1", 61], ["(", 63], ["NF1", 64], [")", 67], ["were", 69], ["screened", 74], ["for", 83], ["mutations", 87], ["in", 97], ["the", 100], ["NF1", 104], ["gene", 108], [".", 112], ["For", 114], ["each", 118], ["patient", 123], [",", 130], ["the", 132], ["whole", 136], ["coding", 142], ["sequence", 149], ["and", 158], ["all", 162], ["splice", 166], ["sites", 173], ["were", 179], ["studied", 184], ["for", 192], ["aberrations", 196], [",", 207], ["either", 209], ["by", 216], ["the", 219], ["protein", 223], ["truncation", 231], ["test", 242], ["(", 247], ["PTT", 248], [")", 251], [",", 252], ["temperature", 254], ["-", 265], ["gradient", 266], ["gel", 275], ["electrophoresis", 279], ["(", 295], ["TGGE", 296], [")", 300], ["of", 302], ["genomic", 305], ["PCR", 313], ["products", 317], [",", 325], ["or", 327], [",", 329], ["most", 331], ["often", 336], [",", 341], ["by", 343], ["direct", 346], ["genomic", 353], ["sequencing", 361], ["(", 372], ["DGS", 373], [")", 376], ["of", 378], ["all", 381], ["individual", 385], ["exons", 396], [".", 401], ["A", 403], ["total", 405], ["of", 411], ["301", 414], ["sequence", 418], ["variants", 427], [",", 435], ["including", 437], ["278", 447], ["bona", 451], ["fide", 456], ["pathogenic", 461], ["mutations", 472], [",", 481], ["were", 483], ["identified", 488], [".", 498], ["As", 500], ["many", 503], ["as", 508], ["216", 511], ["or", 515], ["183", 518], ["of", 522], ["the", 525], ["genuine", 529], ["mutations", 537], [",", 546], ["comprising", 548], ["179", 559], ["or", 563], ["161", 566], ["different", 570], ["ones", 580], [",", 584], ["can", 586], ["be", 590], ["considered", 593], ["novel", 604], ["when", 610], ["compared", 615], ["to", 624], ["the", 627], ["recent", 631], ["findings", 638], ["of", 647], ["Upadhyaya", 650], ["and", 660], ["Cooper", 664], [",", 670], ["or", 672], ["to", 675], ["the", 678], ["NNFF", 682], ["mutation", 687], ["database", 696], [".", 704], ["Mutation", 706], ["-", 714], ["detection", 715], ["efficiencies", 725], ["of", 738], ["the", 741], ["various", 745], ["screening", 753], ["methods", 763], ["were", 771], ["similar", 776], [":", 783], ["47.1", 785], ["%", 789], ["for", 791], ["PTT", 795], [",", 798], ["53.7", 800], ["%", 804], ["for", 806], ["TGGE", 810], [",", 814], ["and", 816], ["54.9", 820], ["%", 824], ["for", 826], ["DGS", 830], [".", 833], ["Some", 835], ["224", 840], ["mutations", 844], ["(", 854], ["80.2", 855], ["%", 859], [")", 860], ["yielded", 862], ["directly", 870], ["or", 879], ["indirectly", 882], ["premature", 893], ["termination", 903], ["codons", 915], [".", 921], ["These", 923], ["mutations", 929], ["showed", 939], ["even", 946], ["distribution", 951], ["over", 964], ["the", 969], ["whole", 973], ["gene", 979], ["from", 984], ["exon", 989], ["1", 994], ["to", 996], ["exon", 999], ["47", 1004], [".", 1006], ["Of", 1008], ["all", 1011], ["sequence", 1015], ["variants", 1024], ["determined", 1033], ["in", 1044], ["our", 1047], ["study", 1051], [",", 1056], ["<", 1058], ["20", 1059], ["%", 1061], ["represent", 1063], ["C-->T", 1073], ["or", 1079], ["G-->A", 1082], ["transitions", 1088], ["within", 1100], ["a", 1107], ["CpG", 1109], ["dinucleotide", 1113], [",", 1125], ["and", 1127], ["only", 1131], ["six", 1136], ["different", 1140], ["mutations", 1150], ["also", 1160], ["occur", 1165], ["in", 1171], ["NF1", 1174], ["pseudogenes", 1178], [",", 1189], ["with", 1191], ["five", 1196], ["being", 1201], ["typical", 1207], ["C-->T", 1215], ["transitions", 1221], ["in", 1233], ["a", 1236], ["CpG.", 1238], ["Thus", 1243], [",", 1247], ["neither", 1249], ["frequent", 1257], ["deamination", 1266], ["of", 1278], ["5-methylcytosines", 1281], ["nor", 1299], ["interchromosomal", 1303], ["gene", 1320], ["conversion", 1325], ["may", 1336], ["account", 1340], ["for", 1348], ["the", 1352], ["high", 1356], ["mutation", 1361], ["rate", 1370], ["of", 1375], ["the", 1378], ["NF1", 1382], ["gene", 1386], [".", 1390], ["As", 1392], ["opposed", 1395], ["to", 1403], ["the", 1406], ["truncating", 1410], ["mutations", 1421], [",", 1430], ["the", 1432], ["28", 1436], ["(", 1439], ["10.1", 1440], ["%", 1444], [")", 1445], ["missense", 1447], ["or", 1456], ["single", 1459], ["-", 1465], ["amino", 1466], ["-", 1471], ["acid", 1472], ["-", 1476], ["deletion", 1477], ["mutations", 1486], ["identified", 1496], ["clustered", 1507], ["in", 1517], ["two", 1520], ["distinct", 1524], ["regions", 1533], [",", 1540], ["the", 1542], ["GAP", 1546], ["-", 1549], ["related", 1550], ["domain", 1558], ["(", 1565], ["GRD", 1566], [")", 1569], ["and", 1571], ["an", 1575], ["upstream", 1578], ["gene", 1587], ["segment", 1592], ["comprising", 1600], ["exons", 1611], ["11", 1617], ["-", 1619], ["17", 1620], [".", 1622], ["The", 1624], ["latter", 1628], ["forms", 1635], ["a", 1641], ["so", 1643], ["-", 1645], ["called", 1646], ["cysteine", 1653], ["/", 1661], ["serine", 1662], ["-", 1668], ["rich", 1669], ["domain", 1674], ["with", 1681], ["three", 1686], ["cysteine", 1692], ["pairs", 1701], ["suggestive", 1707], ["of", 1718], ["ATP", 1721], ["binding", 1725], [",", 1732], ["as", 1734], ["well", 1737], ["as", 1742], ["three", 1745], ["potential", 1751], ["cAMP", 1761], ["-", 1765], ["dependent", 1766], ["protein", 1776], ["kinase", 1784], ["(", 1791], ["PKA", 1792], [")", 1795], ["recognition", 1797], ["sites", 1809], ["obviously", 1815], ["phosphorylated", 1825], ["by", 1840], ["PKA", 1843], [".", 1846], ["Coincidence", 1848], ["of", 1860], ["mutated", 1863], ["amino", 1871], ["acids", 1877], ["and", 1883], ["those", 1887], ["conserved", 1893], ["between", 1903], ["human", 1911], ["and", 1917], ["Drosophila", 1921], ["strongly", 1932], ["suggest", 1941], ["significant", 1949], ["functional", 1961], ["relevance", 1972], ["of", 1982], ["this", 1985], ["region", 1990], [",", 1996], ["with", 1998], ["major", 2003], ["roles", 2009], ["played", 2015], ["by", 2022], ["exons", 2025], ["12a", 2031], ["and", 2035], ["15", 2039], ["and", 2042], ["part", 2046], ["of", 2051], ["exon", 2054], ["16", 2059], [".", 2061]]}
{"context": "The rarity and the inconsistent criteria for defining atypical meningioma prior to the WHO 2007 classification made its management and prognostic factors poorly understood. Only few articles have addressed the survival rates of WHO-classified atypical meningiomas. The small number or the disproportionate representation of irradiated patients was a weakness for these articles. This study evaluated whether the extent of surgery and receiving adjuvant radiotherapy after an initial operation along with other patient characteristics influenced the recurrence and survival rates of atypical meningiomas. The clinical and surgical notes of the 79 patients with grade II atypical meningioma treated at our center over 13 years were retrospectively evaluated. The histology grading was consistent with WHO 2007 classification. The Simpson grading system was used to assess the extent of surgical resection. Kaplan Meier analysis, Cox multivariate regression analysis, and the Log-rank test were conducted using STATA\u00ae statistical package. The average age at the time of initial operation was 58 years, and 54 % were males. The mean follow-up period was 50 months. In Cox multivariate analysis, only Simpson grading was predictive of recurrence (hazard ratio = 2.22 / 1 increase in Simpson grade. p\u2009=\u20090.003). Simpson grade I patients had a relapse-free survival rate of 97 and 74 % at one and five years, respectively, compared with 88 and 32 % in the subtotal resection group (Simpson grades II to IV). There was no statistically significant correlation between recurrence and subjecting patients to postoperative radiotherapy. Apart from Simpson grade I patients, there was a general trend for worse outcome in irradiated patients. The most important prognostic factor in determining recurrence was Simpson grading. There was no statistically significant impact of adjuvant radiotherapy on the recurrence of atypical meningiomas. Meta-analysis for the existing literature is needed.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "8a4e9bb9b22a4d77b479e8ccadb64015", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[9, 9], [101, 101]], "char_spans": [[63, 72], [678, 687]]}]}], "context_tokens": [["The", 0], ["rarity", 4], ["and", 11], ["the", 15], ["inconsistent", 19], ["criteria", 32], ["for", 41], ["defining", 45], ["atypical", 54], ["meningioma", 63], ["prior", 74], ["to", 80], ["the", 83], ["WHO", 87], ["2007", 91], ["classification", 96], ["made", 111], ["its", 116], ["management", 120], ["and", 131], ["prognostic", 135], ["factors", 146], ["poorly", 154], ["understood", 161], [".", 171], ["Only", 173], ["few", 178], ["articles", 182], ["have", 191], ["addressed", 196], ["the", 206], ["survival", 210], ["rates", 219], ["of", 225], ["WHO", 228], ["-", 231], ["classified", 232], ["atypical", 243], ["meningiomas", 252], [".", 263], ["The", 265], ["small", 269], ["number", 275], ["or", 282], ["the", 285], ["disproportionate", 289], ["representation", 306], ["of", 321], ["irradiated", 324], ["patients", 335], ["was", 344], ["a", 348], ["weakness", 350], ["for", 359], ["these", 363], ["articles", 369], [".", 377], ["This", 379], ["study", 384], ["evaluated", 390], ["whether", 400], ["the", 408], ["extent", 412], ["of", 419], ["surgery", 422], ["and", 430], ["receiving", 434], ["adjuvant", 444], ["radiotherapy", 453], ["after", 466], ["an", 472], ["initial", 475], ["operation", 483], ["along", 493], ["with", 499], ["other", 504], ["patient", 510], ["characteristics", 518], ["influenced", 534], ["the", 545], ["recurrence", 549], ["and", 560], ["survival", 564], ["rates", 573], ["of", 579], ["atypical", 582], ["meningiomas", 591], [".", 602], ["The", 604], ["clinical", 608], ["and", 617], ["surgical", 621], ["notes", 630], ["of", 636], ["the", 639], ["79", 643], ["patients", 646], ["with", 655], ["grade", 660], ["II", 666], ["atypical", 669], ["meningioma", 678], ["treated", 689], ["at", 697], ["our", 700], ["center", 704], ["over", 711], ["13", 716], ["years", 719], ["were", 725], ["retrospectively", 730], ["evaluated", 746], [".", 755], ["The", 757], ["histology", 761], ["grading", 771], ["was", 779], ["consistent", 783], ["with", 794], ["WHO", 799], ["2007", 803], ["classification", 808], [".", 822], ["The", 824], ["Simpson", 828], ["grading", 836], ["system", 844], ["was", 851], ["used", 855], ["to", 860], ["assess", 863], ["the", 870], ["extent", 874], ["of", 881], ["surgical", 884], ["resection", 893], [".", 902], ["Kaplan", 904], ["Meier", 911], ["analysis", 917], [",", 925], ["Cox", 927], ["multivariate", 931], ["regression", 944], ["analysis", 955], [",", 963], ["and", 965], ["the", 969], ["Log", 973], ["-", 976], ["rank", 977], ["test", 982], ["were", 987], ["conducted", 992], ["using", 1002], ["STATA", 1008], ["\u00ae", 1013], ["statistical", 1015], ["package", 1027], [".", 1034], ["The", 1036], ["average", 1040], ["age", 1048], ["at", 1052], ["the", 1055], ["time", 1059], ["of", 1064], ["initial", 1067], ["operation", 1075], ["was", 1085], ["58", 1089], ["years", 1092], [",", 1097], ["and", 1099], ["54", 1103], ["%", 1106], ["were", 1108], ["males", 1113], [".", 1118], ["The", 1120], ["mean", 1124], ["follow", 1129], ["-", 1135], ["up", 1136], ["period", 1139], ["was", 1146], ["50", 1150], ["months", 1153], [".", 1159], ["In", 1161], ["Cox", 1164], ["multivariate", 1168], ["analysis", 1181], [",", 1189], ["only", 1191], ["Simpson", 1196], ["grading", 1204], ["was", 1212], ["predictive", 1216], ["of", 1227], ["recurrence", 1230], ["(", 1241], ["hazard", 1242], ["ratio", 1249], ["=", 1255], ["2.22", 1257], ["/", 1262], ["1", 1264], ["increase", 1266], ["in", 1275], ["Simpson", 1278], ["grade", 1286], [".", 1291], ["p", 1293], ["=", 1295], ["0.003", 1297], [")", 1302], [".", 1303], ["Simpson", 1305], ["grade", 1313], ["I", 1319], ["patients", 1321], ["had", 1330], ["a", 1334], ["relapse", 1336], ["-", 1343], ["free", 1344], ["survival", 1349], ["rate", 1358], ["of", 1363], ["97", 1366], ["and", 1369], ["74", 1373], ["%", 1376], ["at", 1378], ["one", 1381], ["and", 1385], ["five", 1389], ["years", 1394], [",", 1399], ["respectively", 1401], [",", 1413], ["compared", 1415], ["with", 1424], ["88", 1429], ["and", 1432], ["32", 1436], ["%", 1439], ["in", 1441], ["the", 1444], ["subtotal", 1448], ["resection", 1457], ["group", 1467], ["(", 1473], ["Simpson", 1474], ["grades", 1482], ["II", 1489], ["to", 1492], ["IV", 1495], [")", 1497], [".", 1498], ["There", 1500], ["was", 1506], ["no", 1510], ["statistically", 1513], ["significant", 1527], ["correlation", 1539], ["between", 1551], ["recurrence", 1559], ["and", 1570], ["subjecting", 1574], ["patients", 1585], ["to", 1594], ["postoperative", 1597], ["radiotherapy", 1611], [".", 1623], ["Apart", 1625], ["from", 1631], ["Simpson", 1636], ["grade", 1644], ["I", 1650], ["patients", 1652], [",", 1660], ["there", 1662], ["was", 1668], ["a", 1672], ["general", 1674], ["trend", 1682], ["for", 1688], ["worse", 1692], ["outcome", 1698], ["in", 1706], ["irradiated", 1709], ["patients", 1720], [".", 1728], ["The", 1730], ["most", 1734], ["important", 1739], ["prognostic", 1749], ["factor", 1760], ["in", 1767], ["determining", 1770], ["recurrence", 1782], ["was", 1793], ["Simpson", 1797], ["grading", 1805], [".", 1812], ["There", 1814], ["was", 1820], ["no", 1824], ["statistically", 1827], ["significant", 1841], ["impact", 1853], ["of", 1860], ["adjuvant", 1863], ["radiotherapy", 1872], ["on", 1885], ["the", 1888], ["recurrence", 1892], ["of", 1903], ["atypical", 1906], ["meningiomas", 1915], [".", 1926], ["Meta", 1928], ["-", 1932], ["analysis", 1933], ["for", 1942], ["the", 1946], ["existing", 1950], ["literature", 1959], ["is", 1970], ["needed", 1973], [".", 1979]]}
{"context": "Disruption of FOXP2, a gene encoding a forkhead-domain transcription factor, causes a severe developmental disorder of verbal communication, involving profound articulation deficits, accompanied by linguistic and grammatical impairments. Investigation of the neural basis of this disorder has been limited previously to neuroimaging of affected children and adults. The discovery of the gene responsible, FOXP2, offers a unique opportunity to explore the relevant neural mechanisms from a molecular perspective. In the present study, we have determined the detailed spatial and temporal expression pattern of FOXP2 mRNA in the developing brain of mouse and human. We find expression in several structures including the cortical plate, basal ganglia, thalamus, inferior olives and cerebellum. These data support a role for FOXP2 in the development of corticostriatal and olivocerebellar circuits involved in motor control. We find intriguing concordance between regions of early expression and later sites of pathology suggested by neuroimaging. Moreover, the homologous pattern of FOXP2/Foxp2 expression in human and mouse argues for a role for this gene in development of motor-related circuits throughout mammalian species. Overall, this study provides support for the hypothesis that impairments in sequencing of movement and procedural learning might be central to the FOXP2-related speech and language disorder.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "2c0e0f4aa55c4021a72dbdfb12a37f40", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[95, 95], [133, 133], [62, 62], [2, 2]], "char_spans": [[609, 613], [822, 826], [405, 409], [14, 18]]}]}], "context_tokens": [["Disruption", 0], ["of", 11], ["FOXP2", 14], [",", 19], ["a", 21], ["gene", 23], ["encoding", 28], ["a", 37], ["forkhead", 39], ["-", 47], ["domain", 48], ["transcription", 55], ["factor", 69], [",", 75], ["causes", 77], ["a", 84], ["severe", 86], ["developmental", 93], ["disorder", 107], ["of", 116], ["verbal", 119], ["communication", 126], [",", 139], ["involving", 141], ["profound", 151], ["articulation", 160], ["deficits", 173], [",", 181], ["accompanied", 183], ["by", 195], ["linguistic", 198], ["and", 209], ["grammatical", 213], ["impairments", 225], [".", 236], ["Investigation", 238], ["of", 252], ["the", 255], ["neural", 259], ["basis", 266], ["of", 272], ["this", 275], ["disorder", 280], ["has", 289], ["been", 293], ["limited", 298], ["previously", 306], ["to", 317], ["neuroimaging", 320], ["of", 333], ["affected", 336], ["children", 345], ["and", 354], ["adults", 358], [".", 364], ["The", 366], ["discovery", 370], ["of", 380], ["the", 383], ["gene", 387], ["responsible", 392], [",", 403], ["FOXP2", 405], [",", 410], ["offers", 412], ["a", 419], ["unique", 421], ["opportunity", 428], ["to", 440], ["explore", 443], ["the", 451], ["relevant", 455], ["neural", 464], ["mechanisms", 471], ["from", 482], ["a", 487], ["molecular", 489], ["perspective", 499], [".", 510], ["In", 512], ["the", 515], ["present", 519], ["study", 527], [",", 532], ["we", 534], ["have", 537], ["determined", 542], ["the", 553], ["detailed", 557], ["spatial", 566], ["and", 574], ["temporal", 578], ["expression", 587], ["pattern", 598], ["of", 606], ["FOXP2", 609], ["mRNA", 615], ["in", 620], ["the", 623], ["developing", 627], ["brain", 638], ["of", 644], ["mouse", 647], ["and", 653], ["human", 657], [".", 662], ["We", 664], ["find", 667], ["expression", 672], ["in", 683], ["several", 686], ["structures", 694], ["including", 705], ["the", 715], ["cortical", 719], ["plate", 728], [",", 733], ["basal", 735], ["ganglia", 741], [",", 748], ["thalamus", 750], [",", 758], ["inferior", 760], ["olives", 769], ["and", 776], ["cerebellum", 780], [".", 790], ["These", 792], ["data", 798], ["support", 803], ["a", 811], ["role", 813], ["for", 818], ["FOXP2", 822], ["in", 828], ["the", 831], ["development", 835], ["of", 847], ["corticostriatal", 850], ["and", 866], ["olivocerebellar", 870], ["circuits", 886], ["involved", 895], ["in", 904], ["motor", 907], ["control", 913], [".", 920], ["We", 922], ["find", 925], ["intriguing", 930], ["concordance", 941], ["between", 953], ["regions", 961], ["of", 969], ["early", 972], ["expression", 978], ["and", 989], ["later", 993], ["sites", 999], ["of", 1005], ["pathology", 1008], ["suggested", 1018], ["by", 1028], ["neuroimaging", 1031], [".", 1043], ["Moreover", 1045], [",", 1053], ["the", 1055], ["homologous", 1059], ["pattern", 1070], ["of", 1078], ["FOXP2/Foxp2", 1081], ["expression", 1093], ["in", 1104], ["human", 1107], ["and", 1113], ["mouse", 1117], ["argues", 1123], ["for", 1130], ["a", 1134], ["role", 1136], ["for", 1141], ["this", 1145], ["gene", 1150], ["in", 1155], ["development", 1158], ["of", 1170], ["motor", 1173], ["-", 1178], ["related", 1179], ["circuits", 1187], ["throughout", 1196], ["mammalian", 1207], ["species", 1217], [".", 1224], ["Overall", 1226], [",", 1233], ["this", 1235], ["study", 1240], ["provides", 1246], ["support", 1255], ["for", 1263], ["the", 1267], ["hypothesis", 1271], ["that", 1282], ["impairments", 1287], ["in", 1299], ["sequencing", 1302], ["of", 1313], ["movement", 1316], ["and", 1325], ["procedural", 1329], ["learning", 1340], ["might", 1349], ["be", 1355], ["central", 1358], ["to", 1366], ["the", 1369], ["FOXP2-related", 1373], ["speech", 1387], ["and", 1394], ["language", 1398], ["disorder", 1407], [".", 1415]]}
{"context": "Mowat-Wilson syndrome is a recently delineated autosomal dominant developmental anomaly, whereby heterozygous mutations in the ZFHX1B gene cause mental retardation, delayed motor development, epilepsy and a wide spectrum of clinically heterogeneous features, suggestive of neurocristopathies at the cephalic, cardiac and vagal levels. However, our understanding of the etiology of this condition at the cellular level remains vague. This study presents the Zfhx1b protein expression domain in mouse embryos and correlates this with a novel mouse model involving a conditional mutation in the Zfhx1b gene in neural crest precursor cells. These mutant mice display craniofacial and gastrointestinal malformations that show resemblance to those found in human patients with Mowat-Wilson syndrome. In addition to these clinically recognized alterations, we document developmental defects in the heart, melanoblasts and sympathetic and parasympathetic anlagen. The latter observations in our mouse model for Mowat-Wilson suggest a hitherto unknown role for Zfhx1b in the development of these particular neural crest derivatives, which is a set of observations that should be acknowledged in the clinical management of this genetic disorder.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "9095328339f447188880bc5412e035d4", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[163, 163], [92, 92], [71, 71], [18, 18]], "char_spans": [[1052, 1057], [592, 597], [457, 462], [127, 132]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["recently", 27], ["delineated", 36], ["autosomal", 47], ["dominant", 57], ["developmental", 66], ["anomaly", 80], [",", 87], ["whereby", 89], ["heterozygous", 97], ["mutations", 110], ["in", 120], ["the", 123], ["ZFHX1B", 127], ["gene", 134], ["cause", 139], ["mental", 145], ["retardation", 152], [",", 163], ["delayed", 165], ["motor", 173], ["development", 179], [",", 190], ["epilepsy", 192], ["and", 201], ["a", 205], ["wide", 207], ["spectrum", 212], ["of", 221], ["clinically", 224], ["heterogeneous", 235], ["features", 249], [",", 257], ["suggestive", 259], ["of", 270], ["neurocristopathies", 273], ["at", 292], ["the", 295], ["cephalic", 299], [",", 307], ["cardiac", 309], ["and", 317], ["vagal", 321], ["levels", 327], [".", 333], ["However", 335], [",", 342], ["our", 344], ["understanding", 348], ["of", 362], ["the", 365], ["etiology", 369], ["of", 378], ["this", 381], ["condition", 386], ["at", 396], ["the", 399], ["cellular", 403], ["level", 412], ["remains", 418], ["vague", 426], [".", 431], ["This", 433], ["study", 438], ["presents", 444], ["the", 453], ["Zfhx1b", 457], ["protein", 464], ["expression", 472], ["domain", 483], ["in", 490], ["mouse", 493], ["embryos", 499], ["and", 507], ["correlates", 511], ["this", 522], ["with", 527], ["a", 532], ["novel", 534], ["mouse", 540], ["model", 546], ["involving", 552], ["a", 562], ["conditional", 564], ["mutation", 576], ["in", 585], ["the", 588], ["Zfhx1b", 592], ["gene", 599], ["in", 604], ["neural", 607], ["crest", 614], ["precursor", 620], ["cells", 630], [".", 635], ["These", 637], ["mutant", 643], ["mice", 650], ["display", 655], ["craniofacial", 663], ["and", 676], ["gastrointestinal", 680], ["malformations", 697], ["that", 711], ["show", 716], ["resemblance", 721], ["to", 733], ["those", 736], ["found", 742], ["in", 748], ["human", 751], ["patients", 757], ["with", 766], ["Mowat", 771], ["-", 776], ["Wilson", 777], ["syndrome", 784], [".", 792], ["In", 794], ["addition", 797], ["to", 806], ["these", 809], ["clinically", 815], ["recognized", 826], ["alterations", 837], [",", 848], ["we", 850], ["document", 853], ["developmental", 862], ["defects", 876], ["in", 884], ["the", 887], ["heart", 891], [",", 896], ["melanoblasts", 898], ["and", 911], ["sympathetic", 915], ["and", 927], ["parasympathetic", 931], ["anlagen", 947], [".", 954], ["The", 956], ["latter", 960], ["observations", 967], ["in", 980], ["our", 983], ["mouse", 987], ["model", 993], ["for", 999], ["Mowat", 1003], ["-", 1008], ["Wilson", 1009], ["suggest", 1016], ["a", 1024], ["hitherto", 1026], ["unknown", 1035], ["role", 1043], ["for", 1048], ["Zfhx1b", 1052], ["in", 1059], ["the", 1062], ["development", 1066], ["of", 1078], ["these", 1081], ["particular", 1087], ["neural", 1098], ["crest", 1105], ["derivatives", 1111], [",", 1122], ["which", 1124], ["is", 1130], ["a", 1133], ["set", 1135], ["of", 1139], ["observations", 1142], ["that", 1155], ["should", 1160], ["be", 1167], ["acknowledged", 1170], ["in", 1183], ["the", 1186], ["clinical", 1190], ["management", 1199], ["of", 1210], ["this", 1213], ["genetic", 1218], ["disorder", 1226], [".", 1234]]}
{"context": "Tuberculosis is responsible for more then 2 million deaths worldwide each year and vies with HIV as the world's most fatal infectious disease. In many developing countries, attempts to control the spread of infection rely solely on identification and treatment of those with active disease, ignoring subclinical infection. However, in developed countries, large efforts are also expended to identify and give prophylactic drugs to people with latent tuberculosis infection. Until recently, the 100-year-old tuberculin skin test (Mantoux) has been the only available diagnostic test for latent tuberculosis infection, despite its many well-known limitations. Advances in scientific knowledge have led to the development of tests for tuberculosis that measure the production of interferon-gamma by T-cells stimulated in vitro with Mycobacterium tuberculosis-specific antigens. These interferon-gamma tests are highly specific and unaffected by prior Bacille Calmette-Gu\u00e9rin vaccination or immune reactivity to most atypical mycobacteria. They are more sensitive than the tuberculin skin test in detecting people with active tuberculosis, and their results correlate more closely with M. tuberculosis exposure risk factors than the tuberculin skin test in people likely to have latent tuberculosis infection. Science has caught up with one of the oldest diagnostic tests still in use worldwide, and the adoption of new, tuberculosis-specific interferon-gamma-based tests should move us one step closer to better control of this insidious pathogen.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "fc2548420f034a03b63b99f76249f358", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[0, 0], [99, 99], [122, 122], [74, 74], [234, 234], [140, 140], [184, 184], [194, 194], [209, 209]], "char_spans": [[0, 11], [593, 604], [732, 743], [450, 461], [1417, 1428], [843, 854], [1122, 1133], [1185, 1196], [1282, 1293]]}]}], "context_tokens": [["Tuberculosis", 0], ["is", 13], ["responsible", 16], ["for", 28], ["more", 32], ["then", 37], ["2", 42], ["million", 44], ["deaths", 52], ["worldwide", 59], ["each", 69], ["year", 74], ["and", 79], ["vies", 83], ["with", 88], ["HIV", 93], ["as", 97], ["the", 100], ["world", 104], ["'s", 109], ["most", 112], ["fatal", 117], ["infectious", 123], ["disease", 134], [".", 141], ["In", 143], ["many", 146], ["developing", 151], ["countries", 162], [",", 171], ["attempts", 173], ["to", 182], ["control", 185], ["the", 193], ["spread", 197], ["of", 204], ["infection", 207], ["rely", 217], ["solely", 222], ["on", 229], ["identification", 232], ["and", 247], ["treatment", 251], ["of", 261], ["those", 264], ["with", 270], ["active", 275], ["disease", 282], [",", 289], ["ignoring", 291], ["subclinical", 300], ["infection", 312], [".", 321], ["However", 323], [",", 330], ["in", 332], ["developed", 335], ["countries", 345], [",", 354], ["large", 356], ["efforts", 362], ["are", 370], ["also", 374], ["expended", 379], ["to", 388], ["identify", 391], ["and", 400], ["give", 404], ["prophylactic", 409], ["drugs", 422], ["to", 428], ["people", 431], ["with", 438], ["latent", 443], ["tuberculosis", 450], ["infection", 463], [".", 472], ["Until", 474], ["recently", 480], [",", 488], ["the", 490], ["100-year", 494], ["-", 502], ["old", 503], ["tuberculin", 507], ["skin", 518], ["test", 523], ["(", 528], ["Mantoux", 529], [")", 536], ["has", 538], ["been", 542], ["the", 547], ["only", 551], ["available", 556], ["diagnostic", 566], ["test", 577], ["for", 582], ["latent", 586], ["tuberculosis", 593], ["infection", 606], [",", 615], ["despite", 617], ["its", 625], ["many", 629], ["well", 634], ["-", 638], ["known", 639], ["limitations", 645], [".", 656], ["Advances", 658], ["in", 667], ["scientific", 670], ["knowledge", 681], ["have", 691], ["led", 696], ["to", 700], ["the", 703], ["development", 707], ["of", 719], ["tests", 722], ["for", 728], ["tuberculosis", 732], ["that", 745], ["measure", 750], ["the", 758], ["production", 762], ["of", 773], ["interferon", 776], ["-", 786], ["gamma", 787], ["by", 793], ["T", 796], ["-", 797], ["cells", 798], ["stimulated", 804], ["in", 815], ["vitro", 818], ["with", 824], ["Mycobacterium", 829], ["tuberculosis", 843], ["-", 855], ["specific", 856], ["antigens", 865], [".", 873], ["These", 875], ["interferon", 881], ["-", 891], ["gamma", 892], ["tests", 898], ["are", 904], ["highly", 908], ["specific", 915], ["and", 924], ["unaffected", 928], ["by", 939], ["prior", 942], ["Bacille", 948], ["Calmette", 956], ["-", 964], ["Gu\u00e9rin", 965], ["vaccination", 972], ["or", 984], ["immune", 987], ["reactivity", 994], ["to", 1005], ["most", 1008], ["atypical", 1013], ["mycobacteria", 1022], [".", 1034], ["They", 1036], ["are", 1041], ["more", 1045], ["sensitive", 1050], ["than", 1060], ["the", 1065], ["tuberculin", 1069], ["skin", 1080], ["test", 1085], ["in", 1090], ["detecting", 1093], ["people", 1103], ["with", 1110], ["active", 1115], ["tuberculosis", 1122], [",", 1134], ["and", 1136], ["their", 1140], ["results", 1146], ["correlate", 1154], ["more", 1164], ["closely", 1169], ["with", 1177], ["M.", 1182], ["tuberculosis", 1185], ["exposure", 1198], ["risk", 1207], ["factors", 1212], ["than", 1220], ["the", 1225], ["tuberculin", 1229], ["skin", 1240], ["test", 1245], ["in", 1250], ["people", 1253], ["likely", 1260], ["to", 1267], ["have", 1270], ["latent", 1275], ["tuberculosis", 1282], ["infection", 1295], [".", 1304], ["Science", 1306], ["has", 1314], ["caught", 1318], ["up", 1325], ["with", 1328], ["one", 1333], ["of", 1337], ["the", 1340], ["oldest", 1344], ["diagnostic", 1351], ["tests", 1362], ["still", 1368], ["in", 1374], ["use", 1377], ["worldwide", 1381], [",", 1390], ["and", 1392], ["the", 1396], ["adoption", 1400], ["of", 1409], ["new", 1412], [",", 1415], ["tuberculosis", 1417], ["-", 1429], ["specific", 1430], ["interferon", 1439], ["-", 1449], ["gamma", 1450], ["-", 1455], ["based", 1456], ["tests", 1462], ["should", 1468], ["move", 1475], ["us", 1480], ["one", 1483], ["step", 1487], ["closer", 1492], ["to", 1499], ["better", 1502], ["control", 1509], ["of", 1517], ["this", 1520], ["insidious", 1525], ["pathogen", 1535], [".", 1543]]}
{"context": "Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs. In 2008, the next-generation NNRTI etravirine was approved for the treatment of HIV-infected antiretroviral therapy-experienced individuals, including those with prior NNRTI exposure. NNRTIs are also increasingly being included in strategies to prevent HIV-1 infection. For example: (1) nevirapine is used to prevent mother-to-child transmission; (2) the ASPIRE (MTN 020) study will test whether a vaginal ring containing dapivirine can prevent HIV-1 infection in women; (3) a microbicide gel formulation containing the urea-PETT derivative MIV-150 is in a phase I study to evaluate safety, pharmacokinetics, pharmacodynamics and acceptability; and (4) a long acting rilpivirine formulation is under-development for pre-exposure prophylaxis. Given their widespread use, particularly in resource-limited settings, as well as their low genetic barriers to resistance, there are concerns about overlapping resistance between the different NNRTIs. Consequently, a better understanding of the resistance and cross-resistance profiles among the NNRTI class is important for predicting response to treatment, and surveillance of transmitted drug-resistance.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "f8585ae680a84b258cfa4b315d1378ba", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[48, 48]], "char_spans": [[309, 311]]}]}], "context_tokens": [["Nonnucleoside", 0], ["reverse", 14], ["transcriptase", 22], ["inhibitors", 36], ["(", 47], ["NNRTIs", 48], [")", 54], ["are", 56], ["widely", 60], ["used", 67], ["to", 72], ["treat", 75], ["HIV-1-infected", 81], ["individuals", 96], [";", 107], ["indeed", 109], ["most", 116], ["first", 121], ["-", 126], ["line", 127], ["antiretroviral", 132], ["therapies", 147], ["typically", 157], ["include", 167], ["one", 175], ["NNRTI", 179], ["in", 185], ["combination", 188], ["with", 200], ["two", 205], ["nucleoside", 209], ["analogs", 220], [".", 227], ["In", 229], ["2008", 232], [",", 236], ["the", 238], ["next", 242], ["-", 246], ["generation", 247], ["NNRTI", 258], ["etravirine", 264], ["was", 275], ["approved", 279], ["for", 288], ["the", 292], ["treatment", 296], ["of", 306], ["HIV", 309], ["-", 312], ["infected", 313], ["antiretroviral", 322], ["therapy", 337], ["-", 344], ["experienced", 345], ["individuals", 357], [",", 368], ["including", 370], ["those", 380], ["with", 386], ["prior", 391], ["NNRTI", 397], ["exposure", 403], [".", 411], ["NNRTIs", 413], ["are", 420], ["also", 424], ["increasingly", 429], ["being", 442], ["included", 448], ["in", 457], ["strategies", 460], ["to", 471], ["prevent", 474], ["HIV-1", 482], ["infection", 488], [".", 497], ["For", 499], ["example", 503], [":", 510], ["(", 512], ["1", 513], [")", 514], ["nevirapine", 516], ["is", 527], ["used", 530], ["to", 535], ["prevent", 538], ["mother", 546], ["-", 552], ["to", 553], ["-", 555], ["child", 556], ["transmission", 562], [";", 574], ["(", 576], ["2", 577], [")", 578], ["the", 580], ["ASPIRE", 584], ["(", 591], ["MTN", 592], ["020", 596], [")", 599], ["study", 601], ["will", 607], ["test", 612], ["whether", 617], ["a", 625], ["vaginal", 627], ["ring", 635], ["containing", 640], ["dapivirine", 651], ["can", 662], ["prevent", 666], ["HIV-1", 674], ["infection", 680], ["in", 690], ["women", 693], [";", 698], ["(", 700], ["3", 701], [")", 702], ["a", 704], ["microbicide", 706], ["gel", 718], ["formulation", 722], ["containing", 734], ["the", 745], ["urea", 749], ["-", 753], ["PETT", 754], ["derivative", 759], ["MIV-150", 770], ["is", 778], ["in", 781], ["a", 784], ["phase", 786], ["I", 792], ["study", 794], ["to", 800], ["evaluate", 803], ["safety", 812], [",", 818], ["pharmacokinetics", 820], [",", 836], ["pharmacodynamics", 838], ["and", 855], ["acceptability", 859], [";", 872], ["and", 874], ["(", 878], ["4", 879], [")", 880], ["a", 882], ["long", 884], ["acting", 889], ["rilpivirine", 896], ["formulation", 908], ["is", 920], ["under", 923], ["-", 928], ["development", 929], ["for", 941], ["pre", 945], ["-", 948], ["exposure", 949], ["prophylaxis", 958], [".", 969], ["Given", 971], ["their", 977], ["widespread", 983], ["use", 994], [",", 997], ["particularly", 999], ["in", 1012], ["resource", 1015], ["-", 1023], ["limited", 1024], ["settings", 1032], [",", 1040], ["as", 1042], ["well", 1045], ["as", 1050], ["their", 1053], ["low", 1059], ["genetic", 1063], ["barriers", 1071], ["to", 1080], ["resistance", 1083], [",", 1093], ["there", 1095], ["are", 1101], ["concerns", 1105], ["about", 1114], ["overlapping", 1120], ["resistance", 1132], ["between", 1143], ["the", 1151], ["different", 1155], ["NNRTIs", 1165], [".", 1171], ["Consequently", 1173], [",", 1185], ["a", 1187], ["better", 1189], ["understanding", 1196], ["of", 1210], ["the", 1213], ["resistance", 1217], ["and", 1228], ["cross", 1232], ["-", 1237], ["resistance", 1238], ["profiles", 1249], ["among", 1258], ["the", 1264], ["NNRTI", 1268], ["class", 1274], ["is", 1280], ["important", 1283], ["for", 1293], ["predicting", 1297], ["response", 1308], ["to", 1317], ["treatment", 1320], [",", 1329], ["and", 1331], ["surveillance", 1335], ["of", 1348], ["transmitted", 1351], ["drug", 1363], ["-", 1367], ["resistance", 1368], [".", 1378]]}
{"context": "Secretory phospholipase A2 (sPLA2), which links surfactant catabolism and lung inflammation, is associated with lung stiffness, surfactant dysfunction, and degree of respiratory support in acute respiratory distress syndrome and in some forms of neonatal lung injury. Varespladib potently inhibits sPLA2 in animal models. The authors investigate varespladib ex vivo efficacy in different forms of neonatal lung injury. Bronchoalveolar lavage fluid was obtained from 40 neonates affected by hyaline membrane disease, infections, or meconium aspiration and divided in 4 aliquots added with increasing varespladib or saline. sPLA2 activity, proteins, and albumin were measured. Dilution was corrected with the urea ratio. Varespladib was also tested in vitro against pancreatic sPLA2 mixed with different albumin concentration. Varespladib was able to inhibit sPLA2 in the types of neonatal lung injury investigated. sPLA2 activity was reduced in hyaline membrane disease (P < .0001), infections (P = .003), and meconium aspiration (P = .04) using 40 \u00b5M varespladib; 10 \u00b5M was able to lower enzyme activity (P = .001), with an IC(50) of 87 \u00b5M. An inverse relationship existed between protein level and activity reduction (r = 0.5; P = .029). The activity reduction/protein ratio tended to be higher in hyaline membrane disease. Varespladib efficacy was higher in vitro than in lavage fluids obtained from neonates (P < .001).", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "1aedf35d15b449439a4efb13c4c5ebd0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[0, 2]], "char_spans": [[0, 25]]}]}], "context_tokens": [["Secretory", 0], ["phospholipase", 10], ["A2", 24], ["(", 27], ["sPLA2", 28], [")", 33], [",", 34], ["which", 36], ["links", 42], ["surfactant", 48], ["catabolism", 59], ["and", 70], ["lung", 74], ["inflammation", 79], [",", 91], ["is", 93], ["associated", 96], ["with", 107], ["lung", 112], ["stiffness", 117], [",", 126], ["surfactant", 128], ["dysfunction", 139], [",", 150], ["and", 152], ["degree", 156], ["of", 163], ["respiratory", 166], ["support", 178], ["in", 186], ["acute", 189], ["respiratory", 195], ["distress", 207], ["syndrome", 216], ["and", 225], ["in", 229], ["some", 232], ["forms", 237], ["of", 243], ["neonatal", 246], ["lung", 255], ["injury", 260], [".", 266], ["Varespladib", 268], ["potently", 280], ["inhibits", 289], ["sPLA2", 298], ["in", 304], ["animal", 307], ["models", 314], [".", 320], ["The", 322], ["authors", 326], ["investigate", 334], ["varespladib", 346], ["ex", 358], ["vivo", 361], ["efficacy", 366], ["in", 375], ["different", 378], ["forms", 388], ["of", 394], ["neonatal", 397], ["lung", 406], ["injury", 411], [".", 417], ["Bronchoalveolar", 419], ["lavage", 435], ["fluid", 442], ["was", 448], ["obtained", 452], ["from", 461], ["40", 466], ["neonates", 469], ["affected", 478], ["by", 487], ["hyaline", 490], ["membrane", 498], ["disease", 507], [",", 514], ["infections", 516], [",", 526], ["or", 528], ["meconium", 531], ["aspiration", 540], ["and", 551], ["divided", 555], ["in", 563], ["4", 566], ["aliquots", 568], ["added", 577], ["with", 583], ["increasing", 588], ["varespladib", 599], ["or", 611], ["saline", 614], [".", 620], ["sPLA2", 622], ["activity", 628], [",", 636], ["proteins", 638], [",", 646], ["and", 648], ["albumin", 652], ["were", 660], ["measured", 665], [".", 673], ["Dilution", 675], ["was", 684], ["corrected", 688], ["with", 698], ["the", 703], ["urea", 707], ["ratio", 712], [".", 717], ["Varespladib", 719], ["was", 731], ["also", 735], ["tested", 740], ["in", 747], ["vitro", 750], ["against", 756], ["pancreatic", 764], ["sPLA2", 775], ["mixed", 781], ["with", 787], ["different", 792], ["albumin", 802], ["concentration", 810], [".", 823], ["Varespladib", 825], ["was", 837], ["able", 841], ["to", 846], ["inhibit", 849], ["sPLA2", 857], ["in", 863], ["the", 866], ["types", 870], ["of", 876], ["neonatal", 879], ["lung", 888], ["injury", 893], ["investigated", 900], [".", 912], ["sPLA2", 914], ["activity", 920], ["was", 929], ["reduced", 933], ["in", 941], ["hyaline", 944], ["membrane", 952], ["disease", 961], ["(", 969], ["P", 970], ["<", 972], [".0001", 974], [")", 979], [",", 980], ["infections", 982], ["(", 993], ["P", 994], ["=", 996], [".003", 998], [")", 1002], [",", 1003], ["and", 1005], ["meconium", 1009], ["aspiration", 1018], ["(", 1029], ["P", 1030], ["=", 1032], [".04", 1034], [")", 1037], ["using", 1039], ["40", 1045], ["\u00b5M", 1048], ["varespladib", 1051], [";", 1062], ["10", 1064], ["\u00b5M", 1067], ["was", 1070], ["able", 1074], ["to", 1079], ["lower", 1082], ["enzyme", 1088], ["activity", 1095], ["(", 1104], ["P", 1105], ["=", 1107], [".001", 1109], [")", 1113], [",", 1114], ["with", 1116], ["an", 1121], ["IC(50", 1124], [")", 1129], ["of", 1131], ["87", 1134], ["\u00b5M.", 1137], ["An", 1141], ["inverse", 1144], ["relationship", 1152], ["existed", 1165], ["between", 1173], ["protein", 1181], ["level", 1189], ["and", 1195], ["activity", 1199], ["reduction", 1208], ["(", 1218], ["r", 1219], ["=", 1221], ["0.5", 1223], [";", 1226], ["P", 1228], ["=", 1230], [".029", 1232], [")", 1236], [".", 1237], ["The", 1239], ["activity", 1243], ["reduction", 1252], ["/", 1261], ["protein", 1262], ["ratio", 1270], ["tended", 1276], ["to", 1283], ["be", 1286], ["higher", 1289], ["in", 1296], ["hyaline", 1299], ["membrane", 1307], ["disease", 1316], [".", 1323], ["Varespladib", 1325], ["efficacy", 1337], ["was", 1346], ["higher", 1350], ["in", 1357], ["vitro", 1360], ["than", 1366], ["in", 1371], ["lavage", 1374], ["fluids", 1381], ["obtained", 1388], ["from", 1397], ["neonates", 1402], ["(", 1411], ["P", 1412], ["<", 1414], [".001", 1416], [")", 1420], [".", 1421]]}
{"context": "Identifying and tackling the social determinants of infectious diseases has become a public health priority following the recognition that individuals with lower socioeconomic status are disproportionately affected by infectious diseases. In many parts of the world, epidemiologically and genotypically defined community-associated (CA) methicillin-resistant Staphylococcus aureus (MRSA) strains have emerged to become frequent causes of hospital infection. The aim of this study was to use spatial models with adjustment for area-level hospital attendance to determine the transmission niche of genotypically defined CA- and health-care-associated (HA)-MRSA strains across a diverse region of South East London and to explore a potential link between MRSA carriage and markers of social and material deprivation. This study involved spatial analysis of cross-sectional data linked with all MRSA isolates identified by three National Health Service (NHS) microbiology laboratories between 1 November 2011 and 29 February 2012. The cohort of hospital-based NHS microbiology diagnostic services serves 867,254 usual residents in the Lambeth, Southwark, and Lewisham boroughs in South East London, United Kingdom (UK). Isolates were classified as HA- or CA-MRSA based on whole genome sequencing. All MRSA cases identified over 4 mo within the three-borough catchment area (n = 471) were mapped to small geographies and linked to area-level aggregated socioeconomic and demographic data. Disease mapping and ecological regression models were used to infer the most likely transmission niches for each MRSA genetic classification and to describe the spatial epidemiology of MRSA in relation to social determinants. Specifically, we aimed to identify demographic and socioeconomic population traits that explain cross-area extra variation in HA- and CA-MRSA relative risks following adjustment for hospital attendance data. We explored the potential for associations with the English Indices of Deprivation 2010 (including the Index of Multiple Deprivation and several deprivation domains and subdomains) and the 2011 England and Wales census demographic and socioeconomic indicators (including numbers of households by deprivation dimension) and indicators of population health. Both CA-and HA-MRSA were associated with household deprivation (CA-MRSA relative risk [RR]: 1.72 [1.03-2.94]; HA-MRSA RR: 1.57 [1.06-2.33]), which was correlated with hospital attendance (Pearson correlation coefficient [PCC] = 0.76). HA-MRSA was also associated with poor health (RR: 1.10 [1.01-1.19]) and residence in communal care homes (RR: 1.24 [1.12-1.37]), whereas CA-MRSA was linked with household overcrowding (RR: 1.58 [1.04-2.41]) and wider barriers, which represent a combined score for household overcrowding, low income, and homelessness (RR: 1.76 [1.16-2.70]). CA-MRSA was also associated with recent immigration to the UK (RR: 1.77 [1.19-2.66]). For the area-level variation in RR for CA-MRSA, 28.67% was attributable to the spatial arrangement of target geographies, compared with only 0.09% for HA-MRSA. An advantage to our study is that it provided a representative sample of usual residents receiving care in the catchment areas. A limitation is that relationships apparent in aggregated data analyses cannot be assumed to operate at the individual level. There was no evidence of community transmission of HA-MRSA strains, implying that HA-MRSA cases identified in the community originate from the hospital reservoir and are maintained by frequent attendance at health care facilities. In contrast, there was a high risk of CA-MRSA in deprived areas linked with overcrowding, homelessness, low income, and recent immigration to the UK, which was not explainable by health care exposure. Furthermore, areas adjacent to these deprived areas were themselves at greater risk of CA-MRSA, indicating community transmission of CA-MRSA. This ongoing community transmission could lead to CA-MRSA becoming the dominant strain types carried by patients admitted to hospital, particularly if successful hospital-based MRSA infection control programmes are maintained. These results suggest that community infection control programmes targeting transmission of CA-MRSA will be required to control MRSA in both the community and hospital. These epidemiological changes will also have implications for effectiveness of risk-factor-based hospital admission MRSA screening programmes.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c8be4f51b2ab4a5381c642b0ef7213c6", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[213, 213], [141, 141], [205, 205], [275, 275], [429, 429], [629, 629], [715, 715], [622, 622], [707, 707], [765, 765], [771, 771], [383, 383], [513, 513], [399, 399], [305, 305], [118, 118], [54, 54], [374, 374], [662, 662], [726, 726], [796, 796], [265, 265], [567, 567], [745, 745], [466, 466], [545, 545]], "char_spans": [[1297, 1300], [891, 894], [1254, 1257], [1669, 1672], [2512, 2515], [3435, 3438], [3918, 3921], [3404, 3407], [3872, 3875], [4246, 4249], [4279, 4282], [2341, 2344], [2853, 2856], [2387, 2390], [1847, 1850], [752, 755], [382, 385], [2289, 2292], [3622, 3625], [3977, 3980], [4436, 4439], [1597, 1600], [3090, 3093], [4101, 4104], [2649, 2652], [2978, 2981]]}]}], "context_tokens": [["Identifying", 0], ["and", 12], ["tackling", 16], ["the", 25], ["social", 29], ["determinants", 36], ["of", 49], ["infectious", 52], ["diseases", 63], ["has", 72], ["become", 76], ["a", 83], ["public", 85], ["health", 92], ["priority", 99], ["following", 108], ["the", 118], ["recognition", 122], ["that", 134], ["individuals", 139], ["with", 151], ["lower", 156], ["socioeconomic", 162], ["status", 176], ["are", 183], ["disproportionately", 187], ["affected", 206], ["by", 215], ["infectious", 218], ["diseases", 229], [".", 237], ["In", 239], ["many", 242], ["parts", 247], ["of", 253], ["the", 256], ["world", 260], [",", 265], ["epidemiologically", 267], ["and", 285], ["genotypically", 289], ["defined", 303], ["community", 311], ["-", 320], ["associated", 321], ["(", 332], ["CA", 333], [")", 335], ["methicillin", 337], ["-", 348], ["resistant", 349], ["Staphylococcus", 359], ["aureus", 374], ["(", 381], ["MRSA", 382], [")", 386], ["strains", 388], ["have", 396], ["emerged", 401], ["to", 409], ["become", 412], ["frequent", 419], ["causes", 428], ["of", 435], ["hospital", 438], ["infection", 447], [".", 456], ["The", 458], ["aim", 462], ["of", 466], ["this", 469], ["study", 474], ["was", 480], ["to", 484], ["use", 487], ["spatial", 491], ["models", 499], ["with", 506], ["adjustment", 511], ["for", 522], ["area", 526], ["-", 530], ["level", 531], ["hospital", 537], ["attendance", 546], ["to", 557], ["determine", 560], ["the", 570], ["transmission", 574], ["niche", 587], ["of", 593], ["genotypically", 596], ["defined", 610], ["CA-", 618], ["and", 622], ["health", 626], ["-", 632], ["care", 633], ["-", 637], ["associated", 638], ["(", 649], ["HA)-MRSA", 650], ["strains", 659], ["across", 667], ["a", 674], ["diverse", 676], ["region", 684], ["of", 691], ["South", 694], ["East", 700], ["London", 705], ["and", 712], ["to", 716], ["explore", 719], ["a", 727], ["potential", 729], ["link", 739], ["between", 744], ["MRSA", 752], ["carriage", 757], ["and", 766], ["markers", 770], ["of", 778], ["social", 781], ["and", 788], ["material", 792], ["deprivation", 801], [".", 812], ["This", 814], ["study", 819], ["involved", 825], ["spatial", 834], ["analysis", 842], ["of", 851], ["cross", 854], ["-", 859], ["sectional", 860], ["data", 870], ["linked", 875], ["with", 882], ["all", 887], ["MRSA", 891], ["isolates", 896], ["identified", 905], ["by", 916], ["three", 919], ["National", 925], ["Health", 934], ["Service", 941], ["(", 949], ["NHS", 950], [")", 953], ["microbiology", 955], ["laboratories", 968], ["between", 981], ["1", 989], ["November", 991], ["2011", 1000], ["and", 1005], ["29", 1009], ["February", 1012], ["2012", 1021], [".", 1025], ["The", 1027], ["cohort", 1031], ["of", 1038], ["hospital", 1041], ["-", 1049], ["based", 1050], ["NHS", 1056], ["microbiology", 1060], ["diagnostic", 1073], ["services", 1084], ["serves", 1093], ["867,254", 1100], ["usual", 1108], ["residents", 1114], ["in", 1124], ["the", 1127], ["Lambeth", 1131], [",", 1138], ["Southwark", 1140], [",", 1149], ["and", 1151], ["Lewisham", 1155], ["boroughs", 1164], ["in", 1173], ["South", 1176], ["East", 1182], ["London", 1187], [",", 1193], ["United", 1195], ["Kingdom", 1202], ["(", 1210], ["UK", 1211], [")", 1213], [".", 1214], ["Isolates", 1216], ["were", 1225], ["classified", 1230], ["as", 1241], ["HA-", 1244], ["or", 1248], ["CA", 1251], ["-", 1253], ["MRSA", 1254], ["based", 1259], ["on", 1265], ["whole", 1268], ["genome", 1274], ["sequencing", 1281], [".", 1291], ["All", 1293], ["MRSA", 1297], ["cases", 1302], ["identified", 1308], ["over", 1319], ["4", 1324], ["mo", 1326], ["within", 1329], ["the", 1336], ["three", 1340], ["-", 1345], ["borough", 1346], ["catchment", 1354], ["area", 1364], ["(", 1369], ["n", 1370], ["=", 1372], ["471", 1374], [")", 1377], ["were", 1379], ["mapped", 1384], ["to", 1391], ["small", 1394], ["geographies", 1400], ["and", 1412], ["linked", 1416], ["to", 1423], ["area", 1426], ["-", 1430], ["level", 1431], ["aggregated", 1437], ["socioeconomic", 1448], ["and", 1462], ["demographic", 1466], ["data", 1478], [".", 1482], ["Disease", 1484], ["mapping", 1492], ["and", 1500], ["ecological", 1504], ["regression", 1515], ["models", 1526], ["were", 1533], ["used", 1538], ["to", 1543], ["infer", 1546], ["the", 1552], ["most", 1556], ["likely", 1561], ["transmission", 1568], ["niches", 1581], ["for", 1588], ["each", 1592], ["MRSA", 1597], ["genetic", 1602], ["classification", 1610], ["and", 1625], ["to", 1629], ["describe", 1632], ["the", 1641], ["spatial", 1645], ["epidemiology", 1653], ["of", 1666], ["MRSA", 1669], ["in", 1674], ["relation", 1677], ["to", 1686], ["social", 1689], ["determinants", 1696], [".", 1708], ["Specifically", 1710], [",", 1722], ["we", 1724], ["aimed", 1727], ["to", 1733], ["identify", 1736], ["demographic", 1745], ["and", 1757], ["socioeconomic", 1761], ["population", 1775], ["traits", 1786], ["that", 1793], ["explain", 1798], ["cross", 1806], ["-", 1811], ["area", 1812], ["extra", 1817], ["variation", 1823], ["in", 1833], ["HA-", 1836], ["and", 1840], ["CA", 1844], ["-", 1846], ["MRSA", 1847], ["relative", 1852], ["risks", 1861], ["following", 1867], ["adjustment", 1877], ["for", 1888], ["hospital", 1892], ["attendance", 1901], ["data", 1912], [".", 1916], ["We", 1918], ["explored", 1921], ["the", 1930], ["potential", 1934], ["for", 1944], ["associations", 1948], ["with", 1961], ["the", 1966], ["English", 1970], ["Indices", 1978], ["of", 1986], ["Deprivation", 1989], ["2010", 2001], ["(", 2006], ["including", 2007], ["the", 2017], ["Index", 2021], ["of", 2027], ["Multiple", 2030], ["Deprivation", 2039], ["and", 2051], ["several", 2055], ["deprivation", 2063], ["domains", 2075], ["and", 2083], ["subdomains", 2087], [")", 2097], ["and", 2099], ["the", 2103], ["2011", 2107], ["England", 2112], ["and", 2120], ["Wales", 2124], ["census", 2130], ["demographic", 2137], ["and", 2149], ["socioeconomic", 2153], ["indicators", 2167], ["(", 2178], ["including", 2179], ["numbers", 2189], ["of", 2197], ["households", 2200], ["by", 2211], ["deprivation", 2214], ["dimension", 2226], [")", 2235], ["and", 2237], ["indicators", 2241], ["of", 2252], ["population", 2255], ["health", 2266], [".", 2272], ["Both", 2274], ["CA", 2279], ["-", 2281], ["and", 2282], ["HA", 2286], ["-", 2288], ["MRSA", 2289], ["were", 2294], ["associated", 2299], ["with", 2310], ["household", 2315], ["deprivation", 2325], ["(", 2337], ["CA", 2338], ["-", 2340], ["MRSA", 2341], ["relative", 2346], ["risk", 2355], ["[", 2360], ["RR", 2361], ["]", 2363], [":", 2364], ["1.72", 2366], ["[", 2371], ["1.03", 2372], ["-", 2376], ["2.94", 2377], ["]", 2381], [";", 2382], ["HA", 2384], ["-", 2386], ["MRSA", 2387], ["RR", 2392], [":", 2394], ["1.57", 2396], ["[", 2401], ["1.06", 2402], ["-", 2406], ["2.33", 2407], ["]", 2411], [")", 2412], [",", 2413], ["which", 2415], ["was", 2421], ["correlated", 2425], ["with", 2436], ["hospital", 2441], ["attendance", 2450], ["(", 2461], ["Pearson", 2462], ["correlation", 2470], ["coefficient", 2482], ["[", 2494], ["PCC", 2495], ["]", 2498], ["=", 2500], ["0.76", 2502], [")", 2506], [".", 2507], ["HA", 2509], ["-", 2511], ["MRSA", 2512], ["was", 2517], ["also", 2521], ["associated", 2526], ["with", 2537], ["poor", 2542], ["health", 2547], ["(", 2554], ["RR", 2555], [":", 2557], ["1.10", 2559], ["[", 2564], ["1.01", 2565], ["-", 2569], ["1.19", 2570], ["]", 2574], [")", 2575], ["and", 2577], ["residence", 2581], ["in", 2591], ["communal", 2594], ["care", 2603], ["homes", 2608], ["(", 2614], ["RR", 2615], [":", 2617], ["1.24", 2619], ["[", 2624], ["1.12", 2625], ["-", 2629], ["1.37", 2630], ["]", 2634], [")", 2635], [",", 2636], ["whereas", 2638], ["CA", 2646], ["-", 2648], ["MRSA", 2649], ["was", 2654], ["linked", 2658], ["with", 2665], ["household", 2670], ["overcrowding", 2680], ["(", 2693], ["RR", 2694], [":", 2696], ["1.58", 2698], ["[", 2703], ["1.04", 2704], ["-", 2708], ["2.41", 2709], ["]", 2713], [")", 2714], ["and", 2716], ["wider", 2720], ["barriers", 2726], [",", 2734], ["which", 2736], ["represent", 2742], ["a", 2752], ["combined", 2754], ["score", 2763], ["for", 2769], ["household", 2773], ["overcrowding", 2783], [",", 2795], ["low", 2797], ["income", 2801], [",", 2807], ["and", 2809], ["homelessness", 2813], ["(", 2826], ["RR", 2827], [":", 2829], ["1.76", 2831], ["[", 2836], ["1.16", 2837], ["-", 2841], ["2.70", 2842], ["]", 2846], [")", 2847], [".", 2848], ["CA", 2850], ["-", 2852], ["MRSA", 2853], ["was", 2858], ["also", 2862], ["associated", 2867], ["with", 2878], ["recent", 2883], ["immigration", 2890], ["to", 2902], ["the", 2905], ["UK", 2909], ["(", 2912], ["RR", 2913], [":", 2915], ["1.77", 2917], ["[", 2922], ["1.19", 2923], ["-", 2927], ["2.66", 2928], ["]", 2932], [")", 2933], [".", 2934], ["For", 2936], ["the", 2940], ["area", 2944], ["-", 2948], ["level", 2949], ["variation", 2955], ["in", 2965], ["RR", 2968], ["for", 2971], ["CA", 2975], ["-", 2977], ["MRSA", 2978], [",", 2982], ["28.67", 2984], ["%", 2989], ["was", 2991], ["attributable", 2995], ["to", 3008], ["the", 3011], ["spatial", 3015], ["arrangement", 3023], ["of", 3035], ["target", 3038], ["geographies", 3045], [",", 3056], ["compared", 3058], ["with", 3067], ["only", 3072], ["0.09", 3077], ["%", 3081], ["for", 3083], ["HA", 3087], ["-", 3089], ["MRSA", 3090], [".", 3094], ["An", 3096], ["advantage", 3099], ["to", 3109], ["our", 3112], ["study", 3116], ["is", 3122], ["that", 3125], ["it", 3130], ["provided", 3133], ["a", 3142], ["representative", 3144], ["sample", 3159], ["of", 3166], ["usual", 3169], ["residents", 3175], ["receiving", 3185], ["care", 3195], ["in", 3200], ["the", 3203], ["catchment", 3207], ["areas", 3217], [".", 3222], ["A", 3224], ["limitation", 3226], ["is", 3237], ["that", 3240], ["relationships", 3245], ["apparent", 3259], ["in", 3268], ["aggregated", 3271], ["data", 3282], ["analyses", 3287], ["can", 3296], ["not", 3299], ["be", 3303], ["assumed", 3306], ["to", 3314], ["operate", 3317], ["at", 3325], ["the", 3328], ["individual", 3332], ["level", 3343], [".", 3348], ["There", 3350], ["was", 3356], ["no", 3360], ["evidence", 3363], ["of", 3372], ["community", 3375], ["transmission", 3385], ["of", 3398], ["HA", 3401], ["-", 3403], ["MRSA", 3404], ["strains", 3409], [",", 3416], ["implying", 3418], ["that", 3427], ["HA", 3432], ["-", 3434], ["MRSA", 3435], ["cases", 3440], ["identified", 3446], ["in", 3457], ["the", 3460], ["community", 3464], ["originate", 3474], ["from", 3484], ["the", 3489], ["hospital", 3493], ["reservoir", 3502], ["and", 3512], ["are", 3516], ["maintained", 3520], ["by", 3531], ["frequent", 3534], ["attendance", 3543], ["at", 3554], ["health", 3557], ["care", 3564], ["facilities", 3569], [".", 3579], ["In", 3581], ["contrast", 3584], [",", 3592], ["there", 3594], ["was", 3600], ["a", 3604], ["high", 3606], ["risk", 3611], ["of", 3616], ["CA", 3619], ["-", 3621], ["MRSA", 3622], ["in", 3627], ["deprived", 3630], ["areas", 3639], ["linked", 3645], ["with", 3652], ["overcrowding", 3657], [",", 3669], ["homelessness", 3671], [",", 3683], ["low", 3685], ["income", 3689], [",", 3695], ["and", 3697], ["recent", 3701], ["immigration", 3708], ["to", 3720], ["the", 3723], ["UK", 3727], [",", 3729], ["which", 3731], ["was", 3737], ["not", 3741], ["explainable", 3745], ["by", 3757], ["health", 3760], ["care", 3767], ["exposure", 3772], [".", 3780], ["Furthermore", 3782], [",", 3793], ["areas", 3795], ["adjacent", 3801], ["to", 3810], ["these", 3813], ["deprived", 3819], ["areas", 3828], ["were", 3834], ["themselves", 3839], ["at", 3850], ["greater", 3853], ["risk", 3861], ["of", 3866], ["CA", 3869], ["-", 3871], ["MRSA", 3872], [",", 3876], ["indicating", 3878], ["community", 3889], ["transmission", 3899], ["of", 3912], ["CA", 3915], ["-", 3917], ["MRSA", 3918], [".", 3922], ["This", 3924], ["ongoing", 3929], ["community", 3937], ["transmission", 3947], ["could", 3960], ["lead", 3966], ["to", 3971], ["CA", 3974], ["-", 3976], ["MRSA", 3977], ["becoming", 3982], ["the", 3991], ["dominant", 3995], ["strain", 4004], ["types", 4011], ["carried", 4017], ["by", 4025], ["patients", 4028], ["admitted", 4037], ["to", 4046], ["hospital", 4049], [",", 4057], ["particularly", 4059], ["if", 4072], ["successful", 4075], ["hospital", 4086], ["-", 4094], ["based", 4095], ["MRSA", 4101], ["infection", 4106], ["control", 4116], ["programmes", 4124], ["are", 4135], ["maintained", 4139], [".", 4149], ["These", 4151], ["results", 4157], ["suggest", 4165], ["that", 4173], ["community", 4178], ["infection", 4188], ["control", 4198], ["programmes", 4206], ["targeting", 4217], ["transmission", 4227], ["of", 4240], ["CA", 4243], ["-", 4245], ["MRSA", 4246], ["will", 4251], ["be", 4256], ["required", 4259], ["to", 4268], ["control", 4271], ["MRSA", 4279], ["in", 4284], ["both", 4287], ["the", 4292], ["community", 4296], ["and", 4306], ["hospital", 4310], [".", 4318], ["These", 4320], ["epidemiological", 4326], ["changes", 4342], ["will", 4350], ["also", 4355], ["have", 4360], ["implications", 4365], ["for", 4378], ["effectiveness", 4382], ["of", 4396], ["risk", 4399], ["-", 4403], ["factor", 4404], ["-", 4410], ["based", 4411], ["hospital", 4417], ["admission", 4426], ["MRSA", 4436], ["screening", 4441], ["programmes", 4451], [".", 4461]]}
{"context": "In order to determine the prevalence of latent infection due to Mycobacterium tuberculosis in drug users and to provide centres for drug users with a practical tool for tuberculosis screening, 237 drug users were subjected to the Monotest and, for reference purposes, to the Mantoux test. The overall prevalence of subjects with a tuberculin skin reaction size > or = 5 mm in the Mantoux test was 25.7%; utilizing a cut-off of > or = 10 mm, the prevalence was 11.4%. Irrespective of cut-off, the Monotest showed a sensitivity of > 90% and a specificity of > 80%. At a prevalence of 25.7%, and with cut-offs of > or = 5 or > or = 10 mm, the positive predictive value was 83% or 62.2%, respectively. Irrespective of cut-off, the negative predictive value was > 97%. In conclusion, the Monotest proved satisfactory as a tool for epidemiological screening in a population with a high prevalence for latent tuberculosis, namely drug users.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "36caa3ccb74340beb0182b812e4fbc13", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[12, 12], [189, 189], [28, 28]], "char_spans": [[78, 89], [902, 913], [169, 180]]}]}], "context_tokens": [["In", 0], ["order", 3], ["to", 9], ["determine", 12], ["the", 22], ["prevalence", 26], ["of", 37], ["latent", 40], ["infection", 47], ["due", 57], ["to", 61], ["Mycobacterium", 64], ["tuberculosis", 78], ["in", 91], ["drug", 94], ["users", 99], ["and", 105], ["to", 109], ["provide", 112], ["centres", 120], ["for", 128], ["drug", 132], ["users", 137], ["with", 143], ["a", 148], ["practical", 150], ["tool", 160], ["for", 165], ["tuberculosis", 169], ["screening", 182], [",", 191], ["237", 193], ["drug", 197], ["users", 202], ["were", 208], ["subjected", 213], ["to", 223], ["the", 226], ["Monotest", 230], ["and", 239], [",", 242], ["for", 244], ["reference", 248], ["purposes", 258], [",", 266], ["to", 268], ["the", 271], ["Mantoux", 275], ["test", 283], [".", 287], ["The", 289], ["overall", 293], ["prevalence", 301], ["of", 312], ["subjects", 315], ["with", 324], ["a", 329], ["tuberculin", 331], ["skin", 342], ["reaction", 347], ["size", 356], [">", 361], ["or", 363], ["=", 366], ["5", 368], ["mm", 370], ["in", 373], ["the", 376], ["Mantoux", 380], ["test", 388], ["was", 393], ["25.7", 397], ["%", 401], [";", 402], ["utilizing", 404], ["a", 414], ["cut", 416], ["-", 419], ["off", 420], ["of", 424], [">", 427], ["or", 429], ["=", 432], ["10", 434], ["mm", 437], [",", 439], ["the", 441], ["prevalence", 445], ["was", 456], ["11.4", 460], ["%", 464], [".", 465], ["Irrespective", 467], ["of", 480], ["cut", 483], ["-", 486], ["off", 487], [",", 490], ["the", 492], ["Monotest", 496], ["showed", 505], ["a", 512], ["sensitivity", 514], ["of", 526], [">", 529], ["90", 531], ["%", 533], ["and", 535], ["a", 539], ["specificity", 541], ["of", 553], [">", 556], ["80", 558], ["%", 560], [".", 561], ["At", 563], ["a", 566], ["prevalence", 568], ["of", 579], ["25.7", 582], ["%", 586], [",", 587], ["and", 589], ["with", 593], ["cut", 598], ["-", 601], ["offs", 602], ["of", 607], [">", 610], ["or", 612], ["=", 615], ["5", 617], ["or", 619], [">", 622], ["or", 624], ["=", 627], ["10", 629], ["mm", 632], [",", 634], ["the", 636], ["positive", 640], ["predictive", 649], ["value", 660], ["was", 666], ["83", 670], ["%", 672], ["or", 674], ["62.2", 677], ["%", 681], [",", 682], ["respectively", 684], [".", 696], ["Irrespective", 698], ["of", 711], ["cut", 714], ["-", 717], ["off", 718], [",", 721], ["the", 723], ["negative", 727], ["predictive", 736], ["value", 747], ["was", 753], [">", 757], ["97", 759], ["%", 761], [".", 762], ["In", 764], ["conclusion", 767], [",", 777], ["the", 779], ["Monotest", 783], ["proved", 792], ["satisfactory", 799], ["as", 812], ["a", 815], ["tool", 817], ["for", 822], ["epidemiological", 826], ["screening", 842], ["in", 852], ["a", 855], ["population", 857], ["with", 868], ["a", 873], ["high", 875], ["prevalence", 880], ["for", 891], ["latent", 895], ["tuberculosis", 902], [",", 914], ["namely", 916], ["drug", 923], ["users", 928], [".", 933]]}
{"context": "Detection of methicillin (meticillin)-resistant Staphylococcus aureus colonization was assessed using combined nose and groin swabs in two commercial PCR assays (the Xpert MRSA assay and the BD GeneOhm MRSA assay). Compared to routine culture, both had similar sensitivities (87.0% versus 84.8%, respectively) and specificities (93.8% versus 92.7%, respectively). Combined PCR assays provide a rapid and more-complete assessment of colonization at a cost similar to that of single-site analysis.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "a21e993c7e5d4f7f8143bd59329ed432", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[24, 24], [30, 30]], "char_spans": [[172, 175], [202, 205]]}]}], "context_tokens": [["Detection", 0], ["of", 10], ["methicillin", 13], ["(", 25], ["meticillin)-resistant", 26], ["Staphylococcus", 48], ["aureus", 63], ["colonization", 70], ["was", 83], ["assessed", 87], ["using", 96], ["combined", 102], ["nose", 111], ["and", 116], ["groin", 120], ["swabs", 126], ["in", 132], ["two", 135], ["commercial", 139], ["PCR", 150], ["assays", 154], ["(", 161], ["the", 162], ["Xpert", 166], ["MRSA", 172], ["assay", 177], ["and", 183], ["the", 187], ["BD", 191], ["GeneOhm", 194], ["MRSA", 202], ["assay", 207], [")", 212], [".", 213], ["Compared", 215], ["to", 224], ["routine", 227], ["culture", 235], [",", 242], ["both", 244], ["had", 249], ["similar", 253], ["sensitivities", 261], ["(", 275], ["87.0", 276], ["%", 280], ["versus", 282], ["84.8", 289], ["%", 293], [",", 294], ["respectively", 296], [")", 308], ["and", 310], ["specificities", 314], ["(", 328], ["93.8", 329], ["%", 333], ["versus", 335], ["92.7", 342], ["%", 346], [",", 347], ["respectively", 349], [")", 361], [".", 362], ["Combined", 364], ["PCR", 373], ["assays", 377], ["provide", 384], ["a", 392], ["rapid", 394], ["and", 400], ["more", 404], ["-", 408], ["complete", 409], ["assessment", 418], ["of", 429], ["colonization", 432], ["at", 445], ["a", 448], ["cost", 450], ["similar", 455], ["to", 463], ["that", 466], ["of", 471], ["single", 474], ["-", 480], ["site", 481], ["analysis", 486], [".", 494]]}
{"context": "Embryonic neuroepithelia and adult subventricular zone (SVZ) stem and progenitor cells express nestin. We characterized a transgenic line that expresses enhanced green fluorescent protein (eGFP) specified to neural tissue by the second intronic enhancer of the nestin promoter that had several novel features. During embryogenesis, the dorsal telencephalon contained many and the ventral telencephalon few eGFP+ cells. eGFP+ cells were found in postnatal and adult neurogenic regions. eGFP+ cells in the SVZ expressed multiple phenotype markers, glial fibrillary acidic protein, Dlx, and neuroblast-specific molecules suggesting the transgene is expressed through the lineage. eGFP+ cell numbers increased in the SVZ after cortical injury, suggesting this line will be useful in probing postinjury neurogenesis. In non-neurogenic regions, eGFP was strongly expressed in oligodendrocyte progenitors, but not in astrocytes, even when they were reactive. This eGFP+ mouse will facilitate studies of proliferative neuroepithelia and adult neurogenesis, as well as of parenchymal oligodendrocytes.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "1f13212b55544ebc9031055963334233", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[41, 41], [14, 14]], "char_spans": [[261, 266], [95, 100]]}]}], "context_tokens": [["Embryonic", 0], ["neuroepithelia", 10], ["and", 25], ["adult", 29], ["subventricular", 35], ["zone", 50], ["(", 55], ["SVZ", 56], [")", 59], ["stem", 61], ["and", 66], ["progenitor", 70], ["cells", 81], ["express", 87], ["nestin", 95], [".", 101], ["We", 103], ["characterized", 106], ["a", 120], ["transgenic", 122], ["line", 133], ["that", 138], ["expresses", 143], ["enhanced", 153], ["green", 162], ["fluorescent", 168], ["protein", 180], ["(", 188], ["eGFP", 189], [")", 193], ["specified", 195], ["to", 205], ["neural", 208], ["tissue", 215], ["by", 222], ["the", 225], ["second", 229], ["intronic", 236], ["enhancer", 245], ["of", 254], ["the", 257], ["nestin", 261], ["promoter", 268], ["that", 277], ["had", 282], ["several", 286], ["novel", 294], ["features", 300], [".", 308], ["During", 310], ["embryogenesis", 317], [",", 330], ["the", 332], ["dorsal", 336], ["telencephalon", 343], ["contained", 357], ["many", 367], ["and", 372], ["the", 376], ["ventral", 380], ["telencephalon", 388], ["few", 402], ["eGFP+", 406], ["cells", 412], [".", 417], ["eGFP+", 419], ["cells", 425], ["were", 431], ["found", 436], ["in", 442], ["postnatal", 445], ["and", 455], ["adult", 459], ["neurogenic", 465], ["regions", 476], [".", 483], ["eGFP+", 485], ["cells", 491], ["in", 497], ["the", 500], ["SVZ", 504], ["expressed", 508], ["multiple", 518], ["phenotype", 527], ["markers", 537], [",", 544], ["glial", 546], ["fibrillary", 552], ["acidic", 563], ["protein", 570], [",", 577], ["Dlx", 579], [",", 582], ["and", 584], ["neuroblast", 588], ["-", 598], ["specific", 599], ["molecules", 608], ["suggesting", 618], ["the", 629], ["transgene", 633], ["is", 643], ["expressed", 646], ["through", 656], ["the", 664], ["lineage", 668], [".", 675], ["eGFP+", 677], ["cell", 683], ["numbers", 688], ["increased", 696], ["in", 706], ["the", 709], ["SVZ", 713], ["after", 717], ["cortical", 723], ["injury", 732], [",", 738], ["suggesting", 740], ["this", 751], ["line", 756], ["will", 761], ["be", 766], ["useful", 769], ["in", 776], ["probing", 779], ["postinjury", 787], ["neurogenesis", 798], [".", 810], ["In", 812], ["non", 815], ["-", 818], ["neurogenic", 819], ["regions", 830], [",", 837], ["eGFP", 839], ["was", 844], ["strongly", 848], ["expressed", 857], ["in", 867], ["oligodendrocyte", 870], ["progenitors", 886], [",", 897], ["but", 899], ["not", 903], ["in", 907], ["astrocytes", 910], [",", 920], ["even", 922], ["when", 927], ["they", 932], ["were", 937], ["reactive", 942], [".", 950], ["This", 952], ["eGFP+", 957], ["mouse", 963], ["will", 969], ["facilitate", 974], ["studies", 985], ["of", 993], ["proliferative", 996], ["neuroepithelia", 1010], ["and", 1025], ["adult", 1029], ["neurogenesis", 1035], [",", 1047], ["as", 1049], ["well", 1052], ["as", 1057], ["of", 1060], ["parenchymal", 1063], ["oligodendrocytes", 1075], [".", 1091]]}
{"context": "Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for posttraumatic stress disorder (PTSD). Serotonergic (5HT) attenuation of stress sensitivity is postulated from SSRIs' effects in other anxiety disorders, and we studied this in PTSD. Ten patients with PTSD fully recovered on SSRIs (Clinical Global Impression Scale-I 1 and 2) were enrolled in the study. Patients were tested on two occasions 1 week apart; in each session, they received a drink containing large neutral amino acids (LNAAs) either with (sham tryptophan depletion [STD], control) or without (acute tryptophan depletion [ATD]) tryptophan. At 5.5 hours after the drink, subjects were exposed to a trauma-related exposure challenge. Self-reports of PTSD (visual analogue scales [VAS] and the Davidson Trauma Scale [DTS]), anxiety (Spielberger State Inventory [STAI] Form Y-1), and mood (Profile of Mood States [POMS]) were obtained. Heart rate (HR), systolic (SBP) and diastolic (DBP) blood pressure were also measured. The trauma-related exposure challenge induced anxiety on both days, with more marked responses on the ATD day according to VAS, DTS, POMS, and DBP (p < .05). A trend of significance (.1 > p > .05) was observed for STAI Form Y-1, HR, and SBP. These data demonstrate that ATD accentuates responses to trauma-related stimuli in SSRI-recovered PTSD. They also suggest that SSRI-induced increases in serotonin function restrain PTSD symptoms, especially under provocation, supporting a role for serotonin in mediating stress resilience.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "a197452996814e96bc9331b41b870709", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[283, 283], [44, 44], [297, 297], [17, 17], [143, 143], [49, 49]], "char_spans": [[1349, 1352], [254, 257], [1432, 1435], [109, 112], [738, 741], [278, 281]]}]}], "context_tokens": [["Selective", 0], ["serotonin", 10], ["reuptake", 20], ["inhibitors", 29], ["(", 40], ["SSRIs", 41], [")", 46], ["are", 48], ["first", 52], ["-", 57], ["line", 58], ["treatments", 63], ["for", 74], ["posttraumatic", 78], ["stress", 92], ["disorder", 99], ["(", 108], ["PTSD", 109], [")", 113], [".", 114], ["Serotonergic", 116], ["(", 129], ["5HT", 130], [")", 133], ["attenuation", 135], ["of", 147], ["stress", 150], ["sensitivity", 157], ["is", 169], ["postulated", 172], ["from", 183], ["SSRIs", 188], ["'", 193], ["effects", 195], ["in", 203], ["other", 206], ["anxiety", 212], ["disorders", 220], [",", 229], ["and", 231], ["we", 235], ["studied", 238], ["this", 246], ["in", 251], ["PTSD", 254], [".", 258], ["Ten", 260], ["patients", 264], ["with", 273], ["PTSD", 278], ["fully", 283], ["recovered", 289], ["on", 299], ["SSRIs", 302], ["(", 308], ["Clinical", 309], ["Global", 318], ["Impression", 325], ["Scale", 336], ["-", 341], ["I", 342], ["1", 344], ["and", 346], ["2", 350], [")", 351], ["were", 353], ["enrolled", 358], ["in", 367], ["the", 370], ["study", 374], [".", 379], ["Patients", 381], ["were", 390], ["tested", 395], ["on", 402], ["two", 405], ["occasions", 409], ["1", 419], ["week", 421], ["apart", 426], [";", 431], ["in", 433], ["each", 436], ["session", 441], [",", 448], ["they", 450], ["received", 455], ["a", 464], ["drink", 466], ["containing", 472], ["large", 483], ["neutral", 489], ["amino", 497], ["acids", 503], ["(", 509], ["LNAAs", 510], [")", 515], ["either", 517], ["with", 524], ["(", 529], ["sham", 530], ["tryptophan", 535], ["depletion", 546], ["[", 556], ["STD", 557], ["]", 560], [",", 561], ["control", 563], [")", 570], ["or", 572], ["without", 575], ["(", 583], ["acute", 584], ["tryptophan", 590], ["depletion", 601], ["[", 611], ["ATD", 612], ["]", 615], [")", 616], ["tryptophan", 618], [".", 628], ["At", 630], ["5.5", 633], ["hours", 637], ["after", 643], ["the", 649], ["drink", 653], [",", 658], ["subjects", 660], ["were", 669], ["exposed", 674], ["to", 682], ["a", 685], ["trauma", 687], ["-", 693], ["related", 694], ["exposure", 702], ["challenge", 711], [".", 720], ["Self", 722], ["-", 726], ["reports", 727], ["of", 735], ["PTSD", 738], ["(", 743], ["visual", 744], ["analogue", 751], ["scales", 760], ["[", 767], ["VAS", 768], ["]", 771], ["and", 773], ["the", 777], ["Davidson", 781], ["Trauma", 790], ["Scale", 797], ["[", 803], ["DTS", 804], ["]", 807], [")", 808], [",", 809], ["anxiety", 811], ["(", 819], ["Spielberger", 820], ["State", 832], ["Inventory", 838], ["[", 848], ["STAI", 849], ["]", 853], ["Form", 855], ["Y-1", 860], [")", 863], [",", 864], ["and", 866], ["mood", 870], ["(", 875], ["Profile", 876], ["of", 884], ["Mood", 887], ["States", 892], ["[", 899], ["POMS", 900], ["]", 904], [")", 905], ["were", 907], ["obtained", 912], [".", 920], ["Heart", 922], ["rate", 928], ["(", 933], ["HR", 934], [")", 936], [",", 937], ["systolic", 939], ["(", 948], ["SBP", 949], [")", 952], ["and", 954], ["diastolic", 958], ["(", 968], ["DBP", 969], [")", 972], ["blood", 974], ["pressure", 980], ["were", 989], ["also", 994], ["measured", 999], [".", 1007], ["The", 1009], ["trauma", 1013], ["-", 1019], ["related", 1020], ["exposure", 1028], ["challenge", 1037], ["induced", 1047], ["anxiety", 1055], ["on", 1063], ["both", 1066], ["days", 1071], [",", 1075], ["with", 1077], ["more", 1082], ["marked", 1087], ["responses", 1094], ["on", 1104], ["the", 1107], ["ATD", 1111], ["day", 1115], ["according", 1119], ["to", 1129], ["VAS", 1132], [",", 1135], ["DTS", 1137], [",", 1140], ["POMS", 1142], [",", 1146], ["and", 1148], ["DBP", 1152], ["(", 1156], ["p", 1157], ["<", 1159], [".05", 1161], [")", 1164], [".", 1165], ["A", 1167], ["trend", 1169], ["of", 1175], ["significance", 1178], ["(", 1191], [".1", 1192], [">", 1195], ["p", 1197], [">", 1199], [".05", 1201], [")", 1204], ["was", 1206], ["observed", 1210], ["for", 1219], ["STAI", 1223], ["Form", 1228], ["Y-1", 1233], [",", 1236], ["HR", 1238], [",", 1240], ["and", 1242], ["SBP", 1246], [".", 1249], ["These", 1251], ["data", 1257], ["demonstrate", 1262], ["that", 1274], ["ATD", 1279], ["accentuates", 1283], ["responses", 1295], ["to", 1305], ["trauma", 1308], ["-", 1314], ["related", 1315], ["stimuli", 1323], ["in", 1331], ["SSRI", 1334], ["-", 1338], ["recovered", 1339], ["PTSD", 1349], [".", 1353], ["They", 1355], ["also", 1360], ["suggest", 1365], ["that", 1373], ["SSRI", 1378], ["-", 1382], ["induced", 1383], ["increases", 1391], ["in", 1401], ["serotonin", 1404], ["function", 1414], ["restrain", 1423], ["PTSD", 1432], ["symptoms", 1437], [",", 1445], ["especially", 1447], ["under", 1458], ["provocation", 1464], [",", 1475], ["supporting", 1477], ["a", 1488], ["role", 1490], ["for", 1495], ["serotonin", 1499], ["in", 1509], ["mediating", 1512], ["stress", 1522], ["resilience", 1529], [".", 1539]]}
{"context": "The actions of benzodiazepines are due to the potentiation of the neural inhibition that is mediated by gamma-aminobutyric acid (GABA). Practically all effects of the benzodiazepines result from their actions on the ionotropic GABA(A) receptors in the central nervous system. Benzodiazepines do not activate GABA(A) receptors directly but they require GABA. The main effects of benzodiazepines are sedation, hypnosis, decreased anxiety, anterograde amnesia, centrally mediated muscle relaxation and anti-convulsant activity. In addition to their action on the central nervous system, benzodiazepines have a dose-dependent ventilatory depressant effect and they also cause a modest reduction in arterial blood pressure and an increase in heart rate as a result of a decrease of systemic vascular resistance. The four benzodiazepines, widely used in clinical anaesthesia, are the agonists midazolam, diazepam and lorazepam and the antagonist flumazenil. Midazolam, diazepam and flumazenil are metabolized by cytochrome P450 (CYP) enzymes and by glucuronide conjugation whereas lorazepam directly undergoes glucuronide conjugation. CYP3A4 is important in the biotransformation of both midazolam and diazepam. CYP2C19 is important in the biotransformation of diazepam. Liver and renal dysfunction have only a minor effect on the pharmacokinetics of lorazepam but they slow down the elimination of the other benzodiazepines used in clinical anaesthesia. The duration of action of all benzodiazepines is strongly dependent on the duration of their administration. Based on clinical studies and computer simulations, midazolam has the shortest recovery profile followed by lorazepam and diazepam. Being metabolized by CYP enzymes, midazolam and diazepam have many clinically significant interactions with inhibitors and inducers of CYP3A4 and 2C19. In addition to pharmacokinetic interactions, benzodiazepines have synergistic interactions with other hypnotics and opioids. Midazolam, diazepam and lorazepam are widely used for sedation and to some extent also for induction and maintenance of anaesthesia. Flumazenil is very useful in reversing benzodiazepine-induced sedation as well as to diagnose or treat benzodiazepine overdose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "0652e34262bc426d97340af838f8da7e", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[161, 161], [155, 155], [330, 330]], "char_spans": [[976, 985], [940, 949], [2100, 2109]]}]}], "context_tokens": [["The", 0], ["actions", 4], ["of", 12], ["benzodiazepines", 15], ["are", 31], ["due", 35], ["to", 39], ["the", 42], ["potentiation", 46], ["of", 59], ["the", 62], ["neural", 66], ["inhibition", 73], ["that", 84], ["is", 89], ["mediated", 92], ["by", 101], ["gamma", 104], ["-", 109], ["aminobutyric", 110], ["acid", 123], ["(", 128], ["GABA", 129], [")", 133], [".", 134], ["Practically", 136], ["all", 148], ["effects", 152], ["of", 160], ["the", 163], ["benzodiazepines", 167], ["result", 183], ["from", 190], ["their", 195], ["actions", 201], ["on", 209], ["the", 212], ["ionotropic", 216], ["GABA(A", 227], [")", 233], ["receptors", 235], ["in", 245], ["the", 248], ["central", 252], ["nervous", 260], ["system", 268], [".", 274], ["Benzodiazepines", 276], ["do", 292], ["not", 295], ["activate", 299], ["GABA(A", 308], [")", 314], ["receptors", 316], ["directly", 326], ["but", 335], ["they", 339], ["require", 344], ["GABA", 352], [".", 356], ["The", 358], ["main", 362], ["effects", 367], ["of", 375], ["benzodiazepines", 378], ["are", 394], ["sedation", 398], [",", 406], ["hypnosis", 408], [",", 416], ["decreased", 418], ["anxiety", 428], [",", 435], ["anterograde", 437], ["amnesia", 449], [",", 456], ["centrally", 458], ["mediated", 468], ["muscle", 477], ["relaxation", 484], ["and", 495], ["anti", 499], ["-", 503], ["convulsant", 504], ["activity", 515], [".", 523], ["In", 525], ["addition", 528], ["to", 537], ["their", 540], ["action", 546], ["on", 553], ["the", 556], ["central", 560], ["nervous", 568], ["system", 576], [",", 582], ["benzodiazepines", 584], ["have", 600], ["a", 605], ["dose", 607], ["-", 611], ["dependent", 612], ["ventilatory", 622], ["depressant", 634], ["effect", 645], ["and", 652], ["they", 656], ["also", 661], ["cause", 666], ["a", 672], ["modest", 674], ["reduction", 681], ["in", 691], ["arterial", 694], ["blood", 703], ["pressure", 709], ["and", 718], ["an", 722], ["increase", 725], ["in", 734], ["heart", 737], ["rate", 743], ["as", 748], ["a", 751], ["result", 753], ["of", 760], ["a", 763], ["decrease", 765], ["of", 774], ["systemic", 777], ["vascular", 786], ["resistance", 795], [".", 805], ["The", 807], ["four", 811], ["benzodiazepines", 816], [",", 831], ["widely", 833], ["used", 840], ["in", 845], ["clinical", 848], ["anaesthesia", 857], [",", 868], ["are", 870], ["the", 874], ["agonists", 878], ["midazolam", 887], [",", 896], ["diazepam", 898], ["and", 907], ["lorazepam", 911], ["and", 921], ["the", 925], ["antagonist", 929], ["flumazenil", 940], [".", 950], ["Midazolam", 952], [",", 961], ["diazepam", 963], ["and", 972], ["flumazenil", 976], ["are", 987], ["metabolized", 991], ["by", 1003], ["cytochrome", 1006], ["P450", 1017], ["(", 1022], ["CYP", 1023], [")", 1026], ["enzymes", 1028], ["and", 1036], ["by", 1040], ["glucuronide", 1043], ["conjugation", 1055], ["whereas", 1067], ["lorazepam", 1075], ["directly", 1085], ["undergoes", 1094], ["glucuronide", 1104], ["conjugation", 1116], [".", 1127], ["CYP3A4", 1129], ["is", 1136], ["important", 1139], ["in", 1149], ["the", 1152], ["biotransformation", 1156], ["of", 1174], ["both", 1177], ["midazolam", 1182], ["and", 1192], ["diazepam", 1196], [".", 1204], ["CYP2C19", 1206], ["is", 1214], ["important", 1217], ["in", 1227], ["the", 1230], ["biotransformation", 1234], ["of", 1252], ["diazepam", 1255], [".", 1263], ["Liver", 1265], ["and", 1271], ["renal", 1275], ["dysfunction", 1281], ["have", 1293], ["only", 1298], ["a", 1303], ["minor", 1305], ["effect", 1311], ["on", 1318], ["the", 1321], ["pharmacokinetics", 1325], ["of", 1342], ["lorazepam", 1345], ["but", 1355], ["they", 1359], ["slow", 1364], ["down", 1369], ["the", 1374], ["elimination", 1378], ["of", 1390], ["the", 1393], ["other", 1397], ["benzodiazepines", 1403], ["used", 1419], ["in", 1424], ["clinical", 1427], ["anaesthesia", 1436], [".", 1447], ["The", 1449], ["duration", 1453], ["of", 1462], ["action", 1465], ["of", 1472], ["all", 1475], ["benzodiazepines", 1479], ["is", 1495], ["strongly", 1498], ["dependent", 1507], ["on", 1517], ["the", 1520], ["duration", 1524], ["of", 1533], ["their", 1536], ["administration", 1542], [".", 1556], ["Based", 1558], ["on", 1564], ["clinical", 1567], ["studies", 1576], ["and", 1584], ["computer", 1588], ["simulations", 1597], [",", 1608], ["midazolam", 1610], ["has", 1620], ["the", 1624], ["shortest", 1628], ["recovery", 1637], ["profile", 1646], ["followed", 1654], ["by", 1663], ["lorazepam", 1666], ["and", 1676], ["diazepam", 1680], [".", 1688], ["Being", 1690], ["metabolized", 1696], ["by", 1708], ["CYP", 1711], ["enzymes", 1715], [",", 1722], ["midazolam", 1724], ["and", 1734], ["diazepam", 1738], ["have", 1747], ["many", 1752], ["clinically", 1757], ["significant", 1768], ["interactions", 1780], ["with", 1793], ["inhibitors", 1798], ["and", 1809], ["inducers", 1813], ["of", 1822], ["CYP3A4", 1825], ["and", 1832], ["2C19", 1836], [".", 1840], ["In", 1842], ["addition", 1845], ["to", 1854], ["pharmacokinetic", 1857], ["interactions", 1873], [",", 1885], ["benzodiazepines", 1887], ["have", 1903], ["synergistic", 1908], ["interactions", 1920], ["with", 1933], ["other", 1938], ["hypnotics", 1944], ["and", 1954], ["opioids", 1958], [".", 1965], ["Midazolam", 1967], [",", 1976], ["diazepam", 1978], ["and", 1987], ["lorazepam", 1991], ["are", 2001], ["widely", 2005], ["used", 2012], ["for", 2017], ["sedation", 2021], ["and", 2030], ["to", 2034], ["some", 2037], ["extent", 2042], ["also", 2049], ["for", 2054], ["induction", 2058], ["and", 2068], ["maintenance", 2072], ["of", 2084], ["anaesthesia", 2087], [".", 2098], ["Flumazenil", 2100], ["is", 2111], ["very", 2114], ["useful", 2119], ["in", 2126], ["reversing", 2129], ["benzodiazepine", 2139], ["-", 2153], ["induced", 2154], ["sedation", 2162], ["as", 2171], ["well", 2174], ["as", 2179], ["to", 2182], ["diagnose", 2185], ["or", 2194], ["treat", 2197], ["benzodiazepine", 2203], ["overdose", 2218], [".", 2226]]}
{"context": "Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib. Two types of mutations account for approximately 90% of mutated cases: short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 (L858R). Screening for these mutations has been based mainly on direct sequencing. We report here the development and validation of polymerase chain reaction-based assays for these two predominant types of EGFR mutations. The assay for exon 19 mutations is based on length analysis of fluorescently labeled polymerase chain reaction products, and the assay for the exon 21 L858R mutation is based on a new Sau96I restriction site created by this mutation. Using serial dilutions of DNAs from lung cancer cell lines harboring either exon 19 or 21 mutations, we detected these mutations in the presence of up to approximately 90% normal DNA. In a test set of 39 lung cancer samples, direct sequencing detected mutations in 25 cases whereas our assays were positive in 29 cases, including 4 cases in which mutations were not apparent by sequencing. These assays offer higher sensitivity and ease of scoring and eliminate the need for sequencing, providing a robust and accessible approach to the rapid identification of most lung cancer patients likely to respond to EGFR inhibitors.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "a19945a83e2d457caf189e2614c1ac05", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[9, 16]], "char_spans": [[55, 98]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["domain", 41], ["of", 48], ["the", 51], ["epidermal", 55], ["growth", 65], ["factor", 72], ["receptor", 79], ["(", 88], ["EGFR", 89], [")", 93], ["gene", 95], ["are", 100], ["present", 104], ["in", 112], ["lung", 115], ["adenocarcinomas", 120], ["that", 136], ["respond", 141], ["to", 149], ["the", 152], ["EGFR", 156], ["inhibitors", 161], ["gefitinib", 172], ["and", 182], ["erlotinib", 186], [".", 195], ["Two", 197], ["types", 201], ["of", 207], ["mutations", 210], ["account", 220], ["for", 228], ["approximately", 232], ["90", 246], ["%", 248], ["of", 250], ["mutated", 253], ["cases", 261], [":", 266], ["short", 268], ["in", 274], ["-", 276], ["frame", 277], ["deletions", 283], ["in", 293], ["exon", 296], ["19", 301], ["and", 304], ["a", 308], ["specific", 310], ["point", 319], ["mutation", 325], ["in", 334], ["exon", 337], ["21", 342], ["at", 345], ["codon", 348], ["858", 354], ["(", 358], ["L858R", 359], [")", 364], [".", 365], ["Screening", 367], ["for", 377], ["these", 381], ["mutations", 387], ["has", 397], ["been", 401], ["based", 406], ["mainly", 412], ["on", 419], ["direct", 422], ["sequencing", 429], [".", 439], ["We", 441], ["report", 444], ["here", 451], ["the", 456], ["development", 460], ["and", 472], ["validation", 476], ["of", 487], ["polymerase", 490], ["chain", 501], ["reaction", 507], ["-", 515], ["based", 516], ["assays", 522], ["for", 529], ["these", 533], ["two", 539], ["predominant", 543], ["types", 555], ["of", 561], ["EGFR", 564], ["mutations", 569], [".", 578], ["The", 580], ["assay", 584], ["for", 590], ["exon", 594], ["19", 599], ["mutations", 602], ["is", 612], ["based", 615], ["on", 621], ["length", 624], ["analysis", 631], ["of", 640], ["fluorescently", 643], ["labeled", 657], ["polymerase", 665], ["chain", 676], ["reaction", 682], ["products", 691], [",", 699], ["and", 701], ["the", 705], ["assay", 709], ["for", 715], ["the", 719], ["exon", 723], ["21", 728], ["L858R", 731], ["mutation", 737], ["is", 746], ["based", 749], ["on", 755], ["a", 758], ["new", 760], ["Sau96I", 764], ["restriction", 771], ["site", 783], ["created", 788], ["by", 796], ["this", 799], ["mutation", 804], [".", 812], ["Using", 814], ["serial", 820], ["dilutions", 827], ["of", 837], ["DNAs", 840], ["from", 845], ["lung", 850], ["cancer", 855], ["cell", 862], ["lines", 867], ["harboring", 873], ["either", 883], ["exon", 890], ["19", 895], ["or", 898], ["21", 901], ["mutations", 904], [",", 913], ["we", 915], ["detected", 918], ["these", 927], ["mutations", 933], ["in", 943], ["the", 946], ["presence", 950], ["of", 959], ["up", 962], ["to", 965], ["approximately", 968], ["90", 982], ["%", 984], ["normal", 986], ["DNA", 993], [".", 996], ["In", 998], ["a", 1001], ["test", 1003], ["set", 1008], ["of", 1012], ["39", 1015], ["lung", 1018], ["cancer", 1023], ["samples", 1030], [",", 1037], ["direct", 1039], ["sequencing", 1046], ["detected", 1057], ["mutations", 1066], ["in", 1076], ["25", 1079], ["cases", 1082], ["whereas", 1088], ["our", 1096], ["assays", 1100], ["were", 1107], ["positive", 1112], ["in", 1121], ["29", 1124], ["cases", 1127], [",", 1132], ["including", 1134], ["4", 1144], ["cases", 1146], ["in", 1152], ["which", 1155], ["mutations", 1161], ["were", 1171], ["not", 1176], ["apparent", 1180], ["by", 1189], ["sequencing", 1192], [".", 1202], ["These", 1204], ["assays", 1210], ["offer", 1217], ["higher", 1223], ["sensitivity", 1230], ["and", 1242], ["ease", 1246], ["of", 1251], ["scoring", 1254], ["and", 1262], ["eliminate", 1266], ["the", 1276], ["need", 1280], ["for", 1285], ["sequencing", 1289], [",", 1299], ["providing", 1301], ["a", 1311], ["robust", 1313], ["and", 1320], ["accessible", 1324], ["approach", 1335], ["to", 1344], ["the", 1347], ["rapid", 1351], ["identification", 1357], ["of", 1372], ["most", 1375], ["lung", 1380], ["cancer", 1385], ["patients", 1392], ["likely", 1401], ["to", 1408], ["respond", 1411], ["to", 1419], ["EGFR", 1422], ["inhibitors", 1427], [".", 1437]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are characterized by abnormal deposition of \u03b1-synuclein aggregates in many regions of the central and peripheral nervous systems. Accumulating evidence suggests that the \u03b1-synuclein pathology initiates in a few discrete regions and spreads to larger areas in the nervous system. Recent pathological studies of PD patients have raised the possibility that the enteric nervous system is one of the initial sites of \u03b1-synuclein aggregation and propagation. Here, we evaluated the induction and propagation of \u03b1-synuclein aggregates in the enteric nervous system of the A53T \u03b1-synuclein transgenic mice after injection of human brain tissue extracts into the gastric walls of the mice. Western analysis of the brain extracts showed that the DLB extract contained detergent-stable \u03b1-synuclein aggregates, but the normal brain extract did not. Injection of the DLB extract resulted in an increased deposition of \u03b1-synuclein in the myenteric neurons, in which \u03b1-synuclein formed punctate aggregates over time up to 4 months. In these mice, inflammatory responses were increased transiently at early time points. None of these changes were observed in the A53T mice injected with saline or the normal brain extract, nor were these found in the wild type mice injected with the DLB extract. These results demonstrate that pathological \u03b1-synuclein aggregates present in the brain of DLB patient can induce the aggregation of endogenous \u03b1-synuclein in the myenteric neurons in A53T mice, suggesting the transmission of synucleinopathy lesions in the enteric nervous system.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "9a225d6aa2034d27a58fc2dea42dbe40", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["(", 55], ["DLB", 56], [")", 59], ["are", 61], ["characterized", 65], ["by", 79], ["abnormal", 82], ["deposition", 91], ["of", 102], ["\u03b1", 105], ["-", 106], ["synuclein", 107], ["aggregates", 117], ["in", 128], ["many", 131], ["regions", 136], ["of", 144], ["the", 147], ["central", 151], ["and", 159], ["peripheral", 163], ["nervous", 174], ["systems", 182], [".", 189], ["Accumulating", 191], ["evidence", 204], ["suggests", 213], ["that", 222], ["the", 227], ["\u03b1", 231], ["-", 232], ["synuclein", 233], ["pathology", 243], ["initiates", 253], ["in", 263], ["a", 266], ["few", 268], ["discrete", 272], ["regions", 281], ["and", 289], ["spreads", 293], ["to", 301], ["larger", 304], ["areas", 311], ["in", 317], ["the", 320], ["nervous", 324], ["system", 332], [".", 338], ["Recent", 340], ["pathological", 347], ["studies", 360], ["of", 368], ["PD", 371], ["patients", 374], ["have", 383], ["raised", 388], ["the", 395], ["possibility", 399], ["that", 411], ["the", 416], ["enteric", 420], ["nervous", 428], ["system", 436], ["is", 443], ["one", 446], ["of", 450], ["the", 453], ["initial", 457], ["sites", 465], ["of", 471], ["\u03b1", 474], ["-", 475], ["synuclein", 476], ["aggregation", 486], ["and", 498], ["propagation", 502], [".", 513], ["Here", 515], [",", 519], ["we", 521], ["evaluated", 524], ["the", 534], ["induction", 538], ["and", 548], ["propagation", 552], ["of", 564], ["\u03b1", 567], ["-", 568], ["synuclein", 569], ["aggregates", 579], ["in", 590], ["the", 593], ["enteric", 597], ["nervous", 605], ["system", 613], ["of", 620], ["the", 623], ["A53", 627], ["T", 630], ["\u03b1", 632], ["-", 633], ["synuclein", 634], ["transgenic", 644], ["mice", 655], ["after", 660], ["injection", 666], ["of", 676], ["human", 679], ["brain", 685], ["tissue", 691], ["extracts", 698], ["into", 707], ["the", 712], ["gastric", 716], ["walls", 724], ["of", 730], ["the", 733], ["mice", 737], [".", 741], ["Western", 743], ["analysis", 751], ["of", 760], ["the", 763], ["brain", 767], ["extracts", 773], ["showed", 782], ["that", 789], ["the", 794], ["DLB", 798], ["extract", 802], ["contained", 810], ["detergent", 820], ["-", 829], ["stable", 830], ["\u03b1", 837], ["-", 838], ["synuclein", 839], ["aggregates", 849], [",", 859], ["but", 861], ["the", 865], ["normal", 869], ["brain", 876], ["extract", 882], ["did", 890], ["not", 894], [".", 897], ["Injection", 899], ["of", 909], ["the", 912], ["DLB", 916], ["extract", 920], ["resulted", 928], ["in", 937], ["an", 940], ["increased", 943], ["deposition", 953], ["of", 964], ["\u03b1", 967], ["-", 968], ["synuclein", 969], ["in", 979], ["the", 982], ["myenteric", 986], ["neurons", 996], [",", 1003], ["in", 1005], ["which", 1008], ["\u03b1", 1014], ["-", 1015], ["synuclein", 1016], ["formed", 1026], ["punctate", 1033], ["aggregates", 1042], ["over", 1053], ["time", 1058], ["up", 1063], ["to", 1066], ["4", 1069], ["months", 1071], [".", 1077], ["In", 1079], ["these", 1082], ["mice", 1088], [",", 1092], ["inflammatory", 1094], ["responses", 1107], ["were", 1117], ["increased", 1122], ["transiently", 1132], ["at", 1144], ["early", 1147], ["time", 1153], ["points", 1158], [".", 1164], ["None", 1166], ["of", 1171], ["these", 1174], ["changes", 1180], ["were", 1188], ["observed", 1193], ["in", 1202], ["the", 1205], ["A53", 1209], ["T", 1212], ["mice", 1214], ["injected", 1219], ["with", 1228], ["saline", 1233], ["or", 1240], ["the", 1243], ["normal", 1247], ["brain", 1254], ["extract", 1260], [",", 1267], ["nor", 1269], ["were", 1273], ["these", 1278], ["found", 1284], ["in", 1290], ["the", 1293], ["wild", 1297], ["type", 1302], ["mice", 1307], ["injected", 1312], ["with", 1321], ["the", 1326], ["DLB", 1330], ["extract", 1334], [".", 1341], ["These", 1343], ["results", 1349], ["demonstrate", 1357], ["that", 1369], ["pathological", 1374], ["\u03b1", 1387], ["-", 1388], ["synuclein", 1389], ["aggregates", 1399], ["present", 1410], ["in", 1418], ["the", 1421], ["brain", 1425], ["of", 1431], ["DLB", 1434], ["patient", 1438], ["can", 1446], ["induce", 1450], ["the", 1457], ["aggregation", 1461], ["of", 1473], ["endogenous", 1476], ["\u03b1", 1487], ["-", 1488], ["synuclein", 1489], ["in", 1499], ["the", 1502], ["myenteric", 1506], ["neurons", 1516], ["in", 1524], ["A53", 1527], ["T", 1530], ["mice", 1532], [",", 1536], ["suggesting", 1538], ["the", 1549], ["transmission", 1553], ["of", 1566], ["synucleinopathy", 1569], ["lesions", 1585], ["in", 1593], ["the", 1596], ["enteric", 1600], ["nervous", 1608], ["system", 1616], [".", 1622]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development. In 115 seropositive arthralgia patients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated. The diagnostic performance of the IFN-score was evaluated using Cox regression and Receiver Operating Characteristics (ROC)-curve analysis. In 44 of the 115 at-risk individuals (38%) from the Amsterdam Reade cohort, arthritis developed after a median period of 8 months (IQR 5-13). Stratification of these individuals based on the IFN-score revealed that 15 out of 25 IFN(high) individuals converted to arthritis, compared with 29 out of 90 IFN(low) individuals (p=0.011). In the Northern Sweden cohort, the level of the IFN-score was also significantly increased in presymptomatic individuals who developed RA compared with population-based controls (p=0.002). Cox regression analysis of the Amsterdam Reade cohort showed that the hazard ratio (HR) for development of arthritis was 2.38 (p=0.008) for IFN(high) at-risk individuals after correction for anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The ROC-curve area under the curve (AUC) for the IFN-score combined with ACPA and RF in the prediction of arthritis was 78.5% (p=0.0001, 95% CI 0.70 to 0.87). The results demonstrated clinical utility for the IFN-signature as a biomarker in the prediction of arthritis development.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["IFN-signature", "Interferon signature", "IFN signature"], "qid": "78f9bca0ee664b74b0be699e63138b9b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[307, 309]], "char_spans": [[1644, 1656]]}]}], "context_tokens": [["To", 0], ["validate", 3], ["the", 12], ["presence", 16], ["and", 25], ["demonstrate", 29], ["the", 41], ["clinical", 45], ["value", 54], ["of", 60], ["the", 63], ["type", 67], ["I", 72], ["interferon", 74], ["(", 85], ["IFN)-signature", 86], ["during", 101], ["arthritis", 108], ["development", 118], [".", 129], ["In", 131], ["115", 134], ["seropositive", 138], ["arthralgia", 151], ["patients", 162], ["who", 171], ["were", 175], ["followed", 180], ["for", 189], ["the", 193], ["development", 197], ["of", 209], ["arthritis", 212], ["(", 222], ["Amsterdam", 223], ["Reade", 233], ["cohort", 239], [")", 245], [",", 246], ["and", 248], ["25", 252], ["presymptomatic", 255], ["individuals", 270], ["who", 282], ["developed", 286], ["rheumatoid", 296], ["arthritis", 307], ["(", 317], ["RA", 318], [")", 320], ["later", 322], [",", 327], ["and", 329], ["45", 333], ["population", 336], ["-", 346], ["based", 347], ["controls", 353], ["(", 362], ["Northern", 363], ["Sweden", 372], ["cohort", 379], [")", 385], [",", 386], ["the", 388], ["expression", 392], ["levels", 403], ["of", 410], ["7", 413], ["type", 415], ["I", 420], ["IFN", 422], ["response", 426], ["genes", 435], ["were", 441], ["determined", 446], ["with", 457], ["multiplex", 462], ["qPCR", 472], ["and", 477], ["an", 481], ["IFN", 484], ["-", 487], ["score", 488], ["was", 494], ["calculated", 498], [".", 508], ["The", 510], ["diagnostic", 514], ["performance", 525], ["of", 537], ["the", 540], ["IFN", 544], ["-", 547], ["score", 548], ["was", 554], ["evaluated", 558], ["using", 568], ["Cox", 574], ["regression", 578], ["and", 589], ["Receiver", 593], ["Operating", 602], ["Characteristics", 612], ["(", 628], ["ROC)-curve", 629], ["analysis", 640], [".", 648], ["In", 650], ["44", 653], ["of", 656], ["the", 659], ["115", 663], ["at", 667], ["-", 669], ["risk", 670], ["individuals", 675], ["(", 687], ["38", 688], ["%", 690], [")", 691], ["from", 693], ["the", 698], ["Amsterdam", 702], ["Reade", 712], ["cohort", 718], [",", 724], ["arthritis", 726], ["developed", 736], ["after", 746], ["a", 752], ["median", 754], ["period", 761], ["of", 768], ["8", 771], ["months", 773], ["(", 780], ["IQR", 781], ["5", 785], ["-", 786], ["13", 787], [")", 789], [".", 790], ["Stratification", 792], ["of", 807], ["these", 810], ["individuals", 816], ["based", 828], ["on", 834], ["the", 837], ["IFN", 841], ["-", 844], ["score", 845], ["revealed", 851], ["that", 860], ["15", 865], ["out", 868], ["of", 872], ["25", 875], ["IFN(high", 878], [")", 886], ["individuals", 888], ["converted", 900], ["to", 910], ["arthritis", 913], [",", 922], ["compared", 924], ["with", 933], ["29", 938], ["out", 941], ["of", 945], ["90", 948], ["IFN(low", 951], [")", 958], ["individuals", 960], ["(", 972], ["p=0.011", 973], [")", 980], [".", 981], ["In", 983], ["the", 986], ["Northern", 990], ["Sweden", 999], ["cohort", 1006], [",", 1012], ["the", 1014], ["level", 1018], ["of", 1024], ["the", 1027], ["IFN", 1031], ["-", 1034], ["score", 1035], ["was", 1041], ["also", 1045], ["significantly", 1050], ["increased", 1064], ["in", 1074], ["presymptomatic", 1077], ["individuals", 1092], ["who", 1104], ["developed", 1108], ["RA", 1118], ["compared", 1121], ["with", 1130], ["population", 1135], ["-", 1145], ["based", 1146], ["controls", 1152], ["(", 1161], ["p=0.002", 1162], [")", 1169], [".", 1170], ["Cox", 1172], ["regression", 1176], ["analysis", 1187], ["of", 1196], ["the", 1199], ["Amsterdam", 1203], ["Reade", 1213], ["cohort", 1219], ["showed", 1226], ["that", 1233], ["the", 1238], ["hazard", 1242], ["ratio", 1249], ["(", 1255], ["HR", 1256], [")", 1258], ["for", 1260], ["development", 1264], ["of", 1276], ["arthritis", 1279], ["was", 1289], ["2.38", 1293], ["(", 1298], ["p=0.008", 1299], [")", 1306], ["for", 1308], ["IFN(high", 1312], [")", 1320], ["at", 1322], ["-", 1324], ["risk", 1325], ["individuals", 1330], ["after", 1342], ["correction", 1348], ["for", 1359], ["anticitrullinated", 1363], ["protein", 1381], ["antibodies", 1389], ["(", 1400], ["ACPA", 1401], [")", 1405], ["and", 1407], ["rheumatoid", 1411], ["factor", 1422], ["(", 1429], ["RF", 1430], [")", 1432], [".", 1433], ["The", 1435], ["ROC", 1439], ["-", 1442], ["curve", 1443], ["area", 1449], ["under", 1454], ["the", 1460], ["curve", 1464], ["(", 1470], ["AUC", 1471], [")", 1474], ["for", 1476], ["the", 1480], ["IFN", 1484], ["-", 1487], ["score", 1488], ["combined", 1494], ["with", 1503], ["ACPA", 1508], ["and", 1513], ["RF", 1517], ["in", 1520], ["the", 1523], ["prediction", 1527], ["of", 1538], ["arthritis", 1541], ["was", 1551], ["78.5", 1555], ["%", 1559], ["(", 1561], ["p=0.0001", 1562], [",", 1570], ["95", 1572], ["%", 1574], ["CI", 1576], ["0.70", 1579], ["to", 1584], ["0.87", 1587], [")", 1591], [".", 1592], ["The", 1594], ["results", 1598], ["demonstrated", 1606], ["clinical", 1619], ["utility", 1628], ["for", 1636], ["the", 1640], ["IFN", 1644], ["-", 1647], ["signature", 1648], ["as", 1658], ["a", 1661], ["biomarker", 1663], ["in", 1673], ["the", 1676], ["prediction", 1680], ["of", 1691], ["arthritis", 1694], ["development", 1704], [".", 1715]]}
{"context": "Notch3 is a single pass transmembrane protein belonging to the Notch receptor family. Notch proteins are involved in a very conserved signaling system (Notch signaling) with a broad spectrum of functions, from cell proliferation and differentiation to apoptosis. Mutations in Notch3 gene are linked to cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a disorder characterized by stroke and dementia in young adults. Studies evaluating Notch3 expression in human differentiated cells and adult tissues have shown high Notch3 levels only in vascular smooth muscle cells (VSMC). However, it has been hypothesized that Notch3 is ubiquitously expressed in adult human tissues. Our aim was to evaluate Notch3 expression in human peripheral blood lymphocytes (PBLs) and fibroblasts from normal healthy subjects. In both cell types, we examined the expression of Notch3 by reverse transcriptase-polymerase chain reaction (RT-PCR) and quantitative real-time polymerase chain reaction (qRT-PCR). Moreover, we assessed Notch3 protein expression by Western blot analysis. RT-PCR and qRT-PCR analysis showed the presence of Notch3 mRNA in both cell types. Western blot analysis confirmed Notch3 protein expression in PBLs and fibroblasts though showing different profiles. Our data support the expression of Notch3 in adult human cell types, and suggests that PBLs and fibroblasts could provide readily available cells for the study of the role of Notch3 expression in the pathogenetic mechanisms leading to different human disease.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "966839ca942444edadde10ae73c038bf", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[45, 46]], "char_spans": [[276, 286]]}]}], "context_tokens": [["Notch3", 0], ["is", 7], ["a", 10], ["single", 12], ["pass", 19], ["transmembrane", 24], ["protein", 38], ["belonging", 46], ["to", 56], ["the", 59], ["Notch", 63], ["receptor", 69], ["family", 78], [".", 84], ["Notch", 86], ["proteins", 92], ["are", 101], ["involved", 105], ["in", 114], ["a", 117], ["very", 119], ["conserved", 124], ["signaling", 134], ["system", 144], ["(", 151], ["Notch", 152], ["signaling", 158], [")", 167], ["with", 169], ["a", 174], ["broad", 176], ["spectrum", 182], ["of", 191], ["functions", 194], [",", 203], ["from", 205], ["cell", 210], ["proliferation", 215], ["and", 229], ["differentiation", 233], ["to", 249], ["apoptosis", 252], [".", 261], ["Mutations", 263], ["in", 273], ["Notch3", 276], ["gene", 283], ["are", 288], ["linked", 292], ["to", 299], ["cerebral", 302], ["autosomal", 311], ["dominant", 321], ["arteriopathy", 330], ["with", 343], ["subcortical", 348], ["infarcts", 360], ["and", 369], ["leukoencephalopathy", 373], ["(", 393], ["CADASIL", 394], [")", 401], [",", 402], ["a", 404], ["disorder", 406], ["characterized", 415], ["by", 429], ["stroke", 432], ["and", 439], ["dementia", 443], ["in", 452], ["young", 455], ["adults", 461], [".", 467], ["Studies", 469], ["evaluating", 477], ["Notch3", 488], ["expression", 495], ["in", 506], ["human", 509], ["differentiated", 515], ["cells", 530], ["and", 536], ["adult", 540], ["tissues", 546], ["have", 554], ["shown", 559], ["high", 565], ["Notch3", 570], ["levels", 577], ["only", 584], ["in", 589], ["vascular", 592], ["smooth", 601], ["muscle", 608], ["cells", 615], ["(", 621], ["VSMC", 622], [")", 626], [".", 627], ["However", 629], [",", 636], ["it", 638], ["has", 641], ["been", 645], ["hypothesized", 650], ["that", 663], ["Notch3", 668], ["is", 675], ["ubiquitously", 678], ["expressed", 691], ["in", 701], ["adult", 704], ["human", 710], ["tissues", 716], [".", 723], ["Our", 725], ["aim", 729], ["was", 733], ["to", 737], ["evaluate", 740], ["Notch3", 749], ["expression", 756], ["in", 767], ["human", 770], ["peripheral", 776], ["blood", 787], ["lymphocytes", 793], ["(", 805], ["PBLs", 806], [")", 810], ["and", 812], ["fibroblasts", 816], ["from", 828], ["normal", 833], ["healthy", 840], ["subjects", 848], [".", 856], ["In", 858], ["both", 861], ["cell", 866], ["types", 871], [",", 876], ["we", 878], ["examined", 881], ["the", 890], ["expression", 894], ["of", 905], ["Notch3", 908], ["by", 915], ["reverse", 918], ["transcriptase", 926], ["-", 939], ["polymerase", 940], ["chain", 951], ["reaction", 957], ["(", 966], ["RT", 967], ["-", 969], ["PCR", 970], [")", 973], ["and", 975], ["quantitative", 979], ["real", 992], ["-", 996], ["time", 997], ["polymerase", 1002], ["chain", 1013], ["reaction", 1019], ["(", 1028], ["qRT", 1029], ["-", 1032], ["PCR", 1033], [")", 1036], [".", 1037], ["Moreover", 1039], [",", 1047], ["we", 1049], ["assessed", 1052], ["Notch3", 1061], ["protein", 1068], ["expression", 1076], ["by", 1087], ["Western", 1090], ["blot", 1098], ["analysis", 1103], [".", 1111], ["RT", 1113], ["-", 1115], ["PCR", 1116], ["and", 1120], ["qRT", 1124], ["-", 1127], ["PCR", 1128], ["analysis", 1132], ["showed", 1141], ["the", 1148], ["presence", 1152], ["of", 1161], ["Notch3", 1164], ["mRNA", 1171], ["in", 1176], ["both", 1179], ["cell", 1184], ["types", 1189], [".", 1194], ["Western", 1196], ["blot", 1204], ["analysis", 1209], ["confirmed", 1218], ["Notch3", 1228], ["protein", 1235], ["expression", 1243], ["in", 1254], ["PBLs", 1257], ["and", 1262], ["fibroblasts", 1266], ["though", 1278], ["showing", 1285], ["different", 1293], ["profiles", 1303], [".", 1311], ["Our", 1313], ["data", 1317], ["support", 1322], ["the", 1330], ["expression", 1334], ["of", 1345], ["Notch3", 1348], ["in", 1355], ["adult", 1358], ["human", 1364], ["cell", 1370], ["types", 1375], [",", 1380], ["and", 1382], ["suggests", 1386], ["that", 1395], ["PBLs", 1400], ["and", 1405], ["fibroblasts", 1409], ["could", 1421], ["provide", 1427], ["readily", 1435], ["available", 1443], ["cells", 1453], ["for", 1459], ["the", 1463], ["study", 1467], ["of", 1473], ["the", 1476], ["role", 1480], ["of", 1485], ["Notch3", 1488], ["expression", 1495], ["in", 1506], ["the", 1509], ["pathogenetic", 1513], ["mechanisms", 1526], ["leading", 1537], ["to", 1545], ["different", 1548], ["human", 1558], ["disease", 1564], [".", 1571]]}
{"context": "Despite numerous reports implicating NADPH oxidases (Nox) in the pathogenesis of many diseases, precise regulation of this family of professional reactive oxygen species (ROS) producers remains unclear. A unique member of this family, Nox1 oxidase, functions as either a canonical or hybrid system using Nox organizing subunit 1 (NoxO1) or p47(phox), respectively, the latter of which is functional in vascular smooth muscle cells (VSMC). In this manuscript, we identify critical requirement of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50; aka NHERF1) for Nox1 activation and downstream responses. Superoxide (O2 (\u2022-)) production induced by angiotensin II (AngII) was absent in mouse EBP50 KO VSMC vs. WT. Moreover, ex vivo incubation of aortas with AngII showed a significant increase in O2 (\u2022-) in WT but not EBP50 or Nox1 nulls. Similarly, lipopolysaccharide (LPS)-induced oxidative stress was attenuated in femoral arteries from EBP50 KO vs. WT. In silico analyses confirmed by confocal microscopy, immunoprecipitation, proximity ligation assay, FRET, and gain-/loss-of-function mutagenesis revealed binding of EBP50, via its PDZ domains, to a specific motif in p47(phox) Functional studies revealed AngII-induced hypertrophy was absent in EBP50 KOs, and in VSMC overexpressing EBP50, Nox1 gene silencing abolished VSMC hypertrophy. Finally, ex vivo measurement of lumen diameter in mouse resistance arteries exhibited attenuated AngII-induced vasoconstriction in EBP50 KO vs. WT. Taken together, our data identify EBP50 as a previously unidentified regulator of Nox1 and support that it promotes Nox1 activity by binding p47(phox) This interaction is pivotal for agonist-induced smooth muscle ROS, hypertrophy, and vasoconstriction and has implications for ROS-mediated physiological and pathophysiological processes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "3d080e8520c34ceca932d863f5e88a76", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[160, 160], [240, 240], [284, 284], [105, 105], [40, 40], [290, 290]], "char_spans": [[830, 833], [1299, 1302], [1577, 1580], [566, 569], [235, 238], [1611, 1614]]}]}], "context_tokens": [["Despite", 0], ["numerous", 8], ["reports", 17], ["implicating", 25], ["NADPH", 37], ["oxidases", 43], ["(", 52], ["Nox", 53], [")", 56], ["in", 58], ["the", 61], ["pathogenesis", 65], ["of", 78], ["many", 81], ["diseases", 86], [",", 94], ["precise", 96], ["regulation", 104], ["of", 115], ["this", 118], ["family", 123], ["of", 130], ["professional", 133], ["reactive", 146], ["oxygen", 155], ["species", 162], ["(", 170], ["ROS", 171], [")", 174], ["producers", 176], ["remains", 186], ["unclear", 194], [".", 201], ["A", 203], ["unique", 205], ["member", 212], ["of", 219], ["this", 222], ["family", 227], [",", 233], ["Nox1", 235], ["oxidase", 240], [",", 247], ["functions", 249], ["as", 259], ["either", 262], ["a", 269], ["canonical", 271], ["or", 281], ["hybrid", 284], ["system", 291], ["using", 298], ["Nox", 304], ["organizing", 308], ["subunit", 319], ["1", 327], ["(", 329], ["NoxO1", 330], [")", 335], ["or", 337], ["p47(phox", 340], [")", 348], [",", 349], ["respectively", 351], [",", 363], ["the", 365], ["latter", 369], ["of", 376], ["which", 379], ["is", 385], ["functional", 388], ["in", 399], ["vascular", 402], ["smooth", 411], ["muscle", 418], ["cells", 425], ["(", 431], ["VSMC", 432], [")", 436], [".", 437], ["In", 439], ["this", 442], ["manuscript", 447], [",", 457], ["we", 459], ["identify", 462], ["critical", 471], ["requirement", 480], ["of", 492], ["ezrin", 495], ["-", 500], ["radixin", 501], ["-", 508], ["moesin", 509], ["-", 515], ["binding", 516], ["phosphoprotein", 524], ["50", 539], ["(", 542], ["EBP50", 543], [";", 548], ["aka", 550], ["NHERF1", 554], [")", 560], ["for", 562], ["Nox1", 566], ["activation", 571], ["and", 582], ["downstream", 586], ["responses", 597], [".", 606], ["Superoxide", 608], ["(", 619], ["O2", 620], ["(", 623], ["\u2022-", 624], [")", 626], [")", 627], ["production", 629], ["induced", 640], ["by", 648], ["angiotensin", 651], ["II", 663], ["(", 666], ["AngII", 667], [")", 672], ["was", 674], ["absent", 678], ["in", 685], ["mouse", 688], ["EBP50", 694], ["KO", 700], ["VSMC", 703], ["vs.", 708], ["WT", 712], [".", 714], ["Moreover", 716], [",", 724], ["ex", 726], ["vivo", 729], ["incubation", 734], ["of", 745], ["aortas", 748], ["with", 755], ["AngII", 760], ["showed", 766], ["a", 773], ["significant", 775], ["increase", 787], ["in", 796], ["O2", 799], ["(", 802], ["\u2022-", 803], [")", 805], ["in", 807], ["WT", 810], ["but", 813], ["not", 817], ["EBP50", 821], ["or", 827], ["Nox1", 830], ["nulls", 835], [".", 840], ["Similarly", 842], [",", 851], ["lipopolysaccharide", 853], ["(", 872], ["LPS)-induced", 873], ["oxidative", 886], ["stress", 896], ["was", 903], ["attenuated", 907], ["in", 918], ["femoral", 921], ["arteries", 929], ["from", 938], ["EBP50", 943], ["KO", 949], ["vs.", 952], ["WT", 956], [".", 958], ["In", 960], ["silico", 963], ["analyses", 970], ["confirmed", 979], ["by", 989], ["confocal", 992], ["microscopy", 1001], [",", 1011], ["immunoprecipitation", 1013], [",", 1032], ["proximity", 1034], ["ligation", 1044], ["assay", 1053], [",", 1058], ["FRET", 1060], [",", 1064], ["and", 1066], ["gain-/loss", 1070], ["-", 1080], ["of", 1081], ["-", 1083], ["function", 1084], ["mutagenesis", 1093], ["revealed", 1105], ["binding", 1114], ["of", 1122], ["EBP50", 1125], [",", 1130], ["via", 1132], ["its", 1136], ["PDZ", 1140], ["domains", 1144], [",", 1151], ["to", 1153], ["a", 1156], ["specific", 1158], ["motif", 1167], ["in", 1173], ["p47(phox", 1176], [")", 1184], ["Functional", 1186], ["studies", 1197], ["revealed", 1205], ["AngII", 1214], ["-", 1219], ["induced", 1220], ["hypertrophy", 1228], ["was", 1240], ["absent", 1244], ["in", 1251], ["EBP50", 1254], ["KOs", 1260], [",", 1263], ["and", 1265], ["in", 1269], ["VSMC", 1272], ["overexpressing", 1277], ["EBP50", 1292], [",", 1297], ["Nox1", 1299], ["gene", 1304], ["silencing", 1309], ["abolished", 1319], ["VSMC", 1329], ["hypertrophy", 1334], [".", 1345], ["Finally", 1347], [",", 1354], ["ex", 1356], ["vivo", 1359], ["measurement", 1364], ["of", 1376], ["lumen", 1379], ["diameter", 1385], ["in", 1394], ["mouse", 1397], ["resistance", 1403], ["arteries", 1414], ["exhibited", 1423], ["attenuated", 1433], ["AngII", 1444], ["-", 1449], ["induced", 1450], ["vasoconstriction", 1458], ["in", 1475], ["EBP50", 1478], ["KO", 1484], ["vs.", 1487], ["WT", 1491], [".", 1493], ["Taken", 1495], ["together", 1501], [",", 1509], ["our", 1511], ["data", 1515], ["identify", 1520], ["EBP50", 1529], ["as", 1535], ["a", 1538], ["previously", 1540], ["unidentified", 1551], ["regulator", 1564], ["of", 1574], ["Nox1", 1577], ["and", 1582], ["support", 1586], ["that", 1594], ["it", 1599], ["promotes", 1602], ["Nox1", 1611], ["activity", 1616], ["by", 1625], ["binding", 1628], ["p47(phox", 1636], [")", 1644], ["This", 1646], ["interaction", 1651], ["is", 1663], ["pivotal", 1666], ["for", 1674], ["agonist", 1678], ["-", 1685], ["induced", 1686], ["smooth", 1694], ["muscle", 1701], ["ROS", 1708], [",", 1711], ["hypertrophy", 1713], [",", 1724], ["and", 1726], ["vasoconstriction", 1730], ["and", 1747], ["has", 1751], ["implications", 1755], ["for", 1768], ["ROS", 1772], ["-", 1775], ["mediated", 1776], ["physiological", 1785], ["and", 1799], ["pathophysiological", 1803], ["processes", 1822], [".", 1831]]}
{"context": "The Sotos syndrome gene product, NSD1, is a SET domain histone methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36 (H3K36). To date, the intrinsic properties of NSD1 that determine its nucleosomal substrate selectivity and dimethyl H3K36 product specificity remain unknown. The 1.7 \u00c5 structure of the catalytic domain of NSD1 presented here shows that a regulatory loop adopts a conformation that prevents free access of H3K36 to the bound S-adenosyl-L-methionine. Molecular dynamics simulation and computational docking revealed that this normally inhibitory loop can adopt an active conformation, allowing H3K36 access to the active site, and that the nucleosome may stabilize the active conformation of the regulatory loop. Hence, our study reveals an autoregulatory mechanism of NSD1 and provides insight into the molecular mechanism of the nucleosomal substrate selectivity of this disease-related H3K36 methyltransferase.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d8dc6dcb02604df98e1a216e74a229fa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[10, 11]], "char_spans": [[44, 53]]}]}], "context_tokens": [["The", 0], ["Sotos", 4], ["syndrome", 10], ["gene", 19], ["product", 24], [",", 31], ["NSD1", 33], [",", 37], ["is", 39], ["a", 42], ["SET", 44], ["domain", 48], ["histone", 55], ["methyltransferase", 63], ["that", 81], ["primarily", 86], ["dimethylates", 96], ["nucleosomal", 109], ["histone", 121], ["H3", 129], ["lysine", 132], ["36", 139], ["(", 142], ["H3K36", 143], [")", 148], [".", 149], ["To", 151], ["date", 154], [",", 158], ["the", 160], ["intrinsic", 164], ["properties", 174], ["of", 185], ["NSD1", 188], ["that", 193], ["determine", 198], ["its", 208], ["nucleosomal", 212], ["substrate", 224], ["selectivity", 234], ["and", 246], ["dimethyl", 250], ["H3K36", 259], ["product", 265], ["specificity", 273], ["remain", 285], ["unknown", 292], [".", 299], ["The", 301], ["1.7", 305], ["\u00c5", 309], ["structure", 311], ["of", 321], ["the", 324], ["catalytic", 328], ["domain", 338], ["of", 345], ["NSD1", 348], ["presented", 353], ["here", 363], ["shows", 368], ["that", 374], ["a", 379], ["regulatory", 381], ["loop", 392], ["adopts", 397], ["a", 404], ["conformation", 406], ["that", 419], ["prevents", 424], ["free", 433], ["access", 438], ["of", 445], ["H3K36", 448], ["to", 454], ["the", 457], ["bound", 461], ["S", 467], ["-", 468], ["adenosyl", 469], ["-", 477], ["L", 478], ["-", 479], ["methionine", 480], [".", 490], ["Molecular", 492], ["dynamics", 502], ["simulation", 511], ["and", 522], ["computational", 526], ["docking", 540], ["revealed", 548], ["that", 557], ["this", 562], ["normally", 567], ["inhibitory", 576], ["loop", 587], ["can", 592], ["adopt", 596], ["an", 602], ["active", 605], ["conformation", 612], [",", 624], ["allowing", 626], ["H3K36", 635], ["access", 641], ["to", 648], ["the", 651], ["active", 655], ["site", 662], [",", 666], ["and", 668], ["that", 672], ["the", 677], ["nucleosome", 681], ["may", 692], ["stabilize", 696], ["the", 706], ["active", 710], ["conformation", 717], ["of", 730], ["the", 733], ["regulatory", 737], ["loop", 748], [".", 752], ["Hence", 754], [",", 759], ["our", 761], ["study", 765], ["reveals", 771], ["an", 779], ["autoregulatory", 782], ["mechanism", 797], ["of", 807], ["NSD1", 810], ["and", 815], ["provides", 819], ["insight", 828], ["into", 836], ["the", 841], ["molecular", 845], ["mechanism", 855], ["of", 865], ["the", 868], ["nucleosomal", 872], ["substrate", 884], ["selectivity", 894], ["of", 906], ["this", 909], ["disease", 914], ["-", 921], ["related", 922], ["H3K36", 930], ["methyltransferase", 936], [".", 953]]}
{"context": "Stress-induced mutagenesis describes the accumulation of mutations that occur in nongrowing cells, in contrast to mutagenesis that occurs in actively dividing populations, and has been referred to as stationary-phase or adaptive mutagenesis. The most widely studied system for stress-induced mutagenesis involves monitoring the appearance of Lac(+) revertants of the strain FC40 under starvation conditions in Escherichia coli. The SOS-inducible translesion DNA polymerase DinB plays an important role in this phenomenon. Loss of DinB (DNA pol IV) function results in a severe reduction of Lac(+) revertants. We previously reported that NusA, an essential component of elongating RNA polymerases, interacts with DinB. Here we report our unexpected observation that wild-type NusA function is required for stress-induced mutagenesis. We present evidence that this effect is unlikely to be due to defects in transcription of lac genes but rather is due to an inability to adapt and mutate in response to environmental stress. Furthermore, we extended our analysis to the formation of stress-induced mutants in response to antibiotic treatment, observing the same striking abolition of mutagenesis under entirely different conditions. Our results are the first to implicate NusA as a crucial participant in the phenomenon of stress-induced mutagenesis.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "1daf44d1e59d499da16d3746bd6277c2", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[32, 34]], "char_spans": [[200, 215]]}]}], "context_tokens": [["Stress", 0], ["-", 6], ["induced", 7], ["mutagenesis", 15], ["describes", 27], ["the", 37], ["accumulation", 41], ["of", 54], ["mutations", 57], ["that", 67], ["occur", 72], ["in", 78], ["nongrowing", 81], ["cells", 92], [",", 97], ["in", 99], ["contrast", 102], ["to", 111], ["mutagenesis", 114], ["that", 126], ["occurs", 131], ["in", 138], ["actively", 141], ["dividing", 150], ["populations", 159], [",", 170], ["and", 172], ["has", 176], ["been", 180], ["referred", 185], ["to", 194], ["as", 197], ["stationary", 200], ["-", 210], ["phase", 211], ["or", 217], ["adaptive", 220], ["mutagenesis", 229], [".", 240], ["The", 242], ["most", 246], ["widely", 251], ["studied", 258], ["system", 266], ["for", 273], ["stress", 277], ["-", 283], ["induced", 284], ["mutagenesis", 292], ["involves", 304], ["monitoring", 313], ["the", 324], ["appearance", 328], ["of", 339], ["Lac(+", 342], [")", 347], ["revertants", 349], ["of", 360], ["the", 363], ["strain", 367], ["FC40", 374], ["under", 379], ["starvation", 385], ["conditions", 396], ["in", 407], ["Escherichia", 410], ["coli", 422], [".", 426], ["The", 428], ["SOS", 432], ["-", 435], ["inducible", 436], ["translesion", 446], ["DNA", 458], ["polymerase", 462], ["DinB", 473], ["plays", 478], ["an", 484], ["important", 487], ["role", 497], ["in", 502], ["this", 505], ["phenomenon", 510], [".", 520], ["Loss", 522], ["of", 527], ["DinB", 530], ["(", 535], ["DNA", 536], ["pol", 540], ["IV", 544], [")", 546], ["function", 548], ["results", 557], ["in", 565], ["a", 568], ["severe", 570], ["reduction", 577], ["of", 587], ["Lac(+", 590], [")", 595], ["revertants", 597], [".", 607], ["We", 609], ["previously", 612], ["reported", 623], ["that", 632], ["NusA", 637], [",", 641], ["an", 643], ["essential", 646], ["component", 656], ["of", 666], ["elongating", 669], ["RNA", 680], ["polymerases", 684], [",", 695], ["interacts", 697], ["with", 707], ["DinB.", 712], ["Here", 718], ["we", 723], ["report", 726], ["our", 733], ["unexpected", 737], ["observation", 748], ["that", 760], ["wild", 765], ["-", 769], ["type", 770], ["NusA", 775], ["function", 780], ["is", 789], ["required", 792], ["for", 801], ["stress", 805], ["-", 811], ["induced", 812], ["mutagenesis", 820], [".", 831], ["We", 833], ["present", 836], ["evidence", 844], ["that", 853], ["this", 858], ["effect", 863], ["is", 870], ["unlikely", 873], ["to", 882], ["be", 885], ["due", 888], ["to", 892], ["defects", 895], ["in", 903], ["transcription", 906], ["of", 920], ["lac", 923], ["genes", 927], ["but", 933], ["rather", 937], ["is", 944], ["due", 947], ["to", 951], ["an", 954], ["inability", 957], ["to", 967], ["adapt", 970], ["and", 976], ["mutate", 980], ["in", 987], ["response", 990], ["to", 999], ["environmental", 1002], ["stress", 1016], [".", 1022], ["Furthermore", 1024], [",", 1035], ["we", 1037], ["extended", 1040], ["our", 1049], ["analysis", 1053], ["to", 1062], ["the", 1065], ["formation", 1069], ["of", 1079], ["stress", 1082], ["-", 1088], ["induced", 1089], ["mutants", 1097], ["in", 1105], ["response", 1108], ["to", 1117], ["antibiotic", 1120], ["treatment", 1131], [",", 1140], ["observing", 1142], ["the", 1152], ["same", 1156], ["striking", 1161], ["abolition", 1170], ["of", 1180], ["mutagenesis", 1183], ["under", 1195], ["entirely", 1201], ["different", 1210], ["conditions", 1220], [".", 1230], ["Our", 1232], ["results", 1236], ["are", 1244], ["the", 1248], ["first", 1252], ["to", 1258], ["implicate", 1261], ["NusA", 1271], ["as", 1276], ["a", 1279], ["crucial", 1281], ["participant", 1289], ["in", 1301], ["the", 1304], ["phenomenon", 1308], ["of", 1319], ["stress", 1322], ["-", 1328], ["induced", 1329], ["mutagenesis", 1337], [".", 1348]]}
{"context": "Probe-to-bone test and simple X-rays are both standard tests for the diagnosis of diabetic foot osteomyelitis. This study demonstrates the importance of considering jointly clinical information (probe-to-bone test) and diagnostic tests (simple radiography) to increase agreement among clinicians on diagnosis of diabetic foot osteomyelitis.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "117440db7a2441f29ff04ebe978b490f", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[56, 58], [19, 21]], "char_spans": [[312, 338], [82, 108]]}]}], "context_tokens": [["Probe", 0], ["-", 5], ["to", 6], ["-", 8], ["bone", 9], ["test", 14], ["and", 19], ["simple", 23], ["X", 30], ["-", 31], ["rays", 32], ["are", 37], ["both", 41], ["standard", 46], ["tests", 55], ["for", 61], ["the", 65], ["diagnosis", 69], ["of", 79], ["diabetic", 82], ["foot", 91], ["osteomyelitis", 96], [".", 109], ["This", 111], ["study", 116], ["demonstrates", 122], ["the", 135], ["importance", 139], ["of", 150], ["considering", 153], ["jointly", 165], ["clinical", 173], ["information", 182], ["(", 194], ["probe", 195], ["-", 200], ["to", 201], ["-", 203], ["bone", 204], ["test", 209], [")", 213], ["and", 215], ["diagnostic", 219], ["tests", 230], ["(", 236], ["simple", 237], ["radiography", 244], [")", 255], ["to", 257], ["increase", 260], ["agreement", 269], ["among", 279], ["clinicians", 285], ["on", 296], ["diagnosis", 299], ["of", 309], ["diabetic", 312], ["foot", 321], ["osteomyelitis", 326], [".", 339]]}
{"context": "Ca2+ is a ubiquitous intracellular messenger responsible for controlling numerous cellular processes including fertilization, mitosis, neuronal transmission, contraction and relaxation of muscles, gene transcription, and cell death. At rest, the cytoplasmic Ca2+ concentration [Ca2+]i is approximately 100 nM, but this level rises to 500-1,000 nM upon activation. In osteoblasts, the elevation of [Ca2+]i is a result of an increase in the release of Ca2+ from endoplasmic reticulum and/or extracellular Ca2+ influx through voltage gated Ca2+ channels. Many of the cellular effects of Ca2+ are mediated by the Ca2+ binding protein, calmodulin (CaM). Upon binding up to four calcium ions, CaM undergoes a conformational change, which enables it to bind to specific proteins eliciting a specific response. Calmodulin kinase II (CaMKII) is a major target of the Ca(2+)/CaM second messenger system. Once bound to Ca(2+)/CaM, the multimeric CaMKII is released from its autoinhibitory status and maximally activated, which then leads to an intraholoenzyme autophosphorylation reaction. Calcineurin (Cn) is another major target protein that is activated by Ca(2+)/CaM. Cn is a serine-threonine phosphatase that consists of a heterodimeric protein complex composed of a catalytic subunit (CnA) and a regulatory subunit (CnB). Upon activation, Cn directly binds to, and dephosphorylates nuclear factor of activated T cells (NFAT) transcription factors within the cytoplasm allowing them to translocate to the nucleus and participate in the regulation of gene expression. This review will examine the potential mechanisms by which calcium, CaM, CaMKII, and Cn/NFAT control osteoblast proliferation and differentiation.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "4739d60b47ce43b3a2834c15aa922cab", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[189, 189]], "char_spans": [[1079, 1089]]}]}], "context_tokens": [["Ca2", 0], ["+", 3], ["is", 5], ["a", 8], ["ubiquitous", 10], ["intracellular", 21], ["messenger", 35], ["responsible", 45], ["for", 57], ["controlling", 61], ["numerous", 73], ["cellular", 82], ["processes", 91], ["including", 101], ["fertilization", 111], [",", 124], ["mitosis", 126], [",", 133], ["neuronal", 135], ["transmission", 144], [",", 156], ["contraction", 158], ["and", 170], ["relaxation", 174], ["of", 185], ["muscles", 188], [",", 195], ["gene", 197], ["transcription", 202], [",", 215], ["and", 217], ["cell", 221], ["death", 226], [".", 231], ["At", 233], ["rest", 236], [",", 240], ["the", 242], ["cytoplasmic", 246], ["Ca2", 258], ["+", 261], ["concentration", 263], ["[", 277], ["Ca2+]i", 278], ["is", 285], ["approximately", 288], ["100", 302], ["nM", 306], [",", 308], ["but", 310], ["this", 314], ["level", 319], ["rises", 325], ["to", 331], ["500", 334], ["-", 337], ["1,000", 338], ["nM", 344], ["upon", 347], ["activation", 352], [".", 362], ["In", 364], ["osteoblasts", 367], [",", 378], ["the", 380], ["elevation", 384], ["of", 394], ["[", 397], ["Ca2+]i", 398], ["is", 405], ["a", 408], ["result", 410], ["of", 417], ["an", 420], ["increase", 423], ["in", 432], ["the", 435], ["release", 439], ["of", 447], ["Ca2", 450], ["+", 453], ["from", 455], ["endoplasmic", 460], ["reticulum", 472], ["and/or", 482], ["extracellular", 489], ["Ca2", 503], ["+", 506], ["influx", 508], ["through", 515], ["voltage", 523], ["gated", 531], ["Ca2", 537], ["+", 540], ["channels", 542], [".", 550], ["Many", 552], ["of", 557], ["the", 560], ["cellular", 564], ["effects", 573], ["of", 581], ["Ca2", 584], ["+", 587], ["are", 589], ["mediated", 593], ["by", 602], ["the", 605], ["Ca2", 609], ["+", 612], ["binding", 614], ["protein", 622], [",", 629], ["calmodulin", 631], ["(", 642], ["CaM", 643], [")", 646], [".", 647], ["Upon", 649], ["binding", 654], ["up", 662], ["to", 665], ["four", 668], ["calcium", 673], ["ions", 681], [",", 685], ["CaM", 687], ["undergoes", 691], ["a", 701], ["conformational", 703], ["change", 718], [",", 724], ["which", 726], ["enables", 732], ["it", 740], ["to", 743], ["bind", 746], ["to", 751], ["specific", 754], ["proteins", 763], ["eliciting", 772], ["a", 782], ["specific", 784], ["response", 793], [".", 801], ["Calmodulin", 803], ["kinase", 814], ["II", 821], ["(", 824], ["CaMKII", 825], [")", 831], ["is", 833], ["a", 836], ["major", 838], ["target", 844], ["of", 851], ["the", 854], ["Ca(2+)/CaM", 858], ["second", 869], ["messenger", 876], ["system", 886], [".", 892], ["Once", 894], ["bound", 899], ["to", 905], ["Ca(2+)/CaM", 908], [",", 918], ["the", 920], ["multimeric", 924], ["CaMKII", 935], ["is", 942], ["released", 945], ["from", 954], ["its", 959], ["autoinhibitory", 963], ["status", 978], ["and", 985], ["maximally", 989], ["activated", 999], [",", 1008], ["which", 1010], ["then", 1016], ["leads", 1021], ["to", 1027], ["an", 1030], ["intraholoenzyme", 1033], ["autophosphorylation", 1049], ["reaction", 1069], [".", 1077], ["Calcineurin", 1079], ["(", 1091], ["Cn", 1092], [")", 1094], ["is", 1096], ["another", 1099], ["major", 1107], ["target", 1113], ["protein", 1120], ["that", 1128], ["is", 1133], ["activated", 1136], ["by", 1146], ["Ca(2+)/CaM.", 1149], ["Cn", 1161], ["is", 1164], ["a", 1167], ["serine", 1169], ["-", 1175], ["threonine", 1176], ["phosphatase", 1186], ["that", 1198], ["consists", 1203], ["of", 1212], ["a", 1215], ["heterodimeric", 1217], ["protein", 1231], ["complex", 1239], ["composed", 1247], ["of", 1256], ["a", 1259], ["catalytic", 1261], ["subunit", 1271], ["(", 1279], ["CnA", 1280], [")", 1283], ["and", 1285], ["a", 1289], ["regulatory", 1291], ["subunit", 1302], ["(", 1310], ["CnB", 1311], [")", 1314], [".", 1315], ["Upon", 1317], ["activation", 1322], [",", 1332], ["Cn", 1334], ["directly", 1337], ["binds", 1346], ["to", 1352], [",", 1354], ["and", 1356], ["dephosphorylates", 1360], ["nuclear", 1377], ["factor", 1385], ["of", 1392], ["activated", 1395], ["T", 1405], ["cells", 1407], ["(", 1413], ["NFAT", 1414], [")", 1418], ["transcription", 1420], ["factors", 1434], ["within", 1442], ["the", 1449], ["cytoplasm", 1453], ["allowing", 1463], ["them", 1472], ["to", 1477], ["translocate", 1480], ["to", 1492], ["the", 1495], ["nucleus", 1499], ["and", 1507], ["participate", 1511], ["in", 1523], ["the", 1526], ["regulation", 1530], ["of", 1541], ["gene", 1544], ["expression", 1549], [".", 1559], ["This", 1561], ["review", 1566], ["will", 1573], ["examine", 1578], ["the", 1586], ["potential", 1590], ["mechanisms", 1600], ["by", 1611], ["which", 1614], ["calcium", 1620], [",", 1627], ["CaM", 1629], [",", 1632], ["CaMKII", 1634], [",", 1640], ["and", 1642], ["Cn", 1646], ["/", 1648], ["NFAT", 1649], ["control", 1654], ["osteoblast", 1662], ["proliferation", 1673], ["and", 1687], ["differentiation", 1691], [".", 1706]]}
{"context": "Transcription of the major Bacillus anthracis virulence genes is triggered by CO2, a signal mimicking the host environment. A 182-kb plasmid, pXO1, carries the anthrax toxin genes and the genes responsible for their regulation of transcription, namely atxA and, pagR, the second gene of the pag operon. AtxA has major effects on the physiology of B. anthracis. It coordinates the transcription activation of the toxin genes with that of the capsule biosynthetic enzyme operon, located on the second virulence plasmid, pXO2. In rich medium, B. anthracis synthesises alternatively two S-layer proteins (Sap and EA1). An exponential phase \"Sap-layer\" is subsequently replaced by a stationary phase \"EA1-layer\". S-layer gene transcription is controlled by alternative sigma factors and by Sap acting as a transcriptional repressor of eag. Furthermore, in vitro in presence of CO2 and in vivo, AtxA is part of the sap and eag regulatory network. Only eag is significantly expressed in these conditions and this is due to AtxA activating eag and repressing sap transcription. PagR, and not AtxA itself, is the direct effector of this regulation by binding to sap and eag promoter regions. Therefore, PagR mediates the effect of AtxA on eag and sap and is the most downstream element of a signalling cascade initiated by AtxA. Taken together, these results indicate that the B. anthracis transcriptional regulator AtxA is controlling the synthesis of the three toxin components and of the surface elements (capsule and S-layer). Thus, AtxA is a master regulator that coordinates the response to host signals by orchestrating positive and negative controls over genes located on all genetic elements.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "877eabc12fb54287bc30ec4db7f37e8a", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[160, 160], [11, 11]], "char_spans": [[872, 874], [78, 80]]}]}], "context_tokens": [["Transcription", 0], ["of", 14], ["the", 17], ["major", 21], ["Bacillus", 27], ["anthracis", 36], ["virulence", 46], ["genes", 56], ["is", 62], ["triggered", 65], ["by", 75], ["CO2", 78], [",", 81], ["a", 83], ["signal", 85], ["mimicking", 92], ["the", 102], ["host", 106], ["environment", 111], [".", 122], ["A", 124], ["182-kb", 126], ["plasmid", 133], [",", 140], ["pXO1", 142], [",", 146], ["carries", 148], ["the", 156], ["anthrax", 160], ["toxin", 168], ["genes", 174], ["and", 180], ["the", 184], ["genes", 188], ["responsible", 194], ["for", 206], ["their", 210], ["regulation", 216], ["of", 227], ["transcription", 230], [",", 243], ["namely", 245], ["atxA", 252], ["and", 257], [",", 260], ["pagR", 262], [",", 266], ["the", 268], ["second", 272], ["gene", 279], ["of", 284], ["the", 287], ["pag", 291], ["operon", 295], [".", 301], ["AtxA", 303], ["has", 308], ["major", 312], ["effects", 318], ["on", 326], ["the", 329], ["physiology", 333], ["of", 344], ["B.", 347], ["anthracis", 350], [".", 359], ["It", 361], ["coordinates", 364], ["the", 376], ["transcription", 380], ["activation", 394], ["of", 405], ["the", 408], ["toxin", 412], ["genes", 418], ["with", 424], ["that", 429], ["of", 434], ["the", 437], ["capsule", 441], ["biosynthetic", 449], ["enzyme", 462], ["operon", 469], [",", 475], ["located", 477], ["on", 485], ["the", 488], ["second", 492], ["virulence", 499], ["plasmid", 509], [",", 516], ["pXO2", 518], [".", 522], ["In", 524], ["rich", 527], ["medium", 532], [",", 538], ["B.", 540], ["anthracis", 543], ["synthesises", 553], ["alternatively", 565], ["two", 579], ["S", 583], ["-", 584], ["layer", 585], ["proteins", 591], ["(", 600], ["Sap", 601], ["and", 605], ["EA1", 609], [")", 612], [".", 613], ["An", 615], ["exponential", 618], ["phase", 630], ["\"", 636], ["Sap", 637], ["-", 640], ["layer", 641], ["\"", 646], ["is", 648], ["subsequently", 651], ["replaced", 664], ["by", 673], ["a", 676], ["stationary", 678], ["phase", 689], ["\"", 695], ["EA1-layer", 696], ["\"", 705], [".", 706], ["S", 708], ["-", 709], ["layer", 710], ["gene", 716], ["transcription", 721], ["is", 735], ["controlled", 738], ["by", 749], ["alternative", 752], ["sigma", 764], ["factors", 770], ["and", 778], ["by", 782], ["Sap", 785], ["acting", 789], ["as", 796], ["a", 799], ["transcriptional", 801], ["repressor", 817], ["of", 827], ["eag", 830], [".", 833], ["Furthermore", 835], [",", 846], ["in", 848], ["vitro", 851], ["in", 857], ["presence", 860], ["of", 869], ["CO2", 872], ["and", 876], ["in", 880], ["vivo", 883], [",", 887], ["AtxA", 889], ["is", 894], ["part", 897], ["of", 902], ["the", 905], ["sap", 909], ["and", 913], ["eag", 917], ["regulatory", 921], ["network", 932], [".", 939], ["Only", 941], ["eag", 946], ["is", 950], ["significantly", 953], ["expressed", 967], ["in", 977], ["these", 980], ["conditions", 986], ["and", 997], ["this", 1001], ["is", 1006], ["due", 1009], ["to", 1013], ["AtxA", 1016], ["activating", 1021], ["eag", 1032], ["and", 1036], ["repressing", 1040], ["sap", 1051], ["transcription", 1055], [".", 1068], ["PagR", 1070], [",", 1074], ["and", 1076], ["not", 1080], ["AtxA", 1084], ["itself", 1089], [",", 1095], ["is", 1097], ["the", 1100], ["direct", 1104], ["effector", 1111], ["of", 1120], ["this", 1123], ["regulation", 1128], ["by", 1139], ["binding", 1142], ["to", 1150], ["sap", 1153], ["and", 1157], ["eag", 1161], ["promoter", 1165], ["regions", 1174], [".", 1181], ["Therefore", 1183], [",", 1192], ["PagR", 1194], ["mediates", 1199], ["the", 1208], ["effect", 1212], ["of", 1219], ["AtxA", 1222], ["on", 1227], ["eag", 1230], ["and", 1234], ["sap", 1238], ["and", 1242], ["is", 1246], ["the", 1249], ["most", 1253], ["downstream", 1258], ["element", 1269], ["of", 1277], ["a", 1280], ["signalling", 1282], ["cascade", 1293], ["initiated", 1301], ["by", 1311], ["AtxA.", 1314], ["Taken", 1320], ["together", 1326], [",", 1334], ["these", 1336], ["results", 1342], ["indicate", 1350], ["that", 1359], ["the", 1364], ["B.", 1368], ["anthracis", 1371], ["transcriptional", 1381], ["regulator", 1397], ["AtxA", 1407], ["is", 1412], ["controlling", 1415], ["the", 1427], ["synthesis", 1431], ["of", 1441], ["the", 1444], ["three", 1448], ["toxin", 1454], ["components", 1460], ["and", 1471], ["of", 1475], ["the", 1478], ["surface", 1482], ["elements", 1490], ["(", 1499], ["capsule", 1500], ["and", 1508], ["S", 1512], ["-", 1513], ["layer", 1514], [")", 1519], [".", 1520], ["Thus", 1522], [",", 1526], ["AtxA", 1528], ["is", 1533], ["a", 1536], ["master", 1538], ["regulator", 1545], ["that", 1555], ["coordinates", 1560], ["the", 1572], ["response", 1576], ["to", 1585], ["host", 1588], ["signals", 1593], ["by", 1601], ["orchestrating", 1604], ["positive", 1618], ["and", 1627], ["negative", 1631], ["controls", 1640], ["over", 1649], ["genes", 1654], ["located", 1660], ["on", 1668], ["all", 1671], ["genetic", 1675], ["elements", 1683], [".", 1691]]}
{"context": "The precursor of the non-Abeta component of Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein) is a presynaptic terminal molecule that abnormally accumulates in the plaques of Alzheimer's disease (AD) and in the Lewy bodies (LBs) of Lewy body variant of AD, diffuse Lewy body disease, and Parkinson's disease. To better understand the distribution of NACP/alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify the patterns of NACP/alpha-synuclein compartmentalization, we studied NACP/alpha-synuclein immunoreactivity using antibodies against the C-terminal, N-terminal, and NAC regions after Proteinase K and formic acid treatment in the cortex of patients with LBs. Furthermore, studies of the subcellular localization of NACP/alpha-synuclein within LB-bearing neurons were performed by immunogold electron microscopy. These studies showed that the N-terminal antibody immunolabeled the LBs and dystrophic neurites with great intensity and, to a lesser extent, the synapses. In contrast, the C-terminal antibody strongly labeled the synapses and, to a lesser extent, the LBs and dystrophic neurites. Whereas Proteinase K treatment enhanced NACP/alpha-synuclein immunoreactivity with the C-terminal antibody, it diminished the N-terminal NACP/alpha-synuclein immunoreactivity. Furthermore, formic acid enhanced LB and dystrophic neurite labeling with both the C- and N-terminal antibodies. In addition, whereas without pretreatment only slight anti-NAC immunoreactivity was found in the LBs, formic acid pretreatment revealed an extensive anti-NAC immunostaining of LBs, plaques, and glial cells. Ultrastructural analysis revealed that NACP/alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as small clusters in the filaments of LBs and neurites. These results support the view that aggregated NACP/alpha-synuclein might play an important role in the pathogenesis of disorders associated with LBs.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "d3600ecb55744469b54fde10d8d1c38e", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[247, 249], [100, 102], [20, 22], [228, 230], [109, 111], [153, 155], [351, 353], [315, 317], [75, 77]], "char_spans": [[1302, 1316], [489, 503], [94, 108], [1205, 1219], [543, 557], [787, 801], [1925, 1939], [1700, 1714], [372, 386]]}]}], "context_tokens": [["The", 0], ["precursor", 4], ["of", 14], ["the", 17], ["non", 21], ["-", 24], ["Abeta", 25], ["component", 31], ["of", 41], ["Alzheimer", 44], ["'s", 53], ["disease", 56], ["amyloid", 64], ["(", 72], ["NACP", 73], [")", 77], ["(", 79], ["also", 80], ["known", 85], ["as", 91], ["alpha", 94], ["-", 99], ["synuclein", 100], [")", 109], ["is", 111], ["a", 114], ["presynaptic", 116], ["terminal", 128], ["molecule", 137], ["that", 146], ["abnormally", 151], ["accumulates", 162], ["in", 174], ["the", 177], ["plaques", 181], ["of", 189], ["Alzheimer", 192], ["'s", 201], ["disease", 204], ["(", 212], ["AD", 213], [")", 215], ["and", 217], ["in", 221], ["the", 224], ["Lewy", 228], ["bodies", 233], ["(", 240], ["LBs", 241], [")", 244], ["of", 246], ["Lewy", 249], ["body", 254], ["variant", 259], ["of", 267], ["AD", 270], [",", 272], ["diffuse", 274], ["Lewy", 282], ["body", 287], ["disease", 292], [",", 299], ["and", 301], ["Parkinson", 305], ["'s", 314], ["disease", 317], [".", 324], ["To", 326], ["better", 329], ["understand", 336], ["the", 347], ["distribution", 351], ["of", 364], ["NACP", 367], ["/", 371], ["alpha", 372], ["-", 377], ["synuclein", 378], ["and", 388], ["its", 392], ["fragments", 396], ["in", 406], ["the", 409], ["LB", 413], ["-", 415], ["bearing", 416], ["neurons", 424], ["and", 432], ["neurites", 436], [",", 444], ["as", 446], ["well", 449], ["as", 454], ["to", 457], ["clarify", 460], ["the", 468], ["patterns", 472], ["of", 481], ["NACP", 484], ["/", 488], ["alpha", 489], ["-", 494], ["synuclein", 495], ["compartmentalization", 505], [",", 525], ["we", 527], ["studied", 530], ["NACP", 538], ["/", 542], ["alpha", 543], ["-", 548], ["synuclein", 549], ["immunoreactivity", 559], ["using", 576], ["antibodies", 582], ["against", 593], ["the", 601], ["C", 605], ["-", 606], ["terminal", 607], [",", 615], ["N", 617], ["-", 618], ["terminal", 619], [",", 627], ["and", 629], ["NAC", 633], ["regions", 637], ["after", 645], ["Proteinase", 651], ["K", 662], ["and", 664], ["formic", 668], ["acid", 675], ["treatment", 680], ["in", 690], ["the", 693], ["cortex", 697], ["of", 704], ["patients", 707], ["with", 716], ["LBs", 721], [".", 724], ["Furthermore", 726], [",", 737], ["studies", 739], ["of", 747], ["the", 750], ["subcellular", 754], ["localization", 766], ["of", 779], ["NACP", 782], ["/", 786], ["alpha", 787], ["-", 792], ["synuclein", 793], ["within", 803], ["LB", 810], ["-", 812], ["bearing", 813], ["neurons", 821], ["were", 829], ["performed", 834], ["by", 844], ["immunogold", 847], ["electron", 858], ["microscopy", 867], [".", 877], ["These", 879], ["studies", 885], ["showed", 893], ["that", 900], ["the", 905], ["N", 909], ["-", 910], ["terminal", 911], ["antibody", 920], ["immunolabeled", 929], ["the", 943], ["LBs", 947], ["and", 951], ["dystrophic", 955], ["neurites", 966], ["with", 975], ["great", 980], ["intensity", 986], ["and", 996], [",", 999], ["to", 1001], ["a", 1004], ["lesser", 1006], ["extent", 1013], [",", 1019], ["the", 1021], ["synapses", 1025], [".", 1033], ["In", 1035], ["contrast", 1038], [",", 1046], ["the", 1048], ["C", 1052], ["-", 1053], ["terminal", 1054], ["antibody", 1063], ["strongly", 1072], ["labeled", 1081], ["the", 1089], ["synapses", 1093], ["and", 1102], [",", 1105], ["to", 1107], ["a", 1110], ["lesser", 1112], ["extent", 1119], [",", 1125], ["the", 1127], ["LBs", 1131], ["and", 1135], ["dystrophic", 1139], ["neurites", 1150], [".", 1158], ["Whereas", 1160], ["Proteinase", 1168], ["K", 1179], ["treatment", 1181], ["enhanced", 1191], ["NACP", 1200], ["/", 1204], ["alpha", 1205], ["-", 1210], ["synuclein", 1211], ["immunoreactivity", 1221], ["with", 1238], ["the", 1243], ["C", 1247], ["-", 1248], ["terminal", 1249], ["antibody", 1258], [",", 1266], ["it", 1268], ["diminished", 1271], ["the", 1282], ["N", 1286], ["-", 1287], ["terminal", 1288], ["NACP", 1297], ["/", 1301], ["alpha", 1302], ["-", 1307], ["synuclein", 1308], ["immunoreactivity", 1318], [".", 1334], ["Furthermore", 1336], [",", 1347], ["formic", 1349], ["acid", 1356], ["enhanced", 1361], ["LB", 1370], ["and", 1373], ["dystrophic", 1377], ["neurite", 1388], ["labeling", 1396], ["with", 1405], ["both", 1410], ["the", 1415], ["C-", 1419], ["and", 1422], ["N", 1426], ["-", 1427], ["terminal", 1428], ["antibodies", 1437], [".", 1447], ["In", 1449], ["addition", 1452], [",", 1460], ["whereas", 1462], ["without", 1470], ["pretreatment", 1478], ["only", 1491], ["slight", 1496], ["anti", 1503], ["-", 1507], ["NAC", 1508], ["immunoreactivity", 1512], ["was", 1529], ["found", 1533], ["in", 1539], ["the", 1542], ["LBs", 1546], [",", 1549], ["formic", 1551], ["acid", 1558], ["pretreatment", 1563], ["revealed", 1576], ["an", 1585], ["extensive", 1588], ["anti", 1598], ["-", 1602], ["NAC", 1603], ["immunostaining", 1607], ["of", 1622], ["LBs", 1625], [",", 1628], ["plaques", 1630], [",", 1637], ["and", 1639], ["glial", 1643], ["cells", 1649], [".", 1654], ["Ultrastructural", 1656], ["analysis", 1672], ["revealed", 1681], ["that", 1690], ["NACP", 1695], ["/", 1699], ["alpha", 1700], ["-", 1705], ["synuclein", 1706], ["immunoreactivity", 1716], ["was", 1733], ["diffusely", 1737], ["distributed", 1747], ["within", 1759], ["the", 1766], ["amorphous", 1770], ["electrodense", 1780], ["material", 1793], ["in", 1802], ["the", 1805], ["LBs", 1809], ["and", 1813], ["as", 1817], ["small", 1820], ["clusters", 1826], ["in", 1835], ["the", 1838], ["filaments", 1842], ["of", 1852], ["LBs", 1855], ["and", 1859], ["neurites", 1863], [".", 1871], ["These", 1873], ["results", 1879], ["support", 1887], ["the", 1895], ["view", 1899], ["that", 1904], ["aggregated", 1909], ["NACP", 1920], ["/", 1924], ["alpha", 1925], ["-", 1930], ["synuclein", 1931], ["might", 1941], ["play", 1947], ["an", 1952], ["important", 1955], ["role", 1965], ["in", 1970], ["the", 1973], ["pathogenesis", 1977], ["of", 1990], ["disorders", 1993], ["associated", 2003], ["with", 2014], ["LBs", 2019], [".", 2022]]}
{"context": "Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal immune disorder characterized by uncontrolled lymphocyte- and macrophage-activation. The resulting hypercytokinemia and cell infiltration of organs lead to the clinical and laboratory features of HLH. Viral infections and other triggers can induce both, inherited and acquired forms of HLH. Disease-causing mutations in the genes encoding perforin (PRF1, FHL2), munc13-4 (UNC13D, FHL3), syntaxin 11 (STX11, FHL4), and munc18-2 (UNC18-2/STXBP2, FHL5) have been previously identified in Familial Hemophagocyic Lymphohistiocytosis (FHL), whereas mutation in RAB27A and LYST account for Griscelli syndome type 2 and Chediak-Higashi syndrome, respectively. These genes all encode proteins which are involved in the cytotoxic activity of lymphocytes. The inability of activated cytotoxic cells to clear antigen-presenting targets results in sustained immune stimulation, likely accounting for the unremitting polyclonal CD8 T-cell activation and hyperimmune reaction which characterizes FHL. Treatment of HLH consists of elimination of the trigger and immunosuppressive treatment in order to induce remission from the uncontrolled inflammation. Allogeneic hematopoietic stem cell transplantation can be indicated in the inherited forms of HLH.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "ec77a7e4587a4882bcd45d55cf28a629", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[122, 125]], "char_spans": [[676, 699]]}]}], "context_tokens": [["Hemophagocytic", 0], ["lymphohistiocytosis", 15], ["(", 35], ["HLH", 36], [")", 39], ["is", 41], ["a", 44], ["potentially", 46], ["fatal", 58], ["immune", 64], ["disorder", 71], ["characterized", 80], ["by", 94], ["uncontrolled", 97], ["lymphocyte-", 110], ["and", 122], ["macrophage", 126], ["-", 136], ["activation", 137], [".", 147], ["The", 149], ["resulting", 153], ["hypercytokinemia", 163], ["and", 180], ["cell", 184], ["infiltration", 189], ["of", 202], ["organs", 205], ["lead", 212], ["to", 217], ["the", 220], ["clinical", 224], ["and", 233], ["laboratory", 237], ["features", 248], ["of", 257], ["HLH", 260], [".", 263], ["Viral", 265], ["infections", 271], ["and", 282], ["other", 286], ["triggers", 292], ["can", 301], ["induce", 305], ["both", 312], [",", 316], ["inherited", 318], ["and", 328], ["acquired", 332], ["forms", 341], ["of", 347], ["HLH", 350], [".", 353], ["Disease", 355], ["-", 362], ["causing", 363], ["mutations", 371], ["in", 381], ["the", 384], ["genes", 388], ["encoding", 394], ["perforin", 403], ["(", 412], ["PRF1", 413], [",", 417], ["FHL2", 419], [")", 423], [",", 424], ["munc13", 426], ["-", 432], ["4", 433], ["(", 435], ["UNC13D", 436], [",", 442], ["FHL3", 444], [")", 448], [",", 449], ["syntaxin", 451], ["11", 460], ["(", 463], ["STX11", 464], [",", 469], ["FHL4", 471], [")", 475], [",", 476], ["and", 478], ["munc18", 482], ["-", 488], ["2", 489], ["(", 491], ["UNC18", 492], ["-", 497], ["2/STXBP2", 498], [",", 506], ["FHL5", 508], [")", 512], ["have", 514], ["been", 519], ["previously", 524], ["identified", 535], ["in", 546], ["Familial", 549], ["Hemophagocyic", 558], ["Lymphohistiocytosis", 572], ["(", 592], ["FHL", 593], [")", 596], [",", 597], ["whereas", 599], ["mutation", 607], ["in", 616], ["RAB27A", 619], ["and", 626], ["LYST", 630], ["account", 635], ["for", 643], ["Griscelli", 647], ["syndome", 657], ["type", 665], ["2", 670], ["and", 672], ["Chediak", 676], ["-", 683], ["Higashi", 684], ["syndrome", 692], [",", 700], ["respectively", 702], [".", 714], ["These", 716], ["genes", 722], ["all", 728], ["encode", 732], ["proteins", 739], ["which", 748], ["are", 754], ["involved", 758], ["in", 767], ["the", 770], ["cytotoxic", 774], ["activity", 784], ["of", 793], ["lymphocytes", 796], [".", 807], ["The", 809], ["inability", 813], ["of", 823], ["activated", 826], ["cytotoxic", 836], ["cells", 846], ["to", 852], ["clear", 855], ["antigen", 861], ["-", 868], ["presenting", 869], ["targets", 880], ["results", 888], ["in", 896], ["sustained", 899], ["immune", 909], ["stimulation", 916], [",", 927], ["likely", 929], ["accounting", 936], ["for", 947], ["the", 951], ["unremitting", 955], ["polyclonal", 967], ["CD8", 978], ["T", 982], ["-", 983], ["cell", 984], ["activation", 989], ["and", 1000], ["hyperimmune", 1004], ["reaction", 1016], ["which", 1025], ["characterizes", 1031], ["FHL", 1045], [".", 1048], ["Treatment", 1050], ["of", 1060], ["HLH", 1063], ["consists", 1067], ["of", 1076], ["elimination", 1079], ["of", 1091], ["the", 1094], ["trigger", 1098], ["and", 1106], ["immunosuppressive", 1110], ["treatment", 1128], ["in", 1138], ["order", 1141], ["to", 1147], ["induce", 1150], ["remission", 1157], ["from", 1167], ["the", 1172], ["uncontrolled", 1176], ["inflammation", 1189], [".", 1201], ["Allogeneic", 1203], ["hematopoietic", 1214], ["stem", 1228], ["cell", 1233], ["transplantation", 1238], ["can", 1254], ["be", 1258], ["indicated", 1261], ["in", 1271], ["the", 1274], ["inherited", 1278], ["forms", 1288], ["of", 1294], ["HLH", 1297], [".", 1300]]}
{"context": "Linkage analysis and DNA sequencing in a family exhibiting an X-linked mental retardation (XLMR) syndrome, characterized by microcephaly, epilepsy, ataxia, and absent speech and resembling Angelman syndrome, identified a deletion in the SLC9A6 gene encoding the Na(+)/H(+) exchanger NHE6. Subsequently, other mutations were found in a male with mental retardation (MR) who had been investigated for Angelman syndrome and in two XLMR families with epilepsy and ataxia, including the family designated as having Christianson syndrome. Therefore, mutations in SLC9A6 cause X-linked mental retardation. Additionally, males with findings suggestive of unexplained Angelman syndrome should be considered as potential candidates for SLC9A6 mutations.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "b926d6e0091141cb9a74f555ced0e3ae", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[95, 95], [120, 120], [41, 41]], "char_spans": [[557, 562], [726, 731], [237, 242]]}]}], "context_tokens": [["Linkage", 0], ["analysis", 8], ["and", 17], ["DNA", 21], ["sequencing", 25], ["in", 36], ["a", 39], ["family", 41], ["exhibiting", 48], ["an", 59], ["X", 62], ["-", 63], ["linked", 64], ["mental", 71], ["retardation", 78], ["(", 90], ["XLMR", 91], [")", 95], ["syndrome", 97], [",", 105], ["characterized", 107], ["by", 121], ["microcephaly", 124], [",", 136], ["epilepsy", 138], [",", 146], ["ataxia", 148], [",", 154], ["and", 156], ["absent", 160], ["speech", 167], ["and", 174], ["resembling", 178], ["Angelman", 189], ["syndrome", 198], [",", 206], ["identified", 208], ["a", 219], ["deletion", 221], ["in", 230], ["the", 233], ["SLC9A6", 237], ["gene", 244], ["encoding", 249], ["the", 258], ["Na(+)/H(+", 262], [")", 271], ["exchanger", 273], ["NHE6", 283], [".", 287], ["Subsequently", 289], [",", 301], ["other", 303], ["mutations", 309], ["were", 319], ["found", 324], ["in", 330], ["a", 333], ["male", 335], ["with", 340], ["mental", 345], ["retardation", 352], ["(", 364], ["MR", 365], [")", 367], ["who", 369], ["had", 373], ["been", 377], ["investigated", 382], ["for", 395], ["Angelman", 399], ["syndrome", 408], ["and", 417], ["in", 421], ["two", 424], ["XLMR", 428], ["families", 433], ["with", 442], ["epilepsy", 447], ["and", 456], ["ataxia", 460], [",", 466], ["including", 468], ["the", 478], ["family", 482], ["designated", 489], ["as", 500], ["having", 503], ["Christianson", 510], ["syndrome", 523], [".", 531], ["Therefore", 533], [",", 542], ["mutations", 544], ["in", 554], ["SLC9A6", 557], ["cause", 564], ["X", 570], ["-", 571], ["linked", 572], ["mental", 579], ["retardation", 586], [".", 597], ["Additionally", 599], [",", 611], ["males", 613], ["with", 619], ["findings", 624], ["suggestive", 633], ["of", 644], ["unexplained", 647], ["Angelman", 659], ["syndrome", 668], ["should", 677], ["be", 684], ["considered", 687], ["as", 698], ["potential", 701], ["candidates", 711], ["for", 722], ["SLC9A6", 726], ["mutations", 733], [".", 742]]}
{"context": "Epigenomic mapping of enhancer-associated chromatin modifications facilitates the genome-wide discovery of tissue-specific enhancers in vivo. However, reliance on single chromatin marks leads to high rates of false-positive predictions. More sophisticated, integrative methods have been described, but commonly suffer from limited accessibility to the resulting predictions and reduced biological interpretability. Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface. We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements. By combining different statistical models, our approach outperforms current state-of-the-art methods and provides interpretable measures of feature importance. Our results indicate that including a previously unappreciated score that quantifies tissue-specific nuclease accessibility significantly improves prediction performance. We demonstrate the utility of our approach through in vivo validation of newly predicted elements. Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.", "qas": [{"question": "Which resource contains accurate enhancer predictions in the developing limb?", "answers": ["Limb-Enhancer Genie (LEG)"], "qid": "a1f4e0c1a4c84385836fb9879b463d73", "question_tokens": [["Which", 0], ["resource", 6], ["contains", 15], ["accurate", 24], ["enhancer", 33], ["predictions", 42], ["in", 54], ["the", 57], ["developing", 61], ["limb", 72], ["?", 76]], "detected_answers": [{"text": "Limb-Enhancer Genie (LEG)", "token_spans": [[67, 72]], "char_spans": [[435, 458]]}]}], "context_tokens": [["Epigenomic", 0], ["mapping", 11], ["of", 19], ["enhancer", 22], ["-", 30], ["associated", 31], ["chromatin", 42], ["modifications", 52], ["facilitates", 66], ["the", 78], ["genome", 82], ["-", 88], ["wide", 89], ["discovery", 94], ["of", 104], ["tissue", 107], ["-", 113], ["specific", 114], ["enhancers", 123], ["in", 133], ["vivo", 136], [".", 140], ["However", 142], [",", 149], ["reliance", 151], ["on", 160], ["single", 163], ["chromatin", 170], ["marks", 180], ["leads", 186], ["to", 192], ["high", 195], ["rates", 200], ["of", 206], ["false", 209], ["-", 214], ["positive", 215], ["predictions", 224], [".", 235], ["More", 237], ["sophisticated", 242], [",", 255], ["integrative", 257], ["methods", 269], ["have", 277], ["been", 282], ["described", 287], [",", 296], ["but", 298], ["commonly", 302], ["suffer", 311], ["from", 318], ["limited", 323], ["accessibility", 331], ["to", 345], ["the", 348], ["resulting", 352], ["predictions", 362], ["and", 374], ["reduced", 378], ["biological", 386], ["interpretability", 397], [".", 413], ["Here", 415], ["we", 420], ["present", 423], ["the", 431], ["Limb", 435], ["-", 439], ["Enhancer", 440], ["Genie", 449], ["(", 455], ["LEG", 456], [")", 459], [",", 460], ["a", 462], ["collection", 464], ["of", 475], ["highly", 478], ["accurate", 485], [",", 493], ["genome", 495], ["-", 501], ["wide", 502], ["predictions", 507], ["of", 519], ["enhancers", 522], ["in", 532], ["the", 535], ["developing", 539], ["limb", 550], [",", 554], ["available", 556], ["through", 566], ["a", 574], ["user", 576], ["-", 580], ["friendly", 581], ["online", 590], ["interface", 597], [".", 606], ["We", 608], ["predict", 611], ["limb", 619], ["enhancers", 624], ["using", 634], ["a", 640], ["combination", 642], ["of", 654], [">", 657], ["50", 658], ["published", 661], ["limb", 671], ["-", 675], ["specific", 676], ["datasets", 685], ["and", 694], ["clusters", 698], ["of", 707], ["evolutionarily", 710], ["conserved", 725], ["transcription", 735], ["factor", 749], ["binding", 756], ["sites", 764], [",", 769], ["taking", 771], ["advantage", 778], ["of", 788], ["the", 791], ["patterns", 795], ["observed", 804], ["at", 813], ["previously", 816], ["in", 827], ["vivo", 830], ["validated", 835], ["elements", 845], [".", 853], ["By", 855], ["combining", 858], ["different", 868], ["statistical", 878], ["models", 890], [",", 896], ["our", 898], ["approach", 902], ["outperforms", 911], ["current", 923], ["state", 931], ["-", 936], ["of", 937], ["-", 939], ["the", 940], ["-", 943], ["art", 944], ["methods", 948], ["and", 956], ["provides", 960], ["interpretable", 969], ["measures", 983], ["of", 992], ["feature", 995], ["importance", 1003], [".", 1013], ["Our", 1015], ["results", 1019], ["indicate", 1027], ["that", 1036], ["including", 1041], ["a", 1051], ["previously", 1053], ["unappreciated", 1064], ["score", 1078], ["that", 1084], ["quantifies", 1089], ["tissue", 1100], ["-", 1106], ["specific", 1107], ["nuclease", 1116], ["accessibility", 1125], ["significantly", 1139], ["improves", 1153], ["prediction", 1162], ["performance", 1173], [".", 1184], ["We", 1186], ["demonstrate", 1189], ["the", 1201], ["utility", 1205], ["of", 1213], ["our", 1216], ["approach", 1220], ["through", 1229], ["in", 1237], ["vivo", 1240], ["validation", 1245], ["of", 1256], ["newly", 1259], ["predicted", 1265], ["elements", 1275], [".", 1283], ["Moreover", 1285], [",", 1293], ["we", 1295], ["describe", 1298], ["general", 1307], ["features", 1315], ["that", 1324], ["can", 1329], ["guide", 1333], ["the", 1339], ["type", 1343], ["of", 1348], ["datasets", 1351], ["to", 1360], ["include", 1363], ["when", 1371], ["predicting", 1376], ["tissue", 1387], ["-", 1393], ["specific", 1394], ["enhancers", 1403], ["genome", 1413], ["-", 1419], ["wide", 1420], [",", 1424], ["while", 1426], ["providing", 1432], ["an", 1442], ["accessible", 1445], ["resource", 1456], ["to", 1465], ["the", 1468], ["general", 1472], ["biological", 1480], ["community", 1491], ["and", 1501], ["facilitating", 1505], ["the", 1518], ["functional", 1522], ["interpretation", 1533], ["of", 1548], ["genetic", 1551], ["studies", 1559], ["of", 1567], ["limb", 1570], ["malformations", 1575], [".", 1588]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a primary muscle disorder with autosomal dominant inheritance. FSHD was mapped to chromosome 4 locus q35, but the gene is not yet known. It is characterised by progressive, often asymmetric, selective muscular weakness and great clinical variability. The aim of the study was to analyze 62 FSHD cases from 44 Polish families in which the diagnosis was confirmed by DNA analyses. FSHD diagnosis was based on the clinical findings and standardized investigations confirming primary muscular involvement (EMG, muscle biopsy). DNA analysis was based on EcoRI/BlnI restriction enzyme digestion followed by hybridization with P13E-11 molecular probe. In our material, we have found a relatively large percentage (41%) of big deletions (EcoRI/BlnI fragment of 10-15 kb [kilo bases]), which in the majority of cases (67%) was present in isolated cases. In 10 families (23%) the phenotype was assessed as severe. These are cases with the onset before the age of 10 and fast progression. \"Middle sized\" deletions (EcoRI/BlnI fragment of 16-29 kb) were prevalent in familial cases and present in 57% of families. \"Small\" deletion was found in one family (EcoRI/BlnI fragment of 30 kb). Somatic mosaicism was confirmed in one case. De novo mutations were shown in 11% of the examined families. The results of this study indicate that the bigger the deletion, the more severe the FSHD course, however there are some exceptions. A similar relationship has been shown by previous research. Molecular analyses are particularly important in atypical and sporadic cases. It is the first genetic presentation of a group of patients' with this kind of dystrophy in the Polish population.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "a5ad0e37d1f0478a95e9c90fe01032e3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[12, 13]], "char_spans": [[80, 97]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["primary", 51], ["muscle", 59], ["disorder", 66], ["with", 75], ["autosomal", 80], ["dominant", 90], ["inheritance", 99], [".", 110], ["FSHD", 112], ["was", 117], ["mapped", 121], ["to", 128], ["chromosome", 131], ["4", 142], ["locus", 144], ["q35", 150], [",", 153], ["but", 155], ["the", 159], ["gene", 163], ["is", 168], ["not", 171], ["yet", 175], ["known", 179], [".", 184], ["It", 186], ["is", 189], ["characterised", 192], ["by", 206], ["progressive", 209], [",", 220], ["often", 222], ["asymmetric", 228], [",", 238], ["selective", 240], ["muscular", 250], ["weakness", 259], ["and", 268], ["great", 272], ["clinical", 278], ["variability", 287], [".", 298], ["The", 300], ["aim", 304], ["of", 308], ["the", 311], ["study", 315], ["was", 321], ["to", 325], ["analyze", 328], ["62", 336], ["FSHD", 339], ["cases", 344], ["from", 350], ["44", 355], ["Polish", 358], ["families", 365], ["in", 374], ["which", 377], ["the", 383], ["diagnosis", 387], ["was", 397], ["confirmed", 401], ["by", 411], ["DNA", 414], ["analyses", 418], [".", 426], ["FSHD", 428], ["diagnosis", 433], ["was", 443], ["based", 447], ["on", 453], ["the", 456], ["clinical", 460], ["findings", 469], ["and", 478], ["standardized", 482], ["investigations", 495], ["confirming", 510], ["primary", 521], ["muscular", 529], ["involvement", 538], ["(", 550], ["EMG", 551], [",", 554], ["muscle", 556], ["biopsy", 563], [")", 569], [".", 570], ["DNA", 572], ["analysis", 576], ["was", 585], ["based", 589], ["on", 595], ["EcoRI", 598], ["/", 603], ["BlnI", 604], ["restriction", 609], ["enzyme", 621], ["digestion", 628], ["followed", 638], ["by", 647], ["hybridization", 650], ["with", 664], ["P13E-11", 669], ["molecular", 677], ["probe", 687], [".", 692], ["In", 694], ["our", 697], ["material", 701], [",", 709], ["we", 711], ["have", 714], ["found", 719], ["a", 725], ["relatively", 727], ["large", 738], ["percentage", 744], ["(", 755], ["41", 756], ["%", 758], [")", 759], ["of", 761], ["big", 764], ["deletions", 768], ["(", 778], ["EcoRI", 779], ["/", 784], ["BlnI", 785], ["fragment", 790], ["of", 799], ["10", 802], ["-", 804], ["15", 805], ["kb", 808], ["[", 811], ["kilo", 812], ["bases", 817], ["]", 822], [")", 823], [",", 824], ["which", 826], ["in", 832], ["the", 835], ["majority", 839], ["of", 848], ["cases", 851], ["(", 857], ["67", 858], ["%", 860], [")", 861], ["was", 863], ["present", 867], ["in", 875], ["isolated", 878], ["cases", 887], [".", 892], ["In", 894], ["10", 897], ["families", 900], ["(", 909], ["23", 910], ["%", 912], [")", 913], ["the", 915], ["phenotype", 919], ["was", 929], ["assessed", 933], ["as", 942], ["severe", 945], [".", 951], ["These", 953], ["are", 959], ["cases", 963], ["with", 969], ["the", 974], ["onset", 978], ["before", 984], ["the", 991], ["age", 995], ["of", 999], ["10", 1002], ["and", 1005], ["fast", 1009], ["progression", 1014], [".", 1025], ["\"", 1027], ["Middle", 1028], ["sized", 1035], ["\"", 1040], ["deletions", 1042], ["(", 1052], ["EcoRI", 1053], ["/", 1058], ["BlnI", 1059], ["fragment", 1064], ["of", 1073], ["16", 1076], ["-", 1078], ["29", 1079], ["kb", 1082], [")", 1084], ["were", 1086], ["prevalent", 1091], ["in", 1101], ["familial", 1104], ["cases", 1113], ["and", 1119], ["present", 1123], ["in", 1131], ["57", 1134], ["%", 1136], ["of", 1138], ["families", 1141], [".", 1149], ["\"", 1151], ["Small", 1152], ["\"", 1157], ["deletion", 1159], ["was", 1168], ["found", 1172], ["in", 1178], ["one", 1181], ["family", 1185], ["(", 1192], ["EcoRI", 1193], ["/", 1198], ["BlnI", 1199], ["fragment", 1204], ["of", 1213], ["30", 1216], ["kb", 1219], [")", 1221], [".", 1222], ["Somatic", 1224], ["mosaicism", 1232], ["was", 1242], ["confirmed", 1246], ["in", 1256], ["one", 1259], ["case", 1263], [".", 1267], ["De", 1269], ["novo", 1272], ["mutations", 1277], ["were", 1287], ["shown", 1292], ["in", 1298], ["11", 1301], ["%", 1303], ["of", 1305], ["the", 1308], ["examined", 1312], ["families", 1321], [".", 1329], ["The", 1331], ["results", 1335], ["of", 1343], ["this", 1346], ["study", 1351], ["indicate", 1357], ["that", 1366], ["the", 1371], ["bigger", 1375], ["the", 1382], ["deletion", 1386], [",", 1394], ["the", 1396], ["more", 1400], ["severe", 1405], ["the", 1412], ["FSHD", 1416], ["course", 1421], [",", 1427], ["however", 1429], ["there", 1437], ["are", 1443], ["some", 1447], ["exceptions", 1452], [".", 1462], ["A", 1464], ["similar", 1466], ["relationship", 1474], ["has", 1487], ["been", 1491], ["shown", 1496], ["by", 1502], ["previous", 1505], ["research", 1514], [".", 1522], ["Molecular", 1524], ["analyses", 1534], ["are", 1543], ["particularly", 1547], ["important", 1560], ["in", 1570], ["atypical", 1573], ["and", 1582], ["sporadic", 1586], ["cases", 1595], [".", 1600], ["It", 1602], ["is", 1605], ["the", 1608], ["first", 1612], ["genetic", 1618], ["presentation", 1626], ["of", 1639], ["a", 1642], ["group", 1644], ["of", 1650], ["patients", 1653], ["'", 1661], ["with", 1663], ["this", 1668], ["kind", 1673], ["of", 1678], ["dystrophy", 1681], ["in", 1691], ["the", 1694], ["Polish", 1698], ["population", 1705], [".", 1715]]}
{"context": "Background Inappropriate use of antibiotic treatment for pharyngitis by community pharmacists is prevalent in developing countries. Little is known about how the pharmacists identify patients with bacterial pharyngitis. Objective To ascertain the appropriateness of diagnosis of streptococcal pharyngitis among Thai community pharmacists according to the Centor criteria and to identify factors related to antibiotic dispensing. Setting 1040 Thai community pharmacists. Method A cross-sectional survey of community pharmacists was conducted in November 2012 to March 2013. The self-administered questionnaires were mailed to 57\u00a0% of community pharmacists in the south of Thailand (n\u00a0=\u00a01040). The survey included questions on diagnosis of streptococcal pharyngitis, knowledge on pharyngitis, and attitudes and control beliefs regarding antibiotic dispensing. Main outcome measure The appropriateness of diagnosis of streptococcal pharyngitis according to the original and modified Centor criteria and determinants of antibiotic dispensing including demographic characteristics of pharmacists, knowledge on pharyngitis, and attitudes and control beliefs on antibiotic dispensing. Results Approximately 68\u00a0% completed the questionnaires (n\u00a0=\u00a0703). Compared to the pharmacists who reported not dispensing antibiotics in the hypothetical case with common cold, those reported dispensing antibiotics were more likely to consider the following conditions-presence of cough, mild sore throat and patients with age >60\u00a0years as cues for diagnosis of streptococcal pharyngitis (p\u00a0<\u00a00.05). The use of fewer scores of the clinical prediction rules for diagnosis was observed in antibiotic dispensers, compared to who did not do so (p\u00a0<\u00a00.005). Antibiotic dispensing was positively associated with period of dispensing experience (>5\u00a0years) [odds ratio (OR) 1.52; 95\u00a0% confidence interval (CI) 1.03-2.23], belief that antibiotics could shorten duration of pharyngitis (OR 1.48; 95\u00a0% CI 1.11-1.99), belief that antibiotics could prevent the complications (OR 1.44; 95\u00a0% CI 1.09-1.91) and belief that dispensing antibiotics could satisfy the patients (OR 1.31; 95\u00a0% CI 1.01-1.71). Nonetheless, antibiotic dispensing was negatively associated with knowledge about pharyngitis (OR 0.83; 95\u00a0% CI 0.75-0.93). Conclusion Pharmacists who are knowledgeable on the Centor criteria are more likely to appropriately diagnose streptococcal pharyngitis and less likely to dispense antibiotics in such case.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "fd56ae32cdb74808971cdd1f6e9b58ae", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[113, 114], [38, 39], [404, 405], [233, 234], [137, 138]], "char_spans": [[738, 762], [279, 303], [2400, 2424], [1541, 1565], [915, 939]]}]}], "context_tokens": [["Background", 0], ["Inappropriate", 11], ["use", 25], ["of", 29], ["antibiotic", 32], ["treatment", 43], ["for", 53], ["pharyngitis", 57], ["by", 69], ["community", 72], ["pharmacists", 82], ["is", 94], ["prevalent", 97], ["in", 107], ["developing", 110], ["countries", 121], [".", 130], ["Little", 132], ["is", 139], ["known", 142], ["about", 148], ["how", 154], ["the", 158], ["pharmacists", 162], ["identify", 174], ["patients", 183], ["with", 192], ["bacterial", 197], ["pharyngitis", 207], [".", 218], ["Objective", 220], ["To", 230], ["ascertain", 233], ["the", 243], ["appropriateness", 247], ["of", 263], ["diagnosis", 266], ["of", 276], ["streptococcal", 279], ["pharyngitis", 293], ["among", 305], ["Thai", 311], ["community", 316], ["pharmacists", 326], ["according", 338], ["to", 348], ["the", 351], ["Centor", 355], ["criteria", 362], ["and", 371], ["to", 375], ["identify", 378], ["factors", 387], ["related", 395], ["to", 403], ["antibiotic", 406], ["dispensing", 417], [".", 427], ["Setting", 429], ["1040", 437], ["Thai", 442], ["community", 447], ["pharmacists", 457], [".", 468], ["Method", 470], ["A", 477], ["cross", 479], ["-", 484], ["sectional", 485], ["survey", 495], ["of", 502], ["community", 505], ["pharmacists", 515], ["was", 527], ["conducted", 531], ["in", 541], ["November", 544], ["2012", 553], ["to", 558], ["March", 561], ["2013", 567], [".", 571], ["The", 573], ["self", 577], ["-", 581], ["administered", 582], ["questionnaires", 595], ["were", 610], ["mailed", 615], ["to", 622], ["57", 625], ["%", 628], ["of", 630], ["community", 633], ["pharmacists", 643], ["in", 655], ["the", 658], ["south", 662], ["of", 668], ["Thailand", 671], ["(", 680], ["n", 681], ["=", 683], ["1040", 685], [")", 689], [".", 690], ["The", 692], ["survey", 696], ["included", 703], ["questions", 712], ["on", 722], ["diagnosis", 725], ["of", 735], ["streptococcal", 738], ["pharyngitis", 752], [",", 763], ["knowledge", 765], ["on", 775], ["pharyngitis", 778], [",", 789], ["and", 791], ["attitudes", 795], ["and", 805], ["control", 809], ["beliefs", 817], ["regarding", 825], ["antibiotic", 835], ["dispensing", 846], [".", 856], ["Main", 858], ["outcome", 863], ["measure", 871], ["The", 879], ["appropriateness", 883], ["of", 899], ["diagnosis", 902], ["of", 912], ["streptococcal", 915], ["pharyngitis", 929], ["according", 941], ["to", 951], ["the", 954], ["original", 958], ["and", 967], ["modified", 971], ["Centor", 980], ["criteria", 987], ["and", 996], ["determinants", 1000], ["of", 1013], ["antibiotic", 1016], ["dispensing", 1027], ["including", 1038], ["demographic", 1048], ["characteristics", 1060], ["of", 1076], ["pharmacists", 1079], [",", 1090], ["knowledge", 1092], ["on", 1102], ["pharyngitis", 1105], [",", 1116], ["and", 1118], ["attitudes", 1122], ["and", 1132], ["control", 1136], ["beliefs", 1144], ["on", 1152], ["antibiotic", 1155], ["dispensing", 1166], [".", 1176], ["Results", 1178], ["Approximately", 1186], ["68", 1200], ["%", 1203], ["completed", 1205], ["the", 1215], ["questionnaires", 1219], ["(", 1234], ["n", 1235], ["=", 1237], ["703", 1239], [")", 1242], [".", 1243], ["Compared", 1245], ["to", 1254], ["the", 1257], ["pharmacists", 1261], ["who", 1273], ["reported", 1277], ["not", 1286], ["dispensing", 1290], ["antibiotics", 1301], ["in", 1313], ["the", 1316], ["hypothetical", 1320], ["case", 1333], ["with", 1338], ["common", 1343], ["cold", 1350], [",", 1354], ["those", 1356], ["reported", 1362], ["dispensing", 1371], ["antibiotics", 1382], ["were", 1394], ["more", 1399], ["likely", 1404], ["to", 1411], ["consider", 1414], ["the", 1423], ["following", 1427], ["conditions", 1437], ["-", 1447], ["presence", 1448], ["of", 1457], ["cough", 1460], [",", 1465], ["mild", 1467], ["sore", 1472], ["throat", 1477], ["and", 1484], ["patients", 1488], ["with", 1497], ["age", 1502], [">", 1506], ["60", 1507], ["years", 1510], ["as", 1516], ["cues", 1519], ["for", 1524], ["diagnosis", 1528], ["of", 1538], ["streptococcal", 1541], ["pharyngitis", 1555], ["(", 1567], ["p", 1568], ["<", 1570], ["0.05", 1572], [")", 1576], [".", 1577], ["The", 1579], ["use", 1583], ["of", 1587], ["fewer", 1590], ["scores", 1596], ["of", 1603], ["the", 1606], ["clinical", 1610], ["prediction", 1619], ["rules", 1630], ["for", 1636], ["diagnosis", 1640], ["was", 1650], ["observed", 1654], ["in", 1663], ["antibiotic", 1666], ["dispensers", 1677], [",", 1687], ["compared", 1689], ["to", 1698], ["who", 1701], ["did", 1705], ["not", 1709], ["do", 1713], ["so", 1716], ["(", 1719], ["p", 1720], ["<", 1722], ["0.005", 1724], [")", 1729], [".", 1730], ["Antibiotic", 1732], ["dispensing", 1743], ["was", 1754], ["positively", 1758], ["associated", 1769], ["with", 1780], ["period", 1785], ["of", 1792], ["dispensing", 1795], ["experience", 1806], ["(", 1817], [">", 1818], ["5", 1819], ["years", 1821], [")", 1826], ["[", 1828], ["odds", 1829], ["ratio", 1834], ["(", 1840], ["OR", 1841], [")", 1843], ["1.52", 1845], [";", 1849], ["95", 1851], ["%", 1854], ["confidence", 1856], ["interval", 1867], ["(", 1876], ["CI", 1877], [")", 1879], ["1.03", 1881], ["-", 1885], ["2.23", 1886], ["]", 1890], [",", 1891], ["belief", 1893], ["that", 1900], ["antibiotics", 1905], ["could", 1917], ["shorten", 1923], ["duration", 1931], ["of", 1940], ["pharyngitis", 1943], ["(", 1955], ["OR", 1956], ["1.48", 1959], [";", 1963], ["95", 1965], ["%", 1968], ["CI", 1970], ["1.11", 1973], ["-", 1977], ["1.99", 1978], [")", 1982], [",", 1983], ["belief", 1985], ["that", 1992], ["antibiotics", 1997], ["could", 2009], ["prevent", 2015], ["the", 2023], ["complications", 2027], ["(", 2041], ["OR", 2042], ["1.44", 2045], [";", 2049], ["95", 2051], ["%", 2054], ["CI", 2056], ["1.09", 2059], ["-", 2063], ["1.91", 2064], [")", 2068], ["and", 2070], ["belief", 2074], ["that", 2081], ["dispensing", 2086], ["antibiotics", 2097], ["could", 2109], ["satisfy", 2115], ["the", 2123], ["patients", 2127], ["(", 2136], ["OR", 2137], ["1.31", 2140], [";", 2144], ["95", 2146], ["%", 2149], ["CI", 2151], ["1.01", 2154], ["-", 2158], ["1.71", 2159], [")", 2163], [".", 2164], ["Nonetheless", 2166], [",", 2177], ["antibiotic", 2179], ["dispensing", 2190], ["was", 2201], ["negatively", 2205], ["associated", 2216], ["with", 2227], ["knowledge", 2232], ["about", 2242], ["pharyngitis", 2248], ["(", 2260], ["OR", 2261], ["0.83", 2264], [";", 2268], ["95", 2270], ["%", 2273], ["CI", 2275], ["0.75", 2278], ["-", 2282], ["0.93", 2283], [")", 2287], [".", 2288], ["Conclusion", 2290], ["Pharmacists", 2301], ["who", 2313], ["are", 2317], ["knowledgeable", 2321], ["on", 2335], ["the", 2338], ["Centor", 2342], ["criteria", 2349], ["are", 2358], ["more", 2362], ["likely", 2367], ["to", 2374], ["appropriately", 2377], ["diagnose", 2391], ["streptococcal", 2400], ["pharyngitis", 2414], ["and", 2426], ["less", 2430], ["likely", 2435], ["to", 2442], ["dispense", 2445], ["antibiotics", 2454], ["in", 2466], ["such", 2469], ["case", 2474], [".", 2478]]}
{"context": "To study the mechanism of centrosome duplication in cycling cells, we established a novel system of multiple centrosome formation in two types of cells: CHO cells treated with RO3306, a Cyclin-dependent kinase 1 (Cdk1) inhibitor and DT40 cells, in which Cdks were knocked out by chemical genetics. Cdk1-inactivated cells initiated DNA replication and centrosome duplication at the onset of S phase. They became arrested at the end of G2, but the centrosome cycle continued to produce supernumerary centrioles/centrosomes without DNA endoreplication in those cells. Centrosomes were amplified in a highly synchronous and reproducible manner: all of them were located next to the nucleus and spread widely apart from each other with several \u03bcm in distance. Double knockout of Cdk1 and Cdk2 caused cell cycle arrest at G1/S and centrosomes were no longer duplicated. However, cells continued to grow and increased their volume over 10-fold during 48 hr of culture. Centrosome components, including \u03b3-tubulin and Cep135, were synthesized and accumulated during the arrest, allowing rapid centrosome multiplication upon recovery from the cell cycle arrest or expression of exogenous Plk4 in G1/S cells. Thus centrosome amplification results from the discoordination of the centrosome cycle from the progression of other cell cycle events, which is controlled by different levels of Cdk activities.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "0c06ab7dd90c4dad83de126afa2b4101", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[5, 5], [82, 82], [188, 188], [215, 215], [18, 18], [168, 168], [62, 62], [207, 207]], "char_spans": [[26, 35], [446, 455], [1084, 1093], [1268, 1277], [109, 118], [962, 971], [351, 360], [1203, 1212]]}]}], "context_tokens": [["To", 0], ["study", 3], ["the", 9], ["mechanism", 13], ["of", 23], ["centrosome", 26], ["duplication", 37], ["in", 49], ["cycling", 52], ["cells", 60], [",", 65], ["we", 67], ["established", 70], ["a", 82], ["novel", 84], ["system", 90], ["of", 97], ["multiple", 100], ["centrosome", 109], ["formation", 120], ["in", 130], ["two", 133], ["types", 137], ["of", 143], ["cells", 146], [":", 151], ["CHO", 153], ["cells", 157], ["treated", 163], ["with", 171], ["RO3306", 176], [",", 182], ["a", 184], ["Cyclin", 186], ["-", 192], ["dependent", 193], ["kinase", 203], ["1", 210], ["(", 212], ["Cdk1", 213], [")", 217], ["inhibitor", 219], ["and", 229], ["DT40", 233], ["cells", 238], [",", 243], ["in", 245], ["which", 248], ["Cdks", 254], ["were", 259], ["knocked", 264], ["out", 272], ["by", 276], ["chemical", 279], ["genetics", 288], [".", 296], ["Cdk1-inactivated", 298], ["cells", 315], ["initiated", 321], ["DNA", 331], ["replication", 335], ["and", 347], ["centrosome", 351], ["duplication", 362], ["at", 374], ["the", 377], ["onset", 381], ["of", 387], ["S", 390], ["phase", 392], [".", 397], ["They", 399], ["became", 404], ["arrested", 411], ["at", 420], ["the", 423], ["end", 427], ["of", 431], ["G2", 434], [",", 436], ["but", 438], ["the", 442], ["centrosome", 446], ["cycle", 457], ["continued", 463], ["to", 473], ["produce", 476], ["supernumerary", 484], ["centrioles", 498], ["/", 508], ["centrosomes", 509], ["without", 521], ["DNA", 529], ["endoreplication", 533], ["in", 549], ["those", 552], ["cells", 558], [".", 563], ["Centrosomes", 565], ["were", 577], ["amplified", 582], ["in", 592], ["a", 595], ["highly", 597], ["synchronous", 604], ["and", 616], ["reproducible", 620], ["manner", 633], [":", 639], ["all", 641], ["of", 645], ["them", 648], ["were", 653], ["located", 658], ["next", 666], ["to", 671], ["the", 674], ["nucleus", 678], ["and", 686], ["spread", 690], ["widely", 697], ["apart", 704], ["from", 710], ["each", 715], ["other", 720], ["with", 726], ["several", 731], ["\u03bcm", 739], ["in", 742], ["distance", 745], [".", 753], ["Double", 755], ["knockout", 762], ["of", 771], ["Cdk1", 774], ["and", 779], ["Cdk2", 783], ["caused", 788], ["cell", 795], ["cycle", 800], ["arrest", 806], ["at", 813], ["G1/S", 816], ["and", 821], ["centrosomes", 825], ["were", 837], ["no", 842], ["longer", 845], ["duplicated", 852], [".", 862], ["However", 864], [",", 871], ["cells", 873], ["continued", 879], ["to", 889], ["grow", 892], ["and", 897], ["increased", 901], ["their", 911], ["volume", 917], ["over", 924], ["10-fold", 929], ["during", 937], ["48", 944], ["hr", 947], ["of", 950], ["culture", 953], [".", 960], ["Centrosome", 962], ["components", 973], [",", 983], ["including", 985], ["\u03b3", 995], ["-", 996], ["tubulin", 997], ["and", 1005], ["Cep135", 1009], [",", 1015], ["were", 1017], ["synthesized", 1022], ["and", 1034], ["accumulated", 1038], ["during", 1050], ["the", 1057], ["arrest", 1061], [",", 1067], ["allowing", 1069], ["rapid", 1078], ["centrosome", 1084], ["multiplication", 1095], ["upon", 1110], ["recovery", 1115], ["from", 1124], ["the", 1129], ["cell", 1133], ["cycle", 1138], ["arrest", 1144], ["or", 1151], ["expression", 1154], ["of", 1165], ["exogenous", 1168], ["Plk4", 1178], ["in", 1183], ["G1/S", 1186], ["cells", 1191], [".", 1196], ["Thus", 1198], ["centrosome", 1203], ["amplification", 1214], ["results", 1228], ["from", 1236], ["the", 1241], ["discoordination", 1245], ["of", 1261], ["the", 1264], ["centrosome", 1268], ["cycle", 1279], ["from", 1285], ["the", 1290], ["progression", 1294], ["of", 1306], ["other", 1309], ["cell", 1315], ["cycle", 1320], ["events", 1326], [",", 1332], ["which", 1334], ["is", 1340], ["controlled", 1343], ["by", 1354], ["different", 1357], ["levels", 1367], ["of", 1374], ["Cdk", 1377], ["activities", 1381], [".", 1391]]}
{"context": "Self-report questionnaires are frequently used to identify PTSD among U.S. military personnel and Veterans. Two common scoring methods used to classify PTSD include: (1) a cut score threshold and (2) endorsement of PTSD symptoms meeting DSM-IV-TR symptom cluster criteria (SCM). A third method requiring a cut score in addition to SCM has been proposed, but has received little study. The current study examined the diagnostic accuracy of three scoring methods for the Davidson Trauma Scale (DTS) among 804 Afghanistan and Iraq war-era military Service Members and Veterans. Data were weighted to approximate the prevalence of PTSD and other Axis I disorders in VA primary care. As expected, adding a cut score criterion to SCM improved specificity and positive predictive power. However, a cut score of 68-72 provided optimal diagnostic accuracy. The utility of the DTS, the role of baseline prevalence, and recommendations for future research are discussed.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "30101ccbda904d208ed2525e9f6e992c", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[117, 117], [24, 24], [9, 9], [40, 40]], "char_spans": [[627, 630], [152, 155], [59, 62], [215, 218]]}]}], "context_tokens": [["Self", 0], ["-", 4], ["report", 5], ["questionnaires", 12], ["are", 27], ["frequently", 31], ["used", 42], ["to", 47], ["identify", 50], ["PTSD", 59], ["among", 64], ["U.S.", 70], ["military", 75], ["personnel", 84], ["and", 94], ["Veterans", 98], [".", 106], ["Two", 108], ["common", 112], ["scoring", 119], ["methods", 127], ["used", 135], ["to", 140], ["classify", 143], ["PTSD", 152], ["include", 157], [":", 164], ["(", 166], ["1", 167], [")", 168], ["a", 170], ["cut", 172], ["score", 176], ["threshold", 182], ["and", 192], ["(", 196], ["2", 197], [")", 198], ["endorsement", 200], ["of", 212], ["PTSD", 215], ["symptoms", 220], ["meeting", 229], ["DSM", 237], ["-", 240], ["IV", 241], ["-", 243], ["TR", 244], ["symptom", 247], ["cluster", 255], ["criteria", 263], ["(", 272], ["SCM", 273], [")", 276], [".", 277], ["A", 279], ["third", 281], ["method", 287], ["requiring", 294], ["a", 304], ["cut", 306], ["score", 310], ["in", 316], ["addition", 319], ["to", 328], ["SCM", 331], ["has", 335], ["been", 339], ["proposed", 344], [",", 352], ["but", 354], ["has", 358], ["received", 362], ["little", 371], ["study", 378], [".", 383], ["The", 385], ["current", 389], ["study", 397], ["examined", 403], ["the", 412], ["diagnostic", 416], ["accuracy", 427], ["of", 436], ["three", 439], ["scoring", 445], ["methods", 453], ["for", 461], ["the", 465], ["Davidson", 469], ["Trauma", 478], ["Scale", 485], ["(", 491], ["DTS", 492], [")", 495], ["among", 497], ["804", 503], ["Afghanistan", 507], ["and", 519], ["Iraq", 523], ["war", 528], ["-", 531], ["era", 532], ["military", 536], ["Service", 545], ["Members", 553], ["and", 561], ["Veterans", 565], [".", 573], ["Data", 575], ["were", 580], ["weighted", 585], ["to", 594], ["approximate", 597], ["the", 609], ["prevalence", 613], ["of", 624], ["PTSD", 627], ["and", 632], ["other", 636], ["Axis", 642], ["I", 647], ["disorders", 649], ["in", 659], ["VA", 662], ["primary", 665], ["care", 673], [".", 677], ["As", 679], ["expected", 682], [",", 690], ["adding", 692], ["a", 699], ["cut", 701], ["score", 705], ["criterion", 711], ["to", 721], ["SCM", 724], ["improved", 728], ["specificity", 737], ["and", 749], ["positive", 753], ["predictive", 762], ["power", 773], [".", 778], ["However", 780], [",", 787], ["a", 789], ["cut", 791], ["score", 795], ["of", 801], ["68", 804], ["-", 806], ["72", 807], ["provided", 810], ["optimal", 819], ["diagnostic", 827], ["accuracy", 838], [".", 846], ["The", 848], ["utility", 852], ["of", 860], ["the", 863], ["DTS", 867], [",", 870], ["the", 872], ["role", 876], ["of", 881], ["baseline", 884], ["prevalence", 893], [",", 903], ["and", 905], ["recommendations", 909], ["for", 925], ["future", 929], ["research", 936], ["are", 945], ["discussed", 949], [".", 958]]}
{"context": "The dynamin-related protein Opa1 is localized to the mitochondrial intermembrane space, where it facilitates fusion between mitochondria. Apoptosis causes Opa1 release into the cytosol and causes mitochondria to fragment. Loss of mitochondrial membrane potential also causes mitochondrial fragmentation but not Opa1 release into the cytosol. Both conditions induce the proteolytic cleavage of Opa1, suggesting that mitochondrial fragmentation is triggered by Opa1 inactivation. The opposite effect was observed with knockdown of the mitochondrial intermembrane space protease Yme1. Knockdown of Yme1 prevents the constitutive cleavage of a subset of Opa1 splice variants but does not affect carbonyl cyanide m-chlorophenyl hydrazone or apoptosis-induced cleavage. Knockdown of Yme1 also increases mitochondrial connectivity, but this effect is independent of Opa1 because it also occurs in Opa1 knockdown cells. We conclude that Yme1 constitutively regulates a subset of Opa1 isoforms and an unknown mitochondrial morphology protein, whereas the loss of membrane potential induces the further proteolysis of Opa1.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "06ee6c4a1f9d4cd19afcd49b8dd40d16", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[10, 12], [79, 81]], "char_spans": [[53, 85], [533, 565]]}]}], "context_tokens": [["The", 0], ["dynamin", 4], ["-", 11], ["related", 12], ["protein", 20], ["Opa1", 28], ["is", 33], ["localized", 36], ["to", 46], ["the", 49], ["mitochondrial", 53], ["intermembrane", 67], ["space", 81], [",", 86], ["where", 88], ["it", 94], ["facilitates", 97], ["fusion", 109], ["between", 116], ["mitochondria", 124], [".", 136], ["Apoptosis", 138], ["causes", 148], ["Opa1", 155], ["release", 160], ["into", 168], ["the", 173], ["cytosol", 177], ["and", 185], ["causes", 189], ["mitochondria", 196], ["to", 209], ["fragment", 212], [".", 220], ["Loss", 222], ["of", 227], ["mitochondrial", 230], ["membrane", 244], ["potential", 253], ["also", 263], ["causes", 268], ["mitochondrial", 275], ["fragmentation", 289], ["but", 303], ["not", 307], ["Opa1", 311], ["release", 316], ["into", 324], ["the", 329], ["cytosol", 333], [".", 340], ["Both", 342], ["conditions", 347], ["induce", 358], ["the", 365], ["proteolytic", 369], ["cleavage", 381], ["of", 390], ["Opa1", 393], [",", 397], ["suggesting", 399], ["that", 410], ["mitochondrial", 415], ["fragmentation", 429], ["is", 443], ["triggered", 446], ["by", 456], ["Opa1", 459], ["inactivation", 464], [".", 476], ["The", 478], ["opposite", 482], ["effect", 491], ["was", 498], ["observed", 502], ["with", 511], ["knockdown", 516], ["of", 526], ["the", 529], ["mitochondrial", 533], ["intermembrane", 547], ["space", 561], ["protease", 567], ["Yme1", 576], [".", 580], ["Knockdown", 582], ["of", 592], ["Yme1", 595], ["prevents", 600], ["the", 609], ["constitutive", 613], ["cleavage", 626], ["of", 635], ["a", 638], ["subset", 640], ["of", 647], ["Opa1", 650], ["splice", 655], ["variants", 662], ["but", 671], ["does", 675], ["not", 680], ["affect", 684], ["carbonyl", 691], ["cyanide", 700], ["m", 708], ["-", 709], ["chlorophenyl", 710], ["hydrazone", 723], ["or", 733], ["apoptosis", 736], ["-", 745], ["induced", 746], ["cleavage", 754], [".", 762], ["Knockdown", 764], ["of", 774], ["Yme1", 777], ["also", 782], ["increases", 787], ["mitochondrial", 797], ["connectivity", 811], [",", 823], ["but", 825], ["this", 829], ["effect", 834], ["is", 841], ["independent", 844], ["of", 856], ["Opa1", 859], ["because", 864], ["it", 872], ["also", 875], ["occurs", 880], ["in", 887], ["Opa1", 890], ["knockdown", 895], ["cells", 905], [".", 910], ["We", 912], ["conclude", 915], ["that", 924], ["Yme1", 929], ["constitutively", 934], ["regulates", 949], ["a", 959], ["subset", 961], ["of", 968], ["Opa1", 971], ["isoforms", 976], ["and", 985], ["an", 989], ["unknown", 992], ["mitochondrial", 1000], ["morphology", 1014], ["protein", 1025], [",", 1032], ["whereas", 1034], ["the", 1042], ["loss", 1046], ["of", 1051], ["membrane", 1054], ["potential", 1063], ["induces", 1073], ["the", 1081], ["further", 1085], ["proteolysis", 1093], ["of", 1105], ["Opa1", 1108], [".", 1112]]}
{"context": "Contrary to earlier beliefs, viruses are not the smallest causative agents of infectious diseases. Single-stranded RNAs as small as 246 nucleotides exist in certain higher plants and cause more than a dozen crop diseases. These RNAs have been termed viroids. Despite their extremely limited information content, viroids replicate autonomously in susceptible cells--that is, they do not require helper functions from simultaneously replicating conventional viruses. Viroids are covalently closed circular molecules with a characteristic rodlike secondary structure in which short helical regions are interrupted by internal and bulge loops. Viroids are not translated; they are replicated by a host enzyme (or enzymes) (probably RNA polymerase II) via oligomeric RNA intermediates by a rolling circle mechanism. Viroidlike satellite RNAs resemble viroids in size and molecular structure, but are found within the capsids of specific helper viruses on which they depend for their own replication. These RNAs are of great interest to molecular biology for at least two reasons: 1) they are the smallest and simplest replicating molecules known, and 2) they may represent living fossils of precellular evolution in a hypothetical RNA world.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "2f0016f1f1004c60afce22d6816d93e1", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[75, 75], [53, 53], [100, 100], [44, 44], [136, 136]], "char_spans": [[465, 471], [312, 318], [640, 646], [250, 256], [846, 852]]}]}], "context_tokens": [["Contrary", 0], ["to", 9], ["earlier", 12], ["beliefs", 20], [",", 27], ["viruses", 29], ["are", 37], ["not", 41], ["the", 45], ["smallest", 49], ["causative", 58], ["agents", 68], ["of", 75], ["infectious", 78], ["diseases", 89], [".", 97], ["Single", 99], ["-", 105], ["stranded", 106], ["RNAs", 115], ["as", 120], ["small", 123], ["as", 129], ["246", 132], ["nucleotides", 136], ["exist", 148], ["in", 154], ["certain", 157], ["higher", 165], ["plants", 172], ["and", 179], ["cause", 183], ["more", 189], ["than", 194], ["a", 199], ["dozen", 201], ["crop", 207], ["diseases", 212], [".", 220], ["These", 222], ["RNAs", 228], ["have", 233], ["been", 238], ["termed", 243], ["viroids", 250], [".", 257], ["Despite", 259], ["their", 267], ["extremely", 273], ["limited", 283], ["information", 291], ["content", 303], [",", 310], ["viroids", 312], ["replicate", 320], ["autonomously", 330], ["in", 343], ["susceptible", 346], ["cells", 358], ["--", 363], ["that", 365], ["is", 370], [",", 372], ["they", 374], ["do", 379], ["not", 382], ["require", 386], ["helper", 394], ["functions", 401], ["from", 411], ["simultaneously", 416], ["replicating", 431], ["conventional", 443], ["viruses", 456], [".", 463], ["Viroids", 465], ["are", 473], ["covalently", 477], ["closed", 488], ["circular", 495], ["molecules", 504], ["with", 514], ["a", 519], ["characteristic", 521], ["rodlike", 536], ["secondary", 544], ["structure", 554], ["in", 564], ["which", 567], ["short", 573], ["helical", 579], ["regions", 587], ["are", 595], ["interrupted", 599], ["by", 611], ["internal", 614], ["and", 623], ["bulge", 627], ["loops", 633], [".", 638], ["Viroids", 640], ["are", 648], ["not", 652], ["translated", 656], [";", 666], ["they", 668], ["are", 673], ["replicated", 677], ["by", 688], ["a", 691], ["host", 693], ["enzyme", 698], ["(", 705], ["or", 706], ["enzymes", 709], [")", 716], ["(", 718], ["probably", 719], ["RNA", 728], ["polymerase", 732], ["II", 743], [")", 745], ["via", 747], ["oligomeric", 751], ["RNA", 762], ["intermediates", 766], ["by", 780], ["a", 783], ["rolling", 785], ["circle", 793], ["mechanism", 800], [".", 809], ["Viroidlike", 811], ["satellite", 822], ["RNAs", 832], ["resemble", 837], ["viroids", 846], ["in", 854], ["size", 857], ["and", 862], ["molecular", 866], ["structure", 876], [",", 885], ["but", 887], ["are", 891], ["found", 895], ["within", 901], ["the", 908], ["capsids", 912], ["of", 920], ["specific", 923], ["helper", 932], ["viruses", 939], ["on", 947], ["which", 950], ["they", 956], ["depend", 961], ["for", 968], ["their", 972], ["own", 978], ["replication", 982], [".", 993], ["These", 995], ["RNAs", 1001], ["are", 1006], ["of", 1010], ["great", 1013], ["interest", 1019], ["to", 1028], ["molecular", 1031], ["biology", 1041], ["for", 1049], ["at", 1053], ["least", 1056], ["two", 1062], ["reasons", 1066], [":", 1073], ["1", 1075], [")", 1076], ["they", 1078], ["are", 1083], ["the", 1087], ["smallest", 1091], ["and", 1100], ["simplest", 1104], ["replicating", 1113], ["molecules", 1125], ["known", 1135], [",", 1140], ["and", 1142], ["2", 1146], [")", 1147], ["they", 1149], ["may", 1154], ["represent", 1158], ["living", 1168], ["fossils", 1175], ["of", 1183], ["precellular", 1186], ["evolution", 1198], ["in", 1208], ["a", 1211], ["hypothetical", 1213], ["RNA", 1226], ["world", 1230], [".", 1235]]}
{"context": "Mutations of presenilin 1 (PS1) causing Alzheimer's disease selectively increase the secretion of the amyloidogenic betaA4(1-42), whereas knocking out the gene results in decreased production of both betaA4(1-40) and (1-42) amyloid peptides (De Strooper et al. 1998). Therefore, PS1 function is closely linked to the gamma-secretase processing of the amyloid precursor protein (APP). Given the ongoing controversy on the subcellular localization of PS1, it remains unclear at what level of the secretory and endocytic pathways PS1 exerts its activity on APP and on the APP carboxy-terminal fragments that are the direct substrates for gamma-secretase. Therefore, we have reinvestigated the subcellular localization of endogenously expressed PS1 in neurons in vitro and in vivo using confocal microscopy and fine-tuned subcellular fractionation. We show that uncleaved PS1 holoprotein is recovered in the nuclear envelope fraction, whereas the cleaved PS fragments are found mainly in post-ER membranes including the intermediate compartment (IC). PS1 is concentrated in discrete sec23p- and p58/ERGIC-53-positive patches, suggesting its localization in subdomains involved in ER export. PS1 is not found to significant amounts beyond the cis-Golgi. Surprisingly, we found that APP carboxy-terminal fragments also coenrich in the pre-Golgi membrane fractions, consistent with the idea that these fragments are the real substrates for gamma-secretase. Functional evidence that PS1 exerts its effects on gamma-secretase processing of APP in the ER/IC was obtained using a series of APP trafficking mutants. These mutants were investigated in hippocampal neurons derived from transgenic mice expressing PS1wt or PS1 containing clinical mutations (PS1(M146L) and PS1(L286V)) at physiologically relevant levels. We demonstrate that the APP-London and PS1 mutations have additive effects on the increased secretion of betaA4(1-42) relative to betaA4(1-40), indicating that both mutations operate independently. Overall, our data clearly establish that PS1 controls gamma(42)-secretase activity in pre-Golgi compartments. We discuss models that reconcile this conclusion with the effects of PS1 deficiency on the generation of betaA4(1-40) peptide in the late biosynthetic and endocytic pathways.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "c6a3fb62d44040b1a6fe442b2aadc722", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[8, 10]], "char_spans": [[40, 58]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["presenilin", 13], ["1", 24], ["(", 26], ["PS1", 27], [")", 30], ["causing", 32], ["Alzheimer", 40], ["'s", 49], ["disease", 52], ["selectively", 60], ["increase", 72], ["the", 81], ["secretion", 85], ["of", 95], ["the", 98], ["amyloidogenic", 102], ["betaA4(1", 116], ["-", 124], ["42", 125], [")", 127], [",", 128], ["whereas", 130], ["knocking", 138], ["out", 147], ["the", 151], ["gene", 155], ["results", 160], ["in", 168], ["decreased", 171], ["production", 181], ["of", 192], ["both", 195], ["betaA4(1", 200], ["-", 208], ["40", 209], [")", 211], ["and", 213], ["(", 217], ["1", 218], ["-", 219], ["42", 220], [")", 222], ["amyloid", 224], ["peptides", 232], ["(", 241], ["De", 242], ["Strooper", 245], ["et", 254], ["al", 257], [".", 259], ["1998", 261], [")", 265], [".", 266], ["Therefore", 268], [",", 277], ["PS1", 279], ["function", 283], ["is", 292], ["closely", 295], ["linked", 303], ["to", 310], ["the", 313], ["gamma", 317], ["-", 322], ["secretase", 323], ["processing", 333], ["of", 344], ["the", 347], ["amyloid", 351], ["precursor", 359], ["protein", 369], ["(", 377], ["APP", 378], [")", 381], [".", 382], ["Given", 384], ["the", 390], ["ongoing", 394], ["controversy", 402], ["on", 414], ["the", 417], ["subcellular", 421], ["localization", 433], ["of", 446], ["PS1", 449], [",", 452], ["it", 454], ["remains", 457], ["unclear", 465], ["at", 473], ["what", 476], ["level", 481], ["of", 487], ["the", 490], ["secretory", 494], ["and", 504], ["endocytic", 508], ["pathways", 518], ["PS1", 527], ["exerts", 531], ["its", 538], ["activity", 542], ["on", 551], ["APP", 554], ["and", 558], ["on", 562], ["the", 565], ["APP", 569], ["carboxy", 573], ["-", 580], ["terminal", 581], ["fragments", 590], ["that", 600], ["are", 605], ["the", 609], ["direct", 613], ["substrates", 620], ["for", 631], ["gamma", 635], ["-", 640], ["secretase", 641], [".", 650], ["Therefore", 652], [",", 661], ["we", 663], ["have", 666], ["reinvestigated", 671], ["the", 686], ["subcellular", 690], ["localization", 702], ["of", 715], ["endogenously", 718], ["expressed", 731], ["PS1", 741], ["in", 745], ["neurons", 748], ["in", 756], ["vitro", 759], ["and", 765], ["in", 769], ["vivo", 772], ["using", 777], ["confocal", 783], ["microscopy", 792], ["and", 803], ["fine", 807], ["-", 811], ["tuned", 812], ["subcellular", 818], ["fractionation", 830], [".", 843], ["We", 845], ["show", 848], ["that", 853], ["uncleaved", 858], ["PS1", 868], ["holoprotein", 872], ["is", 884], ["recovered", 887], ["in", 897], ["the", 900], ["nuclear", 904], ["envelope", 912], ["fraction", 921], [",", 929], ["whereas", 931], ["the", 939], ["cleaved", 943], ["PS", 951], ["fragments", 954], ["are", 964], ["found", 968], ["mainly", 974], ["in", 981], ["post", 984], ["-", 988], ["ER", 989], ["membranes", 992], ["including", 1002], ["the", 1012], ["intermediate", 1016], ["compartment", 1029], ["(", 1041], ["IC", 1042], [")", 1044], [".", 1045], ["PS1", 1047], ["is", 1051], ["concentrated", 1054], ["in", 1067], ["discrete", 1070], ["sec23p-", 1079], ["and", 1087], ["p58/ERGIC-53-positive", 1091], ["patches", 1113], [",", 1120], ["suggesting", 1122], ["its", 1133], ["localization", 1137], ["in", 1150], ["subdomains", 1153], ["involved", 1164], ["in", 1173], ["ER", 1176], ["export", 1179], [".", 1185], ["PS1", 1187], ["is", 1191], ["not", 1194], ["found", 1198], ["to", 1204], ["significant", 1207], ["amounts", 1219], ["beyond", 1227], ["the", 1234], ["cis", 1238], ["-", 1241], ["Golgi", 1242], [".", 1247], ["Surprisingly", 1249], [",", 1261], ["we", 1263], ["found", 1266], ["that", 1272], ["APP", 1277], ["carboxy", 1281], ["-", 1288], ["terminal", 1289], ["fragments", 1298], ["also", 1308], ["coenrich", 1313], ["in", 1322], ["the", 1325], ["pre", 1329], ["-", 1332], ["Golgi", 1333], ["membrane", 1339], ["fractions", 1348], [",", 1357], ["consistent", 1359], ["with", 1370], ["the", 1375], ["idea", 1379], ["that", 1384], ["these", 1389], ["fragments", 1395], ["are", 1405], ["the", 1409], ["real", 1413], ["substrates", 1418], ["for", 1429], ["gamma", 1433], ["-", 1438], ["secretase", 1439], [".", 1448], ["Functional", 1450], ["evidence", 1461], ["that", 1470], ["PS1", 1475], ["exerts", 1479], ["its", 1486], ["effects", 1490], ["on", 1498], ["gamma", 1501], ["-", 1506], ["secretase", 1507], ["processing", 1517], ["of", 1528], ["APP", 1531], ["in", 1535], ["the", 1538], ["ER", 1542], ["/", 1544], ["IC", 1545], ["was", 1548], ["obtained", 1552], ["using", 1561], ["a", 1567], ["series", 1569], ["of", 1576], ["APP", 1579], ["trafficking", 1583], ["mutants", 1595], [".", 1602], ["These", 1604], ["mutants", 1610], ["were", 1618], ["investigated", 1623], ["in", 1636], ["hippocampal", 1639], ["neurons", 1651], ["derived", 1659], ["from", 1667], ["transgenic", 1672], ["mice", 1683], ["expressing", 1688], ["PS1wt", 1699], ["or", 1705], ["PS1", 1708], ["containing", 1712], ["clinical", 1723], ["mutations", 1732], ["(", 1742], ["PS1(M146L", 1743], [")", 1752], ["and", 1754], ["PS1(L286V", 1758], [")", 1767], [")", 1768], ["at", 1770], ["physiologically", 1773], ["relevant", 1789], ["levels", 1798], [".", 1804], ["We", 1806], ["demonstrate", 1809], ["that", 1821], ["the", 1826], ["APP", 1830], ["-", 1833], ["London", 1834], ["and", 1841], ["PS1", 1845], ["mutations", 1849], ["have", 1859], ["additive", 1864], ["effects", 1873], ["on", 1881], ["the", 1884], ["increased", 1888], ["secretion", 1898], ["of", 1908], ["betaA4(1", 1911], ["-", 1919], ["42", 1920], [")", 1922], ["relative", 1924], ["to", 1933], ["betaA4(1", 1936], ["-", 1944], ["40", 1945], [")", 1947], [",", 1948], ["indicating", 1950], ["that", 1961], ["both", 1966], ["mutations", 1971], ["operate", 1981], ["independently", 1989], [".", 2002], ["Overall", 2004], [",", 2011], ["our", 2013], ["data", 2017], ["clearly", 2022], ["establish", 2030], ["that", 2040], ["PS1", 2045], ["controls", 2049], ["gamma(42)-secretase", 2058], ["activity", 2078], ["in", 2087], ["pre", 2090], ["-", 2093], ["Golgi", 2094], ["compartments", 2100], [".", 2112], ["We", 2114], ["discuss", 2117], ["models", 2125], ["that", 2132], ["reconcile", 2137], ["this", 2147], ["conclusion", 2152], ["with", 2163], ["the", 2168], ["effects", 2172], ["of", 2180], ["PS1", 2183], ["deficiency", 2187], ["on", 2198], ["the", 2201], ["generation", 2205], ["of", 2216], ["betaA4(1", 2219], ["-", 2227], ["40", 2228], [")", 2230], ["peptide", 2232], ["in", 2240], ["the", 2243], ["late", 2247], ["biosynthetic", 2252], ["and", 2265], ["endocytic", 2269], ["pathways", 2279], [".", 2287]]}
{"context": "Pannexin2 (Panx2) is the largest of three members of the pannexin proteins. Pannexins are topologically related to connexins and innexins, but serve different functional roles than forming gap junctions. We previously showed that pannexins form oligomeric channels but unlike connexins and innexins, they form only single membrane channels. High levels of Panx2 mRNA and protein in the Central Nervous System (CNS) have been documented. Whereas Pannexin1 (Panx1) is fairly ubiquitous and Pannexin3 (Panx3) is found in skin and connective tissue, both are fully glycosylated, traffic to the plasma membrane and have functions correlated with extracellular ATP release. Here, we describe trafficking and subcellular localizations of exogenous Panx2 and Panx1 protein expression in MDCK, HeLa, and HEK 293T cells as well as endogenous Panx1 and Panx2 patterns in the CNS. Panx2 was found in intracellular localizations, was partially N-glycosylated, and localizations were non-overlapping with Panx1. Confocal images of hippocampal sections immunolabeled for the astrocytic protein GFAP, Panx1 and Panx2 demonstrated that the two isoforms, Panx1 and Panx2, localized at different subcellular compartments in both astrocytes and neurons. Using recombinant fusions of Panx2 with appended genetic tags developed for correlated light and electron microscopy and then expressed in different cell lines, we determined that Panx2 is localized in the membrane of intracellular vesicles and not in the endoplasmic reticulum as initially indicated by calnexin colocalization experiments. Dual immunofluorescence imaging with protein markers for specific vesicle compartments showed that Panx2 vesicles are early endosomal in origin. In electron tomographic volumes, cross-sections of these vesicles displayed fine structural details and close proximity to actin filaments. Thus, pannexins expressed at different subcellular compartments likely exert distinct functional roles, particularly in the nervous system.", "qas": [{"question": "Where is the protein Pannexin1 located?", "answers": ["plasma membrane"], "qid": "08b59657cf0b4a05a3b821cb53bc7eeb", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["protein", 13], ["Pannexin1", 21], ["located", 31], ["?", 38]], "detected_answers": [{"text": "plasma membrane", "token_spans": [[103, 104]], "char_spans": [[590, 604]]}]}], "context_tokens": [["Pannexin2", 0], ["(", 10], ["Panx2", 11], [")", 16], ["is", 18], ["the", 21], ["largest", 25], ["of", 33], ["three", 36], ["members", 42], ["of", 50], ["the", 53], ["pannexin", 57], ["proteins", 66], [".", 74], ["Pannexins", 76], ["are", 86], ["topologically", 90], ["related", 104], ["to", 112], ["connexins", 115], ["and", 125], ["innexins", 129], [",", 137], ["but", 139], ["serve", 143], ["different", 149], ["functional", 159], ["roles", 170], ["than", 176], ["forming", 181], ["gap", 189], ["junctions", 193], [".", 202], ["We", 204], ["previously", 207], ["showed", 218], ["that", 225], ["pannexins", 230], ["form", 240], ["oligomeric", 245], ["channels", 256], ["but", 265], ["unlike", 269], ["connexins", 276], ["and", 286], ["innexins", 290], [",", 298], ["they", 300], ["form", 305], ["only", 310], ["single", 315], ["membrane", 322], ["channels", 331], [".", 339], ["High", 341], ["levels", 346], ["of", 353], ["Panx2", 356], ["mRNA", 362], ["and", 367], ["protein", 371], ["in", 379], ["the", 382], ["Central", 386], ["Nervous", 394], ["System", 402], ["(", 409], ["CNS", 410], [")", 413], ["have", 415], ["been", 420], ["documented", 425], [".", 435], ["Whereas", 437], ["Pannexin1", 445], ["(", 455], ["Panx1", 456], [")", 461], ["is", 463], ["fairly", 466], ["ubiquitous", 473], ["and", 484], ["Pannexin3", 488], ["(", 498], ["Panx3", 499], [")", 504], ["is", 506], ["found", 509], ["in", 515], ["skin", 518], ["and", 523], ["connective", 527], ["tissue", 538], [",", 544], ["both", 546], ["are", 551], ["fully", 555], ["glycosylated", 561], [",", 573], ["traffic", 575], ["to", 583], ["the", 586], ["plasma", 590], ["membrane", 597], ["and", 606], ["have", 610], ["functions", 615], ["correlated", 625], ["with", 636], ["extracellular", 641], ["ATP", 655], ["release", 659], [".", 666], ["Here", 668], [",", 672], ["we", 674], ["describe", 677], ["trafficking", 686], ["and", 698], ["subcellular", 702], ["localizations", 714], ["of", 728], ["exogenous", 731], ["Panx2", 741], ["and", 747], ["Panx1", 751], ["protein", 757], ["expression", 765], ["in", 776], ["MDCK", 779], [",", 783], ["HeLa", 785], [",", 789], ["and", 791], ["HEK", 795], ["293", 799], ["T", 802], ["cells", 804], ["as", 810], ["well", 813], ["as", 818], ["endogenous", 821], ["Panx1", 832], ["and", 838], ["Panx2", 842], ["patterns", 848], ["in", 857], ["the", 860], ["CNS", 864], [".", 867], ["Panx2", 869], ["was", 875], ["found", 879], ["in", 885], ["intracellular", 888], ["localizations", 902], [",", 915], ["was", 917], ["partially", 921], ["N", 931], ["-", 932], ["glycosylated", 933], [",", 945], ["and", 947], ["localizations", 951], ["were", 965], ["non", 970], ["-", 973], ["overlapping", 974], ["with", 986], ["Panx1", 991], [".", 996], ["Confocal", 998], ["images", 1007], ["of", 1014], ["hippocampal", 1017], ["sections", 1029], ["immunolabeled", 1038], ["for", 1052], ["the", 1056], ["astrocytic", 1060], ["protein", 1071], ["GFAP", 1079], [",", 1083], ["Panx1", 1085], ["and", 1091], ["Panx2", 1095], ["demonstrated", 1101], ["that", 1114], ["the", 1119], ["two", 1123], ["isoforms", 1127], [",", 1135], ["Panx1", 1137], ["and", 1143], ["Panx2", 1147], [",", 1152], ["localized", 1154], ["at", 1164], ["different", 1167], ["subcellular", 1177], ["compartments", 1189], ["in", 1202], ["both", 1205], ["astrocytes", 1210], ["and", 1221], ["neurons", 1225], [".", 1232], ["Using", 1234], ["recombinant", 1240], ["fusions", 1252], ["of", 1260], ["Panx2", 1263], ["with", 1269], ["appended", 1274], ["genetic", 1283], ["tags", 1291], ["developed", 1296], ["for", 1306], ["correlated", 1310], ["light", 1321], ["and", 1327], ["electron", 1331], ["microscopy", 1340], ["and", 1351], ["then", 1355], ["expressed", 1360], ["in", 1370], ["different", 1373], ["cell", 1383], ["lines", 1388], [",", 1393], ["we", 1395], ["determined", 1398], ["that", 1409], ["Panx2", 1414], ["is", 1420], ["localized", 1423], ["in", 1433], ["the", 1436], ["membrane", 1440], ["of", 1449], ["intracellular", 1452], ["vesicles", 1466], ["and", 1475], ["not", 1479], ["in", 1483], ["the", 1486], ["endoplasmic", 1490], ["reticulum", 1502], ["as", 1512], ["initially", 1515], ["indicated", 1525], ["by", 1535], ["calnexin", 1538], ["colocalization", 1547], ["experiments", 1562], [".", 1573], ["Dual", 1575], ["immunofluorescence", 1580], ["imaging", 1599], ["with", 1607], ["protein", 1612], ["markers", 1620], ["for", 1628], ["specific", 1632], ["vesicle", 1641], ["compartments", 1649], ["showed", 1662], ["that", 1669], ["Panx2", 1674], ["vesicles", 1680], ["are", 1689], ["early", 1693], ["endosomal", 1699], ["in", 1709], ["origin", 1712], [".", 1718], ["In", 1720], ["electron", 1723], ["tomographic", 1732], ["volumes", 1744], [",", 1751], ["cross", 1753], ["-", 1758], ["sections", 1759], ["of", 1768], ["these", 1771], ["vesicles", 1777], ["displayed", 1786], ["fine", 1796], ["structural", 1801], ["details", 1812], ["and", 1820], ["close", 1824], ["proximity", 1830], ["to", 1840], ["actin", 1843], ["filaments", 1849], [".", 1858], ["Thus", 1860], [",", 1864], ["pannexins", 1866], ["expressed", 1876], ["at", 1886], ["different", 1889], ["subcellular", 1899], ["compartments", 1911], ["likely", 1924], ["exert", 1931], ["distinct", 1937], ["functional", 1946], ["roles", 1957], [",", 1962], ["particularly", 1964], ["in", 1977], ["the", 1980], ["nervous", 1984], ["system", 1992], [".", 1998]]}
{"context": "Quantitative real-time PCR (QPCR) has emerged as an accurate and valuable tool in profiling gene expression levels. One of its many advantages is a lower detection limit compared to other methods of gene expression profiling while using smaller amounts of input for each assay. Automated qPCR setup has improved this field by allowing for greater reproducibility. Its convenient and rapid setup allows for high-throughput experiments, enabling the profiling of many different genes simultaneously in each experiment. This method along with internal plate controls also reduces experimental variables common to other techniques. We recently developed a qPCR assay for profiling of pre-microRNAs (pre-miRNAs) using a set of 186 primer pairs. MicroRNAs have emerged as a novel class of small, non-coding RNAs with the ability to regulate many mRNA targets at the post-transcriptional level. These small RNAs are first transcribed by RNA polymerase II as a primary miRNA (pri-miRNA) transcript, which is then cleaved into the precursor miRNA (pre-miRNA). Pre-miRNAs are exported to the cytoplasm where Dicer cleaves the hairpin loop to yield mature miRNAs. Increases in miRNA levels can be observed at both the precursor and mature miRNA levels and profiling of both of these forms can be useful. There are several commercially available assays for mature miRNAs; however, their high cost may deter researchers from this profiling technique. Here, we discuss a cost-effective, reliable, SYBR-based qPCR method of profiling pre-miRNAs. Changes in pre-miRNA levels often reflect mature miRNA changes and can be a useful indicator of mature miRNA expression. However, simultaneous profiling of both pre-miRNAs and mature miRNAs may be optimal as they can contribute nonredundant information and provide insight into microRNA processing. Furthermore, the technique described here can be expanded to encompass the profiling of other library sets for specific pathways or pathogens.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "d5012159612c4b0b9722b00581b7cf34", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[164, 166]], "char_spans": [[930, 946]]}]}], "context_tokens": [["Quantitative", 0], ["real", 13], ["-", 17], ["time", 18], ["PCR", 23], ["(", 27], ["QPCR", 28], [")", 32], ["has", 34], ["emerged", 38], ["as", 46], ["an", 49], ["accurate", 52], ["and", 61], ["valuable", 65], ["tool", 74], ["in", 79], ["profiling", 82], ["gene", 92], ["expression", 97], ["levels", 108], [".", 114], ["One", 116], ["of", 120], ["its", 123], ["many", 127], ["advantages", 132], ["is", 143], ["a", 146], ["lower", 148], ["detection", 154], ["limit", 164], ["compared", 170], ["to", 179], ["other", 182], ["methods", 188], ["of", 196], ["gene", 199], ["expression", 204], ["profiling", 215], ["while", 225], ["using", 231], ["smaller", 237], ["amounts", 245], ["of", 253], ["input", 256], ["for", 262], ["each", 266], ["assay", 271], [".", 276], ["Automated", 278], ["qPCR", 288], ["setup", 293], ["has", 299], ["improved", 303], ["this", 312], ["field", 317], ["by", 323], ["allowing", 326], ["for", 335], ["greater", 339], ["reproducibility", 347], [".", 362], ["Its", 364], ["convenient", 368], ["and", 379], ["rapid", 383], ["setup", 389], ["allows", 395], ["for", 402], ["high", 406], ["-", 410], ["throughput", 411], ["experiments", 422], [",", 433], ["enabling", 435], ["the", 444], ["profiling", 448], ["of", 458], ["many", 461], ["different", 466], ["genes", 476], ["simultaneously", 482], ["in", 497], ["each", 500], ["experiment", 505], [".", 515], ["This", 517], ["method", 522], ["along", 529], ["with", 535], ["internal", 540], ["plate", 549], ["controls", 555], ["also", 564], ["reduces", 569], ["experimental", 577], ["variables", 590], ["common", 600], ["to", 607], ["other", 610], ["techniques", 616], [".", 626], ["We", 628], ["recently", 631], ["developed", 640], ["a", 650], ["qPCR", 652], ["assay", 657], ["for", 663], ["profiling", 667], ["of", 677], ["pre", 680], ["-", 683], ["microRNAs", 684], ["(", 694], ["pre", 695], ["-", 698], ["miRNAs", 699], [")", 705], ["using", 707], ["a", 713], ["set", 715], ["of", 719], ["186", 722], ["primer", 726], ["pairs", 733], [".", 738], ["MicroRNAs", 740], ["have", 750], ["emerged", 755], ["as", 763], ["a", 766], ["novel", 768], ["class", 774], ["of", 780], ["small", 783], [",", 788], ["non", 790], ["-", 793], ["coding", 794], ["RNAs", 801], ["with", 806], ["the", 811], ["ability", 815], ["to", 823], ["regulate", 826], ["many", 835], ["mRNA", 840], ["targets", 845], ["at", 853], ["the", 856], ["post", 860], ["-", 864], ["transcriptional", 865], ["level", 881], [".", 886], ["These", 888], ["small", 894], ["RNAs", 900], ["are", 905], ["first", 909], ["transcribed", 915], ["by", 927], ["RNA", 930], ["polymerase", 934], ["II", 945], ["as", 948], ["a", 951], ["primary", 953], ["miRNA", 961], ["(", 967], ["pri", 968], ["-", 971], ["miRNA", 972], [")", 977], ["transcript", 979], [",", 989], ["which", 991], ["is", 997], ["then", 1000], ["cleaved", 1005], ["into", 1013], ["the", 1018], ["precursor", 1022], ["miRNA", 1032], ["(", 1038], ["pre", 1039], ["-", 1042], ["miRNA", 1043], [")", 1048], [".", 1049], ["Pre", 1051], ["-", 1054], ["miRNAs", 1055], ["are", 1062], ["exported", 1066], ["to", 1075], ["the", 1078], ["cytoplasm", 1082], ["where", 1092], ["Dicer", 1098], ["cleaves", 1104], ["the", 1112], ["hairpin", 1116], ["loop", 1124], ["to", 1129], ["yield", 1132], ["mature", 1138], ["miRNAs", 1145], [".", 1151], ["Increases", 1153], ["in", 1163], ["miRNA", 1166], ["levels", 1172], ["can", 1179], ["be", 1183], ["observed", 1186], ["at", 1195], ["both", 1198], ["the", 1203], ["precursor", 1207], ["and", 1217], ["mature", 1221], ["miRNA", 1228], ["levels", 1234], ["and", 1241], ["profiling", 1245], ["of", 1255], ["both", 1258], ["of", 1263], ["these", 1266], ["forms", 1272], ["can", 1278], ["be", 1282], ["useful", 1285], [".", 1291], ["There", 1293], ["are", 1299], ["several", 1303], ["commercially", 1311], ["available", 1324], ["assays", 1334], ["for", 1341], ["mature", 1345], ["miRNAs", 1352], [";", 1358], ["however", 1360], [",", 1367], ["their", 1369], ["high", 1375], ["cost", 1380], ["may", 1385], ["deter", 1389], ["researchers", 1395], ["from", 1407], ["this", 1412], ["profiling", 1417], ["technique", 1427], [".", 1436], ["Here", 1438], [",", 1442], ["we", 1444], ["discuss", 1447], ["a", 1455], ["cost", 1457], ["-", 1461], ["effective", 1462], [",", 1471], ["reliable", 1473], [",", 1481], ["SYBR", 1483], ["-", 1487], ["based", 1488], ["qPCR", 1494], ["method", 1499], ["of", 1506], ["profiling", 1509], ["pre", 1519], ["-", 1522], ["miRNAs", 1523], [".", 1529], ["Changes", 1531], ["in", 1539], ["pre", 1542], ["-", 1545], ["miRNA", 1546], ["levels", 1552], ["often", 1559], ["reflect", 1565], ["mature", 1573], ["miRNA", 1580], ["changes", 1586], ["and", 1594], ["can", 1598], ["be", 1602], ["a", 1605], ["useful", 1607], ["indicator", 1614], ["of", 1624], ["mature", 1627], ["miRNA", 1634], ["expression", 1640], [".", 1650], ["However", 1652], [",", 1659], ["simultaneous", 1661], ["profiling", 1674], ["of", 1684], ["both", 1687], ["pre", 1692], ["-", 1695], ["miRNAs", 1696], ["and", 1703], ["mature", 1707], ["miRNAs", 1714], ["may", 1721], ["be", 1725], ["optimal", 1728], ["as", 1736], ["they", 1739], ["can", 1744], ["contribute", 1748], ["nonredundant", 1759], ["information", 1772], ["and", 1784], ["provide", 1788], ["insight", 1796], ["into", 1804], ["microRNA", 1809], ["processing", 1818], [".", 1828], ["Furthermore", 1830], [",", 1841], ["the", 1843], ["technique", 1847], ["described", 1857], ["here", 1867], ["can", 1872], ["be", 1876], ["expanded", 1879], ["to", 1888], ["encompass", 1891], ["the", 1901], ["profiling", 1905], ["of", 1915], ["other", 1918], ["library", 1924], ["sets", 1932], ["for", 1937], ["specific", 1941], ["pathways", 1950], ["or", 1959], ["pathogens", 1962], [".", 1971]]}
{"context": "Katayama fever is an acute clinical condition characterised by high fever, dry cough and general malaise occurring during early Schistosoma spp. infection. It is predominantly reported in travellers from non-endemic regions. Whereas the immunological response to Schistosoma infection is well characterised, alterations in inflammatory markers and coagulation in response to acute infection are poorly understood. Here we report the clinical, laboratory and radiological characteristics of three returning travellers with Katayama fever. Inflammatory markers and coagulation status were assessed repeatedly during follow-up to characterise the host response to infection. Radiographic findings were correlated with clinical and laboratory markers. Clinical symptoms were suggestive of a significant inflammatory response in all patients including high fever (>39\u00b0C), cough, and general malaise. Classical inflammatory markers including blood sedimentation rate, C-reactive protein, and serum amyloid A were only moderately elevated. Marked eosinophilia (33-42% of white blood cells) was observed and persisted despite anti-inflammatory and anthelminthic treatment for up to 32 weeks. Analysis of blood coagulation markers indicated increased coagulability reflected by elevated D-dimer values (0.57-1.17 \u03bcg/ml) and high thrombin generating potentials (peak thrombin activity: 311-384 nM). One patient showed particularly high levels of microparticle-associated tissue factor activity at initial presentation (1.64 pg/ml). Multiple pulmonary and hepatic opacities demonstrated by computed tomography (CT) scanning were associated with raised inflammatory markers in one patient. The characterisation of the inflammatory response, blood coagulation parameters and radiological findings in three patients adds to our current understanding of Katayama fever and serves as a starting point for further systematic investigations of the pathophysiology of this acute helminthic infection.", "qas": [{"question": "What causes Katayama Fever?", "answers": ["Schistosoma spp"], "qid": "89d498b4ba614556a6e601b0a267b76b", "question_tokens": [["What", 0], ["causes", 5], ["Katayama", 12], ["Fever", 21], ["?", 26]], "detected_answers": [{"text": "Schistosoma spp", "token_spans": [[20, 21]], "char_spans": [[128, 142]]}]}], "context_tokens": [["Katayama", 0], ["fever", 9], ["is", 15], ["an", 18], ["acute", 21], ["clinical", 27], ["condition", 36], ["characterised", 46], ["by", 60], ["high", 63], ["fever", 68], [",", 73], ["dry", 75], ["cough", 79], ["and", 85], ["general", 89], ["malaise", 97], ["occurring", 105], ["during", 115], ["early", 122], ["Schistosoma", 128], ["spp", 140], [".", 143], ["infection", 145], [".", 154], ["It", 156], ["is", 159], ["predominantly", 162], ["reported", 176], ["in", 185], ["travellers", 188], ["from", 199], ["non", 204], ["-", 207], ["endemic", 208], ["regions", 216], [".", 223], ["Whereas", 225], ["the", 233], ["immunological", 237], ["response", 251], ["to", 260], ["Schistosoma", 263], ["infection", 275], ["is", 285], ["well", 288], ["characterised", 293], [",", 306], ["alterations", 308], ["in", 320], ["inflammatory", 323], ["markers", 336], ["and", 344], ["coagulation", 348], ["in", 360], ["response", 363], ["to", 372], ["acute", 375], ["infection", 381], ["are", 391], ["poorly", 395], ["understood", 402], [".", 412], ["Here", 414], ["we", 419], ["report", 422], ["the", 429], ["clinical", 433], [",", 441], ["laboratory", 443], ["and", 454], ["radiological", 458], ["characteristics", 471], ["of", 487], ["three", 490], ["returning", 496], ["travellers", 506], ["with", 517], ["Katayama", 522], ["fever", 531], [".", 536], ["Inflammatory", 538], ["markers", 551], ["and", 559], ["coagulation", 563], ["status", 575], ["were", 582], ["assessed", 587], ["repeatedly", 596], ["during", 607], ["follow", 614], ["-", 620], ["up", 621], ["to", 624], ["characterise", 627], ["the", 640], ["host", 644], ["response", 649], ["to", 658], ["infection", 661], [".", 670], ["Radiographic", 672], ["findings", 685], ["were", 694], ["correlated", 699], ["with", 710], ["clinical", 715], ["and", 724], ["laboratory", 728], ["markers", 739], [".", 746], ["Clinical", 748], ["symptoms", 757], ["were", 766], ["suggestive", 771], ["of", 782], ["a", 785], ["significant", 787], ["inflammatory", 799], ["response", 812], ["in", 821], ["all", 824], ["patients", 828], ["including", 837], ["high", 847], ["fever", 852], ["(", 858], [">", 859], ["39", 860], ["\u00b0", 862], ["C", 863], [")", 864], [",", 865], ["cough", 867], [",", 872], ["and", 874], ["general", 878], ["malaise", 886], [".", 893], ["Classical", 895], ["inflammatory", 905], ["markers", 918], ["including", 926], ["blood", 936], ["sedimentation", 942], ["rate", 956], [",", 960], ["C", 962], ["-", 963], ["reactive", 964], ["protein", 973], [",", 980], ["and", 982], ["serum", 986], ["amyloid", 992], ["A", 1000], ["were", 1002], ["only", 1007], ["moderately", 1012], ["elevated", 1023], [".", 1031], ["Marked", 1033], ["eosinophilia", 1040], ["(", 1053], ["33", 1054], ["-", 1056], ["42", 1057], ["%", 1059], ["of", 1061], ["white", 1064], ["blood", 1070], ["cells", 1076], [")", 1081], ["was", 1083], ["observed", 1087], ["and", 1096], ["persisted", 1100], ["despite", 1110], ["anti", 1118], ["-", 1122], ["inflammatory", 1123], ["and", 1136], ["anthelminthic", 1140], ["treatment", 1154], ["for", 1164], ["up", 1168], ["to", 1171], ["32", 1174], ["weeks", 1177], [".", 1182], ["Analysis", 1184], ["of", 1193], ["blood", 1196], ["coagulation", 1202], ["markers", 1214], ["indicated", 1222], ["increased", 1232], ["coagulability", 1242], ["reflected", 1256], ["by", 1266], ["elevated", 1269], ["D", 1278], ["-", 1279], ["dimer", 1280], ["values", 1286], ["(", 1293], ["0.57", 1294], ["-", 1298], ["1.17", 1299], ["\u03bcg", 1304], ["/", 1306], ["ml", 1307], [")", 1309], ["and", 1311], ["high", 1315], ["thrombin", 1320], ["generating", 1329], ["potentials", 1340], ["(", 1351], ["peak", 1352], ["thrombin", 1357], ["activity", 1366], [":", 1374], ["311", 1376], ["-", 1379], ["384", 1380], ["nM", 1384], [")", 1386], [".", 1387], ["One", 1389], ["patient", 1393], ["showed", 1401], ["particularly", 1408], ["high", 1421], ["levels", 1426], ["of", 1433], ["microparticle", 1436], ["-", 1449], ["associated", 1450], ["tissue", 1461], ["factor", 1468], ["activity", 1475], ["at", 1484], ["initial", 1487], ["presentation", 1495], ["(", 1508], ["1.64", 1509], ["pg", 1514], ["/", 1516], ["ml", 1517], [")", 1519], [".", 1520], ["Multiple", 1522], ["pulmonary", 1531], ["and", 1541], ["hepatic", 1545], ["opacities", 1553], ["demonstrated", 1563], ["by", 1576], ["computed", 1579], ["tomography", 1588], ["(", 1599], ["CT", 1600], [")", 1602], ["scanning", 1604], ["were", 1613], ["associated", 1618], ["with", 1629], ["raised", 1634], ["inflammatory", 1641], ["markers", 1654], ["in", 1662], ["one", 1665], ["patient", 1669], [".", 1676], ["The", 1678], ["characterisation", 1682], ["of", 1699], ["the", 1702], ["inflammatory", 1706], ["response", 1719], [",", 1727], ["blood", 1729], ["coagulation", 1735], ["parameters", 1747], ["and", 1758], ["radiological", 1762], ["findings", 1775], ["in", 1784], ["three", 1787], ["patients", 1793], ["adds", 1802], ["to", 1807], ["our", 1810], ["current", 1814], ["understanding", 1822], ["of", 1836], ["Katayama", 1839], ["fever", 1848], ["and", 1854], ["serves", 1858], ["as", 1865], ["a", 1868], ["starting", 1870], ["point", 1879], ["for", 1885], ["further", 1889], ["systematic", 1897], ["investigations", 1908], ["of", 1923], ["the", 1926], ["pathophysiology", 1930], ["of", 1946], ["this", 1949], ["acute", 1954], ["helminthic", 1960], ["infection", 1971], [".", 1980]]}
{"context": "Imatinib is one of the most recent medications used for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). It is an orally administered protein-tyrosine kinase inhibitor, an enzyme which is produced by BCR-ABL fusion which results from translocation of 9:22 chromosome (Philadelphia chromosome). Imatinib blocks proliferation and induces apoptosis of BCR-ABL-expression in CML. Many side effects produced by imatinib have been documented but its induction of hepatotoxcity has been rarely reported. Only a few cases so far have been reported in the literature and almost all were in females. We describe another case of hepatotoxicity due to imatinib in a 17-year old female with clinical, laboratory and histopathological changes. The case described here suggests that imatinib may also induce immune hepatitis, in some patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "1db96bcfd90d49b5af28e24058364cb1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[44, 46], [67, 69]], "char_spans": [[242, 248], [391, 397]]}]}], "context_tokens": [["Imatinib", 0], ["is", 9], ["one", 12], ["of", 16], ["the", 19], ["most", 23], ["recent", 28], ["medications", 35], ["used", 47], ["for", 52], ["the", 56], ["treatment", 60], ["of", 70], ["chronic", 73], ["myeloid", 81], ["leukemia", 89], ["(", 98], ["CML", 99], [")", 102], ["and", 104], ["gastrointestinal", 108], ["stromal", 125], ["tumor", 133], ["(", 139], ["GIST", 140], [")", 144], [".", 145], ["It", 147], ["is", 150], ["an", 153], ["orally", 156], ["administered", 163], ["protein", 176], ["-", 183], ["tyrosine", 184], ["kinase", 193], ["inhibitor", 200], [",", 209], ["an", 211], ["enzyme", 214], ["which", 221], ["is", 227], ["produced", 230], ["by", 239], ["BCR", 242], ["-", 245], ["ABL", 246], ["fusion", 250], ["which", 257], ["results", 263], ["from", 271], ["translocation", 276], ["of", 290], ["9:22", 293], ["chromosome", 298], ["(", 309], ["Philadelphia", 310], ["chromosome", 323], [")", 333], [".", 334], ["Imatinib", 336], ["blocks", 345], ["proliferation", 352], ["and", 366], ["induces", 370], ["apoptosis", 378], ["of", 388], ["BCR", 391], ["-", 394], ["ABL", 395], ["-", 398], ["expression", 399], ["in", 410], ["CML", 413], [".", 416], ["Many", 418], ["side", 423], ["effects", 428], ["produced", 436], ["by", 445], ["imatinib", 448], ["have", 457], ["been", 462], ["documented", 467], ["but", 478], ["its", 482], ["induction", 486], ["of", 496], ["hepatotoxcity", 499], ["has", 513], ["been", 517], ["rarely", 522], ["reported", 529], [".", 537], ["Only", 539], ["a", 544], ["few", 546], ["cases", 550], ["so", 556], ["far", 559], ["have", 563], ["been", 568], ["reported", 573], ["in", 582], ["the", 585], ["literature", 589], ["and", 600], ["almost", 604], ["all", 611], ["were", 615], ["in", 620], ["females", 623], [".", 630], ["We", 632], ["describe", 635], ["another", 644], ["case", 652], ["of", 657], ["hepatotoxicity", 660], ["due", 675], ["to", 679], ["imatinib", 682], ["in", 691], ["a", 694], ["17-year", 696], ["old", 704], ["female", 708], ["with", 715], ["clinical", 720], [",", 728], ["laboratory", 730], ["and", 741], ["histopathological", 745], ["changes", 763], [".", 770], ["The", 772], ["case", 776], ["described", 781], ["here", 791], ["suggests", 796], ["that", 805], ["imatinib", 810], ["may", 819], ["also", 823], ["induce", 828], ["immune", 835], ["hepatitis", 842], [",", 851], ["in", 853], ["some", 856], ["patients", 861], [".", 869]]}
{"context": "We report on maternal first cousins with bilateral microtia, micrognathia, cleft palate and hematologic findings of Diamond-Blackfan anemia (DBA). The similarity of findings shared between our cases and a female reported by Hasan and Inoue [1993] suggests that this is a distinctive syndrome, rather than a chance association. DBA is a heterogeneous disorder, caused in about 25% of cases by heterozygous mutations in the RPS19 gene (DBA1). Mutation analysis in our cases did not show an RPS19 mutation, and 2 alleles were present in each. Segregation analysis for DBA1 on chromosome 19 and DBA2 on 8p23 was not consistent with linkage. We conclude that this syndrome of microtia, cleft palate and DBA is not allelic to known DBA loci.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "18ad572dfb52412caadfcb13edb5accd", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[18, 21]], "char_spans": [[116, 138]]}, {"text": "DBA", "token_spans": [[137, 137], [59, 59], [23, 23], [131, 131]], "char_spans": [[726, 728], [327, 329], [141, 143], [698, 700]]}]}], "context_tokens": [["We", 0], ["report", 3], ["on", 10], ["maternal", 13], ["first", 22], ["cousins", 28], ["with", 36], ["bilateral", 41], ["microtia", 51], [",", 59], ["micrognathia", 61], [",", 73], ["cleft", 75], ["palate", 81], ["and", 88], ["hematologic", 92], ["findings", 104], ["of", 113], ["Diamond", 116], ["-", 123], ["Blackfan", 124], ["anemia", 133], ["(", 140], ["DBA", 141], [")", 144], [".", 145], ["The", 147], ["similarity", 151], ["of", 162], ["findings", 165], ["shared", 174], ["between", 181], ["our", 189], ["cases", 193], ["and", 199], ["a", 203], ["female", 205], ["reported", 212], ["by", 221], ["Hasan", 224], ["and", 230], ["Inoue", 234], ["[", 240], ["1993", 241], ["]", 245], ["suggests", 247], ["that", 256], ["this", 261], ["is", 266], ["a", 269], ["distinctive", 271], ["syndrome", 283], [",", 291], ["rather", 293], ["than", 300], ["a", 305], ["chance", 307], ["association", 314], [".", 325], ["DBA", 327], ["is", 331], ["a", 334], ["heterogeneous", 336], ["disorder", 350], [",", 358], ["caused", 360], ["in", 367], ["about", 370], ["25", 376], ["%", 378], ["of", 380], ["cases", 383], ["by", 389], ["heterozygous", 392], ["mutations", 405], ["in", 415], ["the", 418], ["RPS19", 422], ["gene", 428], ["(", 433], ["DBA1", 434], [")", 438], [".", 439], ["Mutation", 441], ["analysis", 450], ["in", 459], ["our", 462], ["cases", 466], ["did", 472], ["not", 476], ["show", 480], ["an", 485], ["RPS19", 488], ["mutation", 494], [",", 502], ["and", 504], ["2", 508], ["alleles", 510], ["were", 518], ["present", 523], ["in", 531], ["each", 534], [".", 538], ["Segregation", 540], ["analysis", 552], ["for", 561], ["DBA1", 565], ["on", 570], ["chromosome", 573], ["19", 584], ["and", 587], ["DBA2", 591], ["on", 596], ["8p23", 599], ["was", 604], ["not", 608], ["consistent", 612], ["with", 623], ["linkage", 628], [".", 635], ["We", 637], ["conclude", 640], ["that", 649], ["this", 654], ["syndrome", 659], ["of", 668], ["microtia", 671], [",", 679], ["cleft", 681], ["palate", 687], ["and", 694], ["DBA", 698], ["is", 702], ["not", 705], ["allelic", 709], ["to", 717], ["known", 720], ["DBA", 726], ["loci", 730], [".", 734]]}
{"context": "Heroin overdose is a major cause of death among heroin users, and often occurs in the company of other users. However, sudden death after injection is rare, giving ample opportunity for intervention. Naloxone hydrochloride, an injectable opioid antagonist which reverses the respiratory depression, sedation and hypotension associated with opioids, has long been used to treat opioid overdose. Experts have suggested that, as part of a comprehensive overdose prevention strategy, naloxone should be provided to heroin users for peer administration after an overdose. A trial could be conducted to determine whether this intervention improves the management of overdose or results in a net increase in harm (by undermining existing prevention strategies, precipitating naloxone-related complications, or resulting in riskier heroin use).", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "6e72346d9baf4bee8b690349f4e87241", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[80, 80], [37, 37], [125, 125]], "char_spans": [[480, 487], [200, 207], [768, 775]]}]}], "context_tokens": [["Heroin", 0], ["overdose", 7], ["is", 16], ["a", 19], ["major", 21], ["cause", 27], ["of", 33], ["death", 36], ["among", 42], ["heroin", 48], ["users", 55], [",", 60], ["and", 62], ["often", 66], ["occurs", 72], ["in", 79], ["the", 82], ["company", 86], ["of", 94], ["other", 97], ["users", 103], [".", 108], ["However", 110], [",", 117], ["sudden", 119], ["death", 126], ["after", 132], ["injection", 138], ["is", 148], ["rare", 151], [",", 155], ["giving", 157], ["ample", 164], ["opportunity", 170], ["for", 182], ["intervention", 186], [".", 198], ["Naloxone", 200], ["hydrochloride", 209], [",", 222], ["an", 224], ["injectable", 227], ["opioid", 238], ["antagonist", 245], ["which", 256], ["reverses", 262], ["the", 271], ["respiratory", 275], ["depression", 287], [",", 297], ["sedation", 299], ["and", 308], ["hypotension", 312], ["associated", 324], ["with", 335], ["opioids", 340], [",", 347], ["has", 349], ["long", 353], ["been", 358], ["used", 363], ["to", 368], ["treat", 371], ["opioid", 377], ["overdose", 384], [".", 392], ["Experts", 394], ["have", 402], ["suggested", 407], ["that", 417], [",", 421], ["as", 423], ["part", 426], ["of", 431], ["a", 434], ["comprehensive", 436], ["overdose", 450], ["prevention", 459], ["strategy", 470], [",", 478], ["naloxone", 480], ["should", 489], ["be", 496], ["provided", 499], ["to", 508], ["heroin", 511], ["users", 518], ["for", 524], ["peer", 528], ["administration", 533], ["after", 548], ["an", 554], ["overdose", 557], [".", 565], ["A", 567], ["trial", 569], ["could", 575], ["be", 581], ["conducted", 584], ["to", 594], ["determine", 597], ["whether", 607], ["this", 615], ["intervention", 620], ["improves", 633], ["the", 642], ["management", 646], ["of", 657], ["overdose", 660], ["or", 669], ["results", 672], ["in", 680], ["a", 683], ["net", 685], ["increase", 689], ["in", 698], ["harm", 701], ["(", 706], ["by", 707], ["undermining", 710], ["existing", 722], ["prevention", 731], ["strategies", 742], [",", 752], ["precipitating", 754], ["naloxone", 768], ["-", 776], ["related", 777], ["complications", 785], [",", 798], ["or", 800], ["resulting", 803], ["in", 813], ["riskier", 816], ["heroin", 824], ["use", 831], [")", 834], [".", 835]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "1e975a42f37e4673a2b441a56ec1c446", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[0, 1]], "char_spans": [[0, 28]]}, {"text": "FSHD", "token_spans": [[3, 3]], "char_spans": [[31, 34]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "Dendritic cells (DCs), professional antigen-presenting cells with the unique ability to initiate primary T-cell responses, are present in atherosclerotic lesions where they are exposed to oxidative stress that generates cytotoxic reactive oxygen species (ROS). A large body of evidence indicates that cell death is a major modulating factor of atherogenesis. We examined antioxidant defence systems of human monocyte-derived (mo)DCs and monocytes in response to oxidative stress. Oxidative stress was induced by addition of tertiary-butylhydroperoxide (tert-BHP, 30 min). Cellular responses were evaluated using flow cytometry and confocal live cell imaging (both using 5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein diacetate, CM-H(2)DCFDA). Viability was assessed by the neutral red assay. Total RNA was extracted for a PCR profiler array. Five genes were selected for confirmation by Taqman gene expression assays, and by immunoblotting or immunohistochemistry for protein levels. Tert-BHP increased CM-H(2)DCFDA fluorescence and caused cell death. Interestingly, all processes occurred more slowly in moDCs than in monocytes. The mRNA profiler array showed more than 2-fold differential expression of 32 oxidative stress-related genes in unstimulated moDCs, including peroxiredoxin-2 (PRDX2), an enzyme reducing hydrogen peroxide and lipid peroxides. PRDX2 upregulation was confirmed by Taqman assays, immunoblotting and immunohistochemistry. Silencing PRDX2 in moDCs by means of siRNA significantly increased CM-DCF fluorescence and cell death upon tert-BHP-stimulation. Our results indicate that moDCs exhibit higher intracellular antioxidant capacities, making them better equipped to resist oxidative stress than monocytes. Upregulation of PRDX2 is involved in the neutralization of ROS in moDCs. Taken together, this points to better survival skills of DCs in oxidative stress environments, such as atherosclerotic plaques.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "e0afb40c95bf43ecb23eaab63790e3b4", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[64, 64], [270, 270]], "char_spans": [[371, 381], [1644, 1654]]}]}], "context_tokens": [["Dendritic", 0], ["cells", 10], ["(", 16], ["DCs", 17], [")", 20], [",", 21], ["professional", 23], ["antigen", 36], ["-", 43], ["presenting", 44], ["cells", 55], ["with", 61], ["the", 66], ["unique", 70], ["ability", 77], ["to", 85], ["initiate", 88], ["primary", 97], ["T", 105], ["-", 106], ["cell", 107], ["responses", 112], [",", 121], ["are", 123], ["present", 127], ["in", 135], ["atherosclerotic", 138], ["lesions", 154], ["where", 162], ["they", 168], ["are", 173], ["exposed", 177], ["to", 185], ["oxidative", 188], ["stress", 198], ["that", 205], ["generates", 210], ["cytotoxic", 220], ["reactive", 230], ["oxygen", 239], ["species", 246], ["(", 254], ["ROS", 255], [")", 258], [".", 259], ["A", 261], ["large", 263], ["body", 269], ["of", 274], ["evidence", 277], ["indicates", 286], ["that", 296], ["cell", 301], ["death", 306], ["is", 312], ["a", 315], ["major", 317], ["modulating", 323], ["factor", 334], ["of", 341], ["atherogenesis", 344], [".", 357], ["We", 359], ["examined", 362], ["antioxidant", 371], ["defence", 383], ["systems", 391], ["of", 399], ["human", 402], ["monocyte", 408], ["-", 416], ["derived", 417], ["(", 425], ["mo)DCs", 426], ["and", 433], ["monocytes", 437], ["in", 447], ["response", 450], ["to", 459], ["oxidative", 462], ["stress", 472], [".", 478], ["Oxidative", 480], ["stress", 490], ["was", 497], ["induced", 501], ["by", 509], ["addition", 512], ["of", 521], ["tertiary", 524], ["-", 532], ["butylhydroperoxide", 533], ["(", 552], ["tert", 553], ["-", 557], ["BHP", 558], [",", 561], ["30", 563], ["min", 566], [")", 569], [".", 570], ["Cellular", 572], ["responses", 581], ["were", 591], ["evaluated", 596], ["using", 606], ["flow", 612], ["cytometry", 617], ["and", 627], ["confocal", 631], ["live", 640], ["cell", 645], ["imaging", 650], ["(", 658], ["both", 659], ["using", 664], ["5-(and-6)-chloromethyl-2,7-dichlorodihydrofluorescein", 670], ["diacetate", 724], [",", 733], ["CM", 735], ["-", 737], ["H(2)DCFDA", 738], [")", 747], [".", 748], ["Viability", 750], ["was", 760], ["assessed", 764], ["by", 773], ["the", 776], ["neutral", 780], ["red", 788], ["assay", 792], [".", 797], ["Total", 799], ["RNA", 805], ["was", 809], ["extracted", 813], ["for", 823], ["a", 827], ["PCR", 829], ["profiler", 833], ["array", 842], [".", 847], ["Five", 849], ["genes", 854], ["were", 860], ["selected", 865], ["for", 874], ["confirmation", 878], ["by", 891], ["Taqman", 894], ["gene", 901], ["expression", 906], ["assays", 917], [",", 923], ["and", 925], ["by", 929], ["immunoblotting", 932], ["or", 947], ["immunohistochemistry", 950], ["for", 971], ["protein", 975], ["levels", 983], [".", 989], ["Tert", 991], ["-", 995], ["BHP", 996], ["increased", 1000], ["CM", 1010], ["-", 1012], ["H(2)DCFDA", 1013], ["fluorescence", 1023], ["and", 1036], ["caused", 1040], ["cell", 1047], ["death", 1052], [".", 1057], ["Interestingly", 1059], [",", 1072], ["all", 1074], ["processes", 1078], ["occurred", 1088], ["more", 1097], ["slowly", 1102], ["in", 1109], ["moDCs", 1112], ["than", 1118], ["in", 1123], ["monocytes", 1126], [".", 1135], ["The", 1137], ["mRNA", 1141], ["profiler", 1146], ["array", 1155], ["showed", 1161], ["more", 1168], ["than", 1173], ["2-fold", 1178], ["differential", 1185], ["expression", 1198], ["of", 1209], ["32", 1212], ["oxidative", 1215], ["stress", 1225], ["-", 1231], ["related", 1232], ["genes", 1240], ["in", 1246], ["unstimulated", 1249], ["moDCs", 1262], [",", 1267], ["including", 1269], ["peroxiredoxin-2", 1279], ["(", 1295], ["PRDX2", 1296], [")", 1301], [",", 1302], ["an", 1304], ["enzyme", 1307], ["reducing", 1314], ["hydrogen", 1323], ["peroxide", 1332], ["and", 1341], ["lipid", 1345], ["peroxides", 1351], [".", 1360], ["PRDX2", 1362], ["upregulation", 1368], ["was", 1381], ["confirmed", 1385], ["by", 1395], ["Taqman", 1398], ["assays", 1405], [",", 1411], ["immunoblotting", 1413], ["and", 1428], ["immunohistochemistry", 1432], [".", 1452], ["Silencing", 1454], ["PRDX2", 1464], ["in", 1470], ["moDCs", 1473], ["by", 1479], ["means", 1482], ["of", 1488], ["siRNA", 1491], ["significantly", 1497], ["increased", 1511], ["CM", 1521], ["-", 1523], ["DCF", 1524], ["fluorescence", 1528], ["and", 1541], ["cell", 1545], ["death", 1550], ["upon", 1556], ["tert", 1561], ["-", 1565], ["BHP", 1566], ["-", 1569], ["stimulation", 1570], [".", 1581], ["Our", 1583], ["results", 1587], ["indicate", 1595], ["that", 1604], ["moDCs", 1609], ["exhibit", 1615], ["higher", 1623], ["intracellular", 1630], ["antioxidant", 1644], ["capacities", 1656], [",", 1666], ["making", 1668], ["them", 1675], ["better", 1680], ["equipped", 1687], ["to", 1696], ["resist", 1699], ["oxidative", 1706], ["stress", 1716], ["than", 1723], ["monocytes", 1728], [".", 1737], ["Upregulation", 1739], ["of", 1752], ["PRDX2", 1755], ["is", 1761], ["involved", 1764], ["in", 1773], ["the", 1776], ["neutralization", 1780], ["of", 1795], ["ROS", 1798], ["in", 1802], ["moDCs", 1805], [".", 1810], ["Taken", 1812], ["together", 1818], [",", 1826], ["this", 1828], ["points", 1833], ["to", 1840], ["better", 1843], ["survival", 1850], ["skills", 1859], ["of", 1866], ["DCs", 1869], ["in", 1873], ["oxidative", 1876], ["stress", 1886], ["environments", 1893], [",", 1905], ["such", 1907], ["as", 1912], ["atherosclerotic", 1915], ["plaques", 1931], [".", 1938]]}
{"context": "Ten years after Fire and Melo's Nobel Prize for discovery of gene silencing by double-stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes in the chemical structure of synthetic oligonucleotides make them more stable and specific, and new delivery strategies became progressively available. The attention of pharmaceutical industry rapidly turned to RNAi, as an opportunity to explore new drug targets. This review addresses nine small-interfering RNAs (siRNAs) and one unique microRNA (miRNA) inhibitor, which entered the phase 2-3 clinical trials. The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3). Regarding miRNAs, their content can be down- or up-regulated, by using miRNA inhibitors (AntimiRs) or miRNA mimics. Miravirsen is an AntimiR-122 for hepatitis C virus infection. The flexibility of RNAi technology is easily understood taking into account: (i) the different drug targets (i.e. p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral). Although some issues are still matters of concern (delivery, toxicity, cost, and biological barriers), RNAi definitively opens a wide avenue for drug development.", "qas": [{"question": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?", "answers": ["Phase 3"], "qid": "d2fdd08c60094d70a63f61dde1ded606", "question_tokens": [["In", 0], ["November", 3], ["2017", 12], [",", 16], [" ", 18], ["in", 19], ["what", 22], ["phase", 27], [" ", 33], ["was", 34], [" ", 38], ["the", 39], ["clinical", 43], ["trial", 52], ["for", 58], ["the", 62], ["drug", 66], ["SYL040012", 71], ["?", 80]], "detected_answers": [{"text": "Phase 3", "token_spans": [[134, 135]], "char_spans": [[718, 724]]}]}], "context_tokens": [["Ten", 0], ["years", 4], ["after", 10], ["Fire", 16], ["and", 21], ["Melo", 25], ["'s", 29], ["Nobel", 32], ["Prize", 38], ["for", 44], ["discovery", 48], ["of", 58], ["gene", 61], ["silencing", 66], ["by", 76], ["double", 79], ["-", 85], ["stranded", 86], ["RNA", 95], [",", 98], ["a", 100], ["remarkable", 102], ["progress", 113], ["was", 122], ["achieved", 126], ["in", 135], ["RNA", 138], ["interference", 142], ["(", 155], ["RNAi", 156], [")", 160], [".", 161], ["Changes", 163], ["in", 171], ["the", 174], ["chemical", 178], ["structure", 187], ["of", 197], ["synthetic", 200], ["oligonucleotides", 210], ["make", 227], ["them", 232], ["more", 237], ["stable", 242], ["and", 249], ["specific", 253], [",", 261], ["and", 263], ["new", 267], ["delivery", 271], ["strategies", 280], ["became", 291], ["progressively", 298], ["available", 312], [".", 321], ["The", 323], ["attention", 327], ["of", 337], ["pharmaceutical", 340], ["industry", 355], ["rapidly", 364], ["turned", 372], ["to", 379], ["RNAi", 382], [",", 386], ["as", 388], ["an", 391], ["opportunity", 394], ["to", 406], ["explore", 409], ["new", 417], ["drug", 421], ["targets", 426], [".", 433], ["This", 435], ["review", 440], ["addresses", 447], ["nine", 457], ["small", 462], ["-", 467], ["interfering", 468], ["RNAs", 480], ["(", 485], ["siRNAs", 486], [")", 492], ["and", 494], ["one", 498], ["unique", 502], ["microRNA", 509], ["(", 518], ["miRNA", 519], [")", 524], ["inhibitor", 526], [",", 535], ["which", 537], ["entered", 543], ["the", 551], ["phase", 555], ["2", 561], ["-", 562], ["3", 563], ["clinical", 565], ["trials", 574], [".", 580], ["The", 582], ["siRNAs", 586], ["in", 593], ["focus", 596], ["are", 602], ["PF-04523655", 606], [",", 617], ["TKM-080301", 619], [",", 629], ["Atu027", 631], [",", 637], ["SYL040012", 639], [",", 648], ["SYL1001", 650], [",", 657], ["siG12D", 659], ["-", 665], ["LODER", 666], ["(", 672], ["phase", 673], ["2", 679], [")", 680], [",", 681], ["QPI-1002", 683], [",", 691], ["QPI-1007", 693], [",", 701], ["and", 703], ["patisiran", 707], ["(", 717], ["phase", 718], ["3", 724], [")", 725], [".", 726], ["Regarding", 728], ["miRNAs", 738], [",", 744], ["their", 746], ["content", 752], ["can", 760], ["be", 764], ["down-", 767], ["or", 773], ["up", 776], ["-", 778], ["regulated", 779], [",", 788], ["by", 790], ["using", 793], ["miRNA", 799], ["inhibitors", 805], ["(", 816], ["AntimiRs", 817], [")", 825], ["or", 827], ["miRNA", 830], ["mimics", 836], [".", 842], ["Miravirsen", 844], ["is", 855], ["an", 858], ["AntimiR-122", 861], ["for", 873], ["hepatitis", 877], ["C", 887], ["virus", 889], ["infection", 895], [".", 904], ["The", 906], ["flexibility", 910], ["of", 922], ["RNAi", 925], ["technology", 930], ["is", 941], ["easily", 944], ["understood", 951], ["taking", 962], ["into", 969], ["account", 974], [":", 981], ["(", 983], ["i", 984], [")", 985], ["the", 987], ["different", 991], ["drug", 1001], ["targets", 1006], ["(", 1014], ["i.e.", 1015], ["p53", 1020], [",", 1023], ["caspase", 1025], ["2", 1033], [",", 1034], ["PKN3", 1036], [",", 1040], ["\u03b22-adrenergic", 1042], ["receptor", 1056], [",", 1064], ["mutated", 1066], ["KRAS", 1074], [",", 1078], ["microRNAs", 1080], [")", 1089], [";", 1090], ["(", 1092], ["ii", 1093], [")", 1095], ["therapeutic", 1097], ["conditions", 1109], [",", 1119], ["including", 1121], ["ophthalmic", 1131], ["diseases", 1142], [",", 1150], ["kidney", 1152], ["injury", 1159], [",", 1165], ["amyloidosis", 1167], [",", 1178], ["pancreatic", 1180], ["cancer", 1191], [",", 1197], ["viral", 1199], ["hepatitis", 1205], [";", 1214], ["and", 1216], ["(", 1220], ["iii", 1221], [")", 1224], ["routes", 1226], ["of", 1233], ["administration", 1236], ["(", 1251], ["ocular", 1252], [",", 1258], ["intravenous", 1260], [",", 1271], ["subcutaneous", 1273], [",", 1285], ["intratumoral", 1287], [")", 1299], [".", 1300], ["Although", 1302], ["some", 1311], ["issues", 1316], ["are", 1323], ["still", 1327], ["matters", 1333], ["of", 1341], ["concern", 1344], ["(", 1352], ["delivery", 1353], [",", 1361], ["toxicity", 1363], [",", 1371], ["cost", 1373], [",", 1377], ["and", 1379], ["biological", 1383], ["barriers", 1394], [")", 1402], [",", 1403], ["RNAi", 1405], ["definitively", 1410], ["opens", 1423], ["a", 1429], ["wide", 1431], ["avenue", 1436], ["for", 1443], ["drug", 1447], ["development", 1452], [".", 1463]]}
{"context": "Three isoforms of human plasma apolipoprotein E (apoE) are ligands to lipoprotein receptors and influence in different manner the synthesis and catabolism of pro-atherogenic triglyceride-rich lipoproteins. Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). The conformational transitions of beta-amyloid (Abeta) influenced by apoE and serum amyloid P (SAP) component are key events in AD development, the accumulation of intermediate diffusible and soluble oligomers of Abeta being of particular significance. SAP and apoE, in a different manner for the three isoforms, serve as \"pathological\" chaperones during the aggregation of Abeta considered as a conformation-prone process. In turn, apoE consisting of two domains self-associates in solution and intermediate structures differently populated for the three isoforms exist. The different structures of the three isoforms determine their different distribution among various plasma lipoproteins. The structural and metabolic consideration of the common apoE pathway(s) in two pathologies assumes four molecular targets for AD correction: (i) inhibition of the accumulation of diffusible soluble Abeta oligomers; (ii) inhibition of apoE synthesis and secretion by astrocytes, in particular, under lipid-lowering therapy; (iii) inhibition of the binding of apoE and/or SAP to Abeta; (iv) stimulation of the expression of cholesterol transporter ABCA1.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "d2affbf1297d4be7a210c9cbf1cccbba", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[38, 39]], "char_spans": [[232, 244]]}]}], "context_tokens": [["Three", 0], ["isoforms", 6], ["of", 15], ["human", 18], ["plasma", 24], ["apolipoprotein", 31], ["E", 46], ["(", 48], ["apoE", 49], [")", 53], ["are", 55], ["ligands", 59], ["to", 67], ["lipoprotein", 70], ["receptors", 82], ["and", 92], ["influence", 96], ["in", 106], ["different", 109], ["manner", 119], ["the", 126], ["synthesis", 130], ["and", 140], ["catabolism", 144], ["of", 155], ["pro", 158], ["-", 161], ["atherogenic", 162], ["triglyceride", 174], ["-", 186], ["rich", 187], ["lipoproteins", 192], [".", 204], ["Among", 206], ["three", 212], ["isoforms", 218], [",", 226], ["the", 228], ["apoE4", 232], ["isoform", 238], ["is", 246], ["associated", 249], ["with", 260], ["increased", 265], ["frequency", 275], ["of", 285], ["atherosclerosis", 288], ["and", 304], ["Alzheimer", 308], ["'s", 317], ["disease", 320], ["(", 328], ["AD", 329], [")", 331], [".", 332], ["The", 334], ["conformational", 338], ["transitions", 353], ["of", 365], ["beta", 368], ["-", 372], ["amyloid", 373], ["(", 381], ["Abeta", 382], [")", 387], ["influenced", 389], ["by", 400], ["apoE", 403], ["and", 408], ["serum", 412], ["amyloid", 418], ["P", 426], ["(", 428], ["SAP", 429], [")", 432], ["component", 434], ["are", 444], ["key", 448], ["events", 452], ["in", 459], ["AD", 462], ["development", 465], [",", 476], ["the", 478], ["accumulation", 482], ["of", 495], ["intermediate", 498], ["diffusible", 511], ["and", 522], ["soluble", 526], ["oligomers", 534], ["of", 544], ["Abeta", 547], ["being", 553], ["of", 559], ["particular", 562], ["significance", 573], [".", 585], ["SAP", 587], ["and", 591], ["apoE", 595], [",", 599], ["in", 601], ["a", 604], ["different", 606], ["manner", 616], ["for", 623], ["the", 627], ["three", 631], ["isoforms", 637], [",", 645], ["serve", 647], ["as", 653], ["\"", 656], ["pathological", 657], ["\"", 669], ["chaperones", 671], ["during", 682], ["the", 689], ["aggregation", 693], ["of", 705], ["Abeta", 708], ["considered", 714], ["as", 725], ["a", 728], ["conformation", 730], ["-", 742], ["prone", 743], ["process", 749], [".", 756], ["In", 758], ["turn", 761], [",", 765], ["apoE", 767], ["consisting", 772], ["of", 783], ["two", 786], ["domains", 790], ["self", 798], ["-", 802], ["associates", 803], ["in", 814], ["solution", 817], ["and", 826], ["intermediate", 830], ["structures", 843], ["differently", 854], ["populated", 866], ["for", 876], ["the", 880], ["three", 884], ["isoforms", 890], ["exist", 899], [".", 904], ["The", 906], ["different", 910], ["structures", 920], ["of", 931], ["the", 934], ["three", 938], ["isoforms", 944], ["determine", 953], ["their", 963], ["different", 969], ["distribution", 979], ["among", 992], ["various", 998], ["plasma", 1006], ["lipoproteins", 1013], [".", 1025], ["The", 1027], ["structural", 1031], ["and", 1042], ["metabolic", 1046], ["consideration", 1056], ["of", 1070], ["the", 1073], ["common", 1077], ["apoE", 1084], ["pathway(s", 1089], [")", 1098], ["in", 1100], ["two", 1103], ["pathologies", 1107], ["assumes", 1119], ["four", 1127], ["molecular", 1132], ["targets", 1142], ["for", 1150], ["AD", 1154], ["correction", 1157], [":", 1167], ["(", 1169], ["i", 1170], [")", 1171], ["inhibition", 1173], ["of", 1184], ["the", 1187], ["accumulation", 1191], ["of", 1204], ["diffusible", 1207], ["soluble", 1218], ["Abeta", 1226], ["oligomers", 1232], [";", 1241], ["(", 1243], ["ii", 1244], [")", 1246], ["inhibition", 1248], ["of", 1259], ["apoE", 1262], ["synthesis", 1267], ["and", 1277], ["secretion", 1281], ["by", 1291], ["astrocytes", 1294], [",", 1304], ["in", 1306], ["particular", 1309], [",", 1319], ["under", 1321], ["lipid", 1327], ["-", 1332], ["lowering", 1333], ["therapy", 1342], [";", 1349], ["(", 1351], ["iii", 1352], [")", 1355], ["inhibition", 1357], ["of", 1368], ["the", 1371], ["binding", 1375], ["of", 1383], ["apoE", 1386], ["and/or", 1391], ["SAP", 1398], ["to", 1402], ["Abeta", 1405], [";", 1410], ["(", 1412], ["iv", 1413], [")", 1415], ["stimulation", 1417], ["of", 1429], ["the", 1432], ["expression", 1436], ["of", 1447], ["cholesterol", 1450], ["transporter", 1462], ["ABCA1", 1474], [".", 1479]]}
{"context": "A 50-year-old man presented with worsening, virtually lifelong, chorea and progressive behavioural disturbance, involving disinhibition and hoarding, over 10 years. Clinical assessment revealed chorea, dysarthria, areflexia, an inappropriately jovial, impulsive manner and neuropsychological evidence of frontosubcortical dysfunction. Investigation results included an elevated creatine kinase, caudate atrophy and hypoperfusion, acanthocytes in the peripheral blood and the McLeod phenotype. DNA studies demonstrated a single-base deletion at position 172 in exon 1 of the XK gene, giving rise to a premature stop codon at position 129 in exon 2.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c44de3a52803425c8e515bdb5fb039ac", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[88, 88]], "char_spans": [[574, 575]]}]}], "context_tokens": [["A", 0], ["50-year", 2], ["-", 9], ["old", 10], ["man", 14], ["presented", 18], ["with", 28], ["worsening", 33], [",", 42], ["virtually", 44], ["lifelong", 54], [",", 62], ["chorea", 64], ["and", 71], ["progressive", 75], ["behavioural", 87], ["disturbance", 99], [",", 110], ["involving", 112], ["disinhibition", 122], ["and", 136], ["hoarding", 140], [",", 148], ["over", 150], ["10", 155], ["years", 158], [".", 163], ["Clinical", 165], ["assessment", 174], ["revealed", 185], ["chorea", 194], [",", 200], ["dysarthria", 202], [",", 212], ["areflexia", 214], [",", 223], ["an", 225], ["inappropriately", 228], ["jovial", 244], [",", 250], ["impulsive", 252], ["manner", 262], ["and", 269], ["neuropsychological", 273], ["evidence", 292], ["of", 301], ["frontosubcortical", 304], ["dysfunction", 322], [".", 333], ["Investigation", 335], ["results", 349], ["included", 357], ["an", 366], ["elevated", 369], ["creatine", 378], ["kinase", 387], [",", 393], ["caudate", 395], ["atrophy", 403], ["and", 411], ["hypoperfusion", 415], [",", 428], ["acanthocytes", 430], ["in", 443], ["the", 446], ["peripheral", 450], ["blood", 461], ["and", 467], ["the", 471], ["McLeod", 475], ["phenotype", 482], [".", 491], ["DNA", 493], ["studies", 497], ["demonstrated", 505], ["a", 518], ["single", 520], ["-", 526], ["base", 527], ["deletion", 532], ["at", 541], ["position", 544], ["172", 553], ["in", 557], ["exon", 560], ["1", 565], ["of", 567], ["the", 570], ["XK", 574], ["gene", 577], [",", 581], ["giving", 583], ["rise", 590], ["to", 595], ["a", 598], ["premature", 600], ["stop", 610], ["codon", 615], ["at", 621], ["position", 624], ["129", 633], ["in", 637], ["exon", 640], ["2", 645], [".", 646]]}
{"context": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone. A randomized, double-blind, gender-balanced, parallel-group study was performed in 4 groups of 20 healthy subjects each. Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 11 days and on day 12, 200 mg entacapone concomitantly with each levodopa/carbidopa dose (three times separated by a 5-h interval). Sixteen subjects in each of the remaining three groups received respectively 25, 50, and 75 mg opicapone once daily for 11 days and on day 12, placebo concomitantly with each levodopa/carbidopa dose. Levodopa minimum plasma concentration (Cmin) for each levodopa/carbidopa dose and for the mean of all levodopa/carbidopa doses increased substantially with all active treatments (entacapone and opicapone) when compared to the control group (placebo), with values ranging from 1.7-fold (200 mg entacapone) to 3.3-fold (75 mg opicapone). No statistical difference was found for levodopa peak of systemic exposure (as assessed by maximum observed plasma concentration (Cmax)) between all active treatments and placebo. A significant increase in the levodopa extent of systemic exposure (as assessed by concentration-time curve (AUC)) occurred with all opicapone treatments in relation to placebo. No statistical difference was found for levodopa AUC when entacapone was compared to placebo. When compared to entacapone, both 50 and 75 mg opicapone presented a significant increase for the levodopa AUC. All active treatments significantly inhibited both peak (as assessed by Emax) and extent (as assessed by effect-time curve (AUEC)) of the COMT activity in relation to placebo. When compared to entacapone, all opicapone treatments significantly decreased the extent (AUEC) of the COMT activity due to a long-lasting and sustained effect. The tolerability profile was favorable for all active treatments. Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition. The tolerability profile was favorable. On the basis of the results presented in this study and along with the earlier pharmacology studies, it is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "0e5ff4402f1e44c1a1d80868713f9b9f", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[6, 10]], "char_spans": [[38, 65]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["third", 21], ["generation", 27], ["catechol", 38], ["-", 46], ["O", 47], ["-", 48], ["methyltransferase", 49], ["(", 67], ["COMT", 68], [")", 72], ["inhibitor", 74], [".", 83], ["The", 85], ["purpose", 89], ["of", 97], ["this", 100], ["study", 105], ["was", 111], ["to", 115], ["compare", 118], ["the", 126], ["levodopa", 130], ["pharmacokinetic", 139], ["profile", 155], ["throughout", 163], ["a", 174], ["day", 176], ["driven", 180], ["by", 187], ["the", 190], ["COMT", 194], ["inhibition", 199], ["either", 210], ["following", 217], ["repeated", 227], ["doses", 236], ["of", 242], ["opicapone", 245], ["or", 255], ["concomitant", 258], ["administration", 270], ["with", 285], ["entacapone", 290], [".", 300], ["A", 302], ["randomized", 304], [",", 314], ["double", 316], ["-", 322], ["blind", 323], [",", 328], ["gender", 330], ["-", 336], ["balanced", 337], [",", 345], ["parallel", 347], ["-", 355], ["group", 356], ["study", 362], ["was", 368], ["performed", 372], ["in", 382], ["4", 385], ["groups", 387], ["of", 394], ["20", 397], ["healthy", 400], ["subjects", 408], ["each", 417], [".", 421], ["Four", 423], ["subjects", 428], ["in", 437], ["each", 440], ["group", 445], ["received", 451], ["placebo", 460], ["during", 468], ["the", 475], ["entire", 479], ["study", 486], [".", 491], ["Sixteen", 493], ["subjects", 501], ["in", 510], ["one", 513], ["group", 517], ["received", 523], ["placebo", 532], ["once", 540], ["daily", 545], ["for", 551], ["11", 555], ["days", 558], ["and", 563], ["on", 567], ["day", 570], ["12", 574], [",", 576], ["200", 578], ["mg", 582], ["entacapone", 585], ["concomitantly", 596], ["with", 610], ["each", 615], ["levodopa", 620], ["/", 628], ["carbidopa", 629], ["dose", 639], ["(", 644], ["three", 645], ["times", 651], ["separated", 657], ["by", 667], ["a", 670], ["5-h", 672], ["interval", 676], [")", 684], [".", 685], ["Sixteen", 687], ["subjects", 695], ["in", 704], ["each", 707], ["of", 712], ["the", 715], ["remaining", 719], ["three", 729], ["groups", 735], ["received", 742], ["respectively", 751], ["25", 764], [",", 766], ["50", 768], [",", 770], ["and", 772], ["75", 776], ["mg", 779], ["opicapone", 782], ["once", 792], ["daily", 797], ["for", 803], ["11", 807], ["days", 810], ["and", 815], ["on", 819], ["day", 822], ["12", 826], [",", 828], ["placebo", 830], ["concomitantly", 838], ["with", 852], ["each", 857], ["levodopa", 862], ["/", 870], ["carbidopa", 871], ["dose", 881], [".", 885], ["Levodopa", 887], ["minimum", 896], ["plasma", 904], ["concentration", 911], ["(", 925], ["Cmin", 926], [")", 930], ["for", 932], ["each", 936], ["levodopa", 941], ["/", 949], ["carbidopa", 950], ["dose", 960], ["and", 965], ["for", 969], ["the", 973], ["mean", 977], ["of", 982], ["all", 985], ["levodopa", 989], ["/", 997], ["carbidopa", 998], ["doses", 1008], ["increased", 1014], ["substantially", 1024], ["with", 1038], ["all", 1043], ["active", 1047], ["treatments", 1054], ["(", 1065], ["entacapone", 1066], ["and", 1077], ["opicapone", 1081], [")", 1090], ["when", 1092], ["compared", 1097], ["to", 1106], ["the", 1109], ["control", 1113], ["group", 1121], ["(", 1127], ["placebo", 1128], [")", 1135], [",", 1136], ["with", 1138], ["values", 1143], ["ranging", 1150], ["from", 1158], ["1.7-fold", 1163], ["(", 1172], ["200", 1173], ["mg", 1177], ["entacapone", 1180], [")", 1190], ["to", 1192], ["3.3-fold", 1195], ["(", 1204], ["75", 1205], ["mg", 1208], ["opicapone", 1211], [")", 1220], [".", 1221], ["No", 1223], ["statistical", 1226], ["difference", 1238], ["was", 1249], ["found", 1253], ["for", 1259], ["levodopa", 1263], ["peak", 1272], ["of", 1277], ["systemic", 1280], ["exposure", 1289], ["(", 1298], ["as", 1299], ["assessed", 1302], ["by", 1311], ["maximum", 1314], ["observed", 1322], ["plasma", 1331], ["concentration", 1338], ["(", 1352], ["Cmax", 1353], [")", 1357], [")", 1358], ["between", 1360], ["all", 1368], ["active", 1372], ["treatments", 1379], ["and", 1390], ["placebo", 1394], [".", 1401], ["A", 1403], ["significant", 1405], ["increase", 1417], ["in", 1426], ["the", 1429], ["levodopa", 1433], ["extent", 1442], ["of", 1449], ["systemic", 1452], ["exposure", 1461], ["(", 1470], ["as", 1471], ["assessed", 1474], ["by", 1483], ["concentration", 1486], ["-", 1499], ["time", 1500], ["curve", 1505], ["(", 1511], ["AUC", 1512], [")", 1515], [")", 1516], ["occurred", 1518], ["with", 1527], ["all", 1532], ["opicapone", 1536], ["treatments", 1546], ["in", 1557], ["relation", 1560], ["to", 1569], ["placebo", 1572], [".", 1579], ["No", 1581], ["statistical", 1584], ["difference", 1596], ["was", 1607], ["found", 1611], ["for", 1617], ["levodopa", 1621], ["AUC", 1630], ["when", 1634], ["entacapone", 1639], ["was", 1650], ["compared", 1654], ["to", 1663], ["placebo", 1666], [".", 1673], ["When", 1675], ["compared", 1680], ["to", 1689], ["entacapone", 1692], [",", 1702], ["both", 1704], ["50", 1709], ["and", 1712], ["75", 1716], ["mg", 1719], ["opicapone", 1722], ["presented", 1732], ["a", 1742], ["significant", 1744], ["increase", 1756], ["for", 1765], ["the", 1769], ["levodopa", 1773], ["AUC", 1782], [".", 1785], ["All", 1787], ["active", 1791], ["treatments", 1798], ["significantly", 1809], ["inhibited", 1823], ["both", 1833], ["peak", 1838], ["(", 1843], ["as", 1844], ["assessed", 1847], ["by", 1856], ["Emax", 1859], [")", 1863], ["and", 1865], ["extent", 1869], ["(", 1876], ["as", 1877], ["assessed", 1880], ["by", 1889], ["effect", 1892], ["-", 1898], ["time", 1899], ["curve", 1904], ["(", 1910], ["AUEC", 1911], [")", 1915], [")", 1916], ["of", 1918], ["the", 1921], ["COMT", 1925], ["activity", 1930], ["in", 1939], ["relation", 1942], ["to", 1951], ["placebo", 1954], [".", 1961], ["When", 1963], ["compared", 1968], ["to", 1977], ["entacapone", 1980], [",", 1990], ["all", 1992], ["opicapone", 1996], ["treatments", 2006], ["significantly", 2017], ["decreased", 2031], ["the", 2041], ["extent", 2045], ["(", 2052], ["AUEC", 2053], [")", 2057], ["of", 2059], ["the", 2062], ["COMT", 2066], ["activity", 2071], ["due", 2080], ["to", 2084], ["a", 2087], ["long", 2089], ["-", 2093], ["lasting", 2094], ["and", 2102], ["sustained", 2106], ["effect", 2116], [".", 2122], ["The", 2124], ["tolerability", 2128], ["profile", 2141], ["was", 2149], ["favorable", 2153], ["for", 2163], ["all", 2167], ["active", 2171], ["treatments", 2178], [".", 2188], ["Opicapone", 2190], [",", 2199], ["a", 2201], ["novel", 2203], ["third", 2209], ["generation", 2215], ["COMT", 2226], ["inhibitor", 2231], [",", 2240], ["when", 2242], ["compared", 2247], ["to", 2256], ["entacapone", 2259], [",", 2269], ["provides", 2271], ["a", 2280], ["superior", 2282], ["response", 2291], ["upon", 2300], ["the", 2305], ["bioavailability", 2309], ["of", 2325], ["levodopa", 2328], ["associated", 2337], ["to", 2348], ["more", 2351], ["pronounced", 2356], [",", 2366], ["long", 2368], ["-", 2372], ["lasting", 2373], [",", 2380], ["and", 2382], ["sustained", 2386], ["COMT", 2396], ["inhibition", 2401], [".", 2411], ["The", 2413], ["tolerability", 2417], ["profile", 2430], ["was", 2438], ["favorable", 2442], [".", 2451], ["On", 2453], ["the", 2456], ["basis", 2460], ["of", 2466], ["the", 2469], ["results", 2473], ["presented", 2481], ["in", 2491], ["this", 2494], ["study", 2499], ["and", 2505], ["along", 2509], ["with", 2515], ["the", 2520], ["earlier", 2524], ["pharmacology", 2532], ["studies", 2545], [",", 2552], ["it", 2554], ["is", 2557], ["anticipated", 2560], ["that", 2572], ["opicapone", 2577], ["adjunct", 2587], ["therapy", 2595], ["at", 2603], ["the", 2606], ["dosages", 2610], ["of", 2618], ["25", 2621], ["and", 2624], ["50", 2628], ["mg", 2631], ["will", 2634], ["provide", 2639], ["an", 2647], ["enhancement", 2650], ["in", 2662], ["levodopa", 2665], ["availability", 2674], ["that", 2687], ["will", 2692], ["translate", 2697], ["into", 2707], ["clinical", 2712], ["benefit", 2721], ["for", 2729], ["Parkinson", 2733], ["'s", 2742], ["disease", 2745], ["patients", 2753], [".", 2761]]}
{"context": "Protection and replenishment of a functional pancreatic \u03b2-cell mass (BCM) are key goals of all diabetes therapies. Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor. The apelin-APJ signaling system is expressed in rodent and human islet cells. Apelin exposure has been shown to inhibit and to stimulate insulin secretion. Our aim was to assess the influence of a selective APJ deletion in pancreatic islet cells on islet homeostasis and glucose tolerance in mice. Cre-LoxP strategy was utilized to mediate islet APJ deletion. APJ deletion in islet cells (APJ(\u0394islet)) resulted in a significantly reduced islet size, density and BCM. An ip glucose tolerance test showed significantly impaired glucose clearance in APJ(\u0394islet) mice. APJ(\u0394islet) mice were not insulin resistant and in vivo glucose-stimulated insulin secretion was reduced modestly. In vitro glucose-stimulated insulin secretion showed a significantly reduced insulin secretion by islets from APJ(\u0394islet) mice. Glucose clearance in response to ip glucose tolerance test in obese APJ(\u0394islet) mice fed a chronic high-fat (HF) diet, but not pregnant APJ(\u0394islet) mice, was impaired significantly. In addition, the obesity-induced adaptive elevations in mean islet size and fractional islet area were reduced significantly in obese APJ(\u0394islet) mice when compared with wild-type mice. Together, these findings demonstrate a stimulatory role for the islet cell apelin-APJ signaling axis in regulation of pancreatic islet homeostasis and in metabolic induced \u03b2-cell hyperplasia. The results indicate the apelin-APJ system can be exploited for replenishment of BCM.", "qas": [{"question": "What is apelin?", "answers": ["Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor."], "qid": "22b639b52f25417c920ceec18fc765f2", "question_tokens": [["What", 0], ["is", 5], ["apelin", 8], ["?", 14]], "detected_answers": [{"text": "Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor.", "token_spans": [[22, 40]], "char_spans": [[115, 213]]}]}], "context_tokens": [["Protection", 0], ["and", 11], ["replenishment", 15], ["of", 29], ["a", 32], ["functional", 34], ["pancreatic", 45], ["\u03b2", 56], ["-", 57], ["cell", 58], ["mass", 63], ["(", 68], ["BCM", 69], [")", 72], ["are", 74], ["key", 78], ["goals", 82], ["of", 88], ["all", 91], ["diabetes", 95], ["therapies", 104], [".", 113], ["Apelin", 115], [",", 121], ["a", 123], ["small", 125], ["regulatory", 131], ["peptide", 142], [",", 149], ["is", 151], ["the", 154], ["endogenous", 158], ["ligand", 169], ["for", 176], ["the", 180], ["apelin", 184], ["receptor", 191], ["(", 200], ["APJ", 201], [")", 204], ["receptor", 206], [".", 214], ["The", 216], ["apelin", 220], ["-", 226], ["APJ", 227], ["signaling", 231], ["system", 241], ["is", 248], ["expressed", 251], ["in", 261], ["rodent", 264], ["and", 271], ["human", 275], ["islet", 281], ["cells", 287], [".", 292], ["Apelin", 294], ["exposure", 301], ["has", 310], ["been", 314], ["shown", 319], ["to", 325], ["inhibit", 328], ["and", 336], ["to", 340], ["stimulate", 343], ["insulin", 353], ["secretion", 361], [".", 370], ["Our", 372], ["aim", 376], ["was", 380], ["to", 384], ["assess", 387], ["the", 394], ["influence", 398], ["of", 408], ["a", 411], ["selective", 413], ["APJ", 423], ["deletion", 427], ["in", 436], ["pancreatic", 439], ["islet", 450], ["cells", 456], ["on", 462], ["islet", 465], ["homeostasis", 471], ["and", 483], ["glucose", 487], ["tolerance", 495], ["in", 505], ["mice", 508], [".", 512], ["Cre", 514], ["-", 517], ["LoxP", 518], ["strategy", 523], ["was", 532], ["utilized", 536], ["to", 545], ["mediate", 548], ["islet", 556], ["APJ", 562], ["deletion", 566], [".", 574], ["APJ", 576], ["deletion", 580], ["in", 589], ["islet", 592], ["cells", 598], ["(", 604], ["APJ(\u0394islet", 605], [")", 615], [")", 616], ["resulted", 618], ["in", 627], ["a", 630], ["significantly", 632], ["reduced", 646], ["islet", 654], ["size", 660], [",", 664], ["density", 666], ["and", 674], ["BCM", 678], [".", 681], ["An", 683], ["ip", 686], ["glucose", 689], ["tolerance", 697], ["test", 707], ["showed", 712], ["significantly", 719], ["impaired", 733], ["glucose", 742], ["clearance", 750], ["in", 760], ["APJ(\u0394islet", 763], [")", 773], ["mice", 775], [".", 779], ["APJ(\u0394islet", 781], [")", 791], ["mice", 793], ["were", 798], ["not", 803], ["insulin", 807], ["resistant", 815], ["and", 825], ["in", 829], ["vivo", 832], ["glucose", 837], ["-", 844], ["stimulated", 845], ["insulin", 856], ["secretion", 864], ["was", 874], ["reduced", 878], ["modestly", 886], [".", 894], ["In", 896], ["vitro", 899], ["glucose", 905], ["-", 912], ["stimulated", 913], ["insulin", 924], ["secretion", 932], ["showed", 942], ["a", 949], ["significantly", 951], ["reduced", 965], ["insulin", 973], ["secretion", 981], ["by", 991], ["islets", 994], ["from", 1001], ["APJ(\u0394islet", 1006], [")", 1016], ["mice", 1018], [".", 1022], ["Glucose", 1024], ["clearance", 1032], ["in", 1042], ["response", 1045], ["to", 1054], ["ip", 1057], ["glucose", 1060], ["tolerance", 1068], ["test", 1078], ["in", 1083], ["obese", 1086], ["APJ(\u0394islet", 1092], [")", 1102], ["mice", 1104], ["fed", 1109], ["a", 1113], ["chronic", 1115], ["high", 1123], ["-", 1127], ["fat", 1128], ["(", 1132], ["HF", 1133], [")", 1135], ["diet", 1137], [",", 1141], ["but", 1143], ["not", 1147], ["pregnant", 1151], ["APJ(\u0394islet", 1160], [")", 1170], ["mice", 1172], [",", 1176], ["was", 1178], ["impaired", 1182], ["significantly", 1191], [".", 1204], ["In", 1206], ["addition", 1209], [",", 1217], ["the", 1219], ["obesity", 1223], ["-", 1230], ["induced", 1231], ["adaptive", 1239], ["elevations", 1248], ["in", 1259], ["mean", 1262], ["islet", 1267], ["size", 1273], ["and", 1278], ["fractional", 1282], ["islet", 1293], ["area", 1299], ["were", 1304], ["reduced", 1309], ["significantly", 1317], ["in", 1331], ["obese", 1334], ["APJ(\u0394islet", 1340], [")", 1350], ["mice", 1352], ["when", 1357], ["compared", 1362], ["with", 1371], ["wild", 1376], ["-", 1380], ["type", 1381], ["mice", 1386], [".", 1390], ["Together", 1392], [",", 1400], ["these", 1402], ["findings", 1408], ["demonstrate", 1417], ["a", 1429], ["stimulatory", 1431], ["role", 1443], ["for", 1448], ["the", 1452], ["islet", 1456], ["cell", 1462], ["apelin", 1467], ["-", 1473], ["APJ", 1474], ["signaling", 1478], ["axis", 1488], ["in", 1493], ["regulation", 1496], ["of", 1507], ["pancreatic", 1510], ["islet", 1521], ["homeostasis", 1527], ["and", 1539], ["in", 1543], ["metabolic", 1546], ["induced", 1556], ["\u03b2", 1564], ["-", 1565], ["cell", 1566], ["hyperplasia", 1571], [".", 1582], ["The", 1584], ["results", 1588], ["indicate", 1596], ["the", 1605], ["apelin", 1609], ["-", 1615], ["APJ", 1616], ["system", 1620], ["can", 1627], ["be", 1631], ["exploited", 1634], ["for", 1644], ["replenishment", 1648], ["of", 1662], ["BCM", 1665], [".", 1668]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement. In general, FSHD typically presents before age 20 years. Usually, FSHD muscle involvement starts in the face and then progresses to the shoulder girdle, the humeral muscles and the abdominal muscles, and then the anterolateral compartment of the leg. Disease severity is highly variable and progression is very slow. About 20% of FSHD patients become wheelchair-bound. Lifespan is not shortened. The diagnosis of FSHD is based on a genetic test by which a deletion of 3.3kb DNA repeats (named D4Z4 and mapping to the subtelomeric region of chromosome 4q35) is identified. The progressive pattern of FSHD requires that the severity of symptoms as well as their physical, social and psychological impact be evaluated on a regular basis. A yearly assessment is recommended. Multidisciplinary management of FSHD--consisting of a combination of genetic counselling, functional assessment, an assessment by a physical therapist, prescription of symptomatic therapies and prevention of known complications of this disease--is required. Prescription of physical therapy sessions and orthopedic appliances are to be adapted to the patient's deficiencies and contractures.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular\ndystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "938e72116a3b4c978813f177d96b52ba", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["\n", 63], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[14, 15]], "char_spans": [[94, 111]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["neuromuscular", 51], ["disease", 65], [",", 72], ["characterized", 74], ["by", 88], ["an", 91], ["autosomal", 94], ["dominant", 104], ["mode", 113], ["of", 118], ["inheritance", 121], [",", 132], ["facial", 134], ["involvement", 141], [",", 152], ["and", 154], ["selectivity", 158], ["and", 170], ["asymmetry", 174], ["of", 184], ["muscle", 187], ["involvement", 194], [".", 205], ["In", 207], ["general", 210], [",", 217], ["FSHD", 219], ["typically", 224], ["presents", 234], ["before", 243], ["age", 250], ["20", 254], ["years", 257], [".", 262], ["Usually", 264], [",", 271], ["FSHD", 273], ["muscle", 278], ["involvement", 285], ["starts", 297], ["in", 304], ["the", 307], ["face", 311], ["and", 316], ["then", 320], ["progresses", 325], ["to", 336], ["the", 339], ["shoulder", 343], ["girdle", 352], [",", 358], ["the", 360], ["humeral", 364], ["muscles", 372], ["and", 380], ["the", 384], ["abdominal", 388], ["muscles", 398], [",", 405], ["and", 407], ["then", 411], ["the", 416], ["anterolateral", 420], ["compartment", 434], ["of", 446], ["the", 449], ["leg", 453], [".", 456], ["Disease", 458], ["severity", 466], ["is", 475], ["highly", 478], ["variable", 485], ["and", 494], ["progression", 498], ["is", 510], ["very", 513], ["slow", 518], [".", 522], ["About", 524], ["20", 530], ["%", 532], ["of", 534], ["FSHD", 537], ["patients", 542], ["become", 551], ["wheelchair", 558], ["-", 568], ["bound", 569], [".", 574], ["Lifespan", 576], ["is", 585], ["not", 588], ["shortened", 592], [".", 601], ["The", 603], ["diagnosis", 607], ["of", 617], ["FSHD", 620], ["is", 625], ["based", 628], ["on", 634], ["a", 637], ["genetic", 639], ["test", 647], ["by", 652], ["which", 655], ["a", 661], ["deletion", 663], ["of", 672], ["3.3", 675], ["kb", 678], ["DNA", 681], ["repeats", 685], ["(", 693], ["named", 694], ["D4Z4", 700], ["and", 705], ["mapping", 709], ["to", 717], ["the", 720], ["subtelomeric", 724], ["region", 737], ["of", 744], ["chromosome", 747], ["4q35", 758], [")", 762], ["is", 764], ["identified", 767], [".", 777], ["The", 779], ["progressive", 783], ["pattern", 795], ["of", 803], ["FSHD", 806], ["requires", 811], ["that", 820], ["the", 825], ["severity", 829], ["of", 838], ["symptoms", 841], ["as", 850], ["well", 853], ["as", 858], ["their", 861], ["physical", 867], [",", 875], ["social", 877], ["and", 884], ["psychological", 888], ["impact", 902], ["be", 909], ["evaluated", 912], ["on", 922], ["a", 925], ["regular", 927], ["basis", 935], [".", 940], ["A", 942], ["yearly", 944], ["assessment", 951], ["is", 962], ["recommended", 965], [".", 976], ["Multidisciplinary", 978], ["management", 996], ["of", 1007], ["FSHD", 1010], ["--", 1014], ["consisting", 1016], ["of", 1027], ["a", 1030], ["combination", 1032], ["of", 1044], ["genetic", 1047], ["counselling", 1055], [",", 1066], ["functional", 1068], ["assessment", 1079], [",", 1089], ["an", 1091], ["assessment", 1094], ["by", 1105], ["a", 1108], ["physical", 1110], ["therapist", 1119], [",", 1128], ["prescription", 1130], ["of", 1143], ["symptomatic", 1146], ["therapies", 1158], ["and", 1168], ["prevention", 1172], ["of", 1183], ["known", 1186], ["complications", 1192], ["of", 1206], ["this", 1209], ["disease", 1214], ["--", 1221], ["is", 1223], ["required", 1226], [".", 1234], ["Prescription", 1236], ["of", 1249], ["physical", 1252], ["therapy", 1261], ["sessions", 1269], ["and", 1278], ["orthopedic", 1282], ["appliances", 1293], ["are", 1304], ["to", 1308], ["be", 1311], ["adapted", 1314], ["to", 1322], ["the", 1325], ["patient", 1329], ["'s", 1336], ["deficiencies", 1339], ["and", 1352], ["contractures", 1356], [".", 1368]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common genetic disease caused by haploinsufficiency of the NF1 tumor-suppressor gene. Different pathogenetic mechanisms have been identified, with the majority (95%) causing intragenic lesions. Single or multiexon NF1 copy number changes occur in about 2% of patients, but little is known about the molecular mechanisms behind these intragenic deletions. We report here on the molecular characterization of a novel NF1 multiexonic deletion. The application of a multidisciplinary approach including multiplex ligation-dependent probe amplification, allelic segregation analysis, and fluorescent in situ hybridization allowed us to map the breakpoints in IVS27b and IVS48. Furthermore, the breakpoint junction was characterized by sequencing. Using bioinformatic analysis, we identified some recombinogenic motifs in close proximity to the centromeric and telomeric breakpoints and predicted the presence of a mutated messenger ribonucleic acid, which was deleted between exons 28 and 48 and encodes a neurofibromin that lacks some domains essential for its function. Through reverse transcriptase-polymerase chain reaction, the expression of the mutated allele was verified, showing the junction between exons 27b and 49 and, as expected, was not subjected to nonsense-mediated decay. Multiexonic deletions represent 2% of NF1 mutations, and until now, the breakpoint has been identified in only a few cases. The fine characterization of multiexonic deletions broadens the mutational repertoire of the NF1 gene, allowing for the identification of different pathogenetic mechanisms causing NF1.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "354f714bfea84f6b8e02e7acba3f7d67", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [221, 221], [43, 43], [251, 251], [4, 4], [263, 263], [78, 78]], "char_spans": [[95, 97], [1359, 1361], [250, 252], [1538, 1540], [26, 28], [1625, 1627], [451, 453]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["genetic", 43], ["disease", 51], ["caused", 59], ["by", 66], ["haploinsufficiency", 69], ["of", 88], ["the", 91], ["NF1", 95], ["tumor", 99], ["-", 104], ["suppressor", 105], ["gene", 116], [".", 120], ["Different", 122], ["pathogenetic", 132], ["mechanisms", 145], ["have", 156], ["been", 161], ["identified", 166], [",", 176], ["with", 178], ["the", 183], ["majority", 187], ["(", 196], ["95", 197], ["%", 199], [")", 200], ["causing", 202], ["intragenic", 210], ["lesions", 221], [".", 228], ["Single", 230], ["or", 237], ["multiexon", 240], ["NF1", 250], ["copy", 254], ["number", 259], ["changes", 266], ["occur", 274], ["in", 280], ["about", 283], ["2", 289], ["%", 290], ["of", 292], ["patients", 295], [",", 303], ["but", 305], ["little", 309], ["is", 316], ["known", 319], ["about", 325], ["the", 331], ["molecular", 335], ["mechanisms", 345], ["behind", 356], ["these", 363], ["intragenic", 369], ["deletions", 380], [".", 389], ["We", 391], ["report", 394], ["here", 401], ["on", 406], ["the", 409], ["molecular", 413], ["characterization", 423], ["of", 440], ["a", 443], ["novel", 445], ["NF1", 451], ["multiexonic", 455], ["deletion", 467], [".", 475], ["The", 477], ["application", 481], ["of", 493], ["a", 496], ["multidisciplinary", 498], ["approach", 516], ["including", 525], ["multiplex", 535], ["ligation", 545], ["-", 553], ["dependent", 554], ["probe", 564], ["amplification", 570], [",", 583], ["allelic", 585], ["segregation", 593], ["analysis", 605], [",", 613], ["and", 615], ["fluorescent", 619], ["in", 631], ["situ", 634], ["hybridization", 639], ["allowed", 653], ["us", 661], ["to", 664], ["map", 667], ["the", 671], ["breakpoints", 675], ["in", 687], ["IVS27b", 690], ["and", 697], ["IVS48", 701], [".", 706], ["Furthermore", 708], [",", 719], ["the", 721], ["breakpoint", 725], ["junction", 736], ["was", 745], ["characterized", 749], ["by", 763], ["sequencing", 766], [".", 776], ["Using", 778], ["bioinformatic", 784], ["analysis", 798], [",", 806], ["we", 808], ["identified", 811], ["some", 822], ["recombinogenic", 827], ["motifs", 842], ["in", 849], ["close", 852], ["proximity", 858], ["to", 868], ["the", 871], ["centromeric", 875], ["and", 887], ["telomeric", 891], ["breakpoints", 901], ["and", 913], ["predicted", 917], ["the", 927], ["presence", 931], ["of", 940], ["a", 943], ["mutated", 945], ["messenger", 953], ["ribonucleic", 963], ["acid", 975], [",", 979], ["which", 981], ["was", 987], ["deleted", 991], ["between", 999], ["exons", 1007], ["28", 1013], ["and", 1016], ["48", 1020], ["and", 1023], ["encodes", 1027], ["a", 1035], ["neurofibromin", 1037], ["that", 1051], ["lacks", 1056], ["some", 1062], ["domains", 1067], ["essential", 1075], ["for", 1085], ["its", 1089], ["function", 1093], [".", 1101], ["Through", 1103], ["reverse", 1111], ["transcriptase", 1119], ["-", 1132], ["polymerase", 1133], ["chain", 1144], ["reaction", 1150], [",", 1158], ["the", 1160], ["expression", 1164], ["of", 1175], ["the", 1178], ["mutated", 1182], ["allele", 1190], ["was", 1197], ["verified", 1201], [",", 1209], ["showing", 1211], ["the", 1219], ["junction", 1223], ["between", 1232], ["exons", 1240], ["27b", 1246], ["and", 1250], ["49", 1254], ["and", 1257], [",", 1260], ["as", 1262], ["expected", 1265], [",", 1273], ["was", 1275], ["not", 1279], ["subjected", 1283], ["to", 1293], ["nonsense", 1296], ["-", 1304], ["mediated", 1305], ["decay", 1314], [".", 1319], ["Multiexonic", 1321], ["deletions", 1333], ["represent", 1343], ["2", 1353], ["%", 1354], ["of", 1356], ["NF1", 1359], ["mutations", 1363], [",", 1372], ["and", 1374], ["until", 1378], ["now", 1384], [",", 1387], ["the", 1389], ["breakpoint", 1393], ["has", 1404], ["been", 1408], ["identified", 1413], ["in", 1424], ["only", 1427], ["a", 1432], ["few", 1434], ["cases", 1438], [".", 1443], ["The", 1445], ["fine", 1449], ["characterization", 1454], ["of", 1471], ["multiexonic", 1474], ["deletions", 1486], ["broadens", 1496], ["the", 1505], ["mutational", 1509], ["repertoire", 1520], ["of", 1531], ["the", 1534], ["NF1", 1538], ["gene", 1542], [",", 1546], ["allowing", 1548], ["for", 1557], ["the", 1561], ["identification", 1565], ["of", 1580], ["different", 1583], ["pathogenetic", 1593], ["mechanisms", 1606], ["causing", 1617], ["NF1", 1625], [".", 1628]]}
{"context": "The pathogenesis of restless legs syndrome (RLS) is unknown. Although iron deficiency anemia (IDA) is related with RLS, the mechanism of this relationship is still unknown. Therefore, we decided to examine some neurophysiological parameters that reflect the function of brainstem, spinal cord and peripheral nervous system. 34 patients diagnosed with IDA at the hematology department were questioned with a structured battery for RLS and additional symptoms. Of those, 14 patients had symptoms of RLS, while remaining 20 had no signs of this disorder. In both groups, electrophysiological examination including motor and sensory nerve conduction, F-responses, H-reflex, blink-reflex, and mixed nerve silent periods was performed. Neurological examination of all patients was normal. The two groups were identical for age and sex, and the difference between both groups concerning motor and sensory nerve conduction, F-wave, H-reflex, blink-reflex, and mixed nerve silent periods was insignificant. Results suggest that IDA does not cause electrophysiological changes in the peripheral nerves, spinal cord and brainstem, and therefore, measurement of these parameters in IDA patients does not seem effective for the confirmation of RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "c11e38b5379143f9895440d3ed5f0ff2", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[13, 13]], "char_spans": [[70, 73]]}]}], "context_tokens": [["The", 0], ["pathogenesis", 4], ["of", 17], ["restless", 20], ["legs", 29], ["syndrome", 34], ["(", 43], ["RLS", 44], [")", 47], ["is", 49], ["unknown", 52], [".", 59], ["Although", 61], ["iron", 70], ["deficiency", 75], ["anemia", 86], ["(", 93], ["IDA", 94], [")", 97], ["is", 99], ["related", 102], ["with", 110], ["RLS", 115], [",", 118], ["the", 120], ["mechanism", 124], ["of", 134], ["this", 137], ["relationship", 142], ["is", 155], ["still", 158], ["unknown", 164], [".", 171], ["Therefore", 173], [",", 182], ["we", 184], ["decided", 187], ["to", 195], ["examine", 198], ["some", 206], ["neurophysiological", 211], ["parameters", 230], ["that", 241], ["reflect", 246], ["the", 254], ["function", 258], ["of", 267], ["brainstem", 270], [",", 279], ["spinal", 281], ["cord", 288], ["and", 293], ["peripheral", 297], ["nervous", 308], ["system", 316], [".", 322], ["34", 324], ["patients", 327], ["diagnosed", 336], ["with", 346], ["IDA", 351], ["at", 355], ["the", 358], ["hematology", 362], ["department", 373], ["were", 384], ["questioned", 389], ["with", 400], ["a", 405], ["structured", 407], ["battery", 418], ["for", 426], ["RLS", 430], ["and", 434], ["additional", 438], ["symptoms", 449], [".", 457], ["Of", 459], ["those", 462], [",", 467], ["14", 469], ["patients", 472], ["had", 481], ["symptoms", 485], ["of", 494], ["RLS", 497], [",", 500], ["while", 502], ["remaining", 508], ["20", 518], ["had", 521], ["no", 525], ["signs", 528], ["of", 534], ["this", 537], ["disorder", 542], [".", 550], ["In", 552], ["both", 555], ["groups", 560], [",", 566], ["electrophysiological", 568], ["examination", 589], ["including", 601], ["motor", 611], ["and", 617], ["sensory", 621], ["nerve", 629], ["conduction", 635], [",", 645], ["F", 647], ["-", 648], ["responses", 649], [",", 658], ["H", 660], ["-", 661], ["reflex", 662], [",", 668], ["blink", 670], ["-", 675], ["reflex", 676], [",", 682], ["and", 684], ["mixed", 688], ["nerve", 694], ["silent", 700], ["periods", 707], ["was", 715], ["performed", 719], [".", 728], ["Neurological", 730], ["examination", 743], ["of", 755], ["all", 758], ["patients", 762], ["was", 771], ["normal", 775], [".", 781], ["The", 783], ["two", 787], ["groups", 791], ["were", 798], ["identical", 803], ["for", 813], ["age", 817], ["and", 821], ["sex", 825], [",", 828], ["and", 830], ["the", 834], ["difference", 838], ["between", 849], ["both", 857], ["groups", 862], ["concerning", 869], ["motor", 880], ["and", 886], ["sensory", 890], ["nerve", 898], ["conduction", 904], [",", 914], ["F", 916], ["-", 917], ["wave", 918], [",", 922], ["H", 924], ["-", 925], ["reflex", 926], [",", 932], ["blink", 934], ["-", 939], ["reflex", 940], [",", 946], ["and", 948], ["mixed", 952], ["nerve", 958], ["silent", 964], ["periods", 971], ["was", 979], ["insignificant", 983], [".", 996], ["Results", 998], ["suggest", 1006], ["that", 1014], ["IDA", 1019], ["does", 1023], ["not", 1028], ["cause", 1032], ["electrophysiological", 1038], ["changes", 1059], ["in", 1067], ["the", 1070], ["peripheral", 1074], ["nerves", 1085], [",", 1091], ["spinal", 1093], ["cord", 1100], ["and", 1105], ["brainstem", 1109], [",", 1118], ["and", 1120], ["therefore", 1124], [",", 1133], ["measurement", 1135], ["of", 1147], ["these", 1150], ["parameters", 1156], ["in", 1167], ["IDA", 1170], ["patients", 1174], ["does", 1183], ["not", 1188], ["seem", 1192], ["effective", 1197], ["for", 1207], ["the", 1211], ["confirmation", 1215], ["of", 1228], ["RLS", 1231], [".", 1234]]}
{"context": "Increased nerve growth factor levels are associated with chronic pain conditions, including chronic low back pain (LBP). This study examined safety and analgesic efficacy of tanezumab, a humanized anti-nerve growth factor antibody, in adults with chronic LBP. Patients received intravenous tanezumab 200 \u03bcg/kg plus oral placebo (n=88), intravenous placebo plus oral naproxen 500 mg twice a day (n=88), or intravenous placebo plus oral placebo (n=41). Primary outcome was average LBP intensity (aLBPI) at Week 6. Secondary outcomes were proportion of patients with \u226530% or \u226550% reduction in aLBPI, Roland-Morris Disability Questionnaire and Brief Pain Inventory-short form scores, Patients' Global Assessment of LBP, Patients' Global Evaluation of study medication, and rescue medication use. Mean aLBPI change from baseline to Week 6 was greater with tanezumab vs naproxen (P=0.004) and placebo (P<0.001). Greater proportions of patients reported \u226530% and \u226550% reduction in aLBPI with tanezumab vs naproxen (P\u22640.013) and placebo (P<0.001), and greater improvements in Roland-Morris Disability Questionnaire (P<0.001) and other secondary outcomes except rescue medication use. Tanezumab was associated with adverse events (AEs) of abnormal peripheral sensation that were generally mild and resolved before study completion; however, there were no serious AEs. Nine patients (4 of whom were tanezumab-treated) discontinued due to AEs. In conclusion, tanezumab resulted in analgesic efficacy that was clinically and statistically superior to placebo and naproxen in patients with chronic LBP. Tanezumab clinical development is on regulatory hold due to AEs in osteoarthritis patients.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "b57cadd16f7a4c1795c6018b46b69e57", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[1, 3], [35, 37]], "char_spans": [[10, 28], [202, 220]]}]}], "context_tokens": [["Increased", 0], ["nerve", 10], ["growth", 16], ["factor", 23], ["levels", 30], ["are", 37], ["associated", 41], ["with", 52], ["chronic", 57], ["pain", 65], ["conditions", 70], [",", 80], ["including", 82], ["chronic", 92], ["low", 100], ["back", 104], ["pain", 109], ["(", 114], ["LBP", 115], [")", 118], [".", 119], ["This", 121], ["study", 126], ["examined", 132], ["safety", 141], ["and", 148], ["analgesic", 152], ["efficacy", 162], ["of", 171], ["tanezumab", 174], [",", 183], ["a", 185], ["humanized", 187], ["anti", 197], ["-", 201], ["nerve", 202], ["growth", 208], ["factor", 215], ["antibody", 222], [",", 230], ["in", 232], ["adults", 235], ["with", 242], ["chronic", 247], ["LBP", 255], [".", 258], ["Patients", 260], ["received", 269], ["intravenous", 278], ["tanezumab", 290], ["200", 300], ["\u03bcg", 304], ["/", 306], ["kg", 307], ["plus", 310], ["oral", 315], ["placebo", 320], ["(", 328], ["n=88", 329], [")", 333], [",", 334], ["intravenous", 336], ["placebo", 348], ["plus", 356], ["oral", 361], ["naproxen", 366], ["500", 375], ["mg", 379], ["twice", 382], ["a", 388], ["day", 390], ["(", 394], ["n=88", 395], [")", 399], [",", 400], ["or", 402], ["intravenous", 405], ["placebo", 417], ["plus", 425], ["oral", 430], ["placebo", 435], ["(", 443], ["n=41", 444], [")", 448], [".", 449], ["Primary", 451], ["outcome", 459], ["was", 467], ["average", 471], ["LBP", 479], ["intensity", 483], ["(", 493], ["aLBPI", 494], [")", 499], ["at", 501], ["Week", 504], ["6", 509], [".", 510], ["Secondary", 512], ["outcomes", 522], ["were", 531], ["proportion", 536], ["of", 547], ["patients", 550], ["with", 559], ["\u226530", 564], ["%", 567], ["or", 569], ["\u226550", 572], ["%", 575], ["reduction", 577], ["in", 587], ["aLBPI", 590], [",", 595], ["Roland", 597], ["-", 603], ["Morris", 604], ["Disability", 611], ["Questionnaire", 622], ["and", 636], ["Brief", 640], ["Pain", 646], ["Inventory", 651], ["-", 660], ["short", 661], ["form", 667], ["scores", 672], [",", 678], ["Patients", 680], ["'", 688], ["Global", 690], ["Assessment", 697], ["of", 708], ["LBP", 711], [",", 714], ["Patients", 716], ["'", 724], ["Global", 726], ["Evaluation", 733], ["of", 744], ["study", 747], ["medication", 753], [",", 763], ["and", 765], ["rescue", 769], ["medication", 776], ["use", 787], [".", 790], ["Mean", 792], ["aLBPI", 797], ["change", 803], ["from", 810], ["baseline", 815], ["to", 824], ["Week", 827], ["6", 832], ["was", 834], ["greater", 838], ["with", 846], ["tanezumab", 851], ["vs", 861], ["naproxen", 864], ["(", 873], ["P=0.004", 874], [")", 881], ["and", 883], ["placebo", 887], ["(", 895], ["P<0.001", 896], [")", 903], [".", 904], ["Greater", 906], ["proportions", 914], ["of", 926], ["patients", 929], ["reported", 938], ["\u226530", 947], ["%", 950], ["and", 952], ["\u226550", 956], ["%", 959], ["reduction", 961], ["in", 971], ["aLBPI", 974], ["with", 980], ["tanezumab", 985], ["vs", 995], ["naproxen", 998], ["(", 1007], ["P\u22640.013", 1008], [")", 1015], ["and", 1017], ["placebo", 1021], ["(", 1029], ["P<0.001", 1030], [")", 1037], [",", 1038], ["and", 1040], ["greater", 1044], ["improvements", 1052], ["in", 1065], ["Roland", 1068], ["-", 1074], ["Morris", 1075], ["Disability", 1082], ["Questionnaire", 1093], ["(", 1107], ["P<0.001", 1108], [")", 1115], ["and", 1117], ["other", 1121], ["secondary", 1127], ["outcomes", 1137], ["except", 1146], ["rescue", 1153], ["medication", 1160], ["use", 1171], [".", 1174], ["Tanezumab", 1176], ["was", 1186], ["associated", 1190], ["with", 1201], ["adverse", 1206], ["events", 1214], ["(", 1221], ["AEs", 1222], [")", 1225], ["of", 1227], ["abnormal", 1230], ["peripheral", 1239], ["sensation", 1250], ["that", 1260], ["were", 1265], ["generally", 1270], ["mild", 1280], ["and", 1285], ["resolved", 1289], ["before", 1298], ["study", 1305], ["completion", 1311], [";", 1321], ["however", 1323], [",", 1330], ["there", 1332], ["were", 1338], ["no", 1343], ["serious", 1346], ["AEs", 1354], [".", 1357], ["Nine", 1359], ["patients", 1364], ["(", 1373], ["4", 1374], ["of", 1376], ["whom", 1379], ["were", 1384], ["tanezumab", 1389], ["-", 1398], ["treated", 1399], [")", 1406], ["discontinued", 1408], ["due", 1421], ["to", 1425], ["AEs", 1428], [".", 1431], ["In", 1433], ["conclusion", 1436], [",", 1446], ["tanezumab", 1448], ["resulted", 1458], ["in", 1467], ["analgesic", 1470], ["efficacy", 1480], ["that", 1489], ["was", 1494], ["clinically", 1498], ["and", 1509], ["statistically", 1513], ["superior", 1527], ["to", 1536], ["placebo", 1539], ["and", 1547], ["naproxen", 1551], ["in", 1560], ["patients", 1563], ["with", 1572], ["chronic", 1577], ["LBP", 1585], [".", 1588], ["Tanezumab", 1590], ["clinical", 1600], ["development", 1609], ["is", 1621], ["on", 1624], ["regulatory", 1627], ["hold", 1638], ["due", 1643], ["to", 1647], ["AEs", 1650], ["in", 1654], ["osteoarthritis", 1657], ["patients", 1672], [".", 1680]]}
{"context": "Histone methyltransferase (HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain, which shares sequence homology with an independently described sequence motif, the PR domain. Intact PR or SET sequence is required for tumor suppression functions, but it remains unclear whether it is histone methyltransferase activity that underlies tumor suppression. We now show that tumor suppressor RIZ1 (PRDM2) methylates histone H3 on lysine 9, and this activity is reduced by mutations in the PR domain found in human cancers. Also, S-adenosylhomocysteine or methyl donor deficiency inhibits RIZ1 and other H3 lysine 9 methylation activities. These results support the hypothesis that H3 lysine 9 methylation activities of a PR/SET domain have tumor suppression functions and may underlie carcinogenesis associated with dietary methyl donor deficiency.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "bf7e56357754453da53cec3c83cb7ef2", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[22, 23], [134, 135]], "char_spans": [[150, 159], [799, 808]]}]}], "context_tokens": [["Histone", 0], ["methyltransferase", 8], ["(", 26], ["HMT)(1", 27], [")", 33], ["class", 35], ["enzymes", 41], ["that", 49], ["methylate", 54], ["lysine", 64], ["residues", 71], ["of", 80], ["histones", 83], ["or", 92], ["proteins", 95], ["contain", 104], ["a", 112], ["conserved", 114], ["catalytic", 124], ["core", 134], ["termed", 139], ["the", 146], ["SET", 150], ["domain", 154], [",", 160], ["which", 162], ["shares", 168], ["sequence", 175], ["homology", 184], ["with", 193], ["an", 198], ["independently", 201], ["described", 215], ["sequence", 225], ["motif", 234], [",", 239], ["the", 241], ["PR", 245], ["domain", 248], [".", 254], ["Intact", 256], ["PR", 263], ["or", 266], ["SET", 269], ["sequence", 273], ["is", 282], ["required", 285], ["for", 294], ["tumor", 298], ["suppression", 304], ["functions", 316], [",", 325], ["but", 327], ["it", 331], ["remains", 334], ["unclear", 342], ["whether", 350], ["it", 358], ["is", 361], ["histone", 364], ["methyltransferase", 372], ["activity", 390], ["that", 399], ["underlies", 404], ["tumor", 414], ["suppression", 420], [".", 431], ["We", 433], ["now", 436], ["show", 440], ["that", 445], ["tumor", 450], ["suppressor", 456], ["RIZ1", 467], ["(", 472], ["PRDM2", 473], [")", 478], ["methylates", 480], ["histone", 491], ["H3", 499], ["on", 502], ["lysine", 505], ["9", 512], [",", 513], ["and", 515], ["this", 519], ["activity", 524], ["is", 533], ["reduced", 536], ["by", 544], ["mutations", 547], ["in", 557], ["the", 560], ["PR", 564], ["domain", 567], ["found", 574], ["in", 580], ["human", 583], ["cancers", 589], [".", 596], ["Also", 598], [",", 602], ["S", 604], ["-", 605], ["adenosylhomocysteine", 606], ["or", 627], ["methyl", 630], ["donor", 637], ["deficiency", 643], ["inhibits", 654], ["RIZ1", 663], ["and", 668], ["other", 672], ["H3", 678], ["lysine", 681], ["9", 688], ["methylation", 690], ["activities", 702], [".", 712], ["These", 714], ["results", 720], ["support", 728], ["the", 736], ["hypothesis", 740], ["that", 751], ["H3", 756], ["lysine", 759], ["9", 766], ["methylation", 768], ["activities", 780], ["of", 791], ["a", 794], ["PR", 796], ["/", 798], ["SET", 799], ["domain", 803], ["have", 810], ["tumor", 815], ["suppression", 821], ["functions", 833], ["and", 843], ["may", 847], ["underlie", 851], ["carcinogenesis", 860], ["associated", 875], ["with", 886], ["dietary", 891], ["methyl", 899], ["donor", 906], ["deficiency", 912], [".", 922]]}
{"context": "Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "61399ac72d9a4c4397aa7b80ee902d25", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[172, 174], [196, 198], [141, 143], [74, 76], [16, 18], [160, 162], [34, 36], [115, 117]], "char_spans": [[1055, 1069], [1193, 1207], [902, 916], [484, 498], [104, 118], [990, 1004], [221, 235], [753, 767]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["neuropathological", 13], ["hallmarks", 31], ["of", 41], ["Parkinson", 44], ["'s", 53], ["disease", 56], ["and", 64], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], [",", 93], ["comprise", 95], ["alpha", 104], ["-", 109], ["synuclein", 110], ["filaments", 120], ["and", 130], ["other", 134], ["less", 140], ["defined", 145], ["proteins", 153], [".", 161], ["Characterization", 163], ["of", 180], ["Lewy", 183], ["body", 188], ["proteins", 193], ["that", 202], ["interact", 207], ["with", 216], ["alpha", 221], ["-", 226], ["synuclein", 227], ["may", 237], ["provide", 241], ["insight", 249], ["into", 257], ["the", 262], ["mechanism", 266], ["of", 276], ["Lewy", 279], ["body", 284], ["formation", 289], [".", 298], ["Double", 300], ["immunofluorescence", 307], ["labeling", 326], ["and", 335], ["confocal", 339], ["microscopy", 348], ["revealed", 359], ["approximately", 368], ["80", 382], ["%", 384], ["of", 386], ["cortical", 389], ["Lewy", 398], ["bodies", 403], ["contained", 410], ["microtubule", 420], ["-", 431], ["associated", 432], ["protein", 443], ["1B", 451], ["(", 454], ["MAP-1B", 455], [")", 461], ["that", 463], ["overlapped", 468], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], [".", 499], ["Lewy", 501], ["bodies", 506], ["were", 513], ["isolated", 518], ["using", 527], ["an", 533], ["immunomagnetic", 536], ["technique", 551], ["from", 561], ["brain", 566], ["tissue", 572], ["of", 579], ["patients", 582], ["dying", 591], ["with", 597], ["dementia", 602], ["with", 611], ["Lewy", 616], ["bodies", 621], [".", 627], ["Lewy", 629], ["body", 634], ["proteins", 639], ["were", 648], ["resolved", 653], ["by", 662], ["polyacrylamide", 665], ["gel", 680], ["electrophoresis", 684], [".", 699], ["Immunoblotting", 701], ["confirmed", 716], ["the", 726], ["presence", 730], ["of", 739], ["MAP-1B", 742], ["and", 749], ["alpha", 753], ["-", 758], ["synuclein", 759], ["in", 769], ["purified", 772], ["Lewy", 781], ["bodies", 786], [".", 792], ["Direct", 794], ["binding", 801], ["studies", 809], ["revealed", 817], ["a", 826], ["high", 828], ["affinity", 833], ["interaction", 842], ["(", 854], ["IC(50", 855], [")", 860], ["approximately", 862], ["20", 876], ["nm", 879], [")", 881], ["between", 883], ["MAP-1B", 891], ["and", 898], ["alpha", 902], ["-", 907], ["synuclein", 908], [".", 917], ["The", 919], ["MAP-1B", 923], ["-", 929], ["binding", 930], ["sites", 938], ["were", 944], ["mapped", 949], ["to", 956], ["the", 959], ["last", 963], ["45", 968], ["amino", 971], ["acids", 977], ["of", 983], ["the", 986], ["alpha", 990], ["-", 995], ["synuclein", 996], ["C", 1006], ["terminus", 1008], [".", 1016], ["MAP-1B", 1018], ["also", 1025], ["bound", 1030], ["in", 1036], ["vitro", 1039], ["assembled", 1045], ["alpha", 1055], ["-", 1060], ["synuclein", 1061], ["fibrils", 1071], [".", 1078], ["Thus", 1080], [",", 1084], ["MAP-1B", 1086], ["may", 1093], ["be", 1097], ["involved", 1100], ["in", 1109], ["the", 1112], ["pathogenesis", 1116], ["of", 1129], ["Lewy", 1132], ["bodies", 1137], ["via", 1144], ["its", 1148], ["interaction", 1152], ["with", 1164], ["monomeric", 1169], ["and", 1179], ["fibrillar", 1183], ["alpha", 1193], ["-", 1198], ["synuclein", 1199], [".", 1208]]}
{"context": "The aim of this study was to assess the tolerability, pharmacokinetics and inhibitory effect on erythrocyte soluble catechol-O-methyltransferase (S-COMT) activity following repeated doses of opicapone. This randomized, placebo-controlled, double-blind study enrolled healthy male subjects who received either once daily placebo or opicapone 5, 10, 20 or 30\u2009mg for 8 days. Opicapone was well tolerated. Its systemic exposure increased in an approximately dose-proportional manner with an apparent terminal half-life of 1.0 to 1.4\u2009h. Sulphation was the main metabolic pathway. Opicapone metabolites recovered in urine accounted for less than 3% of the amount of opicapone administered suggesting that bile is likely the main route of excretion. Maximum S-COMT inhibition (Emax ) ranged from 69.9% to 98.0% following the last dose of opicapone. The opicapone-induced S-COMT inhibition showed a half-life in excess of 100\u2009h, which was dose-independent and much longer than plasma drug exposure. Such a half-life translates into a putative underlying rate constant that is comparable with the estimated dissociation rate constant of the COMT-opicapone complex. Despite its short elimination half-life, opicapone markedly and sustainably inhibited erythrocyte S-COMT activity making it suitable for a once daily regimen.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "a304967557fb41c5a6ef72141bdd17f8", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[18, 22]], "char_spans": [[116, 143]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["assess", 29], ["the", 36], ["tolerability", 40], [",", 52], ["pharmacokinetics", 54], ["and", 71], ["inhibitory", 75], ["effect", 86], ["on", 93], ["erythrocyte", 96], ["soluble", 108], ["catechol", 116], ["-", 124], ["O", 125], ["-", 126], ["methyltransferase", 127], ["(", 145], ["S", 146], ["-", 147], ["COMT", 148], [")", 152], ["activity", 154], ["following", 163], ["repeated", 173], ["doses", 182], ["of", 188], ["opicapone", 191], [".", 200], ["This", 202], ["randomized", 207], [",", 217], ["placebo", 219], ["-", 226], ["controlled", 227], [",", 237], ["double", 239], ["-", 245], ["blind", 246], ["study", 252], ["enrolled", 258], ["healthy", 267], ["male", 275], ["subjects", 280], ["who", 289], ["received", 293], ["either", 302], ["once", 309], ["daily", 314], ["placebo", 320], ["or", 328], ["opicapone", 331], ["5", 341], [",", 342], ["10", 344], [",", 346], ["20", 348], ["or", 351], ["30", 354], ["mg", 357], ["for", 360], ["8", 364], ["days", 366], [".", 370], ["Opicapone", 372], ["was", 382], ["well", 386], ["tolerated", 391], [".", 400], ["Its", 402], ["systemic", 406], ["exposure", 415], ["increased", 424], ["in", 434], ["an", 437], ["approximately", 440], ["dose", 454], ["-", 458], ["proportional", 459], ["manner", 472], ["with", 479], ["an", 484], ["apparent", 487], ["terminal", 496], ["half", 505], ["-", 509], ["life", 510], ["of", 515], ["1.0", 518], ["to", 522], ["1.4", 525], ["h.", 529], ["Sulphation", 532], ["was", 543], ["the", 547], ["main", 551], ["metabolic", 556], ["pathway", 566], [".", 573], ["Opicapone", 575], ["metabolites", 585], ["recovered", 597], ["in", 607], ["urine", 610], ["accounted", 616], ["for", 626], ["less", 630], ["than", 635], ["3", 640], ["%", 641], ["of", 643], ["the", 646], ["amount", 650], ["of", 657], ["opicapone", 660], ["administered", 670], ["suggesting", 683], ["that", 694], ["bile", 699], ["is", 704], ["likely", 707], ["the", 714], ["main", 718], ["route", 723], ["of", 729], ["excretion", 732], [".", 741], ["Maximum", 743], ["S", 751], ["-", 752], ["COMT", 753], ["inhibition", 758], ["(", 769], ["Emax", 770], [")", 775], ["ranged", 777], ["from", 784], ["69.9", 789], ["%", 793], ["to", 795], ["98.0", 798], ["%", 802], ["following", 804], ["the", 814], ["last", 818], ["dose", 823], ["of", 828], ["opicapone", 831], [".", 840], ["The", 842], ["opicapone", 846], ["-", 855], ["induced", 856], ["S", 864], ["-", 865], ["COMT", 866], ["inhibition", 871], ["showed", 882], ["a", 889], ["half", 891], ["-", 895], ["life", 896], ["in", 901], ["excess", 904], ["of", 911], ["100", 914], ["h", 918], [",", 919], ["which", 921], ["was", 927], ["dose", 931], ["-", 935], ["independent", 936], ["and", 948], ["much", 952], ["longer", 957], ["than", 964], ["plasma", 969], ["drug", 976], ["exposure", 981], [".", 989], ["Such", 991], ["a", 996], ["half", 998], ["-", 1002], ["life", 1003], ["translates", 1008], ["into", 1019], ["a", 1024], ["putative", 1026], ["underlying", 1035], ["rate", 1046], ["constant", 1051], ["that", 1060], ["is", 1065], ["comparable", 1068], ["with", 1079], ["the", 1084], ["estimated", 1088], ["dissociation", 1098], ["rate", 1111], ["constant", 1116], ["of", 1125], ["the", 1128], ["COMT", 1132], ["-", 1136], ["opicapone", 1137], ["complex", 1147], [".", 1154], ["Despite", 1156], ["its", 1164], ["short", 1168], ["elimination", 1174], ["half", 1186], ["-", 1190], ["life", 1191], [",", 1195], ["opicapone", 1197], ["markedly", 1207], ["and", 1216], ["sustainably", 1220], ["inhibited", 1232], ["erythrocyte", 1242], ["S", 1254], ["-", 1255], ["COMT", 1256], ["activity", 1261], ["making", 1270], ["it", 1277], ["suitable", 1280], ["for", 1289], ["a", 1293], ["once", 1295], ["daily", 1300], ["regimen", 1306], [".", 1313]]}
{"context": "With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles aphthous stomatitis than oral mucositis due to conventional anticancer therapies. While most cases of mIAS are mild to moderate and self-limiting, more severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may cause significant pain and mucosal sensitivity may occur in the absence of clinical changes. Use of clinical assessment tools that are primarily driven by ulceration size may underestimate mIAS, and assessment should include patient-reported outcomes. This article provides an up-to-date review of the clinical presentation, terminology, pathogenesis, assessment and management of mIAS and other mTOR inhibitor-associated oral adverse events. In addition, areas of future research are considered.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "51c0f6328c564f34adfee63c41eda084", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[7, 10]], "char_spans": [[46, 74]]}]}], "context_tokens": [["With", 0], ["the", 5], ["recent", 9], ["introduction", 16], ["of", 29], ["inhibitors", 32], ["of", 43], ["mammalian", 46], ["target", 56], ["of", 63], ["rapamycin", 66], ["(", 76], ["mTOR", 77], [")", 81], ["in", 83], ["oncology", 86], [",", 94], ["distinct", 96], ["cutaneous", 105], ["and", 115], ["oral", 119], ["adverse", 124], ["events", 132], ["have", 139], ["been", 144], ["identified", 149], [".", 159], ["In", 161], ["fact", 164], [",", 168], ["stomatitis", 170], ["and", 181], ["rash", 185], ["are", 190], ["documented", 194], ["as", 205], ["the", 208], ["most", 212], ["frequent", 217], ["and", 226], ["potentially", 230], ["dose", 242], ["-", 246], ["limiting", 247], ["side", 256], ["effects", 261], [".", 268], ["Clinically", 270], [",", 280], ["mTOR", 282], ["inhibitor", 287], ["-", 296], ["associated", 297], ["stomatitis", 308], ["(", 319], ["mIAS", 320], [")", 324], ["more", 326], ["closely", 331], ["resembles", 339], ["aphthous", 349], ["stomatitis", 358], ["than", 369], ["oral", 374], ["mucositis", 379], ["due", 389], ["to", 393], ["conventional", 396], ["anticancer", 409], ["therapies", 420], [".", 429], ["While", 431], ["most", 437], ["cases", 442], ["of", 448], ["mIAS", 451], ["are", 456], ["mild", 460], ["to", 465], ["moderate", 468], ["and", 477], ["self", 481], ["-", 485], ["limiting", 486], [",", 494], ["more", 496], ["severe", 501], ["and", 508], ["persistent", 512], ["mIAS", 523], ["can", 528], ["become", 532], ["a", 539], ["dose", 541], ["-", 545], ["limiting", 546], ["toxicity", 555], [".", 563], ["Small", 565], ["ulcerations", 571], ["may", 583], ["cause", 587], ["significant", 593], ["pain", 605], ["and", 610], ["mucosal", 614], ["sensitivity", 622], ["may", 634], ["occur", 638], ["in", 644], ["the", 647], ["absence", 651], ["of", 659], ["clinical", 662], ["changes", 671], [".", 678], ["Use", 680], ["of", 684], ["clinical", 687], ["assessment", 696], ["tools", 707], ["that", 713], ["are", 718], ["primarily", 722], ["driven", 732], ["by", 739], ["ulceration", 742], ["size", 753], ["may", 758], ["underestimate", 762], ["mIAS", 776], [",", 780], ["and", 782], ["assessment", 786], ["should", 797], ["include", 804], ["patient", 812], ["-", 819], ["reported", 820], ["outcomes", 829], [".", 837], ["This", 839], ["article", 844], ["provides", 852], ["an", 861], ["up", 864], ["-", 866], ["to", 867], ["-", 869], ["date", 870], ["review", 875], ["of", 882], ["the", 885], ["clinical", 889], ["presentation", 898], [",", 910], ["terminology", 912], [",", 923], ["pathogenesis", 925], [",", 937], ["assessment", 939], ["and", 950], ["management", 954], ["of", 965], ["mIAS", 968], ["and", 973], ["other", 977], ["mTOR", 983], ["inhibitor", 988], ["-", 997], ["associated", 998], ["oral", 1009], ["adverse", 1014], ["events", 1022], [".", 1028], ["In", 1030], ["addition", 1033], [",", 1041], ["areas", 1043], ["of", 1049], ["future", 1052], ["research", 1059], ["are", 1068], ["considered", 1072], [".", 1082]]}
{"context": "Asymptomatic colonization with methicillin-resistant Staphylococcus aureus (MRSA) has been described as a risk factor for subsequent MRSA infection. MRSA is an important nosocomial pathogen but has currently been reported in patients without typical risk factors for nosocomial acquisition. This study was designed to evaluate the impact of asymptomatic nares MRSA colonization on the development of subsequent MRSA infection. The incidence of MRSA infection was examined in patients with and patients without MRSA or methicillin-susceptible S. aureus (MSSA) colonization at admission to the hospital and in those who developed colonization during hospitalization. Patients admitted to 5 representative hospital units were prospectively evaluated. Nares samples were obtained for culture at admission and during hospitalization. Laboratory culture results were monitored to identify all MRSA infections that occurred during the study period and 1 year thereafter. Of the 758 patients who had cultures of nares samples performed at admission, 3.4% were colonized with MRSA, and 21% were colonized with MSSA. A total of 19% of patients with MRSA colonization at admission and 25% who acquired MRSA colonization during hospitalization developed infection with MRSA, compared with 1.5% and 2.0% of patients colonized with MSSA (P<.01) and uncolonized (P<.01), respectively, at admission. MRSA colonization at admission increased the risk of subsequent MRSA infection, compared with MSSA colonization (relative risk [RR], 13; 95% confidence interval [CI], 2.7-64) or no staphylococcal colonization (RR, 9.5; 95% CI, 3.6-25) at admission. Acquisition of MRSA colonization also increased the risk for subsequent MRSA infection, compared with no acquisition (RR, 12; 95% CI, 4.0-38). MRSA colonization of nares, either present at admission to the hospital or acquired during hospitalization, increases the risk for MRSA infection. Identifying MRSA colonization at admission could target a high-risk population that may benefit from interventions to decrease the risk for subsequent MRSA infection.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "eb949241f90c4716aa3b61abe11efb88", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[237, 237], [341, 341], [134, 134], [363, 363], [20, 20], [184, 184], [337, 337], [68, 68], [316, 316], [78, 78], [62, 62], [193, 193], [166, 166], [295, 295], [228, 228], [23, 23], [9, 9], [55, 55], [200, 200], [287, 287]], "char_spans": [[1448, 1451], [1935, 1938], [887, 890], [2074, 2077], [133, 136], [1139, 1142], [1907, 1910], [444, 447], [1776, 1779], [510, 513], [411, 414], [1191, 1194], [1067, 1070], [1705, 1708], [1384, 1387], [149, 152], [76, 79], [360, 363], [1257, 1260], [1648, 1651]]}]}], "context_tokens": [["Asymptomatic", 0], ["colonization", 13], ["with", 26], ["methicillin", 31], ["-", 42], ["resistant", 43], ["Staphylococcus", 53], ["aureus", 68], ["(", 75], ["MRSA", 76], [")", 80], ["has", 82], ["been", 86], ["described", 91], ["as", 101], ["a", 104], ["risk", 106], ["factor", 111], ["for", 118], ["subsequent", 122], ["MRSA", 133], ["infection", 138], [".", 147], ["MRSA", 149], ["is", 154], ["an", 157], ["important", 160], ["nosocomial", 170], ["pathogen", 181], ["but", 190], ["has", 194], ["currently", 198], ["been", 208], ["reported", 213], ["in", 222], ["patients", 225], ["without", 234], ["typical", 242], ["risk", 250], ["factors", 255], ["for", 263], ["nosocomial", 267], ["acquisition", 278], [".", 289], ["This", 291], ["study", 296], ["was", 302], ["designed", 306], ["to", 315], ["evaluate", 318], ["the", 327], ["impact", 331], ["of", 338], ["asymptomatic", 341], ["nares", 354], ["MRSA", 360], ["colonization", 365], ["on", 378], ["the", 381], ["development", 385], ["of", 397], ["subsequent", 400], ["MRSA", 411], ["infection", 416], [".", 425], ["The", 427], ["incidence", 431], ["of", 441], ["MRSA", 444], ["infection", 449], ["was", 459], ["examined", 463], ["in", 472], ["patients", 475], ["with", 484], ["and", 489], ["patients", 493], ["without", 502], ["MRSA", 510], ["or", 515], ["methicillin", 518], ["-", 529], ["susceptible", 530], ["S.", 542], ["aureus", 545], ["(", 552], ["MSSA", 553], [")", 557], ["colonization", 559], ["at", 572], ["admission", 575], ["to", 585], ["the", 588], ["hospital", 592], ["and", 601], ["in", 605], ["those", 608], ["who", 614], ["developed", 618], ["colonization", 628], ["during", 641], ["hospitalization", 648], [".", 663], ["Patients", 665], ["admitted", 674], ["to", 683], ["5", 686], ["representative", 688], ["hospital", 703], ["units", 712], ["were", 718], ["prospectively", 723], ["evaluated", 737], [".", 746], ["Nares", 748], ["samples", 754], ["were", 762], ["obtained", 767], ["for", 776], ["culture", 780], ["at", 788], ["admission", 791], ["and", 801], ["during", 805], ["hospitalization", 812], [".", 827], ["Laboratory", 829], ["culture", 840], ["results", 848], ["were", 856], ["monitored", 861], ["to", 871], ["identify", 874], ["all", 883], ["MRSA", 887], ["infections", 892], ["that", 903], ["occurred", 908], ["during", 917], ["the", 924], ["study", 928], ["period", 934], ["and", 941], ["1", 945], ["year", 947], ["thereafter", 952], [".", 962], ["Of", 964], ["the", 967], ["758", 971], ["patients", 975], ["who", 984], ["had", 988], ["cultures", 992], ["of", 1001], ["nares", 1004], ["samples", 1010], ["performed", 1018], ["at", 1028], ["admission", 1031], [",", 1040], ["3.4", 1042], ["%", 1045], ["were", 1047], ["colonized", 1052], ["with", 1062], ["MRSA", 1067], [",", 1071], ["and", 1073], ["21", 1077], ["%", 1079], ["were", 1081], ["colonized", 1086], ["with", 1096], ["MSSA", 1101], [".", 1105], ["A", 1107], ["total", 1109], ["of", 1115], ["19", 1118], ["%", 1120], ["of", 1122], ["patients", 1125], ["with", 1134], ["MRSA", 1139], ["colonization", 1144], ["at", 1157], ["admission", 1160], ["and", 1170], ["25", 1174], ["%", 1176], ["who", 1178], ["acquired", 1182], ["MRSA", 1191], ["colonization", 1196], ["during", 1209], ["hospitalization", 1216], ["developed", 1232], ["infection", 1242], ["with", 1252], ["MRSA", 1257], [",", 1261], ["compared", 1263], ["with", 1272], ["1.5", 1277], ["%", 1280], ["and", 1282], ["2.0", 1286], ["%", 1289], ["of", 1291], ["patients", 1294], ["colonized", 1303], ["with", 1313], ["MSSA", 1318], ["(", 1323], ["P<.01", 1324], [")", 1329], ["and", 1331], ["uncolonized", 1335], ["(", 1347], ["P<.01", 1348], [")", 1353], [",", 1354], ["respectively", 1356], [",", 1368], ["at", 1370], ["admission", 1373], [".", 1382], ["MRSA", 1384], ["colonization", 1389], ["at", 1402], ["admission", 1405], ["increased", 1415], ["the", 1425], ["risk", 1429], ["of", 1434], ["subsequent", 1437], ["MRSA", 1448], ["infection", 1453], [",", 1462], ["compared", 1464], ["with", 1473], ["MSSA", 1478], ["colonization", 1483], ["(", 1496], ["relative", 1497], ["risk", 1506], ["[", 1511], ["RR", 1512], ["]", 1514], [",", 1515], ["13", 1517], [";", 1519], ["95", 1521], ["%", 1523], ["confidence", 1525], ["interval", 1536], ["[", 1545], ["CI", 1546], ["]", 1548], [",", 1549], ["2.7", 1551], ["-", 1554], ["64", 1555], [")", 1557], ["or", 1559], ["no", 1562], ["staphylococcal", 1565], ["colonization", 1580], ["(", 1593], ["RR", 1594], [",", 1596], ["9.5", 1598], [";", 1601], ["95", 1603], ["%", 1605], ["CI", 1607], [",", 1609], ["3.6", 1611], ["-", 1614], ["25", 1615], [")", 1617], ["at", 1619], ["admission", 1622], [".", 1631], ["Acquisition", 1633], ["of", 1645], ["MRSA", 1648], ["colonization", 1653], ["also", 1666], ["increased", 1671], ["the", 1681], ["risk", 1685], ["for", 1690], ["subsequent", 1694], ["MRSA", 1705], ["infection", 1710], [",", 1719], ["compared", 1721], ["with", 1730], ["no", 1735], ["acquisition", 1738], ["(", 1750], ["RR", 1751], [",", 1753], ["12", 1755], [";", 1757], ["95", 1759], ["%", 1761], ["CI", 1763], [",", 1765], ["4.0", 1767], ["-", 1770], ["38", 1771], [")", 1773], [".", 1774], ["MRSA", 1776], ["colonization", 1781], ["of", 1794], ["nares", 1797], [",", 1802], ["either", 1804], ["present", 1811], ["at", 1819], ["admission", 1822], ["to", 1832], ["the", 1835], ["hospital", 1839], ["or", 1848], ["acquired", 1851], ["during", 1860], ["hospitalization", 1867], [",", 1882], ["increases", 1884], ["the", 1894], ["risk", 1898], ["for", 1903], ["MRSA", 1907], ["infection", 1912], [".", 1921], ["Identifying", 1923], ["MRSA", 1935], ["colonization", 1940], ["at", 1953], ["admission", 1956], ["could", 1966], ["target", 1972], ["a", 1979], ["high", 1981], ["-", 1985], ["risk", 1986], ["population", 1991], ["that", 2002], ["may", 2007], ["benefit", 2011], ["from", 2019], ["interventions", 2024], ["to", 2038], ["decrease", 2041], ["the", 2050], ["risk", 2054], ["for", 2059], ["subsequent", 2063], ["MRSA", 2074], ["infection", 2079], [".", 2088]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose. Judicious use of flumazenil may provide useful diagnostic information and may obviate the need for mechanical ventilation and other invasive supportive measures. Although some controversy exists regarding the possible precipitation of seizure activity in the setting of mixed tricyclic antidepressant-benzodiazepine overdose, worldwide experience with flumazenil has validated its safety and efficacy.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b4b16d825b304cf98373a45e742826da", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [85, 85], [40, 40]], "char_spans": [[0, 9], [622, 631], [287, 296]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["is", 50], ["useful", 53], ["in", 60], ["reversing", 63], ["the", 73], ["sedation", 77], ["and", 86], ["respiratory", 90], ["depression", 102], ["that", 113], ["often", 118], ["occur", 124], ["when", 130], ["benzodiazepines", 135], ["are", 151], ["administered", 155], ["to", 168], ["patients", 171], ["undergoing", 180], ["anesthesia", 191], ["or", 202], ["when", 205], ["patients", 210], ["have", 219], ["taken", 224], ["an", 230], ["intentional", 233], ["benzodiazepine", 245], ["overdose", 260], [".", 268], ["Judicious", 270], ["use", 280], ["of", 284], ["flumazenil", 287], ["may", 298], ["provide", 302], ["useful", 310], ["diagnostic", 317], ["information", 328], ["and", 340], ["may", 344], ["obviate", 348], ["the", 356], ["need", 360], ["for", 365], ["mechanical", 369], ["ventilation", 380], ["and", 392], ["other", 396], ["invasive", 402], ["supportive", 411], ["measures", 422], [".", 430], ["Although", 432], ["some", 441], ["controversy", 446], ["exists", 458], ["regarding", 465], ["the", 475], ["possible", 479], ["precipitation", 488], ["of", 502], ["seizure", 505], ["activity", 513], ["in", 522], ["the", 525], ["setting", 529], ["of", 537], ["mixed", 540], ["tricyclic", 546], ["antidepressant", 556], ["-", 570], ["benzodiazepine", 571], ["overdose", 586], [",", 594], ["worldwide", 596], ["experience", 606], ["with", 617], ["flumazenil", 622], ["has", 633], ["validated", 637], ["its", 647], ["safety", 651], ["and", 658], ["efficacy", 662], [".", 670]]}
{"context": "Nuclear receptor co-repressor (N-CoR) plays important role in transcriptional control mediated by several tumor suppressor proteins. Recently, we reported a role of misfolded-conformation dependent loss (MCDL) of N-CoR in the activation of oncogenic survival pathway in acute promyelocytic leukemia (APL). Since N-CoR plays important role in cellular homeostasis in various tissues, therefore, we hypothesized that an APL like MCDL of N-CoR might also be involved in other malignancy. Indeed, our initial screening of N-CoR status in various leukemia and solid tumor cells revealed an APL like MCDL of N-CoR in primary and secondary tumor cells derived from non-small cell lung cancer (NSCLC). The NSCLC cell specific N-CoR loss could be blocked by Kaletra, a clinical grade protease inhibitor and by genistein, an inhibitor of N-CoR misfolding previously characterized by us. The misfolded N-CoR presented in NSCLC cells was linked to the amplification of ER stress and was subjected to degradation by NSCLC cell specific aberrant protease activity. In NSCLC cells, misfolded N-CoR was found to be associated with Hsc70, a molecular chaperone involved in chaperone mediated autophagy (CMA). Genetic and chemical inhibition of Lamp2A, a rate limiting factor of CMA, significantly blocked the loss of N-CoR in NSCLC cells, suggesting a crucial role of CMA in N-CoR degradation. These findings identify an important role of CMA-induced degradation of misfolded N-CoR in the neutralization of ER stress and suggest a possible role of misfolded N-CoR protein in the activation of oncogenic survival pathway in NSCLC cells.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "af4403448ae94c1aa52153c83756e095", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[234, 234]], "char_spans": [[1227, 1232]]}]}], "context_tokens": [["Nuclear", 0], ["receptor", 8], ["co", 17], ["-", 19], ["repressor", 20], ["(", 30], ["N", 31], ["-", 32], ["CoR", 33], [")", 36], ["plays", 38], ["important", 44], ["role", 54], ["in", 59], ["transcriptional", 62], ["control", 78], ["mediated", 86], ["by", 95], ["several", 98], ["tumor", 106], ["suppressor", 112], ["proteins", 123], [".", 131], ["Recently", 133], [",", 141], ["we", 143], ["reported", 146], ["a", 155], ["role", 157], ["of", 162], ["misfolded", 165], ["-", 174], ["conformation", 175], ["dependent", 188], ["loss", 198], ["(", 203], ["MCDL", 204], [")", 208], ["of", 210], ["N", 213], ["-", 214], ["CoR", 215], ["in", 219], ["the", 222], ["activation", 226], ["of", 237], ["oncogenic", 240], ["survival", 250], ["pathway", 259], ["in", 267], ["acute", 270], ["promyelocytic", 276], ["leukemia", 290], ["(", 299], ["APL", 300], [")", 303], [".", 304], ["Since", 306], ["N", 312], ["-", 313], ["CoR", 314], ["plays", 318], ["important", 324], ["role", 334], ["in", 339], ["cellular", 342], ["homeostasis", 351], ["in", 363], ["various", 366], ["tissues", 374], [",", 381], ["therefore", 383], [",", 392], ["we", 394], ["hypothesized", 397], ["that", 410], ["an", 415], ["APL", 418], ["like", 422], ["MCDL", 427], ["of", 432], ["N", 435], ["-", 436], ["CoR", 437], ["might", 441], ["also", 447], ["be", 452], ["involved", 455], ["in", 464], ["other", 467], ["malignancy", 473], [".", 483], ["Indeed", 485], [",", 491], ["our", 493], ["initial", 497], ["screening", 505], ["of", 515], ["N", 518], ["-", 519], ["CoR", 520], ["status", 524], ["in", 531], ["various", 534], ["leukemia", 542], ["and", 551], ["solid", 555], ["tumor", 561], ["cells", 567], ["revealed", 573], ["an", 582], ["APL", 585], ["like", 589], ["MCDL", 594], ["of", 599], ["N", 602], ["-", 603], ["CoR", 604], ["in", 608], ["primary", 611], ["and", 619], ["secondary", 623], ["tumor", 633], ["cells", 639], ["derived", 645], ["from", 653], ["non", 658], ["-", 661], ["small", 662], ["cell", 668], ["lung", 673], ["cancer", 678], ["(", 685], ["NSCLC", 686], [")", 691], [".", 692], ["The", 694], ["NSCLC", 698], ["cell", 704], ["specific", 709], ["N", 718], ["-", 719], ["CoR", 720], ["loss", 724], ["could", 729], ["be", 735], ["blocked", 738], ["by", 746], ["Kaletra", 749], [",", 756], ["a", 758], ["clinical", 760], ["grade", 769], ["protease", 775], ["inhibitor", 784], ["and", 794], ["by", 798], ["genistein", 801], [",", 810], ["an", 812], ["inhibitor", 815], ["of", 825], ["N", 828], ["-", 829], ["CoR", 830], ["misfolding", 834], ["previously", 845], ["characterized", 856], ["by", 870], ["us", 873], [".", 875], ["The", 877], ["misfolded", 881], ["N", 891], ["-", 892], ["CoR", 893], ["presented", 897], ["in", 907], ["NSCLC", 910], ["cells", 916], ["was", 922], ["linked", 926], ["to", 933], ["the", 936], ["amplification", 940], ["of", 954], ["ER", 957], ["stress", 960], ["and", 967], ["was", 971], ["subjected", 975], ["to", 985], ["degradation", 988], ["by", 1000], ["NSCLC", 1003], ["cell", 1009], ["specific", 1014], ["aberrant", 1023], ["protease", 1032], ["activity", 1041], [".", 1049], ["In", 1051], ["NSCLC", 1054], ["cells", 1060], [",", 1065], ["misfolded", 1067], ["N", 1077], ["-", 1078], ["CoR", 1079], ["was", 1083], ["found", 1087], ["to", 1093], ["be", 1096], ["associated", 1099], ["with", 1110], ["Hsc70", 1115], [",", 1120], ["a", 1122], ["molecular", 1124], ["chaperone", 1134], ["involved", 1144], ["in", 1153], ["chaperone", 1156], ["mediated", 1166], ["autophagy", 1175], ["(", 1185], ["CMA", 1186], [")", 1189], [".", 1190], ["Genetic", 1192], ["and", 1200], ["chemical", 1204], ["inhibition", 1213], ["of", 1224], ["Lamp2A", 1227], [",", 1233], ["a", 1235], ["rate", 1237], ["limiting", 1242], ["factor", 1251], ["of", 1258], ["CMA", 1261], [",", 1264], ["significantly", 1266], ["blocked", 1280], ["the", 1288], ["loss", 1292], ["of", 1297], ["N", 1300], ["-", 1301], ["CoR", 1302], ["in", 1306], ["NSCLC", 1309], ["cells", 1315], [",", 1320], ["suggesting", 1322], ["a", 1333], ["crucial", 1335], ["role", 1343], ["of", 1348], ["CMA", 1351], ["in", 1355], ["N", 1358], ["-", 1359], ["CoR", 1360], ["degradation", 1364], [".", 1375], ["These", 1377], ["findings", 1383], ["identify", 1392], ["an", 1401], ["important", 1404], ["role", 1414], ["of", 1419], ["CMA", 1422], ["-", 1425], ["induced", 1426], ["degradation", 1434], ["of", 1446], ["misfolded", 1449], ["N", 1459], ["-", 1460], ["CoR", 1461], ["in", 1465], ["the", 1468], ["neutralization", 1472], ["of", 1487], ["ER", 1490], ["stress", 1493], ["and", 1500], ["suggest", 1504], ["a", 1512], ["possible", 1514], ["role", 1523], ["of", 1528], ["misfolded", 1531], ["N", 1541], ["-", 1542], ["CoR", 1543], ["protein", 1547], ["in", 1555], ["the", 1558], ["activation", 1562], ["of", 1573], ["oncogenic", 1576], ["survival", 1586], ["pathway", 1595], ["in", 1603], ["NSCLC", 1606], ["cells", 1612], [".", 1617]]}
{"context": "Empirical data have challenged chronic posttraumatic stress disorder (PTSD) consisting of three dimensions. In the present study we aimed to determine the factor structure of acute posttraumatic symptoms in two recently traumatized samples. In sample 1, 203 civilian trauma survivors were administered the Davidson Trauma Scale (DTS) approximately 1 week posttrauma. In sample 2, 182 civilian treatment seeking trauma survivors completed the DTS at an average of 41.4 days posttrauma. Our confirmatory factor analyses indicated that a 4-factor intercorrelated model provided the best representation of the data in both samples. The four factors are best described as reexperiencing, active avoidance, dysphoria, and hyperarousal. For acute posttraumatic symptoms, the empirical data suggest to split the avoidance cluster into 'Active avoidance' and 'Dysphoria'-confirming findings in studies on chronic PTSD. In future revisions of the DSM, the diagnostic criteria for PTSD may need to be adapted to fit the research findings.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "154d75312f834698b4172f50c831682d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[145, 145], [9, 9], [158, 158]], "char_spans": [[904, 907], [70, 73], [970, 973]]}]}], "context_tokens": [["Empirical", 0], ["data", 10], ["have", 15], ["challenged", 20], ["chronic", 31], ["posttraumatic", 39], ["stress", 53], ["disorder", 60], ["(", 69], ["PTSD", 70], [")", 74], ["consisting", 76], ["of", 87], ["three", 90], ["dimensions", 96], [".", 106], ["In", 108], ["the", 111], ["present", 115], ["study", 123], ["we", 129], ["aimed", 132], ["to", 138], ["determine", 141], ["the", 151], ["factor", 155], ["structure", 162], ["of", 172], ["acute", 175], ["posttraumatic", 181], ["symptoms", 195], ["in", 204], ["two", 207], ["recently", 211], ["traumatized", 220], ["samples", 232], [".", 239], ["In", 241], ["sample", 244], ["1", 251], [",", 252], ["203", 254], ["civilian", 258], ["trauma", 267], ["survivors", 274], ["were", 284], ["administered", 289], ["the", 302], ["Davidson", 306], ["Trauma", 315], ["Scale", 322], ["(", 328], ["DTS", 329], [")", 332], ["approximately", 334], ["1", 348], ["week", 350], ["posttrauma", 355], [".", 365], ["In", 367], ["sample", 370], ["2", 377], [",", 378], ["182", 380], ["civilian", 384], ["treatment", 393], ["seeking", 403], ["trauma", 411], ["survivors", 418], ["completed", 428], ["the", 438], ["DTS", 442], ["at", 446], ["an", 449], ["average", 452], ["of", 460], ["41.4", 463], ["days", 468], ["posttrauma", 473], [".", 483], ["Our", 485], ["confirmatory", 489], ["factor", 502], ["analyses", 509], ["indicated", 518], ["that", 528], ["a", 533], ["4-factor", 535], ["intercorrelated", 544], ["model", 560], ["provided", 566], ["the", 575], ["best", 579], ["representation", 584], ["of", 599], ["the", 602], ["data", 606], ["in", 611], ["both", 614], ["samples", 619], [".", 626], ["The", 628], ["four", 632], ["factors", 637], ["are", 645], ["best", 649], ["described", 654], ["as", 664], ["reexperiencing", 667], [",", 681], ["active", 683], ["avoidance", 690], [",", 699], ["dysphoria", 701], [",", 710], ["and", 712], ["hyperarousal", 716], [".", 728], ["For", 730], ["acute", 734], ["posttraumatic", 740], ["symptoms", 754], [",", 762], ["the", 764], ["empirical", 768], ["data", 778], ["suggest", 783], ["to", 791], ["split", 794], ["the", 800], ["avoidance", 804], ["cluster", 814], ["into", 822], ["'", 827], ["Active", 828], ["avoidance", 835], ["'", 844], ["and", 846], ["'", 850], ["Dysphoria'-confirming", 851], ["findings", 873], ["in", 882], ["studies", 885], ["on", 893], ["chronic", 896], ["PTSD", 904], [".", 908], ["In", 910], ["future", 913], ["revisions", 920], ["of", 930], ["the", 933], ["DSM", 937], [",", 940], ["the", 942], ["diagnostic", 946], ["criteria", 957], ["for", 966], ["PTSD", 970], ["may", 975], ["need", 979], ["to", 984], ["be", 987], ["adapted", 990], ["to", 998], ["fit", 1001], ["the", 1005], ["research", 1009], ["findings", 1018], [".", 1026]]}
{"context": "Patients with multiple myeloma (MM) experience pathologic fractures, bone pain, hypercalcemia, neurologic symptoms, and renal insufficiency with substantial morbidity and mortality. Bisphosphonates have been used successfully for the management of MM-related bone disease. Increased incidence of osteonecrosis of the jaw has been observed in patients with cancer receiving bisphosphonate therapy. Recent advances in the pathobiology of MM-related bone disease and other cancer-related bone metastases have led to the identification of novel therapeutic targets, such as receptor activator of nuclear factor-kappaB (RANK); its ligand (RANKL); and a decoy receptor, osteoprotegerin, for the development of potential targeted agents. Initials studies have demonstrated that targeting RANK/ RANKL signaling with the fully human monoclonal antibody denosumab prevented skeletal complications in patients with MM and other cancers with bone metastases. Ongoing studies evaluating the clinical utility of denosumab in cancer- related bone destruction have been discussed. In addition, several potential targets, such as macrophage inflammatory protein-1alpha, chemokine receptors 1 and 5, interleukin-3, and Wnt signaling, are b riefly described.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "3e9485482dda405c9488b643f9e2b125", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[105, 105], [130, 130]], "char_spans": [[634, 638], [787, 791]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["multiple", 14], ["myeloma", 23], ["(", 31], ["MM", 32], [")", 34], ["experience", 36], ["pathologic", 47], ["fractures", 58], [",", 67], ["bone", 69], ["pain", 74], [",", 78], ["hypercalcemia", 80], [",", 93], ["neurologic", 95], ["symptoms", 106], [",", 114], ["and", 116], ["renal", 120], ["insufficiency", 126], ["with", 140], ["substantial", 145], ["morbidity", 157], ["and", 167], ["mortality", 171], [".", 180], ["Bisphosphonates", 182], ["have", 198], ["been", 203], ["used", 208], ["successfully", 213], ["for", 226], ["the", 230], ["management", 234], ["of", 245], ["MM", 248], ["-", 250], ["related", 251], ["bone", 259], ["disease", 264], [".", 271], ["Increased", 273], ["incidence", 283], ["of", 293], ["osteonecrosis", 296], ["of", 310], ["the", 313], ["jaw", 317], ["has", 321], ["been", 325], ["observed", 330], ["in", 339], ["patients", 342], ["with", 351], ["cancer", 356], ["receiving", 363], ["bisphosphonate", 373], ["therapy", 388], [".", 395], ["Recent", 397], ["advances", 404], ["in", 413], ["the", 416], ["pathobiology", 420], ["of", 433], ["MM", 436], ["-", 438], ["related", 439], ["bone", 447], ["disease", 452], ["and", 460], ["other", 464], ["cancer", 470], ["-", 476], ["related", 477], ["bone", 485], ["metastases", 490], ["have", 501], ["led", 506], ["to", 510], ["the", 513], ["identification", 517], ["of", 532], ["novel", 535], ["therapeutic", 541], ["targets", 553], [",", 560], ["such", 562], ["as", 567], ["receptor", 570], ["activator", 579], ["of", 589], ["nuclear", 592], ["factor", 600], ["-", 606], ["kappaB", 607], ["(", 614], ["RANK", 615], [")", 619], [";", 620], ["its", 622], ["ligand", 626], ["(", 633], ["RANKL", 634], [")", 639], [";", 640], ["and", 642], ["a", 646], ["decoy", 648], ["receptor", 654], [",", 662], ["osteoprotegerin", 664], [",", 679], ["for", 681], ["the", 685], ["development", 689], ["of", 701], ["potential", 704], ["targeted", 714], ["agents", 723], [".", 729], ["Initials", 731], ["studies", 740], ["have", 748], ["demonstrated", 753], ["that", 766], ["targeting", 771], ["RANK/", 781], ["RANKL", 787], ["signaling", 793], ["with", 803], ["the", 808], ["fully", 812], ["human", 818], ["monoclonal", 824], ["antibody", 835], ["denosumab", 844], ["prevented", 854], ["skeletal", 864], ["complications", 873], ["in", 887], ["patients", 890], ["with", 899], ["MM", 904], ["and", 907], ["other", 911], ["cancers", 917], ["with", 925], ["bone", 930], ["metastases", 935], [".", 945], ["Ongoing", 947], ["studies", 955], ["evaluating", 963], ["the", 974], ["clinical", 978], ["utility", 987], ["of", 995], ["denosumab", 998], ["in", 1008], ["cancer-", 1011], ["related", 1019], ["bone", 1027], ["destruction", 1032], ["have", 1044], ["been", 1049], ["discussed", 1054], [".", 1063], ["In", 1065], ["addition", 1068], [",", 1076], ["several", 1078], ["potential", 1086], ["targets", 1096], [",", 1103], ["such", 1105], ["as", 1110], ["macrophage", 1113], ["inflammatory", 1124], ["protein-1alpha", 1137], [",", 1151], ["chemokine", 1153], ["receptors", 1163], ["1", 1173], ["and", 1175], ["5", 1179], [",", 1180], ["interleukin-3", 1182], [",", 1195], ["and", 1197], ["Wnt", 1201], ["signaling", 1205], [",", 1214], ["are", 1216], ["b", 1220], ["riefly", 1222], ["described", 1229], [".", 1238]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome that is characterized by pure red-cell aplasia and associated physical deformities. It has been proven that defects of ribosomal proteins can lead to this disease and that RPS19 is the most frequently mutated gene in DBA patients. Previous studies suggest that p53-dependent genes and pathways play important roles in RPS19-deficient embryos. However, whether there are other vital factors linked to DBA has not been fully clarified. In this study, we compared the whole genome RNA-Seq data of zebrafish embryos injected with RPS19 morpholino (RPS19 MO), RPS19 and p53 morpholino simultaneously (RPS19+p53 MO) and control morpholino (control). We found that genes enriched in the functions of hematological systems, nervous system development and skeletal and muscular disorders had significant differential expression in RPS19 MO embryos compared with controls. Co-inhibition of p53 partially alleviates the abnormalities for RPS19-deficient embryos. However, the hematopoietic genes, which were down-regulated significantly in RPS19 MO embryos, were not completely recovered by the co-inhibition of p53. Furthermore, we identified the genome-wide p53-dependent and -independent genes and pathways. These results indicate that not only p53 family members but also other factors have important impacts on RPS19-deficient embryos. The detection of potential pathogenic genes and pathways provides us a new paradigm for future research on DBA, which is a systematic and complex hereditary disease.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "2ff9e79323fb48ad9fe911c391aecaa8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[81, 81], [53, 53], [255, 255], [5, 5]], "char_spans": [[479, 481], [296, 298], [1516, 1518], [25, 27]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["inherited", 40], ["bone", 50], ["marrow", 55], ["failure", 62], ["syndrome", 70], ["that", 79], ["is", 84], ["characterized", 87], ["by", 101], ["pure", 104], ["red", 109], ["-", 112], ["cell", 113], ["aplasia", 118], ["and", 126], ["associated", 130], ["physical", 141], ["deformities", 150], [".", 161], ["It", 163], ["has", 166], ["been", 170], ["proven", 175], ["that", 182], ["defects", 187], ["of", 195], ["ribosomal", 198], ["proteins", 208], ["can", 217], ["lead", 221], ["to", 226], ["this", 229], ["disease", 234], ["and", 242], ["that", 246], ["RPS19", 251], ["is", 257], ["the", 260], ["most", 264], ["frequently", 269], ["mutated", 280], ["gene", 288], ["in", 293], ["DBA", 296], ["patients", 300], [".", 308], ["Previous", 310], ["studies", 319], ["suggest", 327], ["that", 335], ["p53-dependent", 340], ["genes", 354], ["and", 360], ["pathways", 364], ["play", 373], ["important", 378], ["roles", 388], ["in", 394], ["RPS19-deficient", 397], ["embryos", 413], [".", 420], ["However", 422], [",", 429], ["whether", 431], ["there", 439], ["are", 445], ["other", 449], ["vital", 455], ["factors", 461], ["linked", 469], ["to", 476], ["DBA", 479], ["has", 483], ["not", 487], ["been", 491], ["fully", 496], ["clarified", 502], [".", 511], ["In", 513], ["this", 516], ["study", 521], [",", 526], ["we", 528], ["compared", 531], ["the", 540], ["whole", 544], ["genome", 550], ["RNA", 557], ["-", 560], ["Seq", 561], ["data", 565], ["of", 570], ["zebrafish", 573], ["embryos", 583], ["injected", 591], ["with", 600], ["RPS19", 605], ["morpholino", 611], ["(", 622], ["RPS19", 623], ["MO", 629], [")", 631], [",", 632], ["RPS19", 634], ["and", 640], ["p53", 644], ["morpholino", 648], ["simultaneously", 659], ["(", 674], ["RPS19+p53", 675], ["MO", 685], [")", 687], ["and", 689], ["control", 693], ["morpholino", 701], ["(", 712], ["control", 713], [")", 720], [".", 721], ["We", 723], ["found", 726], ["that", 732], ["genes", 737], ["enriched", 743], ["in", 752], ["the", 755], ["functions", 759], ["of", 769], ["hematological", 772], ["systems", 786], [",", 793], ["nervous", 795], ["system", 803], ["development", 810], ["and", 822], ["skeletal", 826], ["and", 835], ["muscular", 839], ["disorders", 848], ["had", 858], ["significant", 862], ["differential", 874], ["expression", 887], ["in", 898], ["RPS19", 901], ["MO", 907], ["embryos", 910], ["compared", 918], ["with", 927], ["controls", 932], [".", 940], ["Co", 942], ["-", 944], ["inhibition", 945], ["of", 956], ["p53", 959], ["partially", 963], ["alleviates", 973], ["the", 984], ["abnormalities", 988], ["for", 1002], ["RPS19-deficient", 1006], ["embryos", 1022], [".", 1029], ["However", 1031], [",", 1038], ["the", 1040], ["hematopoietic", 1044], ["genes", 1058], [",", 1063], ["which", 1065], ["were", 1071], ["down", 1076], ["-", 1080], ["regulated", 1081], ["significantly", 1091], ["in", 1105], ["RPS19", 1108], ["MO", 1114], ["embryos", 1117], [",", 1124], ["were", 1126], ["not", 1131], ["completely", 1135], ["recovered", 1146], ["by", 1156], ["the", 1159], ["co", 1163], ["-", 1165], ["inhibition", 1166], ["of", 1177], ["p53", 1180], [".", 1183], ["Furthermore", 1185], [",", 1196], ["we", 1198], ["identified", 1201], ["the", 1212], ["genome", 1216], ["-", 1222], ["wide", 1223], ["p53-dependent", 1228], ["and", 1242], ["-independent", 1246], ["genes", 1259], ["and", 1265], ["pathways", 1269], [".", 1277], ["These", 1279], ["results", 1285], ["indicate", 1293], ["that", 1302], ["not", 1307], ["only", 1311], ["p53", 1316], ["family", 1320], ["members", 1327], ["but", 1335], ["also", 1339], ["other", 1344], ["factors", 1350], ["have", 1358], ["important", 1363], ["impacts", 1373], ["on", 1381], ["RPS19-deficient", 1384], ["embryos", 1400], [".", 1407], ["The", 1409], ["detection", 1413], ["of", 1423], ["potential", 1426], ["pathogenic", 1436], ["genes", 1447], ["and", 1453], ["pathways", 1457], ["provides", 1466], ["us", 1475], ["a", 1478], ["new", 1480], ["paradigm", 1484], ["for", 1493], ["future", 1497], ["research", 1504], ["on", 1513], ["DBA", 1516], [",", 1519], ["which", 1521], ["is", 1527], ["a", 1530], ["systematic", 1532], ["and", 1543], ["complex", 1547], ["hereditary", 1555], ["disease", 1566], [".", 1573]]}
{"context": "Epilepsy, a neurologic disorder characterized by the predisposition to recurrent unprovoked seizures, is reported in more than 300 genetic syndromes. Muenke syndrome is an autosomal-dominant craniosynostosis syndrome characterized by unilateral or bilateral coronal craniosynostosis, hearing loss, intellectual disability, and relatively subtle limb findings such as carpal bone fusion and tarsal bone fusion. Muenke syndrome is caused by a single defining point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. Epilepsy rarely occurs in individuals with Muenke syndrome, and little detail is reported on types of epilepsy, patient characteristics, and long-term outcomes. We present seven patients with Muenke syndrome and seizures. A review of 789 published cases of Muenke syndrome, with a focus on epilepsy and intracranial anomalies in Muenke syndrome, revealed epilepsy in six patients, with intracranial anomalies in five. The occurrence of epilepsy in Muenke syndrome within our cohort of 58 patients, of whom seven manifested epilepsy, and the intracranial anomalies and epilepsy reported in the literature, suggest that patients with Muenke syndrome may be at risk for epilepsy and intracranial anomalies. Furthermore, the impact of Muenke syndrome on the central nervous system may be greater than previously thought.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "9e843dbf324d404f9ec7fd6b491f8693", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[73, 79]], "char_spans": [[479, 520]]}]}], "context_tokens": [["Epilepsy", 0], [",", 8], ["a", 10], ["neurologic", 12], ["disorder", 23], ["characterized", 32], ["by", 46], ["the", 49], ["predisposition", 53], ["to", 68], ["recurrent", 71], ["unprovoked", 81], ["seizures", 92], [",", 100], ["is", 102], ["reported", 105], ["in", 114], ["more", 117], ["than", 122], ["300", 127], ["genetic", 131], ["syndromes", 139], [".", 148], ["Muenke", 150], ["syndrome", 157], ["is", 166], ["an", 169], ["autosomal", 172], ["-", 181], ["dominant", 182], ["craniosynostosis", 191], ["syndrome", 208], ["characterized", 217], ["by", 231], ["unilateral", 234], ["or", 245], ["bilateral", 248], ["coronal", 258], ["craniosynostosis", 266], [",", 282], ["hearing", 284], ["loss", 292], [",", 296], ["intellectual", 298], ["disability", 311], [",", 321], ["and", 323], ["relatively", 327], ["subtle", 338], ["limb", 345], ["findings", 350], ["such", 359], ["as", 364], ["carpal", 367], ["bone", 374], ["fusion", 379], ["and", 386], ["tarsal", 390], ["bone", 397], ["fusion", 402], [".", 408], ["Muenke", 410], ["syndrome", 417], ["is", 426], ["caused", 429], ["by", 436], ["a", 439], ["single", 441], ["defining", 448], ["point", 457], ["mutation", 463], ["in", 472], ["the", 475], ["fibroblast", 479], ["growth", 490], ["factor", 497], ["receptor", 504], ["3", 513], ["(", 515], ["FGFR3", 516], [")", 521], ["gene", 523], [".", 527], ["Epilepsy", 529], ["rarely", 538], ["occurs", 545], ["in", 552], ["individuals", 555], ["with", 567], ["Muenke", 572], ["syndrome", 579], [",", 587], ["and", 589], ["little", 593], ["detail", 600], ["is", 607], ["reported", 610], ["on", 619], ["types", 622], ["of", 628], ["epilepsy", 631], [",", 639], ["patient", 641], ["characteristics", 649], [",", 664], ["and", 666], ["long", 670], ["-", 674], ["term", 675], ["outcomes", 680], [".", 688], ["We", 690], ["present", 693], ["seven", 701], ["patients", 707], ["with", 716], ["Muenke", 721], ["syndrome", 728], ["and", 737], ["seizures", 741], [".", 749], ["A", 751], ["review", 753], ["of", 760], ["789", 763], ["published", 767], ["cases", 777], ["of", 783], ["Muenke", 786], ["syndrome", 793], [",", 801], ["with", 803], ["a", 808], ["focus", 810], ["on", 816], ["epilepsy", 819], ["and", 828], ["intracranial", 832], ["anomalies", 845], ["in", 855], ["Muenke", 858], ["syndrome", 865], [",", 873], ["revealed", 875], ["epilepsy", 884], ["in", 893], ["six", 896], ["patients", 900], [",", 908], ["with", 910], ["intracranial", 915], ["anomalies", 928], ["in", 938], ["five", 941], [".", 945], ["The", 947], ["occurrence", 951], ["of", 962], ["epilepsy", 965], ["in", 974], ["Muenke", 977], ["syndrome", 984], ["within", 993], ["our", 1000], ["cohort", 1004], ["of", 1011], ["58", 1014], ["patients", 1017], [",", 1025], ["of", 1027], ["whom", 1030], ["seven", 1035], ["manifested", 1041], ["epilepsy", 1052], [",", 1060], ["and", 1062], ["the", 1066], ["intracranial", 1070], ["anomalies", 1083], ["and", 1093], ["epilepsy", 1097], ["reported", 1106], ["in", 1115], ["the", 1118], ["literature", 1122], [",", 1132], ["suggest", 1134], ["that", 1142], ["patients", 1147], ["with", 1156], ["Muenke", 1161], ["syndrome", 1168], ["may", 1177], ["be", 1181], ["at", 1184], ["risk", 1187], ["for", 1192], ["epilepsy", 1196], ["and", 1205], ["intracranial", 1209], ["anomalies", 1222], [".", 1231], ["Furthermore", 1233], [",", 1244], ["the", 1246], ["impact", 1250], ["of", 1257], ["Muenke", 1260], ["syndrome", 1267], ["on", 1276], ["the", 1279], ["central", 1283], ["nervous", 1291], ["system", 1299], ["may", 1306], ["be", 1310], ["greater", 1313], ["than", 1321], ["previously", 1326], ["thought", 1337], [".", 1344]]}
{"context": "Ehlers-Danlos syndrome type 4, the vascular type, is a rare, life-threatening inherited disorder of the connective tissue. Affected patients are at risk of arterial, bowel and uterine rupture during pregnancy. Generally, this syndrome remains undiagnosed until a sudden, acute presentation with organ rupture, and results in premature death, even if the patients survive the first and second major complications. An early diagnosis with genetic assays can help to plan the best treatment, which is often challenging due to the frailty of the arterial tissue. We report on a 28-year-old lady who presented with spontaneous rupture of a pseudoaneurysm of the posterior tibial artery.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "1a2e7aaf9e9148c98bfc8b68db1ea274", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[22, 23]], "char_spans": [[104, 120]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["type", 23], ["4", 28], [",", 29], ["the", 31], ["vascular", 35], ["type", 44], [",", 48], ["is", 50], ["a", 53], ["rare", 55], [",", 59], ["life", 61], ["-", 65], ["threatening", 66], ["inherited", 78], ["disorder", 88], ["of", 97], ["the", 100], ["connective", 104], ["tissue", 115], [".", 121], ["Affected", 123], ["patients", 132], ["are", 141], ["at", 145], ["risk", 148], ["of", 153], ["arterial", 156], [",", 164], ["bowel", 166], ["and", 172], ["uterine", 176], ["rupture", 184], ["during", 192], ["pregnancy", 199], [".", 208], ["Generally", 210], [",", 219], ["this", 221], ["syndrome", 226], ["remains", 235], ["undiagnosed", 243], ["until", 255], ["a", 261], ["sudden", 263], [",", 269], ["acute", 271], ["presentation", 277], ["with", 290], ["organ", 295], ["rupture", 301], [",", 308], ["and", 310], ["results", 314], ["in", 322], ["premature", 325], ["death", 335], [",", 340], ["even", 342], ["if", 347], ["the", 350], ["patients", 354], ["survive", 363], ["the", 371], ["first", 375], ["and", 381], ["second", 385], ["major", 392], ["complications", 398], [".", 411], ["An", 413], ["early", 416], ["diagnosis", 422], ["with", 432], ["genetic", 437], ["assays", 445], ["can", 452], ["help", 456], ["to", 461], ["plan", 464], ["the", 469], ["best", 473], ["treatment", 478], [",", 487], ["which", 489], ["is", 495], ["often", 498], ["challenging", 504], ["due", 516], ["to", 520], ["the", 523], ["frailty", 527], ["of", 535], ["the", 538], ["arterial", 542], ["tissue", 551], [".", 557], ["We", 559], ["report", 562], ["on", 569], ["a", 572], ["28-year", 574], ["-", 581], ["old", 582], ["lady", 586], ["who", 591], ["presented", 595], ["with", 605], ["spontaneous", 610], ["rupture", 622], ["of", 630], ["a", 633], ["pseudoaneurysm", 635], ["of", 650], ["the", 653], ["posterior", 657], ["tibial", 667], ["artery", 674], [".", 680]]}
{"context": "ZFHX1B encodes Smad-interacting protein 1, a transcriptional corepressor involved in the transforming growth factors beta (TGFbeta) signaling pathway. ZFHX1B mutations cause a complex developmental phenotype characterized by severe mental retardation (MR) and multiple congenital defects. We compared the distribution of ZFHX1B transcripts during mouse and human embryogenesis as well as in adult mice and humans. This showed that this gene is strongly transcribed at an early stage in the developing peripheral and central nervous systems of both mice and humans, in all neuronal regions of the brains of 25-week human fetuses and adult mice, and at varying levels in numerous nonneural tissues. Northern blot analysis suggested that ZFHX1B undergoes tissue-specific alternative splicing in both species. These results strongly suggest that ZFHX1B determines the transcriptional levels of target genes in various tissues through the combinatorial interactions of its isoforms with different Smad proteins. Thus, as well as causing neural defects, ZFHX1B mutations may also cause other malformations.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "8870a7ba64174735af9856e72fd82aaa", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[0, 0], [24, 24], [120, 120], [136, 136], [168, 168], [49, 49]], "char_spans": [[0, 5], [151, 156], [735, 740], [842, 847], [1048, 1053], [321, 326]]}]}], "context_tokens": [["ZFHX1B", 0], ["encodes", 7], ["Smad", 15], ["-", 19], ["interacting", 20], ["protein", 32], ["1", 40], [",", 41], ["a", 43], ["transcriptional", 45], ["corepressor", 61], ["involved", 73], ["in", 82], ["the", 85], ["transforming", 89], ["growth", 102], ["factors", 109], ["beta", 117], ["(", 122], ["TGFbeta", 123], [")", 130], ["signaling", 132], ["pathway", 142], [".", 149], ["ZFHX1B", 151], ["mutations", 158], ["cause", 168], ["a", 174], ["complex", 176], ["developmental", 184], ["phenotype", 198], ["characterized", 208], ["by", 222], ["severe", 225], ["mental", 232], ["retardation", 239], ["(", 251], ["MR", 252], [")", 254], ["and", 256], ["multiple", 260], ["congenital", 269], ["defects", 280], [".", 287], ["We", 289], ["compared", 292], ["the", 301], ["distribution", 305], ["of", 318], ["ZFHX1B", 321], ["transcripts", 328], ["during", 340], ["mouse", 347], ["and", 353], ["human", 357], ["embryogenesis", 363], ["as", 377], ["well", 380], ["as", 385], ["in", 388], ["adult", 391], ["mice", 397], ["and", 402], ["humans", 406], [".", 412], ["This", 414], ["showed", 419], ["that", 426], ["this", 431], ["gene", 436], ["is", 441], ["strongly", 444], ["transcribed", 453], ["at", 465], ["an", 468], ["early", 471], ["stage", 477], ["in", 483], ["the", 486], ["developing", 490], ["peripheral", 501], ["and", 512], ["central", 516], ["nervous", 524], ["systems", 532], ["of", 540], ["both", 543], ["mice", 548], ["and", 553], ["humans", 557], [",", 563], ["in", 565], ["all", 568], ["neuronal", 572], ["regions", 581], ["of", 589], ["the", 592], ["brains", 596], ["of", 603], ["25-week", 606], ["human", 614], ["fetuses", 620], ["and", 628], ["adult", 632], ["mice", 638], [",", 642], ["and", 644], ["at", 648], ["varying", 651], ["levels", 659], ["in", 666], ["numerous", 669], ["nonneural", 678], ["tissues", 688], [".", 695], ["Northern", 697], ["blot", 706], ["analysis", 711], ["suggested", 720], ["that", 730], ["ZFHX1B", 735], ["undergoes", 742], ["tissue", 752], ["-", 758], ["specific", 759], ["alternative", 768], ["splicing", 780], ["in", 789], ["both", 792], ["species", 797], [".", 804], ["These", 806], ["results", 812], ["strongly", 820], ["suggest", 829], ["that", 837], ["ZFHX1B", 842], ["determines", 849], ["the", 860], ["transcriptional", 864], ["levels", 880], ["of", 887], ["target", 890], ["genes", 897], ["in", 903], ["various", 906], ["tissues", 914], ["through", 922], ["the", 930], ["combinatorial", 934], ["interactions", 948], ["of", 961], ["its", 964], ["isoforms", 968], ["with", 977], ["different", 982], ["Smad", 992], ["proteins", 997], [".", 1005], ["Thus", 1007], [",", 1011], ["as", 1013], ["well", 1016], ["as", 1021], ["causing", 1024], ["neural", 1032], ["defects", 1039], [",", 1046], ["ZFHX1B", 1048], ["mutations", 1055], ["may", 1065], ["also", 1069], ["cause", 1074], ["other", 1080], ["malformations", 1086], [".", 1099]]}
{"context": "In vivo brain microdialysis was used to assess the effects of tolcapone, a novel central and peripheral inhibitor of catechol-O-methyltransferase on striatal 3,4-dihydroxyphenyl-L-alanine (L-dopa) and dopamine metabolism. The oral administration of 30 mg/kg of tolcapone failed to change dopamine output but elicited a marked and long-lasting decrease of the extracellular levels of homovanillic acid (HVA) and 3-methoxytyramine with a concomitant increase of 3,4-dihydroxyphenylacetic acid (DOPAC). The administration of L-dopa (20 and 60 mg/kg p.o.) + benserazide (15 mg/kg p.o.) resulted in dose-dependent increase of dialysate levels of L-dopa and 3-O-methyl-DOPA. Tolcapone (30 mg/kg p.o.), given as adjunct to both doses of L-dopa, markedly enhanced the elevation or extracellular L-dopa, while it completely prevented the formation of 3-O-methyl-DOPA. In another experiment, the administration of L-dopa + benserazide (30 + 15 mg/kg p.o.) resulted in increased extracellular levels of dopamine, DOPAC, HVA and 3-methoxytyramine. The co-administration of tolcapone (30 mg/kg p.o.) further increased dopamine and DOPAC levels, whereas HVA and 3-methoxytyramine effluxes were reduced. These findings support the notion that tolcapone has the ability to enhance striatal dopamine neurotransmission by increasing L-dopa bioavailability through peripheral and central inhibition of L-dopa O-methylation, as well as by blocking the central conversion of dopamine into 3-methoxytyramine.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "08994280294d46b78596738f2a8bd39a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[33, 35], [161, 163], [124, 126], [91, 93], [260, 262], [270, 272], [185, 187], [151, 153]], "char_spans": [[189, 194], [787, 792], [641, 646], [522, 527], [1315, 1320], [1383, 1388], [904, 909], [730, 735]]}]}], "context_tokens": [["In", 0], ["vivo", 3], ["brain", 8], ["microdialysis", 14], ["was", 28], ["used", 32], ["to", 37], ["assess", 40], ["the", 47], ["effects", 51], ["of", 59], ["tolcapone", 62], [",", 71], ["a", 73], ["novel", 75], ["central", 81], ["and", 89], ["peripheral", 93], ["inhibitor", 104], ["of", 114], ["catechol", 117], ["-", 125], ["O", 126], ["-", 127], ["methyltransferase", 128], ["on", 146], ["striatal", 149], ["3,4-dihydroxyphenyl", 158], ["-", 177], ["L", 178], ["-", 179], ["alanine", 180], ["(", 188], ["L", 189], ["-", 190], ["dopa", 191], [")", 195], ["and", 197], ["dopamine", 201], ["metabolism", 210], [".", 220], ["The", 222], ["oral", 226], ["administration", 231], ["of", 246], ["30", 249], ["mg", 252], ["/", 254], ["kg", 255], ["of", 258], ["tolcapone", 261], ["failed", 271], ["to", 278], ["change", 281], ["dopamine", 288], ["output", 297], ["but", 304], ["elicited", 308], ["a", 317], ["marked", 319], ["and", 326], ["long", 330], ["-", 334], ["lasting", 335], ["decrease", 343], ["of", 352], ["the", 355], ["extracellular", 359], ["levels", 373], ["of", 380], ["homovanillic", 383], ["acid", 396], ["(", 401], ["HVA", 402], [")", 405], ["and", 407], ["3-methoxytyramine", 411], ["with", 429], ["a", 434], ["concomitant", 436], ["increase", 448], ["of", 457], ["3,4-dihydroxyphenylacetic", 460], ["acid", 486], ["(", 491], ["DOPAC", 492], [")", 497], [".", 498], ["The", 500], ["administration", 504], ["of", 519], ["L", 522], ["-", 523], ["dopa", 524], ["(", 529], ["20", 530], ["and", 533], ["60", 537], ["mg", 540], ["/", 542], ["kg", 543], ["p.o", 546], [".", 549], [")", 550], ["+", 552], ["benserazide", 554], ["(", 566], ["15", 567], ["mg", 570], ["/", 572], ["kg", 573], ["p.o", 576], [".", 579], [")", 580], ["resulted", 582], ["in", 591], ["dose", 594], ["-", 598], ["dependent", 599], ["increase", 609], ["of", 618], ["dialysate", 621], ["levels", 631], ["of", 638], ["L", 641], ["-", 642], ["dopa", 643], ["and", 648], ["3-O", 652], ["-", 655], ["methyl", 656], ["-", 662], ["DOPA", 663], [".", 667], ["Tolcapone", 669], ["(", 679], ["30", 680], ["mg", 683], ["/", 685], ["kg", 686], ["p.o", 689], [".", 692], [")", 693], [",", 694], ["given", 696], ["as", 702], ["adjunct", 705], ["to", 713], ["both", 716], ["doses", 721], ["of", 727], ["L", 730], ["-", 731], ["dopa", 732], [",", 736], ["markedly", 738], ["enhanced", 747], ["the", 756], ["elevation", 760], ["or", 770], ["extracellular", 773], ["L", 787], ["-", 788], ["dopa", 789], [",", 793], ["while", 795], ["it", 801], ["completely", 804], ["prevented", 815], ["the", 825], ["formation", 829], ["of", 839], ["3-O", 842], ["-", 845], ["methyl", 846], ["-", 852], ["DOPA", 853], [".", 857], ["In", 859], ["another", 862], ["experiment", 870], [",", 880], ["the", 882], ["administration", 886], ["of", 901], ["L", 904], ["-", 905], ["dopa", 906], ["+", 911], ["benserazide", 913], ["(", 925], ["30", 926], ["+", 929], ["15", 931], ["mg", 934], ["/", 936], ["kg", 937], ["p.o", 940], [".", 943], [")", 944], ["resulted", 946], ["in", 955], ["increased", 958], ["extracellular", 968], ["levels", 982], ["of", 989], ["dopamine", 992], [",", 1000], ["DOPAC", 1002], [",", 1007], ["HVA", 1009], ["and", 1013], ["3-methoxytyramine", 1017], [".", 1034], ["The", 1036], ["co", 1040], ["-", 1042], ["administration", 1043], ["of", 1058], ["tolcapone", 1061], ["(", 1071], ["30", 1072], ["mg", 1075], ["/", 1077], ["kg", 1078], ["p.o", 1081], [".", 1084], [")", 1085], ["further", 1087], ["increased", 1095], ["dopamine", 1105], ["and", 1114], ["DOPAC", 1118], ["levels", 1124], [",", 1130], ["whereas", 1132], ["HVA", 1140], ["and", 1144], ["3-methoxytyramine", 1148], ["effluxes", 1166], ["were", 1175], ["reduced", 1180], [".", 1187], ["These", 1189], ["findings", 1195], ["support", 1204], ["the", 1212], ["notion", 1216], ["that", 1223], ["tolcapone", 1228], ["has", 1238], ["the", 1242], ["ability", 1246], ["to", 1254], ["enhance", 1257], ["striatal", 1265], ["dopamine", 1274], ["neurotransmission", 1283], ["by", 1301], ["increasing", 1304], ["L", 1315], ["-", 1316], ["dopa", 1317], ["bioavailability", 1322], ["through", 1338], ["peripheral", 1346], ["and", 1357], ["central", 1361], ["inhibition", 1369], ["of", 1380], ["L", 1383], ["-", 1384], ["dopa", 1385], ["O", 1390], ["-", 1391], ["methylation", 1392], [",", 1403], ["as", 1405], ["well", 1408], ["as", 1413], ["by", 1416], ["blocking", 1419], ["the", 1428], ["central", 1432], ["conversion", 1440], ["of", 1451], ["dopamine", 1454], ["into", 1463], ["3-methoxytyramine", 1468], [".", 1485]]}
{"context": "Restless legs syndrome, now called Willis-Ekbom Disease (RLS/WED), is a sensorimotor-related sleep disorder. Little is known of the effect of RLS/WED on motor function. The current study investigated upper limb function in RLS/WED patients. We hypothesised that RLS/WED patients exhibit subtle changes in tremor amplitude but normal dexterity and movement speed and rhythmicity compared to healthy controls. RLS/WED patients (n=17, 59 \u00b1 7 years) with moderate disease and healthy controls (n=17, 58 \u00b1 6 years) completed screening tests and five tasks including object manipulation, maximal pinch grip, flexion and extension of the index finger (tremor assessment), maximal finger tapping (movement speed and rhythmicity assessment), and the grooved pegboard test. Force, acceleration, and/or first dorsal interosseus EMG were recorded during four of the tasks. Task performance did not differ between groups. Learning was evident on tasks with repeated trials and the magnitude of learning did not differ between groups. Hand function, tremor, and task learning were unaffected in RLS/WED patients. Patients manipulated objects in a normal manner and exhibited normal movement speed, rhythmicity, and tremor. Further research is needed to assess other types of movement in RLS/WED patients to gain insight into the motor circuitry affected and the underlying pathophysiology.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3e5986f118e1472abdf00781a69c02a0", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], [",", 22], ["now", 24], ["called", 28], ["Willis", 35], ["-", 41], ["Ekbom", 42], ["Disease", 48], ["(", 56], ["RLS", 57], ["/", 60], ["WED", 61], [")", 64], [",", 65], ["is", 67], ["a", 70], ["sensorimotor", 72], ["-", 84], ["related", 85], ["sleep", 93], ["disorder", 99], [".", 107], ["Little", 109], ["is", 116], ["known", 119], ["of", 125], ["the", 128], ["effect", 132], ["of", 139], ["RLS", 142], ["/", 145], ["WED", 146], ["on", 150], ["motor", 153], ["function", 159], [".", 167], ["The", 169], ["current", 173], ["study", 181], ["investigated", 187], ["upper", 200], ["limb", 206], ["function", 211], ["in", 220], ["RLS", 223], ["/", 226], ["WED", 227], ["patients", 231], [".", 239], ["We", 241], ["hypothesised", 244], ["that", 257], ["RLS", 262], ["/", 265], ["WED", 266], ["patients", 270], ["exhibit", 279], ["subtle", 287], ["changes", 294], ["in", 302], ["tremor", 305], ["amplitude", 312], ["but", 322], ["normal", 326], ["dexterity", 333], ["and", 343], ["movement", 347], ["speed", 356], ["and", 362], ["rhythmicity", 366], ["compared", 378], ["to", 387], ["healthy", 390], ["controls", 398], [".", 406], ["RLS", 408], ["/", 411], ["WED", 412], ["patients", 416], ["(", 425], ["n=17", 426], [",", 430], ["59", 432], ["\u00b1", 435], ["7", 437], ["years", 439], [")", 444], ["with", 446], ["moderate", 451], ["disease", 460], ["and", 468], ["healthy", 472], ["controls", 480], ["(", 489], ["n=17", 490], [",", 494], ["58", 496], ["\u00b1", 499], ["6", 501], ["years", 503], [")", 508], ["completed", 510], ["screening", 520], ["tests", 530], ["and", 536], ["five", 540], ["tasks", 545], ["including", 551], ["object", 561], ["manipulation", 568], [",", 580], ["maximal", 582], ["pinch", 590], ["grip", 596], [",", 600], ["flexion", 602], ["and", 610], ["extension", 614], ["of", 624], ["the", 627], ["index", 631], ["finger", 637], ["(", 644], ["tremor", 645], ["assessment", 652], [")", 662], [",", 663], ["maximal", 665], ["finger", 673], ["tapping", 680], ["(", 688], ["movement", 689], ["speed", 698], ["and", 704], ["rhythmicity", 708], ["assessment", 720], [")", 730], [",", 731], ["and", 733], ["the", 737], ["grooved", 741], ["pegboard", 749], ["test", 758], [".", 762], ["Force", 764], [",", 769], ["acceleration", 771], [",", 783], ["and/or", 785], ["first", 792], ["dorsal", 798], ["interosseus", 805], ["EMG", 817], ["were", 821], ["recorded", 826], ["during", 835], ["four", 842], ["of", 847], ["the", 850], ["tasks", 854], [".", 859], ["Task", 861], ["performance", 866], ["did", 878], ["not", 882], ["differ", 886], ["between", 893], ["groups", 901], [".", 907], ["Learning", 909], ["was", 918], ["evident", 922], ["on", 930], ["tasks", 933], ["with", 939], ["repeated", 944], ["trials", 953], ["and", 960], ["the", 964], ["magnitude", 968], ["of", 978], ["learning", 981], ["did", 990], ["not", 994], ["differ", 998], ["between", 1005], ["groups", 1013], [".", 1019], ["Hand", 1021], ["function", 1026], [",", 1034], ["tremor", 1036], [",", 1042], ["and", 1044], ["task", 1048], ["learning", 1053], ["were", 1062], ["unaffected", 1067], ["in", 1078], ["RLS", 1081], ["/", 1084], ["WED", 1085], ["patients", 1089], [".", 1097], ["Patients", 1099], ["manipulated", 1108], ["objects", 1120], ["in", 1128], ["a", 1131], ["normal", 1133], ["manner", 1140], ["and", 1147], ["exhibited", 1151], ["normal", 1161], ["movement", 1168], ["speed", 1177], [",", 1182], ["rhythmicity", 1184], [",", 1195], ["and", 1197], ["tremor", 1201], [".", 1207], ["Further", 1209], ["research", 1217], ["is", 1226], ["needed", 1229], ["to", 1236], ["assess", 1239], ["other", 1246], ["types", 1252], ["of", 1258], ["movement", 1261], ["in", 1270], ["RLS", 1273], ["/", 1276], ["WED", 1277], ["patients", 1281], ["to", 1290], ["gain", 1293], ["insight", 1298], ["into", 1306], ["the", 1311], ["motor", 1315], ["circuitry", 1321], ["affected", 1331], ["and", 1340], ["the", 1344], ["underlying", 1348], ["pathophysiology", 1359], [".", 1374]]}
{"context": "Inherited ventricular arrhythmias such as the long QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), idiopathic ventricular fibrillation (VF), and arrhythmogenic right ventricular cardiomyopathy (ARVC) account for a relevant proportion of sudden cardiac death cases in young patients cohorts. The detailed pathogenetic mechanisms of inherited ventricular arrhythmias are still poorly understood because systematic investigations are difficult to perform due to low patient numbers and the lack of appropriate experimental models. However, recent advances in research and science have identified a genetic background for many of these diseases. In LQTS, various mutations in different genes encoding for cardiac potassium and sodium channel proteins have been identified (\"channelopathy\"), and initial progress in genotype-phenotype correlation is made. Mutations in the cardiac sodium channel gene have also been identified in a subset of patients with Brugada syndrome, whereas a genetic background has not yet been demonstrated in idiopathic VF and right ventricular outflow-tract tachycardia (RVO-VT). Very recently, mutations in the cardiac ryanodine receptor gene have been identified in CPVT and in a subgroup of patients with ARVC. Although several chromosomal loci were suggested, no other responsible genes or mutations have been found in autosomal dominant forms of ARVC. However, in Naxos disease, a recessive form of ARVC with coexpression of palmoplantar keratoderma and woolly hair, a mutation in the plakoglobin gene has recently been discovered, thus underscoring the potential role of genetic alterations in cytoskeletal proteins in ARVC. In the next years, significant progress in the genetic diagnosis pathophysiologic understanding of disease mechanisms, genotype-phenotype correlation, and the development of gene- or target-directed treatment strategies can be expected in the field of inherited ventricular arrhythmias. This review summarizes the current knowledge of the molecular mechanisms, including aspects of pathoanatomy, autonomic innervation, genetics, and genotype-phenotype correlations with their potential implications for diagnosis and treatment of inherited ventricular arrhythmias.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "82cb45ef0dce4731bfd7549461b332ab", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[257, 258]], "char_spans": [[1565, 1580]]}]}], "context_tokens": [["Inherited", 0], ["ventricular", 10], ["arrhythmias", 22], ["such", 34], ["as", 39], ["the", 42], ["long", 46], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], [",", 69], ["Brugada", 71], ["syndrome", 79], [",", 87], ["catecholaminergic", 89], ["polymorphic", 107], ["ventricular", 119], ["tachycardia", 131], ["(", 143], ["CPVT", 144], [")", 148], [",", 149], ["idiopathic", 151], ["ventricular", 162], ["fibrillation", 174], ["(", 187], ["VF", 188], [")", 190], [",", 191], ["and", 193], ["arrhythmogenic", 197], ["right", 212], ["ventricular", 218], ["cardiomyopathy", 230], ["(", 245], ["ARVC", 246], [")", 250], ["account", 252], ["for", 260], ["a", 264], ["relevant", 266], ["proportion", 275], ["of", 286], ["sudden", 289], ["cardiac", 296], ["death", 304], ["cases", 310], ["in", 316], ["young", 319], ["patients", 325], ["cohorts", 334], [".", 341], ["The", 343], ["detailed", 347], ["pathogenetic", 356], ["mechanisms", 369], ["of", 380], ["inherited", 383], ["ventricular", 393], ["arrhythmias", 405], ["are", 417], ["still", 421], ["poorly", 427], ["understood", 434], ["because", 445], ["systematic", 453], ["investigations", 464], ["are", 479], ["difficult", 483], ["to", 493], ["perform", 496], ["due", 504], ["to", 508], ["low", 511], ["patient", 515], ["numbers", 523], ["and", 531], ["the", 535], ["lack", 539], ["of", 544], ["appropriate", 547], ["experimental", 559], ["models", 572], [".", 578], ["However", 580], [",", 587], ["recent", 589], ["advances", 596], ["in", 605], ["research", 608], ["and", 617], ["science", 621], ["have", 629], ["identified", 634], ["a", 645], ["genetic", 647], ["background", 655], ["for", 666], ["many", 670], ["of", 675], ["these", 678], ["diseases", 684], [".", 692], ["In", 694], ["LQTS", 697], [",", 701], ["various", 703], ["mutations", 711], ["in", 721], ["different", 724], ["genes", 734], ["encoding", 740], ["for", 749], ["cardiac", 753], ["potassium", 761], ["and", 771], ["sodium", 775], ["channel", 782], ["proteins", 790], ["have", 799], ["been", 804], ["identified", 809], ["(", 820], ["\"", 821], ["channelopathy", 822], ["\"", 835], [")", 836], [",", 837], ["and", 839], ["initial", 843], ["progress", 851], ["in", 860], ["genotype", 863], ["-", 871], ["phenotype", 872], ["correlation", 882], ["is", 894], ["made", 897], [".", 901], ["Mutations", 903], ["in", 913], ["the", 916], ["cardiac", 920], ["sodium", 928], ["channel", 935], ["gene", 943], ["have", 948], ["also", 953], ["been", 958], ["identified", 963], ["in", 974], ["a", 977], ["subset", 979], ["of", 986], ["patients", 989], ["with", 998], ["Brugada", 1003], ["syndrome", 1011], [",", 1019], ["whereas", 1021], ["a", 1029], ["genetic", 1031], ["background", 1039], ["has", 1050], ["not", 1054], ["yet", 1058], ["been", 1062], ["demonstrated", 1067], ["in", 1080], ["idiopathic", 1083], ["VF", 1094], ["and", 1097], ["right", 1101], ["ventricular", 1107], ["outflow", 1119], ["-", 1126], ["tract", 1127], ["tachycardia", 1133], ["(", 1145], ["RVO", 1146], ["-", 1149], ["VT", 1150], [")", 1152], [".", 1153], ["Very", 1155], ["recently", 1160], [",", 1168], ["mutations", 1170], ["in", 1180], ["the", 1183], ["cardiac", 1187], ["ryanodine", 1195], ["receptor", 1205], ["gene", 1214], ["have", 1219], ["been", 1224], ["identified", 1229], ["in", 1240], ["CPVT", 1243], ["and", 1248], ["in", 1252], ["a", 1255], ["subgroup", 1257], ["of", 1266], ["patients", 1269], ["with", 1278], ["ARVC", 1283], [".", 1287], ["Although", 1289], ["several", 1298], ["chromosomal", 1306], ["loci", 1318], ["were", 1323], ["suggested", 1328], [",", 1337], ["no", 1339], ["other", 1342], ["responsible", 1348], ["genes", 1360], ["or", 1366], ["mutations", 1369], ["have", 1379], ["been", 1384], ["found", 1389], ["in", 1395], ["autosomal", 1398], ["dominant", 1408], ["forms", 1417], ["of", 1423], ["ARVC", 1426], [".", 1430], ["However", 1432], [",", 1439], ["in", 1441], ["Naxos", 1444], ["disease", 1450], [",", 1457], ["a", 1459], ["recessive", 1461], ["form", 1471], ["of", 1476], ["ARVC", 1479], ["with", 1484], ["coexpression", 1489], ["of", 1502], ["palmoplantar", 1505], ["keratoderma", 1518], ["and", 1530], ["woolly", 1534], ["hair", 1541], [",", 1545], ["a", 1547], ["mutation", 1549], ["in", 1558], ["the", 1561], ["plakoglobin", 1565], ["gene", 1577], ["has", 1582], ["recently", 1586], ["been", 1595], ["discovered", 1600], [",", 1610], ["thus", 1612], ["underscoring", 1617], ["the", 1630], ["potential", 1634], ["role", 1644], ["of", 1649], ["genetic", 1652], ["alterations", 1660], ["in", 1672], ["cytoskeletal", 1675], ["proteins", 1688], ["in", 1697], ["ARVC", 1700], [".", 1704], ["In", 1706], ["the", 1709], ["next", 1713], ["years", 1718], [",", 1723], ["significant", 1725], ["progress", 1737], ["in", 1746], ["the", 1749], ["genetic", 1753], ["diagnosis", 1761], ["pathophysiologic", 1771], ["understanding", 1788], ["of", 1802], ["disease", 1805], ["mechanisms", 1813], [",", 1823], ["genotype", 1825], ["-", 1833], ["phenotype", 1834], ["correlation", 1844], [",", 1855], ["and", 1857], ["the", 1861], ["development", 1865], ["of", 1877], ["gene-", 1880], ["or", 1886], ["target", 1889], ["-", 1895], ["directed", 1896], ["treatment", 1905], ["strategies", 1915], ["can", 1926], ["be", 1930], ["expected", 1933], ["in", 1942], ["the", 1945], ["field", 1949], ["of", 1955], ["inherited", 1958], ["ventricular", 1968], ["arrhythmias", 1980], [".", 1991], ["This", 1993], ["review", 1998], ["summarizes", 2005], ["the", 2016], ["current", 2020], ["knowledge", 2028], ["of", 2038], ["the", 2041], ["molecular", 2045], ["mechanisms", 2055], [",", 2065], ["including", 2067], ["aspects", 2077], ["of", 2085], ["pathoanatomy", 2088], [",", 2100], ["autonomic", 2102], ["innervation", 2112], [",", 2123], ["genetics", 2125], [",", 2133], ["and", 2135], ["genotype", 2139], ["-", 2147], ["phenotype", 2148], ["correlations", 2158], ["with", 2171], ["their", 2176], ["potential", 2182], ["implications", 2192], ["for", 2205], ["diagnosis", 2209], ["and", 2219], ["treatment", 2223], ["of", 2233], ["inherited", 2236], ["ventricular", 2246], ["arrhythmias", 2258], [".", 2269]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete hematological and complete cytogenetic remissions, with minimal toxicity. In contrast, responses are less stable in patients with advanced CML. This review highlights the pathogenesis of CML, its clinical features, and the development of imatinib as a specific molecularly targeted therapy. Aspects of disease monitoring and side effects are covered as well as resistance to imatinib and strategies to overcome resistance, such as alternative signal transduction inhibitors and drug combinations. Perspectives for further development are also discussed.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d31cc811c4ed4d9a840643c3c97ec8b6", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[30, 32], [63, 65]], "char_spans": [[183, 189], [373, 379]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["the", 51], ["Philadelphia", 55], ["translocation", 68], ["that", 82], ["fuses", 87], ["BCR", 93], ["sequences", 97], ["from", 107], ["chromosome", 112], ["22", 123], ["upstream", 126], ["of", 135], ["the", 138], ["ABL", 142], ["gene", 146], ["on", 151], ["chromosome", 154], ["9", 165], [".", 166], ["The", 168], ["chimerical", 172], ["Bcr", 183], ["-", 186], ["Abl", 187], ["protein", 191], ["expressed", 199], ["by", 209], ["CML", 212], ["cells", 216], ["has", 222], ["constitutive", 226], ["tyrosine", 239], ["kinase", 248], ["activity", 255], [",", 263], ["which", 265], ["is", 271], ["essential", 274], ["for", 284], ["the", 288], ["pathogenesis", 292], ["of", 305], ["the", 308], ["disease", 312], [".", 319], ["Imatinib", 321], [",", 329], ["an", 331], ["ATP", 334], ["-", 337], ["competitive", 338], ["selective", 350], ["inhibitor", 360], ["of", 370], ["Bcr", 373], ["-", 376], ["Abl", 377], [",", 380], ["has", 382], ["unprecedented", 386], ["efficacy", 400], ["for", 409], ["the", 413], ["treatment", 417], ["of", 427], ["CML", 430], [".", 433], ["Most", 435], ["patients", 440], ["with", 449], ["early", 454], ["stage", 460], ["disease", 466], ["achieve", 474], ["durable", 482], ["complete", 490], ["hematological", 499], ["and", 513], ["complete", 517], ["cytogenetic", 526], ["remissions", 538], [",", 548], ["with", 550], ["minimal", 555], ["toxicity", 563], [".", 571], ["In", 573], ["contrast", 576], [",", 584], ["responses", 586], ["are", 596], ["less", 600], ["stable", 605], ["in", 612], ["patients", 615], ["with", 624], ["advanced", 629], ["CML", 638], [".", 641], ["This", 643], ["review", 648], ["highlights", 655], ["the", 666], ["pathogenesis", 670], ["of", 683], ["CML", 686], [",", 689], ["its", 691], ["clinical", 695], ["features", 704], [",", 712], ["and", 714], ["the", 718], ["development", 722], ["of", 734], ["imatinib", 737], ["as", 746], ["a", 749], ["specific", 751], ["molecularly", 760], ["targeted", 772], ["therapy", 781], [".", 788], ["Aspects", 790], ["of", 798], ["disease", 801], ["monitoring", 809], ["and", 820], ["side", 824], ["effects", 829], ["are", 837], ["covered", 841], ["as", 849], ["well", 852], ["as", 857], ["resistance", 860], ["to", 871], ["imatinib", 874], ["and", 883], ["strategies", 887], ["to", 898], ["overcome", 901], ["resistance", 910], [",", 920], ["such", 922], ["as", 927], ["alternative", 930], ["signal", 942], ["transduction", 949], ["inhibitors", 962], ["and", 973], ["drug", 977], ["combinations", 982], [".", 994], ["Perspectives", 996], ["for", 1009], ["further", 1013], ["development", 1021], ["are", 1033], ["also", 1037], ["discussed", 1042], [".", 1051]]}
{"context": "Romano-Ward syndrome is an autosomal dominant long-QT syndrome (LQTS) that predisposes affected individuals to sudden death from tachyarrhythmias. We investigated the molecular basis of LQTS in a Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG). The coding sequences and exon-intron borders of HERG were amplified by means of polymerase chain reaction and subjected to single-strand conformation polymorphism (SSCP) analysis. An exon with an aberrant SSCP pattern was cloned and sequenced to study the molecular lesion. A C-->T transition in codon 614, leading to substitution of a valine for an alanine residue in the pore region of the HERG protein, was identified. Analysis with Bsp12861 endonuclease digestion showed the mutation to be present in all affected family members. Given that an unaffected paternal uncle had inherited the same allele from the grandfather as the proband's father, a de novo mutation had apparently occurred in the father and was transmitted to his offspring. In addition to offering presymptomatic genetic diagnosis, identification of the disease-causing mutation may suggest new therapeutic approaches for treatment and prevention of this cardiovascular disease.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "d838cda896684309ac3a07c8d28d403e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[6, 7]], "char_spans": [[27, 44]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["an", 24], ["autosomal", 27], ["dominant", 37], ["long", 46], ["-", 50], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], ["that", 70], ["predisposes", 75], ["affected", 87], ["individuals", 96], ["to", 108], ["sudden", 111], ["death", 118], ["from", 124], ["tachyarrhythmias", 129], [".", 145], ["We", 147], ["investigated", 150], ["the", 163], ["molecular", 167], ["basis", 177], ["of", 183], ["LQTS", 186], ["in", 191], ["a", 194], ["Taiwanese", 196], ["kindred", 206], [".", 213], ["Clinical", 215], ["and", 224], ["genetic", 228], ["analyses", 236], ["revealed", 245], ["that", 254], ["a", 259], ["mutation", 261], ["was", 270], ["linked", 274], ["to", 281], ["the", 284], ["human", 288], ["ether", 294], ["-", 299], ["a", 300], ["-", 301], ["go", 302], ["-", 304], ["go", 305], ["-", 307], ["related", 308], ["gene", 316], ["(", 321], ["HERG", 322], [")", 326], [".", 327], ["The", 329], ["coding", 333], ["sequences", 340], ["and", 350], ["exon", 354], ["-", 358], ["intron", 359], ["borders", 366], ["of", 374], ["HERG", 377], ["were", 382], ["amplified", 387], ["by", 397], ["means", 400], ["of", 406], ["polymerase", 409], ["chain", 420], ["reaction", 426], ["and", 435], ["subjected", 439], ["to", 449], ["single", 452], ["-", 458], ["strand", 459], ["conformation", 466], ["polymorphism", 479], ["(", 492], ["SSCP", 493], [")", 497], ["analysis", 499], [".", 507], ["An", 509], ["exon", 512], ["with", 517], ["an", 522], ["aberrant", 525], ["SSCP", 534], ["pattern", 539], ["was", 547], ["cloned", 551], ["and", 558], ["sequenced", 562], ["to", 572], ["study", 575], ["the", 581], ["molecular", 585], ["lesion", 595], [".", 601], ["A", 603], ["C-->T", 605], ["transition", 611], ["in", 622], ["codon", 625], ["614", 631], [",", 634], ["leading", 636], ["to", 644], ["substitution", 647], ["of", 660], ["a", 663], ["valine", 665], ["for", 672], ["an", 676], ["alanine", 679], ["residue", 687], ["in", 695], ["the", 698], ["pore", 702], ["region", 707], ["of", 714], ["the", 717], ["HERG", 721], ["protein", 726], [",", 733], ["was", 735], ["identified", 739], [".", 749], ["Analysis", 751], ["with", 760], ["Bsp12861", 765], ["endonuclease", 774], ["digestion", 787], ["showed", 797], ["the", 804], ["mutation", 808], ["to", 817], ["be", 820], ["present", 823], ["in", 831], ["all", 834], ["affected", 838], ["family", 847], ["members", 854], [".", 861], ["Given", 863], ["that", 869], ["an", 874], ["unaffected", 877], ["paternal", 888], ["uncle", 897], ["had", 903], ["inherited", 907], ["the", 917], ["same", 921], ["allele", 926], ["from", 933], ["the", 938], ["grandfather", 942], ["as", 954], ["the", 957], ["proband", 961], ["'s", 968], ["father", 971], [",", 977], ["a", 979], ["de", 981], ["novo", 984], ["mutation", 989], ["had", 998], ["apparently", 1002], ["occurred", 1013], ["in", 1022], ["the", 1025], ["father", 1029], ["and", 1036], ["was", 1040], ["transmitted", 1044], ["to", 1056], ["his", 1059], ["offspring", 1063], [".", 1072], ["In", 1074], ["addition", 1077], ["to", 1086], ["offering", 1089], ["presymptomatic", 1098], ["genetic", 1113], ["diagnosis", 1121], [",", 1130], ["identification", 1132], ["of", 1147], ["the", 1150], ["disease", 1154], ["-", 1161], ["causing", 1162], ["mutation", 1170], ["may", 1179], ["suggest", 1183], ["new", 1191], ["therapeutic", 1195], ["approaches", 1207], ["for", 1218], ["treatment", 1222], ["and", 1232], ["prevention", 1236], ["of", 1247], ["this", 1250], ["cardiovascular", 1255], ["disease", 1270], [".", 1277]]}
{"context": "To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis. Three multicenter, randomized, double-masked, placebo-controlled, dose-ranging phase III studies: SHIELD, INSURE, and ENDURE. A total of 118 patients with Beh\u00e7et's uveitis (SHIELD study); 31 patients with active, noninfectious, non-Beh\u00e7et's uveitis (INSURE study); and 125 patients with quiescent, noninfectious, non-Beh\u00e7et's uveitis (ENDURE study) were enrolled. After an initial subcutaneous (s.c.) loading phase in each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2 weeks (q2w), secukinumab 300 mg monthly (q4w), or placebo in the SHIELD study; secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the INSURE study; or secukinumab 300 mg q2w, secukinumab 300 mg q4w, secukinumab 150 mg q4w, or placebo in the ENDURE study. Reduction of uveitis recurrence or vitreous haze score during withdrawal of concomitant immunosuppressive medication (ISM). Other end points included best-corrected visual acuity, ISM use (expressed as a standardized ISM score), and safety outcomes. After completion or early termination of each trial, there were no statistically significant differences in uveitis recurrence between the secukinumab treatment groups and placebo groups in any study. Secukinumab was associated with a significant reduction in mean total post-baseline ISM score (P = 0.019; 300 mg q4w vs. placebo) in the SHIELD study. Likewise, secukinumab was associated with a greater median reduction in ISM score versus placebo in the INSURE study, although no statistical analysis of the difference was conducted because of the small sample size. Overall, there was no loss in visual acuity reported in any treatment group during follow-up in all 3 studies. According to descriptive safety statistics, the frequencies of ocular and nonocular adverse events seemed to be slightly higher among secukinumab groups versus placebo across the 3 studies. The primary efficacy end points of the 3 studies were not met. The secondary efficacy data from these studies suggest a beneficial effect of secukinumab in reducing the use of concomitant ISM.", "qas": [{"question": "Which molecule is targeted by a monoclonal antibody Secukinumab?", "answers": ["interleukin-17A"], "qid": "a40b195dc80a430a92a47b3b524bd7c3", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["a", 30], ["monoclonal", 32], ["antibody", 43], ["Secukinumab", 52], ["?", 63]], "detected_answers": [{"text": "interleukin-17A", "token_spans": [[19, 19]], "char_spans": [[119, 133]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["efficacy", 17], ["and", 26], ["safety", 30], ["of", 37], ["different", 40], ["doses", 50], ["of", 56], ["secukinumab", 59], [",", 70], ["a", 72], ["fully", 74], ["human", 80], ["monoclonal", 86], ["antibody", 97], ["for", 106], ["targeted", 110], ["interleukin-17A", 119], ["blockade", 135], [",", 143], ["in", 145], ["patients", 148], ["with", 157], ["noninfectious", 162], ["uveitis", 176], [".", 183], ["Three", 185], ["multicenter", 191], [",", 202], ["randomized", 204], [",", 214], ["double", 216], ["-", 222], ["masked", 223], [",", 229], ["placebo", 231], ["-", 238], ["controlled", 239], [",", 249], ["dose", 251], ["-", 255], ["ranging", 256], ["phase", 264], ["III", 270], ["studies", 274], [":", 281], ["SHIELD", 283], [",", 289], ["INSURE", 291], [",", 297], ["and", 299], ["ENDURE", 303], [".", 309], ["A", 311], ["total", 313], ["of", 319], ["118", 322], ["patients", 326], ["with", 335], ["Beh\u00e7et", 340], ["'s", 346], ["uveitis", 349], ["(", 357], ["SHIELD", 358], ["study", 365], [")", 370], [";", 371], ["31", 373], ["patients", 376], ["with", 385], ["active", 390], [",", 396], ["noninfectious", 398], [",", 411], ["non", 413], ["-", 416], ["Beh\u00e7et", 417], ["'s", 423], ["uveitis", 426], ["(", 434], ["INSURE", 435], ["study", 442], [")", 447], [";", 448], ["and", 450], ["125", 454], ["patients", 458], ["with", 467], ["quiescent", 472], [",", 481], ["noninfectious", 483], [",", 496], ["non", 498], ["-", 501], ["Beh\u00e7et", 502], ["'s", 508], ["uveitis", 511], ["(", 519], ["ENDURE", 520], ["study", 527], [")", 532], ["were", 534], ["enrolled", 539], [".", 547], ["After", 549], ["an", 555], ["initial", 558], ["subcutaneous", 566], ["(", 579], ["s.c", 580], [".", 583], [")", 584], ["loading", 586], ["phase", 594], ["in", 600], ["each", 603], ["treatment", 608], ["arm", 618], [",", 621], ["patients", 623], ["received", 632], ["s.c", 641], [".", 644], ["maintenance", 646], ["therapy", 658], ["with", 666], ["secukinumab", 671], ["300", 683], ["mg", 687], ["every", 690], ["2", 696], ["weeks", 698], ["(", 704], ["q2w", 705], [")", 708], [",", 709], ["secukinumab", 711], ["300", 723], ["mg", 727], ["monthly", 730], ["(", 738], ["q4w", 739], [")", 742], [",", 743], ["or", 745], ["placebo", 748], ["in", 756], ["the", 759], ["SHIELD", 763], ["study", 770], [";", 775], ["secukinumab", 777], ["300", 789], ["mg", 793], ["q2w", 796], [",", 799], ["secukinumab", 801], ["300", 813], ["mg", 817], ["q4w", 820], [",", 823], ["secukinumab", 825], ["150", 837], ["mg", 841], ["q4w", 844], [",", 847], ["or", 849], ["placebo", 852], ["in", 860], ["the", 863], ["INSURE", 867], ["study", 874], [";", 879], ["or", 881], ["secukinumab", 884], ["300", 896], ["mg", 900], ["q2w", 903], [",", 906], ["secukinumab", 908], ["300", 920], ["mg", 924], ["q4w", 927], [",", 930], ["secukinumab", 932], ["150", 944], ["mg", 948], ["q4w", 951], [",", 954], ["or", 956], ["placebo", 959], ["in", 967], ["the", 970], ["ENDURE", 974], ["study", 981], [".", 986], ["Reduction", 988], ["of", 998], ["uveitis", 1001], ["recurrence", 1009], ["or", 1020], ["vitreous", 1023], ["haze", 1032], ["score", 1037], ["during", 1043], ["withdrawal", 1050], ["of", 1061], ["concomitant", 1064], ["immunosuppressive", 1076], ["medication", 1094], ["(", 1105], ["ISM", 1106], [")", 1109], [".", 1110], ["Other", 1112], ["end", 1118], ["points", 1122], ["included", 1129], ["best", 1138], ["-", 1142], ["corrected", 1143], ["visual", 1153], ["acuity", 1160], [",", 1166], ["ISM", 1168], ["use", 1172], ["(", 1176], ["expressed", 1177], ["as", 1187], ["a", 1190], ["standardized", 1192], ["ISM", 1205], ["score", 1209], [")", 1214], [",", 1215], ["and", 1217], ["safety", 1221], ["outcomes", 1228], [".", 1236], ["After", 1238], ["completion", 1244], ["or", 1255], ["early", 1258], ["termination", 1264], ["of", 1276], ["each", 1279], ["trial", 1284], [",", 1289], ["there", 1291], ["were", 1297], ["no", 1302], ["statistically", 1305], ["significant", 1319], ["differences", 1331], ["in", 1343], ["uveitis", 1346], ["recurrence", 1354], ["between", 1365], ["the", 1373], ["secukinumab", 1377], ["treatment", 1389], ["groups", 1399], ["and", 1406], ["placebo", 1410], ["groups", 1418], ["in", 1425], ["any", 1428], ["study", 1432], [".", 1437], ["Secukinumab", 1439], ["was", 1451], ["associated", 1455], ["with", 1466], ["a", 1471], ["significant", 1473], ["reduction", 1485], ["in", 1495], ["mean", 1498], ["total", 1503], ["post", 1509], ["-", 1513], ["baseline", 1514], ["ISM", 1523], ["score", 1527], ["(", 1533], ["P", 1534], ["=", 1536], ["0.019", 1538], [";", 1543], ["300", 1545], ["mg", 1549], ["q4w", 1552], ["vs.", 1556], ["placebo", 1560], [")", 1567], ["in", 1569], ["the", 1572], ["SHIELD", 1576], ["study", 1583], [".", 1588], ["Likewise", 1590], [",", 1598], ["secukinumab", 1600], ["was", 1612], ["associated", 1616], ["with", 1627], ["a", 1632], ["greater", 1634], ["median", 1642], ["reduction", 1649], ["in", 1659], ["ISM", 1662], ["score", 1666], ["versus", 1672], ["placebo", 1679], ["in", 1687], ["the", 1690], ["INSURE", 1694], ["study", 1701], [",", 1706], ["although", 1708], ["no", 1717], ["statistical", 1720], ["analysis", 1732], ["of", 1741], ["the", 1744], ["difference", 1748], ["was", 1759], ["conducted", 1763], ["because", 1773], ["of", 1781], ["the", 1784], ["small", 1788], ["sample", 1794], ["size", 1801], [".", 1805], ["Overall", 1807], [",", 1814], ["there", 1816], ["was", 1822], ["no", 1826], ["loss", 1829], ["in", 1834], ["visual", 1837], ["acuity", 1844], ["reported", 1851], ["in", 1860], ["any", 1863], ["treatment", 1867], ["group", 1877], ["during", 1883], ["follow", 1890], ["-", 1896], ["up", 1897], ["in", 1900], ["all", 1903], ["3", 1907], ["studies", 1909], [".", 1916], ["According", 1918], ["to", 1928], ["descriptive", 1931], ["safety", 1943], ["statistics", 1950], [",", 1960], ["the", 1962], ["frequencies", 1966], ["of", 1978], ["ocular", 1981], ["and", 1988], ["nonocular", 1992], ["adverse", 2002], ["events", 2010], ["seemed", 2017], ["to", 2024], ["be", 2027], ["slightly", 2030], ["higher", 2039], ["among", 2046], ["secukinumab", 2052], ["groups", 2064], ["versus", 2071], ["placebo", 2078], ["across", 2086], ["the", 2093], ["3", 2097], ["studies", 2099], [".", 2106], ["The", 2108], ["primary", 2112], ["efficacy", 2120], ["end", 2129], ["points", 2133], ["of", 2140], ["the", 2143], ["3", 2147], ["studies", 2149], ["were", 2157], ["not", 2162], ["met", 2166], [".", 2169], ["The", 2171], ["secondary", 2175], ["efficacy", 2185], ["data", 2194], ["from", 2199], ["these", 2204], ["studies", 2210], ["suggest", 2218], ["a", 2226], ["beneficial", 2228], ["effect", 2239], ["of", 2246], ["secukinumab", 2249], ["in", 2261], ["reducing", 2264], ["the", 2273], ["use", 2277], ["of", 2281], ["concomitant", 2284], ["ISM", 2296], [".", 2299]]}
{"context": "A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "a684e2797a984c48b274c3513981d491", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[137, 139], [18, 20], [6, 8]], "char_spans": [[846, 867], [105, 126], [37, 58]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["approach", 8], ["to", 17], ["design", 20], ["selective", 27], ["spleen", 37], ["tyrosine", 44], ["kinase", 53], ["(", 60], ["Syk", 61], [")", 64], ["inhibitors", 66], ["is", 77], ["described", 80], [".", 89], ["Inhibition", 91], ["of", 102], ["spleen", 105], ["tyrosine", 112], ["kinase", 121], ["has", 128], ["attracted", 132], ["much", 142], ["attention", 147], ["as", 157], ["a", 160], ["mechanism", 162], ["for", 172], ["the", 176], ["treatment", 180], ["of", 190], ["autoimmune", 193], ["diseases", 204], ["such", 213], ["as", 218], ["asthma", 221], [",", 227], ["rheumatoid", 229], ["arthritis", 240], [",", 249], ["and", 251], ["SLE", 255], [".", 258], ["Fostamatinib", 260], [",", 272], ["a", 274], ["Syk", 276], ["inhibitor", 280], ["that", 290], ["successfully", 295], ["completed", 308], ["phase", 318], ["II", 324], ["clinical", 327], ["trials", 336], [",", 342], ["also", 344], ["exhibits", 349], ["some", 358], ["undesirable", 363], ["side", 375], ["effects", 380], [".", 387], ["More", 389], ["selective", 394], ["Syk", 404], ["inhibitors", 408], ["could", 419], ["offer", 425], ["safer", 431], [",", 436], ["alternative", 438], ["treatments", 450], [".", 460], ["Through", 462], ["a", 470], ["systematic", 472], ["evaluation", 483], ["of", 494], ["the", 497], ["kinome", 501], [",", 507], ["we", 509], ["identified", 512], ["Pro455", 523], ["and", 530], ["Asn457", 534], ["in", 541], ["the", 544], ["Syk", 548], ["ATP", 552], ["binding", 556], ["site", 564], ["as", 569], ["a", 572], ["rare", 574], ["combination", 579], ["among", 591], ["sequence", 597], ["aligned", 606], ["kinases", 614], ["and", 622], ["hypothesized", 626], ["that", 639], ["optimizing", 644], ["the", 655], ["interaction", 659], ["between", 671], ["them", 679], ["and", 684], ["a", 688], ["Syk", 690], ["inhibitor", 694], ["molecule", 704], ["would", 713], ["impart", 719], ["high", 726], ["selectivity", 731], ["for", 743], ["Syk", 747], ["over", 751], ["other", 756], ["kinases", 762], [".", 769], ["We", 771], ["report", 774], ["the", 781], ["structure", 785], ["-", 794], ["guided", 795], ["identification", 802], ["of", 817], ["three", 820], ["series", 826], ["of", 833], ["selective", 836], ["spleen", 846], ["tyrosine", 853], ["kinase", 862], ["inhibitors", 869], ["that", 880], ["support", 885], ["our", 893], ["hypothesis", 897], ["and", 908], ["offer", 912], ["useful", 918], ["guidance", 925], ["to", 934], ["other", 937], ["researchers", 943], ["in", 955], ["the", 958], ["field", 962], [".", 967]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is characterised by abnormal sensations in the legs as well as dysaesthesia. Although the aetiology of RLS has not yet been determined, it may be associated with systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a new and simple marker indicating systemic inflammation. The present study aimed to investigate the relationship between systemic inflammation and RLS through the use of the NLR. A total of 75 newly diagnosed patients with RLS and 56 healthy control subjects were included in the study. Baseline NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The NLRs of the two groups were compared. There were no significant differences in gender and age between the two groups. The NLR was 1.96 \u00b1 0.66 in the patient group and 1.67 \u00b1 0.68 in the control group (p = 0.005). Receiver operating characteristic analysis was performed to determine the cut-off value of NLR to predict RLS. The NLR was predictive at 1.58 with a 64% sensitivity and 50% specificity (95% confidence interval 0.55-0.74, area under curve 0.648 \u00b1 0.05). The NLR was found to be statistically higher in patients with RLS and may be used to predict RLS. The aetiology of RLS remains undetermined. The present study showed that systemic inflammation may play a role in RLS. However, RLS could also be associated with systemic inflammatory diseases. This relationship is supported by high NLR values, which are related to chronic systemic inflammation.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "10121cea2cf84ddb98d1d1e853f2f446", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["characterised", 69], ["by", 83], ["abnormal", 86], ["sensations", 95], ["in", 106], ["the", 109], ["legs", 113], ["as", 118], ["well", 121], ["as", 126], ["dysaesthesia", 129], [".", 141], ["Although", 143], ["the", 152], ["aetiology", 156], ["of", 166], ["RLS", 169], ["has", 173], ["not", 177], ["yet", 181], ["been", 185], ["determined", 190], [",", 200], ["it", 202], ["may", 205], ["be", 209], ["associated", 212], ["with", 223], ["systemic", 228], ["inflammation", 237], [".", 249], ["The", 251], ["neutrophil", 255], ["-", 265], ["to", 266], ["-", 268], ["lymphocyte", 269], ["ratio", 280], ["(", 286], ["NLR", 287], [")", 290], ["is", 292], ["a", 295], ["new", 297], ["and", 301], ["simple", 305], ["marker", 312], ["indicating", 319], ["systemic", 330], ["inflammation", 339], [".", 351], ["The", 353], ["present", 357], ["study", 365], ["aimed", 371], ["to", 377], ["investigate", 380], ["the", 392], ["relationship", 396], ["between", 409], ["systemic", 417], ["inflammation", 426], ["and", 439], ["RLS", 443], ["through", 447], ["the", 455], ["use", 459], ["of", 463], ["the", 466], ["NLR", 470], [".", 473], ["A", 475], ["total", 477], ["of", 483], ["75", 486], ["newly", 489], ["diagnosed", 495], ["patients", 505], ["with", 514], ["RLS", 519], ["and", 523], ["56", 527], ["healthy", 530], ["control", 538], ["subjects", 546], ["were", 555], ["included", 560], ["in", 569], ["the", 572], ["study", 576], [".", 581], ["Baseline", 583], ["NLR", 592], ["was", 596], ["calculated", 600], ["by", 611], ["dividing", 614], ["the", 623], ["absolute", 627], ["neutrophil", 636], ["count", 647], ["by", 653], ["the", 656], ["absolute", 660], ["lymphocyte", 669], ["count", 680], [".", 685], ["The", 687], ["NLRs", 691], ["of", 696], ["the", 699], ["two", 703], ["groups", 707], ["were", 714], ["compared", 719], [".", 727], ["There", 729], ["were", 735], ["no", 740], ["significant", 743], ["differences", 755], ["in", 767], ["gender", 770], ["and", 777], ["age", 781], ["between", 785], ["the", 793], ["two", 797], ["groups", 801], [".", 807], ["The", 809], ["NLR", 813], ["was", 817], ["1.96", 821], ["\u00b1", 826], ["0.66", 828], ["in", 833], ["the", 836], ["patient", 840], ["group", 848], ["and", 854], ["1.67", 858], ["\u00b1", 863], ["0.68", 865], ["in", 870], ["the", 873], ["control", 877], ["group", 885], ["(", 891], ["p", 892], ["=", 894], ["0.005", 896], [")", 901], [".", 902], ["Receiver", 904], ["operating", 913], ["characteristic", 923], ["analysis", 938], ["was", 947], ["performed", 951], ["to", 961], ["determine", 964], ["the", 974], ["cut", 978], ["-", 981], ["off", 982], ["value", 986], ["of", 992], ["NLR", 995], ["to", 999], ["predict", 1002], ["RLS", 1010], [".", 1013], ["The", 1015], ["NLR", 1019], ["was", 1023], ["predictive", 1027], ["at", 1038], ["1.58", 1041], ["with", 1046], ["a", 1051], ["64", 1053], ["%", 1055], ["sensitivity", 1057], ["and", 1069], ["50", 1073], ["%", 1075], ["specificity", 1077], ["(", 1089], ["95", 1090], ["%", 1092], ["confidence", 1094], ["interval", 1105], ["0.55", 1114], ["-", 1118], ["0.74", 1119], [",", 1123], ["area", 1125], ["under", 1130], ["curve", 1136], ["0.648", 1142], ["\u00b1", 1148], ["0.05", 1150], [")", 1154], [".", 1155], ["The", 1157], ["NLR", 1161], ["was", 1165], ["found", 1169], ["to", 1175], ["be", 1178], ["statistically", 1181], ["higher", 1195], ["in", 1202], ["patients", 1205], ["with", 1214], ["RLS", 1219], ["and", 1223], ["may", 1227], ["be", 1231], ["used", 1234], ["to", 1239], ["predict", 1242], ["RLS", 1250], [".", 1253], ["The", 1255], ["aetiology", 1259], ["of", 1269], ["RLS", 1272], ["remains", 1276], ["undetermined", 1284], [".", 1296], ["The", 1298], ["present", 1302], ["study", 1310], ["showed", 1316], ["that", 1323], ["systemic", 1328], ["inflammation", 1337], ["may", 1350], ["play", 1354], ["a", 1359], ["role", 1361], ["in", 1366], ["RLS", 1369], [".", 1372], ["However", 1374], [",", 1381], ["RLS", 1383], ["could", 1387], ["also", 1393], ["be", 1398], ["associated", 1401], ["with", 1412], ["systemic", 1417], ["inflammatory", 1426], ["diseases", 1439], [".", 1447], ["This", 1449], ["relationship", 1454], ["is", 1467], ["supported", 1470], ["by", 1480], ["high", 1483], ["NLR", 1488], ["values", 1492], [",", 1498], ["which", 1500], ["are", 1506], ["related", 1510], ["to", 1518], ["chronic", 1521], ["systemic", 1529], ["inflammation", 1538], [".", 1550]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a proinflammatory cytokine that is implicated in many autoinflammatory disorders, but is also important in defense against pathogens. Thus, there is a need to safely and effectively modulate IL-1\u03b2 activity to reduce pathology while maintaining function. Gevokizumab is a potent anti-IL-1\u03b2 antibody being developed as a treatment for diseases in which IL-1\u03b2 has been associated with pathogenesis. Previous data indicated that gevokizumab negatively modulates IL-1\u03b2 signaling through an allosteric mechanism. Because IL-1\u03b2 signaling is a complex, dynamic process involving multiple components, it is important to understand the kinetics of IL-1\u03b2 signaling and the impact of gevokizumab on this process. In the present study, we measured the impact of gevokizumab on the IL-1\u03b2 system using Schild analysis and surface plasmon resonance studies, both of which demonstrated that gevokizumab decreases the binding affinity of IL-1\u03b2 for the IL-1 receptor type I (IL-1RI) signaling receptor, but not the IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). Gevokizumab inhibits both the binding of IL-1\u03b2 to IL-1RI and the subsequent recruitment of IL-1 accessory protein primarily by reducing the association rates of these interactions. Based on this information and recently published structural data, we propose that gevokizumab decreases the association rate for binding of IL-1\u03b2 to its receptor by altering the electrostatic surface potential of IL-1\u03b2, thus reducing the contribution of electrostatic steering to the rapid association rate. These data indicate, therefore, that gevokizumab is a unique inhibitor of IL-1\u03b2 signaling that may offer an alternative to current therapies for IL-1\u03b2-associated autoinflammatory diseases.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "5389373ddbe048119c1dbeb0494dd528", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[128, 128], [51, 51], [227, 227], [150, 150], [266, 266], [2, 2], [277, 277], [36, 36], [76, 76], [84, 84], [185, 185], [238, 238], [104, 104], [62, 62]], "char_spans": [[794, 798], [309, 313], [1407, 1411], [946, 950], [1649, 1653], [16, 20], [1720, 1724], [217, 221], [484, 488], [541, 545], [1127, 1131], [1480, 1484], [664, 668], [377, 381]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["proinflammatory", 28], ["cytokine", 44], ["that", 53], ["is", 58], ["implicated", 61], ["in", 72], ["many", 75], ["autoinflammatory", 80], ["disorders", 97], [",", 106], ["but", 108], ["is", 112], ["also", 115], ["important", 120], ["in", 130], ["defense", 133], ["against", 141], ["pathogens", 149], [".", 158], ["Thus", 160], [",", 164], ["there", 166], ["is", 172], ["a", 175], ["need", 177], ["to", 182], ["safely", 185], ["and", 192], ["effectively", 196], ["modulate", 208], ["IL-1\u03b2", 217], ["activity", 223], ["to", 232], ["reduce", 235], ["pathology", 242], ["while", 252], ["maintaining", 258], ["function", 270], [".", 278], ["Gevokizumab", 280], ["is", 292], ["a", 295], ["potent", 297], ["anti", 304], ["-", 308], ["IL-1\u03b2", 309], ["antibody", 315], ["being", 324], ["developed", 330], ["as", 340], ["a", 343], ["treatment", 345], ["for", 355], ["diseases", 359], ["in", 368], ["which", 371], ["IL-1\u03b2", 377], ["has", 383], ["been", 387], ["associated", 392], ["with", 403], ["pathogenesis", 408], [".", 420], ["Previous", 422], ["data", 431], ["indicated", 436], ["that", 446], ["gevokizumab", 451], ["negatively", 463], ["modulates", 474], ["IL-1\u03b2", 484], ["signaling", 490], ["through", 500], ["an", 508], ["allosteric", 511], ["mechanism", 522], [".", 531], ["Because", 533], ["IL-1\u03b2", 541], ["signaling", 547], ["is", 557], ["a", 560], ["complex", 562], [",", 569], ["dynamic", 571], ["process", 579], ["involving", 587], ["multiple", 597], ["components", 606], [",", 616], ["it", 618], ["is", 621], ["important", 624], ["to", 634], ["understand", 637], ["the", 648], ["kinetics", 652], ["of", 661], ["IL-1\u03b2", 664], ["signaling", 670], ["and", 680], ["the", 684], ["impact", 688], ["of", 695], ["gevokizumab", 698], ["on", 710], ["this", 713], ["process", 718], [".", 725], ["In", 727], ["the", 730], ["present", 734], ["study", 742], [",", 747], ["we", 749], ["measured", 752], ["the", 761], ["impact", 765], ["of", 772], ["gevokizumab", 775], ["on", 787], ["the", 790], ["IL-1\u03b2", 794], ["system", 800], ["using", 807], ["Schild", 813], ["analysis", 820], ["and", 829], ["surface", 833], ["plasmon", 841], ["resonance", 849], ["studies", 859], [",", 866], ["both", 868], ["of", 873], ["which", 876], ["demonstrated", 882], ["that", 895], ["gevokizumab", 900], ["decreases", 912], ["the", 922], ["binding", 926], ["affinity", 934], ["of", 943], ["IL-1\u03b2", 946], ["for", 952], ["the", 956], ["IL-1", 960], ["receptor", 965], ["type", 974], ["I", 979], ["(", 981], ["IL-1RI", 982], [")", 988], ["signaling", 990], ["receptor", 1000], [",", 1008], ["but", 1010], ["not", 1014], ["the", 1018], ["IL-1", 1022], ["counter", 1027], ["-", 1034], ["regulatory", 1035], ["decoy", 1046], ["receptor", 1052], ["(", 1061], ["IL-1", 1062], ["receptor", 1067], ["type", 1076], ["II", 1081], [")", 1083], [".", 1084], ["Gevokizumab", 1086], ["inhibits", 1098], ["both", 1107], ["the", 1112], ["binding", 1116], ["of", 1124], ["IL-1\u03b2", 1127], ["to", 1133], ["IL-1RI", 1136], ["and", 1143], ["the", 1147], ["subsequent", 1151], ["recruitment", 1162], ["of", 1174], ["IL-1", 1177], ["accessory", 1182], ["protein", 1192], ["primarily", 1200], ["by", 1210], ["reducing", 1213], ["the", 1222], ["association", 1226], ["rates", 1238], ["of", 1244], ["these", 1247], ["interactions", 1253], [".", 1265], ["Based", 1267], ["on", 1273], ["this", 1276], ["information", 1281], ["and", 1293], ["recently", 1297], ["published", 1306], ["structural", 1316], ["data", 1327], [",", 1331], ["we", 1333], ["propose", 1336], ["that", 1344], ["gevokizumab", 1349], ["decreases", 1361], ["the", 1371], ["association", 1375], ["rate", 1387], ["for", 1392], ["binding", 1396], ["of", 1404], ["IL-1\u03b2", 1407], ["to", 1413], ["its", 1416], ["receptor", 1420], ["by", 1429], ["altering", 1432], ["the", 1441], ["electrostatic", 1445], ["surface", 1459], ["potential", 1467], ["of", 1477], ["IL-1\u03b2", 1480], [",", 1485], ["thus", 1487], ["reducing", 1492], ["the", 1501], ["contribution", 1505], ["of", 1518], ["electrostatic", 1521], ["steering", 1535], ["to", 1544], ["the", 1547], ["rapid", 1551], ["association", 1557], ["rate", 1569], [".", 1573], ["These", 1575], ["data", 1581], ["indicate", 1586], [",", 1594], ["therefore", 1596], [",", 1605], ["that", 1607], ["gevokizumab", 1612], ["is", 1624], ["a", 1627], ["unique", 1629], ["inhibitor", 1636], ["of", 1646], ["IL-1\u03b2", 1649], ["signaling", 1655], ["that", 1665], ["may", 1670], ["offer", 1674], ["an", 1680], ["alternative", 1683], ["to", 1695], ["current", 1698], ["therapies", 1706], ["for", 1716], ["IL-1\u03b2", 1720], ["-", 1725], ["associated", 1726], ["autoinflammatory", 1737], ["diseases", 1754], [".", 1762]]}
{"context": "We evaluated the new, fully automated molecular BD Max methicillin-resistant Staphylococcus aureus (MRSA) assay for detection of methicillin-resistant S. aureus in a low-prevalence (4.1%) setting. Sensitivity, specificity, and positive and negative predictive values were 93.9%, 99.2%, 83.8%, and 99.7%, respectively. The assay reported fewer unresolved results than the BD GeneOhm MRSA ACP assay.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "66854406960a4a4ba4cff23625202de8", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "methicillin-resistant S. aureus", "token_spans": [[22, 26]], "char_spans": [[129, 159]]}, {"text": "MRSA", "token_spans": [[16, 16], [74, 74]], "char_spans": [[100, 103], [382, 385]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["new", 17], [",", 20], ["fully", 22], ["automated", 28], ["molecular", 38], ["BD", 48], ["Max", 51], ["methicillin", 55], ["-", 66], ["resistant", 67], ["Staphylococcus", 77], ["aureus", 92], ["(", 99], ["MRSA", 100], [")", 104], ["assay", 106], ["for", 112], ["detection", 116], ["of", 126], ["methicillin", 129], ["-", 140], ["resistant", 141], ["S.", 151], ["aureus", 154], ["in", 161], ["a", 164], ["low", 166], ["-", 169], ["prevalence", 170], ["(", 181], ["4.1", 182], ["%", 185], [")", 186], ["setting", 188], [".", 195], ["Sensitivity", 197], [",", 208], ["specificity", 210], [",", 221], ["and", 223], ["positive", 227], ["and", 236], ["negative", 240], ["predictive", 249], ["values", 260], ["were", 267], ["93.9", 272], ["%", 276], [",", 277], ["99.2", 279], ["%", 283], [",", 284], ["83.8", 286], ["%", 290], [",", 291], ["and", 293], ["99.7", 297], ["%", 301], [",", 302], ["respectively", 304], [".", 316], ["The", 318], ["assay", 322], ["reported", 328], ["fewer", 337], ["unresolved", 343], ["results", 354], ["than", 362], ["the", 367], ["BD", 371], ["GeneOhm", 374], ["MRSA", 382], ["ACP", 387], ["assay", 391], [".", 396]]}
{"context": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary glucose excretion. The physiologic response to pharmacologically induced acute or chronic glycosuria has not been investigated in human diabetes. We evaluated 66 patients with type 2 diabetes (62 \u00b1 7 years, BMI = 31.6 \u00b1 4.6 kg/m(2), HbA1c = 55 \u00b1 8 mmol/mol, mean \u00b1 SD) at baseline, after a single dose, and following 4-week treatment with empagliflozin (25 mg). At each time point, patients received a mixed meal coupled with dual-tracer glucose administration and indirect calorimetry. Both single-dose and chronic empagliflozin treatment caused glycosuria during fasting (median, 7.8 [interquartile range {IQR}, 4.4] g/3 hours and 9.2 [IQR, 5.2] g/3 hours) and after meal ingestion (median, 29.0 [IQR, 12.5] g/5 hours and 28.2 [IQR, 15.4] g/5 hours). After 3 hours of fasting, endogenous glucose production (EGP) was increased 25%, while glycemia was 0.9 \u00b1 0.7 mmol/l lower (P < 0.0001 vs. baseline). After meal ingestion, glucose and insulin AUC decreased, whereas the glucagon response increased (all P < 0.001). While oral glucose appearance was unchanged, EGP was increased (median, 40 [IQR, 14] g and 37 [IQR, 11] g vs. 34 [IQR, 11] g, both P < 0.01). Tissue glucose disposal was reduced (median, 75 [IQR, 16] g and 70 [IQR, 21] g vs. 93 [IQR, 18] g, P < 0.0001), due to a decrease in both glucose oxidation and nonoxidative glucose disposal, with a concomitant rise in lipid oxidation after chronic administration (all P < 0.01). \u03b2 Cell glucose sensitivity increased (median, 55 [IQR, 35] pmol \u2022 min(-1) \u2022 m(-2) \u2022 mM(-1) and 55 [IQR, 39] pmol \u2022 min(-1) \u2022 m(-2) \u2022 mM(-1) vs. 44 [IQR, 32] pmol \u2022 min(-1) \u2022 m(-2) \u2022 mM(-1), P < 0.0001), and insulin sensitivity was improved. Resting energy expenditure rates and those after meal ingestion were unchanged. In patients with type 2 diabetes, empagliflozin-induced glycosuria improved \u03b2 cell function and insulin sensitivity, despite the fall in insulin secretion and tissue glucose disposal and the rise in EGP after one dose, thereby lowering fasting and postprandial glycemia. Chronic dosing shifted substrate utilization from carbohydrate to lipid. Trial registration. ClinicalTrials.Gov NCT01248364 (EudraCT no. 2010-018708-99). Funding. This study was funded by Boehringer Ingelheim.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "b5538b30d15c497e8eafc6e1d38b50cf", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[6, 6]], "char_spans": [[32, 36]]}]}], "context_tokens": [["Sodium", 0], ["-", 6], ["glucose", 7], ["cotransporter", 15], ["2", 29], ["(", 31], ["SGLT2", 32], [")", 37], ["inhibitors", 39], ["lower", 50], ["glycemia", 56], ["by", 65], ["enhancing", 68], ["urinary", 78], ["glucose", 86], ["excretion", 94], [".", 103], ["The", 105], ["physiologic", 109], ["response", 121], ["to", 130], ["pharmacologically", 133], ["induced", 151], ["acute", 159], ["or", 165], ["chronic", 168], ["glycosuria", 176], ["has", 187], ["not", 191], ["been", 195], ["investigated", 200], ["in", 213], ["human", 216], ["diabetes", 222], [".", 230], ["We", 232], ["evaluated", 235], ["66", 245], ["patients", 248], ["with", 257], ["type", 262], ["2", 267], ["diabetes", 269], ["(", 278], ["62", 279], ["\u00b1", 282], ["7", 284], ["years", 286], [",", 291], ["BMI", 293], ["=", 297], ["31.6", 299], ["\u00b1", 304], ["4.6", 306], ["kg", 310], ["/", 312], ["m(2", 313], [")", 316], [",", 317], ["HbA1c", 319], ["=", 325], ["55", 327], ["\u00b1", 330], ["8", 332], ["mmol", 334], ["/", 338], ["mol", 339], [",", 342], ["mean", 344], ["\u00b1", 349], ["SD", 351], [")", 353], ["at", 355], ["baseline", 358], [",", 366], ["after", 368], ["a", 374], ["single", 376], ["dose", 383], [",", 387], ["and", 389], ["following", 393], ["4-week", 403], ["treatment", 410], ["with", 420], ["empagliflozin", 425], ["(", 439], ["25", 440], ["mg", 443], [")", 445], [".", 446], ["At", 448], ["each", 451], ["time", 456], ["point", 461], [",", 466], ["patients", 468], ["received", 477], ["a", 486], ["mixed", 488], ["meal", 494], ["coupled", 499], ["with", 507], ["dual", 512], ["-", 516], ["tracer", 517], ["glucose", 524], ["administration", 532], ["and", 547], ["indirect", 551], ["calorimetry", 560], [".", 571], ["Both", 573], ["single", 578], ["-", 584], ["dose", 585], ["and", 590], ["chronic", 594], ["empagliflozin", 602], ["treatment", 616], ["caused", 626], ["glycosuria", 633], ["during", 644], ["fasting", 651], ["(", 659], ["median", 660], [",", 666], ["7.8", 668], ["[", 672], ["interquartile", 673], ["range", 687], ["{", 693], ["IQR", 694], ["}", 697], [",", 698], ["4.4", 700], ["]", 703], ["g/3", 705], ["hours", 709], ["and", 715], ["9.2", 719], ["[", 723], ["IQR", 724], [",", 727], ["5.2", 729], ["]", 732], ["g/3", 734], ["hours", 738], [")", 743], ["and", 745], ["after", 749], ["meal", 755], ["ingestion", 760], ["(", 770], ["median", 771], [",", 777], ["29.0", 779], ["[", 784], ["IQR", 785], [",", 788], ["12.5", 790], ["]", 794], ["g/5", 796], ["hours", 800], ["and", 806], ["28.2", 810], ["[", 815], ["IQR", 816], [",", 819], ["15.4", 821], ["]", 825], ["g/5", 827], ["hours", 831], [")", 836], [".", 837], ["After", 839], ["3", 845], ["hours", 847], ["of", 853], ["fasting", 856], [",", 863], ["endogenous", 865], ["glucose", 876], ["production", 884], ["(", 895], ["EGP", 896], [")", 899], ["was", 901], ["increased", 905], ["25", 915], ["%", 917], [",", 918], ["while", 920], ["glycemia", 926], ["was", 935], ["0.9", 939], ["\u00b1", 943], ["0.7", 945], ["mmol", 949], ["/", 953], ["l", 954], ["lower", 956], ["(", 962], ["P", 963], ["<", 965], ["0.0001", 967], ["vs.", 974], ["baseline", 978], [")", 986], [".", 987], ["After", 989], ["meal", 995], ["ingestion", 1000], [",", 1009], ["glucose", 1011], ["and", 1019], ["insulin", 1023], ["AUC", 1031], ["decreased", 1035], [",", 1044], ["whereas", 1046], ["the", 1054], ["glucagon", 1058], ["response", 1067], ["increased", 1076], ["(", 1086], ["all", 1087], ["P", 1091], ["<", 1093], ["0.001", 1095], [")", 1100], [".", 1101], ["While", 1103], ["oral", 1109], ["glucose", 1114], ["appearance", 1122], ["was", 1133], ["unchanged", 1137], [",", 1146], ["EGP", 1148], ["was", 1152], ["increased", 1156], ["(", 1166], ["median", 1167], [",", 1173], ["40", 1175], ["[", 1178], ["IQR", 1179], [",", 1182], ["14", 1184], ["]", 1186], ["g", 1188], ["and", 1190], ["37", 1194], ["[", 1197], ["IQR", 1198], [",", 1201], ["11", 1203], ["]", 1205], ["g", 1207], ["vs.", 1209], ["34", 1213], ["[", 1216], ["IQR", 1217], [",", 1220], ["11", 1222], ["]", 1224], ["g", 1226], [",", 1227], ["both", 1229], ["P", 1234], ["<", 1236], ["0.01", 1238], [")", 1242], [".", 1243], ["Tissue", 1245], ["glucose", 1252], ["disposal", 1260], ["was", 1269], ["reduced", 1273], ["(", 1281], ["median", 1282], [",", 1288], ["75", 1290], ["[", 1293], ["IQR", 1294], [",", 1297], ["16", 1299], ["]", 1301], ["g", 1303], ["and", 1305], ["70", 1309], ["[", 1312], ["IQR", 1313], [",", 1316], ["21", 1318], ["]", 1320], ["g", 1322], ["vs.", 1324], ["93", 1328], ["[", 1331], ["IQR", 1332], [",", 1335], ["18", 1337], ["]", 1339], ["g", 1341], [",", 1342], ["P", 1344], ["<", 1346], ["0.0001", 1348], [")", 1354], [",", 1355], ["due", 1357], ["to", 1361], ["a", 1364], ["decrease", 1366], ["in", 1375], ["both", 1378], ["glucose", 1383], ["oxidation", 1391], ["and", 1401], ["nonoxidative", 1405], ["glucose", 1418], ["disposal", 1426], [",", 1434], ["with", 1436], ["a", 1441], ["concomitant", 1443], ["rise", 1455], ["in", 1460], ["lipid", 1463], ["oxidation", 1469], ["after", 1479], ["chronic", 1485], ["administration", 1493], ["(", 1508], ["all", 1509], ["P", 1513], ["<", 1515], ["0.01", 1517], [")", 1521], [".", 1522], ["\u03b2", 1524], ["Cell", 1526], ["glucose", 1531], ["sensitivity", 1539], ["increased", 1551], ["(", 1561], ["median", 1562], [",", 1568], ["55", 1570], ["[", 1573], ["IQR", 1574], [",", 1577], ["35", 1579], ["]", 1581], ["pmol", 1583], ["\u2022", 1588], ["min(-1", 1590], [")", 1596], ["\u2022", 1598], ["m(-2", 1600], [")", 1604], ["\u2022", 1606], ["mM(-1", 1608], [")", 1613], ["and", 1615], ["55", 1619], ["[", 1622], ["IQR", 1623], [",", 1626], ["39", 1628], ["]", 1630], ["pmol", 1632], ["\u2022", 1637], ["min(-1", 1639], [")", 1645], ["\u2022", 1647], ["m(-2", 1649], [")", 1653], ["\u2022", 1655], ["mM(-1", 1657], [")", 1662], ["vs.", 1664], ["44", 1668], ["[", 1671], ["IQR", 1672], [",", 1675], ["32", 1677], ["]", 1679], ["pmol", 1681], ["\u2022", 1686], ["min(-1", 1688], [")", 1694], ["\u2022", 1696], ["m(-2", 1698], [")", 1702], ["\u2022", 1704], ["mM(-1", 1706], [")", 1711], [",", 1712], ["P", 1714], ["<", 1716], ["0.0001", 1718], [")", 1724], [",", 1725], ["and", 1727], ["insulin", 1731], ["sensitivity", 1739], ["was", 1751], ["improved", 1755], [".", 1763], ["Resting", 1765], ["energy", 1773], ["expenditure", 1780], ["rates", 1792], ["and", 1798], ["those", 1802], ["after", 1808], ["meal", 1814], ["ingestion", 1819], ["were", 1829], ["unchanged", 1834], [".", 1843], ["In", 1845], ["patients", 1848], ["with", 1857], ["type", 1862], ["2", 1867], ["diabetes", 1869], [",", 1877], ["empagliflozin", 1879], ["-", 1892], ["induced", 1893], ["glycosuria", 1901], ["improved", 1912], ["\u03b2", 1921], ["cell", 1923], ["function", 1928], ["and", 1937], ["insulin", 1941], ["sensitivity", 1949], [",", 1960], ["despite", 1962], ["the", 1970], ["fall", 1974], ["in", 1979], ["insulin", 1982], ["secretion", 1990], ["and", 2000], ["tissue", 2004], ["glucose", 2011], ["disposal", 2019], ["and", 2028], ["the", 2032], ["rise", 2036], ["in", 2041], ["EGP", 2044], ["after", 2048], ["one", 2054], ["dose", 2058], [",", 2062], ["thereby", 2064], ["lowering", 2072], ["fasting", 2081], ["and", 2089], ["postprandial", 2093], ["glycemia", 2106], [".", 2114], ["Chronic", 2116], ["dosing", 2124], ["shifted", 2131], ["substrate", 2139], ["utilization", 2149], ["from", 2161], ["carbohydrate", 2166], ["to", 2179], ["lipid", 2182], [".", 2187], ["Trial", 2189], ["registration", 2195], [".", 2207], ["ClinicalTrials", 2209], [".", 2223], ["Gov", 2224], ["NCT01248364", 2228], ["(", 2240], ["EudraCT", 2241], ["no", 2249], [".", 2251], ["2010", 2253], ["-", 2257], ["018708", 2258], ["-", 2264], ["99", 2265], [")", 2267], [".", 2268], ["Funding", 2270], [".", 2277], ["This", 2279], ["study", 2284], ["was", 2290], ["funded", 2294], ["by", 2301], ["Boehringer", 2304], ["Ingelheim", 2315], [".", 2324]]}
{"context": "The membranous structure of vestibular schwannoma is an important factor in its surgical treatment. Herein, we report intraoperative and microscopic findings relating to an outermost dura-like membrane in cases of vestibular schwannoma and the importance of these findings. Intraoperative findings of 16 cases of vestibular schwannoma treated with an initial surgery were studied with an aim to determine if the cases had a dura-like membrane. Then we studied microscopic findings of the dura-like membrane using hematoxylin and eosin, Masson trichrome, and immunohistochemical staining in 2 cases. The dura-like membrane was observed in 8 out of 16 cases. The average tumor size of the cases that had a dura-like membrane was 30 \u00b1 8.1 mm, and Koos grading 4 was in 7 out of 8 cases, and one was grade 3. In cases without a dura-like membrane, these values were significantly smaller, with an average tumor size of 12.8 \u00b1 5.2 mm, and Koos grading 4 was only in 1 of 8 cases, grade 3 was in 2 cases, and other 5 cases were grade 2. The outermost dura-like membrane enveloped the vestibular schwannoma around the internal acoustic meatus and was continuous with the dura mater. Reactive angiogenesis was observed in the dura mater. Microscopic findings proved its continuity with the dura mater. In one case, the facial nerve was damaged before it was identified during subcapsular dissection. In that case, the dura-like membrane negatively affected our ability to identify the facial nerve. A dura-like membrane sometimes envelops vestibular schwannoma around the internal acoustic meatus. Recognition of this membranous structure is important for the surgical preservation of facial and acoustic nerves.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "49b937d0ed614da79079221407d48ab8", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[49, 50], [289, 290], [4, 5], [212, 213], [34, 35]], "char_spans": [[313, 333], [1531, 1551], [28, 48], [1078, 1098], [214, 234]]}]}], "context_tokens": [["The", 0], ["membranous", 4], ["structure", 15], ["of", 25], ["vestibular", 28], ["schwannoma", 39], ["is", 50], ["an", 53], ["important", 56], ["factor", 66], ["in", 73], ["its", 76], ["surgical", 80], ["treatment", 89], [".", 98], ["Herein", 100], [",", 106], ["we", 108], ["report", 111], ["intraoperative", 118], ["and", 133], ["microscopic", 137], ["findings", 149], ["relating", 158], ["to", 167], ["an", 170], ["outermost", 173], ["dura", 183], ["-", 187], ["like", 188], ["membrane", 193], ["in", 202], ["cases", 205], ["of", 211], ["vestibular", 214], ["schwannoma", 225], ["and", 236], ["the", 240], ["importance", 244], ["of", 255], ["these", 258], ["findings", 264], [".", 272], ["Intraoperative", 274], ["findings", 289], ["of", 298], ["16", 301], ["cases", 304], ["of", 310], ["vestibular", 313], ["schwannoma", 324], ["treated", 335], ["with", 343], ["an", 348], ["initial", 351], ["surgery", 359], ["were", 367], ["studied", 372], ["with", 380], ["an", 385], ["aim", 388], ["to", 392], ["determine", 395], ["if", 405], ["the", 408], ["cases", 412], ["had", 418], ["a", 422], ["dura", 424], ["-", 428], ["like", 429], ["membrane", 434], [".", 442], ["Then", 444], ["we", 449], ["studied", 452], ["microscopic", 460], ["findings", 472], ["of", 481], ["the", 484], ["dura", 488], ["-", 492], ["like", 493], ["membrane", 498], ["using", 507], ["hematoxylin", 513], ["and", 525], ["eosin", 529], [",", 534], ["Masson", 536], ["trichrome", 543], [",", 552], ["and", 554], ["immunohistochemical", 558], ["staining", 578], ["in", 587], ["2", 590], ["cases", 592], [".", 597], ["The", 599], ["dura", 603], ["-", 607], ["like", 608], ["membrane", 613], ["was", 622], ["observed", 626], ["in", 635], ["8", 638], ["out", 640], ["of", 644], ["16", 647], ["cases", 650], [".", 655], ["The", 657], ["average", 661], ["tumor", 669], ["size", 675], ["of", 680], ["the", 683], ["cases", 687], ["that", 693], ["had", 698], ["a", 702], ["dura", 704], ["-", 708], ["like", 709], ["membrane", 714], ["was", 723], ["30", 727], ["\u00b1", 730], ["8.1", 732], ["mm", 736], [",", 738], ["and", 740], ["Koos", 744], ["grading", 749], ["4", 757], ["was", 759], ["in", 763], ["7", 766], ["out", 768], ["of", 772], ["8", 775], ["cases", 777], [",", 782], ["and", 784], ["one", 788], ["was", 792], ["grade", 796], ["3", 802], [".", 803], ["In", 805], ["cases", 808], ["without", 814], ["a", 822], ["dura", 824], ["-", 828], ["like", 829], ["membrane", 834], [",", 842], ["these", 844], ["values", 850], ["were", 857], ["significantly", 862], ["smaller", 876], [",", 883], ["with", 885], ["an", 890], ["average", 893], ["tumor", 901], ["size", 907], ["of", 912], ["12.8", 915], ["\u00b1", 920], ["5.2", 922], ["mm", 926], [",", 928], ["and", 930], ["Koos", 934], ["grading", 939], ["4", 947], ["was", 949], ["only", 953], ["in", 958], ["1", 961], ["of", 963], ["8", 966], ["cases", 968], [",", 973], ["grade", 975], ["3", 981], ["was", 983], ["in", 987], ["2", 990], ["cases", 992], [",", 997], ["and", 999], ["other", 1003], ["5", 1009], ["cases", 1011], ["were", 1017], ["grade", 1022], ["2", 1028], [".", 1029], ["The", 1031], ["outermost", 1035], ["dura", 1045], ["-", 1049], ["like", 1050], ["membrane", 1055], ["enveloped", 1064], ["the", 1074], ["vestibular", 1078], ["schwannoma", 1089], ["around", 1100], ["the", 1107], ["internal", 1111], ["acoustic", 1120], ["meatus", 1129], ["and", 1136], ["was", 1140], ["continuous", 1144], ["with", 1155], ["the", 1160], ["dura", 1164], ["mater", 1169], [".", 1174], ["Reactive", 1176], ["angiogenesis", 1185], ["was", 1198], ["observed", 1202], ["in", 1211], ["the", 1214], ["dura", 1218], ["mater", 1223], [".", 1228], ["Microscopic", 1230], ["findings", 1242], ["proved", 1251], ["its", 1258], ["continuity", 1262], ["with", 1273], ["the", 1278], ["dura", 1282], ["mater", 1287], [".", 1292], ["In", 1294], ["one", 1297], ["case", 1301], [",", 1305], ["the", 1307], ["facial", 1311], ["nerve", 1318], ["was", 1324], ["damaged", 1328], ["before", 1336], ["it", 1343], ["was", 1346], ["identified", 1350], ["during", 1361], ["subcapsular", 1368], ["dissection", 1380], [".", 1390], ["In", 1392], ["that", 1395], ["case", 1400], [",", 1404], ["the", 1406], ["dura", 1410], ["-", 1414], ["like", 1415], ["membrane", 1420], ["negatively", 1429], ["affected", 1440], ["our", 1449], ["ability", 1453], ["to", 1461], ["identify", 1464], ["the", 1473], ["facial", 1477], ["nerve", 1484], [".", 1489], ["A", 1491], ["dura", 1493], ["-", 1497], ["like", 1498], ["membrane", 1503], ["sometimes", 1512], ["envelops", 1522], ["vestibular", 1531], ["schwannoma", 1542], ["around", 1553], ["the", 1560], ["internal", 1564], ["acoustic", 1573], ["meatus", 1582], [".", 1588], ["Recognition", 1590], ["of", 1602], ["this", 1605], ["membranous", 1610], ["structure", 1621], ["is", 1631], ["important", 1634], ["for", 1644], ["the", 1648], ["surgical", 1652], ["preservation", 1661], ["of", 1674], ["facial", 1677], ["and", 1684], ["acoustic", 1688], ["nerves", 1697], [".", 1703]]}
{"context": "We report the development of OikoBase (http://oikoarrays.biology.uiowa.edu/Oiko/), a tiling array-based genome browser resource for Oikopleura dioica, a metazoan belonging to the urochordates, the closest extant group to vertebrates. OikoBase facilitates retrieval and mining of a variety of useful genomics information. First, it includes a genome browser which interrogates 1260 genomic sequence scaffolds and features gene, transcript and CDS annotation tracks. Second, we annotated gene models with gene ontology (GO) terms and InterPro domains which are directly accessible in the browser with links to their entries in the GO (http://www.geneontology.org/) and InterPro (http://www.ebi.ac.uk/interpro/) databases, and we provide transcript and peptide links for sequence downloads. Third, we introduce the transcriptomics of a comprehensive set of developmental stages of O. dioica at high resolution and provide downloadable gene expression data for all developmental stages. Fourth, we incorporate a BLAST tool to identify homologs of genes and proteins. Finally, we include a tutorial that describes how to use OikoBase as well as a link to detailed methods, explaining the data generation and analysis pipeline. OikoBase will provide a valuable resource for research in chordate development, genome evolution and plasticity and the molecular ecology of this important marine planktonic organism.", "qas": [{"question": "Mention the only available genomics and developmental transcriptomics resource for the urochordate Oikopleura dioica", "answers": ["OikoBase"], "qid": "6fc08188d45a419184053b7f1897cddc", "question_tokens": [["Mention", 0], ["the", 8], ["only", 12], ["available", 17], ["genomics", 27], ["and", 36], ["developmental", 40], ["transcriptomics", 54], ["resource", 70], ["for", 79], ["the", 83], ["urochordate", 87], ["Oikopleura", 99], ["dioica", 110]], "detected_answers": [{"text": "OikoBase", "token_spans": [[36, 36], [180, 180], [5, 5], [198, 198]], "char_spans": [[234, 241], [1120, 1127], [29, 36], [1222, 1229]]}]}], "context_tokens": [["We", 0], ["report", 3], ["the", 10], ["development", 14], ["of", 26], ["OikoBase", 29], ["(", 38], ["http://oikoarrays.biology.uiowa.edu/Oiko/", 39], [")", 80], [",", 81], ["a", 83], ["tiling", 85], ["array", 92], ["-", 97], ["based", 98], ["genome", 104], ["browser", 111], ["resource", 119], ["for", 128], ["Oikopleura", 132], ["dioica", 143], [",", 149], ["a", 151], ["metazoan", 153], ["belonging", 162], ["to", 172], ["the", 175], ["urochordates", 179], [",", 191], ["the", 193], ["closest", 197], ["extant", 205], ["group", 212], ["to", 218], ["vertebrates", 221], [".", 232], ["OikoBase", 234], ["facilitates", 243], ["retrieval", 255], ["and", 265], ["mining", 269], ["of", 276], ["a", 279], ["variety", 281], ["of", 289], ["useful", 292], ["genomics", 299], ["information", 308], [".", 319], ["First", 321], [",", 326], ["it", 328], ["includes", 331], ["a", 340], ["genome", 342], ["browser", 349], ["which", 357], ["interrogates", 363], ["1260", 376], ["genomic", 381], ["sequence", 389], ["scaffolds", 398], ["and", 408], ["features", 412], ["gene", 421], [",", 425], ["transcript", 427], ["and", 438], ["CDS", 442], ["annotation", 446], ["tracks", 457], [".", 463], ["Second", 465], [",", 471], ["we", 473], ["annotated", 476], ["gene", 486], ["models", 491], ["with", 498], ["gene", 503], ["ontology", 508], ["(", 517], ["GO", 518], [")", 520], ["terms", 522], ["and", 528], ["InterPro", 532], ["domains", 541], ["which", 549], ["are", 555], ["directly", 559], ["accessible", 568], ["in", 579], ["the", 582], ["browser", 586], ["with", 594], ["links", 599], ["to", 605], ["their", 608], ["entries", 614], ["in", 622], ["the", 625], ["GO", 629], ["(", 632], ["http://www.geneontology.org/", 633], [")", 661], ["and", 663], ["InterPro", 667], ["(", 676], ["http://www.ebi.ac.uk/interpro/", 677], [")", 707], ["databases", 709], [",", 718], ["and", 720], ["we", 724], ["provide", 727], ["transcript", 735], ["and", 746], ["peptide", 750], ["links", 758], ["for", 764], ["sequence", 768], ["downloads", 777], [".", 786], ["Third", 788], [",", 793], ["we", 795], ["introduce", 798], ["the", 808], ["transcriptomics", 812], ["of", 828], ["a", 831], ["comprehensive", 833], ["set", 847], ["of", 851], ["developmental", 854], ["stages", 868], ["of", 875], ["O.", 878], ["dioica", 881], ["at", 888], ["high", 891], ["resolution", 896], ["and", 907], ["provide", 911], ["downloadable", 919], ["gene", 932], ["expression", 937], ["data", 948], ["for", 953], ["all", 957], ["developmental", 961], ["stages", 975], [".", 981], ["Fourth", 983], [",", 989], ["we", 991], ["incorporate", 994], ["a", 1006], ["BLAST", 1008], ["tool", 1014], ["to", 1019], ["identify", 1022], ["homologs", 1031], ["of", 1040], ["genes", 1043], ["and", 1049], ["proteins", 1053], [".", 1061], ["Finally", 1063], [",", 1070], ["we", 1072], ["include", 1075], ["a", 1083], ["tutorial", 1085], ["that", 1094], ["describes", 1099], ["how", 1109], ["to", 1113], ["use", 1116], ["OikoBase", 1120], ["as", 1129], ["well", 1132], ["as", 1137], ["a", 1140], ["link", 1142], ["to", 1147], ["detailed", 1150], ["methods", 1159], [",", 1166], ["explaining", 1168], ["the", 1179], ["data", 1183], ["generation", 1188], ["and", 1199], ["analysis", 1203], ["pipeline", 1212], [".", 1220], ["OikoBase", 1222], ["will", 1231], ["provide", 1236], ["a", 1244], ["valuable", 1246], ["resource", 1255], ["for", 1264], ["research", 1268], ["in", 1277], ["chordate", 1280], ["development", 1289], [",", 1300], ["genome", 1302], ["evolution", 1309], ["and", 1319], ["plasticity", 1323], ["and", 1334], ["the", 1338], ["molecular", 1342], ["ecology", 1352], ["of", 1360], ["this", 1363], ["important", 1368], ["marine", 1378], ["planktonic", 1385], ["organism", 1396], [".", 1404]]}
{"context": "RNA editing is proposed as a modulator of transcriptomes, but its biological impact has not been fully elucidated. In particular, its importance for transposable elements is controversial. We found RNA editing on antisense read-through transcripts of KP elements, one of the deletion derivatives of P transposable elements in Drosophila melanogaster. Three kinds of RNA editing were detected at 20 sites around the terminal inverted repeats (TIR); 15 A-to-G, four U-to-C, and one C-to-U conversions. A-to-G conversions are suggested to be attributed to A-to-I RNA editing on KP element RNAs, because inosine (I) in RNA is recognized as G by reverse transcriptase. TIRs were deduced to form dsRNAs as a putative target of ADAR. This is the first report of RNA editing on mobile elements of Drosophila.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "ed3c30f4b2954727ac67c7b6e40750c9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[150, 150]], "char_spans": [[721, 724]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["is", 12], ["proposed", 15], ["as", 24], ["a", 27], ["modulator", 29], ["of", 39], ["transcriptomes", 42], [",", 56], ["but", 58], ["its", 62], ["biological", 66], ["impact", 77], ["has", 84], ["not", 88], ["been", 92], ["fully", 97], ["elucidated", 103], [".", 113], ["In", 115], ["particular", 118], [",", 128], ["its", 130], ["importance", 134], ["for", 145], ["transposable", 149], ["elements", 162], ["is", 171], ["controversial", 174], [".", 187], ["We", 189], ["found", 192], ["RNA", 198], ["editing", 202], ["on", 210], ["antisense", 213], ["read", 223], ["-", 227], ["through", 228], ["transcripts", 236], ["of", 248], ["KP", 251], ["elements", 254], [",", 262], ["one", 264], ["of", 268], ["the", 271], ["deletion", 275], ["derivatives", 284], ["of", 296], ["P", 299], ["transposable", 301], ["elements", 314], ["in", 323], ["Drosophila", 326], ["melanogaster", 337], [".", 349], ["Three", 351], ["kinds", 357], ["of", 363], ["RNA", 366], ["editing", 370], ["were", 378], ["detected", 383], ["at", 392], ["20", 395], ["sites", 398], ["around", 404], ["the", 411], ["terminal", 415], ["inverted", 424], ["repeats", 433], ["(", 441], ["TIR", 442], [")", 445], [";", 446], ["15", 448], ["A", 451], ["-", 452], ["to", 453], ["-", 455], ["G", 456], [",", 457], ["four", 459], ["U", 464], ["-", 465], ["to", 466], ["-", 468], ["C", 469], [",", 470], ["and", 472], ["one", 476], ["C", 480], ["-", 481], ["to", 482], ["-", 484], ["U", 485], ["conversions", 487], [".", 498], ["A", 500], ["-", 501], ["to", 502], ["-", 504], ["G", 505], ["conversions", 507], ["are", 519], ["suggested", 523], ["to", 533], ["be", 536], ["attributed", 539], ["to", 550], ["A", 553], ["-", 554], ["to", 555], ["-", 557], ["I", 558], ["RNA", 560], ["editing", 564], ["on", 572], ["KP", 575], ["element", 578], ["RNAs", 586], [",", 590], ["because", 592], ["inosine", 600], ["(", 608], ["I", 609], [")", 610], ["in", 612], ["RNA", 615], ["is", 619], ["recognized", 622], ["as", 633], ["G", 636], ["by", 638], ["reverse", 641], ["transcriptase", 649], [".", 662], ["TIRs", 664], ["were", 669], ["deduced", 674], ["to", 682], ["form", 685], ["dsRNAs", 690], ["as", 697], ["a", 700], ["putative", 702], ["target", 711], ["of", 718], ["ADAR", 721], [".", 725], ["This", 727], ["is", 732], ["the", 735], ["first", 739], ["report", 745], ["of", 752], ["RNA", 755], ["editing", 759], ["on", 767], ["mobile", 770], ["elements", 777], ["of", 786], ["Drosophila", 789], [".", 799]]}
{"context": "Chediak-Higashi syndrome is a genetic disorder caused by mutations in a gene encoding a protein named LYST in humans (\"lysosomal trafficking regulator\") or Beige in mice. A prominent feature of this disease is the accumulation of enlarged lysosome-related granules in a variety of cells. The genome of Dictyostelium discoideum contains six genes encoding proteins that are related to LYST/Beige in amino acid sequence, and disruption of one of these genes, lvsA (large volume sphere), results in profound defects in cytokinesis. To better understand the function of this family of proteins in membrane trafficking, we have analyzed mutants disrupted in lvsA, lvsB, lvsC, lvsD, lvsE, and lvsF. Of all these, only lvsA and lvsB mutants displayed interesting phenotypes in our assays. lvsA-null cells exhibited defects in phagocytosis and contained abnormal looking contractile vacuole membranes. Loss of LvsB, the Dictyostelium protein most similar to LYST/Beige, resulted in the formation of enlarged vesicles that by multiple criteria appeared to be acidic lysosomes. The rates of endocytosis, phagocytosis, and fluid phase exocytosis were normal in lvsB-null cells. Also, the rates of processing and the efficiency of targeting of lysosomal alpha-mannosidase were normal, although lvsB mutants inefficiently retained alpha-mannosidase, as well as two other lysosomal cysteine proteinases. Finally, results of pulse-chase experiments indicated that an increase in fusion rates accounted for the enlarged lysosomes in lvsB-null cells, suggesting that LvsB acts as a negative regulator of fusion. Our results support the notion that LvsB/LYST/Beige function in a similar manner to regulate lysosome biogenesis.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "40cc928d16714c79baadc63e10e82c30", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["is", 25], ["a", 28], ["genetic", 30], ["disorder", 38], ["caused", 47], ["by", 54], ["mutations", 57], ["in", 67], ["a", 70], ["gene", 72], ["encoding", 77], ["a", 86], ["protein", 88], ["named", 96], ["LYST", 102], ["in", 107], ["humans", 110], ["(", 117], ["\"", 118], ["lysosomal", 119], ["trafficking", 129], ["regulator", 141], ["\"", 150], [")", 151], ["or", 153], ["Beige", 156], ["in", 162], ["mice", 165], [".", 169], ["A", 171], ["prominent", 173], ["feature", 183], ["of", 191], ["this", 194], ["disease", 199], ["is", 207], ["the", 210], ["accumulation", 214], ["of", 227], ["enlarged", 230], ["lysosome", 239], ["-", 247], ["related", 248], ["granules", 256], ["in", 265], ["a", 268], ["variety", 270], ["of", 278], ["cells", 281], [".", 286], ["The", 288], ["genome", 292], ["of", 299], ["Dictyostelium", 302], ["discoideum", 316], ["contains", 327], ["six", 336], ["genes", 340], ["encoding", 346], ["proteins", 355], ["that", 364], ["are", 369], ["related", 373], ["to", 381], ["LYST", 384], ["/", 388], ["Beige", 389], ["in", 395], ["amino", 398], ["acid", 404], ["sequence", 409], [",", 417], ["and", 419], ["disruption", 423], ["of", 434], ["one", 437], ["of", 441], ["these", 444], ["genes", 450], [",", 455], ["lvsA", 457], ["(", 462], ["large", 463], ["volume", 469], ["sphere", 476], [")", 482], [",", 483], ["results", 485], ["in", 493], ["profound", 496], ["defects", 505], ["in", 513], ["cytokinesis", 516], [".", 527], ["To", 529], ["better", 532], ["understand", 539], ["the", 550], ["function", 554], ["of", 563], ["this", 566], ["family", 571], ["of", 578], ["proteins", 581], ["in", 590], ["membrane", 593], ["trafficking", 602], [",", 613], ["we", 615], ["have", 618], ["analyzed", 623], ["mutants", 632], ["disrupted", 640], ["in", 650], ["lvsA", 653], [",", 657], ["lvsB", 659], [",", 663], ["lvsC", 665], [",", 669], ["lvsD", 671], [",", 675], ["lvsE", 677], [",", 681], ["and", 683], ["lvsF.", 687], ["Of", 693], ["all", 696], ["these", 700], [",", 705], ["only", 707], ["lvsA", 712], ["and", 717], ["lvsB", 721], ["mutants", 726], ["displayed", 734], ["interesting", 744], ["phenotypes", 756], ["in", 767], ["our", 770], ["assays", 774], [".", 780], ["lvsA", 782], ["-", 786], ["null", 787], ["cells", 792], ["exhibited", 798], ["defects", 808], ["in", 816], ["phagocytosis", 819], ["and", 832], ["contained", 836], ["abnormal", 846], ["looking", 855], ["contractile", 863], ["vacuole", 875], ["membranes", 883], [".", 892], ["Loss", 894], ["of", 899], ["LvsB", 902], [",", 906], ["the", 908], ["Dictyostelium", 912], ["protein", 926], ["most", 934], ["similar", 939], ["to", 947], ["LYST", 950], ["/", 954], ["Beige", 955], [",", 960], ["resulted", 962], ["in", 971], ["the", 974], ["formation", 978], ["of", 988], ["enlarged", 991], ["vesicles", 1000], ["that", 1009], ["by", 1014], ["multiple", 1017], ["criteria", 1026], ["appeared", 1035], ["to", 1044], ["be", 1047], ["acidic", 1050], ["lysosomes", 1057], [".", 1066], ["The", 1068], ["rates", 1072], ["of", 1078], ["endocytosis", 1081], [",", 1092], ["phagocytosis", 1094], [",", 1106], ["and", 1108], ["fluid", 1112], ["phase", 1118], ["exocytosis", 1124], ["were", 1135], ["normal", 1140], ["in", 1147], ["lvsB", 1150], ["-", 1154], ["null", 1155], ["cells", 1160], [".", 1165], ["Also", 1167], [",", 1171], ["the", 1173], ["rates", 1177], ["of", 1183], ["processing", 1186], ["and", 1197], ["the", 1201], ["efficiency", 1205], ["of", 1216], ["targeting", 1219], ["of", 1229], ["lysosomal", 1232], ["alpha", 1242], ["-", 1247], ["mannosidase", 1248], ["were", 1260], ["normal", 1265], [",", 1271], ["although", 1273], ["lvsB", 1282], ["mutants", 1287], ["inefficiently", 1295], ["retained", 1309], ["alpha", 1318], ["-", 1323], ["mannosidase", 1324], [",", 1335], ["as", 1337], ["well", 1340], ["as", 1345], ["two", 1348], ["other", 1352], ["lysosomal", 1358], ["cysteine", 1368], ["proteinases", 1377], [".", 1388], ["Finally", 1390], [",", 1397], ["results", 1399], ["of", 1407], ["pulse", 1410], ["-", 1415], ["chase", 1416], ["experiments", 1422], ["indicated", 1434], ["that", 1444], ["an", 1449], ["increase", 1452], ["in", 1461], ["fusion", 1464], ["rates", 1471], ["accounted", 1477], ["for", 1487], ["the", 1491], ["enlarged", 1495], ["lysosomes", 1504], ["in", 1514], ["lvsB", 1517], ["-", 1521], ["null", 1522], ["cells", 1527], [",", 1532], ["suggesting", 1534], ["that", 1545], ["LvsB", 1550], ["acts", 1555], ["as", 1560], ["a", 1563], ["negative", 1565], ["regulator", 1574], ["of", 1584], ["fusion", 1587], [".", 1593], ["Our", 1595], ["results", 1599], ["support", 1607], ["the", 1615], ["notion", 1619], ["that", 1626], ["LvsB", 1631], ["/", 1635], ["LYST", 1636], ["/", 1640], ["Beige", 1641], ["function", 1647], ["in", 1656], ["a", 1659], ["similar", 1661], ["manner", 1669], ["to", 1676], ["regulate", 1679], ["lysosome", 1688], ["biogenesis", 1697], [".", 1707]]}
{"context": "The CRISPR-Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated genes) is an adaptive immunity system in bacteria and archaea that functions via a distinct self-non-self recognition mechanism that is partially analogous to the mechanism of eukaryotic RNA interference (RNAi). The CRISPR-Cas system incorporates fragments of virus or plasmid DNA into the CRISPR repeat cassettes and employs the processed transcripts of these spacers as guide RNAs to cleave the cognate foreign DNA or RNA. The Cas proteins, however, are not homologous to the proteins involved in RNAi and comprise numerous, highly diverged families. The majority of the Cas proteins contain diverse variants of the RNA recognition motif (RRM), a widespread RNA-binding domain. Despite the fast evolution that is typical of the cas genes, the presence of diverse versions of the RRM in most Cas proteins provides for a simple scenario for the evolution of the three distinct types of CRISPR-cas systems. In addition to several proteins that are directly implicated in the immune response, the cas genes encode a variety of proteins that are homologous to prokaryotic toxins that typically possess nuclease activity. The predicted toxins associated with CRISPR-Cas systems include the essential Cas2 protein, proteins of COG1517 that, in addition to a ligand-binding domain and a helix-turn-helix domain, typically contain different nuclease domains and several other predicted nucleases. The tight association of the CRISPR-Cas immunity systems with predicted toxins that, upon activation, would induce dormancy or cell death suggests that adaptive immunity and dormancy/suicide response are functionally coupled. Such coupling could manifest in the persistence state being induced and potentially providing conditions for more effective action of the immune system or in cell death being triggered when immunity fails.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "c40581ee9c7a4286b6e7d0e14ece96df", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3], [268, 270], [54, 56], [220, 222], [176, 178]], "char_spans": [[4, 13], [1512, 1521], [309, 318], [1248, 1257], [979, 988]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["-", 10], ["Cas", 11], ["(", 15], ["clustered", 16], ["regularly", 26], ["interspaced", 36], ["short", 48], ["palindromic", 54], ["repeats", 66], [",", 73], ["CRISPR", 75], ["-", 81], ["associated", 82], ["genes", 93], [")", 98], ["is", 100], ["an", 103], ["adaptive", 106], ["immunity", 115], ["system", 124], ["in", 131], ["bacteria", 134], ["and", 143], ["archaea", 147], ["that", 155], ["functions", 160], ["via", 170], ["a", 174], ["distinct", 176], ["self", 185], ["-", 189], ["non", 190], ["-", 193], ["self", 194], ["recognition", 199], ["mechanism", 211], ["that", 221], ["is", 226], ["partially", 229], ["analogous", 239], ["to", 249], ["the", 252], ["mechanism", 256], ["of", 266], ["eukaryotic", 269], ["RNA", 280], ["interference", 284], ["(", 297], ["RNAi", 298], [")", 302], [".", 303], ["The", 305], ["CRISPR", 309], ["-", 315], ["Cas", 316], ["system", 320], ["incorporates", 327], ["fragments", 340], ["of", 350], ["virus", 353], ["or", 359], ["plasmid", 362], ["DNA", 370], ["into", 374], ["the", 379], ["CRISPR", 383], ["repeat", 390], ["cassettes", 397], ["and", 407], ["employs", 411], ["the", 419], ["processed", 423], ["transcripts", 433], ["of", 445], ["these", 448], ["spacers", 454], ["as", 462], ["guide", 465], ["RNAs", 471], ["to", 476], ["cleave", 479], ["the", 486], ["cognate", 490], ["foreign", 498], ["DNA", 506], ["or", 510], ["RNA", 513], [".", 516], ["The", 518], ["Cas", 522], ["proteins", 526], [",", 534], ["however", 536], [",", 543], ["are", 545], ["not", 549], ["homologous", 553], ["to", 564], ["the", 567], ["proteins", 571], ["involved", 580], ["in", 589], ["RNAi", 592], ["and", 597], ["comprise", 601], ["numerous", 610], [",", 618], ["highly", 620], ["diverged", 627], ["families", 636], [".", 644], ["The", 646], ["majority", 650], ["of", 659], ["the", 662], ["Cas", 666], ["proteins", 670], ["contain", 679], ["diverse", 687], ["variants", 695], ["of", 704], ["the", 707], ["RNA", 711], ["recognition", 715], ["motif", 727], ["(", 733], ["RRM", 734], [")", 737], [",", 738], ["a", 740], ["widespread", 742], ["RNA", 753], ["-", 756], ["binding", 757], ["domain", 765], [".", 771], ["Despite", 773], ["the", 781], ["fast", 785], ["evolution", 790], ["that", 800], ["is", 805], ["typical", 808], ["of", 816], ["the", 819], ["cas", 823], ["genes", 827], [",", 832], ["the", 834], ["presence", 838], ["of", 847], ["diverse", 850], ["versions", 858], ["of", 867], ["the", 870], ["RRM", 874], ["in", 878], ["most", 881], ["Cas", 886], ["proteins", 890], ["provides", 899], ["for", 908], ["a", 912], ["simple", 914], ["scenario", 921], ["for", 930], ["the", 934], ["evolution", 938], ["of", 948], ["the", 951], ["three", 955], ["distinct", 961], ["types", 970], ["of", 976], ["CRISPR", 979], ["-", 985], ["cas", 986], ["systems", 990], [".", 997], ["In", 999], ["addition", 1002], ["to", 1011], ["several", 1014], ["proteins", 1022], ["that", 1031], ["are", 1036], ["directly", 1040], ["implicated", 1049], ["in", 1060], ["the", 1063], ["immune", 1067], ["response", 1074], [",", 1082], ["the", 1084], ["cas", 1088], ["genes", 1092], ["encode", 1098], ["a", 1105], ["variety", 1107], ["of", 1115], ["proteins", 1118], ["that", 1127], ["are", 1132], ["homologous", 1136], ["to", 1147], ["prokaryotic", 1150], ["toxins", 1162], ["that", 1169], ["typically", 1174], ["possess", 1184], ["nuclease", 1192], ["activity", 1201], [".", 1209], ["The", 1211], ["predicted", 1215], ["toxins", 1225], ["associated", 1232], ["with", 1243], ["CRISPR", 1248], ["-", 1254], ["Cas", 1255], ["systems", 1259], ["include", 1267], ["the", 1275], ["essential", 1279], ["Cas2", 1289], ["protein", 1294], [",", 1301], ["proteins", 1303], ["of", 1312], ["COG1517", 1315], ["that", 1323], [",", 1327], ["in", 1329], ["addition", 1332], ["to", 1341], ["a", 1344], ["ligand", 1346], ["-", 1352], ["binding", 1353], ["domain", 1361], ["and", 1368], ["a", 1372], ["helix", 1374], ["-", 1379], ["turn", 1380], ["-", 1384], ["helix", 1385], ["domain", 1391], [",", 1397], ["typically", 1399], ["contain", 1409], ["different", 1417], ["nuclease", 1427], ["domains", 1436], ["and", 1444], ["several", 1448], ["other", 1456], ["predicted", 1462], ["nucleases", 1472], [".", 1481], ["The", 1483], ["tight", 1487], ["association", 1493], ["of", 1505], ["the", 1508], ["CRISPR", 1512], ["-", 1518], ["Cas", 1519], ["immunity", 1523], ["systems", 1532], ["with", 1540], ["predicted", 1545], ["toxins", 1555], ["that", 1562], [",", 1566], ["upon", 1568], ["activation", 1573], [",", 1583], ["would", 1585], ["induce", 1591], ["dormancy", 1598], ["or", 1607], ["cell", 1610], ["death", 1615], ["suggests", 1621], ["that", 1630], ["adaptive", 1635], ["immunity", 1644], ["and", 1653], ["dormancy", 1657], ["/", 1665], ["suicide", 1666], ["response", 1674], ["are", 1683], ["functionally", 1687], ["coupled", 1700], [".", 1707], ["Such", 1709], ["coupling", 1714], ["could", 1723], ["manifest", 1729], ["in", 1738], ["the", 1741], ["persistence", 1745], ["state", 1757], ["being", 1763], ["induced", 1769], ["and", 1777], ["potentially", 1781], ["providing", 1793], ["conditions", 1803], ["for", 1814], ["more", 1818], ["effective", 1823], ["action", 1833], ["of", 1840], ["the", 1843], ["immune", 1847], ["system", 1854], ["or", 1861], ["in", 1864], ["cell", 1867], ["death", 1872], ["being", 1878], ["triggered", 1884], ["when", 1894], ["immunity", 1899], ["fails", 1908], [".", 1913]]}
{"context": "The BCR/ABL gene fusion, the hallmark of chronic myelogenous leukemia (CML) is generated in 2-10% of patients by a variant Ph translocation involving 9q34, 22q11.2, and one or more additional genomic regions. The objective of this study was the characterization by conventional and molecular cytogenetics of complex variant Ph translocations present at diagnosis. FISH studies were performed in 7 cases using the LSI BCR/ABL ES probe allowing the detection of the fusion BCR/ABL gene on the Ph chromosome in all of them and 9q34 deletions in 2 cases. Three cryptic complex rearrangements were detected by FISH studies. The third and the fourth chromosome regions involved in the 8 complex variant translocations were: 1q21, 1p36, 5q31, 11q13, 12q13, 12p13, and 20q12. In conclusion, FISH studies have been useful in the detection of the BCR/ABL rearrangements and 9q34 deletions, and to identify complex rearrangements that differ from the ones previously established by conventional cytogenetics.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "85a18e64fb2d47b0afeee4832c599891", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[1, 5]], "char_spans": [[4, 22]]}]}], "context_tokens": [["The", 0], ["BCR", 4], ["/", 7], ["ABL", 8], ["gene", 12], ["fusion", 17], [",", 23], ["the", 25], ["hallmark", 29], ["of", 38], ["chronic", 41], ["myelogenous", 49], ["leukemia", 61], ["(", 70], ["CML", 71], [")", 74], ["is", 76], ["generated", 79], ["in", 89], ["2", 92], ["-", 93], ["10", 94], ["%", 96], ["of", 98], ["patients", 101], ["by", 110], ["a", 113], ["variant", 115], ["Ph", 123], ["translocation", 126], ["involving", 140], ["9q34", 150], [",", 154], ["22q11.2", 156], [",", 163], ["and", 165], ["one", 169], ["or", 173], ["more", 176], ["additional", 181], ["genomic", 192], ["regions", 200], [".", 207], ["The", 209], ["objective", 213], ["of", 223], ["this", 226], ["study", 231], ["was", 237], ["the", 241], ["characterization", 245], ["by", 262], ["conventional", 265], ["and", 278], ["molecular", 282], ["cytogenetics", 292], ["of", 305], ["complex", 308], ["variant", 316], ["Ph", 324], ["translocations", 327], ["present", 342], ["at", 350], ["diagnosis", 353], [".", 362], ["FISH", 364], ["studies", 369], ["were", 377], ["performed", 382], ["in", 392], ["7", 395], ["cases", 397], ["using", 403], ["the", 409], ["LSI", 413], ["BCR", 417], ["/", 420], ["ABL", 421], ["ES", 425], ["probe", 428], ["allowing", 434], ["the", 443], ["detection", 447], ["of", 457], ["the", 460], ["fusion", 464], ["BCR", 471], ["/", 474], ["ABL", 475], ["gene", 479], ["on", 484], ["the", 487], ["Ph", 491], ["chromosome", 494], ["in", 505], ["all", 508], ["of", 512], ["them", 515], ["and", 520], ["9q34", 524], ["deletions", 529], ["in", 539], ["2", 542], ["cases", 544], [".", 549], ["Three", 551], ["cryptic", 557], ["complex", 565], ["rearrangements", 573], ["were", 588], ["detected", 593], ["by", 602], ["FISH", 605], ["studies", 610], [".", 617], ["The", 619], ["third", 623], ["and", 629], ["the", 633], ["fourth", 637], ["chromosome", 644], ["regions", 655], ["involved", 663], ["in", 672], ["the", 675], ["8", 679], ["complex", 681], ["variant", 689], ["translocations", 697], ["were", 712], [":", 716], ["1q21", 718], [",", 722], ["1p36", 724], [",", 728], ["5q31", 730], [",", 734], ["11q13", 736], [",", 741], ["12q13", 743], [",", 748], ["12p13", 750], [",", 755], ["and", 757], ["20q12", 761], [".", 766], ["In", 768], ["conclusion", 771], [",", 781], ["FISH", 783], ["studies", 788], ["have", 796], ["been", 801], ["useful", 806], ["in", 813], ["the", 816], ["detection", 820], ["of", 830], ["the", 833], ["BCR", 837], ["/", 840], ["ABL", 841], ["rearrangements", 845], ["and", 860], ["9q34", 864], ["deletions", 869], [",", 878], ["and", 880], ["to", 884], ["identify", 887], ["complex", 896], ["rearrangements", 904], ["that", 919], ["differ", 924], ["from", 931], ["the", 936], ["ones", 940], ["previously", 945], ["established", 956], ["by", 968], ["conventional", 971], ["cytogenetics", 984], [".", 996]]}
{"context": "Parkinson's disease (PD) is the second most common neurodegenerative disease. A key pathological feature of PD is Lewy bodies, of which the major protein component is \u03b1-synuclein (\u03b1-syn). Human genetic studies have shown that mutations (A53T, A30P, E46K) and multiplication of the \u03b1-syn gene are linked to familial PD. Mice overexpressing the human A53T mutant \u03b1-syn gene develop severe movement disorders. However, the molecular mechanisms of \u03b1-syn toxicity are not well understood. Recently, mitochondrial dysfunction has been linked with multiple neurodegenerative diseases including Parkinson's disease. Here we investigated whether mitochondrial motility, dynamics and respiratory function are affected in primary neurons from a mouse model expressing the human A53T mutation. We found that mitochondrial motility was selectively inhibited in A53T neurons while transport of other organelles was not affected. In addition, A53T expressing neurons showed impairment in mitochondrial membrane potential and mitochondrial respiratory function. Furthermore, we found that rapamycin, an autophagy inducer, rescued the decreased mitochondrial mobility. Taken together, these data demonstrate that A53T \u03b1-syn impairs mitochondrial function and dynamics and the deficit of mitochondrial transport is reversible, providing further understanding of the disease pathogenesis and a potential therapeutic strategy for PD.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "4687700336544ca7b5e25c199a0d7523", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[31, 33]], "char_spans": [[167, 177]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["the", 28], ["second", 32], ["most", 39], ["common", 44], ["neurodegenerative", 51], ["disease", 69], [".", 76], ["A", 78], ["key", 80], ["pathological", 84], ["feature", 97], ["of", 105], ["PD", 108], ["is", 111], ["Lewy", 114], ["bodies", 119], [",", 125], ["of", 127], ["which", 130], ["the", 136], ["major", 140], ["protein", 146], ["component", 154], ["is", 164], ["\u03b1", 167], ["-", 168], ["synuclein", 169], ["(", 179], ["\u03b1", 180], ["-", 181], ["syn", 182], [")", 185], [".", 186], ["Human", 188], ["genetic", 194], ["studies", 202], ["have", 210], ["shown", 215], ["that", 221], ["mutations", 226], ["(", 236], ["A53", 237], ["T", 240], [",", 241], ["A30P", 243], [",", 247], ["E46", 249], ["K", 252], [")", 253], ["and", 255], ["multiplication", 259], ["of", 274], ["the", 277], ["\u03b1", 281], ["-", 282], ["syn", 283], ["gene", 287], ["are", 292], ["linked", 296], ["to", 303], ["familial", 306], ["PD", 315], [".", 317], ["Mice", 319], ["overexpressing", 324], ["the", 339], ["human", 343], ["A53", 349], ["T", 352], ["mutant", 354], ["\u03b1", 361], ["-", 362], ["syn", 363], ["gene", 367], ["develop", 372], ["severe", 380], ["movement", 387], ["disorders", 396], [".", 405], ["However", 407], [",", 414], ["the", 416], ["molecular", 420], ["mechanisms", 430], ["of", 441], ["\u03b1", 444], ["-", 445], ["syn", 446], ["toxicity", 450], ["are", 459], ["not", 463], ["well", 467], ["understood", 472], [".", 482], ["Recently", 484], [",", 492], ["mitochondrial", 494], ["dysfunction", 508], ["has", 520], ["been", 524], ["linked", 529], ["with", 536], ["multiple", 541], ["neurodegenerative", 550], ["diseases", 568], ["including", 577], ["Parkinson", 587], ["'s", 596], ["disease", 599], [".", 606], ["Here", 608], ["we", 613], ["investigated", 616], ["whether", 629], ["mitochondrial", 637], ["motility", 651], [",", 659], ["dynamics", 661], ["and", 670], ["respiratory", 674], ["function", 686], ["are", 695], ["affected", 699], ["in", 708], ["primary", 711], ["neurons", 719], ["from", 727], ["a", 732], ["mouse", 734], ["model", 740], ["expressing", 746], ["the", 757], ["human", 761], ["A53", 767], ["T", 770], ["mutation", 772], [".", 780], ["We", 782], ["found", 785], ["that", 791], ["mitochondrial", 796], ["motility", 810], ["was", 819], ["selectively", 823], ["inhibited", 835], ["in", 845], ["A53", 848], ["T", 851], ["neurons", 853], ["while", 861], ["transport", 867], ["of", 877], ["other", 880], ["organelles", 886], ["was", 897], ["not", 901], ["affected", 905], [".", 913], ["In", 915], ["addition", 918], [",", 926], ["A53", 928], ["T", 931], ["expressing", 933], ["neurons", 944], ["showed", 952], ["impairment", 959], ["in", 970], ["mitochondrial", 973], ["membrane", 987], ["potential", 996], ["and", 1006], ["mitochondrial", 1010], ["respiratory", 1024], ["function", 1036], [".", 1044], ["Furthermore", 1046], [",", 1057], ["we", 1059], ["found", 1062], ["that", 1068], ["rapamycin", 1073], [",", 1082], ["an", 1084], ["autophagy", 1087], ["inducer", 1097], [",", 1104], ["rescued", 1106], ["the", 1114], ["decreased", 1118], ["mitochondrial", 1128], ["mobility", 1142], [".", 1150], ["Taken", 1152], ["together", 1158], [",", 1166], ["these", 1168], ["data", 1174], ["demonstrate", 1179], ["that", 1191], ["A53", 1196], ["T", 1199], ["\u03b1", 1201], ["-", 1202], ["syn", 1203], ["impairs", 1207], ["mitochondrial", 1215], ["function", 1229], ["and", 1238], ["dynamics", 1242], ["and", 1251], ["the", 1255], ["deficit", 1259], ["of", 1267], ["mitochondrial", 1270], ["transport", 1284], ["is", 1294], ["reversible", 1297], [",", 1307], ["providing", 1309], ["further", 1319], ["understanding", 1327], ["of", 1341], ["the", 1344], ["disease", 1348], ["pathogenesis", 1356], ["and", 1369], ["a", 1373], ["potential", 1375], ["therapeutic", 1385], ["strategy", 1397], ["for", 1406], ["PD", 1410], [".", 1412]]}
{"context": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites. The aim of this study was to assess the morphology and distribution of alpha-synuclein immunoreactivity in cases of dementia with LB (DLB), and to compare alpha-synuclein with ubiquitin immunostaining. We examined substantia nigra, paralimbic regions (entorhinal cortex, cingulate gyrus, insula and hippocampus), and neocortex (frontal and occipital association cortices) with double alpha-synuclein and ubiquitin immunostaining in 25 cases meeting neuropathological criteria for DLB. alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles. It was also slightly more sensitive, staining 4-5% more intracytoplasmic structures, especially diffuse alpha-synuclein deposits that were ubiquitin negative. In addition to LB, alpha-synuclein staining showed filiform and globose neurites in the substantia nigra, CA2-3 regions of the hippocampus, and entorhinal cortex. A spectrum of alpha-synuclein staining was seen in substantia nigra: from diffuse \"cloud-like\" inclusions to aggregated intracytoplasmic inclusions with variable ubiquitin staining to classic LB. We hypothesize that these represent different stages in LB formation.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "657d5d7eecf249cb96e36f5b3a818fcf", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[36, 38], [142, 144], [156, 158], [53, 55], [90, 92], [105, 107], [185, 187], [0, 2]], "char_spans": [[195, 209], [843, 857], [917, 931], [279, 293], [508, 522], [609, 623], [1075, 1089], [0, 14]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["is", 16], ["a", 19], ["presynaptic", 21], ["protein", 33], ["recently", 41], ["identified", 50], ["as", 61], ["a", 64], ["specific", 66], ["component", 75], ["of", 85], ["Lewy", 88], ["bodies", 93], ["(", 100], ["LB", 101], [")", 103], ["and", 105], ["Lewy", 109], ["neurites", 114], [".", 122], ["The", 124], ["aim", 128], ["of", 132], ["this", 135], ["study", 140], ["was", 146], ["to", 150], ["assess", 153], ["the", 160], ["morphology", 164], ["and", 175], ["distribution", 179], ["of", 192], ["alpha", 195], ["-", 200], ["synuclein", 201], ["immunoreactivity", 211], ["in", 228], ["cases", 231], ["of", 237], ["dementia", 240], ["with", 249], ["LB", 254], ["(", 257], ["DLB", 258], [")", 261], [",", 262], ["and", 264], ["to", 268], ["compare", 271], ["alpha", 279], ["-", 284], ["synuclein", 285], ["with", 295], ["ubiquitin", 300], ["immunostaining", 310], [".", 324], ["We", 326], ["examined", 329], ["substantia", 338], ["nigra", 349], [",", 354], ["paralimbic", 356], ["regions", 367], ["(", 375], ["entorhinal", 376], ["cortex", 387], [",", 393], ["cingulate", 395], ["gyrus", 405], [",", 410], ["insula", 412], ["and", 419], ["hippocampus", 423], [")", 434], [",", 435], ["and", 437], ["neocortex", 441], ["(", 451], ["frontal", 452], ["and", 460], ["occipital", 464], ["association", 474], ["cortices", 486], [")", 494], ["with", 496], ["double", 501], ["alpha", 508], ["-", 513], ["synuclein", 514], ["and", 524], ["ubiquitin", 528], ["immunostaining", 538], ["in", 553], ["25", 556], ["cases", 559], ["meeting", 565], ["neuropathological", 573], ["criteria", 591], ["for", 600], ["DLB", 604], [".", 607], ["alpha", 609], ["-", 614], ["Synuclein", 615], ["immunostaining", 625], ["was", 640], ["more", 644], ["specific", 649], ["than", 658], ["ubiquitin", 663], ["immunostaining", 673], ["in", 688], ["that", 691], ["it", 696], ["differentiated", 699], ["LB", 714], ["from", 717], ["globose", 722], ["tangles", 730], [".", 737], ["It", 739], ["was", 742], ["also", 746], ["slightly", 751], ["more", 760], ["sensitive", 765], [",", 774], ["staining", 776], ["4", 785], ["-", 786], ["5", 787], ["%", 788], ["more", 790], ["intracytoplasmic", 795], ["structures", 812], [",", 822], ["especially", 824], ["diffuse", 835], ["alpha", 843], ["-", 848], ["synuclein", 849], ["deposits", 859], ["that", 868], ["were", 873], ["ubiquitin", 878], ["negative", 888], [".", 896], ["In", 898], ["addition", 901], ["to", 910], ["LB", 913], [",", 915], ["alpha", 917], ["-", 922], ["synuclein", 923], ["staining", 933], ["showed", 942], ["filiform", 949], ["and", 958], ["globose", 962], ["neurites", 970], ["in", 979], ["the", 982], ["substantia", 986], ["nigra", 997], [",", 1002], ["CA2", 1004], ["-", 1007], ["3", 1008], ["regions", 1010], ["of", 1018], ["the", 1021], ["hippocampus", 1025], [",", 1036], ["and", 1038], ["entorhinal", 1042], ["cortex", 1053], [".", 1059], ["A", 1061], ["spectrum", 1063], ["of", 1072], ["alpha", 1075], ["-", 1080], ["synuclein", 1081], ["staining", 1091], ["was", 1100], ["seen", 1104], ["in", 1109], ["substantia", 1112], ["nigra", 1123], [":", 1128], ["from", 1130], ["diffuse", 1135], ["\"", 1143], ["cloud", 1144], ["-", 1149], ["like", 1150], ["\"", 1154], ["inclusions", 1156], ["to", 1167], ["aggregated", 1170], ["intracytoplasmic", 1181], ["inclusions", 1198], ["with", 1209], ["variable", 1214], ["ubiquitin", 1223], ["staining", 1233], ["to", 1242], ["classic", 1245], ["LB", 1253], [".", 1255], ["We", 1257], ["hypothesize", 1260], ["that", 1272], ["these", 1277], ["represent", 1283], ["different", 1293], ["stages", 1303], ["in", 1310], ["LB", 1313], ["formation", 1316], [".", 1325]]}
{"context": "It has been previously shown that disruption of RAD26 in yeast strain W303-1B results in a strain that is deficient in transcription-coupled repair (TCR), the preferential repair of the transcribed strand of an expressed gene over the non-transcribed strand and the rest of the genome. RAD26 encodes a protein that is homologous to Cockayne syndrome group B protein (CSB) and is a member of the SWI2/SNF2 family of DNA-dependent ATPases involved in chromatin remodeling. Like the rad26 mutant, cells from Cockayne syndrome patients are defective in TCR. We examined the role of Rad26 in TCR by disrupting RAD26 in two repair-proficient laboratory strains and, remarkably, observed no effect upon TCR. Our results indicate that disruption of RAD26 alone is insufficient to impair TCR. Thus, W303-1B must already possess a mutation that, together with disruption of RAD26, causes a deficiency in TCR. We suggest that other genes are mutated in Cockayne syndrome cells that contribute to the deficiency in TCR. Surprisingly, deletion of RAD26 results in expression of genes that are repressed by flanking transposon delta elements, an Spt(-) phenotype. The delta elements appear to perturb local chromatin structure. Expression of genes flanked by delta elements in rad26Delta mutants is consistent with a role for Rad26 in chromatin remodeling.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "d013353ea4e742219ed6b636f0489445", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[36, 37], [46, 47]], "char_spans": [[186, 203], [239, 256]]}]}], "context_tokens": [["It", 0], ["has", 3], ["been", 7], ["previously", 12], ["shown", 23], ["that", 29], ["disruption", 34], ["of", 45], ["RAD26", 48], ["in", 54], ["yeast", 57], ["strain", 63], ["W303", 70], ["-", 74], ["1B", 75], ["results", 78], ["in", 86], ["a", 89], ["strain", 91], ["that", 98], ["is", 103], ["deficient", 106], ["in", 116], ["transcription", 119], ["-", 132], ["coupled", 133], ["repair", 141], ["(", 148], ["TCR", 149], [")", 152], [",", 153], ["the", 155], ["preferential", 159], ["repair", 172], ["of", 179], ["the", 182], ["transcribed", 186], ["strand", 198], ["of", 205], ["an", 208], ["expressed", 211], ["gene", 221], ["over", 226], ["the", 231], ["non", 235], ["-", 238], ["transcribed", 239], ["strand", 251], ["and", 258], ["the", 262], ["rest", 266], ["of", 271], ["the", 274], ["genome", 278], [".", 284], ["RAD26", 286], ["encodes", 292], ["a", 300], ["protein", 302], ["that", 310], ["is", 315], ["homologous", 318], ["to", 329], ["Cockayne", 332], ["syndrome", 341], ["group", 350], ["B", 356], ["protein", 358], ["(", 366], ["CSB", 367], [")", 370], ["and", 372], ["is", 376], ["a", 379], ["member", 381], ["of", 388], ["the", 391], ["SWI2/SNF2", 395], ["family", 405], ["of", 412], ["DNA", 415], ["-", 418], ["dependent", 419], ["ATPases", 429], ["involved", 437], ["in", 446], ["chromatin", 449], ["remodeling", 459], [".", 469], ["Like", 471], ["the", 476], ["rad26", 480], ["mutant", 486], [",", 492], ["cells", 494], ["from", 500], ["Cockayne", 505], ["syndrome", 514], ["patients", 523], ["are", 532], ["defective", 536], ["in", 546], ["TCR", 549], [".", 552], ["We", 554], ["examined", 557], ["the", 566], ["role", 570], ["of", 575], ["Rad26", 578], ["in", 584], ["TCR", 587], ["by", 591], ["disrupting", 594], ["RAD26", 605], ["in", 611], ["two", 614], ["repair", 618], ["-", 624], ["proficient", 625], ["laboratory", 636], ["strains", 647], ["and", 655], [",", 658], ["remarkably", 660], [",", 670], ["observed", 672], ["no", 681], ["effect", 684], ["upon", 691], ["TCR", 696], [".", 699], ["Our", 701], ["results", 705], ["indicate", 713], ["that", 722], ["disruption", 727], ["of", 738], ["RAD26", 741], ["alone", 747], ["is", 753], ["insufficient", 756], ["to", 769], ["impair", 772], ["TCR", 779], [".", 782], ["Thus", 784], [",", 788], ["W303", 790], ["-", 794], ["1B", 795], ["must", 798], ["already", 803], ["possess", 811], ["a", 819], ["mutation", 821], ["that", 830], [",", 834], ["together", 836], ["with", 845], ["disruption", 850], ["of", 861], ["RAD26", 864], [",", 869], ["causes", 871], ["a", 878], ["deficiency", 880], ["in", 891], ["TCR", 894], [".", 897], ["We", 899], ["suggest", 902], ["that", 910], ["other", 915], ["genes", 921], ["are", 927], ["mutated", 931], ["in", 939], ["Cockayne", 942], ["syndrome", 951], ["cells", 960], ["that", 966], ["contribute", 971], ["to", 982], ["the", 985], ["deficiency", 989], ["in", 1000], ["TCR", 1003], [".", 1006], ["Surprisingly", 1008], [",", 1020], ["deletion", 1022], ["of", 1031], ["RAD26", 1034], ["results", 1040], ["in", 1048], ["expression", 1051], ["of", 1062], ["genes", 1065], ["that", 1071], ["are", 1076], ["repressed", 1080], ["by", 1090], ["flanking", 1093], ["transposon", 1102], ["delta", 1113], ["elements", 1119], [",", 1127], ["an", 1129], ["Spt(-", 1132], [")", 1137], ["phenotype", 1139], [".", 1148], ["The", 1150], ["delta", 1154], ["elements", 1160], ["appear", 1169], ["to", 1176], ["perturb", 1179], ["local", 1187], ["chromatin", 1193], ["structure", 1203], [".", 1212], ["Expression", 1214], ["of", 1225], ["genes", 1228], ["flanked", 1234], ["by", 1242], ["delta", 1245], ["elements", 1251], ["in", 1260], ["rad26Delta", 1263], ["mutants", 1274], ["is", 1282], ["consistent", 1285], ["with", 1296], ["a", 1301], ["role", 1303], ["for", 1308], ["Rad26", 1312], ["in", 1318], ["chromatin", 1321], ["remodeling", 1331], [".", 1341]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f7e5563396b64495a72b3ad4feedde3e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[89, 90], [39, 40], [51, 52]], "char_spans": [[517, 526], [250, 259], [315, 324]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "To investigate the influence of age and gender on the components of the 28-joint Disease Activity Score (DAS28) in patients with rheumatoid arthritis (RA), and to clarify whether a high DAS28 can be equally interpreted in all age groups, independent of gender. A prospective cohort of 553 patients with RA was studied for approximately 20 years after diagnosis. The single measures of disease activity and the share of different components of the DAS28 (eg, erythrocyte sedimentation rate; ESR) were analysed and compared between three age groups (<45, 45-65 and >65 years) and per gender, using analysis of variance (ANOVA). The performance of the DAS28 and its components was explored in moderate to high and low DAS28 categories. Linear mixed model analysis was used to design the models best predicting ESR and the share of ESR. ESR significantly increased with age, independent of other variables of disease activity. This increase was more pronounced in male than in female patients. Nevertheless, the share of ESR increased with age only in male patients with a low DAS28 (<3.2). If the DAS28 score was >3.2, age and gender did not have a significant effect on any components of the DAS28. C-reactive protein (CRP) and DAS28(CRP) were not influenced by age. A high DAS28 was found to perform equally in all age groups, in men and women, despite the elevating effect of age on ESR. In elderly men with low disease activity, remission rate could be underestimated by an elevated ESR.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "a41b67e4e4004aa6a155ea9bb5d45fc4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[264, 264]], "char_spans": [[1337, 1341]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["influence", 19], ["of", 29], ["age", 32], ["and", 36], ["gender", 40], ["on", 47], ["the", 50], ["components", 54], ["of", 65], ["the", 68], ["28-joint", 72], ["Disease", 81], ["Activity", 89], ["Score", 98], ["(", 104], ["DAS28", 105], [")", 110], ["in", 112], ["patients", 115], ["with", 124], ["rheumatoid", 129], ["arthritis", 140], ["(", 150], ["RA", 151], [")", 153], [",", 154], ["and", 156], ["to", 160], ["clarify", 163], ["whether", 171], ["a", 179], ["high", 181], ["DAS28", 186], ["can", 192], ["be", 196], ["equally", 199], ["interpreted", 207], ["in", 219], ["all", 222], ["age", 226], ["groups", 230], [",", 236], ["independent", 238], ["of", 250], ["gender", 253], [".", 259], ["A", 261], ["prospective", 263], ["cohort", 275], ["of", 282], ["553", 285], ["patients", 289], ["with", 298], ["RA", 303], ["was", 306], ["studied", 310], ["for", 318], ["approximately", 322], ["20", 336], ["years", 339], ["after", 345], ["diagnosis", 351], [".", 360], ["The", 362], ["single", 366], ["measures", 373], ["of", 382], ["disease", 385], ["activity", 393], ["and", 402], ["the", 406], ["share", 410], ["of", 416], ["different", 419], ["components", 429], ["of", 440], ["the", 443], ["DAS28", 447], ["(", 453], ["eg", 454], [",", 456], ["erythrocyte", 458], ["sedimentation", 470], ["rate", 484], [";", 488], ["ESR", 490], [")", 493], ["were", 495], ["analysed", 500], ["and", 509], ["compared", 513], ["between", 522], ["three", 530], ["age", 536], ["groups", 540], ["(", 547], ["<", 548], ["45", 549], [",", 551], ["45", 553], ["-", 555], ["65", 556], ["and", 559], [">", 563], ["65", 564], ["years", 567], [")", 572], ["and", 574], ["per", 578], ["gender", 582], [",", 588], ["using", 590], ["analysis", 596], ["of", 605], ["variance", 608], ["(", 617], ["ANOVA", 618], [")", 623], [".", 624], ["The", 626], ["performance", 630], ["of", 642], ["the", 645], ["DAS28", 649], ["and", 655], ["its", 659], ["components", 663], ["was", 674], ["explored", 678], ["in", 687], ["moderate", 690], ["to", 699], ["high", 702], ["and", 707], ["low", 711], ["DAS28", 715], ["categories", 721], [".", 731], ["Linear", 733], ["mixed", 740], ["model", 746], ["analysis", 752], ["was", 761], ["used", 765], ["to", 770], ["design", 773], ["the", 780], ["models", 784], ["best", 791], ["predicting", 796], ["ESR", 807], ["and", 811], ["the", 815], ["share", 819], ["of", 825], ["ESR", 828], [".", 831], ["ESR", 833], ["significantly", 837], ["increased", 851], ["with", 861], ["age", 866], [",", 869], ["independent", 871], ["of", 883], ["other", 886], ["variables", 892], ["of", 902], ["disease", 905], ["activity", 913], [".", 921], ["This", 923], ["increase", 928], ["was", 937], ["more", 941], ["pronounced", 946], ["in", 957], ["male", 960], ["than", 965], ["in", 970], ["female", 973], ["patients", 980], [".", 988], ["Nevertheless", 990], [",", 1002], ["the", 1004], ["share", 1008], ["of", 1014], ["ESR", 1017], ["increased", 1021], ["with", 1031], ["age", 1036], ["only", 1040], ["in", 1045], ["male", 1048], ["patients", 1053], ["with", 1062], ["a", 1067], ["low", 1069], ["DAS28", 1073], ["(", 1079], ["<", 1080], ["3.2", 1081], [")", 1084], [".", 1085], ["If", 1087], ["the", 1090], ["DAS28", 1094], ["score", 1100], ["was", 1106], [">", 1110], ["3.2", 1111], [",", 1114], ["age", 1116], ["and", 1120], ["gender", 1124], ["did", 1131], ["not", 1135], ["have", 1139], ["a", 1144], ["significant", 1146], ["effect", 1158], ["on", 1165], ["any", 1168], ["components", 1172], ["of", 1183], ["the", 1186], ["DAS28", 1190], [".", 1195], ["C", 1197], ["-", 1198], ["reactive", 1199], ["protein", 1208], ["(", 1216], ["CRP", 1217], [")", 1220], ["and", 1222], ["DAS28(CRP", 1226], [")", 1235], ["were", 1237], ["not", 1242], ["influenced", 1246], ["by", 1257], ["age", 1260], [".", 1263], ["A", 1265], ["high", 1267], ["DAS28", 1272], ["was", 1278], ["found", 1282], ["to", 1288], ["perform", 1291], ["equally", 1299], ["in", 1307], ["all", 1310], ["age", 1314], ["groups", 1318], [",", 1324], ["in", 1326], ["men", 1329], ["and", 1333], ["women", 1337], [",", 1342], ["despite", 1344], ["the", 1352], ["elevating", 1356], ["effect", 1366], ["of", 1373], ["age", 1376], ["on", 1380], ["ESR", 1383], [".", 1386], ["In", 1388], ["elderly", 1391], ["men", 1399], ["with", 1403], ["low", 1408], ["disease", 1412], ["activity", 1420], [",", 1428], ["remission", 1430], ["rate", 1440], ["could", 1445], ["be", 1451], ["underestimated", 1454], ["by", 1469], ["an", 1472], ["elevated", 1475], ["ESR", 1484], [".", 1487]]}
{"context": "Desmosomes are cell-cell adhesion structures that integrate cytoskeletal networks. In addition to binding intermediate filaments, the desmosomal protein desmoplakin (DP) regulates microtubule reorganization in the epidermis. In this paper, we identify a specific subset of centrosomal proteins that are recruited to the cell cortex by DP upon epidermal differentiation. These include Lis1 and Ndel1, which are centrosomal proteins that regulate microtubule organization and anchoring in other cell types. This recruitment was mediated by a region of DP specific to a single isoform, DPI. Furthermore, we demonstrate that the epidermal-specific loss of Lis1 results in dramatic defects in microtubule reorganization. Lis1 ablation also causes desmosomal defects, characterized by decreased levels of desmosomal components, decreased attachment of keratin filaments, and increased turnover of desmosomal proteins at the cell cortex. This contributes to loss of epidermal barrier activity, resulting in completely penetrant perinatal lethality. This work reveals essential desmosome-associated components that control cortical microtubule organization and unexpected roles for centrosomal proteins in epidermal function.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "d4ee2e1fb7364cd6bb5931d72186c5bb", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[16, 17]], "char_spans": [[106, 127]]}]}], "context_tokens": [["Desmosomes", 0], ["are", 11], ["cell", 15], ["-", 19], ["cell", 20], ["adhesion", 25], ["structures", 34], ["that", 45], ["integrate", 50], ["cytoskeletal", 60], ["networks", 73], [".", 81], ["In", 83], ["addition", 86], ["to", 95], ["binding", 98], ["intermediate", 106], ["filaments", 119], [",", 128], ["the", 130], ["desmosomal", 134], ["protein", 145], ["desmoplakin", 153], ["(", 165], ["DP", 166], [")", 168], ["regulates", 170], ["microtubule", 180], ["reorganization", 192], ["in", 207], ["the", 210], ["epidermis", 214], [".", 223], ["In", 225], ["this", 228], ["paper", 233], [",", 238], ["we", 240], ["identify", 243], ["a", 252], ["specific", 254], ["subset", 263], ["of", 270], ["centrosomal", 273], ["proteins", 285], ["that", 294], ["are", 299], ["recruited", 303], ["to", 313], ["the", 316], ["cell", 320], ["cortex", 325], ["by", 332], ["DP", 335], ["upon", 338], ["epidermal", 343], ["differentiation", 353], [".", 368], ["These", 370], ["include", 376], ["Lis1", 384], ["and", 389], ["Ndel1", 393], [",", 398], ["which", 400], ["are", 406], ["centrosomal", 410], ["proteins", 422], ["that", 431], ["regulate", 436], ["microtubule", 445], ["organization", 457], ["and", 470], ["anchoring", 474], ["in", 484], ["other", 487], ["cell", 493], ["types", 498], [".", 503], ["This", 505], ["recruitment", 510], ["was", 522], ["mediated", 526], ["by", 535], ["a", 538], ["region", 540], ["of", 547], ["DP", 550], ["specific", 553], ["to", 562], ["a", 565], ["single", 567], ["isoform", 574], [",", 581], ["DPI", 583], [".", 586], ["Furthermore", 588], [",", 599], ["we", 601], ["demonstrate", 604], ["that", 616], ["the", 621], ["epidermal", 625], ["-", 634], ["specific", 635], ["loss", 644], ["of", 649], ["Lis1", 652], ["results", 657], ["in", 665], ["dramatic", 668], ["defects", 677], ["in", 685], ["microtubule", 688], ["reorganization", 700], [".", 714], ["Lis1", 716], ["ablation", 721], ["also", 730], ["causes", 735], ["desmosomal", 742], ["defects", 753], [",", 760], ["characterized", 762], ["by", 776], ["decreased", 779], ["levels", 789], ["of", 796], ["desmosomal", 799], ["components", 810], [",", 820], ["decreased", 822], ["attachment", 832], ["of", 843], ["keratin", 846], ["filaments", 854], [",", 863], ["and", 865], ["increased", 869], ["turnover", 879], ["of", 888], ["desmosomal", 891], ["proteins", 902], ["at", 911], ["the", 914], ["cell", 918], ["cortex", 923], [".", 929], ["This", 931], ["contributes", 936], ["to", 948], ["loss", 951], ["of", 956], ["epidermal", 959], ["barrier", 969], ["activity", 977], [",", 985], ["resulting", 987], ["in", 997], ["completely", 1000], ["penetrant", 1011], ["perinatal", 1021], ["lethality", 1031], [".", 1040], ["This", 1042], ["work", 1047], ["reveals", 1052], ["essential", 1060], ["desmosome", 1070], ["-", 1079], ["associated", 1080], ["components", 1091], ["that", 1102], ["control", 1107], ["cortical", 1115], ["microtubule", 1124], ["organization", 1136], ["and", 1149], ["unexpected", 1153], ["roles", 1164], ["for", 1170], ["centrosomal", 1174], ["proteins", 1186], ["in", 1195], ["epidermal", 1198], ["function", 1208], [".", 1216]]}
{"context": "Tanezumab, an antibody to nerve growth factor, was administered to pregnant cynomolgus monkeys at 0, 0.5, 4, and 30\u2009mg/kg weekly, beginning gestation day (GD) 20 through parturition (\u223cGD165). Maternal tanezumab administration appeared to increase stillbirths and infant mortality, but no consistent pattern of gross and/or microscopic change was detected to explain the mortality. Offspring exposed in utero were evaluated at 12 months of age using light microscopy (all tissues), stereology (basal forebrain cholinergic and dorsal root ganglia neurons), and morphometry (sural nerve). Light microscopy revealed decreased number of neurons in sympathetic ganglia (superior mesenteric, cervicothoracic, and ganglia in the thoracic sympathetic trunk). Stereologic assessment indicated an overall decrease in dorsal root ganglion (thoracic) volume and number of neurons in animals exposed to tanezumab 4\u2009mg/kg (n\u2009=\u20099) and 30\u2009mg/kg (n\u2009=\u20091). At all tanezumab doses, the sural nerve was small due to decreases in myelinated and unmyelinated axons. Existing axons/myelin sheaths appeared normal when viewed with light and transmission electron microscopy. There was no indication of tanezumab-related, active neuron/nerve fiber degeneration/necrosis in any tissue, indicating decreased sensory/sympathetic neurons and axonal changes were due to hypoplasia or atrophy. These changes in the sensory and sympathetic portions of the peripheral nervous system suggest some degree of developmental neurotoxicity, although what effect, if any, the changes had on normal function and survival was not apparent. Overall, these changes were consistent with published data from rodent studies.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "341ad31d93c34ba196d196dbeca4aa12", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[5, 7]], "char_spans": [[26, 44]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["an", 11], ["antibody", 14], ["to", 23], ["nerve", 26], ["growth", 32], ["factor", 39], [",", 45], ["was", 47], ["administered", 51], ["to", 64], ["pregnant", 67], ["cynomolgus", 76], ["monkeys", 87], ["at", 95], ["0", 98], [",", 99], ["0.5", 101], [",", 104], ["4", 106], [",", 107], ["and", 109], ["30", 113], ["mg", 116], ["/", 118], ["kg", 119], ["weekly", 122], [",", 128], ["beginning", 130], ["gestation", 140], ["day", 150], ["(", 154], ["GD", 155], [")", 157], ["20", 159], ["through", 162], ["parturition", 170], ["(", 182], ["\u223cGD165", 183], [")", 189], [".", 190], ["Maternal", 192], ["tanezumab", 201], ["administration", 211], ["appeared", 226], ["to", 235], ["increase", 238], ["stillbirths", 247], ["and", 259], ["infant", 263], ["mortality", 270], [",", 279], ["but", 281], ["no", 285], ["consistent", 288], ["pattern", 299], ["of", 307], ["gross", 310], ["and/or", 316], ["microscopic", 323], ["change", 335], ["was", 342], ["detected", 346], ["to", 355], ["explain", 358], ["the", 366], ["mortality", 370], [".", 379], ["Offspring", 381], ["exposed", 391], ["in", 399], ["utero", 402], ["were", 408], ["evaluated", 413], ["at", 423], ["12", 426], ["months", 429], ["of", 436], ["age", 439], ["using", 443], ["light", 449], ["microscopy", 455], ["(", 466], ["all", 467], ["tissues", 471], [")", 478], [",", 479], ["stereology", 481], ["(", 492], ["basal", 493], ["forebrain", 499], ["cholinergic", 509], ["and", 521], ["dorsal", 525], ["root", 532], ["ganglia", 537], ["neurons", 545], [")", 552], [",", 553], ["and", 555], ["morphometry", 559], ["(", 571], ["sural", 572], ["nerve", 578], [")", 583], [".", 584], ["Light", 586], ["microscopy", 592], ["revealed", 603], ["decreased", 612], ["number", 622], ["of", 629], ["neurons", 632], ["in", 640], ["sympathetic", 643], ["ganglia", 655], ["(", 663], ["superior", 664], ["mesenteric", 673], [",", 683], ["cervicothoracic", 685], [",", 700], ["and", 702], ["ganglia", 706], ["in", 714], ["the", 717], ["thoracic", 721], ["sympathetic", 730], ["trunk", 742], [")", 747], [".", 748], ["Stereologic", 750], ["assessment", 762], ["indicated", 773], ["an", 783], ["overall", 786], ["decrease", 794], ["in", 803], ["dorsal", 806], ["root", 813], ["ganglion", 818], ["(", 827], ["thoracic", 828], [")", 836], ["volume", 838], ["and", 845], ["number", 849], ["of", 856], ["neurons", 859], ["in", 867], ["animals", 870], ["exposed", 878], ["to", 886], ["tanezumab", 889], ["4", 899], ["mg", 901], ["/", 903], ["kg", 904], ["(", 907], ["n", 908], ["=", 910], ["9", 912], [")", 913], ["and", 915], ["30", 919], ["mg", 922], ["/", 924], ["kg", 925], ["(", 928], ["n", 929], ["=", 931], ["1", 933], [")", 934], [".", 935], ["At", 937], ["all", 940], ["tanezumab", 944], ["doses", 954], [",", 959], ["the", 961], ["sural", 965], ["nerve", 971], ["was", 977], ["small", 981], ["due", 987], ["to", 991], ["decreases", 994], ["in", 1004], ["myelinated", 1007], ["and", 1018], ["unmyelinated", 1022], ["axons", 1035], [".", 1040], ["Existing", 1042], ["axons", 1051], ["/", 1056], ["myelin", 1057], ["sheaths", 1064], ["appeared", 1072], ["normal", 1081], ["when", 1088], ["viewed", 1093], ["with", 1100], ["light", 1105], ["and", 1111], ["transmission", 1115], ["electron", 1128], ["microscopy", 1137], [".", 1147], ["There", 1149], ["was", 1155], ["no", 1159], ["indication", 1162], ["of", 1173], ["tanezumab", 1176], ["-", 1185], ["related", 1186], [",", 1193], ["active", 1195], ["neuron", 1202], ["/", 1208], ["nerve", 1209], ["fiber", 1215], ["degeneration", 1221], ["/", 1233], ["necrosis", 1234], ["in", 1243], ["any", 1246], ["tissue", 1250], [",", 1256], ["indicating", 1258], ["decreased", 1269], ["sensory", 1279], ["/", 1286], ["sympathetic", 1287], ["neurons", 1299], ["and", 1307], ["axonal", 1311], ["changes", 1318], ["were", 1326], ["due", 1331], ["to", 1335], ["hypoplasia", 1338], ["or", 1349], ["atrophy", 1352], [".", 1359], ["These", 1361], ["changes", 1367], ["in", 1375], ["the", 1378], ["sensory", 1382], ["and", 1390], ["sympathetic", 1394], ["portions", 1406], ["of", 1415], ["the", 1418], ["peripheral", 1422], ["nervous", 1433], ["system", 1441], ["suggest", 1448], ["some", 1456], ["degree", 1461], ["of", 1468], ["developmental", 1471], ["neurotoxicity", 1485], [",", 1498], ["although", 1500], ["what", 1509], ["effect", 1514], [",", 1520], ["if", 1522], ["any", 1525], [",", 1528], ["the", 1530], ["changes", 1534], ["had", 1542], ["on", 1546], ["normal", 1549], ["function", 1556], ["and", 1565], ["survival", 1569], ["was", 1578], ["not", 1582], ["apparent", 1586], [".", 1594], ["Overall", 1596], [",", 1603], ["these", 1605], ["changes", 1611], ["were", 1619], ["consistent", 1624], ["with", 1635], ["published", 1640], ["data", 1650], ["from", 1655], ["rodent", 1660], ["studies", 1667], [".", 1674]]}
{"context": "Ghrelin exhibits its biological effect through binding to the growth hormone secretagogue 1a receptor (GHS-R1a). Recently, it has been reported that ghrelin has an anti-apoptotic effect in several cell types. However, the molecule mechanisms underlying the anti-apoptotic effect of ghrelin remain poorly understood. In this study, we investigated the intracellular mechanisms responsible for anti-apoptotic effect of ghrelin on human umbilical vein endothelial cells (HUVEC). Treatment of HUVEC with ghrelin inhibited high glucose-induced cell apoptosis. Ghrelin stimulated the rapid phosphorylation of mammalian target of rapamycin (mTOR), P70S6K and S6. The GHS-R1a-specific antagonist [D-Lys3]-GHRP-6 abolished the anti-apoptotic effect and inhibited the activation of mTOR, P70S6K, S6 induced by ghrelin. Pretreatment of cells with specific inhibitor of mTOR blocked the anti-apoptotic effect of ghrelin. In addition, ghrelin protected HUVECs against high glucose induced apoptosis by increasing Bcl-2/Bax ratio. Taken together, our results demonstrate that ghrelin produces a protective effect on HUVECs through activating GHS-R1a and mTOR/P70S6K signaling pathway mediates the effect of ghrelin. These observations suggest that ghrelin may act as a survival factor in preventing HUVECs apoptosis caused by high glucose.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "f64f5b4347d34aeba65aabe6813b3e13", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[102, 105]], "char_spans": [[603, 631]]}]}], "context_tokens": [["Ghrelin", 0], ["exhibits", 8], ["its", 17], ["biological", 21], ["effect", 32], ["through", 39], ["binding", 47], ["to", 55], ["the", 58], ["growth", 62], ["hormone", 69], ["secretagogue", 77], ["1a", 90], ["receptor", 93], ["(", 102], ["GHS", 103], ["-", 106], ["R1a", 107], [")", 110], [".", 111], ["Recently", 113], [",", 121], ["it", 123], ["has", 126], ["been", 130], ["reported", 135], ["that", 144], ["ghrelin", 149], ["has", 157], ["an", 161], ["anti", 164], ["-", 168], ["apoptotic", 169], ["effect", 179], ["in", 186], ["several", 189], ["cell", 197], ["types", 202], [".", 207], ["However", 209], [",", 216], ["the", 218], ["molecule", 222], ["mechanisms", 231], ["underlying", 242], ["the", 253], ["anti", 257], ["-", 261], ["apoptotic", 262], ["effect", 272], ["of", 279], ["ghrelin", 282], ["remain", 290], ["poorly", 297], ["understood", 304], [".", 314], ["In", 316], ["this", 319], ["study", 324], [",", 329], ["we", 331], ["investigated", 334], ["the", 347], ["intracellular", 351], ["mechanisms", 365], ["responsible", 376], ["for", 388], ["anti", 392], ["-", 396], ["apoptotic", 397], ["effect", 407], ["of", 414], ["ghrelin", 417], ["on", 425], ["human", 428], ["umbilical", 434], ["vein", 444], ["endothelial", 449], ["cells", 461], ["(", 467], ["HUVEC", 468], [")", 473], [".", 474], ["Treatment", 476], ["of", 486], ["HUVEC", 489], ["with", 495], ["ghrelin", 500], ["inhibited", 508], ["high", 518], ["glucose", 523], ["-", 530], ["induced", 531], ["cell", 539], ["apoptosis", 544], [".", 553], ["Ghrelin", 555], ["stimulated", 563], ["the", 574], ["rapid", 578], ["phosphorylation", 584], ["of", 600], ["mammalian", 603], ["target", 613], ["of", 620], ["rapamycin", 623], ["(", 633], ["mTOR", 634], [")", 638], [",", 639], ["P70S6", 641], ["K", 646], ["and", 648], ["S6", 652], [".", 654], ["The", 656], ["GHS", 660], ["-", 663], ["R1a", 664], ["-", 667], ["specific", 668], ["antagonist", 677], ["[", 688], ["D", 689], ["-", 690], ["Lys3]-GHRP-6", 691], ["abolished", 704], ["the", 714], ["anti", 718], ["-", 722], ["apoptotic", 723], ["effect", 733], ["and", 740], ["inhibited", 744], ["the", 754], ["activation", 758], ["of", 769], ["mTOR", 772], [",", 776], ["P70S6", 778], ["K", 783], [",", 784], ["S6", 786], ["induced", 789], ["by", 797], ["ghrelin", 800], [".", 807], ["Pretreatment", 809], ["of", 822], ["cells", 825], ["with", 831], ["specific", 836], ["inhibitor", 845], ["of", 855], ["mTOR", 858], ["blocked", 863], ["the", 871], ["anti", 875], ["-", 879], ["apoptotic", 880], ["effect", 890], ["of", 897], ["ghrelin", 900], [".", 907], ["In", 909], ["addition", 912], [",", 920], ["ghrelin", 922], ["protected", 930], ["HUVECs", 940], ["against", 947], ["high", 955], ["glucose", 960], ["induced", 968], ["apoptosis", 976], ["by", 986], ["increasing", 989], ["Bcl-2/Bax", 1000], ["ratio", 1010], [".", 1015], ["Taken", 1017], ["together", 1023], [",", 1031], ["our", 1033], ["results", 1037], ["demonstrate", 1045], ["that", 1057], ["ghrelin", 1062], ["produces", 1070], ["a", 1079], ["protective", 1081], ["effect", 1092], ["on", 1099], ["HUVECs", 1102], ["through", 1109], ["activating", 1117], ["GHS", 1128], ["-", 1131], ["R1a", 1132], ["and", 1136], ["mTOR", 1140], ["/", 1144], ["P70S6", 1145], ["K", 1150], ["signaling", 1152], ["pathway", 1162], ["mediates", 1170], ["the", 1179], ["effect", 1183], ["of", 1190], ["ghrelin", 1193], [".", 1200], ["These", 1202], ["observations", 1208], ["suggest", 1221], ["that", 1229], ["ghrelin", 1234], ["may", 1242], ["act", 1246], ["as", 1250], ["a", 1253], ["survival", 1255], ["factor", 1264], ["in", 1271], ["preventing", 1274], ["HUVECs", 1285], ["apoptosis", 1292], ["caused", 1302], ["by", 1309], ["high", 1312], ["glucose", 1317], [".", 1324]]}
{"context": "Magnetic resonance imaging (MRI) has a higher sensitivity and specificity (90% and 79%) than plain radiography (54% and 68%) for diagnosing diabetic foot osteomyelitis. MRI performs somewhat better than any of several common tests--probe to bone (PTB), erythrocyte sedimentation rate (ESR) >70 mm/hr, C-reactive protein (CRP) >14 mg/L, procalcitonin >0.3 ng/mL, and ulcer size >2 cm\u00b2--although PTB has the highest specificity of any test and is commonly used together with MRI. No studies have directly compared MRI with a combination of these tests, which may assist in diagnosis.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "63e453c58aac4f2abda1af843d1f2c50", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[31, 33]], "char_spans": [[140, 166]]}]}], "context_tokens": [["Magnetic", 0], ["resonance", 9], ["imaging", 19], ["(", 27], ["MRI", 28], [")", 31], ["has", 33], ["a", 37], ["higher", 39], ["sensitivity", 46], ["and", 58], ["specificity", 62], ["(", 74], ["90", 75], ["%", 77], ["and", 79], ["79", 83], ["%", 85], [")", 86], ["than", 88], ["plain", 93], ["radiography", 99], ["(", 111], ["54", 112], ["%", 114], ["and", 116], ["68", 120], ["%", 122], [")", 123], ["for", 125], ["diagnosing", 129], ["diabetic", 140], ["foot", 149], ["osteomyelitis", 154], [".", 167], ["MRI", 169], ["performs", 173], ["somewhat", 182], ["better", 191], ["than", 198], ["any", 203], ["of", 207], ["several", 210], ["common", 218], ["tests", 225], ["--", 230], ["probe", 232], ["to", 238], ["bone", 241], ["(", 246], ["PTB", 247], [")", 250], [",", 251], ["erythrocyte", 253], ["sedimentation", 265], ["rate", 279], ["(", 284], ["ESR", 285], [")", 288], [">", 290], ["70", 291], ["mm", 294], ["/", 296], ["hr", 297], [",", 299], ["C", 301], ["-", 302], ["reactive", 303], ["protein", 312], ["(", 320], ["CRP", 321], [")", 324], [">", 326], ["14", 327], ["mg", 330], ["/", 332], ["L", 333], [",", 334], ["procalcitonin", 336], [">", 350], ["0.3", 351], ["ng", 355], ["/", 357], ["mL", 358], [",", 360], ["and", 362], ["ulcer", 366], ["size", 372], [">", 377], ["2", 378], ["cm\u00b2--although", 380], ["PTB", 394], ["has", 398], ["the", 402], ["highest", 406], ["specificity", 414], ["of", 426], ["any", 429], ["test", 433], ["and", 438], ["is", 442], ["commonly", 445], ["used", 454], ["together", 459], ["with", 468], ["MRI", 473], [".", 476], ["No", 478], ["studies", 481], ["have", 489], ["directly", 494], ["compared", 503], ["MRI", 512], ["with", 516], ["a", 521], ["combination", 523], ["of", 535], ["these", 538], ["tests", 544], [",", 549], ["which", 551], ["may", 557], ["assist", 561], ["in", 568], ["diagnosis", 571], [".", 580]]}
{"context": "Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Nearly 90% of the EGFR mutations are either short, in-frame deletions in exon 19 or point mutations that result in substitution of arginine for leucine at amino acid 858 (L858R). To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant (EGFR(DeltaL747-S752)) or the L858R mutant (EGFR(L858R)) in type II pneumocytes under the control of doxycycline. Expression of either EGFR mutant leads to the development of lung adenocarcinomas. Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas. In contrast, mice expressing EGFR(DeltaL747-S752) develop multifocal tumors embedded in normal lung parenchyma with a longer latency. With mice carrying either EGFR allele, withdrawal of doxycycline (to reduce expression of the transgene) or treatment with erlotinib (to inhibit kinase activity) causes rapid tumor regression, as assessed by magnetic resonance imaging and histopathology, demonstrating that mutant EGFR is required for tumor maintenance. These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "c1fed25571dd435caf919c7770d931d8", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[70, 113]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["exons", 21], ["encoding", 27], ["the", 36], ["tyrosine", 40], ["kinase", 49], ["domain", 56], ["of", 63], ["the", 66], ["epidermal", 70], ["growth", 80], ["factor", 87], ["receptor", 94], ["(", 103], ["EGFR", 104], [")", 108], ["gene", 110], ["are", 115], ["found", 119], ["in", 125], ["human", 128], ["lung", 134], ["adenocarcinomas", 139], ["and", 155], ["are", 159], ["associated", 163], ["with", 174], ["sensitivity", 179], ["to", 191], ["the", 194], ["tyrosine", 198], ["kinase", 207], ["inhibitors", 214], ["gefitinib", 225], ["and", 235], ["erlotinib", 239], [".", 248], ["Nearly", 250], ["90", 257], ["%", 259], ["of", 261], ["the", 264], ["EGFR", 268], ["mutations", 273], ["are", 283], ["either", 287], ["short", 294], [",", 299], ["in", 301], ["-", 303], ["frame", 304], ["deletions", 310], ["in", 320], ["exon", 323], ["19", 328], ["or", 331], ["point", 334], ["mutations", 340], ["that", 350], ["result", 355], ["in", 362], ["substitution", 365], ["of", 378], ["arginine", 381], ["for", 390], ["leucine", 394], ["at", 402], ["amino", 405], ["acid", 411], ["858", 416], ["(", 420], ["L858R", 421], [")", 426], [".", 427], ["To", 429], ["study", 432], ["further", 438], ["the", 446], ["role", 450], ["of", 455], ["these", 458], ["mutations", 464], ["in", 474], ["the", 477], ["initiation", 481], ["and", 492], ["maintenance", 496], ["of", 508], ["lung", 511], ["cancer", 516], [",", 522], ["we", 524], ["have", 527], ["developed", 532], ["transgenic", 542], ["mice", 553], ["that", 558], ["express", 563], ["an", 571], ["exon", 574], ["19", 579], ["deletion", 582], ["mutant", 591], ["(", 598], ["EGFR(DeltaL747-S752", 599], [")", 618], [")", 619], ["or", 621], ["the", 624], ["L858R", 628], ["mutant", 634], ["(", 641], ["EGFR(L858R", 642], [")", 652], [")", 653], ["in", 655], ["type", 658], ["II", 663], ["pneumocytes", 666], ["under", 678], ["the", 684], ["control", 688], ["of", 696], ["doxycycline", 699], [".", 710], ["Expression", 712], ["of", 723], ["either", 726], ["EGFR", 733], ["mutant", 738], ["leads", 745], ["to", 751], ["the", 754], ["development", 758], ["of", 770], ["lung", 773], ["adenocarcinomas", 778], [".", 793], ["Two", 795], ["weeks", 799], ["after", 805], ["induction", 811], ["with", 821], ["doxycycline", 826], [",", 837], ["mice", 839], ["that", 844], ["express", 849], ["the", 857], ["EGFR(L858R", 861], [")", 871], ["allele", 873], ["show", 880], ["diffuse", 885], ["lung", 893], ["cancer", 898], ["highly", 905], ["reminiscent", 912], ["of", 924], ["human", 927], ["bronchioloalveolar", 933], ["carcinoma", 952], ["and", 962], ["later", 966], ["develop", 972], ["interspersed", 980], ["multifocal", 993], ["adenocarcinomas", 1004], [".", 1019], ["In", 1021], ["contrast", 1024], [",", 1032], ["mice", 1034], ["expressing", 1039], ["EGFR(DeltaL747-S752", 1050], [")", 1069], ["develop", 1071], ["multifocal", 1079], ["tumors", 1090], ["embedded", 1097], ["in", 1106], ["normal", 1109], ["lung", 1116], ["parenchyma", 1121], ["with", 1132], ["a", 1137], ["longer", 1139], ["latency", 1146], [".", 1153], ["With", 1155], ["mice", 1160], ["carrying", 1165], ["either", 1174], ["EGFR", 1181], ["allele", 1186], [",", 1192], ["withdrawal", 1194], ["of", 1205], ["doxycycline", 1208], ["(", 1220], ["to", 1221], ["reduce", 1224], ["expression", 1231], ["of", 1242], ["the", 1245], ["transgene", 1249], [")", 1258], ["or", 1260], ["treatment", 1263], ["with", 1273], ["erlotinib", 1278], ["(", 1288], ["to", 1289], ["inhibit", 1292], ["kinase", 1300], ["activity", 1307], [")", 1315], ["causes", 1317], ["rapid", 1324], ["tumor", 1330], ["regression", 1336], [",", 1346], ["as", 1348], ["assessed", 1351], ["by", 1360], ["magnetic", 1363], ["resonance", 1372], ["imaging", 1382], ["and", 1390], ["histopathology", 1394], [",", 1408], ["demonstrating", 1410], ["that", 1424], ["mutant", 1429], ["EGFR", 1436], ["is", 1441], ["required", 1444], ["for", 1453], ["tumor", 1457], ["maintenance", 1463], [".", 1474], ["These", 1476], ["models", 1482], ["may", 1489], ["be", 1493], ["useful", 1496], ["for", 1503], ["developing", 1507], ["improved", 1518], ["therapies", 1527], ["for", 1537], ["patients", 1541], ["with", 1550], ["lung", 1555], ["cancers", 1560], ["bearing", 1568], ["EGFR", 1576], ["mutations", 1581], [".", 1590]]}
{"context": "A 29-year-old man with a history of elevated creatine kinase and necrotizing myopathy was reviewed. Prominent red cell acanthocytosis in association with reduced Kell antigen expression was present, findings consistent with the McLeod syndrome. Investigation of the patient's XK gene revealed a novel TGG- to-TAG transition at position 1023 in exon 3. This point mutation creates an in-frame stop codon (W314X), and predicts a truncated XK protein of 313 amino acids, compared with 444 amino acids in the normal XK protein. The mutation was not identified in the patient's mother or sister indicating that this mutation was spontaneous.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "d82fcc5243f04463a79983358c686ff9", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[44, 44], [79, 79], [94, 94]], "char_spans": [[276, 277], [437, 438], [512, 513]]}]}], "context_tokens": [["A", 0], ["29-year", 2], ["-", 9], ["old", 10], ["man", 14], ["with", 18], ["a", 23], ["history", 25], ["of", 33], ["elevated", 36], ["creatine", 45], ["kinase", 54], ["and", 61], ["necrotizing", 65], ["myopathy", 77], ["was", 86], ["reviewed", 90], [".", 98], ["Prominent", 100], ["red", 110], ["cell", 114], ["acanthocytosis", 119], ["in", 134], ["association", 137], ["with", 149], ["reduced", 154], ["Kell", 162], ["antigen", 167], ["expression", 175], ["was", 186], ["present", 190], [",", 197], ["findings", 199], ["consistent", 208], ["with", 219], ["the", 224], ["McLeod", 228], ["syndrome", 235], [".", 243], ["Investigation", 245], ["of", 259], ["the", 262], ["patient", 266], ["'s", 273], ["XK", 276], ["gene", 279], ["revealed", 284], ["a", 293], ["novel", 295], ["TGG-", 301], ["to", 306], ["-", 308], ["TAG", 309], ["transition", 313], ["at", 324], ["position", 327], ["1023", 336], ["in", 341], ["exon", 344], ["3", 349], [".", 350], ["This", 352], ["point", 357], ["mutation", 363], ["creates", 372], ["an", 380], ["in", 383], ["-", 385], ["frame", 386], ["stop", 392], ["codon", 397], ["(", 403], ["W314X", 404], [")", 409], [",", 410], ["and", 412], ["predicts", 416], ["a", 425], ["truncated", 427], ["XK", 437], ["protein", 440], ["of", 448], ["313", 451], ["amino", 455], ["acids", 461], [",", 466], ["compared", 468], ["with", 477], ["444", 482], ["amino", 486], ["acids", 492], ["in", 498], ["the", 501], ["normal", 505], ["XK", 512], ["protein", 515], [".", 522], ["The", 524], ["mutation", 528], ["was", 537], ["not", 541], ["identified", 545], ["in", 556], ["the", 559], ["patient", 563], ["'s", 570], ["mother", 573], ["or", 580], ["sister", 583], ["indicating", 590], ["that", 601], ["this", 606], ["mutation", 611], ["was", 620], ["spontaneous", 624], [".", 635]]}
{"context": "CLIP-Seq protocols such as PAR-CLIP, HITS-CLIP or iCLIP allow a genome-wide analysis of protein-RNA interactions. For the processing of the resulting short read data, various tools are utilized. Some of these tools were specifically developed for CLIP-Seq data, whereas others were designed for the analysis of RNA-Seq data. To this date, however, it has not been assessed which of the available tools are most appropriate for the analysis of CLIP-Seq data. This is because an experimental gold standard dataset on which methods can be accessed and compared, is still not available. To address this lack of a gold-standard dataset, we here present Cseq-Simulator, a simulator for PAR-CLIP, HITS-CLIP and iCLIP-data. This simulator can be applied to generate realistic datasets that can serve as surrogates for experimental gold standard dataset. In this work, we also show how Cseq-Simulator can be used to perform a comparison of steps of typical CLIP-Seq analysis pipelines, such as the read alignment or the peak calling. These comparisons show which tools are useful in different settings and also allow identifying pitfalls in the data analysis.", "qas": [{"question": "Which data simulator is available for CLIP-SEQ experiments?", "answers": ["Cseq-Simulator"], "qid": "eb43bbf0c4bb484dba710614100c1204", "question_tokens": [["Which", 0], ["data", 6], ["simulator", 11], ["is", 21], ["available", 24], ["for", 34], ["CLIP", 38], ["-", 42], ["SEQ", 43], ["experiments", 47], ["?", 58]], "detected_answers": [{"text": "Cseq-Simulator", "token_spans": [[132, 134], [179, 181]], "char_spans": [[648, 661], [877, 890]]}]}], "context_tokens": [["CLIP", 0], ["-", 4], ["Seq", 5], ["protocols", 9], ["such", 19], ["as", 24], ["PAR", 27], ["-", 30], ["CLIP", 31], [",", 35], ["HITS", 37], ["-", 41], ["CLIP", 42], ["or", 47], ["iCLIP", 50], ["allow", 56], ["a", 62], ["genome", 64], ["-", 70], ["wide", 71], ["analysis", 76], ["of", 85], ["protein", 88], ["-", 95], ["RNA", 96], ["interactions", 100], [".", 112], ["For", 114], ["the", 118], ["processing", 122], ["of", 133], ["the", 136], ["resulting", 140], ["short", 150], ["read", 156], ["data", 161], [",", 165], ["various", 167], ["tools", 175], ["are", 181], ["utilized", 185], [".", 193], ["Some", 195], ["of", 200], ["these", 203], ["tools", 209], ["were", 215], ["specifically", 220], ["developed", 233], ["for", 243], ["CLIP", 247], ["-", 251], ["Seq", 252], ["data", 256], [",", 260], ["whereas", 262], ["others", 270], ["were", 277], ["designed", 282], ["for", 291], ["the", 295], ["analysis", 299], ["of", 308], ["RNA", 311], ["-", 314], ["Seq", 315], ["data", 319], [".", 323], ["To", 325], ["this", 328], ["date", 333], [",", 337], ["however", 339], [",", 346], ["it", 348], ["has", 351], ["not", 355], ["been", 359], ["assessed", 364], ["which", 373], ["of", 379], ["the", 382], ["available", 386], ["tools", 396], ["are", 402], ["most", 406], ["appropriate", 411], ["for", 423], ["the", 427], ["analysis", 431], ["of", 440], ["CLIP", 443], ["-", 447], ["Seq", 448], ["data", 452], [".", 456], ["This", 458], ["is", 463], ["because", 466], ["an", 474], ["experimental", 477], ["gold", 490], ["standard", 495], ["dataset", 504], ["on", 512], ["which", 515], ["methods", 521], ["can", 529], ["be", 533], ["accessed", 536], ["and", 545], ["compared", 549], [",", 557], ["is", 559], ["still", 562], ["not", 568], ["available", 572], [".", 581], ["To", 583], ["address", 586], ["this", 594], ["lack", 599], ["of", 604], ["a", 607], ["gold", 609], ["-", 613], ["standard", 614], ["dataset", 623], [",", 630], ["we", 632], ["here", 635], ["present", 640], ["Cseq", 648], ["-", 652], ["Simulator", 653], [",", 662], ["a", 664], ["simulator", 666], ["for", 676], ["PAR", 680], ["-", 683], ["CLIP", 684], [",", 688], ["HITS", 690], ["-", 694], ["CLIP", 695], ["and", 700], ["iCLIP", 704], ["-", 709], ["data", 710], [".", 714], ["This", 716], ["simulator", 721], ["can", 731], ["be", 735], ["applied", 738], ["to", 746], ["generate", 749], ["realistic", 758], ["datasets", 768], ["that", 777], ["can", 782], ["serve", 786], ["as", 792], ["surrogates", 795], ["for", 806], ["experimental", 810], ["gold", 823], ["standard", 828], ["dataset", 837], [".", 844], ["In", 846], ["this", 849], ["work", 854], [",", 858], ["we", 860], ["also", 863], ["show", 868], ["how", 873], ["Cseq", 877], ["-", 881], ["Simulator", 882], ["can", 892], ["be", 896], ["used", 899], ["to", 904], ["perform", 907], ["a", 915], ["comparison", 917], ["of", 928], ["steps", 931], ["of", 937], ["typical", 940], ["CLIP", 948], ["-", 952], ["Seq", 953], ["analysis", 957], ["pipelines", 966], [",", 975], ["such", 977], ["as", 982], ["the", 985], ["read", 989], ["alignment", 994], ["or", 1004], ["the", 1007], ["peak", 1011], ["calling", 1016], [".", 1023], ["These", 1025], ["comparisons", 1031], ["show", 1043], ["which", 1048], ["tools", 1054], ["are", 1060], ["useful", 1064], ["in", 1071], ["different", 1074], ["settings", 1084], ["and", 1093], ["also", 1097], ["allow", 1102], ["identifying", 1108], ["pitfalls", 1120], ["in", 1129], ["the", 1132], ["data", 1136], ["analysis", 1141], [".", 1149]]}
{"context": "Chediak-Higashi syndrome (CHS) is an inherited immunodeficiency disease characterized by giant lysosomes and impaired leukocyte degranulation. CHS results from mutations in the lysosomal trafficking regulator (LYST) gene, which encodes a 425-kD cytoplasmic protein of unknown function. The goal of this study was to identify proteins that interact with LYST as a first step in understanding how LYST modulates lysosomal exocytosis. Fourteen cDNA fragments, covering the entire coding domain of LYST, were used as baits to screen five human cDNA libraries by a yeast two-hybrid method, modified to allow screening in the activation and the binding domain, three selectable markers, and more stringent confirmation procedures. Five of the interactions were confirmed by an in vitro binding assay. Twenty-one proteins that interact with LYST were identified in yeast two-hybrid screens. Four interactions, confirmed directly, were with proteins important in vesicular transport and signal transduction (the SNARE-complex protein HRS, 14-3-3, and casein kinase II). On the basis of protein interactions, LYST appears to function as an adapter protein that may juxtapose proteins that mediate intracellular membrane fusion reactions. The pathologic manifestations observed in CHS patients and in mice with the homologous mutation beige suggest that understanding the role of LYST may be relevant to the treatment of not only CHS but also of diseases such as asthma, urticaria, and lupus, as well as to the molecular dissection of the CHS-associated cancer predisposition.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "6a6c0c5ae87d4079ad03b0e1d5ecdd40", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["an", 34], ["inherited", 37], ["immunodeficiency", 47], ["disease", 64], ["characterized", 72], ["by", 86], ["giant", 89], ["lysosomes", 95], ["and", 105], ["impaired", 109], ["leukocyte", 118], ["degranulation", 128], [".", 141], ["CHS", 143], ["results", 147], ["from", 155], ["mutations", 160], ["in", 170], ["the", 173], ["lysosomal", 177], ["trafficking", 187], ["regulator", 199], ["(", 209], ["LYST", 210], [")", 214], ["gene", 216], [",", 220], ["which", 222], ["encodes", 228], ["a", 236], ["425-kD", 238], ["cytoplasmic", 245], ["protein", 257], ["of", 265], ["unknown", 268], ["function", 276], [".", 284], ["The", 286], ["goal", 290], ["of", 295], ["this", 298], ["study", 303], ["was", 309], ["to", 313], ["identify", 316], ["proteins", 325], ["that", 334], ["interact", 339], ["with", 348], ["LYST", 353], ["as", 358], ["a", 361], ["first", 363], ["step", 369], ["in", 374], ["understanding", 377], ["how", 391], ["LYST", 395], ["modulates", 400], ["lysosomal", 410], ["exocytosis", 420], [".", 430], ["Fourteen", 432], ["cDNA", 441], ["fragments", 446], [",", 455], ["covering", 457], ["the", 466], ["entire", 470], ["coding", 477], ["domain", 484], ["of", 491], ["LYST", 494], [",", 498], ["were", 500], ["used", 505], ["as", 510], ["baits", 513], ["to", 519], ["screen", 522], ["five", 529], ["human", 534], ["cDNA", 540], ["libraries", 545], ["by", 555], ["a", 558], ["yeast", 560], ["two", 566], ["-", 569], ["hybrid", 570], ["method", 577], [",", 583], ["modified", 585], ["to", 594], ["allow", 597], ["screening", 603], ["in", 613], ["the", 616], ["activation", 620], ["and", 631], ["the", 635], ["binding", 639], ["domain", 647], [",", 653], ["three", 655], ["selectable", 661], ["markers", 672], [",", 679], ["and", 681], ["more", 685], ["stringent", 690], ["confirmation", 700], ["procedures", 713], [".", 723], ["Five", 725], ["of", 730], ["the", 733], ["interactions", 737], ["were", 750], ["confirmed", 755], ["by", 765], ["an", 768], ["in", 771], ["vitro", 774], ["binding", 780], ["assay", 788], [".", 793], ["Twenty", 795], ["-", 801], ["one", 802], ["proteins", 806], ["that", 815], ["interact", 820], ["with", 829], ["LYST", 834], ["were", 839], ["identified", 844], ["in", 855], ["yeast", 858], ["two", 864], ["-", 867], ["hybrid", 868], ["screens", 875], [".", 882], ["Four", 884], ["interactions", 889], [",", 901], ["confirmed", 903], ["directly", 913], [",", 921], ["were", 923], ["with", 928], ["proteins", 933], ["important", 942], ["in", 952], ["vesicular", 955], ["transport", 965], ["and", 975], ["signal", 979], ["transduction", 986], ["(", 999], ["the", 1000], ["SNARE", 1004], ["-", 1009], ["complex", 1010], ["protein", 1018], ["HRS", 1026], [",", 1029], ["14", 1031], ["-", 1033], ["3", 1034], ["-", 1035], ["3", 1036], [",", 1037], ["and", 1039], ["casein", 1043], ["kinase", 1050], ["II", 1057], [")", 1059], [".", 1060], ["On", 1062], ["the", 1065], ["basis", 1069], ["of", 1075], ["protein", 1078], ["interactions", 1086], [",", 1098], ["LYST", 1100], ["appears", 1105], ["to", 1113], ["function", 1116], ["as", 1125], ["an", 1128], ["adapter", 1131], ["protein", 1139], ["that", 1147], ["may", 1152], ["juxtapose", 1156], ["proteins", 1166], ["that", 1175], ["mediate", 1180], ["intracellular", 1188], ["membrane", 1202], ["fusion", 1211], ["reactions", 1218], [".", 1227], ["The", 1229], ["pathologic", 1233], ["manifestations", 1244], ["observed", 1259], ["in", 1268], ["CHS", 1271], ["patients", 1275], ["and", 1284], ["in", 1288], ["mice", 1291], ["with", 1296], ["the", 1301], ["homologous", 1305], ["mutation", 1316], ["beige", 1325], ["suggest", 1331], ["that", 1339], ["understanding", 1344], ["the", 1358], ["role", 1362], ["of", 1367], ["LYST", 1370], ["may", 1375], ["be", 1379], ["relevant", 1382], ["to", 1391], ["the", 1394], ["treatment", 1398], ["of", 1408], ["not", 1411], ["only", 1415], ["CHS", 1420], ["but", 1424], ["also", 1428], ["of", 1433], ["diseases", 1436], ["such", 1445], ["as", 1450], ["asthma", 1453], [",", 1459], ["urticaria", 1461], [",", 1470], ["and", 1472], ["lupus", 1476], [",", 1481], ["as", 1483], ["well", 1486], ["as", 1491], ["to", 1494], ["the", 1497], ["molecular", 1501], ["dissection", 1511], ["of", 1522], ["the", 1525], ["CHS", 1529], ["-", 1532], ["associated", 1533], ["cancer", 1544], ["predisposition", 1551], [".", 1565]]}
{"context": "Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder that is characterized by splenomegaly and marked elevation of the blood leukocyte count with granulocyte in maturity. Ph chromosome was identified in CML in 1960 and was found to clearly result from reciprocal translocation between chromosome 9 and chromosome 22 (t(q;22)) (q34;q11). CML arises from a single pluripotent hematopoietic stem cell with the Ph chromosome and demonstration of the Ph chromosome in blood or marrow cells establishes and unequivocal diagnosis of CML. The Ph chromosome is recognized as the cytogenetic result of a rearrangement of the ABL gene on chromosome 9 and the BCL gene on chromosome 22, which leads to the creation of a BCR/ABL fusion gene on chromosome 22. Abnormal ABL-related protein with increased tyrosine kinase activity suggested a molecular mechanism of CML. The BCR/ABL fusion gene can be found not only in the chromosome but in interphase nuclei by fluorescence in situ hybridization (FISH). We employed both fluorescence activated cell sorter (FACS) and FISH to study the lineage involvement of individual stem cells and progenitor cells in patients with CML. Evidence of BCR/ABL fusion was found in pluripotent stem cells (CD34+, Thy1+), myeloid cells, B progenitor cells (CD34+, CD19+) and T/NK progenitor cells (CD34+, CD7+, CD5+) but not mature T cells (CD3+) or natural killer cells (CD3-, CD56+). These data suggested that BCR/ABL gene fusion occurs in pluripotent stem cells and that Ph+ T cells and natural killer cells are eliminated during differentiation.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "6d9bef92c6174aa29bde5d03ae2f5809", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[281, 285]], "char_spans": [[1444, 1462]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["hematopoietic", 36], ["stem", 50], ["cell", 55], ["disorder", 60], ["that", 69], ["is", 74], ["characterized", 77], ["by", 91], ["splenomegaly", 94], ["and", 107], ["marked", 111], ["elevation", 118], ["of", 128], ["the", 131], ["blood", 135], ["leukocyte", 141], ["count", 151], ["with", 157], ["granulocyte", 162], ["in", 174], ["maturity", 177], [".", 185], ["Ph", 187], ["chromosome", 190], ["was", 201], ["identified", 205], ["in", 216], ["CML", 219], ["in", 223], ["1960", 226], ["and", 231], ["was", 235], ["found", 239], ["to", 245], ["clearly", 248], ["result", 256], ["from", 263], ["reciprocal", 268], ["translocation", 279], ["between", 293], ["chromosome", 301], ["9", 312], ["and", 314], ["chromosome", 318], ["22", 329], ["(", 332], ["t(q;22", 333], [")", 339], [")", 340], ["(", 342], ["q34;q11", 343], [")", 350], [".", 351], ["CML", 353], ["arises", 357], ["from", 364], ["a", 369], ["single", 371], ["pluripotent", 378], ["hematopoietic", 390], ["stem", 404], ["cell", 409], ["with", 414], ["the", 419], ["Ph", 423], ["chromosome", 426], ["and", 437], ["demonstration", 441], ["of", 455], ["the", 458], ["Ph", 462], ["chromosome", 465], ["in", 476], ["blood", 479], ["or", 485], ["marrow", 488], ["cells", 495], ["establishes", 501], ["and", 513], ["unequivocal", 517], ["diagnosis", 529], ["of", 539], ["CML", 542], [".", 545], ["The", 547], ["Ph", 551], ["chromosome", 554], ["is", 565], ["recognized", 568], ["as", 579], ["the", 582], ["cytogenetic", 586], ["result", 598], ["of", 605], ["a", 608], ["rearrangement", 610], ["of", 624], ["the", 627], ["ABL", 631], ["gene", 635], ["on", 640], ["chromosome", 643], ["9", 654], ["and", 656], ["the", 660], ["BCL", 664], ["gene", 668], ["on", 673], ["chromosome", 676], ["22", 687], [",", 689], ["which", 691], ["leads", 697], ["to", 703], ["the", 706], ["creation", 710], ["of", 719], ["a", 722], ["BCR", 724], ["/", 727], ["ABL", 728], ["fusion", 732], ["gene", 739], ["on", 744], ["chromosome", 747], ["22", 758], [".", 760], ["Abnormal", 762], ["ABL", 771], ["-", 774], ["related", 775], ["protein", 783], ["with", 791], ["increased", 796], ["tyrosine", 806], ["kinase", 815], ["activity", 822], ["suggested", 831], ["a", 841], ["molecular", 843], ["mechanism", 853], ["of", 863], ["CML", 866], [".", 869], ["The", 871], ["BCR", 875], ["/", 878], ["ABL", 879], ["fusion", 883], ["gene", 890], ["can", 895], ["be", 899], ["found", 902], ["not", 908], ["only", 912], ["in", 917], ["the", 920], ["chromosome", 924], ["but", 935], ["in", 939], ["interphase", 942], ["nuclei", 953], ["by", 960], ["fluorescence", 963], ["in", 976], ["situ", 979], ["hybridization", 984], ["(", 998], ["FISH", 999], [")", 1003], [".", 1004], ["We", 1006], ["employed", 1009], ["both", 1018], ["fluorescence", 1023], ["activated", 1036], ["cell", 1046], ["sorter", 1051], ["(", 1058], ["FACS", 1059], [")", 1063], ["and", 1065], ["FISH", 1069], ["to", 1074], ["study", 1077], ["the", 1083], ["lineage", 1087], ["involvement", 1095], ["of", 1107], ["individual", 1110], ["stem", 1121], ["cells", 1126], ["and", 1132], ["progenitor", 1136], ["cells", 1147], ["in", 1153], ["patients", 1156], ["with", 1165], ["CML", 1170], [".", 1173], ["Evidence", 1175], ["of", 1184], ["BCR", 1187], ["/", 1190], ["ABL", 1191], ["fusion", 1195], ["was", 1202], ["found", 1206], ["in", 1212], ["pluripotent", 1215], ["stem", 1227], ["cells", 1232], ["(", 1238], ["CD34", 1239], ["+", 1243], [",", 1244], ["Thy1", 1246], ["+", 1250], [")", 1251], [",", 1252], ["myeloid", 1254], ["cells", 1262], [",", 1267], ["B", 1269], ["progenitor", 1271], ["cells", 1282], ["(", 1288], ["CD34", 1289], ["+", 1293], [",", 1294], ["CD19", 1296], ["+", 1300], [")", 1301], ["and", 1303], ["T", 1307], ["/", 1308], ["NK", 1309], ["progenitor", 1312], ["cells", 1323], ["(", 1329], ["CD34", 1330], ["+", 1334], [",", 1335], ["CD7", 1337], ["+", 1340], [",", 1341], ["CD5", 1343], ["+", 1346], [")", 1347], ["but", 1349], ["not", 1353], ["mature", 1357], ["T", 1364], ["cells", 1366], ["(", 1372], ["CD3", 1373], ["+", 1376], [")", 1377], ["or", 1379], ["natural", 1382], ["killer", 1390], ["cells", 1397], ["(", 1403], ["CD3-", 1404], [",", 1408], ["CD56", 1410], ["+", 1414], [")", 1415], [".", 1416], ["These", 1418], ["data", 1424], ["suggested", 1429], ["that", 1439], ["BCR", 1444], ["/", 1447], ["ABL", 1448], ["gene", 1452], ["fusion", 1457], ["occurs", 1464], ["in", 1471], ["pluripotent", 1474], ["stem", 1486], ["cells", 1491], ["and", 1497], ["that", 1501], ["Ph+", 1506], ["T", 1510], ["cells", 1512], ["and", 1518], ["natural", 1522], ["killer", 1530], ["cells", 1537], ["are", 1543], ["eliminated", 1547], ["during", 1558], ["differentiation", 1565], [".", 1580]]}
{"context": "A frequent complication of Clostridium difficile infection (CDI) is recurrent disease. The aim of this study was to determine whether early recurrence risk was higher after infection with ribotype 027 (outbreak strain) compared with infection with endemic strain types of C.\u00a0difficile. Consecutive patients diagnosed with CDI between May 2013 and March 2014 were included (outbreak strain, and non-outbreak strains). Patients who developed recurrent CDI within 30\u00a0days after completion of CDI treatment, were compared with patients without a recurrence. Medical charts were reviewed for demographic and clinical characteristics. General practitioners were contacted to complete data about the occurrence of recurrent CDI, and the use of medication after hospital discharge. In total, 135 patients were at risk for the development of recurrent CDI; 74 patients were infected by ribotype 027, and 61 patients by other ribotypes. Thirty-nine patients (29%) developed recurrent CDI within 30\u00a0days after completion of CDI treatment. In multivariable analysis, age \u226570\u00a0years (HR 3.05, 95% CI 1.54-6.03), and a duration of CDI treatment \u226511\u00a0days (HR 1.92, 95% CI 1.00-3.69) were clearly associated with recurrence; infection with ribotype 027 showed a HR of 1.72 (95% CI 0.88-3.33). During this outbreak of C.\u00a0difficile in a tertiary care centre, age and a prolonged duration of CDI therapy (which is most likely a marker of underlying disease severity) were the main risk factors for recurrent CDI. This points to host factors as more important predictors for recurrent CDI than strain type or antibiotic use.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "a94ba8afc3494df7a5e9de4ccc47fbf0", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[147, 148], [31, 32], [223, 224]], "char_spans": [[877, 888], [188, 199], [1223, 1234]]}]}], "context_tokens": [["A", 0], ["frequent", 2], ["complication", 11], ["of", 24], ["Clostridium", 27], ["difficile", 39], ["infection", 49], ["(", 59], ["CDI", 60], [")", 63], ["is", 65], ["recurrent", 68], ["disease", 78], [".", 85], ["The", 87], ["aim", 91], ["of", 95], ["this", 98], ["study", 103], ["was", 109], ["to", 113], ["determine", 116], ["whether", 126], ["early", 134], ["recurrence", 140], ["risk", 151], ["was", 156], ["higher", 160], ["after", 167], ["infection", 173], ["with", 183], ["ribotype", 188], ["027", 197], ["(", 201], ["outbreak", 202], ["strain", 211], [")", 217], ["compared", 219], ["with", 228], ["infection", 233], ["with", 243], ["endemic", 248], ["strain", 256], ["types", 263], ["of", 269], ["C.", 272], ["difficile", 275], [".", 284], ["Consecutive", 286], ["patients", 298], ["diagnosed", 307], ["with", 317], ["CDI", 322], ["between", 326], ["May", 334], ["2013", 338], ["and", 343], ["March", 347], ["2014", 353], ["were", 358], ["included", 363], ["(", 372], ["outbreak", 373], ["strain", 382], [",", 388], ["and", 390], ["non", 394], ["-", 397], ["outbreak", 398], ["strains", 407], [")", 414], [".", 415], ["Patients", 417], ["who", 426], ["developed", 430], ["recurrent", 440], ["CDI", 450], ["within", 454], ["30", 461], ["days", 464], ["after", 469], ["completion", 475], ["of", 486], ["CDI", 489], ["treatment", 493], [",", 502], ["were", 504], ["compared", 509], ["with", 518], ["patients", 523], ["without", 532], ["a", 540], ["recurrence", 542], [".", 552], ["Medical", 554], ["charts", 562], ["were", 569], ["reviewed", 574], ["for", 583], ["demographic", 587], ["and", 599], ["clinical", 603], ["characteristics", 612], [".", 627], ["General", 629], ["practitioners", 637], ["were", 651], ["contacted", 656], ["to", 666], ["complete", 669], ["data", 678], ["about", 683], ["the", 689], ["occurrence", 693], ["of", 704], ["recurrent", 707], ["CDI", 717], [",", 720], ["and", 722], ["the", 726], ["use", 730], ["of", 734], ["medication", 737], ["after", 748], ["hospital", 754], ["discharge", 763], [".", 772], ["In", 774], ["total", 777], [",", 782], ["135", 784], ["patients", 788], ["were", 797], ["at", 802], ["risk", 805], ["for", 810], ["the", 814], ["development", 818], ["of", 830], ["recurrent", 833], ["CDI", 843], [";", 846], ["74", 848], ["patients", 851], ["were", 860], ["infected", 865], ["by", 874], ["ribotype", 877], ["027", 886], [",", 889], ["and", 891], ["61", 895], ["patients", 898], ["by", 907], ["other", 910], ["ribotypes", 916], [".", 925], ["Thirty", 927], ["-", 933], ["nine", 934], ["patients", 939], ["(", 948], ["29", 949], ["%", 951], [")", 952], ["developed", 954], ["recurrent", 964], ["CDI", 974], ["within", 978], ["30", 985], ["days", 988], ["after", 993], ["completion", 999], ["of", 1010], ["CDI", 1013], ["treatment", 1017], [".", 1026], ["In", 1028], ["multivariable", 1031], ["analysis", 1045], [",", 1053], ["age", 1055], ["\u226570", 1059], ["years", 1063], ["(", 1069], ["HR", 1070], ["3.05", 1073], [",", 1077], ["95", 1079], ["%", 1081], ["CI", 1083], ["1.54", 1086], ["-", 1090], ["6.03", 1091], [")", 1095], [",", 1096], ["and", 1098], ["a", 1102], ["duration", 1104], ["of", 1113], ["CDI", 1116], ["treatment", 1120], ["\u226511", 1130], ["days", 1134], ["(", 1139], ["HR", 1140], ["1.92", 1143], [",", 1147], ["95", 1149], ["%", 1151], ["CI", 1153], ["1.00", 1156], ["-", 1160], ["3.69", 1161], [")", 1165], ["were", 1167], ["clearly", 1172], ["associated", 1180], ["with", 1191], ["recurrence", 1196], [";", 1206], ["infection", 1208], ["with", 1218], ["ribotype", 1223], ["027", 1232], ["showed", 1236], ["a", 1243], ["HR", 1245], ["of", 1248], ["1.72", 1251], ["(", 1256], ["95", 1257], ["%", 1259], ["CI", 1261], ["0.88", 1264], ["-", 1268], ["3.33", 1269], [")", 1273], [".", 1274], ["During", 1276], ["this", 1283], ["outbreak", 1288], ["of", 1297], ["C.", 1300], ["difficile", 1303], ["in", 1313], ["a", 1316], ["tertiary", 1318], ["care", 1327], ["centre", 1332], [",", 1338], ["age", 1340], ["and", 1344], ["a", 1348], ["prolonged", 1350], ["duration", 1360], ["of", 1369], ["CDI", 1372], ["therapy", 1376], ["(", 1384], ["which", 1385], ["is", 1391], ["most", 1394], ["likely", 1399], ["a", 1406], ["marker", 1408], ["of", 1415], ["underlying", 1418], ["disease", 1429], ["severity", 1437], [")", 1445], ["were", 1447], ["the", 1452], ["main", 1456], ["risk", 1461], ["factors", 1466], ["for", 1474], ["recurrent", 1478], ["CDI", 1488], [".", 1491], ["This", 1493], ["points", 1498], ["to", 1505], ["host", 1508], ["factors", 1513], ["as", 1521], ["more", 1524], ["important", 1529], ["predictors", 1539], ["for", 1550], ["recurrent", 1554], ["CDI", 1564], ["than", 1568], ["strain", 1573], ["type", 1580], ["or", 1585], ["antibiotic", 1588], ["use", 1599], [".", 1602]]}
{"context": "Suppression subtractive hybridization performed on Down syndrome (DS) versus control fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways regulating apoptosis. The under-expression of PRDX2 observed in DS samples was confirmed by real-time PCR (0.73-fold). To test whether decreased expression is associated with enhanced sensitivity of DS neurons to reactive oxygen species, we down-regulated PRDX2 through stable transfections of SH-SY5Y neuroblastoma cells with antisense contructs of the complete PRDX2 coding sequence. In addition, we over-expressed SOD1 and compared the effects of the two genes on cell viability. Cells transfected with either construct showed similar sensitivity to oxidative stress in addition to increased apoptosis under basal conditions and after treatment with oxidative cytotoxic agents. This suggests that the decreased expression of PRDX2 may contribute to the altered redox state in DS at levels comparable to that of the increased expression of SOD1.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "733e977ad4f14caf9148b8dbb151fd8c", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[30, 30]], "char_spans": [[195, 205]]}]}], "context_tokens": [["Suppression", 0], ["subtractive", 12], ["hybridization", 24], ["performed", 38], ["on", 48], ["Down", 51], ["syndrome", 56], ["(", 65], ["DS", 66], [")", 68], ["versus", 70], ["control", 77], ["fetal", 85], ["brains", 91], ["revealed", 98], ["differential", 107], ["expression", 120], ["of", 131], ["peroxiredoxin", 134], ["2", 148], ["(", 150], ["PRDX2", 151], [")", 156], [",", 157], ["mapped", 159], ["at", 166], ["13q12", 169], [".", 174], ["Peroxiredoxins", 176], ["are", 191], ["antioxidant", 195], ["enzymes", 207], ["involved", 215], ["in", 224], ["protein", 227], ["and", 235], ["lipid", 239], ["protection", 245], ["against", 256], ["oxidative", 264], ["injury", 274], ["and", 281], ["in", 285], ["cellular", 288], ["signalling", 297], ["pathways", 308], ["regulating", 317], ["apoptosis", 328], [".", 337], ["The", 339], ["under", 343], ["-", 348], ["expression", 349], ["of", 360], ["PRDX2", 363], ["observed", 369], ["in", 378], ["DS", 381], ["samples", 384], ["was", 392], ["confirmed", 396], ["by", 406], ["real", 409], ["-", 413], ["time", 414], ["PCR", 419], ["(", 423], ["0.73-fold", 424], [")", 433], [".", 434], ["To", 436], ["test", 439], ["whether", 444], ["decreased", 452], ["expression", 462], ["is", 473], ["associated", 476], ["with", 487], ["enhanced", 492], ["sensitivity", 501], ["of", 513], ["DS", 516], ["neurons", 519], ["to", 527], ["reactive", 530], ["oxygen", 539], ["species", 546], [",", 553], ["we", 555], ["down", 558], ["-", 562], ["regulated", 563], ["PRDX2", 573], ["through", 579], ["stable", 587], ["transfections", 594], ["of", 608], ["SH", 611], ["-", 613], ["SY5Y", 614], ["neuroblastoma", 619], ["cells", 633], ["with", 639], ["antisense", 644], ["contructs", 654], ["of", 664], ["the", 667], ["complete", 671], ["PRDX2", 680], ["coding", 686], ["sequence", 693], [".", 701], ["In", 703], ["addition", 706], [",", 714], ["we", 716], ["over", 719], ["-", 723], ["expressed", 724], ["SOD1", 734], ["and", 739], ["compared", 743], ["the", 752], ["effects", 756], ["of", 764], ["the", 767], ["two", 771], ["genes", 775], ["on", 781], ["cell", 784], ["viability", 789], [".", 798], ["Cells", 800], ["transfected", 806], ["with", 818], ["either", 823], ["construct", 830], ["showed", 840], ["similar", 847], ["sensitivity", 855], ["to", 867], ["oxidative", 870], ["stress", 880], ["in", 887], ["addition", 890], ["to", 899], ["increased", 902], ["apoptosis", 912], ["under", 922], ["basal", 928], ["conditions", 934], ["and", 945], ["after", 949], ["treatment", 955], ["with", 965], ["oxidative", 970], ["cytotoxic", 980], ["agents", 990], [".", 996], ["This", 998], ["suggests", 1003], ["that", 1012], ["the", 1017], ["decreased", 1021], ["expression", 1031], ["of", 1042], ["PRDX2", 1045], ["may", 1051], ["contribute", 1055], ["to", 1066], ["the", 1069], ["altered", 1073], ["redox", 1081], ["state", 1087], ["in", 1093], ["DS", 1096], ["at", 1099], ["levels", 1102], ["comparable", 1109], ["to", 1120], ["that", 1123], ["of", 1128], ["the", 1131], ["increased", 1135], ["expression", 1145], ["of", 1156], ["SOD1", 1159], [".", 1163]]}
{"context": "In Russia, an intradermal Diaskintest\u00ae drug has been designed, which is a recombinant tuberculosis allergen based on M. tuberculosis-- specific proteins: ESAT-6 and CFP-10 produced by a genetically modified Escherichia coli culture. Diaskintest\u00ae test and Mantoux test with 2TE PPD-L were concurrently carried out in 300 children and adolescents with tuberculosis and followed up in risk groups at a tuberculosis dispensary to determine the sensitivity of the new skin test in active tuberculosis infection. Diaskintest\u00ae showed a high sensitivity not only in active tuberculosis, but also in occult, the so-called latent, tuberculosis infection. This is suggested by the following evidence. The high percentage (83.8%) of positive responses to Diaskintest\u00ae is noted in children and adolescents with tuberculosis, receiving an intensive course of chemotherapy. Negative tests were observed only in minor forms at the resolution stage. In the children who had completed treatment, positive tests were seen in 78.3%, moreover in those with prior tuberculosis of intrathoracic lymph nodes; negative tests were observed not earlier than 18 months after start of treatment. The highest sensitivity of Diaskintest\u00ae was shown in children with early primary tuberculosis infection and through family contact with bacteria-excreting subjects (91.7%). These children may be judged with the highest assurance to have latent tuberculosis infection, the population of which is in an active state at the moment of the study. The children with early primary tuberculosis infection, but in no family contact with bacteria-excreting individuals, showed a lower percentage of positive responses to Diaskintest\u00ae both before (37.5%) and after (10%) treatment, which suggests that there must be a lower bacterial burden in the child. A high percentage of positive responses to Diaskintest\u00ae (76.2%) were found in subjects with hyperergic reactions to tuberculin. These were in only 16.7% in the group of patients receiving preventive therapy. In children and adolescents with a persistent positive Mantoux test (for more than 3 years), the response to Diaskintest\u00ae was negative in most cases since in early infection when mycobacteria propagated, the reaction to the drug was positive, but as 3 years pass the probability of the infection transition to the persistence stage is high--at that time the response to Diaskintest\u00ae becomes negative. Diaskintest\u00ae induces no delayed hypersensitivity associated with BCG vaccination, suggesting its high specificity. There were no positive reactions in patients with nonspecific lung diseases.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "bceaab52532745f2b18e2703008352a9", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[16, 16], [80, 80], [67, 67], [21, 21], [58, 58], [93, 93], [106, 106], [213, 213], [180, 180], [137, 137], [265, 265], [241, 241]], "char_spans": [[86, 97], [483, 494], [399, 410], [120, 133], [350, 361], [565, 576], [621, 632], [1248, 1259], [1042, 1053], [798, 809], [1541, 1552], [1411, 1422]]}]}], "context_tokens": [["In", 0], ["Russia", 3], [",", 9], ["an", 11], ["intradermal", 14], ["Diaskintest", 26], ["\u00ae", 37], ["drug", 39], ["has", 44], ["been", 48], ["designed", 53], [",", 61], ["which", 63], ["is", 69], ["a", 72], ["recombinant", 74], ["tuberculosis", 86], ["allergen", 99], ["based", 108], ["on", 114], ["M.", 117], ["tuberculosis--", 120], ["specific", 135], ["proteins", 144], [":", 152], ["ESAT-6", 154], ["and", 161], ["CFP-10", 165], ["produced", 172], ["by", 181], ["a", 184], ["genetically", 186], ["modified", 198], ["Escherichia", 207], ["coli", 219], ["culture", 224], [".", 231], ["Diaskintest", 233], ["\u00ae", 244], ["test", 246], ["and", 251], ["Mantoux", 255], ["test", 263], ["with", 268], ["2TE", 273], ["PPD", 277], ["-", 280], ["L", 281], ["were", 283], ["concurrently", 288], ["carried", 301], ["out", 309], ["in", 313], ["300", 316], ["children", 320], ["and", 329], ["adolescents", 333], ["with", 345], ["tuberculosis", 350], ["and", 363], ["followed", 367], ["up", 376], ["in", 379], ["risk", 382], ["groups", 387], ["at", 394], ["a", 397], ["tuberculosis", 399], ["dispensary", 412], ["to", 423], ["determine", 426], ["the", 436], ["sensitivity", 440], ["of", 452], ["the", 455], ["new", 459], ["skin", 463], ["test", 468], ["in", 473], ["active", 476], ["tuberculosis", 483], ["infection", 496], [".", 505], ["Diaskintest", 507], ["\u00ae", 518], ["showed", 520], ["a", 527], ["high", 529], ["sensitivity", 534], ["not", 546], ["only", 550], ["in", 555], ["active", 558], ["tuberculosis", 565], [",", 577], ["but", 579], ["also", 583], ["in", 588], ["occult", 591], [",", 597], ["the", 599], ["so", 603], ["-", 605], ["called", 606], ["latent", 613], [",", 619], ["tuberculosis", 621], ["infection", 634], [".", 643], ["This", 645], ["is", 650], ["suggested", 653], ["by", 663], ["the", 666], ["following", 670], ["evidence", 680], [".", 688], ["The", 690], ["high", 694], ["percentage", 699], ["(", 710], ["83.8", 711], ["%", 715], [")", 716], ["of", 718], ["positive", 721], ["responses", 730], ["to", 740], ["Diaskintest", 743], ["\u00ae", 754], ["is", 756], ["noted", 759], ["in", 765], ["children", 768], ["and", 777], ["adolescents", 781], ["with", 793], ["tuberculosis", 798], [",", 810], ["receiving", 812], ["an", 822], ["intensive", 825], ["course", 835], ["of", 842], ["chemotherapy", 845], [".", 857], ["Negative", 859], ["tests", 868], ["were", 874], ["observed", 879], ["only", 888], ["in", 893], ["minor", 896], ["forms", 902], ["at", 908], ["the", 911], ["resolution", 915], ["stage", 926], [".", 931], ["In", 933], ["the", 936], ["children", 940], ["who", 949], ["had", 953], ["completed", 957], ["treatment", 967], [",", 976], ["positive", 978], ["tests", 987], ["were", 993], ["seen", 998], ["in", 1003], ["78.3", 1006], ["%", 1010], [",", 1011], ["moreover", 1013], ["in", 1022], ["those", 1025], ["with", 1031], ["prior", 1036], ["tuberculosis", 1042], ["of", 1055], ["intrathoracic", 1058], ["lymph", 1072], ["nodes", 1078], [";", 1083], ["negative", 1085], ["tests", 1094], ["were", 1100], ["observed", 1105], ["not", 1114], ["earlier", 1118], ["than", 1126], ["18", 1131], ["months", 1134], ["after", 1141], ["start", 1147], ["of", 1153], ["treatment", 1156], [".", 1165], ["The", 1167], ["highest", 1171], ["sensitivity", 1179], ["of", 1191], ["Diaskintest", 1194], ["\u00ae", 1205], ["was", 1207], ["shown", 1211], ["in", 1217], ["children", 1220], ["with", 1229], ["early", 1234], ["primary", 1240], ["tuberculosis", 1248], ["infection", 1261], ["and", 1271], ["through", 1275], ["family", 1283], ["contact", 1290], ["with", 1298], ["bacteria", 1303], ["-", 1311], ["excreting", 1312], ["subjects", 1322], ["(", 1331], ["91.7", 1332], ["%", 1336], [")", 1337], [".", 1338], ["These", 1340], ["children", 1346], ["may", 1355], ["be", 1359], ["judged", 1362], ["with", 1369], ["the", 1374], ["highest", 1378], ["assurance", 1386], ["to", 1396], ["have", 1399], ["latent", 1404], ["tuberculosis", 1411], ["infection", 1424], [",", 1433], ["the", 1435], ["population", 1439], ["of", 1450], ["which", 1453], ["is", 1459], ["in", 1462], ["an", 1465], ["active", 1468], ["state", 1475], ["at", 1481], ["the", 1484], ["moment", 1488], ["of", 1495], ["the", 1498], ["study", 1502], [".", 1507], ["The", 1509], ["children", 1513], ["with", 1522], ["early", 1527], ["primary", 1533], ["tuberculosis", 1541], ["infection", 1554], [",", 1563], ["but", 1565], ["in", 1569], ["no", 1572], ["family", 1575], ["contact", 1582], ["with", 1590], ["bacteria", 1595], ["-", 1603], ["excreting", 1604], ["individuals", 1614], [",", 1625], ["showed", 1627], ["a", 1634], ["lower", 1636], ["percentage", 1642], ["of", 1653], ["positive", 1656], ["responses", 1665], ["to", 1675], ["Diaskintest", 1678], ["\u00ae", 1689], ["both", 1691], ["before", 1696], ["(", 1703], ["37.5", 1704], ["%", 1708], [")", 1709], ["and", 1711], ["after", 1715], ["(", 1721], ["10", 1722], ["%", 1724], [")", 1725], ["treatment", 1727], [",", 1736], ["which", 1738], ["suggests", 1744], ["that", 1753], ["there", 1758], ["must", 1764], ["be", 1769], ["a", 1772], ["lower", 1774], ["bacterial", 1780], ["burden", 1790], ["in", 1797], ["the", 1800], ["child", 1804], [".", 1809], ["A", 1811], ["high", 1813], ["percentage", 1818], ["of", 1829], ["positive", 1832], ["responses", 1841], ["to", 1851], ["Diaskintest", 1854], ["\u00ae", 1865], ["(", 1867], ["76.2", 1868], ["%", 1872], [")", 1873], ["were", 1875], ["found", 1880], ["in", 1886], ["subjects", 1889], ["with", 1898], ["hyperergic", 1903], ["reactions", 1914], ["to", 1924], ["tuberculin", 1927], [".", 1937], ["These", 1939], ["were", 1945], ["in", 1950], ["only", 1953], ["16.7", 1958], ["%", 1962], ["in", 1964], ["the", 1967], ["group", 1971], ["of", 1977], ["patients", 1980], ["receiving", 1989], ["preventive", 1999], ["therapy", 2010], [".", 2017], ["In", 2019], ["children", 2022], ["and", 2031], ["adolescents", 2035], ["with", 2047], ["a", 2052], ["persistent", 2054], ["positive", 2065], ["Mantoux", 2074], ["test", 2082], ["(", 2087], ["for", 2088], ["more", 2092], ["than", 2097], ["3", 2102], ["years", 2104], [")", 2109], [",", 2110], ["the", 2112], ["response", 2116], ["to", 2125], ["Diaskintest", 2128], ["\u00ae", 2139], ["was", 2141], ["negative", 2145], ["in", 2154], ["most", 2157], ["cases", 2162], ["since", 2168], ["in", 2174], ["early", 2177], ["infection", 2183], ["when", 2193], ["mycobacteria", 2198], ["propagated", 2211], [",", 2221], ["the", 2223], ["reaction", 2227], ["to", 2236], ["the", 2239], ["drug", 2243], ["was", 2248], ["positive", 2252], [",", 2260], ["but", 2262], ["as", 2266], ["3", 2269], ["years", 2271], ["pass", 2277], ["the", 2282], ["probability", 2286], ["of", 2298], ["the", 2301], ["infection", 2305], ["transition", 2315], ["to", 2326], ["the", 2329], ["persistence", 2333], ["stage", 2345], ["is", 2351], ["high", 2354], ["--", 2358], ["at", 2360], ["that", 2363], ["time", 2368], ["the", 2373], ["response", 2377], ["to", 2386], ["Diaskintest", 2389], ["\u00ae", 2400], ["becomes", 2402], ["negative", 2410], [".", 2418], ["Diaskintest", 2420], ["\u00ae", 2431], ["induces", 2433], ["no", 2441], ["delayed", 2444], ["hypersensitivity", 2452], ["associated", 2469], ["with", 2480], ["BCG", 2485], ["vaccination", 2489], [",", 2500], ["suggesting", 2502], ["its", 2513], ["high", 2517], ["specificity", 2522], [".", 2533], ["There", 2535], ["were", 2541], ["no", 2546], ["positive", 2549], ["reactions", 2558], ["in", 2568], ["patients", 2571], ["with", 2580], ["nonspecific", 2585], ["lung", 2597], ["diseases", 2602], [".", 2610]]}
{"context": "The effects of SEA0400, a selective inhibitor of the Na(+)/Ca(2+) exchanger (NCX), on Na(+)-dependent Ca(2+) uptake and catecholamine (CA) release were examined in bovine adrenal chromaffin cells that were loaded with Na(+) by treatment with ouabain and veratridine. SEA0400 inhibited Na(+)-dependent (45)Ca(2+) uptake and CA release, with the IC(50) values of 40 and 100 nM, respectively. The IC(50) values of another NCX inhibitor KB-R7943 were 1.8 and 3.7 microM, respectively. These results indicate that SEA0400 is about 40 times more potent than KB-R7943 in inhibiting NCX working in the reverse mode. In intact cells, SEA0400 and KB-R7943 inhibited CA release induced by acetylcholine and DMPP. The IC(50) values of SEA0400 were 5.1 and 4.5 microM and the values of KB-R7943 were 2.6 and 2.1 microM against the release induced by acetylcholine and DMPP, respectively, indicating that the potency of SEA0400 is about a half of that of KB-R7943 in inhibiting the nicotinic receptor-mediated CA release. The binding of [(3)H]nicotine with nicotinic receptors was inhibited by SEA0400 (IC(50) = 90 microM) and KB-R7943 (IC(50) = 12 microM). From these results, it is concluded that unlike KB-R7943, SEA0400 has a potent and selective action on NCX in bovine adrenal chromaffin cells.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "5d94e2adbfb64ff1b3a5b25d968b5828", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[10, 13]], "char_spans": [[53, 74]]}, {"text": "NCX", "token_spans": [[81, 81], [111, 111], [15, 15], [249, 249]], "char_spans": [[419, 421], [575, 577], [77, 79], [1247, 1249]]}]}], "context_tokens": [["The", 0], ["effects", 4], ["of", 12], ["SEA0400", 15], [",", 22], ["a", 24], ["selective", 26], ["inhibitor", 36], ["of", 46], ["the", 49], ["Na(+)/Ca(2", 53], ["+", 63], [")", 64], ["exchanger", 66], ["(", 76], ["NCX", 77], [")", 80], [",", 81], ["on", 83], ["Na(+)-dependent", 86], ["Ca(2", 102], ["+", 106], [")", 107], ["uptake", 109], ["and", 116], ["catecholamine", 120], ["(", 134], ["CA", 135], [")", 137], ["release", 139], ["were", 147], ["examined", 152], ["in", 161], ["bovine", 164], ["adrenal", 171], ["chromaffin", 179], ["cells", 190], ["that", 196], ["were", 201], ["loaded", 206], ["with", 213], ["Na(+", 218], [")", 222], ["by", 224], ["treatment", 227], ["with", 237], ["ouabain", 242], ["and", 250], ["veratridine", 254], [".", 265], ["SEA0400", 267], ["inhibited", 275], ["Na(+)-dependent", 285], ["(", 301], ["45)Ca(2", 302], ["+", 309], [")", 310], ["uptake", 312], ["and", 319], ["CA", 323], ["release", 326], [",", 333], ["with", 335], ["the", 340], ["IC(50", 344], [")", 349], ["values", 351], ["of", 358], ["40", 361], ["and", 364], ["100", 368], ["nM", 372], [",", 374], ["respectively", 376], [".", 388], ["The", 390], ["IC(50", 394], [")", 399], ["values", 401], ["of", 408], ["another", 411], ["NCX", 419], ["inhibitor", 423], ["KB", 433], ["-", 435], ["R7943", 436], ["were", 442], ["1.8", 447], ["and", 451], ["3.7", 455], ["microM", 459], [",", 465], ["respectively", 467], [".", 479], ["These", 481], ["results", 487], ["indicate", 495], ["that", 504], ["SEA0400", 509], ["is", 517], ["about", 520], ["40", 526], ["times", 529], ["more", 535], ["potent", 540], ["than", 547], ["KB", 552], ["-", 554], ["R7943", 555], ["in", 561], ["inhibiting", 564], ["NCX", 575], ["working", 579], ["in", 587], ["the", 590], ["reverse", 594], ["mode", 602], [".", 606], ["In", 608], ["intact", 611], ["cells", 618], [",", 623], ["SEA0400", 625], ["and", 633], ["KB", 637], ["-", 639], ["R7943", 640], ["inhibited", 646], ["CA", 656], ["release", 659], ["induced", 667], ["by", 675], ["acetylcholine", 678], ["and", 692], ["DMPP", 696], [".", 700], ["The", 702], ["IC(50", 706], [")", 711], ["values", 713], ["of", 720], ["SEA0400", 723], ["were", 731], ["5.1", 736], ["and", 740], ["4.5", 744], ["microM", 748], ["and", 755], ["the", 759], ["values", 763], ["of", 770], ["KB", 773], ["-", 775], ["R7943", 776], ["were", 782], ["2.6", 787], ["and", 791], ["2.1", 795], ["microM", 799], ["against", 806], ["the", 814], ["release", 818], ["induced", 826], ["by", 834], ["acetylcholine", 837], ["and", 851], ["DMPP", 855], [",", 859], ["respectively", 861], [",", 873], ["indicating", 875], ["that", 886], ["the", 891], ["potency", 895], ["of", 903], ["SEA0400", 906], ["is", 914], ["about", 917], ["a", 923], ["half", 925], ["of", 930], ["that", 933], ["of", 938], ["KB", 941], ["-", 943], ["R7943", 944], ["in", 950], ["inhibiting", 953], ["the", 964], ["nicotinic", 968], ["receptor", 978], ["-", 986], ["mediated", 987], ["CA", 996], ["release", 999], [".", 1006], ["The", 1008], ["binding", 1012], ["of", 1020], ["[", 1023], ["(", 1024], ["3)H]nicotine", 1025], ["with", 1038], ["nicotinic", 1043], ["receptors", 1053], ["was", 1063], ["inhibited", 1067], ["by", 1077], ["SEA0400", 1080], ["(", 1088], ["IC(50", 1089], [")", 1094], ["=", 1096], ["90", 1098], ["microM", 1101], [")", 1107], ["and", 1109], ["KB", 1113], ["-", 1115], ["R7943", 1116], ["(", 1122], ["IC(50", 1123], [")", 1128], ["=", 1130], ["12", 1132], ["microM", 1135], [")", 1141], [".", 1142], ["From", 1144], ["these", 1149], ["results", 1155], [",", 1162], ["it", 1164], ["is", 1167], ["concluded", 1170], ["that", 1180], ["unlike", 1185], ["KB", 1192], ["-", 1194], ["R7943", 1195], [",", 1200], ["SEA0400", 1202], ["has", 1210], ["a", 1214], ["potent", 1216], ["and", 1223], ["selective", 1227], ["action", 1237], ["on", 1244], ["NCX", 1247], ["in", 1251], ["bovine", 1254], ["adrenal", 1261], ["chromaffin", 1269], ["cells", 1280], [".", 1285]]}
{"context": "The pathogenesis of RA is a complex and ever-changing landscape but amid the chaos of the disease process we have found effective treatment regimes. However, our current therapeutics, although targeting various components of both the innate and adaptive immune response, do not result in disease remission. Protein kinase inhibitors are attractive targets due to their ability to influence downstream signalling and their oral bioavailability. Fostamatinib (R788) inhibits spleen tyrosine kinase (Syk) and has been in clinical trials involving both MTX inadequate responders (MTX-IRs) and biologic inadequate responders. Studies on the MTX-IR population revealed ACR20 responses of 67-72% at higher doses (150 mg bd and 100 mg bd), ACR50 responses of 43-57% and ACR70 responses of 28-40%. The trial in the biologic non-responder population showed no efficacy, however, post hoc analyses of the data suggested that a further trial in this population is warranted. The most common adverse events included gastrointestinal effects, hypertension, neutropenia and transaminitis. Many adverse effects were dose responsive and hypertension was amenable to treatment. Upper respiratory tract infections were more likely at higher doses, but no serious infections with tuberculosis, fungi or opportunistic infections were reported. The oral availability of these agents makes them attractive treatment options for our patients, although the literature from the oncology field suggests that patients will only choose the oral route if efficacy is equivalent. Long-term follow-up studies are ongoing and will be critical for rare side effects. The role of these agents in our current arsenal is unclear and economic analyses are awaited.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "817590b6c9a647a5aef10b85199aef9b", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[77, 79]], "char_spans": [[473, 494]]}]}], "context_tokens": [["The", 0], ["pathogenesis", 4], ["of", 17], ["RA", 20], ["is", 23], ["a", 26], ["complex", 28], ["and", 36], ["ever", 40], ["-", 44], ["changing", 45], ["landscape", 54], ["but", 64], ["amid", 68], ["the", 73], ["chaos", 77], ["of", 83], ["the", 86], ["disease", 90], ["process", 98], ["we", 106], ["have", 109], ["found", 114], ["effective", 120], ["treatment", 130], ["regimes", 140], [".", 147], ["However", 149], [",", 156], ["our", 158], ["current", 162], ["therapeutics", 170], [",", 182], ["although", 184], ["targeting", 193], ["various", 203], ["components", 211], ["of", 222], ["both", 225], ["the", 230], ["innate", 234], ["and", 241], ["adaptive", 245], ["immune", 254], ["response", 261], [",", 269], ["do", 271], ["not", 274], ["result", 278], ["in", 285], ["disease", 288], ["remission", 296], [".", 305], ["Protein", 307], ["kinase", 315], ["inhibitors", 322], ["are", 333], ["attractive", 337], ["targets", 348], ["due", 356], ["to", 360], ["their", 363], ["ability", 369], ["to", 377], ["influence", 380], ["downstream", 390], ["signalling", 401], ["and", 412], ["their", 416], ["oral", 422], ["bioavailability", 427], [".", 442], ["Fostamatinib", 444], ["(", 457], ["R788", 458], [")", 462], ["inhibits", 464], ["spleen", 473], ["tyrosine", 480], ["kinase", 489], ["(", 496], ["Syk", 497], [")", 500], ["and", 502], ["has", 506], ["been", 510], ["in", 515], ["clinical", 518], ["trials", 527], ["involving", 534], ["both", 544], ["MTX", 549], ["inadequate", 553], ["responders", 564], ["(", 575], ["MTX", 576], ["-", 579], ["IRs", 580], [")", 583], ["and", 585], ["biologic", 589], ["inadequate", 598], ["responders", 609], [".", 619], ["Studies", 621], ["on", 629], ["the", 632], ["MTX", 636], ["-", 639], ["IR", 640], ["population", 643], ["revealed", 654], ["ACR20", 663], ["responses", 669], ["of", 679], ["67", 682], ["-", 684], ["72", 685], ["%", 687], ["at", 689], ["higher", 692], ["doses", 699], ["(", 705], ["150", 706], ["mg", 710], ["bd", 713], ["and", 716], ["100", 720], ["mg", 724], ["bd", 727], [")", 729], [",", 730], ["ACR50", 732], ["responses", 738], ["of", 748], ["43", 751], ["-", 753], ["57", 754], ["%", 756], ["and", 758], ["ACR70", 762], ["responses", 768], ["of", 778], ["28", 781], ["-", 783], ["40", 784], ["%", 786], [".", 787], ["The", 789], ["trial", 793], ["in", 799], ["the", 802], ["biologic", 806], ["non", 815], ["-", 818], ["responder", 819], ["population", 829], ["showed", 840], ["no", 847], ["efficacy", 850], [",", 858], ["however", 860], [",", 867], ["post", 869], ["hoc", 874], ["analyses", 878], ["of", 887], ["the", 890], ["data", 894], ["suggested", 899], ["that", 909], ["a", 914], ["further", 916], ["trial", 924], ["in", 930], ["this", 933], ["population", 938], ["is", 949], ["warranted", 952], [".", 961], ["The", 963], ["most", 967], ["common", 972], ["adverse", 979], ["events", 987], ["included", 994], ["gastrointestinal", 1003], ["effects", 1020], [",", 1027], ["hypertension", 1029], [",", 1041], ["neutropenia", 1043], ["and", 1055], ["transaminitis", 1059], [".", 1072], ["Many", 1074], ["adverse", 1079], ["effects", 1087], ["were", 1095], ["dose", 1100], ["responsive", 1105], ["and", 1116], ["hypertension", 1120], ["was", 1133], ["amenable", 1137], ["to", 1146], ["treatment", 1149], [".", 1158], ["Upper", 1160], ["respiratory", 1166], ["tract", 1178], ["infections", 1184], ["were", 1195], ["more", 1200], ["likely", 1205], ["at", 1212], ["higher", 1215], ["doses", 1222], [",", 1227], ["but", 1229], ["no", 1233], ["serious", 1236], ["infections", 1244], ["with", 1255], ["tuberculosis", 1260], [",", 1272], ["fungi", 1274], ["or", 1280], ["opportunistic", 1283], ["infections", 1297], ["were", 1308], ["reported", 1313], [".", 1321], ["The", 1323], ["oral", 1327], ["availability", 1332], ["of", 1345], ["these", 1348], ["agents", 1354], ["makes", 1361], ["them", 1367], ["attractive", 1372], ["treatment", 1383], ["options", 1393], ["for", 1401], ["our", 1405], ["patients", 1409], [",", 1417], ["although", 1419], ["the", 1428], ["literature", 1432], ["from", 1443], ["the", 1448], ["oncology", 1452], ["field", 1461], ["suggests", 1467], ["that", 1476], ["patients", 1481], ["will", 1490], ["only", 1495], ["choose", 1500], ["the", 1507], ["oral", 1511], ["route", 1516], ["if", 1522], ["efficacy", 1525], ["is", 1534], ["equivalent", 1537], [".", 1547], ["Long", 1549], ["-", 1553], ["term", 1554], ["follow", 1559], ["-", 1565], ["up", 1566], ["studies", 1569], ["are", 1577], ["ongoing", 1581], ["and", 1589], ["will", 1593], ["be", 1598], ["critical", 1601], ["for", 1610], ["rare", 1614], ["side", 1619], ["effects", 1624], [".", 1631], ["The", 1633], ["role", 1637], ["of", 1642], ["these", 1645], ["agents", 1651], ["in", 1658], ["our", 1661], ["current", 1665], ["arsenal", 1673], ["is", 1681], ["unclear", 1684], ["and", 1692], ["economic", 1696], ["analyses", 1705], ["are", 1714], ["awaited", 1718], [".", 1725]]}
{"context": "We investigated the expression of Na(+)/Ca(2+) exchanger (NCX) and the functional role of NCX in retinal damage by using NCX1-heterozygous deficient mice (NCX1(+/-)) and SEA0400 (2-[4-[(2,5-difluorophenyl)methoxy] phenoxy]-5-ethoxyaniline), a selective NCX inhibitor in vivo. We also examined the role of NCX in oxygen-glucose deprivation (OGD) stress with a retinal ganglion cell line (RGC-5) cell culture in vitro. The expression of NCX1 was confirmed and entirely localized in retina by immunoblotting and immunohistochemistry, respectively. NCX1(+/-) mice possessed significant protection against retinal damage induced by intravitreal injection of N-methyl-D-aspartate (NMDA). SEA0400 at 3 and 10 mg/kg significantly reduced NMDA- or high intraocular pressure-induced retinal cell damage in mice. Furthermore, SEA0400 reduced the number of TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling)-positive cells and the expression of phosphorylated mitogen-activated protein kinases (ERK1/2, JNK, p38) induced by NMDA injection. In RGC-5, SEA0400 at 0.3 and 1 microM significantly inhibited OGD-induced cell damage. OGD-induced cell damage was aggravated by ouabain (a Na(+),K(+)-ATPase inhibitor) at 100 microM, and this increased damage was significantly reduced by SEA0400 at 1 microM. In conclusion, these results suggest that NCX1 may play a role in retinal cell death induced by NMDA and ischemia-reperfusion.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "251f6ff810384420b6df79a29f772ff0", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[5, 8]], "char_spans": [[34, 55]]}, {"text": "NCX", "token_spans": [[40, 40], [17, 17], [51, 51], [10, 10]], "char_spans": [[253, 255], [90, 92], [305, 307], [58, 60]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["expression", 20], ["of", 31], ["Na(+)/Ca(2", 34], ["+", 44], [")", 45], ["exchanger", 47], ["(", 57], ["NCX", 58], [")", 61], ["and", 63], ["the", 67], ["functional", 71], ["role", 82], ["of", 87], ["NCX", 90], ["in", 94], ["retinal", 97], ["damage", 105], ["by", 112], ["using", 115], ["NCX1-heterozygous", 121], ["deficient", 139], ["mice", 149], ["(", 154], ["NCX1(+/-", 155], [")", 163], [")", 164], ["and", 166], ["SEA0400", 170], ["(", 178], ["2-[4-[(2,5-difluorophenyl)methoxy", 179], ["]", 212], ["phenoxy]-5-ethoxyaniline", 214], [")", 238], [",", 239], ["a", 241], ["selective", 243], ["NCX", 253], ["inhibitor", 257], ["in", 267], ["vivo", 270], [".", 274], ["We", 276], ["also", 279], ["examined", 284], ["the", 293], ["role", 297], ["of", 302], ["NCX", 305], ["in", 309], ["oxygen", 312], ["-", 318], ["glucose", 319], ["deprivation", 327], ["(", 339], ["OGD", 340], [")", 343], ["stress", 345], ["with", 352], ["a", 357], ["retinal", 359], ["ganglion", 367], ["cell", 376], ["line", 381], ["(", 386], ["RGC-5", 387], [")", 392], ["cell", 394], ["culture", 399], ["in", 407], ["vitro", 410], [".", 415], ["The", 417], ["expression", 421], ["of", 432], ["NCX1", 435], ["was", 440], ["confirmed", 444], ["and", 454], ["entirely", 458], ["localized", 467], ["in", 477], ["retina", 480], ["by", 487], ["immunoblotting", 490], ["and", 505], ["immunohistochemistry", 509], [",", 529], ["respectively", 531], [".", 543], ["NCX1(+/-", 545], [")", 553], ["mice", 555], ["possessed", 560], ["significant", 570], ["protection", 582], ["against", 593], ["retinal", 601], ["damage", 609], ["induced", 616], ["by", 624], ["intravitreal", 627], ["injection", 640], ["of", 650], ["N", 653], ["-", 654], ["methyl", 655], ["-", 661], ["D", 662], ["-", 663], ["aspartate", 664], ["(", 674], ["NMDA", 675], [")", 679], [".", 680], ["SEA0400", 682], ["at", 690], ["3", 693], ["and", 695], ["10", 699], ["mg", 702], ["/", 704], ["kg", 705], ["significantly", 708], ["reduced", 722], ["NMDA-", 730], ["or", 736], ["high", 739], ["intraocular", 744], ["pressure", 756], ["-", 764], ["induced", 765], ["retinal", 773], ["cell", 781], ["damage", 786], ["in", 793], ["mice", 796], [".", 800], ["Furthermore", 802], [",", 813], ["SEA0400", 815], ["reduced", 823], ["the", 831], ["number", 835], ["of", 842], ["TUNEL", 845], ["(", 851], ["terminal", 852], ["deoxynucleotidyl", 861], ["transferase", 878], ["dUTP", 890], ["nick", 895], ["-", 899], ["end", 900], ["labeling)-positive", 904], ["cells", 923], ["and", 929], ["the", 933], ["expression", 937], ["of", 948], ["phosphorylated", 951], ["mitogen", 966], ["-", 973], ["activated", 974], ["protein", 984], ["kinases", 992], ["(", 1000], ["ERK1/2", 1001], [",", 1007], ["JNK", 1009], [",", 1012], ["p38", 1014], [")", 1017], ["induced", 1019], ["by", 1027], ["NMDA", 1030], ["injection", 1035], [".", 1044], ["In", 1046], ["RGC-5", 1049], [",", 1054], ["SEA0400", 1056], ["at", 1064], ["0.3", 1067], ["and", 1071], ["1", 1075], ["microM", 1077], ["significantly", 1084], ["inhibited", 1098], ["OGD", 1108], ["-", 1111], ["induced", 1112], ["cell", 1120], ["damage", 1125], [".", 1131], ["OGD", 1133], ["-", 1136], ["induced", 1137], ["cell", 1145], ["damage", 1150], ["was", 1157], ["aggravated", 1161], ["by", 1172], ["ouabain", 1175], ["(", 1183], ["a", 1184], ["Na(+),K(+)-ATPase", 1186], ["inhibitor", 1204], [")", 1213], ["at", 1215], ["100", 1218], ["microM", 1222], [",", 1228], ["and", 1230], ["this", 1234], ["increased", 1239], ["damage", 1249], ["was", 1256], ["significantly", 1260], ["reduced", 1274], ["by", 1282], ["SEA0400", 1285], ["at", 1293], ["1", 1296], ["microM.", 1298], ["In", 1306], ["conclusion", 1309], [",", 1319], ["these", 1321], ["results", 1327], ["suggest", 1335], ["that", 1343], ["NCX1", 1348], ["may", 1353], ["play", 1357], ["a", 1362], ["role", 1364], ["in", 1369], ["retinal", 1372], ["cell", 1380], ["death", 1385], ["induced", 1391], ["by", 1399], ["NMDA", 1402], ["and", 1407], ["ischemia", 1411], ["-", 1419], ["reperfusion", 1420], [".", 1431]]}
{"context": "Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-\u03baB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid.", "qas": [{"question": "Which is the target of the drug Denosumab?", "answers": ["receptor activator of nuclear factor-\u03baB ligand", "RANKL"], "qid": "ce4f694e2894496cb11f3d96bd206a41", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["the", 23], ["drug", 27], ["Denosumab", 32], ["?", 41]], "detected_answers": [{"text": "receptor activator of nuclear factor-\u03baB ligand", "token_spans": [[79, 86]], "char_spans": [[432, 477]]}, {"text": "RANKL", "token_spans": [[88, 88], [112, 112]], "char_spans": [[480, 484], [601, 605]]}]}], "context_tokens": [["Giant", 0], ["-", 5], ["cell", 6], ["tumor", 11], ["of", 17], ["bone", 20], ["is", 25], ["a", 28], ["rare", 30], [",", 34], ["locally", 36], ["aggressive", 44], ["tumor", 55], ["that", 61], ["typically", 66], ["occurs", 76], ["in", 83], ["the", 86], ["bones", 90], ["of", 96], ["skeletally", 99], ["mature", 110], ["young", 117], ["adults", 123], ["in", 130], ["their", 133], ["second", 139], ["to", 146], ["fourth", 149], ["decades", 156], [".", 163], ["Traditionally", 165], [",", 178], ["surgery", 180], ["has", 188], ["been", 192], ["the", 197], ["mainstay", 201], ["of", 210], ["therapy", 213], ["for", 221], ["this", 225], ["disease", 230], [",", 237], ["but", 239], ["the", 243], ["disease", 247], ["can", 255], ["recur", 259], ["even", 265], ["with", 270], ["optimal", 275], ["procedures", 283], [".", 293], ["Furthermore", 295], [",", 306], ["it", 308], ["may", 311], ["occur", 315], ["in", 321], ["locations", 324], ["where", 334], ["a", 340], ["surgical", 342], ["approach", 351], ["would", 360], ["be", 366], ["morbid", 369], [".", 375], ["The", 377], ["maturation", 381], ["of", 392], ["the", 395], ["understanding", 399], ["of", 413], ["the", 416], ["role", 420], ["of", 425], ["the", 428], ["receptor", 432], ["activator", 441], ["of", 451], ["nuclear", 454], ["factor", 462], ["-", 468], ["\u03baB", 469], ["ligand", 472], ["(", 479], ["RANKL", 480], [")", 485], ["in", 487], ["the", 490], ["pathophysiology", 494], ["of", 510], ["giant", 513], ["-", 518], ["cell", 519], ["tumor", 524], ["of", 530], ["bone", 533], ["has", 538], ["led", 542], ["to", 546], ["the", 549], ["use", 553], ["of", 557], ["denosumab", 560], [",", 569], ["a", 571], ["monoclonal", 573], ["antibody", 584], ["against", 593], ["RANKL", 601], [",", 606], ["in", 608], ["this", 611], ["disease", 616], [".", 623], ["In", 625], ["2013", 628], [",", 632], ["the", 634], ["US", 638], ["Food", 641], ["and", 646], ["Drug", 650], ["Administration", 655], ["approved", 670], ["denosumab", 679], ["for", 689], ["use", 693], ["in", 697], ["patients", 700], ["with", 709], ["recurrent", 714], ["/", 723], ["unresectable", 724], ["/", 736], ["metastatic", 737], ["giant", 748], ["-", 753], ["cell", 754], ["tumor", 759], ["of", 765], ["bone", 768], ["or", 773], ["for", 776], ["patients", 780], ["in", 789], ["whom", 792], ["surgery", 797], ["would", 805], ["be", 811], ["morbid", 814], [".", 820]]}
{"context": "Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is a clinically and genetically heterogeneous neuromuscular disorder. DM is characterized by autosomal dominant inheritance, muscular dystrophy, myotonia, and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)(n) expansion in the 3' untranslated region of DMPK in 19q13.3. Multiple families, predominantly of German descent and with clinically variable presentation that included proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed linkage to the 3q21 region and were recently shown to segregate a (CCTG)(n) expansion mutation in intron 1 of ZNF9. Here, we present linkage to 3q21 and mutational confirmation in 17 kindreds of European origin with PROMM and proximal myotonic dystrophy, from geographically distinct populations. All patients have the DM2 (CCTG)(n) expansion. To study the evolution of this mutation, we constructed a comprehensive physical map of the DM2 region around ZNF9. High-resolution haplotype analysis of disease chromosomes with five microsatellite and 22 single-nucleotide polymorphism markers around the DM2 mutation identified extensive linkage disequilibrium and a single shared haplotype of at least 132 kb among patients from the different populations. With the exception of the (CCTG)(n) expansion, the available markers indicate that the DM2 haplotype is identical to the most common haplotype in normal individuals. This situation is reminiscent of that seen in DM1. Taken together, these data suggest a single founding mutation in DM2 patients of European origin. We estimate the age of the founding haplotype and of the DM2 (CCTG) expansion mutation to be approximately 200-540 generations.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "3dff550077ca471a8137430b2d11722c", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[29, 30]], "char_spans": [[172, 189]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["(", 19], ["DM", 20], [")", 22], [",", 23], ["the", 25], ["most", 29], ["common", 34], ["form", 41], ["of", 46], ["muscular", 49], ["dystrophy", 58], ["in", 68], ["adults", 71], [",", 77], ["is", 79], ["a", 82], ["clinically", 84], ["and", 95], ["genetically", 99], ["heterogeneous", 111], ["neuromuscular", 125], ["disorder", 139], [".", 147], ["DM", 149], ["is", 152], ["characterized", 155], ["by", 169], ["autosomal", 172], ["dominant", 182], ["inheritance", 191], [",", 202], ["muscular", 204], ["dystrophy", 213], [",", 222], ["myotonia", 224], [",", 232], ["and", 234], ["multisystem", 238], ["involvement", 250], [".", 261], ["Type", 263], ["1", 268], ["DM", 270], ["(", 273], ["DM1", 274], [")", 277], ["is", 279], ["caused", 282], ["by", 289], ["a", 292], ["(", 294], ["CTG)(n", 295], [")", 301], ["expansion", 303], ["in", 313], ["the", 316], ["3", 320], ["'", 321], ["untranslated", 323], ["region", 336], ["of", 343], ["DMPK", 346], ["in", 351], ["19q13.3", 354], [".", 361], ["Multiple", 363], ["families", 372], [",", 380], ["predominantly", 382], ["of", 396], ["German", 399], ["descent", 406], ["and", 414], ["with", 418], ["clinically", 423], ["variable", 434], ["presentation", 443], ["that", 456], ["included", 461], ["proximal", 470], ["myotonic", 479], ["myopathy", 488], ["(", 497], ["PROMM", 498], [")", 503], ["and", 505], ["type", 509], ["2", 514], ["DM", 516], ["(", 519], ["DM2", 520], [")", 523], ["but", 525], ["without", 529], ["the", 537], ["DM1", 541], ["mutation", 545], [",", 553], ["showed", 555], ["linkage", 562], ["to", 570], ["the", 573], ["3q21", 577], ["region", 582], ["and", 589], ["were", 593], ["recently", 598], ["shown", 607], ["to", 613], ["segregate", 616], ["a", 626], ["(", 628], ["CCTG)(n", 629], [")", 636], ["expansion", 638], ["mutation", 648], ["in", 657], ["intron", 660], ["1", 667], ["of", 669], ["ZNF9", 672], [".", 676], ["Here", 678], [",", 682], ["we", 684], ["present", 687], ["linkage", 695], ["to", 703], ["3q21", 706], ["and", 711], ["mutational", 715], ["confirmation", 726], ["in", 739], ["17", 742], ["kindreds", 745], ["of", 754], ["European", 757], ["origin", 766], ["with", 773], ["PROMM", 778], ["and", 784], ["proximal", 788], ["myotonic", 797], ["dystrophy", 806], [",", 815], ["from", 817], ["geographically", 822], ["distinct", 837], ["populations", 846], [".", 857], ["All", 859], ["patients", 863], ["have", 872], ["the", 877], ["DM2", 881], ["(", 885], ["CCTG)(n", 886], [")", 893], ["expansion", 895], [".", 904], ["To", 906], ["study", 909], ["the", 915], ["evolution", 919], ["of", 929], ["this", 932], ["mutation", 937], [",", 945], ["we", 947], ["constructed", 950], ["a", 962], ["comprehensive", 964], ["physical", 978], ["map", 987], ["of", 991], ["the", 994], ["DM2", 998], ["region", 1002], ["around", 1009], ["ZNF9", 1016], [".", 1020], ["High", 1022], ["-", 1026], ["resolution", 1027], ["haplotype", 1038], ["analysis", 1048], ["of", 1057], ["disease", 1060], ["chromosomes", 1068], ["with", 1080], ["five", 1085], ["microsatellite", 1090], ["and", 1105], ["22", 1109], ["single", 1112], ["-", 1118], ["nucleotide", 1119], ["polymorphism", 1130], ["markers", 1143], ["around", 1151], ["the", 1158], ["DM2", 1162], ["mutation", 1166], ["identified", 1175], ["extensive", 1186], ["linkage", 1196], ["disequilibrium", 1204], ["and", 1219], ["a", 1223], ["single", 1225], ["shared", 1232], ["haplotype", 1239], ["of", 1249], ["at", 1252], ["least", 1255], ["132", 1261], ["kb", 1265], ["among", 1268], ["patients", 1274], ["from", 1283], ["the", 1288], ["different", 1292], ["populations", 1302], [".", 1313], ["With", 1315], ["the", 1320], ["exception", 1324], ["of", 1334], ["the", 1337], ["(", 1341], ["CCTG)(n", 1342], [")", 1349], ["expansion", 1351], [",", 1360], ["the", 1362], ["available", 1366], ["markers", 1376], ["indicate", 1384], ["that", 1393], ["the", 1398], ["DM2", 1402], ["haplotype", 1406], ["is", 1416], ["identical", 1419], ["to", 1429], ["the", 1432], ["most", 1436], ["common", 1441], ["haplotype", 1448], ["in", 1458], ["normal", 1461], ["individuals", 1468], [".", 1479], ["This", 1481], ["situation", 1486], ["is", 1496], ["reminiscent", 1499], ["of", 1511], ["that", 1514], ["seen", 1519], ["in", 1524], ["DM1", 1527], [".", 1530], ["Taken", 1532], ["together", 1538], [",", 1546], ["these", 1548], ["data", 1554], ["suggest", 1559], ["a", 1567], ["single", 1569], ["founding", 1576], ["mutation", 1585], ["in", 1594], ["DM2", 1597], ["patients", 1601], ["of", 1610], ["European", 1613], ["origin", 1622], [".", 1628], ["We", 1630], ["estimate", 1633], ["the", 1642], ["age", 1646], ["of", 1650], ["the", 1653], ["founding", 1657], ["haplotype", 1666], ["and", 1676], ["of", 1680], ["the", 1683], ["DM2", 1687], ["(", 1691], ["CCTG", 1692], [")", 1696], ["expansion", 1698], ["mutation", 1708], ["to", 1717], ["be", 1720], ["approximately", 1723], ["200", 1737], ["-", 1740], ["540", 1741], ["generations", 1745], [".", 1756]]}
{"context": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides. Prx2 is the third most abundant protein in erythrocytes, and competes effectively with catalase and glutathione peroxidase to scavenge low levels of hydrogen peroxide, including that derived from hemoglobin autoxidation. Low thioredoxin reductase activity in the erythrocyte is able to keep up with this basal oxidation and maintain the Prx2 in its reduced form, but exposure to exogenous hydrogen peroxide causes accumulation of the disulfide-linked dimer. The high cellular concentration means that although turnover is slow, erythrocyte Prx2 can act as a noncatalytic scavenger of hydrogen peroxide and a sink for hydrogen peroxide before turnover becomes limiting. The consequences of Prx2 oxidation for the erythrocyte are not well characterized, but mice deficient in this protein develop severe hemolytic anemia associated with Heinz body formation. Prx2, also known as calpromotin, regulates ion transport by associating with the membrane and activating the G\u00e1rdos channel. How Prx2 redox transformations are linked to membrane association and channel activation is yet to be established. In this review, we discuss the functional properties of Prx2 and its role as a major component of the erythrocyte antioxidant system.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "26a83e722adc4516a5e0f6a8f7c8caaa", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[212, 212], [7, 7]], "char_spans": [[1311, 1321], [29, 39]]}]}], "context_tokens": [["Peroxiredoxin", 0], ["2", 14], ["(", 16], ["Prx2", 17], [")", 21], ["is", 23], ["an", 26], ["antioxidant", 29], ["enzyme", 41], ["that", 48], ["uses", 53], ["cysteine", 58], ["residues", 67], ["to", 76], ["decompose", 79], ["peroxides", 89], [".", 98], ["Prx2", 100], ["is", 105], ["the", 108], ["third", 112], ["most", 118], ["abundant", 123], ["protein", 132], ["in", 140], ["erythrocytes", 143], [",", 155], ["and", 157], ["competes", 161], ["effectively", 170], ["with", 182], ["catalase", 187], ["and", 196], ["glutathione", 200], ["peroxidase", 212], ["to", 223], ["scavenge", 226], ["low", 235], ["levels", 239], ["of", 246], ["hydrogen", 249], ["peroxide", 258], [",", 266], ["including", 268], ["that", 278], ["derived", 283], ["from", 291], ["hemoglobin", 296], ["autoxidation", 307], [".", 319], ["Low", 321], ["thioredoxin", 325], ["reductase", 337], ["activity", 347], ["in", 356], ["the", 359], ["erythrocyte", 363], ["is", 375], ["able", 378], ["to", 383], ["keep", 386], ["up", 391], ["with", 394], ["this", 399], ["basal", 404], ["oxidation", 410], ["and", 420], ["maintain", 424], ["the", 433], ["Prx2", 437], ["in", 442], ["its", 445], ["reduced", 449], ["form", 457], [",", 461], ["but", 463], ["exposure", 467], ["to", 476], ["exogenous", 479], ["hydrogen", 489], ["peroxide", 498], ["causes", 507], ["accumulation", 514], ["of", 527], ["the", 530], ["disulfide", 534], ["-", 543], ["linked", 544], ["dimer", 551], [".", 556], ["The", 558], ["high", 562], ["cellular", 567], ["concentration", 576], ["means", 590], ["that", 596], ["although", 601], ["turnover", 610], ["is", 619], ["slow", 622], [",", 626], ["erythrocyte", 628], ["Prx2", 640], ["can", 645], ["act", 649], ["as", 653], ["a", 656], ["noncatalytic", 658], ["scavenger", 671], ["of", 681], ["hydrogen", 684], ["peroxide", 693], ["and", 702], ["a", 706], ["sink", 708], ["for", 713], ["hydrogen", 717], ["peroxide", 726], ["before", 735], ["turnover", 742], ["becomes", 751], ["limiting", 759], [".", 767], ["The", 769], ["consequences", 773], ["of", 786], ["Prx2", 789], ["oxidation", 794], ["for", 804], ["the", 808], ["erythrocyte", 812], ["are", 824], ["not", 828], ["well", 832], ["characterized", 837], [",", 850], ["but", 852], ["mice", 856], ["deficient", 861], ["in", 871], ["this", 874], ["protein", 879], ["develop", 887], ["severe", 895], ["hemolytic", 902], ["anemia", 912], ["associated", 919], ["with", 930], ["Heinz", 935], ["body", 941], ["formation", 946], [".", 955], ["Prx2", 957], [",", 961], ["also", 963], ["known", 968], ["as", 974], ["calpromotin", 977], [",", 988], ["regulates", 990], ["ion", 1000], ["transport", 1004], ["by", 1014], ["associating", 1017], ["with", 1029], ["the", 1034], ["membrane", 1038], ["and", 1047], ["activating", 1051], ["the", 1062], ["G\u00e1rdos", 1066], ["channel", 1073], [".", 1080], ["How", 1082], ["Prx2", 1086], ["redox", 1091], ["transformations", 1097], ["are", 1113], ["linked", 1117], ["to", 1124], ["membrane", 1127], ["association", 1136], ["and", 1148], ["channel", 1152], ["activation", 1160], ["is", 1171], ["yet", 1174], ["to", 1178], ["be", 1181], ["established", 1184], [".", 1195], ["In", 1197], ["this", 1200], ["review", 1205], [",", 1211], ["we", 1213], ["discuss", 1216], ["the", 1224], ["functional", 1228], ["properties", 1239], ["of", 1250], ["Prx2", 1253], ["and", 1258], ["its", 1262], ["role", 1266], ["as", 1271], ["a", 1274], ["major", 1276], ["component", 1282], ["of", 1292], ["the", 1295], ["erythrocyte", 1299], ["antioxidant", 1311], ["system", 1323], [".", 1329]]}
{"context": "To elucidate the phenotype, genotype, and MRI findings of Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and mutation carriers. The authors studied 40 members of nine unrelated Korean CADASIL families. After genetic analysis of Notch3, clinical and MRI findings were correlated in 27 mutation carriers. Notch3 mutation sites were C174R (one family, n = 3), R133C (one family, n = 3), R587C (one family, n = 1), R544C (two families, n = 5), and R75P (four families, n = 15). The clinical features were typical of CADASIL, but the frequency of migraine in the Korean population appears low. MRI abnormalities were found in 54% of the mutant carriers, the most common being white matter hyperintensities. The prevalence of lacunes and microbleeds increased with patient age. Anterior temporal areas were less often involved in subjects with R75P mutations than in those where mutations occurred in other sites (p = 0.02). Gradient echo imaging identified microbleedings in 33% of mutation carriers (64% of those with abnormal MRI), whereas diffusion-weighted MRI showed abnormal findings in only one patient. Neurologic disability was related to the number of lacunar infarcts and the lesion volume of white matter hyperintensities (p < 0.001) whereas MMSE score was related to the number of lacunar infarcts (p < 0.005). Although Korean cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) mutation carriers show similar clinical and MRI findings, these abnormalities appear less frequently than in other populations. Relatively frequent microbleedings on gradient echo imaging suggest that treatment should be individualized according to MRI findings. The novel mutation of R75P, not involving a cysteine residue, is related to less frequent involvement of the anterior temporal area, thus broadening the spectrum of CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "ea472668bef643f08d9793d914e6370d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[326, 326]], "char_spans": [[1818, 1825]]}]}], "context_tokens": [["To", 0], ["elucidate", 3], ["the", 13], ["phenotype", 17], [",", 26], ["genotype", 28], [",", 36], ["and", 38], ["MRI", 42], ["findings", 46], ["of", 55], ["Korean", 58], ["patients", 65], ["with", 74], ["cerebral", 79], ["autosomal", 88], ["dominant", 98], ["arteriopathy", 107], ["with", 120], ["subcortical", 125], ["infarcts", 137], ["and", 146], ["leukoencephalopathy", 150], ["(", 170], ["CADASIL", 171], [")", 178], ["and", 180], ["mutation", 184], ["carriers", 193], [".", 201], ["The", 203], ["authors", 207], ["studied", 215], ["40", 223], ["members", 226], ["of", 234], ["nine", 237], ["unrelated", 242], ["Korean", 252], ["CADASIL", 259], ["families", 267], [".", 275], ["After", 277], ["genetic", 283], ["analysis", 291], ["of", 300], ["Notch3", 303], [",", 309], ["clinical", 311], ["and", 320], ["MRI", 324], ["findings", 328], ["were", 337], ["correlated", 342], ["in", 353], ["27", 356], ["mutation", 359], ["carriers", 368], [".", 376], ["Notch3", 378], ["mutation", 385], ["sites", 394], ["were", 400], ["C174R", 405], ["(", 411], ["one", 412], ["family", 416], [",", 422], ["n", 424], ["=", 426], ["3", 428], [")", 429], [",", 430], ["R133C", 432], ["(", 438], ["one", 439], ["family", 443], [",", 449], ["n", 451], ["=", 453], ["3", 455], [")", 456], [",", 457], ["R587C", 459], ["(", 465], ["one", 466], ["family", 470], [",", 476], ["n", 478], ["=", 480], ["1", 482], [")", 483], [",", 484], ["R544C", 486], ["(", 492], ["two", 493], ["families", 497], [",", 505], ["n", 507], ["=", 509], ["5", 511], [")", 512], [",", 513], ["and", 515], ["R75P", 519], ["(", 524], ["four", 525], ["families", 530], [",", 538], ["n", 540], ["=", 542], ["15", 544], [")", 546], [".", 547], ["The", 549], ["clinical", 553], ["features", 562], ["were", 571], ["typical", 576], ["of", 584], ["CADASIL", 587], [",", 594], ["but", 596], ["the", 600], ["frequency", 604], ["of", 614], ["migraine", 617], ["in", 626], ["the", 629], ["Korean", 633], ["population", 640], ["appears", 651], ["low", 659], [".", 662], ["MRI", 664], ["abnormalities", 668], ["were", 682], ["found", 687], ["in", 693], ["54", 696], ["%", 698], ["of", 700], ["the", 703], ["mutant", 707], ["carriers", 714], [",", 722], ["the", 724], ["most", 728], ["common", 733], ["being", 740], ["white", 746], ["matter", 752], ["hyperintensities", 759], [".", 775], ["The", 777], ["prevalence", 781], ["of", 792], ["lacunes", 795], ["and", 803], ["microbleeds", 807], ["increased", 819], ["with", 829], ["patient", 834], ["age", 842], [".", 845], ["Anterior", 847], ["temporal", 856], ["areas", 865], ["were", 871], ["less", 876], ["often", 881], ["involved", 887], ["in", 896], ["subjects", 899], ["with", 908], ["R75P", 913], ["mutations", 918], ["than", 928], ["in", 933], ["those", 936], ["where", 942], ["mutations", 948], ["occurred", 958], ["in", 967], ["other", 970], ["sites", 976], ["(", 982], ["p", 983], ["=", 985], ["0.02", 987], [")", 991], [".", 992], ["Gradient", 994], ["echo", 1003], ["imaging", 1008], ["identified", 1016], ["microbleedings", 1027], ["in", 1042], ["33", 1045], ["%", 1047], ["of", 1049], ["mutation", 1052], ["carriers", 1061], ["(", 1070], ["64", 1071], ["%", 1073], ["of", 1075], ["those", 1078], ["with", 1084], ["abnormal", 1089], ["MRI", 1098], [")", 1101], [",", 1102], ["whereas", 1104], ["diffusion", 1112], ["-", 1121], ["weighted", 1122], ["MRI", 1131], ["showed", 1135], ["abnormal", 1142], ["findings", 1151], ["in", 1160], ["only", 1163], ["one", 1168], ["patient", 1172], [".", 1179], ["Neurologic", 1181], ["disability", 1192], ["was", 1203], ["related", 1207], ["to", 1215], ["the", 1218], ["number", 1222], ["of", 1229], ["lacunar", 1232], ["infarcts", 1240], ["and", 1249], ["the", 1253], ["lesion", 1257], ["volume", 1264], ["of", 1271], ["white", 1274], ["matter", 1280], ["hyperintensities", 1287], ["(", 1304], ["p", 1305], ["<", 1307], ["0.001", 1309], [")", 1314], ["whereas", 1316], ["MMSE", 1324], ["score", 1329], ["was", 1335], ["related", 1339], ["to", 1347], ["the", 1350], ["number", 1354], ["of", 1361], ["lacunar", 1364], ["infarcts", 1372], ["(", 1381], ["p", 1382], ["<", 1384], ["0.005", 1386], [")", 1391], [".", 1392], ["Although", 1394], ["Korean", 1403], ["cerebral", 1410], ["autosomal", 1419], ["dominant", 1429], ["arteriopathy", 1438], ["with", 1451], ["subcortical", 1456], ["infarcts", 1468], ["and", 1477], ["leukoencephalopathy", 1481], ["(", 1501], ["CADASIL", 1502], [")", 1509], ["mutation", 1511], ["carriers", 1520], ["show", 1529], ["similar", 1534], ["clinical", 1542], ["and", 1551], ["MRI", 1555], ["findings", 1559], [",", 1567], ["these", 1569], ["abnormalities", 1575], ["appear", 1589], ["less", 1596], ["frequently", 1601], ["than", 1612], ["in", 1617], ["other", 1620], ["populations", 1626], [".", 1637], ["Relatively", 1639], ["frequent", 1650], ["microbleedings", 1659], ["on", 1674], ["gradient", 1677], ["echo", 1686], ["imaging", 1691], ["suggest", 1699], ["that", 1707], ["treatment", 1712], ["should", 1722], ["be", 1729], ["individualized", 1732], ["according", 1747], ["to", 1757], ["MRI", 1760], ["findings", 1764], [".", 1772], ["The", 1774], ["novel", 1778], ["mutation", 1784], ["of", 1793], ["R75P", 1796], [",", 1800], ["not", 1802], ["involving", 1806], ["a", 1816], ["cysteine", 1818], ["residue", 1827], [",", 1834], ["is", 1836], ["related", 1839], ["to", 1847], ["less", 1850], ["frequent", 1855], ["involvement", 1864], ["of", 1876], ["the", 1879], ["anterior", 1883], ["temporal", 1892], ["area", 1901], [",", 1905], ["thus", 1907], ["broadening", 1912], ["the", 1923], ["spectrum", 1927], ["of", 1936], ["CADASIL", 1939], [".", 1946]]}
{"context": "Batten disease (juvenile-onset neuronal ceroid lipofuscinosis, JNCL), the most common neurodegenerative disorder of childhood, is caused by mutations in a recently identified gene ( CLN3 ) localized to chromosome 16p11.2-12.1. To elucidate the biosynthesis and localization of the CLN3 protein, we expressed CLN3 cDNA in COS-1 and HeLa cell lines. In vitro translation, immunoprecipitation and Western blotting analyses detected an approximately 43 kDa polypeptide. Pulse-chase experiments indicated that the CLN3 protein is synthesized as an N -glycosylated single-chain polypeptide, which was not detected in growth medium. Confocal immunofluorescence microscopy revealed that the CLN3 protein is localized to the lysosomal compartment. These results provide evidence that Batten disease can be classified as a member of lysosomal diseases.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "4a70e96cd685482787d78a9a40f450ca", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[0, 1], [126, 127]], "char_spans": [[0, 13], [775, 788]]}, {"text": "juvenile-onset neuronal ceroid lipofuscinosis", "token_spans": [[3, 8]], "char_spans": [[16, 60]]}, {"text": "JNCL", "token_spans": [[10, 10]], "char_spans": [[63, 66]]}]}], "context_tokens": [["Batten", 0], ["disease", 7], ["(", 15], ["juvenile", 16], ["-", 24], ["onset", 25], ["neuronal", 31], ["ceroid", 40], ["lipofuscinosis", 47], [",", 61], ["JNCL", 63], [")", 67], [",", 68], ["the", 70], ["most", 74], ["common", 79], ["neurodegenerative", 86], ["disorder", 104], ["of", 113], ["childhood", 116], [",", 125], ["is", 127], ["caused", 130], ["by", 137], ["mutations", 140], ["in", 150], ["a", 153], ["recently", 155], ["identified", 164], ["gene", 175], ["(", 180], ["CLN3", 182], [")", 187], ["localized", 189], ["to", 199], ["chromosome", 202], ["16p11.2", 213], ["-", 220], ["12.1", 221], [".", 225], ["To", 227], ["elucidate", 230], ["the", 240], ["biosynthesis", 244], ["and", 257], ["localization", 261], ["of", 274], ["the", 277], ["CLN3", 281], ["protein", 286], [",", 293], ["we", 295], ["expressed", 298], ["CLN3", 308], ["cDNA", 313], ["in", 318], ["COS-1", 321], ["and", 327], ["HeLa", 331], ["cell", 336], ["lines", 341], [".", 346], ["In", 348], ["vitro", 351], ["translation", 357], [",", 368], ["immunoprecipitation", 370], ["and", 390], ["Western", 394], ["blotting", 402], ["analyses", 411], ["detected", 420], ["an", 429], ["approximately", 432], ["43", 446], ["kDa", 449], ["polypeptide", 453], [".", 464], ["Pulse", 466], ["-", 471], ["chase", 472], ["experiments", 478], ["indicated", 490], ["that", 500], ["the", 505], ["CLN3", 509], ["protein", 514], ["is", 522], ["synthesized", 525], ["as", 537], ["an", 540], ["N", 543], ["-glycosylated", 545], ["single", 559], ["-", 565], ["chain", 566], ["polypeptide", 572], [",", 583], ["which", 585], ["was", 591], ["not", 595], ["detected", 599], ["in", 608], ["growth", 611], ["medium", 618], [".", 624], ["Confocal", 626], ["immunofluorescence", 635], ["microscopy", 654], ["revealed", 665], ["that", 674], ["the", 679], ["CLN3", 683], ["protein", 688], ["is", 696], ["localized", 699], ["to", 709], ["the", 712], ["lysosomal", 716], ["compartment", 726], [".", 737], ["These", 739], ["results", 745], ["provide", 753], ["evidence", 761], ["that", 770], ["Batten", 775], ["disease", 782], ["can", 790], ["be", 794], ["classified", 797], ["as", 808], ["a", 811], ["member", 813], ["of", 820], ["lysosomal", 823], ["diseases", 833], [".", 841]]}
{"context": "Transcription coupled repair (TCR) is a nucleotide excision repair (NER) pathway that is dedicated to repair in the transcribed strand of an active gene. The genome overall NER is called global genomic repair (GGR). Elc1, the yeast homolog of the mammalian elongation factor elongin C, has been shown to be a component of a ubiquitin ligase complex that contains Rad7 and Rad16, two factors that are specifically required for GGR. Elc1 has also been suggested to be present in another ubiquitin ligase complex that lacks Rad7 and Rad16 and is involved in UV-induced ubiquitylation and subsequent degradation of RNA polymerase II. Here we show that elc1 deletion increases UV sensitivity of TCR-deficient cells but does not affect the UV sensitivity of otherwise wild type and GGR-deficient cells. Cells deleted for elc1 show normal NER in the transcribed strand of an active gene but have no detectable NER in the non-transcribed strand. Elc1 does not affect UV-induced mutagenesis when TCR is operative, but plays an important role in preventing the mutagenesis if TCR is defective. Furthermore, the levels of Rad7 and Rad16 proteins are not significantly decreased in elc1 cells, and overexpression of Rad7 and Rad16 individually or simultaneously in elc1 cells does not restore repair in the non-transcribed strand of an active gene. Our results suggest that Elc1 has no function in TCR but plays an important role in GGR. Furthermore, the role of Elc1 in GGR may not be subsidiary to that of Rad7 and Rad16.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "e0f30444851747c08e3a6c06ba0be328", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[156, 157], [22, 23], [238, 239], [171, 172]], "char_spans": [[843, 860], [116, 133], [1299, 1316], [918, 935]]}]}], "context_tokens": [["Transcription", 0], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["a", 38], ["nucleotide", 40], ["excision", 51], ["repair", 60], ["(", 67], ["NER", 68], [")", 71], ["pathway", 73], ["that", 81], ["is", 86], ["dedicated", 89], ["to", 99], ["repair", 102], ["in", 109], ["the", 112], ["transcribed", 116], ["strand", 128], ["of", 135], ["an", 138], ["active", 141], ["gene", 148], [".", 152], ["The", 154], ["genome", 158], ["overall", 165], ["NER", 173], ["is", 177], ["called", 180], ["global", 187], ["genomic", 194], ["repair", 202], ["(", 209], ["GGR", 210], [")", 213], [".", 214], ["Elc1", 216], [",", 220], ["the", 222], ["yeast", 226], ["homolog", 232], ["of", 240], ["the", 243], ["mammalian", 247], ["elongation", 257], ["factor", 268], ["elongin", 275], ["C", 283], [",", 284], ["has", 286], ["been", 290], ["shown", 295], ["to", 301], ["be", 304], ["a", 307], ["component", 309], ["of", 319], ["a", 322], ["ubiquitin", 324], ["ligase", 334], ["complex", 341], ["that", 349], ["contains", 354], ["Rad7", 363], ["and", 368], ["Rad16", 372], [",", 377], ["two", 379], ["factors", 383], ["that", 391], ["are", 396], ["specifically", 400], ["required", 413], ["for", 422], ["GGR", 426], [".", 429], ["Elc1", 431], ["has", 436], ["also", 440], ["been", 445], ["suggested", 450], ["to", 460], ["be", 463], ["present", 466], ["in", 474], ["another", 477], ["ubiquitin", 485], ["ligase", 495], ["complex", 502], ["that", 510], ["lacks", 515], ["Rad7", 521], ["and", 526], ["Rad16", 530], ["and", 536], ["is", 540], ["involved", 543], ["in", 552], ["UV", 555], ["-", 557], ["induced", 558], ["ubiquitylation", 566], ["and", 581], ["subsequent", 585], ["degradation", 596], ["of", 608], ["RNA", 611], ["polymerase", 615], ["II", 626], [".", 628], ["Here", 630], ["we", 635], ["show", 638], ["that", 643], ["elc1", 648], ["deletion", 653], ["increases", 662], ["UV", 672], ["sensitivity", 675], ["of", 687], ["TCR", 690], ["-", 693], ["deficient", 694], ["cells", 704], ["but", 710], ["does", 714], ["not", 719], ["affect", 723], ["the", 730], ["UV", 734], ["sensitivity", 737], ["of", 749], ["otherwise", 752], ["wild", 762], ["type", 767], ["and", 772], ["GGR", 776], ["-", 779], ["deficient", 780], ["cells", 790], [".", 795], ["Cells", 797], ["deleted", 803], ["for", 811], ["elc1", 815], ["show", 820], ["normal", 825], ["NER", 832], ["in", 836], ["the", 839], ["transcribed", 843], ["strand", 855], ["of", 862], ["an", 865], ["active", 868], ["gene", 875], ["but", 880], ["have", 884], ["no", 889], ["detectable", 892], ["NER", 903], ["in", 907], ["the", 910], ["non", 914], ["-", 917], ["transcribed", 918], ["strand", 930], [".", 936], ["Elc1", 938], ["does", 943], ["not", 948], ["affect", 952], ["UV", 959], ["-", 961], ["induced", 962], ["mutagenesis", 970], ["when", 982], ["TCR", 987], ["is", 991], ["operative", 994], [",", 1003], ["but", 1005], ["plays", 1009], ["an", 1015], ["important", 1018], ["role", 1028], ["in", 1033], ["preventing", 1036], ["the", 1047], ["mutagenesis", 1051], ["if", 1063], ["TCR", 1066], ["is", 1070], ["defective", 1073], [".", 1082], ["Furthermore", 1084], [",", 1095], ["the", 1097], ["levels", 1101], ["of", 1108], ["Rad7", 1111], ["and", 1116], ["Rad16", 1120], ["proteins", 1126], ["are", 1135], ["not", 1139], ["significantly", 1143], ["decreased", 1157], ["in", 1167], ["elc1", 1170], ["cells", 1175], [",", 1180], ["and", 1182], ["overexpression", 1186], ["of", 1201], ["Rad7", 1204], ["and", 1209], ["Rad16", 1213], ["individually", 1219], ["or", 1232], ["simultaneously", 1235], ["in", 1250], ["elc1", 1253], ["cells", 1258], ["does", 1264], ["not", 1269], ["restore", 1273], ["repair", 1281], ["in", 1288], ["the", 1291], ["non", 1295], ["-", 1298], ["transcribed", 1299], ["strand", 1311], ["of", 1318], ["an", 1321], ["active", 1324], ["gene", 1331], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["Elc1", 1362], ["has", 1367], ["no", 1371], ["function", 1374], ["in", 1383], ["TCR", 1386], ["but", 1390], ["plays", 1394], ["an", 1400], ["important", 1403], ["role", 1413], ["in", 1418], ["GGR", 1421], [".", 1424], ["Furthermore", 1426], [",", 1437], ["the", 1439], ["role", 1443], ["of", 1448], ["Elc1", 1451], ["in", 1456], ["GGR", 1459], ["may", 1463], ["not", 1467], ["be", 1471], ["subsidiary", 1474], ["to", 1485], ["that", 1488], ["of", 1493], ["Rad7", 1496], ["and", 1501], ["Rad16", 1505], [".", 1510]]}
{"context": "A proteomic study predicted that about one hundred kinds of proteins constitute a basic structure of the centrosome. Most of the core centrosomal proteins contain extensive coiled-coil domains, suggesting that the protein-protein interaction is a critical force for the core centrosome configuration. In the present study, we investigated a novel interaction between CEP135 and C-NAP1, two core centriolar proteins. Depletion of CEP135 caused a premature centrosome splitting. Reduction of the centrosomal C-NAP1 level was accompanied in a specific manner. Ectopic expression of the CEP135 mutant proteins also caused centrosome splitting in association with the reduction of the centrosomal C-NAP1 levels. Based on these results, we propose that CEP135 acts as a platform protein for C-NAP1 at the centriole.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "ed3f5c3a0167499384a5f2031c714e92", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[104, 104], [17, 17], [77, 77], [46, 46]], "char_spans": [[618, 627], [105, 114], [455, 464], [275, 284]]}]}], "context_tokens": [["A", 0], ["proteomic", 2], ["study", 12], ["predicted", 18], ["that", 28], ["about", 33], ["one", 39], ["hundred", 43], ["kinds", 51], ["of", 57], ["proteins", 60], ["constitute", 69], ["a", 80], ["basic", 82], ["structure", 88], ["of", 98], ["the", 101], ["centrosome", 105], [".", 115], ["Most", 117], ["of", 122], ["the", 125], ["core", 129], ["centrosomal", 134], ["proteins", 146], ["contain", 155], ["extensive", 163], ["coiled", 173], ["-", 179], ["coil", 180], ["domains", 185], [",", 192], ["suggesting", 194], ["that", 205], ["the", 210], ["protein", 214], ["-", 221], ["protein", 222], ["interaction", 230], ["is", 242], ["a", 245], ["critical", 247], ["force", 256], ["for", 262], ["the", 266], ["core", 270], ["centrosome", 275], ["configuration", 286], [".", 299], ["In", 301], ["the", 304], ["present", 308], ["study", 316], [",", 321], ["we", 323], ["investigated", 326], ["a", 339], ["novel", 341], ["interaction", 347], ["between", 359], ["CEP135", 367], ["and", 374], ["C", 378], ["-", 379], ["NAP1", 380], [",", 384], ["two", 386], ["core", 390], ["centriolar", 395], ["proteins", 406], [".", 414], ["Depletion", 416], ["of", 426], ["CEP135", 429], ["caused", 436], ["a", 443], ["premature", 445], ["centrosome", 455], ["splitting", 466], [".", 475], ["Reduction", 477], ["of", 487], ["the", 490], ["centrosomal", 494], ["C", 506], ["-", 507], ["NAP1", 508], ["level", 513], ["was", 519], ["accompanied", 523], ["in", 535], ["a", 538], ["specific", 540], ["manner", 549], [".", 555], ["Ectopic", 557], ["expression", 565], ["of", 576], ["the", 579], ["CEP135", 583], ["mutant", 590], ["proteins", 597], ["also", 606], ["caused", 611], ["centrosome", 618], ["splitting", 629], ["in", 639], ["association", 642], ["with", 654], ["the", 659], ["reduction", 663], ["of", 673], ["the", 676], ["centrosomal", 680], ["C", 692], ["-", 693], ["NAP1", 694], ["levels", 699], [".", 705], ["Based", 707], ["on", 713], ["these", 716], ["results", 722], [",", 729], ["we", 731], ["propose", 734], ["that", 742], ["CEP135", 747], ["acts", 754], ["as", 759], ["a", 762], ["platform", 764], ["protein", 773], ["for", 781], ["C", 785], ["-", 786], ["NAP1", 787], ["at", 792], ["the", 795], ["centriole", 799], [".", 808]]}
{"context": "7,8-Dihydro-8-oxoguanine (8-oxoG) is the most frequent mutagenic lesion caused by oxidative stress. Eukaryotic cells use a specific DNA glycosylase, OGG1, to excise 8-oxoG from DNA. The mild phenotype of OGG1 null mice has been attributed to the existence of alternative pathways, including Cockayne syndrome B (CSB)-dependent transcription coupled repair (TCR), for removal of 8-oxoG. We have studied repair and transcription activities at 8-oxoG lesions with a reconstituted transcription system (RTS; RNA polymerase II, TBP, TFIIA, TFIIB, TFIIE, TFIIF and TFIIH), as well as in cellular extracts and in vivo. All measurable repair activity at 8-oxoG lesions takes place in the 3'-direction from the lesion, indicating base excision repair (BER) activity and negligible role of nucleotide excision repair (NER). Although 8-oxoG has been shown to be preferentially removed from the transcribed strand, in vitro experiments with purified transcription factors failed to identify a definite block for RNA polymerase II at the lesion. However, a weak block was observed at the lesion during transcription carried out with RTS as well as with cellular extracts. RNA polymerase II was identified at the site of the lesion on obstructed templates. Wild-type cells, as well as cells carrying targeted mutations of genes required for removal of 8-oxoG, were transfected with a luciferase expression vector containing an 8-oxoG lesion. No significant obstruction at 8-oxoG lesions was observed by this in vivo approach. In control experiments transcription elongation was completely blocked by cisplatin.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "efd1383cd601413086509fe1a865e7fd", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[156, 157]], "char_spans": [[883, 900]]}]}], "context_tokens": [["7,8-Dihydro-8-oxoguanine", 0], ["(", 25], ["8-oxoG", 26], [")", 32], ["is", 34], ["the", 37], ["most", 41], ["frequent", 46], ["mutagenic", 55], ["lesion", 65], ["caused", 72], ["by", 79], ["oxidative", 82], ["stress", 92], [".", 98], ["Eukaryotic", 100], ["cells", 111], ["use", 117], ["a", 121], ["specific", 123], ["DNA", 132], ["glycosylase", 136], [",", 147], ["OGG1", 149], [",", 153], ["to", 155], ["excise", 158], ["8-oxoG", 165], ["from", 172], ["DNA", 177], [".", 180], ["The", 182], ["mild", 186], ["phenotype", 191], ["of", 201], ["OGG1", 204], ["null", 209], ["mice", 214], ["has", 219], ["been", 223], ["attributed", 228], ["to", 239], ["the", 242], ["existence", 246], ["of", 256], ["alternative", 259], ["pathways", 271], [",", 279], ["including", 281], ["Cockayne", 291], ["syndrome", 300], ["B", 309], ["(", 311], ["CSB)-dependent", 312], ["transcription", 327], ["coupled", 341], ["repair", 349], ["(", 356], ["TCR", 357], [")", 360], [",", 361], ["for", 363], ["removal", 367], ["of", 375], ["8-oxoG.", 378], ["We", 386], ["have", 389], ["studied", 394], ["repair", 402], ["and", 409], ["transcription", 413], ["activities", 427], ["at", 438], ["8-oxoG", 441], ["lesions", 448], ["with", 456], ["a", 461], ["reconstituted", 463], ["transcription", 477], ["system", 491], ["(", 498], ["RTS", 499], [";", 502], ["RNA", 504], ["polymerase", 508], ["II", 519], [",", 521], ["TBP", 523], [",", 526], ["TFIIA", 528], [",", 533], ["TFIIB", 535], [",", 540], ["TFIIE", 542], [",", 547], ["TFIIF", 549], ["and", 555], ["TFIIH", 559], [")", 564], [",", 565], ["as", 567], ["well", 570], ["as", 575], ["in", 578], ["cellular", 581], ["extracts", 590], ["and", 599], ["in", 603], ["vivo", 606], [".", 610], ["All", 612], ["measurable", 616], ["repair", 627], ["activity", 634], ["at", 643], ["8-oxoG", 646], ["lesions", 653], ["takes", 661], ["place", 667], ["in", 673], ["the", 676], ["3'-direction", 680], ["from", 693], ["the", 698], ["lesion", 702], [",", 708], ["indicating", 710], ["base", 721], ["excision", 726], ["repair", 735], ["(", 742], ["BER", 743], [")", 746], ["activity", 748], ["and", 757], ["negligible", 761], ["role", 772], ["of", 777], ["nucleotide", 780], ["excision", 791], ["repair", 800], ["(", 807], ["NER", 808], [")", 811], [".", 812], ["Although", 814], ["8-oxoG", 823], ["has", 830], ["been", 834], ["shown", 839], ["to", 845], ["be", 848], ["preferentially", 851], ["removed", 866], ["from", 874], ["the", 879], ["transcribed", 883], ["strand", 895], [",", 901], ["in", 903], ["vitro", 906], ["experiments", 912], ["with", 924], ["purified", 929], ["transcription", 938], ["factors", 952], ["failed", 960], ["to", 967], ["identify", 970], ["a", 979], ["definite", 981], ["block", 990], ["for", 996], ["RNA", 1000], ["polymerase", 1004], ["II", 1015], ["at", 1018], ["the", 1021], ["lesion", 1025], [".", 1031], ["However", 1033], [",", 1040], ["a", 1042], ["weak", 1044], ["block", 1049], ["was", 1055], ["observed", 1059], ["at", 1068], ["the", 1071], ["lesion", 1075], ["during", 1082], ["transcription", 1089], ["carried", 1103], ["out", 1111], ["with", 1115], ["RTS", 1120], ["as", 1124], ["well", 1127], ["as", 1132], ["with", 1135], ["cellular", 1140], ["extracts", 1149], [".", 1157], ["RNA", 1159], ["polymerase", 1163], ["II", 1174], ["was", 1177], ["identified", 1181], ["at", 1192], ["the", 1195], ["site", 1199], ["of", 1204], ["the", 1207], ["lesion", 1211], ["on", 1218], ["obstructed", 1221], ["templates", 1232], [".", 1241], ["Wild", 1243], ["-", 1247], ["type", 1248], ["cells", 1253], [",", 1258], ["as", 1260], ["well", 1263], ["as", 1268], ["cells", 1271], ["carrying", 1277], ["targeted", 1286], ["mutations", 1295], ["of", 1305], ["genes", 1308], ["required", 1314], ["for", 1323], ["removal", 1327], ["of", 1335], ["8-oxoG", 1338], [",", 1344], ["were", 1346], ["transfected", 1351], ["with", 1363], ["a", 1368], ["luciferase", 1370], ["expression", 1381], ["vector", 1392], ["containing", 1399], ["an", 1410], ["8-oxoG", 1413], ["lesion", 1420], [".", 1426], ["No", 1428], ["significant", 1431], ["obstruction", 1443], ["at", 1455], ["8-oxoG", 1458], ["lesions", 1465], ["was", 1473], ["observed", 1477], ["by", 1486], ["this", 1489], ["in", 1494], ["vivo", 1497], ["approach", 1502], [".", 1510], ["In", 1512], ["control", 1515], ["experiments", 1523], ["transcription", 1535], ["elongation", 1549], ["was", 1560], ["completely", 1564], ["blocked", 1575], ["by", 1583], ["cisplatin", 1586], [".", 1595]]}
{"context": "The methylation of lysine residues of histones plays a pivotal role in the regulation of chromatin structure and gene expression. Here, we report two crystal structures of SET7/9, a histone methyltransferase (HMTase) that transfers methyl groups to Lys4 of histone H3, in complex with S-adenosyl-L-methionine (AdoMet) determined at 1.7 and 2.3 A resolution. The structures reveal an active site consisting of: (i) a binding pocket between the SET domain and a c-SET helix where an AdoMet molecule in an unusual conformation binds; (ii) a narrow substrate-specific channel that only unmethylated lysine residues can access; and (iii) a catalytic tyrosine residue. The methyl group of AdoMet is directed to the narrow channel where a substrate lysine enters from the opposite side. We demonstrate that SET7/9 can transfer two but not three methyl groups to unmodified Lys4 of H3 without substrate dissociation. The unusual features of the SET domain-containing HMTase discriminate between the un- and methylated lysine substrate, and the methylation sites for the histone H3 tail.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "56ed50d7657b481ea0e2512c19bb0438", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[85, 86], [176, 177]], "char_spans": [[443, 452], [937, 946]]}]}], "context_tokens": [["The", 0], ["methylation", 4], ["of", 16], ["lysine", 19], ["residues", 26], ["of", 35], ["histones", 38], ["plays", 47], ["a", 53], ["pivotal", 55], ["role", 63], ["in", 68], ["the", 71], ["regulation", 75], ["of", 86], ["chromatin", 89], ["structure", 99], ["and", 109], ["gene", 113], ["expression", 118], [".", 128], ["Here", 130], [",", 134], ["we", 136], ["report", 139], ["two", 146], ["crystal", 150], ["structures", 158], ["of", 169], ["SET7/9", 172], [",", 178], ["a", 180], ["histone", 182], ["methyltransferase", 190], ["(", 208], ["HMTase", 209], [")", 215], ["that", 217], ["transfers", 222], ["methyl", 232], ["groups", 239], ["to", 246], ["Lys4", 249], ["of", 254], ["histone", 257], ["H3", 265], [",", 267], ["in", 269], ["complex", 272], ["with", 280], ["S", 285], ["-", 286], ["adenosyl", 287], ["-", 295], ["L", 296], ["-", 297], ["methionine", 298], ["(", 309], ["AdoMet", 310], [")", 316], ["determined", 318], ["at", 329], ["1.7", 332], ["and", 336], ["2.3", 340], ["A", 344], ["resolution", 346], [".", 356], ["The", 358], ["structures", 362], ["reveal", 373], ["an", 380], ["active", 383], ["site", 390], ["consisting", 395], ["of", 406], [":", 408], ["(", 410], ["i", 411], [")", 412], ["a", 414], ["binding", 416], ["pocket", 424], ["between", 431], ["the", 439], ["SET", 443], ["domain", 447], ["and", 454], ["a", 458], ["c", 460], ["-", 461], ["SET", 462], ["helix", 466], ["where", 472], ["an", 478], ["AdoMet", 481], ["molecule", 488], ["in", 497], ["an", 500], ["unusual", 503], ["conformation", 511], ["binds", 524], [";", 529], ["(", 531], ["ii", 532], [")", 534], ["a", 536], ["narrow", 538], ["substrate", 545], ["-", 554], ["specific", 555], ["channel", 564], ["that", 572], ["only", 577], ["unmethylated", 582], ["lysine", 595], ["residues", 602], ["can", 611], ["access", 615], [";", 621], ["and", 623], ["(", 627], ["iii", 628], [")", 631], ["a", 633], ["catalytic", 635], ["tyrosine", 645], ["residue", 654], [".", 661], ["The", 663], ["methyl", 667], ["group", 674], ["of", 680], ["AdoMet", 683], ["is", 690], ["directed", 693], ["to", 702], ["the", 705], ["narrow", 709], ["channel", 716], ["where", 724], ["a", 730], ["substrate", 732], ["lysine", 742], ["enters", 749], ["from", 756], ["the", 761], ["opposite", 765], ["side", 774], [".", 778], ["We", 780], ["demonstrate", 783], ["that", 795], ["SET7/9", 800], ["can", 807], ["transfer", 811], ["two", 820], ["but", 824], ["not", 828], ["three", 832], ["methyl", 838], ["groups", 845], ["to", 852], ["unmodified", 855], ["Lys4", 866], ["of", 871], ["H3", 874], ["without", 877], ["substrate", 885], ["dissociation", 895], [".", 907], ["The", 909], ["unusual", 913], ["features", 921], ["of", 930], ["the", 933], ["SET", 937], ["domain", 941], ["-", 947], ["containing", 948], ["HMTase", 959], ["discriminate", 966], ["between", 979], ["the", 987], ["un-", 991], ["and", 995], ["methylated", 999], ["lysine", 1010], ["substrate", 1017], [",", 1026], ["and", 1028], ["the", 1032], ["methylation", 1036], ["sites", 1048], ["for", 1054], ["the", 1058], ["histone", 1062], ["H3", 1070], ["tail", 1073], [".", 1077]]}
{"context": "Ehlers-Danlos syndrome (EDS), a heterogeneous group of inheritable connective tissue disorders, is attributed to mutations in connective tissue genes. These mutations cause defects in collagen. Collagen, a connective tissue protein that acts like glue, gives strength to the body and provides support and elasticity for movement. Thus, the altered gene affects the mechanical properties of skin, joints, ligaments, and blood vessels. Ehlers-Danlos syndrome is transmitted through autosomal dominant, autosomal recessive, or x-linked patterns of inheritance. The life expectancy of an affected infant varies with the type of EDS. This article provides an overview of the 6 major classifications of EDS, their unique clinical presentations, a focused physical assessment guide, considerations for nursing care, and resources for parents. Ehlers-Danlos syndrome can be a potentially debilitating syndrome. It requires preventative and protective measures starting at birth to preserve joint function to improve infant outcomes. Caring for patients with EDS requires an understanding of the potential associated complications to help minimize the physical and emotional impact of the syndrome and improve the quality of life for affected individuals.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "10f8119b74f94e56b81c9c59ad105093", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14], [36, 37], [22, 23]], "char_spans": [[67, 83], [206, 222], [126, 142]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["(", 23], ["EDS", 24], [")", 27], [",", 28], ["a", 30], ["heterogeneous", 32], ["group", 46], ["of", 52], ["inheritable", 55], ["connective", 67], ["tissue", 78], ["disorders", 85], [",", 94], ["is", 96], ["attributed", 99], ["to", 110], ["mutations", 113], ["in", 123], ["connective", 126], ["tissue", 137], ["genes", 144], [".", 149], ["These", 151], ["mutations", 157], ["cause", 167], ["defects", 173], ["in", 181], ["collagen", 184], [".", 192], ["Collagen", 194], [",", 202], ["a", 204], ["connective", 206], ["tissue", 217], ["protein", 224], ["that", 232], ["acts", 237], ["like", 242], ["glue", 247], [",", 251], ["gives", 253], ["strength", 259], ["to", 268], ["the", 271], ["body", 275], ["and", 280], ["provides", 284], ["support", 293], ["and", 301], ["elasticity", 305], ["for", 316], ["movement", 320], [".", 328], ["Thus", 330], [",", 334], ["the", 336], ["altered", 340], ["gene", 348], ["affects", 353], ["the", 361], ["mechanical", 365], ["properties", 376], ["of", 387], ["skin", 390], [",", 394], ["joints", 396], [",", 402], ["ligaments", 404], [",", 413], ["and", 415], ["blood", 419], ["vessels", 425], [".", 432], ["Ehlers", 434], ["-", 440], ["Danlos", 441], ["syndrome", 448], ["is", 457], ["transmitted", 460], ["through", 472], ["autosomal", 480], ["dominant", 490], [",", 498], ["autosomal", 500], ["recessive", 510], [",", 519], ["or", 521], ["x", 524], ["-", 525], ["linked", 526], ["patterns", 533], ["of", 542], ["inheritance", 545], [".", 556], ["The", 558], ["life", 562], ["expectancy", 567], ["of", 578], ["an", 581], ["affected", 584], ["infant", 593], ["varies", 600], ["with", 607], ["the", 612], ["type", 616], ["of", 621], ["EDS", 624], [".", 627], ["This", 629], ["article", 634], ["provides", 642], ["an", 651], ["overview", 654], ["of", 663], ["the", 666], ["6", 670], ["major", 672], ["classifications", 678], ["of", 694], ["EDS", 697], [",", 700], ["their", 702], ["unique", 708], ["clinical", 715], ["presentations", 724], [",", 737], ["a", 739], ["focused", 741], ["physical", 749], ["assessment", 758], ["guide", 769], [",", 774], ["considerations", 776], ["for", 791], ["nursing", 795], ["care", 803], [",", 807], ["and", 809], ["resources", 813], ["for", 823], ["parents", 827], [".", 834], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], ["can", 859], ["be", 863], ["a", 866], ["potentially", 868], ["debilitating", 880], ["syndrome", 893], [".", 901], ["It", 903], ["requires", 906], ["preventative", 915], ["and", 928], ["protective", 932], ["measures", 943], ["starting", 952], ["at", 961], ["birth", 964], ["to", 970], ["preserve", 973], ["joint", 982], ["function", 988], ["to", 997], ["improve", 1000], ["infant", 1008], ["outcomes", 1015], [".", 1023], ["Caring", 1025], ["for", 1032], ["patients", 1036], ["with", 1045], ["EDS", 1050], ["requires", 1054], ["an", 1063], ["understanding", 1066], ["of", 1080], ["the", 1083], ["potential", 1087], ["associated", 1097], ["complications", 1108], ["to", 1122], ["help", 1125], ["minimize", 1130], ["the", 1139], ["physical", 1143], ["and", 1152], ["emotional", 1156], ["impact", 1166], ["of", 1173], ["the", 1176], ["syndrome", 1180], ["and", 1189], ["improve", 1193], ["the", 1201], ["quality", 1205], ["of", 1213], ["life", 1216], ["for", 1221], ["affected", 1225], ["individuals", 1234], [".", 1245]]}
{"context": "To assess the pharmacokinetics of dapivirine in plasma and dapivirine concentrations in cervicovaginal fluids (CVF) and cervicovaginal tissues following vaginal administration of dapivirine microbicide gel in healthy, HIV-negative women for 10 days. A randomized, double-blind, phase I study was conducted at a single research center in South Africa. A total of 18 women used dapivirine gel (0.001%, 0.005%, or 0.02%) once daily on Days 1 and 10 and twice daily on Days 2-9. Pharmacokinetics of dapivirine were assessed in plasma on Days 1 and 10. Dapivirine concentrations were measured in CVF on Days 1 and 10 and in cervicovaginal tissues on Day 10. Safety was evaluated through laboratory tests (hematology, clinical chemistry, and urinalysis), physical examinations, and assessment of adverse events. Plasma concentrations of dapivirine increased over time with gel dose and were greater on Day 10 (C(max) 31 to 471\u2009pg/ml) than Day 1 (C(max) 23 to 80\u2009pg/ml). T(max) was 10-12\u2009h on Day 1, and 9\u2009h on Day 10. Concentrations in CVF generally increased with dose but were highly variable among participants. Mean peak values ranged from 4.6-8.3\u2009\u00d7\u200910(6) pg/ml on Day 1 and from 2.3-20.7\u2009\u00d7\u200910(6) pg/ml on Day 10 across dose groups. Dapivirine was detectable in all tissue biopsies on Day 10 at concentrations of 1.0-356\u2009\u00d7\u200910(3) pg/mg. Dapivirine was widely distributed throughout the lower genital tract with low systemic absorption when administered in a vaginal gel formulation for 10 consecutive days. The gel was safe and well tolerated.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "8e635a9039f64438813f3959150c7590", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[30, 30]], "char_spans": [[218, 220]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["pharmacokinetics", 14], ["of", 31], ["dapivirine", 34], ["in", 45], ["plasma", 48], ["and", 55], ["dapivirine", 59], ["concentrations", 70], ["in", 85], ["cervicovaginal", 88], ["fluids", 103], ["(", 110], ["CVF", 111], [")", 114], ["and", 116], ["cervicovaginal", 120], ["tissues", 135], ["following", 143], ["vaginal", 153], ["administration", 161], ["of", 176], ["dapivirine", 179], ["microbicide", 190], ["gel", 202], ["in", 206], ["healthy", 209], [",", 216], ["HIV", 218], ["-", 221], ["negative", 222], ["women", 231], ["for", 237], ["10", 241], ["days", 244], [".", 248], ["A", 250], ["randomized", 252], [",", 262], ["double", 264], ["-", 270], ["blind", 271], [",", 276], ["phase", 278], ["I", 284], ["study", 286], ["was", 292], ["conducted", 296], ["at", 306], ["a", 309], ["single", 311], ["research", 318], ["center", 327], ["in", 334], ["South", 337], ["Africa", 343], [".", 349], ["A", 351], ["total", 353], ["of", 359], ["18", 362], ["women", 365], ["used", 371], ["dapivirine", 376], ["gel", 387], ["(", 391], ["0.001", 392], ["%", 397], [",", 398], ["0.005", 400], ["%", 405], [",", 406], ["or", 408], ["0.02", 411], ["%", 415], [")", 416], ["once", 418], ["daily", 423], ["on", 429], ["Days", 432], ["1", 437], ["and", 439], ["10", 443], ["and", 446], ["twice", 450], ["daily", 456], ["on", 462], ["Days", 465], ["2", 470], ["-", 471], ["9", 472], [".", 473], ["Pharmacokinetics", 475], ["of", 492], ["dapivirine", 495], ["were", 506], ["assessed", 511], ["in", 520], ["plasma", 523], ["on", 530], ["Days", 533], ["1", 538], ["and", 540], ["10", 544], [".", 546], ["Dapivirine", 548], ["concentrations", 559], ["were", 574], ["measured", 579], ["in", 588], ["CVF", 591], ["on", 595], ["Days", 598], ["1", 603], ["and", 605], ["10", 609], ["and", 612], ["in", 616], ["cervicovaginal", 619], ["tissues", 634], ["on", 642], ["Day", 645], ["10", 649], [".", 651], ["Safety", 653], ["was", 660], ["evaluated", 664], ["through", 674], ["laboratory", 682], ["tests", 693], ["(", 699], ["hematology", 700], [",", 710], ["clinical", 712], ["chemistry", 721], [",", 730], ["and", 732], ["urinalysis", 736], [")", 746], [",", 747], ["physical", 749], ["examinations", 758], [",", 770], ["and", 772], ["assessment", 776], ["of", 787], ["adverse", 790], ["events", 798], [".", 804], ["Plasma", 806], ["concentrations", 813], ["of", 828], ["dapivirine", 831], ["increased", 842], ["over", 852], ["time", 857], ["with", 862], ["gel", 867], ["dose", 871], ["and", 876], ["were", 880], ["greater", 885], ["on", 893], ["Day", 896], ["10", 900], ["(", 903], ["C(max", 904], [")", 909], ["31", 911], ["to", 914], ["471", 917], ["pg", 921], ["/", 923], ["ml", 924], [")", 926], ["than", 928], ["Day", 933], ["1", 937], ["(", 939], ["C(max", 940], [")", 945], ["23", 947], ["to", 950], ["80", 953], ["pg", 956], ["/", 958], ["ml", 959], [")", 961], [".", 962], ["T(max", 964], [")", 969], ["was", 971], ["10", 975], ["-", 977], ["12", 978], ["h", 981], ["on", 983], ["Day", 986], ["1", 990], [",", 991], ["and", 993], ["9", 997], ["h", 999], ["on", 1001], ["Day", 1004], ["10", 1008], [".", 1010], ["Concentrations", 1012], ["in", 1027], ["CVF", 1030], ["generally", 1034], ["increased", 1044], ["with", 1054], ["dose", 1059], ["but", 1064], ["were", 1068], ["highly", 1073], ["variable", 1080], ["among", 1089], ["participants", 1095], [".", 1107], ["Mean", 1109], ["peak", 1114], ["values", 1119], ["ranged", 1126], ["from", 1133], ["4.6", 1138], ["-", 1141], ["8.3", 1142], ["\u00d7", 1146], ["10(6", 1148], [")", 1152], ["pg", 1154], ["/", 1156], ["ml", 1157], ["on", 1160], ["Day", 1163], ["1", 1167], ["and", 1169], ["from", 1173], ["2.3", 1178], ["-", 1181], ["20.7", 1182], ["\u00d7", 1187], ["10(6", 1189], [")", 1193], ["pg", 1195], ["/", 1197], ["ml", 1198], ["on", 1201], ["Day", 1204], ["10", 1208], ["across", 1211], ["dose", 1218], ["groups", 1223], [".", 1229], ["Dapivirine", 1231], ["was", 1242], ["detectable", 1246], ["in", 1257], ["all", 1260], ["tissue", 1264], ["biopsies", 1271], ["on", 1280], ["Day", 1283], ["10", 1287], ["at", 1290], ["concentrations", 1293], ["of", 1308], ["1.0", 1311], ["-", 1314], ["356", 1315], ["\u00d7", 1319], ["10(3", 1321], [")", 1325], ["pg", 1327], ["/", 1329], ["mg", 1330], [".", 1332], ["Dapivirine", 1334], ["was", 1345], ["widely", 1349], ["distributed", 1356], ["throughout", 1368], ["the", 1379], ["lower", 1383], ["genital", 1389], ["tract", 1397], ["with", 1403], ["low", 1408], ["systemic", 1412], ["absorption", 1421], ["when", 1432], ["administered", 1437], ["in", 1450], ["a", 1453], ["vaginal", 1455], ["gel", 1463], ["formulation", 1467], ["for", 1479], ["10", 1483], ["consecutive", 1486], ["days", 1498], [".", 1502], ["The", 1504], ["gel", 1508], ["was", 1512], ["safe", 1516], ["and", 1521], ["well", 1525], ["tolerated", 1530], [".", 1539]]}
{"context": "The susceptibility to arbekacin (ABK) of methicillin-resistant Staphylococcus aureus (MRSA) was investigated to find out how it related to aac(6')/aph(2\") gene. In 49 isolates of MRSA for which MIC of ABK ranged from 0.125 to 64 micrograms/ml, the MICs of ABK for 38 strains carrying aac(6')/aph(2\") gene were widely distributed from 0.25 to 64, whereas those for 11 strains without that gene were all < or = 0.5 microgram/ml. Residual rate of ABK activity was higher than that of gentamicin after the reaction with each crude enzyme preparation extracted from 3 isolates of MRSA, carrying aac(6')/aph(2\") and aad(4',4\") genes. Furthermore, 97 strains of MRSA isolated at Kanagawa prefecture in Japan in 1999 were all sensitive to ABK, although 28 strains of them carried aac(6')/aph(2\") gene. These results showed that ABK resistance was not necessarily related to carrying aac(6')/aph(2\") gene in clinical isolates of MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c28f41488c09478c988e4e82f733d188", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[14, 14], [128, 128], [34, 34], [174, 174], [111, 111]], "char_spans": [[86, 89], [655, 658], [179, 182], [920, 923], [575, 578]]}]}], "context_tokens": [["The", 0], ["susceptibility", 4], ["to", 19], ["arbekacin", 22], ["(", 32], ["ABK", 33], [")", 36], ["of", 38], ["methicillin", 41], ["-", 52], ["resistant", 53], ["Staphylococcus", 63], ["aureus", 78], ["(", 85], ["MRSA", 86], [")", 90], ["was", 92], ["investigated", 96], ["to", 109], ["find", 112], ["out", 117], ["how", 121], ["it", 125], ["related", 128], ["to", 136], ["aac(6')/aph(2", 139], ["\"", 152], [")", 153], ["gene", 155], [".", 159], ["In", 161], ["49", 164], ["isolates", 167], ["of", 176], ["MRSA", 179], ["for", 184], ["which", 188], ["MIC", 194], ["of", 198], ["ABK", 201], ["ranged", 205], ["from", 212], ["0.125", 217], ["to", 223], ["64", 226], ["micrograms", 229], ["/", 239], ["ml", 240], [",", 242], ["the", 244], ["MICs", 248], ["of", 253], ["ABK", 256], ["for", 260], ["38", 264], ["strains", 267], ["carrying", 275], ["aac(6')/aph(2", 284], ["\"", 297], [")", 298], ["gene", 300], ["were", 305], ["widely", 310], ["distributed", 317], ["from", 329], ["0.25", 334], ["to", 339], ["64", 342], [",", 344], ["whereas", 346], ["those", 354], ["for", 360], ["11", 364], ["strains", 367], ["without", 375], ["that", 383], ["gene", 388], ["were", 393], ["all", 398], ["<", 402], ["or", 404], ["=", 407], ["0.5", 409], ["microgram", 413], ["/", 422], ["ml", 423], [".", 425], ["Residual", 427], ["rate", 436], ["of", 441], ["ABK", 444], ["activity", 448], ["was", 457], ["higher", 461], ["than", 468], ["that", 473], ["of", 478], ["gentamicin", 481], ["after", 492], ["the", 498], ["reaction", 502], ["with", 511], ["each", 516], ["crude", 521], ["enzyme", 527], ["preparation", 534], ["extracted", 546], ["from", 556], ["3", 561], ["isolates", 563], ["of", 572], ["MRSA", 575], [",", 579], ["carrying", 581], ["aac(6')/aph(2", 590], ["\"", 603], [")", 604], ["and", 606], ["aad(4',4", 610], ["\"", 618], [")", 619], ["genes", 621], [".", 626], ["Furthermore", 628], [",", 639], ["97", 641], ["strains", 644], ["of", 652], ["MRSA", 655], ["isolated", 660], ["at", 669], ["Kanagawa", 672], ["prefecture", 681], ["in", 692], ["Japan", 695], ["in", 701], ["1999", 704], ["were", 709], ["all", 714], ["sensitive", 718], ["to", 728], ["ABK", 731], [",", 734], ["although", 736], ["28", 745], ["strains", 748], ["of", 756], ["them", 759], ["carried", 764], ["aac(6')/aph(2", 772], ["\"", 785], [")", 786], ["gene", 788], [".", 792], ["These", 794], ["results", 800], ["showed", 808], ["that", 815], ["ABK", 820], ["resistance", 824], ["was", 835], ["not", 839], ["necessarily", 843], ["related", 855], ["to", 863], ["carrying", 866], ["aac(6')/aph(2", 875], ["\"", 888], [")", 889], ["gene", 891], ["in", 896], ["clinical", 899], ["isolates", 908], ["of", 917], ["MRSA", 920], [".", 924]]}
{"context": "During mitosis, Promyelocytic leukemia nuclear bodies (PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis. Here, we show that PML is phosphorylated at T409 (PML p409) in a mitosis-specific manner. More importantly, PML p409 contributes to maintain the duration of pro-metaphase and regulates spindle checkpoint. Deficient PML p409 caused a shortening of pro-metaphase and challenged the nocodazole-triggered mitotic arrest. T409A mutation led to a higher frequency of misaligned chromosomes on metaphase plate, and subsequently death in late mitosis. In addition, inhibition of PML p409 repressed growth of tumor cells, suggesting that PML p409 is a potential target for cancer therapy. Collectively, our study demonstrated an important phosphorylated site of PML, which contributed to explore the role of PML in mitosis.", "qas": [{"question": "What is the effect of nocodazole cell treatment?", "answers": ["Mitotic arrest"], "qid": "fb1932c2568743f8a7e02da6141a50f9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["nocodazole", 22], ["cell", 33], ["treatment", 38], ["?", 47]], "detected_answers": [{"text": "Mitotic arrest", "token_spans": [[85, 86]], "char_spans": [[470, 483]]}]}], "context_tokens": [["During", 0], ["mitosis", 7], [",", 14], ["Promyelocytic", 16], ["leukemia", 30], ["nuclear", 39], ["bodies", 47], ["(", 54], ["PML", 55], ["NBs", 59], [")", 62], ["change", 64], ["dramatically", 71], ["in", 84], ["morphology", 87], ["and", 98], ["composition", 102], [",", 113], ["but", 115], ["little", 119], ["is", 126], ["known", 129], ["about", 135], ["function", 141], ["of", 150], ["PML", 153], ["in", 157], ["mitosis", 160], [".", 167], ["Here", 169], [",", 173], ["we", 175], ["show", 178], ["that", 183], ["PML", 188], ["is", 192], ["phosphorylated", 195], ["at", 210], ["T409", 213], ["(", 218], ["PML", 219], ["p409", 223], [")", 227], ["in", 229], ["a", 232], ["mitosis", 234], ["-", 241], ["specific", 242], ["manner", 251], [".", 257], ["More", 259], ["importantly", 264], [",", 275], ["PML", 277], ["p409", 281], ["contributes", 286], ["to", 298], ["maintain", 301], ["the", 310], ["duration", 314], ["of", 323], ["pro", 326], ["-", 329], ["metaphase", 330], ["and", 340], ["regulates", 344], ["spindle", 354], ["checkpoint", 362], [".", 372], ["Deficient", 374], ["PML", 384], ["p409", 388], ["caused", 393], ["a", 400], ["shortening", 402], ["of", 413], ["pro", 416], ["-", 419], ["metaphase", 420], ["and", 430], ["challenged", 434], ["the", 445], ["nocodazole", 449], ["-", 459], ["triggered", 460], ["mitotic", 470], ["arrest", 478], [".", 484], ["T409A", 486], ["mutation", 492], ["led", 501], ["to", 505], ["a", 508], ["higher", 510], ["frequency", 517], ["of", 527], ["misaligned", 530], ["chromosomes", 541], ["on", 553], ["metaphase", 556], ["plate", 566], [",", 571], ["and", 573], ["subsequently", 577], ["death", 590], ["in", 596], ["late", 599], ["mitosis", 604], [".", 611], ["In", 613], ["addition", 616], [",", 624], ["inhibition", 626], ["of", 637], ["PML", 640], ["p409", 644], ["repressed", 649], ["growth", 659], ["of", 666], ["tumor", 669], ["cells", 675], [",", 680], ["suggesting", 682], ["that", 693], ["PML", 698], ["p409", 702], ["is", 707], ["a", 710], ["potential", 712], ["target", 722], ["for", 729], ["cancer", 733], ["therapy", 740], [".", 747], ["Collectively", 749], [",", 761], ["our", 763], ["study", 767], ["demonstrated", 773], ["an", 786], ["important", 789], ["phosphorylated", 799], ["site", 814], ["of", 819], ["PML", 822], [",", 825], ["which", 827], ["contributed", 833], ["to", 845], ["explore", 848], ["the", 856], ["role", 860], ["of", 865], ["PML", 868], ["in", 872], ["mitosis", 875], [".", 882]]}
{"context": "The secreted glycoprotein, sclerostin alters bone formation. To gain insights into the mechanism of action of sclerostin, we examined the interactions of sclerostin with bone proteins using a sclerostin affinity capture technique. Proteins from decalcified rat bone were captured on a sclerostin-maltose binding protein (MBP) amylose column, or on a MBP amylose column. The columns were extensively washed with low ionic strength buffer, and bound proteins were eluted with buffer containing 1M sodium chloride. Eluted proteins were separated by denaturing sodium-dodecyl sulfate gel electrophoresis and were identified by mass spectrometry. Several previously unidentified full-length sclerostin-interacting proteins such as alkaline phosphatase, carbonic anhydrase, gremlin-1, fetuin A, midkine, annexin A1 and A2, and collagen \u03b11, which have established roles in bone formation or resorption processes, were bound to the sclerostin-MBP amylose resin but not to the MBP amylose resin. Other full-length sclerostin-interacting proteins such as casein kinase II and secreted frizzled related protein 4 that modulate Wnt signaling were identified. Several peptides derived from proteins such as Phex, asporin and follistatin that regulate bone metabolism also bound sclerostin. Sclerostin interacts with multiple proteins that alter bone formation and resorption and is likely to function by altering several biologically relevant pathways in bone.", "qas": [{"question": "Sclerostin regulates what process?", "answers": ["bone metabolism"], "qid": "c769d26d6d6e49a8bccbfa8ca3020245", "question_tokens": [["Sclerostin", 0], ["regulates", 11], ["what", 21], ["process", 26], ["?", 33]], "detected_answers": [{"text": "bone metabolism", "token_spans": [[208, 209]], "char_spans": [[1238, 1252]]}]}], "context_tokens": [["The", 0], ["secreted", 4], ["glycoprotein", 13], [",", 25], ["sclerostin", 27], ["alters", 38], ["bone", 45], ["formation", 50], [".", 59], ["To", 61], ["gain", 64], ["insights", 69], ["into", 78], ["the", 83], ["mechanism", 87], ["of", 97], ["action", 100], ["of", 107], ["sclerostin", 110], [",", 120], ["we", 122], ["examined", 125], ["the", 134], ["interactions", 138], ["of", 151], ["sclerostin", 154], ["with", 165], ["bone", 170], ["proteins", 175], ["using", 184], ["a", 190], ["sclerostin", 192], ["affinity", 203], ["capture", 212], ["technique", 220], [".", 229], ["Proteins", 231], ["from", 240], ["decalcified", 245], ["rat", 257], ["bone", 261], ["were", 266], ["captured", 271], ["on", 280], ["a", 283], ["sclerostin", 285], ["-", 295], ["maltose", 296], ["binding", 304], ["protein", 312], ["(", 320], ["MBP", 321], [")", 324], ["amylose", 326], ["column", 334], [",", 340], ["or", 342], ["on", 345], ["a", 348], ["MBP", 350], ["amylose", 354], ["column", 362], [".", 368], ["The", 370], ["columns", 374], ["were", 382], ["extensively", 387], ["washed", 399], ["with", 406], ["low", 411], ["ionic", 415], ["strength", 421], ["buffer", 430], [",", 436], ["and", 438], ["bound", 442], ["proteins", 448], ["were", 457], ["eluted", 462], ["with", 469], ["buffer", 474], ["containing", 481], ["1", 492], ["M", 493], ["sodium", 495], ["chloride", 502], [".", 510], ["Eluted", 512], ["proteins", 519], ["were", 528], ["separated", 533], ["by", 543], ["denaturing", 546], ["sodium", 557], ["-", 563], ["dodecyl", 564], ["sulfate", 572], ["gel", 580], ["electrophoresis", 584], ["and", 600], ["were", 604], ["identified", 609], ["by", 620], ["mass", 623], ["spectrometry", 628], [".", 640], ["Several", 642], ["previously", 650], ["unidentified", 661], ["full", 674], ["-", 678], ["length", 679], ["sclerostin", 686], ["-", 696], ["interacting", 697], ["proteins", 709], ["such", 718], ["as", 723], ["alkaline", 726], ["phosphatase", 735], [",", 746], ["carbonic", 748], ["anhydrase", 757], [",", 766], ["gremlin-1", 768], [",", 777], ["fetuin", 779], ["A", 786], [",", 787], ["midkine", 789], [",", 796], ["annexin", 798], ["A1", 806], ["and", 809], ["A2", 813], [",", 815], ["and", 817], ["collagen", 821], ["\u03b11", 830], [",", 832], ["which", 834], ["have", 840], ["established", 845], ["roles", 857], ["in", 863], ["bone", 866], ["formation", 871], ["or", 881], ["resorption", 884], ["processes", 895], [",", 904], ["were", 906], ["bound", 911], ["to", 917], ["the", 920], ["sclerostin", 924], ["-", 934], ["MBP", 935], ["amylose", 939], ["resin", 947], ["but", 953], ["not", 957], ["to", 961], ["the", 964], ["MBP", 968], ["amylose", 972], ["resin", 980], [".", 985], ["Other", 987], ["full", 993], ["-", 997], ["length", 998], ["sclerostin", 1005], ["-", 1015], ["interacting", 1016], ["proteins", 1028], ["such", 1037], ["as", 1042], ["casein", 1045], ["kinase", 1052], ["II", 1059], ["and", 1062], ["secreted", 1066], ["frizzled", 1075], ["related", 1084], ["protein", 1092], ["4", 1100], ["that", 1102], ["modulate", 1107], ["Wnt", 1116], ["signaling", 1120], ["were", 1130], ["identified", 1135], [".", 1145], ["Several", 1147], ["peptides", 1155], ["derived", 1164], ["from", 1172], ["proteins", 1177], ["such", 1186], ["as", 1191], ["Phex", 1194], [",", 1198], ["asporin", 1200], ["and", 1208], ["follistatin", 1212], ["that", 1224], ["regulate", 1229], ["bone", 1238], ["metabolism", 1243], ["also", 1254], ["bound", 1259], ["sclerostin", 1265], [".", 1275], ["Sclerostin", 1277], ["interacts", 1288], ["with", 1298], ["multiple", 1303], ["proteins", 1312], ["that", 1321], ["alter", 1326], ["bone", 1332], ["formation", 1337], ["and", 1347], ["resorption", 1351], ["and", 1362], ["is", 1366], ["likely", 1369], ["to", 1376], ["function", 1379], ["by", 1388], ["altering", 1391], ["several", 1400], ["biologically", 1408], ["relevant", 1421], ["pathways", 1430], ["in", 1439], ["bone", 1442], [".", 1446]]}
{"context": "Malaria is a widespread and infectious disease that is a leading cause of death in many parts of the world. Eradication of malaria has been a major world health goal for decades, but one that still remains elusive. Other diseases have been eradicated using vaccination, but traditional vaccination methods have thus far been unsuccessful for malaria. Infection by Plasmodium species, the causative agent of malaria, is currently treated with drug-based therapies, but an increase in drug resistance has led to the need for new methods of treatment. A promising strategy for malaria treatment is to combine transmission blocking vaccines (TBVs) that prevent spread of disease with drug-based therapies to treat infected individuals. TBVs can be developed against surface protein antigens that are expressed during parasite reproduction in the mosquito. When the mosquito ingests blood from a vaccinated individual harboring the Plasmodium parasite, the antibodies generated by vaccination prevent completion of the parasites life-cycle. Animal studies have shown that immunization with Pfs48/45 results in the production of malaria transmission blocking antibodies; however, the development of this vaccine candidate has been hindered by poor expression in both prokaryotic and eukaryotic hosts. Recently, the chloroplast of Chlamydomonas reinhardtii has been used to express complex recombinant proteins. In this study, we show that the C-terminal antigenic region of the Pfs48/45 antigen can be expressed in the chloroplast of the green algae C. reinhardtii and that this recombinant protein has a conformation recognized by known transmission blocking antibodies. Production of this protein in algae has the potential to scale to the very large volumes required to meet the needs of millions at risk for contracting malaria.", "qas": [{"question": "Which is the causative agent of malaria?", "answers": ["Plasmodium species", "Plasmodium spp."], "qid": "4b472a6cb9d048dd9901e39d6b2bb9d0", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["causative", 13], ["agent", 23], ["of", 29], ["malaria", 32], ["?", 39]], "detected_answers": [{"text": "Plasmodium species", "token_spans": [[63, 64]], "char_spans": [[364, 381]]}]}], "context_tokens": [["Malaria", 0], ["is", 8], ["a", 11], ["widespread", 13], ["and", 24], ["infectious", 28], ["disease", 39], ["that", 47], ["is", 52], ["a", 55], ["leading", 57], ["cause", 65], ["of", 71], ["death", 74], ["in", 80], ["many", 83], ["parts", 88], ["of", 94], ["the", 97], ["world", 101], [".", 106], ["Eradication", 108], ["of", 120], ["malaria", 123], ["has", 131], ["been", 135], ["a", 140], ["major", 142], ["world", 148], ["health", 154], ["goal", 161], ["for", 166], ["decades", 170], [",", 177], ["but", 179], ["one", 183], ["that", 187], ["still", 192], ["remains", 198], ["elusive", 206], [".", 213], ["Other", 215], ["diseases", 221], ["have", 230], ["been", 235], ["eradicated", 240], ["using", 251], ["vaccination", 257], [",", 268], ["but", 270], ["traditional", 274], ["vaccination", 286], ["methods", 298], ["have", 306], ["thus", 311], ["far", 316], ["been", 320], ["unsuccessful", 325], ["for", 338], ["malaria", 342], [".", 349], ["Infection", 351], ["by", 361], ["Plasmodium", 364], ["species", 375], [",", 382], ["the", 384], ["causative", 388], ["agent", 398], ["of", 404], ["malaria", 407], [",", 414], ["is", 416], ["currently", 419], ["treated", 429], ["with", 437], ["drug", 442], ["-", 446], ["based", 447], ["therapies", 453], [",", 462], ["but", 464], ["an", 468], ["increase", 471], ["in", 480], ["drug", 483], ["resistance", 488], ["has", 499], ["led", 503], ["to", 507], ["the", 510], ["need", 514], ["for", 519], ["new", 523], ["methods", 527], ["of", 535], ["treatment", 538], [".", 547], ["A", 549], ["promising", 551], ["strategy", 561], ["for", 570], ["malaria", 574], ["treatment", 582], ["is", 592], ["to", 595], ["combine", 598], ["transmission", 606], ["blocking", 619], ["vaccines", 628], ["(", 637], ["TBVs", 638], [")", 642], ["that", 644], ["prevent", 649], ["spread", 657], ["of", 664], ["disease", 667], ["with", 675], ["drug", 680], ["-", 684], ["based", 685], ["therapies", 691], ["to", 701], ["treat", 704], ["infected", 710], ["individuals", 719], [".", 730], ["TBVs", 732], ["can", 737], ["be", 741], ["developed", 744], ["against", 754], ["surface", 762], ["protein", 770], ["antigens", 778], ["that", 787], ["are", 792], ["expressed", 796], ["during", 806], ["parasite", 813], ["reproduction", 822], ["in", 835], ["the", 838], ["mosquito", 842], [".", 850], ["When", 852], ["the", 857], ["mosquito", 861], ["ingests", 870], ["blood", 878], ["from", 884], ["a", 889], ["vaccinated", 891], ["individual", 902], ["harboring", 913], ["the", 923], ["Plasmodium", 927], ["parasite", 938], [",", 946], ["the", 948], ["antibodies", 952], ["generated", 963], ["by", 973], ["vaccination", 976], ["prevent", 988], ["completion", 996], ["of", 1007], ["the", 1010], ["parasites", 1014], ["life", 1024], ["-", 1028], ["cycle", 1029], [".", 1034], ["Animal", 1036], ["studies", 1043], ["have", 1051], ["shown", 1056], ["that", 1062], ["immunization", 1067], ["with", 1080], ["Pfs48/45", 1085], ["results", 1094], ["in", 1102], ["the", 1105], ["production", 1109], ["of", 1120], ["malaria", 1123], ["transmission", 1131], ["blocking", 1144], ["antibodies", 1153], [";", 1163], ["however", 1165], [",", 1172], ["the", 1174], ["development", 1178], ["of", 1190], ["this", 1193], ["vaccine", 1198], ["candidate", 1206], ["has", 1216], ["been", 1220], ["hindered", 1225], ["by", 1234], ["poor", 1237], ["expression", 1242], ["in", 1253], ["both", 1256], ["prokaryotic", 1261], ["and", 1273], ["eukaryotic", 1277], ["hosts", 1288], [".", 1293], ["Recently", 1295], [",", 1303], ["the", 1305], ["chloroplast", 1309], ["of", 1321], ["Chlamydomonas", 1324], ["reinhardtii", 1338], ["has", 1350], ["been", 1354], ["used", 1359], ["to", 1364], ["express", 1367], ["complex", 1375], ["recombinant", 1383], ["proteins", 1395], [".", 1403], ["In", 1405], ["this", 1408], ["study", 1413], [",", 1418], ["we", 1420], ["show", 1423], ["that", 1428], ["the", 1433], ["C", 1437], ["-", 1438], ["terminal", 1439], ["antigenic", 1448], ["region", 1458], ["of", 1465], ["the", 1468], ["Pfs48/45", 1472], ["antigen", 1481], ["can", 1489], ["be", 1493], ["expressed", 1496], ["in", 1506], ["the", 1509], ["chloroplast", 1513], ["of", 1525], ["the", 1528], ["green", 1532], ["algae", 1538], ["C.", 1544], ["reinhardtii", 1547], ["and", 1559], ["that", 1563], ["this", 1568], ["recombinant", 1573], ["protein", 1585], ["has", 1593], ["a", 1597], ["conformation", 1599], ["recognized", 1612], ["by", 1623], ["known", 1626], ["transmission", 1632], ["blocking", 1645], ["antibodies", 1654], [".", 1664], ["Production", 1666], ["of", 1677], ["this", 1680], ["protein", 1685], ["in", 1693], ["algae", 1696], ["has", 1702], ["the", 1706], ["potential", 1710], ["to", 1720], ["scale", 1723], ["to", 1729], ["the", 1732], ["very", 1736], ["large", 1741], ["volumes", 1747], ["required", 1755], ["to", 1764], ["meet", 1767], ["the", 1772], ["needs", 1776], ["of", 1782], ["millions", 1785], ["at", 1794], ["risk", 1797], ["for", 1802], ["contracting", 1806], ["malaria", 1818], [".", 1825]]}
{"context": "Women in sub-Saharan Africa are a priority population for evaluation of new biomedical HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising prevention approach; however, clinical trials among young women using daily or coitally-dependent products have found low adherence. Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges. ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection. We describe the baseline characteristics of African women enrolled in the ASPIRE trial. Between August 2012 and June 2014, 5516 women were screened and 2629 HIV-1 seronegative women between 18-45 years of age were enrolled from 15 research sites in Malawi, South Africa, Uganda, and Zimbabwe. The median age was 26 years (IQR 22-31) and the majority (59%) were unmarried. Nearly 100% of participants reported having a primary sex partner in the prior three months but 43% did not know the HIV-1 status of their primary partner; 17% reported additional concurrent partners. Nearly two-thirds (64%) reported having disclosed to primary partners about planned vaginal ring use in the trial. Sexually transmitted infections were prevalent: 12% had Chlamydia trachomatis, 7% Trichomonas vaginalis, 4% Neisseria gonorrhoeae, and 1% syphilis. African HIV-1 seronegative women at risk of HIV -1 infection were successfully enrolled into a phase III trial of dapivirine vaginal ring for HIV-1 prevention.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "5c077ce1a2b84aa199040b93309cc5b6", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[294, 294]], "char_spans": [[1622, 1624]]}]}], "context_tokens": [["Women", 0], ["in", 6], ["sub", 9], ["-", 12], ["Saharan", 13], ["Africa", 21], ["are", 28], ["a", 32], ["priority", 34], ["population", 43], ["for", 54], ["evaluation", 58], ["of", 69], ["new", 72], ["biomedical", 76], ["HIV-1", 87], ["prevention", 93], ["strategies", 104], [".", 114], ["Antiretroviral", 116], ["pre", 131], ["-", 134], ["exposure", 135], ["prophylaxis", 144], ["is", 156], ["a", 159], ["promising", 161], ["prevention", 171], ["approach", 182], [";", 190], ["however", 192], [",", 199], ["clinical", 201], ["trials", 210], ["among", 217], ["young", 223], ["women", 229], ["using", 235], ["daily", 241], ["or", 247], ["coitally", 250], ["-", 258], ["dependent", 259], ["products", 269], ["have", 278], ["found", 283], ["low", 289], ["adherence", 293], [".", 302], ["Antiretroviral", 304], ["-", 318], ["containing", 319], ["vaginal", 330], ["microbicide", 338], ["rings", 350], [",", 355], ["which", 357], ["release", 363], ["medication", 371], ["over", 382], ["a", 387], ["month", 389], ["or", 395], ["longer", 398], [",", 404], ["may", 406], ["reduce", 410], ["these", 417], ["adherence", 423], ["challenges", 433], [".", 443], ["ASPIRE", 445], ["(", 452], ["A", 453], ["Study", 455], ["to", 461], ["Prevent", 464], ["Infection", 472], ["with", 482], ["a", 487], ["Ring", 489], ["for", 494], ["Extended", 498], ["Use", 507], [")", 510], ["is", 512], ["a", 515], ["phase", 517], ["III", 523], [",", 526], ["randomized", 528], [",", 538], ["double", 540], ["-", 546], ["blind", 547], [",", 552], ["placebo", 554], ["-", 561], ["controlled", 562], ["trial", 573], ["testing", 579], ["the", 587], ["safety", 591], ["and", 598], ["effectiveness", 602], ["of", 616], ["a", 619], ["vaginal", 621], ["ring", 629], ["containing", 634], ["the", 645], ["non", 649], ["-", 652], ["nucleoside", 653], ["reverse", 664], ["transcriptase", 672], ["inhibitor", 686], ["dapivirine", 696], ["for", 707], ["prevention", 711], ["of", 722], ["HIV-1", 725], ["infection", 731], [".", 740], ["We", 742], ["describe", 745], ["the", 754], ["baseline", 758], ["characteristics", 767], ["of", 783], ["African", 786], ["women", 794], ["enrolled", 800], ["in", 809], ["the", 812], ["ASPIRE", 816], ["trial", 823], [".", 828], ["Between", 830], ["August", 838], ["2012", 845], ["and", 850], ["June", 854], ["2014", 859], [",", 863], ["5516", 865], ["women", 870], ["were", 876], ["screened", 881], ["and", 890], ["2629", 894], ["HIV-1", 899], ["seronegative", 905], ["women", 918], ["between", 924], ["18", 932], ["-", 934], ["45", 935], ["years", 938], ["of", 944], ["age", 947], ["were", 951], ["enrolled", 956], ["from", 965], ["15", 970], ["research", 973], ["sites", 982], ["in", 988], ["Malawi", 991], [",", 997], ["South", 999], ["Africa", 1005], [",", 1011], ["Uganda", 1013], [",", 1019], ["and", 1021], ["Zimbabwe", 1025], [".", 1033], ["The", 1035], ["median", 1039], ["age", 1046], ["was", 1050], ["26", 1054], ["years", 1057], ["(", 1063], ["IQR", 1064], ["22", 1068], ["-", 1070], ["31", 1071], [")", 1073], ["and", 1075], ["the", 1079], ["majority", 1083], ["(", 1092], ["59", 1093], ["%", 1095], [")", 1096], ["were", 1098], ["unmarried", 1103], [".", 1112], ["Nearly", 1114], ["100", 1121], ["%", 1124], ["of", 1126], ["participants", 1129], ["reported", 1142], ["having", 1151], ["a", 1158], ["primary", 1160], ["sex", 1168], ["partner", 1172], ["in", 1180], ["the", 1183], ["prior", 1187], ["three", 1193], ["months", 1199], ["but", 1206], ["43", 1210], ["%", 1212], ["did", 1214], ["not", 1218], ["know", 1222], ["the", 1227], ["HIV-1", 1231], ["status", 1237], ["of", 1244], ["their", 1247], ["primary", 1253], ["partner", 1261], [";", 1268], ["17", 1270], ["%", 1272], ["reported", 1274], ["additional", 1283], ["concurrent", 1294], ["partners", 1305], [".", 1313], ["Nearly", 1315], ["two", 1322], ["-", 1325], ["thirds", 1326], ["(", 1333], ["64", 1334], ["%", 1336], [")", 1337], ["reported", 1339], ["having", 1348], ["disclosed", 1355], ["to", 1365], ["primary", 1368], ["partners", 1376], ["about", 1385], ["planned", 1391], ["vaginal", 1399], ["ring", 1407], ["use", 1412], ["in", 1416], ["the", 1419], ["trial", 1423], [".", 1428], ["Sexually", 1430], ["transmitted", 1439], ["infections", 1451], ["were", 1462], ["prevalent", 1467], [":", 1476], ["12", 1478], ["%", 1480], ["had", 1482], ["Chlamydia", 1486], ["trachomatis", 1496], [",", 1507], ["7", 1509], ["%", 1510], ["Trichomonas", 1512], ["vaginalis", 1524], [",", 1533], ["4", 1535], ["%", 1536], ["Neisseria", 1538], ["gonorrhoeae", 1548], [",", 1559], ["and", 1561], ["1", 1565], ["%", 1566], ["syphilis", 1568], [".", 1576], ["African", 1578], ["HIV-1", 1586], ["seronegative", 1592], ["women", 1605], ["at", 1611], ["risk", 1614], ["of", 1619], ["HIV", 1622], ["-1", 1626], ["infection", 1629], ["were", 1639], ["successfully", 1644], ["enrolled", 1657], ["into", 1666], ["a", 1671], ["phase", 1673], ["III", 1679], ["trial", 1683], ["of", 1689], ["dapivirine", 1692], ["vaginal", 1703], ["ring", 1711], ["for", 1716], ["HIV-1", 1720], ["prevention", 1726], [".", 1736]]}
{"context": "The approval of the oral direct thrombin inhibitor, dabigatran etexilate, gave patients an alternative to oral anticoagulation with warfarin. Like all anticoagulants, the primary adverse event (AE) associated with dabigatran is bleeding. Until the FDA approval of idarucizumab, there had been no reversal agent for dabigatran-induced anticoagulation in patients with life-threatening or uncontrollable bleeding, or those requiring emergent procedures. The primary purpose of this review is to summarize the safety and efficacy of idarucizumab, a monoclonal antibody fragment, and its use as a reversal agent for dabigatran. A literature search was conducted through MEDLINE (1946 to November week 1 2015) and Embase (1980-2015 week 46) using the search term idarucizumab. Clinicaltrials.gov was consulted for a comprehensive list of ongoing and completed studies. Additional studies were identified through bibliographical citations. Clinical trials in animals and humans published in English evaluating the safety and efficacy of idarucizumab for reversal of anticoagulant treatment with dabigatran were included for review. Idarucizumab has been shown to significantly reverse the anticoagulant effects of dabigatran in both healthy volunteers and patients requiring a reversal agent because of either overt bleeding or an emergency surgery or invasive procedure. The most common AEs were headache, nasopharyngitis, back pain, skin irritation, hypokalemia, delirium, constipation, pyrexia, and pneumonia. Deaths reported in idarucizumab studies were attributed to either the index event or a preexisting comorbidity. Most adverse effects were minor, but 21 serious AEs have been reported in the published data including thrombotic events. Given the increased use of direct oral anticoagulants, such as dabigatran, a need for specific reversal agents exists. Idarucizumab has been shown to be safe and effective in the reversal of dabigatran-induced anticoagulation in patients requiring emergent or urgent surgery or in patients with severe bleeding.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "2e849ad8ec784301ae7f31f0261ab00e", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[35, 35], [53, 53], [102, 102], [293, 293], [316, 316], [9, 9], [194, 194], [177, 177]], "char_spans": [[214, 223], [315, 324], [612, 621], [1804, 1813], [1932, 1941], [52, 61], [1208, 1217], [1089, 1098]]}]}], "context_tokens": [["The", 0], ["approval", 4], ["of", 13], ["the", 16], ["oral", 20], ["direct", 25], ["thrombin", 32], ["inhibitor", 41], [",", 50], ["dabigatran", 52], ["etexilate", 63], [",", 72], ["gave", 74], ["patients", 79], ["an", 88], ["alternative", 91], ["to", 103], ["oral", 106], ["anticoagulation", 111], ["with", 127], ["warfarin", 132], [".", 140], ["Like", 142], ["all", 147], ["anticoagulants", 151], [",", 165], ["the", 167], ["primary", 171], ["adverse", 179], ["event", 187], ["(", 193], ["AE", 194], [")", 196], ["associated", 198], ["with", 209], ["dabigatran", 214], ["is", 225], ["bleeding", 228], [".", 236], ["Until", 238], ["the", 244], ["FDA", 248], ["approval", 252], ["of", 261], ["idarucizumab", 264], [",", 276], ["there", 278], ["had", 284], ["been", 288], ["no", 293], ["reversal", 296], ["agent", 305], ["for", 311], ["dabigatran", 315], ["-", 325], ["induced", 326], ["anticoagulation", 334], ["in", 350], ["patients", 353], ["with", 362], ["life", 367], ["-", 371], ["threatening", 372], ["or", 384], ["uncontrollable", 387], ["bleeding", 402], [",", 410], ["or", 412], ["those", 415], ["requiring", 421], ["emergent", 431], ["procedures", 440], [".", 450], ["The", 452], ["primary", 456], ["purpose", 464], ["of", 472], ["this", 475], ["review", 480], ["is", 487], ["to", 490], ["summarize", 493], ["the", 503], ["safety", 507], ["and", 514], ["efficacy", 518], ["of", 527], ["idarucizumab", 530], [",", 542], ["a", 544], ["monoclonal", 546], ["antibody", 557], ["fragment", 566], [",", 574], ["and", 576], ["its", 580], ["use", 584], ["as", 588], ["a", 591], ["reversal", 593], ["agent", 602], ["for", 608], ["dabigatran", 612], [".", 622], ["A", 624], ["literature", 626], ["search", 637], ["was", 644], ["conducted", 648], ["through", 658], ["MEDLINE", 666], ["(", 674], ["1946", 675], ["to", 680], ["November", 683], ["week", 692], ["1", 697], ["2015", 699], [")", 703], ["and", 705], ["Embase", 709], ["(", 716], ["1980", 717], ["-", 721], ["2015", 722], ["week", 727], ["46", 732], [")", 734], ["using", 736], ["the", 742], ["search", 746], ["term", 753], ["idarucizumab", 758], [".", 770], ["Clinicaltrials.gov", 772], ["was", 791], ["consulted", 795], ["for", 805], ["a", 809], ["comprehensive", 811], ["list", 825], ["of", 830], ["ongoing", 833], ["and", 841], ["completed", 845], ["studies", 855], [".", 862], ["Additional", 864], ["studies", 875], ["were", 883], ["identified", 888], ["through", 899], ["bibliographical", 907], ["citations", 923], [".", 932], ["Clinical", 934], ["trials", 943], ["in", 950], ["animals", 953], ["and", 961], ["humans", 965], ["published", 972], ["in", 982], ["English", 985], ["evaluating", 993], ["the", 1004], ["safety", 1008], ["and", 1015], ["efficacy", 1019], ["of", 1028], ["idarucizumab", 1031], ["for", 1044], ["reversal", 1048], ["of", 1057], ["anticoagulant", 1060], ["treatment", 1074], ["with", 1084], ["dabigatran", 1089], ["were", 1100], ["included", 1105], ["for", 1114], ["review", 1118], [".", 1124], ["Idarucizumab", 1126], ["has", 1139], ["been", 1143], ["shown", 1148], ["to", 1154], ["significantly", 1157], ["reverse", 1171], ["the", 1179], ["anticoagulant", 1183], ["effects", 1197], ["of", 1205], ["dabigatran", 1208], ["in", 1219], ["both", 1222], ["healthy", 1227], ["volunteers", 1235], ["and", 1246], ["patients", 1250], ["requiring", 1259], ["a", 1269], ["reversal", 1271], ["agent", 1280], ["because", 1286], ["of", 1294], ["either", 1297], ["overt", 1304], ["bleeding", 1310], ["or", 1319], ["an", 1322], ["emergency", 1325], ["surgery", 1335], ["or", 1343], ["invasive", 1346], ["procedure", 1355], [".", 1364], ["The", 1366], ["most", 1370], ["common", 1375], ["AEs", 1382], ["were", 1386], ["headache", 1391], [",", 1399], ["nasopharyngitis", 1401], [",", 1416], ["back", 1418], ["pain", 1423], [",", 1427], ["skin", 1429], ["irritation", 1434], [",", 1444], ["hypokalemia", 1446], [",", 1457], ["delirium", 1459], [",", 1467], ["constipation", 1469], [",", 1481], ["pyrexia", 1483], [",", 1490], ["and", 1492], ["pneumonia", 1496], [".", 1505], ["Deaths", 1507], ["reported", 1514], ["in", 1523], ["idarucizumab", 1526], ["studies", 1539], ["were", 1547], ["attributed", 1552], ["to", 1563], ["either", 1566], ["the", 1573], ["index", 1577], ["event", 1583], ["or", 1589], ["a", 1592], ["preexisting", 1594], ["comorbidity", 1606], [".", 1617], ["Most", 1619], ["adverse", 1624], ["effects", 1632], ["were", 1640], ["minor", 1645], [",", 1650], ["but", 1652], ["21", 1656], ["serious", 1659], ["AEs", 1667], ["have", 1671], ["been", 1676], ["reported", 1681], ["in", 1690], ["the", 1693], ["published", 1697], ["data", 1707], ["including", 1712], ["thrombotic", 1722], ["events", 1733], [".", 1739], ["Given", 1741], ["the", 1747], ["increased", 1751], ["use", 1761], ["of", 1765], ["direct", 1768], ["oral", 1775], ["anticoagulants", 1780], [",", 1794], ["such", 1796], ["as", 1801], ["dabigatran", 1804], [",", 1814], ["a", 1816], ["need", 1818], ["for", 1823], ["specific", 1827], ["reversal", 1836], ["agents", 1845], ["exists", 1852], [".", 1858], ["Idarucizumab", 1860], ["has", 1873], ["been", 1877], ["shown", 1882], ["to", 1888], ["be", 1891], ["safe", 1894], ["and", 1899], ["effective", 1903], ["in", 1913], ["the", 1916], ["reversal", 1920], ["of", 1929], ["dabigatran", 1932], ["-", 1942], ["induced", 1943], ["anticoagulation", 1951], ["in", 1967], ["patients", 1970], ["requiring", 1979], ["emergent", 1989], ["or", 1998], ["urgent", 2001], ["surgery", 2008], ["or", 2016], ["in", 2019], ["patients", 2022], ["with", 2031], ["severe", 2036], ["bleeding", 2043], [".", 2051]]}
{"context": "We evaluated the adherence and acceptability of a vaginal ring containing dapivirine, maraviroc, or both drugs for 28\u00a0days during a Phase I placebo-controlled trial in 48 HIV-negative sexually abstinent U.S. women aged 18-40. Adherence was assessed weekly by clinical interview and computer-assisted self-interviewing; acceptability assessment occurred at the last product-use visit. Study retention was 98\u00a0% (47/48); 94\u00a0% (45/48) reported being fully adherent with ring use during the 28-day period. Two participants experienced the ring partially coming out. Analysis was blinded and behavioral data were combined across study groups. Most women reported being very comfortable having the ring in their vagina; 44\u00a0% preferred continuous use, whereas 51\u00a0% had no preference compared to episodic use. Although a range of minor ring concerns were expressed, few were actually experienced. High adherence to and acceptability of this vaginal ring in this Phase I trial contributes to its promise as a sustained mechanism for multidrug vaginal microbicide delivery.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c1f471c321514f0caf736b5b44d25ecb", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[31, 31]], "char_spans": [[171, 173]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["adherence", 17], ["and", 27], ["acceptability", 31], ["of", 45], ["a", 48], ["vaginal", 50], ["ring", 58], ["containing", 63], ["dapivirine", 74], [",", 84], ["maraviroc", 86], [",", 95], ["or", 97], ["both", 100], ["drugs", 105], ["for", 111], ["28", 115], ["days", 118], ["during", 123], ["a", 130], ["Phase", 132], ["I", 138], ["placebo", 140], ["-", 147], ["controlled", 148], ["trial", 159], ["in", 165], ["48", 168], ["HIV", 171], ["-", 174], ["negative", 175], ["sexually", 184], ["abstinent", 193], ["U.S.", 203], ["women", 208], ["aged", 214], ["18", 219], ["-", 221], ["40", 222], [".", 224], ["Adherence", 226], ["was", 236], ["assessed", 240], ["weekly", 249], ["by", 256], ["clinical", 259], ["interview", 268], ["and", 278], ["computer", 282], ["-", 290], ["assisted", 291], ["self", 300], ["-", 304], ["interviewing", 305], [";", 317], ["acceptability", 319], ["assessment", 333], ["occurred", 344], ["at", 353], ["the", 356], ["last", 360], ["product", 365], ["-", 372], ["use", 373], ["visit", 377], [".", 382], ["Study", 384], ["retention", 390], ["was", 400], ["98", 404], ["%", 407], ["(", 409], ["47/48", 410], [")", 415], [";", 416], ["94", 418], ["%", 421], ["(", 423], ["45/48", 424], [")", 429], ["reported", 431], ["being", 440], ["fully", 446], ["adherent", 452], ["with", 461], ["ring", 466], ["use", 471], ["during", 475], ["the", 482], ["28-day", 486], ["period", 493], [".", 499], ["Two", 501], ["participants", 505], ["experienced", 518], ["the", 530], ["ring", 534], ["partially", 539], ["coming", 549], ["out", 556], [".", 559], ["Analysis", 561], ["was", 570], ["blinded", 574], ["and", 582], ["behavioral", 586], ["data", 597], ["were", 602], ["combined", 607], ["across", 616], ["study", 623], ["groups", 629], [".", 635], ["Most", 637], ["women", 642], ["reported", 648], ["being", 657], ["very", 663], ["comfortable", 668], ["having", 680], ["the", 687], ["ring", 691], ["in", 696], ["their", 699], ["vagina", 705], [";", 711], ["44", 713], ["%", 716], ["preferred", 718], ["continuous", 728], ["use", 739], [",", 742], ["whereas", 744], ["51", 752], ["%", 755], ["had", 757], ["no", 761], ["preference", 764], ["compared", 775], ["to", 784], ["episodic", 787], ["use", 796], [".", 799], ["Although", 801], ["a", 810], ["range", 812], ["of", 818], ["minor", 821], ["ring", 827], ["concerns", 832], ["were", 841], ["expressed", 846], [",", 855], ["few", 857], ["were", 861], ["actually", 866], ["experienced", 875], [".", 886], ["High", 888], ["adherence", 893], ["to", 903], ["and", 906], ["acceptability", 910], ["of", 924], ["this", 927], ["vaginal", 932], ["ring", 940], ["in", 945], ["this", 948], ["Phase", 953], ["I", 959], ["trial", 961], ["contributes", 967], ["to", 979], ["its", 982], ["promise", 986], ["as", 994], ["a", 997], ["sustained", 999], ["mechanism", 1009], ["for", 1019], ["multidrug", 1023], ["vaginal", 1033], ["microbicide", 1041], ["delivery", 1053], [".", 1061]]}
{"context": "Selective degradation of proteins by the ubiquitin-proteasome pathway is a critical determinant for maintaining cellular homeostasis. Most intracellular proteins are degraded by the proteasome, a multicatalytic enzyme complex containing a 20S catalytic core and two 19S regulatory complexes. Many proteasome target proteins are involved in the regulation of important processes of carcinogenesis and cancer cell survival, such as cell cycle progression, cell proliferation, differentiation and apoptosis. Indeed, the ubiquitin-proteasome-dependent degradation pathway plays an essential role in both the up-regulation of cell proliferation and down-regulation of cell death in human cancer cells. Both in vitro and in vivo experimental and clinical results have demonstrated the potential use of proteasome inhibitors as novel anticancer drugs. Proteasome inhibition in cancer cells leads to accumulation of pro-apoptotic target proteins followed by induction of cell death. The clinical efficacy of the proteasome inhibitor bortezomib toward multiple myeloma and other hematologic malignancies provides the \"proof of concept\" that targeting the proteasome is a promising strategy for cancer treatment. Several other proteasome inhibitors have also been identified from natural resources, such as marine microbial metabolites, green tea polyphenols, flavonoids, and medicinal compounds. Additionally, the use of metal complexes as proteasome inhibitors has also been investigated as a potential anticancer strategy. The clinical significance of targeting the tumor survival-associated proteasome pathway for cancer treatment, intervention and prevention will be discussed.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "db311c7e2115419da83e01e6c5610862", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[6, 9]], "char_spans": [[41, 68]]}]}], "context_tokens": [["Selective", 0], ["degradation", 10], ["of", 22], ["proteins", 25], ["by", 34], ["the", 37], ["ubiquitin", 41], ["-", 50], ["proteasome", 51], ["pathway", 62], ["is", 70], ["a", 73], ["critical", 75], ["determinant", 84], ["for", 96], ["maintaining", 100], ["cellular", 112], ["homeostasis", 121], [".", 132], ["Most", 134], ["intracellular", 139], ["proteins", 153], ["are", 162], ["degraded", 166], ["by", 175], ["the", 178], ["proteasome", 182], [",", 192], ["a", 194], ["multicatalytic", 196], ["enzyme", 211], ["complex", 218], ["containing", 226], ["a", 237], ["20S", 239], ["catalytic", 243], ["core", 253], ["and", 258], ["two", 262], ["19S", 266], ["regulatory", 270], ["complexes", 281], [".", 290], ["Many", 292], ["proteasome", 297], ["target", 308], ["proteins", 315], ["are", 324], ["involved", 328], ["in", 337], ["the", 340], ["regulation", 344], ["of", 355], ["important", 358], ["processes", 368], ["of", 378], ["carcinogenesis", 381], ["and", 396], ["cancer", 400], ["cell", 407], ["survival", 412], [",", 420], ["such", 422], ["as", 427], ["cell", 430], ["cycle", 435], ["progression", 441], [",", 452], ["cell", 454], ["proliferation", 459], [",", 472], ["differentiation", 474], ["and", 490], ["apoptosis", 494], [".", 503], ["Indeed", 505], [",", 511], ["the", 513], ["ubiquitin", 517], ["-", 526], ["proteasome", 527], ["-", 537], ["dependent", 538], ["degradation", 548], ["pathway", 560], ["plays", 568], ["an", 574], ["essential", 577], ["role", 587], ["in", 592], ["both", 595], ["the", 600], ["up", 604], ["-", 606], ["regulation", 607], ["of", 618], ["cell", 621], ["proliferation", 626], ["and", 640], ["down", 644], ["-", 648], ["regulation", 649], ["of", 660], ["cell", 663], ["death", 668], ["in", 674], ["human", 677], ["cancer", 683], ["cells", 690], [".", 695], ["Both", 697], ["in", 702], ["vitro", 705], ["and", 711], ["in", 715], ["vivo", 718], ["experimental", 723], ["and", 736], ["clinical", 740], ["results", 749], ["have", 757], ["demonstrated", 762], ["the", 775], ["potential", 779], ["use", 789], ["of", 793], ["proteasome", 796], ["inhibitors", 807], ["as", 818], ["novel", 821], ["anticancer", 827], ["drugs", 838], [".", 843], ["Proteasome", 845], ["inhibition", 856], ["in", 867], ["cancer", 870], ["cells", 877], ["leads", 883], ["to", 889], ["accumulation", 892], ["of", 905], ["pro", 908], ["-", 911], ["apoptotic", 912], ["target", 922], ["proteins", 929], ["followed", 938], ["by", 947], ["induction", 950], ["of", 960], ["cell", 963], ["death", 968], [".", 973], ["The", 975], ["clinical", 979], ["efficacy", 988], ["of", 997], ["the", 1000], ["proteasome", 1004], ["inhibitor", 1015], ["bortezomib", 1025], ["toward", 1036], ["multiple", 1043], ["myeloma", 1052], ["and", 1060], ["other", 1064], ["hematologic", 1070], ["malignancies", 1082], ["provides", 1095], ["the", 1104], ["\"", 1108], ["proof", 1109], ["of", 1115], ["concept", 1118], ["\"", 1125], ["that", 1127], ["targeting", 1132], ["the", 1142], ["proteasome", 1146], ["is", 1157], ["a", 1160], ["promising", 1162], ["strategy", 1172], ["for", 1181], ["cancer", 1185], ["treatment", 1192], [".", 1201], ["Several", 1203], ["other", 1211], ["proteasome", 1217], ["inhibitors", 1228], ["have", 1239], ["also", 1244], ["been", 1249], ["identified", 1254], ["from", 1265], ["natural", 1270], ["resources", 1278], [",", 1287], ["such", 1289], ["as", 1294], ["marine", 1297], ["microbial", 1304], ["metabolites", 1314], [",", 1325], ["green", 1327], ["tea", 1333], ["polyphenols", 1337], [",", 1348], ["flavonoids", 1350], [",", 1360], ["and", 1362], ["medicinal", 1366], ["compounds", 1376], [".", 1385], ["Additionally", 1387], [",", 1399], ["the", 1401], ["use", 1405], ["of", 1409], ["metal", 1412], ["complexes", 1418], ["as", 1428], ["proteasome", 1431], ["inhibitors", 1442], ["has", 1453], ["also", 1457], ["been", 1462], ["investigated", 1467], ["as", 1480], ["a", 1483], ["potential", 1485], ["anticancer", 1495], ["strategy", 1506], [".", 1514], ["The", 1516], ["clinical", 1520], ["significance", 1529], ["of", 1542], ["targeting", 1545], ["the", 1555], ["tumor", 1559], ["survival", 1565], ["-", 1573], ["associated", 1574], ["proteasome", 1585], ["pathway", 1596], ["for", 1604], ["cancer", 1608], ["treatment", 1615], [",", 1624], ["intervention", 1626], ["and", 1639], ["prevention", 1643], ["will", 1654], ["be", 1659], ["discussed", 1662], [".", 1671]]}
{"context": "The Long QT syndrome (LQTS) is a relatively rare disorder. It has a major clinical impact as affected individuals are prone to syncope and sudden arrhythmogenic cardiac death. The LQTS comprises three groups of patients. The Jervell-Lange-Nielsen syndrome is characterized by an autosomal recessive pattern of inheritance and congenital neural deafness. The Romano-Ward syndrome shows an autosomal dominant pattern of inheritance and normal hearing. Patients with the sporadic form of LQTS have no evidence of familial transmission and have normal hearing. Imbalance of sympathetic cardiac innervation with predominance of the left stellate ganglion and an intrinsic myocardial defect leading to early afterdepolarization are the two pathogenetic mechanisms of LQTS discussed today. More recently a genetic basis for the Romano-Ward LQTS has been reported. The genetic linkage to the Harvey ras-1 gene provides the basis for a new hypothesis that an impairment of guanine nucleotide binding proteins is responsible for symptoms observed in LQTS. This paper discusses the genetic basis, pathology and pathophysiology of LQTS and tries to unify the different theories.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "26694e93ebbc4962895a9d5377a2e4e8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[68, 69]], "char_spans": [[388, 405]]}]}], "context_tokens": [["The", 0], ["Long", 4], ["QT", 9], ["syndrome", 12], ["(", 21], ["LQTS", 22], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["rare", 44], ["disorder", 49], [".", 57], ["It", 59], ["has", 62], ["a", 66], ["major", 68], ["clinical", 74], ["impact", 83], ["as", 90], ["affected", 93], ["individuals", 102], ["are", 114], ["prone", 118], ["to", 124], ["syncope", 127], ["and", 135], ["sudden", 139], ["arrhythmogenic", 146], ["cardiac", 161], ["death", 169], [".", 174], ["The", 176], ["LQTS", 180], ["comprises", 185], ["three", 195], ["groups", 201], ["of", 208], ["patients", 211], [".", 219], ["The", 221], ["Jervell", 225], ["-", 232], ["Lange", 233], ["-", 238], ["Nielsen", 239], ["syndrome", 247], ["is", 256], ["characterized", 259], ["by", 273], ["an", 276], ["autosomal", 279], ["recessive", 289], ["pattern", 299], ["of", 307], ["inheritance", 310], ["and", 322], ["congenital", 326], ["neural", 337], ["deafness", 344], [".", 352], ["The", 354], ["Romano", 358], ["-", 364], ["Ward", 365], ["syndrome", 370], ["shows", 379], ["an", 385], ["autosomal", 388], ["dominant", 398], ["pattern", 407], ["of", 415], ["inheritance", 418], ["and", 430], ["normal", 434], ["hearing", 441], [".", 448], ["Patients", 450], ["with", 459], ["the", 464], ["sporadic", 468], ["form", 477], ["of", 482], ["LQTS", 485], ["have", 490], ["no", 495], ["evidence", 498], ["of", 507], ["familial", 510], ["transmission", 519], ["and", 532], ["have", 536], ["normal", 541], ["hearing", 548], [".", 555], ["Imbalance", 557], ["of", 567], ["sympathetic", 570], ["cardiac", 582], ["innervation", 590], ["with", 602], ["predominance", 607], ["of", 620], ["the", 623], ["left", 627], ["stellate", 632], ["ganglion", 641], ["and", 650], ["an", 654], ["intrinsic", 657], ["myocardial", 667], ["defect", 678], ["leading", 685], ["to", 693], ["early", 696], ["afterdepolarization", 702], ["are", 722], ["the", 726], ["two", 730], ["pathogenetic", 734], ["mechanisms", 747], ["of", 758], ["LQTS", 761], ["discussed", 766], ["today", 776], [".", 781], ["More", 783], ["recently", 788], ["a", 797], ["genetic", 799], ["basis", 807], ["for", 813], ["the", 817], ["Romano", 821], ["-", 827], ["Ward", 828], ["LQTS", 833], ["has", 838], ["been", 842], ["reported", 847], [".", 855], ["The", 857], ["genetic", 861], ["linkage", 869], ["to", 877], ["the", 880], ["Harvey", 884], ["ras-1", 891], ["gene", 897], ["provides", 902], ["the", 911], ["basis", 915], ["for", 921], ["a", 925], ["new", 927], ["hypothesis", 931], ["that", 942], ["an", 947], ["impairment", 950], ["of", 961], ["guanine", 964], ["nucleotide", 972], ["binding", 983], ["proteins", 991], ["is", 1000], ["responsible", 1003], ["for", 1015], ["symptoms", 1019], ["observed", 1028], ["in", 1037], ["LQTS", 1040], [".", 1044], ["This", 1046], ["paper", 1051], ["discusses", 1057], ["the", 1067], ["genetic", 1071], ["basis", 1079], [",", 1084], ["pathology", 1086], ["and", 1096], ["pathophysiology", 1100], ["of", 1116], ["LQTS", 1119], ["and", 1124], ["tries", 1128], ["to", 1134], ["unify", 1137], ["the", 1143], ["different", 1147], ["theories", 1157], [".", 1165]]}
{"context": "Activation of the non-phagocytic superoxide-producing NADPH oxidase Nox1, complexed with p22(phox) at the membrane, requires its regulatory soluble proteins Noxo1 and Noxa1. However, the role of the small GTPase Rac remained to be clarified. Here we show that Rac directly participates in Nox1 activation via interacting with Noxa1. Electropermeabilized HeLa cells, ectopically expressing Nox1, Noxo1, and Noxa1, produce superoxide in a GTP-dependent manner, which is abrogated by expression of a mutant Noxa1(R103E), defective in Rac binding. Superoxide production in Nox1-expressing HeLa and Caco-2 cells is decreased by depletion or sequestration of Rac; on the other hand, it is enhanced by expression of the constitutively active Rac1(Q61L), but not by that of a mutant Rac1 with the A27K substitution, deficient in binding to Noxa1. We also demonstrate that Nox1 activation requires membrane recruitment of Noxa1, which is normally mediated via Noxa1 binding to Noxo1, a protein tethered to the Nox1 partner p22(phox): the Noxa1-Noxo1 and Noxo1-p22(phox) interactions are both essential for Nox1 activity. Rac likely facilitates the membrane localization of Noxa1: although Noxa1(W436R), defective in Noxo1 binding, neither associates with the membrane nor activates Nox1, the effects of the W436R substitution are restored by expression of Rac1(Q61L). The Rac-Noxa1 interaction also serves at a step different from the Noxa1 localization, because the binding-defective Noxa1(R103E), albeit targeted to the membrane, does not support superoxide production by Nox1. Furthermore, a mutant Noxa1 carrying the substitution of Ala for Val-205 in the activation domain, which is expected to undergo a conformational change upon Rac binding, fully localizes to the membrane but fails to activate Nox1.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "7b72b7fbe25641d2afc299fbcc7284d8", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[11, 11], [155, 155], [221, 221], [52, 52], [313, 313], [178, 178], [273, 273], [193, 193], [65, 65]], "char_spans": [[68, 71], [864, 867], [1273, 1276], [289, 292], [1795, 1798], [1001, 1004], [1565, 1568], [1097, 1100], [389, 392]]}]}], "context_tokens": [["Activation", 0], ["of", 11], ["the", 14], ["non", 18], ["-", 21], ["phagocytic", 22], ["superoxide", 33], ["-", 43], ["producing", 44], ["NADPH", 54], ["oxidase", 60], ["Nox1", 68], [",", 72], ["complexed", 74], ["with", 84], ["p22(phox", 89], [")", 97], ["at", 99], ["the", 102], ["membrane", 106], [",", 114], ["requires", 116], ["its", 125], ["regulatory", 129], ["soluble", 140], ["proteins", 148], ["Noxo1", 157], ["and", 163], ["Noxa1", 167], [".", 172], ["However", 174], [",", 181], ["the", 183], ["role", 187], ["of", 192], ["the", 195], ["small", 199], ["GTPase", 205], ["Rac", 212], ["remained", 216], ["to", 225], ["be", 228], ["clarified", 231], [".", 240], ["Here", 242], ["we", 247], ["show", 250], ["that", 255], ["Rac", 260], ["directly", 264], ["participates", 273], ["in", 286], ["Nox1", 289], ["activation", 294], ["via", 305], ["interacting", 309], ["with", 321], ["Noxa1", 326], [".", 331], ["Electropermeabilized", 333], ["HeLa", 354], ["cells", 359], [",", 364], ["ectopically", 366], ["expressing", 378], ["Nox1", 389], [",", 393], ["Noxo1", 395], [",", 400], ["and", 402], ["Noxa1", 406], [",", 411], ["produce", 413], ["superoxide", 421], ["in", 432], ["a", 435], ["GTP", 437], ["-", 440], ["dependent", 441], ["manner", 451], [",", 457], ["which", 459], ["is", 465], ["abrogated", 468], ["by", 478], ["expression", 481], ["of", 492], ["a", 495], ["mutant", 497], ["Noxa1(R103E", 504], [")", 515], [",", 516], ["defective", 518], ["in", 528], ["Rac", 531], ["binding", 535], [".", 542], ["Superoxide", 544], ["production", 555], ["in", 566], ["Nox1-expressing", 569], ["HeLa", 585], ["and", 590], ["Caco-2", 594], ["cells", 601], ["is", 607], ["decreased", 610], ["by", 620], ["depletion", 623], ["or", 633], ["sequestration", 636], ["of", 650], ["Rac", 653], [";", 656], ["on", 658], ["the", 661], ["other", 665], ["hand", 671], [",", 675], ["it", 677], ["is", 680], ["enhanced", 683], ["by", 692], ["expression", 695], ["of", 706], ["the", 709], ["constitutively", 713], ["active", 728], ["Rac1(Q61L", 735], [")", 744], [",", 745], ["but", 747], ["not", 751], ["by", 755], ["that", 758], ["of", 763], ["a", 766], ["mutant", 768], ["Rac1", 775], ["with", 780], ["the", 785], ["A27", 789], ["K", 792], ["substitution", 794], [",", 806], ["deficient", 808], ["in", 818], ["binding", 821], ["to", 829], ["Noxa1", 832], [".", 837], ["We", 839], ["also", 842], ["demonstrate", 847], ["that", 859], ["Nox1", 864], ["activation", 869], ["requires", 880], ["membrane", 889], ["recruitment", 898], ["of", 910], ["Noxa1", 913], [",", 918], ["which", 920], ["is", 926], ["normally", 929], ["mediated", 938], ["via", 947], ["Noxa1", 951], ["binding", 957], ["to", 965], ["Noxo1", 968], [",", 973], ["a", 975], ["protein", 977], ["tethered", 985], ["to", 994], ["the", 997], ["Nox1", 1001], ["partner", 1006], ["p22(phox", 1014], [")", 1022], [":", 1023], ["the", 1025], ["Noxa1-Noxo1", 1029], ["and", 1041], ["Noxo1-p22(phox", 1045], [")", 1059], ["interactions", 1061], ["are", 1074], ["both", 1078], ["essential", 1083], ["for", 1093], ["Nox1", 1097], ["activity", 1102], [".", 1110], ["Rac", 1112], ["likely", 1116], ["facilitates", 1123], ["the", 1135], ["membrane", 1139], ["localization", 1148], ["of", 1161], ["Noxa1", 1164], [":", 1169], ["although", 1171], ["Noxa1(W436R", 1180], [")", 1191], [",", 1192], ["defective", 1194], ["in", 1204], ["Noxo1", 1207], ["binding", 1213], [",", 1220], ["neither", 1222], ["associates", 1230], ["with", 1241], ["the", 1246], ["membrane", 1250], ["nor", 1259], ["activates", 1263], ["Nox1", 1273], [",", 1277], ["the", 1279], ["effects", 1283], ["of", 1291], ["the", 1294], ["W436R", 1298], ["substitution", 1304], ["are", 1317], ["restored", 1321], ["by", 1330], ["expression", 1333], ["of", 1344], ["Rac1(Q61L", 1347], [")", 1356], [".", 1357], ["The", 1359], ["Rac", 1363], ["-", 1366], ["Noxa1", 1367], ["interaction", 1373], ["also", 1385], ["serves", 1390], ["at", 1397], ["a", 1400], ["step", 1402], ["different", 1407], ["from", 1417], ["the", 1422], ["Noxa1", 1426], ["localization", 1432], [",", 1444], ["because", 1446], ["the", 1454], ["binding", 1458], ["-", 1465], ["defective", 1466], ["Noxa1(R103E", 1476], [")", 1487], [",", 1488], ["albeit", 1490], ["targeted", 1497], ["to", 1506], ["the", 1509], ["membrane", 1513], [",", 1521], ["does", 1523], ["not", 1528], ["support", 1532], ["superoxide", 1540], ["production", 1551], ["by", 1562], ["Nox1", 1565], [".", 1569], ["Furthermore", 1571], [",", 1582], ["a", 1584], ["mutant", 1586], ["Noxa1", 1593], ["carrying", 1599], ["the", 1608], ["substitution", 1612], ["of", 1625], ["Ala", 1628], ["for", 1632], ["Val-205", 1636], ["in", 1644], ["the", 1647], ["activation", 1651], ["domain", 1662], [",", 1668], ["which", 1670], ["is", 1676], ["expected", 1679], ["to", 1688], ["undergo", 1691], ["a", 1699], ["conformational", 1701], ["change", 1716], ["upon", 1723], ["Rac", 1728], ["binding", 1732], [",", 1739], ["fully", 1741], ["localizes", 1747], ["to", 1757], ["the", 1760], ["membrane", 1764], ["but", 1773], ["fails", 1777], ["to", 1783], ["activate", 1786], ["Nox1", 1795], [".", 1799]]}
{"context": "Turner syndrome is a chromosomal disorder in which all or part of one X chromosome is missing. The meiotic or mitotic origin of most cases remains unknown due to the difficulty in detecting hidden mosaicism and to the lack of meiotic segregation studies. We analyzed 15 Turner patients, 10 with a 45,X whereas the rest had a second cell line with abnormal X-chromosomes: a pseudodicentric, an isochromosome, one large and one small ring, and the last with a long arm deletion. Our aims were: to detect X cryptic mosaicism in patients with a 45,X constitution; to determine the parental origin of the abnormality; to infer the zygotic origin of the karyotype and to suggest the timing and mechanism of the error(s) leading to the formation of abnormal X chromosomes from maternal origin. Molecular investigation did not revealed heterozygosity for any microsatellite, excluding X mosaicism in the 45,X cases. Parental origin of the single X chromosome was maternal in 90% of these patients. Three of the structurally abnormal Xs were maternally derived whereas the other two were paternal. These results allowed us to corroborate breakpoints in these abnormal X chromosomes and suggest that the pseudodicentric chromosome originated from post-zygotic sister chromatid exchange, whereas the Xq deleted chromosome probably arose after a recombination event during maternal meiosis.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "fb9765068c0047e8994ba18eabf79e88", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[13, 13], [97, 97], [141, 141], [170, 170], [158, 158], [65, 65], [207, 207]], "char_spans": [[70, 70], [502, 502], [751, 751], [938, 938], [877, 877], [356, 356], [1159, 1159]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["chromosomal", 21], ["disorder", 33], ["in", 42], ["which", 45], ["all", 51], ["or", 55], ["part", 58], ["of", 63], ["one", 66], ["X", 70], ["chromosome", 72], ["is", 83], ["missing", 86], [".", 93], ["The", 95], ["meiotic", 99], ["or", 107], ["mitotic", 110], ["origin", 118], ["of", 125], ["most", 128], ["cases", 133], ["remains", 139], ["unknown", 147], ["due", 155], ["to", 159], ["the", 162], ["difficulty", 166], ["in", 177], ["detecting", 180], ["hidden", 190], ["mosaicism", 197], ["and", 207], ["to", 211], ["the", 214], ["lack", 218], ["of", 223], ["meiotic", 226], ["segregation", 234], ["studies", 246], [".", 253], ["We", 255], ["analyzed", 258], ["15", 267], ["Turner", 270], ["patients", 277], [",", 285], ["10", 287], ["with", 290], ["a", 295], ["45,X", 297], ["whereas", 302], ["the", 310], ["rest", 314], ["had", 319], ["a", 323], ["second", 325], ["cell", 332], ["line", 337], ["with", 342], ["abnormal", 347], ["X", 356], ["-", 357], ["chromosomes", 358], [":", 369], ["a", 371], ["pseudodicentric", 373], [",", 388], ["an", 390], ["isochromosome", 393], [",", 406], ["one", 408], ["large", 412], ["and", 418], ["one", 422], ["small", 426], ["ring", 432], [",", 436], ["and", 438], ["the", 442], ["last", 446], ["with", 451], ["a", 456], ["long", 458], ["arm", 463], ["deletion", 467], [".", 475], ["Our", 477], ["aims", 481], ["were", 486], [":", 490], ["to", 492], ["detect", 495], ["X", 502], ["cryptic", 504], ["mosaicism", 512], ["in", 522], ["patients", 525], ["with", 534], ["a", 539], ["45,X", 541], ["constitution", 546], [";", 558], ["to", 560], ["determine", 563], ["the", 573], ["parental", 577], ["origin", 586], ["of", 593], ["the", 596], ["abnormality", 600], [";", 611], ["to", 613], ["infer", 616], ["the", 622], ["zygotic", 626], ["origin", 634], ["of", 641], ["the", 644], ["karyotype", 648], ["and", 658], ["to", 662], ["suggest", 665], ["the", 673], ["timing", 677], ["and", 684], ["mechanism", 688], ["of", 698], ["the", 701], ["error(s", 705], [")", 712], ["leading", 714], ["to", 722], ["the", 725], ["formation", 729], ["of", 739], ["abnormal", 742], ["X", 751], ["chromosomes", 753], ["from", 765], ["maternal", 770], ["origin", 779], [".", 785], ["Molecular", 787], ["investigation", 797], ["did", 811], ["not", 815], ["revealed", 819], ["heterozygosity", 828], ["for", 843], ["any", 847], ["microsatellite", 851], [",", 865], ["excluding", 867], ["X", 877], ["mosaicism", 879], ["in", 889], ["the", 892], ["45,X", 896], ["cases", 901], [".", 906], ["Parental", 908], ["origin", 917], ["of", 924], ["the", 927], ["single", 931], ["X", 938], ["chromosome", 940], ["was", 951], ["maternal", 955], ["in", 964], ["90", 967], ["%", 969], ["of", 971], ["these", 974], ["patients", 980], [".", 988], ["Three", 990], ["of", 996], ["the", 999], ["structurally", 1003], ["abnormal", 1016], ["Xs", 1025], ["were", 1028], ["maternally", 1033], ["derived", 1044], ["whereas", 1052], ["the", 1060], ["other", 1064], ["two", 1070], ["were", 1074], ["paternal", 1079], [".", 1087], ["These", 1089], ["results", 1095], ["allowed", 1103], ["us", 1111], ["to", 1114], ["corroborate", 1117], ["breakpoints", 1129], ["in", 1141], ["these", 1144], ["abnormal", 1150], ["X", 1159], ["chromosomes", 1161], ["and", 1173], ["suggest", 1177], ["that", 1185], ["the", 1190], ["pseudodicentric", 1194], ["chromosome", 1210], ["originated", 1221], ["from", 1232], ["post", 1237], ["-", 1241], ["zygotic", 1242], ["sister", 1250], ["chromatid", 1257], ["exchange", 1267], [",", 1275], ["whereas", 1277], ["the", 1285], ["Xq", 1289], ["deleted", 1292], ["chromosome", 1300], ["probably", 1311], ["arose", 1320], ["after", 1326], ["a", 1332], ["recombination", 1334], ["event", 1348], ["during", 1354], ["maternal", 1361], ["meiosis", 1370], [".", 1377]]}
{"context": "Cytoskeletal proteins belonging to the spectrin family have an elongated structure composed of repetitive units. The three-dimensional solution structure of the 16th repeat from chicken brain alpha-spectrin (R16) has been determined by NMR spectroscopy and distance geometry-simulated annealing calculations. We used a total of 1035 distance restraints, which included 719 NOE-based values obtained by applying the ambiguous restraints for iterative assignment (ARIA) method. In addition, we performed a direct refinement against 1H-chemical shifts. The final ensemble of 20 structures shows an average RMSD of 1.52 A from the mean for the backbone atoms, excluding loops and N and C termini. R16 is made up of three antiparallel alpha-helices separated by two loops, and folds into a left-handed coiled-coil. The basic unit of spectrin is an antiparallel heterodimer composed of two homologous chains, beta and alpha. These assemble a tetramer via a mechanism that relies on the completion of a single repeat by association of the partial repeats located at the C terminus of the beta-chain (two helices) and at the N terminus of the alpha-chain (one helix). This tetramer is the assemblage able to cross-link actin filaments. Model building by homology of the \"tetramerization\" repeat from human erythrocyte spectrin illuminates the possible role of point mutations which cause hemolytic anemias.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "792b104e025543b5b32f47d3bb1b5c44", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[128, 128], [155, 155]], "char_spans": [[717, 728], [843, 854]]}]}], "context_tokens": [["Cytoskeletal", 0], ["proteins", 13], ["belonging", 22], ["to", 32], ["the", 35], ["spectrin", 39], ["family", 48], ["have", 55], ["an", 60], ["elongated", 63], ["structure", 73], ["composed", 83], ["of", 92], ["repetitive", 95], ["units", 106], [".", 111], ["The", 113], ["three", 117], ["-", 122], ["dimensional", 123], ["solution", 135], ["structure", 144], ["of", 154], ["the", 157], ["16th", 161], ["repeat", 166], ["from", 173], ["chicken", 178], ["brain", 186], ["alpha", 192], ["-", 197], ["spectrin", 198], ["(", 207], ["R16", 208], [")", 211], ["has", 213], ["been", 217], ["determined", 222], ["by", 233], ["NMR", 236], ["spectroscopy", 240], ["and", 253], ["distance", 257], ["geometry", 266], ["-", 274], ["simulated", 275], ["annealing", 285], ["calculations", 295], [".", 307], ["We", 309], ["used", 312], ["a", 317], ["total", 319], ["of", 325], ["1035", 328], ["distance", 333], ["restraints", 342], [",", 352], ["which", 354], ["included", 360], ["719", 369], ["NOE", 373], ["-", 376], ["based", 377], ["values", 383], ["obtained", 390], ["by", 399], ["applying", 402], ["the", 411], ["ambiguous", 415], ["restraints", 425], ["for", 436], ["iterative", 440], ["assignment", 450], ["(", 461], ["ARIA", 462], [")", 466], ["method", 468], [".", 474], ["In", 476], ["addition", 479], [",", 487], ["we", 489], ["performed", 492], ["a", 502], ["direct", 504], ["refinement", 511], ["against", 522], ["1H", 530], ["-", 532], ["chemical", 533], ["shifts", 542], [".", 548], ["The", 550], ["final", 554], ["ensemble", 560], ["of", 569], ["20", 572], ["structures", 575], ["shows", 586], ["an", 592], ["average", 595], ["RMSD", 603], ["of", 608], ["1.52", 611], ["A", 616], ["from", 618], ["the", 623], ["mean", 627], ["for", 632], ["the", 636], ["backbone", 640], ["atoms", 649], [",", 654], ["excluding", 656], ["loops", 666], ["and", 672], ["N", 676], ["and", 678], ["C", 682], ["termini", 684], [".", 691], ["R16", 693], ["is", 697], ["made", 700], ["up", 705], ["of", 708], ["three", 711], ["antiparallel", 717], ["alpha", 730], ["-", 735], ["helices", 736], ["separated", 744], ["by", 754], ["two", 757], ["loops", 761], [",", 766], ["and", 768], ["folds", 772], ["into", 778], ["a", 783], ["left", 785], ["-", 789], ["handed", 790], ["coiled", 797], ["-", 803], ["coil", 804], [".", 808], ["The", 810], ["basic", 814], ["unit", 820], ["of", 825], ["spectrin", 828], ["is", 837], ["an", 840], ["antiparallel", 843], ["heterodimer", 856], ["composed", 868], ["of", 877], ["two", 880], ["homologous", 884], ["chains", 895], [",", 901], ["beta", 903], ["and", 908], ["alpha", 912], [".", 917], ["These", 919], ["assemble", 925], ["a", 934], ["tetramer", 936], ["via", 945], ["a", 949], ["mechanism", 951], ["that", 961], ["relies", 966], ["on", 973], ["the", 976], ["completion", 980], ["of", 991], ["a", 994], ["single", 996], ["repeat", 1003], ["by", 1010], ["association", 1013], ["of", 1025], ["the", 1028], ["partial", 1032], ["repeats", 1040], ["located", 1048], ["at", 1056], ["the", 1059], ["C", 1063], ["terminus", 1065], ["of", 1074], ["the", 1077], ["beta", 1081], ["-", 1085], ["chain", 1086], ["(", 1092], ["two", 1093], ["helices", 1097], [")", 1104], ["and", 1106], ["at", 1110], ["the", 1113], ["N", 1117], ["terminus", 1119], ["of", 1128], ["the", 1131], ["alpha", 1135], ["-", 1140], ["chain", 1141], ["(", 1147], ["one", 1148], ["helix", 1152], [")", 1157], [".", 1158], ["This", 1160], ["tetramer", 1165], ["is", 1174], ["the", 1177], ["assemblage", 1181], ["able", 1192], ["to", 1197], ["cross", 1200], ["-", 1205], ["link", 1206], ["actin", 1211], ["filaments", 1217], [".", 1226], ["Model", 1228], ["building", 1234], ["by", 1243], ["homology", 1246], ["of", 1255], ["the", 1258], ["\"", 1262], ["tetramerization", 1263], ["\"", 1278], ["repeat", 1280], ["from", 1287], ["human", 1292], ["erythrocyte", 1298], ["spectrin", 1310], ["illuminates", 1319], ["the", 1331], ["possible", 1335], ["role", 1344], ["of", 1349], ["point", 1352], ["mutations", 1358], ["which", 1368], ["cause", 1374], ["hemolytic", 1380], ["anemias", 1390], [".", 1397]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Methylation of lysine 9 (K9) in the N-terminus tail of histone H3 (H3) in chromatin is associated with transcriptionally silenced genes and is mediated by histone methyltransferases. Murine G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain and ANK repeats. In this paper, we have used a series of green fluorescent protein-tagged deletion constructs to identify two nuclear localization signals (NLS), the first NLS embedded between amino acids 24 and 109 and the second between amino acids 394 and 401 of murine G9a. Our data show that both long and short G9a isoforms were capable of entering the nucleus to methylate chromatin. Full-length or N-terminus-deleted G9a isoforms were also catalytically active enzymes that methylated recombinant H3 or synthetic peptides representing the N-terminus tail of H3. In vitro methylation reactions using N-terminus tail peptides resulted in tri-methylation of K9 that remained processive, even in G9a enzymes that lacked an N-terminus region by deletion. Co-expression of G9a and H3 resulted in di- and tri-methylation of H3-K9, while siRNA-mediated knockdown of G9a in HeLa cells resulted in reduction of global H3-K9 di- and tri-methylation. A recombinant deletion mutant enzyme fused with maltose-binding protein (MBP-G9aDelta634) was used for steady-state kinetic analysis with various substrates and was compared with full-length G9a (G9aFL). Turnover numbers of MBP-G9aDelta634 for various substrates was approximately 3-fold less compared with G9aFL, while their Michaelis constants (K(m)) for recombinant H3 were similar. The K(AdoMet)m for MBP-G9aDelta634 was approximately 2.3-2.65 microM with various substrates. Catalytic efficiencies (kcat/K(m)) for both MBP-G9aDelta634 and G9aFL were similar, suggesting that the N-terminus is not essential for catalysis. Furthermore, mutation of conserved amino acids R1097A, W1103A, Y1120A, Y1138A and R1162A, or the metal binding C1168A in the catalytic region, resulted in catalytically impaired enzymes, thereby confirming the involvement of the C-terminus of G9a in catalysis. Thus, distinct domains modulate nuclear targeting and catalytic functions of G9a.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "e57c68a8293d462f9fdab7bb2767c729", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[46, 47]], "char_spans": [[269, 278]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["9", 22], ["(", 24], ["K9", 25], [")", 27], ["in", 29], ["the", 32], ["N", 36], ["-", 37], ["terminus", 38], ["tail", 47], ["of", 52], ["histone", 55], ["H3", 63], ["(", 66], ["H3", 67], [")", 69], ["in", 71], ["chromatin", 74], ["is", 84], ["associated", 87], ["with", 98], ["transcriptionally", 103], ["silenced", 121], ["genes", 130], ["and", 136], ["is", 140], ["mediated", 143], ["by", 152], ["histone", 155], ["methyltransferases", 163], [".", 181], ["Murine", 183], ["G9a", 190], ["is", 194], ["a", 197], ["1263", 199], ["amino", 204], ["acid", 210], ["H3-K9", 215], ["methyltransferase", 221], ["that", 239], ["possesses", 244], ["characteristic", 254], ["SET", 269], ["domain", 273], ["and", 280], ["ANK", 284], ["repeats", 288], [".", 295], ["In", 297], ["this", 300], ["paper", 305], [",", 310], ["we", 312], ["have", 315], ["used", 320], ["a", 325], ["series", 327], ["of", 334], ["green", 337], ["fluorescent", 343], ["protein", 355], ["-", 362], ["tagged", 363], ["deletion", 370], ["constructs", 379], ["to", 390], ["identify", 393], ["two", 402], ["nuclear", 406], ["localization", 414], ["signals", 427], ["(", 435], ["NLS", 436], [")", 439], [",", 440], ["the", 442], ["first", 446], ["NLS", 452], ["embedded", 456], ["between", 465], ["amino", 473], ["acids", 479], ["24", 485], ["and", 488], ["109", 492], ["and", 496], ["the", 500], ["second", 504], ["between", 511], ["amino", 519], ["acids", 525], ["394", 531], ["and", 535], ["401", 539], ["of", 543], ["murine", 546], ["G9a", 553], [".", 556], ["Our", 558], ["data", 562], ["show", 567], ["that", 572], ["both", 577], ["long", 582], ["and", 587], ["short", 591], ["G9a", 597], ["isoforms", 601], ["were", 610], ["capable", 615], ["of", 623], ["entering", 626], ["the", 635], ["nucleus", 639], ["to", 647], ["methylate", 650], ["chromatin", 660], [".", 669], ["Full", 671], ["-", 675], ["length", 676], ["or", 683], ["N", 686], ["-", 687], ["terminus", 688], ["-", 696], ["deleted", 697], ["G9a", 705], ["isoforms", 709], ["were", 718], ["also", 723], ["catalytically", 728], ["active", 742], ["enzymes", 749], ["that", 757], ["methylated", 762], ["recombinant", 773], ["H3", 785], ["or", 788], ["synthetic", 791], ["peptides", 801], ["representing", 810], ["the", 823], ["N", 827], ["-", 828], ["terminus", 829], ["tail", 838], ["of", 843], ["H3", 846], [".", 848], ["In", 850], ["vitro", 853], ["methylation", 859], ["reactions", 871], ["using", 881], ["N", 887], ["-", 888], ["terminus", 889], ["tail", 898], ["peptides", 903], ["resulted", 912], ["in", 921], ["tri", 924], ["-", 927], ["methylation", 928], ["of", 940], ["K9", 943], ["that", 946], ["remained", 951], ["processive", 960], [",", 970], ["even", 972], ["in", 977], ["G9a", 980], ["enzymes", 984], ["that", 992], ["lacked", 997], ["an", 1004], ["N", 1007], ["-", 1008], ["terminus", 1009], ["region", 1018], ["by", 1025], ["deletion", 1028], [".", 1036], ["Co", 1038], ["-", 1040], ["expression", 1041], ["of", 1052], ["G9a", 1055], ["and", 1059], ["H3", 1063], ["resulted", 1066], ["in", 1075], ["di-", 1078], ["and", 1082], ["tri", 1086], ["-", 1089], ["methylation", 1090], ["of", 1102], ["H3-K9", 1105], [",", 1110], ["while", 1112], ["siRNA", 1118], ["-", 1123], ["mediated", 1124], ["knockdown", 1133], ["of", 1143], ["G9a", 1146], ["in", 1150], ["HeLa", 1153], ["cells", 1158], ["resulted", 1164], ["in", 1173], ["reduction", 1176], ["of", 1186], ["global", 1189], ["H3-K9", 1196], ["di-", 1202], ["and", 1206], ["tri", 1210], ["-", 1213], ["methylation", 1214], [".", 1225], ["A", 1227], ["recombinant", 1229], ["deletion", 1241], ["mutant", 1250], ["enzyme", 1257], ["fused", 1264], ["with", 1270], ["maltose", 1275], ["-", 1282], ["binding", 1283], ["protein", 1291], ["(", 1299], ["MBP", 1300], ["-", 1303], ["G9aDelta634", 1304], [")", 1315], ["was", 1317], ["used", 1321], ["for", 1326], ["steady", 1330], ["-", 1336], ["state", 1337], ["kinetic", 1343], ["analysis", 1351], ["with", 1360], ["various", 1365], ["substrates", 1373], ["and", 1384], ["was", 1388], ["compared", 1392], ["with", 1401], ["full", 1406], ["-", 1410], ["length", 1411], ["G9a", 1418], ["(", 1422], ["G9aFL", 1423], [")", 1428], [".", 1429], ["Turnover", 1431], ["numbers", 1440], ["of", 1448], ["MBP", 1451], ["-", 1454], ["G9aDelta634", 1455], ["for", 1467], ["various", 1471], ["substrates", 1479], ["was", 1490], ["approximately", 1494], ["3-fold", 1508], ["less", 1515], ["compared", 1520], ["with", 1529], ["G9aFL", 1534], [",", 1539], ["while", 1541], ["their", 1547], ["Michaelis", 1553], ["constants", 1563], ["(", 1573], ["K(m", 1574], [")", 1577], [")", 1578], ["for", 1580], ["recombinant", 1584], ["H3", 1596], ["were", 1599], ["similar", 1604], [".", 1611], ["The", 1613], ["K(AdoMet)m", 1617], ["for", 1628], ["MBP", 1632], ["-", 1635], ["G9aDelta634", 1636], ["was", 1648], ["approximately", 1652], ["2.3", 1666], ["-", 1669], ["2.65", 1670], ["microM", 1675], ["with", 1682], ["various", 1687], ["substrates", 1695], [".", 1705], ["Catalytic", 1707], ["efficiencies", 1717], ["(", 1730], ["kcat", 1731], ["/", 1735], ["K(m", 1736], [")", 1739], [")", 1740], ["for", 1742], ["both", 1746], ["MBP", 1751], ["-", 1754], ["G9aDelta634", 1755], ["and", 1767], ["G9aFL", 1771], ["were", 1777], ["similar", 1782], [",", 1789], ["suggesting", 1791], ["that", 1802], ["the", 1807], ["N", 1811], ["-", 1812], ["terminus", 1813], ["is", 1822], ["not", 1825], ["essential", 1829], ["for", 1839], ["catalysis", 1843], [".", 1852], ["Furthermore", 1854], [",", 1865], ["mutation", 1867], ["of", 1876], ["conserved", 1879], ["amino", 1889], ["acids", 1895], ["R1097A", 1901], [",", 1907], ["W1103A", 1909], [",", 1915], ["Y1120A", 1917], [",", 1923], ["Y1138A", 1925], ["and", 1932], ["R1162A", 1936], [",", 1942], ["or", 1944], ["the", 1947], ["metal", 1951], ["binding", 1957], ["C1168A", 1965], ["in", 1972], ["the", 1975], ["catalytic", 1979], ["region", 1989], [",", 1995], ["resulted", 1997], ["in", 2006], ["catalytically", 2009], ["impaired", 2023], ["enzymes", 2032], [",", 2039], ["thereby", 2041], ["confirming", 2049], ["the", 2060], ["involvement", 2064], ["of", 2076], ["the", 2079], ["C", 2083], ["-", 2084], ["terminus", 2085], ["of", 2094], ["G9a", 2097], ["in", 2101], ["catalysis", 2104], [".", 2113], ["Thus", 2115], [",", 2119], ["distinct", 2121], ["domains", 2130], ["modulate", 2138], ["nuclear", 2147], ["targeting", 2155], ["and", 2165], ["catalytic", 2169], ["functions", 2179], ["of", 2189], ["G9a", 2192], [".", 2195]]}
{"context": "Loss of consciousness in childhood may be due to cardiovascular causes, and the Long Q-T syndromes can present with seizures. The Romano-Ward syndrome is of autosomal dominant inheritance, and the Jervell and Lange-Nielson syndrome, with associated deafness, of autosomal recessive inheritance. The diagnosis is often delayed, but a careful history can avoid this. The syndromes can appear to be due to an imbalance in the sympathetic nerve to the ventricular myocardium, and precipitating causes such as stress suggest a CNS influence on this. The electrocardiogram can confirm the prolonged Q-T interval, but this is not always present, at least without an exercise test. Treatment with beta-blockers is often successful. If a wrong diagnosis of epilepsy is made a chance may be missed of avoiding sudden death, quite apart from all the medical, and social consequences that can result from such a diagnosis.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "8f255d79fc124b75bbeb22b7b675d5cd", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[31, 32]], "char_spans": [[157, 174]]}]}], "context_tokens": [["Loss", 0], ["of", 5], ["consciousness", 8], ["in", 22], ["childhood", 25], ["may", 35], ["be", 39], ["due", 42], ["to", 46], ["cardiovascular", 49], ["causes", 64], [",", 70], ["and", 72], ["the", 76], ["Long", 80], ["Q", 85], ["-", 86], ["T", 87], ["syndromes", 89], ["can", 99], ["present", 103], ["with", 111], ["seizures", 116], [".", 124], ["The", 126], ["Romano", 130], ["-", 136], ["Ward", 137], ["syndrome", 142], ["is", 151], ["of", 154], ["autosomal", 157], ["dominant", 167], ["inheritance", 176], [",", 187], ["and", 189], ["the", 193], ["Jervell", 197], ["and", 205], ["Lange", 209], ["-", 214], ["Nielson", 215], ["syndrome", 223], [",", 231], ["with", 233], ["associated", 238], ["deafness", 249], [",", 257], ["of", 259], ["autosomal", 262], ["recessive", 272], ["inheritance", 282], [".", 293], ["The", 295], ["diagnosis", 299], ["is", 309], ["often", 312], ["delayed", 318], [",", 325], ["but", 327], ["a", 331], ["careful", 333], ["history", 341], ["can", 349], ["avoid", 353], ["this", 359], [".", 363], ["The", 365], ["syndromes", 369], ["can", 379], ["appear", 383], ["to", 390], ["be", 393], ["due", 396], ["to", 400], ["an", 403], ["imbalance", 406], ["in", 416], ["the", 419], ["sympathetic", 423], ["nerve", 435], ["to", 441], ["the", 444], ["ventricular", 448], ["myocardium", 460], [",", 470], ["and", 472], ["precipitating", 476], ["causes", 490], ["such", 497], ["as", 502], ["stress", 505], ["suggest", 512], ["a", 520], ["CNS", 522], ["influence", 526], ["on", 536], ["this", 539], [".", 543], ["The", 545], ["electrocardiogram", 549], ["can", 567], ["confirm", 571], ["the", 579], ["prolonged", 583], ["Q", 593], ["-", 594], ["T", 595], ["interval", 597], [",", 605], ["but", 607], ["this", 611], ["is", 616], ["not", 619], ["always", 623], ["present", 630], [",", 637], ["at", 639], ["least", 642], ["without", 648], ["an", 656], ["exercise", 659], ["test", 668], [".", 672], ["Treatment", 674], ["with", 684], ["beta", 689], ["-", 693], ["blockers", 694], ["is", 703], ["often", 706], ["successful", 712], [".", 722], ["If", 724], ["a", 727], ["wrong", 729], ["diagnosis", 735], ["of", 745], ["epilepsy", 748], ["is", 757], ["made", 760], ["a", 765], ["chance", 767], ["may", 774], ["be", 778], ["missed", 781], ["of", 788], ["avoiding", 791], ["sudden", 800], ["death", 807], [",", 812], ["quite", 814], ["apart", 820], ["from", 826], ["all", 831], ["the", 835], ["medical", 839], [",", 846], ["and", 848], ["social", 852], ["consequences", 859], ["that", 872], ["can", 877], ["result", 881], ["from", 888], ["such", 893], ["a", 898], ["diagnosis", 900], [".", 909]]}
{"context": "The enzyme telomerase is activated in 80-90% of all human malignancies and immortal cell lines, where it functions to maintain the integrity of chromosomal-end structures called telomeres. Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP). The TRAP assay involves extension of an oligonucleotide through telomerase-mediated enzymatic addition of telomeric DNA repeats and subsequent PCR amplification of the extension products. While the TRAP assay as originally developed utilizes radioactively labelled nucleotides, protocols are provided herein for nonradioactive versions of the TRAP assay, with options for either qualitative assessment of TRAP products by polyacrylamide gel electrophoresis (standard TRAP), or quantitative analysis by real-time PCR (Q-TRAP). The Q-TRAP method poses the additional advantages of exquisite sensitivity, rapidity, and potential for adoption to a high-throughput format.", "qas": [{"question": "What is the aim of the TRAP assay?", "answers": ["Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP)."], "qid": "8076404cfda8488c9fbc09080b95dccf", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["aim", 12], ["of", 16], ["the", 19], ["TRAP", 23], ["assay", 28], ["?", 33]], "detected_answers": [{"text": "Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP).", "token_spans": [[34, 61]], "char_spans": [[189, 367]]}]}], "context_tokens": [["The", 0], ["enzyme", 4], ["telomerase", 11], ["is", 22], ["activated", 25], ["in", 35], ["80", 38], ["-", 40], ["90", 41], ["%", 43], ["of", 45], ["all", 48], ["human", 52], ["malignancies", 58], ["and", 71], ["immortal", 75], ["cell", 84], ["lines", 89], [",", 94], ["where", 96], ["it", 102], ["functions", 105], ["to", 115], ["maintain", 118], ["the", 127], ["integrity", 131], ["of", 141], ["chromosomal", 144], ["-", 155], ["end", 156], ["structures", 160], ["called", 171], ["telomeres", 178], [".", 187], ["Telomerase", 189], ["enzyme", 200], ["activity", 207], ["can", 216], ["be", 220], ["detected", 223], ["in", 232], ["whole", 235], ["cell", 241], ["lysates", 246], ["by", 254], ["a", 257], ["polymerase", 259], ["chain", 270], ["reaction", 276], ["(", 285], ["PCR)-based", 286], ["method", 297], ["referred", 304], ["to", 313], ["as", 316], ["the", 319], ["telomeric", 323], ["repeat", 333], ["amplification", 340], ["protocol", 354], ["(", 363], ["TRAP", 364], [")", 368], [".", 369], ["The", 371], ["TRAP", 375], ["assay", 380], ["involves", 386], ["extension", 395], ["of", 405], ["an", 408], ["oligonucleotide", 411], ["through", 427], ["telomerase", 435], ["-", 445], ["mediated", 446], ["enzymatic", 455], ["addition", 465], ["of", 474], ["telomeric", 477], ["DNA", 487], ["repeats", 491], ["and", 499], ["subsequent", 503], ["PCR", 514], ["amplification", 518], ["of", 532], ["the", 535], ["extension", 539], ["products", 549], [".", 557], ["While", 559], ["the", 565], ["TRAP", 569], ["assay", 574], ["as", 580], ["originally", 583], ["developed", 594], ["utilizes", 604], ["radioactively", 613], ["labelled", 627], ["nucleotides", 636], [",", 647], ["protocols", 649], ["are", 659], ["provided", 663], ["herein", 672], ["for", 679], ["nonradioactive", 683], ["versions", 698], ["of", 707], ["the", 710], ["TRAP", 714], ["assay", 719], [",", 724], ["with", 726], ["options", 731], ["for", 739], ["either", 743], ["qualitative", 750], ["assessment", 762], ["of", 773], ["TRAP", 776], ["products", 781], ["by", 790], ["polyacrylamide", 793], ["gel", 808], ["electrophoresis", 812], ["(", 828], ["standard", 829], ["TRAP", 838], [")", 842], [",", 843], ["or", 845], ["quantitative", 848], ["analysis", 861], ["by", 870], ["real", 873], ["-", 877], ["time", 878], ["PCR", 883], ["(", 887], ["Q", 888], ["-", 889], ["TRAP", 890], [")", 894], [".", 895], ["The", 897], ["Q", 901], ["-", 902], ["TRAP", 903], ["method", 908], ["poses", 915], ["the", 921], ["additional", 925], ["advantages", 936], ["of", 947], ["exquisite", 950], ["sensitivity", 960], [",", 971], ["rapidity", 973], [",", 981], ["and", 983], ["potential", 987], ["for", 997], ["adoption", 1001], ["to", 1010], ["a", 1013], ["high", 1015], ["-", 1019], ["throughput", 1020], ["format", 1031], [".", 1037]]}
{"context": "Loss-of-function mutations in the gene ced-8 lead to the late appearance of cell corpses during embryonic development in C. elegans. ced-8 functions downstream of or in parallel to-the regulatory cell death gene ced-9 and may function as a cell death effector downstream of the caspase encoded by the programmed cell death killer gene ced-3. In ced-8 mutants, embryonic programmed cell death probably initiates normally but proceeds slowly. ced-8 encodes a transmembrane protein that appears to be localized to the plasma membrane. The CED-8 protein is similar to human XK, a putative membrane transport protein implicated in McLeod Syndrome, a form of hereditary neuroacanthocytosis.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "0574b68d8a1845829336d0bb8c46aef6", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[99, 99]], "char_spans": [[570, 571]]}]}], "context_tokens": [["Loss", 0], ["-", 4], ["of", 5], ["-", 7], ["function", 8], ["mutations", 17], ["in", 27], ["the", 30], ["gene", 34], ["ced-8", 39], ["lead", 45], ["to", 50], ["the", 53], ["late", 57], ["appearance", 62], ["of", 73], ["cell", 76], ["corpses", 81], ["during", 89], ["embryonic", 96], ["development", 106], ["in", 118], ["C.", 121], ["elegans", 124], [".", 131], ["ced-8", 133], ["functions", 139], ["downstream", 149], ["of", 160], ["or", 163], ["in", 166], ["parallel", 169], ["to", 178], ["-", 180], ["the", 181], ["regulatory", 185], ["cell", 196], ["death", 201], ["gene", 207], ["ced-9", 212], ["and", 218], ["may", 222], ["function", 226], ["as", 235], ["a", 238], ["cell", 240], ["death", 245], ["effector", 251], ["downstream", 260], ["of", 271], ["the", 274], ["caspase", 278], ["encoded", 286], ["by", 294], ["the", 297], ["programmed", 301], ["cell", 312], ["death", 317], ["killer", 323], ["gene", 330], ["ced-3", 335], [".", 340], ["In", 342], ["ced-8", 345], ["mutants", 351], [",", 358], ["embryonic", 360], ["programmed", 370], ["cell", 381], ["death", 386], ["probably", 392], ["initiates", 401], ["normally", 411], ["but", 420], ["proceeds", 424], ["slowly", 433], [".", 439], ["ced-8", 441], ["encodes", 447], ["a", 455], ["transmembrane", 457], ["protein", 471], ["that", 479], ["appears", 484], ["to", 492], ["be", 495], ["localized", 498], ["to", 508], ["the", 511], ["plasma", 515], ["membrane", 522], [".", 530], ["The", 532], ["CED-8", 536], ["protein", 542], ["is", 550], ["similar", 553], ["to", 561], ["human", 564], ["XK", 570], [",", 572], ["a", 574], ["putative", 576], ["membrane", 585], ["transport", 594], ["protein", 604], ["implicated", 612], ["in", 623], ["McLeod", 626], ["Syndrome", 633], [",", 641], ["a", 643], ["form", 645], ["of", 650], ["hereditary", 653], ["neuroacanthocytosis", 664], [".", 683]]}
{"context": "Recurrent syncope, malignant ventricular arrhythmias, and sudden death are complications of the long QT syndrome (LQTS). Two well-known syndromes with long QT intervals are known. The Jervell and Lange-Nielsen syndrome (JLNS) is characterized by prolongation of the QT interval, deafness, and autosomal-recessive inheritance, and the Romano-Ward syndrome is characterized by a prolonged QT interval, autosomal-dominant inheritance, and no deafness. In the present study assessment was performed of the diagnostic importance of the ventricular derepolarization parameters, clinical features, and prevalence of JLNS among 132 children with congenital hearing loss (CHL). In the CHL group the mean QT, QTc, JT, and JTc intervals and the dispersion values (QT-d, JT-d, QTc-d, and JTc-d) were significantly longer than those of control subjects (n = 96) (P < 0.05). Patients with CHL and JLNS (n = 5) had significantly longer mean values of QT, QTc, JT, and JTc intervals and dispersion values than those of CHL without JLNS (n = 127) and control subjects (P < 0.05). The results suggest that assessment of ventricular derepolarization parameters in children with CHL will be helpful in the early detection of JLNS because infants with CHL cannot accurately describe the symptoms of syncope.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "e5d58ee5c70045e09f9863cc375814b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[74, 76]], "char_spans": [[400, 417]]}]}], "context_tokens": [["Recurrent", 0], ["syncope", 10], [",", 17], ["malignant", 19], ["ventricular", 29], ["arrhythmias", 41], [",", 52], ["and", 54], ["sudden", 58], ["death", 65], ["are", 71], ["complications", 75], ["of", 89], ["the", 92], ["long", 96], ["QT", 101], ["syndrome", 104], ["(", 113], ["LQTS", 114], [")", 118], [".", 119], ["Two", 121], ["well", 125], ["-", 129], ["known", 130], ["syndromes", 136], ["with", 146], ["long", 151], ["QT", 156], ["intervals", 159], ["are", 169], ["known", 173], [".", 178], ["The", 180], ["Jervell", 184], ["and", 192], ["Lange", 196], ["-", 201], ["Nielsen", 202], ["syndrome", 210], ["(", 219], ["JLNS", 220], [")", 224], ["is", 226], ["characterized", 229], ["by", 243], ["prolongation", 246], ["of", 259], ["the", 262], ["QT", 266], ["interval", 269], [",", 277], ["deafness", 279], [",", 287], ["and", 289], ["autosomal", 293], ["-", 302], ["recessive", 303], ["inheritance", 313], [",", 324], ["and", 326], ["the", 330], ["Romano", 334], ["-", 340], ["Ward", 341], ["syndrome", 346], ["is", 355], ["characterized", 358], ["by", 372], ["a", 375], ["prolonged", 377], ["QT", 387], ["interval", 390], [",", 398], ["autosomal", 400], ["-", 409], ["dominant", 410], ["inheritance", 419], [",", 430], ["and", 432], ["no", 436], ["deafness", 439], [".", 447], ["In", 449], ["the", 452], ["present", 456], ["study", 464], ["assessment", 470], ["was", 481], ["performed", 485], ["of", 495], ["the", 498], ["diagnostic", 502], ["importance", 513], ["of", 524], ["the", 527], ["ventricular", 531], ["derepolarization", 543], ["parameters", 560], [",", 570], ["clinical", 572], ["features", 581], [",", 589], ["and", 591], ["prevalence", 595], ["of", 606], ["JLNS", 609], ["among", 614], ["132", 620], ["children", 624], ["with", 633], ["congenital", 638], ["hearing", 649], ["loss", 657], ["(", 662], ["CHL", 663], [")", 666], [".", 667], ["In", 669], ["the", 672], ["CHL", 676], ["group", 680], ["the", 686], ["mean", 690], ["QT", 695], [",", 697], ["QTc", 699], [",", 702], ["JT", 704], [",", 706], ["and", 708], ["JTc", 712], ["intervals", 716], ["and", 726], ["the", 730], ["dispersion", 734], ["values", 745], ["(", 752], ["QT", 753], ["-", 755], ["d", 756], [",", 757], ["JT", 759], ["-", 761], ["d", 762], [",", 763], ["QTc", 765], ["-", 768], ["d", 769], [",", 770], ["and", 772], ["JTc", 776], ["-", 779], ["d", 780], [")", 781], ["were", 783], ["significantly", 788], ["longer", 802], ["than", 809], ["those", 814], ["of", 820], ["control", 823], ["subjects", 831], ["(", 840], ["n", 841], ["=", 843], ["96", 845], [")", 847], ["(", 849], ["P", 850], ["<", 852], ["0.05", 854], [")", 858], [".", 859], ["Patients", 861], ["with", 870], ["CHL", 875], ["and", 879], ["JLNS", 883], ["(", 888], ["n", 889], ["=", 891], ["5", 893], [")", 894], ["had", 896], ["significantly", 900], ["longer", 914], ["mean", 921], ["values", 926], ["of", 933], ["QT", 936], [",", 938], ["QTc", 940], [",", 943], ["JT", 945], [",", 947], ["and", 949], ["JTc", 953], ["intervals", 957], ["and", 967], ["dispersion", 971], ["values", 982], ["than", 989], ["those", 994], ["of", 1000], ["CHL", 1003], ["without", 1007], ["JLNS", 1015], ["(", 1020], ["n", 1021], ["=", 1023], ["127", 1025], [")", 1028], ["and", 1030], ["control", 1034], ["subjects", 1042], ["(", 1051], ["P", 1052], ["<", 1054], ["0.05", 1056], [")", 1060], [".", 1061], ["The", 1063], ["results", 1067], ["suggest", 1075], ["that", 1083], ["assessment", 1088], ["of", 1099], ["ventricular", 1102], ["derepolarization", 1114], ["parameters", 1131], ["in", 1142], ["children", 1145], ["with", 1154], ["CHL", 1159], ["will", 1163], ["be", 1168], ["helpful", 1171], ["in", 1179], ["the", 1182], ["early", 1186], ["detection", 1192], ["of", 1202], ["JLNS", 1205], ["because", 1210], ["infants", 1218], ["with", 1226], ["CHL", 1231], ["can", 1235], ["not", 1238], ["accurately", 1242], ["describe", 1253], ["the", 1262], ["symptoms", 1266], ["of", 1275], ["syncope", 1278], [".", 1285]]}
{"context": "An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months. The aim of this study is to describe this outbreak, assess risk factors for recurrence of CDI-027 and to analyze the implementation of a novel treatment strategy. This is a prospective study of all patients with CDI-027, from November 2014 to November 2015. The epidemiological data were collected daily for each patient. We compared clinical characteristics and treatment between patients with and without recurrence of CDI-027. Interestingly, liver cirrhosis was present in 22% of the patients, and most of them received prophylaxis for hepatic encephalopathy with rifaximin. Patients were also taking antimicrobial drugs (93.6%) and proton pump inhibitors (80.1%). Overall, 27 (23.5%) patients had a first recurrence of CDI-027. Liver cirrhosis increased the risk of recurrence (44.4% vs 14.8%). Patients treated with a prolonged oral vancomycin regimen vs the conventional regimen (oral metronidazole or 10\u00a0days of vancomycin) had fewer recurrences (8.6 versus 44.7% [p\u00a0\u2264\u00a00.01]; OR, 0.91; 95% CI, 0.028-0.294) and less attributable mortality (0% versus 7.1%; p\u00a0=\u00a00.058). We report an outbreak of CDI-027, mainly in patients with liver cirrhosis. Recurrence of CDI-027 was more common in those patients. A novel approach involving high-dose prolonged vancomycin taper as a first-line treatment, together with a bundle of outbreak measures, seemed to reduce the number of cases of CDI-027, recurrences, and attributable mortality. Nevertheless, this approach warrants further investigation.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "38addabed56946b49d470b639537d475", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[11, 12]], "char_spans": [[63, 74]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["infection", 37], ["(", 47], ["CDI", 48], [")", 51], ["caused", 53], ["by", 60], ["ribotype", 63], ["027", 72], ["(", 76], ["B1/NAP1", 77], [")", 84], ["began", 86], ["in", 92], ["our", 95], ["hospital", 99], ["in", 108], ["November", 111], ["2014", 120], [",", 124], ["and", 126], ["produced", 130], ["141", 139], ["episodes", 143], ["in", 152], ["the", 155], ["following", 159], ["months", 169], [".", 175], ["The", 177], ["aim", 181], ["of", 185], ["this", 188], ["study", 193], ["is", 199], ["to", 202], ["describe", 205], ["this", 214], ["outbreak", 219], [",", 227], ["assess", 229], ["risk", 236], ["factors", 241], ["for", 249], ["recurrence", 253], ["of", 264], ["CDI-027", 267], ["and", 275], ["to", 279], ["analyze", 282], ["the", 290], ["implementation", 294], ["of", 309], ["a", 312], ["novel", 314], ["treatment", 320], ["strategy", 330], [".", 338], ["This", 340], ["is", 345], ["a", 348], ["prospective", 350], ["study", 362], ["of", 368], ["all", 371], ["patients", 375], ["with", 384], ["CDI-027", 389], [",", 396], ["from", 398], ["November", 403], ["2014", 412], ["to", 417], ["November", 420], ["2015", 429], [".", 433], ["The", 435], ["epidemiological", 439], ["data", 455], ["were", 460], ["collected", 465], ["daily", 475], ["for", 481], ["each", 485], ["patient", 490], [".", 497], ["We", 499], ["compared", 502], ["clinical", 511], ["characteristics", 520], ["and", 536], ["treatment", 540], ["between", 550], ["patients", 558], ["with", 567], ["and", 572], ["without", 576], ["recurrence", 584], ["of", 595], ["CDI-027", 598], [".", 605], ["Interestingly", 607], [",", 620], ["liver", 622], ["cirrhosis", 628], ["was", 638], ["present", 642], ["in", 650], ["22", 653], ["%", 655], ["of", 657], ["the", 660], ["patients", 664], [",", 672], ["and", 674], ["most", 678], ["of", 683], ["them", 686], ["received", 691], ["prophylaxis", 700], ["for", 712], ["hepatic", 716], ["encephalopathy", 724], ["with", 739], ["rifaximin", 744], [".", 753], ["Patients", 755], ["were", 764], ["also", 769], ["taking", 774], ["antimicrobial", 781], ["drugs", 795], ["(", 801], ["93.6", 802], ["%", 806], [")", 807], ["and", 809], ["proton", 813], ["pump", 820], ["inhibitors", 825], ["(", 836], ["80.1", 837], ["%", 841], [")", 842], [".", 843], ["Overall", 845], [",", 852], ["27", 854], ["(", 857], ["23.5", 858], ["%", 862], [")", 863], ["patients", 865], ["had", 874], ["a", 878], ["first", 880], ["recurrence", 886], ["of", 897], ["CDI-027", 900], [".", 907], ["Liver", 909], ["cirrhosis", 915], ["increased", 925], ["the", 935], ["risk", 939], ["of", 944], ["recurrence", 947], ["(", 958], ["44.4", 959], ["%", 963], ["vs", 965], ["14.8", 968], ["%", 972], [")", 973], [".", 974], ["Patients", 976], ["treated", 985], ["with", 993], ["a", 998], ["prolonged", 1000], ["oral", 1010], ["vancomycin", 1015], ["regimen", 1026], ["vs", 1034], ["the", 1037], ["conventional", 1041], ["regimen", 1054], ["(", 1062], ["oral", 1063], ["metronidazole", 1068], ["or", 1082], ["10", 1085], ["days", 1088], ["of", 1093], ["vancomycin", 1096], [")", 1106], ["had", 1108], ["fewer", 1112], ["recurrences", 1118], ["(", 1130], ["8.6", 1131], ["versus", 1135], ["44.7", 1142], ["%", 1146], ["[", 1148], ["p", 1149], ["\u2264", 1151], ["0.01", 1153], ["]", 1157], [";", 1158], ["OR", 1160], [",", 1162], ["0.91", 1164], [";", 1168], ["95", 1170], ["%", 1172], ["CI", 1174], [",", 1176], ["0.028", 1178], ["-", 1183], ["0.294", 1184], [")", 1189], ["and", 1191], ["less", 1195], ["attributable", 1200], ["mortality", 1213], ["(", 1223], ["0", 1224], ["%", 1225], ["versus", 1227], ["7.1", 1234], ["%", 1237], [";", 1238], ["p", 1240], ["=", 1242], ["0.058", 1244], [")", 1249], [".", 1250], ["We", 1252], ["report", 1255], ["an", 1262], ["outbreak", 1265], ["of", 1274], ["CDI-027", 1277], [",", 1284], ["mainly", 1286], ["in", 1293], ["patients", 1296], ["with", 1305], ["liver", 1310], ["cirrhosis", 1316], [".", 1325], ["Recurrence", 1327], ["of", 1338], ["CDI-027", 1341], ["was", 1349], ["more", 1353], ["common", 1358], ["in", 1365], ["those", 1368], ["patients", 1374], [".", 1382], ["A", 1384], ["novel", 1386], ["approach", 1392], ["involving", 1401], ["high", 1411], ["-", 1415], ["dose", 1416], ["prolonged", 1421], ["vancomycin", 1431], ["taper", 1442], ["as", 1448], ["a", 1451], ["first", 1453], ["-", 1458], ["line", 1459], ["treatment", 1464], [",", 1473], ["together", 1475], ["with", 1484], ["a", 1489], ["bundle", 1491], ["of", 1498], ["outbreak", 1501], ["measures", 1510], [",", 1518], ["seemed", 1520], ["to", 1527], ["reduce", 1530], ["the", 1537], ["number", 1541], ["of", 1548], ["cases", 1551], ["of", 1557], ["CDI-027", 1560], [",", 1567], ["recurrences", 1569], [",", 1580], ["and", 1582], ["attributable", 1586], ["mortality", 1599], [".", 1608], ["Nevertheless", 1610], [",", 1622], ["this", 1624], ["approach", 1629], ["warrants", 1638], ["further", 1647], ["investigation", 1655], [".", 1668]]}
{"context": "Reactive oxygen species are involved in ovulation. The aim of this study was to examine gonadotropin regulation of antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats. Administration of antioxidants in vivo reduced ovulation rate and cumulus expansion. LH treatment increased H(2)O(2) levels within 15 min, which, in turn, induced Srx gene expression in cultured preovulatory follicles. Treatment of preovulatory follicles with catalase suppressed the stimulatory effect of LH on Akt phosphorylation. LH- or H(2)O(2)-stimulated Srx mRNA levels were suppressed by inhibitors of antioxidant agents and MAPK kinase. An in vivo injection of equine chorionic gonadotropin-human chorionic gonadotropin (hCG) stimulated Srx mRNA within 1 h in granulosa but not thecal cells of preovulatory follicles. Srx protein levels were stimulated from 3 h post-hCG injection. Immunofluorescence analysis revealed that oocytes expressed the Srx protein. Furthermore, hCG treatment increased Srx expression in mural granulosa, theca and cumulus cells, but the Srx protein was not detected in corpora lutea. Gene expression of PRDX2, identified as an Srx-dependent modified enzyme, was stimulated by gonadotropins. In situ hybridization analysis demonstrated that PRDX2 mRNA was detected in oocytes and theca cells as well as granulosa cells of some antral and preovulatory follicles. High levels of PRDX2 mRNA were detected in corpora lutea. Total levels of PRDX2 protein were not changed by gonadotropins. However, levels of hyperoxidized PRDX2 increased within 2-3 h after the hCG injection. Taken together, gonadotropin stimulation of Srx expression and PRDX2 modification in the ovary suggest the existence of an antioxidant system to maintain H(2)O(2) production and elimination during the periovulatory period.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "b7b765a669484522bfdfa013ced2bc9d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[104, 104], [295, 295], [19, 19]], "char_spans": [[657, 667], [1777, 1787], [115, 125]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["are", 24], ["involved", 28], ["in", 37], ["ovulation", 40], [".", 49], ["The", 51], ["aim", 55], ["of", 59], ["this", 62], ["study", 67], ["was", 73], ["to", 77], ["examine", 80], ["gonadotropin", 88], ["regulation", 101], ["of", 112], ["antioxidant", 115], ["enzyme", 127], ["sulfiredoxin", 134], ["(", 147], ["Srx", 148], [")", 151], ["and", 153], ["peroxiredoxin", 157], ["2", 171], ["(", 173], ["PRDX2", 174], [")", 179], ["expressions", 181], ["and", 193], ["modification", 197], ["during", 210], ["the", 217], ["ovulatory", 221], ["process", 231], ["in", 239], ["rats", 242], [".", 246], ["Administration", 248], ["of", 263], ["antioxidants", 266], ["in", 279], ["vivo", 282], ["reduced", 287], ["ovulation", 295], ["rate", 305], ["and", 310], ["cumulus", 314], ["expansion", 322], [".", 331], ["LH", 333], ["treatment", 336], ["increased", 346], ["H(2)O(2", 356], [")", 363], ["levels", 365], ["within", 372], ["15", 379], ["min", 382], [",", 385], ["which", 387], [",", 392], ["in", 394], ["turn", 397], [",", 401], ["induced", 403], ["Srx", 411], ["gene", 415], ["expression", 420], ["in", 431], ["cultured", 434], ["preovulatory", 443], ["follicles", 456], [".", 465], ["Treatment", 467], ["of", 477], ["preovulatory", 480], ["follicles", 493], ["with", 503], ["catalase", 508], ["suppressed", 517], ["the", 528], ["stimulatory", 532], ["effect", 544], ["of", 551], ["LH", 554], ["on", 557], ["Akt", 560], ["phosphorylation", 564], [".", 579], ["LH-", 581], ["or", 585], ["H(2)O(2)-stimulated", 588], ["Srx", 608], ["mRNA", 612], ["levels", 617], ["were", 624], ["suppressed", 629], ["by", 640], ["inhibitors", 643], ["of", 654], ["antioxidant", 657], ["agents", 669], ["and", 676], ["MAPK", 680], ["kinase", 685], [".", 691], ["An", 693], ["in", 696], ["vivo", 699], ["injection", 704], ["of", 714], ["equine", 717], ["chorionic", 724], ["gonadotropin", 734], ["-", 746], ["human", 747], ["chorionic", 753], ["gonadotropin", 763], ["(", 776], ["hCG", 777], [")", 780], ["stimulated", 782], ["Srx", 793], ["mRNA", 797], ["within", 802], ["1", 809], ["h", 811], ["in", 813], ["granulosa", 816], ["but", 826], ["not", 830], ["thecal", 834], ["cells", 841], ["of", 847], ["preovulatory", 850], ["follicles", 863], [".", 872], ["Srx", 874], ["protein", 878], ["levels", 886], ["were", 893], ["stimulated", 898], ["from", 909], ["3", 914], ["h", 916], ["post", 918], ["-", 922], ["hCG", 923], ["injection", 927], [".", 936], ["Immunofluorescence", 938], ["analysis", 957], ["revealed", 966], ["that", 975], ["oocytes", 980], ["expressed", 988], ["the", 998], ["Srx", 1002], ["protein", 1006], [".", 1013], ["Furthermore", 1015], [",", 1026], ["hCG", 1028], ["treatment", 1032], ["increased", 1042], ["Srx", 1052], ["expression", 1056], ["in", 1067], ["mural", 1070], ["granulosa", 1076], [",", 1085], ["theca", 1087], ["and", 1093], ["cumulus", 1097], ["cells", 1105], [",", 1110], ["but", 1112], ["the", 1116], ["Srx", 1120], ["protein", 1124], ["was", 1132], ["not", 1136], ["detected", 1140], ["in", 1149], ["corpora", 1152], ["lutea", 1160], [".", 1165], ["Gene", 1167], ["expression", 1172], ["of", 1183], ["PRDX2", 1186], [",", 1191], ["identified", 1193], ["as", 1204], ["an", 1207], ["Srx", 1210], ["-", 1213], ["dependent", 1214], ["modified", 1224], ["enzyme", 1233], [",", 1239], ["was", 1241], ["stimulated", 1245], ["by", 1256], ["gonadotropins", 1259], [".", 1272], ["In", 1274], ["situ", 1277], ["hybridization", 1282], ["analysis", 1296], ["demonstrated", 1305], ["that", 1318], ["PRDX2", 1323], ["mRNA", 1329], ["was", 1334], ["detected", 1338], ["in", 1347], ["oocytes", 1350], ["and", 1358], ["theca", 1362], ["cells", 1368], ["as", 1374], ["well", 1377], ["as", 1382], ["granulosa", 1385], ["cells", 1395], ["of", 1401], ["some", 1404], ["antral", 1409], ["and", 1416], ["preovulatory", 1420], ["follicles", 1433], [".", 1442], ["High", 1444], ["levels", 1449], ["of", 1456], ["PRDX2", 1459], ["mRNA", 1465], ["were", 1470], ["detected", 1475], ["in", 1484], ["corpora", 1487], ["lutea", 1495], [".", 1500], ["Total", 1502], ["levels", 1508], ["of", 1515], ["PRDX2", 1518], ["protein", 1524], ["were", 1532], ["not", 1537], ["changed", 1541], ["by", 1549], ["gonadotropins", 1552], [".", 1565], ["However", 1567], [",", 1574], ["levels", 1576], ["of", 1583], ["hyperoxidized", 1586], ["PRDX2", 1600], ["increased", 1606], ["within", 1616], ["2", 1623], ["-", 1624], ["3", 1625], ["h", 1627], ["after", 1629], ["the", 1635], ["hCG", 1639], ["injection", 1643], [".", 1652], ["Taken", 1654], ["together", 1660], [",", 1668], ["gonadotropin", 1670], ["stimulation", 1683], ["of", 1695], ["Srx", 1698], ["expression", 1702], ["and", 1713], ["PRDX2", 1717], ["modification", 1723], ["in", 1736], ["the", 1739], ["ovary", 1743], ["suggest", 1749], ["the", 1757], ["existence", 1761], ["of", 1771], ["an", 1774], ["antioxidant", 1777], ["system", 1789], ["to", 1796], ["maintain", 1799], ["H(2)O(2", 1808], [")", 1815], ["production", 1817], ["and", 1828], ["elimination", 1832], ["during", 1844], ["the", 1851], ["periovulatory", 1855], ["period", 1869], [".", 1875]]}
{"context": "In this randomized, double-blind, placebo controlled phase 2 study we investigated tanezumab, a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for interstitial cystitis pain. Patients with interstitial cystitis received a single intravenous dose of 200 \u03bcg/kg tanezumab or placebo. Patients recorded daily pain scores (on an 11-point numerical rating scale) 7 days before attending study visits and completed a urinary symptom diary for 3 of those days. Patients also completed the Interstitial Cystitis Symptom Index questionnaire and a global response assessment. The primary end point was change in average daily numerical rating scale pain score from baseline to week 6. Secondary end points included global response assessment, Interstitial Cystitis Symptom Index score, micturition and urgency episode frequency per 24 hours, and mean voided volume per micturition. The incidence of adverse events was also assessed. A total of 34 patients received tanezumab and 30 received placebo. At week 6 tanezumab produced a significant reduction from baseline in average daily pain score vs placebo (treatment difference [LS mean, 90% CI] was -1.4 [-2.2, -0.5]). A significantly higher proportion of patients on tanezumab responded as improved in the global response assessment and tanezumab also significantly reduced urgency episode frequency vs placebo. Tanezumab had no significant effect on Interstitial Cystitis Symptom Index score, micturition frequency or mean voided volume per micturition. The most common adverse events were headache (tanezumab 20.6%, placebo 16.7%) and paresthesia (tanezumab 17.6%, placebo 3.3%). Tanezumab has shown preliminary efficacy in the treatment of pain associated with interstitial cystitis.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "e516230f0c0040adab7360b90e76c7e0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[153, 171]]}]}], "context_tokens": [["In", 0], ["this", 3], ["randomized", 8], [",", 18], ["double", 20], ["-", 26], ["blind", 27], [",", 32], ["placebo", 34], ["controlled", 42], ["phase", 53], ["2", 59], ["study", 61], ["we", 67], ["investigated", 70], ["tanezumab", 83], [",", 92], ["a", 94], ["humanized", 96], ["monoclonal", 106], ["antibody", 117], ["that", 126], ["specifically", 131], ["inhibits", 144], ["nerve", 153], ["growth", 159], ["factor", 166], ["as", 173], ["a", 176], ["treatment", 178], ["for", 188], ["interstitial", 192], ["cystitis", 205], ["pain", 214], [".", 218], ["Patients", 220], ["with", 229], ["interstitial", 234], ["cystitis", 247], ["received", 256], ["a", 265], ["single", 267], ["intravenous", 274], ["dose", 286], ["of", 291], ["200", 294], ["\u03bcg", 298], ["/", 300], ["kg", 301], ["tanezumab", 304], ["or", 314], ["placebo", 317], [".", 324], ["Patients", 326], ["recorded", 335], ["daily", 344], ["pain", 350], ["scores", 355], ["(", 362], ["on", 363], ["an", 366], ["11-point", 369], ["numerical", 378], ["rating", 388], ["scale", 395], [")", 400], ["7", 402], ["days", 404], ["before", 409], ["attending", 416], ["study", 426], ["visits", 432], ["and", 439], ["completed", 443], ["a", 453], ["urinary", 455], ["symptom", 463], ["diary", 471], ["for", 477], ["3", 481], ["of", 483], ["those", 486], ["days", 492], [".", 496], ["Patients", 498], ["also", 507], ["completed", 512], ["the", 522], ["Interstitial", 526], ["Cystitis", 539], ["Symptom", 548], ["Index", 556], ["questionnaire", 562], ["and", 576], ["a", 580], ["global", 582], ["response", 589], ["assessment", 598], [".", 608], ["The", 610], ["primary", 614], ["end", 622], ["point", 626], ["was", 632], ["change", 636], ["in", 643], ["average", 646], ["daily", 654], ["numerical", 660], ["rating", 670], ["scale", 677], ["pain", 683], ["score", 688], ["from", 694], ["baseline", 699], ["to", 708], ["week", 711], ["6", 716], [".", 717], ["Secondary", 719], ["end", 729], ["points", 733], ["included", 740], ["global", 749], ["response", 756], ["assessment", 765], [",", 775], ["Interstitial", 777], ["Cystitis", 790], ["Symptom", 799], ["Index", 807], ["score", 813], [",", 818], ["micturition", 820], ["and", 832], ["urgency", 836], ["episode", 844], ["frequency", 852], ["per", 862], ["24", 866], ["hours", 869], [",", 874], ["and", 876], ["mean", 880], ["voided", 885], ["volume", 892], ["per", 899], ["micturition", 903], [".", 914], ["The", 916], ["incidence", 920], ["of", 930], ["adverse", 933], ["events", 941], ["was", 948], ["also", 952], ["assessed", 957], [".", 965], ["A", 967], ["total", 969], ["of", 975], ["34", 978], ["patients", 981], ["received", 990], ["tanezumab", 999], ["and", 1009], ["30", 1013], ["received", 1016], ["placebo", 1025], [".", 1032], ["At", 1034], ["week", 1037], ["6", 1042], ["tanezumab", 1044], ["produced", 1054], ["a", 1063], ["significant", 1065], ["reduction", 1077], ["from", 1087], ["baseline", 1092], ["in", 1101], ["average", 1104], ["daily", 1112], ["pain", 1118], ["score", 1123], ["vs", 1129], ["placebo", 1132], ["(", 1140], ["treatment", 1141], ["difference", 1151], ["[", 1162], ["LS", 1163], ["mean", 1166], [",", 1170], ["90", 1172], ["%", 1174], ["CI", 1176], ["]", 1178], ["was", 1180], ["-1.4", 1184], ["[", 1189], ["-2.2", 1190], [",", 1194], ["-0.5", 1196], ["]", 1200], [")", 1201], [".", 1202], ["A", 1204], ["significantly", 1206], ["higher", 1220], ["proportion", 1227], ["of", 1238], ["patients", 1241], ["on", 1250], ["tanezumab", 1253], ["responded", 1263], ["as", 1273], ["improved", 1276], ["in", 1285], ["the", 1288], ["global", 1292], ["response", 1299], ["assessment", 1308], ["and", 1319], ["tanezumab", 1323], ["also", 1333], ["significantly", 1338], ["reduced", 1352], ["urgency", 1360], ["episode", 1368], ["frequency", 1376], ["vs", 1386], ["placebo", 1389], [".", 1396], ["Tanezumab", 1398], ["had", 1408], ["no", 1412], ["significant", 1415], ["effect", 1427], ["on", 1434], ["Interstitial", 1437], ["Cystitis", 1450], ["Symptom", 1459], ["Index", 1467], ["score", 1473], [",", 1478], ["micturition", 1480], ["frequency", 1492], ["or", 1502], ["mean", 1505], ["voided", 1510], ["volume", 1517], ["per", 1524], ["micturition", 1528], [".", 1539], ["The", 1541], ["most", 1545], ["common", 1550], ["adverse", 1557], ["events", 1565], ["were", 1572], ["headache", 1577], ["(", 1586], ["tanezumab", 1587], ["20.6", 1597], ["%", 1601], [",", 1602], ["placebo", 1604], ["16.7", 1612], ["%", 1616], [")", 1617], ["and", 1619], ["paresthesia", 1623], ["(", 1635], ["tanezumab", 1636], ["17.6", 1646], ["%", 1650], [",", 1651], ["placebo", 1653], ["3.3", 1661], ["%", 1664], [")", 1665], [".", 1666], ["Tanezumab", 1668], ["has", 1678], ["shown", 1682], ["preliminary", 1688], ["efficacy", 1700], ["in", 1709], ["the", 1712], ["treatment", 1716], ["of", 1726], ["pain", 1729], ["associated", 1734], ["with", 1745], ["interstitial", 1750], ["cystitis", 1763], [".", 1771]]}
{"context": "Chronic myeloid leukemia (CML) is characterized by formation of a BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22. Recently the development of new fluorescence in-situ hybridization (FISH) techniques has allowed identification of unexpected deletions of the reciprocal translocation product, the derivative chromosome 9, in 10% to 15% of patients with CML. These deletions are large, span the translocation breakpoint, and occur at the same time as the Ph translocation. Such deletions therefore give rise to previously unsuspected molecular heterogeneity from the very beginning of this disease, and there is mounting evidence for similar deletions associated with other translocations. Several studies have demonstrated that CML patients who carry derivative chromosome 9 deletions exhibit a more rapid progression to blast crisis and a shorter survival. Deletion status is independent of, and more powerful than, the Sokal and Hasford/European prognostic scoring systems. The poor prognosis associated with deletions is seen in patients treated with hydroxyurea or interferon, and preliminary evidence suggests that patients with deletions may also have a worse outcome than nondeleted patients following stem cell transplantation or treatment with imatinib. Poor outcome cannot be attributed to loss of the reciprocal ABL-BCR fusion gene expression alone, and is likely to reflect loss of one or more critical genes within the deleted region. The molecular heterogeneity associated with the Philadelphia translocation provides a new paradigm with potential relevance to all malignancies associated with reciprocal chromosomal translocations and/or fusion gene formation.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "1d0edfd264d5465fadb7c6268c608128", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "ABL/BCR fusion", "token_spans": [[229, 232]], "char_spans": [[1388, 1401]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["characterized", 34], ["by", 48], ["formation", 51], ["of", 61], ["a", 64], ["BCR", 66], ["-", 69], ["ABL", 70], ["fusion", 74], ["gene", 81], [",", 85], ["usually", 87], ["as", 95], ["a", 98], ["consequence", 100], ["of", 112], ["the", 115], ["Philadelphia", 119], ["(", 132], ["Ph", 133], [")", 135], ["translocation", 137], ["between", 151], ["chromosomes", 159], ["9", 171], ["and", 173], ["22", 177], [".", 179], ["Recently", 181], ["the", 190], ["development", 194], ["of", 206], ["new", 209], ["fluorescence", 213], ["in", 226], ["-", 228], ["situ", 229], ["hybridization", 234], ["(", 248], ["FISH", 249], [")", 253], ["techniques", 255], ["has", 266], ["allowed", 270], ["identification", 278], ["of", 293], ["unexpected", 296], ["deletions", 307], ["of", 317], ["the", 320], ["reciprocal", 324], ["translocation", 335], ["product", 349], [",", 356], ["the", 358], ["derivative", 362], ["chromosome", 373], ["9", 384], [",", 385], ["in", 387], ["10", 390], ["%", 392], ["to", 394], ["15", 397], ["%", 399], ["of", 401], ["patients", 404], ["with", 413], ["CML", 418], [".", 421], ["These", 423], ["deletions", 429], ["are", 439], ["large", 443], [",", 448], ["span", 450], ["the", 455], ["translocation", 459], ["breakpoint", 473], [",", 483], ["and", 485], ["occur", 489], ["at", 495], ["the", 498], ["same", 502], ["time", 507], ["as", 512], ["the", 515], ["Ph", 519], ["translocation", 522], [".", 535], ["Such", 537], ["deletions", 542], ["therefore", 552], ["give", 562], ["rise", 567], ["to", 572], ["previously", 575], ["unsuspected", 586], ["molecular", 598], ["heterogeneity", 608], ["from", 622], ["the", 627], ["very", 631], ["beginning", 636], ["of", 646], ["this", 649], ["disease", 654], [",", 661], ["and", 663], ["there", 667], ["is", 673], ["mounting", 676], ["evidence", 685], ["for", 694], ["similar", 698], ["deletions", 706], ["associated", 716], ["with", 727], ["other", 732], ["translocations", 738], [".", 752], ["Several", 754], ["studies", 762], ["have", 770], ["demonstrated", 775], ["that", 788], ["CML", 793], ["patients", 797], ["who", 806], ["carry", 810], ["derivative", 816], ["chromosome", 827], ["9", 838], ["deletions", 840], ["exhibit", 850], ["a", 858], ["more", 860], ["rapid", 865], ["progression", 871], ["to", 883], ["blast", 886], ["crisis", 892], ["and", 899], ["a", 903], ["shorter", 905], ["survival", 913], [".", 921], ["Deletion", 923], ["status", 932], ["is", 939], ["independent", 942], ["of", 954], [",", 956], ["and", 958], ["more", 962], ["powerful", 967], ["than", 976], [",", 980], ["the", 982], ["Sokal", 986], ["and", 992], ["Hasford", 996], ["/", 1003], ["European", 1004], ["prognostic", 1013], ["scoring", 1024], ["systems", 1032], [".", 1039], ["The", 1041], ["poor", 1045], ["prognosis", 1050], ["associated", 1060], ["with", 1071], ["deletions", 1076], ["is", 1086], ["seen", 1089], ["in", 1094], ["patients", 1097], ["treated", 1106], ["with", 1114], ["hydroxyurea", 1119], ["or", 1131], ["interferon", 1134], [",", 1144], ["and", 1146], ["preliminary", 1150], ["evidence", 1162], ["suggests", 1171], ["that", 1180], ["patients", 1185], ["with", 1194], ["deletions", 1199], ["may", 1209], ["also", 1213], ["have", 1218], ["a", 1223], ["worse", 1225], ["outcome", 1231], ["than", 1239], ["nondeleted", 1244], ["patients", 1255], ["following", 1264], ["stem", 1274], ["cell", 1279], ["transplantation", 1284], ["or", 1300], ["treatment", 1303], ["with", 1313], ["imatinib", 1318], [".", 1326], ["Poor", 1328], ["outcome", 1333], ["can", 1341], ["not", 1344], ["be", 1348], ["attributed", 1351], ["to", 1362], ["loss", 1365], ["of", 1370], ["the", 1373], ["reciprocal", 1377], ["ABL", 1388], ["-", 1391], ["BCR", 1392], ["fusion", 1396], ["gene", 1403], ["expression", 1408], ["alone", 1419], [",", 1424], ["and", 1426], ["is", 1430], ["likely", 1433], ["to", 1440], ["reflect", 1443], ["loss", 1451], ["of", 1456], ["one", 1459], ["or", 1463], ["more", 1466], ["critical", 1471], ["genes", 1480], ["within", 1486], ["the", 1493], ["deleted", 1497], ["region", 1505], [".", 1511], ["The", 1513], ["molecular", 1517], ["heterogeneity", 1527], ["associated", 1541], ["with", 1552], ["the", 1557], ["Philadelphia", 1561], ["translocation", 1574], ["provides", 1588], ["a", 1597], ["new", 1599], ["paradigm", 1603], ["with", 1612], ["potential", 1617], ["relevance", 1627], ["to", 1637], ["all", 1640], ["malignancies", 1644], ["associated", 1657], ["with", 1668], ["reciprocal", 1673], ["chromosomal", 1684], ["translocations", 1696], ["and/or", 1711], ["fusion", 1718], ["gene", 1725], ["formation", 1730], [".", 1739]]}
{"context": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium. But there is no consensus as to what constitutes an alpha-proteobacterial gene. Is it a gene found in all or several alpha-proteobacteria, or in only one? Here, we examine the proportion of alpha-proteobacterial genes in alpha-proteobacterial genomes by means of sequence comparisons. We find that each alpha-proteobacterium harbours a particular collection of genes and that, depending upon the lineage examined, between 97 and 33% are alpha-proteobacterial by the nearest-neighbour criterion. Our findings bear upon attempts to reconstruct the mitochondrial ancestor and upon inferences concerning the collection of genes that the mitochondrial ancestor possessed at the time that it became an endosymbiont.", "qas": [{"question": "Which species of bacteria did the mitochondria originate from?", "answers": ["Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium."], "qid": "1bcd341d9896445e8554027ad01ed066", "question_tokens": [["Which", 0], ["species", 6], ["of", 14], ["bacteria", 17], ["did", 26], ["the", 30], ["mitochondria", 34], ["originate", 47], ["from", 57], ["?", 61]], "detected_answers": [{"text": "Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium.", "token_spans": [[0, 11]], "char_spans": [[0, 78]]}]}], "context_tokens": [["Biologists", 0], ["agree", 11], ["that", 17], ["the", 22], ["ancestor", 26], ["of", 35], ["mitochondria", 38], ["was", 51], ["an", 55], ["alpha", 58], ["-", 63], ["proteobacterium", 64], [".", 79], ["But", 81], ["there", 85], ["is", 91], ["no", 94], ["consensus", 97], ["as", 107], ["to", 110], ["what", 113], ["constitutes", 118], ["an", 130], ["alpha", 133], ["-", 138], ["proteobacterial", 139], ["gene", 155], [".", 159], ["Is", 161], ["it", 164], ["a", 167], ["gene", 169], ["found", 174], ["in", 180], ["all", 183], ["or", 187], ["several", 190], ["alpha", 198], ["-", 203], ["proteobacteria", 204], [",", 218], ["or", 220], ["in", 223], ["only", 226], ["one", 231], ["?", 234], ["Here", 236], [",", 240], ["we", 242], ["examine", 245], ["the", 253], ["proportion", 257], ["of", 268], ["alpha", 271], ["-", 276], ["proteobacterial", 277], ["genes", 293], ["in", 299], ["alpha", 302], ["-", 307], ["proteobacterial", 308], ["genomes", 324], ["by", 332], ["means", 335], ["of", 341], ["sequence", 344], ["comparisons", 353], [".", 364], ["We", 366], ["find", 369], ["that", 374], ["each", 379], ["alpha", 384], ["-", 389], ["proteobacterium", 390], ["harbours", 406], ["a", 415], ["particular", 417], ["collection", 428], ["of", 439], ["genes", 442], ["and", 448], ["that", 452], [",", 456], ["depending", 458], ["upon", 468], ["the", 473], ["lineage", 477], ["examined", 485], [",", 493], ["between", 495], ["97", 503], ["and", 506], ["33", 510], ["%", 512], ["are", 514], ["alpha", 518], ["-", 523], ["proteobacterial", 524], ["by", 540], ["the", 543], ["nearest", 547], ["-", 554], ["neighbour", 555], ["criterion", 565], [".", 574], ["Our", 576], ["findings", 580], ["bear", 589], ["upon", 594], ["attempts", 599], ["to", 608], ["reconstruct", 611], ["the", 623], ["mitochondrial", 627], ["ancestor", 641], ["and", 650], ["upon", 654], ["inferences", 659], ["concerning", 670], ["the", 681], ["collection", 685], ["of", 696], ["genes", 699], ["that", 705], ["the", 710], ["mitochondrial", 714], ["ancestor", 728], ["possessed", 737], ["at", 747], ["the", 750], ["time", 754], ["that", 759], ["it", 764], ["became", 767], ["an", 774], ["endosymbiont", 777], [".", 789]]}
{"context": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma. Prevalence rates of PTSD and subthreshold PTSD with impairment were 2.2 and 4.1%, respectively. In this general population sample, 438 subjects endorsed at least one trauma, and four groups were generated: A) threshold PTSD (n = 13), B) subthreshold PTSD with impairment (n = 26), C) subthreshold PTSD without impairment (n = 78), and D) no PTSD (n = 321). Mean (SD) DTS score in the entire population was 11.0 +/- 18.1. Differences were found in four of the five pairwise between-group contrasts. In a second sample of 447 clinical trial participants from three SSRI vs. placebo studies, we assessed treatment effect size according to different measures. In all three clinical trials, effect size with the DTS was equal to, or better than, those found for the Impact of Event Scale (IES), Clinician Administered PTSD Scale (CAPS), and Structured Interview for PTSD (SIP). These results further affirm the utility of the DTS as a self-rating measure of PTSD symptom severity and in evaluating treatment response.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "73a1af5a2b084b75a3a2d56d9cdceaf4", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[26, 30]], "char_spans": [[141, 170]]}, {"text": "PTSD", "token_spans": [[32, 32], [91, 91], [101, 101], [54, 54], [253, 253], [57, 57], [222, 222], [232, 232], [126, 126], [113, 113]], "char_spans": [[173, 176], [491, 494], [522, 525], [292, 295], [1225, 1228], [314, 317], [1085, 1088], [1133, 1136], [613, 616], [569, 572]]}]}], "context_tokens": [["The", 0], ["Davidson", 4], ["Trauma", 13], ["Scale", 20], ["(", 26], ["DTS", 27], [")", 30], ["was", 32], ["developed", 36], ["as", 46], ["a", 49], ["self", 51], ["-", 55], ["rating", 56], ["for", 63], ["use", 67], ["in", 71], ["diagnosing", 74], ["and", 85], ["measuring", 89], ["symptom", 99], ["severity", 107], ["and", 116], ["treatment", 120], ["outcome", 130], ["in", 138], ["post", 141], ["-", 145], ["traumatic", 146], ["stress", 156], ["disorder", 163], ["(", 172], ["PTSD", 173], [")", 177], [";", 178], ["630", 180], ["subjects", 184], ["were", 193], ["identified", 198], ["by", 209], ["random", 212], ["digit", 219], ["dialing", 225], ["and", 233], ["evaluated", 237], ["for", 247], ["a", 251], ["history", 253], ["of", 261], ["trauma", 264], [".", 270], ["Prevalence", 272], ["rates", 283], ["of", 289], ["PTSD", 292], ["and", 297], ["subthreshold", 301], ["PTSD", 314], ["with", 319], ["impairment", 324], ["were", 335], ["2.2", 340], ["and", 344], ["4.1", 348], ["%", 351], [",", 352], ["respectively", 354], [".", 366], ["In", 368], ["this", 371], ["general", 376], ["population", 384], ["sample", 395], [",", 401], ["438", 403], ["subjects", 407], ["endorsed", 416], ["at", 425], ["least", 428], ["one", 434], ["trauma", 438], [",", 444], ["and", 446], ["four", 450], ["groups", 455], ["were", 462], ["generated", 467], [":", 476], ["A", 478], [")", 479], ["threshold", 481], ["PTSD", 491], ["(", 496], ["n", 497], ["=", 499], ["13", 501], [")", 503], [",", 504], ["B", 506], [")", 507], ["subthreshold", 509], ["PTSD", 522], ["with", 527], ["impairment", 532], ["(", 543], ["n", 544], ["=", 546], ["26", 548], [")", 550], [",", 551], ["C", 553], [")", 554], ["subthreshold", 556], ["PTSD", 569], ["without", 574], ["impairment", 582], ["(", 593], ["n", 594], ["=", 596], ["78", 598], [")", 600], [",", 601], ["and", 603], ["D", 607], [")", 608], ["no", 610], ["PTSD", 613], ["(", 618], ["n", 619], ["=", 621], ["321", 623], [")", 626], [".", 627], ["Mean", 629], ["(", 634], ["SD", 635], [")", 637], ["DTS", 639], ["score", 643], ["in", 649], ["the", 652], ["entire", 656], ["population", 663], ["was", 674], ["11.0", 678], ["+", 683], ["/-", 684], ["18.1", 687], [".", 691], ["Differences", 693], ["were", 705], ["found", 710], ["in", 716], ["four", 719], ["of", 724], ["the", 727], ["five", 731], ["pairwise", 736], ["between", 745], ["-", 752], ["group", 753], ["contrasts", 759], [".", 768], ["In", 770], ["a", 773], ["second", 775], ["sample", 782], ["of", 789], ["447", 792], ["clinical", 796], ["trial", 805], ["participants", 811], ["from", 824], ["three", 829], ["SSRI", 835], ["vs.", 840], ["placebo", 844], ["studies", 852], [",", 859], ["we", 861], ["assessed", 864], ["treatment", 873], ["effect", 883], ["size", 890], ["according", 895], ["to", 905], ["different", 908], ["measures", 918], [".", 926], ["In", 928], ["all", 931], ["three", 935], ["clinical", 941], ["trials", 950], [",", 956], ["effect", 958], ["size", 965], ["with", 970], ["the", 975], ["DTS", 979], ["was", 983], ["equal", 987], ["to", 993], [",", 995], ["or", 997], ["better", 1000], ["than", 1007], [",", 1011], ["those", 1013], ["found", 1019], ["for", 1025], ["the", 1029], ["Impact", 1033], ["of", 1040], ["Event", 1043], ["Scale", 1049], ["(", 1055], ["IES", 1056], [")", 1059], [",", 1060], ["Clinician", 1062], ["Administered", 1072], ["PTSD", 1085], ["Scale", 1090], ["(", 1096], ["CAPS", 1097], [")", 1101], [",", 1102], ["and", 1104], ["Structured", 1108], ["Interview", 1119], ["for", 1129], ["PTSD", 1133], ["(", 1138], ["SIP", 1139], [")", 1142], [".", 1143], ["These", 1145], ["results", 1151], ["further", 1159], ["affirm", 1167], ["the", 1174], ["utility", 1178], ["of", 1186], ["the", 1189], ["DTS", 1193], ["as", 1197], ["a", 1200], ["self", 1202], ["-", 1206], ["rating", 1207], ["measure", 1214], ["of", 1222], ["PTSD", 1225], ["symptom", 1230], ["severity", 1238], ["and", 1247], ["in", 1251], ["evaluating", 1254], ["treatment", 1265], ["response", 1275], [".", 1283]]}
{"context": "The Ehlers-Danlos syndromes (EDS) comprise a heterogenous group of heritable disorders of connective tissue, characterized by joint hypermobility, skin hyperextensibility and tissue fragility. Most EDS types are caused by mutations in genes encoding different types of collagen or enzymes, essential for normal processing of collagen. Oral health was assessed in 31 subjects with EDS (16 with hypermobility EDS, nine with classical EDS and six with vascular EDS), including signs and symptoms of temporomandibular disorders (TMD), alterations of dental hard tissues, oral mucosa and periodontium, and was compared with matched controls. All EDS subjects were symptomatic for TMD and reported recurrent temporomandibular joint (TMJ) dislocations. Abnormal pulp shape (13%) and pulp calcification (78%) were observed in subjects affected with classical EDS. Caries experience was higher in EDS compared with controls and was related to poor oral hygiene, influenced by increased mucosal fragility and restraint of (wrist) joint mobility. The overall periodontal status in EDS was poor, with 62% of EDS subjects presenting high periodontal treatment needs (community periodontal index for treatment need, CPITN = II). Oral health may be severely compromised in EDS as a result of specific alterations of collagen in orofacial structures. When considering dental treatment in EDS, a number of tissue responses (mucosa, periodontium, pulp) and precautions (TMJ dislocation) should be anticipated.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "e43d93e0fc3b425690165278b7db59e3", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[16, 17]], "char_spans": [[90, 106]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["comprise", 34], ["a", 43], ["heterogenous", 45], ["group", 58], ["of", 64], ["heritable", 67], ["disorders", 77], ["of", 87], ["connective", 90], ["tissue", 101], [",", 107], ["characterized", 109], ["by", 123], ["joint", 126], ["hypermobility", 132], [",", 145], ["skin", 147], ["hyperextensibility", 152], ["and", 171], ["tissue", 175], ["fragility", 182], [".", 191], ["Most", 193], ["EDS", 198], ["types", 202], ["are", 208], ["caused", 212], ["by", 219], ["mutations", 222], ["in", 232], ["genes", 235], ["encoding", 241], ["different", 250], ["types", 260], ["of", 266], ["collagen", 269], ["or", 278], ["enzymes", 281], [",", 288], ["essential", 290], ["for", 300], ["normal", 304], ["processing", 311], ["of", 322], ["collagen", 325], [".", 333], ["Oral", 335], ["health", 340], ["was", 347], ["assessed", 351], ["in", 360], ["31", 363], ["subjects", 366], ["with", 375], ["EDS", 380], ["(", 384], ["16", 385], ["with", 388], ["hypermobility", 393], ["EDS", 407], [",", 410], ["nine", 412], ["with", 417], ["classical", 422], ["EDS", 432], ["and", 436], ["six", 440], ["with", 444], ["vascular", 449], ["EDS", 458], [")", 461], [",", 462], ["including", 464], ["signs", 474], ["and", 480], ["symptoms", 484], ["of", 493], ["temporomandibular", 496], ["disorders", 514], ["(", 524], ["TMD", 525], [")", 528], [",", 529], ["alterations", 531], ["of", 543], ["dental", 546], ["hard", 553], ["tissues", 558], [",", 565], ["oral", 567], ["mucosa", 572], ["and", 579], ["periodontium", 583], [",", 595], ["and", 597], ["was", 601], ["compared", 605], ["with", 614], ["matched", 619], ["controls", 627], [".", 635], ["All", 637], ["EDS", 641], ["subjects", 645], ["were", 654], ["symptomatic", 659], ["for", 671], ["TMD", 675], ["and", 679], ["reported", 683], ["recurrent", 692], ["temporomandibular", 702], ["joint", 720], ["(", 726], ["TMJ", 727], [")", 730], ["dislocations", 732], [".", 744], ["Abnormal", 746], ["pulp", 755], ["shape", 760], ["(", 766], ["13", 767], ["%", 769], [")", 770], ["and", 772], ["pulp", 776], ["calcification", 781], ["(", 795], ["78", 796], ["%", 798], [")", 799], ["were", 801], ["observed", 806], ["in", 815], ["subjects", 818], ["affected", 827], ["with", 836], ["classical", 841], ["EDS", 851], [".", 854], ["Caries", 856], ["experience", 863], ["was", 874], ["higher", 878], ["in", 885], ["EDS", 888], ["compared", 892], ["with", 901], ["controls", 906], ["and", 915], ["was", 919], ["related", 923], ["to", 931], ["poor", 934], ["oral", 939], ["hygiene", 944], [",", 951], ["influenced", 953], ["by", 964], ["increased", 967], ["mucosal", 977], ["fragility", 985], ["and", 995], ["restraint", 999], ["of", 1009], ["(", 1012], ["wrist", 1013], [")", 1018], ["joint", 1020], ["mobility", 1026], [".", 1034], ["The", 1036], ["overall", 1040], ["periodontal", 1048], ["status", 1060], ["in", 1067], ["EDS", 1070], ["was", 1074], ["poor", 1078], [",", 1082], ["with", 1084], ["62", 1089], ["%", 1091], ["of", 1093], ["EDS", 1096], ["subjects", 1100], ["presenting", 1109], ["high", 1120], ["periodontal", 1125], ["treatment", 1137], ["needs", 1147], ["(", 1153], ["community", 1154], ["periodontal", 1164], ["index", 1176], ["for", 1182], ["treatment", 1186], ["need", 1196], [",", 1200], ["CPITN", 1202], ["=", 1208], ["II", 1210], [")", 1212], [".", 1213], ["Oral", 1215], ["health", 1220], ["may", 1227], ["be", 1231], ["severely", 1234], ["compromised", 1243], ["in", 1255], ["EDS", 1258], ["as", 1262], ["a", 1265], ["result", 1267], ["of", 1274], ["specific", 1277], ["alterations", 1286], ["of", 1298], ["collagen", 1301], ["in", 1310], ["orofacial", 1313], ["structures", 1323], [".", 1333], ["When", 1335], ["considering", 1340], ["dental", 1352], ["treatment", 1359], ["in", 1369], ["EDS", 1372], [",", 1375], ["a", 1377], ["number", 1379], ["of", 1386], ["tissue", 1389], ["responses", 1396], ["(", 1406], ["mucosa", 1407], [",", 1413], ["periodontium", 1415], [",", 1427], ["pulp", 1429], [")", 1433], ["and", 1435], ["precautions", 1439], ["(", 1451], ["TMJ", 1452], ["dislocation", 1456], [")", 1467], ["should", 1469], ["be", 1476], ["anticipated", 1479], [".", 1490]]}
{"context": "Many neurodegenerative diseases are associated with the aggregation of misfolded proteins into amyloid oligomers or fibrils that are deposited as pathological lesions within areas of the brain. An attractive therapeutic strategy for preventing or ameliorating amyloid formation is to identify agents that inhibit the onset or propagation of protein aggregation. Here we demonstrate how solid-state nuclear magnetic resonance (ssNMR) may be used to identify key residues within amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). We used our new structural information to design a peptide derived from residues 77 to 82 of alpha-synuclein with an N-methyl group at the C-terminal residue, which was able to disrupt the aggregation of alpha-synuclein. Thus, we have shown how structural data obtained from ssNMR can guide the design of modified peptides for use as amyloid inhibitors, as a primary step toward developing therapeutic compounds for prevention and/or treatment of amyloid diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ec3fbfeea1b541fd86801d3f230fe7ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[179, 181], [90, 92], [155, 157]], "char_spans": [[1031, 1045], [582, 596], [920, 934]]}]}], "context_tokens": [["Many", 0], ["neurodegenerative", 5], ["diseases", 23], ["are", 32], ["associated", 36], ["with", 47], ["the", 52], ["aggregation", 56], ["of", 68], ["misfolded", 71], ["proteins", 81], ["into", 90], ["amyloid", 95], ["oligomers", 103], ["or", 113], ["fibrils", 116], ["that", 124], ["are", 129], ["deposited", 133], ["as", 143], ["pathological", 146], ["lesions", 159], ["within", 167], ["areas", 174], ["of", 180], ["the", 183], ["brain", 187], [".", 192], ["An", 194], ["attractive", 197], ["therapeutic", 208], ["strategy", 220], ["for", 229], ["preventing", 233], ["or", 244], ["ameliorating", 247], ["amyloid", 260], ["formation", 268], ["is", 278], ["to", 281], ["identify", 284], ["agents", 293], ["that", 300], ["inhibit", 305], ["the", 313], ["onset", 317], ["or", 323], ["propagation", 326], ["of", 338], ["protein", 341], ["aggregation", 349], [".", 360], ["Here", 362], ["we", 367], ["demonstrate", 370], ["how", 382], ["solid", 386], ["-", 391], ["state", 392], ["nuclear", 398], ["magnetic", 406], ["resonance", 415], ["(", 425], ["ssNMR", 426], [")", 431], ["may", 433], ["be", 437], ["used", 440], ["to", 445], ["identify", 448], ["key", 457], ["residues", 461], ["within", 470], ["amyloidogenic", 477], ["protein", 491], ["sequences", 499], ["that", 509], ["may", 514], ["be", 518], ["targeted", 521], ["to", 530], ["inhibit", 533], ["the", 541], ["aggregation", 545], ["of", 557], ["the", 560], ["host", 564], ["protein", 569], [".", 576], ["For", 578], ["alpha", 582], ["-", 587], ["synuclein", 588], [",", 597], ["the", 599], ["major", 603], ["protein", 609], ["component", 617], ["of", 627], ["Lewy", 630], ["bodies", 635], ["associated", 642], ["with", 653], ["Parkinson", 658], ["'s", 667], ["disease", 670], [",", 677], ["we", 679], ["have", 682], ["used", 687], ["a", 692], ["combination", 694], ["of", 706], ["ssNMR", 709], ["and", 715], ["biochemical", 719], ["data", 731], ["to", 736], ["identify", 739], ["the", 748], ["key", 752], ["region", 756], ["for", 763], ["self", 767], ["-", 771], ["aggregation", 772], ["of", 784], ["the", 787], ["protein", 791], ["as", 799], ["residues", 802], ["77", 811], ["-", 813], ["82", 814], ["(", 817], ["VAQKTV", 818], [")", 824], [".", 825], ["We", 827], ["used", 830], ["our", 835], ["new", 839], ["structural", 843], ["information", 854], ["to", 866], ["design", 869], ["a", 876], ["peptide", 878], ["derived", 886], ["from", 894], ["residues", 899], ["77", 908], ["to", 911], ["82", 914], ["of", 917], ["alpha", 920], ["-", 925], ["synuclein", 926], ["with", 936], ["an", 941], ["N", 944], ["-", 945], ["methyl", 946], ["group", 953], ["at", 959], ["the", 962], ["C", 966], ["-", 967], ["terminal", 968], ["residue", 977], [",", 984], ["which", 986], ["was", 992], ["able", 996], ["to", 1001], ["disrupt", 1004], ["the", 1012], ["aggregation", 1016], ["of", 1028], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], [".", 1046], ["Thus", 1048], [",", 1052], ["we", 1054], ["have", 1057], ["shown", 1062], ["how", 1068], ["structural", 1072], ["data", 1083], ["obtained", 1088], ["from", 1097], ["ssNMR", 1102], ["can", 1108], ["guide", 1112], ["the", 1118], ["design", 1122], ["of", 1129], ["modified", 1132], ["peptides", 1141], ["for", 1150], ["use", 1154], ["as", 1158], ["amyloid", 1161], ["inhibitors", 1169], [",", 1179], ["as", 1181], ["a", 1184], ["primary", 1186], ["step", 1194], ["toward", 1199], ["developing", 1206], ["therapeutic", 1217], ["compounds", 1229], ["for", 1239], ["prevention", 1243], ["and/or", 1254], ["treatment", 1261], ["of", 1271], ["amyloid", 1274], ["diseases", 1282], [".", 1290]]}
{"context": "To investigate the accuracy of the sequential combination of the probe-to-bone test and plain X-rays for diagnosing osteomyelitis in the foot of patients with diabetes. We prospectively compiled data on a series of 338 patients with diabetes with 356 episodes of foot infection who were hospitalized in the Diabetic Foot Unit of La Paloma Hospital from 1 October 2002 to 31 April 2010. For each patient we did a probe-to-bone test at the time of the initial evaluation and then obtained plain X-rays of the involved foot. All patients with positive results on either the probe-to-bone test or plain X-ray underwent an appropriate surgical procedure, which included obtaining a bone specimen that was processed for histology and culture. We calculated the sensitivity, specificity, predictive values and likelihood ratios of the procedures, using the histopathological diagnosis of osteomyelitis as the criterion standard. Overall, 72.4% of patients had histologically proven osteomyelitis, 85.2% of whom had positive bone culture. The performance characteristics of both the probe-to-bone test and plain X-rays were excellent. The sequential diagnostic approach had a sensitivity of 0.97, specificity of 0.92, positive predictive value of 0.97, negative predictive value of 0.93, positive likelihood ratio of 12.8 and negative likelihood ratio of 0.02. Only 6.6% of patients with negative results on both diagnostic studies had osteomyelitis. Clinicians seeing patients in a setting similar to ours (specialized diabetic foot unit with a high prevalence of osteomyelitis) can confidently diagnose diabetic foot osteomyelitis when either the probe-to-bone test or a plain X-ray, or especially both, are positive.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "a31831baf7b64813bd2cd193e35c0c77", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[285, 287]], "char_spans": [[1597, 1623]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["accuracy", 19], ["of", 28], ["the", 31], ["sequential", 35], ["combination", 46], ["of", 58], ["the", 61], ["probe", 65], ["-", 70], ["to", 71], ["-", 73], ["bone", 74], ["test", 79], ["and", 84], ["plain", 88], ["X", 94], ["-", 95], ["rays", 96], ["for", 101], ["diagnosing", 105], ["osteomyelitis", 116], ["in", 130], ["the", 133], ["foot", 137], ["of", 142], ["patients", 145], ["with", 154], ["diabetes", 159], [".", 167], ["We", 169], ["prospectively", 172], ["compiled", 186], ["data", 195], ["on", 200], ["a", 203], ["series", 205], ["of", 212], ["338", 215], ["patients", 219], ["with", 228], ["diabetes", 233], ["with", 242], ["356", 247], ["episodes", 251], ["of", 260], ["foot", 263], ["infection", 268], ["who", 278], ["were", 282], ["hospitalized", 287], ["in", 300], ["the", 303], ["Diabetic", 307], ["Foot", 316], ["Unit", 321], ["of", 326], ["La", 329], ["Paloma", 332], ["Hospital", 339], ["from", 348], ["1", 353], ["October", 355], ["2002", 363], ["to", 368], ["31", 371], ["April", 374], ["2010", 380], [".", 384], ["For", 386], ["each", 390], ["patient", 395], ["we", 403], ["did", 406], ["a", 410], ["probe", 412], ["-", 417], ["to", 418], ["-", 420], ["bone", 421], ["test", 426], ["at", 431], ["the", 434], ["time", 438], ["of", 443], ["the", 446], ["initial", 450], ["evaluation", 458], ["and", 469], ["then", 473], ["obtained", 478], ["plain", 487], ["X", 493], ["-", 494], ["rays", 495], ["of", 500], ["the", 503], ["involved", 507], ["foot", 516], [".", 520], ["All", 522], ["patients", 526], ["with", 535], ["positive", 540], ["results", 549], ["on", 557], ["either", 560], ["the", 567], ["probe", 571], ["-", 576], ["to", 577], ["-", 579], ["bone", 580], ["test", 585], ["or", 590], ["plain", 593], ["X", 599], ["-", 600], ["ray", 601], ["underwent", 605], ["an", 615], ["appropriate", 618], ["surgical", 630], ["procedure", 639], [",", 648], ["which", 650], ["included", 656], ["obtaining", 665], ["a", 675], ["bone", 677], ["specimen", 682], ["that", 691], ["was", 696], ["processed", 700], ["for", 710], ["histology", 714], ["and", 724], ["culture", 728], [".", 735], ["We", 737], ["calculated", 740], ["the", 751], ["sensitivity", 755], [",", 766], ["specificity", 768], [",", 779], ["predictive", 781], ["values", 792], ["and", 799], ["likelihood", 803], ["ratios", 814], ["of", 821], ["the", 824], ["procedures", 828], [",", 838], ["using", 840], ["the", 846], ["histopathological", 850], ["diagnosis", 868], ["of", 878], ["osteomyelitis", 881], ["as", 895], ["the", 898], ["criterion", 902], ["standard", 912], [".", 920], ["Overall", 922], [",", 929], ["72.4", 931], ["%", 935], ["of", 937], ["patients", 940], ["had", 949], ["histologically", 953], ["proven", 968], ["osteomyelitis", 975], [",", 988], ["85.2", 990], ["%", 994], ["of", 996], ["whom", 999], ["had", 1004], ["positive", 1008], ["bone", 1017], ["culture", 1022], [".", 1029], ["The", 1031], ["performance", 1035], ["characteristics", 1047], ["of", 1063], ["both", 1066], ["the", 1071], ["probe", 1075], ["-", 1080], ["to", 1081], ["-", 1083], ["bone", 1084], ["test", 1089], ["and", 1094], ["plain", 1098], ["X", 1104], ["-", 1105], ["rays", 1106], ["were", 1111], ["excellent", 1116], [".", 1125], ["The", 1127], ["sequential", 1131], ["diagnostic", 1142], ["approach", 1153], ["had", 1162], ["a", 1166], ["sensitivity", 1168], ["of", 1180], ["0.97", 1183], [",", 1187], ["specificity", 1189], ["of", 1201], ["0.92", 1204], [",", 1208], ["positive", 1210], ["predictive", 1219], ["value", 1230], ["of", 1236], ["0.97", 1239], [",", 1243], ["negative", 1245], ["predictive", 1254], ["value", 1265], ["of", 1271], ["0.93", 1274], [",", 1278], ["positive", 1280], ["likelihood", 1289], ["ratio", 1300], ["of", 1306], ["12.8", 1309], ["and", 1314], ["negative", 1318], ["likelihood", 1327], ["ratio", 1338], ["of", 1344], ["0.02", 1347], [".", 1351], ["Only", 1353], ["6.6", 1358], ["%", 1361], ["of", 1363], ["patients", 1366], ["with", 1375], ["negative", 1380], ["results", 1389], ["on", 1397], ["both", 1400], ["diagnostic", 1405], ["studies", 1416], ["had", 1424], ["osteomyelitis", 1428], [".", 1441], ["Clinicians", 1443], ["seeing", 1454], ["patients", 1461], ["in", 1470], ["a", 1473], ["setting", 1475], ["similar", 1483], ["to", 1491], ["ours", 1494], ["(", 1499], ["specialized", 1500], ["diabetic", 1512], ["foot", 1521], ["unit", 1526], ["with", 1531], ["a", 1536], ["high", 1538], ["prevalence", 1543], ["of", 1554], ["osteomyelitis", 1557], [")", 1570], ["can", 1572], ["confidently", 1576], ["diagnose", 1588], ["diabetic", 1597], ["foot", 1606], ["osteomyelitis", 1611], ["when", 1625], ["either", 1630], ["the", 1637], ["probe", 1641], ["-", 1646], ["to", 1647], ["-", 1649], ["bone", 1650], ["test", 1655], ["or", 1660], ["a", 1663], ["plain", 1665], ["X", 1671], ["-", 1672], ["ray", 1673], [",", 1676], ["or", 1678], ["especially", 1681], ["both", 1692], [",", 1696], ["are", 1698], ["positive", 1702], [".", 1710]]}
{"context": "Type 2 diabetes mellitus (T2DM) is increasing worldwide. Treatment of T2DM continues to present challenges, with a significant proportion of patients failing to achieve and maintain glycemic targets. Despite the availability of many oral antidiabetic agents, therapeutic efficacy is also offset by side effects such as weight gain and hypoglycemia. Therefore, the search for novel therapeutic agents with an improved benefit-risk profile continues. In the following review we focus on a novel class of oral antidiabetic drugs, the sodium glucose transporter protein 2 (SGLT2) inhibitors, which have unique characteristics. SGLT2 inhibitors focus on the kidney as a therapeutic target, where they inhibit the reabsorption of glucose in the proximal tubule, causing an increase in urinary glucose excretion. Doing this, they reduce plasma glucose independently of the \u03b2-cell function of the pancreas. SGLT2 inhibitors are effective at lowering hemoglobin A1c, but also induce weight loss and reduce blood pressure, with a low risk of hypoglycemia. In general, the SGLT2 inhibitors are well tolerated, with the most frequent adverse events being mild urinal and genital infections. Since their primary site of effect is the kidney, these drugs are less effective in patients with impaired kidney function but evidence is emerging that these drugs may also have a protective effect against diabetic nephropathy. This review focuses on the most extensively studied SGLT2 inhibitors dapagliflozin, canagliflozin and empagliflozin. Dapagliflozin and canagliflozin have already been approved for marketing by the US Food and Drug Administration. The European Medicines Agency has accepted all three drugs for marketing.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "4978663209ad4e3098899ad04290262e", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[96, 96], [154, 154], [105, 105], [249, 249], [184, 184]], "char_spans": [[569, 573], [899, 903], [623, 627], [1460, 1464], [1062, 1066]]}]}], "context_tokens": [["Type", 0], ["2", 5], ["diabetes", 7], ["mellitus", 16], ["(", 25], ["T2DM", 26], [")", 30], ["is", 32], ["increasing", 35], ["worldwide", 46], [".", 55], ["Treatment", 57], ["of", 67], ["T2DM", 70], ["continues", 75], ["to", 85], ["present", 88], ["challenges", 96], [",", 106], ["with", 108], ["a", 113], ["significant", 115], ["proportion", 127], ["of", 138], ["patients", 141], ["failing", 150], ["to", 158], ["achieve", 161], ["and", 169], ["maintain", 173], ["glycemic", 182], ["targets", 191], [".", 198], ["Despite", 200], ["the", 208], ["availability", 212], ["of", 225], ["many", 228], ["oral", 233], ["antidiabetic", 238], ["agents", 251], [",", 257], ["therapeutic", 259], ["efficacy", 271], ["is", 280], ["also", 283], ["offset", 288], ["by", 295], ["side", 298], ["effects", 303], ["such", 311], ["as", 316], ["weight", 319], ["gain", 326], ["and", 331], ["hypoglycemia", 335], [".", 347], ["Therefore", 349], [",", 358], ["the", 360], ["search", 364], ["for", 371], ["novel", 375], ["therapeutic", 381], ["agents", 393], ["with", 400], ["an", 405], ["improved", 408], ["benefit", 417], ["-", 424], ["risk", 425], ["profile", 430], ["continues", 438], [".", 447], ["In", 449], ["the", 452], ["following", 456], ["review", 466], ["we", 473], ["focus", 476], ["on", 482], ["a", 485], ["novel", 487], ["class", 493], ["of", 499], ["oral", 502], ["antidiabetic", 507], ["drugs", 520], [",", 525], ["the", 527], ["sodium", 531], ["glucose", 538], ["transporter", 546], ["protein", 558], ["2", 566], ["(", 568], ["SGLT2", 569], [")", 574], ["inhibitors", 576], [",", 586], ["which", 588], ["have", 594], ["unique", 599], ["characteristics", 606], [".", 621], ["SGLT2", 623], ["inhibitors", 629], ["focus", 640], ["on", 646], ["the", 649], ["kidney", 653], ["as", 660], ["a", 663], ["therapeutic", 665], ["target", 677], [",", 683], ["where", 685], ["they", 691], ["inhibit", 696], ["the", 704], ["reabsorption", 708], ["of", 721], ["glucose", 724], ["in", 732], ["the", 735], ["proximal", 739], ["tubule", 748], [",", 754], ["causing", 756], ["an", 764], ["increase", 767], ["in", 776], ["urinary", 779], ["glucose", 787], ["excretion", 795], [".", 804], ["Doing", 806], ["this", 812], [",", 816], ["they", 818], ["reduce", 823], ["plasma", 830], ["glucose", 837], ["independently", 845], ["of", 859], ["the", 862], ["\u03b2", 866], ["-", 867], ["cell", 868], ["function", 873], ["of", 882], ["the", 885], ["pancreas", 889], [".", 897], ["SGLT2", 899], ["inhibitors", 905], ["are", 916], ["effective", 920], ["at", 930], ["lowering", 933], ["hemoglobin", 942], ["A1c", 953], [",", 956], ["but", 958], ["also", 962], ["induce", 967], ["weight", 974], ["loss", 981], ["and", 986], ["reduce", 990], ["blood", 997], ["pressure", 1003], [",", 1011], ["with", 1013], ["a", 1018], ["low", 1020], ["risk", 1024], ["of", 1029], ["hypoglycemia", 1032], [".", 1044], ["In", 1046], ["general", 1049], [",", 1056], ["the", 1058], ["SGLT2", 1062], ["inhibitors", 1068], ["are", 1079], ["well", 1083], ["tolerated", 1088], [",", 1097], ["with", 1099], ["the", 1104], ["most", 1108], ["frequent", 1113], ["adverse", 1122], ["events", 1130], ["being", 1137], ["mild", 1143], ["urinal", 1148], ["and", 1155], ["genital", 1159], ["infections", 1167], [".", 1177], ["Since", 1179], ["their", 1185], ["primary", 1191], ["site", 1199], ["of", 1204], ["effect", 1207], ["is", 1214], ["the", 1217], ["kidney", 1221], [",", 1227], ["these", 1229], ["drugs", 1235], ["are", 1241], ["less", 1245], ["effective", 1250], ["in", 1260], ["patients", 1263], ["with", 1272], ["impaired", 1277], ["kidney", 1286], ["function", 1293], ["but", 1302], ["evidence", 1306], ["is", 1315], ["emerging", 1318], ["that", 1327], ["these", 1332], ["drugs", 1338], ["may", 1344], ["also", 1348], ["have", 1353], ["a", 1358], ["protective", 1360], ["effect", 1371], ["against", 1378], ["diabetic", 1386], ["nephropathy", 1395], [".", 1406], ["This", 1408], ["review", 1413], ["focuses", 1420], ["on", 1428], ["the", 1431], ["most", 1435], ["extensively", 1440], ["studied", 1452], ["SGLT2", 1460], ["inhibitors", 1466], ["dapagliflozin", 1477], [",", 1490], ["canagliflozin", 1492], ["and", 1506], ["empagliflozin", 1510], [".", 1523], ["Dapagliflozin", 1525], ["and", 1539], ["canagliflozin", 1543], ["have", 1557], ["already", 1562], ["been", 1570], ["approved", 1575], ["for", 1584], ["marketing", 1588], ["by", 1598], ["the", 1601], ["US", 1605], ["Food", 1608], ["and", 1613], ["Drug", 1617], ["Administration", 1622], [".", 1636], ["The", 1638], ["European", 1642], ["Medicines", 1651], ["Agency", 1661], ["has", 1668], ["accepted", 1672], ["all", 1681], ["three", 1685], ["drugs", 1691], ["for", 1697], ["marketing", 1701], [".", 1710]]}
{"context": "Antibody-mediated glomerulonephritis, including that resulting from immune complexes, is an important cause of renal failure and is in need of more specific and effective treatment. Binding of antibody or immune complexes to Fc receptors activates intracellular signal transduction pathways, including spleen tyrosine kinase (Syk), leading to the production of inflammatory cytokines. We examined the effect of R788 (fostamatinib disodium), an oral prodrug of the selective Syk inhibitor R406, in nephrotoxic nephritis in Wistar-Kyoto rats. Treatment with R788 reduced proteinuria, tissue injury, glomerular macrophage and CD8+ cell numbers, and renal monocyte chemoattractant protein-1 (MCP-1) and IL-1beta, even when we started treatment after the onset of glomerulonephritis. When we administered R788 from days 4 to 10, glomerular crescents reduced by 100% (P < 0.01) compared with the vehicle group. When we administered R788 treatment from days 7 to 14, established glomerular crescents reversed (reduced by 21%, P < 0.001), and renal function was better than the vehicle group (P < 0.001). In vitro, R406 downregulated MCP-1 production from mesangial cells and macrophages stimulated with aggregated IgG. These results suggest that Syk is an important therapeutic target for the treatment of glomerulonephritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "5742d0bc42aa44c8a4614ab95fa1c3ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[46, 48]], "char_spans": [[302, 323]]}]}], "context_tokens": [["Antibody", 0], ["-", 8], ["mediated", 9], ["glomerulonephritis", 18], [",", 36], ["including", 38], ["that", 48], ["resulting", 53], ["from", 63], ["immune", 68], ["complexes", 75], [",", 84], ["is", 86], ["an", 89], ["important", 92], ["cause", 102], ["of", 108], ["renal", 111], ["failure", 117], ["and", 125], ["is", 129], ["in", 132], ["need", 135], ["of", 140], ["more", 143], ["specific", 148], ["and", 157], ["effective", 161], ["treatment", 171], [".", 180], ["Binding", 182], ["of", 190], ["antibody", 193], ["or", 202], ["immune", 205], ["complexes", 212], ["to", 222], ["Fc", 225], ["receptors", 228], ["activates", 238], ["intracellular", 248], ["signal", 262], ["transduction", 269], ["pathways", 282], [",", 290], ["including", 292], ["spleen", 302], ["tyrosine", 309], ["kinase", 318], ["(", 325], ["Syk", 326], [")", 329], [",", 330], ["leading", 332], ["to", 340], ["the", 343], ["production", 347], ["of", 358], ["inflammatory", 361], ["cytokines", 374], [".", 383], ["We", 385], ["examined", 388], ["the", 397], ["effect", 401], ["of", 408], ["R788", 411], ["(", 416], ["fostamatinib", 417], ["disodium", 430], [")", 438], [",", 439], ["an", 441], ["oral", 444], ["prodrug", 449], ["of", 457], ["the", 460], ["selective", 464], ["Syk", 474], ["inhibitor", 478], ["R406", 488], [",", 492], ["in", 494], ["nephrotoxic", 497], ["nephritis", 509], ["in", 519], ["Wistar", 522], ["-", 528], ["Kyoto", 529], ["rats", 535], [".", 539], ["Treatment", 541], ["with", 551], ["R788", 556], ["reduced", 561], ["proteinuria", 569], [",", 580], ["tissue", 582], ["injury", 589], [",", 595], ["glomerular", 597], ["macrophage", 608], ["and", 619], ["CD8", 623], ["+", 626], ["cell", 628], ["numbers", 633], [",", 640], ["and", 642], ["renal", 646], ["monocyte", 652], ["chemoattractant", 661], ["protein-1", 677], ["(", 687], ["MCP-1", 688], [")", 693], ["and", 695], ["IL-1beta", 699], [",", 707], ["even", 709], ["when", 714], ["we", 719], ["started", 722], ["treatment", 730], ["after", 740], ["the", 746], ["onset", 750], ["of", 756], ["glomerulonephritis", 759], [".", 777], ["When", 779], ["we", 784], ["administered", 787], ["R788", 800], ["from", 805], ["days", 810], ["4", 815], ["to", 817], ["10", 820], [",", 822], ["glomerular", 824], ["crescents", 835], ["reduced", 845], ["by", 853], ["100", 856], ["%", 859], ["(", 861], ["P", 862], ["<", 864], ["0.01", 866], [")", 870], ["compared", 872], ["with", 881], ["the", 886], ["vehicle", 890], ["group", 898], [".", 903], ["When", 905], ["we", 910], ["administered", 913], ["R788", 926], ["treatment", 931], ["from", 941], ["days", 946], ["7", 951], ["to", 953], ["14", 956], [",", 958], ["established", 960], ["glomerular", 972], ["crescents", 983], ["reversed", 993], ["(", 1002], ["reduced", 1003], ["by", 1011], ["21", 1014], ["%", 1016], [",", 1017], ["P", 1019], ["<", 1021], ["0.001", 1023], [")", 1028], [",", 1029], ["and", 1031], ["renal", 1035], ["function", 1041], ["was", 1050], ["better", 1054], ["than", 1061], ["the", 1066], ["vehicle", 1070], ["group", 1078], ["(", 1084], ["P", 1085], ["<", 1087], ["0.001", 1089], [")", 1094], [".", 1095], ["In", 1097], ["vitro", 1100], [",", 1105], ["R406", 1107], ["downregulated", 1112], ["MCP-1", 1126], ["production", 1132], ["from", 1143], ["mesangial", 1148], ["cells", 1158], ["and", 1164], ["macrophages", 1168], ["stimulated", 1180], ["with", 1191], ["aggregated", 1196], ["IgG.", 1207], ["These", 1212], ["results", 1218], ["suggest", 1226], ["that", 1234], ["Syk", 1239], ["is", 1243], ["an", 1246], ["important", 1249], ["therapeutic", 1259], ["target", 1271], ["for", 1278], ["the", 1282], ["treatment", 1286], ["of", 1296], ["glomerulonephritis", 1299], [".", 1317]]}
{"context": "Mutations in the K-ras oncogene and in the p53 tumor suppressor gene are commonly identified in sporadic cases of pancreatic adenocarcinoma. Although these genes might serve as useful markers for early diagnosis of pancreatic carcinoma in patients at risk for the development of this disease, familial pancreatic carcinomas have not been studied for these mutations. We recently had the opportunity to examine a pancreas prophylactically removed from a patient with a strong family history of pancreatic carcinoma. This gave us the unique opportunity to study the early events in the development of familial adenocarcinoma of the pancreas. Histopathological examination of the pancreas revealed multifocal papillary and nonpapillary mucinous duct hyperplasia. Seven of these foci were microdissected and analyzed for K-ras and p53 mutations. The K-ras mutations were detected by combined mutant-enriched polymerase chain reaction-restriction fragment length polymorphism analysis and characterized further by allele-specific oligonucleotide hybridization. Five of the seven duct lesions harbored activating point mutations in codon 12 of K-ras; a G to A transition was found in four and a G to C transversion in one. In contrast, these lesions did not harbor detectable p53 mutations as determined by denaturing gradient gel electrophoresis of exons 5 to 8, nor was there overexpression of the p53 protein as determined by immunohistochemistry. These findings suggest that mutations in K-ras represent an early event in the pathogenesis of pancreatic carcinoma. In addition, monitoring of patients with a strong family history of pancreatic carcinoma for K-ras mutations may identify patients at risk for the development of invasive carcinoma.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "1a7c755b01c04164ba29934405c67228", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[173, 174]], "char_spans": [[1107, 1121]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["K", 17], ["-", 18], ["ras", 19], ["oncogene", 23], ["and", 32], ["in", 36], ["the", 39], ["p53", 43], ["tumor", 47], ["suppressor", 53], ["gene", 64], ["are", 69], ["commonly", 73], ["identified", 82], ["in", 93], ["sporadic", 96], ["cases", 105], ["of", 111], ["pancreatic", 114], ["adenocarcinoma", 125], [".", 139], ["Although", 141], ["these", 150], ["genes", 156], ["might", 162], ["serve", 168], ["as", 174], ["useful", 177], ["markers", 184], ["for", 192], ["early", 196], ["diagnosis", 202], ["of", 212], ["pancreatic", 215], ["carcinoma", 226], ["in", 236], ["patients", 239], ["at", 248], ["risk", 251], ["for", 256], ["the", 260], ["development", 264], ["of", 276], ["this", 279], ["disease", 284], [",", 291], ["familial", 293], ["pancreatic", 302], ["carcinomas", 313], ["have", 324], ["not", 329], ["been", 333], ["studied", 338], ["for", 346], ["these", 350], ["mutations", 356], [".", 365], ["We", 367], ["recently", 370], ["had", 379], ["the", 383], ["opportunity", 387], ["to", 399], ["examine", 402], ["a", 410], ["pancreas", 412], ["prophylactically", 421], ["removed", 438], ["from", 446], ["a", 451], ["patient", 453], ["with", 461], ["a", 466], ["strong", 468], ["family", 475], ["history", 482], ["of", 490], ["pancreatic", 493], ["carcinoma", 504], [".", 513], ["This", 515], ["gave", 520], ["us", 525], ["the", 528], ["unique", 532], ["opportunity", 539], ["to", 551], ["study", 554], ["the", 560], ["early", 564], ["events", 570], ["in", 577], ["the", 580], ["development", 584], ["of", 596], ["familial", 599], ["adenocarcinoma", 608], ["of", 623], ["the", 626], ["pancreas", 630], [".", 638], ["Histopathological", 640], ["examination", 658], ["of", 670], ["the", 673], ["pancreas", 677], ["revealed", 686], ["multifocal", 695], ["papillary", 706], ["and", 716], ["nonpapillary", 720], ["mucinous", 733], ["duct", 742], ["hyperplasia", 747], [".", 758], ["Seven", 760], ["of", 766], ["these", 769], ["foci", 775], ["were", 780], ["microdissected", 785], ["and", 800], ["analyzed", 804], ["for", 813], ["K", 817], ["-", 818], ["ras", 819], ["and", 823], ["p53", 827], ["mutations", 831], [".", 840], ["The", 842], ["K", 846], ["-", 847], ["ras", 848], ["mutations", 852], ["were", 862], ["detected", 867], ["by", 876], ["combined", 879], ["mutant", 888], ["-", 894], ["enriched", 895], ["polymerase", 904], ["chain", 915], ["reaction", 921], ["-", 929], ["restriction", 930], ["fragment", 942], ["length", 951], ["polymorphism", 958], ["analysis", 971], ["and", 980], ["characterized", 984], ["further", 998], ["by", 1006], ["allele", 1009], ["-", 1015], ["specific", 1016], ["oligonucleotide", 1025], ["hybridization", 1041], [".", 1054], ["Five", 1056], ["of", 1061], ["the", 1064], ["seven", 1068], ["duct", 1074], ["lesions", 1079], ["harbored", 1087], ["activating", 1096], ["point", 1107], ["mutations", 1113], ["in", 1123], ["codon", 1126], ["12", 1132], ["of", 1135], ["K", 1138], ["-", 1139], ["ras", 1140], [";", 1143], ["a", 1145], ["G", 1147], ["to", 1149], ["A", 1152], ["transition", 1154], ["was", 1165], ["found", 1169], ["in", 1175], ["four", 1178], ["and", 1183], ["a", 1187], ["G", 1189], ["to", 1191], ["C", 1194], ["transversion", 1196], ["in", 1209], ["one", 1212], [".", 1215], ["In", 1217], ["contrast", 1220], [",", 1228], ["these", 1230], ["lesions", 1236], ["did", 1244], ["not", 1248], ["harbor", 1252], ["detectable", 1259], ["p53", 1270], ["mutations", 1274], ["as", 1284], ["determined", 1287], ["by", 1298], ["denaturing", 1301], ["gradient", 1312], ["gel", 1321], ["electrophoresis", 1325], ["of", 1341], ["exons", 1344], ["5", 1350], ["to", 1352], ["8", 1355], [",", 1356], ["nor", 1358], ["was", 1362], ["there", 1366], ["overexpression", 1372], ["of", 1387], ["the", 1390], ["p53", 1394], ["protein", 1398], ["as", 1406], ["determined", 1409], ["by", 1420], ["immunohistochemistry", 1423], [".", 1443], ["These", 1445], ["findings", 1451], ["suggest", 1460], ["that", 1468], ["mutations", 1473], ["in", 1483], ["K", 1486], ["-", 1487], ["ras", 1488], ["represent", 1492], ["an", 1502], ["early", 1505], ["event", 1511], ["in", 1517], ["the", 1520], ["pathogenesis", 1524], ["of", 1537], ["pancreatic", 1540], ["carcinoma", 1551], [".", 1560], ["In", 1562], ["addition", 1565], [",", 1573], ["monitoring", 1575], ["of", 1586], ["patients", 1589], ["with", 1598], ["a", 1603], ["strong", 1605], ["family", 1612], ["history", 1619], ["of", 1627], ["pancreatic", 1630], ["carcinoma", 1641], ["for", 1651], ["K", 1655], ["-", 1656], ["ras", 1657], ["mutations", 1661], ["may", 1671], ["identify", 1675], ["patients", 1684], ["at", 1693], ["risk", 1696], ["for", 1701], ["the", 1705], ["development", 1709], ["of", 1721], ["invasive", 1724], ["carcinoma", 1733], [".", 1742]]}
{"context": "The tumorigenesis of sporadic endocrine tumors is still not fully understood. It is well known that patients with von Recklinghausen syndrome (NF-1) (OMIM 162200) carrying NF1 germline mutations are predisposed to endocrine tumors including pheochromocytomas and duodenal somatostatinomas. It is unclear, however, whether the rarely reported occurrence of pancreatic insulinomas in NF-1 patients represents a coincidental finding or whether insulinomas are a rare manifestation of the NF-1 syndrome. To determine the potential association between the NF-1 syndrome and pancreatic endocrine tumors, we analyzed a NF-1 patient with a well-differentiated pancreatic endocrine carcinoma for NF1 mutation, allelic loss of the NF1 gene and its expression in peripheral blood and tumor cells. The germline mutation c. 499 del TGTT known in the family was confirmed by polymerase chain reaction (PCR) and direct sequencing of exon 4 in DNA extracted from peripheral blood. Loss of heterozygosity (LOH) analysis of the NF1 gene was carried out using 3 intragenic microsatellite markers on 17q11.2. RNA expression was examined by reverse transcription and a consecutive PCR spanning intron 3 of the NF1 gene including the mutated site in exon 4. Immunohistochemistry was used to analyze NF-1 protein expression. Mutation analysis of peripheral blood leukocytes confirmed the 4 base pair deletion in exon 4 starting at codon 167 (499 del TGTT). LOH analysis of tumor tissue revealed retention of both NF1 alleles. While reverse transcriptase-PCR of peripheral blood showed bi-allelic expression of both the wild-type NF1 and the mutated form, reverse transcriptase-PCR of tumor extracts demonstrated expression of the mutated but not the wild-type NF1 allele. Additionally, neurofibromin, the NF1 gene product, was absent in the tumor tissue of the NF-1 patient. These results show that the wild-type NF1 transcrips and protein are reduced, in the reported insulinoma, supposedly by epigenetic mechanisms. This provides strong evidence that there is a relationship between von Recklinghausen disease and the patient's insulinoma. In this line, insulinomas may be viewed as a rare manifestation of the NF-1 syndrome. Furthermore, the NF1 gene must be considered as a candidate tumor suppressor gene for sporadic insulinomas and probably other pancreatic endocrine tumors.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "c0d1452ed8b34c4d932f62aae61d37a4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[112, 112], [195, 195], [302, 302], [166, 166], [294, 294], [325, 325], [381, 381], [105, 105], [270, 270], [248, 248], [30, 30]], "char_spans": [[721, 723], [1189, 1191], [1782, 1784], [1010, 1012], [1737, 1739], [1890, 1892], [2222, 2224], [687, 689], [1606, 1608], [1490, 1492], [172, 174]]}]}], "context_tokens": [["The", 0], ["tumorigenesis", 4], ["of", 18], ["sporadic", 21], ["endocrine", 30], ["tumors", 40], ["is", 47], ["still", 50], ["not", 56], ["fully", 60], ["understood", 66], [".", 76], ["It", 78], ["is", 81], ["well", 84], ["known", 89], ["that", 95], ["patients", 100], ["with", 109], ["von", 114], ["Recklinghausen", 118], ["syndrome", 133], ["(", 142], ["NF-1", 143], [")", 147], ["(", 149], ["OMIM", 150], ["162200", 155], [")", 161], ["carrying", 163], ["NF1", 172], ["germline", 176], ["mutations", 185], ["are", 195], ["predisposed", 199], ["to", 211], ["endocrine", 214], ["tumors", 224], ["including", 231], ["pheochromocytomas", 241], ["and", 259], ["duodenal", 263], ["somatostatinomas", 272], [".", 288], ["It", 290], ["is", 293], ["unclear", 296], [",", 303], ["however", 305], [",", 312], ["whether", 314], ["the", 322], ["rarely", 326], ["reported", 333], ["occurrence", 342], ["of", 353], ["pancreatic", 356], ["insulinomas", 367], ["in", 379], ["NF-1", 382], ["patients", 387], ["represents", 396], ["a", 407], ["coincidental", 409], ["finding", 422], ["or", 430], ["whether", 433], ["insulinomas", 441], ["are", 453], ["a", 457], ["rare", 459], ["manifestation", 464], ["of", 478], ["the", 481], ["NF-1", 485], ["syndrome", 490], [".", 498], ["To", 500], ["determine", 503], ["the", 513], ["potential", 517], ["association", 527], ["between", 539], ["the", 547], ["NF-1", 551], ["syndrome", 556], ["and", 565], ["pancreatic", 569], ["endocrine", 580], ["tumors", 590], [",", 596], ["we", 598], ["analyzed", 601], ["a", 610], ["NF-1", 612], ["patient", 617], ["with", 625], ["a", 630], ["well", 632], ["-", 636], ["differentiated", 637], ["pancreatic", 652], ["endocrine", 663], ["carcinoma", 673], ["for", 683], ["NF1", 687], ["mutation", 691], [",", 699], ["allelic", 701], ["loss", 709], ["of", 714], ["the", 717], ["NF1", 721], ["gene", 725], ["and", 730], ["its", 734], ["expression", 738], ["in", 749], ["peripheral", 752], ["blood", 763], ["and", 769], ["tumor", 773], ["cells", 779], [".", 784], ["The", 786], ["germline", 790], ["mutation", 799], ["c.", 808], ["499", 811], ["del", 815], ["TGTT", 819], ["known", 824], ["in", 830], ["the", 833], ["family", 837], ["was", 844], ["confirmed", 848], ["by", 858], ["polymerase", 861], ["chain", 872], ["reaction", 878], ["(", 887], ["PCR", 888], [")", 891], ["and", 893], ["direct", 897], ["sequencing", 904], ["of", 915], ["exon", 918], ["4", 923], ["in", 925], ["DNA", 928], ["extracted", 932], ["from", 942], ["peripheral", 947], ["blood", 958], [".", 963], ["Loss", 965], ["of", 970], ["heterozygosity", 973], ["(", 988], ["LOH", 989], [")", 992], ["analysis", 994], ["of", 1003], ["the", 1006], ["NF1", 1010], ["gene", 1014], ["was", 1019], ["carried", 1023], ["out", 1031], ["using", 1035], ["3", 1041], ["intragenic", 1043], ["microsatellite", 1054], ["markers", 1069], ["on", 1077], ["17q11.2", 1080], [".", 1087], ["RNA", 1089], ["expression", 1093], ["was", 1104], ["examined", 1108], ["by", 1117], ["reverse", 1120], ["transcription", 1128], ["and", 1142], ["a", 1146], ["consecutive", 1148], ["PCR", 1160], ["spanning", 1164], ["intron", 1173], ["3", 1180], ["of", 1182], ["the", 1185], ["NF1", 1189], ["gene", 1193], ["including", 1198], ["the", 1208], ["mutated", 1212], ["site", 1220], ["in", 1225], ["exon", 1228], ["4", 1233], [".", 1234], ["Immunohistochemistry", 1236], ["was", 1257], ["used", 1261], ["to", 1266], ["analyze", 1269], ["NF-1", 1277], ["protein", 1282], ["expression", 1290], [".", 1300], ["Mutation", 1302], ["analysis", 1311], ["of", 1320], ["peripheral", 1323], ["blood", 1334], ["leukocytes", 1340], ["confirmed", 1351], ["the", 1361], ["4", 1365], ["base", 1367], ["pair", 1372], ["deletion", 1377], ["in", 1386], ["exon", 1389], ["4", 1394], ["starting", 1396], ["at", 1405], ["codon", 1408], ["167", 1414], ["(", 1418], ["499", 1419], ["del", 1423], ["TGTT", 1427], [")", 1431], [".", 1432], ["LOH", 1434], ["analysis", 1438], ["of", 1447], ["tumor", 1450], ["tissue", 1456], ["revealed", 1463], ["retention", 1472], ["of", 1482], ["both", 1485], ["NF1", 1490], ["alleles", 1494], [".", 1501], ["While", 1503], ["reverse", 1509], ["transcriptase", 1517], ["-", 1530], ["PCR", 1531], ["of", 1535], ["peripheral", 1538], ["blood", 1549], ["showed", 1555], ["bi", 1562], ["-", 1564], ["allelic", 1565], ["expression", 1573], ["of", 1584], ["both", 1587], ["the", 1592], ["wild", 1596], ["-", 1600], ["type", 1601], ["NF1", 1606], ["and", 1610], ["the", 1614], ["mutated", 1618], ["form", 1626], [",", 1630], ["reverse", 1632], ["transcriptase", 1640], ["-", 1653], ["PCR", 1654], ["of", 1658], ["tumor", 1661], ["extracts", 1667], ["demonstrated", 1676], ["expression", 1689], ["of", 1700], ["the", 1703], ["mutated", 1707], ["but", 1715], ["not", 1719], ["the", 1723], ["wild", 1727], ["-", 1731], ["type", 1732], ["NF1", 1737], ["allele", 1741], [".", 1747], ["Additionally", 1749], [",", 1761], ["neurofibromin", 1763], [",", 1776], ["the", 1778], ["NF1", 1782], ["gene", 1786], ["product", 1791], [",", 1798], ["was", 1800], ["absent", 1804], ["in", 1811], ["the", 1814], ["tumor", 1818], ["tissue", 1824], ["of", 1831], ["the", 1834], ["NF-1", 1838], ["patient", 1843], [".", 1850], ["These", 1852], ["results", 1858], ["show", 1866], ["that", 1871], ["the", 1876], ["wild", 1880], ["-", 1884], ["type", 1885], ["NF1", 1890], ["transcrips", 1894], ["and", 1905], ["protein", 1909], ["are", 1917], ["reduced", 1921], [",", 1928], ["in", 1930], ["the", 1933], ["reported", 1937], ["insulinoma", 1946], [",", 1956], ["supposedly", 1958], ["by", 1969], ["epigenetic", 1972], ["mechanisms", 1983], [".", 1993], ["This", 1995], ["provides", 2000], ["strong", 2009], ["evidence", 2016], ["that", 2025], ["there", 2030], ["is", 2036], ["a", 2039], ["relationship", 2041], ["between", 2054], ["von", 2062], ["Recklinghausen", 2066], ["disease", 2081], ["and", 2089], ["the", 2093], ["patient", 2097], ["'s", 2104], ["insulinoma", 2107], [".", 2117], ["In", 2119], ["this", 2122], ["line", 2127], [",", 2131], ["insulinomas", 2133], ["may", 2145], ["be", 2149], ["viewed", 2152], ["as", 2159], ["a", 2162], ["rare", 2164], ["manifestation", 2169], ["of", 2183], ["the", 2186], ["NF-1", 2190], ["syndrome", 2195], [".", 2203], ["Furthermore", 2205], [",", 2216], ["the", 2218], ["NF1", 2222], ["gene", 2226], ["must", 2231], ["be", 2236], ["considered", 2239], ["as", 2250], ["a", 2253], ["candidate", 2255], ["tumor", 2265], ["suppressor", 2271], ["gene", 2282], ["for", 2287], ["sporadic", 2291], ["insulinomas", 2300], ["and", 2312], ["probably", 2316], ["other", 2325], ["pancreatic", 2331], ["endocrine", 2342], ["tumors", 2352], [".", 2358]]}
{"context": "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is triggered by constitutively activated BCR-ABL and SRC family tyrosine kinases.They account for the activations of multiple growth-signaling pathways, including Raf/MEK/ERK, Akt/mTOR and STAT5 pathways. The BCR-ABL tyrosine kinase inhibitor imatinib is the standard treatment for Ph+ leukemia and plays efficacious role in CML. However, imatinib has few inhibitory effects on SRC tyrosine kinase with response rate of Ph+ ALL lower and relapse more frequent and quicker compared with CML. Previous studies showed that oridonin inhibits proliferation and induces apoptosis in many tumor cells. However, the anticancer activity and mechanism of oridonin in Ph+ ALL is unknown. To investigate the anticancer activity of oridonin, we examined its role in constitutively activated Akt/mTOR, Raf/MEK/ERK, STAT5 and SRC pathway, mRNA level of bcr/abl gene, cell viability and apoptosis in Ph+ ALL SUP-B15 cells. Furthermore, we detected synergetic effect of oridonin plus imatinib. Our results showed that oridonin inhibiting activations of LYN (one of SRC family kinases) and ABL and their downstream Akt/mTOR, Raf/MEK/ERK and STAT5 pathways, downregulated Bcl-2 but upregulated Bax protein and then induced apoptosis in Ph+ ALL cells. Oridonin plus imatinib exerted synergetic effects by overcoming imatinib defect of upregulating Akt/mTOR and LYN signaling. Additionally, we examined the effect of oridonin on the signaling pathways in the primary specimens from Ph+ ALL patients. Our data showed that oridonin remarkably suppressed activations of Akt/mTOR, Raf/MEK and STAT5 pathway in these primary specimens and oridonin with imatinib exerted synergetic suppressive effects on mTOR, STAT5 and LYN signaling in one imatinib resistant patient specimen. Additional evaluation of oridonin as a potential therapeutic agent for Ph+ ALL seems warranted.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "86cf7cabdc464986812d7f76361ff136", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[52, 54], [16, 18], [164, 166]], "char_spans": [[281, 287], [113, 119], [910, 916]]}]}], "context_tokens": [["Philadelphia", 0], ["chromosome", 13], ["-", 23], ["positive", 24], ["acute", 33], ["lymphoblastic", 39], ["leukemia", 53], ["(", 62], ["Ph+", 63], ["ALL", 67], [")", 70], ["is", 72], ["triggered", 75], ["by", 85], ["constitutively", 88], ["activated", 103], ["BCR", 113], ["-", 116], ["ABL", 117], ["and", 121], ["SRC", 125], ["family", 129], ["tyrosine", 136], ["kinases", 145], [".", 152], ["They", 153], ["account", 158], ["for", 166], ["the", 170], ["activations", 174], ["of", 186], ["multiple", 189], ["growth", 198], ["-", 204], ["signaling", 205], ["pathways", 215], [",", 223], ["including", 225], ["Raf", 235], ["/", 238], ["MEK", 239], ["/", 242], ["ERK", 243], [",", 246], ["Akt", 248], ["/", 251], ["mTOR", 252], ["and", 257], ["STAT5", 261], ["pathways", 267], [".", 275], ["The", 277], ["BCR", 281], ["-", 284], ["ABL", 285], ["tyrosine", 289], ["kinase", 298], ["inhibitor", 305], ["imatinib", 315], ["is", 324], ["the", 327], ["standard", 331], ["treatment", 340], ["for", 350], ["Ph+", 354], ["leukemia", 358], ["and", 367], ["plays", 371], ["efficacious", 377], ["role", 389], ["in", 394], ["CML", 397], [".", 400], ["However", 402], [",", 409], ["imatinib", 411], ["has", 420], ["few", 424], ["inhibitory", 428], ["effects", 439], ["on", 447], ["SRC", 450], ["tyrosine", 454], ["kinase", 463], ["with", 470], ["response", 475], ["rate", 484], ["of", 489], ["Ph+", 492], ["ALL", 496], ["lower", 500], ["and", 506], ["relapse", 510], ["more", 518], ["frequent", 523], ["and", 532], ["quicker", 536], ["compared", 544], ["with", 553], ["CML", 558], [".", 561], ["Previous", 563], ["studies", 572], ["showed", 580], ["that", 587], ["oridonin", 592], ["inhibits", 601], ["proliferation", 610], ["and", 624], ["induces", 628], ["apoptosis", 636], ["in", 646], ["many", 649], ["tumor", 654], ["cells", 660], [".", 665], ["However", 667], [",", 674], ["the", 676], ["anticancer", 680], ["activity", 691], ["and", 700], ["mechanism", 704], ["of", 714], ["oridonin", 717], ["in", 726], ["Ph+", 729], ["ALL", 733], ["is", 737], ["unknown", 740], [".", 747], ["To", 749], ["investigate", 752], ["the", 764], ["anticancer", 768], ["activity", 779], ["of", 788], ["oridonin", 791], [",", 799], ["we", 801], ["examined", 804], ["its", 813], ["role", 817], ["in", 822], ["constitutively", 825], ["activated", 840], ["Akt", 850], ["/", 853], ["mTOR", 854], [",", 858], ["Raf", 860], ["/", 863], ["MEK", 864], ["/", 867], ["ERK", 868], [",", 871], ["STAT5", 873], ["and", 879], ["SRC", 883], ["pathway", 887], [",", 894], ["mRNA", 896], ["level", 901], ["of", 907], ["bcr", 910], ["/", 913], ["abl", 914], ["gene", 918], [",", 922], ["cell", 924], ["viability", 929], ["and", 939], ["apoptosis", 943], ["in", 953], ["Ph+", 956], ["ALL", 960], ["SUP", 964], ["-", 967], ["B15", 968], ["cells", 972], [".", 977], ["Furthermore", 979], [",", 990], ["we", 992], ["detected", 995], ["synergetic", 1004], ["effect", 1015], ["of", 1022], ["oridonin", 1025], ["plus", 1034], ["imatinib", 1039], [".", 1047], ["Our", 1049], ["results", 1053], ["showed", 1061], ["that", 1068], ["oridonin", 1073], ["inhibiting", 1082], ["activations", 1093], ["of", 1105], ["LYN", 1108], ["(", 1112], ["one", 1113], ["of", 1117], ["SRC", 1120], ["family", 1124], ["kinases", 1131], [")", 1138], ["and", 1140], ["ABL", 1144], ["and", 1148], ["their", 1152], ["downstream", 1158], ["Akt", 1169], ["/", 1172], ["mTOR", 1173], [",", 1177], ["Raf", 1179], ["/", 1182], ["MEK", 1183], ["/", 1186], ["ERK", 1187], ["and", 1191], ["STAT5", 1195], ["pathways", 1201], [",", 1209], ["downregulated", 1211], ["Bcl-2", 1225], ["but", 1231], ["upregulated", 1235], ["Bax", 1247], ["protein", 1251], ["and", 1259], ["then", 1263], ["induced", 1268], ["apoptosis", 1276], ["in", 1286], ["Ph+", 1289], ["ALL", 1293], ["cells", 1297], [".", 1302], ["Oridonin", 1304], ["plus", 1313], ["imatinib", 1318], ["exerted", 1327], ["synergetic", 1335], ["effects", 1346], ["by", 1354], ["overcoming", 1357], ["imatinib", 1368], ["defect", 1377], ["of", 1384], ["upregulating", 1387], ["Akt", 1400], ["/", 1403], ["mTOR", 1404], ["and", 1409], ["LYN", 1413], ["signaling", 1417], [".", 1426], ["Additionally", 1428], [",", 1440], ["we", 1442], ["examined", 1445], ["the", 1454], ["effect", 1458], ["of", 1465], ["oridonin", 1468], ["on", 1477], ["the", 1480], ["signaling", 1484], ["pathways", 1494], ["in", 1503], ["the", 1506], ["primary", 1510], ["specimens", 1518], ["from", 1528], ["Ph+", 1533], ["ALL", 1537], ["patients", 1541], [".", 1549], ["Our", 1551], ["data", 1555], ["showed", 1560], ["that", 1567], ["oridonin", 1572], ["remarkably", 1581], ["suppressed", 1592], ["activations", 1603], ["of", 1615], ["Akt", 1618], ["/", 1621], ["mTOR", 1622], [",", 1626], ["Raf", 1628], ["/", 1631], ["MEK", 1632], ["and", 1636], ["STAT5", 1640], ["pathway", 1646], ["in", 1654], ["these", 1657], ["primary", 1663], ["specimens", 1671], ["and", 1681], ["oridonin", 1685], ["with", 1694], ["imatinib", 1699], ["exerted", 1708], ["synergetic", 1716], ["suppressive", 1727], ["effects", 1739], ["on", 1747], ["mTOR", 1750], [",", 1754], ["STAT5", 1756], ["and", 1762], ["LYN", 1766], ["signaling", 1770], ["in", 1780], ["one", 1783], ["imatinib", 1787], ["resistant", 1796], ["patient", 1806], ["specimen", 1814], [".", 1822], ["Additional", 1824], ["evaluation", 1835], ["of", 1846], ["oridonin", 1849], ["as", 1858], ["a", 1861], ["potential", 1863], ["therapeutic", 1873], ["agent", 1885], ["for", 1891], ["Ph+", 1895], ["ALL", 1899], ["seems", 1903], ["warranted", 1909], [".", 1918]]}
{"context": "Hepcidin, a 25-amino-acid peptide secreted by the liver, distributed in the plasma and excreted in urine, is a key central regulator of body iron homeostasis. This hormone decreases export of cellular iron by binding to ferroportin, an iron exporter present at the basolateral surface of enterocytes and macrophages (the sites of dietary iron absorption and iron recycling, respectively), inducing its internalization and degradation. Hepcidin contains eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets. We noticed in the sequence of hepcidin a Cys*-X-Cys* motif which can act as a metal binding site able to trap iron and/or copper. We have tested this hypothesis using a pseudopeptidic synthetic bis-disulfide analogue and we have shown that direct metalation of such ligand leads to the formation of a copper(III) complex with the typical N(2)S(2)\u00a0donor set. This compound crystallizes in the orthorhombic system, space group Imma. The Cu(III) configuration is square planar, built up from two carboximado-N and two thiolato-S donors. This complex is converted back to the bis-disulfide, with release of the copper salt, upon oxidation with iodine.", "qas": [{"question": "How many disulfide bridges has the protein hepcidin got?", "answers": ["Hepcidin contains eight cysteine residues that form four disulfide bridges"], "qid": "1f9ba193c3004e76bc6c7b235f7af430", "question_tokens": [["How", 0], ["many", 4], ["disulfide", 9], ["bridges", 19], ["has", 27], ["the", 31], ["protein", 35], ["hepcidin", 43], ["got", 52], ["?", 55]], "detected_answers": [{"text": "Hepcidin contains eight cysteine residues that form four disulfide bridges", "token_spans": [[75, 84]], "char_spans": [[435, 508]]}]}], "context_tokens": [["Hepcidin", 0], [",", 8], ["a", 10], ["25-amino", 12], ["-", 20], ["acid", 21], ["peptide", 26], ["secreted", 34], ["by", 43], ["the", 46], ["liver", 50], [",", 55], ["distributed", 57], ["in", 69], ["the", 72], ["plasma", 76], ["and", 83], ["excreted", 87], ["in", 96], ["urine", 99], [",", 104], ["is", 106], ["a", 109], ["key", 111], ["central", 115], ["regulator", 123], ["of", 133], ["body", 136], ["iron", 141], ["homeostasis", 146], [".", 157], ["This", 159], ["hormone", 164], ["decreases", 172], ["export", 182], ["of", 189], ["cellular", 192], ["iron", 201], ["by", 206], ["binding", 209], ["to", 217], ["ferroportin", 220], [",", 231], ["an", 233], ["iron", 236], ["exporter", 241], ["present", 250], ["at", 258], ["the", 261], ["basolateral", 265], ["surface", 277], ["of", 285], ["enterocytes", 288], ["and", 300], ["macrophages", 304], ["(", 316], ["the", 317], ["sites", 321], ["of", 327], ["dietary", 330], ["iron", 338], ["absorption", 343], ["and", 354], ["iron", 358], ["recycling", 363], [",", 372], ["respectively", 374], [")", 386], [",", 387], ["inducing", 389], ["its", 398], ["internalization", 402], ["and", 418], ["degradation", 422], [".", 433], ["Hepcidin", 435], ["contains", 444], ["eight", 453], ["cysteine", 459], ["residues", 468], ["that", 477], ["form", 482], ["four", 487], ["disulfide", 492], ["bridges", 502], [",", 509], ["which", 511], ["stabilize", 517], ["a", 527], ["hairpin", 529], ["-", 536], ["shaped", 537], ["structure", 544], ["with", 554], ["two", 559], ["beta", 563], ["sheets", 568], [".", 574], ["We", 576], ["noticed", 579], ["in", 587], ["the", 590], ["sequence", 594], ["of", 603], ["hepcidin", 606], ["a", 615], ["Cys*-X", 617], ["-", 623], ["Cys", 624], ["*", 627], ["motif", 629], ["which", 635], ["can", 641], ["act", 645], ["as", 649], ["a", 652], ["metal", 654], ["binding", 660], ["site", 668], ["able", 673], ["to", 678], ["trap", 681], ["iron", 686], ["and/or", 691], ["copper", 698], [".", 704], ["We", 706], ["have", 709], ["tested", 714], ["this", 721], ["hypothesis", 726], ["using", 737], ["a", 743], ["pseudopeptidic", 745], ["synthetic", 760], ["bis", 770], ["-", 773], ["disulfide", 774], ["analogue", 784], ["and", 793], ["we", 797], ["have", 800], ["shown", 805], ["that", 811], ["direct", 816], ["metalation", 823], ["of", 834], ["such", 837], ["ligand", 842], ["leads", 849], ["to", 855], ["the", 858], ["formation", 862], ["of", 872], ["a", 875], ["copper(III", 877], [")", 887], ["complex", 889], ["with", 897], ["the", 902], ["typical", 906], ["N(2)S(2", 914], [")", 921], ["donor", 923], ["set", 929], [".", 932], ["This", 934], ["compound", 939], ["crystallizes", 948], ["in", 961], ["the", 964], ["orthorhombic", 968], ["system", 981], [",", 987], ["space", 989], ["group", 995], ["Imma", 1001], [".", 1005], ["The", 1007], ["Cu(III", 1011], [")", 1017], ["configuration", 1019], ["is", 1033], ["square", 1036], ["planar", 1043], [",", 1049], ["built", 1051], ["up", 1057], ["from", 1060], ["two", 1065], ["carboximado", 1069], ["-", 1080], ["N", 1081], ["and", 1083], ["two", 1087], ["thiolato", 1091], ["-", 1099], ["S", 1100], ["donors", 1102], [".", 1108], ["This", 1110], ["complex", 1115], ["is", 1123], ["converted", 1126], ["back", 1136], ["to", 1141], ["the", 1144], ["bis", 1148], ["-", 1151], ["disulfide", 1152], [",", 1161], ["with", 1163], ["release", 1168], ["of", 1176], ["the", 1179], ["copper", 1183], ["salt", 1190], [",", 1194], ["upon", 1196], ["oxidation", 1201], ["with", 1211], ["iodine", 1216], [".", 1222]]}
{"context": "To determine the validity of the rapid antigen test (RAT) OSOM StrepA Genzyme for the diagnosis of acute pharyngitis caused by group A beta-haemolytic strep (GABHS). Diagnostic techniques survey. Urban primary care centre, Spain. All patients over 14 years old seen in 6 surgeries with sore throat and 2 or more Centor criteria: pharyngotonsillar exudate, tender laterocervical nodes, absence of coughing, and/or history or presence of fever. Pharyngeal swabs were taken from all the patients, one for RAT and another to send for culture in the microbiology department. A total of 182 patients were evaluable, with a mean age of 30.6 (12.1) years of which 116 were women (63.7%); 63 patients had 2 Centor criteria; 83 had 3 and 36, the 4 criteria. The culture was positive in 102 patients (56%), with GABHS showing infection in forty (22%; 95% confidence interval [CI], 21.2-22.8). Group C Streptococcus was isolated in 26 patients (14.3%). GABHS was higher among patients with four Centor criteria (38.9% vs 25.3% observed among those with 3 criteria and 7.9% with 2 criteria; P<.001). Sensitivity of RAT was 95%, with a specificity of 93%, a positive predictive value of 79.2% and a negative predictive value of 98.5%. These results show the usefulness of RAT for diagnosing streptococcal pharyngitis. Its use should be spread to all primary care practices.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "e8f16ae3e5874a4181985bd826ce59f8", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[268, 269]], "char_spans": [[1277, 1301]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["validity", 17], ["of", 26], ["the", 29], ["rapid", 33], ["antigen", 39], ["test", 47], ["(", 52], ["RAT", 53], [")", 56], ["OSOM", 58], ["StrepA", 63], ["Genzyme", 70], ["for", 78], ["the", 82], ["diagnosis", 86], ["of", 96], ["acute", 99], ["pharyngitis", 105], ["caused", 117], ["by", 124], ["group", 127], ["A", 133], ["beta", 135], ["-", 139], ["haemolytic", 140], ["strep", 151], ["(", 157], ["GABHS", 158], [")", 163], [".", 164], ["Diagnostic", 166], ["techniques", 177], ["survey", 188], [".", 194], ["Urban", 196], ["primary", 202], ["care", 210], ["centre", 215], [",", 221], ["Spain", 223], [".", 228], ["All", 230], ["patients", 234], ["over", 243], ["14", 248], ["years", 251], ["old", 257], ["seen", 261], ["in", 266], ["6", 269], ["surgeries", 271], ["with", 281], ["sore", 286], ["throat", 291], ["and", 298], ["2", 302], ["or", 304], ["more", 307], ["Centor", 312], ["criteria", 319], [":", 327], ["pharyngotonsillar", 329], ["exudate", 347], [",", 354], ["tender", 356], ["laterocervical", 363], ["nodes", 378], [",", 383], ["absence", 385], ["of", 393], ["coughing", 396], [",", 404], ["and/or", 406], ["history", 413], ["or", 421], ["presence", 424], ["of", 433], ["fever", 436], [".", 441], ["Pharyngeal", 443], ["swabs", 454], ["were", 460], ["taken", 465], ["from", 471], ["all", 476], ["the", 480], ["patients", 484], [",", 492], ["one", 494], ["for", 498], ["RAT", 502], ["and", 506], ["another", 510], ["to", 518], ["send", 521], ["for", 526], ["culture", 530], ["in", 538], ["the", 541], ["microbiology", 545], ["department", 558], [".", 568], ["A", 570], ["total", 572], ["of", 578], ["182", 581], ["patients", 585], ["were", 594], ["evaluable", 599], [",", 608], ["with", 610], ["a", 615], ["mean", 617], ["age", 622], ["of", 626], ["30.6", 629], ["(", 634], ["12.1", 635], [")", 639], ["years", 641], ["of", 647], ["which", 650], ["116", 656], ["were", 660], ["women", 665], ["(", 671], ["63.7", 672], ["%", 676], [")", 677], [";", 678], ["63", 680], ["patients", 683], ["had", 692], ["2", 696], ["Centor", 698], ["criteria", 705], [";", 713], ["83", 715], ["had", 718], ["3", 722], ["and", 724], ["36", 728], [",", 730], ["the", 732], ["4", 736], ["criteria", 738], [".", 746], ["The", 748], ["culture", 752], ["was", 760], ["positive", 764], ["in", 773], ["102", 776], ["patients", 780], ["(", 789], ["56", 790], ["%", 792], [")", 793], [",", 794], ["with", 796], ["GABHS", 801], ["showing", 807], ["infection", 815], ["in", 825], ["forty", 828], ["(", 834], ["22", 835], ["%", 837], [";", 838], ["95", 840], ["%", 842], ["confidence", 844], ["interval", 855], ["[", 864], ["CI", 865], ["]", 867], [",", 868], ["21.2", 870], ["-", 874], ["22.8", 875], [")", 879], [".", 880], ["Group", 882], ["C", 888], ["Streptococcus", 890], ["was", 904], ["isolated", 908], ["in", 917], ["26", 920], ["patients", 923], ["(", 932], ["14.3", 933], ["%", 937], [")", 938], [".", 939], ["GABHS", 941], ["was", 947], ["higher", 951], ["among", 958], ["patients", 964], ["with", 973], ["four", 978], ["Centor", 983], ["criteria", 990], ["(", 999], ["38.9", 1000], ["%", 1004], ["vs", 1006], ["25.3", 1009], ["%", 1013], ["observed", 1015], ["among", 1024], ["those", 1030], ["with", 1036], ["3", 1041], ["criteria", 1043], ["and", 1052], ["7.9", 1056], ["%", 1059], ["with", 1061], ["2", 1066], ["criteria", 1068], [";", 1076], ["P<.001", 1078], [")", 1084], [".", 1085], ["Sensitivity", 1087], ["of", 1099], ["RAT", 1102], ["was", 1106], ["95", 1110], ["%", 1112], [",", 1113], ["with", 1115], ["a", 1120], ["specificity", 1122], ["of", 1134], ["93", 1137], ["%", 1139], [",", 1140], ["a", 1142], ["positive", 1144], ["predictive", 1153], ["value", 1164], ["of", 1170], ["79.2", 1173], ["%", 1177], ["and", 1179], ["a", 1183], ["negative", 1185], ["predictive", 1194], ["value", 1205], ["of", 1211], ["98.5", 1214], ["%", 1218], [".", 1219], ["These", 1221], ["results", 1227], ["show", 1235], ["the", 1240], ["usefulness", 1244], ["of", 1255], ["RAT", 1258], ["for", 1262], ["diagnosing", 1266], ["streptococcal", 1277], ["pharyngitis", 1291], [".", 1302], ["Its", 1304], ["use", 1308], ["should", 1312], ["be", 1319], ["spread", 1322], ["to", 1329], ["all", 1332], ["primary", 1336], ["care", 1344], ["practices", 1349], [".", 1358]]}
{"context": "Mowat-Wilson syndrome (MWS) is a severe intellectual disability (ID)-distinctive facial gestalt-multiple congenital anomaly syndrome, commonly associating microcephaly, epilepsy, corpus callosum agenesis, conotruncal heart defects, urogenital malformations and Hirschsprung disease (HSCR). MWS is caused by de novo heterozygous mutations in the ZEB2 gene. The majority of mutations lead to haplo-insufficiency through premature stop codons or large gene deletions. Only three missense mutations have been reported so far; none of which resides in a known functional domain of ZEB2. In this study, we report and analyze the functional consequences of three novel missense mutations, p.Tyr1055Cys, p.Ser1071Pro and p.His1045Arg, identified in the highly conserved C-zinc-finger (C-ZF) domain of ZEB2. Patients' phenotype included the facial gestalt of MWS and moderate ID, but no microcephaly, heart defects or HSCR. In vitro studies showed that all the three mutations prevented binding and repression of the E-cadherin promoter, a characterized ZEB2 target gene. Taking advantage of the zebrafish morphant technology, we performed rescue experiments using wild-type (WT) and mutant human ZEB2 mRNAs. Variable, mutation-dependent, embryo rescue, correlating with the severity of patients' phenotype, was observed. Our data provide evidence that these missense mutations cause a partial loss of function of ZEB2, suggesting that its role is not restricted to repression of E-cadherin. Functional domains other than C-ZF may play a role in early embryonic development. Finally, these findings broaden the clinical spectrum of ZEB2 mutations, indicating that MWS ought to be considered in patients with lesser degrees of ID and a suggestive facial gestalt, even in the absence of congenital malformation.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "66de6d84167b4ec996cf97c56aab9b0c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[96, 96], [144, 144], [55, 55], [216, 216], [296, 296], [190, 190], [255, 255]], "char_spans": [[576, 579], [793, 796], [345, 348], [1188, 1191], [1623, 1626], [1045, 1048], [1405, 1408]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["severe", 33], ["intellectual", 40], ["disability", 53], ["(", 64], ["ID)-distinctive", 65], ["facial", 81], ["gestalt", 88], ["-", 95], ["multiple", 96], ["congenital", 105], ["anomaly", 116], ["syndrome", 124], [",", 132], ["commonly", 134], ["associating", 143], ["microcephaly", 155], [",", 167], ["epilepsy", 169], [",", 177], ["corpus", 179], ["callosum", 186], ["agenesis", 195], [",", 203], ["conotruncal", 205], ["heart", 217], ["defects", 223], [",", 230], ["urogenital", 232], ["malformations", 243], ["and", 257], ["Hirschsprung", 261], ["disease", 274], ["(", 282], ["HSCR", 283], [")", 287], [".", 288], ["MWS", 290], ["is", 294], ["caused", 297], ["by", 304], ["de", 307], ["novo", 310], ["heterozygous", 315], ["mutations", 328], ["in", 338], ["the", 341], ["ZEB2", 345], ["gene", 350], [".", 354], ["The", 356], ["majority", 360], ["of", 369], ["mutations", 372], ["lead", 382], ["to", 387], ["haplo", 390], ["-", 395], ["insufficiency", 396], ["through", 410], ["premature", 418], ["stop", 428], ["codons", 433], ["or", 440], ["large", 443], ["gene", 449], ["deletions", 454], [".", 463], ["Only", 465], ["three", 470], ["missense", 476], ["mutations", 485], ["have", 495], ["been", 500], ["reported", 505], ["so", 514], ["far", 517], [";", 520], ["none", 522], ["of", 527], ["which", 530], ["resides", 536], ["in", 544], ["a", 547], ["known", 549], ["functional", 555], ["domain", 566], ["of", 573], ["ZEB2", 576], [".", 580], ["In", 582], ["this", 585], ["study", 590], [",", 595], ["we", 597], ["report", 600], ["and", 607], ["analyze", 611], ["the", 619], ["functional", 623], ["consequences", 634], ["of", 647], ["three", 650], ["novel", 656], ["missense", 662], ["mutations", 671], [",", 680], ["p", 682], [".", 683], ["Tyr1055Cys", 684], [",", 694], ["p", 696], [".", 697], ["Ser1071Pro", 698], ["and", 709], ["p", 713], [".", 714], ["His1045Arg", 715], [",", 725], ["identified", 727], ["in", 738], ["the", 741], ["highly", 745], ["conserved", 752], ["C", 762], ["-", 763], ["zinc", 764], ["-", 768], ["finger", 769], ["(", 776], ["C", 777], ["-", 778], ["ZF", 779], [")", 781], ["domain", 783], ["of", 790], ["ZEB2", 793], [".", 797], ["Patients", 799], ["'", 807], ["phenotype", 809], ["included", 819], ["the", 828], ["facial", 832], ["gestalt", 839], ["of", 847], ["MWS", 850], ["and", 854], ["moderate", 858], ["ID", 867], [",", 869], ["but", 871], ["no", 875], ["microcephaly", 878], [",", 890], ["heart", 892], ["defects", 898], ["or", 906], ["HSCR", 909], [".", 913], ["In", 915], ["vitro", 918], ["studies", 924], ["showed", 932], ["that", 939], ["all", 944], ["the", 948], ["three", 952], ["mutations", 958], ["prevented", 968], ["binding", 978], ["and", 986], ["repression", 990], ["of", 1001], ["the", 1004], ["E", 1008], ["-", 1009], ["cadherin", 1010], ["promoter", 1019], [",", 1027], ["a", 1029], ["characterized", 1031], ["ZEB2", 1045], ["target", 1050], ["gene", 1057], [".", 1061], ["Taking", 1063], ["advantage", 1070], ["of", 1080], ["the", 1083], ["zebrafish", 1087], ["morphant", 1097], ["technology", 1106], [",", 1116], ["we", 1118], ["performed", 1121], ["rescue", 1131], ["experiments", 1138], ["using", 1150], ["wild", 1156], ["-", 1160], ["type", 1161], ["(", 1166], ["WT", 1167], [")", 1169], ["and", 1171], ["mutant", 1175], ["human", 1182], ["ZEB2", 1188], ["mRNAs", 1193], [".", 1198], ["Variable", 1200], [",", 1208], ["mutation", 1210], ["-", 1218], ["dependent", 1219], [",", 1228], ["embryo", 1230], ["rescue", 1237], [",", 1243], ["correlating", 1245], ["with", 1257], ["the", 1262], ["severity", 1266], ["of", 1275], ["patients", 1278], ["'", 1286], ["phenotype", 1288], [",", 1297], ["was", 1299], ["observed", 1303], [".", 1311], ["Our", 1313], ["data", 1317], ["provide", 1322], ["evidence", 1330], ["that", 1339], ["these", 1344], ["missense", 1350], ["mutations", 1359], ["cause", 1369], ["a", 1375], ["partial", 1377], ["loss", 1385], ["of", 1390], ["function", 1393], ["of", 1402], ["ZEB2", 1405], [",", 1409], ["suggesting", 1411], ["that", 1422], ["its", 1427], ["role", 1431], ["is", 1436], ["not", 1439], ["restricted", 1443], ["to", 1454], ["repression", 1457], ["of", 1468], ["E", 1471], ["-", 1472], ["cadherin", 1473], [".", 1481], ["Functional", 1483], ["domains", 1494], ["other", 1502], ["than", 1508], ["C", 1513], ["-", 1514], ["ZF", 1515], ["may", 1518], ["play", 1522], ["a", 1527], ["role", 1529], ["in", 1534], ["early", 1537], ["embryonic", 1543], ["development", 1553], [".", 1564], ["Finally", 1566], [",", 1573], ["these", 1575], ["findings", 1581], ["broaden", 1590], ["the", 1598], ["clinical", 1602], ["spectrum", 1611], ["of", 1620], ["ZEB2", 1623], ["mutations", 1628], [",", 1637], ["indicating", 1639], ["that", 1650], ["MWS", 1655], ["ought", 1659], ["to", 1665], ["be", 1668], ["considered", 1671], ["in", 1682], ["patients", 1685], ["with", 1694], ["lesser", 1699], ["degrees", 1706], ["of", 1714], ["ID", 1717], ["and", 1720], ["a", 1724], ["suggestive", 1726], ["facial", 1737], ["gestalt", 1744], [",", 1751], ["even", 1753], ["in", 1758], ["the", 1761], ["absence", 1765], ["of", 1773], ["congenital", 1776], ["malformation", 1787], [".", 1799]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is increasing in prevalence among asymptomatic carriers and in cases of paediatric soft-tissue infections alike. CA-MRSA may express virulence factors such as Panton-Valentine leukocidin, which makes soft-tissue and hard-tissue infections due to such organisms challenging to treat. We report a case of osteomyelitis of the proximal tibia in a 10-year-old boy and discuss its management in what is to the authors' knowledge the first case report of Panton-Valentine leukocidin-positive CA-MRSA osteomyelitis in a child in the UK.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "aee842a768df4abebce2612c194f1e62", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[33, 33], [104, 104], [11, 11]], "char_spans": [[191, 194], [564, 567], [69, 72]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus", 58], ["(", 65], ["CA", 66], ["-", 68], ["MRSA", 69], [")", 73], ["is", 75], ["increasing", 78], ["in", 89], ["prevalence", 92], ["among", 103], ["asymptomatic", 109], ["carriers", 122], ["and", 131], ["in", 135], ["cases", 138], ["of", 144], ["paediatric", 147], ["soft", 158], ["-", 162], ["tissue", 163], ["infections", 170], ["alike", 181], [".", 186], ["CA", 188], ["-", 190], ["MRSA", 191], ["may", 196], ["express", 200], ["virulence", 208], ["factors", 218], ["such", 226], ["as", 231], ["Panton", 234], ["-", 240], ["Valentine", 241], ["leukocidin", 251], [",", 261], ["which", 263], ["makes", 269], ["soft", 275], ["-", 279], ["tissue", 280], ["and", 287], ["hard", 291], ["-", 295], ["tissue", 296], ["infections", 303], ["due", 314], ["to", 318], ["such", 321], ["organisms", 326], ["challenging", 336], ["to", 348], ["treat", 351], [".", 356], ["We", 358], ["report", 361], ["a", 368], ["case", 370], ["of", 375], ["osteomyelitis", 378], ["of", 392], ["the", 395], ["proximal", 399], ["tibia", 408], ["in", 414], ["a", 417], ["10-year", 419], ["-", 426], ["old", 427], ["boy", 431], ["and", 435], ["discuss", 439], ["its", 447], ["management", 451], ["in", 462], ["what", 465], ["is", 470], ["to", 473], ["the", 476], ["authors", 480], ["'", 487], ["knowledge", 489], ["the", 499], ["first", 503], ["case", 509], ["report", 514], ["of", 521], ["Panton", 524], ["-", 530], ["Valentine", 531], ["leukocidin", 541], ["-", 551], ["positive", 552], ["CA", 561], ["-", 563], ["MRSA", 564], ["osteomyelitis", 569], ["in", 583], ["a", 586], ["child", 588], ["in", 594], ["the", 597], ["UK", 601], [".", 603]]}
{"context": "Chronic myeloid leukemia (CML) is arguably the best understood of all human malignancies. Its origins in the hematopoietic stem cell can be traced to a reciprocal translocation involving chromosomes 9 and 22, dubbed the Philadelphia chromosome, which is observed in essentially all patients. The resulting fusion gene, BCR/ABL, encodes an activated tyrosine kinase that can act alone to induce a CML-like syndrome in mouse models. These animal models have validated BCR/ABL as a target for the development of specific pharmaceutical inhibitors. The kinase inhibitor imatinib mesylate (Gleevec) is highly specific, effective, and minimally toxic, but may not effect cures as a single agent, particularly in patients with accelerated and blast-phase disease. Resistance to imatinib can confound therapy. Surprisingly, a high percentage of resistant cases manifest intact or augmented BCR/ABL signaling, suggesting that this oncoprotein, or signaling pathways emanating from it, remain viable targets. Combination chemotherapy is under active investigation, and among the most compelling strategies is dual treatment with agents that both target BCR/ABL signal transduction. BCR/ABL activates Ras, and compounds designed to antagonize Ras function called farnesyl transferase inhibitors (FTIs) have shown potent activity in vitro and in animal models of BCR/ABL-induced leukemia. Initial clinical trials in patients with refractory acute myeloid leukemia and CML in blast crisis have shown significant activity, suggesting that trials combining imatinib and FTIs are warranted.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7ab997001a3a4c77a2cb4d78612ac48f", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[54, 56], [197, 199], [234, 236], [203, 205], [83, 85], [155, 157]], "char_spans": [[319, 325], [1143, 1149], [1351, 1357], [1172, 1178], [466, 472], [882, 888]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["arguably", 34], ["the", 43], ["best", 47], ["understood", 52], ["of", 63], ["all", 66], ["human", 70], ["malignancies", 76], [".", 88], ["Its", 90], ["origins", 94], ["in", 102], ["the", 105], ["hematopoietic", 109], ["stem", 123], ["cell", 128], ["can", 133], ["be", 137], ["traced", 140], ["to", 147], ["a", 150], ["reciprocal", 152], ["translocation", 163], ["involving", 177], ["chromosomes", 187], ["9", 199], ["and", 201], ["22", 205], [",", 207], ["dubbed", 209], ["the", 216], ["Philadelphia", 220], ["chromosome", 233], [",", 243], ["which", 245], ["is", 251], ["observed", 254], ["in", 263], ["essentially", 266], ["all", 278], ["patients", 282], [".", 290], ["The", 292], ["resulting", 296], ["fusion", 306], ["gene", 313], [",", 317], ["BCR", 319], ["/", 322], ["ABL", 323], [",", 326], ["encodes", 328], ["an", 336], ["activated", 339], ["tyrosine", 349], ["kinase", 358], ["that", 365], ["can", 370], ["act", 374], ["alone", 378], ["to", 384], ["induce", 387], ["a", 394], ["CML", 396], ["-", 399], ["like", 400], ["syndrome", 405], ["in", 414], ["mouse", 417], ["models", 423], [".", 429], ["These", 431], ["animal", 437], ["models", 444], ["have", 451], ["validated", 456], ["BCR", 466], ["/", 469], ["ABL", 470], ["as", 474], ["a", 477], ["target", 479], ["for", 486], ["the", 490], ["development", 494], ["of", 506], ["specific", 509], ["pharmaceutical", 518], ["inhibitors", 533], [".", 543], ["The", 545], ["kinase", 549], ["inhibitor", 556], ["imatinib", 566], ["mesylate", 575], ["(", 584], ["Gleevec", 585], [")", 592], ["is", 594], ["highly", 597], ["specific", 604], [",", 612], ["effective", 614], [",", 623], ["and", 625], ["minimally", 629], ["toxic", 639], [",", 644], ["but", 646], ["may", 650], ["not", 654], ["effect", 658], ["cures", 665], ["as", 671], ["a", 674], ["single", 676], ["agent", 683], [",", 688], ["particularly", 690], ["in", 703], ["patients", 706], ["with", 715], ["accelerated", 720], ["and", 732], ["blast", 736], ["-", 741], ["phase", 742], ["disease", 748], [".", 755], ["Resistance", 757], ["to", 768], ["imatinib", 771], ["can", 780], ["confound", 784], ["therapy", 793], [".", 800], ["Surprisingly", 802], [",", 814], ["a", 816], ["high", 818], ["percentage", 823], ["of", 834], ["resistant", 837], ["cases", 847], ["manifest", 853], ["intact", 862], ["or", 869], ["augmented", 872], ["BCR", 882], ["/", 885], ["ABL", 886], ["signaling", 890], [",", 899], ["suggesting", 901], ["that", 912], ["this", 917], ["oncoprotein", 922], [",", 933], ["or", 935], ["signaling", 938], ["pathways", 948], ["emanating", 957], ["from", 967], ["it", 972], [",", 974], ["remain", 976], ["viable", 983], ["targets", 990], [".", 997], ["Combination", 999], ["chemotherapy", 1011], ["is", 1024], ["under", 1027], ["active", 1033], ["investigation", 1040], [",", 1053], ["and", 1055], ["among", 1059], ["the", 1065], ["most", 1069], ["compelling", 1074], ["strategies", 1085], ["is", 1096], ["dual", 1099], ["treatment", 1104], ["with", 1114], ["agents", 1119], ["that", 1126], ["both", 1131], ["target", 1136], ["BCR", 1143], ["/", 1146], ["ABL", 1147], ["signal", 1151], ["transduction", 1158], [".", 1170], ["BCR", 1172], ["/", 1175], ["ABL", 1176], ["activates", 1180], ["Ras", 1190], [",", 1193], ["and", 1195], ["compounds", 1199], ["designed", 1209], ["to", 1218], ["antagonize", 1221], ["Ras", 1232], ["function", 1236], ["called", 1245], ["farnesyl", 1252], ["transferase", 1261], ["inhibitors", 1273], ["(", 1284], ["FTIs", 1285], [")", 1289], ["have", 1291], ["shown", 1296], ["potent", 1302], ["activity", 1309], ["in", 1318], ["vitro", 1321], ["and", 1327], ["in", 1331], ["animal", 1334], ["models", 1341], ["of", 1348], ["BCR", 1351], ["/", 1354], ["ABL", 1355], ["-", 1358], ["induced", 1359], ["leukemia", 1367], [".", 1375], ["Initial", 1377], ["clinical", 1385], ["trials", 1394], ["in", 1401], ["patients", 1404], ["with", 1413], ["refractory", 1418], ["acute", 1429], ["myeloid", 1435], ["leukemia", 1443], ["and", 1452], ["CML", 1456], ["in", 1460], ["blast", 1463], ["crisis", 1469], ["have", 1476], ["shown", 1481], ["significant", 1487], ["activity", 1499], [",", 1507], ["suggesting", 1509], ["that", 1520], ["trials", 1525], ["combining", 1532], ["imatinib", 1542], ["and", 1551], ["FTIs", 1555], ["are", 1560], ["warranted", 1564], [".", 1573]]}
{"context": "Universal surveillance upon patient admission is important in reducing the transmission of methicillin-resistant Staphylococcus aureus (MRSA) and associated disease in hospitals. High costs for the health care system in conjunction with MRSA have promoted the development of rapid screening methods to detect MRSA carriers. This study compared two real-time PCR methods, the BD GeneOhm MRSA assay (BDGO) and the Xpert MRSA assay, with broth-enriched culture to define their performance characteristics and rapidity in an area with low MRSA prevalence. In total, 414 swabs from the nose and 389 swabs from the groin from 425 patients were tested. Of those 425 patients, 378 had swabs from both the nose and groin in parallel. Two hundred thirty-one and 194 patients were randomly assigned to the BDGO group and the Xpert MRSA group, respectively. In general, sensitivity, specificity, and negative predictive value (NPV) were high for the BDGO (100%, 98.5%, and 100%, respectively) and the Xpert MRSA (100%, 98.2%, and 100%, respectively), irrespective of whether or not nasal and inguinal specimens were considered alone or combined. In contrast, the positive predictive value (PPV) was lower: before the resolution of discrepant results, the PPVs for nasal and inguinal specimens alone and combined were 87.5%, 86.7%, and 82.4% for the BDGO and 91.7%, 66.7%, and 92.9% for the Xpert MRSA, respectively. After the resolution of discrepant results, PPVs were 93.8%, 93.3% and 94.1% for the BDGO and 91.7%, 88.9% and 92.9% for the Xpert MRSA, respectively. With the BDGO, 4 of 16 carriers were each identified by nasal or inguinal swabs alone, whereas in the Xpert MRSA group, 4 of 13 carriers were exclusively identified by nasal swabs and 2 of 13 were identified by inguinal swabs alone. Both PCR methods showed no significant difference in the number of discrepant results (odds ratio, 0.70 [P = 0.789]), but specimens from wounds and other body sites (axilla, vagina, and throat) produced discrepancies more often than nasal and groin specimens (odds ratios, 4.724 [P = 0.058] and 12.163 [P < 0.001], respectively). The facts that no false-negative PCR results were detected and increased PPVs were found after the resolution of discrepant results point to PCR as the actual gold standard. Since both sensitivity and NPV were exceptionally high for PCR, backup cultures may, therefore, be unnecessary in an area with low prevalence and with a preemptive isolation strategy but may still be useful for PCR-positive specimens because of the lower PPV for both methods and the possibility of susceptibility testing. The median time for analysis, including extraction, hands-on time, and actual PCR was 2 h 20 min for the Xpert MRSA versus 5 h 40 min for the BDGO. Concerning reporting time, including administration and specimen collection, the Xpert MRSA was faster than the BDGO (7 h 50 min versus 17 h).", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "2502a276bbc94f61908c215b2f64ddd4", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[544, 544], [47, 47], [91, 91], [149, 149], [189, 189], [275, 275], [566, 566], [36, 36], [71, 71], [311, 311], [337, 337], [18, 18], [63, 63]], "char_spans": [[2726, 2729], [309, 312], [535, 538], [820, 823], [995, 998], [1384, 1387], [2850, 2853], [237, 240], [418, 421], [1535, 1538], [1663, 1666], [136, 139], [386, 389]]}]}], "context_tokens": [["Universal", 0], ["surveillance", 10], ["upon", 23], ["patient", 28], ["admission", 36], ["is", 46], ["important", 49], ["in", 59], ["reducing", 62], ["the", 71], ["transmission", 75], ["of", 88], ["methicillin", 91], ["-", 102], ["resistant", 103], ["Staphylococcus", 113], ["aureus", 128], ["(", 135], ["MRSA", 136], [")", 140], ["and", 142], ["associated", 146], ["disease", 157], ["in", 165], ["hospitals", 168], [".", 177], ["High", 179], ["costs", 184], ["for", 190], ["the", 194], ["health", 198], ["care", 205], ["system", 210], ["in", 217], ["conjunction", 220], ["with", 232], ["MRSA", 237], ["have", 242], ["promoted", 247], ["the", 256], ["development", 260], ["of", 272], ["rapid", 275], ["screening", 281], ["methods", 291], ["to", 299], ["detect", 302], ["MRSA", 309], ["carriers", 314], [".", 322], ["This", 324], ["study", 329], ["compared", 335], ["two", 344], ["real", 348], ["-", 352], ["time", 353], ["PCR", 358], ["methods", 362], [",", 369], ["the", 371], ["BD", 375], ["GeneOhm", 378], ["MRSA", 386], ["assay", 391], ["(", 397], ["BDGO", 398], [")", 402], ["and", 404], ["the", 408], ["Xpert", 412], ["MRSA", 418], ["assay", 423], [",", 428], ["with", 430], ["broth", 435], ["-", 440], ["enriched", 441], ["culture", 450], ["to", 458], ["define", 461], ["their", 468], ["performance", 474], ["characteristics", 486], ["and", 502], ["rapidity", 506], ["in", 515], ["an", 518], ["area", 521], ["with", 526], ["low", 531], ["MRSA", 535], ["prevalence", 540], [".", 550], ["In", 552], ["total", 555], [",", 560], ["414", 562], ["swabs", 566], ["from", 572], ["the", 577], ["nose", 581], ["and", 586], ["389", 590], ["swabs", 594], ["from", 600], ["the", 605], ["groin", 609], ["from", 615], ["425", 620], ["patients", 624], ["were", 633], ["tested", 638], [".", 644], ["Of", 646], ["those", 649], ["425", 655], ["patients", 659], [",", 667], ["378", 669], ["had", 673], ["swabs", 677], ["from", 683], ["both", 688], ["the", 693], ["nose", 697], ["and", 702], ["groin", 706], ["in", 712], ["parallel", 715], [".", 723], ["Two", 725], ["hundred", 729], ["thirty", 737], ["-", 743], ["one", 744], ["and", 748], ["194", 752], ["patients", 756], ["were", 765], ["randomly", 770], ["assigned", 779], ["to", 788], ["the", 791], ["BDGO", 795], ["group", 800], ["and", 806], ["the", 810], ["Xpert", 814], ["MRSA", 820], ["group", 825], [",", 830], ["respectively", 832], [".", 844], ["In", 846], ["general", 849], [",", 856], ["sensitivity", 858], [",", 869], ["specificity", 871], [",", 882], ["and", 884], ["negative", 888], ["predictive", 897], ["value", 908], ["(", 914], ["NPV", 915], [")", 918], ["were", 920], ["high", 925], ["for", 930], ["the", 934], ["BDGO", 938], ["(", 943], ["100", 944], ["%", 947], [",", 948], ["98.5", 950], ["%", 954], [",", 955], ["and", 957], ["100", 961], ["%", 964], [",", 965], ["respectively", 967], [")", 979], ["and", 981], ["the", 985], ["Xpert", 989], ["MRSA", 995], ["(", 1000], ["100", 1001], ["%", 1004], [",", 1005], ["98.2", 1007], ["%", 1011], [",", 1012], ["and", 1014], ["100", 1018], ["%", 1021], [",", 1022], ["respectively", 1024], [")", 1036], [",", 1037], ["irrespective", 1039], ["of", 1052], ["whether", 1055], ["or", 1063], ["not", 1066], ["nasal", 1070], ["and", 1076], ["inguinal", 1080], ["specimens", 1089], ["were", 1099], ["considered", 1104], ["alone", 1115], ["or", 1121], ["combined", 1124], [".", 1132], ["In", 1134], ["contrast", 1137], [",", 1145], ["the", 1147], ["positive", 1151], ["predictive", 1160], ["value", 1171], ["(", 1177], ["PPV", 1178], [")", 1181], ["was", 1183], ["lower", 1187], [":", 1192], ["before", 1194], ["the", 1201], ["resolution", 1205], ["of", 1216], ["discrepant", 1219], ["results", 1230], [",", 1237], ["the", 1239], ["PPVs", 1243], ["for", 1248], ["nasal", 1252], ["and", 1258], ["inguinal", 1262], ["specimens", 1271], ["alone", 1281], ["and", 1287], ["combined", 1291], ["were", 1300], ["87.5", 1305], ["%", 1309], [",", 1310], ["86.7", 1312], ["%", 1316], [",", 1317], ["and", 1319], ["82.4", 1323], ["%", 1327], ["for", 1329], ["the", 1333], ["BDGO", 1337], ["and", 1342], ["91.7", 1346], ["%", 1350], [",", 1351], ["66.7", 1353], ["%", 1357], [",", 1358], ["and", 1360], ["92.9", 1364], ["%", 1368], ["for", 1370], ["the", 1374], ["Xpert", 1378], ["MRSA", 1384], [",", 1388], ["respectively", 1390], [".", 1402], ["After", 1404], ["the", 1410], ["resolution", 1414], ["of", 1425], ["discrepant", 1428], ["results", 1439], [",", 1446], ["PPVs", 1448], ["were", 1453], ["93.8", 1458], ["%", 1462], [",", 1463], ["93.3", 1465], ["%", 1469], ["and", 1471], ["94.1", 1475], ["%", 1479], ["for", 1481], ["the", 1485], ["BDGO", 1489], ["and", 1494], ["91.7", 1498], ["%", 1502], [",", 1503], ["88.9", 1505], ["%", 1509], ["and", 1511], ["92.9", 1515], ["%", 1519], ["for", 1521], ["the", 1525], ["Xpert", 1529], ["MRSA", 1535], [",", 1539], ["respectively", 1541], [".", 1553], ["With", 1555], ["the", 1560], ["BDGO", 1564], [",", 1568], ["4", 1570], ["of", 1572], ["16", 1575], ["carriers", 1578], ["were", 1587], ["each", 1592], ["identified", 1597], ["by", 1608], ["nasal", 1611], ["or", 1617], ["inguinal", 1620], ["swabs", 1629], ["alone", 1635], [",", 1640], ["whereas", 1642], ["in", 1650], ["the", 1653], ["Xpert", 1657], ["MRSA", 1663], ["group", 1668], [",", 1673], ["4", 1675], ["of", 1677], ["13", 1680], ["carriers", 1683], ["were", 1692], ["exclusively", 1697], ["identified", 1709], ["by", 1720], ["nasal", 1723], ["swabs", 1729], ["and", 1735], ["2", 1739], ["of", 1741], ["13", 1744], ["were", 1747], ["identified", 1752], ["by", 1763], ["inguinal", 1766], ["swabs", 1775], ["alone", 1781], [".", 1786], ["Both", 1788], ["PCR", 1793], ["methods", 1797], ["showed", 1805], ["no", 1812], ["significant", 1815], ["difference", 1827], ["in", 1838], ["the", 1841], ["number", 1845], ["of", 1852], ["discrepant", 1855], ["results", 1866], ["(", 1874], ["odds", 1875], ["ratio", 1880], [",", 1885], ["0.70", 1887], ["[", 1892], ["P", 1893], ["=", 1895], ["0.789", 1897], ["]", 1902], [")", 1903], [",", 1904], ["but", 1906], ["specimens", 1910], ["from", 1920], ["wounds", 1925], ["and", 1932], ["other", 1936], ["body", 1942], ["sites", 1947], ["(", 1953], ["axilla", 1954], [",", 1960], ["vagina", 1962], [",", 1968], ["and", 1970], ["throat", 1974], [")", 1980], ["produced", 1982], ["discrepancies", 1991], ["more", 2005], ["often", 2010], ["than", 2016], ["nasal", 2021], ["and", 2027], ["groin", 2031], ["specimens", 2037], ["(", 2047], ["odds", 2048], ["ratios", 2053], [",", 2059], ["4.724", 2061], ["[", 2067], ["P", 2068], ["=", 2070], ["0.058", 2072], ["]", 2077], ["and", 2079], ["12.163", 2083], ["[", 2090], ["P", 2091], ["<", 2093], ["0.001", 2095], ["]", 2100], [",", 2101], ["respectively", 2103], [")", 2115], [".", 2116], ["The", 2118], ["facts", 2122], ["that", 2128], ["no", 2133], ["false", 2136], ["-", 2141], ["negative", 2142], ["PCR", 2151], ["results", 2155], ["were", 2163], ["detected", 2168], ["and", 2177], ["increased", 2181], ["PPVs", 2191], ["were", 2196], ["found", 2201], ["after", 2207], ["the", 2213], ["resolution", 2217], ["of", 2228], ["discrepant", 2231], ["results", 2242], ["point", 2250], ["to", 2256], ["PCR", 2259], ["as", 2263], ["the", 2266], ["actual", 2270], ["gold", 2277], ["standard", 2282], [".", 2290], ["Since", 2292], ["both", 2298], ["sensitivity", 2303], ["and", 2315], ["NPV", 2319], ["were", 2323], ["exceptionally", 2328], ["high", 2342], ["for", 2347], ["PCR", 2351], [",", 2354], ["backup", 2356], ["cultures", 2363], ["may", 2372], [",", 2375], ["therefore", 2377], [",", 2386], ["be", 2388], ["unnecessary", 2391], ["in", 2403], ["an", 2406], ["area", 2409], ["with", 2414], ["low", 2419], ["prevalence", 2423], ["and", 2434], ["with", 2438], ["a", 2443], ["preemptive", 2445], ["isolation", 2456], ["strategy", 2466], ["but", 2475], ["may", 2479], ["still", 2483], ["be", 2489], ["useful", 2492], ["for", 2499], ["PCR", 2503], ["-", 2506], ["positive", 2507], ["specimens", 2516], ["because", 2526], ["of", 2534], ["the", 2537], ["lower", 2541], ["PPV", 2547], ["for", 2551], ["both", 2555], ["methods", 2560], ["and", 2568], ["the", 2572], ["possibility", 2576], ["of", 2588], ["susceptibility", 2591], ["testing", 2606], [".", 2613], ["The", 2615], ["median", 2619], ["time", 2626], ["for", 2631], ["analysis", 2635], [",", 2643], ["including", 2645], ["extraction", 2655], [",", 2665], ["hands", 2667], ["-", 2672], ["on", 2673], ["time", 2676], [",", 2680], ["and", 2682], ["actual", 2686], ["PCR", 2693], ["was", 2697], ["2", 2701], ["h", 2703], ["20", 2705], ["min", 2708], ["for", 2712], ["the", 2716], ["Xpert", 2720], ["MRSA", 2726], ["versus", 2731], ["5", 2738], ["h", 2740], ["40", 2742], ["min", 2745], ["for", 2749], ["the", 2753], ["BDGO", 2757], [".", 2761], ["Concerning", 2763], ["reporting", 2774], ["time", 2784], [",", 2788], ["including", 2790], ["administration", 2800], ["and", 2815], ["specimen", 2819], ["collection", 2828], [",", 2838], ["the", 2840], ["Xpert", 2844], ["MRSA", 2850], ["was", 2855], ["faster", 2859], ["than", 2866], ["the", 2871], ["BDGO", 2875], ["(", 2880], ["7", 2881], ["h", 2883], ["50", 2885], ["min", 2888], ["versus", 2892], ["17", 2899], ["h", 2902], [")", 2903], [".", 2904]]}
{"context": "The SWR1 complex (SWR1C) in yeast catalyzes the replacement of nucleosomal H2A with the H2AZ variant, which ensures full activation of underlying genes. We compared the phenotype of mutants in the homologs of SWR1C components in Arabidopsis thaliana. Mutations in Arabidopsis SWC6 (AtSWC6), SUPPRESSOR OF FRIGIDA 3 (SUF3) and PHOTOPERIOD-INDEPENDENT EARLY FLOWERING 1 (PIE1), homologs of SWC6, ARP6 and SWR1, respectively, caused similar developmental defects, including leaf serration, weak apical dominance, flowers with extra petals and early flowering by reduction in expression of FLOWERING LOCUS C (FLC), a strong floral repressor. Chromatin immunoprecipitation assays showed that AtSWC6 and SUF3 bind to the proximal region of the FLC promoter, and protoplast transfection assays showed that AtSWC6 colocalizes with SUF3. Protein interaction analyses suggested the formation of a complex between PIE1, SUF3, AtSWC6 and AtSWC2. In addition, H2AZ, a substrate of SWR1C, interacts with both PIE1 and AtSWC2. Finally, knockdown of the H2AZ genes by RNA interference or artificial microRNA caused a phenotype similar to that of atswc6 or suf3. Our results strongly support the presence of an SWR1C-like complex in Arabidopsis that ensures proper development, including floral repression through full activation of FLC.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "40d8ce56de49432180bd5735b35937f1", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[75, 75], [1, 1]], "char_spans": [[403, 406], [4, 7]]}]}], "context_tokens": [["The", 0], ["SWR1", 4], ["complex", 9], ["(", 17], ["SWR1C", 18], [")", 23], ["in", 25], ["yeast", 28], ["catalyzes", 34], ["the", 44], ["replacement", 48], ["of", 60], ["nucleosomal", 63], ["H2A", 75], ["with", 79], ["the", 84], ["H2AZ", 88], ["variant", 93], [",", 100], ["which", 102], ["ensures", 108], ["full", 116], ["activation", 121], ["of", 132], ["underlying", 135], ["genes", 146], [".", 151], ["We", 153], ["compared", 156], ["the", 165], ["phenotype", 169], ["of", 179], ["mutants", 182], ["in", 190], ["the", 193], ["homologs", 197], ["of", 206], ["SWR1C", 209], ["components", 215], ["in", 226], ["Arabidopsis", 229], ["thaliana", 241], [".", 249], ["Mutations", 251], ["in", 261], ["Arabidopsis", 264], ["SWC6", 276], ["(", 281], ["AtSWC6", 282], [")", 288], [",", 289], ["SUPPRESSOR", 291], ["OF", 302], ["FRIGIDA", 305], ["3", 313], ["(", 315], ["SUF3", 316], [")", 320], ["and", 322], ["PHOTOPERIOD", 326], ["-", 337], ["INDEPENDENT", 338], ["EARLY", 350], ["FLOWERING", 356], ["1", 366], ["(", 368], ["PIE1", 369], [")", 373], [",", 374], ["homologs", 376], ["of", 385], ["SWC6", 388], [",", 392], ["ARP6", 394], ["and", 399], ["SWR1", 403], [",", 407], ["respectively", 409], [",", 421], ["caused", 423], ["similar", 430], ["developmental", 438], ["defects", 452], [",", 459], ["including", 461], ["leaf", 471], ["serration", 476], [",", 485], ["weak", 487], ["apical", 492], ["dominance", 499], [",", 508], ["flowers", 510], ["with", 518], ["extra", 523], ["petals", 529], ["and", 536], ["early", 540], ["flowering", 546], ["by", 556], ["reduction", 559], ["in", 569], ["expression", 572], ["of", 583], ["FLOWERING", 586], ["LOCUS", 596], ["C", 602], ["(", 604], ["FLC", 605], [")", 608], [",", 609], ["a", 611], ["strong", 613], ["floral", 620], ["repressor", 627], [".", 636], ["Chromatin", 638], ["immunoprecipitation", 648], ["assays", 668], ["showed", 675], ["that", 682], ["AtSWC6", 687], ["and", 694], ["SUF3", 698], ["bind", 703], ["to", 708], ["the", 711], ["proximal", 715], ["region", 724], ["of", 731], ["the", 734], ["FLC", 738], ["promoter", 742], [",", 750], ["and", 752], ["protoplast", 756], ["transfection", 767], ["assays", 780], ["showed", 787], ["that", 794], ["AtSWC6", 799], ["colocalizes", 806], ["with", 818], ["SUF3", 823], [".", 827], ["Protein", 829], ["interaction", 837], ["analyses", 849], ["suggested", 858], ["the", 868], ["formation", 872], ["of", 882], ["a", 885], ["complex", 887], ["between", 895], ["PIE1", 903], [",", 907], ["SUF3", 909], [",", 913], ["AtSWC6", 915], ["and", 922], ["AtSWC2", 926], [".", 932], ["In", 934], ["addition", 937], [",", 945], ["H2AZ", 947], [",", 951], ["a", 953], ["substrate", 955], ["of", 965], ["SWR1C", 968], [",", 973], ["interacts", 975], ["with", 985], ["both", 990], ["PIE1", 995], ["and", 1000], ["AtSWC2", 1004], [".", 1010], ["Finally", 1012], [",", 1019], ["knockdown", 1021], ["of", 1031], ["the", 1034], ["H2AZ", 1038], ["genes", 1043], ["by", 1049], ["RNA", 1052], ["interference", 1056], ["or", 1069], ["artificial", 1072], ["microRNA", 1083], ["caused", 1092], ["a", 1099], ["phenotype", 1101], ["similar", 1111], ["to", 1119], ["that", 1122], ["of", 1127], ["atswc6", 1130], ["or", 1137], ["suf3", 1140], [".", 1144], ["Our", 1146], ["results", 1150], ["strongly", 1158], ["support", 1167], ["the", 1175], ["presence", 1179], ["of", 1188], ["an", 1191], ["SWR1C", 1194], ["-", 1199], ["like", 1200], ["complex", 1205], ["in", 1213], ["Arabidopsis", 1216], ["that", 1228], ["ensures", 1233], ["proper", 1241], ["development", 1248], [",", 1259], ["including", 1261], ["floral", 1271], ["repression", 1278], ["through", 1289], ["full", 1297], ["activation", 1302], ["of", 1313], ["FLC", 1316], [".", 1319]]}
{"context": "Neurofibromatosis type 1 (NF1) is a neurocutaneous disorder resulting in the growth of a variety of tumours, and is inherited in an autosomal dominant pattern. Gastrointestinal stromal tumours (GISTs) are mesenchymal tumours that commonly harbour oncogenic mutations in KIT or PDGFRA and are thought to arise from the interstitial cells of Cajal (ICC; the pacemaker cells of the gut). To characterise two patients with NF1 and GISTs. Two patients were genotyped for germline mutations in NF1. GISTs from both patients were genotyped for somatic mutations in KIT and PDGFRA. Loss of heterozygosity (LOH) of NF1 in one GIST was assessed by genotyping seven microsatellite markers spanning 2.39 Mb of the NF1 locus in the tumour and in genomic DNA. The known germline mutation in NF1 was confirmed in GIST DNA by sequencing. The copy number of the mutated NF1 allele was determined by multiplex ligand-dependent probe amplification. GISTs from both patients were of wild type for mutations in KIT and PDGFRA. In the GIST with adequate DNA, all seven markers were informative and showed LOH at the NF1 locus; sequencing of NF1 from that GIST showed no wild-type sequence, suggesting that it was lost in the tumour. Multiplex ligand-dependent probe amplification analysis showed that two copies of all NF1 exons were present. This is the first evidence of mitotic recombination resulting in a reduction to homozygosity of a germline NF1 mutation in an NF1-associated GIST. We hypothesise that the LOH of NF1 and lack of KIT and PDGFRA mutations are evidence of an alternative pathogenesis in NF1-associated GISTs.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "66fb49bd52204318bfa262bfd21dadd7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[272, 272], [109, 109], [125, 125], [86, 86], [74, 74], [155, 155], [237, 237], [4, 4], [140, 140], [199, 199], [204, 204], [259, 259]], "char_spans": [[1499, 1501], [606, 608], [702, 704], [488, 490], [419, 421], [853, 855], [1297, 1299], [26, 28], [777, 779], [1094, 1096], [1119, 1121], [1428, 1430]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["neurocutaneous", 36], ["disorder", 51], ["resulting", 60], ["in", 70], ["the", 73], ["growth", 77], ["of", 84], ["a", 87], ["variety", 89], ["of", 97], ["tumours", 100], [",", 107], ["and", 109], ["is", 113], ["inherited", 116], ["in", 126], ["an", 129], ["autosomal", 132], ["dominant", 142], ["pattern", 151], [".", 158], ["Gastrointestinal", 160], ["stromal", 177], ["tumours", 185], ["(", 193], ["GISTs", 194], [")", 199], ["are", 201], ["mesenchymal", 205], ["tumours", 217], ["that", 225], ["commonly", 230], ["harbour", 239], ["oncogenic", 247], ["mutations", 257], ["in", 267], ["KIT", 270], ["or", 274], ["PDGFRA", 277], ["and", 284], ["are", 288], ["thought", 292], ["to", 300], ["arise", 303], ["from", 309], ["the", 314], ["interstitial", 318], ["cells", 331], ["of", 337], ["Cajal", 340], ["(", 346], ["ICC", 347], [";", 350], ["the", 352], ["pacemaker", 356], ["cells", 366], ["of", 372], ["the", 375], ["gut", 379], [")", 382], [".", 383], ["To", 385], ["characterise", 388], ["two", 401], ["patients", 405], ["with", 414], ["NF1", 419], ["and", 423], ["GISTs", 427], [".", 432], ["Two", 434], ["patients", 438], ["were", 447], ["genotyped", 452], ["for", 462], ["germline", 466], ["mutations", 475], ["in", 485], ["NF1", 488], [".", 491], ["GISTs", 493], ["from", 499], ["both", 504], ["patients", 509], ["were", 518], ["genotyped", 523], ["for", 533], ["somatic", 537], ["mutations", 545], ["in", 555], ["KIT", 558], ["and", 562], ["PDGFRA", 566], [".", 572], ["Loss", 574], ["of", 579], ["heterozygosity", 582], ["(", 597], ["LOH", 598], [")", 601], ["of", 603], ["NF1", 606], ["in", 610], ["one", 613], ["GIST", 617], ["was", 622], ["assessed", 626], ["by", 635], ["genotyping", 638], ["seven", 649], ["microsatellite", 655], ["markers", 670], ["spanning", 678], ["2.39", 687], ["Mb", 692], ["of", 695], ["the", 698], ["NF1", 702], ["locus", 706], ["in", 712], ["the", 715], ["tumour", 719], ["and", 726], ["in", 730], ["genomic", 733], ["DNA", 741], [".", 744], ["The", 746], ["known", 750], ["germline", 756], ["mutation", 765], ["in", 774], ["NF1", 777], ["was", 781], ["confirmed", 785], ["in", 795], ["GIST", 798], ["DNA", 803], ["by", 807], ["sequencing", 810], [".", 820], ["The", 822], ["copy", 826], ["number", 831], ["of", 838], ["the", 841], ["mutated", 845], ["NF1", 853], ["allele", 857], ["was", 864], ["determined", 868], ["by", 879], ["multiplex", 882], ["ligand", 892], ["-", 898], ["dependent", 899], ["probe", 909], ["amplification", 915], [".", 928], ["GISTs", 930], ["from", 936], ["both", 941], ["patients", 946], ["were", 955], ["of", 960], ["wild", 963], ["type", 968], ["for", 973], ["mutations", 977], ["in", 987], ["KIT", 990], ["and", 994], ["PDGFRA", 998], [".", 1004], ["In", 1006], ["the", 1009], ["GIST", 1013], ["with", 1018], ["adequate", 1023], ["DNA", 1032], [",", 1035], ["all", 1037], ["seven", 1041], ["markers", 1047], ["were", 1055], ["informative", 1060], ["and", 1072], ["showed", 1076], ["LOH", 1083], ["at", 1087], ["the", 1090], ["NF1", 1094], ["locus", 1098], [";", 1103], ["sequencing", 1105], ["of", 1116], ["NF1", 1119], ["from", 1123], ["that", 1128], ["GIST", 1133], ["showed", 1138], ["no", 1145], ["wild", 1148], ["-", 1152], ["type", 1153], ["sequence", 1158], [",", 1166], ["suggesting", 1168], ["that", 1179], ["it", 1184], ["was", 1187], ["lost", 1191], ["in", 1196], ["the", 1199], ["tumour", 1203], [".", 1209], ["Multiplex", 1211], ["ligand", 1221], ["-", 1227], ["dependent", 1228], ["probe", 1238], ["amplification", 1244], ["analysis", 1258], ["showed", 1267], ["that", 1274], ["two", 1279], ["copies", 1283], ["of", 1290], ["all", 1293], ["NF1", 1297], ["exons", 1301], ["were", 1307], ["present", 1312], [".", 1319], ["This", 1321], ["is", 1326], ["the", 1329], ["first", 1333], ["evidence", 1339], ["of", 1348], ["mitotic", 1351], ["recombination", 1359], ["resulting", 1373], ["in", 1383], ["a", 1386], ["reduction", 1388], ["to", 1398], ["homozygosity", 1401], ["of", 1414], ["a", 1417], ["germline", 1419], ["NF1", 1428], ["mutation", 1432], ["in", 1441], ["an", 1444], ["NF1-associated", 1447], ["GIST", 1462], [".", 1466], ["We", 1468], ["hypothesise", 1471], ["that", 1483], ["the", 1488], ["LOH", 1492], ["of", 1496], ["NF1", 1499], ["and", 1503], ["lack", 1507], ["of", 1512], ["KIT", 1515], ["and", 1519], ["PDGFRA", 1523], ["mutations", 1530], ["are", 1540], ["evidence", 1544], ["of", 1553], ["an", 1556], ["alternative", 1559], ["pathogenesis", 1571], ["in", 1584], ["NF1-associated", 1587], ["GISTs", 1602], [".", 1607]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare congenital red-cell aplasia characterized by anemia, bone-marrow erythroblastopenia, and congenital anomalies and is associated with heterozygous mutations in the ribosomal protein (RP) S19 gene (RPS19) in approximately 25% of probands. We report identification of de novo nonsense and splice-site mutations in another RP, RPS24 (encoded by RPS24 [10q22-q23]) in approximately 2% of RPS19 mutation-negative probands. This finding strongly suggests that DBA is a disorder of ribosome synthesis and that mutations in other RP or associated genes that lead to disrupted ribosomal biogenesis and/or function may also cause DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "f987a6c739454ffa9a27e24c4e5235c2", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[93, 93], [120, 120], [5, 5]], "char_spans": [[493, 495], [659, 661], [25, 27]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["congenital", 40], ["red", 51], ["-", 54], ["cell", 55], ["aplasia", 60], ["characterized", 68], ["by", 82], ["anemia", 85], [",", 91], ["bone", 93], ["-", 97], ["marrow", 98], ["erythroblastopenia", 105], [",", 123], ["and", 125], ["congenital", 129], ["anomalies", 140], ["and", 150], ["is", 154], ["associated", 157], ["with", 168], ["heterozygous", 173], ["mutations", 186], ["in", 196], ["the", 199], ["ribosomal", 203], ["protein", 213], ["(", 221], ["RP", 222], [")", 224], ["S19", 226], ["gene", 230], ["(", 235], ["RPS19", 236], [")", 241], ["in", 243], ["approximately", 246], ["25", 260], ["%", 262], ["of", 264], ["probands", 267], [".", 275], ["We", 277], ["report", 280], ["identification", 287], ["of", 302], ["de", 305], ["novo", 308], ["nonsense", 313], ["and", 322], ["splice", 326], ["-", 332], ["site", 333], ["mutations", 338], ["in", 348], ["another", 351], ["RP", 359], [",", 361], ["RPS24", 363], ["(", 369], ["encoded", 370], ["by", 378], ["RPS24", 381], ["[", 387], ["10q22-q23", 388], ["]", 397], [")", 398], ["in", 400], ["approximately", 403], ["2", 417], ["%", 418], ["of", 420], ["RPS19", 423], ["mutation", 429], ["-", 437], ["negative", 438], ["probands", 447], [".", 455], ["This", 457], ["finding", 462], ["strongly", 470], ["suggests", 479], ["that", 488], ["DBA", 493], ["is", 497], ["a", 500], ["disorder", 502], ["of", 511], ["ribosome", 514], ["synthesis", 523], ["and", 533], ["that", 537], ["mutations", 542], ["in", 552], ["other", 555], ["RP", 561], ["or", 564], ["associated", 567], ["genes", 578], ["that", 584], ["lead", 589], ["to", 594], ["disrupted", 597], ["ribosomal", 607], ["biogenesis", 617], ["and/or", 628], ["function", 635], ["may", 644], ["also", 648], ["cause", 653], ["DBA", 659], [".", 662]]}
{"context": "Systemic autoinflammatory diseases are caused by mutations in genes that function in innate immunity. Here, we report an autoinflammatory disease caused by loss-of-function mutations in OTULIN (FAM105B), encoding a deubiquitinase with linear linkage specificity. We identified two missense and one frameshift mutations in one Pakistani and two Turkish families with four affected patients. Patients presented with neonatal-onset fever, neutrophilic dermatitis/panniculitis, and failure to thrive, but without obvious primary immunodeficiency. HEK293 cells transfected with mutated OTULIN had decreased enzyme activity relative to cells transfected with WT OTULIN, and showed a substantial defect in the linear deubiquitination of target molecules. Stimulated patients' fibroblasts and peripheral blood mononuclear cells showed evidence for increased signaling in the canonical NF-\u03baB pathway and accumulated linear ubiquitin aggregates. Levels of proinflammatory cytokines were significantly increased in the supernatants of stimulated primary cells and serum samples. This discovery adds to the emerging spectrum of human diseases caused by defects in the ubiquitin pathway and suggests a role for targeted cytokine therapies.", "qas": [{"question": "Which is the enzymatic activity of OTULIN?", "answers": ["deubiquitination"], "qid": "f85c2449871b49c598f41e1f233256be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["OTULIN", 35], ["?", 41]], "detected_answers": [{"text": "deubiquitination", "token_spans": [[114, 114]], "char_spans": [[710, 725]]}]}], "context_tokens": [["Systemic", 0], ["autoinflammatory", 9], ["diseases", 26], ["are", 35], ["caused", 39], ["by", 46], ["mutations", 49], ["in", 59], ["genes", 62], ["that", 68], ["function", 73], ["in", 82], ["innate", 85], ["immunity", 92], [".", 100], ["Here", 102], [",", 106], ["we", 108], ["report", 111], ["an", 118], ["autoinflammatory", 121], ["disease", 138], ["caused", 146], ["by", 153], ["loss", 156], ["-", 160], ["of", 161], ["-", 163], ["function", 164], ["mutations", 173], ["in", 183], ["OTULIN", 186], ["(", 193], ["FAM105B", 194], [")", 201], [",", 202], ["encoding", 204], ["a", 213], ["deubiquitinase", 215], ["with", 230], ["linear", 235], ["linkage", 242], ["specificity", 250], [".", 261], ["We", 263], ["identified", 266], ["two", 277], ["missense", 281], ["and", 290], ["one", 294], ["frameshift", 298], ["mutations", 309], ["in", 319], ["one", 322], ["Pakistani", 326], ["and", 336], ["two", 340], ["Turkish", 344], ["families", 352], ["with", 361], ["four", 366], ["affected", 371], ["patients", 380], [".", 388], ["Patients", 390], ["presented", 399], ["with", 409], ["neonatal", 414], ["-", 422], ["onset", 423], ["fever", 429], [",", 434], ["neutrophilic", 436], ["dermatitis", 449], ["/", 459], ["panniculitis", 460], [",", 472], ["and", 474], ["failure", 478], ["to", 486], ["thrive", 489], [",", 495], ["but", 497], ["without", 501], ["obvious", 509], ["primary", 517], ["immunodeficiency", 525], [".", 541], ["HEK293", 543], ["cells", 550], ["transfected", 556], ["with", 568], ["mutated", 573], ["OTULIN", 581], ["had", 588], ["decreased", 592], ["enzyme", 602], ["activity", 609], ["relative", 618], ["to", 627], ["cells", 630], ["transfected", 636], ["with", 648], ["WT", 653], ["OTULIN", 656], [",", 662], ["and", 664], ["showed", 668], ["a", 675], ["substantial", 677], ["defect", 689], ["in", 696], ["the", 699], ["linear", 703], ["deubiquitination", 710], ["of", 727], ["target", 730], ["molecules", 737], [".", 746], ["Stimulated", 748], ["patients", 759], ["'", 767], ["fibroblasts", 769], ["and", 781], ["peripheral", 785], ["blood", 796], ["mononuclear", 802], ["cells", 814], ["showed", 820], ["evidence", 827], ["for", 836], ["increased", 840], ["signaling", 850], ["in", 860], ["the", 863], ["canonical", 867], ["NF", 877], ["-", 879], ["\u03baB", 880], ["pathway", 883], ["and", 891], ["accumulated", 895], ["linear", 907], ["ubiquitin", 914], ["aggregates", 924], [".", 934], ["Levels", 936], ["of", 943], ["proinflammatory", 946], ["cytokines", 962], ["were", 972], ["significantly", 977], ["increased", 991], ["in", 1001], ["the", 1004], ["supernatants", 1008], ["of", 1021], ["stimulated", 1024], ["primary", 1035], ["cells", 1043], ["and", 1049], ["serum", 1053], ["samples", 1059], [".", 1066], ["This", 1068], ["discovery", 1073], ["adds", 1083], ["to", 1088], ["the", 1091], ["emerging", 1095], ["spectrum", 1104], ["of", 1113], ["human", 1116], ["diseases", 1122], ["caused", 1131], ["by", 1138], ["defects", 1141], ["in", 1149], ["the", 1152], ["ubiquitin", 1156], ["pathway", 1166], ["and", 1174], ["suggests", 1178], ["a", 1187], ["role", 1189], ["for", 1194], ["targeted", 1198], ["cytokine", 1207], ["therapies", 1216], [".", 1225]]}
{"context": "Chronic myeloid leukemia cells contain a BCR-ABL oncoprotein with an enhanced tyrosine kinase activity, which is considered to be the principal 'cause' of the leukemia. Though the precise mechanisms underlying the leukemogenesis remains enigmatic, the use of imatinib to inhibit the dysregulated kinase activity has proved remarkably successful in clinical practice. Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase activity and its success introduced the current era of molecularly targeted therapies for a number of other malignancies. In patients with chronic myeloid leukaemia who develop resistance to imatinib, the Bcr-Abl signaling pathway is often re-established. This has led to the emergence of a number of alternative treatment strategies designed to target the leukemic cell which are resistant to imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "34f1609a5e28421ea7ca56e3a8591062", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[104, 106], [6, 8], [67, 69]], "char_spans": [[655, 661], [41, 47], [426, 432]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["cells", 25], ["contain", 31], ["a", 39], ["BCR", 41], ["-", 44], ["ABL", 45], ["oncoprotein", 49], ["with", 61], ["an", 66], ["enhanced", 69], ["tyrosine", 78], ["kinase", 87], ["activity", 94], [",", 102], ["which", 104], ["is", 110], ["considered", 113], ["to", 124], ["be", 127], ["the", 130], ["principal", 134], ["'cause", 144], ["'", 150], ["of", 152], ["the", 155], ["leukemia", 159], [".", 167], ["Though", 169], ["the", 176], ["precise", 180], ["mechanisms", 188], ["underlying", 199], ["the", 210], ["leukemogenesis", 214], ["remains", 229], ["enigmatic", 237], [",", 246], ["the", 248], ["use", 252], ["of", 256], ["imatinib", 259], ["to", 268], ["inhibit", 271], ["the", 279], ["dysregulated", 283], ["kinase", 296], ["activity", 303], ["has", 312], ["proved", 316], ["remarkably", 323], ["successful", 334], ["in", 345], ["clinical", 348], ["practice", 357], [".", 365], ["Imatinib", 367], ["was", 376], ["the", 380], ["first", 384], ["small", 390], ["molecule", 396], ["developed", 405], ["to", 415], ["inhibit", 418], ["BCR", 426], ["-", 429], ["ABL", 430], ["tyrosine", 434], ["kinase", 443], ["activity", 450], ["and", 459], ["its", 463], ["success", 467], ["introduced", 475], ["the", 486], ["current", 490], ["era", 498], ["of", 502], ["molecularly", 505], ["targeted", 517], ["therapies", 526], ["for", 536], ["a", 540], ["number", 542], ["of", 549], ["other", 552], ["malignancies", 558], [".", 570], ["In", 572], ["patients", 575], ["with", 584], ["chronic", 589], ["myeloid", 597], ["leukaemia", 605], ["who", 615], ["develop", 619], ["resistance", 627], ["to", 638], ["imatinib", 641], [",", 649], ["the", 651], ["Bcr", 655], ["-", 658], ["Abl", 659], ["signaling", 663], ["pathway", 673], ["is", 681], ["often", 684], ["re", 690], ["-", 692], ["established", 693], [".", 704], ["This", 706], ["has", 711], ["led", 715], ["to", 719], ["the", 722], ["emergence", 726], ["of", 736], ["a", 739], ["number", 741], ["of", 748], ["alternative", 751], ["treatment", 763], ["strategies", 773], ["designed", 784], ["to", 793], ["target", 796], ["the", 803], ["leukemic", 807], ["cell", 816], ["which", 821], ["are", 827], ["resistant", 831], ["to", 841], ["imatinib", 844], [".", 852]]}
{"context": "Transcription-coupled repair (TCR) is a subpathway of nucleotide excision repair (NER) that acts specifically on lesions in the transcribed strand of expressed genes. First reported in mammalian cells, TCR was then documented in Escherichia coli. In this organism, an RNA polymerase arrested at a lesion is displaced by the transcription repair coupling factor, Mfd. This protein recruits the NER lesion-recognition factor UvrA, and then dissociates from the DNA. UvrA binds UvrB, and the assembled UvrAB* complex initiates repair. In mutants lacking active Mfd, TCR is absent. A gene transcribed by the bacteriophage T7 RNA polymerase in E. coli also requires Mfd for TCR. The CSB protein (missing or defective in cells of patients with Cockayne syndrome, complementation group B) is essential for TCR in humans. CSB and its homologs in higher eukaryotes are likely functional equivalents of Mfd.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "a9840cebbd6f4308916ff40aa8133f59", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[24, 25]], "char_spans": [[128, 145]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["a", 38], ["subpathway", 40], ["of", 51], ["nucleotide", 54], ["excision", 65], ["repair", 74], ["(", 81], ["NER", 82], [")", 85], ["that", 87], ["acts", 92], ["specifically", 97], ["on", 110], ["lesions", 113], ["in", 121], ["the", 124], ["transcribed", 128], ["strand", 140], ["of", 147], ["expressed", 150], ["genes", 160], [".", 165], ["First", 167], ["reported", 173], ["in", 182], ["mammalian", 185], ["cells", 195], [",", 200], ["TCR", 202], ["was", 206], ["then", 210], ["documented", 215], ["in", 226], ["Escherichia", 229], ["coli", 241], [".", 245], ["In", 247], ["this", 250], ["organism", 255], [",", 263], ["an", 265], ["RNA", 268], ["polymerase", 272], ["arrested", 283], ["at", 292], ["a", 295], ["lesion", 297], ["is", 304], ["displaced", 307], ["by", 317], ["the", 320], ["transcription", 324], ["repair", 338], ["coupling", 345], ["factor", 354], [",", 360], ["Mfd", 362], [".", 365], ["This", 367], ["protein", 372], ["recruits", 380], ["the", 389], ["NER", 393], ["lesion", 397], ["-", 403], ["recognition", 404], ["factor", 416], ["UvrA", 423], [",", 427], ["and", 429], ["then", 433], ["dissociates", 438], ["from", 450], ["the", 455], ["DNA", 459], [".", 462], ["UvrA", 464], ["binds", 469], ["UvrB", 475], [",", 479], ["and", 481], ["the", 485], ["assembled", 489], ["UvrAB", 499], ["*", 504], ["complex", 506], ["initiates", 514], ["repair", 524], [".", 530], ["In", 532], ["mutants", 535], ["lacking", 543], ["active", 551], ["Mfd", 558], [",", 561], ["TCR", 563], ["is", 567], ["absent", 570], [".", 576], ["A", 578], ["gene", 580], ["transcribed", 585], ["by", 597], ["the", 600], ["bacteriophage", 604], ["T7", 618], ["RNA", 621], ["polymerase", 625], ["in", 636], ["E.", 639], ["coli", 642], ["also", 647], ["requires", 652], ["Mfd", 661], ["for", 665], ["TCR", 669], [".", 672], ["The", 674], ["CSB", 678], ["protein", 682], ["(", 690], ["missing", 691], ["or", 699], ["defective", 702], ["in", 712], ["cells", 715], ["of", 721], ["patients", 724], ["with", 733], ["Cockayne", 738], ["syndrome", 747], [",", 755], ["complementation", 757], ["group", 773], ["B", 779], [")", 780], ["is", 782], ["essential", 785], ["for", 795], ["TCR", 799], ["in", 803], ["humans", 806], [".", 812], ["CSB", 814], ["and", 818], ["its", 822], ["homologs", 826], ["in", 835], ["higher", 838], ["eukaryotes", 845], ["are", 856], ["likely", 860], ["functional", 867], ["equivalents", 878], ["of", 890], ["Mfd", 893], [".", 896]]}
{"context": "The skeletal and immune systems have a complex relationship. Both systems are intimately coupled, with osteoclastogenesis and hematopoiesis occurring in the bone marrow. Bone and immune cells also share common hematopoietic precursors. Furthermore, the skeletal and immune systems share various cytokines, receptors, and transcription factors that regulate signal transduction pathways involved in osteoclastogenesis and immune system activation, including the receptor activator of nuclear factor-\u03ba\u0392 ligand/receptor activator of nuclear factor-\u03ba\u0392/osteoprotegerin (RANKL-RANK-OPG) pathway. Cancer cells can disrupt both the skeletal and immune systems. Interaction between cancer and bone cells results in a vicious cycle of bone destruction and cancer growth. Bone remodeling generates a growth-factor-rich environment that attracts cancer cells and promotes their proliferation. In turn, cancer cells stimulate osteoclast formation and activity, resulting in additional bone resorption that further stimulates cancer cell growth. Currently available bone-targeted therapies may also modulate the immune system. Bisphosphonates such as zoledronic acid exert stimulating effects on the immune system, resulting in possible anticancer activity against malignant cells. Denosumab, an anti-RANKL monoclonal antibody with proven antiosteoclast activity, may suppress immune responses. This may result in the reported association with an increased risk of neoplasms, as well as serious skin and other infections as reported in some studies, mainly in the postmenopausal setting. When assessing bone-targeted therapies, it is important to consider the shared signaling pathways between bone and the immune system, as well as the clinical risk:benefit ratio.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "0fbe0e984dcb489284a2e09de385fb16", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[205, 205], [86, 86]], "char_spans": [[1287, 1291], [565, 569]]}]}], "context_tokens": [["The", 0], ["skeletal", 4], ["and", 13], ["immune", 17], ["systems", 24], ["have", 32], ["a", 37], ["complex", 39], ["relationship", 47], [".", 59], ["Both", 61], ["systems", 66], ["are", 74], ["intimately", 78], ["coupled", 89], [",", 96], ["with", 98], ["osteoclastogenesis", 103], ["and", 122], ["hematopoiesis", 126], ["occurring", 140], ["in", 150], ["the", 153], ["bone", 157], ["marrow", 162], [".", 168], ["Bone", 170], ["and", 175], ["immune", 179], ["cells", 186], ["also", 192], ["share", 197], ["common", 203], ["hematopoietic", 210], ["precursors", 224], [".", 234], ["Furthermore", 236], [",", 247], ["the", 249], ["skeletal", 253], ["and", 262], ["immune", 266], ["systems", 273], ["share", 281], ["various", 287], ["cytokines", 295], [",", 304], ["receptors", 306], [",", 315], ["and", 317], ["transcription", 321], ["factors", 335], ["that", 343], ["regulate", 348], ["signal", 357], ["transduction", 364], ["pathways", 377], ["involved", 386], ["in", 395], ["osteoclastogenesis", 398], ["and", 417], ["immune", 421], ["system", 428], ["activation", 435], [",", 445], ["including", 447], ["the", 457], ["receptor", 461], ["activator", 470], ["of", 480], ["nuclear", 483], ["factor", 491], ["-", 497], ["\u03ba\u0392", 498], ["ligand", 501], ["/", 507], ["receptor", 508], ["activator", 517], ["of", 527], ["nuclear", 530], ["factor", 538], ["-", 544], ["\u03ba\u0392", 545], ["/", 547], ["osteoprotegerin", 548], ["(", 564], ["RANKL", 565], ["-", 570], ["RANK", 571], ["-", 575], ["OPG", 576], [")", 579], ["pathway", 581], [".", 588], ["Cancer", 590], ["cells", 597], ["can", 603], ["disrupt", 607], ["both", 615], ["the", 620], ["skeletal", 624], ["and", 633], ["immune", 637], ["systems", 644], [".", 651], ["Interaction", 653], ["between", 665], ["cancer", 673], ["and", 680], ["bone", 684], ["cells", 689], ["results", 695], ["in", 703], ["a", 706], ["vicious", 708], ["cycle", 716], ["of", 722], ["bone", 725], ["destruction", 730], ["and", 742], ["cancer", 746], ["growth", 753], [".", 759], ["Bone", 761], ["remodeling", 766], ["generates", 777], ["a", 787], ["growth", 789], ["-", 795], ["factor", 796], ["-", 802], ["rich", 803], ["environment", 808], ["that", 820], ["attracts", 825], ["cancer", 834], ["cells", 841], ["and", 847], ["promotes", 851], ["their", 860], ["proliferation", 866], [".", 879], ["In", 881], ["turn", 884], [",", 888], ["cancer", 890], ["cells", 897], ["stimulate", 903], ["osteoclast", 913], ["formation", 924], ["and", 934], ["activity", 938], [",", 946], ["resulting", 948], ["in", 958], ["additional", 961], ["bone", 972], ["resorption", 977], ["that", 988], ["further", 993], ["stimulates", 1001], ["cancer", 1012], ["cell", 1019], ["growth", 1024], [".", 1030], ["Currently", 1032], ["available", 1042], ["bone", 1052], ["-", 1056], ["targeted", 1057], ["therapies", 1066], ["may", 1076], ["also", 1080], ["modulate", 1085], ["the", 1094], ["immune", 1098], ["system", 1105], [".", 1111], ["Bisphosphonates", 1113], ["such", 1129], ["as", 1134], ["zoledronic", 1137], ["acid", 1148], ["exert", 1153], ["stimulating", 1159], ["effects", 1171], ["on", 1179], ["the", 1182], ["immune", 1186], ["system", 1193], [",", 1199], ["resulting", 1201], ["in", 1211], ["possible", 1214], ["anticancer", 1223], ["activity", 1234], ["against", 1243], ["malignant", 1251], ["cells", 1261], [".", 1266], ["Denosumab", 1268], [",", 1277], ["an", 1279], ["anti", 1282], ["-", 1286], ["RANKL", 1287], ["monoclonal", 1293], ["antibody", 1304], ["with", 1313], ["proven", 1318], ["antiosteoclast", 1325], ["activity", 1340], [",", 1348], ["may", 1350], ["suppress", 1354], ["immune", 1363], ["responses", 1370], [".", 1379], ["This", 1381], ["may", 1386], ["result", 1390], ["in", 1397], ["the", 1400], ["reported", 1404], ["association", 1413], ["with", 1425], ["an", 1430], ["increased", 1433], ["risk", 1443], ["of", 1448], ["neoplasms", 1451], [",", 1460], ["as", 1462], ["well", 1465], ["as", 1470], ["serious", 1473], ["skin", 1481], ["and", 1486], ["other", 1490], ["infections", 1496], ["as", 1507], ["reported", 1510], ["in", 1519], ["some", 1522], ["studies", 1527], [",", 1534], ["mainly", 1536], ["in", 1543], ["the", 1546], ["postmenopausal", 1550], ["setting", 1565], [".", 1572], ["When", 1574], ["assessing", 1579], ["bone", 1589], ["-", 1593], ["targeted", 1594], ["therapies", 1603], [",", 1612], ["it", 1614], ["is", 1617], ["important", 1620], ["to", 1630], ["consider", 1633], ["the", 1642], ["shared", 1646], ["signaling", 1653], ["pathways", 1663], ["between", 1672], ["bone", 1680], ["and", 1685], ["the", 1689], ["immune", 1693], ["system", 1700], [",", 1706], ["as", 1708], ["well", 1711], ["as", 1716], ["the", 1719], ["clinical", 1723], ["risk", 1732], [":", 1736], ["benefit", 1737], ["ratio", 1745], [".", 1750]]}
{"context": "CML (chronic myeloid leukaemia) is a myeloproliferative disease that originates in an HSC (haemopoietic stem cell) as a result of the t(9;22) translocation, giving rise to the Ph (Philadelphia chromosome) and bcr-abl oncoprotein. The disease starts in CP (chronic phase), but as a result of genomic instability, it progresses over time to accelerated phase and then to BC (blast crisis), becoming increasingly resistant to therapy. bcr-abl is a constitutively active tyrosine kinase that has been targeted by TKIs (tyrosine kinase inhibitors), including IM (imatinib mesylate), nilotinib and dasatinib. We have developed various flow cytometry techniques to enable us to isolate candidate CML stem cells from CP patients at diagnosis that efflux Hoechst dye, express CD34, lack CD38 and are cytokine-non-responsive in culture over periods of up to 12 days in growth factors. These stem cells have been shown to regenerate bcr-abl-positive haemopoiesis in immunocompromised mice upon transplantation. We previously demonstrated that IM was antiproliferative for CML stem cells but did not induce apoptosis. Clinical experience now confirms that IM may not target CML stem cells in vivo with few patients achieving complete molecular remission and relapse occurring rapidly upon drug withdrawal. Our recent efforts have focused on understanding why CML stem cells are resistant to IM and on trying to find novel ways to induce apoptosis of this population. We have shown that CML stem cells express very high levels of functional wild-type bcr-abl; no kinase domain mutations have been detected in the stem cell population. Dasatinib, a more potent multitargeted TKI than IM, inhibits bcr-abl activity more efficiently than IM but still does not induce apoptosis of the stem cell population. Most recently, we have tested a number of novel drug combinations and found that FTIs (farnesyl transferase inhibitors) have activity against CML. BMS-214662 is the most effective of these and induces apoptosis of phenotypically and functionally defined CML stem cells in vitro, as a single agent and in combination with IM or dasatinib. The effect against CML stem cells is selective with little effect on normal stem cells. The drug is also effective against BC CML stem cells and equally effective against wild-type and mutant bcr-abl, including the most resistant mutant T315I. In association with apoptosis, there is activation of caspase 8 and caspase 3, inhibition of the MAPK pathway, IAP-1 (inhibitor of apoptosis protein-1), NF-kappaB (nuclear factor kappaB) and iNOS (inducible nitric oxide synthase). Furthermore, BMS-214662 synergizes with MEK1/2 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 1/2] inhibitors, suggesting a second mechanism other that RAS inhibition for induction of apoptosis. Our intentions are now to explore the activity of BMS-214662 in other cancer stem cell disorders and to move this preclinical work to a clinical trial combining dasatinib with BMS-214662 in CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "88390fb06cb44b229884042b868e9663", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[84, 86], [278, 280], [420, 422], [39, 41], [306, 308], [175, 177]], "char_spans": [[432, 438], [1538, 1544], [2320, 2326], [209, 215], [1683, 1689], [922, 928]]}]}], "context_tokens": [["CML", 0], ["(", 4], ["chronic", 5], ["myeloid", 13], ["leukaemia", 21], [")", 30], ["is", 32], ["a", 35], ["myeloproliferative", 37], ["disease", 56], ["that", 64], ["originates", 69], ["in", 80], ["an", 83], ["HSC", 86], ["(", 90], ["haemopoietic", 91], ["stem", 104], ["cell", 109], [")", 113], ["as", 115], ["a", 118], ["result", 120], ["of", 127], ["the", 130], ["t(9;22", 134], [")", 140], ["translocation", 142], [",", 155], ["giving", 157], ["rise", 164], ["to", 169], ["the", 172], ["Ph", 176], ["(", 179], ["Philadelphia", 180], ["chromosome", 193], [")", 203], ["and", 205], ["bcr", 209], ["-", 212], ["abl", 213], ["oncoprotein", 217], [".", 228], ["The", 230], ["disease", 234], ["starts", 242], ["in", 249], ["CP", 252], ["(", 255], ["chronic", 256], ["phase", 264], [")", 269], [",", 270], ["but", 272], ["as", 276], ["a", 279], ["result", 281], ["of", 288], ["genomic", 291], ["instability", 299], [",", 310], ["it", 312], ["progresses", 315], ["over", 326], ["time", 331], ["to", 336], ["accelerated", 339], ["phase", 351], ["and", 357], ["then", 361], ["to", 366], ["BC", 369], ["(", 372], ["blast", 373], ["crisis", 379], [")", 385], [",", 386], ["becoming", 388], ["increasingly", 397], ["resistant", 410], ["to", 420], ["therapy", 423], [".", 430], ["bcr", 432], ["-", 435], ["abl", 436], ["is", 440], ["a", 443], ["constitutively", 445], ["active", 460], ["tyrosine", 467], ["kinase", 476], ["that", 483], ["has", 488], ["been", 492], ["targeted", 497], ["by", 506], ["TKIs", 509], ["(", 514], ["tyrosine", 515], ["kinase", 524], ["inhibitors", 531], [")", 541], [",", 542], ["including", 544], ["IM", 554], ["(", 557], ["imatinib", 558], ["mesylate", 567], [")", 575], [",", 576], ["nilotinib", 578], ["and", 588], ["dasatinib", 592], [".", 601], ["We", 603], ["have", 606], ["developed", 611], ["various", 621], ["flow", 629], ["cytometry", 634], ["techniques", 644], ["to", 655], ["enable", 658], ["us", 665], ["to", 668], ["isolate", 671], ["candidate", 679], ["CML", 689], ["stem", 693], ["cells", 698], ["from", 704], ["CP", 709], ["patients", 712], ["at", 721], ["diagnosis", 724], ["that", 734], ["efflux", 739], ["Hoechst", 746], ["dye", 754], [",", 757], ["express", 759], ["CD34", 767], [",", 771], ["lack", 773], ["CD38", 778], ["and", 783], ["are", 787], ["cytokine", 791], ["-", 799], ["non", 800], ["-", 803], ["responsive", 804], ["in", 815], ["culture", 818], ["over", 826], ["periods", 831], ["of", 839], ["up", 842], ["to", 845], ["12", 848], ["days", 851], ["in", 856], ["growth", 859], ["factors", 866], [".", 873], ["These", 875], ["stem", 881], ["cells", 886], ["have", 892], ["been", 897], ["shown", 902], ["to", 908], ["regenerate", 911], ["bcr", 922], ["-", 925], ["abl", 926], ["-", 929], ["positive", 930], ["haemopoiesis", 939], ["in", 952], ["immunocompromised", 955], ["mice", 973], ["upon", 978], ["transplantation", 983], [".", 998], ["We", 1000], ["previously", 1003], ["demonstrated", 1014], ["that", 1027], ["IM", 1032], ["was", 1035], ["antiproliferative", 1039], ["for", 1057], ["CML", 1061], ["stem", 1065], ["cells", 1070], ["but", 1076], ["did", 1080], ["not", 1084], ["induce", 1088], ["apoptosis", 1095], [".", 1104], ["Clinical", 1106], ["experience", 1115], ["now", 1126], ["confirms", 1130], ["that", 1139], ["IM", 1144], ["may", 1147], ["not", 1151], ["target", 1155], ["CML", 1162], ["stem", 1166], ["cells", 1171], ["in", 1177], ["vivo", 1180], ["with", 1185], ["few", 1190], ["patients", 1194], ["achieving", 1203], ["complete", 1213], ["molecular", 1222], ["remission", 1232], ["and", 1242], ["relapse", 1246], ["occurring", 1254], ["rapidly", 1264], ["upon", 1272], ["drug", 1277], ["withdrawal", 1282], [".", 1292], ["Our", 1294], ["recent", 1298], ["efforts", 1305], ["have", 1313], ["focused", 1318], ["on", 1326], ["understanding", 1329], ["why", 1343], ["CML", 1347], ["stem", 1351], ["cells", 1356], ["are", 1362], ["resistant", 1366], ["to", 1376], ["IM", 1379], ["and", 1382], ["on", 1386], ["trying", 1389], ["to", 1396], ["find", 1399], ["novel", 1404], ["ways", 1410], ["to", 1415], ["induce", 1418], ["apoptosis", 1425], ["of", 1435], ["this", 1438], ["population", 1443], [".", 1453], ["We", 1455], ["have", 1458], ["shown", 1463], ["that", 1469], ["CML", 1474], ["stem", 1478], ["cells", 1483], ["express", 1489], ["very", 1497], ["high", 1502], ["levels", 1507], ["of", 1514], ["functional", 1517], ["wild", 1528], ["-", 1532], ["type", 1533], ["bcr", 1538], ["-", 1541], ["abl", 1542], [";", 1545], ["no", 1547], ["kinase", 1550], ["domain", 1557], ["mutations", 1564], ["have", 1574], ["been", 1579], ["detected", 1584], ["in", 1593], ["the", 1596], ["stem", 1600], ["cell", 1605], ["population", 1610], [".", 1620], ["Dasatinib", 1622], [",", 1631], ["a", 1633], ["more", 1635], ["potent", 1640], ["multitargeted", 1647], ["TKI", 1661], ["than", 1665], ["IM", 1670], [",", 1672], ["inhibits", 1674], ["bcr", 1683], ["-", 1686], ["abl", 1687], ["activity", 1691], ["more", 1700], ["efficiently", 1705], ["than", 1717], ["IM", 1722], ["but", 1725], ["still", 1729], ["does", 1735], ["not", 1740], ["induce", 1744], ["apoptosis", 1751], ["of", 1761], ["the", 1764], ["stem", 1768], ["cell", 1773], ["population", 1778], [".", 1788], ["Most", 1790], ["recently", 1795], [",", 1803], ["we", 1805], ["have", 1808], ["tested", 1813], ["a", 1820], ["number", 1822], ["of", 1829], ["novel", 1832], ["drug", 1838], ["combinations", 1843], ["and", 1856], ["found", 1860], ["that", 1866], ["FTIs", 1871], ["(", 1876], ["farnesyl", 1877], ["transferase", 1886], ["inhibitors", 1898], [")", 1908], ["have", 1910], ["activity", 1915], ["against", 1924], ["CML", 1932], [".", 1935], ["BMS-214662", 1937], ["is", 1948], ["the", 1951], ["most", 1955], ["effective", 1960], ["of", 1970], ["these", 1973], ["and", 1979], ["induces", 1983], ["apoptosis", 1991], ["of", 2001], ["phenotypically", 2004], ["and", 2019], ["functionally", 2023], ["defined", 2036], ["CML", 2044], ["stem", 2048], ["cells", 2053], ["in", 2059], ["vitro", 2062], [",", 2067], ["as", 2069], ["a", 2072], ["single", 2074], ["agent", 2081], ["and", 2087], ["in", 2091], ["combination", 2094], ["with", 2106], ["IM", 2111], ["or", 2114], ["dasatinib", 2117], [".", 2126], ["The", 2128], ["effect", 2132], ["against", 2139], ["CML", 2147], ["stem", 2151], ["cells", 2156], ["is", 2162], ["selective", 2165], ["with", 2175], ["little", 2180], ["effect", 2187], ["on", 2194], ["normal", 2197], ["stem", 2204], ["cells", 2209], [".", 2214], ["The", 2216], ["drug", 2220], ["is", 2225], ["also", 2228], ["effective", 2233], ["against", 2243], ["BC", 2251], ["CML", 2254], ["stem", 2258], ["cells", 2263], ["and", 2269], ["equally", 2273], ["effective", 2281], ["against", 2291], ["wild", 2299], ["-", 2303], ["type", 2304], ["and", 2309], ["mutant", 2313], ["bcr", 2320], ["-", 2323], ["abl", 2324], [",", 2327], ["including", 2329], ["the", 2339], ["most", 2343], ["resistant", 2348], ["mutant", 2358], ["T315I.", 2365], ["In", 2372], ["association", 2375], ["with", 2387], ["apoptosis", 2392], [",", 2401], ["there", 2403], ["is", 2409], ["activation", 2412], ["of", 2423], ["caspase", 2426], ["8", 2434], ["and", 2436], ["caspase", 2440], ["3", 2448], [",", 2449], ["inhibition", 2451], ["of", 2462], ["the", 2465], ["MAPK", 2469], ["pathway", 2474], [",", 2481], ["IAP-1", 2483], ["(", 2489], ["inhibitor", 2490], ["of", 2500], ["apoptosis", 2503], ["protein-1", 2513], [")", 2522], [",", 2523], ["NF", 2525], ["-", 2527], ["kappaB", 2528], ["(", 2535], ["nuclear", 2536], ["factor", 2544], ["kappaB", 2551], [")", 2557], ["and", 2559], ["iNOS", 2563], ["(", 2568], ["inducible", 2569], ["nitric", 2579], ["oxide", 2586], ["synthase", 2592], [")", 2600], [".", 2601], ["Furthermore", 2603], [",", 2614], ["BMS-214662", 2616], ["synergizes", 2627], ["with", 2638], ["MEK1/2", 2643], ["[", 2650], ["MAPK", 2651], ["(", 2656], ["mitogen", 2657], ["-", 2664], ["activated", 2665], ["protein", 2675], ["kinase)/ERK", 2683], ["(", 2695], ["extracellular", 2696], ["-", 2709], ["signal", 2710], ["-", 2716], ["regulated", 2717], ["kinase", 2727], [")", 2733], ["kinase", 2735], ["1/2", 2742], ["]", 2745], ["inhibitors", 2747], [",", 2757], ["suggesting", 2759], ["a", 2770], ["second", 2772], ["mechanism", 2779], ["other", 2789], ["that", 2795], ["RAS", 2800], ["inhibition", 2804], ["for", 2815], ["induction", 2819], ["of", 2829], ["apoptosis", 2832], [".", 2841], ["Our", 2843], ["intentions", 2847], ["are", 2858], ["now", 2862], ["to", 2866], ["explore", 2869], ["the", 2877], ["activity", 2881], ["of", 2890], ["BMS-214662", 2893], ["in", 2904], ["other", 2907], ["cancer", 2913], ["stem", 2920], ["cell", 2925], ["disorders", 2930], ["and", 2940], ["to", 2944], ["move", 2947], ["this", 2952], ["preclinical", 2957], ["work", 2969], ["to", 2974], ["a", 2977], ["clinical", 2979], ["trial", 2988], ["combining", 2994], ["dasatinib", 3004], ["with", 3014], ["BMS-214662", 3019], ["in", 3030], ["CML", 3033], [".", 3036]]}
{"context": "Patients with lung adenocarcinoma who carry epidermal growth factor receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib, or erlotinib. However, the effect of EGFR-TKI treatment on the prolongation of overall survival (OS) of these patients remains uncertain, although several recent studies have shown prolongation of progression free survival compared with cytotoxic chemotherapy. A total of 304 patients with lung adenocarcinoma who had postoperative recurrent disease were studied. To eliminate potential biases as possible, the matching of four potential predictive factors of responsiveness to EGFR-TKI led to the identification of 81 pairs of patients (those who were treated with gefitinib and those who were not). A deletion mutation in exon 19 and a point mutation (L858R) in exon 21 of the EGFR gene were also analyzed. We compared the OS between the two groups. OS in the gefitinib group was significantly longer than in the control group (median, 63 vs. 41 months; p\u00a0=\u00a00.015). EGFR mutations were detected in 65 out of 129 patients (50%) in the whole sample. EGFR mutational status was not an independent prognostic factor of gefitinib benefit; rather, it was a predictive factor. This study strongly suggested that gefitinib treatment improved OS of lung adenocarcinoma patients who had postoperative recurrence, especially those carrying EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "4c43e1cef300429f95de389403fe64ce", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[6, 13]], "char_spans": [[44, 87]]}]}], "context_tokens": [["Patients", 0], ["with", 9], ["lung", 14], ["adenocarcinoma", 19], ["who", 34], ["carry", 38], ["epidermal", 44], ["growth", 54], ["factor", 61], ["receptor", 68], ["(", 77], ["EGFR", 78], [")", 82], ["gene", 84], ["mutations", 89], ["respond", 99], ["remarkably", 107], ["well", 118], ["to", 123], ["EGFR", 126], ["tyrosine", 131], ["kinase", 140], ["inhibitor", 147], ["(", 157], ["EGFR", 158], ["-", 162], ["TKI", 163], [")", 166], [",", 167], ["gefitinib", 169], [",", 178], ["or", 180], ["erlotinib", 183], [".", 192], ["However", 194], [",", 201], ["the", 203], ["effect", 207], ["of", 214], ["EGFR", 217], ["-", 221], ["TKI", 222], ["treatment", 226], ["on", 236], ["the", 239], ["prolongation", 243], ["of", 256], ["overall", 259], ["survival", 267], ["(", 276], ["OS", 277], [")", 279], ["of", 281], ["these", 284], ["patients", 290], ["remains", 299], ["uncertain", 307], [",", 316], ["although", 318], ["several", 327], ["recent", 335], ["studies", 342], ["have", 350], ["shown", 355], ["prolongation", 361], ["of", 374], ["progression", 377], ["free", 389], ["survival", 394], ["compared", 403], ["with", 412], ["cytotoxic", 417], ["chemotherapy", 427], [".", 439], ["A", 441], ["total", 443], ["of", 449], ["304", 452], ["patients", 456], ["with", 465], ["lung", 470], ["adenocarcinoma", 475], ["who", 490], ["had", 494], ["postoperative", 498], ["recurrent", 512], ["disease", 522], ["were", 530], ["studied", 535], [".", 542], ["To", 544], ["eliminate", 547], ["potential", 557], ["biases", 567], ["as", 574], ["possible", 577], [",", 585], ["the", 587], ["matching", 591], ["of", 600], ["four", 603], ["potential", 608], ["predictive", 618], ["factors", 629], ["of", 637], ["responsiveness", 640], ["to", 655], ["EGFR", 658], ["-", 662], ["TKI", 663], ["led", 667], ["to", 671], ["the", 674], ["identification", 678], ["of", 693], ["81", 696], ["pairs", 699], ["of", 705], ["patients", 708], ["(", 717], ["those", 718], ["who", 724], ["were", 728], ["treated", 733], ["with", 741], ["gefitinib", 746], ["and", 756], ["those", 760], ["who", 766], ["were", 770], ["not", 775], [")", 778], [".", 779], ["A", 781], ["deletion", 783], ["mutation", 792], ["in", 801], ["exon", 804], ["19", 809], ["and", 812], ["a", 816], ["point", 818], ["mutation", 824], ["(", 833], ["L858R", 834], [")", 839], ["in", 841], ["exon", 844], ["21", 849], ["of", 852], ["the", 855], ["EGFR", 859], ["gene", 864], ["were", 869], ["also", 874], ["analyzed", 879], [".", 887], ["We", 889], ["compared", 892], ["the", 901], ["OS", 905], ["between", 908], ["the", 916], ["two", 920], ["groups", 924], [".", 930], ["OS", 932], ["in", 935], ["the", 938], ["gefitinib", 942], ["group", 952], ["was", 958], ["significantly", 962], ["longer", 976], ["than", 983], ["in", 988], ["the", 991], ["control", 995], ["group", 1003], ["(", 1009], ["median", 1010], [",", 1016], ["63", 1018], ["vs.", 1021], ["41", 1025], ["months", 1028], [";", 1034], ["p", 1036], ["=", 1038], ["0.015", 1040], [")", 1045], [".", 1046], ["EGFR", 1048], ["mutations", 1053], ["were", 1063], ["detected", 1068], ["in", 1077], ["65", 1080], ["out", 1083], ["of", 1087], ["129", 1090], ["patients", 1094], ["(", 1103], ["50", 1104], ["%", 1106], [")", 1107], ["in", 1109], ["the", 1112], ["whole", 1116], ["sample", 1122], [".", 1128], ["EGFR", 1130], ["mutational", 1135], ["status", 1146], ["was", 1153], ["not", 1157], ["an", 1161], ["independent", 1164], ["prognostic", 1176], ["factor", 1187], ["of", 1194], ["gefitinib", 1197], ["benefit", 1207], [";", 1214], ["rather", 1216], [",", 1222], ["it", 1224], ["was", 1227], ["a", 1231], ["predictive", 1233], ["factor", 1244], [".", 1250], ["This", 1252], ["study", 1257], ["strongly", 1263], ["suggested", 1272], ["that", 1282], ["gefitinib", 1287], ["treatment", 1297], ["improved", 1307], ["OS", 1316], ["of", 1319], ["lung", 1322], ["adenocarcinoma", 1327], ["patients", 1342], ["who", 1351], ["had", 1355], ["postoperative", 1359], ["recurrence", 1373], [",", 1383], ["especially", 1385], ["those", 1396], ["carrying", 1402], ["EGFR", 1411], ["mutations", 1416], [".", 1425]]}
{"context": "Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, which causes progressive and eventually fatal loss of motor function. Here, we describe genetic and pathologic characterization of brain tissue banked from 19 ALS patients over nearly 20\u00a0years at the Department of Anatomy and the Centre for Brain Research, University of Auckland, New Zealand. We screened for mutations in SOD1, TARDBP, FUS, and C9ORF72 genes and for neuropathology caused by phosphorylated TDP-43, dipeptide repeats (DPRs), and ubiquilin. We identified 2 cases with C9ORF72 repeat expansions. Both harbored phosphorylated TDP-43 and DPR inclusions. We show that DPR inclusions can incorporate or occur independently of ubiquilin. We also identified 1 case with a UBQLN2 mutation, which showed phosphorylated TDP-43 and characteristic ubiquilin protein inclusions. This is the first study of ALS genetics in New Zealand, adding New Zealand to the growing list of countries in which C9ORF72 repeat expansion and UBQLN2 mutations are detected in ALS cases.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "56561ee2c5e6437da905d1d0cb1db046", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[175, 175], [4, 4], [37, 37], [149, 149]], "char_spans": [[1041, 1043], [31, 33], [239, 241], [889, 891]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[0, 2]], "char_spans": [[0, 28]]}]}], "context_tokens": [["Amyotrophic", 0], ["lateral", 12], ["sclerosis", 20], ["(", 30], ["ALS", 31], [")", 34], ["is", 36], ["a", 39], ["devastating", 41], ["neurodegenerative", 53], ["disease", 71], [",", 78], ["which", 80], ["causes", 86], ["progressive", 93], ["and", 105], ["eventually", 109], ["fatal", 120], ["loss", 126], ["of", 131], ["motor", 134], ["function", 140], [".", 148], ["Here", 150], [",", 154], ["we", 156], ["describe", 159], ["genetic", 168], ["and", 176], ["pathologic", 180], ["characterization", 191], ["of", 208], ["brain", 211], ["tissue", 217], ["banked", 224], ["from", 231], ["19", 236], ["ALS", 239], ["patients", 243], ["over", 252], ["nearly", 257], ["20", 264], ["years", 267], ["at", 273], ["the", 276], ["Department", 280], ["of", 291], ["Anatomy", 294], ["and", 302], ["the", 306], ["Centre", 310], ["for", 317], ["Brain", 321], ["Research", 327], [",", 335], ["University", 337], ["of", 348], ["Auckland", 351], [",", 359], ["New", 361], ["Zealand", 365], [".", 372], ["We", 374], ["screened", 377], ["for", 386], ["mutations", 390], ["in", 400], ["SOD1", 403], [",", 407], ["TARDBP", 409], [",", 415], ["FUS", 417], [",", 420], ["and", 422], ["C9ORF72", 426], ["genes", 434], ["and", 440], ["for", 444], ["neuropathology", 448], ["caused", 463], ["by", 470], ["phosphorylated", 473], ["TDP-43", 488], [",", 494], ["dipeptide", 496], ["repeats", 506], ["(", 514], ["DPRs", 515], [")", 519], [",", 520], ["and", 522], ["ubiquilin", 526], [".", 535], ["We", 537], ["identified", 540], ["2", 551], ["cases", 553], ["with", 559], ["C9ORF72", 564], ["repeat", 572], ["expansions", 579], [".", 589], ["Both", 591], ["harbored", 596], ["phosphorylated", 605], ["TDP-43", 620], ["and", 627], ["DPR", 631], ["inclusions", 635], [".", 645], ["We", 647], ["show", 650], ["that", 655], ["DPR", 660], ["inclusions", 664], ["can", 675], ["incorporate", 679], ["or", 691], ["occur", 694], ["independently", 700], ["of", 714], ["ubiquilin", 717], [".", 726], ["We", 728], ["also", 731], ["identified", 736], ["1", 747], ["case", 749], ["with", 754], ["a", 759], ["UBQLN2", 761], ["mutation", 768], [",", 776], ["which", 778], ["showed", 784], ["phosphorylated", 791], ["TDP-43", 806], ["and", 813], ["characteristic", 817], ["ubiquilin", 832], ["protein", 842], ["inclusions", 850], [".", 860], ["This", 862], ["is", 867], ["the", 870], ["first", 874], ["study", 880], ["of", 886], ["ALS", 889], ["genetics", 893], ["in", 902], ["New", 905], ["Zealand", 909], [",", 916], ["adding", 918], ["New", 925], ["Zealand", 929], ["to", 937], ["the", 940], ["growing", 944], ["list", 952], ["of", 957], ["countries", 960], ["in", 970], ["which", 973], ["C9ORF72", 979], ["repeat", 987], ["expansion", 994], ["and", 1004], ["UBQLN2", 1008], ["mutations", 1015], ["are", 1025], ["detected", 1029], ["in", 1038], ["ALS", 1041], ["cases", 1045], [".", 1050]]}
{"context": "Selenoproteins are an elite group of proteins containing a rare amino acid, selenocysteine (Sec), encoded by the codon, UGA. In eukaryotes, incorporation of Sec requires a Sec insertion sequence (SECIS) element, a stem-loop structure located in the 3'-untranslated regions of selenoprotein mRNAs. Here we report identification of a noncanonical form of SECIS element in Toxoplasma gondii and Neospora canine, single-celled apicomplexan parasites of humans and domestic animals. This SECIS has a GGGA sequence in the SBP2-binding site in place of AUGA previously considered invariant. Using a combination of computational and molecular techniques, we show that Toxoplasma and Neospora possess both canonical and noncanonical SECIS elements. The GGGA-type SECIS element supported Sec insertion in mammalian HEK 293 and NIH 3T3 cells and did so more efficiently than the natural mammalian SECIS elements tested. In addition, mammalian type I and type II SECIS elements mutated into the GGGA forms were functional but manifested decreased Sec insertion efficiency. We carried out computational searches for both AUGA and GGGA forms of SECIS elements in Toxoplasma and detected five selenoprotein genes, including one coding for a previously undescribed selenoprotein, designated SelQ, and two containing the GGGA form of the SECIS element. In contrast, the GGGA-type SECIS elements were not detected in mammals and nematodes. As a practical outcome of the study, we developed pSelExpress1, a vector for convenient expression of selenoproteins in mammalian cells. It contains an SBP2 gene and the most efficient tested SECIS element: an AUGA mutant of the GGGA-type Toxoplasma SelT structure.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "60845a786b424b11bfedd9ec58170947", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[64, 64], [192, 192], [37, 37], [85, 85], [122, 122], [275, 275], [164, 164], [151, 151], [232, 232], [222, 222], [129, 129]], "char_spans": [[353, 357], [1131, 1135], [196, 200], [483, 487], [724, 728], [1614, 1618], [951, 955], [886, 890], [1363, 1367], [1321, 1325], [754, 758]]}]}], "context_tokens": [["Selenoproteins", 0], ["are", 15], ["an", 19], ["elite", 22], ["group", 28], ["of", 34], ["proteins", 37], ["containing", 46], ["a", 57], ["rare", 59], ["amino", 64], ["acid", 70], [",", 74], ["selenocysteine", 76], ["(", 91], ["Sec", 92], [")", 95], [",", 96], ["encoded", 98], ["by", 106], ["the", 109], ["codon", 113], [",", 118], ["UGA", 120], [".", 123], ["In", 125], ["eukaryotes", 128], [",", 138], ["incorporation", 140], ["of", 154], ["Sec", 157], ["requires", 161], ["a", 170], ["Sec", 172], ["insertion", 176], ["sequence", 186], ["(", 195], ["SECIS", 196], [")", 201], ["element", 203], [",", 210], ["a", 212], ["stem", 214], ["-", 218], ["loop", 219], ["structure", 224], ["located", 234], ["in", 242], ["the", 245], ["3'-untranslated", 249], ["regions", 265], ["of", 273], ["selenoprotein", 276], ["mRNAs", 290], [".", 295], ["Here", 297], ["we", 302], ["report", 305], ["identification", 312], ["of", 327], ["a", 330], ["noncanonical", 332], ["form", 345], ["of", 350], ["SECIS", 353], ["element", 359], ["in", 367], ["Toxoplasma", 370], ["gondii", 381], ["and", 388], ["Neospora", 392], ["canine", 401], [",", 407], ["single", 409], ["-", 415], ["celled", 416], ["apicomplexan", 423], ["parasites", 436], ["of", 446], ["humans", 449], ["and", 456], ["domestic", 460], ["animals", 469], [".", 476], ["This", 478], ["SECIS", 483], ["has", 489], ["a", 493], ["GGGA", 495], ["sequence", 500], ["in", 509], ["the", 512], ["SBP2-binding", 516], ["site", 529], ["in", 534], ["place", 537], ["of", 543], ["AUGA", 546], ["previously", 551], ["considered", 562], ["invariant", 573], [".", 582], ["Using", 584], ["a", 590], ["combination", 592], ["of", 604], ["computational", 607], ["and", 621], ["molecular", 625], ["techniques", 635], [",", 645], ["we", 647], ["show", 650], ["that", 655], ["Toxoplasma", 660], ["and", 671], ["Neospora", 675], ["possess", 684], ["both", 692], ["canonical", 697], ["and", 707], ["noncanonical", 711], ["SECIS", 724], ["elements", 730], [".", 738], ["The", 740], ["GGGA", 744], ["-", 748], ["type", 749], ["SECIS", 754], ["element", 760], ["supported", 768], ["Sec", 778], ["insertion", 782], ["in", 792], ["mammalian", 795], ["HEK", 805], ["293", 809], ["and", 813], ["NIH", 817], ["3T3", 821], ["cells", 825], ["and", 831], ["did", 835], ["so", 839], ["more", 842], ["efficiently", 847], ["than", 859], ["the", 864], ["natural", 868], ["mammalian", 876], ["SECIS", 886], ["elements", 892], ["tested", 901], [".", 907], ["In", 909], ["addition", 912], [",", 920], ["mammalian", 922], ["type", 932], ["I", 937], ["and", 939], ["type", 943], ["II", 948], ["SECIS", 951], ["elements", 957], ["mutated", 966], ["into", 974], ["the", 979], ["GGGA", 983], ["forms", 988], ["were", 994], ["functional", 999], ["but", 1010], ["manifested", 1014], ["decreased", 1025], ["Sec", 1035], ["insertion", 1039], ["efficiency", 1049], [".", 1059], ["We", 1061], ["carried", 1064], ["out", 1072], ["computational", 1076], ["searches", 1090], ["for", 1099], ["both", 1103], ["AUGA", 1108], ["and", 1113], ["GGGA", 1117], ["forms", 1122], ["of", 1128], ["SECIS", 1131], ["elements", 1137], ["in", 1146], ["Toxoplasma", 1149], ["and", 1160], ["detected", 1164], ["five", 1173], ["selenoprotein", 1178], ["genes", 1192], [",", 1197], ["including", 1199], ["one", 1209], ["coding", 1213], ["for", 1220], ["a", 1224], ["previously", 1226], ["undescribed", 1237], ["selenoprotein", 1249], [",", 1262], ["designated", 1264], ["SelQ", 1275], [",", 1279], ["and", 1281], ["two", 1285], ["containing", 1289], ["the", 1300], ["GGGA", 1304], ["form", 1309], ["of", 1314], ["the", 1317], ["SECIS", 1321], ["element", 1327], [".", 1334], ["In", 1336], ["contrast", 1339], [",", 1347], ["the", 1349], ["GGGA", 1353], ["-", 1357], ["type", 1358], ["SECIS", 1363], ["elements", 1369], ["were", 1378], ["not", 1383], ["detected", 1387], ["in", 1396], ["mammals", 1399], ["and", 1407], ["nematodes", 1411], [".", 1420], ["As", 1422], ["a", 1425], ["practical", 1427], ["outcome", 1437], ["of", 1445], ["the", 1448], ["study", 1452], [",", 1457], ["we", 1459], ["developed", 1462], ["pSelExpress1", 1472], [",", 1484], ["a", 1486], ["vector", 1488], ["for", 1495], ["convenient", 1499], ["expression", 1510], ["of", 1521], ["selenoproteins", 1524], ["in", 1539], ["mammalian", 1542], ["cells", 1552], [".", 1557], ["It", 1559], ["contains", 1562], ["an", 1571], ["SBP2", 1574], ["gene", 1579], ["and", 1584], ["the", 1588], ["most", 1592], ["efficient", 1597], ["tested", 1607], ["SECIS", 1614], ["element", 1620], [":", 1627], ["an", 1629], ["AUGA", 1632], ["mutant", 1637], ["of", 1644], ["the", 1647], ["GGGA", 1651], ["-", 1655], ["type", 1656], ["Toxoplasma", 1661], ["SelT", 1672], ["structure", 1677], [".", 1686]]}
{"context": "Rigel Pharmaceuticals Inc is developing fostamatinib, a prodrug of the spleen tyrosine kinase (Syk) inhibitor R-406, for the potential treatment of autoimmune diseases such as rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP) and B-cell lymphomas. Syk is a key mediator of Fc and B-cell receptor signaling in inflammatory cells, such as B-cells, mast cells, macrophages and neutrophils. Preclinical studies of R-406 or fostamatinib demonstrated a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of RA. In a phase II clinical trial, fostamatinib treatment effectively improved American College of Rheumatology response rates in patients with RA. Preclinical studies and phase II trials also suggested the potential of using fostamatinib for the treatment of ITP and B-cell lymphomas, by increasing platelet counts and inducing response rates, respectively. Fostamatinib is orally bioavailable and was well tolerated in phase I and II trials, with the most common side effect being gastrointestinal symptoms. At the time of publication, phase II trials for fostamatinib were ongoing in patients with RA, ITP and B-cell lymphomas. The Syk inhibitor appears to be a promising therapeutic for immunological diseases, but further data are required to establish the efficacy and long-term safety of the drug in humans.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7a4fa67d3e7042d388d3a34034a61556", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[11, 13]], "char_spans": [[71, 92]]}]}], "context_tokens": [["Rigel", 0], ["Pharmaceuticals", 6], ["Inc", 22], ["is", 26], ["developing", 29], ["fostamatinib", 40], [",", 52], ["a", 54], ["prodrug", 56], ["of", 64], ["the", 67], ["spleen", 71], ["tyrosine", 78], ["kinase", 87], ["(", 94], ["Syk", 95], [")", 98], ["inhibitor", 100], ["R-406", 110], [",", 115], ["for", 117], ["the", 121], ["potential", 125], ["treatment", 135], ["of", 145], ["autoimmune", 148], ["diseases", 159], ["such", 168], ["as", 173], ["rheumatoid", 176], ["arthritis", 187], ["(", 197], ["RA", 198], [")", 200], [",", 201], ["idiopathic", 203], ["thrombocytopenic", 214], ["purpura", 231], ["(", 239], ["ITP", 240], [")", 243], ["and", 245], ["B", 249], ["-", 250], ["cell", 251], ["lymphomas", 256], [".", 265], ["Syk", 267], ["is", 271], ["a", 274], ["key", 276], ["mediator", 280], ["of", 289], ["Fc", 292], ["and", 295], ["B", 299], ["-", 300], ["cell", 301], ["receptor", 306], ["signaling", 315], ["in", 325], ["inflammatory", 328], ["cells", 341], [",", 346], ["such", 348], ["as", 353], ["B", 356], ["-", 357], ["cells", 358], [",", 363], ["mast", 365], ["cells", 370], [",", 375], ["macrophages", 377], ["and", 389], ["neutrophils", 393], [".", 404], ["Preclinical", 406], ["studies", 418], ["of", 426], ["R-406", 429], ["or", 435], ["fostamatinib", 438], ["demonstrated", 451], ["a", 464], ["significant", 466], ["reduction", 478], ["in", 488], ["major", 491], ["inflammatory", 497], ["mediators", 510], ["such", 520], ["as", 525], ["TNFalpha", 528], [",", 536], ["IL-1", 538], [",", 542], ["IL-6", 544], ["and", 549], ["IL-18", 553], [",", 558], ["leading", 560], ["to", 568], ["reduced", 571], ["inflammation", 579], ["and", 592], ["bone", 596], ["degradation", 601], ["in", 613], ["models", 616], ["of", 623], ["RA", 626], [".", 628], ["In", 630], ["a", 633], ["phase", 635], ["II", 641], ["clinical", 644], ["trial", 653], [",", 658], ["fostamatinib", 660], ["treatment", 673], ["effectively", 683], ["improved", 695], ["American", 704], ["College", 713], ["of", 721], ["Rheumatology", 724], ["response", 737], ["rates", 746], ["in", 752], ["patients", 755], ["with", 764], ["RA", 769], [".", 771], ["Preclinical", 773], ["studies", 785], ["and", 793], ["phase", 797], ["II", 803], ["trials", 806], ["also", 813], ["suggested", 818], ["the", 828], ["potential", 832], ["of", 842], ["using", 845], ["fostamatinib", 851], ["for", 864], ["the", 868], ["treatment", 872], ["of", 882], ["ITP", 885], ["and", 889], ["B", 893], ["-", 894], ["cell", 895], ["lymphomas", 900], [",", 909], ["by", 911], ["increasing", 914], ["platelet", 925], ["counts", 934], ["and", 941], ["inducing", 945], ["response", 954], ["rates", 963], [",", 968], ["respectively", 970], [".", 982], ["Fostamatinib", 984], ["is", 997], ["orally", 1000], ["bioavailable", 1007], ["and", 1020], ["was", 1024], ["well", 1028], ["tolerated", 1033], ["in", 1043], ["phase", 1046], ["I", 1052], ["and", 1054], ["II", 1058], ["trials", 1061], [",", 1067], ["with", 1069], ["the", 1074], ["most", 1078], ["common", 1083], ["side", 1090], ["effect", 1095], ["being", 1102], ["gastrointestinal", 1108], ["symptoms", 1125], [".", 1133], ["At", 1135], ["the", 1138], ["time", 1142], ["of", 1147], ["publication", 1150], [",", 1161], ["phase", 1163], ["II", 1169], ["trials", 1172], ["for", 1179], ["fostamatinib", 1183], ["were", 1196], ["ongoing", 1201], ["in", 1209], ["patients", 1212], ["with", 1221], ["RA", 1226], [",", 1228], ["ITP", 1230], ["and", 1234], ["B", 1238], ["-", 1239], ["cell", 1240], ["lymphomas", 1245], [".", 1254], ["The", 1256], ["Syk", 1260], ["inhibitor", 1264], ["appears", 1274], ["to", 1282], ["be", 1285], ["a", 1288], ["promising", 1290], ["therapeutic", 1300], ["for", 1312], ["immunological", 1316], ["diseases", 1330], [",", 1338], ["but", 1340], ["further", 1344], ["data", 1352], ["are", 1357], ["required", 1361], ["to", 1370], ["establish", 1373], ["the", 1383], ["efficacy", 1387], ["and", 1396], ["long", 1400], ["-", 1404], ["term", 1405], ["safety", 1410], ["of", 1417], ["the", 1420], ["drug", 1424], ["in", 1429], ["humans", 1432], [".", 1438]]}
{"context": "Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "93b3fce4ac844f3493818175471378b0", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[7, 7]], "char_spans": [[35, 39]]}]}], "context_tokens": [["Empagliflozin", 0], ["(", 14], ["Jardiance", 15], [")", 24], [":", 25], ["a", 27], ["novel", 29], ["SGLT2", 35], ["inhibitor", 41], ["for", 51], ["the", 55], ["treatment", 59], ["of", 69], ["type-2", 72], ["diabetes", 79], [".", 87]]}
{"context": "Marfanoid phenotype with craniosynostosis (Shprintzen-Goldberg syndrome) is a rare disorder previously described in only 5 patients. We report on the sixth known patient with this condition. The findings which distinguish our patient from others reported previously are that she was ascertained prenatally as having a cloverleaf skull; this is the first female patient described with this condition. Postnatally, she presented with arachnodactyly, camptodactyly, and clover-leaf skull. Imaging studies of the brain documented microcephaly with malformed brain, hydrocephaly, and hypoplasia of the corpus callosum. She also had choanal atresia and stenosis, a clinical finding previously reported only once, in this disorder.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "78c142601b5048dd9ab83e39d4e8e15f", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[3, 3]], "char_spans": [[25, 40]]}]}], "context_tokens": [["Marfanoid", 0], ["phenotype", 10], ["with", 20], ["craniosynostosis", 25], ["(", 42], ["Shprintzen", 43], ["-", 53], ["Goldberg", 54], ["syndrome", 63], [")", 71], ["is", 73], ["a", 76], ["rare", 78], ["disorder", 83], ["previously", 92], ["described", 103], ["in", 113], ["only", 116], ["5", 121], ["patients", 123], [".", 131], ["We", 133], ["report", 136], ["on", 143], ["the", 146], ["sixth", 150], ["known", 156], ["patient", 162], ["with", 170], ["this", 175], ["condition", 180], [".", 189], ["The", 191], ["findings", 195], ["which", 204], ["distinguish", 210], ["our", 222], ["patient", 226], ["from", 234], ["others", 239], ["reported", 246], ["previously", 255], ["are", 266], ["that", 270], ["she", 275], ["was", 279], ["ascertained", 283], ["prenatally", 295], ["as", 306], ["having", 309], ["a", 316], ["cloverleaf", 318], ["skull", 329], [";", 334], ["this", 336], ["is", 341], ["the", 344], ["first", 348], ["female", 354], ["patient", 361], ["described", 369], ["with", 379], ["this", 384], ["condition", 389], [".", 398], ["Postnatally", 400], [",", 411], ["she", 413], ["presented", 417], ["with", 427], ["arachnodactyly", 432], [",", 446], ["camptodactyly", 448], [",", 461], ["and", 463], ["clover", 467], ["-", 473], ["leaf", 474], ["skull", 479], [".", 484], ["Imaging", 486], ["studies", 494], ["of", 502], ["the", 505], ["brain", 509], ["documented", 515], ["microcephaly", 526], ["with", 539], ["malformed", 544], ["brain", 554], [",", 559], ["hydrocephaly", 561], [",", 573], ["and", 575], ["hypoplasia", 579], ["of", 590], ["the", 593], ["corpus", 597], ["callosum", 604], [".", 612], ["She", 614], ["also", 618], ["had", 623], ["choanal", 627], ["atresia", 635], ["and", 643], ["stenosis", 647], [",", 655], ["a", 657], ["clinical", 659], ["finding", 668], ["previously", 676], ["reported", 687], ["only", 696], ["once", 701], [",", 705], ["in", 707], ["this", 710], ["disorder", 715], [".", 723]]}
{"context": "Dopa decarboxylase (DDC), a pyridoxal 5'-phosphate (PLP) enzyme responsible for the biosynthesis of dopamine and serotonin, is involved in Parkinson's disease (PD). PD is a neurodegenerative disease mainly due to a progressive loss of dopamine-producing cells in the midbrain. Co-administration of L-Dopa with peripheral DDC inhibitors (carbidopa or benserazide) is the most effective symptomatic treatment for PD. Although carbidopa and trihydroxybenzylhydrazine (the in vivo hydrolysis product of benserazide) are both powerful irreversible DDC inhibitors, they are not selective because they irreversibly bind to free PLP and PLP-enzymes, thus inducing diverse side effects. Therefore, the main goals of this study were (a) to use virtual screening to identify potential human DDC inhibitors and (b) to evaluate the reliability of our virtual-screening (VS) protocol by experimentally testing the \"in vitro\" activity of selected molecules. Starting from the crystal structure of the DDC-carbidopa complex, a new VS protocol, integrating pharmacophore searches and molecular docking, was developed. Analysis of 15 selected compounds, obtained by filtering the public ZINC database, yielded two molecules that bind to the active site of human DDC and behave as competitive inhibitors with K(i) values \u226510 \u00b5M. By performing in silico similarity search on the latter compounds followed by a substructure search using the core of the most active compound we identified several competitive inhibitors of human DDC with K(i) values in the low micromolar range, unable to bind free PLP, and predicted to not cross the blood-brain barrier. The most potent inhibitor with a K(i) value of 500 nM represents a new lead compound, targeting human DDC, that may be the basis for lead optimization in the development of new DDC inhibitors. To our knowledge, a similar approach has not been reported yet in the field of DDC inhibitors discovery.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "d11256fd28f844698bd688152f464ae5", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[56, 58]], "char_spans": [[298, 303]]}]}], "context_tokens": [["Dopa", 0], ["decarboxylase", 5], ["(", 19], ["DDC", 20], [")", 23], [",", 24], ["a", 26], ["pyridoxal", 28], ["5'-phosphate", 38], ["(", 51], ["PLP", 52], [")", 55], ["enzyme", 57], ["responsible", 64], ["for", 76], ["the", 80], ["biosynthesis", 84], ["of", 97], ["dopamine", 100], ["and", 109], ["serotonin", 113], [",", 122], ["is", 124], ["involved", 127], ["in", 136], ["Parkinson", 139], ["'s", 148], ["disease", 151], ["(", 159], ["PD", 160], [")", 162], [".", 163], ["PD", 165], ["is", 168], ["a", 171], ["neurodegenerative", 173], ["disease", 191], ["mainly", 199], ["due", 206], ["to", 210], ["a", 213], ["progressive", 215], ["loss", 227], ["of", 232], ["dopamine", 235], ["-", 243], ["producing", 244], ["cells", 254], ["in", 260], ["the", 263], ["midbrain", 267], [".", 275], ["Co", 277], ["-", 279], ["administration", 280], ["of", 295], ["L", 298], ["-", 299], ["Dopa", 300], ["with", 305], ["peripheral", 310], ["DDC", 321], ["inhibitors", 325], ["(", 336], ["carbidopa", 337], ["or", 347], ["benserazide", 350], [")", 361], ["is", 363], ["the", 366], ["most", 370], ["effective", 375], ["symptomatic", 385], ["treatment", 397], ["for", 407], ["PD", 411], [".", 413], ["Although", 415], ["carbidopa", 424], ["and", 434], ["trihydroxybenzylhydrazine", 438], ["(", 464], ["the", 465], ["in", 469], ["vivo", 472], ["hydrolysis", 477], ["product", 488], ["of", 496], ["benserazide", 499], [")", 510], ["are", 512], ["both", 516], ["powerful", 521], ["irreversible", 530], ["DDC", 543], ["inhibitors", 547], [",", 557], ["they", 559], ["are", 564], ["not", 568], ["selective", 572], ["because", 582], ["they", 590], ["irreversibly", 595], ["bind", 608], ["to", 613], ["free", 616], ["PLP", 621], ["and", 625], ["PLP", 629], ["-", 632], ["enzymes", 633], [",", 640], ["thus", 642], ["inducing", 647], ["diverse", 656], ["side", 664], ["effects", 669], [".", 676], ["Therefore", 678], [",", 687], ["the", 689], ["main", 693], ["goals", 698], ["of", 704], ["this", 707], ["study", 712], ["were", 718], ["(", 723], ["a", 724], [")", 725], ["to", 727], ["use", 730], ["virtual", 734], ["screening", 742], ["to", 752], ["identify", 755], ["potential", 764], ["human", 774], ["DDC", 780], ["inhibitors", 784], ["and", 795], ["(", 799], ["b", 800], [")", 801], ["to", 803], ["evaluate", 806], ["the", 815], ["reliability", 819], ["of", 831], ["our", 834], ["virtual", 838], ["-", 845], ["screening", 846], ["(", 856], ["VS", 857], [")", 859], ["protocol", 861], ["by", 870], ["experimentally", 873], ["testing", 888], ["the", 896], ["\"", 900], ["in", 901], ["vitro", 904], ["\"", 909], ["activity", 911], ["of", 920], ["selected", 923], ["molecules", 932], [".", 941], ["Starting", 943], ["from", 952], ["the", 957], ["crystal", 961], ["structure", 969], ["of", 979], ["the", 982], ["DDC", 986], ["-", 989], ["carbidopa", 990], ["complex", 1000], [",", 1007], ["a", 1009], ["new", 1011], ["VS", 1015], ["protocol", 1018], [",", 1026], ["integrating", 1028], ["pharmacophore", 1040], ["searches", 1054], ["and", 1063], ["molecular", 1067], ["docking", 1077], [",", 1084], ["was", 1086], ["developed", 1090], [".", 1099], ["Analysis", 1101], ["of", 1110], ["15", 1113], ["selected", 1116], ["compounds", 1125], [",", 1134], ["obtained", 1136], ["by", 1145], ["filtering", 1148], ["the", 1158], ["public", 1162], ["ZINC", 1169], ["database", 1174], [",", 1182], ["yielded", 1184], ["two", 1192], ["molecules", 1196], ["that", 1206], ["bind", 1211], ["to", 1216], ["the", 1219], ["active", 1223], ["site", 1230], ["of", 1235], ["human", 1238], ["DDC", 1244], ["and", 1248], ["behave", 1252], ["as", 1259], ["competitive", 1262], ["inhibitors", 1274], ["with", 1285], ["K(i", 1290], [")", 1293], ["values", 1295], ["\u226510", 1302], ["\u00b5M.", 1306], ["By", 1310], ["performing", 1313], ["in", 1324], ["silico", 1327], ["similarity", 1334], ["search", 1345], ["on", 1352], ["the", 1355], ["latter", 1359], ["compounds", 1366], ["followed", 1376], ["by", 1385], ["a", 1388], ["substructure", 1390], ["search", 1403], ["using", 1410], ["the", 1416], ["core", 1420], ["of", 1425], ["the", 1428], ["most", 1432], ["active", 1437], ["compound", 1444], ["we", 1453], ["identified", 1456], ["several", 1467], ["competitive", 1475], ["inhibitors", 1487], ["of", 1498], ["human", 1501], ["DDC", 1507], ["with", 1511], ["K(i", 1516], [")", 1519], ["values", 1521], ["in", 1528], ["the", 1531], ["low", 1535], ["micromolar", 1539], ["range", 1550], [",", 1555], ["unable", 1557], ["to", 1564], ["bind", 1567], ["free", 1572], ["PLP", 1577], [",", 1580], ["and", 1582], ["predicted", 1586], ["to", 1596], ["not", 1599], ["cross", 1603], ["the", 1609], ["blood", 1613], ["-", 1618], ["brain", 1619], ["barrier", 1625], [".", 1632], ["The", 1634], ["most", 1638], ["potent", 1643], ["inhibitor", 1650], ["with", 1660], ["a", 1665], ["K(i", 1667], [")", 1670], ["value", 1672], ["of", 1678], ["500", 1681], ["nM", 1685], ["represents", 1688], ["a", 1699], ["new", 1701], ["lead", 1705], ["compound", 1710], [",", 1718], ["targeting", 1720], ["human", 1730], ["DDC", 1736], [",", 1739], ["that", 1741], ["may", 1746], ["be", 1750], ["the", 1753], ["basis", 1757], ["for", 1763], ["lead", 1767], ["optimization", 1772], ["in", 1785], ["the", 1788], ["development", 1792], ["of", 1804], ["new", 1807], ["DDC", 1811], ["inhibitors", 1815], [".", 1825], ["To", 1827], ["our", 1830], ["knowledge", 1834], [",", 1843], ["a", 1845], ["similar", 1847], ["approach", 1855], ["has", 1864], ["not", 1868], ["been", 1872], ["reported", 1877], ["yet", 1886], ["in", 1890], ["the", 1893], ["field", 1897], ["of", 1903], ["DDC", 1906], ["inhibitors", 1910], ["discovery", 1921], [".", 1930]]}
{"context": "To develop polymeric films containing dual combinations of anti-HIV drug candidate tenofovir, maraviroc and dapivirine for vaginal application as topical microbicides. A solvent casting method was used to manufacture the films. Solid phase solubility was used to identify potential polymers for use in the film formulation. Physical and chemical properties (such as water content, puncture strength and in vitro release) and product stability were determined. The bioactivity of the film products against HIV was assessed using the TZM-bl assay and a cervical explant model. Polymers identified from the solid phase solubility study maintained tenofovir and maraviroc in an amorphous state and prevented drug crystallization. Three combination film products were developed using cellulose polymers and polyvinyl alcohol. The residual water content in all films was <10% (w/w). All films delivered the active agents with release of >50% of film drug content within 30 min. Stability testing confirmed that the combination film products were stable for 12 months at ambient temperature and 6 months under stressed conditions. Antiviral activity was confirmed in TZM-bl and cervical explant models. Polymeric films can be used as a stable dosage form for the delivery of antiretroviral combinations as microbicides.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "387330c38e704509996ffc03774c1391", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[82, 82], [10, 10]], "char_spans": [[505, 507], [64, 66]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["polymeric", 11], ["films", 21], ["containing", 27], ["dual", 38], ["combinations", 43], ["of", 56], ["anti", 59], ["-", 63], ["HIV", 64], ["drug", 68], ["candidate", 73], ["tenofovir", 83], [",", 92], ["maraviroc", 94], ["and", 104], ["dapivirine", 108], ["for", 119], ["vaginal", 123], ["application", 131], ["as", 143], ["topical", 146], ["microbicides", 154], [".", 166], ["A", 168], ["solvent", 170], ["casting", 178], ["method", 186], ["was", 193], ["used", 197], ["to", 202], ["manufacture", 205], ["the", 217], ["films", 221], [".", 226], ["Solid", 228], ["phase", 234], ["solubility", 240], ["was", 251], ["used", 255], ["to", 260], ["identify", 263], ["potential", 272], ["polymers", 282], ["for", 291], ["use", 295], ["in", 299], ["the", 302], ["film", 306], ["formulation", 311], [".", 322], ["Physical", 324], ["and", 333], ["chemical", 337], ["properties", 346], ["(", 357], ["such", 358], ["as", 363], ["water", 366], ["content", 372], [",", 379], ["puncture", 381], ["strength", 390], ["and", 399], ["in", 403], ["vitro", 406], ["release", 412], [")", 419], ["and", 421], ["product", 425], ["stability", 433], ["were", 443], ["determined", 448], [".", 458], ["The", 460], ["bioactivity", 464], ["of", 476], ["the", 479], ["film", 483], ["products", 488], ["against", 497], ["HIV", 505], ["was", 509], ["assessed", 513], ["using", 522], ["the", 528], ["TZM", 532], ["-", 535], ["bl", 536], ["assay", 539], ["and", 545], ["a", 549], ["cervical", 551], ["explant", 560], ["model", 568], [".", 573], ["Polymers", 575], ["identified", 584], ["from", 595], ["the", 600], ["solid", 604], ["phase", 610], ["solubility", 616], ["study", 627], ["maintained", 633], ["tenofovir", 644], ["and", 654], ["maraviroc", 658], ["in", 668], ["an", 671], ["amorphous", 674], ["state", 684], ["and", 690], ["prevented", 694], ["drug", 704], ["crystallization", 709], [".", 724], ["Three", 726], ["combination", 732], ["film", 744], ["products", 749], ["were", 758], ["developed", 763], ["using", 773], ["cellulose", 779], ["polymers", 789], ["and", 798], ["polyvinyl", 802], ["alcohol", 812], [".", 819], ["The", 821], ["residual", 825], ["water", 834], ["content", 840], ["in", 848], ["all", 851], ["films", 855], ["was", 861], ["<", 865], ["10", 866], ["%", 868], ["(", 870], ["w", 871], ["/", 872], ["w", 873], [")", 874], [".", 875], ["All", 877], ["films", 881], ["delivered", 887], ["the", 897], ["active", 901], ["agents", 908], ["with", 915], ["release", 920], ["of", 928], [">", 931], ["50", 932], ["%", 934], ["of", 936], ["film", 939], ["drug", 944], ["content", 949], ["within", 957], ["30", 964], ["min", 967], [".", 970], ["Stability", 972], ["testing", 982], ["confirmed", 990], ["that", 1000], ["the", 1005], ["combination", 1009], ["film", 1021], ["products", 1026], ["were", 1035], ["stable", 1040], ["for", 1047], ["12", 1051], ["months", 1054], ["at", 1061], ["ambient", 1064], ["temperature", 1072], ["and", 1084], ["6", 1088], ["months", 1090], ["under", 1097], ["stressed", 1103], ["conditions", 1112], [".", 1122], ["Antiviral", 1124], ["activity", 1134], ["was", 1143], ["confirmed", 1147], ["in", 1157], ["TZM", 1160], ["-", 1163], ["bl", 1164], ["and", 1167], ["cervical", 1171], ["explant", 1180], ["models", 1188], [".", 1194], ["Polymeric", 1196], ["films", 1206], ["can", 1212], ["be", 1216], ["used", 1219], ["as", 1224], ["a", 1227], ["stable", 1229], ["dosage", 1236], ["form", 1243], ["for", 1248], ["the", 1252], ["delivery", 1256], ["of", 1265], ["antiretroviral", 1268], ["combinations", 1283], ["as", 1296], ["microbicides", 1299], [".", 1311]]}
{"context": "Spleen tyrosine kinase (Syk) has been identified as an important modulator of immune signaling in B cells and cells bearing Fcgamma-activating receptors. R788, a prodrug of active metabolite R406, has been shown to be an inhibitor of Syk kinase, active in a variety of in vitro and in vivo models, suggesting potential activity in the treatment of rheumatoid arthritis (RA). We enrolled 189 patients with active RA despite methotrexate therapy in a 3-month, multicenter, ascending-dose, double-blind, placebo-controlled trial. The primary end point was the American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 12. Twice-daily oral doses of 100 mg and 150 mg of R788 were significantly superior to placebo or twice-daily oral doses of 50 mg at week 12 (ACR20 achieved in 65% and 72% versus 38% and 32% of patients, respectively [P < 0.01]). ACR50 (achieved in 49% and 57% versus 19% and 17% of patients, respectively) and ACR70 (achieved in 33% and 40% versus 4% and 2% of patients, respectively) scores showed a similar pattern. Clinical effect was noted as early as 1 week after initiation of therapy. Reductions in serum interleukin-6 and matrix metalloproteinase 3 levels also occurred as early as week 1 in the groups receiving 100 mg and 150 mg R788. The major adverse effects were gastrointestinal side effects (predominantly diarrhea) and neutropenia (<1,500/mm3), both of which were dose related. These results indicate that an inhibitor of Syk kinase produces significant clinical benefits at 12 weeks in a population of patients with active RA receiving methotrexate therapy. Syk kinase may be an important new therapeutic target in RA and related autoimmune conditions.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "782a069dddc14cda828565a5f8c628ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Spleen", 0], ["tyrosine", 7], ["kinase", 16], ["(", 23], ["Syk", 24], [")", 27], ["has", 29], ["been", 33], ["identified", 38], ["as", 49], ["an", 52], ["important", 55], ["modulator", 65], ["of", 75], ["immune", 78], ["signaling", 85], ["in", 95], ["B", 98], ["cells", 100], ["and", 106], ["cells", 110], ["bearing", 116], ["Fcgamma", 124], ["-", 131], ["activating", 132], ["receptors", 143], [".", 152], ["R788", 154], [",", 158], ["a", 160], ["prodrug", 162], ["of", 170], ["active", 173], ["metabolite", 180], ["R406", 191], [",", 195], ["has", 197], ["been", 201], ["shown", 206], ["to", 212], ["be", 215], ["an", 218], ["inhibitor", 221], ["of", 231], ["Syk", 234], ["kinase", 238], [",", 244], ["active", 246], ["in", 253], ["a", 256], ["variety", 258], ["of", 266], ["in", 269], ["vitro", 272], ["and", 278], ["in", 282], ["vivo", 285], ["models", 290], [",", 296], ["suggesting", 298], ["potential", 309], ["activity", 319], ["in", 328], ["the", 331], ["treatment", 335], ["of", 345], ["rheumatoid", 348], ["arthritis", 359], ["(", 369], ["RA", 370], [")", 372], [".", 373], ["We", 375], ["enrolled", 378], ["189", 387], ["patients", 391], ["with", 400], ["active", 405], ["RA", 412], ["despite", 415], ["methotrexate", 423], ["therapy", 436], ["in", 444], ["a", 447], ["3-month", 449], [",", 456], ["multicenter", 458], [",", 469], ["ascending", 471], ["-", 480], ["dose", 481], [",", 485], ["double", 487], ["-", 493], ["blind", 494], [",", 499], ["placebo", 501], ["-", 508], ["controlled", 509], ["trial", 520], [".", 525], ["The", 527], ["primary", 531], ["end", 539], ["point", 543], ["was", 549], ["the", 553], ["American", 557], ["College", 566], ["of", 574], ["Rheumatology", 577], ["20", 590], ["%", 592], ["improvement", 594], ["criteria", 606], ["(", 615], ["ACR20", 616], [")", 621], ["response", 623], ["rate", 632], ["at", 637], ["week", 640], ["12", 645], [".", 647], ["Twice", 649], ["-", 654], ["daily", 655], ["oral", 661], ["doses", 666], ["of", 672], ["100", 675], ["mg", 679], ["and", 682], ["150", 686], ["mg", 690], ["of", 693], ["R788", 696], ["were", 701], ["significantly", 706], ["superior", 720], ["to", 729], ["placebo", 732], ["or", 740], ["twice", 743], ["-", 748], ["daily", 749], ["oral", 755], ["doses", 760], ["of", 766], ["50", 769], ["mg", 772], ["at", 775], ["week", 778], ["12", 783], ["(", 786], ["ACR20", 787], ["achieved", 793], ["in", 802], ["65", 805], ["%", 807], ["and", 809], ["72", 813], ["%", 815], ["versus", 817], ["38", 824], ["%", 826], ["and", 828], ["32", 832], ["%", 834], ["of", 836], ["patients", 839], [",", 847], ["respectively", 849], ["[", 862], ["P", 863], ["<", 865], ["0.01", 867], ["]", 871], [")", 872], [".", 873], ["ACR50", 875], ["(", 881], ["achieved", 882], ["in", 891], ["49", 894], ["%", 896], ["and", 898], ["57", 902], ["%", 904], ["versus", 906], ["19", 913], ["%", 915], ["and", 917], ["17", 921], ["%", 923], ["of", 925], ["patients", 928], [",", 936], ["respectively", 938], [")", 950], ["and", 952], ["ACR70", 956], ["(", 962], ["achieved", 963], ["in", 972], ["33", 975], ["%", 977], ["and", 979], ["40", 983], ["%", 985], ["versus", 987], ["4", 994], ["%", 995], ["and", 997], ["2", 1001], ["%", 1002], ["of", 1004], ["patients", 1007], [",", 1015], ["respectively", 1017], [")", 1029], ["scores", 1031], ["showed", 1038], ["a", 1045], ["similar", 1047], ["pattern", 1055], [".", 1062], ["Clinical", 1064], ["effect", 1073], ["was", 1080], ["noted", 1084], ["as", 1090], ["early", 1093], ["as", 1099], ["1", 1102], ["week", 1104], ["after", 1109], ["initiation", 1115], ["of", 1126], ["therapy", 1129], [".", 1136], ["Reductions", 1138], ["in", 1149], ["serum", 1152], ["interleukin-6", 1158], ["and", 1172], ["matrix", 1176], ["metalloproteinase", 1183], ["3", 1201], ["levels", 1203], ["also", 1210], ["occurred", 1215], ["as", 1224], ["early", 1227], ["as", 1233], ["week", 1236], ["1", 1241], ["in", 1243], ["the", 1246], ["groups", 1250], ["receiving", 1257], ["100", 1267], ["mg", 1271], ["and", 1274], ["150", 1278], ["mg", 1282], ["R788", 1285], [".", 1289], ["The", 1291], ["major", 1295], ["adverse", 1301], ["effects", 1309], ["were", 1317], ["gastrointestinal", 1322], ["side", 1339], ["effects", 1344], ["(", 1352], ["predominantly", 1353], ["diarrhea", 1367], [")", 1375], ["and", 1377], ["neutropenia", 1381], ["(", 1393], ["<", 1394], ["1,500/mm3", 1395], [")", 1404], [",", 1405], ["both", 1407], ["of", 1412], ["which", 1415], ["were", 1421], ["dose", 1426], ["related", 1431], [".", 1438], ["These", 1440], ["results", 1446], ["indicate", 1454], ["that", 1463], ["an", 1468], ["inhibitor", 1471], ["of", 1481], ["Syk", 1484], ["kinase", 1488], ["produces", 1495], ["significant", 1504], ["clinical", 1516], ["benefits", 1525], ["at", 1534], ["12", 1537], ["weeks", 1540], ["in", 1546], ["a", 1549], ["population", 1551], ["of", 1562], ["patients", 1565], ["with", 1574], ["active", 1579], ["RA", 1586], ["receiving", 1589], ["methotrexate", 1599], ["therapy", 1612], [".", 1619], ["Syk", 1621], ["kinase", 1625], ["may", 1632], ["be", 1636], ["an", 1639], ["important", 1642], ["new", 1652], ["therapeutic", 1656], ["target", 1668], ["in", 1675], ["RA", 1678], ["and", 1681], ["related", 1685], ["autoimmune", 1693], ["conditions", 1704], [".", 1714]]}
{"context": "The Na(+)/Ca(2+) exchanger (NCX) plays a role in the regulation of intracellular Ca(2+) levels, and nitric oxide (NO) is involved in many pathological conditions including neurodegenerative disorders. We have previously found that sodium nitroprusside (SNP), an NO donor, causes apoptotic-like cell death in cultured glial cells via NCX-mediated pathways and the mechanism for NO-induced cytotoxicity is cell type-dependent. The present study examined using the specific NCX inhibitor 2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline (SEA0400) whether NCX is involved in NO-induced injury in cultured neuronal cells. The treatment of neuroblastoma SH-SY5Y cells with SNP resulted in apoptosis and the cytotoxicity was blocked by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor U0126 and the p38 MAP kinase (MAPK) inhibitor SB203580, but not by the c-Jun N-terminal kinase (JNK) inhibitor SP60012. SNP increased Ca(2+) influx and intracellular Ca(2+) levels. In addition, SNP increased ERK and p38 MAPK phosphorylation, and production of reactive oxygen species (ROS) in an extracellular Ca(2+)-dependent manner. These effects of SNP were prevented by SEA0400. SNP-induced cytotoxicity was not affected by inhibitors of the Ca(2+), Na(+) and store-operated/capacitative channels. Moreover, SNP-induced increase in intracellular Ca(2+) levels, ROS production and decrease in cell viability were blocked by a cGMP-dependent protein kinase (PKG) inhibitor. These results suggest that Ca(2+) influx via the reverse of NCX is involved in the cascade of NO-induced neuronal apoptosis and NO activates the NCX through guanylate cyclase/PKG pathway.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "78c14f714e4744988b69ad994964895d", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[1, 4]], "char_spans": [[4, 25]]}, {"text": "NCX", "token_spans": [[291, 291], [307, 307], [6, 6], [63, 63], [88, 88], [95, 95]], "char_spans": [[1572, 1574], [1657, 1659], [28, 30], [333, 335], [471, 473], [562, 564]]}]}], "context_tokens": [["The", 0], ["Na(+)/Ca(2", 4], ["+", 14], [")", 15], ["exchanger", 17], ["(", 27], ["NCX", 28], [")", 31], ["plays", 33], ["a", 39], ["role", 41], ["in", 46], ["the", 49], ["regulation", 53], ["of", 64], ["intracellular", 67], ["Ca(2", 81], ["+", 85], [")", 86], ["levels", 88], [",", 94], ["and", 96], ["nitric", 100], ["oxide", 107], ["(", 113], ["NO", 114], [")", 116], ["is", 118], ["involved", 121], ["in", 130], ["many", 133], ["pathological", 138], ["conditions", 151], ["including", 162], ["neurodegenerative", 172], ["disorders", 190], [".", 199], ["We", 201], ["have", 204], ["previously", 209], ["found", 220], ["that", 226], ["sodium", 231], ["nitroprusside", 238], ["(", 252], ["SNP", 253], [")", 256], [",", 257], ["an", 259], ["NO", 262], ["donor", 265], [",", 270], ["causes", 272], ["apoptotic", 279], ["-", 288], ["like", 289], ["cell", 294], ["death", 299], ["in", 305], ["cultured", 308], ["glial", 317], ["cells", 323], ["via", 329], ["NCX", 333], ["-", 336], ["mediated", 337], ["pathways", 346], ["and", 355], ["the", 359], ["mechanism", 363], ["for", 373], ["NO", 377], ["-", 379], ["induced", 380], ["cytotoxicity", 388], ["is", 401], ["cell", 404], ["type", 409], ["-", 413], ["dependent", 414], [".", 423], ["The", 425], ["present", 429], ["study", 437], ["examined", 443], ["using", 452], ["the", 458], ["specific", 462], ["NCX", 471], ["inhibitor", 475], ["2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline", 485], ["(", 544], ["SEA0400", 545], [")", 552], ["whether", 554], ["NCX", 562], ["is", 566], ["involved", 569], ["in", 578], ["NO", 581], ["-", 583], ["induced", 584], ["injury", 592], ["in", 599], ["cultured", 602], ["neuronal", 611], ["cells", 620], [".", 625], ["The", 627], ["treatment", 631], ["of", 641], ["neuroblastoma", 644], ["SH", 658], ["-", 660], ["SY5Y", 661], ["cells", 666], ["with", 672], ["SNP", 677], ["resulted", 681], ["in", 690], ["apoptosis", 693], ["and", 703], ["the", 707], ["cytotoxicity", 711], ["was", 724], ["blocked", 728], ["by", 736], ["the", 739], ["mitogen", 743], ["-", 750], ["activated", 751], ["protein", 761], ["(", 769], ["MAP)/extracellular", 770], ["signal", 789], ["-", 795], ["regulated", 796], ["kinase", 806], ["(", 813], ["ERK", 814], [")", 817], ["kinase", 819], ["inhibitor", 826], ["U0126", 836], ["and", 842], ["the", 846], ["p38", 850], ["MAP", 854], ["kinase", 858], ["(", 865], ["MAPK", 866], [")", 870], ["inhibitor", 872], ["SB203580", 882], [",", 890], ["but", 892], ["not", 896], ["by", 900], ["the", 903], ["c", 907], ["-", 908], ["Jun", 909], ["N", 913], ["-", 914], ["terminal", 915], ["kinase", 924], ["(", 931], ["JNK", 932], [")", 935], ["inhibitor", 937], ["SP60012", 947], [".", 954], ["SNP", 956], ["increased", 960], ["Ca(2", 970], ["+", 974], [")", 975], ["influx", 977], ["and", 984], ["intracellular", 988], ["Ca(2", 1002], ["+", 1006], [")", 1007], ["levels", 1009], [".", 1015], ["In", 1017], ["addition", 1020], [",", 1028], ["SNP", 1030], ["increased", 1034], ["ERK", 1044], ["and", 1048], ["p38", 1052], ["MAPK", 1056], ["phosphorylation", 1061], [",", 1076], ["and", 1078], ["production", 1082], ["of", 1093], ["reactive", 1096], ["oxygen", 1105], ["species", 1112], ["(", 1120], ["ROS", 1121], [")", 1124], ["in", 1126], ["an", 1129], ["extracellular", 1132], ["Ca(2+)-dependent", 1146], ["manner", 1163], [".", 1169], ["These", 1171], ["effects", 1177], ["of", 1185], ["SNP", 1188], ["were", 1192], ["prevented", 1197], ["by", 1207], ["SEA0400", 1210], [".", 1217], ["SNP", 1219], ["-", 1222], ["induced", 1223], ["cytotoxicity", 1231], ["was", 1244], ["not", 1248], ["affected", 1252], ["by", 1261], ["inhibitors", 1264], ["of", 1275], ["the", 1278], ["Ca(2", 1282], ["+", 1286], [")", 1287], [",", 1288], ["Na(+", 1290], [")", 1294], ["and", 1296], ["store", 1300], ["-", 1305], ["operated", 1306], ["/", 1314], ["capacitative", 1315], ["channels", 1328], [".", 1336], ["Moreover", 1338], [",", 1346], ["SNP", 1348], ["-", 1351], ["induced", 1352], ["increase", 1360], ["in", 1369], ["intracellular", 1372], ["Ca(2", 1386], ["+", 1390], [")", 1391], ["levels", 1393], [",", 1399], ["ROS", 1401], ["production", 1405], ["and", 1416], ["decrease", 1420], ["in", 1429], ["cell", 1432], ["viability", 1437], ["were", 1447], ["blocked", 1452], ["by", 1460], ["a", 1463], ["cGMP", 1465], ["-", 1469], ["dependent", 1470], ["protein", 1480], ["kinase", 1488], ["(", 1495], ["PKG", 1496], [")", 1499], ["inhibitor", 1501], [".", 1510], ["These", 1512], ["results", 1518], ["suggest", 1526], ["that", 1534], ["Ca(2", 1539], ["+", 1543], [")", 1544], ["influx", 1546], ["via", 1553], ["the", 1557], ["reverse", 1561], ["of", 1569], ["NCX", 1572], ["is", 1576], ["involved", 1579], ["in", 1588], ["the", 1591], ["cascade", 1595], ["of", 1603], ["NO", 1606], ["-", 1608], ["induced", 1609], ["neuronal", 1617], ["apoptosis", 1626], ["and", 1636], ["NO", 1640], ["activates", 1643], ["the", 1653], ["NCX", 1657], ["through", 1661], ["guanylate", 1669], ["cyclase", 1679], ["/", 1686], ["PKG", 1687], ["pathway", 1691], [".", 1698]]}
{"context": "Using a rat model of L-DOPA-induced dyskinesia (LID), the contributions of dopamine D1 and D2 receptors to axial, limb, and orolingual (ALO) abnormal involuntary movements (AIMs) elicited by L-DOPA were examined. Chronic L-DOPA-treated rats received the D1 receptor antagonist SCH23390 (0.01, 0.1, and 1.0 mg/kg; i.p.), the D2 receptor antagonist Eticlopride (0.01, 0.1, and 1.0 mg/kg; i.p.), a mixture of both antagonists (0.01, 0.1, 1.0 mg/kg each; i.p.), or vehicle 30 min prior to L-DOPA (6 mg/kg; i.p.)+Benserazide (15 mg/kg; i.p.). SCH23390 (0.1 and 1.0 mg/kg) significantly reduced axial and limb AIMs, while the same doses of Eticlopride significantly decreased axial, limb, and orolingual AIMs. Co-administration of SCH23390+Eticlopride significantly reduced axial (0.01, 0.1 and 1.0 mg/kg), limb (0.1 and 1.0 mg/kg), and orolingual (0.1 and 1.0 mg/kg) AIMs. These results indicate the importance of D1 and D2 receptors to LID and further validate the rat AIMs model.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "cef4a7fbb56948418ee4895ae79c5294", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[121, 123], [5, 7], [48, 50], [41, 43]], "char_spans": [[485, 490], [21, 26], [221, 226], [191, 196]]}]}], "context_tokens": [["Using", 0], ["a", 6], ["rat", 8], ["model", 12], ["of", 18], ["L", 21], ["-", 22], ["DOPA", 23], ["-", 27], ["induced", 28], ["dyskinesia", 36], ["(", 47], ["LID", 48], [")", 51], [",", 52], ["the", 54], ["contributions", 58], ["of", 72], ["dopamine", 75], ["D1", 84], ["and", 87], ["D2", 91], ["receptors", 94], ["to", 104], ["axial", 107], [",", 112], ["limb", 114], [",", 118], ["and", 120], ["orolingual", 124], ["(", 135], ["ALO", 136], [")", 139], ["abnormal", 141], ["involuntary", 150], ["movements", 162], ["(", 172], ["AIMs", 173], [")", 177], ["elicited", 179], ["by", 188], ["L", 191], ["-", 192], ["DOPA", 193], ["were", 198], ["examined", 203], [".", 211], ["Chronic", 213], ["L", 221], ["-", 222], ["DOPA", 223], ["-", 227], ["treated", 228], ["rats", 236], ["received", 241], ["the", 250], ["D1", 254], ["receptor", 257], ["antagonist", 266], ["SCH23390", 277], ["(", 286], ["0.01", 287], [",", 291], ["0.1", 293], [",", 296], ["and", 298], ["1.0", 302], ["mg", 306], ["/", 308], ["kg", 309], [";", 311], ["i.p", 313], [".", 316], [")", 317], [",", 318], ["the", 320], ["D2", 324], ["receptor", 327], ["antagonist", 336], ["Eticlopride", 347], ["(", 359], ["0.01", 360], [",", 364], ["0.1", 366], [",", 369], ["and", 371], ["1.0", 375], ["mg", 379], ["/", 381], ["kg", 382], [";", 384], ["i.p", 386], [".", 389], [")", 390], [",", 391], ["a", 393], ["mixture", 395], ["of", 403], ["both", 406], ["antagonists", 411], ["(", 423], ["0.01", 424], [",", 428], ["0.1", 430], [",", 433], ["1.0", 435], ["mg", 439], ["/", 441], ["kg", 442], ["each", 445], [";", 449], ["i.p", 451], [".", 454], [")", 455], [",", 456], ["or", 458], ["vehicle", 461], ["30", 469], ["min", 472], ["prior", 476], ["to", 482], ["L", 485], ["-", 486], ["DOPA", 487], ["(", 492], ["6", 493], ["mg", 495], ["/", 497], ["kg", 498], [";", 500], ["i.p.)+Benserazide", 502], ["(", 520], ["15", 521], ["mg", 524], ["/", 526], ["kg", 527], [";", 529], ["i.p", 531], [".", 534], [")", 535], [".", 536], ["SCH23390", 538], ["(", 547], ["0.1", 548], ["and", 552], ["1.0", 556], ["mg", 560], ["/", 562], ["kg", 563], [")", 565], ["significantly", 567], ["reduced", 581], ["axial", 589], ["and", 595], ["limb", 599], ["AIMs", 604], [",", 608], ["while", 610], ["the", 616], ["same", 620], ["doses", 625], ["of", 631], ["Eticlopride", 634], ["significantly", 646], ["decreased", 660], ["axial", 670], [",", 675], ["limb", 677], [",", 681], ["and", 683], ["orolingual", 687], ["AIMs", 698], [".", 702], ["Co", 704], ["-", 706], ["administration", 707], ["of", 722], ["SCH23390+Eticlopride", 725], ["significantly", 746], ["reduced", 760], ["axial", 768], ["(", 774], ["0.01", 775], [",", 779], ["0.1", 781], ["and", 785], ["1.0", 789], ["mg", 793], ["/", 795], ["kg", 796], [")", 798], [",", 799], ["limb", 801], ["(", 806], ["0.1", 807], ["and", 811], ["1.0", 815], ["mg", 819], ["/", 821], ["kg", 822], [")", 824], [",", 825], ["and", 827], ["orolingual", 831], ["(", 842], ["0.1", 843], ["and", 847], ["1.0", 851], ["mg", 855], ["/", 857], ["kg", 858], [")", 860], ["AIMs", 862], [".", 866], ["These", 868], ["results", 874], ["indicate", 882], ["the", 891], ["importance", 895], ["of", 906], ["D1", 909], ["and", 912], ["D2", 916], ["receptors", 919], ["to", 929], ["LID", 932], ["and", 936], ["further", 940], ["validate", 948], ["the", 957], ["rat", 961], ["AIMs", 965], ["model", 970], [".", 975]]}
{"context": "The transcriptional networks that regulate embryonic stem (ES) cell pluripotency and lineage specification are the subject of considerable attention. To date such studies have focused almost exclusively on protein-coding transcripts. However, recent transcriptome analyses show that the mammalian genome contains thousands of long noncoding RNAs (ncRNAs), many of which appear to be expressed in a developmentally regulated manner. The functions of these remain untested. To identify ncRNAs involved in ES cell biology, we used a custom-designed microarray to examine the expression profiles of mouse ES cells differentiating as embryoid bodies (EBs) over a 16-d time course. We identified 945 ncRNAs expressed during EB differentiation, of which 174 were differentially expressed, many correlating with pluripotency or specific differentiation events. Candidate ncRNAs were identified for further characterization by an integrated examination of expression profiles, genomic context, chromatin state, and promoter analysis. Many ncRNAs showed coordinated expression with genomically associated developmental genes, such as Dlx1, Dlx4, Gata6, and Ecsit. We examined two novel developmentally regulated ncRNAs, Evx1as and Hoxb5/6as, which are derived from homeotic loci and share similar expression patterns and localization in mouse embryos with their associated protein-coding genes. Using chromatin immunoprecipitation, we provide evidence that both ncRNAs are associated with trimethylated H3K4 histones and histone methyltransferase MLL1, suggesting a role in epigenetic regulation of homeotic loci during ES cell differentiation. Taken together, our data indicate that long ncRNAs are likely to be important in processes directing pluripotency and alternative differentiation programs, in some cases through engagement of the epigenetic machinery.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "7f852a929e6a4b24adcfac462afb1477", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[236, 236]], "char_spans": [[1493, 1496]]}]}], "context_tokens": [["The", 0], ["transcriptional", 4], ["networks", 20], ["that", 29], ["regulate", 34], ["embryonic", 43], ["stem", 53], ["(", 58], ["ES", 59], [")", 61], ["cell", 63], ["pluripotency", 68], ["and", 81], ["lineage", 85], ["specification", 93], ["are", 107], ["the", 111], ["subject", 115], ["of", 123], ["considerable", 126], ["attention", 139], [".", 148], ["To", 150], ["date", 153], ["such", 158], ["studies", 163], ["have", 171], ["focused", 176], ["almost", 184], ["exclusively", 191], ["on", 203], ["protein", 206], ["-", 213], ["coding", 214], ["transcripts", 221], [".", 232], ["However", 234], [",", 241], ["recent", 243], ["transcriptome", 250], ["analyses", 264], ["show", 273], ["that", 278], ["the", 283], ["mammalian", 287], ["genome", 297], ["contains", 304], ["thousands", 313], ["of", 323], ["long", 326], ["noncoding", 331], ["RNAs", 341], ["(", 346], ["ncRNAs", 347], [")", 353], [",", 354], ["many", 356], ["of", 361], ["which", 364], ["appear", 370], ["to", 377], ["be", 380], ["expressed", 383], ["in", 393], ["a", 396], ["developmentally", 398], ["regulated", 414], ["manner", 424], [".", 430], ["The", 432], ["functions", 436], ["of", 446], ["these", 449], ["remain", 455], ["untested", 462], [".", 470], ["To", 472], ["identify", 475], ["ncRNAs", 484], ["involved", 491], ["in", 500], ["ES", 503], ["cell", 506], ["biology", 511], [",", 518], ["we", 520], ["used", 523], ["a", 528], ["custom", 530], ["-", 536], ["designed", 537], ["microarray", 546], ["to", 557], ["examine", 560], ["the", 568], ["expression", 572], ["profiles", 583], ["of", 592], ["mouse", 595], ["ES", 601], ["cells", 604], ["differentiating", 610], ["as", 626], ["embryoid", 629], ["bodies", 638], ["(", 645], ["EBs", 646], [")", 649], ["over", 651], ["a", 656], ["16-d", 658], ["time", 663], ["course", 668], [".", 674], ["We", 676], ["identified", 679], ["945", 690], ["ncRNAs", 694], ["expressed", 701], ["during", 711], ["EB", 718], ["differentiation", 721], [",", 736], ["of", 738], ["which", 741], ["174", 747], ["were", 751], ["differentially", 756], ["expressed", 771], [",", 780], ["many", 782], ["correlating", 787], ["with", 799], ["pluripotency", 804], ["or", 817], ["specific", 820], ["differentiation", 829], ["events", 845], [".", 851], ["Candidate", 853], ["ncRNAs", 863], ["were", 870], ["identified", 875], ["for", 886], ["further", 890], ["characterization", 898], ["by", 915], ["an", 918], ["integrated", 921], ["examination", 932], ["of", 944], ["expression", 947], ["profiles", 958], [",", 966], ["genomic", 968], ["context", 976], [",", 983], ["chromatin", 985], ["state", 995], [",", 1000], ["and", 1002], ["promoter", 1006], ["analysis", 1015], [".", 1023], ["Many", 1025], ["ncRNAs", 1030], ["showed", 1037], ["coordinated", 1044], ["expression", 1056], ["with", 1067], ["genomically", 1072], ["associated", 1084], ["developmental", 1095], ["genes", 1109], [",", 1114], ["such", 1116], ["as", 1121], ["Dlx1", 1124], [",", 1128], ["Dlx4", 1130], [",", 1134], ["Gata6", 1136], [",", 1141], ["and", 1143], ["Ecsit", 1147], [".", 1152], ["We", 1154], ["examined", 1157], ["two", 1166], ["novel", 1170], ["developmentally", 1176], ["regulated", 1192], ["ncRNAs", 1202], [",", 1208], ["Evx1as", 1210], ["and", 1217], ["Hoxb5/6as", 1221], [",", 1230], ["which", 1232], ["are", 1238], ["derived", 1242], ["from", 1250], ["homeotic", 1255], ["loci", 1264], ["and", 1269], ["share", 1273], ["similar", 1279], ["expression", 1287], ["patterns", 1298], ["and", 1307], ["localization", 1311], ["in", 1324], ["mouse", 1327], ["embryos", 1333], ["with", 1341], ["their", 1346], ["associated", 1352], ["protein", 1363], ["-", 1370], ["coding", 1371], ["genes", 1378], [".", 1383], ["Using", 1385], ["chromatin", 1391], ["immunoprecipitation", 1401], [",", 1420], ["we", 1422], ["provide", 1425], ["evidence", 1433], ["that", 1442], ["both", 1447], ["ncRNAs", 1452], ["are", 1459], ["associated", 1463], ["with", 1474], ["trimethylated", 1479], ["H3K4", 1493], ["histones", 1498], ["and", 1507], ["histone", 1511], ["methyltransferase", 1519], ["MLL1", 1537], [",", 1541], ["suggesting", 1543], ["a", 1554], ["role", 1556], ["in", 1561], ["epigenetic", 1564], ["regulation", 1575], ["of", 1586], ["homeotic", 1589], ["loci", 1598], ["during", 1603], ["ES", 1610], ["cell", 1613], ["differentiation", 1618], [".", 1633], ["Taken", 1635], ["together", 1641], [",", 1649], ["our", 1651], ["data", 1655], ["indicate", 1660], ["that", 1669], ["long", 1674], ["ncRNAs", 1679], ["are", 1686], ["likely", 1690], ["to", 1697], ["be", 1700], ["important", 1703], ["in", 1713], ["processes", 1716], ["directing", 1726], ["pluripotency", 1736], ["and", 1749], ["alternative", 1753], ["differentiation", 1765], ["programs", 1781], [",", 1789], ["in", 1791], ["some", 1794], ["cases", 1799], ["through", 1805], ["engagement", 1813], ["of", 1824], ["the", 1827], ["epigenetic", 1831], ["machinery", 1842], [".", 1851]]}
{"context": "The literature is divided as to the necessity of an intact posterior cruciate ligament for functional stability. Presented here is a prospective study of isolated posterior cruciate injuries seen in the acute stage in 13 patients, 6 males and 7 females. The diagnosis of posterior cruciate ligament tear was made clinically and confirmed by arthroscopy. The average age at injury was 22 years. The athletic activity at injury was varied. Hyperflexion was the most common mechanism of injury, followed by pretibial trauma in the hyperflexed knee or in the \"dashboard\" injury. There were seven complete midsubstance tears and five partial tears. Direct visualization of the posterior cruciate ligament was not attained in one patient. All patients were treated nonoperatively on a physiotherapy routine. Average followup was 2.6 years. Patients were clinically examined and subjected to KT-1000 and Cybex testing. All patients were able to return to their previous activity and experienced no limitations with their injured knees. Using Hughston's criteria, subjective and functional ratings were all good. However, only 3 rated good and 10 fair when assessed objectively. We conclude that acceptable functional stability in these patients does not necessarily require absolute static stability. Nonoperative treatment of the isolated posterior cruciate ligament midsubstance injury may be a viable alternative to the difficult repair/reconstruction procedure.", "qas": [{"question": "Which ligament is most commonly injured in dashboard injury?", "answers": ["Posterior cruciate ligament"], "qid": "227ac45c39224b96946662810578c154", "question_tokens": [["Which", 0], ["ligament", 6], ["is", 15], ["most", 18], ["commonly", 23], ["injured", 32], ["in", 40], ["dashboard", 43], ["injury", 53], ["?", 59]], "detected_answers": [{"text": "Posterior cruciate ligament", "token_spans": [[47, 49], [221, 223], [116, 118], [11, 13]], "char_spans": [[271, 297], [1333, 1359], [672, 698], [59, 85]]}]}], "context_tokens": [["The", 0], ["literature", 4], ["is", 15], ["divided", 18], ["as", 26], ["to", 29], ["the", 32], ["necessity", 36], ["of", 46], ["an", 49], ["intact", 52], ["posterior", 59], ["cruciate", 69], ["ligament", 78], ["for", 87], ["functional", 91], ["stability", 102], [".", 111], ["Presented", 113], ["here", 123], ["is", 128], ["a", 131], ["prospective", 133], ["study", 145], ["of", 151], ["isolated", 154], ["posterior", 163], ["cruciate", 173], ["injuries", 182], ["seen", 191], ["in", 196], ["the", 199], ["acute", 203], ["stage", 209], ["in", 215], ["13", 218], ["patients", 221], [",", 229], ["6", 231], ["males", 233], ["and", 239], ["7", 243], ["females", 245], [".", 252], ["The", 254], ["diagnosis", 258], ["of", 268], ["posterior", 271], ["cruciate", 281], ["ligament", 290], ["tear", 299], ["was", 304], ["made", 308], ["clinically", 313], ["and", 324], ["confirmed", 328], ["by", 338], ["arthroscopy", 341], [".", 352], ["The", 354], ["average", 358], ["age", 366], ["at", 370], ["injury", 373], ["was", 380], ["22", 384], ["years", 387], [".", 392], ["The", 394], ["athletic", 398], ["activity", 407], ["at", 416], ["injury", 419], ["was", 426], ["varied", 430], [".", 436], ["Hyperflexion", 438], ["was", 451], ["the", 455], ["most", 459], ["common", 464], ["mechanism", 471], ["of", 481], ["injury", 484], [",", 490], ["followed", 492], ["by", 501], ["pretibial", 504], ["trauma", 514], ["in", 521], ["the", 524], ["hyperflexed", 528], ["knee", 540], ["or", 545], ["in", 548], ["the", 551], ["\"", 555], ["dashboard", 556], ["\"", 565], ["injury", 567], [".", 573], ["There", 575], ["were", 581], ["seven", 586], ["complete", 592], ["midsubstance", 601], ["tears", 614], ["and", 620], ["five", 624], ["partial", 629], ["tears", 637], [".", 642], ["Direct", 644], ["visualization", 651], ["of", 665], ["the", 668], ["posterior", 672], ["cruciate", 682], ["ligament", 691], ["was", 700], ["not", 704], ["attained", 708], ["in", 717], ["one", 720], ["patient", 724], [".", 731], ["All", 733], ["patients", 737], ["were", 746], ["treated", 751], ["nonoperatively", 759], ["on", 774], ["a", 777], ["physiotherapy", 779], ["routine", 793], [".", 800], ["Average", 802], ["followup", 810], ["was", 819], ["2.6", 823], ["years", 827], [".", 832], ["Patients", 834], ["were", 843], ["clinically", 848], ["examined", 859], ["and", 868], ["subjected", 872], ["to", 882], ["KT-1000", 885], ["and", 893], ["Cybex", 897], ["testing", 903], [".", 910], ["All", 912], ["patients", 916], ["were", 925], ["able", 930], ["to", 935], ["return", 938], ["to", 945], ["their", 948], ["previous", 954], ["activity", 963], ["and", 972], ["experienced", 976], ["no", 988], ["limitations", 991], ["with", 1003], ["their", 1008], ["injured", 1014], ["knees", 1022], [".", 1027], ["Using", 1029], ["Hughston", 1035], ["'s", 1043], ["criteria", 1046], [",", 1054], ["subjective", 1056], ["and", 1067], ["functional", 1071], ["ratings", 1082], ["were", 1090], ["all", 1095], ["good", 1099], [".", 1103], ["However", 1105], [",", 1112], ["only", 1114], ["3", 1119], ["rated", 1121], ["good", 1127], ["and", 1132], ["10", 1136], ["fair", 1139], ["when", 1144], ["assessed", 1149], ["objectively", 1158], [".", 1169], ["We", 1171], ["conclude", 1174], ["that", 1183], ["acceptable", 1188], ["functional", 1199], ["stability", 1210], ["in", 1220], ["these", 1223], ["patients", 1229], ["does", 1238], ["not", 1243], ["necessarily", 1247], ["require", 1259], ["absolute", 1267], ["static", 1276], ["stability", 1283], [".", 1292], ["Nonoperative", 1294], ["treatment", 1307], ["of", 1317], ["the", 1320], ["isolated", 1324], ["posterior", 1333], ["cruciate", 1343], ["ligament", 1352], ["midsubstance", 1361], ["injury", 1374], ["may", 1381], ["be", 1385], ["a", 1388], ["viable", 1390], ["alternative", 1397], ["to", 1409], ["the", 1412], ["difficult", 1416], ["repair", 1426], ["/", 1432], ["reconstruction", 1433], ["procedure", 1448], [".", 1457]]}
{"context": "The purpose of this study is to determine the sensibility of each imaging tool in identifying focal cortical dysplasia (FCD) in children and adolescents with epilepsy and to define the prognostic factors of pediatric and adolescent epilepsy surgery. We identified 48 children with FCD who underwent resective surgery and analyzed their preoperative data. The results of various anatomic and functional neuroimaging studies were compared for accuracy in locating the lesion. We also investigated clinical factors that affected the outcome of surgical treatment. Brain magnetic resonance imaging (MRI) was able to localize FCD in 30 patients and fluorodeoxyglucose positron emission tomography (FDG-PET) and/or subtraction ictal single photon emission computed tomography (SPECT) coregistered with MRI provided additional information that helped to define the lesion in 13 patients. When comparing the pathologic results between a mild malformation of cortical development (MCD) and FCD type I and II, we noted a strong tendency for patients with FCD to have MRI abnormalities (p = 0.005). In addition, severe pathologic features (Palmini's classification, FCD type II) (p = 0.025) showed significant correlation with a better surgical outcome. To define the primary epileptogenic area, various interictal epileptiform discharges and the results of multimodal neuroimaging studies were helpful, and younger age at the time of operation could aid in more favorable surgical outcomes (p = 0.048). Our study showed a significant relationship between pathologic grade and the detectability of FCD by brain MRI. In addition, early surgery can be justified by showing that advanced neuroimaging studies in children with FCD and even with extensive epileptiform discharges have a higher rate of success.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "4e97ba94bae54666969f2d440b9221ff", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[16, 18]], "char_spans": [[94, 117]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["study", 20], ["is", 26], ["to", 29], ["determine", 32], ["the", 42], ["sensibility", 46], ["of", 58], ["each", 61], ["imaging", 66], ["tool", 74], ["in", 79], ["identifying", 82], ["focal", 94], ["cortical", 100], ["dysplasia", 109], ["(", 119], ["FCD", 120], [")", 123], ["in", 125], ["children", 128], ["and", 137], ["adolescents", 141], ["with", 153], ["epilepsy", 158], ["and", 167], ["to", 171], ["define", 174], ["the", 181], ["prognostic", 185], ["factors", 196], ["of", 204], ["pediatric", 207], ["and", 217], ["adolescent", 221], ["epilepsy", 232], ["surgery", 241], [".", 248], ["We", 250], ["identified", 253], ["48", 264], ["children", 267], ["with", 276], ["FCD", 281], ["who", 285], ["underwent", 289], ["resective", 299], ["surgery", 309], ["and", 317], ["analyzed", 321], ["their", 330], ["preoperative", 336], ["data", 349], [".", 353], ["The", 355], ["results", 359], ["of", 367], ["various", 370], ["anatomic", 378], ["and", 387], ["functional", 391], ["neuroimaging", 402], ["studies", 415], ["were", 423], ["compared", 428], ["for", 437], ["accuracy", 441], ["in", 450], ["locating", 453], ["the", 462], ["lesion", 466], [".", 472], ["We", 474], ["also", 477], ["investigated", 482], ["clinical", 495], ["factors", 504], ["that", 512], ["affected", 517], ["the", 526], ["outcome", 530], ["of", 538], ["surgical", 541], ["treatment", 550], [".", 559], ["Brain", 561], ["magnetic", 567], ["resonance", 576], ["imaging", 586], ["(", 594], ["MRI", 595], [")", 598], ["was", 600], ["able", 604], ["to", 609], ["localize", 612], ["FCD", 621], ["in", 625], ["30", 628], ["patients", 631], ["and", 640], ["fluorodeoxyglucose", 644], ["positron", 663], ["emission", 672], ["tomography", 681], ["(", 692], ["FDG", 693], ["-", 696], ["PET", 697], [")", 700], ["and/or", 702], ["subtraction", 709], ["ictal", 721], ["single", 727], ["photon", 734], ["emission", 741], ["computed", 750], ["tomography", 759], ["(", 770], ["SPECT", 771], [")", 776], ["coregistered", 778], ["with", 791], ["MRI", 796], ["provided", 800], ["additional", 809], ["information", 820], ["that", 832], ["helped", 837], ["to", 844], ["define", 847], ["the", 854], ["lesion", 858], ["in", 865], ["13", 868], ["patients", 871], [".", 879], ["When", 881], ["comparing", 886], ["the", 896], ["pathologic", 900], ["results", 911], ["between", 919], ["a", 927], ["mild", 929], ["malformation", 934], ["of", 947], ["cortical", 950], ["development", 959], ["(", 971], ["MCD", 972], [")", 975], ["and", 977], ["FCD", 981], ["type", 985], ["I", 990], ["and", 992], ["II", 996], [",", 998], ["we", 1000], ["noted", 1003], ["a", 1009], ["strong", 1011], ["tendency", 1018], ["for", 1027], ["patients", 1031], ["with", 1040], ["FCD", 1045], ["to", 1049], ["have", 1052], ["MRI", 1057], ["abnormalities", 1061], ["(", 1075], ["p", 1076], ["=", 1078], ["0.005", 1080], [")", 1085], [".", 1086], ["In", 1088], ["addition", 1091], [",", 1099], ["severe", 1101], ["pathologic", 1108], ["features", 1119], ["(", 1128], ["Palmini", 1129], ["'s", 1136], ["classification", 1139], [",", 1153], ["FCD", 1155], ["type", 1159], ["II", 1164], [")", 1166], ["(", 1168], ["p", 1169], ["=", 1171], ["0.025", 1173], [")", 1178], ["showed", 1180], ["significant", 1187], ["correlation", 1199], ["with", 1211], ["a", 1216], ["better", 1218], ["surgical", 1225], ["outcome", 1234], [".", 1241], ["To", 1243], ["define", 1246], ["the", 1253], ["primary", 1257], ["epileptogenic", 1265], ["area", 1279], [",", 1283], ["various", 1285], ["interictal", 1293], ["epileptiform", 1304], ["discharges", 1317], ["and", 1328], ["the", 1332], ["results", 1336], ["of", 1344], ["multimodal", 1347], ["neuroimaging", 1358], ["studies", 1371], ["were", 1379], ["helpful", 1384], [",", 1391], ["and", 1393], ["younger", 1397], ["age", 1405], ["at", 1409], ["the", 1412], ["time", 1416], ["of", 1421], ["operation", 1424], ["could", 1434], ["aid", 1440], ["in", 1444], ["more", 1447], ["favorable", 1452], ["surgical", 1462], ["outcomes", 1471], ["(", 1480], ["p", 1481], ["=", 1483], ["0.048", 1485], [")", 1490], [".", 1491], ["Our", 1493], ["study", 1497], ["showed", 1503], ["a", 1510], ["significant", 1512], ["relationship", 1524], ["between", 1537], ["pathologic", 1545], ["grade", 1556], ["and", 1562], ["the", 1566], ["detectability", 1570], ["of", 1584], ["FCD", 1587], ["by", 1591], ["brain", 1594], ["MRI", 1600], [".", 1603], ["In", 1605], ["addition", 1608], [",", 1616], ["early", 1618], ["surgery", 1624], ["can", 1632], ["be", 1636], ["justified", 1639], ["by", 1649], ["showing", 1652], ["that", 1660], ["advanced", 1665], ["neuroimaging", 1674], ["studies", 1687], ["in", 1695], ["children", 1698], ["with", 1707], ["FCD", 1712], ["and", 1716], ["even", 1720], ["with", 1725], ["extensive", 1730], ["epileptiform", 1740], ["discharges", 1753], ["have", 1764], ["a", 1769], ["higher", 1771], ["rate", 1778], ["of", 1783], ["success", 1786], [".", 1793]]}
{"context": "Proteins of the Notch family are cell surface receptors that transduce signals between neighbouring cells. The Notch signalling pathway is highly evolutionarily conserved and critical for cell fate determination during embryonic development, including many aspects of vascular development. The interaction of Notch receptors with ligands leads to cleavage of the Notch intracellular domain (NICD) which then translocates to the nucleus and activates the transcription factor CBF1/JBP-Jkappa, regulating downstream gene expression. To date four Notch receptors have been found in mammals. Of these, Notch3 is predominantly expressed in adult arterial smooth muscle cells in human. NOTCH3 gene mutations cause the autosomal dominant condition, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoecephelopathy (CADASIL), an inherited early stroke syndrome leading to dementia due to systemic vascular degeneration. This suggests that Notch3 plays a critical role in maintaining the phenotypic stability of vascular smooth muscle cells (VSMCs). Recent publications indicate that Notch3 is involved in vascular injury and is a determinant of VSMC survival, but its exact function is unknown. The molecular mechanisms underlying CADASIL pathology are therefore intriguing. Investigation of CADASIL mutant Notch3 shows that the majority of mutations do not change CBF1/JBP-Jkappa mediated classic Notch activation, so the pathological consequences of NOTCH3 mutations in CADASIL patients can not be simply explained by loss- or gain-of-function in the classic Notch signalling pathway. This suggests that a novel Notch3-mediated signalling pathway may be present in VSMCs, or cross-regulation of Notch3 to other signalling pathway(s) may play a critical role on VSMCs survival. Alternatively, the mutant Notch3 may gain a novel or toxic function in VSMCs. This review will focus on recent findings of Notch3 in vascular development and in regulating the VSMC behaviour and phenotype, and will use findings on investigating the molecular pathology of the single gene disorder CADASIL to understand the function of Notch3 in VSMCs.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "2c9f414f7a3a499893e29b02c1e7994e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[106, 107]], "char_spans": [[680, 690]]}]}], "context_tokens": [["Proteins", 0], ["of", 9], ["the", 12], ["Notch", 16], ["family", 22], ["are", 29], ["cell", 33], ["surface", 38], ["receptors", 46], ["that", 56], ["transduce", 61], ["signals", 71], ["between", 79], ["neighbouring", 87], ["cells", 100], [".", 105], ["The", 107], ["Notch", 111], ["signalling", 117], ["pathway", 128], ["is", 136], ["highly", 139], ["evolutionarily", 146], ["conserved", 161], ["and", 171], ["critical", 175], ["for", 184], ["cell", 188], ["fate", 193], ["determination", 198], ["during", 212], ["embryonic", 219], ["development", 229], [",", 240], ["including", 242], ["many", 252], ["aspects", 257], ["of", 265], ["vascular", 268], ["development", 277], [".", 288], ["The", 290], ["interaction", 294], ["of", 306], ["Notch", 309], ["receptors", 315], ["with", 325], ["ligands", 330], ["leads", 338], ["to", 344], ["cleavage", 347], ["of", 356], ["the", 359], ["Notch", 363], ["intracellular", 369], ["domain", 383], ["(", 390], ["NICD", 391], [")", 395], ["which", 397], ["then", 403], ["translocates", 408], ["to", 421], ["the", 424], ["nucleus", 428], ["and", 436], ["activates", 440], ["the", 450], ["transcription", 454], ["factor", 468], ["CBF1/JBP", 475], ["-", 483], ["Jkappa", 484], [",", 490], ["regulating", 492], ["downstream", 503], ["gene", 514], ["expression", 519], [".", 529], ["To", 531], ["date", 534], ["four", 539], ["Notch", 544], ["receptors", 550], ["have", 560], ["been", 565], ["found", 570], ["in", 576], ["mammals", 579], [".", 586], ["Of", 588], ["these", 591], [",", 596], ["Notch3", 598], ["is", 605], ["predominantly", 608], ["expressed", 622], ["in", 632], ["adult", 635], ["arterial", 641], ["smooth", 650], ["muscle", 657], ["cells", 664], ["in", 670], ["human", 673], [".", 678], ["NOTCH3", 680], ["gene", 687], ["mutations", 692], ["cause", 702], ["the", 708], ["autosomal", 712], ["dominant", 722], ["condition", 731], [",", 740], ["cerebral", 742], ["autosomal", 751], ["dominant", 761], ["arteriopathy", 770], ["with", 783], ["subcortical", 788], ["infarcts", 800], ["and", 809], ["leukoecephelopathy", 813], ["(", 832], ["CADASIL", 833], [")", 840], [",", 841], ["an", 843], ["inherited", 846], ["early", 856], ["stroke", 862], ["syndrome", 869], ["leading", 878], ["to", 886], ["dementia", 889], ["due", 898], ["to", 902], ["systemic", 905], ["vascular", 914], ["degeneration", 923], [".", 935], ["This", 937], ["suggests", 942], ["that", 951], ["Notch3", 956], ["plays", 963], ["a", 969], ["critical", 971], ["role", 980], ["in", 985], ["maintaining", 988], ["the", 1000], ["phenotypic", 1004], ["stability", 1015], ["of", 1025], ["vascular", 1028], ["smooth", 1037], ["muscle", 1044], ["cells", 1051], ["(", 1057], ["VSMCs", 1058], [")", 1063], [".", 1064], ["Recent", 1066], ["publications", 1073], ["indicate", 1086], ["that", 1095], ["Notch3", 1100], ["is", 1107], ["involved", 1110], ["in", 1119], ["vascular", 1122], ["injury", 1131], ["and", 1138], ["is", 1142], ["a", 1145], ["determinant", 1147], ["of", 1159], ["VSMC", 1162], ["survival", 1167], [",", 1175], ["but", 1177], ["its", 1181], ["exact", 1185], ["function", 1191], ["is", 1200], ["unknown", 1203], [".", 1210], ["The", 1212], ["molecular", 1216], ["mechanisms", 1226], ["underlying", 1237], ["CADASIL", 1248], ["pathology", 1256], ["are", 1266], ["therefore", 1270], ["intriguing", 1280], [".", 1290], ["Investigation", 1292], ["of", 1306], ["CADASIL", 1309], ["mutant", 1317], ["Notch3", 1324], ["shows", 1331], ["that", 1337], ["the", 1342], ["majority", 1346], ["of", 1355], ["mutations", 1358], ["do", 1368], ["not", 1371], ["change", 1375], ["CBF1/JBP", 1382], ["-", 1390], ["Jkappa", 1391], ["mediated", 1398], ["classic", 1407], ["Notch", 1415], ["activation", 1421], [",", 1431], ["so", 1433], ["the", 1436], ["pathological", 1440], ["consequences", 1453], ["of", 1466], ["NOTCH3", 1469], ["mutations", 1476], ["in", 1486], ["CADASIL", 1489], ["patients", 1497], ["can", 1506], ["not", 1510], ["be", 1514], ["simply", 1517], ["explained", 1524], ["by", 1534], ["loss-", 1537], ["or", 1543], ["gain", 1546], ["-", 1550], ["of", 1551], ["-", 1553], ["function", 1554], ["in", 1563], ["the", 1566], ["classic", 1570], ["Notch", 1578], ["signalling", 1584], ["pathway", 1595], [".", 1602], ["This", 1604], ["suggests", 1609], ["that", 1618], ["a", 1623], ["novel", 1625], ["Notch3-mediated", 1631], ["signalling", 1647], ["pathway", 1658], ["may", 1666], ["be", 1670], ["present", 1673], ["in", 1681], ["VSMCs", 1684], [",", 1689], ["or", 1691], ["cross", 1694], ["-", 1699], ["regulation", 1700], ["of", 1711], ["Notch3", 1714], ["to", 1721], ["other", 1724], ["signalling", 1730], ["pathway(s", 1741], [")", 1750], ["may", 1752], ["play", 1756], ["a", 1761], ["critical", 1763], ["role", 1772], ["on", 1777], ["VSMCs", 1780], ["survival", 1786], [".", 1794], ["Alternatively", 1796], [",", 1809], ["the", 1811], ["mutant", 1815], ["Notch3", 1822], ["may", 1829], ["gain", 1833], ["a", 1838], ["novel", 1840], ["or", 1846], ["toxic", 1849], ["function", 1855], ["in", 1864], ["VSMCs", 1867], [".", 1872], ["This", 1874], ["review", 1879], ["will", 1886], ["focus", 1891], ["on", 1897], ["recent", 1900], ["findings", 1907], ["of", 1916], ["Notch3", 1919], ["in", 1926], ["vascular", 1929], ["development", 1938], ["and", 1950], ["in", 1954], ["regulating", 1957], ["the", 1968], ["VSMC", 1972], ["behaviour", 1977], ["and", 1987], ["phenotype", 1991], [",", 2000], ["and", 2002], ["will", 2006], ["use", 2011], ["findings", 2015], ["on", 2024], ["investigating", 2027], ["the", 2041], ["molecular", 2045], ["pathology", 2055], ["of", 2065], ["the", 2068], ["single", 2072], ["gene", 2079], ["disorder", 2084], ["CADASIL", 2093], ["to", 2101], ["understand", 2104], ["the", 2115], ["function", 2119], ["of", 2128], ["Notch3", 2131], ["in", 2138], ["VSMCs", 2141], [".", 2146]]}
{"context": "SECIS elements are stem-loop structures located in the 3' untranslated regions (UTRs) of eukaryotic selenoprotein mRNAs that are required for directing cotranslational selenocysteine incorporation at UGA codons. In prokaryotes, stem-loops mediating selenocysteine incorporation are located immediately downstream of the UGA selenocysteine codon, in the coding region. Previous characterization studies of the mammalian SECIS elements of type 1 deiodinase, glutathione peroxidase, and selenoprotein P showed that conserved nucleotides in the loops and unpaired bulges, and base pairing in the stems are required for SECIS function. These initial studies utilized approximately 175-230-nt segments of the 3'UTRs of the selenoprotein mRNAs. Here we define the minimal functional rat type 1 deiodinase SECIS element, a 45-nt segment, the 5' boundary of which corresponds precisely to the 5'-most critical conserved nucleotide identified previously. We also define base pairing requirements in the stem of this element. In view of the presence of SECIS elements in the open reading frames (ORFs) of bacterial selenoproteins, we examine the effects in the type 1 deiodinase of extending the ORF into the SECIS element, and find that this dramatically inhibits SECIS function. Finally, we define a minimal spacing requirement of 51-111 nt between a eukaryotic UGA selenocysteine codon and SECIS element.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "5798e357ab44416ea1ecd5323e3e7ae4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [96, 96], [198, 198], [230, 230], [169, 169], [126, 126], [63, 63], [207, 207]], "char_spans": [[0, 4], [615, 619], [1198, 1202], [1382, 1386], [1042, 1046], [798, 802], [419, 423], [1254, 1258]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["are", 15], ["stem", 19], ["-", 23], ["loop", 24], ["structures", 29], ["located", 40], ["in", 48], ["the", 51], ["3", 55], ["'", 56], ["untranslated", 58], ["regions", 71], ["(", 79], ["UTRs", 80], [")", 84], ["of", 86], ["eukaryotic", 89], ["selenoprotein", 100], ["mRNAs", 114], ["that", 120], ["are", 125], ["required", 129], ["for", 138], ["directing", 142], ["cotranslational", 152], ["selenocysteine", 168], ["incorporation", 183], ["at", 197], ["UGA", 200], ["codons", 204], [".", 210], ["In", 212], ["prokaryotes", 215], [",", 226], ["stem", 228], ["-", 232], ["loops", 233], ["mediating", 239], ["selenocysteine", 249], ["incorporation", 264], ["are", 278], ["located", 282], ["immediately", 290], ["downstream", 302], ["of", 313], ["the", 316], ["UGA", 320], ["selenocysteine", 324], ["codon", 339], [",", 344], ["in", 346], ["the", 349], ["coding", 353], ["region", 360], [".", 366], ["Previous", 368], ["characterization", 377], ["studies", 394], ["of", 402], ["the", 405], ["mammalian", 409], ["SECIS", 419], ["elements", 425], ["of", 434], ["type", 437], ["1", 442], ["deiodinase", 444], [",", 454], ["glutathione", 456], ["peroxidase", 468], [",", 478], ["and", 480], ["selenoprotein", 484], ["P", 498], ["showed", 500], ["that", 507], ["conserved", 512], ["nucleotides", 522], ["in", 534], ["the", 537], ["loops", 541], ["and", 547], ["unpaired", 551], ["bulges", 560], [",", 566], ["and", 568], ["base", 572], ["pairing", 577], ["in", 585], ["the", 588], ["stems", 592], ["are", 598], ["required", 602], ["for", 611], ["SECIS", 615], ["function", 621], [".", 629], ["These", 631], ["initial", 637], ["studies", 645], ["utilized", 653], ["approximately", 662], ["175", 676], ["-", 679], ["230-nt", 680], ["segments", 687], ["of", 696], ["the", 699], ["3'UTRs", 703], ["of", 710], ["the", 713], ["selenoprotein", 717], ["mRNAs", 731], [".", 736], ["Here", 738], ["we", 743], ["define", 746], ["the", 753], ["minimal", 757], ["functional", 765], ["rat", 776], ["type", 780], ["1", 785], ["deiodinase", 787], ["SECIS", 798], ["element", 804], [",", 811], ["a", 813], ["45-nt", 815], ["segment", 821], [",", 828], ["the", 830], ["5", 834], ["'", 835], ["boundary", 837], ["of", 846], ["which", 849], ["corresponds", 855], ["precisely", 867], ["to", 877], ["the", 880], ["5'-most", 884], ["critical", 892], ["conserved", 901], ["nucleotide", 911], ["identified", 922], ["previously", 933], [".", 943], ["We", 945], ["also", 948], ["define", 953], ["base", 960], ["pairing", 965], ["requirements", 973], ["in", 986], ["the", 989], ["stem", 993], ["of", 998], ["this", 1001], ["element", 1006], [".", 1013], ["In", 1015], ["view", 1018], ["of", 1023], ["the", 1026], ["presence", 1030], ["of", 1039], ["SECIS", 1042], ["elements", 1048], ["in", 1057], ["the", 1060], ["open", 1064], ["reading", 1069], ["frames", 1077], ["(", 1084], ["ORFs", 1085], [")", 1089], ["of", 1091], ["bacterial", 1094], ["selenoproteins", 1104], [",", 1118], ["we", 1120], ["examine", 1123], ["the", 1131], ["effects", 1135], ["in", 1143], ["the", 1146], ["type", 1150], ["1", 1155], ["deiodinase", 1157], ["of", 1168], ["extending", 1171], ["the", 1181], ["ORF", 1185], ["into", 1189], ["the", 1194], ["SECIS", 1198], ["element", 1204], [",", 1211], ["and", 1213], ["find", 1217], ["that", 1222], ["this", 1227], ["dramatically", 1232], ["inhibits", 1245], ["SECIS", 1254], ["function", 1260], [".", 1268], ["Finally", 1270], [",", 1277], ["we", 1279], ["define", 1282], ["a", 1289], ["minimal", 1291], ["spacing", 1299], ["requirement", 1307], ["of", 1319], ["51", 1322], ["-", 1324], ["111", 1325], ["nt", 1329], ["between", 1332], ["a", 1340], ["eukaryotic", 1342], ["UGA", 1353], ["selenocysteine", 1357], ["codon", 1372], ["and", 1378], ["SECIS", 1382], ["element", 1388], [".", 1395]]}
{"context": "Fostamatinib (R788) is an orally dosed prodrug designed to deliver the active metabolite R940406 (R406), a spleen tyrosine kinase (SYK) inhibitor, for the treatment of rheumatoid arthritis. The objectives were to evaluate the human pharmacokinetic properties of fostamatinib and R406. Three clinical studies were conducted in healthy subjects: (A) A single ascending dose study for R406 with doses ranging from 80-600\u2009mg, (B) a single- and multiple-dose study of fostamatinib in aqueous suspension, with single doses ranging from 80-400\u2009mg and multiple doses at 160\u2009mg twice daily and (C) a study comparing suspension and tablet of fostamatinib, with the latter tested in both fed and fasted states. These studies demonstrated that when administered as a solution, R406 was rapidly absorbed. Increases in exposure were observed with doses up to 400\u2009mg. A terminal half-life of 12-21\u2009h was observed. Similar R406 exposure could be achieved with fostamatinib suspension and steady-state was achieved after 3-4 days following twice daily administration. Fostamatinib tablet and suspension exhibited similar R406 exposure. Upon co-administration with food, a delay in peak time and lower peak concentrations of R406 were observed but at the same time the overall exposure did not change. Fostamatinib demonstrates rapid and extensive conversion to R406, an inhibitor of SYK. Solid dosage forms of fostamatinib overcome the challenge of low aqueous solubility of R406. The PK profile of R406 could potentially allow once daily or twice daily oral administration of fostamatinib.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "68d14ce5231c4bba93f1b52c90dd2f8c", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[21, 23]], "char_spans": [[107, 128]]}]}], "context_tokens": [["Fostamatinib", 0], ["(", 13], ["R788", 14], [")", 18], ["is", 20], ["an", 23], ["orally", 26], ["dosed", 33], ["prodrug", 39], ["designed", 47], ["to", 56], ["deliver", 59], ["the", 67], ["active", 71], ["metabolite", 78], ["R940406", 89], ["(", 97], ["R406", 98], [")", 102], [",", 103], ["a", 105], ["spleen", 107], ["tyrosine", 114], ["kinase", 123], ["(", 130], ["SYK", 131], [")", 134], ["inhibitor", 136], [",", 145], ["for", 147], ["the", 151], ["treatment", 155], ["of", 165], ["rheumatoid", 168], ["arthritis", 179], [".", 188], ["The", 190], ["objectives", 194], ["were", 205], ["to", 210], ["evaluate", 213], ["the", 222], ["human", 226], ["pharmacokinetic", 232], ["properties", 248], ["of", 259], ["fostamatinib", 262], ["and", 275], ["R406", 279], [".", 283], ["Three", 285], ["clinical", 291], ["studies", 300], ["were", 308], ["conducted", 313], ["in", 323], ["healthy", 326], ["subjects", 334], [":", 342], ["(", 344], ["A", 345], [")", 346], ["A", 348], ["single", 350], ["ascending", 357], ["dose", 367], ["study", 372], ["for", 378], ["R406", 382], ["with", 387], ["doses", 392], ["ranging", 398], ["from", 406], ["80", 411], ["-", 413], ["600", 414], ["mg", 418], [",", 420], ["(", 422], ["B", 423], [")", 424], ["a", 426], ["single-", 428], ["and", 436], ["multiple", 440], ["-", 448], ["dose", 449], ["study", 454], ["of", 460], ["fostamatinib", 463], ["in", 476], ["aqueous", 479], ["suspension", 487], [",", 497], ["with", 499], ["single", 504], ["doses", 511], ["ranging", 517], ["from", 525], ["80", 530], ["-", 532], ["400", 533], ["mg", 537], ["and", 540], ["multiple", 544], ["doses", 553], ["at", 559], ["160", 562], ["mg", 566], ["twice", 569], ["daily", 575], ["and", 581], ["(", 585], ["C", 586], [")", 587], ["a", 589], ["study", 591], ["comparing", 597], ["suspension", 607], ["and", 618], ["tablet", 622], ["of", 629], ["fostamatinib", 632], [",", 644], ["with", 646], ["the", 651], ["latter", 655], ["tested", 662], ["in", 669], ["both", 672], ["fed", 677], ["and", 681], ["fasted", 685], ["states", 692], [".", 698], ["These", 700], ["studies", 706], ["demonstrated", 714], ["that", 727], ["when", 732], ["administered", 737], ["as", 750], ["a", 753], ["solution", 755], [",", 763], ["R406", 765], ["was", 770], ["rapidly", 774], ["absorbed", 782], [".", 790], ["Increases", 792], ["in", 802], ["exposure", 805], ["were", 814], ["observed", 819], ["with", 828], ["doses", 833], ["up", 839], ["to", 842], ["400", 845], ["mg", 849], [".", 851], ["A", 853], ["terminal", 855], ["half", 864], ["-", 868], ["life", 869], ["of", 874], ["12", 877], ["-", 879], ["21", 880], ["h", 883], ["was", 885], ["observed", 889], [".", 897], ["Similar", 899], ["R406", 907], ["exposure", 912], ["could", 921], ["be", 927], ["achieved", 930], ["with", 939], ["fostamatinib", 944], ["suspension", 957], ["and", 968], ["steady", 972], ["-", 978], ["state", 979], ["was", 985], ["achieved", 989], ["after", 998], ["3", 1004], ["-", 1005], ["4", 1006], ["days", 1008], ["following", 1013], ["twice", 1023], ["daily", 1029], ["administration", 1035], [".", 1049], ["Fostamatinib", 1051], ["tablet", 1064], ["and", 1071], ["suspension", 1075], ["exhibited", 1086], ["similar", 1096], ["R406", 1104], ["exposure", 1109], [".", 1117], ["Upon", 1119], ["co", 1124], ["-", 1126], ["administration", 1127], ["with", 1142], ["food", 1147], [",", 1151], ["a", 1153], ["delay", 1155], ["in", 1161], ["peak", 1164], ["time", 1169], ["and", 1174], ["lower", 1178], ["peak", 1184], ["concentrations", 1189], ["of", 1204], ["R406", 1207], ["were", 1212], ["observed", 1217], ["but", 1226], ["at", 1230], ["the", 1233], ["same", 1237], ["time", 1242], ["the", 1247], ["overall", 1251], ["exposure", 1259], ["did", 1268], ["not", 1272], ["change", 1276], [".", 1282], ["Fostamatinib", 1284], ["demonstrates", 1297], ["rapid", 1310], ["and", 1316], ["extensive", 1320], ["conversion", 1330], ["to", 1341], ["R406", 1344], [",", 1348], ["an", 1350], ["inhibitor", 1353], ["of", 1363], ["SYK", 1366], [".", 1369], ["Solid", 1371], ["dosage", 1377], ["forms", 1384], ["of", 1390], ["fostamatinib", 1393], ["overcome", 1406], ["the", 1415], ["challenge", 1419], ["of", 1429], ["low", 1432], ["aqueous", 1436], ["solubility", 1444], ["of", 1455], ["R406", 1458], [".", 1462], ["The", 1464], ["PK", 1468], ["profile", 1471], ["of", 1479], ["R406", 1482], ["could", 1487], ["potentially", 1493], ["allow", 1505], ["once", 1511], ["daily", 1516], ["or", 1522], ["twice", 1525], ["daily", 1531], ["oral", 1537], ["administration", 1542], ["of", 1557], ["fostamatinib", 1560], [".", 1572]]}
{"context": "Prior studies, all using SPECT techniques, failed to find any differences for dopamine transporter (DAT) in restless legs syndrome (RLS) subjects. The distinct pharmacokinetic properties associated with SPECT-determined DAT along with rapid biodynamic changes in DAT may, however, have missed membrane-bound DAT differences. The current studies assessed real-time DAT binding potentials (BP) in striatum of RLS patients using (11)C-methylphenidate and PET techniques. RLS medications were stopped at least 11 days prior to the PET study. Clinical severity of RLS was also assessed. PET scans were performed at 2 different times of day (starting at 08:30 and 19:30) in separate groups of subjects. The primary outcome measure was total striatal DAT BP. Thirty-six patients with primary RLS and 34 age- and gender-matched controls. RLS subjects had significantly lower DAT binding in the striatum compared to controls on both the Day and the Night scans. DAT was decreased in putamen and caudate but not the ventral striatum of RLS subjects. There were no diurnal differences in DAT for the total group or for control and RLS separately. DAT BP did not correlate with any clinical measures of RLS. The current study found a significant decrease in DAT BP in two independent studies. These results when viewed along with prior RLS SPECT and autopsy studies of DAT, and cell culture studies with iron deficiency and DAT, suggest that membrane-bound striatal DAT, but not total cellular DAT, may be decreased in RLS.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "b2a12b8918344a65a2cc5f9b028e8d2b", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[258, 258]], "char_spans": [[1392, 1395]]}]}], "context_tokens": [["Prior", 0], ["studies", 6], [",", 13], ["all", 15], ["using", 19], ["SPECT", 25], ["techniques", 31], [",", 41], ["failed", 43], ["to", 50], ["find", 53], ["any", 58], ["differences", 62], ["for", 74], ["dopamine", 78], ["transporter", 87], ["(", 99], ["DAT", 100], [")", 103], ["in", 105], ["restless", 108], ["legs", 117], ["syndrome", 122], ["(", 131], ["RLS", 132], [")", 135], ["subjects", 137], [".", 145], ["The", 147], ["distinct", 151], ["pharmacokinetic", 160], ["properties", 176], ["associated", 187], ["with", 198], ["SPECT", 203], ["-", 208], ["determined", 209], ["DAT", 220], ["along", 224], ["with", 230], ["rapid", 235], ["biodynamic", 241], ["changes", 252], ["in", 260], ["DAT", 263], ["may", 267], [",", 270], ["however", 272], [",", 279], ["have", 281], ["missed", 286], ["membrane", 293], ["-", 301], ["bound", 302], ["DAT", 308], ["differences", 312], [".", 323], ["The", 325], ["current", 329], ["studies", 337], ["assessed", 345], ["real", 354], ["-", 358], ["time", 359], ["DAT", 364], ["binding", 368], ["potentials", 376], ["(", 387], ["BP", 388], [")", 390], ["in", 392], ["striatum", 395], ["of", 404], ["RLS", 407], ["patients", 411], ["using", 420], ["(", 426], ["11)C", 427], ["-", 431], ["methylphenidate", 432], ["and", 448], ["PET", 452], ["techniques", 456], [".", 466], ["RLS", 468], ["medications", 472], ["were", 484], ["stopped", 489], ["at", 497], ["least", 500], ["11", 506], ["days", 509], ["prior", 514], ["to", 520], ["the", 523], ["PET", 527], ["study", 531], [".", 536], ["Clinical", 538], ["severity", 547], ["of", 556], ["RLS", 559], ["was", 563], ["also", 567], ["assessed", 572], [".", 580], ["PET", 582], ["scans", 586], ["were", 592], ["performed", 597], ["at", 607], ["2", 610], ["different", 612], ["times", 622], ["of", 628], ["day", 631], ["(", 635], ["starting", 636], ["at", 645], ["08:30", 648], ["and", 654], ["19:30", 658], [")", 663], ["in", 665], ["separate", 668], ["groups", 677], ["of", 684], ["subjects", 687], [".", 695], ["The", 697], ["primary", 701], ["outcome", 709], ["measure", 717], ["was", 725], ["total", 729], ["striatal", 735], ["DAT", 744], ["BP", 748], [".", 750], ["Thirty", 752], ["-", 758], ["six", 759], ["patients", 763], ["with", 772], ["primary", 777], ["RLS", 785], ["and", 789], ["34", 793], ["age-", 796], ["and", 801], ["gender", 805], ["-", 811], ["matched", 812], ["controls", 820], [".", 828], ["RLS", 830], ["subjects", 834], ["had", 843], ["significantly", 847], ["lower", 861], ["DAT", 867], ["binding", 871], ["in", 879], ["the", 882], ["striatum", 886], ["compared", 895], ["to", 904], ["controls", 907], ["on", 916], ["both", 919], ["the", 924], ["Day", 928], ["and", 932], ["the", 936], ["Night", 940], ["scans", 946], [".", 951], ["DAT", 953], ["was", 957], ["decreased", 961], ["in", 971], ["putamen", 974], ["and", 982], ["caudate", 986], ["but", 994], ["not", 998], ["the", 1002], ["ventral", 1006], ["striatum", 1014], ["of", 1023], ["RLS", 1026], ["subjects", 1030], [".", 1038], ["There", 1040], ["were", 1046], ["no", 1051], ["diurnal", 1054], ["differences", 1062], ["in", 1074], ["DAT", 1077], ["for", 1081], ["the", 1085], ["total", 1089], ["group", 1095], ["or", 1101], ["for", 1104], ["control", 1108], ["and", 1116], ["RLS", 1120], ["separately", 1124], [".", 1134], ["DAT", 1136], ["BP", 1140], ["did", 1143], ["not", 1147], ["correlate", 1151], ["with", 1161], ["any", 1166], ["clinical", 1170], ["measures", 1179], ["of", 1188], ["RLS", 1191], [".", 1194], ["The", 1196], ["current", 1200], ["study", 1208], ["found", 1214], ["a", 1220], ["significant", 1222], ["decrease", 1234], ["in", 1243], ["DAT", 1246], ["BP", 1250], ["in", 1253], ["two", 1256], ["independent", 1260], ["studies", 1272], [".", 1279], ["These", 1281], ["results", 1287], ["when", 1295], ["viewed", 1300], ["along", 1307], ["with", 1313], ["prior", 1318], ["RLS", 1324], ["SPECT", 1328], ["and", 1334], ["autopsy", 1338], ["studies", 1346], ["of", 1354], ["DAT", 1357], [",", 1360], ["and", 1362], ["cell", 1366], ["culture", 1371], ["studies", 1379], ["with", 1387], ["iron", 1392], ["deficiency", 1397], ["and", 1408], ["DAT", 1412], [",", 1415], ["suggest", 1417], ["that", 1425], ["membrane", 1430], ["-", 1438], ["bound", 1439], ["striatal", 1445], ["DAT", 1454], [",", 1457], ["but", 1459], ["not", 1463], ["total", 1467], ["cellular", 1473], ["DAT", 1482], [",", 1485], ["may", 1487], ["be", 1491], ["decreased", 1494], ["in", 1504], ["RLS", 1507], [".", 1510]]}
{"context": "Diamond-Blackfan anemia (DBA) is a rare congenital pure red cell aplasia characterized by normochromic macrocytic anemia, reticulocytopenia, and normocellular bone marrow with a selective deficiency of erythroid precursors. Ribosomal protein S19 (RPS19), currently the only gene associated with DBA, is mutated in 25% of DBA patients, but its role in erythropoiesis is unknown. We attempted to elucidate the importance of RPS19 in translation in relation to the pathogenesis of DBA. We measured translation and proliferation rates in unstimulated and phytohemagglutinin (PHA)-stimulated lymphocytes isolated from DBA patients, as well as in K562 cells expressing several RPS19 mutants to directly test the effect of RPS19 mutations on translation. The effect of leucine on overall translation was also studied. We found that the level of translation was on average 48-73% of controls in both unstimulated and PHA-activated DBA lymphocytes irrespective of mutations in RPS19. The addition of leucine increased the translational level in RPS19-non-mutated DBA cells, but not in cells with an RPS19 mutation. In unstimulated DBA cells, proliferation was significantly impaired in both RPS19-mutated and non-mutated cells, but in both groups could be efficiently activated by PHA. Studies on K562 cells showed that RPS19 mutations affecting RPS19 conserved arginines R56Q and R62Q could significantly inhibit the rate of protein synthesis, indicating the importance of RPS19 in translation. Our results indicate that inefficient translation may be the main cause of DBA, and administration of leucine may be beneficial for at least some DBA patients.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "f06fc76bb7624c4ba8baf1c01fb0c0a8", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[48, 48], [192, 192], [83, 83], [5, 5], [100, 100], [276, 276], [263, 263], [56, 56], [158, 158], [178, 178]], "char_spans": [[295, 297], [1122, 1124], [478, 480], [25, 27], [613, 615], [1633, 1635], [1562, 1564], [321, 323], [923, 925], [1054, 1056]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["rare", 35], ["congenital", 40], ["pure", 51], ["red", 56], ["cell", 60], ["aplasia", 65], ["characterized", 73], ["by", 87], ["normochromic", 90], ["macrocytic", 103], ["anemia", 114], [",", 120], ["reticulocytopenia", 122], [",", 139], ["and", 141], ["normocellular", 145], ["bone", 159], ["marrow", 164], ["with", 171], ["a", 176], ["selective", 178], ["deficiency", 188], ["of", 199], ["erythroid", 202], ["precursors", 212], [".", 222], ["Ribosomal", 224], ["protein", 234], ["S19", 242], ["(", 246], ["RPS19", 247], [")", 252], [",", 253], ["currently", 255], ["the", 265], ["only", 269], ["gene", 274], ["associated", 279], ["with", 290], ["DBA", 295], [",", 298], ["is", 300], ["mutated", 303], ["in", 311], ["25", 314], ["%", 316], ["of", 318], ["DBA", 321], ["patients", 325], [",", 333], ["but", 335], ["its", 339], ["role", 343], ["in", 348], ["erythropoiesis", 351], ["is", 366], ["unknown", 369], [".", 376], ["We", 378], ["attempted", 381], ["to", 391], ["elucidate", 394], ["the", 404], ["importance", 408], ["of", 419], ["RPS19", 422], ["in", 428], ["translation", 431], ["in", 443], ["relation", 446], ["to", 455], ["the", 458], ["pathogenesis", 462], ["of", 475], ["DBA", 478], [".", 481], ["We", 483], ["measured", 486], ["translation", 495], ["and", 507], ["proliferation", 511], ["rates", 525], ["in", 531], ["unstimulated", 534], ["and", 547], ["phytohemagglutinin", 551], ["(", 570], ["PHA)-stimulated", 571], ["lymphocytes", 587], ["isolated", 599], ["from", 608], ["DBA", 613], ["patients", 617], [",", 625], ["as", 627], ["well", 630], ["as", 635], ["in", 638], ["K562", 641], ["cells", 646], ["expressing", 652], ["several", 663], ["RPS19", 671], ["mutants", 677], ["to", 685], ["directly", 688], ["test", 697], ["the", 702], ["effect", 706], ["of", 713], ["RPS19", 716], ["mutations", 722], ["on", 732], ["translation", 735], [".", 746], ["The", 748], ["effect", 752], ["of", 759], ["leucine", 762], ["on", 770], ["overall", 773], ["translation", 781], ["was", 793], ["also", 797], ["studied", 802], [".", 809], ["We", 811], ["found", 814], ["that", 820], ["the", 825], ["level", 829], ["of", 835], ["translation", 838], ["was", 850], ["on", 854], ["average", 857], ["48", 865], ["-", 867], ["73", 868], ["%", 870], ["of", 872], ["controls", 875], ["in", 884], ["both", 887], ["unstimulated", 892], ["and", 905], ["PHA", 909], ["-", 912], ["activated", 913], ["DBA", 923], ["lymphocytes", 927], ["irrespective", 939], ["of", 952], ["mutations", 955], ["in", 965], ["RPS19", 968], [".", 973], ["The", 975], ["addition", 979], ["of", 988], ["leucine", 991], ["increased", 999], ["the", 1009], ["translational", 1013], ["level", 1027], ["in", 1033], ["RPS19-non", 1036], ["-", 1045], ["mutated", 1046], ["DBA", 1054], ["cells", 1058], [",", 1063], ["but", 1065], ["not", 1069], ["in", 1073], ["cells", 1076], ["with", 1082], ["an", 1087], ["RPS19", 1090], ["mutation", 1096], [".", 1104], ["In", 1106], ["unstimulated", 1109], ["DBA", 1122], ["cells", 1126], [",", 1131], ["proliferation", 1133], ["was", 1147], ["significantly", 1151], ["impaired", 1165], ["in", 1174], ["both", 1177], ["RPS19-mutated", 1182], ["and", 1196], ["non", 1200], ["-", 1203], ["mutated", 1204], ["cells", 1212], [",", 1217], ["but", 1219], ["in", 1223], ["both", 1226], ["groups", 1231], ["could", 1238], ["be", 1244], ["efficiently", 1247], ["activated", 1259], ["by", 1269], ["PHA", 1272], [".", 1275], ["Studies", 1277], ["on", 1285], ["K562", 1288], ["cells", 1293], ["showed", 1299], ["that", 1306], ["RPS19", 1311], ["mutations", 1317], ["affecting", 1327], ["RPS19", 1337], ["conserved", 1343], ["arginines", 1353], ["R56Q", 1363], ["and", 1368], ["R62Q", 1372], ["could", 1377], ["significantly", 1383], ["inhibit", 1397], ["the", 1405], ["rate", 1409], ["of", 1414], ["protein", 1417], ["synthesis", 1425], [",", 1434], ["indicating", 1436], ["the", 1447], ["importance", 1451], ["of", 1462], ["RPS19", 1465], ["in", 1471], ["translation", 1474], [".", 1485], ["Our", 1487], ["results", 1491], ["indicate", 1499], ["that", 1508], ["inefficient", 1513], ["translation", 1525], ["may", 1537], ["be", 1541], ["the", 1544], ["main", 1548], ["cause", 1553], ["of", 1559], ["DBA", 1562], [",", 1565], ["and", 1567], ["administration", 1571], ["of", 1586], ["leucine", 1589], ["may", 1597], ["be", 1601], ["beneficial", 1604], ["for", 1615], ["at", 1619], ["least", 1622], ["some", 1628], ["DBA", 1633], ["patients", 1637], [".", 1645]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
{"context": "Excessive neointima formation often occurs after arterial injury. Interleukin-1\u03b2 (IL-1\u03b2) is a potent pleiotropic cytokine that has been shown to regulate neointimal proliferation. We investigated the effects of the IL-1\u03b2 modulator gevokizumab in a rat carotid denudation model. Sprague-Dawley rats were subjected to balloon denudation of the right carotid artery and were then randomized to receive a single subcutaneous infusion immediately after balloon injury of saline (control group, n\u00a0=\u00a013) or gevokizumab (gevokizumab groups, n\u00a0=\u00a015 in each group: 1, 10 and 50\u00a0mg/kg). We evaluated the treatment effects on carotid intima-media thickness (IMT) using ultrasonography, on endothelial regrowth using Evans Blue staining and on inflammatory response using histology. We also assessed the effects of IL-1\u03b2 and gevokizumab on human umbilical vein endothelial cells (HUVEC) and rat smooth muscle cells. We found that carotid IMT, in the proximal part of the denuded artery at day 28, was decreased by gevokizumab 1\u00a0mg/kg compared with controls. Neointima area and the intima/media area ratio were both reduced in the gevokizumab 1 mg/kg-treated group. Gevokizumab at the 1\u00a0mg/kg dose also improved endothelial regrowth. No effect was observed with gevokizumab 10 or 50\u00a0mg/kg. Gevokizumab also decreased the inflammatory effect of IL-1\u03b2 in in\u00a0vitro cell experiments and protected HUVECs from IL-1\u03b2's deleterious effects on cell migration, apoptosis and proliferation. A single administration of gevokizumab 1\u00a0mg/kg improves endothelial regrowth and reduces neointima formation in rats following carotid denudation, at least in part through its beneficial effects on endothelial cells.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "8ed1ba42499c4aceadfd18b13356a2ba", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[245, 245], [11, 11], [141, 141], [255, 255], [33, 33]], "char_spans": [[1330, 1334], [82, 86], [802, 806], [1391, 1395], [215, 219]]}]}], "context_tokens": [["Excessive", 0], ["neointima", 10], ["formation", 20], ["often", 30], ["occurs", 36], ["after", 43], ["arterial", 49], ["injury", 58], [".", 64], ["Interleukin-1\u03b2", 66], ["(", 81], ["IL-1\u03b2", 82], [")", 87], ["is", 89], ["a", 92], ["potent", 94], ["pleiotropic", 101], ["cytokine", 113], ["that", 122], ["has", 127], ["been", 131], ["shown", 136], ["to", 142], ["regulate", 145], ["neointimal", 154], ["proliferation", 165], [".", 178], ["We", 180], ["investigated", 183], ["the", 196], ["effects", 200], ["of", 208], ["the", 211], ["IL-1\u03b2", 215], ["modulator", 221], ["gevokizumab", 231], ["in", 243], ["a", 246], ["rat", 248], ["carotid", 252], ["denudation", 260], ["model", 271], [".", 276], ["Sprague", 278], ["-", 285], ["Dawley", 286], ["rats", 293], ["were", 298], ["subjected", 303], ["to", 313], ["balloon", 316], ["denudation", 324], ["of", 335], ["the", 338], ["right", 342], ["carotid", 348], ["artery", 356], ["and", 363], ["were", 367], ["then", 372], ["randomized", 377], ["to", 388], ["receive", 391], ["a", 399], ["single", 401], ["subcutaneous", 408], ["infusion", 421], ["immediately", 430], ["after", 442], ["balloon", 448], ["injury", 456], ["of", 463], ["saline", 466], ["(", 473], ["control", 474], ["group", 482], [",", 487], ["n", 489], ["=", 491], ["13", 493], [")", 495], ["or", 497], ["gevokizumab", 500], ["(", 512], ["gevokizumab", 513], ["groups", 525], [",", 531], ["n", 533], ["=", 535], ["15", 537], ["in", 540], ["each", 543], ["group", 548], [":", 553], ["1", 555], [",", 556], ["10", 558], ["and", 561], ["50", 565], ["mg", 568], ["/", 570], ["kg", 571], [")", 573], [".", 574], ["We", 576], ["evaluated", 579], ["the", 589], ["treatment", 593], ["effects", 603], ["on", 611], ["carotid", 614], ["intima", 622], ["-", 628], ["media", 629], ["thickness", 635], ["(", 645], ["IMT", 646], [")", 649], ["using", 651], ["ultrasonography", 657], [",", 672], ["on", 674], ["endothelial", 677], ["regrowth", 689], ["using", 698], ["Evans", 704], ["Blue", 710], ["staining", 715], ["and", 724], ["on", 728], ["inflammatory", 731], ["response", 744], ["using", 753], ["histology", 759], [".", 768], ["We", 770], ["also", 773], ["assessed", 778], ["the", 787], ["effects", 791], ["of", 799], ["IL-1\u03b2", 802], ["and", 808], ["gevokizumab", 812], ["on", 824], ["human", 827], ["umbilical", 833], ["vein", 843], ["endothelial", 848], ["cells", 860], ["(", 866], ["HUVEC", 867], [")", 872], ["and", 874], ["rat", 878], ["smooth", 882], ["muscle", 889], ["cells", 896], [".", 901], ["We", 903], ["found", 906], ["that", 912], ["carotid", 917], ["IMT", 925], [",", 928], ["in", 930], ["the", 933], ["proximal", 937], ["part", 946], ["of", 951], ["the", 954], ["denuded", 958], ["artery", 966], ["at", 973], ["day", 976], ["28", 980], [",", 982], ["was", 984], ["decreased", 988], ["by", 998], ["gevokizumab", 1001], ["1", 1013], ["mg", 1015], ["/", 1017], ["kg", 1018], ["compared", 1021], ["with", 1030], ["controls", 1035], [".", 1043], ["Neointima", 1045], ["area", 1055], ["and", 1060], ["the", 1064], ["intima", 1068], ["/", 1074], ["media", 1075], ["area", 1081], ["ratio", 1086], ["were", 1092], ["both", 1097], ["reduced", 1102], ["in", 1110], ["the", 1113], ["gevokizumab", 1117], ["1", 1129], ["mg", 1131], ["/", 1133], ["kg", 1134], ["-", 1136], ["treated", 1137], ["group", 1145], [".", 1150], ["Gevokizumab", 1152], ["at", 1164], ["the", 1167], ["1", 1171], ["mg", 1173], ["/", 1175], ["kg", 1176], ["dose", 1179], ["also", 1184], ["improved", 1189], ["endothelial", 1198], ["regrowth", 1210], [".", 1218], ["No", 1220], ["effect", 1223], ["was", 1230], ["observed", 1234], ["with", 1243], ["gevokizumab", 1248], ["10", 1260], ["or", 1263], ["50", 1266], ["mg", 1269], ["/", 1271], ["kg", 1272], [".", 1274], ["Gevokizumab", 1276], ["also", 1288], ["decreased", 1293], ["the", 1303], ["inflammatory", 1307], ["effect", 1320], ["of", 1327], ["IL-1\u03b2", 1330], ["in", 1336], ["in", 1339], ["vitro", 1342], ["cell", 1348], ["experiments", 1353], ["and", 1365], ["protected", 1369], ["HUVECs", 1379], ["from", 1386], ["IL-1\u03b2", 1391], ["'s", 1396], ["deleterious", 1399], ["effects", 1411], ["on", 1419], ["cell", 1422], ["migration", 1427], [",", 1436], ["apoptosis", 1438], ["and", 1448], ["proliferation", 1452], [".", 1465], ["A", 1467], ["single", 1469], ["administration", 1476], ["of", 1491], ["gevokizumab", 1494], ["1", 1506], ["mg", 1508], ["/", 1510], ["kg", 1511], ["improves", 1514], ["endothelial", 1523], ["regrowth", 1535], ["and", 1544], ["reduces", 1548], ["neointima", 1556], ["formation", 1566], ["in", 1576], ["rats", 1579], ["following", 1584], ["carotid", 1594], ["denudation", 1602], [",", 1612], ["at", 1614], ["least", 1617], ["in", 1623], ["part", 1626], ["through", 1631], ["its", 1639], ["beneficial", 1643], ["effects", 1654], ["on", 1662], ["endothelial", 1665], ["cells", 1677], [".", 1682]]}
{"context": "We have investigated the contribution of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) and mitogen-activated protein kinase (MAP kinase) in norepinephrine (NE)-induced arachidonic acid (AA) release in rabbit aortic vascular smooth muscle cells (VSMC). NE enhanced release of AA via activation of cytosolic phospholipase A2 (cPLA2) but not secretory PLA2 in VSMC prelabeled with [3H]AA. NE (10 microM) enhanced CaM kinase II and MAP kinase activity. In cells transiently transfected with antisense oligonucleotides complementary to the translation initiation sites of CaM kinase II and MAP kinase, NE-induced AA release was inhibited by 100 and 35% respectively. Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA2. NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. On the other hand, inhibition of MAP kinase kinase with PD-098059 or of MAP kinase with antisense oligonucleotides did not alter the NE-induced increase in CaM kinase II activity. Phosphorylation of MAP kinase and CaM kinase II by NE, studied by 32P incorporation and immune complex kinase assays, was inhibited by KN-93. Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA2 to release AA for prostacyclin synthesis in the rabbit VSMC. This novel pathway for activation of MAP kinase by CaM kinase II appears to be mediated through stimulation of MAP kinase kinase. Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA2 to the nuclear envelope only in the presence of extracellular Ca2+. Okadaic acid, which increased phosphorylation and activity, did not translocate these enzymes. Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA2 and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "4c1e2ae7b3044ebdbc54ebb2645c4732", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[247, 249], [305, 307], [220, 222], [101, 103], [13, 15], [210, 212], [280, 282], [79, 81], [361, 363], [176, 178], [167, 169]], "char_spans": [[1369, 1381], [1704, 1716], [1223, 1235], [581, 593], [86, 98], [1165, 1177], [1550, 1562], [424, 436], [2001, 2013], [968, 980], [928, 940]]}]}], "context_tokens": [["We", 0], ["have", 3], ["investigated", 8], ["the", 21], ["contribution", 25], ["of", 38], ["Ca2+/calmodulin", 41], ["-", 56], ["dependent", 57], ["protein", 67], ["kinase", 75], ["II", 82], ["(", 85], ["CaM", 86], ["kinase", 90], ["II", 97], [")", 99], ["and", 101], ["mitogen", 105], ["-", 112], ["activated", 113], ["protein", 123], ["kinase", 131], ["(", 138], ["MAP", 139], ["kinase", 143], [")", 149], ["in", 151], ["norepinephrine", 154], ["(", 169], ["NE)-induced", 170], ["arachidonic", 182], ["acid", 194], ["(", 199], ["AA", 200], [")", 202], ["release", 204], ["in", 212], ["rabbit", 215], ["aortic", 222], ["vascular", 229], ["smooth", 238], ["muscle", 245], ["cells", 252], ["(", 258], ["VSMC", 259], [")", 263], [".", 264], ["NE", 266], ["enhanced", 269], ["release", 278], ["of", 286], ["AA", 289], ["via", 292], ["activation", 296], ["of", 307], ["cytosolic", 310], ["phospholipase", 320], ["A2", 334], ["(", 337], ["cPLA2", 338], [")", 343], ["but", 345], ["not", 349], ["secretory", 353], ["PLA2", 363], ["in", 368], ["VSMC", 371], ["prelabeled", 376], ["with", 387], ["[", 392], ["3H]AA", 393], [".", 398], ["NE", 400], ["(", 403], ["10", 404], ["microM", 407], [")", 413], ["enhanced", 415], ["CaM", 424], ["kinase", 428], ["II", 435], ["and", 438], ["MAP", 442], ["kinase", 446], ["activity", 453], [".", 461], ["In", 463], ["cells", 466], ["transiently", 472], ["transfected", 484], ["with", 496], ["antisense", 501], ["oligonucleotides", 511], ["complementary", 528], ["to", 542], ["the", 545], ["translation", 549], ["initiation", 561], ["sites", 572], ["of", 578], ["CaM", 581], ["kinase", 585], ["II", 592], ["and", 595], ["MAP", 599], ["kinase", 603], [",", 609], ["NE", 611], ["-", 613], ["induced", 614], ["AA", 622], ["release", 625], ["was", 633], ["inhibited", 637], ["by", 647], ["100", 650], ["and", 654], ["35", 658], ["%", 660], ["respectively", 662], [".", 674], ["Treatment", 676], ["of", 686], ["cells", 689], ["with", 695], ["PD-098059", 700], [",", 709], ["a", 711], ["MAP", 713], ["kinase", 717], ["kinase", 724], ["inhibitor", 731], [",", 740], ["or", 742], ["with", 745], ["MAP", 750], ["kinase", 754], ["antisense", 761], ["oligonucleotide", 771], ["reduced", 787], ["NE", 795], ["-", 797], ["induced", 798], ["activation", 806], ["of", 817], ["MAP", 820], ["kinase", 824], ["and", 831], ["cPLA2", 835], [".", 840], ["NE", 842], ["-", 844], ["induced", 845], ["MAP", 853], ["kinase", 857], ["and", 864], ["cPLA2", 868], ["activation", 874], ["was", 885], ["also", 889], ["inhibited", 894], ["in", 904], ["cells", 907], ["treated", 913], ["with", 921], ["a", 926], ["CaM", 928], ["kinase", 932], ["II", 939], ["inhibitor", 942], [",", 951], ["KN-93", 953], [",", 958], ["or", 960], ["with", 963], ["CaM", 968], ["kinase", 972], ["II", 979], ["antisense", 982], ["oligonucleotide", 992], [".", 1007], ["On", 1009], ["the", 1012], ["other", 1016], ["hand", 1022], [",", 1026], ["inhibition", 1028], ["of", 1039], ["MAP", 1042], ["kinase", 1046], ["kinase", 1053], ["with", 1060], ["PD-098059", 1065], ["or", 1075], ["of", 1078], ["MAP", 1081], ["kinase", 1085], ["with", 1092], ["antisense", 1097], ["oligonucleotides", 1107], ["did", 1124], ["not", 1128], ["alter", 1132], ["the", 1138], ["NE", 1142], ["-", 1144], ["induced", 1145], ["increase", 1153], ["in", 1162], ["CaM", 1165], ["kinase", 1169], ["II", 1176], ["activity", 1179], [".", 1187], ["Phosphorylation", 1189], ["of", 1205], ["MAP", 1208], ["kinase", 1212], ["and", 1219], ["CaM", 1223], ["kinase", 1227], ["II", 1234], ["by", 1237], ["NE", 1240], [",", 1242], ["studied", 1244], ["by", 1252], ["32P", 1255], ["incorporation", 1259], ["and", 1273], ["immune", 1277], ["complex", 1284], ["kinase", 1292], ["assays", 1299], [",", 1305], ["was", 1307], ["inhibited", 1311], ["by", 1321], ["KN-93", 1324], [".", 1329], ["Collectively", 1331], [",", 1343], ["these", 1345], ["data", 1351], ["suggest", 1356], ["that", 1364], ["CaM", 1369], ["kinase", 1373], ["II", 1380], ["can", 1383], ["activate", 1387], ["MAP", 1396], ["kinase", 1400], [",", 1406], ["which", 1408], ["in", 1414], ["turn", 1417], ["activates", 1422], ["cPLA2", 1432], ["to", 1438], ["release", 1441], ["AA", 1449], ["for", 1452], ["prostacyclin", 1456], ["synthesis", 1469], ["in", 1479], ["the", 1482], ["rabbit", 1486], ["VSMC", 1493], [".", 1497], ["This", 1499], ["novel", 1504], ["pathway", 1510], ["for", 1518], ["activation", 1522], ["of", 1533], ["MAP", 1536], ["kinase", 1540], ["by", 1547], ["CaM", 1550], ["kinase", 1554], ["II", 1561], ["appears", 1564], ["to", 1572], ["be", 1575], ["mediated", 1578], ["through", 1587], ["stimulation", 1595], ["of", 1607], ["MAP", 1610], ["kinase", 1614], ["kinase", 1621], [".", 1627], ["Activation", 1629], ["of", 1640], ["adrenergic", 1643], ["receptors", 1654], ["with", 1664], ["NE", 1669], ["in", 1672], ["VSMC", 1675], ["caused", 1680], ["translocation", 1687], ["of", 1701], ["CaM", 1704], ["kinase", 1708], ["II", 1715], [",", 1717], ["MAP", 1719], ["kinase", 1723], [",", 1729], ["and", 1731], ["cPLA2", 1735], ["to", 1741], ["the", 1744], ["nuclear", 1748], ["envelope", 1756], ["only", 1765], ["in", 1770], ["the", 1773], ["presence", 1777], ["of", 1786], ["extracellular", 1789], ["Ca2", 1803], ["+", 1806], [".", 1807], ["Okadaic", 1809], ["acid", 1817], [",", 1821], ["which", 1823], ["increased", 1829], ["phosphorylation", 1839], ["and", 1855], ["activity", 1859], [",", 1867], ["did", 1869], ["not", 1873], ["translocate", 1877], ["these", 1889], ["enzymes", 1895], [".", 1902], ["Therefore", 1904], [",", 1913], ["it", 1915], ["appears", 1918], ["that", 1926], ["in", 1931], ["rabbit", 1934], ["VSMC", 1941], [",", 1945], ["NE", 1947], [",", 1949], ["by", 1951], ["promoting", 1954], ["extracellular", 1964], ["Ca2", 1978], ["+", 1981], ["influx", 1983], [",", 1989], ["increases", 1991], ["CaM", 2001], ["kinase", 2005], ["II", 2012], ["activity", 2015], [",", 2023], ["leading", 2025], ["to", 2033], ["activation", 2036], ["of", 2047], ["MAP", 2050], ["kinase", 2054], ["and", 2061], ["cPLA2", 2065], ["and", 2071], ["translocation", 2075], ["to", 2089], ["the", 2092], ["nuclear", 2096], ["envelope", 2104], [",", 2112], ["resulting", 2114], ["in", 2124], ["release", 2127], ["of", 2135], ["AA", 2138], ["from", 2141], ["the", 2146], ["nuclear", 2150], ["envelope", 2158], ["for", 2167], ["prostacyclin", 2171], ["synthesis", 2184], [".", 2193]]}
{"context": "Nivolumab was developed as a monoclonal antibody against programmed death receptor-1, an immune checkpoint inhibitor which negatively regulates T-cell proliferation and activation. Intravenous administration of nivolumab was approved for the treatment of unresectable malignant melanoma in 2014 in Japan. When advanced melanoma patients were treated with nivolumab, median overall survival became longer. Overall survival rate was significantly better in nivolumab-treated melanoma patients than dacarbazine-treated melanoma patients. Nivolumab had an acceptable long-term tolerability profile, with 22% of patients experiencing grade 3 or 4 adverse events related to the drug. Therefore, nivolumab can become an alternative therapy for advanced malignant melanoma.", "qas": [{"question": "Which is the target protein of the drug nivolumab?", "answers": ["programmed death receptor-1"], "qid": "2b04e73544f7459d9232316ec0e13a4a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["protein", 20], ["of", 28], ["the", 31], ["drug", 35], ["nivolumab", 40], ["?", 49]], "detected_answers": [{"text": "programmed death receptor-1", "token_spans": [[8, 10]], "char_spans": [[57, 83]]}]}], "context_tokens": [["Nivolumab", 0], ["was", 10], ["developed", 14], ["as", 24], ["a", 27], ["monoclonal", 29], ["antibody", 40], ["against", 49], ["programmed", 57], ["death", 68], ["receptor-1", 74], [",", 84], ["an", 86], ["immune", 89], ["checkpoint", 96], ["inhibitor", 107], ["which", 117], ["negatively", 123], ["regulates", 134], ["T", 144], ["-", 145], ["cell", 146], ["proliferation", 151], ["and", 165], ["activation", 169], [".", 179], ["Intravenous", 181], ["administration", 193], ["of", 208], ["nivolumab", 211], ["was", 221], ["approved", 225], ["for", 234], ["the", 238], ["treatment", 242], ["of", 252], ["unresectable", 255], ["malignant", 268], ["melanoma", 278], ["in", 287], ["2014", 290], ["in", 295], ["Japan", 298], [".", 303], ["When", 305], ["advanced", 310], ["melanoma", 319], ["patients", 328], ["were", 337], ["treated", 342], ["with", 350], ["nivolumab", 355], [",", 364], ["median", 366], ["overall", 373], ["survival", 381], ["became", 390], ["longer", 397], [".", 403], ["Overall", 405], ["survival", 413], ["rate", 422], ["was", 427], ["significantly", 431], ["better", 445], ["in", 452], ["nivolumab", 455], ["-", 464], ["treated", 465], ["melanoma", 473], ["patients", 482], ["than", 491], ["dacarbazine", 496], ["-", 507], ["treated", 508], ["melanoma", 516], ["patients", 525], [".", 533], ["Nivolumab", 535], ["had", 545], ["an", 549], ["acceptable", 552], ["long", 563], ["-", 567], ["term", 568], ["tolerability", 573], ["profile", 586], [",", 593], ["with", 595], ["22", 600], ["%", 602], ["of", 604], ["patients", 607], ["experiencing", 616], ["grade", 629], ["3", 635], ["or", 637], ["4", 640], ["adverse", 642], ["events", 650], ["related", 657], ["to", 665], ["the", 668], ["drug", 672], [".", 676], ["Therefore", 678], [",", 687], ["nivolumab", 689], ["can", 699], ["become", 703], ["an", 710], ["alternative", 713], ["therapy", 725], ["for", 733], ["advanced", 737], ["malignant", 746], ["melanoma", 756], [".", 764]]}
{"context": "Neurofibromatosis type 1 (NF1) gene is a tumor suppressor gene, and the NF1 gene product, neurofibromin, can downregulate the N-ras gene. Because the N-ras gene is often mutated in acute myelogenous leukemia (AML), we wondered if the NF1 gene might be mutated in those AML samples not having N-ras mutations. We investigated the mutational status of the N-ras gene and the FLR exon of codons 1371-1423 of the open reading frame of the full-length NF1 cDNA, which has a strong homology with the mammalian ras GTPase-activating protein (GAP), especially for a stretch of three consecutive amino acids (F, L, R), by single-strand conformation polymorphism analysis and direct sequencing in samples from patients with AML. Of 48 AML patients, 10 (21%) had point (missense) mutations of the N-ras gene involving codons 12, 13 and 61. However, mutations in the FLR exon of the NF1 gene were not detected in any of the AML samples. We also examined the difference of clinical response to induction therapy between AML patients with and without N-ras mutation. A significantly lower rate of complete remission was noted in individuals with N-ras gene mutations. These results suggest that mutation of the NF1 gene, at least in the FLR exon, is very rare in AML and the NF1 gene probably is not a functional complement of the N-ras gene mutation. The presence of N-ras gene mutation may be associated with a lower clinical response to antileukemic therapy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "fb9d60b81eed4b7e93174fdf341800eb", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[96, 96], [189, 189], [4, 4], [265, 265], [248, 248], [50, 50], [15, 15]], "char_spans": [[447, 449], [871, 873], [26, 28], [1261, 1263], [1197, 1199], [234, 236], [72, 74]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["gene", 31], ["is", 36], ["a", 39], ["tumor", 41], ["suppressor", 47], ["gene", 58], [",", 62], ["and", 64], ["the", 68], ["NF1", 72], ["gene", 76], ["product", 81], [",", 88], ["neurofibromin", 90], [",", 103], ["can", 105], ["downregulate", 109], ["the", 122], ["N", 126], ["-", 127], ["ras", 128], ["gene", 132], [".", 136], ["Because", 138], ["the", 146], ["N", 150], ["-", 151], ["ras", 152], ["gene", 156], ["is", 161], ["often", 164], ["mutated", 170], ["in", 178], ["acute", 181], ["myelogenous", 187], ["leukemia", 199], ["(", 208], ["AML", 209], [")", 212], [",", 213], ["we", 215], ["wondered", 218], ["if", 227], ["the", 230], ["NF1", 234], ["gene", 238], ["might", 243], ["be", 249], ["mutated", 252], ["in", 260], ["those", 263], ["AML", 269], ["samples", 273], ["not", 281], ["having", 285], ["N", 292], ["-", 293], ["ras", 294], ["mutations", 298], [".", 307], ["We", 309], ["investigated", 312], ["the", 325], ["mutational", 329], ["status", 340], ["of", 347], ["the", 350], ["N", 354], ["-", 355], ["ras", 356], ["gene", 360], ["and", 365], ["the", 369], ["FLR", 373], ["exon", 377], ["of", 382], ["codons", 385], ["1371", 392], ["-", 396], ["1423", 397], ["of", 402], ["the", 405], ["open", 409], ["reading", 414], ["frame", 422], ["of", 428], ["the", 431], ["full", 435], ["-", 439], ["length", 440], ["NF1", 447], ["cDNA", 451], [",", 455], ["which", 457], ["has", 463], ["a", 467], ["strong", 469], ["homology", 476], ["with", 485], ["the", 490], ["mammalian", 494], ["ras", 504], ["GTPase", 508], ["-", 514], ["activating", 515], ["protein", 526], ["(", 534], ["GAP", 535], [")", 538], [",", 539], ["especially", 541], ["for", 552], ["a", 556], ["stretch", 558], ["of", 566], ["three", 569], ["consecutive", 575], ["amino", 587], ["acids", 593], ["(", 599], ["F", 600], [",", 601], ["L", 603], [",", 604], ["R", 606], [")", 607], [",", 608], ["by", 610], ["single", 613], ["-", 619], ["strand", 620], ["conformation", 627], ["polymorphism", 640], ["analysis", 653], ["and", 662], ["direct", 666], ["sequencing", 673], ["in", 684], ["samples", 687], ["from", 695], ["patients", 700], ["with", 709], ["AML", 714], [".", 717], ["Of", 719], ["48", 722], ["AML", 725], ["patients", 729], [",", 737], ["10", 739], ["(", 742], ["21", 743], ["%", 745], [")", 746], ["had", 748], ["point", 752], ["(", 758], ["missense", 759], [")", 767], ["mutations", 769], ["of", 779], ["the", 782], ["N", 786], ["-", 787], ["ras", 788], ["gene", 792], ["involving", 797], ["codons", 807], ["12", 814], [",", 816], ["13", 818], ["and", 821], ["61", 825], [".", 827], ["However", 829], [",", 836], ["mutations", 838], ["in", 848], ["the", 851], ["FLR", 855], ["exon", 859], ["of", 864], ["the", 867], ["NF1", 871], ["gene", 875], ["were", 880], ["not", 885], ["detected", 889], ["in", 898], ["any", 901], ["of", 905], ["the", 908], ["AML", 912], ["samples", 916], [".", 923], ["We", 925], ["also", 928], ["examined", 933], ["the", 942], ["difference", 946], ["of", 957], ["clinical", 960], ["response", 969], ["to", 978], ["induction", 981], ["therapy", 991], ["between", 999], ["AML", 1007], ["patients", 1011], ["with", 1020], ["and", 1025], ["without", 1029], ["N", 1037], ["-", 1038], ["ras", 1039], ["mutation", 1043], [".", 1051], ["A", 1053], ["significantly", 1055], ["lower", 1069], ["rate", 1075], ["of", 1080], ["complete", 1083], ["remission", 1092], ["was", 1102], ["noted", 1106], ["in", 1112], ["individuals", 1115], ["with", 1127], ["N", 1132], ["-", 1133], ["ras", 1134], ["gene", 1138], ["mutations", 1143], [".", 1152], ["These", 1154], ["results", 1160], ["suggest", 1168], ["that", 1176], ["mutation", 1181], ["of", 1190], ["the", 1193], ["NF1", 1197], ["gene", 1201], [",", 1205], ["at", 1207], ["least", 1210], ["in", 1216], ["the", 1219], ["FLR", 1223], ["exon", 1227], [",", 1231], ["is", 1233], ["very", 1236], ["rare", 1241], ["in", 1246], ["AML", 1249], ["and", 1253], ["the", 1257], ["NF1", 1261], ["gene", 1265], ["probably", 1270], ["is", 1279], ["not", 1282], ["a", 1286], ["functional", 1288], ["complement", 1299], ["of", 1310], ["the", 1313], ["N", 1317], ["-", 1318], ["ras", 1319], ["gene", 1323], ["mutation", 1328], [".", 1336], ["The", 1338], ["presence", 1342], ["of", 1351], ["N", 1354], ["-", 1355], ["ras", 1356], ["gene", 1360], ["mutation", 1365], ["may", 1374], ["be", 1378], ["associated", 1381], ["with", 1392], ["a", 1397], ["lower", 1399], ["clinical", 1405], ["response", 1414], ["to", 1423], ["antileukemic", 1426], ["therapy", 1439], [".", 1446]]}
{"context": "We conducted a review of patient medical records to assess treatment response patterns and prognostic indicators of response among chronic myeloid leukemia (CML) patients in the United States, the United Kingdom, Germany, and Japan. All 1,063 patients selected met the following inclusion criteria: aged 18 or older and in chronic phase at the time of diagnosis, Philadelphia chromosome and/or BCR-ABL positive, received first-line treatment with imatinib, and not enrolled in a randomized clinical trial during the period of retrospective review. Multivariable logistic regression models were used to evaluate prognostic indicators of complete hematological response (CHR), complete cytogenetic response (CCyR), and complete or major molecular response (C/MMR). Among patients treated with first-line imatinib, CHR at three months, CCyR at 12 months, and C/MMR at 18 months were observed in 53, 53.1, and 57.8 % of patients, respectively. Among patients treated with second-line dasatinib or nilotinib, CHR was achieved at three months in 49 and 42 %, CCyR at 12 months in 32 and 23 %, and MMR at 18 months in 30.5 and 26.1 % of patients, respectively. Prognostic indicators of first-line response included age, race, and Sokal score. For second-line treatment, duration of first-line hematological response and choice of drug used were also significant.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7f2a7d1273d0421f802f06a3bb2fdbbe", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[67, 69]], "char_spans": [[394, 400]]}]}], "context_tokens": [["We", 0], ["conducted", 3], ["a", 13], ["review", 15], ["of", 22], ["patient", 25], ["medical", 33], ["records", 41], ["to", 49], ["assess", 52], ["treatment", 59], ["response", 69], ["patterns", 78], ["and", 87], ["prognostic", 91], ["indicators", 102], ["of", 113], ["response", 116], ["among", 125], ["chronic", 131], ["myeloid", 139], ["leukemia", 147], ["(", 156], ["CML", 157], [")", 160], ["patients", 162], ["in", 171], ["the", 174], ["United", 178], ["States", 185], [",", 191], ["the", 193], ["United", 197], ["Kingdom", 204], [",", 211], ["Germany", 213], [",", 220], ["and", 222], ["Japan", 226], [".", 231], ["All", 233], ["1,063", 237], ["patients", 243], ["selected", 252], ["met", 261], ["the", 265], ["following", 269], ["inclusion", 279], ["criteria", 289], [":", 297], ["aged", 299], ["18", 304], ["or", 307], ["older", 310], ["and", 316], ["in", 320], ["chronic", 323], ["phase", 331], ["at", 337], ["the", 340], ["time", 344], ["of", 349], ["diagnosis", 352], [",", 361], ["Philadelphia", 363], ["chromosome", 376], ["and/or", 387], ["BCR", 394], ["-", 397], ["ABL", 398], ["positive", 402], [",", 410], ["received", 412], ["first", 421], ["-", 426], ["line", 427], ["treatment", 432], ["with", 442], ["imatinib", 447], [",", 455], ["and", 457], ["not", 461], ["enrolled", 465], ["in", 474], ["a", 477], ["randomized", 479], ["clinical", 490], ["trial", 499], ["during", 505], ["the", 512], ["period", 516], ["of", 523], ["retrospective", 526], ["review", 540], [".", 546], ["Multivariable", 548], ["logistic", 562], ["regression", 571], ["models", 582], ["were", 589], ["used", 594], ["to", 599], ["evaluate", 602], ["prognostic", 611], ["indicators", 622], ["of", 633], ["complete", 636], ["hematological", 645], ["response", 659], ["(", 668], ["CHR", 669], [")", 672], [",", 673], ["complete", 675], ["cytogenetic", 684], ["response", 696], ["(", 705], ["CCyR", 706], [")", 710], [",", 711], ["and", 713], ["complete", 717], ["or", 726], ["major", 729], ["molecular", 735], ["response", 745], ["(", 754], ["C", 755], ["/", 756], ["MMR", 757], [")", 760], [".", 761], ["Among", 763], ["patients", 769], ["treated", 778], ["with", 786], ["first", 791], ["-", 796], ["line", 797], ["imatinib", 802], [",", 810], ["CHR", 812], ["at", 816], ["three", 819], ["months", 825], [",", 831], ["CCyR", 833], ["at", 838], ["12", 841], ["months", 844], [",", 850], ["and", 852], ["C", 856], ["/", 857], ["MMR", 858], ["at", 862], ["18", 865], ["months", 868], ["were", 875], ["observed", 880], ["in", 889], ["53", 892], [",", 894], ["53.1", 896], [",", 900], ["and", 902], ["57.8", 906], ["%", 911], ["of", 913], ["patients", 916], [",", 924], ["respectively", 926], [".", 938], ["Among", 940], ["patients", 946], ["treated", 955], ["with", 963], ["second", 968], ["-", 974], ["line", 975], ["dasatinib", 980], ["or", 990], ["nilotinib", 993], [",", 1002], ["CHR", 1004], ["was", 1008], ["achieved", 1012], ["at", 1021], ["three", 1024], ["months", 1030], ["in", 1037], ["49", 1040], ["and", 1043], ["42", 1047], ["%", 1050], [",", 1051], ["CCyR", 1053], ["at", 1058], ["12", 1061], ["months", 1064], ["in", 1071], ["32", 1074], ["and", 1077], ["23", 1081], ["%", 1084], [",", 1085], ["and", 1087], ["MMR", 1091], ["at", 1095], ["18", 1098], ["months", 1101], ["in", 1108], ["30.5", 1111], ["and", 1116], ["26.1", 1120], ["%", 1125], ["of", 1127], ["patients", 1130], [",", 1138], ["respectively", 1140], [".", 1152], ["Prognostic", 1154], ["indicators", 1165], ["of", 1176], ["first", 1179], ["-", 1184], ["line", 1185], ["response", 1190], ["included", 1199], ["age", 1208], [",", 1211], ["race", 1213], [",", 1217], ["and", 1219], ["Sokal", 1223], ["score", 1229], [".", 1234], ["For", 1236], ["second", 1240], ["-", 1246], ["line", 1247], ["treatment", 1252], [",", 1261], ["duration", 1263], ["of", 1272], ["first", 1275], ["-", 1280], ["line", 1281], ["hematological", 1286], ["response", 1300], ["and", 1309], ["choice", 1313], ["of", 1320], ["drug", 1323], ["used", 1328], ["were", 1333], ["also", 1338], ["significant", 1343], [".", 1354]]}
{"context": "Monosomy for the X chromosome is the most frequent cause of Turner's syndrome, a common clinical syndrome associated with particular physical and neurobehavioral features. The results from comprehensive assessment of prepubertal monozygotic female twins discordant for X monosomy are presented. Zygosity was established with DNA Fingerprinting and no evidence of chromosomal mosaicism was seen in either child. Physical features in the affected twin were relatively mild with respect to the full spectrum of physical malformations and disabilities associated with Turner's syndrome. The neurobehavioral phenotypes of the twins were compared. Although both sisters scored in the superior range of intelligence, the affected twin's Performance IQ was 18 points less than her sister, whereas Verbal IQ showed only a 3-point difference between the sisters. Other relative differences were noted within the executive, visuospatial, and visuomotor domains of function. Behavioral evaluation indicated greater problems with attention, hyperactivity, and anxiety in the affected twin. Quantitative analysis of brain anatomy revealed evidence of both general and regional effects of X monosomy on neurodevelopment. Cerebrospinal fluid volume was increased by 25% in the affected twin compared with her sister with a corresponding decrease in gray matter volume. The right frontal, right parietal-occipital, and left parietal-perisylvian regions showed the greatest discrepancy between the sisters with respect to increased cerebrospinal fluid and decreased gray matter volumes in twin with X monosomy. Differences in the posterior fossa were also noted with a 50% relative increase in the volumes of the fourth ventricle and cisterna magna and a 10 to 15% relative reduction in size of the cerebellar vermis, pons, and medulla in the affected twin. The association between the neurobehavioral and neuroanatomical findings in the affected twin is discussed. The unique nature of the naturally occurring genetic phenomenon seen in this twin pair provides an opportunity to more fully elucidate the neurobehavioral phenotype associated with X monosomy and Turner's syndrome.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "7e00d62adabb4717889af97b4ed46c4c", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[3, 3], [182, 182], [340, 340], [39, 39], [248, 248]], "char_spans": [[17, 17], [1174, 1174], [2129, 2129], [269, 269], [1581, 1581]]}]}], "context_tokens": [["Monosomy", 0], ["for", 9], ["the", 13], ["X", 17], ["chromosome", 19], ["is", 30], ["the", 33], ["most", 37], ["frequent", 42], ["cause", 51], ["of", 57], ["Turner", 60], ["'s", 66], ["syndrome", 69], [",", 77], ["a", 79], ["common", 81], ["clinical", 88], ["syndrome", 97], ["associated", 106], ["with", 117], ["particular", 122], ["physical", 133], ["and", 142], ["neurobehavioral", 146], ["features", 162], [".", 170], ["The", 172], ["results", 176], ["from", 184], ["comprehensive", 189], ["assessment", 203], ["of", 214], ["prepubertal", 217], ["monozygotic", 229], ["female", 241], ["twins", 248], ["discordant", 254], ["for", 265], ["X", 269], ["monosomy", 271], ["are", 280], ["presented", 284], [".", 293], ["Zygosity", 295], ["was", 304], ["established", 308], ["with", 320], ["DNA", 325], ["Fingerprinting", 329], ["and", 344], ["no", 348], ["evidence", 351], ["of", 360], ["chromosomal", 363], ["mosaicism", 375], ["was", 385], ["seen", 389], ["in", 394], ["either", 397], ["child", 404], [".", 409], ["Physical", 411], ["features", 420], ["in", 429], ["the", 432], ["affected", 436], ["twin", 445], ["were", 450], ["relatively", 455], ["mild", 466], ["with", 471], ["respect", 476], ["to", 484], ["the", 487], ["full", 491], ["spectrum", 496], ["of", 505], ["physical", 508], ["malformations", 517], ["and", 531], ["disabilities", 535], ["associated", 548], ["with", 559], ["Turner", 564], ["'s", 570], ["syndrome", 573], [".", 581], ["The", 583], ["neurobehavioral", 587], ["phenotypes", 603], ["of", 614], ["the", 617], ["twins", 621], ["were", 627], ["compared", 632], [".", 640], ["Although", 642], ["both", 651], ["sisters", 656], ["scored", 664], ["in", 671], ["the", 674], ["superior", 678], ["range", 687], ["of", 693], ["intelligence", 696], [",", 708], ["the", 710], ["affected", 714], ["twin", 723], ["'s", 727], ["Performance", 730], ["IQ", 742], ["was", 745], ["18", 749], ["points", 752], ["less", 759], ["than", 764], ["her", 769], ["sister", 773], [",", 779], ["whereas", 781], ["Verbal", 789], ["IQ", 796], ["showed", 799], ["only", 806], ["a", 811], ["3-point", 813], ["difference", 821], ["between", 832], ["the", 840], ["sisters", 844], [".", 851], ["Other", 853], ["relative", 859], ["differences", 868], ["were", 880], ["noted", 885], ["within", 891], ["the", 898], ["executive", 902], [",", 911], ["visuospatial", 913], [",", 925], ["and", 927], ["visuomotor", 931], ["domains", 942], ["of", 950], ["function", 953], [".", 961], ["Behavioral", 963], ["evaluation", 974], ["indicated", 985], ["greater", 995], ["problems", 1003], ["with", 1012], ["attention", 1017], [",", 1026], ["hyperactivity", 1028], [",", 1041], ["and", 1043], ["anxiety", 1047], ["in", 1055], ["the", 1058], ["affected", 1062], ["twin", 1071], [".", 1075], ["Quantitative", 1077], ["analysis", 1090], ["of", 1099], ["brain", 1102], ["anatomy", 1108], ["revealed", 1116], ["evidence", 1125], ["of", 1134], ["both", 1137], ["general", 1142], ["and", 1150], ["regional", 1154], ["effects", 1163], ["of", 1171], ["X", 1174], ["monosomy", 1176], ["on", 1185], ["neurodevelopment", 1188], [".", 1204], ["Cerebrospinal", 1206], ["fluid", 1220], ["volume", 1226], ["was", 1233], ["increased", 1237], ["by", 1247], ["25", 1250], ["%", 1252], ["in", 1254], ["the", 1257], ["affected", 1261], ["twin", 1270], ["compared", 1275], ["with", 1284], ["her", 1289], ["sister", 1293], ["with", 1300], ["a", 1305], ["corresponding", 1307], ["decrease", 1321], ["in", 1330], ["gray", 1333], ["matter", 1338], ["volume", 1345], [".", 1351], ["The", 1353], ["right", 1357], ["frontal", 1363], [",", 1370], ["right", 1372], ["parietal", 1378], ["-", 1386], ["occipital", 1387], [",", 1396], ["and", 1398], ["left", 1402], ["parietal", 1407], ["-", 1415], ["perisylvian", 1416], ["regions", 1428], ["showed", 1436], ["the", 1443], ["greatest", 1447], ["discrepancy", 1456], ["between", 1468], ["the", 1476], ["sisters", 1480], ["with", 1488], ["respect", 1493], ["to", 1501], ["increased", 1504], ["cerebrospinal", 1514], ["fluid", 1528], ["and", 1534], ["decreased", 1538], ["gray", 1548], ["matter", 1553], ["volumes", 1560], ["in", 1568], ["twin", 1571], ["with", 1576], ["X", 1581], ["monosomy", 1583], [".", 1591], ["Differences", 1593], ["in", 1605], ["the", 1608], ["posterior", 1612], ["fossa", 1622], ["were", 1628], ["also", 1633], ["noted", 1638], ["with", 1644], ["a", 1649], ["50", 1651], ["%", 1653], ["relative", 1655], ["increase", 1664], ["in", 1673], ["the", 1676], ["volumes", 1680], ["of", 1688], ["the", 1691], ["fourth", 1695], ["ventricle", 1702], ["and", 1712], ["cisterna", 1716], ["magna", 1725], ["and", 1731], ["a", 1735], ["10", 1737], ["to", 1740], ["15", 1743], ["%", 1745], ["relative", 1747], ["reduction", 1756], ["in", 1766], ["size", 1769], ["of", 1774], ["the", 1777], ["cerebellar", 1781], ["vermis", 1792], [",", 1798], ["pons", 1800], [",", 1804], ["and", 1806], ["medulla", 1810], ["in", 1818], ["the", 1821], ["affected", 1825], ["twin", 1834], [".", 1838], ["The", 1840], ["association", 1844], ["between", 1856], ["the", 1864], ["neurobehavioral", 1868], ["and", 1884], ["neuroanatomical", 1888], ["findings", 1904], ["in", 1913], ["the", 1916], ["affected", 1920], ["twin", 1929], ["is", 1934], ["discussed", 1937], [".", 1946], ["The", 1948], ["unique", 1952], ["nature", 1959], ["of", 1966], ["the", 1969], ["naturally", 1973], ["occurring", 1983], ["genetic", 1993], ["phenomenon", 2001], ["seen", 2012], ["in", 2017], ["this", 2020], ["twin", 2025], ["pair", 2030], ["provides", 2035], ["an", 2044], ["opportunity", 2047], ["to", 2059], ["more", 2062], ["fully", 2067], ["elucidate", 2073], ["the", 2083], ["neurobehavioral", 2087], ["phenotype", 2103], ["associated", 2113], ["with", 2124], ["X", 2129], ["monosomy", 2131], ["and", 2140], ["Turner", 2144], ["'s", 2150], ["syndrome", 2153], [".", 2161]]}
{"context": "Focal cortical dysplasia is a malformation of cortical development, which is the most common cause of medically refractory epilepsy in the pediatric population and the second/third most common etiology of medically intractable seizures in adults.Both genetic and acquired factors are involved in the pathogenesis of cortical dysplasia. Numerous classifications of the complex structural abnormalities of focal cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made by Blumcke in 2011. In general, three types of cortical dysplasia are recognized.Type I focal cortical dysplasia with mild symptomatic expression and late onset, is more often seen in adults, with changes present in the temporal lobe.Clinical symptoms are more severe in type II of cortical dysplasia usually seen in children. In this type, more extensive changes occur outside the temporal lobe with predilection for the frontal lobes.New type III is one of the above dysplasias with associated another principal lesion as hippocampal sclerosis, tumor, vascular malformation or acquired pathology during early life.Brain MRI imaging shows abnormalities in the majority of type II dysplasias and in only some of type I cortical dysplasias.THE MOST COMMON FINDINGS ON MRI IMAGING INCLUDE: focal cortical thickening or thinning, areas of focal brain atrophy, blurring of the gray-white junction, increased signal on T2- and FLAIR-weighted images in the gray and subcortical white matter often tapering toward the ventricle. On the basis of the MRI findings, it is possible to differentiate between type I and type II cortical dysplasia. A complete resection of the epileptogenic zone is required for seizure-free life. MRI imaging is very helpful to identify those patients who are likely to benefit from surgical treatment in a group of patients with drug-resistant epilepsy.However, in type I cortical dysplasia, MR imaging is often normal, and also in both types the lesion seen on MRI may be smaller than the seizure-generating region seen in the EEG. The abnormalities may also involve vital for life brain parts, where curative surgery will not be an option. Therefore, other diagnostic imaging techniques such as FDG PET, MEG, DTI and intra-cranial EEG are widely used to establish the diagnosis and to decide on management.With advances in both genetics and neuroimaging, we may develop a better understanding of patients with drug-resistant epilepsy, which will help us to provide more successful pharmacological and/or surgical treatment in the future.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "6016428d0f8e493c8cbd0a4863c7c102", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[101, 103], [61, 63], [0, 2]], "char_spans": [[621, 644], [404, 427], [0, 23]]}]}], "context_tokens": [["Focal", 0], ["cortical", 6], ["dysplasia", 15], ["is", 25], ["a", 28], ["malformation", 30], ["of", 43], ["cortical", 46], ["development", 55], [",", 66], ["which", 68], ["is", 74], ["the", 77], ["most", 81], ["common", 86], ["cause", 93], ["of", 99], ["medically", 102], ["refractory", 112], ["epilepsy", 123], ["in", 132], ["the", 135], ["pediatric", 139], ["population", 149], ["and", 160], ["the", 164], ["second", 168], ["/", 174], ["third", 175], ["most", 181], ["common", 186], ["etiology", 193], ["of", 202], ["medically", 205], ["intractable", 215], ["seizures", 227], ["in", 236], ["adults", 239], [".", 245], ["Both", 246], ["genetic", 251], ["and", 259], ["acquired", 263], ["factors", 272], ["are", 280], ["involved", 284], ["in", 293], ["the", 296], ["pathogenesis", 300], ["of", 313], ["cortical", 316], ["dysplasia", 325], [".", 334], ["Numerous", 336], ["classifications", 345], ["of", 361], ["the", 364], ["complex", 368], ["structural", 376], ["abnormalities", 387], ["of", 401], ["focal", 404], ["cortical", 410], ["dysplasia", 419], ["have", 429], ["been", 434], ["proposed", 439], ["-", 448], ["from", 450], ["Taylor", 455], ["et", 462], ["al", 465], [".", 467], ["in", 469], ["1971", 472], ["to", 477], ["the", 480], ["last", 484], ["modification", 489], ["of", 502], ["Palmini", 505], ["classification", 513], ["made", 528], ["by", 533], ["Blumcke", 536], ["in", 544], ["2011", 547], [".", 551], ["In", 553], ["general", 556], [",", 563], ["three", 565], ["types", 571], ["of", 577], ["cortical", 580], ["dysplasia", 589], ["are", 599], ["recognized", 603], [".", 613], ["Type", 614], ["I", 619], ["focal", 621], ["cortical", 627], ["dysplasia", 636], ["with", 646], ["mild", 651], ["symptomatic", 656], ["expression", 668], ["and", 679], ["late", 683], ["onset", 688], [",", 693], ["is", 695], ["more", 698], ["often", 703], ["seen", 709], ["in", 714], ["adults", 717], [",", 723], ["with", 725], ["changes", 730], ["present", 738], ["in", 746], ["the", 749], ["temporal", 753], ["lobe", 762], [".", 766], ["Clinical", 767], ["symptoms", 776], ["are", 785], ["more", 789], ["severe", 794], ["in", 801], ["type", 804], ["II", 809], ["of", 812], ["cortical", 815], ["dysplasia", 824], ["usually", 834], ["seen", 842], ["in", 847], ["children", 850], [".", 858], ["In", 860], ["this", 863], ["type", 868], [",", 872], ["more", 874], ["extensive", 879], ["changes", 889], ["occur", 897], ["outside", 903], ["the", 911], ["temporal", 915], ["lobe", 924], ["with", 929], ["predilection", 934], ["for", 947], ["the", 951], ["frontal", 955], ["lobes", 963], [".", 968], ["New", 969], ["type", 973], ["III", 978], ["is", 982], ["one", 985], ["of", 989], ["the", 992], ["above", 996], ["dysplasias", 1002], ["with", 1013], ["associated", 1018], ["another", 1029], ["principal", 1037], ["lesion", 1047], ["as", 1054], ["hippocampal", 1057], ["sclerosis", 1069], [",", 1078], ["tumor", 1080], [",", 1085], ["vascular", 1087], ["malformation", 1096], ["or", 1109], ["acquired", 1112], ["pathology", 1121], ["during", 1131], ["early", 1138], ["life", 1144], [".", 1148], ["Brain", 1149], ["MRI", 1155], ["imaging", 1159], ["shows", 1167], ["abnormalities", 1173], ["in", 1187], ["the", 1190], ["majority", 1194], ["of", 1203], ["type", 1206], ["II", 1211], ["dysplasias", 1214], ["and", 1225], ["in", 1229], ["only", 1232], ["some", 1237], ["of", 1242], ["type", 1245], ["I", 1250], ["cortical", 1252], ["dysplasias", 1261], [".", 1271], ["THE", 1272], ["MOST", 1276], ["COMMON", 1281], ["FINDINGS", 1288], ["ON", 1297], ["MRI", 1300], ["IMAGING", 1304], ["INCLUDE", 1312], [":", 1319], ["focal", 1321], ["cortical", 1327], ["thickening", 1336], ["or", 1347], ["thinning", 1350], [",", 1358], ["areas", 1360], ["of", 1366], ["focal", 1369], ["brain", 1375], ["atrophy", 1381], [",", 1388], ["blurring", 1390], ["of", 1399], ["the", 1402], ["gray", 1406], ["-", 1410], ["white", 1411], ["junction", 1417], [",", 1425], ["increased", 1427], ["signal", 1437], ["on", 1444], ["T2-", 1447], ["and", 1451], ["FLAIR", 1455], ["-", 1460], ["weighted", 1461], ["images", 1470], ["in", 1477], ["the", 1480], ["gray", 1484], ["and", 1489], ["subcortical", 1493], ["white", 1505], ["matter", 1511], ["often", 1518], ["tapering", 1524], ["toward", 1533], ["the", 1540], ["ventricle", 1544], [".", 1553], ["On", 1555], ["the", 1558], ["basis", 1562], ["of", 1568], ["the", 1571], ["MRI", 1575], ["findings", 1579], [",", 1587], ["it", 1589], ["is", 1592], ["possible", 1595], ["to", 1604], ["differentiate", 1607], ["between", 1621], ["type", 1629], ["I", 1634], ["and", 1636], ["type", 1640], ["II", 1645], ["cortical", 1648], ["dysplasia", 1657], [".", 1666], ["A", 1668], ["complete", 1670], ["resection", 1679], ["of", 1689], ["the", 1692], ["epileptogenic", 1696], ["zone", 1710], ["is", 1715], ["required", 1718], ["for", 1727], ["seizure", 1731], ["-", 1738], ["free", 1739], ["life", 1744], [".", 1748], ["MRI", 1750], ["imaging", 1754], ["is", 1762], ["very", 1765], ["helpful", 1770], ["to", 1778], ["identify", 1781], ["those", 1790], ["patients", 1796], ["who", 1805], ["are", 1809], ["likely", 1813], ["to", 1820], ["benefit", 1823], ["from", 1831], ["surgical", 1836], ["treatment", 1845], ["in", 1855], ["a", 1858], ["group", 1860], ["of", 1866], ["patients", 1869], ["with", 1878], ["drug", 1883], ["-", 1887], ["resistant", 1888], ["epilepsy", 1898], [".", 1906], ["However", 1907], [",", 1914], ["in", 1916], ["type", 1919], ["I", 1924], ["cortical", 1926], ["dysplasia", 1935], [",", 1944], ["MR", 1946], ["imaging", 1949], ["is", 1957], ["often", 1960], ["normal", 1966], [",", 1972], ["and", 1974], ["also", 1978], ["in", 1983], ["both", 1986], ["types", 1991], ["the", 1997], ["lesion", 2001], ["seen", 2008], ["on", 2013], ["MRI", 2016], ["may", 2020], ["be", 2024], ["smaller", 2027], ["than", 2035], ["the", 2040], ["seizure", 2044], ["-", 2051], ["generating", 2052], ["region", 2063], ["seen", 2070], ["in", 2075], ["the", 2078], ["EEG", 2082], [".", 2085], ["The", 2087], ["abnormalities", 2091], ["may", 2105], ["also", 2109], ["involve", 2114], ["vital", 2122], ["for", 2128], ["life", 2132], ["brain", 2137], ["parts", 2143], [",", 2148], ["where", 2150], ["curative", 2156], ["surgery", 2165], ["will", 2173], ["not", 2178], ["be", 2182], ["an", 2185], ["option", 2188], [".", 2194], ["Therefore", 2196], [",", 2205], ["other", 2207], ["diagnostic", 2213], ["imaging", 2224], ["techniques", 2232], ["such", 2243], ["as", 2248], ["FDG", 2251], ["PET", 2255], [",", 2258], ["MEG", 2260], [",", 2263], ["DTI", 2265], ["and", 2269], ["intra", 2273], ["-", 2278], ["cranial", 2279], ["EEG", 2287], ["are", 2291], ["widely", 2295], ["used", 2302], ["to", 2307], ["establish", 2310], ["the", 2320], ["diagnosis", 2324], ["and", 2334], ["to", 2338], ["decide", 2341], ["on", 2348], ["management", 2351], [".", 2361], ["With", 2362], ["advances", 2367], ["in", 2376], ["both", 2379], ["genetics", 2384], ["and", 2393], ["neuroimaging", 2397], [",", 2409], ["we", 2411], ["may", 2414], ["develop", 2418], ["a", 2426], ["better", 2428], ["understanding", 2435], ["of", 2449], ["patients", 2452], ["with", 2461], ["drug", 2466], ["-", 2470], ["resistant", 2471], ["epilepsy", 2481], [",", 2489], ["which", 2491], ["will", 2497], ["help", 2502], ["us", 2507], ["to", 2510], ["provide", 2513], ["more", 2521], ["successful", 2526], ["pharmacological", 2537], ["and/or", 2553], ["surgical", 2560], ["treatment", 2569], ["in", 2579], ["the", 2582], ["future", 2586], [".", 2592]]}
{"context": "To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. A literature search was conducted consisting of a PubMed database using the MeSH term idarucizumab and the key word dabigatran antidote. Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of idarucizumab for the reversal of the anticoagulant activity of dabigatran were included. Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran. Studies evaluating reversal of dabigatran-induced anticoagulation have demonstrated immediate, complete, and sustained effects with idarucizumab. Idarucizumab did not overcorrect thrombin generation. Additionally, evaluations have shown that dabigatran can be safely reinitiated 24 hours after the administration of idarucizumab. The United States Food and Drug Administration granted priority review for the biologic license application and accelerated approval for idarucizumab. Idarucizumab represents an encouraging development in the reversal of dabigatran. Its novel mechanism of action, pharmacokinetics, tolerability, and lack of thrombotic events contribute positively to its use in patients who experience bleeding or for those who require emergent surgery or procedures.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "ef28a6cc8b5d472b98e489b35d514e0b", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[186, 186], [108, 108], [60, 60], [84, 84], [23, 23], [114, 114], [143, 143]], "char_spans": [[1252, 1261], [689, 698], [366, 375], [529, 538], [143, 152], [732, 741], [943, 952]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["role", 16], ["of", 21], ["idarucizumab", 24], [",", 36], ["a", 38], ["humanized", 40], ["monoclonal", 50], ["antibody", 61], ["fragment", 70], [",", 78], ["as", 80], ["a", 83], ["specific", 85], ["reversal", 94], ["agent", 103], ["for", 109], ["the", 113], ["anticoagulant", 117], ["activity", 131], ["of", 140], ["dabigatran", 143], ["and", 154], ["to", 158], ["review", 161], ["the", 168], ["pharmacology", 172], [",", 184], ["pharmacokinetic", 186], ["properties", 202], [",", 212], ["efficacy", 214], [",", 222], ["and", 224], ["safety", 228], ["of", 235], ["this", 238], ["agent", 243], [".", 248], ["A", 250], ["literature", 252], ["search", 263], ["was", 270], ["conducted", 274], ["consisting", 284], ["of", 295], ["a", 298], ["PubMed", 300], ["database", 307], ["using", 316], ["the", 322], ["MeSH", 326], ["term", 331], ["idarucizumab", 336], ["and", 349], ["the", 353], ["key", 357], ["word", 361], ["dabigatran", 366], ["antidote", 377], [".", 385], ["Studies", 387], ["evaluating", 395], ["the", 406], ["pharmacology", 410], [",", 422], ["pharmacokinetics", 424], [",", 440], ["safety", 442], [",", 448], ["and", 450], ["efficacy", 454], ["of", 463], ["idarucizumab", 466], ["for", 479], ["the", 483], ["reversal", 487], ["of", 496], ["the", 499], ["anticoagulant", 503], ["activity", 517], ["of", 526], ["dabigatran", 529], ["were", 540], ["included", 545], [".", 553], ["Idarucizumab", 555], ["represents", 568], ["a", 579], ["novel", 581], ["treatment", 587], ["option", 597], ["as", 604], ["it", 607], ["is", 610], ["the", 613], ["only", 617], ["humanized", 622], [",", 631], ["monoclonal", 633], ["antibody", 644], ["fragment", 653], ["that", 662], ["specifically", 667], ["binds", 680], ["to", 686], ["dabigatran", 689], [".", 699], ["Studies", 701], ["evaluating", 709], ["reversal", 720], ["of", 729], ["dabigatran", 732], ["-", 742], ["induced", 743], ["anticoagulation", 751], ["have", 767], ["demonstrated", 772], ["immediate", 785], [",", 794], ["complete", 796], [",", 804], ["and", 806], ["sustained", 810], ["effects", 820], ["with", 828], ["idarucizumab", 833], [".", 845], ["Idarucizumab", 847], ["did", 860], ["not", 864], ["overcorrect", 868], ["thrombin", 880], ["generation", 889], [".", 899], ["Additionally", 901], [",", 913], ["evaluations", 915], ["have", 927], ["shown", 932], ["that", 938], ["dabigatran", 943], ["can", 954], ["be", 958], ["safely", 961], ["reinitiated", 968], ["24", 980], ["hours", 983], ["after", 989], ["the", 995], ["administration", 999], ["of", 1014], ["idarucizumab", 1017], [".", 1029], ["The", 1031], ["United", 1035], ["States", 1042], ["Food", 1049], ["and", 1054], ["Drug", 1058], ["Administration", 1063], ["granted", 1078], ["priority", 1086], ["review", 1095], ["for", 1102], ["the", 1106], ["biologic", 1110], ["license", 1119], ["application", 1127], ["and", 1139], ["accelerated", 1143], ["approval", 1155], ["for", 1164], ["idarucizumab", 1168], [".", 1180], ["Idarucizumab", 1182], ["represents", 1195], ["an", 1206], ["encouraging", 1209], ["development", 1221], ["in", 1233], ["the", 1236], ["reversal", 1240], ["of", 1249], ["dabigatran", 1252], [".", 1262], ["Its", 1264], ["novel", 1268], ["mechanism", 1274], ["of", 1284], ["action", 1287], [",", 1293], ["pharmacokinetics", 1295], [",", 1311], ["tolerability", 1313], [",", 1325], ["and", 1327], ["lack", 1331], ["of", 1336], ["thrombotic", 1339], ["events", 1350], ["contribute", 1357], ["positively", 1368], ["to", 1379], ["its", 1382], ["use", 1386], ["in", 1390], ["patients", 1393], ["who", 1402], ["experience", 1406], ["bleeding", 1417], ["or", 1426], ["for", 1429], ["those", 1433], ["who", 1439], ["require", 1443], ["emergent", 1451], ["surgery", 1460], ["or", 1468], ["procedures", 1471], [".", 1481]]}
{"context": "The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations. The usual clinical dose of gefitinib (250 mg/d) is only one third of its maximum tolerated dose, whereas the dose of erlotinib (150 mg/d) is at its maximum tolerated dose. In NSCLC cell lines, both TKIs have similar micromolar inhibitory concentrations. We explored whether erlotinib at 25 mg/d (trough serum concentration similar to gefitinib 250 mg/d) would be efficacious in EGFR-mutated NSCLC. To study the inhibitory concentrations of gefitinib and erlotinib, we exposed EGFR-mutated cell lines (HCC827, H3255, PC-9, and H1975) to increasing concentrations of these TKIs. Further on, we performed a retrospective evaluation of seven patients with advanced EGFR-mutated (exon 19 deletions and L858R) NSCLC that were given erlotinib at 25 mg/d as their first EGFR TKI. Gefitinib and erlotinib generated similar inhibitory curves across our panel of EGFR-mutated NSCLC cell lines with overlapping mean 50% inhibitory concentration 95% confidence intervals for HCC827, PC-9, and H1975. Both drugs also displayed a high degree of correlation in mean 50% inhibitory concentration (Pearson's r = 0.99, p = 0.0417). Of the seven patients, five patients (71.5%) had partial responses to erlotinib 25 mg/d. Median progression-free survival was 17 months (95% confidence interval, 6-35 months). Toxicities were minimal, with only two (28.5%) patients having a rash and none experiencing (0%) diarrhea. In NSCLC cell lines, gefitinib and erlotinib have similar inhibitory profiles. In patients with NSCLC and EGFR-activating mutations, a dose of erlotinib 25 mg/d (equivalent to gefitinib 250 mg/d) leads to impressive response rates and progression-free survival similar to the growing experience with the approved doses of gefitinib (250 mg/d) and erlotinib (150 mg/d). Identifying prospectively the lowest and clinically active dose ranges of erlotinib and gefitinib will help further to personalize care for patients with tumors harboring EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "2e559521de4543c0bcd36ddc1c47fc44", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[23, 30]], "char_spans": [[121, 164]]}]}], "context_tokens": [["The", 0], ["tyrosine", 4], ["kinase", 13], ["inhibitors", 20], ["(", 31], ["TKIs", 32], [")", 36], ["gefitinib", 38], ["and", 48], ["erlotinib", 52], ["are", 62], ["effective", 66], ["in", 76], ["non", 79], ["-", 82], ["small", 83], ["cell", 89], ["lung", 94], ["cancers", 99], ["(", 107], ["NSCLCs", 108], [")", 114], ["with", 116], ["epidermal", 121], ["growth", 131], ["factor", 138], ["receptor", 145], ["(", 154], ["EGFR", 155], [")", 159], ["gene", 161], ["mutations", 166], [".", 175], ["The", 177], ["usual", 181], ["clinical", 187], ["dose", 196], ["of", 201], ["gefitinib", 204], ["(", 214], ["250", 215], ["mg", 219], ["/", 221], ["d", 222], [")", 223], ["is", 225], ["only", 228], ["one", 233], ["third", 237], ["of", 243], ["its", 246], ["maximum", 250], ["tolerated", 258], ["dose", 268], [",", 272], ["whereas", 274], ["the", 282], ["dose", 286], ["of", 291], ["erlotinib", 294], ["(", 304], ["150", 305], ["mg", 309], ["/", 311], ["d", 312], [")", 313], ["is", 315], ["at", 318], ["its", 321], ["maximum", 325], ["tolerated", 333], ["dose", 343], [".", 347], ["In", 349], ["NSCLC", 352], ["cell", 358], ["lines", 363], [",", 368], ["both", 370], ["TKIs", 375], ["have", 380], ["similar", 385], ["micromolar", 393], ["inhibitory", 404], ["concentrations", 415], [".", 429], ["We", 431], ["explored", 434], ["whether", 443], ["erlotinib", 451], ["at", 461], ["25", 464], ["mg", 467], ["/", 469], ["d", 470], ["(", 472], ["trough", 473], ["serum", 480], ["concentration", 486], ["similar", 500], ["to", 508], ["gefitinib", 511], ["250", 521], ["mg", 525], ["/", 527], ["d", 528], [")", 529], ["would", 531], ["be", 537], ["efficacious", 540], ["in", 552], ["EGFR", 555], ["-", 559], ["mutated", 560], ["NSCLC", 568], [".", 573], ["To", 575], ["study", 578], ["the", 584], ["inhibitory", 588], ["concentrations", 599], ["of", 614], ["gefitinib", 617], ["and", 627], ["erlotinib", 631], [",", 640], ["we", 642], ["exposed", 645], ["EGFR", 653], ["-", 657], ["mutated", 658], ["cell", 666], ["lines", 671], ["(", 677], ["HCC827", 678], [",", 684], ["H3255", 686], [",", 691], ["PC-9", 693], [",", 697], ["and", 699], ["H1975", 703], [")", 708], ["to", 710], ["increasing", 713], ["concentrations", 724], ["of", 739], ["these", 742], ["TKIs", 748], [".", 752], ["Further", 754], ["on", 762], [",", 764], ["we", 766], ["performed", 769], ["a", 779], ["retrospective", 781], ["evaluation", 795], ["of", 806], ["seven", 809], ["patients", 815], ["with", 824], ["advanced", 829], ["EGFR", 838], ["-", 842], ["mutated", 843], ["(", 851], ["exon", 852], ["19", 857], ["deletions", 860], ["and", 870], ["L858R", 874], [")", 879], ["NSCLC", 881], ["that", 887], ["were", 892], ["given", 897], ["erlotinib", 903], ["at", 913], ["25", 916], ["mg", 919], ["/", 921], ["d", 922], ["as", 924], ["their", 927], ["first", 933], ["EGFR", 939], ["TKI", 944], [".", 947], ["Gefitinib", 949], ["and", 959], ["erlotinib", 963], ["generated", 973], ["similar", 983], ["inhibitory", 991], ["curves", 1002], ["across", 1009], ["our", 1016], ["panel", 1020], ["of", 1026], ["EGFR", 1029], ["-", 1033], ["mutated", 1034], ["NSCLC", 1042], ["cell", 1048], ["lines", 1053], ["with", 1059], ["overlapping", 1064], ["mean", 1076], ["50", 1081], ["%", 1083], ["inhibitory", 1085], ["concentration", 1096], ["95", 1110], ["%", 1112], ["confidence", 1114], ["intervals", 1125], ["for", 1135], ["HCC827", 1139], [",", 1145], ["PC-9", 1147], [",", 1151], ["and", 1153], ["H1975", 1157], [".", 1162], ["Both", 1164], ["drugs", 1169], ["also", 1175], ["displayed", 1180], ["a", 1190], ["high", 1192], ["degree", 1197], ["of", 1204], ["correlation", 1207], ["in", 1219], ["mean", 1222], ["50", 1227], ["%", 1229], ["inhibitory", 1231], ["concentration", 1242], ["(", 1256], ["Pearson", 1257], ["'s", 1264], ["r", 1267], ["=", 1269], ["0.99", 1271], [",", 1275], ["p", 1277], ["=", 1279], ["0.0417", 1281], [")", 1287], [".", 1288], ["Of", 1290], ["the", 1293], ["seven", 1297], ["patients", 1303], [",", 1311], ["five", 1313], ["patients", 1318], ["(", 1327], ["71.5", 1328], ["%", 1332], [")", 1333], ["had", 1335], ["partial", 1339], ["responses", 1347], ["to", 1357], ["erlotinib", 1360], ["25", 1370], ["mg", 1373], ["/", 1375], ["d", 1376], [".", 1377], ["Median", 1379], ["progression", 1386], ["-", 1397], ["free", 1398], ["survival", 1403], ["was", 1412], ["17", 1416], ["months", 1419], ["(", 1426], ["95", 1427], ["%", 1429], ["confidence", 1431], ["interval", 1442], [",", 1450], ["6", 1452], ["-", 1453], ["35", 1454], ["months", 1457], [")", 1463], [".", 1464], ["Toxicities", 1466], ["were", 1477], ["minimal", 1482], [",", 1489], ["with", 1491], ["only", 1496], ["two", 1501], ["(", 1505], ["28.5", 1506], ["%", 1510], [")", 1511], ["patients", 1513], ["having", 1522], ["a", 1529], ["rash", 1531], ["and", 1536], ["none", 1540], ["experiencing", 1545], ["(", 1558], ["0", 1559], ["%", 1560], [")", 1561], ["diarrhea", 1563], [".", 1571], ["In", 1573], ["NSCLC", 1576], ["cell", 1582], ["lines", 1587], [",", 1592], ["gefitinib", 1594], ["and", 1604], ["erlotinib", 1608], ["have", 1618], ["similar", 1623], ["inhibitory", 1631], ["profiles", 1642], [".", 1650], ["In", 1652], ["patients", 1655], ["with", 1664], ["NSCLC", 1669], ["and", 1675], ["EGFR", 1679], ["-", 1683], ["activating", 1684], ["mutations", 1695], [",", 1704], ["a", 1706], ["dose", 1708], ["of", 1713], ["erlotinib", 1716], ["25", 1726], ["mg", 1729], ["/", 1731], ["d", 1732], ["(", 1734], ["equivalent", 1735], ["to", 1746], ["gefitinib", 1749], ["250", 1759], ["mg", 1763], ["/", 1765], ["d", 1766], [")", 1767], ["leads", 1769], ["to", 1775], ["impressive", 1778], ["response", 1789], ["rates", 1798], ["and", 1804], ["progression", 1808], ["-", 1819], ["free", 1820], ["survival", 1825], ["similar", 1834], ["to", 1842], ["the", 1845], ["growing", 1849], ["experience", 1857], ["with", 1868], ["the", 1873], ["approved", 1877], ["doses", 1886], ["of", 1892], ["gefitinib", 1895], ["(", 1905], ["250", 1906], ["mg", 1910], ["/", 1912], ["d", 1913], [")", 1914], ["and", 1916], ["erlotinib", 1920], ["(", 1930], ["150", 1931], ["mg", 1935], ["/", 1937], ["d", 1938], [")", 1939], [".", 1940], ["Identifying", 1942], ["prospectively", 1954], ["the", 1968], ["lowest", 1972], ["and", 1979], ["clinically", 1983], ["active", 1994], ["dose", 2001], ["ranges", 2006], ["of", 2013], ["erlotinib", 2016], ["and", 2026], ["gefitinib", 2030], ["will", 2040], ["help", 2045], ["further", 2050], ["to", 2058], ["personalize", 2061], ["care", 2073], ["for", 2078], ["patients", 2082], ["with", 2091], ["tumors", 2096], ["harboring", 2103], ["EGFR", 2113], ["mutations", 2118], [".", 2127]]}
{"context": "In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Silencing Prx2 expression stimulated proliferation and migration, whereas ectopic expression of Prx2 produced the opposite effect. Mechanistic investigations indicated that Prx2 negatively regulated Src/ERK activation status, which in turn fortified adherens junctions function by increasing E-cadherin expression and phospho-Y654-dependent retention of \u03b2-catenin in the plasma membrane. In murine melanoma cells, Prx2 silencing enhanced lung metastasis in vivo. Interestingly, the natural compound gliotoxin, which is known to exert a Prx-like activity, inhibited proliferation and migration as well as lung metastasis of Prx2-deficient melanoma cells. Overall, our findings reveal that Prx2 is a key regulator of invasion and metastasis in melanoma, and also suggest a pharmacologic strategy to effectively decrease deadly malignant forms of this disease.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4725ab4959074b2b82db8e9b8383de5d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[44, 44], [30, 30]], "char_spans": [[233, 243], [161, 171]]}]}], "context_tokens": [["In", 0], ["melanoma", 3], [",", 11], ["transition", 13], ["to", 24], ["the", 27], ["vertical", 31], ["growth", 40], ["phase", 47], ["is", 53], ["the", 56], ["critical", 60], ["step", 69], ["in", 74], ["conversion", 77], ["to", 88], ["a", 91], ["deadly", 93], ["malignant", 100], ["disease", 110], [".", 117], ["Here", 119], [",", 123], ["we", 125], ["offer", 128], ["the", 134], ["first", 138], ["evidence", 144], ["that", 153], ["an", 158], ["antioxidant", 161], ["enzyme", 173], ["has", 180], ["a", 184], ["key", 186], ["role", 190], ["in", 195], ["this", 198], ["transition", 203], [".", 213], ["We", 215], ["found", 218], ["that", 224], ["the", 229], ["antioxidant", 233], ["enzyme", 245], ["peroxiredoxin-2", 252], ["(", 268], ["Prx2", 269], [")", 273], ["inversely", 275], ["correlated", 285], ["with", 296], ["the", 301], ["metastatic", 305], ["capacity", 316], ["of", 325], ["human", 328], ["melanoma", 334], ["cells", 343], [".", 348], ["Silencing", 350], ["Prx2", 360], ["expression", 365], ["stimulated", 376], ["proliferation", 387], ["and", 401], ["migration", 405], [",", 414], ["whereas", 416], ["ectopic", 424], ["expression", 432], ["of", 443], ["Prx2", 446], ["produced", 451], ["the", 460], ["opposite", 464], ["effect", 473], [".", 479], ["Mechanistic", 481], ["investigations", 493], ["indicated", 508], ["that", 518], ["Prx2", 523], ["negatively", 528], ["regulated", 539], ["Src", 549], ["/", 552], ["ERK", 553], ["activation", 557], ["status", 568], [",", 574], ["which", 576], ["in", 582], ["turn", 585], ["fortified", 590], ["adherens", 600], ["junctions", 609], ["function", 619], ["by", 628], ["increasing", 631], ["E", 642], ["-", 643], ["cadherin", 644], ["expression", 653], ["and", 664], ["phospho", 668], ["-", 675], ["Y654-dependent", 676], ["retention", 691], ["of", 701], ["\u03b2", 704], ["-", 705], ["catenin", 706], ["in", 714], ["the", 717], ["plasma", 721], ["membrane", 728], [".", 736], ["In", 738], ["murine", 741], ["melanoma", 748], ["cells", 757], [",", 762], ["Prx2", 764], ["silencing", 769], ["enhanced", 779], ["lung", 788], ["metastasis", 793], ["in", 804], ["vivo", 807], [".", 811], ["Interestingly", 813], [",", 826], ["the", 828], ["natural", 832], ["compound", 840], ["gliotoxin", 849], [",", 858], ["which", 860], ["is", 866], ["known", 869], ["to", 875], ["exert", 878], ["a", 884], ["Prx", 886], ["-", 889], ["like", 890], ["activity", 895], [",", 903], ["inhibited", 905], ["proliferation", 915], ["and", 929], ["migration", 933], ["as", 943], ["well", 946], ["as", 951], ["lung", 954], ["metastasis", 959], ["of", 970], ["Prx2-deficient", 973], ["melanoma", 988], ["cells", 997], [".", 1002], ["Overall", 1004], [",", 1011], ["our", 1013], ["findings", 1017], ["reveal", 1026], ["that", 1033], ["Prx2", 1038], ["is", 1043], ["a", 1046], ["key", 1048], ["regulator", 1052], ["of", 1062], ["invasion", 1065], ["and", 1074], ["metastasis", 1078], ["in", 1089], ["melanoma", 1092], [",", 1100], ["and", 1102], ["also", 1106], ["suggest", 1111], ["a", 1119], ["pharmacologic", 1121], ["strategy", 1135], ["to", 1144], ["effectively", 1147], ["decrease", 1159], ["deadly", 1168], ["malignant", 1175], ["forms", 1185], ["of", 1191], ["this", 1194], ["disease", 1199], [".", 1206]]}
{"context": "Infections generally occur in intravenous drug abuse (IVDA) patients, most commonly affecting the spine and proximal joints. Numerous serious musculoskeletal complications of IVDA may involve the upper extremity, however. Soft-tissue complications in the upper extremity of IVDA patients include cellulitis, ulceration, abscess, pyomyositis, septic bursitis, tenosynovitis, and necrotizing fasciitis. Foreign bodies in soft tissue due to needle fragments are common findings. Primary bone and joint IVDA complications include osteomyelitis (acute and chronic) and septic arthritis. Other IVDA complications in the upper extremity affecting blood vessels and lymphatics include hematoma, arterial aneurysm and pseudoaneurysm, thrombosis, thrombophlebitis, \"puffy hand\" syndrome, and lymphadenopathy. These complications usually present as urgent issues requiring prompt and accurate evaluation in the acute setting. Diagnostic imaging not only aids in making the correct diagnosis but also permits precise definition of the location and extent of these abnormalities. We review the imaging findings and illustrate a wide range of disabling and even life-threatening complications affecting the upper extremity of IVDA patients that require early diagnosis for optimal outcome.", "qas": [{"question": "What causes \"Puffy hand syndrome\"?", "answers": ["intravenous drug abuse"], "qid": "b303b77c66f64d6c905ec9262e272043", "question_tokens": [["What", 0], ["causes", 5], ["\"", 12], ["Puffy", 13], ["hand", 19], ["syndrome", 24], ["\"", 32], ["?", 33]], "detected_answers": [{"text": "intravenous drug abuse", "token_spans": [[4, 6]], "char_spans": [[30, 51]]}]}], "context_tokens": [["Infections", 0], ["generally", 11], ["occur", 21], ["in", 27], ["intravenous", 30], ["drug", 42], ["abuse", 47], ["(", 53], ["IVDA", 54], [")", 58], ["patients", 60], [",", 68], ["most", 70], ["commonly", 75], ["affecting", 84], ["the", 94], ["spine", 98], ["and", 104], ["proximal", 108], ["joints", 117], [".", 123], ["Numerous", 125], ["serious", 134], ["musculoskeletal", 142], ["complications", 158], ["of", 172], ["IVDA", 175], ["may", 180], ["involve", 184], ["the", 192], ["upper", 196], ["extremity", 202], [",", 211], ["however", 213], [".", 220], ["Soft", 222], ["-", 226], ["tissue", 227], ["complications", 234], ["in", 248], ["the", 251], ["upper", 255], ["extremity", 261], ["of", 271], ["IVDA", 274], ["patients", 279], ["include", 288], ["cellulitis", 296], [",", 306], ["ulceration", 308], [",", 318], ["abscess", 320], [",", 327], ["pyomyositis", 329], [",", 340], ["septic", 342], ["bursitis", 349], [",", 357], ["tenosynovitis", 359], [",", 372], ["and", 374], ["necrotizing", 378], ["fasciitis", 390], [".", 399], ["Foreign", 401], ["bodies", 409], ["in", 416], ["soft", 419], ["tissue", 424], ["due", 431], ["to", 435], ["needle", 438], ["fragments", 445], ["are", 455], ["common", 459], ["findings", 466], [".", 474], ["Primary", 476], ["bone", 484], ["and", 489], ["joint", 493], ["IVDA", 499], ["complications", 504], ["include", 518], ["osteomyelitis", 526], ["(", 540], ["acute", 541], ["and", 547], ["chronic", 551], [")", 558], ["and", 560], ["septic", 564], ["arthritis", 571], [".", 580], ["Other", 582], ["IVDA", 588], ["complications", 593], ["in", 607], ["the", 610], ["upper", 614], ["extremity", 620], ["affecting", 630], ["blood", 640], ["vessels", 646], ["and", 654], ["lymphatics", 658], ["include", 669], ["hematoma", 677], [",", 685], ["arterial", 687], ["aneurysm", 696], ["and", 705], ["pseudoaneurysm", 709], [",", 723], ["thrombosis", 725], [",", 735], ["thrombophlebitis", 737], [",", 753], ["\"", 755], ["puffy", 756], ["hand", 762], ["\"", 766], ["syndrome", 768], [",", 776], ["and", 778], ["lymphadenopathy", 782], [".", 797], ["These", 799], ["complications", 805], ["usually", 819], ["present", 827], ["as", 835], ["urgent", 838], ["issues", 845], ["requiring", 852], ["prompt", 862], ["and", 869], ["accurate", 873], ["evaluation", 882], ["in", 893], ["the", 896], ["acute", 900], ["setting", 906], [".", 913], ["Diagnostic", 915], ["imaging", 926], ["not", 934], ["only", 938], ["aids", 943], ["in", 948], ["making", 951], ["the", 958], ["correct", 962], ["diagnosis", 970], ["but", 980], ["also", 984], ["permits", 989], ["precise", 997], ["definition", 1005], ["of", 1016], ["the", 1019], ["location", 1023], ["and", 1032], ["extent", 1036], ["of", 1043], ["these", 1046], ["abnormalities", 1052], [".", 1065], ["We", 1067], ["review", 1070], ["the", 1077], ["imaging", 1081], ["findings", 1089], ["and", 1098], ["illustrate", 1102], ["a", 1113], ["wide", 1115], ["range", 1120], ["of", 1126], ["disabling", 1129], ["and", 1139], ["even", 1143], ["life", 1148], ["-", 1152], ["threatening", 1153], ["complications", 1165], ["affecting", 1179], ["the", 1189], ["upper", 1193], ["extremity", 1199], ["of", 1209], ["IVDA", 1212], ["patients", 1217], ["that", 1226], ["require", 1231], ["early", 1239], ["diagnosis", 1245], ["for", 1255], ["optimal", 1259], ["outcome", 1267], [".", 1274]]}
{"context": "The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants used for the long-term treatment or prevention of venous thromboembolism or stroke in patients with atrial fibrillation. The coagulopathy induced by VKAs can be reversed with vitamin K, and in urgent situations, the vitamin K-dependent coagulation factors can be replaced by transfusion. In the last decade, a new class of oral anticoagulants has been developed, direct oral anticoagulants that bind to a specific coagulation factor and neutralize it. These compounds were shown to be effective and safe compared with the VKAs and were licensed for specific indications, but without a specific reversal agent. The absence of a reversal agent is a barrier to more widespread use of these agents. Currently, for the management of major life-threatening bleeding with the direct oral anticoagulants, most authorities recommend the use of four factor prothrombin complex concentrates. There are now three reversal agents in development and poised to enter the market. Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the USA. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Ciraparantag is an antidote targeted to reverse the direct thrombin and factor Xa inhibitors as well as the indirect inhibitor enoxaparin.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "708d81adb4e44a03ab3e302e8165cec5", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[197, 197]], "char_spans": [[1138, 1147]]}]}], "context_tokens": [["The", 0], ["vitamin", 4], ["K", 12], ["antagonists", 14], ["(", 26], ["VKAs", 27], [")", 31], ["have", 33], ["been", 38], ["the", 43], ["standard", 47], ["(", 56], ["and", 57], ["only", 61], [")", 65], ["oral", 67], ["anticoagulants", 72], ["used", 87], ["for", 92], ["the", 96], ["long", 100], ["-", 104], ["term", 105], ["treatment", 110], ["or", 120], ["prevention", 123], ["of", 134], ["venous", 137], ["thromboembolism", 144], ["or", 160], ["stroke", 163], ["in", 170], ["patients", 173], ["with", 182], ["atrial", 187], ["fibrillation", 194], [".", 206], ["The", 208], ["coagulopathy", 212], ["induced", 225], ["by", 233], ["VKAs", 236], ["can", 241], ["be", 245], ["reversed", 248], ["with", 257], ["vitamin", 262], ["K", 270], [",", 271], ["and", 273], ["in", 277], ["urgent", 280], ["situations", 287], [",", 297], ["the", 299], ["vitamin", 303], ["K", 311], ["-", 312], ["dependent", 313], ["coagulation", 323], ["factors", 335], ["can", 343], ["be", 347], ["replaced", 350], ["by", 359], ["transfusion", 362], [".", 373], ["In", 375], ["the", 378], ["last", 382], ["decade", 387], [",", 393], ["a", 395], ["new", 397], ["class", 401], ["of", 407], ["oral", 410], ["anticoagulants", 415], ["has", 430], ["been", 434], ["developed", 439], [",", 448], ["direct", 450], ["oral", 457], ["anticoagulants", 462], ["that", 477], ["bind", 482], ["to", 487], ["a", 490], ["specific", 492], ["coagulation", 501], ["factor", 513], ["and", 520], ["neutralize", 524], ["it", 535], [".", 537], ["These", 539], ["compounds", 545], ["were", 555], ["shown", 560], ["to", 566], ["be", 569], ["effective", 572], ["and", 582], ["safe", 586], ["compared", 591], ["with", 600], ["the", 605], ["VKAs", 609], ["and", 614], ["were", 618], ["licensed", 623], ["for", 632], ["specific", 636], ["indications", 645], [",", 656], ["but", 658], ["without", 662], ["a", 670], ["specific", 672], ["reversal", 681], ["agent", 690], [".", 695], ["The", 697], ["absence", 701], ["of", 709], ["a", 712], ["reversal", 714], ["agent", 723], ["is", 729], ["a", 732], ["barrier", 734], ["to", 742], ["more", 745], ["widespread", 750], ["use", 761], ["of", 765], ["these", 768], ["agents", 774], [".", 780], ["Currently", 782], [",", 791], ["for", 793], ["the", 797], ["management", 801], ["of", 812], ["major", 815], ["life", 821], ["-", 825], ["threatening", 826], ["bleeding", 838], ["with", 847], ["the", 852], ["direct", 856], ["oral", 863], ["anticoagulants", 868], [",", 882], ["most", 884], ["authorities", 889], ["recommend", 901], ["the", 911], ["use", 915], ["of", 919], ["four", 922], ["factor", 927], ["prothrombin", 934], ["complex", 946], ["concentrates", 954], [".", 966], ["There", 968], ["are", 974], ["now", 978], ["three", 982], ["reversal", 988], ["agents", 997], ["in", 1004], ["development", 1007], ["and", 1019], ["poised", 1023], ["to", 1030], ["enter", 1033], ["the", 1039], ["market", 1043], [".", 1049], ["Idarucizumab", 1051], ["is", 1064], ["a", 1067], ["specific", 1069], ["antidote", 1078], ["targeted", 1087], ["to", 1096], ["reverse", 1099], ["the", 1107], ["direct", 1111], ["thrombin", 1118], ["inhibitor", 1127], [",", 1136], ["dabigatran", 1138], [",", 1148], ["which", 1150], ["was", 1156], ["recently", 1160], ["approved", 1169], ["for", 1178], ["use", 1182], ["in", 1186], ["the", 1189], ["USA", 1193], [".", 1196], ["Andexanet", 1198], ["alfa", 1208], ["is", 1213], ["an", 1216], ["antidote", 1219], ["targeted", 1228], ["to", 1237], ["reverse", 1240], ["the", 1248], ["oral", 1252], ["direct", 1257], ["factor", 1264], ["Xa", 1271], ["inhibitors", 1274], ["as", 1285], ["well", 1288], ["as", 1293], ["the", 1296], ["indirect", 1300], ["inhibitor", 1309], ["enoxaparin", 1319], [".", 1329], ["Ciraparantag", 1331], ["is", 1344], ["an", 1347], ["antidote", 1350], ["targeted", 1359], ["to", 1368], ["reverse", 1371], ["the", 1379], ["direct", 1383], ["thrombin", 1390], ["and", 1399], ["factor", 1403], ["Xa", 1410], ["inhibitors", 1413], ["as", 1424], ["well", 1427], ["as", 1432], ["the", 1435], ["indirect", 1439], ["inhibitor", 1448], ["enoxaparin", 1458], [".", 1468]]}
{"context": "Molecular remodeling in heart failure includes slowing of repolarization, leading to proarrhythmia. To evaluate the effects of Na(+)/Ca(2+) exchanger (NCX) inhibition on repolarization as a novel antiarrhythmic concept in chronic heart failure (CHF). CHF was induced by rapid ventricular pacing in rabbits. Left ventricular function was assessed by echocardiography. Monophasic action potentials (MAPs) showed a prolongation of repolarization in CHF after atrioventricular block and stimulation at different cycle lengths. Sotalol (100 \u03bcM, n = 13) or veratridine (0.5 \u03bcM; n = 15) resulted in a further significant increase in the MAP duration. CHF was associated with an increased dispersion of repolarization, as compared with sotalol-treated (+22 \u00b1 7 ms; P < .05) and veratridine-treated (+20 \u00b1 6 ms; P < .05) sham hearts. In the presence of a low potassium concentration, sotalol and veratridine reproducibly induced early afterdepolarizations (EADs) and polymorphic ventricular tachyarrhythmias (VTs). SEA0400 (1 \u03bcM), a pharmacological inhibitor of NCX, significantly shortened the MAP duration (P < .01) and reduced dispersion (P < .05). It suppressed EAD in 6 of 13 sotalol-treated failing hearts and in 9 of 10 veratridine-treated failing hearts, leading to a reduction in VT (60% in sotalol-treated failing hearts and 83% in veratridine-treated failing hearts). Simulations using a mathematical model showed a reduction in the action potential duration and the number of EADs by the NCX block in all subgroups. In an experimental model of CHF, the acute inhibition of NCX (1) reduces the MAP duration, (2) decreases dispersion of repolarization, and (3) suppresses EAD and VT. Our observations indicate for the first time that pharmacological NCX inhibition increases repolarization reserve and protects against VTs in heart failure.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "71fee14086b941aea68a85c15ba9b987", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[19, 22]], "char_spans": [[127, 148]]}, {"text": "NCX", "token_spans": [[283, 283], [335, 335], [300, 300], [24, 24], [193, 193]], "char_spans": [[1491, 1493], [1751, 1753], [1576, 1578], [151, 153], [1053, 1055]]}]}], "context_tokens": [["Molecular", 0], ["remodeling", 10], ["in", 21], ["heart", 24], ["failure", 30], ["includes", 38], ["slowing", 47], ["of", 55], ["repolarization", 58], [",", 72], ["leading", 74], ["to", 82], ["proarrhythmia", 85], [".", 98], ["To", 100], ["evaluate", 103], ["the", 112], ["effects", 116], ["of", 124], ["Na(+)/Ca(2", 127], ["+", 137], [")", 138], ["exchanger", 140], ["(", 150], ["NCX", 151], [")", 154], ["inhibition", 156], ["on", 167], ["repolarization", 170], ["as", 185], ["a", 188], ["novel", 190], ["antiarrhythmic", 196], ["concept", 211], ["in", 219], ["chronic", 222], ["heart", 230], ["failure", 236], ["(", 244], ["CHF", 245], [")", 248], [".", 249], ["CHF", 251], ["was", 255], ["induced", 259], ["by", 267], ["rapid", 270], ["ventricular", 276], ["pacing", 288], ["in", 295], ["rabbits", 298], [".", 305], ["Left", 307], ["ventricular", 312], ["function", 324], ["was", 333], ["assessed", 337], ["by", 346], ["echocardiography", 349], [".", 365], ["Monophasic", 367], ["action", 378], ["potentials", 385], ["(", 396], ["MAPs", 397], [")", 401], ["showed", 403], ["a", 410], ["prolongation", 412], ["of", 425], ["repolarization", 428], ["in", 443], ["CHF", 446], ["after", 450], ["atrioventricular", 456], ["block", 473], ["and", 479], ["stimulation", 483], ["at", 495], ["different", 498], ["cycle", 508], ["lengths", 514], [".", 521], ["Sotalol", 523], ["(", 531], ["100", 532], ["\u03bcM", 536], [",", 538], ["n", 540], ["=", 542], ["13", 544], [")", 546], ["or", 548], ["veratridine", 551], ["(", 563], ["0.5", 564], ["\u03bcM", 568], [";", 570], ["n", 572], ["=", 574], ["15", 576], [")", 578], ["resulted", 580], ["in", 589], ["a", 592], ["further", 594], ["significant", 602], ["increase", 614], ["in", 623], ["the", 626], ["MAP", 630], ["duration", 634], [".", 642], ["CHF", 644], ["was", 648], ["associated", 652], ["with", 663], ["an", 668], ["increased", 671], ["dispersion", 681], ["of", 692], ["repolarization", 695], [",", 709], ["as", 711], ["compared", 714], ["with", 723], ["sotalol", 728], ["-", 735], ["treated", 736], ["(", 744], ["+22", 745], ["\u00b1", 749], ["7", 751], ["ms", 753], [";", 755], ["P", 757], ["<", 759], [".05", 761], [")", 764], ["and", 766], ["veratridine", 770], ["-", 781], ["treated", 782], ["(", 790], ["+20", 791], ["\u00b1", 795], ["6", 797], ["ms", 799], [";", 801], ["P", 803], ["<", 805], [".05", 807], [")", 810], ["sham", 812], ["hearts", 817], [".", 823], ["In", 825], ["the", 828], ["presence", 832], ["of", 841], ["a", 844], ["low", 846], ["potassium", 850], ["concentration", 860], [",", 873], ["sotalol", 875], ["and", 883], ["veratridine", 887], ["reproducibly", 899], ["induced", 912], ["early", 920], ["afterdepolarizations", 926], ["(", 947], ["EADs", 948], [")", 952], ["and", 954], ["polymorphic", 958], ["ventricular", 970], ["tachyarrhythmias", 982], ["(", 999], ["VTs", 1000], [")", 1003], [".", 1004], ["SEA0400", 1006], ["(", 1014], ["1", 1015], ["\u03bcM", 1017], [")", 1019], [",", 1020], ["a", 1022], ["pharmacological", 1024], ["inhibitor", 1040], ["of", 1050], ["NCX", 1053], [",", 1056], ["significantly", 1058], ["shortened", 1072], ["the", 1082], ["MAP", 1086], ["duration", 1090], ["(", 1099], ["P", 1100], ["<", 1102], [".01", 1104], [")", 1107], ["and", 1109], ["reduced", 1113], ["dispersion", 1121], ["(", 1132], ["P", 1133], ["<", 1135], [".05", 1137], [")", 1140], [".", 1141], ["It", 1143], ["suppressed", 1146], ["EAD", 1157], ["in", 1161], ["6", 1164], ["of", 1166], ["13", 1169], ["sotalol", 1172], ["-", 1179], ["treated", 1180], ["failing", 1188], ["hearts", 1196], ["and", 1203], ["in", 1207], ["9", 1210], ["of", 1212], ["10", 1215], ["veratridine", 1218], ["-", 1229], ["treated", 1230], ["failing", 1238], ["hearts", 1246], [",", 1252], ["leading", 1254], ["to", 1262], ["a", 1265], ["reduction", 1267], ["in", 1277], ["VT", 1280], ["(", 1283], ["60", 1284], ["%", 1286], ["in", 1288], ["sotalol", 1291], ["-", 1298], ["treated", 1299], ["failing", 1307], ["hearts", 1315], ["and", 1322], ["83", 1326], ["%", 1328], ["in", 1330], ["veratridine", 1333], ["-", 1344], ["treated", 1345], ["failing", 1353], ["hearts", 1361], [")", 1367], [".", 1368], ["Simulations", 1370], ["using", 1382], ["a", 1388], ["mathematical", 1390], ["model", 1403], ["showed", 1409], ["a", 1416], ["reduction", 1418], ["in", 1428], ["the", 1431], ["action", 1435], ["potential", 1442], ["duration", 1452], ["and", 1461], ["the", 1465], ["number", 1469], ["of", 1476], ["EADs", 1479], ["by", 1484], ["the", 1487], ["NCX", 1491], ["block", 1495], ["in", 1501], ["all", 1504], ["subgroups", 1508], [".", 1517], ["In", 1519], ["an", 1522], ["experimental", 1525], ["model", 1538], ["of", 1544], ["CHF", 1547], [",", 1550], ["the", 1552], ["acute", 1556], ["inhibition", 1562], ["of", 1573], ["NCX", 1576], ["(", 1580], ["1", 1581], [")", 1582], ["reduces", 1584], ["the", 1592], ["MAP", 1596], ["duration", 1600], [",", 1608], ["(", 1610], ["2", 1611], [")", 1612], ["decreases", 1614], ["dispersion", 1624], ["of", 1635], ["repolarization", 1638], [",", 1652], ["and", 1654], ["(", 1658], ["3", 1659], [")", 1660], ["suppresses", 1662], ["EAD", 1673], ["and", 1677], ["VT", 1681], [".", 1683], ["Our", 1685], ["observations", 1689], ["indicate", 1702], ["for", 1711], ["the", 1715], ["first", 1719], ["time", 1725], ["that", 1730], ["pharmacological", 1735], ["NCX", 1751], ["inhibition", 1755], ["increases", 1766], ["repolarization", 1776], ["reserve", 1791], ["and", 1799], ["protects", 1803], ["against", 1812], ["VTs", 1820], ["in", 1824], ["heart", 1827], ["failure", 1833], [".", 1840]]}
{"context": "Neurofibromatosis type 1 is one of the most common autosomal dominant disorders, affecting about 1:3,500 individuals. NF1 exon 7 displays weakly defined exon-intron boundaries, and is particularly prone to missplicing. In this study we investigated the expression of exon 7 transcripts using bioinformatic identification of splicing regulatory sequences, and functional minigene analysis of four sequence changes [c.910C>T (R304X), c.945G>A/c.946C>A (Q315Q/L316M), c.1005T>C (N335N)] identified in exon 7 of three different NF1 patients. Our results detected the presence of three exonic splicing enhancers (ESEs) and one putative exonic splicing silencer (ESS) element. The wild type minigene assay resulted in three alternative isoforms, including a transcript lacking NF1 exon 7 (NF1DeltaE7). Both the wild type and the mutated constructs shared NF1DeltaE7 in addition to the complete messenger, but displayed a different ratio between the two transcripts. In the presence of R304X and Q315Q/L316M mutations, the relative proportion between the different isoforms is shifted toward the expression of NF1DeltaE7, while in the presence of N335N variant, the NF1DeltaE7 expression is abolished. In conclusion, it appears mandatory to investigate the role of each nucleotide change within the NF1 coding sequence, since a significant proportion of NF1 exon 7 mutations affects pre-mRNA splicing, by disrupting exonic splicing motifs and modifying the delicate balance between aberrantly and correctly spliced transcripts.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "8264477aefe0438e81189bea1f1be19d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[99, 99], [141, 141], [232, 232], [18, 18], [241, 241]], "char_spans": [[524, 526], [771, 773], [1292, 1294], [118, 120], [1347, 1349]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["is", 25], ["one", 28], ["of", 32], ["the", 35], ["most", 39], ["common", 44], ["autosomal", 51], ["dominant", 61], ["disorders", 70], [",", 79], ["affecting", 81], ["about", 91], ["1:3,500", 97], ["individuals", 105], [".", 116], ["NF1", 118], ["exon", 122], ["7", 127], ["displays", 129], ["weakly", 138], ["defined", 145], ["exon", 153], ["-", 157], ["intron", 158], ["boundaries", 165], [",", 175], ["and", 177], ["is", 181], ["particularly", 184], ["prone", 197], ["to", 203], ["missplicing", 206], [".", 217], ["In", 219], ["this", 222], ["study", 227], ["we", 233], ["investigated", 236], ["the", 249], ["expression", 253], ["of", 264], ["exon", 267], ["7", 272], ["transcripts", 274], ["using", 286], ["bioinformatic", 292], ["identification", 306], ["of", 321], ["splicing", 324], ["regulatory", 333], ["sequences", 344], [",", 353], ["and", 355], ["functional", 359], ["minigene", 370], ["analysis", 379], ["of", 388], ["four", 391], ["sequence", 396], ["changes", 405], ["[", 413], ["c.910C", 414], [">", 420], ["T", 421], ["(", 423], ["R304X", 424], [")", 429], [",", 430], ["c.945G", 432], [">", 438], ["A", 439], ["/", 440], ["c.946C", 441], [">", 447], ["A", 448], ["(", 450], ["Q315Q", 451], ["/", 456], ["L316", 457], ["M", 461], [")", 462], [",", 463], ["c.1005T", 465], [">", 472], ["C", 473], ["(", 475], ["N335N", 476], [")", 481], ["]", 482], ["identified", 484], ["in", 495], ["exon", 498], ["7", 503], ["of", 505], ["three", 508], ["different", 514], ["NF1", 524], ["patients", 528], [".", 536], ["Our", 538], ["results", 542], ["detected", 550], ["the", 559], ["presence", 563], ["of", 572], ["three", 575], ["exonic", 581], ["splicing", 588], ["enhancers", 597], ["(", 607], ["ESEs", 608], [")", 612], ["and", 614], ["one", 618], ["putative", 622], ["exonic", 631], ["splicing", 638], ["silencer", 647], ["(", 656], ["ESS", 657], [")", 660], ["element", 662], [".", 669], ["The", 671], ["wild", 675], ["type", 680], ["minigene", 685], ["assay", 694], ["resulted", 700], ["in", 709], ["three", 712], ["alternative", 718], ["isoforms", 730], [",", 738], ["including", 740], ["a", 750], ["transcript", 752], ["lacking", 763], ["NF1", 771], ["exon", 775], ["7", 780], ["(", 782], ["NF1DeltaE7", 783], [")", 793], [".", 794], ["Both", 796], ["the", 801], ["wild", 805], ["type", 810], ["and", 815], ["the", 819], ["mutated", 823], ["constructs", 831], ["shared", 842], ["NF1DeltaE7", 849], ["in", 860], ["addition", 863], ["to", 872], ["the", 875], ["complete", 879], ["messenger", 888], [",", 897], ["but", 899], ["displayed", 903], ["a", 913], ["different", 915], ["ratio", 925], ["between", 931], ["the", 939], ["two", 943], ["transcripts", 947], [".", 958], ["In", 960], ["the", 963], ["presence", 967], ["of", 976], ["R304X", 979], ["and", 985], ["Q315Q", 989], ["/", 994], ["L316", 995], ["M", 999], ["mutations", 1001], [",", 1010], ["the", 1012], ["relative", 1016], ["proportion", 1025], ["between", 1036], ["the", 1044], ["different", 1048], ["isoforms", 1058], ["is", 1067], ["shifted", 1070], ["toward", 1078], ["the", 1085], ["expression", 1089], ["of", 1100], ["NF1DeltaE7", 1103], [",", 1113], ["while", 1115], ["in", 1121], ["the", 1124], ["presence", 1128], ["of", 1137], ["N335N", 1140], ["variant", 1146], [",", 1153], ["the", 1155], ["NF1DeltaE7", 1159], ["expression", 1170], ["is", 1181], ["abolished", 1184], [".", 1193], ["In", 1195], ["conclusion", 1198], [",", 1208], ["it", 1210], ["appears", 1213], ["mandatory", 1221], ["to", 1231], ["investigate", 1234], ["the", 1246], ["role", 1250], ["of", 1255], ["each", 1258], ["nucleotide", 1263], ["change", 1274], ["within", 1281], ["the", 1288], ["NF1", 1292], ["coding", 1296], ["sequence", 1303], [",", 1311], ["since", 1313], ["a", 1319], ["significant", 1321], ["proportion", 1333], ["of", 1344], ["NF1", 1347], ["exon", 1351], ["7", 1356], ["mutations", 1358], ["affects", 1368], ["pre", 1376], ["-", 1379], ["mRNA", 1380], ["splicing", 1385], [",", 1393], ["by", 1395], ["disrupting", 1398], ["exonic", 1409], ["splicing", 1416], ["motifs", 1425], ["and", 1432], ["modifying", 1436], ["the", 1446], ["delicate", 1450], ["balance", 1459], ["between", 1467], ["aberrantly", 1475], ["and", 1486], ["correctly", 1490], ["spliced", 1500], ["transcripts", 1508], [".", 1519]]}
{"context": "Small supernumerary marker chromosomes (sSMC) can be present in numerically abnormal karyotypes like in a 'Turner-syndrome karyotype' mos 45,X/46,X,+mar. Here we report the first case of an sSMC found in Turner syndrome karyotypes (sSMCT) derived from chromosome 14 in a Turner syndrome patient. According to cytogenetic and molecular cytogenetic characterization the karyotype was 46,X,+del(14)(q11.1). The present case is the third Turner syndrome case with an sSMCT not derived from the X- or the Y-chromosome. More comprehensive characterization of such sSMCT might identify them to be more frequent than only ~0.6% in Turner syndrome cases according to available data.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "d691510d9c1e401ebf6364b876537b48", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[82, 82]], "char_spans": [[490, 491]]}]}], "context_tokens": [["Small", 0], ["supernumerary", 6], ["marker", 20], ["chromosomes", 27], ["(", 39], ["sSMC", 40], [")", 44], ["can", 46], ["be", 50], ["present", 53], ["in", 61], ["numerically", 64], ["abnormal", 76], ["karyotypes", 85], ["like", 96], ["in", 101], ["a", 104], ["'", 106], ["Turner", 107], ["-", 113], ["syndrome", 114], ["karyotype", 123], ["'", 132], ["mos", 134], ["45,X/46,X,+mar", 138], [".", 152], ["Here", 154], ["we", 159], ["report", 162], ["the", 169], ["first", 173], ["case", 179], ["of", 184], ["an", 187], ["sSMC", 190], ["found", 195], ["in", 201], ["Turner", 204], ["syndrome", 211], ["karyotypes", 220], ["(", 231], ["sSMCT", 232], [")", 237], ["derived", 239], ["from", 247], ["chromosome", 252], ["14", 263], ["in", 266], ["a", 269], ["Turner", 271], ["syndrome", 278], ["patient", 287], [".", 294], ["According", 296], ["to", 306], ["cytogenetic", 309], ["and", 321], ["molecular", 325], ["cytogenetic", 335], ["characterization", 347], ["the", 364], ["karyotype", 368], ["was", 378], ["46,X,+del(14)(q11.1", 382], [")", 401], [".", 402], ["The", 404], ["present", 408], ["case", 416], ["is", 421], ["the", 424], ["third", 428], ["Turner", 434], ["syndrome", 441], ["case", 450], ["with", 455], ["an", 460], ["sSMCT", 463], ["not", 469], ["derived", 473], ["from", 481], ["the", 486], ["X-", 490], ["or", 493], ["the", 496], ["Y", 500], ["-", 501], ["chromosome", 502], [".", 512], ["More", 514], ["comprehensive", 519], ["characterization", 533], ["of", 550], ["such", 553], ["sSMCT", 558], ["might", 564], ["identify", 570], ["them", 579], ["to", 584], ["be", 587], ["more", 590], ["frequent", 595], ["than", 604], ["only", 609], ["~0.6", 614], ["%", 618], ["in", 620], ["Turner", 623], ["syndrome", 630], ["cases", 639], ["according", 645], ["to", 655], ["available", 658], ["data", 668], [".", 672]]}
{"context": "Selenoprotein P (Sepp1) is a secreted protein that is made up of 2 domains. The larger N-terminal domain contains 1 selenocysteine residue in a redox motif and the smaller C-terminal domain contains the other 9 selenocysteines. Sepp1 isoforms of varying lengths occur but quantitation of them has not been achieved. Hepatic synthesis of Sepp1 affects whole-body selenium content and the liver is the source of most plasma Sepp1. ApoER2, a member of the lipoprotein receptor family, binds Sepp1 and facilitates its uptake into the testis and retention of its selenium by the brain. Megalin, another lipoprotein receptor, facilitates uptake of filtered Sepp1 into proximal tubule cells of the kidney. Thus, Sepp1 serves in homeostasis and distribution of selenium. Mice with deletion of Sepp1 suffer greater morbidity and mortality from infection with Trypanosoma congolense than do wild-type mice. Mice that express only the N-terminal domain of Sepp1 have the same severity of illness as wild-type mice, indicating that the protective function of Sepp1 against the infection resides in the N-terminal (redox) domain. Thus, Sepp1 has several functions. In addition, plasma Sepp1 concentration falls in selenium deficiency and, therefore, it can be used as an index of selenium nutritional status.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "109aecf700c048eb8d16d5d20b654c22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["Sepp1", 17], [")", 22], ["is", 24], ["a", 27], ["secreted", 29], ["protein", 38], ["that", 46], ["is", 51], ["made", 54], ["up", 59], ["of", 62], ["2", 65], ["domains", 67], [".", 74], ["The", 76], ["larger", 80], ["N", 87], ["-", 88], ["terminal", 89], ["domain", 98], ["contains", 105], ["1", 114], ["selenocysteine", 116], ["residue", 131], ["in", 139], ["a", 142], ["redox", 144], ["motif", 150], ["and", 156], ["the", 160], ["smaller", 164], ["C", 172], ["-", 173], ["terminal", 174], ["domain", 183], ["contains", 190], ["the", 199], ["other", 203], ["9", 209], ["selenocysteines", 211], [".", 226], ["Sepp1", 228], ["isoforms", 234], ["of", 243], ["varying", 246], ["lengths", 254], ["occur", 262], ["but", 268], ["quantitation", 272], ["of", 285], ["them", 288], ["has", 293], ["not", 297], ["been", 301], ["achieved", 306], [".", 314], ["Hepatic", 316], ["synthesis", 324], ["of", 334], ["Sepp1", 337], ["affects", 343], ["whole", 351], ["-", 356], ["body", 357], ["selenium", 362], ["content", 371], ["and", 379], ["the", 383], ["liver", 387], ["is", 393], ["the", 396], ["source", 400], ["of", 407], ["most", 410], ["plasma", 415], ["Sepp1", 422], [".", 427], ["ApoER2", 429], [",", 435], ["a", 437], ["member", 439], ["of", 446], ["the", 449], ["lipoprotein", 453], ["receptor", 465], ["family", 474], [",", 480], ["binds", 482], ["Sepp1", 488], ["and", 494], ["facilitates", 498], ["its", 510], ["uptake", 514], ["into", 521], ["the", 526], ["testis", 530], ["and", 537], ["retention", 541], ["of", 551], ["its", 554], ["selenium", 558], ["by", 567], ["the", 570], ["brain", 574], [".", 579], ["Megalin", 581], [",", 588], ["another", 590], ["lipoprotein", 598], ["receptor", 610], [",", 618], ["facilitates", 620], ["uptake", 632], ["of", 639], ["filtered", 642], ["Sepp1", 651], ["into", 657], ["proximal", 662], ["tubule", 671], ["cells", 678], ["of", 684], ["the", 687], ["kidney", 691], [".", 697], ["Thus", 699], [",", 703], ["Sepp1", 705], ["serves", 711], ["in", 718], ["homeostasis", 721], ["and", 733], ["distribution", 737], ["of", 750], ["selenium", 753], [".", 761], ["Mice", 763], ["with", 768], ["deletion", 773], ["of", 782], ["Sepp1", 785], ["suffer", 791], ["greater", 798], ["morbidity", 806], ["and", 816], ["mortality", 820], ["from", 830], ["infection", 835], ["with", 845], ["Trypanosoma", 850], ["congolense", 862], ["than", 873], ["do", 878], ["wild", 881], ["-", 885], ["type", 886], ["mice", 891], [".", 895], ["Mice", 897], ["that", 902], ["express", 907], ["only", 915], ["the", 920], ["N", 924], ["-", 925], ["terminal", 926], ["domain", 935], ["of", 942], ["Sepp1", 945], ["have", 951], ["the", 956], ["same", 960], ["severity", 965], ["of", 974], ["illness", 977], ["as", 985], ["wild", 988], ["-", 992], ["type", 993], ["mice", 998], [",", 1002], ["indicating", 1004], ["that", 1015], ["the", 1020], ["protective", 1024], ["function", 1035], ["of", 1044], ["Sepp1", 1047], ["against", 1053], ["the", 1061], ["infection", 1065], ["resides", 1075], ["in", 1083], ["the", 1086], ["N", 1090], ["-", 1091], ["terminal", 1092], ["(", 1101], ["redox", 1102], [")", 1107], ["domain", 1109], [".", 1115], ["Thus", 1117], [",", 1121], ["Sepp1", 1123], ["has", 1129], ["several", 1133], ["functions", 1141], [".", 1150], ["In", 1152], ["addition", 1155], [",", 1163], ["plasma", 1165], ["Sepp1", 1172], ["concentration", 1178], ["falls", 1192], ["in", 1198], ["selenium", 1201], ["deficiency", 1210], ["and", 1221], [",", 1224], ["therefore", 1226], [",", 1235], ["it", 1237], ["can", 1240], ["be", 1244], ["used", 1247], ["as", 1252], ["an", 1255], ["index", 1258], ["of", 1264], ["selenium", 1267], ["nutritional", 1276], ["status", 1288], [".", 1294]]}
{"context": "The large size of spectrin, the flexible protein promoting reversible deformation of red cells, has been an obstacle to elucidating the molecular mechanism of its function. By studying cloned fragments of the repeating unit domain, we have found a correspondence between positions of selected spectrin repeats in a tetramer with their stabilities of folding. Six fragments consisting of two spectrin repeats were selected for study primarily on the basis of the predicted secondary structures of their linker regions. Fragments with a putatively helical linker were more stable to urea- and heat-induced unfolding than those with a putatively nonhelical linker. Two of the less stably folded fragments, human erythroid alpha-spectrin repeats 13 and 14 (HEalpha13,14) and human erythroid beta-spectrin repeats 8 and 9 (HEbeta8,9), are located opposite each other on antiparallel spectrin dimers. At least partial unfolding of these repeats under physiological conditions indicates that they may serve as a hinge. Also less stably folded, the fragment of human erythroid alpha-spectrin repeats 4 and 5 (HEalpha4,5) lies opposite the site of interaction between the partial repeats at the C- and N-terminal ends of beta- and alpha-spectrin, respectively, on the opposing dimer. More stably folded fragments, human erythroid alpha-spectrin repeats 1 and 2 (HEalpha1,2) and human erythroid alpha-spectrin repeats 2 and 3 (HEalpha2,3), lie nearly opposite each other on antiparallel spectrin dimers of a tetramer. These clusterings along the spectrin tetramer of repeats with similar stabilities of folding may have relevance for spectrin function, particularly for its well known flexibility.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "47e09473d3cd4d209e14ce17285a816e", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[148, 148], [260, 260]], "char_spans": [[865, 876], [1464, 1475]]}]}], "context_tokens": [["The", 0], ["large", 4], ["size", 10], ["of", 15], ["spectrin", 18], [",", 26], ["the", 28], ["flexible", 32], ["protein", 41], ["promoting", 49], ["reversible", 59], ["deformation", 70], ["of", 82], ["red", 85], ["cells", 89], [",", 94], ["has", 96], ["been", 100], ["an", 105], ["obstacle", 108], ["to", 117], ["elucidating", 120], ["the", 132], ["molecular", 136], ["mechanism", 146], ["of", 156], ["its", 159], ["function", 163], [".", 171], ["By", 173], ["studying", 176], ["cloned", 185], ["fragments", 192], ["of", 202], ["the", 205], ["repeating", 209], ["unit", 219], ["domain", 224], [",", 230], ["we", 232], ["have", 235], ["found", 240], ["a", 246], ["correspondence", 248], ["between", 263], ["positions", 271], ["of", 281], ["selected", 284], ["spectrin", 293], ["repeats", 302], ["in", 310], ["a", 313], ["tetramer", 315], ["with", 324], ["their", 329], ["stabilities", 335], ["of", 347], ["folding", 350], [".", 357], ["Six", 359], ["fragments", 363], ["consisting", 373], ["of", 384], ["two", 387], ["spectrin", 391], ["repeats", 400], ["were", 408], ["selected", 413], ["for", 422], ["study", 426], ["primarily", 432], ["on", 442], ["the", 445], ["basis", 449], ["of", 455], ["the", 458], ["predicted", 462], ["secondary", 472], ["structures", 482], ["of", 493], ["their", 496], ["linker", 502], ["regions", 509], [".", 516], ["Fragments", 518], ["with", 528], ["a", 533], ["putatively", 535], ["helical", 546], ["linker", 554], ["were", 561], ["more", 566], ["stable", 571], ["to", 578], ["urea-", 581], ["and", 587], ["heat", 591], ["-", 595], ["induced", 596], ["unfolding", 604], ["than", 614], ["those", 619], ["with", 625], ["a", 630], ["putatively", 632], ["nonhelical", 643], ["linker", 654], [".", 660], ["Two", 662], ["of", 666], ["the", 669], ["less", 673], ["stably", 678], ["folded", 685], ["fragments", 692], [",", 701], ["human", 703], ["erythroid", 709], ["alpha", 719], ["-", 724], ["spectrin", 725], ["repeats", 734], ["13", 742], ["and", 745], ["14", 749], ["(", 752], ["HEalpha13,14", 753], [")", 765], ["and", 767], ["human", 771], ["erythroid", 777], ["beta", 787], ["-", 791], ["spectrin", 792], ["repeats", 801], ["8", 809], ["and", 811], ["9", 815], ["(", 817], ["HEbeta8,9", 818], [")", 827], [",", 828], ["are", 830], ["located", 834], ["opposite", 842], ["each", 851], ["other", 856], ["on", 862], ["antiparallel", 865], ["spectrin", 878], ["dimers", 887], [".", 893], ["At", 895], ["least", 898], ["partial", 904], ["unfolding", 912], ["of", 922], ["these", 925], ["repeats", 931], ["under", 939], ["physiological", 945], ["conditions", 959], ["indicates", 970], ["that", 980], ["they", 985], ["may", 990], ["serve", 994], ["as", 1000], ["a", 1003], ["hinge", 1005], [".", 1010], ["Also", 1012], ["less", 1017], ["stably", 1022], ["folded", 1029], [",", 1035], ["the", 1037], ["fragment", 1041], ["of", 1050], ["human", 1053], ["erythroid", 1059], ["alpha", 1069], ["-", 1074], ["spectrin", 1075], ["repeats", 1084], ["4", 1092], ["and", 1094], ["5", 1098], ["(", 1100], ["HEalpha4,5", 1101], [")", 1111], ["lies", 1113], ["opposite", 1118], ["the", 1127], ["site", 1131], ["of", 1136], ["interaction", 1139], ["between", 1151], ["the", 1159], ["partial", 1163], ["repeats", 1171], ["at", 1179], ["the", 1182], ["C-", 1186], ["and", 1189], ["N", 1193], ["-", 1194], ["terminal", 1195], ["ends", 1204], ["of", 1209], ["beta-", 1212], ["and", 1218], ["alpha", 1222], ["-", 1227], ["spectrin", 1228], [",", 1236], ["respectively", 1238], [",", 1250], ["on", 1252], ["the", 1255], ["opposing", 1259], ["dimer", 1268], [".", 1273], ["More", 1275], ["stably", 1280], ["folded", 1287], ["fragments", 1294], [",", 1303], ["human", 1305], ["erythroid", 1311], ["alpha", 1321], ["-", 1326], ["spectrin", 1327], ["repeats", 1336], ["1", 1344], ["and", 1346], ["2", 1350], ["(", 1352], ["HEalpha1,2", 1353], [")", 1363], ["and", 1365], ["human", 1369], ["erythroid", 1375], ["alpha", 1385], ["-", 1390], ["spectrin", 1391], ["repeats", 1400], ["2", 1408], ["and", 1410], ["3", 1414], ["(", 1416], ["HEalpha2,3", 1417], [")", 1427], [",", 1428], ["lie", 1430], ["nearly", 1434], ["opposite", 1441], ["each", 1450], ["other", 1455], ["on", 1461], ["antiparallel", 1464], ["spectrin", 1477], ["dimers", 1486], ["of", 1493], ["a", 1496], ["tetramer", 1498], [".", 1506], ["These", 1508], ["clusterings", 1514], ["along", 1526], ["the", 1532], ["spectrin", 1536], ["tetramer", 1545], ["of", 1554], ["repeats", 1557], ["with", 1565], ["similar", 1570], ["stabilities", 1578], ["of", 1590], ["folding", 1593], ["may", 1601], ["have", 1605], ["relevance", 1610], ["for", 1620], ["spectrin", 1624], ["function", 1633], [",", 1641], ["particularly", 1643], ["for", 1656], ["its", 1660], ["well", 1664], ["known", 1669], ["flexibility", 1675], [".", 1686]]}
{"context": "Oral empagliflozin (Jardiance(\u00ae)), a sodium glucose cotransporter-2 (SGLT2) inhibitor, is a convenient once-daily treatment for adult patients with type 2 diabetes mellitus. By inhibiting reabsorption of glucose from the proximal tubules in the kidney via inhibition of SGLT2, empagliflozin provides a novel insulin-independent mechanism of lowering blood glucose. In several phase III trials (\u2264104\u00a0weeks' duration; typically 24\u00a0weeks' duration) and extension studies (typically\u00a0\u226576\u00a0weeks' treatment), empagliflozin monotherapy or add-on therapy to other antihyperglycaemics, including insulin, improved glycaemic control and reduced bodyweight and systolic blood pressure in adult patients with type 2 diabetes. In a large phase III trial, as add-on therapy to metformin, empagliflozin was shown to be noninferior to glimepiride at 52 and 104\u00a0weeks and superior to glimepiride at 104\u00a0weeks, in terms of reductions in glycated haemoglobin level (primary endpoint). Empagliflozin was well tolerated by participants in these clinical trials, with most adverse events being mild or moderate in intensity. Empagliflozin treatment appeared to have no intrinsic risk of hypoglycaemia, although hypoglycaemia occurred more frequently when empagliflozin was coadministered with insulin and/or a sulfonylurea. With its insulin-independent mechanism of action, empagliflozin monotherapy or combination therapy with other antidiabetic drugs, including insulin, provides a useful addition to the therapeutic options for the management of type 2 diabetes. This article reviews the pharmacological properties and clinical use of empagliflozin in patients with type 2 diabetes.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "95f5fe67a6334781a72627254072209a", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[49, 49], [14, 14]], "char_spans": [[270, 274], [69, 73]]}]}], "context_tokens": [["Oral", 0], ["empagliflozin", 5], ["(", 19], ["Jardiance", 20], ["(", 29], ["\u00ae", 30], [")", 31], [")", 32], [",", 33], ["a", 35], ["sodium", 37], ["glucose", 44], ["cotransporter-2", 52], ["(", 68], ["SGLT2", 69], [")", 74], ["inhibitor", 76], [",", 85], ["is", 87], ["a", 90], ["convenient", 92], ["once", 103], ["-", 107], ["daily", 108], ["treatment", 114], ["for", 124], ["adult", 128], ["patients", 134], ["with", 143], ["type", 148], ["2", 153], ["diabetes", 155], ["mellitus", 164], [".", 172], ["By", 174], ["inhibiting", 177], ["reabsorption", 188], ["of", 201], ["glucose", 204], ["from", 212], ["the", 217], ["proximal", 221], ["tubules", 230], ["in", 238], ["the", 241], ["kidney", 245], ["via", 252], ["inhibition", 256], ["of", 267], ["SGLT2", 270], [",", 275], ["empagliflozin", 277], ["provides", 291], ["a", 300], ["novel", 302], ["insulin", 308], ["-", 315], ["independent", 316], ["mechanism", 328], ["of", 338], ["lowering", 341], ["blood", 350], ["glucose", 356], [".", 363], ["In", 365], ["several", 368], ["phase", 376], ["III", 382], ["trials", 386], ["(", 393], ["\u2264104", 394], ["weeks", 399], ["'", 404], ["duration", 406], [";", 414], ["typically", 416], ["24", 426], ["weeks", 429], ["'", 434], ["duration", 436], [")", 444], ["and", 446], ["extension", 450], ["studies", 460], ["(", 468], ["typically", 469], ["\u226576", 479], ["weeks", 483], ["'", 488], ["treatment", 490], [")", 499], [",", 500], ["empagliflozin", 502], ["monotherapy", 516], ["or", 528], ["add", 531], ["-", 534], ["on", 535], ["therapy", 538], ["to", 546], ["other", 549], ["antihyperglycaemics", 555], [",", 574], ["including", 576], ["insulin", 586], [",", 593], ["improved", 595], ["glycaemic", 604], ["control", 614], ["and", 622], ["reduced", 626], ["bodyweight", 634], ["and", 645], ["systolic", 649], ["blood", 658], ["pressure", 664], ["in", 673], ["adult", 676], ["patients", 682], ["with", 691], ["type", 696], ["2", 701], ["diabetes", 703], [".", 711], ["In", 713], ["a", 716], ["large", 718], ["phase", 724], ["III", 730], ["trial", 734], [",", 739], ["as", 741], ["add", 744], ["-", 747], ["on", 748], ["therapy", 751], ["to", 759], ["metformin", 762], [",", 771], ["empagliflozin", 773], ["was", 787], ["shown", 791], ["to", 797], ["be", 800], ["noninferior", 803], ["to", 815], ["glimepiride", 818], ["at", 830], ["52", 833], ["and", 836], ["104", 840], ["weeks", 844], ["and", 850], ["superior", 854], ["to", 863], ["glimepiride", 866], ["at", 878], ["104", 881], ["weeks", 885], [",", 890], ["in", 892], ["terms", 895], ["of", 901], ["reductions", 904], ["in", 915], ["glycated", 918], ["haemoglobin", 927], ["level", 939], ["(", 945], ["primary", 946], ["endpoint", 954], [")", 962], [".", 963], ["Empagliflozin", 965], ["was", 979], ["well", 983], ["tolerated", 988], ["by", 998], ["participants", 1001], ["in", 1014], ["these", 1017], ["clinical", 1023], ["trials", 1032], [",", 1038], ["with", 1040], ["most", 1045], ["adverse", 1050], ["events", 1058], ["being", 1065], ["mild", 1071], ["or", 1076], ["moderate", 1079], ["in", 1088], ["intensity", 1091], [".", 1100], ["Empagliflozin", 1102], ["treatment", 1116], ["appeared", 1126], ["to", 1135], ["have", 1138], ["no", 1143], ["intrinsic", 1146], ["risk", 1156], ["of", 1161], ["hypoglycaemia", 1164], [",", 1177], ["although", 1179], ["hypoglycaemia", 1188], ["occurred", 1202], ["more", 1211], ["frequently", 1216], ["when", 1227], ["empagliflozin", 1232], ["was", 1246], ["coadministered", 1250], ["with", 1265], ["insulin", 1270], ["and/or", 1278], ["a", 1285], ["sulfonylurea", 1287], [".", 1299], ["With", 1301], ["its", 1306], ["insulin", 1310], ["-", 1317], ["independent", 1318], ["mechanism", 1330], ["of", 1340], ["action", 1343], [",", 1349], ["empagliflozin", 1351], ["monotherapy", 1365], ["or", 1377], ["combination", 1380], ["therapy", 1392], ["with", 1400], ["other", 1405], ["antidiabetic", 1411], ["drugs", 1424], [",", 1429], ["including", 1431], ["insulin", 1441], [",", 1448], ["provides", 1450], ["a", 1459], ["useful", 1461], ["addition", 1468], ["to", 1477], ["the", 1480], ["therapeutic", 1484], ["options", 1496], ["for", 1504], ["the", 1508], ["management", 1512], ["of", 1523], ["type", 1526], ["2", 1531], ["diabetes", 1533], [".", 1541], ["This", 1543], ["article", 1548], ["reviews", 1556], ["the", 1564], ["pharmacological", 1568], ["properties", 1584], ["and", 1595], ["clinical", 1599], ["use", 1608], ["of", 1612], ["empagliflozin", 1615], ["in", 1629], ["patients", 1632], ["with", 1641], ["type", 1646], ["2", 1651], ["diabetes", 1653], [".", 1661]]}
{"context": "Selenoprotein S (SelS) is a 189 amino acid trans-membrane protein that plays an important yet undefined role in the unfolded protein response. It has been proposed that SelS may function as a reductase, with the penultimate selenocysteine (Sec(188)) residue participating in a selenosulfide bond with cysteine (Cys(174)). Cotranslational incorporation of Sec into SelS depends on the recoding of the UGA codon, which requires a Selenocysteine Insertion Sequence (SECIS) element in the 3'UTR of the transcript. Here we identify multiple mechanisms that regulate the expression of SelS. The human SelS gene encodes two transcripts (variants 1 and 2), which differ in their 3'UTR sequences due to an alternative splicing event that removes the SECIS element from the variant 1 transcript. Both transcripts are widely expressed in human cell lines, with the SECIS-containing variant 2 mRNA being more abundant. In vitro experiments demonstrate that the variant 1 3'UTR does not allow readthrough of the UGA/Sec codon. Thus, this transcript would produce a truncated protein that does not contain Sec and cannot make the selenosulfide bond. While the variant 2 3'UTR does support Sec insertion, its activity is weak. Bioinformatic analysis revealed two highly conserved stem-loop structures, one in the proximal part of the variant 2 3'UTR and the other immediately downstream of the SECIS element. The proximal stem-loop promotes Sec insertion in the native context but not when positioned far from the UGA/Sec codon in a heterologous mRNA. In contrast, the 140 nucleotides downstream of the SECIS element inhibit Sec insertion. We also show that endogenous SelS is enriched at perinuclear speckles, in addition to its known localization in the endoplasmic reticulum. Our results suggest the expression of endogenous SelS is more complex than previously appreciated, which has implications for past and future studies on the function of this protein.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "a90edaed7fbb4491a6476503ca82d435", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[132, 132], [247, 247], [152, 152], [82, 82], [287, 287]], "char_spans": [[741, 745], [1379, 1383], [854, 858], [463, 467], [1588, 1592]]}]}], "context_tokens": [["Selenoprotein", 0], ["S", 14], ["(", 16], ["SelS", 17], [")", 21], ["is", 23], ["a", 26], ["189", 28], ["amino", 32], ["acid", 38], ["trans", 43], ["-", 48], ["membrane", 49], ["protein", 58], ["that", 66], ["plays", 71], ["an", 77], ["important", 80], ["yet", 90], ["undefined", 94], ["role", 104], ["in", 109], ["the", 112], ["unfolded", 116], ["protein", 125], ["response", 133], [".", 141], ["It", 143], ["has", 146], ["been", 150], ["proposed", 155], ["that", 164], ["SelS", 169], ["may", 174], ["function", 178], ["as", 187], ["a", 190], ["reductase", 192], [",", 201], ["with", 203], ["the", 208], ["penultimate", 212], ["selenocysteine", 224], ["(", 239], ["Sec(188", 240], [")", 247], [")", 248], ["residue", 250], ["participating", 258], ["in", 272], ["a", 275], ["selenosulfide", 277], ["bond", 291], ["with", 296], ["cysteine", 301], ["(", 310], ["Cys(174", 311], [")", 318], [")", 319], [".", 320], ["Cotranslational", 322], ["incorporation", 338], ["of", 352], ["Sec", 355], ["into", 359], ["SelS", 364], ["depends", 369], ["on", 377], ["the", 380], ["recoding", 384], ["of", 393], ["the", 396], ["UGA", 400], ["codon", 404], [",", 409], ["which", 411], ["requires", 417], ["a", 426], ["Selenocysteine", 428], ["Insertion", 443], ["Sequence", 453], ["(", 462], ["SECIS", 463], [")", 468], ["element", 470], ["in", 478], ["the", 481], ["3'UTR", 485], ["of", 491], ["the", 494], ["transcript", 498], [".", 508], ["Here", 510], ["we", 515], ["identify", 518], ["multiple", 527], ["mechanisms", 536], ["that", 547], ["regulate", 552], ["the", 561], ["expression", 565], ["of", 576], ["SelS.", 579], ["The", 585], ["human", 589], ["SelS", 595], ["gene", 600], ["encodes", 605], ["two", 613], ["transcripts", 617], ["(", 629], ["variants", 630], ["1", 639], ["and", 641], ["2", 645], [")", 646], [",", 647], ["which", 649], ["differ", 655], ["in", 662], ["their", 665], ["3'UTR", 671], ["sequences", 677], ["due", 687], ["to", 691], ["an", 694], ["alternative", 697], ["splicing", 709], ["event", 718], ["that", 724], ["removes", 729], ["the", 737], ["SECIS", 741], ["element", 747], ["from", 755], ["the", 760], ["variant", 764], ["1", 772], ["transcript", 774], [".", 784], ["Both", 786], ["transcripts", 791], ["are", 803], ["widely", 807], ["expressed", 814], ["in", 824], ["human", 827], ["cell", 833], ["lines", 838], [",", 843], ["with", 845], ["the", 850], ["SECIS", 854], ["-", 859], ["containing", 860], ["variant", 871], ["2", 879], ["mRNA", 881], ["being", 886], ["more", 892], ["abundant", 897], [".", 905], ["In", 907], ["vitro", 910], ["experiments", 916], ["demonstrate", 928], ["that", 940], ["the", 945], ["variant", 949], ["1", 957], ["3'UTR", 959], ["does", 965], ["not", 970], ["allow", 974], ["readthrough", 980], ["of", 992], ["the", 995], ["UGA", 999], ["/", 1002], ["Sec", 1003], ["codon", 1007], [".", 1012], ["Thus", 1014], [",", 1018], ["this", 1020], ["transcript", 1025], ["would", 1036], ["produce", 1042], ["a", 1050], ["truncated", 1052], ["protein", 1062], ["that", 1070], ["does", 1075], ["not", 1080], ["contain", 1084], ["Sec", 1092], ["and", 1096], ["can", 1100], ["not", 1103], ["make", 1107], ["the", 1112], ["selenosulfide", 1116], ["bond", 1130], [".", 1134], ["While", 1136], ["the", 1142], ["variant", 1146], ["2", 1154], ["3'UTR", 1156], ["does", 1162], ["support", 1167], ["Sec", 1175], ["insertion", 1179], [",", 1188], ["its", 1190], ["activity", 1194], ["is", 1203], ["weak", 1206], [".", 1210], ["Bioinformatic", 1212], ["analysis", 1226], ["revealed", 1235], ["two", 1244], ["highly", 1248], ["conserved", 1255], ["stem", 1265], ["-", 1269], ["loop", 1270], ["structures", 1275], [",", 1285], ["one", 1287], ["in", 1291], ["the", 1294], ["proximal", 1298], ["part", 1307], ["of", 1312], ["the", 1315], ["variant", 1319], ["2", 1327], ["3'UTR", 1329], ["and", 1335], ["the", 1339], ["other", 1343], ["immediately", 1349], ["downstream", 1361], ["of", 1372], ["the", 1375], ["SECIS", 1379], ["element", 1385], [".", 1392], ["The", 1394], ["proximal", 1398], ["stem", 1407], ["-", 1411], ["loop", 1412], ["promotes", 1417], ["Sec", 1426], ["insertion", 1430], ["in", 1440], ["the", 1443], ["native", 1447], ["context", 1454], ["but", 1462], ["not", 1466], ["when", 1470], ["positioned", 1475], ["far", 1486], ["from", 1490], ["the", 1495], ["UGA", 1499], ["/", 1502], ["Sec", 1503], ["codon", 1507], ["in", 1513], ["a", 1516], ["heterologous", 1518], ["mRNA", 1531], [".", 1535], ["In", 1537], ["contrast", 1540], [",", 1548], ["the", 1550], ["140", 1554], ["nucleotides", 1558], ["downstream", 1570], ["of", 1581], ["the", 1584], ["SECIS", 1588], ["element", 1594], ["inhibit", 1602], ["Sec", 1610], ["insertion", 1614], [".", 1623], ["We", 1625], ["also", 1628], ["show", 1633], ["that", 1638], ["endogenous", 1643], ["SelS", 1654], ["is", 1659], ["enriched", 1662], ["at", 1671], ["perinuclear", 1674], ["speckles", 1686], [",", 1694], ["in", 1696], ["addition", 1699], ["to", 1708], ["its", 1711], ["known", 1715], ["localization", 1721], ["in", 1734], ["the", 1737], ["endoplasmic", 1741], ["reticulum", 1753], [".", 1762], ["Our", 1764], ["results", 1768], ["suggest", 1776], ["the", 1784], ["expression", 1788], ["of", 1799], ["endogenous", 1802], ["SelS", 1813], ["is", 1818], ["more", 1821], ["complex", 1826], ["than", 1834], ["previously", 1839], ["appreciated", 1850], [",", 1861], ["which", 1863], ["has", 1869], ["implications", 1873], ["for", 1886], ["past", 1890], ["and", 1895], ["future", 1899], ["studies", 1906], ["on", 1914], ["the", 1917], ["function", 1921], ["of", 1930], ["this", 1933], ["protein", 1938], [".", 1945]]}
{"context": "Selexipag is a novel, oral, selective prostacyclin (PGI2) receptor agonist in clinical development for the treatment of pulmonary arterial hypertension. Film-coated tablets with strength between 200 and 1,600 \u03bcg were used. Bioequivalence between 8 x 200 \u03bcg and a new 1,600 \u03bcg tablet was evaluated at steady state in healthy male subjects. This was an open-label, 2-treatment, 2-period, crossover, up-titration, phase 1 study. The treatments were selexipag at 1,600 \u03bcg b.i.d. for 4.5 days either as 8 x 200 \u03bcg tablets (reference: A) or 1 x 1,600 \u03bcg tablet (test: B), both preceded by an up-titration phase starting from 400 \u03bcg b.i.d. doses, in 200-\u03bcg steps every 4th day. Subjects were randomized 1 : 1 to the A-B or B-A sequence. The pharmacokinetics and tolerability of selexipag and its active metabolite, ACT-333679, were investigated. 80 subjects were enrolled in the study: 65 subjects completed the study according to protocol, and 15 subjects withdrew from the study. The most frequent adverse events (AEs) were headache (86%), myalgia (73%), and jaw pain (73%). There was no difference in nature and overall frequency of AEs between the two treatments. Steady state was attained within 3 days of the selexipag 1,600 \u00ce\u00bcg b.i.d. The 90% confidence intervals (CIs) of the geometric mean ratio (B/A) at steady state for AUC\u00cf\u0084 and Cmax,ss were within (0.80, 1.25) bioequivalence interval: (0.92, 1.06) and (0.95, 1.14), respectively, for selexipag and (0.95, 1.06) and (0.94, 1.07), respectively, for the active metabolite, ACT-333679. Bioequivalence was demonstrated between 8 x 200 \u03bcg and 1 x 1,600 \u03bcg selexipag at steady state.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "990c3fbed6b34ba08dd9a7685e257613", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[21, 23]], "char_spans": [[120, 150]]}]}], "context_tokens": [["Selexipag", 0], ["is", 10], ["a", 13], ["novel", 15], [",", 20], ["oral", 22], [",", 26], ["selective", 28], ["prostacyclin", 38], ["(", 51], ["PGI2", 52], [")", 56], ["receptor", 58], ["agonist", 67], ["in", 75], ["clinical", 78], ["development", 87], ["for", 99], ["the", 103], ["treatment", 107], ["of", 117], ["pulmonary", 120], ["arterial", 130], ["hypertension", 139], [".", 151], ["Film", 153], ["-", 157], ["coated", 158], ["tablets", 165], ["with", 173], ["strength", 178], ["between", 187], ["200", 195], ["and", 199], ["1,600", 203], ["\u03bcg", 209], ["were", 212], ["used", 217], [".", 221], ["Bioequivalence", 223], ["between", 238], ["8", 246], ["x", 248], ["200", 250], ["\u03bcg", 254], ["and", 257], ["a", 261], ["new", 263], ["1,600", 267], ["\u03bcg", 273], ["tablet", 276], ["was", 283], ["evaluated", 287], ["at", 297], ["steady", 300], ["state", 307], ["in", 313], ["healthy", 316], ["male", 324], ["subjects", 329], [".", 337], ["This", 339], ["was", 344], ["an", 348], ["open", 351], ["-", 355], ["label", 356], [",", 361], ["2-treatment", 363], [",", 374], ["2-period", 376], [",", 384], ["crossover", 386], [",", 395], ["up", 397], ["-", 399], ["titration", 400], [",", 409], ["phase", 411], ["1", 417], ["study", 419], [".", 424], ["The", 426], ["treatments", 430], ["were", 441], ["selexipag", 446], ["at", 456], ["1,600", 459], ["\u03bcg", 465], ["b.i.d", 468], [".", 473], ["for", 475], ["4.5", 479], ["days", 483], ["either", 488], ["as", 495], ["8", 498], ["x", 500], ["200", 502], ["\u03bcg", 506], ["tablets", 509], ["(", 517], ["reference", 518], [":", 527], ["A", 529], [")", 530], ["or", 532], ["1", 535], ["x", 537], ["1,600", 539], ["\u03bcg", 545], ["tablet", 548], ["(", 555], ["test", 556], [":", 560], ["B", 562], [")", 563], [",", 564], ["both", 566], ["preceded", 571], ["by", 580], ["an", 583], ["up", 586], ["-", 588], ["titration", 589], ["phase", 599], ["starting", 605], ["from", 614], ["400", 619], ["\u03bcg", 623], ["b.i.d", 626], [".", 631], ["doses", 633], [",", 638], ["in", 640], ["200-\u03bcg", 643], ["steps", 650], ["every", 656], ["4th", 662], ["day", 666], [".", 669], ["Subjects", 671], ["were", 680], ["randomized", 685], ["1", 696], [":", 698], ["1", 700], ["to", 702], ["the", 705], ["A", 709], ["-", 710], ["B", 711], ["or", 713], ["B", 716], ["-", 717], ["A", 718], ["sequence", 720], [".", 728], ["The", 730], ["pharmacokinetics", 734], ["and", 751], ["tolerability", 755], ["of", 768], ["selexipag", 771], ["and", 781], ["its", 785], ["active", 789], ["metabolite", 796], [",", 806], ["ACT-333679", 808], [",", 818], ["were", 820], ["investigated", 825], [".", 837], ["80", 839], ["subjects", 842], ["were", 851], ["enrolled", 856], ["in", 865], ["the", 868], ["study", 872], [":", 877], ["65", 879], ["subjects", 882], ["completed", 891], ["the", 901], ["study", 905], ["according", 911], ["to", 921], ["protocol", 924], [",", 932], ["and", 934], ["15", 938], ["subjects", 941], ["withdrew", 950], ["from", 959], ["the", 964], ["study", 968], [".", 973], ["The", 975], ["most", 979], ["frequent", 984], ["adverse", 993], ["events", 1001], ["(", 1008], ["AEs", 1009], [")", 1012], ["were", 1014], ["headache", 1019], ["(", 1028], ["86", 1029], ["%", 1031], [")", 1032], [",", 1033], ["myalgia", 1035], ["(", 1043], ["73", 1044], ["%", 1046], [")", 1047], [",", 1048], ["and", 1050], ["jaw", 1054], ["pain", 1058], ["(", 1063], ["73", 1064], ["%", 1066], [")", 1067], [".", 1068], ["There", 1070], ["was", 1076], ["no", 1080], ["difference", 1083], ["in", 1094], ["nature", 1097], ["and", 1104], ["overall", 1108], ["frequency", 1116], ["of", 1126], ["AEs", 1129], ["between", 1133], ["the", 1141], ["two", 1145], ["treatments", 1149], [".", 1159], ["Steady", 1161], ["state", 1168], ["was", 1174], ["attained", 1178], ["within", 1187], ["3", 1194], ["days", 1196], ["of", 1201], ["the", 1204], ["selexipag", 1208], ["1,600", 1218], ["\u00ce\u00bcg", 1224], ["b.i.d", 1228], [".", 1233], ["The", 1235], ["90", 1239], ["%", 1241], ["confidence", 1243], ["intervals", 1254], ["(", 1264], ["CIs", 1265], [")", 1268], ["of", 1270], ["the", 1273], ["geometric", 1277], ["mean", 1287], ["ratio", 1292], ["(", 1298], ["B", 1299], ["/", 1300], ["A", 1301], [")", 1302], ["at", 1304], ["steady", 1307], ["state", 1314], ["for", 1320], ["AUC\u00cf\u0084", 1324], ["and", 1330], ["Cmax", 1334], [",", 1338], ["ss", 1339], ["were", 1342], ["within", 1347], ["(", 1354], ["0.80", 1355], [",", 1359], ["1.25", 1361], [")", 1365], ["bioequivalence", 1367], ["interval", 1382], [":", 1390], ["(", 1392], ["0.92", 1393], [",", 1397], ["1.06", 1399], [")", 1403], ["and", 1405], ["(", 1409], ["0.95", 1410], [",", 1414], ["1.14", 1416], [")", 1420], [",", 1421], ["respectively", 1423], [",", 1435], ["for", 1437], ["selexipag", 1441], ["and", 1451], ["(", 1455], ["0.95", 1456], [",", 1460], ["1.06", 1462], [")", 1466], ["and", 1468], ["(", 1472], ["0.94", 1473], [",", 1477], ["1.07", 1479], [")", 1483], [",", 1484], ["respectively", 1486], [",", 1498], ["for", 1500], ["the", 1504], ["active", 1508], ["metabolite", 1515], [",", 1525], ["ACT-333679", 1527], [".", 1537], ["Bioequivalence", 1539], ["was", 1554], ["demonstrated", 1558], ["between", 1571], ["8", 1579], ["x", 1581], ["200", 1583], ["\u03bcg", 1587], ["and", 1590], ["1", 1594], ["x", 1596], ["1,600", 1598], ["\u03bcg", 1604], ["selexipag", 1607], ["at", 1617], ["steady", 1620], ["state", 1627], [".", 1632]]}
{"context": "Neural stem/progenitor cells (NSCs) reside in the subventricular zone (SVZ) and subgranular zone of the hippocampal dentate gyrus in adult mammals. The ubiquitin ligase HRD1 is associated with degradation of amyloid precursor protein and believed to be specifically expressed in neurons and not in astrocytes. We investigated expression of HRD1 using immunohistochemistry and found colocalization of HRD1 with the NSC marker protein nestin and glial fibrillary acidic protein in the NSCs of the SVZ (the SVZ astrocytes) but not in the hippocampus. In the hippocampal dentate gyrus, HRD1 is localized in the nucleus of nestin-positive cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "2955684affa14660b9c3b54689b9b2d2", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[106, 106], [70, 70]], "char_spans": [[618, 623], [433, 438]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cells", 23], ["(", 29], ["NSCs", 30], [")", 34], ["reside", 36], ["in", 43], ["the", 46], ["subventricular", 50], ["zone", 65], ["(", 70], ["SVZ", 71], [")", 74], ["and", 76], ["subgranular", 80], ["zone", 92], ["of", 97], ["the", 100], ["hippocampal", 104], ["dentate", 116], ["gyrus", 124], ["in", 130], ["adult", 133], ["mammals", 139], [".", 146], ["The", 148], ["ubiquitin", 152], ["ligase", 162], ["HRD1", 169], ["is", 174], ["associated", 177], ["with", 188], ["degradation", 193], ["of", 205], ["amyloid", 208], ["precursor", 216], ["protein", 226], ["and", 234], ["believed", 238], ["to", 247], ["be", 250], ["specifically", 253], ["expressed", 266], ["in", 276], ["neurons", 279], ["and", 287], ["not", 291], ["in", 295], ["astrocytes", 298], [".", 308], ["We", 310], ["investigated", 313], ["expression", 326], ["of", 337], ["HRD1", 340], ["using", 345], ["immunohistochemistry", 351], ["and", 372], ["found", 376], ["colocalization", 382], ["of", 397], ["HRD1", 400], ["with", 405], ["the", 410], ["NSC", 414], ["marker", 418], ["protein", 425], ["nestin", 433], ["and", 440], ["glial", 444], ["fibrillary", 450], ["acidic", 461], ["protein", 468], ["in", 476], ["the", 479], ["NSCs", 483], ["of", 488], ["the", 491], ["SVZ", 495], ["(", 499], ["the", 500], ["SVZ", 504], ["astrocytes", 508], [")", 518], ["but", 520], ["not", 524], ["in", 528], ["the", 531], ["hippocampus", 535], [".", 546], ["In", 548], ["the", 551], ["hippocampal", 555], ["dentate", 567], ["gyrus", 575], [",", 580], ["HRD1", 582], ["is", 587], ["localized", 590], ["in", 600], ["the", 603], ["nucleus", 607], ["of", 615], ["nestin", 618], ["-", 624], ["positive", 625], ["cells", 634], [".", 639]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a vascular dementing disease caused by mutations in the NOTCH3 gene, most which are missense mutations leading to an uneven number of cysteine residues in epidermal growth factor-like repeats in the extracellular domain of Notch3 receptor (N3ECD). CADASIL is characterized by degeneration of vascular smooth muscle cells (VSMC) and accumulation of N3ECD on the VSMCs of small and middle-sized arteries. Recent studies have demonstrated that impairment of Notch3 signaling is not the primary cause of the disease. In the present study we used proteomic analysis to characterize the protein expression pattern of a unique material of genetically genuine cultured human CADASIL VSMCs. We identified 11 differentially expressed proteins, which are involved in protein degradation and folding, contraction of VSMCs, and cellular stress. Our findings indicate that misfolding of Notch3 may cause endoplasmic reticulum stress and activation of unfolded protein response, leading to increased reactive oxygen species and inhibition of cell proliferation. In addition, upregulation of contractile proteins suggests an alteration in the signaling system of VSMC contraction. The accumulation of N3ECD on the cell surface possibly upregulates the angiotensin II regulatory feedback loop and thereby enhances the readiness of the cells to respond to angiotensin II stimulation.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "23e49b37f14a466999405fd5b5603a3b", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[22, 23]], "char_spans": [[160, 170]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["a", 104], ["vascular", 106], ["dementing", 115], ["disease", 125], ["caused", 133], ["by", 140], ["mutations", 143], ["in", 153], ["the", 156], ["NOTCH3", 160], ["gene", 167], [",", 171], ["most", 173], ["which", 178], ["are", 184], ["missense", 188], ["mutations", 197], ["leading", 207], ["to", 215], ["an", 218], ["uneven", 221], ["number", 228], ["of", 235], ["cysteine", 238], ["residues", 247], ["in", 256], ["epidermal", 259], ["growth", 269], ["factor", 276], ["-", 282], ["like", 283], ["repeats", 288], ["in", 296], ["the", 299], ["extracellular", 303], ["domain", 317], ["of", 324], ["Notch3", 327], ["receptor", 334], ["(", 343], ["N3ECD", 344], [")", 349], [".", 350], ["CADASIL", 352], ["is", 360], ["characterized", 363], ["by", 377], ["degeneration", 380], ["of", 393], ["vascular", 396], ["smooth", 405], ["muscle", 412], ["cells", 419], ["(", 425], ["VSMC", 426], [")", 430], ["and", 432], ["accumulation", 436], ["of", 449], ["N3ECD", 452], ["on", 458], ["the", 461], ["VSMCs", 465], ["of", 471], ["small", 474], ["and", 480], ["middle", 484], ["-", 490], ["sized", 491], ["arteries", 497], [".", 505], ["Recent", 507], ["studies", 514], ["have", 522], ["demonstrated", 527], ["that", 540], ["impairment", 545], ["of", 556], ["Notch3", 559], ["signaling", 566], ["is", 576], ["not", 579], ["the", 583], ["primary", 587], ["cause", 595], ["of", 601], ["the", 604], ["disease", 608], [".", 615], ["In", 617], ["the", 620], ["present", 624], ["study", 632], ["we", 638], ["used", 641], ["proteomic", 646], ["analysis", 656], ["to", 665], ["characterize", 668], ["the", 681], ["protein", 685], ["expression", 693], ["pattern", 704], ["of", 712], ["a", 715], ["unique", 717], ["material", 724], ["of", 733], ["genetically", 736], ["genuine", 748], ["cultured", 756], ["human", 765], ["CADASIL", 771], ["VSMCs", 779], [".", 784], ["We", 786], ["identified", 789], ["11", 800], ["differentially", 803], ["expressed", 818], ["proteins", 828], [",", 836], ["which", 838], ["are", 844], ["involved", 848], ["in", 857], ["protein", 860], ["degradation", 868], ["and", 880], ["folding", 884], [",", 891], ["contraction", 893], ["of", 905], ["VSMCs", 908], [",", 913], ["and", 915], ["cellular", 919], ["stress", 928], [".", 934], ["Our", 936], ["findings", 940], ["indicate", 949], ["that", 958], ["misfolding", 963], ["of", 974], ["Notch3", 977], ["may", 984], ["cause", 988], ["endoplasmic", 994], ["reticulum", 1006], ["stress", 1016], ["and", 1023], ["activation", 1027], ["of", 1038], ["unfolded", 1041], ["protein", 1050], ["response", 1058], [",", 1066], ["leading", 1068], ["to", 1076], ["increased", 1079], ["reactive", 1089], ["oxygen", 1098], ["species", 1105], ["and", 1113], ["inhibition", 1117], ["of", 1128], ["cell", 1131], ["proliferation", 1136], [".", 1149], ["In", 1151], ["addition", 1154], [",", 1162], ["upregulation", 1164], ["of", 1177], ["contractile", 1180], ["proteins", 1192], ["suggests", 1201], ["an", 1210], ["alteration", 1213], ["in", 1224], ["the", 1227], ["signaling", 1231], ["system", 1241], ["of", 1248], ["VSMC", 1251], ["contraction", 1256], [".", 1267], ["The", 1269], ["accumulation", 1273], ["of", 1286], ["N3ECD", 1289], ["on", 1295], ["the", 1298], ["cell", 1302], ["surface", 1307], ["possibly", 1315], ["upregulates", 1324], ["the", 1336], ["angiotensin", 1340], ["II", 1352], ["regulatory", 1355], ["feedback", 1366], ["loop", 1375], ["and", 1380], ["thereby", 1384], ["enhances", 1392], ["the", 1401], ["readiness", 1405], ["of", 1415], ["the", 1418], ["cells", 1422], ["to", 1428], ["respond", 1431], ["to", 1439], ["angiotensin", 1442], ["II", 1454], ["stimulation", 1457], [".", 1468]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA) in the clinical laboratory. Under disk diffusion testing conditions designed to maximize detection of MRSA (incubation at 32 degrees C, pre-induction with methicillin, or plating on 4% NaCl-supplemented agar), BORSA strains also tend to appear resistant to semisynthetic penicillins. Under these conditions, ampicillin/sulbactam appears to be more accurate than amoxicillin/clavulanic acid for differentiating BORSA from MRSA.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "a859d7dd48d14f7ba82f37892f524538", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["may", 61], ["be", 65], ["misidentified", 68], ["as", 82], ["intrinsically", 85], ["methicillin", 99], ["-", 110], ["resistant", 111], ["Staphylococcus", 121], ["aureus", 136], ["(", 143], ["MRSA", 144], [")", 148], ["in", 150], ["the", 153], ["clinical", 157], ["laboratory", 166], [".", 176], ["Under", 178], ["disk", 184], ["diffusion", 189], ["testing", 199], ["conditions", 207], ["designed", 218], ["to", 227], ["maximize", 230], ["detection", 239], ["of", 249], ["MRSA", 252], ["(", 257], ["incubation", 258], ["at", 269], ["32", 272], ["degrees", 275], ["C", 283], [",", 284], ["pre", 286], ["-", 289], ["induction", 290], ["with", 300], ["methicillin", 305], [",", 316], ["or", 318], ["plating", 321], ["on", 329], ["4", 332], ["%", 333], ["NaCl", 335], ["-", 339], ["supplemented", 340], ["agar", 353], [")", 357], [",", 358], ["BORSA", 360], ["strains", 366], ["also", 374], ["tend", 379], ["to", 384], ["appear", 387], ["resistant", 394], ["to", 404], ["semisynthetic", 407], ["penicillins", 421], [".", 432], ["Under", 434], ["these", 440], ["conditions", 446], [",", 456], ["ampicillin", 458], ["/", 468], ["sulbactam", 469], ["appears", 479], ["to", 487], ["be", 490], ["more", 493], ["accurate", 498], ["than", 507], ["amoxicillin", 512], ["/", 523], ["clavulanic", 524], ["acid", 535], ["for", 540], ["differentiating", 544], ["BORSA", 560], ["from", 566], ["MRSA", 571], [".", 575]]}
{"context": "Circular RNAs (circRNAs) are a class of newly-identified non-coding RNA molecules. CircRNAs are conserved across different species and display specific organization, sequence, and expression in disease. Moreover, circRNAs' closed ring structure, insensitivity to RNase, and stability are advantages over linear RNAs in terms of development and application as a new kind of clinical marker. In addition, according to recent studies, circular RNA-7 (ciRS-7) acts as a sponge of miR-7 and thus inhibits its activity. Numerous evidences have confirmed expression of miR-7 is dysregulated in cancer tissues, however, whether ciRS-7 invovled in oncogenesis by acting as sponge of miR-7 remains unclear. Most recently, a study reported ciRS-7 acted as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. This suggest ciRS-7/ miR-7 axis affects oncogenesis, and it provides a new perspective on the mechanisms of decreased miR-7 expression in cancer tissues. Discovery of sponge role of circRNAs caused researchers to more closely explore the underlying mechanism of carcinogenesis and has significant clinical implications, and may open a new chapter in research on the pathology and treatment of cancers. This review summarizes the structure and function of circRNAs and provides evidence for the impact of ciRS-7 in promoting the development of cancer by acting as sponge of miR-7.", "qas": [{"question": "Which miRNA is associated with the circular RNA ciRS-7?", "answers": ["miR-7"], "qid": "8d3460a44ce34647a536fc55cd18a4e1", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["associated", 15], ["with", 26], ["the", 31], ["circular", 35], ["RNA", 44], ["ciRS-7", 48], ["?", 54]], "detected_answers": [{"text": "miR-7", "token_spans": [[161, 161], [139, 139], [234, 234], [100, 100], [119, 119], [87, 87], [145, 145]], "char_spans": [[939, 943], [803, 807], [1394, 1398], [562, 566], [674, 678], [476, 480], [842, 846]]}]}], "context_tokens": [["Circular", 0], ["RNAs", 9], ["(", 14], ["circRNAs", 15], [")", 23], ["are", 25], ["a", 29], ["class", 31], ["of", 37], ["newly", 40], ["-", 45], ["identified", 46], ["non", 57], ["-", 60], ["coding", 61], ["RNA", 68], ["molecules", 72], [".", 81], ["CircRNAs", 83], ["are", 92], ["conserved", 96], ["across", 106], ["different", 113], ["species", 123], ["and", 131], ["display", 135], ["specific", 143], ["organization", 152], [",", 164], ["sequence", 166], [",", 174], ["and", 176], ["expression", 180], ["in", 191], ["disease", 194], [".", 201], ["Moreover", 203], [",", 211], ["circRNAs", 213], ["'", 221], ["closed", 223], ["ring", 230], ["structure", 235], [",", 244], ["insensitivity", 246], ["to", 260], ["RNase", 263], [",", 268], ["and", 270], ["stability", 274], ["are", 284], ["advantages", 288], ["over", 299], ["linear", 304], ["RNAs", 311], ["in", 316], ["terms", 319], ["of", 325], ["development", 328], ["and", 340], ["application", 344], ["as", 356], ["a", 359], ["new", 361], ["kind", 365], ["of", 370], ["clinical", 373], ["marker", 382], [".", 388], ["In", 390], ["addition", 393], [",", 401], ["according", 403], ["to", 413], ["recent", 416], ["studies", 423], [",", 430], ["circular", 432], ["RNA-7", 441], ["(", 447], ["ciRS-7", 448], [")", 454], ["acts", 456], ["as", 461], ["a", 464], ["sponge", 466], ["of", 473], ["miR-7", 476], ["and", 482], ["thus", 486], ["inhibits", 491], ["its", 500], ["activity", 504], [".", 512], ["Numerous", 514], ["evidences", 523], ["have", 533], ["confirmed", 538], ["expression", 548], ["of", 559], ["miR-7", 562], ["is", 568], ["dysregulated", 571], ["in", 584], ["cancer", 587], ["tissues", 594], [",", 601], ["however", 603], [",", 610], ["whether", 612], ["ciRS-7", 620], ["invovled", 627], ["in", 636], ["oncogenesis", 639], ["by", 651], ["acting", 654], ["as", 661], ["sponge", 664], ["of", 671], ["miR-7", 674], ["remains", 680], ["unclear", 688], [".", 695], ["Most", 697], ["recently", 702], [",", 710], ["a", 712], ["study", 714], ["reported", 720], ["ciRS-7", 729], ["acted", 736], ["as", 742], ["an", 745], ["oncogene", 748], ["in", 757], ["hepatocellular", 760], ["carcinoma", 775], ["through", 785], ["targeting", 793], ["miR-7", 803], ["expression", 809], [".", 819], ["This", 821], ["suggest", 826], ["ciRS-7/", 834], ["miR-7", 842], ["axis", 848], ["affects", 853], ["oncogenesis", 861], [",", 872], ["and", 874], ["it", 878], ["provides", 881], ["a", 890], ["new", 892], ["perspective", 896], ["on", 908], ["the", 911], ["mechanisms", 915], ["of", 926], ["decreased", 929], ["miR-7", 939], ["expression", 945], ["in", 956], ["cancer", 959], ["tissues", 966], [".", 973], ["Discovery", 975], ["of", 985], ["sponge", 988], ["role", 995], ["of", 1000], ["circRNAs", 1003], ["caused", 1012], ["researchers", 1019], ["to", 1031], ["more", 1034], ["closely", 1039], ["explore", 1047], ["the", 1055], ["underlying", 1059], ["mechanism", 1070], ["of", 1080], ["carcinogenesis", 1083], ["and", 1098], ["has", 1102], ["significant", 1106], ["clinical", 1118], ["implications", 1127], [",", 1139], ["and", 1141], ["may", 1145], ["open", 1149], ["a", 1154], ["new", 1156], ["chapter", 1160], ["in", 1168], ["research", 1171], ["on", 1180], ["the", 1183], ["pathology", 1187], ["and", 1197], ["treatment", 1201], ["of", 1211], ["cancers", 1214], [".", 1221], ["This", 1223], ["review", 1228], ["summarizes", 1235], ["the", 1246], ["structure", 1250], ["and", 1260], ["function", 1264], ["of", 1273], ["circRNAs", 1276], ["and", 1285], ["provides", 1289], ["evidence", 1298], ["for", 1307], ["the", 1311], ["impact", 1315], ["of", 1322], ["ciRS-7", 1325], ["in", 1332], ["promoting", 1335], ["the", 1345], ["development", 1349], ["of", 1361], ["cancer", 1364], ["by", 1371], ["acting", 1374], ["as", 1381], ["sponge", 1384], ["of", 1391], ["miR-7", 1394], [".", 1399]]}
{"context": "Chediak-Higashi syndrome, a rare autosomal recessive disorder, was described over 50 years ago. Patients show hypopigmentation, recurrent infections, mild coagulation defects and varying neurologic problems. Treatment is bone marrow transplant, which is effective in treating the hematologic and immune defects, however the neurologic problems persist. The CHS1/LYST gene was identified over 10 years ago and homologous CHS1/LYST genes are present in all eukaryotes. This review will discuss the advances made in understanding the clinical aspects of the syndrome and the function of CHS1/LYST/Beige. Clinical reports of Chediak-Higashi syndrome have identified mutations throughout the CHS1/LYST gene. The nature of the mutation can be a predictor of the severity of the disease. Over the past decade the CHS1/LYST family of proteins has been analyzed using model organisms, two-hybrid analysis, overexpression phenotypes and dominant negatives. These studies suggest that the CHS1/LYST protein is involved in either vesicle fusion or fission. Although CHS is a rare disease, the Chediak-like family of proteins is providing insight into the regulation of vesicle trafficking. Understanding the basic mechanisms that govern vesicle trafficking will provide essential information regarding how loss of CHS1/LYST affects hematologic, immunologic and neurologic processes.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "8283a8628bfe440b908b5fe0ef0625ea", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3], [101, 104]], "char_spans": [[0, 23], [621, 644]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], [",", 24], ["a", 26], ["rare", 28], ["autosomal", 33], ["recessive", 43], ["disorder", 53], [",", 61], ["was", 63], ["described", 67], ["over", 77], ["50", 82], ["years", 85], ["ago", 91], [".", 94], ["Patients", 96], ["show", 105], ["hypopigmentation", 110], [",", 126], ["recurrent", 128], ["infections", 138], [",", 148], ["mild", 150], ["coagulation", 155], ["defects", 167], ["and", 175], ["varying", 179], ["neurologic", 187], ["problems", 198], [".", 206], ["Treatment", 208], ["is", 218], ["bone", 221], ["marrow", 226], ["transplant", 233], [",", 243], ["which", 245], ["is", 251], ["effective", 254], ["in", 264], ["treating", 267], ["the", 276], ["hematologic", 280], ["and", 292], ["immune", 296], ["defects", 303], [",", 310], ["however", 312], ["the", 320], ["neurologic", 324], ["problems", 335], ["persist", 344], [".", 351], ["The", 353], ["CHS1/LYST", 357], ["gene", 367], ["was", 372], ["identified", 376], ["over", 387], ["10", 392], ["years", 395], ["ago", 401], ["and", 405], ["homologous", 409], ["CHS1/LYST", 420], ["genes", 430], ["are", 436], ["present", 440], ["in", 448], ["all", 451], ["eukaryotes", 455], [".", 465], ["This", 467], ["review", 472], ["will", 479], ["discuss", 484], ["the", 492], ["advances", 496], ["made", 505], ["in", 510], ["understanding", 513], ["the", 527], ["clinical", 531], ["aspects", 540], ["of", 548], ["the", 551], ["syndrome", 555], ["and", 564], ["the", 568], ["function", 572], ["of", 581], ["CHS1/LYST", 584], ["/", 593], ["Beige", 594], [".", 599], ["Clinical", 601], ["reports", 610], ["of", 618], ["Chediak", 621], ["-", 628], ["Higashi", 629], ["syndrome", 637], ["have", 646], ["identified", 651], ["mutations", 662], ["throughout", 672], ["the", 683], ["CHS1/LYST", 687], ["gene", 697], [".", 701], ["The", 703], ["nature", 707], ["of", 714], ["the", 717], ["mutation", 721], ["can", 730], ["be", 734], ["a", 737], ["predictor", 739], ["of", 749], ["the", 752], ["severity", 756], ["of", 765], ["the", 768], ["disease", 772], [".", 779], ["Over", 781], ["the", 786], ["past", 790], ["decade", 795], ["the", 802], ["CHS1/LYST", 806], ["family", 816], ["of", 823], ["proteins", 826], ["has", 835], ["been", 839], ["analyzed", 844], ["using", 853], ["model", 859], ["organisms", 865], [",", 874], ["two", 876], ["-", 879], ["hybrid", 880], ["analysis", 887], [",", 895], ["overexpression", 897], ["phenotypes", 912], ["and", 923], ["dominant", 927], ["negatives", 936], [".", 945], ["These", 947], ["studies", 953], ["suggest", 961], ["that", 969], ["the", 974], ["CHS1/LYST", 978], ["protein", 988], ["is", 996], ["involved", 999], ["in", 1008], ["either", 1011], ["vesicle", 1018], ["fusion", 1026], ["or", 1033], ["fission", 1036], [".", 1043], ["Although", 1045], ["CHS", 1054], ["is", 1058], ["a", 1061], ["rare", 1063], ["disease", 1068], [",", 1075], ["the", 1077], ["Chediak", 1081], ["-", 1088], ["like", 1089], ["family", 1094], ["of", 1101], ["proteins", 1104], ["is", 1113], ["providing", 1116], ["insight", 1126], ["into", 1134], ["the", 1139], ["regulation", 1143], ["of", 1154], ["vesicle", 1157], ["trafficking", 1165], [".", 1176], ["Understanding", 1178], ["the", 1192], ["basic", 1196], ["mechanisms", 1202], ["that", 1213], ["govern", 1218], ["vesicle", 1225], ["trafficking", 1233], ["will", 1245], ["provide", 1250], ["essential", 1258], ["information", 1268], ["regarding", 1280], ["how", 1290], ["loss", 1294], ["of", 1299], ["CHS1/LYST", 1302], ["affects", 1312], ["hematologic", 1320], [",", 1331], ["immunologic", 1333], ["and", 1345], ["neurologic", 1349], ["processes", 1360], [".", 1369]]}
{"context": "The proto-oncogene ras is an essential gene for the growth and the differentiation for various types of cells. Ras, ras gene product, is a GTP binding protein which controls the signal transduction by GTP hydrolysis. The ras gene is frequently activated by point mutations in various types of human cancers, which results in a decrease in the GTPase activity of its product. A GTPase-activating protein p120 (p120GAP) was identified as a factor which stimulates the GTPase of normal ras gene product p21 but not of the mutated. An NF1 gene was identified as a gene whose loss of function causes an onset of human disorder, neurofibromatosis type I. The NF1 gene encodes a protein which contains a region with a similarity to the catalytic domain of p120GAP. We recently purified a novel Ras GAP whose molecular weight and immunogenecity are different from those of p120GAP and NF1. We named the novel mammalian Ras GAP as Gap1m. Isolation and sequencing of Gap1m cDNA revealed that Gap1m is indeed a novel Ras GAP. We also succeeded in isolation of another novel Ras GAP gene, GapIII/Gap1IP4BP, which is closely related to Gap1m. Recently, it is shown that GapIII/Gap1IP4BP binds inositol-tetrakis phosphate compounds. The overview of these Ras GAP molecules is described.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "5f0e0e9c78bd4056be4db4e527d130c7", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[161, 161], [123, 123], [101, 101]], "char_spans": [[877, 879], [653, 655], [531, 533]]}]}], "context_tokens": [["The", 0], ["proto", 4], ["-", 9], ["oncogene", 10], ["ras", 19], ["is", 23], ["an", 26], ["essential", 29], ["gene", 39], ["for", 44], ["the", 48], ["growth", 52], ["and", 59], ["the", 63], ["differentiation", 67], ["for", 83], ["various", 87], ["types", 95], ["of", 101], ["cells", 104], [".", 109], ["Ras", 111], [",", 114], ["ras", 116], ["gene", 120], ["product", 125], [",", 132], ["is", 134], ["a", 137], ["GTP", 139], ["binding", 143], ["protein", 151], ["which", 159], ["controls", 165], ["the", 174], ["signal", 178], ["transduction", 185], ["by", 198], ["GTP", 201], ["hydrolysis", 205], [".", 215], ["The", 217], ["ras", 221], ["gene", 225], ["is", 230], ["frequently", 233], ["activated", 244], ["by", 254], ["point", 257], ["mutations", 263], ["in", 273], ["various", 276], ["types", 284], ["of", 290], ["human", 293], ["cancers", 299], [",", 306], ["which", 308], ["results", 314], ["in", 322], ["a", 325], ["decrease", 327], ["in", 336], ["the", 339], ["GTPase", 343], ["activity", 350], ["of", 359], ["its", 362], ["product", 366], [".", 373], ["A", 375], ["GTPase", 377], ["-", 383], ["activating", 384], ["protein", 395], ["p120", 403], ["(", 408], ["p120GAP", 409], [")", 416], ["was", 418], ["identified", 422], ["as", 433], ["a", 436], ["factor", 438], ["which", 445], ["stimulates", 451], ["the", 462], ["GTPase", 466], ["of", 473], ["normal", 476], ["ras", 483], ["gene", 487], ["product", 492], ["p21", 500], ["but", 504], ["not", 508], ["of", 512], ["the", 515], ["mutated", 519], [".", 526], ["An", 528], ["NF1", 531], ["gene", 535], ["was", 540], ["identified", 544], ["as", 555], ["a", 558], ["gene", 560], ["whose", 565], ["loss", 571], ["of", 576], ["function", 579], ["causes", 588], ["an", 595], ["onset", 598], ["of", 604], ["human", 607], ["disorder", 613], [",", 621], ["neurofibromatosis", 623], ["type", 641], ["I.", 646], ["The", 649], ["NF1", 653], ["gene", 657], ["encodes", 662], ["a", 670], ["protein", 672], ["which", 680], ["contains", 686], ["a", 695], ["region", 697], ["with", 704], ["a", 709], ["similarity", 711], ["to", 722], ["the", 725], ["catalytic", 729], ["domain", 739], ["of", 746], ["p120GAP", 749], [".", 756], ["We", 758], ["recently", 761], ["purified", 770], ["a", 779], ["novel", 781], ["Ras", 787], ["GAP", 791], ["whose", 795], ["molecular", 801], ["weight", 811], ["and", 818], ["immunogenecity", 822], ["are", 837], ["different", 841], ["from", 851], ["those", 856], ["of", 862], ["p120GAP", 865], ["and", 873], ["NF1", 877], [".", 880], ["We", 882], ["named", 885], ["the", 891], ["novel", 895], ["mammalian", 901], ["Ras", 911], ["GAP", 915], ["as", 919], ["Gap1", 922], ["m", 926], [".", 927], ["Isolation", 929], ["and", 939], ["sequencing", 943], ["of", 954], ["Gap1", 957], ["m", 961], ["cDNA", 963], ["revealed", 968], ["that", 977], ["Gap1", 982], ["m", 986], ["is", 988], ["indeed", 991], ["a", 998], ["novel", 1000], ["Ras", 1006], ["GAP", 1010], [".", 1013], ["We", 1015], ["also", 1018], ["succeeded", 1023], ["in", 1033], ["isolation", 1036], ["of", 1046], ["another", 1049], ["novel", 1057], ["Ras", 1063], ["GAP", 1067], ["gene", 1071], [",", 1075], ["GapIII", 1077], ["/", 1083], ["Gap1IP4BP", 1084], [",", 1093], ["which", 1095], ["is", 1101], ["closely", 1104], ["related", 1112], ["to", 1120], ["Gap1", 1123], ["m", 1127], [".", 1128], ["Recently", 1130], [",", 1138], ["it", 1140], ["is", 1143], ["shown", 1146], ["that", 1152], ["GapIII", 1157], ["/", 1163], ["Gap1IP4BP", 1164], ["binds", 1174], ["inositol", 1180], ["-", 1188], ["tetrakis", 1189], ["phosphate", 1198], ["compounds", 1208], [".", 1217], ["The", 1219], ["overview", 1223], ["of", 1232], ["these", 1235], ["Ras", 1241], ["GAP", 1245], ["molecules", 1249], ["is", 1259], ["described", 1262], [".", 1271]]}
{"context": "Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer. This response requires the presence of the pXO1 virulence plasmid-encoded pleiotropic regulator AtxA. To better understand the genetic basis of this response, we utilized a controlled in vitro system and Next Generation sequencing to determine and compare RNA expression profiles of the parental strain and an isogenic AtxA-deficient strain in a 2 \u00d7 2 factorial design with growth environments containing or lacking carbon dioxide. We found 15 pXO1-encoded genes and 3 chromosomal genes that were strongly regulated by the separate or synergistic actions of AtxA and carbon dioxide. The majority of the regulated genes responded to both AtxA and carbon dioxide rather than to just one of these factors. Interestingly, we identified two previously unrecognized small RNAs that are highly expressed under physiological carbon dioxide concentrations in an AtxA-dependent manner. Expression levels of the two small RNAs were found to be higher than that of any other gene differentially expressed in response to these conditions. Secondary structure and small RNA-mRNA binding predictions for the two small RNAs suggest that they may perform important functions in regulating B. anthracis virulence. A majority of genes on the virulence plasmid pXO1 that are regulated by the presence of either CO2 or AtxA separately are also regulated synergistically in the presence of both. These results also elucidate novel pXO1-encoded small RNAs that are associated with virulence conditions.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "2ef046659f484e2c81027f2213ef0759", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[27, 27], [258, 258]], "char_spans": [[142, 144], [1566, 1568]]}, {"text": "bicarbonate", "token_spans": [[25, 25]], "char_spans": [[130, 140]]}]}], "context_tokens": [["Upon", 0], ["infection", 5], ["of", 15], ["a", 18], ["mammalian", 20], ["host", 30], [",", 34], ["Bacillus", 36], ["anthracis", 45], ["responds", 55], ["to", 64], ["host", 67], ["cues", 72], [",", 76], ["and", 78], ["particularly", 82], ["to", 95], ["elevated", 98], ["temperature", 107], ["(", 119], ["37", 120], ["\u00b0", 122], ["C", 123], [")", 124], ["and", 126], ["bicarbonate", 130], ["/", 141], ["CO2", 142], ["concentrations", 146], [",", 160], ["with", 162], ["increased", 167], ["expression", 177], ["of", 188], ["virulence", 191], ["factors", 201], ["that", 209], ["include", 214], ["the", 222], ["anthrax", 226], ["toxins", 234], ["and", 241], ["extracellular", 245], ["capsular", 259], ["layer", 268], [".", 273], ["This", 275], ["response", 280], ["requires", 289], ["the", 298], ["presence", 302], ["of", 311], ["the", 314], ["pXO1", 318], ["virulence", 323], ["plasmid", 333], ["-", 340], ["encoded", 341], ["pleiotropic", 349], ["regulator", 361], ["AtxA.", 371], ["To", 377], ["better", 380], ["understand", 387], ["the", 398], ["genetic", 402], ["basis", 410], ["of", 416], ["this", 419], ["response", 424], [",", 432], ["we", 434], ["utilized", 437], ["a", 446], ["controlled", 448], ["in", 459], ["vitro", 462], ["system", 468], ["and", 475], ["Next", 479], ["Generation", 484], ["sequencing", 495], ["to", 506], ["determine", 509], ["and", 519], ["compare", 523], ["RNA", 531], ["expression", 535], ["profiles", 546], ["of", 555], ["the", 558], ["parental", 562], ["strain", 571], ["and", 578], ["an", 582], ["isogenic", 585], ["AtxA", 594], ["-", 598], ["deficient", 599], ["strain", 609], ["in", 616], ["a", 619], ["2", 621], ["\u00d7", 623], ["2", 625], ["factorial", 627], ["design", 637], ["with", 644], ["growth", 649], ["environments", 656], ["containing", 669], ["or", 680], ["lacking", 683], ["carbon", 691], ["dioxide", 698], [".", 705], ["We", 707], ["found", 710], ["15", 716], ["pXO1-encoded", 719], ["genes", 732], ["and", 738], ["3", 742], ["chromosomal", 744], ["genes", 756], ["that", 762], ["were", 767], ["strongly", 772], ["regulated", 781], ["by", 791], ["the", 794], ["separate", 798], ["or", 807], ["synergistic", 810], ["actions", 822], ["of", 830], ["AtxA", 833], ["and", 838], ["carbon", 842], ["dioxide", 849], [".", 856], ["The", 858], ["majority", 862], ["of", 871], ["the", 874], ["regulated", 878], ["genes", 888], ["responded", 894], ["to", 904], ["both", 907], ["AtxA", 912], ["and", 917], ["carbon", 921], ["dioxide", 928], ["rather", 936], ["than", 943], ["to", 948], ["just", 951], ["one", 956], ["of", 960], ["these", 963], ["factors", 969], [".", 976], ["Interestingly", 978], [",", 991], ["we", 993], ["identified", 996], ["two", 1007], ["previously", 1011], ["unrecognized", 1022], ["small", 1035], ["RNAs", 1041], ["that", 1046], ["are", 1051], ["highly", 1055], ["expressed", 1062], ["under", 1072], ["physiological", 1078], ["carbon", 1092], ["dioxide", 1099], ["concentrations", 1107], ["in", 1122], ["an", 1125], ["AtxA", 1128], ["-", 1132], ["dependent", 1133], ["manner", 1143], [".", 1149], ["Expression", 1151], ["levels", 1162], ["of", 1169], ["the", 1172], ["two", 1176], ["small", 1180], ["RNAs", 1186], ["were", 1191], ["found", 1196], ["to", 1202], ["be", 1205], ["higher", 1208], ["than", 1215], ["that", 1220], ["of", 1225], ["any", 1228], ["other", 1232], ["gene", 1238], ["differentially", 1243], ["expressed", 1258], ["in", 1268], ["response", 1271], ["to", 1280], ["these", 1283], ["conditions", 1289], [".", 1299], ["Secondary", 1301], ["structure", 1311], ["and", 1321], ["small", 1325], ["RNA", 1331], ["-", 1334], ["mRNA", 1335], ["binding", 1340], ["predictions", 1348], ["for", 1360], ["the", 1364], ["two", 1368], ["small", 1372], ["RNAs", 1378], ["suggest", 1383], ["that", 1391], ["they", 1396], ["may", 1401], ["perform", 1405], ["important", 1413], ["functions", 1423], ["in", 1433], ["regulating", 1436], ["B.", 1447], ["anthracis", 1450], ["virulence", 1460], [".", 1469], ["A", 1471], ["majority", 1473], ["of", 1482], ["genes", 1485], ["on", 1491], ["the", 1494], ["virulence", 1498], ["plasmid", 1508], ["pXO1", 1516], ["that", 1521], ["are", 1526], ["regulated", 1530], ["by", 1540], ["the", 1543], ["presence", 1547], ["of", 1556], ["either", 1559], ["CO2", 1566], ["or", 1570], ["AtxA", 1573], ["separately", 1578], ["are", 1589], ["also", 1593], ["regulated", 1598], ["synergistically", 1608], ["in", 1624], ["the", 1627], ["presence", 1631], ["of", 1640], ["both", 1643], [".", 1647], ["These", 1649], ["results", 1655], ["also", 1663], ["elucidate", 1668], ["novel", 1678], ["pXO1-encoded", 1684], ["small", 1697], ["RNAs", 1703], ["that", 1708], ["are", 1713], ["associated", 1717], ["with", 1728], ["virulence", 1733], ["conditions", 1743], [".", 1753]]}
{"context": "To evaluate gender differences in score on 28-joint Disease Activity Score (DAS28), Health Assessment Questionnaire (HAQ) and Signals Of Functional Impairment (SOFI) and to relate these scores to radiographic joint destruction. In all, 549 patients with early RA (62% women) from the BARFOT (for \"Better Anti-Rheumatic FarmacOTherapy\") study were included. At baseline, 1, 2 and 5 years DAS28, HAQ and SOFI scoring, and radiographs of hands and feet were performed. The radiographs were scored using the van der Heijde-Sharp score. In women the DAS28 was significantly higher than in men due to higher scores for general health and tender joints. Likewise, HAQ and VAS pain were rated significantly higher in women. The SOFI score was worse in men during the first 2 years, depending on higher upper limb scores. Total Sharp score (TotSharp), erosion score and joint space narrowing score did not differ between the sexes at any time point. The DAS28 area under the curve (AUC) correlated significantly with TotSharp at 5 years in both genders (r = 0.316, r = 0.313) mainly owing to swollen joints and erythrocyte sedimentation rate (ESR). The SOFI AUC correlated significantly with TotSharp in women (r = 0.135 to 0.220) but not in men. Despite a similar degree of radiographic joint destruction women had, compared with men, worse scores for DAS28 and HAQ, possibly due to higher pain perception and less muscular strength and perhaps because men overestimate their functional capacity.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "3a09c991f94d49ac9f85560e9ef63b8f", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[256, 256], [139, 139], [235, 235], [108, 108], [50, 50]], "char_spans": [[1297, 1301], [709, 713], [1195, 1199], [535, 539], [268, 272]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["gender", 12], ["differences", 19], ["in", 31], ["score", 34], ["on", 40], ["28-joint", 43], ["Disease", 52], ["Activity", 60], ["Score", 69], ["(", 75], ["DAS28", 76], [")", 81], [",", 82], ["Health", 84], ["Assessment", 91], ["Questionnaire", 102], ["(", 116], ["HAQ", 117], [")", 120], ["and", 122], ["Signals", 126], ["Of", 134], ["Functional", 137], ["Impairment", 148], ["(", 159], ["SOFI", 160], [")", 164], ["and", 166], ["to", 170], ["relate", 173], ["these", 180], ["scores", 186], ["to", 193], ["radiographic", 196], ["joint", 209], ["destruction", 215], [".", 226], ["In", 228], ["all", 231], [",", 234], ["549", 236], ["patients", 240], ["with", 249], ["early", 254], ["RA", 260], ["(", 263], ["62", 264], ["%", 266], ["women", 268], [")", 273], ["from", 275], ["the", 280], ["BARFOT", 284], ["(", 291], ["for", 292], ["\"", 296], ["Better", 297], ["Anti", 304], ["-", 308], ["Rheumatic", 309], ["FarmacOTherapy", 319], ["\"", 333], [")", 334], ["study", 336], ["were", 342], ["included", 347], [".", 355], ["At", 357], ["baseline", 360], [",", 368], ["1", 370], [",", 371], ["2", 373], ["and", 375], ["5", 379], ["years", 381], ["DAS28", 387], [",", 392], ["HAQ", 394], ["and", 398], ["SOFI", 402], ["scoring", 407], [",", 414], ["and", 416], ["radiographs", 420], ["of", 432], ["hands", 435], ["and", 441], ["feet", 445], ["were", 450], ["performed", 455], [".", 464], ["The", 466], ["radiographs", 470], ["were", 482], ["scored", 487], ["using", 494], ["the", 500], ["van", 504], ["der", 508], ["Heijde", 512], ["-", 518], ["Sharp", 519], ["score", 525], [".", 530], ["In", 532], ["women", 535], ["the", 541], ["DAS28", 545], ["was", 551], ["significantly", 555], ["higher", 569], ["than", 576], ["in", 581], ["men", 584], ["due", 588], ["to", 592], ["higher", 595], ["scores", 602], ["for", 609], ["general", 613], ["health", 621], ["and", 628], ["tender", 632], ["joints", 639], [".", 645], ["Likewise", 647], [",", 655], ["HAQ", 657], ["and", 661], ["VAS", 665], ["pain", 669], ["were", 674], ["rated", 679], ["significantly", 685], ["higher", 699], ["in", 706], ["women", 709], [".", 714], ["The", 716], ["SOFI", 720], ["score", 725], ["was", 731], ["worse", 735], ["in", 741], ["men", 744], ["during", 748], ["the", 755], ["first", 759], ["2", 765], ["years", 767], [",", 772], ["depending", 774], ["on", 784], ["higher", 787], ["upper", 794], ["limb", 800], ["scores", 805], [".", 811], ["Total", 813], ["Sharp", 819], ["score", 825], ["(", 831], ["TotSharp", 832], [")", 840], [",", 841], ["erosion", 843], ["score", 851], ["and", 857], ["joint", 861], ["space", 867], ["narrowing", 873], ["score", 883], ["did", 889], ["not", 893], ["differ", 897], ["between", 904], ["the", 912], ["sexes", 916], ["at", 922], ["any", 925], ["time", 929], ["point", 934], [".", 939], ["The", 941], ["DAS28", 945], ["area", 951], ["under", 956], ["the", 962], ["curve", 966], ["(", 972], ["AUC", 973], [")", 976], ["correlated", 978], ["significantly", 989], ["with", 1003], ["TotSharp", 1008], ["at", 1017], ["5", 1020], ["years", 1022], ["in", 1028], ["both", 1031], ["genders", 1036], ["(", 1044], ["r", 1045], ["=", 1047], ["0.316", 1049], [",", 1054], ["r", 1056], ["=", 1058], ["0.313", 1060], [")", 1065], ["mainly", 1067], ["owing", 1074], ["to", 1080], ["swollen", 1083], ["joints", 1091], ["and", 1098], ["erythrocyte", 1102], ["sedimentation", 1114], ["rate", 1128], ["(", 1133], ["ESR", 1134], [")", 1137], [".", 1138], ["The", 1140], ["SOFI", 1144], ["AUC", 1149], ["correlated", 1153], ["significantly", 1164], ["with", 1178], ["TotSharp", 1183], ["in", 1192], ["women", 1195], ["(", 1201], ["r", 1202], ["=", 1204], ["0.135", 1206], ["to", 1212], ["0.220", 1215], [")", 1220], ["but", 1222], ["not", 1226], ["in", 1230], ["men", 1233], [".", 1236], ["Despite", 1238], ["a", 1246], ["similar", 1248], ["degree", 1256], ["of", 1263], ["radiographic", 1266], ["joint", 1279], ["destruction", 1285], ["women", 1297], ["had", 1303], [",", 1306], ["compared", 1308], ["with", 1317], ["men", 1322], [",", 1325], ["worse", 1327], ["scores", 1333], ["for", 1340], ["DAS28", 1344], ["and", 1350], ["HAQ", 1354], [",", 1357], ["possibly", 1359], ["due", 1368], ["to", 1372], ["higher", 1375], ["pain", 1382], ["perception", 1387], ["and", 1398], ["less", 1402], ["muscular", 1407], ["strength", 1416], ["and", 1425], ["perhaps", 1429], ["because", 1437], ["men", 1445], ["overestimate", 1449], ["their", 1462], ["functional", 1468], ["capacity", 1479], [".", 1487]]}
{"context": "Accumulation and deposition of \u03b2-amyloid peptides (A\u03b2) in the brain is a central event in the pathogenesis of Alzheimer's disease (AD). Besides the parenchymal pathology, A\u03b2 is known to undergo active transport across the blood-brain barrier and cerebral amyloid angiopathy (CAA) is a prominent feature in the majority of AD. Although impaired cerebral blood flow (CBF) has been implicated in faulty A\u03b2 transport and clearance, and cerebral hypoperfusion can exist in the pre-clinical phase of Alzheimer's disease (AD), it is still unclear whether it is one of the causal factors for AD pathogenesis, or an early consequence of a multi-factor condition that would lead to AD at late stage. To study the potential interaction between faulty CBF and amyloid accumulation in clinical-relevant situation, we generated a new amyloid precursor protein (APP) knock-in allele that expresses humanized A\u03b2 and a Dutch mutation in addition to Swedish/London mutations and compared this line with an equivalent knock-in line but in the absence of the Dutch mutation, both crossed onto the PS1M146V knock-in background. Introduction of the Dutch mutation results in robust CAA and parenchymal A\u03b2 pathology, age-dependent reduction of spatial learning and memory deficits, and CBF reduction as detected by fMRI. Direct manipulation of CBF by transverse aortic constriction surgery on the left common carotid artery caused differential changes in CBF in the anterior and middle region of the cortex, where it is reduced on the left side and increased on the right side. However these perturbations in CBF resulted in the same effect: both significantly exacerbate CAA and amyloid pathology. Our study reveals a direct and positive link between vascular and parenchymal A\u03b2; both can be modulated by CBF. The new APP knock-in mouse model recapitulates many symptoms of AD including progressive vascular and parenchymal A\u03b2 pathology and behavioral deficits in the absence of APP overexpression.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "fd787f32d19848dbb65fe34c00222562", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[22, 24], [94, 96]], "char_spans": [[110, 128], [494, 512]]}, {"text": "AD", "token_spans": [[131, 131], [98, 98], [26, 26], [342, 342], [62, 62], [114, 114]], "char_spans": [[672, 673], [515, 516], [131, 132], [1852, 1853], [322, 323], [584, 585]]}]}], "context_tokens": [["Accumulation", 0], ["and", 13], ["deposition", 17], ["of", 28], ["\u03b2", 31], ["-", 32], ["amyloid", 33], ["peptides", 41], ["(", 50], ["A\u03b2", 51], [")", 53], ["in", 55], ["the", 58], ["brain", 62], ["is", 68], ["a", 71], ["central", 73], ["event", 81], ["in", 87], ["the", 90], ["pathogenesis", 94], ["of", 107], ["Alzheimer", 110], ["'s", 119], ["disease", 122], ["(", 130], ["AD", 131], [")", 133], [".", 134], ["Besides", 136], ["the", 144], ["parenchymal", 148], ["pathology", 160], [",", 169], ["A\u03b2", 171], ["is", 174], ["known", 177], ["to", 183], ["undergo", 186], ["active", 194], ["transport", 201], ["across", 211], ["the", 218], ["blood", 222], ["-", 227], ["brain", 228], ["barrier", 234], ["and", 242], ["cerebral", 246], ["amyloid", 255], ["angiopathy", 263], ["(", 274], ["CAA", 275], [")", 278], ["is", 280], ["a", 283], ["prominent", 285], ["feature", 295], ["in", 303], ["the", 306], ["majority", 310], ["of", 319], ["AD", 322], [".", 324], ["Although", 326], ["impaired", 335], ["cerebral", 344], ["blood", 353], ["flow", 359], ["(", 364], ["CBF", 365], [")", 368], ["has", 370], ["been", 374], ["implicated", 379], ["in", 390], ["faulty", 393], ["A\u03b2", 400], ["transport", 403], ["and", 413], ["clearance", 417], [",", 426], ["and", 428], ["cerebral", 432], ["hypoperfusion", 441], ["can", 455], ["exist", 459], ["in", 465], ["the", 468], ["pre", 472], ["-", 475], ["clinical", 476], ["phase", 485], ["of", 491], ["Alzheimer", 494], ["'s", 503], ["disease", 506], ["(", 514], ["AD", 515], [")", 517], [",", 518], ["it", 520], ["is", 523], ["still", 526], ["unclear", 532], ["whether", 540], ["it", 548], ["is", 551], ["one", 554], ["of", 558], ["the", 561], ["causal", 565], ["factors", 572], ["for", 580], ["AD", 584], ["pathogenesis", 587], [",", 599], ["or", 601], ["an", 604], ["early", 607], ["consequence", 613], ["of", 625], ["a", 628], ["multi", 630], ["-", 635], ["factor", 636], ["condition", 643], ["that", 653], ["would", 658], ["lead", 664], ["to", 669], ["AD", 672], ["at", 675], ["late", 678], ["stage", 683], [".", 688], ["To", 690], ["study", 693], ["the", 699], ["potential", 703], ["interaction", 713], ["between", 725], ["faulty", 733], ["CBF", 740], ["and", 744], ["amyloid", 748], ["accumulation", 756], ["in", 769], ["clinical", 772], ["-", 780], ["relevant", 781], ["situation", 790], [",", 799], ["we", 801], ["generated", 804], ["a", 814], ["new", 816], ["amyloid", 820], ["precursor", 828], ["protein", 838], ["(", 846], ["APP", 847], [")", 850], ["knock", 852], ["-", 857], ["in", 858], ["allele", 861], ["that", 868], ["expresses", 873], ["humanized", 883], ["A\u03b2", 893], ["and", 896], ["a", 900], ["Dutch", 902], ["mutation", 908], ["in", 917], ["addition", 920], ["to", 929], ["Swedish", 932], ["/", 939], ["London", 940], ["mutations", 947], ["and", 957], ["compared", 961], ["this", 970], ["line", 975], ["with", 980], ["an", 985], ["equivalent", 988], ["knock", 999], ["-", 1004], ["in", 1005], ["line", 1008], ["but", 1013], ["in", 1017], ["the", 1020], ["absence", 1024], ["of", 1032], ["the", 1035], ["Dutch", 1039], ["mutation", 1045], [",", 1053], ["both", 1055], ["crossed", 1060], ["onto", 1068], ["the", 1073], ["PS1M146V", 1077], ["knock", 1086], ["-", 1091], ["in", 1092], ["background", 1095], [".", 1105], ["Introduction", 1107], ["of", 1120], ["the", 1123], ["Dutch", 1127], ["mutation", 1133], ["results", 1142], ["in", 1150], ["robust", 1153], ["CAA", 1160], ["and", 1164], ["parenchymal", 1168], ["A\u03b2", 1180], ["pathology", 1183], [",", 1192], ["age", 1194], ["-", 1197], ["dependent", 1198], ["reduction", 1208], ["of", 1218], ["spatial", 1221], ["learning", 1229], ["and", 1238], ["memory", 1242], ["deficits", 1249], [",", 1257], ["and", 1259], ["CBF", 1263], ["reduction", 1267], ["as", 1277], ["detected", 1280], ["by", 1289], ["fMRI", 1292], [".", 1296], ["Direct", 1298], ["manipulation", 1305], ["of", 1318], ["CBF", 1321], ["by", 1325], ["transverse", 1328], ["aortic", 1339], ["constriction", 1346], ["surgery", 1359], ["on", 1367], ["the", 1370], ["left", 1374], ["common", 1379], ["carotid", 1386], ["artery", 1394], ["caused", 1401], ["differential", 1408], ["changes", 1421], ["in", 1429], ["CBF", 1432], ["in", 1436], ["the", 1439], ["anterior", 1443], ["and", 1452], ["middle", 1456], ["region", 1463], ["of", 1470], ["the", 1473], ["cortex", 1477], [",", 1483], ["where", 1485], ["it", 1491], ["is", 1494], ["reduced", 1497], ["on", 1505], ["the", 1508], ["left", 1512], ["side", 1517], ["and", 1522], ["increased", 1526], ["on", 1536], ["the", 1539], ["right", 1543], ["side", 1549], [".", 1553], ["However", 1555], ["these", 1563], ["perturbations", 1569], ["in", 1583], ["CBF", 1586], ["resulted", 1590], ["in", 1599], ["the", 1602], ["same", 1606], ["effect", 1611], [":", 1617], ["both", 1619], ["significantly", 1624], ["exacerbate", 1638], ["CAA", 1649], ["and", 1653], ["amyloid", 1657], ["pathology", 1665], [".", 1674], ["Our", 1676], ["study", 1680], ["reveals", 1686], ["a", 1694], ["direct", 1696], ["and", 1703], ["positive", 1707], ["link", 1716], ["between", 1721], ["vascular", 1729], ["and", 1738], ["parenchymal", 1742], ["A\u03b2", 1754], [";", 1756], ["both", 1758], ["can", 1763], ["be", 1767], ["modulated", 1770], ["by", 1780], ["CBF", 1783], [".", 1786], ["The", 1788], ["new", 1792], ["APP", 1796], ["knock", 1800], ["-", 1805], ["in", 1806], ["mouse", 1809], ["model", 1815], ["recapitulates", 1821], ["many", 1835], ["symptoms", 1840], ["of", 1849], ["AD", 1852], ["including", 1855], ["progressive", 1865], ["vascular", 1877], ["and", 1886], ["parenchymal", 1890], ["A\u03b2", 1902], ["pathology", 1905], ["and", 1915], ["behavioral", 1919], ["deficits", 1930], ["in", 1939], ["the", 1942], ["absence", 1946], ["of", 1954], ["APP", 1957], ["overexpression", 1961], [".", 1975]]}
{"context": "To compare the outcome of outside-in biological and synthetic transobturator tape (TOT) operation, including subjective and objective success rates, urodynamics, and quality of life. One hundred patients suffering from clinical and/or urodynamic stress urinary incontinence (SUI) were randomized into biological material TOT (PELVILACE\u00ae TO) or synthetic material TOT (ALIGN\u00aeTO Urethral Support System) groups. Preoperative and at 1 year postoperative urogynecological symptom assessment, 1-h pad test, 4-day bladder diary, stress test, Q-tip test, and urodynamics were performed. For the evaluation of quality of life, the King's Health Questionnaire, Urogenital Distress Inventory-6, Incontinence Impact Questionnaire-7, and Prolapse Quality of Life were used. There was no significant difference between the two groups regarding objective and subjective cure rates and quality of life. At 1-year follow-up, the subjective cure rate was 68 % in the biological material TOT and 70 % in the synthetic material TOT group. No perioperative complications developed. Groin pain developed in 2 patients in the biological TOT group and 1 patient had dehiscence in the periurethral incision, which healed with local estrogen. Two patients had transient urinary retention in the synthetic TOT group, 1 patient developed groin pain, and 1 patient had mesh erosion observed at the 1-year follow-up. Transobturator tape with biological material in the management of SUI has a rate of success and patient satisfaction similar to those of synthetic material at 1-year follow-up. Studies with longer follow-up and larger cohorts are necessary to evaluate possible autolysis and degradation of biological slings and a possible reduction in efficacy over time.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "bc7735fd4a4446a7a5c1378082daf71f", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[40, 42]], "char_spans": [[246, 272]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["the", 11], ["outcome", 15], ["of", 23], ["outside", 26], ["-", 33], ["in", 34], ["biological", 37], ["and", 48], ["synthetic", 52], ["transobturator", 62], ["tape", 77], ["(", 82], ["TOT", 83], [")", 86], ["operation", 88], [",", 97], ["including", 99], ["subjective", 109], ["and", 120], ["objective", 124], ["success", 134], ["rates", 142], [",", 147], ["urodynamics", 149], [",", 160], ["and", 162], ["quality", 166], ["of", 174], ["life", 177], [".", 181], ["One", 183], ["hundred", 187], ["patients", 195], ["suffering", 204], ["from", 214], ["clinical", 219], ["and/or", 228], ["urodynamic", 235], ["stress", 246], ["urinary", 253], ["incontinence", 261], ["(", 274], ["SUI", 275], [")", 278], ["were", 280], ["randomized", 285], ["into", 296], ["biological", 301], ["material", 312], ["TOT", 321], ["(", 325], ["PELVILACE", 326], ["\u00ae", 335], ["TO", 337], [")", 339], ["or", 341], ["synthetic", 344], ["material", 354], ["TOT", 363], ["(", 367], ["ALIGN", 368], ["\u00ae", 373], ["TO", 374], ["Urethral", 377], ["Support", 386], ["System", 394], [")", 400], ["groups", 402], [".", 408], ["Preoperative", 410], ["and", 423], ["at", 427], ["1", 430], ["year", 432], ["postoperative", 437], ["urogynecological", 451], ["symptom", 468], ["assessment", 476], [",", 486], ["1-h", 488], ["pad", 492], ["test", 496], [",", 500], ["4-day", 502], ["bladder", 508], ["diary", 516], [",", 521], ["stress", 523], ["test", 530], [",", 534], ["Q", 536], ["-", 537], ["tip", 538], ["test", 542], [",", 546], ["and", 548], ["urodynamics", 552], ["were", 564], ["performed", 569], [".", 578], ["For", 580], ["the", 584], ["evaluation", 588], ["of", 599], ["quality", 602], ["of", 610], ["life", 613], [",", 617], ["the", 619], ["King", 623], ["'s", 627], ["Health", 630], ["Questionnaire", 637], [",", 650], ["Urogenital", 652], ["Distress", 663], ["Inventory-6", 672], [",", 683], ["Incontinence", 685], ["Impact", 698], ["Questionnaire-7", 705], [",", 720], ["and", 722], ["Prolapse", 726], ["Quality", 735], ["of", 743], ["Life", 746], ["were", 751], ["used", 756], [".", 760], ["There", 762], ["was", 768], ["no", 772], ["significant", 775], ["difference", 787], ["between", 798], ["the", 806], ["two", 810], ["groups", 814], ["regarding", 821], ["objective", 831], ["and", 841], ["subjective", 845], ["cure", 856], ["rates", 861], ["and", 867], ["quality", 871], ["of", 879], ["life", 882], [".", 886], ["At", 888], ["1-year", 891], ["follow", 898], ["-", 904], ["up", 905], [",", 907], ["the", 909], ["subjective", 913], ["cure", 924], ["rate", 929], ["was", 934], ["68", 938], ["%", 941], ["in", 943], ["the", 946], ["biological", 950], ["material", 961], ["TOT", 970], ["and", 974], ["70", 978], ["%", 981], ["in", 983], ["the", 986], ["synthetic", 990], ["material", 1000], ["TOT", 1009], ["group", 1013], [".", 1018], ["No", 1020], ["perioperative", 1023], ["complications", 1037], ["developed", 1051], [".", 1060], ["Groin", 1062], ["pain", 1068], ["developed", 1073], ["in", 1083], ["2", 1086], ["patients", 1088], ["in", 1097], ["the", 1100], ["biological", 1104], ["TOT", 1115], ["group", 1119], ["and", 1125], ["1", 1129], ["patient", 1131], ["had", 1139], ["dehiscence", 1143], ["in", 1154], ["the", 1157], ["periurethral", 1161], ["incision", 1174], [",", 1182], ["which", 1184], ["healed", 1190], ["with", 1197], ["local", 1202], ["estrogen", 1208], [".", 1216], ["Two", 1218], ["patients", 1222], ["had", 1231], ["transient", 1235], ["urinary", 1245], ["retention", 1253], ["in", 1263], ["the", 1266], ["synthetic", 1270], ["TOT", 1280], ["group", 1284], [",", 1289], ["1", 1291], ["patient", 1293], ["developed", 1301], ["groin", 1311], ["pain", 1317], [",", 1321], ["and", 1323], ["1", 1327], ["patient", 1329], ["had", 1337], ["mesh", 1341], ["erosion", 1346], ["observed", 1354], ["at", 1363], ["the", 1366], ["1-year", 1370], ["follow", 1377], ["-", 1383], ["up", 1384], [".", 1386], ["Transobturator", 1388], ["tape", 1403], ["with", 1408], ["biological", 1413], ["material", 1424], ["in", 1433], ["the", 1436], ["management", 1440], ["of", 1451], ["SUI", 1454], ["has", 1458], ["a", 1462], ["rate", 1464], ["of", 1469], ["success", 1472], ["and", 1480], ["patient", 1484], ["satisfaction", 1492], ["similar", 1505], ["to", 1513], ["those", 1516], ["of", 1522], ["synthetic", 1525], ["material", 1535], ["at", 1544], ["1-year", 1547], ["follow", 1554], ["-", 1560], ["up", 1561], [".", 1563], ["Studies", 1565], ["with", 1573], ["longer", 1578], ["follow", 1585], ["-", 1591], ["up", 1592], ["and", 1595], ["larger", 1599], ["cohorts", 1606], ["are", 1614], ["necessary", 1618], ["to", 1628], ["evaluate", 1631], ["possible", 1640], ["autolysis", 1649], ["and", 1659], ["degradation", 1663], ["of", 1675], ["biological", 1678], ["slings", 1689], ["and", 1696], ["a", 1700], ["possible", 1702], ["reduction", 1711], ["in", 1721], ["efficacy", 1724], ["over", 1733], ["time", 1738], [".", 1742]]}
{"context": "S100A4 is a small calcium-binding protein that is commonly overexpressed in a range of different tumor types, and it is widely accepted that S100A4 has an important role in the process of cancer metastasis. In vitro binding assays has shown that S100A4 interacts with the tumor suppressor protein p53, indicating that S100A4 may have additional roles in tumor development. In the present study, we show that endogenous S100A4 and p53 interact in complex samples, and that the interaction increases after inhibition of MDM2-dependent p53 degradation using Nutlin-3A. Further, using proximity ligation assay, we show that the interaction takes place in the cell nucleus. S100A4 knockdown experiments in two p53 wild-type cell lines, A549 and HeLa, resulted in stabilization of p53 protein, indicating that S100A4 is promoting p53 degradation. Finally, we demonstrate that S100A4 knockdown leads to p53-dependent cell cycle arrest and increased cisplatin-induced apoptosis. Thus, our data add a new layer to the oncogenic properties of S100A4 through its inhibition of p53-dependent processes.", "qas": [{"question": "Where in the cell does the proteins S100A4 and p53 interact ?", "answers": ["nucleus"], "qid": "b2838cb187da4004873628ecd5e3851c", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["does", 18], ["the", 23], ["proteins", 27], ["S100A4", 36], ["and", 43], ["p53", 47], ["interact", 51], ["?", 60]], "detected_answers": [{"text": "nucleus", "token_spans": [[112, 112]], "char_spans": [[660, 666]]}]}], "context_tokens": [["S100A4", 0], ["is", 7], ["a", 10], ["small", 12], ["calcium", 18], ["-", 25], ["binding", 26], ["protein", 34], ["that", 42], ["is", 47], ["commonly", 50], ["overexpressed", 59], ["in", 73], ["a", 76], ["range", 78], ["of", 84], ["different", 87], ["tumor", 97], ["types", 103], [",", 108], ["and", 110], ["it", 114], ["is", 117], ["widely", 120], ["accepted", 127], ["that", 136], ["S100A4", 141], ["has", 148], ["an", 152], ["important", 155], ["role", 165], ["in", 170], ["the", 173], ["process", 177], ["of", 185], ["cancer", 188], ["metastasis", 195], [".", 205], ["In", 207], ["vitro", 210], ["binding", 216], ["assays", 224], ["has", 231], ["shown", 235], ["that", 241], ["S100A4", 246], ["interacts", 253], ["with", 263], ["the", 268], ["tumor", 272], ["suppressor", 278], ["protein", 289], ["p53", 297], [",", 300], ["indicating", 302], ["that", 313], ["S100A4", 318], ["may", 325], ["have", 329], ["additional", 334], ["roles", 345], ["in", 351], ["tumor", 354], ["development", 360], [".", 371], ["In", 373], ["the", 376], ["present", 380], ["study", 388], [",", 393], ["we", 395], ["show", 398], ["that", 403], ["endogenous", 408], ["S100A4", 419], ["and", 426], ["p53", 430], ["interact", 434], ["in", 443], ["complex", 446], ["samples", 454], [",", 461], ["and", 463], ["that", 467], ["the", 472], ["interaction", 476], ["increases", 488], ["after", 498], ["inhibition", 504], ["of", 515], ["MDM2-dependent", 518], ["p53", 533], ["degradation", 537], ["using", 549], ["Nutlin-3A.", 555], ["Further", 566], [",", 573], ["using", 575], ["proximity", 581], ["ligation", 591], ["assay", 600], [",", 605], ["we", 607], ["show", 610], ["that", 615], ["the", 620], ["interaction", 624], ["takes", 636], ["place", 642], ["in", 648], ["the", 651], ["cell", 655], ["nucleus", 660], [".", 667], ["S100A4", 669], ["knockdown", 676], ["experiments", 686], ["in", 698], ["two", 701], ["p53", 705], ["wild", 709], ["-", 713], ["type", 714], ["cell", 719], ["lines", 724], [",", 729], ["A549", 731], ["and", 736], ["HeLa", 740], [",", 744], ["resulted", 746], ["in", 755], ["stabilization", 758], ["of", 772], ["p53", 775], ["protein", 779], [",", 786], ["indicating", 788], ["that", 799], ["S100A4", 804], ["is", 811], ["promoting", 814], ["p53", 824], ["degradation", 828], [".", 839], ["Finally", 841], [",", 848], ["we", 850], ["demonstrate", 853], ["that", 865], ["S100A4", 870], ["knockdown", 877], ["leads", 887], ["to", 893], ["p53-dependent", 896], ["cell", 910], ["cycle", 915], ["arrest", 921], ["and", 928], ["increased", 932], ["cisplatin", 942], ["-", 951], ["induced", 952], ["apoptosis", 960], [".", 969], ["Thus", 971], [",", 975], ["our", 977], ["data", 981], ["add", 986], ["a", 990], ["new", 992], ["layer", 996], ["to", 1002], ["the", 1005], ["oncogenic", 1009], ["properties", 1019], ["of", 1030], ["S100A4", 1033], ["through", 1040], ["its", 1048], ["inhibition", 1052], ["of", 1063], ["p53-dependent", 1066], ["processes", 1080], [".", 1089]]}
{"context": "The ubiquitin-proteasome pathway plays a central role in the degradation of proteins involved in several pathways including the cell cycle, cellular proliferation and apoptosis. Bortezomib is the first proteasome inhibitor to enter clinical use, and received approval by the Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma, therefore validating inhibition of the proteasome as an anticancer target. The approval of Bortezomib was based on a large, international, multicenter phase III trial showing its efficacy and safety compared with conventional therapy. Preclinical data also demonstrates the synergistic effect of bortezomib with other chemotherapeutic agents and its ability to overcome drug resistance. Since then several other proteasome inhibitors have been developed. The anti-tumor activities of bortezomib have been attributed to its effect on pro-apoptotic pathways including the inhibition of NF-kappaB and induction of endoplasmic reticulum stress. However, the molecular mechanisms are not fully understood. In this review, we will summarize the molecular mechanism of apoptosis by bortezomib.", "qas": [{"question": "Which is the target of bortezomib used in cancer therapy?", "answers": ["The ubiquitin/proteasome pathway"], "qid": "19e748f08da643a884cd0cba3332ced8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["bortezomib", 23], ["used", 34], ["in", 39], ["cancer", 42], ["therapy", 49], ["?", 56]], "detected_answers": [{"text": "The ubiquitin/proteasome pathway", "token_spans": [[1, 4]], "char_spans": [[4, 31]]}]}], "context_tokens": [["The", 0], ["ubiquitin", 4], ["-", 13], ["proteasome", 14], ["pathway", 25], ["plays", 33], ["a", 39], ["central", 41], ["role", 49], ["in", 54], ["the", 57], ["degradation", 61], ["of", 73], ["proteins", 76], ["involved", 85], ["in", 94], ["several", 97], ["pathways", 105], ["including", 114], ["the", 124], ["cell", 128], ["cycle", 133], [",", 138], ["cellular", 140], ["proliferation", 149], ["and", 163], ["apoptosis", 167], [".", 176], ["Bortezomib", 178], ["is", 189], ["the", 192], ["first", 196], ["proteasome", 202], ["inhibitor", 213], ["to", 223], ["enter", 226], ["clinical", 232], ["use", 241], [",", 244], ["and", 246], ["received", 250], ["approval", 259], ["by", 268], ["the", 271], ["Food", 275], ["and", 280], ["Drug", 284], ["Administration", 289], ["(", 304], ["FDA", 305], [")", 308], ["for", 310], ["the", 314], ["treatment", 318], ["of", 328], ["patients", 331], ["with", 340], ["multiple", 345], ["myeloma", 354], [",", 361], ["therefore", 363], ["validating", 373], ["inhibition", 384], ["of", 395], ["the", 398], ["proteasome", 402], ["as", 413], ["an", 416], ["anticancer", 419], ["target", 430], [".", 436], ["The", 438], ["approval", 442], ["of", 451], ["Bortezomib", 454], ["was", 465], ["based", 469], ["on", 475], ["a", 478], ["large", 480], [",", 485], ["international", 487], [",", 500], ["multicenter", 502], ["phase", 514], ["III", 520], ["trial", 524], ["showing", 530], ["its", 538], ["efficacy", 542], ["and", 551], ["safety", 555], ["compared", 562], ["with", 571], ["conventional", 576], ["therapy", 589], [".", 596], ["Preclinical", 598], ["data", 610], ["also", 615], ["demonstrates", 620], ["the", 633], ["synergistic", 637], ["effect", 649], ["of", 656], ["bortezomib", 659], ["with", 670], ["other", 675], ["chemotherapeutic", 681], ["agents", 698], ["and", 705], ["its", 709], ["ability", 713], ["to", 721], ["overcome", 724], ["drug", 733], ["resistance", 738], [".", 748], ["Since", 750], ["then", 756], ["several", 761], ["other", 769], ["proteasome", 775], ["inhibitors", 786], ["have", 797], ["been", 802], ["developed", 807], [".", 816], ["The", 818], ["anti", 822], ["-", 826], ["tumor", 827], ["activities", 833], ["of", 844], ["bortezomib", 847], ["have", 858], ["been", 863], ["attributed", 868], ["to", 879], ["its", 882], ["effect", 886], ["on", 893], ["pro", 896], ["-", 899], ["apoptotic", 900], ["pathways", 910], ["including", 919], ["the", 929], ["inhibition", 933], ["of", 944], ["NF", 947], ["-", 949], ["kappaB", 950], ["and", 957], ["induction", 961], ["of", 971], ["endoplasmic", 974], ["reticulum", 986], ["stress", 996], [".", 1002], ["However", 1004], [",", 1011], ["the", 1013], ["molecular", 1017], ["mechanisms", 1027], ["are", 1038], ["not", 1042], ["fully", 1046], ["understood", 1052], [".", 1062], ["In", 1064], ["this", 1067], ["review", 1072], [",", 1078], ["we", 1080], ["will", 1083], ["summarize", 1088], ["the", 1098], ["molecular", 1102], ["mechanism", 1112], ["of", 1122], ["apoptosis", 1125], ["by", 1135], ["bortezomib", 1138], [".", 1148]]}
{"context": "Interstitial deletions of chromosome band Xq26.3 are rare. We report on a 2-year-old boy in whom array comparative genomic hybridization analysis revealed an interstitial 314 kb deletion in Xq26.3 affecting SLC9A6 and FHL1. Mutations in SLC9A6 are associated with Christianson syndrome (OMIM 300243), a syndromic form of X-linked mental retardation (XLMR) characterized by microcephaly, severe global developmental delay, ataxia and seizures. FHL1 mutations cause Emery-Dreifuss muscular dystrophy (OMIM 310300), X-linked myopathy with postural muscle atrophy (XMPMA, OMIM 300696), scapuloperoneal myopathy (OMIM 300695), or reducing body myopathy (OMIM 300717, 300718). The clinical problems of the patient reported here comprised severe intellectual disability, absent speech, ataxia, epilepsy, and gastroesophageal reflux, and could mostly be attributed to SLC9A6 insufficiency. In contrast to the majority of reported Christianson syndrome patients who were microcephalic, this patient was normocephalic, but his head circumference had decelerated from the 50th centile at birth to the 25th centile at the age of 2 \u00b2/\u00b9\u00b2 years. Muscle problems due to the FHL1 deletion are not to be expected before late childhood, which is the earliest age of onset for FHL1 associated Emery-Dreifuss muscular dystrophy. This patient broadens the spectrum of SLC9A6 mutations and contributes to the clinical delineation of Christianson syndrome. This is also the first patient with a deletion affecting both SLC9A6 and the complete FHL1 gene.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "66ed19703ab9429588260046aacc2ac1", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[235, 235], [151, 151], [39, 39], [258, 258], [33, 33]], "char_spans": [[1346, 1351], [860, 865], [237, 242], [1495, 1500], [207, 212]]}]}], "context_tokens": [["Interstitial", 0], ["deletions", 13], ["of", 23], ["chromosome", 26], ["band", 37], ["Xq26.3", 42], ["are", 49], ["rare", 53], [".", 57], ["We", 59], ["report", 62], ["on", 69], ["a", 72], ["2-year", 74], ["-", 80], ["old", 81], ["boy", 85], ["in", 89], ["whom", 92], ["array", 97], ["comparative", 103], ["genomic", 115], ["hybridization", 123], ["analysis", 137], ["revealed", 146], ["an", 155], ["interstitial", 158], ["314", 171], ["kb", 175], ["deletion", 178], ["in", 187], ["Xq26.3", 190], ["affecting", 197], ["SLC9A6", 207], ["and", 214], ["FHL1", 218], [".", 222], ["Mutations", 224], ["in", 234], ["SLC9A6", 237], ["are", 244], ["associated", 248], ["with", 259], ["Christianson", 264], ["syndrome", 277], ["(", 286], ["OMIM", 287], ["300243", 292], [")", 298], [",", 299], ["a", 301], ["syndromic", 303], ["form", 313], ["of", 318], ["X", 321], ["-", 322], ["linked", 323], ["mental", 330], ["retardation", 337], ["(", 349], ["XLMR", 350], [")", 354], ["characterized", 356], ["by", 370], ["microcephaly", 373], [",", 385], ["severe", 387], ["global", 394], ["developmental", 401], ["delay", 415], [",", 420], ["ataxia", 422], ["and", 429], ["seizures", 433], [".", 441], ["FHL1", 443], ["mutations", 448], ["cause", 458], ["Emery", 464], ["-", 469], ["Dreifuss", 470], ["muscular", 479], ["dystrophy", 488], ["(", 498], ["OMIM", 499], ["310300", 504], [")", 510], [",", 511], ["X", 513], ["-", 514], ["linked", 515], ["myopathy", 522], ["with", 531], ["postural", 536], ["muscle", 545], ["atrophy", 552], ["(", 560], ["XMPMA", 561], [",", 566], ["OMIM", 568], ["300696", 573], [")", 579], [",", 580], ["scapuloperoneal", 582], ["myopathy", 598], ["(", 607], ["OMIM", 608], ["300695", 613], [")", 619], [",", 620], ["or", 622], ["reducing", 625], ["body", 634], ["myopathy", 639], ["(", 648], ["OMIM", 649], ["300717", 654], [",", 660], ["300718", 662], [")", 668], [".", 669], ["The", 671], ["clinical", 675], ["problems", 684], ["of", 693], ["the", 696], ["patient", 700], ["reported", 708], ["here", 717], ["comprised", 722], ["severe", 732], ["intellectual", 739], ["disability", 752], [",", 762], ["absent", 764], ["speech", 771], [",", 777], ["ataxia", 779], [",", 785], ["epilepsy", 787], [",", 795], ["and", 797], ["gastroesophageal", 801], ["reflux", 818], [",", 824], ["and", 826], ["could", 830], ["mostly", 836], ["be", 843], ["attributed", 846], ["to", 857], ["SLC9A6", 860], ["insufficiency", 867], [".", 880], ["In", 882], ["contrast", 885], ["to", 894], ["the", 897], ["majority", 901], ["of", 910], ["reported", 913], ["Christianson", 922], ["syndrome", 935], ["patients", 944], ["who", 953], ["were", 957], ["microcephalic", 962], [",", 975], ["this", 977], ["patient", 982], ["was", 990], ["normocephalic", 994], [",", 1007], ["but", 1009], ["his", 1013], ["head", 1017], ["circumference", 1022], ["had", 1036], ["decelerated", 1040], ["from", 1052], ["the", 1057], ["50th", 1061], ["centile", 1066], ["at", 1074], ["birth", 1077], ["to", 1083], ["the", 1086], ["25th", 1090], ["centile", 1095], ["at", 1103], ["the", 1106], ["age", 1110], ["of", 1114], ["2", 1117], ["\u00b2/\u00b9\u00b2", 1119], ["years", 1124], [".", 1129], ["Muscle", 1131], ["problems", 1138], ["due", 1147], ["to", 1151], ["the", 1154], ["FHL1", 1158], ["deletion", 1163], ["are", 1172], ["not", 1176], ["to", 1180], ["be", 1183], ["expected", 1186], ["before", 1195], ["late", 1202], ["childhood", 1207], [",", 1216], ["which", 1218], ["is", 1224], ["the", 1227], ["earliest", 1231], ["age", 1240], ["of", 1244], ["onset", 1247], ["for", 1253], ["FHL1", 1257], ["associated", 1262], ["Emery", 1273], ["-", 1278], ["Dreifuss", 1279], ["muscular", 1288], ["dystrophy", 1297], [".", 1306], ["This", 1308], ["patient", 1313], ["broadens", 1321], ["the", 1330], ["spectrum", 1334], ["of", 1343], ["SLC9A6", 1346], ["mutations", 1353], ["and", 1363], ["contributes", 1367], ["to", 1379], ["the", 1382], ["clinical", 1386], ["delineation", 1395], ["of", 1407], ["Christianson", 1410], ["syndrome", 1423], [".", 1431], ["This", 1433], ["is", 1438], ["also", 1441], ["the", 1446], ["first", 1450], ["patient", 1456], ["with", 1464], ["a", 1469], ["deletion", 1471], ["affecting", 1480], ["both", 1490], ["SLC9A6", 1495], ["and", 1502], ["the", 1506], ["complete", 1510], ["FHL1", 1519], ["gene", 1524], [".", 1528]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) is the most common sleep-related movement disorder in pregnancy. We designed a prospective longitudinal study to investigate the correlates of WED/RLS during and after pregnancy. A total of 138 pregnant women with WED/RLS and a control group of 251 age-matched pregnant women were enrolled prospectively. A questionnaire was administered during a face-to-face interview at first evaluation during pregnancy and three months after delivery. Among all women in the first trimester, 15.6% were diagnosed with WED/RLS, whereas 32.8% of those in the second trimester and 38.8% of those in the third trimester were diagnosed with WED/RLS (p\u2009=\u20090.032). In regression analysis, later gestational age [p\u2009<\u20090.001; odds ratio (OR) 1.054] and previous history of WED/RLS (p\u2009=\u20090.001; OR 2.795) were positively correlated with the presence of WED/RLS, while ferritin levels (p\u2009=\u20090.001; OR 0.956) were negatively correlated with the presence of WED/RLS. Ferritin levels were also negatively correlated with the International RLS Study Group severity index (p\u2009=\u20090.041). Forty-eight patients (34.8%) experienced WED/RLS symptomatology after delivery. The ferritin levels were lower, and the mean number of pregnancies was higher, in women with residual WED/RLS (p\u2009=\u20090.008). Our survey showed that WED/RLS was more common in the second and third trimesters. Emergence of WED/RLS during the second trimester was strongly associated with residual WED/RLS. Lower ferritin levels were associated with both WED/RLS in pregnancy and residual WED/RLS after delivery. A higher number of pregnancies were also associated with a greater likelihood of having residual WED/RLS after delivery.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c13bddb9e37b47c69428caa895cea7ae", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["is", 54], ["the", 57], ["most", 61], ["common", 66], ["sleep", 73], ["-", 78], ["related", 79], ["movement", 87], ["disorder", 96], ["in", 105], ["pregnancy", 108], [".", 117], ["We", 119], ["designed", 122], ["a", 131], ["prospective", 133], ["longitudinal", 145], ["study", 158], ["to", 164], ["investigate", 167], ["the", 179], ["correlates", 183], ["of", 194], ["WED", 197], ["/", 200], ["RLS", 201], ["during", 205], ["and", 212], ["after", 216], ["pregnancy", 222], [".", 231], ["A", 233], ["total", 235], ["of", 241], ["138", 244], ["pregnant", 248], ["women", 257], ["with", 263], ["WED", 268], ["/", 271], ["RLS", 272], ["and", 276], ["a", 280], ["control", 282], ["group", 290], ["of", 296], ["251", 299], ["age", 303], ["-", 306], ["matched", 307], ["pregnant", 315], ["women", 324], ["were", 330], ["enrolled", 335], ["prospectively", 344], [".", 357], ["A", 359], ["questionnaire", 361], ["was", 375], ["administered", 379], ["during", 392], ["a", 399], ["face", 401], ["-", 405], ["to", 406], ["-", 408], ["face", 409], ["interview", 414], ["at", 424], ["first", 427], ["evaluation", 433], ["during", 444], ["pregnancy", 451], ["and", 461], ["three", 465], ["months", 471], ["after", 478], ["delivery", 484], [".", 492], ["Among", 494], ["all", 500], ["women", 504], ["in", 510], ["the", 513], ["first", 517], ["trimester", 523], [",", 532], ["15.6", 534], ["%", 538], ["were", 540], ["diagnosed", 545], ["with", 555], ["WED", 560], ["/", 563], ["RLS", 564], [",", 567], ["whereas", 569], ["32.8", 577], ["%", 581], ["of", 583], ["those", 586], ["in", 592], ["the", 595], ["second", 599], ["trimester", 606], ["and", 616], ["38.8", 620], ["%", 624], ["of", 626], ["those", 629], ["in", 635], ["the", 638], ["third", 642], ["trimester", 648], ["were", 658], ["diagnosed", 663], ["with", 673], ["WED", 678], ["/", 681], ["RLS", 682], ["(", 686], ["p", 687], ["=", 689], ["0.032", 691], [")", 696], [".", 697], ["In", 699], ["regression", 702], ["analysis", 713], [",", 721], ["later", 723], ["gestational", 729], ["age", 741], ["[", 745], ["p", 746], ["<", 748], ["0.001", 750], [";", 755], ["odds", 757], ["ratio", 762], ["(", 768], ["OR", 769], [")", 771], ["1.054", 773], ["]", 778], ["and", 780], ["previous", 784], ["history", 793], ["of", 801], ["WED", 804], ["/", 807], ["RLS", 808], ["(", 812], ["p", 813], ["=", 815], ["0.001", 817], [";", 822], ["OR", 824], ["2.795", 827], [")", 832], ["were", 834], ["positively", 839], ["correlated", 850], ["with", 861], ["the", 866], ["presence", 870], ["of", 879], ["WED", 882], ["/", 885], ["RLS", 886], [",", 889], ["while", 891], ["ferritin", 897], ["levels", 906], ["(", 913], ["p", 914], ["=", 916], ["0.001", 918], [";", 923], ["OR", 925], ["0.956", 928], [")", 933], ["were", 935], ["negatively", 940], ["correlated", 951], ["with", 962], ["the", 967], ["presence", 971], ["of", 980], ["WED", 983], ["/", 986], ["RLS", 987], [".", 990], ["Ferritin", 992], ["levels", 1001], ["were", 1008], ["also", 1013], ["negatively", 1018], ["correlated", 1029], ["with", 1040], ["the", 1045], ["International", 1049], ["RLS", 1063], ["Study", 1067], ["Group", 1073], ["severity", 1079], ["index", 1088], ["(", 1094], ["p", 1095], ["=", 1097], ["0.041", 1099], [")", 1104], [".", 1105], ["Forty", 1107], ["-", 1112], ["eight", 1113], ["patients", 1119], ["(", 1128], ["34.8", 1129], ["%", 1133], [")", 1134], ["experienced", 1136], ["WED", 1148], ["/", 1151], ["RLS", 1152], ["symptomatology", 1156], ["after", 1171], ["delivery", 1177], [".", 1185], ["The", 1187], ["ferritin", 1191], ["levels", 1200], ["were", 1207], ["lower", 1212], [",", 1217], ["and", 1219], ["the", 1223], ["mean", 1227], ["number", 1232], ["of", 1239], ["pregnancies", 1242], ["was", 1254], ["higher", 1258], [",", 1264], ["in", 1266], ["women", 1269], ["with", 1275], ["residual", 1280], ["WED", 1289], ["/", 1292], ["RLS", 1293], ["(", 1297], ["p", 1298], ["=", 1300], ["0.008", 1302], [")", 1307], [".", 1308], ["Our", 1310], ["survey", 1314], ["showed", 1321], ["that", 1328], ["WED", 1333], ["/", 1336], ["RLS", 1337], ["was", 1341], ["more", 1345], ["common", 1350], ["in", 1357], ["the", 1360], ["second", 1364], ["and", 1371], ["third", 1375], ["trimesters", 1381], [".", 1391], ["Emergence", 1393], ["of", 1403], ["WED", 1406], ["/", 1409], ["RLS", 1410], ["during", 1414], ["the", 1421], ["second", 1425], ["trimester", 1432], ["was", 1442], ["strongly", 1446], ["associated", 1455], ["with", 1466], ["residual", 1471], ["WED", 1480], ["/", 1483], ["RLS", 1484], [".", 1487], ["Lower", 1489], ["ferritin", 1495], ["levels", 1504], ["were", 1511], ["associated", 1516], ["with", 1527], ["both", 1532], ["WED", 1537], ["/", 1540], ["RLS", 1541], ["in", 1545], ["pregnancy", 1548], ["and", 1558], ["residual", 1562], ["WED", 1571], ["/", 1574], ["RLS", 1575], ["after", 1579], ["delivery", 1585], [".", 1593], ["A", 1595], ["higher", 1597], ["number", 1604], ["of", 1611], ["pregnancies", 1614], ["were", 1626], ["also", 1631], ["associated", 1636], ["with", 1647], ["a", 1652], ["greater", 1654], ["likelihood", 1662], ["of", 1673], ["having", 1676], ["residual", 1683], ["WED", 1692], ["/", 1695], ["RLS", 1696], ["after", 1700], ["delivery", 1706], [".", 1714]]}
{"context": "Mitogen-activated protein kinase (MAPK) cascades are involved in the regulation of cellular proliferation, differentiation, survival, apoptosis, as well as in inflammatory responses. Signal intensity and duration have been recognized as crucial parameters determining MAPK signaling output. Phosphatases play a particularly important role in this respect, by tightly controlling MAPK phosphorylation and activation. M3/6 (DUSP8) is a dual-specificity phosphatase implicated in the dephosphorylation and inactivation of JNK and, to a lesser extent, p38 MAPKs and is found in a complex with these kinases, along with other pathway components, held together by scaffold proteins. The JNK family consists of three genes, giving rise to at least ten different splice variants. Some functional differences between these gene products have been demonstrated, but the underlying molecular mechanisms and the roles of individual splice variants are still incompletely understood. We have investigated the interaction of M3/6 with JNK isoforms, as well as scaffold proteins of the JNK interacting protein (JIP) family, in order to elucidate the contribution of M3/6 to the regulation of distinct JNK signaling modules. M3/6 exhibited stronger binding towards JNK1\u03b2 and JNK2\u03b1 isoforms and this was reflected in higher enzymatic activity towards JNK2\u03b12 when compared to JNK1\u03b11 in vitro. After activation of the pathway by exposure of cells to arsenite, the interaction of M3/6 with JNK1\u03b1 and JNK3 was enhanced, whereas that with JNK1\u03b2 or JNK2\u03b1 decreased. The modulation of binding affinities was found to be independent of JNK-mediated M3/6 phosphorylation. Furthermore, arsenite treatment resulted in an inducible recruitment of M3/6 to JNK-interacting protein 3 (JIP3) scaffold complexes, while its interaction with JIP1 or JIP2 was constitutive. The presented data suggest an isoform-specific role for the M3/6 phosphatase and the dynamic targeting of M3/6 towards distinct JNK-containing signaling complexes.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "0e17fa4dc2be4a299e36c5cf49b2fbee", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[288, 288], [81, 81], [198, 198], [330, 330], [167, 167], [270, 270], [114, 114], [177, 177]], "char_spans": [[1726, 1728], [519, 521], [1186, 1188], [1965, 1967], [1021, 1023], [1611, 1613], [681, 683], [1071, 1073]]}]}], "context_tokens": [["Mitogen", 0], ["-", 7], ["activated", 8], ["protein", 18], ["kinase", 26], ["(", 33], ["MAPK", 34], [")", 38], ["cascades", 40], ["are", 49], ["involved", 53], ["in", 62], ["the", 65], ["regulation", 69], ["of", 80], ["cellular", 83], ["proliferation", 92], [",", 105], ["differentiation", 107], [",", 122], ["survival", 124], [",", 132], ["apoptosis", 134], [",", 143], ["as", 145], ["well", 148], ["as", 153], ["in", 156], ["inflammatory", 159], ["responses", 172], [".", 181], ["Signal", 183], ["intensity", 190], ["and", 200], ["duration", 204], ["have", 213], ["been", 218], ["recognized", 223], ["as", 234], ["crucial", 237], ["parameters", 245], ["determining", 256], ["MAPK", 268], ["signaling", 273], ["output", 283], [".", 289], ["Phosphatases", 291], ["play", 304], ["a", 309], ["particularly", 311], ["important", 324], ["role", 334], ["in", 339], ["this", 342], ["respect", 347], [",", 354], ["by", 356], ["tightly", 359], ["controlling", 367], ["MAPK", 379], ["phosphorylation", 384], ["and", 400], ["activation", 404], [".", 414], ["M3/6", 416], ["(", 421], ["DUSP8", 422], [")", 427], ["is", 429], ["a", 432], ["dual", 434], ["-", 438], ["specificity", 439], ["phosphatase", 451], ["implicated", 463], ["in", 474], ["the", 477], ["dephosphorylation", 481], ["and", 499], ["inactivation", 503], ["of", 516], ["JNK", 519], ["and", 523], [",", 526], ["to", 528], ["a", 531], ["lesser", 533], ["extent", 540], [",", 546], ["p38", 548], ["MAPKs", 552], ["and", 558], ["is", 562], ["found", 565], ["in", 571], ["a", 574], ["complex", 576], ["with", 584], ["these", 589], ["kinases", 595], [",", 602], ["along", 604], ["with", 610], ["other", 615], ["pathway", 621], ["components", 629], [",", 639], ["held", 641], ["together", 646], ["by", 655], ["scaffold", 658], ["proteins", 667], [".", 675], ["The", 677], ["JNK", 681], ["family", 685], ["consists", 692], ["of", 701], ["three", 704], ["genes", 710], [",", 715], ["giving", 717], ["rise", 724], ["to", 729], ["at", 732], ["least", 735], ["ten", 741], ["different", 745], ["splice", 755], ["variants", 762], [".", 770], ["Some", 772], ["functional", 777], ["differences", 788], ["between", 800], ["these", 808], ["gene", 814], ["products", 819], ["have", 828], ["been", 833], ["demonstrated", 838], [",", 850], ["but", 852], ["the", 856], ["underlying", 860], ["molecular", 871], ["mechanisms", 881], ["and", 892], ["the", 896], ["roles", 900], ["of", 906], ["individual", 909], ["splice", 920], ["variants", 927], ["are", 936], ["still", 940], ["incompletely", 946], ["understood", 959], [".", 969], ["We", 971], ["have", 974], ["investigated", 979], ["the", 992], ["interaction", 996], ["of", 1008], ["M3/6", 1011], ["with", 1016], ["JNK", 1021], ["isoforms", 1025], [",", 1033], ["as", 1035], ["well", 1038], ["as", 1043], ["scaffold", 1046], ["proteins", 1055], ["of", 1064], ["the", 1067], ["JNK", 1071], ["interacting", 1075], ["protein", 1087], ["(", 1095], ["JIP", 1096], [")", 1099], ["family", 1101], [",", 1107], ["in", 1109], ["order", 1112], ["to", 1118], ["elucidate", 1121], ["the", 1131], ["contribution", 1135], ["of", 1148], ["M3/6", 1151], ["to", 1156], ["the", 1159], ["regulation", 1163], ["of", 1174], ["distinct", 1177], ["JNK", 1186], ["signaling", 1190], ["modules", 1200], [".", 1207], ["M3/6", 1209], ["exhibited", 1214], ["stronger", 1224], ["binding", 1233], ["towards", 1241], ["JNK1\u03b2", 1249], ["and", 1255], ["JNK2\u03b1", 1259], ["isoforms", 1265], ["and", 1274], ["this", 1278], ["was", 1283], ["reflected", 1287], ["in", 1297], ["higher", 1300], ["enzymatic", 1307], ["activity", 1317], ["towards", 1326], ["JNK2\u03b12", 1334], ["when", 1341], ["compared", 1346], ["to", 1355], ["JNK1\u03b11", 1358], ["in", 1365], ["vitro", 1368], [".", 1373], ["After", 1375], ["activation", 1381], ["of", 1392], ["the", 1395], ["pathway", 1399], ["by", 1407], ["exposure", 1410], ["of", 1419], ["cells", 1422], ["to", 1428], ["arsenite", 1431], [",", 1439], ["the", 1441], ["interaction", 1445], ["of", 1457], ["M3/6", 1460], ["with", 1465], ["JNK1\u03b1", 1470], ["and", 1476], ["JNK3", 1480], ["was", 1485], ["enhanced", 1489], [",", 1497], ["whereas", 1499], ["that", 1507], ["with", 1512], ["JNK1\u03b2", 1517], ["or", 1523], ["JNK2\u03b1", 1526], ["decreased", 1532], [".", 1541], ["The", 1543], ["modulation", 1547], ["of", 1558], ["binding", 1561], ["affinities", 1569], ["was", 1580], ["found", 1584], ["to", 1590], ["be", 1593], ["independent", 1596], ["of", 1608], ["JNK", 1611], ["-", 1614], ["mediated", 1615], ["M3/6", 1624], ["phosphorylation", 1629], [".", 1644], ["Furthermore", 1646], [",", 1657], ["arsenite", 1659], ["treatment", 1668], ["resulted", 1678], ["in", 1687], ["an", 1690], ["inducible", 1693], ["recruitment", 1703], ["of", 1715], ["M3/6", 1718], ["to", 1723], ["JNK", 1726], ["-", 1729], ["interacting", 1730], ["protein", 1742], ["3", 1750], ["(", 1752], ["JIP3", 1753], [")", 1757], ["scaffold", 1759], ["complexes", 1768], [",", 1777], ["while", 1779], ["its", 1785], ["interaction", 1789], ["with", 1801], ["JIP1", 1806], ["or", 1811], ["JIP2", 1814], ["was", 1819], ["constitutive", 1823], [".", 1835], ["The", 1837], ["presented", 1841], ["data", 1851], ["suggest", 1856], ["an", 1864], ["isoform", 1867], ["-", 1874], ["specific", 1875], ["role", 1884], ["for", 1889], ["the", 1893], ["M3/6", 1897], ["phosphatase", 1902], ["and", 1914], ["the", 1918], ["dynamic", 1922], ["targeting", 1930], ["of", 1940], ["M3/6", 1943], ["towards", 1948], ["distinct", 1956], ["JNK", 1965], ["-", 1968], ["containing", 1969], ["signaling", 1980], ["complexes", 1990], [".", 1999]]}
{"context": "We describe the clinical characteristics and epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in children with cystic fibrosis (CF) from the U.S. CF center with the highest MRSA prevalence. Medical records of children with CF were retrospectively reviewed from 1997-2009. MRSA clinical isolates from 2007-2009 were analyzed by polymerase chain reaction and pulsed field gel electrophoresis. The prevalence of MRSA was 1% in 1997 and 49% in 2009. Fifty-five children (26%) had persistent MRSA infection. Sixty-eight percent of MRSA isolates were hospital-associated (HA) MRSA, of which 52% were pulsed-field type USA 100. Ninety-three percent of HA MRSA isolates were clindamycin resistant. Twelve children acquired MRSA before 1 year of age, 83% of whom were hospitalized prior to acquisition of MRSA. Ten of 11 sibling pairs carried indistinguishable MRSA strains. Children with persistent MRSA were hospitalized more often (P\u2009=\u2009.01), required inhaled medications more frequently (P\u2009=\u2009.01), and had higher rates of Pseudomonas aeruginosa coinfection (P\u2009<\u2009.001). MRSA prevalence in children with CF is increasing, and most children are infected with HA MRSA. Exposure to health care facilities and gastrointestinal surgeries may facilitate early acquisition of MRSA. Siblings carry indistinguishable MRSA strains, indicating household transmission of MRSA. Children with persistent MRSA had worse pulmonary morbidity. Coinfection with MRSA and P aeruginosa is likely associated with further increased pulmonary morbidity.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4e1c49bbf28c4f2e9198848bf13a61dc", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[32, 32], [139, 139], [171, 171], [243, 243], [250, 250], [71, 71], [263, 263], [14, 14], [130, 130], [255, 255], [207, 207], [49, 49], [110, 110], [93, 93], [101, 101], [165, 165], [156, 156], [238, 238], [223, 223]], "char_spans": [[191, 194], [733, 736], [909, 912], [1318, 1321], [1369, 1372], [427, 430], [1453, 1456], [106, 109], [666, 669], [1400, 1403], [1081, 1084], [290, 293], [588, 591], [505, 508], [544, 547], [870, 873], [814, 817], [1279, 1282], [1171, 1174]]}]}], "context_tokens": [["We", 0], ["describe", 3], ["the", 12], ["clinical", 16], ["characteristics", 25], ["and", 41], ["epidemiology", 45], ["of", 58], ["methicillin", 61], ["-", 72], ["resistant", 73], ["Staphylococcus", 83], ["aureus", 98], ["(", 105], ["MRSA", 106], [")", 110], ["in", 112], ["children", 115], ["with", 124], ["cystic", 129], ["fibrosis", 136], ["(", 145], ["CF", 146], [")", 148], ["from", 150], ["the", 155], ["U.S.", 159], ["CF", 164], ["center", 167], ["with", 174], ["the", 179], ["highest", 183], ["MRSA", 191], ["prevalence", 196], [".", 206], ["Medical", 208], ["records", 216], ["of", 224], ["children", 227], ["with", 236], ["CF", 241], ["were", 244], ["retrospectively", 249], ["reviewed", 265], ["from", 274], ["1997", 279], ["-", 283], ["2009", 284], [".", 288], ["MRSA", 290], ["clinical", 295], ["isolates", 304], ["from", 313], ["2007", 318], ["-", 322], ["2009", 323], ["were", 328], ["analyzed", 333], ["by", 342], ["polymerase", 345], ["chain", 356], ["reaction", 362], ["and", 371], ["pulsed", 375], ["field", 382], ["gel", 388], ["electrophoresis", 392], [".", 407], ["The", 409], ["prevalence", 413], ["of", 424], ["MRSA", 427], ["was", 432], ["1", 436], ["%", 437], ["in", 439], ["1997", 442], ["and", 447], ["49", 451], ["%", 453], ["in", 455], ["2009", 458], [".", 462], ["Fifty", 464], ["-", 469], ["five", 470], ["children", 475], ["(", 484], ["26", 485], ["%", 487], [")", 488], ["had", 490], ["persistent", 494], ["MRSA", 505], ["infection", 510], [".", 519], ["Sixty", 521], ["-", 526], ["eight", 527], ["percent", 533], ["of", 541], ["MRSA", 544], ["isolates", 549], ["were", 558], ["hospital", 563], ["-", 571], ["associated", 572], ["(", 583], ["HA", 584], [")", 586], ["MRSA", 588], [",", 592], ["of", 594], ["which", 597], ["52", 603], ["%", 605], ["were", 607], ["pulsed", 612], ["-", 618], ["field", 619], ["type", 625], ["USA", 630], ["100", 634], [".", 637], ["Ninety", 639], ["-", 645], ["three", 646], ["percent", 652], ["of", 660], ["HA", 663], ["MRSA", 666], ["isolates", 671], ["were", 680], ["clindamycin", 685], ["resistant", 697], [".", 706], ["Twelve", 708], ["children", 715], ["acquired", 724], ["MRSA", 733], ["before", 738], ["1", 745], ["year", 747], ["of", 752], ["age", 755], [",", 758], ["83", 760], ["%", 762], ["of", 764], ["whom", 767], ["were", 772], ["hospitalized", 777], ["prior", 790], ["to", 796], ["acquisition", 799], ["of", 811], ["MRSA", 814], [".", 818], ["Ten", 820], ["of", 824], ["11", 827], ["sibling", 830], ["pairs", 838], ["carried", 844], ["indistinguishable", 852], ["MRSA", 870], ["strains", 875], [".", 882], ["Children", 884], ["with", 893], ["persistent", 898], ["MRSA", 909], ["were", 914], ["hospitalized", 919], ["more", 932], ["often", 937], ["(", 943], ["P", 944], ["=", 946], [".01", 948], [")", 951], [",", 952], ["required", 954], ["inhaled", 963], ["medications", 971], ["more", 983], ["frequently", 988], ["(", 999], ["P", 1000], ["=", 1002], [".01", 1004], [")", 1007], [",", 1008], ["and", 1010], ["had", 1014], ["higher", 1018], ["rates", 1025], ["of", 1031], ["Pseudomonas", 1034], ["aeruginosa", 1046], ["coinfection", 1057], ["(", 1069], ["P", 1070], ["<", 1072], [".001", 1074], [")", 1078], [".", 1079], ["MRSA", 1081], ["prevalence", 1086], ["in", 1097], ["children", 1100], ["with", 1109], ["CF", 1114], ["is", 1117], ["increasing", 1120], [",", 1130], ["and", 1132], ["most", 1136], ["children", 1141], ["are", 1150], ["infected", 1154], ["with", 1163], ["HA", 1168], ["MRSA", 1171], [".", 1175], ["Exposure", 1177], ["to", 1186], ["health", 1189], ["care", 1196], ["facilities", 1201], ["and", 1212], ["gastrointestinal", 1216], ["surgeries", 1233], ["may", 1243], ["facilitate", 1247], ["early", 1258], ["acquisition", 1264], ["of", 1276], ["MRSA", 1279], [".", 1283], ["Siblings", 1285], ["carry", 1294], ["indistinguishable", 1300], ["MRSA", 1318], ["strains", 1323], [",", 1330], ["indicating", 1332], ["household", 1343], ["transmission", 1353], ["of", 1366], ["MRSA", 1369], [".", 1373], ["Children", 1375], ["with", 1384], ["persistent", 1389], ["MRSA", 1400], ["had", 1405], ["worse", 1409], ["pulmonary", 1415], ["morbidity", 1425], [".", 1434], ["Coinfection", 1436], ["with", 1448], ["MRSA", 1453], ["and", 1458], ["P", 1462], ["aeruginosa", 1464], ["is", 1475], ["likely", 1478], ["associated", 1485], ["with", 1496], ["further", 1501], ["increased", 1509], ["pulmonary", 1519], ["morbidity", 1529], [".", 1538]]}
{"context": "Clinical features variability between familial and sporadic restless legs syndrome/Willis-Ekbom disease (RLS/WED) has been previously reported. With this retrospective cohort study, we aimed to determine the clinical and polysomnographic characteristics of 400 RLS/WED patients. Patients with familial RLS/WED were significantly younger than sporadic RLS/WED, while clinical and polysomnographic characteristics were similar in both groups. No difference was found for the age-at-onset between idiopathic and secondary RLS/WED. Periodic limb movements (PLM) index and REM sleep time were higher in idiopathic RLS/WED. Time of onset of symptoms was in the evening or at bedtime in 28.04 and 37.80% of patients, respectively, while in 21.34% of patients onset was more than 1 h after sleep onset. Impulse control and compulsive behaviours (ICBs) were found in 13.29% patients on dopamine agonist therapy. Our analyses support the hypothesis that patients with a familial history of RLS/WED may have a genetic component. Nevertheless, the dichotomy between early and late onset disease seems to be less sharp than previously reported. A large proportion of RLS/WED patients can have atypical features, therefore making the diagnosis challenging. Some cases can be missed even when the patient refers to a sleep specialist, as revealed by the partial absence of daytime symptoms, the high comorbidity with insomnia and other sleep complaints and the high percentage of symptoms beginning after sleep onset. This draws attention on the importance of a careful evaluation of the patient, to recognize potentially treatable secondary forms of RLS/WED.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "c287836b570a4d18b1c683334df92f91", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[7, 9]], "char_spans": [[60, 81]]}]}], "context_tokens": [["Clinical", 0], ["features", 9], ["variability", 18], ["between", 30], ["familial", 38], ["and", 47], ["sporadic", 51], ["restless", 60], ["legs", 69], ["syndrome", 74], ["/", 82], ["Willis", 83], ["-", 89], ["Ekbom", 90], ["disease", 96], ["(", 104], ["RLS", 105], ["/", 108], ["WED", 109], [")", 112], ["has", 114], ["been", 118], ["previously", 123], ["reported", 134], [".", 142], ["With", 144], ["this", 149], ["retrospective", 154], ["cohort", 168], ["study", 175], [",", 180], ["we", 182], ["aimed", 185], ["to", 191], ["determine", 194], ["the", 204], ["clinical", 208], ["and", 217], ["polysomnographic", 221], ["characteristics", 238], ["of", 254], ["400", 257], ["RLS", 261], ["/", 264], ["WED", 265], ["patients", 269], [".", 277], ["Patients", 279], ["with", 288], ["familial", 293], ["RLS", 302], ["/", 305], ["WED", 306], ["were", 310], ["significantly", 315], ["younger", 329], ["than", 337], ["sporadic", 342], ["RLS", 351], ["/", 354], ["WED", 355], [",", 358], ["while", 360], ["clinical", 366], ["and", 375], ["polysomnographic", 379], ["characteristics", 396], ["were", 412], ["similar", 417], ["in", 425], ["both", 428], ["groups", 433], [".", 439], ["No", 441], ["difference", 444], ["was", 455], ["found", 459], ["for", 465], ["the", 469], ["age", 473], ["-", 476], ["at", 477], ["-", 479], ["onset", 480], ["between", 486], ["idiopathic", 494], ["and", 505], ["secondary", 509], ["RLS", 519], ["/", 522], ["WED", 523], [".", 526], ["Periodic", 528], ["limb", 537], ["movements", 542], ["(", 552], ["PLM", 553], [")", 556], ["index", 558], ["and", 564], ["REM", 568], ["sleep", 572], ["time", 578], ["were", 583], ["higher", 588], ["in", 595], ["idiopathic", 598], ["RLS", 609], ["/", 612], ["WED", 613], [".", 616], ["Time", 618], ["of", 623], ["onset", 626], ["of", 632], ["symptoms", 635], ["was", 644], ["in", 648], ["the", 651], ["evening", 655], ["or", 663], ["at", 666], ["bedtime", 669], ["in", 677], ["28.04", 680], ["and", 686], ["37.80", 690], ["%", 695], ["of", 697], ["patients", 700], [",", 708], ["respectively", 710], [",", 722], ["while", 724], ["in", 730], ["21.34", 733], ["%", 738], ["of", 740], ["patients", 743], ["onset", 752], ["was", 758], ["more", 762], ["than", 767], ["1", 772], ["h", 774], ["after", 776], ["sleep", 782], ["onset", 788], [".", 793], ["Impulse", 795], ["control", 803], ["and", 811], ["compulsive", 815], ["behaviours", 826], ["(", 837], ["ICBs", 838], [")", 842], ["were", 844], ["found", 849], ["in", 855], ["13.29", 858], ["%", 863], ["patients", 865], ["on", 874], ["dopamine", 877], ["agonist", 886], ["therapy", 894], [".", 901], ["Our", 903], ["analyses", 907], ["support", 916], ["the", 924], ["hypothesis", 928], ["that", 939], ["patients", 944], ["with", 953], ["a", 958], ["familial", 960], ["history", 969], ["of", 977], ["RLS", 980], ["/", 983], ["WED", 984], ["may", 988], ["have", 992], ["a", 997], ["genetic", 999], ["component", 1007], [".", 1016], ["Nevertheless", 1018], [",", 1030], ["the", 1032], ["dichotomy", 1036], ["between", 1046], ["early", 1054], ["and", 1060], ["late", 1064], ["onset", 1069], ["disease", 1075], ["seems", 1083], ["to", 1089], ["be", 1092], ["less", 1095], ["sharp", 1100], ["than", 1106], ["previously", 1111], ["reported", 1122], [".", 1130], ["A", 1132], ["large", 1134], ["proportion", 1140], ["of", 1151], ["RLS", 1154], ["/", 1157], ["WED", 1158], ["patients", 1162], ["can", 1171], ["have", 1175], ["atypical", 1180], ["features", 1189], [",", 1197], ["therefore", 1199], ["making", 1209], ["the", 1216], ["diagnosis", 1220], ["challenging", 1230], [".", 1241], ["Some", 1243], ["cases", 1248], ["can", 1254], ["be", 1258], ["missed", 1261], ["even", 1268], ["when", 1273], ["the", 1278], ["patient", 1282], ["refers", 1290], ["to", 1297], ["a", 1300], ["sleep", 1302], ["specialist", 1308], [",", 1318], ["as", 1320], ["revealed", 1323], ["by", 1332], ["the", 1335], ["partial", 1339], ["absence", 1347], ["of", 1355], ["daytime", 1358], ["symptoms", 1366], [",", 1374], ["the", 1376], ["high", 1380], ["comorbidity", 1385], ["with", 1397], ["insomnia", 1402], ["and", 1411], ["other", 1415], ["sleep", 1421], ["complaints", 1427], ["and", 1438], ["the", 1442], ["high", 1446], ["percentage", 1451], ["of", 1462], ["symptoms", 1465], ["beginning", 1474], ["after", 1484], ["sleep", 1490], ["onset", 1496], [".", 1501], ["This", 1503], ["draws", 1508], ["attention", 1514], ["on", 1524], ["the", 1527], ["importance", 1531], ["of", 1542], ["a", 1545], ["careful", 1547], ["evaluation", 1555], ["of", 1566], ["the", 1569], ["patient", 1573], [",", 1580], ["to", 1582], ["recognize", 1585], ["potentially", 1595], ["treatable", 1607], ["secondary", 1617], ["forms", 1627], ["of", 1633], ["RLS", 1636], ["/", 1639], ["WED", 1640], [".", 1643]]}
{"context": "Membrane antigens are critical to the pathogenesis of chronic lymphocytic leukemia (CLL) as they facilitate microenvironment homing, proliferation, and survival. Targeting the CLL membrane and associated signaling patterns is a current focus of therapeutic development. Many tumor membrane targets are simultaneously targeted by humoral immunity, thus forming recognizable immunoglobulin responses. We sought to use this immune response to identify novel membrane-associated targets for CLL. Using a novel strategy, we interrogated CLL membrane-specific autologous immunoglobulin G reactivity. Our analysis unveiled lymphocyte cytosolic protein 1 (LCP1), a lymphocyte-specific target that is highly expressed in CLL. LCP1 plays a critical role in B-cell biology by crosslinking F-actin filaments, thereby solidifying cytoskeletal structures and providing a scaffold for critical signaling pathways. Small interfering RNA knockdown of LCP1 blocked migration toward CXCL12 in transwell assays and to bone marrow in an in vivo xenotransplant model, confirming a role for LCP1 in leukemia migration. Furthermore, we demonstrate that the Bruton's tyrosine kinase inhibitor ibrutinib or the PI3K inhibitor idelalisib block B-cell receptor induced activation of LCP1. Our data demonstrate a novel strategy to identify cancer membrane target antigens using humoral anti-tumor immunity. In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance. This clinical trial was registered at clinicaltrials.gov; study ID number: OSU-0025 OSU-0156.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "692ffa1dbcd344f7b86b7f0d61e5403f", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[188, 188]], "char_spans": [[1168, 1176]]}]}], "context_tokens": [["Membrane", 0], ["antigens", 9], ["are", 18], ["critical", 22], ["to", 31], ["the", 34], ["pathogenesis", 38], ["of", 51], ["chronic", 54], ["lymphocytic", 62], ["leukemia", 74], ["(", 83], ["CLL", 84], [")", 87], ["as", 89], ["they", 92], ["facilitate", 97], ["microenvironment", 108], ["homing", 125], [",", 131], ["proliferation", 133], [",", 146], ["and", 148], ["survival", 152], [".", 160], ["Targeting", 162], ["the", 172], ["CLL", 176], ["membrane", 180], ["and", 189], ["associated", 193], ["signaling", 204], ["patterns", 214], ["is", 223], ["a", 226], ["current", 228], ["focus", 236], ["of", 242], ["therapeutic", 245], ["development", 257], [".", 268], ["Many", 270], ["tumor", 275], ["membrane", 281], ["targets", 290], ["are", 298], ["simultaneously", 302], ["targeted", 317], ["by", 326], ["humoral", 329], ["immunity", 337], [",", 345], ["thus", 347], ["forming", 352], ["recognizable", 360], ["immunoglobulin", 373], ["responses", 388], [".", 397], ["We", 399], ["sought", 402], ["to", 409], ["use", 412], ["this", 416], ["immune", 421], ["response", 428], ["to", 437], ["identify", 440], ["novel", 449], ["membrane", 455], ["-", 463], ["associated", 464], ["targets", 475], ["for", 483], ["CLL", 487], [".", 490], ["Using", 492], ["a", 498], ["novel", 500], ["strategy", 506], [",", 514], ["we", 516], ["interrogated", 519], ["CLL", 532], ["membrane", 536], ["-", 544], ["specific", 545], ["autologous", 554], ["immunoglobulin", 565], ["G", 580], ["reactivity", 582], [".", 592], ["Our", 594], ["analysis", 598], ["unveiled", 607], ["lymphocyte", 616], ["cytosolic", 627], ["protein", 637], ["1", 645], ["(", 647], ["LCP1", 648], [")", 652], [",", 653], ["a", 655], ["lymphocyte", 657], ["-", 667], ["specific", 668], ["target", 677], ["that", 684], ["is", 689], ["highly", 692], ["expressed", 699], ["in", 709], ["CLL", 712], [".", 715], ["LCP1", 717], ["plays", 722], ["a", 728], ["critical", 730], ["role", 739], ["in", 744], ["B", 747], ["-", 748], ["cell", 749], ["biology", 754], ["by", 762], ["crosslinking", 765], ["F", 778], ["-", 779], ["actin", 780], ["filaments", 786], [",", 795], ["thereby", 797], ["solidifying", 805], ["cytoskeletal", 817], ["structures", 830], ["and", 841], ["providing", 845], ["a", 855], ["scaffold", 857], ["for", 866], ["critical", 870], ["signaling", 879], ["pathways", 889], [".", 897], ["Small", 899], ["interfering", 905], ["RNA", 917], ["knockdown", 921], ["of", 931], ["LCP1", 934], ["blocked", 939], ["migration", 947], ["toward", 957], ["CXCL12", 964], ["in", 971], ["transwell", 974], ["assays", 984], ["and", 991], ["to", 995], ["bone", 998], ["marrow", 1003], ["in", 1010], ["an", 1013], ["in", 1016], ["vivo", 1019], ["xenotransplant", 1024], ["model", 1039], [",", 1044], ["confirming", 1046], ["a", 1057], ["role", 1059], ["for", 1064], ["LCP1", 1068], ["in", 1073], ["leukemia", 1076], ["migration", 1085], [".", 1094], ["Furthermore", 1096], [",", 1107], ["we", 1109], ["demonstrate", 1112], ["that", 1124], ["the", 1129], ["Bruton", 1133], ["'s", 1139], ["tyrosine", 1142], ["kinase", 1151], ["inhibitor", 1158], ["ibrutinib", 1168], ["or", 1178], ["the", 1181], ["PI3", 1185], ["K", 1188], ["inhibitor", 1190], ["idelalisib", 1200], ["block", 1211], ["B", 1217], ["-", 1218], ["cell", 1219], ["receptor", 1224], ["induced", 1233], ["activation", 1241], ["of", 1252], ["LCP1", 1255], [".", 1259], ["Our", 1261], ["data", 1265], ["demonstrate", 1270], ["a", 1282], ["novel", 1284], ["strategy", 1290], ["to", 1299], ["identify", 1302], ["cancer", 1311], ["membrane", 1318], ["target", 1327], ["antigens", 1334], ["using", 1343], ["humoral", 1349], ["anti", 1357], ["-", 1361], ["tumor", 1362], ["immunity", 1368], [".", 1376], ["In", 1378], ["addition", 1381], [",", 1389], ["we", 1391], ["identify", 1394], ["LCP1", 1403], ["as", 1408], ["a", 1411], ["membrane", 1413], ["-", 1421], ["associated", 1422], ["target", 1433], ["in", 1440], ["CLL", 1443], ["with", 1447], ["confirmed", 1452], ["pathogenic", 1462], ["significance", 1473], [".", 1485], ["This", 1487], ["clinical", 1492], ["trial", 1501], ["was", 1507], ["registered", 1511], ["at", 1522], ["clinicaltrials.gov", 1525], [";", 1543], ["study", 1545], ["ID", 1551], ["number", 1554], [":", 1560], ["OSU-0025", 1562], ["OSU-0156", 1571], [".", 1579]]}
{"context": "Opicapone is a novel catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to evaluate the tolerability, pharmacokinetics (including the effect of food) and pharmacodynamics (effect on COMT activity) following single oral doses of opicapone in young healthy male volunteers. Single rising oral doses of opicapone (10, 25, 50, 100, 200, 400, 800 and 1,200 mg) were administered to eight groups of eight subjects per group (two subjects randomized to placebo and six subjects to opicapone), under a double-blind, randomized, placebo-controlled design. In an additional group of 12 subjects, a 50 mg single dose of opicapone was administered on two occasions, once having fasted overnight and once with a high-fat high-calorie meal. Opicapone was well tolerated at all doses tested. The extent of systemic exposure (area under the plasma concentration-time curve and maximum plasma concentration) to opicapone and metabolites increased in an approximately dose-proportional manner and showed a decrease following concomitant ingestion of a high-fat high-calorie meal. The apparent terminal elimination half-life of opicapone was 0.8-3.2 h. Sulphation appeared to be the main metabolic pathway for opicapone, and both opicapone and the main sulphated metabolite are likely excreted by the biliary route. Maximum COMT inhibition by opicapone was dose dependent, ranged from 36.1% (10 mg) to 100% (200 mg and above), and reached statistical significance at all doses tested. The long duration of COMT inhibition by opicapone, however, tended to be independent from the dose taken. The observed half-life of opicapone-induced COMT inhibition in human erythrocytes was 61.6 h (standard deviation [SD] = 37.6 h), which reflects an underlying dissociative process with a kinetic rate constant of 3.1 \u00d7 10(-6) s(-1) (SD = 1.9 \u00d7 10(-6) s(-1)). Such a process compares well to the estimated dissociation rate constant (k(off)) of the COMT-opicapone molecular complex (k(off) = 1.9 \u00d7 10(-6) s(-1)). Opicapone was well-tolerated and presented dose-proportional kinetics. Opicapone demonstrated marked and sustained inhibition of erythrocyte soluble COMT activity. Based on the observation that the half-life of COMT inhibition is independent of the dose and that it reflects an underlying kinetic process that is consistent with the k(off) value of the COMT-opicapone complex, we propose that the sustained COMT inhibition, far beyond the observable point of clearance of circulating drug, is due to the long residence time of the reversible complex formed between COMT and opicapone. Globally, these promising results provide a basis for further clinical development of opicapone.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "27c5cce16a694b1292f9a384c43beab6", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[4, 8]], "char_spans": [[21, 48]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["catechol", 21], ["-", 29], ["O", 30], ["-", 31], ["methyltransferase", 32], ["(", 50], ["COMT", 51], [")", 55], ["inhibitor", 57], [".", 66], ["The", 68], ["purpose", 72], ["of", 80], ["this", 83], ["study", 88], ["was", 94], ["to", 98], ["evaluate", 101], ["the", 110], ["tolerability", 114], [",", 126], ["pharmacokinetics", 128], ["(", 145], ["including", 146], ["the", 156], ["effect", 160], ["of", 167], ["food", 170], [")", 174], ["and", 176], ["pharmacodynamics", 180], ["(", 197], ["effect", 198], ["on", 205], ["COMT", 208], ["activity", 213], [")", 221], ["following", 223], ["single", 233], ["oral", 240], ["doses", 245], ["of", 251], ["opicapone", 254], ["in", 264], ["young", 267], ["healthy", 273], ["male", 281], ["volunteers", 286], [".", 296], ["Single", 298], ["rising", 305], ["oral", 312], ["doses", 317], ["of", 323], ["opicapone", 326], ["(", 336], ["10", 337], [",", 339], ["25", 341], [",", 343], ["50", 345], [",", 347], ["100", 349], [",", 352], ["200", 354], [",", 357], ["400", 359], [",", 362], ["800", 364], ["and", 368], ["1,200", 372], ["mg", 378], [")", 380], ["were", 382], ["administered", 387], ["to", 400], ["eight", 403], ["groups", 409], ["of", 416], ["eight", 419], ["subjects", 425], ["per", 434], ["group", 438], ["(", 444], ["two", 445], ["subjects", 449], ["randomized", 458], ["to", 469], ["placebo", 472], ["and", 480], ["six", 484], ["subjects", 488], ["to", 497], ["opicapone", 500], [")", 509], [",", 510], ["under", 512], ["a", 518], ["double", 520], ["-", 526], ["blind", 527], [",", 532], ["randomized", 534], [",", 544], ["placebo", 546], ["-", 553], ["controlled", 554], ["design", 565], [".", 571], ["In", 573], ["an", 576], ["additional", 579], ["group", 590], ["of", 596], ["12", 599], ["subjects", 602], [",", 610], ["a", 612], ["50", 614], ["mg", 617], ["single", 620], ["dose", 627], ["of", 632], ["opicapone", 635], ["was", 645], ["administered", 649], ["on", 662], ["two", 665], ["occasions", 669], [",", 678], ["once", 680], ["having", 685], ["fasted", 692], ["overnight", 699], ["and", 709], ["once", 713], ["with", 718], ["a", 723], ["high", 725], ["-", 729], ["fat", 730], ["high", 734], ["-", 738], ["calorie", 739], ["meal", 747], [".", 751], ["Opicapone", 753], ["was", 763], ["well", 767], ["tolerated", 772], ["at", 782], ["all", 785], ["doses", 789], ["tested", 795], [".", 801], ["The", 803], ["extent", 807], ["of", 814], ["systemic", 817], ["exposure", 826], ["(", 835], ["area", 836], ["under", 841], ["the", 847], ["plasma", 851], ["concentration", 858], ["-", 871], ["time", 872], ["curve", 877], ["and", 883], ["maximum", 887], ["plasma", 895], ["concentration", 902], [")", 915], ["to", 917], ["opicapone", 920], ["and", 930], ["metabolites", 934], ["increased", 946], ["in", 956], ["an", 959], ["approximately", 962], ["dose", 976], ["-", 980], ["proportional", 981], ["manner", 994], ["and", 1001], ["showed", 1005], ["a", 1012], ["decrease", 1014], ["following", 1023], ["concomitant", 1033], ["ingestion", 1045], ["of", 1055], ["a", 1058], ["high", 1060], ["-", 1064], ["fat", 1065], ["high", 1069], ["-", 1073], ["calorie", 1074], ["meal", 1082], [".", 1086], ["The", 1088], ["apparent", 1092], ["terminal", 1101], ["elimination", 1110], ["half", 1122], ["-", 1126], ["life", 1127], ["of", 1132], ["opicapone", 1135], ["was", 1145], ["0.8", 1149], ["-", 1152], ["3.2", 1153], ["h.", 1157], ["Sulphation", 1160], ["appeared", 1171], ["to", 1180], ["be", 1183], ["the", 1186], ["main", 1190], ["metabolic", 1195], ["pathway", 1205], ["for", 1213], ["opicapone", 1217], [",", 1226], ["and", 1228], ["both", 1232], ["opicapone", 1237], ["and", 1247], ["the", 1251], ["main", 1255], ["sulphated", 1260], ["metabolite", 1270], ["are", 1281], ["likely", 1285], ["excreted", 1292], ["by", 1301], ["the", 1304], ["biliary", 1308], ["route", 1316], [".", 1321], ["Maximum", 1323], ["COMT", 1331], ["inhibition", 1336], ["by", 1347], ["opicapone", 1350], ["was", 1360], ["dose", 1364], ["dependent", 1369], [",", 1378], ["ranged", 1380], ["from", 1387], ["36.1", 1392], ["%", 1396], ["(", 1398], ["10", 1399], ["mg", 1402], [")", 1404], ["to", 1406], ["100", 1409], ["%", 1412], ["(", 1414], ["200", 1415], ["mg", 1419], ["and", 1422], ["above", 1426], [")", 1431], [",", 1432], ["and", 1434], ["reached", 1438], ["statistical", 1446], ["significance", 1458], ["at", 1471], ["all", 1474], ["doses", 1478], ["tested", 1484], [".", 1490], ["The", 1492], ["long", 1496], ["duration", 1501], ["of", 1510], ["COMT", 1513], ["inhibition", 1518], ["by", 1529], ["opicapone", 1532], [",", 1541], ["however", 1543], [",", 1550], ["tended", 1552], ["to", 1559], ["be", 1562], ["independent", 1565], ["from", 1577], ["the", 1582], ["dose", 1586], ["taken", 1591], [".", 1596], ["The", 1598], ["observed", 1602], ["half", 1611], ["-", 1615], ["life", 1616], ["of", 1621], ["opicapone", 1624], ["-", 1633], ["induced", 1634], ["COMT", 1642], ["inhibition", 1647], ["in", 1658], ["human", 1661], ["erythrocytes", 1667], ["was", 1680], ["61.6", 1684], ["h", 1689], ["(", 1691], ["standard", 1692], ["deviation", 1701], ["[", 1711], ["SD", 1712], ["]", 1714], ["=", 1716], ["37.6", 1718], ["h", 1723], [")", 1724], [",", 1725], ["which", 1727], ["reflects", 1733], ["an", 1742], ["underlying", 1745], ["dissociative", 1756], ["process", 1769], ["with", 1777], ["a", 1782], ["kinetic", 1784], ["rate", 1792], ["constant", 1797], ["of", 1806], ["3.1", 1809], ["\u00d7", 1813], ["10(-6", 1815], [")", 1820], ["s(-1", 1822], [")", 1826], ["(", 1828], ["SD", 1829], ["=", 1832], ["1.9", 1834], ["\u00d7", 1838], ["10(-6", 1840], [")", 1845], ["s(-1", 1847], [")", 1851], [")", 1852], [".", 1853], ["Such", 1855], ["a", 1860], ["process", 1862], ["compares", 1870], ["well", 1879], ["to", 1884], ["the", 1887], ["estimated", 1891], ["dissociation", 1901], ["rate", 1914], ["constant", 1919], ["(", 1928], ["k(off", 1929], [")", 1934], [")", 1935], ["of", 1937], ["the", 1940], ["COMT", 1944], ["-", 1948], ["opicapone", 1949], ["molecular", 1959], ["complex", 1969], ["(", 1977], ["k(off", 1978], [")", 1983], ["=", 1985], ["1.9", 1987], ["\u00d7", 1991], ["10(-6", 1993], [")", 1998], ["s(-1", 2000], [")", 2004], [")", 2005], [".", 2006], ["Opicapone", 2008], ["was", 2018], ["well", 2022], ["-", 2026], ["tolerated", 2027], ["and", 2037], ["presented", 2041], ["dose", 2051], ["-", 2055], ["proportional", 2056], ["kinetics", 2069], [".", 2077], ["Opicapone", 2079], ["demonstrated", 2089], ["marked", 2102], ["and", 2109], ["sustained", 2113], ["inhibition", 2123], ["of", 2134], ["erythrocyte", 2137], ["soluble", 2149], ["COMT", 2157], ["activity", 2162], [".", 2170], ["Based", 2172], ["on", 2178], ["the", 2181], ["observation", 2185], ["that", 2197], ["the", 2202], ["half", 2206], ["-", 2210], ["life", 2211], ["of", 2216], ["COMT", 2219], ["inhibition", 2224], ["is", 2235], ["independent", 2238], ["of", 2250], ["the", 2253], ["dose", 2257], ["and", 2262], ["that", 2266], ["it", 2271], ["reflects", 2274], ["an", 2283], ["underlying", 2286], ["kinetic", 2297], ["process", 2305], ["that", 2313], ["is", 2318], ["consistent", 2321], ["with", 2332], ["the", 2337], ["k(off", 2341], [")", 2346], ["value", 2348], ["of", 2354], ["the", 2357], ["COMT", 2361], ["-", 2365], ["opicapone", 2366], ["complex", 2376], [",", 2383], ["we", 2385], ["propose", 2388], ["that", 2396], ["the", 2401], ["sustained", 2405], ["COMT", 2415], ["inhibition", 2420], [",", 2430], ["far", 2432], ["beyond", 2436], ["the", 2443], ["observable", 2447], ["point", 2458], ["of", 2464], ["clearance", 2467], ["of", 2477], ["circulating", 2480], ["drug", 2492], [",", 2496], ["is", 2498], ["due", 2501], ["to", 2505], ["the", 2508], ["long", 2512], ["residence", 2517], ["time", 2527], ["of", 2532], ["the", 2535], ["reversible", 2539], ["complex", 2550], ["formed", 2558], ["between", 2565], ["COMT", 2573], ["and", 2578], ["opicapone", 2582], [".", 2591], ["Globally", 2593], [",", 2601], ["these", 2603], ["promising", 2609], ["results", 2619], ["provide", 2627], ["a", 2635], ["basis", 2637], ["for", 2643], ["further", 2647], ["clinical", 2655], ["development", 2664], ["of", 2676], ["opicapone", 2679], [".", 2688]]}
{"context": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis. In the present study, we analyzed the CaSR gene in a Korean family with familial hypocalciuric hypercalcemia (FHH). Genetic studies were performed by direct sequence analysis of the CaSR gene in genomic DNA obtained from peripheral leukocytes. A novel heterozygous G to T substitution at nucleotide position 1711 in exon 6, resulting in the G571W mutation, was identified in the CaSR gene in a 26-year-old female with asymptomatic hypercalcemia, a low calcium/creatinine clearance ratio, and normal intact parathyroid hormone. To study CaSR expression, the mutation was introduced by site-directed mutagenesis into a wild-type (WT) CaSR-expressing pCR3.1 vector, and COS-7 cells were transfected with either the WT or mutant CaSR-containing vector. Transfected cells loaded with Fura-2/AM, a fluorescent indicator of Ca", "qas": [{"question": "What is the function of calcium-sensing receptor (CaSR)?", "answers": ["The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis."], "qid": "1f0adb77304f4c188ae40ccb27db4e56", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["function", 12], ["of", 21], ["calcium", 24], ["-", 31], ["sensing", 32], ["receptor", 40], ["(", 49], ["CaSR", 50], [")", 54], ["?", 55]], "detected_answers": [{"text": "The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that plays an essential role in maintaining calcium homeostasis.", "token_spans": [[1, 24]], "char_spans": [[4, 130]]}]}], "context_tokens": [["The", 0], ["calcium", 4], ["-", 11], ["sensing", 12], ["receptor", 20], ["(", 29], ["CaSR", 30], [")", 34], ["is", 36], ["a", 39], ["G", 41], ["-", 42], ["protein", 43], ["-", 50], ["coupled", 51], ["receptor", 59], ["that", 68], ["plays", 73], ["an", 79], ["essential", 82], ["role", 92], ["in", 97], ["maintaining", 100], ["calcium", 112], ["homeostasis", 120], [".", 131], ["In", 133], ["the", 136], ["present", 140], ["study", 148], [",", 153], ["we", 155], ["analyzed", 158], ["the", 167], ["CaSR", 171], ["gene", 176], ["in", 181], ["a", 184], ["Korean", 186], ["family", 193], ["with", 200], ["familial", 205], ["hypocalciuric", 214], ["hypercalcemia", 228], ["(", 242], ["FHH", 243], [")", 246], [".", 247], ["Genetic", 249], ["studies", 257], ["were", 265], ["performed", 270], ["by", 280], ["direct", 283], ["sequence", 290], ["analysis", 299], ["of", 308], ["the", 311], ["CaSR", 315], ["gene", 320], ["in", 325], ["genomic", 328], ["DNA", 336], ["obtained", 340], ["from", 349], ["peripheral", 354], ["leukocytes", 365], [".", 375], ["A", 377], ["novel", 379], ["heterozygous", 385], ["G", 398], ["to", 400], ["T", 403], ["substitution", 405], ["at", 418], ["nucleotide", 421], ["position", 432], ["1711", 441], ["in", 446], ["exon", 449], ["6", 454], [",", 455], ["resulting", 457], ["in", 467], ["the", 470], ["G571W", 474], ["mutation", 480], [",", 488], ["was", 490], ["identified", 494], ["in", 505], ["the", 508], ["CaSR", 512], ["gene", 517], ["in", 522], ["a", 525], ["26-year", 527], ["-", 534], ["old", 535], ["female", 539], ["with", 546], ["asymptomatic", 551], ["hypercalcemia", 564], [",", 577], ["a", 579], ["low", 581], ["calcium", 585], ["/", 592], ["creatinine", 593], ["clearance", 604], ["ratio", 614], [",", 619], ["and", 621], ["normal", 625], ["intact", 632], ["parathyroid", 639], ["hormone", 651], [".", 658], ["To", 660], ["study", 663], ["CaSR", 669], ["expression", 674], [",", 684], ["the", 686], ["mutation", 690], ["was", 699], ["introduced", 703], ["by", 714], ["site", 717], ["-", 721], ["directed", 722], ["mutagenesis", 731], ["into", 743], ["a", 748], ["wild", 750], ["-", 754], ["type", 755], ["(", 760], ["WT", 761], [")", 763], ["CaSR", 765], ["-", 769], ["expressing", 770], ["pCR3.1", 781], ["vector", 788], [",", 794], ["and", 796], ["COS-7", 800], ["cells", 806], ["were", 812], ["transfected", 817], ["with", 829], ["either", 834], ["the", 841], ["WT", 845], ["or", 848], ["mutant", 851], ["CaSR", 858], ["-", 862], ["containing", 863], ["vector", 874], [".", 880], ["Transfected", 882], ["cells", 894], ["loaded", 900], ["with", 907], ["Fura-2/AM", 912], [",", 921], ["a", 923], ["fluorescent", 925], ["indicator", 937], ["of", 947], ["Ca", 950]]}
{"context": "Ehlers-Danlos syndromes (EDSs) constitute a rare group of inherited connective tissue diseases, characterized by multisystemic manifestations and general tissue fragility. Most severe complications include vascular and gastrointestinal (GI) emergencies requiring acute surgery. The purpose of this systematic review was to assess the causes of GI-related surgery and related mortality and morbidity in patients with EDSs. A systematic search was conducted in PubMed, Embase, and Scopus to identify relevant studies. Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines for systematic reviews were followed. According to eligibility criteria, data were extracted and systematically screened by 2 authors. Screening process identified 11 studies with a total of 1,567 patients. Findings indicated that patients with EDSs had a higher occurrence of surgery demanding GI manifestations, including perforation, hemorrhage, rupture of intra-abdominal organs, and rectal prolapse. Most affected was the vascular subtype, of which up to 33% underwent GI surgery and suffered from a lowered average life expectancy of 48 years (range 6-78). Secondary complications of surgery were common in all patients with EDSs. Studies suggested that patients with EDSs present an increased need for GI surgery, but also an increased risk of surgery-related complications, most predominantly seen in the vascular subtype.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "3db08ec88fe14bf684b334546499f137", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[68, 84]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDSs", 25], [")", 29], ["constitute", 31], ["a", 42], ["rare", 44], ["group", 49], ["of", 55], ["inherited", 58], ["connective", 68], ["tissue", 79], ["diseases", 86], [",", 94], ["characterized", 96], ["by", 110], ["multisystemic", 113], ["manifestations", 127], ["and", 142], ["general", 146], ["tissue", 154], ["fragility", 161], [".", 170], ["Most", 172], ["severe", 177], ["complications", 184], ["include", 198], ["vascular", 206], ["and", 215], ["gastrointestinal", 219], ["(", 236], ["GI", 237], [")", 239], ["emergencies", 241], ["requiring", 253], ["acute", 263], ["surgery", 269], [".", 276], ["The", 278], ["purpose", 282], ["of", 290], ["this", 293], ["systematic", 298], ["review", 309], ["was", 316], ["to", 320], ["assess", 323], ["the", 330], ["causes", 334], ["of", 341], ["GI", 344], ["-", 346], ["related", 347], ["surgery", 355], ["and", 363], ["related", 367], ["mortality", 375], ["and", 385], ["morbidity", 389], ["in", 399], ["patients", 402], ["with", 411], ["EDSs", 416], [".", 420], ["A", 422], ["systematic", 424], ["search", 435], ["was", 442], ["conducted", 446], ["in", 456], ["PubMed", 459], [",", 465], ["Embase", 467], [",", 473], ["and", 475], ["Scopus", 479], ["to", 486], ["identify", 489], ["relevant", 498], ["studies", 507], [".", 514], ["Preferred", 516], ["Reporting", 526], ["Items", 536], ["for", 542], ["Systematic", 546], ["Reviews", 557], ["and", 565], ["Meta", 569], ["-", 573], ["Analysis", 574], ["guidelines", 583], ["for", 594], ["systematic", 598], ["reviews", 609], ["were", 617], ["followed", 622], [".", 630], ["According", 632], ["to", 642], ["eligibility", 645], ["criteria", 657], [",", 665], ["data", 667], ["were", 672], ["extracted", 677], ["and", 687], ["systematically", 691], ["screened", 706], ["by", 715], ["2", 718], ["authors", 720], [".", 727], ["Screening", 729], ["process", 739], ["identified", 747], ["11", 758], ["studies", 761], ["with", 769], ["a", 774], ["total", 776], ["of", 782], ["1,567", 785], ["patients", 791], [".", 799], ["Findings", 801], ["indicated", 810], ["that", 820], ["patients", 825], ["with", 834], ["EDSs", 839], ["had", 844], ["a", 848], ["higher", 850], ["occurrence", 857], ["of", 868], ["surgery", 871], ["demanding", 879], ["GI", 889], ["manifestations", 892], [",", 906], ["including", 908], ["perforation", 918], [",", 929], ["hemorrhage", 931], [",", 941], ["rupture", 943], ["of", 951], ["intra", 954], ["-", 959], ["abdominal", 960], ["organs", 970], [",", 976], ["and", 978], ["rectal", 982], ["prolapse", 989], [".", 997], ["Most", 999], ["affected", 1004], ["was", 1013], ["the", 1017], ["vascular", 1021], ["subtype", 1030], [",", 1037], ["of", 1039], ["which", 1042], ["up", 1048], ["to", 1051], ["33", 1054], ["%", 1056], ["underwent", 1058], ["GI", 1068], ["surgery", 1071], ["and", 1079], ["suffered", 1083], ["from", 1092], ["a", 1097], ["lowered", 1099], ["average", 1107], ["life", 1115], ["expectancy", 1120], ["of", 1131], ["48", 1134], ["years", 1137], ["(", 1143], ["range", 1144], ["6", 1150], ["-", 1151], ["78", 1152], [")", 1154], [".", 1155], ["Secondary", 1157], ["complications", 1167], ["of", 1181], ["surgery", 1184], ["were", 1192], ["common", 1197], ["in", 1204], ["all", 1207], ["patients", 1211], ["with", 1220], ["EDSs", 1225], [".", 1229], ["Studies", 1231], ["suggested", 1239], ["that", 1249], ["patients", 1254], ["with", 1263], ["EDSs", 1268], ["present", 1273], ["an", 1281], ["increased", 1284], ["need", 1294], ["for", 1299], ["GI", 1303], ["surgery", 1306], [",", 1313], ["but", 1315], ["also", 1319], ["an", 1324], ["increased", 1327], ["risk", 1337], ["of", 1342], ["surgery", 1345], ["-", 1352], ["related", 1353], ["complications", 1361], [",", 1374], ["most", 1376], ["predominantly", 1381], ["seen", 1395], ["in", 1400], ["the", 1403], ["vascular", 1407], ["subtype", 1416], [".", 1423]]}
{"context": "Viroids are small, circular, single-stranded RNA molecules that cause several infectious plant diseases. Viroids do not encode any pathogen-specific peptides but nonetheless, the subviral pathogens replicate autonomously and spread in the plant by recruiting host proteins via functional motifs encoded in their RNA genome. During the past couple of years, considerable progress has been made towards comprehending how viroids interact with their hosts. Here, we summarize recent findings on the structure-function relationships of viroids, their strategies and mechanisms of replication and trafficking, and the identification and characterization of interacting host proteins. We also describe the impact of the RNA silencing machinery of plants on viroid RNAs and how this has started to influence our models of viroid replication and pathogenicity.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "4bcc2386dcef433497f13c0ffbc668e1", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[68, 68], [0, 0], [87, 87], [18, 18]], "char_spans": [[419, 425], [0, 6], [532, 538], [105, 111]]}]}], "context_tokens": [["Viroids", 0], ["are", 8], ["small", 12], [",", 17], ["circular", 19], [",", 27], ["single", 29], ["-", 35], ["stranded", 36], ["RNA", 45], ["molecules", 49], ["that", 59], ["cause", 64], ["several", 70], ["infectious", 78], ["plant", 89], ["diseases", 95], [".", 103], ["Viroids", 105], ["do", 113], ["not", 116], ["encode", 120], ["any", 127], ["pathogen", 131], ["-", 139], ["specific", 140], ["peptides", 149], ["but", 158], ["nonetheless", 162], [",", 173], ["the", 175], ["subviral", 179], ["pathogens", 188], ["replicate", 198], ["autonomously", 208], ["and", 221], ["spread", 225], ["in", 232], ["the", 235], ["plant", 239], ["by", 245], ["recruiting", 248], ["host", 259], ["proteins", 264], ["via", 273], ["functional", 277], ["motifs", 288], ["encoded", 295], ["in", 303], ["their", 306], ["RNA", 312], ["genome", 316], [".", 322], ["During", 324], ["the", 331], ["past", 335], ["couple", 340], ["of", 347], ["years", 350], [",", 355], ["considerable", 357], ["progress", 370], ["has", 379], ["been", 383], ["made", 388], ["towards", 393], ["comprehending", 401], ["how", 415], ["viroids", 419], ["interact", 427], ["with", 436], ["their", 441], ["hosts", 447], [".", 452], ["Here", 454], [",", 458], ["we", 460], ["summarize", 463], ["recent", 473], ["findings", 480], ["on", 489], ["the", 492], ["structure", 496], ["-", 505], ["function", 506], ["relationships", 515], ["of", 529], ["viroids", 532], [",", 539], ["their", 541], ["strategies", 547], ["and", 558], ["mechanisms", 562], ["of", 573], ["replication", 576], ["and", 588], ["trafficking", 592], [",", 603], ["and", 605], ["the", 609], ["identification", 613], ["and", 628], ["characterization", 632], ["of", 649], ["interacting", 652], ["host", 664], ["proteins", 669], [".", 677], ["We", 679], ["also", 682], ["describe", 687], ["the", 696], ["impact", 700], ["of", 707], ["the", 710], ["RNA", 714], ["silencing", 718], ["machinery", 728], ["of", 738], ["plants", 741], ["on", 748], ["viroid", 751], ["RNAs", 758], ["and", 763], ["how", 767], ["this", 771], ["has", 776], ["started", 780], ["to", 788], ["influence", 791], ["our", 801], ["models", 805], ["of", 812], ["viroid", 815], ["replication", 822], ["and", 834], ["pathogenicity", 838], [".", 851]]}
{"context": "Dot1 is an evolutionarily conserved histone methyltransferase that methylates lysine-79 of histone H3 in the core domain. Unlike other histone methyltransferases, Dot1 does not contain a SET domain, and it specifically methylates nucleosomal histone H3. We have solved a 2.5 A resolution structure of the catalytic domain of human Dot1, hDOT1L, in complex with S-adenosyl-L-methionine (SAM). The structure reveals a unique organization of a mainly alpha-helical N-terminal domain and a central open alpha/beta structure, an active site consisting of a SAM binding pocket, and a potential lysine binding channel. We also show that a flexible, positively charged region at the C terminus of the catalytic domain is critical for nucleosome binding and enzymatic activity. These structural and biochemical analyses, combined with molecular modeling, provide mechanistic insights into the catalytic mechanism and nucleosomal specificity of Dot1 proteins.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "aa7139e1cfe6425786610c4bf1781099", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[28, 29]], "char_spans": [[187, 196]]}]}], "context_tokens": [["Dot1", 0], ["is", 5], ["an", 8], ["evolutionarily", 11], ["conserved", 26], ["histone", 36], ["methyltransferase", 44], ["that", 62], ["methylates", 67], ["lysine-79", 78], ["of", 88], ["histone", 91], ["H3", 99], ["in", 102], ["the", 105], ["core", 109], ["domain", 114], [".", 120], ["Unlike", 122], ["other", 129], ["histone", 135], ["methyltransferases", 143], [",", 161], ["Dot1", 163], ["does", 168], ["not", 173], ["contain", 177], ["a", 185], ["SET", 187], ["domain", 191], [",", 197], ["and", 199], ["it", 203], ["specifically", 206], ["methylates", 219], ["nucleosomal", 230], ["histone", 242], ["H3", 250], [".", 252], ["We", 254], ["have", 257], ["solved", 262], ["a", 269], ["2.5", 271], ["A", 275], ["resolution", 277], ["structure", 288], ["of", 298], ["the", 301], ["catalytic", 305], ["domain", 315], ["of", 322], ["human", 325], ["Dot1", 331], [",", 335], ["hDOT1L", 337], [",", 343], ["in", 345], ["complex", 348], ["with", 356], ["S", 361], ["-", 362], ["adenosyl", 363], ["-", 371], ["L", 372], ["-", 373], ["methionine", 374], ["(", 385], ["SAM", 386], [")", 389], [".", 390], ["The", 392], ["structure", 396], ["reveals", 406], ["a", 414], ["unique", 416], ["organization", 423], ["of", 436], ["a", 439], ["mainly", 441], ["alpha", 448], ["-", 453], ["helical", 454], ["N", 462], ["-", 463], ["terminal", 464], ["domain", 473], ["and", 480], ["a", 484], ["central", 486], ["open", 494], ["alpha", 499], ["/", 504], ["beta", 505], ["structure", 510], [",", 519], ["an", 521], ["active", 524], ["site", 531], ["consisting", 536], ["of", 547], ["a", 550], ["SAM", 552], ["binding", 556], ["pocket", 564], [",", 570], ["and", 572], ["a", 576], ["potential", 578], ["lysine", 588], ["binding", 595], ["channel", 603], [".", 610], ["We", 612], ["also", 615], ["show", 620], ["that", 625], ["a", 630], ["flexible", 632], [",", 640], ["positively", 642], ["charged", 653], ["region", 661], ["at", 668], ["the", 671], ["C", 675], ["terminus", 677], ["of", 686], ["the", 689], ["catalytic", 693], ["domain", 703], ["is", 710], ["critical", 713], ["for", 722], ["nucleosome", 726], ["binding", 737], ["and", 745], ["enzymatic", 749], ["activity", 759], [".", 767], ["These", 769], ["structural", 775], ["and", 786], ["biochemical", 790], ["analyses", 802], [",", 810], ["combined", 812], ["with", 821], ["molecular", 826], ["modeling", 836], [",", 844], ["provide", 846], ["mechanistic", 854], ["insights", 866], ["into", 875], ["the", 880], ["catalytic", 884], ["mechanism", 894], ["and", 904], ["nucleosomal", 908], ["specificity", 920], ["of", 932], ["Dot1", 935], ["proteins", 940], [".", 948]]}
{"context": "Prominin-1 (CD133) is commonly used to isolate stem and progenitor cells from the developing and adult nervous system and to identify cancer stem cells in brain tumors. However, despite extensive characterization of Prominin-1(+) precursor cells from the adult subventricular zone, no information about the expression of Prominin-1 by precursor cells in the subgranular zone (SGZ) of the adult hippocampus has been available. We show here that Prominin-1 is expressed by a significant number of cells in the SGZ of adult mice in vivo and ex vivo, including postmitotic astrocytes. A small subset of Prominin-1(+) cells coexpressed the nonspecific precursor cell marker Nestin as well as GFAP and Sox2. Upon fluorescence-activated cell sorting, only Prominin-1/Nestin double-positive cells fulfilled the defining stem cell criteria of proliferation, self-renewal, and multipotentiality as assessed by a neurosphere assay. In addition, isolated primary Prominin-1(+) cells preferentially migrated to the neurogenic niche in the SGZ upon transplantation in vivo. Finally, despite its expression by various stem and progenitor cells, Prominin-1 turned out to be dispensable for precursor cell proliferation in vitro and in vivo. Nevertheless, a net decrease in hippocampal neurogenesis, by \u223c30% was found in Prominin-1 knock-out mice, suggesting other roles in controlling adult hippocampal neurogenesis. Remarkably, an upregulation of Prominin-2 was detected in Prominin-1-deficient mice highlighting a potential compensatory mechanism, which might explain the lack of severe symptoms in individuals carrying mutations in the Prom1 gene.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "6cc9877ac4fc485b8865be0daa1ae5a3", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113]], "char_spans": [[669, 674]]}]}], "context_tokens": [["Prominin-1", 0], ["(", 11], ["CD133", 12], [")", 17], ["is", 19], ["commonly", 22], ["used", 31], ["to", 36], ["isolate", 39], ["stem", 47], ["and", 52], ["progenitor", 56], ["cells", 67], ["from", 73], ["the", 78], ["developing", 82], ["and", 93], ["adult", 97], ["nervous", 103], ["system", 111], ["and", 118], ["to", 122], ["identify", 125], ["cancer", 134], ["stem", 141], ["cells", 146], ["in", 152], ["brain", 155], ["tumors", 161], [".", 167], ["However", 169], [",", 176], ["despite", 178], ["extensive", 186], ["characterization", 196], ["of", 213], ["Prominin-1(+", 216], [")", 228], ["precursor", 230], ["cells", 240], ["from", 246], ["the", 251], ["adult", 255], ["subventricular", 261], ["zone", 276], [",", 280], ["no", 282], ["information", 285], ["about", 297], ["the", 303], ["expression", 307], ["of", 318], ["Prominin-1", 321], ["by", 332], ["precursor", 335], ["cells", 345], ["in", 351], ["the", 354], ["subgranular", 358], ["zone", 370], ["(", 375], ["SGZ", 376], [")", 379], ["of", 381], ["the", 384], ["adult", 388], ["hippocampus", 394], ["has", 406], ["been", 410], ["available", 415], [".", 424], ["We", 426], ["show", 429], ["here", 434], ["that", 439], ["Prominin-1", 444], ["is", 455], ["expressed", 458], ["by", 468], ["a", 471], ["significant", 473], ["number", 485], ["of", 492], ["cells", 495], ["in", 501], ["the", 504], ["SGZ", 508], ["of", 512], ["adult", 515], ["mice", 521], ["in", 526], ["vivo", 529], ["and", 534], ["ex", 538], ["vivo", 541], [",", 545], ["including", 547], ["postmitotic", 557], ["astrocytes", 569], [".", 579], ["A", 581], ["small", 583], ["subset", 589], ["of", 596], ["Prominin-1(+", 599], [")", 611], ["cells", 613], ["coexpressed", 619], ["the", 631], ["nonspecific", 635], ["precursor", 647], ["cell", 657], ["marker", 662], ["Nestin", 669], ["as", 676], ["well", 679], ["as", 684], ["GFAP", 687], ["and", 692], ["Sox2", 696], [".", 700], ["Upon", 702], ["fluorescence", 707], ["-", 719], ["activated", 720], ["cell", 730], ["sorting", 735], [",", 742], ["only", 744], ["Prominin-1/Nestin", 749], ["double", 767], ["-", 773], ["positive", 774], ["cells", 783], ["fulfilled", 789], ["the", 799], ["defining", 803], ["stem", 812], ["cell", 817], ["criteria", 822], ["of", 831], ["proliferation", 834], [",", 847], ["self", 849], ["-", 853], ["renewal", 854], [",", 861], ["and", 863], ["multipotentiality", 867], ["as", 885], ["assessed", 888], ["by", 897], ["a", 900], ["neurosphere", 902], ["assay", 914], [".", 919], ["In", 921], ["addition", 924], [",", 932], ["isolated", 934], ["primary", 943], ["Prominin-1(+", 951], [")", 963], ["cells", 965], ["preferentially", 971], ["migrated", 986], ["to", 995], ["the", 998], ["neurogenic", 1002], ["niche", 1013], ["in", 1019], ["the", 1022], ["SGZ", 1026], ["upon", 1030], ["transplantation", 1035], ["in", 1051], ["vivo", 1054], [".", 1058], ["Finally", 1060], [",", 1067], ["despite", 1069], ["its", 1077], ["expression", 1081], ["by", 1092], ["various", 1095], ["stem", 1103], ["and", 1108], ["progenitor", 1112], ["cells", 1123], [",", 1128], ["Prominin-1", 1130], ["turned", 1141], ["out", 1148], ["to", 1152], ["be", 1155], ["dispensable", 1158], ["for", 1170], ["precursor", 1174], ["cell", 1184], ["proliferation", 1189], ["in", 1203], ["vitro", 1206], ["and", 1212], ["in", 1216], ["vivo", 1219], [".", 1223], ["Nevertheless", 1225], [",", 1237], ["a", 1239], ["net", 1241], ["decrease", 1245], ["in", 1254], ["hippocampal", 1257], ["neurogenesis", 1269], [",", 1281], ["by", 1283], ["\u223c30", 1286], ["%", 1289], ["was", 1291], ["found", 1295], ["in", 1301], ["Prominin-1", 1304], ["knock", 1315], ["-", 1320], ["out", 1321], ["mice", 1325], [",", 1329], ["suggesting", 1331], ["other", 1342], ["roles", 1348], ["in", 1354], ["controlling", 1357], ["adult", 1369], ["hippocampal", 1375], ["neurogenesis", 1387], [".", 1399], ["Remarkably", 1401], [",", 1411], ["an", 1413], ["upregulation", 1416], ["of", 1429], ["Prominin-2", 1432], ["was", 1443], ["detected", 1447], ["in", 1456], ["Prominin-1-deficient", 1459], ["mice", 1480], ["highlighting", 1485], ["a", 1498], ["potential", 1500], ["compensatory", 1510], ["mechanism", 1523], [",", 1532], ["which", 1534], ["might", 1540], ["explain", 1546], ["the", 1554], ["lack", 1558], ["of", 1563], ["severe", 1566], ["symptoms", 1573], ["in", 1582], ["individuals", 1585], ["carrying", 1597], ["mutations", 1606], ["in", 1616], ["the", 1619], ["Prom1", 1623], ["gene", 1629], [".", 1633]]}
{"context": "Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with an incidence of one-two cases per 100,000 adults and accounts for \u223c15% of newly diagnosed cases of leukemia in adults. CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR-ABL fusion oncogene, which in turn translates into a Bcr-Abl oncoprotein. Three tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, and dasatinib, have been approved by the US Food and Drug Administration for the first-line treatment of patients with newly diagnosed CML in chronic phase (CML-CP). Clinical trials with 2nd generation TKIs reported significantly deeper and faster responses; their impact on long-term survival remains to be determined. For patients who fail standard-dose imatinib therapy, imatinib dose escalation is a second-line option. Alternative second-line options include 2nd generation TKIs. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacological profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutational status. Patients who develop the T315I \"gatekeeper\" mutation display resistance to all currently available TKIs and are candidate for clinical trials. Allogeneic transplantation remains an important therapeutic option for CML-CP harboring the T315I mutation, patients who fail 2nd generation TKIs, and for all patients in advanced phase disease.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "e71892e90a214ef1be0a9cb61da4dd09", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[217, 219], [93, 95], [105, 107], [243, 245]], "char_spans": [[1199, 1205], [536, 542], [593, 599], [1372, 1378]]}]}], "context_tokens": [["Chronic", 0], ["Myeloid", 8], ["Leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["myeloproliferative", 36], ["neoplasm", 55], ["with", 64], ["an", 69], ["incidence", 72], ["of", 82], ["one", 85], ["-", 88], ["two", 89], ["cases", 93], ["per", 99], ["100,000", 103], ["adults", 111], ["and", 118], ["accounts", 122], ["for", 131], ["\u223c15", 135], ["%", 138], ["of", 140], ["newly", 143], ["diagnosed", 149], ["cases", 159], ["of", 165], ["leukemia", 168], ["in", 177], ["adults", 180], [".", 186], ["CML", 188], ["is", 192], ["characterized", 195], ["by", 209], ["a", 212], ["balanced", 214], ["genetic", 223], ["translocation", 231], [",", 244], ["t(9;22)(q34;q11.2", 246], [")", 263], [",", 264], ["involving", 266], ["a", 276], ["fusion", 278], ["of", 285], ["the", 288], ["Abelson", 292], ["oncogene", 300], ["(", 309], ["ABL", 310], [")", 313], ["from", 315], ["chromosome", 320], ["9q34", 331], ["with", 336], ["the", 341], ["breakpoint", 345], ["cluster", 356], ["region", 364], ["(", 371], ["BCR", 372], [")", 375], ["gene", 377], ["on", 382], ["chromosome", 385], ["22q11.2", 396], [".", 403], ["This", 405], ["rearrangement", 410], ["is", 424], ["known", 427], ["as", 433], ["the", 436], ["Philadelphia", 440], ["chromosome", 453], [".", 463], ["The", 465], ["molecular", 469], ["consequence", 479], ["of", 491], ["this", 494], ["translocation", 499], ["is", 513], ["the", 516], ["generation", 520], ["of", 531], ["a", 534], ["BCR", 536], ["-", 539], ["ABL", 540], ["fusion", 544], ["oncogene", 551], [",", 559], ["which", 561], ["in", 567], ["turn", 570], ["translates", 575], ["into", 586], ["a", 591], ["Bcr", 593], ["-", 596], ["Abl", 597], ["oncoprotein", 601], [".", 612], ["Three", 614], ["tyrosine", 620], ["kinase", 629], ["inhibitors", 636], ["(", 647], ["TKIs", 648], [")", 652], [",", 653], ["imatinib", 655], [",", 663], ["nilotinib", 665], [",", 674], ["and", 676], ["dasatinib", 680], [",", 689], ["have", 691], ["been", 696], ["approved", 701], ["by", 710], ["the", 713], ["US", 717], ["Food", 720], ["and", 725], ["Drug", 729], ["Administration", 734], ["for", 749], ["the", 753], ["first", 757], ["-", 762], ["line", 763], ["treatment", 768], ["of", 778], ["patients", 781], ["with", 790], ["newly", 795], ["diagnosed", 801], ["CML", 811], ["in", 815], ["chronic", 818], ["phase", 826], ["(", 832], ["CML", 833], ["-", 836], ["CP", 837], [")", 839], [".", 840], ["Clinical", 842], ["trials", 851], ["with", 858], ["2nd", 863], ["generation", 867], ["TKIs", 878], ["reported", 883], ["significantly", 892], ["deeper", 906], ["and", 913], ["faster", 917], ["responses", 924], [";", 933], ["their", 935], ["impact", 941], ["on", 948], ["long", 951], ["-", 955], ["term", 956], ["survival", 961], ["remains", 970], ["to", 978], ["be", 981], ["determined", 984], [".", 994], ["For", 996], ["patients", 1000], ["who", 1009], ["fail", 1013], ["standard", 1018], ["-", 1026], ["dose", 1027], ["imatinib", 1032], ["therapy", 1041], [",", 1048], ["imatinib", 1050], ["dose", 1059], ["escalation", 1064], ["is", 1075], ["a", 1078], ["second", 1080], ["-", 1086], ["line", 1087], ["option", 1092], [".", 1098], ["Alternative", 1100], ["second", 1112], ["-", 1118], ["line", 1119], ["options", 1124], ["include", 1132], ["2nd", 1140], ["generation", 1144], ["TKIs", 1155], [".", 1159], ["Although", 1161], ["both", 1170], ["are", 1175], ["potent", 1179], ["and", 1186], ["specific", 1190], ["BCR", 1199], ["-", 1202], ["ABL", 1203], ["TKIs", 1207], [",", 1211], ["dasatinib", 1213], ["and", 1223], ["nilotinib", 1227], ["exhibit", 1237], ["unique", 1245], ["pharmacological", 1252], ["profiles", 1268], ["and", 1277], ["response", 1281], ["patterns", 1290], ["relative", 1299], ["to", 1308], ["different", 1311], ["patient", 1321], ["characteristics", 1329], [",", 1344], ["such", 1346], ["as", 1351], ["disease", 1354], ["stage", 1362], ["and", 1368], ["BCR", 1372], ["-", 1375], ["ABL", 1376], ["mutational", 1380], ["status", 1391], [".", 1397], ["Patients", 1399], ["who", 1408], ["develop", 1412], ["the", 1420], ["T315I", 1424], ["\"", 1430], ["gatekeeper", 1431], ["\"", 1441], ["mutation", 1443], ["display", 1452], ["resistance", 1460], ["to", 1471], ["all", 1474], ["currently", 1478], ["available", 1488], ["TKIs", 1498], ["and", 1503], ["are", 1507], ["candidate", 1511], ["for", 1521], ["clinical", 1525], ["trials", 1534], [".", 1540], ["Allogeneic", 1542], ["transplantation", 1553], ["remains", 1569], ["an", 1577], ["important", 1580], ["therapeutic", 1590], ["option", 1602], ["for", 1609], ["CML", 1613], ["-", 1616], ["CP", 1617], ["harboring", 1620], ["the", 1630], ["T315I", 1634], ["mutation", 1640], [",", 1648], ["patients", 1650], ["who", 1659], ["fail", 1663], ["2nd", 1668], ["generation", 1672], ["TKIs", 1683], [",", 1687], ["and", 1689], ["for", 1693], ["all", 1697], ["patients", 1701], ["in", 1710], ["advanced", 1713], ["phase", 1722], ["disease", 1728], [".", 1735]]}
{"context": "The serotonergic system is implicated in the pathophysiology of posttraumatic stress disorder (PTSD) and depression. The present study focused on platelet serotonin (5-HT) concentration and symptoms of comorbid depression in war veterans with or without PTSD. PTSD and depression were evaluated using Clinician Administered PTSD Scale, Davidson Trauma Scale, Montgomery-Asberg Depression Rating Scale and Hamilton Anxiety Scale. Sixty-five male drug-free war veterans (48 with PTSD and 17 without PTSD) and 65 age- and sex-matched healthy controls were studied. Comorbid depression occurred in 54 and 31% of war veterans with PTSD and without PTSD, respectively. Platelet 5-HT concentration was similar in the groups of depressed and nondepressed war veterans with or without PTSD and healthy controls. Platelet 5-HT concentration was found to differ between war veterans with various degrees of appetite loss. A positive correlation was observed between platelet 5-HT concentration and severity of appetite loss in veterans with PTSD. There was no relationship between platelet 5-HT concentration and severity of other symptoms of PTSD or depression. War veterans included in the study were outpatients. War veterans with PTSD had a high incidence of comorbid depression, that was not related to platelet 5-HT concentration. The marked relationship between platelet 5-HT concentration and severity of appetite loss, suggested that 5-HT system is involved in the regulation of appetite, at least in depressed war veterans with PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "3a4f863ee8e149ab960b2f0eccb04cdd", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[80, 80], [13, 13], [173, 173], [42, 42], [134, 134], [189, 189], [205, 205], [84, 84], [40, 40], [255, 255], [50, 50], [113, 113], [110, 110]], "char_spans": [[477, 480], [95, 98], [1030, 1033], [260, 263], [776, 779], [1132, 1135], [1223, 1226], [497, 500], [254, 257], [1527, 1530], [324, 327], [643, 646], [626, 629]]}]}], "context_tokens": [["The", 0], ["serotonergic", 4], ["system", 17], ["is", 24], ["implicated", 27], ["in", 38], ["the", 41], ["pathophysiology", 45], ["of", 61], ["posttraumatic", 64], ["stress", 78], ["disorder", 85], ["(", 94], ["PTSD", 95], [")", 99], ["and", 101], ["depression", 105], [".", 115], ["The", 117], ["present", 121], ["study", 129], ["focused", 135], ["on", 143], ["platelet", 146], ["serotonin", 155], ["(", 165], ["5-HT", 166], [")", 170], ["concentration", 172], ["and", 186], ["symptoms", 190], ["of", 199], ["comorbid", 202], ["depression", 211], ["in", 222], ["war", 225], ["veterans", 229], ["with", 238], ["or", 243], ["without", 246], ["PTSD", 254], [".", 258], ["PTSD", 260], ["and", 265], ["depression", 269], ["were", 280], ["evaluated", 285], ["using", 295], ["Clinician", 301], ["Administered", 311], ["PTSD", 324], ["Scale", 329], [",", 334], ["Davidson", 336], ["Trauma", 345], ["Scale", 352], [",", 357], ["Montgomery", 359], ["-", 369], ["Asberg", 370], ["Depression", 377], ["Rating", 388], ["Scale", 395], ["and", 401], ["Hamilton", 405], ["Anxiety", 414], ["Scale", 422], [".", 427], ["Sixty", 429], ["-", 434], ["five", 435], ["male", 440], ["drug", 445], ["-", 449], ["free", 450], ["war", 455], ["veterans", 459], ["(", 468], ["48", 469], ["with", 472], ["PTSD", 477], ["and", 482], ["17", 486], ["without", 489], ["PTSD", 497], [")", 501], ["and", 503], ["65", 507], ["age-", 510], ["and", 515], ["sex", 519], ["-", 522], ["matched", 523], ["healthy", 531], ["controls", 539], ["were", 548], ["studied", 553], [".", 560], ["Comorbid", 562], ["depression", 571], ["occurred", 582], ["in", 591], ["54", 594], ["and", 597], ["31", 601], ["%", 603], ["of", 605], ["war", 608], ["veterans", 612], ["with", 621], ["PTSD", 626], ["and", 631], ["without", 635], ["PTSD", 643], [",", 647], ["respectively", 649], [".", 661], ["Platelet", 663], ["5-HT", 672], ["concentration", 677], ["was", 691], ["similar", 695], ["in", 703], ["the", 706], ["groups", 710], ["of", 717], ["depressed", 720], ["and", 730], ["nondepressed", 734], ["war", 747], ["veterans", 751], ["with", 760], ["or", 765], ["without", 768], ["PTSD", 776], ["and", 781], ["healthy", 785], ["controls", 793], [".", 801], ["Platelet", 803], ["5-HT", 812], ["concentration", 817], ["was", 831], ["found", 835], ["to", 841], ["differ", 844], ["between", 851], ["war", 859], ["veterans", 863], ["with", 872], ["various", 877], ["degrees", 885], ["of", 893], ["appetite", 896], ["loss", 905], [".", 909], ["A", 911], ["positive", 913], ["correlation", 922], ["was", 934], ["observed", 938], ["between", 947], ["platelet", 955], ["5-HT", 964], ["concentration", 969], ["and", 983], ["severity", 987], ["of", 996], ["appetite", 999], ["loss", 1008], ["in", 1013], ["veterans", 1016], ["with", 1025], ["PTSD", 1030], [".", 1034], ["There", 1036], ["was", 1042], ["no", 1046], ["relationship", 1049], ["between", 1062], ["platelet", 1070], ["5-HT", 1079], ["concentration", 1084], ["and", 1098], ["severity", 1102], ["of", 1111], ["other", 1114], ["symptoms", 1120], ["of", 1129], ["PTSD", 1132], ["or", 1137], ["depression", 1140], [".", 1150], ["War", 1152], ["veterans", 1156], ["included", 1165], ["in", 1174], ["the", 1177], ["study", 1181], ["were", 1187], ["outpatients", 1192], [".", 1203], ["War", 1205], ["veterans", 1209], ["with", 1218], ["PTSD", 1223], ["had", 1228], ["a", 1232], ["high", 1234], ["incidence", 1239], ["of", 1249], ["comorbid", 1252], ["depression", 1261], [",", 1271], ["that", 1273], ["was", 1278], ["not", 1282], ["related", 1286], ["to", 1294], ["platelet", 1297], ["5-HT", 1306], ["concentration", 1311], [".", 1324], ["The", 1326], ["marked", 1330], ["relationship", 1337], ["between", 1350], ["platelet", 1358], ["5-HT", 1367], ["concentration", 1372], ["and", 1386], ["severity", 1390], ["of", 1399], ["appetite", 1402], ["loss", 1411], [",", 1415], ["suggested", 1417], ["that", 1427], ["5-HT", 1432], ["system", 1437], ["is", 1444], ["involved", 1447], ["in", 1456], ["the", 1459], ["regulation", 1463], ["of", 1474], ["appetite", 1477], [",", 1485], ["at", 1487], ["least", 1490], ["in", 1496], ["depressed", 1499], ["war", 1509], ["veterans", 1513], ["with", 1522], ["PTSD", 1527], [".", 1531]]}
{"context": "Previously, autosomal dominant catecholaminergic polymorphic ventricular tachycardia (CPVT [1]) was mapped to chromosome 1q42-43 with identification of pathogenic mutations in RYR2. Autosomal recessive CPVT (2) was mapped to chromosome 1p13-21, leading to the identification of mutations in CASQ2. In this study, we aimed to elucidate clinical phenotypes of a new variant of CPVT (3) in an inbred Arab family and also delineate the chromosomal location of the gene causing CPVT (3). In a highly inbred family, clinical symptoms of CPVT appeared early in childhood (7-12 years) and in three of the four cases, the first appearance of symptoms turned into a fatal outcome. Parents of the affected children were first-degree cousins and without any symptoms. Segregation analysis suggested an autosomal recessive inheritance. A genome-wide search using polymorphic DNA markers mapped the disease locus to a 25-Mb interval on chromosome 7p14-p22. A maximal multipoint LOD score of 3.17 was obtained at marker D7S493. Sequencing of putative candidate genes, SP4, NPY, FKBP9, FKBP14, PDE1C, and TBX20, in and around this locus, did not reveal any mutation. We have identified a novel highly malignant autosomal recessive form of CPVT and mapped this disorder to a 25-Mb interval on chromosome 7p14-p22.", "qas": [{"question": "What is the inheritance pattern of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) caused by RYR2 mutations?", "answers": ["autosomal dominant"], "qid": "67b5647fc6814b5d880a3bc12a5c419c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["inheritance", 12], ["pattern", 24], ["of", 32], ["Catecholaminergic", 35], ["Polymorphic", 53], ["Ventricular", 65], ["Tachycardia", 77], ["(", 89], ["CPVT", 90], [")", 94], ["caused", 96], ["by", 103], ["RYR2", 106], ["mutations", 111], ["?", 120]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[2, 3]], "char_spans": [[12, 29]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["autosomal", 12], ["dominant", 22], ["catecholaminergic", 31], ["polymorphic", 49], ["ventricular", 61], ["tachycardia", 73], ["(", 85], ["CPVT", 86], ["[", 91], ["1", 92], ["]", 93], [")", 94], ["was", 96], ["mapped", 100], ["to", 107], ["chromosome", 110], ["1q42", 121], ["-", 125], ["43", 126], ["with", 129], ["identification", 134], ["of", 149], ["pathogenic", 152], ["mutations", 163], ["in", 173], ["RYR2", 176], [".", 180], ["Autosomal", 182], ["recessive", 192], ["CPVT", 202], ["(", 207], ["2", 208], [")", 209], ["was", 211], ["mapped", 215], ["to", 222], ["chromosome", 225], ["1p13", 236], ["-", 240], ["21", 241], [",", 243], ["leading", 245], ["to", 253], ["the", 256], ["identification", 260], ["of", 275], ["mutations", 278], ["in", 288], ["CASQ2", 291], [".", 296], ["In", 298], ["this", 301], ["study", 306], [",", 311], ["we", 313], ["aimed", 316], ["to", 322], ["elucidate", 325], ["clinical", 335], ["phenotypes", 344], ["of", 355], ["a", 358], ["new", 360], ["variant", 364], ["of", 372], ["CPVT", 375], ["(", 380], ["3", 381], [")", 382], ["in", 384], ["an", 387], ["inbred", 390], ["Arab", 397], ["family", 402], ["and", 409], ["also", 413], ["delineate", 418], ["the", 428], ["chromosomal", 432], ["location", 444], ["of", 453], ["the", 456], ["gene", 460], ["causing", 465], ["CPVT", 473], ["(", 478], ["3", 479], [")", 480], [".", 481], ["In", 483], ["a", 486], ["highly", 488], ["inbred", 495], ["family", 502], [",", 508], ["clinical", 510], ["symptoms", 519], ["of", 528], ["CPVT", 531], ["appeared", 536], ["early", 545], ["in", 551], ["childhood", 554], ["(", 564], ["7", 565], ["-", 566], ["12", 567], ["years", 570], [")", 575], ["and", 577], ["in", 581], ["three", 584], ["of", 590], ["the", 593], ["four", 597], ["cases", 602], [",", 607], ["the", 609], ["first", 613], ["appearance", 619], ["of", 630], ["symptoms", 633], ["turned", 642], ["into", 649], ["a", 654], ["fatal", 656], ["outcome", 662], [".", 669], ["Parents", 671], ["of", 679], ["the", 682], ["affected", 686], ["children", 695], ["were", 704], ["first", 709], ["-", 714], ["degree", 715], ["cousins", 722], ["and", 730], ["without", 734], ["any", 742], ["symptoms", 746], [".", 754], ["Segregation", 756], ["analysis", 768], ["suggested", 777], ["an", 787], ["autosomal", 790], ["recessive", 800], ["inheritance", 810], [".", 821], ["A", 823], ["genome", 825], ["-", 831], ["wide", 832], ["search", 837], ["using", 844], ["polymorphic", 850], ["DNA", 862], ["markers", 866], ["mapped", 874], ["the", 881], ["disease", 885], ["locus", 893], ["to", 899], ["a", 902], ["25-Mb", 904], ["interval", 910], ["on", 919], ["chromosome", 922], ["7p14-p22", 933], [".", 941], ["A", 943], ["maximal", 945], ["multipoint", 953], ["LOD", 964], ["score", 968], ["of", 974], ["3.17", 977], ["was", 982], ["obtained", 986], ["at", 995], ["marker", 998], ["D7S493", 1005], [".", 1011], ["Sequencing", 1013], ["of", 1024], ["putative", 1027], ["candidate", 1036], ["genes", 1046], [",", 1051], ["SP4", 1053], [",", 1056], ["NPY", 1058], [",", 1061], ["FKBP9", 1063], [",", 1068], ["FKBP14", 1070], [",", 1076], ["PDE1C", 1078], [",", 1083], ["and", 1085], ["TBX20", 1089], [",", 1094], ["in", 1096], ["and", 1099], ["around", 1103], ["this", 1110], ["locus", 1115], [",", 1120], ["did", 1122], ["not", 1126], ["reveal", 1130], ["any", 1137], ["mutation", 1141], [".", 1149], ["We", 1151], ["have", 1154], ["identified", 1159], ["a", 1170], ["novel", 1172], ["highly", 1178], ["malignant", 1185], ["autosomal", 1195], ["recessive", 1205], ["form", 1215], ["of", 1220], ["CPVT", 1223], ["and", 1228], ["mapped", 1232], ["this", 1239], ["disorder", 1244], ["to", 1253], ["a", 1256], ["25-Mb", 1258], ["interval", 1264], ["on", 1273], ["chromosome", 1276], ["7p14-p22", 1287], [".", 1295]]}
{"context": "Defects in DNA mismatch repair have been shown to lead to increased genomic instability and mutability. We recently found that human cells defective in the DNA mismatch repair gene, hMSH2, were deficient in the transcription-coupled repair (TCR) of both oxidative DNA damage, including thymine glycols, and UV-induced DNA damage. However, in a hMLH1 mutant, only a reduction in the TCR of UV damage was observed. In this study, we examined whether TCR of thymine glycols in Saccharomyces cerecisiae also requires the genes involved in DNA mismatch repair. We found that yeast cells containing mutations in MSH2 were deficient in the removal of thymine glycols from the transcribed strand of the RPB2 gene, while cells with mutations in either MLH1 or PMS1 alone showed near normal levels of TCR of thymine glycols. Interestingly, double mutants in the MLH1 and PMS1 genes were deficient in TCR of thymine glycols. Taken together, these results suggest that these two MutL homologues can act independently of each other, but that they have overlapping roles in TCR. Overall levels of thymine glycol removal were not reduced in the mismatch repair mutants. In contrast to the results with thymine glycols, no defects in TCR of pyrimidine dimers were found in cells with mutations in MSH2, MLH1, PMS1, and MLH1/PMS1.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "e3dbeab284f84daeb820a11a28cd701d", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[123, 124]], "char_spans": [[669, 686]]}]}], "context_tokens": [["Defects", 0], ["in", 8], ["DNA", 11], ["mismatch", 15], ["repair", 24], ["have", 31], ["been", 36], ["shown", 41], ["to", 47], ["lead", 50], ["to", 55], ["increased", 58], ["genomic", 68], ["instability", 76], ["and", 88], ["mutability", 92], [".", 102], ["We", 104], ["recently", 107], ["found", 116], ["that", 122], ["human", 127], ["cells", 133], ["defective", 139], ["in", 149], ["the", 152], ["DNA", 156], ["mismatch", 160], ["repair", 169], ["gene", 176], [",", 180], ["hMSH2", 182], [",", 187], ["were", 189], ["deficient", 194], ["in", 204], ["the", 207], ["transcription", 211], ["-", 224], ["coupled", 225], ["repair", 233], ["(", 240], ["TCR", 241], [")", 244], ["of", 246], ["both", 249], ["oxidative", 254], ["DNA", 264], ["damage", 268], [",", 274], ["including", 276], ["thymine", 286], ["glycols", 294], [",", 301], ["and", 303], ["UV", 307], ["-", 309], ["induced", 310], ["DNA", 318], ["damage", 322], [".", 328], ["However", 330], [",", 337], ["in", 339], ["a", 342], ["hMLH1", 344], ["mutant", 350], [",", 356], ["only", 358], ["a", 363], ["reduction", 365], ["in", 375], ["the", 378], ["TCR", 382], ["of", 386], ["UV", 389], ["damage", 392], ["was", 399], ["observed", 403], [".", 411], ["In", 413], ["this", 416], ["study", 421], [",", 426], ["we", 428], ["examined", 431], ["whether", 440], ["TCR", 448], ["of", 452], ["thymine", 455], ["glycols", 463], ["in", 471], ["Saccharomyces", 474], ["cerecisiae", 488], ["also", 499], ["requires", 504], ["the", 513], ["genes", 517], ["involved", 523], ["in", 532], ["DNA", 535], ["mismatch", 539], ["repair", 548], [".", 554], ["We", 556], ["found", 559], ["that", 565], ["yeast", 570], ["cells", 576], ["containing", 582], ["mutations", 593], ["in", 603], ["MSH2", 606], ["were", 611], ["deficient", 616], ["in", 626], ["the", 629], ["removal", 633], ["of", 641], ["thymine", 644], ["glycols", 652], ["from", 660], ["the", 665], ["transcribed", 669], ["strand", 681], ["of", 688], ["the", 691], ["RPB2", 695], ["gene", 700], [",", 704], ["while", 706], ["cells", 712], ["with", 718], ["mutations", 723], ["in", 733], ["either", 736], ["MLH1", 743], ["or", 748], ["PMS1", 751], ["alone", 756], ["showed", 762], ["near", 769], ["normal", 774], ["levels", 781], ["of", 788], ["TCR", 791], ["of", 795], ["thymine", 798], ["glycols", 806], [".", 813], ["Interestingly", 815], [",", 828], ["double", 830], ["mutants", 837], ["in", 845], ["the", 848], ["MLH1", 852], ["and", 857], ["PMS1", 861], ["genes", 866], ["were", 872], ["deficient", 877], ["in", 887], ["TCR", 890], ["of", 894], ["thymine", 897], ["glycols", 905], [".", 912], ["Taken", 914], ["together", 920], [",", 928], ["these", 930], ["results", 936], ["suggest", 944], ["that", 952], ["these", 957], ["two", 963], ["MutL", 967], ["homologues", 972], ["can", 983], ["act", 987], ["independently", 991], ["of", 1005], ["each", 1008], ["other", 1013], [",", 1018], ["but", 1020], ["that", 1024], ["they", 1029], ["have", 1034], ["overlapping", 1039], ["roles", 1051], ["in", 1057], ["TCR", 1060], [".", 1063], ["Overall", 1065], ["levels", 1073], ["of", 1080], ["thymine", 1083], ["glycol", 1091], ["removal", 1098], ["were", 1106], ["not", 1111], ["reduced", 1115], ["in", 1123], ["the", 1126], ["mismatch", 1130], ["repair", 1139], ["mutants", 1146], [".", 1153], ["In", 1155], ["contrast", 1158], ["to", 1167], ["the", 1170], ["results", 1174], ["with", 1182], ["thymine", 1187], ["glycols", 1195], [",", 1202], ["no", 1204], ["defects", 1207], ["in", 1215], ["TCR", 1218], ["of", 1222], ["pyrimidine", 1225], ["dimers", 1236], ["were", 1243], ["found", 1248], ["in", 1254], ["cells", 1257], ["with", 1263], ["mutations", 1268], ["in", 1278], ["MSH2", 1281], [",", 1285], ["MLH1", 1287], [",", 1291], ["PMS1", 1293], [",", 1297], ["and", 1299], ["MLH1/PMS1", 1303], [".", 1312]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "56f2ae49145640039f519cc53fd849b2", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "Epidermal growth factor receptor (EGFR) gene mutations have been found in a subset of non-small cell lung cancer (NSCLC) with good clinical response to gefitinib therapy. A quick and sensitive method with large throughput is required to utilize the information to determine whether the molecular targeted therapy should be applied for the particular NSCLC patients. Using probes for the 13 different mutations including 11 that have already been reported, we have genotyped the EGFR mutation status in 94 NSCLC patients using the TaqMan PCR assay. We have also genotyped the EGFR mutations status in additional 182 NSCLC patients, as well as 63 gastric, 95 esophagus and 70 colon carcinoma patients. In 94 NSCLC samples, the result of the TaqMan PCR assay perfectly matched with that of the sequencing excluding one patient. In one sample in which no EGFR mutation was detected by direct sequencing, the TaqMan PCR assay detected a mutation. This patient was a gefitinib responder. In a serial dilution study, the assay could detect a mutant sample diluted in 1/10 with a wild-type sample. Of 182 NSCLC samples, 46 mutations were detected. EGFR mutation was significantly correlated with gender, smoking status, pathological subtypes, and differentiation of lung cancers. There was no mutation detected by the TaqMan PCR assay in gastric, esophagus and colon carcinomas. TaqMan PCR assay is a rapid and sensitive method of detection of EGFR mutations with high throughput, and may be useful to determine whether gefitinib should be offered for the treatment of NSCLC patients. The TaqMan PCR assay can offer us a complementary and confirmative test.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "db82e6a831de4a5e9ce53368a088128a", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[0, 7]], "char_spans": [[0, 43]]}]}], "context_tokens": [["Epidermal", 0], ["growth", 10], ["factor", 17], ["receptor", 24], ["(", 33], ["EGFR", 34], [")", 38], ["gene", 40], ["mutations", 45], ["have", 55], ["been", 60], ["found", 65], ["in", 71], ["a", 74], ["subset", 76], ["of", 83], ["non", 86], ["-", 89], ["small", 90], ["cell", 96], ["lung", 101], ["cancer", 106], ["(", 113], ["NSCLC", 114], [")", 119], ["with", 121], ["good", 126], ["clinical", 131], ["response", 140], ["to", 149], ["gefitinib", 152], ["therapy", 162], [".", 169], ["A", 171], ["quick", 173], ["and", 179], ["sensitive", 183], ["method", 193], ["with", 200], ["large", 205], ["throughput", 211], ["is", 222], ["required", 225], ["to", 234], ["utilize", 237], ["the", 245], ["information", 249], ["to", 261], ["determine", 264], ["whether", 274], ["the", 282], ["molecular", 286], ["targeted", 296], ["therapy", 305], ["should", 313], ["be", 320], ["applied", 323], ["for", 331], ["the", 335], ["particular", 339], ["NSCLC", 350], ["patients", 356], [".", 364], ["Using", 366], ["probes", 372], ["for", 379], ["the", 383], ["13", 387], ["different", 390], ["mutations", 400], ["including", 410], ["11", 420], ["that", 423], ["have", 428], ["already", 433], ["been", 441], ["reported", 446], [",", 454], ["we", 456], ["have", 459], ["genotyped", 464], ["the", 474], ["EGFR", 478], ["mutation", 483], ["status", 492], ["in", 499], ["94", 502], ["NSCLC", 505], ["patients", 511], ["using", 520], ["the", 526], ["TaqMan", 530], ["PCR", 537], ["assay", 541], [".", 546], ["We", 548], ["have", 551], ["also", 556], ["genotyped", 561], ["the", 571], ["EGFR", 575], ["mutations", 580], ["status", 590], ["in", 597], ["additional", 600], ["182", 611], ["NSCLC", 615], ["patients", 621], [",", 629], ["as", 631], ["well", 634], ["as", 639], ["63", 642], ["gastric", 645], [",", 652], ["95", 654], ["esophagus", 657], ["and", 667], ["70", 671], ["colon", 674], ["carcinoma", 680], ["patients", 690], [".", 698], ["In", 700], ["94", 703], ["NSCLC", 706], ["samples", 712], [",", 719], ["the", 721], ["result", 725], ["of", 732], ["the", 735], ["TaqMan", 739], ["PCR", 746], ["assay", 750], ["perfectly", 756], ["matched", 766], ["with", 774], ["that", 779], ["of", 784], ["the", 787], ["sequencing", 791], ["excluding", 802], ["one", 812], ["patient", 816], [".", 823], ["In", 825], ["one", 828], ["sample", 832], ["in", 839], ["which", 842], ["no", 848], ["EGFR", 851], ["mutation", 856], ["was", 865], ["detected", 869], ["by", 878], ["direct", 881], ["sequencing", 888], [",", 898], ["the", 900], ["TaqMan", 904], ["PCR", 911], ["assay", 915], ["detected", 921], ["a", 930], ["mutation", 932], [".", 940], ["This", 942], ["patient", 947], ["was", 955], ["a", 959], ["gefitinib", 961], ["responder", 971], [".", 980], ["In", 982], ["a", 985], ["serial", 987], ["dilution", 994], ["study", 1003], [",", 1008], ["the", 1010], ["assay", 1014], ["could", 1020], ["detect", 1026], ["a", 1033], ["mutant", 1035], ["sample", 1042], ["diluted", 1049], ["in", 1057], ["1/10", 1060], ["with", 1065], ["a", 1070], ["wild", 1072], ["-", 1076], ["type", 1077], ["sample", 1082], [".", 1088], ["Of", 1090], ["182", 1093], ["NSCLC", 1097], ["samples", 1103], [",", 1110], ["46", 1112], ["mutations", 1115], ["were", 1125], ["detected", 1130], [".", 1138], ["EGFR", 1140], ["mutation", 1145], ["was", 1154], ["significantly", 1158], ["correlated", 1172], ["with", 1183], ["gender", 1188], [",", 1194], ["smoking", 1196], ["status", 1204], [",", 1210], ["pathological", 1212], ["subtypes", 1225], [",", 1233], ["and", 1235], ["differentiation", 1239], ["of", 1255], ["lung", 1258], ["cancers", 1263], [".", 1270], ["There", 1272], ["was", 1278], ["no", 1282], ["mutation", 1285], ["detected", 1294], ["by", 1303], ["the", 1306], ["TaqMan", 1310], ["PCR", 1317], ["assay", 1321], ["in", 1327], ["gastric", 1330], [",", 1337], ["esophagus", 1339], ["and", 1349], ["colon", 1353], ["carcinomas", 1359], [".", 1369], ["TaqMan", 1371], ["PCR", 1378], ["assay", 1382], ["is", 1388], ["a", 1391], ["rapid", 1393], ["and", 1399], ["sensitive", 1403], ["method", 1413], ["of", 1420], ["detection", 1423], ["of", 1433], ["EGFR", 1436], ["mutations", 1441], ["with", 1451], ["high", 1456], ["throughput", 1461], [",", 1471], ["and", 1473], ["may", 1477], ["be", 1481], ["useful", 1484], ["to", 1491], ["determine", 1494], ["whether", 1504], ["gefitinib", 1512], ["should", 1522], ["be", 1529], ["offered", 1532], ["for", 1540], ["the", 1544], ["treatment", 1548], ["of", 1558], ["NSCLC", 1561], ["patients", 1567], [".", 1575], ["The", 1577], ["TaqMan", 1581], ["PCR", 1588], ["assay", 1592], ["can", 1598], ["offer", 1602], ["us", 1608], ["a", 1611], ["complementary", 1613], ["and", 1627], ["confirmative", 1631], ["test", 1644], [".", 1648]]}
{"context": "de Quervain's disease is an inadequacy into the first extensor compartment of wrist between the osteofibrous tunnel and the tendons. This mechanical conflict generates a tenosynovitis of the extensor pollicis brevis and the abductor pollicis longus tendons in first dorsal extensor compartment of the wrist. (1) To compare the clinical results obtained by longitudinal and transverse incisions and (2) the implication of clinical results in Indian population. This study was conducted at Kalpana Chawla Government Medical College, Karnal, Haryana. The inclusion criteria were positive Finkelstein's test and no response to non-surgical treatment for 6 weeks. Forty-eight patients with de Quervain's disease who did not respond to conservative treatment were operated with two different incisions. The patients were followed at 6 weeks, 3 and 6 months to compare the surgical outcomes. During a three-month follow-up, a significant difference was shown between the two methods (p = 0.0001). Results of surgical treatment with longitudinal incision were better (only one hypertrophic scar), but there were 12 postoperative complications with transverse incision. Visual analog scale (VAS) was used to evaluate the hypertrophic scar. In transverse incision group, out of five patients, four patients who developed hypertrophic scar have poor score according to VAS. Overall, longitudinal incision should be used for surgical treatment for de Quervain's disease due to lower risk of complications.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "ec3c96601d8840c58a8302933740c8a2", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[0, 3], [249, 252], [115, 118]], "char_spans": [[0, 20], [1436, 1456], [685, 705]]}]}], "context_tokens": [["de", 0], ["Quervain", 3], ["'s", 11], ["disease", 14], ["is", 22], ["an", 25], ["inadequacy", 28], ["into", 39], ["the", 44], ["first", 48], ["extensor", 54], ["compartment", 63], ["of", 75], ["wrist", 78], ["between", 84], ["the", 92], ["osteofibrous", 96], ["tunnel", 109], ["and", 116], ["the", 120], ["tendons", 124], [".", 131], ["This", 133], ["mechanical", 138], ["conflict", 149], ["generates", 158], ["a", 168], ["tenosynovitis", 170], ["of", 184], ["the", 187], ["extensor", 191], ["pollicis", 200], ["brevis", 209], ["and", 216], ["the", 220], ["abductor", 224], ["pollicis", 233], ["longus", 242], ["tendons", 249], ["in", 257], ["first", 260], ["dorsal", 266], ["extensor", 273], ["compartment", 282], ["of", 294], ["the", 297], ["wrist", 301], [".", 306], ["(", 308], ["1", 309], [")", 310], ["To", 312], ["compare", 315], ["the", 323], ["clinical", 327], ["results", 336], ["obtained", 344], ["by", 353], ["longitudinal", 356], ["and", 369], ["transverse", 373], ["incisions", 384], ["and", 394], ["(", 398], ["2", 399], [")", 400], ["the", 402], ["implication", 406], ["of", 418], ["clinical", 421], ["results", 430], ["in", 438], ["Indian", 441], ["population", 448], [".", 458], ["This", 460], ["study", 465], ["was", 471], ["conducted", 475], ["at", 485], ["Kalpana", 488], ["Chawla", 496], ["Government", 503], ["Medical", 514], ["College", 522], [",", 529], ["Karnal", 531], [",", 537], ["Haryana", 539], [".", 546], ["The", 548], ["inclusion", 552], ["criteria", 562], ["were", 571], ["positive", 576], ["Finkelstein", 585], ["'s", 596], ["test", 599], ["and", 604], ["no", 608], ["response", 611], ["to", 620], ["non", 623], ["-", 626], ["surgical", 627], ["treatment", 636], ["for", 646], ["6", 650], ["weeks", 652], [".", 657], ["Forty", 659], ["-", 664], ["eight", 665], ["patients", 671], ["with", 680], ["de", 685], ["Quervain", 688], ["'s", 696], ["disease", 699], ["who", 707], ["did", 711], ["not", 715], ["respond", 719], ["to", 727], ["conservative", 730], ["treatment", 743], ["were", 753], ["operated", 758], ["with", 767], ["two", 772], ["different", 776], ["incisions", 786], [".", 795], ["The", 797], ["patients", 801], ["were", 810], ["followed", 815], ["at", 824], ["6", 827], ["weeks", 829], [",", 834], ["3", 836], ["and", 838], ["6", 842], ["months", 844], ["to", 851], ["compare", 854], ["the", 862], ["surgical", 866], ["outcomes", 875], [".", 883], ["During", 885], ["a", 892], ["three", 894], ["-", 899], ["month", 900], ["follow", 906], ["-", 912], ["up", 913], [",", 915], ["a", 917], ["significant", 919], ["difference", 931], ["was", 942], ["shown", 946], ["between", 952], ["the", 960], ["two", 964], ["methods", 968], ["(", 976], ["p", 977], ["=", 979], ["0.0001", 981], [")", 987], [".", 988], ["Results", 990], ["of", 998], ["surgical", 1001], ["treatment", 1010], ["with", 1020], ["longitudinal", 1025], ["incision", 1038], ["were", 1047], ["better", 1052], ["(", 1059], ["only", 1060], ["one", 1065], ["hypertrophic", 1069], ["scar", 1082], [")", 1086], [",", 1087], ["but", 1089], ["there", 1093], ["were", 1099], ["12", 1104], ["postoperative", 1107], ["complications", 1121], ["with", 1135], ["transverse", 1140], ["incision", 1151], [".", 1159], ["Visual", 1161], ["analog", 1168], ["scale", 1175], ["(", 1181], ["VAS", 1182], [")", 1185], ["was", 1187], ["used", 1191], ["to", 1196], ["evaluate", 1199], ["the", 1208], ["hypertrophic", 1212], ["scar", 1225], [".", 1229], ["In", 1231], ["transverse", 1234], ["incision", 1245], ["group", 1254], [",", 1259], ["out", 1261], ["of", 1265], ["five", 1268], ["patients", 1273], [",", 1281], ["four", 1283], ["patients", 1288], ["who", 1297], ["developed", 1301], ["hypertrophic", 1311], ["scar", 1324], ["have", 1329], ["poor", 1334], ["score", 1339], ["according", 1345], ["to", 1355], ["VAS", 1358], [".", 1361], ["Overall", 1363], [",", 1370], ["longitudinal", 1372], ["incision", 1385], ["should", 1394], ["be", 1401], ["used", 1404], ["for", 1409], ["surgical", 1413], ["treatment", 1422], ["for", 1432], ["de", 1436], ["Quervain", 1439], ["'s", 1447], ["disease", 1450], ["due", 1458], ["to", 1462], ["lower", 1465], ["risk", 1471], ["of", 1476], ["complications", 1479], [".", 1492]]}
{"context": "In 2005, a distinct clone of methicillin resistant Staphylococcus aureus (MRSA CC398) was found in pigs and people in contact with pigs. The structure of the pig production chain in high technology pig husbandry enables pathogens to spread during animal trading, with an increasing prevalence in herds further down the chain. The objective of this study was to quantify the effect of the MRSA status of the supplying herd on the MRSA status of the receiving herd in order to gain more insight into the role of animal trading as a transmission route for MRSA CC398. Nasal samples (60-80 pigs per herd) were collected from 38 herds; in 20 herds, environmental samples were collected as well. Ten MRSA-positive herds (based on the results of nasal swabs of 10 individual pigs per herd) from a prior study were included in the data analysis. Herds were classified as MRSA positive if at least one sample tested positive. The 48 herds were part of 14 complete (40 herds) and 4 incomplete (8 herds) pig production chains. Fifty-six percent of the herds were classified as MRSA positive. MRSA-positive herds were observed at the start (breeding herds), middle (farrowing herds) and the end (finishing herds) of the pig production chain. All of the herds in 8 chains tested MRSA positive;, all of the herds in 5 chains tested MRSA negative and in the remaining 5 chains, MRSA-positive and MRSA-negative herds were detected. Seven spa types were found, which were all previously confirmed to belong to CC398. All of the isolates were susceptible to mupirocin, linezolid, rifampicin, fusidic acid and cotrimoxazole. Resistance against tetracycline, erythromycin and clindamycin was found in 100, 74 and 76% of the isolates, respectively. Seventy-nine percent of herds with a MRSA-positive supplier of pigs were MRSA positive, whereas 23% of herds with a MRSA-negative supplier were MRSA positive (OR=10.8; 95% CI: 1.5-110.1; P=0.011). The presence of entirely MRSA-positive and MRSA-negative chains and the strong association between the MRSA status of herds and their suppliers illustrates a large risk associated with purchasing pigs from MRSA-positive herds; a top-down strategy for future control programs is, therefore, a basic requirement. However, 23% of herds with a MRSA-negative supplier were MRSA positive and furthermore, 46% of the herds at the top of the pig production chain without a supplier tested MRSA positive. This underlined the need for the identification of additional risk factors for MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "f4ea9fa4a4b04d9bb9a697ce1418abdb", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[208, 208], [272, 272], [403, 403], [77, 77], [211, 211], [454, 454], [491, 491], [12, 12], [276, 276], [263, 263], [364, 364], [69, 69], [131, 131], [251, 251], [389, 389], [369, 369], [449, 449], [165, 165], [347, 347], [419, 419], [100, 100], [476, 476], [393, 393], [354, 354]], "char_spans": [[1066, 1069], [1363, 1366], [2028, 2031], [429, 432], [1081, 1084], [2293, 2296], [2500, 2503], [74, 77], [1381, 1384], [1318, 1321], [1844, 1847], [388, 391], [694, 697], [1266, 1269], [1950, 1953], [1872, 1875], [2265, 2268], [863, 866], [1765, 1768], [2131, 2134], [553, 556], [2406, 2409], [1968, 1971], [1801, 1804]]}]}], "context_tokens": [["In", 0], ["2005", 3], [",", 7], ["a", 9], ["distinct", 11], ["clone", 20], ["of", 26], ["methicillin", 29], ["resistant", 41], ["Staphylococcus", 51], ["aureus", 66], ["(", 73], ["MRSA", 74], ["CC398", 79], [")", 84], ["was", 86], ["found", 90], ["in", 96], ["pigs", 99], ["and", 104], ["people", 108], ["in", 115], ["contact", 118], ["with", 126], ["pigs", 131], [".", 135], ["The", 137], ["structure", 141], ["of", 151], ["the", 154], ["pig", 158], ["production", 162], ["chain", 173], ["in", 179], ["high", 182], ["technology", 187], ["pig", 198], ["husbandry", 202], ["enables", 212], ["pathogens", 220], ["to", 230], ["spread", 233], ["during", 240], ["animal", 247], ["trading", 254], [",", 261], ["with", 263], ["an", 268], ["increasing", 271], ["prevalence", 282], ["in", 293], ["herds", 296], ["further", 302], ["down", 310], ["the", 315], ["chain", 319], [".", 324], ["The", 326], ["objective", 330], ["of", 340], ["this", 343], ["study", 348], ["was", 354], ["to", 358], ["quantify", 361], ["the", 370], ["effect", 374], ["of", 381], ["the", 384], ["MRSA", 388], ["status", 393], ["of", 400], ["the", 403], ["supplying", 407], ["herd", 417], ["on", 422], ["the", 425], ["MRSA", 429], ["status", 434], ["of", 441], ["the", 444], ["receiving", 448], ["herd", 458], ["in", 463], ["order", 466], ["to", 472], ["gain", 475], ["more", 480], ["insight", 485], ["into", 493], ["the", 498], ["role", 502], ["of", 507], ["animal", 510], ["trading", 517], ["as", 525], ["a", 528], ["transmission", 530], ["route", 543], ["for", 549], ["MRSA", 553], ["CC398", 558], [".", 563], ["Nasal", 565], ["samples", 571], ["(", 579], ["60", 580], ["-", 582], ["80", 583], ["pigs", 586], ["per", 591], ["herd", 595], [")", 599], ["were", 601], ["collected", 606], ["from", 616], ["38", 621], ["herds", 624], [";", 629], ["in", 631], ["20", 634], ["herds", 637], [",", 642], ["environmental", 644], ["samples", 658], ["were", 666], ["collected", 671], ["as", 681], ["well", 684], [".", 688], ["Ten", 690], ["MRSA", 694], ["-", 698], ["positive", 699], ["herds", 708], ["(", 714], ["based", 715], ["on", 721], ["the", 724], ["results", 728], ["of", 736], ["nasal", 739], ["swabs", 745], ["of", 751], ["10", 754], ["individual", 757], ["pigs", 768], ["per", 773], ["herd", 777], [")", 781], ["from", 783], ["a", 788], ["prior", 790], ["study", 796], ["were", 802], ["included", 807], ["in", 816], ["the", 819], ["data", 823], ["analysis", 828], [".", 836], ["Herds", 838], ["were", 844], ["classified", 849], ["as", 860], ["MRSA", 863], ["positive", 868], ["if", 877], ["at", 880], ["least", 883], ["one", 889], ["sample", 893], ["tested", 900], ["positive", 907], [".", 915], ["The", 917], ["48", 921], ["herds", 924], ["were", 930], ["part", 935], ["of", 940], ["14", 943], ["complete", 946], ["(", 955], ["40", 956], ["herds", 959], [")", 964], ["and", 966], ["4", 970], ["incomplete", 972], ["(", 983], ["8", 984], ["herds", 986], [")", 991], ["pig", 993], ["production", 997], ["chains", 1008], [".", 1014], ["Fifty", 1016], ["-", 1021], ["six", 1022], ["percent", 1026], ["of", 1034], ["the", 1037], ["herds", 1041], ["were", 1047], ["classified", 1052], ["as", 1063], ["MRSA", 1066], ["positive", 1071], [".", 1079], ["MRSA", 1081], ["-", 1085], ["positive", 1086], ["herds", 1095], ["were", 1101], ["observed", 1106], ["at", 1115], ["the", 1118], ["start", 1122], ["(", 1128], ["breeding", 1129], ["herds", 1138], [")", 1143], [",", 1144], ["middle", 1146], ["(", 1153], ["farrowing", 1154], ["herds", 1164], [")", 1169], ["and", 1171], ["the", 1175], ["end", 1179], ["(", 1183], ["finishing", 1184], ["herds", 1194], [")", 1199], ["of", 1201], ["the", 1204], ["pig", 1208], ["production", 1212], ["chain", 1223], [".", 1228], ["All", 1230], ["of", 1234], ["the", 1237], ["herds", 1241], ["in", 1247], ["8", 1250], ["chains", 1252], ["tested", 1259], ["MRSA", 1266], ["positive", 1271], [";", 1279], [",", 1280], ["all", 1282], ["of", 1286], ["the", 1289], ["herds", 1293], ["in", 1299], ["5", 1302], ["chains", 1304], ["tested", 1311], ["MRSA", 1318], ["negative", 1323], ["and", 1332], ["in", 1336], ["the", 1339], ["remaining", 1343], ["5", 1353], ["chains", 1355], [",", 1361], ["MRSA", 1363], ["-", 1367], ["positive", 1368], ["and", 1377], ["MRSA", 1381], ["-", 1385], ["negative", 1386], ["herds", 1395], ["were", 1401], ["detected", 1406], [".", 1414], ["Seven", 1416], ["spa", 1422], ["types", 1426], ["were", 1432], ["found", 1437], [",", 1442], ["which", 1444], ["were", 1450], ["all", 1455], ["previously", 1459], ["confirmed", 1470], ["to", 1480], ["belong", 1483], ["to", 1490], ["CC398", 1493], [".", 1498], ["All", 1500], ["of", 1504], ["the", 1507], ["isolates", 1511], ["were", 1520], ["susceptible", 1525], ["to", 1537], ["mupirocin", 1540], [",", 1549], ["linezolid", 1551], [",", 1560], ["rifampicin", 1562], [",", 1572], ["fusidic", 1574], ["acid", 1582], ["and", 1587], ["cotrimoxazole", 1591], [".", 1604], ["Resistance", 1606], ["against", 1617], ["tetracycline", 1625], [",", 1637], ["erythromycin", 1639], ["and", 1652], ["clindamycin", 1656], ["was", 1668], ["found", 1672], ["in", 1678], ["100", 1681], [",", 1684], ["74", 1686], ["and", 1689], ["76", 1693], ["%", 1695], ["of", 1697], ["the", 1700], ["isolates", 1704], [",", 1712], ["respectively", 1714], [".", 1726], ["Seventy", 1728], ["-", 1735], ["nine", 1736], ["percent", 1741], ["of", 1749], ["herds", 1752], ["with", 1758], ["a", 1763], ["MRSA", 1765], ["-", 1769], ["positive", 1770], ["supplier", 1779], ["of", 1788], ["pigs", 1791], ["were", 1796], ["MRSA", 1801], ["positive", 1806], [",", 1814], ["whereas", 1816], ["23", 1824], ["%", 1826], ["of", 1828], ["herds", 1831], ["with", 1837], ["a", 1842], ["MRSA", 1844], ["-", 1848], ["negative", 1849], ["supplier", 1858], ["were", 1867], ["MRSA", 1872], ["positive", 1877], ["(", 1886], ["OR=10.8", 1887], [";", 1894], ["95", 1896], ["%", 1898], ["CI", 1900], [":", 1902], ["1.5", 1904], ["-", 1907], ["110.1", 1908], [";", 1913], ["P=0.011", 1915], [")", 1922], [".", 1923], ["The", 1925], ["presence", 1929], ["of", 1938], ["entirely", 1941], ["MRSA", 1950], ["-", 1954], ["positive", 1955], ["and", 1964], ["MRSA", 1968], ["-", 1972], ["negative", 1973], ["chains", 1982], ["and", 1989], ["the", 1993], ["strong", 1997], ["association", 2004], ["between", 2016], ["the", 2024], ["MRSA", 2028], ["status", 2033], ["of", 2040], ["herds", 2043], ["and", 2049], ["their", 2053], ["suppliers", 2059], ["illustrates", 2069], ["a", 2081], ["large", 2083], ["risk", 2089], ["associated", 2094], ["with", 2105], ["purchasing", 2110], ["pigs", 2121], ["from", 2126], ["MRSA", 2131], ["-", 2135], ["positive", 2136], ["herds", 2145], [";", 2150], ["a", 2152], ["top", 2154], ["-", 2157], ["down", 2158], ["strategy", 2163], ["for", 2172], ["future", 2176], ["control", 2183], ["programs", 2191], ["is", 2200], [",", 2202], ["therefore", 2204], [",", 2213], ["a", 2215], ["basic", 2217], ["requirement", 2223], [".", 2234], ["However", 2236], [",", 2243], ["23", 2245], ["%", 2247], ["of", 2249], ["herds", 2252], ["with", 2258], ["a", 2263], ["MRSA", 2265], ["-", 2269], ["negative", 2270], ["supplier", 2279], ["were", 2288], ["MRSA", 2293], ["positive", 2298], ["and", 2307], ["furthermore", 2311], [",", 2322], ["46", 2324], ["%", 2326], ["of", 2328], ["the", 2331], ["herds", 2335], ["at", 2341], ["the", 2344], ["top", 2348], ["of", 2352], ["the", 2355], ["pig", 2359], ["production", 2363], ["chain", 2374], ["without", 2380], ["a", 2388], ["supplier", 2390], ["tested", 2399], ["MRSA", 2406], ["positive", 2411], [".", 2419], ["This", 2421], ["underlined", 2426], ["the", 2437], ["need", 2441], ["for", 2446], ["the", 2450], ["identification", 2454], ["of", 2469], ["additional", 2472], ["risk", 2483], ["factors", 2488], ["for", 2496], ["MRSA", 2500], [".", 2504]]}
{"context": "Ataxin-3 (AT3) is the protein that triggers the inherited neurodegenerative disorder spinocerebellar ataxia type 3 when its polyglutamine (polyQ) stretch close to the C-terminus exceeds a critical length. AT3 consists of the N-terminal globular Josephin domain (JD) and the C-terminal disordered one. It cleaves isopeptide bonds between ubiquitin monomers, an event involved in protein quality control mechanisms. AT3 has been implicated in the pathway that sorts aggregated protein to aggresomes via microtubules, in which dynein and histone deacetylase 6 (HDAC6) also seem to be involved. By taking advantage of small angle X-ray scattering (SAXS) and surface plasmon resonance (SPR), we have investigated the interaction of AT3 with tubulin and HDAC6. Based on SAXS results, the AT3 oligomer, consisting of 6-7 subunits, tightly binds to the tubulin hexameric oligomer in a \"parallel\" fashion. By SPR analysis we have demonstrated that AT3 binds to tubulin dimer with a 50nM affinity. Binding fits with a Langmuir 1:1 model and involves a single binding interface. Nevertheless, the interaction surface consists of three distinct, discontinuous tubulin-binding regions (TBR), one located in the JD, and the two others in the disordered domain, upstream and downstream of the polyQ stretch. In the absence of any of the three TBRs, the affinity is drastically reduced. By SPR we have also provided the first evidence of direct binding of AT3 to HDAC6, with affinity in the range 0.1-1\u03bcM. These results shed light on the interactions among the components of the transport machinery that sorts aggregate protein to the aggresome, and pave the way to in vivo studies aimed at further clarifying their roles.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "ff352f0d6455402e93166f8e35e032b3", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0]], "char_spans": [[0, 7]]}]}], "context_tokens": [["Ataxin-3", 0], ["(", 9], ["AT3", 10], [")", 13], ["is", 15], ["the", 18], ["protein", 22], ["that", 30], ["triggers", 35], ["the", 44], ["inherited", 48], ["neurodegenerative", 58], ["disorder", 76], ["spinocerebellar", 85], ["ataxia", 101], ["type", 108], ["3", 113], ["when", 115], ["its", 120], ["polyglutamine", 124], ["(", 138], ["polyQ", 139], [")", 144], ["stretch", 146], ["close", 154], ["to", 160], ["the", 163], ["C", 167], ["-", 168], ["terminus", 169], ["exceeds", 178], ["a", 186], ["critical", 188], ["length", 197], [".", 203], ["AT3", 205], ["consists", 209], ["of", 218], ["the", 221], ["N", 225], ["-", 226], ["terminal", 227], ["globular", 236], ["Josephin", 245], ["domain", 254], ["(", 261], ["JD", 262], [")", 264], ["and", 266], ["the", 270], ["C", 274], ["-", 275], ["terminal", 276], ["disordered", 285], ["one", 296], [".", 299], ["It", 301], ["cleaves", 304], ["isopeptide", 312], ["bonds", 323], ["between", 329], ["ubiquitin", 337], ["monomers", 347], [",", 355], ["an", 357], ["event", 360], ["involved", 366], ["in", 375], ["protein", 378], ["quality", 386], ["control", 394], ["mechanisms", 402], [".", 412], ["AT3", 414], ["has", 418], ["been", 422], ["implicated", 427], ["in", 438], ["the", 441], ["pathway", 445], ["that", 453], ["sorts", 458], ["aggregated", 464], ["protein", 475], ["to", 483], ["aggresomes", 486], ["via", 497], ["microtubules", 501], [",", 513], ["in", 515], ["which", 518], ["dynein", 524], ["and", 531], ["histone", 535], ["deacetylase", 543], ["6", 555], ["(", 557], ["HDAC6", 558], [")", 563], ["also", 565], ["seem", 570], ["to", 575], ["be", 578], ["involved", 581], [".", 589], ["By", 591], ["taking", 594], ["advantage", 601], ["of", 611], ["small", 614], ["angle", 620], ["X", 626], ["-", 627], ["ray", 628], ["scattering", 632], ["(", 643], ["SAXS", 644], [")", 648], ["and", 650], ["surface", 654], ["plasmon", 662], ["resonance", 670], ["(", 680], ["SPR", 681], [")", 684], [",", 685], ["we", 687], ["have", 690], ["investigated", 695], ["the", 708], ["interaction", 712], ["of", 724], ["AT3", 727], ["with", 731], ["tubulin", 736], ["and", 744], ["HDAC6", 748], [".", 753], ["Based", 755], ["on", 761], ["SAXS", 764], ["results", 769], [",", 776], ["the", 778], ["AT3", 782], ["oligomer", 786], [",", 794], ["consisting", 796], ["of", 807], ["6", 810], ["-", 811], ["7", 812], ["subunits", 814], [",", 822], ["tightly", 824], ["binds", 832], ["to", 838], ["the", 841], ["tubulin", 845], ["hexameric", 853], ["oligomer", 863], ["in", 872], ["a", 875], ["\"", 877], ["parallel", 878], ["\"", 886], ["fashion", 888], [".", 895], ["By", 897], ["SPR", 900], ["analysis", 904], ["we", 913], ["have", 916], ["demonstrated", 921], ["that", 934], ["AT3", 939], ["binds", 943], ["to", 949], ["tubulin", 952], ["dimer", 960], ["with", 966], ["a", 971], ["50nM", 973], ["affinity", 978], [".", 986], ["Binding", 988], ["fits", 996], ["with", 1001], ["a", 1006], ["Langmuir", 1008], ["1:1", 1017], ["model", 1021], ["and", 1027], ["involves", 1031], ["a", 1040], ["single", 1042], ["binding", 1049], ["interface", 1057], [".", 1066], ["Nevertheless", 1068], [",", 1080], ["the", 1082], ["interaction", 1086], ["surface", 1098], ["consists", 1106], ["of", 1115], ["three", 1118], ["distinct", 1124], [",", 1132], ["discontinuous", 1134], ["tubulin", 1148], ["-", 1155], ["binding", 1156], ["regions", 1164], ["(", 1172], ["TBR", 1173], [")", 1176], [",", 1177], ["one", 1179], ["located", 1183], ["in", 1191], ["the", 1194], ["JD", 1198], [",", 1200], ["and", 1202], ["the", 1206], ["two", 1210], ["others", 1214], ["in", 1221], ["the", 1224], ["disordered", 1228], ["domain", 1239], [",", 1245], ["upstream", 1247], ["and", 1256], ["downstream", 1260], ["of", 1271], ["the", 1274], ["polyQ", 1278], ["stretch", 1284], [".", 1291], ["In", 1293], ["the", 1296], ["absence", 1300], ["of", 1308], ["any", 1311], ["of", 1315], ["the", 1318], ["three", 1322], ["TBRs", 1328], [",", 1332], ["the", 1334], ["affinity", 1338], ["is", 1347], ["drastically", 1350], ["reduced", 1362], [".", 1369], ["By", 1371], ["SPR", 1374], ["we", 1378], ["have", 1381], ["also", 1386], ["provided", 1391], ["the", 1400], ["first", 1404], ["evidence", 1410], ["of", 1419], ["direct", 1422], ["binding", 1429], ["of", 1437], ["AT3", 1440], ["to", 1444], ["HDAC6", 1447], [",", 1452], ["with", 1454], ["affinity", 1459], ["in", 1468], ["the", 1471], ["range", 1475], ["0.1", 1481], ["-", 1484], ["1\u03bcM.", 1485], ["These", 1490], ["results", 1496], ["shed", 1504], ["light", 1509], ["on", 1515], ["the", 1518], ["interactions", 1522], ["among", 1535], ["the", 1541], ["components", 1545], ["of", 1556], ["the", 1559], ["transport", 1563], ["machinery", 1573], ["that", 1583], ["sorts", 1588], ["aggregate", 1594], ["protein", 1604], ["to", 1612], ["the", 1615], ["aggresome", 1619], [",", 1628], ["and", 1630], ["pave", 1634], ["the", 1639], ["way", 1643], ["to", 1647], ["in", 1650], ["vivo", 1653], ["studies", 1658], ["aimed", 1666], ["at", 1672], ["further", 1675], ["clarifying", 1683], ["their", 1694], ["roles", 1700], [".", 1705]]}
{"context": "Dasatinib is an oral small molecule inhibitor of Abl and Src family tyrosine kinases (SFK), including p56(Lck) (Lck). Given the central importance of Lck in transmitting signals from the T-cell receptor (TCR) signaling complex and the potent ability of dasatinib to inhibit Lck activity, we hypothesized this agent could provide a novel route of immunomodulation via targeted inhibition of antigen-induced signaling. Herein, we show that dasatinib inhibits TCR-mediated signal transduction, cellular proliferation, cytokine production, and in vivo T-cell responses. However, dasatinib-mediated inhibition does not induce apoptosis because the effect is reversible or may be overcome by signals bypassing the TCR, such as phorbol ester. Signal transduction and proliferative responses via IL-2 remain essentially unperturbed, suggesting that dasatinib displays specificity for TCR signaling. In addition, dasatinib combined with cyclosporine A or rapamycin led to a much more potent inhibition of T-cell activation, suggesting that targeted inhibition of Lck could be a useful adjunct for enhanced immunomodulation. In combination with currently available immunomodulatory agents, SFK inhibition could potentially increase immunomodulatory efficacy while minimizing toxicity of individual agents.", "qas": [{"question": "Does dasatinib promote or inhibit T-cell proliferation?", "answers": ["inhibits"], "qid": "61ec5684d44c4296809c466509051021", "question_tokens": [["Does", 0], ["dasatinib", 5], ["promote", 15], ["or", 23], ["inhibit", 26], ["T", 34], ["-", 35], ["cell", 36], ["proliferation", 41], ["?", 54]], "detected_answers": [{"text": "inhibits", "token_spans": [[82, 82]], "char_spans": [[448, 455]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["an", 13], ["oral", 16], ["small", 21], ["molecule", 27], ["inhibitor", 36], ["of", 46], ["Abl", 49], ["and", 53], ["Src", 57], ["family", 61], ["tyrosine", 68], ["kinases", 77], ["(", 85], ["SFK", 86], [")", 89], [",", 90], ["including", 92], ["p56(Lck", 102], [")", 109], ["(", 111], ["Lck", 112], [")", 115], [".", 116], ["Given", 118], ["the", 124], ["central", 128], ["importance", 136], ["of", 147], ["Lck", 150], ["in", 154], ["transmitting", 157], ["signals", 170], ["from", 178], ["the", 183], ["T", 187], ["-", 188], ["cell", 189], ["receptor", 194], ["(", 203], ["TCR", 204], [")", 207], ["signaling", 209], ["complex", 219], ["and", 227], ["the", 231], ["potent", 235], ["ability", 242], ["of", 250], ["dasatinib", 253], ["to", 263], ["inhibit", 266], ["Lck", 274], ["activity", 278], [",", 286], ["we", 288], ["hypothesized", 291], ["this", 304], ["agent", 309], ["could", 315], ["provide", 321], ["a", 329], ["novel", 331], ["route", 337], ["of", 343], ["immunomodulation", 346], ["via", 363], ["targeted", 367], ["inhibition", 376], ["of", 387], ["antigen", 390], ["-", 397], ["induced", 398], ["signaling", 406], [".", 415], ["Herein", 417], [",", 423], ["we", 425], ["show", 428], ["that", 433], ["dasatinib", 438], ["inhibits", 448], ["TCR", 457], ["-", 460], ["mediated", 461], ["signal", 470], ["transduction", 477], [",", 489], ["cellular", 491], ["proliferation", 500], [",", 513], ["cytokine", 515], ["production", 524], [",", 534], ["and", 536], ["in", 540], ["vivo", 543], ["T", 548], ["-", 549], ["cell", 550], ["responses", 555], [".", 564], ["However", 566], [",", 573], ["dasatinib", 575], ["-", 584], ["mediated", 585], ["inhibition", 594], ["does", 605], ["not", 610], ["induce", 614], ["apoptosis", 621], ["because", 631], ["the", 639], ["effect", 643], ["is", 650], ["reversible", 653], ["or", 664], ["may", 667], ["be", 671], ["overcome", 674], ["by", 683], ["signals", 686], ["bypassing", 694], ["the", 704], ["TCR", 708], [",", 711], ["such", 713], ["as", 718], ["phorbol", 721], ["ester", 729], [".", 734], ["Signal", 736], ["transduction", 743], ["and", 756], ["proliferative", 760], ["responses", 774], ["via", 784], ["IL-2", 788], ["remain", 793], ["essentially", 800], ["unperturbed", 812], [",", 823], ["suggesting", 825], ["that", 836], ["dasatinib", 841], ["displays", 851], ["specificity", 860], ["for", 872], ["TCR", 876], ["signaling", 880], [".", 889], ["In", 891], ["addition", 894], [",", 902], ["dasatinib", 904], ["combined", 914], ["with", 923], ["cyclosporine", 928], ["A", 941], ["or", 943], ["rapamycin", 946], ["led", 956], ["to", 960], ["a", 963], ["much", 965], ["more", 970], ["potent", 975], ["inhibition", 982], ["of", 993], ["T", 996], ["-", 997], ["cell", 998], ["activation", 1003], [",", 1013], ["suggesting", 1015], ["that", 1026], ["targeted", 1031], ["inhibition", 1040], ["of", 1051], ["Lck", 1054], ["could", 1058], ["be", 1064], ["a", 1067], ["useful", 1069], ["adjunct", 1076], ["for", 1084], ["enhanced", 1088], ["immunomodulation", 1097], [".", 1113], ["In", 1115], ["combination", 1118], ["with", 1130], ["currently", 1135], ["available", 1145], ["immunomodulatory", 1155], ["agents", 1172], [",", 1178], ["SFK", 1180], ["inhibition", 1184], ["could", 1195], ["potentially", 1201], ["increase", 1213], ["immunomodulatory", 1222], ["efficacy", 1239], ["while", 1248], ["minimizing", 1254], ["toxicity", 1265], ["of", 1274], ["individual", 1277], ["agents", 1288], [".", 1294]]}
{"context": "The eukaryotic cell encounters more than one million various kinds of DNA lesions per day. The nucleotide excision repair (NER) pathway is one of the most important repair mechanisms that removes a wide spectrum of different DNA lesions. NER operates through two sub pathways: global genome repair (GGR) and transcription-coupled repair (TCR). GGR repairs the DNA damage throughout the entire genome and is initiated by the HR23B/XPC complex, while the CSB protein-governed TCR process removes DNA lesions from the actively transcribed strand. The sequence of events and the role of particular NER proteins are currently being extensively discussed. NER proteins also participate in other cellular processes like replication, transcription, chromatin maintenance and protein turnover. Defects in NER underlay severe genetic disorders: xeroderma pigmentosum (XP), Cockayne syndrome (CS) and trichothiodystrophy (TTD).", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "ffeaee2811f94587ba59b0c3f1305a3a", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[97, 98]], "char_spans": [[524, 541]]}]}], "context_tokens": [["The", 0], ["eukaryotic", 4], ["cell", 15], ["encounters", 20], ["more", 31], ["than", 36], ["one", 41], ["million", 45], ["various", 53], ["kinds", 61], ["of", 67], ["DNA", 70], ["lesions", 74], ["per", 82], ["day", 86], [".", 89], ["The", 91], ["nucleotide", 95], ["excision", 106], ["repair", 115], ["(", 122], ["NER", 123], [")", 126], ["pathway", 128], ["is", 136], ["one", 139], ["of", 143], ["the", 146], ["most", 150], ["important", 155], ["repair", 165], ["mechanisms", 172], ["that", 183], ["removes", 188], ["a", 196], ["wide", 198], ["spectrum", 203], ["of", 212], ["different", 215], ["DNA", 225], ["lesions", 229], [".", 236], ["NER", 238], ["operates", 242], ["through", 251], ["two", 259], ["sub", 263], ["pathways", 267], [":", 275], ["global", 277], ["genome", 284], ["repair", 291], ["(", 298], ["GGR", 299], [")", 302], ["and", 304], ["transcription", 308], ["-", 321], ["coupled", 322], ["repair", 330], ["(", 337], ["TCR", 338], [")", 341], [".", 342], ["GGR", 344], ["repairs", 348], ["the", 356], ["DNA", 360], ["damage", 364], ["throughout", 371], ["the", 382], ["entire", 386], ["genome", 393], ["and", 400], ["is", 404], ["initiated", 407], ["by", 417], ["the", 420], ["HR23B", 424], ["/", 429], ["XPC", 430], ["complex", 434], [",", 441], ["while", 443], ["the", 449], ["CSB", 453], ["protein", 457], ["-", 464], ["governed", 465], ["TCR", 474], ["process", 478], ["removes", 486], ["DNA", 494], ["lesions", 498], ["from", 506], ["the", 511], ["actively", 515], ["transcribed", 524], ["strand", 536], [".", 542], ["The", 544], ["sequence", 548], ["of", 557], ["events", 560], ["and", 567], ["the", 571], ["role", 575], ["of", 580], ["particular", 583], ["NER", 594], ["proteins", 598], ["are", 607], ["currently", 611], ["being", 621], ["extensively", 627], ["discussed", 639], [".", 648], ["NER", 650], ["proteins", 654], ["also", 663], ["participate", 668], ["in", 680], ["other", 683], ["cellular", 689], ["processes", 698], ["like", 708], ["replication", 713], [",", 724], ["transcription", 726], [",", 739], ["chromatin", 741], ["maintenance", 751], ["and", 763], ["protein", 767], ["turnover", 775], [".", 783], ["Defects", 785], ["in", 793], ["NER", 796], ["underlay", 800], ["severe", 809], ["genetic", 816], ["disorders", 824], [":", 833], ["xeroderma", 835], ["pigmentosum", 845], ["(", 857], ["XP", 858], [")", 860], [",", 861], ["Cockayne", 863], ["syndrome", 872], ["(", 881], ["CS", 882], [")", 884], ["and", 886], ["trichothiodystrophy", 890], ["(", 910], ["TTD", 911], [")", 914], [".", 915]]}
{"context": "Neurofibromatosis type 1 (NF1) is the most frequent neurocutaneous disorder with autosomal dominant inheritance. Phenotype variability is high ranging from merely several caf\u00e9-au-lait spots to malignant peripheral nerve sheath tumors or severe disfigurement through plexiform neurofibromas. Identification of genetic factors that modify the NF1 phenotype would contribute to the understanding of NF1 pathophysiology and improve patient counselling. As even monozygotic (MZ) twins with NF1 may differ phenotypically, we wondered whether these variations might be inherited in a non-Mendelian fashion. Mitochondrial DNA (mtDNA) is inherited extrachromosomally through the cytoplasm of the oocyte and often harbours heteroplasmic sequence variations. At the time of blastomere separation, these variants may be skewedly distributed and effect phenotypic differences. Because of their co-localization with the tumor suppressor protein neurofibromin, which is mutated in NF1, mitochondria were particular attractive candidates for investigation. MtDNA was extracted from nucleated blood cells of four pairs of discordant MZ twins with NF1 and from cutaneous neurofibromas of one twin pair. We sequenced the entire mitochondrial genome and determined the state of heteroplasmy by investigating a microsatellite region of the mitochondrial D-loop (D310-tract). The clinical diagnosis was confirmed in all patients by detection of pathogenic mutations in the NF1 gene. Monozygosity was verified by genotyping. However, we did not detect evidence for mtDNA sequence differences or for different degrees of heteroplasmy between individuals of the same twin pair. The phenotypic discordance of MZ twins with NF1 cannot be explained by skewed distribution of mtDNA mutations or polymorphisms.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "1c8a233817e24aaf970974c3d66dfce4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[59, 59], [51, 51], [150, 150], [74, 74], [227, 227], [4, 4], [268, 268], [175, 175]], "char_spans": [[396, 398], [341, 343], [966, 968], [485, 487], [1451, 1453], [26, 28], [1697, 1699], [1130, 1132]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["frequent", 43], ["neurocutaneous", 52], ["disorder", 67], ["with", 76], ["autosomal", 81], ["dominant", 91], ["inheritance", 100], [".", 111], ["Phenotype", 113], ["variability", 123], ["is", 135], ["high", 138], ["ranging", 143], ["from", 151], ["merely", 156], ["several", 163], ["caf\u00e9", 171], ["-", 175], ["au", 176], ["-", 178], ["lait", 179], ["spots", 184], ["to", 190], ["malignant", 193], ["peripheral", 203], ["nerve", 214], ["sheath", 220], ["tumors", 227], ["or", 234], ["severe", 237], ["disfigurement", 244], ["through", 258], ["plexiform", 266], ["neurofibromas", 276], [".", 289], ["Identification", 291], ["of", 306], ["genetic", 309], ["factors", 317], ["that", 325], ["modify", 330], ["the", 337], ["NF1", 341], ["phenotype", 345], ["would", 355], ["contribute", 361], ["to", 372], ["the", 375], ["understanding", 379], ["of", 393], ["NF1", 396], ["pathophysiology", 400], ["and", 416], ["improve", 420], ["patient", 428], ["counselling", 436], [".", 447], ["As", 449], ["even", 452], ["monozygotic", 457], ["(", 469], ["MZ", 470], [")", 472], ["twins", 474], ["with", 480], ["NF1", 485], ["may", 489], ["differ", 493], ["phenotypically", 500], [",", 514], ["we", 516], ["wondered", 519], ["whether", 528], ["these", 536], ["variations", 542], ["might", 553], ["be", 559], ["inherited", 562], ["in", 572], ["a", 575], ["non", 577], ["-", 580], ["Mendelian", 581], ["fashion", 591], [".", 598], ["Mitochondrial", 600], ["DNA", 614], ["(", 618], ["mtDNA", 619], [")", 624], ["is", 626], ["inherited", 629], ["extrachromosomally", 639], ["through", 658], ["the", 666], ["cytoplasm", 670], ["of", 680], ["the", 683], ["oocyte", 687], ["and", 694], ["often", 698], ["harbours", 704], ["heteroplasmic", 713], ["sequence", 727], ["variations", 736], [".", 746], ["At", 748], ["the", 751], ["time", 755], ["of", 760], ["blastomere", 763], ["separation", 774], [",", 784], ["these", 786], ["variants", 792], ["may", 801], ["be", 805], ["skewedly", 808], ["distributed", 817], ["and", 829], ["effect", 833], ["phenotypic", 840], ["differences", 851], [".", 862], ["Because", 864], ["of", 872], ["their", 875], ["co", 881], ["-", 883], ["localization", 884], ["with", 897], ["the", 902], ["tumor", 906], ["suppressor", 912], ["protein", 923], ["neurofibromin", 931], [",", 944], ["which", 946], ["is", 952], ["mutated", 955], ["in", 963], ["NF1", 966], [",", 969], ["mitochondria", 971], ["were", 984], ["particular", 989], ["attractive", 1000], ["candidates", 1011], ["for", 1022], ["investigation", 1026], [".", 1039], ["MtDNA", 1041], ["was", 1047], ["extracted", 1051], ["from", 1061], ["nucleated", 1066], ["blood", 1076], ["cells", 1082], ["of", 1088], ["four", 1091], ["pairs", 1096], ["of", 1102], ["discordant", 1105], ["MZ", 1116], ["twins", 1119], ["with", 1125], ["NF1", 1130], ["and", 1134], ["from", 1138], ["cutaneous", 1143], ["neurofibromas", 1153], ["of", 1167], ["one", 1170], ["twin", 1174], ["pair", 1179], [".", 1183], ["We", 1185], ["sequenced", 1188], ["the", 1198], ["entire", 1202], ["mitochondrial", 1209], ["genome", 1223], ["and", 1230], ["determined", 1234], ["the", 1245], ["state", 1249], ["of", 1255], ["heteroplasmy", 1258], ["by", 1271], ["investigating", 1274], ["a", 1288], ["microsatellite", 1290], ["region", 1305], ["of", 1312], ["the", 1315], ["mitochondrial", 1319], ["D", 1333], ["-", 1334], ["loop", 1335], ["(", 1340], ["D310-tract", 1341], [")", 1351], [".", 1352], ["The", 1354], ["clinical", 1358], ["diagnosis", 1367], ["was", 1377], ["confirmed", 1381], ["in", 1391], ["all", 1394], ["patients", 1398], ["by", 1407], ["detection", 1410], ["of", 1420], ["pathogenic", 1423], ["mutations", 1434], ["in", 1444], ["the", 1447], ["NF1", 1451], ["gene", 1455], [".", 1459], ["Monozygosity", 1461], ["was", 1474], ["verified", 1478], ["by", 1487], ["genotyping", 1490], [".", 1500], ["However", 1502], [",", 1509], ["we", 1511], ["did", 1514], ["not", 1518], ["detect", 1522], ["evidence", 1529], ["for", 1538], ["mtDNA", 1542], ["sequence", 1548], ["differences", 1557], ["or", 1569], ["for", 1572], ["different", 1576], ["degrees", 1586], ["of", 1594], ["heteroplasmy", 1597], ["between", 1610], ["individuals", 1618], ["of", 1630], ["the", 1633], ["same", 1637], ["twin", 1642], ["pair", 1647], [".", 1651], ["The", 1653], ["phenotypic", 1657], ["discordance", 1668], ["of", 1680], ["MZ", 1683], ["twins", 1686], ["with", 1692], ["NF1", 1697], ["can", 1701], ["not", 1704], ["be", 1708], ["explained", 1711], ["by", 1721], ["skewed", 1724], ["distribution", 1731], ["of", 1744], ["mtDNA", 1747], ["mutations", 1753], ["or", 1763], ["polymorphisms", 1766], [".", 1779]]}
{"context": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML). Its hematologic and cytogenetic effects have been evaluated in a series of clinical trials. The aim of this study was to report hematologic and cytogenetic response in CML patients during the treatment with imatinib mesylate. A total of 21 patients were treated and observed from July 2006 to December 2008. The median time from CML diagnosis was no more than 12 months, so all the patients received previous treatment with hydroxyurea for which the median time was 3 months. The patients received imatinib mesylate in an effective oral dose of 400 to 800 mg daily, which was followed with peripheral blood counts, bone marrow examination, and cytogenetic studies at 6, 12, 18 and 24 months. Complete hematologic responses were reported for 19 (90.48%) of 21 patients studied. Among 19 patients who had a response, 16 (86%) did so within 3 months. The best cytogenetic response rate at any time during the study treatment with imatinib mesylate, among 14 patients in which cytogenetic response evaluated was: complete cytogenetic response in 7 (50%) patients, partial cytogenetic response in 6 (42.9%) patients and minor cytogenetic response in 1 (7.1%) patient. No patients had progressed to accelerated or blastic phase. The most frequent adverse effects that seemed to be related to treatment with imatinib mesylate were edema and musculoskeletal pain; overall, most were mild. Only one patient discontinued treatment because of hematologic toxic effects. The results obtained in this study confirm that imatinib mesylate induces a complete hematological and cytogenetic response in a high percentage of patients with chronic-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a1078ce36c74d609a098b1b566be822", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[20, 22]], "char_spans": [[134, 140]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["tyrosine", 21], ["kinase", 30], ["inhibitor", 37], ["with", 47], ["specific", 52], ["activity", 61], ["against", 70], ["the", 78], ["breakpoint", 82], ["cluster", 93], ["region", 101], ["--", 107], ["Abelson", 109], ["murine", 117], ["leukemia", 124], ["(", 133], ["BCR", 134], ["-", 137], ["ABL", 138], [")", 141], ["tyrosine", 143], ["kinase", 152], ["has", 159], ["been", 163], ["developed", 168], ["for", 178], ["treatment", 182], ["of", 192], ["chronic", 195], ["myelogenous", 203], ["leukemia", 215], ["(", 224], ["CML", 225], [")", 228], [".", 229], ["Its", 231], ["hematologic", 235], ["and", 247], ["cytogenetic", 251], ["effects", 263], ["have", 271], ["been", 276], ["evaluated", 281], ["in", 291], ["a", 294], ["series", 296], ["of", 303], ["clinical", 306], ["trials", 315], [".", 321], ["The", 323], ["aim", 327], ["of", 331], ["this", 334], ["study", 339], ["was", 345], ["to", 349], ["report", 352], ["hematologic", 359], ["and", 371], ["cytogenetic", 375], ["response", 387], ["in", 396], ["CML", 399], ["patients", 403], ["during", 412], ["the", 419], ["treatment", 423], ["with", 433], ["imatinib", 438], ["mesylate", 447], [".", 455], ["A", 457], ["total", 459], ["of", 465], ["21", 468], ["patients", 471], ["were", 480], ["treated", 485], ["and", 493], ["observed", 497], ["from", 506], ["July", 511], ["2006", 516], ["to", 521], ["December", 524], ["2008", 533], [".", 537], ["The", 539], ["median", 543], ["time", 550], ["from", 555], ["CML", 560], ["diagnosis", 564], ["was", 574], ["no", 578], ["more", 581], ["than", 586], ["12", 591], ["months", 594], [",", 600], ["so", 602], ["all", 605], ["the", 609], ["patients", 613], ["received", 622], ["previous", 631], ["treatment", 640], ["with", 650], ["hydroxyurea", 655], ["for", 667], ["which", 671], ["the", 677], ["median", 681], ["time", 688], ["was", 693], ["3", 697], ["months", 699], [".", 705], ["The", 707], ["patients", 711], ["received", 720], ["imatinib", 729], ["mesylate", 738], ["in", 747], ["an", 750], ["effective", 753], ["oral", 763], ["dose", 768], ["of", 773], ["400", 776], ["to", 780], ["800", 783], ["mg", 787], ["daily", 790], [",", 795], ["which", 797], ["was", 803], ["followed", 807], ["with", 816], ["peripheral", 821], ["blood", 832], ["counts", 838], [",", 844], ["bone", 846], ["marrow", 851], ["examination", 858], [",", 869], ["and", 871], ["cytogenetic", 875], ["studies", 887], ["at", 895], ["6", 898], [",", 899], ["12", 901], [",", 903], ["18", 905], ["and", 908], ["24", 912], ["months", 915], [".", 921], ["Complete", 923], ["hematologic", 932], ["responses", 944], ["were", 954], ["reported", 959], ["for", 968], ["19", 972], ["(", 975], ["90.48", 976], ["%", 981], [")", 982], ["of", 984], ["21", 987], ["patients", 990], ["studied", 999], [".", 1006], ["Among", 1008], ["19", 1014], ["patients", 1017], ["who", 1026], ["had", 1030], ["a", 1034], ["response", 1036], [",", 1044], ["16", 1046], ["(", 1049], ["86", 1050], ["%", 1052], [")", 1053], ["did", 1055], ["so", 1059], ["within", 1062], ["3", 1069], ["months", 1071], [".", 1077], ["The", 1079], ["best", 1083], ["cytogenetic", 1088], ["response", 1100], ["rate", 1109], ["at", 1114], ["any", 1117], ["time", 1121], ["during", 1126], ["the", 1133], ["study", 1137], ["treatment", 1143], ["with", 1153], ["imatinib", 1158], ["mesylate", 1167], [",", 1175], ["among", 1177], ["14", 1183], ["patients", 1186], ["in", 1195], ["which", 1198], ["cytogenetic", 1204], ["response", 1216], ["evaluated", 1225], ["was", 1235], [":", 1238], ["complete", 1240], ["cytogenetic", 1249], ["response", 1261], ["in", 1270], ["7", 1273], ["(", 1275], ["50", 1276], ["%", 1278], [")", 1279], ["patients", 1281], [",", 1289], ["partial", 1291], ["cytogenetic", 1299], ["response", 1311], ["in", 1320], ["6", 1323], ["(", 1325], ["42.9", 1326], ["%", 1330], [")", 1331], ["patients", 1333], ["and", 1342], ["minor", 1346], ["cytogenetic", 1352], ["response", 1364], ["in", 1373], ["1", 1376], ["(", 1378], ["7.1", 1379], ["%", 1382], [")", 1383], ["patient", 1385], [".", 1392], ["No", 1394], ["patients", 1397], ["had", 1406], ["progressed", 1410], ["to", 1421], ["accelerated", 1424], ["or", 1436], ["blastic", 1439], ["phase", 1447], [".", 1452], ["The", 1454], ["most", 1458], ["frequent", 1463], ["adverse", 1472], ["effects", 1480], ["that", 1488], ["seemed", 1493], ["to", 1500], ["be", 1503], ["related", 1506], ["to", 1514], ["treatment", 1517], ["with", 1527], ["imatinib", 1532], ["mesylate", 1541], ["were", 1550], ["edema", 1555], ["and", 1561], ["musculoskeletal", 1565], ["pain", 1581], [";", 1585], ["overall", 1587], [",", 1594], ["most", 1596], ["were", 1601], ["mild", 1606], [".", 1610], ["Only", 1612], ["one", 1617], ["patient", 1621], ["discontinued", 1629], ["treatment", 1642], ["because", 1652], ["of", 1660], ["hematologic", 1663], ["toxic", 1675], ["effects", 1681], [".", 1688], ["The", 1690], ["results", 1694], ["obtained", 1702], ["in", 1711], ["this", 1714], ["study", 1719], ["confirm", 1725], ["that", 1733], ["imatinib", 1738], ["mesylate", 1747], ["induces", 1756], ["a", 1764], ["complete", 1766], ["hematological", 1775], ["and", 1789], ["cytogenetic", 1793], ["response", 1805], ["in", 1814], ["a", 1817], ["high", 1819], ["percentage", 1824], ["of", 1835], ["patients", 1838], ["with", 1847], ["chronic", 1852], ["-", 1859], ["phase", 1860], ["CML", 1866], [".", 1869]]}
{"context": "To assess the efficacy, usefulness, safety, and dosages of flumazenil required when flumazenil is used in the diagnosis of benzodiazepine-induced coma (vs. other drug-induced coma), and to reverse or prevent the recurrence of unconsciousness. A two-phase study: a controlled, randomized, double-blind study followed by a prospective, open study. An 800-bed, teaching, university-affiliated hospital. Unconscious patients (n = 110) suspected of benzodiazepine overdose, graded 2 to 4 on the Matthew and Lawson coma scale, were treated with flumazenil, the specific benzodiazepine receptor antagonist. The first 31 patients were studied in a double-blind fashion, while the rest of the patients were given flumazenil according to an open protocol. INTERVENTIONS; All patients received supplemental oxygen; endotracheal intubation was performed, and synchronized intermittent mandatory ventilation was initiated whenever it was deemed necessary. A peripheral intravenous cannula was inserted, as were indwelling arterial and urinary bladder catheters. Blood pressure, electrocardiogram, respiratory rate, end-tidal CO2, and core temperature were continuously monitored. The first 31 double-blind patients received either intravenous flumazenil (to a maximum of 1 mg) or saline, while the rest of the patients were given flumazenil until either regaining consciousness or a maximum of 2.5 mg was injected. Patients remaining unconscious among double-blind patients or those patients relapsing into coma after the first dose were later treated in the open phase of the study. Treatment continued by boluses or infusion as long as efficacious. Fourteen of 17 double-blind, flumazenil-treated patients woke after a mean of 0.8 +/- 0.3 (SD) mg vs. one of 14 placebo patients (p < .001). Seventy-five percent of the aggregated controlled and uncontrolled patients awoke from coma scores of 3.1 +/- 0.6 to 0.4 +/- 0.5 (p < .01) after the injection of 0.7 +/- 0.3 mg of flumazenil. These patients had high benzodiazepine serum blood concentrations. Twenty-five percent of the patients did not regain consciousness. These patients had very high serum concentrations of nonbenzodiazepine drugs. Sixty percent of the responders who had primarily ingested benzodiazepines remained awake for 72 +/- 37 mins after flumazenil administration; 40% relapsed into coma after 18 +/- 7 mins and various central nervous system depressant drugs were detected in their blood in addition to benzodiazepines. Seventy-one percent of the patients had ingested tricyclic antidepressants. Seventy-eight percent of the responders were continually and efficaciously treated for < or = 8 days. Fourteen (25%) of the intubated patients were extubated safely while 12 patients, who had shown increased respiratory insufficiency, resumed satisfactory respiration after flumazenil injection. Five cases of transient increase in blood pressure and heart rate were encountered. There were 27 mildly unpleasant \"waking\" episodes, such as anxiety, restlessness, and aggression, but no patient had benzodiazepine withdrawal signs, convulsions, or dysrhythmia, most noticeably absent in tricyclic antidepressant-intoxicated patients. Flumazenil is a valid diagnostic tool for distinguishing pure benzodiazepine from mixed-drug intoxication or nondrug-induced coma. Flumazenil is effective in preventing recurrence of benzodiazepine-induced coma. Respiratory insufficiency is reversed after its administration. Flumazenil is safe when administered cautiously, even in patients with coma caused by a mixed overdose of benzodiazepine plus tricyclic antidepressants.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "703c26f6e3614fc3ad84fedea34fc7ed", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[416, 416], [213, 213], [363, 363], [134, 134], [294, 294], [605, 605], [12, 12], [564, 564], [105, 105], [233, 233], [505, 505], [585, 585], [15, 15]], "char_spans": [[2297, 2306], [1230, 1239], [1959, 1968], [704, 713], [1667, 1676], [3464, 3473], [59, 68], [3188, 3197], [539, 548], [1317, 1326], [2830, 2839], [3319, 3328], [84, 93]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], [",", 22], ["usefulness", 24], [",", 34], ["safety", 36], [",", 42], ["and", 44], ["dosages", 48], ["of", 56], ["flumazenil", 59], ["required", 70], ["when", 79], ["flumazenil", 84], ["is", 95], ["used", 98], ["in", 103], ["the", 106], ["diagnosis", 110], ["of", 120], ["benzodiazepine", 123], ["-", 137], ["induced", 138], ["coma", 146], ["(", 151], ["vs.", 152], ["other", 156], ["drug", 162], ["-", 166], ["induced", 167], ["coma", 175], [")", 179], [",", 180], ["and", 182], ["to", 186], ["reverse", 189], ["or", 197], ["prevent", 200], ["the", 208], ["recurrence", 212], ["of", 223], ["unconsciousness", 226], [".", 241], ["A", 243], ["two", 245], ["-", 248], ["phase", 249], ["study", 255], [":", 260], ["a", 262], ["controlled", 264], [",", 274], ["randomized", 276], [",", 286], ["double", 288], ["-", 294], ["blind", 295], ["study", 301], ["followed", 307], ["by", 316], ["a", 319], ["prospective", 321], [",", 332], ["open", 334], ["study", 339], [".", 344], ["An", 346], ["800-bed", 349], [",", 356], ["teaching", 358], [",", 366], ["university", 368], ["-", 378], ["affiliated", 379], ["hospital", 390], [".", 398], ["Unconscious", 400], ["patients", 412], ["(", 421], ["n", 422], ["=", 424], ["110", 426], [")", 429], ["suspected", 431], ["of", 441], ["benzodiazepine", 444], ["overdose", 459], [",", 467], ["graded", 469], ["2", 476], ["to", 478], ["4", 481], ["on", 483], ["the", 486], ["Matthew", 490], ["and", 498], ["Lawson", 502], ["coma", 509], ["scale", 514], [",", 519], ["were", 521], ["treated", 526], ["with", 534], ["flumazenil", 539], [",", 549], ["the", 551], ["specific", 555], ["benzodiazepine", 564], ["receptor", 579], ["antagonist", 588], [".", 598], ["The", 600], ["first", 604], ["31", 610], ["patients", 613], ["were", 622], ["studied", 627], ["in", 635], ["a", 638], ["double", 640], ["-", 646], ["blind", 647], ["fashion", 653], [",", 660], ["while", 662], ["the", 668], ["rest", 672], ["of", 677], ["the", 680], ["patients", 684], ["were", 693], ["given", 698], ["flumazenil", 704], ["according", 715], ["to", 725], ["an", 728], ["open", 731], ["protocol", 736], [".", 744], ["INTERVENTIONS", 746], [";", 759], ["All", 761], ["patients", 765], ["received", 774], ["supplemental", 783], ["oxygen", 796], [";", 802], ["endotracheal", 804], ["intubation", 817], ["was", 828], ["performed", 832], [",", 841], ["and", 843], ["synchronized", 847], ["intermittent", 860], ["mandatory", 873], ["ventilation", 883], ["was", 895], ["initiated", 899], ["whenever", 909], ["it", 918], ["was", 921], ["deemed", 925], ["necessary", 932], [".", 941], ["A", 943], ["peripheral", 945], ["intravenous", 956], ["cannula", 968], ["was", 976], ["inserted", 980], [",", 988], ["as", 990], ["were", 993], ["indwelling", 998], ["arterial", 1009], ["and", 1018], ["urinary", 1022], ["bladder", 1030], ["catheters", 1038], [".", 1047], ["Blood", 1049], ["pressure", 1055], [",", 1063], ["electrocardiogram", 1065], [",", 1082], ["respiratory", 1084], ["rate", 1096], [",", 1100], ["end", 1102], ["-", 1105], ["tidal", 1106], ["CO2", 1112], [",", 1115], ["and", 1117], ["core", 1121], ["temperature", 1126], ["were", 1138], ["continuously", 1143], ["monitored", 1156], [".", 1165], ["The", 1167], ["first", 1171], ["31", 1177], ["double", 1180], ["-", 1186], ["blind", 1187], ["patients", 1193], ["received", 1202], ["either", 1211], ["intravenous", 1218], ["flumazenil", 1230], ["(", 1241], ["to", 1242], ["a", 1245], ["maximum", 1247], ["of", 1255], ["1", 1258], ["mg", 1260], [")", 1262], ["or", 1264], ["saline", 1267], [",", 1273], ["while", 1275], ["the", 1281], ["rest", 1285], ["of", 1290], ["the", 1293], ["patients", 1297], ["were", 1306], ["given", 1311], ["flumazenil", 1317], ["until", 1328], ["either", 1334], ["regaining", 1341], ["consciousness", 1351], ["or", 1365], ["a", 1368], ["maximum", 1370], ["of", 1378], ["2.5", 1381], ["mg", 1385], ["was", 1388], ["injected", 1392], [".", 1400], ["Patients", 1402], ["remaining", 1411], ["unconscious", 1421], ["among", 1433], ["double", 1439], ["-", 1445], ["blind", 1446], ["patients", 1452], ["or", 1461], ["those", 1464], ["patients", 1470], ["relapsing", 1479], ["into", 1489], ["coma", 1494], ["after", 1499], ["the", 1505], ["first", 1509], ["dose", 1515], ["were", 1520], ["later", 1525], ["treated", 1531], ["in", 1539], ["the", 1542], ["open", 1546], ["phase", 1551], ["of", 1557], ["the", 1560], ["study", 1564], [".", 1569], ["Treatment", 1571], ["continued", 1581], ["by", 1591], ["boluses", 1594], ["or", 1602], ["infusion", 1605], ["as", 1614], ["long", 1617], ["as", 1622], ["efficacious", 1625], [".", 1636], ["Fourteen", 1638], ["of", 1647], ["17", 1650], ["double", 1653], ["-", 1659], ["blind", 1660], [",", 1665], ["flumazenil", 1667], ["-", 1677], ["treated", 1678], ["patients", 1686], ["woke", 1695], ["after", 1700], ["a", 1706], ["mean", 1708], ["of", 1713], ["0.8", 1716], ["+", 1720], ["/-", 1721], ["0.3", 1724], ["(", 1728], ["SD", 1729], [")", 1731], ["mg", 1733], ["vs.", 1736], ["one", 1740], ["of", 1744], ["14", 1747], ["placebo", 1750], ["patients", 1758], ["(", 1767], ["p", 1768], ["<", 1770], [".001", 1772], [")", 1776], [".", 1777], ["Seventy", 1779], ["-", 1786], ["five", 1787], ["percent", 1792], ["of", 1800], ["the", 1803], ["aggregated", 1807], ["controlled", 1818], ["and", 1829], ["uncontrolled", 1833], ["patients", 1846], ["awoke", 1855], ["from", 1861], ["coma", 1866], ["scores", 1871], ["of", 1878], ["3.1", 1881], ["+", 1885], ["/-", 1886], ["0.6", 1889], ["to", 1893], ["0.4", 1896], ["+", 1900], ["/-", 1901], ["0.5", 1904], ["(", 1908], ["p", 1909], ["<", 1911], [".01", 1913], [")", 1916], ["after", 1918], ["the", 1924], ["injection", 1928], ["of", 1938], ["0.7", 1941], ["+", 1945], ["/-", 1946], ["0.3", 1949], ["mg", 1953], ["of", 1956], ["flumazenil", 1959], [".", 1969], ["These", 1971], ["patients", 1977], ["had", 1986], ["high", 1990], ["benzodiazepine", 1995], ["serum", 2010], ["blood", 2016], ["concentrations", 2022], [".", 2036], ["Twenty", 2038], ["-", 2044], ["five", 2045], ["percent", 2050], ["of", 2058], ["the", 2061], ["patients", 2065], ["did", 2074], ["not", 2078], ["regain", 2082], ["consciousness", 2089], [".", 2102], ["These", 2104], ["patients", 2110], ["had", 2119], ["very", 2123], ["high", 2128], ["serum", 2133], ["concentrations", 2139], ["of", 2154], ["nonbenzodiazepine", 2157], ["drugs", 2175], [".", 2180], ["Sixty", 2182], ["percent", 2188], ["of", 2196], ["the", 2199], ["responders", 2203], ["who", 2214], ["had", 2218], ["primarily", 2222], ["ingested", 2232], ["benzodiazepines", 2241], ["remained", 2257], ["awake", 2266], ["for", 2272], ["72", 2276], ["+", 2279], ["/-", 2280], ["37", 2283], ["mins", 2286], ["after", 2291], ["flumazenil", 2297], ["administration", 2308], [";", 2322], ["40", 2324], ["%", 2326], ["relapsed", 2328], ["into", 2337], ["coma", 2342], ["after", 2347], ["18", 2353], ["+", 2356], ["/-", 2357], ["7", 2360], ["mins", 2362], ["and", 2367], ["various", 2371], ["central", 2379], ["nervous", 2387], ["system", 2395], ["depressant", 2402], ["drugs", 2413], ["were", 2419], ["detected", 2424], ["in", 2433], ["their", 2436], ["blood", 2442], ["in", 2448], ["addition", 2451], ["to", 2460], ["benzodiazepines", 2463], [".", 2478], ["Seventy", 2480], ["-", 2487], ["one", 2488], ["percent", 2492], ["of", 2500], ["the", 2503], ["patients", 2507], ["had", 2516], ["ingested", 2520], ["tricyclic", 2529], ["antidepressants", 2539], [".", 2554], ["Seventy", 2556], ["-", 2563], ["eight", 2564], ["percent", 2570], ["of", 2578], ["the", 2581], ["responders", 2585], ["were", 2596], ["continually", 2601], ["and", 2613], ["efficaciously", 2617], ["treated", 2631], ["for", 2639], ["<", 2643], ["or", 2645], ["=", 2648], ["8", 2650], ["days", 2652], [".", 2656], ["Fourteen", 2658], ["(", 2667], ["25", 2668], ["%", 2670], [")", 2671], ["of", 2673], ["the", 2676], ["intubated", 2680], ["patients", 2690], ["were", 2699], ["extubated", 2704], ["safely", 2714], ["while", 2721], ["12", 2727], ["patients", 2730], [",", 2738], ["who", 2740], ["had", 2744], ["shown", 2748], ["increased", 2754], ["respiratory", 2764], ["insufficiency", 2776], [",", 2789], ["resumed", 2791], ["satisfactory", 2799], ["respiration", 2812], ["after", 2824], ["flumazenil", 2830], ["injection", 2841], [".", 2850], ["Five", 2852], ["cases", 2857], ["of", 2863], ["transient", 2866], ["increase", 2876], ["in", 2885], ["blood", 2888], ["pressure", 2894], ["and", 2903], ["heart", 2907], ["rate", 2913], ["were", 2918], ["encountered", 2923], [".", 2934], ["There", 2936], ["were", 2942], ["27", 2947], ["mildly", 2950], ["unpleasant", 2957], ["\"", 2968], ["waking", 2969], ["\"", 2975], ["episodes", 2977], [",", 2985], ["such", 2987], ["as", 2992], ["anxiety", 2995], [",", 3002], ["restlessness", 3004], [",", 3016], ["and", 3018], ["aggression", 3022], [",", 3032], ["but", 3034], ["no", 3038], ["patient", 3041], ["had", 3049], ["benzodiazepine", 3053], ["withdrawal", 3068], ["signs", 3079], [",", 3084], ["convulsions", 3086], [",", 3097], ["or", 3099], ["dysrhythmia", 3102], [",", 3113], ["most", 3115], ["noticeably", 3120], ["absent", 3131], ["in", 3138], ["tricyclic", 3141], ["antidepressant", 3151], ["-", 3165], ["intoxicated", 3166], ["patients", 3178], [".", 3186], ["Flumazenil", 3188], ["is", 3199], ["a", 3202], ["valid", 3204], ["diagnostic", 3210], ["tool", 3221], ["for", 3226], ["distinguishing", 3230], ["pure", 3245], ["benzodiazepine", 3250], ["from", 3265], ["mixed", 3270], ["-", 3275], ["drug", 3276], ["intoxication", 3281], ["or", 3294], ["nondrug", 3297], ["-", 3304], ["induced", 3305], ["coma", 3313], [".", 3317], ["Flumazenil", 3319], ["is", 3330], ["effective", 3333], ["in", 3343], ["preventing", 3346], ["recurrence", 3357], ["of", 3368], ["benzodiazepine", 3371], ["-", 3385], ["induced", 3386], ["coma", 3394], [".", 3398], ["Respiratory", 3400], ["insufficiency", 3412], ["is", 3426], ["reversed", 3429], ["after", 3438], ["its", 3444], ["administration", 3448], [".", 3462], ["Flumazenil", 3464], ["is", 3475], ["safe", 3478], ["when", 3483], ["administered", 3488], ["cautiously", 3501], [",", 3511], ["even", 3513], ["in", 3518], ["patients", 3521], ["with", 3530], ["coma", 3535], ["caused", 3540], ["by", 3547], ["a", 3550], ["mixed", 3552], ["overdose", 3558], ["of", 3567], ["benzodiazepine", 3570], ["plus", 3585], ["tricyclic", 3590], ["antidepressants", 3600], [".", 3615]]}
{"context": "Chronic myeloid leukemia (CML) is a clonal malignant myeloproliferative disorder characterized by the expansion of hematopoietic cells carrying the Philadelphia chromosome (t 9.22). Our main objective was to assess the efficacy of imatinib in CML patients, measured by their survival. Over a six-year period (June 2003 through May 2009), 25 patients were seen regularly for CML at the Lom\u00e9 Campus teaching hospital. Patients received imatinib after diagnosis and underwent regular laboratory monitoring (quantification of BCR-ABL ratio by RT-PCR). Patients' survival and treatment response were evaluated. Patients' mean age at diagnosis was 40 years (range: 9 to 72 years). Men predominated (17 compared with 7 women). Splenomegaly was found in 80% of cases. The mean leukocyte level was 188.71 g/L (24.4-350). Six patients (24%) had thrombocytosis with a mean platelet count of 491.15 g/L (108-2000). Six patients (24%) died after developing accelerated-phase CML or blast crisis. Estimated overall survival of patients at 6 years was 60%. Molecular biology monitoring detected a secondary G250E mutation with resistance to imatinib in one patient. Standard hematological side effects led to reduction in imatinib doses. The principal nonhematological side effects were weight gain and transient digestible disorders. At six years after diagnosis, imatinib was effective in treating patients with CML, even in sub-Saharan Africa. Mutation-induced resistance required regular molecular biological monitoring to determine the need to switch to later-generation tyrosine kinase inhibitors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5d0e918abb8649f49a8cdb096d471c53", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[88, 90]], "char_spans": [[522, 528]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["clonal", 36], ["malignant", 43], ["myeloproliferative", 53], ["disorder", 72], ["characterized", 81], ["by", 95], ["the", 98], ["expansion", 102], ["of", 112], ["hematopoietic", 115], ["cells", 129], ["carrying", 135], ["the", 144], ["Philadelphia", 148], ["chromosome", 161], ["(", 172], ["t", 173], ["9.22", 175], [")", 179], [".", 180], ["Our", 182], ["main", 186], ["objective", 191], ["was", 201], ["to", 205], ["assess", 208], ["the", 215], ["efficacy", 219], ["of", 228], ["imatinib", 231], ["in", 240], ["CML", 243], ["patients", 247], [",", 255], ["measured", 257], ["by", 266], ["their", 269], ["survival", 275], [".", 283], ["Over", 285], ["a", 290], ["six", 292], ["-", 295], ["year", 296], ["period", 301], ["(", 308], ["June", 309], ["2003", 314], ["through", 319], ["May", 327], ["2009", 331], [")", 335], [",", 336], ["25", 338], ["patients", 341], ["were", 350], ["seen", 355], ["regularly", 360], ["for", 370], ["CML", 374], ["at", 378], ["the", 381], ["Lom\u00e9", 385], ["Campus", 390], ["teaching", 397], ["hospital", 406], [".", 414], ["Patients", 416], ["received", 425], ["imatinib", 434], ["after", 443], ["diagnosis", 449], ["and", 459], ["underwent", 463], ["regular", 473], ["laboratory", 481], ["monitoring", 492], ["(", 503], ["quantification", 504], ["of", 519], ["BCR", 522], ["-", 525], ["ABL", 526], ["ratio", 530], ["by", 536], ["RT", 539], ["-", 541], ["PCR", 542], [")", 545], [".", 546], ["Patients", 548], ["'", 556], ["survival", 558], ["and", 567], ["treatment", 571], ["response", 581], ["were", 590], ["evaluated", 595], [".", 604], ["Patients", 606], ["'", 614], ["mean", 616], ["age", 621], ["at", 625], ["diagnosis", 628], ["was", 638], ["40", 642], ["years", 645], ["(", 651], ["range", 652], [":", 657], ["9", 659], ["to", 661], ["72", 664], ["years", 667], [")", 672], [".", 673], ["Men", 675], ["predominated", 679], ["(", 692], ["17", 693], ["compared", 696], ["with", 705], ["7", 710], ["women", 712], [")", 717], [".", 718], ["Splenomegaly", 720], ["was", 733], ["found", 737], ["in", 743], ["80", 746], ["%", 748], ["of", 750], ["cases", 753], [".", 758], ["The", 760], ["mean", 764], ["leukocyte", 769], ["level", 779], ["was", 785], ["188.71", 789], ["g", 796], ["/", 797], ["L", 798], ["(", 800], ["24.4", 801], ["-", 805], ["350", 806], [")", 809], [".", 810], ["Six", 812], ["patients", 816], ["(", 825], ["24", 826], ["%", 828], [")", 829], ["had", 831], ["thrombocytosis", 835], ["with", 850], ["a", 855], ["mean", 857], ["platelet", 862], ["count", 871], ["of", 877], ["491.15", 880], ["g", 887], ["/", 888], ["L", 889], ["(", 891], ["108", 892], ["-", 895], ["2000", 896], [")", 900], [".", 901], ["Six", 903], ["patients", 907], ["(", 916], ["24", 917], ["%", 919], [")", 920], ["died", 922], ["after", 927], ["developing", 933], ["accelerated", 944], ["-", 955], ["phase", 956], ["CML", 962], ["or", 966], ["blast", 969], ["crisis", 975], [".", 981], ["Estimated", 983], ["overall", 993], ["survival", 1001], ["of", 1010], ["patients", 1013], ["at", 1022], ["6", 1025], ["years", 1027], ["was", 1033], ["60", 1037], ["%", 1039], [".", 1040], ["Molecular", 1042], ["biology", 1052], ["monitoring", 1060], ["detected", 1071], ["a", 1080], ["secondary", 1082], ["G250E", 1092], ["mutation", 1098], ["with", 1107], ["resistance", 1112], ["to", 1123], ["imatinib", 1126], ["in", 1135], ["one", 1138], ["patient", 1142], [".", 1149], ["Standard", 1151], ["hematological", 1160], ["side", 1174], ["effects", 1179], ["led", 1187], ["to", 1191], ["reduction", 1194], ["in", 1204], ["imatinib", 1207], ["doses", 1216], [".", 1221], ["The", 1223], ["principal", 1227], ["nonhematological", 1237], ["side", 1254], ["effects", 1259], ["were", 1267], ["weight", 1272], ["gain", 1279], ["and", 1284], ["transient", 1288], ["digestible", 1298], ["disorders", 1309], [".", 1318], ["At", 1320], ["six", 1323], ["years", 1327], ["after", 1333], ["diagnosis", 1339], [",", 1348], ["imatinib", 1350], ["was", 1359], ["effective", 1363], ["in", 1373], ["treating", 1376], ["patients", 1385], ["with", 1394], ["CML", 1399], [",", 1402], ["even", 1404], ["in", 1409], ["sub", 1412], ["-", 1415], ["Saharan", 1416], ["Africa", 1424], [".", 1430], ["Mutation", 1432], ["-", 1440], ["induced", 1441], ["resistance", 1449], ["required", 1460], ["regular", 1469], ["molecular", 1477], ["biological", 1487], ["monitoring", 1498], ["to", 1509], ["determine", 1512], ["the", 1522], ["need", 1526], ["to", 1531], ["switch", 1534], ["to", 1541], ["later", 1544], ["-", 1549], ["generation", 1550], ["tyrosine", 1561], ["kinase", 1570], ["inhibitors", 1577], [".", 1587]]}
{"context": "Christianson syndrome (CS) is an X-linked neurodevelopmental and neurological disorder characterized in males by core symptoms that include non-verbal status, intellectual disability, epilepsy, truncal ataxia, postnatal microcephaly and hyperkinesis. CS is caused by mutations in the SLC9A6 gene, which encodes a multipass transmembrane sodium (potassium)-hydrogen exchanger 6 (NHE6) protein, functional in early recycling endosomes. The extent and variability of the CS phenotype in female heterozygotes, who presumably express the wild-type and mutant SLC9A6 alleles mosaically as a result of X-chromosome inactivation (XCI), have not yet been systematically characterized. Slc9a6 knockout mice (Slc9a6 KO) were generated by insertion of the bacterial lacZ/\u03b2-galactosidase (\u03b2-Gal) reporter into exon 6 of the X-linked gene. Mutant Slc9a6 KO male mice have been shown to develop late endosomal/lysosomal dysfunction associated with glycolipid accumulation in selected neuronal populations and patterned degeneration of Purkinje cells (PCs). In heterozygous female Slc9a6 KO mice, \u03b2-Gal serves as a transcriptional/XCI reporter and thus facilitates testing of effects of mosaic expression of the mutant allele on penetrance of the abnormal phenotype. Using \u03b2-Gal, we demonstrated mosaic expression of the mutant Slc9a6 allele and mosaically distributed lysosomal glycolipid accumulation and PC pathology in the brains of heterozygous Slc9a6 KO female mice. At the behavioral level, we showed that heterozygous female mice suffer from visuospatial memory and motor coordination deficits similar to but less severe than those observed in X-chromosome hemizygous mutant males. Our studies in heterozygous Slc9a6 KO female mice provide important clues for understanding the likely phenotypic range of Christianson syndrome among females heterozygous for SLC9A6 mutations and might improve diagnostic practice and genetic counseling by helping to characterize this presumably underappreciated patient/carrier group.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "d941cbf53efb4218a8348c71b146a2d2", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[291, 291], [150, 150], [118, 118], [92, 92], [185, 185], [231, 231], [247, 247], [311, 311], [114, 114], [47, 47]], "char_spans": [[1702, 1707], [833, 838], [698, 703], [554, 559], [1065, 1070], [1312, 1317], [1434, 1439], [1850, 1855], [676, 681], [284, 289]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["CS", 23], [")", 25], ["is", 27], ["an", 30], ["X", 33], ["-", 34], ["linked", 35], ["neurodevelopmental", 42], ["and", 61], ["neurological", 65], ["disorder", 78], ["characterized", 87], ["in", 101], ["males", 104], ["by", 110], ["core", 113], ["symptoms", 118], ["that", 127], ["include", 132], ["non", 140], ["-", 143], ["verbal", 144], ["status", 151], [",", 157], ["intellectual", 159], ["disability", 172], [",", 182], ["epilepsy", 184], [",", 192], ["truncal", 194], ["ataxia", 202], [",", 208], ["postnatal", 210], ["microcephaly", 220], ["and", 233], ["hyperkinesis", 237], [".", 249], ["CS", 251], ["is", 254], ["caused", 257], ["by", 264], ["mutations", 267], ["in", 277], ["the", 280], ["SLC9A6", 284], ["gene", 291], [",", 295], ["which", 297], ["encodes", 303], ["a", 311], ["multipass", 313], ["transmembrane", 323], ["sodium", 337], ["(", 344], ["potassium)-hydrogen", 345], ["exchanger", 365], ["6", 375], ["(", 377], ["NHE6", 378], [")", 382], ["protein", 384], [",", 391], ["functional", 393], ["in", 404], ["early", 407], ["recycling", 413], ["endosomes", 423], [".", 432], ["The", 434], ["extent", 438], ["and", 445], ["variability", 449], ["of", 461], ["the", 464], ["CS", 468], ["phenotype", 471], ["in", 481], ["female", 484], ["heterozygotes", 491], [",", 504], ["who", 506], ["presumably", 510], ["express", 521], ["the", 529], ["wild", 533], ["-", 537], ["type", 538], ["and", 543], ["mutant", 547], ["SLC9A6", 554], ["alleles", 561], ["mosaically", 569], ["as", 580], ["a", 583], ["result", 585], ["of", 592], ["X", 595], ["-", 596], ["chromosome", 597], ["inactivation", 608], ["(", 621], ["XCI", 622], [")", 625], [",", 626], ["have", 628], ["not", 633], ["yet", 637], ["been", 641], ["systematically", 646], ["characterized", 661], [".", 674], ["Slc9a6", 676], ["knockout", 683], ["mice", 692], ["(", 697], ["Slc9a6", 698], ["KO", 705], [")", 707], ["were", 709], ["generated", 714], ["by", 724], ["insertion", 727], ["of", 737], ["the", 740], ["bacterial", 744], ["lacZ", 754], ["/", 758], ["\u03b2", 759], ["-", 760], ["galactosidase", 761], ["(", 775], ["\u03b2", 776], ["-", 777], ["Gal", 778], [")", 781], ["reporter", 783], ["into", 792], ["exon", 797], ["6", 802], ["of", 804], ["the", 807], ["X", 811], ["-", 812], ["linked", 813], ["gene", 820], [".", 824], ["Mutant", 826], ["Slc9a6", 833], ["KO", 840], ["male", 843], ["mice", 848], ["have", 853], ["been", 858], ["shown", 863], ["to", 869], ["develop", 872], ["late", 880], ["endosomal", 885], ["/", 894], ["lysosomal", 895], ["dysfunction", 905], ["associated", 917], ["with", 928], ["glycolipid", 933], ["accumulation", 944], ["in", 957], ["selected", 960], ["neuronal", 969], ["populations", 978], ["and", 990], ["patterned", 994], ["degeneration", 1004], ["of", 1017], ["Purkinje", 1020], ["cells", 1029], ["(", 1035], ["PCs", 1036], [")", 1039], [".", 1040], ["In", 1042], ["heterozygous", 1045], ["female", 1058], ["Slc9a6", 1065], ["KO", 1072], ["mice", 1075], [",", 1079], ["\u03b2", 1081], ["-", 1082], ["Gal", 1083], ["serves", 1087], ["as", 1094], ["a", 1097], ["transcriptional", 1099], ["/", 1114], ["XCI", 1115], ["reporter", 1119], ["and", 1128], ["thus", 1132], ["facilitates", 1137], ["testing", 1149], ["of", 1157], ["effects", 1160], ["of", 1168], ["mosaic", 1171], ["expression", 1178], ["of", 1189], ["the", 1192], ["mutant", 1196], ["allele", 1203], ["on", 1210], ["penetrance", 1213], ["of", 1224], ["the", 1227], ["abnormal", 1231], ["phenotype", 1240], [".", 1249], ["Using", 1251], ["\u03b2", 1257], ["-", 1258], ["Gal", 1259], [",", 1262], ["we", 1264], ["demonstrated", 1267], ["mosaic", 1280], ["expression", 1287], ["of", 1298], ["the", 1301], ["mutant", 1305], ["Slc9a6", 1312], ["allele", 1319], ["and", 1326], ["mosaically", 1330], ["distributed", 1341], ["lysosomal", 1353], ["glycolipid", 1363], ["accumulation", 1374], ["and", 1387], ["PC", 1391], ["pathology", 1394], ["in", 1404], ["the", 1407], ["brains", 1411], ["of", 1418], ["heterozygous", 1421], ["Slc9a6", 1434], ["KO", 1441], ["female", 1444], ["mice", 1451], [".", 1455], ["At", 1457], ["the", 1460], ["behavioral", 1464], ["level", 1475], [",", 1480], ["we", 1482], ["showed", 1485], ["that", 1492], ["heterozygous", 1497], ["female", 1510], ["mice", 1517], ["suffer", 1522], ["from", 1529], ["visuospatial", 1534], ["memory", 1547], ["and", 1554], ["motor", 1558], ["coordination", 1564], ["deficits", 1577], ["similar", 1586], ["to", 1594], ["but", 1597], ["less", 1601], ["severe", 1606], ["than", 1613], ["those", 1618], ["observed", 1624], ["in", 1633], ["X", 1636], ["-", 1637], ["chromosome", 1638], ["hemizygous", 1649], ["mutant", 1660], ["males", 1667], [".", 1672], ["Our", 1674], ["studies", 1678], ["in", 1686], ["heterozygous", 1689], ["Slc9a6", 1702], ["KO", 1709], ["female", 1712], ["mice", 1719], ["provide", 1724], ["important", 1732], ["clues", 1742], ["for", 1748], ["understanding", 1752], ["the", 1766], ["likely", 1770], ["phenotypic", 1777], ["range", 1788], ["of", 1794], ["Christianson", 1797], ["syndrome", 1810], ["among", 1819], ["females", 1825], ["heterozygous", 1833], ["for", 1846], ["SLC9A6", 1850], ["mutations", 1857], ["and", 1867], ["might", 1871], ["improve", 1877], ["diagnostic", 1885], ["practice", 1896], ["and", 1905], ["genetic", 1909], ["counseling", 1917], ["by", 1928], ["helping", 1931], ["to", 1939], ["characterize", 1942], ["this", 1955], ["presumably", 1960], ["underappreciated", 1971], ["patient", 1988], ["/", 1995], ["carrier", 1996], ["group", 2004], [".", 2009]]}
{"context": "Sotos syndrome is an overgrowth syndrome with characteristic facial gestalt and mental retardation of variable severity. Haploinsufficiency of the NSD1 gene has been implicated as the major cause of Sotos syndrome, with a predominance of microdeletions reported in Japanese patients. This study was conducted to investigate into the spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome. Thirty-six Chinese patients with Sotos syndrome and two patients with Weaver syndrome were subject to molecular testing. NSD1 gene mutations were detected in 26 (72%) Sotos patients. Microdeletion was found in only 3 patients, while the other 23 had point mutations (6 frameshift, 8 nonsense, 2 spice site, and 7 missense). Of these, 19 mutations were never reported. NSD1 gene mutations were not found in the two patients with Weaver syndrome. Most cases of Sotos syndrome are caused by NSD1 gene defects, but the spectrum of mutations is different from that of Japanese patients. Genotype-phenotype correlation showed that patients with microdeletions might be more prone to congenital heart disease but less likely to have somatic overgrowth. The two patients with Weaver syndrome were not found to have NSD1 gene mutations, but the number was too small for any conclusion to be drawn.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "2cf9e36ee549421b84170a93d439b69d", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[160, 161], [138, 139], [20, 21], [84, 85], [53, 54], [213, 214]], "char_spans": [[903, 911], [783, 791], [147, 155], [536, 544], [345, 353], [1222, 1230]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["an", 18], ["overgrowth", 21], ["syndrome", 32], ["with", 41], ["characteristic", 46], ["facial", 61], ["gestalt", 68], ["and", 76], ["mental", 80], ["retardation", 87], ["of", 99], ["variable", 102], ["severity", 111], [".", 119], ["Haploinsufficiency", 121], ["of", 140], ["the", 143], ["NSD1", 147], ["gene", 152], ["has", 157], ["been", 161], ["implicated", 166], ["as", 177], ["the", 180], ["major", 184], ["cause", 190], ["of", 196], ["Sotos", 199], ["syndrome", 205], [",", 213], ["with", 215], ["a", 220], ["predominance", 222], ["of", 235], ["microdeletions", 238], ["reported", 253], ["in", 262], ["Japanese", 265], ["patients", 274], [".", 282], ["This", 284], ["study", 289], ["was", 295], ["conducted", 299], ["to", 309], ["investigate", 312], ["into", 324], ["the", 329], ["spectrum", 333], ["of", 342], ["NSD1", 345], ["gene", 350], ["mutations", 355], ["in", 365], ["southern", 368], ["Chinese", 377], ["patients", 385], ["with", 394], ["Sotos", 399], ["syndrome", 405], [".", 413], ["Thirty", 415], ["-", 421], ["six", 422], ["Chinese", 426], ["patients", 434], ["with", 443], ["Sotos", 448], ["syndrome", 454], ["and", 463], ["two", 467], ["patients", 471], ["with", 480], ["Weaver", 485], ["syndrome", 492], ["were", 501], ["subject", 506], ["to", 514], ["molecular", 517], ["testing", 527], [".", 534], ["NSD1", 536], ["gene", 541], ["mutations", 546], ["were", 556], ["detected", 561], ["in", 570], ["26", 573], ["(", 576], ["72", 577], ["%", 579], [")", 580], ["Sotos", 582], ["patients", 588], [".", 596], ["Microdeletion", 598], ["was", 612], ["found", 616], ["in", 622], ["only", 625], ["3", 630], ["patients", 632], [",", 640], ["while", 642], ["the", 648], ["other", 652], ["23", 658], ["had", 661], ["point", 665], ["mutations", 671], ["(", 681], ["6", 682], ["frameshift", 684], [",", 694], ["8", 696], ["nonsense", 698], [",", 706], ["2", 708], ["spice", 710], ["site", 716], [",", 720], ["and", 722], ["7", 726], ["missense", 728], [")", 736], [".", 737], ["Of", 739], ["these", 742], [",", 747], ["19", 749], ["mutations", 752], ["were", 762], ["never", 767], ["reported", 773], [".", 781], ["NSD1", 783], ["gene", 788], ["mutations", 793], ["were", 803], ["not", 808], ["found", 812], ["in", 818], ["the", 821], ["two", 825], ["patients", 829], ["with", 838], ["Weaver", 843], ["syndrome", 850], [".", 858], ["Most", 860], ["cases", 865], ["of", 871], ["Sotos", 874], ["syndrome", 880], ["are", 889], ["caused", 893], ["by", 900], ["NSD1", 903], ["gene", 908], ["defects", 913], [",", 920], ["but", 922], ["the", 926], ["spectrum", 930], ["of", 939], ["mutations", 942], ["is", 952], ["different", 955], ["from", 965], ["that", 970], ["of", 975], ["Japanese", 978], ["patients", 987], [".", 995], ["Genotype", 997], ["-", 1005], ["phenotype", 1006], ["correlation", 1016], ["showed", 1028], ["that", 1035], ["patients", 1040], ["with", 1049], ["microdeletions", 1054], ["might", 1069], ["be", 1075], ["more", 1078], ["prone", 1083], ["to", 1089], ["congenital", 1092], ["heart", 1103], ["disease", 1109], ["but", 1117], ["less", 1121], ["likely", 1126], ["to", 1133], ["have", 1136], ["somatic", 1141], ["overgrowth", 1149], [".", 1159], ["The", 1161], ["two", 1165], ["patients", 1169], ["with", 1178], ["Weaver", 1183], ["syndrome", 1190], ["were", 1199], ["not", 1204], ["found", 1208], ["to", 1214], ["have", 1217], ["NSD1", 1222], ["gene", 1227], ["mutations", 1232], [",", 1241], ["but", 1243], ["the", 1247], ["number", 1251], ["was", 1258], ["too", 1262], ["small", 1266], ["for", 1272], ["any", 1276], ["conclusion", 1280], ["to", 1291], ["be", 1294], ["drawn", 1297], [".", 1302]]}
{"context": "Low back pain with or without radiculopathy is an important cause of disability and economic expenditure. However, many patients are not meeting optimal pain control through existing treatments. Recent studies have linked nerve growth factor (NGF) and the pathophysiology of persistent pain. Anti-NGF could be an alternative drug treatment for low back pain. Systematically review the efficacy and safety of anti-NGF in the treatment of low back pain. A systematic review of the literature with no language, date or publication status restriction, using Medline, EMBASE, Cochrane Library, and the clinicaltrials.gov database. Additional literature was retrieved by conferring with experts in the field or reviewing bibliographies and annals of meetings and congresses. Search terms included \"monoclonal antibodies,\" \"nerve growth factor,\" \"anti-ngf,\" \"fulranumab,\" \"tanezumab,\" \"sciatica,\" \"back pain,\" and \"spine.\" Inclusion criteria were observational studies with safety as an outcome and randomized or nonrandomized controlled trials studying the efficacy and/or the safety of anti-NGF drugs on low back pain. Exclusion criteria included patients with autoimmune conditions or osteoporosis. Studies were assessed independently by 2 authors regarding inclusion/exclusion criteria, risk of bias, clinical relevance, and quality of evidence (GRADE approach). 1,168 studies were retrieved. After excluding duplicates and applying the inclusion/exclusion criteria, 4 RCTs remained (n = 2,109): 2 for tanezumab, one for REGN475, and one for fulranumab. Only the tanezumab studies showed any significant difference over placebo (n = 1,563) for both pain relief and functional improvement. There is very low evidence that systemically administered anti-NGF therapy has a small positive effect compared to placebo for both pain relief (standarized mean difference [SMD] = -0.29, 95% confidence interval [CI] -0.58 to 0.00) and functional improvement (SMD = -0.21, 95%CI -0.37 to -0.05 ) of low back pain. There was low evidence of adverse effects (AEs) compared to placebo and low evidence of neurological AEs than placebo (relative risk = 1.93, 95%CI 1.41 to 2.64).Tanezumab, as a specific anti-NGF treatment, showed low evidence of a small to moderate effect for pain relief of low back pain (SMD = -0.44, 95%CI -0.81 to -0.07); and low evidence of a small effect for functional improvement (SMD = -0.26, 95%CI -0.40 to -0.12) with systemic administration, although not clinically significant. Tanezumab and anti-NGFs overall had, respectively, moderate and low evidence of overall AEs and serious AEs and a higher risk of developing neurological AEs when compared with placebo. Although anti-NGF, specifically tanezumab, showed a low-to-moderate effect on pain relief and functional improvement, it cannot be recommended for low back pain treatment. Without more research on the pathophysiology of anti-NGFs and adverse effects, its use is not safe in the overall population. However, as corroborated by the US Food and Drug Administration, this meta-analysis underscores a role for greater insight into anti-NGF therapy for painful conditions that are refractory to current drugs, such as oncologic pain, chronic pancreatitis, and phantom-limb pain. Given the pathophysiology of axial pain involving inflammatory mediators and the adverse effects of systemic anti-NGF use, consideration of local therapies may warrant further exploration.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "2ab00371c0644e0ca45158c35d6dbf8e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[139, 141], [35, 37]], "char_spans": [[817, 835], [222, 240]]}, {"text": "NGF", "token_spans": [[147, 147], [197, 197], [314, 314], [499, 499], [579, 579], [404, 404], [39, 39], [71, 71], [50, 50], [622, 622]], "char_spans": [[845, 847], [1086, 1088], [1749, 1751], [2690, 2692], [3107, 3109], [2191, 2193], [243, 245], [413, 415], [297, 299], [3363, 3365]]}]}], "context_tokens": [["Low", 0], ["back", 4], ["pain", 9], ["with", 14], ["or", 19], ["without", 22], ["radiculopathy", 30], ["is", 44], ["an", 47], ["important", 50], ["cause", 60], ["of", 66], ["disability", 69], ["and", 80], ["economic", 84], ["expenditure", 93], [".", 104], ["However", 106], [",", 113], ["many", 115], ["patients", 120], ["are", 129], ["not", 133], ["meeting", 137], ["optimal", 145], ["pain", 153], ["control", 158], ["through", 166], ["existing", 174], ["treatments", 183], [".", 193], ["Recent", 195], ["studies", 202], ["have", 210], ["linked", 215], ["nerve", 222], ["growth", 228], ["factor", 235], ["(", 242], ["NGF", 243], [")", 246], ["and", 248], ["the", 252], ["pathophysiology", 256], ["of", 272], ["persistent", 275], ["pain", 286], [".", 290], ["Anti", 292], ["-", 296], ["NGF", 297], ["could", 301], ["be", 307], ["an", 310], ["alternative", 313], ["drug", 325], ["treatment", 330], ["for", 340], ["low", 344], ["back", 348], ["pain", 353], [".", 357], ["Systematically", 359], ["review", 374], ["the", 381], ["efficacy", 385], ["and", 394], ["safety", 398], ["of", 405], ["anti", 408], ["-", 412], ["NGF", 413], ["in", 417], ["the", 420], ["treatment", 424], ["of", 434], ["low", 437], ["back", 441], ["pain", 446], [".", 450], ["A", 452], ["systematic", 454], ["review", 465], ["of", 472], ["the", 475], ["literature", 479], ["with", 490], ["no", 495], ["language", 498], [",", 506], ["date", 508], ["or", 513], ["publication", 516], ["status", 528], ["restriction", 535], [",", 546], ["using", 548], ["Medline", 554], [",", 561], ["EMBASE", 563], [",", 569], ["Cochrane", 571], ["Library", 580], [",", 587], ["and", 589], ["the", 593], ["clinicaltrials.gov", 597], ["database", 616], [".", 624], ["Additional", 626], ["literature", 637], ["was", 648], ["retrieved", 652], ["by", 662], ["conferring", 665], ["with", 676], ["experts", 681], ["in", 689], ["the", 692], ["field", 696], ["or", 702], ["reviewing", 705], ["bibliographies", 715], ["and", 730], ["annals", 734], ["of", 741], ["meetings", 744], ["and", 753], ["congresses", 757], [".", 767], ["Search", 769], ["terms", 776], ["included", 782], ["\"", 791], ["monoclonal", 792], ["antibodies", 803], [",", 813], ["\"", 814], ["\"", 816], ["nerve", 817], ["growth", 823], ["factor", 830], [",", 836], ["\"", 837], ["\"", 839], ["anti", 840], ["-", 844], ["ngf", 845], [",", 848], ["\"", 849], ["\"", 851], ["fulranumab", 852], [",", 862], ["\"", 863], ["\"", 865], ["tanezumab", 866], [",", 875], ["\"", 876], ["\"", 878], ["sciatica", 879], [",", 887], ["\"", 888], ["\"", 890], ["back", 891], ["pain", 896], [",", 900], ["\"", 901], ["and", 903], ["\"", 907], ["spine", 908], [".", 913], ["\"", 914], ["Inclusion", 916], ["criteria", 926], ["were", 935], ["observational", 940], ["studies", 954], ["with", 962], ["safety", 967], ["as", 974], ["an", 977], ["outcome", 980], ["and", 988], ["randomized", 992], ["or", 1003], ["nonrandomized", 1006], ["controlled", 1020], ["trials", 1031], ["studying", 1038], ["the", 1047], ["efficacy", 1051], ["and/or", 1060], ["the", 1067], ["safety", 1071], ["of", 1078], ["anti", 1081], ["-", 1085], ["NGF", 1086], ["drugs", 1090], ["on", 1096], ["low", 1099], ["back", 1103], ["pain", 1108], [".", 1112], ["Exclusion", 1114], ["criteria", 1124], ["included", 1133], ["patients", 1142], ["with", 1151], ["autoimmune", 1156], ["conditions", 1167], ["or", 1178], ["osteoporosis", 1181], [".", 1193], ["Studies", 1195], ["were", 1203], ["assessed", 1208], ["independently", 1217], ["by", 1231], ["2", 1234], ["authors", 1236], ["regarding", 1244], ["inclusion", 1254], ["/", 1263], ["exclusion", 1264], ["criteria", 1274], [",", 1282], ["risk", 1284], ["of", 1289], ["bias", 1292], [",", 1296], ["clinical", 1298], ["relevance", 1307], [",", 1316], ["and", 1318], ["quality", 1322], ["of", 1330], ["evidence", 1333], ["(", 1342], ["GRADE", 1343], ["approach", 1349], [")", 1357], [".", 1358], ["1,168", 1360], ["studies", 1366], ["were", 1374], ["retrieved", 1379], [".", 1388], ["After", 1390], ["excluding", 1396], ["duplicates", 1406], ["and", 1417], ["applying", 1421], ["the", 1430], ["inclusion", 1434], ["/", 1443], ["exclusion", 1444], ["criteria", 1454], [",", 1462], ["4", 1464], ["RCTs", 1466], ["remained", 1471], ["(", 1480], ["n", 1481], ["=", 1483], ["2,109", 1485], [")", 1490], [":", 1491], ["2", 1493], ["for", 1495], ["tanezumab", 1499], [",", 1508], ["one", 1510], ["for", 1514], ["REGN475", 1518], [",", 1525], ["and", 1527], ["one", 1531], ["for", 1535], ["fulranumab", 1539], [".", 1549], ["Only", 1551], ["the", 1556], ["tanezumab", 1560], ["studies", 1570], ["showed", 1578], ["any", 1585], ["significant", 1589], ["difference", 1601], ["over", 1612], ["placebo", 1617], ["(", 1625], ["n", 1626], ["=", 1628], ["1,563", 1630], [")", 1635], ["for", 1637], ["both", 1641], ["pain", 1646], ["relief", 1651], ["and", 1658], ["functional", 1662], ["improvement", 1673], [".", 1684], ["There", 1686], ["is", 1692], ["very", 1695], ["low", 1700], ["evidence", 1704], ["that", 1713], ["systemically", 1718], ["administered", 1731], ["anti", 1744], ["-", 1748], ["NGF", 1749], ["therapy", 1753], ["has", 1761], ["a", 1765], ["small", 1767], ["positive", 1773], ["effect", 1782], ["compared", 1789], ["to", 1798], ["placebo", 1801], ["for", 1809], ["both", 1813], ["pain", 1818], ["relief", 1823], ["(", 1830], ["standarized", 1831], ["mean", 1843], ["difference", 1848], ["[", 1859], ["SMD", 1860], ["]", 1863], ["=", 1865], ["-0.29", 1867], [",", 1872], ["95", 1874], ["%", 1876], ["confidence", 1878], ["interval", 1889], ["[", 1898], ["CI", 1899], ["]", 1901], ["-0.58", 1903], ["to", 1909], ["0.00", 1912], [")", 1916], ["and", 1918], ["functional", 1922], ["improvement", 1933], ["(", 1945], ["SMD", 1946], ["=", 1950], ["-0.21", 1952], [",", 1957], ["95%CI", 1959], ["-0.37", 1965], ["to", 1971], ["-0.05", 1974], [")", 1980], ["of", 1982], ["low", 1985], ["back", 1989], ["pain", 1994], [".", 1998], ["There", 2000], ["was", 2006], ["low", 2010], ["evidence", 2014], ["of", 2023], ["adverse", 2026], ["effects", 2034], ["(", 2042], ["AEs", 2043], [")", 2046], ["compared", 2048], ["to", 2057], ["placebo", 2060], ["and", 2068], ["low", 2072], ["evidence", 2076], ["of", 2085], ["neurological", 2088], ["AEs", 2101], ["than", 2105], ["placebo", 2110], ["(", 2118], ["relative", 2119], ["risk", 2128], ["=", 2133], ["1.93", 2135], [",", 2139], ["95%CI", 2141], ["1.41", 2147], ["to", 2152], ["2.64).Tanezumab", 2155], [",", 2170], ["as", 2172], ["a", 2175], ["specific", 2177], ["anti", 2186], ["-", 2190], ["NGF", 2191], ["treatment", 2195], [",", 2204], ["showed", 2206], ["low", 2213], ["evidence", 2217], ["of", 2226], ["a", 2229], ["small", 2231], ["to", 2237], ["moderate", 2240], ["effect", 2249], ["for", 2256], ["pain", 2260], ["relief", 2265], ["of", 2272], ["low", 2275], ["back", 2279], ["pain", 2284], ["(", 2289], ["SMD", 2290], ["=", 2294], ["-0.44", 2296], [",", 2301], ["95%CI", 2303], ["-0.81", 2309], ["to", 2315], ["-0.07", 2318], [")", 2323], [";", 2324], ["and", 2326], ["low", 2330], ["evidence", 2334], ["of", 2343], ["a", 2346], ["small", 2348], ["effect", 2354], ["for", 2361], ["functional", 2365], ["improvement", 2376], ["(", 2388], ["SMD", 2389], ["=", 2393], ["-0.26", 2395], [",", 2400], ["95%CI", 2402], ["-0.40", 2408], ["to", 2414], ["-0.12", 2417], [")", 2422], ["with", 2424], ["systemic", 2429], ["administration", 2438], [",", 2452], ["although", 2454], ["not", 2463], ["clinically", 2467], ["significant", 2478], [".", 2489], ["Tanezumab", 2491], ["and", 2501], ["anti", 2505], ["-", 2509], ["NGFs", 2510], ["overall", 2515], ["had", 2523], [",", 2526], ["respectively", 2528], [",", 2540], ["moderate", 2542], ["and", 2551], ["low", 2555], ["evidence", 2559], ["of", 2568], ["overall", 2571], ["AEs", 2579], ["and", 2583], ["serious", 2587], ["AEs", 2595], ["and", 2599], ["a", 2603], ["higher", 2605], ["risk", 2612], ["of", 2617], ["developing", 2620], ["neurological", 2631], ["AEs", 2644], ["when", 2648], ["compared", 2653], ["with", 2662], ["placebo", 2667], [".", 2674], ["Although", 2676], ["anti", 2685], ["-", 2689], ["NGF", 2690], [",", 2693], ["specifically", 2695], ["tanezumab", 2708], [",", 2717], ["showed", 2719], ["a", 2726], ["low", 2728], ["-", 2731], ["to", 2732], ["-", 2734], ["moderate", 2735], ["effect", 2744], ["on", 2751], ["pain", 2754], ["relief", 2759], ["and", 2766], ["functional", 2770], ["improvement", 2781], [",", 2792], ["it", 2794], ["can", 2797], ["not", 2800], ["be", 2804], ["recommended", 2807], ["for", 2819], ["low", 2823], ["back", 2827], ["pain", 2832], ["treatment", 2837], [".", 2846], ["Without", 2848], ["more", 2856], ["research", 2861], ["on", 2870], ["the", 2873], ["pathophysiology", 2877], ["of", 2893], ["anti", 2896], ["-", 2900], ["NGFs", 2901], ["and", 2906], ["adverse", 2910], ["effects", 2918], [",", 2925], ["its", 2927], ["use", 2931], ["is", 2935], ["not", 2938], ["safe", 2942], ["in", 2947], ["the", 2950], ["overall", 2954], ["population", 2962], [".", 2972], ["However", 2974], [",", 2981], ["as", 2983], ["corroborated", 2986], ["by", 2999], ["the", 3002], ["US", 3006], ["Food", 3009], ["and", 3014], ["Drug", 3018], ["Administration", 3023], [",", 3037], ["this", 3039], ["meta", 3044], ["-", 3048], ["analysis", 3049], ["underscores", 3058], ["a", 3070], ["role", 3072], ["for", 3077], ["greater", 3081], ["insight", 3089], ["into", 3097], ["anti", 3102], ["-", 3106], ["NGF", 3107], ["therapy", 3111], ["for", 3119], ["painful", 3123], ["conditions", 3131], ["that", 3142], ["are", 3147], ["refractory", 3151], ["to", 3162], ["current", 3165], ["drugs", 3173], [",", 3178], ["such", 3180], ["as", 3185], ["oncologic", 3188], ["pain", 3198], [",", 3202], ["chronic", 3204], ["pancreatitis", 3212], [",", 3224], ["and", 3226], ["phantom", 3230], ["-", 3237], ["limb", 3238], ["pain", 3243], [".", 3247], ["Given", 3249], ["the", 3255], ["pathophysiology", 3259], ["of", 3275], ["axial", 3278], ["pain", 3284], ["involving", 3289], ["inflammatory", 3299], ["mediators", 3312], ["and", 3322], ["the", 3326], ["adverse", 3330], ["effects", 3338], ["of", 3346], ["systemic", 3349], ["anti", 3358], ["-", 3362], ["NGF", 3363], ["use", 3367], [",", 3370], ["consideration", 3372], ["of", 3386], ["local", 3389], ["therapies", 3395], ["may", 3405], ["warrant", 3409], ["further", 3417], ["exploration", 3425], [".", 3436]]}
{"context": "Seven women in three generations of a family have been affected by Turner syndrome. Turner phenotype in this family is the result of deletion of the entire short arm of one X chromosome. The short arm deletion is transmitted by carriers of a balanced X-1 translocation. Autoradiographic findings showed that the deleted X chromosome was late labeling in those persons with Turner syndrome, whereas the normal X chromosome was late replicating in carriers of the balanced translocation. The results of Xga typing of erythrocytes suggest that the Xg locus is on the short arm of the X chromosome. Because of the clinical implications, we believe that families of persons with structural chromosomal abnormalities should be studied to exclude familial transmission.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "8a95f412e40d4b0ba12e01f67102652b", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[32, 32], [55, 55], [101, 101], [70, 70]], "char_spans": [[173, 173], [320, 320], [581, 581], [409, 409]]}]}], "context_tokens": [["Seven", 0], ["women", 6], ["in", 12], ["three", 15], ["generations", 21], ["of", 33], ["a", 36], ["family", 38], ["have", 45], ["been", 50], ["affected", 55], ["by", 64], ["Turner", 67], ["syndrome", 74], [".", 82], ["Turner", 84], ["phenotype", 91], ["in", 101], ["this", 104], ["family", 109], ["is", 116], ["the", 119], ["result", 123], ["of", 130], ["deletion", 133], ["of", 142], ["the", 145], ["entire", 149], ["short", 156], ["arm", 162], ["of", 166], ["one", 169], ["X", 173], ["chromosome", 175], [".", 185], ["The", 187], ["short", 191], ["arm", 197], ["deletion", 201], ["is", 210], ["transmitted", 213], ["by", 225], ["carriers", 228], ["of", 237], ["a", 240], ["balanced", 242], ["X-1", 251], ["translocation", 255], [".", 268], ["Autoradiographic", 270], ["findings", 287], ["showed", 296], ["that", 303], ["the", 308], ["deleted", 312], ["X", 320], ["chromosome", 322], ["was", 333], ["late", 337], ["labeling", 342], ["in", 351], ["those", 354], ["persons", 360], ["with", 368], ["Turner", 373], ["syndrome", 380], [",", 388], ["whereas", 390], ["the", 398], ["normal", 402], ["X", 409], ["chromosome", 411], ["was", 422], ["late", 426], ["replicating", 431], ["in", 443], ["carriers", 446], ["of", 455], ["the", 458], ["balanced", 462], ["translocation", 471], [".", 484], ["The", 486], ["results", 490], ["of", 498], ["Xga", 501], ["typing", 505], ["of", 512], ["erythrocytes", 515], ["suggest", 528], ["that", 536], ["the", 541], ["Xg", 545], ["locus", 548], ["is", 554], ["on", 557], ["the", 560], ["short", 564], ["arm", 570], ["of", 574], ["the", 577], ["X", 581], ["chromosome", 583], [".", 593], ["Because", 595], ["of", 603], ["the", 606], ["clinical", 610], ["implications", 619], [",", 631], ["we", 633], ["believe", 636], ["that", 644], ["families", 649], ["of", 658], ["persons", 661], ["with", 669], ["structural", 674], ["chromosomal", 685], ["abnormalities", 697], ["should", 711], ["be", 718], ["studied", 721], ["to", 729], ["exclude", 732], ["familial", 740], ["transmission", 749], [".", 761]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Our findings suggest that NF1 should be considered as being \"associated with PAH as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "d0289ed00e594970840413f51ee34e30", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[243, 243], [299, 299], [22, 22], [236, 236], [4, 4], [73, 73], [270, 270], [33, 33]], "char_spans": [[1370, 1372], [1723, 1725], [134, 136], [1338, 1340], [26, 28], [424, 426], [1541, 1543], [194, 196]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["disorder", 43], ["of", 52], ["dysregulated", 55], ["tissue", 68], ["growth", 75], ["secondary", 82], ["to", 92], ["mutations", 95], ["in", 105], ["the", 108], ["tumor", 112], ["suppressor", 118], ["gene", 129], ["NF1", 134], [".", 137], ["Pulmonary", 139], ["arterial", 149], ["hypertension", 158], ["(", 171], ["PAH", 172], [")", 175], ["in", 177], ["patients", 180], ["with", 189], ["NF1", 194], ["is", 198], ["hypothesized", 201], ["to", 214], ["be", 217], ["secondary", 220], ["to", 230], ["an", 233], ["underlying", 236], ["vasculopathy", 247], [".", 259], ["We", 261], ["describe", 264], ["the", 273], ["entity", 277], ["we", 284], ["term", 287], ["NF1-associated", 292], ["PAH", 307], ["(", 311], ["NF1-PAH", 312], [")", 319], ["in", 321], ["four", 324], ["new", 329], ["patients", 333], ["and", 342], ["update", 346], ["the", 353], ["data", 357], ["on", 362], ["four", 365], ["previously", 370], ["published", 381], ["reports", 391], ["of", 399], ["patients", 402], ["with", 411], ["PAH", 416], ["and", 420], ["NF1", 424], [".", 427], ["We", 429], ["performed", 432], ["genetic", 442], ["testing", 450], ["of", 458], ["the", 461], ["bone", 465], ["morphogenic", 470], ["protein", 482], ["receptor", 490], ["2", 499], ["(", 501], ["BMPR2", 502], [")", 507], ["gene", 509], [",", 513], ["which", 515], ["mutated", 521], ["in", 529], ["70", 532], ["%", 534], ["of", 536], ["patients", 539], ["with", 548], ["familial", 553], ["PAH", 562], ["and", 566], ["approximately", 570], ["25", 584], ["%", 586], ["of", 588], ["patients", 591], ["with", 600], ["idiopathic", 605], ["PAH", 616], [".", 619], ["We", 621], ["report", 624], [",", 630], ["for", 632], ["the", 636], ["first", 640], ["time", 646], [",", 650], ["pathologic", 652], ["findings", 663], ["in", 672], ["the", 675], ["autopsy", 679], ["-", 686], ["obtained", 687], ["lung", 696], ["of", 701], ["one", 704], ["patient", 708], ["with", 716], ["NF1-PAH", 721], [".", 728], ["Patients", 730], ["with", 739], ["NF1-PAH", 744], ["have", 752], ["a", 757], ["generally", 759], ["poor", 769], ["long", 774], ["-", 778], ["term", 779], ["prognosis", 784], [".", 793], ["In", 795], ["four", 798], ["patients", 803], [",", 811], ["we", 813], ["observed", 816], ["the", 825], ["mosaic", 829], ["pattern", 836], ["of", 844], ["lung", 847], ["attenuation", 852], ["on", 864], ["a", 867], ["CT", 869], ["scan", 872], ["of", 877], ["the", 880], ["chest", 884], [",", 889], ["a", 891], ["radiographic", 893], ["finding", 906], ["that", 914], ["can", 919], ["be", 923], ["consistent", 926], ["with", 937], ["an", 942], ["underlying", 945], ["vasculopathy", 956], [".", 968], ["No", 970], ["mutations", 973], ["or", 983], ["rearrangements", 986], ["in", 1001], ["the", 1004], ["BMPR2", 1008], ["gene", 1014], ["were", 1019], ["found", 1024], [".", 1029], ["We", 1031], ["observed", 1034], ["complex", 1043], ["plexiform", 1051], ["lesions", 1061], ["in", 1069], ["the", 1072], ["one", 1076], ["available", 1080], ["autopsy", 1090], ["specimen", 1098], [".", 1106], ["Similar", 1108], ["lesions", 1116], ["are", 1124], ["a", 1128], ["hallmark", 1130], ["of", 1139], ["plexogenic", 1142], ["pulmonary", 1153], ["arteriopathy", 1163], ["and", 1176], ["are", 1180], ["associated", 1184], ["with", 1195], ["several", 1200], ["severe", 1208], ["types", 1215], ["of", 1221], ["PAH", 1224], [".", 1227], ["(", 1229], ["Plexiform", 1230], ["lesions", 1240], ["should", 1248], ["not", 1255], ["be", 1259], ["confused", 1262], ["with", 1271], ["plexiform", 1276], ["neurofibromas", 1286], [",", 1299], ["which", 1301], ["are", 1307], ["distinctive", 1311], ["tumors", 1323], ["seen", 1330], ["in", 1335], ["NF1", 1338], [".", 1341], [")", 1342], ["Our", 1344], ["findings", 1348], ["suggest", 1357], ["that", 1365], ["NF1", 1370], ["should", 1374], ["be", 1381], ["considered", 1384], ["as", 1395], ["being", 1398], ["\"", 1404], ["associated", 1405], ["with", 1416], ["PAH", 1421], ["as", 1425], ["outlined", 1428], ["in", 1437], ["the", 1440], ["Revised", 1444], ["Clinical", 1452], ["Classification", 1461], ["of", 1476], ["Pulmonary", 1479], ["Hypertension", 1489], [".", 1501], ["Understanding", 1503], ["the", 1517], ["mechanism", 1521], ["of", 1531], ["PAH", 1534], ["in", 1538], ["NF1", 1541], ["may", 1545], ["inform", 1549], ["the", 1556], ["pathogenesis", 1560], ["of", 1573], ["PAH", 1576], [",", 1579], ["NF1-PAH", 1581], ["itself", 1589], [",", 1595], ["and", 1597], ["other", 1601], ["NF1-associated", 1607], ["vasculopathies", 1622], [".", 1636], ["The", 1638], ["pulmonary", 1642], ["vasculature", 1652], ["should", 1664], ["now", 1671], ["be", 1675], ["included", 1678], ["among", 1687], ["the", 1693], ["arterial", 1697], ["beds", 1706], ["affected", 1711], ["by", 1720], ["NF1", 1723], ["vasculopathy", 1727], [".", 1739]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is a progressive muscular dystrophy caused by decreased epigenetic repression of the D4Z4 macrosatellite repeats and ectopic expression of DUX4, a retrogene encoding a germline transcription factor encoded in each repeat. Unaffected individuals generally have more than 10 repeats arrayed in the subtelomeric region of chromosome 4, whereas the most common form of FSHD (FSHD1) is caused by a contraction of the array to fewer than 10 repeats, associated with decreased epigenetic repression and variegated expression of DUX4 in skeletal muscle. We have generated transgenic mice carrying D4Z4 arrays from an FSHD1 allele and from a control allele. These mice recapitulate important epigenetic and DUX4 expression attributes seen in patients and controls, respectively, including high DUX4 expression levels in the germline, (incomplete) epigenetic repression in somatic tissue, and FSHD-specific variegated DUX4 expression in sporadic muscle nuclei associated with D4Z4 chromatin relaxation. In addition we show that DUX4 is able to activate similar functional gene groups in mouse muscle cells as it does in human muscle cells. These transgenic mice therefore represent a valuable animal model for FSHD and will be a useful resource to study the molecular mechanisms underlying FSHD and to test new therapeutic intervention strategies.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7e10e131bea248ff97cf2ce156eb3fbb", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[0, 1]], "char_spans": [[0, 28]]}, {"text": "FSHD", "token_spans": [[147, 147], [3, 3], [61, 61], [212, 212], [199, 199]], "char_spans": [[920, 923], [31, 34], [402, 405], [1317, 1320], [1237, 1240]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["a", 40], ["progressive", 42], ["muscular", 54], ["dystrophy", 63], ["caused", 73], ["by", 80], ["decreased", 83], ["epigenetic", 93], ["repression", 104], ["of", 115], ["the", 118], ["D4Z4", 122], ["macrosatellite", 127], ["repeats", 142], ["and", 150], ["ectopic", 154], ["expression", 162], ["of", 173], ["DUX4", 176], [",", 180], ["a", 182], ["retrogene", 184], ["encoding", 194], ["a", 203], ["germline", 205], ["transcription", 214], ["factor", 228], ["encoded", 235], ["in", 243], ["each", 246], ["repeat", 251], [".", 257], ["Unaffected", 259], ["individuals", 270], ["generally", 282], ["have", 292], ["more", 297], ["than", 302], ["10", 307], ["repeats", 310], ["arrayed", 318], ["in", 326], ["the", 329], ["subtelomeric", 333], ["region", 346], ["of", 353], ["chromosome", 356], ["4", 367], [",", 368], ["whereas", 370], ["the", 378], ["most", 382], ["common", 387], ["form", 394], ["of", 399], ["FSHD", 402], ["(", 407], ["FSHD1", 408], [")", 413], ["is", 415], ["caused", 418], ["by", 425], ["a", 428], ["contraction", 430], ["of", 442], ["the", 445], ["array", 449], ["to", 455], ["fewer", 458], ["than", 464], ["10", 469], ["repeats", 472], [",", 479], ["associated", 481], ["with", 492], ["decreased", 497], ["epigenetic", 507], ["repression", 518], ["and", 529], ["variegated", 533], ["expression", 544], ["of", 555], ["DUX4", 558], ["in", 563], ["skeletal", 566], ["muscle", 575], [".", 581], ["We", 583], ["have", 586], ["generated", 591], ["transgenic", 601], ["mice", 612], ["carrying", 617], ["D4Z4", 626], ["arrays", 631], ["from", 638], ["an", 643], ["FSHD1", 646], ["allele", 652], ["and", 659], ["from", 663], ["a", 668], ["control", 670], ["allele", 678], [".", 684], ["These", 686], ["mice", 692], ["recapitulate", 697], ["important", 710], ["epigenetic", 720], ["and", 731], ["DUX4", 735], ["expression", 740], ["attributes", 751], ["seen", 762], ["in", 767], ["patients", 770], ["and", 779], ["controls", 783], [",", 791], ["respectively", 793], [",", 805], ["including", 807], ["high", 817], ["DUX4", 822], ["expression", 827], ["levels", 838], ["in", 845], ["the", 848], ["germline", 852], [",", 860], ["(", 862], ["incomplete", 863], [")", 873], ["epigenetic", 875], ["repression", 886], ["in", 897], ["somatic", 900], ["tissue", 908], [",", 914], ["and", 916], ["FSHD", 920], ["-", 924], ["specific", 925], ["variegated", 934], ["DUX4", 945], ["expression", 950], ["in", 961], ["sporadic", 964], ["muscle", 973], ["nuclei", 980], ["associated", 987], ["with", 998], ["D4Z4", 1003], ["chromatin", 1008], ["relaxation", 1018], [".", 1028], ["In", 1030], ["addition", 1033], ["we", 1042], ["show", 1045], ["that", 1050], ["DUX4", 1055], ["is", 1060], ["able", 1063], ["to", 1068], ["activate", 1071], ["similar", 1080], ["functional", 1088], ["gene", 1099], ["groups", 1104], ["in", 1111], ["mouse", 1114], ["muscle", 1120], ["cells", 1127], ["as", 1133], ["it", 1136], ["does", 1139], ["in", 1144], ["human", 1147], ["muscle", 1153], ["cells", 1160], [".", 1165], ["These", 1167], ["transgenic", 1173], ["mice", 1184], ["therefore", 1189], ["represent", 1199], ["a", 1209], ["valuable", 1211], ["animal", 1220], ["model", 1227], ["for", 1233], ["FSHD", 1237], ["and", 1242], ["will", 1246], ["be", 1251], ["a", 1254], ["useful", 1256], ["resource", 1263], ["to", 1272], ["study", 1275], ["the", 1281], ["molecular", 1285], ["mechanisms", 1295], ["underlying", 1306], ["FSHD", 1317], ["and", 1322], ["to", 1326], ["test", 1329], ["new", 1334], ["therapeutic", 1338], ["intervention", 1350], ["strategies", 1363], [".", 1373]]}
{"context": "Since the initial approval of imatinib much has been learned about its resistance mechanisms, and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy. Targeted therapy with TKIs has continued to be an area of active research and development in the care of acute and chronic leukemia patients. This article reviews current approved and investigational TKI treatments for chronic myelogenous leukemia (CML), Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph + ALL) and acute myelogenous leukemia (AML). There are now more potent BCR-ABL TKIs approved, which allow for additional options when determining front-line and second-line CML and Ph + ALL treatments. The T315I mutation is an ever-present challenge. Ponatinib, a pan BCR-ABL TKI, while still under investigation, is very hopeful with its ability to overcome T315I mutations in resistant CML and Ph + ALL patients. Because nilotinib and dasatinib have not been directly compared, at present we recommend selecting one or the other based on the side-effect profile, drug interactions, patient comorbidities, and mutational status. FLT-3 inhibition is of particular interest in AML patients with FLT-3 internal tandem duplication mutations; this type of targeted therapy continues to be studied.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "20881870f0d2416882fd571c09f5bccb", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[97, 99], [22, 24], [138, 140]], "char_spans": [[572, 578], [137, 143], [769, 775]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["initial", 10], ["approval", 18], ["of", 27], ["imatinib", 30], ["much", 39], ["has", 44], ["been", 48], ["learned", 53], ["about", 61], ["its", 67], ["resistance", 71], ["mechanisms", 82], [",", 92], ["and", 94], ["efforts", 98], ["have", 106], ["continued", 111], ["to", 121], ["improve", 124], ["upon", 132], ["BCR", 137], ["-", 140], ["ABL", 141], ["tyrosine", 145], ["kinase", 154], ["inhibitor", 161], ["therapy", 171], [".", 178], ["Targeted", 180], ["therapy", 189], ["with", 197], ["TKIs", 202], ["has", 207], ["continued", 211], ["to", 221], ["be", 224], ["an", 227], ["area", 230], ["of", 235], ["active", 238], ["research", 245], ["and", 254], ["development", 258], ["in", 270], ["the", 273], ["care", 277], ["of", 282], ["acute", 285], ["and", 291], ["chronic", 295], ["leukemia", 303], ["patients", 312], [".", 320], ["This", 322], ["article", 327], ["reviews", 335], ["current", 343], ["approved", 351], ["and", 360], ["investigational", 364], ["TKI", 380], ["treatments", 384], ["for", 395], ["chronic", 399], ["myelogenous", 407], ["leukemia", 419], ["(", 428], ["CML", 429], [")", 432], [",", 433], ["Philadelphia", 435], ["-", 447], ["chromosome", 448], ["positive", 459], ["acute", 468], ["lymphoblastic", 474], ["leukemia", 488], ["(", 497], ["Ph", 498], ["+", 501], ["ALL", 503], [")", 506], ["and", 508], ["acute", 512], ["myelogenous", 518], ["leukemia", 530], ["(", 539], ["AML", 540], [")", 543], [".", 544], ["There", 546], ["are", 552], ["now", 556], ["more", 560], ["potent", 565], ["BCR", 572], ["-", 575], ["ABL", 576], ["TKIs", 580], ["approved", 585], [",", 593], ["which", 595], ["allow", 601], ["for", 607], ["additional", 611], ["options", 622], ["when", 630], ["determining", 635], ["front", 647], ["-", 652], ["line", 653], ["and", 658], ["second", 662], ["-", 668], ["line", 669], ["CML", 674], ["and", 678], ["Ph", 682], ["+", 685], ["ALL", 687], ["treatments", 691], [".", 701], ["The", 703], ["T315I", 707], ["mutation", 713], ["is", 722], ["an", 725], ["ever", 728], ["-", 732], ["present", 733], ["challenge", 741], [".", 750], ["Ponatinib", 752], [",", 761], ["a", 763], ["pan", 765], ["BCR", 769], ["-", 772], ["ABL", 773], ["TKI", 777], [",", 780], ["while", 782], ["still", 788], ["under", 794], ["investigation", 800], [",", 813], ["is", 815], ["very", 818], ["hopeful", 823], ["with", 831], ["its", 836], ["ability", 840], ["to", 848], ["overcome", 851], ["T315I", 860], ["mutations", 866], ["in", 876], ["resistant", 879], ["CML", 889], ["and", 893], ["Ph", 897], ["+", 900], ["ALL", 902], ["patients", 906], [".", 914], ["Because", 916], ["nilotinib", 924], ["and", 934], ["dasatinib", 938], ["have", 948], ["not", 953], ["been", 957], ["directly", 962], ["compared", 971], [",", 979], ["at", 981], ["present", 984], ["we", 992], ["recommend", 995], ["selecting", 1005], ["one", 1015], ["or", 1019], ["the", 1022], ["other", 1026], ["based", 1032], ["on", 1038], ["the", 1041], ["side", 1045], ["-", 1049], ["effect", 1050], ["profile", 1057], [",", 1064], ["drug", 1066], ["interactions", 1071], [",", 1083], ["patient", 1085], ["comorbidities", 1093], [",", 1106], ["and", 1108], ["mutational", 1112], ["status", 1123], [".", 1129], ["FLT-3", 1131], ["inhibition", 1137], ["is", 1148], ["of", 1151], ["particular", 1154], ["interest", 1165], ["in", 1174], ["AML", 1177], ["patients", 1181], ["with", 1190], ["FLT-3", 1195], ["internal", 1201], ["tandem", 1210], ["duplication", 1217], ["mutations", 1229], [";", 1238], ["this", 1240], ["type", 1245], ["of", 1250], ["targeted", 1253], ["therapy", 1262], ["continues", 1270], ["to", 1280], ["be", 1283], ["studied", 1286], [".", 1293]]}
{"context": "Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor that directly interacts with the histone deacetylase Rpd3. Although previous studies suggest that this interaction is required for repression of Gro-responsive reporters in cultured cells, the in vivo significance of this interaction and the mechanism by which it leads to repression remain largely unexplored. In this study, we show that Gro is partially dependent on Rpd3 for repression, supporting the idea that Rpd3-mediated repression is one mode of Gro-mediated repression. We demonstrate that Gro colocalizes with Rpd3 to the chromatin of a target gene and that this is accompanied by the deacetylation of specific lysines within the N-terminal tails of histones H3 and H4. Gro overexpression leads to wing patterning defects and ectopic repression in the wing disc of transcription directed by the vestigial quadrant enhancer. These effects are reversed by the histone deacetylase inhibitors TSA and HC-Toxin and by the reduction of Rpd3 gene dosage. Furthermore, repression of the vestigial quadrant enhancer is accompanied by a Gro-mediated increase in nucleosome density, an effect that is reversed by histone deacetylase inhibitors. We propose a model in which Gro-mediated histone deacetylation results in increased nucleosome density leading to transcriptional repression.", "qas": [{"question": "What is the Drosophila melanogaster Groucho protein?", "answers": ["Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor"], "qid": "cb1860ac490e4c2cb4db0aaf636faa83", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["Drosophila", 12], ["melanogaster", 23], ["Groucho", 36], ["protein", 44], ["?", 51]], "detected_answers": [{"text": "Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor", "token_spans": [[0, 9]], "char_spans": [[0, 69]]}]}], "context_tokens": [["Groucho", 0], ["(", 8], ["Gro", 9], [")", 12], ["is", 14], ["a", 17], ["Drosophila", 19], ["melanogaster", 30], ["transcriptional", 43], ["corepressor", 59], ["that", 71], ["directly", 76], ["interacts", 85], ["with", 95], ["the", 100], ["histone", 104], ["deacetylase", 112], ["Rpd3", 124], [".", 128], ["Although", 130], ["previous", 139], ["studies", 148], ["suggest", 156], ["that", 164], ["this", 169], ["interaction", 174], ["is", 186], ["required", 189], ["for", 198], ["repression", 202], ["of", 213], ["Gro", 216], ["-", 219], ["responsive", 220], ["reporters", 231], ["in", 241], ["cultured", 244], ["cells", 253], [",", 258], ["the", 260], ["in", 264], ["vivo", 267], ["significance", 272], ["of", 285], ["this", 288], ["interaction", 293], ["and", 305], ["the", 309], ["mechanism", 313], ["by", 323], ["which", 326], ["it", 332], ["leads", 335], ["to", 341], ["repression", 344], ["remain", 355], ["largely", 362], ["unexplored", 370], [".", 380], ["In", 382], ["this", 385], ["study", 390], [",", 395], ["we", 397], ["show", 400], ["that", 405], ["Gro", 410], ["is", 414], ["partially", 417], ["dependent", 427], ["on", 437], ["Rpd3", 440], ["for", 445], ["repression", 449], [",", 459], ["supporting", 461], ["the", 472], ["idea", 476], ["that", 481], ["Rpd3-mediated", 486], ["repression", 500], ["is", 511], ["one", 514], ["mode", 518], ["of", 523], ["Gro", 526], ["-", 529], ["mediated", 530], ["repression", 539], [".", 549], ["We", 551], ["demonstrate", 554], ["that", 566], ["Gro", 571], ["colocalizes", 575], ["with", 587], ["Rpd3", 592], ["to", 597], ["the", 600], ["chromatin", 604], ["of", 614], ["a", 617], ["target", 619], ["gene", 626], ["and", 631], ["that", 635], ["this", 640], ["is", 645], ["accompanied", 648], ["by", 660], ["the", 663], ["deacetylation", 667], ["of", 681], ["specific", 684], ["lysines", 693], ["within", 701], ["the", 708], ["N", 712], ["-", 713], ["terminal", 714], ["tails", 723], ["of", 729], ["histones", 732], ["H3", 741], ["and", 744], ["H4", 748], [".", 750], ["Gro", 752], ["overexpression", 756], ["leads", 771], ["to", 777], ["wing", 780], ["patterning", 785], ["defects", 796], ["and", 804], ["ectopic", 808], ["repression", 816], ["in", 827], ["the", 830], ["wing", 834], ["disc", 839], ["of", 844], ["transcription", 847], ["directed", 861], ["by", 870], ["the", 873], ["vestigial", 877], ["quadrant", 887], ["enhancer", 896], [".", 904], ["These", 906], ["effects", 912], ["are", 920], ["reversed", 924], ["by", 933], ["the", 936], ["histone", 940], ["deacetylase", 948], ["inhibitors", 960], ["TSA", 971], ["and", 975], ["HC", 979], ["-", 981], ["Toxin", 982], ["and", 988], ["by", 992], ["the", 995], ["reduction", 999], ["of", 1009], ["Rpd3", 1012], ["gene", 1017], ["dosage", 1022], [".", 1028], ["Furthermore", 1030], [",", 1041], ["repression", 1043], ["of", 1054], ["the", 1057], ["vestigial", 1061], ["quadrant", 1071], ["enhancer", 1080], ["is", 1089], ["accompanied", 1092], ["by", 1104], ["a", 1107], ["Gro", 1109], ["-", 1112], ["mediated", 1113], ["increase", 1122], ["in", 1131], ["nucleosome", 1134], ["density", 1145], [",", 1152], ["an", 1154], ["effect", 1157], ["that", 1164], ["is", 1169], ["reversed", 1172], ["by", 1181], ["histone", 1184], ["deacetylase", 1192], ["inhibitors", 1204], [".", 1214], ["We", 1216], ["propose", 1219], ["a", 1227], ["model", 1229], ["in", 1235], ["which", 1238], ["Gro", 1244], ["-", 1247], ["mediated", 1248], ["histone", 1257], ["deacetylation", 1265], ["results", 1279], ["in", 1287], ["increased", 1290], ["nucleosome", 1300], ["density", 1311], ["leading", 1319], ["to", 1327], ["transcriptional", 1330], ["repression", 1346], [".", 1356]]}
{"context": "Although methicillin (meticillin)-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to vancomycin (RVS-MRSA; including vancomycin-intermediate S. aureus [VISA] and heterogeneous VISA [hVISA]) have been linked with vancomycin treatment failure, it is unclear whether they are more pathogenic than vancomycin-susceptible MRSA (VS-MRSA). We prospectively assessed patients with clinical MRSA isolates during a 10-month period to determine clinical status (infection versus colonization) and therapeutic outcome before correlating these findings with the results of detailed in vitro assessment of vancomycin susceptibility, including population analysis profile (PAP) testing. hVISA and VISA were defined by standard PAP criteria (area-under-the-curve ratio compared to that of the reference hVISA strain Mu3 [>or=0.9]) and routine CLSI criteria (vancomycin MIC, 4 to 8 microg/ml), respectively. Among the 117 patients assessed, 58 had RVS-MRSA isolates (56 hVISA and 2 VISA) and 59 had VS-MRSA isolates; the patient demographics and comorbidities were similar. RVS-MRSA was associated with a lower rate of infection than VS-MRSA (29/58 versus 46/59; P = 0.003), including a lower rate of bacteremia (3/58 versus 20/59, respectively; P < 0.001). The cure rates in RVS-MRSA and VS-MRSA groups were not statistically different (16/26 versus 31/42; P = 0.43), but the post hoc assessment of treatment regimes and study size made detailed conclusions difficult. The results of the macro method Etest correlated well with the PAP results (sensitivity, 98.3%, and specificity, 91.5%), but broth microdilution and our preliminary RVS-MRSA detection method correlated poorly. All isolates were susceptible to linezolid and daptomycin. These data suggest that detailed prospective laboratory identification of RVS-MRSA isolates may be of limited value and that, instead, such in vitro investigation should be reserved for isolates from patients who are failing appropriate anti-MRSA therapy.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "ceea58daf75a47a2a1f4006fe10ba779", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[69, 69], [211, 211], [186, 186], [246, 246], [250, 250], [342, 342], [60, 60], [172, 172], [7, 7], [199, 199], [316, 316], [371, 371], [56, 56], [18, 18]], "char_spans": [[409, 412], [1147, 1150], [1012, 1015], [1290, 1293], [1302, 1305], [1827, 1830], [353, 356], [962, 965], [67, 70], [1088, 1091], [1649, 1652], [1991, 1994], [344, 347], [128, 131]]}]}], "context_tokens": [["Although", 0], ["methicillin", 9], ["(", 21], ["meticillin)-resistant", 22], ["Staphylococcus", 44], ["aureus", 59], ["(", 66], ["MRSA", 67], [")", 71], ["strains", 73], ["with", 81], ["reduced", 86], ["susceptibility", 94], ["to", 109], ["vancomycin", 112], ["(", 123], ["RVS", 124], ["-", 127], ["MRSA", 128], [";", 132], ["including", 134], ["vancomycin", 144], ["-", 154], ["intermediate", 155], ["S.", 168], ["aureus", 171], ["[", 178], ["VISA", 179], ["]", 183], ["and", 185], ["heterogeneous", 189], ["VISA", 203], ["[", 208], ["hVISA", 209], ["]", 214], [")", 215], ["have", 217], ["been", 222], ["linked", 227], ["with", 234], ["vancomycin", 239], ["treatment", 250], ["failure", 260], [",", 267], ["it", 269], ["is", 272], ["unclear", 275], ["whether", 283], ["they", 291], ["are", 296], ["more", 300], ["pathogenic", 305], ["than", 316], ["vancomycin", 321], ["-", 331], ["susceptible", 332], ["MRSA", 344], ["(", 349], ["VS", 350], ["-", 352], ["MRSA", 353], [")", 357], [".", 358], ["We", 360], ["prospectively", 363], ["assessed", 377], ["patients", 386], ["with", 395], ["clinical", 400], ["MRSA", 409], ["isolates", 414], ["during", 423], ["a", 430], ["10-month", 432], ["period", 441], ["to", 448], ["determine", 451], ["clinical", 461], ["status", 470], ["(", 477], ["infection", 478], ["versus", 488], ["colonization", 495], [")", 507], ["and", 509], ["therapeutic", 513], ["outcome", 525], ["before", 533], ["correlating", 540], ["these", 552], ["findings", 558], ["with", 567], ["the", 572], ["results", 576], ["of", 584], ["detailed", 587], ["in", 596], ["vitro", 599], ["assessment", 605], ["of", 616], ["vancomycin", 619], ["susceptibility", 630], [",", 644], ["including", 646], ["population", 656], ["analysis", 667], ["profile", 676], ["(", 684], ["PAP", 685], [")", 688], ["testing", 690], [".", 697], ["hVISA", 699], ["and", 705], ["VISA", 709], ["were", 714], ["defined", 719], ["by", 727], ["standard", 730], ["PAP", 739], ["criteria", 743], ["(", 752], ["area", 753], ["-", 757], ["under", 758], ["-", 763], ["the", 764], ["-", 767], ["curve", 768], ["ratio", 774], ["compared", 780], ["to", 789], ["that", 792], ["of", 797], ["the", 800], ["reference", 804], ["hVISA", 814], ["strain", 820], ["Mu3", 827], ["[", 831], [">", 832], ["or=0.9", 833], ["]", 839], [")", 840], ["and", 842], ["routine", 846], ["CLSI", 854], ["criteria", 859], ["(", 868], ["vancomycin", 869], ["MIC", 880], [",", 883], ["4", 885], ["to", 887], ["8", 890], ["microg", 892], ["/", 898], ["ml", 899], [")", 901], [",", 902], ["respectively", 904], [".", 916], ["Among", 918], ["the", 924], ["117", 928], ["patients", 932], ["assessed", 941], [",", 949], ["58", 951], ["had", 954], ["RVS", 958], ["-", 961], ["MRSA", 962], ["isolates", 967], ["(", 976], ["56", 977], ["hVISA", 980], ["and", 986], ["2", 990], ["VISA", 992], [")", 996], ["and", 998], ["59", 1002], ["had", 1005], ["VS", 1009], ["-", 1011], ["MRSA", 1012], ["isolates", 1017], [";", 1025], ["the", 1027], ["patient", 1031], ["demographics", 1039], ["and", 1052], ["comorbidities", 1056], ["were", 1070], ["similar", 1075], [".", 1082], ["RVS", 1084], ["-", 1087], ["MRSA", 1088], ["was", 1093], ["associated", 1097], ["with", 1108], ["a", 1113], ["lower", 1115], ["rate", 1121], ["of", 1126], ["infection", 1129], ["than", 1139], ["VS", 1144], ["-", 1146], ["MRSA", 1147], ["(", 1152], ["29/58", 1153], ["versus", 1159], ["46/59", 1166], [";", 1171], ["P", 1173], ["=", 1175], ["0.003", 1177], [")", 1182], [",", 1183], ["including", 1185], ["a", 1195], ["lower", 1197], ["rate", 1203], ["of", 1208], ["bacteremia", 1211], ["(", 1222], ["3/58", 1223], ["versus", 1228], ["20/59", 1235], [",", 1240], ["respectively", 1242], [";", 1254], ["P", 1256], ["<", 1258], ["0.001", 1260], [")", 1265], [".", 1266], ["The", 1268], ["cure", 1272], ["rates", 1277], ["in", 1283], ["RVS", 1286], ["-", 1289], ["MRSA", 1290], ["and", 1295], ["VS", 1299], ["-", 1301], ["MRSA", 1302], ["groups", 1307], ["were", 1314], ["not", 1319], ["statistically", 1323], ["different", 1337], ["(", 1347], ["16/26", 1348], ["versus", 1354], ["31/42", 1361], [";", 1366], ["P", 1368], ["=", 1370], ["0.43", 1372], [")", 1376], [",", 1377], ["but", 1379], ["the", 1383], ["post", 1387], ["hoc", 1392], ["assessment", 1396], ["of", 1407], ["treatment", 1410], ["regimes", 1420], ["and", 1428], ["study", 1432], ["size", 1438], ["made", 1443], ["detailed", 1448], ["conclusions", 1457], ["difficult", 1469], [".", 1478], ["The", 1480], ["results", 1484], ["of", 1492], ["the", 1495], ["macro", 1499], ["method", 1505], ["Etest", 1512], ["correlated", 1518], ["well", 1529], ["with", 1534], ["the", 1539], ["PAP", 1543], ["results", 1547], ["(", 1555], ["sensitivity", 1556], [",", 1567], ["98.3", 1569], ["%", 1573], [",", 1574], ["and", 1576], ["specificity", 1580], [",", 1591], ["91.5", 1593], ["%", 1597], [")", 1598], [",", 1599], ["but", 1601], ["broth", 1605], ["microdilution", 1611], ["and", 1625], ["our", 1629], ["preliminary", 1633], ["RVS", 1645], ["-", 1648], ["MRSA", 1649], ["detection", 1654], ["method", 1664], ["correlated", 1671], ["poorly", 1682], [".", 1688], ["All", 1690], ["isolates", 1694], ["were", 1703], ["susceptible", 1708], ["to", 1720], ["linezolid", 1723], ["and", 1733], ["daptomycin", 1737], [".", 1747], ["These", 1749], ["data", 1755], ["suggest", 1760], ["that", 1768], ["detailed", 1773], ["prospective", 1782], ["laboratory", 1794], ["identification", 1805], ["of", 1820], ["RVS", 1823], ["-", 1826], ["MRSA", 1827], ["isolates", 1832], ["may", 1841], ["be", 1845], ["of", 1848], ["limited", 1851], ["value", 1859], ["and", 1865], ["that", 1869], [",", 1873], ["instead", 1875], [",", 1882], ["such", 1884], ["in", 1889], ["vitro", 1892], ["investigation", 1898], ["should", 1912], ["be", 1919], ["reserved", 1922], ["for", 1931], ["isolates", 1935], ["from", 1944], ["patients", 1949], ["who", 1958], ["are", 1962], ["failing", 1966], ["appropriate", 1974], ["anti", 1986], ["-", 1990], ["MRSA", 1991], ["therapy", 1996], [".", 2003]]}
{"context": "The light-harvesting chlorophyll a/b-protein complex of photosystem II (LHCII) is the most abundant membrane protein in green plants, and its degradation is a crucial process for the acclimation to high light conditions and for the recovery of nitrogen (N) and carbon (C) during senescence. However, the molecular mechanism of LHCII degradation is largely unknown. Here, we report that chlorophyll b reductase, which catalyzes the first step of chlorophyll b degradation, plays a central role in LHCII degradation. When the genes for chlorophyll b reductases NOL and NYC1 were disrupted in Arabidopsis thaliana, chlorophyll b and LHCII were not degraded during senescence, whereas other pigment complexes completely disappeared. When purified trimeric LHCII was incubated with recombinant chlorophyll b reductase (NOL), expressed in Escherichia coli, the chlorophyll b in LHCII was converted to 7-hydroxymethyl chlorophyll a. Accompanying this conversion, chlorophylls were released from LHCII apoproteins until all the chlorophyll molecules in LHCII dissociated from the complexes. Chlorophyll-depleted LHCII apoproteins did not dissociate into monomeric forms but remained in the trimeric form. Based on these results, we propose the novel hypothesis that chlorophyll b reductase catalyzes the initial step of LHCII degradation, and that trimeric LHCII is a substrate of LHCII degradation.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "e65867b72b4e4b6cab1e8ae033a60312", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[64, 64], [226, 226], [133, 133], [154, 154], [177, 177], [186, 186], [116, 116], [220, 220], [169, 169], [231, 231], [94, 94], [15, 15]], "char_spans": [[327, 331], [1349, 1353], [752, 756], [872, 876], [1045, 1049], [1104, 1108], [630, 634], [1312, 1316], [988, 992], [1373, 1377], [496, 500], [72, 76]]}]}], "context_tokens": [["The", 0], ["light", 4], ["-", 9], ["harvesting", 10], ["chlorophyll", 21], ["a", 33], ["/", 34], ["b", 35], ["-", 36], ["protein", 37], ["complex", 45], ["of", 53], ["photosystem", 56], ["II", 68], ["(", 71], ["LHCII", 72], [")", 77], ["is", 79], ["the", 82], ["most", 86], ["abundant", 91], ["membrane", 100], ["protein", 109], ["in", 117], ["green", 120], ["plants", 126], [",", 132], ["and", 134], ["its", 138], ["degradation", 142], ["is", 154], ["a", 157], ["crucial", 159], ["process", 167], ["for", 175], ["the", 179], ["acclimation", 183], ["to", 195], ["high", 198], ["light", 203], ["conditions", 209], ["and", 220], ["for", 224], ["the", 228], ["recovery", 232], ["of", 241], ["nitrogen", 244], ["(", 253], ["N", 254], [")", 255], ["and", 257], ["carbon", 261], ["(", 268], ["C", 269], [")", 270], ["during", 272], ["senescence", 279], [".", 289], ["However", 291], [",", 298], ["the", 300], ["molecular", 304], ["mechanism", 314], ["of", 324], ["LHCII", 327], ["degradation", 333], ["is", 345], ["largely", 348], ["unknown", 356], [".", 363], ["Here", 365], [",", 369], ["we", 371], ["report", 374], ["that", 381], ["chlorophyll", 386], ["b", 398], ["reductase", 400], [",", 409], ["which", 411], ["catalyzes", 417], ["the", 427], ["first", 431], ["step", 437], ["of", 442], ["chlorophyll", 445], ["b", 457], ["degradation", 459], [",", 470], ["plays", 472], ["a", 478], ["central", 480], ["role", 488], ["in", 493], ["LHCII", 496], ["degradation", 502], [".", 513], ["When", 515], ["the", 520], ["genes", 524], ["for", 530], ["chlorophyll", 534], ["b", 546], ["reductases", 548], ["NOL", 559], ["and", 563], ["NYC1", 567], ["were", 572], ["disrupted", 577], ["in", 587], ["Arabidopsis", 590], ["thaliana", 602], [",", 610], ["chlorophyll", 612], ["b", 624], ["and", 626], ["LHCII", 630], ["were", 636], ["not", 641], ["degraded", 645], ["during", 654], ["senescence", 661], [",", 671], ["whereas", 673], ["other", 681], ["pigment", 687], ["complexes", 695], ["completely", 705], ["disappeared", 716], [".", 727], ["When", 729], ["purified", 734], ["trimeric", 743], ["LHCII", 752], ["was", 758], ["incubated", 762], ["with", 772], ["recombinant", 777], ["chlorophyll", 789], ["b", 801], ["reductase", 803], ["(", 813], ["NOL", 814], [")", 817], [",", 818], ["expressed", 820], ["in", 830], ["Escherichia", 833], ["coli", 845], [",", 849], ["the", 851], ["chlorophyll", 855], ["b", 867], ["in", 869], ["LHCII", 872], ["was", 878], ["converted", 882], ["to", 892], ["7-hydroxymethyl", 895], ["chlorophyll", 911], ["a.", 923], ["Accompanying", 926], ["this", 939], ["conversion", 944], [",", 954], ["chlorophylls", 956], ["were", 969], ["released", 974], ["from", 983], ["LHCII", 988], ["apoproteins", 994], ["until", 1006], ["all", 1012], ["the", 1016], ["chlorophyll", 1020], ["molecules", 1032], ["in", 1042], ["LHCII", 1045], ["dissociated", 1051], ["from", 1063], ["the", 1068], ["complexes", 1072], [".", 1081], ["Chlorophyll", 1083], ["-", 1094], ["depleted", 1095], ["LHCII", 1104], ["apoproteins", 1110], ["did", 1122], ["not", 1126], ["dissociate", 1130], ["into", 1141], ["monomeric", 1146], ["forms", 1156], ["but", 1162], ["remained", 1166], ["in", 1175], ["the", 1178], ["trimeric", 1182], ["form", 1191], [".", 1195], ["Based", 1197], ["on", 1203], ["these", 1206], ["results", 1212], [",", 1219], ["we", 1221], ["propose", 1224], ["the", 1232], ["novel", 1236], ["hypothesis", 1242], ["that", 1253], ["chlorophyll", 1258], ["b", 1270], ["reductase", 1272], ["catalyzes", 1282], ["the", 1292], ["initial", 1296], ["step", 1304], ["of", 1309], ["LHCII", 1312], ["degradation", 1318], [",", 1329], ["and", 1331], ["that", 1335], ["trimeric", 1340], ["LHCII", 1349], ["is", 1355], ["a", 1358], ["substrate", 1360], ["of", 1370], ["LHCII", 1373], ["degradation", 1379], [".", 1390]]}
{"context": "The superoxide-producing phagocyte NADPH oxidase gp91(phox)/Nox2 and the non-phagocytic oxidases Nox1 and Nox3 each form a complex in the membrane with p22(phox), which provides both stabilization and a docking site for organizer proteins. The p22(phox)-complexed Nox2 and Nox1 are dormant on their own, and their activation requires soluble supportive proteins such as a Nox organizer (p47(phox) or Noxo1) and a Nox activator (p67(phox) or Noxa1). The small GTPase Rac directly binds to the activators, and thus plays an essential role in the Nox2-based oxidase containing p47(phox) and p67(phox) or a positive role in Nox1 activity supported by Noxo1 and Noxa1. Although Nox3 complexed with p22(phox) constitutively produce superoxide, the production can be enhanced by supportive proteins. Here we compare the roles of Rac in these p22(phox)-dependent oxidases using the organizer and activator in different combinations. Expression of constitutively active Rac1(Q61L) is essential for activation of the Nox2- or Nox1-based oxidase containing the organizer p47(phox) and either p67(phox) or Noxa1. When these oxidases use Noxo1 as an organizer instead of p47(phox), they produce a small but significant amount of superoxide without expression of Rac1(Q61L), although the production is enhanced by Rac1(Q61L). Thus p47(phox) is likely related to strict dependence on Rac. The Nox3-based oxidase has a similar tendency in the change of the dependence: Rac plays a positive role in Nox3 activation in the presence of p47(phox) and either p67(phox) or Noxa1, whereas Rac fails to upregulate Nox3 activity when p47(phox) is replaced with Noxo1. We also demonstrate that, in the Nox3-based oxidase containing solely p67(phox) as supportive protein, expression of Rac1(Q61L) enhances not only superoxide production but also membrane translocation of p67(phox). Since the enhancements are not observed with a mutant p67(phox) defective in binding to Rac, this GTPase appear to directly recruit p67(phox) to the membrane.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "3e6978c75bef49edbd8b728bbe7b06de", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[44, 44], [111, 111], [14, 14]], "char_spans": [[273, 276], [620, 623], [97, 100]]}]}], "context_tokens": [["The", 0], ["superoxide", 4], ["-", 14], ["producing", 15], ["phagocyte", 25], ["NADPH", 35], ["oxidase", 41], ["gp91(phox)/Nox2", 49], ["and", 65], ["the", 69], ["non", 73], ["-", 76], ["phagocytic", 77], ["oxidases", 88], ["Nox1", 97], ["and", 102], ["Nox3", 106], ["each", 111], ["form", 116], ["a", 121], ["complex", 123], ["in", 131], ["the", 134], ["membrane", 138], ["with", 147], ["p22(phox", 152], [")", 160], [",", 161], ["which", 163], ["provides", 169], ["both", 178], ["stabilization", 183], ["and", 197], ["a", 201], ["docking", 203], ["site", 211], ["for", 216], ["organizer", 220], ["proteins", 230], [".", 238], ["The", 240], ["p22(phox)-complexed", 244], ["Nox2", 264], ["and", 269], ["Nox1", 273], ["are", 278], ["dormant", 282], ["on", 290], ["their", 293], ["own", 299], [",", 302], ["and", 304], ["their", 308], ["activation", 314], ["requires", 325], ["soluble", 334], ["supportive", 342], ["proteins", 353], ["such", 362], ["as", 367], ["a", 370], ["Nox", 372], ["organizer", 376], ["(", 386], ["p47(phox", 387], [")", 395], ["or", 397], ["Noxo1", 400], [")", 405], ["and", 407], ["a", 411], ["Nox", 413], ["activator", 417], ["(", 427], ["p67(phox", 428], [")", 436], ["or", 438], ["Noxa1", 441], [")", 446], [".", 447], ["The", 449], ["small", 453], ["GTPase", 459], ["Rac", 466], ["directly", 470], ["binds", 479], ["to", 485], ["the", 488], ["activators", 492], [",", 502], ["and", 504], ["thus", 508], ["plays", 513], ["an", 519], ["essential", 522], ["role", 532], ["in", 537], ["the", 540], ["Nox2-based", 544], ["oxidase", 555], ["containing", 563], ["p47(phox", 574], [")", 582], ["and", 584], ["p67(phox", 588], [")", 596], ["or", 598], ["a", 601], ["positive", 603], ["role", 612], ["in", 617], ["Nox1", 620], ["activity", 625], ["supported", 634], ["by", 644], ["Noxo1", 647], ["and", 653], ["Noxa1", 657], [".", 662], ["Although", 664], ["Nox3", 673], ["complexed", 678], ["with", 688], ["p22(phox", 693], [")", 701], ["constitutively", 703], ["produce", 718], ["superoxide", 726], [",", 736], ["the", 738], ["production", 742], ["can", 753], ["be", 757], ["enhanced", 760], ["by", 769], ["supportive", 772], ["proteins", 783], [".", 791], ["Here", 793], ["we", 798], ["compare", 801], ["the", 809], ["roles", 813], ["of", 819], ["Rac", 822], ["in", 826], ["these", 829], ["p22(phox)-dependent", 835], ["oxidases", 855], ["using", 864], ["the", 870], ["organizer", 874], ["and", 884], ["activator", 888], ["in", 898], ["different", 901], ["combinations", 911], [".", 923], ["Expression", 925], ["of", 936], ["constitutively", 939], ["active", 954], ["Rac1(Q61L", 961], [")", 970], ["is", 972], ["essential", 975], ["for", 985], ["activation", 989], ["of", 1000], ["the", 1003], ["Nox2-", 1007], ["or", 1013], ["Nox1-based", 1016], ["oxidase", 1027], ["containing", 1035], ["the", 1046], ["organizer", 1050], ["p47(phox", 1060], [")", 1068], ["and", 1070], ["either", 1074], ["p67(phox", 1081], [")", 1089], ["or", 1091], ["Noxa1", 1094], [".", 1099], ["When", 1101], ["these", 1106], ["oxidases", 1112], ["use", 1121], ["Noxo1", 1125], ["as", 1131], ["an", 1134], ["organizer", 1137], ["instead", 1147], ["of", 1155], ["p47(phox", 1158], [")", 1166], [",", 1167], ["they", 1169], ["produce", 1174], ["a", 1182], ["small", 1184], ["but", 1190], ["significant", 1194], ["amount", 1206], ["of", 1213], ["superoxide", 1216], ["without", 1227], ["expression", 1235], ["of", 1246], ["Rac1(Q61L", 1249], [")", 1258], [",", 1259], ["although", 1261], ["the", 1270], ["production", 1274], ["is", 1285], ["enhanced", 1288], ["by", 1297], ["Rac1(Q61L", 1300], [")", 1309], [".", 1310], ["Thus", 1312], ["p47(phox", 1317], [")", 1325], ["is", 1327], ["likely", 1330], ["related", 1337], ["to", 1345], ["strict", 1348], ["dependence", 1355], ["on", 1366], ["Rac", 1369], [".", 1372], ["The", 1374], ["Nox3-based", 1378], ["oxidase", 1389], ["has", 1397], ["a", 1401], ["similar", 1403], ["tendency", 1411], ["in", 1420], ["the", 1423], ["change", 1427], ["of", 1434], ["the", 1437], ["dependence", 1441], [":", 1451], ["Rac", 1453], ["plays", 1457], ["a", 1463], ["positive", 1465], ["role", 1474], ["in", 1479], ["Nox3", 1482], ["activation", 1487], ["in", 1498], ["the", 1501], ["presence", 1505], ["of", 1514], ["p47(phox", 1517], [")", 1525], ["and", 1527], ["either", 1531], ["p67(phox", 1538], [")", 1546], ["or", 1548], ["Noxa1", 1551], [",", 1556], ["whereas", 1558], ["Rac", 1566], ["fails", 1570], ["to", 1576], ["upregulate", 1579], ["Nox3", 1590], ["activity", 1595], ["when", 1604], ["p47(phox", 1609], [")", 1617], ["is", 1619], ["replaced", 1622], ["with", 1631], ["Noxo1", 1636], [".", 1641], ["We", 1643], ["also", 1646], ["demonstrate", 1651], ["that", 1663], [",", 1667], ["in", 1669], ["the", 1672], ["Nox3-based", 1676], ["oxidase", 1687], ["containing", 1695], ["solely", 1706], ["p67(phox", 1713], [")", 1721], ["as", 1723], ["supportive", 1726], ["protein", 1737], [",", 1744], ["expression", 1746], ["of", 1757], ["Rac1(Q61L", 1760], [")", 1769], ["enhances", 1771], ["not", 1780], ["only", 1784], ["superoxide", 1789], ["production", 1800], ["but", 1811], ["also", 1815], ["membrane", 1820], ["translocation", 1829], ["of", 1843], ["p67(phox", 1846], [")", 1854], [".", 1855], ["Since", 1857], ["the", 1863], ["enhancements", 1867], ["are", 1880], ["not", 1884], ["observed", 1888], ["with", 1897], ["a", 1902], ["mutant", 1904], ["p67(phox", 1911], [")", 1919], ["defective", 1921], ["in", 1931], ["binding", 1934], ["to", 1942], ["Rac", 1945], [",", 1948], ["this", 1950], ["GTPase", 1955], ["appear", 1962], ["to", 1969], ["directly", 1972], ["recruit", 1981], ["p67(phox", 1989], [")", 1997], ["to", 1999], ["the", 2002], ["membrane", 2006], [".", 2014]]}
{"context": "{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) is the main metabolite of the selective prostacyclin (PGI(2)) receptor (IP receptor) agonist selexipag. The goal of this study was to determine the influence of IP receptor selectivity on the vasorelaxant efficacy of ACT-333679 and the PGI(2) analog treprostinil in pulmonary artery under conditions associated with pulmonary arterial hypertension (PAH). Selexipag and ACT-333679 evoked full relaxation of pulmonary artery from control and monocrotaline (MCT)-PAH rats, and ACT-333679 relaxed normal pulmonary artery contracted with either endothelin-1 (ET-1) or phenylephrine. In contrast, treprostinil evoked weaker relaxation than ACT-333679 of control pulmonary artery and failed to induce relaxation of pulmonary artery from MCT-PAH rats. Treprostinil did not evoke relaxation of normal pulmonary artery contracted with either ET-1 or phenylephrine. Expression of prostaglandin E(3) (EP(3)) receptor mRNA was increased in pulmonary artery from MCT-PAH rats. In contraction experiments, the selective EP(3) receptor agonist sulprostone evoked significantly greater contraction of pulmonary artery from MCT-PAH rats compared with control rats. The presence of a threshold concentration of ET-1 significantly augmented the contractile response to sulprostone in normal pulmonary artery. ACT-333679 did not evoke direct contraction of rat pulmonary artery, whereas treprostinil evoked concentration-dependent contraction that was inhibited by the EP(3) receptor antagonist (2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide. Antagonism of EP(3) receptors also revealed a relaxant response to treprostinil in normal pulmonary artery contracted with ET-1. These data demonstrate that the relaxant efficacy of the selective IP receptor agonist selexipag and its metabolite ACT-333679 is not modified under conditions associated with PAH, whereas relaxation to treprostinil may be limited in the presence of mediators of disease.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "69acbdb73b2c414cb48a711bb6da31f1", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[59, 61]], "char_spans": [[395, 425]]}]}], "context_tokens": [["{", 0], ["4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic", 1], ["acid", 61], ["(", 66], ["ACT-333679", 67], [")", 77], ["is", 79], ["the", 82], ["main", 86], ["metabolite", 91], ["of", 102], ["the", 105], ["selective", 109], ["prostacyclin", 119], ["(", 132], ["PGI(2", 133], [")", 138], [")", 139], ["receptor", 141], ["(", 150], ["IP", 151], ["receptor", 154], [")", 162], ["agonist", 164], ["selexipag", 172], [".", 181], ["The", 183], ["goal", 187], ["of", 192], ["this", 195], ["study", 200], ["was", 206], ["to", 210], ["determine", 213], ["the", 223], ["influence", 227], ["of", 237], ["IP", 240], ["receptor", 243], ["selectivity", 252], ["on", 264], ["the", 267], ["vasorelaxant", 271], ["efficacy", 284], ["of", 293], ["ACT-333679", 296], ["and", 307], ["the", 311], ["PGI(2", 315], [")", 320], ["analog", 322], ["treprostinil", 329], ["in", 342], ["pulmonary", 345], ["artery", 355], ["under", 362], ["conditions", 368], ["associated", 379], ["with", 390], ["pulmonary", 395], ["arterial", 405], ["hypertension", 414], ["(", 427], ["PAH", 428], [")", 431], [".", 432], ["Selexipag", 434], ["and", 444], ["ACT-333679", 448], ["evoked", 459], ["full", 466], ["relaxation", 471], ["of", 482], ["pulmonary", 485], ["artery", 495], ["from", 502], ["control", 507], ["and", 515], ["monocrotaline", 519], ["(", 533], ["MCT)-PAH", 534], ["rats", 543], [",", 547], ["and", 549], ["ACT-333679", 553], ["relaxed", 564], ["normal", 572], ["pulmonary", 579], ["artery", 589], ["contracted", 596], ["with", 607], ["either", 612], ["endothelin-1", 619], ["(", 632], ["ET-1", 633], [")", 637], ["or", 639], ["phenylephrine", 642], [".", 655], ["In", 657], ["contrast", 660], [",", 668], ["treprostinil", 670], ["evoked", 683], ["weaker", 690], ["relaxation", 697], ["than", 708], ["ACT-333679", 713], ["of", 724], ["control", 727], ["pulmonary", 735], ["artery", 745], ["and", 752], ["failed", 756], ["to", 763], ["induce", 766], ["relaxation", 773], ["of", 784], ["pulmonary", 787], ["artery", 797], ["from", 804], ["MCT", 809], ["-", 812], ["PAH", 813], ["rats", 817], [".", 821], ["Treprostinil", 823], ["did", 836], ["not", 840], ["evoke", 844], ["relaxation", 850], ["of", 861], ["normal", 864], ["pulmonary", 871], ["artery", 881], ["contracted", 888], ["with", 899], ["either", 904], ["ET-1", 911], ["or", 916], ["phenylephrine", 919], [".", 932], ["Expression", 934], ["of", 945], ["prostaglandin", 948], ["E(3", 962], [")", 965], ["(", 967], ["EP(3", 968], [")", 972], [")", 973], ["receptor", 975], ["mRNA", 984], ["was", 989], ["increased", 993], ["in", 1003], ["pulmonary", 1006], ["artery", 1016], ["from", 1023], ["MCT", 1028], ["-", 1031], ["PAH", 1032], ["rats", 1036], [".", 1040], ["In", 1042], ["contraction", 1045], ["experiments", 1057], [",", 1068], ["the", 1070], ["selective", 1074], ["EP(3", 1084], [")", 1088], ["receptor", 1090], ["agonist", 1099], ["sulprostone", 1107], ["evoked", 1119], ["significantly", 1126], ["greater", 1140], ["contraction", 1148], ["of", 1160], ["pulmonary", 1163], ["artery", 1173], ["from", 1180], ["MCT", 1185], ["-", 1188], ["PAH", 1189], ["rats", 1193], ["compared", 1198], ["with", 1207], ["control", 1212], ["rats", 1220], [".", 1224], ["The", 1226], ["presence", 1230], ["of", 1239], ["a", 1242], ["threshold", 1244], ["concentration", 1254], ["of", 1268], ["ET-1", 1271], ["significantly", 1276], ["augmented", 1290], ["the", 1300], ["contractile", 1304], ["response", 1316], ["to", 1325], ["sulprostone", 1328], ["in", 1340], ["normal", 1343], ["pulmonary", 1350], ["artery", 1360], [".", 1366], ["ACT-333679", 1368], ["did", 1379], ["not", 1383], ["evoke", 1387], ["direct", 1393], ["contraction", 1400], ["of", 1412], ["rat", 1415], ["pulmonary", 1419], ["artery", 1429], [",", 1435], ["whereas", 1437], ["treprostinil", 1445], ["evoked", 1458], ["concentration", 1465], ["-", 1478], ["dependent", 1479], ["contraction", 1489], ["that", 1501], ["was", 1506], ["inhibited", 1510], ["by", 1520], ["the", 1523], ["EP(3", 1527], [")", 1531], ["receptor", 1533], ["antagonist", 1542], ["(", 1553], ["2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide", 1554], [".", 1621], ["Antagonism", 1623], ["of", 1634], ["EP(3", 1637], [")", 1641], ["receptors", 1643], ["also", 1653], ["revealed", 1658], ["a", 1667], ["relaxant", 1669], ["response", 1678], ["to", 1687], ["treprostinil", 1690], ["in", 1703], ["normal", 1706], ["pulmonary", 1713], ["artery", 1723], ["contracted", 1730], ["with", 1741], ["ET-1", 1746], [".", 1750], ["These", 1752], ["data", 1758], ["demonstrate", 1763], ["that", 1775], ["the", 1780], ["relaxant", 1784], ["efficacy", 1793], ["of", 1802], ["the", 1805], ["selective", 1809], ["IP", 1819], ["receptor", 1822], ["agonist", 1831], ["selexipag", 1839], ["and", 1849], ["its", 1853], ["metabolite", 1857], ["ACT-333679", 1868], ["is", 1879], ["not", 1882], ["modified", 1886], ["under", 1895], ["conditions", 1901], ["associated", 1912], ["with", 1923], ["PAH", 1928], [",", 1931], ["whereas", 1933], ["relaxation", 1941], ["to", 1952], ["treprostinil", 1955], ["may", 1968], ["be", 1972], ["limited", 1975], ["in", 1983], ["the", 1986], ["presence", 1990], ["of", 1999], ["mediators", 2002], ["of", 2012], ["disease", 2015], [".", 2022]]}
{"context": "The CRISPR/Cas system in prokaryotes provides resistance against invading viruses and plasmids. Three distinct stages in the mechanism can be recognized. Initially, fragments of invader DNA are integrated as new spacers into the repetitive CRISPR locus. Subsequently, the CRISPR is transcribed and the transcript is cleaved by a Cas protein within the repeats, generating short RNAs (crRNAs) that contain the spacer sequence. Finally, crRNAs guide the Cas protein machinery to a complementary invader target, either DNA or RNA, resulting in inhibition of virus or plasmid proliferation. In this article, we discuss our current understanding of this fascinating adaptive and heritable defense system, and describe functional similarities and differences with RNAi in eukaryotes.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "3b60bd7ce68145749fb65cfe5ee7d2cf", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3]], "char_spans": [[4, 13]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["/", 10], ["Cas", 11], ["system", 15], ["in", 22], ["prokaryotes", 25], ["provides", 37], ["resistance", 46], ["against", 57], ["invading", 65], ["viruses", 74], ["and", 82], ["plasmids", 86], [".", 94], ["Three", 96], ["distinct", 102], ["stages", 111], ["in", 118], ["the", 121], ["mechanism", 125], ["can", 135], ["be", 139], ["recognized", 142], [".", 152], ["Initially", 154], [",", 163], ["fragments", 165], ["of", 175], ["invader", 178], ["DNA", 186], ["are", 190], ["integrated", 194], ["as", 205], ["new", 208], ["spacers", 212], ["into", 220], ["the", 225], ["repetitive", 229], ["CRISPR", 240], ["locus", 247], [".", 252], ["Subsequently", 254], [",", 266], ["the", 268], ["CRISPR", 272], ["is", 279], ["transcribed", 282], ["and", 294], ["the", 298], ["transcript", 302], ["is", 313], ["cleaved", 316], ["by", 324], ["a", 327], ["Cas", 329], ["protein", 333], ["within", 341], ["the", 348], ["repeats", 352], [",", 359], ["generating", 361], ["short", 372], ["RNAs", 378], ["(", 383], ["crRNAs", 384], [")", 390], ["that", 392], ["contain", 397], ["the", 405], ["spacer", 409], ["sequence", 416], [".", 424], ["Finally", 426], [",", 433], ["crRNAs", 435], ["guide", 442], ["the", 448], ["Cas", 452], ["protein", 456], ["machinery", 464], ["to", 474], ["a", 477], ["complementary", 479], ["invader", 493], ["target", 501], [",", 507], ["either", 509], ["DNA", 516], ["or", 520], ["RNA", 523], [",", 526], ["resulting", 528], ["in", 538], ["inhibition", 541], ["of", 552], ["virus", 555], ["or", 561], ["plasmid", 564], ["proliferation", 572], [".", 585], ["In", 587], ["this", 590], ["article", 595], [",", 602], ["we", 604], ["discuss", 607], ["our", 615], ["current", 619], ["understanding", 627], ["of", 641], ["this", 644], ["fascinating", 649], ["adaptive", 661], ["and", 670], ["heritable", 674], ["defense", 684], ["system", 692], [",", 698], ["and", 700], ["describe", 704], ["functional", 713], ["similarities", 724], ["and", 737], ["differences", 741], ["with", 753], ["RNAi", 758], ["in", 763], ["eukaryotes", 766], [".", 776]]}
{"context": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function. This study examined whether the levels of lymphocyte PRDX-2 are altered over 1 month following ultra-endurance exercise. Nine middle-aged men undertook a single-stage, multi-day 233 km (145 mile) ultra-endurance running race. Blood was collected immediately before (Pre), upon completion/retirement (Post), and following the race at Day 1, Day 7 and Day 28. Lymphocyte lysates were examined for PRDX-2 by reducing and non-reducing SDS-PAGE with western blotting. In a sub-group of men who completed the race (n = 4), PRDX-2 oligomeric state (indicative of redox status) was investigated. Ultra-endurance exercise caused significant changes in lymphocyte PRDX-2 (F(4,32) 3.409, p = 0.020, \u03b7(2) = 0.299): 7 days after the race, PRDX-2 levels in lymphocytes had fallen to 30% of pre-race values (p = 0.013) and returned to near-normal levels at Day 28. Non-reducing gels demonstrated that dimeric PRDX-2 (intracellular reduced PRDX-2 monomers) was increased in three of four race completers immediately post-race, indicative of an 'antioxidant response'. Moreover, monomeric PRDX-2 was also increased immediately post-race in two of four race-completing subjects, indicative of oxidative damage, which was not detectable by Day 7. Lymphocyte PRDX-2 was decreased below normal levels 7 days after ultra-endurance exercise. Excessive accumulation of reactive oxygen species induced by ultra-endurance exercise may underlie depletion of lymphocyte PRDX-2 by triggering its turnover after oxidation. Low levels of lymphocyte PRDX-2 could influence cell function and might, in part, explain reports of dysregulated immunity following ultra-endurance exercise.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "5972815d8210470eb84c3da30f0aa090", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[234, 234], [6, 6]], "char_spans": [[1127, 1137], [31, 41]]}]}], "context_tokens": [["Peroxiredoxin-2", 0], ["(", 16], ["PRDX-2", 17], [")", 23], ["is", 25], ["an", 28], ["antioxidant", 31], ["and", 43], ["chaperone", 47], ["-", 56], ["like", 57], ["protein", 62], ["critical", 70], ["for", 79], ["cell", 83], ["function", 88], [".", 96], ["This", 98], ["study", 103], ["examined", 109], ["whether", 118], ["the", 126], ["levels", 130], ["of", 137], ["lymphocyte", 140], ["PRDX-2", 151], ["are", 158], ["altered", 162], ["over", 170], ["1", 175], ["month", 177], ["following", 183], ["ultra", 193], ["-", 198], ["endurance", 199], ["exercise", 209], [".", 217], ["Nine", 219], ["middle", 224], ["-", 230], ["aged", 231], ["men", 236], ["undertook", 240], ["a", 250], ["single", 252], ["-", 258], ["stage", 259], [",", 264], ["multi", 266], ["-", 271], ["day", 272], ["233", 276], ["km", 280], ["(", 283], ["145", 284], ["mile", 288], [")", 292], ["ultra", 294], ["-", 299], ["endurance", 300], ["running", 310], ["race", 318], [".", 322], ["Blood", 324], ["was", 330], ["collected", 334], ["immediately", 344], ["before", 356], ["(", 363], ["Pre", 364], [")", 367], [",", 368], ["upon", 370], ["completion", 375], ["/", 385], ["retirement", 386], ["(", 397], ["Post", 398], [")", 402], [",", 403], ["and", 405], ["following", 409], ["the", 419], ["race", 423], ["at", 428], ["Day", 431], ["1", 435], [",", 436], ["Day", 438], ["7", 442], ["and", 444], ["Day", 448], ["28", 452], [".", 454], ["Lymphocyte", 456], ["lysates", 467], ["were", 475], ["examined", 480], ["for", 489], ["PRDX-2", 493], ["by", 500], ["reducing", 503], ["and", 512], ["non", 516], ["-", 519], ["reducing", 520], ["SDS", 529], ["-", 532], ["PAGE", 533], ["with", 538], ["western", 543], ["blotting", 551], [".", 559], ["In", 561], ["a", 564], ["sub", 566], ["-", 569], ["group", 570], ["of", 576], ["men", 579], ["who", 583], ["completed", 587], ["the", 597], ["race", 601], ["(", 606], ["n", 607], ["=", 609], ["4", 611], [")", 612], [",", 613], ["PRDX-2", 615], ["oligomeric", 622], ["state", 633], ["(", 639], ["indicative", 640], ["of", 651], ["redox", 654], ["status", 660], [")", 666], ["was", 668], ["investigated", 672], [".", 684], ["Ultra", 686], ["-", 691], ["endurance", 692], ["exercise", 702], ["caused", 711], ["significant", 718], ["changes", 730], ["in", 738], ["lymphocyte", 741], ["PRDX-2", 752], ["(", 759], ["F(4,32", 760], [")", 766], ["3.409", 768], [",", 773], ["p", 775], ["=", 777], ["0.020", 779], [",", 784], ["\u03b7(2", 786], [")", 789], ["=", 791], ["0.299", 793], [")", 798], [":", 799], ["7", 801], ["days", 803], ["after", 808], ["the", 814], ["race", 818], [",", 822], ["PRDX-2", 824], ["levels", 831], ["in", 838], ["lymphocytes", 841], ["had", 853], ["fallen", 857], ["to", 864], ["30", 867], ["%", 869], ["of", 871], ["pre", 874], ["-", 877], ["race", 878], ["values", 883], ["(", 890], ["p", 891], ["=", 893], ["0.013", 895], [")", 900], ["and", 902], ["returned", 906], ["to", 915], ["near", 918], ["-", 922], ["normal", 923], ["levels", 930], ["at", 937], ["Day", 940], ["28", 944], [".", 946], ["Non", 948], ["-", 951], ["reducing", 952], ["gels", 961], ["demonstrated", 966], ["that", 979], ["dimeric", 984], ["PRDX-2", 992], ["(", 999], ["intracellular", 1000], ["reduced", 1014], ["PRDX-2", 1022], ["monomers", 1029], [")", 1037], ["was", 1039], ["increased", 1043], ["in", 1053], ["three", 1056], ["of", 1062], ["four", 1065], ["race", 1070], ["completers", 1075], ["immediately", 1086], ["post", 1098], ["-", 1102], ["race", 1103], [",", 1107], ["indicative", 1109], ["of", 1120], ["an", 1123], ["'", 1126], ["antioxidant", 1127], ["response", 1139], ["'", 1147], [".", 1148], ["Moreover", 1150], [",", 1158], ["monomeric", 1160], ["PRDX-2", 1170], ["was", 1177], ["also", 1181], ["increased", 1186], ["immediately", 1196], ["post", 1208], ["-", 1212], ["race", 1213], ["in", 1218], ["two", 1221], ["of", 1225], ["four", 1228], ["race", 1233], ["-", 1237], ["completing", 1238], ["subjects", 1249], [",", 1257], ["indicative", 1259], ["of", 1270], ["oxidative", 1273], ["damage", 1283], [",", 1289], ["which", 1291], ["was", 1297], ["not", 1301], ["detectable", 1305], ["by", 1316], ["Day", 1319], ["7", 1323], [".", 1324], ["Lymphocyte", 1326], ["PRDX-2", 1337], ["was", 1344], ["decreased", 1348], ["below", 1358], ["normal", 1364], ["levels", 1371], ["7", 1378], ["days", 1380], ["after", 1385], ["ultra", 1391], ["-", 1396], ["endurance", 1397], ["exercise", 1407], [".", 1415], ["Excessive", 1417], ["accumulation", 1427], ["of", 1440], ["reactive", 1443], ["oxygen", 1452], ["species", 1459], ["induced", 1467], ["by", 1475], ["ultra", 1478], ["-", 1483], ["endurance", 1484], ["exercise", 1494], ["may", 1503], ["underlie", 1507], ["depletion", 1516], ["of", 1526], ["lymphocyte", 1529], ["PRDX-2", 1540], ["by", 1547], ["triggering", 1550], ["its", 1561], ["turnover", 1565], ["after", 1574], ["oxidation", 1580], [".", 1589], ["Low", 1591], ["levels", 1595], ["of", 1602], ["lymphocyte", 1605], ["PRDX-2", 1616], ["could", 1623], ["influence", 1629], ["cell", 1639], ["function", 1644], ["and", 1653], ["might", 1657], [",", 1662], ["in", 1664], ["part", 1667], [",", 1671], ["explain", 1673], ["reports", 1681], ["of", 1689], ["dysregulated", 1692], ["immunity", 1705], ["following", 1714], ["ultra", 1724], ["-", 1729], ["endurance", 1730], ["exercise", 1740], [".", 1748]]}
{"context": "Recent reports have described a distinct and recurrent pattern of systemic malformation that associates craniosynostosis and neurodevelopmental abnormalities with many clinical features of the Marfan syndrome (MFS), an autosomal dominant disorder of the extracellular microfibril caused by defects in the gene encoding fibrillin-1, FBN1 (ref. 8). Additional common findings include other craniofacial anomalies, hypotonia, obstructive apnea, foot deformity, and congenital weakness of the abdominal wall. So far, only 11 cases have been reported precluding the assignment of definitive diagnostic criteria. While it remains unclear whether these cases represent a discrete clinical entity with a single aetiology, they have been pragmatically grouped under the rubric Marfanoid-craniosynostosis or Shprintzen-Goldberg syndrome (SGS). Because of the significant clinical overlap between MFS and SGS, we proposed that they may be caused by allelic mutations. We now report two SGS patients who harbour mutations in FBN1. While it remains unclear whether these mutations are sufficient for the clinical expression of the entire SGS phenotype, these data suggest a role for fibrillin-1 in early craniofacial and central nervous system development. Our recent observation that FBN1 transcript is expressed as early as the 8-cell stage of human embryogenesis is consistent with this hypothesis.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "0d848258b8d84a2a99aa7452c73c0752", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[121, 121], [14, 14]], "char_spans": [[778, 793], [104, 119]]}]}], "context_tokens": [["Recent", 0], ["reports", 7], ["have", 15], ["described", 20], ["a", 30], ["distinct", 32], ["and", 41], ["recurrent", 45], ["pattern", 55], ["of", 63], ["systemic", 66], ["malformation", 75], ["that", 88], ["associates", 93], ["craniosynostosis", 104], ["and", 121], ["neurodevelopmental", 125], ["abnormalities", 144], ["with", 158], ["many", 163], ["clinical", 168], ["features", 177], ["of", 186], ["the", 189], ["Marfan", 193], ["syndrome", 200], ["(", 209], ["MFS", 210], [")", 213], [",", 214], ["an", 216], ["autosomal", 219], ["dominant", 229], ["disorder", 238], ["of", 247], ["the", 250], ["extracellular", 254], ["microfibril", 268], ["caused", 280], ["by", 287], ["defects", 290], ["in", 298], ["the", 301], ["gene", 305], ["encoding", 310], ["fibrillin-1", 319], [",", 330], ["FBN1", 332], ["(", 337], ["ref", 338], [".", 341], ["8)", 343], [".", 345], ["Additional", 347], ["common", 358], ["findings", 365], ["include", 374], ["other", 382], ["craniofacial", 388], ["anomalies", 401], [",", 410], ["hypotonia", 412], [",", 421], ["obstructive", 423], ["apnea", 435], [",", 440], ["foot", 442], ["deformity", 447], [",", 456], ["and", 458], ["congenital", 462], ["weakness", 473], ["of", 482], ["the", 485], ["abdominal", 489], ["wall", 499], [".", 503], ["So", 505], ["far", 508], [",", 511], ["only", 513], ["11", 518], ["cases", 521], ["have", 527], ["been", 532], ["reported", 537], ["precluding", 546], ["the", 557], ["assignment", 561], ["of", 572], ["definitive", 575], ["diagnostic", 586], ["criteria", 597], [".", 605], ["While", 607], ["it", 613], ["remains", 616], ["unclear", 624], ["whether", 632], ["these", 640], ["cases", 646], ["represent", 652], ["a", 662], ["discrete", 664], ["clinical", 673], ["entity", 682], ["with", 689], ["a", 694], ["single", 696], ["aetiology", 703], [",", 712], ["they", 714], ["have", 719], ["been", 724], ["pragmatically", 729], ["grouped", 743], ["under", 751], ["the", 757], ["rubric", 761], ["Marfanoid", 768], ["-", 777], ["craniosynostosis", 778], ["or", 795], ["Shprintzen", 798], ["-", 808], ["Goldberg", 809], ["syndrome", 818], ["(", 827], ["SGS", 828], [")", 831], [".", 832], ["Because", 834], ["of", 842], ["the", 845], ["significant", 849], ["clinical", 861], ["overlap", 870], ["between", 878], ["MFS", 886], ["and", 890], ["SGS", 894], [",", 897], ["we", 899], ["proposed", 902], ["that", 911], ["they", 916], ["may", 921], ["be", 925], ["caused", 928], ["by", 935], ["allelic", 938], ["mutations", 946], [".", 955], ["We", 957], ["now", 960], ["report", 964], ["two", 971], ["SGS", 975], ["patients", 979], ["who", 988], ["harbour", 992], ["mutations", 1000], ["in", 1010], ["FBN1", 1013], [".", 1017], ["While", 1019], ["it", 1025], ["remains", 1028], ["unclear", 1036], ["whether", 1044], ["these", 1052], ["mutations", 1058], ["are", 1068], ["sufficient", 1072], ["for", 1083], ["the", 1087], ["clinical", 1091], ["expression", 1100], ["of", 1111], ["the", 1114], ["entire", 1118], ["SGS", 1125], ["phenotype", 1129], [",", 1138], ["these", 1140], ["data", 1146], ["suggest", 1151], ["a", 1159], ["role", 1161], ["for", 1166], ["fibrillin-1", 1170], ["in", 1182], ["early", 1185], ["craniofacial", 1191], ["and", 1204], ["central", 1208], ["nervous", 1216], ["system", 1224], ["development", 1231], [".", 1242], ["Our", 1244], ["recent", 1248], ["observation", 1255], ["that", 1267], ["FBN1", 1272], ["transcript", 1277], ["is", 1288], ["expressed", 1291], ["as", 1301], ["early", 1304], ["as", 1310], ["the", 1313], ["8-cell", 1317], ["stage", 1324], ["of", 1330], ["human", 1333], ["embryogenesis", 1339], ["is", 1353], ["consistent", 1356], ["with", 1367], ["this", 1372], ["hypothesis", 1377], [".", 1387]]}
{"context": "Interdigital foot infections are mostly caused initially by dermatophytes, yeasts and less frequently by bacteria. Erythrasma caused by Corynebacterium minutissimum can be confused with superficial mycoses. The aim of the study was to determine the prevalence of the etiologic agents of superficial mycoses and the frequency of Corynebacterium minutissimum in interdigital foot infections. All the samples obtained from the 121 patients with interdigital foot infections were examined directly with the use of 20% potassium hydroxide mounts and Gram stain under the microscope and cultured on Sabouraud's dextrose agar plates. In identification of superficial mycoses, the rate was found to be 14% with the cultural method and 14% with direct microscopic examination. Using a combination of direct microscopic examination and culture, a 33.8% ratio was achieved. In the culture of these samples, the most isolated factor was Trichophyton rubrum (33.7%). In 24 of the patients (19.8%) Corynebacterium minutissimum was detected by Gram staining, in 6 of these patients Trichophyton rubrum was found, Trichophyton mentagrophytes was found in 2 and Trichosporon spp. was found in 1. The examination of interdigital foot lesions in the laboratory, the coexistence of erythrasma with dermatophytes and yeast should be considered.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "f20fb69656624faba286b877bd7b0c35", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[20, 21], [50, 51], [167, 168]], "char_spans": [[136, 163], [328, 355], [984, 1011]]}]}], "context_tokens": [["Interdigital", 0], ["foot", 13], ["infections", 18], ["are", 29], ["mostly", 33], ["caused", 40], ["initially", 47], ["by", 57], ["dermatophytes", 60], [",", 73], ["yeasts", 75], ["and", 82], ["less", 86], ["frequently", 91], ["by", 102], ["bacteria", 105], [".", 113], ["Erythrasma", 115], ["caused", 126], ["by", 133], ["Corynebacterium", 136], ["minutissimum", 152], ["can", 165], ["be", 169], ["confused", 172], ["with", 181], ["superficial", 186], ["mycoses", 198], [".", 205], ["The", 207], ["aim", 211], ["of", 215], ["the", 218], ["study", 222], ["was", 228], ["to", 232], ["determine", 235], ["the", 245], ["prevalence", 249], ["of", 260], ["the", 263], ["etiologic", 267], ["agents", 277], ["of", 284], ["superficial", 287], ["mycoses", 299], ["and", 307], ["the", 311], ["frequency", 315], ["of", 325], ["Corynebacterium", 328], ["minutissimum", 344], ["in", 357], ["interdigital", 360], ["foot", 373], ["infections", 378], [".", 388], ["All", 390], ["the", 394], ["samples", 398], ["obtained", 406], ["from", 415], ["the", 420], ["121", 424], ["patients", 428], ["with", 437], ["interdigital", 442], ["foot", 455], ["infections", 460], ["were", 471], ["examined", 476], ["directly", 485], ["with", 494], ["the", 499], ["use", 503], ["of", 507], ["20", 510], ["%", 512], ["potassium", 514], ["hydroxide", 524], ["mounts", 534], ["and", 541], ["Gram", 545], ["stain", 550], ["under", 556], ["the", 562], ["microscope", 566], ["and", 577], ["cultured", 581], ["on", 590], ["Sabouraud", 593], ["'s", 602], ["dextrose", 605], ["agar", 614], ["plates", 619], [".", 625], ["In", 627], ["identification", 630], ["of", 645], ["superficial", 648], ["mycoses", 660], [",", 667], ["the", 669], ["rate", 673], ["was", 678], ["found", 682], ["to", 688], ["be", 691], ["14", 694], ["%", 696], ["with", 698], ["the", 703], ["cultural", 707], ["method", 716], ["and", 723], ["14", 727], ["%", 729], ["with", 731], ["direct", 736], ["microscopic", 743], ["examination", 755], [".", 766], ["Using", 768], ["a", 774], ["combination", 776], ["of", 788], ["direct", 791], ["microscopic", 798], ["examination", 810], ["and", 822], ["culture", 826], [",", 833], ["a", 835], ["33.8", 837], ["%", 841], ["ratio", 843], ["was", 849], ["achieved", 853], [".", 861], ["In", 863], ["the", 866], ["culture", 870], ["of", 878], ["these", 881], ["samples", 887], [",", 894], ["the", 896], ["most", 900], ["isolated", 905], ["factor", 914], ["was", 921], ["Trichophyton", 925], ["rubrum", 938], ["(", 945], ["33.7", 946], ["%", 950], [")", 951], [".", 952], ["In", 954], ["24", 957], ["of", 960], ["the", 963], ["patients", 967], ["(", 976], ["19.8", 977], ["%", 981], [")", 982], ["Corynebacterium", 984], ["minutissimum", 1000], ["was", 1013], ["detected", 1017], ["by", 1026], ["Gram", 1029], ["staining", 1034], [",", 1042], ["in", 1044], ["6", 1047], ["of", 1049], ["these", 1052], ["patients", 1058], ["Trichophyton", 1067], ["rubrum", 1080], ["was", 1087], ["found", 1091], [",", 1096], ["Trichophyton", 1098], ["mentagrophytes", 1111], ["was", 1126], ["found", 1130], ["in", 1136], ["2", 1139], ["and", 1141], ["Trichosporon", 1145], ["spp", 1158], [".", 1161], ["was", 1163], ["found", 1167], ["in", 1173], ["1", 1176], [".", 1177], ["The", 1179], ["examination", 1183], ["of", 1195], ["interdigital", 1198], ["foot", 1211], ["lesions", 1216], ["in", 1224], ["the", 1227], ["laboratory", 1231], [",", 1241], ["the", 1243], ["coexistence", 1247], ["of", 1259], ["erythrasma", 1262], ["with", 1273], ["dermatophytes", 1278], ["and", 1292], ["yeast", 1296], ["should", 1302], ["be", 1309], ["considered", 1312], [".", 1322]]}
{"context": "Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by extracellular plaques containing amyloid \u03b2 (A\u03b2)-protein and intracellular tangles containing hyperphosphorylated Tau protein. Here, we describe the generation of inducible pluripotent stem cell lines from patients harboring the London familial AD (fAD) amyloid precursor protein (APP) mutation (V717I). We examine AD-relevant phenotypes following directed differentiation to forebrain neuronal fates vulnerable in AD. We observe that over differentiation time to mature neuronal fates, APP expression and levels of A\u03b2 increase dramatically. In both immature and mature neuronal fates, the APPV717I mutation affects both \u03b2- and \u03b3-secretase cleavage of APP. Although the mutation lies near the \u03b3-secretase cleavage site in the transmembrane domain of APP, we find that \u03b2-secretase cleavage of APP is elevated leading to generation of increased levels of both APPs\u03b2 and A\u03b2. Furthermore, we find that this mutation alters the initial cleavage site of \u03b3-secretase, resulting in an increased generation of both A\u03b242 and A\u03b238. In addition to altered APP processing, an increase in levels of total and phosphorylated Tau is observed in neurons with the APPV717I mutation. We show that treatment with A\u03b2-specific antibodies early in culture reverses the phenotype of increased total Tau levels, implicating altered A\u03b2 production in fAD neurons in this phenotype. These studies use human neurons to reveal previously unrecognized effects of the most common fAD APP mutation and provide a model system for testing therapeutic strategies in the cell types most relevant to disease processes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "cded98aedc6a494e8a1a1d00dd9f85aa", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "AD", "token_spans": [[4, 4], [76, 76], [63, 63], [46, 46]], "char_spans": [[21, 22], [496, 497], [396, 397], [326, 327]]}]}], "context_tokens": [["Alzheimer", 0], ["'s", 9], ["disease", 12], ["(", 20], ["AD", 21], [")", 23], ["is", 25], ["a", 28], ["complex", 30], ["neurodegenerative", 38], ["disorder", 56], ["characterized", 65], ["by", 79], ["extracellular", 82], ["plaques", 96], ["containing", 104], ["amyloid", 115], ["\u03b2", 123], ["(", 125], ["A\u03b2)-protein", 126], ["and", 138], ["intracellular", 142], ["tangles", 156], ["containing", 164], ["hyperphosphorylated", 175], ["Tau", 195], ["protein", 199], [".", 206], ["Here", 208], [",", 212], ["we", 214], ["describe", 217], ["the", 226], ["generation", 230], ["of", 241], ["inducible", 244], ["pluripotent", 254], ["stem", 266], ["cell", 271], ["lines", 276], ["from", 282], ["patients", 287], ["harboring", 296], ["the", 306], ["London", 310], ["familial", 317], ["AD", 326], ["(", 329], ["fAD", 330], [")", 333], ["amyloid", 335], ["precursor", 343], ["protein", 353], ["(", 361], ["APP", 362], [")", 365], ["mutation", 367], ["(", 376], ["V717I", 377], [")", 382], [".", 383], ["We", 385], ["examine", 388], ["AD", 396], ["-", 398], ["relevant", 399], ["phenotypes", 408], ["following", 419], ["directed", 429], ["differentiation", 438], ["to", 454], ["forebrain", 457], ["neuronal", 467], ["fates", 476], ["vulnerable", 482], ["in", 493], ["AD", 496], [".", 498], ["We", 500], ["observe", 503], ["that", 511], ["over", 516], ["differentiation", 521], ["time", 537], ["to", 542], ["mature", 545], ["neuronal", 552], ["fates", 561], [",", 566], ["APP", 568], ["expression", 572], ["and", 583], ["levels", 587], ["of", 594], ["A\u03b2", 597], ["increase", 600], ["dramatically", 609], [".", 621], ["In", 623], ["both", 626], ["immature", 631], ["and", 640], ["mature", 644], ["neuronal", 651], ["fates", 660], [",", 665], ["the", 667], ["APPV717I", 671], ["mutation", 680], ["affects", 689], ["both", 697], ["\u03b2-", 702], ["and", 705], ["\u03b3", 709], ["-", 710], ["secretase", 711], ["cleavage", 721], ["of", 730], ["APP", 733], [".", 736], ["Although", 738], ["the", 747], ["mutation", 751], ["lies", 760], ["near", 765], ["the", 770], ["\u03b3", 774], ["-", 775], ["secretase", 776], ["cleavage", 786], ["site", 795], ["in", 800], ["the", 803], ["transmembrane", 807], ["domain", 821], ["of", 828], ["APP", 831], [",", 834], ["we", 836], ["find", 839], ["that", 844], ["\u03b2", 849], ["-", 850], ["secretase", 851], ["cleavage", 861], ["of", 870], ["APP", 873], ["is", 877], ["elevated", 880], ["leading", 889], ["to", 897], ["generation", 900], ["of", 911], ["increased", 914], ["levels", 924], ["of", 931], ["both", 934], ["APPs\u03b2", 939], ["and", 945], ["A\u03b2", 949], [".", 951], ["Furthermore", 953], [",", 964], ["we", 966], ["find", 969], ["that", 974], ["this", 979], ["mutation", 984], ["alters", 993], ["the", 1000], ["initial", 1004], ["cleavage", 1012], ["site", 1021], ["of", 1026], ["\u03b3", 1029], ["-", 1030], ["secretase", 1031], [",", 1040], ["resulting", 1042], ["in", 1052], ["an", 1055], ["increased", 1058], ["generation", 1068], ["of", 1079], ["both", 1082], ["A\u03b242", 1087], ["and", 1092], ["A\u03b238", 1096], [".", 1100], ["In", 1102], ["addition", 1105], ["to", 1114], ["altered", 1117], ["APP", 1125], ["processing", 1129], [",", 1139], ["an", 1141], ["increase", 1144], ["in", 1153], ["levels", 1156], ["of", 1163], ["total", 1166], ["and", 1172], ["phosphorylated", 1176], ["Tau", 1191], ["is", 1195], ["observed", 1198], ["in", 1207], ["neurons", 1210], ["with", 1218], ["the", 1223], ["APPV717I", 1227], ["mutation", 1236], [".", 1244], ["We", 1246], ["show", 1249], ["that", 1254], ["treatment", 1259], ["with", 1269], ["A\u03b2", 1274], ["-", 1276], ["specific", 1277], ["antibodies", 1286], ["early", 1297], ["in", 1303], ["culture", 1306], ["reverses", 1314], ["the", 1323], ["phenotype", 1327], ["of", 1337], ["increased", 1340], ["total", 1350], ["Tau", 1356], ["levels", 1360], [",", 1366], ["implicating", 1368], ["altered", 1380], ["A\u03b2", 1388], ["production", 1391], ["in", 1402], ["fAD", 1405], ["neurons", 1409], ["in", 1417], ["this", 1420], ["phenotype", 1425], [".", 1434], ["These", 1436], ["studies", 1442], ["use", 1450], ["human", 1454], ["neurons", 1460], ["to", 1468], ["reveal", 1471], ["previously", 1478], ["unrecognized", 1489], ["effects", 1502], ["of", 1510], ["the", 1513], ["most", 1517], ["common", 1522], ["fAD", 1529], ["APP", 1533], ["mutation", 1537], ["and", 1546], ["provide", 1550], ["a", 1558], ["model", 1560], ["system", 1566], ["for", 1573], ["testing", 1577], ["therapeutic", 1585], ["strategies", 1597], ["in", 1608], ["the", 1611], ["cell", 1615], ["types", 1620], ["most", 1626], ["relevant", 1631], ["to", 1640], ["disease", 1643], ["processes", 1651], [".", 1660]]}
{"context": "Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52% (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16% (12 patients: 5 complete, 3 partial [Ph(+) below 35%], and 4 minor [Ph(+), 34% to 90%]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22%. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55% versus 29%, P =.001), longer median survival (7 versus 4 months, P =.04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "130270c72b1842a69ae47929d7075090", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[42, 44], [6, 8]], "char_spans": [[238, 244], [45, 51]]}]}], "context_tokens": [["Molecular", 0], ["abnormalities", 10], ["caused", 24], ["by", 31], ["the", 34], ["hybrid", 38], ["Bcr", 45], ["-", 48], ["Abl", 49], ["gene", 53], ["are", 58], ["causally", 62], ["associated", 71], ["with", 82], ["the", 87], ["development", 91], ["and", 103], ["progression", 107], ["of", 119], ["Philadelphia", 122], ["chromosome", 135], ["-", 145], ["positive", 146], ["(", 155], ["Ph(+", 156], [")", 160], [")", 161], ["chronic", 163], ["myelogenous", 171], ["leukemia", 183], ["(", 192], ["CML", 193], [")", 196], [".", 197], ["Imatinib", 199], ["mesylate", 208], ["(", 217], ["STI571", 218], [")", 224], [",", 225], ["a", 227], ["specific", 229], ["Bcr", 238], ["-", 241], ["Abl", 242], ["tyrosine", 246], ["-", 254], ["kinase", 255], ["signal", 262], ["-", 268], ["transduction", 269], ["inhibitor", 282], [",", 291], ["has", 293], ["shown", 297], ["encouraging", 303], ["activity", 315], ["in", 324], ["phase", 327], ["I", 333], ["and", 335], ["II", 339], ["studies", 342], ["of", 350], ["CML", 353], [".", 356], ["Here", 358], [",", 362], ["we", 364], ["describe", 367], ["the", 376], ["use", 380], ["of", 384], ["imatinib", 387], ["mesylate", 396], ["to", 405], ["treat", 408], ["75", 414], ["patients", 417], ["in", 426], ["blast", 429], ["-", 434], ["phase", 435], ["CML", 441], ["(", 445], ["median", 446], ["age", 453], [",", 456], ["53", 458], ["years", 461], [";", 466], ["65", 468], ["with", 471], ["nonlymphoid", 476], ["and", 488], ["10", 492], ["with", 495], ["lymphoid", 500], ["blasts", 509], [")", 515], [",", 516], ["and", 518], ["compare", 522], ["the", 530], ["results", 534], ["with", 542], ["those", 547], ["of", 553], ["a", 556], ["historical", 558], ["control", 569], ["group", 577], ["treated", 583], ["with", 591], ["standard", 596], ["cytarabine", 605], ["-", 615], ["based", 616], ["therapy", 622], [".", 629], ["Imatinib", 631], ["mesylate", 640], ["was", 649], ["given", 653], ["as", 659], ["oral", 662], ["doses", 667], ["at", 673], ["300", 676], ["to", 680], ["1000", 683], ["mg", 688], ["per", 691], ["day", 695], ["and", 699], ["was", 703], ["the", 707], ["first", 711], ["salvage", 717], ["therapy", 725], ["for", 733], ["47", 737], ["patients", 740], [".", 748], ["The", 750], ["objective", 754], ["response", 764], ["rate", 773], ["was", 778], ["52", 782], ["%", 784], ["(", 786], ["39", 787], ["of", 790], ["75", 793], ["patients", 796], [":", 804], ["16", 806], ["had", 809], ["complete", 813], ["and", 822], ["3", 826], ["had", 828], ["partial", 832], ["hematologic", 840], ["response", 852], [";", 860], ["12", 862], ["had", 865], ["hematologic", 869], ["improvement", 881], [";", 892], ["7", 894], ["returned", 896], ["to", 905], ["second", 908], ["chronic", 915], ["phase", 923], [";", 928], ["and", 930], ["1", 934], ["had", 936], ["a", 940], ["complete", 942], ["response", 951], ["in", 960], ["extramedullary", 963], ["blastic", 978], ["disease", 986], [")", 993], [".", 994], ["Response", 996], ["rates", 1005], ["were", 1011], ["not", 1016], ["different", 1020], ["between", 1030], ["nonlymphoid", 1038], ["and", 1050], ["lymphoid", 1054], ["groups", 1063], [".", 1069], ["The", 1071], ["cytogenetic", 1075], ["response", 1087], ["rate", 1096], ["was", 1101], ["16", 1105], ["%", 1107], ["(", 1109], ["12", 1110], ["patients", 1113], [":", 1121], ["5", 1123], ["complete", 1125], [",", 1133], ["3", 1135], ["partial", 1137], ["[", 1145], ["Ph(+", 1146], [")", 1150], ["below", 1152], ["35", 1158], ["%", 1160], ["]", 1161], [",", 1162], ["and", 1164], ["4", 1168], ["minor", 1170], ["[", 1176], ["Ph(+", 1177], [")", 1181], [",", 1182], ["34", 1184], ["%", 1186], ["to", 1188], ["90", 1191], ["%", 1193], ["]", 1194], [")", 1195], [".", 1196], ["The", 1198], ["estimated", 1202], ["median", 1212], ["overall", 1219], ["survival", 1227], ["was", 1236], ["6.5", 1240], ["months", 1244], [";", 1250], ["the", 1252], ["estimated", 1256], ["1-year", 1266], ["survival", 1273], ["was", 1282], ["22", 1286], ["%", 1288], [".", 1289], ["Response", 1291], ["to", 1300], ["therapy", 1303], ["(", 1311], ["landmark", 1312], ["analysis", 1321], ["at", 1330], ["8", 1333], ["weeks", 1335], [")", 1340], ["was", 1342], ["associated", 1346], ["with", 1357], ["survival", 1362], ["prolongation", 1371], [".", 1383], ["Compared", 1385], ["with", 1394], ["standard", 1399], ["cytarabine", 1408], ["combinations", 1419], [",", 1431], ["imatinib", 1433], ["mesylate", 1442], ["therapy", 1451], ["was", 1459], ["less", 1463], ["toxic", 1468], ["and", 1474], ["produced", 1478], ["a", 1487], ["higher", 1489], ["response", 1496], ["rate", 1505], ["(", 1510], ["55", 1511], ["%", 1513], ["versus", 1515], ["29", 1522], ["%", 1524], [",", 1525], ["P", 1527], ["=", 1529], [".001", 1530], [")", 1534], [",", 1535], ["longer", 1537], ["median", 1544], ["survival", 1551], ["(", 1560], ["7", 1561], ["versus", 1563], ["4", 1570], ["months", 1572], [",", 1578], ["P", 1580], ["=", 1582], [".04", 1583], [")", 1586], [",", 1587], ["and", 1589], ["lower", 1593], ["4-week", 1599], ["induction", 1606], ["mortality", 1616], ["(", 1626], ["4", 1627], ["%", 1628], ["versus", 1630], ["15", 1637], ["%", 1639], [",", 1640], ["P", 1642], ["=", 1644], [".07", 1645], [")", 1648], [".", 1649], ["Imatinib", 1651], ["mesylate", 1660], ["is", 1669], ["currently", 1672], ["being", 1682], ["tested", 1688], ["in", 1695], ["combination", 1698], ["with", 1710], ["other", 1715], ["drugs", 1721], ["to", 1727], ["improve", 1730], ["the", 1738], ["prognosis", 1742], ["for", 1752], ["blast", 1756], ["-", 1761], ["phase", 1762], ["CML", 1768], [".", 1771]]}
{"context": "Emerging data suggest that second-generation antipsychotics such as aripiprazole may be effective in the treatment of post-traumatic stress disorder (PTSD). However, few clinical trials have used aripiprazole in PTSD, and data are limited on its use in Veterans with PTSD. The objective of this pilot trial was to investigate the safety and efficacy of aripiprazole in Veterans with PTSD. Ten individuals (five men and five women) meeting the Diagnostic and statistical manual of mental disorders, 4th ed., PTSD criteria participated in this 12-week, open-label, flexibly dosed monotherapy trial. The dose range of aripiprazole was 5-30 mg/day, titrated to tolerability and clinical response. The primary outcome measure was the Clinician-Administered PTSD Scale. Additional outcomes included the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale (Top-8), the Davidson Trauma Scale, the Positive and Negative Syndrome Scale, the Beck Depression Inventory-Fast Screen, and Clinical Global Impressions-Improvement. Eight participants completed the study, and aripiprazole was generally well tolerated and associated with a significant improvement in PTSD symptoms, as measured by the Clinician-Administered PTSD Scale (primary outcome measure) and by the Short PTSD Rating Interview, the Treatment Outcome PTSD Scale, and the Davidson Trauma Scale. An improvement was also observed on all three Positive and Negative Syndrome Scale subscales and the Beck Depression Inventory-Fast Screen, and the average Clinical Global Impressions-Improvement ratings indicated that patients were 'much improved'. These promising initial results merit further investigation in a larger, randomized-controlled trial.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "0b4eb5fc8d864052918d6cffa3730c7d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[118, 147]]}, {"text": "PTSD", "token_spans": [[48, 48], [226, 226], [93, 93], [205, 205], [138, 138], [36, 36], [68, 68], [153, 153], [215, 215], [233, 233], [24, 24], [146, 146]], "char_spans": [[267, 270], [1271, 1274], [507, 510], [1160, 1163], [752, 755], [212, 215], [383, 386], [848, 851], [1217, 1220], [1316, 1319], [150, 153], [803, 806]]}]}], "context_tokens": [["Emerging", 0], ["data", 9], ["suggest", 14], ["that", 22], ["second", 27], ["-", 33], ["generation", 34], ["antipsychotics", 45], ["such", 60], ["as", 65], ["aripiprazole", 68], ["may", 81], ["be", 85], ["effective", 88], ["in", 98], ["the", 101], ["treatment", 105], ["of", 115], ["post", 118], ["-", 122], ["traumatic", 123], ["stress", 133], ["disorder", 140], ["(", 149], ["PTSD", 150], [")", 154], [".", 155], ["However", 157], [",", 164], ["few", 166], ["clinical", 170], ["trials", 179], ["have", 186], ["used", 191], ["aripiprazole", 196], ["in", 209], ["PTSD", 212], [",", 216], ["and", 218], ["data", 222], ["are", 227], ["limited", 231], ["on", 239], ["its", 242], ["use", 246], ["in", 250], ["Veterans", 253], ["with", 262], ["PTSD", 267], [".", 271], ["The", 273], ["objective", 277], ["of", 287], ["this", 290], ["pilot", 295], ["trial", 301], ["was", 307], ["to", 311], ["investigate", 314], ["the", 326], ["safety", 330], ["and", 337], ["efficacy", 341], ["of", 350], ["aripiprazole", 353], ["in", 366], ["Veterans", 369], ["with", 378], ["PTSD", 383], [".", 387], ["Ten", 389], ["individuals", 393], ["(", 405], ["five", 406], ["men", 411], ["and", 415], ["five", 419], ["women", 424], [")", 429], ["meeting", 431], ["the", 439], ["Diagnostic", 443], ["and", 454], ["statistical", 458], ["manual", 470], ["of", 477], ["mental", 480], ["disorders", 487], [",", 496], ["4th", 498], ["ed", 502], [".", 504], [",", 505], ["PTSD", 507], ["criteria", 512], ["participated", 521], ["in", 534], ["this", 537], ["12-week", 542], [",", 549], ["open", 551], ["-", 555], ["label", 556], [",", 561], ["flexibly", 563], ["dosed", 572], ["monotherapy", 578], ["trial", 590], [".", 595], ["The", 597], ["dose", 601], ["range", 606], ["of", 612], ["aripiprazole", 615], ["was", 628], ["5", 632], ["-", 633], ["30", 634], ["mg", 637], ["/", 639], ["day", 640], [",", 643], ["titrated", 645], ["to", 654], ["tolerability", 657], ["and", 670], ["clinical", 674], ["response", 683], [".", 691], ["The", 693], ["primary", 697], ["outcome", 705], ["measure", 713], ["was", 721], ["the", 725], ["Clinician", 729], ["-", 738], ["Administered", 739], ["PTSD", 752], ["Scale", 757], [".", 762], ["Additional", 764], ["outcomes", 775], ["included", 784], ["the", 793], ["Short", 797], ["PTSD", 803], ["Rating", 808], ["Interview", 815], [",", 824], ["the", 826], ["Treatment", 830], ["Outcome", 840], ["PTSD", 848], ["Scale", 853], ["(", 859], ["Top-8", 860], [")", 865], [",", 866], ["the", 868], ["Davidson", 872], ["Trauma", 881], ["Scale", 888], [",", 893], ["the", 895], ["Positive", 899], ["and", 908], ["Negative", 912], ["Syndrome", 921], ["Scale", 930], [",", 935], ["the", 937], ["Beck", 941], ["Depression", 946], ["Inventory", 957], ["-", 966], ["Fast", 967], ["Screen", 972], [",", 978], ["and", 980], ["Clinical", 984], ["Global", 993], ["Impressions", 1000], ["-", 1011], ["Improvement", 1012], [".", 1023], ["Eight", 1025], ["participants", 1031], ["completed", 1044], ["the", 1054], ["study", 1058], [",", 1063], ["and", 1065], ["aripiprazole", 1069], ["was", 1082], ["generally", 1086], ["well", 1096], ["tolerated", 1101], ["and", 1111], ["associated", 1115], ["with", 1126], ["a", 1131], ["significant", 1133], ["improvement", 1145], ["in", 1157], ["PTSD", 1160], ["symptoms", 1165], [",", 1173], ["as", 1175], ["measured", 1178], ["by", 1187], ["the", 1190], ["Clinician", 1194], ["-", 1203], ["Administered", 1204], ["PTSD", 1217], ["Scale", 1222], ["(", 1228], ["primary", 1229], ["outcome", 1237], ["measure", 1245], [")", 1252], ["and", 1254], ["by", 1258], ["the", 1261], ["Short", 1265], ["PTSD", 1271], ["Rating", 1276], ["Interview", 1283], [",", 1292], ["the", 1294], ["Treatment", 1298], ["Outcome", 1308], ["PTSD", 1316], ["Scale", 1321], [",", 1326], ["and", 1328], ["the", 1332], ["Davidson", 1336], ["Trauma", 1345], ["Scale", 1352], [".", 1357], ["An", 1359], ["improvement", 1362], ["was", 1374], ["also", 1378], ["observed", 1383], ["on", 1392], ["all", 1395], ["three", 1399], ["Positive", 1405], ["and", 1414], ["Negative", 1418], ["Syndrome", 1427], ["Scale", 1436], ["subscales", 1442], ["and", 1452], ["the", 1456], ["Beck", 1460], ["Depression", 1465], ["Inventory", 1476], ["-", 1485], ["Fast", 1486], ["Screen", 1491], [",", 1497], ["and", 1499], ["the", 1503], ["average", 1507], ["Clinical", 1515], ["Global", 1524], ["Impressions", 1531], ["-", 1542], ["Improvement", 1543], ["ratings", 1555], ["indicated", 1563], ["that", 1573], ["patients", 1578], ["were", 1587], ["'", 1592], ["much", 1593], ["improved", 1598], ["'", 1606], [".", 1607], ["These", 1609], ["promising", 1615], ["initial", 1625], ["results", 1633], ["merit", 1641], ["further", 1647], ["investigation", 1655], ["in", 1669], ["a", 1672], ["larger", 1674], [",", 1680], ["randomized", 1682], ["-", 1692], ["controlled", 1693], ["trial", 1704], [".", 1709]]}
{"context": "We investigated the requirements for selenocysteine insertion at single or multiple UGA codons in eukaryotic selenoproteins. Two functional SECIS elements were identified in the 3' untranslated region of the rat selenoprotein P mRNA, with predicted stem-loops and critical nucleotides similar to those in the SECIS elements in the type I iodothyronine 5' deiodinase (5'DI) and glutathione peroxidase selenoprotein mRNAs. Site-directed mutational analyses of three SECIS elements confirmed that conserved nucleotides in the loop and in unpaired regions of the stem are critical for activity. This indicates that multiple contact sites are required for SECIS function. Stop codon function at any of five out-of-context UGA codons in the 5'DI mRNA was suppressed by SECIS elements from the 5'DI or selenoprotein P genes linked downstream. Thus, the presence of SECIS elements in eukaryotic selenoprotein mRNAs permits complete flexibility in UGA codon position.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "03e383d3bf6142a5983cf58fc309b81d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[75, 75], [19, 19], [105, 105], [146, 146], [129, 129], [49, 49]], "char_spans": [[464, 468], [140, 144], [651, 655], [858, 862], [763, 767], [309, 313]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["requirements", 20], ["for", 33], ["selenocysteine", 37], ["insertion", 52], ["at", 62], ["single", 65], ["or", 72], ["multiple", 75], ["UGA", 84], ["codons", 88], ["in", 95], ["eukaryotic", 98], ["selenoproteins", 109], [".", 123], ["Two", 125], ["functional", 129], ["SECIS", 140], ["elements", 146], ["were", 155], ["identified", 160], ["in", 171], ["the", 174], ["3", 178], ["'", 179], ["untranslated", 181], ["region", 194], ["of", 201], ["the", 204], ["rat", 208], ["selenoprotein", 212], ["P", 226], ["mRNA", 228], [",", 232], ["with", 234], ["predicted", 239], ["stem", 249], ["-", 253], ["loops", 254], ["and", 260], ["critical", 264], ["nucleotides", 273], ["similar", 285], ["to", 293], ["those", 296], ["in", 302], ["the", 305], ["SECIS", 309], ["elements", 315], ["in", 324], ["the", 327], ["type", 331], ["I", 336], ["iodothyronine", 338], ["5", 352], ["'", 353], ["deiodinase", 355], ["(", 366], ["5'DI", 367], [")", 371], ["and", 373], ["glutathione", 377], ["peroxidase", 389], ["selenoprotein", 400], ["mRNAs", 414], [".", 419], ["Site", 421], ["-", 425], ["directed", 426], ["mutational", 435], ["analyses", 446], ["of", 455], ["three", 458], ["SECIS", 464], ["elements", 470], ["confirmed", 479], ["that", 489], ["conserved", 494], ["nucleotides", 504], ["in", 516], ["the", 519], ["loop", 523], ["and", 528], ["in", 532], ["unpaired", 535], ["regions", 544], ["of", 552], ["the", 555], ["stem", 559], ["are", 564], ["critical", 568], ["for", 577], ["activity", 581], [".", 589], ["This", 591], ["indicates", 596], ["that", 606], ["multiple", 611], ["contact", 620], ["sites", 628], ["are", 634], ["required", 638], ["for", 647], ["SECIS", 651], ["function", 657], [".", 665], ["Stop", 667], ["codon", 672], ["function", 678], ["at", 687], ["any", 690], ["of", 694], ["five", 697], ["out", 702], ["-", 705], ["of", 706], ["-", 708], ["context", 709], ["UGA", 717], ["codons", 721], ["in", 728], ["the", 731], ["5'DI", 735], ["mRNA", 740], ["was", 745], ["suppressed", 749], ["by", 760], ["SECIS", 763], ["elements", 769], ["from", 778], ["the", 783], ["5'DI", 787], ["or", 792], ["selenoprotein", 795], ["P", 809], ["genes", 811], ["linked", 817], ["downstream", 824], [".", 834], ["Thus", 836], [",", 840], ["the", 842], ["presence", 846], ["of", 855], ["SECIS", 858], ["elements", 864], ["in", 873], ["eukaryotic", 876], ["selenoprotein", 887], ["mRNAs", 901], ["permits", 907], ["complete", 915], ["flexibility", 924], ["in", 936], ["UGA", 939], ["codon", 943], ["position", 949], [".", 957]]}
{"context": "One of the major histopathological hallmarks of Alzheimer's disease (AD) is cerebral deposits of extracellular \u03b2-amyloid peptides. Preclinical studies have pointed to glucagon-like peptide 1 (GLP-1) receptors as a potential novel target in the treatment of AD. GLP-1 receptor agonists, including exendin-4 and liraglutide, have been shown to promote plaque-lowering and mnemonic effects of in a number of experimental models of AD. Transgenic mouse models carrying genetic mutations of amyloid protein precursor (APP) and presenilin-1 (PS1) are commonly used to assess the pharmacodynamics of potential amyloidosis-lowering and pro-cognitive compounds. In this study, effects of long-term liraglutide treatment were therefore determined in two double APP/PS1 transgenic mouse models of Alzheimer's disease carrying different clinical APP/PS1 mutations, i.e. the 'London' (hAPPLon/PS1A246E) and 'Swedish' mutation variant (hAPPSwe/PS1\u0394E9) of APP, with co-expression of distinct PS1 variants. Liraglutide was administered in 5 month-old hAPPLon/PS1A246E mice for 3 months (100 or 500 ng/kg/day, s.c.), or 7 month-old hAPPSwe/PS1\u0394E9 mice for 5 months (500 ng/kg/day, s.c.). In both models, regional plaque load was quantified throughout the brain using stereological methods. Vehicle-dosed hAPPSwe/PS1\u0394E9 mice exhibited considerably higher cerebral plaque load than hAPPLon/PS1A246E control mice. Compared to vehicle-dosed transgenic controls, liraglutide treatment had no effect on the plaque levels in hAPPLon/PS1A246E and hAPPSwe/PS1\u0394E9 mice. In conclusion, long-term liraglutide treatment exhibited no effect on cerebral plaque load in two transgenic mouse models of low- and high-grade amyloidosis, which suggests differential sensitivity to long-term liraglutide treatment in various transgenic mouse models mimicking distinct pathological hallmarks of AD.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "9e28aa040a2f43c3ab63eeba84b5f4de", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[138, 140], [7, 9]], "char_spans": [[786, 804], [48, 66]]}, {"text": "AD", "token_spans": [[76, 76], [11, 11], [346, 346], [46, 46]], "char_spans": [[428, 429], [69, 70], [1856, 1857], [257, 258]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["major", 11], ["histopathological", 17], ["hallmarks", 35], ["of", 45], ["Alzheimer", 48], ["'s", 57], ["disease", 60], ["(", 68], ["AD", 69], [")", 71], ["is", 73], ["cerebral", 76], ["deposits", 85], ["of", 94], ["extracellular", 97], ["\u03b2", 111], ["-", 112], ["amyloid", 113], ["peptides", 121], [".", 129], ["Preclinical", 131], ["studies", 143], ["have", 151], ["pointed", 156], ["to", 164], ["glucagon", 167], ["-", 175], ["like", 176], ["peptide", 181], ["1", 189], ["(", 191], ["GLP-1", 192], [")", 197], ["receptors", 199], ["as", 209], ["a", 212], ["potential", 214], ["novel", 224], ["target", 230], ["in", 237], ["the", 240], ["treatment", 244], ["of", 254], ["AD", 257], [".", 259], ["GLP-1", 261], ["receptor", 267], ["agonists", 276], [",", 284], ["including", 286], ["exendin-4", 296], ["and", 306], ["liraglutide", 310], [",", 321], ["have", 323], ["been", 328], ["shown", 333], ["to", 339], ["promote", 342], ["plaque", 350], ["-", 356], ["lowering", 357], ["and", 366], ["mnemonic", 370], ["effects", 379], ["of", 387], ["in", 390], ["a", 393], ["number", 395], ["of", 402], ["experimental", 405], ["models", 418], ["of", 425], ["AD", 428], [".", 430], ["Transgenic", 432], ["mouse", 443], ["models", 449], ["carrying", 456], ["genetic", 465], ["mutations", 473], ["of", 483], ["amyloid", 486], ["protein", 494], ["precursor", 502], ["(", 512], ["APP", 513], [")", 516], ["and", 518], ["presenilin-1", 522], ["(", 535], ["PS1", 536], [")", 539], ["are", 541], ["commonly", 545], ["used", 554], ["to", 559], ["assess", 562], ["the", 569], ["pharmacodynamics", 573], ["of", 590], ["potential", 593], ["amyloidosis", 603], ["-", 614], ["lowering", 615], ["and", 624], ["pro", 628], ["-", 631], ["cognitive", 632], ["compounds", 642], [".", 651], ["In", 653], ["this", 656], ["study", 661], [",", 666], ["effects", 668], ["of", 676], ["long", 679], ["-", 683], ["term", 684], ["liraglutide", 689], ["treatment", 701], ["were", 711], ["therefore", 716], ["determined", 726], ["in", 737], ["two", 740], ["double", 744], ["APP", 751], ["/", 754], ["PS1", 755], ["transgenic", 759], ["mouse", 770], ["models", 776], ["of", 783], ["Alzheimer", 786], ["'s", 795], ["disease", 798], ["carrying", 806], ["different", 815], ["clinical", 825], ["APP", 834], ["/", 837], ["PS1", 838], ["mutations", 842], [",", 851], ["i.e.", 853], ["the", 858], ["'", 862], ["London", 863], ["'", 869], ["(", 871], ["hAPPLon", 872], ["/", 879], ["PS1A246E", 880], [")", 888], ["and", 890], ["'", 894], ["Swedish", 895], ["'", 902], ["mutation", 904], ["variant", 913], ["(", 921], ["hAPPSwe", 922], ["/", 929], ["PS1\u0394E9", 930], [")", 936], ["of", 938], ["APP", 941], [",", 944], ["with", 946], ["co", 951], ["-", 953], ["expression", 954], ["of", 965], ["distinct", 968], ["PS1", 977], ["variants", 981], [".", 989], ["Liraglutide", 991], ["was", 1003], ["administered", 1007], ["in", 1020], ["5", 1023], ["month", 1025], ["-", 1030], ["old", 1031], ["hAPPLon", 1035], ["/", 1042], ["PS1A246E", 1043], ["mice", 1052], ["for", 1057], ["3", 1061], ["months", 1063], ["(", 1070], ["100", 1071], ["or", 1075], ["500", 1078], ["ng", 1082], ["/", 1084], ["kg", 1085], ["/", 1087], ["day", 1088], [",", 1091], ["s.c", 1093], [".", 1096], [")", 1097], [",", 1098], ["or", 1100], ["7", 1103], ["month", 1105], ["-", 1110], ["old", 1111], ["hAPPSwe", 1115], ["/", 1122], ["PS1\u0394E9", 1123], ["mice", 1130], ["for", 1135], ["5", 1139], ["months", 1141], ["(", 1148], ["500", 1149], ["ng", 1153], ["/", 1155], ["kg", 1156], ["/", 1158], ["day", 1159], [",", 1162], ["s.c", 1164], [".", 1167], [")", 1168], [".", 1169], ["In", 1171], ["both", 1174], ["models", 1179], [",", 1185], ["regional", 1187], ["plaque", 1196], ["load", 1203], ["was", 1208], ["quantified", 1212], ["throughout", 1223], ["the", 1234], ["brain", 1238], ["using", 1244], ["stereological", 1250], ["methods", 1264], [".", 1271], ["Vehicle", 1273], ["-", 1280], ["dosed", 1281], ["hAPPSwe", 1287], ["/", 1294], ["PS1\u0394E9", 1295], ["mice", 1302], ["exhibited", 1307], ["considerably", 1317], ["higher", 1330], ["cerebral", 1337], ["plaque", 1346], ["load", 1353], ["than", 1358], ["hAPPLon", 1363], ["/", 1370], ["PS1A246E", 1371], ["control", 1380], ["mice", 1388], [".", 1392], ["Compared", 1394], ["to", 1403], ["vehicle", 1406], ["-", 1413], ["dosed", 1414], ["transgenic", 1420], ["controls", 1431], [",", 1439], ["liraglutide", 1441], ["treatment", 1453], ["had", 1463], ["no", 1467], ["effect", 1470], ["on", 1477], ["the", 1480], ["plaque", 1484], ["levels", 1491], ["in", 1498], ["hAPPLon", 1501], ["/", 1508], ["PS1A246E", 1509], ["and", 1518], ["hAPPSwe", 1522], ["/", 1529], ["PS1\u0394E9", 1530], ["mice", 1537], [".", 1541], ["In", 1543], ["conclusion", 1546], [",", 1556], ["long", 1558], ["-", 1562], ["term", 1563], ["liraglutide", 1568], ["treatment", 1580], ["exhibited", 1590], ["no", 1600], ["effect", 1603], ["on", 1610], ["cerebral", 1613], ["plaque", 1622], ["load", 1629], ["in", 1634], ["two", 1637], ["transgenic", 1641], ["mouse", 1652], ["models", 1658], ["of", 1665], ["low-", 1668], ["and", 1673], ["high", 1677], ["-", 1681], ["grade", 1682], ["amyloidosis", 1688], [",", 1699], ["which", 1701], ["suggests", 1707], ["differential", 1716], ["sensitivity", 1729], ["to", 1741], ["long", 1744], ["-", 1748], ["term", 1749], ["liraglutide", 1754], ["treatment", 1766], ["in", 1776], ["various", 1779], ["transgenic", 1787], ["mouse", 1798], ["models", 1804], ["mimicking", 1811], ["distinct", 1821], ["pathological", 1830], ["hallmarks", 1843], ["of", 1853], ["AD", 1856], [".", 1858]]}
{"context": "Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family. The nerve growth factor antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA pathway in pain. As an alternative modality, small-molecule inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications. This paper reviews the patent literature between mid-2009 and 2013, claiming inhibitors of Trk family members as the primary biological targets. Additional patents have been reviewed where Trk is not the main kinase of interest but in which high Trk potency is observed and the chemical matter is particularly noteworthy. Patents pre-dating this period have been reviewed previously. Scifinder and Google were used to find relevant patents and clinical information using Trk or Tropomyosin as the search term. Considerable recent progress has been made in the identification of selective pan Trk inhibitors with pharmacodynamic and pharmacokinetic properties appropriate for clinical evaluation. Inhibitors of both active and inactive conformations of the Trks as well as peripherally restricted molecules have been identified. Furthermore, TrkA-selective allosteric inhibitors have recently been disclosed, which enables the biology of this isoform to be probed. The recent identification of a TrkA gene fusion in a subset of lung cancer patients will increase further the attraction of Trk inhibition to the pharmaceutical industry.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "6f76097048934cc28e54c79c8ca57345", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[24, 26]], "char_spans": [[145, 163]]}]}], "context_tokens": [["Tropomyosin", 0], ["receptor", 12], ["kinases", 21], ["(", 29], ["Trks", 30], [")", 34], ["are", 36], ["a", 40], ["family", 42], ["of", 49], ["three", 52], ["similar", 58], ["tyrosine", 66], ["kinases", 75], ["activated", 83], ["by", 93], ["peptide", 96], ["hormones", 104], ["of", 113], ["the", 116], ["neurotrophin", 120], ["family", 133], [".", 139], ["The", 141], ["nerve", 145], ["growth", 151], ["factor", 158], ["antibody", 165], ["tanezumab", 174], ["has", 184], ["provided", 188], ["clinical", 197], ["proof", 206], ["of", 212], ["concept", 215], ["for", 223], ["inhibition", 227], ["of", 238], ["the", 241], ["TrkA", 245], ["pathway", 250], ["in", 258], ["pain", 261], [".", 265], ["As", 267], ["an", 270], ["alternative", 273], ["modality", 285], [",", 293], ["small", 295], ["-", 300], ["molecule", 301], ["inhibitors", 310], ["of", 321], ["the", 324], ["Trks", 328], ["have", 333], ["been", 338], ["pursued", 343], ["in", 351], ["recent", 354], ["years", 361], ["to", 367], ["probe", 370], ["the", 376], ["role", 380], ["of", 385], ["these", 388], ["neurotrophin", 394], ["pathways", 407], ["in", 416], ["pain", 419], [",", 423], ["cancer", 425], ["and", 432], ["other", 436], ["indications", 442], [".", 453], ["This", 455], ["paper", 460], ["reviews", 466], ["the", 474], ["patent", 478], ["literature", 485], ["between", 496], ["mid-2009", 504], ["and", 513], ["2013", 517], [",", 521], ["claiming", 523], ["inhibitors", 532], ["of", 543], ["Trk", 546], ["family", 550], ["members", 557], ["as", 565], ["the", 568], ["primary", 572], ["biological", 580], ["targets", 591], [".", 598], ["Additional", 600], ["patents", 611], ["have", 619], ["been", 624], ["reviewed", 629], ["where", 638], ["Trk", 644], ["is", 648], ["not", 651], ["the", 655], ["main", 659], ["kinase", 664], ["of", 671], ["interest", 674], ["but", 683], ["in", 687], ["which", 690], ["high", 696], ["Trk", 701], ["potency", 705], ["is", 713], ["observed", 716], ["and", 725], ["the", 729], ["chemical", 733], ["matter", 742], ["is", 749], ["particularly", 752], ["noteworthy", 765], [".", 775], ["Patents", 777], ["pre", 785], ["-", 788], ["dating", 789], ["this", 796], ["period", 801], ["have", 808], ["been", 813], ["reviewed", 818], ["previously", 827], [".", 837], ["Scifinder", 839], ["and", 849], ["Google", 853], ["were", 860], ["used", 865], ["to", 870], ["find", 873], ["relevant", 878], ["patents", 887], ["and", 895], ["clinical", 899], ["information", 908], ["using", 920], ["Trk", 926], ["or", 930], ["Tropomyosin", 933], ["as", 945], ["the", 948], ["search", 952], ["term", 959], [".", 963], ["Considerable", 965], ["recent", 978], ["progress", 985], ["has", 994], ["been", 998], ["made", 1003], ["in", 1008], ["the", 1011], ["identification", 1015], ["of", 1030], ["selective", 1033], ["pan", 1043], ["Trk", 1047], ["inhibitors", 1051], ["with", 1062], ["pharmacodynamic", 1067], ["and", 1083], ["pharmacokinetic", 1087], ["properties", 1103], ["appropriate", 1114], ["for", 1126], ["clinical", 1130], ["evaluation", 1139], [".", 1149], ["Inhibitors", 1151], ["of", 1162], ["both", 1165], ["active", 1170], ["and", 1177], ["inactive", 1181], ["conformations", 1190], ["of", 1204], ["the", 1207], ["Trks", 1211], ["as", 1216], ["well", 1219], ["as", 1224], ["peripherally", 1227], ["restricted", 1240], ["molecules", 1251], ["have", 1261], ["been", 1266], ["identified", 1271], [".", 1281], ["Furthermore", 1283], [",", 1294], ["TrkA", 1296], ["-", 1300], ["selective", 1301], ["allosteric", 1311], ["inhibitors", 1322], ["have", 1333], ["recently", 1338], ["been", 1347], ["disclosed", 1352], [",", 1361], ["which", 1363], ["enables", 1369], ["the", 1377], ["biology", 1381], ["of", 1389], ["this", 1392], ["isoform", 1397], ["to", 1405], ["be", 1408], ["probed", 1411], [".", 1417], ["The", 1419], ["recent", 1423], ["identification", 1430], ["of", 1445], ["a", 1448], ["TrkA", 1450], ["gene", 1455], ["fusion", 1460], ["in", 1467], ["a", 1470], ["subset", 1472], ["of", 1479], ["lung", 1482], ["cancer", 1487], ["patients", 1494], ["will", 1503], ["increase", 1508], ["further", 1517], ["the", 1525], ["attraction", 1529], ["of", 1540], ["Trk", 1543], ["inhibition", 1547], ["to", 1558], ["the", 1561], ["pharmaceutical", 1565], ["industry", 1580], [".", 1588]]}
{"context": "Methylation of lysine residues of histones is an important epigenetic mark that correlates with functionally distinct regions of chromatin. We present here the crystal structure of a ternary complex of the enzyme Pr-Set7 (also known as Set8) that methylates Lys 20 of histone H4 (H4-K20). We show that the enzyme is exclusively a mono-methylase and is therefore responsible for a signaling role quite distinct from that established by other enzymes that target this histone residue. We provide evidence from NMR for the C-flanking domains of SET proteins becoming ordered upon addition of AdoMet cofactor and develop a model for the catalytic cycle of these enzymes. The crystal structure reveals the basis of the specificity of the enzyme for H4-K20 because a histidine residue within the substrate, close to the target lysine, is required for completion of the active site. We also show how a highly variable component of the SET domain is responsible for many of the enzymes' interactions with its target histone peptide and probably also how this part of the structure ensures that Pr-Set7 is nucleosome specific.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f424eb5bb7c24c5185b12545eb402821", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[166, 167]], "char_spans": [[928, 937]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["of", 31], ["histones", 34], ["is", 43], ["an", 46], ["important", 49], ["epigenetic", 59], ["mark", 70], ["that", 75], ["correlates", 80], ["with", 91], ["functionally", 96], ["distinct", 109], ["regions", 118], ["of", 126], ["chromatin", 129], [".", 138], ["We", 140], ["present", 143], ["here", 151], ["the", 156], ["crystal", 160], ["structure", 168], ["of", 178], ["a", 181], ["ternary", 183], ["complex", 191], ["of", 199], ["the", 202], ["enzyme", 206], ["Pr", 213], ["-", 215], ["Set7", 216], ["(", 221], ["also", 222], ["known", 227], ["as", 233], ["Set8", 236], [")", 240], ["that", 242], ["methylates", 247], ["Lys", 258], ["20", 262], ["of", 265], ["histone", 268], ["H4", 276], ["(", 279], ["H4-K20", 280], [")", 286], [".", 287], ["We", 289], ["show", 292], ["that", 297], ["the", 302], ["enzyme", 306], ["is", 313], ["exclusively", 316], ["a", 328], ["mono", 330], ["-", 334], ["methylase", 335], ["and", 345], ["is", 349], ["therefore", 352], ["responsible", 362], ["for", 374], ["a", 378], ["signaling", 380], ["role", 390], ["quite", 395], ["distinct", 401], ["from", 410], ["that", 415], ["established", 420], ["by", 432], ["other", 435], ["enzymes", 441], ["that", 449], ["target", 454], ["this", 461], ["histone", 466], ["residue", 474], [".", 481], ["We", 483], ["provide", 486], ["evidence", 494], ["from", 503], ["NMR", 508], ["for", 512], ["the", 516], ["C", 520], ["-", 521], ["flanking", 522], ["domains", 531], ["of", 539], ["SET", 542], ["proteins", 546], ["becoming", 555], ["ordered", 564], ["upon", 572], ["addition", 577], ["of", 586], ["AdoMet", 589], ["cofactor", 596], ["and", 605], ["develop", 609], ["a", 617], ["model", 619], ["for", 625], ["the", 629], ["catalytic", 633], ["cycle", 643], ["of", 649], ["these", 652], ["enzymes", 658], [".", 665], ["The", 667], ["crystal", 671], ["structure", 679], ["reveals", 689], ["the", 697], ["basis", 701], ["of", 707], ["the", 710], ["specificity", 714], ["of", 726], ["the", 729], ["enzyme", 733], ["for", 740], ["H4-K20", 744], ["because", 751], ["a", 759], ["histidine", 761], ["residue", 771], ["within", 779], ["the", 786], ["substrate", 790], [",", 799], ["close", 801], ["to", 807], ["the", 810], ["target", 814], ["lysine", 821], [",", 827], ["is", 829], ["required", 832], ["for", 841], ["completion", 845], ["of", 856], ["the", 859], ["active", 863], ["site", 870], [".", 874], ["We", 876], ["also", 879], ["show", 884], ["how", 889], ["a", 893], ["highly", 895], ["variable", 902], ["component", 911], ["of", 921], ["the", 924], ["SET", 928], ["domain", 932], ["is", 939], ["responsible", 942], ["for", 954], ["many", 958], ["of", 963], ["the", 966], ["enzymes", 970], ["'", 977], ["interactions", 979], ["with", 992], ["its", 997], ["target", 1001], ["histone", 1008], ["peptide", 1016], ["and", 1024], ["probably", 1028], ["also", 1037], ["how", 1042], ["this", 1046], ["part", 1051], ["of", 1056], ["the", 1059], ["structure", 1063], ["ensures", 1073], ["that", 1081], ["Pr", 1086], ["-", 1088], ["Set7", 1089], ["is", 1094], ["nucleosome", 1097], ["specific", 1108], [".", 1116]]}
{"context": "To identify the origin and study the morphology of small supernumerary marker chromosome (sSMC) in Turner syndrome with 45, X/46, X, + mar karyotype. Using the conventional chromosome G-banding technique, 10 cases of Turner syndrome with 45, X/46, X, + mar chromosome karyotype were obtained, dual-color fluorescence in situ hybridization was applied to study the origin and morphology of the sSMC. In the 10 cases of Turner syndrome with 45, X/46, X, + mar karyotype, the sSMC of 7 cases was derived from X chromosome [sSMC(X)], the sSMC of 2 cases was derived from Y chromosome [sSMC(Y)] and the remaining 1 case was derived from the autosome. There were 4 cases of ring(r) chromosomes and 3 of centric minutes (min) in the 7 sSMC (X) cases. In the 2 sSMC(Y), one case was dicentric (dic) and the other was centric minute (min). The sSMC originated from the autosome was a centric minute (min). The origin of sSMC of Turner syndrome with 45, X/46, X, + mar karyotype was almost all from sex chromosomes, and rarely from autosomes. sSMC can exist as isodicentric, ring, or centric minute. The molecular cytogenetic features of the sSMC can provide useful information for genetic counseling, prenatal diagnosis and treatment of the Turner syndrome patients with a 45, X/46, X, + mar karyotype.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "00f4c5c0e5df41acb2f90c62057cceb8", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[156, 156], [268, 268], [103, 103], [89, 89], [24, 24], [209, 209], [49, 49]], "char_spans": [[734, 734], [1274, 1274], [506, 506], [449, 449], [130, 130], [950, 950], [248, 248]]}]}], "context_tokens": [["To", 0], ["identify", 3], ["the", 12], ["origin", 16], ["and", 23], ["study", 27], ["the", 33], ["morphology", 37], ["of", 48], ["small", 51], ["supernumerary", 57], ["marker", 71], ["chromosome", 78], ["(", 89], ["sSMC", 90], [")", 94], ["in", 96], ["Turner", 99], ["syndrome", 106], ["with", 115], ["45", 120], [",", 122], ["X/46", 124], [",", 128], ["X", 130], [",", 131], ["+", 133], ["mar", 135], ["karyotype", 139], [".", 148], ["Using", 150], ["the", 156], ["conventional", 160], ["chromosome", 173], ["G", 184], ["-", 185], ["banding", 186], ["technique", 194], [",", 203], ["10", 205], ["cases", 208], ["of", 214], ["Turner", 217], ["syndrome", 224], ["with", 233], ["45", 238], [",", 240], ["X/46", 242], [",", 246], ["X", 248], [",", 249], ["+", 251], ["mar", 253], ["chromosome", 257], ["karyotype", 268], ["were", 278], ["obtained", 283], [",", 291], ["dual", 293], ["-", 297], ["color", 298], ["fluorescence", 304], ["in", 317], ["situ", 320], ["hybridization", 325], ["was", 339], ["applied", 343], ["to", 351], ["study", 354], ["the", 360], ["origin", 364], ["and", 371], ["morphology", 375], ["of", 386], ["the", 389], ["sSMC", 393], [".", 397], ["In", 399], ["the", 402], ["10", 406], ["cases", 409], ["of", 415], ["Turner", 418], ["syndrome", 425], ["with", 434], ["45", 439], [",", 441], ["X/46", 443], [",", 447], ["X", 449], [",", 450], ["+", 452], ["mar", 454], ["karyotype", 458], [",", 467], ["the", 469], ["sSMC", 473], ["of", 478], ["7", 481], ["cases", 483], ["was", 489], ["derived", 493], ["from", 501], ["X", 506], ["chromosome", 508], ["[", 519], ["sSMC(X", 520], [")", 526], ["]", 527], [",", 528], ["the", 530], ["sSMC", 534], ["of", 539], ["2", 542], ["cases", 544], ["was", 550], ["derived", 554], ["from", 562], ["Y", 567], ["chromosome", 569], ["[", 580], ["sSMC(Y", 581], [")", 587], ["]", 588], ["and", 590], ["the", 594], ["remaining", 598], ["1", 608], ["case", 610], ["was", 615], ["derived", 619], ["from", 627], ["the", 632], ["autosome", 636], [".", 644], ["There", 646], ["were", 652], ["4", 657], ["cases", 659], ["of", 665], ["ring(r", 668], [")", 674], ["chromosomes", 676], ["and", 688], ["3", 692], ["of", 694], ["centric", 697], ["minutes", 705], ["(", 713], ["min", 714], [")", 717], ["in", 719], ["the", 722], ["7", 726], ["sSMC", 728], ["(", 733], ["X", 734], [")", 735], ["cases", 737], [".", 742], ["In", 744], ["the", 747], ["2", 751], ["sSMC(Y", 753], [")", 759], [",", 760], ["one", 762], ["case", 766], ["was", 771], ["dicentric", 775], ["(", 785], ["dic", 786], [")", 789], ["and", 791], ["the", 795], ["other", 799], ["was", 805], ["centric", 809], ["minute", 817], ["(", 824], ["min", 825], [")", 828], [".", 829], ["The", 831], ["sSMC", 835], ["originated", 840], ["from", 851], ["the", 856], ["autosome", 860], ["was", 869], ["a", 873], ["centric", 875], ["minute", 883], ["(", 890], ["min", 891], [")", 894], [".", 895], ["The", 897], ["origin", 901], ["of", 908], ["sSMC", 911], ["of", 916], ["Turner", 919], ["syndrome", 926], ["with", 935], ["45", 940], [",", 942], ["X/46", 944], [",", 948], ["X", 950], [",", 951], ["+", 953], ["mar", 955], ["karyotype", 959], ["was", 969], ["almost", 973], ["all", 980], ["from", 984], ["sex", 989], ["chromosomes", 993], [",", 1004], ["and", 1006], ["rarely", 1010], ["from", 1017], ["autosomes", 1022], [".", 1031], ["sSMC", 1033], ["can", 1038], ["exist", 1042], ["as", 1048], ["isodicentric", 1051], [",", 1063], ["ring", 1065], [",", 1069], ["or", 1071], ["centric", 1074], ["minute", 1082], [".", 1088], ["The", 1090], ["molecular", 1094], ["cytogenetic", 1104], ["features", 1116], ["of", 1125], ["the", 1128], ["sSMC", 1132], ["can", 1137], ["provide", 1141], ["useful", 1149], ["information", 1156], ["for", 1168], ["genetic", 1172], ["counseling", 1180], [",", 1190], ["prenatal", 1192], ["diagnosis", 1201], ["and", 1211], ["treatment", 1215], ["of", 1225], ["the", 1228], ["Turner", 1232], ["syndrome", 1239], ["patients", 1248], ["with", 1257], ["a", 1262], ["45", 1264], [",", 1266], ["X/46", 1268], [",", 1272], ["X", 1274], [",", 1275], ["+", 1277], ["mar", 1279], ["karyotype", 1283], [".", 1292]]}
{"context": "Posterior cruciate ligament (PCL) injuries have a reported incidence of between 3 and 37%, depending on the clinical setting. The most common mechanism of injury in motor vehicle accidents is a dashboard injury or direct force to the proximal anterior tibia. Sports related injuries result from hyperflexion of the knee with the foot typically plantarflexed. The latter mechanism is the most common cause of isolated PCL injuries, while in the trauma population as many as 95% of patients with knee injuries have combined ligamentous damage. Improved knowledge at an anatomical, biomechanical and clinical level has provided the orthopaedist with a more defined treatment algorithm. Isolated, partial PCL injuries (grades I and II) can best be treated nonoperatively while complete injuries (grade III) may require operative treatment based on clinical symptoms. All combined ligamentous injuries usually respond best with surgical management.", "qas": [{"question": "Which ligament is most commonly injured in dashboard injury?", "answers": ["Posterior cruciate ligament"], "qid": "39e074f0b0694efe8d9c2907bb62096b", "question_tokens": [["Which", 0], ["ligament", 6], ["is", 15], ["most", 18], ["commonly", 23], ["injured", 32], ["in", 40], ["dashboard", 43], ["injury", 53], ["?", 59]], "detected_answers": [{"text": "Posterior cruciate ligament", "token_spans": [[0, 2]], "char_spans": [[0, 26]]}]}], "context_tokens": [["Posterior", 0], ["cruciate", 10], ["ligament", 19], ["(", 28], ["PCL", 29], [")", 32], ["injuries", 34], ["have", 43], ["a", 48], ["reported", 50], ["incidence", 59], ["of", 69], ["between", 72], ["3", 80], ["and", 82], ["37", 86], ["%", 88], [",", 89], ["depending", 91], ["on", 101], ["the", 104], ["clinical", 108], ["setting", 117], [".", 124], ["The", 126], ["most", 130], ["common", 135], ["mechanism", 142], ["of", 152], ["injury", 155], ["in", 162], ["motor", 165], ["vehicle", 171], ["accidents", 179], ["is", 189], ["a", 192], ["dashboard", 194], ["injury", 204], ["or", 211], ["direct", 214], ["force", 221], ["to", 227], ["the", 230], ["proximal", 234], ["anterior", 243], ["tibia", 252], [".", 257], ["Sports", 259], ["related", 266], ["injuries", 274], ["result", 283], ["from", 290], ["hyperflexion", 295], ["of", 308], ["the", 311], ["knee", 315], ["with", 320], ["the", 325], ["foot", 329], ["typically", 334], ["plantarflexed", 344], [".", 357], ["The", 359], ["latter", 363], ["mechanism", 370], ["is", 380], ["the", 383], ["most", 387], ["common", 392], ["cause", 399], ["of", 405], ["isolated", 408], ["PCL", 417], ["injuries", 421], [",", 429], ["while", 431], ["in", 437], ["the", 440], ["trauma", 444], ["population", 451], ["as", 462], ["many", 465], ["as", 470], ["95", 473], ["%", 475], ["of", 477], ["patients", 480], ["with", 489], ["knee", 494], ["injuries", 499], ["have", 508], ["combined", 513], ["ligamentous", 522], ["damage", 534], [".", 540], ["Improved", 542], ["knowledge", 551], ["at", 561], ["an", 564], ["anatomical", 567], [",", 577], ["biomechanical", 579], ["and", 593], ["clinical", 597], ["level", 606], ["has", 612], ["provided", 616], ["the", 625], ["orthopaedist", 629], ["with", 642], ["a", 647], ["more", 649], ["defined", 654], ["treatment", 662], ["algorithm", 672], [".", 681], ["Isolated", 683], [",", 691], ["partial", 693], ["PCL", 701], ["injuries", 705], ["(", 714], ["grades", 715], ["I", 722], ["and", 724], ["II", 728], [")", 730], ["can", 732], ["best", 736], ["be", 741], ["treated", 744], ["nonoperatively", 752], ["while", 767], ["complete", 773], ["injuries", 782], ["(", 791], ["grade", 792], ["III", 798], [")", 801], ["may", 803], ["require", 807], ["operative", 815], ["treatment", 825], ["based", 835], ["on", 841], ["clinical", 844], ["symptoms", 853], [".", 861], ["All", 863], ["combined", 867], ["ligamentous", 876], ["injuries", 888], ["usually", 897], ["respond", 905], ["best", 913], ["with", 918], ["surgical", 923], ["management", 932], [".", 942]]}
{"context": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies. We examined the relationship between alpha-synuclein, ubiquitin, and lipids in Lewy bodies of fixed brain sections or isolated from cortical tissues of dementia with Lewy bodies. Lewy bodies exhibited a range of labeling patterns for alpha-synuclein and ubiquitin, from a homogeneous pattern in which alpha-synuclein and ubiquitin were evenly distributed and overlapped across the inclusion body to a concentric pattern in which alpha-synuclein and ubiquitin were partially segregated, with alpha-synuclein labeling concentrated in the peripheral domain and ubiquitin in the central domain of the Lewy body. Lipids represented a significant component in both homogeneous and concentric Lewy bodies. These results suggest that Lewy bodies are heterogeneous in their subregional composition. The segregation of alpha-synuclein to Lewy body peripheral domain is consistent with the hypothesis that alpha-synuclein is continually deposited onto Lewy bodies.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "84268ced61744024a40b6f8d2316d275", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[63, 65], [28, 30], [154, 156], [168, 170], [95, 97], [105, 107], [0, 2], [75, 77]], "char_spans": [[370, 384], [173, 187], [945, 959], [1031, 1045], [565, 579], [627, 641], [0, 14], [437, 451]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["and", 16], ["ubiquitin", 20], ["are", 30], ["two", 34], ["Lewy", 38], ["body", 43], ["protein", 48], ["components", 56], ["that", 67], ["may", 72], ["play", 76], ["antagonistic", 81], ["roles", 94], ["in", 100], ["the", 103], ["pathogenesis", 107], ["of", 120], ["Lewy", 123], ["bodies", 128], [".", 134], ["We", 136], ["examined", 139], ["the", 148], ["relationship", 152], ["between", 165], ["alpha", 173], ["-", 178], ["synuclein", 179], [",", 188], ["ubiquitin", 190], [",", 199], ["and", 201], ["lipids", 205], ["in", 212], ["Lewy", 215], ["bodies", 220], ["of", 227], ["fixed", 230], ["brain", 236], ["sections", 242], ["or", 251], ["isolated", 254], ["from", 263], ["cortical", 268], ["tissues", 277], ["of", 285], ["dementia", 288], ["with", 297], ["Lewy", 302], ["bodies", 307], [".", 313], ["Lewy", 315], ["bodies", 320], ["exhibited", 327], ["a", 337], ["range", 339], ["of", 345], ["labeling", 348], ["patterns", 357], ["for", 366], ["alpha", 370], ["-", 375], ["synuclein", 376], ["and", 386], ["ubiquitin", 390], [",", 399], ["from", 401], ["a", 406], ["homogeneous", 408], ["pattern", 420], ["in", 428], ["which", 431], ["alpha", 437], ["-", 442], ["synuclein", 443], ["and", 453], ["ubiquitin", 457], ["were", 467], ["evenly", 472], ["distributed", 479], ["and", 491], ["overlapped", 495], ["across", 506], ["the", 513], ["inclusion", 517], ["body", 527], ["to", 532], ["a", 535], ["concentric", 537], ["pattern", 548], ["in", 556], ["which", 559], ["alpha", 565], ["-", 570], ["synuclein", 571], ["and", 581], ["ubiquitin", 585], ["were", 595], ["partially", 600], ["segregated", 610], [",", 620], ["with", 622], ["alpha", 627], ["-", 632], ["synuclein", 633], ["labeling", 643], ["concentrated", 652], ["in", 665], ["the", 668], ["peripheral", 672], ["domain", 683], ["and", 690], ["ubiquitin", 694], ["in", 704], ["the", 707], ["central", 711], ["domain", 719], ["of", 726], ["the", 729], ["Lewy", 733], ["body", 738], [".", 742], ["Lipids", 744], ["represented", 751], ["a", 763], ["significant", 765], ["component", 777], ["in", 787], ["both", 790], ["homogeneous", 795], ["and", 807], ["concentric", 811], ["Lewy", 822], ["bodies", 827], [".", 833], ["These", 835], ["results", 841], ["suggest", 849], ["that", 857], ["Lewy", 862], ["bodies", 867], ["are", 874], ["heterogeneous", 878], ["in", 892], ["their", 895], ["subregional", 901], ["composition", 913], [".", 924], ["The", 926], ["segregation", 930], ["of", 942], ["alpha", 945], ["-", 950], ["synuclein", 951], ["to", 961], ["Lewy", 964], ["body", 969], ["peripheral", 974], ["domain", 985], ["is", 992], ["consistent", 995], ["with", 1006], ["the", 1011], ["hypothesis", 1015], ["that", 1026], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["is", 1047], ["continually", 1050], ["deposited", 1062], ["onto", 1072], ["Lewy", 1077], ["bodies", 1082], [".", 1088]]}
{"context": "Romano-Ward syndrome is a subtype of prolonged QT syndrome with autosomal dominant inheritance. Stress-induced syncope and sudden death are secondary to ventricular tachydysrhythmias. A case report of Romano-Ward syndrome complicating pregnancy is presented. Successful therapy with propranolol for life-threatening dysrhythmias was achieved. An excellent neonatal outcome occurred.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "34757c8e5ca444a192856060543f7791", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[12, 13]], "char_spans": [[64, 81]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["a", 24], ["subtype", 26], ["of", 34], ["prolonged", 37], ["QT", 47], ["syndrome", 50], ["with", 59], ["autosomal", 64], ["dominant", 74], ["inheritance", 83], [".", 94], ["Stress", 96], ["-", 102], ["induced", 103], ["syncope", 111], ["and", 119], ["sudden", 123], ["death", 130], ["are", 136], ["secondary", 140], ["to", 150], ["ventricular", 153], ["tachydysrhythmias", 165], [".", 182], ["A", 184], ["case", 186], ["report", 191], ["of", 198], ["Romano", 201], ["-", 207], ["Ward", 208], ["syndrome", 213], ["complicating", 222], ["pregnancy", 235], ["is", 245], ["presented", 248], [".", 257], ["Successful", 259], ["therapy", 270], ["with", 278], ["propranolol", 283], ["for", 295], ["life", 299], ["-", 303], ["threatening", 304], ["dysrhythmias", 316], ["was", 329], ["achieved", 333], [".", 341], ["An", 343], ["excellent", 346], ["neonatal", 356], ["outcome", 365], ["occurred", 373], [".", 381]]}
{"context": "Treatment of CLL patients with conventional cytotoxic agents is often combined with significant toxicity that prevents broad application especially in elderly patients. In addition, relapse frequently occurs after application of conventional chemotherapy in CLL. Recently several new chemo-free treatment options have been introduced within clinical trials. Among them are monoclonal antibodies, most of them targeting the CD20 molecule: besides the licensed drugs rituximab and ofatumumab obinutuzumab, although in combination with chemotherapy, has recently shown high clinical efficacy in front-line treatment of elderly patients with CLL. Lenalidomide as monotherapy has demonstrated clinical efficacy in patients with relapsed disease and first data within clinical trials have been generated in the front-line setting. A promising class of novel agents has been designed to block aberrant signaling from the B-cell receptor. Ibrutinib acts by inhibiting the Bruton's tyrosine kinase (BTK) while idelalisib represents a first-in-class specific inhibitor of the phosphoinositol-3 kinase (PI3K) delta isoform. Another class of drugs with potential impact for chemo-free treatment strategies in CLL are the BH3-mimetic inhibitors of the Bcl-2 family of pro-survival proteins. Other interesting candidate drugs that are currently explored for CLL patients include small modular immunopharmaceutical (SMIP) proteins (e. g. TRU-016), CDK inhibitors (e. g. dinaciclib), HDAC inhibitors and others. Given all these novel agents and targets, chemo-free or at least chemo-reduced concepts may become reality in the near future for our patients suffering from CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "f2a99dbd8b2344b8b93f9e08e0029f24", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[146, 146]], "char_spans": [[931, 939]]}]}], "context_tokens": [["Treatment", 0], ["of", 10], ["CLL", 13], ["patients", 17], ["with", 26], ["conventional", 31], ["cytotoxic", 44], ["agents", 54], ["is", 61], ["often", 64], ["combined", 70], ["with", 79], ["significant", 84], ["toxicity", 96], ["that", 105], ["prevents", 110], ["broad", 119], ["application", 125], ["especially", 137], ["in", 148], ["elderly", 151], ["patients", 159], [".", 167], ["In", 169], ["addition", 172], [",", 180], ["relapse", 182], ["frequently", 190], ["occurs", 201], ["after", 208], ["application", 214], ["of", 226], ["conventional", 229], ["chemotherapy", 242], ["in", 255], ["CLL", 258], [".", 261], ["Recently", 263], ["several", 272], ["new", 280], ["chemo", 284], ["-", 289], ["free", 290], ["treatment", 295], ["options", 305], ["have", 313], ["been", 318], ["introduced", 323], ["within", 334], ["clinical", 341], ["trials", 350], [".", 356], ["Among", 358], ["them", 364], ["are", 369], ["monoclonal", 373], ["antibodies", 384], [",", 394], ["most", 396], ["of", 401], ["them", 404], ["targeting", 409], ["the", 419], ["CD20", 423], ["molecule", 428], [":", 436], ["besides", 438], ["the", 446], ["licensed", 450], ["drugs", 459], ["rituximab", 465], ["and", 475], ["ofatumumab", 479], ["obinutuzumab", 490], [",", 502], ["although", 504], ["in", 513], ["combination", 516], ["with", 528], ["chemotherapy", 533], [",", 545], ["has", 547], ["recently", 551], ["shown", 560], ["high", 566], ["clinical", 571], ["efficacy", 580], ["in", 589], ["front", 592], ["-", 597], ["line", 598], ["treatment", 603], ["of", 613], ["elderly", 616], ["patients", 624], ["with", 633], ["CLL", 638], [".", 641], ["Lenalidomide", 643], ["as", 656], ["monotherapy", 659], ["has", 671], ["demonstrated", 675], ["clinical", 688], ["efficacy", 697], ["in", 706], ["patients", 709], ["with", 718], ["relapsed", 723], ["disease", 732], ["and", 740], ["first", 744], ["data", 750], ["within", 755], ["clinical", 762], ["trials", 771], ["have", 778], ["been", 783], ["generated", 788], ["in", 798], ["the", 801], ["front", 805], ["-", 810], ["line", 811], ["setting", 816], [".", 823], ["A", 825], ["promising", 827], ["class", 837], ["of", 843], ["novel", 846], ["agents", 852], ["has", 859], ["been", 863], ["designed", 868], ["to", 877], ["block", 880], ["aberrant", 886], ["signaling", 895], ["from", 905], ["the", 910], ["B", 914], ["-", 915], ["cell", 916], ["receptor", 921], [".", 929], ["Ibrutinib", 931], ["acts", 941], ["by", 946], ["inhibiting", 949], ["the", 960], ["Bruton", 964], ["'s", 970], ["tyrosine", 973], ["kinase", 982], ["(", 989], ["BTK", 990], [")", 993], ["while", 995], ["idelalisib", 1001], ["represents", 1012], ["a", 1023], ["first", 1025], ["-", 1030], ["in", 1031], ["-", 1033], ["class", 1034], ["specific", 1040], ["inhibitor", 1049], ["of", 1059], ["the", 1062], ["phosphoinositol-3", 1066], ["kinase", 1084], ["(", 1091], ["PI3", 1092], ["K", 1095], [")", 1096], ["delta", 1098], ["isoform", 1104], [".", 1111], ["Another", 1113], ["class", 1121], ["of", 1127], ["drugs", 1130], ["with", 1136], ["potential", 1141], ["impact", 1151], ["for", 1158], ["chemo", 1162], ["-", 1167], ["free", 1168], ["treatment", 1173], ["strategies", 1183], ["in", 1194], ["CLL", 1197], ["are", 1201], ["the", 1205], ["BH3-mimetic", 1209], ["inhibitors", 1221], ["of", 1232], ["the", 1235], ["Bcl-2", 1239], ["family", 1245], ["of", 1252], ["pro", 1255], ["-", 1258], ["survival", 1259], ["proteins", 1268], [".", 1276], ["Other", 1278], ["interesting", 1284], ["candidate", 1296], ["drugs", 1306], ["that", 1312], ["are", 1317], ["currently", 1321], ["explored", 1331], ["for", 1340], ["CLL", 1344], ["patients", 1348], ["include", 1357], ["small", 1365], ["modular", 1371], ["immunopharmaceutical", 1379], ["(", 1400], ["SMIP", 1401], [")", 1405], ["proteins", 1407], ["(", 1416], ["e.", 1417], ["g.", 1420], ["TRU-016", 1423], [")", 1430], [",", 1431], ["CDK", 1433], ["inhibitors", 1437], ["(", 1448], ["e.", 1449], ["g.", 1452], ["dinaciclib", 1455], [")", 1465], [",", 1466], ["HDAC", 1468], ["inhibitors", 1473], ["and", 1484], ["others", 1488], [".", 1494], ["Given", 1496], ["all", 1502], ["these", 1506], ["novel", 1512], ["agents", 1518], ["and", 1525], ["targets", 1529], [",", 1536], ["chemo", 1538], ["-", 1543], ["free", 1544], ["or", 1549], ["at", 1552], ["least", 1555], ["chemo", 1561], ["-", 1566], ["reduced", 1567], ["concepts", 1575], ["may", 1584], ["become", 1588], ["reality", 1595], ["in", 1603], ["the", 1606], ["near", 1610], ["future", 1615], ["for", 1622], ["our", 1626], ["patients", 1630], ["suffering", 1639], ["from", 1649], ["CLL", 1654], [".", 1657]]}
{"context": "In the present study, we tested the hypothesis that having migraine in middle age is related to late-life parkinsonism and a related disorder, restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED). The AGES-Reykjavik cohort (born 1907-1935) has been followed since 1967. Headaches were classified based on symptoms assessed in middle age. From 2002 to 2006, 5,764 participants were reexamined to assess symptoms of parkinsonism, diagnosis of Parkinson disease (PD), family history of PD, and RLS/WED. Subjects with midlife migraine, particularly migraine with aura (MA), were in later life more likely than others to report parkinsonian symptoms (odds ratio [OR]MA = 3.6 [95% CI 2.7-4.8]) and diagnosed PD (ORMA = 2.5 [95% CI 1.2-5.2]). Women with MA were more likely than others to have a parent (ORMA = 2.26 [95% CI 1.3-4.0]) or sibling (ORMA = 1.78 [95% CI 1.1-2.9]) with PD. Late-life RLS/WED was increased for headache generally. Associations were independent of cardiovascular disease and MRI-evident presumed ischemic lesions. These findings suggest there may be a common vulnerability to, or consequences of, migraine and multiple indicators of parkinsonism. Additional genetic and longitudinal observational studies are needed to identify candidate pathways that may account for the comorbid constellation of symptoms.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "bfb32502385540e989c8cc4fc56e54bd", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[27, 29]], "char_spans": [[143, 164]]}]}], "context_tokens": [["In", 0], ["the", 3], ["present", 7], ["study", 15], [",", 20], ["we", 22], ["tested", 25], ["the", 32], ["hypothesis", 36], ["that", 47], ["having", 52], ["migraine", 59], ["in", 68], ["middle", 71], ["age", 78], ["is", 82], ["related", 85], ["to", 93], ["late", 96], ["-", 100], ["life", 101], ["parkinsonism", 106], ["and", 119], ["a", 123], ["related", 125], ["disorder", 133], [",", 141], ["restless", 143], ["legs", 152], ["syndrome", 157], ["(", 166], ["RLS", 167], [")", 170], [",", 171], ["also", 173], ["known", 178], ["as", 184], ["Willis", 187], ["-", 193], ["Ekbom", 194], ["disease", 200], ["(", 208], ["WED", 209], [")", 212], [".", 213], ["The", 215], ["AGES", 219], ["-", 223], ["Reykjavik", 224], ["cohort", 234], ["(", 241], ["born", 242], ["1907", 247], ["-", 251], ["1935", 252], [")", 256], ["has", 258], ["been", 262], ["followed", 267], ["since", 276], ["1967", 282], [".", 286], ["Headaches", 288], ["were", 298], ["classified", 303], ["based", 314], ["on", 320], ["symptoms", 323], ["assessed", 332], ["in", 341], ["middle", 344], ["age", 351], [".", 354], ["From", 356], ["2002", 361], ["to", 366], ["2006", 369], [",", 373], ["5,764", 375], ["participants", 381], ["were", 394], ["reexamined", 399], ["to", 410], ["assess", 413], ["symptoms", 420], ["of", 429], ["parkinsonism", 432], [",", 444], ["diagnosis", 446], ["of", 456], ["Parkinson", 459], ["disease", 469], ["(", 477], ["PD", 478], [")", 480], [",", 481], ["family", 483], ["history", 490], ["of", 498], ["PD", 501], [",", 503], ["and", 505], ["RLS", 509], ["/", 512], ["WED", 513], [".", 516], ["Subjects", 518], ["with", 527], ["midlife", 532], ["migraine", 540], [",", 548], ["particularly", 550], ["migraine", 563], ["with", 572], ["aura", 577], ["(", 582], ["MA", 583], [")", 585], [",", 586], ["were", 588], ["in", 593], ["later", 596], ["life", 602], ["more", 607], ["likely", 612], ["than", 619], ["others", 624], ["to", 631], ["report", 634], ["parkinsonian", 641], ["symptoms", 654], ["(", 663], ["odds", 664], ["ratio", 669], ["[", 675], ["OR]MA", 676], ["=", 682], ["3.6", 684], ["[", 688], ["95", 689], ["%", 691], ["CI", 693], ["2.7", 696], ["-", 699], ["4.8", 700], ["]", 703], [")", 704], ["and", 706], ["diagnosed", 710], ["PD", 720], ["(", 723], ["ORMA", 724], ["=", 729], ["2.5", 731], ["[", 735], ["95", 736], ["%", 738], ["CI", 740], ["1.2", 743], ["-", 746], ["5.2", 747], ["]", 750], [")", 751], [".", 752], ["Women", 754], ["with", 760], ["MA", 765], ["were", 768], ["more", 773], ["likely", 778], ["than", 785], ["others", 790], ["to", 797], ["have", 800], ["a", 805], ["parent", 807], ["(", 814], ["ORMA", 815], ["=", 820], ["2.26", 822], ["[", 827], ["95", 828], ["%", 830], ["CI", 832], ["1.3", 835], ["-", 838], ["4.0", 839], ["]", 842], [")", 843], ["or", 845], ["sibling", 848], ["(", 856], ["ORMA", 857], ["=", 862], ["1.78", 864], ["[", 869], ["95", 870], ["%", 872], ["CI", 874], ["1.1", 877], ["-", 880], ["2.9", 881], ["]", 884], [")", 885], ["with", 887], ["PD", 892], [".", 894], ["Late", 896], ["-", 900], ["life", 901], ["RLS", 906], ["/", 909], ["WED", 910], ["was", 914], ["increased", 918], ["for", 928], ["headache", 932], ["generally", 941], [".", 950], ["Associations", 952], ["were", 965], ["independent", 970], ["of", 982], ["cardiovascular", 985], ["disease", 1000], ["and", 1008], ["MRI", 1012], ["-", 1015], ["evident", 1016], ["presumed", 1024], ["ischemic", 1033], ["lesions", 1042], [".", 1049], ["These", 1051], ["findings", 1057], ["suggest", 1066], ["there", 1074], ["may", 1080], ["be", 1084], ["a", 1087], ["common", 1089], ["vulnerability", 1096], ["to", 1110], [",", 1112], ["or", 1114], ["consequences", 1117], ["of", 1130], [",", 1132], ["migraine", 1134], ["and", 1143], ["multiple", 1147], ["indicators", 1156], ["of", 1167], ["parkinsonism", 1170], [".", 1182], ["Additional", 1184], ["genetic", 1195], ["and", 1203], ["longitudinal", 1207], ["observational", 1220], ["studies", 1234], ["are", 1242], ["needed", 1246], ["to", 1253], ["identify", 1256], ["candidate", 1265], ["pathways", 1275], ["that", 1284], ["may", 1289], ["account", 1293], ["for", 1301], ["the", 1305], ["comorbid", 1309], ["constellation", 1318], ["of", 1332], ["symptoms", 1335], [".", 1343]]}
{"context": "A family with the Romano-Ward syndrome is presented. This family showed typical features of this syndrome with QT prolongation, torsades de pointes ventricular tachycardia, sudden death and an autosomal dominant inheritance pattern. The index case presented with an exacerbation of torsades de pointes ventricular tachycardia from diuretic induced hypokalaemia, and responded to diuretic withdrawal and beta blocker therapy.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "f3e0556321574bc9984f02992df32320", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[33, 34]], "char_spans": [[193, 210]]}]}], "context_tokens": [["A", 0], ["family", 2], ["with", 9], ["the", 14], ["Romano", 18], ["-", 24], ["Ward", 25], ["syndrome", 30], ["is", 39], ["presented", 42], [".", 51], ["This", 53], ["family", 58], ["showed", 65], ["typical", 72], ["features", 80], ["of", 89], ["this", 92], ["syndrome", 97], ["with", 106], ["QT", 111], ["prolongation", 114], [",", 126], ["torsades", 128], ["de", 137], ["pointes", 140], ["ventricular", 148], ["tachycardia", 160], [",", 171], ["sudden", 173], ["death", 180], ["and", 186], ["an", 190], ["autosomal", 193], ["dominant", 203], ["inheritance", 212], ["pattern", 224], [".", 231], ["The", 233], ["index", 237], ["case", 243], ["presented", 248], ["with", 258], ["an", 263], ["exacerbation", 266], ["of", 279], ["torsades", 282], ["de", 291], ["pointes", 294], ["ventricular", 302], ["tachycardia", 314], ["from", 326], ["diuretic", 331], ["induced", 340], ["hypokalaemia", 348], [",", 360], ["and", 362], ["responded", 366], ["to", 376], ["diuretic", 379], ["withdrawal", 388], ["and", 399], ["beta", 403], ["blocker", 408], ["therapy", 416], [".", 423]]}
{"context": "The Ehlers-Danlos syndrome is a heritable connective-tissue disorder caused by defects in fibrillar-collagen metabolism. Mutations in the type V collagen genes account for up to 50 percent of cases of classic Ehlers-Danlos syndrome, but many other cases are unexplained. We investigated whether the deficiency of the tenascins, extracellular-matrix proteins that are highly expressed in connective tissues, was associated with the Ehlers-Danlos syndrome. We screened serum samples from 151 patients with the classic, hypermobility, or vascular types of the Ehlers-Danlos syndrome; 75 patients with psoriasis; 93 patients with rheumatoid arthritis; and 21 healthy persons for the presence of tenascin-X and tenascin-C by enzyme-linked immunosorbent assay. We examined the expression of tenascins and type V collagen in skin by immunohistochemical methods and sequenced the tenascin-X gene. Tenascin-X was present in serum from all normal subjects, all patients with psoriasis, all patients with rheumatoid arthritis, and 146 of 151 patients with the Ehlers-Danlos syndrome. Tenascin-X was absent from the serum of the 5 remaining patients with Ehlers-Danlos syndrome, who were unrelated. Tenascin-X deficiency was confirmed in these patients by analysis of skin fibroblasts and by immunostaining of skin. The expression of tenascin-C and type V collagen was normal in these patients. All five of these patients had hypermobile joints, hyperelastic skin, and easy bruising, without atrophic scarring. Tenascin-X mutations were identified in all tenascin-X-deficient patients; one patient had a homozygous tenascin-X gene deletion, one was heterozygous for the deletion, and three others had homozygous truncating point mutations, confirming a causative role for tenascin-X and a recessive pattern of inheritance. Tenascin-X deficiency causes a clinically distinct, recessive form of the Ehlers-Danlos syndrome. This finding indicates that factors other than the collagens or collagen-processing enzymes can cause the syndrome and suggests a central role for tenascin-X in maintaining the integrity of collagenous matrix.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective-tissue", "connective tissue"], "qid": "84ecb54e06cc44c78c9482f8b29d119c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 10]], "char_spans": [[42, 58]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["heritable", 32], ["connective", 42], ["-", 52], ["tissue", 53], ["disorder", 60], ["caused", 69], ["by", 76], ["defects", 79], ["in", 87], ["fibrillar", 90], ["-", 99], ["collagen", 100], ["metabolism", 109], [".", 119], ["Mutations", 121], ["in", 131], ["the", 134], ["type", 138], ["V", 143], ["collagen", 145], ["genes", 154], ["account", 160], ["for", 168], ["up", 172], ["to", 175], ["50", 178], ["percent", 181], ["of", 189], ["cases", 192], ["of", 198], ["classic", 201], ["Ehlers", 209], ["-", 215], ["Danlos", 216], ["syndrome", 223], [",", 231], ["but", 233], ["many", 237], ["other", 242], ["cases", 248], ["are", 254], ["unexplained", 258], [".", 269], ["We", 271], ["investigated", 274], ["whether", 287], ["the", 295], ["deficiency", 299], ["of", 310], ["the", 313], ["tenascins", 317], [",", 326], ["extracellular", 328], ["-", 341], ["matrix", 342], ["proteins", 349], ["that", 358], ["are", 363], ["highly", 367], ["expressed", 374], ["in", 384], ["connective", 387], ["tissues", 398], [",", 405], ["was", 407], ["associated", 411], ["with", 422], ["the", 427], ["Ehlers", 431], ["-", 437], ["Danlos", 438], ["syndrome", 445], [".", 453], ["We", 455], ["screened", 458], ["serum", 467], ["samples", 473], ["from", 481], ["151", 486], ["patients", 490], ["with", 499], ["the", 504], ["classic", 508], [",", 515], ["hypermobility", 517], [",", 530], ["or", 532], ["vascular", 535], ["types", 544], ["of", 550], ["the", 553], ["Ehlers", 557], ["-", 563], ["Danlos", 564], ["syndrome", 571], [";", 579], ["75", 581], ["patients", 584], ["with", 593], ["psoriasis", 598], [";", 607], ["93", 609], ["patients", 612], ["with", 621], ["rheumatoid", 626], ["arthritis", 637], [";", 646], ["and", 648], ["21", 652], ["healthy", 655], ["persons", 663], ["for", 671], ["the", 675], ["presence", 679], ["of", 688], ["tenascin", 691], ["-", 699], ["X", 700], ["and", 702], ["tenascin", 706], ["-", 714], ["C", 715], ["by", 717], ["enzyme", 720], ["-", 726], ["linked", 727], ["immunosorbent", 734], ["assay", 748], [".", 753], ["We", 755], ["examined", 758], ["the", 767], ["expression", 771], ["of", 782], ["tenascins", 785], ["and", 795], ["type", 799], ["V", 804], ["collagen", 806], ["in", 815], ["skin", 818], ["by", 823], ["immunohistochemical", 826], ["methods", 846], ["and", 854], ["sequenced", 858], ["the", 868], ["tenascin", 872], ["-", 880], ["X", 881], ["gene", 883], [".", 887], ["Tenascin", 889], ["-", 897], ["X", 898], ["was", 900], ["present", 904], ["in", 912], ["serum", 915], ["from", 921], ["all", 926], ["normal", 930], ["subjects", 937], [",", 945], ["all", 947], ["patients", 951], ["with", 960], ["psoriasis", 965], [",", 974], ["all", 976], ["patients", 980], ["with", 989], ["rheumatoid", 994], ["arthritis", 1005], [",", 1014], ["and", 1016], ["146", 1020], ["of", 1024], ["151", 1027], ["patients", 1031], ["with", 1040], ["the", 1045], ["Ehlers", 1049], ["-", 1055], ["Danlos", 1056], ["syndrome", 1063], [".", 1071], ["Tenascin", 1073], ["-", 1081], ["X", 1082], ["was", 1084], ["absent", 1088], ["from", 1095], ["the", 1100], ["serum", 1104], ["of", 1110], ["the", 1113], ["5", 1117], ["remaining", 1119], ["patients", 1129], ["with", 1138], ["Ehlers", 1143], ["-", 1149], ["Danlos", 1150], ["syndrome", 1157], [",", 1165], ["who", 1167], ["were", 1171], ["unrelated", 1176], [".", 1185], ["Tenascin", 1187], ["-", 1195], ["X", 1196], ["deficiency", 1198], ["was", 1209], ["confirmed", 1213], ["in", 1223], ["these", 1226], ["patients", 1232], ["by", 1241], ["analysis", 1244], ["of", 1253], ["skin", 1256], ["fibroblasts", 1261], ["and", 1273], ["by", 1277], ["immunostaining", 1280], ["of", 1295], ["skin", 1298], [".", 1302], ["The", 1304], ["expression", 1308], ["of", 1319], ["tenascin", 1322], ["-", 1330], ["C", 1331], ["and", 1333], ["type", 1337], ["V", 1342], ["collagen", 1344], ["was", 1353], ["normal", 1357], ["in", 1364], ["these", 1367], ["patients", 1373], [".", 1381], ["All", 1383], ["five", 1387], ["of", 1392], ["these", 1395], ["patients", 1401], ["had", 1410], ["hypermobile", 1414], ["joints", 1426], [",", 1432], ["hyperelastic", 1434], ["skin", 1447], [",", 1451], ["and", 1453], ["easy", 1457], ["bruising", 1462], [",", 1470], ["without", 1472], ["atrophic", 1480], ["scarring", 1489], [".", 1497], ["Tenascin", 1499], ["-", 1507], ["X", 1508], ["mutations", 1510], ["were", 1520], ["identified", 1525], ["in", 1536], ["all", 1539], ["tenascin", 1543], ["-", 1551], ["X", 1552], ["-", 1553], ["deficient", 1554], ["patients", 1564], [";", 1572], ["one", 1574], ["patient", 1578], ["had", 1586], ["a", 1590], ["homozygous", 1592], ["tenascin", 1603], ["-", 1611], ["X", 1612], ["gene", 1614], ["deletion", 1619], [",", 1627], ["one", 1629], ["was", 1633], ["heterozygous", 1637], ["for", 1650], ["the", 1654], ["deletion", 1658], [",", 1666], ["and", 1668], ["three", 1672], ["others", 1678], ["had", 1685], ["homozygous", 1689], ["truncating", 1700], ["point", 1711], ["mutations", 1717], [",", 1726], ["confirming", 1728], ["a", 1739], ["causative", 1741], ["role", 1751], ["for", 1756], ["tenascin", 1760], ["-", 1768], ["X", 1769], ["and", 1771], ["a", 1775], ["recessive", 1777], ["pattern", 1787], ["of", 1795], ["inheritance", 1798], [".", 1809], ["Tenascin", 1811], ["-", 1819], ["X", 1820], ["deficiency", 1822], ["causes", 1833], ["a", 1840], ["clinically", 1842], ["distinct", 1853], [",", 1861], ["recessive", 1863], ["form", 1873], ["of", 1878], ["the", 1881], ["Ehlers", 1885], ["-", 1891], ["Danlos", 1892], ["syndrome", 1899], [".", 1907], ["This", 1909], ["finding", 1914], ["indicates", 1922], ["that", 1932], ["factors", 1937], ["other", 1945], ["than", 1951], ["the", 1956], ["collagens", 1960], ["or", 1970], ["collagen", 1973], ["-", 1981], ["processing", 1982], ["enzymes", 1993], ["can", 2001], ["cause", 2005], ["the", 2011], ["syndrome", 2015], ["and", 2024], ["suggests", 2028], ["a", 2037], ["central", 2039], ["role", 2047], ["for", 2052], ["tenascin", 2056], ["-", 2064], ["X", 2065], ["in", 2067], ["maintaining", 2070], ["the", 2082], ["integrity", 2086], ["of", 2096], ["collagenous", 2099], ["matrix", 2111], [".", 2117]]}
{"context": "Mowat-Wilson syndrome (MWS) is a relatively newly described multiple congenital anomaly/mental retardation syndrome. Haploinsufficiency of a gene termed ZFHX1B (also known as SIP1) on chromosome 2 is responsible for this condition, and clinical genetic testing for MWS recently became available. The majority of reports in the literature originate from Northern Europe and Australia. Here we report our clinical experience with 12 patients diagnosed with MWS within a 2-year period of time in the United States, with particular emphasis on clinical characteristics and management strategies. Individuals with this condition have characteristic facial features, including microcephaly, hypertelorism, medially flared and broad eyebrows, prominent columella, pointed chin, and uplifted earlobes, which typically prompt the clinician to consider the diagnosis. Medical issues in our cohort of patients included seizures (75%) with no predeliction for any particular seizure type; agenesis of the corpus callosum (60% of our patients studied); congenital heart defects (75%), particularly involving the pulmonary arteries and/or valves; hypospadias (55% of males); severely impaired or absent speech (100% of individuals over 1 year of age) with relatively spared receptive language; and Hirschsprung disease (50%) or chronic constipation (25%). The incidence of MWS is unknown, but based on the number of patients identified in a short period of time within the US, it is likely greatly under recognized. MWS should be considered in any individual with severely impaired or absent speech, especially in the presence of seizures and anomalies involving the pulmonary arteries (particularly pulmonary artery sling) or pulmonary valves.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ba508f5b8dfb4fbc83ecf9831706b686", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[25, 25]], "char_spans": [[153, 158]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["newly", 44], ["described", 50], ["multiple", 60], ["congenital", 69], ["anomaly", 80], ["/", 87], ["mental", 88], ["retardation", 95], ["syndrome", 107], [".", 115], ["Haploinsufficiency", 117], ["of", 136], ["a", 139], ["gene", 141], ["termed", 146], ["ZFHX1B", 153], ["(", 160], ["also", 161], ["known", 166], ["as", 172], ["SIP1", 175], [")", 179], ["on", 181], ["chromosome", 184], ["2", 195], ["is", 197], ["responsible", 200], ["for", 212], ["this", 216], ["condition", 221], [",", 230], ["and", 232], ["clinical", 236], ["genetic", 245], ["testing", 253], ["for", 261], ["MWS", 265], ["recently", 269], ["became", 278], ["available", 285], [".", 294], ["The", 296], ["majority", 300], ["of", 309], ["reports", 312], ["in", 320], ["the", 323], ["literature", 327], ["originate", 338], ["from", 348], ["Northern", 353], ["Europe", 362], ["and", 369], ["Australia", 373], [".", 382], ["Here", 384], ["we", 389], ["report", 392], ["our", 399], ["clinical", 403], ["experience", 412], ["with", 423], ["12", 428], ["patients", 431], ["diagnosed", 440], ["with", 450], ["MWS", 455], ["within", 459], ["a", 466], ["2-year", 468], ["period", 475], ["of", 482], ["time", 485], ["in", 490], ["the", 493], ["United", 497], ["States", 504], [",", 510], ["with", 512], ["particular", 517], ["emphasis", 528], ["on", 537], ["clinical", 540], ["characteristics", 549], ["and", 565], ["management", 569], ["strategies", 580], [".", 590], ["Individuals", 592], ["with", 604], ["this", 609], ["condition", 614], ["have", 624], ["characteristic", 629], ["facial", 644], ["features", 651], [",", 659], ["including", 661], ["microcephaly", 671], [",", 683], ["hypertelorism", 685], [",", 698], ["medially", 700], ["flared", 709], ["and", 716], ["broad", 720], ["eyebrows", 726], [",", 734], ["prominent", 736], ["columella", 746], [",", 755], ["pointed", 757], ["chin", 765], [",", 769], ["and", 771], ["uplifted", 775], ["earlobes", 784], [",", 792], ["which", 794], ["typically", 800], ["prompt", 810], ["the", 817], ["clinician", 821], ["to", 831], ["consider", 834], ["the", 843], ["diagnosis", 847], [".", 856], ["Medical", 858], ["issues", 866], ["in", 873], ["our", 876], ["cohort", 880], ["of", 887], ["patients", 890], ["included", 899], ["seizures", 908], ["(", 917], ["75", 918], ["%", 920], [")", 921], ["with", 923], ["no", 928], ["predeliction", 931], ["for", 944], ["any", 948], ["particular", 952], ["seizure", 963], ["type", 971], [";", 975], ["agenesis", 977], ["of", 986], ["the", 989], ["corpus", 993], ["callosum", 1000], ["(", 1009], ["60", 1010], ["%", 1012], ["of", 1014], ["our", 1017], ["patients", 1021], ["studied", 1030], [")", 1037], [";", 1038], ["congenital", 1040], ["heart", 1051], ["defects", 1057], ["(", 1065], ["75", 1066], ["%", 1068], [")", 1069], [",", 1070], ["particularly", 1072], ["involving", 1085], ["the", 1095], ["pulmonary", 1099], ["arteries", 1109], ["and/or", 1118], ["valves", 1125], [";", 1131], ["hypospadias", 1133], ["(", 1145], ["55", 1146], ["%", 1148], ["of", 1150], ["males", 1153], [")", 1158], [";", 1159], ["severely", 1161], ["impaired", 1170], ["or", 1179], ["absent", 1182], ["speech", 1189], ["(", 1196], ["100", 1197], ["%", 1200], ["of", 1202], ["individuals", 1205], ["over", 1217], ["1", 1222], ["year", 1224], ["of", 1229], ["age", 1232], [")", 1235], ["with", 1237], ["relatively", 1242], ["spared", 1253], ["receptive", 1260], ["language", 1270], [";", 1278], ["and", 1280], ["Hirschsprung", 1284], ["disease", 1297], ["(", 1305], ["50", 1306], ["%", 1308], [")", 1309], ["or", 1311], ["chronic", 1314], ["constipation", 1322], ["(", 1335], ["25", 1336], ["%", 1338], [")", 1339], [".", 1340], ["The", 1342], ["incidence", 1346], ["of", 1356], ["MWS", 1359], ["is", 1363], ["unknown", 1366], [",", 1373], ["but", 1375], ["based", 1379], ["on", 1385], ["the", 1388], ["number", 1392], ["of", 1399], ["patients", 1402], ["identified", 1411], ["in", 1422], ["a", 1425], ["short", 1427], ["period", 1433], ["of", 1440], ["time", 1443], ["within", 1448], ["the", 1455], ["US", 1459], [",", 1461], ["it", 1463], ["is", 1466], ["likely", 1469], ["greatly", 1476], ["under", 1484], ["recognized", 1490], [".", 1500], ["MWS", 1502], ["should", 1506], ["be", 1513], ["considered", 1516], ["in", 1527], ["any", 1530], ["individual", 1534], ["with", 1545], ["severely", 1550], ["impaired", 1559], ["or", 1568], ["absent", 1571], ["speech", 1578], [",", 1584], ["especially", 1586], ["in", 1597], ["the", 1600], ["presence", 1604], ["of", 1613], ["seizures", 1616], ["and", 1625], ["anomalies", 1629], ["involving", 1639], ["the", 1649], ["pulmonary", 1653], ["arteries", 1663], ["(", 1672], ["particularly", 1673], ["pulmonary", 1686], ["artery", 1696], ["sling", 1703], [")", 1708], ["or", 1710], ["pulmonary", 1713], ["valves", 1723], [".", 1729]]}
{"context": "The present case-control study was conducted to investigate the relationship between smoking and rheumatoid arthritis, and to investigate formally the interaction between sex, smoking, and risk for developing rheumatoid arthritis. The study was performed in the Central District of Finland. Cases were patients with rheumatoid arthritis and the control group was a random sample of the general population. Logistic regression models were used to evaluate the effect of smoking on risk for rheumatoid arthritis, after adjusting for the effects of age, education, body mass index, and indices of general health and pain. Overall, 1095 patients with rheumatoid arthritis and 1530 control individuals were included. Patients were older, less well educated, more disabled, and had poorer levels of general health as compared with control individuals (all P < 0.01). Preliminary analyses revealed the presence of substantial statistical interaction between smoking and sex (P < 0.001). In separate multivariable analyses, past history of smoking was associated with increased risk for rheumatoid arthritis overall in men (odds ratio 2.0, 95% confidence interval 1.2-3.2) but not in women. Among men, this effect was seen only for rheumatoid factor-positive rheumatoid arthritis. There were significant interactions between smoking and age among women but not among men. We conclude that sex is a biologic effect modifier in the association between smoking and rheumatoid arthritis. The role of menopause in the etiology of rheumatoid arthritis merits further research.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "69fcba3609b5468a8fd5f00111a3756d", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[204, 204], [231, 231]], "char_spans": [[1176, 1180], [1339, 1343]]}]}], "context_tokens": [["The", 0], ["present", 4], ["case", 12], ["-", 16], ["control", 17], ["study", 25], ["was", 31], ["conducted", 35], ["to", 45], ["investigate", 48], ["the", 60], ["relationship", 64], ["between", 77], ["smoking", 85], ["and", 93], ["rheumatoid", 97], ["arthritis", 108], [",", 117], ["and", 119], ["to", 123], ["investigate", 126], ["formally", 138], ["the", 147], ["interaction", 151], ["between", 163], ["sex", 171], [",", 174], ["smoking", 176], [",", 183], ["and", 185], ["risk", 189], ["for", 194], ["developing", 198], ["rheumatoid", 209], ["arthritis", 220], [".", 229], ["The", 231], ["study", 235], ["was", 241], ["performed", 245], ["in", 255], ["the", 258], ["Central", 262], ["District", 270], ["of", 279], ["Finland", 282], [".", 289], ["Cases", 291], ["were", 297], ["patients", 302], ["with", 311], ["rheumatoid", 316], ["arthritis", 327], ["and", 337], ["the", 341], ["control", 345], ["group", 353], ["was", 359], ["a", 363], ["random", 365], ["sample", 372], ["of", 379], ["the", 382], ["general", 386], ["population", 394], [".", 404], ["Logistic", 406], ["regression", 415], ["models", 426], ["were", 433], ["used", 438], ["to", 443], ["evaluate", 446], ["the", 455], ["effect", 459], ["of", 466], ["smoking", 469], ["on", 477], ["risk", 480], ["for", 485], ["rheumatoid", 489], ["arthritis", 500], [",", 509], ["after", 511], ["adjusting", 517], ["for", 527], ["the", 531], ["effects", 535], ["of", 543], ["age", 546], [",", 549], ["education", 551], [",", 560], ["body", 562], ["mass", 567], ["index", 572], [",", 577], ["and", 579], ["indices", 583], ["of", 591], ["general", 594], ["health", 602], ["and", 609], ["pain", 613], [".", 617], ["Overall", 619], [",", 626], ["1095", 628], ["patients", 633], ["with", 642], ["rheumatoid", 647], ["arthritis", 658], ["and", 668], ["1530", 672], ["control", 677], ["individuals", 685], ["were", 697], ["included", 702], [".", 710], ["Patients", 712], ["were", 721], ["older", 726], [",", 731], ["less", 733], ["well", 738], ["educated", 743], [",", 751], ["more", 753], ["disabled", 758], [",", 766], ["and", 768], ["had", 772], ["poorer", 776], ["levels", 783], ["of", 790], ["general", 793], ["health", 801], ["as", 808], ["compared", 811], ["with", 820], ["control", 825], ["individuals", 833], ["(", 845], ["all", 846], ["P", 850], ["<", 852], ["0.01", 854], [")", 858], [".", 859], ["Preliminary", 861], ["analyses", 873], ["revealed", 882], ["the", 891], ["presence", 895], ["of", 904], ["substantial", 907], ["statistical", 919], ["interaction", 931], ["between", 943], ["smoking", 951], ["and", 959], ["sex", 963], ["(", 967], ["P", 968], ["<", 970], ["0.001", 972], [")", 977], [".", 978], ["In", 980], ["separate", 983], ["multivariable", 992], ["analyses", 1006], [",", 1014], ["past", 1016], ["history", 1021], ["of", 1029], ["smoking", 1032], ["was", 1040], ["associated", 1044], ["with", 1055], ["increased", 1060], ["risk", 1070], ["for", 1075], ["rheumatoid", 1079], ["arthritis", 1090], ["overall", 1100], ["in", 1108], ["men", 1111], ["(", 1115], ["odds", 1116], ["ratio", 1121], ["2.0", 1127], [",", 1130], ["95", 1132], ["%", 1134], ["confidence", 1136], ["interval", 1147], ["1.2", 1156], ["-", 1159], ["3.2", 1160], [")", 1163], ["but", 1165], ["not", 1169], ["in", 1173], ["women", 1176], [".", 1181], ["Among", 1183], ["men", 1189], [",", 1192], ["this", 1194], ["effect", 1199], ["was", 1206], ["seen", 1210], ["only", 1215], ["for", 1220], ["rheumatoid", 1224], ["factor", 1235], ["-", 1241], ["positive", 1242], ["rheumatoid", 1251], ["arthritis", 1262], [".", 1271], ["There", 1273], ["were", 1279], ["significant", 1284], ["interactions", 1296], ["between", 1309], ["smoking", 1317], ["and", 1325], ["age", 1329], ["among", 1333], ["women", 1339], ["but", 1345], ["not", 1349], ["among", 1353], ["men", 1359], [".", 1362], ["We", 1364], ["conclude", 1367], ["that", 1376], ["sex", 1381], ["is", 1385], ["a", 1388], ["biologic", 1390], ["effect", 1399], ["modifier", 1406], ["in", 1415], ["the", 1418], ["association", 1422], ["between", 1434], ["smoking", 1442], ["and", 1450], ["rheumatoid", 1454], ["arthritis", 1465], [".", 1474], ["The", 1476], ["role", 1480], ["of", 1485], ["menopause", 1488], ["in", 1498], ["the", 1501], ["etiology", 1505], ["of", 1514], ["rheumatoid", 1517], ["arthritis", 1528], ["merits", 1538], ["further", 1545], ["research", 1553], [".", 1561]]}
{"context": "Since the early 2000s, the incidence of methicillin-resistant Staphylococcus aureus (MRSA) infections among the community of people lacking known healthcare risk factors has increased. This MRSA infection is referred to as community-associated MRSA (CA-MRSA) infection and is distinct from hospital-associated MRSA (HA-MRSA) infection, which occurs among people with known healthcare risk factors. Understanding the epidemiology of CA-MRSA infections is critical; however, this has not been investigated in detail in Japan. Our objective was to investigate the incidence of CA-MRSA infections in a regional hospital. We investigated CA-MRSA isolates and infections in a rural regional hospital by reviewing medical records of one year. Infections were classified as CA-MRSA if no established risk factors were identified. During 2008, 31 Staphylococcus aureus (S. aureus) isolates were detected in 29 unique patients, with 1 methicillin-sensitive S. aureus (MSSA) isolates obtained from 19 patients (66%) and MRSA obtained from 10 patients (34%). In the 10 patients with MRSA, the number of HA-MRSA and CA-MRSA cases were nine (32% of patients with S. aureus isolates) and one (3%), respectively. The patient with CA-MRSA was diagnosed with cellulitis due to CA-MRSA. All nine patients with HA-MRSA exhibited colonization. We observed a CA-MRSA case in a regional hospital in Japan, suggesting that incidence trends of CA-MRSA should be considered in future research and treatment.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "0d5291094d50485392d99b2aa3d5c380", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[208, 208], [139, 139], [58, 58], [186, 186], [44, 44], [116, 116], [212, 212], [249, 249], [78, 78], [14, 14], [257, 257], [240, 240], [282, 282], [54, 54], [266, 266], [105, 105], [201, 201], [40, 40], [31, 31]], "char_spans": [[1094, 1097], [769, 772], [319, 322], [1009, 1012], [253, 256], [636, 639], [1106, 1109], [1262, 1265], [435, 438], [85, 88], [1294, 1297], [1217, 1220], [1422, 1425], [310, 313], [1340, 1343], [577, 580], [1071, 1074], [244, 247], [190, 193]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["early", 10], ["2000s", 16], [",", 21], ["the", 23], ["incidence", 27], ["of", 37], ["methicillin", 40], ["-", 51], ["resistant", 52], ["Staphylococcus", 62], ["aureus", 77], ["(", 84], ["MRSA", 85], [")", 89], ["infections", 91], ["among", 102], ["the", 108], ["community", 112], ["of", 122], ["people", 125], ["lacking", 132], ["known", 140], ["healthcare", 146], ["risk", 157], ["factors", 162], ["has", 170], ["increased", 174], [".", 183], ["This", 185], ["MRSA", 190], ["infection", 195], ["is", 205], ["referred", 208], ["to", 217], ["as", 220], ["community", 223], ["-", 232], ["associated", 233], ["MRSA", 244], ["(", 249], ["CA", 250], ["-", 252], ["MRSA", 253], [")", 257], ["infection", 259], ["and", 269], ["is", 273], ["distinct", 276], ["from", 285], ["hospital", 290], ["-", 298], ["associated", 299], ["MRSA", 310], ["(", 315], ["HA", 316], ["-", 318], ["MRSA", 319], [")", 323], ["infection", 325], [",", 334], ["which", 336], ["occurs", 342], ["among", 349], ["people", 355], ["with", 362], ["known", 367], ["healthcare", 373], ["risk", 384], ["factors", 389], [".", 396], ["Understanding", 398], ["the", 412], ["epidemiology", 416], ["of", 429], ["CA", 432], ["-", 434], ["MRSA", 435], ["infections", 440], ["is", 451], ["critical", 454], [";", 462], ["however", 464], [",", 471], ["this", 473], ["has", 478], ["not", 482], ["been", 486], ["investigated", 491], ["in", 504], ["detail", 507], ["in", 514], ["Japan", 517], [".", 522], ["Our", 524], ["objective", 528], ["was", 538], ["to", 542], ["investigate", 545], ["the", 557], ["incidence", 561], ["of", 571], ["CA", 574], ["-", 576], ["MRSA", 577], ["infections", 582], ["in", 593], ["a", 596], ["regional", 598], ["hospital", 607], [".", 615], ["We", 617], ["investigated", 620], ["CA", 633], ["-", 635], ["MRSA", 636], ["isolates", 641], ["and", 650], ["infections", 654], ["in", 665], ["a", 668], ["rural", 670], ["regional", 676], ["hospital", 685], ["by", 694], ["reviewing", 697], ["medical", 707], ["records", 715], ["of", 723], ["one", 726], ["year", 730], [".", 734], ["Infections", 736], ["were", 747], ["classified", 752], ["as", 763], ["CA", 766], ["-", 768], ["MRSA", 769], ["if", 774], ["no", 777], ["established", 780], ["risk", 792], ["factors", 797], ["were", 805], ["identified", 810], [".", 820], ["During", 822], ["2008", 829], [",", 833], ["31", 835], ["Staphylococcus", 838], ["aureus", 853], ["(", 860], ["S.", 861], ["aureus", 864], [")", 870], ["isolates", 872], ["were", 881], ["detected", 886], ["in", 895], ["29", 898], ["unique", 901], ["patients", 908], [",", 916], ["with", 918], ["1", 923], ["methicillin", 925], ["-", 936], ["sensitive", 937], ["S.", 947], ["aureus", 950], ["(", 957], ["MSSA", 958], [")", 962], ["isolates", 964], ["obtained", 973], ["from", 982], ["19", 987], ["patients", 990], ["(", 999], ["66", 1000], ["%", 1002], [")", 1003], ["and", 1005], ["MRSA", 1009], ["obtained", 1014], ["from", 1023], ["10", 1028], ["patients", 1031], ["(", 1040], ["34", 1041], ["%", 1043], [")", 1044], [".", 1045], ["In", 1047], ["the", 1050], ["10", 1054], ["patients", 1057], ["with", 1066], ["MRSA", 1071], [",", 1075], ["the", 1077], ["number", 1081], ["of", 1088], ["HA", 1091], ["-", 1093], ["MRSA", 1094], ["and", 1099], ["CA", 1103], ["-", 1105], ["MRSA", 1106], ["cases", 1111], ["were", 1117], ["nine", 1122], ["(", 1127], ["32", 1128], ["%", 1130], ["of", 1132], ["patients", 1135], ["with", 1144], ["S.", 1149], ["aureus", 1152], ["isolates", 1159], [")", 1167], ["and", 1169], ["one", 1173], ["(", 1177], ["3", 1178], ["%", 1179], [")", 1180], [",", 1181], ["respectively", 1183], [".", 1195], ["The", 1197], ["patient", 1201], ["with", 1209], ["CA", 1214], ["-", 1216], ["MRSA", 1217], ["was", 1222], ["diagnosed", 1226], ["with", 1236], ["cellulitis", 1241], ["due", 1252], ["to", 1256], ["CA", 1259], ["-", 1261], ["MRSA", 1262], [".", 1266], ["All", 1268], ["nine", 1272], ["patients", 1277], ["with", 1286], ["HA", 1291], ["-", 1293], ["MRSA", 1294], ["exhibited", 1299], ["colonization", 1309], [".", 1321], ["We", 1323], ["observed", 1326], ["a", 1335], ["CA", 1337], ["-", 1339], ["MRSA", 1340], ["case", 1345], ["in", 1350], ["a", 1353], ["regional", 1355], ["hospital", 1364], ["in", 1373], ["Japan", 1376], [",", 1381], ["suggesting", 1383], ["that", 1394], ["incidence", 1399], ["trends", 1409], ["of", 1416], ["CA", 1419], ["-", 1421], ["MRSA", 1422], ["should", 1427], ["be", 1434], ["considered", 1437], ["in", 1448], ["future", 1451], ["research", 1458], ["and", 1467], ["treatment", 1471], [".", 1480]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) seems to be a frequent cause of intractable chronic insomnia (ICI) but is under-recognized in children/adolescents with neurodevelopmental conditions (NDCs), as many patients do not have the ability to express the underlying \"urge-to-move\". In light of this, we aim to develop a protocol for behavioral observations supporting the diagnosis of WED/RLS. We investigated 26 pediatric patients (age 1-16 years, median 8) with NDCs, ICI and evidence of familial WED/RLS employing (1) \"emplotted narratives\" for description of the various \"urge-to-move\" presentations and (2) self-description and \"behavioral observations\" during a \"suggested clinical immobilization test\" (SCIT). Parental narratives reflected typical WED/RLS-related \"urge-to-move\" symptoms during day-, bed-, and nighttime in all patients. Fifteen out of 26 patients could describe the \"urge-to-move\" during the SCIT. Ten out of 26 patients, unable to describe their symptoms due to cognitive disabilities, showed patterns of \"relieving-movements\" upon observation. Sensory processing abnormalities were reported in all patients, with tactile sensitivities (26/26) (including shifted pain threshold) as the most common sensory domain. \"Emplotted narratives\" and structured \"behavioral observations\" support recognition of familial WED/RLS associated movement patterns and provide a useful tool for the diagnosis of WED/RLS in children with NDCs in a clinical office setting.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "b7c3669e630a465892c5b64dbd7a9d82", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["seems", 54], ["to", 60], ["be", 63], ["a", 66], ["frequent", 68], ["cause", 77], ["of", 83], ["intractable", 86], ["chronic", 98], ["insomnia", 106], ["(", 115], ["ICI", 116], [")", 119], ["but", 121], ["is", 125], ["under", 128], ["-", 133], ["recognized", 134], ["in", 145], ["children", 148], ["/", 156], ["adolescents", 157], ["with", 169], ["neurodevelopmental", 174], ["conditions", 193], ["(", 204], ["NDCs", 205], [")", 209], [",", 210], ["as", 212], ["many", 215], ["patients", 220], ["do", 229], ["not", 232], ["have", 236], ["the", 241], ["ability", 245], ["to", 253], ["express", 256], ["the", 264], ["underlying", 268], ["\"", 279], ["urge", 280], ["-", 284], ["to", 285], ["-", 287], ["move", 288], ["\"", 292], [".", 293], ["In", 295], ["light", 298], ["of", 304], ["this", 307], [",", 311], ["we", 313], ["aim", 316], ["to", 320], ["develop", 323], ["a", 331], ["protocol", 333], ["for", 342], ["behavioral", 346], ["observations", 357], ["supporting", 370], ["the", 381], ["diagnosis", 385], ["of", 395], ["WED", 398], ["/", 401], ["RLS", 402], [".", 405], ["We", 407], ["investigated", 410], ["26", 423], ["pediatric", 426], ["patients", 436], ["(", 445], ["age", 446], ["1", 450], ["-", 451], ["16", 452], ["years", 455], [",", 460], ["median", 462], ["8)", 469], ["with", 472], ["NDCs", 477], [",", 481], ["ICI", 483], ["and", 487], ["evidence", 491], ["of", 500], ["familial", 503], ["WED", 512], ["/", 515], ["RLS", 516], ["employing", 520], ["(", 530], ["1", 531], [")", 532], ["\"", 534], ["emplotted", 535], ["narratives", 545], ["\"", 555], ["for", 557], ["description", 561], ["of", 573], ["the", 576], ["various", 580], ["\"", 588], ["urge", 589], ["-", 593], ["to", 594], ["-", 596], ["move", 597], ["\"", 601], ["presentations", 603], ["and", 617], ["(", 621], ["2", 622], [")", 623], ["self", 625], ["-", 629], ["description", 630], ["and", 642], ["\"", 646], ["behavioral", 647], ["observations", 658], ["\"", 670], ["during", 672], ["a", 679], ["\"", 681], ["suggested", 682], ["clinical", 692], ["immobilization", 701], ["test", 716], ["\"", 720], ["(", 722], ["SCIT", 723], [")", 727], [".", 728], ["Parental", 730], ["narratives", 739], ["reflected", 750], ["typical", 760], ["WED", 768], ["/", 771], ["RLS", 772], ["-", 775], ["related", 776], ["\"", 784], ["urge", 785], ["-", 789], ["to", 790], ["-", 792], ["move", 793], ["\"", 797], ["symptoms", 799], ["during", 808], ["day-", 815], [",", 819], ["bed-", 821], [",", 825], ["and", 827], ["nighttime", 831], ["in", 841], ["all", 844], ["patients", 848], [".", 856], ["Fifteen", 858], ["out", 866], ["of", 870], ["26", 873], ["patients", 876], ["could", 885], ["describe", 891], ["the", 900], ["\"", 904], ["urge", 905], ["-", 909], ["to", 910], ["-", 912], ["move", 913], ["\"", 917], ["during", 919], ["the", 926], ["SCIT", 930], [".", 934], ["Ten", 936], ["out", 940], ["of", 944], ["26", 947], ["patients", 950], [",", 958], ["unable", 960], ["to", 967], ["describe", 970], ["their", 979], ["symptoms", 985], ["due", 994], ["to", 998], ["cognitive", 1001], ["disabilities", 1011], [",", 1023], ["showed", 1025], ["patterns", 1032], ["of", 1041], ["\"", 1044], ["relieving", 1045], ["-", 1054], ["movements", 1055], ["\"", 1064], ["upon", 1066], ["observation", 1071], [".", 1082], ["Sensory", 1084], ["processing", 1092], ["abnormalities", 1103], ["were", 1117], ["reported", 1122], ["in", 1131], ["all", 1134], ["patients", 1138], [",", 1146], ["with", 1148], ["tactile", 1153], ["sensitivities", 1161], ["(", 1175], ["26/26", 1176], [")", 1181], ["(", 1183], ["including", 1184], ["shifted", 1194], ["pain", 1202], ["threshold", 1207], [")", 1216], ["as", 1218], ["the", 1221], ["most", 1225], ["common", 1230], ["sensory", 1237], ["domain", 1245], [".", 1251], ["\"", 1253], ["Emplotted", 1254], ["narratives", 1264], ["\"", 1274], ["and", 1276], ["structured", 1280], ["\"", 1291], ["behavioral", 1292], ["observations", 1303], ["\"", 1315], ["support", 1317], ["recognition", 1325], ["of", 1337], ["familial", 1340], ["WED", 1349], ["/", 1352], ["RLS", 1353], ["associated", 1357], ["movement", 1368], ["patterns", 1377], ["and", 1386], ["provide", 1390], ["a", 1398], ["useful", 1400], ["tool", 1407], ["for", 1412], ["the", 1416], ["diagnosis", 1420], ["of", 1430], ["WED", 1433], ["/", 1436], ["RLS", 1437], ["in", 1441], ["children", 1444], ["with", 1453], ["NDCs", 1458], ["in", 1463], ["a", 1466], ["clinical", 1468], ["office", 1477], ["setting", 1484], [".", 1491]]}
{"context": "A blinded, retrospective study was performed to determine the value of supine abdominal radiographs in diagnosing pneumoperitoneum. Supine films from 44 cases of pneumoperitoneum were randomly interspersed among supine films from 87 control subjects without free air, and the films were reviewed for the presence or absence of various signs of pneumoperitoneum, including Rigler's sign (gas on both sides of the bowel wall), the falciform ligament sign (gas outlining the falciform ligament), the football sign (gas outlining the peritoneal cavity), the inverted-V sign (gas outlining the medial umbilical folds), and the right-upper-quadrant gas sign (localized gas in the right upper quadrant). One or more of these signs were present in 26 cases (59%) of pneumoperitoneum, including the right-upper-quadrant gas sign in 18 cases (41%), Rigler's sign in 14 cases (32%), and the falciform ligament and football signs in one case each (2%). Unfortunately, there were frequent errors in the interpretation of the right-upper-quadrant gas sign and Rigler's sign, with a total of 11 false-positive cases (13%). Further analysis of the true-positive right-upper-quadrant gas signs showed that these gas collections were always triangular or linear with an inferolateral to superomedial orientation and, if triangular, a concave superolateral border. In the true-positive Rigler's signs, the bowel wall thickness ranged from 1 to 8 mm, whereas the false positives all had a bowel wall thickness of 1 mm or less. Proper interpretation of the various signs of pneumoperitoneum on supine films should lead to more accurate diagnosis of this condition.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "9305f4338a854725ab83e9b81c3c35b4", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[309, 309], [54, 54], [25, 25], [17, 17], [143, 143]], "char_spans": [[1553, 1568], [344, 359], [162, 177], [114, 129], [758, 773]]}]}], "context_tokens": [["A", 0], ["blinded", 2], [",", 9], ["retrospective", 11], ["study", 25], ["was", 31], ["performed", 35], ["to", 45], ["determine", 48], ["the", 58], ["value", 62], ["of", 68], ["supine", 71], ["abdominal", 78], ["radiographs", 88], ["in", 100], ["diagnosing", 103], ["pneumoperitoneum", 114], [".", 130], ["Supine", 132], ["films", 139], ["from", 145], ["44", 150], ["cases", 153], ["of", 159], ["pneumoperitoneum", 162], ["were", 179], ["randomly", 184], ["interspersed", 193], ["among", 206], ["supine", 212], ["films", 219], ["from", 225], ["87", 230], ["control", 233], ["subjects", 241], ["without", 250], ["free", 258], ["air", 263], [",", 266], ["and", 268], ["the", 272], ["films", 276], ["were", 282], ["reviewed", 287], ["for", 296], ["the", 300], ["presence", 304], ["or", 313], ["absence", 316], ["of", 324], ["various", 327], ["signs", 335], ["of", 341], ["pneumoperitoneum", 344], [",", 360], ["including", 362], ["Rigler", 372], ["'s", 378], ["sign", 381], ["(", 386], ["gas", 387], ["on", 391], ["both", 394], ["sides", 399], ["of", 405], ["the", 408], ["bowel", 412], ["wall", 418], [")", 422], [",", 423], ["the", 425], ["falciform", 429], ["ligament", 439], ["sign", 448], ["(", 453], ["gas", 454], ["outlining", 458], ["the", 468], ["falciform", 472], ["ligament", 482], [")", 490], [",", 491], ["the", 493], ["football", 497], ["sign", 506], ["(", 511], ["gas", 512], ["outlining", 516], ["the", 526], ["peritoneal", 530], ["cavity", 541], [")", 547], [",", 548], ["the", 550], ["inverted", 554], ["-", 562], ["V", 563], ["sign", 565], ["(", 570], ["gas", 571], ["outlining", 575], ["the", 585], ["medial", 589], ["umbilical", 596], ["folds", 606], [")", 611], [",", 612], ["and", 614], ["the", 618], ["right", 622], ["-", 627], ["upper", 628], ["-", 633], ["quadrant", 634], ["gas", 643], ["sign", 647], ["(", 652], ["localized", 653], ["gas", 663], ["in", 667], ["the", 670], ["right", 674], ["upper", 680], ["quadrant", 686], [")", 694], [".", 695], ["One", 697], ["or", 701], ["more", 704], ["of", 709], ["these", 712], ["signs", 718], ["were", 724], ["present", 729], ["in", 737], ["26", 740], ["cases", 743], ["(", 749], ["59", 750], ["%", 752], [")", 753], ["of", 755], ["pneumoperitoneum", 758], [",", 774], ["including", 776], ["the", 786], ["right", 790], ["-", 795], ["upper", 796], ["-", 801], ["quadrant", 802], ["gas", 811], ["sign", 815], ["in", 820], ["18", 823], ["cases", 826], ["(", 832], ["41", 833], ["%", 835], [")", 836], [",", 837], ["Rigler", 839], ["'s", 845], ["sign", 848], ["in", 853], ["14", 856], ["cases", 859], ["(", 865], ["32", 866], ["%", 868], [")", 869], [",", 870], ["and", 872], ["the", 876], ["falciform", 880], ["ligament", 890], ["and", 899], ["football", 903], ["signs", 912], ["in", 918], ["one", 921], ["case", 925], ["each", 930], ["(", 935], ["2", 936], ["%", 937], [")", 938], [".", 939], ["Unfortunately", 941], [",", 954], ["there", 956], ["were", 962], ["frequent", 967], ["errors", 976], ["in", 983], ["the", 986], ["interpretation", 990], ["of", 1005], ["the", 1008], ["right", 1012], ["-", 1017], ["upper", 1018], ["-", 1023], ["quadrant", 1024], ["gas", 1033], ["sign", 1037], ["and", 1042], ["Rigler", 1046], ["'s", 1052], ["sign", 1055], [",", 1059], ["with", 1061], ["a", 1066], ["total", 1068], ["of", 1074], ["11", 1077], ["false", 1080], ["-", 1085], ["positive", 1086], ["cases", 1095], ["(", 1101], ["13", 1102], ["%", 1104], [")", 1105], [".", 1106], ["Further", 1108], ["analysis", 1116], ["of", 1125], ["the", 1128], ["true", 1132], ["-", 1136], ["positive", 1137], ["right", 1146], ["-", 1151], ["upper", 1152], ["-", 1157], ["quadrant", 1158], ["gas", 1167], ["signs", 1171], ["showed", 1177], ["that", 1184], ["these", 1189], ["gas", 1195], ["collections", 1199], ["were", 1211], ["always", 1216], ["triangular", 1223], ["or", 1234], ["linear", 1237], ["with", 1244], ["an", 1249], ["inferolateral", 1252], ["to", 1266], ["superomedial", 1269], ["orientation", 1282], ["and", 1294], [",", 1297], ["if", 1299], ["triangular", 1302], [",", 1312], ["a", 1314], ["concave", 1316], ["superolateral", 1324], ["border", 1338], [".", 1344], ["In", 1346], ["the", 1349], ["true", 1353], ["-", 1357], ["positive", 1358], ["Rigler", 1367], ["'s", 1373], ["signs", 1376], [",", 1381], ["the", 1383], ["bowel", 1387], ["wall", 1393], ["thickness", 1398], ["ranged", 1408], ["from", 1415], ["1", 1420], ["to", 1422], ["8", 1425], ["mm", 1427], [",", 1429], ["whereas", 1431], ["the", 1439], ["false", 1443], ["positives", 1449], ["all", 1459], ["had", 1463], ["a", 1467], ["bowel", 1469], ["wall", 1475], ["thickness", 1480], ["of", 1490], ["1", 1493], ["mm", 1495], ["or", 1498], ["less", 1501], [".", 1505], ["Proper", 1507], ["interpretation", 1514], ["of", 1529], ["the", 1532], ["various", 1536], ["signs", 1544], ["of", 1550], ["pneumoperitoneum", 1553], ["on", 1570], ["supine", 1573], ["films", 1580], ["should", 1586], ["lead", 1593], ["to", 1598], ["more", 1601], ["accurate", 1606], ["diagnosis", 1615], ["of", 1625], ["this", 1628], ["condition", 1633], [".", 1642]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, was evaluated as adjunctive therapy in the management of benzodiazepine overdose. Thirteen emergency departments enrolled 326 patients in this double-blind, placebo-controlled trial; 162 patients were randomly allocated to receive flumazenil (maximum dose, 30 ml, providing 3 mg of flumazenil), and 164 were allocated to receive placebo (maximum dose, 30 ml). A successful response was the attainment of a score of 1 or 2 on the Clinical Global Impression Scale (CGIS), denoting a very much improved or much improved status, 10 minutes after the start of intravenous administration of the test drug. Among those patients whose drug screen revealed the presence of benzodiazepines, 75 (77%) of 97 patients given flumazenil and 13 (16%) of 83 given placebo attained such a response. The mean CGIS score at 10 minutes for benzodiazepine-positive patients treated with flumazenil was 1.95 versus 3.58 for those given placebo. As determined by the Neurobehavioral Assessment Scale, 61% of patients who initially responded became resedated; in these patients, the effect of flumazenil lasted a median of 90 minutes. At the investigator's discretion, patients who did not achieve a criterion response in the double-blind trial could receive open-label flumazenil, titrated as in the double-blind phase. Among the benzodiazepine-positive patients, 9 (53%) of 17 patients from the flumazenil group responded to the additional flumazenil, and 58 (81%) of patients previously given placebo responded. Safety was assessed in all 326 patients given the test drug. The most frequent adverse experiences after the administration of flumazenil were agitation (7%), vomiting (7%), abnormal crying (4%), and nausea (4%); these effects were observed with a lower frequency in the placebo group. Serious adverse experiences were reported in 4 patients; these included seizures and cardiac arrhythmias. Of the 3 patients with seizures, 2 had ingested large doses of cyclic antidepressants in addition to the benzodiazepine. The toxicology screen for 1 of the 2 showed 1900 ng/ml of amoxapine and 900 ng/ml of nortriptyline; the toxicology screen for the other, who also had ventricular tachycardia, showed 1928 ng/ml of loxapine and 301 ng/ml of amoxapine. The results of this study confirm published reports of the efficacy of flumazenil in reversing benzodiazepine-induced sedation in patients with benzodiazepine overdose. This was accomplished irrespective of the presence of coingested drugs. Flumazenil is not recommended for patients with serious cyclic antidepressant poisoning or those who use benzodiazepines therapeutically to control seizure disorders. When used as recommended, however, flumazenil has been shown to have an acceptable safety level.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "c0676b791a034e7e90ddf7a04c68ddd2", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [272, 272], [43, 43], [205, 205], [170, 170], [266, 266], [502, 502], [140, 140], [308, 308], [55, 55], [473, 473], [238, 238], [449, 449]], "char_spans": [[0, 9], [1467, 1476], [281, 290], [1118, 1127], [915, 924], [1422, 1431], [2729, 2738], [761, 770], [1667, 1676], [332, 341], [2527, 2536], [1295, 1304], [2357, 2366]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["was", 50], ["evaluated", 54], ["as", 64], ["adjunctive", 67], ["therapy", 78], ["in", 86], ["the", 89], ["management", 93], ["of", 104], ["benzodiazepine", 107], ["overdose", 122], [".", 130], ["Thirteen", 132], ["emergency", 141], ["departments", 151], ["enrolled", 163], ["326", 172], ["patients", 176], ["in", 185], ["this", 188], ["double", 193], ["-", 199], ["blind", 200], [",", 205], ["placebo", 207], ["-", 214], ["controlled", 215], ["trial", 226], [";", 231], ["162", 233], ["patients", 237], ["were", 246], ["randomly", 251], ["allocated", 260], ["to", 270], ["receive", 273], ["flumazenil", 281], ["(", 292], ["maximum", 293], ["dose", 301], [",", 305], ["30", 307], ["ml", 310], [",", 312], ["providing", 314], ["3", 324], ["mg", 326], ["of", 329], ["flumazenil", 332], [")", 342], [",", 343], ["and", 345], ["164", 349], ["were", 353], ["allocated", 358], ["to", 368], ["receive", 371], ["placebo", 379], ["(", 387], ["maximum", 388], ["dose", 396], [",", 400], ["30", 402], ["ml", 405], [")", 407], [".", 408], ["A", 410], ["successful", 412], ["response", 423], ["was", 432], ["the", 436], ["attainment", 440], ["of", 451], ["a", 454], ["score", 456], ["of", 462], ["1", 465], ["or", 467], ["2", 470], ["on", 472], ["the", 475], ["Clinical", 479], ["Global", 488], ["Impression", 495], ["Scale", 506], ["(", 512], ["CGIS", 513], [")", 517], [",", 518], ["denoting", 520], ["a", 529], ["very", 531], ["much", 536], ["improved", 541], ["or", 550], ["much", 553], ["improved", 558], ["status", 567], [",", 573], ["10", 575], ["minutes", 578], ["after", 586], ["the", 592], ["start", 596], ["of", 602], ["intravenous", 605], ["administration", 617], ["of", 632], ["the", 635], ["test", 639], ["drug", 644], [".", 648], ["Among", 650], ["those", 656], ["patients", 662], ["whose", 671], ["drug", 677], ["screen", 682], ["revealed", 689], ["the", 698], ["presence", 702], ["of", 711], ["benzodiazepines", 714], [",", 729], ["75", 731], ["(", 734], ["77", 735], ["%", 737], [")", 738], ["of", 740], ["97", 743], ["patients", 746], ["given", 755], ["flumazenil", 761], ["and", 772], ["13", 776], ["(", 779], ["16", 780], ["%", 782], [")", 783], ["of", 785], ["83", 788], ["given", 791], ["placebo", 797], ["attained", 805], ["such", 814], ["a", 819], ["response", 821], [".", 829], ["The", 831], ["mean", 835], ["CGIS", 840], ["score", 845], ["at", 851], ["10", 854], ["minutes", 857], ["for", 865], ["benzodiazepine", 869], ["-", 883], ["positive", 884], ["patients", 893], ["treated", 902], ["with", 910], ["flumazenil", 915], ["was", 926], ["1.95", 930], ["versus", 935], ["3.58", 942], ["for", 947], ["those", 951], ["given", 957], ["placebo", 963], [".", 970], ["As", 972], ["determined", 975], ["by", 986], ["the", 989], ["Neurobehavioral", 993], ["Assessment", 1009], ["Scale", 1020], [",", 1025], ["61", 1027], ["%", 1029], ["of", 1031], ["patients", 1034], ["who", 1043], ["initially", 1047], ["responded", 1057], ["became", 1067], ["resedated", 1074], [";", 1083], ["in", 1085], ["these", 1088], ["patients", 1094], [",", 1102], ["the", 1104], ["effect", 1108], ["of", 1115], ["flumazenil", 1118], ["lasted", 1129], ["a", 1136], ["median", 1138], ["of", 1145], ["90", 1148], ["minutes", 1151], [".", 1158], ["At", 1160], ["the", 1163], ["investigator", 1167], ["'s", 1179], ["discretion", 1182], [",", 1192], ["patients", 1194], ["who", 1203], ["did", 1207], ["not", 1211], ["achieve", 1215], ["a", 1223], ["criterion", 1225], ["response", 1235], ["in", 1244], ["the", 1247], ["double", 1251], ["-", 1257], ["blind", 1258], ["trial", 1264], ["could", 1270], ["receive", 1276], ["open", 1284], ["-", 1288], ["label", 1289], ["flumazenil", 1295], [",", 1305], ["titrated", 1307], ["as", 1316], ["in", 1319], ["the", 1322], ["double", 1326], ["-", 1332], ["blind", 1333], ["phase", 1339], [".", 1344], ["Among", 1346], ["the", 1352], ["benzodiazepine", 1356], ["-", 1370], ["positive", 1371], ["patients", 1380], [",", 1388], ["9", 1390], ["(", 1392], ["53", 1393], ["%", 1395], [")", 1396], ["of", 1398], ["17", 1401], ["patients", 1404], ["from", 1413], ["the", 1418], ["flumazenil", 1422], ["group", 1433], ["responded", 1439], ["to", 1449], ["the", 1452], ["additional", 1456], ["flumazenil", 1467], [",", 1477], ["and", 1479], ["58", 1483], ["(", 1486], ["81", 1487], ["%", 1489], [")", 1490], ["of", 1492], ["patients", 1495], ["previously", 1504], ["given", 1515], ["placebo", 1521], ["responded", 1529], [".", 1538], ["Safety", 1540], ["was", 1547], ["assessed", 1551], ["in", 1560], ["all", 1563], ["326", 1567], ["patients", 1571], ["given", 1580], ["the", 1586], ["test", 1590], ["drug", 1595], [".", 1599], ["The", 1601], ["most", 1605], ["frequent", 1610], ["adverse", 1619], ["experiences", 1627], ["after", 1639], ["the", 1645], ["administration", 1649], ["of", 1664], ["flumazenil", 1667], ["were", 1678], ["agitation", 1683], ["(", 1693], ["7", 1694], ["%", 1695], [")", 1696], [",", 1697], ["vomiting", 1699], ["(", 1708], ["7", 1709], ["%", 1710], [")", 1711], [",", 1712], ["abnormal", 1714], ["crying", 1723], ["(", 1730], ["4", 1731], ["%", 1732], [")", 1733], [",", 1734], ["and", 1736], ["nausea", 1740], ["(", 1747], ["4", 1748], ["%", 1749], [")", 1750], [";", 1751], ["these", 1753], ["effects", 1759], ["were", 1767], ["observed", 1772], ["with", 1781], ["a", 1786], ["lower", 1788], ["frequency", 1794], ["in", 1804], ["the", 1807], ["placebo", 1811], ["group", 1819], [".", 1824], ["Serious", 1826], ["adverse", 1834], ["experiences", 1842], ["were", 1854], ["reported", 1859], ["in", 1868], ["4", 1871], ["patients", 1873], [";", 1881], ["these", 1883], ["included", 1889], ["seizures", 1898], ["and", 1907], ["cardiac", 1911], ["arrhythmias", 1919], [".", 1930], ["Of", 1932], ["the", 1935], ["3", 1939], ["patients", 1941], ["with", 1950], ["seizures", 1955], [",", 1963], ["2", 1965], ["had", 1967], ["ingested", 1971], ["large", 1980], ["doses", 1986], ["of", 1992], ["cyclic", 1995], ["antidepressants", 2002], ["in", 2018], ["addition", 2021], ["to", 2030], ["the", 2033], ["benzodiazepine", 2037], [".", 2051], ["The", 2053], ["toxicology", 2057], ["screen", 2068], ["for", 2075], ["1", 2079], ["of", 2081], ["the", 2084], ["2", 2088], ["showed", 2090], ["1900", 2097], ["ng", 2102], ["/", 2104], ["ml", 2105], ["of", 2108], ["amoxapine", 2111], ["and", 2121], ["900", 2125], ["ng", 2129], ["/", 2131], ["ml", 2132], ["of", 2135], ["nortriptyline", 2138], [";", 2151], ["the", 2153], ["toxicology", 2157], ["screen", 2168], ["for", 2175], ["the", 2179], ["other", 2183], [",", 2188], ["who", 2190], ["also", 2194], ["had", 2199], ["ventricular", 2203], ["tachycardia", 2215], [",", 2226], ["showed", 2228], ["1928", 2235], ["ng", 2240], ["/", 2242], ["ml", 2243], ["of", 2246], ["loxapine", 2249], ["and", 2258], ["301", 2262], ["ng", 2266], ["/", 2268], ["ml", 2269], ["of", 2272], ["amoxapine", 2275], [".", 2284], ["The", 2286], ["results", 2290], ["of", 2298], ["this", 2301], ["study", 2306], ["confirm", 2312], ["published", 2320], ["reports", 2330], ["of", 2338], ["the", 2341], ["efficacy", 2345], ["of", 2354], ["flumazenil", 2357], ["in", 2368], ["reversing", 2371], ["benzodiazepine", 2381], ["-", 2395], ["induced", 2396], ["sedation", 2404], ["in", 2413], ["patients", 2416], ["with", 2425], ["benzodiazepine", 2430], ["overdose", 2445], [".", 2453], ["This", 2455], ["was", 2460], ["accomplished", 2464], ["irrespective", 2477], ["of", 2490], ["the", 2493], ["presence", 2497], ["of", 2506], ["coingested", 2509], ["drugs", 2520], [".", 2525], ["Flumazenil", 2527], ["is", 2538], ["not", 2541], ["recommended", 2545], ["for", 2557], ["patients", 2561], ["with", 2570], ["serious", 2575], ["cyclic", 2583], ["antidepressant", 2590], ["poisoning", 2605], ["or", 2615], ["those", 2618], ["who", 2624], ["use", 2628], ["benzodiazepines", 2632], ["therapeutically", 2648], ["to", 2664], ["control", 2667], ["seizure", 2675], ["disorders", 2683], [".", 2692], ["When", 2694], ["used", 2699], ["as", 2704], ["recommended", 2707], [",", 2718], ["however", 2720], [",", 2727], ["flumazenil", 2729], ["has", 2740], ["been", 2744], ["shown", 2749], ["to", 2755], ["have", 2758], ["an", 2763], ["acceptable", 2766], ["safety", 2777], ["level", 2784], [".", 2789]]}
{"context": "Phosphorylation of cytoplasmic polyadenylation element binding protein (CPEB) regulates protein synthesis in hippocampal dendrites. CPEB binds the 3' untranslated region (UTR) of cytoplasmic mRNAs and, when phosphorylated, initiates mRNA polyadenylation and translation. We report that, of the protein kinases activated in the hippocampus during synaptic plasticity, calcium/calmodulin-dependent protein kinase II (CaMKII) robustly phosphorylated the regulatory site (threonine 171) in CPEB in vitro. In postsynaptic density fractions or hippocampal neurons, CPEB phosphorylation increased when CaMKII was activated. These increases in CPEB phosphorylation were attenuated by a specific peptide inhibitor of CaMKII and by the general CaM-kinase inhibitor KN-93. Inhibitors of protein phosphatase 1 increased basal CPEB phosphorylation in neurons; this was also attenuated by a CaM-kinase inhibitor. To determine whether CaM-kinase activity regulates CPEB-dependent mRNA translation, hippocampal neurons were transfected with luciferase fused to a 3' UTR containing CPE-binding elements. Depolarization of neurons stimulated synthesis of luciferase; this was abrogated by inhibitors of protein synthesis, mRNA polyadenylation, and CaMKII. These results demonstrate that CPEB phosphorylation and translation are regulated by CaMKII activity and provide a possible mechanism for how dendritic protein synthesis in the hippocampus may be stimulated during synaptic plasticity.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["CAMK2", "calcium/calmodulin-dependent protein kinase II", "The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II"], "qid": "7d3d225c01ba4d0daa3bfa2341e0caf8", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "The calcium/calmodulin-dependent protein kinase-II", "token_spans": [[57, 64]], "char_spans": [[367, 412]]}]}], "context_tokens": [["Phosphorylation", 0], ["of", 16], ["cytoplasmic", 19], ["polyadenylation", 31], ["element", 47], ["binding", 55], ["protein", 63], ["(", 71], ["CPEB", 72], [")", 76], ["regulates", 78], ["protein", 88], ["synthesis", 96], ["in", 106], ["hippocampal", 109], ["dendrites", 121], [".", 130], ["CPEB", 132], ["binds", 137], ["the", 143], ["3", 147], ["'", 148], ["untranslated", 150], ["region", 163], ["(", 170], ["UTR", 171], [")", 174], ["of", 176], ["cytoplasmic", 179], ["mRNAs", 191], ["and", 197], [",", 200], ["when", 202], ["phosphorylated", 207], [",", 221], ["initiates", 223], ["mRNA", 233], ["polyadenylation", 238], ["and", 254], ["translation", 258], [".", 269], ["We", 271], ["report", 274], ["that", 281], [",", 285], ["of", 287], ["the", 290], ["protein", 294], ["kinases", 302], ["activated", 310], ["in", 320], ["the", 323], ["hippocampus", 327], ["during", 339], ["synaptic", 346], ["plasticity", 355], [",", 365], ["calcium", 367], ["/", 374], ["calmodulin", 375], ["-", 385], ["dependent", 386], ["protein", 396], ["kinase", 404], ["II", 411], ["(", 414], ["CaMKII", 415], [")", 421], ["robustly", 423], ["phosphorylated", 432], ["the", 447], ["regulatory", 451], ["site", 462], ["(", 467], ["threonine", 468], ["171", 478], [")", 481], ["in", 483], ["CPEB", 486], ["in", 491], ["vitro", 494], [".", 499], ["In", 501], ["postsynaptic", 504], ["density", 517], ["fractions", 525], ["or", 535], ["hippocampal", 538], ["neurons", 550], [",", 557], ["CPEB", 559], ["phosphorylation", 564], ["increased", 580], ["when", 590], ["CaMKII", 595], ["was", 602], ["activated", 606], [".", 615], ["These", 617], ["increases", 623], ["in", 633], ["CPEB", 636], ["phosphorylation", 641], ["were", 657], ["attenuated", 662], ["by", 673], ["a", 676], ["specific", 678], ["peptide", 687], ["inhibitor", 695], ["of", 705], ["CaMKII", 708], ["and", 715], ["by", 719], ["the", 722], ["general", 726], ["CaM", 734], ["-", 737], ["kinase", 738], ["inhibitor", 745], ["KN-93", 755], [".", 760], ["Inhibitors", 762], ["of", 773], ["protein", 776], ["phosphatase", 784], ["1", 796], ["increased", 798], ["basal", 808], ["CPEB", 814], ["phosphorylation", 819], ["in", 835], ["neurons", 838], [";", 845], ["this", 847], ["was", 852], ["also", 856], ["attenuated", 861], ["by", 872], ["a", 875], ["CaM", 877], ["-", 880], ["kinase", 881], ["inhibitor", 888], [".", 897], ["To", 899], ["determine", 902], ["whether", 912], ["CaM", 920], ["-", 923], ["kinase", 924], ["activity", 931], ["regulates", 940], ["CPEB", 950], ["-", 954], ["dependent", 955], ["mRNA", 965], ["translation", 970], [",", 981], ["hippocampal", 983], ["neurons", 995], ["were", 1003], ["transfected", 1008], ["with", 1020], ["luciferase", 1025], ["fused", 1036], ["to", 1042], ["a", 1045], ["3", 1047], ["'", 1048], ["UTR", 1050], ["containing", 1054], ["CPE", 1065], ["-", 1068], ["binding", 1069], ["elements", 1077], [".", 1085], ["Depolarization", 1087], ["of", 1102], ["neurons", 1105], ["stimulated", 1113], ["synthesis", 1124], ["of", 1134], ["luciferase", 1137], [";", 1147], ["this", 1149], ["was", 1154], ["abrogated", 1158], ["by", 1168], ["inhibitors", 1171], ["of", 1182], ["protein", 1185], ["synthesis", 1193], [",", 1202], ["mRNA", 1204], ["polyadenylation", 1209], [",", 1224], ["and", 1226], ["CaMKII", 1230], [".", 1236], ["These", 1238], ["results", 1244], ["demonstrate", 1252], ["that", 1264], ["CPEB", 1269], ["phosphorylation", 1274], ["and", 1290], ["translation", 1294], ["are", 1306], ["regulated", 1310], ["by", 1320], ["CaMKII", 1323], ["activity", 1330], ["and", 1339], ["provide", 1343], ["a", 1351], ["possible", 1353], ["mechanism", 1362], ["for", 1372], ["how", 1376], ["dendritic", 1380], ["protein", 1390], ["synthesis", 1398], ["in", 1408], ["the", 1411], ["hippocampus", 1415], ["may", 1427], ["be", 1431], ["stimulated", 1434], ["during", 1445], ["synaptic", 1452], ["plasticity", 1461], [".", 1471]]}
{"context": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1. Contrary to that of its phagocyte counterpart NOX2, the molecular basis of NOX1 regulation is not clear. Because NOXO1 lacks the phosphorylated region found in its homolog p47(PHOX), the current view is that NOX1 activation occurs without NOXO1 phosphorylation. Here, however, we demonstrate that phorbol myristate acetate (PMA) stimulates NOXO1 phosphorylation in a transfected human embryonic kidney (HEK) 293 epithelial cell model via protein kinase C and identify Ser-154 as the major phosphorylated site. Endogenous NOXO1 from T84 colon epithelial cells was also phosphorylated, suggesting that NOXO1 phosphorylation is physiologically relevant. In transfected HEK-293 cells, PMA-induced phosphorylation on Ser-154 enhanced NOXO1 binding to NOXA1 (+97%) and to the p22(PHOX) C-terminal region (+384%), increased NOXO1 colocalization with p22(PHOX), and allowed optimal ROS production by NOX1 as demonstrated by the use of S154A and S154D mutants compared with that by wild-type NOXO1 (P<0.05). Pulldown experiments revealed that phos-phorylation on Ser-154 was sufficient to markedly enhance NOXO1 binding to NOXA1, which in turn acts as a molecular switch, allowing optimal interaction of NOXO1 with p22(PHOX). This study unexpectedly revealed that full assembly and activation of NOX1 is a tightly regulated process in which NOXO1 phosphorylation on Ser-154 is the initial trigger.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "ce8e78ef06ed459386b6f776879b5c3c", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[8, 10]], "char_spans": [[44, 58]]}, {"text": "NOX1", "token_spans": [[275, 275], [205, 205], [90, 90], [12, 12], [66, 66]], "char_spans": [[1543, 1546], [1148, 1151], [464, 467], [61, 64], [331, 334]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["(", 24], ["ROS", 25], [")", 28], ["production", 30], ["by", 41], ["NADPH", 44], ["oxidase", 50], ["1", 58], ["(", 60], ["NOX1", 61], [")", 65], [",", 66], ["which", 68], ["is", 74], ["mainly", 77], ["expressed", 84], ["in", 94], ["colon", 97], ["epithelial", 103], ["cells", 114], [",", 119], ["requires", 121], ["the", 130], ["membrane", 134], ["-", 142], ["bound", 143], ["component", 149], ["p22(PHOX", 159], [")", 167], ["and", 169], ["the", 173], ["cytosolic", 177], ["partners", 187], ["NOX", 196], ["organizer", 200], ["1", 210], ["(", 212], ["NOXO1", 213], [")", 218], [",", 219], ["NOX", 221], ["activator", 225], ["1", 235], ["(", 237], ["NOXA1", 238], [")", 243], [",", 244], ["and", 246], ["Rac1", 250], [".", 254], ["Contrary", 256], ["to", 265], ["that", 268], ["of", 273], ["its", 276], ["phagocyte", 280], ["counterpart", 290], ["NOX2", 302], [",", 306], ["the", 308], ["molecular", 312], ["basis", 322], ["of", 328], ["NOX1", 331], ["regulation", 336], ["is", 347], ["not", 350], ["clear", 354], [".", 359], ["Because", 361], ["NOXO1", 369], ["lacks", 375], ["the", 381], ["phosphorylated", 385], ["region", 400], ["found", 407], ["in", 413], ["its", 416], ["homolog", 420], ["p47(PHOX", 428], [")", 436], [",", 437], ["the", 439], ["current", 443], ["view", 451], ["is", 456], ["that", 459], ["NOX1", 464], ["activation", 469], ["occurs", 480], ["without", 487], ["NOXO1", 495], ["phosphorylation", 501], [".", 516], ["Here", 518], [",", 522], ["however", 524], [",", 531], ["we", 533], ["demonstrate", 536], ["that", 548], ["phorbol", 553], ["myristate", 561], ["acetate", 571], ["(", 579], ["PMA", 580], [")", 583], ["stimulates", 585], ["NOXO1", 596], ["phosphorylation", 602], ["in", 618], ["a", 621], ["transfected", 623], ["human", 635], ["embryonic", 641], ["kidney", 651], ["(", 658], ["HEK", 659], [")", 662], ["293", 664], ["epithelial", 668], ["cell", 679], ["model", 684], ["via", 690], ["protein", 694], ["kinase", 702], ["C", 709], ["and", 711], ["identify", 715], ["Ser-154", 724], ["as", 732], ["the", 735], ["major", 739], ["phosphorylated", 745], ["site", 760], [".", 764], ["Endogenous", 766], ["NOXO1", 777], ["from", 783], ["T84", 788], ["colon", 792], ["epithelial", 798], ["cells", 809], ["was", 815], ["also", 819], ["phosphorylated", 824], [",", 838], ["suggesting", 840], ["that", 851], ["NOXO1", 856], ["phosphorylation", 862], ["is", 878], ["physiologically", 881], ["relevant", 897], [".", 905], ["In", 907], ["transfected", 910], ["HEK-293", 922], ["cells", 930], [",", 935], ["PMA", 937], ["-", 940], ["induced", 941], ["phosphorylation", 949], ["on", 965], ["Ser-154", 968], ["enhanced", 976], ["NOXO1", 985], ["binding", 991], ["to", 999], ["NOXA1", 1002], ["(", 1008], ["+97", 1009], ["%", 1012], [")", 1013], ["and", 1015], ["to", 1019], ["the", 1022], ["p22(PHOX", 1026], [")", 1034], ["C", 1036], ["-", 1037], ["terminal", 1038], ["region", 1047], ["(", 1054], ["+384", 1055], ["%", 1059], [")", 1060], [",", 1061], ["increased", 1063], ["NOXO1", 1073], ["colocalization", 1079], ["with", 1094], ["p22(PHOX", 1099], [")", 1107], [",", 1108], ["and", 1110], ["allowed", 1114], ["optimal", 1122], ["ROS", 1130], ["production", 1134], ["by", 1145], ["NOX1", 1148], ["as", 1153], ["demonstrated", 1156], ["by", 1169], ["the", 1172], ["use", 1176], ["of", 1180], ["S154A", 1183], ["and", 1189], ["S154D", 1193], ["mutants", 1199], ["compared", 1207], ["with", 1216], ["that", 1221], ["by", 1226], ["wild", 1229], ["-", 1233], ["type", 1234], ["NOXO1", 1239], ["(", 1245], ["P<0.05", 1246], [")", 1252], [".", 1253], ["Pulldown", 1255], ["experiments", 1264], ["revealed", 1276], ["that", 1285], ["phos", 1290], ["-", 1294], ["phorylation", 1295], ["on", 1307], ["Ser-154", 1310], ["was", 1318], ["sufficient", 1322], ["to", 1333], ["markedly", 1336], ["enhance", 1345], ["NOXO1", 1353], ["binding", 1359], ["to", 1367], ["NOXA1", 1370], [",", 1375], ["which", 1377], ["in", 1383], ["turn", 1386], ["acts", 1391], ["as", 1396], ["a", 1399], ["molecular", 1401], ["switch", 1411], [",", 1417], ["allowing", 1419], ["optimal", 1428], ["interaction", 1436], ["of", 1448], ["NOXO1", 1451], ["with", 1457], ["p22(PHOX", 1462], [")", 1470], [".", 1471], ["This", 1473], ["study", 1478], ["unexpectedly", 1484], ["revealed", 1497], ["that", 1506], ["full", 1511], ["assembly", 1516], ["and", 1525], ["activation", 1529], ["of", 1540], ["NOX1", 1543], ["is", 1548], ["a", 1551], ["tightly", 1553], ["regulated", 1561], ["process", 1571], ["in", 1579], ["which", 1582], ["NOXO1", 1588], ["phosphorylation", 1594], ["on", 1610], ["Ser-154", 1613], ["is", 1621], ["the", 1624], ["initial", 1628], ["trigger", 1636], [".", 1643]]}
{"context": "A 54-y-old man ingested 2 g of bulk laboratory diazepam and was treated with activated charcoal, enhanced diuresis and flumazenil infusion. The treatment resulted in awakening, but the patient had drowsiness, dysarthria, diplopia, and dizziness for 9 d. Blood levels of diazepam and its main metabolite, nordiazepam, were obtained for 1 mo. The half-lives in this benzodiazepine overdose were longer than those seen with therapeutic doses. Benzodiazepines should not be readministrated when patients awake after suicide attempts.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "f11fbd28f9c1426ebef6f55f607da505", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[22, 22]], "char_spans": [[119, 128]]}]}], "context_tokens": [["A", 0], ["54-y", 2], ["-", 6], ["old", 7], ["man", 11], ["ingested", 15], ["2", 24], ["g", 26], ["of", 28], ["bulk", 31], ["laboratory", 36], ["diazepam", 47], ["and", 56], ["was", 60], ["treated", 64], ["with", 72], ["activated", 77], ["charcoal", 87], [",", 95], ["enhanced", 97], ["diuresis", 106], ["and", 115], ["flumazenil", 119], ["infusion", 130], [".", 138], ["The", 140], ["treatment", 144], ["resulted", 154], ["in", 163], ["awakening", 166], [",", 175], ["but", 177], ["the", 181], ["patient", 185], ["had", 193], ["drowsiness", 197], [",", 207], ["dysarthria", 209], [",", 219], ["diplopia", 221], [",", 229], ["and", 231], ["dizziness", 235], ["for", 245], ["9", 249], ["d.", 251], ["Blood", 254], ["levels", 260], ["of", 267], ["diazepam", 270], ["and", 279], ["its", 283], ["main", 287], ["metabolite", 292], [",", 302], ["nordiazepam", 304], [",", 315], ["were", 317], ["obtained", 322], ["for", 331], ["1", 335], ["mo", 337], [".", 339], ["The", 341], ["half", 345], ["-", 349], ["lives", 350], ["in", 356], ["this", 359], ["benzodiazepine", 364], ["overdose", 379], ["were", 388], ["longer", 393], ["than", 400], ["those", 405], ["seen", 411], ["with", 416], ["therapeutic", 421], ["doses", 433], [".", 438], ["Benzodiazepines", 440], ["should", 456], ["not", 463], ["be", 467], ["readministrated", 470], ["when", 486], ["patients", 491], ["awake", 500], ["after", 506], ["suicide", 512], ["attempts", 520], [".", 528]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement. In general, FSHD typically presents before age 20 years. Usually, FSHD muscle involvement starts in the face and then progresses to the shoulder girdle, the humeral muscles and the abdominal muscles, and then the anterolateral compartment of the leg. Disease severity is highly variable and progression is very slow. About 20% of FSHD patients become wheelchair-bound. Lifespan is not shortened. The diagnosis of FSHD is based on a genetic test by which a deletion of 3.3kb DNA repeats (named D4Z4 and mapping to the subtelomeric region of chromosome 4q35) is identified. The progressive pattern of FSHD requires that the severity of symptoms as well as their physical, social and psychological impact be evaluated on a regular basis. A yearly assessment is recommended. Multidisciplinary management of FSHD--consisting of a combination of genetic counselling, functional assessment, an assessment by a physical therapist, prescription of symptomatic therapies and prevention of known complications of this disease--is required. Prescription of physical therapy sessions and orthopedic appliances are to be adapted to the patient's deficiencies and contractures.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "9366db61286b41f79e9e069494d2c271", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[14, 15]], "char_spans": [[94, 111]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["neuromuscular", 51], ["disease", 65], [",", 72], ["characterized", 74], ["by", 88], ["an", 91], ["autosomal", 94], ["dominant", 104], ["mode", 113], ["of", 118], ["inheritance", 121], [",", 132], ["facial", 134], ["involvement", 141], [",", 152], ["and", 154], ["selectivity", 158], ["and", 170], ["asymmetry", 174], ["of", 184], ["muscle", 187], ["involvement", 194], [".", 205], ["In", 207], ["general", 210], [",", 217], ["FSHD", 219], ["typically", 224], ["presents", 234], ["before", 243], ["age", 250], ["20", 254], ["years", 257], [".", 262], ["Usually", 264], [",", 271], ["FSHD", 273], ["muscle", 278], ["involvement", 285], ["starts", 297], ["in", 304], ["the", 307], ["face", 311], ["and", 316], ["then", 320], ["progresses", 325], ["to", 336], ["the", 339], ["shoulder", 343], ["girdle", 352], [",", 358], ["the", 360], ["humeral", 364], ["muscles", 372], ["and", 380], ["the", 384], ["abdominal", 388], ["muscles", 398], [",", 405], ["and", 407], ["then", 411], ["the", 416], ["anterolateral", 420], ["compartment", 434], ["of", 446], ["the", 449], ["leg", 453], [".", 456], ["Disease", 458], ["severity", 466], ["is", 475], ["highly", 478], ["variable", 485], ["and", 494], ["progression", 498], ["is", 510], ["very", 513], ["slow", 518], [".", 522], ["About", 524], ["20", 530], ["%", 532], ["of", 534], ["FSHD", 537], ["patients", 542], ["become", 551], ["wheelchair", 558], ["-", 568], ["bound", 569], [".", 574], ["Lifespan", 576], ["is", 585], ["not", 588], ["shortened", 592], [".", 601], ["The", 603], ["diagnosis", 607], ["of", 617], ["FSHD", 620], ["is", 625], ["based", 628], ["on", 634], ["a", 637], ["genetic", 639], ["test", 647], ["by", 652], ["which", 655], ["a", 661], ["deletion", 663], ["of", 672], ["3.3", 675], ["kb", 678], ["DNA", 681], ["repeats", 685], ["(", 693], ["named", 694], ["D4Z4", 700], ["and", 705], ["mapping", 709], ["to", 717], ["the", 720], ["subtelomeric", 724], ["region", 737], ["of", 744], ["chromosome", 747], ["4q35", 758], [")", 762], ["is", 764], ["identified", 767], [".", 777], ["The", 779], ["progressive", 783], ["pattern", 795], ["of", 803], ["FSHD", 806], ["requires", 811], ["that", 820], ["the", 825], ["severity", 829], ["of", 838], ["symptoms", 841], ["as", 850], ["well", 853], ["as", 858], ["their", 861], ["physical", 867], [",", 875], ["social", 877], ["and", 884], ["psychological", 888], ["impact", 902], ["be", 909], ["evaluated", 912], ["on", 922], ["a", 925], ["regular", 927], ["basis", 935], [".", 940], ["A", 942], ["yearly", 944], ["assessment", 951], ["is", 962], ["recommended", 965], [".", 976], ["Multidisciplinary", 978], ["management", 996], ["of", 1007], ["FSHD", 1010], ["--", 1014], ["consisting", 1016], ["of", 1027], ["a", 1030], ["combination", 1032], ["of", 1044], ["genetic", 1047], ["counselling", 1055], [",", 1066], ["functional", 1068], ["assessment", 1079], [",", 1089], ["an", 1091], ["assessment", 1094], ["by", 1105], ["a", 1108], ["physical", 1110], ["therapist", 1119], [",", 1128], ["prescription", 1130], ["of", 1143], ["symptomatic", 1146], ["therapies", 1158], ["and", 1168], ["prevention", 1172], ["of", 1183], ["known", 1186], ["complications", 1192], ["of", 1206], ["this", 1209], ["disease", 1214], ["--", 1221], ["is", 1223], ["required", 1226], [".", 1234], ["Prescription", 1236], ["of", 1249], ["physical", 1252], ["therapy", 1261], ["sessions", 1269], ["and", 1278], ["orthopedic", 1282], ["appliances", 1293], ["are", 1304], ["to", 1308], ["be", 1311], ["adapted", 1314], ["to", 1322], ["the", 1325], ["patient", 1329], ["'s", 1336], ["deficiencies", 1339], ["and", 1352], ["contractures", 1356], [".", 1368]]}
{"context": "Spectrins comprise \u03b1- and \u03b2-subunits made up predominantly of a series of homologous repeating units of about 106 amino acids; the \u03b1- and \u03b2-chains form antiparallel dimers by lateral association, and tetramers through head-to-head contacts between the dimers. Here we consider the first of these interactions. (1) We confirm earlier observations, showing that the first two paired repeats (\u03b2IR1 with \u03b1IR21, and \u03b2IR2 with \u03b1RI20) at one end of the erythroid spectrin (\u03b1I\u03b2I) dimer are necessary and sufficient to unite the chains; (2) we resolve a conflict in published reports by showing that the strength of the interaction is considerably increased on adding the adjoining pair of repeats (\u03b2IR3-\u03b1IR19); (3) in brain (\u03b1II\u03b2II) spectrin the first two pairs of repeats are similarly essential and sufficient for heterodimer formation; (4) this interaction is ~60-fold stronger than that in the erythroid counterpart, but no enhancement can be detected on addition of three further pairs of repeats; (5) formation of a tight \u03b1I\u03b2I dimer probably depends on structural coupling of the first two repeats in each chain; (6) an analysis of the sequences of the strongly interacting repeats, \u03b2IR1, \u03b2IIR1, \u03b1IR21 and \u03b1IIR20 and repeats in \u03b1-actinin, which also interact very strongly in forming an antiparallel dimer, affords a possible explanation for the different properties of the two spectrin isoforms in respect of the stability of the inter-chain interactions, and also suggests the evolutionary path by which the erythroid and non-erythroid sequences diverged.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "0cf3e09ca48743ab8afcd531f7b306e9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[248, 248], [30, 30]], "char_spans": [[1285, 1296], [152, 163]]}]}], "context_tokens": [["Spectrins", 0], ["comprise", 10], ["\u03b1-", 19], ["and", 22], ["\u03b2", 26], ["-", 27], ["subunits", 28], ["made", 37], ["up", 42], ["predominantly", 45], ["of", 59], ["a", 62], ["series", 64], ["of", 71], ["homologous", 74], ["repeating", 85], ["units", 95], ["of", 101], ["about", 104], ["106", 110], ["amino", 114], ["acids", 120], [";", 125], ["the", 127], ["\u03b1-", 131], ["and", 134], ["\u03b2", 138], ["-", 139], ["chains", 140], ["form", 147], ["antiparallel", 152], ["dimers", 165], ["by", 172], ["lateral", 175], ["association", 183], [",", 194], ["and", 196], ["tetramers", 200], ["through", 210], ["head", 218], ["-", 222], ["to", 223], ["-", 225], ["head", 226], ["contacts", 231], ["between", 240], ["the", 248], ["dimers", 252], [".", 258], ["Here", 260], ["we", 265], ["consider", 268], ["the", 277], ["first", 281], ["of", 287], ["these", 290], ["interactions", 296], [".", 308], ["(", 310], ["1", 311], [")", 312], ["We", 314], ["confirm", 317], ["earlier", 325], ["observations", 333], [",", 345], ["showing", 347], ["that", 355], ["the", 360], ["first", 364], ["two", 370], ["paired", 374], ["repeats", 381], ["(", 389], ["\u03b2IR1", 390], ["with", 395], ["\u03b1IR21", 400], [",", 405], ["and", 407], ["\u03b2IR2", 411], ["with", 416], ["\u03b1RI20", 421], [")", 426], ["at", 428], ["one", 431], ["end", 435], ["of", 439], ["the", 442], ["erythroid", 446], ["spectrin", 456], ["(", 465], ["\u03b1I\u03b2I", 466], [")", 470], ["dimer", 472], ["are", 478], ["necessary", 482], ["and", 492], ["sufficient", 496], ["to", 507], ["unite", 510], ["the", 516], ["chains", 520], [";", 526], ["(", 528], ["2", 529], [")", 530], ["we", 532], ["resolve", 535], ["a", 543], ["conflict", 545], ["in", 554], ["published", 557], ["reports", 567], ["by", 575], ["showing", 578], ["that", 586], ["the", 591], ["strength", 595], ["of", 604], ["the", 607], ["interaction", 611], ["is", 623], ["considerably", 626], ["increased", 639], ["on", 649], ["adding", 652], ["the", 659], ["adjoining", 663], ["pair", 673], ["of", 678], ["repeats", 681], ["(", 689], ["\u03b2IR3-\u03b1IR19", 690], [")", 700], [";", 701], ["(", 703], ["3", 704], [")", 705], ["in", 707], ["brain", 710], ["(", 716], ["\u03b1II\u03b2II", 717], [")", 723], ["spectrin", 725], ["the", 734], ["first", 738], ["two", 744], ["pairs", 748], ["of", 754], ["repeats", 757], ["are", 765], ["similarly", 769], ["essential", 779], ["and", 789], ["sufficient", 793], ["for", 804], ["heterodimer", 808], ["formation", 820], [";", 829], ["(", 831], ["4", 832], [")", 833], ["this", 835], ["interaction", 840], ["is", 852], ["~60-fold", 855], ["stronger", 864], ["than", 873], ["that", 878], ["in", 883], ["the", 886], ["erythroid", 890], ["counterpart", 900], [",", 911], ["but", 913], ["no", 917], ["enhancement", 920], ["can", 932], ["be", 936], ["detected", 939], ["on", 948], ["addition", 951], ["of", 960], ["three", 963], ["further", 969], ["pairs", 977], ["of", 983], ["repeats", 986], [";", 993], ["(", 995], ["5", 996], [")", 997], ["formation", 999], ["of", 1009], ["a", 1012], ["tight", 1014], ["\u03b1I\u03b2I", 1020], ["dimer", 1025], ["probably", 1031], ["depends", 1040], ["on", 1048], ["structural", 1051], ["coupling", 1062], ["of", 1071], ["the", 1074], ["first", 1078], ["two", 1084], ["repeats", 1088], ["in", 1096], ["each", 1099], ["chain", 1104], [";", 1109], ["(", 1111], ["6", 1112], [")", 1113], ["an", 1115], ["analysis", 1118], ["of", 1127], ["the", 1130], ["sequences", 1134], ["of", 1144], ["the", 1147], ["strongly", 1151], ["interacting", 1160], ["repeats", 1172], [",", 1179], ["\u03b2IR1", 1181], [",", 1185], ["\u03b2IIR1", 1187], [",", 1192], ["\u03b1IR21", 1194], ["and", 1200], ["\u03b1IIR20", 1204], ["and", 1211], ["repeats", 1215], ["in", 1223], ["\u03b1", 1226], ["-", 1227], ["actinin", 1228], [",", 1235], ["which", 1237], ["also", 1243], ["interact", 1248], ["very", 1257], ["strongly", 1262], ["in", 1271], ["forming", 1274], ["an", 1282], ["antiparallel", 1285], ["dimer", 1298], [",", 1303], ["affords", 1305], ["a", 1313], ["possible", 1315], ["explanation", 1324], ["for", 1336], ["the", 1340], ["different", 1344], ["properties", 1354], ["of", 1365], ["the", 1368], ["two", 1372], ["spectrin", 1376], ["isoforms", 1385], ["in", 1394], ["respect", 1397], ["of", 1405], ["the", 1408], ["stability", 1412], ["of", 1422], ["the", 1425], ["inter", 1429], ["-", 1434], ["chain", 1435], ["interactions", 1441], [",", 1453], ["and", 1455], ["also", 1459], ["suggests", 1464], ["the", 1473], ["evolutionary", 1477], ["path", 1490], ["by", 1495], ["which", 1498], ["the", 1504], ["erythroid", 1508], ["and", 1518], ["non", 1522], ["-", 1525], ["erythroid", 1526], ["sequences", 1536], ["diverged", 1546], [".", 1554]]}
{"context": "Spectrin, the major component of the erythroid membrane skeleton, is a long, asymmetrical rodlike protein that interacts with several other proteins to form a two-dimensional membrane skeleton. Progress in several laboratories over the past few years including substantial partial peptide and nucleotide sequence determination has greatly enhanced our knowledge of the structural properties of this large molecule (heterodimer = 465,000 daltons). The alpha and beta subunits are homologous with approximately 30% identity. They are aligned in an antiparallel side-to-side orientation with the amino- and carboxy-termini near opposite physical ends of the molecule. The predominant structural feature elucidated from sequencing this large molecule is the nearly universal occurrence in both subunits of a single type of repetitive structure. The periodicity of this homologous structure is exactly 106 amino acid residues. As many as 36 homologous, but nonidentical, repeats exist and comprise more than 90% of the mass of the heterodimer. Each of these repetitive units is folded into a triple-stranded structure that is highly helical. Peptide maps, antibody crossreactivity, peptide sequence analysis, and more recently nucleic acid sequences have defined several major properties of the erythroid molecule and related proteins in other tissues. Tissue-specific spectrins have the same 106-residue repetitive structure and show sequence homology to erythroid spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "98eb6a6cc03a4c00a5f1dbda3e4cead5", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[88, 88]], "char_spans": [[546, 557]]}]}], "context_tokens": [["Spectrin", 0], [",", 8], ["the", 10], ["major", 14], ["component", 20], ["of", 30], ["the", 33], ["erythroid", 37], ["membrane", 47], ["skeleton", 56], [",", 64], ["is", 66], ["a", 69], ["long", 71], [",", 75], ["asymmetrical", 77], ["rodlike", 90], ["protein", 98], ["that", 106], ["interacts", 111], ["with", 121], ["several", 126], ["other", 134], ["proteins", 140], ["to", 149], ["form", 152], ["a", 157], ["two", 159], ["-", 162], ["dimensional", 163], ["membrane", 175], ["skeleton", 184], [".", 192], ["Progress", 194], ["in", 203], ["several", 206], ["laboratories", 214], ["over", 227], ["the", 232], ["past", 236], ["few", 241], ["years", 245], ["including", 251], ["substantial", 261], ["partial", 273], ["peptide", 281], ["and", 289], ["nucleotide", 293], ["sequence", 304], ["determination", 313], ["has", 327], ["greatly", 331], ["enhanced", 339], ["our", 348], ["knowledge", 352], ["of", 362], ["the", 365], ["structural", 369], ["properties", 380], ["of", 391], ["this", 394], ["large", 399], ["molecule", 405], ["(", 414], ["heterodimer", 415], ["=", 427], ["465,000", 429], ["daltons", 437], [")", 444], [".", 445], ["The", 447], ["alpha", 451], ["and", 457], ["beta", 461], ["subunits", 466], ["are", 475], ["homologous", 479], ["with", 490], ["approximately", 495], ["30", 509], ["%", 511], ["identity", 513], [".", 521], ["They", 523], ["are", 528], ["aligned", 532], ["in", 540], ["an", 543], ["antiparallel", 546], ["side", 559], ["-", 563], ["to", 564], ["-", 566], ["side", 567], ["orientation", 572], ["with", 584], ["the", 589], ["amino-", 593], ["and", 600], ["carboxy", 604], ["-", 611], ["termini", 612], ["near", 620], ["opposite", 625], ["physical", 634], ["ends", 643], ["of", 648], ["the", 651], ["molecule", 655], [".", 663], ["The", 665], ["predominant", 669], ["structural", 681], ["feature", 692], ["elucidated", 700], ["from", 711], ["sequencing", 716], ["this", 727], ["large", 732], ["molecule", 738], ["is", 747], ["the", 750], ["nearly", 754], ["universal", 761], ["occurrence", 771], ["in", 782], ["both", 785], ["subunits", 790], ["of", 799], ["a", 802], ["single", 804], ["type", 811], ["of", 816], ["repetitive", 819], ["structure", 830], [".", 839], ["The", 841], ["periodicity", 845], ["of", 857], ["this", 860], ["homologous", 865], ["structure", 876], ["is", 886], ["exactly", 889], ["106", 897], ["amino", 901], ["acid", 907], ["residues", 912], [".", 920], ["As", 922], ["many", 925], ["as", 930], ["36", 933], ["homologous", 936], [",", 946], ["but", 948], ["nonidentical", 952], [",", 964], ["repeats", 966], ["exist", 974], ["and", 980], ["comprise", 984], ["more", 993], ["than", 998], ["90", 1003], ["%", 1005], ["of", 1007], ["the", 1010], ["mass", 1014], ["of", 1019], ["the", 1022], ["heterodimer", 1026], [".", 1037], ["Each", 1039], ["of", 1044], ["these", 1047], ["repetitive", 1053], ["units", 1064], ["is", 1070], ["folded", 1073], ["into", 1080], ["a", 1085], ["triple", 1087], ["-", 1093], ["stranded", 1094], ["structure", 1103], ["that", 1113], ["is", 1118], ["highly", 1121], ["helical", 1128], [".", 1135], ["Peptide", 1137], ["maps", 1145], [",", 1149], ["antibody", 1151], ["crossreactivity", 1160], [",", 1175], ["peptide", 1177], ["sequence", 1185], ["analysis", 1194], [",", 1202], ["and", 1204], ["more", 1208], ["recently", 1213], ["nucleic", 1222], ["acid", 1230], ["sequences", 1235], ["have", 1245], ["defined", 1250], ["several", 1258], ["major", 1266], ["properties", 1272], ["of", 1283], ["the", 1286], ["erythroid", 1290], ["molecule", 1300], ["and", 1309], ["related", 1313], ["proteins", 1321], ["in", 1330], ["other", 1333], ["tissues", 1339], [".", 1346], ["Tissue", 1348], ["-", 1354], ["specific", 1355], ["spectrins", 1364], ["have", 1374], ["the", 1379], ["same", 1383], ["106-residue", 1388], ["repetitive", 1400], ["structure", 1411], ["and", 1421], ["show", 1425], ["sequence", 1430], ["homology", 1439], ["to", 1448], ["erythroid", 1451], ["spectrin", 1461], [".", 1469]]}
{"context": "Chaperone-mediated autophagy (CMA) is a selective autophagy-lysosome protein degradation pathway. The role of CMA in normal neuronal functions and in neural disease pathogenesis remains unclear, in part because there is no available method to monitor CMA activity at the single-cell level. We sought to establish a single-cell monitoring method by visualizing translocation of CMA substrates from the cytosol to lysosomes using the HaloTag (HT) system. GAPDH, a CMA substrate, was fused to HT (GAPDH-HT); this protein accumulated in the lysosomes of HeLa cells and cultured cerebellar Purkinje cells (PCs) after labeling with fluorescent dye-conjugated HT ligand. Lysosomal accumulation was enhanced by treatments that activate CMA and prevented by siRNA-mediated knockdown of LAMP2A, a lysosomal receptor for CMA, and by treatments that inactivate CMA. These results suggest that lysosomal accumulation of GAPDH-HT reflects CMA activity. Using this method, we revealed that mutant \u03b3PKC, which causes spinocerebellar ataxia type 14, decreased CMA activity in cultured PCs. In the present study, we established a novel fluorescent-based method to evaluate CMA activity in a single neuron. This novel method should be useful and valuable for evaluating the role of CMA in various neuronal functions and neural disease pathogenesis.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "86bd299403624adfa79bf2ac1de79528", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[141, 141]], "char_spans": [[777, 782]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["(", 29], ["CMA", 30], [")", 33], ["is", 35], ["a", 38], ["selective", 40], ["autophagy", 50], ["-", 59], ["lysosome", 60], ["protein", 69], ["degradation", 77], ["pathway", 89], [".", 96], ["The", 98], ["role", 102], ["of", 107], ["CMA", 110], ["in", 114], ["normal", 117], ["neuronal", 124], ["functions", 133], ["and", 143], ["in", 147], ["neural", 150], ["disease", 157], ["pathogenesis", 165], ["remains", 178], ["unclear", 186], [",", 193], ["in", 195], ["part", 198], ["because", 203], ["there", 211], ["is", 217], ["no", 220], ["available", 223], ["method", 233], ["to", 240], ["monitor", 243], ["CMA", 251], ["activity", 255], ["at", 264], ["the", 267], ["single", 271], ["-", 277], ["cell", 278], ["level", 283], [".", 288], ["We", 290], ["sought", 293], ["to", 300], ["establish", 303], ["a", 313], ["single", 315], ["-", 321], ["cell", 322], ["monitoring", 327], ["method", 338], ["by", 345], ["visualizing", 348], ["translocation", 360], ["of", 374], ["CMA", 377], ["substrates", 381], ["from", 392], ["the", 397], ["cytosol", 401], ["to", 409], ["lysosomes", 412], ["using", 422], ["the", 428], ["HaloTag", 432], ["(", 440], ["HT", 441], [")", 443], ["system", 445], [".", 451], ["GAPDH", 453], [",", 458], ["a", 460], ["CMA", 462], ["substrate", 466], [",", 475], ["was", 477], ["fused", 481], ["to", 487], ["HT", 490], ["(", 493], ["GAPDH", 494], ["-", 499], ["HT", 500], [")", 502], [";", 503], ["this", 505], ["protein", 510], ["accumulated", 518], ["in", 530], ["the", 533], ["lysosomes", 537], ["of", 547], ["HeLa", 550], ["cells", 555], ["and", 561], ["cultured", 565], ["cerebellar", 574], ["Purkinje", 585], ["cells", 594], ["(", 600], ["PCs", 601], [")", 604], ["after", 606], ["labeling", 612], ["with", 621], ["fluorescent", 626], ["dye", 638], ["-", 641], ["conjugated", 642], ["HT", 653], ["ligand", 656], [".", 662], ["Lysosomal", 664], ["accumulation", 674], ["was", 687], ["enhanced", 691], ["by", 700], ["treatments", 703], ["that", 714], ["activate", 719], ["CMA", 728], ["and", 732], ["prevented", 736], ["by", 746], ["siRNA", 749], ["-", 754], ["mediated", 755], ["knockdown", 764], ["of", 774], ["LAMP2A", 777], [",", 783], ["a", 785], ["lysosomal", 787], ["receptor", 797], ["for", 806], ["CMA", 810], [",", 813], ["and", 815], ["by", 819], ["treatments", 822], ["that", 833], ["inactivate", 838], ["CMA", 849], [".", 852], ["These", 854], ["results", 860], ["suggest", 868], ["that", 876], ["lysosomal", 881], ["accumulation", 891], ["of", 904], ["GAPDH", 907], ["-", 912], ["HT", 913], ["reflects", 916], ["CMA", 925], ["activity", 929], [".", 937], ["Using", 939], ["this", 945], ["method", 950], [",", 956], ["we", 958], ["revealed", 961], ["that", 970], ["mutant", 975], ["\u03b3PKC", 982], [",", 986], ["which", 988], ["causes", 994], ["spinocerebellar", 1001], ["ataxia", 1017], ["type", 1024], ["14", 1029], [",", 1031], ["decreased", 1033], ["CMA", 1043], ["activity", 1047], ["in", 1056], ["cultured", 1059], ["PCs", 1068], [".", 1071], ["In", 1073], ["the", 1076], ["present", 1080], ["study", 1088], [",", 1093], ["we", 1095], ["established", 1098], ["a", 1110], ["novel", 1112], ["fluorescent", 1118], ["-", 1129], ["based", 1130], ["method", 1136], ["to", 1143], ["evaluate", 1146], ["CMA", 1155], ["activity", 1159], ["in", 1168], ["a", 1171], ["single", 1173], ["neuron", 1180], [".", 1186], ["This", 1188], ["novel", 1193], ["method", 1199], ["should", 1206], ["be", 1213], ["useful", 1216], ["and", 1223], ["valuable", 1227], ["for", 1236], ["evaluating", 1240], ["the", 1251], ["role", 1255], ["of", 1260], ["CMA", 1263], ["in", 1267], ["various", 1270], ["neuronal", 1278], ["functions", 1287], ["and", 1297], ["neural", 1301], ["disease", 1308], ["pathogenesis", 1316], [".", 1328]]}
{"context": "L-DOPA-induced dyskinesia is a common side effect developed after chronic treatment with 3,4-dihydroxyphenyl-l-alanine (l-DOPA) in Parkinson's disease. The biological mechanisms behind this side effect are not fully comprehended although involvement of dopaminergic, serotonergic, and glutamatergic systems has been suggested. The present study utilizes in vivo amperometry to investigate the impact from unilateral 6-hydroxydopamine lesions and l-DOPA (4 mg/kg, including benserazide 15 mg/kg) -induced dyskinetic behavior on striatal basal extracellular glutamate concentration and potassium-evoked glutamate release in urethane-anesthetized rats. Recordings were performed before and after local L-DOPA application in the striatum. In addition, effects from the 5-HT(1A) receptor agonist (2R)-(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OHDPAT; 1 mg/kg) was assessed on glutamate release and on dyskinetic behavior. The results revealed a bilateral \u2248 30% reduction of basal extracellular glutamate concentration and attenuated potassium-evoked glutamate release after a unilateral dopamine-depletion in L-DOPA na\u00efve animals. In dyskinetic subjects, basal glutamate concentration was comparable to normal controls, although potassium-evoked glutamate release was reduced to similar levels as in drug na\u00efve dopamine-lesioned animals. Furthermore, acute striatal L-DOPA administration attenuated glutamate release in all groups, except in the dopamine-lesioned striatum of dyskinetic animals. Co-administration of 8-OHDPAT and L-DOPA decreased dyskinesia in dopamine-lesioned animals, but did not affect potassium-evoked glutamate release, which was seen in normal animals. These findings indicate altered glutamate transmission upon dopamine-depletion and dyskinesia.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "51cc9b8c720b4a8da80558914feaa7f7", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[258, 260], [22, 24], [116, 118], [230, 232], [72, 74], [0, 2], [187, 189]], "char_spans": [[1542, 1547], [120, 125], [699, 704], [1378, 1383], [446, 451], [0, 5], [1121, 1126]]}]}], "context_tokens": [["L", 0], ["-", 1], ["DOPA", 2], ["-", 6], ["induced", 7], ["dyskinesia", 15], ["is", 26], ["a", 29], ["common", 31], ["side", 38], ["effect", 43], ["developed", 50], ["after", 60], ["chronic", 66], ["treatment", 74], ["with", 84], ["3,4-dihydroxyphenyl", 89], ["-", 108], ["l", 109], ["-", 110], ["alanine", 111], ["(", 119], ["l", 120], ["-", 121], ["DOPA", 122], [")", 126], ["in", 128], ["Parkinson", 131], ["'s", 140], ["disease", 143], [".", 150], ["The", 152], ["biological", 156], ["mechanisms", 167], ["behind", 178], ["this", 185], ["side", 190], ["effect", 195], ["are", 202], ["not", 206], ["fully", 210], ["comprehended", 216], ["although", 229], ["involvement", 238], ["of", 250], ["dopaminergic", 253], [",", 265], ["serotonergic", 267], [",", 279], ["and", 281], ["glutamatergic", 285], ["systems", 299], ["has", 307], ["been", 311], ["suggested", 316], [".", 325], ["The", 327], ["present", 331], ["study", 339], ["utilizes", 345], ["in", 354], ["vivo", 357], ["amperometry", 362], ["to", 374], ["investigate", 377], ["the", 389], ["impact", 393], ["from", 400], ["unilateral", 405], ["6-hydroxydopamine", 416], ["lesions", 434], ["and", 442], ["l", 446], ["-", 447], ["DOPA", 448], ["(", 453], ["4", 454], ["mg", 456], ["/", 458], ["kg", 459], [",", 461], ["including", 463], ["benserazide", 473], ["15", 485], ["mg", 488], ["/", 490], ["kg", 491], [")", 493], ["-induced", 495], ["dyskinetic", 504], ["behavior", 515], ["on", 524], ["striatal", 527], ["basal", 536], ["extracellular", 542], ["glutamate", 556], ["concentration", 566], ["and", 580], ["potassium", 584], ["-", 593], ["evoked", 594], ["glutamate", 601], ["release", 611], ["in", 619], ["urethane", 622], ["-", 630], ["anesthetized", 631], ["rats", 644], [".", 648], ["Recordings", 650], ["were", 661], ["performed", 666], ["before", 676], ["and", 683], ["after", 687], ["local", 693], ["L", 699], ["-", 700], ["DOPA", 701], ["application", 706], ["in", 718], ["the", 721], ["striatum", 725], [".", 733], ["In", 735], ["addition", 738], [",", 746], ["effects", 748], ["from", 756], ["the", 761], ["5-HT(1A", 765], [")", 772], ["receptor", 774], ["agonist", 783], ["(", 791], ["2R)-(+)-8-hydroxy-2-(di", 792], ["-", 815], ["n", 816], ["-", 817], ["propylamino)tetralin", 818], ["hydrobromide", 839], ["(", 852], ["8-OHDPAT", 853], [";", 861], ["1", 863], ["mg", 865], ["/", 867], ["kg", 868], [")", 870], ["was", 872], ["assessed", 876], ["on", 885], ["glutamate", 888], ["release", 898], ["and", 906], ["on", 910], ["dyskinetic", 913], ["behavior", 924], [".", 932], ["The", 934], ["results", 938], ["revealed", 946], ["a", 955], ["bilateral", 957], ["\u2248", 967], ["30", 969], ["%", 971], ["reduction", 973], ["of", 983], ["basal", 986], ["extracellular", 992], ["glutamate", 1006], ["concentration", 1016], ["and", 1030], ["attenuated", 1034], ["potassium", 1045], ["-", 1054], ["evoked", 1055], ["glutamate", 1062], ["release", 1072], ["after", 1080], ["a", 1086], ["unilateral", 1088], ["dopamine", 1099], ["-", 1107], ["depletion", 1108], ["in", 1118], ["L", 1121], ["-", 1122], ["DOPA", 1123], ["na\u00efve", 1128], ["animals", 1134], [".", 1141], ["In", 1143], ["dyskinetic", 1146], ["subjects", 1157], [",", 1165], ["basal", 1167], ["glutamate", 1173], ["concentration", 1183], ["was", 1197], ["comparable", 1201], ["to", 1212], ["normal", 1215], ["controls", 1222], [",", 1230], ["although", 1232], ["potassium", 1241], ["-", 1250], ["evoked", 1251], ["glutamate", 1258], ["release", 1268], ["was", 1276], ["reduced", 1280], ["to", 1288], ["similar", 1291], ["levels", 1299], ["as", 1306], ["in", 1309], ["drug", 1312], ["na\u00efve", 1317], ["dopamine", 1323], ["-", 1331], ["lesioned", 1332], ["animals", 1341], [".", 1348], ["Furthermore", 1350], [",", 1361], ["acute", 1363], ["striatal", 1369], ["L", 1378], ["-", 1379], ["DOPA", 1380], ["administration", 1385], ["attenuated", 1400], ["glutamate", 1411], ["release", 1421], ["in", 1429], ["all", 1432], ["groups", 1436], [",", 1442], ["except", 1444], ["in", 1451], ["the", 1454], ["dopamine", 1458], ["-", 1466], ["lesioned", 1467], ["striatum", 1476], ["of", 1485], ["dyskinetic", 1488], ["animals", 1499], [".", 1506], ["Co", 1508], ["-", 1510], ["administration", 1511], ["of", 1526], ["8-OHDPAT", 1529], ["and", 1538], ["L", 1542], ["-", 1543], ["DOPA", 1544], ["decreased", 1549], ["dyskinesia", 1559], ["in", 1570], ["dopamine", 1573], ["-", 1581], ["lesioned", 1582], ["animals", 1591], [",", 1598], ["but", 1600], ["did", 1604], ["not", 1608], ["affect", 1612], ["potassium", 1619], ["-", 1628], ["evoked", 1629], ["glutamate", 1636], ["release", 1646], [",", 1653], ["which", 1655], ["was", 1661], ["seen", 1665], ["in", 1670], ["normal", 1673], ["animals", 1680], [".", 1687], ["These", 1689], ["findings", 1695], ["indicate", 1704], ["altered", 1713], ["glutamate", 1721], ["transmission", 1731], ["upon", 1744], ["dopamine", 1749], ["-", 1757], ["depletion", 1758], ["and", 1768], ["dyskinesia", 1772], [".", 1782]]}
{"context": "Osteoporosis and several other bone disorders occur when there is an imbalance between the resorption and formation components of bone remodeling activity. Therapies available for some of these conditions modulate the activity of osteoclasts and/or osteoblasts. The recent discoveries of receptor activator of NF-kappaB ligand (RANKL), an endogenous activator of osteoclastogenenesis and osteoclast activity and its inhibitor, osteoprotegerin (OPG) as pivotal regulatory factors in the pathogenesis of bone diseases like osteoporosis provide unique targets for therapeutic agents. In laboratory animals and now in humans, administering forms of OPG markedly inhibits osteoclast activity and improves bone strength, documenting that the strategy of inhibiting RANKL activity has therapeutic promise. A highly specific, fully human antibody against RANKL has been produced (denosumab) that in early studies in humans reduces bone turnover and improves bone density. Attributes of denosumab in these clinical studies include a very rapid onset of action, sustained effects for several months after a single injection, and good tolerability. These results provide the basis for studies evaluating the effectiveness of denosumab in several clinical conditions characterized by increased osteoclastic activity.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "93cde7c0b055488588b25d93e9cddb8a", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[129, 129], [115, 115], [50, 50]], "char_spans": [[847, 851], [759, 763], [328, 332]]}]}], "context_tokens": [["Osteoporosis", 0], ["and", 13], ["several", 17], ["other", 25], ["bone", 31], ["disorders", 36], ["occur", 46], ["when", 52], ["there", 57], ["is", 63], ["an", 66], ["imbalance", 69], ["between", 79], ["the", 87], ["resorption", 91], ["and", 102], ["formation", 106], ["components", 116], ["of", 127], ["bone", 130], ["remodeling", 135], ["activity", 146], [".", 154], ["Therapies", 156], ["available", 166], ["for", 176], ["some", 180], ["of", 185], ["these", 188], ["conditions", 194], ["modulate", 205], ["the", 214], ["activity", 218], ["of", 227], ["osteoclasts", 230], ["and/or", 242], ["osteoblasts", 249], [".", 260], ["The", 262], ["recent", 266], ["discoveries", 273], ["of", 285], ["receptor", 288], ["activator", 297], ["of", 307], ["NF", 310], ["-", 312], ["kappaB", 313], ["ligand", 320], ["(", 327], ["RANKL", 328], [")", 333], [",", 334], ["an", 336], ["endogenous", 339], ["activator", 350], ["of", 360], ["osteoclastogenenesis", 363], ["and", 384], ["osteoclast", 388], ["activity", 399], ["and", 408], ["its", 412], ["inhibitor", 416], [",", 425], ["osteoprotegerin", 427], ["(", 443], ["OPG", 444], [")", 447], ["as", 449], ["pivotal", 452], ["regulatory", 460], ["factors", 471], ["in", 479], ["the", 482], ["pathogenesis", 486], ["of", 499], ["bone", 502], ["diseases", 507], ["like", 516], ["osteoporosis", 521], ["provide", 534], ["unique", 542], ["targets", 549], ["for", 557], ["therapeutic", 561], ["agents", 573], [".", 579], ["In", 581], ["laboratory", 584], ["animals", 595], ["and", 603], ["now", 607], ["in", 611], ["humans", 614], [",", 620], ["administering", 622], ["forms", 636], ["of", 642], ["OPG", 645], ["markedly", 649], ["inhibits", 658], ["osteoclast", 667], ["activity", 678], ["and", 687], ["improves", 691], ["bone", 700], ["strength", 705], [",", 713], ["documenting", 715], ["that", 727], ["the", 732], ["strategy", 736], ["of", 745], ["inhibiting", 748], ["RANKL", 759], ["activity", 765], ["has", 774], ["therapeutic", 778], ["promise", 790], [".", 797], ["A", 799], ["highly", 801], ["specific", 808], [",", 816], ["fully", 818], ["human", 824], ["antibody", 830], ["against", 839], ["RANKL", 847], ["has", 853], ["been", 857], ["produced", 862], ["(", 871], ["denosumab", 872], [")", 881], ["that", 883], ["in", 888], ["early", 891], ["studies", 897], ["in", 905], ["humans", 908], ["reduces", 915], ["bone", 923], ["turnover", 928], ["and", 937], ["improves", 941], ["bone", 950], ["density", 955], [".", 962], ["Attributes", 964], ["of", 975], ["denosumab", 978], ["in", 988], ["these", 991], ["clinical", 997], ["studies", 1006], ["include", 1014], ["a", 1022], ["very", 1024], ["rapid", 1029], ["onset", 1035], ["of", 1041], ["action", 1044], [",", 1050], ["sustained", 1052], ["effects", 1062], ["for", 1070], ["several", 1074], ["months", 1082], ["after", 1089], ["a", 1095], ["single", 1097], ["injection", 1104], [",", 1113], ["and", 1115], ["good", 1119], ["tolerability", 1124], [".", 1136], ["These", 1138], ["results", 1144], ["provide", 1152], ["the", 1160], ["basis", 1164], ["for", 1170], ["studies", 1174], ["evaluating", 1182], ["the", 1193], ["effectiveness", 1197], ["of", 1211], ["denosumab", 1214], ["in", 1224], ["several", 1227], ["clinical", 1235], ["conditions", 1244], ["characterized", 1255], ["by", 1269], ["increased", 1272], ["osteoclastic", 1282], ["activity", 1295], [".", 1303]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a potent mediator of inflammatory responses and plays a role in the differentiation of a number of lymphoid cells. In several inflammatory and autoimmune diseases, serum levels of IL-1\u03b2 are elevated and correlate with disease development and severity. The central role of the IL-1 pathway in several diseases has been validated by inhibitors currently in clinical development or approved by the FDA. However, the need to effectively modulate IL-1\u03b2-mediated local inflammation with the systemic delivery of an efficacious, safe and convenient drug still exists. To meet these challenges, we developed XOMA 052 (gevokizumab), a potent anti-IL-1\u03b2 neutralizing antibody that was designed in silico and humanized using Human Engineering\u2122 technology. XOMA 052 has a 300 femtomolar binding affinity for human IL-1\u03b2 and an in vitro potency in the low picomolar range. XOMA 052 binds to a unique IL-1\u03b2 epitope where residues critical for binding have been identified. We have previously reported that XOMA 052 is efficacious in vivo in a diet-induced obesity mouse model thought to be driven by low levels of chronic inflammation. We report here that XOMA 052 also reduces acute inflammation in vivo, neutralizing the effect of exogenously administered human IL-1\u03b2 and blocking peritonitis in a mouse model of acute gout. Based on its high potency, novel mechanism of action, long half-life, and high affinity, XOMA 052 provides a new strategy for the treatment of a number of inflammatory, autoimmune and metabolic diseases in which the role of IL-1\u03b2 is central to pathogenesis.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "f129d78a420746cd9b0364aa8ac1fa28", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[141, 141], [35, 35], [115, 115], [2, 2], [220, 220], [276, 276], [78, 78], [159, 159]], "char_spans": [[828, 832], [206, 210], [664, 668], [16, 20], [1276, 1280], [1563, 1567], [468, 472], [913, 917]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["potent", 28], ["mediator", 35], ["of", 44], ["inflammatory", 47], ["responses", 60], ["and", 70], ["plays", 74], ["a", 80], ["role", 82], ["in", 87], ["the", 90], ["differentiation", 94], ["of", 110], ["a", 113], ["number", 115], ["of", 122], ["lymphoid", 125], ["cells", 134], [".", 139], ["In", 141], ["several", 144], ["inflammatory", 152], ["and", 165], ["autoimmune", 169], ["diseases", 180], [",", 188], ["serum", 190], ["levels", 196], ["of", 203], ["IL-1\u03b2", 206], ["are", 212], ["elevated", 216], ["and", 225], ["correlate", 229], ["with", 239], ["disease", 244], ["development", 252], ["and", 264], ["severity", 268], [".", 276], ["The", 278], ["central", 282], ["role", 290], ["of", 295], ["the", 298], ["IL-1", 302], ["pathway", 307], ["in", 315], ["several", 318], ["diseases", 326], ["has", 335], ["been", 339], ["validated", 344], ["by", 354], ["inhibitors", 357], ["currently", 368], ["in", 378], ["clinical", 381], ["development", 390], ["or", 402], ["approved", 405], ["by", 414], ["the", 417], ["FDA", 421], [".", 424], ["However", 426], [",", 433], ["the", 435], ["need", 439], ["to", 444], ["effectively", 447], ["modulate", 459], ["IL-1\u03b2", 468], ["-", 473], ["mediated", 474], ["local", 483], ["inflammation", 489], ["with", 502], ["the", 507], ["systemic", 511], ["delivery", 520], ["of", 529], ["an", 532], ["efficacious", 535], [",", 546], ["safe", 548], ["and", 553], ["convenient", 557], ["drug", 568], ["still", 573], ["exists", 579], [".", 585], ["To", 587], ["meet", 590], ["these", 595], ["challenges", 601], [",", 611], ["we", 613], ["developed", 616], ["XOMA", 626], ["052", 631], ["(", 635], ["gevokizumab", 636], [")", 647], [",", 648], ["a", 650], ["potent", 652], ["anti", 659], ["-", 663], ["IL-1\u03b2", 664], ["neutralizing", 670], ["antibody", 683], ["that", 692], ["was", 697], ["designed", 701], ["in", 710], ["silico", 713], ["and", 720], ["humanized", 724], ["using", 734], ["Human", 740], ["Engineering", 746], ["\u2122", 757], ["technology", 759], [".", 769], ["XOMA", 771], ["052", 776], ["has", 780], ["a", 784], ["300", 786], ["femtomolar", 790], ["binding", 801], ["affinity", 809], ["for", 818], ["human", 822], ["IL-1\u03b2", 828], ["and", 834], ["an", 838], ["in", 841], ["vitro", 844], ["potency", 850], ["in", 858], ["the", 861], ["low", 865], ["picomolar", 869], ["range", 879], [".", 884], ["XOMA", 886], ["052", 891], ["binds", 895], ["to", 901], ["a", 904], ["unique", 906], ["IL-1\u03b2", 913], ["epitope", 919], ["where", 927], ["residues", 933], ["critical", 942], ["for", 951], ["binding", 955], ["have", 963], ["been", 968], ["identified", 973], [".", 983], ["We", 985], ["have", 988], ["previously", 993], ["reported", 1004], ["that", 1013], ["XOMA", 1018], ["052", 1023], ["is", 1027], ["efficacious", 1030], ["in", 1042], ["vivo", 1045], ["in", 1050], ["a", 1053], ["diet", 1055], ["-", 1059], ["induced", 1060], ["obesity", 1068], ["mouse", 1076], ["model", 1082], ["thought", 1088], ["to", 1096], ["be", 1099], ["driven", 1102], ["by", 1109], ["low", 1112], ["levels", 1116], ["of", 1123], ["chronic", 1126], ["inflammation", 1134], [".", 1146], ["We", 1148], ["report", 1151], ["here", 1158], ["that", 1163], ["XOMA", 1168], ["052", 1173], ["also", 1177], ["reduces", 1182], ["acute", 1190], ["inflammation", 1196], ["in", 1209], ["vivo", 1212], [",", 1216], ["neutralizing", 1218], ["the", 1231], ["effect", 1235], ["of", 1242], ["exogenously", 1245], ["administered", 1257], ["human", 1270], ["IL-1\u03b2", 1276], ["and", 1282], ["blocking", 1286], ["peritonitis", 1295], ["in", 1307], ["a", 1310], ["mouse", 1312], ["model", 1318], ["of", 1324], ["acute", 1327], ["gout", 1333], [".", 1337], ["Based", 1339], ["on", 1345], ["its", 1348], ["high", 1352], ["potency", 1357], [",", 1364], ["novel", 1366], ["mechanism", 1372], ["of", 1382], ["action", 1385], [",", 1391], ["long", 1393], ["half", 1398], ["-", 1402], ["life", 1403], [",", 1407], ["and", 1409], ["high", 1413], ["affinity", 1418], [",", 1426], ["XOMA", 1428], ["052", 1433], ["provides", 1437], ["a", 1446], ["new", 1448], ["strategy", 1452], ["for", 1461], ["the", 1465], ["treatment", 1469], ["of", 1479], ["a", 1482], ["number", 1484], ["of", 1491], ["inflammatory", 1494], [",", 1506], ["autoimmune", 1508], ["and", 1519], ["metabolic", 1523], ["diseases", 1533], ["in", 1542], ["which", 1545], ["the", 1551], ["role", 1555], ["of", 1560], ["IL-1\u03b2", 1563], ["is", 1569], ["central", 1572], ["to", 1580], ["pathogenesis", 1583], [".", 1595]]}
{"context": "We previously identified a mammalian Set1A complex analogous to the yeast Set1/COMPASS histone H3-Lys4 methyltransferase complex (Lee, J.-H., and Skalnik, D. G. (2005) J. Biol. Chem. 280, 41725-41731). Data base analysis indicates that human Set1A protein shares 39% identity with an uncharacterized SET domain protein, KIAA1076, hereafter denoted Set1B. Immunoprecipitation and mass spectrometry reveal that Set1B associates with a approximately 450 kDa complex that contains all five non-catalytic components of the Set1A complex, including CFP1, Rbbp5, Ash2, Wdr5, and Wdr82. These data reveal two human protein complexes that differ only in the identity of the catalytic histone methyltransferase. In vitro assays demonstrate that the Set1B complex is a histone methyltransferase that produces trimethylated histone H3 at Lys(4). Both Set1A and Set1B are widely expressed. Inducible expression of the carboxyl terminus of either Set1A or Set1B decreases steady-state levels of both endogenous Set1A and Set1B protein, but does not alter the expression of the non-catalytic components of the Set1 complexes. A 123-amino acid fragment upstream of the Set1A SET domain is necessary for interaction with CFP1, Ash2, Rbbp5, and Wdr5. This protein domain is also required to mediate feedback inhibition of Set1A and Set1B expression, which is a consequence of reduced Set1A and Set1B stability when not associated with the methyltransferase complex. Confocal microscopy reveals that Set1A and Set1B each localize to a largely non-overlapping set of euchromatic nuclear speckles, suggesting that Set1A and Set1B each bind to a unique set of target genes and thus make non-redundant contributions to the epigenetic control of chromatin structure and gene expression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "7b483c4cbcd8422c8a975ae0c76fa06c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[56, 57], [201, 202]], "char_spans": [[300, 309], [1159, 1168]]}]}], "context_tokens": [["We", 0], ["previously", 3], ["identified", 14], ["a", 25], ["mammalian", 27], ["Set1A", 37], ["complex", 43], ["analogous", 51], ["to", 61], ["the", 64], ["yeast", 68], ["Set1/COMPASS", 74], ["histone", 87], ["H3-Lys4", 95], ["methyltransferase", 103], ["complex", 121], ["(", 129], ["Lee", 130], [",", 133], ["J.-H.", 135], [",", 140], ["and", 142], ["Skalnik", 146], [",", 153], ["D.", 155], ["G.", 158], ["(", 161], ["2005", 162], [")", 166], ["J.", 168], ["Biol", 171], [".", 175], ["Chem", 177], [".", 181], ["280", 183], [",", 186], ["41725", 188], ["-", 193], ["41731", 194], [")", 199], [".", 200], ["Data", 202], ["base", 207], ["analysis", 212], ["indicates", 221], ["that", 231], ["human", 236], ["Set1A", 242], ["protein", 248], ["shares", 256], ["39", 263], ["%", 265], ["identity", 267], ["with", 276], ["an", 281], ["uncharacterized", 284], ["SET", 300], ["domain", 304], ["protein", 311], [",", 318], ["KIAA1076", 320], [",", 328], ["hereafter", 330], ["denoted", 340], ["Set1B.", 348], ["Immunoprecipitation", 355], ["and", 375], ["mass", 379], ["spectrometry", 384], ["reveal", 397], ["that", 404], ["Set1B", 409], ["associates", 415], ["with", 426], ["a", 431], ["approximately", 433], ["450", 447], ["kDa", 451], ["complex", 455], ["that", 463], ["contains", 468], ["all", 477], ["five", 481], ["non", 486], ["-", 489], ["catalytic", 490], ["components", 500], ["of", 511], ["the", 514], ["Set1A", 518], ["complex", 524], [",", 531], ["including", 533], ["CFP1", 543], [",", 547], ["Rbbp5", 549], [",", 554], ["Ash2", 556], [",", 560], ["Wdr5", 562], [",", 566], ["and", 568], ["Wdr82", 572], [".", 577], ["These", 579], ["data", 585], ["reveal", 590], ["two", 597], ["human", 601], ["protein", 607], ["complexes", 615], ["that", 625], ["differ", 630], ["only", 637], ["in", 642], ["the", 645], ["identity", 649], ["of", 658], ["the", 661], ["catalytic", 665], ["histone", 675], ["methyltransferase", 683], [".", 700], ["In", 702], ["vitro", 705], ["assays", 711], ["demonstrate", 718], ["that", 730], ["the", 735], ["Set1B", 739], ["complex", 745], ["is", 753], ["a", 756], ["histone", 758], ["methyltransferase", 766], ["that", 784], ["produces", 789], ["trimethylated", 798], ["histone", 812], ["H3", 820], ["at", 823], ["Lys(4", 826], [")", 831], [".", 832], ["Both", 834], ["Set1A", 839], ["and", 845], ["Set1B", 849], ["are", 855], ["widely", 859], ["expressed", 866], [".", 875], ["Inducible", 877], ["expression", 887], ["of", 898], ["the", 901], ["carboxyl", 905], ["terminus", 914], ["of", 923], ["either", 926], ["Set1A", 933], ["or", 939], ["Set1B", 942], ["decreases", 948], ["steady", 958], ["-", 964], ["state", 965], ["levels", 971], ["of", 978], ["both", 981], ["endogenous", 986], ["Set1A", 997], ["and", 1003], ["Set1B", 1007], ["protein", 1013], [",", 1020], ["but", 1022], ["does", 1026], ["not", 1031], ["alter", 1035], ["the", 1041], ["expression", 1045], ["of", 1056], ["the", 1059], ["non", 1063], ["-", 1066], ["catalytic", 1067], ["components", 1077], ["of", 1088], ["the", 1091], ["Set1", 1095], ["complexes", 1100], [".", 1109], ["A", 1111], ["123-amino", 1113], ["acid", 1123], ["fragment", 1128], ["upstream", 1137], ["of", 1146], ["the", 1149], ["Set1A", 1153], ["SET", 1159], ["domain", 1163], ["is", 1170], ["necessary", 1173], ["for", 1183], ["interaction", 1187], ["with", 1199], ["CFP1", 1204], [",", 1208], ["Ash2", 1210], [",", 1214], ["Rbbp5", 1216], [",", 1221], ["and", 1223], ["Wdr5", 1227], [".", 1231], ["This", 1233], ["protein", 1238], ["domain", 1246], ["is", 1253], ["also", 1256], ["required", 1261], ["to", 1270], ["mediate", 1273], ["feedback", 1281], ["inhibition", 1290], ["of", 1301], ["Set1A", 1304], ["and", 1310], ["Set1B", 1314], ["expression", 1320], [",", 1330], ["which", 1332], ["is", 1338], ["a", 1341], ["consequence", 1343], ["of", 1355], ["reduced", 1358], ["Set1A", 1366], ["and", 1372], ["Set1B", 1376], ["stability", 1382], ["when", 1392], ["not", 1397], ["associated", 1401], ["with", 1412], ["the", 1417], ["methyltransferase", 1421], ["complex", 1439], [".", 1446], ["Confocal", 1448], ["microscopy", 1457], ["reveals", 1468], ["that", 1476], ["Set1A", 1481], ["and", 1487], ["Set1B", 1491], ["each", 1497], ["localize", 1502], ["to", 1511], ["a", 1514], ["largely", 1516], ["non", 1524], ["-", 1527], ["overlapping", 1528], ["set", 1540], ["of", 1544], ["euchromatic", 1547], ["nuclear", 1559], ["speckles", 1567], [",", 1575], ["suggesting", 1577], ["that", 1588], ["Set1A", 1593], ["and", 1599], ["Set1B", 1603], ["each", 1609], ["bind", 1614], ["to", 1619], ["a", 1622], ["unique", 1624], ["set", 1631], ["of", 1635], ["target", 1638], ["genes", 1645], ["and", 1651], ["thus", 1655], ["make", 1660], ["non", 1665], ["-", 1668], ["redundant", 1669], ["contributions", 1679], ["to", 1693], ["the", 1696], ["epigenetic", 1700], ["control", 1711], ["of", 1719], ["chromatin", 1722], ["structure", 1732], ["and", 1742], ["gene", 1746], ["expression", 1751], [".", 1761]]}
{"context": "Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by Philadelphia chromosome and resultant production of the constitutively activated BCR-ABL tyrosine kinase. Imatinib (STI571), selective inhibitor of the ABL-tyrosine kinase, inhibits the activity of BCR-ABL tyrosine kinase. A phase I and II study of STI571 showed remarkable cytogenetic effect in patients with interferon-refractory CML, offering new hope for therapy for CML. It will, however, require long-term follow-up data from phase II and III clinical studies to validate the effect of STI571 on survival. As therapy for CML improves, monitoring minimal residual disease will be important.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0bb3119e6d6d48ffa24785cf272e280e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[48, 50], [24, 26]], "char_spans": [[291, 297], [174, 180]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["clonal", 36], ["hematopoietic", 43], ["stem", 57], ["cell", 62], ["disorder", 67], ["characterized", 76], ["by", 90], ["Philadelphia", 93], ["chromosome", 106], ["and", 117], ["resultant", 121], ["production", 131], ["of", 142], ["the", 145], ["constitutively", 149], ["activated", 164], ["BCR", 174], ["-", 177], ["ABL", 178], ["tyrosine", 182], ["kinase", 191], [".", 197], ["Imatinib", 199], ["(", 208], ["STI571", 209], [")", 215], [",", 216], ["selective", 218], ["inhibitor", 228], ["of", 238], ["the", 241], ["ABL", 245], ["-", 248], ["tyrosine", 249], ["kinase", 258], [",", 264], ["inhibits", 266], ["the", 275], ["activity", 279], ["of", 288], ["BCR", 291], ["-", 294], ["ABL", 295], ["tyrosine", 299], ["kinase", 308], [".", 314], ["A", 316], ["phase", 318], ["I", 324], ["and", 326], ["II", 330], ["study", 333], ["of", 339], ["STI571", 342], ["showed", 349], ["remarkable", 356], ["cytogenetic", 367], ["effect", 379], ["in", 386], ["patients", 389], ["with", 398], ["interferon", 403], ["-", 413], ["refractory", 414], ["CML", 425], [",", 428], ["offering", 430], ["new", 439], ["hope", 443], ["for", 448], ["therapy", 452], ["for", 460], ["CML", 464], [".", 467], ["It", 469], ["will", 472], [",", 476], ["however", 478], [",", 485], ["require", 487], ["long", 495], ["-", 499], ["term", 500], ["follow", 505], ["-", 511], ["up", 512], ["data", 515], ["from", 520], ["phase", 525], ["II", 531], ["and", 534], ["III", 538], ["clinical", 542], ["studies", 551], ["to", 559], ["validate", 562], ["the", 571], ["effect", 575], ["of", 582], ["STI571", 585], ["on", 592], ["survival", 595], [".", 603], ["As", 605], ["therapy", 608], ["for", 616], ["CML", 620], ["improves", 624], [",", 632], ["monitoring", 634], ["minimal", 645], ["residual", 653], ["disease", 662], ["will", 670], ["be", 675], ["important", 678], [".", 687]]}
{"context": "The new International League Against Epilepsy (ILAE) classification for focal cortical dysplasia (FCD) differentiates between patients with isolated FCD (type 1) and FCD with an associated hippocampal sclerosis (HS) (type 3a). In contrast to the former FCD classification by Palmini, which considered only histologic features, the novel ILAE classification also relies on magnetic resonance imaging (MRI) findings and presumed pathogenesis. We investigated in a cohort of 100 patients with exclusively temporal FCD if the new subdivision of FCD is reflected in clinical characteristics. Thirty-one patients with FCD type 1 and 50 patients with FCD type 3a in the temporal lobe were included. In all patients MRI and histology of the FCD were available. Both patient groups were compared to 19 patients with temporal FCD type 2 with clearly different histologic appearance. Patients with FCD type 1 and type 3a presented with similar clinical features in many respects. In univariate analyses, no statistically significant differences were found as to age at epilepsy onset (p = 0.07) and epilepsy surgery (p = 0.14), a normal appearing neocortical temporal lobe (p = 0.08) or diagnosis of FCD by visual inspection of MRI (p = 0.08), preoperative seizure frequency (p = 0.06), and the predominance of an epigastric aura (p = 0.08). The postoperative outcome was nearly identical 1 year (p = 0.8) and 2 (p = 0.8), 3 (p = 0.8), 5 (p = 0.7), and 8 (p = 1.0) years postoperatively. Only febrile seizures (p = 0.025) and an aura (p = 0.03) were significantly more frequently reported in patients with FCD type 3a. Similar results were obtained from a multivariate logistic regression analysis. Patients with FCD type 2 were more different: Compared to FCD type 3a, age at epilepsy surgery was significantly lower (p = 0.004) and auras (p = 0.005) were significantly less frequently reported. Epigastric auras (p = 0.04) and febrile seizures (p = 0.025) occurred significantly less frequently in patients with FCD type 2 without HS compared to FCD type 3a. The diagnosis of an FCD was significantly more frequently made (p = 0.03) by visual inspection of the MRI compared to FCD type 1. Clinical features did not allow to clear separation of temporal FCD types 1 and 3a. Statistically significant differences were seen in a history of febrile seizures and the occurrence of auras more common in FCD type 3a. However, FCD type 2 in the same localization but with different histology presented with further differences such as more frequent FCD diagnosis by visual inspection of MRI, earlier operation, and less frequent epigastric auras.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "b9e939ba9f2c4fa89af0a12d34b058f2", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[11, 13]], "char_spans": [[72, 95]]}]}], "context_tokens": [["The", 0], ["new", 4], ["International", 8], ["League", 22], ["Against", 29], ["Epilepsy", 37], ["(", 46], ["ILAE", 47], [")", 51], ["classification", 53], ["for", 68], ["focal", 72], ["cortical", 78], ["dysplasia", 87], ["(", 97], ["FCD", 98], [")", 101], ["differentiates", 103], ["between", 118], ["patients", 126], ["with", 135], ["isolated", 140], ["FCD", 149], ["(", 153], ["type", 154], ["1", 159], [")", 160], ["and", 162], ["FCD", 166], ["with", 170], ["an", 175], ["associated", 178], ["hippocampal", 189], ["sclerosis", 201], ["(", 211], ["HS", 212], [")", 214], ["(", 216], ["type", 217], ["3a", 222], [")", 224], [".", 225], ["In", 227], ["contrast", 230], ["to", 239], ["the", 242], ["former", 246], ["FCD", 253], ["classification", 257], ["by", 272], ["Palmini", 275], [",", 282], ["which", 284], ["considered", 290], ["only", 301], ["histologic", 306], ["features", 317], [",", 325], ["the", 327], ["novel", 331], ["ILAE", 337], ["classification", 342], ["also", 357], ["relies", 362], ["on", 369], ["magnetic", 372], ["resonance", 381], ["imaging", 391], ["(", 399], ["MRI", 400], [")", 403], ["findings", 405], ["and", 414], ["presumed", 418], ["pathogenesis", 427], [".", 439], ["We", 441], ["investigated", 444], ["in", 457], ["a", 460], ["cohort", 462], ["of", 469], ["100", 472], ["patients", 476], ["with", 485], ["exclusively", 490], ["temporal", 502], ["FCD", 511], ["if", 515], ["the", 518], ["new", 522], ["subdivision", 526], ["of", 538], ["FCD", 541], ["is", 545], ["reflected", 548], ["in", 558], ["clinical", 561], ["characteristics", 570], [".", 585], ["Thirty", 587], ["-", 593], ["one", 594], ["patients", 598], ["with", 607], ["FCD", 612], ["type", 616], ["1", 621], ["and", 623], ["50", 627], ["patients", 630], ["with", 639], ["FCD", 644], ["type", 648], ["3a", 653], ["in", 656], ["the", 659], ["temporal", 663], ["lobe", 672], ["were", 677], ["included", 682], [".", 690], ["In", 692], ["all", 695], ["patients", 699], ["MRI", 708], ["and", 712], ["histology", 716], ["of", 726], ["the", 729], ["FCD", 733], ["were", 737], ["available", 742], [".", 751], ["Both", 753], ["patient", 758], ["groups", 766], ["were", 773], ["compared", 778], ["to", 787], ["19", 790], ["patients", 793], ["with", 802], ["temporal", 807], ["FCD", 816], ["type", 820], ["2", 825], ["with", 827], ["clearly", 832], ["different", 840], ["histologic", 850], ["appearance", 861], [".", 871], ["Patients", 873], ["with", 882], ["FCD", 887], ["type", 891], ["1", 896], ["and", 898], ["type", 902], ["3a", 907], ["presented", 910], ["with", 920], ["similar", 925], ["clinical", 933], ["features", 942], ["in", 951], ["many", 954], ["respects", 959], [".", 967], ["In", 969], ["univariate", 972], ["analyses", 983], [",", 991], ["no", 993], ["statistically", 996], ["significant", 1010], ["differences", 1022], ["were", 1034], ["found", 1039], ["as", 1045], ["to", 1048], ["age", 1051], ["at", 1055], ["epilepsy", 1058], ["onset", 1067], ["(", 1073], ["p", 1074], ["=", 1076], ["0.07", 1078], [")", 1082], ["and", 1084], ["epilepsy", 1088], ["surgery", 1097], ["(", 1105], ["p", 1106], ["=", 1108], ["0.14", 1110], [")", 1114], [",", 1115], ["a", 1117], ["normal", 1119], ["appearing", 1126], ["neocortical", 1136], ["temporal", 1148], ["lobe", 1157], ["(", 1162], ["p", 1163], ["=", 1165], ["0.08", 1167], [")", 1171], ["or", 1173], ["diagnosis", 1176], ["of", 1186], ["FCD", 1189], ["by", 1193], ["visual", 1196], ["inspection", 1203], ["of", 1214], ["MRI", 1217], ["(", 1221], ["p", 1222], ["=", 1224], ["0.08", 1226], [")", 1230], [",", 1231], ["preoperative", 1233], ["seizure", 1246], ["frequency", 1254], ["(", 1264], ["p", 1265], ["=", 1267], ["0.06", 1269], [")", 1273], [",", 1274], ["and", 1276], ["the", 1280], ["predominance", 1284], ["of", 1297], ["an", 1300], ["epigastric", 1303], ["aura", 1314], ["(", 1319], ["p", 1320], ["=", 1322], ["0.08", 1324], [")", 1328], [".", 1329], ["The", 1331], ["postoperative", 1335], ["outcome", 1349], ["was", 1357], ["nearly", 1361], ["identical", 1368], ["1", 1378], ["year", 1380], ["(", 1385], ["p", 1386], ["=", 1388], ["0.8", 1390], [")", 1393], ["and", 1395], ["2", 1399], ["(", 1401], ["p", 1402], ["=", 1404], ["0.8", 1406], [")", 1409], [",", 1410], ["3", 1412], ["(", 1414], ["p", 1415], ["=", 1417], ["0.8", 1419], [")", 1422], [",", 1423], ["5", 1425], ["(", 1427], ["p", 1428], ["=", 1430], ["0.7", 1432], [")", 1435], [",", 1436], ["and", 1438], ["8", 1442], ["(", 1444], ["p", 1445], ["=", 1447], ["1.0", 1449], [")", 1452], ["years", 1454], ["postoperatively", 1460], [".", 1475], ["Only", 1477], ["febrile", 1482], ["seizures", 1490], ["(", 1499], ["p", 1500], ["=", 1502], ["0.025", 1504], [")", 1509], ["and", 1511], ["an", 1515], ["aura", 1518], ["(", 1523], ["p", 1524], ["=", 1526], ["0.03", 1528], [")", 1532], ["were", 1534], ["significantly", 1539], ["more", 1553], ["frequently", 1558], ["reported", 1569], ["in", 1578], ["patients", 1581], ["with", 1590], ["FCD", 1595], ["type", 1599], ["3a", 1604], [".", 1606], ["Similar", 1608], ["results", 1616], ["were", 1624], ["obtained", 1629], ["from", 1638], ["a", 1643], ["multivariate", 1645], ["logistic", 1658], ["regression", 1667], ["analysis", 1678], [".", 1686], ["Patients", 1688], ["with", 1697], ["FCD", 1702], ["type", 1706], ["2", 1711], ["were", 1713], ["more", 1718], ["different", 1723], [":", 1732], ["Compared", 1734], ["to", 1743], ["FCD", 1746], ["type", 1750], ["3a", 1755], [",", 1757], ["age", 1759], ["at", 1763], ["epilepsy", 1766], ["surgery", 1775], ["was", 1783], ["significantly", 1787], ["lower", 1801], ["(", 1807], ["p", 1808], ["=", 1810], ["0.004", 1812], [")", 1817], ["and", 1819], ["auras", 1823], ["(", 1829], ["p", 1830], ["=", 1832], ["0.005", 1834], [")", 1839], ["were", 1841], ["significantly", 1846], ["less", 1860], ["frequently", 1865], ["reported", 1876], [".", 1884], ["Epigastric", 1886], ["auras", 1897], ["(", 1903], ["p", 1904], ["=", 1906], ["0.04", 1908], [")", 1912], ["and", 1914], ["febrile", 1918], ["seizures", 1926], ["(", 1935], ["p", 1936], ["=", 1938], ["0.025", 1940], [")", 1945], ["occurred", 1947], ["significantly", 1956], ["less", 1970], ["frequently", 1975], ["in", 1986], ["patients", 1989], ["with", 1998], ["FCD", 2003], ["type", 2007], ["2", 2012], ["without", 2014], ["HS", 2022], ["compared", 2025], ["to", 2034], ["FCD", 2037], ["type", 2041], ["3a", 2046], [".", 2048], ["The", 2050], ["diagnosis", 2054], ["of", 2064], ["an", 2067], ["FCD", 2070], ["was", 2074], ["significantly", 2078], ["more", 2092], ["frequently", 2097], ["made", 2108], ["(", 2113], ["p", 2114], ["=", 2116], ["0.03", 2118], [")", 2122], ["by", 2124], ["visual", 2127], ["inspection", 2134], ["of", 2145], ["the", 2148], ["MRI", 2152], ["compared", 2156], ["to", 2165], ["FCD", 2168], ["type", 2172], ["1", 2177], [".", 2178], ["Clinical", 2180], ["features", 2189], ["did", 2198], ["not", 2202], ["allow", 2206], ["to", 2212], ["clear", 2215], ["separation", 2221], ["of", 2232], ["temporal", 2235], ["FCD", 2244], ["types", 2248], ["1", 2254], ["and", 2256], ["3a", 2260], [".", 2262], ["Statistically", 2264], ["significant", 2278], ["differences", 2290], ["were", 2302], ["seen", 2307], ["in", 2312], ["a", 2315], ["history", 2317], ["of", 2325], ["febrile", 2328], ["seizures", 2336], ["and", 2345], ["the", 2349], ["occurrence", 2353], ["of", 2364], ["auras", 2367], ["more", 2373], ["common", 2378], ["in", 2385], ["FCD", 2388], ["type", 2392], ["3a", 2397], [".", 2399], ["However", 2401], [",", 2408], ["FCD", 2410], ["type", 2414], ["2", 2419], ["in", 2421], ["the", 2424], ["same", 2428], ["localization", 2433], ["but", 2446], ["with", 2450], ["different", 2455], ["histology", 2465], ["presented", 2475], ["with", 2485], ["further", 2490], ["differences", 2498], ["such", 2510], ["as", 2515], ["more", 2518], ["frequent", 2523], ["FCD", 2532], ["diagnosis", 2536], ["by", 2546], ["visual", 2549], ["inspection", 2556], ["of", 2567], ["MRI", 2570], [",", 2573], ["earlier", 2575], ["operation", 2583], [",", 2592], ["and", 2594], ["less", 2598], ["frequent", 2603], ["epigastric", 2612], ["auras", 2623], [".", 2628]]}
{"context": "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Although a potent blocker of hERG, it produced no serious adverse events. We attributed the unexpected result to offsetting Multiple Ion Channel Effects (MICE). Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. Vanoxerine terminated AF/AFL in an animal model and a dose-ranging clinical trial. Reversion to normal rhythm was associated with QT prolongation yet absent proarrhythmia markers for Torsade de Pointes (TdP). To understand the QT/TdP discordance, we used quantitative profiling and compared vanoxerine with dofetilide, a selective hERG-blocking torsadogen used for intractable AF, verapamil, a non-torsadogenic MICE comparator and bepridil, a torsadogenic MICE comparator. At clinically relevant concentrations, verapamil blocked hCav1.2 and hERG, as did vanoxerine and bepridil both of which also blocked hNav1.5. In acute experiments and simulations, dofetilide produced early after depolarizations (EADs) and arrhythmias, whereas verapamil, vanoxerine and bepridil produced no proarrhythmia markers. Of the MICE drugs only bepridil inhibited hERG trafficking following overnight exposure. The results are consistent with the emphasis on MICE of the CiPA assay. Additionally we propose that trafficking inhibition of hERG be added to CiPA.", "qas": [{"question": "What alternate indication has Vanoxerine been repositioned for?", "answers": ["atrial fibrillation and flutter"], "qid": "1a4946e6636c4ab3a37f421bb4397409", "question_tokens": [["What", 0], ["alternate", 5], ["indication", 15], ["has", 26], ["Vanoxerine", 30], ["been", 41], ["repositioned", 46], ["for", 59], ["?", 62]], "detected_answers": [{"text": "atrial fibrillation and flutter", "token_spans": [[61, 64]], "char_spans": [[367, 397]]}]}], "context_tokens": [["Vanoxerine", 0], ["has", 11], ["been", 15], ["in", 20], ["clinical", 23], ["trials", 32], ["for", 39], ["Parkinsonism", 43], [",", 55], ["depression", 57], ["and", 68], ["cocaine", 72], ["addiction", 80], ["but", 90], ["lacked", 94], ["efficacy", 101], [".", 109], ["Although", 111], ["a", 120], ["potent", 122], ["blocker", 129], ["of", 137], ["hERG", 140], [",", 144], ["it", 146], ["produced", 149], ["no", 158], ["serious", 161], ["adverse", 169], ["events", 177], [".", 183], ["We", 185], ["attributed", 188], ["the", 199], ["unexpected", 203], ["result", 214], ["to", 221], ["offsetting", 224], ["Multiple", 235], ["Ion", 244], ["Channel", 248], ["Effects", 256], ["(", 264], ["MICE", 265], [")", 269], [".", 270], ["Vanoxerine", 272], ["'s", 282], ["effects", 285], ["were", 293], ["strongly", 298], ["frequency", 307], ["-", 316], ["dependent", 317], ["and", 327], ["we", 331], ["repositioned", 334], ["it", 347], ["for", 350], ["treatment", 354], ["of", 364], ["atrial", 367], ["fibrillation", 374], ["and", 387], ["flutter", 391], [".", 398], ["Vanoxerine", 400], ["terminated", 411], ["AF", 422], ["/", 424], ["AFL", 425], ["in", 429], ["an", 432], ["animal", 435], ["model", 442], ["and", 448], ["a", 452], ["dose", 454], ["-", 458], ["ranging", 459], ["clinical", 467], ["trial", 476], [".", 481], ["Reversion", 483], ["to", 493], ["normal", 496], ["rhythm", 503], ["was", 510], ["associated", 514], ["with", 525], ["QT", 530], ["prolongation", 533], ["yet", 546], ["absent", 550], ["proarrhythmia", 557], ["markers", 571], ["for", 579], ["Torsade", 583], ["de", 591], ["Pointes", 594], ["(", 602], ["TdP", 603], [")", 606], [".", 607], ["To", 609], ["understand", 612], ["the", 623], ["QT", 627], ["/", 629], ["TdP", 630], ["discordance", 634], [",", 645], ["we", 647], ["used", 650], ["quantitative", 655], ["profiling", 668], ["and", 678], ["compared", 682], ["vanoxerine", 691], ["with", 702], ["dofetilide", 707], [",", 717], ["a", 719], ["selective", 721], ["hERG", 731], ["-", 735], ["blocking", 736], ["torsadogen", 745], ["used", 756], ["for", 761], ["intractable", 765], ["AF", 777], [",", 779], ["verapamil", 781], [",", 790], ["a", 792], ["non", 794], ["-", 797], ["torsadogenic", 798], ["MICE", 811], ["comparator", 816], ["and", 827], ["bepridil", 831], [",", 839], ["a", 841], ["torsadogenic", 843], ["MICE", 856], ["comparator", 861], [".", 871], ["At", 873], ["clinically", 876], ["relevant", 887], ["concentrations", 896], [",", 910], ["verapamil", 912], ["blocked", 922], ["hCav1.2", 930], ["and", 938], ["hERG", 942], [",", 946], ["as", 948], ["did", 951], ["vanoxerine", 955], ["and", 966], ["bepridil", 970], ["both", 979], ["of", 984], ["which", 987], ["also", 993], ["blocked", 998], ["hNav1.5", 1006], [".", 1013], ["In", 1015], ["acute", 1018], ["experiments", 1024], ["and", 1036], ["simulations", 1040], [",", 1051], ["dofetilide", 1053], ["produced", 1064], ["early", 1073], ["after", 1079], ["depolarizations", 1085], ["(", 1101], ["EADs", 1102], [")", 1106], ["and", 1108], ["arrhythmias", 1112], [",", 1123], ["whereas", 1125], ["verapamil", 1133], [",", 1142], ["vanoxerine", 1144], ["and", 1155], ["bepridil", 1159], ["produced", 1168], ["no", 1177], ["proarrhythmia", 1180], ["markers", 1194], [".", 1201], ["Of", 1203], ["the", 1206], ["MICE", 1210], ["drugs", 1215], ["only", 1221], ["bepridil", 1226], ["inhibited", 1235], ["hERG", 1245], ["trafficking", 1250], ["following", 1262], ["overnight", 1272], ["exposure", 1282], [".", 1290], ["The", 1292], ["results", 1296], ["are", 1304], ["consistent", 1308], ["with", 1319], ["the", 1324], ["emphasis", 1328], ["on", 1337], ["MICE", 1340], ["of", 1345], ["the", 1348], ["CiPA", 1352], ["assay", 1357], [".", 1362], ["Additionally", 1364], ["we", 1377], ["propose", 1380], ["that", 1388], ["trafficking", 1393], ["inhibition", 1405], ["of", 1416], ["hERG", 1419], ["be", 1424], ["added", 1427], ["to", 1433], ["CiPA", 1436], [".", 1440]]}
{"context": "Mowat-Wilson syndrome (MWS) is a multiple congenital anomaly-mental retardation complex caused by mutations in the Zinc Finger Homeobox 1 B gene (ZFHX1B). MWS has been reported in association with Hirschsprung disease (HSCR). MWS is sometimes difficult to diagnose clinically, especially when HSCR is absent. Thus, it is necessary to detect gene abnormalities at the molecular level. Here we report two Japanese girls with MWS, who showed a distinct facial phenotype, severe intellectual disability and epileptic seizures. Major congenital anomalies of the patients were very different. Patient 1 suffered from severe congenital heart disease, but did not show apparent HSCR. Patient 2 suffered from typical HSCR and underwent surgical treatment, but did not have congenital heart disease. According to the gene analysis using white blood cells, they had nonsense mutations in ZFHX1B, R695X and Q433X, respectively. In conclusion, molecular genetic analysis of ZFHX1B is important for a definite diagnosis of MWS which has a wide phenotypic spectrum of congenital anomalies.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "fec222083ea440d4a439d10720ceb994", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[28, 28], [155, 155], [170, 170]], "char_spans": [[146, 151], [877, 882], [961, 966]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["multiple", 33], ["congenital", 42], ["anomaly", 53], ["-", 60], ["mental", 61], ["retardation", 68], ["complex", 80], ["caused", 88], ["by", 95], ["mutations", 98], ["in", 108], ["the", 111], ["Zinc", 115], ["Finger", 120], ["Homeobox", 127], ["1", 136], ["B", 138], ["gene", 140], ["(", 145], ["ZFHX1B", 146], [")", 152], [".", 153], ["MWS", 155], ["has", 159], ["been", 163], ["reported", 168], ["in", 177], ["association", 180], ["with", 192], ["Hirschsprung", 197], ["disease", 210], ["(", 218], ["HSCR", 219], [")", 223], [".", 224], ["MWS", 226], ["is", 230], ["sometimes", 233], ["difficult", 243], ["to", 253], ["diagnose", 256], ["clinically", 265], [",", 275], ["especially", 277], ["when", 288], ["HSCR", 293], ["is", 298], ["absent", 301], [".", 307], ["Thus", 309], [",", 313], ["it", 315], ["is", 318], ["necessary", 321], ["to", 331], ["detect", 334], ["gene", 341], ["abnormalities", 346], ["at", 360], ["the", 363], ["molecular", 367], ["level", 377], [".", 382], ["Here", 384], ["we", 389], ["report", 392], ["two", 399], ["Japanese", 403], ["girls", 412], ["with", 418], ["MWS", 423], [",", 426], ["who", 428], ["showed", 432], ["a", 439], ["distinct", 441], ["facial", 450], ["phenotype", 457], [",", 466], ["severe", 468], ["intellectual", 475], ["disability", 488], ["and", 499], ["epileptic", 503], ["seizures", 513], [".", 521], ["Major", 523], ["congenital", 529], ["anomalies", 540], ["of", 550], ["the", 553], ["patients", 557], ["were", 566], ["very", 571], ["different", 576], [".", 585], ["Patient", 587], ["1", 595], ["suffered", 597], ["from", 606], ["severe", 611], ["congenital", 618], ["heart", 629], ["disease", 635], [",", 642], ["but", 644], ["did", 648], ["not", 652], ["show", 656], ["apparent", 661], ["HSCR", 670], [".", 674], ["Patient", 676], ["2", 684], ["suffered", 686], ["from", 695], ["typical", 700], ["HSCR", 708], ["and", 713], ["underwent", 717], ["surgical", 727], ["treatment", 736], [",", 745], ["but", 747], ["did", 751], ["not", 755], ["have", 759], ["congenital", 764], ["heart", 775], ["disease", 781], [".", 788], ["According", 790], ["to", 800], ["the", 803], ["gene", 807], ["analysis", 812], ["using", 821], ["white", 827], ["blood", 833], ["cells", 839], [",", 844], ["they", 846], ["had", 851], ["nonsense", 855], ["mutations", 864], ["in", 874], ["ZFHX1B", 877], [",", 883], ["R695X", 885], ["and", 891], ["Q433X", 895], [",", 900], ["respectively", 902], [".", 914], ["In", 916], ["conclusion", 919], [",", 929], ["molecular", 931], ["genetic", 941], ["analysis", 949], ["of", 958], ["ZFHX1B", 961], ["is", 968], ["important", 971], ["for", 981], ["a", 985], ["definite", 987], ["diagnosis", 996], ["of", 1006], ["MWS", 1009], ["which", 1013], ["has", 1019], ["a", 1023], ["wide", 1025], ["phenotypic", 1030], ["spectrum", 1041], ["of", 1050], ["congenital", 1053], ["anomalies", 1064], [".", 1073]]}
{"context": "Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis. In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly all of whom were negative for the human immunodeficiency virus) with pulmonary multidrug-resistant tuberculosis to receive delamanid, at a dose of 100 mg twice daily (161 patients) or 200 mg twice daily (160 patients), or placebo (160 patients) for 2 months in combination with a background drug regimen developed according to World Health Organization guidelines. Sputum cultures were assessed weekly with the use of both liquid broth and solid medium; sputum-culture conversion was defined as a series of five or more consecutive cultures that were negative for growth of M. tuberculosis. The primary efficacy end point was the proportion of patients with sputum-culture conversion in liquid broth medium at 2 months. Among patients who received a background drug regimen plus 100 mg of delamanid twice daily, 45.4% had sputum-culture conversion in liquid broth at 2 months, as compared with 29.6% of patients who received a background drug regimen plus placebo (P=0.008). Likewise, as compared with the placebo group, the group that received the background drug regimen plus 200 mg of delamanid twice daily had a higher proportion of patients with sputum-culture conversion (41.9%, P=0.04). The findings were similar with assessment of sputum-culture conversion in solid medium. Most adverse events were mild to moderate in severity and were evenly distributed across groups. Although no clinical events due to QT prolongation on electrocardiography were observed, QT prolongation was reported significantly more frequently in the groups that received delamanid. Delamanid was associated with an increase in sputum-culture conversion at 2 months among patients with multidrug-resistant tuberculosis. This finding suggests that delamanid could enhance treatment options for multidrug-resistant tuberculosis. (Funded by Otsuka Pharmaceutical Development and Commercialization; ClinicalTrials.gov number, NCT00685360.).", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "9dd06b2102304cdc8188c97c503ffb35", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[165, 165], [374, 374], [76, 76], [359, 359], [40, 40]], "char_spans": [[933, 944], [2152, 2163], [455, 466], [2045, 2056], [239, 250]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["OPC-67683", 11], [")", 20], [",", 21], ["a", 23], ["nitro", 25], ["-", 30], ["dihydro", 31], ["-", 38], ["imidazooxazole", 39], ["derivative", 54], [",", 64], ["is", 66], ["a", 69], ["new", 71], ["antituberculosis", 75], ["medication", 92], ["that", 103], ["inhibits", 108], ["mycolic", 117], ["acid", 125], ["synthesis", 130], ["and", 140], ["has", 144], ["shown", 148], ["potent", 154], ["in", 161], ["vitro", 164], ["and", 170], ["in", 174], ["vivo", 177], ["activity", 182], ["against", 191], ["drug", 199], ["-", 203], ["resistant", 204], ["strains", 214], ["of", 222], ["Mycobacterium", 225], ["tuberculosis", 239], [".", 251], ["In", 253], ["this", 256], ["randomized", 261], [",", 271], ["placebo", 273], ["-", 280], ["controlled", 281], [",", 291], ["multinational", 293], ["clinical", 307], ["trial", 316], [",", 321], ["we", 323], ["assigned", 326], ["481", 335], ["patients", 339], ["(", 348], ["nearly", 349], ["all", 356], ["of", 360], ["whom", 363], ["were", 368], ["negative", 373], ["for", 382], ["the", 386], ["human", 390], ["immunodeficiency", 396], ["virus", 413], [")", 418], ["with", 420], ["pulmonary", 425], ["multidrug", 435], ["-", 444], ["resistant", 445], ["tuberculosis", 455], ["to", 468], ["receive", 471], ["delamanid", 479], [",", 488], ["at", 490], ["a", 493], ["dose", 495], ["of", 500], ["100", 503], ["mg", 507], ["twice", 510], ["daily", 516], ["(", 522], ["161", 523], ["patients", 527], [")", 535], ["or", 537], ["200", 540], ["mg", 544], ["twice", 547], ["daily", 553], ["(", 559], ["160", 560], ["patients", 564], [")", 572], [",", 573], ["or", 575], ["placebo", 578], ["(", 586], ["160", 587], ["patients", 591], [")", 599], ["for", 601], ["2", 605], ["months", 607], ["in", 614], ["combination", 617], ["with", 629], ["a", 634], ["background", 636], ["drug", 647], ["regimen", 652], ["developed", 660], ["according", 670], ["to", 680], ["World", 683], ["Health", 689], ["Organization", 696], ["guidelines", 709], [".", 719], ["Sputum", 721], ["cultures", 728], ["were", 737], ["assessed", 742], ["weekly", 751], ["with", 758], ["the", 763], ["use", 767], ["of", 771], ["both", 774], ["liquid", 779], ["broth", 786], ["and", 792], ["solid", 796], ["medium", 802], [";", 808], ["sputum", 810], ["-", 816], ["culture", 817], ["conversion", 825], ["was", 836], ["defined", 840], ["as", 848], ["a", 851], ["series", 853], ["of", 860], ["five", 863], ["or", 868], ["more", 871], ["consecutive", 876], ["cultures", 888], ["that", 897], ["were", 902], ["negative", 907], ["for", 916], ["growth", 920], ["of", 927], ["M.", 930], ["tuberculosis", 933], [".", 945], ["The", 947], ["primary", 951], ["efficacy", 959], ["end", 968], ["point", 972], ["was", 978], ["the", 982], ["proportion", 986], ["of", 997], ["patients", 1000], ["with", 1009], ["sputum", 1014], ["-", 1020], ["culture", 1021], ["conversion", 1029], ["in", 1040], ["liquid", 1043], ["broth", 1050], ["medium", 1056], ["at", 1063], ["2", 1066], ["months", 1068], [".", 1074], ["Among", 1076], ["patients", 1082], ["who", 1091], ["received", 1095], ["a", 1104], ["background", 1106], ["drug", 1117], ["regimen", 1122], ["plus", 1130], ["100", 1135], ["mg", 1139], ["of", 1142], ["delamanid", 1145], ["twice", 1155], ["daily", 1161], [",", 1166], ["45.4", 1168], ["%", 1172], ["had", 1174], ["sputum", 1178], ["-", 1184], ["culture", 1185], ["conversion", 1193], ["in", 1204], ["liquid", 1207], ["broth", 1214], ["at", 1220], ["2", 1223], ["months", 1225], [",", 1231], ["as", 1233], ["compared", 1236], ["with", 1245], ["29.6", 1250], ["%", 1254], ["of", 1256], ["patients", 1259], ["who", 1268], ["received", 1272], ["a", 1281], ["background", 1283], ["drug", 1294], ["regimen", 1299], ["plus", 1307], ["placebo", 1312], ["(", 1320], ["P=0.008", 1321], [")", 1328], [".", 1329], ["Likewise", 1331], [",", 1339], ["as", 1341], ["compared", 1344], ["with", 1353], ["the", 1358], ["placebo", 1362], ["group", 1370], [",", 1375], ["the", 1377], ["group", 1381], ["that", 1387], ["received", 1392], ["the", 1401], ["background", 1405], ["drug", 1416], ["regimen", 1421], ["plus", 1429], ["200", 1434], ["mg", 1438], ["of", 1441], ["delamanid", 1444], ["twice", 1454], ["daily", 1460], ["had", 1466], ["a", 1470], ["higher", 1472], ["proportion", 1479], ["of", 1490], ["patients", 1493], ["with", 1502], ["sputum", 1507], ["-", 1513], ["culture", 1514], ["conversion", 1522], ["(", 1533], ["41.9", 1534], ["%", 1538], [",", 1539], ["P=0.04", 1541], [")", 1547], [".", 1548], ["The", 1550], ["findings", 1554], ["were", 1563], ["similar", 1568], ["with", 1576], ["assessment", 1581], ["of", 1592], ["sputum", 1595], ["-", 1601], ["culture", 1602], ["conversion", 1610], ["in", 1621], ["solid", 1624], ["medium", 1630], [".", 1636], ["Most", 1638], ["adverse", 1643], ["events", 1651], ["were", 1658], ["mild", 1663], ["to", 1668], ["moderate", 1671], ["in", 1680], ["severity", 1683], ["and", 1692], ["were", 1696], ["evenly", 1701], ["distributed", 1708], ["across", 1720], ["groups", 1727], [".", 1733], ["Although", 1735], ["no", 1744], ["clinical", 1747], ["events", 1756], ["due", 1763], ["to", 1767], ["QT", 1770], ["prolongation", 1773], ["on", 1786], ["electrocardiography", 1789], ["were", 1809], ["observed", 1814], [",", 1822], ["QT", 1824], ["prolongation", 1827], ["was", 1840], ["reported", 1844], ["significantly", 1853], ["more", 1867], ["frequently", 1872], ["in", 1883], ["the", 1886], ["groups", 1890], ["that", 1897], ["received", 1902], ["delamanid", 1911], [".", 1920], ["Delamanid", 1922], ["was", 1932], ["associated", 1936], ["with", 1947], ["an", 1952], ["increase", 1955], ["in", 1964], ["sputum", 1967], ["-", 1973], ["culture", 1974], ["conversion", 1982], ["at", 1993], ["2", 1996], ["months", 1998], ["among", 2005], ["patients", 2011], ["with", 2020], ["multidrug", 2025], ["-", 2034], ["resistant", 2035], ["tuberculosis", 2045], [".", 2057], ["This", 2059], ["finding", 2064], ["suggests", 2072], ["that", 2081], ["delamanid", 2086], ["could", 2096], ["enhance", 2102], ["treatment", 2110], ["options", 2120], ["for", 2128], ["multidrug", 2132], ["-", 2141], ["resistant", 2142], ["tuberculosis", 2152], [".", 2164], ["(", 2166], ["Funded", 2167], ["by", 2174], ["Otsuka", 2177], ["Pharmaceutical", 2184], ["Development", 2199], ["and", 2211], ["Commercialization", 2215], [";", 2232], ["ClinicalTrials.gov", 2234], ["number", 2253], [",", 2259], ["NCT00685360", 2261], [".", 2272], [")", 2273], [".", 2274]]}
{"context": "The objective of this study was to determine the performance of the Recognition Of Stroke In the Emergency Room (ROSIER) scale in risk-stratifying Chinese patients with suspected stroke in Hong Kong. This was a prospective cohort study in an urban academic emergency department (ED) over a 7-month period. Patients over 18 years of age with suspected stroke were recruited between June 2011 and December 2011. ROSIER scale assessment was performed in the ED triage area. Logistic regression analysis was used to estimate the impacts of diagnostic variables, including ROSIER scale, past history and ED characteristics. 715 suspected stroke patients were recruited for assessment, of whom 371 (52%) had acute cerebrovascular disease (302 ischaemic strokes, 24 transient ischaemic attacks (TIA), 45 intracerebral haemorrhages), and 344 (48%) had other illnesses i.e. stroke mimics. Common stroke mimics were spinal neuropathy, dementia, labyrinthitis and sepsis. The suggested cut-off score of>0 for the ROSIER scale for stroke diagnosis gave a sensitivity of 87% (95%CI 83-90), a specificity of 41% (95%CI 36-47), a positive predictive value of 62% (95%CI 57-66), and a negative predictive value of 75% (95%CI 68-81), and the AUC was 0.723. The overall accuracy at cut off>0 was 65% i.e. (323+141)/715. The ROSIER scale was not as effective at differentiating acute stroke from stroke mimics in Chinese patients in Hong Kong as it was in the original studies, primarily due to a much lower specificity. If the ROSIER scale is to be clinically useful in Chinese suspected stroke patients, it requires further refinement.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "382bb11c7a004d7c8c8db92c09fbed6f", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[14, 14], [64, 64], [160, 160], [309, 309], [156, 156], [184, 184], [110, 110], [273, 273], [31, 31], [271, 271]], "char_spans": [[83, 88], [351, 356], [887, 892], [1570, 1575], [865, 870], [1019, 1024], [633, 638], [1377, 1382], [179, 184], [1365, 1370]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["of", 14], ["this", 17], ["study", 22], ["was", 28], ["to", 32], ["determine", 35], ["the", 45], ["performance", 49], ["of", 61], ["the", 64], ["Recognition", 68], ["Of", 80], ["Stroke", 83], ["In", 90], ["the", 93], ["Emergency", 97], ["Room", 107], ["(", 112], ["ROSIER", 113], [")", 119], ["scale", 121], ["in", 127], ["risk", 130], ["-", 134], ["stratifying", 135], ["Chinese", 147], ["patients", 155], ["with", 164], ["suspected", 169], ["stroke", 179], ["in", 186], ["Hong", 189], ["Kong", 194], [".", 198], ["This", 200], ["was", 205], ["a", 209], ["prospective", 211], ["cohort", 223], ["study", 230], ["in", 236], ["an", 239], ["urban", 242], ["academic", 248], ["emergency", 257], ["department", 267], ["(", 278], ["ED", 279], [")", 281], ["over", 283], ["a", 288], ["7-month", 290], ["period", 298], [".", 304], ["Patients", 306], ["over", 315], ["18", 320], ["years", 323], ["of", 329], ["age", 332], ["with", 336], ["suspected", 341], ["stroke", 351], ["were", 358], ["recruited", 363], ["between", 373], ["June", 381], ["2011", 386], ["and", 391], ["December", 395], ["2011", 404], [".", 408], ["ROSIER", 410], ["scale", 417], ["assessment", 423], ["was", 434], ["performed", 438], ["in", 448], ["the", 451], ["ED", 455], ["triage", 458], ["area", 465], [".", 469], ["Logistic", 471], ["regression", 480], ["analysis", 491], ["was", 500], ["used", 504], ["to", 509], ["estimate", 512], ["the", 521], ["impacts", 525], ["of", 533], ["diagnostic", 536], ["variables", 547], [",", 556], ["including", 558], ["ROSIER", 568], ["scale", 575], [",", 580], ["past", 582], ["history", 587], ["and", 595], ["ED", 599], ["characteristics", 602], [".", 617], ["715", 619], ["suspected", 623], ["stroke", 633], ["patients", 640], ["were", 649], ["recruited", 654], ["for", 664], ["assessment", 668], [",", 678], ["of", 680], ["whom", 683], ["371", 688], ["(", 692], ["52", 693], ["%", 695], [")", 696], ["had", 698], ["acute", 702], ["cerebrovascular", 708], ["disease", 724], ["(", 732], ["302", 733], ["ischaemic", 737], ["strokes", 747], [",", 754], ["24", 756], ["transient", 759], ["ischaemic", 769], ["attacks", 779], ["(", 787], ["TIA", 788], [")", 791], [",", 792], ["45", 794], ["intracerebral", 797], ["haemorrhages", 811], [")", 823], [",", 824], ["and", 826], ["344", 830], ["(", 834], ["48", 835], ["%", 837], [")", 838], ["had", 840], ["other", 844], ["illnesses", 850], ["i.e.", 860], ["stroke", 865], ["mimics", 872], [".", 878], ["Common", 880], ["stroke", 887], ["mimics", 894], ["were", 901], ["spinal", 906], ["neuropathy", 913], [",", 923], ["dementia", 925], [",", 933], ["labyrinthitis", 935], ["and", 949], ["sepsis", 953], [".", 959], ["The", 961], ["suggested", 965], ["cut", 975], ["-", 978], ["off", 979], ["score", 983], ["of>0", 989], ["for", 994], ["the", 998], ["ROSIER", 1002], ["scale", 1009], ["for", 1015], ["stroke", 1019], ["diagnosis", 1026], ["gave", 1036], ["a", 1041], ["sensitivity", 1043], ["of", 1055], ["87", 1058], ["%", 1060], ["(", 1062], ["95%CI", 1063], ["83", 1069], ["-", 1071], ["90", 1072], [")", 1074], [",", 1075], ["a", 1077], ["specificity", 1079], ["of", 1091], ["41", 1094], ["%", 1096], ["(", 1098], ["95%CI", 1099], ["36", 1105], ["-", 1107], ["47", 1108], [")", 1110], [",", 1111], ["a", 1113], ["positive", 1115], ["predictive", 1124], ["value", 1135], ["of", 1141], ["62", 1144], ["%", 1146], ["(", 1148], ["95%CI", 1149], ["57", 1155], ["-", 1157], ["66", 1158], [")", 1160], [",", 1161], ["and", 1163], ["a", 1167], ["negative", 1169], ["predictive", 1178], ["value", 1189], ["of", 1195], ["75", 1198], ["%", 1200], ["(", 1202], ["95%CI", 1203], ["68", 1209], ["-", 1211], ["81", 1212], [")", 1214], [",", 1215], ["and", 1217], ["the", 1221], ["AUC", 1225], ["was", 1229], ["0.723", 1233], [".", 1238], ["The", 1240], ["overall", 1244], ["accuracy", 1252], ["at", 1261], ["cut", 1264], ["off>0", 1268], ["was", 1274], ["65", 1278], ["%", 1280], ["i.e.", 1282], ["(", 1287], ["323", 1288], ["+", 1291], ["141)/715", 1292], [".", 1300], ["The", 1302], ["ROSIER", 1306], ["scale", 1313], ["was", 1319], ["not", 1323], ["as", 1327], ["effective", 1330], ["at", 1340], ["differentiating", 1343], ["acute", 1359], ["stroke", 1365], ["from", 1372], ["stroke", 1377], ["mimics", 1384], ["in", 1391], ["Chinese", 1394], ["patients", 1402], ["in", 1411], ["Hong", 1414], ["Kong", 1419], ["as", 1424], ["it", 1427], ["was", 1430], ["in", 1434], ["the", 1437], ["original", 1441], ["studies", 1450], [",", 1457], ["primarily", 1459], ["due", 1469], ["to", 1473], ["a", 1476], ["much", 1478], ["lower", 1483], ["specificity", 1489], [".", 1500], ["If", 1502], ["the", 1505], ["ROSIER", 1509], ["scale", 1516], ["is", 1522], ["to", 1525], ["be", 1528], ["clinically", 1531], ["useful", 1542], ["in", 1549], ["Chinese", 1552], ["suspected", 1560], ["stroke", 1570], ["patients", 1577], [",", 1585], ["it", 1587], ["requires", 1590], ["further", 1599], ["refinement", 1607], [".", 1617]]}
{"context": "Missense mutations in ubiquilin 2 (UBQLN2) cause ALS with frontotemporal dementia (ALS-FTD). Animal models of ALS are useful for understanding the mechanisms of pathogenesis and for preclinical investigations. However, previous rodent models carrying UBQLN2 mutations failed to manifest any sign of motor neuron disease. Here, we show that lines of mice expressing either the ALS-FTD-linked P497S or P506T UBQLN2 mutations have cognitive deficits, shortened lifespans, and develop motor neuron disease, mimicking the human disease. Neuropathologic analysis of the mice with end-stage disease revealed the accumulation of ubiquitinated inclusions in the brain and spinal cord, astrocytosis, a reduction in the number of hippocampal neurons, and reduced staining of TAR-DNA binding protein 43 in the nucleus, with concomitant formation of ubiquitin", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "020cf00b943b468f9e50ce04bee47b9f", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[65, 65], [22, 22], [9, 9], [14, 14]], "char_spans": [[376, 378], [110, 112], [49, 51], [83, 85]]}]}], "context_tokens": [["Missense", 0], ["mutations", 9], ["in", 19], ["ubiquilin", 22], ["2", 32], ["(", 34], ["UBQLN2", 35], [")", 41], ["cause", 43], ["ALS", 49], ["with", 53], ["frontotemporal", 58], ["dementia", 73], ["(", 82], ["ALS", 83], ["-", 86], ["FTD", 87], [")", 90], [".", 91], ["Animal", 93], ["models", 100], ["of", 107], ["ALS", 110], ["are", 114], ["useful", 118], ["for", 125], ["understanding", 129], ["the", 143], ["mechanisms", 147], ["of", 158], ["pathogenesis", 161], ["and", 174], ["for", 178], ["preclinical", 182], ["investigations", 194], [".", 208], ["However", 210], [",", 217], ["previous", 219], ["rodent", 228], ["models", 235], ["carrying", 242], ["UBQLN2", 251], ["mutations", 258], ["failed", 268], ["to", 275], ["manifest", 278], ["any", 287], ["sign", 291], ["of", 296], ["motor", 299], ["neuron", 305], ["disease", 312], [".", 319], ["Here", 321], [",", 325], ["we", 327], ["show", 330], ["that", 335], ["lines", 340], ["of", 346], ["mice", 349], ["expressing", 354], ["either", 365], ["the", 372], ["ALS", 376], ["-", 379], ["FTD", 380], ["-", 383], ["linked", 384], ["P497S", 391], ["or", 397], ["P506", 400], ["T", 404], ["UBQLN2", 406], ["mutations", 413], ["have", 423], ["cognitive", 428], ["deficits", 438], [",", 446], ["shortened", 448], ["lifespans", 458], [",", 467], ["and", 469], ["develop", 473], ["motor", 481], ["neuron", 487], ["disease", 494], [",", 501], ["mimicking", 503], ["the", 513], ["human", 517], ["disease", 523], [".", 530], ["Neuropathologic", 532], ["analysis", 548], ["of", 557], ["the", 560], ["mice", 564], ["with", 569], ["end", 574], ["-", 577], ["stage", 578], ["disease", 584], ["revealed", 592], ["the", 601], ["accumulation", 605], ["of", 618], ["ubiquitinated", 621], ["inclusions", 635], ["in", 646], ["the", 649], ["brain", 653], ["and", 659], ["spinal", 663], ["cord", 670], [",", 674], ["astrocytosis", 676], [",", 688], ["a", 690], ["reduction", 692], ["in", 702], ["the", 705], ["number", 709], ["of", 716], ["hippocampal", 719], ["neurons", 731], [",", 738], ["and", 740], ["reduced", 744], ["staining", 752], ["of", 761], ["TAR", 764], ["-", 767], ["DNA", 768], ["binding", 772], ["protein", 780], ["43", 788], ["in", 791], ["the", 794], ["nucleus", 798], [",", 805], ["with", 807], ["concomitant", 812], ["formation", 824], ["of", 834], ["ubiquitin", 837]]}
{"context": "To investigate the use of tanezumab, a humanized monoclonal antibody that inhibits nerve growth factor, for the treatment of moderate to severe osteoarthritis in Japanese patients. Patients received tanezumab 10, 25, 50, 100, 200\u00a0\u03bcg/kg, or placebo and were followed for 92 or 120 days. Endpoints included the incidence of adverse events (AEs) and the change from baseline to week 8 in pain intensity and the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) subscales. Patients (n\u00a0=\u00a083) were 69% female, age 44-73 years, with a Kellgren-Lawrence X-ray grade of 2-4. At week 8, compared with placebo, tanezumab 25, 100, and 200\u00a0\u03bcg/kg improved index knee pain during walking (-18.5,\u00a0-14.3, and\u00a0-27.6, respectively), index knee pain in the past 24\u00a0h (-19.1,\u00a0-14.6, and\u00a0-24.2, respectively), current index knee pain (-16.5,\u00a0-10.9, and\u00a0-22.8, respectively), and the WOMAC pain (-11.5,\u00a0-9.6, and\u00a0-18.8, respectively), physical function (-8.7,\u00a0-9.5, and\u00a0-17.6, respectively), and stiffness (-20.4,\u00a0-11.2, and\u00a0-10.2, respectively) subscales. Overall, seven patients reported AEs of abnormal peripheral sensation: allodynia (two in the tanezumab 200\u00a0\u03bcg/kg group); paresthesia (two in the tanezumab 200\u00a0\u03bcg/kg group), dysesthesia (one in the tanezumab 200\u00a0\u03bcg/kg group); thermohypoesthesia (one in the tanezumab 100\u00a0\u03bcg/kg group), and decreased vibratory sense (one in the placebo group). All of these AEs were mild to moderate in severity and transient in nature. Tanezumab was safe and generally well tolerated and may improve pain symptoms in Japanese patients with moderate to severe osteoarthritis of the knee. CLINICALTRIALS.GOV IDENTIFIER: NCT00669409.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "6039fcd253ac44cb9e8813354f3d424a", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[13, 15]], "char_spans": [[83, 101]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["use", 19], ["of", 23], ["tanezumab", 26], [",", 35], ["a", 37], ["humanized", 39], ["monoclonal", 49], ["antibody", 60], ["that", 69], ["inhibits", 74], ["nerve", 83], ["growth", 89], ["factor", 96], [",", 102], ["for", 104], ["the", 108], ["treatment", 112], ["of", 122], ["moderate", 125], ["to", 134], ["severe", 137], ["osteoarthritis", 144], ["in", 159], ["Japanese", 162], ["patients", 171], [".", 179], ["Patients", 181], ["received", 190], ["tanezumab", 199], ["10", 209], [",", 211], ["25", 213], [",", 215], ["50", 217], [",", 219], ["100", 221], [",", 224], ["200", 226], ["\u03bcg", 230], ["/", 232], ["kg", 233], [",", 235], ["or", 237], ["placebo", 240], ["and", 248], ["were", 252], ["followed", 257], ["for", 266], ["92", 270], ["or", 273], ["120", 276], ["days", 280], [".", 284], ["Endpoints", 286], ["included", 296], ["the", 305], ["incidence", 309], ["of", 319], ["adverse", 322], ["events", 330], ["(", 337], ["AEs", 338], [")", 341], ["and", 343], ["the", 347], ["change", 351], ["from", 358], ["baseline", 363], ["to", 372], ["week", 375], ["8", 380], ["in", 382], ["pain", 385], ["intensity", 390], ["and", 400], ["the", 404], ["Western", 408], ["Ontario", 416], ["and", 424], ["McMaster", 428], ["Universities", 437], ["Osteoarthritis", 450], ["(", 465], ["WOMAC", 466], [")", 471], ["subscales", 473], [".", 482], ["Patients", 484], ["(", 493], ["n", 494], ["=", 496], ["83", 498], [")", 500], ["were", 502], ["69", 507], ["%", 509], ["female", 511], [",", 517], ["age", 519], ["44", 523], ["-", 525], ["73", 526], ["years", 529], [",", 534], ["with", 536], ["a", 541], ["Kellgren", 543], ["-", 551], ["Lawrence", 552], ["X", 561], ["-", 562], ["ray", 563], ["grade", 567], ["of", 573], ["2", 576], ["-", 577], ["4", 578], [".", 579], ["At", 581], ["week", 584], ["8", 589], [",", 590], ["compared", 592], ["with", 601], ["placebo", 606], [",", 613], ["tanezumab", 615], ["25", 625], [",", 627], ["100", 629], [",", 632], ["and", 634], ["200", 638], ["\u03bcg", 642], ["/", 644], ["kg", 645], ["improved", 648], ["index", 657], ["knee", 663], ["pain", 668], ["during", 673], ["walking", 680], ["(", 688], ["-18.5", 689], [",", 694], ["-14.3", 696], [",", 701], ["and", 703], ["-27.6", 707], [",", 712], ["respectively", 714], [")", 726], [",", 727], ["index", 729], ["knee", 735], ["pain", 740], ["in", 745], ["the", 748], ["past", 752], ["24", 757], ["h", 760], ["(", 762], ["-19.1", 763], [",", 768], ["-14.6", 770], [",", 775], ["and", 777], ["-24.2", 781], [",", 786], ["respectively", 788], [")", 800], [",", 801], ["current", 803], ["index", 811], ["knee", 817], ["pain", 822], ["(", 827], ["-16.5", 828], [",", 833], ["-10.9", 835], [",", 840], ["and", 842], ["-22.8", 846], [",", 851], ["respectively", 853], [")", 865], [",", 866], ["and", 868], ["the", 872], ["WOMAC", 876], ["pain", 882], ["(", 887], ["-11.5", 888], [",", 893], ["-9.6", 895], [",", 899], ["and", 901], ["-18.8", 905], [",", 910], ["respectively", 912], [")", 924], [",", 925], ["physical", 927], ["function", 936], ["(", 945], ["-8.7", 946], [",", 950], ["-9.5", 952], [",", 956], ["and", 958], ["-17.6", 962], [",", 967], ["respectively", 969], [")", 981], [",", 982], ["and", 984], ["stiffness", 988], ["(", 998], ["-20.4", 999], [",", 1004], ["-11.2", 1006], [",", 1011], ["and", 1013], ["-10.2", 1017], [",", 1022], ["respectively", 1024], [")", 1036], ["subscales", 1038], [".", 1047], ["Overall", 1049], [",", 1056], ["seven", 1058], ["patients", 1064], ["reported", 1073], ["AEs", 1082], ["of", 1086], ["abnormal", 1089], ["peripheral", 1098], ["sensation", 1109], [":", 1118], ["allodynia", 1120], ["(", 1130], ["two", 1131], ["in", 1135], ["the", 1138], ["tanezumab", 1142], ["200", 1152], ["\u03bcg", 1156], ["/", 1158], ["kg", 1159], ["group", 1162], [")", 1167], [";", 1168], ["paresthesia", 1170], ["(", 1182], ["two", 1183], ["in", 1187], ["the", 1190], ["tanezumab", 1194], ["200", 1204], ["\u03bcg", 1208], ["/", 1210], ["kg", 1211], ["group", 1214], [")", 1219], [",", 1220], ["dysesthesia", 1222], ["(", 1234], ["one", 1235], ["in", 1239], ["the", 1242], ["tanezumab", 1246], ["200", 1256], ["\u03bcg", 1260], ["/", 1262], ["kg", 1263], ["group", 1266], [")", 1271], [";", 1272], ["thermohypoesthesia", 1274], ["(", 1293], ["one", 1294], ["in", 1298], ["the", 1301], ["tanezumab", 1305], ["100", 1315], ["\u03bcg", 1319], ["/", 1321], ["kg", 1322], ["group", 1325], [")", 1330], [",", 1331], ["and", 1333], ["decreased", 1337], ["vibratory", 1347], ["sense", 1357], ["(", 1363], ["one", 1364], ["in", 1368], ["the", 1371], ["placebo", 1375], ["group", 1383], [")", 1388], [".", 1389], ["All", 1391], ["of", 1395], ["these", 1398], ["AEs", 1404], ["were", 1408], ["mild", 1413], ["to", 1418], ["moderate", 1421], ["in", 1430], ["severity", 1433], ["and", 1442], ["transient", 1446], ["in", 1456], ["nature", 1459], [".", 1465], ["Tanezumab", 1467], ["was", 1477], ["safe", 1481], ["and", 1486], ["generally", 1490], ["well", 1500], ["tolerated", 1505], ["and", 1515], ["may", 1519], ["improve", 1523], ["pain", 1531], ["symptoms", 1536], ["in", 1545], ["Japanese", 1548], ["patients", 1557], ["with", 1566], ["moderate", 1571], ["to", 1580], ["severe", 1583], ["osteoarthritis", 1590], ["of", 1605], ["the", 1608], ["knee", 1612], [".", 1616], ["CLINICALTRIALS.GOV", 1618], ["IDENTIFIER", 1637], [":", 1647], ["NCT00669409", 1649], [".", 1660]]}
{"context": "Tumors of the central nervous system are the most frequent solid tumors in childhood. With 30-40% of this heterogenous group, low-grade astrocytomas represent the most common subtype. Neurofibromatosis type 1 (NF1) is strongly associated with the development of pilocytic astrocytoma (PA), frequently appearing as optic glioma. Neurofibromatosis 1 gene (NF1 ) fulfills the criteria of a tumor suppressor gene and is deleted or mutated heterozygously in patients with NF1. This suggests an involvement in the development of PA. To clarify whether silencing of NF1 by promoter methylation plays a role in PA and especially in optic glioma, the authors investigated the methylation status in 30 PA, 6 of which had optic glioma. However, no methylation was found at the NF1 promoter region in PA. To rule out that silencing of NF1 by promoter methylation is restricted to higher-grade astrocytomas, 15 pediatric WHO II degree and IV degree astrocytomas were analyzed: 12 astrocytomas II and 3 glioblastomas displayed no NF1 promoter methylation. The authors conclude that NF1 silencing by methylation plays no role in low-grade astrocytoma.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "50efbe779a774f9abfa654638c3497ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[64, 64], [192, 192], [83, 83], [100, 100], [140, 140], [39, 39], [152, 152], [184, 184]], "char_spans": [[354, 356], [1068, 1070], [467, 469], [559, 561], [766, 768], [210, 212], [823, 825], [1016, 1018]]}]}], "context_tokens": [["Tumors", 0], ["of", 7], ["the", 10], ["central", 14], ["nervous", 22], ["system", 30], ["are", 37], ["the", 41], ["most", 45], ["frequent", 50], ["solid", 59], ["tumors", 65], ["in", 72], ["childhood", 75], [".", 84], ["With", 86], ["30", 91], ["-", 93], ["40", 94], ["%", 96], ["of", 98], ["this", 101], ["heterogenous", 106], ["group", 119], [",", 124], ["low", 126], ["-", 129], ["grade", 130], ["astrocytomas", 136], ["represent", 149], ["the", 159], ["most", 163], ["common", 168], ["subtype", 175], [".", 182], ["Neurofibromatosis", 184], ["type", 202], ["1", 207], ["(", 209], ["NF1", 210], [")", 213], ["is", 215], ["strongly", 218], ["associated", 227], ["with", 238], ["the", 243], ["development", 247], ["of", 259], ["pilocytic", 262], ["astrocytoma", 272], ["(", 284], ["PA", 285], [")", 287], [",", 288], ["frequently", 290], ["appearing", 301], ["as", 311], ["optic", 314], ["glioma", 320], [".", 326], ["Neurofibromatosis", 328], ["1", 346], ["gene", 348], ["(", 353], ["NF1", 354], [")", 358], ["fulfills", 360], ["the", 369], ["criteria", 373], ["of", 382], ["a", 385], ["tumor", 387], ["suppressor", 393], ["gene", 404], ["and", 409], ["is", 413], ["deleted", 416], ["or", 424], ["mutated", 427], ["heterozygously", 435], ["in", 450], ["patients", 453], ["with", 462], ["NF1", 467], [".", 470], ["This", 472], ["suggests", 477], ["an", 486], ["involvement", 489], ["in", 501], ["the", 504], ["development", 508], ["of", 520], ["PA", 523], [".", 525], ["To", 527], ["clarify", 530], ["whether", 538], ["silencing", 546], ["of", 556], ["NF1", 559], ["by", 563], ["promoter", 566], ["methylation", 575], ["plays", 587], ["a", 593], ["role", 595], ["in", 600], ["PA", 603], ["and", 606], ["especially", 610], ["in", 621], ["optic", 624], ["glioma", 630], [",", 636], ["the", 638], ["authors", 642], ["investigated", 650], ["the", 663], ["methylation", 667], ["status", 679], ["in", 686], ["30", 689], ["PA", 692], [",", 694], ["6", 696], ["of", 698], ["which", 701], ["had", 707], ["optic", 711], ["glioma", 717], [".", 723], ["However", 725], [",", 732], ["no", 734], ["methylation", 737], ["was", 749], ["found", 753], ["at", 759], ["the", 762], ["NF1", 766], ["promoter", 770], ["region", 779], ["in", 786], ["PA", 789], [".", 791], ["To", 793], ["rule", 796], ["out", 801], ["that", 805], ["silencing", 810], ["of", 820], ["NF1", 823], ["by", 827], ["promoter", 830], ["methylation", 839], ["is", 851], ["restricted", 854], ["to", 865], ["higher", 868], ["-", 874], ["grade", 875], ["astrocytomas", 881], [",", 893], ["15", 895], ["pediatric", 898], ["WHO", 908], ["II", 912], ["degree", 915], ["and", 922], ["IV", 926], ["degree", 929], ["astrocytomas", 936], ["were", 949], ["analyzed", 954], [":", 962], ["12", 964], ["astrocytomas", 967], ["II", 980], ["and", 983], ["3", 987], ["glioblastomas", 989], ["displayed", 1003], ["no", 1013], ["NF1", 1016], ["promoter", 1020], ["methylation", 1029], [".", 1040], ["The", 1042], ["authors", 1046], ["conclude", 1054], ["that", 1063], ["NF1", 1068], ["silencing", 1072], ["by", 1082], ["methylation", 1085], ["plays", 1097], ["no", 1103], ["role", 1106], ["in", 1111], ["low", 1114], ["-", 1117], ["grade", 1118], ["astrocytoma", 1124], [".", 1135]]}
{"context": "The APP/PS1ki mouse model for Alzheimer's disease (AD) exhibits robust brain and spinal cord axonal degeneration and hippocampal CA1 neuron loss starting at 6 months of age. It expresses human mutant APP751 with the Swedish and London mutations together with two FAD-linked knocked-in mutations (PS1 M233T and PS1 L235P) in the murine PS1 gene. The present report covers a phenotypical analysis of this model using either behavioral tests for working memory and motor performance, as well as an analysis of weight development and body shape. At the age of 6 months, a dramatic, age-dependent change in all of these properties and characteristics was observed, accompanied by a significantly reduced ability to perform working memory and motor tasks. The APP/PS1ki mice were smaller and showed development of a thoracolumbar kyphosis, together with an incremental loss of body weight. While 2-month-old APP/PS1ki mice were inconspicuous in all of these tasks and properties, there is a massive age-related impairment in all tested behavioral paradigms. We have previously reported robust axonal degeneration in brain and spinal cord, as well as abundant hippocampal CA1 neuron loss starting at 6 months of age in the APP/PS1ki mouse model, which coincides with the onset of motor and memory deficits described in the present report.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "8060a2992f724000a8c3de198bfabc09", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[7, 9]], "char_spans": [[30, 48]]}, {"text": "AD", "token_spans": [[11, 11]], "char_spans": [[51, 52]]}]}], "context_tokens": [["The", 0], ["APP", 4], ["/", 7], ["PS1ki", 8], ["mouse", 14], ["model", 20], ["for", 26], ["Alzheimer", 30], ["'s", 39], ["disease", 42], ["(", 50], ["AD", 51], [")", 53], ["exhibits", 55], ["robust", 64], ["brain", 71], ["and", 77], ["spinal", 81], ["cord", 88], ["axonal", 93], ["degeneration", 100], ["and", 113], ["hippocampal", 117], ["CA1", 129], ["neuron", 133], ["loss", 140], ["starting", 145], ["at", 154], ["6", 157], ["months", 159], ["of", 166], ["age", 169], [".", 172], ["It", 174], ["expresses", 177], ["human", 187], ["mutant", 193], ["APP751", 200], ["with", 207], ["the", 212], ["Swedish", 216], ["and", 224], ["London", 228], ["mutations", 235], ["together", 245], ["with", 254], ["two", 259], ["FAD", 263], ["-", 266], ["linked", 267], ["knocked", 274], ["-", 281], ["in", 282], ["mutations", 285], ["(", 295], ["PS1", 296], ["M233", 300], ["T", 304], ["and", 306], ["PS1", 310], ["L235P", 314], [")", 319], ["in", 321], ["the", 324], ["murine", 328], ["PS1", 335], ["gene", 339], [".", 343], ["The", 345], ["present", 349], ["report", 357], ["covers", 364], ["a", 371], ["phenotypical", 373], ["analysis", 386], ["of", 395], ["this", 398], ["model", 403], ["using", 409], ["either", 415], ["behavioral", 422], ["tests", 433], ["for", 439], ["working", 443], ["memory", 451], ["and", 458], ["motor", 462], ["performance", 468], [",", 479], ["as", 481], ["well", 484], ["as", 489], ["an", 492], ["analysis", 495], ["of", 504], ["weight", 507], ["development", 514], ["and", 526], ["body", 530], ["shape", 535], [".", 540], ["At", 542], ["the", 545], ["age", 549], ["of", 553], ["6", 556], ["months", 558], [",", 564], ["a", 566], ["dramatic", 568], [",", 576], ["age", 578], ["-", 581], ["dependent", 582], ["change", 592], ["in", 599], ["all", 602], ["of", 606], ["these", 609], ["properties", 615], ["and", 626], ["characteristics", 630], ["was", 646], ["observed", 650], [",", 658], ["accompanied", 660], ["by", 672], ["a", 675], ["significantly", 677], ["reduced", 691], ["ability", 699], ["to", 707], ["perform", 710], ["working", 718], ["memory", 726], ["and", 733], ["motor", 737], ["tasks", 743], [".", 748], ["The", 750], ["APP", 754], ["/", 757], ["PS1ki", 758], ["mice", 764], ["were", 769], ["smaller", 774], ["and", 782], ["showed", 786], ["development", 793], ["of", 805], ["a", 808], ["thoracolumbar", 810], ["kyphosis", 824], [",", 832], ["together", 834], ["with", 843], ["an", 848], ["incremental", 851], ["loss", 863], ["of", 868], ["body", 871], ["weight", 876], [".", 882], ["While", 884], ["2-month", 890], ["-", 897], ["old", 898], ["APP", 902], ["/", 905], ["PS1ki", 906], ["mice", 912], ["were", 917], ["inconspicuous", 922], ["in", 936], ["all", 939], ["of", 943], ["these", 946], ["tasks", 952], ["and", 958], ["properties", 962], [",", 972], ["there", 974], ["is", 980], ["a", 983], ["massive", 985], ["age", 993], ["-", 996], ["related", 997], ["impairment", 1005], ["in", 1016], ["all", 1019], ["tested", 1023], ["behavioral", 1030], ["paradigms", 1041], [".", 1050], ["We", 1052], ["have", 1055], ["previously", 1060], ["reported", 1071], ["robust", 1080], ["axonal", 1087], ["degeneration", 1094], ["in", 1107], ["brain", 1110], ["and", 1116], ["spinal", 1120], ["cord", 1127], [",", 1131], ["as", 1133], ["well", 1136], ["as", 1141], ["abundant", 1144], ["hippocampal", 1153], ["CA1", 1165], ["neuron", 1169], ["loss", 1176], ["starting", 1181], ["at", 1190], ["6", 1193], ["months", 1195], ["of", 1202], ["age", 1205], ["in", 1209], ["the", 1212], ["APP", 1216], ["/", 1219], ["PS1ki", 1220], ["mouse", 1226], ["model", 1232], [",", 1237], ["which", 1239], ["coincides", 1245], ["with", 1255], ["the", 1260], ["onset", 1264], ["of", 1270], ["motor", 1273], ["and", 1279], ["memory", 1283], ["deficits", 1290], ["described", 1299], ["in", 1309], ["the", 1312], ["present", 1316], ["report", 1324], [".", 1330]]}
{"context": "Centrosome forms the backbone of cell cycle progression mechanism. Recent debates have occurred regarding the essentiality of centrosome in cell cycle regulation. CEP family protein is the active component of centrosome and plays a vital role in centriole biogenesis and cell cycle progression control. A total of 31 proteins have been categorized into CEP family protein category and many more are under candidate evaluation. Furthermore, by the recent advancements in genomics and proteomics researches, several new CEP proteins have also been characterized. Here we have summarized the importance of CEP family proteins and their regulation mechanism involved in proper cell cycle progression. Further, we have reviewed the detailed molecular mechanism behind the associated pathological phenotypes and the possible therapeutic approaches. Proteins such as CEP57, CEP63, CEP152, CEP164, and CEP215 have been extensively studied with a detailed description of their molecular mechanisms, which are among the primary targets for drug discovery. Moreover, CEP27, CEP55, CEP70, CEP110, CEP120, CEP135, CEP192, CEP250, CEP290, and CEP350 also seem promising for future drug discovery approaches. Since the overview implicates that the overall researches on CEP proteins are not yet able to present significant details required for effective therapeutics development, thus, it is timely to discuss the importance of future investigations in this field.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "bc41177a6b044b729aab22fd26e9d225", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[0, 0], [32, 32], [18, 18]], "char_spans": [[0, 9], [209, 218], [126, 135]]}]}], "context_tokens": [["Centrosome", 0], ["forms", 11], ["the", 17], ["backbone", 21], ["of", 30], ["cell", 33], ["cycle", 38], ["progression", 44], ["mechanism", 56], [".", 65], ["Recent", 67], ["debates", 74], ["have", 82], ["occurred", 87], ["regarding", 96], ["the", 106], ["essentiality", 110], ["of", 123], ["centrosome", 126], ["in", 137], ["cell", 140], ["cycle", 145], ["regulation", 151], [".", 161], ["CEP", 163], ["family", 167], ["protein", 174], ["is", 182], ["the", 185], ["active", 189], ["component", 196], ["of", 206], ["centrosome", 209], ["and", 220], ["plays", 224], ["a", 230], ["vital", 232], ["role", 238], ["in", 243], ["centriole", 246], ["biogenesis", 256], ["and", 267], ["cell", 271], ["cycle", 276], ["progression", 282], ["control", 294], [".", 301], ["A", 303], ["total", 305], ["of", 311], ["31", 314], ["proteins", 317], ["have", 326], ["been", 331], ["categorized", 336], ["into", 348], ["CEP", 353], ["family", 357], ["protein", 364], ["category", 372], ["and", 381], ["many", 385], ["more", 390], ["are", 395], ["under", 399], ["candidate", 405], ["evaluation", 415], [".", 425], ["Furthermore", 427], [",", 438], ["by", 440], ["the", 443], ["recent", 447], ["advancements", 454], ["in", 467], ["genomics", 470], ["and", 479], ["proteomics", 483], ["researches", 494], [",", 504], ["several", 506], ["new", 514], ["CEP", 518], ["proteins", 522], ["have", 531], ["also", 536], ["been", 541], ["characterized", 546], [".", 559], ["Here", 561], ["we", 566], ["have", 569], ["summarized", 574], ["the", 585], ["importance", 589], ["of", 600], ["CEP", 603], ["family", 607], ["proteins", 614], ["and", 623], ["their", 627], ["regulation", 633], ["mechanism", 644], ["involved", 654], ["in", 663], ["proper", 666], ["cell", 673], ["cycle", 678], ["progression", 684], [".", 695], ["Further", 697], [",", 704], ["we", 706], ["have", 709], ["reviewed", 714], ["the", 723], ["detailed", 727], ["molecular", 736], ["mechanism", 746], ["behind", 756], ["the", 763], ["associated", 767], ["pathological", 778], ["phenotypes", 791], ["and", 802], ["the", 806], ["possible", 810], ["therapeutic", 819], ["approaches", 831], [".", 841], ["Proteins", 843], ["such", 852], ["as", 857], ["CEP57", 860], [",", 865], ["CEP63", 867], [",", 872], ["CEP152", 874], [",", 880], ["CEP164", 882], [",", 888], ["and", 890], ["CEP215", 894], ["have", 901], ["been", 906], ["extensively", 911], ["studied", 923], ["with", 931], ["a", 936], ["detailed", 938], ["description", 947], ["of", 959], ["their", 962], ["molecular", 968], ["mechanisms", 978], [",", 988], ["which", 990], ["are", 996], ["among", 1000], ["the", 1006], ["primary", 1010], ["targets", 1018], ["for", 1026], ["drug", 1030], ["discovery", 1035], [".", 1044], ["Moreover", 1046], [",", 1054], ["CEP27", 1056], [",", 1061], ["CEP55", 1063], [",", 1068], ["CEP70", 1070], [",", 1075], ["CEP110", 1077], [",", 1083], ["CEP120", 1085], [",", 1091], ["CEP135", 1093], [",", 1099], ["CEP192", 1101], [",", 1107], ["CEP250", 1109], [",", 1115], ["CEP290", 1117], [",", 1123], ["and", 1125], ["CEP350", 1129], ["also", 1136], ["seem", 1141], ["promising", 1146], ["for", 1156], ["future", 1160], ["drug", 1167], ["discovery", 1172], ["approaches", 1182], [".", 1192], ["Since", 1194], ["the", 1200], ["overview", 1204], ["implicates", 1213], ["that", 1224], ["the", 1229], ["overall", 1233], ["researches", 1241], ["on", 1252], ["CEP", 1255], ["proteins", 1259], ["are", 1268], ["not", 1272], ["yet", 1276], ["able", 1280], ["to", 1285], ["present", 1288], ["significant", 1296], ["details", 1308], ["required", 1316], ["for", 1325], ["effective", 1329], ["therapeutics", 1339], ["development", 1352], [",", 1363], ["thus", 1365], [",", 1369], ["it", 1371], ["is", 1374], ["timely", 1377], ["to", 1384], ["discuss", 1387], ["the", 1395], ["importance", 1399], ["of", 1410], ["future", 1413], ["investigations", 1420], ["in", 1435], ["this", 1438], ["field", 1443], [".", 1448]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been implicated in several physiological and pathophysiological processes. To date seven members of this family have been reported, including Nox1-5 and Duox1 and 2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase, for its activity. Recently, we identified the c-Src substrate proteins Tks4 and Tks5 as functional members of a p47(phox)-related organizer superfamily. As a functional consequence of this interaction, Nox1 localizes to invadopodia, actin-rich membrane protrusions of cancer cells which facilitate pericellular proteolysis and invasive behavior. Here, we report that Tks4 and Tks5 directly bind to NoxA1. Moreover, the integrity of the N-terminal PRR of NoxA1 is essential for this direct interaction with the Tks proteins. When the PRR in NoxA1 is disrupted, Tks proteins cannot bind NoxA1 and lose their ability to support Nox1-dependent ROS generation. Consistent with this, Tks4 and Tks5 are unable to act as organizers for Nox2 because of their inability to interact with p67(phox), which lacks the N-terminal PRR, thus conferring a unique specificity to Tks4 and 5. Taken together, these results clarify the molecular basis for the interaction between NoxA1 and the Tks proteins and may provide new insights into the pharmacological design of a more effective anti-metastatic strategy.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "809980294d6346f88b44bf8f45d50ed7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[137, 137], [45, 45], [70, 70]], "char_spans": [[753, 756], [259, 262], [373, 376]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["implicated", 122], ["in", 133], ["several", 136], ["physiological", 144], ["and", 158], ["pathophysiological", 162], ["processes", 181], [".", 190], ["To", 192], ["date", 195], ["seven", 200], ["members", 206], ["of", 214], ["this", 217], ["family", 222], ["have", 229], ["been", 234], ["reported", 239], [",", 247], ["including", 249], ["Nox1", 259], ["-", 263], ["5", 264], ["and", 266], ["Duox1", 270], ["and", 276], ["2", 280], [".", 281], ["With", 283], ["the", 288], ["exception", 292], ["of", 302], ["Nox2", 305], [",", 309], ["the", 311], ["regulation", 315], ["of", 326], ["the", 329], ["Nox", 333], ["enzymes", 337], ["is", 345], ["still", 348], ["poorly", 354], ["understood", 361], [".", 371], ["Nox1", 373], ["is", 378], ["highly", 381], ["expressed", 388], ["in", 398], ["the", 401], ["colon", 405], [",", 410], ["and", 412], ["requires", 416], ["two", 425], ["cytosolic", 429], ["regulators", 439], [",", 449], ["the", 451], ["organizer", 455], ["subunit", 465], ["NoxO1", 473], ["and", 479], ["the", 483], ["activator", 487], ["subunit", 497], ["NoxA1", 505], [",", 510], ["as", 512], ["well", 515], ["as", 520], ["the", 523], ["binding", 527], ["of", 535], ["Rac1", 538], ["GTPase", 543], [",", 549], ["for", 551], ["its", 555], ["activity", 559], [".", 567], ["Recently", 569], [",", 577], ["we", 579], ["identified", 582], ["the", 593], ["c", 597], ["-", 598], ["Src", 599], ["substrate", 603], ["proteins", 613], ["Tks4", 622], ["and", 627], ["Tks5", 631], ["as", 636], ["functional", 639], ["members", 650], ["of", 658], ["a", 661], ["p47(phox)-related", 663], ["organizer", 681], ["superfamily", 691], [".", 702], ["As", 704], ["a", 707], ["functional", 709], ["consequence", 720], ["of", 732], ["this", 735], ["interaction", 740], [",", 751], ["Nox1", 753], ["localizes", 758], ["to", 768], ["invadopodia", 771], [",", 782], ["actin", 784], ["-", 789], ["rich", 790], ["membrane", 795], ["protrusions", 804], ["of", 816], ["cancer", 819], ["cells", 826], ["which", 832], ["facilitate", 838], ["pericellular", 849], ["proteolysis", 862], ["and", 874], ["invasive", 878], ["behavior", 887], [".", 895], ["Here", 897], [",", 901], ["we", 903], ["report", 906], ["that", 913], ["Tks4", 918], ["and", 923], ["Tks5", 927], ["directly", 932], ["bind", 941], ["to", 946], ["NoxA1", 949], [".", 954], ["Moreover", 956], [",", 964], ["the", 966], ["integrity", 970], ["of", 980], ["the", 983], ["N", 987], ["-", 988], ["terminal", 989], ["PRR", 998], ["of", 1002], ["NoxA1", 1005], ["is", 1011], ["essential", 1014], ["for", 1024], ["this", 1028], ["direct", 1033], ["interaction", 1040], ["with", 1052], ["the", 1057], ["Tks", 1061], ["proteins", 1065], [".", 1073], ["When", 1075], ["the", 1080], ["PRR", 1084], ["in", 1088], ["NoxA1", 1091], ["is", 1097], ["disrupted", 1100], [",", 1109], ["Tks", 1111], ["proteins", 1115], ["can", 1124], ["not", 1127], ["bind", 1131], ["NoxA1", 1136], ["and", 1142], ["lose", 1146], ["their", 1151], ["ability", 1157], ["to", 1165], ["support", 1168], ["Nox1-dependent", 1176], ["ROS", 1191], ["generation", 1195], [".", 1205], ["Consistent", 1207], ["with", 1218], ["this", 1223], [",", 1227], ["Tks4", 1229], ["and", 1234], ["Tks5", 1238], ["are", 1243], ["unable", 1247], ["to", 1254], ["act", 1257], ["as", 1261], ["organizers", 1264], ["for", 1275], ["Nox2", 1279], ["because", 1284], ["of", 1292], ["their", 1295], ["inability", 1301], ["to", 1311], ["interact", 1314], ["with", 1323], ["p67(phox", 1328], [")", 1336], [",", 1337], ["which", 1339], ["lacks", 1345], ["the", 1351], ["N", 1355], ["-", 1356], ["terminal", 1357], ["PRR", 1366], [",", 1369], ["thus", 1371], ["conferring", 1376], ["a", 1387], ["unique", 1389], ["specificity", 1396], ["to", 1408], ["Tks4", 1411], ["and", 1416], ["5", 1420], [".", 1421], ["Taken", 1423], ["together", 1429], [",", 1437], ["these", 1439], ["results", 1445], ["clarify", 1453], ["the", 1461], ["molecular", 1465], ["basis", 1475], ["for", 1481], ["the", 1485], ["interaction", 1489], ["between", 1501], ["NoxA1", 1509], ["and", 1515], ["the", 1519], ["Tks", 1523], ["proteins", 1527], ["and", 1536], ["may", 1540], ["provide", 1544], ["new", 1552], ["insights", 1556], ["into", 1565], ["the", 1570], ["pharmacological", 1574], ["design", 1590], ["of", 1597], ["a", 1600], ["more", 1602], ["effective", 1607], ["anti", 1617], ["-", 1621], ["metastatic", 1622], ["strategy", 1633], [".", 1641]]}
{"context": "The multidrug resistance 1 gene (MDR1) encodes P-glycoprotein (Pgp), a member of the ATP-binding cassette (ABC) transporter family that confers tumor drug resistance by actively effluxing a number of antitumor agents. We had previously shown that MDR1 transcription is regulated by epigenetic events such as histone acetylation, and had identified the histone acetylase P/CAF and the transcription factor NF-Y as the factors mediating the enzymatic and DNA-anchoring functions, respectively, at the MDR1 promoter. It has also been shown that MDR1 activation is accompanied by increased methylation on lysine 4 of histone H3 (H3K4). In this study, we further investigated histone methylation in MDR1 regulation and function. We show that the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4, is required for MDR1 promoter methylation, as knockdown of MLL1 resulted in a decrease in MDR1 expression. The regulation of MDR1 by MLL1 has functional consequences in that downregulation of MLL1 led to increased retention of the Pgp-specific substrate DIOC(2)(3), as well as increased cellular sensitivity to several Pgp substrates. Regulation of MDR1 by MLL1 was dependent on the CCAAT box within the proximal MDR1 promoter, similar to what we had shown for MDR1 promoter acetylation, and also requires NF-Y. Finally, overexpression of the most prevalent MLL fusion protein, MLL-AF4, led to increased MDR1 expression. This is the first identification of a histone methyltransferase and its leukemogenic rearrangement that regulates expression of an ABC drug transporter, suggesting a new target for circumvention of tumor multidrug resistance.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "c52217c869064579a2201e621fdbf60c", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[151, 151], [115, 115]], "char_spans": [[823, 826], [625, 628]]}]}], "context_tokens": [["The", 0], ["multidrug", 4], ["resistance", 14], ["1", 25], ["gene", 27], ["(", 32], ["MDR1", 33], [")", 37], ["encodes", 39], ["P", 47], ["-", 48], ["glycoprotein", 49], ["(", 62], ["Pgp", 63], [")", 66], [",", 67], ["a", 69], ["member", 71], ["of", 78], ["the", 81], ["ATP", 85], ["-", 88], ["binding", 89], ["cassette", 97], ["(", 106], ["ABC", 107], [")", 110], ["transporter", 112], ["family", 124], ["that", 131], ["confers", 136], ["tumor", 144], ["drug", 150], ["resistance", 155], ["by", 166], ["actively", 169], ["effluxing", 178], ["a", 188], ["number", 190], ["of", 197], ["antitumor", 200], ["agents", 210], [".", 216], ["We", 218], ["had", 221], ["previously", 225], ["shown", 236], ["that", 242], ["MDR1", 247], ["transcription", 252], ["is", 266], ["regulated", 269], ["by", 279], ["epigenetic", 282], ["events", 293], ["such", 300], ["as", 305], ["histone", 308], ["acetylation", 316], [",", 327], ["and", 329], ["had", 333], ["identified", 337], ["the", 348], ["histone", 352], ["acetylase", 360], ["P", 370], ["/", 371], ["CAF", 372], ["and", 376], ["the", 380], ["transcription", 384], ["factor", 398], ["NF", 405], ["-", 407], ["Y", 408], ["as", 410], ["the", 413], ["factors", 417], ["mediating", 425], ["the", 435], ["enzymatic", 439], ["and", 449], ["DNA", 453], ["-", 456], ["anchoring", 457], ["functions", 467], [",", 476], ["respectively", 478], [",", 490], ["at", 492], ["the", 495], ["MDR1", 499], ["promoter", 504], [".", 512], ["It", 514], ["has", 517], ["also", 521], ["been", 526], ["shown", 531], ["that", 537], ["MDR1", 542], ["activation", 547], ["is", 558], ["accompanied", 561], ["by", 573], ["increased", 576], ["methylation", 586], ["on", 598], ["lysine", 601], ["4", 608], ["of", 610], ["histone", 613], ["H3", 621], ["(", 624], ["H3K4", 625], [")", 629], [".", 630], ["In", 632], ["this", 635], ["study", 640], [",", 645], ["we", 647], ["further", 650], ["investigated", 658], ["histone", 671], ["methylation", 679], ["in", 691], ["MDR1", 694], ["regulation", 699], ["and", 710], ["function", 714], [".", 722], ["We", 724], ["show", 727], ["that", 732], ["the", 737], ["mixed", 741], ["lineage", 747], ["leukemia", 755], ["1", 764], ["(", 766], ["MLL1", 767], [")", 771], ["protein", 773], [",", 780], ["a", 782], ["histone", 784], ["methyltransferase", 792], ["specific", 810], ["for", 819], ["H3K4", 823], [",", 827], ["is", 829], ["required", 832], ["for", 841], ["MDR1", 845], ["promoter", 850], ["methylation", 859], [",", 870], ["as", 872], ["knockdown", 875], ["of", 885], ["MLL1", 888], ["resulted", 893], ["in", 902], ["a", 905], ["decrease", 907], ["in", 916], ["MDR1", 919], ["expression", 924], [".", 934], ["The", 936], ["regulation", 940], ["of", 951], ["MDR1", 954], ["by", 959], ["MLL1", 962], ["has", 967], ["functional", 971], ["consequences", 982], ["in", 995], ["that", 998], ["downregulation", 1003], ["of", 1018], ["MLL1", 1021], ["led", 1026], ["to", 1030], ["increased", 1033], ["retention", 1043], ["of", 1053], ["the", 1056], ["Pgp", 1060], ["-", 1063], ["specific", 1064], ["substrate", 1073], ["DIOC(2)(3", 1083], [")", 1092], [",", 1093], ["as", 1095], ["well", 1098], ["as", 1103], ["increased", 1106], ["cellular", 1116], ["sensitivity", 1125], ["to", 1137], ["several", 1140], ["Pgp", 1148], ["substrates", 1152], [".", 1162], ["Regulation", 1164], ["of", 1175], ["MDR1", 1178], ["by", 1183], ["MLL1", 1186], ["was", 1191], ["dependent", 1195], ["on", 1205], ["the", 1208], ["CCAAT", 1212], ["box", 1218], ["within", 1222], ["the", 1229], ["proximal", 1233], ["MDR1", 1242], ["promoter", 1247], [",", 1255], ["similar", 1257], ["to", 1265], ["what", 1268], ["we", 1273], ["had", 1276], ["shown", 1280], ["for", 1286], ["MDR1", 1290], ["promoter", 1295], ["acetylation", 1304], [",", 1315], ["and", 1317], ["also", 1321], ["requires", 1326], ["NF", 1335], ["-", 1337], ["Y.", 1338], ["Finally", 1341], [",", 1348], ["overexpression", 1350], ["of", 1365], ["the", 1368], ["most", 1372], ["prevalent", 1377], ["MLL", 1387], ["fusion", 1391], ["protein", 1398], [",", 1405], ["MLL", 1407], ["-", 1410], ["AF4", 1411], [",", 1414], ["led", 1416], ["to", 1420], ["increased", 1423], ["MDR1", 1433], ["expression", 1438], [".", 1448], ["This", 1450], ["is", 1455], ["the", 1458], ["first", 1462], ["identification", 1468], ["of", 1483], ["a", 1486], ["histone", 1488], ["methyltransferase", 1496], ["and", 1514], ["its", 1518], ["leukemogenic", 1522], ["rearrangement", 1535], ["that", 1549], ["regulates", 1554], ["expression", 1564], ["of", 1575], ["an", 1578], ["ABC", 1581], ["drug", 1585], ["transporter", 1590], [",", 1601], ["suggesting", 1603], ["a", 1614], ["new", 1616], ["target", 1620], ["for", 1627], ["circumvention", 1631], ["of", 1645], ["tumor", 1648], ["multidrug", 1654], ["resistance", 1664], [".", 1674]]}
{"context": "To clarify the association between clinically defined simple stress urinary incontinence (SUI) symptoms and urodynamic SUI, we examined the relationship between Valsalva leak point pressure (VLPP) as measured by the Q-tip test and Stamey grade in simple female SUI. Two hundred grade I or II female SUI patients with SUI symptom were examined by reviewing medical history; physical examination; urethral mobility as assessed by Q-tip test; stress test; and cystometry, including VLPP measurement. On the basis of the VLPP, patients were classified into urethral hypermobility [UH, subdivided into anatomical incontinence (AI) and equivocal incontinence (EI)] or intrinsic sphincter deficiency groups for analysis of the relationship between VLPP and Stamey grade and Q-tip angle. Seventy-eight patients were included, and the mean patient age was 54 \u00b1 7.5 years, mean SUI symptom duration 2.8 years (range 0.5-6 years), mean VLPP 103.6 \u00b1 18.4 cm H2O, and mean Q-tip angle 28.6\u00b0 \u00b1 7.2\u00b0. Fifty-three patients were categorized as Stamey grade I, 25 as Stamey grade II, 51 as AI, and 27 as EI. VLPP was found to be negatively correlated with Q-tip angle (Rs = -0.798, Y = -0.313X + 60.95, P < 0.001), and classifications of VLPP and Stamey grade have positive correlation (\u03c7 (2) = 4.9130, P = 0.0267). In simple female SUI, VLPP is associated with the Q-tip angle and Stamey grade, which may help to reduce some of urodynamic items.", "qas": [{"question": "Which type of urinary incontinence is diagnosed with the Q tip test?", "answers": ["stress urinary incontinence"], "qid": "804f275edde947989343c29d6110428e", "question_tokens": [["Which", 0], ["type", 6], ["of", 11], ["urinary", 14], ["incontinence", 22], ["is", 35], ["diagnosed", 38], ["with", 48], ["the", 53], ["Q", 57], ["tip", 59], ["test", 63], ["?", 67]], "detected_answers": [{"text": "stress urinary incontinence", "token_spans": [[8, 10]], "char_spans": [[61, 87]]}]}], "context_tokens": [["To", 0], ["clarify", 3], ["the", 11], ["association", 15], ["between", 27], ["clinically", 35], ["defined", 46], ["simple", 54], ["stress", 61], ["urinary", 68], ["incontinence", 76], ["(", 89], ["SUI", 90], [")", 93], ["symptoms", 95], ["and", 104], ["urodynamic", 108], ["SUI", 119], [",", 122], ["we", 124], ["examined", 127], ["the", 136], ["relationship", 140], ["between", 153], ["Valsalva", 161], ["leak", 170], ["point", 175], ["pressure", 181], ["(", 190], ["VLPP", 191], [")", 195], ["as", 197], ["measured", 200], ["by", 209], ["the", 212], ["Q", 216], ["-", 217], ["tip", 218], ["test", 222], ["and", 227], ["Stamey", 231], ["grade", 238], ["in", 244], ["simple", 247], ["female", 254], ["SUI", 261], [".", 264], ["Two", 266], ["hundred", 270], ["grade", 278], ["I", 284], ["or", 286], ["II", 289], ["female", 292], ["SUI", 299], ["patients", 303], ["with", 312], ["SUI", 317], ["symptom", 321], ["were", 329], ["examined", 334], ["by", 343], ["reviewing", 346], ["medical", 356], ["history", 364], [";", 371], ["physical", 373], ["examination", 382], [";", 393], ["urethral", 395], ["mobility", 404], ["as", 413], ["assessed", 416], ["by", 425], ["Q", 428], ["-", 429], ["tip", 430], ["test", 434], [";", 438], ["stress", 440], ["test", 447], [";", 451], ["and", 453], ["cystometry", 457], [",", 467], ["including", 469], ["VLPP", 479], ["measurement", 484], [".", 495], ["On", 497], ["the", 500], ["basis", 504], ["of", 510], ["the", 513], ["VLPP", 517], [",", 521], ["patients", 523], ["were", 532], ["classified", 537], ["into", 548], ["urethral", 553], ["hypermobility", 562], ["[", 576], ["UH", 577], [",", 579], ["subdivided", 581], ["into", 592], ["anatomical", 597], ["incontinence", 608], ["(", 621], ["AI", 622], [")", 624], ["and", 626], ["equivocal", 630], ["incontinence", 640], ["(", 653], ["EI", 654], [")", 656], ["]", 657], ["or", 659], ["intrinsic", 662], ["sphincter", 672], ["deficiency", 682], ["groups", 693], ["for", 700], ["analysis", 704], ["of", 713], ["the", 716], ["relationship", 720], ["between", 733], ["VLPP", 741], ["and", 746], ["Stamey", 750], ["grade", 757], ["and", 763], ["Q", 767], ["-", 768], ["tip", 769], ["angle", 773], [".", 778], ["Seventy", 780], ["-", 787], ["eight", 788], ["patients", 794], ["were", 803], ["included", 808], [",", 816], ["and", 818], ["the", 822], ["mean", 826], ["patient", 831], ["age", 839], ["was", 843], ["54", 847], ["\u00b1", 850], ["7.5", 852], ["years", 856], [",", 861], ["mean", 863], ["SUI", 868], ["symptom", 872], ["duration", 880], ["2.8", 889], ["years", 893], ["(", 899], ["range", 900], ["0.5", 906], ["-", 909], ["6", 910], ["years", 912], [")", 917], [",", 918], ["mean", 920], ["VLPP", 925], ["103.6", 930], ["\u00b1", 936], ["18.4", 938], ["cm", 943], ["H2O", 946], [",", 949], ["and", 951], ["mean", 955], ["Q", 960], ["-", 961], ["tip", 962], ["angle", 966], ["28.6", 972], ["\u00b0", 976], ["\u00b1", 978], ["7.2", 980], ["\u00b0", 983], [".", 984], ["Fifty", 986], ["-", 991], ["three", 992], ["patients", 998], ["were", 1007], ["categorized", 1012], ["as", 1024], ["Stamey", 1027], ["grade", 1034], ["I", 1040], [",", 1041], ["25", 1043], ["as", 1046], ["Stamey", 1049], ["grade", 1056], ["II", 1062], [",", 1064], ["51", 1066], ["as", 1069], ["AI", 1072], [",", 1074], ["and", 1076], ["27", 1080], ["as", 1083], ["EI", 1086], [".", 1088], ["VLPP", 1090], ["was", 1095], ["found", 1099], ["to", 1105], ["be", 1108], ["negatively", 1111], ["correlated", 1122], ["with", 1133], ["Q", 1138], ["-", 1139], ["tip", 1140], ["angle", 1144], ["(", 1150], ["Rs", 1151], ["=", 1154], ["-0.798", 1156], [",", 1162], ["Y", 1164], ["=", 1166], ["-0.313X", 1168], ["+", 1176], ["60.95", 1178], [",", 1183], ["P", 1185], ["<", 1187], ["0.001", 1189], [")", 1194], [",", 1195], ["and", 1197], ["classifications", 1201], ["of", 1217], ["VLPP", 1220], ["and", 1225], ["Stamey", 1229], ["grade", 1236], ["have", 1242], ["positive", 1247], ["correlation", 1256], ["(", 1268], ["\u03c7", 1269], ["(", 1271], ["2", 1272], [")", 1273], ["=", 1275], ["4.9130", 1277], [",", 1283], ["P", 1285], ["=", 1287], ["0.0267", 1289], [")", 1295], [".", 1296], ["In", 1298], ["simple", 1301], ["female", 1308], ["SUI", 1315], [",", 1318], ["VLPP", 1320], ["is", 1325], ["associated", 1328], ["with", 1339], ["the", 1344], ["Q", 1348], ["-", 1349], ["tip", 1350], ["angle", 1354], ["and", 1360], ["Stamey", 1364], ["grade", 1371], [",", 1376], ["which", 1378], ["may", 1384], ["help", 1388], ["to", 1393], ["reduce", 1396], ["some", 1403], ["of", 1408], ["urodynamic", 1411], ["items", 1422], [".", 1427]]}
{"context": "Opicapone (OPC) is a novel catechol-O-methyltransferase (COMT) inhibitor to be used as adjunctive therapy in levodopa-treated patients with Parkinson's disease. The purpose of this study was to evaluate the effect of moderate liver impairment on the pharmacokinetics (PK) and pharmacodynamics (PD; effect on COMT activity) of OPC. An open-label, parallel-group study in patients (n\u2009=\u20098) with moderate liver impairment (Child-Pugh category B, score of 7 to 9) and matched healthy subjects (n\u2009=\u20098, control) with normal liver function. All subjects received a single 50-mg oral dose of OPC, with plasma and urine concentrations of opicapone and its metabolites measured up to 72\u00a0h post-dose, including soluble COMT (S-COMT) activity. A one-way analysis of variance (ANOVA) was used to compare the main PK and PD parameters between groups. Point estimates (PE) of geometric mean ratios (GMR) and corresponding 90\u00a0% confidence intervals (90%CI) for the ratio hepatic/control subjects of each parameter were calculated and compared with the reference interval (80-125\u00a0%). Exposure to opicapone (AUC and Cmax) increased significantly in patients with moderate hepatic impairment (PE [90%CI]: AUC0-\u221e, 184\u00a0% [135-250\u00a0%]; Cmax, 189\u00a0% [144-249\u00a0%]). Although apparent total clearance (CL/F) of opicapone was decreased by \u223c35\u00a0%, similar elimination half-life and unbound/bound fractions of opicapone were observed between the two groups. Both rate and extent of exposure to BIA 9-1103 were higher in the hepatically impaired group, but not statistically significant compared with the control group. Similar to the parent (opicapone), the observed increase in exposure to BIA 9-1106 was statistically significant in the hepatically impaired group over the control group. BIA 9-1106 was the only metabolite detected in urine and its urine PK parameters were in accordance with plasma data. Maximum S-COMT inhibition (Emax) occurred earlier for the hepatically impaired group with values of 100\u00a0% and 91.2\u00a0% for the hepatically impaired and control groups respectively. Both Emax and AUEC for the hepatically impaired group reached statistical significance over the control group. OPC was well tolerated in both hepatically impaired and control groups. The bioavailability of an orally administered single dose of 50\u00a0mg OPC was significantly higher in patients with moderate chronic hepatic impairment, perhaps by a reduced first-pass effect. As the tolerability profile of OPC was favourable under the conditions of this study and its exposure is completely purged from systemic circulation before the subsequent dose administration, no OPC dose adjustment is needed in patients with mild to moderate chronic hepatic impairment. However, as OPC is under clinical development for use as adjunctive therapy in levodopa-treated patients with Parkinson's disease, an adjustment of levodopa and/or OPC regimens in patients should be carefully considered based on a potentially enhanced levodopa dopaminergic response and the associated tolerability.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "6bedca90e5b9429482c8374aa747b8c4", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[7, 11]], "char_spans": [[27, 54]]}]}], "context_tokens": [["Opicapone", 0], ["(", 10], ["OPC", 11], [")", 14], ["is", 16], ["a", 19], ["novel", 21], ["catechol", 27], ["-", 35], ["O", 36], ["-", 37], ["methyltransferase", 38], ["(", 56], ["COMT", 57], [")", 61], ["inhibitor", 63], ["to", 73], ["be", 76], ["used", 79], ["as", 84], ["adjunctive", 87], ["therapy", 98], ["in", 106], ["levodopa", 109], ["-", 117], ["treated", 118], ["patients", 126], ["with", 135], ["Parkinson", 140], ["'s", 149], ["disease", 152], [".", 159], ["The", 161], ["purpose", 165], ["of", 173], ["this", 176], ["study", 181], ["was", 187], ["to", 191], ["evaluate", 194], ["the", 203], ["effect", 207], ["of", 214], ["moderate", 217], ["liver", 226], ["impairment", 232], ["on", 243], ["the", 246], ["pharmacokinetics", 250], ["(", 267], ["PK", 268], [")", 270], ["and", 272], ["pharmacodynamics", 276], ["(", 293], ["PD", 294], [";", 296], ["effect", 298], ["on", 305], ["COMT", 308], ["activity", 313], [")", 321], ["of", 323], ["OPC", 326], [".", 329], ["An", 331], ["open", 334], ["-", 338], ["label", 339], [",", 344], ["parallel", 346], ["-", 354], ["group", 355], ["study", 361], ["in", 367], ["patients", 370], ["(", 379], ["n", 380], ["=", 382], ["8)", 384], ["with", 387], ["moderate", 392], ["liver", 401], ["impairment", 407], ["(", 418], ["Child", 419], ["-", 424], ["Pugh", 425], ["category", 430], ["B", 439], [",", 440], ["score", 442], ["of", 448], ["7", 451], ["to", 453], ["9", 456], [")", 457], ["and", 459], ["matched", 463], ["healthy", 471], ["subjects", 479], ["(", 488], ["n", 489], ["=", 491], ["8", 493], [",", 494], ["control", 496], [")", 503], ["with", 505], ["normal", 510], ["liver", 517], ["function", 523], [".", 531], ["All", 533], ["subjects", 537], ["received", 546], ["a", 555], ["single", 557], ["50-mg", 564], ["oral", 570], ["dose", 575], ["of", 580], ["OPC", 583], [",", 586], ["with", 588], ["plasma", 593], ["and", 600], ["urine", 604], ["concentrations", 610], ["of", 625], ["opicapone", 628], ["and", 638], ["its", 642], ["metabolites", 646], ["measured", 658], ["up", 667], ["to", 670], ["72", 673], ["h", 676], ["post", 678], ["-", 682], ["dose", 683], [",", 687], ["including", 689], ["soluble", 699], ["COMT", 707], ["(", 712], ["S", 713], ["-", 714], ["COMT", 715], [")", 719], ["activity", 721], [".", 729], ["A", 731], ["one", 733], ["-", 736], ["way", 737], ["analysis", 741], ["of", 750], ["variance", 753], ["(", 762], ["ANOVA", 763], [")", 768], ["was", 770], ["used", 774], ["to", 779], ["compare", 782], ["the", 790], ["main", 794], ["PK", 799], ["and", 802], ["PD", 806], ["parameters", 809], ["between", 820], ["groups", 828], [".", 834], ["Point", 836], ["estimates", 842], ["(", 852], ["PE", 853], [")", 855], ["of", 857], ["geometric", 860], ["mean", 870], ["ratios", 875], ["(", 882], ["GMR", 883], [")", 886], ["and", 888], ["corresponding", 892], ["90", 906], ["%", 909], ["confidence", 911], ["intervals", 922], ["(", 932], ["90%CI", 933], [")", 938], ["for", 940], ["the", 944], ["ratio", 948], ["hepatic", 954], ["/", 961], ["control", 962], ["subjects", 970], ["of", 979], ["each", 982], ["parameter", 987], ["were", 997], ["calculated", 1002], ["and", 1013], ["compared", 1017], ["with", 1026], ["the", 1031], ["reference", 1035], ["interval", 1045], ["(", 1054], ["80", 1055], ["-", 1057], ["125", 1058], ["%", 1062], [")", 1063], [".", 1064], ["Exposure", 1066], ["to", 1075], ["opicapone", 1078], ["(", 1088], ["AUC", 1089], ["and", 1093], ["Cmax", 1097], [")", 1101], ["increased", 1103], ["significantly", 1113], ["in", 1127], ["patients", 1130], ["with", 1139], ["moderate", 1144], ["hepatic", 1153], ["impairment", 1161], ["(", 1172], ["PE", 1173], ["[", 1176], ["90%CI", 1177], ["]", 1182], [":", 1183], ["AUC0-\u221e", 1185], [",", 1191], ["184", 1193], ["%", 1197], ["[", 1199], ["135", 1200], ["-", 1203], ["250", 1204], ["%", 1208], ["]", 1209], [";", 1210], ["Cmax", 1212], [",", 1216], ["189", 1218], ["%", 1222], ["[", 1224], ["144", 1225], ["-", 1228], ["249", 1229], ["%", 1233], ["]", 1234], [")", 1235], [".", 1236], ["Although", 1238], ["apparent", 1247], ["total", 1256], ["clearance", 1262], ["(", 1272], ["CL", 1273], ["/", 1275], ["F", 1276], [")", 1277], ["of", 1279], ["opicapone", 1282], ["was", 1292], ["decreased", 1296], ["by", 1306], ["\u223c35", 1309], ["%", 1313], [",", 1314], ["similar", 1316], ["elimination", 1324], ["half", 1336], ["-", 1340], ["life", 1341], ["and", 1346], ["unbound", 1350], ["/", 1357], ["bound", 1358], ["fractions", 1364], ["of", 1374], ["opicapone", 1377], ["were", 1387], ["observed", 1392], ["between", 1401], ["the", 1409], ["two", 1413], ["groups", 1417], [".", 1423], ["Both", 1425], ["rate", 1430], ["and", 1435], ["extent", 1439], ["of", 1446], ["exposure", 1449], ["to", 1458], ["BIA", 1461], ["9", 1465], ["-", 1466], ["1103", 1467], ["were", 1472], ["higher", 1477], ["in", 1484], ["the", 1487], ["hepatically", 1491], ["impaired", 1503], ["group", 1512], [",", 1517], ["but", 1519], ["not", 1523], ["statistically", 1527], ["significant", 1541], ["compared", 1553], ["with", 1562], ["the", 1567], ["control", 1571], ["group", 1579], [".", 1584], ["Similar", 1586], ["to", 1594], ["the", 1597], ["parent", 1601], ["(", 1608], ["opicapone", 1609], [")", 1618], [",", 1619], ["the", 1621], ["observed", 1625], ["increase", 1634], ["in", 1643], ["exposure", 1646], ["to", 1655], ["BIA", 1658], ["9", 1662], ["-", 1663], ["1106", 1664], ["was", 1669], ["statistically", 1673], ["significant", 1687], ["in", 1699], ["the", 1702], ["hepatically", 1706], ["impaired", 1718], ["group", 1727], ["over", 1733], ["the", 1738], ["control", 1742], ["group", 1750], [".", 1755], ["BIA", 1757], ["9", 1761], ["-", 1762], ["1106", 1763], ["was", 1768], ["the", 1772], ["only", 1776], ["metabolite", 1781], ["detected", 1792], ["in", 1801], ["urine", 1804], ["and", 1810], ["its", 1814], ["urine", 1818], ["PK", 1824], ["parameters", 1827], ["were", 1838], ["in", 1843], ["accordance", 1846], ["with", 1857], ["plasma", 1862], ["data", 1869], [".", 1873], ["Maximum", 1875], ["S", 1883], ["-", 1884], ["COMT", 1885], ["inhibition", 1890], ["(", 1901], ["Emax", 1902], [")", 1906], ["occurred", 1908], ["earlier", 1917], ["for", 1925], ["the", 1929], ["hepatically", 1933], ["impaired", 1945], ["group", 1954], ["with", 1960], ["values", 1965], ["of", 1972], ["100", 1975], ["%", 1979], ["and", 1981], ["91.2", 1985], ["%", 1990], ["for", 1992], ["the", 1996], ["hepatically", 2000], ["impaired", 2012], ["and", 2021], ["control", 2025], ["groups", 2033], ["respectively", 2040], [".", 2052], ["Both", 2054], ["Emax", 2059], ["and", 2064], ["AUEC", 2068], ["for", 2073], ["the", 2077], ["hepatically", 2081], ["impaired", 2093], ["group", 2102], ["reached", 2108], ["statistical", 2116], ["significance", 2128], ["over", 2141], ["the", 2146], ["control", 2150], ["group", 2158], [".", 2163], ["OPC", 2165], ["was", 2169], ["well", 2173], ["tolerated", 2178], ["in", 2188], ["both", 2191], ["hepatically", 2196], ["impaired", 2208], ["and", 2217], ["control", 2221], ["groups", 2229], [".", 2235], ["The", 2237], ["bioavailability", 2241], ["of", 2257], ["an", 2260], ["orally", 2263], ["administered", 2270], ["single", 2283], ["dose", 2290], ["of", 2295], ["50", 2298], ["mg", 2301], ["OPC", 2304], ["was", 2308], ["significantly", 2312], ["higher", 2326], ["in", 2333], ["patients", 2336], ["with", 2345], ["moderate", 2350], ["chronic", 2359], ["hepatic", 2367], ["impairment", 2375], [",", 2385], ["perhaps", 2387], ["by", 2395], ["a", 2398], ["reduced", 2400], ["first", 2408], ["-", 2413], ["pass", 2414], ["effect", 2419], [".", 2425], ["As", 2427], ["the", 2430], ["tolerability", 2434], ["profile", 2447], ["of", 2455], ["OPC", 2458], ["was", 2462], ["favourable", 2466], ["under", 2477], ["the", 2483], ["conditions", 2487], ["of", 2498], ["this", 2501], ["study", 2506], ["and", 2512], ["its", 2516], ["exposure", 2520], ["is", 2529], ["completely", 2532], ["purged", 2543], ["from", 2550], ["systemic", 2555], ["circulation", 2564], ["before", 2576], ["the", 2583], ["subsequent", 2587], ["dose", 2598], ["administration", 2603], [",", 2617], ["no", 2619], ["OPC", 2622], ["dose", 2626], ["adjustment", 2631], ["is", 2642], ["needed", 2645], ["in", 2652], ["patients", 2655], ["with", 2664], ["mild", 2669], ["to", 2674], ["moderate", 2677], ["chronic", 2686], ["hepatic", 2694], ["impairment", 2702], [".", 2712], ["However", 2714], [",", 2721], ["as", 2723], ["OPC", 2726], ["is", 2730], ["under", 2733], ["clinical", 2739], ["development", 2748], ["for", 2760], ["use", 2764], ["as", 2768], ["adjunctive", 2771], ["therapy", 2782], ["in", 2790], ["levodopa", 2793], ["-", 2801], ["treated", 2802], ["patients", 2810], ["with", 2819], ["Parkinson", 2824], ["'s", 2833], ["disease", 2836], [",", 2843], ["an", 2845], ["adjustment", 2848], ["of", 2859], ["levodopa", 2862], ["and/or", 2871], ["OPC", 2878], ["regimens", 2882], ["in", 2891], ["patients", 2894], ["should", 2903], ["be", 2910], ["carefully", 2913], ["considered", 2923], ["based", 2934], ["on", 2940], ["a", 2943], ["potentially", 2945], ["enhanced", 2957], ["levodopa", 2966], ["dopaminergic", 2975], ["response", 2988], ["and", 2997], ["the", 3001], ["associated", 3005], ["tolerability", 3016], [".", 3028]]}
{"context": "Biallelic mutations of the DNA annealing helicase SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1) cause Schimke immuno-osseous dysplasia (SIOD, MIM 242900), an incompletely penetrant autosomal recessive disorder. Using human, Drosophila and mouse models, we show that the proteins encoded by SMARCAL1 orthologs localize to transcriptionally active chromatin and modulate gene expression. We also show that, as found in SIOD patients, deficiency of the SMARCAL1 orthologs alone is insufficient to cause disease in fruit flies and mice, although such deficiency causes modest diffuse alterations in gene expression. Rather, disease manifests when SMARCAL1 deficiency interacts with genetic and environmental factors that further alter gene expression. We conclude that the SMARCAL1 annealing helicase buffers fluctuations in gene expression and that alterations in gene expression contribute to the penetrance of SIOD.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["HARP", "SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1", "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)"], "qid": "549c82a2fcb04e38a84c3f7661eeeaf0", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[7, 30]], "char_spans": [[50, 153]]}]}], "context_tokens": [["Biallelic", 0], ["mutations", 10], ["of", 20], ["the", 23], ["DNA", 27], ["annealing", 31], ["helicase", 41], ["SMARCAL1", 50], ["(", 59], ["SWI", 60], ["/", 63], ["SNF", 64], ["-", 67], ["related", 68], [",", 75], ["matrix", 77], ["-", 83], ["associated", 84], [",", 94], ["actin", 96], ["-", 101], ["dependent", 102], ["regulator", 112], ["of", 122], ["chromatin", 125], [",", 134], ["subfamily", 136], ["a", 146], ["-", 147], ["like", 148], ["1", 153], [")", 154], ["cause", 156], ["Schimke", 162], ["immuno", 170], ["-", 176], ["osseous", 177], ["dysplasia", 185], ["(", 195], ["SIOD", 196], [",", 200], ["MIM", 202], ["242900", 206], [")", 212], [",", 213], ["an", 215], ["incompletely", 218], ["penetrant", 231], ["autosomal", 241], ["recessive", 251], ["disorder", 261], [".", 269], ["Using", 271], ["human", 277], [",", 282], ["Drosophila", 284], ["and", 295], ["mouse", 299], ["models", 305], [",", 311], ["we", 313], ["show", 316], ["that", 321], ["the", 326], ["proteins", 330], ["encoded", 339], ["by", 347], ["SMARCAL1", 350], ["orthologs", 359], ["localize", 369], ["to", 378], ["transcriptionally", 381], ["active", 399], ["chromatin", 406], ["and", 416], ["modulate", 420], ["gene", 429], ["expression", 434], [".", 444], ["We", 446], ["also", 449], ["show", 454], ["that", 459], [",", 463], ["as", 465], ["found", 468], ["in", 474], ["SIOD", 477], ["patients", 482], [",", 490], ["deficiency", 492], ["of", 503], ["the", 506], ["SMARCAL1", 510], ["orthologs", 519], ["alone", 529], ["is", 535], ["insufficient", 538], ["to", 551], ["cause", 554], ["disease", 560], ["in", 568], ["fruit", 571], ["flies", 577], ["and", 583], ["mice", 587], [",", 591], ["although", 593], ["such", 602], ["deficiency", 607], ["causes", 618], ["modest", 625], ["diffuse", 632], ["alterations", 640], ["in", 652], ["gene", 655], ["expression", 660], [".", 670], ["Rather", 672], [",", 678], ["disease", 680], ["manifests", 688], ["when", 698], ["SMARCAL1", 703], ["deficiency", 712], ["interacts", 723], ["with", 733], ["genetic", 738], ["and", 746], ["environmental", 750], ["factors", 764], ["that", 772], ["further", 777], ["alter", 785], ["gene", 791], ["expression", 796], [".", 806], ["We", 808], ["conclude", 811], ["that", 820], ["the", 825], ["SMARCAL1", 829], ["annealing", 838], ["helicase", 848], ["buffers", 857], ["fluctuations", 865], ["in", 878], ["gene", 881], ["expression", 886], ["and", 897], ["that", 901], ["alterations", 906], ["in", 918], ["gene", 921], ["expression", 926], ["contribute", 937], ["to", 948], ["the", 951], ["penetrance", 955], ["of", 966], ["SIOD", 969], [".", 973]]}
{"context": "GATA-1 and the ets factor PU.1 have been reported to functionally antagonize one another in the regulation of erythroid versus myeloid gene transcription and development. The CCAAT enhancer binding protein epsilon (C/EBPepsilon) is expressed as multiple isoforms and has been shown to be essential to myeloid (granulocyte) terminal differentiation. We have defined a novel synergistic, as opposed to antagonistic, combinatorial interaction between GATA-1 and PU.1, and a unique repressor role for certain C/EBPepsilon isoforms in the transcriptional regulation of a model eosinophil granulocyte gene, the major basic protein (MBP). The eosinophil-specific P2 promoter of the MBP gene contains GATA-1, C/EBP, and PU.1 consensus sites that bind these factors in nuclear extracts of the eosinophil myelocyte cell line, AML14.3D10. The promoter is transactivated by GATA-1 alone but is synergistically transactivated by low levels of PU.1 in the context of optimal levels of GATA-1. The C/EBPepsilon(27) isoform strongly represses GATA-1 activity and completely blocks GATA-1/PU.1 synergy. In vitro mutational analyses of the MBP-P2 promoter showed that both the GATA-1/PU.1 synergy, and repressor activity of C/EBPepsilon(27) are mediated via protein-protein interactions through the C/EBP and/or GATA-binding sites but not the PU.1 sites. Co-immunoprecipitations using lysates of AML14.3D10 eosinophils show that both C/EBPepsilon(32/30) and epsilon(27) physically interact in vivo with PU.1 and GATA-1, demonstrating functional interactions among these factors in eosinophil progenitors. Our findings identify novel combinatorial protein-protein interactions for GATA-1, PU.1, and C/EBPepsilon isoforms in eosinophil gene transcription that include GATA-1/PU.1 synergy and repressor activity for C/EBPepsilon(27).", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "301b11ff9a5742d3b24508da29ebffcd", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[229, 229], [5, 5], [74, 74], [124, 124], [281, 281], [158, 158], [255, 255]], "char_spans": [[1325, 1328], [26, 29], [459, 462], [712, 715], [1670, 1673], [930, 933], [1485, 1488]]}]}], "context_tokens": [["GATA-1", 0], ["and", 7], ["the", 11], ["ets", 15], ["factor", 19], ["PU.1", 26], ["have", 31], ["been", 36], ["reported", 41], ["to", 50], ["functionally", 53], ["antagonize", 66], ["one", 77], ["another", 81], ["in", 89], ["the", 92], ["regulation", 96], ["of", 107], ["erythroid", 110], ["versus", 120], ["myeloid", 127], ["gene", 135], ["transcription", 140], ["and", 154], ["development", 158], [".", 169], ["The", 171], ["CCAAT", 175], ["enhancer", 181], ["binding", 190], ["protein", 198], ["epsilon", 206], ["(", 214], ["C", 215], ["/", 216], ["EBPepsilon", 217], [")", 227], ["is", 229], ["expressed", 232], ["as", 242], ["multiple", 245], ["isoforms", 254], ["and", 263], ["has", 267], ["been", 271], ["shown", 276], ["to", 282], ["be", 285], ["essential", 288], ["to", 298], ["myeloid", 301], ["(", 309], ["granulocyte", 310], [")", 321], ["terminal", 323], ["differentiation", 332], [".", 347], ["We", 349], ["have", 352], ["defined", 357], ["a", 365], ["novel", 367], ["synergistic", 373], [",", 384], ["as", 386], ["opposed", 389], ["to", 397], ["antagonistic", 400], [",", 412], ["combinatorial", 414], ["interaction", 428], ["between", 440], ["GATA-1", 448], ["and", 455], ["PU.1", 459], [",", 463], ["and", 465], ["a", 469], ["unique", 471], ["repressor", 478], ["role", 488], ["for", 493], ["certain", 497], ["C", 505], ["/", 506], ["EBPepsilon", 507], ["isoforms", 518], ["in", 527], ["the", 530], ["transcriptional", 534], ["regulation", 550], ["of", 561], ["a", 564], ["model", 566], ["eosinophil", 572], ["granulocyte", 583], ["gene", 595], [",", 599], ["the", 601], ["major", 605], ["basic", 611], ["protein", 617], ["(", 625], ["MBP", 626], [")", 629], [".", 630], ["The", 632], ["eosinophil", 636], ["-", 646], ["specific", 647], ["P2", 656], ["promoter", 659], ["of", 668], ["the", 671], ["MBP", 675], ["gene", 679], ["contains", 684], ["GATA-1", 693], [",", 699], ["C", 701], ["/", 702], ["EBP", 703], [",", 706], ["and", 708], ["PU.1", 712], ["consensus", 717], ["sites", 727], ["that", 733], ["bind", 738], ["these", 743], ["factors", 749], ["in", 757], ["nuclear", 760], ["extracts", 768], ["of", 777], ["the", 780], ["eosinophil", 784], ["myelocyte", 795], ["cell", 805], ["line", 810], [",", 814], ["AML14.3D10", 816], [".", 826], ["The", 828], ["promoter", 832], ["is", 841], ["transactivated", 844], ["by", 859], ["GATA-1", 862], ["alone", 869], ["but", 875], ["is", 879], ["synergistically", 882], ["transactivated", 898], ["by", 913], ["low", 916], ["levels", 920], ["of", 927], ["PU.1", 930], ["in", 935], ["the", 938], ["context", 942], ["of", 950], ["optimal", 953], ["levels", 961], ["of", 968], ["GATA-1", 971], [".", 977], ["The", 979], ["C", 983], ["/", 984], ["EBPepsilon(27", 985], [")", 998], ["isoform", 1000], ["strongly", 1008], ["represses", 1017], ["GATA-1", 1027], ["activity", 1034], ["and", 1043], ["completely", 1047], ["blocks", 1058], ["GATA-1/PU.1", 1065], ["synergy", 1077], [".", 1084], ["In", 1086], ["vitro", 1089], ["mutational", 1095], ["analyses", 1106], ["of", 1115], ["the", 1118], ["MBP", 1122], ["-", 1125], ["P2", 1126], ["promoter", 1129], ["showed", 1138], ["that", 1145], ["both", 1150], ["the", 1155], ["GATA-1/PU.1", 1159], ["synergy", 1171], [",", 1178], ["and", 1180], ["repressor", 1184], ["activity", 1194], ["of", 1203], ["C", 1206], ["/", 1207], ["EBPepsilon(27", 1208], [")", 1221], ["are", 1223], ["mediated", 1227], ["via", 1236], ["protein", 1240], ["-", 1247], ["protein", 1248], ["interactions", 1256], ["through", 1269], ["the", 1277], ["C", 1281], ["/", 1282], ["EBP", 1283], ["and/or", 1287], ["GATA", 1294], ["-", 1298], ["binding", 1299], ["sites", 1307], ["but", 1313], ["not", 1317], ["the", 1321], ["PU.1", 1325], ["sites", 1330], [".", 1335], ["Co", 1337], ["-", 1339], ["immunoprecipitations", 1340], ["using", 1361], ["lysates", 1367], ["of", 1375], ["AML14.3D10", 1378], ["eosinophils", 1389], ["show", 1401], ["that", 1406], ["both", 1411], ["C", 1416], ["/", 1417], ["EBPepsilon(32/30", 1418], [")", 1434], ["and", 1436], ["epsilon(27", 1440], [")", 1450], ["physically", 1452], ["interact", 1463], ["in", 1472], ["vivo", 1475], ["with", 1480], ["PU.1", 1485], ["and", 1490], ["GATA-1", 1494], [",", 1500], ["demonstrating", 1502], ["functional", 1516], ["interactions", 1527], ["among", 1540], ["these", 1546], ["factors", 1552], ["in", 1560], ["eosinophil", 1563], ["progenitors", 1574], [".", 1585], ["Our", 1587], ["findings", 1591], ["identify", 1600], ["novel", 1609], ["combinatorial", 1615], ["protein", 1629], ["-", 1636], ["protein", 1637], ["interactions", 1645], ["for", 1658], ["GATA-1", 1662], [",", 1668], ["PU.1", 1670], [",", 1674], ["and", 1676], ["C", 1680], ["/", 1681], ["EBPepsilon", 1682], ["isoforms", 1693], ["in", 1702], ["eosinophil", 1705], ["gene", 1716], ["transcription", 1721], ["that", 1735], ["include", 1740], ["GATA-1/PU.1", 1748], ["synergy", 1760], ["and", 1768], ["repressor", 1772], ["activity", 1782], ["for", 1791], ["C", 1795], ["/", 1796], ["EBPepsilon(27", 1797], [")", 1810], [".", 1811]]}
{"context": "Angiopoietin-like protein 3 (ANGPTL3) affects lipid metabolism by inhibiting the activity of lipoprotein and endothelial lipases. Angptl3 knockout mice have marked hypolipidemia, and heterozygous carriers of ANGPLT3, loss-of-function mutations were found among individuals in the lowest quartile of plasma triglycerides in population studies. Recently, 4 related individuals with primary hypolipidemia were found to be compound heterozygotes for ANGPTL3 loss-of-function mutations. We resequenced ANGPTL3 in 4 members of 3 kindreds originally identified for very low levels of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (0.97\u00b10.16 and 0.56\u00b10.20 mmol/L, respectively) in whom no mutations of known candidate genes for monogenic hypobetalipoproteinemia and hypoalphalipoproteinemia had been detected. These subjects were found to be homozygous or compound heterozygous for ANGPTL3 loss-of-function mutations (p.G400VfsX5, p.I19LfsX22/p.N147X) associated with the absence of ANGPTL3 in plasma. They had reduced plasma levels of triglyceride-containing lipoproteins and of HDL particles that contained only apolipoprotein A-I and pre-\u03b2-high-density lipoprotein. In addition, their apolipoprotein B-depleted sera had a reduced capacity to promote cell cholesterol efflux through the various pathways (ABCA1-, SR-BI-, and ABCG1-mediated efflux); however, these subjects had no clinical evidence of accelerated atherosclerosis. Heterozygous carriers of the ANGPTL3 mutations had low plasma ANGPTL3 and moderately reduced low-density lipoprotein cholesterol (2.52\u00b10.38 mmol/L) but normal plasma high-density lipoprotein cholesterol. Complete ANGPTL3 deficiency caused by loss-of-function mutations of ANGPTL3 is associated with a recessive hypolipidemia characterized by a reduction of apolipoprotein B and apolipoprotein A-I-containing lipoproteins, changes in subclasses of high-density lipoprotein, and reduced cholesterol efflux potential of serum. Partial ANGPTL3 deficiency is associated only with a moderate reduction of low-density lipoprotein.", "qas": [{"question": "What is the results of inactivated ANGPLT3?", "answers": ["Recessive hypolipidemia"], "qid": "945a16348aeb4d0eb69c3c58a1a53610", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["results", 12], ["of", 20], ["inactivated", 23], ["ANGPLT3", 35], ["?", 42]], "detected_answers": [{"text": "Recessive hypolipidemia", "token_spans": [[297, 298]], "char_spans": [[1756, 1778]]}]}], "context_tokens": [["Angiopoietin", 0], ["-", 12], ["like", 13], ["protein", 18], ["3", 26], ["(", 28], ["ANGPTL3", 29], [")", 36], ["affects", 38], ["lipid", 46], ["metabolism", 52], ["by", 63], ["inhibiting", 66], ["the", 77], ["activity", 81], ["of", 90], ["lipoprotein", 93], ["and", 105], ["endothelial", 109], ["lipases", 121], [".", 128], ["Angptl3", 130], ["knockout", 138], ["mice", 147], ["have", 152], ["marked", 157], ["hypolipidemia", 164], [",", 177], ["and", 179], ["heterozygous", 183], ["carriers", 196], ["of", 205], ["ANGPLT3", 208], [",", 215], ["loss", 217], ["-", 221], ["of", 222], ["-", 224], ["function", 225], ["mutations", 234], ["were", 244], ["found", 249], ["among", 255], ["individuals", 261], ["in", 273], ["the", 276], ["lowest", 280], ["quartile", 287], ["of", 296], ["plasma", 299], ["triglycerides", 306], ["in", 320], ["population", 323], ["studies", 334], [".", 341], ["Recently", 343], [",", 351], ["4", 353], ["related", 355], ["individuals", 363], ["with", 375], ["primary", 380], ["hypolipidemia", 388], ["were", 402], ["found", 407], ["to", 413], ["be", 416], ["compound", 419], ["heterozygotes", 428], ["for", 442], ["ANGPTL3", 446], ["loss", 454], ["-", 458], ["of", 459], ["-", 461], ["function", 462], ["mutations", 471], [".", 480], ["We", 482], ["resequenced", 485], ["ANGPTL3", 497], ["in", 505], ["4", 508], ["members", 510], ["of", 518], ["3", 521], ["kindreds", 523], ["originally", 532], ["identified", 543], ["for", 554], ["very", 558], ["low", 563], ["levels", 567], ["of", 574], ["low", 577], ["-", 580], ["density", 581], ["lipoprotein", 589], ["cholesterol", 601], ["and", 613], ["high", 617], ["-", 621], ["density", 622], ["lipoprotein", 630], ["cholesterol", 642], ["(", 654], ["0.97\u00b10.16", 655], ["and", 665], ["0.56\u00b10.20", 669], ["mmol", 679], ["/", 683], ["L", 684], [",", 685], ["respectively", 687], [")", 699], ["in", 701], ["whom", 704], ["no", 709], ["mutations", 712], ["of", 722], ["known", 725], ["candidate", 731], ["genes", 741], ["for", 747], ["monogenic", 751], ["hypobetalipoproteinemia", 761], ["and", 785], ["hypoalphalipoproteinemia", 789], ["had", 814], ["been", 818], ["detected", 823], [".", 831], ["These", 833], ["subjects", 839], ["were", 848], ["found", 853], ["to", 859], ["be", 862], ["homozygous", 865], ["or", 876], ["compound", 879], ["heterozygous", 888], ["for", 901], ["ANGPTL3", 905], ["loss", 913], ["-", 917], ["of", 918], ["-", 920], ["function", 921], ["mutations", 930], ["(", 940], ["p", 941], [".", 942], ["G400VfsX5", 943], [",", 952], ["p", 954], [".", 955], ["I19LfsX22/p", 956], [".", 967], ["N147X", 968], [")", 973], ["associated", 975], ["with", 986], ["the", 991], ["absence", 995], ["of", 1003], ["ANGPTL3", 1006], ["in", 1014], ["plasma", 1017], [".", 1023], ["They", 1025], ["had", 1030], ["reduced", 1034], ["plasma", 1042], ["levels", 1049], ["of", 1056], ["triglyceride", 1059], ["-", 1071], ["containing", 1072], ["lipoproteins", 1083], ["and", 1096], ["of", 1100], ["HDL", 1103], ["particles", 1107], ["that", 1117], ["contained", 1122], ["only", 1132], ["apolipoprotein", 1137], ["A", 1152], ["-", 1153], ["I", 1154], ["and", 1156], ["pre", 1160], ["-", 1163], ["\u03b2", 1164], ["-", 1165], ["high", 1166], ["-", 1170], ["density", 1171], ["lipoprotein", 1179], [".", 1190], ["In", 1192], ["addition", 1195], [",", 1203], ["their", 1205], ["apolipoprotein", 1211], ["B", 1226], ["-", 1227], ["depleted", 1228], ["sera", 1237], ["had", 1242], ["a", 1246], ["reduced", 1248], ["capacity", 1256], ["to", 1265], ["promote", 1268], ["cell", 1276], ["cholesterol", 1281], ["efflux", 1293], ["through", 1300], ["the", 1308], ["various", 1312], ["pathways", 1320], ["(", 1329], ["ABCA1-", 1330], [",", 1336], ["SR", 1338], ["-", 1340], ["BI-", 1341], [",", 1344], ["and", 1346], ["ABCG1-mediated", 1350], ["efflux", 1365], [")", 1371], [";", 1372], ["however", 1374], [",", 1381], ["these", 1383], ["subjects", 1389], ["had", 1398], ["no", 1402], ["clinical", 1405], ["evidence", 1414], ["of", 1423], ["accelerated", 1426], ["atherosclerosis", 1438], [".", 1453], ["Heterozygous", 1455], ["carriers", 1468], ["of", 1477], ["the", 1480], ["ANGPTL3", 1484], ["mutations", 1492], ["had", 1502], ["low", 1506], ["plasma", 1510], ["ANGPTL3", 1517], ["and", 1525], ["moderately", 1529], ["reduced", 1540], ["low", 1548], ["-", 1551], ["density", 1552], ["lipoprotein", 1560], ["cholesterol", 1572], ["(", 1584], ["2.52\u00b10.38", 1585], ["mmol", 1595], ["/", 1599], ["L", 1600], [")", 1601], ["but", 1603], ["normal", 1607], ["plasma", 1614], ["high", 1621], ["-", 1625], ["density", 1626], ["lipoprotein", 1634], ["cholesterol", 1646], [".", 1657], ["Complete", 1659], ["ANGPTL3", 1668], ["deficiency", 1676], ["caused", 1687], ["by", 1694], ["loss", 1697], ["-", 1701], ["of", 1702], ["-", 1704], ["function", 1705], ["mutations", 1714], ["of", 1724], ["ANGPTL3", 1727], ["is", 1735], ["associated", 1738], ["with", 1749], ["a", 1754], ["recessive", 1756], ["hypolipidemia", 1766], ["characterized", 1780], ["by", 1794], ["a", 1797], ["reduction", 1799], ["of", 1809], ["apolipoprotein", 1812], ["B", 1827], ["and", 1829], ["apolipoprotein", 1833], ["A", 1848], ["-", 1849], ["I", 1850], ["-", 1851], ["containing", 1852], ["lipoproteins", 1863], [",", 1875], ["changes", 1877], ["in", 1885], ["subclasses", 1888], ["of", 1899], ["high", 1902], ["-", 1906], ["density", 1907], ["lipoprotein", 1915], [",", 1926], ["and", 1928], ["reduced", 1932], ["cholesterol", 1940], ["efflux", 1952], ["potential", 1959], ["of", 1969], ["serum", 1972], [".", 1977], ["Partial", 1979], ["ANGPTL3", 1987], ["deficiency", 1995], ["is", 2006], ["associated", 2009], ["only", 2020], ["with", 2025], ["a", 2030], ["moderate", 2032], ["reduction", 2041], ["of", 2051], ["low", 2054], ["-", 2057], ["density", 2058], ["lipoprotein", 2066], [".", 2077]]}
{"context": "Polycomb gene silencing requires histone methyltransferase activity of Polycomb repressive complex 2 (PRC2), which methylates lysine 27 of histone H3. Information on how PRC2 works is limited by lack of structural data on the catalytic subunit, Enhancer of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain. Here we analyze missense alleles of Drosophila E(z), selected for molecular study because of their dominant genetic effects. Four missense alleles identify key E(Z) SET domain residues, and a fifth is located in the adjacent CXC domain. Analysis of mutant PRC2 complexes in vitro, and H3-K27 methylation in vivo, shows that each SET domain mutation disrupts PRC2 histone methyltransferase. Based on known SET domain structures, the mutations likely affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine methyl donor, or a critical tyrosine predicted to interact with the substrate lysine epsilon-amino group. In contrast, the CXC mutant retains catalytic activity, Lys-27 specificity, and trimethylation capacity. Deletion analysis also reveals a functional requirement for a conserved E(Z) domain N-terminal to CXC and SET. These results identify critical SET domain residues needed for PRC2 enzyme function, and they also emphasize functional inputs from outside the SET domain.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "94917b06092641a5af6b7e211171d69d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[134, 135], [60, 61], [123, 124], [217, 218], [91, 92], [235, 236]], "char_spans": [[742, 751], [325, 334], [666, 675], [1235, 1244], [502, 511], [1347, 1356]]}]}], "context_tokens": [["Polycomb", 0], ["gene", 9], ["silencing", 14], ["requires", 24], ["histone", 33], ["methyltransferase", 41], ["activity", 59], ["of", 68], ["Polycomb", 71], ["repressive", 80], ["complex", 91], ["2", 99], ["(", 101], ["PRC2", 102], [")", 106], [",", 107], ["which", 109], ["methylates", 115], ["lysine", 126], ["27", 133], ["of", 136], ["histone", 139], ["H3", 147], [".", 149], ["Information", 151], ["on", 163], ["how", 166], ["PRC2", 170], ["works", 175], ["is", 181], ["limited", 184], ["by", 192], ["lack", 195], ["of", 200], ["structural", 203], ["data", 214], ["on", 219], ["the", 222], ["catalytic", 226], ["subunit", 236], [",", 243], ["Enhancer", 245], ["of", 254], ["zeste", 257], ["(", 263], ["E(Z", 264], [")", 267], [")", 268], [",", 269], ["and", 271], ["the", 275], ["paucity", 279], ["of", 287], ["E(z", 290], [")", 293], ["mutant", 295], ["alleles", 302], ["that", 310], ["alter", 315], ["its", 321], ["SET", 325], ["domain", 329], [".", 335], ["Here", 337], ["we", 342], ["analyze", 345], ["missense", 353], ["alleles", 362], ["of", 370], ["Drosophila", 373], ["E(z", 384], [")", 387], [",", 388], ["selected", 390], ["for", 399], ["molecular", 403], ["study", 413], ["because", 419], ["of", 427], ["their", 430], ["dominant", 436], ["genetic", 445], ["effects", 453], [".", 460], ["Four", 462], ["missense", 467], ["alleles", 476], ["identify", 484], ["key", 493], ["E(Z", 497], [")", 500], ["SET", 502], ["domain", 506], ["residues", 513], [",", 521], ["and", 523], ["a", 527], ["fifth", 529], ["is", 535], ["located", 538], ["in", 546], ["the", 549], ["adjacent", 553], ["CXC", 562], ["domain", 566], [".", 572], ["Analysis", 574], ["of", 583], ["mutant", 586], ["PRC2", 593], ["complexes", 598], ["in", 608], ["vitro", 611], [",", 616], ["and", 618], ["H3-K27", 622], ["methylation", 629], ["in", 641], ["vivo", 644], [",", 648], ["shows", 650], ["that", 656], ["each", 661], ["SET", 666], ["domain", 670], ["mutation", 677], ["disrupts", 686], ["PRC2", 695], ["histone", 700], ["methyltransferase", 708], [".", 725], ["Based", 727], ["on", 733], ["known", 736], ["SET", 742], ["domain", 746], ["structures", 753], [",", 763], ["the", 765], ["mutations", 769], ["likely", 779], ["affect", 786], ["either", 793], ["the", 800], ["lysine", 804], ["-", 810], ["substrate", 811], ["binding", 821], ["pocket", 829], [",", 835], ["the", 837], ["binding", 841], ["site", 849], ["for", 854], ["the", 858], ["adenosylmethionine", 862], ["methyl", 881], ["donor", 888], [",", 893], ["or", 895], ["a", 898], ["critical", 900], ["tyrosine", 909], ["predicted", 918], ["to", 928], ["interact", 931], ["with", 940], ["the", 945], ["substrate", 949], ["lysine", 959], ["epsilon", 966], ["-", 973], ["amino", 974], ["group", 980], [".", 985], ["In", 987], ["contrast", 990], [",", 998], ["the", 1000], ["CXC", 1004], ["mutant", 1008], ["retains", 1015], ["catalytic", 1023], ["activity", 1033], [",", 1041], ["Lys-27", 1043], ["specificity", 1050], [",", 1061], ["and", 1063], ["trimethylation", 1067], ["capacity", 1082], [".", 1090], ["Deletion", 1092], ["analysis", 1101], ["also", 1110], ["reveals", 1115], ["a", 1123], ["functional", 1125], ["requirement", 1136], ["for", 1148], ["a", 1152], ["conserved", 1154], ["E(Z", 1164], [")", 1167], ["domain", 1169], ["N", 1176], ["-", 1177], ["terminal", 1178], ["to", 1187], ["CXC", 1190], ["and", 1194], ["SET", 1198], [".", 1201], ["These", 1203], ["results", 1209], ["identify", 1217], ["critical", 1226], ["SET", 1235], ["domain", 1239], ["residues", 1246], ["needed", 1255], ["for", 1262], ["PRC2", 1266], ["enzyme", 1271], ["function", 1278], [",", 1286], ["and", 1288], ["they", 1292], ["also", 1297], ["emphasize", 1302], ["functional", 1312], ["inputs", 1323], ["from", 1330], ["outside", 1335], ["the", 1343], ["SET", 1347], ["domain", 1351], [".", 1357]]}
{"context": "Many mutations of the NF1 gene have been reported in patients with neurofibromatosis type 1 (NF1); however, there have been no documented NF1 gene mutations in Japanese NF1 patients. In the present study, we used the polymerase chain reaction (PCR) and DNA sequencing analysis to characterize the NF1 gene in a 53-year-old Japanese patient with NF1 who suffered from neurofibroma, pheochromocytoma, and gastrointestinal stromal tumor (GIST). Direct sequence analyses revealed a single base substitution in the splicing donor site of intron 6 (IVS6 888+1, G --> A) in one NF1 allele, resulting in an altered splice site (ss) in the mutated allele. Splicing at the cryptic 5' ss in the mutated allele generated mRNA with an insertion of 60 nucleotides. In addition, we screened for mutations in exons 9, 11, 13, and 17 of the c-kit gene in GIST and the succinate dehydrogenase subunit D (SDHD) gene in the pheochromocytoma, but we did not detect any somatic mutations. We report here the first case of an NF1 patient with four neoplasms: neurofibroma, pheochromocytoma, astrocytoma and GIST. Our results suggest that the molecular pathogenesis of GISTs in NF1 patients is different from that in non-NF1 patients.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "5976ad62650747a3bc3be03c0e430c7d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[16, 16], [203, 203], [227, 227], [26, 26], [4, 4], [65, 65], [55, 55], [236, 236], [110, 110], [31, 31]], "char_spans": [[93, 95], [1003, 1005], [1154, 1156], [138, 140], [22, 24], [345, 347], [297, 299], [1197, 1199], [571, 573], [169, 171]]}]}], "context_tokens": [["Many", 0], ["mutations", 5], ["of", 15], ["the", 18], ["NF1", 22], ["gene", 26], ["have", 31], ["been", 36], ["reported", 41], ["in", 50], ["patients", 53], ["with", 62], ["neurofibromatosis", 67], ["type", 85], ["1", 90], ["(", 92], ["NF1", 93], [")", 96], [";", 97], ["however", 99], [",", 106], ["there", 108], ["have", 114], ["been", 119], ["no", 124], ["documented", 127], ["NF1", 138], ["gene", 142], ["mutations", 147], ["in", 157], ["Japanese", 160], ["NF1", 169], ["patients", 173], [".", 181], ["In", 183], ["the", 186], ["present", 190], ["study", 198], [",", 203], ["we", 205], ["used", 208], ["the", 213], ["polymerase", 217], ["chain", 228], ["reaction", 234], ["(", 243], ["PCR", 244], [")", 247], ["and", 249], ["DNA", 253], ["sequencing", 257], ["analysis", 268], ["to", 277], ["characterize", 280], ["the", 293], ["NF1", 297], ["gene", 301], ["in", 306], ["a", 309], ["53-year", 311], ["-", 318], ["old", 319], ["Japanese", 323], ["patient", 332], ["with", 340], ["NF1", 345], ["who", 349], ["suffered", 353], ["from", 362], ["neurofibroma", 367], [",", 379], ["pheochromocytoma", 381], [",", 397], ["and", 399], ["gastrointestinal", 403], ["stromal", 420], ["tumor", 428], ["(", 434], ["GIST", 435], [")", 439], [".", 440], ["Direct", 442], ["sequence", 449], ["analyses", 458], ["revealed", 467], ["a", 476], ["single", 478], ["base", 485], ["substitution", 490], ["in", 503], ["the", 506], ["splicing", 510], ["donor", 519], ["site", 525], ["of", 530], ["intron", 533], ["6", 540], ["(", 542], ["IVS6", 543], ["888", 548], ["+", 551], ["1", 552], [",", 553], ["G", 555], ["--", 557], [">", 559], ["A", 561], [")", 562], ["in", 564], ["one", 567], ["NF1", 571], ["allele", 575], [",", 581], ["resulting", 583], ["in", 593], ["an", 596], ["altered", 599], ["splice", 607], ["site", 614], ["(", 619], ["ss", 620], [")", 622], ["in", 624], ["the", 627], ["mutated", 631], ["allele", 639], [".", 645], ["Splicing", 647], ["at", 656], ["the", 659], ["cryptic", 663], ["5", 671], ["'", 672], ["ss", 674], ["in", 677], ["the", 680], ["mutated", 684], ["allele", 692], ["generated", 699], ["mRNA", 709], ["with", 714], ["an", 719], ["insertion", 722], ["of", 732], ["60", 735], ["nucleotides", 738], [".", 749], ["In", 751], ["addition", 754], [",", 762], ["we", 764], ["screened", 767], ["for", 776], ["mutations", 780], ["in", 790], ["exons", 793], ["9", 799], [",", 800], ["11", 802], [",", 804], ["13", 806], [",", 808], ["and", 810], ["17", 814], ["of", 817], ["the", 820], ["c", 824], ["-", 825], ["kit", 826], ["gene", 830], ["in", 835], ["GIST", 838], ["and", 843], ["the", 847], ["succinate", 851], ["dehydrogenase", 861], ["subunit", 875], ["D", 883], ["(", 885], ["SDHD", 886], [")", 890], ["gene", 892], ["in", 897], ["the", 900], ["pheochromocytoma", 904], [",", 920], ["but", 922], ["we", 926], ["did", 929], ["not", 933], ["detect", 937], ["any", 944], ["somatic", 948], ["mutations", 956], [".", 965], ["We", 967], ["report", 970], ["here", 977], ["the", 982], ["first", 986], ["case", 992], ["of", 997], ["an", 1000], ["NF1", 1003], ["patient", 1007], ["with", 1015], ["four", 1020], ["neoplasms", 1025], [":", 1034], ["neurofibroma", 1036], [",", 1048], ["pheochromocytoma", 1050], [",", 1066], ["astrocytoma", 1068], ["and", 1080], ["GIST", 1084], [".", 1088], ["Our", 1090], ["results", 1094], ["suggest", 1102], ["that", 1110], ["the", 1115], ["molecular", 1119], ["pathogenesis", 1129], ["of", 1142], ["GISTs", 1145], ["in", 1151], ["NF1", 1154], ["patients", 1158], ["is", 1167], ["different", 1170], ["from", 1180], ["that", 1185], ["in", 1190], ["non", 1193], ["-", 1196], ["NF1", 1197], ["patients", 1201], [".", 1209]]}
{"context": "A specialized nucleotide excision repair pathway known as transcription-coupled repair (TCR) counteracts the toxic effects of DNA damage in transcriptionally active genes. The clustering of active genes into gene-rich chromosomal domains predicts that the sites of TCR are unevenly distributed through the genome. To elucidate the genomic organization and chromosomal localization of TCR, we isolated DNA fragments encompassing TCR-mediated repair sites from UV-C irradiated xeroderma pigmentosum group C cells, which can only repair the transcribed strand of active genes. This DNA was used as a molecular probe to visualize TCR in normal metaphase spreads by reverse fluorescence in situ hybridization. Whereas DNA repair sites in normal human cells are evenly distributed through the genome, TCR is highly localized at specific chromosomal domains. Particularly, clusters of TCR sites were identified at early-replicating gene-rich bands and telomeric regions of several chromosomes. High gene-density chromosomes such as chromosome 19 and the GC-rich domains of several chromosomes (T bands) are preferential locations of TCR. Our results demonstrate that the intragenomic localization of TCR resembles the uneven distribution of the human transcriptome, CpG islands, and hyperacetylated histones, enforcing the basic link between DNA repair, transcription, and nuclear organization in a complex genome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "a279fbb04c944d8dbfb90dbe26a570cd", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[88, 89]], "char_spans": [[538, 555]]}]}], "context_tokens": [["A", 0], ["specialized", 2], ["nucleotide", 14], ["excision", 25], ["repair", 34], ["pathway", 41], ["known", 49], ["as", 55], ["transcription", 58], ["-", 71], ["coupled", 72], ["repair", 80], ["(", 87], ["TCR", 88], [")", 91], ["counteracts", 93], ["the", 105], ["toxic", 109], ["effects", 115], ["of", 123], ["DNA", 126], ["damage", 130], ["in", 137], ["transcriptionally", 140], ["active", 158], ["genes", 165], [".", 170], ["The", 172], ["clustering", 176], ["of", 187], ["active", 190], ["genes", 197], ["into", 203], ["gene", 208], ["-", 212], ["rich", 213], ["chromosomal", 218], ["domains", 230], ["predicts", 238], ["that", 247], ["the", 252], ["sites", 256], ["of", 262], ["TCR", 265], ["are", 269], ["unevenly", 273], ["distributed", 282], ["through", 294], ["the", 302], ["genome", 306], [".", 312], ["To", 314], ["elucidate", 317], ["the", 327], ["genomic", 331], ["organization", 339], ["and", 352], ["chromosomal", 356], ["localization", 368], ["of", 381], ["TCR", 384], [",", 387], ["we", 389], ["isolated", 392], ["DNA", 401], ["fragments", 405], ["encompassing", 415], ["TCR", 428], ["-", 431], ["mediated", 432], ["repair", 441], ["sites", 448], ["from", 454], ["UV", 459], ["-", 461], ["C", 462], ["irradiated", 464], ["xeroderma", 475], ["pigmentosum", 485], ["group", 497], ["C", 503], ["cells", 505], [",", 510], ["which", 512], ["can", 518], ["only", 522], ["repair", 527], ["the", 534], ["transcribed", 538], ["strand", 550], ["of", 557], ["active", 560], ["genes", 567], [".", 572], ["This", 574], ["DNA", 579], ["was", 583], ["used", 587], ["as", 592], ["a", 595], ["molecular", 597], ["probe", 607], ["to", 613], ["visualize", 616], ["TCR", 626], ["in", 630], ["normal", 633], ["metaphase", 640], ["spreads", 650], ["by", 658], ["reverse", 661], ["fluorescence", 669], ["in", 682], ["situ", 685], ["hybridization", 690], [".", 703], ["Whereas", 705], ["DNA", 713], ["repair", 717], ["sites", 724], ["in", 730], ["normal", 733], ["human", 740], ["cells", 746], ["are", 752], ["evenly", 756], ["distributed", 763], ["through", 775], ["the", 783], ["genome", 787], [",", 793], ["TCR", 795], ["is", 799], ["highly", 802], ["localized", 809], ["at", 819], ["specific", 822], ["chromosomal", 831], ["domains", 843], [".", 850], ["Particularly", 852], [",", 864], ["clusters", 866], ["of", 875], ["TCR", 878], ["sites", 882], ["were", 888], ["identified", 893], ["at", 904], ["early", 907], ["-", 912], ["replicating", 913], ["gene", 925], ["-", 929], ["rich", 930], ["bands", 935], ["and", 941], ["telomeric", 945], ["regions", 955], ["of", 963], ["several", 966], ["chromosomes", 974], [".", 985], ["High", 987], ["gene", 992], ["-", 996], ["density", 997], ["chromosomes", 1005], ["such", 1017], ["as", 1022], ["chromosome", 1025], ["19", 1036], ["and", 1039], ["the", 1043], ["GC", 1047], ["-", 1049], ["rich", 1050], ["domains", 1055], ["of", 1063], ["several", 1066], ["chromosomes", 1074], ["(", 1086], ["T", 1087], ["bands", 1089], [")", 1094], ["are", 1096], ["preferential", 1100], ["locations", 1113], ["of", 1123], ["TCR", 1126], [".", 1129], ["Our", 1131], ["results", 1135], ["demonstrate", 1143], ["that", 1155], ["the", 1160], ["intragenomic", 1164], ["localization", 1177], ["of", 1190], ["TCR", 1193], ["resembles", 1197], ["the", 1207], ["uneven", 1211], ["distribution", 1218], ["of", 1231], ["the", 1234], ["human", 1238], ["transcriptome", 1244], [",", 1257], ["CpG", 1259], ["islands", 1263], [",", 1270], ["and", 1272], ["hyperacetylated", 1276], ["histones", 1292], [",", 1300], ["enforcing", 1302], ["the", 1312], ["basic", 1316], ["link", 1322], ["between", 1327], ["DNA", 1335], ["repair", 1339], [",", 1345], ["transcription", 1347], [",", 1360], ["and", 1362], ["nuclear", 1366], ["organization", 1374], ["in", 1387], ["a", 1390], ["complex", 1392], ["genome", 1400], [".", 1406]]}
{"context": "Imatinib mesylate was designed as an inhibitor targeting the BCR-ABL tyrosine kinase, the molecular counterpart of the Philadelphia translocation t(9;22)(q34;q11). We report on a patient with chronic myeloid leukemia (CML) undergoing acceleration during imatinib treatment. Cytogenetic analysis revealed four different cell populations: 46,XX,t(9;22)(q34;q11),der(18)t(2;18)(p11;p11)[1]/47,idem,i(17)(q10),-der(18)t(2;18),+der(22)t(9;22)[1]/46,idem,-t(9;22),der(9)t(9;22),ider(22)t(9;22)[12]/ 47,idem,-t(9;22),der(9)t(9;22),+22,ider(22)t(9;22)x2[1]. FISH analysis confirmed the presence of these four clones. Moreover, 49% of the interphase nuclei contained either one or two clustered fusion signals, indicating a low-level amplification of the BCR-ABL fusion gene. With quantitative real-time RT-PCR, a BCR-ABL/G6PDH ratio of 0.8 was determined, which is comparable to that measured in the K562 cell line with a known BCR-ABL amplification and which is increased by more than about 60-fold compared to a CML at diagnosis with >80% Philadelphia-positive cells. We give further evidence that the genomic BCR-ABL amplification results in an increased level of BCR-ABL transcript linking two potent mechanisms of resistance against imatinib treatment.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "513d7255d5544f56ac4e2cdea3c6e3c5", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[108, 110], [92, 94], [133, 135], [168, 170], [9, 11], [178, 180]], "char_spans": [[805, 811], [746, 752], [920, 926], [1104, 1110], [61, 67], [1159, 1165]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["was", 18], ["designed", 22], ["as", 31], ["an", 34], ["inhibitor", 37], ["targeting", 47], ["the", 57], ["BCR", 61], ["-", 64], ["ABL", 65], ["tyrosine", 69], ["kinase", 78], [",", 84], ["the", 86], ["molecular", 90], ["counterpart", 100], ["of", 112], ["the", 115], ["Philadelphia", 119], ["translocation", 132], ["t(9;22)(q34;q11", 146], [")", 161], [".", 162], ["We", 164], ["report", 167], ["on", 174], ["a", 177], ["patient", 179], ["with", 187], ["chronic", 192], ["myeloid", 200], ["leukemia", 208], ["(", 217], ["CML", 218], [")", 221], ["undergoing", 223], ["acceleration", 234], ["during", 247], ["imatinib", 254], ["treatment", 263], [".", 272], ["Cytogenetic", 274], ["analysis", 286], ["revealed", 295], ["four", 304], ["different", 309], ["cell", 319], ["populations", 324], [":", 335], ["46,XX", 337], [",", 342], ["t(9;22)(q34;q11),der(18)t(2;18)(p11;p11)[1]/47,idem", 343], [",", 394], ["i(17)(q10),-der(18)t(2;18),+der(22)t(9;22)[1]/46,idem,-t(9;22),der(9)t(9;22),ider(22)t(9;22)[12]/", 395], ["47,idem,-t(9;22),der(9)t(9;22),+22,ider(22)t(9;22)x2[1].", 493], ["FISH", 550], ["analysis", 555], ["confirmed", 564], ["the", 574], ["presence", 578], ["of", 587], ["these", 590], ["four", 596], ["clones", 601], [".", 607], ["Moreover", 609], [",", 617], ["49", 619], ["%", 621], ["of", 623], ["the", 626], ["interphase", 630], ["nuclei", 641], ["contained", 648], ["either", 658], ["one", 665], ["or", 669], ["two", 672], ["clustered", 676], ["fusion", 686], ["signals", 693], [",", 700], ["indicating", 702], ["a", 713], ["low", 715], ["-", 718], ["level", 719], ["amplification", 725], ["of", 739], ["the", 742], ["BCR", 746], ["-", 749], ["ABL", 750], ["fusion", 754], ["gene", 761], [".", 765], ["With", 767], ["quantitative", 772], ["real", 785], ["-", 789], ["time", 790], ["RT", 795], ["-", 797], ["PCR", 798], [",", 801], ["a", 803], ["BCR", 805], ["-", 808], ["ABL", 809], ["/", 812], ["G6PDH", 813], ["ratio", 819], ["of", 825], ["0.8", 828], ["was", 832], ["determined", 836], [",", 846], ["which", 848], ["is", 854], ["comparable", 857], ["to", 868], ["that", 871], ["measured", 876], ["in", 885], ["the", 888], ["K562", 892], ["cell", 897], ["line", 902], ["with", 907], ["a", 912], ["known", 914], ["BCR", 920], ["-", 923], ["ABL", 924], ["amplification", 928], ["and", 942], ["which", 946], ["is", 952], ["increased", 955], ["by", 965], ["more", 968], ["than", 973], ["about", 978], ["60-fold", 984], ["compared", 992], ["to", 1001], ["a", 1004], ["CML", 1006], ["at", 1010], ["diagnosis", 1013], ["with", 1023], [">", 1028], ["80", 1029], ["%", 1031], ["Philadelphia", 1033], ["-", 1045], ["positive", 1046], ["cells", 1055], [".", 1060], ["We", 1062], ["give", 1065], ["further", 1070], ["evidence", 1078], ["that", 1087], ["the", 1092], ["genomic", 1096], ["BCR", 1104], ["-", 1107], ["ABL", 1108], ["amplification", 1112], ["results", 1126], ["in", 1134], ["an", 1137], ["increased", 1140], ["level", 1150], ["of", 1156], ["BCR", 1159], ["-", 1162], ["ABL", 1163], ["transcript", 1167], ["linking", 1178], ["two", 1186], ["potent", 1190], ["mechanisms", 1197], ["of", 1208], ["resistance", 1211], ["against", 1222], ["imatinib", 1230], ["treatment", 1239], [".", 1248]]}
{"context": "Carpal tunnel syndrome is a complex of symptoms as a result of compression of the median nerve in the carpal tunnel. As nerve entrapment induces impairment of somatic fibres followed by clinical symptoms and signs of the syndrome, one can assume that sympathetic fibres are involved too. Results of studies focused on this problem show presence of sympathetic symptoms in about half of patients, including Raynaud phenomenon, blanching of hands, painful swelling of fingers, dry or excessive sweating of palms. Activity of sympathetic system can be investigated by means of sympathetic skin response and vasomotor response. Eight papers presenting the results of sympathetic skin response from median nerve in carpal tunnel syndrome were analysed. Results of 4 studies showed decreased sympathetic activity, in 2 findings were equivocal and 2 studies failed to reveal any abnormalities. The following variables were considered in the interpretation of sympathetic skin response curve: amplitude, latency and area under the chart, each of them having limited diagnostic value due to inter-and intrasubject variation of these parameters. Vasomotor response was investigated in 2 studies by means of Doppler ultrasound flow examination in digital arteries. Results of both studies showed decreased vasomotor response in carpal tunnel syndrome. The review of current knowledge on sympathetic impairment in carpal tunnel syndrome fails to provide a definitive determination of its range and clinical consequences. It confirms, however, that routine examination of sympathetic disturbances is unnecessary due to their minor clinical significance.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "3da4e2bccf984afb8212d78a6eab3d6f", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[15, 15], [115, 115]], "char_spans": [[82, 87], [694, 699]]}]}], "context_tokens": [["Carpal", 0], ["tunnel", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["complex", 28], ["of", 36], ["symptoms", 39], ["as", 48], ["a", 51], ["result", 53], ["of", 60], ["compression", 63], ["of", 75], ["the", 78], ["median", 82], ["nerve", 89], ["in", 95], ["the", 98], ["carpal", 102], ["tunnel", 109], [".", 115], ["As", 117], ["nerve", 120], ["entrapment", 126], ["induces", 137], ["impairment", 145], ["of", 156], ["somatic", 159], ["fibres", 167], ["followed", 174], ["by", 183], ["clinical", 186], ["symptoms", 195], ["and", 204], ["signs", 208], ["of", 214], ["the", 217], ["syndrome", 221], [",", 229], ["one", 231], ["can", 235], ["assume", 239], ["that", 246], ["sympathetic", 251], ["fibres", 263], ["are", 270], ["involved", 274], ["too", 283], [".", 286], ["Results", 288], ["of", 296], ["studies", 299], ["focused", 307], ["on", 315], ["this", 318], ["problem", 323], ["show", 331], ["presence", 336], ["of", 345], ["sympathetic", 348], ["symptoms", 360], ["in", 369], ["about", 372], ["half", 378], ["of", 383], ["patients", 386], [",", 394], ["including", 396], ["Raynaud", 406], ["phenomenon", 414], [",", 424], ["blanching", 426], ["of", 436], ["hands", 439], [",", 444], ["painful", 446], ["swelling", 454], ["of", 463], ["fingers", 466], [",", 473], ["dry", 475], ["or", 479], ["excessive", 482], ["sweating", 492], ["of", 501], ["palms", 504], [".", 509], ["Activity", 511], ["of", 520], ["sympathetic", 523], ["system", 535], ["can", 542], ["be", 546], ["investigated", 549], ["by", 562], ["means", 565], ["of", 571], ["sympathetic", 574], ["skin", 586], ["response", 591], ["and", 600], ["vasomotor", 604], ["response", 614], [".", 622], ["Eight", 624], ["papers", 630], ["presenting", 637], ["the", 648], ["results", 652], ["of", 660], ["sympathetic", 663], ["skin", 675], ["response", 680], ["from", 689], ["median", 694], ["nerve", 701], ["in", 707], ["carpal", 710], ["tunnel", 717], ["syndrome", 724], ["were", 733], ["analysed", 738], [".", 746], ["Results", 748], ["of", 756], ["4", 759], ["studies", 761], ["showed", 769], ["decreased", 776], ["sympathetic", 786], ["activity", 798], [",", 806], ["in", 808], ["2", 811], ["findings", 813], ["were", 822], ["equivocal", 827], ["and", 837], ["2", 841], ["studies", 843], ["failed", 851], ["to", 858], ["reveal", 861], ["any", 868], ["abnormalities", 872], [".", 885], ["The", 887], ["following", 891], ["variables", 901], ["were", 911], ["considered", 916], ["in", 927], ["the", 930], ["interpretation", 934], ["of", 949], ["sympathetic", 952], ["skin", 964], ["response", 969], ["curve", 978], [":", 983], ["amplitude", 985], [",", 994], ["latency", 996], ["and", 1004], ["area", 1008], ["under", 1013], ["the", 1019], ["chart", 1023], [",", 1028], ["each", 1030], ["of", 1035], ["them", 1038], ["having", 1043], ["limited", 1050], ["diagnostic", 1058], ["value", 1069], ["due", 1075], ["to", 1079], ["inter", 1082], ["-", 1087], ["and", 1088], ["intrasubject", 1092], ["variation", 1105], ["of", 1115], ["these", 1118], ["parameters", 1124], [".", 1134], ["Vasomotor", 1136], ["response", 1146], ["was", 1155], ["investigated", 1159], ["in", 1172], ["2", 1175], ["studies", 1177], ["by", 1185], ["means", 1188], ["of", 1194], ["Doppler", 1197], ["ultrasound", 1205], ["flow", 1216], ["examination", 1221], ["in", 1233], ["digital", 1236], ["arteries", 1244], [".", 1252], ["Results", 1254], ["of", 1262], ["both", 1265], ["studies", 1270], ["showed", 1278], ["decreased", 1285], ["vasomotor", 1295], ["response", 1305], ["in", 1314], ["carpal", 1317], ["tunnel", 1324], ["syndrome", 1331], [".", 1339], ["The", 1341], ["review", 1345], ["of", 1352], ["current", 1355], ["knowledge", 1363], ["on", 1373], ["sympathetic", 1376], ["impairment", 1388], ["in", 1399], ["carpal", 1402], ["tunnel", 1409], ["syndrome", 1416], ["fails", 1425], ["to", 1431], ["provide", 1434], ["a", 1442], ["definitive", 1444], ["determination", 1455], ["of", 1469], ["its", 1472], ["range", 1476], ["and", 1482], ["clinical", 1486], ["consequences", 1495], [".", 1507], ["It", 1509], ["confirms", 1512], [",", 1520], ["however", 1522], [",", 1529], ["that", 1531], ["routine", 1536], ["examination", 1544], ["of", 1556], ["sympathetic", 1559], ["disturbances", 1571], ["is", 1584], ["unnecessary", 1587], ["due", 1599], ["to", 1603], ["their", 1606], ["minor", 1612], ["clinical", 1618], ["significance", 1627], [".", 1639]]}
{"context": "Psychiatric disorders have a great impact on morbidity and mortality. Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients. PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts. We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation. The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function. Psygenet2r is especially suited for network medicine analysis of psychiatric disorders. The package is implemented in R and is available under MIT license from Bioconductor (http://bioconductor.org/packages/release/bioc/html/psygenet2r.html). juanr.gonzalez@isglobal.org or laura.furlong@upf.edu. Supplementary data are available at Bioinformatics online.", "qas": [{"question": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?", "answers": ["Psygenet2r"], "qid": "4d4e76e2c6944123bd9d9709e0e9d250", "question_tokens": [["Which", 0], ["R", 6], ["/", 7], ["Bioconductor", 8], ["package", 21], ["has", 29], ["been", 33], ["developed", 38], ["for", 48], ["the", 52], ["analysis", 56], ["of", 65], ["psychiatric", 68], ["disease", 80], ["genes", 88], ["?", 93]], "detected_answers": [{"text": "Psygenet2r", "token_spans": [[121, 121], [58, 58]], "char_spans": [[745, 754], [350, 359]]}]}], "context_tokens": [["Psychiatric", 0], ["disorders", 12], ["have", 22], ["a", 27], ["great", 29], ["impact", 35], ["on", 42], ["morbidity", 45], ["and", 55], ["mortality", 59], [".", 68], ["Genotype", 70], ["-", 78], ["phenotype", 79], ["resources", 89], ["for", 99], ["psychiatric", 103], ["diseases", 115], ["are", 124], ["key", 128], ["to", 132], ["enable", 135], ["the", 142], ["translation", 146], ["of", 158], ["research", 161], ["findings", 170], ["to", 179], ["a", 182], ["better", 184], ["care", 191], ["of", 196], ["patients", 199], [".", 207], ["PsyGeNET", 209], ["is", 218], ["a", 221], ["knowledge", 223], ["resource", 233], ["on", 242], ["psychiatric", 245], ["diseases", 257], ["and", 266], ["their", 270], ["genes", 276], [",", 281], ["developed", 283], ["by", 293], ["text", 296], ["mining", 301], ["and", 308], ["curated", 312], ["by", 320], ["domain", 323], ["experts", 330], [".", 337], ["We", 339], ["present", 342], ["psygenet2r", 350], [",", 360], ["an", 362], ["R", 365], ["package", 367], ["that", 375], ["contains", 380], ["a", 389], ["variety", 391], ["of", 399], ["functions", 402], ["for", 412], ["leveraging", 416], ["PsyGeNET", 427], ["database", 436], ["and", 445], ["facilitating", 449], ["its", 462], ["analysis", 466], ["and", 475], ["interpretation", 479], [".", 493], ["The", 495], ["package", 499], ["offers", 507], ["different", 514], ["types", 524], ["of", 530], ["queries", 533], ["to", 541], ["the", 544], ["database", 548], ["along", 557], ["with", 563], ["variety", 568], ["of", 576], ["analysis", 579], ["and", 588], ["visualization", 592], ["tools", 606], [",", 611], ["including", 613], ["the", 623], ["study", 627], ["of", 633], ["the", 636], ["anatomical", 640], ["structures", 651], ["in", 662], ["which", 665], ["the", 671], ["genes", 675], ["are", 681], ["expressed", 685], ["and", 695], ["gaining", 699], ["insight", 707], ["of", 715], ["gene", 718], ["'s", 722], ["molecular", 725], ["function", 735], [".", 743], ["Psygenet2r", 745], ["is", 756], ["especially", 759], ["suited", 770], ["for", 777], ["network", 781], ["medicine", 789], ["analysis", 798], ["of", 807], ["psychiatric", 810], ["disorders", 822], [".", 831], ["The", 833], ["package", 837], ["is", 845], ["implemented", 848], ["in", 860], ["R", 863], ["and", 865], ["is", 869], ["available", 872], ["under", 882], ["MIT", 888], ["license", 892], ["from", 900], ["Bioconductor", 905], ["(", 918], ["http://bioconductor.org/packages/release/bioc/html/psygenet2r.html", 919], [")", 985], [".", 986], ["juanr.gonzalez@isglobal.org", 988], ["or", 1016], ["laura.furlong@upf.edu", 1019], [".", 1040], ["Supplementary", 1042], ["data", 1056], ["are", 1061], ["available", 1065], ["at", 1075], ["Bioinformatics", 1078], ["online", 1093], [".", 1099]]}
{"context": "Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran. We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B). The primary end point was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of idarucizumab, on the basis of the determination at a central laboratory of the dilute thrombin time or ecarin clotting time. A key secondary end point was the restoration of hemostasis. This interim analysis included 90 patients who received idarucizumab (51 patients in group A and 39 in group B). Among 68 patients with an elevated dilute thrombin time and 81 with an elevated ecarin clotting time at baseline, the median maximum percentage reversal was 100% (95% confidence interval, 100 to 100). Idarucizumab normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes. Concentrations of unbound dabigatran remained below 20 ng per milliliter at 24 hours in 79% of the patients. Among 35 patients in group A who could be assessed, hemostasis, as determined by local investigators, was restored at a median of 11.4 hours. Among 36 patients in group B who underwent a procedure, normal intraoperative hemostasis was reported in 33, and mildly or moderately abnormal hemostasis was reported in 2 patients and 1 patient, respectively. One thrombotic event occurred within 72 hours after idarucizumab administration in a patient in whom anticoagulants had not been reinitiated. Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947.).", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "ed0c4a0629ff46d1b8993188f8a0e5c4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[326, 326], [90, 90], [28, 28], [217, 217], [55, 55]], "char_spans": [[1870, 1879], [538, 547], [177, 186], [1232, 1241], [348, 357]]}]}], "context_tokens": [["Specific", 0], ["reversal", 9], ["agents", 18], ["for", 25], ["non", 29], ["-", 32], ["vitamin", 33], ["K", 41], ["antagonist", 43], ["oral", 54], ["anticoagulants", 59], ["are", 74], ["lacking", 78], [".", 85], ["Idarucizumab", 87], [",", 99], ["an", 101], ["antibody", 104], ["fragment", 113], [",", 121], ["was", 123], ["developed", 127], ["to", 137], ["reverse", 140], ["the", 148], ["anticoagulant", 152], ["effects", 166], ["of", 174], ["dabigatran", 177], [".", 187], ["We", 189], ["undertook", 192], ["this", 202], ["prospective", 207], ["cohort", 219], ["study", 226], ["to", 232], ["determine", 235], ["the", 245], ["safety", 249], ["of", 256], ["5", 259], ["g", 261], ["of", 263], ["intravenous", 266], ["idarucizumab", 278], ["and", 291], ["its", 295], ["capacity", 299], ["to", 308], ["reverse", 311], ["the", 319], ["anticoagulant", 323], ["effects", 337], ["of", 345], ["dabigatran", 348], ["in", 359], ["patients", 362], ["who", 371], ["had", 375], ["serious", 379], ["bleeding", 387], ["(", 396], ["group", 397], ["A", 403], [")", 404], ["or", 406], ["required", 409], ["an", 418], ["urgent", 421], ["procedure", 428], ["(", 438], ["group", 439], ["B", 445], [")", 446], [".", 447], ["The", 449], ["primary", 453], ["end", 461], ["point", 465], ["was", 471], ["the", 475], ["maximum", 479], ["percentage", 487], ["reversal", 498], ["of", 507], ["the", 510], ["anticoagulant", 514], ["effect", 528], ["of", 535], ["dabigatran", 538], ["within", 549], ["4", 556], ["hours", 558], ["after", 564], ["the", 570], ["administration", 574], ["of", 589], ["idarucizumab", 592], [",", 604], ["on", 606], ["the", 609], ["basis", 613], ["of", 619], ["the", 622], ["determination", 626], ["at", 640], ["a", 643], ["central", 645], ["laboratory", 653], ["of", 664], ["the", 667], ["dilute", 671], ["thrombin", 678], ["time", 687], ["or", 692], ["ecarin", 695], ["clotting", 702], ["time", 711], [".", 715], ["A", 717], ["key", 719], ["secondary", 723], ["end", 733], ["point", 737], ["was", 743], ["the", 747], ["restoration", 751], ["of", 763], ["hemostasis", 766], [".", 776], ["This", 778], ["interim", 783], ["analysis", 791], ["included", 800], ["90", 809], ["patients", 812], ["who", 821], ["received", 825], ["idarucizumab", 834], ["(", 847], ["51", 848], ["patients", 851], ["in", 860], ["group", 863], ["A", 869], ["and", 871], ["39", 875], ["in", 878], ["group", 881], ["B", 887], [")", 888], [".", 889], ["Among", 891], ["68", 897], ["patients", 900], ["with", 909], ["an", 914], ["elevated", 917], ["dilute", 926], ["thrombin", 933], ["time", 942], ["and", 947], ["81", 951], ["with", 954], ["an", 959], ["elevated", 962], ["ecarin", 971], ["clotting", 978], ["time", 987], ["at", 992], ["baseline", 995], [",", 1003], ["the", 1005], ["median", 1009], ["maximum", 1016], ["percentage", 1024], ["reversal", 1035], ["was", 1044], ["100", 1048], ["%", 1051], ["(", 1053], ["95", 1054], ["%", 1056], ["confidence", 1058], ["interval", 1069], [",", 1077], ["100", 1079], ["to", 1083], ["100", 1086], [")", 1089], [".", 1090], ["Idarucizumab", 1092], ["normalized", 1105], ["the", 1116], ["test", 1120], ["results", 1125], ["in", 1133], ["88", 1136], ["to", 1139], ["98", 1142], ["%", 1144], ["of", 1146], ["the", 1149], ["patients", 1153], [",", 1161], ["an", 1163], ["effect", 1166], ["that", 1173], ["was", 1178], ["evident", 1182], ["within", 1190], ["minutes", 1197], [".", 1204], ["Concentrations", 1206], ["of", 1221], ["unbound", 1224], ["dabigatran", 1232], ["remained", 1243], ["below", 1252], ["20", 1258], ["ng", 1261], ["per", 1264], ["milliliter", 1268], ["at", 1279], ["24", 1282], ["hours", 1285], ["in", 1291], ["79", 1294], ["%", 1296], ["of", 1298], ["the", 1301], ["patients", 1305], [".", 1313], ["Among", 1315], ["35", 1321], ["patients", 1324], ["in", 1333], ["group", 1336], ["A", 1342], ["who", 1344], ["could", 1348], ["be", 1354], ["assessed", 1357], [",", 1365], ["hemostasis", 1367], [",", 1377], ["as", 1379], ["determined", 1382], ["by", 1393], ["local", 1396], ["investigators", 1402], [",", 1415], ["was", 1417], ["restored", 1421], ["at", 1430], ["a", 1433], ["median", 1435], ["of", 1442], ["11.4", 1445], ["hours", 1450], [".", 1455], ["Among", 1457], ["36", 1463], ["patients", 1466], ["in", 1475], ["group", 1478], ["B", 1484], ["who", 1486], ["underwent", 1490], ["a", 1500], ["procedure", 1502], [",", 1511], ["normal", 1513], ["intraoperative", 1520], ["hemostasis", 1535], ["was", 1546], ["reported", 1550], ["in", 1559], ["33", 1562], [",", 1564], ["and", 1566], ["mildly", 1570], ["or", 1577], ["moderately", 1580], ["abnormal", 1591], ["hemostasis", 1600], ["was", 1611], ["reported", 1615], ["in", 1624], ["2", 1627], ["patients", 1629], ["and", 1638], ["1", 1642], ["patient", 1644], [",", 1651], ["respectively", 1653], [".", 1665], ["One", 1667], ["thrombotic", 1671], ["event", 1682], ["occurred", 1688], ["within", 1697], ["72", 1704], ["hours", 1707], ["after", 1713], ["idarucizumab", 1719], ["administration", 1732], ["in", 1747], ["a", 1750], ["patient", 1752], ["in", 1760], ["whom", 1763], ["anticoagulants", 1768], ["had", 1783], ["not", 1787], ["been", 1791], ["reinitiated", 1796], [".", 1807], ["Idarucizumab", 1809], ["completely", 1822], ["reversed", 1833], ["the", 1842], ["anticoagulant", 1846], ["effect", 1860], ["of", 1867], ["dabigatran", 1870], ["within", 1881], ["minutes", 1888], [".", 1895], ["(", 1897], ["Funded", 1898], ["by", 1905], ["Boehringer", 1908], ["Ingelheim", 1919], [";", 1928], ["RE", 1930], ["-", 1932], ["VERSE", 1933], ["AD", 1939], ["ClinicalTrials.gov", 1942], ["number", 1961], [",", 1967], ["NCT02104947", 1969], [".", 1980], [")", 1981], [".", 1982]]}
{"context": "Batten disease [juvenile-onset neuronal ceroid lipofuscinosis (JNCL)], the most common progressive encephalopathy of childhood, is caused by mutations in a novel lysosomal membrane protein (CLN3) with unknown function. In this study, we have confirmed the lysosomal localization of the CLN3 protein by immunoelectron microscopy by co-localizing it with soluble and membrane-associated lysosomal proteins. We have analysed the intracellular processing and localization of two mutants, 461-677del, which is present in 85% of CLN3 alleles and causes the classical JNCL, and E295K [corrected], which is a rare missense mutation associated with an atypical form of JNCL. Pulse-chase labelling and immunoprecipitation of the two mutant proteins in COS-1-cells indicated that 461-677del is synthesized as an approximately 24 kDa truncated polypeptide, whereas the maturation of E295K [corrected] resembles that of the wild-type CLN3 polypeptide. Transient expression of the two mutants in BHK cells showed that 461-677del is retained in the endoplasmic reticulum, whereas E295K [corrected] was capable of reaching the lysosomal compartment. The CLN3 polypeptides were expressed further in mouse primary neurons where the wild-type CLN3 protein was localized both in the cell soma and in neuronal extensions, whereas the 461-677del mutant was arrested in the cell soma. Interestingly, co-localization of the wild-type CLN3 and E295K [corrected] proteins with a synaptic vesicle marker indicates that the CLN3 protein might participate in synaptic vesicle transport/transmission. The data presented here provide clear evidence for a cellular distinction between classical and atypical forms of Batten disease both in neural and non-neural cells.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "6d7b3c37d90b4259923fc6b4defc1056", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[0, 1], [300, 301]], "char_spans": [[0, 13], [1685, 1698]]}, {"text": "juvenile-onset neuronal ceroid lipofuscinosis", "token_spans": [[3, 8]], "char_spans": [[16, 60]]}, {"text": "JNCL", "token_spans": [[120, 120], [99, 99], [10, 10]], "char_spans": [[660, 663], [561, 564], [63, 66]]}]}], "context_tokens": [["Batten", 0], ["disease", 7], ["[", 15], ["juvenile", 16], ["-", 24], ["onset", 25], ["neuronal", 31], ["ceroid", 40], ["lipofuscinosis", 47], ["(", 62], ["JNCL", 63], [")", 67], ["]", 68], [",", 69], ["the", 71], ["most", 75], ["common", 80], ["progressive", 87], ["encephalopathy", 99], ["of", 114], ["childhood", 117], [",", 126], ["is", 128], ["caused", 131], ["by", 138], ["mutations", 141], ["in", 151], ["a", 154], ["novel", 156], ["lysosomal", 162], ["membrane", 172], ["protein", 181], ["(", 189], ["CLN3", 190], [")", 194], ["with", 196], ["unknown", 201], ["function", 209], [".", 217], ["In", 219], ["this", 222], ["study", 227], [",", 232], ["we", 234], ["have", 237], ["confirmed", 242], ["the", 252], ["lysosomal", 256], ["localization", 266], ["of", 279], ["the", 282], ["CLN3", 286], ["protein", 291], ["by", 299], ["immunoelectron", 302], ["microscopy", 317], ["by", 328], ["co", 331], ["-", 333], ["localizing", 334], ["it", 345], ["with", 348], ["soluble", 353], ["and", 361], ["membrane", 365], ["-", 373], ["associated", 374], ["lysosomal", 385], ["proteins", 395], [".", 403], ["We", 405], ["have", 408], ["analysed", 413], ["the", 422], ["intracellular", 426], ["processing", 440], ["and", 451], ["localization", 455], ["of", 468], ["two", 471], ["mutants", 475], [",", 482], ["461", 484], ["-", 487], ["677del", 488], [",", 494], ["which", 496], ["is", 502], ["present", 505], ["in", 513], ["85", 516], ["%", 518], ["of", 520], ["CLN3", 523], ["alleles", 528], ["and", 536], ["causes", 540], ["the", 547], ["classical", 551], ["JNCL", 561], [",", 565], ["and", 567], ["E295", 571], ["K", 575], ["[", 577], ["corrected", 578], ["]", 587], [",", 588], ["which", 590], ["is", 596], ["a", 599], ["rare", 601], ["missense", 606], ["mutation", 615], ["associated", 624], ["with", 635], ["an", 640], ["atypical", 643], ["form", 652], ["of", 657], ["JNCL", 660], [".", 664], ["Pulse", 666], ["-", 671], ["chase", 672], ["labelling", 678], ["and", 688], ["immunoprecipitation", 692], ["of", 712], ["the", 715], ["two", 719], ["mutant", 723], ["proteins", 730], ["in", 739], ["COS-1-cells", 742], ["indicated", 754], ["that", 764], ["461", 769], ["-", 772], ["677del", 773], ["is", 780], ["synthesized", 783], ["as", 795], ["an", 798], ["approximately", 801], ["24", 815], ["kDa", 818], ["truncated", 822], ["polypeptide", 832], [",", 843], ["whereas", 845], ["the", 853], ["maturation", 857], ["of", 868], ["E295", 871], ["K", 875], ["[", 877], ["corrected", 878], ["]", 887], ["resembles", 889], ["that", 899], ["of", 904], ["the", 907], ["wild", 911], ["-", 915], ["type", 916], ["CLN3", 921], ["polypeptide", 926], [".", 937], ["Transient", 939], ["expression", 949], ["of", 960], ["the", 963], ["two", 967], ["mutants", 971], ["in", 979], ["BHK", 982], ["cells", 986], ["showed", 992], ["that", 999], ["461", 1004], ["-", 1007], ["677del", 1008], ["is", 1015], ["retained", 1018], ["in", 1027], ["the", 1030], ["endoplasmic", 1034], ["reticulum", 1046], [",", 1055], ["whereas", 1057], ["E295", 1065], ["K", 1069], ["[", 1071], ["corrected", 1072], ["]", 1081], ["was", 1083], ["capable", 1087], ["of", 1095], ["reaching", 1098], ["the", 1107], ["lysosomal", 1111], ["compartment", 1121], [".", 1132], ["The", 1134], ["CLN3", 1138], ["polypeptides", 1143], ["were", 1156], ["expressed", 1161], ["further", 1171], ["in", 1179], ["mouse", 1182], ["primary", 1188], ["neurons", 1196], ["where", 1204], ["the", 1210], ["wild", 1214], ["-", 1218], ["type", 1219], ["CLN3", 1224], ["protein", 1229], ["was", 1237], ["localized", 1241], ["both", 1251], ["in", 1256], ["the", 1259], ["cell", 1263], ["soma", 1268], ["and", 1273], ["in", 1277], ["neuronal", 1280], ["extensions", 1289], [",", 1299], ["whereas", 1301], ["the", 1309], ["461", 1313], ["-", 1316], ["677del", 1317], ["mutant", 1324], ["was", 1331], ["arrested", 1335], ["in", 1344], ["the", 1347], ["cell", 1351], ["soma", 1356], [".", 1360], ["Interestingly", 1362], [",", 1375], ["co", 1377], ["-", 1379], ["localization", 1380], ["of", 1393], ["the", 1396], ["wild", 1400], ["-", 1404], ["type", 1405], ["CLN3", 1410], ["and", 1415], ["E295", 1419], ["K", 1423], ["[", 1425], ["corrected", 1426], ["]", 1435], ["proteins", 1437], ["with", 1446], ["a", 1451], ["synaptic", 1453], ["vesicle", 1462], ["marker", 1470], ["indicates", 1477], ["that", 1487], ["the", 1492], ["CLN3", 1496], ["protein", 1501], ["might", 1509], ["participate", 1515], ["in", 1527], ["synaptic", 1530], ["vesicle", 1539], ["transport", 1547], ["/", 1556], ["transmission", 1557], [".", 1569], ["The", 1571], ["data", 1575], ["presented", 1580], ["here", 1590], ["provide", 1595], ["clear", 1603], ["evidence", 1609], ["for", 1618], ["a", 1622], ["cellular", 1624], ["distinction", 1633], ["between", 1645], ["classical", 1653], ["and", 1663], ["atypical", 1667], ["forms", 1676], ["of", 1682], ["Batten", 1685], ["disease", 1692], ["both", 1700], ["in", 1705], ["neural", 1708], ["and", 1715], ["non", 1719], ["-", 1722], ["neural", 1723], ["cells", 1730], [".", 1735]]}
{"context": "Chronic pain arising from various pathological conditions such as osteoarthritis, low back or spinal injuries, cancer, and urological chronic pelvic pain syndromes presents significant challenges in diagnosis and treatment. Specifically, since the underlying cause of these pain syndromes is unknown or heterogeneous, physicians diagnose and treat patients based on the symptoms presented. Nerve growth factor (NGF) has been recognized as an important mediator of chronic pain in many pathological conditions, and has been shown to be upregulated in a subset of individuals suffering from such pain syndromes. These findings have led to the development of anti-NGF monoclonal antibodies such as tanezumab as potentially effective therapeutics for chronic pain. Although tanezumab has reached Phase II and III clinical trials, the trials of anti-NGF antibodies were halted due to safety concerns. Some of these trials of anti-NGF treatment have had statistically significant decreases in pain, while others have yielded inconclusive results. These findings are suggestive of, though do not prove, target (NGF) neutralization in chronic pain syndromes. A biomarker-driven anti-NGF clinical study layout is proposed that incorporates NGF measurements in the relevant samples before and after treatment, in addition to collecting the pain scores. This approach might not only confirm the mechanism of tanezumab's action in these chronic pain patients, but should establish NGF levels as a predictive biomarker for patients who can benefit from anti-NGF treatment, thereby creating a personalized approach to pain treatment.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "325680c55d7146c69a2cdebde92b66df", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[59, 61]], "char_spans": [[390, 408]]}, {"text": "NGF", "token_spans": [[154, 154], [138, 138], [198, 198], [246, 246], [108, 108], [260, 260], [184, 184], [206, 206], [63, 63]], "char_spans": [[925, 927], [845, 847], [1175, 1177], [1469, 1471], [661, 663], [1545, 1547], [1104, 1106], [1231, 1233], [411, 413]]}]}], "context_tokens": [["Chronic", 0], ["pain", 8], ["arising", 13], ["from", 21], ["various", 26], ["pathological", 34], ["conditions", 47], ["such", 58], ["as", 63], ["osteoarthritis", 66], [",", 80], ["low", 82], ["back", 86], ["or", 91], ["spinal", 94], ["injuries", 101], [",", 109], ["cancer", 111], [",", 117], ["and", 119], ["urological", 123], ["chronic", 134], ["pelvic", 142], ["pain", 149], ["syndromes", 154], ["presents", 164], ["significant", 173], ["challenges", 185], ["in", 196], ["diagnosis", 199], ["and", 209], ["treatment", 213], [".", 222], ["Specifically", 224], [",", 236], ["since", 238], ["the", 244], ["underlying", 248], ["cause", 259], ["of", 265], ["these", 268], ["pain", 274], ["syndromes", 279], ["is", 289], ["unknown", 292], ["or", 300], ["heterogeneous", 303], [",", 316], ["physicians", 318], ["diagnose", 329], ["and", 338], ["treat", 342], ["patients", 348], ["based", 357], ["on", 363], ["the", 366], ["symptoms", 370], ["presented", 379], [".", 388], ["Nerve", 390], ["growth", 396], ["factor", 403], ["(", 410], ["NGF", 411], [")", 414], ["has", 416], ["been", 420], ["recognized", 425], ["as", 436], ["an", 439], ["important", 442], ["mediator", 452], ["of", 461], ["chronic", 464], ["pain", 472], ["in", 477], ["many", 480], ["pathological", 485], ["conditions", 498], [",", 508], ["and", 510], ["has", 514], ["been", 518], ["shown", 523], ["to", 529], ["be", 532], ["upregulated", 535], ["in", 547], ["a", 550], ["subset", 552], ["of", 559], ["individuals", 562], ["suffering", 574], ["from", 584], ["such", 589], ["pain", 594], ["syndromes", 599], [".", 608], ["These", 610], ["findings", 616], ["have", 625], ["led", 630], ["to", 634], ["the", 637], ["development", 641], ["of", 653], ["anti", 656], ["-", 660], ["NGF", 661], ["monoclonal", 665], ["antibodies", 676], ["such", 687], ["as", 692], ["tanezumab", 695], ["as", 705], ["potentially", 708], ["effective", 720], ["therapeutics", 730], ["for", 743], ["chronic", 747], ["pain", 755], [".", 759], ["Although", 761], ["tanezumab", 770], ["has", 780], ["reached", 784], ["Phase", 792], ["II", 798], ["and", 801], ["III", 805], ["clinical", 809], ["trials", 818], [",", 824], ["the", 826], ["trials", 830], ["of", 837], ["anti", 840], ["-", 844], ["NGF", 845], ["antibodies", 849], ["were", 860], ["halted", 865], ["due", 872], ["to", 876], ["safety", 879], ["concerns", 886], [".", 894], ["Some", 896], ["of", 901], ["these", 904], ["trials", 910], ["of", 917], ["anti", 920], ["-", 924], ["NGF", 925], ["treatment", 929], ["have", 939], ["had", 944], ["statistically", 948], ["significant", 962], ["decreases", 974], ["in", 984], ["pain", 987], [",", 991], ["while", 993], ["others", 999], ["have", 1006], ["yielded", 1011], ["inconclusive", 1019], ["results", 1032], [".", 1039], ["These", 1041], ["findings", 1047], ["are", 1056], ["suggestive", 1060], ["of", 1071], [",", 1073], ["though", 1075], ["do", 1082], ["not", 1085], ["prove", 1089], [",", 1094], ["target", 1096], ["(", 1103], ["NGF", 1104], [")", 1107], ["neutralization", 1109], ["in", 1124], ["chronic", 1127], ["pain", 1135], ["syndromes", 1140], [".", 1149], ["A", 1151], ["biomarker", 1153], ["-", 1162], ["driven", 1163], ["anti", 1170], ["-", 1174], ["NGF", 1175], ["clinical", 1179], ["study", 1188], ["layout", 1194], ["is", 1201], ["proposed", 1204], ["that", 1213], ["incorporates", 1218], ["NGF", 1231], ["measurements", 1235], ["in", 1248], ["the", 1251], ["relevant", 1255], ["samples", 1264], ["before", 1272], ["and", 1279], ["after", 1283], ["treatment", 1289], [",", 1298], ["in", 1300], ["addition", 1303], ["to", 1312], ["collecting", 1315], ["the", 1326], ["pain", 1330], ["scores", 1335], [".", 1341], ["This", 1343], ["approach", 1348], ["might", 1357], ["not", 1363], ["only", 1367], ["confirm", 1372], ["the", 1380], ["mechanism", 1384], ["of", 1394], ["tanezumab", 1397], ["'s", 1406], ["action", 1409], ["in", 1416], ["these", 1419], ["chronic", 1425], ["pain", 1433], ["patients", 1438], [",", 1446], ["but", 1448], ["should", 1452], ["establish", 1459], ["NGF", 1469], ["levels", 1473], ["as", 1480], ["a", 1483], ["predictive", 1485], ["biomarker", 1496], ["for", 1506], ["patients", 1510], ["who", 1519], ["can", 1523], ["benefit", 1527], ["from", 1535], ["anti", 1540], ["-", 1544], ["NGF", 1545], ["treatment", 1549], [",", 1558], ["thereby", 1560], ["creating", 1568], ["a", 1577], ["personalized", 1579], ["approach", 1592], ["to", 1601], ["pain", 1604], ["treatment", 1609], [".", 1618]]}
{"context": "Deletions of the proximal long arm of chromosome 15 (bands 15q11q13) are found in the majority of patients with two distinct genetic disorders, Angelman syndrome (AS) and Prader-Willi syndrome (PWS). The deleted regions in the two syndromes, defined cytogenetically and by using cloned DNA probes, are similar. However, deletions in AS occur on the maternally inherited chromosome 15, and deletions in PWS occur on the paternally derived chromosome 15. This observation has led to the suggestion that one or more genes in this region show differential expression dependent on parental origin (genetic imprinting). No genes of known function have previously been mapped to this region. We show here that the gene encoding the GABAA (gamma-aminobutyric acid) receptor beta 3 subunit maps to the AS/PWS region. Deletion of this gene (GABRB3) was found in AS and PWS patients with interstitial cytogenetic deletions. Evidence of beta 3 gene deletion was also found in an AS patient with an unbalanced 13;15 translocation but not in a PWS patient with an unbalanced 9;15 translocation. The localization of this receptor gene to the AS/PWS region suggests a possible role of the inhibitory neurotransmitter GABA in the pathogenesis of one or both of these syndromes.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "b2abafc04b054092acd209ab0f099725", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[32, 35]], "char_spans": [[171, 191]]}]}], "context_tokens": [["Deletions", 0], ["of", 10], ["the", 13], ["proximal", 17], ["long", 26], ["arm", 31], ["of", 35], ["chromosome", 38], ["15", 49], ["(", 52], ["bands", 53], ["15q11q13", 59], [")", 67], ["are", 69], ["found", 73], ["in", 79], ["the", 82], ["majority", 86], ["of", 95], ["patients", 98], ["with", 107], ["two", 112], ["distinct", 116], ["genetic", 125], ["disorders", 133], [",", 142], ["Angelman", 144], ["syndrome", 153], ["(", 162], ["AS", 163], [")", 165], ["and", 167], ["Prader", 171], ["-", 177], ["Willi", 178], ["syndrome", 184], ["(", 193], ["PWS", 194], [")", 197], [".", 198], ["The", 200], ["deleted", 204], ["regions", 212], ["in", 220], ["the", 223], ["two", 227], ["syndromes", 231], [",", 240], ["defined", 242], ["cytogenetically", 250], ["and", 266], ["by", 270], ["using", 273], ["cloned", 279], ["DNA", 286], ["probes", 290], [",", 296], ["are", 298], ["similar", 302], [".", 309], ["However", 311], [",", 318], ["deletions", 320], ["in", 330], ["AS", 333], ["occur", 336], ["on", 342], ["the", 345], ["maternally", 349], ["inherited", 360], ["chromosome", 370], ["15", 381], [",", 383], ["and", 385], ["deletions", 389], ["in", 399], ["PWS", 402], ["occur", 406], ["on", 412], ["the", 415], ["paternally", 419], ["derived", 430], ["chromosome", 438], ["15", 449], [".", 451], ["This", 453], ["observation", 458], ["has", 470], ["led", 474], ["to", 478], ["the", 481], ["suggestion", 485], ["that", 496], ["one", 501], ["or", 505], ["more", 508], ["genes", 513], ["in", 519], ["this", 522], ["region", 527], ["show", 534], ["differential", 539], ["expression", 552], ["dependent", 563], ["on", 573], ["parental", 576], ["origin", 585], ["(", 592], ["genetic", 593], ["imprinting", 601], [")", 611], [".", 612], ["No", 614], ["genes", 617], ["of", 623], ["known", 626], ["function", 632], ["have", 641], ["previously", 646], ["been", 657], ["mapped", 662], ["to", 669], ["this", 672], ["region", 677], [".", 683], ["We", 685], ["show", 688], ["here", 693], ["that", 698], ["the", 703], ["gene", 707], ["encoding", 712], ["the", 721], ["GABAA", 725], ["(", 731], ["gamma", 732], ["-", 737], ["aminobutyric", 738], ["acid", 751], [")", 755], ["receptor", 757], ["beta", 766], ["3", 771], ["subunit", 773], ["maps", 781], ["to", 786], ["the", 789], ["AS", 793], ["/", 795], ["PWS", 796], ["region", 800], [".", 806], ["Deletion", 808], ["of", 817], ["this", 820], ["gene", 825], ["(", 830], ["GABRB3", 831], [")", 837], ["was", 839], ["found", 843], ["in", 849], ["AS", 852], ["and", 855], ["PWS", 859], ["patients", 863], ["with", 872], ["interstitial", 877], ["cytogenetic", 890], ["deletions", 902], [".", 911], ["Evidence", 913], ["of", 922], ["beta", 925], ["3", 930], ["gene", 932], ["deletion", 937], ["was", 946], ["also", 950], ["found", 955], ["in", 961], ["an", 964], ["AS", 967], ["patient", 970], ["with", 978], ["an", 983], ["unbalanced", 986], ["13;15", 997], ["translocation", 1003], ["but", 1017], ["not", 1021], ["in", 1025], ["a", 1028], ["PWS", 1030], ["patient", 1034], ["with", 1042], ["an", 1047], ["unbalanced", 1050], ["9;15", 1061], ["translocation", 1066], [".", 1079], ["The", 1081], ["localization", 1085], ["of", 1098], ["this", 1101], ["receptor", 1106], ["gene", 1115], ["to", 1120], ["the", 1123], ["AS", 1127], ["/", 1129], ["PWS", 1130], ["region", 1134], ["suggests", 1141], ["a", 1150], ["possible", 1152], ["role", 1161], ["of", 1166], ["the", 1169], ["inhibitory", 1173], ["neurotransmitter", 1184], ["GABA", 1201], ["in", 1206], ["the", 1209], ["pathogenesis", 1213], ["of", 1226], ["one", 1229], ["or", 1233], ["both", 1236], ["of", 1241], ["these", 1244], ["syndromes", 1250], [".", 1259]]}
{"context": "Combination microbicide vaginal rings may be more effective than single microbicide rings at reducing/preventing sexual transmission of HIV. Here, we report the pre-clinical development and macaque pharmacokinetics of matrix-type silicone elastomer vaginal rings containing dapivirine and darunavir. Macaque rings containing 25 mg dapivirine, 100 mg dapivirine, 300 mg darunavir or 100 mg dapivirine+300 mg darunavir were manufactured and characterized by differential scanning calorimetry. In vitro release was assessed into isopropanol/water and simulated vaginal fluid. Macaque vaginal fluid and blood serum concentrations for both antiretrovirals were measured during 28 day ring use. Tissue levels were measured on day 28. Ex vivo challenge studies were performed on vaginal fluid samples and IC50 values were calculated. Darunavir caused a concentration-dependent reduction in the dapivirine melting temperature in both solid drug mixes and in the combination ring. In vitro release from rings was dependent on drug loading, the number of drugs present and the release medium. In macaques, serum concentrations of both microbicides were maintained between 10(1) and 10(2) pg/mL. Vaginal fluid levels ranged between 10(3) and 10(4) ng/g and between 10(4) and 10(5) ng/g for dapivirine and darunavir, respectively. Both dapivirine and darunavir showed very similar concentrations in each tissue type; the range of drug tissue concentrations followed the general rank order: vagina (1.8\u200a\u00d7\u200a10(3)-3.8\u200a\u00d7\u200a10(3) ng/g) \u200a>\u200acervix (9.4\u200a\u00d7\u200a10(1)-3.9\u200a\u00d7\u200a10(2) ng/g) \u200a>\u200auterus (0-108 ng/g) \u200a>\u200arectum (0-40 ng/g). Measured IC50 values were >2 ng/mL for both compounds. Based on these results, and in light of recent clinical progress of the 25 mg dapivirine ring, a combination vaginal ring containing dapivirine and darunavir is a viable second-generation HIV microbicide candidate.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "dc9bceb110f546b884dbdd371fc5a5b9", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[19, 19], [341, 341]], "char_spans": [[136, 138], [1846, 1848]]}]}], "context_tokens": [["Combination", 0], ["microbicide", 12], ["vaginal", 24], ["rings", 32], ["may", 38], ["be", 42], ["more", 45], ["effective", 50], ["than", 60], ["single", 65], ["microbicide", 72], ["rings", 84], ["at", 90], ["reducing", 93], ["/", 101], ["preventing", 102], ["sexual", 113], ["transmission", 120], ["of", 133], ["HIV", 136], [".", 139], ["Here", 141], [",", 145], ["we", 147], ["report", 150], ["the", 157], ["pre", 161], ["-", 164], ["clinical", 165], ["development", 174], ["and", 186], ["macaque", 190], ["pharmacokinetics", 198], ["of", 215], ["matrix", 218], ["-", 224], ["type", 225], ["silicone", 230], ["elastomer", 239], ["vaginal", 249], ["rings", 257], ["containing", 263], ["dapivirine", 274], ["and", 285], ["darunavir", 289], [".", 298], ["Macaque", 300], ["rings", 308], ["containing", 314], ["25", 325], ["mg", 328], ["dapivirine", 331], [",", 341], ["100", 343], ["mg", 347], ["dapivirine", 350], [",", 360], ["300", 362], ["mg", 366], ["darunavir", 369], ["or", 379], ["100", 382], ["mg", 386], ["dapivirine+300", 389], ["mg", 404], ["darunavir", 407], ["were", 417], ["manufactured", 422], ["and", 435], ["characterized", 439], ["by", 453], ["differential", 456], ["scanning", 469], ["calorimetry", 478], [".", 489], ["In", 491], ["vitro", 494], ["release", 500], ["was", 508], ["assessed", 512], ["into", 521], ["isopropanol", 526], ["/", 537], ["water", 538], ["and", 544], ["simulated", 548], ["vaginal", 558], ["fluid", 566], [".", 571], ["Macaque", 573], ["vaginal", 581], ["fluid", 589], ["and", 595], ["blood", 599], ["serum", 605], ["concentrations", 611], ["for", 626], ["both", 630], ["antiretrovirals", 635], ["were", 651], ["measured", 656], ["during", 665], ["28", 672], ["day", 675], ["ring", 679], ["use", 684], [".", 687], ["Tissue", 689], ["levels", 696], ["were", 703], ["measured", 708], ["on", 717], ["day", 720], ["28", 724], [".", 726], ["Ex", 728], ["vivo", 731], ["challenge", 736], ["studies", 746], ["were", 754], ["performed", 759], ["on", 769], ["vaginal", 772], ["fluid", 780], ["samples", 786], ["and", 794], ["IC50", 798], ["values", 803], ["were", 810], ["calculated", 815], [".", 825], ["Darunavir", 827], ["caused", 837], ["a", 844], ["concentration", 846], ["-", 859], ["dependent", 860], ["reduction", 870], ["in", 880], ["the", 883], ["dapivirine", 887], ["melting", 898], ["temperature", 906], ["in", 918], ["both", 921], ["solid", 926], ["drug", 932], ["mixes", 937], ["and", 943], ["in", 947], ["the", 950], ["combination", 954], ["ring", 966], [".", 970], ["In", 972], ["vitro", 975], ["release", 981], ["from", 989], ["rings", 994], ["was", 1000], ["dependent", 1004], ["on", 1014], ["drug", 1017], ["loading", 1022], [",", 1029], ["the", 1031], ["number", 1035], ["of", 1042], ["drugs", 1045], ["present", 1051], ["and", 1059], ["the", 1063], ["release", 1067], ["medium", 1075], [".", 1081], ["In", 1083], ["macaques", 1086], [",", 1094], ["serum", 1096], ["concentrations", 1102], ["of", 1117], ["both", 1120], ["microbicides", 1125], ["were", 1138], ["maintained", 1143], ["between", 1154], ["10(1", 1162], [")", 1166], ["and", 1168], ["10(2", 1172], [")", 1176], ["pg", 1178], ["/", 1180], ["mL.", 1181], ["Vaginal", 1185], ["fluid", 1193], ["levels", 1199], ["ranged", 1206], ["between", 1213], ["10(3", 1221], [")", 1225], ["and", 1227], ["10(4", 1231], [")", 1235], ["ng", 1237], ["/", 1239], ["g", 1240], ["and", 1242], ["between", 1246], ["10(4", 1254], [")", 1258], ["and", 1260], ["10(5", 1264], [")", 1268], ["ng", 1270], ["/", 1272], ["g", 1273], ["for", 1275], ["dapivirine", 1279], ["and", 1290], ["darunavir", 1294], [",", 1303], ["respectively", 1305], [".", 1317], ["Both", 1319], ["dapivirine", 1324], ["and", 1335], ["darunavir", 1339], ["showed", 1349], ["very", 1356], ["similar", 1361], ["concentrations", 1369], ["in", 1384], ["each", 1387], ["tissue", 1392], ["type", 1399], [";", 1403], ["the", 1405], ["range", 1409], ["of", 1415], ["drug", 1418], ["tissue", 1423], ["concentrations", 1430], ["followed", 1445], ["the", 1454], ["general", 1458], ["rank", 1466], ["order", 1471], [":", 1476], ["vagina", 1478], ["(", 1485], ["1.8", 1486], ["\u00d7", 1490], ["10(3)-3.8", 1492], ["\u00d7", 1502], ["10(3", 1504], [")", 1508], ["ng", 1510], ["/", 1512], ["g", 1513], [")", 1514], [">", 1517], ["cervix", 1519], ["(", 1526], ["9.4", 1527], ["\u00d7", 1531], ["10(1)-3.9", 1533], ["\u00d7", 1543], ["10(2", 1545], [")", 1549], ["ng", 1551], ["/", 1553], ["g", 1554], [")", 1555], [">", 1558], ["uterus", 1560], ["(", 1567], ["0", 1568], ["-", 1569], ["108", 1570], ["ng", 1574], ["/", 1576], ["g", 1577], [")", 1578], [">", 1581], ["rectum", 1583], ["(", 1590], ["0", 1591], ["-", 1592], ["40", 1593], ["ng", 1596], ["/", 1598], ["g", 1599], [")", 1600], [".", 1601], ["Measured", 1603], ["IC50", 1612], ["values", 1617], ["were", 1624], [">", 1629], ["2", 1630], ["ng", 1632], ["/", 1634], ["mL", 1635], ["for", 1638], ["both", 1642], ["compounds", 1647], [".", 1656], ["Based", 1658], ["on", 1664], ["these", 1667], ["results", 1673], [",", 1680], ["and", 1682], ["in", 1686], ["light", 1689], ["of", 1695], ["recent", 1698], ["clinical", 1705], ["progress", 1714], ["of", 1723], ["the", 1726], ["25", 1730], ["mg", 1733], ["dapivirine", 1736], ["ring", 1747], [",", 1751], ["a", 1753], ["combination", 1755], ["vaginal", 1767], ["ring", 1775], ["containing", 1780], ["dapivirine", 1791], ["and", 1802], ["darunavir", 1806], ["is", 1816], ["a", 1819], ["viable", 1821], ["second", 1828], ["-", 1834], ["generation", 1835], ["HIV", 1846], ["microbicide", 1850], ["candidate", 1862], [".", 1871]]}
{"context": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1), also known as HARP, is an ATP-dependent annealing helicase that stabilizes replication forks during DNA damage. Mutations in this gene are the cause of Schimke immune-osseous dysplasia (SIOD), an autosomal recessive disorder characterized by T-cell immunodeficiency and growth dysfunctions. In this review, we summarize the main roles of SMARCAL1 in DNA repair, telomere maintenance and replication fork stability in response to DNA replication stress.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "HARP"], "qid": "94ca9bf4ee72459085a2b6464d531562", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[0, 20]], "char_spans": [[0, 103]]}, {"text": "HARP", "token_spans": [[26, 26]], "char_spans": [[121, 124]]}]}], "context_tokens": [["SMARCAL1", 0], ["(", 9], ["SWI", 10], ["/", 13], ["SNF", 14], ["Related", 18], [",", 25], ["Matrix", 27], ["Associated", 34], [",", 44], ["Actin", 46], ["Dependent", 52], ["Regulator", 62], ["Of", 72], ["Chromatin", 75], [",", 84], ["Subfamily", 86], ["A", 96], ["-", 97], ["Like", 98], ["1", 103], [")", 104], [",", 105], ["also", 107], ["known", 112], ["as", 118], ["HARP", 121], [",", 125], ["is", 127], ["an", 130], ["ATP", 133], ["-", 136], ["dependent", 137], ["annealing", 147], ["helicase", 157], ["that", 166], ["stabilizes", 171], ["replication", 182], ["forks", 194], ["during", 200], ["DNA", 207], ["damage", 211], [".", 217], ["Mutations", 219], ["in", 229], ["this", 232], ["gene", 237], ["are", 242], ["the", 246], ["cause", 250], ["of", 256], ["Schimke", 259], ["immune", 267], ["-", 273], ["osseous", 274], ["dysplasia", 282], ["(", 292], ["SIOD", 293], [")", 297], [",", 298], ["an", 300], ["autosomal", 303], ["recessive", 313], ["disorder", 323], ["characterized", 332], ["by", 346], ["T", 349], ["-", 350], ["cell", 351], ["immunodeficiency", 356], ["and", 373], ["growth", 377], ["dysfunctions", 384], [".", 396], ["In", 398], ["this", 401], ["review", 406], [",", 412], ["we", 414], ["summarize", 417], ["the", 427], ["main", 431], ["roles", 436], ["of", 442], ["SMARCAL1", 445], ["in", 454], ["DNA", 457], ["repair", 461], [",", 467], ["telomere", 469], ["maintenance", 478], ["and", 490], ["replication", 494], ["fork", 506], ["stability", 511], ["in", 521], ["response", 524], ["to", 533], ["DNA", 536], ["replication", 540], ["stress", 552], [".", 558]]}
{"context": "The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey. Four monkeys, implanted with guiding cannulas for microdialysis probes, in the substantia nigra, dorsal striatum and prefrontal cortex, were randomized in two groups that received, in a crossover design, vehicle or 100 mg/kg opicapone for 14 days. Twenty-three hours after last administration of vehicle or opicapone, animals were challenged with levodopa/benserazide (12/3 mg/kg). Extracellular dialysate and blood samples were collected over 360 min (at 30 min intervals) for the assays of catecholamine and COMT activity. Opicapone increased levodopa systemic exposure by 2-fold not changing Cmax values and reduced both 3-O-methyldopa (3-OMD) exposure and Cmax values by 5-fold. These changes were accompanied by \u223c76-84% reduction in erythrocyte COMT activity. In dorsal striatum and substantia nigra, opicapone increased levodopa exposure by 1.7- and 1.4-fold, respectively, reducing 3-OMD exposure by 5- and 7-fold respectively. DOPAC exposure was increased by 4-fold in the substantia nigra. In the prefrontal cortex, opicapone increased levodopa exposure and reduced 3-OMD levels by 2.3- and 2.4-fold, respectively. Opicapone behaved as long-acting COMT inhibitor that markedly increased systemic and central levodopa bioavailability. Opicapone is a strong candidate to fill the unmet need for COMT inhibitors that lead to more sustained levodopa levels in Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "ca9ef69c3b7343959201d7a68ea4835c", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[15, 19]], "char_spans": [[96, 123]]}]}], "context_tokens": [["The", 0], ["present", 4], ["study", 12], ["aimed", 18], ["at", 24], ["evaluating", 27], ["the", 38], ["effect", 42], ["of", 49], ["opicapone", 52], [",", 61], ["a", 63], ["third", 65], ["generation", 71], ["nitrocatechol", 82], ["catechol", 96], ["-", 104], ["O", 105], ["-", 106], ["methyltransferase", 107], ["(", 125], ["COMT", 126], [")", 130], ["inhibitor", 132], [",", 141], ["on", 143], ["the", 146], ["systemic", 150], ["and", 159], ["central", 163], ["bioavailability", 171], ["of", 187], ["3,4-dihydroxy", 190], ["-", 203], ["l", 204], ["-", 205], ["phenylalanine", 206], ["(", 220], ["levodopa", 221], [")", 229], ["and", 231], ["related", 235], ["metabolites", 243], ["in", 255], ["the", 258], ["cynomolgus", 262], ["monkey", 273], [".", 279], ["Four", 281], ["monkeys", 286], [",", 293], ["implanted", 295], ["with", 305], ["guiding", 310], ["cannulas", 318], ["for", 327], ["microdialysis", 331], ["probes", 345], [",", 351], ["in", 353], ["the", 356], ["substantia", 360], ["nigra", 371], [",", 376], ["dorsal", 378], ["striatum", 385], ["and", 394], ["prefrontal", 398], ["cortex", 409], [",", 415], ["were", 417], ["randomized", 422], ["in", 433], ["two", 436], ["groups", 440], ["that", 447], ["received", 452], [",", 460], ["in", 462], ["a", 465], ["crossover", 467], ["design", 477], [",", 483], ["vehicle", 485], ["or", 493], ["100", 496], ["mg", 500], ["/", 502], ["kg", 503], ["opicapone", 506], ["for", 516], ["14", 520], ["days", 523], [".", 527], ["Twenty", 529], ["-", 535], ["three", 536], ["hours", 542], ["after", 548], ["last", 554], ["administration", 559], ["of", 574], ["vehicle", 577], ["or", 585], ["opicapone", 588], [",", 597], ["animals", 599], ["were", 607], ["challenged", 612], ["with", 623], ["levodopa", 628], ["/", 636], ["benserazide", 637], ["(", 649], ["12/3", 650], ["mg", 655], ["/", 657], ["kg", 658], [")", 660], [".", 661], ["Extracellular", 663], ["dialysate", 677], ["and", 687], ["blood", 691], ["samples", 697], ["were", 705], ["collected", 710], ["over", 720], ["360", 725], ["min", 729], ["(", 733], ["at", 734], ["30", 737], ["min", 740], ["intervals", 744], [")", 753], ["for", 755], ["the", 759], ["assays", 763], ["of", 770], ["catecholamine", 773], ["and", 787], ["COMT", 791], ["activity", 796], [".", 804], ["Opicapone", 806], ["increased", 816], ["levodopa", 826], ["systemic", 835], ["exposure", 844], ["by", 853], ["2-fold", 856], ["not", 863], ["changing", 867], ["Cmax", 876], ["values", 881], ["and", 888], ["reduced", 892], ["both", 900], ["3-O", 905], ["-", 908], ["methyldopa", 909], ["(", 920], ["3-OMD", 921], [")", 926], ["exposure", 928], ["and", 937], ["Cmax", 941], ["values", 946], ["by", 953], ["5-fold", 956], [".", 962], ["These", 964], ["changes", 970], ["were", 978], ["accompanied", 983], ["by", 995], ["\u223c76", 998], ["-", 1001], ["84", 1002], ["%", 1004], ["reduction", 1006], ["in", 1016], ["erythrocyte", 1019], ["COMT", 1031], ["activity", 1036], [".", 1044], ["In", 1046], ["dorsal", 1049], ["striatum", 1056], ["and", 1065], ["substantia", 1069], ["nigra", 1080], [",", 1085], ["opicapone", 1087], ["increased", 1097], ["levodopa", 1107], ["exposure", 1116], ["by", 1125], ["1.7-", 1128], ["and", 1133], ["1.4-fold", 1137], [",", 1145], ["respectively", 1147], [",", 1159], ["reducing", 1161], ["3-OMD", 1170], ["exposure", 1176], ["by", 1185], ["5-", 1188], ["and", 1191], ["7-fold", 1195], ["respectively", 1202], [".", 1214], ["DOPAC", 1216], ["exposure", 1222], ["was", 1231], ["increased", 1235], ["by", 1245], ["4-fold", 1248], ["in", 1255], ["the", 1258], ["substantia", 1262], ["nigra", 1273], [".", 1278], ["In", 1280], ["the", 1283], ["prefrontal", 1287], ["cortex", 1298], [",", 1304], ["opicapone", 1306], ["increased", 1316], ["levodopa", 1326], ["exposure", 1335], ["and", 1344], ["reduced", 1348], ["3-OMD", 1356], ["levels", 1362], ["by", 1369], ["2.3-", 1372], ["and", 1377], ["2.4-fold", 1381], [",", 1389], ["respectively", 1391], [".", 1403], ["Opicapone", 1405], ["behaved", 1415], ["as", 1423], ["long", 1426], ["-", 1430], ["acting", 1431], ["COMT", 1438], ["inhibitor", 1443], ["that", 1453], ["markedly", 1458], ["increased", 1467], ["systemic", 1477], ["and", 1486], ["central", 1490], ["levodopa", 1498], ["bioavailability", 1507], [".", 1522], ["Opicapone", 1524], ["is", 1534], ["a", 1537], ["strong", 1539], ["candidate", 1546], ["to", 1556], ["fill", 1559], ["the", 1564], ["unmet", 1568], ["need", 1574], ["for", 1579], ["COMT", 1583], ["inhibitors", 1588], ["that", 1599], ["lead", 1604], ["to", 1609], ["more", 1612], ["sustained", 1617], ["levodopa", 1627], ["levels", 1636], ["in", 1643], ["Parkinson", 1646], ["'s", 1655], ["disease", 1658], ["patients", 1666], [".", 1674]]}
{"context": "Erythrasma is a superficial infection caused by Corynebacterium minutissimum and affects the major skin folds and the interdigital regions of the feet. It is characterized by erythematous, brown, scaly patches and maceration, and exhibits coral-red fluorescence under Wood light. The aim of this study was to determine the frequency of erythrasma in patients with interdigital lesions. An open, prospective, longitudinal, observational study was performed in a hospital in Mexico City between March and December, 2006. All patients with interdigital lesions were examined with a Wood lamp and direct examination was performed with 20 % potassium hydroxide. Cultures were done in Sabouraud dextrose agar and brain heart infusion agar, and smears were analyzed. General characteristics and concomitant diseases were recorded. We examined 73 patients, of whom 24 (32.8 %) were diagnosed with erythrasma based on coral-red fluorescence under Wood light and identification of corynebacteria by Gram staining. The disease was more common in women (83.33 %) and the mean age of the patients was 43.5 years. The main clinical findings were scaling and maceration, and the fourth interdigital web was the most commonly affected. Corynebacterium could not be isolated in any of the cases. Mycology was positive in 15 cases (62.5 %) and the following microorganisms were isolated: Candida (16.6 %), dermatophytes (12.5 %), and Trichosporon (4.1 %). Interdigital erythrasma is a common condition and can be easily confused with interdigital tinea. It persists if not treated appropriately. Rapid diagnosis is easily obtained by examination with a Wood lamp, while culture is difficult and unnecessary for diagnosis. The coexistence of erythrasma with dermatophytes and Candida should be considered when the interdigital webs are affected.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5a3515ce38440f0bf803e4cbe2c9b10", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[7, 8]], "char_spans": [[48, 75]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["infection", 28], ["caused", 38], ["by", 45], ["Corynebacterium", 48], ["minutissimum", 64], ["and", 77], ["affects", 81], ["the", 89], ["major", 93], ["skin", 99], ["folds", 104], ["and", 110], ["the", 114], ["interdigital", 118], ["regions", 131], ["of", 139], ["the", 142], ["feet", 146], [".", 150], ["It", 152], ["is", 155], ["characterized", 158], ["by", 172], ["erythematous", 175], [",", 187], ["brown", 189], [",", 194], ["scaly", 196], ["patches", 202], ["and", 210], ["maceration", 214], [",", 224], ["and", 226], ["exhibits", 230], ["coral", 239], ["-", 244], ["red", 245], ["fluorescence", 249], ["under", 262], ["Wood", 268], ["light", 273], [".", 278], ["The", 280], ["aim", 284], ["of", 288], ["this", 291], ["study", 296], ["was", 302], ["to", 306], ["determine", 309], ["the", 319], ["frequency", 323], ["of", 333], ["erythrasma", 336], ["in", 347], ["patients", 350], ["with", 359], ["interdigital", 364], ["lesions", 377], [".", 384], ["An", 386], ["open", 389], [",", 393], ["prospective", 395], [",", 406], ["longitudinal", 408], [",", 420], ["observational", 422], ["study", 436], ["was", 442], ["performed", 446], ["in", 456], ["a", 459], ["hospital", 461], ["in", 470], ["Mexico", 473], ["City", 480], ["between", 485], ["March", 493], ["and", 499], ["December", 503], [",", 511], ["2006", 513], [".", 517], ["All", 519], ["patients", 523], ["with", 532], ["interdigital", 537], ["lesions", 550], ["were", 558], ["examined", 563], ["with", 572], ["a", 577], ["Wood", 579], ["lamp", 584], ["and", 589], ["direct", 593], ["examination", 600], ["was", 612], ["performed", 616], ["with", 626], ["20", 631], ["%", 634], ["potassium", 636], ["hydroxide", 646], [".", 655], ["Cultures", 657], ["were", 666], ["done", 671], ["in", 676], ["Sabouraud", 679], ["dextrose", 689], ["agar", 698], ["and", 703], ["brain", 707], ["heart", 713], ["infusion", 719], ["agar", 728], [",", 732], ["and", 734], ["smears", 738], ["were", 745], ["analyzed", 750], [".", 758], ["General", 760], ["characteristics", 768], ["and", 784], ["concomitant", 788], ["diseases", 800], ["were", 809], ["recorded", 814], [".", 822], ["We", 824], ["examined", 827], ["73", 836], ["patients", 839], [",", 847], ["of", 849], ["whom", 852], ["24", 857], ["(", 860], ["32.8", 861], ["%", 866], [")", 867], ["were", 869], ["diagnosed", 874], ["with", 884], ["erythrasma", 889], ["based", 900], ["on", 906], ["coral", 909], ["-", 914], ["red", 915], ["fluorescence", 919], ["under", 932], ["Wood", 938], ["light", 943], ["and", 949], ["identification", 953], ["of", 968], ["corynebacteria", 971], ["by", 986], ["Gram", 989], ["staining", 994], [".", 1002], ["The", 1004], ["disease", 1008], ["was", 1016], ["more", 1020], ["common", 1025], ["in", 1032], ["women", 1035], ["(", 1041], ["83.33", 1042], ["%", 1048], [")", 1049], ["and", 1051], ["the", 1055], ["mean", 1059], ["age", 1064], ["of", 1068], ["the", 1071], ["patients", 1075], ["was", 1084], ["43.5", 1088], ["years", 1093], [".", 1098], ["The", 1100], ["main", 1104], ["clinical", 1109], ["findings", 1118], ["were", 1127], ["scaling", 1132], ["and", 1140], ["maceration", 1144], [",", 1154], ["and", 1156], ["the", 1160], ["fourth", 1164], ["interdigital", 1171], ["web", 1184], ["was", 1188], ["the", 1192], ["most", 1196], ["commonly", 1201], ["affected", 1210], [".", 1218], ["Corynebacterium", 1220], ["could", 1236], ["not", 1242], ["be", 1246], ["isolated", 1249], ["in", 1258], ["any", 1261], ["of", 1265], ["the", 1268], ["cases", 1272], [".", 1277], ["Mycology", 1279], ["was", 1288], ["positive", 1292], ["in", 1301], ["15", 1304], ["cases", 1307], ["(", 1313], ["62.5", 1314], ["%", 1319], [")", 1320], ["and", 1322], ["the", 1326], ["following", 1330], ["microorganisms", 1340], ["were", 1355], ["isolated", 1360], [":", 1368], ["Candida", 1370], ["(", 1378], ["16.6", 1379], ["%", 1384], [")", 1385], [",", 1386], ["dermatophytes", 1388], ["(", 1402], ["12.5", 1403], ["%", 1408], [")", 1409], [",", 1410], ["and", 1412], ["Trichosporon", 1416], ["(", 1429], ["4.1", 1430], ["%", 1434], [")", 1435], [".", 1436], ["Interdigital", 1438], ["erythrasma", 1451], ["is", 1462], ["a", 1465], ["common", 1467], ["condition", 1474], ["and", 1484], ["can", 1488], ["be", 1492], ["easily", 1495], ["confused", 1502], ["with", 1511], ["interdigital", 1516], ["tinea", 1529], [".", 1534], ["It", 1536], ["persists", 1539], ["if", 1548], ["not", 1551], ["treated", 1555], ["appropriately", 1563], [".", 1576], ["Rapid", 1578], ["diagnosis", 1584], ["is", 1594], ["easily", 1597], ["obtained", 1604], ["by", 1613], ["examination", 1616], ["with", 1628], ["a", 1633], ["Wood", 1635], ["lamp", 1640], [",", 1644], ["while", 1646], ["culture", 1652], ["is", 1660], ["difficult", 1663], ["and", 1673], ["unnecessary", 1677], ["for", 1689], ["diagnosis", 1693], [".", 1702], ["The", 1704], ["coexistence", 1708], ["of", 1720], ["erythrasma", 1723], ["with", 1734], ["dermatophytes", 1739], ["and", 1753], ["Candida", 1757], ["should", 1765], ["be", 1772], ["considered", 1775], ["when", 1786], ["the", 1791], ["interdigital", 1795], ["webs", 1808], ["are", 1813], ["affected", 1817], [".", 1825]]}
{"context": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1. Interleukin-1beta, flagellin, interferon-gamma, and tumor necrosis factor alpha (TNF-alpha) similarly induced Nox1 in a colon cancer cell line (T84), whereas only TNF-alpha fully induced NOXO1 and upregulated superoxide-producing activity by ninefold. This upregulation was canceled by knockdown of NOXO1 with small interfering RNAs. TNF-alpha rapidly phosphorylated p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 1/2, followed by phosphorylation of c-Jun and c-Fos and appearance of an AP-1 binding activity within 30 min. We cloned the 5' flank of the human NOXO1 gene (-3888 to +263 bp), and found that the region between -585 and -452 bp, which contains consensus elements of YY-1, AP-1, and Ets, and the GC-rich region encoding three putative binding sites for SP-1, was crucial for TNF-alpha-dependent promoter activity. Serial mutation analysis of the elements identified an AP-1 binding site (from -561 to -551 bp, agtAAGtcatg) as a crucial element for TNF-alpha-stimulated transcription of the human NOXO1 gene, which was also confirmed by the AP-1 decoy experiments. Thus, TNF-alpha acts as a potent activator of Nox1-based oxidase in colon epithelial cells, suggesting a potential role of this oxidase in inflammation of the colon.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "6779bef390824d269a423840772240f6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}, {"text": "NOX1", "token_spans": [[4, 4], [49, 49], [22, 22]], "char_spans": [[17, 20], [238, 241], [100, 103]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["1", 14], ["(", 16], ["Nox1", 17], [")", 21], ["is", 23], ["a", 26], ["multicomponent", 28], ["enzyme", 43], ["consisting", 50], ["of", 61], ["p22(phox", 64], [")", 72], [",", 73], ["Nox", 75], ["organizer", 79], ["1", 89], ["(", 91], ["NOXO1", 92], [")", 97], [",", 98], ["Nox1", 100], ["activator", 105], ["1", 115], [",", 116], ["and", 118], ["Rac1", 122], [".", 126], ["Interleukin-1beta", 128], [",", 145], ["flagellin", 147], [",", 156], ["interferon", 158], ["-", 168], ["gamma", 169], [",", 174], ["and", 176], ["tumor", 180], ["necrosis", 186], ["factor", 195], ["alpha", 202], ["(", 208], ["TNF", 209], ["-", 212], ["alpha", 213], [")", 218], ["similarly", 220], ["induced", 230], ["Nox1", 238], ["in", 243], ["a", 246], ["colon", 248], ["cancer", 254], ["cell", 261], ["line", 266], ["(", 271], ["T84", 272], [")", 275], [",", 276], ["whereas", 278], ["only", 286], ["TNF", 291], ["-", 294], ["alpha", 295], ["fully", 301], ["induced", 307], ["NOXO1", 315], ["and", 321], ["upregulated", 325], ["superoxide", 337], ["-", 347], ["producing", 348], ["activity", 358], ["by", 367], ["ninefold", 370], [".", 378], ["This", 380], ["upregulation", 385], ["was", 398], ["canceled", 402], ["by", 411], ["knockdown", 414], ["of", 424], ["NOXO1", 427], ["with", 433], ["small", 438], ["interfering", 444], ["RNAs", 456], [".", 460], ["TNF", 462], ["-", 465], ["alpha", 466], ["rapidly", 472], ["phosphorylated", 480], ["p38", 495], ["mitogen", 499], ["-", 506], ["activated", 507], ["protein", 517], ["kinase", 525], ["and", 532], ["c", 536], ["-", 537], ["Jun", 538], ["N", 542], ["-", 543], ["terminal", 544], ["kinase", 553], ["1/2", 560], [",", 563], ["followed", 565], ["by", 574], ["phosphorylation", 577], ["of", 593], ["c", 596], ["-", 597], ["Jun", 598], ["and", 602], ["c", 606], ["-", 607], ["Fos", 608], ["and", 612], ["appearance", 616], ["of", 627], ["an", 630], ["AP-1", 633], ["binding", 638], ["activity", 646], ["within", 655], ["30", 662], ["min", 665], [".", 668], ["We", 670], ["cloned", 673], ["the", 680], ["5", 684], ["'", 685], ["flank", 687], ["of", 693], ["the", 696], ["human", 700], ["NOXO1", 706], ["gene", 712], ["(", 717], ["-3888", 718], ["to", 724], ["+263", 727], ["bp", 732], [")", 734], [",", 735], ["and", 737], ["found", 741], ["that", 747], ["the", 752], ["region", 756], ["between", 763], ["-585", 771], ["and", 776], ["-452", 780], ["bp", 785], [",", 787], ["which", 789], ["contains", 795], ["consensus", 804], ["elements", 814], ["of", 823], ["YY-1", 826], [",", 830], ["AP-1", 832], [",", 836], ["and", 838], ["Ets", 842], [",", 845], ["and", 847], ["the", 851], ["GC", 855], ["-", 857], ["rich", 858], ["region", 863], ["encoding", 870], ["three", 879], ["putative", 885], ["binding", 894], ["sites", 902], ["for", 908], ["SP-1", 912], [",", 916], ["was", 918], ["crucial", 922], ["for", 930], ["TNF", 934], ["-", 937], ["alpha", 938], ["-", 943], ["dependent", 944], ["promoter", 954], ["activity", 963], [".", 971], ["Serial", 973], ["mutation", 980], ["analysis", 989], ["of", 998], ["the", 1001], ["elements", 1005], ["identified", 1014], ["an", 1025], ["AP-1", 1028], ["binding", 1033], ["site", 1041], ["(", 1046], ["from", 1047], ["-561", 1052], ["to", 1057], ["-551", 1060], ["bp", 1065], [",", 1067], ["agtAAGtcatg", 1069], [")", 1080], ["as", 1082], ["a", 1085], ["crucial", 1087], ["element", 1095], ["for", 1103], ["TNF", 1107], ["-", 1110], ["alpha", 1111], ["-", 1116], ["stimulated", 1117], ["transcription", 1128], ["of", 1142], ["the", 1145], ["human", 1149], ["NOXO1", 1155], ["gene", 1161], [",", 1165], ["which", 1167], ["was", 1173], ["also", 1177], ["confirmed", 1182], ["by", 1192], ["the", 1195], ["AP-1", 1199], ["decoy", 1204], ["experiments", 1210], [".", 1221], ["Thus", 1223], [",", 1227], ["TNF", 1229], ["-", 1232], ["alpha", 1233], ["acts", 1239], ["as", 1244], ["a", 1247], ["potent", 1249], ["activator", 1256], ["of", 1266], ["Nox1-based", 1269], ["oxidase", 1280], ["in", 1288], ["colon", 1291], ["epithelial", 1297], ["cells", 1308], [",", 1313], ["suggesting", 1315], ["a", 1326], ["potential", 1328], ["role", 1338], ["of", 1343], ["this", 1346], ["oxidase", 1351], ["in", 1359], ["inflammation", 1362], ["of", 1375], ["the", 1378], ["colon", 1382], [".", 1387]]}
{"context": "The RTS,S/AS01(E) candidate malaria vaccine is being developed for immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 month follow-up data have been reported for safety and immunogenicity of RTS,S/AS01(E) when integrated into the EPI. We report extended follow-up to 19 months, including efficacy results. We did a randomised, open-label, phase 2 trial of safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with EPI vaccines between April 30, 2007, and Oct 7, 2009, in Ghana, Tanzania, and Gabon. Eligible children were 6-10 weeks of age at first vaccination, without serious acute or chronic illness. All children received the EPI diphtheria, tetanus, pertussis (inactivated whole-cell), and hepatitis-B vaccines, Haemophilus influenzae type b vaccine, and oral polio vaccine at study months 0, 1, and 2, and measles vaccine and yellow fever vaccines at study month 7. Participants were randomly assigned (1:1:1) to receive three doses of RTS,S/AS01(E) at 6, 10, and 14 weeks (0, 1, 2 month schedule) or at 6 weeks, 10 weeks, and 9 months (0, 2, 7 month schedule) or placebo. Randomisation was according to a predefined block list with a computer-generated randomisation code. Detection of serious adverse events and malaria was by passive case detection. Antibodies against Plasmodium falciparum circumsporozoite protein and HBsAg were monitored for 19 months. This study is registered with ClinicalTrials.gov, number NCT00436007. 511 children were enrolled. Serious adverse events occurred in 57 participants in the RTS,S/AS01(E) 0, 1, 2 month group (34%, 95% CI 27-41), 47 in the 0, 1, 7 month group (28%, 21-35), and 49 (29%, 22-36) in the control group; none were judged to be related to study vaccination. At month 19, anticircumsporozoite immune responses were significantly higher in the RTS,S/AS01(E) groups than in the control group. Vaccine efficacy for the 0, 1, 2 month schedule (2 weeks after dose three to month 19, site-adjusted according-to-protocol analysis) was 53% (95% CI 26-70; p=0\u00b70012) against first malaria episodes and 59% (36-74; p=0\u00b70001) against all malaria episodes. For the entire study period, (total vaccinated cohort) vaccine efficacy against all malaria episodes was higher with the 0, 1, 2 month schedule (57%, 95% CI 33-73; p=0\u00b70002) than with the 0, 1, 7 month schedule (32% CI 16-45; p=0\u00b70003). 1 year after dose three, vaccine efficacy against first malaria episodes was similar for both schedules (0, 1, 2 month group, 61\u00b76% [95% CI 35\u00b76-77\u00b71], p<0\u00b7001; 0, 1, 7 month group, 63\u00b78% [40\u00b74-78\u00b70], p<0\u00b7001, according-to-protocol cohort). Vaccine efficacy was consistent with the target put forward by the WHO-sponsored malaria vaccine technology roadmap for a first-generation malaria vaccine. The 0, 1, 2 month vaccine schedule has been selected for phase 3 candidate vaccine assessment. Program for Appropriate Technology in Health Malaria Vaccine Initiative; GlaxoSmithKline Biologicals.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e902e6f0d961453ba6bc3e8ea9ab9588", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[275, 275], [549, 549], [474, 474], [618, 618], [627, 627], [460, 460], [492, 492], [8, 8], [94, 94], [655, 655]], "char_spans": [[1279, 1285], [2452, 2458], [2141, 2147], [2718, 2724], [2776, 2782], [2086, 2092], [2243, 2249], [28, 34], [446, 452], [2933, 2939]]}]}], "context_tokens": [["The", 0], ["RTS", 4], [",", 7], ["S", 8], ["/", 9], ["AS01(E", 10], [")", 16], ["candidate", 18], ["malaria", 28], ["vaccine", 36], ["is", 44], ["being", 47], ["developed", 53], ["for", 63], ["immunisation", 67], ["of", 80], ["infants", 83], ["in", 91], ["Africa", 94], ["through", 101], ["the", 109], ["expanded", 113], ["programme", 122], ["on", 132], ["immunisation", 135], ["(", 148], ["EPI", 149], [")", 152], [".", 153], ["8", 155], ["month", 157], ["follow", 163], ["-", 169], ["up", 170], ["data", 173], ["have", 178], ["been", 183], ["reported", 188], ["for", 197], ["safety", 201], ["and", 208], ["immunogenicity", 212], ["of", 227], ["RTS", 230], [",", 233], ["S", 234], ["/", 235], ["AS01(E", 236], [")", 242], ["when", 244], ["integrated", 249], ["into", 260], ["the", 265], ["EPI", 269], [".", 272], ["We", 274], ["report", 277], ["extended", 284], ["follow", 293], ["-", 299], ["up", 300], ["to", 303], ["19", 306], ["months", 309], [",", 315], ["including", 317], ["efficacy", 327], ["results", 336], [".", 343], ["We", 345], ["did", 348], ["a", 352], ["randomised", 354], [",", 364], ["open", 366], ["-", 370], ["label", 371], [",", 376], ["phase", 378], ["2", 384], ["trial", 386], ["of", 392], ["safety", 395], ["and", 402], ["efficacy", 406], ["of", 415], ["the", 418], ["RTS", 422], [",", 425], ["S", 426], ["/", 427], ["AS01(E", 428], [")", 434], ["candidate", 436], ["malaria", 446], ["vaccine", 454], ["given", 462], ["with", 468], ["EPI", 473], ["vaccines", 477], ["between", 486], ["April", 494], ["30", 500], [",", 502], ["2007", 504], [",", 508], ["and", 510], ["Oct", 514], ["7", 518], [",", 519], ["2009", 521], [",", 525], ["in", 527], ["Ghana", 530], [",", 535], ["Tanzania", 537], [",", 545], ["and", 547], ["Gabon", 551], [".", 556], ["Eligible", 558], ["children", 567], ["were", 576], ["6", 581], ["-", 582], ["10", 583], ["weeks", 586], ["of", 592], ["age", 595], ["at", 599], ["first", 602], ["vaccination", 608], [",", 619], ["without", 621], ["serious", 629], ["acute", 637], ["or", 643], ["chronic", 646], ["illness", 654], [".", 661], ["All", 663], ["children", 667], ["received", 676], ["the", 685], ["EPI", 689], ["diphtheria", 693], [",", 703], ["tetanus", 705], [",", 712], ["pertussis", 714], ["(", 724], ["inactivated", 725], ["whole", 737], ["-", 742], ["cell", 743], [")", 747], [",", 748], ["and", 750], ["hepatitis", 754], ["-", 763], ["B", 764], ["vaccines", 766], [",", 774], ["Haemophilus", 776], ["influenzae", 788], ["type", 799], ["b", 804], ["vaccine", 806], [",", 813], ["and", 815], ["oral", 819], ["polio", 824], ["vaccine", 830], ["at", 838], ["study", 841], ["months", 847], ["0", 854], [",", 855], ["1", 857], [",", 858], ["and", 860], ["2", 864], [",", 865], ["and", 867], ["measles", 871], ["vaccine", 879], ["and", 887], ["yellow", 891], ["fever", 898], ["vaccines", 904], ["at", 913], ["study", 916], ["month", 922], ["7", 928], [".", 929], ["Participants", 931], ["were", 944], ["randomly", 949], ["assigned", 958], ["(", 967], ["1:1:1", 968], [")", 973], ["to", 975], ["receive", 978], ["three", 986], ["doses", 992], ["of", 998], ["RTS", 1001], [",", 1004], ["S", 1005], ["/", 1006], ["AS01(E", 1007], [")", 1013], ["at", 1015], ["6", 1018], [",", 1019], ["10", 1021], [",", 1023], ["and", 1025], ["14", 1029], ["weeks", 1032], ["(", 1038], ["0", 1039], [",", 1040], ["1", 1042], [",", 1043], ["2", 1045], ["month", 1047], ["schedule", 1053], [")", 1061], ["or", 1063], ["at", 1066], ["6", 1069], ["weeks", 1071], [",", 1076], ["10", 1078], ["weeks", 1081], [",", 1086], ["and", 1088], ["9", 1092], ["months", 1094], ["(", 1101], ["0", 1102], [",", 1103], ["2", 1105], [",", 1106], ["7", 1108], ["month", 1110], ["schedule", 1116], [")", 1124], ["or", 1126], ["placebo", 1129], [".", 1136], ["Randomisation", 1138], ["was", 1152], ["according", 1156], ["to", 1166], ["a", 1169], ["predefined", 1171], ["block", 1182], ["list", 1188], ["with", 1193], ["a", 1198], ["computer", 1200], ["-", 1208], ["generated", 1209], ["randomisation", 1219], ["code", 1233], [".", 1237], ["Detection", 1239], ["of", 1249], ["serious", 1252], ["adverse", 1260], ["events", 1268], ["and", 1275], ["malaria", 1279], ["was", 1287], ["by", 1291], ["passive", 1294], ["case", 1302], ["detection", 1307], [".", 1316], ["Antibodies", 1318], ["against", 1329], ["Plasmodium", 1337], ["falciparum", 1348], ["circumsporozoite", 1359], ["protein", 1376], ["and", 1384], ["HBsAg", 1388], ["were", 1394], ["monitored", 1399], ["for", 1409], ["19", 1413], ["months", 1416], [".", 1422], ["This", 1424], ["study", 1429], ["is", 1435], ["registered", 1438], ["with", 1449], ["ClinicalTrials.gov", 1454], [",", 1472], ["number", 1474], ["NCT00436007", 1481], [".", 1492], ["511", 1494], ["children", 1498], ["were", 1507], ["enrolled", 1512], [".", 1520], ["Serious", 1522], ["adverse", 1530], ["events", 1538], ["occurred", 1545], ["in", 1554], ["57", 1557], ["participants", 1560], ["in", 1573], ["the", 1576], ["RTS", 1580], [",", 1583], ["S", 1584], ["/", 1585], ["AS01(E", 1586], [")", 1592], ["0", 1594], [",", 1595], ["1", 1597], [",", 1598], ["2", 1600], ["month", 1602], ["group", 1608], ["(", 1614], ["34", 1615], ["%", 1617], [",", 1618], ["95", 1620], ["%", 1622], ["CI", 1624], ["27", 1627], ["-", 1629], ["41", 1630], [")", 1632], [",", 1633], ["47", 1635], ["in", 1638], ["the", 1641], ["0", 1645], [",", 1646], ["1", 1648], [",", 1649], ["7", 1651], ["month", 1653], ["group", 1659], ["(", 1665], ["28", 1666], ["%", 1668], [",", 1669], ["21", 1671], ["-", 1673], ["35", 1674], [")", 1676], [",", 1677], ["and", 1679], ["49", 1683], ["(", 1686], ["29", 1687], ["%", 1689], [",", 1690], ["22", 1692], ["-", 1694], ["36", 1695], [")", 1697], ["in", 1699], ["the", 1702], ["control", 1706], ["group", 1714], [";", 1719], ["none", 1721], ["were", 1726], ["judged", 1731], ["to", 1738], ["be", 1741], ["related", 1744], ["to", 1752], ["study", 1755], ["vaccination", 1761], [".", 1772], ["At", 1774], ["month", 1777], ["19", 1783], [",", 1785], ["anticircumsporozoite", 1787], ["immune", 1808], ["responses", 1815], ["were", 1825], ["significantly", 1830], ["higher", 1844], ["in", 1851], ["the", 1854], ["RTS", 1858], [",", 1861], ["S", 1862], ["/", 1863], ["AS01(E", 1864], [")", 1870], ["groups", 1872], ["than", 1879], ["in", 1884], ["the", 1887], ["control", 1891], ["group", 1899], [".", 1904], ["Vaccine", 1906], ["efficacy", 1914], ["for", 1923], ["the", 1927], ["0", 1931], [",", 1932], ["1", 1934], [",", 1935], ["2", 1937], ["month", 1939], ["schedule", 1945], ["(", 1954], ["2", 1955], ["weeks", 1957], ["after", 1963], ["dose", 1969], ["three", 1974], ["to", 1980], ["month", 1983], ["19", 1989], [",", 1991], ["site", 1993], ["-", 1997], ["adjusted", 1998], ["according", 2007], ["-", 2016], ["to", 2017], ["-", 2019], ["protocol", 2020], ["analysis", 2029], [")", 2037], ["was", 2039], ["53", 2043], ["%", 2045], ["(", 2047], ["95", 2048], ["%", 2050], ["CI", 2052], ["26", 2055], ["-", 2057], ["70", 2058], [";", 2060], ["p=0\u00b70012", 2062], [")", 2070], ["against", 2072], ["first", 2080], ["malaria", 2086], ["episodes", 2094], ["and", 2103], ["59", 2107], ["%", 2109], ["(", 2111], ["36", 2112], ["-", 2114], ["74", 2115], [";", 2117], ["p=0\u00b70001", 2119], [")", 2127], ["against", 2129], ["all", 2137], ["malaria", 2141], ["episodes", 2149], [".", 2157], ["For", 2159], ["the", 2163], ["entire", 2167], ["study", 2174], ["period", 2180], [",", 2186], ["(", 2188], ["total", 2189], ["vaccinated", 2195], ["cohort", 2206], [")", 2212], ["vaccine", 2214], ["efficacy", 2222], ["against", 2231], ["all", 2239], ["malaria", 2243], ["episodes", 2251], ["was", 2260], ["higher", 2264], ["with", 2271], ["the", 2276], ["0", 2280], [",", 2281], ["1", 2283], [",", 2284], ["2", 2286], ["month", 2288], ["schedule", 2294], ["(", 2303], ["57", 2304], ["%", 2306], [",", 2307], ["95", 2309], ["%", 2311], ["CI", 2313], ["33", 2316], ["-", 2318], ["73", 2319], [";", 2321], ["p=0\u00b70002", 2323], [")", 2331], ["than", 2333], ["with", 2338], ["the", 2343], ["0", 2347], [",", 2348], ["1", 2350], [",", 2351], ["7", 2353], ["month", 2355], ["schedule", 2361], ["(", 2370], ["32", 2371], ["%", 2373], ["CI", 2375], ["16", 2378], ["-", 2380], ["45", 2381], [";", 2383], ["p=0\u00b70003", 2385], [")", 2393], [".", 2394], ["1", 2396], ["year", 2398], ["after", 2403], ["dose", 2409], ["three", 2414], [",", 2419], ["vaccine", 2421], ["efficacy", 2429], ["against", 2438], ["first", 2446], ["malaria", 2452], ["episodes", 2460], ["was", 2469], ["similar", 2473], ["for", 2481], ["both", 2485], ["schedules", 2490], ["(", 2500], ["0", 2501], [",", 2502], ["1", 2504], [",", 2505], ["2", 2507], ["month", 2509], ["group", 2515], [",", 2520], ["61\u00b76", 2522], ["%", 2526], ["[", 2528], ["95", 2529], ["%", 2531], ["CI", 2533], ["35\u00b76", 2536], ["-", 2540], ["77\u00b71", 2541], ["]", 2545], [",", 2546], ["p<0\u00b7001", 2548], [";", 2555], ["0", 2557], [",", 2558], ["1", 2560], [",", 2561], ["7", 2563], ["month", 2565], ["group", 2571], [",", 2576], ["63\u00b78", 2578], ["%", 2582], ["[", 2584], ["40\u00b74", 2585], ["-", 2589], ["78\u00b70", 2590], ["]", 2594], [",", 2595], ["p<0\u00b7001", 2597], [",", 2604], ["according", 2606], ["-", 2615], ["to", 2616], ["-", 2618], ["protocol", 2619], ["cohort", 2628], [")", 2634], [".", 2635], ["Vaccine", 2637], ["efficacy", 2645], ["was", 2654], ["consistent", 2658], ["with", 2669], ["the", 2674], ["target", 2678], ["put", 2685], ["forward", 2689], ["by", 2697], ["the", 2700], ["WHO", 2704], ["-", 2707], ["sponsored", 2708], ["malaria", 2718], ["vaccine", 2726], ["technology", 2734], ["roadmap", 2745], ["for", 2753], ["a", 2757], ["first", 2759], ["-", 2764], ["generation", 2765], ["malaria", 2776], ["vaccine", 2784], [".", 2791], ["The", 2793], ["0", 2797], [",", 2798], ["1", 2800], [",", 2801], ["2", 2803], ["month", 2805], ["vaccine", 2811], ["schedule", 2819], ["has", 2828], ["been", 2832], ["selected", 2837], ["for", 2846], ["phase", 2850], ["3", 2856], ["candidate", 2858], ["vaccine", 2868], ["assessment", 2876], [".", 2886], ["Program", 2888], ["for", 2896], ["Appropriate", 2900], ["Technology", 2912], ["in", 2923], ["Health", 2926], ["Malaria", 2933], ["Vaccine", 2941], ["Initiative", 2949], [";", 2959], ["GlaxoSmithKline", 2961], ["Biologicals", 2977], [".", 2988]]}
{"context": "Alpha-synuclein (alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease. Aggregation of alphaS is thought to proceed from a primarily disordered state with nascent secondary structure through intermediate conformations to oligomeric forms and finally to mature amyloid fibrils. Low pH conditions lead to conformational changes associated with increased alphaS fibril formation. Here we characterize these structural and dynamic changes using solution state NMR measurements of secondary chemical shifts, relaxation parameters, residual dipolar couplings, and paramagnetic relaxation enhancement. We find that the neutralization of negatively charged side-chains eliminates electrostatic repulsion in the C-terminal tail of alphaS and leads to a collapse of this region at low pH. Hydrophobic contacts between the compact C-terminal tail and the NAC (non-amyloid-beta component) region are maintained and may lead to the formation of a globular domain. Transient long-range contacts between the C-terminus of the protein and regions N-terminal to the NAC region are also preserved. Thus, the release of long-range contacts does not play a role in the increased aggregation of alphaS at low pH, which we instead attribute to the increased hydrophobicity of the protein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "49df234dddfb4af6b70443ee0df3e00d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["alphaS", 17], [")", 23], ["is", 25], ["the", 28], ["primary", 32], ["component", 40], ["of", 50], ["Lewy", 53], ["bodies", 58], [",", 64], ["the", 66], ["pathological", 70], ["hallmark", 83], ["of", 92], ["Parkinson", 95], ["'s", 104], ["Disease", 107], [".", 114], ["Aggregation", 116], ["of", 128], ["alphaS", 131], ["is", 138], ["thought", 141], ["to", 149], ["proceed", 152], ["from", 160], ["a", 165], ["primarily", 167], ["disordered", 177], ["state", 188], ["with", 194], ["nascent", 199], ["secondary", 207], ["structure", 217], ["through", 227], ["intermediate", 235], ["conformations", 248], ["to", 262], ["oligomeric", 265], ["forms", 276], ["and", 282], ["finally", 286], ["to", 294], ["mature", 297], ["amyloid", 304], ["fibrils", 312], [".", 319], ["Low", 321], ["pH", 325], ["conditions", 328], ["lead", 339], ["to", 344], ["conformational", 347], ["changes", 362], ["associated", 370], ["with", 381], ["increased", 386], ["alphaS", 396], ["fibril", 403], ["formation", 410], [".", 419], ["Here", 421], ["we", 426], ["characterize", 429], ["these", 442], ["structural", 448], ["and", 459], ["dynamic", 463], ["changes", 471], ["using", 479], ["solution", 485], ["state", 494], ["NMR", 500], ["measurements", 504], ["of", 517], ["secondary", 520], ["chemical", 530], ["shifts", 539], [",", 545], ["relaxation", 547], ["parameters", 558], [",", 568], ["residual", 570], ["dipolar", 579], ["couplings", 587], [",", 596], ["and", 598], ["paramagnetic", 602], ["relaxation", 615], ["enhancement", 626], [".", 637], ["We", 639], ["find", 642], ["that", 647], ["the", 652], ["neutralization", 656], ["of", 671], ["negatively", 674], ["charged", 685], ["side", 693], ["-", 697], ["chains", 698], ["eliminates", 705], ["electrostatic", 716], ["repulsion", 730], ["in", 740], ["the", 743], ["C", 747], ["-", 748], ["terminal", 749], ["tail", 758], ["of", 763], ["alphaS", 766], ["and", 773], ["leads", 777], ["to", 783], ["a", 786], ["collapse", 788], ["of", 797], ["this", 800], ["region", 805], ["at", 812], ["low", 815], ["pH.", 819], ["Hydrophobic", 823], ["contacts", 835], ["between", 844], ["the", 852], ["compact", 856], ["C", 864], ["-", 865], ["terminal", 866], ["tail", 875], ["and", 880], ["the", 884], ["NAC", 888], ["(", 892], ["non", 893], ["-", 896], ["amyloid", 897], ["-", 904], ["beta", 905], ["component", 910], [")", 919], ["region", 921], ["are", 928], ["maintained", 932], ["and", 943], ["may", 947], ["lead", 951], ["to", 956], ["the", 959], ["formation", 963], ["of", 973], ["a", 976], ["globular", 978], ["domain", 987], [".", 993], ["Transient", 995], ["long", 1005], ["-", 1009], ["range", 1010], ["contacts", 1016], ["between", 1025], ["the", 1033], ["C", 1037], ["-", 1038], ["terminus", 1039], ["of", 1048], ["the", 1051], ["protein", 1055], ["and", 1063], ["regions", 1067], ["N", 1075], ["-", 1076], ["terminal", 1077], ["to", 1086], ["the", 1089], ["NAC", 1093], ["region", 1097], ["are", 1104], ["also", 1108], ["preserved", 1113], [".", 1122], ["Thus", 1124], [",", 1128], ["the", 1130], ["release", 1134], ["of", 1142], ["long", 1145], ["-", 1149], ["range", 1150], ["contacts", 1156], ["does", 1165], ["not", 1170], ["play", 1174], ["a", 1179], ["role", 1181], ["in", 1186], ["the", 1189], ["increased", 1193], ["aggregation", 1203], ["of", 1215], ["alphaS", 1218], ["at", 1225], ["low", 1228], ["pH", 1232], [",", 1234], ["which", 1236], ["we", 1242], ["instead", 1245], ["attribute", 1253], ["to", 1263], ["the", 1266], ["increased", 1270], ["hydrophobicity", 1280], ["of", 1295], ["the", 1298], ["protein", 1302], [".", 1309]]}
{"context": "Alterations in GABAergic mRNA expression play a key role for prefrontal dysfunction in schizophrenia and other neurodevelopmental disease. Here, we show that histone H3-lysine 4 methylation, a chromatin mark associated with the transcriptional process, progressively increased at GAD1 and other GABAergic gene promoters (GAD2, NPY, SST) in human prefrontal cortex (PFC) from prenatal to peripubertal ages and throughout adulthood. Alterations in schizophrenia included decreased GAD1 expression and H3K4-trimethylation, predominantly in females and in conjunction with a risk haplotype at the 5' end of GAD1. Heterozygosity for a truncated, lacZ knock-in allele of mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4 methylation at GABAergic gene promoters. In contrast, Gad1 H3K4 (tri)methylation and Mll1 occupancy was increased in cerebral cortex of mice after treatment with the atypical antipsychotic, clozapine. These effects were not mimicked by haloperidol or genetic ablation of dopamine D2 and D3 receptors, suggesting that blockade of D2-like signaling is not sufficient for clozapine-induced histone methylation. Therefore, chromatin remodeling mechanisms at GABAergic gene promoters, including MLL1-mediated histone methylation, operate throughout an extended period of normal human PFC development and play a role in the neurobiology of schizophrenia.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "e6d3491bc82b418c870a7d4356305e46", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[132, 132], [143, 143]], "char_spans": [[799, 802], [863, 866]]}]}], "context_tokens": [["Alterations", 0], ["in", 12], ["GABAergic", 15], ["mRNA", 25], ["expression", 30], ["play", 41], ["a", 46], ["key", 48], ["role", 52], ["for", 57], ["prefrontal", 61], ["dysfunction", 72], ["in", 84], ["schizophrenia", 87], ["and", 101], ["other", 105], ["neurodevelopmental", 111], ["disease", 130], [".", 137], ["Here", 139], [",", 143], ["we", 145], ["show", 148], ["that", 153], ["histone", 158], ["H3-lysine", 166], ["4", 176], ["methylation", 178], [",", 189], ["a", 191], ["chromatin", 193], ["mark", 203], ["associated", 208], ["with", 219], ["the", 224], ["transcriptional", 228], ["process", 244], [",", 251], ["progressively", 253], ["increased", 267], ["at", 277], ["GAD1", 280], ["and", 285], ["other", 289], ["GABAergic", 295], ["gene", 305], ["promoters", 310], ["(", 320], ["GAD2", 321], [",", 325], ["NPY", 327], [",", 330], ["SST", 332], [")", 335], ["in", 337], ["human", 340], ["prefrontal", 346], ["cortex", 357], ["(", 364], ["PFC", 365], [")", 368], ["from", 370], ["prenatal", 375], ["to", 384], ["peripubertal", 387], ["ages", 400], ["and", 405], ["throughout", 409], ["adulthood", 420], [".", 429], ["Alterations", 431], ["in", 443], ["schizophrenia", 446], ["included", 460], ["decreased", 469], ["GAD1", 479], ["expression", 484], ["and", 495], ["H3K4-trimethylation", 499], [",", 518], ["predominantly", 520], ["in", 534], ["females", 537], ["and", 545], ["in", 549], ["conjunction", 552], ["with", 564], ["a", 569], ["risk", 571], ["haplotype", 576], ["at", 586], ["the", 589], ["5", 593], ["'", 594], ["end", 596], ["of", 600], ["GAD1", 603], [".", 607], ["Heterozygosity", 609], ["for", 624], ["a", 628], ["truncated", 630], [",", 639], ["lacZ", 641], ["knock", 646], ["-", 651], ["in", 652], ["allele", 655], ["of", 662], ["mixed", 665], ["-", 670], ["lineage", 671], ["leukemia", 679], ["1", 688], ["(", 690], ["Mll1", 691], [")", 695], [",", 696], ["a", 698], ["histone", 700], ["methyltransferase", 708], ["expressed", 726], ["in", 736], ["GABAergic", 739], ["and", 749], ["other", 753], ["cortical", 759], ["neurons", 768], [",", 775], ["resulted", 777], ["in", 786], ["decreased", 789], ["H3K4", 799], ["methylation", 804], ["at", 816], ["GABAergic", 819], ["gene", 829], ["promoters", 834], [".", 843], ["In", 845], ["contrast", 848], [",", 856], ["Gad1", 858], ["H3K4", 863], ["(", 868], ["tri)methylation", 869], ["and", 885], ["Mll1", 889], ["occupancy", 894], ["was", 904], ["increased", 908], ["in", 918], ["cerebral", 921], ["cortex", 930], ["of", 937], ["mice", 940], ["after", 945], ["treatment", 951], ["with", 961], ["the", 966], ["atypical", 970], ["antipsychotic", 979], [",", 992], ["clozapine", 994], [".", 1003], ["These", 1005], ["effects", 1011], ["were", 1019], ["not", 1024], ["mimicked", 1028], ["by", 1037], ["haloperidol", 1040], ["or", 1052], ["genetic", 1055], ["ablation", 1063], ["of", 1072], ["dopamine", 1075], ["D2", 1084], ["and", 1087], ["D3", 1091], ["receptors", 1094], [",", 1103], ["suggesting", 1105], ["that", 1116], ["blockade", 1121], ["of", 1130], ["D2-like", 1133], ["signaling", 1141], ["is", 1151], ["not", 1154], ["sufficient", 1158], ["for", 1169], ["clozapine", 1173], ["-", 1182], ["induced", 1183], ["histone", 1191], ["methylation", 1199], [".", 1210], ["Therefore", 1212], [",", 1221], ["chromatin", 1223], ["remodeling", 1233], ["mechanisms", 1244], ["at", 1255], ["GABAergic", 1258], ["gene", 1268], ["promoters", 1273], [",", 1282], ["including", 1284], ["MLL1-mediated", 1294], ["histone", 1308], ["methylation", 1316], [",", 1327], ["operate", 1329], ["throughout", 1337], ["an", 1348], ["extended", 1351], ["period", 1360], ["of", 1367], ["normal", 1370], ["human", 1377], ["PFC", 1383], ["development", 1387], ["and", 1399], ["play", 1403], ["a", 1408], ["role", 1410], ["in", 1415], ["the", 1418], ["neurobiology", 1422], ["of", 1435], ["schizophrenia", 1438], [".", 1451]]}
{"context": "To define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography. Body indices (height, weight, and body mass index) were analyzed in 60 healthy adults, and electromyography and sonography were also performed. The cross-sectional areas of the proximal and distal median nerve and carpal tunnel were obtained by sonography. The proximal and distal nerve/tunnel indices were obtained by calculating the ratio between the proximal and distal cross-sectional areas of the median nerve to those of the carpal tunnel and multiplying the value by 100. Although the proximal cross-sectional areas of the median nerve and body indices showed statistically significant relationships with weak positive correlations, the proximal and distal areas of the carpal tunnel showed relatively stronger correlations with body indices. Between sexes, there were significant differences in the proximal median nerve cross-sectional area (mean \u00b1 SD: male, 10.48 \u00b1 3.21 mm(2); female, 8.81 \u00b1 3.21 mm(2); P < .05) and proximal carpal tunnel area (male, 182.50 \u00b1 21.15 mm(2); female, 151.23 \u00b1 21.14 mm(2); P < .05). There was no difference in the proximal nerve/tunnel index (male, 5.80% \u00b1 1.72%; female, 5.91% \u00b1 1.63%). There was a statistically significant difference in the distal carpal tunnel cross-sectional area (male, 138.90 \u00b1 20.95 mm(2); female, 121.50 \u00b1 18.99 mm(2); P < .05) between sexes, but the distal median area (male, 9.99 \u00b1 3.42 mm(2); female, 8.46 \u00b1 1.84 mm(2)) and distal nerve/tunnel index (male, 7.15% \u00b1 2.00%; female, 7.01% \u00b1 1.38%) showed no significant differences. The proximal index was significantly higher than the distal index (proximal, 5.85% \u00b1 1.66%; distal, 7.08% \u00b1 1.71%). The nerve/tunnel index is unaffected by body indices or sex and thus may be a useful and objective standard for diagnosing carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "75f0878c248e4bbab73420d14772e958", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[181, 181], [310, 310], [116, 116], [140, 140], [20, 20], [81, 81]], "char_spans": [[1072, 1077], [1582, 1587], [658, 663], [786, 791], [117, 122], [453, 458]]}]}], "context_tokens": [["To", 0], ["define", 3], ["the", 10], ["relationship", 14], ["between", 27], ["body", 35], ["indices", 40], ["of", 48], ["healthy", 51], ["adults", 59], ["and", 66], ["cross", 70], ["-", 75], ["sectional", 76], ["areas", 86], ["of", 92], ["the", 95], ["carpal", 99], ["tunnel", 106], ["and", 113], ["median", 117], ["nerve", 124], ["and", 130], ["to", 134], ["obtain", 137], ["the", 144], ["nerve", 148], ["/", 153], ["tunnel", 154], ["index", 161], [",", 166], ["which", 168], ["represents", 174], ["a", 185], ["new", 187], ["standard", 191], ["for", 200], ["diagnosing", 204], ["carpal", 215], ["tunnel", 222], ["syndrome", 229], ["using", 238], ["sonography", 244], [".", 254], ["Body", 256], ["indices", 261], ["(", 269], ["height", 270], [",", 276], ["weight", 278], [",", 284], ["and", 286], ["body", 290], ["mass", 295], ["index", 300], [")", 305], ["were", 307], ["analyzed", 312], ["in", 321], ["60", 324], ["healthy", 327], ["adults", 335], [",", 341], ["and", 343], ["electromyography", 347], ["and", 364], ["sonography", 368], ["were", 379], ["also", 384], ["performed", 389], [".", 398], ["The", 400], ["cross", 404], ["-", 409], ["sectional", 410], ["areas", 420], ["of", 426], ["the", 429], ["proximal", 433], ["and", 442], ["distal", 446], ["median", 453], ["nerve", 460], ["and", 466], ["carpal", 470], ["tunnel", 477], ["were", 484], ["obtained", 489], ["by", 498], ["sonography", 501], [".", 511], ["The", 513], ["proximal", 517], ["and", 526], ["distal", 530], ["nerve", 537], ["/", 542], ["tunnel", 543], ["indices", 550], ["were", 558], ["obtained", 563], ["by", 572], ["calculating", 575], ["the", 587], ["ratio", 591], ["between", 597], ["the", 605], ["proximal", 609], ["and", 618], ["distal", 622], ["cross", 629], ["-", 634], ["sectional", 635], ["areas", 645], ["of", 651], ["the", 654], ["median", 658], ["nerve", 665], ["to", 671], ["those", 674], ["of", 680], ["the", 683], ["carpal", 687], ["tunnel", 694], ["and", 701], ["multiplying", 705], ["the", 717], ["value", 721], ["by", 727], ["100", 730], [".", 733], ["Although", 735], ["the", 744], ["proximal", 748], ["cross", 757], ["-", 762], ["sectional", 763], ["areas", 773], ["of", 779], ["the", 782], ["median", 786], ["nerve", 793], ["and", 799], ["body", 803], ["indices", 808], ["showed", 816], ["statistically", 823], ["significant", 837], ["relationships", 849], ["with", 863], ["weak", 868], ["positive", 873], ["correlations", 882], [",", 894], ["the", 896], ["proximal", 900], ["and", 909], ["distal", 913], ["areas", 920], ["of", 926], ["the", 929], ["carpal", 933], ["tunnel", 940], ["showed", 947], ["relatively", 954], ["stronger", 965], ["correlations", 974], ["with", 987], ["body", 992], ["indices", 997], [".", 1004], ["Between", 1006], ["sexes", 1014], [",", 1019], ["there", 1021], ["were", 1027], ["significant", 1032], ["differences", 1044], ["in", 1056], ["the", 1059], ["proximal", 1063], ["median", 1072], ["nerve", 1079], ["cross", 1085], ["-", 1090], ["sectional", 1091], ["area", 1101], ["(", 1106], ["mean", 1107], ["\u00b1", 1112], ["SD", 1114], [":", 1116], ["male", 1118], [",", 1122], ["10.48", 1124], ["\u00b1", 1130], ["3.21", 1132], ["mm(2", 1137], [")", 1141], [";", 1142], ["female", 1144], [",", 1150], ["8.81", 1152], ["\u00b1", 1157], ["3.21", 1159], ["mm(2", 1164], [")", 1168], [";", 1169], ["P", 1171], ["<", 1173], [".05", 1175], [")", 1178], ["and", 1180], ["proximal", 1184], ["carpal", 1193], ["tunnel", 1200], ["area", 1207], ["(", 1212], ["male", 1213], [",", 1217], ["182.50", 1219], ["\u00b1", 1226], ["21.15", 1228], ["mm(2", 1234], [")", 1238], [";", 1239], ["female", 1241], [",", 1247], ["151.23", 1249], ["\u00b1", 1256], ["21.14", 1258], ["mm(2", 1264], [")", 1268], [";", 1269], ["P", 1271], ["<", 1273], [".05", 1275], [")", 1278], [".", 1279], ["There", 1281], ["was", 1287], ["no", 1291], ["difference", 1294], ["in", 1305], ["the", 1308], ["proximal", 1312], ["nerve", 1321], ["/", 1326], ["tunnel", 1327], ["index", 1334], ["(", 1340], ["male", 1341], [",", 1345], ["5.80", 1347], ["%", 1351], ["\u00b1", 1353], ["1.72", 1355], ["%", 1359], [";", 1360], ["female", 1362], [",", 1368], ["5.91", 1370], ["%", 1374], ["\u00b1", 1376], ["1.63", 1378], ["%", 1382], [")", 1383], [".", 1384], ["There", 1386], ["was", 1392], ["a", 1396], ["statistically", 1398], ["significant", 1412], ["difference", 1424], ["in", 1435], ["the", 1438], ["distal", 1442], ["carpal", 1449], ["tunnel", 1456], ["cross", 1463], ["-", 1468], ["sectional", 1469], ["area", 1479], ["(", 1484], ["male", 1485], [",", 1489], ["138.90", 1491], ["\u00b1", 1498], ["20.95", 1500], ["mm(2", 1506], [")", 1510], [";", 1511], ["female", 1513], [",", 1519], ["121.50", 1521], ["\u00b1", 1528], ["18.99", 1530], ["mm(2", 1536], [")", 1540], [";", 1541], ["P", 1543], ["<", 1545], [".05", 1547], [")", 1550], ["between", 1552], ["sexes", 1560], [",", 1565], ["but", 1567], ["the", 1571], ["distal", 1575], ["median", 1582], ["area", 1589], ["(", 1594], ["male", 1595], [",", 1599], ["9.99", 1601], ["\u00b1", 1606], ["3.42", 1608], ["mm(2", 1613], [")", 1617], [";", 1618], ["female", 1620], [",", 1626], ["8.46", 1628], ["\u00b1", 1633], ["1.84", 1635], ["mm(2", 1640], [")", 1644], [")", 1645], ["and", 1647], ["distal", 1651], ["nerve", 1658], ["/", 1663], ["tunnel", 1664], ["index", 1671], ["(", 1677], ["male", 1678], [",", 1682], ["7.15", 1684], ["%", 1688], ["\u00b1", 1690], ["2.00", 1692], ["%", 1696], [";", 1697], ["female", 1699], [",", 1705], ["7.01", 1707], ["%", 1711], ["\u00b1", 1713], ["1.38", 1715], ["%", 1719], [")", 1720], ["showed", 1722], ["no", 1729], ["significant", 1732], ["differences", 1744], [".", 1755], ["The", 1757], ["proximal", 1761], ["index", 1770], ["was", 1776], ["significantly", 1780], ["higher", 1794], ["than", 1801], ["the", 1806], ["distal", 1810], ["index", 1817], ["(", 1823], ["proximal", 1824], [",", 1832], ["5.85", 1834], ["%", 1838], ["\u00b1", 1840], ["1.66", 1842], ["%", 1846], [";", 1847], ["distal", 1849], [",", 1855], ["7.08", 1857], ["%", 1861], ["\u00b1", 1863], ["1.71", 1865], ["%", 1869], [")", 1870], [".", 1871], ["The", 1873], ["nerve", 1877], ["/", 1882], ["tunnel", 1883], ["index", 1890], ["is", 1896], ["unaffected", 1899], ["by", 1910], ["body", 1913], ["indices", 1918], ["or", 1926], ["sex", 1929], ["and", 1933], ["thus", 1937], ["may", 1942], ["be", 1946], ["a", 1949], ["useful", 1951], ["and", 1958], ["objective", 1962], ["standard", 1972], ["for", 1981], ["diagnosing", 1985], ["carpal", 1996], ["tunnel", 2003], ["syndrome", 2010], [".", 2018]]}
{"context": "Mutations in the solute carrier family 9, subfamily A member 6 (SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome, a syndromic form of X-linked intellectual disability characterized by microcephaly, severe global developmental delay, autistic behavior, early onset seizures and ataxia. In a 7-year-old boy with characteristic clinical and neuroimaging features of Christianson syndrome and epileptic encephalopathy with continuous spikes and waves during sleep, we identified a novel splice site mutation (IVS10-1G>A) in SLC9A6. These findings expand the clinical spectrum of the syndrome and indicate NHE6 dysfunction as a new cause of electrical status epilepticus during slow-wave sleep (ESES).", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "9051b478ee6f41f98b58e2be06353573", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[100, 100], [13, 13]], "char_spans": [[576, 581], [64, 69]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["solute", 17], ["carrier", 24], ["family", 32], ["9", 39], [",", 40], ["subfamily", 42], ["A", 52], ["member", 54], ["6", 61], ["(", 63], ["SLC9A6", 64], [")", 70], ["gene", 72], [",", 76], ["encoding", 78], ["the", 87], ["endosomal", 91], ["Na+/H+", 101], ["exchanger", 108], ["6", 118], ["(", 120], ["NHE6", 121], [")", 125], ["are", 127], ["associated", 131], ["with", 142], ["Christianson", 147], ["syndrome", 160], [",", 168], ["a", 170], ["syndromic", 172], ["form", 182], ["of", 187], ["X", 190], ["-", 191], ["linked", 192], ["intellectual", 199], ["disability", 212], ["characterized", 223], ["by", 237], ["microcephaly", 240], [",", 252], ["severe", 254], ["global", 261], ["developmental", 268], ["delay", 282], [",", 287], ["autistic", 289], ["behavior", 298], [",", 306], ["early", 308], ["onset", 314], ["seizures", 320], ["and", 329], ["ataxia", 333], [".", 339], ["In", 341], ["a", 344], ["7-year", 346], ["-", 352], ["old", 353], ["boy", 357], ["with", 361], ["characteristic", 366], ["clinical", 381], ["and", 390], ["neuroimaging", 394], ["features", 407], ["of", 416], ["Christianson", 419], ["syndrome", 432], ["and", 441], ["epileptic", 445], ["encephalopathy", 455], ["with", 470], ["continuous", 475], ["spikes", 486], ["and", 493], ["waves", 497], ["during", 503], ["sleep", 510], [",", 515], ["we", 517], ["identified", 520], ["a", 531], ["novel", 533], ["splice", 539], ["site", 546], ["mutation", 551], ["(", 560], ["IVS10", 561], ["-", 566], ["1G", 567], [">", 569], ["A", 570], [")", 571], ["in", 573], ["SLC9A6", 576], [".", 582], ["These", 584], ["findings", 590], ["expand", 599], ["the", 606], ["clinical", 610], ["spectrum", 619], ["of", 628], ["the", 631], ["syndrome", 635], ["and", 644], ["indicate", 648], ["NHE6", 657], ["dysfunction", 662], ["as", 674], ["a", 677], ["new", 679], ["cause", 683], ["of", 689], ["electrical", 692], ["status", 703], ["epilepticus", 710], ["during", 722], ["slow", 729], ["-", 733], ["wave", 734], ["sleep", 739], ["(", 745], ["ESES", 746], [")", 750], [".", 751]]}
{"context": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues. It is usually ascertained due to abnormal skin texture, scarring complications, vascular fragility, or chronic symptoms, such as fatigue and musculoskeletal pain. Sometimes, Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas. In this scenario, the misdiagnosis of Ehlers-Danlos syndrome with child abuse is a possibility, as occasionally reported in the literature. Recently, more attention was posed by lay people between the possible association of Ehlers-Danlos syndrome and bone fragility. Literature and personal experience show a strong association between Ehlers-Danlos syndrome, generalized joint hypermobility and reduced bone mass density in older children and adults, especially fertile women. The existence of a true increased risk of fracture in Ehlers-Danlos syndrome is still a matter of debate in children and adults with little and conflicting evidence. In case of suspected child abuse, Ehlers-Danlos syndrome is certainly on the differential for bruising, especially in EDS types with marked cutaneous and capillary involvement. In suspected child abuse cases, careful examination of the index case and her/his extended family is routine, as well as exclusion of other disorders such as osteogenesis imperfecta. The hypothesis of Ehlers-Danlos syndrome as an alternative explanation for infantile fractures remains speculative.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "ea17a6333c81457d803d594917b8f0b9", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[10, 11]], "char_spans": [[61, 77]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["heterogeneous", 28], ["group", 42], ["of", 48], ["heritable", 51], ["connective", 61], ["tissue", 72], ["disorders", 79], ["characterized", 89], ["by", 103], ["increased", 106], ["fragility", 116], ["of", 126], ["various", 129], ["non", 137], ["-", 140], ["ossified", 141], ["tissues", 150], [".", 157], ["It", 159], ["is", 162], ["usually", 165], ["ascertained", 173], ["due", 185], ["to", 189], ["abnormal", 192], ["skin", 201], ["texture", 206], [",", 213], ["scarring", 215], ["complications", 224], [",", 237], ["vascular", 239], ["fragility", 248], [",", 257], ["or", 259], ["chronic", 262], ["symptoms", 270], [",", 278], ["such", 280], ["as", 285], ["fatigue", 288], ["and", 296], ["musculoskeletal", 300], ["pain", 316], [".", 320], ["Sometimes", 322], [",", 331], ["Ehlers", 333], ["-", 339], ["Danlos", 340], ["syndrome", 347], ["remains", 356], ["undetected", 364], ["until", 375], ["the", 381], ["patient", 385], [",", 392], ["usually", 394], ["in", 402], ["the", 405], ["pediatric", 409], ["age", 419], [",", 422], ["shows", 424], ["extensive", 430], ["or", 440], ["severe", 443], ["mucocutaneous", 450], ["injuries", 464], ["after", 473], ["only", 479], ["minor", 484], ["traumas", 490], [".", 497], ["In", 499], ["this", 502], ["scenario", 507], [",", 515], ["the", 517], ["misdiagnosis", 521], ["of", 534], ["Ehlers", 537], ["-", 543], ["Danlos", 544], ["syndrome", 551], ["with", 560], ["child", 565], ["abuse", 571], ["is", 577], ["a", 580], ["possibility", 582], [",", 593], ["as", 595], ["occasionally", 598], ["reported", 611], ["in", 620], ["the", 623], ["literature", 627], [".", 637], ["Recently", 639], [",", 647], ["more", 649], ["attention", 654], ["was", 664], ["posed", 668], ["by", 674], ["lay", 677], ["people", 681], ["between", 688], ["the", 696], ["possible", 700], ["association", 709], ["of", 721], ["Ehlers", 724], ["-", 730], ["Danlos", 731], ["syndrome", 738], ["and", 747], ["bone", 751], ["fragility", 756], [".", 765], ["Literature", 767], ["and", 778], ["personal", 782], ["experience", 791], ["show", 802], ["a", 807], ["strong", 809], ["association", 816], ["between", 828], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], [",", 858], ["generalized", 860], ["joint", 872], ["hypermobility", 878], ["and", 892], ["reduced", 896], ["bone", 904], ["mass", 909], ["density", 914], ["in", 922], ["older", 925], ["children", 931], ["and", 940], ["adults", 944], [",", 950], ["especially", 952], ["fertile", 963], ["women", 971], [".", 976], ["The", 978], ["existence", 982], ["of", 992], ["a", 995], ["true", 997], ["increased", 1002], ["risk", 1012], ["of", 1017], ["fracture", 1020], ["in", 1029], ["Ehlers", 1032], ["-", 1038], ["Danlos", 1039], ["syndrome", 1046], ["is", 1055], ["still", 1058], ["a", 1064], ["matter", 1066], ["of", 1073], ["debate", 1076], ["in", 1083], ["children", 1086], ["and", 1095], ["adults", 1099], ["with", 1106], ["little", 1111], ["and", 1118], ["conflicting", 1122], ["evidence", 1134], [".", 1142], ["In", 1144], ["case", 1147], ["of", 1152], ["suspected", 1155], ["child", 1165], ["abuse", 1171], [",", 1176], ["Ehlers", 1178], ["-", 1184], ["Danlos", 1185], ["syndrome", 1192], ["is", 1201], ["certainly", 1204], ["on", 1214], ["the", 1217], ["differential", 1221], ["for", 1234], ["bruising", 1238], [",", 1246], ["especially", 1248], ["in", 1259], ["EDS", 1262], ["types", 1266], ["with", 1272], ["marked", 1277], ["cutaneous", 1284], ["and", 1294], ["capillary", 1298], ["involvement", 1308], [".", 1319], ["In", 1321], ["suspected", 1324], ["child", 1334], ["abuse", 1340], ["cases", 1346], [",", 1351], ["careful", 1353], ["examination", 1361], ["of", 1373], ["the", 1376], ["index", 1380], ["case", 1386], ["and", 1391], ["her", 1395], ["/", 1398], ["his", 1399], ["extended", 1403], ["family", 1412], ["is", 1419], ["routine", 1422], [",", 1429], ["as", 1431], ["well", 1434], ["as", 1439], ["exclusion", 1442], ["of", 1452], ["other", 1455], ["disorders", 1461], ["such", 1471], ["as", 1476], ["osteogenesis", 1479], ["imperfecta", 1492], [".", 1502], ["The", 1504], ["hypothesis", 1508], ["of", 1519], ["Ehlers", 1522], ["-", 1528], ["Danlos", 1529], ["syndrome", 1536], ["as", 1545], ["an", 1548], ["alternative", 1551], ["explanation", 1563], ["for", 1575], ["infantile", 1579], ["fractures", 1589], ["remains", 1599], ["speculative", 1607], [".", 1618]]}
{"context": "Parkinson's disease (PD) is one of many neurodegenerative diseases that are characterized by amyloid fibril formation. Alpha-synuclein is a primary component of the fibrillar neuronal inclusions, known as Lewy bodies, that are diagnostic of PD. In addition, the alpha-synuclein gene is linked to familial PD. Fibril formation by alpha-synuclein proceeds via discrete beta-sheet-rich oligomers, or protofibrils, that are consumed as fibrils grow. Both FPD mutations accelerate formation of protofibrils, suggesting that these intermediates, rather than the fibril product, trigger neuronal loss. In idiopathic PD, other factors may be responsible for accelerating protofibril formation by wild-type alpha-synuclein. One possible factor could be molecular crowding in the neuronal cytoplasm. We demonstrate here that crowding using inert polymers significantly reduced the lag time for protofibril formation and the conversion of the protofibril to the fibril, but did not affect the morphology of either species. Physiologically realistic changes in the degree of in vitro crowding have significant kinetic consequences. Thus, nonspecific changes in the total cytoplasmic protein concentration, induced by cell volume changes and/or altered protein degradation, could promote formation of and stabilize the alpha-synuclein protofibril.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "7206b07769574e8793fa79da4f2aab29", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[124, 126], [20, 22], [61, 63], [48, 50], [219, 221]], "char_spans": [[698, 712], [119, 133], [329, 343], [262, 276], [1306, 1320]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["one", 28], ["of", 32], ["many", 35], ["neurodegenerative", 40], ["diseases", 58], ["that", 67], ["are", 72], ["characterized", 76], ["by", 90], ["amyloid", 93], ["fibril", 101], ["formation", 108], [".", 117], ["Alpha", 119], ["-", 124], ["synuclein", 125], ["is", 135], ["a", 138], ["primary", 140], ["component", 148], ["of", 158], ["the", 161], ["fibrillar", 165], ["neuronal", 175], ["inclusions", 184], [",", 194], ["known", 196], ["as", 202], ["Lewy", 205], ["bodies", 210], [",", 216], ["that", 218], ["are", 223], ["diagnostic", 227], ["of", 238], ["PD", 241], [".", 243], ["In", 245], ["addition", 248], [",", 256], ["the", 258], ["alpha", 262], ["-", 267], ["synuclein", 268], ["gene", 278], ["is", 283], ["linked", 286], ["to", 293], ["familial", 296], ["PD", 305], [".", 307], ["Fibril", 309], ["formation", 316], ["by", 326], ["alpha", 329], ["-", 334], ["synuclein", 335], ["proceeds", 345], ["via", 354], ["discrete", 358], ["beta", 367], ["-", 371], ["sheet", 372], ["-", 377], ["rich", 378], ["oligomers", 383], [",", 392], ["or", 394], ["protofibrils", 397], [",", 409], ["that", 411], ["are", 416], ["consumed", 420], ["as", 429], ["fibrils", 432], ["grow", 440], [".", 444], ["Both", 446], ["FPD", 451], ["mutations", 455], ["accelerate", 465], ["formation", 476], ["of", 486], ["protofibrils", 489], [",", 501], ["suggesting", 503], ["that", 514], ["these", 519], ["intermediates", 525], [",", 538], ["rather", 540], ["than", 547], ["the", 552], ["fibril", 556], ["product", 563], [",", 570], ["trigger", 572], ["neuronal", 580], ["loss", 589], [".", 593], ["In", 595], ["idiopathic", 598], ["PD", 609], [",", 611], ["other", 613], ["factors", 619], ["may", 627], ["be", 631], ["responsible", 634], ["for", 646], ["accelerating", 650], ["protofibril", 663], ["formation", 675], ["by", 685], ["wild", 688], ["-", 692], ["type", 693], ["alpha", 698], ["-", 703], ["synuclein", 704], [".", 713], ["One", 715], ["possible", 719], ["factor", 728], ["could", 735], ["be", 741], ["molecular", 744], ["crowding", 754], ["in", 763], ["the", 766], ["neuronal", 770], ["cytoplasm", 779], [".", 788], ["We", 790], ["demonstrate", 793], ["here", 805], ["that", 810], ["crowding", 815], ["using", 824], ["inert", 830], ["polymers", 836], ["significantly", 845], ["reduced", 859], ["the", 867], ["lag", 871], ["time", 875], ["for", 880], ["protofibril", 884], ["formation", 896], ["and", 906], ["the", 910], ["conversion", 914], ["of", 925], ["the", 928], ["protofibril", 932], ["to", 944], ["the", 947], ["fibril", 951], [",", 957], ["but", 959], ["did", 963], ["not", 967], ["affect", 971], ["the", 978], ["morphology", 982], ["of", 993], ["either", 996], ["species", 1003], [".", 1010], ["Physiologically", 1012], ["realistic", 1028], ["changes", 1038], ["in", 1046], ["the", 1049], ["degree", 1053], ["of", 1060], ["in", 1063], ["vitro", 1066], ["crowding", 1072], ["have", 1081], ["significant", 1086], ["kinetic", 1098], ["consequences", 1106], [".", 1118], ["Thus", 1120], [",", 1124], ["nonspecific", 1126], ["changes", 1138], ["in", 1146], ["the", 1149], ["total", 1153], ["cytoplasmic", 1159], ["protein", 1171], ["concentration", 1179], [",", 1192], ["induced", 1194], ["by", 1202], ["cell", 1205], ["volume", 1210], ["changes", 1217], ["and/or", 1225], ["altered", 1232], ["protein", 1240], ["degradation", 1248], [",", 1259], ["could", 1261], ["promote", 1267], ["formation", 1275], ["of", 1285], ["and", 1288], ["stabilize", 1292], ["the", 1302], ["alpha", 1306], ["-", 1311], ["synuclein", 1312], ["protofibril", 1322], [".", 1333]]}
{"context": "Turner syndrome is a genetic disorder caused by the complete or partial absence of an X chromosome in affected women. Individuals with TS show characteristic difficulties with executive functions, visual-spatial and mathematical cognition, with relatively intact verbal skills, and congruent abnormalities in structural development of the posterior parietal cortex (PPC). The functionally heterogeneous PPC has recently been investigated using connectivity-based clustering methods, which sub-divide a given region into clusters of voxels showing similar structural or functional connectivity to other brain regions. In the present study, we extended this method to compare connectivity-based clustering between groups and investigate whether functional networks differentially recruit the PPC in TS. To this end, we parcellated the PPC into sub-regions based on temporal correlations with other regions of the brain. fMRI data were collected from 15 girls with TS and 14 typically developing (TD) girls, aged 7-14, while they performed a visual-spatial task. Temporal correlations between voxels in the PPC and a set of seed regions were calculated, and the PPC divided into clusters of voxels showing similar connectivity. It was found that in general the PPC parcellates similarly in TS and TD girls, but that regions in bilateral inferior parietal lobules, and posterior right superior parietal lobule, were reliably recruited by different networks in TS relative to TD participants. These regions showed weaker correlation in TS with a set of regions involved in visual processing. These results suggest that abnormal development of visuospatial functional networks in TS may relate to the well documented cognitive difficulties in this disorder.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "9aae75f96acc4b5ba4f5bc32a39f1e8f", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[15, 15]], "char_spans": [[86, 86]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["genetic", 21], ["disorder", 29], ["caused", 38], ["by", 45], ["the", 48], ["complete", 52], ["or", 61], ["partial", 64], ["absence", 72], ["of", 80], ["an", 83], ["X", 86], ["chromosome", 88], ["in", 99], ["affected", 102], ["women", 111], [".", 116], ["Individuals", 118], ["with", 130], ["TS", 135], ["show", 138], ["characteristic", 143], ["difficulties", 158], ["with", 171], ["executive", 176], ["functions", 186], [",", 195], ["visual", 197], ["-", 203], ["spatial", 204], ["and", 212], ["mathematical", 216], ["cognition", 229], [",", 238], ["with", 240], ["relatively", 245], ["intact", 256], ["verbal", 263], ["skills", 270], [",", 276], ["and", 278], ["congruent", 282], ["abnormalities", 292], ["in", 306], ["structural", 309], ["development", 320], ["of", 332], ["the", 335], ["posterior", 339], ["parietal", 349], ["cortex", 358], ["(", 365], ["PPC", 366], [")", 369], [".", 370], ["The", 372], ["functionally", 376], ["heterogeneous", 389], ["PPC", 403], ["has", 407], ["recently", 411], ["been", 420], ["investigated", 425], ["using", 438], ["connectivity", 444], ["-", 456], ["based", 457], ["clustering", 463], ["methods", 474], [",", 481], ["which", 483], ["sub", 489], ["-", 492], ["divide", 493], ["a", 500], ["given", 502], ["region", 508], ["into", 515], ["clusters", 520], ["of", 529], ["voxels", 532], ["showing", 539], ["similar", 547], ["structural", 555], ["or", 566], ["functional", 569], ["connectivity", 580], ["to", 593], ["other", 596], ["brain", 602], ["regions", 608], [".", 615], ["In", 617], ["the", 620], ["present", 624], ["study", 632], [",", 637], ["we", 639], ["extended", 642], ["this", 651], ["method", 656], ["to", 663], ["compare", 666], ["connectivity", 674], ["-", 686], ["based", 687], ["clustering", 693], ["between", 704], ["groups", 712], ["and", 719], ["investigate", 723], ["whether", 735], ["functional", 743], ["networks", 754], ["differentially", 763], ["recruit", 778], ["the", 786], ["PPC", 790], ["in", 794], ["TS", 797], [".", 799], ["To", 801], ["this", 804], ["end", 809], [",", 812], ["we", 814], ["parcellated", 817], ["the", 829], ["PPC", 833], ["into", 837], ["sub", 842], ["-", 845], ["regions", 846], ["based", 854], ["on", 860], ["temporal", 863], ["correlations", 872], ["with", 885], ["other", 890], ["regions", 896], ["of", 904], ["the", 907], ["brain", 911], [".", 916], ["fMRI", 918], ["data", 923], ["were", 928], ["collected", 933], ["from", 943], ["15", 948], ["girls", 951], ["with", 957], ["TS", 962], ["and", 965], ["14", 969], ["typically", 972], ["developing", 982], ["(", 993], ["TD", 994], [")", 996], ["girls", 998], [",", 1003], ["aged", 1005], ["7", 1010], ["-", 1011], ["14", 1012], [",", 1014], ["while", 1016], ["they", 1022], ["performed", 1027], ["a", 1037], ["visual", 1039], ["-", 1045], ["spatial", 1046], ["task", 1054], [".", 1058], ["Temporal", 1060], ["correlations", 1069], ["between", 1082], ["voxels", 1090], ["in", 1097], ["the", 1100], ["PPC", 1104], ["and", 1108], ["a", 1112], ["set", 1114], ["of", 1118], ["seed", 1121], ["regions", 1126], ["were", 1134], ["calculated", 1139], [",", 1149], ["and", 1151], ["the", 1155], ["PPC", 1159], ["divided", 1163], ["into", 1171], ["clusters", 1176], ["of", 1185], ["voxels", 1188], ["showing", 1195], ["similar", 1203], ["connectivity", 1211], [".", 1223], ["It", 1225], ["was", 1228], ["found", 1232], ["that", 1238], ["in", 1243], ["general", 1246], ["the", 1254], ["PPC", 1258], ["parcellates", 1262], ["similarly", 1274], ["in", 1284], ["TS", 1287], ["and", 1290], ["TD", 1294], ["girls", 1297], [",", 1302], ["but", 1304], ["that", 1308], ["regions", 1313], ["in", 1321], ["bilateral", 1324], ["inferior", 1334], ["parietal", 1343], ["lobules", 1352], [",", 1359], ["and", 1361], ["posterior", 1365], ["right", 1375], ["superior", 1381], ["parietal", 1390], ["lobule", 1399], [",", 1405], ["were", 1407], ["reliably", 1412], ["recruited", 1421], ["by", 1431], ["different", 1434], ["networks", 1444], ["in", 1453], ["TS", 1456], ["relative", 1459], ["to", 1468], ["TD", 1471], ["participants", 1474], [".", 1486], ["These", 1488], ["regions", 1494], ["showed", 1502], ["weaker", 1509], ["correlation", 1516], ["in", 1528], ["TS", 1531], ["with", 1534], ["a", 1539], ["set", 1541], ["of", 1545], ["regions", 1548], ["involved", 1556], ["in", 1565], ["visual", 1568], ["processing", 1575], [".", 1585], ["These", 1587], ["results", 1593], ["suggest", 1601], ["that", 1609], ["abnormal", 1614], ["development", 1623], ["of", 1635], ["visuospatial", 1638], ["functional", 1651], ["networks", 1662], ["in", 1671], ["TS", 1674], ["may", 1677], ["relate", 1681], ["to", 1688], ["the", 1691], ["well", 1695], ["documented", 1700], ["cognitive", 1711], ["difficulties", 1721], ["in", 1734], ["this", 1737], ["disorder", 1742], [".", 1750]]}
{"context": "Muenke syndrome, defined by heterozygosity for a Pro250Arg substitution in fibroblast growth factor receptor 3 (FGFR3), is the most common genetic cause of craniosynostosis in humans. We have used gene targeting to introduce the Muenke syndrome mutation (equivalent to P244R) into the murine Fgfr3 gene. A rounded skull and shortened snout (often skewed) with dental malocclusion was observed in a minority of heterozygotes and many homozygotes. Development of this incompletely penetrant skull phenotype was dependent on genetic background and sex, with males more often affected. However, these cranial abnormalities were rarely attributable to craniosynostosis, which was only present in 2/364 mutants; more commonly, we found fusion of the premaxillary and/or zygomatic sutures. We also found decreased cortical thickness and bone mineral densities in long bones. We conclude that although both cranial and long bone development is variably affected by the murine Fgfr3(P244R) mutation, coronal craniosynostosis is not reliably reproduced.", "qas": [{"question": "Which gene is associated with Muenke syndrome?", "answers": ["Fibroblast Growth Factor Receptor 3 (FGFR3)"], "qid": "0e24607baaa74369a7171110551ca197", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["Muenke", 30], ["syndrome", 37], ["?", 45]], "detected_answers": [{"text": "Fibroblast Growth Factor Receptor 3 (FGFR3)", "token_spans": [[11, 17]], "char_spans": [[75, 116]]}]}], "context_tokens": [["Muenke", 0], ["syndrome", 7], [",", 15], ["defined", 17], ["by", 25], ["heterozygosity", 28], ["for", 43], ["a", 47], ["Pro250Arg", 49], ["substitution", 59], ["in", 72], ["fibroblast", 75], ["growth", 86], ["factor", 93], ["receptor", 100], ["3", 109], ["(", 111], ["FGFR3", 112], [")", 117], [",", 118], ["is", 120], ["the", 123], ["most", 127], ["common", 132], ["genetic", 139], ["cause", 147], ["of", 153], ["craniosynostosis", 156], ["in", 173], ["humans", 176], [".", 182], ["We", 184], ["have", 187], ["used", 192], ["gene", 197], ["targeting", 202], ["to", 212], ["introduce", 215], ["the", 225], ["Muenke", 229], ["syndrome", 236], ["mutation", 245], ["(", 254], ["equivalent", 255], ["to", 266], ["P244R", 269], [")", 274], ["into", 276], ["the", 281], ["murine", 285], ["Fgfr3", 292], ["gene", 298], [".", 302], ["A", 304], ["rounded", 306], ["skull", 314], ["and", 320], ["shortened", 324], ["snout", 334], ["(", 340], ["often", 341], ["skewed", 347], [")", 353], ["with", 355], ["dental", 360], ["malocclusion", 367], ["was", 380], ["observed", 384], ["in", 393], ["a", 396], ["minority", 398], ["of", 407], ["heterozygotes", 410], ["and", 424], ["many", 428], ["homozygotes", 433], [".", 444], ["Development", 446], ["of", 458], ["this", 461], ["incompletely", 466], ["penetrant", 479], ["skull", 489], ["phenotype", 495], ["was", 505], ["dependent", 509], ["on", 519], ["genetic", 522], ["background", 530], ["and", 541], ["sex", 545], [",", 548], ["with", 550], ["males", 555], ["more", 561], ["often", 566], ["affected", 572], [".", 580], ["However", 582], [",", 589], ["these", 591], ["cranial", 597], ["abnormalities", 605], ["were", 619], ["rarely", 624], ["attributable", 631], ["to", 644], ["craniosynostosis", 647], [",", 663], ["which", 665], ["was", 671], ["only", 675], ["present", 680], ["in", 688], ["2/364", 691], ["mutants", 697], [";", 704], ["more", 706], ["commonly", 711], [",", 719], ["we", 721], ["found", 724], ["fusion", 730], ["of", 737], ["the", 740], ["premaxillary", 744], ["and/or", 757], ["zygomatic", 764], ["sutures", 774], [".", 781], ["We", 783], ["also", 786], ["found", 791], ["decreased", 797], ["cortical", 807], ["thickness", 816], ["and", 826], ["bone", 830], ["mineral", 835], ["densities", 843], ["in", 853], ["long", 856], ["bones", 861], [".", 866], ["We", 868], ["conclude", 871], ["that", 880], ["although", 885], ["both", 894], ["cranial", 899], ["and", 907], ["long", 911], ["bone", 916], ["development", 921], ["is", 933], ["variably", 936], ["affected", 945], ["by", 954], ["the", 957], ["murine", 961], ["Fgfr3(P244R", 968], [")", 979], ["mutation", 981], [",", 989], ["coronal", 991], ["craniosynostosis", 999], ["is", 1016], ["not", 1019], ["reliably", 1023], ["reproduced", 1032], [".", 1042]]}
{"context": "Oxidatively damaged proteins accumulate with age in almost all cell types and tissues. The activity of chaperone-mediated autophagy (CMA), a selective pathway for the degradation of cytosolic proteins in lysosomes, decreases with age. We have analyzed the possible participation of CMA in the removal of oxidized proteins in rat liver and cultured mouse fibroblasts. Added to the fact that CMA substrates, when oxidized, are more efficiently internalized into lysosomes, we have found a constitutive activation of CMA during oxidative stress. Oxidation-induced activation of CMA correlates with higher levels of several components of the lysosomal translocation complex, but in particular of the lumenal chaperone, required for substrate uptake, and of the lysosomal membrane protein (lamp) type 2a, previously identified as a receptor for this pathway. In contrast with the well characterized mechanism of CMA activation during nutritional stress, which does not require de novo synthesis of the receptor, oxidation-induced activation of CMA is attained through transcriptional up-regulation of lamp2a. We conclude that CMA is activated during oxidative stress and that the higher activity of this pathway under these conditions, along with the higher susceptibility of the oxidized proteins to be taken up by lysosomes, both contribute to the efficient removal of oxidized proteins.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "231d54cde09548338f239c48ff1fd357", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[185, 185]], "char_spans": [[1096, 1101]]}]}], "context_tokens": [["Oxidatively", 0], ["damaged", 12], ["proteins", 20], ["accumulate", 29], ["with", 40], ["age", 45], ["in", 49], ["almost", 52], ["all", 59], ["cell", 63], ["types", 68], ["and", 74], ["tissues", 78], [".", 85], ["The", 87], ["activity", 91], ["of", 100], ["chaperone", 103], ["-", 112], ["mediated", 113], ["autophagy", 122], ["(", 132], ["CMA", 133], [")", 136], [",", 137], ["a", 139], ["selective", 141], ["pathway", 151], ["for", 159], ["the", 163], ["degradation", 167], ["of", 179], ["cytosolic", 182], ["proteins", 192], ["in", 201], ["lysosomes", 204], [",", 213], ["decreases", 215], ["with", 225], ["age", 230], [".", 233], ["We", 235], ["have", 238], ["analyzed", 243], ["the", 252], ["possible", 256], ["participation", 265], ["of", 279], ["CMA", 282], ["in", 286], ["the", 289], ["removal", 293], ["of", 301], ["oxidized", 304], ["proteins", 313], ["in", 322], ["rat", 325], ["liver", 329], ["and", 335], ["cultured", 339], ["mouse", 348], ["fibroblasts", 354], [".", 365], ["Added", 367], ["to", 373], ["the", 376], ["fact", 380], ["that", 385], ["CMA", 390], ["substrates", 394], [",", 404], ["when", 406], ["oxidized", 411], [",", 419], ["are", 421], ["more", 425], ["efficiently", 430], ["internalized", 442], ["into", 455], ["lysosomes", 460], [",", 469], ["we", 471], ["have", 474], ["found", 479], ["a", 485], ["constitutive", 487], ["activation", 500], ["of", 511], ["CMA", 514], ["during", 518], ["oxidative", 525], ["stress", 535], [".", 541], ["Oxidation", 543], ["-", 552], ["induced", 553], ["activation", 561], ["of", 572], ["CMA", 575], ["correlates", 579], ["with", 590], ["higher", 595], ["levels", 602], ["of", 609], ["several", 612], ["components", 620], ["of", 631], ["the", 634], ["lysosomal", 638], ["translocation", 648], ["complex", 662], [",", 669], ["but", 671], ["in", 675], ["particular", 678], ["of", 689], ["the", 692], ["lumenal", 696], ["chaperone", 704], [",", 713], ["required", 715], ["for", 724], ["substrate", 728], ["uptake", 738], [",", 744], ["and", 746], ["of", 750], ["the", 753], ["lysosomal", 757], ["membrane", 767], ["protein", 776], ["(", 784], ["lamp", 785], [")", 789], ["type", 791], ["2a", 796], [",", 798], ["previously", 800], ["identified", 811], ["as", 822], ["a", 825], ["receptor", 827], ["for", 836], ["this", 840], ["pathway", 845], [".", 852], ["In", 854], ["contrast", 857], ["with", 866], ["the", 871], ["well", 875], ["characterized", 880], ["mechanism", 894], ["of", 904], ["CMA", 907], ["activation", 911], ["during", 922], ["nutritional", 929], ["stress", 941], [",", 947], ["which", 949], ["does", 955], ["not", 960], ["require", 964], ["de", 972], ["novo", 975], ["synthesis", 980], ["of", 990], ["the", 993], ["receptor", 997], [",", 1005], ["oxidation", 1007], ["-", 1016], ["induced", 1017], ["activation", 1025], ["of", 1036], ["CMA", 1039], ["is", 1043], ["attained", 1046], ["through", 1055], ["transcriptional", 1063], ["up", 1079], ["-", 1081], ["regulation", 1082], ["of", 1093], ["lamp2a", 1096], [".", 1102], ["We", 1104], ["conclude", 1107], ["that", 1116], ["CMA", 1121], ["is", 1125], ["activated", 1128], ["during", 1138], ["oxidative", 1145], ["stress", 1155], ["and", 1162], ["that", 1166], ["the", 1171], ["higher", 1175], ["activity", 1182], ["of", 1191], ["this", 1194], ["pathway", 1199], ["under", 1207], ["these", 1213], ["conditions", 1219], [",", 1229], ["along", 1231], ["with", 1237], ["the", 1242], ["higher", 1246], ["susceptibility", 1253], ["of", 1268], ["the", 1271], ["oxidized", 1275], ["proteins", 1284], ["to", 1293], ["be", 1296], ["taken", 1299], ["up", 1305], ["by", 1308], ["lysosomes", 1311], [",", 1320], ["both", 1322], ["contribute", 1327], ["to", 1338], ["the", 1341], ["efficient", 1345], ["removal", 1355], ["of", 1363], ["oxidized", 1366], ["proteins", 1375], [".", 1383]]}
{"context": "A case of mosaic Turner's syndrome with a 45,X/46,XX/47,XXX karyotype, who was also a fragile X obligate carrier as the mother of an affected boy, was identified by molecular diagnosis. Complete haplotyping and direct DNA analysis showed that the X chromosome in all metaphases was the normal X. At the age of 57, she is mentally normal. Her external appearance was typical of Turner's syndrome. This report shows that molecular studies in conjunction with cytogenetic analysis can help in the clinical diagnosis of a rare case and can show the uniqueness of a case such as the one here described.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "1fea59437aaa4c8d9584b01338bcf0c7", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[51, 51], [17, 17], [43, 43]], "char_spans": [[293, 294], [94, 94], [247, 247]]}]}], "context_tokens": [["A", 0], ["case", 2], ["of", 7], ["mosaic", 10], ["Turner", 17], ["'s", 23], ["syndrome", 26], ["with", 35], ["a", 40], ["45,X/46,XX/47,XXX", 42], ["karyotype", 60], [",", 69], ["who", 71], ["was", 75], ["also", 79], ["a", 84], ["fragile", 86], ["X", 94], ["obligate", 96], ["carrier", 105], ["as", 113], ["the", 116], ["mother", 120], ["of", 127], ["an", 130], ["affected", 133], ["boy", 142], [",", 145], ["was", 147], ["identified", 151], ["by", 162], ["molecular", 165], ["diagnosis", 175], [".", 184], ["Complete", 186], ["haplotyping", 195], ["and", 207], ["direct", 211], ["DNA", 218], ["analysis", 222], ["showed", 231], ["that", 238], ["the", 243], ["X", 247], ["chromosome", 249], ["in", 260], ["all", 263], ["metaphases", 267], ["was", 278], ["the", 282], ["normal", 286], ["X.", 293], ["At", 296], ["the", 299], ["age", 303], ["of", 307], ["57", 310], [",", 312], ["she", 314], ["is", 318], ["mentally", 321], ["normal", 330], [".", 336], ["Her", 338], ["external", 342], ["appearance", 351], ["was", 362], ["typical", 366], ["of", 374], ["Turner", 377], ["'s", 383], ["syndrome", 386], [".", 394], ["This", 396], ["report", 401], ["shows", 408], ["that", 414], ["molecular", 419], ["studies", 429], ["in", 437], ["conjunction", 440], ["with", 452], ["cytogenetic", 457], ["analysis", 469], ["can", 478], ["help", 482], ["in", 487], ["the", 490], ["clinical", 494], ["diagnosis", 503], ["of", 513], ["a", 516], ["rare", 518], ["case", 523], ["and", 528], ["can", 532], ["show", 536], ["the", 541], ["uniqueness", 545], ["of", 556], ["a", 559], ["case", 561], ["such", 566], ["as", 571], ["the", 574], ["one", 578], ["here", 582], ["described", 587], [".", 596]]}
{"context": "Recently, deletions encompassing the nuclear receptor binding SET-Domain 1 (NSD1) gene have been described as the major cause of Japanese patients with the Sotos syndrome, whereas point mutations have been identified in the majority of European Sotos syndrome patients. In order to investigate a possible phenotype-genotype correlation and to further define the predictive value of NSD1 mutations, we performed mutational analysis of the NSD1 gene in 20 patients and one familial case with Sotos syndrome, five patients with Weaver syndrome, six patients with unclassified overgrowth/mental retardation, and six patients with macrocephaly/mental retardation. We were able to identify mutations within the NSD1 gene in 18 patients and the familial case with Sotos syndrome (90%). The mutations (six nonsense, eight frame shifts, three splice site, one missense, one in-frame deletion) are expected to result in an impairment of NSD1 function. The best correlation between clinical assessment and molecular results was obtained for the Sotos facial gestalt in conjunction with overgrowth, macrocephaly, and developmental delay. In contrast to the high mutation detection rate in Sotos syndrome, none of the patients with Weaver syndrome, unclassified overgrowth/mental retardation and macrocephaly/mental retardation, harbored NSD1 mutations. We tested for large deletions by FISH analysis but were not able to identify any deletion cases. The results indicate that the great majority of patients with Sotos syndrome are caused by mutations in NSD1. Deletions covering the NSD1 locus were not found in the patients analyzed here.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "c0eee31746d343f19dcd03ff0c8496b2", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[73, 74], [13, 15], [118, 119]], "char_spans": [[438, 446], [76, 85], [705, 713]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["deletions", 10], ["encompassing", 20], ["the", 33], ["nuclear", 37], ["receptor", 45], ["binding", 54], ["SET", 62], ["-", 65], ["Domain", 66], ["1", 73], ["(", 75], ["NSD1", 76], [")", 80], ["gene", 82], ["have", 87], ["been", 92], ["described", 97], ["as", 107], ["the", 110], ["major", 114], ["cause", 120], ["of", 126], ["Japanese", 129], ["patients", 138], ["with", 147], ["the", 152], ["Sotos", 156], ["syndrome", 162], [",", 170], ["whereas", 172], ["point", 180], ["mutations", 186], ["have", 196], ["been", 201], ["identified", 206], ["in", 217], ["the", 220], ["majority", 224], ["of", 233], ["European", 236], ["Sotos", 245], ["syndrome", 251], ["patients", 260], [".", 268], ["In", 270], ["order", 273], ["to", 279], ["investigate", 282], ["a", 294], ["possible", 296], ["phenotype", 305], ["-", 314], ["genotype", 315], ["correlation", 324], ["and", 336], ["to", 340], ["further", 343], ["define", 351], ["the", 358], ["predictive", 362], ["value", 373], ["of", 379], ["NSD1", 382], ["mutations", 387], [",", 396], ["we", 398], ["performed", 401], ["mutational", 411], ["analysis", 422], ["of", 431], ["the", 434], ["NSD1", 438], ["gene", 443], ["in", 448], ["20", 451], ["patients", 454], ["and", 463], ["one", 467], ["familial", 471], ["case", 480], ["with", 485], ["Sotos", 490], ["syndrome", 496], [",", 504], ["five", 506], ["patients", 511], ["with", 520], ["Weaver", 525], ["syndrome", 532], [",", 540], ["six", 542], ["patients", 546], ["with", 555], ["unclassified", 560], ["overgrowth", 573], ["/", 583], ["mental", 584], ["retardation", 591], [",", 602], ["and", 604], ["six", 608], ["patients", 612], ["with", 621], ["macrocephaly", 626], ["/", 638], ["mental", 639], ["retardation", 646], [".", 657], ["We", 659], ["were", 662], ["able", 667], ["to", 672], ["identify", 675], ["mutations", 684], ["within", 694], ["the", 701], ["NSD1", 705], ["gene", 710], ["in", 715], ["18", 718], ["patients", 721], ["and", 730], ["the", 734], ["familial", 738], ["case", 747], ["with", 752], ["Sotos", 757], ["syndrome", 763], ["(", 772], ["90", 773], ["%", 775], [")", 776], [".", 777], ["The", 779], ["mutations", 783], ["(", 793], ["six", 794], ["nonsense", 798], [",", 806], ["eight", 808], ["frame", 814], ["shifts", 820], [",", 826], ["three", 828], ["splice", 834], ["site", 841], [",", 845], ["one", 847], ["missense", 851], [",", 859], ["one", 861], ["in", 865], ["-", 867], ["frame", 868], ["deletion", 874], [")", 882], ["are", 884], ["expected", 888], ["to", 897], ["result", 900], ["in", 907], ["an", 910], ["impairment", 913], ["of", 924], ["NSD1", 927], ["function", 932], [".", 940], ["The", 942], ["best", 946], ["correlation", 951], ["between", 963], ["clinical", 971], ["assessment", 980], ["and", 991], ["molecular", 995], ["results", 1005], ["was", 1013], ["obtained", 1017], ["for", 1026], ["the", 1030], ["Sotos", 1034], ["facial", 1040], ["gestalt", 1047], ["in", 1055], ["conjunction", 1058], ["with", 1070], ["overgrowth", 1075], [",", 1085], ["macrocephaly", 1087], [",", 1099], ["and", 1101], ["developmental", 1105], ["delay", 1119], [".", 1124], ["In", 1126], ["contrast", 1129], ["to", 1138], ["the", 1141], ["high", 1145], ["mutation", 1150], ["detection", 1159], ["rate", 1169], ["in", 1174], ["Sotos", 1177], ["syndrome", 1183], [",", 1191], ["none", 1193], ["of", 1198], ["the", 1201], ["patients", 1205], ["with", 1214], ["Weaver", 1219], ["syndrome", 1226], [",", 1234], ["unclassified", 1236], ["overgrowth", 1249], ["/", 1259], ["mental", 1260], ["retardation", 1267], ["and", 1279], ["macrocephaly", 1283], ["/", 1295], ["mental", 1296], ["retardation", 1303], [",", 1314], ["harbored", 1316], ["NSD1", 1325], ["mutations", 1330], [".", 1339], ["We", 1341], ["tested", 1344], ["for", 1351], ["large", 1355], ["deletions", 1361], ["by", 1371], ["FISH", 1374], ["analysis", 1379], ["but", 1388], ["were", 1392], ["not", 1397], ["able", 1401], ["to", 1406], ["identify", 1409], ["any", 1418], ["deletion", 1422], ["cases", 1431], [".", 1436], ["The", 1438], ["results", 1442], ["indicate", 1450], ["that", 1459], ["the", 1464], ["great", 1468], ["majority", 1474], ["of", 1483], ["patients", 1486], ["with", 1495], ["Sotos", 1500], ["syndrome", 1506], ["are", 1515], ["caused", 1519], ["by", 1526], ["mutations", 1529], ["in", 1539], ["NSD1", 1542], [".", 1546], ["Deletions", 1548], ["covering", 1558], ["the", 1567], ["NSD1", 1571], ["locus", 1576], ["were", 1582], ["not", 1587], ["found", 1591], ["in", 1597], ["the", 1600], ["patients", 1604], ["analyzed", 1613], ["here", 1622], [".", 1626]]}
{"context": "Imatinib mesylate (STI571, Glivec, Gleevec) is a powerful inhibitor of the tyrosine kinase activity of Bcr-Abl, the oncoprotein responsible for chronic myeloid leukemia (CML). The drug shows great efficacy in chronic phase, but is less effective in maintaining hematologic remissions in blast crisis patients. Our group has previously described several cell lines made resistant to imatinib. We now examine the question of cross-resistance to other chemotherapeutic drugs used in CML. Four paired imatinib-sensitive/resistant CML cell lines were assessed by caspase-3 and MTS assays for their proliferative response to cytosine arabinoside (Ara-C), daunorubicin (DNR), homoharringtonine (HHT) and hydroxyurea (HU), either alone or in combination with imatinib. Primary blasts from advanced-stage CML patients refractory to imatinib therapy were studied by semi-solid media clonogenic assays. We found that these drugs are generally capable of major inhibition of proliferation of the CML cell lines, although differential responses to DNR and HHT were noted between some sensitive and resistant cell line pairs, implying that resistance to imatinib may confer a growth advantage under such conditions. The four drugs were also effective in preventing the formation of progenitor cell colonies from CML patients both before treatment with imatinib, and after relapse on the drug. Isobolographic analysis implied that these drugs will generally combine well with imatinib, and in some cases will be synergistic. We conclude that Ara-C, DNR or HHT, either alone or in combination with imatinib, are likely to be the best therapeutic alternatives in the management of patients who become resistant to imatinib monotherapy.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "29e2e1a616a44ac1921297ac7f7c34c6", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[19, 21]], "char_spans": [[103, 109]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["STI571", 19], [",", 25], ["Glivec", 27], [",", 33], ["Gleevec", 35], [")", 42], ["is", 44], ["a", 47], ["powerful", 49], ["inhibitor", 58], ["of", 68], ["the", 71], ["tyrosine", 75], ["kinase", 84], ["activity", 91], ["of", 100], ["Bcr", 103], ["-", 106], ["Abl", 107], [",", 110], ["the", 112], ["oncoprotein", 116], ["responsible", 128], ["for", 140], ["chronic", 144], ["myeloid", 152], ["leukemia", 160], ["(", 169], ["CML", 170], [")", 173], [".", 174], ["The", 176], ["drug", 180], ["shows", 185], ["great", 191], ["efficacy", 197], ["in", 206], ["chronic", 209], ["phase", 217], [",", 222], ["but", 224], ["is", 228], ["less", 231], ["effective", 236], ["in", 246], ["maintaining", 249], ["hematologic", 261], ["remissions", 273], ["in", 284], ["blast", 287], ["crisis", 293], ["patients", 300], [".", 308], ["Our", 310], ["group", 314], ["has", 320], ["previously", 324], ["described", 335], ["several", 345], ["cell", 353], ["lines", 358], ["made", 364], ["resistant", 369], ["to", 379], ["imatinib", 382], [".", 390], ["We", 392], ["now", 395], ["examine", 399], ["the", 407], ["question", 411], ["of", 420], ["cross", 423], ["-", 428], ["resistance", 429], ["to", 440], ["other", 443], ["chemotherapeutic", 449], ["drugs", 466], ["used", 472], ["in", 477], ["CML", 480], [".", 483], ["Four", 485], ["paired", 490], ["imatinib", 497], ["-", 505], ["sensitive", 506], ["/", 515], ["resistant", 516], ["CML", 526], ["cell", 530], ["lines", 535], ["were", 541], ["assessed", 546], ["by", 555], ["caspase-3", 558], ["and", 568], ["MTS", 572], ["assays", 576], ["for", 583], ["their", 587], ["proliferative", 593], ["response", 607], ["to", 616], ["cytosine", 619], ["arabinoside", 628], ["(", 640], ["Ara", 641], ["-", 644], ["C", 645], [")", 646], [",", 647], ["daunorubicin", 649], ["(", 662], ["DNR", 663], [")", 666], [",", 667], ["homoharringtonine", 669], ["(", 687], ["HHT", 688], [")", 691], ["and", 693], ["hydroxyurea", 697], ["(", 709], ["HU", 710], [")", 712], [",", 713], ["either", 715], ["alone", 722], ["or", 728], ["in", 731], ["combination", 734], ["with", 746], ["imatinib", 751], [".", 759], ["Primary", 761], ["blasts", 769], ["from", 776], ["advanced", 781], ["-", 789], ["stage", 790], ["CML", 796], ["patients", 800], ["refractory", 809], ["to", 820], ["imatinib", 823], ["therapy", 832], ["were", 840], ["studied", 845], ["by", 853], ["semi", 856], ["-", 860], ["solid", 861], ["media", 867], ["clonogenic", 873], ["assays", 884], [".", 890], ["We", 892], ["found", 895], ["that", 901], ["these", 906], ["drugs", 912], ["are", 918], ["generally", 922], ["capable", 932], ["of", 940], ["major", 943], ["inhibition", 949], ["of", 960], ["proliferation", 963], ["of", 977], ["the", 980], ["CML", 984], ["cell", 988], ["lines", 993], [",", 998], ["although", 1000], ["differential", 1009], ["responses", 1022], ["to", 1032], ["DNR", 1035], ["and", 1039], ["HHT", 1043], ["were", 1047], ["noted", 1052], ["between", 1058], ["some", 1066], ["sensitive", 1071], ["and", 1081], ["resistant", 1085], ["cell", 1095], ["line", 1100], ["pairs", 1105], [",", 1110], ["implying", 1112], ["that", 1121], ["resistance", 1126], ["to", 1137], ["imatinib", 1140], ["may", 1149], ["confer", 1153], ["a", 1160], ["growth", 1162], ["advantage", 1169], ["under", 1179], ["such", 1185], ["conditions", 1190], [".", 1200], ["The", 1202], ["four", 1206], ["drugs", 1211], ["were", 1217], ["also", 1222], ["effective", 1227], ["in", 1237], ["preventing", 1240], ["the", 1251], ["formation", 1255], ["of", 1265], ["progenitor", 1268], ["cell", 1279], ["colonies", 1284], ["from", 1293], ["CML", 1298], ["patients", 1302], ["both", 1311], ["before", 1316], ["treatment", 1323], ["with", 1333], ["imatinib", 1338], [",", 1346], ["and", 1348], ["after", 1352], ["relapse", 1358], ["on", 1366], ["the", 1369], ["drug", 1373], [".", 1377], ["Isobolographic", 1379], ["analysis", 1394], ["implied", 1403], ["that", 1411], ["these", 1416], ["drugs", 1422], ["will", 1428], ["generally", 1433], ["combine", 1443], ["well", 1451], ["with", 1456], ["imatinib", 1461], [",", 1469], ["and", 1471], ["in", 1475], ["some", 1478], ["cases", 1483], ["will", 1489], ["be", 1494], ["synergistic", 1497], [".", 1508], ["We", 1510], ["conclude", 1513], ["that", 1522], ["Ara", 1527], ["-", 1530], ["C", 1531], [",", 1532], ["DNR", 1534], ["or", 1538], ["HHT", 1541], [",", 1544], ["either", 1546], ["alone", 1553], ["or", 1559], ["in", 1562], ["combination", 1565], ["with", 1577], ["imatinib", 1582], [",", 1590], ["are", 1592], ["likely", 1596], ["to", 1603], ["be", 1606], ["the", 1609], ["best", 1613], ["therapeutic", 1618], ["alternatives", 1630], ["in", 1643], ["the", 1646], ["management", 1650], ["of", 1661], ["patients", 1664], ["who", 1673], ["become", 1677], ["resistant", 1684], ["to", 1694], ["imatinib", 1697], ["monotherapy", 1706], [".", 1717]]}
{"context": "The rash in infectious mononucleosis is usually diffusely macular. A 15-year-old boy presented to us with high grade fever, sore throat, malaise, body aches, and polyarthralgia. He developed annular, erythematous, and non-scaly eruptions on chest and right arm. Blanching erythema was noted on his trunk. He had bilateral tender cervical lymph nodes, severe pharyngeal congestion, petechiae on soft palate, uvular edema, infraorbital edema, and marginal tender hepatomegaly. Investigations revealed lymphocytosis and activated atypical lymphocytes in the peripheral smear, and positive monospot test. The boy subsequently recovered in one week with total disappearance of his rash. Epstein-Barr virus-related infectious mononucleosis was considered the most likely diagnosis for our patient. To our knowledge, this atypical case is the third reported case of annular lesions in infectious mononucleosis. Dermatologists and other clinicians should be alerted to this special presentation of primary EBV infection.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "2fa6c155febe4bc2bb8a93675adab78c", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[118, 121]], "char_spans": [[682, 699]]}]}], "context_tokens": [["The", 0], ["rash", 4], ["in", 9], ["infectious", 12], ["mononucleosis", 23], ["is", 37], ["usually", 40], ["diffusely", 48], ["macular", 58], [".", 65], ["A", 67], ["15-year", 69], ["-", 76], ["old", 77], ["boy", 81], ["presented", 85], ["to", 95], ["us", 98], ["with", 101], ["high", 106], ["grade", 111], ["fever", 117], [",", 122], ["sore", 124], ["throat", 129], [",", 135], ["malaise", 137], [",", 144], ["body", 146], ["aches", 151], [",", 156], ["and", 158], ["polyarthralgia", 162], [".", 176], ["He", 178], ["developed", 181], ["annular", 191], [",", 198], ["erythematous", 200], [",", 212], ["and", 214], ["non", 218], ["-", 221], ["scaly", 222], ["eruptions", 228], ["on", 238], ["chest", 241], ["and", 247], ["right", 251], ["arm", 257], [".", 260], ["Blanching", 262], ["erythema", 272], ["was", 281], ["noted", 285], ["on", 291], ["his", 294], ["trunk", 298], [".", 303], ["He", 305], ["had", 308], ["bilateral", 312], ["tender", 322], ["cervical", 329], ["lymph", 338], ["nodes", 344], [",", 349], ["severe", 351], ["pharyngeal", 358], ["congestion", 369], [",", 379], ["petechiae", 381], ["on", 391], ["soft", 394], ["palate", 399], [",", 405], ["uvular", 407], ["edema", 414], [",", 419], ["infraorbital", 421], ["edema", 434], [",", 439], ["and", 441], ["marginal", 445], ["tender", 454], ["hepatomegaly", 461], [".", 473], ["Investigations", 475], ["revealed", 490], ["lymphocytosis", 499], ["and", 513], ["activated", 517], ["atypical", 527], ["lymphocytes", 536], ["in", 548], ["the", 551], ["peripheral", 555], ["smear", 566], [",", 571], ["and", 573], ["positive", 577], ["monospot", 586], ["test", 595], [".", 599], ["The", 601], ["boy", 605], ["subsequently", 609], ["recovered", 622], ["in", 632], ["one", 635], ["week", 639], ["with", 644], ["total", 649], ["disappearance", 655], ["of", 669], ["his", 672], ["rash", 676], [".", 680], ["Epstein", 682], ["-", 689], ["Barr", 690], ["virus", 695], ["-", 700], ["related", 701], ["infectious", 709], ["mononucleosis", 720], ["was", 734], ["considered", 738], ["the", 749], ["most", 753], ["likely", 758], ["diagnosis", 765], ["for", 775], ["our", 779], ["patient", 783], [".", 790], ["To", 792], ["our", 795], ["knowledge", 799], [",", 808], ["this", 810], ["atypical", 815], ["case", 824], ["is", 829], ["the", 832], ["third", 836], ["reported", 842], ["case", 851], ["of", 856], ["annular", 859], ["lesions", 867], ["in", 875], ["infectious", 878], ["mononucleosis", 889], [".", 902], ["Dermatologists", 904], ["and", 919], ["other", 923], ["clinicians", 929], ["should", 940], ["be", 947], ["alerted", 950], ["to", 958], ["this", 961], ["special", 966], ["presentation", 974], ["of", 987], ["primary", 990], ["EBV", 998], ["infection", 1002], [".", 1011]]}
{"context": "Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB). These defects were unaltered in rrm3 sir2 cells. When the RFB binding Fob1p was deleted, rrm3-generated defects at the RFB were eliminated, but defects at other rDNA sites were not affected. Thus, specific protein-DNA complexes make replication Rrm3p-dependent. Because rrm3-induced increases in recombination and cell cycle length were only partially suppressed in rrm3 fob1 cells, which still required checkpoint and fork restart activities for viability, non-RFB rrm3-induced defects contribute to rDNA fragility and genome instability.", "qas": [{"question": "What is the effect of the absence of Saccharomyces cerevisiae Rrm3p?", "answers": ["Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB)."], "qid": "04968485f4484dcc9b26ebe6b289ca4e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["the", 22], ["absence", 26], ["of", 34], ["Saccharomyces", 37], ["cerevisiae", 51], ["Rrm3p", 62], ["?", 67]], "detected_answers": [{"text": "Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB).", "token_spans": [[0, 27]], "char_spans": [[0, 156]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["the", 8], ["yeast", 12], ["Rrm3p", 18], ["DNA", 24], ["helicase", 28], ["causes", 37], ["replication", 44], ["defects", 56], ["at", 64], ["multiple", 67], ["sites", 76], ["within", 82], ["ribosomal", 89], ["DNA", 99], ["(", 103], ["rDNA", 104], [")", 108], [",", 109], ["including", 111], ["at", 121], ["the", 124], ["replication", 128], ["fork", 140], ["barrier", 145], ["(", 153], ["RFB", 154], [")", 157], [".", 158], ["These", 160], ["defects", 166], ["were", 174], ["unaltered", 179], ["in", 189], ["rrm3", 192], ["sir2", 197], ["cells", 202], [".", 207], ["When", 209], ["the", 214], ["RFB", 218], ["binding", 222], ["Fob1p", 230], ["was", 236], ["deleted", 240], [",", 247], ["rrm3-generated", 249], ["defects", 264], ["at", 272], ["the", 275], ["RFB", 279], ["were", 283], ["eliminated", 288], [",", 298], ["but", 300], ["defects", 304], ["at", 312], ["other", 315], ["rDNA", 321], ["sites", 326], ["were", 332], ["not", 337], ["affected", 341], [".", 349], ["Thus", 351], [",", 355], ["specific", 357], ["protein", 366], ["-", 373], ["DNA", 374], ["complexes", 378], ["make", 388], ["replication", 393], ["Rrm3p", 405], ["-", 410], ["dependent", 411], [".", 420], ["Because", 422], ["rrm3-induced", 430], ["increases", 443], ["in", 453], ["recombination", 456], ["and", 470], ["cell", 474], ["cycle", 479], ["length", 485], ["were", 492], ["only", 497], ["partially", 502], ["suppressed", 512], ["in", 523], ["rrm3", 526], ["fob1", 531], ["cells", 536], [",", 541], ["which", 543], ["still", 549], ["required", 555], ["checkpoint", 564], ["and", 575], ["fork", 579], ["restart", 584], ["activities", 592], ["for", 603], ["viability", 607], [",", 616], ["non", 618], ["-", 621], ["RFB", 622], ["rrm3-induced", 626], ["defects", 639], ["contribute", 647], ["to", 658], ["rDNA", 661], ["fragility", 666], ["and", 676], ["genome", 680], ["instability", 687], [".", 698]]}
{"context": "Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "e0187e9fdece45e5bba46192786ac6b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[124, 124], [19, 19], [101, 101]], "char_spans": [[713, 720], [93, 100], [569, 576]]}]}], "context_tokens": [["Machado", 0], ["-", 7], ["Joseph", 8], ["disease", 15], ["(", 23], ["MJD", 24], [")", 27], [",", 28], ["also", 30], ["called", 35], ["spinocerebellar", 42], ["ataxia", 58], ["type", 65], ["3", 70], [",", 71], ["is", 73], ["caused", 76], ["by", 83], ["mutant", 86], ["ataxin-3", 93], ["with", 102], ["a", 107], ["polyglutamine", 109], ["expansion", 123], [".", 132], ["Although", 134], ["there", 143], ["is", 149], ["no", 152], ["treatment", 155], ["available", 165], ["at", 175], ["present", 178], ["to", 186], ["cure", 189], ["or", 194], ["delay", 197], ["the", 203], ["onset", 207], ["of", 213], ["MJD", 216], [",", 219], ["mouse", 221], ["models", 227], ["have", 234], ["been", 239], ["generated", 244], ["to", 254], ["facilitate", 257], ["the", 268], ["development", 272], ["of", 284], ["a", 287], ["therapy", 289], [".", 296], ["In", 298], ["this", 301], ["review", 306], [",", 312], ["the", 314], ["published", 318], ["reports", 328], ["on", 336], ["mouse", 339], ["models", 345], ["of", 352], ["MJD", 355], ["and", 359], ["other", 363], ["polyglutamine", 369], ["spinocerebellar", 383], ["ataxias", 399], ["are", 407], ["compared", 411], [".", 419], ["Based", 421], ["on", 427], ["these", 430], ["studies", 436], [",", 443], ["the", 445], ["following", 449], ["approaches", 459], ["will", 470], ["be", 475], ["discussed", 478], ["as", 488], ["candidate", 491], ["treatments", 501], ["for", 512], ["MJD", 516], [":", 519], ["1", 521], [")", 522], ["interfering", 524], ["with", 536], ["the", 541], ["formation", 545], ["of", 555], ["the", 558], ["mutant", 562], ["ataxin-3", 569], ["cleavage", 578], ["fragment", 587], ["and", 596], ["possibly", 600], ["aggregate", 609], ["or", 619], ["inclusions", 622], [",", 632], ["2", 634], [")", 635], ["reducing", 637], ["the", 646], ["disease", 650], ["protein", 658], ["nuclear", 666], ["localization", 674], [",", 686], ["and", 688], ["3", 692], [")", 693], ["decreasing", 695], ["mutant", 706], ["ataxin-3", 713], ["expression", 722], ["in", 733], ["neurons", 736], [".", 743]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "The objective of this study was to analyze the expression levels of multiple components in the mammalian target of rapamycin (mTOR) signaling pathway in radical nephrectomy specimens from patients with metastatic renal-cell carcinoma (RCC) treated with mTOR inhibitors in order to identify factors predicting susceptibility to these agents. This study retrospectively included a total of 48 consecutive patients undergoing radical nephrectomy, who were diagnosed with metastatic RCC and subsequently treated with an mTOR inhibitor (everolimus or temsirolimus) as either first- or second-line systemic therapy. Expression levels of 5 molecular markers involved in the signaling pathway associated with mTOR, including PTEN, phosphorylated (p)-Akt, p-mTOR, p-p70 ribosomal S6 kinase, and p-4E-binding protein 1 (4E-BP1), were measured by immunohistochemical staining of primary RCC specimens. Of several factors examined, bone metastasis, liver metastasis, and the expression level of p-4E-BP1 were shown to have significant impacts on the response to the mTOR inhibitors. Progression-free survival (PFS) was significantly correlated with the expression levels of PTEN and p-4E-BP1 in addition to the presence of bone metastasis on univariate analysis. Of these significant factors, p-4E-BP1 expression and bone metastasis appeared to be independently associated with PFS on multivariate analysis. These findings suggest that it would be useful to consider the expression levels of potential molecular markers in the mTOR signaling pathway, particularly p-4E-BP1, as well as conventional clinical parameters when selecting patients with metastatic RCC who are likely to benefit from treatment with mTOR inhibitors.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "ed55487bc74e470cb49c16f051371c9e", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[16, 19]], "char_spans": [[95, 123]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["of", 14], ["this", 17], ["study", 22], ["was", 28], ["to", 32], ["analyze", 35], ["the", 43], ["expression", 47], ["levels", 58], ["of", 65], ["multiple", 68], ["components", 77], ["in", 88], ["the", 91], ["mammalian", 95], ["target", 105], ["of", 112], ["rapamycin", 115], ["(", 125], ["mTOR", 126], [")", 130], ["signaling", 132], ["pathway", 142], ["in", 150], ["radical", 153], ["nephrectomy", 161], ["specimens", 173], ["from", 183], ["patients", 188], ["with", 197], ["metastatic", 202], ["renal", 213], ["-", 218], ["cell", 219], ["carcinoma", 224], ["(", 234], ["RCC", 235], [")", 238], ["treated", 240], ["with", 248], ["mTOR", 253], ["inhibitors", 258], ["in", 269], ["order", 272], ["to", 278], ["identify", 281], ["factors", 290], ["predicting", 298], ["susceptibility", 309], ["to", 324], ["these", 327], ["agents", 333], [".", 339], ["This", 341], ["study", 346], ["retrospectively", 352], ["included", 368], ["a", 377], ["total", 379], ["of", 385], ["48", 388], ["consecutive", 391], ["patients", 403], ["undergoing", 412], ["radical", 423], ["nephrectomy", 431], [",", 442], ["who", 444], ["were", 448], ["diagnosed", 453], ["with", 463], ["metastatic", 468], ["RCC", 479], ["and", 483], ["subsequently", 487], ["treated", 500], ["with", 508], ["an", 513], ["mTOR", 516], ["inhibitor", 521], ["(", 531], ["everolimus", 532], ["or", 543], ["temsirolimus", 546], [")", 558], ["as", 560], ["either", 563], ["first-", 570], ["or", 577], ["second", 580], ["-", 586], ["line", 587], ["systemic", 592], ["therapy", 601], [".", 608], ["Expression", 610], ["levels", 621], ["of", 628], ["5", 631], ["molecular", 633], ["markers", 643], ["involved", 651], ["in", 660], ["the", 663], ["signaling", 667], ["pathway", 677], ["associated", 685], ["with", 696], ["mTOR", 701], [",", 705], ["including", 707], ["PTEN", 717], [",", 721], ["phosphorylated", 723], ["(", 738], ["p)-Akt", 739], [",", 745], ["p", 747], ["-", 748], ["mTOR", 749], [",", 753], ["p", 755], ["-", 756], ["p70", 757], ["ribosomal", 761], ["S6", 771], ["kinase", 774], [",", 780], ["and", 782], ["p-4E", 786], ["-", 790], ["binding", 791], ["protein", 799], ["1", 807], ["(", 809], ["4E", 810], ["-", 812], ["BP1", 813], [")", 816], [",", 817], ["were", 819], ["measured", 824], ["by", 833], ["immunohistochemical", 836], ["staining", 856], ["of", 865], ["primary", 868], ["RCC", 876], ["specimens", 880], [".", 889], ["Of", 891], ["several", 894], ["factors", 902], ["examined", 910], [",", 918], ["bone", 920], ["metastasis", 925], [",", 935], ["liver", 937], ["metastasis", 943], [",", 953], ["and", 955], ["the", 959], ["expression", 963], ["level", 974], ["of", 980], ["p-4E", 983], ["-", 987], ["BP1", 988], ["were", 992], ["shown", 997], ["to", 1003], ["have", 1006], ["significant", 1011], ["impacts", 1023], ["on", 1031], ["the", 1034], ["response", 1038], ["to", 1047], ["the", 1050], ["mTOR", 1054], ["inhibitors", 1059], [".", 1069], ["Progression", 1071], ["-", 1082], ["free", 1083], ["survival", 1088], ["(", 1097], ["PFS", 1098], [")", 1101], ["was", 1103], ["significantly", 1107], ["correlated", 1121], ["with", 1132], ["the", 1137], ["expression", 1141], ["levels", 1152], ["of", 1159], ["PTEN", 1162], ["and", 1167], ["p-4E", 1171], ["-", 1175], ["BP1", 1176], ["in", 1180], ["addition", 1183], ["to", 1192], ["the", 1195], ["presence", 1199], ["of", 1208], ["bone", 1211], ["metastasis", 1216], ["on", 1227], ["univariate", 1230], ["analysis", 1241], [".", 1249], ["Of", 1251], ["these", 1254], ["significant", 1260], ["factors", 1272], [",", 1279], ["p-4E", 1281], ["-", 1285], ["BP1", 1286], ["expression", 1290], ["and", 1301], ["bone", 1305], ["metastasis", 1310], ["appeared", 1321], ["to", 1330], ["be", 1333], ["independently", 1336], ["associated", 1350], ["with", 1361], ["PFS", 1366], ["on", 1370], ["multivariate", 1373], ["analysis", 1386], [".", 1394], ["These", 1396], ["findings", 1402], ["suggest", 1411], ["that", 1419], ["it", 1424], ["would", 1427], ["be", 1433], ["useful", 1436], ["to", 1443], ["consider", 1446], ["the", 1455], ["expression", 1459], ["levels", 1470], ["of", 1477], ["potential", 1480], ["molecular", 1490], ["markers", 1500], ["in", 1508], ["the", 1511], ["mTOR", 1515], ["signaling", 1520], ["pathway", 1530], [",", 1537], ["particularly", 1539], ["p-4E", 1552], ["-", 1556], ["BP1", 1557], [",", 1560], ["as", 1562], ["well", 1565], ["as", 1570], ["conventional", 1573], ["clinical", 1586], ["parameters", 1595], ["when", 1606], ["selecting", 1611], ["patients", 1621], ["with", 1630], ["metastatic", 1635], ["RCC", 1646], ["who", 1650], ["are", 1654], ["likely", 1658], ["to", 1665], ["benefit", 1668], ["from", 1676], ["treatment", 1681], ["with", 1691], ["mTOR", 1696], ["inhibitors", 1701], [".", 1711]]}
{"context": "Approximately 2-4% of genetic material in human populations outside Africa is derived from Neanderthals who interbred with anatomically modern humans. Recent studies have shown that this Neanderthal DNA is depleted around functional genomic regions; this has been suggested to be a consequence of harmful epistatic interactions between human and Neanderthal alleles. However, using published estimates of Neanderthal inbreeding and the distribution of mutational fitness effects, we infer that Neanderthals had at least 40% lower fitness than humans on average; this increased load predicts the reduction in Neanderthal introgression around genes without the need to invoke epistasis. We also predict a residual Neanderthal mutational load in non-Africans, leading to a fitness reduction of at least 0.5%. This effect of Neanderthal admixture has been left out of previous debate on mutation load differences between Africans and non-Africans. We also show that if many deleterious mutations are recessive, the Neanderthal admixture fraction could increase over time due to the protective effect of Neanderthal haplotypes against deleterious alleles that arose recently in the human population. This might partially explain why so many organisms retain gene flow from other species and appear to derive adaptive benefits from introgression.", "qas": [{"question": "What percentage of Homo sapiens DNA is of Neanderthal origin?", "answers": ["2-4%"], "qid": "483a3885738d4b65a527e3fd3445ef78", "question_tokens": [["What", 0], ["percentage", 5], ["of", 16], ["Homo", 19], ["sapiens", 24], ["DNA", 32], ["is", 36], ["of", 39], ["Neanderthal", 42], ["origin", 54], ["?", 60]], "detected_answers": [{"text": "2-4%", "token_spans": [[1, 3]], "char_spans": [[14, 16]]}]}], "context_tokens": [["Approximately", 0], ["2", 14], ["-", 15], ["4", 16], ["%", 17], ["of", 19], ["genetic", 22], ["material", 30], ["in", 39], ["human", 42], ["populations", 48], ["outside", 60], ["Africa", 68], ["is", 75], ["derived", 78], ["from", 86], ["Neanderthals", 91], ["who", 104], ["interbred", 108], ["with", 118], ["anatomically", 123], ["modern", 136], ["humans", 143], [".", 149], ["Recent", 151], ["studies", 158], ["have", 166], ["shown", 171], ["that", 177], ["this", 182], ["Neanderthal", 187], ["DNA", 199], ["is", 203], ["depleted", 206], ["around", 215], ["functional", 222], ["genomic", 233], ["regions", 241], [";", 248], ["this", 250], ["has", 255], ["been", 259], ["suggested", 264], ["to", 274], ["be", 277], ["a", 280], ["consequence", 282], ["of", 294], ["harmful", 297], ["epistatic", 305], ["interactions", 315], ["between", 328], ["human", 336], ["and", 342], ["Neanderthal", 346], ["alleles", 358], [".", 365], ["However", 367], [",", 374], ["using", 376], ["published", 382], ["estimates", 392], ["of", 402], ["Neanderthal", 405], ["inbreeding", 417], ["and", 428], ["the", 432], ["distribution", 436], ["of", 449], ["mutational", 452], ["fitness", 463], ["effects", 471], [",", 478], ["we", 480], ["infer", 483], ["that", 489], ["Neanderthals", 494], ["had", 507], ["at", 511], ["least", 514], ["40", 520], ["%", 522], ["lower", 524], ["fitness", 530], ["than", 538], ["humans", 543], ["on", 550], ["average", 553], [";", 560], ["this", 562], ["increased", 567], ["load", 577], ["predicts", 582], ["the", 591], ["reduction", 595], ["in", 605], ["Neanderthal", 608], ["introgression", 620], ["around", 634], ["genes", 641], ["without", 647], ["the", 655], ["need", 659], ["to", 664], ["invoke", 667], ["epistasis", 674], [".", 683], ["We", 685], ["also", 688], ["predict", 693], ["a", 701], ["residual", 703], ["Neanderthal", 712], ["mutational", 724], ["load", 735], ["in", 740], ["non", 743], ["-", 746], ["Africans", 747], [",", 755], ["leading", 757], ["to", 765], ["a", 768], ["fitness", 770], ["reduction", 778], ["of", 788], ["at", 791], ["least", 794], ["0.5", 800], ["%", 803], [".", 804], ["This", 806], ["effect", 811], ["of", 818], ["Neanderthal", 821], ["admixture", 833], ["has", 843], ["been", 847], ["left", 852], ["out", 857], ["of", 861], ["previous", 864], ["debate", 873], ["on", 880], ["mutation", 883], ["load", 892], ["differences", 897], ["between", 909], ["Africans", 917], ["and", 926], ["non", 930], ["-", 933], ["Africans", 934], [".", 942], ["We", 944], ["also", 947], ["show", 952], ["that", 957], ["if", 962], ["many", 965], ["deleterious", 970], ["mutations", 982], ["are", 992], ["recessive", 996], [",", 1005], ["the", 1007], ["Neanderthal", 1011], ["admixture", 1023], ["fraction", 1033], ["could", 1042], ["increase", 1048], ["over", 1057], ["time", 1062], ["due", 1067], ["to", 1071], ["the", 1074], ["protective", 1078], ["effect", 1089], ["of", 1096], ["Neanderthal", 1099], ["haplotypes", 1111], ["against", 1122], ["deleterious", 1130], ["alleles", 1142], ["that", 1150], ["arose", 1155], ["recently", 1161], ["in", 1170], ["the", 1173], ["human", 1177], ["population", 1183], [".", 1193], ["This", 1195], ["might", 1200], ["partially", 1206], ["explain", 1216], ["why", 1224], ["so", 1228], ["many", 1231], ["organisms", 1236], ["retain", 1246], ["gene", 1253], ["flow", 1258], ["from", 1263], ["other", 1268], ["species", 1274], ["and", 1282], ["appear", 1286], ["to", 1293], ["derive", 1296], ["adaptive", 1303], ["benefits", 1312], ["from", 1321], ["introgression", 1326], [".", 1339]]}
{"context": "Denosumab is a human monoclonal antibody which specifically blocks receptor activator of nuclear factor \u03baB ligand and is a very potent antiresorptive drug. Its efficacy in reducing the risk of vertebral, hip and nonskeletal fracture has been proven in a large prospective, randomized multicenter study of 7808 postmenopausal women with osteoporosis [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial]. Denosumab causes somewhat greater increases in bone mineral density (BMD) than the class of bisphosphonate antiresorptives. Denosumab also causes an increase in bone mass and bone strength in the spine, ultradistal and diaphysis of the radius, proximal tibia and the hip. Recently long-term treatment with denosumab has been shown to cause a continued almost linear increase in total hip and femoral neck BMD beyond 3 years up to 8 years. In this respect, denosumab seems to differ from the bisphosphonate group in which the rate of improvement of BMD diminishes and for some drugs becomes negative after 3-4 years when the process of secondary mineralization flattens out. This unique property of an antiresorptive drug points towards mechanisms of action which differ from the bisphosphonate group. Both types of antiresorptives decrease cortical porosity but contrary to bisphosphonates the reduction in cortical porosity continues with denosumab which, in addition, also seems to cause a slight continuous modeling-based formation of new bone despite suppression of bone remodeling. The net effect is an increase in cortical thickening and bone mass, and increased strength of cortical bone. This may contribute substantially to the significant further reduction of the nonvertebral fracture risk which was found in the long-term denosumab arm of the FREEDOM extension trial during years 4-7.", "qas": [{"question": "Which is the target of the drug Denosumab?", "answers": ["receptor activator of nuclear factor \u03baB ligand", "RANKL", "receptor activator of nuclear factor-\u03baB ligand"], "qid": "d38d490c5d9f45a0818bec552463879b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["the", 23], ["drug", 27], ["Denosumab", 32], ["?", 41]], "detected_answers": [{"text": "receptor activator of nuclear factor-\u03baB ligand", "token_spans": [[9, 15]], "char_spans": [[67, 112]]}]}], "context_tokens": [["Denosumab", 0], ["is", 10], ["a", 13], ["human", 15], ["monoclonal", 21], ["antibody", 32], ["which", 41], ["specifically", 47], ["blocks", 60], ["receptor", 67], ["activator", 76], ["of", 86], ["nuclear", 89], ["factor", 97], ["\u03baB", 104], ["ligand", 107], ["and", 114], ["is", 118], ["a", 121], ["very", 123], ["potent", 128], ["antiresorptive", 135], ["drug", 150], [".", 154], ["Its", 156], ["efficacy", 160], ["in", 169], ["reducing", 172], ["the", 181], ["risk", 185], ["of", 190], ["vertebral", 193], [",", 202], ["hip", 204], ["and", 208], ["nonskeletal", 212], ["fracture", 224], ["has", 233], ["been", 237], ["proven", 242], ["in", 249], ["a", 252], ["large", 254], ["prospective", 260], [",", 271], ["randomized", 273], ["multicenter", 284], ["study", 296], ["of", 302], ["7808", 305], ["postmenopausal", 310], ["women", 325], ["with", 331], ["osteoporosis", 336], ["[", 349], ["Fracture", 350], ["Reduction", 359], ["Evaluation", 369], ["of", 380], ["Denosumab", 383], ["in", 393], ["Osteoporosis", 396], ["Every", 409], ["6", 415], ["Months", 417], ["(", 424], ["FREEDOM", 425], [")", 432], ["trial].", 434], ["Denosumab", 442], ["causes", 452], ["somewhat", 459], ["greater", 468], ["increases", 476], ["in", 486], ["bone", 489], ["mineral", 494], ["density", 502], ["(", 510], ["BMD", 511], [")", 514], ["than", 516], ["the", 521], ["class", 525], ["of", 531], ["bisphosphonate", 534], ["antiresorptives", 549], [".", 564], ["Denosumab", 566], ["also", 576], ["causes", 581], ["an", 588], ["increase", 591], ["in", 600], ["bone", 603], ["mass", 608], ["and", 613], ["bone", 617], ["strength", 622], ["in", 631], ["the", 634], ["spine", 638], [",", 643], ["ultradistal", 645], ["and", 657], ["diaphysis", 661], ["of", 671], ["the", 674], ["radius", 678], [",", 684], ["proximal", 686], ["tibia", 695], ["and", 701], ["the", 705], ["hip", 709], [".", 712], ["Recently", 714], ["long", 723], ["-", 727], ["term", 728], ["treatment", 733], ["with", 743], ["denosumab", 748], ["has", 758], ["been", 762], ["shown", 767], ["to", 773], ["cause", 776], ["a", 782], ["continued", 784], ["almost", 794], ["linear", 801], ["increase", 808], ["in", 817], ["total", 820], ["hip", 826], ["and", 830], ["femoral", 834], ["neck", 842], ["BMD", 847], ["beyond", 851], ["3", 858], ["years", 860], ["up", 866], ["to", 869], ["8", 872], ["years", 874], [".", 879], ["In", 881], ["this", 884], ["respect", 889], [",", 896], ["denosumab", 898], ["seems", 908], ["to", 914], ["differ", 917], ["from", 924], ["the", 929], ["bisphosphonate", 933], ["group", 948], ["in", 954], ["which", 957], ["the", 963], ["rate", 967], ["of", 972], ["improvement", 975], ["of", 987], ["BMD", 990], ["diminishes", 994], ["and", 1005], ["for", 1009], ["some", 1013], ["drugs", 1018], ["becomes", 1024], ["negative", 1032], ["after", 1041], ["3", 1047], ["-", 1048], ["4", 1049], ["years", 1051], ["when", 1057], ["the", 1062], ["process", 1066], ["of", 1074], ["secondary", 1077], ["mineralization", 1087], ["flattens", 1102], ["out", 1111], [".", 1114], ["This", 1116], ["unique", 1121], ["property", 1128], ["of", 1137], ["an", 1140], ["antiresorptive", 1143], ["drug", 1158], ["points", 1163], ["towards", 1170], ["mechanisms", 1178], ["of", 1189], ["action", 1192], ["which", 1199], ["differ", 1205], ["from", 1212], ["the", 1217], ["bisphosphonate", 1221], ["group", 1236], [".", 1241], ["Both", 1243], ["types", 1248], ["of", 1254], ["antiresorptives", 1257], ["decrease", 1273], ["cortical", 1282], ["porosity", 1291], ["but", 1300], ["contrary", 1304], ["to", 1313], ["bisphosphonates", 1316], ["the", 1332], ["reduction", 1336], ["in", 1346], ["cortical", 1349], ["porosity", 1358], ["continues", 1367], ["with", 1377], ["denosumab", 1382], ["which", 1392], [",", 1397], ["in", 1399], ["addition", 1402], [",", 1410], ["also", 1412], ["seems", 1417], ["to", 1423], ["cause", 1426], ["a", 1432], ["slight", 1434], ["continuous", 1441], ["modeling", 1452], ["-", 1460], ["based", 1461], ["formation", 1467], ["of", 1477], ["new", 1480], ["bone", 1484], ["despite", 1489], ["suppression", 1497], ["of", 1509], ["bone", 1512], ["remodeling", 1517], [".", 1527], ["The", 1529], ["net", 1533], ["effect", 1537], ["is", 1544], ["an", 1547], ["increase", 1550], ["in", 1559], ["cortical", 1562], ["thickening", 1571], ["and", 1582], ["bone", 1586], ["mass", 1591], [",", 1595], ["and", 1597], ["increased", 1601], ["strength", 1611], ["of", 1620], ["cortical", 1623], ["bone", 1632], [".", 1636], ["This", 1638], ["may", 1643], ["contribute", 1647], ["substantially", 1658], ["to", 1672], ["the", 1675], ["significant", 1679], ["further", 1691], ["reduction", 1699], ["of", 1709], ["the", 1712], ["nonvertebral", 1716], ["fracture", 1729], ["risk", 1738], ["which", 1743], ["was", 1749], ["found", 1753], ["in", 1759], ["the", 1762], ["long", 1766], ["-", 1770], ["term", 1771], ["denosumab", 1776], ["arm", 1786], ["of", 1790], ["the", 1793], ["FREEDOM", 1797], ["extension", 1805], ["trial", 1815], ["during", 1821], ["years", 1828], ["4", 1834], ["-", 1835], ["7", 1836], [".", 1837]]}
{"context": "The McLeod syndrome is an X-linked disorder caused by mutations of the XK gene encoding the XK protein. The syndrome is characterized by absent Kx erythrocyte antigen, weak expression of Kell blood group system antigens, and acanthocytosis. In some allelic variants, elevated creatine kinase, myopathy, neurogenic muscle atrophy, and progressive chorea are found. We describe a family with a novel point mutation in the XK gene consisting of a C to T base transition at nucleotide position 977, introducing a stop codon. Among seven affected males, five manifested with psychiatric disorders such as depression, bipolar disorder, or personality disorder, but only two presented with chorea Positron emission tomography and magnetic resonance volumetry revealed reduced striatal 2-fluoro-2-deoxy-glucose (FDG) uptake and diminished volumes of the caudate nucleus and putamen that correlated with disease duration. In contrast, none of 12 female mutation carriers showed psychiatric or movement disorders. However, a semidominant effect of the mutation was suggested by erythrocyte and blood group mosaicism and reduced striatal FDG uptake without structural abnormalities. Therefore, patients with psychiatric signs or symptoms segregating in an X-linked trait should be examined for acanthocytosis and Kell/Kx blood group serology.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "2f7b7e71153e42089cfb1ba8aff9bd9e", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[18, 18], [75, 75], [14, 14]], "char_spans": [[92, 93], [420, 421], [71, 72]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["an", 23], ["X", 26], ["-", 27], ["linked", 28], ["disorder", 35], ["caused", 44], ["by", 51], ["mutations", 54], ["of", 64], ["the", 67], ["XK", 71], ["gene", 74], ["encoding", 79], ["the", 88], ["XK", 92], ["protein", 95], [".", 102], ["The", 104], ["syndrome", 108], ["is", 117], ["characterized", 120], ["by", 134], ["absent", 137], ["Kx", 144], ["erythrocyte", 147], ["antigen", 159], [",", 166], ["weak", 168], ["expression", 173], ["of", 184], ["Kell", 187], ["blood", 192], ["group", 198], ["system", 204], ["antigens", 211], [",", 219], ["and", 221], ["acanthocytosis", 225], [".", 239], ["In", 241], ["some", 244], ["allelic", 249], ["variants", 257], [",", 265], ["elevated", 267], ["creatine", 276], ["kinase", 285], [",", 291], ["myopathy", 293], [",", 301], ["neurogenic", 303], ["muscle", 314], ["atrophy", 321], [",", 328], ["and", 330], ["progressive", 334], ["chorea", 346], ["are", 353], ["found", 357], [".", 362], ["We", 364], ["describe", 367], ["a", 376], ["family", 378], ["with", 385], ["a", 390], ["novel", 392], ["point", 398], ["mutation", 404], ["in", 413], ["the", 416], ["XK", 420], ["gene", 423], ["consisting", 428], ["of", 439], ["a", 442], ["C", 444], ["to", 446], ["T", 449], ["base", 451], ["transition", 456], ["at", 467], ["nucleotide", 470], ["position", 481], ["977", 490], [",", 493], ["introducing", 495], ["a", 507], ["stop", 509], ["codon", 514], [".", 519], ["Among", 521], ["seven", 527], ["affected", 533], ["males", 542], [",", 547], ["five", 549], ["manifested", 554], ["with", 565], ["psychiatric", 570], ["disorders", 582], ["such", 592], ["as", 597], ["depression", 600], [",", 610], ["bipolar", 612], ["disorder", 620], [",", 628], ["or", 630], ["personality", 633], ["disorder", 645], [",", 653], ["but", 655], ["only", 659], ["two", 664], ["presented", 668], ["with", 678], ["chorea", 683], ["Positron", 690], ["emission", 699], ["tomography", 708], ["and", 719], ["magnetic", 723], ["resonance", 732], ["volumetry", 742], ["revealed", 752], ["reduced", 761], ["striatal", 769], ["2-fluoro-2-deoxy", 778], ["-", 794], ["glucose", 795], ["(", 803], ["FDG", 804], [")", 807], ["uptake", 809], ["and", 816], ["diminished", 820], ["volumes", 831], ["of", 839], ["the", 842], ["caudate", 846], ["nucleus", 854], ["and", 862], ["putamen", 866], ["that", 874], ["correlated", 879], ["with", 890], ["disease", 895], ["duration", 903], [".", 911], ["In", 913], ["contrast", 916], [",", 924], ["none", 926], ["of", 931], ["12", 934], ["female", 937], ["mutation", 944], ["carriers", 953], ["showed", 962], ["psychiatric", 969], ["or", 981], ["movement", 984], ["disorders", 993], [".", 1002], ["However", 1004], [",", 1011], ["a", 1013], ["semidominant", 1015], ["effect", 1028], ["of", 1035], ["the", 1038], ["mutation", 1042], ["was", 1051], ["suggested", 1055], ["by", 1065], ["erythrocyte", 1068], ["and", 1080], ["blood", 1084], ["group", 1090], ["mosaicism", 1096], ["and", 1106], ["reduced", 1110], ["striatal", 1118], ["FDG", 1127], ["uptake", 1131], ["without", 1138], ["structural", 1146], ["abnormalities", 1157], [".", 1170], ["Therefore", 1172], [",", 1181], ["patients", 1183], ["with", 1192], ["psychiatric", 1197], ["signs", 1209], ["or", 1215], ["symptoms", 1218], ["segregating", 1227], ["in", 1239], ["an", 1242], ["X", 1245], ["-", 1246], ["linked", 1247], ["trait", 1254], ["should", 1260], ["be", 1267], ["examined", 1270], ["for", 1279], ["acanthocytosis", 1283], ["and", 1298], ["Kell", 1302], ["/", 1306], ["Kx", 1307], ["blood", 1310], ["group", 1316], ["serology", 1322], [".", 1330]]}
{"context": "MicroRNAs (miRNAs) are non-coding, short (21-23nt) regulators of protein-coding genes that are generally transcribed first into primary miRNA (pri-miR), followed by the generation of precursor miRNA (pre-miR). This finally leads to the production of the mature miRNA. A large amount of information is available on the pre- and mature miRNAs. However, very little is known about the pri-miRs, due to a lack of knowledge about their transcription start sites (TSSs). Based on the genomic loci, miRNAs can be categorized into two types --intragenic (intra-miR) and intergenic (inter-miR). While it is already an established fact that intra-miRs are commonly transcribed in conjunction with their host genes, the transcription machinery of inter-miRs is poorly understood. Although it is assumed that miRNA promoters are similar in structure to gene promoters, since both are transcribed by RNA polymerase II (Pol II), computational validations exhibit poor performance of gene promoter prediction methods on miRNAs. In this paper, we concentrate on the problem of TSS prediction for miRNAs. The present study begins with the identification of positive and negative promoter samples from recently published data stemming from RNA-sequencing studies. From these samples of experimentally validated miRNA TSSs, a number of standard sequence features are extracted. Furthermore, to account for potential footprints related to promoter regulation by CpG dinucleotide targeted DNA methylation, a number of novel features are defined. We develop a support vector machine (SVM) with RBF kernel for the prediction of miRNA TSSs trained on human miRNA promoters. A novel feature reduction technique based on archived multi-objective simulated annealing (AMOSA) identifies the final set of features. The resulting model trained on miRNA promoters shows improved performance over the one trained on protein-coding gene promoters in terms of classification accuracy, sensitivity and specificity. Results are also reported for a completely independent biologically validated test set. In a part of the investigation, the proposed approach is used to predict protein-coding gene TSSs. It shows a significantly improved performance when compared to previously published gene TSS prediction methods.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "cdd96acd2fc94e268b146391bc401383", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[179, 181]], "char_spans": [[887, 903]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["short", 35], ["(", 41], ["21", 42], ["-", 44], ["23nt", 45], [")", 49], ["regulators", 51], ["of", 62], ["protein", 65], ["-", 72], ["coding", 73], ["genes", 80], ["that", 86], ["are", 91], ["generally", 95], ["transcribed", 105], ["first", 117], ["into", 123], ["primary", 128], ["miRNA", 136], ["(", 142], ["pri", 143], ["-", 146], ["miR", 147], [")", 150], [",", 151], ["followed", 153], ["by", 162], ["the", 165], ["generation", 169], ["of", 180], ["precursor", 183], ["miRNA", 193], ["(", 199], ["pre", 200], ["-", 203], ["miR", 204], [")", 207], [".", 208], ["This", 210], ["finally", 215], ["leads", 223], ["to", 229], ["the", 232], ["production", 236], ["of", 247], ["the", 250], ["mature", 254], ["miRNA", 261], [".", 266], ["A", 268], ["large", 270], ["amount", 276], ["of", 283], ["information", 286], ["is", 298], ["available", 301], ["on", 311], ["the", 314], ["pre-", 318], ["and", 323], ["mature", 327], ["miRNAs", 334], [".", 340], ["However", 342], [",", 349], ["very", 351], ["little", 356], ["is", 363], ["known", 366], ["about", 372], ["the", 378], ["pri", 382], ["-", 385], ["miRs", 386], [",", 390], ["due", 392], ["to", 396], ["a", 399], ["lack", 401], ["of", 406], ["knowledge", 409], ["about", 419], ["their", 425], ["transcription", 431], ["start", 445], ["sites", 451], ["(", 457], ["TSSs", 458], [")", 462], [".", 463], ["Based", 465], ["on", 471], ["the", 474], ["genomic", 478], ["loci", 486], [",", 490], ["miRNAs", 492], ["can", 499], ["be", 503], ["categorized", 506], ["into", 518], ["two", 523], ["types", 527], ["--intragenic", 533], ["(", 546], ["intra", 547], ["-", 552], ["miR", 553], [")", 556], ["and", 558], ["intergenic", 562], ["(", 573], ["inter", 574], ["-", 579], ["miR", 580], [")", 583], [".", 584], ["While", 586], ["it", 592], ["is", 595], ["already", 598], ["an", 606], ["established", 609], ["fact", 621], ["that", 626], ["intra", 631], ["-", 636], ["miRs", 637], ["are", 642], ["commonly", 646], ["transcribed", 655], ["in", 667], ["conjunction", 670], ["with", 682], ["their", 687], ["host", 693], ["genes", 698], [",", 703], ["the", 705], ["transcription", 709], ["machinery", 723], ["of", 733], ["inter", 736], ["-", 741], ["miRs", 742], ["is", 747], ["poorly", 750], ["understood", 757], [".", 767], ["Although", 769], ["it", 778], ["is", 781], ["assumed", 784], ["that", 792], ["miRNA", 797], ["promoters", 803], ["are", 813], ["similar", 817], ["in", 825], ["structure", 828], ["to", 838], ["gene", 841], ["promoters", 846], [",", 855], ["since", 857], ["both", 863], ["are", 868], ["transcribed", 872], ["by", 884], ["RNA", 887], ["polymerase", 891], ["II", 902], ["(", 905], ["Pol", 906], ["II", 910], [")", 912], [",", 913], ["computational", 915], ["validations", 929], ["exhibit", 941], ["poor", 949], ["performance", 954], ["of", 966], ["gene", 969], ["promoter", 974], ["prediction", 983], ["methods", 994], ["on", 1002], ["miRNAs", 1005], [".", 1011], ["In", 1013], ["this", 1016], ["paper", 1021], [",", 1026], ["we", 1028], ["concentrate", 1031], ["on", 1043], ["the", 1046], ["problem", 1050], ["of", 1058], ["TSS", 1061], ["prediction", 1065], ["for", 1076], ["miRNAs", 1080], [".", 1086], ["The", 1088], ["present", 1092], ["study", 1100], ["begins", 1106], ["with", 1113], ["the", 1118], ["identification", 1122], ["of", 1137], ["positive", 1140], ["and", 1149], ["negative", 1153], ["promoter", 1162], ["samples", 1171], ["from", 1179], ["recently", 1184], ["published", 1193], ["data", 1203], ["stemming", 1208], ["from", 1217], ["RNA", 1222], ["-", 1225], ["sequencing", 1226], ["studies", 1237], [".", 1244], ["From", 1246], ["these", 1251], ["samples", 1257], ["of", 1265], ["experimentally", 1268], ["validated", 1283], ["miRNA", 1293], ["TSSs", 1299], [",", 1303], ["a", 1305], ["number", 1307], ["of", 1314], ["standard", 1317], ["sequence", 1326], ["features", 1335], ["are", 1344], ["extracted", 1348], [".", 1357], ["Furthermore", 1359], [",", 1370], ["to", 1372], ["account", 1375], ["for", 1383], ["potential", 1387], ["footprints", 1397], ["related", 1408], ["to", 1416], ["promoter", 1419], ["regulation", 1428], ["by", 1439], ["CpG", 1442], ["dinucleotide", 1446], ["targeted", 1459], ["DNA", 1468], ["methylation", 1472], [",", 1483], ["a", 1485], ["number", 1487], ["of", 1494], ["novel", 1497], ["features", 1503], ["are", 1512], ["defined", 1516], [".", 1523], ["We", 1525], ["develop", 1528], ["a", 1536], ["support", 1538], ["vector", 1546], ["machine", 1553], ["(", 1561], ["SVM", 1562], [")", 1565], ["with", 1567], ["RBF", 1572], ["kernel", 1576], ["for", 1583], ["the", 1587], ["prediction", 1591], ["of", 1602], ["miRNA", 1605], ["TSSs", 1611], ["trained", 1616], ["on", 1624], ["human", 1627], ["miRNA", 1633], ["promoters", 1639], [".", 1648], ["A", 1650], ["novel", 1652], ["feature", 1658], ["reduction", 1666], ["technique", 1676], ["based", 1686], ["on", 1692], ["archived", 1695], ["multi", 1704], ["-", 1709], ["objective", 1710], ["simulated", 1720], ["annealing", 1730], ["(", 1740], ["AMOSA", 1741], [")", 1746], ["identifies", 1748], ["the", 1759], ["final", 1763], ["set", 1769], ["of", 1773], ["features", 1776], [".", 1784], ["The", 1786], ["resulting", 1790], ["model", 1800], ["trained", 1806], ["on", 1814], ["miRNA", 1817], ["promoters", 1823], ["shows", 1833], ["improved", 1839], ["performance", 1848], ["over", 1860], ["the", 1865], ["one", 1869], ["trained", 1873], ["on", 1881], ["protein", 1884], ["-", 1891], ["coding", 1892], ["gene", 1899], ["promoters", 1904], ["in", 1914], ["terms", 1917], ["of", 1923], ["classification", 1926], ["accuracy", 1941], [",", 1949], ["sensitivity", 1951], ["and", 1963], ["specificity", 1967], [".", 1978], ["Results", 1980], ["are", 1988], ["also", 1992], ["reported", 1997], ["for", 2006], ["a", 2010], ["completely", 2012], ["independent", 2023], ["biologically", 2035], ["validated", 2048], ["test", 2058], ["set", 2063], [".", 2066], ["In", 2068], ["a", 2071], ["part", 2073], ["of", 2078], ["the", 2081], ["investigation", 2085], [",", 2098], ["the", 2100], ["proposed", 2104], ["approach", 2113], ["is", 2122], ["used", 2125], ["to", 2130], ["predict", 2133], ["protein", 2141], ["-", 2148], ["coding", 2149], ["gene", 2156], ["TSSs", 2161], [".", 2165], ["It", 2167], ["shows", 2170], ["a", 2176], ["significantly", 2178], ["improved", 2192], ["performance", 2201], ["when", 2213], ["compared", 2218], ["to", 2227], ["previously", 2230], ["published", 2241], ["gene", 2251], ["TSS", 2256], ["prediction", 2260], ["methods", 2271], [".", 2278]]}
{"context": "In eukaryotes, co-translational insertion of selenocysteine into selenoproteins necessitates the participation of the selenocysteine insertion sequence (SECIS), an element lying in the 3'-untranslated region of selenoprotein mRNAs. We report a detailed experimental study of the secondary structures of the SECIS elements of three selenoprotein mRNAs, the rat and human type I iodothyronine deiodinase (5'DI) and rat glutathione peroxidase (GPx). Based on RNase and chemical probing, a new secondary structure model is established. It is characterized by a stem-loop structure, comprising two helices (I and II) separated by an internal loop, with an apical loop surmounting helix II. Sequence comparisons of 20 SECIS elements, arising from 2 5'DI, 13 GPx, 2 selenoprotein P, and 1 selenoprotein W mRNAs, confirm the secondary structure model. The most striking finding of the experimental study concerns a set of conserved sequences in helix II that interact to form a novel RNA structural motif consisting of a quartet composed of non-Watson-Crick base pairs 5'UGAY3': 5'UGAU3'. The potential for forming the quartet is preserved in 15 SECIS elements, but three consecutive non-Watson-Crick base pairs can nevertheless form in the other five SECIS, the central G.A tandem being invariant in all cases. A 3D model, derived by computer modeling with the use of the solution data, suggests that the base pairing interactions in the G.A tandem are of the type found in GNRA loops. The 3D model displays the quartet lying in an accessible position at the foot of helix II, which is bent at the internal loop, suggesting that the non-Watson-Crick base pair arrangement provides an unusual pattern of chemical groups for putative ligand interaction.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "3fe09fafae1c4200bf36faea155c3c62", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[123, 123], [205, 205], [20, 20], [46, 46], [225, 225]], "char_spans": [[712, 716], [1138, 1142], [153, 157], [307, 311], [1244, 1248]]}]}], "context_tokens": [["In", 0], ["eukaryotes", 3], [",", 13], ["co", 15], ["-", 17], ["translational", 18], ["insertion", 32], ["of", 42], ["selenocysteine", 45], ["into", 60], ["selenoproteins", 65], ["necessitates", 80], ["the", 93], ["participation", 97], ["of", 111], ["the", 114], ["selenocysteine", 118], ["insertion", 133], ["sequence", 143], ["(", 152], ["SECIS", 153], [")", 158], [",", 159], ["an", 161], ["element", 164], ["lying", 172], ["in", 178], ["the", 181], ["3'-untranslated", 185], ["region", 201], ["of", 208], ["selenoprotein", 211], ["mRNAs", 225], [".", 230], ["We", 232], ["report", 235], ["a", 242], ["detailed", 244], ["experimental", 253], ["study", 266], ["of", 272], ["the", 275], ["secondary", 279], ["structures", 289], ["of", 300], ["the", 303], ["SECIS", 307], ["elements", 313], ["of", 322], ["three", 325], ["selenoprotein", 331], ["mRNAs", 345], [",", 350], ["the", 352], ["rat", 356], ["and", 360], ["human", 364], ["type", 370], ["I", 375], ["iodothyronine", 377], ["deiodinase", 391], ["(", 402], ["5'DI", 403], [")", 407], ["and", 409], ["rat", 413], ["glutathione", 417], ["peroxidase", 429], ["(", 440], ["GPx", 441], [")", 444], [".", 445], ["Based", 447], ["on", 453], ["RNase", 456], ["and", 462], ["chemical", 466], ["probing", 475], [",", 482], ["a", 484], ["new", 486], ["secondary", 490], ["structure", 500], ["model", 510], ["is", 516], ["established", 519], [".", 530], ["It", 532], ["is", 535], ["characterized", 538], ["by", 552], ["a", 555], ["stem", 557], ["-", 561], ["loop", 562], ["structure", 567], [",", 576], ["comprising", 578], ["two", 589], ["helices", 593], ["(", 601], ["I", 602], ["and", 604], ["II", 608], [")", 610], ["separated", 612], ["by", 622], ["an", 625], ["internal", 628], ["loop", 637], [",", 641], ["with", 643], ["an", 648], ["apical", 651], ["loop", 658], ["surmounting", 663], ["helix", 675], ["II", 681], [".", 683], ["Sequence", 685], ["comparisons", 694], ["of", 706], ["20", 709], ["SECIS", 712], ["elements", 718], [",", 726], ["arising", 728], ["from", 736], ["2", 741], ["5'DI", 743], [",", 747], ["13", 749], ["GPx", 752], [",", 755], ["2", 757], ["selenoprotein", 759], ["P", 773], [",", 774], ["and", 776], ["1", 780], ["selenoprotein", 782], ["W", 796], ["mRNAs", 798], [",", 803], ["confirm", 805], ["the", 813], ["secondary", 817], ["structure", 827], ["model", 837], [".", 842], ["The", 844], ["most", 848], ["striking", 853], ["finding", 862], ["of", 870], ["the", 873], ["experimental", 877], ["study", 890], ["concerns", 896], ["a", 905], ["set", 907], ["of", 911], ["conserved", 914], ["sequences", 924], ["in", 934], ["helix", 937], ["II", 943], ["that", 946], ["interact", 951], ["to", 960], ["form", 963], ["a", 968], ["novel", 970], ["RNA", 976], ["structural", 980], ["motif", 991], ["consisting", 997], ["of", 1008], ["a", 1011], ["quartet", 1013], ["composed", 1021], ["of", 1030], ["non", 1033], ["-", 1036], ["Watson", 1037], ["-", 1043], ["Crick", 1044], ["base", 1050], ["pairs", 1055], ["5'UGAY3", 1061], ["'", 1068], [":", 1069], ["5'UGAU3", 1071], ["'", 1078], [".", 1079], ["The", 1081], ["potential", 1085], ["for", 1095], ["forming", 1099], ["the", 1107], ["quartet", 1111], ["is", 1119], ["preserved", 1122], ["in", 1132], ["15", 1135], ["SECIS", 1138], ["elements", 1144], [",", 1152], ["but", 1154], ["three", 1158], ["consecutive", 1164], ["non", 1176], ["-", 1179], ["Watson", 1180], ["-", 1186], ["Crick", 1187], ["base", 1193], ["pairs", 1198], ["can", 1204], ["nevertheless", 1208], ["form", 1221], ["in", 1226], ["the", 1229], ["other", 1233], ["five", 1239], ["SECIS", 1244], [",", 1249], ["the", 1251], ["central", 1255], ["G.A", 1263], ["tandem", 1267], ["being", 1274], ["invariant", 1280], ["in", 1290], ["all", 1293], ["cases", 1297], [".", 1302], ["A", 1304], ["3D", 1306], ["model", 1309], [",", 1314], ["derived", 1316], ["by", 1324], ["computer", 1327], ["modeling", 1336], ["with", 1345], ["the", 1350], ["use", 1354], ["of", 1358], ["the", 1361], ["solution", 1365], ["data", 1374], [",", 1378], ["suggests", 1380], ["that", 1389], ["the", 1394], ["base", 1398], ["pairing", 1403], ["interactions", 1411], ["in", 1424], ["the", 1427], ["G.A", 1431], ["tandem", 1435], ["are", 1442], ["of", 1446], ["the", 1449], ["type", 1453], ["found", 1458], ["in", 1464], ["GNRA", 1467], ["loops", 1472], [".", 1477], ["The", 1479], ["3D", 1483], ["model", 1486], ["displays", 1492], ["the", 1501], ["quartet", 1505], ["lying", 1513], ["in", 1519], ["an", 1522], ["accessible", 1525], ["position", 1536], ["at", 1545], ["the", 1548], ["foot", 1552], ["of", 1557], ["helix", 1560], ["II", 1566], [",", 1568], ["which", 1570], ["is", 1576], ["bent", 1579], ["at", 1584], ["the", 1587], ["internal", 1591], ["loop", 1600], [",", 1604], ["suggesting", 1606], ["that", 1617], ["the", 1622], ["non", 1626], ["-", 1629], ["Watson", 1630], ["-", 1636], ["Crick", 1637], ["base", 1643], ["pair", 1648], ["arrangement", 1653], ["provides", 1665], ["an", 1674], ["unusual", 1677], ["pattern", 1685], ["of", 1693], ["chemical", 1696], ["groups", 1705], ["for", 1712], ["putative", 1716], ["ligand", 1725], ["interaction", 1732], [".", 1743]]}
{"context": "Specific outcomes upon activation of the c-Jun N-terminal kinase (JNK) pathway critically depend on the intensity and duration of signal transmission. Dual-specificity phosphatases (DUSPs) play a very important role in these events by modulating the extent of JNK phosphorylation and activation and thus regulating cellular responses to stress. M3/6 (DUSP8) is one of the dual-specificity protein phosphatases with distinct specificity towards JNK. It has been shown that M3/6 itself is phosphorylated by JNK upon stimulation with arsenite, but the role of this phosphorylation has not been investigated. In this study, we mapped JNK-induced phosphorylation sites on M3/6 using mass spectrometry. Phosphorylated residues Ser 515, Thr 518 and Ser 520 were identified and site-directed mutagenesis was employed to investigate their role. Upon arsenite stimulation, M3/6 mutated at these sites exhibited decreased phosphorylation compared to the wild-type protein. No difference was observed in terms of the enzyme's in vitro phosphatase activity, its substrate specificity towards JNK isoforms, its interactions with JNK and the scaffold family of JNK-interacting proteins (JIPs), its stability or its subcellular localization. Interestingly, expression of M3/6 phosphorylation mutants delayed the time-course of JNK phosphorylation and activation by arsenite. We propose that phosphorylation of the M3/6 phosphatase by JNK in response to stress stimuli results in attenuation of phosphatase activity and acceleration of JNK activation.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "a351b22b820341a499b92892e91315d8", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [112, 112], [77, 77], [192, 192], [186, 186], [198, 198], [226, 226], [89, 89], [242, 242], [14, 14], [257, 257]], "char_spans": [[260, 262], [630, 632], [444, 446], [1115, 1117], [1079, 1081], [1146, 1148], [1311, 1313], [505, 507], [1418, 1420], [66, 68], [1519, 1521]]}]}], "context_tokens": [["Specific", 0], ["outcomes", 9], ["upon", 18], ["activation", 23], ["of", 34], ["the", 37], ["c", 41], ["-", 42], ["Jun", 43], ["N", 47], ["-", 48], ["terminal", 49], ["kinase", 58], ["(", 65], ["JNK", 66], [")", 69], ["pathway", 71], ["critically", 79], ["depend", 90], ["on", 97], ["the", 100], ["intensity", 104], ["and", 114], ["duration", 118], ["of", 127], ["signal", 130], ["transmission", 137], [".", 149], ["Dual", 151], ["-", 155], ["specificity", 156], ["phosphatases", 168], ["(", 181], ["DUSPs", 182], [")", 187], ["play", 189], ["a", 194], ["very", 196], ["important", 201], ["role", 211], ["in", 216], ["these", 219], ["events", 225], ["by", 232], ["modulating", 235], ["the", 246], ["extent", 250], ["of", 257], ["JNK", 260], ["phosphorylation", 264], ["and", 280], ["activation", 284], ["and", 295], ["thus", 299], ["regulating", 304], ["cellular", 315], ["responses", 324], ["to", 334], ["stress", 337], [".", 343], ["M3/6", 345], ["(", 350], ["DUSP8", 351], [")", 356], ["is", 358], ["one", 361], ["of", 365], ["the", 368], ["dual", 372], ["-", 376], ["specificity", 377], ["protein", 389], ["phosphatases", 397], ["with", 410], ["distinct", 415], ["specificity", 424], ["towards", 436], ["JNK", 444], [".", 447], ["It", 449], ["has", 452], ["been", 456], ["shown", 461], ["that", 467], ["M3/6", 472], ["itself", 477], ["is", 484], ["phosphorylated", 487], ["by", 502], ["JNK", 505], ["upon", 509], ["stimulation", 514], ["with", 526], ["arsenite", 531], [",", 539], ["but", 541], ["the", 545], ["role", 549], ["of", 554], ["this", 557], ["phosphorylation", 562], ["has", 578], ["not", 582], ["been", 586], ["investigated", 591], [".", 603], ["In", 605], ["this", 608], ["study", 613], [",", 618], ["we", 620], ["mapped", 623], ["JNK", 630], ["-", 633], ["induced", 634], ["phosphorylation", 642], ["sites", 658], ["on", 664], ["M3/6", 667], ["using", 672], ["mass", 678], ["spectrometry", 683], [".", 695], ["Phosphorylated", 697], ["residues", 712], ["Ser", 721], ["515", 725], [",", 728], ["Thr", 730], ["518", 734], ["and", 738], ["Ser", 742], ["520", 746], ["were", 750], ["identified", 755], ["and", 766], ["site", 770], ["-", 774], ["directed", 775], ["mutagenesis", 784], ["was", 796], ["employed", 800], ["to", 809], ["investigate", 812], ["their", 824], ["role", 830], [".", 834], ["Upon", 836], ["arsenite", 841], ["stimulation", 850], [",", 861], ["M3/6", 863], ["mutated", 868], ["at", 876], ["these", 879], ["sites", 885], ["exhibited", 891], ["decreased", 901], ["phosphorylation", 911], ["compared", 927], ["to", 936], ["the", 939], ["wild", 943], ["-", 947], ["type", 948], ["protein", 953], [".", 960], ["No", 962], ["difference", 965], ["was", 976], ["observed", 980], ["in", 989], ["terms", 992], ["of", 998], ["the", 1001], ["enzyme", 1005], ["'s", 1011], ["in", 1014], ["vitro", 1017], ["phosphatase", 1023], ["activity", 1035], [",", 1043], ["its", 1045], ["substrate", 1049], ["specificity", 1059], ["towards", 1071], ["JNK", 1079], ["isoforms", 1083], [",", 1091], ["its", 1093], ["interactions", 1097], ["with", 1110], ["JNK", 1115], ["and", 1119], ["the", 1123], ["scaffold", 1127], ["family", 1136], ["of", 1143], ["JNK", 1146], ["-", 1149], ["interacting", 1150], ["proteins", 1162], ["(", 1171], ["JIPs", 1172], [")", 1176], [",", 1177], ["its", 1179], ["stability", 1183], ["or", 1193], ["its", 1196], ["subcellular", 1200], ["localization", 1212], [".", 1224], ["Interestingly", 1226], [",", 1239], ["expression", 1241], ["of", 1252], ["M3/6", 1255], ["phosphorylation", 1260], ["mutants", 1276], ["delayed", 1284], ["the", 1292], ["time", 1296], ["-", 1300], ["course", 1301], ["of", 1308], ["JNK", 1311], ["phosphorylation", 1315], ["and", 1331], ["activation", 1335], ["by", 1346], ["arsenite", 1349], [".", 1357], ["We", 1359], ["propose", 1362], ["that", 1370], ["phosphorylation", 1375], ["of", 1391], ["the", 1394], ["M3/6", 1398], ["phosphatase", 1403], ["by", 1415], ["JNK", 1418], ["in", 1422], ["response", 1425], ["to", 1434], ["stress", 1437], ["stimuli", 1444], ["results", 1452], ["in", 1460], ["attenuation", 1463], ["of", 1475], ["phosphatase", 1478], ["activity", 1490], ["and", 1499], ["acceleration", 1503], ["of", 1516], ["JNK", 1519], ["activation", 1523], [".", 1533]]}
{"context": "In chronic lymphocytic leukemia (CLL) signals from the B cell receptor (BCR) play a major role in disease development and progression. In this light, new therapies that specifically target signaling molecules downstream of the BCR continue to be developed. While first studies on the selective small molecule inhibitor of Bruton's tyrosine kinase (Btk), Ibrutinib (PCI-32765), demonstrated that Btk inhibition sensitizes CLL cells to apoptosis and alters their migratory behavior, these studies however did not address whether Btk-mediated signaling is involved in the process of CLL leukemogenesis. To investigate the requirement of Btk signaling for CLL development, we modulated Btk expression in the IgH.ET\u03bc CLL mouse model, which is based on sporadic expression of the simian oncovirus SV40 T-antigen in mature B cells. To this end, we crossed IgH.ET\u03bc mice on a Btk-deficient background or introduced a human Btk transgene (CD19-hBtk). Here we show that Btk deficiency fully abrogates CLL formation in IgH.ET\u03bc mice, and that leukemias formed in Btk haplo-insufficient mice selectively expressed the wild-type Btk allele on their active X chromosome. Conversely, Btk overexpression accelerated CLL onset, increased mortality, and was associated with selection of non-stereotypical BCRs into CLL clones. Taken together, these data show that Btk expression represents an absolute prerequisite for CLL development and that Btk mediated signaling enhances leukemogenesis in mice. We therefore conclude that in CLL Btk expression levels set the threshold for malignant transformation.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "f0635aa1d547406894740b04dba27d43", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[64, 64]], "char_spans": [[354, 362]]}]}], "context_tokens": [["In", 0], ["chronic", 3], ["lymphocytic", 11], ["leukemia", 23], ["(", 32], ["CLL", 33], [")", 36], ["signals", 38], ["from", 46], ["the", 51], ["B", 55], ["cell", 57], ["receptor", 62], ["(", 71], ["BCR", 72], [")", 75], ["play", 77], ["a", 82], ["major", 84], ["role", 90], ["in", 95], ["disease", 98], ["development", 106], ["and", 118], ["progression", 122], [".", 133], ["In", 135], ["this", 138], ["light", 143], [",", 148], ["new", 150], ["therapies", 154], ["that", 164], ["specifically", 169], ["target", 182], ["signaling", 189], ["molecules", 199], ["downstream", 209], ["of", 220], ["the", 223], ["BCR", 227], ["continue", 231], ["to", 240], ["be", 243], ["developed", 246], [".", 255], ["While", 257], ["first", 263], ["studies", 269], ["on", 277], ["the", 280], ["selective", 284], ["small", 294], ["molecule", 300], ["inhibitor", 309], ["of", 319], ["Bruton", 322], ["'s", 328], ["tyrosine", 331], ["kinase", 340], ["(", 347], ["Btk", 348], [")", 351], [",", 352], ["Ibrutinib", 354], ["(", 364], ["PCI-32765", 365], [")", 374], [",", 375], ["demonstrated", 377], ["that", 390], ["Btk", 395], ["inhibition", 399], ["sensitizes", 410], ["CLL", 421], ["cells", 425], ["to", 431], ["apoptosis", 434], ["and", 444], ["alters", 448], ["their", 455], ["migratory", 461], ["behavior", 471], [",", 479], ["these", 481], ["studies", 487], ["however", 495], ["did", 503], ["not", 507], ["address", 511], ["whether", 519], ["Btk", 527], ["-", 530], ["mediated", 531], ["signaling", 540], ["is", 550], ["involved", 553], ["in", 562], ["the", 565], ["process", 569], ["of", 577], ["CLL", 580], ["leukemogenesis", 584], [".", 598], ["To", 600], ["investigate", 603], ["the", 615], ["requirement", 619], ["of", 631], ["Btk", 634], ["signaling", 638], ["for", 648], ["CLL", 652], ["development", 656], [",", 667], ["we", 669], ["modulated", 672], ["Btk", 682], ["expression", 686], ["in", 697], ["the", 700], ["IgH.ET\u03bc", 704], ["CLL", 712], ["mouse", 716], ["model", 722], [",", 727], ["which", 729], ["is", 735], ["based", 738], ["on", 744], ["sporadic", 747], ["expression", 756], ["of", 767], ["the", 770], ["simian", 774], ["oncovirus", 781], ["SV40", 791], ["T", 796], ["-", 797], ["antigen", 798], ["in", 806], ["mature", 809], ["B", 816], ["cells", 818], [".", 823], ["To", 825], ["this", 828], ["end", 833], [",", 836], ["we", 838], ["crossed", 841], ["IgH.ET\u03bc", 849], ["mice", 857], ["on", 862], ["a", 865], ["Btk", 867], ["-", 870], ["deficient", 871], ["background", 881], ["or", 892], ["introduced", 895], ["a", 906], ["human", 908], ["Btk", 914], ["transgene", 918], ["(", 928], ["CD19-hBtk", 929], [")", 938], [".", 939], ["Here", 941], ["we", 946], ["show", 949], ["that", 954], ["Btk", 959], ["deficiency", 963], ["fully", 974], ["abrogates", 980], ["CLL", 990], ["formation", 994], ["in", 1004], ["IgH.ET\u03bc", 1007], ["mice", 1015], [",", 1019], ["and", 1021], ["that", 1025], ["leukemias", 1030], ["formed", 1040], ["in", 1047], ["Btk", 1050], ["haplo", 1054], ["-", 1059], ["insufficient", 1060], ["mice", 1073], ["selectively", 1078], ["expressed", 1090], ["the", 1100], ["wild", 1104], ["-", 1108], ["type", 1109], ["Btk", 1114], ["allele", 1118], ["on", 1125], ["their", 1128], ["active", 1134], ["X", 1141], ["chromosome", 1143], [".", 1153], ["Conversely", 1155], [",", 1165], ["Btk", 1167], ["overexpression", 1171], ["accelerated", 1186], ["CLL", 1198], ["onset", 1202], [",", 1207], ["increased", 1209], ["mortality", 1219], [",", 1228], ["and", 1230], ["was", 1234], ["associated", 1238], ["with", 1249], ["selection", 1254], ["of", 1264], ["non", 1267], ["-", 1270], ["stereotypical", 1271], ["BCRs", 1285], ["into", 1290], ["CLL", 1295], ["clones", 1299], [".", 1305], ["Taken", 1307], ["together", 1313], [",", 1321], ["these", 1323], ["data", 1329], ["show", 1334], ["that", 1339], ["Btk", 1344], ["expression", 1348], ["represents", 1359], ["an", 1370], ["absolute", 1373], ["prerequisite", 1382], ["for", 1395], ["CLL", 1399], ["development", 1403], ["and", 1415], ["that", 1419], ["Btk", 1424], ["mediated", 1428], ["signaling", 1437], ["enhances", 1447], ["leukemogenesis", 1456], ["in", 1471], ["mice", 1474], [".", 1478], ["We", 1480], ["therefore", 1483], ["conclude", 1493], ["that", 1502], ["in", 1507], ["CLL", 1510], ["Btk", 1514], ["expression", 1518], ["levels", 1529], ["set", 1536], ["the", 1540], ["threshold", 1544], ["for", 1554], ["malignant", 1558], ["transformation", 1568], [".", 1582]]}
{"context": "This study examined the accuracy of the 17-item Dutch version of the Davidson Trauma Scale (DTS) and the four-item SPAN (Startle, Physiological Arousal, Anger and Numbness) to detect survivors at risk for posttraumatic stress disorder (PTSD) within the first 2 weeks after the trauma. 203 civilian survivors of recent trauma with relatively mild symptoms completed the DTS a mean of 8.7 days after experiencing trauma. SPAN scores were computed from the DTS. At a mean of 64.6 days posttrauma, 160 respondents were assessed for diagnosis of PTSD with the Structured Interview for PTSD. Receiver operating characteristic curves showed that the DTS showed good overall screening accuracy (84%). At a cut-off value of 64, the DTS demonstrated a sensitivity of 0.86, a specificity of 0.70, a positive predictive value (PPV) of 0.12, and a negative predictive value (NPV) of 0.98. Overall accuracy of the SPAN was good (89%). At a cut-off of 10 the SPAN showed a sensitivity of 0.86, a specificity of 0.86, a PPV of 0.22, and a NPV of 0.98. The low PPVs were possibly due to the low of prevalence of PTSD in our sample (4.4%). This study shows that both the DTS and the SPAN are comparably accurate in screening early trauma survivors at risk for developing PTSD. The very brief four-item SPAN may be preferred over the longer 17-item DTS especially in settings in which time and resources are limited. Future studies should aim to cross-validate these results in random samples.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "f39ba0ef13d74fbbbee6b6a7495a7da1", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[224, 224], [106, 106], [44, 44], [100, 100], [255, 255]], "char_spans": [[1095, 1098], [580, 583], [236, 239], [541, 544], [1253, 1256]]}]}], "context_tokens": [["This", 0], ["study", 5], ["examined", 11], ["the", 20], ["accuracy", 24], ["of", 33], ["the", 36], ["17-item", 40], ["Dutch", 48], ["version", 54], ["of", 62], ["the", 65], ["Davidson", 69], ["Trauma", 78], ["Scale", 85], ["(", 91], ["DTS", 92], [")", 95], ["and", 97], ["the", 101], ["four", 105], ["-", 109], ["item", 110], ["SPAN", 115], ["(", 120], ["Startle", 121], [",", 128], ["Physiological", 130], ["Arousal", 144], [",", 151], ["Anger", 153], ["and", 159], ["Numbness", 163], [")", 171], ["to", 173], ["detect", 176], ["survivors", 183], ["at", 193], ["risk", 196], ["for", 201], ["posttraumatic", 205], ["stress", 219], ["disorder", 226], ["(", 235], ["PTSD", 236], [")", 240], ["within", 242], ["the", 249], ["first", 253], ["2", 259], ["weeks", 261], ["after", 267], ["the", 273], ["trauma", 277], [".", 283], ["203", 285], ["civilian", 289], ["survivors", 298], ["of", 308], ["recent", 311], ["trauma", 318], ["with", 325], ["relatively", 330], ["mild", 341], ["symptoms", 346], ["completed", 355], ["the", 365], ["DTS", 369], ["a", 373], ["mean", 375], ["of", 380], ["8.7", 383], ["days", 387], ["after", 392], ["experiencing", 398], ["trauma", 411], [".", 417], ["SPAN", 419], ["scores", 424], ["were", 431], ["computed", 436], ["from", 445], ["the", 450], ["DTS", 454], [".", 457], ["At", 459], ["a", 462], ["mean", 464], ["of", 469], ["64.6", 472], ["days", 477], ["posttrauma", 482], [",", 492], ["160", 494], ["respondents", 498], ["were", 510], ["assessed", 515], ["for", 524], ["diagnosis", 528], ["of", 538], ["PTSD", 541], ["with", 546], ["the", 551], ["Structured", 555], ["Interview", 566], ["for", 576], ["PTSD", 580], [".", 584], ["Receiver", 586], ["operating", 595], ["characteristic", 605], ["curves", 620], ["showed", 627], ["that", 634], ["the", 639], ["DTS", 643], ["showed", 647], ["good", 654], ["overall", 659], ["screening", 667], ["accuracy", 677], ["(", 686], ["84", 687], ["%", 689], [")", 690], [".", 691], ["At", 693], ["a", 696], ["cut", 698], ["-", 701], ["off", 702], ["value", 706], ["of", 712], ["64", 715], [",", 717], ["the", 719], ["DTS", 723], ["demonstrated", 727], ["a", 740], ["sensitivity", 742], ["of", 754], ["0.86", 757], [",", 761], ["a", 763], ["specificity", 765], ["of", 777], ["0.70", 780], [",", 784], ["a", 786], ["positive", 788], ["predictive", 797], ["value", 808], ["(", 814], ["PPV", 815], [")", 818], ["of", 820], ["0.12", 823], [",", 827], ["and", 829], ["a", 833], ["negative", 835], ["predictive", 844], ["value", 855], ["(", 861], ["NPV", 862], [")", 865], ["of", 867], ["0.98", 870], [".", 874], ["Overall", 876], ["accuracy", 884], ["of", 893], ["the", 896], ["SPAN", 900], ["was", 905], ["good", 909], ["(", 914], ["89", 915], ["%", 917], [")", 918], [".", 919], ["At", 921], ["a", 924], ["cut", 926], ["-", 929], ["off", 930], ["of", 934], ["10", 937], ["the", 940], ["SPAN", 944], ["showed", 949], ["a", 956], ["sensitivity", 958], ["of", 970], ["0.86", 973], [",", 977], ["a", 979], ["specificity", 981], ["of", 993], ["0.86", 996], [",", 1000], ["a", 1002], ["PPV", 1004], ["of", 1008], ["0.22", 1011], [",", 1015], ["and", 1017], ["a", 1021], ["NPV", 1023], ["of", 1027], ["0.98", 1030], [".", 1034], ["The", 1036], ["low", 1040], ["PPVs", 1044], ["were", 1049], ["possibly", 1054], ["due", 1063], ["to", 1067], ["the", 1070], ["low", 1074], ["of", 1078], ["prevalence", 1081], ["of", 1092], ["PTSD", 1095], ["in", 1100], ["our", 1103], ["sample", 1107], ["(", 1114], ["4.4", 1115], ["%", 1118], [")", 1119], [".", 1120], ["This", 1122], ["study", 1127], ["shows", 1133], ["that", 1139], ["both", 1144], ["the", 1149], ["DTS", 1153], ["and", 1157], ["the", 1161], ["SPAN", 1165], ["are", 1170], ["comparably", 1174], ["accurate", 1185], ["in", 1194], ["screening", 1197], ["early", 1207], ["trauma", 1213], ["survivors", 1220], ["at", 1230], ["risk", 1233], ["for", 1238], ["developing", 1242], ["PTSD", 1253], [".", 1257], ["The", 1259], ["very", 1263], ["brief", 1268], ["four", 1274], ["-", 1278], ["item", 1279], ["SPAN", 1284], ["may", 1289], ["be", 1293], ["preferred", 1296], ["over", 1306], ["the", 1311], ["longer", 1315], ["17-item", 1322], ["DTS", 1330], ["especially", 1334], ["in", 1345], ["settings", 1348], ["in", 1357], ["which", 1360], ["time", 1366], ["and", 1371], ["resources", 1375], ["are", 1385], ["limited", 1389], [".", 1396], ["Future", 1398], ["studies", 1405], ["should", 1413], ["aim", 1420], ["to", 1424], ["cross", 1427], ["-", 1432], ["validate", 1433], ["these", 1442], ["results", 1448], ["in", 1456], ["random", 1459], ["samples", 1466], [".", 1473]]}
{"context": "Restless Legs Syndrome (RLS) or Willis-Ekbom Disease (WED) is highly prevalent, but patients and healthcare providers alike know little about it. Furthermore, controversy persists as to the best way of diagnosing this nosological entity. To verify whether the term used to refer to this disease entity (Restless Legs Syndrome or Willis-Ekbom Disease) affects the prevalence of self-diagnosed RLS/WED in a sample of newly graduated physicians. Newly graduated physicians were asked to self-evaluate for the presence of RLS/WED. Briefly, participants were allocated randomly across two groups. One was asked to self-assess for RLS, while the other was asked to self-assess for WED. The evaluation form given to one group asked 'Do you have Restless Legs Syndrome?' whereas the form given to participants in the other group asked 'Do you have Willis-Ekbom Disease?'. Both forms also contained the four criteria for diagnosing RLS proposed by the International Restless Legs Syndrome Study Group (IRLSSG) and instructions for self-diagnosis according to these criteria. The study sample comprised 1413 newly graduated physicians. Of the 708 participants who were given the form that used the term RLS, 87 (12.28%) diagnosed themselves with the condition. Conversely, of 705 physicians given the form with the term WED, 13 (1.84%) diagnosed themselves with the condition (p\u2009<0.0001). A greater proportion of newly graduated physicians diagnosed themselves with RLS/WED when presented with the term Restless Legs Syndrome than when presented with the term Willis-Ekbom Disease. This suggests that the term Restless Legs Syndrome may not be the most appropriate term to denote this nosological entity.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "16a25da84839436a89074d9ddedd979f", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[145, 147], [306, 308], [186, 188], [57, 59], [0, 2], [287, 289]], "char_spans": [[738, 759], [1600, 1621], [957, 978], [303, 324], [0, 21], [1493, 1514]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["or", 29], ["Willis", 32], ["-", 38], ["Ekbom", 39], ["Disease", 45], ["(", 53], ["WED", 54], [")", 57], ["is", 59], ["highly", 62], ["prevalent", 69], [",", 78], ["but", 80], ["patients", 84], ["and", 93], ["healthcare", 97], ["providers", 108], ["alike", 118], ["know", 124], ["little", 129], ["about", 136], ["it", 142], [".", 144], ["Furthermore", 146], [",", 157], ["controversy", 159], ["persists", 171], ["as", 180], ["to", 183], ["the", 186], ["best", 190], ["way", 195], ["of", 199], ["diagnosing", 202], ["this", 213], ["nosological", 218], ["entity", 230], [".", 236], ["To", 238], ["verify", 241], ["whether", 248], ["the", 256], ["term", 260], ["used", 265], ["to", 270], ["refer", 273], ["to", 279], ["this", 282], ["disease", 287], ["entity", 295], ["(", 302], ["Restless", 303], ["Legs", 312], ["Syndrome", 317], ["or", 326], ["Willis", 329], ["-", 335], ["Ekbom", 336], ["Disease", 342], [")", 349], ["affects", 351], ["the", 359], ["prevalence", 363], ["of", 374], ["self", 377], ["-", 381], ["diagnosed", 382], ["RLS", 392], ["/", 395], ["WED", 396], ["in", 400], ["a", 403], ["sample", 405], ["of", 412], ["newly", 415], ["graduated", 421], ["physicians", 431], [".", 441], ["Newly", 443], ["graduated", 449], ["physicians", 459], ["were", 470], ["asked", 475], ["to", 481], ["self", 484], ["-", 488], ["evaluate", 489], ["for", 498], ["the", 502], ["presence", 506], ["of", 515], ["RLS", 518], ["/", 521], ["WED", 522], [".", 525], ["Briefly", 527], [",", 534], ["participants", 536], ["were", 549], ["allocated", 554], ["randomly", 564], ["across", 573], ["two", 580], ["groups", 584], [".", 590], ["One", 592], ["was", 596], ["asked", 600], ["to", 606], ["self", 609], ["-", 613], ["assess", 614], ["for", 621], ["RLS", 625], [",", 628], ["while", 630], ["the", 636], ["other", 640], ["was", 646], ["asked", 650], ["to", 656], ["self", 659], ["-", 663], ["assess", 664], ["for", 671], ["WED", 675], [".", 678], ["The", 680], ["evaluation", 684], ["form", 695], ["given", 700], ["to", 706], ["one", 709], ["group", 713], ["asked", 719], ["'", 725], ["Do", 726], ["you", 729], ["have", 733], ["Restless", 738], ["Legs", 747], ["Syndrome", 752], ["?", 760], ["'", 761], ["whereas", 763], ["the", 771], ["form", 775], ["given", 780], ["to", 786], ["participants", 789], ["in", 802], ["the", 805], ["other", 809], ["group", 815], ["asked", 821], ["'", 827], ["Do", 828], ["you", 831], ["have", 835], ["Willis", 840], ["-", 846], ["Ekbom", 847], ["Disease", 853], ["?", 860], ["'", 861], [".", 862], ["Both", 864], ["forms", 869], ["also", 875], ["contained", 880], ["the", 890], ["four", 894], ["criteria", 899], ["for", 908], ["diagnosing", 912], ["RLS", 923], ["proposed", 927], ["by", 936], ["the", 939], ["International", 943], ["Restless", 957], ["Legs", 966], ["Syndrome", 971], ["Study", 980], ["Group", 986], ["(", 992], ["IRLSSG", 993], [")", 999], ["and", 1001], ["instructions", 1005], ["for", 1018], ["self", 1022], ["-", 1026], ["diagnosis", 1027], ["according", 1037], ["to", 1047], ["these", 1050], ["criteria", 1056], [".", 1064], ["The", 1066], ["study", 1070], ["sample", 1076], ["comprised", 1083], ["1413", 1093], ["newly", 1098], ["graduated", 1104], ["physicians", 1114], [".", 1124], ["Of", 1126], ["the", 1129], ["708", 1133], ["participants", 1137], ["who", 1150], ["were", 1154], ["given", 1159], ["the", 1165], ["form", 1169], ["that", 1174], ["used", 1179], ["the", 1184], ["term", 1188], ["RLS", 1193], [",", 1196], ["87", 1198], ["(", 1201], ["12.28", 1202], ["%", 1207], [")", 1208], ["diagnosed", 1210], ["themselves", 1220], ["with", 1231], ["the", 1236], ["condition", 1240], [".", 1249], ["Conversely", 1251], [",", 1261], ["of", 1263], ["705", 1266], ["physicians", 1270], ["given", 1281], ["the", 1287], ["form", 1291], ["with", 1296], ["the", 1301], ["term", 1305], ["WED", 1310], [",", 1313], ["13", 1315], ["(", 1318], ["1.84", 1319], ["%", 1323], [")", 1324], ["diagnosed", 1326], ["themselves", 1336], ["with", 1347], ["the", 1352], ["condition", 1356], ["(", 1366], ["p", 1367], ["<", 1369], ["0.0001", 1370], [")", 1376], [".", 1377], ["A", 1379], ["greater", 1381], ["proportion", 1389], ["of", 1400], ["newly", 1403], ["graduated", 1409], ["physicians", 1419], ["diagnosed", 1430], ["themselves", 1440], ["with", 1451], ["RLS", 1456], ["/", 1459], ["WED", 1460], ["when", 1464], ["presented", 1469], ["with", 1479], ["the", 1484], ["term", 1488], ["Restless", 1493], ["Legs", 1502], ["Syndrome", 1507], ["than", 1516], ["when", 1521], ["presented", 1526], ["with", 1536], ["the", 1541], ["term", 1545], ["Willis", 1550], ["-", 1556], ["Ekbom", 1557], ["Disease", 1563], [".", 1570], ["This", 1572], ["suggests", 1577], ["that", 1586], ["the", 1591], ["term", 1595], ["Restless", 1600], ["Legs", 1609], ["Syndrome", 1614], ["may", 1623], ["not", 1627], ["be", 1631], ["the", 1634], ["most", 1638], ["appropriate", 1643], ["term", 1655], ["to", 1660], ["denote", 1663], ["this", 1670], ["nosological", 1675], ["entity", 1687], [".", 1693]]}
{"context": "The objective of this guideline is to assist poison center personnel in the appropriate out-of-hospital triage and initial out-of-hospital management of patients with a suspected ingestion of dextromethorphan by 1) describing the process by which an ingestion of dextromethorphan might be managed, 2) identifying the key decision elements in managing cases of dextromethorphan ingestion, 3) providing clear and practical recommendations that reflect the current state of knowledge, and 4) identifying needs for research. This guideline applies to the ingestion of dextromethorphan alone. Co-ingestion of additional substances could require different referral and management recommendations depending on the combined toxicities of the substances. This guideline is based on an assessment of current scientific and clinical information. The expert consensus panel recognizes that specific patient care decisions might be at variance with this guideline and are the prerogative of the patient and the health professionals providing care, considering all of the circumstances involved. This guideline does not substitute for clinical judgment. The grade of recommendation is in parentheses. 1) All patients with suicidal intent, intentional abuse, or in cases in which a malicious intent is suspected (e.g., child abuse or neglect) should be referred to an emergency department (Grade D). 2) Patients who exhibit more than mild effects (e.g., infrequent vomiting or somnolence [lightly sedated and arousable with speaking voice or light touch]) after an acute dextromethorphan ingestion should be referred to an emergency department (Grade C). 3) Patients who have ingested 5-7.5 mg/kg should receive poison center-initiated follow-up approximately every 2 hours for up to 4 hours after ingestion. Refer to an emergency department if more than mild symptoms develop (Grade D). 4) Patients who have ingested more than 7.5 mg/kg should be referred to an emergency department for evaluation (Grade C). 5) If the patient is taking other medications likely to interact with dextromethorphan and cause serotonin syndrome, such as monoamine oxidase inhibitors or selective serotonin reuptake inhibitors, poison center-initiated follow-up every 2 hours for 8 hours is recommended (Grade D). 6) Patients who are asymptomatic and more than 4 hours have elapsed since the time of ingestion can be observed at home (Grade C). 7) Do not induce emesis (Grade D). 8) Do not use activated charcoal at home. Activated charcoal can be administered to asymptomatic patients who have ingested overdoses of dextromethorphan within the preceding hour. Its administration, if available, should only be carried out by health professionals and only if no contraindications are present. Do not delay transportation in order to administer activated charcoal (Grade D). 9) For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in the usual doses for treatment of opioid overdose, can be considered for prehospital administration, particularly if the patient has respiratory depression (Grade C). 10) Use intravenous benzodiazepines for seizures and benzodiazepines and external cooling measures for hyperthermia (>104 degrees F, >40 degrees C) for serotonin syndrome. This should be done in consultation with and authorized by EMS medical direction, by a written treatment protocol or policy, or with direct medical oversight (Grade C). 11) Carefully ascertain by history whether other drugs, such as acetaminophen, were involved in the incident and assess the risk for toxicity or for a drug interaction.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "bb05ffd715264fdf8fc2a8c7edaf0d04", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[520, 520]], "char_spans": [[2918, 2925]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["of", 14], ["this", 17], ["guideline", 22], ["is", 32], ["to", 35], ["assist", 38], ["poison", 45], ["center", 52], ["personnel", 59], ["in", 69], ["the", 72], ["appropriate", 76], ["out", 88], ["-", 91], ["of", 92], ["-", 94], ["hospital", 95], ["triage", 104], ["and", 111], ["initial", 115], ["out", 123], ["-", 126], ["of", 127], ["-", 129], ["hospital", 130], ["management", 139], ["of", 150], ["patients", 153], ["with", 162], ["a", 167], ["suspected", 169], ["ingestion", 179], ["of", 189], ["dextromethorphan", 192], ["by", 209], ["1", 212], [")", 213], ["describing", 215], ["the", 226], ["process", 230], ["by", 238], ["which", 241], ["an", 247], ["ingestion", 250], ["of", 260], ["dextromethorphan", 263], ["might", 280], ["be", 286], ["managed", 289], [",", 296], ["2", 298], [")", 299], ["identifying", 301], ["the", 313], ["key", 317], ["decision", 321], ["elements", 330], ["in", 339], ["managing", 342], ["cases", 351], ["of", 357], ["dextromethorphan", 360], ["ingestion", 377], [",", 386], ["3", 388], [")", 389], ["providing", 391], ["clear", 401], ["and", 407], ["practical", 411], ["recommendations", 421], ["that", 437], ["reflect", 442], ["the", 450], ["current", 454], ["state", 462], ["of", 468], ["knowledge", 471], [",", 480], ["and", 482], ["4", 486], [")", 487], ["identifying", 489], ["needs", 501], ["for", 507], ["research", 511], [".", 519], ["This", 521], ["guideline", 526], ["applies", 536], ["to", 544], ["the", 547], ["ingestion", 551], ["of", 561], ["dextromethorphan", 564], ["alone", 581], [".", 586], ["Co", 588], ["-", 590], ["ingestion", 591], ["of", 601], ["additional", 604], ["substances", 615], ["could", 626], ["require", 632], ["different", 640], ["referral", 650], ["and", 659], ["management", 663], ["recommendations", 674], ["depending", 690], ["on", 700], ["the", 703], ["combined", 707], ["toxicities", 716], ["of", 727], ["the", 730], ["substances", 734], [".", 744], ["This", 746], ["guideline", 751], ["is", 761], ["based", 764], ["on", 770], ["an", 773], ["assessment", 776], ["of", 787], ["current", 790], ["scientific", 798], ["and", 809], ["clinical", 813], ["information", 822], [".", 833], ["The", 835], ["expert", 839], ["consensus", 846], ["panel", 856], ["recognizes", 862], ["that", 873], ["specific", 878], ["patient", 887], ["care", 895], ["decisions", 900], ["might", 910], ["be", 916], ["at", 919], ["variance", 922], ["with", 931], ["this", 936], ["guideline", 941], ["and", 951], ["are", 955], ["the", 959], ["prerogative", 963], ["of", 975], ["the", 978], ["patient", 982], ["and", 990], ["the", 994], ["health", 998], ["professionals", 1005], ["providing", 1019], ["care", 1029], [",", 1033], ["considering", 1035], ["all", 1047], ["of", 1051], ["the", 1054], ["circumstances", 1058], ["involved", 1072], [".", 1080], ["This", 1082], ["guideline", 1087], ["does", 1097], ["not", 1102], ["substitute", 1106], ["for", 1117], ["clinical", 1121], ["judgment", 1130], [".", 1138], ["The", 1140], ["grade", 1144], ["of", 1150], ["recommendation", 1153], ["is", 1168], ["in", 1171], ["parentheses", 1174], [".", 1185], ["1", 1187], [")", 1188], ["All", 1190], ["patients", 1194], ["with", 1203], ["suicidal", 1208], ["intent", 1217], [",", 1223], ["intentional", 1225], ["abuse", 1237], [",", 1242], ["or", 1244], ["in", 1247], ["cases", 1250], ["in", 1256], ["which", 1259], ["a", 1265], ["malicious", 1267], ["intent", 1277], ["is", 1284], ["suspected", 1287], ["(", 1297], ["e.g.", 1298], [",", 1302], ["child", 1304], ["abuse", 1310], ["or", 1316], ["neglect", 1319], [")", 1326], ["should", 1328], ["be", 1335], ["referred", 1338], ["to", 1347], ["an", 1350], ["emergency", 1353], ["department", 1363], ["(", 1374], ["Grade", 1375], ["D", 1381], [")", 1382], [".", 1383], ["2", 1385], [")", 1386], ["Patients", 1388], ["who", 1397], ["exhibit", 1401], ["more", 1409], ["than", 1414], ["mild", 1419], ["effects", 1424], ["(", 1432], ["e.g.", 1433], [",", 1437], ["infrequent", 1439], ["vomiting", 1450], ["or", 1459], ["somnolence", 1462], ["[", 1473], ["lightly", 1474], ["sedated", 1482], ["and", 1490], ["arousable", 1494], ["with", 1504], ["speaking", 1509], ["voice", 1518], ["or", 1524], ["light", 1527], ["touch", 1533], ["]", 1538], [")", 1539], ["after", 1541], ["an", 1547], ["acute", 1550], ["dextromethorphan", 1556], ["ingestion", 1573], ["should", 1583], ["be", 1590], ["referred", 1593], ["to", 1602], ["an", 1605], ["emergency", 1608], ["department", 1618], ["(", 1629], ["Grade", 1630], ["C", 1636], [")", 1637], [".", 1638], ["3", 1640], [")", 1641], ["Patients", 1643], ["who", 1652], ["have", 1656], ["ingested", 1661], ["5", 1670], ["-", 1671], ["7.5", 1672], ["mg", 1676], ["/", 1678], ["kg", 1679], ["should", 1682], ["receive", 1689], ["poison", 1697], ["center", 1704], ["-", 1710], ["initiated", 1711], ["follow", 1721], ["-", 1727], ["up", 1728], ["approximately", 1731], ["every", 1745], ["2", 1751], ["hours", 1753], ["for", 1759], ["up", 1763], ["to", 1766], ["4", 1769], ["hours", 1771], ["after", 1777], ["ingestion", 1783], [".", 1792], ["Refer", 1794], ["to", 1800], ["an", 1803], ["emergency", 1806], ["department", 1816], ["if", 1827], ["more", 1830], ["than", 1835], ["mild", 1840], ["symptoms", 1845], ["develop", 1854], ["(", 1862], ["Grade", 1863], ["D", 1869], [")", 1870], [".", 1871], ["4", 1873], [")", 1874], ["Patients", 1876], ["who", 1885], ["have", 1889], ["ingested", 1894], ["more", 1903], ["than", 1908], ["7.5", 1913], ["mg", 1917], ["/", 1919], ["kg", 1920], ["should", 1923], ["be", 1930], ["referred", 1933], ["to", 1942], ["an", 1945], ["emergency", 1948], ["department", 1958], ["for", 1969], ["evaluation", 1973], ["(", 1984], ["Grade", 1985], ["C", 1991], [")", 1992], [".", 1993], ["5", 1995], [")", 1996], ["If", 1998], ["the", 2001], ["patient", 2005], ["is", 2013], ["taking", 2016], ["other", 2023], ["medications", 2029], ["likely", 2041], ["to", 2048], ["interact", 2051], ["with", 2060], ["dextromethorphan", 2065], ["and", 2082], ["cause", 2086], ["serotonin", 2092], ["syndrome", 2102], [",", 2110], ["such", 2112], ["as", 2117], ["monoamine", 2120], ["oxidase", 2130], ["inhibitors", 2138], ["or", 2149], ["selective", 2152], ["serotonin", 2162], ["reuptake", 2172], ["inhibitors", 2181], [",", 2191], ["poison", 2193], ["center", 2200], ["-", 2206], ["initiated", 2207], ["follow", 2217], ["-", 2223], ["up", 2224], ["every", 2227], ["2", 2233], ["hours", 2235], ["for", 2241], ["8", 2245], ["hours", 2247], ["is", 2253], ["recommended", 2256], ["(", 2268], ["Grade", 2269], ["D", 2275], [")", 2276], [".", 2277], ["6", 2279], [")", 2280], ["Patients", 2282], ["who", 2291], ["are", 2295], ["asymptomatic", 2299], ["and", 2312], ["more", 2316], ["than", 2321], ["4", 2326], ["hours", 2328], ["have", 2334], ["elapsed", 2339], ["since", 2347], ["the", 2353], ["time", 2357], ["of", 2362], ["ingestion", 2365], ["can", 2375], ["be", 2379], ["observed", 2382], ["at", 2391], ["home", 2394], ["(", 2399], ["Grade", 2400], ["C", 2406], [")", 2407], [".", 2408], ["7", 2410], [")", 2411], ["Do", 2413], ["not", 2416], ["induce", 2420], ["emesis", 2427], ["(", 2434], ["Grade", 2435], ["D", 2441], [")", 2442], [".", 2443], ["8)", 2445], ["Do", 2448], ["not", 2451], ["use", 2455], ["activated", 2459], ["charcoal", 2469], ["at", 2478], ["home", 2481], [".", 2485], ["Activated", 2487], ["charcoal", 2497], ["can", 2506], ["be", 2510], ["administered", 2513], ["to", 2526], ["asymptomatic", 2529], ["patients", 2542], ["who", 2551], ["have", 2555], ["ingested", 2560], ["overdoses", 2569], ["of", 2579], ["dextromethorphan", 2582], ["within", 2599], ["the", 2606], ["preceding", 2610], ["hour", 2620], [".", 2624], ["Its", 2626], ["administration", 2630], [",", 2644], ["if", 2646], ["available", 2649], [",", 2658], ["should", 2660], ["only", 2667], ["be", 2672], ["carried", 2675], ["out", 2683], ["by", 2687], ["health", 2690], ["professionals", 2697], ["and", 2711], ["only", 2715], ["if", 2720], ["no", 2723], ["contraindications", 2726], ["are", 2744], ["present", 2748], [".", 2755], ["Do", 2757], ["not", 2760], ["delay", 2764], ["transportation", 2770], ["in", 2785], ["order", 2788], ["to", 2794], ["administer", 2797], ["activated", 2808], ["charcoal", 2818], ["(", 2827], ["Grade", 2828], ["D", 2834], [")", 2835], [".", 2836], ["9", 2838], [")", 2839], ["For", 2841], ["patients", 2845], ["who", 2854], ["have", 2858], ["ingested", 2863], ["dextromethorphan", 2872], ["and", 2889], ["are", 2893], ["sedated", 2897], ["or", 2905], ["comatose", 2908], [",", 2916], ["naloxone", 2918], [",", 2926], ["in", 2928], ["the", 2931], ["usual", 2935], ["doses", 2941], ["for", 2947], ["treatment", 2951], ["of", 2961], ["opioid", 2964], ["overdose", 2971], [",", 2979], ["can", 2981], ["be", 2985], ["considered", 2988], ["for", 2999], ["prehospital", 3003], ["administration", 3015], [",", 3029], ["particularly", 3031], ["if", 3044], ["the", 3047], ["patient", 3051], ["has", 3059], ["respiratory", 3063], ["depression", 3075], ["(", 3086], ["Grade", 3087], ["C", 3093], [")", 3094], [".", 3095], ["10", 3097], [")", 3099], ["Use", 3101], ["intravenous", 3105], ["benzodiazepines", 3117], ["for", 3133], ["seizures", 3137], ["and", 3146], ["benzodiazepines", 3150], ["and", 3166], ["external", 3170], ["cooling", 3179], ["measures", 3187], ["for", 3196], ["hyperthermia", 3200], ["(", 3213], [">", 3214], ["104", 3215], ["degrees", 3219], ["F", 3227], [",", 3228], [">", 3230], ["40", 3231], ["degrees", 3234], ["C", 3242], [")", 3243], ["for", 3245], ["serotonin", 3249], ["syndrome", 3259], [".", 3267], ["This", 3269], ["should", 3274], ["be", 3281], ["done", 3284], ["in", 3289], ["consultation", 3292], ["with", 3305], ["and", 3310], ["authorized", 3314], ["by", 3325], ["EMS", 3328], ["medical", 3332], ["direction", 3340], [",", 3349], ["by", 3351], ["a", 3354], ["written", 3356], ["treatment", 3364], ["protocol", 3374], ["or", 3383], ["policy", 3386], [",", 3392], ["or", 3394], ["with", 3397], ["direct", 3402], ["medical", 3409], ["oversight", 3417], ["(", 3427], ["Grade", 3428], ["C", 3434], [")", 3435], [".", 3436], ["11", 3438], [")", 3440], ["Carefully", 3442], ["ascertain", 3452], ["by", 3462], ["history", 3465], ["whether", 3473], ["other", 3481], ["drugs", 3487], [",", 3492], ["such", 3494], ["as", 3499], ["acetaminophen", 3502], [",", 3515], ["were", 3517], ["involved", 3522], ["in", 3531], ["the", 3534], ["incident", 3538], ["and", 3547], ["assess", 3551], ["the", 3558], ["risk", 3562], ["for", 3567], ["toxicity", 3571], ["or", 3580], ["for", 3583], ["a", 3587], ["drug", 3589], ["interaction", 3594], [".", 3605]]}
{"context": "Rates of remission were examined in two controlled 12-week studies of sertraline and placebo for post-traumatic stress disorder (PTSD). The performance of three scales was evaluated: the self-rated Davidson Trauma Scale (DTS), and two interviewer scales: the Clinician Administered PTSD Scale (CAPS) and Clinical Global Impressions (CGI). Sertraline proved significantly superior to placebo with respect to remission on all three ratings. Rates of remission were very similar for all scales, ranging from 23.1-26.3% for sertraline and 13.9-14.9% for placebo. Traditional thresholds for the CAPS and DTS were tested relative to the CGI and to each other. The CAPS and DTS thresholds of < 20 and < 18 were found to be valid.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b086ca841a4040e58142b56004268573", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[15, 19]], "char_spans": [[97, 126]]}, {"text": "PTSD", "token_spans": [[21, 21], [51, 51]], "char_spans": [[129, 132], [282, 285]]}]}], "context_tokens": [["Rates", 0], ["of", 6], ["remission", 9], ["were", 19], ["examined", 24], ["in", 33], ["two", 36], ["controlled", 40], ["12-week", 51], ["studies", 59], ["of", 67], ["sertraline", 70], ["and", 81], ["placebo", 85], ["for", 93], ["post", 97], ["-", 101], ["traumatic", 102], ["stress", 112], ["disorder", 119], ["(", 128], ["PTSD", 129], [")", 133], [".", 134], ["The", 136], ["performance", 140], ["of", 152], ["three", 155], ["scales", 161], ["was", 168], ["evaluated", 172], [":", 181], ["the", 183], ["self", 187], ["-", 191], ["rated", 192], ["Davidson", 198], ["Trauma", 207], ["Scale", 214], ["(", 220], ["DTS", 221], [")", 224], [",", 225], ["and", 227], ["two", 231], ["interviewer", 235], ["scales", 247], [":", 253], ["the", 255], ["Clinician", 259], ["Administered", 269], ["PTSD", 282], ["Scale", 287], ["(", 293], ["CAPS", 294], [")", 298], ["and", 300], ["Clinical", 304], ["Global", 313], ["Impressions", 320], ["(", 332], ["CGI", 333], [")", 336], [".", 337], ["Sertraline", 339], ["proved", 350], ["significantly", 357], ["superior", 371], ["to", 380], ["placebo", 383], ["with", 391], ["respect", 396], ["to", 404], ["remission", 407], ["on", 417], ["all", 420], ["three", 424], ["ratings", 430], [".", 437], ["Rates", 439], ["of", 445], ["remission", 448], ["were", 458], ["very", 463], ["similar", 468], ["for", 476], ["all", 480], ["scales", 484], [",", 490], ["ranging", 492], ["from", 500], ["23.1", 505], ["-", 509], ["26.3", 510], ["%", 514], ["for", 516], ["sertraline", 520], ["and", 531], ["13.9", 535], ["-", 539], ["14.9", 540], ["%", 544], ["for", 546], ["placebo", 550], [".", 557], ["Traditional", 559], ["thresholds", 571], ["for", 582], ["the", 586], ["CAPS", 590], ["and", 595], ["DTS", 599], ["were", 603], ["tested", 608], ["relative", 615], ["to", 624], ["the", 627], ["CGI", 631], ["and", 635], ["to", 639], ["each", 642], ["other", 647], [".", 652], ["The", 654], ["CAPS", 658], ["and", 663], ["DTS", 667], ["thresholds", 671], ["of", 682], ["<", 685], ["20", 687], ["and", 690], ["<", 694], ["18", 696], ["were", 699], ["found", 704], ["to", 710], ["be", 713], ["valid", 716], [".", 721]]}
{"context": "It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "9345b19e2b08406092884e3a093f3bd3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[48, 50]], "char_spans": [[271, 289]]}, {"text": "NGF", "token_spans": [[77, 77], [262, 262], [52, 52], [244, 244], [199, 199], [284, 284], [396, 396], [88, 88], [146, 146], [159, 159]], "char_spans": [[422, 424], [1489, 1491], [292, 294], [1386, 1388], [1121, 1123], [1614, 1616], [2276, 2278], [490, 492], [841, 843], [907, 909]]}]}], "context_tokens": [["It", 0], ["is", 3], ["unanimously", 6], ["accepted", 18], ["that", 27], ["there", 32], ["is", 38], ["an", 41], ["unmet", 44], ["need", 50], ["for", 55], ["pain", 59], ["medications", 64], ["that", 76], ["are", 81], ["both", 85], ["effective", 90], ["and", 100], ["safe", 104], [".", 108], ["Unfortunately", 110], [",", 123], ["no", 125], ["really", 128], ["novel", 135], ["analgesics", 141], ["have", 152], ["been", 157], ["approved", 162], ["over", 171], ["the", 176], ["past", 180], ["three", 185], ["decades", 191], [".", 198], ["In", 200], ["view", 203], ["of", 208], ["both", 211], ["experimental", 216], ["and", 229], ["clinical", 233], ["evidence", 242], ["of", 251], ["a", 254], ["major", 256], ["role", 262], ["for", 267], ["nerve", 271], ["growth", 277], ["factor", 284], ["(", 291], ["NGF", 292], [")", 295], ["in", 297], ["the", 300], ["generation", 304], ["and", 315], ["maintenance", 319], ["of", 331], ["a", 334], ["wide", 336], ["range", 341], ["of", 347], ["pain", 350], ["states", 355], [",", 361], ["drug", 363], ["discovery", 368], ["efforts", 378], ["focusing", 386], ["on", 395], ["the", 398], ["development", 402], ["of", 414], ["anti", 417], ["-", 421], ["NGF", 422], ["agents", 426], ["have", 433], ["aroused", 438], ["particular", 446], ["interest", 457], [".", 465], ["Several", 467], ["humanized", 475], ["anti", 485], ["-", 489], ["NGF", 490], ["monoclonal", 494], ["antibodies", 505], ["(", 516], ["mAbs", 517], [")", 521], ["have", 523], ["entered", 528], ["clinical", 536], ["trials", 545], ["as", 552], ["potential", 555], ["analgesics", 565], [".", 575], ["In", 577], ["this", 580], ["respect", 585], [",", 592], ["tanezumab", 594], ["is", 604], ["at", 607], ["an", 610], ["advanced", 613], ["stage", 622], ["of", 628], ["clinical", 631], ["development", 640], ["while", 652], ["fulranumab", 658], [",", 668], ["fasinumab", 670], ["and", 680], ["ABT-110", 684], [",", 691], ["previously", 693], ["known", 704], ["as", 710], ["PG110", 713], [",", 718], ["are", 720], ["in", 724], ["early", 727], ["phases", 733], ["of", 740], ["clinical", 743], ["development", 752], [".", 763], ["This", 765], ["Current", 770], ["Opinion", 778], ["article", 786], ["aims", 794], ["at", 799], ["describing", 802], ["the", 813], ["rationale", 817], ["for", 827], ["targeting", 831], ["NGF", 841], ["for", 845], ["pain", 849], [",", 853], ["reviewing", 855], ["the", 865], ["analgesic", 869], ["efficacy", 879], ["and", 888], ["safety", 892], ["of", 899], ["anti", 902], ["-", 906], ["NGF", 907], ["agents", 911], ["based", 918], ["on", 924], ["data", 927], ["from", 932], ["fully", 937], ["published", 943], ["studies", 953], [",", 960], ["conference", 962], ["abstracts", 973], [",", 982], ["and", 984], ["the", 988], ["US", 992], ["Food", 995], ["and", 1000], ["Drug", 1004], ["Administration", 1009], ["(", 1024], ["FDA", 1025], [")", 1028], ["website", 1030], [",", 1037], ["and", 1039], ["discussing", 1043], ["the", 1054], ["possible", 1058], ["future", 1067], ["of", 1074], ["these", 1077], ["agents", 1083], ["in", 1090], ["managing", 1093], ["chronic", 1102], ["pain", 1110], [".", 1114], ["Anti", 1116], ["-", 1120], ["NGF", 1121], ["mAbs", 1125], ["produced", 1130], ["significant", 1139], ["pain", 1151], ["relief", 1156], ["and", 1163], ["functional", 1167], ["improvement", 1178], ["in", 1190], ["patients", 1193], ["with", 1202], ["osteoarthritis", 1207], ["of", 1222], ["the", 1225], ["knee", 1229], ["and/or", 1234], ["hip", 1241], [".", 1244], ["Conversely", 1246], [",", 1256], ["studies", 1258], ["in", 1266], ["non", 1269], ["-", 1272], ["specific", 1273], ["lower", 1282], ["back", 1288], ["pain", 1293], ["generated", 1298], ["mixed", 1308], ["results", 1314], [";", 1321], ["overall", 1323], [",", 1330], ["this", 1332], ["condition", 1337], ["appeared", 1347], ["to", 1356], ["be", 1359], ["less", 1362], ["responsive", 1367], ["to", 1378], ["anti", 1381], ["-", 1385], ["NGF", 1386], ["agents", 1390], ["than", 1397], ["osteoarthritis", 1402], [".", 1416], ["Finally", 1418], [",", 1425], ["there", 1427], ["was", 1433], ["no", 1437], ["conclusive", 1440], ["evidence", 1451], ["of", 1460], ["the", 1463], ["effectiveness", 1467], ["of", 1481], ["anti", 1484], ["-", 1488], ["NGF", 1489], ["mAbs", 1493], ["in", 1498], ["some", 1501], ["types", 1506], ["of", 1512], ["chronic", 1515], ["visceral", 1523], ["or", 1532], ["neuropathic", 1535], ["pain", 1547], [".", 1551], ["Furthermore", 1553], [",", 1564], ["these", 1566], ["studies", 1572], ["raised", 1580], ["safety", 1587], ["concerns", 1594], ["about", 1603], ["anti", 1609], ["-", 1613], ["NGF", 1614], ["mAbs", 1618], [".", 1622], ["As", 1624], ["a", 1627], ["class", 1629], [",", 1634], ["these", 1636], ["drugs", 1642], ["may", 1648], ["cause", 1652], ["or", 1658], ["worsen", 1661], ["peripheral", 1668], ["neuropathies", 1679], [".", 1691], ["But", 1693], ["the", 1697], ["most", 1701], ["problematic", 1706], ["issue", 1718], ["-", 1723], ["which", 1724], ["prompted", 1730], ["the", 1739], ["FDA", 1743], ["to", 1747], ["place", 1750], ["studies", 1756], ["of", 1764], ["these", 1767], ["compounds", 1773], ["on", 1783], ["clinical", 1786], ["hold", 1795], ["in", 1800], ["2010-was", 1803], ["rapid", 1812], ["joint", 1818], ["destruction", 1824], ["leading", 1836], ["to", 1844], ["joint", 1847], ["replacement", 1853], ["surgery", 1865], [".", 1872], ["The", 1874], ["aetiologies", 1878], ["of", 1890], ["these", 1893], ["side", 1899], ["effects", 1904], ["have", 1912], ["been", 1917], ["much", 1922], ["debated", 1927], ["and", 1935], ["their", 1939], ["pathophysiology", 1945], ["is", 1961], ["poorly", 1964], ["understood", 1971], [".", 1981], ["After", 1983], ["an", 1989], ["Arthritis", 1992], ["Advisory", 2002], ["Committee", 2011], ["meeting", 2021], ["held", 2029], ["in", 2034], ["March", 2037], ["2012", 2043], [",", 2047], ["pharmaceutical", 2049], ["companies", 2064], ["negotiated", 2074], ["with", 2085], ["the", 2090], ["FDA", 2094], ["on", 2098], ["the", 2101], ["conditions", 2105], ["for", 2116], ["restarting", 2120], ["clinical", 2131], ["studies", 2140], [".", 2147], ["Although", 2149], ["the", 2158], ["FDA", 2162], ["lifted", 2166], ["its", 2173], ["clinical", 2177], ["hold", 2186], [",", 2190], ["there", 2192], ["remain", 2198], ["many", 2205], ["unresolved", 2210], ["issues", 2221], ["about", 2228], ["the", 2234], ["long", 2238], ["-", 2242], ["term", 2243], ["efficacy", 2248], ["and", 2257], ["safety", 2261], ["of", 2268], ["anti", 2271], ["-", 2275], ["NGF", 2276], ["mAbs", 2280], [".", 2284], ["While", 2286], ["acknowledging", 2292], ["that", 2306], ["the", 2311], ["future", 2315], ["of", 2322], ["these", 2325], ["drugs", 2331], ["is", 2337], ["unforeseeable", 2340], [",", 2353], ["it", 2355], ["appears", 2358], ["that", 2366], ["they", 2371], ["may", 2376], ["not", 2380], ["be", 2384], ["the", 2387], ["safe", 2391], ["and", 2396], ["effective", 2400], ["painkillers", 2410], ["that", 2422], ["have", 2427], ["been", 2432], ["awaited", 2437], ["for", 2445], ["decades", 2449], [".", 2456]]}
{"context": "In breast cancer the development of metastasis is a major turning point in the treatment and outcome of the disease. Throughout tumour development, and especially in the development of metastasis, epithelial mesenchymal transition takes place. During this transformation into a mesenchymal phenotype, the tumour cells undergo a series of structural changes. The loss of structural integrity and adoption of mesenchymal filaments enables cells to detach from the epithelial cell layer and metastasise. Keratins form the intermediate filaments of the cytoskeleton and provide scaffold structures within cells. During cancer progression the intermediate filaments are reorganised, and dramatic changes are seen in their protein components. Keratins K8, K18, K19 and vimentin are intermediate filament proteins with altered expression profiles during tumour development. We have used in vivo and in vitro models to analyse changes in intermediate filament proteins. Antibody-based methods were used to study K8 levels and proteomic analysis to profile the protein content of metastatic breast cancer cell variants. K8 expression declines as human breast tumours progress into an invasive phenotype. Analysis of IF proteins indicated altered expression profiles of K8, K18, K19 and vimentin, with K8, K18, K19 expressed in high levels in the T47D and MCF-7 cell lines, whereas the highly metastatic cell lines expressed lower levels of K8 and K18 and no detectable K19. Vimentin showed reverse expression profile with T47D and MCF-7 cells having no detectable vimentin expression whereas the highly metastatic MDA-MB-231 and MDA-MB-436 showed high levels. Analysis of acetylation status using specific antibodies suggested acetylation occurred within the central coiled domain in the MCF-7 and T47D cells. Inhibition of tumour growth by tissue factor (TF) shRNA resulted in a dramatic re-elevation of expression of K8 in xenographs of the highly metastatic MDA-MB-436 line. Intermediate filament expression alters during epithelial mesenchymal transition. Identified post translational modifications may play a role in alterations seen in the organisation, solubility and stability of these filaments. Epithelial mesenchymal transition can be reversed and an epithelial phenotype re-established.", "qas": [{"question": "What are the structures formed when keratin molecules come together?", "answers": ["Intermediate filaments"], "qid": "0b44e46a198e44a3a793781a09543148", "question_tokens": [["What", 0], ["are", 5], ["the", 9], ["structures", 13], ["formed", 24], ["when", 31], ["keratin", 36], ["molecules", 44], ["come", 54], ["together", 59], ["?", 67]], "detected_answers": [{"text": "Intermediate filaments", "token_spans": [[82, 83], [98, 99]], "char_spans": [[519, 540], [638, 659]]}]}], "context_tokens": [["In", 0], ["breast", 3], ["cancer", 10], ["the", 17], ["development", 21], ["of", 33], ["metastasis", 36], ["is", 47], ["a", 50], ["major", 52], ["turning", 58], ["point", 66], ["in", 72], ["the", 75], ["treatment", 79], ["and", 89], ["outcome", 93], ["of", 101], ["the", 104], ["disease", 108], [".", 115], ["Throughout", 117], ["tumour", 128], ["development", 135], [",", 146], ["and", 148], ["especially", 152], ["in", 163], ["the", 166], ["development", 170], ["of", 182], ["metastasis", 185], [",", 195], ["epithelial", 197], ["mesenchymal", 208], ["transition", 220], ["takes", 231], ["place", 237], [".", 242], ["During", 244], ["this", 251], ["transformation", 256], ["into", 271], ["a", 276], ["mesenchymal", 278], ["phenotype", 290], [",", 299], ["the", 301], ["tumour", 305], ["cells", 312], ["undergo", 318], ["a", 326], ["series", 328], ["of", 335], ["structural", 338], ["changes", 349], [".", 356], ["The", 358], ["loss", 362], ["of", 367], ["structural", 370], ["integrity", 381], ["and", 391], ["adoption", 395], ["of", 404], ["mesenchymal", 407], ["filaments", 419], ["enables", 429], ["cells", 437], ["to", 443], ["detach", 446], ["from", 453], ["the", 458], ["epithelial", 462], ["cell", 473], ["layer", 478], ["and", 484], ["metastasise", 488], [".", 499], ["Keratins", 501], ["form", 510], ["the", 515], ["intermediate", 519], ["filaments", 532], ["of", 542], ["the", 545], ["cytoskeleton", 549], ["and", 562], ["provide", 566], ["scaffold", 574], ["structures", 583], ["within", 594], ["cells", 601], [".", 606], ["During", 608], ["cancer", 615], ["progression", 622], ["the", 634], ["intermediate", 638], ["filaments", 651], ["are", 661], ["reorganised", 665], [",", 676], ["and", 678], ["dramatic", 682], ["changes", 691], ["are", 699], ["seen", 703], ["in", 708], ["their", 711], ["protein", 717], ["components", 725], [".", 735], ["Keratins", 737], ["K8", 746], [",", 748], ["K18", 750], [",", 753], ["K19", 755], ["and", 759], ["vimentin", 763], ["are", 772], ["intermediate", 776], ["filament", 789], ["proteins", 798], ["with", 807], ["altered", 812], ["expression", 820], ["profiles", 831], ["during", 840], ["tumour", 847], ["development", 854], [".", 865], ["We", 867], ["have", 870], ["used", 875], ["in", 880], ["vivo", 883], ["and", 888], ["in", 892], ["vitro", 895], ["models", 901], ["to", 908], ["analyse", 911], ["changes", 919], ["in", 927], ["intermediate", 930], ["filament", 943], ["proteins", 952], [".", 960], ["Antibody", 962], ["-", 970], ["based", 971], ["methods", 977], ["were", 985], ["used", 990], ["to", 995], ["study", 998], ["K8", 1004], ["levels", 1007], ["and", 1014], ["proteomic", 1018], ["analysis", 1028], ["to", 1037], ["profile", 1040], ["the", 1048], ["protein", 1052], ["content", 1060], ["of", 1068], ["metastatic", 1071], ["breast", 1082], ["cancer", 1089], ["cell", 1096], ["variants", 1101], [".", 1109], ["K8", 1111], ["expression", 1114], ["declines", 1125], ["as", 1134], ["human", 1137], ["breast", 1143], ["tumours", 1150], ["progress", 1158], ["into", 1167], ["an", 1172], ["invasive", 1175], ["phenotype", 1184], [".", 1193], ["Analysis", 1195], ["of", 1204], ["IF", 1207], ["proteins", 1210], ["indicated", 1219], ["altered", 1229], ["expression", 1237], ["profiles", 1248], ["of", 1257], ["K8", 1260], [",", 1262], ["K18", 1264], [",", 1267], ["K19", 1269], ["and", 1273], ["vimentin", 1277], [",", 1285], ["with", 1287], ["K8", 1292], [",", 1294], ["K18", 1296], [",", 1299], ["K19", 1301], ["expressed", 1305], ["in", 1315], ["high", 1318], ["levels", 1323], ["in", 1330], ["the", 1333], ["T47D", 1337], ["and", 1342], ["MCF-7", 1346], ["cell", 1352], ["lines", 1357], [",", 1362], ["whereas", 1364], ["the", 1372], ["highly", 1376], ["metastatic", 1383], ["cell", 1394], ["lines", 1399], ["expressed", 1405], ["lower", 1415], ["levels", 1421], ["of", 1428], ["K8", 1431], ["and", 1434], ["K18", 1438], ["and", 1442], ["no", 1446], ["detectable", 1449], ["K19", 1460], [".", 1463], ["Vimentin", 1465], ["showed", 1474], ["reverse", 1481], ["expression", 1489], ["profile", 1500], ["with", 1508], ["T47D", 1513], ["and", 1518], ["MCF-7", 1522], ["cells", 1528], ["having", 1534], ["no", 1541], ["detectable", 1544], ["vimentin", 1555], ["expression", 1564], ["whereas", 1575], ["the", 1583], ["highly", 1587], ["metastatic", 1594], ["MDA", 1605], ["-", 1608], ["MB-231", 1609], ["and", 1616], ["MDA", 1620], ["-", 1623], ["MB-436", 1624], ["showed", 1631], ["high", 1638], ["levels", 1643], [".", 1649], ["Analysis", 1651], ["of", 1660], ["acetylation", 1663], ["status", 1675], ["using", 1682], ["specific", 1688], ["antibodies", 1697], ["suggested", 1708], ["acetylation", 1718], ["occurred", 1730], ["within", 1739], ["the", 1746], ["central", 1750], ["coiled", 1758], ["domain", 1765], ["in", 1772], ["the", 1775], ["MCF-7", 1779], ["and", 1785], ["T47D", 1789], ["cells", 1794], [".", 1799], ["Inhibition", 1801], ["of", 1812], ["tumour", 1815], ["growth", 1822], ["by", 1829], ["tissue", 1832], ["factor", 1839], ["(", 1846], ["TF", 1847], [")", 1849], ["shRNA", 1851], ["resulted", 1857], ["in", 1866], ["a", 1869], ["dramatic", 1871], ["re", 1880], ["-", 1882], ["elevation", 1883], ["of", 1893], ["expression", 1896], ["of", 1907], ["K8", 1910], ["in", 1913], ["xenographs", 1916], ["of", 1927], ["the", 1930], ["highly", 1934], ["metastatic", 1941], ["MDA", 1952], ["-", 1955], ["MB-436", 1956], ["line", 1963], [".", 1967], ["Intermediate", 1969], ["filament", 1982], ["expression", 1991], ["alters", 2002], ["during", 2009], ["epithelial", 2016], ["mesenchymal", 2027], ["transition", 2039], [".", 2049], ["Identified", 2051], ["post", 2062], ["translational", 2067], ["modifications", 2081], ["may", 2095], ["play", 2099], ["a", 2104], ["role", 2106], ["in", 2111], ["alterations", 2114], ["seen", 2126], ["in", 2131], ["the", 2134], ["organisation", 2138], [",", 2150], ["solubility", 2152], ["and", 2163], ["stability", 2167], ["of", 2177], ["these", 2180], ["filaments", 2186], [".", 2195], ["Epithelial", 2197], ["mesenchymal", 2208], ["transition", 2220], ["can", 2231], ["be", 2235], ["reversed", 2238], ["and", 2247], ["an", 2251], ["epithelial", 2254], ["phenotype", 2265], ["re", 2275], ["-", 2277], ["established", 2278], [".", 2289]]}
{"context": "MicroRNAs (miRNAs) constitute a large family of noncoding RNAs that function as guide molecules in diverse gene silencing pathways. Current efforts are focused on the regulatory function of miRNAs, while little is known about how these unusual genes themselves are regulated. Here we present the first direct evidence that miRNA genes are transcribed by RNA polymerase II (pol II). The primary miRNA transcripts (pri-miRNAs) contain cap structures as well as poly(A) tails, which are the unique properties of class II gene transcripts. The treatment of human cells with alpha-amanitin decreased the level of pri-miRNAs at a concentration that selectively inhibits pol II activity. Furthermore, chromatin immunoprecipitation analyses show that pol II is physically associated with a miRNA promoter. We also describe, for the first time, the detailed structure of a miRNA gene by determining the promoter and the terminator of mir-23a approximately 27a approximately 24-2. These data indicate that pol II is the main, if not the only, RNA polymerase for miRNA gene transcription. Our study offers a basis for understanding the structure and regulation of miRNA genes.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "bfbcb1b432584aff8df5bc3c70e56f62", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[59, 61]], "char_spans": [[354, 370]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["constitute", 19], ["a", 30], ["large", 32], ["family", 38], ["of", 45], ["noncoding", 48], ["RNAs", 58], ["that", 63], ["function", 68], ["as", 77], ["guide", 80], ["molecules", 86], ["in", 96], ["diverse", 99], ["gene", 107], ["silencing", 112], ["pathways", 122], [".", 130], ["Current", 132], ["efforts", 140], ["are", 148], ["focused", 152], ["on", 160], ["the", 163], ["regulatory", 167], ["function", 178], ["of", 187], ["miRNAs", 190], [",", 196], ["while", 198], ["little", 204], ["is", 211], ["known", 214], ["about", 220], ["how", 226], ["these", 230], ["unusual", 236], ["genes", 244], ["themselves", 250], ["are", 261], ["regulated", 265], [".", 274], ["Here", 276], ["we", 281], ["present", 284], ["the", 292], ["first", 296], ["direct", 302], ["evidence", 309], ["that", 318], ["miRNA", 323], ["genes", 329], ["are", 335], ["transcribed", 339], ["by", 351], ["RNA", 354], ["polymerase", 358], ["II", 369], ["(", 372], ["pol", 373], ["II", 377], [")", 379], [".", 380], ["The", 382], ["primary", 386], ["miRNA", 394], ["transcripts", 400], ["(", 412], ["pri", 413], ["-", 416], ["miRNAs", 417], [")", 423], ["contain", 425], ["cap", 433], ["structures", 437], ["as", 448], ["well", 451], ["as", 456], ["poly(A", 459], [")", 465], ["tails", 467], [",", 472], ["which", 474], ["are", 480], ["the", 484], ["unique", 488], ["properties", 495], ["of", 506], ["class", 509], ["II", 515], ["gene", 518], ["transcripts", 523], [".", 534], ["The", 536], ["treatment", 540], ["of", 550], ["human", 553], ["cells", 559], ["with", 565], ["alpha", 570], ["-", 575], ["amanitin", 576], ["decreased", 585], ["the", 595], ["level", 599], ["of", 605], ["pri", 608], ["-", 611], ["miRNAs", 612], ["at", 619], ["a", 622], ["concentration", 624], ["that", 638], ["selectively", 643], ["inhibits", 655], ["pol", 664], ["II", 668], ["activity", 671], [".", 679], ["Furthermore", 681], [",", 692], ["chromatin", 694], ["immunoprecipitation", 704], ["analyses", 724], ["show", 733], ["that", 738], ["pol", 743], ["II", 747], ["is", 750], ["physically", 753], ["associated", 764], ["with", 775], ["a", 780], ["miRNA", 782], ["promoter", 788], [".", 796], ["We", 798], ["also", 801], ["describe", 806], [",", 814], ["for", 816], ["the", 820], ["first", 824], ["time", 830], [",", 834], ["the", 836], ["detailed", 840], ["structure", 849], ["of", 859], ["a", 862], ["miRNA", 864], ["gene", 870], ["by", 875], ["determining", 878], ["the", 890], ["promoter", 894], ["and", 903], ["the", 907], ["terminator", 911], ["of", 922], ["mir-23a", 925], ["approximately", 933], ["27a", 947], ["approximately", 951], ["24", 965], ["-", 967], ["2", 968], [".", 969], ["These", 971], ["data", 977], ["indicate", 982], ["that", 991], ["pol", 996], ["II", 1000], ["is", 1003], ["the", 1006], ["main", 1010], [",", 1014], ["if", 1016], ["not", 1019], ["the", 1023], ["only", 1027], [",", 1031], ["RNA", 1033], ["polymerase", 1037], ["for", 1048], ["miRNA", 1052], ["gene", 1058], ["transcription", 1063], [".", 1076], ["Our", 1078], ["study", 1082], ["offers", 1088], ["a", 1095], ["basis", 1097], ["for", 1103], ["understanding", 1107], ["the", 1121], ["structure", 1125], ["and", 1135], ["regulation", 1139], ["of", 1150], ["miRNA", 1153], ["genes", 1159], [".", 1164]]}
{"context": "The aim of this study was to analyze complications of vestibular schwannoma (VS) microsurgery. A retrospective study was performed in 333 patients with unilateral vestibular schwannoma indicated for surgical treatment between January 1997 and December 2012. Postoperative complications were assessed immediately after VS surgery as well as during outpatient followup. In all 333 patients microsurgical vestibular schwannoma (Koos grade 1: 12, grade 2: 34, grade 3: 62, and grade 4: 225) removal was performed. The main neurological complication was facial nerve dysfunction. The intermediate and poor function (HB III-VI) was observed in 124 cases (45%) immediately after surgery and in 104 cases (33%) on the last followup. We encountered disordered vestibular compensation in 13%, permanent trigeminal nerve dysfunction in 1%, and transient lower cranial nerves (IX-XI) deficit in 6%. Nonneurological complications included CSF leakage in 63% (lateral/medial variant: 99/1%), headache in 9%, and intracerebral hemorrhage in 5%. We did not encounter any case of meningitis. Our study demonstrates that despite the benefits of advanced high-tech equipment, refined microsurgical instruments, and highly developed neuroimaging technologies, there are still various and significant complications associated with vestibular schwannomas microsurgery.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "9a266ab5385a487db6485e67274c6e1d", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[60, 61], [10, 11], [27, 28]], "char_spans": [[402, 422], [54, 74], [163, 183]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["analyze", 29], ["complications", 37], ["of", 51], ["vestibular", 54], ["schwannoma", 65], ["(", 76], ["VS", 77], [")", 79], ["microsurgery", 81], [".", 93], ["A", 95], ["retrospective", 97], ["study", 111], ["was", 117], ["performed", 121], ["in", 131], ["333", 134], ["patients", 138], ["with", 147], ["unilateral", 152], ["vestibular", 163], ["schwannoma", 174], ["indicated", 185], ["for", 195], ["surgical", 199], ["treatment", 208], ["between", 218], ["January", 226], ["1997", 234], ["and", 239], ["December", 243], ["2012", 252], [".", 256], ["Postoperative", 258], ["complications", 272], ["were", 286], ["assessed", 291], ["immediately", 300], ["after", 312], ["VS", 318], ["surgery", 321], ["as", 329], ["well", 332], ["as", 337], ["during", 340], ["outpatient", 347], ["followup", 358], [".", 366], ["In", 368], ["all", 371], ["333", 375], ["patients", 379], ["microsurgical", 388], ["vestibular", 402], ["schwannoma", 413], ["(", 424], ["Koos", 425], ["grade", 430], ["1", 436], [":", 437], ["12", 439], [",", 441], ["grade", 443], ["2", 449], [":", 450], ["34", 452], [",", 454], ["grade", 456], ["3", 462], [":", 463], ["62", 465], [",", 467], ["and", 469], ["grade", 473], ["4", 479], [":", 480], ["225", 482], [")", 485], ["removal", 487], ["was", 495], ["performed", 499], [".", 508], ["The", 510], ["main", 514], ["neurological", 519], ["complication", 532], ["was", 545], ["facial", 549], ["nerve", 556], ["dysfunction", 562], [".", 573], ["The", 575], ["intermediate", 579], ["and", 592], ["poor", 596], ["function", 601], ["(", 610], ["HB", 611], ["III", 614], ["-", 617], ["VI", 618], [")", 620], ["was", 622], ["observed", 626], ["in", 635], ["124", 638], ["cases", 642], ["(", 648], ["45", 649], ["%", 651], [")", 652], ["immediately", 654], ["after", 666], ["surgery", 672], ["and", 680], ["in", 684], ["104", 687], ["cases", 691], ["(", 697], ["33", 698], ["%", 700], [")", 701], ["on", 703], ["the", 706], ["last", 710], ["followup", 715], [".", 723], ["We", 725], ["encountered", 728], ["disordered", 740], ["vestibular", 751], ["compensation", 762], ["in", 775], ["13", 778], ["%", 780], [",", 781], ["permanent", 783], ["trigeminal", 793], ["nerve", 804], ["dysfunction", 810], ["in", 822], ["1", 825], ["%", 826], [",", 827], ["and", 829], ["transient", 833], ["lower", 843], ["cranial", 849], ["nerves", 857], ["(", 864], ["IX", 865], ["-", 867], ["XI", 868], [")", 870], ["deficit", 872], ["in", 880], ["6", 883], ["%", 884], [".", 885], ["Nonneurological", 887], ["complications", 903], ["included", 917], ["CSF", 926], ["leakage", 930], ["in", 938], ["63", 941], ["%", 943], ["(", 945], ["lateral", 946], ["/", 953], ["medial", 954], ["variant", 961], [":", 968], ["99/1", 970], ["%", 974], [")", 975], [",", 976], ["headache", 978], ["in", 987], ["9", 990], ["%", 991], [",", 992], ["and", 994], ["intracerebral", 998], ["hemorrhage", 1012], ["in", 1023], ["5", 1026], ["%", 1027], [".", 1028], ["We", 1030], ["did", 1033], ["not", 1037], ["encounter", 1041], ["any", 1051], ["case", 1055], ["of", 1060], ["meningitis", 1063], [".", 1073], ["Our", 1075], ["study", 1079], ["demonstrates", 1085], ["that", 1098], ["despite", 1103], ["the", 1111], ["benefits", 1115], ["of", 1124], ["advanced", 1127], ["high", 1136], ["-", 1140], ["tech", 1141], ["equipment", 1146], [",", 1155], ["refined", 1157], ["microsurgical", 1165], ["instruments", 1179], [",", 1190], ["and", 1192], ["highly", 1196], ["developed", 1203], ["neuroimaging", 1213], ["technologies", 1226], [",", 1238], ["there", 1240], ["are", 1246], ["still", 1250], ["various", 1256], ["and", 1264], ["significant", 1268], ["complications", 1280], ["associated", 1294], ["with", 1305], ["vestibular", 1310], ["schwannomas", 1321], ["microsurgery", 1333], [".", 1345]]}
{"context": "We immunohistochemically investigated the degeneration processes of the nigro-striatal and nigro-amygdaloid pathways and the relationship between the loss of dopaminergic neurons and Lewy bodies (LB) formation in the substantia nigra using 15 autopsied cases of dementia with Lewy bodies (DLB). The number of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra and TH-positive axonal terminals in the putamen decreased with a specific pattern. The substantia nigra possessed alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein-immunostaining. Most of the granular stains were positive for anti-phosphorylated alpha-synuclein antibody, whereas the diffuse stains were negative. These findings suggest that the axonal terminals in the putamen undergo abnormal alpha-synuclein accumulation, but may not always originate from LB-bearing neurons in the substantia nigra. The central amygdaloid nucleus contained anti-alpha-synuclein- and -phosphorylated alpha-synuclein-positive dystrophic axonal terminals, the degree of which was greater for cases with granular staining in the putamen, and which was proportional to the number of alpha-synuclein-positive neurons in the substantia nigra. Thus, the axonal terminals in the central amygdaloid nucleus may have originated from LB-bearing neurons in the substantia nigra. The results of the present study indicate that the nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in DLB, and suggest that the degeneration of the nigro-amygdaloid pathway more strongly reflects LB formation in dopaminergic neurons of the substantia nigra than that of the nigro-striatal pathway. In addition, they indicate that there is no direct relationship between the loss of dopaminergic neurons and LB formation in the substantia nigra.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "838f259cf3d94ed1a4628e26a79fa183", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[102, 104], [170, 172], [175, 177], [119, 121], [207, 209], [80, 82], [143, 145]], "char_spans": [[619, 633], [1020, 1035], [1057, 1071], [717, 731], [1236, 1250], [490, 504], [866, 880]]}]}], "context_tokens": [["We", 0], ["immunohistochemically", 3], ["investigated", 25], ["the", 38], ["degeneration", 42], ["processes", 55], ["of", 65], ["the", 68], ["nigro", 72], ["-", 77], ["striatal", 78], ["and", 87], ["nigro", 91], ["-", 96], ["amygdaloid", 97], ["pathways", 108], ["and", 117], ["the", 121], ["relationship", 125], ["between", 138], ["the", 146], ["loss", 150], ["of", 155], ["dopaminergic", 158], ["neurons", 171], ["and", 179], ["Lewy", 183], ["bodies", 188], ["(", 195], ["LB", 196], [")", 198], ["formation", 200], ["in", 210], ["the", 213], ["substantia", 217], ["nigra", 228], ["using", 234], ["15", 240], ["autopsied", 243], ["cases", 253], ["of", 259], ["dementia", 262], ["with", 271], ["Lewy", 276], ["bodies", 281], ["(", 288], ["DLB", 289], [")", 292], [".", 293], ["The", 295], ["number", 299], ["of", 306], ["tyrosine", 309], ["hydroxylase", 318], ["(", 330], ["TH)-positive", 331], ["neurons", 344], ["in", 352], ["the", 355], ["substantia", 359], ["nigra", 370], ["and", 376], ["TH", 380], ["-", 382], ["positive", 383], ["axonal", 392], ["terminals", 399], ["in", 409], ["the", 412], ["putamen", 416], ["decreased", 424], ["with", 434], ["a", 439], ["specific", 441], ["pattern", 450], [".", 457], ["The", 459], ["substantia", 463], ["nigra", 474], ["possessed", 480], ["alpha", 490], ["-", 495], ["synuclein", 496], ["-", 505], ["positive", 506], ["LB", 515], ["-", 517], ["bearing", 518], ["neurons", 526], ["that", 534], ["were", 539], ["almost", 544], ["evenly", 551], ["distributed", 558], [",", 569], ["while", 571], ["the", 577], ["putamen", 581], ["exhibited", 589], ["diffuse", 599], ["or", 607], ["granular", 610], ["alpha", 619], ["-", 624], ["synuclein", 625], ["-", 634], ["immunostaining", 635], [".", 649], ["Most", 651], ["of", 656], ["the", 659], ["granular", 663], ["stains", 672], ["were", 679], ["positive", 684], ["for", 693], ["anti", 697], ["-", 701], ["phosphorylated", 702], ["alpha", 717], ["-", 722], ["synuclein", 723], ["antibody", 733], [",", 741], ["whereas", 743], ["the", 751], ["diffuse", 755], ["stains", 763], ["were", 770], ["negative", 775], [".", 783], ["These", 785], ["findings", 791], ["suggest", 800], ["that", 808], ["the", 813], ["axonal", 817], ["terminals", 824], ["in", 834], ["the", 837], ["putamen", 841], ["undergo", 849], ["abnormal", 857], ["alpha", 866], ["-", 871], ["synuclein", 872], ["accumulation", 882], [",", 894], ["but", 896], ["may", 900], ["not", 904], ["always", 908], ["originate", 915], ["from", 925], ["LB", 930], ["-", 932], ["bearing", 933], ["neurons", 941], ["in", 949], ["the", 952], ["substantia", 956], ["nigra", 967], [".", 972], ["The", 974], ["central", 978], ["amygdaloid", 986], ["nucleus", 997], ["contained", 1005], ["anti", 1015], ["-", 1019], ["alpha", 1020], ["-", 1025], ["synuclein-", 1026], ["and", 1037], ["-phosphorylated", 1041], ["alpha", 1057], ["-", 1062], ["synuclein", 1063], ["-", 1072], ["positive", 1073], ["dystrophic", 1082], ["axonal", 1093], ["terminals", 1100], [",", 1109], ["the", 1111], ["degree", 1115], ["of", 1122], ["which", 1125], ["was", 1131], ["greater", 1135], ["for", 1143], ["cases", 1147], ["with", 1153], ["granular", 1158], ["staining", 1167], ["in", 1176], ["the", 1179], ["putamen", 1183], [",", 1190], ["and", 1192], ["which", 1196], ["was", 1202], ["proportional", 1206], ["to", 1219], ["the", 1222], ["number", 1226], ["of", 1233], ["alpha", 1236], ["-", 1241], ["synuclein", 1242], ["-", 1251], ["positive", 1252], ["neurons", 1261], ["in", 1269], ["the", 1272], ["substantia", 1276], ["nigra", 1287], [".", 1292], ["Thus", 1294], [",", 1298], ["the", 1300], ["axonal", 1304], ["terminals", 1311], ["in", 1321], ["the", 1324], ["central", 1328], ["amygdaloid", 1336], ["nucleus", 1347], ["may", 1355], ["have", 1359], ["originated", 1364], ["from", 1375], ["LB", 1380], ["-", 1382], ["bearing", 1383], ["neurons", 1391], ["in", 1399], ["the", 1402], ["substantia", 1406], ["nigra", 1417], [".", 1422], ["The", 1424], ["results", 1428], ["of", 1436], ["the", 1439], ["present", 1443], ["study", 1451], ["indicate", 1457], ["that", 1466], ["the", 1471], ["nigro", 1475], ["-", 1480], ["striatal", 1481], ["and", 1490], ["nigro", 1494], ["-", 1499], ["amygdaloid", 1500], ["pathways", 1511], ["undergo", 1520], ["different", 1528], ["degeneration", 1538], ["processes", 1551], ["in", 1561], ["DLB", 1564], [",", 1567], ["and", 1569], ["suggest", 1573], ["that", 1581], ["the", 1586], ["degeneration", 1590], ["of", 1603], ["the", 1606], ["nigro", 1610], ["-", 1615], ["amygdaloid", 1616], ["pathway", 1627], ["more", 1635], ["strongly", 1640], ["reflects", 1649], ["LB", 1658], ["formation", 1661], ["in", 1671], ["dopaminergic", 1674], ["neurons", 1687], ["of", 1695], ["the", 1698], ["substantia", 1702], ["nigra", 1713], ["than", 1719], ["that", 1724], ["of", 1729], ["the", 1732], ["nigro", 1736], ["-", 1741], ["striatal", 1742], ["pathway", 1751], [".", 1758], ["In", 1760], ["addition", 1763], [",", 1771], ["they", 1773], ["indicate", 1778], ["that", 1787], ["there", 1792], ["is", 1798], ["no", 1801], ["direct", 1804], ["relationship", 1811], ["between", 1824], ["the", 1832], ["loss", 1836], ["of", 1841], ["dopaminergic", 1844], ["neurons", 1857], ["and", 1865], ["LB", 1869], ["formation", 1872], ["in", 1882], ["the", 1885], ["substantia", 1889], ["nigra", 1900], [".", 1905]]}
{"context": "An 11-day embryonic Swiss Webster/NIH mouse cDNA library was screened with a partial murine selenoprotein P cDNA probe and a murine selenoprotein-P-type cDNA clone of 2075 bp length was obtained. The clone contained a 5'-leader sequence of 132 bp length, the selenoprotein P coding frame, and 803 base pairs in the 3' untranslated region. Alignment and RNA folding studies revealed the presence of two well conserved selenocysteine inserting motifs in the 3' flanking region. The deduced polypeptide sequence comprises 380 residues including ten selenocysteines. Identical amino acid residues in homologous positions are 86%, 71%, and 64% when compared to the previously reported selenoprotein P sequences of rat, man, and cattle, respectively. The comparatively low similarity between the selenoprotein P sequences reported so far leaves open the question whether they belong to the same molecular clade.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["selenoprotein P", "selenoprotein-P", "Selenoprotein P"], "qid": "acb923e812724d94bc4863897a19ef39", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[16, 17], [49, 50], [140, 141], [121, 122], [23, 25]], "char_spans": [[92, 106], [259, 273], [790, 804], [680, 694], [132, 146]]}]}], "context_tokens": [["An", 0], ["11-day", 3], ["embryonic", 10], ["Swiss", 20], ["Webster", 26], ["/", 33], ["NIH", 34], ["mouse", 38], ["cDNA", 44], ["library", 49], ["was", 57], ["screened", 61], ["with", 70], ["a", 75], ["partial", 77], ["murine", 85], ["selenoprotein", 92], ["P", 106], ["cDNA", 108], ["probe", 113], ["and", 119], ["a", 123], ["murine", 125], ["selenoprotein", 132], ["-", 145], ["P", 146], ["-", 147], ["type", 148], ["cDNA", 153], ["clone", 158], ["of", 164], ["2075", 167], ["bp", 172], ["length", 175], ["was", 182], ["obtained", 186], [".", 194], ["The", 196], ["clone", 200], ["contained", 206], ["a", 216], ["5'-leader", 218], ["sequence", 228], ["of", 237], ["132", 240], ["bp", 244], ["length", 247], [",", 253], ["the", 255], ["selenoprotein", 259], ["P", 273], ["coding", 275], ["frame", 282], [",", 287], ["and", 289], ["803", 293], ["base", 297], ["pairs", 302], ["in", 308], ["the", 311], ["3", 315], ["'", 316], ["untranslated", 318], ["region", 331], [".", 337], ["Alignment", 339], ["and", 349], ["RNA", 353], ["folding", 357], ["studies", 365], ["revealed", 373], ["the", 382], ["presence", 386], ["of", 395], ["two", 398], ["well", 402], ["conserved", 407], ["selenocysteine", 417], ["inserting", 432], ["motifs", 442], ["in", 449], ["the", 452], ["3", 456], ["'", 457], ["flanking", 459], ["region", 468], [".", 474], ["The", 476], ["deduced", 480], ["polypeptide", 488], ["sequence", 500], ["comprises", 509], ["380", 519], ["residues", 523], ["including", 532], ["ten", 542], ["selenocysteines", 546], [".", 561], ["Identical", 563], ["amino", 573], ["acid", 579], ["residues", 584], ["in", 593], ["homologous", 596], ["positions", 607], ["are", 617], ["86", 621], ["%", 623], [",", 624], ["71", 626], ["%", 628], [",", 629], ["and", 631], ["64", 635], ["%", 637], ["when", 639], ["compared", 644], ["to", 653], ["the", 656], ["previously", 660], ["reported", 671], ["selenoprotein", 680], ["P", 694], ["sequences", 696], ["of", 706], ["rat", 709], [",", 712], ["man", 714], [",", 717], ["and", 719], ["cattle", 723], [",", 729], ["respectively", 731], [".", 743], ["The", 745], ["comparatively", 749], ["low", 763], ["similarity", 767], ["between", 778], ["the", 786], ["selenoprotein", 790], ["P", 804], ["sequences", 806], ["reported", 816], ["so", 825], ["far", 828], ["leaves", 832], ["open", 839], ["the", 844], ["question", 848], ["whether", 857], ["they", 865], ["belong", 870], ["to", 877], ["the", 880], ["same", 884], ["molecular", 889], ["clade", 899], [".", 904]]}
{"context": "Selenoproteins are proteins containing an uncommon amino acid selenocysteine (Sec). Sec is inserted by a specific translational machinery that recognizes a stem-loop structure, the SECIS element, at the 3' UTR of selenoprotein genes and recodes a UGA codon within the coding sequence. As UGA is normally a translational stop signal, selenoproteins are generally misannotated and designated tools have to be developed for this class of proteins. Here, we present two new computational methods for selenoprotein identification and analysis, which we provide publicly through the web servers at http://gladyshevlab.org/SelenoproteinPredictionServer or http://seblastian.crg.es. SECISearch3 replaces its predecessor SECISearch as a tool for prediction of eukaryotic SECIS elements. Seblastian is a new method for selenoprotein gene detection that uses SECISearch3 and then predicts selenoprotein sequences encoded upstream of SECIS elements. Seblastian is able to both identify known selenoproteins and predict new selenoproteins. By applying these tools to diverse eukaryotic genomes, we provide a ranked list of newly predicted selenoproteins together with their annotated cysteine-containing homologues. An analysis of a representative candidate belonging to the AhpC family shows how the use of Sec in this protein evolved in bacterial and eukaryotic lineages.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0dbd2d5ca0924a50a3508f121aec86a6", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[116, 116], [139, 139], [30, 30]], "char_spans": [[762, 766], [922, 926], [181, 185]]}]}], "context_tokens": [["Selenoproteins", 0], ["are", 15], ["proteins", 19], ["containing", 28], ["an", 39], ["uncommon", 42], ["amino", 51], ["acid", 57], ["selenocysteine", 62], ["(", 77], ["Sec", 78], [")", 81], [".", 82], ["Sec", 84], ["is", 88], ["inserted", 91], ["by", 100], ["a", 103], ["specific", 105], ["translational", 114], ["machinery", 128], ["that", 138], ["recognizes", 143], ["a", 154], ["stem", 156], ["-", 160], ["loop", 161], ["structure", 166], [",", 175], ["the", 177], ["SECIS", 181], ["element", 187], [",", 194], ["at", 196], ["the", 199], ["3", 203], ["'", 204], ["UTR", 206], ["of", 210], ["selenoprotein", 213], ["genes", 227], ["and", 233], ["recodes", 237], ["a", 245], ["UGA", 247], ["codon", 251], ["within", 257], ["the", 264], ["coding", 268], ["sequence", 275], [".", 283], ["As", 285], ["UGA", 288], ["is", 292], ["normally", 295], ["a", 304], ["translational", 306], ["stop", 320], ["signal", 325], [",", 331], ["selenoproteins", 333], ["are", 348], ["generally", 352], ["misannotated", 362], ["and", 375], ["designated", 379], ["tools", 390], ["have", 396], ["to", 401], ["be", 404], ["developed", 407], ["for", 417], ["this", 421], ["class", 426], ["of", 432], ["proteins", 435], [".", 443], ["Here", 445], [",", 449], ["we", 451], ["present", 454], ["two", 462], ["new", 466], ["computational", 470], ["methods", 484], ["for", 492], ["selenoprotein", 496], ["identification", 510], ["and", 525], ["analysis", 529], [",", 537], ["which", 539], ["we", 545], ["provide", 548], ["publicly", 556], ["through", 565], ["the", 573], ["web", 577], ["servers", 581], ["at", 589], ["http://gladyshevlab.org/SelenoproteinPredictionServer", 592], ["or", 646], ["http://seblastian.crg.es", 649], [".", 673], ["SECISearch3", 675], ["replaces", 687], ["its", 696], ["predecessor", 700], ["SECISearch", 712], ["as", 723], ["a", 726], ["tool", 728], ["for", 733], ["prediction", 737], ["of", 748], ["eukaryotic", 751], ["SECIS", 762], ["elements", 768], [".", 776], ["Seblastian", 778], ["is", 789], ["a", 792], ["new", 794], ["method", 798], ["for", 805], ["selenoprotein", 809], ["gene", 823], ["detection", 828], ["that", 838], ["uses", 843], ["SECISearch3", 848], ["and", 860], ["then", 864], ["predicts", 869], ["selenoprotein", 878], ["sequences", 892], ["encoded", 902], ["upstream", 910], ["of", 919], ["SECIS", 922], ["elements", 928], [".", 936], ["Seblastian", 938], ["is", 949], ["able", 952], ["to", 957], ["both", 960], ["identify", 965], ["known", 974], ["selenoproteins", 980], ["and", 995], ["predict", 999], ["new", 1007], ["selenoproteins", 1011], [".", 1025], ["By", 1027], ["applying", 1030], ["these", 1039], ["tools", 1045], ["to", 1051], ["diverse", 1054], ["eukaryotic", 1062], ["genomes", 1073], [",", 1080], ["we", 1082], ["provide", 1085], ["a", 1093], ["ranked", 1095], ["list", 1102], ["of", 1107], ["newly", 1110], ["predicted", 1116], ["selenoproteins", 1126], ["together", 1141], ["with", 1150], ["their", 1155], ["annotated", 1161], ["cysteine", 1171], ["-", 1179], ["containing", 1180], ["homologues", 1191], [".", 1201], ["An", 1203], ["analysis", 1206], ["of", 1215], ["a", 1218], ["representative", 1220], ["candidate", 1235], ["belonging", 1245], ["to", 1255], ["the", 1258], ["AhpC", 1262], ["family", 1267], ["shows", 1274], ["how", 1280], ["the", 1284], ["use", 1288], ["of", 1292], ["Sec", 1295], ["in", 1299], ["this", 1302], ["protein", 1307], ["evolved", 1315], ["in", 1323], ["bacterial", 1326], ["and", 1336], ["eukaryotic", 1340], ["lineages", 1351], [".", 1359]]}
{"context": "The origin of brain tumors has attracted much controversy. Recent advances in neural stem cell biology coupled with the new concepts of central nervous system development have raised interesting possibilities regarding the oncogenic properties of neural stem/progenitor cells. To elucidate these putative properties further, the clinical materials from an infant brain tumor were analyzed, focusing on the relation with the neural stem/progenitor cells. The expression of neural stem/progenitor cell markers in the tumor cells and the cellular components of the infant brain tumor were examined using immunohistochemistry. The tumor cell biology was analyzed both in culture and in the grafted brain environment. Three main bodies of evidence were demonstrated indicating that the tumor was of possible subventricular zone postnatal or adult normal neural stem cell origin. First, in the tumor specimen we demonstrated the strong positive expression of the neural stem/progenitor cell markers, nestin and Musashi-1. Second, immunohistochemistry revealed the presence of neuronal, astrocytic, and immature precursor cells in the tumor tissue, similar to the cellular components of the subventricular zone, thereby pointing to the subventricular zone as the possible origin of the tumor. The subventricular zone also is one of the strong candidates for the location of postnatal/adult neural stem cells. This cellular evidence was strengthened further by the clinicoradiological findings that demonstrated the involvement of the subventricular zone of the lateral ventricle by the tumor. Third, in the in vitro and in vivo experiments, a dynamic shift in expression patterns between neural stem cells (nestin, Musashi-1) and differentiated cells (glial fibrillary acidic protein, neuron-specific Class III beta-tubulin) markers was seen, similar to the proposed behavior of postnatal/adult neural stem cells in situ. These findings suggest that this brain tumor originated from neural stem cells located in the subventricular zone, and the further possibility of the general oncogenic potential of neural stem cells.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "71a8f4bdfee54f928c7a8b69ef3ca448", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[161, 161], [278, 278]], "char_spans": [[994, 999], [1700, 1705]]}]}], "context_tokens": [["The", 0], ["origin", 4], ["of", 11], ["brain", 14], ["tumors", 20], ["has", 27], ["attracted", 31], ["much", 41], ["controversy", 46], [".", 57], ["Recent", 59], ["advances", 66], ["in", 75], ["neural", 78], ["stem", 85], ["cell", 90], ["biology", 95], ["coupled", 103], ["with", 111], ["the", 116], ["new", 120], ["concepts", 124], ["of", 133], ["central", 136], ["nervous", 144], ["system", 152], ["development", 159], ["have", 171], ["raised", 176], ["interesting", 183], ["possibilities", 195], ["regarding", 209], ["the", 219], ["oncogenic", 223], ["properties", 233], ["of", 244], ["neural", 247], ["stem", 254], ["/", 258], ["progenitor", 259], ["cells", 270], [".", 275], ["To", 277], ["elucidate", 280], ["these", 290], ["putative", 296], ["properties", 305], ["further", 316], [",", 323], ["the", 325], ["clinical", 329], ["materials", 338], ["from", 348], ["an", 353], ["infant", 356], ["brain", 363], ["tumor", 369], ["were", 375], ["analyzed", 380], [",", 388], ["focusing", 390], ["on", 399], ["the", 402], ["relation", 406], ["with", 415], ["the", 420], ["neural", 424], ["stem", 431], ["/", 435], ["progenitor", 436], ["cells", 447], [".", 452], ["The", 454], ["expression", 458], ["of", 469], ["neural", 472], ["stem", 479], ["/", 483], ["progenitor", 484], ["cell", 495], ["markers", 500], ["in", 508], ["the", 511], ["tumor", 515], ["cells", 521], ["and", 527], ["the", 531], ["cellular", 535], ["components", 544], ["of", 555], ["the", 558], ["infant", 562], ["brain", 569], ["tumor", 575], ["were", 581], ["examined", 586], ["using", 595], ["immunohistochemistry", 601], [".", 621], ["The", 623], ["tumor", 627], ["cell", 633], ["biology", 638], ["was", 646], ["analyzed", 650], ["both", 659], ["in", 664], ["culture", 667], ["and", 675], ["in", 679], ["the", 682], ["grafted", 686], ["brain", 694], ["environment", 700], [".", 711], ["Three", 713], ["main", 719], ["bodies", 724], ["of", 731], ["evidence", 734], ["were", 743], ["demonstrated", 748], ["indicating", 761], ["that", 772], ["the", 777], ["tumor", 781], ["was", 787], ["of", 791], ["possible", 794], ["subventricular", 803], ["zone", 818], ["postnatal", 823], ["or", 833], ["adult", 836], ["normal", 842], ["neural", 849], ["stem", 856], ["cell", 861], ["origin", 866], [".", 872], ["First", 874], [",", 879], ["in", 881], ["the", 884], ["tumor", 888], ["specimen", 894], ["we", 903], ["demonstrated", 906], ["the", 919], ["strong", 923], ["positive", 930], ["expression", 939], ["of", 950], ["the", 953], ["neural", 957], ["stem", 964], ["/", 968], ["progenitor", 969], ["cell", 980], ["markers", 985], [",", 992], ["nestin", 994], ["and", 1001], ["Musashi-1", 1005], [".", 1014], ["Second", 1016], [",", 1022], ["immunohistochemistry", 1024], ["revealed", 1045], ["the", 1054], ["presence", 1058], ["of", 1067], ["neuronal", 1070], [",", 1078], ["astrocytic", 1080], [",", 1090], ["and", 1092], ["immature", 1096], ["precursor", 1105], ["cells", 1115], ["in", 1121], ["the", 1124], ["tumor", 1128], ["tissue", 1134], [",", 1140], ["similar", 1142], ["to", 1150], ["the", 1153], ["cellular", 1157], ["components", 1166], ["of", 1177], ["the", 1180], ["subventricular", 1184], ["zone", 1199], [",", 1203], ["thereby", 1205], ["pointing", 1213], ["to", 1222], ["the", 1225], ["subventricular", 1229], ["zone", 1244], ["as", 1249], ["the", 1252], ["possible", 1256], ["origin", 1265], ["of", 1272], ["the", 1275], ["tumor", 1279], [".", 1284], ["The", 1286], ["subventricular", 1290], ["zone", 1305], ["also", 1310], ["is", 1315], ["one", 1318], ["of", 1322], ["the", 1325], ["strong", 1329], ["candidates", 1336], ["for", 1347], ["the", 1351], ["location", 1355], ["of", 1364], ["postnatal", 1367], ["/", 1376], ["adult", 1377], ["neural", 1383], ["stem", 1390], ["cells", 1395], [".", 1400], ["This", 1402], ["cellular", 1407], ["evidence", 1416], ["was", 1425], ["strengthened", 1429], ["further", 1442], ["by", 1450], ["the", 1453], ["clinicoradiological", 1457], ["findings", 1477], ["that", 1486], ["demonstrated", 1491], ["the", 1504], ["involvement", 1508], ["of", 1520], ["the", 1523], ["subventricular", 1527], ["zone", 1542], ["of", 1547], ["the", 1550], ["lateral", 1554], ["ventricle", 1562], ["by", 1572], ["the", 1575], ["tumor", 1579], [".", 1584], ["Third", 1586], [",", 1591], ["in", 1593], ["the", 1596], ["in", 1600], ["vitro", 1603], ["and", 1609], ["in", 1613], ["vivo", 1616], ["experiments", 1621], [",", 1632], ["a", 1634], ["dynamic", 1636], ["shift", 1644], ["in", 1650], ["expression", 1653], ["patterns", 1664], ["between", 1673], ["neural", 1681], ["stem", 1688], ["cells", 1693], ["(", 1699], ["nestin", 1700], [",", 1706], ["Musashi-1", 1708], [")", 1717], ["and", 1719], ["differentiated", 1723], ["cells", 1738], ["(", 1744], ["glial", 1745], ["fibrillary", 1751], ["acidic", 1762], ["protein", 1769], [",", 1776], ["neuron", 1778], ["-", 1784], ["specific", 1785], ["Class", 1794], ["III", 1800], ["beta", 1804], ["-", 1808], ["tubulin", 1809], [")", 1816], ["markers", 1818], ["was", 1826], ["seen", 1830], [",", 1834], ["similar", 1836], ["to", 1844], ["the", 1847], ["proposed", 1851], ["behavior", 1860], ["of", 1869], ["postnatal", 1872], ["/", 1881], ["adult", 1882], ["neural", 1888], ["stem", 1895], ["cells", 1900], ["in", 1906], ["situ", 1909], [".", 1913], ["These", 1915], ["findings", 1921], ["suggest", 1930], ["that", 1938], ["this", 1943], ["brain", 1948], ["tumor", 1954], ["originated", 1960], ["from", 1971], ["neural", 1976], ["stem", 1983], ["cells", 1988], ["located", 1994], ["in", 2002], ["the", 2005], ["subventricular", 2009], ["zone", 2024], [",", 2028], ["and", 2030], ["the", 2034], ["further", 2038], ["possibility", 2046], ["of", 2058], ["the", 2061], ["general", 2065], ["oncogenic", 2073], ["potential", 2083], ["of", 2093], ["neural", 2096], ["stem", 2103], ["cells", 2108], [".", 2113]]}
{"context": "The RNA editing enzyme ADAR chemically modifies adenosine (A) to inosine (I), which is interpreted by the ribosome as a guanosine. Here we assess cotranscriptional A-to-I editing in Drosophila by isolating nascent RNA from adult fly heads and subjecting samples to high throughput sequencing. There are a large number of edited sites within nascent exons. Nascent RNA from an ADAR-null strain was also sequenced, indicating that almost all A-to-I events require ADAR. Moreover, mRNA editing levels correlate with editing levels within the cognate nascent RNA sequence, indicating that the extent of editing is set cotranscriptionally. Surprisingly, the nascent data also identify an excess of intronic over exonic editing sites. These intronic sites occur preferentially within introns that are poorly spliced cotranscriptionally, suggesting a link between editing and splicing. We conclude that ADAR-mediated editing is more widespread than previously indicated and largely occurs cotranscriptionally.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "3b3c2659bbbc4cff90c610175d5dae05", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[158, 158], [4, 4], [71, 71], [90, 90]], "char_spans": [[896, 899], [23, 26], [376, 379], [462, 465]]}]}], "context_tokens": [["The", 0], ["RNA", 4], ["editing", 8], ["enzyme", 16], ["ADAR", 23], ["chemically", 28], ["modifies", 39], ["adenosine", 48], ["(", 58], ["A", 59], [")", 60], ["to", 62], ["inosine", 65], ["(", 73], ["I", 74], [")", 75], [",", 76], ["which", 78], ["is", 84], ["interpreted", 87], ["by", 99], ["the", 102], ["ribosome", 106], ["as", 115], ["a", 118], ["guanosine", 120], [".", 129], ["Here", 131], ["we", 136], ["assess", 139], ["cotranscriptional", 146], ["A", 164], ["-", 165], ["to", 166], ["-", 168], ["I", 169], ["editing", 171], ["in", 179], ["Drosophila", 182], ["by", 193], ["isolating", 196], ["nascent", 206], ["RNA", 214], ["from", 218], ["adult", 223], ["fly", 229], ["heads", 233], ["and", 239], ["subjecting", 243], ["samples", 254], ["to", 262], ["high", 265], ["throughput", 270], ["sequencing", 281], [".", 291], ["There", 293], ["are", 299], ["a", 303], ["large", 305], ["number", 311], ["of", 318], ["edited", 321], ["sites", 328], ["within", 334], ["nascent", 341], ["exons", 349], [".", 354], ["Nascent", 356], ["RNA", 364], ["from", 368], ["an", 373], ["ADAR", 376], ["-", 380], ["null", 381], ["strain", 386], ["was", 393], ["also", 397], ["sequenced", 402], [",", 411], ["indicating", 413], ["that", 424], ["almost", 429], ["all", 436], ["A", 440], ["-", 441], ["to", 442], ["-", 444], ["I", 445], ["events", 447], ["require", 454], ["ADAR", 462], [".", 466], ["Moreover", 468], [",", 476], ["mRNA", 478], ["editing", 483], ["levels", 491], ["correlate", 498], ["with", 508], ["editing", 513], ["levels", 521], ["within", 528], ["the", 535], ["cognate", 539], ["nascent", 547], ["RNA", 555], ["sequence", 559], [",", 567], ["indicating", 569], ["that", 580], ["the", 585], ["extent", 589], ["of", 596], ["editing", 599], ["is", 607], ["set", 610], ["cotranscriptionally", 614], [".", 633], ["Surprisingly", 635], [",", 647], ["the", 649], ["nascent", 653], ["data", 661], ["also", 666], ["identify", 671], ["an", 680], ["excess", 683], ["of", 690], ["intronic", 693], ["over", 702], ["exonic", 707], ["editing", 714], ["sites", 722], [".", 727], ["These", 729], ["intronic", 735], ["sites", 744], ["occur", 750], ["preferentially", 756], ["within", 771], ["introns", 778], ["that", 786], ["are", 791], ["poorly", 795], ["spliced", 802], ["cotranscriptionally", 810], [",", 829], ["suggesting", 831], ["a", 842], ["link", 844], ["between", 849], ["editing", 857], ["and", 865], ["splicing", 869], [".", 877], ["We", 879], ["conclude", 882], ["that", 891], ["ADAR", 896], ["-", 900], ["mediated", 901], ["editing", 910], ["is", 918], ["more", 921], ["widespread", 926], ["than", 937], ["previously", 942], ["indicated", 953], ["and", 963], ["largely", 967], ["occurs", 975], ["cotranscriptionally", 982], [".", 1001]]}
{"context": "SET domain genes have been identified in numbers of bacterial genomes based on similarity to SET domains of eukaryotic histone methyltransferases. Herein, a Chlamydophila pneumoniae SET domain gene was clarified to be coincidently expressed with hctA and hctB genes encoding chlamydial histone H1-like proteins, Hc1 and Hc2, respectively. The SET domain protein (cpnSET) is localized in chlamydial cells and interacts with Hc1 and Hc2 through the C-terminal SET domain. As expected from conservation of catalytic sites in cpnSET, it functions as a protein methyltransferase to murine histone H3 and Hc1. However, little is known about protein methylation in the molecular pathogenesis of chlamydial infection. cpnSET may play an important role in chlamydial cell maturation due to modification of chlamydial histone H1-like proteins.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "bf4ddb3d39ae4a8ebc75f6c6b7218fbb", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[0, 1], [76, 77], [27, 28], [54, 55]], "char_spans": [[0, 9], [458, 467], [182, 191], [343, 352]]}]}], "context_tokens": [["SET", 0], ["domain", 4], ["genes", 11], ["have", 17], ["been", 22], ["identified", 27], ["in", 38], ["numbers", 41], ["of", 49], ["bacterial", 52], ["genomes", 62], ["based", 70], ["on", 76], ["similarity", 79], ["to", 90], ["SET", 93], ["domains", 97], ["of", 105], ["eukaryotic", 108], ["histone", 119], ["methyltransferases", 127], [".", 145], ["Herein", 147], [",", 153], ["a", 155], ["Chlamydophila", 157], ["pneumoniae", 171], ["SET", 182], ["domain", 186], ["gene", 193], ["was", 198], ["clarified", 202], ["to", 212], ["be", 215], ["coincidently", 218], ["expressed", 231], ["with", 241], ["hctA", 246], ["and", 251], ["hctB", 255], ["genes", 260], ["encoding", 266], ["chlamydial", 275], ["histone", 286], ["H1-like", 294], ["proteins", 302], [",", 310], ["Hc1", 312], ["and", 316], ["Hc2", 320], [",", 323], ["respectively", 325], [".", 337], ["The", 339], ["SET", 343], ["domain", 347], ["protein", 354], ["(", 362], ["cpnSET", 363], [")", 369], ["is", 371], ["localized", 374], ["in", 384], ["chlamydial", 387], ["cells", 398], ["and", 404], ["interacts", 408], ["with", 418], ["Hc1", 423], ["and", 427], ["Hc2", 431], ["through", 435], ["the", 443], ["C", 447], ["-", 448], ["terminal", 449], ["SET", 458], ["domain", 462], [".", 468], ["As", 470], ["expected", 473], ["from", 482], ["conservation", 487], ["of", 500], ["catalytic", 503], ["sites", 513], ["in", 519], ["cpnSET", 522], [",", 528], ["it", 530], ["functions", 533], ["as", 543], ["a", 546], ["protein", 548], ["methyltransferase", 556], ["to", 574], ["murine", 577], ["histone", 584], ["H3", 592], ["and", 595], ["Hc1", 599], [".", 602], ["However", 604], [",", 611], ["little", 613], ["is", 620], ["known", 623], ["about", 629], ["protein", 635], ["methylation", 643], ["in", 655], ["the", 658], ["molecular", 662], ["pathogenesis", 672], ["of", 685], ["chlamydial", 688], ["infection", 699], [".", 708], ["cpnSET", 710], ["may", 717], ["play", 721], ["an", 726], ["important", 729], ["role", 739], ["in", 744], ["chlamydial", 747], ["cell", 758], ["maturation", 763], ["due", 774], ["to", 778], ["modification", 781], ["of", 794], ["chlamydial", 797], ["histone", 808], ["H1-like", 816], ["proteins", 824], [".", 832]]}
{"context": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies. There are no pathognomonic signs of SGS and diagnosis depends on recognition of a characteristic combination of anomalies. Here, we describe 14 persons with SGS and compare their clinical findings with those of 23 previously reported individuals, including two families with more than one affected individual. Our analysis suggests that there is a characteristic facial appearance, with more than two thirds of all individuals having hypertelorism, down-slanting palpebral fissures, a high-arched palate, micrognathia, and apparently low-set and posteriorly rotated ears. Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. The degree of reported intellectual impairment ranges from mild to severe. The most common skeletal manifestations in SGS were arachnodactyly, pectus deformity, camptodactyly, scoliosis, and joint hypermobility. None of the skeletal signs alone is specific for SGS. Our study includes 14 mainly German individuals with SGS evaluated over a period of 10 years. Given that only 23 other persons with SGS have been reported to date worldwide, we suggest that SGS may be more common than previously assumed.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "2406a794568840628014804927e40975", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[15, 15]], "char_spans": [[81, 96]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["(", 33], ["SGS", 34], [")", 37], ["is", 39], ["a", 42], ["disorder", 44], ["of", 53], ["unknown", 56], ["cause", 64], ["comprising", 70], ["craniosynostosis", 81], [",", 97], ["a", 99], ["marfanoid", 101], ["habitus", 111], ["and", 119], ["skeletal", 123], [",", 131], ["neurological", 133], [",", 145], ["cardiovascular", 147], [",", 161], ["and", 163], ["connective", 167], ["-", 177], ["tissue", 178], ["anomalies", 185], [".", 194], ["There", 196], ["are", 202], ["no", 206], ["pathognomonic", 209], ["signs", 223], ["of", 229], ["SGS", 232], ["and", 236], ["diagnosis", 240], ["depends", 250], ["on", 258], ["recognition", 261], ["of", 273], ["a", 276], ["characteristic", 278], ["combination", 293], ["of", 305], ["anomalies", 308], [".", 317], ["Here", 319], [",", 323], ["we", 325], ["describe", 328], ["14", 337], ["persons", 340], ["with", 348], ["SGS", 353], ["and", 357], ["compare", 361], ["their", 369], ["clinical", 375], ["findings", 384], ["with", 393], ["those", 398], ["of", 404], ["23", 407], ["previously", 410], ["reported", 421], ["individuals", 430], [",", 441], ["including", 443], ["two", 453], ["families", 457], ["with", 466], ["more", 471], ["than", 476], ["one", 481], ["affected", 485], ["individual", 494], [".", 504], ["Our", 506], ["analysis", 510], ["suggests", 519], ["that", 528], ["there", 533], ["is", 539], ["a", 542], ["characteristic", 544], ["facial", 559], ["appearance", 566], [",", 576], ["with", 578], ["more", 583], ["than", 588], ["two", 593], ["thirds", 597], ["of", 604], ["all", 607], ["individuals", 611], ["having", 623], ["hypertelorism", 630], [",", 643], ["down", 645], ["-", 649], ["slanting", 650], ["palpebral", 659], ["fissures", 669], [",", 677], ["a", 679], ["high", 681], ["-", 685], ["arched", 686], ["palate", 693], [",", 699], ["micrognathia", 701], [",", 713], ["and", 715], ["apparently", 719], ["low", 730], ["-", 733], ["set", 734], ["and", 738], ["posteriorly", 742], ["rotated", 754], ["ears", 762], [".", 766], ["Other", 768], ["commonly", 774], ["reported", 783], ["manifestations", 792], ["include", 807], ["hypotonia", 815], ["in", 825], ["at", 828], ["least", 831], ["the", 837], ["neonatal", 841], ["period", 850], [",", 856], ["developmental", 858], ["delay", 872], [",", 877], ["and", 879], ["inguinal", 883], ["or", 892], ["umbilical", 895], ["hernia", 905], [".", 911], ["The", 913], ["degree", 917], ["of", 924], ["reported", 927], ["intellectual", 936], ["impairment", 949], ["ranges", 960], ["from", 967], ["mild", 972], ["to", 977], ["severe", 980], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["skeletal", 1004], ["manifestations", 1013], ["in", 1028], ["SGS", 1031], ["were", 1035], ["arachnodactyly", 1040], [",", 1054], ["pectus", 1056], ["deformity", 1063], [",", 1072], ["camptodactyly", 1074], [",", 1087], ["scoliosis", 1089], [",", 1098], ["and", 1100], ["joint", 1104], ["hypermobility", 1110], [".", 1123], ["None", 1125], ["of", 1130], ["the", 1133], ["skeletal", 1137], ["signs", 1146], ["alone", 1152], ["is", 1158], ["specific", 1161], ["for", 1170], ["SGS", 1174], [".", 1177], ["Our", 1179], ["study", 1183], ["includes", 1189], ["14", 1198], ["mainly", 1201], ["German", 1208], ["individuals", 1215], ["with", 1227], ["SGS", 1232], ["evaluated", 1236], ["over", 1246], ["a", 1251], ["period", 1253], ["of", 1260], ["10", 1263], ["years", 1266], [".", 1271], ["Given", 1273], ["that", 1279], ["only", 1284], ["23", 1289], ["other", 1292], ["persons", 1298], ["with", 1306], ["SGS", 1311], ["have", 1315], ["been", 1320], ["reported", 1325], ["to", 1334], ["date", 1337], ["worldwide", 1342], [",", 1351], ["we", 1353], ["suggest", 1356], ["that", 1364], ["SGS", 1369], ["may", 1373], ["be", 1377], ["more", 1380], ["common", 1385], ["than", 1392], ["previously", 1397], ["assumed", 1408], [".", 1415]]}
{"context": "Chronic myeloid leukaemia (CML) is a genetically associated malignancy of haematopoietic stem cells, characterized by a t(9;22) translocation that forms the Philadelphia chromosome and creates a novel fusion gene, BCR-ABL. Treatment with molecular-targeted therapy is usually initiated with imatinib, an inhibitor of BCR-ABL tyrosine kinase. Imatinib resistance is, however, observed in some CML patients, especially in those with advanced disease. Through computerized literature searches, a systematic analysis was conducted to examine the efficacy and benefits of dasatinib therapy for imatinib resistant or intolerant CML patients in the chronic phase (CP), accelerated phase (AP) and fatal blast crisis phase (BC). In terms of major haematological and cytogenetic responses, this meta-analysis showed no significant differences in dasatinib treatment between myeloid BC-CML and lymphoid BC-CML patients with imatinib resistance or intolerance. Dasatinib therapy was, however, significantly more effective in improving major haematological and cytogenetic responses for CP-CML patients than for AP-CML patients with imatinib resistance or intolerance.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "4039d749db1e402c81b273c51d21f59b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[53, 55], [34, 36]], "char_spans": [[317, 323], [214, 220]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukaemia", 16], ["(", 26], ["CML", 27], [")", 30], ["is", 32], ["a", 35], ["genetically", 37], ["associated", 49], ["malignancy", 60], ["of", 71], ["haematopoietic", 74], ["stem", 89], ["cells", 94], [",", 99], ["characterized", 101], ["by", 115], ["a", 118], ["t(9;22", 120], [")", 126], ["translocation", 128], ["that", 142], ["forms", 147], ["the", 153], ["Philadelphia", 157], ["chromosome", 170], ["and", 181], ["creates", 185], ["a", 193], ["novel", 195], ["fusion", 201], ["gene", 208], [",", 212], ["BCR", 214], ["-", 217], ["ABL", 218], [".", 221], ["Treatment", 223], ["with", 233], ["molecular", 238], ["-", 247], ["targeted", 248], ["therapy", 257], ["is", 265], ["usually", 268], ["initiated", 276], ["with", 286], ["imatinib", 291], [",", 299], ["an", 301], ["inhibitor", 304], ["of", 314], ["BCR", 317], ["-", 320], ["ABL", 321], ["tyrosine", 325], ["kinase", 334], [".", 340], ["Imatinib", 342], ["resistance", 351], ["is", 362], [",", 364], ["however", 366], [",", 373], ["observed", 375], ["in", 384], ["some", 387], ["CML", 392], ["patients", 396], [",", 404], ["especially", 406], ["in", 417], ["those", 420], ["with", 426], ["advanced", 431], ["disease", 440], [".", 447], ["Through", 449], ["computerized", 457], ["literature", 470], ["searches", 481], [",", 489], ["a", 491], ["systematic", 493], ["analysis", 504], ["was", 513], ["conducted", 517], ["to", 527], ["examine", 530], ["the", 538], ["efficacy", 542], ["and", 551], ["benefits", 555], ["of", 564], ["dasatinib", 567], ["therapy", 577], ["for", 585], ["imatinib", 589], ["resistant", 598], ["or", 608], ["intolerant", 611], ["CML", 622], ["patients", 626], ["in", 635], ["the", 638], ["chronic", 642], ["phase", 650], ["(", 656], ["CP", 657], [")", 659], [",", 660], ["accelerated", 662], ["phase", 674], ["(", 680], ["AP", 681], [")", 683], ["and", 685], ["fatal", 689], ["blast", 695], ["crisis", 701], ["phase", 708], ["(", 714], ["BC", 715], [")", 717], [".", 718], ["In", 720], ["terms", 723], ["of", 729], ["major", 732], ["haematological", 738], ["and", 753], ["cytogenetic", 757], ["responses", 769], [",", 778], ["this", 780], ["meta", 785], ["-", 789], ["analysis", 790], ["showed", 799], ["no", 806], ["significant", 809], ["differences", 821], ["in", 833], ["dasatinib", 836], ["treatment", 846], ["between", 856], ["myeloid", 864], ["BC", 872], ["-", 874], ["CML", 875], ["and", 879], ["lymphoid", 883], ["BC", 892], ["-", 894], ["CML", 895], ["patients", 899], ["with", 908], ["imatinib", 913], ["resistance", 922], ["or", 933], ["intolerance", 936], [".", 947], ["Dasatinib", 949], ["therapy", 959], ["was", 967], [",", 970], ["however", 972], [",", 979], ["significantly", 981], ["more", 995], ["effective", 1000], ["in", 1010], ["improving", 1013], ["major", 1023], ["haematological", 1029], ["and", 1044], ["cytogenetic", 1048], ["responses", 1060], ["for", 1070], ["CP", 1074], ["-", 1076], ["CML", 1077], ["patients", 1081], ["than", 1090], ["for", 1095], ["AP", 1099], ["-", 1101], ["CML", 1102], ["patients", 1106], ["with", 1115], ["imatinib", 1120], ["resistance", 1129], ["or", 1140], ["intolerance", 1143], [".", 1154]]}
{"context": "Stress signals elicit a wide variety of cellular responses, many of which converge on the phosphorylation of JNK and p38 kinases, the activation of which has been well-characterized. How these kinases are switched off by dephosphorylation is not well understood. Here we describe how diverse cellular stresses affect differently the stability and activity of a JNK-inactivating dual-specificity threonine-tyrosine phosphatase M3/6. Both anisomycin and arsenite activate the JNK pathway and, in addition, inactivate the M3/6 phosphatase. However, while anisomycin treatment of cells leads to M3/6 protein degradation, arsenite appears to inactivate M3/6 directly. These results might have implications for the mechanism of tumour promotion by arsenic.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "b7441dc6481f4a8c8ea767fe70d618bb", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[79, 79], [61, 61], [18, 18]], "char_spans": [[474, 476], [361, 363], [109, 111]]}]}], "context_tokens": [["Stress", 0], ["signals", 7], ["elicit", 15], ["a", 22], ["wide", 24], ["variety", 29], ["of", 37], ["cellular", 40], ["responses", 49], [",", 58], ["many", 60], ["of", 65], ["which", 68], ["converge", 74], ["on", 83], ["the", 86], ["phosphorylation", 90], ["of", 106], ["JNK", 109], ["and", 113], ["p38", 117], ["kinases", 121], [",", 128], ["the", 130], ["activation", 134], ["of", 145], ["which", 148], ["has", 154], ["been", 158], ["well", 163], ["-", 167], ["characterized", 168], [".", 181], ["How", 183], ["these", 187], ["kinases", 193], ["are", 201], ["switched", 205], ["off", 214], ["by", 218], ["dephosphorylation", 221], ["is", 239], ["not", 242], ["well", 246], ["understood", 251], [".", 261], ["Here", 263], ["we", 268], ["describe", 271], ["how", 280], ["diverse", 284], ["cellular", 292], ["stresses", 301], ["affect", 310], ["differently", 317], ["the", 329], ["stability", 333], ["and", 343], ["activity", 347], ["of", 356], ["a", 359], ["JNK", 361], ["-", 364], ["inactivating", 365], ["dual", 378], ["-", 382], ["specificity", 383], ["threonine", 395], ["-", 404], ["tyrosine", 405], ["phosphatase", 414], ["M3/6", 426], [".", 430], ["Both", 432], ["anisomycin", 437], ["and", 448], ["arsenite", 452], ["activate", 461], ["the", 470], ["JNK", 474], ["pathway", 478], ["and", 486], [",", 489], ["in", 491], ["addition", 494], [",", 502], ["inactivate", 504], ["the", 515], ["M3/6", 519], ["phosphatase", 524], [".", 535], ["However", 537], [",", 544], ["while", 546], ["anisomycin", 552], ["treatment", 563], ["of", 573], ["cells", 576], ["leads", 582], ["to", 588], ["M3/6", 591], ["protein", 596], ["degradation", 604], [",", 615], ["arsenite", 617], ["appears", 626], ["to", 634], ["inactivate", 637], ["M3/6", 648], ["directly", 653], [".", 661], ["These", 663], ["results", 669], ["might", 677], ["have", 683], ["implications", 688], ["for", 701], ["the", 705], ["mechanism", 709], ["of", 719], ["tumour", 722], ["promotion", 729], ["by", 739], ["arsenic", 742], [".", 749]]}
{"context": "To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies. A total of 219 patients with active RA in whom treatment with biologic agents had failed were enrolled in a 3-month multicenter, randomized, double-blind, placebo-controlled trial of R788. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at month 3. Secondary end points included changes in inflammation and damage, as assessed by magnetic resonance imaging (MRI), and changes in the Disease Activity Score. The ACR20 response in the R788 100 mg twice daily group was 38%, versus 37% in the placebo group, at month 3. No significant differences were achieved in the ACR20, ACR50, or ACR70 response levels at 3 months. There were differences between the groups from baseline to month 3 in the secondary end points C-reactive protein (CRP) level and synovitis score on MRI. There were baseline differences in steroid use, prior biologic use, and synovitis score on MRI between the R788 group and the placebo group that may have affected the outcomes. A high placebo response rate was seen in this trial, and exploratory analysis suggested that this may in part have been driven by patients who entered the trial with an elevated erythrocyte sedimentation rate but normal CRP level. Our findings indicate that there were no differences in the primary end point between the R788 and placebo groups. Differences were observed between the R788 and placebo groups in secondary end points, particularly in those patients who entered the study with an elevated CRP level.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "da2a8dc6772a49fb956f810030d12b53", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[16, 18]], "char_spans": [[83, 104]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], ["and", 23], ["safety", 27], ["of", 34], ["R788", 37], ["(", 42], ["fostamatinib", 43], ["disodium", 56], [")", 64], [",", 65], ["an", 67], ["inhibitor", 70], ["of", 80], ["spleen", 83], ["tyrosine", 90], ["kinase", 99], ["(", 106], ["Syk", 107], [")", 110], [",", 111], ["in", 113], ["patients", 116], ["with", 125], ["active", 130], ["rheumatoid", 137], ["arthritis", 148], ["(", 158], ["RA", 159], [")", 161], ["that", 163], ["did", 168], ["not", 172], ["respond", 176], ["to", 184], ["biologic", 187], ["therapies", 196], [".", 205], ["A", 207], ["total", 209], ["of", 215], ["219", 218], ["patients", 222], ["with", 231], ["active", 236], ["RA", 243], ["in", 246], ["whom", 249], ["treatment", 254], ["with", 264], ["biologic", 269], ["agents", 278], ["had", 285], ["failed", 289], ["were", 296], ["enrolled", 301], ["in", 310], ["a", 313], ["3-month", 315], ["multicenter", 323], [",", 334], ["randomized", 336], [",", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["placebo", 362], ["-", 369], ["controlled", 370], ["trial", 381], ["of", 387], ["R788", 390], [".", 394], ["The", 396], ["primary", 400], ["end", 408], ["point", 412], ["was", 418], ["the", 422], ["percentage", 426], ["of", 437], ["patients", 440], ["who", 449], ["met", 453], ["the", 457], ["American", 461], ["College", 470], ["of", 478], ["Rheumatology", 481], ["20", 494], ["%", 496], ["improvement", 498], ["criteria", 510], ["(", 519], ["achieved", 520], ["an", 529], ["ACR20", 532], ["response", 538], [")", 546], ["at", 548], ["month", 551], ["3", 557], [".", 558], ["Secondary", 560], ["end", 570], ["points", 574], ["included", 581], ["changes", 590], ["in", 598], ["inflammation", 601], ["and", 614], ["damage", 618], [",", 624], ["as", 626], ["assessed", 629], ["by", 638], ["magnetic", 641], ["resonance", 650], ["imaging", 660], ["(", 668], ["MRI", 669], [")", 672], [",", 673], ["and", 675], ["changes", 679], ["in", 687], ["the", 690], ["Disease", 694], ["Activity", 702], ["Score", 711], [".", 716], ["The", 718], ["ACR20", 722], ["response", 728], ["in", 737], ["the", 740], ["R788", 744], ["100", 749], ["mg", 753], ["twice", 756], ["daily", 762], ["group", 768], ["was", 774], ["38", 778], ["%", 780], [",", 781], ["versus", 783], ["37", 790], ["%", 792], ["in", 794], ["the", 797], ["placebo", 801], ["group", 809], [",", 814], ["at", 816], ["month", 819], ["3", 825], [".", 826], ["No", 828], ["significant", 831], ["differences", 843], ["were", 855], ["achieved", 860], ["in", 869], ["the", 872], ["ACR20", 876], [",", 881], ["ACR50", 883], [",", 888], ["or", 890], ["ACR70", 893], ["response", 899], ["levels", 908], ["at", 915], ["3", 918], ["months", 920], [".", 926], ["There", 928], ["were", 934], ["differences", 939], ["between", 951], ["the", 959], ["groups", 963], ["from", 970], ["baseline", 975], ["to", 984], ["month", 987], ["3", 993], ["in", 995], ["the", 998], ["secondary", 1002], ["end", 1012], ["points", 1016], ["C", 1023], ["-", 1024], ["reactive", 1025], ["protein", 1034], ["(", 1042], ["CRP", 1043], [")", 1046], ["level", 1048], ["and", 1054], ["synovitis", 1058], ["score", 1068], ["on", 1074], ["MRI", 1077], [".", 1080], ["There", 1082], ["were", 1088], ["baseline", 1093], ["differences", 1102], ["in", 1114], ["steroid", 1117], ["use", 1125], [",", 1128], ["prior", 1130], ["biologic", 1136], ["use", 1145], [",", 1148], ["and", 1150], ["synovitis", 1154], ["score", 1164], ["on", 1170], ["MRI", 1173], ["between", 1177], ["the", 1185], ["R788", 1189], ["group", 1194], ["and", 1200], ["the", 1204], ["placebo", 1208], ["group", 1216], ["that", 1222], ["may", 1227], ["have", 1231], ["affected", 1236], ["the", 1245], ["outcomes", 1249], [".", 1257], ["A", 1259], ["high", 1261], ["placebo", 1266], ["response", 1274], ["rate", 1283], ["was", 1288], ["seen", 1292], ["in", 1297], ["this", 1300], ["trial", 1305], [",", 1310], ["and", 1312], ["exploratory", 1316], ["analysis", 1328], ["suggested", 1337], ["that", 1347], ["this", 1352], ["may", 1357], ["in", 1361], ["part", 1364], ["have", 1369], ["been", 1374], ["driven", 1379], ["by", 1386], ["patients", 1389], ["who", 1398], ["entered", 1402], ["the", 1410], ["trial", 1414], ["with", 1420], ["an", 1425], ["elevated", 1428], ["erythrocyte", 1437], ["sedimentation", 1449], ["rate", 1463], ["but", 1468], ["normal", 1472], ["CRP", 1479], ["level", 1483], [".", 1488], ["Our", 1490], ["findings", 1494], ["indicate", 1503], ["that", 1512], ["there", 1517], ["were", 1523], ["no", 1528], ["differences", 1531], ["in", 1543], ["the", 1546], ["primary", 1550], ["end", 1558], ["point", 1562], ["between", 1568], ["the", 1576], ["R788", 1580], ["and", 1585], ["placebo", 1589], ["groups", 1597], [".", 1603], ["Differences", 1605], ["were", 1617], ["observed", 1622], ["between", 1631], ["the", 1639], ["R788", 1643], ["and", 1648], ["placebo", 1652], ["groups", 1660], ["in", 1667], ["secondary", 1670], ["end", 1680], ["points", 1684], [",", 1690], ["particularly", 1692], ["in", 1705], ["those", 1708], ["patients", 1714], ["who", 1723], ["entered", 1727], ["the", 1735], ["study", 1739], ["with", 1745], ["an", 1750], ["elevated", 1753], ["CRP", 1762], ["level", 1766], [".", 1771]]}
{"context": "Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis (TB), despite its variable protective efficacy. Relatively little is known about the immune response profiles following BCG vaccination in relation to protection against TB. Here we tested whether BCG vaccination results in immune responses to DosR (Rv3133c) regulon-encoded proteins. These so-called TB latency antigens are targeted by the immune system during persistent Mycobacterium tuberculosis infection and have been associated with immunity against latent M. tuberculosis infection. In silico analysis of the DosR regulon in BCG and M. tuberculosis showed at least 97% amino acid sequence homology, with 41 out of 48 genes being identical. Transcriptional profiling of 14 different BCG strains, under hypoxia and nitric oxide exposure in vitro, revealed a functional DosR regulon similar to that observed in M. tuberculosis. Next, we assessed human immune responses to a series of immunodominant TB latency antigens and found that BCG vaccination fails to induce significant responses to latency antigens. Similar results were obtained with BCG-vaccinated BALB/c mice. In contrast, responses to latency antigens were observed in individuals with suspected exposure to TB (as indicated by positive gamma interferon responses to TB-specific antigens ESAT-6 and CFP-10) and in mice vaccinated with plasmid DNA encoding selected latency antigens. Since immune responses to TB latency antigens have been associated with control of latent M. tuberculosis infection, our findings support the development of vaccination strategies incorporating DosR regulon antigens to complement and improve the current BCG vaccine.", "qas": [{"question": "How many genes constitute the DosR regulon, controlled by the dormancy survival regulator (DosR) in Mycobacterium tuberculosis?", "answers": ["48 genes"], "qid": "f40c5ca38b964c3fbfd353444320a3b9", "question_tokens": [["How", 0], ["many", 4], ["genes", 9], ["constitute", 15], ["the", 26], ["DosR", 30], ["regulon", 35], [",", 42], ["controlled", 44], ["by", 55], ["the", 58], ["dormancy", 62], ["survival", 71], ["regulator", 80], ["(", 90], ["DosR", 91], [")", 95], ["in", 97], ["Mycobacterium", 100], ["tuberculosis", 114], ["?", 126]], "detected_answers": [{"text": "48 genes", "token_spans": [[116, 117]], "char_spans": [[695, 702]]}]}], "context_tokens": [["Mycobacterium", 0], ["bovis", 14], ["BCG", 20], ["is", 24], ["widely", 27], ["used", 34], ["as", 39], ["a", 42], ["vaccine", 44], ["against", 52], ["tuberculosis", 60], ["(", 73], ["TB", 74], [")", 76], [",", 77], ["despite", 79], ["its", 87], ["variable", 91], ["protective", 100], ["efficacy", 111], [".", 119], ["Relatively", 121], ["little", 132], ["is", 139], ["known", 142], ["about", 148], ["the", 154], ["immune", 158], ["response", 165], ["profiles", 174], ["following", 183], ["BCG", 193], ["vaccination", 197], ["in", 209], ["relation", 212], ["to", 221], ["protection", 224], ["against", 235], ["TB", 243], [".", 245], ["Here", 247], ["we", 252], ["tested", 255], ["whether", 262], ["BCG", 270], ["vaccination", 274], ["results", 286], ["in", 294], ["immune", 297], ["responses", 304], ["to", 314], ["DosR", 317], ["(", 322], ["Rv3133c", 323], [")", 330], ["regulon", 332], ["-", 339], ["encoded", 340], ["proteins", 348], [".", 356], ["These", 358], ["so", 364], ["-", 366], ["called", 367], ["TB", 374], ["latency", 377], ["antigens", 385], ["are", 394], ["targeted", 398], ["by", 407], ["the", 410], ["immune", 414], ["system", 421], ["during", 428], ["persistent", 435], ["Mycobacterium", 446], ["tuberculosis", 460], ["infection", 473], ["and", 483], ["have", 487], ["been", 492], ["associated", 497], ["with", 508], ["immunity", 513], ["against", 522], ["latent", 530], ["M.", 537], ["tuberculosis", 540], ["infection", 553], [".", 562], ["In", 564], ["silico", 567], ["analysis", 574], ["of", 583], ["the", 586], ["DosR", 590], ["regulon", 595], ["in", 603], ["BCG", 606], ["and", 610], ["M.", 614], ["tuberculosis", 617], ["showed", 630], ["at", 637], ["least", 640], ["97", 646], ["%", 648], ["amino", 650], ["acid", 656], ["sequence", 661], ["homology", 670], [",", 678], ["with", 680], ["41", 685], ["out", 688], ["of", 692], ["48", 695], ["genes", 698], ["being", 704], ["identical", 710], [".", 719], ["Transcriptional", 721], ["profiling", 737], ["of", 747], ["14", 750], ["different", 753], ["BCG", 763], ["strains", 767], [",", 774], ["under", 776], ["hypoxia", 782], ["and", 790], ["nitric", 794], ["oxide", 801], ["exposure", 807], ["in", 816], ["vitro", 819], [",", 824], ["revealed", 826], ["a", 835], ["functional", 837], ["DosR", 848], ["regulon", 853], ["similar", 861], ["to", 869], ["that", 872], ["observed", 877], ["in", 886], ["M.", 889], ["tuberculosis", 892], [".", 904], ["Next", 906], [",", 910], ["we", 912], ["assessed", 915], ["human", 924], ["immune", 930], ["responses", 937], ["to", 947], ["a", 950], ["series", 952], ["of", 959], ["immunodominant", 962], ["TB", 977], ["latency", 980], ["antigens", 988], ["and", 997], ["found", 1001], ["that", 1007], ["BCG", 1012], ["vaccination", 1016], ["fails", 1028], ["to", 1034], ["induce", 1037], ["significant", 1044], ["responses", 1056], ["to", 1066], ["latency", 1069], ["antigens", 1077], [".", 1085], ["Similar", 1087], ["results", 1095], ["were", 1103], ["obtained", 1108], ["with", 1117], ["BCG", 1122], ["-", 1125], ["vaccinated", 1126], ["BALB", 1137], ["/", 1141], ["c", 1142], ["mice", 1144], [".", 1148], ["In", 1150], ["contrast", 1153], [",", 1161], ["responses", 1163], ["to", 1173], ["latency", 1176], ["antigens", 1184], ["were", 1193], ["observed", 1198], ["in", 1207], ["individuals", 1210], ["with", 1222], ["suspected", 1227], ["exposure", 1237], ["to", 1246], ["TB", 1249], ["(", 1252], ["as", 1253], ["indicated", 1256], ["by", 1266], ["positive", 1269], ["gamma", 1278], ["interferon", 1284], ["responses", 1295], ["to", 1305], ["TB", 1308], ["-", 1310], ["specific", 1311], ["antigens", 1320], ["ESAT-6", 1329], ["and", 1336], ["CFP-10", 1340], [")", 1346], ["and", 1348], ["in", 1352], ["mice", 1355], ["vaccinated", 1360], ["with", 1371], ["plasmid", 1376], ["DNA", 1384], ["encoding", 1388], ["selected", 1397], ["latency", 1406], ["antigens", 1414], [".", 1422], ["Since", 1424], ["immune", 1430], ["responses", 1437], ["to", 1447], ["TB", 1450], ["latency", 1453], ["antigens", 1461], ["have", 1470], ["been", 1475], ["associated", 1480], ["with", 1491], ["control", 1496], ["of", 1504], ["latent", 1507], ["M.", 1514], ["tuberculosis", 1517], ["infection", 1530], [",", 1539], ["our", 1541], ["findings", 1545], ["support", 1554], ["the", 1562], ["development", 1566], ["of", 1578], ["vaccination", 1581], ["strategies", 1593], ["incorporating", 1604], ["DosR", 1618], ["regulon", 1623], ["antigens", 1631], ["to", 1640], ["complement", 1643], ["and", 1654], ["improve", 1658], ["the", 1666], ["current", 1670], ["BCG", 1678], ["vaccine", 1682], [".", 1689]]}
{"context": "The acromelic dysplasia group includes three rare disorders: Weill-Marchesani syndrome (WMS), Geleophysic dysplasia (GD) and Acromicric dysplasia (AD) all characterized by short stature, short hands and stiff joints. The clinical overlap between the three disorders is striking. Indeed, in addition to the diagnostic criteria, they all share common features including delayed bone age, cone shaped epiphyses, thick skin and heart disease. In contrast, a microspherophakic lens seems to be a characteristic feature of WMS whereas hepatomegaly and a severe outcome are encountered only in the most severe forms of GD. Finally, WMS is transmitted either by an autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance. Using genetic approaches, we have identified the molecular basis of WMS and GD which both involved the same superfamily of proteins, the ADAMTS [A Disintegrin-like And Metalloproteinase domain (reprolysin type) with ThromboSpondin type 1 repeats (TSR)]. We have found ADAMTS10 mutations in the recessive form of WMS and Fibrillin 1 mutations in the dominant form of WMS. More recently, we have identified ADAMTSL2 mutations in GD. The function of ADAMTS1 0 and AD AMTSL 2 are unknown. But the findings of FBN1 and ADAMTS10 mutations in WMS suggest a direct link between the two proteins. Using a yeast double hybrid screen, we have identified LTBP1 (Latent TGFbeta Binding protein 1) as a partner of ADAMTSL2. The combination of these findings suggests that ADAMTS10 and ADAMTSL2 are both involved in the microfibrillar network.", "qas": [{"question": "What is the mode of inheritance of Acromicric dysplasia?", "answers": ["autosomal dominant"], "qid": "30fd38ce62fe459b88937446ee06bcbb", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Acromicric", 35], ["dysplasia", 46], ["?", 55]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[143, 144], [118, 119]], "char_spans": [[790, 807], [657, 674]]}]}], "context_tokens": [["The", 0], ["acromelic", 4], ["dysplasia", 14], ["group", 24], ["includes", 30], ["three", 39], ["rare", 45], ["disorders", 50], [":", 59], ["Weill", 61], ["-", 66], ["Marchesani", 67], ["syndrome", 78], ["(", 87], ["WMS", 88], [")", 91], [",", 92], ["Geleophysic", 94], ["dysplasia", 106], ["(", 116], ["GD", 117], [")", 119], ["and", 121], ["Acromicric", 125], ["dysplasia", 136], ["(", 146], ["AD", 147], [")", 149], ["all", 151], ["characterized", 155], ["by", 169], ["short", 172], ["stature", 178], [",", 185], ["short", 187], ["hands", 193], ["and", 199], ["stiff", 203], ["joints", 209], [".", 215], ["The", 217], ["clinical", 221], ["overlap", 230], ["between", 238], ["the", 246], ["three", 250], ["disorders", 256], ["is", 266], ["striking", 269], [".", 277], ["Indeed", 279], [",", 285], ["in", 287], ["addition", 290], ["to", 299], ["the", 302], ["diagnostic", 306], ["criteria", 317], [",", 325], ["they", 327], ["all", 332], ["share", 336], ["common", 342], ["features", 349], ["including", 358], ["delayed", 368], ["bone", 376], ["age", 381], [",", 384], ["cone", 386], ["shaped", 391], ["epiphyses", 398], [",", 407], ["thick", 409], ["skin", 415], ["and", 420], ["heart", 424], ["disease", 430], [".", 437], ["In", 439], ["contrast", 442], [",", 450], ["a", 452], ["microspherophakic", 454], ["lens", 472], ["seems", 477], ["to", 483], ["be", 486], ["a", 489], ["characteristic", 491], ["feature", 506], ["of", 514], ["WMS", 517], ["whereas", 521], ["hepatomegaly", 529], ["and", 542], ["a", 546], ["severe", 548], ["outcome", 555], ["are", 563], ["encountered", 567], ["only", 579], ["in", 584], ["the", 587], ["most", 591], ["severe", 596], ["forms", 603], ["of", 609], ["GD", 612], [".", 614], ["Finally", 616], [",", 623], ["WMS", 625], ["is", 629], ["transmitted", 632], ["either", 644], ["by", 651], ["an", 654], ["autosomal", 657], ["dominant", 667], ["or", 676], ["an", 679], ["autosomal", 682], ["recessive", 692], ["(", 702], ["AR", 703], [")", 705], ["mode", 707], ["of", 712], ["inheritance", 715], [",", 726], ["GD", 728], ["by", 731], ["an", 734], ["autosomal", 737], ["recessive", 747], ["mode", 757], ["of", 762], ["inheritance", 765], ["and", 777], ["AD", 781], ["by", 784], ["an", 787], ["autosomal", 790], ["dominant", 800], ["mode", 809], ["of", 814], ["inheritance", 817], [".", 828], ["Using", 830], ["genetic", 836], ["approaches", 844], [",", 854], ["we", 856], ["have", 859], ["identified", 864], ["the", 875], ["molecular", 879], ["basis", 889], ["of", 895], ["WMS", 898], ["and", 902], ["GD", 906], ["which", 909], ["both", 915], ["involved", 920], ["the", 929], ["same", 933], ["superfamily", 938], ["of", 950], ["proteins", 953], [",", 961], ["the", 963], ["ADAMTS", 967], ["[", 974], ["A", 975], ["Disintegrin", 977], ["-", 988], ["like", 989], ["And", 994], ["Metalloproteinase", 998], ["domain", 1016], ["(", 1023], ["reprolysin", 1024], ["type", 1035], [")", 1039], ["with", 1041], ["ThromboSpondin", 1046], ["type", 1061], ["1", 1066], ["repeats", 1068], ["(", 1076], ["TSR)].", 1077], ["We", 1084], ["have", 1087], ["found", 1092], ["ADAMTS10", 1098], ["mutations", 1107], ["in", 1117], ["the", 1120], ["recessive", 1124], ["form", 1134], ["of", 1139], ["WMS", 1142], ["and", 1146], ["Fibrillin", 1150], ["1", 1160], ["mutations", 1162], ["in", 1172], ["the", 1175], ["dominant", 1179], ["form", 1188], ["of", 1193], ["WMS", 1196], [".", 1199], ["More", 1201], ["recently", 1206], [",", 1214], ["we", 1216], ["have", 1219], ["identified", 1224], ["ADAMTSL2", 1235], ["mutations", 1244], ["in", 1254], ["GD", 1257], [".", 1259], ["The", 1261], ["function", 1265], ["of", 1274], ["ADAMTS1", 1277], ["0", 1285], ["and", 1287], ["AD", 1291], ["AMTSL", 1294], ["2", 1300], ["are", 1302], ["unknown", 1306], [".", 1313], ["But", 1315], ["the", 1319], ["findings", 1323], ["of", 1332], ["FBN1", 1335], ["and", 1340], ["ADAMTS10", 1344], ["mutations", 1353], ["in", 1363], ["WMS", 1366], ["suggest", 1370], ["a", 1378], ["direct", 1380], ["link", 1387], ["between", 1392], ["the", 1400], ["two", 1404], ["proteins", 1408], [".", 1416], ["Using", 1418], ["a", 1424], ["yeast", 1426], ["double", 1432], ["hybrid", 1439], ["screen", 1446], [",", 1452], ["we", 1454], ["have", 1457], ["identified", 1462], ["LTBP1", 1473], ["(", 1479], ["Latent", 1480], ["TGFbeta", 1487], ["Binding", 1495], ["protein", 1503], ["1", 1511], [")", 1512], ["as", 1514], ["a", 1517], ["partner", 1519], ["of", 1527], ["ADAMTSL2", 1530], [".", 1538], ["The", 1540], ["combination", 1544], ["of", 1556], ["these", 1559], ["findings", 1565], ["suggests", 1574], ["that", 1583], ["ADAMTS10", 1588], ["and", 1597], ["ADAMTSL2", 1601], ["are", 1610], ["both", 1614], ["involved", 1619], ["in", 1628], ["the", 1631], ["microfibrillar", 1635], ["network", 1650], [".", 1657]]}
{"context": "Detection of latent tuberculosis infection is an important step in the control of tuberculosis. The tuberculin skin test is the only proven method for identifying tuberculosis infection in patients who do not have tuberculosis disease. The prevalence of tuberculosis infection among hospitalized patients in a pneumological department of an inner-city hospital was evaluated, using the intradermal tuberculin skin test (Mantoux technique). Interpretation of the Mantoux test was based on the size of induration in millimeters and the individual risk profile of the patients, according to the guidelines of the American Thoracic Society and the Centers for Disease Control, revised in 1989. Of 697 tested patients, 252 showed test results consistent with tuberculosis infection (36.2%). 55 of these 697 patients had active tuberculosis disease or a prior history of tuberculosis (7.9%). A positive tuberculin skin test was found in 197 of 642 patients (30.7%) with a diagnosis different from tuberculosis (COPD, pneumonia, cancer and others). In our study, the sensitivity of the tuberculin skin test for active tuberculosis infection was 95%. The present study revealed a high prevalence of tuberculosis infection among hospitalized patients in a pneumological department. Further studies are needed to assess the usefulness of routine tuberculin skin testing in hospitalized populations.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "a2d8fa1d4aec4b51af662fbe80cc7535", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[144, 144], [3, 3], [13, 13], [26, 26], [123, 123], [171, 171], [195, 195], [137, 137], [40, 40], [34, 34], [209, 209]], "char_spans": [[865, 876], [20, 31], [82, 93], [163, 174], [754, 765], [991, 1002], [1111, 1122], [822, 833], [254, 265], [214, 225], [1191, 1202]]}]}], "context_tokens": [["Detection", 0], ["of", 10], ["latent", 13], ["tuberculosis", 20], ["infection", 33], ["is", 43], ["an", 46], ["important", 49], ["step", 59], ["in", 64], ["the", 67], ["control", 71], ["of", 79], ["tuberculosis", 82], [".", 94], ["The", 96], ["tuberculin", 100], ["skin", 111], ["test", 116], ["is", 121], ["the", 124], ["only", 128], ["proven", 133], ["method", 140], ["for", 147], ["identifying", 151], ["tuberculosis", 163], ["infection", 176], ["in", 186], ["patients", 189], ["who", 198], ["do", 202], ["not", 205], ["have", 209], ["tuberculosis", 214], ["disease", 227], [".", 234], ["The", 236], ["prevalence", 240], ["of", 251], ["tuberculosis", 254], ["infection", 267], ["among", 277], ["hospitalized", 283], ["patients", 296], ["in", 305], ["a", 308], ["pneumological", 310], ["department", 324], ["of", 335], ["an", 338], ["inner", 341], ["-", 346], ["city", 347], ["hospital", 352], ["was", 361], ["evaluated", 365], [",", 374], ["using", 376], ["the", 382], ["intradermal", 386], ["tuberculin", 398], ["skin", 409], ["test", 414], ["(", 419], ["Mantoux", 420], ["technique", 428], [")", 437], [".", 438], ["Interpretation", 440], ["of", 455], ["the", 458], ["Mantoux", 462], ["test", 470], ["was", 475], ["based", 479], ["on", 485], ["the", 488], ["size", 492], ["of", 497], ["induration", 500], ["in", 511], ["millimeters", 514], ["and", 526], ["the", 530], ["individual", 534], ["risk", 545], ["profile", 550], ["of", 558], ["the", 561], ["patients", 565], [",", 573], ["according", 575], ["to", 585], ["the", 588], ["guidelines", 592], ["of", 603], ["the", 606], ["American", 610], ["Thoracic", 619], ["Society", 628], ["and", 636], ["the", 640], ["Centers", 644], ["for", 652], ["Disease", 656], ["Control", 664], [",", 671], ["revised", 673], ["in", 681], ["1989", 684], [".", 688], ["Of", 690], ["697", 693], ["tested", 697], ["patients", 704], [",", 712], ["252", 714], ["showed", 718], ["test", 725], ["results", 730], ["consistent", 738], ["with", 749], ["tuberculosis", 754], ["infection", 767], ["(", 777], ["36.2", 778], ["%", 782], [")", 783], [".", 784], ["55", 786], ["of", 789], ["these", 792], ["697", 798], ["patients", 802], ["had", 811], ["active", 815], ["tuberculosis", 822], ["disease", 835], ["or", 843], ["a", 846], ["prior", 848], ["history", 854], ["of", 862], ["tuberculosis", 865], ["(", 878], ["7.9", 879], ["%", 882], [")", 883], [".", 884], ["A", 886], ["positive", 888], ["tuberculin", 897], ["skin", 908], ["test", 913], ["was", 918], ["found", 922], ["in", 928], ["197", 931], ["of", 935], ["642", 938], ["patients", 942], ["(", 951], ["30.7", 952], ["%", 956], [")", 957], ["with", 959], ["a", 964], ["diagnosis", 966], ["different", 976], ["from", 986], ["tuberculosis", 991], ["(", 1004], ["COPD", 1005], [",", 1009], ["pneumonia", 1011], [",", 1020], ["cancer", 1022], ["and", 1029], ["others", 1033], [")", 1039], [".", 1040], ["In", 1042], ["our", 1045], ["study", 1049], [",", 1054], ["the", 1056], ["sensitivity", 1060], ["of", 1072], ["the", 1075], ["tuberculin", 1079], ["skin", 1090], ["test", 1095], ["for", 1100], ["active", 1104], ["tuberculosis", 1111], ["infection", 1124], ["was", 1134], ["95", 1138], ["%", 1140], [".", 1141], ["The", 1143], ["present", 1147], ["study", 1155], ["revealed", 1161], ["a", 1170], ["high", 1172], ["prevalence", 1177], ["of", 1188], ["tuberculosis", 1191], ["infection", 1204], ["among", 1214], ["hospitalized", 1220], ["patients", 1233], ["in", 1242], ["a", 1245], ["pneumological", 1247], ["department", 1261], [".", 1271], ["Further", 1273], ["studies", 1281], ["are", 1289], ["needed", 1293], ["to", 1300], ["assess", 1303], ["the", 1310], ["usefulness", 1314], ["of", 1325], ["routine", 1328], ["tuberculin", 1336], ["skin", 1347], ["testing", 1352], ["in", 1360], ["hospitalized", 1363], ["populations", 1376], [".", 1387]]}
{"context": "The histone variant H2AZ is incorporated preferentially at specific locations in chromatin to modulate chromosome functions. In Saccharomyces cerevisiae, deposition of histone H2AZ is mediated by the multiprotein SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. Here, we define interactions between SWR1 components and H2AZ, revealing a link between the ATPase domain of Swr1 and three subunits required for the binding of H2AZ. We discovered that Swc2 binds directly to and is essential for transfer of H2AZ. Swc6 and Arp6 are necessary for the association of Swc2 and for nucleosome binding, whereas other subunits, Swc5 and Yaf9, are required for H2AZ transfer but neither H2AZ nor nucleosome binding. Finally, the C-terminal alpha-helix of H2AZ is crucial for its recognition by SWR1. These findings provide insight on the initial events of histone exchange.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "62476e02ad284ed2b1d1125d42c416a2", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[143, 143], [52, 52], [65, 65], [30, 30]], "char_spans": [[824, 827], [340, 343], [412, 415], [213, 216]]}]}], "context_tokens": [["The", 0], ["histone", 4], ["variant", 12], ["H2AZ", 20], ["is", 25], ["incorporated", 28], ["preferentially", 41], ["at", 56], ["specific", 59], ["locations", 68], ["in", 78], ["chromatin", 81], ["to", 91], ["modulate", 94], ["chromosome", 103], ["functions", 114], [".", 123], ["In", 125], ["Saccharomyces", 128], ["cerevisiae", 142], [",", 152], ["deposition", 154], ["of", 165], ["histone", 168], ["H2AZ", 176], ["is", 181], ["mediated", 184], ["by", 193], ["the", 196], ["multiprotein", 200], ["SWR1", 213], ["complex", 218], [",", 225], ["which", 227], ["catalyzes", 233], ["ATP", 243], ["-", 246], ["dependent", 247], ["exchange", 257], ["of", 266], ["nucleosomal", 269], ["histone", 281], ["H2A", 289], ["for", 293], ["H2AZ", 297], [".", 301], ["Here", 303], [",", 307], ["we", 309], ["define", 312], ["interactions", 319], ["between", 332], ["SWR1", 340], ["components", 345], ["and", 356], ["H2AZ", 360], [",", 364], ["revealing", 366], ["a", 376], ["link", 378], ["between", 383], ["the", 391], ["ATPase", 395], ["domain", 402], ["of", 409], ["Swr1", 412], ["and", 417], ["three", 421], ["subunits", 427], ["required", 436], ["for", 445], ["the", 449], ["binding", 453], ["of", 461], ["H2AZ", 464], [".", 468], ["We", 470], ["discovered", 473], ["that", 484], ["Swc2", 489], ["binds", 494], ["directly", 500], ["to", 509], ["and", 512], ["is", 516], ["essential", 519], ["for", 529], ["transfer", 533], ["of", 542], ["H2AZ", 545], [".", 549], ["Swc6", 551], ["and", 556], ["Arp6", 560], ["are", 565], ["necessary", 569], ["for", 579], ["the", 583], ["association", 587], ["of", 599], ["Swc2", 602], ["and", 607], ["for", 611], ["nucleosome", 615], ["binding", 626], [",", 633], ["whereas", 635], ["other", 643], ["subunits", 649], [",", 657], ["Swc5", 659], ["and", 664], ["Yaf9", 668], [",", 672], ["are", 674], ["required", 678], ["for", 687], ["H2AZ", 691], ["transfer", 696], ["but", 705], ["neither", 709], ["H2AZ", 717], ["nor", 722], ["nucleosome", 726], ["binding", 737], [".", 744], ["Finally", 746], [",", 753], ["the", 755], ["C", 759], ["-", 760], ["terminal", 761], ["alpha", 770], ["-", 775], ["helix", 776], ["of", 782], ["H2AZ", 785], ["is", 790], ["crucial", 793], ["for", 801], ["its", 805], ["recognition", 809], ["by", 821], ["SWR1", 824], [".", 828], ["These", 830], ["findings", 836], ["provide", 845], ["insight", 853], ["on", 861], ["the", 864], ["initial", 868], ["events", 876], ["of", 883], ["histone", 886], ["exchange", 894], [".", 902]]}
{"context": "Ataxin-3, the disease protein in the neurodegenerative disorder Spinocerebellar Ataxia Type 3 or Machado Joseph disease, is a cysteine protease implicated in the ubiquitin proteasome pathway. It contains multiple ubiquitin binding sites through which it anchors polyubiquitin chains of different linkages that are then cleaved by the N-terminal catalytic (Josephin) domain. The properties of the ubiquitin interacting motifs (UIMs) in the C-terminus of ataxin-3 are well established. Very little is known, however, about how two recently identified ubiquitin-binding sites in the Josephin domain contribute to ubiquitin chain binding and cleavage. In the current study, we sought to define the specific contribution of the Josephin domain to the catalytic properties of ataxin-3 and assess how the topology and affinity of these binding sites modulate ataxin-3 activity. Using NMR we modeled the structure of diUb/Josephin complexes and showed that linkage preferences are imposed by the topology of the two binding sites. Enzymatic studies further helped us to determine a precise hierarchy between the sites. We establish that the structure of Josephin dictates specificity for K48-linked chains. Site 1, which is close to the active site, is indispensable for cleavage. Our studies open the way to understand better the cellular function of ataxin-3 and its link to pathology.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5e25c3d45f5646e79edcd84d6308a178", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [227, 227], [75, 75], [142, 142], [129, 129]], "char_spans": [[0, 7], [1344, 1351], [453, 460], [852, 859], [770, 777]]}]}], "context_tokens": [["Ataxin-3", 0], [",", 8], ["the", 10], ["disease", 14], ["protein", 22], ["in", 30], ["the", 33], ["neurodegenerative", 37], ["disorder", 55], ["Spinocerebellar", 64], ["Ataxia", 80], ["Type", 87], ["3", 92], ["or", 94], ["Machado", 97], ["Joseph", 105], ["disease", 112], [",", 119], ["is", 121], ["a", 124], ["cysteine", 126], ["protease", 135], ["implicated", 144], ["in", 155], ["the", 158], ["ubiquitin", 162], ["proteasome", 172], ["pathway", 183], [".", 190], ["It", 192], ["contains", 195], ["multiple", 204], ["ubiquitin", 213], ["binding", 223], ["sites", 231], ["through", 237], ["which", 245], ["it", 251], ["anchors", 254], ["polyubiquitin", 262], ["chains", 276], ["of", 283], ["different", 286], ["linkages", 296], ["that", 305], ["are", 310], ["then", 314], ["cleaved", 319], ["by", 327], ["the", 330], ["N", 334], ["-", 335], ["terminal", 336], ["catalytic", 345], ["(", 355], ["Josephin", 356], [")", 364], ["domain", 366], [".", 372], ["The", 374], ["properties", 378], ["of", 389], ["the", 392], ["ubiquitin", 396], ["interacting", 406], ["motifs", 418], ["(", 425], ["UIMs", 426], [")", 430], ["in", 432], ["the", 435], ["C", 439], ["-", 440], ["terminus", 441], ["of", 450], ["ataxin-3", 453], ["are", 462], ["well", 466], ["established", 471], [".", 482], ["Very", 484], ["little", 489], ["is", 496], ["known", 499], [",", 504], ["however", 506], [",", 513], ["about", 515], ["how", 521], ["two", 525], ["recently", 529], ["identified", 538], ["ubiquitin", 549], ["-", 558], ["binding", 559], ["sites", 567], ["in", 573], ["the", 576], ["Josephin", 580], ["domain", 589], ["contribute", 596], ["to", 607], ["ubiquitin", 610], ["chain", 620], ["binding", 626], ["and", 634], ["cleavage", 638], [".", 646], ["In", 648], ["the", 651], ["current", 655], ["study", 663], [",", 668], ["we", 670], ["sought", 673], ["to", 680], ["define", 683], ["the", 690], ["specific", 694], ["contribution", 703], ["of", 716], ["the", 719], ["Josephin", 723], ["domain", 732], ["to", 739], ["the", 742], ["catalytic", 746], ["properties", 756], ["of", 767], ["ataxin-3", 770], ["and", 779], ["assess", 783], ["how", 790], ["the", 794], ["topology", 798], ["and", 807], ["affinity", 811], ["of", 820], ["these", 823], ["binding", 829], ["sites", 837], ["modulate", 843], ["ataxin-3", 852], ["activity", 861], [".", 869], ["Using", 871], ["NMR", 877], ["we", 881], ["modeled", 884], ["the", 892], ["structure", 896], ["of", 906], ["diUb", 909], ["/", 913], ["Josephin", 914], ["complexes", 923], ["and", 933], ["showed", 937], ["that", 944], ["linkage", 949], ["preferences", 957], ["are", 969], ["imposed", 973], ["by", 981], ["the", 984], ["topology", 988], ["of", 997], ["the", 1000], ["two", 1004], ["binding", 1008], ["sites", 1016], [".", 1021], ["Enzymatic", 1023], ["studies", 1033], ["further", 1041], ["helped", 1049], ["us", 1056], ["to", 1059], ["determine", 1062], ["a", 1072], ["precise", 1074], ["hierarchy", 1082], ["between", 1092], ["the", 1100], ["sites", 1104], [".", 1109], ["We", 1111], ["establish", 1114], ["that", 1124], ["the", 1129], ["structure", 1133], ["of", 1143], ["Josephin", 1146], ["dictates", 1155], ["specificity", 1164], ["for", 1176], ["K48-linked", 1180], ["chains", 1191], [".", 1197], ["Site", 1199], ["1", 1204], [",", 1205], ["which", 1207], ["is", 1213], ["close", 1216], ["to", 1222], ["the", 1225], ["active", 1229], ["site", 1236], [",", 1240], ["is", 1242], ["indispensable", 1245], ["for", 1259], ["cleavage", 1263], [".", 1271], ["Our", 1273], ["studies", 1277], ["open", 1285], ["the", 1290], ["way", 1294], ["to", 1298], ["understand", 1301], ["better", 1312], ["the", 1319], ["cellular", 1323], ["function", 1332], ["of", 1341], ["ataxin-3", 1344], ["and", 1353], ["its", 1357], ["link", 1361], ["to", 1366], ["pathology", 1369], [".", 1378]]}
{"context": "MicroRNAs (miRNAs) are non-coding RNAs with important roles in regulating gene expression. Recent studies indicate that transcription and cleavage of miRNA are coupled, and that chromatin structure may influence miRNA transcription. However, little is known about the relationship between the chromatin structure and cleavage of pre-miRNA from pri-miRNA. By analysis of genome-wide nucleosome positioning data sets from human and Caenorhabditis elegans (C. elegans), we found an enrichment of positioned nucleosome on pre-miRNA genomic sequences, which is highly correlated with GC content within pre-miRNA. In addition, obvious enrichments of three histone modifications (H2BK5me1, H3K36me3 and H4K20me1) as well as RNA Polymerase II (RNAPII) were observed on pre-miRNA genomic sequences corresponding to the active-promoter miRNAs and expressed miRNAs. Our results revealed the chromatin structure characteristics of pre-miRNA genomic sequences, and implied potential mechanisms that can recognize these characteristics, thus improving pre-miRNA cleavage.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "800083a0aff44406b0a95cb46cf7343b", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[126, 128]], "char_spans": [[717, 733]]}, {"text": "RNAPII", "token_spans": [[130, 130]], "char_spans": [[736, 741]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["non", 23], ["-", 26], ["coding", 27], ["RNAs", 34], ["with", 39], ["important", 44], ["roles", 54], ["in", 60], ["regulating", 63], ["gene", 74], ["expression", 79], [".", 89], ["Recent", 91], ["studies", 98], ["indicate", 106], ["that", 115], ["transcription", 120], ["and", 134], ["cleavage", 138], ["of", 147], ["miRNA", 150], ["are", 156], ["coupled", 160], [",", 167], ["and", 169], ["that", 173], ["chromatin", 178], ["structure", 188], ["may", 198], ["influence", 202], ["miRNA", 212], ["transcription", 218], [".", 231], ["However", 233], [",", 240], ["little", 242], ["is", 249], ["known", 252], ["about", 258], ["the", 264], ["relationship", 268], ["between", 281], ["the", 289], ["chromatin", 293], ["structure", 303], ["and", 313], ["cleavage", 317], ["of", 326], ["pre", 329], ["-", 332], ["miRNA", 333], ["from", 339], ["pri", 344], ["-", 347], ["miRNA", 348], [".", 353], ["By", 355], ["analysis", 358], ["of", 367], ["genome", 370], ["-", 376], ["wide", 377], ["nucleosome", 382], ["positioning", 393], ["data", 405], ["sets", 410], ["from", 415], ["human", 420], ["and", 426], ["Caenorhabditis", 430], ["elegans", 445], ["(", 453], ["C.", 454], ["elegans", 457], [")", 464], [",", 465], ["we", 467], ["found", 470], ["an", 476], ["enrichment", 479], ["of", 490], ["positioned", 493], ["nucleosome", 504], ["on", 515], ["pre", 518], ["-", 521], ["miRNA", 522], ["genomic", 528], ["sequences", 536], [",", 545], ["which", 547], ["is", 553], ["highly", 556], ["correlated", 563], ["with", 574], ["GC", 579], ["content", 582], ["within", 590], ["pre", 597], ["-", 600], ["miRNA", 601], [".", 606], ["In", 608], ["addition", 611], [",", 619], ["obvious", 621], ["enrichments", 629], ["of", 641], ["three", 644], ["histone", 650], ["modifications", 658], ["(", 672], ["H2BK5me1", 673], [",", 681], ["H3K36me3", 683], ["and", 692], ["H4K20me1", 696], [")", 704], ["as", 706], ["well", 709], ["as", 714], ["RNA", 717], ["Polymerase", 721], ["II", 732], ["(", 735], ["RNAPII", 736], [")", 742], ["were", 744], ["observed", 749], ["on", 758], ["pre", 761], ["-", 764], ["miRNA", 765], ["genomic", 771], ["sequences", 779], ["corresponding", 789], ["to", 803], ["the", 806], ["active", 810], ["-", 816], ["promoter", 817], ["miRNAs", 826], ["and", 833], ["expressed", 837], ["miRNAs", 847], [".", 853], ["Our", 855], ["results", 859], ["revealed", 867], ["the", 876], ["chromatin", 880], ["structure", 890], ["characteristics", 900], ["of", 916], ["pre", 919], ["-", 922], ["miRNA", 923], ["genomic", 929], ["sequences", 937], [",", 946], ["and", 948], ["implied", 952], ["potential", 960], ["mechanisms", 970], ["that", 981], ["can", 986], ["recognize", 990], ["these", 1000], ["characteristics", 1006], [",", 1021], ["thus", 1023], ["improving", 1028], ["pre", 1038], ["-", 1041], ["miRNA", 1042], ["cleavage", 1048], [".", 1056]]}
{"context": "The lysosomal storage disorder Fabry disease is characterized by excessive globotriaosylceramide (Gb3) accumulation in major organs such as the heart and kidney. Defective lysosomal alpha-galactosidase A (Gla) is responsible for excessive Gb3 accumulation, and one cell sensitive to the effects of Gb3 accumulation is vascular endothelium. Endothelial dysfunction is associated with Fabry disease and excessive cellular Gb3. We previously demonstrated that excessive vascular Gb3 in a mouse model of Fabry disease, the Gla-knockout (Gla(-/0)) mouse, results in abnormal vascular function, which includes abnormal endothelium-dependent contractions, a vascular phenomenon known to involve cyclooxygenase (COX). Therefore, we hypothesized that the vasculopathy in the Gla knockout mouse may be due to a vasoactive COX-derived product. To test this hypothesis, vascular reactivity experiments were performed in aortic rings from wild-type (Gla(+/0)) and Gla(-/0) mice in the presence and absence of specific and nonspecific COX inhibitors. Specific inhibition of COX1 or COX2 in endothelium-intact rings from Gla(-/0) mice decreased overall phenylephrine contractility compared with untreated Gla(-/0) rings, whereas COX inhibitors had no effect on contractility in endothelium-denuded rings. Nonspecific inhibition of COX with indomethacin (10 micromol/l) or COX1 inhibition with valeryl salicylate (3 mmol/l) improved endothelial function in rings from Gla(-/0) mice, but COX2 inhibition with NS-398 (1 micromol/l) further increased endothelial dysfunction in rings from Gla(-/0) mice. These results suggest that, in the Gla(-/0) mice, COX1 and COX2 activity are increased and localized in the endothelium, producing vasopressor and vasorelaxant products, which contribute to the Fabry-related vasculopathy.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "16952fa330f540e6884c87a1a0567566", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[27, 29]], "char_spans": [[182, 200]]}]}], "context_tokens": [["The", 0], ["lysosomal", 4], ["storage", 14], ["disorder", 22], ["Fabry", 31], ["disease", 37], ["is", 45], ["characterized", 48], ["by", 62], ["excessive", 65], ["globotriaosylceramide", 75], ["(", 97], ["Gb3", 98], [")", 101], ["accumulation", 103], ["in", 116], ["major", 119], ["organs", 125], ["such", 132], ["as", 137], ["the", 140], ["heart", 144], ["and", 150], ["kidney", 154], [".", 160], ["Defective", 162], ["lysosomal", 172], ["alpha", 182], ["-", 187], ["galactosidase", 188], ["A", 202], ["(", 204], ["Gla", 205], [")", 208], ["is", 210], ["responsible", 213], ["for", 225], ["excessive", 229], ["Gb3", 239], ["accumulation", 243], [",", 255], ["and", 257], ["one", 261], ["cell", 265], ["sensitive", 270], ["to", 280], ["the", 283], ["effects", 287], ["of", 295], ["Gb3", 298], ["accumulation", 302], ["is", 315], ["vascular", 318], ["endothelium", 327], [".", 338], ["Endothelial", 340], ["dysfunction", 352], ["is", 364], ["associated", 367], ["with", 378], ["Fabry", 383], ["disease", 389], ["and", 397], ["excessive", 401], ["cellular", 411], ["Gb3", 420], [".", 423], ["We", 425], ["previously", 428], ["demonstrated", 439], ["that", 452], ["excessive", 457], ["vascular", 467], ["Gb3", 476], ["in", 480], ["a", 483], ["mouse", 485], ["model", 491], ["of", 497], ["Fabry", 500], ["disease", 506], [",", 513], ["the", 515], ["Gla", 519], ["-", 522], ["knockout", 523], ["(", 532], ["Gla(-/0", 533], [")", 540], [")", 541], ["mouse", 543], [",", 548], ["results", 550], ["in", 558], ["abnormal", 561], ["vascular", 570], ["function", 579], [",", 587], ["which", 589], ["includes", 595], ["abnormal", 604], ["endothelium", 613], ["-", 624], ["dependent", 625], ["contractions", 635], [",", 647], ["a", 649], ["vascular", 651], ["phenomenon", 660], ["known", 671], ["to", 677], ["involve", 680], ["cyclooxygenase", 688], ["(", 703], ["COX", 704], [")", 707], [".", 708], ["Therefore", 710], [",", 719], ["we", 721], ["hypothesized", 724], ["that", 737], ["the", 742], ["vasculopathy", 746], ["in", 759], ["the", 762], ["Gla", 766], ["knockout", 770], ["mouse", 779], ["may", 785], ["be", 789], ["due", 792], ["to", 796], ["a", 799], ["vasoactive", 801], ["COX", 812], ["-", 815], ["derived", 816], ["product", 824], [".", 831], ["To", 833], ["test", 836], ["this", 841], ["hypothesis", 846], [",", 856], ["vascular", 858], ["reactivity", 867], ["experiments", 878], ["were", 890], ["performed", 895], ["in", 905], ["aortic", 908], ["rings", 915], ["from", 921], ["wild", 926], ["-", 930], ["type", 931], ["(", 936], ["Gla(+/0", 937], [")", 944], [")", 945], ["and", 947], ["Gla(-/0", 951], [")", 958], ["mice", 960], ["in", 965], ["the", 968], ["presence", 972], ["and", 981], ["absence", 985], ["of", 993], ["specific", 996], ["and", 1005], ["nonspecific", 1009], ["COX", 1021], ["inhibitors", 1025], [".", 1035], ["Specific", 1037], ["inhibition", 1046], ["of", 1057], ["COX1", 1060], ["or", 1065], ["COX2", 1068], ["in", 1073], ["endothelium", 1076], ["-", 1087], ["intact", 1088], ["rings", 1095], ["from", 1101], ["Gla(-/0", 1106], [")", 1113], ["mice", 1115], ["decreased", 1120], ["overall", 1130], ["phenylephrine", 1138], ["contractility", 1152], ["compared", 1166], ["with", 1175], ["untreated", 1180], ["Gla(-/0", 1190], [")", 1197], ["rings", 1199], [",", 1204], ["whereas", 1206], ["COX", 1214], ["inhibitors", 1218], ["had", 1229], ["no", 1233], ["effect", 1236], ["on", 1243], ["contractility", 1246], ["in", 1260], ["endothelium", 1263], ["-", 1274], ["denuded", 1275], ["rings", 1283], [".", 1288], ["Nonspecific", 1290], ["inhibition", 1302], ["of", 1313], ["COX", 1316], ["with", 1320], ["indomethacin", 1325], ["(", 1338], ["10", 1339], ["micromol", 1342], ["/", 1350], ["l", 1351], [")", 1352], ["or", 1354], ["COX1", 1357], ["inhibition", 1362], ["with", 1373], ["valeryl", 1378], ["salicylate", 1386], ["(", 1397], ["3", 1398], ["mmol", 1400], ["/", 1404], ["l", 1405], [")", 1406], ["improved", 1408], ["endothelial", 1417], ["function", 1429], ["in", 1438], ["rings", 1441], ["from", 1447], ["Gla(-/0", 1452], [")", 1459], ["mice", 1461], [",", 1465], ["but", 1467], ["COX2", 1471], ["inhibition", 1476], ["with", 1487], ["NS-398", 1492], ["(", 1499], ["1", 1500], ["micromol", 1502], ["/", 1510], ["l", 1511], [")", 1512], ["further", 1514], ["increased", 1522], ["endothelial", 1532], ["dysfunction", 1544], ["in", 1556], ["rings", 1559], ["from", 1565], ["Gla(-/0", 1570], [")", 1577], ["mice", 1579], [".", 1583], ["These", 1585], ["results", 1591], ["suggest", 1599], ["that", 1607], [",", 1611], ["in", 1613], ["the", 1616], ["Gla(-/0", 1620], [")", 1627], ["mice", 1629], [",", 1633], ["COX1", 1635], ["and", 1640], ["COX2", 1644], ["activity", 1649], ["are", 1658], ["increased", 1662], ["and", 1672], ["localized", 1676], ["in", 1686], ["the", 1689], ["endothelium", 1693], [",", 1704], ["producing", 1706], ["vasopressor", 1716], ["and", 1728], ["vasorelaxant", 1732], ["products", 1745], [",", 1753], ["which", 1755], ["contribute", 1761], ["to", 1772], ["the", 1775], ["Fabry", 1779], ["-", 1784], ["related", 1785], ["vasculopathy", 1793], [".", 1805]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is one of the most prevalent adult muscular dystrophies. The common clinical signs usually appear during the second decade of life but when the first molecular dysregulations occur is still unknown. Our aim was to determine whether molecular dysregulations can be identified during FSHD fetal muscle development. We compared muscle biopsies derived from FSHD1 fetuses and the cells derived from some of these biopsies with biopsies and cells derived from control fetuses. We mainly focus on DUX4 isoform expression because the expression of DUX4 has been confirmed in both FSHD cells and biopsies by several laboratories. We measured DUX4 isoform expression by using qRT-PCR in fetal FSHD1 myotubes treated or not with an shRNA directed against DUX4 mRNA. We also analyzed DUX4 downstream target gene expression in myotubes and fetal or adult FSHD1 and control quadriceps biopsies. We show that both DUX4-FL isoforms are already expressed in FSHD1 myotubes. Interestingly, DUX4-FL expression level is much lower in trapezius than in quadriceps myotubes, which is confirmed by the level of expression of DUX4 downstream genes. We observed that TRIM43 and MBD3L2 are already overexpressed in FSHD1 fetal quadriceps biopsies, at similar levels to those observed in adult FSHD1 quadriceps biopsies. These results indicate that molecular markers of the disease are already expressed during fetal life, thus opening a new field of investigation for mechanisms leading to FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "ecab61b49d944c2daff330eafcf4f174", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[99, 99], [4, 4], [51, 51], [247, 247]], "char_spans": [[619, 622], [40, 43], [328, 331], [1511, 1514]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["one", 49], ["of", 53], ["the", 56], ["most", 60], ["prevalent", 65], ["adult", 75], ["muscular", 81], ["dystrophies", 90], [".", 101], ["The", 103], ["common", 107], ["clinical", 114], ["signs", 123], ["usually", 129], ["appear", 137], ["during", 144], ["the", 151], ["second", 155], ["decade", 162], ["of", 169], ["life", 172], ["but", 177], ["when", 181], ["the", 186], ["first", 190], ["molecular", 196], ["dysregulations", 206], ["occur", 221], ["is", 227], ["still", 230], ["unknown", 236], [".", 243], ["Our", 245], ["aim", 249], ["was", 253], ["to", 257], ["determine", 260], ["whether", 270], ["molecular", 278], ["dysregulations", 288], ["can", 303], ["be", 307], ["identified", 310], ["during", 321], ["FSHD", 328], ["fetal", 333], ["muscle", 339], ["development", 346], [".", 357], ["We", 359], ["compared", 362], ["muscle", 371], ["biopsies", 378], ["derived", 387], ["from", 395], ["FSHD1", 400], ["fetuses", 406], ["and", 414], ["the", 418], ["cells", 422], ["derived", 428], ["from", 436], ["some", 441], ["of", 446], ["these", 449], ["biopsies", 455], ["with", 464], ["biopsies", 469], ["and", 478], ["cells", 482], ["derived", 488], ["from", 496], ["control", 501], ["fetuses", 509], [".", 516], ["We", 518], ["mainly", 521], ["focus", 528], ["on", 534], ["DUX4", 537], ["isoform", 542], ["expression", 550], ["because", 561], ["the", 569], ["expression", 573], ["of", 584], ["DUX4", 587], ["has", 592], ["been", 596], ["confirmed", 601], ["in", 611], ["both", 614], ["FSHD", 619], ["cells", 624], ["and", 630], ["biopsies", 634], ["by", 643], ["several", 646], ["laboratories", 654], [".", 666], ["We", 668], ["measured", 671], ["DUX4", 680], ["isoform", 685], ["expression", 693], ["by", 704], ["using", 707], ["qRT", 713], ["-", 716], ["PCR", 717], ["in", 721], ["fetal", 724], ["FSHD1", 730], ["myotubes", 736], ["treated", 745], ["or", 753], ["not", 756], ["with", 760], ["an", 765], ["shRNA", 768], ["directed", 774], ["against", 783], ["DUX4", 791], ["mRNA", 796], [".", 800], ["We", 802], ["also", 805], ["analyzed", 810], ["DUX4", 819], ["downstream", 824], ["target", 835], ["gene", 842], ["expression", 847], ["in", 858], ["myotubes", 861], ["and", 870], ["fetal", 874], ["or", 880], ["adult", 883], ["FSHD1", 889], ["and", 895], ["control", 899], ["quadriceps", 907], ["biopsies", 918], [".", 926], ["We", 928], ["show", 931], ["that", 936], ["both", 941], ["DUX4-FL", 946], ["isoforms", 954], ["are", 963], ["already", 967], ["expressed", 975], ["in", 985], ["FSHD1", 988], ["myotubes", 994], [".", 1002], ["Interestingly", 1004], [",", 1017], ["DUX4-FL", 1019], ["expression", 1027], ["level", 1038], ["is", 1044], ["much", 1047], ["lower", 1052], ["in", 1058], ["trapezius", 1061], ["than", 1071], ["in", 1076], ["quadriceps", 1079], ["myotubes", 1090], [",", 1098], ["which", 1100], ["is", 1106], ["confirmed", 1109], ["by", 1119], ["the", 1122], ["level", 1126], ["of", 1132], ["expression", 1135], ["of", 1146], ["DUX4", 1149], ["downstream", 1154], ["genes", 1165], [".", 1170], ["We", 1172], ["observed", 1175], ["that", 1184], ["TRIM43", 1189], ["and", 1196], ["MBD3L2", 1200], ["are", 1207], ["already", 1211], ["overexpressed", 1219], ["in", 1233], ["FSHD1", 1236], ["fetal", 1242], ["quadriceps", 1248], ["biopsies", 1259], [",", 1267], ["at", 1269], ["similar", 1272], ["levels", 1280], ["to", 1287], ["those", 1290], ["observed", 1296], ["in", 1305], ["adult", 1308], ["FSHD1", 1314], ["quadriceps", 1320], ["biopsies", 1331], [".", 1339], ["These", 1341], ["results", 1347], ["indicate", 1355], ["that", 1364], ["molecular", 1369], ["markers", 1379], ["of", 1387], ["the", 1390], ["disease", 1394], ["are", 1402], ["already", 1406], ["expressed", 1414], ["during", 1424], ["fetal", 1431], ["life", 1437], [",", 1441], ["thus", 1443], ["opening", 1448], ["a", 1456], ["new", 1458], ["field", 1462], ["of", 1468], ["investigation", 1471], ["for", 1485], ["mechanisms", 1489], ["leading", 1500], ["to", 1508], ["FSHD", 1511], [".", 1515]]}
{"context": "Infection with Epstein-Barr virus (EBV) is almost ubiquitous in humans and generally occurs at two ages: infantile, which is usually asymptomatic and associated with poorer socioeconomic conditions, and adolescent, which causes infectious mononucleosis (IM) in ~25% cases. The determinants of whether the infection causes IM remain uncertain. We aimed to evaluate seasonality and temporal trends in IM. Data from all Monospot tests, used as a marker for IM, were collected from the Grampian population over 16 years. Positive Monospot test results peaked at 17 years in females and 19 in males. Females had 16% more diagnoses, although 55% more tests. IM was ~38% more common in winter than summer. The annual rate of positive tests decreased progressively over the study period, from 174/100 000 (95% CI 171-178) in 1997 to 67/100 000 (95% CI 65-69) in 2012. IM appears to be decreasing in incidence, which may be caused by changing environmental influences on immune systems. One such factor may be exposure to sunlight.Words 168. The Medical Research Council and NHS Grampian-MS endowments.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "80319100e57e4e6bae3dd5bfdc5b1543", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[2, 5]], "char_spans": [[15, 32]]}]}], "context_tokens": [["Infection", 0], ["with", 10], ["Epstein", 15], ["-", 22], ["Barr", 23], ["virus", 28], ["(", 34], ["EBV", 35], [")", 38], ["is", 40], ["almost", 43], ["ubiquitous", 50], ["in", 61], ["humans", 64], ["and", 71], ["generally", 75], ["occurs", 85], ["at", 92], ["two", 95], ["ages", 99], [":", 103], ["infantile", 105], [",", 114], ["which", 116], ["is", 122], ["usually", 125], ["asymptomatic", 133], ["and", 146], ["associated", 150], ["with", 161], ["poorer", 166], ["socioeconomic", 173], ["conditions", 187], [",", 197], ["and", 199], ["adolescent", 203], [",", 213], ["which", 215], ["causes", 221], ["infectious", 228], ["mononucleosis", 239], ["(", 253], ["IM", 254], [")", 256], ["in", 258], ["~25", 261], ["%", 264], ["cases", 266], [".", 271], ["The", 273], ["determinants", 277], ["of", 290], ["whether", 293], ["the", 301], ["infection", 305], ["causes", 315], ["IM", 322], ["remain", 325], ["uncertain", 332], [".", 341], ["We", 343], ["aimed", 346], ["to", 352], ["evaluate", 355], ["seasonality", 364], ["and", 376], ["temporal", 380], ["trends", 389], ["in", 396], ["IM", 399], [".", 401], ["Data", 403], ["from", 408], ["all", 413], ["Monospot", 417], ["tests", 426], [",", 431], ["used", 433], ["as", 438], ["a", 441], ["marker", 443], ["for", 450], ["IM", 454], [",", 456], ["were", 458], ["collected", 463], ["from", 473], ["the", 478], ["Grampian", 482], ["population", 491], ["over", 502], ["16", 507], ["years", 510], [".", 515], ["Positive", 517], ["Monospot", 526], ["test", 535], ["results", 540], ["peaked", 548], ["at", 555], ["17", 558], ["years", 561], ["in", 567], ["females", 570], ["and", 578], ["19", 582], ["in", 585], ["males", 588], [".", 593], ["Females", 595], ["had", 603], ["16", 607], ["%", 609], ["more", 611], ["diagnoses", 616], [",", 625], ["although", 627], ["55", 636], ["%", 638], ["more", 640], ["tests", 645], [".", 650], ["IM", 652], ["was", 655], ["~38", 659], ["%", 662], ["more", 664], ["common", 669], ["in", 676], ["winter", 679], ["than", 686], ["summer", 691], [".", 697], ["The", 699], ["annual", 703], ["rate", 710], ["of", 715], ["positive", 718], ["tests", 727], ["decreased", 733], ["progressively", 743], ["over", 757], ["the", 762], ["study", 766], ["period", 772], [",", 778], ["from", 780], ["174/100", 785], ["000", 793], ["(", 797], ["95", 798], ["%", 800], ["CI", 802], ["171", 805], ["-", 808], ["178", 809], [")", 812], ["in", 814], ["1997", 817], ["to", 822], ["67/100", 825], ["000", 832], ["(", 836], ["95", 837], ["%", 839], ["CI", 841], ["65", 844], ["-", 846], ["69", 847], [")", 849], ["in", 851], ["2012", 854], [".", 858], ["IM", 860], ["appears", 863], ["to", 871], ["be", 874], ["decreasing", 877], ["in", 888], ["incidence", 891], [",", 900], ["which", 902], ["may", 908], ["be", 912], ["caused", 915], ["by", 922], ["changing", 925], ["environmental", 934], ["influences", 948], ["on", 959], ["immune", 962], ["systems", 969], [".", 976], ["One", 978], ["such", 982], ["factor", 987], ["may", 994], ["be", 998], ["exposure", 1001], ["to", 1010], ["sunlight", 1013], [".", 1021], ["Words", 1022], ["168", 1028], [".", 1031], ["The", 1033], ["Medical", 1037], ["Research", 1045], ["Council", 1054], ["and", 1062], ["NHS", 1066], ["Grampian", 1070], ["-", 1078], ["MS", 1079], ["endowments", 1082], [".", 1092]]}
{"context": "Iron deficiency is the most common nutritional disorder affecting at least one third of world's population. Though anemia is common manifestation of iron deficiency, other effects of iron deficiency on various tissues, organs and systems are usually under recognized. Impaired brain development and cognitive, behavioural and psychomotor impairment are most worrisome manifestations of iron deficiency. Studies have demonstrated that some of these changes occurring during period of brain growth spurt (<2 years age) may be irreversible. Association of iron deficiency with febrile seizures, pica, breath holding spells, restless leg syndrome and thrombosis is increasingly being recognized. Impaired cell-mediated immunity and bactericidal function are generally noted in iron-deficient persons; however, the findings are inconsistent. Despite proven reversible functional immunological defects in vitro studies, a clinically important relationship between states of iron deficiency and susceptibility to infections remains controversial. Studies from malaria endemic regions have reported increased incidence of malaria in association with iron supplementation. These and some other aspects of iron deficiency are reviewed in this article.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "012f50f15b46427a95f71bd22cb9066f", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[0, 0], [59, 59], [123, 123], [89, 89], [24, 24], [152, 152], [184, 184], [30, 30], [175, 175]], "char_spans": [[0, 3], [386, 389], [773, 776], [553, 556], [149, 152], [968, 971], [1196, 1199], [183, 186], [1142, 1145]]}]}], "context_tokens": [["Iron", 0], ["deficiency", 5], ["is", 16], ["the", 19], ["most", 23], ["common", 28], ["nutritional", 35], ["disorder", 47], ["affecting", 56], ["at", 66], ["least", 69], ["one", 75], ["third", 79], ["of", 85], ["world", 88], ["'s", 93], ["population", 96], [".", 106], ["Though", 108], ["anemia", 115], ["is", 122], ["common", 125], ["manifestation", 132], ["of", 146], ["iron", 149], ["deficiency", 154], [",", 164], ["other", 166], ["effects", 172], ["of", 180], ["iron", 183], ["deficiency", 188], ["on", 199], ["various", 202], ["tissues", 210], [",", 217], ["organs", 219], ["and", 226], ["systems", 230], ["are", 238], ["usually", 242], ["under", 250], ["recognized", 256], [".", 266], ["Impaired", 268], ["brain", 277], ["development", 283], ["and", 295], ["cognitive", 299], [",", 308], ["behavioural", 310], ["and", 322], ["psychomotor", 326], ["impairment", 338], ["are", 349], ["most", 353], ["worrisome", 358], ["manifestations", 368], ["of", 383], ["iron", 386], ["deficiency", 391], [".", 401], ["Studies", 403], ["have", 411], ["demonstrated", 416], ["that", 429], ["some", 434], ["of", 439], ["these", 442], ["changes", 448], ["occurring", 456], ["during", 466], ["period", 473], ["of", 480], ["brain", 483], ["growth", 489], ["spurt", 496], ["(", 502], ["<", 503], ["2", 504], ["years", 506], ["age", 512], [")", 515], ["may", 517], ["be", 521], ["irreversible", 524], [".", 536], ["Association", 538], ["of", 550], ["iron", 553], ["deficiency", 558], ["with", 569], ["febrile", 574], ["seizures", 582], [",", 590], ["pica", 592], [",", 596], ["breath", 598], ["holding", 605], ["spells", 613], [",", 619], ["restless", 621], ["leg", 630], ["syndrome", 634], ["and", 643], ["thrombosis", 647], ["is", 658], ["increasingly", 661], ["being", 674], ["recognized", 680], [".", 690], ["Impaired", 692], ["cell", 701], ["-", 705], ["mediated", 706], ["immunity", 715], ["and", 724], ["bactericidal", 728], ["function", 741], ["are", 750], ["generally", 754], ["noted", 764], ["in", 770], ["iron", 773], ["-", 777], ["deficient", 778], ["persons", 788], [";", 795], ["however", 797], [",", 804], ["the", 806], ["findings", 810], ["are", 819], ["inconsistent", 823], [".", 835], ["Despite", 837], ["proven", 845], ["reversible", 852], ["functional", 863], ["immunological", 874], ["defects", 888], ["in", 896], ["vitro", 899], ["studies", 905], [",", 912], ["a", 914], ["clinically", 916], ["important", 927], ["relationship", 937], ["between", 950], ["states", 958], ["of", 965], ["iron", 968], ["deficiency", 973], ["and", 984], ["susceptibility", 988], ["to", 1003], ["infections", 1006], ["remains", 1017], ["controversial", 1025], [".", 1038], ["Studies", 1040], ["from", 1048], ["malaria", 1053], ["endemic", 1061], ["regions", 1069], ["have", 1077], ["reported", 1082], ["increased", 1091], ["incidence", 1101], ["of", 1111], ["malaria", 1114], ["in", 1122], ["association", 1125], ["with", 1137], ["iron", 1142], ["supplementation", 1147], [".", 1162], ["These", 1164], ["and", 1170], ["some", 1174], ["other", 1179], ["aspects", 1185], ["of", 1193], ["iron", 1196], ["deficiency", 1201], ["are", 1212], ["reviewed", 1216], ["in", 1225], ["this", 1228], ["article", 1233], [".", 1240]]}
{"context": "Reactive oxygen species (ROS) have been known for a long time to play important roles in host defense against microbial infections. In addition, it has become apparent that they also perform regulatory roles in signal transduction and cell proliferation. The source of these chemicals are members of the NOX family of NADPH oxidases that are found in a variety of tissues. NOX1, an NADPH oxidase homologue that is most abundantly expressed in colon epithelial cells, requires the regulatory subunits NOXO1 (NOX organizing protein 1) and NOXA1 (NOX activating protein 1), as well as the flavocytochrome component p22(phox) for maximal activity. Unlike NOX2, the phagocytic NADPH oxidase whose activity is tightly repressed in the resting state, NOX1 produces superoxide constitutively at low levels. These levels can be further increased in a stimulus-dependent manner, yet the molecular details regulating this activity are not fully understood. Here we present the first quantitative characterization of the interactions made between the cytosolic regulators NOXO1 and NOXA1 and membrane-bound p22(phox). Using isothermal titration calorimetry we show that the isolated tandem SH3 domains of NOXO1 bind to p22(phox) with high affinity, most likely adopting a superSH3 domain conformation. In contrast, complex formation is severely inhibited in the presence of the C-terminal tail of NOXO1, suggesting that this region competes for binding to p22(phox) and thereby contributes to the regulation of superoxide production. Furthermore, we provide data indicating that the molecular details of the interaction between NOXO1 and NOXA1 is significantly different from that between the homologous proteins of the phagocytic oxidase, suggesting that there are important functional differences between the two systems. Taken together, this study provides clear evidence that the assembly of the NOX1 oxidase complex can be regulated through reversible protein-protein interactions.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "976535f8681e45c9881400b1e940a908", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[316, 316], [132, 132], [67, 67]], "char_spans": [[1888, 1891], [744, 747], [373, 376]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["(", 24], ["ROS", 25], [")", 28], ["have", 30], ["been", 35], ["known", 40], ["for", 46], ["a", 50], ["long", 52], ["time", 57], ["to", 62], ["play", 65], ["important", 70], ["roles", 80], ["in", 86], ["host", 89], ["defense", 94], ["against", 102], ["microbial", 110], ["infections", 120], [".", 130], ["In", 132], ["addition", 135], [",", 143], ["it", 145], ["has", 148], ["become", 152], ["apparent", 159], ["that", 168], ["they", 173], ["also", 178], ["perform", 183], ["regulatory", 191], ["roles", 202], ["in", 208], ["signal", 211], ["transduction", 218], ["and", 231], ["cell", 235], ["proliferation", 240], [".", 253], ["The", 255], ["source", 259], ["of", 266], ["these", 269], ["chemicals", 275], ["are", 285], ["members", 289], ["of", 297], ["the", 300], ["NOX", 304], ["family", 308], ["of", 315], ["NADPH", 318], ["oxidases", 324], ["that", 333], ["are", 338], ["found", 342], ["in", 348], ["a", 351], ["variety", 353], ["of", 361], ["tissues", 364], [".", 371], ["NOX1", 373], [",", 377], ["an", 379], ["NADPH", 382], ["oxidase", 388], ["homologue", 396], ["that", 406], ["is", 411], ["most", 414], ["abundantly", 419], ["expressed", 430], ["in", 440], ["colon", 443], ["epithelial", 449], ["cells", 460], [",", 465], ["requires", 467], ["the", 476], ["regulatory", 480], ["subunits", 491], ["NOXO1", 500], ["(", 506], ["NOX", 507], ["organizing", 511], ["protein", 522], ["1", 530], [")", 531], ["and", 533], ["NOXA1", 537], ["(", 543], ["NOX", 544], ["activating", 548], ["protein", 559], ["1", 567], [")", 568], [",", 569], ["as", 571], ["well", 574], ["as", 579], ["the", 582], ["flavocytochrome", 586], ["component", 602], ["p22(phox", 612], [")", 620], ["for", 622], ["maximal", 626], ["activity", 634], [".", 642], ["Unlike", 644], ["NOX2", 651], [",", 655], ["the", 657], ["phagocytic", 661], ["NADPH", 672], ["oxidase", 678], ["whose", 686], ["activity", 692], ["is", 701], ["tightly", 704], ["repressed", 712], ["in", 722], ["the", 725], ["resting", 729], ["state", 737], [",", 742], ["NOX1", 744], ["produces", 749], ["superoxide", 758], ["constitutively", 769], ["at", 784], ["low", 787], ["levels", 791], [".", 797], ["These", 799], ["levels", 805], ["can", 812], ["be", 816], ["further", 819], ["increased", 827], ["in", 837], ["a", 840], ["stimulus", 842], ["-", 850], ["dependent", 851], ["manner", 861], [",", 867], ["yet", 869], ["the", 873], ["molecular", 877], ["details", 887], ["regulating", 895], ["this", 906], ["activity", 911], ["are", 920], ["not", 924], ["fully", 928], ["understood", 934], [".", 944], ["Here", 946], ["we", 951], ["present", 954], ["the", 962], ["first", 966], ["quantitative", 972], ["characterization", 985], ["of", 1002], ["the", 1005], ["interactions", 1009], ["made", 1022], ["between", 1027], ["the", 1035], ["cytosolic", 1039], ["regulators", 1049], ["NOXO1", 1060], ["and", 1066], ["NOXA1", 1070], ["and", 1076], ["membrane", 1080], ["-", 1088], ["bound", 1089], ["p22(phox", 1095], [")", 1103], [".", 1104], ["Using", 1106], ["isothermal", 1112], ["titration", 1123], ["calorimetry", 1133], ["we", 1145], ["show", 1148], ["that", 1153], ["the", 1158], ["isolated", 1162], ["tandem", 1171], ["SH3", 1178], ["domains", 1182], ["of", 1190], ["NOXO1", 1193], ["bind", 1199], ["to", 1204], ["p22(phox", 1207], [")", 1215], ["with", 1217], ["high", 1222], ["affinity", 1227], [",", 1235], ["most", 1237], ["likely", 1242], ["adopting", 1249], ["a", 1258], ["superSH3", 1260], ["domain", 1269], ["conformation", 1276], [".", 1288], ["In", 1290], ["contrast", 1293], [",", 1301], ["complex", 1303], ["formation", 1311], ["is", 1321], ["severely", 1324], ["inhibited", 1333], ["in", 1343], ["the", 1346], ["presence", 1350], ["of", 1359], ["the", 1362], ["C", 1366], ["-", 1367], ["terminal", 1368], ["tail", 1377], ["of", 1382], ["NOXO1", 1385], [",", 1390], ["suggesting", 1392], ["that", 1403], ["this", 1408], ["region", 1413], ["competes", 1420], ["for", 1429], ["binding", 1433], ["to", 1441], ["p22(phox", 1444], [")", 1452], ["and", 1454], ["thereby", 1458], ["contributes", 1466], ["to", 1478], ["the", 1481], ["regulation", 1485], ["of", 1496], ["superoxide", 1499], ["production", 1510], [".", 1520], ["Furthermore", 1522], [",", 1533], ["we", 1535], ["provide", 1538], ["data", 1546], ["indicating", 1551], ["that", 1562], ["the", 1567], ["molecular", 1571], ["details", 1581], ["of", 1589], ["the", 1592], ["interaction", 1596], ["between", 1608], ["NOXO1", 1616], ["and", 1622], ["NOXA1", 1626], ["is", 1632], ["significantly", 1635], ["different", 1649], ["from", 1659], ["that", 1664], ["between", 1669], ["the", 1677], ["homologous", 1681], ["proteins", 1692], ["of", 1701], ["the", 1704], ["phagocytic", 1708], ["oxidase", 1719], [",", 1726], ["suggesting", 1728], ["that", 1739], ["there", 1744], ["are", 1750], ["important", 1754], ["functional", 1764], ["differences", 1775], ["between", 1787], ["the", 1795], ["two", 1799], ["systems", 1803], [".", 1810], ["Taken", 1812], ["together", 1818], [",", 1826], ["this", 1828], ["study", 1833], ["provides", 1839], ["clear", 1848], ["evidence", 1854], ["that", 1863], ["the", 1868], ["assembly", 1872], ["of", 1881], ["the", 1884], ["NOX1", 1888], ["oxidase", 1893], ["complex", 1901], ["can", 1909], ["be", 1913], ["regulated", 1916], ["through", 1926], ["reversible", 1934], ["protein", 1945], ["-", 1952], ["protein", 1953], ["interactions", 1961], [".", 1973]]}
{"context": "Selenium, an essential trace element, is incorporated into selenoproteins as selenocysteine (Sec), the 21st amino acid. In order to synthesize selenoproteins, a translational reprogramming event must occur since Sec is encoded by the UGA stop codon. In mammals, the recoding of UGA as Sec depends on the selenocysteine insertion sequence (SECIS) element, a stem-loop structure in the 3' untranslated region of the transcript. The SECIS acts as a platform for RNA-binding proteins, which mediate or regulate the recoding mechanism. Using UV crosslinking, we identified a 110 kDa protein, which binds with high affinity to SECIS elements from a subset of selenoprotein mRNAs. The crosslinking activity was purified by RNA affinity chromatography and identified as nucleolin by mass spectrometry analysis. In vitro binding assays showed that purified nucleolin discriminates among SECIS elements in the absence of other factors. Based on siRNA experiments, nucleolin is required for the optimal expression of certain selenoproteins. There was a good correlation between the affinity of nucleolin for a SECIS and its effect on selenoprotein expression. As selenoprotein transcript levels and localization did not change in siRNA-treated cells, our results suggest that nucleolin selectively enhances the expression of a subset of selenoproteins at the translational level.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0a4156b343cd4fec9fc3e8a4b0331052", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[80, 80], [116, 116], [60, 60], [153, 153], [190, 190]], "char_spans": [[430, 434], [621, 625], [339, 343], [878, 882], [1099, 1103]]}]}], "context_tokens": [["Selenium", 0], [",", 8], ["an", 10], ["essential", 13], ["trace", 23], ["element", 29], [",", 36], ["is", 38], ["incorporated", 41], ["into", 54], ["selenoproteins", 59], ["as", 74], ["selenocysteine", 77], ["(", 92], ["Sec", 93], [")", 96], [",", 97], ["the", 99], ["21st", 103], ["amino", 108], ["acid", 114], [".", 118], ["In", 120], ["order", 123], ["to", 129], ["synthesize", 132], ["selenoproteins", 143], [",", 157], ["a", 159], ["translational", 161], ["reprogramming", 175], ["event", 189], ["must", 195], ["occur", 200], ["since", 206], ["Sec", 212], ["is", 216], ["encoded", 219], ["by", 227], ["the", 230], ["UGA", 234], ["stop", 238], ["codon", 243], [".", 248], ["In", 250], ["mammals", 253], [",", 260], ["the", 262], ["recoding", 266], ["of", 275], ["UGA", 278], ["as", 282], ["Sec", 285], ["depends", 289], ["on", 297], ["the", 300], ["selenocysteine", 304], ["insertion", 319], ["sequence", 329], ["(", 338], ["SECIS", 339], [")", 344], ["element", 346], [",", 353], ["a", 355], ["stem", 357], ["-", 361], ["loop", 362], ["structure", 367], ["in", 377], ["the", 380], ["3", 384], ["'", 385], ["untranslated", 387], ["region", 400], ["of", 407], ["the", 410], ["transcript", 414], [".", 424], ["The", 426], ["SECIS", 430], ["acts", 436], ["as", 441], ["a", 444], ["platform", 446], ["for", 455], ["RNA", 459], ["-", 462], ["binding", 463], ["proteins", 471], [",", 479], ["which", 481], ["mediate", 487], ["or", 495], ["regulate", 498], ["the", 507], ["recoding", 511], ["mechanism", 520], [".", 529], ["Using", 531], ["UV", 537], ["crosslinking", 540], [",", 552], ["we", 554], ["identified", 557], ["a", 568], ["110", 570], ["kDa", 574], ["protein", 578], [",", 585], ["which", 587], ["binds", 593], ["with", 599], ["high", 604], ["affinity", 609], ["to", 618], ["SECIS", 621], ["elements", 627], ["from", 636], ["a", 641], ["subset", 643], ["of", 650], ["selenoprotein", 653], ["mRNAs", 667], [".", 672], ["The", 674], ["crosslinking", 678], ["activity", 691], ["was", 700], ["purified", 704], ["by", 713], ["RNA", 716], ["affinity", 720], ["chromatography", 729], ["and", 744], ["identified", 748], ["as", 759], ["nucleolin", 762], ["by", 772], ["mass", 775], ["spectrometry", 780], ["analysis", 793], [".", 801], ["In", 803], ["vitro", 806], ["binding", 812], ["assays", 820], ["showed", 827], ["that", 834], ["purified", 839], ["nucleolin", 848], ["discriminates", 858], ["among", 872], ["SECIS", 878], ["elements", 884], ["in", 893], ["the", 896], ["absence", 900], ["of", 908], ["other", 911], ["factors", 917], [".", 924], ["Based", 926], ["on", 932], ["siRNA", 935], ["experiments", 941], [",", 952], ["nucleolin", 954], ["is", 964], ["required", 967], ["for", 976], ["the", 980], ["optimal", 984], ["expression", 992], ["of", 1003], ["certain", 1006], ["selenoproteins", 1014], [".", 1028], ["There", 1030], ["was", 1036], ["a", 1040], ["good", 1042], ["correlation", 1047], ["between", 1059], ["the", 1067], ["affinity", 1071], ["of", 1080], ["nucleolin", 1083], ["for", 1093], ["a", 1097], ["SECIS", 1099], ["and", 1105], ["its", 1109], ["effect", 1113], ["on", 1120], ["selenoprotein", 1123], ["expression", 1137], [".", 1147], ["As", 1149], ["selenoprotein", 1152], ["transcript", 1166], ["levels", 1177], ["and", 1184], ["localization", 1188], ["did", 1201], ["not", 1205], ["change", 1209], ["in", 1216], ["siRNA", 1219], ["-", 1224], ["treated", 1225], ["cells", 1233], [",", 1238], ["our", 1240], ["results", 1244], ["suggest", 1252], ["that", 1260], ["nucleolin", 1265], ["selectively", 1275], ["enhances", 1287], ["the", 1296], ["expression", 1300], ["of", 1311], ["a", 1314], ["subset", 1316], ["of", 1323], ["selenoproteins", 1326], ["at", 1341], ["the", 1344], ["translational", 1348], ["level", 1362], [".", 1367]]}
{"context": "The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 mg BID) and individually titrated of up to 4 mg/d weekly to a maximum dose of 16 mg/d. Assessments included the Clinician-Administered PTSD Scale, Clinical Global Impressions of Change, Treatment Outcome PTSD Scale, Davidson Trauma Scale, Connor-Davidson Resilience Scale, Sheehan Disability Scale, Massachusetts General Hospital Sexual Functioning Questionnaire, and Montgomery-Asberg Depression Rating Scale. A total of 232 patients (tiagabine, n = 116; placebo, n = 116) were randomized. There were no significant differences in change from baseline in the Clinician-Administered PTSD Scale total score at final visit for tiagabine compared with placebo (P = 0.85). Similarly, no significant differences were observed with tiagabine on the other efficacy outcome measures (described above) compared with placebo. Tiagabine was generally well tolerated and not associated with weight gain, changes in sexual function, or worsening of depressive symptoms. Tiagabine was not significantly different from placebo in the treatment of symptoms of PTSD. Additional studies are needed to assess the role of drugs that target the gamma-aminobutyric acid system in the treatment of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b5c03080f08845128cbb48af0b93fc6d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[104, 133]]}, {"text": "PTSD", "token_spans": [[91, 91], [246, 246], [102, 102], [169, 169], [24, 24], [270, 270]], "char_spans": [[453, 456], [1362, 1365], [522, 525], [901, 904], [136, 139], [1493, 1496]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["evaluate", 29], ["the", 38], ["efficacy", 42], ["and", 51], ["tolerability", 55], ["of", 68], ["tiagabine", 71], ["in", 81], ["adult", 84], ["patients", 90], ["with", 99], ["post", 104], ["-", 108], ["traumatic", 109], ["stress", 119], ["disorder", 126], ["(", 135], ["PTSD", 136], [")", 140], [".", 141], ["This", 143], ["12-week", 148], [",", 155], ["multicenter", 157], [",", 168], ["double", 170], ["-", 176], ["blind", 177], ["study", 183], ["randomized", 189], ["patients", 200], ["to", 209], ["receive", 212], ["either", 220], ["tiagabine", 227], ["or", 237], ["placebo", 240], [".", 247], ["Tiagabine", 249], ["(", 259], ["administered", 260], ["in", 273], ["divided", 276], ["doses", 284], [")", 289], ["was", 291], ["initiated", 295], ["at", 305], ["4", 308], ["mg", 310], ["/", 312], ["d", 313], ["(", 315], ["2", 316], ["mg", 318], ["BID", 321], [")", 324], ["and", 326], ["individually", 330], ["titrated", 343], ["of", 352], ["up", 355], ["to", 358], ["4", 361], ["mg", 363], ["/", 365], ["d", 366], ["weekly", 368], ["to", 375], ["a", 378], ["maximum", 380], ["dose", 388], ["of", 393], ["16", 396], ["mg", 399], ["/", 401], ["d", 402], [".", 403], ["Assessments", 405], ["included", 417], ["the", 426], ["Clinician", 430], ["-", 439], ["Administered", 440], ["PTSD", 453], ["Scale", 458], [",", 463], ["Clinical", 465], ["Global", 474], ["Impressions", 481], ["of", 493], ["Change", 496], [",", 502], ["Treatment", 504], ["Outcome", 514], ["PTSD", 522], ["Scale", 527], [",", 532], ["Davidson", 534], ["Trauma", 543], ["Scale", 550], [",", 555], ["Connor", 557], ["-", 563], ["Davidson", 564], ["Resilience", 573], ["Scale", 584], [",", 589], ["Sheehan", 591], ["Disability", 599], ["Scale", 610], [",", 615], ["Massachusetts", 617], ["General", 631], ["Hospital", 639], ["Sexual", 648], ["Functioning", 655], ["Questionnaire", 667], [",", 680], ["and", 682], ["Montgomery", 686], ["-", 696], ["Asberg", 697], ["Depression", 704], ["Rating", 715], ["Scale", 722], [".", 727], ["A", 729], ["total", 731], ["of", 737], ["232", 740], ["patients", 744], ["(", 753], ["tiagabine", 754], [",", 763], ["n", 765], ["=", 767], ["116", 769], [";", 772], ["placebo", 774], [",", 781], ["n", 783], ["=", 785], ["116", 787], [")", 790], ["were", 792], ["randomized", 797], [".", 807], ["There", 809], ["were", 815], ["no", 820], ["significant", 823], ["differences", 835], ["in", 847], ["change", 850], ["from", 857], ["baseline", 862], ["in", 871], ["the", 874], ["Clinician", 878], ["-", 887], ["Administered", 888], ["PTSD", 901], ["Scale", 906], ["total", 912], ["score", 918], ["at", 924], ["final", 927], ["visit", 933], ["for", 939], ["tiagabine", 943], ["compared", 953], ["with", 962], ["placebo", 967], ["(", 975], ["P", 976], ["=", 978], ["0.85", 980], [")", 984], [".", 985], ["Similarly", 987], [",", 996], ["no", 998], ["significant", 1001], ["differences", 1013], ["were", 1025], ["observed", 1030], ["with", 1039], ["tiagabine", 1044], ["on", 1054], ["the", 1057], ["other", 1061], ["efficacy", 1067], ["outcome", 1076], ["measures", 1084], ["(", 1093], ["described", 1094], ["above", 1104], [")", 1109], ["compared", 1111], ["with", 1120], ["placebo", 1125], [".", 1132], ["Tiagabine", 1134], ["was", 1144], ["generally", 1148], ["well", 1158], ["tolerated", 1163], ["and", 1173], ["not", 1177], ["associated", 1181], ["with", 1192], ["weight", 1197], ["gain", 1204], [",", 1208], ["changes", 1210], ["in", 1218], ["sexual", 1221], ["function", 1228], [",", 1236], ["or", 1238], ["worsening", 1241], ["of", 1251], ["depressive", 1254], ["symptoms", 1265], [".", 1273], ["Tiagabine", 1275], ["was", 1285], ["not", 1289], ["significantly", 1293], ["different", 1307], ["from", 1317], ["placebo", 1322], ["in", 1330], ["the", 1333], ["treatment", 1337], ["of", 1347], ["symptoms", 1350], ["of", 1359], ["PTSD", 1362], [".", 1366], ["Additional", 1368], ["studies", 1379], ["are", 1387], ["needed", 1391], ["to", 1398], ["assess", 1401], ["the", 1408], ["role", 1412], ["of", 1417], ["drugs", 1420], ["that", 1426], ["target", 1431], ["the", 1438], ["gamma", 1442], ["-", 1447], ["aminobutyric", 1448], ["acid", 1461], ["system", 1466], ["in", 1473], ["the", 1476], ["treatment", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention of cancers including non-small-cell lung cancer. STAT proteins can be phosphorylated and activated by diverse upstream kinases including cytokine receptors and tyrosine kinases. We examined STAT protein activation in lung cancer cell lines including those with activating mutations in the EGFR and examined upstream kinases responsible for STAT3 phosphorylation and activation using small molecules, antibodies, and RNA interference. We found more pronounced STAT3 activation in cells with activating EGFR mutations, yet inhibition of EGFR activity had no effect on STAT3 activation. Inhibition of JAK1 with small molecules or RNA interference resulted in loss of STAT3 tyrosine phosphorylation and inhibition of cell growth. An interleukin-6 neutralizing antibody, siltuximab (CNTO 328) could inhibit STAT3 tyrosine phosphorylation in a cell-dependent manner. Siltuximab could completely inhibit STAT3 tyrosine phosphorylation in H1650 cells, and this resulted in inhibition of lung cancer cell growth in vivo. Combined EGFR inhibition with erlotinib and siltuximab resulted in dual inhibition of both tyrosine and serine STAT3 phosphorylation, more pronounced inhibition of STAT3 transcriptional activity, and translated into combined effects on lung cancer growth in a mouse model. Our results suggest that JAK1 is responsible for STAT3 activation in lung cancer cells and that indirect attacks on JAK1-STAT3 using an IL-6 neutralizing antibody with or without EGFR inhibition can inhibit lung cancer growth in lung cancer subsets.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "fc6f88c8ca2e451284d7c33fa8b5071a", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[139, 139]], "char_spans": [[887, 899]]}]}], "context_tokens": [["Members", 0], ["of", 8], ["the", 11], ["signal", 15], ["transducer", 22], ["and", 33], ["activator", 37], ["of", 47], ["transcription", 50], ["(", 64], ["STAT", 65], [")", 69], ["family", 71], ["of", 78], ["transcription", 81], ["factors", 95], ["are", 103], ["potential", 107], ["targets", 117], ["for", 125], ["the", 129], ["treatment", 133], ["and", 143], ["prevention", 147], ["of", 158], ["cancers", 161], ["including", 169], ["non", 179], ["-", 182], ["small", 183], ["-", 188], ["cell", 189], ["lung", 194], ["cancer", 199], [".", 205], ["STAT", 207], ["proteins", 212], ["can", 221], ["be", 225], ["phosphorylated", 228], ["and", 243], ["activated", 247], ["by", 257], ["diverse", 260], ["upstream", 268], ["kinases", 277], ["including", 285], ["cytokine", 295], ["receptors", 304], ["and", 314], ["tyrosine", 318], ["kinases", 327], [".", 334], ["We", 336], ["examined", 339], ["STAT", 348], ["protein", 353], ["activation", 361], ["in", 372], ["lung", 375], ["cancer", 380], ["cell", 387], ["lines", 392], ["including", 398], ["those", 408], ["with", 414], ["activating", 419], ["mutations", 430], ["in", 440], ["the", 443], ["EGFR", 447], ["and", 452], ["examined", 456], ["upstream", 465], ["kinases", 474], ["responsible", 482], ["for", 494], ["STAT3", 498], ["phosphorylation", 504], ["and", 520], ["activation", 524], ["using", 535], ["small", 541], ["molecules", 547], [",", 556], ["antibodies", 558], [",", 568], ["and", 570], ["RNA", 574], ["interference", 578], [".", 590], ["We", 592], ["found", 595], ["more", 601], ["pronounced", 606], ["STAT3", 617], ["activation", 623], ["in", 634], ["cells", 637], ["with", 643], ["activating", 648], ["EGFR", 659], ["mutations", 664], [",", 673], ["yet", 675], ["inhibition", 679], ["of", 690], ["EGFR", 693], ["activity", 698], ["had", 707], ["no", 711], ["effect", 714], ["on", 721], ["STAT3", 724], ["activation", 730], [".", 740], ["Inhibition", 742], ["of", 753], ["JAK1", 756], ["with", 761], ["small", 766], ["molecules", 772], ["or", 782], ["RNA", 785], ["interference", 789], ["resulted", 802], ["in", 811], ["loss", 814], ["of", 819], ["STAT3", 822], ["tyrosine", 828], ["phosphorylation", 837], ["and", 853], ["inhibition", 857], ["of", 868], ["cell", 871], ["growth", 876], [".", 882], ["An", 884], ["interleukin-6", 887], ["neutralizing", 901], ["antibody", 914], [",", 922], ["siltuximab", 924], ["(", 935], ["CNTO", 936], ["328", 941], [")", 944], ["could", 946], ["inhibit", 952], ["STAT3", 960], ["tyrosine", 966], ["phosphorylation", 975], ["in", 991], ["a", 994], ["cell", 996], ["-", 1000], ["dependent", 1001], ["manner", 1011], [".", 1017], ["Siltuximab", 1019], ["could", 1030], ["completely", 1036], ["inhibit", 1047], ["STAT3", 1055], ["tyrosine", 1061], ["phosphorylation", 1070], ["in", 1086], ["H1650", 1089], ["cells", 1095], [",", 1100], ["and", 1102], ["this", 1106], ["resulted", 1111], ["in", 1120], ["inhibition", 1123], ["of", 1134], ["lung", 1137], ["cancer", 1142], ["cell", 1149], ["growth", 1154], ["in", 1161], ["vivo", 1164], [".", 1168], ["Combined", 1170], ["EGFR", 1179], ["inhibition", 1184], ["with", 1195], ["erlotinib", 1200], ["and", 1210], ["siltuximab", 1214], ["resulted", 1225], ["in", 1234], ["dual", 1237], ["inhibition", 1242], ["of", 1253], ["both", 1256], ["tyrosine", 1261], ["and", 1270], ["serine", 1274], ["STAT3", 1281], ["phosphorylation", 1287], [",", 1302], ["more", 1304], ["pronounced", 1309], ["inhibition", 1320], ["of", 1331], ["STAT3", 1334], ["transcriptional", 1340], ["activity", 1356], [",", 1364], ["and", 1366], ["translated", 1370], ["into", 1381], ["combined", 1386], ["effects", 1395], ["on", 1403], ["lung", 1406], ["cancer", 1411], ["growth", 1418], ["in", 1425], ["a", 1428], ["mouse", 1430], ["model", 1436], [".", 1441], ["Our", 1443], ["results", 1447], ["suggest", 1455], ["that", 1463], ["JAK1", 1468], ["is", 1473], ["responsible", 1476], ["for", 1488], ["STAT3", 1492], ["activation", 1498], ["in", 1509], ["lung", 1512], ["cancer", 1517], ["cells", 1524], ["and", 1530], ["that", 1534], ["indirect", 1539], ["attacks", 1548], ["on", 1556], ["JAK1-STAT3", 1559], ["using", 1570], ["an", 1576], ["IL-6", 1579], ["neutralizing", 1584], ["antibody", 1597], ["with", 1606], ["or", 1611], ["without", 1614], ["EGFR", 1622], ["inhibition", 1627], ["can", 1638], ["inhibit", 1642], ["lung", 1650], ["cancer", 1655], ["growth", 1662], ["in", 1669], ["lung", 1672], ["cancer", 1677], ["subsets", 1684], [".", 1691]]}
{"context": "To summarize the use of tyrosine kinase inhibitors (TKIs) for treatment of patients with chronic myeloid leukemia (CML) and provide practical information for patient management. Literature was retrieved from PubMed (2000-January 2011), using the search terms chronic myeloid leukemia and tyrosine kinase inhibitor. Abstracts presented at the 2008-2010 annual meetings of the American Society of Hematology and the American Society of Clinical Oncology, reference citations from identified publications, as well as the manufacturers' full prescribing information for cited drugs, also were reviewed. Articles evaluating the efficacy and safety of the TKIs imatinib, nilotinib, and dasatinib were evaluated. Focus was placed on publications supporting management of patients with CML in the chronic phase. Reports presenting clinical trial information of TKIs in development also were included. The discovery of targeted tyrosine kinase inhibition of BCR-ABL kinase dramatically changed the treatment of CML. Imatinib, the first TKI approved for treatment of patients with Philadelphia chromosome--positive CML, demonstrated significant superiority over the previous standard of care: interferon plus cytarabine. The newer, more potent TKIs, nilotinib and dasatinib, have demonstrated improved efficacy over imatinib as first-line therapy and provide an effective option for patients with resistance or intolerance to imatinib. To maximize efficacy of TKI therapy, close patient management, involving frequent monitoring of patient response, is essential. Given the importance of continuing TKI therapy, early recognition and management of adverse events are critical to optimizing outcomes in patients with CML. In addition to the safety profile and considerations of comorbidities, additional factors can affect therapeutic selection, including drug-drug and drug-food interactions. Research investigating new therapies, particularly for patients harboring the T315I mutation-which remains refractory to current TKIs-continues in the quest to improve outcomes in patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "71db12729a584f868ff6889568d33526", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[153, 155]], "char_spans": [[949, 955]]}]}], "context_tokens": [["To", 0], ["summarize", 3], ["the", 13], ["use", 17], ["of", 21], ["tyrosine", 24], ["kinase", 33], ["inhibitors", 40], ["(", 51], ["TKIs", 52], [")", 56], ["for", 58], ["treatment", 62], ["of", 72], ["patients", 75], ["with", 84], ["chronic", 89], ["myeloid", 97], ["leukemia", 105], ["(", 114], ["CML", 115], [")", 118], ["and", 120], ["provide", 124], ["practical", 132], ["information", 142], ["for", 154], ["patient", 158], ["management", 166], [".", 176], ["Literature", 178], ["was", 189], ["retrieved", 193], ["from", 203], ["PubMed", 208], ["(", 215], ["2000-January", 216], ["2011", 229], [")", 233], [",", 234], ["using", 236], ["the", 242], ["search", 246], ["terms", 253], ["chronic", 259], ["myeloid", 267], ["leukemia", 275], ["and", 284], ["tyrosine", 288], ["kinase", 297], ["inhibitor", 304], [".", 313], ["Abstracts", 315], ["presented", 325], ["at", 335], ["the", 338], ["2008", 342], ["-", 346], ["2010", 347], ["annual", 352], ["meetings", 359], ["of", 368], ["the", 371], ["American", 375], ["Society", 384], ["of", 392], ["Hematology", 395], ["and", 406], ["the", 410], ["American", 414], ["Society", 423], ["of", 431], ["Clinical", 434], ["Oncology", 443], [",", 451], ["reference", 453], ["citations", 463], ["from", 473], ["identified", 478], ["publications", 489], [",", 501], ["as", 503], ["well", 506], ["as", 511], ["the", 514], ["manufacturers", 518], ["'", 531], ["full", 533], ["prescribing", 538], ["information", 550], ["for", 562], ["cited", 566], ["drugs", 572], [",", 577], ["also", 579], ["were", 584], ["reviewed", 589], [".", 597], ["Articles", 599], ["evaluating", 608], ["the", 619], ["efficacy", 623], ["and", 632], ["safety", 636], ["of", 643], ["the", 646], ["TKIs", 650], ["imatinib", 655], [",", 663], ["nilotinib", 665], [",", 674], ["and", 676], ["dasatinib", 680], ["were", 690], ["evaluated", 695], [".", 704], ["Focus", 706], ["was", 712], ["placed", 716], ["on", 723], ["publications", 726], ["supporting", 739], ["management", 750], ["of", 761], ["patients", 764], ["with", 773], ["CML", 778], ["in", 782], ["the", 785], ["chronic", 789], ["phase", 797], [".", 802], ["Reports", 804], ["presenting", 812], ["clinical", 823], ["trial", 832], ["information", 838], ["of", 850], ["TKIs", 853], ["in", 858], ["development", 861], ["also", 873], ["were", 878], ["included", 883], [".", 891], ["The", 893], ["discovery", 897], ["of", 907], ["targeted", 910], ["tyrosine", 919], ["kinase", 928], ["inhibition", 935], ["of", 946], ["BCR", 949], ["-", 952], ["ABL", 953], ["kinase", 957], ["dramatically", 964], ["changed", 977], ["the", 985], ["treatment", 989], ["of", 999], ["CML", 1002], [".", 1005], ["Imatinib", 1007], [",", 1015], ["the", 1017], ["first", 1021], ["TKI", 1027], ["approved", 1031], ["for", 1040], ["treatment", 1044], ["of", 1054], ["patients", 1057], ["with", 1066], ["Philadelphia", 1071], ["chromosome", 1084], ["--", 1094], ["positive", 1096], ["CML", 1105], [",", 1108], ["demonstrated", 1110], ["significant", 1123], ["superiority", 1135], ["over", 1147], ["the", 1152], ["previous", 1156], ["standard", 1165], ["of", 1174], ["care", 1177], [":", 1181], ["interferon", 1183], ["plus", 1194], ["cytarabine", 1199], [".", 1209], ["The", 1211], ["newer", 1215], [",", 1220], ["more", 1222], ["potent", 1227], ["TKIs", 1234], [",", 1238], ["nilotinib", 1240], ["and", 1250], ["dasatinib", 1254], [",", 1263], ["have", 1265], ["demonstrated", 1270], ["improved", 1283], ["efficacy", 1292], ["over", 1301], ["imatinib", 1306], ["as", 1315], ["first", 1318], ["-", 1323], ["line", 1324], ["therapy", 1329], ["and", 1337], ["provide", 1341], ["an", 1349], ["effective", 1352], ["option", 1362], ["for", 1369], ["patients", 1373], ["with", 1382], ["resistance", 1387], ["or", 1398], ["intolerance", 1401], ["to", 1413], ["imatinib", 1416], [".", 1424], ["To", 1426], ["maximize", 1429], ["efficacy", 1438], ["of", 1447], ["TKI", 1450], ["therapy", 1454], [",", 1461], ["close", 1463], ["patient", 1469], ["management", 1477], [",", 1487], ["involving", 1489], ["frequent", 1499], ["monitoring", 1508], ["of", 1519], ["patient", 1522], ["response", 1530], [",", 1538], ["is", 1540], ["essential", 1543], [".", 1552], ["Given", 1554], ["the", 1560], ["importance", 1564], ["of", 1575], ["continuing", 1578], ["TKI", 1589], ["therapy", 1593], [",", 1600], ["early", 1602], ["recognition", 1608], ["and", 1620], ["management", 1624], ["of", 1635], ["adverse", 1638], ["events", 1646], ["are", 1653], ["critical", 1657], ["to", 1666], ["optimizing", 1669], ["outcomes", 1680], ["in", 1689], ["patients", 1692], ["with", 1701], ["CML", 1706], [".", 1709], ["In", 1711], ["addition", 1714], ["to", 1723], ["the", 1726], ["safety", 1730], ["profile", 1737], ["and", 1745], ["considerations", 1749], ["of", 1764], ["comorbidities", 1767], [",", 1780], ["additional", 1782], ["factors", 1793], ["can", 1801], ["affect", 1805], ["therapeutic", 1812], ["selection", 1824], [",", 1833], ["including", 1835], ["drug", 1845], ["-", 1849], ["drug", 1850], ["and", 1855], ["drug", 1859], ["-", 1863], ["food", 1864], ["interactions", 1869], [".", 1881], ["Research", 1883], ["investigating", 1892], ["new", 1906], ["therapies", 1910], [",", 1919], ["particularly", 1921], ["for", 1934], ["patients", 1938], ["harboring", 1947], ["the", 1957], ["T315I", 1961], ["mutation", 1967], ["-", 1975], ["which", 1976], ["remains", 1982], ["refractory", 1990], ["to", 2001], ["current", 2004], ["TKIs", 2012], ["-", 2016], ["continues", 2017], ["in", 2027], ["the", 2030], ["quest", 2034], ["to", 2040], ["improve", 2043], ["outcomes", 2051], ["in", 2060], ["patients", 2063], ["with", 2072], ["CML", 2077], [".", 2080]]}
{"context": "The focus of this article is acrokeratosis paraneoplastica, one of two disorders that have acquired the eponym Bazex syndrome. To date, all of the patients reported in the literature have had an underlying neoplasm, most commonly squamous cell carcinoma of the upper aerodigestive tract. In this review of 113 cases of acrokeratosis paraneoplastica (mean age, 61 years; 105 males, 8 females), the psoriasiform lesions preceded the diagnosis of the associated malignancy in 73 (67%) of 109 patients, whereas the cutaneous manifestations followed the diagnosis of the neoplasm in only 16 (15%) of 109; in the remainder, the onset of the skin lesions and the diagnosis of the tumor occurred simultaneously. Therefore, awareness of the cutaneous signs of Bazex syndrome is of obvious importance to dermatologists. Evidence in favor of the paraneoplastic nature of this disease is as follows: in 81 (93%) of 87 patients with adequate clinical descriptions, the skin lesions either improved significantly (or resolved) when the underlying neoplasm was treated or they remained unchanged in the setting of persistent disease. Occasionally, the reappearance of skin lesions has signaled a recurrence of the tumor.", "qas": [{"question": "Name synonym of Acrokeratosis paraneoplastica.", "answers": ["Bazex syndrome"], "qid": "d451ee65e0e14baaa98a29b68092c5fc", "question_tokens": [["Name", 0], ["synonym", 5], ["of", 13], ["Acrokeratosis", 16], ["paraneoplastica", 30], [".", 45]], "detected_answers": [{"text": "Bazex syndrome", "token_spans": [[139, 140], [18, 19]], "char_spans": [[751, 764], [111, 124]]}]}], "context_tokens": [["The", 0], ["focus", 4], ["of", 10], ["this", 13], ["article", 18], ["is", 26], ["acrokeratosis", 29], ["paraneoplastica", 43], [",", 58], ["one", 60], ["of", 64], ["two", 67], ["disorders", 71], ["that", 81], ["have", 86], ["acquired", 91], ["the", 100], ["eponym", 104], ["Bazex", 111], ["syndrome", 117], [".", 125], ["To", 127], ["date", 130], [",", 134], ["all", 136], ["of", 140], ["the", 143], ["patients", 147], ["reported", 156], ["in", 165], ["the", 168], ["literature", 172], ["have", 183], ["had", 188], ["an", 192], ["underlying", 195], ["neoplasm", 206], [",", 214], ["most", 216], ["commonly", 221], ["squamous", 230], ["cell", 239], ["carcinoma", 244], ["of", 254], ["the", 257], ["upper", 261], ["aerodigestive", 267], ["tract", 281], [".", 286], ["In", 288], ["this", 291], ["review", 296], ["of", 303], ["113", 306], ["cases", 310], ["of", 316], ["acrokeratosis", 319], ["paraneoplastica", 333], ["(", 349], ["mean", 350], ["age", 355], [",", 358], ["61", 360], ["years", 363], [";", 368], ["105", 370], ["males", 374], [",", 379], ["8", 381], ["females", 383], [")", 390], [",", 391], ["the", 393], ["psoriasiform", 397], ["lesions", 410], ["preceded", 418], ["the", 427], ["diagnosis", 431], ["of", 441], ["the", 444], ["associated", 448], ["malignancy", 459], ["in", 470], ["73", 473], ["(", 476], ["67", 477], ["%", 479], [")", 480], ["of", 482], ["109", 485], ["patients", 489], [",", 497], ["whereas", 499], ["the", 507], ["cutaneous", 511], ["manifestations", 521], ["followed", 536], ["the", 545], ["diagnosis", 549], ["of", 559], ["the", 562], ["neoplasm", 566], ["in", 575], ["only", 578], ["16", 583], ["(", 586], ["15", 587], ["%", 589], [")", 590], ["of", 592], ["109", 595], [";", 598], ["in", 600], ["the", 603], ["remainder", 607], [",", 616], ["the", 618], ["onset", 622], ["of", 628], ["the", 631], ["skin", 635], ["lesions", 640], ["and", 648], ["the", 652], ["diagnosis", 656], ["of", 666], ["the", 669], ["tumor", 673], ["occurred", 679], ["simultaneously", 688], [".", 702], ["Therefore", 704], [",", 713], ["awareness", 715], ["of", 725], ["the", 728], ["cutaneous", 732], ["signs", 742], ["of", 748], ["Bazex", 751], ["syndrome", 757], ["is", 766], ["of", 769], ["obvious", 772], ["importance", 780], ["to", 791], ["dermatologists", 794], [".", 808], ["Evidence", 810], ["in", 819], ["favor", 822], ["of", 828], ["the", 831], ["paraneoplastic", 835], ["nature", 850], ["of", 857], ["this", 860], ["disease", 865], ["is", 873], ["as", 876], ["follows", 879], [":", 886], ["in", 888], ["81", 891], ["(", 894], ["93", 895], ["%", 897], [")", 898], ["of", 900], ["87", 903], ["patients", 906], ["with", 915], ["adequate", 920], ["clinical", 929], ["descriptions", 938], [",", 950], ["the", 952], ["skin", 956], ["lesions", 961], ["either", 969], ["improved", 976], ["significantly", 985], ["(", 999], ["or", 1000], ["resolved", 1003], [")", 1011], ["when", 1013], ["the", 1018], ["underlying", 1022], ["neoplasm", 1033], ["was", 1042], ["treated", 1046], ["or", 1054], ["they", 1057], ["remained", 1062], ["unchanged", 1071], ["in", 1081], ["the", 1084], ["setting", 1088], ["of", 1096], ["persistent", 1099], ["disease", 1110], [".", 1117], ["Occasionally", 1119], [",", 1131], ["the", 1133], ["reappearance", 1137], ["of", 1150], ["skin", 1153], ["lesions", 1158], ["has", 1166], ["signaled", 1170], ["a", 1179], ["recurrence", 1181], ["of", 1192], ["the", 1195], ["tumor", 1199], [".", 1204]]}
{"context": "Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR-ABL-targeted TKI that inhibits BCR-ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed. This is a review of the relevant literature regarding dasatinib development in CML (2003-2013). Dasatinib demonstrates efficacy against most BCR-ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported. Dasatinib is an effective treatment option for patients with CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5c2cbb8eaf4742919bc8a56682ea0e5a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[138, 140], [20, 22], [28, 30]], "char_spans": [[779, 785], [98, 104], [133, 139]]}]}], "context_tokens": [["Dasatinib", 0], ["is", 10], ["a", 13], ["dual", 15], ["Abl", 20], ["/", 23], ["Src", 24], ["tyrosine", 28], ["kinase", 37], ["inhibitor", 44], ["(", 54], ["TKI", 55], [")", 58], ["designed", 60], ["as", 69], ["a", 72], ["prototypic", 74], ["short", 85], ["-", 90], ["acting", 91], ["BCR", 98], ["-", 101], ["ABL", 102], ["-", 105], ["targeted", 106], ["TKI", 115], ["that", 119], ["inhibits", 124], ["BCR", 133], ["-", 136], ["ABL", 137], ["with", 141], ["greater", 146], ["potency", 154], ["compared", 162], ["with", 171], ["imatinib", 176], [",", 184], ["nilotinib", 186], [",", 195], ["bosutinib", 197], [",", 206], ["and", 208], ["ponatinib", 212], ["and", 222], ["has", 226], ["been", 230], ["shown", 235], ["to", 241], ["have", 244], ["potential", 249], ["immunomodulatory", 259], ["effects", 276], [".", 283], ["Dasatinib", 285], ["is", 295], ["approved", 298], ["for", 307], ["the", 311], ["treatment", 315], ["of", 325], ["all", 328], ["phases", 332], ["of", 339], ["chronic", 342], ["myeloid", 350], ["leukemia", 358], ["(", 367], ["CML", 368], [")", 371], ["and", 373], ["Philadelphia", 377], ["chromosome", 390], ["-", 400], ["positive", 401], ["acute", 410], ["lymphoblastic", 416], ["leukemia", 430], ["resistant", 439], ["or", 449], ["intolerant", 452], ["to", 463], ["prior", 466], ["imatinib", 472], ["treatment", 481], ["and", 491], ["first", 495], ["-", 500], ["line", 501], ["treatment", 506], ["for", 516], ["CML", 520], ["in", 524], ["chronic", 527], ["phase", 535], [".", 540], ["In", 542], ["this", 545], ["article", 550], [",", 557], ["the", 559], ["development", 563], ["of", 575], ["dasatinib", 578], ["as", 588], ["a", 591], ["treatment", 593], ["for", 603], ["patients", 607], ["with", 616], ["CML", 621], ["is", 625], ["reviewed", 628], [".", 636], ["This", 638], ["is", 643], ["a", 646], ["review", 648], ["of", 655], ["the", 658], ["relevant", 662], ["literature", 671], ["regarding", 682], ["dasatinib", 692], ["development", 702], ["in", 714], ["CML", 717], ["(", 721], ["2003", 722], ["-", 726], ["2013", 727], [")", 731], [".", 732], ["Dasatinib", 734], ["demonstrates", 744], ["efficacy", 757], ["against", 766], ["most", 774], ["BCR", 779], ["-", 782], ["ABL", 783], ["mutations", 787], ["arising", 797], ["during", 805], ["imatinib", 812], ["therapy", 821], ["and", 829], ["is", 833], ["effective", 836], ["in", 846], ["treating", 849], ["patients", 858], ["with", 867], ["imatinib", 872], ["resistance", 881], ["due", 892], ["to", 896], ["other", 899], ["mechanisms", 905], [".", 915], ["Randomized", 917], ["trial", 928], ["data", 934], ["show", 939], ["that", 944], ["first", 949], ["-", 954], ["line", 955], ["dasatinib", 960], ["provides", 970], ["superior", 979], ["responses", 988], ["compared", 998], ["with", 1007], ["imatinib", 1012], ["and", 1021], ["enables", 1025], ["patients", 1033], ["to", 1042], ["achieve", 1045], ["early", 1053], [",", 1058], ["deep", 1060], ["responses", 1065], ["correlated", 1075], ["with", 1086], ["improved", 1091], ["longer", 1100], ["-", 1106], ["term", 1107], ["outcomes", 1112], [".", 1120], ["Dasatinib", 1122], ["has", 1132], ["a", 1136], ["generally", 1138], ["acceptable", 1148], ["safety", 1159], ["profile", 1166], [",", 1173], ["with", 1175], ["most", 1180], ["adverse", 1185], ["events", 1193], ["(", 1200], ["AEs", 1201], [")", 1204], ["proving", 1206], ["manageable", 1214], ["and", 1225], ["reversible", 1229], [".", 1239], ["Cytopenias", 1241], ["are", 1252], ["commonly", 1256], ["observed", 1265], ["with", 1274], ["dasatinib", 1279], [",", 1288], ["and", 1290], ["some", 1294], ["nonhematologic", 1299], ["AEs", 1314], ["including", 1318], ["pleural", 1328], ["effusion", 1336], ["have", 1345], ["been", 1350], ["consistently", 1355], ["reported", 1368], [".", 1376], ["Dasatinib", 1378], ["is", 1388], ["an", 1391], ["effective", 1394], ["treatment", 1404], ["option", 1414], ["for", 1421], ["patients", 1425], ["with", 1434], ["CML", 1439], [".", 1442]]}
{"context": "Consensual diagnostic criteria for facioscapulohumeral dystrophy (FSHD) include onset of the disease in facial or shoulder girdle muscles, facial weakness in more than 50% of affected family members, autosomal dominant inheritance in familial cases, and evidence of myopathic disease in at least one affected member without biopsy features specific to alternative diagnoses. Six patients did not meet most of these criteria but were diagnosed as FSHD by DNA testing, which showed small EcoRI fragments on chromosome 4q. Their clinical signs and symptoms and results of auxiliary investigations are reported. The patients presented with foot extensor, thigh, or calf muscle weakness. None of them had apparent facial weakness, only one complained of weakness in the shoulders, none had a positive family history. Expert physical examination, however, showed a typical facial expression, an abnormal shoulder configuration on lifting the arms, or scapular winging. This raised the suspicion of FSHD, whereupon DNA analysis was done. In conclusion, the clinical expression of FSHD is much broader than indicated by the nomenclature. The possibility to perform DNA tests is likely to greatly expand the clinical range of FSHD.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "6c9b255f11a04caa992ae6ef8de912b0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[33, 34]], "char_spans": [[200, 217]]}]}], "context_tokens": [["Consensual", 0], ["diagnostic", 11], ["criteria", 22], ["for", 31], ["facioscapulohumeral", 35], ["dystrophy", 55], ["(", 65], ["FSHD", 66], [")", 70], ["include", 72], ["onset", 80], ["of", 86], ["the", 89], ["disease", 93], ["in", 101], ["facial", 104], ["or", 111], ["shoulder", 114], ["girdle", 123], ["muscles", 130], [",", 137], ["facial", 139], ["weakness", 146], ["in", 155], ["more", 158], ["than", 163], ["50", 168], ["%", 170], ["of", 172], ["affected", 175], ["family", 184], ["members", 191], [",", 198], ["autosomal", 200], ["dominant", 210], ["inheritance", 219], ["in", 231], ["familial", 234], ["cases", 243], [",", 248], ["and", 250], ["evidence", 254], ["of", 263], ["myopathic", 266], ["disease", 276], ["in", 284], ["at", 287], ["least", 290], ["one", 296], ["affected", 300], ["member", 309], ["without", 316], ["biopsy", 324], ["features", 331], ["specific", 340], ["to", 349], ["alternative", 352], ["diagnoses", 364], [".", 373], ["Six", 375], ["patients", 379], ["did", 388], ["not", 392], ["meet", 396], ["most", 401], ["of", 406], ["these", 409], ["criteria", 415], ["but", 424], ["were", 428], ["diagnosed", 433], ["as", 443], ["FSHD", 446], ["by", 451], ["DNA", 454], ["testing", 458], [",", 465], ["which", 467], ["showed", 473], ["small", 480], ["EcoRI", 486], ["fragments", 492], ["on", 502], ["chromosome", 505], ["4q", 516], [".", 518], ["Their", 520], ["clinical", 526], ["signs", 535], ["and", 541], ["symptoms", 545], ["and", 554], ["results", 558], ["of", 566], ["auxiliary", 569], ["investigations", 579], ["are", 594], ["reported", 598], [".", 606], ["The", 608], ["patients", 612], ["presented", 621], ["with", 631], ["foot", 636], ["extensor", 641], [",", 649], ["thigh", 651], [",", 656], ["or", 658], ["calf", 661], ["muscle", 666], ["weakness", 673], [".", 681], ["None", 683], ["of", 688], ["them", 691], ["had", 696], ["apparent", 700], ["facial", 709], ["weakness", 716], [",", 724], ["only", 726], ["one", 731], ["complained", 735], ["of", 746], ["weakness", 749], ["in", 758], ["the", 761], ["shoulders", 765], [",", 774], ["none", 776], ["had", 781], ["a", 785], ["positive", 787], ["family", 796], ["history", 803], [".", 810], ["Expert", 812], ["physical", 819], ["examination", 828], [",", 839], ["however", 841], [",", 848], ["showed", 850], ["a", 857], ["typical", 859], ["facial", 867], ["expression", 874], [",", 884], ["an", 886], ["abnormal", 889], ["shoulder", 898], ["configuration", 907], ["on", 921], ["lifting", 924], ["the", 932], ["arms", 936], [",", 940], ["or", 942], ["scapular", 945], ["winging", 954], [".", 961], ["This", 963], ["raised", 968], ["the", 975], ["suspicion", 979], ["of", 989], ["FSHD", 992], [",", 996], ["whereupon", 998], ["DNA", 1008], ["analysis", 1012], ["was", 1021], ["done", 1025], [".", 1029], ["In", 1031], ["conclusion", 1034], [",", 1044], ["the", 1046], ["clinical", 1050], ["expression", 1059], ["of", 1070], ["FSHD", 1073], ["is", 1078], ["much", 1081], ["broader", 1086], ["than", 1094], ["indicated", 1099], ["by", 1109], ["the", 1112], ["nomenclature", 1116], [".", 1128], ["The", 1130], ["possibility", 1134], ["to", 1146], ["perform", 1149], ["DNA", 1157], ["tests", 1161], ["is", 1167], ["likely", 1170], ["to", 1177], ["greatly", 1180], ["expand", 1188], ["the", 1195], ["clinical", 1199], ["range", 1208], ["of", 1214], ["FSHD", 1217], [".", 1221]]}
{"context": "Recently, bi-allelic mutations in the transcription factor RFX6 were described as the cause of a rare condition characterized by neonatal diabetes with pancreatic and biliary hypoplasia and duodenal/jejunal atresia. A male infant developed severe hyperglycemia (446\u2009mg/dL) within 24\u2009h of birth. Acute abdominal concerns by day five necessitated exploratory surgery that revealed duodenal atresia, gallbladder agenesis, annular pancreas and intestinal malrotation. He also exhibited chronic diarrhea and feeding intolerance, cholestatic jaundice, and subsequent liver failure. He died of sepsis at four months old while awaiting liver transplantation. The phenotype of neonatal diabetes with intestinal atresia and biliary agenesis clearly pointed to RFX6 as the causative gene; indeed, whole exome sequencing revealed a novel homozygous RFX6 mutation c.779A>C; p.Lys260Thr (K260T). This missense mutation also changes the consensus 5' splice donor site before intron 7 and is thus predicted to cause disruption in splicing. Both parents, who were not known to be related, were heterozygous carriers. Targeted genetic testing based on consideration of phenotypic features may reveal a cause among the many genes now associated with heterogeneous forms of monogenic neonatal diabetes. Our study demonstrates the feasibility of using modern sequencing technology to identify one such rare cause. Continued research is needed to determine the possible cost-effectiveness of this approach, especially when clear phenotypic clues are absent. Further study of patients with RFX6 mutations should clarify its role in pancreatic, intestinal and enteroendocrine cellular development and explain features such as the diarrhea exhibited in our case.", "qas": [{"question": "Which gene is associated with the Mitchell-Riley syndrome?", "answers": ["RFX6"], "qid": "2e07fab624c345f486c1445ba1811034", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["the", 30], ["Mitchell", 34], ["-", 42], ["Riley", 43], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "RFX6", "token_spans": [[120, 120], [135, 135], [261, 261], [10, 10]], "char_spans": [[750, 753], [837, 840], [1567, 1570], [59, 62]]}]}], "context_tokens": [["Recently", 0], [",", 8], ["bi", 10], ["-", 12], ["allelic", 13], ["mutations", 21], ["in", 31], ["the", 34], ["transcription", 38], ["factor", 52], ["RFX6", 59], ["were", 64], ["described", 69], ["as", 79], ["the", 82], ["cause", 86], ["of", 92], ["a", 95], ["rare", 97], ["condition", 102], ["characterized", 112], ["by", 126], ["neonatal", 129], ["diabetes", 138], ["with", 147], ["pancreatic", 152], ["and", 163], ["biliary", 167], ["hypoplasia", 175], ["and", 186], ["duodenal", 190], ["/", 198], ["jejunal", 199], ["atresia", 207], [".", 214], ["A", 216], ["male", 218], ["infant", 223], ["developed", 230], ["severe", 240], ["hyperglycemia", 247], ["(", 261], ["446", 262], ["mg", 266], ["/", 268], ["dL", 269], [")", 271], ["within", 273], ["24", 280], ["h", 283], ["of", 285], ["birth", 288], [".", 293], ["Acute", 295], ["abdominal", 301], ["concerns", 311], ["by", 320], ["day", 323], ["five", 327], ["necessitated", 332], ["exploratory", 345], ["surgery", 357], ["that", 365], ["revealed", 370], ["duodenal", 379], ["atresia", 388], [",", 395], ["gallbladder", 397], ["agenesis", 409], [",", 417], ["annular", 419], ["pancreas", 427], ["and", 436], ["intestinal", 440], ["malrotation", 451], [".", 462], ["He", 464], ["also", 467], ["exhibited", 472], ["chronic", 482], ["diarrhea", 490], ["and", 499], ["feeding", 503], ["intolerance", 511], [",", 522], ["cholestatic", 524], ["jaundice", 536], [",", 544], ["and", 546], ["subsequent", 550], ["liver", 561], ["failure", 567], [".", 574], ["He", 576], ["died", 579], ["of", 584], ["sepsis", 587], ["at", 594], ["four", 597], ["months", 602], ["old", 609], ["while", 613], ["awaiting", 619], ["liver", 628], ["transplantation", 634], [".", 649], ["The", 651], ["phenotype", 655], ["of", 665], ["neonatal", 668], ["diabetes", 677], ["with", 686], ["intestinal", 691], ["atresia", 702], ["and", 710], ["biliary", 714], ["agenesis", 722], ["clearly", 731], ["pointed", 739], ["to", 747], ["RFX6", 750], ["as", 755], ["the", 758], ["causative", 762], ["gene", 772], [";", 776], ["indeed", 778], [",", 784], ["whole", 786], ["exome", 792], ["sequencing", 798], ["revealed", 809], ["a", 818], ["novel", 820], ["homozygous", 826], ["RFX6", 837], ["mutation", 842], ["c.779A", 851], [">", 857], ["C", 858], [";", 859], ["p", 861], [".", 862], ["Lys260Thr", 863], ["(", 873], ["K260", 874], ["T", 878], [")", 879], [".", 880], ["This", 882], ["missense", 887], ["mutation", 896], ["also", 905], ["changes", 910], ["the", 918], ["consensus", 922], ["5", 932], ["'", 933], ["splice", 935], ["donor", 942], ["site", 948], ["before", 953], ["intron", 960], ["7", 967], ["and", 969], ["is", 973], ["thus", 976], ["predicted", 981], ["to", 991], ["cause", 994], ["disruption", 1000], ["in", 1011], ["splicing", 1014], [".", 1022], ["Both", 1024], ["parents", 1029], [",", 1036], ["who", 1038], ["were", 1042], ["not", 1047], ["known", 1051], ["to", 1057], ["be", 1060], ["related", 1063], [",", 1070], ["were", 1072], ["heterozygous", 1077], ["carriers", 1090], [".", 1098], ["Targeted", 1100], ["genetic", 1109], ["testing", 1117], ["based", 1125], ["on", 1131], ["consideration", 1134], ["of", 1148], ["phenotypic", 1151], ["features", 1162], ["may", 1171], ["reveal", 1175], ["a", 1182], ["cause", 1184], ["among", 1190], ["the", 1196], ["many", 1200], ["genes", 1205], ["now", 1211], ["associated", 1215], ["with", 1226], ["heterogeneous", 1231], ["forms", 1245], ["of", 1251], ["monogenic", 1254], ["neonatal", 1264], ["diabetes", 1273], [".", 1281], ["Our", 1283], ["study", 1287], ["demonstrates", 1293], ["the", 1306], ["feasibility", 1310], ["of", 1322], ["using", 1325], ["modern", 1331], ["sequencing", 1338], ["technology", 1349], ["to", 1360], ["identify", 1363], ["one", 1372], ["such", 1376], ["rare", 1381], ["cause", 1386], [".", 1391], ["Continued", 1393], ["research", 1403], ["is", 1412], ["needed", 1415], ["to", 1422], ["determine", 1425], ["the", 1435], ["possible", 1439], ["cost", 1448], ["-", 1452], ["effectiveness", 1453], ["of", 1467], ["this", 1470], ["approach", 1475], [",", 1483], ["especially", 1485], ["when", 1496], ["clear", 1501], ["phenotypic", 1507], ["clues", 1518], ["are", 1524], ["absent", 1528], [".", 1534], ["Further", 1536], ["study", 1544], ["of", 1550], ["patients", 1553], ["with", 1562], ["RFX6", 1567], ["mutations", 1572], ["should", 1582], ["clarify", 1589], ["its", 1597], ["role", 1601], ["in", 1606], ["pancreatic", 1609], [",", 1619], ["intestinal", 1621], ["and", 1632], ["enteroendocrine", 1636], ["cellular", 1652], ["development", 1661], ["and", 1673], ["explain", 1677], ["features", 1685], ["such", 1694], ["as", 1699], ["the", 1702], ["diarrhea", 1706], ["exhibited", 1715], ["in", 1725], ["our", 1728], ["case", 1732], [".", 1736]]}
{"context": "MicroRNAs (miRNAs) are 21 nt RNAs that regulate many biological processes in plants by mediating translational inhibition or cleavage of target transcripts. Arabidopsis mutants defective in miRNA biogenesis have overlapping and highly pleiotropic phenotypes including serrated leaves and ABA hypersensitivity. Recent evidence indicates that miRNA genes are transcribed by RNA polymerase II (Pol II). Since Pol II transcripts are capped, we hypothesized that CBP (cap-binding protein) 20 and 80 may bind to capped primary miRNA (pri-miRNA) transcripts and play a role in their processing. Here, we show that cbp20 and cbp80 mutants have reduced miRNA levels and increased pri-miRNA levels. Co-immunoprecipitation experiments revealed that pri-miRNAs 159, 166, 168 and 172 could be associated with CBP20 and CBP80. We found that CBP20 and CBP80 are stabilized by ABA by a post-translational mechanism, and these proteins are needed for ABA induction of miR159 during seed germination. The lack of miR159 accumulation in ABA-treated seeds of cbp20/80 mutants leads to increased MYB33 and MYB101 transcript levels, and presumably higher levels of these positive regulators result in ABA hypersensitivity. Genetic and molecular analyses show that CBP20 and 80 have overlapping function in the same developmental pathway as SE and HYL1. Our results identify new components in miRNA biogenesis.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "f8691bdd04254433a162cdef7998689e", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[53, 55]], "char_spans": [[372, 388]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["21", 23], ["nt", 26], ["RNAs", 29], ["that", 34], ["regulate", 39], ["many", 48], ["biological", 53], ["processes", 64], ["in", 74], ["plants", 77], ["by", 84], ["mediating", 87], ["translational", 97], ["inhibition", 111], ["or", 122], ["cleavage", 125], ["of", 134], ["target", 137], ["transcripts", 144], [".", 155], ["Arabidopsis", 157], ["mutants", 169], ["defective", 177], ["in", 187], ["miRNA", 190], ["biogenesis", 196], ["have", 207], ["overlapping", 212], ["and", 224], ["highly", 228], ["pleiotropic", 235], ["phenotypes", 247], ["including", 258], ["serrated", 268], ["leaves", 277], ["and", 284], ["ABA", 288], ["hypersensitivity", 292], [".", 308], ["Recent", 310], ["evidence", 317], ["indicates", 326], ["that", 336], ["miRNA", 341], ["genes", 347], ["are", 353], ["transcribed", 357], ["by", 369], ["RNA", 372], ["polymerase", 376], ["II", 387], ["(", 390], ["Pol", 391], ["II", 395], [")", 397], [".", 398], ["Since", 400], ["Pol", 406], ["II", 410], ["transcripts", 413], ["are", 425], ["capped", 429], [",", 435], ["we", 437], ["hypothesized", 440], ["that", 453], ["CBP", 458], ["(", 462], ["cap", 463], ["-", 466], ["binding", 467], ["protein", 475], [")", 482], ["20", 484], ["and", 487], ["80", 491], ["may", 494], ["bind", 498], ["to", 503], ["capped", 506], ["primary", 513], ["miRNA", 521], ["(", 527], ["pri", 528], ["-", 531], ["miRNA", 532], [")", 537], ["transcripts", 539], ["and", 551], ["play", 555], ["a", 560], ["role", 562], ["in", 567], ["their", 570], ["processing", 576], [".", 586], ["Here", 588], [",", 592], ["we", 594], ["show", 597], ["that", 602], ["cbp20", 607], ["and", 613], ["cbp80", 617], ["mutants", 623], ["have", 631], ["reduced", 636], ["miRNA", 644], ["levels", 650], ["and", 657], ["increased", 661], ["pri", 671], ["-", 674], ["miRNA", 675], ["levels", 681], [".", 687], ["Co", 689], ["-", 691], ["immunoprecipitation", 692], ["experiments", 712], ["revealed", 724], ["that", 733], ["pri", 738], ["-", 741], ["miRNAs", 742], ["159", 749], [",", 752], ["166", 754], [",", 757], ["168", 759], ["and", 763], ["172", 767], ["could", 771], ["be", 777], ["associated", 780], ["with", 791], ["CBP20", 796], ["and", 802], ["CBP80", 806], [".", 811], ["We", 813], ["found", 816], ["that", 822], ["CBP20", 827], ["and", 833], ["CBP80", 837], ["are", 843], ["stabilized", 847], ["by", 858], ["ABA", 861], ["by", 865], ["a", 868], ["post", 870], ["-", 874], ["translational", 875], ["mechanism", 889], [",", 898], ["and", 900], ["these", 904], ["proteins", 910], ["are", 919], ["needed", 923], ["for", 930], ["ABA", 934], ["induction", 938], ["of", 948], ["miR159", 951], ["during", 958], ["seed", 965], ["germination", 970], [".", 981], ["The", 983], ["lack", 987], ["of", 992], ["miR159", 995], ["accumulation", 1002], ["in", 1015], ["ABA", 1018], ["-", 1021], ["treated", 1022], ["seeds", 1030], ["of", 1036], ["cbp20/80", 1039], ["mutants", 1048], ["leads", 1056], ["to", 1062], ["increased", 1065], ["MYB33", 1075], ["and", 1081], ["MYB101", 1085], ["transcript", 1092], ["levels", 1103], [",", 1109], ["and", 1111], ["presumably", 1115], ["higher", 1126], ["levels", 1133], ["of", 1140], ["these", 1143], ["positive", 1149], ["regulators", 1158], ["result", 1169], ["in", 1176], ["ABA", 1179], ["hypersensitivity", 1183], [".", 1199], ["Genetic", 1201], ["and", 1209], ["molecular", 1213], ["analyses", 1223], ["show", 1232], ["that", 1237], ["CBP20", 1242], ["and", 1248], ["80", 1252], ["have", 1255], ["overlapping", 1260], ["function", 1272], ["in", 1281], ["the", 1284], ["same", 1288], ["developmental", 1293], ["pathway", 1307], ["as", 1315], ["SE", 1318], ["and", 1321], ["HYL1", 1325], [".", 1329], ["Our", 1331], ["results", 1335], ["identify", 1343], ["new", 1352], ["components", 1356], ["in", 1367], ["miRNA", 1370], ["biogenesis", 1376], [".", 1386]]}
{"context": "Dear sir, one of the most common entrapment neuropathy syndromes in clinical practice is \"Entrapment of median nerve in carpal tunnel\" also called \"Carpal tunnel syndrome (CTS)\" (Aydin et al., 2007; Huisstede et al., 2010). This syndrome is caused by entrapment of the median nerve in the wrist (Preston and Shapiro, 2005) when the pressure increases in the carpal tunnel. A high division of the median nerve proximal to the carpal tunnel, also known as a bifid median nerve, is a rare anatomic variation that may be associated with CTS and with persistent median vessels (Lanz, 1977). This anatomic variation has an incidence of 0,8% to 2,3% in patients with CTS. Lanz (1977) has characterized this anatomic condition of the median nerve in the carpal tunnel. These anatomic variants have been classified into four groups: - Group 0: extraligamentous thenar branch (standard anatomy); - Group 1: variations of the course of the thenar branch; - Group 2: accessory branches at the distal portion of the carpal tunnel; - Group 3: divided or duplicated median nerve inside the carpal tunnel; - Group 4: accessory branches proximal to the carpal tunnel. During dissection of the wrist performed for the treatment of a CTS under local anesthesia, we found an anatomical variation of the median nerve that was divided in two branches inside the carpal tunnel (Group 3 of Lanz Classification) and in which its radial branch passed through its own compartment. The two parts of the nerve seems to be unequal in size (Fig. 1). Moreover the nerve passed in carpal tunnel associated with a median artery, so we classified this variation in the group 3b of Lanz Classification (Fig. 2). The persistence of median artery coexisting with a bifid median nerve has been widely reported in surgical literature (Lanz, 1977; Barbe et al., 2005). Before surgical intervention clinical evaluation of patient and electrophysiological examination showed no differences compared to a non bifid median nerve entrapment syndrome. In conclusion the bifid median nerve may facilitate compression of median nerve in the carpal tunnel because of its increased cross sectional area even if it has no electrophysiological or clinical differential diagnosis in case of CTS. The aim of this letter is aware the physicians in order to borne in mind the possible presence of a median nerve variation during dissection of carpal tunnel in order to avoid the damage of this non common anatomical structures.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "0460fb3061fd40ec8e30bfca61c596bb", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[256, 256], [385, 385], [315, 315], [339, 339], [58, 58], [150, 150], [214, 214], [394, 394], [84, 84], [400, 400], [345, 345], [448, 448], [18, 18], [114, 114], [97, 97]], "char_spans": [[1283, 1288], [1971, 1976], [1580, 1585], [1695, 1700], [269, 274], [726, 731], [1051, 1056], [2029, 2034], [396, 401], [2072, 2077], [1733, 1738], [2342, 2347], [104, 109], [557, 562], [462, 467]]}]}], "context_tokens": [["Dear", 0], ["sir", 5], [",", 8], ["one", 10], ["of", 14], ["the", 17], ["most", 21], ["common", 26], ["entrapment", 33], ["neuropathy", 44], ["syndromes", 55], ["in", 65], ["clinical", 68], ["practice", 77], ["is", 86], ["\"", 89], ["Entrapment", 90], ["of", 101], ["median", 104], ["nerve", 111], ["in", 117], ["carpal", 120], ["tunnel", 127], ["\"", 133], ["also", 135], ["called", 140], ["\"", 147], ["Carpal", 148], ["tunnel", 155], ["syndrome", 162], ["(", 171], ["CTS", 172], [")", 175], ["\"", 176], ["(", 178], ["Aydin", 179], ["et", 185], ["al", 188], [".", 190], [",", 191], ["2007", 193], [";", 197], ["Huisstede", 199], ["et", 209], ["al", 212], [".", 214], [",", 215], ["2010", 217], [")", 221], [".", 222], ["This", 224], ["syndrome", 229], ["is", 238], ["caused", 241], ["by", 248], ["entrapment", 251], ["of", 262], ["the", 265], ["median", 269], ["nerve", 276], ["in", 282], ["the", 285], ["wrist", 289], ["(", 295], ["Preston", 296], ["and", 304], ["Shapiro", 308], [",", 315], ["2005", 317], [")", 321], ["when", 323], ["the", 328], ["pressure", 332], ["increases", 341], ["in", 351], ["the", 354], ["carpal", 358], ["tunnel", 365], [".", 371], ["A", 373], ["high", 375], ["division", 380], ["of", 389], ["the", 392], ["median", 396], ["nerve", 403], ["proximal", 409], ["to", 418], ["the", 421], ["carpal", 425], ["tunnel", 432], [",", 438], ["also", 440], ["known", 445], ["as", 451], ["a", 454], ["bifid", 456], ["median", 462], ["nerve", 469], [",", 474], ["is", 476], ["a", 479], ["rare", 481], ["anatomic", 486], ["variation", 495], ["that", 505], ["may", 510], ["be", 514], ["associated", 517], ["with", 528], ["CTS", 533], ["and", 537], ["with", 541], ["persistent", 546], ["median", 557], ["vessels", 564], ["(", 572], ["Lanz", 573], [",", 577], ["1977", 579], [")", 583], [".", 584], ["This", 586], ["anatomic", 591], ["variation", 600], ["has", 610], ["an", 614], ["incidence", 617], ["of", 627], ["0,8", 630], ["%", 633], ["to", 635], ["2,3", 638], ["%", 641], ["in", 643], ["patients", 646], ["with", 655], ["CTS", 660], [".", 663], ["Lanz", 665], ["(", 670], ["1977", 671], [")", 675], ["has", 677], ["characterized", 681], ["this", 695], ["anatomic", 700], ["condition", 709], ["of", 719], ["the", 722], ["median", 726], ["nerve", 733], ["in", 739], ["the", 742], ["carpal", 746], ["tunnel", 753], [".", 759], ["These", 761], ["anatomic", 767], ["variants", 776], ["have", 785], ["been", 790], ["classified", 795], ["into", 806], ["four", 811], ["groups", 816], [":", 822], ["-", 824], ["Group", 826], ["0", 832], [":", 833], ["extraligamentous", 835], ["thenar", 852], ["branch", 859], ["(", 866], ["standard", 867], ["anatomy", 876], [")", 883], [";", 884], ["-", 886], ["Group", 888], ["1", 894], [":", 895], ["variations", 897], ["of", 908], ["the", 911], ["course", 915], ["of", 922], ["the", 925], ["thenar", 929], ["branch", 936], [";", 942], ["-", 944], ["Group", 946], ["2", 952], [":", 953], ["accessory", 955], ["branches", 965], ["at", 974], ["the", 977], ["distal", 981], ["portion", 988], ["of", 996], ["the", 999], ["carpal", 1003], ["tunnel", 1010], [";", 1016], ["-", 1018], ["Group", 1020], ["3", 1026], [":", 1027], ["divided", 1029], ["or", 1037], ["duplicated", 1040], ["median", 1051], ["nerve", 1058], ["inside", 1064], ["the", 1071], ["carpal", 1075], ["tunnel", 1082], [";", 1088], ["-", 1090], ["Group", 1092], ["4", 1098], [":", 1099], ["accessory", 1101], ["branches", 1111], ["proximal", 1120], ["to", 1129], ["the", 1132], ["carpal", 1136], ["tunnel", 1143], [".", 1149], ["During", 1151], ["dissection", 1158], ["of", 1169], ["the", 1172], ["wrist", 1176], ["performed", 1182], ["for", 1192], ["the", 1196], ["treatment", 1200], ["of", 1210], ["a", 1213], ["CTS", 1215], ["under", 1219], ["local", 1225], ["anesthesia", 1231], [",", 1241], ["we", 1243], ["found", 1246], ["an", 1252], ["anatomical", 1255], ["variation", 1266], ["of", 1276], ["the", 1279], ["median", 1283], ["nerve", 1290], ["that", 1296], ["was", 1301], ["divided", 1305], ["in", 1313], ["two", 1316], ["branches", 1320], ["inside", 1329], ["the", 1336], ["carpal", 1340], ["tunnel", 1347], ["(", 1354], ["Group", 1355], ["3", 1361], ["of", 1363], ["Lanz", 1366], ["Classification", 1371], [")", 1385], ["and", 1387], ["in", 1391], ["which", 1394], ["its", 1400], ["radial", 1404], ["branch", 1411], ["passed", 1418], ["through", 1425], ["its", 1433], ["own", 1437], ["compartment", 1441], [".", 1452], ["The", 1454], ["two", 1458], ["parts", 1462], ["of", 1468], ["the", 1471], ["nerve", 1475], ["seems", 1481], ["to", 1487], ["be", 1490], ["unequal", 1493], ["in", 1501], ["size", 1504], ["(", 1509], ["Fig", 1510], [".", 1513], ["1", 1515], [")", 1516], [".", 1517], ["Moreover", 1519], ["the", 1528], ["nerve", 1532], ["passed", 1538], ["in", 1545], ["carpal", 1548], ["tunnel", 1555], ["associated", 1562], ["with", 1573], ["a", 1578], ["median", 1580], ["artery", 1587], [",", 1593], ["so", 1595], ["we", 1598], ["classified", 1601], ["this", 1612], ["variation", 1617], ["in", 1627], ["the", 1630], ["group", 1634], ["3b", 1640], ["of", 1643], ["Lanz", 1646], ["Classification", 1651], ["(", 1666], ["Fig", 1667], [".", 1670], ["2", 1672], [")", 1673], [".", 1674], ["The", 1676], ["persistence", 1680], ["of", 1692], ["median", 1695], ["artery", 1702], ["coexisting", 1709], ["with", 1720], ["a", 1725], ["bifid", 1727], ["median", 1733], ["nerve", 1740], ["has", 1746], ["been", 1750], ["widely", 1755], ["reported", 1762], ["in", 1771], ["surgical", 1774], ["literature", 1783], ["(", 1794], ["Lanz", 1795], [",", 1799], ["1977", 1801], [";", 1805], ["Barbe", 1807], ["et", 1813], ["al", 1816], [".", 1818], [",", 1819], ["2005", 1821], [")", 1825], [".", 1826], ["Before", 1828], ["surgical", 1835], ["intervention", 1844], ["clinical", 1857], ["evaluation", 1866], ["of", 1877], ["patient", 1880], ["and", 1888], ["electrophysiological", 1892], ["examination", 1913], ["showed", 1925], ["no", 1932], ["differences", 1935], ["compared", 1947], ["to", 1956], ["a", 1959], ["non", 1961], ["bifid", 1965], ["median", 1971], ["nerve", 1978], ["entrapment", 1984], ["syndrome", 1995], [".", 2003], ["In", 2005], ["conclusion", 2008], ["the", 2019], ["bifid", 2023], ["median", 2029], ["nerve", 2036], ["may", 2042], ["facilitate", 2046], ["compression", 2057], ["of", 2069], ["median", 2072], ["nerve", 2079], ["in", 2085], ["the", 2088], ["carpal", 2092], ["tunnel", 2099], ["because", 2106], ["of", 2114], ["its", 2117], ["increased", 2121], ["cross", 2131], ["sectional", 2137], ["area", 2147], ["even", 2152], ["if", 2157], ["it", 2160], ["has", 2163], ["no", 2167], ["electrophysiological", 2170], ["or", 2191], ["clinical", 2194], ["differential", 2203], ["diagnosis", 2216], ["in", 2226], ["case", 2229], ["of", 2234], ["CTS", 2237], [".", 2240], ["The", 2242], ["aim", 2246], ["of", 2250], ["this", 2253], ["letter", 2258], ["is", 2265], ["aware", 2268], ["the", 2274], ["physicians", 2278], ["in", 2289], ["order", 2292], ["to", 2298], ["borne", 2301], ["in", 2307], ["mind", 2310], ["the", 2315], ["possible", 2319], ["presence", 2328], ["of", 2337], ["a", 2340], ["median", 2342], ["nerve", 2349], ["variation", 2355], ["during", 2365], ["dissection", 2372], ["of", 2383], ["carpal", 2386], ["tunnel", 2393], ["in", 2400], ["order", 2403], ["to", 2409], ["avoid", 2412], ["the", 2418], ["damage", 2422], ["of", 2429], ["this", 2432], ["non", 2437], ["common", 2441], ["anatomical", 2448], ["structures", 2459], [".", 2469]]}
{"context": "Natively disordered proteins are a growing class of anomalies to the structure-function paradigm. The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. We noticed a dramatic difference in dilute solution 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra of wild-type alpha-synuclein and two disease-related mutants (A30P and A53T), with spectra collected at 35 degrees C showing fewer cross-peaks than spectra acquired at 10 degrees C. Here, we show the change to be the result of a reversible conformational exchange linked to an increase in hydrodynamic radius and secondary structure as the temperature is raised. Combined with analytical ultracentrifugation data showing alpha-synuclein to be monomeric at both temperatures, we conclude that the poor quality of the 1H-15N HSQC spectra obtained at 35 degrees C is due to conformational fluctuations that occur on the proton chemical shift time scale. Using a truncated variant of alpha-synuclein, we show the conformational exchange occurs in the first 100 amino acids of the protein. Our data illustrate a key difference between globular and natively disordered proteins. The properties of globular proteins change little with solution conditions until they denature cooperatively, but the properties of natively disordered proteins can vary dramatically with solution conditions.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8af93cd51edd4155854b8bc805023cf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[132, 134], [60, 62], [20, 22], [178, 180]], "char_spans": [[767, 781], [359, 373], [130, 144], [1026, 1040]]}]}], "context_tokens": [["Natively", 0], ["disordered", 9], ["proteins", 20], ["are", 29], ["a", 33], ["growing", 35], ["class", 43], ["of", 49], ["anomalies", 52], ["to", 62], ["the", 65], ["structure", 69], ["-", 78], ["function", 79], ["paradigm", 88], [".", 96], ["The", 98], ["natively", 102], ["disordered", 111], ["protein", 122], ["alpha", 130], ["-", 135], ["synuclein", 136], ["is", 146], ["the", 149], ["primary", 153], ["component", 161], ["of", 171], ["Lewy", 174], ["bodies", 179], [",", 185], ["the", 187], ["cellular", 191], ["hallmark", 200], ["of", 209], ["Parkinson", 212], ["'s", 221], ["disease", 224], [".", 231], ["We", 233], ["noticed", 236], ["a", 244], ["dramatic", 246], ["difference", 255], ["in", 266], ["dilute", 269], ["solution", 276], ["1H-15N", 285], ["Heteronuclear", 292], ["Single", 306], ["Quantum", 313], ["Coherence", 321], ["(", 331], ["HSQC", 332], [")", 336], ["spectra", 338], ["of", 346], ["wild", 349], ["-", 353], ["type", 354], ["alpha", 359], ["-", 364], ["synuclein", 365], ["and", 375], ["two", 379], ["disease", 383], ["-", 390], ["related", 391], ["mutants", 399], ["(", 407], ["A30P", 408], ["and", 413], ["A53", 417], ["T", 420], [")", 421], [",", 422], ["with", 424], ["spectra", 429], ["collected", 437], ["at", 447], ["35", 450], ["degrees", 453], ["C", 461], ["showing", 463], ["fewer", 471], ["cross", 477], ["-", 482], ["peaks", 483], ["than", 489], ["spectra", 494], ["acquired", 502], ["at", 511], ["10", 514], ["degrees", 517], ["C.", 525], ["Here", 528], [",", 532], ["we", 534], ["show", 537], ["the", 542], ["change", 546], ["to", 553], ["be", 556], ["the", 559], ["result", 563], ["of", 570], ["a", 573], ["reversible", 575], ["conformational", 586], ["exchange", 601], ["linked", 610], ["to", 617], ["an", 620], ["increase", 623], ["in", 632], ["hydrodynamic", 635], ["radius", 648], ["and", 655], ["secondary", 659], ["structure", 669], ["as", 679], ["the", 682], ["temperature", 686], ["is", 698], ["raised", 701], [".", 707], ["Combined", 709], ["with", 718], ["analytical", 723], ["ultracentrifugation", 734], ["data", 754], ["showing", 759], ["alpha", 767], ["-", 772], ["synuclein", 773], ["to", 783], ["be", 786], ["monomeric", 789], ["at", 799], ["both", 802], ["temperatures", 807], [",", 819], ["we", 821], ["conclude", 824], ["that", 833], ["the", 838], ["poor", 842], ["quality", 847], ["of", 855], ["the", 858], ["1H-15N", 862], ["HSQC", 869], ["spectra", 874], ["obtained", 882], ["at", 891], ["35", 894], ["degrees", 897], ["C", 905], ["is", 907], ["due", 910], ["to", 914], ["conformational", 917], ["fluctuations", 932], ["that", 945], ["occur", 950], ["on", 956], ["the", 959], ["proton", 963], ["chemical", 970], ["shift", 979], ["time", 985], ["scale", 990], [".", 995], ["Using", 997], ["a", 1003], ["truncated", 1005], ["variant", 1015], ["of", 1023], ["alpha", 1026], ["-", 1031], ["synuclein", 1032], [",", 1041], ["we", 1043], ["show", 1046], ["the", 1051], ["conformational", 1055], ["exchange", 1070], ["occurs", 1079], ["in", 1086], ["the", 1089], ["first", 1093], ["100", 1099], ["amino", 1103], ["acids", 1109], ["of", 1115], ["the", 1118], ["protein", 1122], [".", 1129], ["Our", 1131], ["data", 1135], ["illustrate", 1140], ["a", 1151], ["key", 1153], ["difference", 1157], ["between", 1168], ["globular", 1176], ["and", 1185], ["natively", 1189], ["disordered", 1198], ["proteins", 1209], [".", 1217], ["The", 1219], ["properties", 1223], ["of", 1234], ["globular", 1237], ["proteins", 1246], ["change", 1255], ["little", 1262], ["with", 1269], ["solution", 1274], ["conditions", 1283], ["until", 1294], ["they", 1300], ["denature", 1305], ["cooperatively", 1314], [",", 1327], ["but", 1329], ["the", 1333], ["properties", 1337], ["of", 1348], ["natively", 1351], ["disordered", 1360], ["proteins", 1371], ["can", 1380], ["vary", 1384], ["dramatically", 1389], ["with", 1402], ["solution", 1407], ["conditions", 1416], [".", 1426]]}
{"context": "To investigate the clinicopathologic features of focal cortical dysplasia (FCD) in patients with refractory epilepsy. The clinical, radiologic and pathologic features of 38 cases of FCD receiving surgical treatment in 2005 were reviewed retrospectively. The mean age of disease onset was 9.2 years. The disease lasted for 11.9 years on average and often presented as complex partial seizure. Radiologic examination revealed hippocampal sclerosis, or abnormal signals in the grey matter in 21 cases. According to Palmini's classification system, the following pathologic subgroups were identified: FCD type IA (3/38), FCD type IB (20/38), FCD type IIA (5/38) and FCD type IIB (5/38). The remaining 5 cases were classified as mild cortical dysplasia. Topographically, FCD type II was often seen in the extratemporal region (8/10), predominantly in the frontal lobe (5/8). Dual pathology was identified only in cases with FCD type IB. Immunohistochemical study showed that the giant neurons, immature neurons and dysmorphic neurons were strongly positive for NeuN. A small number of balloon cells expressed nestin. FCD is a common cause of refractory epilepsy. FCD type IB is the predominant pathologic subtype. Associated hippocampal sclerosis is sometimes seen. Clinicopathologic differences between FCD type I and FCD type II are observed.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "c273e4acf5d244feb5d5fca095c0254f", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[6, 8]], "char_spans": [[49, 72]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["clinicopathologic", 19], ["features", 37], ["of", 46], ["focal", 49], ["cortical", 55], ["dysplasia", 64], ["(", 74], ["FCD", 75], [")", 78], ["in", 80], ["patients", 83], ["with", 92], ["refractory", 97], ["epilepsy", 108], [".", 116], ["The", 118], ["clinical", 122], [",", 130], ["radiologic", 132], ["and", 143], ["pathologic", 147], ["features", 158], ["of", 167], ["38", 170], ["cases", 173], ["of", 179], ["FCD", 182], ["receiving", 186], ["surgical", 196], ["treatment", 205], ["in", 215], ["2005", 218], ["were", 223], ["reviewed", 228], ["retrospectively", 237], [".", 252], ["The", 254], ["mean", 258], ["age", 263], ["of", 267], ["disease", 270], ["onset", 278], ["was", 284], ["9.2", 288], ["years", 292], [".", 297], ["The", 299], ["disease", 303], ["lasted", 311], ["for", 318], ["11.9", 322], ["years", 327], ["on", 333], ["average", 336], ["and", 344], ["often", 348], ["presented", 354], ["as", 364], ["complex", 367], ["partial", 375], ["seizure", 383], [".", 390], ["Radiologic", 392], ["examination", 403], ["revealed", 415], ["hippocampal", 424], ["sclerosis", 436], [",", 445], ["or", 447], ["abnormal", 450], ["signals", 459], ["in", 467], ["the", 470], ["grey", 474], ["matter", 479], ["in", 486], ["21", 489], ["cases", 492], [".", 497], ["According", 499], ["to", 509], ["Palmini", 512], ["'s", 519], ["classification", 522], ["system", 537], [",", 543], ["the", 545], ["following", 549], ["pathologic", 559], ["subgroups", 570], ["were", 580], ["identified", 585], [":", 595], ["FCD", 597], ["type", 601], ["IA", 606], ["(", 609], ["3/38", 610], [")", 614], [",", 615], ["FCD", 617], ["type", 621], ["IB", 626], ["(", 629], ["20/38", 630], [")", 635], [",", 636], ["FCD", 638], ["type", 642], ["IIA", 647], ["(", 651], ["5/38", 652], [")", 656], ["and", 658], ["FCD", 662], ["type", 666], ["IIB", 671], ["(", 675], ["5/38", 676], [")", 680], [".", 681], ["The", 683], ["remaining", 687], ["5", 697], ["cases", 699], ["were", 705], ["classified", 710], ["as", 721], ["mild", 724], ["cortical", 729], ["dysplasia", 738], [".", 747], ["Topographically", 749], [",", 764], ["FCD", 766], ["type", 770], ["II", 775], ["was", 778], ["often", 782], ["seen", 788], ["in", 793], ["the", 796], ["extratemporal", 800], ["region", 814], ["(", 821], ["8/10", 822], [")", 826], [",", 827], ["predominantly", 829], ["in", 843], ["the", 846], ["frontal", 850], ["lobe", 858], ["(", 863], ["5/8", 864], [")", 867], [".", 868], ["Dual", 870], ["pathology", 875], ["was", 885], ["identified", 889], ["only", 900], ["in", 905], ["cases", 908], ["with", 914], ["FCD", 919], ["type", 923], ["IB", 928], [".", 930], ["Immunohistochemical", 932], ["study", 952], ["showed", 958], ["that", 965], ["the", 970], ["giant", 974], ["neurons", 980], [",", 987], ["immature", 989], ["neurons", 998], ["and", 1006], ["dysmorphic", 1010], ["neurons", 1021], ["were", 1029], ["strongly", 1034], ["positive", 1043], ["for", 1052], ["NeuN.", 1056], ["A", 1062], ["small", 1064], ["number", 1070], ["of", 1077], ["balloon", 1080], ["cells", 1088], ["expressed", 1094], ["nestin", 1104], [".", 1110], ["FCD", 1112], ["is", 1116], ["a", 1119], ["common", 1121], ["cause", 1128], ["of", 1134], ["refractory", 1137], ["epilepsy", 1148], [".", 1156], ["FCD", 1158], ["type", 1162], ["IB", 1167], ["is", 1170], ["the", 1173], ["predominant", 1177], ["pathologic", 1189], ["subtype", 1200], [".", 1207], ["Associated", 1209], ["hippocampal", 1220], ["sclerosis", 1232], ["is", 1242], ["sometimes", 1245], ["seen", 1255], [".", 1259], ["Clinicopathologic", 1261], ["differences", 1279], ["between", 1291], ["FCD", 1299], ["type", 1303], ["I", 1308], ["and", 1310], ["FCD", 1314], ["type", 1318], ["II", 1323], ["are", 1326], ["observed", 1330], [".", 1338]]}
{"context": "The aim of the study was to determine the frequency and type of MRSA strains and antibiotic susceptibility in Al-Zahra Hospital, Isfahan, Iran. In an analytic descriptive survey in 2005 and early 2006, patients admitted to the hospital who contracted S. aureus nosocomial infections were enrolled in the study. All isolates were identified by the conventional laboratory tests. Minimal Inhibitory Concentration (MIC) of oxacillin on isolated bacteria was determined by E-Test method. According to Clinical and Laboratory Standard Institute (CLSI) criteria all strains with MIC of > or = 4 microg for oxacillin were identified as MRSA. Intrinsic high level resistance (mecA positive) and borderline oxacillin resistant Staphylococcus aureus (BORSA) were detected by amoxicillin-clavulanate E-test strips. Strains with MIC of > or = 4 microg for oxacillin and > or = 8 microg for amoxicillin-clavulanate were identified as mecA positive MRSA. Other staphylococcus with MIC > or = 4 microg for oxacillin and < or = 4 for amoxicillin-clavulanate were identified as mecA negative MRSA (BORSA). MIC of vancomycin also was determined on isolated bacteria. Data were analyzed by SPSS version 13 and Who net version 5. Out of 134 Staphylococcus aureus samples which were isolated from nosocomial infections 90 (67.2%) were MRSA. Sixty seven out of 90 (74.5%) MRSA were mecA positive and 23 out of 90 (25.5%) were mecA negative (BORSA). Although most of the MRSA strains were isolated from surgical site infections, there were no statistically significant differences between types of Staphylococcus aureus growing from variant sites of infections. Only one (1.49) of the mecA positive MRSA had reduced susceptibility to vancomycin but all of the mecA-negative MRSA (BORSA) were sensitive to it. Because one fourth of our staphylococcus strains are mecA negative BORSA and there is no alternative for vancomycin against mecA positive MRSA and Enterococcus spp. in our hospital, vancomycin should be reserved only for life threatening infections due to these organisms. Thus MRSA typing should be done to choose appropriate antibiotic for optimal treatment of MRSA infections.", "qas": [{"question": "What is BORSA?", "answers": ["borderline oxacillin resistant Staphylococcus aureus", "Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "d3cb2ae20ed644fa9da62fd47344b395", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[122, 126]], "char_spans": [[687, 738]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["the", 11], ["study", 15], ["was", 21], ["to", 25], ["determine", 28], ["the", 38], ["frequency", 42], ["and", 52], ["type", 56], ["of", 61], ["MRSA", 64], ["strains", 69], ["and", 77], ["antibiotic", 81], ["susceptibility", 92], ["in", 107], ["Al", 110], ["-", 112], ["Zahra", 113], ["Hospital", 119], [",", 127], ["Isfahan", 129], [",", 136], ["Iran", 138], [".", 142], ["In", 144], ["an", 147], ["analytic", 150], ["descriptive", 159], ["survey", 171], ["in", 178], ["2005", 181], ["and", 186], ["early", 190], ["2006", 196], [",", 200], ["patients", 202], ["admitted", 211], ["to", 220], ["the", 223], ["hospital", 227], ["who", 236], ["contracted", 240], ["S.", 251], ["aureus", 254], ["nosocomial", 261], ["infections", 272], ["were", 283], ["enrolled", 288], ["in", 297], ["the", 300], ["study", 304], [".", 309], ["All", 311], ["isolates", 315], ["were", 324], ["identified", 329], ["by", 340], ["the", 343], ["conventional", 347], ["laboratory", 360], ["tests", 371], [".", 376], ["Minimal", 378], ["Inhibitory", 386], ["Concentration", 397], ["(", 411], ["MIC", 412], [")", 415], ["of", 417], ["oxacillin", 420], ["on", 430], ["isolated", 433], ["bacteria", 442], ["was", 451], ["determined", 455], ["by", 466], ["E", 469], ["-", 470], ["Test", 471], ["method", 476], [".", 482], ["According", 484], ["to", 494], ["Clinical", 497], ["and", 506], ["Laboratory", 510], ["Standard", 521], ["Institute", 530], ["(", 540], ["CLSI", 541], [")", 545], ["criteria", 547], ["all", 556], ["strains", 560], ["with", 568], ["MIC", 573], ["of", 577], [">", 580], ["or", 582], ["=", 585], ["4", 587], ["microg", 589], ["for", 596], ["oxacillin", 600], ["were", 610], ["identified", 615], ["as", 626], ["MRSA", 629], [".", 633], ["Intrinsic", 635], ["high", 645], ["level", 650], ["resistance", 656], ["(", 667], ["mecA", 668], ["positive", 673], [")", 681], ["and", 683], ["borderline", 687], ["oxacillin", 698], ["resistant", 708], ["Staphylococcus", 718], ["aureus", 733], ["(", 740], ["BORSA", 741], [")", 746], ["were", 748], ["detected", 753], ["by", 762], ["amoxicillin", 765], ["-", 776], ["clavulanate", 777], ["E", 789], ["-", 790], ["test", 791], ["strips", 796], [".", 802], ["Strains", 804], ["with", 812], ["MIC", 817], ["of", 821], [">", 824], ["or", 826], ["=", 829], ["4", 831], ["microg", 833], ["for", 840], ["oxacillin", 844], ["and", 854], [">", 858], ["or", 860], ["=", 863], ["8", 865], ["microg", 867], ["for", 874], ["amoxicillin", 878], ["-", 889], ["clavulanate", 890], ["were", 902], ["identified", 907], ["as", 918], ["mecA", 921], ["positive", 926], ["MRSA", 935], [".", 939], ["Other", 941], ["staphylococcus", 947], ["with", 962], ["MIC", 967], [">", 971], ["or", 973], ["=", 976], ["4", 978], ["microg", 980], ["for", 987], ["oxacillin", 991], ["and", 1001], ["<", 1005], ["or", 1007], ["=", 1010], ["4", 1012], ["for", 1014], ["amoxicillin", 1018], ["-", 1029], ["clavulanate", 1030], ["were", 1042], ["identified", 1047], ["as", 1058], ["mecA", 1061], ["negative", 1066], ["MRSA", 1075], ["(", 1080], ["BORSA", 1081], [")", 1086], [".", 1087], ["MIC", 1089], ["of", 1093], ["vancomycin", 1096], ["also", 1107], ["was", 1112], ["determined", 1116], ["on", 1127], ["isolated", 1130], ["bacteria", 1139], [".", 1147], ["Data", 1149], ["were", 1154], ["analyzed", 1159], ["by", 1168], ["SPSS", 1171], ["version", 1176], ["13", 1184], ["and", 1187], ["Who", 1191], ["net", 1195], ["version", 1199], ["5", 1207], [".", 1208], ["Out", 1210], ["of", 1214], ["134", 1217], ["Staphylococcus", 1221], ["aureus", 1236], ["samples", 1243], ["which", 1251], ["were", 1257], ["isolated", 1262], ["from", 1271], ["nosocomial", 1276], ["infections", 1287], ["90", 1298], ["(", 1301], ["67.2", 1302], ["%", 1306], [")", 1307], ["were", 1309], ["MRSA", 1314], [".", 1318], ["Sixty", 1320], ["seven", 1326], ["out", 1332], ["of", 1336], ["90", 1339], ["(", 1342], ["74.5", 1343], ["%", 1347], [")", 1348], ["MRSA", 1350], ["were", 1355], ["mecA", 1360], ["positive", 1365], ["and", 1374], ["23", 1378], ["out", 1381], ["of", 1385], ["90", 1388], ["(", 1391], ["25.5", 1392], ["%", 1396], [")", 1397], ["were", 1399], ["mecA", 1404], ["negative", 1409], ["(", 1418], ["BORSA", 1419], [")", 1424], [".", 1425], ["Although", 1427], ["most", 1436], ["of", 1441], ["the", 1444], ["MRSA", 1448], ["strains", 1453], ["were", 1461], ["isolated", 1466], ["from", 1475], ["surgical", 1480], ["site", 1489], ["infections", 1494], [",", 1504], ["there", 1506], ["were", 1512], ["no", 1517], ["statistically", 1520], ["significant", 1534], ["differences", 1546], ["between", 1558], ["types", 1566], ["of", 1572], ["Staphylococcus", 1575], ["aureus", 1590], ["growing", 1597], ["from", 1605], ["variant", 1610], ["sites", 1618], ["of", 1624], ["infections", 1627], [".", 1637], ["Only", 1639], ["one", 1644], ["(", 1648], ["1.49", 1649], [")", 1653], ["of", 1655], ["the", 1658], ["mecA", 1662], ["positive", 1667], ["MRSA", 1676], ["had", 1681], ["reduced", 1685], ["susceptibility", 1693], ["to", 1708], ["vancomycin", 1711], ["but", 1722], ["all", 1726], ["of", 1730], ["the", 1733], ["mecA", 1737], ["-", 1741], ["negative", 1742], ["MRSA", 1751], ["(", 1756], ["BORSA", 1757], [")", 1762], ["were", 1764], ["sensitive", 1769], ["to", 1779], ["it", 1782], [".", 1784], ["Because", 1786], ["one", 1794], ["fourth", 1798], ["of", 1805], ["our", 1808], ["staphylococcus", 1812], ["strains", 1827], ["are", 1835], ["mecA", 1839], ["negative", 1844], ["BORSA", 1853], ["and", 1859], ["there", 1863], ["is", 1869], ["no", 1872], ["alternative", 1875], ["for", 1887], ["vancomycin", 1891], ["against", 1902], ["mecA", 1910], ["positive", 1915], ["MRSA", 1924], ["and", 1929], ["Enterococcus", 1933], ["spp", 1946], [".", 1949], ["in", 1951], ["our", 1954], ["hospital", 1958], [",", 1966], ["vancomycin", 1968], ["should", 1979], ["be", 1986], ["reserved", 1989], ["only", 1998], ["for", 2003], ["life", 2007], ["threatening", 2012], ["infections", 2024], ["due", 2035], ["to", 2039], ["these", 2042], ["organisms", 2048], [".", 2057], ["Thus", 2059], ["MRSA", 2064], ["typing", 2069], ["should", 2076], ["be", 2083], ["done", 2086], ["to", 2091], ["choose", 2094], ["appropriate", 2101], ["antibiotic", 2113], ["for", 2124], ["optimal", 2128], ["treatment", 2136], ["of", 2146], ["MRSA", 2149], ["infections", 2154], [".", 2164]]}
{"context": "Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "0f0142c6d85345b6ad31f47e1f7b98d4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[144, 144], [96, 96], [10, 10], [76, 76], [47, 47]], "char_spans": [[856, 865], [577, 586], [44, 53], [429, 438], [286, 295]]}]}], "context_tokens": [["Non", 0], ["-", 3], ["vitamin", 4], ["K", 12], ["anticoagulants", 14], ["(", 29], ["NOAC", 30], [")", 34], ["such", 36], ["as", 41], ["dabigatran", 44], ["have", 55], ["become", 60], ["important", 67], ["therapeutic", 77], ["options", 89], ["for", 97], ["the", 101], ["prevention", 105], ["of", 116], ["stroke", 119], [".", 125], ["Until", 127], ["recently", 133], [",", 141], ["there", 143], ["were", 149], ["only", 154], ["nonspecific", 159], ["agents", 171], ["to", 178], ["reverse", 181], ["their", 189], ["anticoagulant", 195], ["effects", 209], ["in", 217], ["a", 220], ["case", 222], ["of", 227], ["emergency", 230], [".", 239], ["Idarucizumab", 241], [",", 253], ["an", 255], ["antibody", 258], ["fragment", 267], ["targeting", 276], ["dabigatran", 286], [",", 296], ["is", 298], ["the", 301], ["first", 305], ["specific", 311], ["antidote", 320], ["for", 329], ["a", 333], ["NOAC", 335], ["to", 340], ["be", 343], ["approved", 346], [",", 354], ["but", 356], ["real", 360], ["-", 364], ["world", 365], ["experience", 371], ["is", 382], ["limited", 385], [".", 392], ["We", 394], ["report", 397], ["two", 404], ["cases", 408], ["of", 414], ["patients", 417], ["on", 426], ["dabigatran", 429], ["with", 440], ["acute", 445], ["intracerebral", 451], ["hemorrhage", 465], ["who", 476], ["received", 480], ["idarucizumab", 489], [".", 501], ["In", 503], ["both", 506], ["cases", 511], [",", 516], ["idarucizumab", 518], ["promptly", 531], ["reversed", 540], ["the", 549], ["anticoagulant", 553], ["effect", 567], ["of", 574], ["dabigatran", 577], ["and", 588], ["there", 592], ["was", 598], ["no", 602], ["hematoma", 605], ["expansion", 614], ["in", 624], ["follow", 627], ["-", 633], ["up", 634], ["imaging", 637], [".", 644], ["In", 646], ["addition", 649], ["to", 658], ["clinical", 661], ["and", 670], ["preclinical", 674], ["studies", 686], [",", 693], ["our", 695], ["cases", 699], ["add", 705], ["to", 709], ["the", 712], ["experience", 716], ["regarding", 727], ["the", 737], ["safety", 741], ["and", 748], ["efficacy", 752], ["of", 761], ["idarucizumab", 764], [".", 776], ["They", 778], ["show", 783], ["that", 788], ["idarucizumab", 793], ["may", 806], ["be", 810], ["an", 813], ["important", 816], ["safety", 826], ["option", 833], ["for", 840], ["patients", 844], ["on", 853], ["dabigatran", 856], ["in", 867], ["emergency", 870], ["situations", 880], [".", 890]]}
{"context": "Adaptive (stationary phase) mutagenesis is a phenomenon by which nondividing cells acquire beneficial mutations as a response to stress. Although the generation of adaptive mutations is essentially stochastic, genetic factors are involved in this phenomenon. We examined how defects in a transcriptional factor, previously reported to alter the acquisition of adaptive mutations, affected mutation levels in a gene under selection. The acquisition of mutations was directly correlated to the level of transcription of a defective leuC allele placed under selection. To further examine the correlation between transcription and adaptive mutation, we placed a point-mutated allele, leuC427, under the control of an inducible promoter and assayed the level of reversion to leucine prototrophy under conditions of leucine starvation. Our results demonstrate that the level of Leu(+) reversions increased significantly in parallel with the induced increase in transcription levels. This mutagenic response was not observed under conditions of exponential growth. Since transcription is a ubiquitous biological process, transcription-associated mutagenesis may influence evolutionary processes in all organisms.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase"], "qid": "ec31bfcdb41d4c6f9c960d1d6c2dbf2c", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[2, 3]], "char_spans": [[10, 25]]}]}], "context_tokens": [["Adaptive", 0], ["(", 9], ["stationary", 10], ["phase", 21], [")", 26], ["mutagenesis", 28], ["is", 40], ["a", 43], ["phenomenon", 45], ["by", 56], ["which", 59], ["nondividing", 65], ["cells", 77], ["acquire", 83], ["beneficial", 91], ["mutations", 102], ["as", 112], ["a", 115], ["response", 117], ["to", 126], ["stress", 129], [".", 135], ["Although", 137], ["the", 146], ["generation", 150], ["of", 161], ["adaptive", 164], ["mutations", 173], ["is", 183], ["essentially", 186], ["stochastic", 198], [",", 208], ["genetic", 210], ["factors", 218], ["are", 226], ["involved", 230], ["in", 239], ["this", 242], ["phenomenon", 247], [".", 257], ["We", 259], ["examined", 262], ["how", 271], ["defects", 275], ["in", 283], ["a", 286], ["transcriptional", 288], ["factor", 304], [",", 310], ["previously", 312], ["reported", 323], ["to", 332], ["alter", 335], ["the", 341], ["acquisition", 345], ["of", 357], ["adaptive", 360], ["mutations", 369], [",", 378], ["affected", 380], ["mutation", 389], ["levels", 398], ["in", 405], ["a", 408], ["gene", 410], ["under", 415], ["selection", 421], [".", 430], ["The", 432], ["acquisition", 436], ["of", 448], ["mutations", 451], ["was", 461], ["directly", 465], ["correlated", 474], ["to", 485], ["the", 488], ["level", 492], ["of", 498], ["transcription", 501], ["of", 515], ["a", 518], ["defective", 520], ["leuC", 530], ["allele", 535], ["placed", 542], ["under", 549], ["selection", 555], [".", 564], ["To", 566], ["further", 569], ["examine", 577], ["the", 585], ["correlation", 589], ["between", 601], ["transcription", 609], ["and", 623], ["adaptive", 627], ["mutation", 636], [",", 644], ["we", 646], ["placed", 649], ["a", 656], ["point", 658], ["-", 663], ["mutated", 664], ["allele", 672], [",", 678], ["leuC427", 680], [",", 687], ["under", 689], ["the", 695], ["control", 699], ["of", 707], ["an", 710], ["inducible", 713], ["promoter", 723], ["and", 732], ["assayed", 736], ["the", 744], ["level", 748], ["of", 754], ["reversion", 757], ["to", 767], ["leucine", 770], ["prototrophy", 778], ["under", 790], ["conditions", 796], ["of", 807], ["leucine", 810], ["starvation", 818], [".", 828], ["Our", 830], ["results", 834], ["demonstrate", 842], ["that", 854], ["the", 859], ["level", 863], ["of", 869], ["Leu(+", 872], [")", 877], ["reversions", 879], ["increased", 890], ["significantly", 900], ["in", 914], ["parallel", 917], ["with", 926], ["the", 931], ["induced", 935], ["increase", 943], ["in", 952], ["transcription", 955], ["levels", 969], [".", 975], ["This", 977], ["mutagenic", 982], ["response", 992], ["was", 1001], ["not", 1005], ["observed", 1009], ["under", 1018], ["conditions", 1024], ["of", 1035], ["exponential", 1038], ["growth", 1050], [".", 1056], ["Since", 1058], ["transcription", 1064], ["is", 1078], ["a", 1081], ["ubiquitous", 1083], ["biological", 1094], ["process", 1105], [",", 1112], ["transcription", 1114], ["-", 1127], ["associated", 1128], ["mutagenesis", 1139], ["may", 1151], ["influence", 1155], ["evolutionary", 1165], ["processes", 1178], ["in", 1188], ["all", 1191], ["organisms", 1195], [".", 1204]]}
{"context": "High circulating levels of group IIA secretory phospholipase A2 (sPLA2-IIA) activity and mass are independent cardiovascular risk factors. Therefore, inhibition of sPLA2-IIA may be a target for the treatment of atherosclerotic cardiovascular disease. The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (apoB)/human cholesteryl ester transfer protein (CETP)/human sPLA2-IIA triple transgenic mice (TTT) fed a Western-type diet. sPLA2-IIA expression increased atherosclerotic lesion formation in TTT compared with human apoB/human CETP double transgenic mice (P<0.01). Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity. In the TTT model, sPLA2-IIA decreased CETP activity by reducing the acceptor properties of sPLA2-IIA-modified very low-density lipoproteins specifically because of a significantly lower apoE content. Increasing very low-density lipoprotein-apoE content by means of adenovirus-mediated gene transfer in sPLA2-IIA transgenic mice restored the acceptor properties for CETP. These data show that in a humanized triple transgenic mouse model with hypercholesterolemia, sPLA2-IIA inhibition increases CETP activity via increasing the very low-density lipoprotein-apoE content, resulting in a proatherogenic lipoprotein profile.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9f57803776af4b0bbe0deae68fbd40b0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[6, 8]], "char_spans": [[37, 62]]}]}], "context_tokens": [["High", 0], ["circulating", 5], ["levels", 17], ["of", 24], ["group", 27], ["IIA", 33], ["secretory", 37], ["phospholipase", 47], ["A2", 61], ["(", 64], ["sPLA2-IIA", 65], [")", 74], ["activity", 76], ["and", 85], ["mass", 89], ["are", 94], ["independent", 98], ["cardiovascular", 110], ["risk", 125], ["factors", 130], [".", 137], ["Therefore", 139], [",", 148], ["inhibition", 150], ["of", 161], ["sPLA2-IIA", 164], ["may", 174], ["be", 178], ["a", 181], ["target", 183], ["for", 190], ["the", 194], ["treatment", 198], ["of", 208], ["atherosclerotic", 211], ["cardiovascular", 227], ["disease", 242], [".", 249], ["The", 251], ["present", 255], ["study", 263], ["evaluated", 269], ["the", 279], ["effects", 283], ["of", 291], ["sPLA2-IIA", 294], ["inhibition", 304], ["with", 315], ["varespladib", 320], ["acid", 332], ["in", 337], ["a", 340], ["novel", 342], ["mouse", 348], ["model", 354], [",", 359], ["human", 361], ["apolipoprotein", 367], ["B", 382], ["(", 384], ["apoB)/human", 385], ["cholesteryl", 397], ["ester", 409], ["transfer", 415], ["protein", 424], ["(", 432], ["CETP)/human", 433], ["sPLA2-IIA", 445], ["triple", 455], ["transgenic", 462], ["mice", 473], ["(", 478], ["TTT", 479], [")", 482], ["fed", 484], ["a", 488], ["Western", 490], ["-", 497], ["type", 498], ["diet", 503], [".", 507], ["sPLA2-IIA", 509], ["expression", 519], ["increased", 530], ["atherosclerotic", 540], ["lesion", 556], ["formation", 563], ["in", 573], ["TTT", 576], ["compared", 580], ["with", 589], ["human", 594], ["apoB", 600], ["/", 604], ["human", 605], ["CETP", 611], ["double", 616], ["transgenic", 623], ["mice", 634], ["(", 639], ["P<0.01", 640], [")", 646], [".", 647], ["Varespladib", 649], ["acid", 661], ["effectively", 666], ["inhibited", 678], ["plasma", 688], ["sPLA2-IIA", 695], ["activity", 705], [".", 713], ["Surprisingly", 715], [",", 727], ["however", 729], [",", 736], ["administration", 738], ["of", 753], ["varespladib", 756], ["acid", 768], ["to", 773], ["TTT", 776], ["had", 780], ["no", 784], ["impact", 787], ["on", 794], ["atherosclerosis", 797], [",", 812], ["which", 814], ["could", 820], ["be", 826], ["attributed", 829], ["to", 840], ["a", 843], ["proatherogenic", 845], ["plasma", 860], ["lipoprotein", 867], ["profile", 879], ["that", 887], ["appears", 892], ["in", 900], ["response", 903], ["to", 912], ["sPLA2-IIA", 915], ["inhibition", 925], ["because", 936], ["of", 944], ["increased", 947], ["plasma", 957], ["CETP", 964], ["activity", 969], [".", 977], ["In", 979], ["the", 982], ["TTT", 986], ["model", 990], [",", 995], ["sPLA2-IIA", 997], ["decreased", 1007], ["CETP", 1017], ["activity", 1022], ["by", 1031], ["reducing", 1034], ["the", 1043], ["acceptor", 1047], ["properties", 1056], ["of", 1067], ["sPLA2-IIA", 1070], ["-", 1079], ["modified", 1080], ["very", 1089], ["low", 1094], ["-", 1097], ["density", 1098], ["lipoproteins", 1106], ["specifically", 1119], ["because", 1132], ["of", 1140], ["a", 1143], ["significantly", 1145], ["lower", 1159], ["apoE", 1165], ["content", 1170], [".", 1177], ["Increasing", 1179], ["very", 1190], ["low", 1195], ["-", 1198], ["density", 1199], ["lipoprotein", 1207], ["-", 1218], ["apoE", 1219], ["content", 1224], ["by", 1232], ["means", 1235], ["of", 1241], ["adenovirus", 1244], ["-", 1254], ["mediated", 1255], ["gene", 1264], ["transfer", 1269], ["in", 1278], ["sPLA2-IIA", 1281], ["transgenic", 1291], ["mice", 1302], ["restored", 1307], ["the", 1316], ["acceptor", 1320], ["properties", 1329], ["for", 1340], ["CETP", 1344], [".", 1348], ["These", 1350], ["data", 1356], ["show", 1361], ["that", 1366], ["in", 1371], ["a", 1374], ["humanized", 1376], ["triple", 1386], ["transgenic", 1393], ["mouse", 1404], ["model", 1410], ["with", 1416], ["hypercholesterolemia", 1421], [",", 1441], ["sPLA2-IIA", 1443], ["inhibition", 1453], ["increases", 1464], ["CETP", 1474], ["activity", 1479], ["via", 1488], ["increasing", 1492], ["the", 1503], ["very", 1507], ["low", 1512], ["-", 1515], ["density", 1516], ["lipoprotein", 1524], ["-", 1535], ["apoE", 1536], ["content", 1541], [",", 1548], ["resulting", 1550], ["in", 1560], ["a", 1563], ["proatherogenic", 1565], ["lipoprotein", 1580], ["profile", 1592], [".", 1599]]}
{"context": "Calcineurin, a Ca(2+)/calmodulin-stimulated protein phosphatase, plays a key role in T-cell activation by regulating the activity of NFAT (nuclear factor of activated T cells), a family of transcription factors required for the synthesis of several cytokine genes. Calcineurin is the target of the immunosuppressive drugs cyclosporin A and FK506 complexed with their cytoplasmic receptors cyclophilin and FKBP12, respectively. In this study we report that calcineurin is also the target of a recently identified Ca(2+)-binding protein, CHP (for calcineurin homologous protein), which shares a high degree of homology with the regulatory B subunit of calcineurin and with calmodulin. In Jurkat and HeLa cells, overexpression of CHP specifically impaired the nuclear translocation and transcriptional activity of NFAT but had no effect on AP-1 transcriptional activity and only a small (<25%) inhibitory effect on the transcriptional activity of NFkappaB. Further study indicated that CHP inhibits calcineurin activity. In cells overexpressing CHP, the phosphatase activity of immunoprecipitated calcineurin was inhibited by approximately 50%; and in a reconstituted assay, the activity of purified calcineurin was inhibited up to 97% by the addition of purified recombinant CHP in a dose-dependent manner. Moreover, prolonged activation of Jurkat cells was associated with a decreased abundance of CHP, suggesting a possible regulatory mechanism allowing activation of calcineurin. CHP, therefore, is a previously unrecognized endogenous inhibitor of calcineurin activity.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "e689ed17e25f4a969ae75153c594f23b", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [240, 240], [91, 91], [109, 109], [177, 177], [195, 195], [253, 253], [76, 76], [164, 164], [47, 47]], "char_spans": [[0, 10], [1468, 1478], [545, 555], [650, 660], [1094, 1104], [1197, 1207], [1550, 1560], [456, 466], [996, 1006], [265, 275]]}]}], "context_tokens": [["Calcineurin", 0], [",", 11], ["a", 13], ["Ca(2+)/calmodulin", 15], ["-", 32], ["stimulated", 33], ["protein", 44], ["phosphatase", 52], [",", 63], ["plays", 65], ["a", 71], ["key", 73], ["role", 77], ["in", 82], ["T", 85], ["-", 86], ["cell", 87], ["activation", 92], ["by", 103], ["regulating", 106], ["the", 117], ["activity", 121], ["of", 130], ["NFAT", 133], ["(", 138], ["nuclear", 139], ["factor", 147], ["of", 154], ["activated", 157], ["T", 167], ["cells", 169], [")", 174], [",", 175], ["a", 177], ["family", 179], ["of", 186], ["transcription", 189], ["factors", 203], ["required", 211], ["for", 220], ["the", 224], ["synthesis", 228], ["of", 238], ["several", 241], ["cytokine", 249], ["genes", 258], [".", 263], ["Calcineurin", 265], ["is", 277], ["the", 280], ["target", 284], ["of", 291], ["the", 294], ["immunosuppressive", 298], ["drugs", 316], ["cyclosporin", 322], ["A", 334], ["and", 336], ["FK506", 340], ["complexed", 346], ["with", 356], ["their", 361], ["cytoplasmic", 367], ["receptors", 379], ["cyclophilin", 389], ["and", 401], ["FKBP12", 405], [",", 411], ["respectively", 413], [".", 425], ["In", 427], ["this", 430], ["study", 435], ["we", 441], ["report", 444], ["that", 451], ["calcineurin", 456], ["is", 468], ["also", 471], ["the", 476], ["target", 480], ["of", 487], ["a", 490], ["recently", 492], ["identified", 501], ["Ca(2+)-binding", 512], ["protein", 527], [",", 534], ["CHP", 536], ["(", 540], ["for", 541], ["calcineurin", 545], ["homologous", 557], ["protein", 568], [")", 575], [",", 576], ["which", 578], ["shares", 584], ["a", 591], ["high", 593], ["degree", 598], ["of", 605], ["homology", 608], ["with", 617], ["the", 622], ["regulatory", 626], ["B", 637], ["subunit", 639], ["of", 647], ["calcineurin", 650], ["and", 662], ["with", 666], ["calmodulin", 671], [".", 681], ["In", 683], ["Jurkat", 686], ["and", 693], ["HeLa", 697], ["cells", 702], [",", 707], ["overexpression", 709], ["of", 724], ["CHP", 727], ["specifically", 731], ["impaired", 744], ["the", 753], ["nuclear", 757], ["translocation", 765], ["and", 779], ["transcriptional", 783], ["activity", 799], ["of", 808], ["NFAT", 811], ["but", 816], ["had", 820], ["no", 824], ["effect", 827], ["on", 834], ["AP-1", 837], ["transcriptional", 842], ["activity", 858], ["and", 867], ["only", 871], ["a", 876], ["small", 878], ["(", 884], ["<", 885], ["25", 886], ["%", 888], [")", 889], ["inhibitory", 891], ["effect", 902], ["on", 909], ["the", 912], ["transcriptional", 916], ["activity", 932], ["of", 941], ["NFkappaB.", 944], ["Further", 954], ["study", 962], ["indicated", 968], ["that", 978], ["CHP", 983], ["inhibits", 987], ["calcineurin", 996], ["activity", 1008], [".", 1016], ["In", 1018], ["cells", 1021], ["overexpressing", 1027], ["CHP", 1042], [",", 1045], ["the", 1047], ["phosphatase", 1051], ["activity", 1063], ["of", 1072], ["immunoprecipitated", 1075], ["calcineurin", 1094], ["was", 1106], ["inhibited", 1110], ["by", 1120], ["approximately", 1123], ["50", 1137], ["%", 1139], [";", 1140], ["and", 1142], ["in", 1146], ["a", 1149], ["reconstituted", 1151], ["assay", 1165], [",", 1170], ["the", 1172], ["activity", 1176], ["of", 1185], ["purified", 1188], ["calcineurin", 1197], ["was", 1209], ["inhibited", 1213], ["up", 1223], ["to", 1226], ["97", 1229], ["%", 1231], ["by", 1233], ["the", 1236], ["addition", 1240], ["of", 1249], ["purified", 1252], ["recombinant", 1261], ["CHP", 1273], ["in", 1277], ["a", 1280], ["dose", 1282], ["-", 1286], ["dependent", 1287], ["manner", 1297], [".", 1303], ["Moreover", 1305], [",", 1313], ["prolonged", 1315], ["activation", 1325], ["of", 1336], ["Jurkat", 1339], ["cells", 1346], ["was", 1352], ["associated", 1356], ["with", 1367], ["a", 1372], ["decreased", 1374], ["abundance", 1384], ["of", 1394], ["CHP", 1397], [",", 1400], ["suggesting", 1402], ["a", 1413], ["possible", 1415], ["regulatory", 1424], ["mechanism", 1435], ["allowing", 1445], ["activation", 1454], ["of", 1465], ["calcineurin", 1468], [".", 1479], ["CHP", 1481], [",", 1484], ["therefore", 1486], [",", 1495], ["is", 1497], ["a", 1500], ["previously", 1502], ["unrecognized", 1513], ["endogenous", 1526], ["inhibitor", 1537], ["of", 1547], ["calcineurin", 1550], ["activity", 1562], [".", 1570]]}
{"context": "Flumazenil is a benzodiazepine antagonist. It is widely used as an antidote in comatose patients suspected of having ingested a benzodiazepine overdose. Flumazenil is known to induce cardiac arythmias and seizures, in part because of drug interactions. We present a 75-year-old woman, who was brought to the Emergency Department with a drug overdose following a suicide attempt. She developed generalized seizures shortly after the administration of flumazenil.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b31d0f65b3754a4091a4d59b39e2a6a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[24, 24], [0, 0], [74, 74]], "char_spans": [[153, 162], [0, 9], [450, 459]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["benzodiazepine", 16], ["antagonist", 31], [".", 41], ["It", 43], ["is", 46], ["widely", 49], ["used", 56], ["as", 61], ["an", 64], ["antidote", 67], ["in", 76], ["comatose", 79], ["patients", 88], ["suspected", 97], ["of", 107], ["having", 110], ["ingested", 117], ["a", 126], ["benzodiazepine", 128], ["overdose", 143], [".", 151], ["Flumazenil", 153], ["is", 164], ["known", 167], ["to", 173], ["induce", 176], ["cardiac", 183], ["arythmias", 191], ["and", 201], ["seizures", 205], [",", 213], ["in", 215], ["part", 218], ["because", 223], ["of", 231], ["drug", 234], ["interactions", 239], [".", 251], ["We", 253], ["present", 256], ["a", 264], ["75-year", 266], ["-", 273], ["old", 274], ["woman", 278], [",", 283], ["who", 285], ["was", 289], ["brought", 293], ["to", 301], ["the", 304], ["Emergency", 308], ["Department", 318], ["with", 329], ["a", 334], ["drug", 336], ["overdose", 341], ["following", 350], ["a", 360], ["suicide", 362], ["attempt", 370], [".", 377], ["She", 379], ["developed", 383], ["generalized", 393], ["seizures", 405], ["shortly", 414], ["after", 422], ["the", 428], ["administration", 432], ["of", 447], ["flumazenil", 450], [".", 460]]}
{"context": "Despite that deep brain stimulation (DBS) of the globus pallidus internus (GPi) is emerging as the favored intervention for patients with medically intractable dystonia, the pathophysiological mechanisms of dystonia are largely unclear. In eight patients with primary dystonia who were treated with bilateral chronic pallidal stimulation, we correlated symptom-related electromyogram (EMG) activity of the most affected muscles with the local field potentials (LFPs) recorded from the globus pallidus electrodes. In 5 dystonic patients with mobile involuntary movements, rhythmic EMG bursts in the contralateral muscles were coherent with the oscillations in the pallidal LFPs at the burst frequency. In contrast, no significant coherence was seen between EMG and LFPs either for the sustained activity separated out from the compound EMGs in those 5 cases, or in the EMGs in 3 other cases without mobile involuntary movements and rhythmic EMG bursts. In comparison with the resting condition, in both active and passive movements, significant modulation in the GPi LFPs was seen in the range of 8-16 Hz. The finding of significant coherence between GPi oscillations and rhythmic EMG bursts but not sustained tonic EMG activity suggests that the synchronized pallidal activity may be directly related to the rhythmic involuntary movements. In contrast, the sustained hypertonic muscle activity may be represented by less synchronized activity in the pallidum. Thus, the pallidum may play different roles in generating different components of the dystonic symptom complex.", "qas": [{"question": "Neurostimulation of which nucleus is used for treatment of dystonia?", "answers": ["globus pallidus internus"], "qid": "f2a831f2a3fc46d1a5b456712da85b80", "question_tokens": [["Neurostimulation", 0], ["of", 17], ["which", 20], ["nucleus", 26], ["is", 34], ["used", 37], ["for", 42], ["treatment", 46], ["of", 56], ["dystonia", 59], ["?", 67]], "detected_answers": [{"text": "globus pallidus internus", "token_spans": [[10, 12]], "char_spans": [[49, 72]]}]}], "context_tokens": [["Despite", 0], ["that", 8], ["deep", 13], ["brain", 18], ["stimulation", 24], ["(", 36], ["DBS", 37], [")", 40], ["of", 42], ["the", 45], ["globus", 49], ["pallidus", 56], ["internus", 65], ["(", 74], ["GPi", 75], [")", 78], ["is", 80], ["emerging", 83], ["as", 92], ["the", 95], ["favored", 99], ["intervention", 107], ["for", 120], ["patients", 124], ["with", 133], ["medically", 138], ["intractable", 148], ["dystonia", 160], [",", 168], ["the", 170], ["pathophysiological", 174], ["mechanisms", 193], ["of", 204], ["dystonia", 207], ["are", 216], ["largely", 220], ["unclear", 228], [".", 235], ["In", 237], ["eight", 240], ["patients", 246], ["with", 255], ["primary", 260], ["dystonia", 268], ["who", 277], ["were", 281], ["treated", 286], ["with", 294], ["bilateral", 299], ["chronic", 309], ["pallidal", 317], ["stimulation", 326], [",", 337], ["we", 339], ["correlated", 342], ["symptom", 353], ["-", 360], ["related", 361], ["electromyogram", 369], ["(", 384], ["EMG", 385], [")", 388], ["activity", 390], ["of", 399], ["the", 402], ["most", 406], ["affected", 411], ["muscles", 420], ["with", 428], ["the", 433], ["local", 437], ["field", 443], ["potentials", 449], ["(", 460], ["LFPs", 461], [")", 465], ["recorded", 467], ["from", 476], ["the", 481], ["globus", 485], ["pallidus", 492], ["electrodes", 501], [".", 511], ["In", 513], ["5", 516], ["dystonic", 518], ["patients", 527], ["with", 536], ["mobile", 541], ["involuntary", 548], ["movements", 560], [",", 569], ["rhythmic", 571], ["EMG", 580], ["bursts", 584], ["in", 591], ["the", 594], ["contralateral", 598], ["muscles", 612], ["were", 620], ["coherent", 625], ["with", 634], ["the", 639], ["oscillations", 643], ["in", 656], ["the", 659], ["pallidal", 663], ["LFPs", 672], ["at", 677], ["the", 680], ["burst", 684], ["frequency", 690], [".", 699], ["In", 701], ["contrast", 704], [",", 712], ["no", 714], ["significant", 717], ["coherence", 729], ["was", 739], ["seen", 743], ["between", 748], ["EMG", 756], ["and", 760], ["LFPs", 764], ["either", 769], ["for", 776], ["the", 780], ["sustained", 784], ["activity", 794], ["separated", 803], ["out", 813], ["from", 817], ["the", 822], ["compound", 826], ["EMGs", 835], ["in", 840], ["those", 843], ["5", 849], ["cases", 851], [",", 856], ["or", 858], ["in", 861], ["the", 864], ["EMGs", 868], ["in", 873], ["3", 876], ["other", 878], ["cases", 884], ["without", 890], ["mobile", 898], ["involuntary", 905], ["movements", 917], ["and", 927], ["rhythmic", 931], ["EMG", 940], ["bursts", 944], [".", 950], ["In", 952], ["comparison", 955], ["with", 966], ["the", 971], ["resting", 975], ["condition", 983], [",", 992], ["in", 994], ["both", 997], ["active", 1002], ["and", 1009], ["passive", 1013], ["movements", 1021], [",", 1030], ["significant", 1032], ["modulation", 1044], ["in", 1055], ["the", 1058], ["GPi", 1062], ["LFPs", 1066], ["was", 1071], ["seen", 1075], ["in", 1080], ["the", 1083], ["range", 1087], ["of", 1093], ["8", 1096], ["-", 1097], ["16", 1098], ["Hz", 1101], [".", 1103], ["The", 1105], ["finding", 1109], ["of", 1117], ["significant", 1120], ["coherence", 1132], ["between", 1142], ["GPi", 1150], ["oscillations", 1154], ["and", 1167], ["rhythmic", 1171], ["EMG", 1180], ["bursts", 1184], ["but", 1191], ["not", 1195], ["sustained", 1199], ["tonic", 1209], ["EMG", 1215], ["activity", 1219], ["suggests", 1228], ["that", 1237], ["the", 1242], ["synchronized", 1246], ["pallidal", 1259], ["activity", 1268], ["may", 1277], ["be", 1281], ["directly", 1284], ["related", 1293], ["to", 1301], ["the", 1304], ["rhythmic", 1308], ["involuntary", 1317], ["movements", 1329], [".", 1338], ["In", 1340], ["contrast", 1343], [",", 1351], ["the", 1353], ["sustained", 1357], ["hypertonic", 1367], ["muscle", 1378], ["activity", 1385], ["may", 1394], ["be", 1398], ["represented", 1401], ["by", 1413], ["less", 1416], ["synchronized", 1421], ["activity", 1434], ["in", 1443], ["the", 1446], ["pallidum", 1450], [".", 1458], ["Thus", 1460], [",", 1464], ["the", 1466], ["pallidum", 1470], ["may", 1479], ["play", 1483], ["different", 1488], ["roles", 1498], ["in", 1504], ["generating", 1507], ["different", 1518], ["components", 1528], ["of", 1539], ["the", 1542], ["dystonic", 1546], ["symptom", 1555], ["complex", 1563], [".", 1570]]}
{"context": "Alzheimer's disease (AD) is the most common cause of dementia in humans. A pathological hallmark in the brain of an AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP). Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD. For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants. Selective silencing of these mutant alleles holds therapeutic promise for AD. Here we show that the expression of the mutant APPs was selectively inhibited by RNA interference. The best selectivity was obtained when the mismatches were centrally placed in the antisense strand of small interfering RNAs. Introducing an additional mismatch in the antisense strand may improve the selectivity. The addition of a G at 5' end of the antisense strand may enhance the efficacy of gene silencing by RNA interference. Our results illustrate the guiding principles for selection of targeted sequences to achieve allele-specific silencing. The sequences that are effective to silence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD development.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "7f2e06512c64492fae5b7778eda5946f", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "AD", "token_spans": [[269, 269], [92, 92], [4, 4], [73, 73], [135, 135], [24, 24]], "char_spans": [[1472, 1473], [479, 480], [21, 22], [367, 368], [702, 703], [116, 117]]}]}], "context_tokens": [["Alzheimer", 0], ["'s", 9], ["disease", 12], ["(", 20], ["AD", 21], [")", 23], ["is", 25], ["the", 28], ["most", 32], ["common", 37], ["cause", 44], ["of", 50], ["dementia", 53], ["in", 62], ["humans", 65], [".", 71], ["A", 73], ["pathological", 75], ["hallmark", 88], ["in", 97], ["the", 100], ["brain", 104], ["of", 110], ["an", 113], ["AD", 116], ["patient", 119], ["is", 127], ["extracellular", 130], ["amyloid", 144], ["plaques", 152], ["formed", 160], ["by", 167], ["accumulated", 170], ["beta", 182], ["-", 186], ["amyloid", 187], ["protein", 195], ["(", 203], ["Abeta", 204], [")", 209], [",", 210], ["a", 212], ["metabolic", 214], ["product", 224], ["of", 232], ["amyloid", 235], ["precursor", 243], ["protein", 253], ["(", 261], ["APP", 262], [")", 265], [".", 266], ["Studies", 268], ["have", 276], ["revealed", 281], ["a", 290], ["strong", 292], ["genetic", 299], ["linkage", 307], ["in", 315], ["the", 318], ["early", 322], ["-", 327], ["onset", 328], ["familial", 334], ["form", 343], ["(", 348], ["<", 349], ["60", 350], ["years", 353], ["old", 359], [")", 362], ["of", 364], ["AD", 367], [".", 369], ["For", 371], ["example", 375], [",", 382], ["some", 384], ["mutant", 389], ["APPs", 396], ["are", 401], ["transmitted", 405], ["dominantly", 417], ["and", 428], ["are", 432], ["segregated", 436], ["with", 447], ["inheritance", 452], ["of", 464], ["early", 467], ["onset", 473], ["AD", 479], [".", 481], ["These", 483], ["mutants", 489], ["facilitate", 497], ["Abeta", 508], ["production", 514], [".", 524], ["The", 526], ["\"", 530], ["Swedish", 531], ["\"", 538], ["mutations", 540], ["(", 550], ["APP(SW", 551], [")", 557], [")", 558], ["and", 560], ["the", 564], ["\"", 568], ["London", 569], ["\"", 575], ["mutation", 577], ["(", 586], ["APP(LON", 587], [")", 594], [")", 595], ["are", 597], ["examples", 601], ["of", 610], ["these", 613], ["mutants", 619], [".", 626], ["Selective", 628], ["silencing", 638], ["of", 648], ["these", 651], ["mutant", 657], ["alleles", 664], ["holds", 672], ["therapeutic", 678], ["promise", 690], ["for", 698], ["AD", 702], [".", 704], ["Here", 706], ["we", 711], ["show", 714], ["that", 719], ["the", 724], ["expression", 728], ["of", 739], ["the", 742], ["mutant", 746], ["APPs", 753], ["was", 758], ["selectively", 762], ["inhibited", 774], ["by", 784], ["RNA", 787], ["interference", 791], [".", 803], ["The", 805], ["best", 809], ["selectivity", 814], ["was", 826], ["obtained", 830], ["when", 839], ["the", 844], ["mismatches", 848], ["were", 859], ["centrally", 864], ["placed", 874], ["in", 881], ["the", 884], ["antisense", 888], ["strand", 898], ["of", 905], ["small", 908], ["interfering", 914], ["RNAs", 926], [".", 930], ["Introducing", 932], ["an", 944], ["additional", 947], ["mismatch", 958], ["in", 967], ["the", 970], ["antisense", 974], ["strand", 984], ["may", 991], ["improve", 995], ["the", 1003], ["selectivity", 1007], [".", 1018], ["The", 1020], ["addition", 1024], ["of", 1033], ["a", 1036], ["G", 1038], ["at", 1040], ["5", 1043], ["'", 1044], ["end", 1046], ["of", 1050], ["the", 1053], ["antisense", 1057], ["strand", 1067], ["may", 1074], ["enhance", 1078], ["the", 1086], ["efficacy", 1090], ["of", 1099], ["gene", 1102], ["silencing", 1107], ["by", 1117], ["RNA", 1120], ["interference", 1124], [".", 1136], ["Our", 1138], ["results", 1142], ["illustrate", 1150], ["the", 1161], ["guiding", 1165], ["principles", 1173], ["for", 1184], ["selection", 1188], ["of", 1198], ["targeted", 1201], ["sequences", 1210], ["to", 1220], ["achieve", 1223], ["allele", 1231], ["-", 1237], ["specific", 1238], ["silencing", 1247], [".", 1256], ["The", 1258], ["sequences", 1262], ["that", 1272], ["are", 1277], ["effective", 1281], ["to", 1291], ["silence", 1294], ["APP(SW", 1302], [")", 1308], ["and", 1310], ["APP(LON", 1314], [")", 1321], ["as", 1323], ["identified", 1326], ["in", 1337], ["this", 1340], ["study", 1345], ["may", 1351], ["be", 1355], ["useful", 1358], ["in", 1365], ["both", 1368], ["in", 1373], ["vivo", 1376], ["and", 1381], ["in", 1385], ["vitro", 1388], ["studies", 1394], ["to", 1402], ["investigate", 1405], ["the", 1417], ["pathophysiological", 1421], ["role", 1440], ["of", 1445], ["APP(SW", 1448], [")", 1454], ["and", 1456], ["APP(LON", 1460], [")", 1467], ["in", 1469], ["AD", 1472], ["development", 1475], [".", 1486]]}
{"context": "Aggregation of \u03b1-synuclein (\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson's disease, arises when the normally soluble intrinsically disordered protein converts to amyloid fibrils. In this work, we provide a mechanistic view of the role of N-terminal acetylation on fibrillation by first establishing a quantitative relationship between monomer secondary structural propensity and fibril assembly kinetics, and secondly by demonstrating in the N-terminal acetylated form of the early onset A53T mutation, that N-terminal transient helices formed and/or inhibited by N-terminal acetylation modulate the fibril assembly rates. Using NMR chemical shifts and fluorescence experiments, we report that secondary structural propensity in residues 5-8, 14-31, and 50-57 are highly correlated to fibril growth rate. A four-way comparison of secondary structure propensity and fibril growth rates of N-terminally acetylated A53T and WT \u03b1Syn with non-acetylated A53T and WT \u03b1Syn present novel mechanistic insight into the role of N-terminal acetylation in amyloid fibril formation. We show that N-terminal acetylation inhibits the formation of the \"fibrillation promoting\" transient helix at residues 14-31 resulting from the A53T mutation in the non-acetylated variant and supports the formation of the \"fibrillation inhibiting\" transient helix in residues 1-12 thereby resulting in slower fibrillation rates relative to the previously studied non-acetylated A53T variant. Our results highlight the critical interplay of the region-specific transient secondary structure of the N-terminal region with fibrillation, and the inhibitory role of the N-terminal acetyl group in fibril formation.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "98e46197609848b39e1fb5db6b9f7fa8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[2, 4]], "char_spans": [[15, 25]]}, {"text": "\u03b1Syn", "token_spans": [[169, 169], [178, 178], [6, 6]], "char_spans": [[967, 970], [1004, 1007], [28, 31]]}]}], "context_tokens": [["Aggregation", 0], ["of", 12], ["\u03b1", 15], ["-", 16], ["synuclein", 17], ["(", 27], ["\u03b1Syn", 28], [")", 32], [",", 33], ["the", 35], ["primary", 39], ["protein", 47], ["component", 55], ["in", 65], ["Lewy", 68], ["body", 73], ["inclusions", 78], ["of", 89], ["patients", 92], ["with", 101], ["Parkinson", 106], ["'s", 115], ["disease", 118], [",", 125], ["arises", 127], ["when", 134], ["the", 139], ["normally", 143], ["soluble", 152], ["intrinsically", 160], ["disordered", 174], ["protein", 185], ["converts", 193], ["to", 202], ["amyloid", 205], ["fibrils", 213], [".", 220], ["In", 222], ["this", 225], ["work", 230], [",", 234], ["we", 236], ["provide", 239], ["a", 247], ["mechanistic", 249], ["view", 261], ["of", 266], ["the", 269], ["role", 273], ["of", 278], ["N", 281], ["-", 282], ["terminal", 283], ["acetylation", 292], ["on", 304], ["fibrillation", 307], ["by", 320], ["first", 323], ["establishing", 329], ["a", 342], ["quantitative", 344], ["relationship", 357], ["between", 370], ["monomer", 378], ["secondary", 386], ["structural", 396], ["propensity", 407], ["and", 418], ["fibril", 422], ["assembly", 429], ["kinetics", 438], [",", 446], ["and", 448], ["secondly", 452], ["by", 461], ["demonstrating", 464], ["in", 478], ["the", 481], ["N", 485], ["-", 486], ["terminal", 487], ["acetylated", 496], ["form", 507], ["of", 512], ["the", 515], ["early", 519], ["onset", 525], ["A53", 531], ["T", 534], ["mutation", 536], [",", 544], ["that", 546], ["N", 551], ["-", 552], ["terminal", 553], ["transient", 562], ["helices", 572], ["formed", 580], ["and/or", 587], ["inhibited", 594], ["by", 604], ["N", 607], ["-", 608], ["terminal", 609], ["acetylation", 618], ["modulate", 630], ["the", 639], ["fibril", 643], ["assembly", 650], ["rates", 659], [".", 664], ["Using", 666], ["NMR", 672], ["chemical", 676], ["shifts", 685], ["and", 692], ["fluorescence", 696], ["experiments", 709], [",", 720], ["we", 722], ["report", 725], ["that", 732], ["secondary", 737], ["structural", 747], ["propensity", 758], ["in", 769], ["residues", 772], ["5", 781], ["-", 782], ["8", 783], [",", 784], ["14", 786], ["-", 788], ["31", 789], [",", 791], ["and", 793], ["50", 797], ["-", 799], ["57", 800], ["are", 803], ["highly", 807], ["correlated", 814], ["to", 825], ["fibril", 828], ["growth", 835], ["rate", 842], [".", 846], ["A", 848], ["four", 850], ["-", 854], ["way", 855], ["comparison", 859], ["of", 870], ["secondary", 873], ["structure", 883], ["propensity", 893], ["and", 904], ["fibril", 908], ["growth", 915], ["rates", 922], ["of", 928], ["N", 931], ["-", 932], ["terminally", 933], ["acetylated", 944], ["A53", 955], ["T", 958], ["and", 960], ["WT", 964], ["\u03b1Syn", 967], ["with", 972], ["non", 977], ["-", 980], ["acetylated", 981], ["A53", 992], ["T", 995], ["and", 997], ["WT", 1001], ["\u03b1Syn", 1004], ["present", 1009], ["novel", 1017], ["mechanistic", 1023], ["insight", 1035], ["into", 1043], ["the", 1048], ["role", 1052], ["of", 1057], ["N", 1060], ["-", 1061], ["terminal", 1062], ["acetylation", 1071], ["in", 1083], ["amyloid", 1086], ["fibril", 1094], ["formation", 1101], [".", 1110], ["We", 1112], ["show", 1115], ["that", 1120], ["N", 1125], ["-", 1126], ["terminal", 1127], ["acetylation", 1136], ["inhibits", 1148], ["the", 1157], ["formation", 1161], ["of", 1171], ["the", 1174], ["\"", 1178], ["fibrillation", 1179], ["promoting", 1192], ["\"", 1201], ["transient", 1203], ["helix", 1213], ["at", 1219], ["residues", 1222], ["14", 1231], ["-", 1233], ["31", 1234], ["resulting", 1237], ["from", 1247], ["the", 1252], ["A53", 1256], ["T", 1259], ["mutation", 1261], ["in", 1270], ["the", 1273], ["non", 1277], ["-", 1280], ["acetylated", 1281], ["variant", 1292], ["and", 1300], ["supports", 1304], ["the", 1313], ["formation", 1317], ["of", 1327], ["the", 1330], ["\"", 1334], ["fibrillation", 1335], ["inhibiting", 1348], ["\"", 1358], ["transient", 1360], ["helix", 1370], ["in", 1376], ["residues", 1379], ["1", 1388], ["-", 1389], ["12", 1390], ["thereby", 1393], ["resulting", 1401], ["in", 1411], ["slower", 1414], ["fibrillation", 1421], ["rates", 1434], ["relative", 1440], ["to", 1449], ["the", 1452], ["previously", 1456], ["studied", 1467], ["non", 1475], ["-", 1478], ["acetylated", 1479], ["A53", 1490], ["T", 1493], ["variant", 1495], [".", 1502], ["Our", 1504], ["results", 1508], ["highlight", 1516], ["the", 1526], ["critical", 1530], ["interplay", 1539], ["of", 1549], ["the", 1552], ["region", 1556], ["-", 1562], ["specific", 1563], ["transient", 1572], ["secondary", 1582], ["structure", 1592], ["of", 1602], ["the", 1605], ["N", 1609], ["-", 1610], ["terminal", 1611], ["region", 1620], ["with", 1627], ["fibrillation", 1632], [",", 1644], ["and", 1646], ["the", 1650], ["inhibitory", 1654], ["role", 1665], ["of", 1670], ["the", 1673], ["N", 1677], ["-", 1678], ["terminal", 1679], ["acetyl", 1688], ["group", 1695], ["in", 1701], ["fibril", 1704], ["formation", 1711], [".", 1720]]}
{"context": "Sedation is an important aspect of care for critically ill newborns. Proper sedation reduces stress during procedures such as mechanical ventilation. Midazolam, a short-acting benzodiazepine, is widely administered as a sedative in newborn intensive care units but is not without side effects. Three term newborns developed myoclonic-like abnormal movements after receiving midazolam. In one, flumazenil controlled the abnormal movements. Flumazenil is a potent benzodiazepine antagonist that competitively blocks the central effects of benzodiazepines. It can reverse the sedative effects of benzodiazepines occurring after diagnostic or therapeutic procedures or after benzodiazepine overdose. Flumazenil may be considered in cases of abnormal movements associated with midazolam. However, further studies are needed to provide guidelines for the administration of this drug in newborns.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "53789d187e204d27ba5d871adbcd3fd2", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[105, 105], [65, 65], [71, 71]], "char_spans": [[696, 705], [393, 402], [439, 448]]}]}], "context_tokens": [["Sedation", 0], ["is", 9], ["an", 12], ["important", 15], ["aspect", 25], ["of", 32], ["care", 35], ["for", 40], ["critically", 44], ["ill", 55], ["newborns", 59], [".", 67], ["Proper", 69], ["sedation", 76], ["reduces", 85], ["stress", 93], ["during", 100], ["procedures", 107], ["such", 118], ["as", 123], ["mechanical", 126], ["ventilation", 137], [".", 148], ["Midazolam", 150], [",", 159], ["a", 161], ["short", 163], ["-", 168], ["acting", 169], ["benzodiazepine", 176], [",", 190], ["is", 192], ["widely", 195], ["administered", 202], ["as", 215], ["a", 218], ["sedative", 220], ["in", 229], ["newborn", 232], ["intensive", 240], ["care", 250], ["units", 255], ["but", 261], ["is", 265], ["not", 268], ["without", 272], ["side", 280], ["effects", 285], [".", 292], ["Three", 294], ["term", 300], ["newborns", 305], ["developed", 314], ["myoclonic", 324], ["-", 333], ["like", 334], ["abnormal", 339], ["movements", 348], ["after", 358], ["receiving", 364], ["midazolam", 374], [".", 383], ["In", 385], ["one", 388], [",", 391], ["flumazenil", 393], ["controlled", 404], ["the", 415], ["abnormal", 419], ["movements", 428], [".", 437], ["Flumazenil", 439], ["is", 450], ["a", 453], ["potent", 455], ["benzodiazepine", 462], ["antagonist", 477], ["that", 488], ["competitively", 493], ["blocks", 507], ["the", 514], ["central", 518], ["effects", 526], ["of", 534], ["benzodiazepines", 537], [".", 552], ["It", 554], ["can", 557], ["reverse", 561], ["the", 569], ["sedative", 573], ["effects", 582], ["of", 590], ["benzodiazepines", 593], ["occurring", 609], ["after", 619], ["diagnostic", 625], ["or", 636], ["therapeutic", 639], ["procedures", 651], ["or", 662], ["after", 665], ["benzodiazepine", 671], ["overdose", 686], [".", 694], ["Flumazenil", 696], ["may", 707], ["be", 711], ["considered", 714], ["in", 725], ["cases", 728], ["of", 734], ["abnormal", 737], ["movements", 746], ["associated", 756], ["with", 767], ["midazolam", 772], [".", 781], ["However", 783], [",", 790], ["further", 792], ["studies", 800], ["are", 808], ["needed", 812], ["to", 819], ["provide", 822], ["guidelines", 830], ["for", 841], ["the", 845], ["administration", 849], ["of", 864], ["this", 867], ["drug", 872], ["in", 877], ["newborns", 880], [".", 888]]}
{"context": "We generated a genome-wide replication profile in the genome of Lachancea kluyveri and assessed the relationship between replication and base composition. This species diverged from Saccharomyces cerevisiae before the ancestral whole genome duplication. The genome comprises eight chromosomes among which a chromosomal arm of 1 Mb has a G + C-content much higher than the rest of the genome. We identified 252 active replication origins in L. kluyveri and found considerable divergence in origin location with S. cerevisiae and with Lachancea waltii. Although some global features of S. cerevisiae replication are conserved: Centromeres replicate early, whereas telomeres replicate late, we found that replication origins both in L. kluyveri and L. waltii do not behave as evolutionary fragile sites. In L. kluyveri, replication timing along chromosomes alternates between regions of early and late activating origins, except for the 1 Mb GC-rich chromosomal arm. This chromosomal arm contains an origin consensus motif different from other chromosomes and is replicated early during S-phase. We showed that precocious replication results from the specific absence of late firing origins in this chromosomal arm. In addition, we found a correlation between GC-content and distance from replication origins as well as a lack of replication-associated compositional skew between leading and lagging strands specifically in this GC-rich chromosomal arm. These findings suggest that the unusual base composition in the genome of L. kluyveri could be linked to replication.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "d8b6714eca6845d68ff4a83b405e4a77", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[174, 174], [103, 103], [142, 142]], "char_spans": [[1071, 1075], [647, 651], [884, 888]]}]}], "context_tokens": [["We", 0], ["generated", 3], ["a", 13], ["genome", 15], ["-", 21], ["wide", 22], ["replication", 27], ["profile", 39], ["in", 47], ["the", 50], ["genome", 54], ["of", 61], ["Lachancea", 64], ["kluyveri", 74], ["and", 83], ["assessed", 87], ["the", 96], ["relationship", 100], ["between", 113], ["replication", 121], ["and", 133], ["base", 137], ["composition", 142], [".", 153], ["This", 155], ["species", 160], ["diverged", 168], ["from", 177], ["Saccharomyces", 182], ["cerevisiae", 196], ["before", 207], ["the", 214], ["ancestral", 218], ["whole", 228], ["genome", 234], ["duplication", 241], [".", 252], ["The", 254], ["genome", 258], ["comprises", 265], ["eight", 275], ["chromosomes", 281], ["among", 293], ["which", 299], ["a", 305], ["chromosomal", 307], ["arm", 319], ["of", 323], ["1", 326], ["Mb", 328], ["has", 331], ["a", 335], ["G", 337], ["+", 339], ["C", 341], ["-", 342], ["content", 343], ["much", 351], ["higher", 356], ["than", 363], ["the", 368], ["rest", 372], ["of", 377], ["the", 380], ["genome", 384], [".", 390], ["We", 392], ["identified", 395], ["252", 406], ["active", 410], ["replication", 417], ["origins", 429], ["in", 437], ["L.", 440], ["kluyveri", 443], ["and", 452], ["found", 456], ["considerable", 462], ["divergence", 475], ["in", 486], ["origin", 489], ["location", 496], ["with", 505], ["S.", 510], ["cerevisiae", 513], ["and", 524], ["with", 528], ["Lachancea", 533], ["waltii", 543], [".", 549], ["Although", 551], ["some", 560], ["global", 565], ["features", 572], ["of", 581], ["S.", 584], ["cerevisiae", 587], ["replication", 598], ["are", 610], ["conserved", 614], [":", 623], ["Centromeres", 625], ["replicate", 637], ["early", 647], [",", 652], ["whereas", 654], ["telomeres", 662], ["replicate", 672], ["late", 682], [",", 686], ["we", 688], ["found", 691], ["that", 697], ["replication", 702], ["origins", 714], ["both", 722], ["in", 727], ["L.", 730], ["kluyveri", 733], ["and", 742], ["L.", 746], ["waltii", 749], ["do", 756], ["not", 759], ["behave", 763], ["as", 770], ["evolutionary", 773], ["fragile", 786], ["sites", 794], [".", 799], ["In", 801], ["L.", 804], ["kluyveri", 807], [",", 815], ["replication", 817], ["timing", 829], ["along", 836], ["chromosomes", 842], ["alternates", 854], ["between", 865], ["regions", 873], ["of", 881], ["early", 884], ["and", 890], ["late", 894], ["activating", 899], ["origins", 910], [",", 917], ["except", 919], ["for", 926], ["the", 930], ["1", 934], ["Mb", 936], ["GC", 939], ["-", 941], ["rich", 942], ["chromosomal", 947], ["arm", 959], [".", 962], ["This", 964], ["chromosomal", 969], ["arm", 981], ["contains", 985], ["an", 994], ["origin", 997], ["consensus", 1004], ["motif", 1014], ["different", 1020], ["from", 1030], ["other", 1035], ["chromosomes", 1041], ["and", 1053], ["is", 1057], ["replicated", 1060], ["early", 1071], ["during", 1077], ["S", 1084], ["-", 1085], ["phase", 1086], [".", 1091], ["We", 1093], ["showed", 1096], ["that", 1103], ["precocious", 1108], ["replication", 1119], ["results", 1131], ["from", 1139], ["the", 1144], ["specific", 1148], ["absence", 1157], ["of", 1165], ["late", 1168], ["firing", 1173], ["origins", 1180], ["in", 1188], ["this", 1191], ["chromosomal", 1196], ["arm", 1208], [".", 1211], ["In", 1213], ["addition", 1216], [",", 1224], ["we", 1226], ["found", 1229], ["a", 1235], ["correlation", 1237], ["between", 1249], ["GC", 1257], ["-", 1259], ["content", 1260], ["and", 1268], ["distance", 1272], ["from", 1281], ["replication", 1286], ["origins", 1298], ["as", 1306], ["well", 1309], ["as", 1314], ["a", 1317], ["lack", 1319], ["of", 1324], ["replication", 1327], ["-", 1338], ["associated", 1339], ["compositional", 1350], ["skew", 1364], ["between", 1369], ["leading", 1377], ["and", 1385], ["lagging", 1389], ["strands", 1397], ["specifically", 1405], ["in", 1418], ["this", 1421], ["GC", 1426], ["-", 1428], ["rich", 1429], ["chromosomal", 1434], ["arm", 1446], [".", 1449], ["These", 1451], ["findings", 1457], ["suggest", 1466], ["that", 1474], ["the", 1479], ["unusual", 1483], ["base", 1491], ["composition", 1496], ["in", 1508], ["the", 1511], ["genome", 1515], ["of", 1522], ["L.", 1525], ["kluyveri", 1528], ["could", 1537], ["be", 1543], ["linked", 1546], ["to", 1553], ["replication", 1556], [".", 1567]]}
{"context": "Imatinib mesylate (Glivec) is a selective inhibitor of bcr-abl tyrosine kinase, the product of the Philadelphia chromosome, which is the hallmark of chronic myeloid leukaemia (CML). With imatinib, complete cytogenetic response (CCR) can be achieved in over 70% of newly diagnosed patients with CML. However, the optimal long-term management of patients who achieve CCR after imatinib is unknown. With longer follow-up, it is anticipated that some patients are likely to progress and become candidates for autologous transplantation. We studied filgrastim (r-metHuG-CSF) mobilisation of peripheral blood stem cells (PBSC) in 32 patients who have achieved CCR with imatinib. Our data demonstrate that (1) the target CD34(+) cell yields of >/=2.0 x 10(6)/kg were attained with filgrastim 10 microg/kg/day, in 9/18 (50%) of patients during uninterrupted imatinib therapy, and in 10/14 (70%) when imatinib was temporarily withheld. The median CD34(+) cell yield per aphaeresis was 0.70 x 10(6)/kg (range 0.14-2.18) and 2.90 x 10(6)/kg (range 0.15-8.71) in the two groups, respectively (P&<0.005). (2) The cell yields did not correlate with the duration of imatinib administration. (3) There was no impact of the mobilisation procedure on the level of leukaemia as measured by serial blood bcr-abl levels using real-time quantitative PCR with either protocol. (4) bcr-abl remained detectable at low levels in the harvests in most but not all patients. In conclusion, filgrastim can safely be used to mobilise PBSC in patients who have achieved CCR with imatinib, but CD34(+) cell yields are significantly improved when imatinib is temporarily withheld.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "5900db93e2d94cedaf489326063c2ede", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[258, 260], [10, 12], [275, 277]], "char_spans": [[1284, 1290], [55, 61], [1358, 1364]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["Glivec", 19], [")", 25], ["is", 27], ["a", 30], ["selective", 32], ["inhibitor", 42], ["of", 52], ["bcr", 55], ["-", 58], ["abl", 59], ["tyrosine", 63], ["kinase", 72], [",", 78], ["the", 80], ["product", 84], ["of", 92], ["the", 95], ["Philadelphia", 99], ["chromosome", 112], [",", 122], ["which", 124], ["is", 130], ["the", 133], ["hallmark", 137], ["of", 146], ["chronic", 149], ["myeloid", 157], ["leukaemia", 165], ["(", 175], ["CML", 176], [")", 179], [".", 180], ["With", 182], ["imatinib", 187], [",", 195], ["complete", 197], ["cytogenetic", 206], ["response", 218], ["(", 227], ["CCR", 228], [")", 231], ["can", 233], ["be", 237], ["achieved", 240], ["in", 249], ["over", 252], ["70", 257], ["%", 259], ["of", 261], ["newly", 264], ["diagnosed", 270], ["patients", 280], ["with", 289], ["CML", 294], [".", 297], ["However", 299], [",", 306], ["the", 308], ["optimal", 312], ["long", 320], ["-", 324], ["term", 325], ["management", 330], ["of", 341], ["patients", 344], ["who", 353], ["achieve", 357], ["CCR", 365], ["after", 369], ["imatinib", 375], ["is", 384], ["unknown", 387], [".", 394], ["With", 396], ["longer", 401], ["follow", 408], ["-", 414], ["up", 415], [",", 417], ["it", 419], ["is", 422], ["anticipated", 425], ["that", 437], ["some", 442], ["patients", 447], ["are", 456], ["likely", 460], ["to", 467], ["progress", 470], ["and", 479], ["become", 483], ["candidates", 490], ["for", 501], ["autologous", 505], ["transplantation", 516], [".", 531], ["We", 533], ["studied", 536], ["filgrastim", 544], ["(", 555], ["r", 556], ["-", 557], ["metHuG", 558], ["-", 564], ["CSF", 565], [")", 568], ["mobilisation", 570], ["of", 583], ["peripheral", 586], ["blood", 597], ["stem", 603], ["cells", 608], ["(", 614], ["PBSC", 615], [")", 619], ["in", 621], ["32", 624], ["patients", 627], ["who", 636], ["have", 640], ["achieved", 645], ["CCR", 654], ["with", 658], ["imatinib", 663], [".", 671], ["Our", 673], ["data", 677], ["demonstrate", 682], ["that", 694], ["(", 699], ["1", 700], [")", 701], ["the", 703], ["target", 707], ["CD34(+", 714], [")", 720], ["cell", 722], ["yields", 727], ["of", 734], [">", 737], ["/=2.0", 738], ["x", 744], ["10(6)/kg", 746], ["were", 755], ["attained", 760], ["with", 769], ["filgrastim", 774], ["10", 785], ["microg", 788], ["/", 794], ["kg", 795], ["/", 797], ["day", 798], [",", 801], ["in", 803], ["9/18", 806], ["(", 811], ["50", 812], ["%", 814], [")", 815], ["of", 817], ["patients", 820], ["during", 829], ["uninterrupted", 836], ["imatinib", 850], ["therapy", 859], [",", 866], ["and", 868], ["in", 872], ["10/14", 875], ["(", 881], ["70", 882], ["%", 884], [")", 885], ["when", 887], ["imatinib", 892], ["was", 901], ["temporarily", 905], ["withheld", 917], [".", 925], ["The", 927], ["median", 931], ["CD34(+", 938], [")", 944], ["cell", 946], ["yield", 951], ["per", 957], ["aphaeresis", 961], ["was", 972], ["0.70", 976], ["x", 981], ["10(6)/kg", 983], ["(", 992], ["range", 993], ["0.14", 999], ["-", 1003], ["2.18", 1004], [")", 1008], ["and", 1010], ["2.90", 1014], ["x", 1019], ["10(6)/kg", 1021], ["(", 1030], ["range", 1031], ["0.15", 1037], ["-", 1041], ["8.71", 1042], [")", 1046], ["in", 1048], ["the", 1051], ["two", 1055], ["groups", 1059], [",", 1065], ["respectively", 1067], ["(", 1080], ["P&<0.005", 1081], [")", 1089], [".", 1090], ["(", 1092], ["2", 1093], [")", 1094], ["The", 1096], ["cell", 1100], ["yields", 1105], ["did", 1112], ["not", 1116], ["correlate", 1120], ["with", 1130], ["the", 1135], ["duration", 1139], ["of", 1148], ["imatinib", 1151], ["administration", 1160], [".", 1174], ["(", 1176], ["3", 1177], [")", 1178], ["There", 1180], ["was", 1186], ["no", 1190], ["impact", 1193], ["of", 1200], ["the", 1203], ["mobilisation", 1207], ["procedure", 1220], ["on", 1230], ["the", 1233], ["level", 1237], ["of", 1243], ["leukaemia", 1246], ["as", 1256], ["measured", 1259], ["by", 1268], ["serial", 1271], ["blood", 1278], ["bcr", 1284], ["-", 1287], ["abl", 1288], ["levels", 1292], ["using", 1299], ["real", 1305], ["-", 1309], ["time", 1310], ["quantitative", 1315], ["PCR", 1328], ["with", 1332], ["either", 1337], ["protocol", 1344], [".", 1352], ["(", 1354], ["4", 1355], [")", 1356], ["bcr", 1358], ["-", 1361], ["abl", 1362], ["remained", 1366], ["detectable", 1375], ["at", 1386], ["low", 1389], ["levels", 1393], ["in", 1400], ["the", 1403], ["harvests", 1407], ["in", 1416], ["most", 1419], ["but", 1424], ["not", 1428], ["all", 1432], ["patients", 1436], [".", 1444], ["In", 1446], ["conclusion", 1449], [",", 1459], ["filgrastim", 1461], ["can", 1472], ["safely", 1476], ["be", 1483], ["used", 1486], ["to", 1491], ["mobilise", 1494], ["PBSC", 1503], ["in", 1508], ["patients", 1511], ["who", 1520], ["have", 1524], ["achieved", 1529], ["CCR", 1538], ["with", 1542], ["imatinib", 1547], [",", 1555], ["but", 1557], ["CD34(+", 1561], [")", 1567], ["cell", 1569], ["yields", 1574], ["are", 1581], ["significantly", 1585], ["improved", 1599], ["when", 1608], ["imatinib", 1613], ["is", 1622], ["temporarily", 1625], ["withheld", 1637], [".", 1645]]}
{"context": "In a double-blind placebo-controlled prospective clinical trial we studied the efficacy and safety of the benzodiazepine antagonist, flumazenil. In 23 patients admitted to the Intensive Care Unit with coma due to overdose with benzodiazepines or other sedatives, flumazenil i.v. (up to 2 mg or placebo) was given. In 13 patients given flumazenil the Glasgow Coma Scale (GCS) increased significantly from 4.9 to 7.8 (p less than 0.05). Six of these 13 patients, including mainly benzodiazepine mono-intoxications, needed only one series of injections (up to 1.0 mg flumazenil); the GCS increased thereby from 4.5 to 10.7 within a maximum of 5 min (p less than 0.01). In the remaining 7 patients, needing two series of injections of flumazenil (up to 2.0 mg), GCS did not rise significantly and coma was related to intoxications with nonbenzodiazepine sedatives, flunitrazepam and in one patient, encephalitis. In the 10 patients receiving placebo, the GCS did not change. A significant increase in the GCS from 5.5 to 10.8 (p less than 0.001) was, however, observed when flumazenil (up to 1.0 mg) was given after placebo. In patients with EEG monitoring the changes in waveform pattern paralleled the clinical response. Effects could be detected within 1-2 min after flumazenil injection and lasted up to 45 min. There were no adverse reactions or benzodiazepine withdrawal symptoms. We conclude that flumazenil is an effective and safe drug in the treatment of benzodiazepine overdose. The use of flumazenil is of diagnostic value in mixed-drug intoxications or coma of unknown origin and is of therapeutic importance for reversal of benzodiazepine intoxications.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "59303c35c98b49d191c1a3ae65d248b9", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[107, 107], [285, 285], [22, 22], [246, 246], [44, 44], [268, 268], [209, 209], [62, 62], [143, 143]], "char_spans": [[564, 573], [1497, 1506], [133, 142], [1266, 1275], [263, 272], [1400, 1409], [1070, 1079], [335, 344], [731, 740]]}]}], "context_tokens": [["In", 0], ["a", 3], ["double", 5], ["-", 11], ["blind", 12], ["placebo", 18], ["-", 25], ["controlled", 26], ["prospective", 37], ["clinical", 49], ["trial", 58], ["we", 64], ["studied", 67], ["the", 75], ["efficacy", 79], ["and", 88], ["safety", 92], ["of", 99], ["the", 102], ["benzodiazepine", 106], ["antagonist", 121], [",", 131], ["flumazenil", 133], [".", 143], ["In", 145], ["23", 148], ["patients", 151], ["admitted", 160], ["to", 169], ["the", 172], ["Intensive", 176], ["Care", 186], ["Unit", 191], ["with", 196], ["coma", 201], ["due", 206], ["to", 210], ["overdose", 213], ["with", 222], ["benzodiazepines", 227], ["or", 243], ["other", 246], ["sedatives", 252], [",", 261], ["flumazenil", 263], ["i.v", 274], [".", 277], ["(", 279], ["up", 280], ["to", 283], ["2", 286], ["mg", 288], ["or", 291], ["placebo", 294], [")", 301], ["was", 303], ["given", 307], [".", 312], ["In", 314], ["13", 317], ["patients", 320], ["given", 329], ["flumazenil", 335], ["the", 346], ["Glasgow", 350], ["Coma", 358], ["Scale", 363], ["(", 369], ["GCS", 370], [")", 373], ["increased", 375], ["significantly", 385], ["from", 399], ["4.9", 404], ["to", 408], ["7.8", 411], ["(", 415], ["p", 416], ["less", 418], ["than", 423], ["0.05", 428], [")", 432], [".", 433], ["Six", 435], ["of", 439], ["these", 442], ["13", 448], ["patients", 451], [",", 459], ["including", 461], ["mainly", 471], ["benzodiazepine", 478], ["mono", 493], ["-", 497], ["intoxications", 498], [",", 511], ["needed", 513], ["only", 520], ["one", 525], ["series", 529], ["of", 536], ["injections", 539], ["(", 550], ["up", 551], ["to", 554], ["1.0", 557], ["mg", 561], ["flumazenil", 564], [")", 574], [";", 575], ["the", 577], ["GCS", 581], ["increased", 585], ["thereby", 595], ["from", 603], ["4.5", 608], ["to", 612], ["10.7", 615], ["within", 620], ["a", 627], ["maximum", 629], ["of", 637], ["5", 640], ["min", 642], ["(", 646], ["p", 647], ["less", 649], ["than", 654], ["0.01", 659], [")", 663], [".", 664], ["In", 666], ["the", 669], ["remaining", 673], ["7", 683], ["patients", 685], [",", 693], ["needing", 695], ["two", 703], ["series", 707], ["of", 714], ["injections", 717], ["of", 728], ["flumazenil", 731], ["(", 742], ["up", 743], ["to", 746], ["2.0", 749], ["mg", 753], [")", 755], [",", 756], ["GCS", 758], ["did", 762], ["not", 766], ["rise", 770], ["significantly", 775], ["and", 789], ["coma", 793], ["was", 798], ["related", 802], ["to", 810], ["intoxications", 813], ["with", 827], ["nonbenzodiazepine", 832], ["sedatives", 850], [",", 859], ["flunitrazepam", 861], ["and", 875], ["in", 879], ["one", 882], ["patient", 886], [",", 893], ["encephalitis", 895], [".", 907], ["In", 909], ["the", 912], ["10", 916], ["patients", 919], ["receiving", 928], ["placebo", 938], [",", 945], ["the", 947], ["GCS", 951], ["did", 955], ["not", 959], ["change", 963], [".", 969], ["A", 971], ["significant", 973], ["increase", 985], ["in", 994], ["the", 997], ["GCS", 1001], ["from", 1005], ["5.5", 1010], ["to", 1014], ["10.8", 1017], ["(", 1022], ["p", 1023], ["less", 1025], ["than", 1030], ["0.001", 1035], [")", 1040], ["was", 1042], [",", 1045], ["however", 1047], [",", 1054], ["observed", 1056], ["when", 1065], ["flumazenil", 1070], ["(", 1081], ["up", 1082], ["to", 1085], ["1.0", 1088], ["mg", 1092], [")", 1094], ["was", 1096], ["given", 1100], ["after", 1106], ["placebo", 1112], [".", 1119], ["In", 1121], ["patients", 1124], ["with", 1133], ["EEG", 1138], ["monitoring", 1142], ["the", 1153], ["changes", 1157], ["in", 1165], ["waveform", 1168], ["pattern", 1177], ["paralleled", 1185], ["the", 1196], ["clinical", 1200], ["response", 1209], [".", 1217], ["Effects", 1219], ["could", 1227], ["be", 1233], ["detected", 1236], ["within", 1245], ["1", 1252], ["-", 1253], ["2", 1254], ["min", 1256], ["after", 1260], ["flumazenil", 1266], ["injection", 1277], ["and", 1287], ["lasted", 1291], ["up", 1298], ["to", 1301], ["45", 1304], ["min", 1307], [".", 1310], ["There", 1312], ["were", 1318], ["no", 1323], ["adverse", 1326], ["reactions", 1334], ["or", 1344], ["benzodiazepine", 1347], ["withdrawal", 1362], ["symptoms", 1373], [".", 1381], ["We", 1383], ["conclude", 1386], ["that", 1395], ["flumazenil", 1400], ["is", 1411], ["an", 1414], ["effective", 1417], ["and", 1427], ["safe", 1431], ["drug", 1436], ["in", 1441], ["the", 1444], ["treatment", 1448], ["of", 1458], ["benzodiazepine", 1461], ["overdose", 1476], [".", 1484], ["The", 1486], ["use", 1490], ["of", 1494], ["flumazenil", 1497], ["is", 1508], ["of", 1511], ["diagnostic", 1514], ["value", 1525], ["in", 1531], ["mixed", 1534], ["-", 1539], ["drug", 1540], ["intoxications", 1545], ["or", 1559], ["coma", 1562], ["of", 1567], ["unknown", 1570], ["origin", 1578], ["and", 1585], ["is", 1589], ["of", 1592], ["therapeutic", 1595], ["importance", 1607], ["for", 1618], ["reversal", 1622], ["of", 1631], ["benzodiazepine", 1634], ["intoxications", 1649], [".", 1662]]}
{"context": "The ESC-E(Z) complex of Drosophila melanogaster Polycomb group (PcG) repressors is a histone H3 methyltransferase (HMTase). This complex silences fly Hox genes, and related HMTases control germ line development in worms, flowering in plants, and X inactivation in mammals. The fly complex contains a catalytic SET domain subunit, E(Z), plus three noncatalytic subunits, SU(Z)12, ESC, and NURF-55. The four-subunit complex is >1,000-fold more active than E(Z) alone. Here we show that ESC and SU(Z)12 play key roles in potentiating E(Z) HMTase activity. We also show that loss of ESC disrupts global methylation of histone H3-lysine 27 in fly embryos. Subunit mutations identify domains required for catalytic activity and/or binding to specific partners. We describe missense mutations in surface loops of ESC, in the CXC domain of E(Z), and in the conserved VEFS domain of SU(Z)12, which each disrupt HMTase activity but preserve complex assembly. Thus, the E(Z) SET domain requires multiple partner inputs to produce active HMTase. We also find that a recombinant worm complex containing the E(Z) homolog, MES-2, has robust HMTase activity, which depends upon both MES-6, an ESC homolog, and MES-3, a pioneer protein. Thus, although the fly and mammalian PcG complexes absolutely require SU(Z)12, the worm complex generates HMTase activity from a distinct partner set.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "455d3e2bfca04bab969414f28100925b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[57, 58], [182, 183]], "char_spans": [[310, 319], [964, 973]]}]}], "context_tokens": [["The", 0], ["ESC", 4], ["-", 7], ["E(Z", 8], [")", 11], ["complex", 13], ["of", 21], ["Drosophila", 24], ["melanogaster", 35], ["Polycomb", 48], ["group", 57], ["(", 63], ["PcG", 64], [")", 67], ["repressors", 69], ["is", 80], ["a", 83], ["histone", 85], ["H3", 93], ["methyltransferase", 96], ["(", 114], ["HMTase", 115], [")", 121], [".", 122], ["This", 124], ["complex", 129], ["silences", 137], ["fly", 146], ["Hox", 150], ["genes", 154], [",", 159], ["and", 161], ["related", 165], ["HMTases", 173], ["control", 181], ["germ", 189], ["line", 194], ["development", 199], ["in", 211], ["worms", 214], [",", 219], ["flowering", 221], ["in", 231], ["plants", 234], [",", 240], ["and", 242], ["X", 246], ["inactivation", 248], ["in", 261], ["mammals", 264], [".", 271], ["The", 273], ["fly", 277], ["complex", 281], ["contains", 289], ["a", 298], ["catalytic", 300], ["SET", 310], ["domain", 314], ["subunit", 321], [",", 328], ["E(Z", 330], [")", 333], [",", 334], ["plus", 336], ["three", 341], ["noncatalytic", 347], ["subunits", 360], [",", 368], ["SU(Z)12", 370], [",", 377], ["ESC", 379], [",", 382], ["and", 384], ["NURF-55", 388], [".", 395], ["The", 397], ["four", 401], ["-", 405], ["subunit", 406], ["complex", 414], ["is", 422], [">", 425], ["1,000-fold", 426], ["more", 437], ["active", 442], ["than", 449], ["E(Z", 454], [")", 457], ["alone", 459], [".", 464], ["Here", 466], ["we", 471], ["show", 474], ["that", 479], ["ESC", 484], ["and", 488], ["SU(Z)12", 492], ["play", 500], ["key", 505], ["roles", 509], ["in", 515], ["potentiating", 518], ["E(Z", 531], [")", 534], ["HMTase", 536], ["activity", 543], [".", 551], ["We", 553], ["also", 556], ["show", 561], ["that", 566], ["loss", 571], ["of", 576], ["ESC", 579], ["disrupts", 583], ["global", 592], ["methylation", 599], ["of", 611], ["histone", 614], ["H3-lysine", 622], ["27", 632], ["in", 635], ["fly", 638], ["embryos", 642], [".", 649], ["Subunit", 651], ["mutations", 659], ["identify", 669], ["domains", 678], ["required", 686], ["for", 695], ["catalytic", 699], ["activity", 709], ["and/or", 718], ["binding", 725], ["to", 733], ["specific", 736], ["partners", 745], [".", 753], ["We", 755], ["describe", 758], ["missense", 767], ["mutations", 776], ["in", 786], ["surface", 789], ["loops", 797], ["of", 803], ["ESC", 806], [",", 809], ["in", 811], ["the", 814], ["CXC", 818], ["domain", 822], ["of", 829], ["E(Z", 832], [")", 835], [",", 836], ["and", 838], ["in", 842], ["the", 845], ["conserved", 849], ["VEFS", 859], ["domain", 864], ["of", 871], ["SU(Z)12", 874], [",", 881], ["which", 883], ["each", 889], ["disrupt", 894], ["HMTase", 902], ["activity", 909], ["but", 918], ["preserve", 922], ["complex", 931], ["assembly", 939], [".", 947], ["Thus", 949], [",", 953], ["the", 955], ["E(Z", 959], [")", 962], ["SET", 964], ["domain", 968], ["requires", 975], ["multiple", 984], ["partner", 993], ["inputs", 1001], ["to", 1008], ["produce", 1011], ["active", 1019], ["HMTase", 1026], [".", 1032], ["We", 1034], ["also", 1037], ["find", 1042], ["that", 1047], ["a", 1052], ["recombinant", 1054], ["worm", 1066], ["complex", 1071], ["containing", 1079], ["the", 1090], ["E(Z", 1094], [")", 1097], ["homolog", 1099], [",", 1106], ["MES-2", 1108], [",", 1113], ["has", 1115], ["robust", 1119], ["HMTase", 1126], ["activity", 1133], [",", 1141], ["which", 1143], ["depends", 1149], ["upon", 1157], ["both", 1162], ["MES-6", 1167], [",", 1172], ["an", 1174], ["ESC", 1177], ["homolog", 1181], [",", 1188], ["and", 1190], ["MES-3", 1194], [",", 1199], ["a", 1201], ["pioneer", 1203], ["protein", 1211], [".", 1218], ["Thus", 1220], [",", 1224], ["although", 1226], ["the", 1235], ["fly", 1239], ["and", 1243], ["mammalian", 1247], ["PcG", 1257], ["complexes", 1261], ["absolutely", 1271], ["require", 1282], ["SU(Z)12", 1290], [",", 1297], ["the", 1299], ["worm", 1303], ["complex", 1308], ["generates", 1316], ["HMTase", 1326], ["activity", 1333], ["from", 1342], ["a", 1347], ["distinct", 1349], ["partner", 1358], ["set", 1366], [".", 1369]]}
{"context": "The health benefits of leisure-time physical activity are well known, however the effects of engaging in competitive sports on health are uncertain. This literature review examines mortality and longevity of elite athletes and attempts to understand the association between long-term vigorous exercise training and survival rates. Fourteen articles of epidemiological studies were identified and classified by type of sport. Life expectancy, standardised mortality ratio, standardised proportionate mortality ratio, mortality rate, and mortality odds ratio for all causes of death were used to analyse mortality and longevity of elite athletes. It appears that elite endurance (aerobic) athletes and mixed-sports (aerobic and anaerobic) athletes survive longer than the general population, as indicated by lower mortality and higher longevity. Lower cardiovascular disease mortality is likely the primary reason for their better survival rates. On the other hand, there are inconsistent results among studies of power (anaerobic) athletes. When elite athletes engaging in various sports are analysed together, their mortality is lower than that of the general population. In conclusion, long-term vigorous exercise training is associated with increased survival rates of specific groups of athletes.", "qas": [{"question": "What is the life expectancy of professional athletes in respect to the general population?", "answers": ["longer than the general population", "No clear results indicating improved life expectancy in professional athletes"], "qid": "5a537555a5e843839c53a7739cd95f64", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["life", 12], ["expectancy", 17], ["of", 28], ["professional", 31], ["athletes", 44], ["in", 53], ["respect", 56], ["to", 64], ["the", 67], ["general", 71], ["population", 79], ["?", 89]], "detected_answers": [{"text": "longer than the general population", "token_spans": [[122, 126]], "char_spans": [[754, 787]]}]}], "context_tokens": [["The", 0], ["health", 4], ["benefits", 11], ["of", 20], ["leisure", 23], ["-", 30], ["time", 31], ["physical", 36], ["activity", 45], ["are", 54], ["well", 58], ["known", 63], [",", 68], ["however", 70], ["the", 78], ["effects", 82], ["of", 90], ["engaging", 93], ["in", 102], ["competitive", 105], ["sports", 117], ["on", 124], ["health", 127], ["are", 134], ["uncertain", 138], [".", 147], ["This", 149], ["literature", 154], ["review", 165], ["examines", 172], ["mortality", 181], ["and", 191], ["longevity", 195], ["of", 205], ["elite", 208], ["athletes", 214], ["and", 223], ["attempts", 227], ["to", 236], ["understand", 239], ["the", 250], ["association", 254], ["between", 266], ["long", 274], ["-", 278], ["term", 279], ["vigorous", 284], ["exercise", 293], ["training", 302], ["and", 311], ["survival", 315], ["rates", 324], [".", 329], ["Fourteen", 331], ["articles", 340], ["of", 349], ["epidemiological", 352], ["studies", 368], ["were", 376], ["identified", 381], ["and", 392], ["classified", 396], ["by", 407], ["type", 410], ["of", 415], ["sport", 418], [".", 423], ["Life", 425], ["expectancy", 430], [",", 440], ["standardised", 442], ["mortality", 455], ["ratio", 465], [",", 470], ["standardised", 472], ["proportionate", 485], ["mortality", 499], ["ratio", 509], [",", 514], ["mortality", 516], ["rate", 526], [",", 530], ["and", 532], ["mortality", 536], ["odds", 546], ["ratio", 551], ["for", 557], ["all", 561], ["causes", 565], ["of", 572], ["death", 575], ["were", 581], ["used", 586], ["to", 591], ["analyse", 594], ["mortality", 602], ["and", 612], ["longevity", 616], ["of", 626], ["elite", 629], ["athletes", 635], [".", 643], ["It", 645], ["appears", 648], ["that", 656], ["elite", 661], ["endurance", 667], ["(", 677], ["aerobic", 678], [")", 685], ["athletes", 687], ["and", 696], ["mixed", 700], ["-", 705], ["sports", 706], ["(", 713], ["aerobic", 714], ["and", 722], ["anaerobic", 726], [")", 735], ["athletes", 737], ["survive", 746], ["longer", 754], ["than", 761], ["the", 766], ["general", 770], ["population", 778], [",", 788], ["as", 790], ["indicated", 793], ["by", 803], ["lower", 806], ["mortality", 812], ["and", 822], ["higher", 826], ["longevity", 833], [".", 842], ["Lower", 844], ["cardiovascular", 850], ["disease", 865], ["mortality", 873], ["is", 883], ["likely", 886], ["the", 893], ["primary", 897], ["reason", 905], ["for", 912], ["their", 916], ["better", 922], ["survival", 929], ["rates", 938], [".", 943], ["On", 945], ["the", 948], ["other", 952], ["hand", 958], [",", 962], ["there", 964], ["are", 970], ["inconsistent", 974], ["results", 987], ["among", 995], ["studies", 1001], ["of", 1009], ["power", 1012], ["(", 1018], ["anaerobic", 1019], [")", 1028], ["athletes", 1030], [".", 1038], ["When", 1040], ["elite", 1045], ["athletes", 1051], ["engaging", 1060], ["in", 1069], ["various", 1072], ["sports", 1080], ["are", 1087], ["analysed", 1091], ["together", 1100], [",", 1108], ["their", 1110], ["mortality", 1116], ["is", 1126], ["lower", 1129], ["than", 1135], ["that", 1140], ["of", 1145], ["the", 1148], ["general", 1152], ["population", 1160], [".", 1170], ["In", 1172], ["conclusion", 1175], [",", 1185], ["long", 1187], ["-", 1191], ["term", 1192], ["vigorous", 1197], ["exercise", 1206], ["training", 1215], ["is", 1224], ["associated", 1227], ["with", 1238], ["increased", 1243], ["survival", 1253], ["rates", 1262], ["of", 1268], ["specific", 1271], ["groups", 1280], ["of", 1287], ["athletes", 1290], [".", 1298]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "6aac3d7c2f5e40e09f41b4cb9a267ef5", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "Hallervorden-Spatz syndrome (HSS) is a rare autosomal recessive disorder clinically characterized by extrapyramidal signs and progressive dementia. In a typical case, the clinical symptoms become apparent during late childhood, and usually the course is protracted over a decade or more. We recently had an opportunity to study the brains of two cases of HSS with a clinical course of over 30 years. Case 1 was a 44-year-old female and case 2 was a 37-year-old male. Grossly, the brains showed severe fronto-temporal lobar atrophy with abundant spheroids and mild iron deposits in the globus pallidus, associated with features of motor neuron disease. In addition, there was diffuse sponginess in the atrophic cortex as well as widespread Alzheimer's neurofibrillary tangles (NFTs) and Lewy bodies (LBs) in the cortical and subcortical regions, including the spinal cord. Ultrastructurally, NFTs were composed of paired helical filaments, and LBs of central dense cores with radiating fibrils. Discrete immunostaining was demonstrated in NFTs and neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein. In addition, diffuse, overlapping immunoreactivity of alpha-synuclein and phosphorylated tau was seen within the cytoplasm of many neurons. However, when LBs and NFTs coexisted within the same neurons, they were clearly segregated. The findings of our present cases as well as those reported in the literature may indicate that simultaneous and extensive occurrence of abnormal phosphorylation of tau and accumulation of alpha-synuclein may constitute cardinal pathological features of HSS with protracted clinical course.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "4a2d924caf4d464aa5a7837b4e6e320d", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[214, 216], [202, 204], [275, 277]], "char_spans": [[1220, 1234], [1149, 1163], [1587, 1601]]}]}], "context_tokens": [["Hallervorden", 0], ["-", 12], ["Spatz", 13], ["syndrome", 19], ["(", 28], ["HSS", 29], [")", 32], ["is", 34], ["a", 37], ["rare", 39], ["autosomal", 44], ["recessive", 54], ["disorder", 64], ["clinically", 73], ["characterized", 84], ["by", 98], ["extrapyramidal", 101], ["signs", 116], ["and", 122], ["progressive", 126], ["dementia", 138], [".", 146], ["In", 148], ["a", 151], ["typical", 153], ["case", 161], [",", 165], ["the", 167], ["clinical", 171], ["symptoms", 180], ["become", 189], ["apparent", 196], ["during", 205], ["late", 212], ["childhood", 217], [",", 226], ["and", 228], ["usually", 232], ["the", 240], ["course", 244], ["is", 251], ["protracted", 254], ["over", 265], ["a", 270], ["decade", 272], ["or", 279], ["more", 282], [".", 286], ["We", 288], ["recently", 291], ["had", 300], ["an", 304], ["opportunity", 307], ["to", 319], ["study", 322], ["the", 328], ["brains", 332], ["of", 339], ["two", 342], ["cases", 346], ["of", 352], ["HSS", 355], ["with", 359], ["a", 364], ["clinical", 366], ["course", 375], ["of", 382], ["over", 385], ["30", 390], ["years", 393], [".", 398], ["Case", 400], ["1", 405], ["was", 407], ["a", 411], ["44-year", 413], ["-", 420], ["old", 421], ["female", 425], ["and", 432], ["case", 436], ["2", 441], ["was", 443], ["a", 447], ["37-year", 449], ["-", 456], ["old", 457], ["male", 461], [".", 465], ["Grossly", 467], [",", 474], ["the", 476], ["brains", 480], ["showed", 487], ["severe", 494], ["fronto", 501], ["-", 507], ["temporal", 508], ["lobar", 517], ["atrophy", 523], ["with", 531], ["abundant", 536], ["spheroids", 545], ["and", 555], ["mild", 559], ["iron", 564], ["deposits", 569], ["in", 578], ["the", 581], ["globus", 585], ["pallidus", 592], [",", 600], ["associated", 602], ["with", 613], ["features", 618], ["of", 627], ["motor", 630], ["neuron", 636], ["disease", 643], [".", 650], ["In", 652], ["addition", 655], [",", 663], ["there", 665], ["was", 671], ["diffuse", 675], ["sponginess", 683], ["in", 694], ["the", 697], ["atrophic", 701], ["cortex", 710], ["as", 717], ["well", 720], ["as", 725], ["widespread", 728], ["Alzheimer", 739], ["'s", 748], ["neurofibrillary", 751], ["tangles", 767], ["(", 775], ["NFTs", 776], [")", 780], ["and", 782], ["Lewy", 786], ["bodies", 791], ["(", 798], ["LBs", 799], [")", 802], ["in", 804], ["the", 807], ["cortical", 811], ["and", 820], ["subcortical", 824], ["regions", 836], [",", 843], ["including", 845], ["the", 855], ["spinal", 859], ["cord", 866], [".", 870], ["Ultrastructurally", 872], [",", 889], ["NFTs", 891], ["were", 896], ["composed", 901], ["of", 910], ["paired", 913], ["helical", 920], ["filaments", 928], [",", 937], ["and", 939], ["LBs", 943], ["of", 947], ["central", 950], ["dense", 958], ["cores", 964], ["with", 970], ["radiating", 975], ["fibrils", 985], [".", 992], ["Discrete", 994], ["immunostaining", 1003], ["was", 1018], ["demonstrated", 1022], ["in", 1035], ["NFTs", 1038], ["and", 1043], ["neuropil", 1047], ["threads", 1056], ["with", 1064], ["various", 1069], ["antibodies", 1077], ["against", 1088], ["phosphorylated", 1096], ["tau", 1111], [",", 1114], ["and", 1116], ["in", 1120], ["LBs", 1123], ["with", 1127], ["antibody", 1132], ["against", 1141], ["alpha", 1149], ["-", 1154], ["synuclein", 1155], [".", 1164], ["In", 1166], ["addition", 1169], [",", 1177], ["diffuse", 1179], [",", 1186], ["overlapping", 1188], ["immunoreactivity", 1200], ["of", 1217], ["alpha", 1220], ["-", 1225], ["synuclein", 1226], ["and", 1236], ["phosphorylated", 1240], ["tau", 1255], ["was", 1259], ["seen", 1263], ["within", 1268], ["the", 1275], ["cytoplasm", 1279], ["of", 1289], ["many", 1292], ["neurons", 1297], [".", 1304], ["However", 1306], [",", 1313], ["when", 1315], ["LBs", 1320], ["and", 1324], ["NFTs", 1328], ["coexisted", 1333], ["within", 1343], ["the", 1350], ["same", 1354], ["neurons", 1359], [",", 1366], ["they", 1368], ["were", 1373], ["clearly", 1378], ["segregated", 1386], [".", 1396], ["The", 1398], ["findings", 1402], ["of", 1411], ["our", 1414], ["present", 1418], ["cases", 1426], ["as", 1432], ["well", 1435], ["as", 1440], ["those", 1443], ["reported", 1449], ["in", 1458], ["the", 1461], ["literature", 1465], ["may", 1476], ["indicate", 1480], ["that", 1489], ["simultaneous", 1494], ["and", 1507], ["extensive", 1511], ["occurrence", 1521], ["of", 1532], ["abnormal", 1535], ["phosphorylation", 1544], ["of", 1560], ["tau", 1563], ["and", 1567], ["accumulation", 1571], ["of", 1584], ["alpha", 1587], ["-", 1592], ["synuclein", 1593], ["may", 1603], ["constitute", 1607], ["cardinal", 1618], ["pathological", 1627], ["features", 1640], ["of", 1649], ["HSS", 1652], ["with", 1656], ["protracted", 1661], ["clinical", 1672], ["course", 1681], [".", 1687]]}
{"context": "The first step in the management of restless legs syndrome (RLS) is to identify, and if possible to treat any condition which might cause or worsen RLS, such as iron deficiency or some drug treatments. The patients suffering from RLS should be prompted to keep a healthy sleep schedule. Drug treatment should be restricted to patients with a clear clinical diagnosis, decided on an individual basis, when the clinical impact is serious. Four drug classes are central to the treatment of RLS: dopaminergic agents, some antiepileptics, opioids, and benzodiazepines. Dopaminergic agonists are the treatment of choice, especially when daily treatment is indicated, or if the symptoms are severe. Two dopaminergic agonists are licensed in France for the treatment of RLS: ropinirole (Adartrel) and pramipexole (Sifrol). After initiation of treatment, the patients should benefit from a regular follow-up in order to evaluate the efficacy of treatment and to identify possible side-effects. Special care should be given to the detection of augmentation, a phenomenon characterized by a paradoxical worsening of the symptoms with treatment. Some particular conditions, such as RLS comorbid with renal insufficiency, during pregnancy, and in the child are discussed.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "aea77da44e294600b63d4260d7490d59", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[33, 33]], "char_spans": [[161, 164]]}]}], "context_tokens": [["The", 0], ["first", 4], ["step", 10], ["in", 15], ["the", 18], ["management", 22], ["of", 33], ["restless", 36], ["legs", 45], ["syndrome", 50], ["(", 59], ["RLS", 60], [")", 63], ["is", 65], ["to", 68], ["identify", 71], [",", 79], ["and", 81], ["if", 85], ["possible", 88], ["to", 97], ["treat", 100], ["any", 106], ["condition", 110], ["which", 120], ["might", 126], ["cause", 132], ["or", 138], ["worsen", 141], ["RLS", 148], [",", 151], ["such", 153], ["as", 158], ["iron", 161], ["deficiency", 166], ["or", 177], ["some", 180], ["drug", 185], ["treatments", 190], [".", 200], ["The", 202], ["patients", 206], ["suffering", 215], ["from", 225], ["RLS", 230], ["should", 234], ["be", 241], ["prompted", 244], ["to", 253], ["keep", 256], ["a", 261], ["healthy", 263], ["sleep", 271], ["schedule", 277], [".", 285], ["Drug", 287], ["treatment", 292], ["should", 302], ["be", 309], ["restricted", 312], ["to", 323], ["patients", 326], ["with", 335], ["a", 340], ["clear", 342], ["clinical", 348], ["diagnosis", 357], [",", 366], ["decided", 368], ["on", 376], ["an", 379], ["individual", 382], ["basis", 393], [",", 398], ["when", 400], ["the", 405], ["clinical", 409], ["impact", 418], ["is", 425], ["serious", 428], [".", 435], ["Four", 437], ["drug", 442], ["classes", 447], ["are", 455], ["central", 459], ["to", 467], ["the", 470], ["treatment", 474], ["of", 484], ["RLS", 487], [":", 490], ["dopaminergic", 492], ["agents", 505], [",", 511], ["some", 513], ["antiepileptics", 518], [",", 532], ["opioids", 534], [",", 541], ["and", 543], ["benzodiazepines", 547], [".", 562], ["Dopaminergic", 564], ["agonists", 577], ["are", 586], ["the", 590], ["treatment", 594], ["of", 604], ["choice", 607], [",", 613], ["especially", 615], ["when", 626], ["daily", 631], ["treatment", 637], ["is", 647], ["indicated", 650], [",", 659], ["or", 661], ["if", 664], ["the", 667], ["symptoms", 671], ["are", 680], ["severe", 684], [".", 690], ["Two", 692], ["dopaminergic", 696], ["agonists", 709], ["are", 718], ["licensed", 722], ["in", 731], ["France", 734], ["for", 741], ["the", 745], ["treatment", 749], ["of", 759], ["RLS", 762], [":", 765], ["ropinirole", 767], ["(", 778], ["Adartrel", 779], [")", 787], ["and", 789], ["pramipexole", 793], ["(", 805], ["Sifrol", 806], [")", 812], [".", 813], ["After", 815], ["initiation", 821], ["of", 832], ["treatment", 835], [",", 844], ["the", 846], ["patients", 850], ["should", 859], ["benefit", 866], ["from", 874], ["a", 879], ["regular", 881], ["follow", 889], ["-", 895], ["up", 896], ["in", 899], ["order", 902], ["to", 908], ["evaluate", 911], ["the", 920], ["efficacy", 924], ["of", 933], ["treatment", 936], ["and", 946], ["to", 950], ["identify", 953], ["possible", 962], ["side", 971], ["-", 975], ["effects", 976], [".", 983], ["Special", 985], ["care", 993], ["should", 998], ["be", 1005], ["given", 1008], ["to", 1014], ["the", 1017], ["detection", 1021], ["of", 1031], ["augmentation", 1034], [",", 1046], ["a", 1048], ["phenomenon", 1050], ["characterized", 1061], ["by", 1075], ["a", 1078], ["paradoxical", 1080], ["worsening", 1092], ["of", 1102], ["the", 1105], ["symptoms", 1109], ["with", 1118], ["treatment", 1123], [".", 1132], ["Some", 1134], ["particular", 1139], ["conditions", 1150], [",", 1160], ["such", 1162], ["as", 1167], ["RLS", 1170], ["comorbid", 1174], ["with", 1183], ["renal", 1188], ["insufficiency", 1194], [",", 1207], ["during", 1209], ["pregnancy", 1216], [",", 1225], ["and", 1227], ["in", 1231], ["the", 1234], ["child", 1238], ["are", 1244], ["discussed", 1248], [".", 1257]]}
{"context": "We have determined sequences of PCR-amplified B1 elements from hamster and rat (Myomorpha), chipmunk (Sciuromorpha), and guinea pig (Caviomorpha). Between three and six B1 subfamilies were found in these species. In the phylogenetic analysis B1 sequences of hamster, mouse, and rat clustered separately from those of chipmunk and those of guinea pig. This is consistent with an independent evolution of B1 elements in separate rodent lineages. We exclude the possibility of convergent mutations to explain certain diagnostic characters within the modern B1 quasi-dimers and view these elements as mosaic structures assembling preexisting mutations. Furthermore, the presence of Alu-like structural motifs supports the hypothesis of the monophyletic origin of Alu and B1 repeats, i.e., from a common 7SL RNA-derived retroposing monomeric element.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "e4f9aab09e074c42b56d239bd1ea6bf9", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[140, 141]], "char_spans": [[799, 805]]}]}], "context_tokens": [["We", 0], ["have", 3], ["determined", 8], ["sequences", 19], ["of", 29], ["PCR", 32], ["-", 35], ["amplified", 36], ["B1", 46], ["elements", 49], ["from", 58], ["hamster", 63], ["and", 71], ["rat", 75], ["(", 79], ["Myomorpha", 80], [")", 89], [",", 90], ["chipmunk", 92], ["(", 101], ["Sciuromorpha", 102], [")", 114], [",", 115], ["and", 117], ["guinea", 121], ["pig", 128], ["(", 132], ["Caviomorpha", 133], [")", 144], [".", 145], ["Between", 147], ["three", 155], ["and", 161], ["six", 165], ["B1", 169], ["subfamilies", 172], ["were", 184], ["found", 189], ["in", 195], ["these", 198], ["species", 204], [".", 211], ["In", 213], ["the", 216], ["phylogenetic", 220], ["analysis", 233], ["B1", 242], ["sequences", 245], ["of", 255], ["hamster", 258], [",", 265], ["mouse", 267], [",", 272], ["and", 274], ["rat", 278], ["clustered", 282], ["separately", 292], ["from", 303], ["those", 308], ["of", 314], ["chipmunk", 317], ["and", 326], ["those", 330], ["of", 336], ["guinea", 339], ["pig", 346], [".", 349], ["This", 351], ["is", 356], ["consistent", 359], ["with", 370], ["an", 375], ["independent", 378], ["evolution", 390], ["of", 400], ["B1", 403], ["elements", 406], ["in", 415], ["separate", 418], ["rodent", 427], ["lineages", 434], [".", 442], ["We", 444], ["exclude", 447], ["the", 455], ["possibility", 459], ["of", 471], ["convergent", 474], ["mutations", 485], ["to", 495], ["explain", 498], ["certain", 506], ["diagnostic", 514], ["characters", 525], ["within", 536], ["the", 543], ["modern", 547], ["B1", 554], ["quasi", 557], ["-", 562], ["dimers", 563], ["and", 570], ["view", 574], ["these", 579], ["elements", 585], ["as", 594], ["mosaic", 597], ["structures", 604], ["assembling", 615], ["preexisting", 626], ["mutations", 638], [".", 647], ["Furthermore", 649], [",", 660], ["the", 662], ["presence", 666], ["of", 675], ["Alu", 678], ["-", 681], ["like", 682], ["structural", 687], ["motifs", 698], ["supports", 705], ["the", 714], ["hypothesis", 718], ["of", 729], ["the", 732], ["monophyletic", 736], ["origin", 749], ["of", 756], ["Alu", 759], ["and", 763], ["B1", 767], ["repeats", 770], [",", 777], ["i.e.", 779], [",", 783], ["from", 785], ["a", 790], ["common", 792], ["7SL", 799], ["RNA", 803], ["-", 806], ["derived", 807], ["retroposing", 815], ["monomeric", 827], ["element", 837], [".", 844]]}
{"context": "Mowat-Wilson syndrome is a genetic condition characterized by a recognizable facial phenotype in addition to moderate to severe cognitive disability with severe speech impairment and variable multiple congenital anomalies. The anomalies may include Hirschsprung disease, heart defects, structural eye anomalies including microphthalmia, agenesis of the corpus callosum, and urogenital anomalies. Microcephaly, seizure disorder and constipation are common. All typical cases result from haploinsufficiency of the ZEB2 (also known as ZFHX1B or SIP-1) gene, with over 100 distinct mutations now described. Approximately 80% of patients have a nonsense or frameshift mutation detectable by sequencing, with the rest having gross deletions necessitating a dosage sensitive assay. Here we report on the results of comprehensive molecular testing for 27 patients testing positive for MWS. Twenty-one patients had a nonsense, frameshift, or splice site mutation identified by sequencing; 14 of which localized to exon 8 and 17 of which are novel. Six patients had deletions in the ZEB2 gene, including two novel partial gene deletions. This report, the first such analysis in North American patients, adds to the growing list of both novel pathogenic mutations associated with MWS, as well as other variants in the ZEB2 gene. In addition, we suggest an economical testing strategy.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "6aab95b5bc40449b812caabddc308265", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[80, 80]], "char_spans": [[532, 537]]}, {"text": "ZEB2", "token_spans": [[220, 220], [75, 75], [177, 177]], "char_spans": [[1307, 1310], [512, 515], [1073, 1076]]}, {"text": "SIP-1", "token_spans": [[82, 82]], "char_spans": [[542, 546]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["condition", 35], ["characterized", 45], ["by", 59], ["a", 62], ["recognizable", 64], ["facial", 77], ["phenotype", 84], ["in", 94], ["addition", 97], ["to", 106], ["moderate", 109], ["to", 118], ["severe", 121], ["cognitive", 128], ["disability", 138], ["with", 149], ["severe", 154], ["speech", 161], ["impairment", 168], ["and", 179], ["variable", 183], ["multiple", 192], ["congenital", 201], ["anomalies", 212], [".", 221], ["The", 223], ["anomalies", 227], ["may", 237], ["include", 241], ["Hirschsprung", 249], ["disease", 262], [",", 269], ["heart", 271], ["defects", 277], [",", 284], ["structural", 286], ["eye", 297], ["anomalies", 301], ["including", 311], ["microphthalmia", 321], [",", 335], ["agenesis", 337], ["of", 346], ["the", 349], ["corpus", 353], ["callosum", 360], [",", 368], ["and", 370], ["urogenital", 374], ["anomalies", 385], [".", 394], ["Microcephaly", 396], [",", 408], ["seizure", 410], ["disorder", 418], ["and", 427], ["constipation", 431], ["are", 444], ["common", 448], [".", 454], ["All", 456], ["typical", 460], ["cases", 468], ["result", 474], ["from", 481], ["haploinsufficiency", 486], ["of", 505], ["the", 508], ["ZEB2", 512], ["(", 517], ["also", 518], ["known", 523], ["as", 529], ["ZFHX1B", 532], ["or", 539], ["SIP-1", 542], [")", 547], ["gene", 549], [",", 553], ["with", 555], ["over", 560], ["100", 565], ["distinct", 569], ["mutations", 578], ["now", 588], ["described", 592], [".", 601], ["Approximately", 603], ["80", 617], ["%", 619], ["of", 621], ["patients", 624], ["have", 633], ["a", 638], ["nonsense", 640], ["or", 649], ["frameshift", 652], ["mutation", 663], ["detectable", 672], ["by", 683], ["sequencing", 686], [",", 696], ["with", 698], ["the", 703], ["rest", 707], ["having", 712], ["gross", 719], ["deletions", 725], ["necessitating", 735], ["a", 749], ["dosage", 751], ["sensitive", 758], ["assay", 768], [".", 773], ["Here", 775], ["we", 780], ["report", 783], ["on", 790], ["the", 793], ["results", 797], ["of", 805], ["comprehensive", 808], ["molecular", 822], ["testing", 832], ["for", 840], ["27", 844], ["patients", 847], ["testing", 856], ["positive", 864], ["for", 873], ["MWS", 877], [".", 880], ["Twenty", 882], ["-", 888], ["one", 889], ["patients", 893], ["had", 902], ["a", 906], ["nonsense", 908], [",", 916], ["frameshift", 918], [",", 928], ["or", 930], ["splice", 933], ["site", 940], ["mutation", 945], ["identified", 954], ["by", 965], ["sequencing", 968], [";", 978], ["14", 980], ["of", 983], ["which", 986], ["localized", 992], ["to", 1002], ["exon", 1005], ["8", 1010], ["and", 1012], ["17", 1016], ["of", 1019], ["which", 1022], ["are", 1028], ["novel", 1032], [".", 1037], ["Six", 1039], ["patients", 1043], ["had", 1052], ["deletions", 1056], ["in", 1066], ["the", 1069], ["ZEB2", 1073], ["gene", 1078], [",", 1082], ["including", 1084], ["two", 1094], ["novel", 1098], ["partial", 1104], ["gene", 1112], ["deletions", 1117], [".", 1126], ["This", 1128], ["report", 1133], [",", 1139], ["the", 1141], ["first", 1145], ["such", 1151], ["analysis", 1156], ["in", 1165], ["North", 1168], ["American", 1174], ["patients", 1183], [",", 1191], ["adds", 1193], ["to", 1198], ["the", 1201], ["growing", 1205], ["list", 1213], ["of", 1218], ["both", 1221], ["novel", 1226], ["pathogenic", 1232], ["mutations", 1243], ["associated", 1253], ["with", 1264], ["MWS", 1269], [",", 1272], ["as", 1274], ["well", 1277], ["as", 1282], ["other", 1285], ["variants", 1291], ["in", 1300], ["the", 1303], ["ZEB2", 1307], ["gene", 1312], [".", 1316], ["In", 1318], ["addition", 1321], [",", 1329], ["we", 1331], ["suggest", 1334], ["an", 1342], ["economical", 1345], ["testing", 1356], ["strategy", 1364], [".", 1372]]}
{"context": "The authors discuss the clinical and molecular genetic aspects of genetically determined neuromuscular disorders of some Roma families living in Hungary. Among the autosomal recessively inherited spinal muscular atrophic (SMA) group, 8 Caucasian children had the typical 7-8 exonal deletions of the SMA gene, but only 2 patients belonged to the Roma population. There was no difference in the molecular genetic findings among the Caucasian and the Roma SMA patients. All of them had 7-8 exonal deletions of the SMA gene. We wanted to call attention to the founder mutation of the Roma population in 7 patients suffering from congenital myasthenia (CMS) from 3 Roma families. The 1267G deletion for CMS was detected by molecular genetic method. Clinical onset was pubertal and relatively slow progression of specific and phenotypic features for this founder mutation of acetyl-cholin receptor epsylon gene. In 2 patients (sister and brother) the sarcoglycanopathy 2C type C283Q mutation was proven in one Roma family suffering from limb-girdle muscular dystrophy (LGMD). Two out of the three facioscapular-humeral dystrophy (FSHD) Roma families carried 21.8 kb and 18.5 kb alleles in FSHD A1 gene (D4S139). In one family together with prenatal diagnosis founder mutation in FSHD A1 gene was detected, according to the autosomal dominant (AD) inheritance. In (F2) prenatal diagnosis was carried out, 18.5 kb/18.5 kb homozygosity was proven in the fetus, so the pregnancy was interrupted. In the CMS, LGMD and FSHD Roma patients ancient typical Roma founder mutations were found.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "0219464e052f47129d0aa71da3738b73", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[238, 239]], "char_spans": [[1317, 1334]]}]}], "context_tokens": [["The", 0], ["authors", 4], ["discuss", 12], ["the", 20], ["clinical", 24], ["and", 33], ["molecular", 37], ["genetic", 47], ["aspects", 55], ["of", 63], ["genetically", 66], ["determined", 78], ["neuromuscular", 89], ["disorders", 103], ["of", 113], ["some", 116], ["Roma", 121], ["families", 126], ["living", 135], ["in", 142], ["Hungary", 145], [".", 152], ["Among", 154], ["the", 160], ["autosomal", 164], ["recessively", 174], ["inherited", 186], ["spinal", 196], ["muscular", 203], ["atrophic", 212], ["(", 221], ["SMA", 222], [")", 225], ["group", 227], [",", 232], ["8", 234], ["Caucasian", 236], ["children", 246], ["had", 255], ["the", 259], ["typical", 263], ["7", 271], ["-", 272], ["8", 273], ["exonal", 275], ["deletions", 282], ["of", 292], ["the", 295], ["SMA", 299], ["gene", 303], [",", 307], ["but", 309], ["only", 313], ["2", 318], ["patients", 320], ["belonged", 329], ["to", 338], ["the", 341], ["Roma", 345], ["population", 350], [".", 360], ["There", 362], ["was", 368], ["no", 372], ["difference", 375], ["in", 386], ["the", 389], ["molecular", 393], ["genetic", 403], ["findings", 411], ["among", 420], ["the", 426], ["Caucasian", 430], ["and", 440], ["the", 444], ["Roma", 448], ["SMA", 453], ["patients", 457], [".", 465], ["All", 467], ["of", 471], ["them", 474], ["had", 479], ["7", 483], ["-", 484], ["8", 485], ["exonal", 487], ["deletions", 494], ["of", 504], ["the", 507], ["SMA", 511], ["gene", 515], [".", 519], ["We", 521], ["wanted", 524], ["to", 531], ["call", 534], ["attention", 539], ["to", 549], ["the", 552], ["founder", 556], ["mutation", 564], ["of", 573], ["the", 576], ["Roma", 580], ["population", 585], ["in", 596], ["7", 599], ["patients", 601], ["suffering", 610], ["from", 620], ["congenital", 625], ["myasthenia", 636], ["(", 647], ["CMS", 648], [")", 651], ["from", 653], ["3", 658], ["Roma", 660], ["families", 665], [".", 673], ["The", 675], ["1267", 679], ["G", 683], ["deletion", 685], ["for", 694], ["CMS", 698], ["was", 702], ["detected", 706], ["by", 715], ["molecular", 718], ["genetic", 728], ["method", 736], [".", 742], ["Clinical", 744], ["onset", 753], ["was", 759], ["pubertal", 763], ["and", 772], ["relatively", 776], ["slow", 787], ["progression", 792], ["of", 804], ["specific", 807], ["and", 816], ["phenotypic", 820], ["features", 831], ["for", 840], ["this", 844], ["founder", 849], ["mutation", 857], ["of", 866], ["acetyl", 869], ["-", 875], ["cholin", 876], ["receptor", 883], ["epsylon", 892], ["gene", 900], [".", 904], ["In", 906], ["2", 909], ["patients", 911], ["(", 920], ["sister", 921], ["and", 928], ["brother", 932], [")", 939], ["the", 941], ["sarcoglycanopathy", 945], ["2C", 963], ["type", 966], ["C283Q", 971], ["mutation", 977], ["was", 986], ["proven", 990], ["in", 997], ["one", 1000], ["Roma", 1004], ["family", 1009], ["suffering", 1016], ["from", 1026], ["limb", 1031], ["-", 1035], ["girdle", 1036], ["muscular", 1043], ["dystrophy", 1052], ["(", 1062], ["LGMD", 1063], [")", 1067], [".", 1068], ["Two", 1070], ["out", 1074], ["of", 1078], ["the", 1081], ["three", 1085], ["facioscapular", 1091], ["-", 1104], ["humeral", 1105], ["dystrophy", 1113], ["(", 1123], ["FSHD", 1124], [")", 1128], ["Roma", 1130], ["families", 1135], ["carried", 1144], ["21.8", 1152], ["kb", 1157], ["and", 1160], ["18.5", 1164], ["kb", 1169], ["alleles", 1172], ["in", 1180], ["FSHD", 1183], ["A1", 1188], ["gene", 1191], ["(", 1196], ["D4S139", 1197], [")", 1203], [".", 1204], ["In", 1206], ["one", 1209], ["family", 1213], ["together", 1220], ["with", 1229], ["prenatal", 1234], ["diagnosis", 1243], ["founder", 1253], ["mutation", 1261], ["in", 1270], ["FSHD", 1273], ["A1", 1278], ["gene", 1281], ["was", 1286], ["detected", 1290], [",", 1298], ["according", 1300], ["to", 1310], ["the", 1313], ["autosomal", 1317], ["dominant", 1327], ["(", 1336], ["AD", 1337], [")", 1339], ["inheritance", 1341], [".", 1352], ["In", 1354], ["(", 1357], ["F2", 1358], [")", 1360], ["prenatal", 1362], ["diagnosis", 1371], ["was", 1381], ["carried", 1385], ["out", 1393], [",", 1396], ["18.5", 1398], ["kb/18.5", 1403], ["kb", 1411], ["homozygosity", 1414], ["was", 1427], ["proven", 1431], ["in", 1438], ["the", 1441], ["fetus", 1445], [",", 1450], ["so", 1452], ["the", 1455], ["pregnancy", 1459], ["was", 1469], ["interrupted", 1473], [".", 1484], ["In", 1486], ["the", 1489], ["CMS", 1493], [",", 1496], ["LGMD", 1498], ["and", 1503], ["FSHD", 1507], ["Roma", 1512], ["patients", 1517], ["ancient", 1526], ["typical", 1534], ["Roma", 1542], ["founder", 1547], ["mutations", 1555], ["were", 1565], ["found", 1570], [".", 1575]]}
{"context": "In cancer research, background models for mutation rates have been extensively calibrated in coding regions, leading to the identification of many driver genes, recurrently mutated more than expected. Noncoding regions are also associated with disease; however, background models for them have not been investigated in as much detail. This is partially due to limited noncoding functional annotation. Also, great mutation heterogeneity and potential correlations between neighboring sites give rise to substantial overdispersion in mutation count, resulting in problematic background rate estimation. Here, we address these issues with a new computational framework called LARVA. It integrates variants with a comprehensive set of noncoding functional elements, modeling the mutation counts of the elements with a \u03b2-binomial distribution to handle overdispersion. LARVA, moreover, uses regional genomic features such as replication timing to better estimate local mutation rates and mutational hotspots. We demonstrate LARVA's effectiveness on 760 whole-genome tumor sequences, showing that it identifies well-known noncoding drivers, such as mutations in the TERT promoter. Furthermore, LARVA highlights several novel highly mutated regulatory sites that could potentially be noncoding drivers. We make LARVA available as a software tool and release our highly mutated annotations as an online resource (larva.gersteinlab.org).", "qas": [{"question": "Which tool is used for the identification of recurrent variants in noncoding regions?", "answers": ["LARVA"], "qid": "b64f61ec5c4c4a3383e26a39db26cd14", "question_tokens": [["Which", 0], ["tool", 6], ["is", 11], ["used", 14], ["for", 19], ["the", 23], ["identification", 27], ["of", 42], ["recurrent", 45], ["variants", 55], ["in", 64], ["noncoding", 67], ["regions", 77], ["?", 84]], "detected_answers": [{"text": "LARVA", "token_spans": [[135, 135], [104, 104], [159, 159], [190, 190], [207, 207]], "char_spans": [[864, 868], [673, 677], [1019, 1023], [1188, 1192], [1304, 1308]]}]}], "context_tokens": [["In", 0], ["cancer", 3], ["research", 10], [",", 18], ["background", 20], ["models", 31], ["for", 38], ["mutation", 42], ["rates", 51], ["have", 57], ["been", 62], ["extensively", 67], ["calibrated", 79], ["in", 90], ["coding", 93], ["regions", 100], [",", 107], ["leading", 109], ["to", 117], ["the", 120], ["identification", 124], ["of", 139], ["many", 142], ["driver", 147], ["genes", 154], [",", 159], ["recurrently", 161], ["mutated", 173], ["more", 181], ["than", 186], ["expected", 191], [".", 199], ["Noncoding", 201], ["regions", 211], ["are", 219], ["also", 223], ["associated", 228], ["with", 239], ["disease", 244], [";", 251], ["however", 253], [",", 260], ["background", 262], ["models", 273], ["for", 280], ["them", 284], ["have", 289], ["not", 294], ["been", 298], ["investigated", 303], ["in", 316], ["as", 319], ["much", 322], ["detail", 327], [".", 333], ["This", 335], ["is", 340], ["partially", 343], ["due", 353], ["to", 357], ["limited", 360], ["noncoding", 368], ["functional", 378], ["annotation", 389], [".", 399], ["Also", 401], [",", 405], ["great", 407], ["mutation", 413], ["heterogeneity", 422], ["and", 436], ["potential", 440], ["correlations", 450], ["between", 463], ["neighboring", 471], ["sites", 483], ["give", 489], ["rise", 494], ["to", 499], ["substantial", 502], ["overdispersion", 514], ["in", 529], ["mutation", 532], ["count", 541], [",", 546], ["resulting", 548], ["in", 558], ["problematic", 561], ["background", 573], ["rate", 584], ["estimation", 589], [".", 599], ["Here", 601], [",", 605], ["we", 607], ["address", 610], ["these", 618], ["issues", 624], ["with", 631], ["a", 636], ["new", 638], ["computational", 642], ["framework", 656], ["called", 666], ["LARVA", 673], [".", 678], ["It", 680], ["integrates", 683], ["variants", 694], ["with", 703], ["a", 708], ["comprehensive", 710], ["set", 724], ["of", 728], ["noncoding", 731], ["functional", 741], ["elements", 752], [",", 760], ["modeling", 762], ["the", 771], ["mutation", 775], ["counts", 784], ["of", 791], ["the", 794], ["elements", 798], ["with", 807], ["a", 812], ["\u03b2", 814], ["-", 815], ["binomial", 816], ["distribution", 825], ["to", 838], ["handle", 841], ["overdispersion", 848], [".", 862], ["LARVA", 864], [",", 869], ["moreover", 871], [",", 879], ["uses", 881], ["regional", 886], ["genomic", 895], ["features", 903], ["such", 912], ["as", 917], ["replication", 920], ["timing", 932], ["to", 939], ["better", 942], ["estimate", 949], ["local", 958], ["mutation", 964], ["rates", 973], ["and", 979], ["mutational", 983], ["hotspots", 994], [".", 1002], ["We", 1004], ["demonstrate", 1007], ["LARVA", 1019], ["'s", 1024], ["effectiveness", 1027], ["on", 1041], ["760", 1044], ["whole", 1048], ["-", 1053], ["genome", 1054], ["tumor", 1061], ["sequences", 1067], [",", 1076], ["showing", 1078], ["that", 1086], ["it", 1091], ["identifies", 1094], ["well", 1105], ["-", 1109], ["known", 1110], ["noncoding", 1116], ["drivers", 1126], [",", 1133], ["such", 1135], ["as", 1140], ["mutations", 1143], ["in", 1153], ["the", 1156], ["TERT", 1160], ["promoter", 1165], [".", 1173], ["Furthermore", 1175], [",", 1186], ["LARVA", 1188], ["highlights", 1194], ["several", 1205], ["novel", 1213], ["highly", 1219], ["mutated", 1226], ["regulatory", 1234], ["sites", 1245], ["that", 1251], ["could", 1256], ["potentially", 1262], ["be", 1274], ["noncoding", 1277], ["drivers", 1287], [".", 1294], ["We", 1296], ["make", 1299], ["LARVA", 1304], ["available", 1310], ["as", 1320], ["a", 1323], ["software", 1325], ["tool", 1334], ["and", 1339], ["release", 1343], ["our", 1351], ["highly", 1355], ["mutated", 1362], ["annotations", 1370], ["as", 1382], ["an", 1385], ["online", 1388], ["resource", 1395], ["(", 1404], ["larva.gersteinlab.org", 1405], [")", 1426], [".", 1427]]}
{"context": "SECIS elements form stem-loop structures in the 3' untranslated regions (UTR) of eukaryotic mRNAs that encode selenoproteins. These elements direct incorporation of selenocysteine at UGA codons, provided the SECIS element lies a sufficient distance from the UGA. The cDNAs encoding skeletal muscle selenoprotein W from human, rhesus monkey, sheep, rat, and mouse contained highly similar SECIS elements that retained important features common to all known SECIS elements. Comparative analysis of these SECIS elements showed that in some regions both predicted secondary structure and nucleotide sequences were conserved, in other areas secondary structure was maintained using different primary sequence, and in still other portions, base pairing was not conserved. The rodent and sheep selenoprotein W mRNAs used UGA as a stop codon and as a selenocysteine codon. Thus, UGA specified both selenocysteine incorporation and termination in a single mRNA. The selenoprotein W SECIS elements contained an additional highly conserved base-paired stem that may prevent inappropriate selenocysteine incorporation at the UGA stop codons.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "22a6d5d4fcc740a0998d3d943187fa60", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [35, 35], [77, 77], [67, 67], [84, 84], [161, 161]], "char_spans": [[0, 4], [208, 212], [456, 460], [388, 392], [502, 506], [973, 977]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["form", 15], ["stem", 20], ["-", 24], ["loop", 25], ["structures", 30], ["in", 41], ["the", 44], ["3", 48], ["'", 49], ["untranslated", 51], ["regions", 64], ["(", 72], ["UTR", 73], [")", 76], ["of", 78], ["eukaryotic", 81], ["mRNAs", 92], ["that", 98], ["encode", 103], ["selenoproteins", 110], [".", 124], ["These", 126], ["elements", 132], ["direct", 141], ["incorporation", 148], ["of", 162], ["selenocysteine", 165], ["at", 180], ["UGA", 183], ["codons", 187], [",", 193], ["provided", 195], ["the", 204], ["SECIS", 208], ["element", 214], ["lies", 222], ["a", 227], ["sufficient", 229], ["distance", 240], ["from", 249], ["the", 254], ["UGA", 258], [".", 261], ["The", 263], ["cDNAs", 267], ["encoding", 273], ["skeletal", 282], ["muscle", 291], ["selenoprotein", 298], ["W", 312], ["from", 314], ["human", 319], [",", 324], ["rhesus", 326], ["monkey", 333], [",", 339], ["sheep", 341], [",", 346], ["rat", 348], [",", 351], ["and", 353], ["mouse", 357], ["contained", 363], ["highly", 373], ["similar", 380], ["SECIS", 388], ["elements", 394], ["that", 403], ["retained", 408], ["important", 417], ["features", 427], ["common", 436], ["to", 443], ["all", 446], ["known", 450], ["SECIS", 456], ["elements", 462], [".", 470], ["Comparative", 472], ["analysis", 484], ["of", 493], ["these", 496], ["SECIS", 502], ["elements", 508], ["showed", 517], ["that", 524], ["in", 529], ["some", 532], ["regions", 537], ["both", 545], ["predicted", 550], ["secondary", 560], ["structure", 570], ["and", 580], ["nucleotide", 584], ["sequences", 595], ["were", 605], ["conserved", 610], [",", 619], ["in", 621], ["other", 624], ["areas", 630], ["secondary", 636], ["structure", 646], ["was", 656], ["maintained", 660], ["using", 671], ["different", 677], ["primary", 687], ["sequence", 695], [",", 703], ["and", 705], ["in", 709], ["still", 712], ["other", 718], ["portions", 724], [",", 732], ["base", 734], ["pairing", 739], ["was", 747], ["not", 751], ["conserved", 755], [".", 764], ["The", 766], ["rodent", 770], ["and", 777], ["sheep", 781], ["selenoprotein", 787], ["W", 801], ["mRNAs", 803], ["used", 809], ["UGA", 814], ["as", 818], ["a", 821], ["stop", 823], ["codon", 828], ["and", 834], ["as", 838], ["a", 841], ["selenocysteine", 843], ["codon", 858], [".", 863], ["Thus", 865], [",", 869], ["UGA", 871], ["specified", 875], ["both", 885], ["selenocysteine", 890], ["incorporation", 905], ["and", 919], ["termination", 923], ["in", 935], ["a", 938], ["single", 940], ["mRNA", 947], [".", 951], ["The", 953], ["selenoprotein", 957], ["W", 971], ["SECIS", 973], ["elements", 979], ["contained", 988], ["an", 998], ["additional", 1001], ["highly", 1012], ["conserved", 1019], ["base", 1029], ["-", 1033], ["paired", 1034], ["stem", 1041], ["that", 1046], ["may", 1051], ["prevent", 1055], ["inappropriate", 1063], ["selenocysteine", 1077], ["incorporation", 1092], ["at", 1106], ["the", 1109], ["UGA", 1113], ["stop", 1117], ["codons", 1122], [".", 1128]]}
{"context": "An outbreak of Clostridium difficile ribotype 027 infection (CDI) occurred at an university hospital, involving 19 departments. To determine what hospital-associated factors drove the outbreak of this particular strain we performed a case-control study. Cases (n = 79), diagnosed with CDI due to C. difficile ribotype 027 were matched for age and treating medical specialty to four control patients (n = 316). Patients diagnosed with CDI due to other ribotypes were included as a second control group. A random selection of C. difficile ribotype 027 strains (n = 10) was genotyped by Whole Genome Sequencing (WGS). WGS showed the outbreak was likely caused by a single strain of C. difficile (two or less single-nucleotide variants between isolates). Ninety-five percent of cases had used antibiotics, compared to 56% of controls. Previous admission to the intensive care unit (ICU) (OR: 2.4, 95% CI 1.0-5.6), longer length of stay (LOS), and recent hospital admission were associated with CDI ribotype 027. Cases were less likely to have been admitted to a ward with a known isolated CDI patient (OR: 0.2, 95% CI 0.1-0.6). Analysis of patients who stayed at the ICU (35 cases; 51 controls), indicated that the use of selective decontamination of the digestive tract (SDD) and a longer LOS in the ICU were associated with CDI risk. In this large outbreak, any antibiotic use, including SDD use, appeared as a prerequisite for acquisition of the outbreak strain. The role of use of SDD and prolonged stay on the ICU could not be disentangled, but both factors can play a biologically plausible role in C. difficile acquisition and infection.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "3624fe9b9dca47c98be7dc8c2d2db870", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[5, 6], [57, 58], [199, 200], [99, 100]], "char_spans": [[37, 48], [309, 320], [994, 1005], [537, 548]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["ribotype", 37], ["027", 46], ["infection", 50], ["(", 60], ["CDI", 61], [")", 64], ["occurred", 66], ["at", 75], ["an", 78], ["university", 81], ["hospital", 92], [",", 100], ["involving", 102], ["19", 112], ["departments", 115], [".", 126], ["To", 128], ["determine", 131], ["what", 141], ["hospital", 146], ["-", 154], ["associated", 155], ["factors", 166], ["drove", 174], ["the", 180], ["outbreak", 184], ["of", 193], ["this", 196], ["particular", 201], ["strain", 212], ["we", 219], ["performed", 222], ["a", 232], ["case", 234], ["-", 238], ["control", 239], ["study", 247], [".", 252], ["Cases", 254], ["(", 260], ["n", 261], ["=", 263], ["79", 265], [")", 267], [",", 268], ["diagnosed", 270], ["with", 280], ["CDI", 285], ["due", 289], ["to", 293], ["C.", 296], ["difficile", 299], ["ribotype", 309], ["027", 318], ["were", 322], ["matched", 327], ["for", 335], ["age", 339], ["and", 343], ["treating", 347], ["medical", 356], ["specialty", 364], ["to", 374], ["four", 377], ["control", 382], ["patients", 390], ["(", 399], ["n", 400], ["=", 402], ["316", 404], [")", 407], [".", 408], ["Patients", 410], ["diagnosed", 419], ["with", 429], ["CDI", 434], ["due", 438], ["to", 442], ["other", 445], ["ribotypes", 451], ["were", 461], ["included", 466], ["as", 475], ["a", 478], ["second", 480], ["control", 487], ["group", 495], [".", 500], ["A", 502], ["random", 504], ["selection", 511], ["of", 521], ["C.", 524], ["difficile", 527], ["ribotype", 537], ["027", 546], ["strains", 550], ["(", 558], ["n", 559], ["=", 561], ["10", 563], [")", 565], ["was", 567], ["genotyped", 571], ["by", 581], ["Whole", 584], ["Genome", 590], ["Sequencing", 597], ["(", 608], ["WGS", 609], [")", 612], [".", 613], ["WGS", 615], ["showed", 619], ["the", 626], ["outbreak", 630], ["was", 639], ["likely", 643], ["caused", 650], ["by", 657], ["a", 660], ["single", 662], ["strain", 669], ["of", 676], ["C.", 679], ["difficile", 682], ["(", 692], ["two", 693], ["or", 697], ["less", 700], ["single", 705], ["-", 711], ["nucleotide", 712], ["variants", 723], ["between", 732], ["isolates", 740], [")", 748], [".", 749], ["Ninety", 751], ["-", 757], ["five", 758], ["percent", 763], ["of", 771], ["cases", 774], ["had", 780], ["used", 784], ["antibiotics", 789], [",", 800], ["compared", 802], ["to", 811], ["56", 814], ["%", 816], ["of", 818], ["controls", 821], [".", 829], ["Previous", 831], ["admission", 840], ["to", 850], ["the", 853], ["intensive", 857], ["care", 867], ["unit", 872], ["(", 877], ["ICU", 878], [")", 881], ["(", 883], ["OR", 884], [":", 886], ["2.4", 888], [",", 891], ["95", 893], ["%", 895], ["CI", 897], ["1.0", 900], ["-", 903], ["5.6", 904], [")", 907], [",", 908], ["longer", 910], ["length", 917], ["of", 924], ["stay", 927], ["(", 932], ["LOS", 933], [")", 936], [",", 937], ["and", 939], ["recent", 943], ["hospital", 950], ["admission", 959], ["were", 969], ["associated", 974], ["with", 985], ["CDI", 990], ["ribotype", 994], ["027", 1003], [".", 1006], ["Cases", 1008], ["were", 1014], ["less", 1019], ["likely", 1024], ["to", 1031], ["have", 1034], ["been", 1039], ["admitted", 1044], ["to", 1053], ["a", 1056], ["ward", 1058], ["with", 1063], ["a", 1068], ["known", 1070], ["isolated", 1076], ["CDI", 1085], ["patient", 1089], ["(", 1097], ["OR", 1098], [":", 1100], ["0.2", 1102], [",", 1105], ["95", 1107], ["%", 1109], ["CI", 1111], ["0.1", 1114], ["-", 1117], ["0.6", 1118], [")", 1121], [".", 1122], ["Analysis", 1124], ["of", 1133], ["patients", 1136], ["who", 1145], ["stayed", 1149], ["at", 1156], ["the", 1159], ["ICU", 1163], ["(", 1167], ["35", 1168], ["cases", 1171], [";", 1176], ["51", 1178], ["controls", 1181], [")", 1189], [",", 1190], ["indicated", 1192], ["that", 1202], ["the", 1207], ["use", 1211], ["of", 1215], ["selective", 1218], ["decontamination", 1228], ["of", 1244], ["the", 1247], ["digestive", 1251], ["tract", 1261], ["(", 1267], ["SDD", 1268], [")", 1271], ["and", 1273], ["a", 1277], ["longer", 1279], ["LOS", 1286], ["in", 1290], ["the", 1293], ["ICU", 1297], ["were", 1301], ["associated", 1306], ["with", 1317], ["CDI", 1322], ["risk", 1326], [".", 1330], ["In", 1332], ["this", 1335], ["large", 1340], ["outbreak", 1346], [",", 1354], ["any", 1356], ["antibiotic", 1360], ["use", 1371], [",", 1374], ["including", 1376], ["SDD", 1386], ["use", 1390], [",", 1393], ["appeared", 1395], ["as", 1404], ["a", 1407], ["prerequisite", 1409], ["for", 1422], ["acquisition", 1426], ["of", 1438], ["the", 1441], ["outbreak", 1445], ["strain", 1454], [".", 1460], ["The", 1462], ["role", 1466], ["of", 1471], ["use", 1474], ["of", 1478], ["SDD", 1481], ["and", 1485], ["prolonged", 1489], ["stay", 1499], ["on", 1504], ["the", 1507], ["ICU", 1511], ["could", 1515], ["not", 1521], ["be", 1525], ["disentangled", 1528], [",", 1540], ["but", 1542], ["both", 1546], ["factors", 1551], ["can", 1559], ["play", 1563], ["a", 1568], ["biologically", 1570], ["plausible", 1583], ["role", 1593], ["in", 1598], ["C.", 1601], ["difficile", 1604], ["acquisition", 1614], ["and", 1626], ["infection", 1630], [".", 1639]]}
{"context": "Neurobiology of speech and language has previously been studied in the KE family, in which half of the members have severe impairment in both speech and language. The gene responsible for the phenotype was mapped to chromosome 7q31 and identified as the FOXP2 gene, coding for a transcription factor containing a polyglutamine tract and a forkhead DNA-binding domain. Because of linkage studies implicating 7q31 in autism, where language impairment is a component of the disorder, and in specific language impairment, FOXP2 has also been considered as a potential susceptibility locus for the language deficits in autism and/or specific language impairment. In this study, we characterized mice with a disruption in the murine Foxp2 gene. Disruption of both copies of the Foxp2 gene caused severe motor impairment, premature death, and an absence of ultrasonic vocalizations that are elicited when pups are removed from their mothers. Disruption of a single copy of the gene led to modest developmental delay but a significant alteration in ultrasonic vocalization in response to such separation. Learning and memory appear normal in the heterozygous animals. Cerebellar abnormalities were observed in mice with disruptions in Foxp2, with Purkinje cells particularly affected. Our findings support a role for Foxp2 in cerebellar development and in a developmental process that subsumes social communication functions in diverse organisms.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "7dd09d57cc444e8eb573053076049159", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[123, 123], [218, 218], [132, 132], [44, 44], [204, 204], [89, 89]], "char_spans": [[727, 731], [1309, 1313], [772, 776], [254, 258], [1227, 1231], [518, 522]]}]}], "context_tokens": [["Neurobiology", 0], ["of", 13], ["speech", 16], ["and", 23], ["language", 27], ["has", 36], ["previously", 40], ["been", 51], ["studied", 56], ["in", 64], ["the", 67], ["KE", 71], ["family", 74], [",", 80], ["in", 82], ["which", 85], ["half", 91], ["of", 96], ["the", 99], ["members", 103], ["have", 111], ["severe", 116], ["impairment", 123], ["in", 134], ["both", 137], ["speech", 142], ["and", 149], ["language", 153], [".", 161], ["The", 163], ["gene", 167], ["responsible", 172], ["for", 184], ["the", 188], ["phenotype", 192], ["was", 202], ["mapped", 206], ["to", 213], ["chromosome", 216], ["7q31", 227], ["and", 232], ["identified", 236], ["as", 247], ["the", 250], ["FOXP2", 254], ["gene", 260], [",", 264], ["coding", 266], ["for", 273], ["a", 277], ["transcription", 279], ["factor", 293], ["containing", 300], ["a", 311], ["polyglutamine", 313], ["tract", 327], ["and", 333], ["a", 337], ["forkhead", 339], ["DNA", 348], ["-", 351], ["binding", 352], ["domain", 360], [".", 366], ["Because", 368], ["of", 376], ["linkage", 379], ["studies", 387], ["implicating", 395], ["7q31", 407], ["in", 412], ["autism", 415], [",", 421], ["where", 423], ["language", 429], ["impairment", 438], ["is", 449], ["a", 452], ["component", 454], ["of", 464], ["the", 467], ["disorder", 471], [",", 479], ["and", 481], ["in", 485], ["specific", 488], ["language", 497], ["impairment", 506], [",", 516], ["FOXP2", 518], ["has", 524], ["also", 528], ["been", 533], ["considered", 538], ["as", 549], ["a", 552], ["potential", 554], ["susceptibility", 564], ["locus", 579], ["for", 585], ["the", 589], ["language", 593], ["deficits", 602], ["in", 611], ["autism", 614], ["and/or", 621], ["specific", 628], ["language", 637], ["impairment", 646], [".", 656], ["In", 658], ["this", 661], ["study", 666], [",", 671], ["we", 673], ["characterized", 676], ["mice", 690], ["with", 695], ["a", 700], ["disruption", 702], ["in", 713], ["the", 716], ["murine", 720], ["Foxp2", 727], ["gene", 733], [".", 737], ["Disruption", 739], ["of", 750], ["both", 753], ["copies", 758], ["of", 765], ["the", 768], ["Foxp2", 772], ["gene", 778], ["caused", 783], ["severe", 790], ["motor", 797], ["impairment", 803], [",", 813], ["premature", 815], ["death", 825], [",", 830], ["and", 832], ["an", 836], ["absence", 839], ["of", 847], ["ultrasonic", 850], ["vocalizations", 861], ["that", 875], ["are", 880], ["elicited", 884], ["when", 893], ["pups", 898], ["are", 903], ["removed", 907], ["from", 915], ["their", 920], ["mothers", 926], [".", 933], ["Disruption", 935], ["of", 946], ["a", 949], ["single", 951], ["copy", 958], ["of", 963], ["the", 966], ["gene", 970], ["led", 975], ["to", 979], ["modest", 982], ["developmental", 989], ["delay", 1003], ["but", 1009], ["a", 1013], ["significant", 1015], ["alteration", 1027], ["in", 1038], ["ultrasonic", 1041], ["vocalization", 1052], ["in", 1065], ["response", 1068], ["to", 1077], ["such", 1080], ["separation", 1085], [".", 1095], ["Learning", 1097], ["and", 1106], ["memory", 1110], ["appear", 1117], ["normal", 1124], ["in", 1131], ["the", 1134], ["heterozygous", 1138], ["animals", 1151], [".", 1158], ["Cerebellar", 1160], ["abnormalities", 1171], ["were", 1185], ["observed", 1190], ["in", 1199], ["mice", 1202], ["with", 1207], ["disruptions", 1212], ["in", 1224], ["Foxp2", 1227], [",", 1232], ["with", 1234], ["Purkinje", 1239], ["cells", 1248], ["particularly", 1254], ["affected", 1267], [".", 1275], ["Our", 1277], ["findings", 1281], ["support", 1290], ["a", 1298], ["role", 1300], ["for", 1305], ["Foxp2", 1309], ["in", 1315], ["cerebellar", 1318], ["development", 1329], ["and", 1341], ["in", 1345], ["a", 1348], ["developmental", 1350], ["process", 1364], ["that", 1372], ["subsumes", 1377], ["social", 1386], ["communication", 1393], ["functions", 1407], ["in", 1417], ["diverse", 1420], ["organisms", 1428], [".", 1437]]}
{"context": "Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared to vitamin K antagonists (VKAs) for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Unlike VKAs, DOACs do not require routine laboratory monitoring of anticoagulant effect and dose adjustment. In certain situations, however, laboratory assessment of anticoagulant effect may be desirable. Here we review the utility of currently available assays for assessment of DOAC effect and recommend an optimal assessment strategy for each drug, including calibrated dilute thrombin time or ecarin-based assays for dabigatran and calibrated anti-Xa activity assays for the factor Xa inhibitors. We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "e6ccf71d79284970a5d7adfff0807ec8", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[148, 148], [109, 109]], "char_spans": [[924, 933], [694, 703]]}]}], "context_tokens": [["Direct", 0], ["oral", 7], ["anticoagulants", 12], ["(", 27], ["DOACs", 28], [")", 33], ["offer", 35], ["noninferior", 41], ["efficacy", 53], ["and", 62], ["improved", 66], ["safety", 75], ["compared", 82], ["to", 91], ["vitamin", 94], ["K", 102], ["antagonists", 104], ["(", 116], ["VKAs", 117], [")", 121], ["for", 123], ["the", 127], ["prevention", 131], ["and", 142], ["treatment", 146], ["of", 156], ["venous", 159], ["thromboembolism", 166], ["and", 182], ["for", 186], ["the", 190], ["prevention", 194], ["of", 205], ["stroke", 208], ["and", 215], ["systemic", 219], ["embolism", 228], ["in", 237], ["nonvalvular", 240], ["atrial", 252], ["fibrillation", 259], [".", 271], ["Unlike", 273], ["VKAs", 280], [",", 284], ["DOACs", 286], ["do", 292], ["not", 295], ["require", 299], ["routine", 307], ["laboratory", 315], ["monitoring", 326], ["of", 337], ["anticoagulant", 340], ["effect", 354], ["and", 361], ["dose", 365], ["adjustment", 370], [".", 380], ["In", 382], ["certain", 385], ["situations", 393], [",", 403], ["however", 405], [",", 412], ["laboratory", 414], ["assessment", 425], ["of", 436], ["anticoagulant", 439], ["effect", 453], ["may", 460], ["be", 464], ["desirable", 467], [".", 476], ["Here", 478], ["we", 483], ["review", 486], ["the", 493], ["utility", 497], ["of", 505], ["currently", 508], ["available", 518], ["assays", 528], ["for", 535], ["assessment", 539], ["of", 550], ["DOAC", 553], ["effect", 558], ["and", 565], ["recommend", 569], ["an", 579], ["optimal", 582], ["assessment", 590], ["strategy", 601], ["for", 610], ["each", 614], ["drug", 619], [",", 623], ["including", 625], ["calibrated", 635], ["dilute", 646], ["thrombin", 653], ["time", 662], ["or", 667], ["ecarin", 670], ["-", 676], ["based", 677], ["assays", 683], ["for", 690], ["dabigatran", 694], ["and", 705], ["calibrated", 709], ["anti", 720], ["-", 724], ["Xa", 725], ["activity", 728], ["assays", 737], ["for", 744], ["the", 748], ["factor", 752], ["Xa", 759], ["inhibitors", 762], [".", 772], ["We", 774], ["also", 777], ["discuss", 782], ["reversal", 790], ["strategies", 799], [",", 809], ["both", 811], ["specific", 816], ["and", 825], ["nonspecific", 829], [",", 840], ["for", 842], ["each", 846], ["drug", 851], [",", 855], ["including", 857], ["the", 867], ["preferential", 871], ["use", 884], ["of", 888], ["idarucizumab", 891], ["for", 904], ["the", 908], ["reversal", 912], ["of", 921], ["dabigatran", 924], ["and", 935], ["two", 939], ["agents", 943], [",", 949], ["andexanet", 951], ["and", 961], ["ciraparantag", 965], [",", 977], ["currently", 979], ["under", 989], ["development", 995], ["for", 1007], ["the", 1011], ["reversal", 1015], ["of", 1024], ["rivaroxaban", 1027], [",", 1038], ["apixaban", 1040], [",", 1048], ["and", 1050], ["edoxaban", 1054], [".", 1062]]}
{"context": "\u03b1-Synuclein is the major pathological component of synucleinopathies including Parkinson's disease and dementia with Lewy bodies. Recent studies have demonstrated that \u03b1-synuclein also plays important roles in the release of synaptic vesicles and synaptic membrane recycling in healthy neurons. However, the precise relationship between the pathogenicity and physiological functions of \u03b1-synuclein remains to be elucidated. To address this issue, we investigated the subcellular localization of \u03b1-synuclein in normal and pathological conditions using primary mouse hippocampal neuronal cultures. While some neurons expressed high levels of \u03b1-synuclein in presynaptic boutons and cell bodies, other neurons either did not or only very weakly expressed the protein. These \u03b1-synuclein-negative cells were identified as inhibitory neurons by immunostaining with specific antibodies against glutamic acid decarboxylase (GAD), parvalbumin, and somatostatin. In contrast, \u03b1-synuclein-positive synapses were colocalized with the excitatory synapse marker vesicular glutamate transporter-1. This expression profile of \u03b1-synuclein was conserved in the hippocampus in vivo. In addition, we found that while presynaptic \u03b1-synuclein colocalizes with synapsin, a marker of presynaptic vesicles, it is not essential for activity-dependent membrane recycling induced by high potassium treatment. Exogenous supply of preformed fibrils generated by recombinant \u03b1-synuclein was shown to promote the formation of Lewy body (LB) -like intracellular aggregates involving endogenous \u03b1-synuclein. GAD-positive neurons did not form LB-like aggregates following treatment with preformed fibrils, however, exogenous expression of human \u03b1-synuclein allowed intracellular aggregate formation in these cells. These results suggest the presence of a different mechanism for regulation of the expression of \u03b1-synuclein between excitatory and inhibitory neurons. Furthermore, \u03b1-synuclein expression levels may determine the efficiency of intracellular aggregate formation in different neuronal subtypes.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "02aedd384e0844e18fd9364151f02926", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[195, 197], [305, 307], [176, 178], [252, 254], [316, 318], [155, 157], [77, 79], [58, 60], [232, 234], [279, 281], [25, 27], [123, 125], [0, 2], [99, 101]], "char_spans": [[1208, 1218], [1875, 1885], [1109, 1119], [1560, 1570], [1943, 1953], [965, 975], [495, 505], [386, 396], [1443, 1453], [1709, 1719], [168, 178], [770, 780], [0, 10], [640, 650]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["is", 12], ["the", 15], ["major", 19], ["pathological", 25], ["component", 38], ["of", 48], ["synucleinopathies", 51], ["including", 69], ["Parkinson", 79], ["'s", 88], ["disease", 91], ["and", 99], ["dementia", 103], ["with", 112], ["Lewy", 117], ["bodies", 122], [".", 128], ["Recent", 130], ["studies", 137], ["have", 145], ["demonstrated", 150], ["that", 163], ["\u03b1", 168], ["-", 169], ["synuclein", 170], ["also", 180], ["plays", 185], ["important", 191], ["roles", 201], ["in", 207], ["the", 210], ["release", 214], ["of", 222], ["synaptic", 225], ["vesicles", 234], ["and", 243], ["synaptic", 247], ["membrane", 256], ["recycling", 265], ["in", 275], ["healthy", 278], ["neurons", 286], [".", 293], ["However", 295], [",", 302], ["the", 304], ["precise", 308], ["relationship", 316], ["between", 329], ["the", 337], ["pathogenicity", 341], ["and", 355], ["physiological", 359], ["functions", 373], ["of", 383], ["\u03b1", 386], ["-", 387], ["synuclein", 388], ["remains", 398], ["to", 406], ["be", 409], ["elucidated", 412], [".", 422], ["To", 424], ["address", 427], ["this", 435], ["issue", 440], [",", 445], ["we", 447], ["investigated", 450], ["the", 463], ["subcellular", 467], ["localization", 479], ["of", 492], ["\u03b1", 495], ["-", 496], ["synuclein", 497], ["in", 507], ["normal", 510], ["and", 517], ["pathological", 521], ["conditions", 534], ["using", 545], ["primary", 551], ["mouse", 559], ["hippocampal", 565], ["neuronal", 577], ["cultures", 586], [".", 594], ["While", 596], ["some", 602], ["neurons", 607], ["expressed", 615], ["high", 625], ["levels", 630], ["of", 637], ["\u03b1", 640], ["-", 641], ["synuclein", 642], ["in", 652], ["presynaptic", 655], ["boutons", 667], ["and", 675], ["cell", 679], ["bodies", 684], [",", 690], ["other", 692], ["neurons", 698], ["either", 706], ["did", 713], ["not", 717], ["or", 721], ["only", 724], ["very", 729], ["weakly", 734], ["expressed", 741], ["the", 751], ["protein", 755], [".", 762], ["These", 764], ["\u03b1", 770], ["-", 771], ["synuclein", 772], ["-", 781], ["negative", 782], ["cells", 791], ["were", 797], ["identified", 802], ["as", 813], ["inhibitory", 816], ["neurons", 827], ["by", 835], ["immunostaining", 838], ["with", 853], ["specific", 858], ["antibodies", 867], ["against", 878], ["glutamic", 886], ["acid", 895], ["decarboxylase", 900], ["(", 914], ["GAD", 915], [")", 918], [",", 919], ["parvalbumin", 921], [",", 932], ["and", 934], ["somatostatin", 938], [".", 950], ["In", 952], ["contrast", 955], [",", 963], ["\u03b1", 965], ["-", 966], ["synuclein", 967], ["-", 976], ["positive", 977], ["synapses", 986], ["were", 995], ["colocalized", 1000], ["with", 1012], ["the", 1017], ["excitatory", 1021], ["synapse", 1032], ["marker", 1040], ["vesicular", 1047], ["glutamate", 1057], ["transporter-1", 1067], [".", 1080], ["This", 1082], ["expression", 1087], ["profile", 1098], ["of", 1106], ["\u03b1", 1109], ["-", 1110], ["synuclein", 1111], ["was", 1121], ["conserved", 1125], ["in", 1135], ["the", 1138], ["hippocampus", 1142], ["in", 1154], ["vivo", 1157], [".", 1161], ["In", 1163], ["addition", 1166], [",", 1174], ["we", 1176], ["found", 1179], ["that", 1185], ["while", 1190], ["presynaptic", 1196], ["\u03b1", 1208], ["-", 1209], ["synuclein", 1210], ["colocalizes", 1220], ["with", 1232], ["synapsin", 1237], [",", 1245], ["a", 1247], ["marker", 1249], ["of", 1256], ["presynaptic", 1259], ["vesicles", 1271], [",", 1279], ["it", 1281], ["is", 1284], ["not", 1287], ["essential", 1291], ["for", 1301], ["activity", 1305], ["-", 1313], ["dependent", 1314], ["membrane", 1324], ["recycling", 1333], ["induced", 1343], ["by", 1351], ["high", 1354], ["potassium", 1359], ["treatment", 1369], [".", 1378], ["Exogenous", 1380], ["supply", 1390], ["of", 1397], ["preformed", 1400], ["fibrils", 1410], ["generated", 1418], ["by", 1428], ["recombinant", 1431], ["\u03b1", 1443], ["-", 1444], ["synuclein", 1445], ["was", 1455], ["shown", 1459], ["to", 1465], ["promote", 1468], ["the", 1476], ["formation", 1480], ["of", 1490], ["Lewy", 1493], ["body", 1498], ["(", 1503], ["LB", 1504], [")", 1506], ["-like", 1508], ["intracellular", 1514], ["aggregates", 1528], ["involving", 1539], ["endogenous", 1549], ["\u03b1", 1560], ["-", 1561], ["synuclein", 1562], [".", 1571], ["GAD", 1573], ["-", 1576], ["positive", 1577], ["neurons", 1586], ["did", 1594], ["not", 1598], ["form", 1602], ["LB", 1607], ["-", 1609], ["like", 1610], ["aggregates", 1615], ["following", 1626], ["treatment", 1636], ["with", 1646], ["preformed", 1651], ["fibrils", 1661], [",", 1668], ["however", 1670], [",", 1677], ["exogenous", 1679], ["expression", 1689], ["of", 1700], ["human", 1703], ["\u03b1", 1709], ["-", 1710], ["synuclein", 1711], ["allowed", 1721], ["intracellular", 1729], ["aggregate", 1743], ["formation", 1753], ["in", 1763], ["these", 1766], ["cells", 1772], [".", 1777], ["These", 1779], ["results", 1785], ["suggest", 1793], ["the", 1801], ["presence", 1805], ["of", 1814], ["a", 1817], ["different", 1819], ["mechanism", 1829], ["for", 1839], ["regulation", 1843], ["of", 1854], ["the", 1857], ["expression", 1861], ["of", 1872], ["\u03b1", 1875], ["-", 1876], ["synuclein", 1877], ["between", 1887], ["excitatory", 1895], ["and", 1906], ["inhibitory", 1910], ["neurons", 1921], [".", 1928], ["Furthermore", 1930], [",", 1941], ["\u03b1", 1943], ["-", 1944], ["synuclein", 1945], ["expression", 1955], ["levels", 1966], ["may", 1973], ["determine", 1977], ["the", 1987], ["efficiency", 1991], ["of", 2002], ["intracellular", 2005], ["aggregate", 2019], ["formation", 2029], ["in", 2039], ["different", 2042], ["neuronal", 2052], ["subtypes", 2061], [".", 2069]]}
{"context": "Malformation of cortical development (MCD) is a well-known cause of drug-resistant epilepsy and focal cortical dysplasia (FCD) is the most common neuropathological finding in surgical specimens from drug-resistant epilepsy patients. Palmini's classification proposed in 2004 is now widely used to categorize FCD. Recently, however, Blumcke et al. recommended a new system for classifying FCD in 2011. We applied the new classification system in practical diagnosis of a sample of 117 patients who underwent neurosurgical operations due to drug-resistant epilepsy at Severance Hospital in Seoul, Korea. Among 117 cases, a total of 16 cases were shifted to other FCD subtypes under the new classification system. Five cases were reclassified to type IIIa and five cases were categorized as dual pathology. The other six cases were changed within the type I category. The most remarkable changes in the new classification system are the advent of dual pathology and FCD type III. Thus, it will be very important for pathologists and clinicians to discriminate between these new categories. More large-scale research needs to be conducted to elucidate the clinical influence of the alterations within the classification of type I disease. Although the new FCD classification system has several advantages compared to the former, the correlation with clinical characteristics is not yet clear.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "fcc71128ce954ca0aaa995650ab41118", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[19, 21]], "char_spans": [[96, 119]]}]}], "context_tokens": [["Malformation", 0], ["of", 13], ["cortical", 16], ["development", 25], ["(", 37], ["MCD", 38], [")", 41], ["is", 43], ["a", 46], ["well", 48], ["-", 52], ["known", 53], ["cause", 59], ["of", 65], ["drug", 68], ["-", 72], ["resistant", 73], ["epilepsy", 83], ["and", 92], ["focal", 96], ["cortical", 102], ["dysplasia", 111], ["(", 121], ["FCD", 122], [")", 125], ["is", 127], ["the", 130], ["most", 134], ["common", 139], ["neuropathological", 146], ["finding", 164], ["in", 172], ["surgical", 175], ["specimens", 184], ["from", 194], ["drug", 199], ["-", 203], ["resistant", 204], ["epilepsy", 214], ["patients", 223], [".", 231], ["Palmini", 233], ["'s", 240], ["classification", 243], ["proposed", 258], ["in", 267], ["2004", 270], ["is", 275], ["now", 278], ["widely", 282], ["used", 289], ["to", 294], ["categorize", 297], ["FCD", 308], [".", 311], ["Recently", 313], [",", 321], ["however", 323], [",", 330], ["Blumcke", 332], ["et", 340], ["al", 343], [".", 345], ["recommended", 347], ["a", 359], ["new", 361], ["system", 365], ["for", 372], ["classifying", 376], ["FCD", 388], ["in", 392], ["2011", 395], [".", 399], ["We", 401], ["applied", 404], ["the", 412], ["new", 416], ["classification", 420], ["system", 435], ["in", 442], ["practical", 445], ["diagnosis", 455], ["of", 465], ["a", 468], ["sample", 470], ["of", 477], ["117", 480], ["patients", 484], ["who", 493], ["underwent", 497], ["neurosurgical", 507], ["operations", 521], ["due", 532], ["to", 536], ["drug", 539], ["-", 543], ["resistant", 544], ["epilepsy", 554], ["at", 563], ["Severance", 566], ["Hospital", 576], ["in", 585], ["Seoul", 588], [",", 593], ["Korea", 595], [".", 600], ["Among", 602], ["117", 608], ["cases", 612], [",", 617], ["a", 619], ["total", 621], ["of", 627], ["16", 630], ["cases", 633], ["were", 639], ["shifted", 644], ["to", 652], ["other", 655], ["FCD", 661], ["subtypes", 665], ["under", 674], ["the", 680], ["new", 684], ["classification", 688], ["system", 703], [".", 709], ["Five", 711], ["cases", 716], ["were", 722], ["reclassified", 727], ["to", 740], ["type", 743], ["IIIa", 748], ["and", 753], ["five", 757], ["cases", 762], ["were", 768], ["categorized", 773], ["as", 785], ["dual", 788], ["pathology", 793], [".", 802], ["The", 804], ["other", 808], ["six", 814], ["cases", 818], ["were", 824], ["changed", 829], ["within", 837], ["the", 844], ["type", 848], ["I", 853], ["category", 855], [".", 863], ["The", 865], ["most", 869], ["remarkable", 874], ["changes", 885], ["in", 893], ["the", 896], ["new", 900], ["classification", 904], ["system", 919], ["are", 926], ["the", 930], ["advent", 934], ["of", 941], ["dual", 944], ["pathology", 949], ["and", 959], ["FCD", 963], ["type", 967], ["III", 972], [".", 975], ["Thus", 977], [",", 981], ["it", 983], ["will", 986], ["be", 991], ["very", 994], ["important", 999], ["for", 1009], ["pathologists", 1013], ["and", 1026], ["clinicians", 1030], ["to", 1041], ["discriminate", 1044], ["between", 1057], ["these", 1065], ["new", 1071], ["categories", 1075], [".", 1085], ["More", 1087], ["large", 1092], ["-", 1097], ["scale", 1098], ["research", 1104], ["needs", 1113], ["to", 1119], ["be", 1122], ["conducted", 1125], ["to", 1135], ["elucidate", 1138], ["the", 1148], ["clinical", 1152], ["influence", 1161], ["of", 1171], ["the", 1174], ["alterations", 1178], ["within", 1190], ["the", 1197], ["classification", 1201], ["of", 1216], ["type", 1219], ["I", 1224], ["disease", 1226], [".", 1233], ["Although", 1235], ["the", 1244], ["new", 1248], ["FCD", 1252], ["classification", 1256], ["system", 1271], ["has", 1278], ["several", 1282], ["advantages", 1290], ["compared", 1301], ["to", 1310], ["the", 1313], ["former", 1317], [",", 1323], ["the", 1325], ["correlation", 1329], ["with", 1341], ["clinical", 1346], ["characteristics", 1355], ["is", 1371], ["not", 1374], ["yet", 1378], ["clear", 1382], [".", 1387]]}
{"context": "Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl(+) malignancies. In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1\u00a0h intravenous infusion weekly for 3\u00a0weeks every 4\u00a0weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed. A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30\u00a0months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed. This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee5c985a3d3b4cd89647bbe76b8def7b", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[66, 68], [244, 246], [184, 186], [6, 8]], "char_spans": [[376, 384], [1416, 1422], [1081, 1087], [32, 38]]}]}], "context_tokens": [["Imatinib", 0], ["is", 9], ["an", 12], ["inhibitor", 15], ["of", 25], ["the", 28], ["Bcr", 32], ["-", 35], ["Abl", 36], ["tyrosine", 40], ["kinase", 49], [";", 55], ["however", 57], [",", 64], ["resistance", 66], ["is", 77], ["common", 80], [".", 86], ["Flavopiridol", 88], [",", 100], ["a", 102], ["cyclin", 104], ["-", 110], ["dependent", 111], ["kinase", 121], ["(", 128], ["CDK", 129], [")", 132], ["inhibitor", 134], [",", 143], ["down", 145], ["-", 149], ["regulates", 150], ["short", 160], ["-", 165], ["lived", 166], ["anti", 172], ["-", 176], ["apoptotic", 177], ["proteins", 187], ["via", 196], ["inhibition", 200], ["of", 211], ["transcription", 214], [".", 227], ["In", 229], ["preclinical", 232], ["studies", 244], [",", 251], ["flavopiridol", 253], ["synergizes", 266], ["with", 277], ["imatinib", 282], ["to", 291], ["induce", 294], ["apoptosis", 301], [".", 310], ["We", 312], ["investigated", 315], ["this", 328], ["novel", 333], ["combination", 339], ["regimen", 351], ["in", 359], ["patients", 362], ["with", 371], ["Bcr", 376], ["-", 379], ["Abl(+", 380], [")", 385], ["malignancies", 387], [".", 399], ["In", 401], ["a", 404], ["phase", 406], ["I", 412], ["dose", 414], ["-", 418], ["escalation", 419], ["study", 430], [",", 435], ["imatinib", 437], ["was", 446], ["administered", 450], ["orally", 463], ["daily", 470], [",", 475], ["and", 477], ["flavopiridol", 481], ["by", 494], ["1", 497], ["h", 499], ["intravenous", 501], ["infusion", 513], ["weekly", 522], ["for", 529], ["3", 533], ["weeks", 535], ["every", 541], ["4", 547], ["weeks", 549], [".", 554], ["Adults", 556], ["with", 563], ["chronic", 568], ["myelogenous", 576], ["leukemia", 588], ["or", 597], ["Philadelphia", 600], ["chromosome", 613], ["-", 623], ["positive", 624], ["acute", 633], ["leukemia", 639], ["were", 648], ["eligible", 653], [".", 661], ["Patients", 663], ["were", 672], ["divided", 677], ["into", 685], ["two", 690], ["strata", 694], ["based", 701], ["on", 707], ["peripheral", 710], ["blood", 721], ["and", 727], ["bone", 731], ["marrow", 736], ["blast", 743], ["counts", 749], [".", 755], ["The", 757], ["primary", 761], ["objective", 769], ["was", 779], ["to", 783], ["identify", 786], ["the", 795], ["recommended", 799], ["phase", 811], ["II", 817], ["doses", 820], ["for", 826], ["the", 830], ["combination", 834], [".", 845], ["Correlative", 847], ["pharmacokinetic", 859], ["and", 875], ["pharmacodynamic", 879], ["studies", 895], ["were", 903], ["also", 908], ["performed", 913], [".", 922], ["A", 924], ["total", 926], ["of", 932], ["21", 935], ["patients", 938], ["received", 947], ["study", 956], ["treatment", 962], [".", 971], ["Four", 973], ["dose", 978], ["levels", 983], ["were", 990], ["evaluated", 995], ["before", 1005], ["the", 1012], ["study", 1016], ["was", 1022], ["closed", 1026], ["following", 1033], ["the", 1043], ["approval", 1047], ["of", 1056], ["the", 1059], ["second", 1063], ["-", 1069], ["generation", 1070], ["Bcr", 1081], ["-", 1084], ["Abl", 1085], ["tyrosine", 1089], ["kinase", 1098], ["inhibitors", 1105], ["(", 1116], ["TKIs", 1117], [")", 1121], [".", 1122], ["Five", 1124], ["patients", 1129], ["responded", 1138], [",", 1147], ["including", 1149], ["four", 1159], ["sustained", 1164], ["responses", 1174], [".", 1183], ["Four", 1185], ["patients", 1190], ["had", 1199], ["stable", 1203], ["disease", 1210], [".", 1217], ["All", 1219], ["but", 1223], ["one", 1227], ["responder", 1231], [",", 1240], ["and", 1242], ["all", 1246], ["patients", 1250], ["with", 1259], ["stable", 1264], ["disease", 1271], ["had", 1279], ["previously", 1283], ["been", 1294], ["treated", 1299], ["with", 1307], ["imatinib", 1312], [".", 1320], ["One", 1322], ["patient", 1326], ["had", 1334], ["a", 1338], ["complete", 1340], ["response", 1349], ["sustained", 1358], ["for", 1368], ["30", 1372], ["months", 1375], [".", 1381], ["Changes", 1383], ["in", 1391], ["expression", 1394], ["of", 1405], ["phospho", 1408], ["-", 1415], ["Bcr", 1416], ["/", 1419], ["Abl", 1420], [",", 1423], ["-Stat5", 1425], [",", 1431], ["and", 1433], ["Mcl-1", 1437], ["were", 1443], ["monitored", 1448], [".", 1457], ["No", 1459], ["major", 1462], ["pharmacokinetic", 1468], ["interaction", 1484], ["was", 1496], ["observed", 1500], [".", 1508], ["This", 1510], ["is", 1515], ["the", 1518], ["first", 1522], ["study", 1528], ["to", 1534], ["evaluate", 1537], ["the", 1546], ["combination", 1550], ["of", 1562], ["a", 1565], ["CDK", 1567], ["inhibitor", 1571], ["and", 1581], ["a", 1585], ["TKI", 1587], ["in", 1591], ["humans", 1594], [".", 1600], ["The", 1602], ["combination", 1606], ["of", 1618], ["flavopiridol", 1621], ["and", 1634], ["imatinib", 1638], ["is", 1647], ["tolerable", 1650], ["and", 1660], ["produces", 1664], ["encouraging", 1673], ["responses", 1685], [",", 1694], ["including", 1696], ["in", 1706], ["some", 1709], ["patients", 1714], ["with", 1723], ["imatinib", 1728], ["-", 1736], ["resistant", 1737], ["disease", 1747], [".", 1754]]}
{"context": "Chronic myelogenous leukemia (CML) results from the neoplastic transformation of primitive hematopoietic stem cells, and has been classified as a myeloproliferative disorder. The hallmark of CML is the presence of a balanced translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11.2), which is known as the Philadelphia (Ph) chromosome. This translocation results in the formation of the bcr-abl fusion gene, which, in turn, is translated into a chimeric Bcr-Abl protein with deregulated tyrosine kinase activity. Constitutive Bcr-Abl expression has been shown to be necessary and sufficient for the transformed phenotype of CML cells. CML is unique among human cancers in that a single genetic defect, the Ph chromosome, is responsible for the transformed phenotype. Since this discovery more than 40 years ago, our understanding of the clinical course, therapy, and prognosis of patients with CML has changed significantly. These changes have culminated in the emergence of imatinib, the first rationally designed, molecularly targeted therapy for human malignancy. In this review, the authors describe the molecular biology of CML and the development of imatinib as a therapeutic agent for the treatment of CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "d4a15945d8304a3898c6f391152041af", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[85, 87], [69, 71], [96, 98]], "char_spans": [[476, 482], [409, 415], [548, 554]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["results", 35], ["from", 43], ["the", 48], ["neoplastic", 52], ["transformation", 63], ["of", 78], ["primitive", 81], ["hematopoietic", 91], ["stem", 105], ["cells", 110], [",", 115], ["and", 117], ["has", 121], ["been", 125], ["classified", 130], ["as", 141], ["a", 144], ["myeloproliferative", 146], ["disorder", 165], [".", 173], ["The", 175], ["hallmark", 179], ["of", 188], ["CML", 191], ["is", 195], ["the", 198], ["presence", 202], ["of", 211], ["a", 214], ["balanced", 216], ["translocation", 225], ["between", 239], ["the", 247], ["long", 251], ["arms", 256], ["of", 261], ["chromosomes", 264], ["9", 276], ["and", 278], ["22", 282], [",", 284], ["t(9;22)(q34;q11.2", 286], [")", 303], [",", 304], ["which", 306], ["is", 312], ["known", 315], ["as", 321], ["the", 324], ["Philadelphia", 328], ["(", 341], ["Ph", 342], [")", 344], ["chromosome", 346], [".", 356], ["This", 358], ["translocation", 363], ["results", 377], ["in", 385], ["the", 388], ["formation", 392], ["of", 402], ["the", 405], ["bcr", 409], ["-", 412], ["abl", 413], ["fusion", 417], ["gene", 424], [",", 428], ["which", 430], [",", 435], ["in", 437], ["turn", 440], [",", 444], ["is", 446], ["translated", 449], ["into", 460], ["a", 465], ["chimeric", 467], ["Bcr", 476], ["-", 479], ["Abl", 480], ["protein", 484], ["with", 492], ["deregulated", 497], ["tyrosine", 509], ["kinase", 518], ["activity", 525], [".", 533], ["Constitutive", 535], ["Bcr", 548], ["-", 551], ["Abl", 552], ["expression", 556], ["has", 567], ["been", 571], ["shown", 576], ["to", 582], ["be", 585], ["necessary", 588], ["and", 598], ["sufficient", 602], ["for", 613], ["the", 617], ["transformed", 621], ["phenotype", 633], ["of", 643], ["CML", 646], ["cells", 650], [".", 655], ["CML", 657], ["is", 661], ["unique", 664], ["among", 671], ["human", 677], ["cancers", 683], ["in", 691], ["that", 694], ["a", 699], ["single", 701], ["genetic", 708], ["defect", 716], [",", 722], ["the", 724], ["Ph", 728], ["chromosome", 731], [",", 741], ["is", 743], ["responsible", 746], ["for", 758], ["the", 762], ["transformed", 766], ["phenotype", 778], [".", 787], ["Since", 789], ["this", 795], ["discovery", 800], ["more", 810], ["than", 815], ["40", 820], ["years", 823], ["ago", 829], [",", 832], ["our", 834], ["understanding", 838], ["of", 852], ["the", 855], ["clinical", 859], ["course", 868], [",", 874], ["therapy", 876], [",", 883], ["and", 885], ["prognosis", 889], ["of", 899], ["patients", 902], ["with", 911], ["CML", 916], ["has", 920], ["changed", 924], ["significantly", 932], [".", 945], ["These", 947], ["changes", 953], ["have", 961], ["culminated", 966], ["in", 977], ["the", 980], ["emergence", 984], ["of", 994], ["imatinib", 997], [",", 1005], ["the", 1007], ["first", 1011], ["rationally", 1017], ["designed", 1028], [",", 1036], ["molecularly", 1038], ["targeted", 1050], ["therapy", 1059], ["for", 1067], ["human", 1071], ["malignancy", 1077], [".", 1087], ["In", 1089], ["this", 1092], ["review", 1097], [",", 1103], ["the", 1105], ["authors", 1109], ["describe", 1117], ["the", 1126], ["molecular", 1130], ["biology", 1140], ["of", 1148], ["CML", 1151], ["and", 1155], ["the", 1159], ["development", 1163], ["of", 1175], ["imatinib", 1178], ["as", 1187], ["a", 1190], ["therapeutic", 1192], ["agent", 1204], ["for", 1210], ["the", 1214], ["treatment", 1218], ["of", 1228], ["CML", 1231], [".", 1234]]}
{"context": "Restless legs syndrome (RLS) is a clinically important, common disease and should be diagnosed and treated early and adequately. At present, there have been no clinical biomarkers or methodologies that can contribute to the correct diagnosis of RLS, RLS should be diagnosed on the basis of 4 essential criteria: urge to move the legs, improvement after movement, and worsening or occurrence of symptoms in the evening and at rest. When applying the criteria, RLS mimics should be ruled out and comorbid diseases should be taken into account. The origin and pathogenesis of RLS are still under investigation; however, iron deficiency in the brain has been observed on imaging and cerebrospinal fluid analyses of patients with RLS. In contrast, the results of neuroimaging studies evaluating brain dopaminergic functions in patients with RLS have yielded inconclusive results, although involvement of the hypothalamus (A11) is thought to cause impaired dopaminergic modulation in the dorsal horn and intermediolateral nucleus, resulting in the restlessness of legs.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f86ef5e1ac664cb0a799f69a2e54f94d", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[112, 112]], "char_spans": [[617, 620]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["is", 29], ["a", 32], ["clinically", 34], ["important", 45], [",", 54], ["common", 56], ["disease", 63], ["and", 71], ["should", 75], ["be", 82], ["diagnosed", 85], ["and", 95], ["treated", 99], ["early", 107], ["and", 113], ["adequately", 117], [".", 127], ["At", 129], ["present", 132], [",", 139], ["there", 141], ["have", 147], ["been", 152], ["no", 157], ["clinical", 160], ["biomarkers", 169], ["or", 180], ["methodologies", 183], ["that", 197], ["can", 202], ["contribute", 206], ["to", 217], ["the", 220], ["correct", 224], ["diagnosis", 232], ["of", 242], ["RLS", 245], [",", 248], ["RLS", 250], ["should", 254], ["be", 261], ["diagnosed", 264], ["on", 274], ["the", 277], ["basis", 281], ["of", 287], ["4", 290], ["essential", 292], ["criteria", 302], [":", 310], ["urge", 312], ["to", 317], ["move", 320], ["the", 325], ["legs", 329], [",", 333], ["improvement", 335], ["after", 347], ["movement", 353], [",", 361], ["and", 363], ["worsening", 367], ["or", 377], ["occurrence", 380], ["of", 391], ["symptoms", 394], ["in", 403], ["the", 406], ["evening", 410], ["and", 418], ["at", 422], ["rest", 425], [".", 429], ["When", 431], ["applying", 436], ["the", 445], ["criteria", 449], [",", 457], ["RLS", 459], ["mimics", 463], ["should", 470], ["be", 477], ["ruled", 480], ["out", 486], ["and", 490], ["comorbid", 494], ["diseases", 503], ["should", 512], ["be", 519], ["taken", 522], ["into", 528], ["account", 533], [".", 540], ["The", 542], ["origin", 546], ["and", 553], ["pathogenesis", 557], ["of", 570], ["RLS", 573], ["are", 577], ["still", 581], ["under", 587], ["investigation", 593], [";", 606], ["however", 608], [",", 615], ["iron", 617], ["deficiency", 622], ["in", 633], ["the", 636], ["brain", 640], ["has", 646], ["been", 650], ["observed", 655], ["on", 664], ["imaging", 667], ["and", 675], ["cerebrospinal", 679], ["fluid", 693], ["analyses", 699], ["of", 708], ["patients", 711], ["with", 720], ["RLS", 725], [".", 728], ["In", 730], ["contrast", 733], [",", 741], ["the", 743], ["results", 747], ["of", 755], ["neuroimaging", 758], ["studies", 771], ["evaluating", 779], ["brain", 790], ["dopaminergic", 796], ["functions", 809], ["in", 819], ["patients", 822], ["with", 831], ["RLS", 836], ["have", 840], ["yielded", 845], ["inconclusive", 853], ["results", 866], [",", 873], ["although", 875], ["involvement", 884], ["of", 896], ["the", 899], ["hypothalamus", 903], ["(", 916], ["A11", 917], [")", 920], ["is", 922], ["thought", 925], ["to", 933], ["cause", 936], ["impaired", 942], ["dopaminergic", 951], ["modulation", 964], ["in", 975], ["the", 978], ["dorsal", 982], ["horn", 989], ["and", 994], ["intermediolateral", 998], ["nucleus", 1016], [",", 1023], ["resulting", 1025], ["in", 1035], ["the", 1038], ["restlessness", 1042], ["of", 1055], ["legs", 1058], [".", 1062]]}
{"context": "Interleukin-6 (IL-6) is associated with prostate cancer morbidity. In several experimental models, IL-6 has been reported to have anti-apoptotic and pro-angiogenic effects. Siltuximab (CNTO 328) is a monoclonal anti-IL-6 antibody which has been successfully applied in several models representing prostate cancer. This study was designed to assess preliminary safety of siltuximab in patients with early prostate cancer. Twenty patients scheduled to undergo radical prostatectomy received either no drug or siltuximab (6\u2009mg/kg, five patients per group with administration once, two times, and three times prior to surgery). Blood samples were collected for pharmacokinetic and pharmacodynamic analyses. Expression of elements of IL-6 signaling pathways was analyzed in tumor tissue by immunohistochemistry. Gene analysis in tumor specimens was performed with the DASL array. No adverse events related to siltuximab were observed. Patients treated with siltuximab presented with higher levels of proliferation and apoptosis markers. Following a single dose, serum concentrations of siltuximab declined in a biexponential manner. This study revealed a decrease in phosphorylation of Stat3 and p44/p42 mitogen-activated protein kinases. In addition, gene expression analyses indicate down-regulation of genes immediately downstream of the IL-6 signaling pathway and key enzymes of the androgen signaling pathway. Preliminary safety of siltuximab is favorable. Future studies in which siltuximab could be combined with androgen-deprivation therapy and experimental therapies in advanced prostate cancer are justified.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "918a97ffd8cf4160aebc6fdbfa7df18a", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["is", 21], ["associated", 24], ["with", 35], ["prostate", 40], ["cancer", 49], ["morbidity", 56], [".", 65], ["In", 67], ["several", 70], ["experimental", 78], ["models", 91], [",", 97], ["IL-6", 99], ["has", 104], ["been", 108], ["reported", 113], ["to", 122], ["have", 125], ["anti", 130], ["-", 134], ["apoptotic", 135], ["and", 145], ["pro", 149], ["-", 152], ["angiogenic", 153], ["effects", 164], [".", 171], ["Siltuximab", 173], ["(", 184], ["CNTO", 185], ["328", 190], [")", 193], ["is", 195], ["a", 198], ["monoclonal", 200], ["anti", 211], ["-", 215], ["IL-6", 216], ["antibody", 221], ["which", 230], ["has", 236], ["been", 240], ["successfully", 245], ["applied", 258], ["in", 266], ["several", 269], ["models", 277], ["representing", 284], ["prostate", 297], ["cancer", 306], [".", 312], ["This", 314], ["study", 319], ["was", 325], ["designed", 329], ["to", 338], ["assess", 341], ["preliminary", 348], ["safety", 360], ["of", 367], ["siltuximab", 370], ["in", 381], ["patients", 384], ["with", 393], ["early", 398], ["prostate", 404], ["cancer", 413], [".", 419], ["Twenty", 421], ["patients", 428], ["scheduled", 437], ["to", 447], ["undergo", 450], ["radical", 458], ["prostatectomy", 466], ["received", 480], ["either", 489], ["no", 496], ["drug", 499], ["or", 504], ["siltuximab", 507], ["(", 518], ["6", 519], ["mg", 521], ["/", 523], ["kg", 524], [",", 526], ["five", 528], ["patients", 533], ["per", 542], ["group", 546], ["with", 552], ["administration", 557], ["once", 572], [",", 576], ["two", 578], ["times", 582], [",", 587], ["and", 589], ["three", 593], ["times", 599], ["prior", 605], ["to", 611], ["surgery", 614], [")", 621], [".", 622], ["Blood", 624], ["samples", 630], ["were", 638], ["collected", 643], ["for", 653], ["pharmacokinetic", 657], ["and", 673], ["pharmacodynamic", 677], ["analyses", 693], [".", 701], ["Expression", 703], ["of", 714], ["elements", 717], ["of", 726], ["IL-6", 729], ["signaling", 734], ["pathways", 744], ["was", 753], ["analyzed", 757], ["in", 766], ["tumor", 769], ["tissue", 775], ["by", 782], ["immunohistochemistry", 785], [".", 805], ["Gene", 807], ["analysis", 812], ["in", 821], ["tumor", 824], ["specimens", 830], ["was", 840], ["performed", 844], ["with", 854], ["the", 859], ["DASL", 863], ["array", 868], [".", 873], ["No", 875], ["adverse", 878], ["events", 886], ["related", 893], ["to", 901], ["siltuximab", 904], ["were", 915], ["observed", 920], [".", 928], ["Patients", 930], ["treated", 939], ["with", 947], ["siltuximab", 952], ["presented", 963], ["with", 973], ["higher", 978], ["levels", 985], ["of", 992], ["proliferation", 995], ["and", 1009], ["apoptosis", 1013], ["markers", 1023], [".", 1030], ["Following", 1032], ["a", 1042], ["single", 1044], ["dose", 1051], [",", 1055], ["serum", 1057], ["concentrations", 1063], ["of", 1078], ["siltuximab", 1081], ["declined", 1092], ["in", 1101], ["a", 1104], ["biexponential", 1106], ["manner", 1120], [".", 1126], ["This", 1128], ["study", 1133], ["revealed", 1139], ["a", 1148], ["decrease", 1150], ["in", 1159], ["phosphorylation", 1162], ["of", 1178], ["Stat3", 1181], ["and", 1187], ["p44/p42", 1191], ["mitogen", 1199], ["-", 1206], ["activated", 1207], ["protein", 1217], ["kinases", 1225], [".", 1232], ["In", 1234], ["addition", 1237], [",", 1245], ["gene", 1247], ["expression", 1252], ["analyses", 1263], ["indicate", 1272], ["down", 1281], ["-", 1285], ["regulation", 1286], ["of", 1297], ["genes", 1300], ["immediately", 1306], ["downstream", 1318], ["of", 1329], ["the", 1332], ["IL-6", 1336], ["signaling", 1341], ["pathway", 1351], ["and", 1359], ["key", 1363], ["enzymes", 1367], ["of", 1375], ["the", 1378], ["androgen", 1382], ["signaling", 1391], ["pathway", 1401], [".", 1408], ["Preliminary", 1410], ["safety", 1422], ["of", 1429], ["siltuximab", 1432], ["is", 1443], ["favorable", 1446], [".", 1455], ["Future", 1457], ["studies", 1464], ["in", 1472], ["which", 1475], ["siltuximab", 1481], ["could", 1492], ["be", 1498], ["combined", 1501], ["with", 1510], ["androgen", 1515], ["-", 1523], ["deprivation", 1524], ["therapy", 1536], ["and", 1544], ["experimental", 1548], ["therapies", 1561], ["in", 1571], ["advanced", 1574], ["prostate", 1583], ["cancer", 1592], ["are", 1599], ["justified", 1603], [".", 1612]]}
{"context": "Mutant ataxin-3 is aberrantly folded and proteolytically cleaved in spinocerebellar ataxia type 3. The C-terminal region of the protein includes a polyglutamine stretch that is expanded in spinocerebellar ataxia type 3. Here, we report on the analysis of an ataxin-3 mutant mouse that has been obtained by gene trap integration. The ataxin-3 fusion protein encompasses 259\u2009N-terminal amino acids including the Josephin domain and an ubiquitin-interacting motif but lacks the C-terminus with the polyglutamine stretch, the valosin-containing protein binding region and part of the ubiquitin-interacting motif 2. Homozygous ataxin-3 mutant mice were viable and showed no apparent anatomical defects at birth. However, at the age of 9 months, homozygous and heterozygous mutant mice revealed significantly altered behaviour and progressing deficits of motor coordination followed by premature death at \u223c12 months. At this time, prominent extranuclear protein aggregates and neuronal cell death was found in mutant mice. This was associated with disturbances of the endoplasmic reticulum-mediated unfolded protein response, consistent with the normal role of ataxin-3 in endoplasmic reticulum homeostasis. Thus, the ataxin-3 gene trap model provides evidence for a contribution of the non-polyglutamine containing ataxin-3\u2009N-terminus, which mimics a calpain fragment that has been observed in spinocerebellar ataxia type 3. Consistent with the disease in humans, gene trap mice develop cytoplasmic inclusion bodies and implicate impaired unfolded protein response in the pathogenesis of spinocerebellar ataxia type 3.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "b4fcd51ad7b44e5b973a0b67bc523ce8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[106, 106], [44, 44], [57, 57], [215, 215], [1, 1], [200, 200], [191, 191]], "char_spans": [[622, 629], [258, 265], [333, 340], [1310, 1317], [7, 14], [1212, 1219], [1155, 1162]]}]}], "context_tokens": [["Mutant", 0], ["ataxin-3", 7], ["is", 16], ["aberrantly", 19], ["folded", 30], ["and", 37], ["proteolytically", 41], ["cleaved", 57], ["in", 65], ["spinocerebellar", 68], ["ataxia", 84], ["type", 91], ["3", 96], [".", 97], ["The", 99], ["C", 103], ["-", 104], ["terminal", 105], ["region", 114], ["of", 121], ["the", 124], ["protein", 128], ["includes", 136], ["a", 145], ["polyglutamine", 147], ["stretch", 161], ["that", 169], ["is", 174], ["expanded", 177], ["in", 186], ["spinocerebellar", 189], ["ataxia", 205], ["type", 212], ["3", 217], [".", 218], ["Here", 220], [",", 224], ["we", 226], ["report", 229], ["on", 236], ["the", 239], ["analysis", 243], ["of", 252], ["an", 255], ["ataxin-3", 258], ["mutant", 267], ["mouse", 274], ["that", 280], ["has", 285], ["been", 289], ["obtained", 294], ["by", 303], ["gene", 306], ["trap", 311], ["integration", 316], [".", 327], ["The", 329], ["ataxin-3", 333], ["fusion", 342], ["protein", 349], ["encompasses", 357], ["259", 369], ["N", 373], ["-", 374], ["terminal", 375], ["amino", 384], ["acids", 390], ["including", 396], ["the", 406], ["Josephin", 410], ["domain", 419], ["and", 426], ["an", 430], ["ubiquitin", 433], ["-", 442], ["interacting", 443], ["motif", 455], ["but", 461], ["lacks", 465], ["the", 471], ["C", 475], ["-", 476], ["terminus", 477], ["with", 486], ["the", 491], ["polyglutamine", 495], ["stretch", 509], [",", 516], ["the", 518], ["valosin", 522], ["-", 529], ["containing", 530], ["protein", 541], ["binding", 549], ["region", 557], ["and", 564], ["part", 568], ["of", 573], ["the", 576], ["ubiquitin", 580], ["-", 589], ["interacting", 590], ["motif", 602], ["2", 608], [".", 609], ["Homozygous", 611], ["ataxin-3", 622], ["mutant", 631], ["mice", 638], ["were", 643], ["viable", 648], ["and", 655], ["showed", 659], ["no", 666], ["apparent", 669], ["anatomical", 678], ["defects", 689], ["at", 697], ["birth", 700], [".", 705], ["However", 707], [",", 714], ["at", 716], ["the", 719], ["age", 723], ["of", 727], ["9", 730], ["months", 732], [",", 738], ["homozygous", 740], ["and", 751], ["heterozygous", 755], ["mutant", 768], ["mice", 775], ["revealed", 780], ["significantly", 789], ["altered", 803], ["behaviour", 811], ["and", 821], ["progressing", 825], ["deficits", 837], ["of", 846], ["motor", 849], ["coordination", 855], ["followed", 868], ["by", 877], ["premature", 880], ["death", 890], ["at", 896], ["\u223c12", 899], ["months", 903], [".", 909], ["At", 911], ["this", 914], ["time", 919], [",", 923], ["prominent", 925], ["extranuclear", 935], ["protein", 948], ["aggregates", 956], ["and", 967], ["neuronal", 971], ["cell", 980], ["death", 985], ["was", 991], ["found", 995], ["in", 1001], ["mutant", 1004], ["mice", 1011], [".", 1015], ["This", 1017], ["was", 1022], ["associated", 1026], ["with", 1037], ["disturbances", 1042], ["of", 1055], ["the", 1058], ["endoplasmic", 1062], ["reticulum", 1074], ["-", 1083], ["mediated", 1084], ["unfolded", 1093], ["protein", 1102], ["response", 1110], [",", 1118], ["consistent", 1120], ["with", 1131], ["the", 1136], ["normal", 1140], ["role", 1147], ["of", 1152], ["ataxin-3", 1155], ["in", 1164], ["endoplasmic", 1167], ["reticulum", 1179], ["homeostasis", 1189], [".", 1200], ["Thus", 1202], [",", 1206], ["the", 1208], ["ataxin-3", 1212], ["gene", 1221], ["trap", 1226], ["model", 1231], ["provides", 1237], ["evidence", 1246], ["for", 1255], ["a", 1259], ["contribution", 1261], ["of", 1274], ["the", 1277], ["non", 1281], ["-", 1284], ["polyglutamine", 1285], ["containing", 1299], ["ataxin-3", 1310], ["N", 1319], ["-", 1320], ["terminus", 1321], [",", 1329], ["which", 1331], ["mimics", 1337], ["a", 1344], ["calpain", 1346], ["fragment", 1354], ["that", 1363], ["has", 1368], ["been", 1372], ["observed", 1377], ["in", 1386], ["spinocerebellar", 1389], ["ataxia", 1405], ["type", 1412], ["3", 1417], [".", 1418], ["Consistent", 1420], ["with", 1431], ["the", 1436], ["disease", 1440], ["in", 1448], ["humans", 1451], [",", 1457], ["gene", 1459], ["trap", 1464], ["mice", 1469], ["develop", 1474], ["cytoplasmic", 1482], ["inclusion", 1494], ["bodies", 1504], ["and", 1511], ["implicate", 1515], ["impaired", 1525], ["unfolded", 1534], ["protein", 1543], ["response", 1551], ["in", 1560], ["the", 1563], ["pathogenesis", 1567], ["of", 1580], ["spinocerebellar", 1583], ["ataxia", 1599], ["type", 1606], ["3", 1611], [".", 1612]]}
{"context": "The amino acid selenocysteine is encoded by UGA, usually a stop codon, thus requiring a specialized machinery to enable its incorporation into selenoproteins. The machinery comprises the tRNA(Sec), a 3'-UTR mRNA stem-loop termed SElenoCysteine Insertion Sequence (SECIS), which is mandatory for recoding UGA as a Sec codon, the SECIS Binding Protein 2 (SBP2), and other proteins. Little is known about the molecular mechanism and, in particular, when, where, and how the SECIS and SBP2 contact the ribosome. Previous work by others used the isolated SECIS RNA to address this question. Here, we developed a novel approach using instead engineered minimal selenoprotein mRNAs containing SECIS elements derivatized with photoreactive groups. By cross-linking experiments in rabbit reticulocyte lysate, new information could be gained about the SBP2 and SECIS contacts with components of the translation machinery at various translation steps. In particular, we found that SBP2 was bound only to the SECIS in 48S pre-initiation and 80S pretranslocation complexes. In the complex where the Sec-tRNA(Sec) was accommodated to the A site but transpeptidation was blocked, SBP2 bound the ribosome and possibly the SECIS element as well, and the SECIS had flexible contacts with the 60S ribosomal subunit involving several ribosomal proteins. Altogether, our findings led to broadening our understanding about the unique mechanism of selenocysteine incorporation in mammals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "00475180d274498e9dad745b5ff8c048", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[176, 176], [59, 59], [125, 125], [90, 90], [214, 214], [221, 221], [44, 44], [151, 151], [104, 104]], "char_spans": [[997, 1001], [328, 332], [686, 690], [471, 475], [1206, 1210], [1237, 1241], [264, 268], [851, 855], [550, 554]]}]}], "context_tokens": [["The", 0], ["amino", 4], ["acid", 10], ["selenocysteine", 15], ["is", 30], ["encoded", 33], ["by", 41], ["UGA", 44], [",", 47], ["usually", 49], ["a", 57], ["stop", 59], ["codon", 64], [",", 69], ["thus", 71], ["requiring", 76], ["a", 86], ["specialized", 88], ["machinery", 100], ["to", 110], ["enable", 113], ["its", 120], ["incorporation", 124], ["into", 138], ["selenoproteins", 143], [".", 157], ["The", 159], ["machinery", 163], ["comprises", 173], ["the", 183], ["tRNA(Sec", 187], [")", 195], [",", 196], ["a", 198], ["3'-UTR", 200], ["mRNA", 207], ["stem", 212], ["-", 216], ["loop", 217], ["termed", 222], ["SElenoCysteine", 229], ["Insertion", 244], ["Sequence", 254], ["(", 263], ["SECIS", 264], [")", 269], [",", 270], ["which", 272], ["is", 278], ["mandatory", 281], ["for", 291], ["recoding", 295], ["UGA", 304], ["as", 308], ["a", 311], ["Sec", 313], ["codon", 317], [",", 322], ["the", 324], ["SECIS", 328], ["Binding", 334], ["Protein", 342], ["2", 350], ["(", 352], ["SBP2", 353], [")", 357], [",", 358], ["and", 360], ["other", 364], ["proteins", 370], [".", 378], ["Little", 380], ["is", 387], ["known", 390], ["about", 396], ["the", 402], ["molecular", 406], ["mechanism", 416], ["and", 426], [",", 429], ["in", 431], ["particular", 434], [",", 444], ["when", 446], [",", 450], ["where", 452], [",", 457], ["and", 459], ["how", 463], ["the", 467], ["SECIS", 471], ["and", 477], ["SBP2", 481], ["contact", 486], ["the", 494], ["ribosome", 498], [".", 506], ["Previous", 508], ["work", 517], ["by", 522], ["others", 525], ["used", 532], ["the", 537], ["isolated", 541], ["SECIS", 550], ["RNA", 556], ["to", 560], ["address", 563], ["this", 571], ["question", 576], [".", 584], ["Here", 586], [",", 590], ["we", 592], ["developed", 595], ["a", 605], ["novel", 607], ["approach", 613], ["using", 622], ["instead", 628], ["engineered", 636], ["minimal", 647], ["selenoprotein", 655], ["mRNAs", 669], ["containing", 675], ["SECIS", 686], ["elements", 692], ["derivatized", 701], ["with", 713], ["photoreactive", 718], ["groups", 732], [".", 738], ["By", 740], ["cross", 743], ["-", 748], ["linking", 749], ["experiments", 757], ["in", 769], ["rabbit", 772], ["reticulocyte", 779], ["lysate", 792], [",", 798], ["new", 800], ["information", 804], ["could", 816], ["be", 822], ["gained", 825], ["about", 832], ["the", 838], ["SBP2", 842], ["and", 847], ["SECIS", 851], ["contacts", 857], ["with", 866], ["components", 871], ["of", 882], ["the", 885], ["translation", 889], ["machinery", 901], ["at", 911], ["various", 914], ["translation", 922], ["steps", 934], [".", 939], ["In", 941], ["particular", 944], [",", 954], ["we", 956], ["found", 959], ["that", 965], ["SBP2", 970], ["was", 975], ["bound", 979], ["only", 985], ["to", 990], ["the", 993], ["SECIS", 997], ["in", 1003], ["48S", 1006], ["pre", 1010], ["-", 1013], ["initiation", 1014], ["and", 1025], ["80S", 1029], ["pretranslocation", 1033], ["complexes", 1050], [".", 1059], ["In", 1061], ["the", 1064], ["complex", 1068], ["where", 1076], ["the", 1082], ["Sec", 1086], ["-", 1089], ["tRNA(Sec", 1090], [")", 1098], ["was", 1100], ["accommodated", 1104], ["to", 1117], ["the", 1120], ["A", 1124], ["site", 1126], ["but", 1131], ["transpeptidation", 1135], ["was", 1152], ["blocked", 1156], [",", 1163], ["SBP2", 1165], ["bound", 1170], ["the", 1176], ["ribosome", 1180], ["and", 1189], ["possibly", 1193], ["the", 1202], ["SECIS", 1206], ["element", 1212], ["as", 1220], ["well", 1223], [",", 1227], ["and", 1229], ["the", 1233], ["SECIS", 1237], ["had", 1243], ["flexible", 1247], ["contacts", 1256], ["with", 1265], ["the", 1270], ["60S", 1274], ["ribosomal", 1278], ["subunit", 1288], ["involving", 1296], ["several", 1306], ["ribosomal", 1314], ["proteins", 1324], [".", 1332], ["Altogether", 1334], [",", 1344], ["our", 1346], ["findings", 1350], ["led", 1359], ["to", 1363], ["broadening", 1366], ["our", 1377], ["understanding", 1381], ["about", 1395], ["the", 1401], ["unique", 1405], ["mechanism", 1412], ["of", 1422], ["selenocysteine", 1425], ["incorporation", 1440], ["in", 1454], ["mammals", 1457], [".", 1464]]}
{"context": "The structurally novel macrolide FK506 (refs 1,2) has recently been demonstrated to have potent immunosuppressive activity at concentrations several hundredfold lower than cyclosporin A (CsA). Cyclosporin A, a cyclic peptide, has found widespread clinical use in the prevention of graft rejection following bone marrow and organ transplantation. The mechanisms of immunosuppression mediated by FK506 and CsA appear to be remarkably similar, suggesting that these unrelated structures act on a common receptor or on similar molecular targets, perhaps the CsA receptor, cyclophilin, which has recently been shown by Fischer et al. and Takahashi et al. to have cis-trans peptidyl-prolyl isomerase activity. We have prepared an FK506 affinity matrix and purified a binding protein for FK506 from bovine thymus and from human spleen. This FK506-binding protein (FKBP) has a relative molecular mass (Mr) of approximately 14,000(14K), a pI of 8.8-8.9, and does not cross-react with antisera against cyclophilin. The first 40 N-terminal residues of the bovine and 16 residues of the human FKBP were determined; the 16-residue fragments are identical to each other and unrelated to any known sequences. This protein catalyses the cis-trans isomerization of the proline amide in a tetrapeptide substrate and FK506 inhibits the action of this new isomerase. The FKBP and cyclophilin appear to be members of an emerging class of novel proteins that regulate T cell activation and other metabolic processes, perhaps by the recognition (and possibly the isomerization) of proline-containing epitopes in target proteins.", "qas": [{"question": "Which is the receptor for the immunosuppressive drug cyclosporin A (CsA)?", "answers": ["cyclophilin"], "qid": "90bdfabdb48f4ced82219e53d43212a0", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["the", 26], ["immunosuppressive", 30], ["drug", 48], ["cyclosporin", 53], ["A", 65], ["(", 67], ["CsA", 68], [")", 71], ["?", 72]], "detected_answers": [{"text": "cyclophilin", "token_spans": [[91, 91], [243, 243], [177, 177]], "char_spans": [[568, 578], [1360, 1370], [992, 1002]]}]}], "context_tokens": [["The", 0], ["structurally", 4], ["novel", 17], ["macrolide", 23], ["FK506", 33], ["(", 39], ["refs", 40], ["1,2", 45], [")", 48], ["has", 50], ["recently", 54], ["been", 63], ["demonstrated", 68], ["to", 81], ["have", 84], ["potent", 89], ["immunosuppressive", 96], ["activity", 114], ["at", 123], ["concentrations", 126], ["several", 141], ["hundredfold", 149], ["lower", 161], ["than", 167], ["cyclosporin", 172], ["A", 184], ["(", 186], ["CsA", 187], [")", 190], [".", 191], ["Cyclosporin", 193], ["A", 205], [",", 206], ["a", 208], ["cyclic", 210], ["peptide", 217], [",", 224], ["has", 226], ["found", 230], ["widespread", 236], ["clinical", 247], ["use", 256], ["in", 260], ["the", 263], ["prevention", 267], ["of", 278], ["graft", 281], ["rejection", 287], ["following", 297], ["bone", 307], ["marrow", 312], ["and", 319], ["organ", 323], ["transplantation", 329], [".", 344], ["The", 346], ["mechanisms", 350], ["of", 361], ["immunosuppression", 364], ["mediated", 382], ["by", 391], ["FK506", 394], ["and", 400], ["CsA", 404], ["appear", 408], ["to", 415], ["be", 418], ["remarkably", 421], ["similar", 432], [",", 439], ["suggesting", 441], ["that", 452], ["these", 457], ["unrelated", 463], ["structures", 473], ["act", 484], ["on", 488], ["a", 491], ["common", 493], ["receptor", 500], ["or", 509], ["on", 512], ["similar", 515], ["molecular", 523], ["targets", 533], [",", 540], ["perhaps", 542], ["the", 550], ["CsA", 554], ["receptor", 558], [",", 566], ["cyclophilin", 568], [",", 579], ["which", 581], ["has", 587], ["recently", 591], ["been", 600], ["shown", 605], ["by", 611], ["Fischer", 614], ["et", 622], ["al", 625], [".", 627], ["and", 629], ["Takahashi", 633], ["et", 643], ["al", 646], [".", 648], ["to", 650], ["have", 653], ["cis", 658], ["-", 661], ["trans", 662], ["peptidyl", 668], ["-", 676], ["prolyl", 677], ["isomerase", 684], ["activity", 694], [".", 702], ["We", 704], ["have", 707], ["prepared", 712], ["an", 721], ["FK506", 724], ["affinity", 730], ["matrix", 739], ["and", 746], ["purified", 750], ["a", 759], ["binding", 761], ["protein", 769], ["for", 777], ["FK506", 781], ["from", 787], ["bovine", 792], ["thymus", 799], ["and", 806], ["from", 810], ["human", 815], ["spleen", 821], [".", 827], ["This", 829], ["FK506-binding", 834], ["protein", 848], ["(", 856], ["FKBP", 857], [")", 861], ["has", 863], ["a", 867], ["relative", 869], ["molecular", 878], ["mass", 888], ["(", 893], ["Mr", 894], [")", 896], ["of", 898], ["approximately", 901], ["14,000(14", 915], ["K", 924], [")", 925], [",", 926], ["a", 928], ["pI", 930], ["of", 933], ["8.8", 936], ["-", 939], ["8.9", 940], [",", 943], ["and", 945], ["does", 949], ["not", 954], ["cross", 958], ["-", 963], ["react", 964], ["with", 970], ["antisera", 975], ["against", 984], ["cyclophilin", 992], [".", 1003], ["The", 1005], ["first", 1009], ["40", 1015], ["N", 1018], ["-", 1019], ["terminal", 1020], ["residues", 1029], ["of", 1038], ["the", 1041], ["bovine", 1045], ["and", 1052], ["16", 1056], ["residues", 1059], ["of", 1068], ["the", 1071], ["human", 1075], ["FKBP", 1081], ["were", 1086], ["determined", 1091], [";", 1101], ["the", 1103], ["16-residue", 1107], ["fragments", 1118], ["are", 1128], ["identical", 1132], ["to", 1142], ["each", 1145], ["other", 1150], ["and", 1156], ["unrelated", 1160], ["to", 1170], ["any", 1173], ["known", 1177], ["sequences", 1183], [".", 1192], ["This", 1194], ["protein", 1199], ["catalyses", 1207], ["the", 1217], ["cis", 1221], ["-", 1224], ["trans", 1225], ["isomerization", 1231], ["of", 1245], ["the", 1248], ["proline", 1252], ["amide", 1260], ["in", 1266], ["a", 1269], ["tetrapeptide", 1271], ["substrate", 1284], ["and", 1294], ["FK506", 1298], ["inhibits", 1304], ["the", 1313], ["action", 1317], ["of", 1324], ["this", 1327], ["new", 1332], ["isomerase", 1336], [".", 1345], ["The", 1347], ["FKBP", 1351], ["and", 1356], ["cyclophilin", 1360], ["appear", 1372], ["to", 1379], ["be", 1382], ["members", 1385], ["of", 1393], ["an", 1396], ["emerging", 1399], ["class", 1408], ["of", 1414], ["novel", 1417], ["proteins", 1423], ["that", 1432], ["regulate", 1437], ["T", 1446], ["cell", 1448], ["activation", 1453], ["and", 1464], ["other", 1468], ["metabolic", 1474], ["processes", 1484], [",", 1493], ["perhaps", 1495], ["by", 1503], ["the", 1506], ["recognition", 1510], ["(", 1522], ["and", 1523], ["possibly", 1527], ["the", 1536], ["isomerization", 1540], [")", 1553], ["of", 1555], ["proline", 1558], ["-", 1565], ["containing", 1566], ["epitopes", 1577], ["in", 1586], ["target", 1589], ["proteins", 1596], [".", 1604]]}
{"context": "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small-artery disease of mid-adulthood caused by mutations of the NOTCH3 gene. The disease is responsible for widespread white-matter lesions associated with lacunar infarctions in various subcortical areas. The disease is responsible for migraine with aura and ischemic strokes, and is associated with various degrees of cognitive impairment and with mood disturbances. CADASIL is considered as a unique model to investigate what is known as \"subcortical ischemic vascular dementia.\" Recent data suggest that the number of lacunar infarctions and severity of cerebral atrophy are the main magnetic resonance imaging markers associated with cognitive and motor disabilities in this disorder. Mood disturbances are reported in 10% to 20% of patients, most often in association with cognitive alterations. Their exact origin remains unknown; the presence of ischemic lesions within the basal ganglia or the frontal white matter may promote the occurrence of these symptoms. Further studies are needed to better understand the relationships between cerebral lesions and both cognitive and psychiatric symptoms in this small-vessel disease of the brain.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "b2f73e6827624d46a50622245bc0bc8c", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[28, 29]], "char_spans": [[182, 192]]}]}], "context_tokens": [["Cerebral", 0], ["autosomal", 9], ["dominant", 19], ["arteriopathy", 28], ["with", 41], ["subcortical", 46], ["infarcts", 58], ["and", 67], ["leukoencephalopathy", 71], ["(", 91], ["CADASIL", 92], [")", 99], ["is", 101], ["an", 104], ["inherited", 107], ["small", 117], ["-", 122], ["artery", 123], ["disease", 130], ["of", 138], ["mid", 141], ["-", 144], ["adulthood", 145], ["caused", 155], ["by", 162], ["mutations", 165], ["of", 175], ["the", 178], ["NOTCH3", 182], ["gene", 189], [".", 193], ["The", 195], ["disease", 199], ["is", 207], ["responsible", 210], ["for", 222], ["widespread", 226], ["white", 237], ["-", 242], ["matter", 243], ["lesions", 250], ["associated", 258], ["with", 269], ["lacunar", 274], ["infarctions", 282], ["in", 294], ["various", 297], ["subcortical", 305], ["areas", 317], [".", 322], ["The", 324], ["disease", 328], ["is", 336], ["responsible", 339], ["for", 351], ["migraine", 355], ["with", 364], ["aura", 369], ["and", 374], ["ischemic", 378], ["strokes", 387], [",", 394], ["and", 396], ["is", 400], ["associated", 403], ["with", 414], ["various", 419], ["degrees", 427], ["of", 435], ["cognitive", 438], ["impairment", 448], ["and", 459], ["with", 463], ["mood", 468], ["disturbances", 473], [".", 485], ["CADASIL", 487], ["is", 495], ["considered", 498], ["as", 509], ["a", 512], ["unique", 514], ["model", 521], ["to", 527], ["investigate", 530], ["what", 542], ["is", 547], ["known", 550], ["as", 556], ["\"", 559], ["subcortical", 560], ["ischemic", 572], ["vascular", 581], ["dementia", 590], [".", 598], ["\"", 599], ["Recent", 601], ["data", 608], ["suggest", 613], ["that", 621], ["the", 626], ["number", 630], ["of", 637], ["lacunar", 640], ["infarctions", 648], ["and", 660], ["severity", 664], ["of", 673], ["cerebral", 676], ["atrophy", 685], ["are", 693], ["the", 697], ["main", 701], ["magnetic", 706], ["resonance", 715], ["imaging", 725], ["markers", 733], ["associated", 741], ["with", 752], ["cognitive", 757], ["and", 767], ["motor", 771], ["disabilities", 777], ["in", 790], ["this", 793], ["disorder", 798], [".", 806], ["Mood", 808], ["disturbances", 813], ["are", 826], ["reported", 830], ["in", 839], ["10", 842], ["%", 844], ["to", 846], ["20", 849], ["%", 851], ["of", 853], ["patients", 856], [",", 864], ["most", 866], ["often", 871], ["in", 877], ["association", 880], ["with", 892], ["cognitive", 897], ["alterations", 907], [".", 918], ["Their", 920], ["exact", 926], ["origin", 932], ["remains", 939], ["unknown", 947], [";", 954], ["the", 956], ["presence", 960], ["of", 969], ["ischemic", 972], ["lesions", 981], ["within", 989], ["the", 996], ["basal", 1000], ["ganglia", 1006], ["or", 1014], ["the", 1017], ["frontal", 1021], ["white", 1029], ["matter", 1035], ["may", 1042], ["promote", 1046], ["the", 1054], ["occurrence", 1058], ["of", 1069], ["these", 1072], ["symptoms", 1078], [".", 1086], ["Further", 1088], ["studies", 1096], ["are", 1104], ["needed", 1108], ["to", 1115], ["better", 1118], ["understand", 1125], ["the", 1136], ["relationships", 1140], ["between", 1154], ["cerebral", 1162], ["lesions", 1171], ["and", 1179], ["both", 1183], ["cognitive", 1188], ["and", 1198], ["psychiatric", 1202], ["symptoms", 1214], ["in", 1223], ["this", 1226], ["small", 1231], ["-", 1236], ["vessel", 1237], ["disease", 1244], ["of", 1252], ["the", 1255], ["brain", 1259], [".", 1264]]}
{"context": "Metastasis is the major factor affecting patient survival in ovarian cancer. However, its molecular mechanisms remain unclear. Our study used isogenic pairs of low- and high-invasive ovarian cancer cell lines to demonstrate the downregulation of miRNA-138 in the highly invasive cells, and its functioning as an inhibitor of cell migration and invasion. An orthotopic xenograft mouse model further demonstrated that the expression of miRNA-138 inhibited ovarian cancer metastasis to other organs. Results indicated that miR-138 directly targeted SRY-related high mobility group box 4 (SOX4) and hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1), and overexpression of SOX4 and HIF-1\u03b1 effectively reversed the miR-138-mediated suppression of cell invasion. Epidermal growth factor receptor acted as the downstream molecule of SOX4 by way of direct transcriptional control, whereas Slug was the downstream molecule of HIF-1\u03b1 by way of proteasome-mediated degradation. Analysis of human ovarian tumors further revealed downregulation of miR-138 and upregulation of SOX4 in late-stage tumors. Patients with miR-138(low)/SOX(high) signature are predominant in late stage and tend to have malignant phenotypes including lymph nodes metastasis, larger ascites volume and higher tumor grade. Our study demonstrates the role and clinical relevance of miR-138 in ovarian cancer cell invasion and metastasis, providing a potential therapeutic strategy for suppression of ovarian cancer metastasis by targeting SOX4 and HIF-1\u03b1 pathways.", "qas": [{"question": "Which miRNA is targeted by SRY/Sox9?", "answers": ["mir-138"], "qid": "8975f12eced24dab8b0c41383c7ba4d8", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["targeted", 15], ["by", 24], ["SRY", 27], ["/", 30], ["Sox9", 31], ["?", 35]], "detected_answers": [{"text": "mir-138", "token_spans": [[212, 212], [163, 163], [82, 82]], "char_spans": [[1329, 1335], [1021, 1027], [520, 526]]}]}], "context_tokens": [["Metastasis", 0], ["is", 11], ["the", 14], ["major", 18], ["factor", 24], ["affecting", 31], ["patient", 41], ["survival", 49], ["in", 58], ["ovarian", 61], ["cancer", 69], [".", 75], ["However", 77], [",", 84], ["its", 86], ["molecular", 90], ["mechanisms", 100], ["remain", 111], ["unclear", 118], [".", 125], ["Our", 127], ["study", 131], ["used", 137], ["isogenic", 142], ["pairs", 151], ["of", 157], ["low-", 160], ["and", 165], ["high", 169], ["-", 173], ["invasive", 174], ["ovarian", 183], ["cancer", 191], ["cell", 198], ["lines", 203], ["to", 209], ["demonstrate", 212], ["the", 224], ["downregulation", 228], ["of", 243], ["miRNA-138", 246], ["in", 256], ["the", 259], ["highly", 263], ["invasive", 270], ["cells", 279], [",", 284], ["and", 286], ["its", 290], ["functioning", 294], ["as", 306], ["an", 309], ["inhibitor", 312], ["of", 322], ["cell", 325], ["migration", 330], ["and", 340], ["invasion", 344], [".", 352], ["An", 354], ["orthotopic", 357], ["xenograft", 368], ["mouse", 378], ["model", 384], ["further", 390], ["demonstrated", 398], ["that", 411], ["the", 416], ["expression", 420], ["of", 431], ["miRNA-138", 434], ["inhibited", 444], ["ovarian", 454], ["cancer", 462], ["metastasis", 469], ["to", 480], ["other", 483], ["organs", 489], [".", 495], ["Results", 497], ["indicated", 505], ["that", 515], ["miR-138", 520], ["directly", 528], ["targeted", 537], ["SRY", 546], ["-", 549], ["related", 550], ["high", 558], ["mobility", 563], ["group", 572], ["box", 578], ["4", 582], ["(", 584], ["SOX4", 585], [")", 589], ["and", 591], ["hypoxia", 595], ["-", 602], ["inducible", 603], ["factor-1\u03b1", 613], ["(", 623], ["HIF-1\u03b1", 624], [")", 630], [",", 631], ["and", 633], ["overexpression", 637], ["of", 652], ["SOX4", 655], ["and", 660], ["HIF-1\u03b1", 664], ["effectively", 671], ["reversed", 683], ["the", 692], ["miR-138-mediated", 696], ["suppression", 713], ["of", 725], ["cell", 728], ["invasion", 733], [".", 741], ["Epidermal", 743], ["growth", 753], ["factor", 760], ["receptor", 767], ["acted", 776], ["as", 782], ["the", 785], ["downstream", 789], ["molecule", 800], ["of", 809], ["SOX4", 812], ["by", 817], ["way", 820], ["of", 824], ["direct", 827], ["transcriptional", 834], ["control", 850], [",", 857], ["whereas", 859], ["Slug", 867], ["was", 872], ["the", 876], ["downstream", 880], ["molecule", 891], ["of", 900], ["HIF-1\u03b1", 903], ["by", 910], ["way", 913], ["of", 917], ["proteasome", 920], ["-", 930], ["mediated", 931], ["degradation", 940], [".", 951], ["Analysis", 953], ["of", 962], ["human", 965], ["ovarian", 971], ["tumors", 979], ["further", 986], ["revealed", 994], ["downregulation", 1003], ["of", 1018], ["miR-138", 1021], ["and", 1029], ["upregulation", 1033], ["of", 1046], ["SOX4", 1049], ["in", 1054], ["late", 1057], ["-", 1061], ["stage", 1062], ["tumors", 1068], [".", 1074], ["Patients", 1076], ["with", 1085], ["miR-138(low)/SOX(high", 1090], [")", 1111], ["signature", 1113], ["are", 1123], ["predominant", 1127], ["in", 1139], ["late", 1142], ["stage", 1147], ["and", 1153], ["tend", 1157], ["to", 1162], ["have", 1165], ["malignant", 1170], ["phenotypes", 1180], ["including", 1191], ["lymph", 1201], ["nodes", 1207], ["metastasis", 1213], [",", 1223], ["larger", 1225], ["ascites", 1232], ["volume", 1240], ["and", 1247], ["higher", 1251], ["tumor", 1258], ["grade", 1264], [".", 1269], ["Our", 1271], ["study", 1275], ["demonstrates", 1281], ["the", 1294], ["role", 1298], ["and", 1303], ["clinical", 1307], ["relevance", 1316], ["of", 1326], ["miR-138", 1329], ["in", 1337], ["ovarian", 1340], ["cancer", 1348], ["cell", 1355], ["invasion", 1360], ["and", 1369], ["metastasis", 1373], [",", 1383], ["providing", 1385], ["a", 1395], ["potential", 1397], ["therapeutic", 1407], ["strategy", 1419], ["for", 1428], ["suppression", 1432], ["of", 1444], ["ovarian", 1447], ["cancer", 1455], ["metastasis", 1462], ["by", 1473], ["targeting", 1476], ["SOX4", 1486], ["and", 1491], ["HIF-1\u03b1", 1495], ["pathways", 1502], [".", 1510]]}
{"context": "The completeness of meningioma resection depends on the resection of dura mater invaded by the tumor. The pathological changes of the dura around the tumor can be interpreted by evaluating the dural tail sign (DTS) on MRI studies. The goal of this study was to clarify the pathological characteristics of the DTSs, propose a classification based on the histopathological and radiological correlation, and identify the invasive range of tumor cells in different types of DTS. The authors retrospectively reviewed 179 patients with convexity meningiomas who underwent Simpson Grade I resection. All patients underwent an enhanced MRI examination preoperatively. The convexity meningiomas were dichotomized into various subtypes in accordance with the 2007 WHO classification of tumors of the CNS, and the DTS was identified based on the Goldsher criteria. The range of resection of the involved dura was 3 cm from the base of the tumor, which corresponded with the length of DTS on MRI studies. Histopathological examination of dura at 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 cm from the base of the tumor was conducted, and the findings were correlated with the preoperative MRI appearance of the DTS. A total of 154 (86%) of 179 convexity meningiomas were classified into WHO Grade I subtype, including transitional (44 [28.6%] of 154), meningothelial (36 [23.4%] of 154), fibrous (23 [14.9%] of 154), psammomatous (22 [14.3%] of 154), secretory (10 [6.5%] of 154), and angiomatous (19 [12.3%] of 154). The other 25 (14%) were non-Grade I (WHO) tumors, including atypical (12 [48%] of 25), anaplastic (5 [20%] of 25), and papillary (8 [32%] of 25). The DTS was classified into 5 types: smooth (16 [8.9%] of 179), nodular (36 [20.1%] of 179), mixed (57 [31.8%] of 179), symmetrical multipolar (15 [8.4%] of 179), and asymmetrical multipolar (55 [30.7%] of 179). There was a significant difference in distribution of DTS type between Grade I and non-Grade I tumors (p = 0.004), whereas the difference was not significant among Grade I tumors (0.841) or among non-Grade I tumors (p = 0.818). All smooth-type DTSs were encountered in Grade I tumors, and the mixed DTS (52 [33.8%] of 154) was the most common type in these tumors. Nodular-type DTS was more commonly seen in non-Grade I tumors (12 [48%] of 25). Tumor invasion was found in 88.3% (158 of 179) of convexity meningiomas, of which the range of invasion in 82.3% (130 of 158) was within 2 cm and that in 94.9% (150 of 158) was within 2.5 cm. The incidence of invasion and the range invaded by tumor cells varied in different types of DTS, and differences were statistically significant (p < 0.001). Nodular-type DTS on MRI studies might be associated with non-Grade I tumors. The range of dural resection for convexity meningiomas should be 2.5 cm from the tumor base, and if this extent of resection is not feasible, the type of DTS should be considered. However, for skull base meningiomas, in which mostly Simpson Grade II resection is achieved, the use of this classification should be further validated. The classification of DTS enables the surgeon to predict preoperatively and then to achieve the optimal range of dural resection that might significantly reduce the recurrence rate of meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "dfc371178f7740ec80686c0baf2ecc3a", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[3, 3]], "char_spans": [[20, 29]]}]}], "context_tokens": [["The", 0], ["completeness", 4], ["of", 17], ["meningioma", 20], ["resection", 31], ["depends", 41], ["on", 49], ["the", 52], ["resection", 56], ["of", 66], ["dura", 69], ["mater", 74], ["invaded", 80], ["by", 88], ["the", 91], ["tumor", 95], [".", 100], ["The", 102], ["pathological", 106], ["changes", 119], ["of", 127], ["the", 130], ["dura", 134], ["around", 139], ["the", 146], ["tumor", 150], ["can", 156], ["be", 160], ["interpreted", 163], ["by", 175], ["evaluating", 178], ["the", 189], ["dural", 193], ["tail", 199], ["sign", 204], ["(", 209], ["DTS", 210], [")", 213], ["on", 215], ["MRI", 218], ["studies", 222], [".", 229], ["The", 231], ["goal", 235], ["of", 240], ["this", 243], ["study", 248], ["was", 254], ["to", 258], ["clarify", 261], ["the", 269], ["pathological", 273], ["characteristics", 286], ["of", 302], ["the", 305], ["DTSs", 309], [",", 313], ["propose", 315], ["a", 323], ["classification", 325], ["based", 340], ["on", 346], ["the", 349], ["histopathological", 353], ["and", 371], ["radiological", 375], ["correlation", 388], [",", 399], ["and", 401], ["identify", 405], ["the", 414], ["invasive", 418], ["range", 427], ["of", 433], ["tumor", 436], ["cells", 442], ["in", 448], ["different", 451], ["types", 461], ["of", 467], ["DTS", 470], [".", 473], ["The", 475], ["authors", 479], ["retrospectively", 487], ["reviewed", 503], ["179", 512], ["patients", 516], ["with", 525], ["convexity", 530], ["meningiomas", 540], ["who", 552], ["underwent", 556], ["Simpson", 566], ["Grade", 574], ["I", 580], ["resection", 582], [".", 591], ["All", 593], ["patients", 597], ["underwent", 606], ["an", 616], ["enhanced", 619], ["MRI", 628], ["examination", 632], ["preoperatively", 644], [".", 658], ["The", 660], ["convexity", 664], ["meningiomas", 674], ["were", 686], ["dichotomized", 691], ["into", 704], ["various", 709], ["subtypes", 717], ["in", 726], ["accordance", 729], ["with", 740], ["the", 745], ["2007", 749], ["WHO", 754], ["classification", 758], ["of", 773], ["tumors", 776], ["of", 783], ["the", 786], ["CNS", 790], [",", 793], ["and", 795], ["the", 799], ["DTS", 803], ["was", 807], ["identified", 811], ["based", 822], ["on", 828], ["the", 831], ["Goldsher", 835], ["criteria", 844], [".", 852], ["The", 854], ["range", 858], ["of", 864], ["resection", 867], ["of", 877], ["the", 880], ["involved", 884], ["dura", 893], ["was", 898], ["3", 902], ["cm", 904], ["from", 907], ["the", 912], ["base", 916], ["of", 921], ["the", 924], ["tumor", 928], [",", 933], ["which", 935], ["corresponded", 941], ["with", 954], ["the", 959], ["length", 963], ["of", 970], ["DTS", 973], ["on", 977], ["MRI", 980], ["studies", 984], [".", 991], ["Histopathological", 993], ["examination", 1011], ["of", 1023], ["dura", 1026], ["at", 1031], ["0.5", 1034], [",", 1037], ["1.0", 1039], [",", 1042], ["1.5", 1044], [",", 1047], ["2.0", 1049], [",", 1052], ["2.5", 1054], [",", 1057], ["and", 1059], ["3.0", 1063], ["cm", 1067], ["from", 1070], ["the", 1075], ["base", 1079], ["of", 1084], ["the", 1087], ["tumor", 1091], ["was", 1097], ["conducted", 1101], [",", 1110], ["and", 1112], ["the", 1116], ["findings", 1120], ["were", 1129], ["correlated", 1134], ["with", 1145], ["the", 1150], ["preoperative", 1154], ["MRI", 1167], ["appearance", 1171], ["of", 1182], ["the", 1185], ["DTS", 1189], [".", 1192], ["A", 1194], ["total", 1196], ["of", 1202], ["154", 1205], ["(", 1209], ["86", 1210], ["%", 1212], [")", 1213], ["of", 1215], ["179", 1218], ["convexity", 1222], ["meningiomas", 1232], ["were", 1244], ["classified", 1249], ["into", 1260], ["WHO", 1265], ["Grade", 1269], ["I", 1275], ["subtype", 1277], [",", 1284], ["including", 1286], ["transitional", 1296], ["(", 1309], ["44", 1310], ["[", 1313], ["28.6", 1314], ["%", 1318], ["]", 1319], ["of", 1321], ["154", 1324], [")", 1327], [",", 1328], ["meningothelial", 1330], ["(", 1345], ["36", 1346], ["[", 1349], ["23.4", 1350], ["%", 1354], ["]", 1355], ["of", 1357], ["154", 1360], [")", 1363], [",", 1364], ["fibrous", 1366], ["(", 1374], ["23", 1375], ["[", 1378], ["14.9", 1379], ["%", 1383], ["]", 1384], ["of", 1386], ["154", 1389], [")", 1392], [",", 1393], ["psammomatous", 1395], ["(", 1408], ["22", 1409], ["[", 1412], ["14.3", 1413], ["%", 1417], ["]", 1418], ["of", 1420], ["154", 1423], [")", 1426], [",", 1427], ["secretory", 1429], ["(", 1439], ["10", 1440], ["[", 1443], ["6.5", 1444], ["%", 1447], ["]", 1448], ["of", 1450], ["154", 1453], [")", 1456], [",", 1457], ["and", 1459], ["angiomatous", 1463], ["(", 1475], ["19", 1476], ["[", 1479], ["12.3", 1480], ["%", 1484], ["]", 1485], ["of", 1487], ["154", 1490], [")", 1493], [".", 1494], ["The", 1496], ["other", 1500], ["25", 1506], ["(", 1509], ["14", 1510], ["%", 1512], [")", 1513], ["were", 1515], ["non", 1520], ["-", 1523], ["Grade", 1524], ["I", 1530], ["(", 1532], ["WHO", 1533], [")", 1536], ["tumors", 1538], [",", 1544], ["including", 1546], ["atypical", 1556], ["(", 1565], ["12", 1566], ["[", 1569], ["48", 1570], ["%", 1572], ["]", 1573], ["of", 1575], ["25", 1578], [")", 1580], [",", 1581], ["anaplastic", 1583], ["(", 1594], ["5", 1595], ["[", 1597], ["20", 1598], ["%", 1600], ["]", 1601], ["of", 1603], ["25", 1606], [")", 1608], [",", 1609], ["and", 1611], ["papillary", 1615], ["(", 1625], ["8", 1626], ["[", 1628], ["32", 1629], ["%", 1631], ["]", 1632], ["of", 1634], ["25", 1637], [")", 1639], [".", 1640], ["The", 1642], ["DTS", 1646], ["was", 1650], ["classified", 1654], ["into", 1665], ["5", 1670], ["types", 1672], [":", 1677], ["smooth", 1679], ["(", 1686], ["16", 1687], ["[", 1690], ["8.9", 1691], ["%", 1694], ["]", 1695], ["of", 1697], ["179", 1700], [")", 1703], [",", 1704], ["nodular", 1706], ["(", 1714], ["36", 1715], ["[", 1718], ["20.1", 1719], ["%", 1723], ["]", 1724], ["of", 1726], ["179", 1729], [")", 1732], [",", 1733], ["mixed", 1735], ["(", 1741], ["57", 1742], ["[", 1745], ["31.8", 1746], ["%", 1750], ["]", 1751], ["of", 1753], ["179", 1756], [")", 1759], [",", 1760], ["symmetrical", 1762], ["multipolar", 1774], ["(", 1785], ["15", 1786], ["[", 1789], ["8.4", 1790], ["%", 1793], ["]", 1794], ["of", 1796], ["179", 1799], [")", 1802], [",", 1803], ["and", 1805], ["asymmetrical", 1809], ["multipolar", 1822], ["(", 1833], ["55", 1834], ["[", 1837], ["30.7", 1838], ["%", 1842], ["]", 1843], ["of", 1845], ["179", 1848], [")", 1851], [".", 1852], ["There", 1854], ["was", 1860], ["a", 1864], ["significant", 1866], ["difference", 1878], ["in", 1889], ["distribution", 1892], ["of", 1905], ["DTS", 1908], ["type", 1912], ["between", 1917], ["Grade", 1925], ["I", 1931], ["and", 1933], ["non", 1937], ["-", 1940], ["Grade", 1941], ["I", 1947], ["tumors", 1949], ["(", 1956], ["p", 1957], ["=", 1959], ["0.004", 1961], [")", 1966], [",", 1967], ["whereas", 1969], ["the", 1977], ["difference", 1981], ["was", 1992], ["not", 1996], ["significant", 2000], ["among", 2012], ["Grade", 2018], ["I", 2024], ["tumors", 2026], ["(", 2033], ["0.841", 2034], [")", 2039], ["or", 2041], ["among", 2044], ["non", 2050], ["-", 2053], ["Grade", 2054], ["I", 2060], ["tumors", 2062], ["(", 2069], ["p", 2070], ["=", 2072], ["0.818", 2074], [")", 2079], [".", 2080], ["All", 2082], ["smooth", 2086], ["-", 2092], ["type", 2093], ["DTSs", 2098], ["were", 2103], ["encountered", 2108], ["in", 2120], ["Grade", 2123], ["I", 2129], ["tumors", 2131], [",", 2137], ["and", 2139], ["the", 2143], ["mixed", 2147], ["DTS", 2153], ["(", 2157], ["52", 2158], ["[", 2161], ["33.8", 2162], ["%", 2166], ["]", 2167], ["of", 2169], ["154", 2172], [")", 2175], ["was", 2177], ["the", 2181], ["most", 2185], ["common", 2190], ["type", 2197], ["in", 2202], ["these", 2205], ["tumors", 2211], [".", 2217], ["Nodular", 2219], ["-", 2226], ["type", 2227], ["DTS", 2232], ["was", 2236], ["more", 2240], ["commonly", 2245], ["seen", 2254], ["in", 2259], ["non", 2262], ["-", 2265], ["Grade", 2266], ["I", 2272], ["tumors", 2274], ["(", 2281], ["12", 2282], ["[", 2285], ["48", 2286], ["%", 2288], ["]", 2289], ["of", 2291], ["25", 2294], [")", 2296], [".", 2297], ["Tumor", 2299], ["invasion", 2305], ["was", 2314], ["found", 2318], ["in", 2324], ["88.3", 2327], ["%", 2331], ["(", 2333], ["158", 2334], ["of", 2338], ["179", 2341], [")", 2344], ["of", 2346], ["convexity", 2349], ["meningiomas", 2359], [",", 2370], ["of", 2372], ["which", 2375], ["the", 2381], ["range", 2385], ["of", 2391], ["invasion", 2394], ["in", 2403], ["82.3", 2406], ["%", 2410], ["(", 2412], ["130", 2413], ["of", 2417], ["158", 2420], [")", 2423], ["was", 2425], ["within", 2429], ["2", 2436], ["cm", 2438], ["and", 2441], ["that", 2445], ["in", 2450], ["94.9", 2453], ["%", 2457], ["(", 2459], ["150", 2460], ["of", 2464], ["158", 2467], [")", 2470], ["was", 2472], ["within", 2476], ["2.5", 2483], ["cm", 2487], [".", 2489], ["The", 2491], ["incidence", 2495], ["of", 2505], ["invasion", 2508], ["and", 2517], ["the", 2521], ["range", 2525], ["invaded", 2531], ["by", 2539], ["tumor", 2542], ["cells", 2548], ["varied", 2554], ["in", 2561], ["different", 2564], ["types", 2574], ["of", 2580], ["DTS", 2583], [",", 2586], ["and", 2588], ["differences", 2592], ["were", 2604], ["statistically", 2609], ["significant", 2623], ["(", 2635], ["p", 2636], ["<", 2638], ["0.001", 2640], [")", 2645], [".", 2646], ["Nodular", 2648], ["-", 2655], ["type", 2656], ["DTS", 2661], ["on", 2665], ["MRI", 2668], ["studies", 2672], ["might", 2680], ["be", 2686], ["associated", 2689], ["with", 2700], ["non", 2705], ["-", 2708], ["Grade", 2709], ["I", 2715], ["tumors", 2717], [".", 2723], ["The", 2725], ["range", 2729], ["of", 2735], ["dural", 2738], ["resection", 2744], ["for", 2754], ["convexity", 2758], ["meningiomas", 2768], ["should", 2780], ["be", 2787], ["2.5", 2790], ["cm", 2794], ["from", 2797], ["the", 2802], ["tumor", 2806], ["base", 2812], [",", 2816], ["and", 2818], ["if", 2822], ["this", 2825], ["extent", 2830], ["of", 2837], ["resection", 2840], ["is", 2850], ["not", 2853], ["feasible", 2857], [",", 2865], ["the", 2867], ["type", 2871], ["of", 2876], ["DTS", 2879], ["should", 2883], ["be", 2890], ["considered", 2893], [".", 2903], ["However", 2905], [",", 2912], ["for", 2914], ["skull", 2918], ["base", 2924], ["meningiomas", 2929], [",", 2940], ["in", 2942], ["which", 2945], ["mostly", 2951], ["Simpson", 2958], ["Grade", 2966], ["II", 2972], ["resection", 2975], ["is", 2985], ["achieved", 2988], [",", 2996], ["the", 2998], ["use", 3002], ["of", 3006], ["this", 3009], ["classification", 3014], ["should", 3029], ["be", 3036], ["further", 3039], ["validated", 3047], [".", 3056], ["The", 3058], ["classification", 3062], ["of", 3077], ["DTS", 3080], ["enables", 3084], ["the", 3092], ["surgeon", 3096], ["to", 3104], ["predict", 3107], ["preoperatively", 3115], ["and", 3130], ["then", 3134], ["to", 3139], ["achieve", 3142], ["the", 3150], ["optimal", 3154], ["range", 3162], ["of", 3168], ["dural", 3171], ["resection", 3177], ["that", 3187], ["might", 3192], ["significantly", 3198], ["reduce", 3212], ["the", 3219], ["recurrence", 3223], ["rate", 3234], ["of", 3239], ["meningiomas", 3242], [".", 3253]]}
{"context": "Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity such as gefitinib and erlotinib. Responses to TK inhibitors in the absence of EGFR gene mutation for BAC patients have not been reported. A case of a patient with BAC refractory to chemotherapy who responded to gefitinib in the absence of EGFR gene mutations is reported. Tyrosine kinase inhibitors may have a role in BAC in the absence of EGFR gene mutations. Additional studies on other molecular alterations of the EGFR family members are needed to better predict response to these agents.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "edddbb8cad694d9a8b64e23dfb8292ba", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[52, 95]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["tyrosine", 17], ["kinase", 26], ["(", 33], ["TK", 34], [")", 36], ["domain", 38], ["of", 45], ["the", 48], ["epidermal", 52], ["growth", 62], ["factor", 69], ["receptor", 76], ["(", 85], ["EGFR", 86], [")", 90], ["gene", 92], ["in", 97], ["non", 100], ["-", 103], ["small", 104], ["cell", 110], ["lung", 115], ["cancers", 120], ["are", 128], ["associated", 132], ["with", 143], ["increased", 148], ["sensitivity", 158], ["of", 170], ["these", 173], ["cancers", 179], ["to", 187], ["drugs", 190], ["that", 196], ["inhibit", 201], ["EGFR", 209], ["kinase", 214], ["activity", 221], ["such", 230], ["as", 235], ["gefitinib", 238], ["and", 248], ["erlotinib", 252], [".", 261], ["Responses", 263], ["to", 273], ["TK", 276], ["inhibitors", 279], ["in", 290], ["the", 293], ["absence", 297], ["of", 305], ["EGFR", 308], ["gene", 313], ["mutation", 318], ["for", 327], ["BAC", 331], ["patients", 335], ["have", 344], ["not", 349], ["been", 353], ["reported", 358], [".", 366], ["A", 368], ["case", 370], ["of", 375], ["a", 378], ["patient", 380], ["with", 388], ["BAC", 393], ["refractory", 397], ["to", 408], ["chemotherapy", 411], ["who", 424], ["responded", 428], ["to", 438], ["gefitinib", 441], ["in", 451], ["the", 454], ["absence", 458], ["of", 466], ["EGFR", 469], ["gene", 474], ["mutations", 479], ["is", 489], ["reported", 492], [".", 500], ["Tyrosine", 502], ["kinase", 511], ["inhibitors", 518], ["may", 529], ["have", 533], ["a", 538], ["role", 540], ["in", 545], ["BAC", 548], ["in", 552], ["the", 555], ["absence", 559], ["of", 567], ["EGFR", 570], ["gene", 575], ["mutations", 580], [".", 589], ["Additional", 591], ["studies", 602], ["on", 610], ["other", 613], ["molecular", 619], ["alterations", 629], ["of", 641], ["the", 644], ["EGFR", 648], ["family", 653], ["members", 660], ["are", 668], ["needed", 672], ["to", 679], ["better", 682], ["predict", 689], ["response", 697], ["to", 706], ["these", 709], ["agents", 715], [".", 721]]}
{"context": "Turner's syndrome (TS) is a chromosomal disorder that results from the loss of the entire or a part of the X-chromosome and occurs in 1/2,500 female births. According to the majority of specific reports, intelligence in TS is generally found to be normal and the prevalence of mental retardation does not seem to be increased in TS except for those patients with a small ring X-chromosome. We evaluated 33 girls with TS with chronological age from 6-18 years. Intellectual assessment included the WISC III and the WAIS-R scales. Our results showed: 1) mean full scale intelligence quotient (FSIQ) was significantly lower than expected based on normative data (p < 0.0005); 2) no correlation was present between height and general intellectual ability; 3) mean performance intelligence quotient (PIQ) was significantly lower than both mean verbal intelligence quotient (VIQ) and FSIQ (p < 0.0025 and p < 0.01, respectively), and most patients had a VIQ-PIQ discrepancy; 4) the frequency of mental retardation in our study group was significantly higher than that observed in the general population (15.1% vs 2.3%, p < 0.025); 5) a significant association was found between karyotype and VIQ, and the best score was achieved in the subgroup of patients with structural abnormalities of the X-chromosome. In the light of these findings we conclude that the clinical picture in TS may encompass a slightly reduced FSIQ, VIQ and especially an inadequate PIQ, but this neurocognitive profile is not significantly affected by statural impairment. Since these neurocognitive defects can be responsible for misdiagnosed school difficulties, we suggest that girls with TS should receive specialized educational support and multidisciplinary care.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "12fa90a3c056479a92f47b23fd5275bf", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[252, 252], [72, 72], [23, 23]], "char_spans": [[1288, 1288], [376, 376], [107, 107]]}]}], "context_tokens": [["Turner", 0], ["'s", 6], ["syndrome", 9], ["(", 18], ["TS", 19], [")", 21], ["is", 23], ["a", 26], ["chromosomal", 28], ["disorder", 40], ["that", 49], ["results", 54], ["from", 62], ["the", 67], ["loss", 71], ["of", 76], ["the", 79], ["entire", 83], ["or", 90], ["a", 93], ["part", 95], ["of", 100], ["the", 103], ["X", 107], ["-", 108], ["chromosome", 109], ["and", 120], ["occurs", 124], ["in", 131], ["1/2,500", 134], ["female", 142], ["births", 149], [".", 155], ["According", 157], ["to", 167], ["the", 170], ["majority", 174], ["of", 183], ["specific", 186], ["reports", 195], [",", 202], ["intelligence", 204], ["in", 217], ["TS", 220], ["is", 223], ["generally", 226], ["found", 236], ["to", 242], ["be", 245], ["normal", 248], ["and", 255], ["the", 259], ["prevalence", 263], ["of", 274], ["mental", 277], ["retardation", 284], ["does", 296], ["not", 301], ["seem", 305], ["to", 310], ["be", 313], ["increased", 316], ["in", 326], ["TS", 329], ["except", 332], ["for", 339], ["those", 343], ["patients", 349], ["with", 358], ["a", 363], ["small", 365], ["ring", 371], ["X", 376], ["-", 377], ["chromosome", 378], [".", 388], ["We", 390], ["evaluated", 393], ["33", 403], ["girls", 406], ["with", 412], ["TS", 417], ["with", 420], ["chronological", 425], ["age", 439], ["from", 443], ["6", 448], ["-", 449], ["18", 450], ["years", 453], [".", 458], ["Intellectual", 460], ["assessment", 473], ["included", 484], ["the", 493], ["WISC", 497], ["III", 502], ["and", 506], ["the", 510], ["WAIS", 514], ["-", 518], ["R", 519], ["scales", 521], [".", 527], ["Our", 529], ["results", 533], ["showed", 541], [":", 547], ["1", 549], [")", 550], ["mean", 552], ["full", 557], ["scale", 562], ["intelligence", 568], ["quotient", 581], ["(", 590], ["FSIQ", 591], [")", 595], ["was", 597], ["significantly", 601], ["lower", 615], ["than", 621], ["expected", 626], ["based", 635], ["on", 641], ["normative", 644], ["data", 654], ["(", 659], ["p", 660], ["<", 662], ["0.0005", 664], [")", 670], [";", 671], ["2", 673], [")", 674], ["no", 676], ["correlation", 679], ["was", 691], ["present", 695], ["between", 703], ["height", 711], ["and", 718], ["general", 722], ["intellectual", 730], ["ability", 743], [";", 750], ["3", 752], [")", 753], ["mean", 755], ["performance", 760], ["intelligence", 772], ["quotient", 785], ["(", 794], ["PIQ", 795], [")", 798], ["was", 800], ["significantly", 804], ["lower", 818], ["than", 824], ["both", 829], ["mean", 834], ["verbal", 839], ["intelligence", 846], ["quotient", 859], ["(", 868], ["VIQ", 869], [")", 872], ["and", 874], ["FSIQ", 878], ["(", 883], ["p", 884], ["<", 886], ["0.0025", 888], ["and", 895], ["p", 899], ["<", 901], ["0.01", 903], [",", 907], ["respectively", 909], [")", 921], [",", 922], ["and", 924], ["most", 928], ["patients", 933], ["had", 942], ["a", 946], ["VIQ", 948], ["-", 951], ["PIQ", 952], ["discrepancy", 956], [";", 967], ["4", 969], [")", 970], ["the", 972], ["frequency", 976], ["of", 986], ["mental", 989], ["retardation", 996], ["in", 1008], ["our", 1011], ["study", 1015], ["group", 1021], ["was", 1027], ["significantly", 1031], ["higher", 1045], ["than", 1052], ["that", 1057], ["observed", 1062], ["in", 1071], ["the", 1074], ["general", 1078], ["population", 1086], ["(", 1097], ["15.1", 1098], ["%", 1102], ["vs", 1104], ["2.3", 1107], ["%", 1110], [",", 1111], ["p", 1113], ["<", 1115], ["0.025", 1117], [")", 1122], [";", 1123], ["5", 1125], [")", 1126], ["a", 1128], ["significant", 1130], ["association", 1142], ["was", 1154], ["found", 1158], ["between", 1164], ["karyotype", 1172], ["and", 1182], ["VIQ", 1186], [",", 1189], ["and", 1191], ["the", 1195], ["best", 1199], ["score", 1204], ["was", 1210], ["achieved", 1214], ["in", 1223], ["the", 1226], ["subgroup", 1230], ["of", 1239], ["patients", 1242], ["with", 1251], ["structural", 1256], ["abnormalities", 1267], ["of", 1281], ["the", 1284], ["X", 1288], ["-", 1289], ["chromosome", 1290], [".", 1300], ["In", 1302], ["the", 1305], ["light", 1309], ["of", 1315], ["these", 1318], ["findings", 1324], ["we", 1333], ["conclude", 1336], ["that", 1345], ["the", 1350], ["clinical", 1354], ["picture", 1363], ["in", 1371], ["TS", 1374], ["may", 1377], ["encompass", 1381], ["a", 1391], ["slightly", 1393], ["reduced", 1402], ["FSIQ", 1410], [",", 1414], ["VIQ", 1416], ["and", 1420], ["especially", 1424], ["an", 1435], ["inadequate", 1438], ["PIQ", 1449], [",", 1452], ["but", 1454], ["this", 1458], ["neurocognitive", 1463], ["profile", 1478], ["is", 1486], ["not", 1489], ["significantly", 1493], ["affected", 1507], ["by", 1516], ["statural", 1519], ["impairment", 1528], [".", 1538], ["Since", 1540], ["these", 1546], ["neurocognitive", 1552], ["defects", 1567], ["can", 1575], ["be", 1579], ["responsible", 1582], ["for", 1594], ["misdiagnosed", 1598], ["school", 1611], ["difficulties", 1618], [",", 1630], ["we", 1632], ["suggest", 1635], ["that", 1643], ["girls", 1648], ["with", 1654], ["TS", 1659], ["should", 1662], ["receive", 1669], ["specialized", 1677], ["educational", 1689], ["support", 1701], ["and", 1709], ["multidisciplinary", 1713], ["care", 1731], [".", 1735]]}
{"context": "Clozapine reduces L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesias in parkinsonian patients. To test if the antidyskinetic effect of clozapine is related to antagonism at the dopamine D(4) receptor, we investigated the effect of 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1, 4]benzodiazepine (JL-18), a structural analog of clozapine which is more selective for this receptor. Four 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias to L-Dopa were used in this study. They were injected subcutaneously (s.c.) with L-Dopa methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-Dopa/benserazide) alone or in combination with JL-18 (at the doses of 0.1, 0.3, or 0.9 mg/kg, s.c.). Subcutaneous injection of sterile saline was used as control. L-Dopa/benserazide increased locomotion and improved parkinsonism but also induced dyskinesias. Co-administration of JL-18, at low doses (0.1, 0.3 mg/kg) with L-Dopa/benserazide, produced a dose-dependent reduction in L-Dopa-induced dyskinesias without a parallel return to parkinsonism. The present results suggest that novel selective dopamine D(4) receptor antagonists may represent a useful tool to reduce L-Dopa-induced dyskinesias.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "7084fb7065f745f3870b1046a517cc3a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[231, 233], [199, 201], [93, 95], [186, 188], [153, 155], [112, 114], [75, 77]], "char_spans": [[1279, 1284], [1087, 1092], [628, 633], [1028, 1033], [869, 874], [704, 709], [550, 555]]}]}], "context_tokens": [["Clozapine", 0], ["reduces", 10], ["L-3,4-dihydroxyphenylalanine", 18], ["(", 47], ["L", 48], ["-", 49], ["Dopa)-induced", 50], ["dyskinesias", 64], ["in", 76], ["parkinsonian", 79], ["patients", 92], [".", 100], ["To", 102], ["test", 105], ["if", 110], ["the", 113], ["antidyskinetic", 117], ["effect", 132], ["of", 139], ["clozapine", 142], ["is", 152], ["related", 155], ["to", 163], ["antagonism", 166], ["at", 177], ["the", 180], ["dopamine", 184], ["D(4", 193], [")", 196], ["receptor", 198], [",", 206], ["we", 208], ["investigated", 211], ["the", 224], ["effect", 228], ["of", 235], ["8-methyl-6-(4-methyl-1-piperazinyl)-11H", 238], ["-", 277], ["pyrido[2,3-b][1", 278], [",", 293], ["4]benzodiazepine", 295], ["(", 312], ["JL-18", 313], [")", 318], [",", 319], ["a", 321], ["structural", 323], ["analog", 334], ["of", 341], ["clozapine", 344], ["which", 354], ["is", 360], ["more", 363], ["selective", 368], ["for", 378], ["this", 382], ["receptor", 387], [".", 395], ["Four", 397], ["1-methyl-4-phenyl-1,2,3", 402], [",", 425], ["6-tetrahydropyridine", 427], ["(", 448], ["MPTP)-treated", 449], ["cynomolgus", 463], ["monkeys", 474], ["with", 482], ["a", 487], ["stable", 489], ["parkinsonian", 496], ["syndrome", 509], ["and", 518], ["reproducible", 522], ["dyskinesias", 535], ["to", 547], ["L", 550], ["-", 551], ["Dopa", 552], ["were", 557], ["used", 562], ["in", 567], ["this", 570], ["study", 575], [".", 580], ["They", 582], ["were", 587], ["injected", 592], ["subcutaneously", 601], ["(", 616], ["s.c", 617], [".", 620], [")", 621], ["with", 623], ["L", 628], ["-", 629], ["Dopa", 630], ["methyl", 635], ["ester", 642], ["(", 648], ["125", 649], ["mg", 653], ["per", 656], ["animal", 660], [")", 666], ["plus", 668], ["benserazide", 673], ["(", 685], ["50", 686], ["mg", 689], ["per", 692], ["animal", 696], [";", 702], ["L", 704], ["-", 705], ["Dopa", 706], ["/", 710], ["benserazide", 711], [")", 722], ["alone", 724], ["or", 730], ["in", 733], ["combination", 736], ["with", 748], ["JL-18", 753], ["(", 759], ["at", 760], ["the", 763], ["doses", 767], ["of", 773], ["0.1", 776], [",", 779], ["0.3", 781], [",", 784], ["or", 786], ["0.9", 789], ["mg", 793], ["/", 795], ["kg", 796], [",", 798], ["s.c", 800], [".", 803], [")", 804], [".", 805], ["Subcutaneous", 807], ["injection", 820], ["of", 830], ["sterile", 833], ["saline", 841], ["was", 848], ["used", 852], ["as", 857], ["control", 860], [".", 867], ["L", 869], ["-", 870], ["Dopa", 871], ["/", 875], ["benserazide", 876], ["increased", 888], ["locomotion", 898], ["and", 909], ["improved", 913], ["parkinsonism", 922], ["but", 935], ["also", 939], ["induced", 944], ["dyskinesias", 952], [".", 963], ["Co", 965], ["-", 967], ["administration", 968], ["of", 983], ["JL-18", 986], [",", 991], ["at", 993], ["low", 996], ["doses", 1000], ["(", 1006], ["0.1", 1007], [",", 1010], ["0.3", 1012], ["mg", 1016], ["/", 1018], ["kg", 1019], [")", 1021], ["with", 1023], ["L", 1028], ["-", 1029], ["Dopa", 1030], ["/", 1034], ["benserazide", 1035], [",", 1046], ["produced", 1048], ["a", 1057], ["dose", 1059], ["-", 1063], ["dependent", 1064], ["reduction", 1074], ["in", 1084], ["L", 1087], ["-", 1088], ["Dopa", 1089], ["-", 1093], ["induced", 1094], ["dyskinesias", 1102], ["without", 1114], ["a", 1122], ["parallel", 1124], ["return", 1133], ["to", 1140], ["parkinsonism", 1143], [".", 1155], ["The", 1157], ["present", 1161], ["results", 1169], ["suggest", 1177], ["that", 1185], ["novel", 1190], ["selective", 1196], ["dopamine", 1206], ["D(4", 1215], [")", 1218], ["receptor", 1220], ["antagonists", 1229], ["may", 1241], ["represent", 1245], ["a", 1255], ["useful", 1257], ["tool", 1264], ["to", 1269], ["reduce", 1272], ["L", 1279], ["-", 1280], ["Dopa", 1281], ["-", 1285], ["induced", 1286], ["dyskinesias", 1294], [".", 1305]]}
{"context": "Bone pain is a common symptom in bone metastases. The therapies that are currently available include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, steroids and gabapentin which have been demonstrated to improve neuropathic pain. In addition, preclinical studies indicate that agents such as transient receptor potential vanilloid 1 antagonists and cannabinoid 2 receptor agonist could be considered as adjuncts in ameliorating opioid side effects. New drugs are in the clinical phase of development, among which the most promising molecules seem to be anti-nerve growth factor (NGF) antibodies. Anti-NGF antibody therapy may be particularly effective in blocking bone cancer pain because NGF appears to be integrally involved in the upregulation, sensitization and disinhibition of multiple neurotransmitters, ion channels and receptors in the primary afferent nerve. The best way to treat bone metastases pain is to improve the control of skeletal disease burden. Recently, denosumab, a noncytotoxic IgG2 monoclonal antibody with high affinity for human RANKL, has been demonstrated to significantly prevent clinically relevant increase in pain compared with zoledronic acid across the tumor types. Based on these data, it has been suggested that denosumab has the potential to become a new standard of treatment in bone metastases management.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "19f21e68fc4946c181d7758601dee5d5", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[175, 175]], "char_spans": [[1065, 1069]]}]}], "context_tokens": [["Bone", 0], ["pain", 5], ["is", 10], ["a", 13], ["common", 15], ["symptom", 22], ["in", 30], ["bone", 33], ["metastases", 38], [".", 48], ["The", 50], ["therapies", 54], ["that", 64], ["are", 69], ["currently", 73], ["available", 83], ["include", 93], ["nonsteroidal", 101], ["anti", 114], ["-", 118], ["inflammatory", 119], ["drugs", 132], ["(", 138], ["NSAIDs", 139], [")", 145], [",", 146], ["opioids", 148], [",", 155], ["steroids", 157], ["and", 166], ["gabapentin", 170], ["which", 181], ["have", 187], ["been", 192], ["demonstrated", 197], ["to", 210], ["improve", 213], ["neuropathic", 221], ["pain", 233], [".", 237], ["In", 239], ["addition", 242], [",", 250], ["preclinical", 252], ["studies", 264], ["indicate", 272], ["that", 281], ["agents", 286], ["such", 293], ["as", 298], ["transient", 301], ["receptor", 311], ["potential", 320], ["vanilloid", 330], ["1", 340], ["antagonists", 342], ["and", 354], ["cannabinoid", 358], ["2", 370], ["receptor", 372], ["agonist", 381], ["could", 389], ["be", 395], ["considered", 398], ["as", 409], ["adjuncts", 412], ["in", 421], ["ameliorating", 424], ["opioid", 437], ["side", 444], ["effects", 449], [".", 456], ["New", 458], ["drugs", 462], ["are", 468], ["in", 472], ["the", 475], ["clinical", 479], ["phase", 488], ["of", 494], ["development", 497], [",", 508], ["among", 510], ["which", 516], ["the", 522], ["most", 526], ["promising", 531], ["molecules", 541], ["seem", 551], ["to", 556], ["be", 559], ["anti", 562], ["-", 566], ["nerve", 567], ["growth", 573], ["factor", 580], ["(", 587], ["NGF", 588], [")", 591], ["antibodies", 593], [".", 603], ["Anti", 605], ["-", 609], ["NGF", 610], ["antibody", 614], ["therapy", 623], ["may", 631], ["be", 635], ["particularly", 638], ["effective", 651], ["in", 661], ["blocking", 664], ["bone", 673], ["cancer", 678], ["pain", 685], ["because", 690], ["NGF", 698], ["appears", 702], ["to", 710], ["be", 713], ["integrally", 716], ["involved", 727], ["in", 736], ["the", 739], ["upregulation", 743], [",", 755], ["sensitization", 757], ["and", 771], ["disinhibition", 775], ["of", 789], ["multiple", 792], ["neurotransmitters", 801], [",", 818], ["ion", 820], ["channels", 824], ["and", 833], ["receptors", 837], ["in", 847], ["the", 850], ["primary", 854], ["afferent", 862], ["nerve", 871], [".", 876], ["The", 878], ["best", 882], ["way", 887], ["to", 891], ["treat", 894], ["bone", 900], ["metastases", 905], ["pain", 916], ["is", 921], ["to", 924], ["improve", 927], ["the", 935], ["control", 939], ["of", 947], ["skeletal", 950], ["disease", 959], ["burden", 967], [".", 973], ["Recently", 975], [",", 983], ["denosumab", 985], [",", 994], ["a", 996], ["noncytotoxic", 998], ["IgG2", 1011], ["monoclonal", 1016], ["antibody", 1027], ["with", 1036], ["high", 1041], ["affinity", 1046], ["for", 1055], ["human", 1059], ["RANKL", 1065], [",", 1070], ["has", 1072], ["been", 1076], ["demonstrated", 1081], ["to", 1094], ["significantly", 1097], ["prevent", 1111], ["clinically", 1119], ["relevant", 1130], ["increase", 1139], ["in", 1148], ["pain", 1151], ["compared", 1156], ["with", 1165], ["zoledronic", 1170], ["acid", 1181], ["across", 1186], ["the", 1193], ["tumor", 1197], ["types", 1203], [".", 1208], ["Based", 1210], ["on", 1216], ["these", 1219], ["data", 1225], [",", 1229], ["it", 1231], ["has", 1234], ["been", 1238], ["suggested", 1243], ["that", 1253], ["denosumab", 1258], ["has", 1268], ["the", 1272], ["potential", 1276], ["to", 1286], ["become", 1289], ["a", 1296], ["new", 1298], ["standard", 1302], ["of", 1311], ["treatment", 1314], ["in", 1324], ["bone", 1327], ["metastases", 1332], ["management", 1343], [".", 1353]]}
{"context": "Autosomal-recessive hereditary spastic paraplegias (AR-HSP) consist of a genetically diverse group of neurodegenerative diseases characterised by pyramidal tracts dysfunction. The causative genes for many types of AR-HSP remain elusive. We tried to identify the gene mutation for AR-HSP with cerebellar ataxia and neuropathy. This study included two patients in a Japanese family with their parents who are first cousins. Neurological examination and gene analysis were conducted in the two patients and two normal family members. We undertook genome-wide linkage analysis employing single nucleotide polymorphism arrays using the two patients' DNAs and exome sequencing using one patient's sample. We detected a homozygous missense mutation (c.4189T>G, p.F1397V) in the lysosomal trafficking regulator (LYST) gene, which is described as the causative gene for Ch\u00e9diak-Higashi syndrome (CHS). CHS is a rare autosomal-recessive syndrome characterised by hypopigmentation, severe immune deficiency, a bleeding tendency and progressive neurological dysfunction. This mutation was co-segregated with the disease in the family and was located at well-conserved amino acid. This LYST mutation was not found in 200 Japanese control DNAs. Microscopic observation of peripheral blood in the two patients disclosed large peroxidase-positive granules in both patients' granulocytes, although they had no symptoms of immune deficiency or bleeding tendency. We diagnosed these patients as having adult CHS presenting spastic paraplegia with cerebellar ataxia and neuropathy. The clinical spectrum of CHS is broader than previously recognised. Adult CHS must be considered in the differential diagnosis of AR-HSP.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "25cc4073015c444db3084d4edbb2c04f", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[138, 140]], "char_spans": [[804, 813]]}]}], "context_tokens": [["Autosomal", 0], ["-", 9], ["recessive", 10], ["hereditary", 20], ["spastic", 31], ["paraplegias", 39], ["(", 51], ["AR", 52], ["-", 54], ["HSP", 55], [")", 58], ["consist", 60], ["of", 68], ["a", 71], ["genetically", 73], ["diverse", 85], ["group", 93], ["of", 99], ["neurodegenerative", 102], ["diseases", 120], ["characterised", 129], ["by", 143], ["pyramidal", 146], ["tracts", 156], ["dysfunction", 163], [".", 174], ["The", 176], ["causative", 180], ["genes", 190], ["for", 196], ["many", 200], ["types", 205], ["of", 211], ["AR", 214], ["-", 216], ["HSP", 217], ["remain", 221], ["elusive", 228], [".", 235], ["We", 237], ["tried", 240], ["to", 246], ["identify", 249], ["the", 258], ["gene", 262], ["mutation", 267], ["for", 276], ["AR", 280], ["-", 282], ["HSP", 283], ["with", 287], ["cerebellar", 292], ["ataxia", 303], ["and", 310], ["neuropathy", 314], [".", 324], ["This", 326], ["study", 331], ["included", 337], ["two", 346], ["patients", 350], ["in", 359], ["a", 362], ["Japanese", 364], ["family", 373], ["with", 380], ["their", 385], ["parents", 391], ["who", 399], ["are", 403], ["first", 407], ["cousins", 413], [".", 420], ["Neurological", 422], ["examination", 435], ["and", 447], ["gene", 451], ["analysis", 456], ["were", 465], ["conducted", 470], ["in", 480], ["the", 483], ["two", 487], ["patients", 491], ["and", 500], ["two", 504], ["normal", 508], ["family", 515], ["members", 522], [".", 529], ["We", 531], ["undertook", 534], ["genome", 544], ["-", 550], ["wide", 551], ["linkage", 556], ["analysis", 564], ["employing", 573], ["single", 583], ["nucleotide", 590], ["polymorphism", 601], ["arrays", 614], ["using", 621], ["the", 627], ["two", 631], ["patients", 635], ["'", 643], ["DNAs", 645], ["and", 650], ["exome", 654], ["sequencing", 660], ["using", 671], ["one", 677], ["patient", 681], ["'s", 688], ["sample", 691], [".", 697], ["We", 699], ["detected", 702], ["a", 711], ["homozygous", 713], ["missense", 724], ["mutation", 733], ["(", 742], ["c.4189T", 743], [">", 750], ["G", 751], [",", 752], ["p", 754], [".", 755], ["F1397V", 756], [")", 762], ["in", 764], ["the", 767], ["lysosomal", 771], ["trafficking", 781], ["regulator", 793], ["(", 803], ["LYST", 804], [")", 808], ["gene", 810], [",", 814], ["which", 816], ["is", 822], ["described", 825], ["as", 835], ["the", 838], ["causative", 842], ["gene", 852], ["for", 857], ["Ch\u00e9diak", 861], ["-", 868], ["Higashi", 869], ["syndrome", 877], ["(", 886], ["CHS", 887], [")", 890], [".", 891], ["CHS", 893], ["is", 897], ["a", 900], ["rare", 902], ["autosomal", 907], ["-", 916], ["recessive", 917], ["syndrome", 927], ["characterised", 936], ["by", 950], ["hypopigmentation", 953], [",", 969], ["severe", 971], ["immune", 978], ["deficiency", 985], [",", 995], ["a", 997], ["bleeding", 999], ["tendency", 1008], ["and", 1017], ["progressive", 1021], ["neurological", 1033], ["dysfunction", 1046], [".", 1057], ["This", 1059], ["mutation", 1064], ["was", 1073], ["co", 1077], ["-", 1079], ["segregated", 1080], ["with", 1091], ["the", 1096], ["disease", 1100], ["in", 1108], ["the", 1111], ["family", 1115], ["and", 1122], ["was", 1126], ["located", 1130], ["at", 1138], ["well", 1141], ["-", 1145], ["conserved", 1146], ["amino", 1156], ["acid", 1162], [".", 1166], ["This", 1168], ["LYST", 1173], ["mutation", 1178], ["was", 1187], ["not", 1191], ["found", 1195], ["in", 1201], ["200", 1204], ["Japanese", 1208], ["control", 1217], ["DNAs", 1225], [".", 1229], ["Microscopic", 1231], ["observation", 1243], ["of", 1255], ["peripheral", 1258], ["blood", 1269], ["in", 1275], ["the", 1278], ["two", 1282], ["patients", 1286], ["disclosed", 1295], ["large", 1305], ["peroxidase", 1311], ["-", 1321], ["positive", 1322], ["granules", 1331], ["in", 1340], ["both", 1343], ["patients", 1348], ["'", 1356], ["granulocytes", 1358], [",", 1370], ["although", 1372], ["they", 1381], ["had", 1386], ["no", 1390], ["symptoms", 1393], ["of", 1402], ["immune", 1405], ["deficiency", 1412], ["or", 1423], ["bleeding", 1426], ["tendency", 1435], [".", 1443], ["We", 1445], ["diagnosed", 1448], ["these", 1458], ["patients", 1464], ["as", 1473], ["having", 1476], ["adult", 1483], ["CHS", 1489], ["presenting", 1493], ["spastic", 1504], ["paraplegia", 1512], ["with", 1523], ["cerebellar", 1528], ["ataxia", 1539], ["and", 1546], ["neuropathy", 1550], [".", 1560], ["The", 1562], ["clinical", 1566], ["spectrum", 1575], ["of", 1584], ["CHS", 1587], ["is", 1591], ["broader", 1594], ["than", 1602], ["previously", 1607], ["recognised", 1618], [".", 1628], ["Adult", 1630], ["CHS", 1636], ["must", 1640], ["be", 1645], ["considered", 1648], ["in", 1659], ["the", 1662], ["differential", 1666], ["diagnosis", 1679], ["of", 1689], ["AR", 1692], ["-", 1694], ["HSP", 1695], [".", 1698]]}
{"context": "Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD). Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD. We report interim results from an open-label, dose-finding, seven-cohort, phase I study in which patients with symptomatic, multicentric or unresectable, unicentric CD received siltuximab at 1-, 2-, or 3-week intervals. The main efficacy end point of clinical benefit response (CBR) was defined as a composite of clinical and laboratory measures relevant to the management of CD. In addition, radiologic response was independently assessed by using modified Cheson criteria. Eighteen (78%) of 23 patients (95% CI, 56% to 93%) achieved CBR, and 12 patients (52%) demonstrated objective tumor response. All 11 patients (95% CI, 72% to 100%) treated with the highest dose of 12 mg/kg achieved CBR, and eight patients (73%) achieved objective tumor response. Overall objective-response duration ranged from 44 to > or = 889 days, and one patient had complete response for > or = 318 days. Hemoglobin increased markedly in 19 patients (median increase, 2.1 g/dL; range, 0.2 to 4.7 g/dL) in the absence of transfusion or erythropoiesis-stimulating agents. No dose-limiting toxicity was reported, and only three patients had grade 3 or higher adverse events after a median exposure of 331 days (range, 1 to 1,148 days). These interim results strongly suggest that siltuximab is an effective treatment with favorable safety for the management of CD. An additional study is planned to fully evaluate safety and efficacy at the recommended dose of 12 mg/kg every 3 weeks.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "d7e76d475083479aa3e0f9111bc68897", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["has", 21], ["emerged", 25], ["as", 33], ["a", 36], ["key", 38], ["factor", 42], ["in", 49], ["the", 52], ["pathogenesis", 56], ["of", 69], ["the", 72], ["atypical", 76], ["lymphoproliferative", 85], ["disorder", 105], ["Castleman", 114], ["'s", 123], ["disease", 126], ["(", 134], ["CD", 135], [")", 137], [".", 138], ["Siltuximab", 140], ["is", 151], ["a", 154], ["new", 156], ["anti", 160], ["-", 164], ["IL-6", 165], [",", 169], ["chimeric", 171], ["monoclonal", 180], ["antibody", 191], ["with", 200], ["potential", 205], ["therapeutic", 215], ["benefit", 227], ["in", 235], ["patients", 238], ["with", 247], ["CD", 252], [".", 254], ["We", 256], ["report", 259], ["interim", 266], ["results", 274], ["from", 282], ["an", 287], ["open", 290], ["-", 294], ["label", 295], [",", 300], ["dose", 302], ["-", 306], ["finding", 307], [",", 314], ["seven", 316], ["-", 321], ["cohort", 322], [",", 328], ["phase", 330], ["I", 336], ["study", 338], ["in", 344], ["which", 347], ["patients", 353], ["with", 362], ["symptomatic", 367], [",", 378], ["multicentric", 380], ["or", 393], ["unresectable", 396], [",", 408], ["unicentric", 410], ["CD", 421], ["received", 424], ["siltuximab", 433], ["at", 444], ["1-", 447], [",", 449], ["2-", 451], [",", 453], ["or", 455], ["3-week", 458], ["intervals", 465], [".", 474], ["The", 476], ["main", 480], ["efficacy", 485], ["end", 494], ["point", 498], ["of", 504], ["clinical", 507], ["benefit", 516], ["response", 524], ["(", 533], ["CBR", 534], [")", 537], ["was", 539], ["defined", 543], ["as", 551], ["a", 554], ["composite", 556], ["of", 566], ["clinical", 569], ["and", 578], ["laboratory", 582], ["measures", 593], ["relevant", 602], ["to", 611], ["the", 614], ["management", 618], ["of", 629], ["CD", 632], [".", 634], ["In", 636], ["addition", 639], [",", 647], ["radiologic", 649], ["response", 660], ["was", 669], ["independently", 673], ["assessed", 687], ["by", 696], ["using", 699], ["modified", 705], ["Cheson", 714], ["criteria", 721], [".", 729], ["Eighteen", 731], ["(", 740], ["78", 741], ["%", 743], [")", 744], ["of", 746], ["23", 749], ["patients", 752], ["(", 761], ["95", 762], ["%", 764], ["CI", 766], [",", 768], ["56", 770], ["%", 772], ["to", 774], ["93", 777], ["%", 779], [")", 780], ["achieved", 782], ["CBR", 791], [",", 794], ["and", 796], ["12", 800], ["patients", 803], ["(", 812], ["52", 813], ["%", 815], [")", 816], ["demonstrated", 818], ["objective", 831], ["tumor", 841], ["response", 847], [".", 855], ["All", 857], ["11", 861], ["patients", 864], ["(", 873], ["95", 874], ["%", 876], ["CI", 878], [",", 880], ["72", 882], ["%", 884], ["to", 886], ["100", 889], ["%", 892], [")", 893], ["treated", 895], ["with", 903], ["the", 908], ["highest", 912], ["dose", 920], ["of", 925], ["12", 928], ["mg", 931], ["/", 933], ["kg", 934], ["achieved", 937], ["CBR", 946], [",", 949], ["and", 951], ["eight", 955], ["patients", 961], ["(", 970], ["73", 971], ["%", 973], [")", 974], ["achieved", 976], ["objective", 985], ["tumor", 995], ["response", 1001], [".", 1009], ["Overall", 1011], ["objective", 1019], ["-", 1028], ["response", 1029], ["duration", 1038], ["ranged", 1047], ["from", 1054], ["44", 1059], ["to", 1062], [">", 1065], ["or", 1067], ["=", 1070], ["889", 1072], ["days", 1076], [",", 1080], ["and", 1082], ["one", 1086], ["patient", 1090], ["had", 1098], ["complete", 1102], ["response", 1111], ["for", 1120], [">", 1124], ["or", 1126], ["=", 1129], ["318", 1131], ["days", 1135], [".", 1139], ["Hemoglobin", 1141], ["increased", 1152], ["markedly", 1162], ["in", 1171], ["19", 1174], ["patients", 1177], ["(", 1186], ["median", 1187], ["increase", 1194], [",", 1202], ["2.1", 1204], ["g", 1208], ["/", 1209], ["dL", 1210], [";", 1212], ["range", 1214], [",", 1219], ["0.2", 1221], ["to", 1225], ["4.7", 1228], ["g", 1232], ["/", 1233], ["dL", 1234], [")", 1236], ["in", 1238], ["the", 1241], ["absence", 1245], ["of", 1253], ["transfusion", 1256], ["or", 1268], ["erythropoiesis", 1271], ["-", 1285], ["stimulating", 1286], ["agents", 1298], [".", 1304], ["No", 1306], ["dose", 1309], ["-", 1313], ["limiting", 1314], ["toxicity", 1323], ["was", 1332], ["reported", 1336], [",", 1344], ["and", 1346], ["only", 1350], ["three", 1355], ["patients", 1361], ["had", 1370], ["grade", 1374], ["3", 1380], ["or", 1382], ["higher", 1385], ["adverse", 1392], ["events", 1400], ["after", 1407], ["a", 1413], ["median", 1415], ["exposure", 1422], ["of", 1431], ["331", 1434], ["days", 1438], ["(", 1443], ["range", 1444], [",", 1449], ["1", 1451], ["to", 1453], ["1,148", 1456], ["days", 1462], [")", 1466], [".", 1467], ["These", 1469], ["interim", 1475], ["results", 1483], ["strongly", 1491], ["suggest", 1500], ["that", 1508], ["siltuximab", 1513], ["is", 1524], ["an", 1527], ["effective", 1530], ["treatment", 1540], ["with", 1550], ["favorable", 1555], ["safety", 1565], ["for", 1572], ["the", 1576], ["management", 1580], ["of", 1591], ["CD", 1594], [".", 1596], ["An", 1598], ["additional", 1601], ["study", 1612], ["is", 1618], ["planned", 1621], ["to", 1629], ["fully", 1632], ["evaluate", 1638], ["safety", 1647], ["and", 1654], ["efficacy", 1658], ["at", 1667], ["the", 1670], ["recommended", 1674], ["dose", 1686], ["of", 1691], ["12", 1694], ["mg", 1697], ["/", 1699], ["kg", 1700], ["every", 1703], ["3", 1709], ["weeks", 1711], [".", 1716]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem. Rapid detection of MRSA-colonized patients has the potential to limit spread of the organism. We evaluated the sensitivities and specificities of MRSA detection by two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) and three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA), using 205 (101 nasal, 52 groin, and 52 axillary samples) samples from consecutive known MRSA-infected and/or -colonized patients. All detection methods had higher MRSA detection rates for nasal swabs than for axillary and groin swabs. Detection of MRSA by IDI-MRSA was the most sensitive method, independent of the site (94% for nasal samples, 80% for nonnasal samples, and 90% overall). The sensitivities of the GenoType MRSA Direct assay and the MRSA ID, MRSASelect, and CHROMagar MRSA agars with nasal swabs were 70%, 72%, 68%, and 75%, respectively. All detection methods had high specificities (95 to 99%), independent of the swab site. Extended incubation for a further 24 h with selective MRSA agars increased the detection of MRSA, with a corresponding decline in specificity secondary to a significant increase in false-positive results. There was a noticeable difference in test performance of the GenoType MRSA Direct assay in detection of MRSA (28/38 samples [74%]) compared with detection of nonmultiresistant MRSA (17/31 samples [55%]) (susceptible to two or more non-beta-lactam antibiotics). This was not observed with selective MRSA agar plates or IDI-MRSA. Although it is more expensive, in addition to rapid turnaround times of 2 to 4 h, IDI-MRSA offers greater detection of MRSA colonization, independent of the swab site, than do conventional selective agars and GenoType MRSA Direct.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "b942fc23c0bf4ebe9bf8e76ac4b3a998", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[161, 161], [351, 351], [16, 16], [51, 51], [117, 117], [6, 6], [308, 308], [121, 121], [259, 259], [59, 59], [69, 69], [253, 253], [302, 302], [62, 62], [335, 335], [90, 90], [102, 102], [217, 217], [273, 273], [37, 37], [330, 330], [156, 156], [168, 168], [46, 46], [223, 223]], "char_spans": [[841, 844], [1786, 1789], [96, 99], [296, 299], [641, 644], [45, 48], [1562, 1565], [653, 656], [1344, 1347], [339, 342], [386, 389], [1310, 1313], [1538, 1541], [351, 354], [1687, 1690], [481, 484], [556, 559], [1089, 1092], [1416, 1419], [223, 226], [1654, 1657], [815, 818], [876, 879], [268, 271], [1127, 1130]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["is", 51], ["an", 54], ["increasing", 57], ["problem", 68], [".", 75], ["Rapid", 77], ["detection", 83], ["of", 93], ["MRSA", 96], ["-", 100], ["colonized", 101], ["patients", 111], ["has", 120], ["the", 124], ["potential", 128], ["to", 138], ["limit", 141], ["spread", 147], ["of", 154], ["the", 157], ["organism", 161], [".", 169], ["We", 171], ["evaluated", 174], ["the", 184], ["sensitivities", 188], ["and", 202], ["specificities", 206], ["of", 220], ["MRSA", 223], ["detection", 228], ["by", 238], ["two", 241], ["molecular", 245], ["methods", 255], ["(", 263], ["IDI", 264], ["-", 267], ["MRSA", 268], ["PCR", 273], ["assay", 277], ["and", 283], ["GenoType", 287], ["MRSA", 296], ["Direct", 301], ["PCR", 308], ["assay", 312], [")", 317], ["and", 319], ["three", 323], ["selective", 329], ["MRSA", 339], ["agars", 344], ["(", 350], ["MRSA", 351], ["ID", 356], [",", 358], ["MRSASelect", 360], [",", 370], ["and", 372], ["CHROMagar", 376], ["MRSA", 386], [")", 390], [",", 391], ["using", 393], ["205", 399], ["(", 403], ["101", 404], ["nasal", 408], [",", 413], ["52", 415], ["groin", 418], [",", 423], ["and", 425], ["52", 429], ["axillary", 432], ["samples", 441], [")", 448], ["samples", 450], ["from", 458], ["consecutive", 463], ["known", 475], ["MRSA", 481], ["-", 485], ["infected", 486], ["and/or", 495], ["-colonized", 502], ["patients", 513], [".", 521], ["All", 523], ["detection", 527], ["methods", 537], ["had", 545], ["higher", 549], ["MRSA", 556], ["detection", 561], ["rates", 571], ["for", 577], ["nasal", 581], ["swabs", 587], ["than", 593], ["for", 598], ["axillary", 602], ["and", 611], ["groin", 615], ["swabs", 621], [".", 626], ["Detection", 628], ["of", 638], ["MRSA", 641], ["by", 646], ["IDI", 649], ["-", 652], ["MRSA", 653], ["was", 658], ["the", 662], ["most", 666], ["sensitive", 671], ["method", 681], [",", 687], ["independent", 689], ["of", 701], ["the", 704], ["site", 708], ["(", 713], ["94", 714], ["%", 716], ["for", 718], ["nasal", 722], ["samples", 728], [",", 735], ["80", 737], ["%", 739], ["for", 741], ["nonnasal", 745], ["samples", 754], [",", 761], ["and", 763], ["90", 767], ["%", 769], ["overall", 771], [")", 778], [".", 779], ["The", 781], ["sensitivities", 785], ["of", 799], ["the", 802], ["GenoType", 806], ["MRSA", 815], ["Direct", 820], ["assay", 827], ["and", 833], ["the", 837], ["MRSA", 841], ["ID", 846], [",", 848], ["MRSASelect", 850], [",", 860], ["and", 862], ["CHROMagar", 866], ["MRSA", 876], ["agars", 881], ["with", 887], ["nasal", 892], ["swabs", 898], ["were", 904], ["70", 909], ["%", 911], [",", 912], ["72", 914], ["%", 916], [",", 917], ["68", 919], ["%", 921], [",", 922], ["and", 924], ["75", 928], ["%", 930], [",", 931], ["respectively", 933], [".", 945], ["All", 947], ["detection", 951], ["methods", 961], ["had", 969], ["high", 973], ["specificities", 978], ["(", 992], ["95", 993], ["to", 996], ["99", 999], ["%", 1001], [")", 1002], [",", 1003], ["independent", 1005], ["of", 1017], ["the", 1020], ["swab", 1024], ["site", 1029], [".", 1033], ["Extended", 1035], ["incubation", 1044], ["for", 1055], ["a", 1059], ["further", 1061], ["24", 1069], ["h", 1072], ["with", 1074], ["selective", 1079], ["MRSA", 1089], ["agars", 1094], ["increased", 1100], ["the", 1110], ["detection", 1114], ["of", 1124], ["MRSA", 1127], [",", 1131], ["with", 1133], ["a", 1138], ["corresponding", 1140], ["decline", 1154], ["in", 1162], ["specificity", 1165], ["secondary", 1177], ["to", 1187], ["a", 1190], ["significant", 1192], ["increase", 1204], ["in", 1213], ["false", 1216], ["-", 1221], ["positive", 1222], ["results", 1231], [".", 1238], ["There", 1240], ["was", 1246], ["a", 1250], ["noticeable", 1252], ["difference", 1263], ["in", 1274], ["test", 1277], ["performance", 1282], ["of", 1294], ["the", 1297], ["GenoType", 1301], ["MRSA", 1310], ["Direct", 1315], ["assay", 1322], ["in", 1328], ["detection", 1331], ["of", 1341], ["MRSA", 1344], ["(", 1349], ["28/38", 1350], ["samples", 1356], ["[", 1364], ["74", 1365], ["%", 1367], ["]", 1368], [")", 1369], ["compared", 1371], ["with", 1380], ["detection", 1385], ["of", 1395], ["nonmultiresistant", 1398], ["MRSA", 1416], ["(", 1421], ["17/31", 1422], ["samples", 1428], ["[", 1436], ["55", 1437], ["%", 1439], ["]", 1440], [")", 1441], ["(", 1443], ["susceptible", 1444], ["to", 1456], ["two", 1459], ["or", 1463], ["more", 1466], ["non", 1471], ["-", 1474], ["beta", 1475], ["-", 1479], ["lactam", 1480], ["antibiotics", 1487], [")", 1498], [".", 1499], ["This", 1501], ["was", 1506], ["not", 1510], ["observed", 1514], ["with", 1523], ["selective", 1528], ["MRSA", 1538], ["agar", 1543], ["plates", 1548], ["or", 1555], ["IDI", 1558], ["-", 1561], ["MRSA", 1562], [".", 1566], ["Although", 1568], ["it", 1577], ["is", 1580], ["more", 1583], ["expensive", 1588], [",", 1597], ["in", 1599], ["addition", 1602], ["to", 1611], ["rapid", 1614], ["turnaround", 1620], ["times", 1631], ["of", 1637], ["2", 1640], ["to", 1642], ["4", 1645], ["h", 1647], [",", 1648], ["IDI", 1650], ["-", 1653], ["MRSA", 1654], ["offers", 1659], ["greater", 1666], ["detection", 1674], ["of", 1684], ["MRSA", 1687], ["colonization", 1692], [",", 1704], ["independent", 1706], ["of", 1718], ["the", 1721], ["swab", 1725], ["site", 1730], [",", 1734], ["than", 1736], ["do", 1741], ["conventional", 1744], ["selective", 1757], ["agars", 1767], ["and", 1773], ["GenoType", 1777], ["MRSA", 1786], ["Direct", 1791], [".", 1797]]}
{"context": "The genetic disorders xeroderma pigmentosum (XP) and Cockayne syndrome (CS) exhibit deficiencies in the repair of UV-induced DNA damage. CS fibroblasts retain proficient nucleotide excision repair (NER) of inactive (or bulk) DNA, but are deficient in the transcription-coupled repair (TCR) of active genes. In contrast, XP complementation group C (XP-C) fibroblasts retain proficient TCR, but are deficient in bulk DNA repair. The remaining NER-deficient XP groups exhibit deficiencies in both repair pathways. Ad5HCMVsp1lacZ is a recombinant adenovirus vector that is unable to replicate in human fibroblasts, but can efficiently infect and express the beta-galactosidase reporter gene in these cells. We have examined the host cell reactivation (HCR) of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ in non-irradiated and UV-irradiated normal, XP-B, XP-C, XP-D, XP-F, XP-G, CS-A and CS-B fibroblasts. HCR of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ was reduced in non-irradiated cells from each of the repair-deficient groups examined (including XP-C) relative to that in non-irradiated normal cells. Prior irradiation of cells with low UV fluences resulted in an enhancement of HCR for normal and XP-C strains, but not for the remaining XP and CS strains. HCR of the UV-damaged reporter gene in UV-irradiated XP and CS strains was similar to measurements of TCR reported previously for these cells. These results suggest that UV treatment results in an induced repair of UV-damaged DNA in the transcribed strand of an active gene in XP-C and normal cells through an enhancement of TCR or a mechanism which involves the TCR pathway.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "9ee2e86c5d1a4a1a9251990f2f2d84c6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[310, 311]], "char_spans": [[1531, 1548]]}]}], "context_tokens": [["The", 0], ["genetic", 4], ["disorders", 12], ["xeroderma", 22], ["pigmentosum", 32], ["(", 44], ["XP", 45], [")", 47], ["and", 49], ["Cockayne", 53], ["syndrome", 62], ["(", 71], ["CS", 72], [")", 74], ["exhibit", 76], ["deficiencies", 84], ["in", 97], ["the", 100], ["repair", 104], ["of", 111], ["UV", 114], ["-", 116], ["induced", 117], ["DNA", 125], ["damage", 129], [".", 135], ["CS", 137], ["fibroblasts", 140], ["retain", 152], ["proficient", 159], ["nucleotide", 170], ["excision", 181], ["repair", 190], ["(", 197], ["NER", 198], [")", 201], ["of", 203], ["inactive", 206], ["(", 215], ["or", 216], ["bulk", 219], [")", 223], ["DNA", 225], [",", 228], ["but", 230], ["are", 234], ["deficient", 238], ["in", 248], ["the", 251], ["transcription", 255], ["-", 268], ["coupled", 269], ["repair", 277], ["(", 284], ["TCR", 285], [")", 288], ["of", 290], ["active", 293], ["genes", 300], [".", 305], ["In", 307], ["contrast", 310], [",", 318], ["XP", 320], ["complementation", 323], ["group", 339], ["C", 345], ["(", 347], ["XP", 348], ["-", 350], ["C", 351], [")", 352], ["fibroblasts", 354], ["retain", 366], ["proficient", 373], ["TCR", 384], [",", 387], ["but", 389], ["are", 393], ["deficient", 397], ["in", 407], ["bulk", 410], ["DNA", 415], ["repair", 419], [".", 425], ["The", 427], ["remaining", 431], ["NER", 441], ["-", 444], ["deficient", 445], ["XP", 455], ["groups", 458], ["exhibit", 465], ["deficiencies", 473], ["in", 486], ["both", 489], ["repair", 494], ["pathways", 501], [".", 509], ["Ad5HCMVsp1lacZ", 511], ["is", 526], ["a", 529], ["recombinant", 531], ["adenovirus", 543], ["vector", 554], ["that", 561], ["is", 566], ["unable", 569], ["to", 576], ["replicate", 579], ["in", 589], ["human", 592], ["fibroblasts", 598], [",", 609], ["but", 611], ["can", 615], ["efficiently", 619], ["infect", 631], ["and", 638], ["express", 642], ["the", 650], ["beta", 654], ["-", 658], ["galactosidase", 659], ["reporter", 673], ["gene", 682], ["in", 687], ["these", 690], ["cells", 696], [".", 701], ["We", 703], ["have", 706], ["examined", 711], ["the", 720], ["host", 724], ["cell", 729], ["reactivation", 734], ["(", 747], ["HCR", 748], [")", 751], ["of", 753], ["beta", 756], ["-", 760], ["galactosidase", 761], ["activity", 775], ["for", 784], ["UV", 788], ["-", 790], ["irradiated", 791], ["Ad5HCMVsp1lacZ", 802], ["in", 817], ["non", 820], ["-", 823], ["irradiated", 824], ["and", 835], ["UV", 839], ["-", 841], ["irradiated", 842], ["normal", 853], [",", 859], ["XP", 861], ["-", 863], ["B", 864], [",", 865], ["XP", 867], ["-", 869], ["C", 870], [",", 871], ["XP", 873], ["-", 875], ["D", 876], [",", 877], ["XP", 879], ["-", 881], ["F", 882], [",", 883], ["XP", 885], ["-", 887], ["G", 888], [",", 889], ["CS", 891], ["-", 893], ["A", 894], ["and", 896], ["CS", 900], ["-", 902], ["B", 903], ["fibroblasts", 905], [".", 916], ["HCR", 918], ["of", 922], ["beta", 925], ["-", 929], ["galactosidase", 930], ["activity", 944], ["for", 953], ["UV", 957], ["-", 959], ["irradiated", 960], ["Ad5HCMVsp1lacZ", 971], ["was", 986], ["reduced", 990], ["in", 998], ["non", 1001], ["-", 1004], ["irradiated", 1005], ["cells", 1016], ["from", 1022], ["each", 1027], ["of", 1032], ["the", 1035], ["repair", 1039], ["-", 1045], ["deficient", 1046], ["groups", 1056], ["examined", 1063], ["(", 1072], ["including", 1073], ["XP", 1083], ["-", 1085], ["C", 1086], [")", 1087], ["relative", 1089], ["to", 1098], ["that", 1101], ["in", 1106], ["non", 1109], ["-", 1112], ["irradiated", 1113], ["normal", 1124], ["cells", 1131], [".", 1136], ["Prior", 1138], ["irradiation", 1144], ["of", 1156], ["cells", 1159], ["with", 1165], ["low", 1170], ["UV", 1174], ["fluences", 1177], ["resulted", 1186], ["in", 1195], ["an", 1198], ["enhancement", 1201], ["of", 1213], ["HCR", 1216], ["for", 1220], ["normal", 1224], ["and", 1231], ["XP", 1235], ["-", 1237], ["C", 1238], ["strains", 1240], [",", 1247], ["but", 1249], ["not", 1253], ["for", 1257], ["the", 1261], ["remaining", 1265], ["XP", 1275], ["and", 1278], ["CS", 1282], ["strains", 1285], [".", 1292], ["HCR", 1294], ["of", 1298], ["the", 1301], ["UV", 1305], ["-", 1307], ["damaged", 1308], ["reporter", 1316], ["gene", 1325], ["in", 1330], ["UV", 1333], ["-", 1335], ["irradiated", 1336], ["XP", 1347], ["and", 1350], ["CS", 1354], ["strains", 1357], ["was", 1365], ["similar", 1369], ["to", 1377], ["measurements", 1380], ["of", 1393], ["TCR", 1396], ["reported", 1400], ["previously", 1409], ["for", 1420], ["these", 1424], ["cells", 1430], [".", 1435], ["These", 1437], ["results", 1443], ["suggest", 1451], ["that", 1459], ["UV", 1464], ["treatment", 1467], ["results", 1477], ["in", 1485], ["an", 1488], ["induced", 1491], ["repair", 1499], ["of", 1506], ["UV", 1509], ["-", 1511], ["damaged", 1512], ["DNA", 1520], ["in", 1524], ["the", 1527], ["transcribed", 1531], ["strand", 1543], ["of", 1550], ["an", 1553], ["active", 1556], ["gene", 1563], ["in", 1568], ["XP", 1571], ["-", 1573], ["C", 1574], ["and", 1576], ["normal", 1580], ["cells", 1587], ["through", 1593], ["an", 1601], ["enhancement", 1604], ["of", 1616], ["TCR", 1619], ["or", 1623], ["a", 1626], ["mechanism", 1628], ["which", 1638], ["involves", 1644], ["the", 1653], ["TCR", 1657], ["pathway", 1661], [".", 1668]]}
{"context": "Sleep disorders are frequent comorbidities in neurologic patients. This review focuses on clinical aspects and prognosis of 3 neurologic sleep disorders: narcolepsy, restless legs syndrome/Willis-Ekbom disease (RLS/WED), and REM sleep behavior disorder (RBD). Narcolepsy causes pervasive, enduring excessive daytime sleepiness, adversely affecting patients' daily functioning. RLS/WED is characterized by an uncomfortable urge to move the legs before sleep, often evolving toward augmentation and resulting in daylong bothersome symptoms. RBD causes potentially injurious dream enactment behaviors that often signify future evolution of overt synucleinopathy neurodegeneration in as many as 81% of patients. Timely recognition, referral for polysomnography, and longitudinal follow-up of narcolepsy, RLS/WED, and RBD patients are imperatives for neurologists in providing quality comprehensive patient care.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "2e85dc045cba4859af5eff8296aecc96", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[25, 27]], "char_spans": [[166, 187]]}]}], "context_tokens": [["Sleep", 0], ["disorders", 6], ["are", 16], ["frequent", 20], ["comorbidities", 29], ["in", 43], ["neurologic", 46], ["patients", 57], [".", 65], ["This", 67], ["review", 72], ["focuses", 79], ["on", 87], ["clinical", 90], ["aspects", 99], ["and", 107], ["prognosis", 111], ["of", 121], ["3", 124], ["neurologic", 126], ["sleep", 137], ["disorders", 143], [":", 152], ["narcolepsy", 154], [",", 164], ["restless", 166], ["legs", 175], ["syndrome", 180], ["/", 188], ["Willis", 189], ["-", 195], ["Ekbom", 196], ["disease", 202], ["(", 210], ["RLS", 211], ["/", 214], ["WED", 215], [")", 218], [",", 219], ["and", 221], ["REM", 225], ["sleep", 229], ["behavior", 235], ["disorder", 244], ["(", 253], ["RBD", 254], [")", 257], [".", 258], ["Narcolepsy", 260], ["causes", 271], ["pervasive", 278], [",", 287], ["enduring", 289], ["excessive", 298], ["daytime", 308], ["sleepiness", 316], [",", 326], ["adversely", 328], ["affecting", 338], ["patients", 348], ["'", 356], ["daily", 358], ["functioning", 364], [".", 375], ["RLS", 377], ["/", 380], ["WED", 381], ["is", 385], ["characterized", 388], ["by", 402], ["an", 405], ["uncomfortable", 408], ["urge", 422], ["to", 427], ["move", 430], ["the", 435], ["legs", 439], ["before", 444], ["sleep", 451], [",", 456], ["often", 458], ["evolving", 464], ["toward", 473], ["augmentation", 480], ["and", 493], ["resulting", 497], ["in", 507], ["daylong", 510], ["bothersome", 518], ["symptoms", 529], [".", 537], ["RBD", 539], ["causes", 543], ["potentially", 550], ["injurious", 562], ["dream", 572], ["enactment", 578], ["behaviors", 588], ["that", 598], ["often", 603], ["signify", 609], ["future", 617], ["evolution", 624], ["of", 634], ["overt", 637], ["synucleinopathy", 643], ["neurodegeneration", 659], ["in", 677], ["as", 680], ["many", 683], ["as", 688], ["81", 691], ["%", 693], ["of", 695], ["patients", 698], [".", 706], ["Timely", 708], ["recognition", 715], [",", 726], ["referral", 728], ["for", 737], ["polysomnography", 741], [",", 756], ["and", 758], ["longitudinal", 762], ["follow", 775], ["-", 781], ["up", 782], ["of", 785], ["narcolepsy", 788], [",", 798], ["RLS", 800], ["/", 803], ["WED", 804], [",", 807], ["and", 809], ["RBD", 813], ["patients", 817], ["are", 826], ["imperatives", 830], ["for", 842], ["neurologists", 846], ["in", 859], ["providing", 862], ["quality", 872], ["comprehensive", 880], ["patient", 894], ["care", 902], [".", 906]]}
{"context": "Histone variant H2A.Z-containing nucleosomes are incorporated at most eukaryotic promoters. This incorporation is mediated by the conserved SWR1 complex, which replaces histone H2A in canonical nucleosomes with H2A.Z in an ATP-dependent manner. Here, we show that promoter-proximal nucleosomes are highly heterogeneous for H2A.Z in Saccharomyces cerevisiae, with substantial representation of nucleosomes containing one, two, or zero H2A.Z molecules. SWR1-catalyzed H2A.Z replacement in vitro occurs in a stepwise and unidirectional fashion, one H2A.Z-H2B dimer at a time, producing heterotypic nucleosomes as intermediates and homotypic H2A.Z nucleosomes as end products. The ATPase activity of SWR1 is specifically stimulated by H2A-containing nucleosomes without ensuing histone H2A eviction. Remarkably, further addition of free H2A.Z-H2B dimer leads to hyperstimulation of ATPase activity, eviction of nucleosomal H2A-H2B, and deposition of H2A.Z-H2B. These results suggest that the combination of H2A-containing nucleosome and free H2A.Z-H2B dimer acting as both effector and substrate for SWR1 governs the specificity and outcome of the replacement reaction.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "9473f38b4dee41f9afdbbe99bea8b018", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[20, 20], [180, 180], [111, 111]], "char_spans": [[140, 143], [1096, 1099], [696, 699]]}]}], "context_tokens": [["Histone", 0], ["variant", 8], ["H2A.Z", 16], ["-", 21], ["containing", 22], ["nucleosomes", 33], ["are", 45], ["incorporated", 49], ["at", 62], ["most", 65], ["eukaryotic", 70], ["promoters", 81], [".", 90], ["This", 92], ["incorporation", 97], ["is", 111], ["mediated", 114], ["by", 123], ["the", 126], ["conserved", 130], ["SWR1", 140], ["complex", 145], [",", 152], ["which", 154], ["replaces", 160], ["histone", 169], ["H2A", 177], ["in", 181], ["canonical", 184], ["nucleosomes", 194], ["with", 206], ["H2A.Z", 211], ["in", 217], ["an", 220], ["ATP", 223], ["-", 226], ["dependent", 227], ["manner", 237], [".", 243], ["Here", 245], [",", 249], ["we", 251], ["show", 254], ["that", 259], ["promoter", 264], ["-", 272], ["proximal", 273], ["nucleosomes", 282], ["are", 294], ["highly", 298], ["heterogeneous", 305], ["for", 319], ["H2A.Z", 323], ["in", 329], ["Saccharomyces", 332], ["cerevisiae", 346], [",", 356], ["with", 358], ["substantial", 363], ["representation", 375], ["of", 390], ["nucleosomes", 393], ["containing", 405], ["one", 416], [",", 419], ["two", 421], [",", 424], ["or", 426], ["zero", 429], ["H2A.Z", 434], ["molecules", 440], [".", 449], ["SWR1-catalyzed", 451], ["H2A.Z", 466], ["replacement", 472], ["in", 484], ["vitro", 487], ["occurs", 493], ["in", 500], ["a", 503], ["stepwise", 505], ["and", 514], ["unidirectional", 518], ["fashion", 533], [",", 540], ["one", 542], ["H2A.Z", 546], ["-", 551], ["H2B", 552], ["dimer", 556], ["at", 562], ["a", 565], ["time", 567], [",", 571], ["producing", 573], ["heterotypic", 583], ["nucleosomes", 595], ["as", 607], ["intermediates", 610], ["and", 624], ["homotypic", 628], ["H2A.Z", 638], ["nucleosomes", 644], ["as", 656], ["end", 659], ["products", 663], [".", 671], ["The", 673], ["ATPase", 677], ["activity", 684], ["of", 693], ["SWR1", 696], ["is", 701], ["specifically", 704], ["stimulated", 717], ["by", 728], ["H2A", 731], ["-", 734], ["containing", 735], ["nucleosomes", 746], ["without", 758], ["ensuing", 766], ["histone", 774], ["H2A", 782], ["eviction", 786], [".", 794], ["Remarkably", 796], [",", 806], ["further", 808], ["addition", 816], ["of", 825], ["free", 828], ["H2A.Z", 833], ["-", 838], ["H2B", 839], ["dimer", 843], ["leads", 849], ["to", 855], ["hyperstimulation", 858], ["of", 875], ["ATPase", 878], ["activity", 885], [",", 893], ["eviction", 895], ["of", 904], ["nucleosomal", 907], ["H2A", 919], ["-", 922], ["H2B", 923], [",", 926], ["and", 928], ["deposition", 932], ["of", 943], ["H2A.Z", 946], ["-", 951], ["H2B.", 952], ["These", 957], ["results", 963], ["suggest", 971], ["that", 979], ["the", 984], ["combination", 988], ["of", 1000], ["H2A", 1003], ["-", 1006], ["containing", 1007], ["nucleosome", 1018], ["and", 1029], ["free", 1033], ["H2A.Z", 1038], ["-", 1043], ["H2B", 1044], ["dimer", 1048], ["acting", 1054], ["as", 1061], ["both", 1064], ["effector", 1069], ["and", 1078], ["substrate", 1082], ["for", 1092], ["SWR1", 1096], ["governs", 1101], ["the", 1109], ["specificity", 1113], ["and", 1125], ["outcome", 1129], ["of", 1137], ["the", 1140], ["replacement", 1144], ["reaction", 1156], [".", 1164]]}
{"context": "Nucleotide excision repair (NER) is a remarkably versatile DNA repair system, essential for maintenance of genomic stability. Hereditary alterations in NER enzymes can result in increased cancer propensity, but also in developmental, neurodegenerative, and progeroid syndromes. NER can be operationally divided in three subtypes, which share many common steps: global genomic repair (GGR) operates on the whole genome level, transcription domain-associated repair (DAR) is a concentration of NER activity within transcription factories, and transcription-coupled repair (TCR) provides faster repair of the transcribed strand of active genes. Interestingly, ubiquitination plays an important role in all three classes of NER, as well as in associated phenomena, such as damage signalling by histone ubiquitination, and degradation of stalled RNA polymerase II when repair does not occur in a timely manner.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "eac37c9c5ffd4618bcc7270e473097f6", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[103, 104]], "char_spans": [[606, 623]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], ["is", 33], ["a", 36], ["remarkably", 38], ["versatile", 49], ["DNA", 59], ["repair", 63], ["system", 70], [",", 76], ["essential", 78], ["for", 88], ["maintenance", 92], ["of", 104], ["genomic", 107], ["stability", 115], [".", 124], ["Hereditary", 126], ["alterations", 137], ["in", 149], ["NER", 152], ["enzymes", 156], ["can", 164], ["result", 168], ["in", 175], ["increased", 178], ["cancer", 188], ["propensity", 195], [",", 205], ["but", 207], ["also", 211], ["in", 216], ["developmental", 219], [",", 232], ["neurodegenerative", 234], [",", 251], ["and", 253], ["progeroid", 257], ["syndromes", 267], [".", 276], ["NER", 278], ["can", 282], ["be", 286], ["operationally", 289], ["divided", 303], ["in", 311], ["three", 314], ["subtypes", 320], [",", 328], ["which", 330], ["share", 336], ["many", 342], ["common", 347], ["steps", 354], [":", 359], ["global", 361], ["genomic", 368], ["repair", 376], ["(", 383], ["GGR", 384], [")", 387], ["operates", 389], ["on", 398], ["the", 401], ["whole", 405], ["genome", 411], ["level", 418], [",", 423], ["transcription", 425], ["domain", 439], ["-", 445], ["associated", 446], ["repair", 457], ["(", 464], ["DAR", 465], [")", 468], ["is", 470], ["a", 473], ["concentration", 475], ["of", 489], ["NER", 492], ["activity", 496], ["within", 505], ["transcription", 512], ["factories", 526], [",", 535], ["and", 537], ["transcription", 541], ["-", 554], ["coupled", 555], ["repair", 563], ["(", 570], ["TCR", 571], [")", 574], ["provides", 576], ["faster", 585], ["repair", 592], ["of", 599], ["the", 602], ["transcribed", 606], ["strand", 618], ["of", 625], ["active", 628], ["genes", 635], [".", 640], ["Interestingly", 642], [",", 655], ["ubiquitination", 657], ["plays", 672], ["an", 678], ["important", 681], ["role", 691], ["in", 696], ["all", 699], ["three", 703], ["classes", 709], ["of", 717], ["NER", 720], [",", 723], ["as", 725], ["well", 728], ["as", 733], ["in", 736], ["associated", 739], ["phenomena", 750], [",", 759], ["such", 761], ["as", 766], ["damage", 769], ["signalling", 776], ["by", 787], ["histone", 790], ["ubiquitination", 798], [",", 812], ["and", 814], ["degradation", 818], ["of", 830], ["stalled", 833], ["RNA", 841], ["polymerase", 845], ["II", 856], ["when", 859], ["repair", 864], ["does", 871], ["not", 876], ["occur", 880], ["in", 886], ["a", 889], ["timely", 891], ["manner", 898], [".", 904]]}
{"context": "To determine the utility of the Recognition of Stroke in the Emergency Room (ROSIER) scale as a stroke recognition tool among Chinese patients in the prehospital setting. Compared with the Cincinnati Prehospital Stroke Scale (CPSS), emergency physicians prospectively used the ROSIER as a stroke recognition tool on suspected patients in the prehospital setting. And, the final discharge diagnosis of stroke or transient ischemic attack made by neurologists, after assessment and review of clinical symptomatology and brain imaging findings, was used as the reference standard for diagnosis in the study. Then, the ROSIER and the CPSS like sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), related coefficient (r) and Kappa value were calculated. In this study, 540 of 582 suspected stroke patients met the study criteria. The CPSS showed a diagnostic Se of 88.77% (95% confidence intervals [CI] 86.11-91.43%), Sp of 68.79% (95% CI 64.88-72.70%), PPV of 87.40% (95% CI 85.97-88.83%), NPV of 71.52% (95% CI 67.71-75.33%) and r of 0.503. Relatively, the ROSIER showed a diagnostic Se of 89.97% (95% CI 87.44-92.64%), Sp of 83.23% (95% CI 80.08-86.38%), PPV of 92.66% (95% CI 90.46-94.86%), NPV of 77.91% (95% CI 74.41-81.41%) and r of 0.584. According to the final discharge diagnosis, both the ROSIER and the CPSS were associated with the final discharge diagnosis (P < 0.05).The Kappa statistic value of the ROSIER and the CPSS were 0.718 and 0.582, respectively. However, there was no statistical significance of the positive rate between the ROSIER and the CPSS in this study (P > 0.05). The ROSIER is a sensitive and specific stroke recognition tool for health providers' use among Chinese patients in the prehospital setting. However, it cannot be used to confidently rule out or identify stroke as a diagnosis. Comprehensive clinical assessment and further examination on potential stroke patients are still important and cannot be replaced. When it is difficult to objectively complete the ROSIER for patients, the CPSS could replace it in the prehospital setting.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "25d0a087f52d435dbd25e710f1920dd1", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[367, 367], [35, 35], [67, 67], [19, 19], [396, 396], [151, 151], [409, 409], [8, 8], [49, 49]], "char_spans": [[1681, 1686], [212, 217], [401, 406], [96, 101], [1845, 1850], [835, 840], [1939, 1944], [47, 52], [289, 294]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["utility", 17], ["of", 25], ["the", 28], ["Recognition", 32], ["of", 44], ["Stroke", 47], ["in", 54], ["the", 57], ["Emergency", 61], ["Room", 71], ["(", 76], ["ROSIER", 77], [")", 83], ["scale", 85], ["as", 91], ["a", 94], ["stroke", 96], ["recognition", 103], ["tool", 115], ["among", 120], ["Chinese", 126], ["patients", 134], ["in", 143], ["the", 146], ["prehospital", 150], ["setting", 162], [".", 169], ["Compared", 171], ["with", 180], ["the", 185], ["Cincinnati", 189], ["Prehospital", 200], ["Stroke", 212], ["Scale", 219], ["(", 225], ["CPSS", 226], [")", 230], [",", 231], ["emergency", 233], ["physicians", 243], ["prospectively", 254], ["used", 268], ["the", 273], ["ROSIER", 277], ["as", 284], ["a", 287], ["stroke", 289], ["recognition", 296], ["tool", 308], ["on", 313], ["suspected", 316], ["patients", 326], ["in", 335], ["the", 338], ["prehospital", 342], ["setting", 354], [".", 361], ["And", 363], [",", 366], ["the", 368], ["final", 372], ["discharge", 378], ["diagnosis", 388], ["of", 398], ["stroke", 401], ["or", 408], ["transient", 411], ["ischemic", 421], ["attack", 430], ["made", 437], ["by", 442], ["neurologists", 445], [",", 457], ["after", 459], ["assessment", 465], ["and", 476], ["review", 480], ["of", 487], ["clinical", 490], ["symptomatology", 499], ["and", 514], ["brain", 518], ["imaging", 524], ["findings", 532], [",", 540], ["was", 542], ["used", 546], ["as", 551], ["the", 554], ["reference", 558], ["standard", 568], ["for", 577], ["diagnosis", 581], ["in", 591], ["the", 594], ["study", 598], [".", 603], ["Then", 605], [",", 609], ["the", 611], ["ROSIER", 615], ["and", 622], ["the", 626], ["CPSS", 630], ["like", 635], ["sensitivity", 640], ["(", 652], ["Se", 653], [")", 655], [",", 656], ["specificity", 658], ["(", 670], ["Sp", 671], [")", 673], [",", 674], ["positive", 676], ["predictive", 685], ["value", 696], ["(", 702], ["PPV", 703], [")", 706], [",", 707], ["negative", 709], ["predictive", 718], ["value", 729], ["(", 735], ["NPV", 736], [")", 739], [",", 740], ["related", 742], ["coefficient", 750], ["(", 762], ["r", 763], [")", 764], ["and", 766], ["Kappa", 770], ["value", 776], ["were", 782], ["calculated", 787], [".", 797], ["In", 799], ["this", 802], ["study", 807], [",", 812], ["540", 814], ["of", 818], ["582", 821], ["suspected", 825], ["stroke", 835], ["patients", 842], ["met", 851], ["the", 855], ["study", 859], ["criteria", 865], [".", 873], ["The", 875], ["CPSS", 879], ["showed", 884], ["a", 891], ["diagnostic", 893], ["Se", 904], ["of", 907], ["88.77", 910], ["%", 915], ["(", 917], ["95", 918], ["%", 920], ["confidence", 922], ["intervals", 933], ["[", 943], ["CI", 944], ["]", 946], ["86.11", 948], ["-", 953], ["91.43", 954], ["%", 959], [")", 960], [",", 961], ["Sp", 963], ["of", 966], ["68.79", 969], ["%", 974], ["(", 976], ["95", 977], ["%", 979], ["CI", 981], ["64.88", 984], ["-", 989], ["72.70", 990], ["%", 995], [")", 996], [",", 997], ["PPV", 999], ["of", 1003], ["87.40", 1006], ["%", 1011], ["(", 1013], ["95", 1014], ["%", 1016], ["CI", 1018], ["85.97", 1021], ["-", 1026], ["88.83", 1027], ["%", 1032], [")", 1033], [",", 1034], ["NPV", 1036], ["of", 1040], ["71.52", 1043], ["%", 1048], ["(", 1050], ["95", 1051], ["%", 1053], ["CI", 1055], ["67.71", 1058], ["-", 1063], ["75.33", 1064], ["%", 1069], [")", 1070], ["and", 1072], ["r", 1076], ["of", 1078], ["0.503", 1081], [".", 1086], ["Relatively", 1088], [",", 1098], ["the", 1100], ["ROSIER", 1104], ["showed", 1111], ["a", 1118], ["diagnostic", 1120], ["Se", 1131], ["of", 1134], ["89.97", 1137], ["%", 1142], ["(", 1144], ["95", 1145], ["%", 1147], ["CI", 1149], ["87.44", 1152], ["-", 1157], ["92.64", 1158], ["%", 1163], [")", 1164], [",", 1165], ["Sp", 1167], ["of", 1170], ["83.23", 1173], ["%", 1178], ["(", 1180], ["95", 1181], ["%", 1183], ["CI", 1185], ["80.08", 1188], ["-", 1193], ["86.38", 1194], ["%", 1199], [")", 1200], [",", 1201], ["PPV", 1203], ["of", 1207], ["92.66", 1210], ["%", 1215], ["(", 1217], ["95", 1218], ["%", 1220], ["CI", 1222], ["90.46", 1225], ["-", 1230], ["94.86", 1231], ["%", 1236], [")", 1237], [",", 1238], ["NPV", 1240], ["of", 1244], ["77.91", 1247], ["%", 1252], ["(", 1254], ["95", 1255], ["%", 1257], ["CI", 1259], ["74.41", 1262], ["-", 1267], ["81.41", 1268], ["%", 1273], [")", 1274], ["and", 1276], ["r", 1280], ["of", 1282], ["0.584", 1285], [".", 1290], ["According", 1292], ["to", 1302], ["the", 1305], ["final", 1309], ["discharge", 1315], ["diagnosis", 1325], [",", 1334], ["both", 1336], ["the", 1341], ["ROSIER", 1345], ["and", 1352], ["the", 1356], ["CPSS", 1360], ["were", 1365], ["associated", 1370], ["with", 1381], ["the", 1386], ["final", 1390], ["discharge", 1396], ["diagnosis", 1406], ["(", 1416], ["P", 1417], ["<", 1419], ["0.05).The", 1421], ["Kappa", 1431], ["statistic", 1437], ["value", 1447], ["of", 1453], ["the", 1456], ["ROSIER", 1460], ["and", 1467], ["the", 1471], ["CPSS", 1475], ["were", 1480], ["0.718", 1485], ["and", 1491], ["0.582", 1495], [",", 1500], ["respectively", 1502], [".", 1514], ["However", 1516], [",", 1523], ["there", 1525], ["was", 1531], ["no", 1535], ["statistical", 1538], ["significance", 1550], ["of", 1563], ["the", 1566], ["positive", 1570], ["rate", 1579], ["between", 1584], ["the", 1592], ["ROSIER", 1596], ["and", 1603], ["the", 1607], ["CPSS", 1611], ["in", 1616], ["this", 1619], ["study", 1624], ["(", 1630], ["P", 1631], [">", 1633], ["0.05", 1635], [")", 1639], [".", 1640], ["The", 1642], ["ROSIER", 1646], ["is", 1653], ["a", 1656], ["sensitive", 1658], ["and", 1668], ["specific", 1672], ["stroke", 1681], ["recognition", 1688], ["tool", 1700], ["for", 1705], ["health", 1709], ["providers", 1716], ["'", 1725], ["use", 1727], ["among", 1731], ["Chinese", 1737], ["patients", 1745], ["in", 1754], ["the", 1757], ["prehospital", 1761], ["setting", 1773], [".", 1780], ["However", 1782], [",", 1789], ["it", 1791], ["can", 1794], ["not", 1797], ["be", 1801], ["used", 1804], ["to", 1809], ["confidently", 1812], ["rule", 1824], ["out", 1829], ["or", 1833], ["identify", 1836], ["stroke", 1845], ["as", 1852], ["a", 1855], ["diagnosis", 1857], [".", 1866], ["Comprehensive", 1868], ["clinical", 1882], ["assessment", 1891], ["and", 1902], ["further", 1906], ["examination", 1914], ["on", 1926], ["potential", 1929], ["stroke", 1939], ["patients", 1946], ["are", 1955], ["still", 1959], ["important", 1965], ["and", 1975], ["can", 1979], ["not", 1982], ["be", 1986], ["replaced", 1989], [".", 1997], ["When", 1999], ["it", 2004], ["is", 2007], ["difficult", 2010], ["to", 2020], ["objectively", 2023], ["complete", 2035], ["the", 2044], ["ROSIER", 2048], ["for", 2055], ["patients", 2059], [",", 2067], ["the", 2069], ["CPSS", 2073], ["could", 2078], ["replace", 2084], ["it", 2092], ["in", 2095], ["the", 2098], ["prehospital", 2102], ["setting", 2114], [".", 2121]]}
{"context": "The members of the NOX family of enzymes are expressed in a variety of tissues and serve a number of functions. There is a high level of conservation of primary protein sequence, as well as functional features, although specialized responses are beginning to emerge. In this context, our data demonstrate that the NOX1 cytoplasmic domains interact efficiently with the cytoplasmic subunits of the phagocyte NADPH oxidase and identify the second cytoplasmic loop of NOX electron transporters as a crucial domain for enzyme function. Studies of cytosolic co-factors showed that the C-terminal cytoplasmic domain of NOX1 was absolutely required for activation with NOXO1 and NOXA1 and that this activity required interaction of the putative NADPH-binding region of this domain with NOXA1. Finally, we have provided the first example of how alternative splicing of a NOX co-factor may be involved in the regulation of NADPH oxidase function.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "1d9e22d6ebaa441090217077e2711e57", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[104, 104], [57, 57]], "char_spans": [[613, 616], [314, 317]]}]}], "context_tokens": [["The", 0], ["members", 4], ["of", 12], ["the", 15], ["NOX", 19], ["family", 23], ["of", 30], ["enzymes", 33], ["are", 41], ["expressed", 45], ["in", 55], ["a", 58], ["variety", 60], ["of", 68], ["tissues", 71], ["and", 79], ["serve", 83], ["a", 89], ["number", 91], ["of", 98], ["functions", 101], [".", 110], ["There", 112], ["is", 118], ["a", 121], ["high", 123], ["level", 128], ["of", 134], ["conservation", 137], ["of", 150], ["primary", 153], ["protein", 161], ["sequence", 169], [",", 177], ["as", 179], ["well", 182], ["as", 187], ["functional", 190], ["features", 201], [",", 209], ["although", 211], ["specialized", 220], ["responses", 232], ["are", 242], ["beginning", 246], ["to", 256], ["emerge", 259], [".", 265], ["In", 267], ["this", 270], ["context", 275], [",", 282], ["our", 284], ["data", 288], ["demonstrate", 293], ["that", 305], ["the", 310], ["NOX1", 314], ["cytoplasmic", 319], ["domains", 331], ["interact", 339], ["efficiently", 348], ["with", 360], ["the", 365], ["cytoplasmic", 369], ["subunits", 381], ["of", 390], ["the", 393], ["phagocyte", 397], ["NADPH", 407], ["oxidase", 413], ["and", 421], ["identify", 425], ["the", 434], ["second", 438], ["cytoplasmic", 445], ["loop", 457], ["of", 462], ["NOX", 465], ["electron", 469], ["transporters", 478], ["as", 491], ["a", 494], ["crucial", 496], ["domain", 504], ["for", 511], ["enzyme", 515], ["function", 522], [".", 530], ["Studies", 532], ["of", 540], ["cytosolic", 543], ["co", 553], ["-", 555], ["factors", 556], ["showed", 564], ["that", 571], ["the", 576], ["C", 580], ["-", 581], ["terminal", 582], ["cytoplasmic", 591], ["domain", 603], ["of", 610], ["NOX1", 613], ["was", 618], ["absolutely", 622], ["required", 633], ["for", 642], ["activation", 646], ["with", 657], ["NOXO1", 662], ["and", 668], ["NOXA1", 672], ["and", 678], ["that", 682], ["this", 687], ["activity", 692], ["required", 701], ["interaction", 710], ["of", 722], ["the", 725], ["putative", 729], ["NADPH", 738], ["-", 743], ["binding", 744], ["region", 752], ["of", 759], ["this", 762], ["domain", 767], ["with", 774], ["NOXA1", 779], [".", 784], ["Finally", 786], [",", 793], ["we", 795], ["have", 798], ["provided", 803], ["the", 812], ["first", 816], ["example", 822], ["of", 830], ["how", 833], ["alternative", 837], ["splicing", 849], ["of", 858], ["a", 861], ["NOX", 863], ["co", 867], ["-", 869], ["factor", 870], ["may", 877], ["be", 881], ["involved", 884], ["in", 893], ["the", 896], ["regulation", 900], ["of", 911], ["NADPH", 914], ["oxidase", 920], ["function", 928], [".", 936]]}
{"context": "The 2016 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted hot spots in HIV infection. Men who have sex with men (MSM), transgender populations, people who inject drugs, fisherfolk, migrants, adolescents, and older adults are heavily impacted in a number of regions. Stigma contributes to risk behaviors and HIV acquisition across populations. HIV testing is a crucial first step in the HIV care continuum, and several large community-based surveys are underway in Africa to increase HIV testing, linkage to care, and uptake of antiretroviral treatment. Advances in preexposure prophylaxis (PrEP) featured prominently at CROI 2016. Two large efficacy trials of a vaginal ring containing the investigational drug dapivirine demonstrated efficacy and safety in preventing HIV infections in women in Africa. Data on the safety of long-acting injectable PrEP and several investigational PrEP drugs and formulations were also presented. Knowledge and use of PrEP among MSM in the United States appears to be increasing, and high uptake was seen among black MSM when provided as part of a culturally tailored support program. The use of broadly neutralizing antibodies for HIV prevention is a novel and promising approach to be evaluated in efficacy trials.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "b6d97f2cc9864e81ae3ccfefeac8cedd", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[91, 91], [74, 74], [60, 60], [136, 136], [206, 206], [65, 65], [15, 15]], "char_spans": [[509, 511], [412, 414], [333, 335], [795, 797], [1192, 1194], [369, 371], [97, 99]]}]}], "context_tokens": [["The", 0], ["2016", 4], ["Conference", 9], ["on", 20], ["Retroviruses", 23], ["and", 36], ["Opportunistic", 40], ["Infections", 54], ["(", 65], ["CROI", 66], [")", 70], ["highlighted", 72], ["hot", 84], ["spots", 88], ["in", 94], ["HIV", 97], ["infection", 101], [".", 110], ["Men", 112], ["who", 116], ["have", 120], ["sex", 125], ["with", 129], ["men", 134], ["(", 138], ["MSM", 139], [")", 142], [",", 143], ["transgender", 145], ["populations", 157], [",", 168], ["people", 170], ["who", 177], ["inject", 181], ["drugs", 188], [",", 193], ["fisherfolk", 195], [",", 205], ["migrants", 207], [",", 215], ["adolescents", 217], [",", 228], ["and", 230], ["older", 234], ["adults", 240], ["are", 247], ["heavily", 251], ["impacted", 259], ["in", 268], ["a", 271], ["number", 273], ["of", 280], ["regions", 283], [".", 290], ["Stigma", 292], ["contributes", 299], ["to", 311], ["risk", 314], ["behaviors", 319], ["and", 329], ["HIV", 333], ["acquisition", 337], ["across", 349], ["populations", 356], [".", 367], ["HIV", 369], ["testing", 373], ["is", 381], ["a", 384], ["crucial", 386], ["first", 394], ["step", 400], ["in", 405], ["the", 408], ["HIV", 412], ["care", 416], ["continuum", 421], [",", 430], ["and", 432], ["several", 436], ["large", 444], ["community", 450], ["-", 459], ["based", 460], ["surveys", 466], ["are", 474], ["underway", 478], ["in", 487], ["Africa", 490], ["to", 497], ["increase", 500], ["HIV", 509], ["testing", 513], [",", 520], ["linkage", 522], ["to", 530], ["care", 533], [",", 537], ["and", 539], ["uptake", 543], ["of", 550], ["antiretroviral", 553], ["treatment", 568], [".", 577], ["Advances", 579], ["in", 588], ["preexposure", 591], ["prophylaxis", 603], ["(", 615], ["PrEP", 616], [")", 620], ["featured", 622], ["prominently", 631], ["at", 643], ["CROI", 646], ["2016", 651], [".", 655], ["Two", 657], ["large", 661], ["efficacy", 667], ["trials", 676], ["of", 683], ["a", 686], ["vaginal", 688], ["ring", 696], ["containing", 701], ["the", 712], ["investigational", 716], ["drug", 732], ["dapivirine", 737], ["demonstrated", 748], ["efficacy", 761], ["and", 770], ["safety", 774], ["in", 781], ["preventing", 784], ["HIV", 795], ["infections", 799], ["in", 810], ["women", 813], ["in", 819], ["Africa", 822], [".", 828], ["Data", 830], ["on", 835], ["the", 838], ["safety", 842], ["of", 849], ["long", 852], ["-", 856], ["acting", 857], ["injectable", 864], ["PrEP", 875], ["and", 880], ["several", 884], ["investigational", 892], ["PrEP", 908], ["drugs", 913], ["and", 919], ["formulations", 923], ["were", 936], ["also", 941], ["presented", 946], [".", 955], ["Knowledge", 957], ["and", 967], ["use", 971], ["of", 975], ["PrEP", 978], ["among", 983], ["MSM", 989], ["in", 993], ["the", 996], ["United", 1000], ["States", 1007], ["appears", 1014], ["to", 1022], ["be", 1025], ["increasing", 1028], [",", 1038], ["and", 1040], ["high", 1044], ["uptake", 1049], ["was", 1056], ["seen", 1060], ["among", 1065], ["black", 1071], ["MSM", 1077], ["when", 1081], ["provided", 1086], ["as", 1095], ["part", 1098], ["of", 1103], ["a", 1106], ["culturally", 1108], ["tailored", 1119], ["support", 1128], ["program", 1136], [".", 1143], ["The", 1145], ["use", 1149], ["of", 1153], ["broadly", 1156], ["neutralizing", 1164], ["antibodies", 1177], ["for", 1188], ["HIV", 1192], ["prevention", 1196], ["is", 1207], ["a", 1210], ["novel", 1212], ["and", 1218], ["promising", 1222], ["approach", 1232], ["to", 1241], ["be", 1244], ["evaluated", 1247], ["in", 1257], ["efficacy", 1260], ["trials", 1269], [".", 1275]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant disorder characterized by weakness of the face, upper arm, shoulder, and lower limb musculature, with an onset between the first and third decades. Coats disease is a congenital disorder of retinal vascular development characterized by unilateral peripheral retinal telangiectasia and progressive subretinal and intraretinal exudation. This condition has a predilection for children and is usually isolated. Retinal vascular changes similar to those seen in Coats disease have been demonstrated by fluorescein angiography in 40% to 75% of patients with FSHD. Most patients have asymptomatic retinal telangiectasia found at ocular screening in adulthood after diagnosis of FSHD. We report a 7-month-old infant with bilateral Coats-like retinopathy in which the eye disease was discovered before findings of FSHD were clinically evident. To our knowledge, this patient represents the youngest reported case of preclinical FSHD with ocular disease.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "a40ec3c2b8dd4fa4a955eb489be36aa0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[7, 9]], "char_spans": [[43, 60]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["an", 40], ["autosomal", 43], ["-", 52], ["dominant", 53], ["disorder", 62], ["characterized", 71], ["by", 85], ["weakness", 88], ["of", 97], ["the", 100], ["face", 104], [",", 108], ["upper", 110], ["arm", 116], [",", 119], ["shoulder", 121], [",", 129], ["and", 131], ["lower", 135], ["limb", 141], ["musculature", 146], [",", 157], ["with", 159], ["an", 164], ["onset", 167], ["between", 173], ["the", 181], ["first", 185], ["and", 191], ["third", 195], ["decades", 201], [".", 208], ["Coats", 210], ["disease", 216], ["is", 224], ["a", 227], ["congenital", 229], ["disorder", 240], ["of", 249], ["retinal", 252], ["vascular", 260], ["development", 269], ["characterized", 281], ["by", 295], ["unilateral", 298], ["peripheral", 309], ["retinal", 320], ["telangiectasia", 328], ["and", 343], ["progressive", 347], ["subretinal", 359], ["and", 370], ["intraretinal", 374], ["exudation", 387], [".", 396], ["This", 398], ["condition", 403], ["has", 413], ["a", 417], ["predilection", 419], ["for", 432], ["children", 436], ["and", 445], ["is", 449], ["usually", 452], ["isolated", 460], [".", 468], ["Retinal", 470], ["vascular", 478], ["changes", 487], ["similar", 495], ["to", 503], ["those", 506], ["seen", 512], ["in", 517], ["Coats", 520], ["disease", 526], ["have", 534], ["been", 539], ["demonstrated", 544], ["by", 557], ["fluorescein", 560], ["angiography", 572], ["in", 584], ["40", 587], ["%", 589], ["to", 591], ["75", 594], ["%", 596], ["of", 598], ["patients", 601], ["with", 610], ["FSHD", 615], [".", 619], ["Most", 621], ["patients", 626], ["have", 635], ["asymptomatic", 640], ["retinal", 653], ["telangiectasia", 661], ["found", 676], ["at", 682], ["ocular", 685], ["screening", 692], ["in", 702], ["adulthood", 705], ["after", 715], ["diagnosis", 721], ["of", 731], ["FSHD", 734], [".", 738], ["We", 740], ["report", 743], ["a", 750], ["7-month", 752], ["-", 759], ["old", 760], ["infant", 764], ["with", 771], ["bilateral", 776], ["Coats", 786], ["-", 791], ["like", 792], ["retinopathy", 797], ["in", 809], ["which", 812], ["the", 818], ["eye", 822], ["disease", 826], ["was", 834], ["discovered", 838], ["before", 849], ["findings", 856], ["of", 865], ["FSHD", 868], ["were", 873], ["clinically", 878], ["evident", 889], [".", 896], ["To", 898], ["our", 901], ["knowledge", 905], [",", 914], ["this", 916], ["patient", 921], ["represents", 929], ["the", 940], ["youngest", 944], ["reported", 953], ["case", 962], ["of", 967], ["preclinical", 970], ["FSHD", 982], ["with", 987], ["ocular", 992], ["disease", 999], [".", 1006]]}
{"context": "Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an expansion of a CTG triplet repeat in the DMPK gene. The aims of the present study were to classify a cohort of children with DM1, to describe their neuropsychiatric problems and cognitive level, to estimate the size of the CTG expansion, and to correlate the molecular findings with the neuropsychiatric problems. Fifty-seven children and adolescents (26 females; 31 males) with DM1 (CTG repeats > 40) were included in the study. The following instruments were used: Autism Diagnostic Interview-Revised (ADI-R), 5-15, Griffiths Mental Development Scales, and the Wechsler Scales. Based on age at onset and presenting symptoms, the children were divided into four DM1 groups; severe congenital (n = 19), mild congenital (n = 18), childhood (n = 18), and classical DM1 (n = 2). Forty-nine percent had an autism spectrum disorder (ASD) and autistic disorder was the most common diagnosis present in 35% of the subjects. Eighty-six percent of the individuals with DM1 had mental retardation (MR), most of them moderate or severe MR. ASD was significantly correlated with the DM1 form; the more severe the form of DM1, the higher the frequency of ASD. The frequency of ASD increased with increasing CTG repeat expansions. ASD and/or other neuropsychiatric disorders such as attention deficit hyperactivity disorder, and Tourette's disorder were found in 54% of the total DM1 group. In conclusion, awareness of ASD comorbidity in DM1 is essential. Further studies are warranted to elucidate the molecular etiology causing neurodevelopmental symptoms such as ASD and MR in DM1.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "d33ad3bcc29749269c3aa087a59610af", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[9, 10]], "char_spans": [[38, 55]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["type", 19], ["1", 24], ["(", 26], ["DM1", 27], [")", 30], ["is", 32], ["an", 35], ["autosomal", 38], ["dominant", 48], ["disorder", 57], [",", 65], ["caused", 67], ["by", 74], ["an", 77], ["expansion", 80], ["of", 90], ["a", 93], ["CTG", 95], ["triplet", 99], ["repeat", 107], ["in", 114], ["the", 117], ["DMPK", 121], ["gene", 126], [".", 130], ["The", 132], ["aims", 136], ["of", 141], ["the", 144], ["present", 148], ["study", 156], ["were", 162], ["to", 167], ["classify", 170], ["a", 179], ["cohort", 181], ["of", 188], ["children", 191], ["with", 200], ["DM1", 205], [",", 208], ["to", 210], ["describe", 213], ["their", 222], ["neuropsychiatric", 228], ["problems", 245], ["and", 254], ["cognitive", 258], ["level", 268], [",", 273], ["to", 275], ["estimate", 278], ["the", 287], ["size", 291], ["of", 296], ["the", 299], ["CTG", 303], ["expansion", 307], [",", 316], ["and", 318], ["to", 322], ["correlate", 325], ["the", 335], ["molecular", 339], ["findings", 349], ["with", 358], ["the", 363], ["neuropsychiatric", 367], ["problems", 384], [".", 392], ["Fifty", 394], ["-", 399], ["seven", 400], ["children", 406], ["and", 415], ["adolescents", 419], ["(", 431], ["26", 432], ["females", 435], [";", 442], ["31", 444], ["males", 447], [")", 452], ["with", 454], ["DM1", 459], ["(", 463], ["CTG", 464], ["repeats", 468], [">", 476], ["40", 478], [")", 480], ["were", 482], ["included", 487], ["in", 496], ["the", 499], ["study", 503], [".", 508], ["The", 510], ["following", 514], ["instruments", 524], ["were", 536], ["used", 541], [":", 545], ["Autism", 547], ["Diagnostic", 554], ["Interview", 565], ["-", 574], ["Revised", 575], ["(", 583], ["ADI", 584], ["-", 587], ["R", 588], [")", 589], [",", 590], ["5", 592], ["-", 593], ["15", 594], [",", 596], ["Griffiths", 598], ["Mental", 608], ["Development", 615], ["Scales", 627], [",", 633], ["and", 635], ["the", 639], ["Wechsler", 643], ["Scales", 652], [".", 658], ["Based", 660], ["on", 666], ["age", 669], ["at", 673], ["onset", 676], ["and", 682], ["presenting", 686], ["symptoms", 697], [",", 705], ["the", 707], ["children", 711], ["were", 720], ["divided", 725], ["into", 733], ["four", 738], ["DM1", 743], ["groups", 747], [";", 753], ["severe", 755], ["congenital", 762], ["(", 773], ["n", 774], ["=", 776], ["19", 778], [")", 780], [",", 781], ["mild", 783], ["congenital", 788], ["(", 799], ["n", 800], ["=", 802], ["18", 804], [")", 806], [",", 807], ["childhood", 809], ["(", 819], ["n", 820], ["=", 822], ["18", 824], [")", 826], [",", 827], ["and", 829], ["classical", 833], ["DM1", 843], ["(", 847], ["n", 848], ["=", 850], ["2", 852], [")", 853], [".", 854], ["Forty", 856], ["-", 861], ["nine", 862], ["percent", 867], ["had", 875], ["an", 879], ["autism", 882], ["spectrum", 889], ["disorder", 898], ["(", 907], ["ASD", 908], [")", 911], ["and", 913], ["autistic", 917], ["disorder", 926], ["was", 935], ["the", 939], ["most", 943], ["common", 948], ["diagnosis", 955], ["present", 965], ["in", 973], ["35", 976], ["%", 978], ["of", 980], ["the", 983], ["subjects", 987], [".", 995], ["Eighty", 997], ["-", 1003], ["six", 1004], ["percent", 1008], ["of", 1016], ["the", 1019], ["individuals", 1023], ["with", 1035], ["DM1", 1040], ["had", 1044], ["mental", 1048], ["retardation", 1055], ["(", 1067], ["MR", 1068], [")", 1070], [",", 1071], ["most", 1073], ["of", 1078], ["them", 1081], ["moderate", 1086], ["or", 1095], ["severe", 1098], ["MR", 1105], [".", 1107], ["ASD", 1109], ["was", 1113], ["significantly", 1117], ["correlated", 1131], ["with", 1142], ["the", 1147], ["DM1", 1151], ["form", 1155], [";", 1159], ["the", 1161], ["more", 1165], ["severe", 1170], ["the", 1177], ["form", 1181], ["of", 1186], ["DM1", 1189], [",", 1192], ["the", 1194], ["higher", 1198], ["the", 1205], ["frequency", 1209], ["of", 1219], ["ASD", 1222], [".", 1225], ["The", 1227], ["frequency", 1231], ["of", 1241], ["ASD", 1244], ["increased", 1248], ["with", 1258], ["increasing", 1263], ["CTG", 1274], ["repeat", 1278], ["expansions", 1285], [".", 1295], ["ASD", 1297], ["and/or", 1301], ["other", 1308], ["neuropsychiatric", 1314], ["disorders", 1331], ["such", 1341], ["as", 1346], ["attention", 1349], ["deficit", 1359], ["hyperactivity", 1367], ["disorder", 1381], [",", 1389], ["and", 1391], ["Tourette", 1395], ["'s", 1403], ["disorder", 1406], ["were", 1415], ["found", 1420], ["in", 1426], ["54", 1429], ["%", 1431], ["of", 1433], ["the", 1436], ["total", 1440], ["DM1", 1446], ["group", 1450], [".", 1455], ["In", 1457], ["conclusion", 1460], [",", 1470], ["awareness", 1472], ["of", 1482], ["ASD", 1485], ["comorbidity", 1489], ["in", 1501], ["DM1", 1504], ["is", 1508], ["essential", 1511], [".", 1520], ["Further", 1522], ["studies", 1530], ["are", 1538], ["warranted", 1542], ["to", 1552], ["elucidate", 1555], ["the", 1565], ["molecular", 1569], ["etiology", 1579], ["causing", 1588], ["neurodevelopmental", 1596], ["symptoms", 1615], ["such", 1624], ["as", 1629], ["ASD", 1632], ["and", 1636], ["MR", 1640], ["in", 1643], ["DM1", 1646], [".", 1649]]}
{"context": "In recent years, we have seen remarkable progress in our understanding of the disease mechanism underlying facioscapulohumeral muscular dystrophy (FSHD). The purpose of this review is to provide a comprehensive overview of our current understanding of the disease mechanism and to discuss the observations supporting the possibility of a developmental defect in this disorder. In the majority of cases, FSHD is caused by contraction of the D4Z4 repeat array (FSHD1). This results in local chromatin relaxation and stable expression of the DUX4 retrogene in skeletal muscle, but only when a polymorphic DUX4 polyadenylation signal is present. In some cases (FSHD2), D4Z4 chromatin relaxation and stable DUX4 expression occur in the absence of D4Z4 array contraction. DUX4 is a germline transcription factor and its expression in skeletal muscle leads to activation of early stem cell and germline programs and transcriptional activation of retroelements. Recent studies have provided a plausible disease mechanism for FSHD in which FSHD results from inappropriate expression of the germline transcription factor DUX4. The genes regulated by DUX4 suggest several mechanisms of muscle damage, and provide potential biomarkers and therapeutic targets that should be investigated in future studies.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "942b79bc7d384edd901fe2769f46512d", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[65, 65], [167, 167], [21, 21], [170, 170]], "char_spans": [[403, 406], [1017, 1020], [147, 150], [1031, 1034]]}]}], "context_tokens": [["In", 0], ["recent", 3], ["years", 10], [",", 15], ["we", 17], ["have", 20], ["seen", 25], ["remarkable", 30], ["progress", 41], ["in", 50], ["our", 53], ["understanding", 57], ["of", 71], ["the", 74], ["disease", 78], ["mechanism", 86], ["underlying", 96], ["facioscapulohumeral", 107], ["muscular", 127], ["dystrophy", 136], ["(", 146], ["FSHD", 147], [")", 151], [".", 152], ["The", 154], ["purpose", 158], ["of", 166], ["this", 169], ["review", 174], ["is", 181], ["to", 184], ["provide", 187], ["a", 195], ["comprehensive", 197], ["overview", 211], ["of", 220], ["our", 223], ["current", 227], ["understanding", 235], ["of", 249], ["the", 252], ["disease", 256], ["mechanism", 264], ["and", 274], ["to", 278], ["discuss", 281], ["the", 289], ["observations", 293], ["supporting", 306], ["the", 317], ["possibility", 321], ["of", 333], ["a", 336], ["developmental", 338], ["defect", 352], ["in", 359], ["this", 362], ["disorder", 367], [".", 375], ["In", 377], ["the", 380], ["majority", 384], ["of", 393], ["cases", 396], [",", 401], ["FSHD", 403], ["is", 408], ["caused", 411], ["by", 418], ["contraction", 421], ["of", 433], ["the", 436], ["D4Z4", 440], ["repeat", 445], ["array", 452], ["(", 458], ["FSHD1", 459], [")", 464], [".", 465], ["This", 467], ["results", 472], ["in", 480], ["local", 483], ["chromatin", 489], ["relaxation", 499], ["and", 510], ["stable", 514], ["expression", 521], ["of", 532], ["the", 535], ["DUX4", 539], ["retrogene", 544], ["in", 554], ["skeletal", 557], ["muscle", 566], [",", 572], ["but", 574], ["only", 578], ["when", 583], ["a", 588], ["polymorphic", 590], ["DUX4", 602], ["polyadenylation", 607], ["signal", 623], ["is", 630], ["present", 633], [".", 640], ["In", 642], ["some", 645], ["cases", 650], ["(", 656], ["FSHD2", 657], [")", 662], [",", 663], ["D4Z4", 665], ["chromatin", 670], ["relaxation", 680], ["and", 691], ["stable", 695], ["DUX4", 702], ["expression", 707], ["occur", 718], ["in", 724], ["the", 727], ["absence", 731], ["of", 739], ["D4Z4", 742], ["array", 747], ["contraction", 753], [".", 764], ["DUX4", 766], ["is", 771], ["a", 774], ["germline", 776], ["transcription", 785], ["factor", 799], ["and", 806], ["its", 810], ["expression", 814], ["in", 825], ["skeletal", 828], ["muscle", 837], ["leads", 844], ["to", 850], ["activation", 853], ["of", 864], ["early", 867], ["stem", 873], ["cell", 878], ["and", 883], ["germline", 887], ["programs", 896], ["and", 905], ["transcriptional", 909], ["activation", 925], ["of", 936], ["retroelements", 939], [".", 952], ["Recent", 954], ["studies", 961], ["have", 969], ["provided", 974], ["a", 983], ["plausible", 985], ["disease", 995], ["mechanism", 1003], ["for", 1013], ["FSHD", 1017], ["in", 1022], ["which", 1025], ["FSHD", 1031], ["results", 1036], ["from", 1044], ["inappropriate", 1049], ["expression", 1063], ["of", 1074], ["the", 1077], ["germline", 1081], ["transcription", 1090], ["factor", 1104], ["DUX4", 1111], [".", 1115], ["The", 1117], ["genes", 1121], ["regulated", 1127], ["by", 1137], ["DUX4", 1140], ["suggest", 1145], ["several", 1153], ["mechanisms", 1161], ["of", 1172], ["muscle", 1175], ["damage", 1182], [",", 1188], ["and", 1190], ["provide", 1194], ["potential", 1202], ["biomarkers", 1212], ["and", 1223], ["therapeutic", 1227], ["targets", 1239], ["that", 1247], ["should", 1252], ["be", 1259], ["investigated", 1262], ["in", 1275], ["future", 1278], ["studies", 1285], [".", 1292]]}
{"context": "Spinocerebellar ataxia type 3 is a neurodegenerative disorder caused by the expansion of the polyglutamine repeat region within the ataxin-3 protein. The mutant protein forms intracellular aggregates in the brain. However, the cellular mechanisms causing toxicity are still poorly understood and there are currently no effective treatments. In this study we show that administration of a rapamycin ester (cell cycle inhibitor-779, temsirolimus) improves motor performance in a transgenic mouse model of spinocerebellar ataxia type 3. Temsirolimus inhibits mammalian target of rapamycin and hence upregulates protein degradation by autophagy. Temsirolimus reduces the number of aggregates seen in the brains of transgenic mice and decreases levels of cytosolic soluble mutant ataxin-3, while endogenous wild-type protein levels remain unaffected. Temsirolimus is designed for long-term use in patients and therefore represents a possible therapeutic strategy for the treatment of spinocerebellar ataxia type 3. Using this disease model and treatment paradigm, we employed a microarray approach to investigate transcriptional changes that might be important in the pathogenesis of spinocerebellar ataxia type 3. This identified ubiquitin specific peptidase-15, which showed expression changes at both the messenger ribonucleic acid and protein level. Ubiquitin specific peptidase-15 levels were also changed in mice expressing another mutant polyglutamine protein, huntingtin. In total we identified 16 transcripts that were decreased in transgenic ataxin-3 mice that were normalized following temsirolimus treatment. In this mouse model with relatively mild disease progression, the number of transcripts changed was low and the magnitude of these changes was small. However, the importance of these transcriptional alterations in the pathogenesis of spinocerebellar ataxia type 3 remains unclear.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "179e834f3f064c7188755ef9596db9d9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[233, 233], [117, 117], [19, 19]], "char_spans": [[1547, 1554], [775, 782], [132, 139]]}]}], "context_tokens": [["Spinocerebellar", 0], ["ataxia", 16], ["type", 23], ["3", 28], ["is", 30], ["a", 33], ["neurodegenerative", 35], ["disorder", 53], ["caused", 62], ["by", 69], ["the", 72], ["expansion", 76], ["of", 86], ["the", 89], ["polyglutamine", 93], ["repeat", 107], ["region", 114], ["within", 121], ["the", 128], ["ataxin-3", 132], ["protein", 141], [".", 148], ["The", 150], ["mutant", 154], ["protein", 161], ["forms", 169], ["intracellular", 175], ["aggregates", 189], ["in", 200], ["the", 203], ["brain", 207], [".", 212], ["However", 214], [",", 221], ["the", 223], ["cellular", 227], ["mechanisms", 236], ["causing", 247], ["toxicity", 255], ["are", 264], ["still", 268], ["poorly", 274], ["understood", 281], ["and", 292], ["there", 296], ["are", 302], ["currently", 306], ["no", 316], ["effective", 319], ["treatments", 329], [".", 339], ["In", 341], ["this", 344], ["study", 349], ["we", 355], ["show", 358], ["that", 363], ["administration", 368], ["of", 383], ["a", 386], ["rapamycin", 388], ["ester", 398], ["(", 404], ["cell", 405], ["cycle", 410], ["inhibitor-779", 416], [",", 429], ["temsirolimus", 431], [")", 443], ["improves", 445], ["motor", 454], ["performance", 460], ["in", 472], ["a", 475], ["transgenic", 477], ["mouse", 488], ["model", 494], ["of", 500], ["spinocerebellar", 503], ["ataxia", 519], ["type", 526], ["3", 531], [".", 532], ["Temsirolimus", 534], ["inhibits", 547], ["mammalian", 556], ["target", 566], ["of", 573], ["rapamycin", 576], ["and", 586], ["hence", 590], ["upregulates", 596], ["protein", 608], ["degradation", 616], ["by", 628], ["autophagy", 631], [".", 640], ["Temsirolimus", 642], ["reduces", 655], ["the", 663], ["number", 667], ["of", 674], ["aggregates", 677], ["seen", 688], ["in", 693], ["the", 696], ["brains", 700], ["of", 707], ["transgenic", 710], ["mice", 721], ["and", 726], ["decreases", 730], ["levels", 740], ["of", 747], ["cytosolic", 750], ["soluble", 760], ["mutant", 768], ["ataxin-3", 775], [",", 783], ["while", 785], ["endogenous", 791], ["wild", 802], ["-", 806], ["type", 807], ["protein", 812], ["levels", 820], ["remain", 827], ["unaffected", 834], [".", 844], ["Temsirolimus", 846], ["is", 859], ["designed", 862], ["for", 871], ["long", 875], ["-", 879], ["term", 880], ["use", 885], ["in", 889], ["patients", 892], ["and", 901], ["therefore", 905], ["represents", 915], ["a", 926], ["possible", 928], ["therapeutic", 937], ["strategy", 949], ["for", 958], ["the", 962], ["treatment", 966], ["of", 976], ["spinocerebellar", 979], ["ataxia", 995], ["type", 1002], ["3", 1007], [".", 1008], ["Using", 1010], ["this", 1016], ["disease", 1021], ["model", 1029], ["and", 1035], ["treatment", 1039], ["paradigm", 1049], [",", 1057], ["we", 1059], ["employed", 1062], ["a", 1071], ["microarray", 1073], ["approach", 1084], ["to", 1093], ["investigate", 1096], ["transcriptional", 1108], ["changes", 1124], ["that", 1132], ["might", 1137], ["be", 1143], ["important", 1146], ["in", 1156], ["the", 1159], ["pathogenesis", 1163], ["of", 1176], ["spinocerebellar", 1179], ["ataxia", 1195], ["type", 1202], ["3", 1207], [".", 1208], ["This", 1210], ["identified", 1215], ["ubiquitin", 1226], ["specific", 1236], ["peptidase-15", 1245], [",", 1257], ["which", 1259], ["showed", 1265], ["expression", 1272], ["changes", 1283], ["at", 1291], ["both", 1294], ["the", 1299], ["messenger", 1303], ["ribonucleic", 1313], ["acid", 1325], ["and", 1330], ["protein", 1334], ["level", 1342], [".", 1347], ["Ubiquitin", 1349], ["specific", 1359], ["peptidase-15", 1368], ["levels", 1381], ["were", 1388], ["also", 1393], ["changed", 1398], ["in", 1406], ["mice", 1409], ["expressing", 1414], ["another", 1425], ["mutant", 1433], ["polyglutamine", 1440], ["protein", 1454], [",", 1461], ["huntingtin", 1463], [".", 1473], ["In", 1475], ["total", 1478], ["we", 1484], ["identified", 1487], ["16", 1498], ["transcripts", 1501], ["that", 1513], ["were", 1518], ["decreased", 1523], ["in", 1533], ["transgenic", 1536], ["ataxin-3", 1547], ["mice", 1556], ["that", 1561], ["were", 1566], ["normalized", 1571], ["following", 1582], ["temsirolimus", 1592], ["treatment", 1605], [".", 1614], ["In", 1616], ["this", 1619], ["mouse", 1624], ["model", 1630], ["with", 1636], ["relatively", 1641], ["mild", 1652], ["disease", 1657], ["progression", 1665], [",", 1676], ["the", 1678], ["number", 1682], ["of", 1689], ["transcripts", 1692], ["changed", 1704], ["was", 1712], ["low", 1716], ["and", 1720], ["the", 1724], ["magnitude", 1728], ["of", 1738], ["these", 1741], ["changes", 1747], ["was", 1755], ["small", 1759], [".", 1764], ["However", 1766], [",", 1773], ["the", 1775], ["importance", 1779], ["of", 1790], ["these", 1793], ["transcriptional", 1799], ["alterations", 1815], ["in", 1827], ["the", 1830], ["pathogenesis", 1834], ["of", 1847], ["spinocerebellar", 1850], ["ataxia", 1866], ["type", 1873], ["3", 1878], ["remains", 1880], ["unclear", 1888], [".", 1895]]}
{"context": "Change in gene expression associated with pancreatic cancer could be attributed to the variation in histone posttranslational modifications leading to subsequent remodeling of the chromatin template during transcription. However, the interconnected network of molecules involved in regulating such processes remains elusive. hPaf1/PD2, a subunit of the human PAF-complex, involved in the regulation of transcriptional elongation has oncogenic potential. Our study explores the possibility that regulation of histone methylation by hPaf1 can contribute towards alteration in gene expression by nucleosomal rearrangement. Here, we show that knockdown of hPaf1/PD2 leads to decreased di- and tri-methylation at histone H3 lysine 4 residues in pancreatic cancer cells. Interestingly, hPaf1/PD2 colocalizes with MLL1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4 residues. Also, a reduction in hPaf1 level resulted in reduced MLL1 expression and a corresponding decrease in the level of CHD1 (Chromohelicase DNA-binding protein 1), an ATPase dependent chromatin remodeling enzyme that specifically binds to H3K4 di and trimethyl marks. hPaf1/PD2 was also found to interact and colocalize with CHD1 in both cytoplasmic and nuclear extracts of pancreatic cancer cells. Further, reduced level of CHD1 localization in the nucleus in hPaf1/PD2 Knockdown cells could be rescued by ectopic expression of hPaf1/PD2. Micrococcal nuclease digestion showed an altered chromatin structure in hPaf1/PD2-KD cells. Overall, our results suggest that hPaf1/PD2 in association with MLL1 regulates methylation of H3K4 residues, as well as interacts and regulates nuclear shuttling of chromatin remodeling protein CHD1, facilitating its function in pancreatic cancer cells.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "98cb43e4ec95414598cd781412a5d3b8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[253, 253], [177, 177], [134, 134]], "char_spans": [[1620, 1623], [1133, 1136], [884, 887]]}]}], "context_tokens": [["Change", 0], ["in", 7], ["gene", 10], ["expression", 15], ["associated", 26], ["with", 37], ["pancreatic", 42], ["cancer", 53], ["could", 60], ["be", 66], ["attributed", 69], ["to", 80], ["the", 83], ["variation", 87], ["in", 97], ["histone", 100], ["posttranslational", 108], ["modifications", 126], ["leading", 140], ["to", 148], ["subsequent", 151], ["remodeling", 162], ["of", 173], ["the", 176], ["chromatin", 180], ["template", 190], ["during", 199], ["transcription", 206], [".", 219], ["However", 221], [",", 228], ["the", 230], ["interconnected", 234], ["network", 249], ["of", 257], ["molecules", 260], ["involved", 270], ["in", 279], ["regulating", 282], ["such", 293], ["processes", 298], ["remains", 308], ["elusive", 316], [".", 323], ["hPaf1/PD2", 325], [",", 334], ["a", 336], ["subunit", 338], ["of", 346], ["the", 349], ["human", 353], ["PAF", 359], ["-", 362], ["complex", 363], [",", 370], ["involved", 372], ["in", 381], ["the", 384], ["regulation", 388], ["of", 399], ["transcriptional", 402], ["elongation", 418], ["has", 429], ["oncogenic", 433], ["potential", 443], [".", 452], ["Our", 454], ["study", 458], ["explores", 464], ["the", 473], ["possibility", 477], ["that", 489], ["regulation", 494], ["of", 505], ["histone", 508], ["methylation", 516], ["by", 528], ["hPaf1", 531], ["can", 537], ["contribute", 541], ["towards", 552], ["alteration", 560], ["in", 571], ["gene", 574], ["expression", 579], ["by", 590], ["nucleosomal", 593], ["rearrangement", 605], [".", 618], ["Here", 620], [",", 624], ["we", 626], ["show", 629], ["that", 634], ["knockdown", 639], ["of", 649], ["hPaf1/PD2", 652], ["leads", 662], ["to", 668], ["decreased", 671], ["di-", 681], ["and", 685], ["tri", 689], ["-", 692], ["methylation", 693], ["at", 705], ["histone", 708], ["H3", 716], ["lysine", 719], ["4", 726], ["residues", 728], ["in", 737], ["pancreatic", 740], ["cancer", 751], ["cells", 758], [".", 763], ["Interestingly", 765], [",", 778], ["hPaf1/PD2", 780], ["colocalizes", 790], ["with", 802], ["MLL1", 807], ["(", 812], ["Mixed", 813], ["Lineage", 819], ["Leukemia", 827], ["1", 836], [")", 837], [",", 838], ["a", 840], ["histone", 842], ["methyltransferase", 850], ["that", 868], ["methylates", 873], ["H3K4", 884], ["residues", 889], [".", 897], ["Also", 899], [",", 903], ["a", 905], ["reduction", 907], ["in", 917], ["hPaf1", 920], ["level", 926], ["resulted", 932], ["in", 941], ["reduced", 944], ["MLL1", 952], ["expression", 957], ["and", 968], ["a", 972], ["corresponding", 974], ["decrease", 988], ["in", 997], ["the", 1000], ["level", 1004], ["of", 1010], ["CHD1", 1013], ["(", 1018], ["Chromohelicase", 1019], ["DNA", 1034], ["-", 1037], ["binding", 1038], ["protein", 1046], ["1", 1054], [")", 1055], [",", 1056], ["an", 1058], ["ATPase", 1061], ["dependent", 1068], ["chromatin", 1078], ["remodeling", 1088], ["enzyme", 1099], ["that", 1106], ["specifically", 1111], ["binds", 1124], ["to", 1130], ["H3K4", 1133], ["di", 1138], ["and", 1141], ["trimethyl", 1145], ["marks", 1155], [".", 1160], ["hPaf1/PD2", 1162], ["was", 1172], ["also", 1176], ["found", 1181], ["to", 1187], ["interact", 1190], ["and", 1199], ["colocalize", 1203], ["with", 1214], ["CHD1", 1219], ["in", 1224], ["both", 1227], ["cytoplasmic", 1232], ["and", 1244], ["nuclear", 1248], ["extracts", 1256], ["of", 1265], ["pancreatic", 1268], ["cancer", 1279], ["cells", 1286], [".", 1291], ["Further", 1293], [",", 1300], ["reduced", 1302], ["level", 1310], ["of", 1316], ["CHD1", 1319], ["localization", 1324], ["in", 1337], ["the", 1340], ["nucleus", 1344], ["in", 1352], ["hPaf1/PD2", 1355], ["Knockdown", 1365], ["cells", 1375], ["could", 1381], ["be", 1387], ["rescued", 1390], ["by", 1398], ["ectopic", 1401], ["expression", 1409], ["of", 1420], ["hPaf1/PD2", 1423], [".", 1432], ["Micrococcal", 1434], ["nuclease", 1446], ["digestion", 1455], ["showed", 1465], ["an", 1472], ["altered", 1475], ["chromatin", 1483], ["structure", 1493], ["in", 1503], ["hPaf1/PD2-KD", 1506], ["cells", 1519], [".", 1524], ["Overall", 1526], [",", 1533], ["our", 1535], ["results", 1539], ["suggest", 1547], ["that", 1555], ["hPaf1/PD2", 1560], ["in", 1570], ["association", 1573], ["with", 1585], ["MLL1", 1590], ["regulates", 1595], ["methylation", 1605], ["of", 1617], ["H3K4", 1620], ["residues", 1625], [",", 1633], ["as", 1635], ["well", 1638], ["as", 1643], ["interacts", 1646], ["and", 1656], ["regulates", 1660], ["nuclear", 1670], ["shuttling", 1678], ["of", 1688], ["chromatin", 1691], ["remodeling", 1701], ["protein", 1712], ["CHD1", 1720], [",", 1724], ["facilitating", 1726], ["its", 1739], ["function", 1743], ["in", 1752], ["pancreatic", 1755], ["cancer", 1766], ["cells", 1773], [".", 1778]]}
{"context": "We investigated the validity of probe-to-bone testing in the diagnosis of osteomyelitis in a selected subgroup of patients clinically suspected of having diabetic foot osteomyelitis. Between January 1, 2007, and December 31, 2008, inpatients and outpatients with a diabetic foot ulcer were prospectively evaluated, and those having a clinical diagnosis of foot infection and at least one of the osteomyelitis clinical suspicion criteria were consecutively included in this study. Sixty-five patients met the inclusion criteria and were prospectively enrolled in the study. Forty-nine patients (75.4%) were hospitalized, and the remaining 16 (24.6%) were followed as outpatients. Osteomyelitis was diagnosed in 39 patients (60.0%). Probe-to-bone test results were positive in 30 patients (46.1%). The positive predictive value for the probe-to-bone test was fairly high (87%), but the negative predictive value was only 62%. The sensitivity and specificity of the test were 66% and 84%, respectively. White blood cell counts and mean C-reactive protein levels did not statistically significantly differ between groups. However, erythrocyte sedimentation rates greater than 70 mm/h reached statistical significance between groups. Wound area and depth were not found to be statistically significantly different between groups. Positive probe-to-bone test results and erythrocyte sedimentation rates greater than 70 mm/h provide some support for the diagnosis of diabetic foot osteomyelitis, but it is not strong; magnetic resonance imaging or bone biopsy will probably be required in cases of doubt.", "qas": [{"question": "Which disease can be diagnosed with the \"probe to bone\" test?", "answers": ["diabetic foot osteomyelitis"], "qid": "1b2f285e651143908bfc335257a9a3df", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["diagnosed", 21], ["with", 31], ["the", 36], ["\"", 40], ["probe", 41], ["to", 47], ["bone", 50], ["\"", 54], ["test", 56], ["?", 60]], "detected_answers": [{"text": "diabetic foot osteomyelitis", "token_spans": [[270, 272], [26, 28]], "char_spans": [[1460, 1486], [154, 180]]}]}], "context_tokens": [["We", 0], ["investigated", 3], ["the", 16], ["validity", 20], ["of", 29], ["probe", 32], ["-", 37], ["to", 38], ["-", 40], ["bone", 41], ["testing", 46], ["in", 54], ["the", 57], ["diagnosis", 61], ["of", 71], ["osteomyelitis", 74], ["in", 88], ["a", 91], ["selected", 93], ["subgroup", 102], ["of", 111], ["patients", 114], ["clinically", 123], ["suspected", 134], ["of", 144], ["having", 147], ["diabetic", 154], ["foot", 163], ["osteomyelitis", 168], [".", 181], ["Between", 183], ["January", 191], ["1", 199], [",", 200], ["2007", 202], [",", 206], ["and", 208], ["December", 212], ["31", 221], [",", 223], ["2008", 225], [",", 229], ["inpatients", 231], ["and", 242], ["outpatients", 246], ["with", 258], ["a", 263], ["diabetic", 265], ["foot", 274], ["ulcer", 279], ["were", 285], ["prospectively", 290], ["evaluated", 304], [",", 313], ["and", 315], ["those", 319], ["having", 325], ["a", 332], ["clinical", 334], ["diagnosis", 343], ["of", 353], ["foot", 356], ["infection", 361], ["and", 371], ["at", 375], ["least", 378], ["one", 384], ["of", 388], ["the", 391], ["osteomyelitis", 395], ["clinical", 409], ["suspicion", 418], ["criteria", 428], ["were", 437], ["consecutively", 442], ["included", 456], ["in", 465], ["this", 468], ["study", 473], [".", 478], ["Sixty", 480], ["-", 485], ["five", 486], ["patients", 491], ["met", 500], ["the", 504], ["inclusion", 508], ["criteria", 518], ["and", 527], ["were", 531], ["prospectively", 536], ["enrolled", 550], ["in", 559], ["the", 562], ["study", 566], [".", 571], ["Forty", 573], ["-", 578], ["nine", 579], ["patients", 584], ["(", 593], ["75.4", 594], ["%", 598], [")", 599], ["were", 601], ["hospitalized", 606], [",", 618], ["and", 620], ["the", 624], ["remaining", 628], ["16", 638], ["(", 641], ["24.6", 642], ["%", 646], [")", 647], ["were", 649], ["followed", 654], ["as", 663], ["outpatients", 666], [".", 677], ["Osteomyelitis", 679], ["was", 693], ["diagnosed", 697], ["in", 707], ["39", 710], ["patients", 713], ["(", 722], ["60.0", 723], ["%", 727], [")", 728], [".", 729], ["Probe", 731], ["-", 736], ["to", 737], ["-", 739], ["bone", 740], ["test", 745], ["results", 750], ["were", 758], ["positive", 763], ["in", 772], ["30", 775], ["patients", 778], ["(", 787], ["46.1", 788], ["%", 792], [")", 793], [".", 794], ["The", 796], ["positive", 800], ["predictive", 809], ["value", 820], ["for", 826], ["the", 830], ["probe", 834], ["-", 839], ["to", 840], ["-", 842], ["bone", 843], ["test", 848], ["was", 853], ["fairly", 857], ["high", 864], ["(", 869], ["87", 870], ["%", 872], [")", 873], [",", 874], ["but", 876], ["the", 880], ["negative", 884], ["predictive", 893], ["value", 904], ["was", 910], ["only", 914], ["62", 919], ["%", 921], [".", 922], ["The", 924], ["sensitivity", 928], ["and", 940], ["specificity", 944], ["of", 956], ["the", 959], ["test", 963], ["were", 968], ["66", 973], ["%", 975], ["and", 977], ["84", 981], ["%", 983], [",", 984], ["respectively", 986], [".", 998], ["White", 1000], ["blood", 1006], ["cell", 1012], ["counts", 1017], ["and", 1024], ["mean", 1028], ["C", 1033], ["-", 1034], ["reactive", 1035], ["protein", 1044], ["levels", 1052], ["did", 1059], ["not", 1063], ["statistically", 1067], ["significantly", 1081], ["differ", 1095], ["between", 1102], ["groups", 1110], [".", 1116], ["However", 1118], [",", 1125], ["erythrocyte", 1127], ["sedimentation", 1139], ["rates", 1153], ["greater", 1159], ["than", 1167], ["70", 1172], ["mm", 1175], ["/", 1177], ["h", 1178], ["reached", 1180], ["statistical", 1188], ["significance", 1200], ["between", 1213], ["groups", 1221], [".", 1227], ["Wound", 1229], ["area", 1235], ["and", 1240], ["depth", 1244], ["were", 1250], ["not", 1255], ["found", 1259], ["to", 1265], ["be", 1268], ["statistically", 1271], ["significantly", 1285], ["different", 1299], ["between", 1309], ["groups", 1317], [".", 1323], ["Positive", 1325], ["probe", 1334], ["-", 1339], ["to", 1340], ["-", 1342], ["bone", 1343], ["test", 1348], ["results", 1353], ["and", 1361], ["erythrocyte", 1365], ["sedimentation", 1377], ["rates", 1391], ["greater", 1397], ["than", 1405], ["70", 1410], ["mm", 1413], ["/", 1415], ["h", 1416], ["provide", 1418], ["some", 1426], ["support", 1431], ["for", 1439], ["the", 1443], ["diagnosis", 1447], ["of", 1457], ["diabetic", 1460], ["foot", 1469], ["osteomyelitis", 1474], [",", 1487], ["but", 1489], ["it", 1493], ["is", 1496], ["not", 1499], ["strong", 1503], [";", 1509], ["magnetic", 1511], ["resonance", 1520], ["imaging", 1530], ["or", 1538], ["bone", 1541], ["biopsy", 1546], ["will", 1553], ["probably", 1558], ["be", 1567], ["required", 1570], ["in", 1579], ["cases", 1582], ["of", 1588], ["doubt", 1591], [".", 1596]]}
